PT	AU	BA	BE	GP	AF	BF	CA	TI	SO	SE	BS	LA	DT	CT	CY	CL	SP	HO	DE	ID	AB	C1	C3	RP	EM	RI	OI	FU	FP	FX	CR	NR	TC	Z9	U1	U2	PU	PI	PA	SN	EI	BN	J9	JI	PD	PY	VL	IS	PN	SU	SI	MA	BP	EP	AR	DI	DL	D2	EA	PG	WC	WE	SC	GA	PM	OA	HC	HP	DA	UT
J	Goin, JC; Nathanson, NM				Goin, JC; Nathanson, NM			Quantitative analysis of muscarinic acetylcholine receptor homo- and heterodimerization in live cells - Regulation of receptor down-regulation by heterodimerization	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENERGY-TRANSFER; LIVING CELLS; PAIRED ACTIVATION; 2 COMPONENTS; M-2; OLIGOMERIZATION; INTERNALIZATION; IDENTIFICATION; SEQUESTRATION; DIMERIZATION	Although previous pharmacological and biochemical data support the notion that muscarinic acetylcholine receptors ( mAChR) form homo- and heterodimers, the existence of mAChR oligomers in live cells is still a matter of controversy. Here we used bioluminescence resonance energy transfer to demonstrate that M-1, M-2, and M-3 mAChR can form constitutive homo- and heterodimers in living HEK 293 cells. Quantitative bioluminescence resonance energy transfer analysis has revealed that the cell receptor population in cells expressing a single subtype of M-1, M-2, or M-3 mAChR is predominantly composed of high affinity homodimers. Saturation curve analysis of cells expressing two receptor subtypes demonstrates the existence of high affinity M-1/M-2, M-2/M-3, and M-1/M-3 mAChR heterodimers, although the relative affinity values were slightly lower than those for mAChR homodimers. Short term agonist treatment did not modify the oligomeric status of homo- and heterodimers. When expressed in JEG-3 cells, the M-2 receptor exhibits much higher susceptibility than the M-3 receptor to agonist-induced down-regulation. Coexpression of M-3 mAChR with increasing amounts of the M-2 subtype in JEG-3 cells resulted in an increased agonist-induced down-regulation of M-3, suggesting a novel role of heterodimerization in the mechanism of mAChR long term regulation.	Univ Washington, Sch Med, Dept Pharmacol, Seattle, WA 98195 USA; Consejo Nacl Invest Cient & Tecn, Ctr Estudios Farmacol & Bot, RA-1414 Buenos Aires, DF, Argentina	University of Washington; University of Washington Seattle; Consejo Nacional de Investigaciones Cientificas y Tecnicas (CONICET)	Nathanson, NM (corresponding author), Univ Washington, Sch Med, Dept Pharmacol, Box 357750, Seattle, WA 98195 USA.	nathanso@u.washington.edu			NHLBI NIH HHS [HL 44948] Funding Source: Medline; NINDS NIH HHS [NS 26920] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL044948] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS026920] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Angers S, 2000, P NATL ACAD SCI USA, V97, P3684, DOI 10.1073/pnas.060590697; Angers S, 2002, ANNU REV PHARMACOL, V42, P409, DOI 10.1146/annurev.pharmtox.42.091701.082314; Ayoub MA, 2004, MOL PHARMACOL, V66, P312, DOI 10.1124/mol.104.000398; Ayoub MA, 2002, J BIOL CHEM, V277, P21522, DOI 10.1074/jbc.M200729200; Bouvier M, 2001, NAT REV NEUROSCI, V2, P274, DOI 10.1038/35067575; Breit A, 2004, J BIOL CHEM, V279, P28756, DOI 10.1074/jbc.M313310200; Breitwieser GE, 2004, CIRC RES, V94, P17, DOI 10.1161/01.RES.0000110420.68526.19; Canals M, 2004, J NEUROCHEM, V88, P726, DOI 10.1046/j.1471-4159.2003.02200.x; Chidiac P, 1997, BIOCHEMISTRY-US, V36, P7361, DOI 10.1021/bi961939t; CHIDIAC P, 1992, BIOCHEMISTRY-US, V31, P10908, DOI 10.1021/bi00159a035; Dann CE, 2001, NATURE, V412, P86, DOI 10.1038/35083601; Goin JC, 2002, J NEUROCHEM, V83, P964, DOI 10.1046/j.1471-4159.2002.01209.x; GOLDMAN PS, 1994, J BIOL CHEM, V269, P15640; Goldman PS, 1996, J BIOL CHEM, V271, P4215; Gouldson PR, 2000, NEUROPSYCHOPHARMACOL, V23, pS60, DOI 10.1016/S0893-133X(00)00153-6; Griffin MT, 2003, BIOCHEM PHARMACOL, V65, P1227, DOI 10.1016/S0006-2952(03)00068-6; HALVORSEN SW, 1981, J BIOL CHEM, V256, P7941; HIRSCHBERG BT, 1994, J BIOL CHEM, V269, P26127; Kaykas A, 2004, NAT CELL BIOL, V6, P52, DOI 10.1038/ncb1081; Kroeger KM, 2003, FRONT NEUROENDOCRIN, V24, P254, DOI 10.1016/j.yfrne.2003.10.002; Kurogouchi F, 2002, CLIN EXP PHARMACOL P, V29, P666, DOI 10.1046/j.1440-1681.2002.03714.x; LAMEH J, 1992, J BIOL CHEM, V267, P13406; LOWRY OH, 1951, J BIOL CHEM, V193, P265; LUETJE CW, 1987, BIOCHEMISTRY-US, V26, P6892, DOI 10.1021/bi00396a003; Maggio R, 1999, J PHARMACOL EXP THER, V291, P251; MAGGIO R, 1993, P NATL ACAD SCI USA, V90, P3103, DOI 10.1073/pnas.90.7.3103; MCKINNON LA, 1995, J BIOL CHEM, V270, P20636, DOI 10.1074/jbc.270.35.20636; MELLON P, 1981, CELL, V27, P279, DOI 10.1016/0092-8674(81)90411-6; Mercier JF, 2002, J BIOL CHEM, V277, P44925, DOI 10.1074/jbc.M205767200; Nadler LS, 2001, J BIOL CHEM, V276, P10539, DOI 10.1074/jbc.M007190200; Novi F, 2005, J BIOL CHEM, V280, P19768, DOI 10.1074/jbc.M411281200; Novi F, 2004, J BIOL CHEM, V279, P7476, DOI 10.1074/jbc.M306818200; Oki T, 2005, MOL BRAIN RES, V133, P6, DOI 10.1016/j.molbrainres.2004.09.012; Ostrom RS, 1997, J PHARMACOL EXP THER, V280, P189; Park PSH, 2003, BIOCHEMISTRY-US, V42, P12960, DOI 10.1021/bi034491m; Park PSH, 2004, J NEUROCHEM, V90, P537, DOI 10.1111/j.1471-4159.2004.02536.x; POTTER LT, 1991, MOL PHARMACOL, V39, P211; Ramsay D, 2004, MOL PHARMACOL, V66, P228, DOI 10.1124/mol.66.2.228; Roseberry AG, 1999, J BIOL CHEM, V274, P33671, DOI 10.1074/jbc.274.47.33671; Schlador ML, 2000, J BIOL CHEM, V275, P23295, DOI 10.1074/jbc.M002380200; Schlador ML, 1997, J BIOL CHEM, V272, P18882, DOI 10.1074/jbc.272.30.18882; Tsuga H, 1998, J BIOL CHEM, V273, P5323, DOI 10.1074/jbc.273.9.5323; VEATCH W, 1977, J MOL BIOL, V113, P89, DOI 10.1016/0022-2836(77)90042-0; Wang DX, 2005, MOL PHARMACOL, V67, P2173, DOI 10.1124/mol.104.010272; Xu Y, 1999, P NATL ACAD SCI USA, V96, P151, DOI 10.1073/pnas.96.1.151; Zeng FY, 2000, NEUROPSYCHOPHARMACOL, V23, pS19, DOI 10.1016/S0893-133X(00)00146-9	46	69	74	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 3	2006	281	9					5416	5425		10.1074/jbc.M507476200	http://dx.doi.org/10.1074/jbc.M507476200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	015RQ	16368694	hybrid, Green Published			2022-12-25	WOS:000235568900013
J	Nandigama, R; Padmasekar, M; Wartenberg, M; Sauer, H				Nandigama, R; Padmasekar, M; Wartenberg, M; Sauer, H			Feed forward cycle of hypotonic stress-induced ATP release, purinergic receptor activation, and growth stimulation of prostate cancer cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ARACHIDONIC-ACID RELEASE; INDUCED CA2+ WAVES; EXTRACELLULAR ATP; CONDUCTANCE REGULATOR; ENDOTHELIAL-CELLS; PROSTAGLANDIN E-2; NUCLEOTIDES; MECHANISMS; ASTROCYTES; TRANSPORT	ATP is released in many cell types upon mechanical strain, the physiological function of extracellular ATP is largely unknown, however. Here we report that ATP released upon hypotonic stress stimulated prostate cancer cell proliferation, activated purinergic receptors, increased intracellular [Ca2+](i), and initiated downstream signaling cascades that involved MAPKs ERK1/2 and p38 as well as phosphatidylinositol 3-kinase (PI3K). MAPK activation, the calcium response as well as induction of cell proliferation upon hypotonic stress were inhibited by preincubation with the ATP scavenger apyrase, indicating that hypotonic stress-induced signaling pathways are elicited by released ATP. Hypotonic stress increased prostaglandin E-2 (PGE(2)) synthesis. Consequently, ATP release was inhibited by antagonists of PI3K (LY294002 and wortmannin), phospholipase A(2) ( methyl arachidonyl fluorophosphonate ( MAFP)), cyclooxygenase-2 (COX-2) ( indomethacin, etodolac, NS398) and 5,8,11,14-eicosatetraynoic acid ( ETYA), which are involved in arachidonic acid metabolism. Furthermore, ATP release was abolished in the presence of the adenylate cyclase (AC) inhibitor MDL-12,330A, indicating regulation of ATP-release by cAMP. The hypotonic stress-induced ATP release was significantly blunted when the ATP-mediated signal transduction cascade was inhibited on different levels, i. e. purinergic receptors were blocked by suramin and pyridoxalphosphate-6-azophenyl- 2', 4'-disulfonic acid (PPADS), the Ca2+ response was inhibited upon chelation of intracellular Ca2+ by 1,2-bis(o-aminophenoxy) ethane-N,N,N',N'-tetraacetic acid ( BAPTA), and ERK1,2 as well as p38 were inhibited by UO126 and SB203580, respectively. In summary our data demonstrate that hypotonic stress initiates a feed forward cycle of ATP release and purinergic receptor signaling resulting in proliferation of prostate cancer cells.	Univ Giessen, Dept Physiol, D-35312 Giessen, Germany; GKSS Forschungszentrum Geesthacht GmbH, Dept Cell Biol, D-14513 Teltow, Germany	Justus Liebig University Giessen; Helmholtz Association; Helmholtz-Zentrum Geesthacht - Zentrum fur Material- und Kustenforschung	Sauer, H (corresponding author), Univ Giessen, Dept Physiol, Aulweg 129, D-35392 Giessen, Germany.	heinrich.sauer@physiologie.med.uni-giessen.de		Nandigama, Rajender/0000-0002-7344-4732; Nandigama, Manju Padmasekar/0000-0001-7060-8319				ABRAHAM EH, 1993, P NATL ACAD SCI USA, V90, P312, DOI 10.1073/pnas.90.1.312; Alexander LD, 2004, KIDNEY INT, V65, P551, DOI 10.1111/j.1523-1755.2004.00405.x; Beigi R, 1999, AM J PHYSIOL-CELL PH, V276, pC267, DOI 10.1152/ajpcell.1999.276.1.C267; Bodas E, 2000, J BIOL CHEM, V275, P20268, DOI 10.1074/jbc.M000894200; Braunstein Gavin M, 2004, J Cyst Fibros, V3, P99, DOI 10.1016/j.jcf.2004.01.006; Braunstein GM, 2001, J BIOL CHEM, V276, P6621, DOI 10.1074/jbc.M005893200; Brustovetsky N, 1996, P NATL ACAD SCI USA, V93, P664, DOI 10.1073/pnas.93.2.664; Burnstock G, 2002, CLIN MED, V2, P45, DOI 10.7861/clinmedicine.2-1-45; Burnstock G, 2002, ARTERIOSCL THROM VAS, V22, P364, DOI 10.1161/hq0302.105360; Burnstock G, 1999, J ANAT, V194, P335, DOI 10.1046/j.1469-7580.1999.19430335.x; Calvert RC, 2004, ANTICANCER RES, V24, P2853; Cohen CR, 1997, EXP CELL RES, V231, P184, DOI 10.1006/excr.1996.3450; Cotrina ML, 1998, P NATL ACAD SCI USA, V95, P15735, DOI 10.1073/pnas.95.26.15735; Coutinho-Silva R, 2005, AM J PHYSIOL-GASTR L, V288, pG1024, DOI 10.1152/ajpgi.00211.2004; FANG WG, 1992, J CLIN INVEST, V89, P191, DOI 10.1172/JCI115562; Feranchak AP, 2000, J HEPATOL, V33, P174, DOI 10.1016/S0168-8278(00)80357-8; Franke H, 1999, GLIA, V28, P190, DOI 10.1002/(SICI)1098-1136(199912)28:3<190::AID-GLIA3>3.0.CO;2-0; GORDON JL, 1986, BIOCHEM J, V233, P309, DOI 10.1042/bj2330309; Hazama A, 1998, PFLUG ARCH EUR J PHY, V437, P31, DOI 10.1007/s004240050742; Insel PA, 2001, CLIN EXP PHARMACOL P, V28, P351, DOI 10.1046/j.1440-1681.2001.03452.x; Jakab M, 2002, CELL PHYSIOL BIOCHEM, V12, P235, DOI 10.1159/000067895; Janssens R, 2001, BRIT J PHARMACOL, V132, P536, DOI 10.1038/sj.bjp.0703833; Jo YH, 1999, NAT NEUROSCI, V2, P241, DOI 10.1038/6344; Lader AS, 2000, AM J PHYSIOL-CELL PH, V279, pC173, DOI 10.1152/ajpcell.2000.279.1.C173; Lundgren DW, 1997, J BIOL CHEM, V272, P20118, DOI 10.1074/jbc.272.32.20118; Matsumoto PS, 1997, J MEMBRANE BIOL, V160, P27, DOI 10.1007/s002329900292; Naumann Nora, 2005, J Cyst Fibros, V4, P157, DOI 10.1016/j.jcf.2005.05.003; Okada Y, 2001, J PHYSIOL-LONDON, V532, P3, DOI 10.1111/j.1469-7793.2001.0003g.x; Ostrom RS, 2000, J BIOL CHEM, V275, P11735, DOI 10.1074/jbc.275.16.11735; Parker SL, 1997, CA-CANCER J CLIN, V47, P5, DOI 10.3322/canjclin.47.1.5; Post SR, 1996, J BIOL CHEM, V271, P2029, DOI 10.1074/jbc.271.4.2029; Randriamboavonjy V, 2004, J EXP MED, V199, P347, DOI 10.1084/jem.20030694; Roman RM, 2001, J MEMBRANE BIOL, V183, P165, DOI 10.1007/s00232-001-0064-7; Sauer H, 2000, AM J PHYSIOL-CELL PH, V279, pC295, DOI 10.1152/ajpcell.2000.279.2.C295; Sauer H, 2001, FASEB J, V15, P2539, DOI 10.1096/fj.01-0360fje; SCHULZELOHOFF E, 1992, AM J PHYSIOL, V263, pF374, DOI 10.1152/ajprenal.1992.263.3.F374; Schwiebert EM, 1998, P NATL ACAD SCI USA, V95, P2674, DOI 10.1073/pnas.95.5.2674; Schwiebert EM, 2000, AM J PHYSIOL-CELL PH, V279, pC281, DOI 10.1152/ajpcell.2000.279.2.C281; Schwiebert EM, 2003, BBA-BIOMEMBRANES, V1615, P7, DOI 10.1016/S0005-2736(03)00210-4; SCHWIEBERT EM, 1995, CELL, V81, P1063, DOI 10.1016/S0092-8674(05)80011-X; Schwiebert ER, 2001, CLIN EXP PHARMACOL P, V28, P340, DOI 10.1046/j.1440-1681.2001.03451.x; Stout CE, 2002, J BIOL CHEM, V277, P10482, DOI 10.1074/jbc.M109902200; Welch BD, 2003, AM J PHYSIOL-RENAL, V285, pF711, DOI 10.1152/ajprenal.00096.2003; Xing MZ, 1997, J CLIN INVEST, V99, P805, DOI 10.1172/JCI119227; Xing MZ, 1999, J BIOL CHEM, V274, P10035, DOI 10.1074/jbc.274.15.10035	45	34	36	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 3	2006	281	9					5686	5693		10.1074/jbc.M510452200	http://dx.doi.org/10.1074/jbc.M510452200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	015RQ	16321972	hybrid			2022-12-25	WOS:000235568900045
J	van der Does, C; Presenti, C; Schulze, K; Dinkelaker, S; Tampe, R				van der Does, C; Presenti, C; Schulze, K; Dinkelaker, S; Tampe, R			Kinetics of the ATP hydrolysis cycle of the nucleotide-binding domain of Mdl1 studied by a novel site-specific labeling technique	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ABC TRANSPORTER; P-GLYCOPROTEIN; CATALYTIC CYCLE; CASSETTE TRANSPORTERS; HISTIDINE PERMEASE; MECHANISM; MITOCHONDRIA; VISCOSITY; AFFINITY; PROTEIN	We have recently proposed a "processive clamp" model for the ATP hydrolysis cycle of the nucleotide-binding domain (NBD) of the mitochondrial ABC transporter Mdl1 ( Janas, E., Hofacker, M., Chen, M., Gompf, S., van der Does, C., and Tampe, R. ( 2003) J. Biol. Chem. 278, 26862 - 26869). In this model, ATP binding to two monomeric NBDs leads to formation of an NBD dimer that, after hydrolysis of both ATPs, dissociates and releases ADP. Here, we set out to follow the association and dissociation of NBDs using a novel minimally invasive site-specific labeling technique, which provides stable and stoichiometric attachment of fluorophores. The association and dissociation kinetics of the E599Q-NBD dimer upon addition and removal of ATP were determined by fluorescence self-quenching. Remarkably, the rate of ATP hydrolysis of the wild type NBD is determined by the rate of NBD dimerization. In the E599Q-NBD, however, in which the ATP hydrolysis is 250-fold reduced, the ATP hydrolysis reaction controls dimer dissociation and the overall ATPase cycle. These data explain contradicting observations on the rate-limiting step of various ABC proteins and further demonstrate that dimer formation is an important step in the ATP hydrolysis cycle.	Univ Frankfurt, Bioctr, Inst Biochem, D-60439 Frankfurt, Germany	Goethe University Frankfurt	Tampe, R (corresponding author), Univ Frankfurt, Bioctr, Inst Biochem, Maie Curie Str 9, D-60439 Frankfurt, Germany.	tampe@em.uni-frankfurt.de	Tampé, Robert/H-2953-2015	Tampé, Robert/0000-0002-0403-2160				Arnold I, 2002, BBA-MOL CELL RES, V1592, P89, DOI 10.1016/S0167-4889(02)00267-7; Baykov AA, 1996, EUR J BIOCHEM, V236, P121, DOI 10.1111/j.1432-1033.1996.00121.x; Chen J, 2003, MOL CELL, V12, P651, DOI 10.1016/j.molcel.2003.08.004; COLE PA, 1994, J BIOL CHEM, V269, P30880; Davidson AL, 2004, ANNU REV BIOCHEM, V73, P241, DOI 10.1146/annurev.biochem.73.011303.073626; Fedosova NU, 2003, BIOCHEMISTRY-US, V42, P3536, DOI 10.1021/bi0268302; Gorbulev S, 2001, P NATL ACAD SCI USA, V98, P3732, DOI 10.1073/pnas.061467898; HIGGINS CF, 1992, ANNU REV CELL BIOL, V8, P67, DOI 10.1146/annurev.cb.08.110192.000435; Hopfner KP, 2000, CELL, V101, P789, DOI 10.1016/S0092-8674(00)80890-9; Janas E, 2003, J BIOL CHEM, V278, P26862, DOI 10.1074/jbc.M301227200; Lata S, 2005, J AM CHEM SOC, V127, P10205, DOI 10.1021/ja050690c; Liu PQ, 1998, P NATL ACAD SCI USA, V95, P3495, DOI 10.1073/pnas.95.7.3495; Liu RH, 1996, BIOCHEMISTRY-US, V35, P11865, DOI 10.1021/bi960823u; Lobau S, 1998, BIOCHEMISTRY-US, V37, P10846, DOI 10.1021/bi9807153; Locher KP, 2002, SCIENCE, V296, P1091, DOI 10.1126/science.1071142; Martin SF, 1999, BIOCHEMISTRY-US, V38, P4403, DOI 10.1021/bi9821216; Moody JE, 2002, J BIOL CHEM, V277, P21111, DOI 10.1074/jbc.C200228200; Nikaido K, 1997, J BIOL CHEM, V272, P27745, DOI 10.1074/jbc.272.44.27745; Qu Q, 2003, BIOCHEMISTRY-US, V42, P1170, DOI 10.1021/bi026555j; Rai V, 2005, BIOCHEMISTRY-US, V44, P6650, DOI 10.1021/bi0474160; Sankaran B, 1997, BIOCHEMISTRY-US, V36, P6847, DOI 10.1021/bi970034s; Schmitt L, 2002, CURR OPIN STRUC BIOL, V12, P754, DOI 10.1016/S0959-440X(02)00399-8; SCHNEIDER E, 1994, J BIOL CHEM, V269, P20456; Senior AE, 1995, FEBS LETT, V377, P285, DOI 10.1016/0014-5793(95)01345-8; Senior AE, 1997, SEMIN CANCER BIOL, V8, P143, DOI 10.1006/scbi.1997.0065; Sharma S, 2000, J BACTERIOL, V182, P6570, DOI 10.1128/JB.182.23.6570-6576.2000; Smith PC, 2002, MOL CELL, V10, P139, DOI 10.1016/S1097-2765(02)00576-2; URBATSCH IL, 1995, J BIOL CHEM, V270, P19383, DOI 10.1074/jbc.270.33.19383; van der Does C, 2004, BIOL CHEM, V385, P927, DOI 10.1515/BC.2004.121; Ye JQ, 2004, BBA-BIOENERGETICS, V1659, P1, DOI 10.1016/j.bbabio.2004.06.003; Young L, 2001, SCIENCE, V291, P2135, DOI 10.1126/science.1056957; Zaitseva J, 2005, EMBO J, V24, P1901, DOI 10.1038/sj.emboj.7600657	32	25	25	2	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 3	2006	281	9					5694	5701		10.1074/jbc.M511730200	http://dx.doi.org/10.1074/jbc.M511730200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	015RQ	16352609	hybrid			2022-12-25	WOS:000235568900046
J	De Smet, L; Savvides, SN; Van Horen, E; Pettigrew, G; Van Beeumen, JJ				De Smet, L; Savvides, SN; Van Horen, E; Pettigrew, G; Van Beeumen, JJ			Structural and mutagenesis studies on the cytochrome c peroxidase from Rhodobacter capsulatus provide new insights into structure-function relationships of bacterial di-heme peroxidases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PARACOCCUS-DENITRIFICANS; PSEUDOMONAS-AERUGINOSA; CRYSTAL-STRUCTURE; CHLOROPEROXIDASE; PURIFICATION; MECHANISM; BINDING; KINETICS; REDOX; NMR	Cytochrome c peroxidases (CCP) play a key role in cellular detoxification by catalyzing the reduction of hydrogen peroxide to water. The di-heme CCP from Rhodobacter capsulatus is the fastest enzyme (1060 s(-1)), when tested with its physiological cytochrome c substrate, among all di-heme CCPs characterized to date and has, therefore, been an attractive target to investigate structure-function relationships for this family of enzymes. Here, we combine for the first time structural studies with site-directed mutagenesis and spectroscopic studies of the mutant enzymes to investigate the roles of amino acid residues that have previously been suggested to be important for activity. The crystal structure of R. capsulatus at 2.7 angstrom in the fully oxidized state confirms the overall molecular scaffold seen in other di-heme CCPs but further reveals that a segment of about 10 amino acids near the peroxide binding site is disordered in all four molecules in the asymmetric unit of the crystal. Structural and sequence comparisons with other structurally characterized CCPs suggest that flexibility in this part of the molecular scaffold is an inherent molecular property of the R. capsulatus CCP and of CCPs in general and that it correlates with the levels of activity seen in CCPs characterized, thus, far. Mutagenesis studies support the spin switch model and the roles that Met-118, Glu-117, and Trp-97 play in this model. Our results help to clarify a number of aspects of the debate on structure-function relationships in this family of bacterial CCPs and set the stage for future studies.	Univ Ghent, Lab Prot Biochem & Prot Engn, Dept Biochem Physiol & Microbiol, B-9000 Ghent, Belgium; Univ Edinburgh, Royal Dick Sch Vet Studies, Dept Preclin Vet Sci, Edinburgh EH9 1QH, Midlothian, Scotland	Ghent University; University of Edinburgh	Van Beeumen, JJ (corresponding author), Univ Ghent, Lab Prot Biochem & Prot Engn, Dept Biochem Physiol & Microbiol, Ledeganckstr 35, B-9000 Ghent, Belgium.	jozef.vanbeeumen@ugent.be	Savvides, Savvas/E-1938-2011; De Smet, Lina/A-7354-2013	Savvides, Savvas/0000-0003-3420-5947; 				Alves T, 1999, BBA-PROTEIN STRUCT M, V1434, P248, DOI 10.1016/S0167-4838(99)00188-0; ARCIERO DM, 1994, J BIOL CHEM, V269, P11878; BLACKMORE R, 1986, BIOCHEM J, V233, P547, DOI 10.1042/bj2330547; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Bruns CM, 1999, J MOL BIOL, V288, P427, DOI 10.1006/jmbi.1999.2697; De Smet L, 2002, ACTA CRYSTALLOGR D, V58, P522, DOI 10.1107/S0907444901021710; De Smet L, 2001, EUR J BIOCHEM, V268, P6559, DOI 10.1046/j.0014-2956.2001.02610.x; Dias JM, 2004, STRUCTURE, V12, P961, DOI 10.1016/j.str.2004.03.025; ELLFOLK N, 1991, BIOCHIM BIOPHYS ACTA, V1080, P68, DOI 10.1016/0167-4838(91)90113-E; ELLFOLK N, 1983, BIOCHIM BIOPHYS ACTA, V743, P23, DOI 10.1016/0167-4838(83)90413-2; ELLFOLK N, 1984, BIOCHIM BIOPHYS ACTA, V784, P62, DOI 10.1016/0167-4838(84)90173-0; FOOTE N, 1984, BIOCHEM J, V223, P369, DOI 10.1042/bj2230369; FOOTE N, 1985, BIOCHEM J, V230, P227, DOI 10.1042/bj2300227; FOOTE N, 1992, BIOCHEM J, V283, P839, DOI 10.1042/bj2830839; FOOTE N, 1983, BIOCHEM J, V209, P701, DOI 10.1042/bj2090701; FULOP V, 1995, STRUCTURE, V3, P1225, DOI 10.1016/S0969-2126(01)00258-1; GILMOUR R, 1994, BIOCHEM J, V300, P907, DOI 10.1042/bj3000907; GILMOUR R, 1993, BIOCHEM J, V294, P745, DOI 10.1042/bj2940745; GOODHEW CF, 1990, BIOCHEM J, V271, P707, DOI 10.1042/bj2710707; HANLON SP, 1992, FEMS MICROBIOL LETT, V97, P283, DOI 10.1111/j.1574-6968.1992.tb05476.x; Hu W, 1998, EUR J BIOCHEM, V258, P29, DOI 10.1046/j.1432-1327.1998.2580029.x; Hu W, 1997, BIOCHEMISTRY-US, V36, P7958, DOI 10.1021/bi963131e; Koh M, 2003, ARCH BIOCHEM BIOPHYS, V410, P230, DOI 10.1016/S0003-9861(02)00694-X; Lopes H, 1998, J BIOL INORG CHEM, V3, P632, DOI 10.1007/s007750050277; Lovell SC, 2003, PROTEINS, V50, P437, DOI 10.1002/prot.10286; McGinnity DF, 1996, J BIOL CHEM, V271, P11126, DOI 10.1074/jbc.271.19.11126; Page CC, 2003, CURR OPIN CHEM BIOL, V7, P551, DOI 10.1016/j.cbpa.2003.08.005; PETTIGREW GW, 1991, BIOCHIM BIOPHYS ACTA, V1058, P25, DOI 10.1016/S0005-2728(05)80261-0; PETTIGREW GW, 1990, CYTOCHROMES C BIOL A; Pinakoulaki E, 2003, J BIOL CHEM, V278, P18761, DOI 10.1074/jbc.M211925200; PRAZERES S, 1995, J BIOL CHEM, V270, P24264, DOI 10.1074/jbc.270.41.24264; RONNBERG M, 1979, BIOCHIM BIOPHYS ACTA, V581, P325, DOI 10.1016/0005-2795(79)90252-6; Samyn B, 1995, FEBS LETT, V377, P145, DOI 10.1016/0014-5793(95)01326-1; Shimizu H, 2001, BIOCHEMISTRY-US, V40, P13483, DOI 10.1021/bi011481h; Sundaramoorthy M, 1995, STRUCTURE, V3, P1367, DOI 10.1016/S0969-2126(01)00274-X; Sundaramoorthy M, 1998, CHEM BIOL, V5, P461, DOI 10.1016/S1074-5521(98)90003-5; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; VILLALAIN J, 1984, EUR J BIOCHEM, V141, P305, DOI 10.1111/j.1432-1033.1984.tb08192.x; Wagenknecht HA, 1997, CHEM BIOL, V4, P367, DOI 10.1016/S1074-5521(97)90127-7	39	36	36	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 17	2006	281	7					4371	4379		10.1074/jbc.M509582200	http://dx.doi.org/10.1074/jbc.M509582200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	011NN	16314410	hybrid			2022-12-25	WOS:000235275300073
J	Kobayashi, M; Figaroa, F; Meeuwenoord, N; Jansen, LET; Siegal, G				Kobayashi, M; Figaroa, F; Meeuwenoord, N; Jansen, LET; Siegal, G			Characterization of the DNA binding and structural properties of the BRCT region of human replication factor C p140 subunit	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CRYSTAL-STRUCTURE; LIGASE-III; SECONDARY STRUCTURE; ESCHERICHIA-COLI; TUMOR-SUPPRESSOR; DOMAIN; RECOGNITION; PROTEINS; PHOSPHOPEPTIDE; CANCER	BRCT domains, present in a large number of proteins that are involved in cell cycle regulation and/or DNA replication or repair, are primarily thought to be involved in protein-protein interactions. The large (p140) subunit of replication factor C contains a sequence of similar to 100 amino acids in the N-terminal region that binds DNA and is distantly related to known BRCT domains. Here we show that residues 375-480, which include 28 amino acids N-terminal to the BRCT domain, are required for 5'-phosphorylated double-stranded DNA binding. NMR chemical shift analysis indicated that the N-terminal extension includes an alpha-helix and confirmed the presence of a conserved BRCT domain. Sequence alignment of the BRCT region in the p140 subunit of replication factor C from various eukaryotes has identified very few absolutely conserved amino acid residues within the core BRCT domain, whereas none were found in sequences immediately N-terminal to the BRCT domain. However, mapping of the limited number of conserved, surface-exposed residues that were found onto a homology model of the BRCT domain, revealed a clustering on one side of the molecular surface. The cluster, as well as a number of amino acids in the N-terminal alpha-helix, were mutagenized to determine the importance for DNA binding. To ensure minimal structural changes because of the introduced mutations, proteins were checked using one-dimensional H-1 NMR and CD spectroscopy. Mutation of weakly conserved residues on one face of the N-terminal alpha-helix and of residues within the cluster disrupted DNA binding, suggesting a likely binding interface on the protein.	Leiden Univ, Leiden Inst Chem, NL-2300 RA Leiden, Netherlands	Leiden University; Leiden University - Excl LUMC	Siegal, G (corresponding author), Leiden Univ, Leiden Inst Chem, Postbus 9502, NL-2300 RA Leiden, Netherlands.	g.siegal@chem.leidenuniv.nl		Jansen, Lars/0000-0002-2158-0345; Siegal, Gregg/0000-0003-3806-4811				Allen BL, 1998, NUCLEIC ACIDS RES, V26, P3877, DOI 10.1093/nar/26.17.3877; ANDRADE MA, 1993, PROTEIN ENG, V6, P383, DOI 10.1093/protein/6.4.383; Bates PA, 2001, PROTEINS, P39; Bork P, 1997, FASEB J, V11, P68, DOI 10.1096/fasebj.11.1.9034168; Bowman GD, 2004, NATURE, V429, P724, DOI 10.1038/nature02585; BURBELO PD, 1993, P NATL ACAD SCI USA, V90, P11543, DOI 10.1073/pnas.90.24.11543; Callebaut I, 1997, FEBS LETT, V400, P25, DOI 10.1016/S0014-5793(96)01312-9; Clapperton JA, 2004, NAT STRUCT MOL BIOL, V11, P512, DOI 10.1038/nsmb775; Derbyshire DJ, 2002, EMBO J, V21, P3863, DOI 10.1093/emboj/cdf383; Dulic A, 2001, BIOCHEMISTRY-US, V40, P5906, DOI 10.1021/bi002701e; Dyson HJ, 2002, CURR OPIN STRUC BIOL, V12, P54, DOI 10.1016/S0959-440X(02)00289-0; Ekblad CMS, 2002, J MOL BIOL, V320, P431, DOI 10.1016/S0022-2836(02)00478-3; Feng H, 2004, BIOCHEMISTRY-US, V43, P12648, DOI 10.1021/bi049451c; Fotedar R, 1996, EMBO J, V15, P4423, DOI 10.1002/j.1460-2075.1996.tb00815.x; Gomes XV, 2000, J BIOL CHEM, V275, P14541, DOI 10.1074/jbc.275.19.14541; HORTON RM, 1990, BIOTECHNIQUES, V8, P528; Joo WS, 2002, GENE DEV, V16, P583, DOI 10.1101/gad.959202; Kalodimos CG, 2004, SCIENCE, V305, P386, DOI 10.1126/science.1097064; Karsten R., 1997, BIF FUTURA, V12, P20; Kobayashi M, 2005, J BIOMOL NMR, V31, P183, DOI 10.1007/s10858-004-7913-5; Krishnan VV, 2001, BIOCHEMISTRY-US, V40, P13158, DOI 10.1021/bi010979g; Lee JY, 2000, EMBO J, V19, P1119, DOI 10.1093/emboj/19.5.1119; Liu K, 2003, MOL CELL BIOL, V23, P3287, DOI 10.1128/MCB.23.9.3287-3304.2003; LIVINGSTONE CD, 1993, COMPUT APPL BIOSCI, V9, P745; Ma YM, 2004, MOL CELL, V16, P701, DOI 10.1016/j.molcel.2004.11.017; Manke IA, 2003, SCIENCE, V302, P636, DOI 10.1126/science.1088877; Masson M, 1998, MOL CELL BIOL, V18, P3563, DOI 10.1128/MCB.18.6.3563; McGuffin LJ, 2000, BIOINFORMATICS, V16, P404, DOI 10.1093/bioinformatics/16.4.404; Mossi R, 1998, EUR J BIOCHEM, V254, P209, DOI 10.1046/j.1432-1327.1998.254209.x; Nash RA, 1997, BIOCHEMISTRY-US, V36, P5207, DOI 10.1021/bi962281m; Reynolds N, 1999, NUCLEIC ACIDS RES, V27, P462, DOI 10.1093/nar/27.2.462; Shiozaki EN, 2004, MOL CELL, V14, P405, DOI 10.1016/S1097-2765(04)00238-2; Soulier J, 1999, CURR BIOL, V9, P551, DOI 10.1016/S0960-9822(99)80242-5; TSURIMOTO T, 1991, J BIOL CHEM, V266, P1950; Uhlmann F, 1997, J BIOL CHEM, V272, P10058; Waga S, 1998, ANNU REV BIOCHEM, V67, P721, DOI 10.1146/annurev.biochem.67.1.721; Wilkinson A, 2005, BBA-PROTEINS PROTEOM, V1749, P113, DOI 10.1016/j.bbapap.2005.03.003; Williams RS, 2004, NAT STRUCT MOL BIOL, V11, P519, DOI 10.1038/nsmb776; Williams RS, 2001, NAT STRUCT BIOL, V8, P838, DOI 10.1038/nsb1001-838; WISHART DS, 1994, J BIOMOL NMR, V4, P171; Wuthrich K., 1986, NMR PROTEINS NUCL AC, P1; Yamane K, 1999, ONCOGENE, V18, P5194, DOI 10.1038/sj.onc.1202922; Yu XC, 2003, SCIENCE, V302, P639, DOI 10.1126/science.1088753; Zhang XD, 1998, EMBO J, V17, P6404, DOI 10.1093/emboj/17.21.6404	44	25	25	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 17	2006	281	7					4308	4317		10.1074/jbc.M511090200	http://dx.doi.org/10.1074/jbc.M511090200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	011NN	16361700	hybrid, Green Published			2022-12-25	WOS:000235275300065
J	Venkatesan, RN; Hsu, JJ; Lawrence, NA; Preston, BD; Loeb, LA				Venkatesan, RN; Hsu, JJ; Lawrence, NA; Preston, BD; Loeb, LA			Mutator phenotypes caused by substitution at a conserved motif A residue in eukaryotic DNA polymerase delta	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL NUCLEAR ANTIGEN; ACTIVE-SITE; SACCHAROMYCES-CEREVISIAE; IN-VIVO; REPLICATION FIDELITY; KLENOW FRAGMENT; MISMATCH REPAIR; BUDDING YEAST; AMINO-ACID; ALPHA	Eukaryotic DNA polymerase (Pol) delta replicates chromosomal DNA and is also involved in DNA repair and genetic recombination. Motif A in Pol delta, containing the sequence DXXXLYPSI, includes a catalytically essential aspartic acid as well as other conserved residues of unknown function. Here, we used site-directed mutagenesis to create all 19 amino acid substitutions for the conserved Leu(612) in Motif A of Saccharomyces cerevisiae Pol delta. We show that substitutions at Leu612 differentially affect viability, sensitivity to genotoxic agents, cell cycle progression, and replication fidelity. The eight viable mutants contained Ile, Val, Thr, Met, Phe, Lys, Asn, or Gly substitutions. Individual substitutions varied greatly in the nature and extent of attendant phenotypic deficiencies, exhibiting mutation rates that ranged from near wild type to a 37-fold increase. The L612M mutant exhibited a 7-fold elevation of mutation rate but essentially no detectable effects on other phenotypes monitored; the L612T mutant showed a nearly wild type mutation rate together with marked hypersensitivity to genotoxic agents; and the L612G and L612N strains exhibited relatively high mutation rates and severe deficits overall. We compare our results with those for homologous substitutions in prokaryotic and eukaryotic DNA polymerases and discuss the implications of our findings for the role of Leu612 in replication fidelity.	Univ Washington, Dept Pathol, Seattle, WA 98195 USA	University of Washington; University of Washington Seattle	Loeb, LA (corresponding author), Univ Washington, Dept Pathol, Seattle, WA 98195 USA.	laloeb@u.washington.edu			NCI NIH HHS [R01 CA102029, R01 CA98243, R01 CA098243] Funding Source: Medline; NIA NIH HHS [P01 AG01751, P01 AG001751] Funding Source: Medline; NIEHS NIH HHS [R01 ES 09927] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA098243, R01CA102029] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES009927] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [P01AG001751] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		ARAKI H, 1992, EMBO J, V11, P733, DOI 10.1002/j.1460-2075.1992.tb05106.x; Astatke M, 1998, P NATL ACAD SCI USA, V95, P3402, DOI 10.1073/pnas.95.7.3402; Bell SP, 2002, ANNU REV BIOCHEM, V71, P333, DOI 10.1146/annurev.biochem.71.110601.135425; BLANK A, 1994, P NATL ACAD SCI USA, V91, P9047, DOI 10.1073/pnas.91.19.9047; Burgers PMJ, 2001, J BIOL CHEM, V276, P43487, DOI 10.1074/jbc.R100056200; Burke D., 2000, METHODS YEAST GENETI; CARIELLO NF, 1994, CARCINOGENESIS, V15, P2281, DOI 10.1093/carcin/15.10.2281; Datta A, 2000, MOL CELL, V6, P593, DOI 10.1016/S1097-2765(00)00058-7; DONG Q, 1993, J BIOL CHEM, V268, P24163; DONG Q, 1993, J BIOL CHEM, V268, P24175; Franklin MC, 2001, CELL, V105, P657, DOI 10.1016/S0092-8674(01)00367-1; Gardner R, 1999, EMBO J, V18, P3173, DOI 10.1093/emboj/18.11.3173; Goldsby RE, 2002, P NATL ACAD SCI USA, V99, P15560, DOI 10.1073/pnas.232340999; Goldsby RE, 2001, NAT MED, V7, P638, DOI 10.1038/88963; Hashimoto K, 2003, BIOCHEMISTRY-US, V42, P14207, DOI 10.1021/bi0348359; Hubscher U, 2002, ANNU REV BIOCHEM, V71, P133, DOI 10.1146/annurev.biochem.71.090501.150041; JOYCE CM, 1995, J BACTERIOL, V177, P6321, DOI 10.1128/jb.177.22.6321-6329.1995; Kokoska RJ, 2000, MOL CELL BIOL, V20, P7490, DOI 10.1128/MCB.20.20.7490-7504.2000; Kool ET, 2001, ANNU REV BIOPH BIOM, V30, P1, DOI 10.1146/annurev.biophys.30.1.1; Kunkel TA, 2000, ANNU REV BIOCHEM, V69, P497, DOI 10.1146/annurev.biochem.69.1.497; LEA DE, 1948, J GENET, V49, P248; LEE SH, 1991, J BIOL CHEM, V266, P22707; Li L, 2005, GENETICS, V170, P569, DOI 10.1534/genetics.104.040295; Lopes M, 2001, NATURE, V412, P557, DOI 10.1038/35087613; Minnick DT, 1999, J BIOL CHEM, V274, P3067, DOI 10.1074/jbc.274.5.3067; MORRISON A, 1994, MOL GEN GENET, V242, P289, DOI 10.1007/BF00280418; MORRISON A, 1993, EMBO J, V12, P1467, DOI 10.1002/j.1460-2075.1993.tb05790.x; Niimi A, 2004, MOL CELL BIOL, V24, P2734, DOI 10.1128/MCB.24.7.2734-2746.2004; Patel PH, 2000, P NATL ACAD SCI USA, V97, P5095, DOI 10.1073/pnas.97.10.5095; Patel PH, 2001, J BIOL CHEM, V276, P5044, DOI 10.1074/jbc.M008701200; Patel PH, 2000, J BIOL CHEM, V275, P40266, DOI 10.1074/jbc.M005757200; Pavlov YI, 2001, GENETICS, V159, P47; PERRINO FW, 1989, J BIOL CHEM, V264, P2898; PODUST V, 1992, CHROMOSOMA, V102, pS133, DOI 10.1007/BF02451797; POLESKY AH, 1990, J BIOL CHEM, V265, P14579; PRELICH G, 1987, NATURE, V326, P517, DOI 10.1038/326517a0; RehaKrantz LJ, 1995, METHOD ENZYMOL, V262, P323; REHAKRANTZ LJ, 1994, J BIOL CHEM, V269, P5635; ROSENKRANZ HS, 1965, BIOCHIM BIOPHYS ACTA, V95, P181, DOI 10.1016/0005-2787(65)90225-X; Sambrook J, 2001, MOL CLONING LAB MANU; SCHAAPER RM, 1993, J BIOL CHEM, V268, P23762; Shcherbakova PV, 2003, J BIOL CHEM, V278, P43770, DOI 10.1074/jbc.M306893200; Shimizu K, 2002, J BIOL CHEM, V277, P37422, DOI 10.1074/jbc.M204476200; Shinkai A, 2001, J BIOL CHEM, V276, P46759, DOI 10.1074/jbc.M104780200; Shinkai A, 2001, J BIOL CHEM, V276, P18836, DOI 10.1074/jbc.M011472200; SIMON M, 1991, EMBO J, V10, P2165, DOI 10.1002/j.1460-2075.1991.tb07751.x; Singer B., 1983, MOL BIOL MUTAGENS CA; Steitz TA, 1998, NATURE, V391, P231, DOI 10.1038/34542; Suzuki M, 1996, P NATL ACAD SCI USA, V93, P9670, DOI 10.1073/pnas.93.18.9670; Suzuki M, 1997, J BIOL CHEM, V272, P11228; Tercero JA, 2003, MOL CELL, V11, P1323, DOI 10.1016/S1097-2765(03)00169-2; Tercero JA, 2001, NATURE, V412, P553, DOI 10.1038/35087607; Tran HT, 1997, MOL CELL BIOL, V17, P2859, DOI 10.1128/MCB.17.5.2859; Wang J, 1997, CELL, V89, P1087, DOI 10.1016/S0092-8674(00)80296-2; WEINERT TA, 1994, GENE DEV, V8, P652, DOI 10.1101/gad.8.6.652; ZHOU Z, 1992, GENETICS, V131, P851	56	61	63	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 17	2006	281	7					4486	4494		10.1074/jbc.M510245200	http://dx.doi.org/10.1074/jbc.M510245200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	011NN	16344551	hybrid			2022-12-25	WOS:000235275300084
J	Gengenbacher, M; Fitzpatrick, TB; Raschle, T; Flicker, K; Sinning, I; Muller, S; Macheroux, P; Tews, I; Kappes, B				Gengenbacher, M; Fitzpatrick, TB; Raschle, T; Flicker, K; Sinning, I; Muller, S; Macheroux, P; Tews, I; Kappes, B			Vitamin B6 biosynthesis by the malaria parasite Plasmodium falciparum - Biochemical and structural insights	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CARBAMOYL-PHOSPHATE SYNTHETASE; BACILLUS-SUBTILIS; CRYSTAL-STRUCTURE; PYRIDOXINE SYNTHESIS; PROTEIN-KINASE; SYNTHASE; GENE; PATHWAY; LOCALIZATION; EXPRESSION	Vitamin B6 is one of nature's most versatile cofactors. Most organisms synthesize vitamin B6 via a recently discovered pathway employing the proteins Pdx1 and Pdx2. Here we present an in-depth characterization of the respective orthologs from the malaria parasite, Plasmodium falciparum. Expression profiling of Pdx1 and -2 shows that blood-stage parasites indeed possess a functional vitamin B6 de novo biosynthesis. Recombinant Pdx1 and Pdx2 form a complex that functions as a glutamine amidotransferase with Pdx2 as the glutaminase and Pdx1 as pyridoxal-5'-phosphate synthase domain. Complex formation is required for catalytic activity of either domain. Pdx1 forms a chimeric bi-enzyme with the bacterial YaaE, a Pdx2 ortholog, both in vivo and in vitro, although this chimera does not attain full catalytic activity, emphasizing that species-specific structural features govern the interaction between the protein partners of the PLP synthase complexes in different organisms. To gain insight into the activation mechanism of the parasite bi-enzyme complex, the three-dimensional structure of Pdx2 was determined at 1.62 angstrom. The obstruction of the oxyanion hole indicates that Pdx2 is in a resting state and that activation occurs upon Pdx1-Pdx2 complex formation.	Heidelberg Univ, Dept Biol Struct, Biochemiezentrum, D-69120 Heidelberg, Germany; Univ Glasgow, Inst Biomed & Life Sci, Div Infect & Immun, Glasgow G12 8QQ, Lanark, Scotland; Univ Klinikum Heidelberg, Abt Parasitol, D-69120 Heidelberg, Germany; ETH, Inst Pflanzenwissensch, CH-8092 Zurich, Switzerland; Graz Univ Technol, Inst Biochem, A-8010 Graz, Austria	Ruprecht Karls University Heidelberg; University of Glasgow; Ruprecht Karls University Heidelberg; Swiss Federal Institutes of Technology Domain; ETH Zurich; Graz University of Technology	Tews, I (corresponding author), Heidelberg Univ, Dept Biol Struct, Biochemiezentrum, Neuenheimer Feld 328, D-69120 Heidelberg, Germany.	ivo.tews@bzh.uni-heidelberg.de; barbara.kappes@urz.uni-heidelberg.de	Macheroux, Peter/AAB-5157-2019; Tews, Ivo/A-2750-2010; Gengenbacher, Martin/C-6876-2015; Sinning, Irmgard/A-2982-2010	Macheroux, Peter/0000-0002-0242-454X; Tews, Ivo/0000-0002-4704-1139; Gengenbacher, Martin/0000-0002-0208-5920; 				BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Bauer JA, 2004, J BIOL CHEM, V279, P2704, DOI 10.1074/jbc.M310311200; Bean LE, 2001, GENETICS, V157, P1067; Belitsky BR, 2004, J BACTERIOL, V186, P1191, DOI 10.1128/JB.186.4.1191-1196.2004; BENESCH RE, 1973, P NATL ACAD SCI USA, V70, P2595, DOI 10.1073/pnas.70.9.2595; Bhavsar AP, 2001, APPL ENVIRON MICROB, V67, P403, DOI 10.1128/AEM.67.1.403-410.2001; Burns KE, 2005, J AM CHEM SOC, V127, P3682, DOI 10.1021/ja042792t; Cassera MB, 2004, J BIOL CHEM, V279, P51749, DOI 10.1074/jbc.M408360200; Chaudhuri BN, 2003, BIOCHEMISTRY-US, V42, P7003, DOI 10.1021/bi034320h; Chaudhuri BN, 2001, STRUCTURE, V9, P987, DOI 10.1016/S0969-2126(01)00661-X; Chittur SV, 2000, PROTEIN EXPRES PURIF, V18, P366, DOI 10.1006/prep.2000.1207; CHULAY JD, 1983, EXP PARASITOL, V55, P138, DOI 10.1016/0014-4894(83)90007-3; DeLano W.L., 2002, PYMOL MOL GRAPHICS S; DIVO AA, 1985, J PROTOZOOL, V32, P59, DOI 10.1111/j.1550-7408.1985.tb03013.x; Dong YX, 2004, EUR J BIOCHEM, V271, P745, DOI 10.1111/j.1432-1033.2003.03973.x; Douangamath A, 2002, STRUCTURE, V10, P185, DOI 10.1016/S0969-2126(02)00702-5; Ehrenshaft M, 1999, P NATL ACAD SCI USA, V96, P9374, DOI 10.1073/pnas.96.16.9374; Ehrenshaft M, 2001, J BACTERIOL, V183, P3383, DOI 10.1128/JB.183.11.3383-3390.2001; Fitzpatrick T, 2001, MOL MICROBIOL, V40, P65, DOI 10.1046/j.1365-2958.2001.02366.x; Graeser R, 1996, MOL BIOCHEM PARASIT, V82, P37, DOI 10.1016/0166-6851(96)02716-8; INK SL, 1984, ANNU REV NUTR, V4, P455, DOI 10.1146/annurev.nu.04.070184.002323; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Kirk K, 2001, PHYSIOL REV, V81, P495, DOI 10.1152/physrev.2001.81.2.495; Kissinger JC, 2001, NUCLEIC ACIDS RES, V29, P66; Korolev S, 2002, PROTEINS, V49, P420, DOI 10.1002/prot.10161; KYHSEANDERSEN J, 1984, J BIOCHEM BIOPH METH, V10, P203, DOI 10.1016/0165-022X(84)90040-X; McConkey GA, 2004, TRENDS PARASITOL, V20, P60, DOI 10.1016/j.pt.2003.11.001; Miles BW, 2002, J BIOL CHEM, V277, P4368, DOI 10.1074/jbc.M108582200; Mittenhuber G, 2001, J MOL MICROB BIOTECH, V3, P1; Mohrle JJ, 1997, BIOCHEM J, V328, P677; Murshudov GN, 1997, ACTA CRYSTALLOGR D, V53, P240, DOI 10.1107/S0907444996012255; Ogasawara N, 2000, RES MICROBIOL, V151, P129, DOI 10.1016/S0923-2508(00)00118-2; OLLIS DL, 1992, PROTEIN ENG, V5, P197, DOI 10.1093/protein/5.3.197; Osmani AH, 1999, J BIOL CHEM, V274, P23565, DOI 10.1074/jbc.274.33.23565; Padilla PA, 1998, J BACTERIOL, V180, P5718, DOI 10.1128/JB.180.21.5718-5726.1998; Perrakis A, 1999, NAT STRUCT BIOL, V6, P458, DOI 10.1038/8263; Raschle T, 2005, J BIOL CHEM, V280, P32291, DOI 10.1074/jbc.M501356200; Raushel FM, 1998, CURR OPIN CHEM BIOL, V2, P624, DOI 10.1016/S1367-5931(98)80094-X; Roberts F, 1998, NATURE, V393, P801, DOI 10.1038/31723; ROSSMACDONALD PB, 1994, EUR J BIOCHEM, V220, P693, DOI 10.1111/j.1432-1033.1994.tb18670.x; Sakai A, 2002, J BIOSCI BIOENG, V93, P309, DOI 10.1263/jbb.93.309; Sakai A, 2002, J BIOSCI BIOENG, V93, P334, DOI 10.1263/jbb.93.334; Stolz J, 2005, EUKARYOT CELL, V4, P319, DOI 10.1128/EC.4.2.319-326.2005; Stolz J, 2003, J BIOL CHEM, V278, P18990, DOI 10.1074/jbc.M300949200; SUETTERLIN BW, 1991, MOL BIOCHEM PARASIT, V46, P113, DOI 10.1016/0166-6851(91)90205-K; Tesmer JG, 1996, NAT STRUCT BIOL, V3, P74, DOI 10.1038/nsb0196-74; Thoden JB, 1998, BIOCHEMISTRY-US, V37, P8825, DOI 10.1021/bi9807761; Thoden JB, 1997, BIOCHEMISTRY-US, V36, P6305, DOI 10.1021/bi970503q; TRAGER W, 1976, SCIENCE, V193, P673, DOI 10.1126/science.781840; Wrenger C, 2005, J BIOL CHEM, V280, P5242, DOI 10.1074/jbc.M412475200; Wrenger C, 2004, MOL MICROBIOL, V53, P103, DOI 10.1111/j.1365-2958.2004.04112.x; Zalkin H, 1998, ADV ENZYMOL RAMB, V72, P87; Zhu JH, 2005, J BIOL CHEM, V280, P27914, DOI 10.1074/jbc.M503642200	53	71	74	1	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 10	2006	281	6					3633	3641		10.1074/jbc.M508696200	http://dx.doi.org/10.1074/jbc.M508696200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	009QV	16339145	hybrid, Green Published			2022-12-25	WOS:000235128200075
J	Leliveld, SR; Dame, RT; Wuite, GJL; Stitz, L; Korth, C				Leliveld, SR; Dame, RT; Wuite, GJL; Stitz, L; Korth, C			The expanded octarepeat domain selectively binds prions and disrupts homomeric prion protein interactions	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CREUTZFELDT-JAKOB-DISEASE; PRP KNOCKOUT MICE; MONOCLONAL-ANTIBODY; FULL-LENGTH; IN-VITRO; SCRAPIE; GENE; REPEATS; ENCEPHALOPATHY; SUSCEPTIBILITY	Insertion of additional octarepeats into the prion protein gene has been genetically linked to familial Creutzfeldt Jakob disease and hence to de novo generation of infectious prions. The pivotal event during prion formation is the conversion of the normal prion protein (PrPC) into the pathogenic conformer PrPSc, which subsequently induces further conversion in an autocatalytic manner. Apparently, an expanded octarepeat domain directs folding of PrP toward the PrPSc conformation and initiates a self-replicating conversion process. Here, based on three main observations, we have provided a model on how altered molecular interactions between wild-type and mutant PrP set the stage for familial Creutzfeldt Jakob disease with octarepeat insertions. First, we showed that wildtype octarepeat domains interact in a copper-dependent and reversible manner, a "copper switch." This interaction becomes irreversible upon domain expansion, possibly reflecting a loss of function. Second, expanded octarepeat domains of increasing length gradually form homogenous globular multimers of 11-21 nm in the absence of copper ions when expressed as soluble glutathione S-transferase fusion proteins. Third, octarepeat domain expansion causes a gain of function with at least 10 repeats selectively binding PrPSc in a denaturant-resistant complex in the absence of copper ions. Thus, the combination of both a loss and gain of function profoundly influences homomeric interaction behavior of PrP with an expanded octarepeat domain. A multimeric cluster of prion proteins carrying expanded octarepeat domains may therefore capture and incorporate spontaneously arising short-lived PrPSc-like conformers, thereby providing a matrix for their conversion.	Univ Dusseldorf, Inst Neuropathol, D-40225 Dusseldorf, Germany; Vrije Univ Amsterdam, Fac Exact Sci, Dept Phys & Astron, NL-1081 HV Amsterdam, Netherlands; Friedrich Loeffler Inst, Inst Immunol, D-72076 Tubingen, Germany	Heinrich Heine University Dusseldorf; Vrije Universiteit Amsterdam; Friedrich Loeffler Institute	Korth, C (corresponding author), Univ Dusseldorf, Inst Neuropathol, D-40225 Dusseldorf, Germany.	ckorth@uni-duesseldorf.de	Dame, Remus T./E-1941-2014; Dame, Remus/A-8570-2008; Dame, Remus/AAT-2989-2020; Korth, Carsten/F-7433-2010	Dame, Remus T./0000-0001-9863-1692; Dame, Remus/0000-0001-9863-1692; wuite, gijs/0000-0002-5706-043X				BROWN P, 1994, ANN NEUROL, V35, P513, DOI 10.1002/ana.410350504; Burns CS, 2003, BIOCHEMISTRY-US, V42, P6794, DOI 10.1021/bi027138+; BUTLER DA, 1988, J VIROL, V62, P1558, DOI 10.1128/JVI.62.5.1558-1564.1988; Campbell TA, 1996, NEUROLOGY, V46, P761, DOI 10.1212/WNL.46.3.761; Castilla J, 2005, CELL, V121, P195, DOI 10.1016/j.cell.2005.02.011; CHANDLER RL, 1961, LANCET, V1, P1378; Chen SG, 1997, NAT MED, V3, P1009, DOI 10.1038/nm0997-1009; Chiesa R, 2003, J VIROL, V77, P7611, DOI 10.1128/JVI.77.13.7611-7622.2003; COLLINGE J, 1992, BRAIN, V115, P687, DOI 10.1093/brain/115.3.687; Croes EA, 2004, J NEUROL NEUROSUR PS, V75, P1166, DOI 10.1136/jnnp.2003.020198; Donne DG, 1997, P NATL ACAD SCI USA, V94, P13452, DOI 10.1073/pnas.94.25.13452; Fischer M, 1996, EMBO J, V15, P1255, DOI 10.1002/j.1460-2075.1996.tb00467.x; Flechsig E, 2000, NEURON, V27, P399, DOI 10.1016/S0896-6273(00)00046-5; GOLDFARB LG, 1991, P NATL ACAD SCI USA, V88, P10926, DOI 10.1073/pnas.88.23.10926; KASCSAK RJ, 1987, J VIROL, V61, P3688, DOI 10.1128/JVI.61.12.3688-3693.1987; KONG Q, 2004, PRION BIOL DIS, V41, P673; Korth C, 1997, NATURE, V390, P74, DOI 10.1038/36337; Korth C, 1999, METHOD ENZYMOL, V309, P106; Legname G, 2004, SCIENCE, V305, P673, DOI 10.1126/science.1100195; Leliveld SR, 2003, NUCLEIC ACIDS RES, V31, P4805, DOI 10.1093/nar/gkg661; Liemann S, 1999, BIOCHEMISTRY-US, V38, P3258, DOI 10.1021/bi982714g; Liu JJ, 1999, NATURE, V400, P573, DOI 10.1038/23048; MASTERS CL, 1981, BRAIN, V104, P535, DOI 10.1093/brain/104.3.535; MCKINLEY MP, 1983, CELL, V35, P57, DOI 10.1016/0092-8674(83)90207-6; Moore RC, 2001, AM J HUM GENET, V69, P1385, DOI 10.1086/324414; OWEN F, 1989, LANCET, V1, P51; Paramithiotis E, 2003, NAT MED, V9, P893, DOI 10.1038/nm883; Parham SN, 2001, EMBO J, V20, P2111, DOI 10.1093/emboj/20.9.2111; Priola SA, 1998, J BIOL CHEM, V273, P11980, DOI 10.1074/jbc.273.19.11980; Prusiner SB, 1998, P NATL ACAD SCI USA, V95, P13363, DOI 10.1073/pnas.95.23.13363; RACE RE, 1987, J GEN VIROL, V68, P1391, DOI 10.1099/0022-1317-68-5-1391; Riek R, 1996, NATURE, V382, P180, DOI 10.1038/382180a0; Scherzinger E, 1997, CELL, V90, P549, DOI 10.1016/S0092-8674(00)80514-0; Scott Michael, 2004, VVolume 41, P435; Stockel J, 1998, BIOCHEMISTRY-US, V37, P7185, DOI 10.1021/bi972827k; Sumudhu W, 2001, CURR BIOL, V11, P519, DOI 10.1016/S0960-9822(01)00147-6; Supattapone S, 2001, J VIROL, V75, P1408, DOI 10.1128/JVI.75.3.1408-1413.2001; Supattapone S, 1999, CELL, V96, P869, DOI 10.1016/S0092-8674(00)80596-6; TELLING GC, 1995, CELL, V83, P79, DOI 10.1016/0092-8674(95)90236-8; Viles JH, 1999, P NATL ACAD SCI USA, V96, P2042, DOI 10.1073/pnas.96.5.2042; Zahn R, 2003, J MOL BIOL, V334, P477, DOI 10.1016/j.jmb.2003.09.048	41	30	31	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 10	2006	281	6					3268	3275		10.1074/jbc.M510606200	http://dx.doi.org/10.1074/jbc.M510606200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	009QV	16352600	Green Published, hybrid			2022-12-25	WOS:000235128200032
J	Um, JW; Min, DS; Rhim, H; Kim, J; Paik, SR; Chung, KC				Um, JW; Min, DS; Rhim, H; Kim, J; Paik, SR; Chung, KC			Parkin ubiquitinates and promotes the degradation of RanBP2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MEF2 TRANSCRIPTION FACTOR; HISTONE DEACETYLASES; ALPHA-SYNUCLEIN; PROTEIN LIGASE; MUSCLE DIFFERENTIATION; HDAC4 DEACETYLASE; SUBSTANTIA-NIGRA; DOPAMINE NEURONS; DOWN-REGULATION; HUMAN BRAIN	Parkinson disease (PD) is a common neurodegenerative disorder, which involves the deterioration of dopaminergic neurons in the pars compacta of the substantia nigra. The etiology of PD is still unknown, but recent identification of mutations in familial cases of PD has advanced the understanding of the molecular mechanisms of this neurological disease. Mutations in the parkin gene, which encodes for ubiquitin- protein ligase (E3), have been implicated in autosomal recessive juvenile Parkinsonism, an early onset and common familial form of PD. Here we reported that Parkin selectively binds to RanBP2, which is localized in the cytoplasmic filament of the nuclear pore complex and belongs to the small ubiquitin- related modifier E3 ligase family. We also demonstrated that RanBP2 becomes a target for Parkin E3 ubiquitin- ligase and is processed via Parkin- mediated ubiquitination and subsequent proteasomal degradation. Furthermore, Parkin controls the intracellular levels of sumoylated HDAC4, as a result of the ubiquitination and degradation of RanBP2. Our findings suggested that the intracellular levels of RanBP2 and its functional activity may be modulated by Parkin-mediated ubiquitination and proteasomal pathways.	Yonsei Univ, Coll Sci, Dept Biol, Seoul 120749, South Korea; Pusan Natl Univ, Dept Mol Biol, Coll Nat Sci, Pusan 609735, South Korea; Korea Inst Sci & Technol, Biomed Res Ctr, Seoul 136701, South Korea; Yonsei Univ, Coll Med, Dept Microbiol, Seoul 120752, South Korea; Seoul Natl Univ, Sch Chem & Biol Engn, Coll Engn, Seoul 151744, South Korea	Yonsei University; Pusan National University; Korea Institute of Science & Technology (KIST); Yonsei University; Yonsei University Health System; Seoul National University (SNU)	Chung, KC (corresponding author), Yonsei Univ, Coll Sci, Dept Biol, Shinchon Dong 134, Seoul 120749, South Korea.	kchung@yonsei.ac.kr		Kim, Jongsun/0000-0002-3149-669X				Bernad R, 2004, MOL CELL BIOL, V24, P2373, DOI 10.1128/MCB.24.6.2373-2384.2004; Bonifati V, 2003, SCIENCE, V299, P256, DOI 10.1126/science.1077209; Choi P, 2003, MOL BRAIN RES, V117, P179, DOI 10.1016/S0169-328X(03)00318-8; Chung KKK, 2001, NAT MED, V7, P1144, DOI 10.1038/nm1001-1144; Corti O, 2003, HUM MOL GENET, V12, P1427, DOI 10.1093/hmg/ddg159; Damier P, 1999, BRAIN, V122, P1437, DOI 10.1093/brain/122.8.1437; De Ruijter AJM, 2003, BIOCHEM J, V370, P737, DOI 10.1042/BJ20021321; Doss-Pepe EW, 2005, J BIOL CHEM, V280, P16619, DOI 10.1074/jbc.M413591200; Dressel U, 2001, J BIOL CHEM, V276, P17007, DOI 10.1074/jbc.M101508200; Fischle W, 1999, J BIOL CHEM, V274, P11713, DOI 10.1074/jbc.274.17.11713; Fried H, 2003, CELL MOL LIFE SCI, V60, P1659, DOI 10.1007/s00018-003-3070-3; Grozinger CM, 2002, CHEM BIOL, V9, P3, DOI 10.1016/S1074-5521(02)00092-3; Grozinger CM, 1999, P NATL ACAD SCI USA, V96, P4868, DOI 10.1073/pnas.96.9.4868; Haglund K, 2003, NAT CELL BIOL, V5, P461, DOI 10.1038/ncb983; Hershko A, 1998, ANNU REV BIOCHEM, V67, P425, DOI 10.1146/annurev.biochem.67.1.425; Hicke L, 2001, NAT REV MOL CELL BIO, V2, P195, DOI 10.1038/35056583; Hicke L, 1997, FASEB J, V11, P1215, DOI 10.1096/fasebj.11.14.9409540; Hoege C, 2002, NATURE, V419, P135, DOI 10.1038/nature00991; Imai Y, 2000, J BIOL CHEM, V275, P35661, DOI 10.1074/jbc.C000447200; Imai Y, 2001, CELL, V105, P891, DOI 10.1016/S0092-8674(01)00407-X; Jiang HB, 2004, J BIOL CHEM, V279, P54380, DOI 10.1074/jbc.M409282200; Joseph J, 2004, CURR BIOL, V14, P611, DOI 10.1016/j.cub.2004.03.031; Katzmann DJ, 2002, NAT REV MOL CELL BIO, V3, P893, DOI 10.1038/nrm973; Kim SJ, 2003, J BIOL CHEM, V278, P41890, DOI 10.1074/jbc.M306017200; Kirsh O, 2002, EMBO J, V21, P2682, DOI 10.1093/emboj/21.11.2682; Kitada T, 1998, NATURE, V392, P605, DOI 10.1038/33416; Lemercier C, 2000, J BIOL CHEM, V275, P15594, DOI 10.1074/jbc.M908437199; Lincoln S, 1999, NEUROREPORT, V10, P427, DOI 10.1097/00001756-199902050-00040; Lu JR, 2000, P NATL ACAD SCI USA, V97, P4070, DOI 10.1073/pnas.080064097; McKinsey TA, 2000, NATURE, V408, P106, DOI 10.1038/35040593; Miska EA, 1999, EMBO J, V18, P5099, DOI 10.1093/emboj/18.18.5099; Nakatsu F, 2000, J BIOL CHEM, V275, P26213, DOI 10.1074/jbc.M907720199; Naoi M, 1999, MECH AGEING DEV, V111, P175, DOI 10.1016/S0047-6374(99)00064-0; Olanow CW, 1999, ANNU REV NEUROSCI, V22, P123, DOI 10.1002/mds.23732; Paroni G, 2004, MOL BIOL CELL, V15, P2804, DOI 10.1091/mbc.E03-08-0624; Pichler A, 2002, CELL, V108, P109, DOI 10.1016/S0092-8674(01)00633-X; Polymeropoulos MH, 1997, SCIENCE, V276, P2045, DOI 10.1126/science.276.5321.2045; Ren Y, 2003, J NEUROSCI, V23, P3316; Roth AF, 2000, J BIOL CHEM, V275, P8143, DOI 10.1074/jbc.275.11.8143; Saitoh H, 2002, J BIOL CHEM, V277, P4755, DOI 10.1074/jbc.M104453200; Shih SC, 2000, EMBO J, V19, P187, DOI 10.1093/emboj/19.2.187; Shimura H, 2000, NAT GENET, V25, P302, DOI 10.1038/77060; Shimura H, 2001, SCIENCE, V293, P263, DOI 10.1126/science.1060627; Staropoli JF, 2003, NEURON, V37, P735, DOI 10.1016/S0896-6273(03)00084-9; Tsai YC, 2003, J BIOL CHEM, V278, P22044, DOI 10.1074/jbc.M212235200; Valente EM, 2004, SCIENCE, V304, P1158, DOI 10.1126/science.1096284; Verdin E, 2003, TRENDS GENET, V19, P286, DOI 10.1016/S0168-9525(03)00073-8; Wang AH, 1999, MOL CELL BIOL, V19, P7816; YAMADA T, 1990, BRAIN RES, V526, P303, DOI 10.1016/0006-8993(90)91236-A; Zhang Y, 2000, P NATL ACAD SCI USA, V97, P13354, DOI 10.1073/pnas.240347797	50	75	80	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 10	2006	281	6					3595	3603		10.1074/jbc.M504994200	http://dx.doi.org/10.1074/jbc.M504994200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	009QV	16332688	hybrid			2022-12-25	WOS:000235128200071
J	Schulz, A; Mousallem, T; Venkataramani, M; Persaud-Sawin, DA; Zucker, A; Luberto, C; Bielawska, A; Bielawski, J; Holthuis, JCM; Jazwinski, SM; Kozhaya, L; Dbaibo, GS; Boustany, RMN				Schulz, A; Mousallem, T; Venkataramani, M; Persaud-Sawin, DA; Zucker, A; Luberto, C; Bielawska, A; Bielawski, J; Holthuis, JCM; Jazwinski, SM; Kozhaya, L; Dbaibo, GS; Boustany, RMN			The CLN9 protein, a regulator of dihydroceramide synthase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NEURONAL CEROID-LIPOFUSCINOSIS; TUMOR-CELL LINES; MUTANT MICE; CERAMIDE; FENRETINIDE; MUTATIONS; FAMILY; N-(4-HYDROXYPHENYL)RETINAMIDE; IDENTIFICATION; CYTOTOXICITY	A new variant of a group of pediatric neurodegenerative diseases known as neuronal ceroid lipofuscinosis (NCL) or Batten disease has been identified. It is termed CLN9-deficient. CLN9-deficient fibroblasts have a distinctive phenotype of rapid growth and increased apoptosis and diminished levels of ceramide, dihydroceramide, and sphingomyelin. Transfection with CLN8 but not other NCL genes corrected growth and apoptosis in CLN9-deficient cells, although the entire CLN8 sequence was normal. CLN8 is one of the TRAM-Lag1-CLN8 proteins containing a Lag1 motif. The latter imparts (dihydro) ceramide synthase activity to yeast cells. Transfection with the yeast gene Lag1 Sc and the human homolog LASS1 increased ceramide levels and partially corrected growth and apoptosis in CLN9-deficient cells. LASS2, - 4,, -5, and -6 also corrected growth and apoptosis. Dihydroceramide levels and dihydroceramide synthase activity were markedly diminished in CLN9- deficient cells. Sequencing of LASS1, LASS2, LASS4, LASS5, and LASS6 genes was normal, and expression levels were increased or normal in CLN9-deficient cells by reverse transcription-PCR. N-(4-Hydroxyphenyl) retinamide (4-HPR), a dihydroceramide synthase activator, corrected growth and apoptosis and increased dihydroceramide synthase activity. Ceramide levels dropped further, and there was no increase in de novo ceramide synthesis, probably due to the effects of 4-HPR as activator of dihydroceramide synthase and inhibitor of dihydroceramide desaturase. Fumonisin B-1, a dihydroceramide synthase inhibitor, exaggerated the CLN9- deficient phenotype of accelerated growth, decreased ceramide and increased apoptosis. This was neutralized by 4-HPR. We conclude that the CLN9 protein may be a regulator of dihydroceramide synthase and that 4-HPR could be developed as a treatment for CLN9-deficient patients.	Duke Univ, Med Ctr, Dept Pediat, Durham, NC 27710 USA; Duke Univ, Med Ctr, Dept Neurobiol, Durham, NC 27710 USA; Univ Hamburg, Med Ctr, D-20246 Hamburg, Germany; Med Univ S Carolina, Dept Biochem, Charleston, SC 29425 USA; Univ Utrecht, Dept Membrane Enzymol, NL-3584 CH Utrecht, Netherlands; Louisiana State Univ, Hlth Sci Ctr, Dept Biochem & Mol Biol, New Orleans, LA 70112 USA; Amer Univ Beirut, Ctr Med, Beirut 11072020, Lebanon	Duke University; Duke University; University of Hamburg; Medical University of South Carolina; Utrecht University; Louisiana State University System; Louisiana State University Health Sciences Center New Orleans; American University of Beirut	Boustany, RMN (corresponding author), Duke Univ, Med Ctr, Dept Pediat, MSRB Box 2604, Durham, NC 27710 USA.	boust001@mc.duke.edu	Holthuis, Joost/AAL-9157-2020; Dbaibo, Ghassan S./X-2978-2019	Holthuis, Joost/0000-0001-8912-1586				ABE A, 1992, J BIOCHEM-TOKYO, V111, P191, DOI 10.1093/oxfordjournals.jbchem.a123736; Amado M, 1999, BBA-GEN SUBJECTS, V1473, P35, DOI 10.1016/S0304-4165(99)00168-3; Batra S, 2004, CANCER RES, V64, P5415, DOI 10.1158/0008-5472.CAN-04-0377; Cho S, 2001, Eur J Paediatr Neurol, V5 Suppl A, P53, DOI 10.1053/ejpn.2000.0435; Faderl S, 2003, LEUKEMIA RES, V27, P259, DOI 10.1016/S0145-2126(02)00162-5; Gao HL, 2002, AM J HUM GENET, V70, P324, DOI 10.1086/338190; Garaventa A, 2003, CLIN CANCER RES, V9, P2032; Guillas I, 2001, EMBO J, V20, P2655, DOI 10.1093/emboj/20.11.2655; Haltia M, 2003, J NEUROPATH EXP NEUR, V62, P1; Hanada K, 2003, NATURE, V426, P803, DOI 10.1038/nature02188; Hennet T, 2002, CELL MOL LIFE SCI, V59, P1081, DOI 10.1007/s00018-002-8489-4; Huitema K, 2004, EMBO J, V23, P33, DOI 10.1038/sj.emboj.7600034; Isosomppi J, 2002, HUM MOL GENET, V11, P885, DOI 10.1093/hmg/11.8.885; Jiang JC, 1998, GENOME RES, V8, P1259, DOI 10.1101/gr.8.12.1259; Koybasi S, 2004, J BIOL CHEM, V279, P44311, DOI 10.1074/jbc.M406920200; KRESSE H, 1987, AM J HUM GENET, V41, P436; Lane SC, 1996, J NEUROCHEM, V67, P677; Lee JY, 1996, J BIOL CHEM, V271, P13169, DOI 10.1074/jbc.271.22.13169; LERNER TJ, 1995, CELL, V82, P949, DOI 10.1016/0092-8674(95)90274-0; Lovat PE, 2004, JNCI-J NATL CANCER I, V96, P1288, DOI 10.1093/jnci/djh254; Maurer BJ, 2000, JNCI-J NATL CANCER I, V92, P1897, DOI 10.1093/jnci/92.23.1897; Maurer BJ, 1999, JNCI-J NATL CANCER I, V91, P1138, DOI 10.1093/jnci/91.13.1138; Mizutani Y, 2005, BIOCHEM J, V390, P263, DOI 10.1042/BJ20050291; Persaud-Sawin DA, 2004, PEDIATR RES, V56, P449, DOI 10.1203/01.PDR.0000136152.54638.95; Ranta S, 1999, NAT GENET, V23, P233, DOI 10.1038/13868; Savukoski M, 1998, NAT GENET, V19, P286, DOI 10.1038/975; Schorling S, 2001, MOL BIOL CELL, V12, P3417, DOI 10.1091/mbc.12.11.3417; Schulz A, 2004, ANN NEUROL, V56, P342, DOI 10.1002/ana.20187; Sleat DE, 1997, SCIENCE, V277, P1802, DOI 10.1126/science.277.5333.1802; Vallee B, 2005, EMBO J, V24, P730, DOI 10.1038/sj.emboj.7600562; Venkataraman K, 2002, FEBS LETT, V528, P3, DOI 10.1016/S0014-5793(02)03248-9; Veronesi U, 1999, J NATL CANCER I, V91, P1847, DOI 10.1093/jnci/91.21.1847; VESA J, 1995, NATURE, V376, P584, DOI 10.1038/376584a0; Wang HT, 2003, UROLOGY, V61, P1047, DOI 10.1016/S0090-4295(02)02511-6; Wang HT, 2001, CANCER RES, V61, P5102; Wheeler RB, 2002, AM J HUM GENET, V70, P537, DOI 10.1086/338708; Winter E, 2002, TRENDS BIOCHEM SCI, V27, P381, DOI 10.1016/S0968-0004(02)02154-0; Yamaoka S, 2004, J BIOL CHEM, V279, P18688, DOI 10.1074/jbc.M401205200	38	63	67	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 3	2006	281	5					2784	2794		10.1074/jbc.M509483200	http://dx.doi.org/10.1074/jbc.M509483200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	006XT	16303764	Green Published, hybrid			2022-12-25	WOS:000234931800045
J	Shiio, Y; Suh, KS; Lee, H; Yuspa, SH; Eisenman, RN; Aebersold, R				Shiio, Y; Suh, KS; Lee, H; Yuspa, SH; Eisenman, RN; Aebersold, R			Quantitative proteomic analysis of Myc-induced apoptosis - A direct role for Myc induction of the mitochondrial chloride ion channel, mtCLIC/CLIC4	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TANDEM MASS-SPECTROMETRY; CELL-CYCLE PROGRESSION; DEATH EFFECTOR DOMAIN; BCL-X-L; C-MYC; DNA-DAMAGE; P53-DEPENDENT APOPTOSIS; STATISTICAL-MODEL; PROTEIN; P53	Myc is a key regulatory protein in higher eukaryotes controlling important cellular functions such as proliferation, differentiation, and apoptosis. Myc is profoundly involved in the genesis of many human and animal cancers, and the abrogation of Myc-induced apoptosis is a critical event in cancer progression. Because the mechanisms that mediate Myc-induced apoptosis are largely unknown, we analyzed protein expression during Myc-induced apoptosis using an isotope-coded affinity tag quantitative proteomics approach and identified that a proapoptotic mitochondrial chloride ion channel, mtCLIC/CLIC4, is induced by Myc. Myc binds to the mtCLIC gene promoter and activates its transcription. Suppression of mtCLIC expression by RNA interference inhibited Myc-induced apoptosis in response to different stress conditions and abolished the cooperative induction of apoptosis by Myc and Bax. We also found that Myc reduces the expression of Bcl-2 and Bcl-xL and that the apoptosis-inducing stimuli up-regulate Bax expression. These results suggest that up-regulation of mtCLIC, together with a reduction in Bcl-2 and Bcl-xL, sensitizes Myc-expressing cells to the proapoptotic action of Bax.	Univ Texas, Hlth Sci Ctr, Childrens Canc Res Inst, San Antonio, TX 78229 USA; Fred Hutchinson Canc Res Ctr, Seattle, WA 98109 USA; Inst Syst Biol, Seattle, WA 98103 USA; NCI, Cellular Carcinogenesis & Tumor Promot Lab, NIH, Bethesda, MD 20892 USA; Univ Zurich, Inst Mol Syst Biol, ETH, CH-8093 Zurich, Switzerland; Univ Zurich, Fac Nat Sci, CH-8093 Zurich, Switzerland	University of Texas System; University of Texas Health San Antonio; Fred Hutchinson Cancer Center; Institute for Systems Biology (ISB); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Swiss Federal Institutes of Technology Domain; ETH Zurich; University of Zurich; University of Zurich	Shiio, Y (corresponding author), Univ Texas, Hlth Sci Ctr, Childrens Canc Res Inst, 8403 Floyd Curl Dr, San Antonio, TX 78229 USA.	shiio@uthscsa.edu		Lee, Hookeun/0000-0002-0696-8421	NATIONAL CANCER INSTITUTE [Z01BC004504, ZIABC004504] Funding Source: NIH RePORTER	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Amanullah A, 2000, ONCOGENE, V19, P2967, DOI 10.1038/sj.onc.1203638; AMATI B, 1993, EMBO J, V12, P5083, DOI 10.1002/j.1460-2075.1993.tb06202.x; Arnould T, 2003, FASEB J, V17, P2145, DOI 10.1096/fj.03-0075fje; Asher G, 2001, P NATL ACAD SCI USA, V98, P1188, DOI 10.1073/pnas.021558898; Ashley RH, 2003, MOL MEMBR BIOL, V20, P1, DOI 10.1080/09687680210042746; BADER SA, 1991, CELL GROWTH DIFFER, V2, P245; Beere HM, 2004, J CELL SCI, V117, P2641, DOI 10.1242/jcs.01284; BISSONNETTE RP, 1992, NATURE, V359, P552, DOI 10.1038/359552a0; Chang TS, 2004, J BIOL CHEM, V279, P41975, DOI 10.1074/jbc.M407707200; CHENG NC, 1995, ONCOGENE, V10, P291; Coller HA, 2000, P NATL ACAD SCI USA, V97, P3260, DOI 10.1073/pnas.97.7.3260; Eischen CM, 1999, GENE DEV, V13, P2658, DOI 10.1101/gad.13.20.2658; Eischen CM, 2001, MOL CELL BIOL, V21, P5063, DOI 10.1128/MCB.21.15.5063-5070.2001; Eischen CM, 2001, MOL CELL BIOL, V21, P7653, DOI 10.1128/MCB.21.22.7653-7662.2001; EVAN GI, 1992, CELL, V69, P119, DOI 10.1016/0092-8674(92)90123-T; FANIDI A, 1992, NATURE, V359, P554, DOI 10.1038/359554a0; Fernandez-Salas E, 2002, MOL CELL BIOL, V22, P3610, DOI 10.1128/MCB.22.11.3610-3620.2002; Fernandez-Salas E, 1999, J BIOL CHEM, V274, P36488, DOI 10.1074/jbc.274.51.36488; Frank SR, 2001, GENE DEV, V15, P2069, DOI 10.1101/gad.906601; Galaktionov K, 1996, NATURE, V382, P511, DOI 10.1038/382511a0; Grandori C, 2003, GENE DEV, V17, P1569, DOI 10.1101/gad.1100303; Han DK, 2001, NAT BIOTECHNOL, V19, P946, DOI 10.1038/nbt1001-946; HERMEKING H, 1994, SCIENCE, V265, P2091, DOI 10.1126/science.8091232; Herold S, 2002, MOL CELL, V10, P509, DOI 10.1016/S1097-2765(02)00633-0; Hueber AO, 1997, SCIENCE, V278, P1305, DOI 10.1126/science.278.5341.1305; Jacobs JJL, 1999, GENE DEV, V13, P2678, DOI 10.1101/gad.13.20.2678; Jeffers JR, 2003, CANCER CELL, V4, P321, DOI 10.1016/S1535-6108(03)00244-7; Juin P, 1999, GENE DEV, V13, P1367, DOI 10.1101/gad.13.11.1367; Juin P, 2002, MOL CELL BIOL, V22, P6158, DOI 10.1128/MCB.22.17.6158-6169.2002; KauffmanZeh A, 1997, NATURE, V385, P544, DOI 10.1038/385544a0; Keller A, 2002, ANAL CHEM, V74, P5383, DOI 10.1021/ac025747h; Knies UE, 1998, P NATL ACAD SCI USA, V95, P12322, DOI 10.1073/pnas.95.21.12322; Knuefermann P, 2002, J BIOL CHEM, V277, P23888, DOI 10.1074/jbc.M202937200; Li XJ, 2003, ANAL CHEM, V75, P6648, DOI 10.1021/ac034633i; Lucas PC, 2004, J CELL SCI, V117, P31, DOI 10.1242/jcs.00904; Maclean KH, 2003, MOL CELL BIOL, V23, P7256, DOI 10.1128/MCB.23.20.7256-7270.2003; MALDE P, 1994, INT IMMUNOL, V6, P1169, DOI 10.1093/intimm/6.8.1169; Nesbit CE, 1999, ONCOGENE, V18, P3004, DOI 10.1038/sj.onc.1202746; Nesvizhskii AI, 2003, ANAL CHEM, V75, P4646, DOI 10.1021/ac0341261; Nilsson JA, 2003, ONCOGENE, V22, P9007, DOI 10.1038/sj.onc.1207261; Oster SK, 2002, ADV CANCER RES, V84, P81, DOI 10.1016/S0065-230X(02)84004-0; PACKHAM G, 1994, MOL CELL BIOL, V14, P5741, DOI 10.1128/MCB.14.9.5741; Pelengaris S, 2002, CELL, V109, P321, DOI 10.1016/S0092-8674(02)00738-9; Pelengaris S, 2003, ARCH BIOCHEM BIOPHYS, V416, P129, DOI 10.1016/S0003-9861(03)00294-7; Sakamuro D, 1995, ONCOGENE, V11, P2411; Schickling O, 2001, CELL DEATH DIFFER, V8, P1157, DOI 10.1038/sj.cdd.4400928; Schmitt CA, 1999, GENE DEV, V13, P2670, DOI 10.1101/gad.13.20.2670; Seoane J, 2002, NATURE, V419, P729, DOI 10.1038/nature01119; Sheen JH, 2002, MOL CELL BIOL, V22, P1819, DOI 10.1128/MCB.22.6.1819-1833.2002; Shiio Y, 2003, J AM SOC MASS SPECTR, V14, P696, DOI 10.1016/S1044-0305(03)00204-6; Shiio Y, 2002, EMBO J, V21, P5088, DOI 10.1093/emboj/cdf525; Shilo Y, 2003, P NATL ACAD SCI USA, V100, P13225, DOI 10.1073/pnas.1735528100; Shim H, 1998, P NATL ACAD SCI USA, V95, P1511, DOI 10.1073/pnas.95.4.1511; Shirogane T, 1999, IMMUNITY, V11, P709, DOI 10.1016/S1074-7613(00)80145-4; Soucie EL, 2001, MOL CELL BIOL, V21, P4725, DOI 10.1128/MCB.21.14.4725-4736.2001; Spieker N, 2001, GENE CHROMOSOME CANC, V31, P172, DOI 10.1002/gcc.1130.abs; Stegh AH, 1998, EMBO J, V17, P5974, DOI 10.1093/emboj/17.20.5974; STRASSER A, 1990, NATURE, V348, P331, DOI 10.1038/348331a0; Suh KS, 2004, J BIOL CHEM, V279, P4632, DOI 10.1074/jbc.M311632200; Tanaka H, 2002, MOL CELL, V9, P1017, DOI 10.1016/S1097-2765(02)00522-1; WAGNER AJ, 1994, GENE DEV, V8, P2817, DOI 10.1101/gad.8.23.2817; Weiner AM, 1999, SCIENCE, V284, P63, DOI 10.1126/science.284.5411.63; Zindy F, 1998, GENE DEV, V12, P2424, DOI 10.1101/gad.12.15.2424	63	59	62	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 3	2006	281	5					2750	2756		10.1074/jbc.M509349200	http://dx.doi.org/10.1074/jbc.M509349200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	006XT	16316993	hybrid			2022-12-25	WOS:000234931800041
J	Turk, R; Sterrenburg, E; van der Wees, CGC; de Meijer, EJ; de Menezes, RX; Groh, S; Campbell, KP; Noguchi, S; van Ommen, GJB; den Dunnen, JT; 't Hoen, PAC				Turk, R; Sterrenburg, E; van der Wees, CGC; de Meijer, EJ; de Menezes, RX; Groh, S; Campbell, KP; Noguchi, S; van Ommen, GJB; den Dunnen, JT; 't Hoen, PAC			Common pathological mechanisms in mouse models for muscular dystrophies	FASEB JOURNAL			English	Article						microarray; dystrophin-glycoprotein complex; inflammation; extracellular matrix; biomarker	CDNA MICROARRAY ANALYSIS; GENE-EXPRESSION; SKELETAL-MUSCLE; SARCOGLYCAN COMPLEX; MEMBRANE REPAIR; SMOOTH-MUSCLE; MDX MICE; DYSFERLIN; DEGENERATION; DISRUPTION	Duchenne/Becker and limb-girdle muscular dystrophies share clinical symptoms like muscle weakness and wasting but differ in clinical presentation and severity. To get a closer view on the differentiating molecular events responsible for the muscular dystrophies, we have carried out a comparative gene expression profiling of hindlimb muscles of the following mouse models: dystrophin-deficient (mdx, mdx(3cv)), sarcoglycan-deficient (Sgca null, Sgcb null, Sgcg null, Sgcd null), dysferlin-deficient (Dysf null, SJL(Dysf)), sarcospan-deficient (Sspn null), and wild-type (C57B1/6, C57B1/10) mice. The expression profiles clearly discriminated between severely affected (dystrophinopathies and sarcoglycanopathies) and mildly or nonaffected models (dysferlinopathies, sarcospan-deficiency, wild-type). Dystrophin-deficient and sarcoglycan-deficient profiles were remarkably similar, sharing inflammatory and structural remodeling processes. These processes were also ongoing in dysferlin-deficient animals, albeit at lower levels, in agreement with the later age of onset of this muscular dystrophy. The inflammatory proteins Spp1 and S100a9 were up-regulated in all models, including sarcospan-deficient mice, which points, for the first time, at a subtle phenotype for Sspn null mice. In conclusion, we identified biomarker genes for which expression correlates with the severity of the disease, which can be used for monitoring disease progression. This comparative study is an integrating step toward the development of an expression profiling-based diagnostic approach for muscular dystrophies in humans.	Leiden Univ, Med Ctr, Ctr Human & Clin Genet, NL-2333 AL Leiden, Netherlands; Howard Hughes Med Inst, Dept Physiol & Biophys, Iowa City, IA USA; Natl Inst Neurosci, Dept Neuromuscular Res, Tokyo, Japan	Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC; Howard Hughes Medical Institute; National Center for Neurology & Psychiatry - Japan	't Hoen, PAC (corresponding author), Leiden Univ, Med Ctr, Ctr Human & Clin Genet, Wassenaarseweg 72, NL-2333 AL Leiden, Netherlands.	p.a.c.hoen@lumc.nl	dunnen, johan den/ABH-4228-2020; 't Hoen, Peter/A-4857-2012; Turk, Rolf/E-7832-2010; Hoen, Peter A 't/D-3950-2018	dunnen, johan den/0000-0002-6304-1710; Turk, Rolf/0000-0003-1283-9594; Hoen, Peter A 't/0000-0003-4450-3112; Campbell, Kevin/0000-0003-2066-5889				Abbas AR, 2005, GENES IMMUN, V6, P319, DOI 10.1038/sj.gene.6364173; Araishi K, 1999, HUM MOL GENET, V8, P1589, DOI 10.1093/hmg/8.9.1589; ARBER S, 1994, CELL, V79, P221, DOI 10.1016/0092-8674(94)90192-9; Bakay M, 2002, NEUROMUSCULAR DISORD, V12, pS125, DOI 10.1016/S0960-8966(02)00093-7; Bansal D, 2004, TRENDS CELL BIOL, V14, P206, DOI 10.1016/j.tcb.2004.03.001; Bansal D, 2003, NATURE, V423, P168, DOI 10.1038/nature01573; Bashir R, 1998, NAT GENET, V20, P37, DOI 10.1038/1689; BENJAMINI Y, 1995, J R STAT SOC B, V57, P289, DOI 10.1111/j.2517-6161.1995.tb02031.x; Bittner RE, 1999, NAT GENET, V23, P141, DOI 10.1038/13770; Brussee V, 1997, NEUROMUSCULAR DISORD, V7, P487, DOI 10.1016/S0960-8966(97)00115-6; BULFIELD G, 1984, P NATL ACAD SCI-BIOL, V81, P1189, DOI 10.1073/pnas.81.4.1189; Bushby KMD, 1999, BRAIN, V122, P1403, DOI 10.1093/brain/122.8.1403; Campanaro S, 2002, HUM MOL GENET, V11, P3283, DOI 10.1093/hmg/11.26.3283; CARPENTER S, 1979, BRAIN, V102, P147, DOI 10.1093/brain/102.1.147; Chen YW, 2000, J CELL BIOL, V151, P1321, DOI 10.1083/jcb.151.6.1321; Cohn RD, 2001, J CLIN INVEST, V107, pR1, DOI 10.1172/JCI11642; Cohn RD, 2000, MUSCLE NERVE, V23, P1456, DOI 10.1002/1097-4598(200010)23:10<1456::AID-MUS2>3.0.CO;2-T; Coral-Vazquez R, 1999, CELL, V98, P465, DOI 10.1016/S0092-8674(00)81975-3; COX GA, 1993, NAT GENET, V4, P87, DOI 10.1038/ng0593-87; Dalkilic I, 2003, CURR OPIN GENET DEV, V13, P231, DOI 10.1016/S0959-437X(03)00048-0; Diehn M, 2003, NUCLEIC ACIDS RES, V31, P219, DOI 10.1093/nar/gkg014; Duclos F, 1998, J CELL BIOL, V142, P1461, DOI 10.1083/jcb.142.6.1461; Durbeej M, 2000, MOL CELL, V5, P141, DOI 10.1016/S1097-2765(00)80410-4; Durbeej M, 2002, CURR OPIN GENET DEV, V12, P349, DOI 10.1016/S0959-437X(02)00309-X; Emery AEH, 2002, LANCET, V359, P687, DOI 10.1016/S0140-6736(02)07815-7; Haslett JN, 2002, P NATL ACAD SCI USA, V99, P15000, DOI 10.1073/pnas.192571199; Haslett JN, 2002, INT J DEV NEUROSCI, V20, P359, DOI 10.1016/S0736-5748(02)00041-2; HOFFMAN EP, 1987, CELL, V51, P919, DOI 10.1016/0092-8674(87)90579-4; Huber Wolfgang, 2002, Bioinformatics, V18 Suppl 1, pS96; Inoue K, 2004, NAT GENET, V36, P361, DOI 10.1038/ng1322; Kuznetsov AV, 1998, MOL CELL BIOCHEM, V183, P87, DOI 10.1023/A:1006868130002; Lebakken CS, 2000, MOL CELL BIOL, V20, P1669, DOI 10.1128/MCB.20.5.1669-1677.2000; Lennon NJ, 2003, J BIOL CHEM, V278, P50466, DOI 10.1074/jbc.M307247200; Lim LE, 1998, CURR OPIN NEUROL, V11, P443, DOI 10.1097/00019052-199810000-00006; MCARDLE A, 1995, NEUROMUSCULAR DISORD, V5, P445, DOI 10.1016/0960-8966(95)00001-4; Nagy E, 1998, TRENDS BIOCHEM SCI, V23, P198, DOI 10.1016/S0968-0004(98)01208-0; Noguchi S, 2003, HUM MOL GENET, V12, P595, DOI 10.1093/hmg/ddg065; Ozawa E, 1998, MUSCLE NERVE, V21, P421, DOI 10.1002/(SICI)1097-4598(199804)21:4<421::AID-MUS1>3.3.CO;2-W; OZAWA E, 1995, HUM MOL GENET, V4, P1711, DOI 10.1093/hmg/4.suppl_1.1711; Porter JD, 2003, NEUROMUSCULAR DISORD, V13, P223, DOI 10.1016/S0960-8966(02)00242-0; Porter JD, 2003, HUM MOL GENET, V12, P1813, DOI 10.1093/hmg/ddg197; Porter JD, 2002, HUM MOL GENET, V11, P263, DOI 10.1093/hmg/11.3.263; *R DEV COR TEAM, 2004, R LANG ENV STAT COMP; Rouger K, 2002, AM J PHYSIOL-CELL PH, V283, pC773, DOI 10.1152/ajpcell.00112.2002; Sanoudou D, 2004, NEUROBIOL DIS, V15, P590, DOI 10.1016/j.nbd.2003.12.013; Sasaoka T, 2003, NEUROMUSCULAR DISORD, V13, P193, DOI 10.1016/S0960-8966(02)00220-1; Schafer R, 2005, NEUROMUSCULAR DISORD, V15, P57, DOI 10.1016/j.nmd.2004.09.011; Sharma U, 2003, MAGN RESON IMAGING, V21, P145, DOI 10.1016/S0730-725X(02)00646-X; Straub V, 1998, AM J PATHOL, V153, P1623, DOI 10.1016/S0002-9440(10)65751-3; 't Hoen PAC, 2004, NUCLEIC ACIDS RES, V32, DOI 10.1093/nar/gnh038; 't Hoen PAC, 2003, NUCLEIC ACIDS RES, V31, DOI 10.1093/nar/gng020; TOME FMS, 1994, CR ACAD SCI III-VIE, V317, P351; Tsukahara T, 2002, MUSCLE NERVE, V25, P898, DOI 10.1002/mus.10085; Turk R, 2005, BMC GENOMICS, V6, DOI 10.1186/1471-2164-6-98; Turk R, 2004, BMC GENOMICS, V5, DOI 10.1186/1471-2164-5-57; Williamson RA, 1997, HUM MOL GENET, V6, P831, DOI 10.1093/hmg/6.6.831; Winokur ST, 2003, HUM MOL GENET, V12, P2895, DOI 10.1093/hmg/ddg327; Zhang B, 2004, BMC BIOINFORMATICS, V5, DOI 10.1186/1471-2105-5-16; [No title captured]	59	62	64	0	3	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	NOV	2005	19	13					127	+		10.1096/fj.05-4678fje	http://dx.doi.org/10.1096/fj.05-4678fje			29	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	994TC	16306063				2022-12-25	WOS:000234053100005
J	Ternes, P; Sperling, P; Albrecht, S; Franke, S; Cregg, JM; Warnecke, D; Heinz, E				Ternes, P; Sperling, P; Albrecht, S; Franke, S; Cregg, JM; Warnecke, D; Heinz, E			Identification of fungal sphingolipid C9-methyltransferases by phylogenetic profiling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYCLOPROPANATED MYCOLIC ACIDS; LONG-CHAIN BASES; MYCOBACTERIUM-TUBERCULOSIS; SACCHAROMYCES-CEREVISIAE; UNCHARACTERIZED GENES; PLANT SPHINGOLIPIDS; ESCHERICHIA-COLI; PROTEIN TOPOLOGY; ACTIVE-SITE; RICE PLANTS	Fungal glucosylceramides play an important role in plant-pathogen interactions enabling plants to recognize the fungal attack and initiate specific defense responses. A prime structural feature distinguishing fungal glucosylceramides from those of plants and animals is a methyl group at the C9-position of the sphingoid base, the biosynthesis of which has never been investigated. Using information on the presence or absence of C9-methylated glucosylceramides in different fungal species, we developed a bioinformatics strategy to identify the gene responsible for the biosynthesis of this C9-methyl group. This phylogenetic profiling allowed the selection of a single candidate out of 24 - 71 methyltransferase sequences present in each of the fungal species with C9-methylated glucosylceramides. A Pichia pastoris knock-out strain lacking the candidate sphingolipid C9-methyltransferase was generated, and indeed, this strain contained only non-methylated glucosylceramides. In a complementary approach, a Saccharomyces cerevisiae strain was engineered to produce glucosylceramides suitable as a substrate for C9-methylation. C9-methylated sphingolipids were detected in this strain expressing the candidate from P. pastoris, demonstrating its function as a sphingolipid C9-methyltransferase. The enzyme belongs to the superfamily of S-adenosylmethionine-(SAM)dependent methyltransferases and shows highest sequence similarity to plant and bacterial cyclopropane fatty acid synthases. An in vitro assay showed that sphingolipid C9-methylation is membrane-bound and requires SAM and Delta 4,8-desaturated ceramide as substrates.	Univ Hamburg, Biozentrum Klein Flottbek & Bot Garten, D-22609 Hamburg, Germany; Univ Hamburg, Inst Organ Chem, D-20146 Hamburg, Germany; Keck Grad Inst, Claremont, CA 91711 USA	University of Hamburg; University of Hamburg; Claremont Colleges; Keck Graduate Institute	Ternes, P (corresponding author), Univ Utrecht, Fac Scheikunde, Padualaan 8, NL-3584 CH Utrecht, Netherlands.	p.g.ternes@chem.uu.nl		Ternes, Philipp/0000-0003-0886-5474				Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; Bao XM, 2002, P NATL ACAD SCI USA, V99, P7172, DOI 10.1073/pnas.092152999; Courtois F, 2005, BIOCHEMISTRY-US, V44, P13583, DOI 10.1021/bi051159x; CREGG JM, 1985, MOL CELL BIOL, V5, P3376, DOI 10.1128/MCB.5.12.3376; Daum G, 1998, YEAST, V14, P1471, DOI 10.1002/(SICI)1097-0061(199812)14:16<1471::AID-YEA353>3.0.CO;2-Y; Dickson RC, 1999, BBA-GEN SUBJECTS, V1426, P347, DOI 10.1016/S0304-4165(98)00135-4; Dufayard JF, 2005, BIOINFORMATICS, V21, P2596, DOI 10.1093/bioinformatics/bti325; Dunn TM, 2004, ANN BOT-LONDON, V93, P483, DOI 10.1093/aob/mch071; Duran R, 1998, TETRAHEDRON, V54, P14597, DOI 10.1016/S0040-4020(98)00917-X; Eisen JA, 1998, GENOME RES, V8, P163, DOI 10.1101/gr.8.3.163; Enright AJ, 2002, NUCLEIC ACIDS RES, V30, P1575, DOI 10.1093/nar/30.7.1575; Fitch WM, 2000, TRENDS GENET, V16, P227, DOI 10.1016/S0168-9525(00)02005-9; FITCH WM, 1970, SYST ZOOL, V19, P99, DOI 10.2307/2412448; GABER RF, 1989, MOL CELL BIOL, V9, P3447, DOI 10.1128/MCB.9.8.3447; GEORGE KM, 1995, J BIOL CHEM, V270, P27292, DOI 10.1074/jbc.270.45.27292; Green ML, 2004, BMC BIOINFORMATICS, V5, DOI 10.1186/1471-2105-5-76; Grilley MM, 1998, J BIOL CHEM, V273, P11062, DOI 10.1074/jbc.273.18.11062; Guldener U, 1996, NUCLEIC ACIDS RES, V24, P2519, DOI 10.1093/nar/24.13.2519; GUTIERREZ RA, 2004, GENOME BIOL; Haak D, 1997, J BIOL CHEM, V272, P29704, DOI 10.1074/jbc.272.47.29704; HEINZE FJ, 1984, ANAL BIOCHEM, V139, P126, DOI 10.1016/0003-2697(84)90397-X; Higuchi R, 1996, LIEBIGS ANN-RECL, P593; Huang CC, 2002, J BIOL CHEM, V277, P11559, DOI 10.1074/jbc.M111698200; Imai H, 1997, BIOSCI BIOTECH BIOCH, V61, P351, DOI 10.1271/bbb.61.351; IRIE A, 1990, J BIOCHEM-TOKYO, V107, P578, DOI 10.1093/oxfordjournals.jbchem.a123089; Jenkins KM, 1999, TETRAHEDRON LETT, V40, P7637, DOI 10.1016/S0040-4039(99)01562-2; JIN WZ, 1994, J ORG CHEM, V59, P144, DOI 10.1021/jo00080a023; KARLSSON KA, 1970, CHEM PHYS LIPIDS, V5, P6, DOI 10.1016/0009-3084(70)90008-3; KARLSSON KA, 1979, BIOCHIM BIOPHYS ACTA, V574, P79, DOI 10.1016/0005-2760(79)90087-0; KAWAI G, 1986, J BIOL CHEM, V261, P779; Koga J, 1998, J BIOL CHEM, V273, P31985, DOI 10.1074/jbc.273.48.31985; Krogh A, 2001, J MOL BIOL, V305, P567, DOI 10.1006/jmbi.2000.4315; Leipelt M, 2001, J BIOL CHEM, V276, P33621, DOI 10.1074/jbc.M104952200; Levesque M, 2003, CURR BIOL, V13, P129, DOI 10.1016/S0960-9822(03)00009-5; Lin N, 2004, BMC BIOINFORMATICS, V5, DOI 10.1186/1471-2105-5-154; LUNDBLAD V, 1997, CURRENT PROTOCOLS MO; Mikkelsen TS, 2005, BIOINFORMATICS, V21, P464, DOI 10.1093/bioinformatics/bti027; MORRISON WR, 1970, BIOCHIM BIOPHYS ACTA, V202, P460, DOI 10.1016/0005-2760(70)90116-5; NATORI T, 1994, TETRAHEDRON, V50, P2771, DOI 10.1016/S0040-4020(01)86991-X; Nes WD, 2000, BBA-MOL CELL BIOL L, V1529, P63, DOI 10.1016/S1388-1981(00)00138-4; Pellegrini M, 1999, P NATL ACAD SCI USA, V96, P4285, DOI 10.1073/pnas.96.8.4285; Persson B, 1997, J PROTEIN CHEM, V16, P453, DOI 10.1023/A:1026353225758; Pinto MR, 2002, GLYCOBIOLOGY, V12, P251, DOI 10.1093/glycob/12.4.251; Rodrigues ML, 2000, INFECT IMMUN, V68, P7049, DOI 10.1128/IAI.68.12.7049-7060.2000; Schwede T, 2003, NUCLEIC ACIDS RES, V31, P3381, DOI 10.1093/nar/gkg520; Shevchuk NA, 2004, NUCLEIC ACIDS RES, V32, DOI 10.1093/nar/gnh014; Sperling P, 2000, EUR J BIOCHEM, V267, P3801, DOI 10.1046/j.1432-1327.2000.01418.x; Sperling P, 2004, TOP CURR GENET, V6, P337; Tan RX, 2003, NAT PROD REP, V20, P509, DOI 10.1039/b307243f; Tatusov RL, 1997, SCIENCE, V278, P631, DOI 10.1126/science.278.5338.631; Ternes P, 2002, J BIOL CHEM, V277, P25512, DOI 10.1074/jbc.M202947200; Thevissen K, 2004, J BIOL CHEM, V279, P3900, DOI 10.1074/jbc.M311165200; Thompson JD, 1997, NUCLEIC ACIDS RES, V25, P4876, DOI 10.1093/nar/25.24.4876; Toledo MS, 2000, J LIPID RES, V41, P797; Toledo MS, 1999, BIOCHEMISTRY-US, V38, P7294, DOI 10.1021/bi982898z; TRECO DA, 1993, CURRENT PROTOCOLS MO, pCH13; Tusnady GE, 2001, BIOINFORMATICS, V17, P849, DOI 10.1093/bioinformatics/17.9.849; Umemura K, 2000, PLANT CELL PHYSIOL, V41, P676, DOI 10.1093/pcp/41.6.676; Umemura K, 2002, PLANT CELL PHYSIOL, V43, P778, DOI 10.1093/pcp/pcf090; WANG AY, 1992, BIOCHEMISTRY-US, V31, P11020, DOI 10.1021/bi00160a011; Warnecke D, 2003, CELL MOL LIFE SCI, V60, P919, DOI 10.1007/s00018-003-2243-4; YUAN Y, 1995, P NATL ACAD SCI USA, V92, P6630, DOI 10.1073/pnas.92.14.6630; Zmasek CM, 2001, BIOINFORMATICS, V17, P821, DOI 10.1093/bioinformatics/17.9.821	63	55	58	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 3	2006	281	9					5582	5592		10.1074/jbc.M512864200	http://dx.doi.org/10.1074/jbc.M512864200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	015RQ	16339149	hybrid			2022-12-25	WOS:000235568900034
J	Tang, S; Tao, M; McCoy, J; Zheng, ZM				Tang, S; Tao, M; McCoy, J; Zheng, ZM			Short-term induction and long-term suppression of HPV16 oncogene silencing by RNA interference in cervical cancer cells	ONCOGENE			English	Article						HPV16; E6; E7; oncogene; siRNA; cervical cancer	HUMAN-PAPILLOMAVIRUS TYPE-16; VIRAL SUPPRESSOR; MESSENGER-RNA; IN-VITRO; EXPRESSION; E6; GENE; E7; ONCOPROTEIN; NUCLEAR	RNA interference-mediated gene silencing has the potential to block gene expression. A synthetic double-stranded small interfering RNA (siRNA) based on a sequence motif of 21 nucleotides from human papillomavirus 16 (HPV16) E6E7 bicistronic RNA was found to be a potent siRNA that suppresses expression of both the E6 and E7 oncogenes in HPV16(+) CaSki and SiHa cells. When stably expressed as a short hairpin RNA in these cells, however, siRNA silencing of E6 and E7 expression was efficient only at early cell passages, but became inefficient with increased cell passages despite the continued expression of the siRNA at the same level. The loss of the siRNA function was duplicable in stable p53 siRNA cells, but not in stable lamin A/C siRNA cells, suggesting that it is gene selective. The cells resistant to siRNA function retained normal siRNA processing, duplex unwinding and degradation of the unwound sense strand and RNA-induced silencing complex formation, suggesting that loss of the siRNA function occurred at a later step. Surprisingly, the siRNA-resistant cells were found to express notably a cytoplasmic protein of similar to 50 kDa that specifically and characteristically interacted with the unwound, antisense strand E7 siRNA. Altogether, our data indicate that a potent siRNA targeting to an essential or regulatory gene might induce a cell to develop siRNA-suppressive function.	NCI, HIV & AIDS Malignancy Branch, Ctr Canc Res, NIH, Bethesda, MD 20892 USA; NHLBI, Flow Cytometry Core Facil, NIH, Bethesda, MD USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI)	Zheng, ZM (corresponding author), NCI, HIV & AIDS Malignancy Branch, Ctr Canc Res, NIH, Bldg 10,Room10S255,MSC 1868,10 Ctr Dr, Bethesda, MD 20892 USA.	zhengt@exchange.nih.gov	Tang, Shuang/F-9115-2014	Tang, Shuang/0000-0002-3084-0903; Zheng, Zhi-Ming/0000-0001-5547-7912	NATIONAL CANCER INSTITUTE [Z01SC010357] Funding Source: NIH RePORTER; Intramural NIH HHS Funding Source: Medline; NCI NIH HHS [Z01 SC010357-06] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AEBI U, 1986, NATURE, V323, P560, DOI 10.1038/323560a0; Boyer SN, 1996, CANCER RES, V56, P4620; Bridge AJ, 2003, NAT GENET, V34, P263, DOI 10.1038/ng1173; Brummelkamp TR, 2002, SCIENCE, V296, P550, DOI 10.1126/science.1068999; Butz K, 2003, ONCOGENE, V22, P5938, DOI 10.1038/sj.onc.1206894; Doench JG, 2003, GENE DEV, V17, P438, DOI 10.1101/gad.1064703; Dykxhoorn DM, 2003, NAT REV MOL CELL BIO, V4, P457, DOI 10.1038/nrm1129; Elbashir SM, 2001, GENE DEV, V15, P188, DOI 10.1101/gad.862301; Gonzalez SL, 2001, J VIROL, V75, P7583, DOI 10.1128/JVI.75.16.7583-7591.2001; Goodwin EC, 2000, P NATL ACAD SCI USA, V97, P10978, DOI 10.1073/pnas.97.20.10978; Haley B, 2004, NAT STRUCT MOL BIOL, V11, P599, DOI 10.1038/nsmb780; Hall AHS, 2003, J VIROL, V77, P6066, DOI 10.1128/JVI.77.10.6066-6069.2003; Hammond SM, 2000, NATURE, V404, P293, DOI 10.1038/35005107; Howley P. M., 2001, FIELDS VIROLOGY, V2, P2197; Jiang M, 2002, ONCOGENE, V21, P6041, DOI 10.1038/sj.onc.1205878; Kasschau KD, 2003, DEV CELL, V4, P205, DOI 10.1016/S1534-5807(03)00025-X; KESSIS TD, 1993, P NATL ACAD SCI USA, V90, P3988, DOI 10.1073/pnas.90.9.3988; Knight SW, 2002, MOL CELL, V10, P809, DOI 10.1016/S1097-2765(02)00649-4; Lecellier CH, 2005, SCIENCE, V308, P557, DOI 10.1126/science.1108784; Li HW, 2002, SCIENCE, V296, P1319, DOI 10.1126/science.1070948; Li WX, 2004, P NATL ACAD SCI USA, V101, P1350, DOI 10.1073/pnas.0308308100; Lu SH, 2004, J VIROL, V78, P12868, DOI 10.1128/JVI.78.23.12868-12876.2004; Mallory AC, 2002, P NATL ACAD SCI USA, V99, P15228, DOI 10.1073/pnas.232434999; Martinez J, 2002, CELL, V110, P563, DOI 10.1016/S0092-8674(02)00908-X; Mayeda A, 1999, METH MOL B, V118, P309; Nykanen A, 2001, CELL, V107, P309, DOI 10.1016/S0092-8674(01)00547-5; PFEFFER S, 2003, CURRETN PROTOCOLS MO; Pham JW, 2004, CELL, V117, P83, DOI 10.1016/S0092-8674(04)00258-2; Provost P, 2002, EMBO J, V21, P5864, DOI 10.1093/emboj/cdf578; Reynolds A, 2004, NAT BIOTECHNOL, V22, P326, DOI 10.1038/nbt936; Scadden ADJ, 2001, EMBO REP, V2, P1107, DOI 10.1093/embo-reports/kve244; SCHEFFNER M, 1990, CELL, V63, P1129, DOI 10.1016/0092-8674(90)90409-8; Schulze A, 1998, J VIROL, V72, P2323, DOI 10.1128/JVI.72.3.2323-2334.1998; Schwarz DS, 2003, CELL, V115, P199, DOI 10.1016/S0092-8674(03)00759-1; Sledz CA, 2003, NAT CELL BIOL, V5, P834, DOI 10.1038/ncb1038; SMOTKIN D, 1986, P NATL ACAD SCI USA, V83, P4680, DOI 10.1073/pnas.83.13.4680; Soldan SS, 2005, J VIROL, V79, P234, DOI 10.1128/JVI.79.1.234-244.2005; Tang S, 2002, J BIOL CHEM, V277, P14547, DOI 10.1074/jbc.M111308200; Tao MF, 2003, J VIROL, V77, P13232, DOI 10.1128/JVI.77.24.13232-13247.2003; Tomari Y, 2004, CELL, V116, P831, DOI 10.1016/S0092-8674(04)00218-1; VINDELOV LL, 1977, VIRCHOWS ARCH B, V24, P227; Vousden KH, 2000, CELL, V103, P691, DOI 10.1016/S0092-8674(00)00171-9; YAGINUMA Y, 1991, CANCER RES, V51, P6506; Yang WD, 2005, J BIOL CHEM, V280, P3946, DOI 10.1074/jbc.M407876200; Yoshinouchi M, 2003, MOL THER, V8, P762, DOI 10.1016/j.ymthe.2003.08.004; Yu JY, 2002, P NATL ACAD SCI USA, V99, P6047, DOI 10.1073/pnas.092143499; Zamore PD, 2000, CELL, V101, P25, DOI 10.1016/S0092-8674(00)80620-0; Zeng Y, 2003, P NATL ACAD SCI USA, V100, P9779, DOI 10.1073/pnas.1630797100; Zhang HD, 2002, EMBO J, V21, P5875, DOI 10.1093/emboj/cdf582; Zheng ZM, 2004, J MOL BIOL, V337, P1091, DOI 10.1016/j.jmb.2004.02.023; zur Hausen H, 2002, NAT REV CANCER, V2, P342, DOI 10.1038/nrc798	51	43	48	1	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR	2006	25	14					2094	2104		10.1038/sj.onc.1209244	http://dx.doi.org/10.1038/sj.onc.1209244			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	026RL	16369495	Green Accepted			2022-12-25	WOS:000236359700012
J	Lavillette, D; Bartosch, B; Nourrisson, D; Verney, G; Cosset, FL; Penin, F; Pecheur, EI				Lavillette, D; Bartosch, B; Nourrisson, D; Verney, G; Cosset, FL; Penin, F; Pecheur, EI			Hepatitis C virus glycoproteins mediate low pH-dependent membrane fusion with liposomes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENVELOPE GLYCOPROTEIN; INFLUENZA-VIRUS; LOW-DENSITY; CELL ENTRY; WEST-NILE; DC-SIGN; RECEPTOR; KINETICS; PROTEIN; LIPIDS	It has been suggested that the hepatitis C virus (HCV) infects host cells through a pH-dependent internalization mechanism, but the steps leading from virus attachment to the fusion of viral and cellular membranes remain uncharacterized. Here we studied the mechanism underlying the HCV fusion process in vitro using liposomes and our recently described HCV pseudoparticles (pp) bearing functional E1E2 envelope glycoproteins. The fusion of HCVpp with liposomes was monitored with fluorescent probes incorporated into either the HCVpp or the liposomes. To validate these assays, pseudoparticles bearing either the hemagglutinin of the influenza virus or the amphotropic glycoprotein of murine leukemia virus were used as models for pH-dependent and pH-independent entry, respectively. The use of assays based either on fusion-induced dequenching of fluorescent probes or on reporter systems, which produce fluorescence when the virus and liposome contents are mixed, allowed us to demonstrate that HCVpp mediated a complete fusion process, leading to the merging of both membrane leaflets and to the mixing of the internal contents of pseudoparticle and liposome. This HCVpp-mediated fusion was dependent on low pH, with a threshold of 6.3 and an optimum at about 5.5. Fusion was temperature-dependent and did not require any protein or receptor at the surface of the target liposomes. Most interestingly, fusion was facilitated by the presence of cholesterol in the target membrane. These findings clearly indicate that HCV infection is mediated by a pH-dependent membrane fusion process. This paves the way for future studies of the mechanisms underlying HCV membrane fusion.	Univ Lyon 1, CNRS, IBCP, UMR 5086,Inst Biol Chim Prot,IFR128 Biosci Lyon G, F-69367 Lyon 07, France; Ecole Normale Super Lyon, INSERM, U412, Lab Vectorol Retrovirale & Therapie Gen, F-69365 Lyon, France	Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); UDICE-French Research Universities; Universite Claude Bernard Lyon 1; Ecole Normale Superieure de Lyon (ENS de LYON); Institut National de la Sante et de la Recherche Medicale (Inserm)	Pecheur, EI (corresponding author), Univ Lyon 1, CNRS, IBCP, UMR 5086,Inst Biol Chim Prot,IFR128 Biosci Lyon G, 7 Passage Vercors, F-69367 Lyon 07, France.	e.pecheur@ibcp.fr	PENIN, Francois/A-7315-2008; Cosset, François-Loïc/M-5862-2019; Bartosch, Birke/I-7255-2018	Cosset, François-Loïc/0000-0001-8842-3726; Bartosch, Birke/0000-0001-6354-4660; Pecheur, Eve/0000-0002-8613-862X; Lavillette, Dimitri/0000-0002-4706-1519				Agnello V, 1999, P NATL ACAD SCI USA, V96, P12766, DOI 10.1073/pnas.96.22.12766; Altmeyer R, 2004, CURR PHARM DESIGN, V10, P3701, DOI 10.2174/1381612043382729; Andre P, 2002, J VIROL, V76, P6919, DOI 10.1128/JVI.76.14.6919-6928.2002; Bartosch B, 2003, J BIOL CHEM, V278, P41624, DOI 10.1074/jbc.M305289200; Bartosch B, 2003, J EXP MED, V197, P633, DOI 10.1084/jem.20021756; Bressanelli S, 2004, EMBO J, V23, P728, DOI 10.1038/sj.emboj.7600064; Cavrois M, 2002, NAT BIOTECHNOL, V20, P1151, DOI 10.1038/nbt745; CHERNOMORDIK L, 1995, J MEMBRANE BIOL, V146, P1; CLAGUE MJ, 1990, BIOCHEMISTRY-US, V29, P1303, DOI 10.1021/bi00457a028; Cocquerel L, 2002, EMBO J, V21, P2893, DOI 10.1093/emboj/cdf295; Cormier EG, 2004, P NATL ACAD SCI USA, V101, P7270, DOI 10.1073/pnas.0402253101; Corver J, 2000, VIROLOGY, V269, P37, DOI 10.1006/viro.1999.0172; De Beeck AO, 2000, J BIOL CHEM, V275, P31428, DOI 10.1074/jbc.M003003200; DESPRES P, 1993, VIROLOGY, V196, P209, DOI 10.1006/viro.1993.1469; DUBUISSON J, 1994, J VIROL, V68, P6147, DOI 10.1128/JVI.68.10.6147-6160.1994; Earp LJ, 2005, CURR TOP MICROBIOL, V285, P25; Flint M, 2004, J VIROL, V78, P6875, DOI 10.1128/JVI.78.13.6875-6882.2004; Flint M, 1999, J VIROL, V73, P6235, DOI 10.1128/JVI.73.8.6235-6244.1999; Gibbons DL, 2004, J VIROL, V78, P3312, DOI 10.1128/JVI.78.7.3312-3318.2004; Goffard A, 2003, BIOCHIMIE, V85, P295, DOI 10.1016/S0300-9084(03)00004-X; GOLLINS SW, 1986, J GEN VIROL, V67, P157, DOI 10.1099/0022-1317-67-1-157; Guettouche T, 2005, ANTIVIR THER, V10, P593; GUIRAKHOO F, 1991, J GEN VIROL, V72, P1323, DOI 10.1099/0022-1317-72-6-1323; Hatziioannou T, 1998, J VIROL, V72, P5313, DOI 10.1128/JVI.72.6.5313-5317.1998; HOEKSTRA D, 1984, BIOCHEMISTRY-US, V23, P5675, DOI 10.1021/bi00319a002; Hsu M, 2003, P NATL ACAD SCI USA, V100, P7271, DOI 10.1073/pnas.0832180100; JUSTMAN J, 1993, J VIROL, V67, P7597, DOI 10.1128/JVI.67.12.7597-7607.1993; Keck ZY, 2004, J VIROL, V78, P9224, DOI 10.1128/JVI.78.17.9224-9232.2004; Keck ZY, 2004, J VIROL, V78, P7257, DOI 10.1128/JVI.78.13.7257-7263.2004; Kielian M, 2000, Subcell Biochem, V34, P409; LAPIDOT M, 1987, J BIOL CHEM, V262, P13736; Lavillette D, 2005, J VIROL, V79, P6023, DOI 10.1128/JVI.79.10.6023-6034.2005; Lavillette D, 1998, J VIROL, V72, P9955, DOI 10.1128/JVI.72.12.9955-9965.1998; LAVILLETTE D, 2005, J VIROL, V41, P265; Lindenbach BD, 2005, SCIENCE, V309, P623, DOI 10.1126/science.1114016; LINDENBACH BD, 2001, FIELDS VIROLOGY, V1, P991; Logvinoff C, 2004, P NATL ACAD SCI USA, V101, P10149, DOI 10.1073/pnas.0403519101; Lozach PY, 2004, J BIOL CHEM, V279, P32035, DOI 10.1074/jbc.M402296200; Lozach PY, 2003, J BIOL CHEM, V278, P20358, DOI 10.1074/jbc.M301284200; McKeating JA, 2004, J VIROL, V78, P8496, DOI 10.1128/JVI.78.16.8496-8505.2004; Mukhopadhyay S, 2003, SCIENCE, V302, P248, DOI 10.1126/science.1089316; NEW RRC, 1990, LIPOSOMES PRACTICAL, P1; *NIH, 2002, HEPATOLOGY S1, V36, pS2; Otter-Nilsson M, 1999, EMBO J, V18, P2074, DOI 10.1093/emboj/18.8.2074; Pecheur EI, 2000, J BIOL CHEM, V275, P3936, DOI 10.1074/jbc.275.6.3936; Pecheur EI, 2002, BIOCHEMISTRY-US, V41, P9813, DOI 10.1021/bi0259195; Pelkmans L, 2003, CURR OPIN CELL BIOL, V15, P414, DOI 10.1016/S0955-0674(03)00081-4; Penin F, 2004, HEPATOLOGY, V39, P5, DOI 10.1002/hep.20032; Rawat SS, 2003, MOL MEMBR BIOL, V20, P243, DOI 10.1080/0968768031000104944; Sandrin V, 2005, J GEN VIROL, V86, P3189, DOI 10.1099/vir.0.81428-0; Sandrin V, 2002, BLOOD, V100, P823, DOI 10.1182/blood-2001-11-0042; Scarselli E, 2002, EMBO J, V21, P5017, DOI 10.1093/emboj/cdf529; Smit JM, 1999, J VIROL, V73, P8476, DOI 10.1128/JVI.73.10.8476-8484.1999; STEGMANN T, 1985, BIOCHEMISTRY-US, V24, P3107, DOI 10.1021/bi00334a006; STEGMANN T, 1989, BIOCHEMISTRY-US, V28, P1698, DOI 10.1021/bi00430a041; Stiasny K, 2004, J VIROL, V78, P8536, DOI 10.1128/JVI.78.16.8536-8542.2004; Stiasny K, 2003, J VIROL, V77, P7856, DOI 10.1128/JVI.77.14.7856-7862.2003; Takikawa S, 2000, J VIROL, V74, P5066, DOI 10.1128/JVI.74.11.5066-5074.2000; Voisset C, 2004, BIOL CELL, V96, P413, DOI 10.1016/j.biolcel.2004.03.008; Waarts BL, 2005, J VIROL, V79, P7942, DOI 10.1128/JVI.79.12.7942-7948.2005; Wakita T, 2005, NAT MED, V11, P791, DOI 10.1038/nm1268; WHITE J, 1980, P NATL ACAD SCI-BIOL, V77, P3273, DOI 10.1073/pnas.77.6.3273; Yonezawa A, 2005, J VIROL, V79, P918, DOI 10.1128/JVI.79.2.918-926.2005; Zhang J, 2004, J VIROL, V78, P1448, DOI 10.1128/JVI.78.3.1448-1455.2004; Zhong J, 2005, P NATL ACAD SCI USA, V102, P9294, DOI 10.1073/pnas.0503596102; Zlokarnik G, 1998, SCIENCE, V279, P84, DOI 10.1126/science.279.5347.84	66	113	121	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 17	2006	281	7					3909	3917		10.1074/jbc.M509747200	http://dx.doi.org/10.1074/jbc.M509747200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	011NN	16356932	hybrid			2022-12-25	WOS:000235275300018
J	Rosso, A; Balsamo, A; Gambino, R; Dentelli, P; Falcioni, R; Cassader, M; Pegoraro, L; Pagano, G; Brizzi, MF				Rosso, A; Balsamo, A; Gambino, R; Dentelli, P; Falcioni, R; Cassader, M; Pegoraro, L; Pagano, G; Brizzi, MF			p53 mediates the accelerated onset of senescence of endothelial progenitor cells in diabetes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEPENDENT KINASE INHIBITORS; LOW-DENSITY LIPOPROTEINS; HUMAN FIBROBLASTS; REPLICATIVE SENESCENCE; CELLULAR SENESCENCE; LIFE-SPAN; VASCULAR COMPLICATIONS; OXIDATIVE STRESS; IN-VIVO; P16	Adverse metabolic factors, including oxidized small and dense low density lipoprotein (ox-dmLDL) can contribute to the reduced number and the impaired functions of circulating endothelial progenitors (EPC) in diabetic patients. To elucidate the molecular mechanisms involved, EPC from normal donors were cultured in the presence of alpha-dmLDL. Under these experimental conditions EPC undergo to senescent-like growth arrest. This effect is associated with Akt activation, p21 expression, p53 accumulation, and retinoblastoma protein dephosphorylation and with a reduced protective effect against oxidative damage. Moreover, depletion of endogenous p53 expression by small interfering RNA demonstrates that the integrity of this pathway is essential for senescence to occur. Activation of the Akt/p53/p21 signaling pathway and accelerated onset of senescence are also detectable in EPC from diabetic patients. Finally, diabetic EPC depleted of endogenous p53 do not undergo to senescence-growth arrest and acquire the ability to form tube-like structures in vitro. These observations identify the activation of the p53 signaling pathway as a crucial event that can contribute to the impaired neovascularization in diabetes.	Univ Turin, Dept Internal Med, I-10126 Turin, Italy; Regina Elena Inst Canc Res, Mol Oncogenesis Lab, I-00158 Rome, Italy	University of Turin; IRCCS Istituti Fisioterapici Ospitalieri (IFO); IRCCS Regina Elena	Brizzi, MF (corresponding author), Univ Turin, Dept Internal Med, Corso Dogliotti 14, I-10126 Turin, Italy.	mariafelice.brizzi@unito.it	GAMBINO, Roberto/AAC-7517-2022; Brizzi, Maria Felice/J-7882-2016; Falcioni, Rita/H-8869-2017	GAMBINO, Roberto/0000-0003-1902-3627; Falcioni, Rita/0000-0002-3745-4327				Alcorta DA, 1996, P NATL ACAD SCI USA, V93, P13742, DOI 10.1073/pnas.93.24.13742; Andres V, 2004, CIRCULATION, V110, P3749, DOI 10.1161/01.CIR.0000151787.39451.BC; BAYNES JW, 1991, DIABETES, V40, P405, DOI 10.2337/diabetes.40.4.405; Beausejour CM, 2003, EMBO J, V22, P4212, DOI 10.1093/emboj/cdg417; Boulaire J, 2000, PATHOL BIOL, V48, P190; Brizzi MF, 1999, CIRC RES, V84, P785; Brizzi MF, 2004, FASEB J, V18, P1249, DOI 10.1096/fj.03-1053fje; Brizzi MF, 2002, DIABETES, V51, P3311, DOI 10.2337/diabetes.51.11.3311; Brizzi MF, 2002, J CLIN INVEST, V109, P111, DOI 10.1172/JCI13617; Brown JP, 1997, SCIENCE, V277, P831, DOI 10.1126/science.277.5327.831; Brummelkamp TR, 2002, SCIENCE, V296, P550, DOI 10.1126/science.1068999; Campisi J, 2005, CELL, V120, P513, DOI 10.1016/j.cell.2005.02.003; Ceriello A, 2000, DIABETES, V49, P2170, DOI 10.2337/diabetes.49.12.2170; Chang BD, 2000, P NATL ACAD SCI USA, V97, P4291, DOI 10.1073/pnas.97.8.4291; CHANG MW, 1995, J CLIN INVEST, V96, P2260, DOI 10.1172/JCI118281; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Dimmeler S, 2004, J MOL MED, V82, P671, DOI 10.1007/s00109-004-0580-x; Dimri GP, 2005, CANCER CELL, V7, P505, DOI 10.1016/j.ccr.2005.05.025; DIMRI GP, 1995, P NATL ACAD SCI USA, V92, P9363, DOI 10.1073/pnas.92.20.9363; Dirac AMG, 2003, J BIOL CHEM, V278, P11731, DOI 10.1074/jbc.C300023200; Dzau VJ, 2002, NAT MED, V8, P1249, DOI 10.1038/nm1102-1249; El-Deiry WS, 1998, SEMIN CANCER BIOL, V8, P345, DOI 10.1006/scbi.1998.0097; Giugliano D, 1996, DIABETES CARE, V19, P257, DOI 10.2337/diacare.19.3.257; Guevara NV, 1999, NAT MED, V5, P335, DOI 10.1038/6585; Hibbert B, 2003, TRENDS CARDIOVAS MED, V13, P322, DOI 10.1016/j.tcm.2003.09.002; Hill JM, 2003, NEW ENGL J MED, V348, P593, DOI 10.1056/NEJMoa022287; Howard Barbara V., 1994, Current Opinion in Lipidology, V5, P216, DOI 10.1097/00041433-199405030-00009; Itahana K, 2001, EUR J BIOCHEM, V268, P2784, DOI 10.1046/j.1432-1327.2001.02228.x; Itahana K, 2004, BIOGERONTOLOGY, V5, P1, DOI 10.1023/B:BGEN.0000017682.96395.10; Itahana K, 2003, MOL CELL BIOL, V23, P389, DOI 10.1128/MCB.23.1.389-401.2003; Jascur T, 2005, MOL CELL, V17, P237, DOI 10.1016/j.molcel.2004.11.049; Kontush A, 2002, FASEB J, V16, P88, DOI 10.1096/fj.02-0293fje; Krieger M, 1997, CURR OPIN LIPIDOL, V8, P275, DOI 10.1097/00041433-199710000-00006; Ladislas R, 2000, Pathol Oncol Res, V6, P3; Lombard DB, 2005, CELL, V120, P497, DOI 10.1016/j.cell.2005.01.028; Loomans CJM, 2004, DIABETES, V53, P195, DOI 10.2337/diabetes.53.1.195; Lyons TJ, 1997, CURR OPIN LIPIDOL, V8, P174, DOI 10.1097/00041433-199706000-00008; McConnell BB, 1998, CURR BIOL, V8, P351, DOI 10.1016/S0960-9822(98)70137-X; Merched AJ, 2004, CIRCULATION, V110, P3830, DOI 10.1161/01.CIR.0000148681.01282.89; Miyauchi H, 2004, EMBO J, V23, P212, DOI 10.1038/sj.emboj.7600045; MONTESANO R, 1985, CELL, V42, P469, DOI 10.1016/0092-8674(85)90104-7; Murphy CT, 2003, NATURE, V424, P277, DOI 10.1038/nature01789; Nemoto S, 2002, SCIENCE, V295, P2450, DOI 10.1126/science.1069004; PENN MS, 1994, ATHEROSCLEROSIS, V108, pS21, DOI 10.1016/0021-9150(94)90150-3; Pesce M, 2003, CIRC RES, V93, pE51, DOI 10.1161/01.RES.0000090624.04507.45; REDGRAVE TG, 1979, J LIPID RES, V20, P217; ROSS R, 1993, NATURE, V362, P801, DOI 10.1038/362801a0; SHEN MMS, 1981, J LIPID RES, V22, P236; Stein GH, 1999, MOL CELL BIOL, V19, P2109; Tanner FC, 1998, CIRC RES, V82, P396, DOI 10.1161/01.RES.82.3.396; VEDIE B, 1991, J LIPID RES, V32, P1359; Wei WY, 2003, EMBO REP, V4, P1061, DOI 10.1038/sj.embor7400001; Wong DJ, 1999, MOL CELL BIOL, V19, P5642	53	122	128	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 17	2006	281	7					4339	4347		10.1074/jbc.M509293200	http://dx.doi.org/10.1074/jbc.M509293200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	011NN	16339764	hybrid			2022-12-25	WOS:000235275300069
J	Matsuda, N; Kitami, T; Suzuki, T; Mizuno, Y; Hattori, N; Tanaka, K				Matsuda, N; Kitami, T; Suzuki, T; Mizuno, Y; Hattori, N; Tanaka, K			Diverse effects of pathogenic mutations of parkin that catalyze multiple monoubiquitylation in vitro	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							UBIQUITIN-CONJUGATING ENZYME; LIGASE ACTIVITY; FINGER PROTEIN; DISEASE; LOCALIZATION; COMPLEX; CHAINS; SOLUBILITY; MECHANISMS; PROTEASOME	Mutational dysfunction of PARKIN gene, which encodes a double RING finger protein and has ubiquitin ligase E3 activity, is the major cause of autosomal recessive juvenile Parkinsonism. Although many studies explored the functions of Parkin, its biochemical character is poorly understood. To address this issue, we established an E3 assay system using maltose-binding protein-fused Parkin purified from Escherichia coli. Using this recombinant Parkin, we found that not the front but the rear RING finger motif is responsible for the E3 activity of Parkin, and it catalyzes multiple monoubiquitylation. Intriguingly, for autosomal recessive juvenile Parkinsonism-causing mutations of Parkin, whereas there was loss of E3 activity in the rear RING domain, other pathogenic mutants still exhibited E3 activity equivalent to that of the wild-type Parkin. The evidence presented allows us to reconsider the function of Parkin-catalyzed ubiquitylation and to conclude that autosomal recessive juvenile Parkinsonism is not solely attributable to catalytic impairment of the E3 activity of Parkin.	Tokyo Metropolitan Inst Med Sci, Lab Frontier Sci, Bunkyo Ku, Tokyo 1138613, Japan; Juntendo Univ, Sch Med, Dept Neurol, Bunkyo Ku, Tokyo 1130033, Japan	Tokyo Metropolitan Institute of Medical Science; Juntendo University	Tanaka, K (corresponding author), Tokyo Metropolitan Inst Med Sci, Lab Frontier Sci, Bunkyo Ku, Tokyo 1138613, Japan.	tanakak@rinshoken.or.jp	Matsuda, Noriyuki/AAI-3156-2020	Matsuda, Noriyuki/0000-0001-8199-952X; Suzuki, Toshiaki/0000-0002-0650-6251				Araki K, 2003, J NEUROCHEM, V86, P749, DOI 10.1046/j.1471-4159.2003.01875.x; Chen ZJJ, 2005, NAT CELL BIOL, V7, P758, DOI 10.1038/ncb0805-758; Cookson MR, 2003, HUM MOL GENET, V12, P2957, DOI 10.1093/hmg/ddg328; Corti O, 2003, HUM MOL GENET, V12, P1427, DOI 10.1093/hmg/ddg159; Doss-Pepe EW, 2005, J BIOL CHEM, V280, P16619, DOI 10.1074/jbc.M413591200; Giasson BI, 2003, CELL, V114, P1, DOI 10.1016/S0092-8674(03)00509-9; Gu WJ, 2003, NEUROBIOL DIS, V14, P357, DOI 10.1016/j.nbd.2003.08.011; Hattori N, 2004, LANCET, V364, P722, DOI 10.1016/S0140-6736(04)16901-8; Henn IH, 2005, J NEUROCHEM, V92, P114, DOI 10.1111/j.1471-4159.2004.02854.x; Hicke L, 2001, NAT REV MOL CELL BIO, V2, P195, DOI 10.1038/35056583; Hofmann RM, 1999, CELL, V96, P645, DOI 10.1016/S0092-8674(00)80575-9; Imai N, 2003, J VIROL, V77, P923, DOI 10.1128/JVI.77.2.923-930.2003; Imai Y, 2002, MOL CELL, V10, P55, DOI 10.1016/S1097-2765(02)00583-X; Lim KL, 2005, J NEUROSCI, V25, P2002, DOI 10.1523/JNEUROSCI.4474-04.2005; Lohmann E, 2003, ANN NEUROL, V54, P176, DOI 10.1002/ana.10613; Matsuda N, 2005, DNA REPAIR, V4, P537, DOI 10.1016/j.dnarep.2004.12.012; Matsuda N, 2001, J CELL SCI, V114, P1949; Moore DJ, 2005, ANNU REV NEUROSCI, V28, P57, DOI 10.1146/annurev.neuro.28.061604.135718; Pawlyk AC, 2003, J BIOL CHEM, V278, P48120, DOI 10.1074/jbc.M306889200; Pickart CM, 2000, TRENDS BIOCHEM SCI, V25, P544, DOI 10.1016/S0968-0004(00)01681-9; Rankin CA, 2001, J BIOMED SCI, V8, P421; Ren Y, 2003, J NEUROSCI, V23, P3316; Richly H, 2005, CELL, V120, P73, DOI 10.1016/j.cell.2004.11.013; Ross CA, 2004, TRENDS CELL BIOL, V14, P703, DOI 10.1016/j.tcb.2004.10.006; Shimura H, 1999, ANN NEUROL, V45, P668, DOI 10.1002/1531-8249(199905)45:5<668::AID-ANA19>3.0.CO;2-Z; Sriram SR, 2005, HUM MOL GENET, V14, P2571, DOI 10.1093/hmg/ddi292; Staropoli JF, 2003, NEURON, V37, P735, DOI 10.1016/S0896-6273(03)00084-9; Takai R, 2002, PLANT J, V30, P447, DOI 10.1046/j.1365-313X.2002.01299.x; Tanaka K, 2004, BBA-MOL CELL RES, V1695, P235, DOI 10.1016/j.bbamcr.2004.09.026; Wang C, 2005, J NEUROCHEM, V93, P422, DOI 10.1111/j.1471-4159.2005.03023.x; You JX, 1999, BIOTECHNIQUES, V27, P950, DOI 10.2144/99275st01; Zhong L, 2005, J BIOL CHEM, V280, P9425, DOI 10.1074/jbc.M408955200	32	141	147	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 10	2006	281	6					3204	3209		10.1074/jbc.M510393200	http://dx.doi.org/10.1074/jbc.M510393200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	009QV	16339143	hybrid			2022-12-25	WOS:000235128200024
J	Watanabe, S; Matsuyama, S; Tokuda, H				Watanabe, S; Matsuyama, S; Tokuda, H			Roles of the hydrophobic cavity and lid of LolA in the lipoprotein transfer reaction in Escherichia coli	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							OUTER-MEMBRANE LIPOPROTEIN; GRAM-NEGATIVE BACTERIA; CYTOPLASMIC MEMBRANE; MOLECULAR CHAPERONE; INNER MEMBRANE; PROTEINS; LOCALIZATION; RELEASE; MUTANT; EXPRESSION	LolA, a periplasmic chaperone, binds to outer membrane-specific lipoproteins released from the inner membrane through the action of an ATP-binding cassette transporter, LolCDE and then transfers them to the outer membrane receptor LolB, thereby mediating the inner to outer membrane transport of lipoproteins. The crystal structure of free LolA revealed that it has an internal hydrophobic cavity, which is surrounded by hydrophobic residues and closed by a lid comprising alpha-helices. The hydrophobic cavity most likely represents the binding site for the lipid moiety of a lipoprotein. It is speculated that the lid undergoes opening and closing upon the binding and transfer of lipoproteins, respectively. To determine the functions of the hydrophobic cavity and lid in detail, 14 residues involved in the formation of these structures were subjected to random mutagenesis. Among the obtained 21 LolA derivatives that did not support growth, 14 were active as to the binding of lipoproteins but defective in the transfer of lipoproteins to LolB, causing the periplasmic accumulation of a lipoprotein as a complex with a LolA derivative. A LolA derivative, I93G, bound lipoproteins faster than wild-type LolA did, whereas it did not transfer associated lipoproteins to LolB. When I93G and wild type LolA co-existed, lipoproteins were bound only to I93G; which therefore exhibited a dominant negative property. Another derivative, L59R, was also defective in the transfer of lipoproteins to LolB but did not exhibit a dominant negative property. Taken together, these results indicate that both the hydrophobic cavity and the lid are critically important for not only the binding of lipoproteins but also their transfer.	Univ Tokyo, Inst Mol & Cellular Biosci, Bunkyo Ku, Tokyo 1130032, Japan; Rikkyo Univ, Dept Life Sci, Toshima Ku, Tokyo 1718501, Japan	University of Tokyo; Rikkyo University	Tokuda, H (corresponding author), Univ Tokyo, Inst Mol & Cellular Biosci, Bunkyo Ku, 1-1-1 Yayoi, Tokyo 1130032, Japan.	htokuda@iam.u-tokyo.ac.jp						Brokx SJ, 2004, J BACTERIOL, V186, P3254, DOI 10.1128/JB.186.10.3254-3258.2004; Chou P Y, 1978, Adv Enzymol Relat Areas Mol Biol, V47, P45; Hara T, 2003, J BIOL CHEM, V278, P40408, DOI 10.1074/jbc.M307836200; HAYASHI S, 1990, J BIOENERG BIOMEMBR, V22, P451, DOI 10.1007/BF00763177; HAZELBAUER GL, 1975, J BACTERIOL, V122, P206, DOI 10.1128/JB.122.1.206-214.1975; HIROTA Y, 1977, P NATL ACAD SCI USA, V74, P1417, DOI 10.1073/pnas.74.4.1417; HUSSAIN M, 1980, J BIOL CHEM, V255, P3707; Ikegami A, 2005, BIOSCI BIOTECH BIOCH, V69, P1595, DOI 10.1271/bbb.69.1595; Juncker AS, 2003, PROTEIN SCI, V12, P1652, DOI 10.1110/ps.0303703; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MATSUYAMA S, 1993, EMBO J, V12, P265, DOI 10.1002/j.1460-2075.1993.tb05652.x; MATSUYAMA S, 1995, EMBO J, V14, P3365, DOI 10.1002/j.1460-2075.1995.tb07342.x; Matsuyama S, 1997, EMBO J, V16, P6947, DOI 10.1093/emboj/16.23.6947; Miller J. H., 1972, EXPT MOL GENETICS, P431; Miyadai H, 2004, J BIOL CHEM, V279, P39807, DOI 10.1074/jbc.M406390200; Miyamoto A, 2002, FEBS LETT, V528, P193, DOI 10.1016/S0014-5793(02)03305-7; Miyamoto A, 2001, BIOCHEM BIOPH RES CO, V287, P1125, DOI 10.1006/bbrc.2001.5705; OSBORN MJ, 1972, J BIOL CHEM, V247, P3962; Ponting CP, 1999, TRENDS BIOCHEM SCI, V24, P130, DOI 10.1016/S0968-0004(99)01362-6; PUGSLEY AP, 1993, MICROBIOL REV, V57, P50, DOI 10.1128/MMBR.57.1.50-108.1993; Roderick SL, 2002, NAT STRUCT BIOL, V9, P507, DOI 10.1038/nsb812; SANKARAN K, 1994, J BIOL CHEM, V269, P19701; Seydel A, 1999, MOL MICROBIOL, V34, P810, DOI 10.1046/j.1365-2958.1999.01647.x; Soccio RE, 2003, J BIOL CHEM, V278, P22183, DOI 10.1074/jbc.R300003200; Tajima T, 1998, FEBS LETT, V439, P51, DOI 10.1016/S0014-5793(98)01334-9; Takeda K, 2003, EMBO J, V22, P3199, DOI 10.1093/emboj/cdg324; Taniguchi N, 2005, J BIOL CHEM, V280, P34481, DOI 10.1074/jbc.M507388200; Terada M, 2001, J BIOL CHEM, V276, P47690, DOI 10.1074/jbc.M109307200; Yakushi T, 1998, J BIOL CHEM, V273, P32576, DOI 10.1074/jbc.273.49.32576; Yakushi T, 2000, NAT CELL BIOL, V2, P212, DOI 10.1038/35008635; YAMAGUCHI K, 1988, CELL, V53, P423, DOI 10.1016/0092-8674(88)90162-6	32	12	12	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 10	2006	281	6					3335	3342		10.1074/jbc.M509596200	http://dx.doi.org/10.1074/jbc.M509596200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	009QV	16354671	hybrid			2022-12-25	WOS:000235128200041
J	Benjanirut, C; Paris, M; Wang, WH; Hong, SJ; Kim, KS; Hullinger, RL; Andrisani, OM				Benjanirut, C; Paris, M; Wang, WH; Hong, SJ; Kim, KS; Hullinger, RL; Andrisani, OM			The cAMP pathway in combination with BMP2 regulates Phox2a transcription via cAMP response element binding sites	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GENOME-WIDE ANALYSIS; CIS-ACTING ELEMENTS; PHENOTYPIC MARKERS; GENE; EXPRESSION; DIFFERENTIATION; PROTEIN; CELLS; CREB; HYDROXYLASE	Combined BMP2 and cAMP signaling induces the catecholaminergic lineage in neural crest (NC) cultures by increasing expression of the proneural transcription factor Phox2a, in a cAMP response element (CRE)-binding protein (CREB)-mediated mechanism. To determine whether CREB acts directly on Phox2a transcription induced by BMP2+cAMP-elevating agent IBMX, transient transfections of hPhox2a-reporter constructs were performed in avian NC cultures and murine, catecholaminergic CAD cells. Although BMP2+IBMX increased endogenous Phox2a expression, the 7.5-kb hPhox2a reporters expressing either luciferase or DsRed1-E5 fluorescent protein were unresponsive to BMP2+IBMX, but active in both cell types. Cell sorting of fluorescence-positive NC cells expressing the 7.5-kb hPhox2a fluorescent timer reporter differentiated to equal numbers of catecholaminergic cells as fluorescence-negative cells, suggesting inappropriate transcription from the transfected hPhox2a promoter. NC or CAD cells treated with histone deacetylase inhibitor trichostatin A and BMP2+IBMX display increased endogenous Phox2a transcription and prolonged CREB phosphorylation, indicating Phox2a chromatin remodeling is linked to CREB activation. Chromatin immunoprecipitations employing CREB, CREB-binding protein, and acetylated H4 antibodies identified two CRE half-sites at -5.5 kb in the murine Phox2a promoter, which is also conserved in the human promoter. Proximal to the CRE half-sites, within a 170-bp region, are E-box and CCAAT binding sites, also conserved in mouse and human genes. This 170-bp promoter region confers cAMP, BMP2, and enhanced BMP2+cAMP regulation to Phox2a-luciferase reporters. We conclude these CREs are functional, with CREB directly activating Phox2a transcription. Because the E-box binds bHLH proteins like ASH1 induced in NC cells by BMP2, we propose this novel 170-bp cis-acting element is a composite site, mediating the synergistic regulation by BMP2+cAMP on Phox2a transcription.	Purdue Univ, Dept Basic Med Sci, W Lafayette, IN 47907 USA; Harvard Univ, Sch Med, McLean Hosp, Mol Neurobiol Lab, Belmont, MA 02478 USA	Purdue University System; Purdue University; Purdue University West Lafayette Campus; Harvard University; McLean Hospital	Andrisani, OM (corresponding author), Purdue Univ, Dept Basic Med Sci, 625 Harrison St, W Lafayette, IN 47907 USA.	andrisao@purdue.edu		Andrisani, Ourania/0000-0002-6230-0303				ANDERSON DJ, 1991, J NEUROSCI, V11, P3507; Andrisani OM, 1999, CRIT REV EUKAR GENE, V9, P19, DOI 10.1615/CritRevEukaryotGeneExpr.v9.i1.20; ANDRISANI OM, 1988, MOL CELL BIOL, V8, P1947, DOI 10.1128/MCB.8.5.1947; Bilodeau ML, 2005, MOL CELL NEUROSCI, V29, P394, DOI 10.1016/j.mcn.2005.03.006; Bilodeau ML, 2001, IN VITRO CELL DEV-AN, V37, P185; Bilodeau ML, 2000, MOL CELL BIOL, V20, P3004, DOI 10.1128/MCB.20.9.3004-3014.2000; Cha-Molstad H, 2004, P NATL ACAD SCI USA, V101, P13572, DOI 10.1073/pnas.0405587101; Chen CJ, 2001, MOL CELL BIOL, V21, P476, DOI 10.1128/MCB.21.2.476-487.2001; Chen SG, 2005, J BIOL CHEM, V280, P41025, DOI 10.1074/jbc.M503537200; Creaser PC, 1996, NUCLEIC ACIDS RES, V24, P2597, DOI 10.1093/nar/24.13.2597; ERNSBERGER U, 1995, MECH DEVELOP, V52, P125, DOI 10.1016/0925-4773(95)00396-I; Finnin MS, 1999, NATURE, V401, P188, DOI 10.1038/43710; Ghislain J, 2003, DEVELOPMENT, V130, P941, DOI 10.1242/dev.00318; Goodman RH, 2000, GENE DEV, V14, P1553; GROVES AK, 1995, DEVELOPMENT, V121, P887; GUILLEMOT F, 1993, MECH DEVELOP, V42, P171, DOI 10.1016/0925-4773(93)90006-J; Hirsch MR, 1998, DEVELOPMENT, V125, P599; Hong SJ, 2002, BIOTECHNIQUES, V33, P1236, DOI 10.2144/02336bm11; Hong SJ, 2001, J NEUROCHEM, V79, P1225, DOI 10.1046/j.1471-4159.2001.00672.x; Huber K, 2002, DEVELOPMENT, V129, P4729; Impey S, 2004, CELL, V119, P1041, DOI 10.1016/j.cell.2004.10.032; Johnstone RW, 2002, NAT REV DRUG DISCOV, V1, P287, DOI 10.1038/nrd772; Kilav R, 2001, J BIOL CHEM, V276, P8727, DOI 10.1074/jbc.M005471200; Kim HS, 1998, J NEUROSCI, V18, P8247; KWOK RP, 1994, NATURE, V370, P177; Le Douarin NM, 2004, DEVELOPMENT, V131, P4637, DOI 10.1242/dev.01350; Lee S, 2002, J BIOL CHEM, V277, P8730, DOI 10.1074/jbc.M108025200; Liu T, 2000, J MOL EVOL, V50, P22, DOI 10.1007/s002399910003; LO LC, 1991, GENE DEV, V5, P1524, DOI 10.1101/gad.5.9.1524; Lo LC, 1998, DEVELOPMENT, V125, P609; Lo LC, 1999, NEURON, V22, P693, DOI 10.1016/S0896-6273(00)80729-1; Mandolesi G, 2002, FEBS LETT, V510, P50, DOI 10.1016/S0014-5793(01)03227-6; Michael LF, 2000, MOL CELL BIOL, V20, P1596, DOI 10.1128/MCB.20.5.1596-1603.2000; Montminy M, 1997, ANNU REV BIOCHEM, V66, P807, DOI 10.1146/annurev.biochem.66.1.807; Morin X, 1997, NEURON, V18, P411, DOI 10.1016/S0896-6273(00)81242-8; Qi YP, 1997, J NEUROSCI, V17, P1217; Reissmann E, 1996, DEVELOPMENT, V122, P2079; Roth SY, 2001, ANNU REV BIOCHEM, V70, P81, DOI 10.1146/annurev.biochem.70.1.81; Rowitch DH, 1998, DEVELOPMENT, V125, P2735; Shah NM, 1996, CELL, V85, P331, DOI 10.1016/S0092-8674(00)81112-5; Smale ST, 2002, ANNU REV IMMUNOL, V20, P427, DOI 10.1146/annurev.immunol.20.100301.064739; Spector DL, 2003, ANNU REV BIOCHEM, V72, P573, DOI 10.1146/annurev.biochem.72.121801.161724; SURI C, 1993, J NEUROSCI, V13, P1280; Terskikh A, 2000, SCIENCE, V290, P1585, DOI 10.1126/science.290.5496.1585; VARLEY JE, 1995, DEV DYNAM, V203, P434, DOI 10.1002/aja.1002030406; Varley JE, 1996, EXP NEUROL, V140, P84, DOI 10.1006/exnr.1996.0118; Wilson HL, 2002, MOL CELL ENDOCRINOL, V188, P15, DOI 10.1016/S0303-7207(01)00754-7; Workman JL, 1998, ANNU REV BIOCHEM, V67, P545, DOI 10.1146/annurev.biochem.67.1.545; Yang CY, 1998, J NEUROCHEM, V71, P1813; Zellmer E, 1995, J NEUROSCI, V15, P8109; Zhang XQ, 2005, P NATL ACAD SCI USA, V102, P892, DOI 10.1073/pnas.0408936102	51	15	17	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 3	2006	281	5					2969	2981		10.1074/jbc.M503939200	http://dx.doi.org/10.1074/jbc.M503939200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	006XT	16330553	hybrid			2022-12-25	WOS:000234931800067
J	Roviezzo, F; Bucci, M; Delisle, C; Brancaleone, V; Di Lorenzo, A; Mayo, IP; Fiorucci, S; Fontana, A; Gratton, JP; Cirino, G				Roviezzo, Fiorentina; Bucci, Mariarosaria; Delisle, Chantal; Brancaleone, Vincenzo; Di Lorenzo, Annarita; Mayo, Inmaculada Posadas; Fiorucci, Stefano; Fontana, Angelo; Gratton, Jean-Philippe; Cirino, Giuseppe			Essential requirement for sphingosine kinase activity in eNOS-dependent NO release and vasorelaxation	FASEB JOURNAL			English	Article									[Roviezzo, Fiorentina; Bucci, Mariarosaria; Brancaleone, Vincenzo; Di Lorenzo, Annarita; Mayo, Inmaculada Posadas; Cirino, Giuseppe] Univ Naples Federico 2, Dipartimento Farmacol Sperimentale, I-80131 Naples, Italy; [Delisle, Chantal; Gratton, Jean-Philippe] Inst Rech Clin Montreal, Lab Endothelial Cell Biol, Montreal, PQ H2W 1R7, Canada; [Fontana, Angelo] CNR, Ist Chim Biomol, I-80125 Naples, Italy; [Fiorucci, Stefano] Dipartimento Med Sperimentale, Perugia, Italy	University of Naples Federico II; Institut de Recherche Clinique de Montreal (IRCM); Universite de Montreal; Consiglio Nazionale delle Ricerche (CNR); Istituto di Chimica Biomolecolare (ICB-CNR)	Cirino, G (corresponding author), Univ Naples Federico 2, Dipartimento Farmacol Sperimentale, Via Domenico Montesano 49, I-80131 Naples, Italy.	cirino@unina.it	Fontana, Angelo/C-3354-2012; Fiorucci, Stefano/I-1251-2012; Fontana, Angelo/AAO-2741-2021; Posadas, Inmaculada/M-1124-2014	Fontana, Angelo/0000-0002-5453-461X; Fontana, Angelo/0000-0002-5453-461X; Posadas, Inmaculada/0000-0003-1854-3372; Roviezzo, Fiorentina/0000-0003-1582-7396; Cirino, Giuseppe/0000-0003-3954-4083; Gratton, Jean-Philippe/0000-0001-9877-8520; brancaleone, vincenzo/0000-0002-0063-659X; Di Lorenzo, Annarita/0000-0003-1239-4222					0	32	33	0	2	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	FEB	2006	20	2					340	342		10.1096/fj.05-4647fje	http://dx.doi.org/10.1096/fj.05-4647fje			3	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	V17CJ	16322129				2022-12-25	WOS:000207915000014
J	Izumikawa, T; Egusa, N; Taniguchi, F; Sugahara, K; Kitagawa, H				Izumikawa, T; Egusa, N; Taniguchi, F; Sugahara, K; Kitagawa, H			Heparan sulfate polymerization in Drosophila	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EXT GENE FAMILY; N-ACETYLGLUCOSAMINE; TUMOR SUPPRESSORS; CHAIN INITIATION; TOUT-VELU; BIOSYNTHESIS; PROTEOGLYCANS; IDENTIFICATION; EXPRESSION; EXOSTOSES	The formation of heparan sulfate (HS) chains is catalyzed by glycosyltransferases encoded by EXT (hereditary multiple exostosin gene) family members. Genetic screening for mutations affecting morphogen signaling pathways in Drosophila has identified three genes, tout-velu (ttv), sister of tout-velu (sotv), and brother of tout-velu (botv), which encode homologues of human EXT1, EXT2, and EXTL3, respectively. So far, in vitro glycosyltransferase activities have been demonstrated only for BOTV/DEXTL3, which harbors both N-acetylglucosaminyltransferase-I ( GlcNAcT-I) and N-acetylglucosaminyltransferase-II (GlcNAcT-II) activities responsible for the chain initiation and elongation of HS, and no glucuronyltransferase-II (GlcAT-II) activity. Here we demonstrated that TTV/ DEXT1 and SOTV/DEXT2 had GlcNAcT-II and GlcAT-II activities required for the biosynthesis of repeating disaccharide units of the HS backbone, and the coexpression of TTV with SOTV markedly augmented both glycosyltransferase activities when compared with the expression of TTV or SOTV alone. Moreover, the polymerization of HS was demonstrated on a linkage region analogue as an acceptor substrate by BOTV and an enzyme complex composed of TTV and SOTV (TTV- SOTV). In contrast to human, TTV-SOTV exhibited no GlcNAcT-I activity, indicating that BOTV/DEXT3, which is an EXT-Like gene and possesses GlcNAcT-I activity required for the initiation of HS, is indispensable for the biosynthesis of HS chains in Drosophila. Thus, all three EXT members in Drosophila, TTV, SOTV, and BOTV, are required for the biosynthesis of full-length HS in Drosophila.	Kobe Pharmaceut Univ, Dept Biochem, Higashinada Ku, Kobe, Hyogo 6588558, Japan	Kobe Pharmaceutical University	Sugahara, K (corresponding author), Kobe Pharmaceut Univ, Dept Biochem, Higashinada Ku, 4-19-1 Motoyamakitamachi, Kobe, Hyogo 6588558, Japan.	sugar@kobepharma-u.ac.jp	Kitagawa, Hiroshi/AAJ-1344-2020	Kitagawa, Hiroshi/0000-0002-9307-7079				Bellaiche Y, 1998, NATURE, V394, P85, DOI 10.1038/27932; Bernfield M, 1999, ANNU REV BIOCHEM, V68, P729, DOI 10.1146/annurev.biochem.68.1.729; Bornemann DJ, 2004, DEVELOPMENT, V131, P1927, DOI 10.1242/dev.01061; FRITZ TA, 1994, J BIOL CHEM, V269, P28809; Han C, 2004, DEVELOPMENT, V131, P1563, DOI 10.1242/dev.01051; Izumikawa T, 2004, J BIOL CHEM, V279, P53755, DOI 10.1074/jbc.M409615200; Kim BT, 2003, J BIOL CHEM, V278, P41618, DOI 10.1074/jbc.M304831200; Kim BT, 2002, J BIOL CHEM, V277, P13659, DOI 10.1074/jbc.M111630200; Kim BT, 2001, P NATL ACAD SCI USA, V98, P7176, DOI 10.1073/pnas.131188498; KITAGAWA H, 1994, J BIOL CHEM, V269, P1394; Kitagawa H, 1999, J BIOL CHEM, V274, P13933, DOI 10.1074/jbc.274.20.13933; Lander AD, 2000, J CELL BIOL, V148, P227, DOI 10.1083/jcb.148.2.227; LIDHOLT K, 1992, P NATL ACAD SCI USA, V89, P2267, DOI 10.1073/pnas.89.6.2267; Lin X, 2000, DEV BIOL, V224, P299, DOI 10.1006/dbio.2000.9798; Lin XH, 2000, MATRIX BIOL, V19, P303, DOI 10.1016/S0945-053X(00)00073-1; Lind T, 1998, J BIOL CHEM, V273, P26265, DOI 10.1074/jbc.273.41.26265; McCormick C, 1999, MOL MED TODAY, V5, P481, DOI 10.1016/S1357-4310(99)01593-2; McCormick C, 1998, NAT GENET, V19, P158, DOI 10.1038/514; Mitchell KJ, 2001, NAT GENET, V28, P241, DOI 10.1038/90074; Ninomiya T, 2002, J BIOL CHEM, V277, P21567, DOI 10.1074/jbc.M201719200; Nybakken K, 2002, BBA-GEN SUBJECTS, V1573, P280, DOI 10.1016/S0304-4165(02)00395-1; Pedersen LC, 2003, J BIOL CHEM, V278, P14420, DOI 10.1074/jbc.M210532200; Saito T, 1998, BIOCHEM BIOPH RES CO, V243, P61, DOI 10.1006/bbrc.1997.8062; Senay C, 2000, EMBO REP, V1, P282, DOI 10.1093/embo-reports/kvd045; Stickens D, 2005, DEVELOPMENT, V132, P5055, DOI 10.1242/dev.02088; Takei Y, 2004, DEVELOPMENT, V131, P73, DOI 10.1242/dev.00913; The I, 1999, MOL CELL, V4, P633, DOI 10.1016/S1097-2765(00)80214-2; Van Hul W, 1998, GENOMICS, V47, P230, DOI 10.1006/geno.1997.5101; Wise CA, 1997, GENOME RES, V7, P10, DOI 10.1101/gr.7.1.10; Wuyts W, 1997, EUR J HUM GENET, V5, P382, DOI 10.1159/000484796; Yamada S, 2004, J BIOL CHEM, V279, P32134, DOI 10.1074/jbc.M312624200	31	21	22	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 27	2006	281	4					1929	1934		10.1074/jbc.M509138200	http://dx.doi.org/10.1074/jbc.M509138200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	004NV	16303756	hybrid			2022-12-25	WOS:000234760400011
J	Raymond, WW; Cruz, AC; Caughey, GH				Raymond, WW; Cruz, AC; Caughey, GH			Mast cell and neutrophil peptidases attack an inactivation segment in hepatocyte growth factor to generate NK4-like antagonists	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							C-MET RECEPTOR; SCATTER FACTOR; HUMAN CHYMASE; LUNG INJURY; CATHEPSIN-G; MOUSE; ALPHA; SUBSTRATE; ELASTASE; CLEAVAGE	Hepatocyte growth factor (HGF) is a plasminogen-like protein with an alpha chain linked to a trypsin-like beta chain without peptidase activity. The interaction of HGF with c-met, a receptor tyrosine kinase expressed by many cells, is important in cell growth, migration, and formation of endothelial and epithelial tubes. Stimulation of c-met requires two-chain, disulfide-linked HGF. Portions of an alpha chain containing an N-terminal segment and four kringle domains (NK4) antagonize HGF activity. Until now, no physiological pathway for generating NK4 was known. Here we show that chymases, which are chymotryptic peptidases secreted by mast cells, hydrolyze HGF, thereby abolishing scatter factor activity while generating an NK4-like antagonist of HGF scatter factor activity. Thus, chymase interferes with HGF directly by destroying active protein and indirectly by generating an antagonist. The site of hydrolysis, Leu480, lies in the alpha chain on the N- terminal side of the cysteine linking the alpha and beta chains. This site appears to be specific for HGF because chymase does not hydrolyze other plasminogen-like proteins, such as macrophage-stimulating protein and plasminogen itself. Mast cell/neutrophil cathepsin G and neutrophil elastase generate similar fragments of HGF by cleaving near the chymase site. Mast cell and neutrophil peptidases are secreted during tissue injury, infection, ischemia, and allergic inflammation, where they may oppose HGF effects on epithelial repair. Thus, HGF possesses an "inactivation segment" that serves as an Achilles' heel attacked by inflammatory proteases. This work reveals a potential physiological pathway for inactivation of HGF and generation of NK4-like antagonists.	Vet Affairs Med Ctr, San Francisco, CA 94121 USA; Univ Calif San Francisco, Dept Med, San Francisco, CA 94143 USA; Univ Calif San Francisco, Cardiovasc Res Inst, San Francisco, CA 94143 USA	US Department of Veterans Affairs; Veterans Health Administration (VHA); University of California System; University of California San Francisco; University of California System; University of California San Francisco	Caughey, GH (corresponding author), Vet Affairs Med Ctr, 111-D,4150 Clement St, San Francisco, CA 94121 USA.	George.Caughey@ucsf.edu			NHLBI NIH HHS [P01 HL024136-230014, P01 HL024136, P01 HL024136-27, P01 HL024136-250014, P01 HL024136-25, P01 HL024136-240014, P01 HL024136-260002, P01 HL024136-24, P01 HL024136-270002, P01 HL024136-26, HL024136] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL024136] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Aharinejad S, 2004, LANCET, V363, P1503, DOI 10.1016/S0140-6736(04)16148-5; Birchmeier C, 2003, NAT REV MOL CELL BIO, V4, P915, DOI 10.1038/nrm1261; Campbell EJ, 1999, J CLIN INVEST, V104, P337, DOI 10.1172/JCI6092; Caughey GH, 2000, BBA-PROTEIN STRUCT M, V1480, P245, DOI 10.1016/S0167-4838(00)00076-5; Caughey GH, 2002, MOL IMMUNOL, V38, P1353, DOI 10.1016/S0161-5890(02)00087-1; CHAN AML, 1991, SCIENCE, V254, P1382, DOI 10.1126/science.1720571; Date K, 1997, FEBS LETT, V420, P1, DOI 10.1016/S0014-5793(97)01475-0; Fehlner-Gardiner CC, 1999, DIFFERENTIATION, V65, P27, DOI 10.1046/j.1432-0436.1999.6510027.x; GOHDA E, 1988, J CLIN INVEST, V81, P414, DOI 10.1172/JCI113334; HARTMANN G, 1992, P NATL ACAD SCI USA, V89, P11574, DOI 10.1073/pnas.89.23.11574; HARTMANN T, 1992, AM J PHYSIOL, V262, pL528, DOI 10.1152/ajplung.1992.262.5.L528; IRANI AMA, 1989, J HISTOCHEM CYTOCHEM, V37, P1509, DOI 10.1177/37.10.2674273; Ito W, 2005, AM J RESP CELL MOL, V32, P268, DOI 10.1165/rcmb.2004-0058OC; Karlson U, 2003, J BIOL CHEM, V278, P39625, DOI 10.1074/jbc.M301512200; Kinoshita M, 2002, CIRCULATION, V106, P3133, DOI 10.1161/01.CIR.0000039344.98537.BE; Kofford MW, 1997, J BIOL CHEM, V272, P7127, DOI 10.1074/jbc.272.11.7127; Kunori Y, 2002, EUR J BIOCHEM, V269, P5921, DOI 10.1046/j.1432-1033.2002.03316.x; MATIN R, 1992, J HISTOCHEM CYTOCHEM, V40, P781, DOI 10.1177/40.6.1588024; Matsumori A, 2004, CARDIOVASC DRUG THER, V18, P321, DOI 10.1023/B:CARD.0000041252.33870.74; Matsumoto K, 2003, CANCER SCI, V94, P321, DOI 10.1111/j.1349-7006.2003.tb01440.x; Matsumoto K, 1998, J BIOL CHEM, V273, P22913, DOI 10.1074/jbc.273.36.22913; Nakamura T, 2000, J CLIN INVEST, V106, P1511, DOI 10.1172/JCI10226; Ono M, 2004, CIRCULATION, V110, P2896, DOI 10.1161/01.CIR.0000146342.30470.30; OWEN CA, 1995, J CELL BIOL, V131, P775, DOI 10.1083/jcb.131.3.775; Polanowska J, 1998, BBA-PROTEIN STRUCT M, V1386, P189, DOI 10.1016/S0167-4838(98)00085-5; POWERS JC, 1985, BIOCHEMISTRY-US, V24, P2048, DOI 10.1021/bi00329a037; Raymond WW, 2003, J BIOL CHEM, V278, P34517, DOI 10.1074/jbc.M304087200; SAARINEN J, 1994, J BIOL CHEM, V269, P18134; Saito K, 2003, BIOCHEM BIOPH RES CO, V302, P773, DOI 10.1016/S0006-291X(03)00263-8; Sakamaki Y, 2002, AM J RESP CELL MOL, V26, P525, DOI 10.1165/ajrcmb.26.5.4714; Sanker S, 1997, J BIOL CHEM, V272, P2963, DOI 10.1074/jbc.272.5.2963; SERAFIN WE, 1991, J BIOL CHEM, V266, P1934; SONNENBERG E, 1993, J CELL BIOL, V123, P223, DOI 10.1083/jcb.123.1.223; Tchougounova E, 2003, J EXP MED, V198, P423, DOI 10.1084/jem.20030671; UEHARA Y, 1995, NATURE, V373, P702, DOI 10.1038/373702a0; Verghese GM, 1998, AM J RESP CRIT CARE, V158, P386, DOI 10.1164/ajrccm.158.2.9711111; WEIDNER KM, 1991, P NATL ACAD SCI USA, V88, P7001, DOI 10.1073/pnas.88.16.7001; Yaekashiwa M, 1997, AM J RESP CRIT CARE, V156, P1937, DOI 10.1164/ajrccm.156.6.9611057; YANAGITA K, 1993, J BIOL CHEM, V268, P21212; Yano K, 1997, BIOCHEM BIOPH RES CO, V239, P740, DOI 10.1006/bbrc.1997.7546	40	28	30	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 20	2006	281	3					1489	1494		10.1074/jbc.M511154200	http://dx.doi.org/10.1074/jbc.M511154200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	002ZS	16303761	Green Accepted, hybrid			2022-12-25	WOS:000234652000026
J	Grande, SM; Katz, E; Crowley, JE; Bernardini, MS; Ross, SR; Monroe, JG				Grande, SM; Katz, E; Crowley, JE; Bernardini, MS; Ross, SR; Monroe, JG			Cellular ITAM-containing proteins are oncoproteins in nonhematopoietic cells	ONCOGENE			English	Article						oncogene proteins; cell transformation; neoplastic; mammary glands; animal; fibroblasts; signal transduction	EPSTEIN-BARR-VIRUS; SARCOMA-ASSOCIATED HERPESVIRUS; LYMPHOCYTE ANTIGEN RECEPTOR; EPITHELIAL-CELLS; K1 GENE; LATENT MEMBRANE-PROTEIN-2A; 3-DIMENSIONAL CULTURE; CD22-DEFICIENT MICE; SIGNAL-TRANSDUCTION; NEGATIVE REGULATOR	Immunoreceptor tyrosine-based activation motifs (ITAMs) are involved in the transduction of signals necessary for activation, differentiation, and survival in hematopoietic cells. Several viruses have been shown to encode ITAM-containing transmembrane proteins. Although expression of these viral proteins has in some cases been shown to transform nonhematopoietic cells, a causal role for a functional ITAM in this process has not been elucidated. To examine the potential transforming properties of ITAM-containing proteins, a recombinant protein consisting of ITAM-containing cytoplasmic regions of the B-cell antigen receptor was expressed in immortalized murine mammary epithelial and fibroblast cells. Mammary epithelial cells expressing this construct exhibited depolarized morphology in three-dimensional cultures. This transformed phenotype was characterized by a loss of anchorage dependence and hallmarks of epithelial to mesenchymal transition. Fibroblasts expressing this ITAM construct also lost contact inhibition and anchorage dependence. The transformed phenotype seen in both cell types was abrogated upon tyrosine to phenylalanine substitutions of the ITAMs. Inhibition of Syk tyrosine kinase, which associates with the ITAM, also prevented cell transformation. Our results indicate that expression of a nonviral ITAM-containing protein is sufficient for cell transformation. Despite lacking intrinsic enzymatic activity, ITAM-containing proteins can function as potent oncoproteins by scaffolding downstream mediators.	Univ Penn, Sch Med, Dept Pathol & Lab Med, Philadelphia, PA 19104 USA; Univ Penn, Dept Microbiol, Philadelphia, PA 19104 USA	University of Pennsylvania; University of Pennsylvania	Monroe, JG (corresponding author), Univ Penn, Sch Med, Dept Pathol & Lab Med, Room 311 BRBII,421 Curie Blvd, Philadelphia, PA 19104 USA.	monroej@mail.med.upenn.edu		Ross, Susan R/0000-0002-3094-3769	NATIONAL CANCER INSTITUTE [T32CA009140, P01CA093615] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI032592] Funding Source: NIH RePORTER; NCI NIH HHS [P01-CA093615, CA09140] Funding Source: Medline; NIAID NIH HHS [R01-AI43620, R01-AI32592] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Bannish G, 2001, J EXP MED, V194, P1583, DOI 10.1084/jem.194.11.1583; Caldwell RG, 1998, IMMUNITY, V9, P405, DOI 10.1016/S1074-7613(00)80623-8; Callahan R, 2000, ONCOGENE, V19, P992, DOI 10.1038/sj.onc.1203276; Cannons JL, 2004, CURR OPIN IMMUNOL, V16, P296, DOI 10.1016/j.coi.2004.03.011; Debnath J, 2003, METHODS, V30, P256, DOI 10.1016/S1046-2023(03)00032-X; Harder T, 2004, TRAFFIC, V5, P265, DOI 10.1111/j.1600-0854.2003.00163.x; HOMBACH J, 1990, NATURE, V343, P760, DOI 10.1038/343760a0; Ikeda M, 2000, VIROLOGY, V268, P178, DOI 10.1006/viro.1999.0166; Ikeda M, 2001, J VIROL, V75, P5711, DOI 10.1128/JVI.75.12.5711-5718.2001; Jacks T, 2002, CELL, V111, P923, DOI 10.1016/S0092-8674(02)01229-1; Katz E, 2005, J EXP MED, V201, P431, DOI 10.1084/jem.20041471; Keshvara LM, 1997, J BIOL CHEM, V272, P10377; Lagunoff M, 1999, P NATL ACAD SCI USA, V96, P5704, DOI 10.1073/pnas.96.10.5704; Lai JYQ, 2003, BIOORG MED CHEM LETT, V13, P3111, DOI 10.1016/S0960-894X(03)00658-9; Lee H, 1998, NAT MED, V4, P435, DOI 10.1038/nm0498-435; Lee H, 1998, MOL CELL BIOL, V18, P5219, DOI 10.1128/MCB.18.9.5219; LONGNECKER R, 1991, J VIROL, V65, P3681, DOI 10.1128/JVI.65.7.3681-3692.1991; Mainiero F, 1996, J CELL BIOL, V134, P241, DOI 10.1083/jcb.134.1.241; Mina-Osorio P, 2004, TRENDS IMMUNOL, V25, P529, DOI 10.1016/j.it.2004.08.008; MONROE JG, 2006, IN PRESS NAT REV IMM; Morrison JA, 2005, J VIROL, V79, P2375, DOI 10.1128/JVI.79.4.2375-2382.2005; Morrison JA, 2003, J VIROL, V77, P12276, DOI 10.1128/JVI.77.22.12276-12284.2003; Muthuswamy SK, 2001, NAT CELL BIOL, V3, P785, DOI 10.1038/ncb0901-785; Niiro H, 2002, NAT REV IMMUNOL, V2, P945, DOI 10.1038/nri955; Nitschke L, 1997, CURR BIOL, V7, P133, DOI 10.1016/S0960-9822(06)00057-1; OKeefe TL, 1996, SCIENCE, V274, P798, DOI 10.1126/science.274.5288.798; Portis T, 2004, ONCOGENE, V23, P8619, DOI 10.1038/sj.onc.1207905; Prakash O, 2002, JNCI-J NATL CANCER I, V94, P926; Pui JC, 1999, IMMUNITY, V11, P299, DOI 10.1016/S1074-7613(00)80105-3; RETH M, 1989, NATURE, V338, P383, DOI 10.1038/338383b0; Roose JP, 2003, PLOS BIOL, V1, P271, DOI 10.1371/journal.pbio.0000053; Sato S, 1996, IMMUNITY, V5, P551, DOI 10.1016/S1074-7613(00)80270-8; Scholle F, 2000, J VIROL, V74, P10681, DOI 10.1128/JVI.74.22.10681-10689.2000; Scholle F, 1999, J VIROL, V73, P4767, DOI 10.1128/JVI.73.6.4767-4775.1999; Staub E, 2004, CELL SIGNAL, V16, P435, DOI 10.1016/j.cellsig.2003.08.013; Swart R, 2000, J VIROL, V74, P10838, DOI 10.1128/JVI.74.22.10838-10845.2000; Thiery JP, 2002, NAT REV CANCER, V2, P442, DOI 10.1038/nrc822; Thorley-Lawson DA, 2001, NAT REV IMMUNOL, V1, P75, DOI 10.1038/35095584; Veillette A, 2002, ANNU REV IMMUNOL, V20, P669, DOI 10.1146/annurev.immunol.20.081501.130710; Vivier E, 2004, SCIENCE, V306, P1517, DOI 10.1126/science.1103478; Weaver VM, 2002, CANCER CELL, V2, P205, DOI 10.1016/S1535-6108(02)00125-3; Weaver VM, 1997, J CELL BIOL, V137, P231, DOI 10.1083/jcb.137.1.231; WEISS A, 1984, J EXP MED, V160, P1284, DOI 10.1084/jem.160.5.1284; Zahir N, 2003, J CELL BIOL, V163, P1397, DOI 10.1083/jcb.200302023	44	17	18	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY 4	2006	25	19					2748	2757		10.1038/sj.onc.1209296	http://dx.doi.org/10.1038/sj.onc.1209296			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	039AW	16369490				2022-12-25	WOS:000237272900006
J	Kumar, M; Verma, R; Raghava, GPS				Kumar, M; Verma, R; Raghava, GPS			Prediction of mitochondrial proteins using support vector machine and hidden Markov model	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SUBCELLULAR-LOCALIZATION; PROTEOME; SVM	Mitochondria are considered as one of the core organelles of eukaryotic cells hence prediction of mitochondrial proteins is one of the major challenges in the field of genome annotation. This study describes a method, MitPred, developed for predicting mitochondrial proteins with high accuracy. The data set used in this study was obtained from Guda, C., Fahy, E. & Subramaniam, S. ( 2004) Bioinformatics 20, 1785 - 1794. First support vector machine-based modules/methods were developed using amino acid and dipeptide composition of proteins and achieved accuracy of 78.37 and 79.38%, respectively. The accuracy of prediction further improved to 83.74% when split amino acid composition ( 25 N-terminal, 25 C-terminal, and remaining residues) of proteins was used. Then BLAST search and support vector machine-based method were combined to get 88.22% accuracy. Finally we developed a hybrid approach that combined hidden Markov model profiles of domains ( exclusively found in mitochondrial proteins) and the support vector machine-based method. We were able to predict mitochondrial protein with 100% specificity at a 56.36% sensitivity rate and with 80.50% specificity at 98.95% sensitivity. The method estimated 9.01, 6.35, 4.84, 3.95, and 4.25% of proteins as mitochondrial in Saccharomyces cerevisiae, Drosophila melanogaster, Caenorhabditis elegans, mouse, and human proteomes, respectively. MitPred was developed on the above hybrid approach.	Inst Microbial Technol, Bioinformat Ctr, Chandigarh 160036, India	Council of Scientific & Industrial Research (CSIR) - India; CSIR - Institute of Microbial Technology (IMTECH)	Raghava, GPS (corresponding author), Inst Microbial Technol, Bioinformat Ctr, Sector 39-A, Chandigarh 160036, India.	raghava@imtech.res.in	Raghava, Gajendra P.S./AAA-2413-2022; Raghava, Gajendra/B-1717-2009; Kumar, Manish/AGP-1250-2022	Raghava, Gajendra P.S./0000-0002-8902-2876; Kumar, Manish/0000-0002-7936-9892				ALBERTS B, 2000, MOL BIOL CELL, P678; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; Bannai H, 2002, BIOINFORMATICS, V18, P298, DOI 10.1093/bioinformatics/18.2.298; Bateman A, 2004, NUCLEIC ACIDS RES, V32, pD138, DOI [10.1093/nar/gkt1223, 10.1093/nar/gkp985, 10.1093/nar/gkr1065]; Bhasin M, 2005, BIOINFORMATICS, V21, P2522, DOI 10.1093/bioinformatics/bti309; Bhasin M, 2004, NUCLEIC ACIDS RES, V32, pW414, DOI 10.1093/nar/gkh350; Bhasin M, 2004, J BIOL CHEM, V279, P23262, DOI 10.1074/jbc.M401932200; Bhasin M, 2004, BIOINFORMATICS, V20, P421, DOI 10.1093/bioinformatics/btg424; Cameron JM, 2005, BIOINFORMATICS, V21, P1825, DOI 10.1093/bioinformatics/bti280; Emanuelsson O, 2000, J MOL BIOL, V300, P1005, DOI 10.1006/jmbi.2000.3903; Gardy JL, 2003, NUCLEIC ACIDS RES, V31, P3613, DOI 10.1093/nar/gkg602; Garg A, 2005, J BIOL CHEM, V280, P14427, DOI 10.1074/jbc.M411789200; Gerbitz KD, 1996, DIABETES, V45, P113, DOI 10.2337/diabetes.45.2.113; Gottlieb RA, 2000, CRIT REV EUKAR GENE, V10, P231; Guda C, 2004, BIOINFORMATICS, V20, P1785, DOI 10.1093/bioinformatics/bth171; HUTCHIN T, 1995, P NATL ACAD SCI USA, V92, P6892, DOI 10.1073/pnas.92.15.6892; Jassem W, 2002, TRANSPLANTATION, V73, P493, DOI 10.1097/00007890-200202270-00001; Joachims T., 1999, ADV KERNEL METHODS S; Kaur H, 2003, PROTEIN SCI, V12, P627, DOI 10.1110/ps.0228903; Kumar M, 2005, NUCLEIC ACIDS RES, V33, pW154, DOI 10.1093/nar/gki588; Lopez MF, 2000, ELECTROPHORESIS, V21, P3427, DOI 10.1002/1522-2683(20001001)21:16<3427::AID-ELPS3427>3.0.CO;2-L; Marcotte EM, 2000, P NATL ACAD SCI USA, V97, P12115, DOI 10.1073/pnas.220399497; Orth M, 2002, NEUROCHEM INT, V40, P533, DOI 10.1016/S0197-0186(01)00124-3; Reinhardt A, 1998, NUCLEIC ACIDS RES, V26, P2230, DOI 10.1093/nar/26.9.2230; Sickmann A, 2003, P NATL ACAD SCI USA, V100, P13207, DOI 10.1073/pnas.2135385100; Taylor SW, 2003, TRENDS BIOTECHNOL, V21, P82, DOI 10.1016/S0167-7799(02)00037-9; Wiwatwattana N, 2005, NUCLEIC ACIDS RES, V33, pD598; Xie D, 2005, NUCLEIC ACIDS RES, V33, pW105, DOI 10.1093/nar/gki359	28	87	96	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 3	2006	281	9					5357	5363		10.1074/jbc.M511061200	http://dx.doi.org/10.1074/jbc.M511061200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	015RQ	16339140	hybrid			2022-12-25	WOS:000235568900006
J	Fukumoto, S; Miner, JH; Ida, H; Fukumoto, E; Yuasa, K; Miyazaki, H; Hoffman, MP; Yamada, Y				Fukumoto, S; Miner, JH; Ida, H; Fukumoto, E; Yuasa, K; Miyazaki, H; Hoffman, MP; Yamada, Y			Laminin alpha 5 is required for dental epithelium growth and polarity and the development of tooth bud and shape	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHOINOSITIDE 3-OH KINASE; EMBRYONIC SIGNALING CENTER; GLAND CELL-LINE; ALPHA-6-BETA-4 INTEGRIN; BASEMENT-MEMBRANE; ALPHA(6)BETA(4) INTEGRIN; DYSTROGLYCAN-BINDING; MOUSE TOOTH; ACTIN CYTOSKELETON; LAMELLAE FORMATION	In tooth development, the oral ectoderm and mesenchyme coordinately and reciprocally interact through the basement membrane for their growth and differentiation to form the proper shape and size of the tooth. Laminin alpha 5 subunit-containing laminin-10/11 ( LM-511/521) is the major laminin in the tooth germ basement membrane. Here, we have examined the role of laminin alpha 5 ( Lama5) in tooth development using laminin alpha 5-null mouse primary dental epithelium and tooth germ organ cultures. Lama5-null mice develop a small tooth germ with defective cusp formation and have reduced proliferation of dental epithelium. Also, cell polarity and formation of the monolayer of the inner dental epithelium are disturbed. The enamel knot, a signaling center for tooth germ development, is defective, and there is a significant reduction of Shh and Fgf4 expression in the dental epithelium. In the absence of laminin alpha 5, the basement membrane in the inner dental epithelium becomes discontinuous. In normal mice, integrin alpha 6 beta 4, a receptor for laminin alpha 5, is strongly localized at the basal layer of the epithelium, whereas in mutant mice, integrin alpha 6 beta 4 is expressed around the cell surface. In primary dental epithelium culture, laminin-10/11 promotes cell growth, spreading, and filopodia-like micro-spike formation. This promotion is inhibited by anti-integrin alpha 6 and beta 4 antibodies and by phosphatidylinositol 3-kinase inhibitors and dominant negative Rho-GTPase family proteins Cdc42 and Rac. In organ culture, anti-integrin alpha 6 antibody and wortmannin reduce tooth germ size and shape. Our studies demonstrate that laminin alpha 5 is required for the proliferation and polarity of basal epithelial cells and suggest that the interaction between laminin-10/11-integrin alpha 6 beta 4 and the phosphatidylinositol 3-kinase-Cdc42/Rac pathways play an important role in determining the size and shape of tooth germ.	NIDCR, Craniofacial Dev Biol & Regenerat Branch, NIH, Bethesda, MD 20892 USA; NIDCR, Oral & Pharyngeal Canc Branch, NIH, Bethesda, MD 20892 USA; Washington Univ, Sch Med, Div Renal, St Louis, MO 63110 USA; Nagasaki Univ, Grad Sch Biomed Sci, Nagasaki 8528521, Japan; Kyushu Univ, Fac Dent Sci, Fukuoka 8128582, Japan	National Institutes of Health (NIH) - USA; NIH National Institute of Dental & Craniofacial Research (NIDCR); National Institutes of Health (NIH) - USA; NIH National Institute of Dental & Craniofacial Research (NIDCR); Washington University (WUSTL); Nagasaki University; Kyushu University	Yamada, Y (corresponding author), NIDCR, Craniofacial Dev Biol & Regenerat Branch, NIH, 30 Convent Dr,Bldg 30,Rm 407, Bethesda, MD 20892 USA.	yoshi.yamada@nih.gov		Fukumoto, Satoshi/0000-0002-5046-6891	NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH [ZIADE000720, ZIADE000485, ZIADE000707] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [Z01DE000707, Z01DE000720, Z01DE000485] Funding Source: NIH RePORTER; Intramural NIH HHS Funding Source: Medline	NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)		Aumailley M, 2005, MATRIX BIOL, V24, P326, DOI 10.1016/j.matbio.2005.05.006; BRINGAS P, 1987, SCANNING MICROSCOPY, V1, P1103; Clark EA, 1998, J CELL BIOL, V142, P573, DOI 10.1083/jcb.142.2.573; COHN SA, 1957, AM J ANAT, V101, P295, DOI 10.1002/aja.1001010205; Dassule HR, 2000, DEVELOPMENT, V127, P4775; Deng WM, 2003, DEVELOPMENT, V130, P173, DOI 10.1242/dev.00199; Ekblom P, 2003, MATRIX BIOL, V22, P35, DOI 10.1016/S0945-053X(03)00015-5; Etienne-Manneville S, 2003, CURR OPIN CELL BIOL, V15, P67, DOI 10.1016/S0955-0674(02)00005-4; Fukumoto S, 2004, J CELL BIOL, V167, P973, DOI 10.1083/jcb.200409077; Gambaletta D, 2000, J BIOL CHEM, V275, P10604, DOI 10.1074/jbc.275.14.10604; Gritli-Linde A, 2002, DEVELOPMENT, V129, P5323, DOI 10.1242/dev.00100; Gudjonsson T, 2002, J CELL SCI, V115, P39; Hall A, 1998, SCIENCE, V279, P509, DOI 10.1126/science.279.5350.509; Hoffman MP, 1998, J BIOL CHEM, V273, P28633, DOI 10.1074/jbc.273.44.28633; Hoffman MP, 1996, J CELL SCI, V109, P2013; Ido H, 2004, J BIOL CHEM, V279, P10946, DOI 10.1074/jbc.M313626200; Jernvall J, 1998, DEVELOPMENT, V125, P161; Kettunen P, 1998, DEV DYNAM, V211, P256, DOI 10.1002/(SICI)1097-0177(199803)211:3<256::AID-AJA7>3.0.CO;2-G; Khwaja A, 1997, EMBO J, V16, P2783, DOI 10.1093/emboj/16.10.2783; Kikkawa Y, 2000, J CELL SCI, V113, P869; King WG, 1997, MOL CELL BIOL, V17, P4406, DOI 10.1128/MCB.17.8.4406; Kleinman HK, 2005, SEMIN CANCER BIOL, V15, P378, DOI 10.1016/j.semcancer.2005.05.004; Langenbach KJ, 2002, MUSCLE NERVE, V26, P644, DOI 10.1002/mus.10258; Leighton PA, 2001, NATURE, V410, P174, DOI 10.1038/35065539; Li J, 2003, EMBO J, V22, P2400, DOI 10.1093/emboj/cdg239; Li S, 2002, J CELL BIOL, V157, P1279, DOI 10.1083/jcb.200203073; Li SH, 2003, DEV CELL, V4, P613, DOI 10.1016/S1534-5807(03)00128-X; LUMSDEN AGS, 1988, DEVELOPMENT, V103, P155; Mainiero F, 1996, J CELL BIOL, V134, P241, DOI 10.1083/jcb.134.1.241; Mainiero F, 1997, EMBO J, V16, P2365, DOI 10.1093/emboj/16.9.2365; MARTIN GR, 1988, ADV PROTEIN CHEM, V39, P1; Mercurio AM, 2001, CURR OPIN CELL BIOL, V13, P541, DOI 10.1016/S0955-0674(00)00249-0; Miner JH, 2004, ANNU REV CELL DEV BI, V20, P255, DOI 10.1146/annurev.cellbio.20.010403.094555; MINER JH, 1995, J BIOL CHEM, V270, P28523, DOI 10.1074/jbc.270.48.28523; Miner JH, 2000, DEV BIOL, V217, P278, DOI 10.1006/dbio.1999.9546; Miner JH, 1998, J CELL BIOL, V143, P1713, DOI 10.1083/jcb.143.6.1713; Miner JH, 2004, DEVELOPMENT, V131, P2247, DOI 10.1242/dev.01112; Mitchell KJ, 2001, NAT GENET, V28, P241, DOI 10.1038/90074; Moulson CL, 2001, DEV DYNAM, V222, P101, DOI 10.1002/dvdy.1169; Nguyen BP, 2000, J BIOL CHEM, V275, P31896, DOI 10.1074/jbc.M006379200; Nguyen NM, 2002, DEV BIOL, V246, P231, DOI 10.1006/dbio.2002.0658; O'Brien LE, 2001, NAT CELL BIOL, V3, P831, DOI 10.1038/ncb0901-831; O'Connor KL, 1998, J CELL BIOL, V143, P1749, DOI 10.1083/jcb.143.6.1749; O'Connor KL, 2000, J CELL BIOL, V148, P253, DOI 10.1083/jcb.148.2.253; Patton BL, 1997, J CELL BIOL, V139, P1507, DOI 10.1083/jcb.139.6.1507; Price LS, 1998, MOL BIOL CELL, V9, P1863, DOI 10.1091/mbc.9.7.1863; Rabinovitz I, 1997, J CELL BIOL, V139, P1873, DOI 10.1083/jcb.139.7.1873; Ruch J V, 1987, Revis Biol Celular, V14, P1; Ryan MC, 1999, J CELL BIOL, V145, P1309, DOI 10.1083/jcb.145.6.1309; Salmivirta K, 1998, ANN NY ACAD SCI, V857, P279, DOI 10.1111/j.1749-6632.1998.tb10132.x; Salmivirta K, 1997, DEV DYNAM, V210, P206, DOI 10.1002/(SICI)1097-0177(199711)210:3<206::AID-AJA2>3.3.CO;2-S; Salmivirta K, 1996, DEV DYNAM, V205, P104, DOI 10.1002/(SICI)1097-0177(199602)205:2<104::AID-AJA2>3.0.CO;2-M; Shaw LM, 2001, MOL CELL BIOL, V21, P5082, DOI 10.1128/MCB.21.15.5082-5093.2001; Shaw LM, 1997, CELL, V91, P949, DOI 10.1016/S0092-8674(00)80486-9; Small JV, 1999, CURR OPIN CELL BIOL, V11, P54, DOI 10.1016/S0955-0674(99)80007-6; Smyth N, 1999, J CELL BIOL, V144, P151, DOI 10.1083/jcb.144.1.151; Sorokin LM, 1997, DEV BIOL, V189, P285, DOI 10.1006/dbio.1997.8668; Tabata MJ, 1996, DEVELOPMENT, V122, P1243; THESLEFF I, 1981, DIFFERENTIATION, V18, P75, DOI 10.1111/j.1432-0436.1981.tb01107.x; Timpl R, 1996, CURR OPIN CELL BIOL, V8, P618, DOI 10.1016/S0955-0674(96)80102-5; Tsumaki N, 1998, J BIOL CHEM, V273, P22861, DOI 10.1074/jbc.273.36.22861; Vaahtokari A, 1996, MECH DEVELOP, V54, P39, DOI 10.1016/0925-4773(95)00459-9; Vaahtokari A, 1996, DEVELOPMENT, V122, P121; van Leeuwen FN, 1999, NAT CELL BIOL, V1, P242, DOI 10.1038/12068; VEGASALAS DE, 1987, J CELL BIOL, V104, P1249, DOI 10.1083/jcb.104.5.1249; WANG AZ, 1990, J CELL SCI, V95, P137; WANG AZ, 1990, J CELL SCI, V95, P153; Weiner OD, 2002, NAT CELL BIOL, V4, P509, DOI 10.1038/ncb811; YAMADA M, 1980, J BIOL BUCCALE, V8, P127; Yin Y, 2003, GENESIS, V36, P114, DOI 10.1002/gene.10206; Yu H, 2003, BIOCHEM J, V371, P289, DOI 10.1042/BJ20021500; Yuasa K, 2004, J BIOL CHEM, V279, P10286, DOI 10.1074/jbc.M310013200	72	88	90	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 24	2006	281	8					5008	5016		10.1074/jbc.M509295200	http://dx.doi.org/10.1074/jbc.M509295200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	013RF	16365040	hybrid			2022-12-25	WOS:000235426200053
J	Sato, T; Fujita, N; Yamada, A; Ooshio, T; Okamoto, R; Irie, K; Takai, Y				Sato, T; Fujita, N; Yamada, A; Ooshio, T; Okamoto, R; Irie, K; Takai, Y			Regulation of the assembly and adhesion activity of E-cadherin by nectin and afadin for the formation of adherens junctions in Madin-Darby canine kidney cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SMALL G-PROTEINS; ALPHA-CATENIN; TIGHT JUNCTIONS; EPITHELIAL-CELLS; ACTIN CYTOSKELETON; TRANS-INTERACTIONS; BINDING PROTEIN; INTERCELLULAR-JUNCTIONS; FUNCTIONAL-ANALYSIS; CYTOPLASMIC DOMAIN	The Ca2+-independent immunoglobulin-like molecule nectin first forms cell-cell adhesion and then assembles cadherin at nectin-based cell-cell adhesion sites, resulting in the formation of adherens junctions (AJs). Afadin is a nectin- and actin filament-binding protein that connects nectin to the actin cytoskeleton. Here, we studied the roles and modes of action of nectin and afadin in the formation of AJs in cultured MDCK cells. The trans-interaction of nectin assembled E-cadherin, which associated with p120(ctn), beta-catenin, and alpha-catenin, at the nectin- based cell-cell adhesion sites in an afadin-independent manner. However, the assembled E-cadherin showed weak cell-cell adhesion activity and might be the non-trans-interacting form. This assembly was mediated by the IQGAP1-dependent actin cytoskeleton, which was organized by Cdc42 and Rac small G proteins that were activated by the action of trans-interacting nectin through c-Src and Rap1 small G protein in an afadin-independent manner. However, Rap1 bound to afadin, and this Rap1-afadin complex then interacted with p120(ctn) associated with non-trans-interacting E-cadherin, thereby causing the trans-interaction of E-cadherin. Thus, nectin regulates the assembly and cell-cell adhesion activity of E-cadherin through afadin, nectin signaling, and p120(ctn) for the formation of AJs in Madin-Darby canine kidney cells.	Osaka Univ, Grad Sch Med, Fac Med, Dept Mol Biol & Biochem, Suita, Osaka 5650871, Japan	Osaka University	Takai, Y (corresponding author), Osaka Univ, Grad Sch Med, Fac Med, Dept Mol Biol & Biochem, 2-2 Yamadaoka, Suita, Osaka 5650871, Japan.	ytakai@molbio.med.osaka-u.ac.jp		Ooshio, Takako/0000-0001-6508-8152				Aberle H, 1996, J BIOL CHEM, V271, P1520, DOI 10.1074/jbc.271.3.1520; Adams CL, 1998, CURR OPIN CELL BIOL, V10, P572, DOI 10.1016/S0955-0674(98)80031-8; Aono S, 1999, J CELL BIOL, V145, P551, DOI 10.1083/jcb.145.3.551; Asada M, 2003, J BIOL CHEM, V278, P4103, DOI 10.1074/jbc.M209832200; Bashour AM, 1997, J CELL BIOL, V137, P1555, DOI 10.1083/jcb.137.7.1555; Betson M, 2002, J BIOL CHEM, V277, P36962, DOI 10.1074/jbc.M207358200; Cozzolino M, 2003, MOL BIOL CELL, V14, P1964, DOI 10.1091/mbc.E02-08-0469; DANIEL JM, 1995, MOL CELL BIOL, V15, P4819; Davis MA, 2003, J CELL BIOL, V163, P525, DOI 10.1083/jcb.200307111; Dejana E, 2004, NAT REV MOL CELL BIO, V5, P261, DOI 10.1038/nrm1357; Ebnet K, 2000, J BIOL CHEM, V275, P27979; Erickson JW, 1997, J BIOL CHEM, V272, P24443, DOI 10.1074/jbc.272.39.24443; FARQUHAR MG, 1963, J CELL BIOL, V17, P375, DOI 10.1083/jcb.17.2.375; Fukuhara A, 2002, ONCOGENE, V21, P7642, DOI 10.1038/sj.onc.1205875; Fukuhara A, 2002, GENES CELLS, V7, P1059, DOI 10.1046/j.1365-2443.2002.00578.x; Fukuhara T, 2004, J CELL BIOL, V166, P393, DOI 10.1083/jcb.200401093; Fukuyama T, 2006, ONCOGENE, V25, P8, DOI 10.1038/sj.onc.1209010; Fukuyama T, 2005, J BIOL CHEM, V280, P815, DOI 10.1074/jbc.M411099200; Gumbiner BM, 2000, J CELL BIOL, V148, P399, DOI 10.1083/jcb.148.3.399; Gumbiner BM, 1996, CELL, V84, P345, DOI 10.1016/S0092-8674(00)81279-9; Honda T, 2003, BIOCHEM BIOPH RES CO, V306, P104, DOI 10.1016/S0006-291X(03)00919-7; Honda T, 2003, GENES CELLS, V8, P481, DOI 10.1046/j.1365-2443.2003.00649.x; Honda T, 2003, GENES CELLS, V8, P51, DOI 10.1046/j.1365-2443.2003.00616.x; Hoshino T, 2005, J BIOL CHEM, V280, P24095, DOI 10.1074/jbc.M414447200; Hoshino T, 2004, MOL BIOL CELL, V15, P1077, DOI 10.1091/mbc.E03-05-0321; Ikeda W, 2003, J BIOL CHEM, V278, P28167, DOI 10.1074/jbc.M303586200; Ikeda W, 1999, J CELL BIOL, V146, P1117, DOI 10.1083/jcb.146.5.1117; Inoue O, 2003, J CELL BIOL, V160, P769, DOI 10.1083/jcb.200208043; Ireton RC, 2002, J CELL BIOL, V159, P465, DOI 10.1083/jcb.200205115; Itoh M, 2001, J CELL BIOL, V154, P491, DOI 10.1083/jcb.200103047; Izumi G, 2004, J CELL BIOL, V166, P237, DOI 10.1083/jcb.200401078; KARTENBECK J, 1991, J CELL BIOL, V113, P881, DOI 10.1083/jcb.113.4.881; Katata T, 2003, ONCOGENE, V22, P2097, DOI 10.1038/sj.onc.1206255; Kawakatsu T, 2005, J BIOL CHEM, V280, P4940, DOI 10.1074/jbc.M408710200; Kawakatsu T, 2002, J BIOL CHEM, V277, P50749, DOI 10.1074/jbc.M209846200; KNUDSEN KA, 1995, J CELL BIOL, V130, P67, DOI 10.1083/jcb.130.1.67; Koch AW, 1997, BIOCHEMISTRY-US, V36, P7697, DOI 10.1021/bi9705624; Kovacs EM, 2002, J BIOL CHEM, V277, P6708, DOI 10.1074/jbc.M109640200; Kuroda S, 1996, J BIOL CHEM, V271, P23363, DOI 10.1074/jbc.271.38.23363; Linnemann T, 1999, J BIOL CHEM, V274, P13556, DOI 10.1074/jbc.274.19.13556; Ma TY, 2000, AM J PHYSIOL-GASTR L, V279, pG875, DOI 10.1152/ajpgi.2000.279.5.G875; Mandai K, 1999, J CELL BIOL, V144, P1001, DOI 10.1083/jcb.144.5.1001; Mandai K, 1997, J CELL BIOL, V139, P517, DOI 10.1083/jcb.139.2.517; Miki H, 1998, NATURE, V391, P93, DOI 10.1038/34208; NAGAFUCHI A, 1991, CELL, V65, P849, DOI 10.1016/0092-8674(91)90392-C; NAGAFUCHI A, 1994, J CELL BIOL, V127, P235, DOI 10.1083/jcb.127.1.235; Nagafuchi A, 2001, CURR OPIN CELL BIOL, V13, P600, DOI 10.1016/S0955-0674(00)00257-X; Nakagawa H, 2001, J CELL SCI, V114, P1555; Nieset JE, 1997, J CELL SCI, V110, P1013; Noren NK, 2001, J BIOL CHEM, V276, P33305, DOI 10.1074/jbc.C100306200; Ohkubo T, 1999, J BIOL CHEM, V274, P21409, DOI 10.1074/jbc.274.30.21409; Ohno S, 2001, CURR OPIN CELL BIOL, V13, P641, DOI 10.1016/S0955-0674(00)00264-7; Okamoto R, 2005, GENES CELLS, V10, P435, DOI 10.1111/j.1365-2443.2005.00846.x; Ooshio T, 2004, J BIOL CHEM, V279, P31365, DOI 10.1074/jbc.M401957200; OZAWA M, 1992, J CELL BIOL, V116, P989, DOI 10.1083/jcb.116.4.989; Perez-Moreno M, 2003, CELL, V112, P535, DOI 10.1016/S0092-8674(03)00108-9; Pokutta S, 2002, J BIOL CHEM, V277, P18868, DOI 10.1074/jbc.M201463200; Quinlan MP, 1999, CELL GROWTH DIFFER, V10, P839; Roh MH, 2003, AM J PHYSIOL-RENAL, V285, pF377, DOI 10.1152/ajprenal.00086.2003; RUBINFELD B, 1991, CELL, V65, P1033, DOI 10.1016/0092-8674(91)90555-D; Sakisaka T, 2004, CURR OPIN CELL BIOL, V16, P513, DOI 10.1016/j.ceb.2004.07.007; Sakisaka T, 1999, ONCOGENE, V18, P1609, DOI 10.1038/sj.onc.1202451; Satoh-Horikawa K, 2000, J BIOL CHEM, V275, P10291, DOI 10.1074/jbc.275.14.10291; Shimizu K, 2003, J BIOCHEM, V134, P631, DOI 10.1093/jb/mvg198; STEVENSON BR, 1994, J CELL SCI, V107, P367; Tachibana K, 2000, J CELL BIOL, V150, P1161, DOI 10.1083/jcb.150.5.1161; Takaesu G, 2000, MOL CELL, V5, P649, DOI 10.1016/S1097-2765(00)80244-0; Takahashi K, 1999, J CELL BIOL, V145, P539, DOI 10.1083/jcb.145.3.539; Takai Y, 2003, CANCER SCI, V94, P655, DOI 10.1111/j.1349-7006.2003.tb01499.x; Takai Y, 2003, J CELL SCI, V116, P17, DOI 10.1242/jcs.00167; TAKEICHI M, 1995, CURR OPIN CELL BIOL, V7, P619, DOI 10.1016/0955-0674(95)80102-2; Takekuni K, 2003, J BIOL CHEM, V278, P5497, DOI 10.1074/jbc.C200707200; Takenawa T, 2001, J CELL SCI, V114, P1801; Tsukita S, 2001, NAT REV MOL CELL BIO, V2, P285, DOI 10.1038/35067088; Tsukita S, 1999, TRENDS CELL BIOL, V9, P268, DOI 10.1016/S0962-8924(99)01578-0; Vasioukhin V, 2000, CELL, V100, P209, DOI 10.1016/S0092-8674(00)81559-7; Weiss EE, 1998, J CELL BIOL, V141, P755, DOI 10.1083/jcb.141.3.755; Wittchen ES, 1999, J BIOL CHEM, V274, P35179, DOI 10.1074/jbc.274.49.35179; Yagi T, 2000, GENE DEV, V14, P1169; Yamada A, 2005, J BIOL CHEM, V280, P6016, DOI 10.1074/jbc.M408215200; Yamada A, 2004, GENES CELLS, V9, P843, DOI 10.1111/j.1365-2443.2004.00768.x; Yamamoto T, 1997, J CELL BIOL, V139, P785, DOI 10.1083/jcb.139.3.785; Yap AS, 1997, ANNU REV CELL DEV BI, V13, P119, DOI 10.1146/annurev.cellbio.13.1.119; Yap AS, 1998, J CELL BIOL, V141, P779, DOI 10.1083/jcb.141.3.779; Yokoyama S, 2001, MOL BIOL CELL, V12, P1595, DOI 10.1091/mbc.12.6.1595	85	122	123	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 24	2006	281	8					5288	5299		10.1074/jbc.M510070200	http://dx.doi.org/10.1074/jbc.M510070200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	013RF	16361708	hybrid			2022-12-25	WOS:000235426200083
J	Takaki, E; Fujimoto, M; Sugahara, K; Nakahari, T; Yonemura, S; Tanaka, Y; Hayashida, N; Inouye, S; Takemoto, T; Yamashita, H; Nakai, A				Takaki, E; Fujimoto, M; Sugahara, K; Nakahari, T; Yonemura, S; Tanaka, Y; Hayashida, N; Inouye, S; Takemoto, T; Yamashita, H; Nakai, A			Maintenance of olfactory neurogenesis requires HSF1, a major heat shock transcription factor in mice	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LEUKEMIA INHIBITORY FACTOR; NASAL DEVELOPMENT; LIMB DEVELOPMENT; LENS DEVELOPMENT; BONE-RESORPTION; GENE; DIFFERENTIATION; EXPRESSION; SPERMATOGENESIS; ACTIVATION	Heat shock transcription factors (HSFs) play roles not only in heat shock response but also in development of the reproductive organs, brain, and lens. Here, we analyzed sensory organs and found abnormalities of the olfactory epithelium in adult HSF1-null mice, which is developmentally related to the lens. The olfactory epithelium was normal until postnatal 3 weeks but was not maintained later than 4 weeks in HSF1-null mice. The olfactory epithelium was atrophied with increased cell death of olfactory sensory neurons. Analysis of the epithelium revealed that induction of HSP expression and reduction of LIF expression are lacking in adult HSF1-null mice. We found that DNA binding activity of HSF1 is induced in the olfactory epithelium later than 4 weeks and that HSF1 binds directly to Lif gene and inhibits its expression. HSF4 has opposing effects on LIF expression and olfactory neurogenesis. These data indicate that HSF1 is required for the precise expression of Hsp and cytokine genes that is obligatory for maintenance of olfactory neurogenesis in adult mice and suggest that stress-related processes are involved in its maintenance.	Yamaguchi Univ, Sch Med, Dept Biochem & Mol Biol, Ube, Yamaguchi 7558505, Japan; Yamaguchi Univ, Sch Med, Dept Otolaryngol, Ube, Yamaguchi 7558505, Japan; Osaka Med Coll, Dept Physiol, Osaka 5698686, Japan; RIKEN, Ctr Dev Biol, Lab Cellular Morphogenesis, Kobe, Hyogo 6500047, Japan	Yamaguchi University; Yamaguchi University; Osaka Medical College; RIKEN	Nakai, A (corresponding author), Yamaguchi Univ, Sch Med, Dept Biochem & Mol Biol, Minami Kogushi 1-1-1, Ube, Yamaguchi 7558505, Japan.	anakai@yamaguchi-u.ac.jp	Hayashida, Naoki/HGA-3453-2022	Hayashida, Naoki/0000-0002-8785-8012				Bauer S, 2003, J NEUROSCI, V23, P1792; BERTOLINI DR, 1986, NATURE, V319, P516, DOI 10.1038/319516a0; Bhat SP, 2003, PROG DRUG RES, V60, P205; Bhattacharyya S, 2004, DEV BIOL, V271, P403, DOI 10.1016/j.ydbio.2004.04.010; Boyle WJ, 2003, NATURE, V423, P337, DOI 10.1038/nature01658; Bu L, 2002, NAT GENET, V31, P276, DOI 10.1038/ng921; Cau E, 2002, DEVELOPMENT, V129, P1871; Christians E, 2000, NATURE, V407, P693, DOI 10.1038/35037669; Dudley AT, 2000, CURR OPIN GENET DEV, V10, P387, DOI 10.1016/S0959-437X(00)00101-5; Farbman Albert I., 1994, Seminars in Cell Biology, V5, P3; Fujimoto M, 2004, EMBO J, V23, P4297, DOI 10.1038/sj.emboj.7600435; Gilbert S.F., 2003, DEV BIOL, V7th Edn; GRINDLEY JC, 1995, DEVELOPMENT, V121, P1433; GUILLEMOT F, 1993, CELL, V75, P463, DOI 10.1016/0092-8674(93)90381-Y; Hajihosseini MK, 2002, MECH DEVELOP, V113, P79, DOI 10.1016/S0925-4773(01)00656-6; Inouye S, 2004, J BIOL CHEM, V279, P38701, DOI 10.1074/jbc.M405986200; Inouye S, 2003, MOL CELL BIOL, V23, P5882, DOI 10.1128/MCB.23.16.5882-5895.2003; Izu H, 2004, BIOL REPROD, V70, P18, DOI 10.1095/biolreprod.103.020065; JOHANSSON BM, 1995, MOL CELL BIOL, V15, P141, DOI 10.1128/MCB.15.1.141; Kallio M, 2002, EMBO J, V21, P2591, DOI 10.1093/emboj/21.11.2591; Katsuki K, 2004, FEBS LETT, V571, P187, DOI 10.1016/j.febslet.2004.06.087; LOWE C, 1991, J BONE MINER RES, V6, P1277; Mackay-Sim A, 2000, PROG NEUROBIOL, V62, P527, DOI 10.1016/S0301-0082(00)00009-5; Metcalf D, 2003, STEM CELLS, V21, P5, DOI 10.1634/stemcells.21-1-5; Min JN, 2004, GENESIS, V40, P205, DOI 10.1002/gene.20087; Moon C, 2002, P NATL ACAD SCI USA, V99, P9015, DOI 10.1073/pnas.132131699; Morimoto RI, 1998, GENE DEV, V12, P3788, DOI 10.1101/gad.12.24.3788; Nakai A, 1997, MOL CELL BIOL, V17, P469, DOI 10.1128/MCB.17.1.469; Nakai A, 1999, CELL STRESS CHAPERON, V4, P86, DOI 10.1379/1466-1268(1999)004<0086:NAITVH>2.3.CO;2; Nakai A, 2000, EMBO J, V19, P1545, DOI 10.1093/emboj/19.7.1545; NAKAI A, 1995, MOL CELL BIOL, V15, P5268; Pirkkala L, 2001, FASEB J, V15, P1118, DOI 10.1096/fj00-0294rev; Quinn JC, 1996, GENE DEV, V10, P435, DOI 10.1101/gad.10.4.435; Rallu M, 1997, P NATL ACAD SCI USA, V94, P2392, DOI 10.1073/pnas.94.6.2392; Santos SD, 2004, NEUROSCIENCE, V126, P657, DOI 10.1016/j.neuroscience.2004.03.023; Schwob James E., 2002, Anatomical Record, V269, P33, DOI 10.1002/ar.10047; Singh IS, 2002, J BIOL CHEM, V277, P4981, DOI 10.1074/jbc.M108154200; Somasundaram T, 2004, J BIOL CHEM, V279, P44497, DOI 10.1074/jbc.M405813200; STAHL J, 1993, CYTOKINE, V5, P386, DOI 10.1016/1043-4666(93)90072-D; Sugahara K, 2003, HEARING RES, V182, P88, DOI 10.1016/S0378-5955(03)00180-1; Tanabe M, 1999, J BIOL CHEM, V274, P27845, DOI 10.1074/jbc.274.39.27845; THOMSON BM, 1986, J EXP MED, V164, P104, DOI 10.1084/jem.164.1.104; Trinklein ND, 2004, MOL BIOL CELL, V15, P1254, DOI 10.1091/mbc.E03-10-0738; TRIPP EJ, 1972, STAIN TECHNOL, V47, P129, DOI 10.3109/10520297209116467; Wang GH, 2004, GENESIS, V38, P66, DOI 10.1002/gene.20005; Wang GH, 2003, GENESIS, V36, P48, DOI 10.1002/gene.10200; Weiler E, 1997, J NEUROSCI, V17, P3610; Wu C, 1995, ANNU REV CELL DEV BI, V11, P441, DOI 10.1146/annurev.cellbio.11.1.441; Xiao XZ, 1999, EMBO J, V18, P5943, DOI 10.1093/emboj/18.21.5943; Xie Y, 2002, J BIOL CHEM, V277, P11802, DOI 10.1074/jbc.M109296200; Xu PX, 1997, DEVELOPMENT, V124, P219; Zheng H, 2004, J IMMUNOL, V173, P5929, DOI 10.4049/jimmunol.173.10.5929	52	60	64	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 24	2006	281	8					4931	4937		10.1074/jbc.M506911200	http://dx.doi.org/10.1074/jbc.M506911200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	013RF	16306048	hybrid			2022-12-25	WOS:000235426200044
J	Stanasila, L; Abuin, L; Diviani, D; Cotecchia, S				Stanasila, L; Abuin, L; Diviani, D; Cotecchia, S			Ezrin directly interacts with the alpha 1b-adrenergic receptor and plays a role in receptor recycling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-COUPLED RECEPTOR; ERM PROTEINS; ALPHA(1B)-ADRENERGIC RECEPTOR; ACTIN; BINDING; DOMAIN; PHOSPHORYLATION; ENDOCYTOSIS; INTERNALIZATION; DESENSITIZATION	Using the yeast two-hybrid system, we identified ezrin as a protein interacting with the C-tail of the alpha 1b-adrenergic receptor (AR). The interaction was shown to occur in vitro between the receptor C-tail and the N-terminal portion of ezrin, or Four-point-one ERM (FERM) domain. The alpha 1b-AR/ezrin interaction occurred inside the cells as shown by the finding that the transfected alpha 1b-AR and FERM domain or ezrin could be coimmunoprecipitated from human embryonic kidney 293 cell extracts. Mutational analysis of the alpha 1b-AR revealed that the binding site for ezrin involves a stretch of at least four arginines on the receptor C-tail. The results from both receptor biotinylation and immunofluorescence experiments indicated that the FERM domain impaired alpha 1b-AR recycling to the plasma membrane without affecting receptor internalization. The dominant negative effect of the FERM domain, which relies on its ability to mask the ezrin binding site for actin, was mimicked by treatment of cells with cytochalasin D, an actin depolymerizing agent. A receptor mutant (Delta R8) lacking its binding site in the C-tail for ezrin displayed delayed receptor recycling. These findings identify ezrin as a new protein directly interacting with a G proteincoupled receptor and demonstrate the direct implication of ezrin in GPCR trafficking via an actin-dependent mechanism.	Fac Biol & Med, Dept Pharmacol & Toxicol, CH-1005 Lausanne, Switzerland		Cotecchia, S (corresponding author), Fac Biol & Med, Dept Pharmacol & Toxicol, Rue Bugnon 27, CH-1005 Lausanne, Switzerland.	Susanna.Cotecchia@unil.ch		Diviani, Dario/0000-0003-4375-3718				Bockaert J, 2004, PHARMACOL THERAPEUT, V103, P203, DOI 10.1016/j.pharmthera.2004.06.004; Bretscher A, 2002, NAT REV MOL CELL BIO, V3, P586, DOI 10.1038/nrm882; Burgueno J, 2003, J BIOL CHEM, V278, P37545, DOI 10.1074/jbc.M302809200; Cant SH, 2005, MOL BIOL CELL, V16, P3088, DOI 10.1091/mbc.E04-10-0877; Cao TT, 1999, NATURE, V401, P286, DOI 10.1038/45816; Cao TT, 1998, J BIOL CHEM, V273, P24592, DOI 10.1074/jbc.273.38.24592; Chang FS, 2003, CURR BIOL, V13, P455, DOI 10.1016/S0960-9822(03)00131-3; Crepaldi T, 1997, J CELL BIOL, V138, P423, DOI 10.1083/jcb.138.2.423; Denker SP, 2000, MOL CELL, V6, P1425, DOI 10.1016/S1097-2765(00)00139-8; Dickson TC, 2002, J CELL BIOL, V157, P1105, DOI 10.1083/jcb.200111076; Diviani D, 2003, J BIOL CHEM, V278, P19331, DOI 10.1074/jbc.M302110200; Diviani D, 1996, J BIOL CHEM, V271, P5049; Engqvist-Goldstein AEY, 2003, ANNU REV CELL DEV BI, V19, P287, DOI 10.1146/annurev.cellbio.19.111401.093127; GARY R, 1995, MOL BIOL CELL, V6, P1061, DOI 10.1091/mbc.6.8.1061; Hall RA, 2002, CIRC RES, V91, P672, DOI 10.1161/01.RES.0000037000.74258.03; Hamada K, 2003, EMBO J, V22, P502, DOI 10.1093/emboj/cdg039; Heiska L, 1998, J BIOL CHEM, V273, P21893, DOI 10.1074/jbc.273.34.21893; Hirasawa A, 1998, BRIT J PHARMACOL, V124, P55, DOI 10.1038/sj.bjp.0701795; Laroche G, 2005, J BIOL CHEM, V280, P23215, DOI 10.1074/jbc.M414071200; LATTION AL, 1994, J BIOL CHEM, V269, P22887; Leftowitz RJ, 2005, SCIENCE, V308, P512, DOI 10.1126/science.1109237; Li JG, 2002, J BIOL CHEM, V277, P27545, DOI 10.1074/jbc.M200058200; Mackay DJG, 1997, J CELL BIOL, V138, P927, DOI 10.1083/jcb.138.4.927; Manchanda N, 2005, J BIOL CHEM, V280, P12517, DOI 10.1074/jbc.C400583200; Mueller A, 2004, EUR J BIOCHEM, V271, P243, DOI 10.1046/j.1432-1033.2003.03918.x; Pearson MA, 2000, CELL, V101, P259, DOI 10.1016/S0092-8674(00)80836-3; Schmieder S, 2004, J AM SOC NEPHROL, V15, P2289, DOI 10.1097/01.ASN.0000135968.49899.E8; WEINMAN EJ, 2005, ANN REV PHYSL, V68; Yonemura S, 1998, J CELL BIOL, V140, P885, DOI 10.1083/jcb.140.4.885; Zhao HR, 2004, P NATL ACAD SCI USA, V101, P9485, DOI 10.1073/pnas.0308400101	30	39	40	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 17	2006	281	7					4354	4363		10.1074/jbc.M511989200	http://dx.doi.org/10.1074/jbc.M511989200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	011NN	16352594	hybrid			2022-12-25	WOS:000235275300071
J	Das, S; Ward, SV; Tacke, RS; Suske, G; Samuel, CE				Das, S; Ward, SV; Tacke, RS; Suske, G; Samuel, CE			Activation of the RNA-dependent protein kinase PKR promoter in the absence of interferon is dependent upon sp proteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTION FACTOR SP3; KCS ELEMENT; TARGETED DISRUPTION; ANTIVIRAL ACTIONS; BINDING PROTEINS; GENE-REGULATION; FACTOR FAMILY; EXPRESSION; MECHANISM; CELLS	The protein kinase regulated by RNA (PKR) is interferon (IFN)-inducible and plays important roles in many cellular processes, including virus multiplication, cell growth, and apoptosis. The TATA-less PKR promoter possesses a novel 15-bp DNA element (kinase conserved sequence (KCS)) unique to the human and mouse PKR genes that is conserved in sequence and position. We found that Sp1 and Sp3 of the Sp family of transcription factors bind at the KCS element. Their involvement was analyzed in the activation of basal and IFN-inducible PKR promoter activity. Both the small and large isoforms of Sp3 co-purified with KCS protein binding activity (KBP) by using nuclear extracts from HeLa cells not treated with IFN. Two forms of the KCS-binding protein complex were demonstrated by electrophoretic mobility shift assay analysis; one contained Sp1 and the other Sp3. In mouse cells null for all Sp3 isoforms, PKR expression was reduced to similar to 50% that of wild-type cells in the absence of IFN. The IFN-inducible expression of PKR, however, was Sp3-independent but STAT1- and JAK1-dependent. Overexpression of Sp1 in human U cells resulted in increased PKR promoter activity. In Drosophila SL2 cells lacking Sp proteins, both Sp1 and Sp3 large but not small isoforms activated PKR promoter expression, with the Sp1-mediated activation dominant. Mutational analysis of the PKR promoter region indicated a cooperative interaction between two different Sp sites, one of which is within the KCS element. These results establish that, in the absence of IFN treatment, activation of PKR basal expression is mediated by Sp1 and Sp3 proteins in a cooperative manner.	Univ Calif Santa Barbara, Dept Mol Cellular & Dev Biol, Santa Barbara, CA 93106 USA; Univ Marburg, Inst Mol Biol & Tumor Res, D-35033 Marburg, Germany	University of California System; University of California Santa Barbara; Philipps University Marburg	Samuel, CE (corresponding author), Univ Calif Santa Barbara, Dept Mol Cellular & Dev Biol, Santa Barbara, CA 93106 USA.	samuel@lifesci.ucsb.edu		Suske, Guntram/0000-0002-4807-0513	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI020611] Funding Source: NIH RePORTER; NIAID NIH HHS [AI-20611] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Abraham N, 1999, J BIOL CHEM, V274, P5953, DOI 10.1074/jbc.274.9.5953; Black AR, 2001, J CELL PHYSIOL, V188, P143, DOI 10.1002/jcp.1111; Bouwman P, 2002, MOL CELL ENDOCRINOL, V195, P27, DOI 10.1016/S0303-7207(02)00221-6; Bouwman P, 2000, EMBO J, V19, P655, DOI 10.1093/emboj/19.4.655; BREATHNACH R, 1981, ANNU REV BIOCHEM, V50, P349, DOI 10.1146/annurev.bi.50.070181.002025; Bromberg JF, 1999, CELL, V98, P295, DOI 10.1016/S0092-8674(00)81959-5; Chamboredon S, 2005, ONCOGENE, V24, P2547, DOI 10.1038/sj.onc.1208489; COUREY AJ, 1988, CELL, V55, P887, DOI 10.1016/0092-8674(88)90144-4; Darnell JE, 1997, SCIENCE, V277, P1630, DOI 10.1126/science.277.5332.1630; Das S, 2004, J BIOL CHEM, V279, P7313, DOI 10.1074/jbc.M312585200; DENNIG J, 1995, J BIOL CHEM, V270, P12737, DOI 10.1074/jbc.270.21.12737; Dorris DR, 2000, MOL CELL BIOL, V20, P4350, DOI 10.1128/MCB.20.12.4350-4358.2000; George CX, 1999, P NATL ACAD SCI USA, V96, P4621, DOI 10.1073/pnas.96.8.4621; George CX, 1999, GENE, V229, P203, DOI 10.1016/S0378-1119(99)00017-7; HAGEN G, 1995, J BIOL CHEM, V270, P24989, DOI 10.1074/jbc.270.42.24989; Hata Y, 1998, J BIOL CHEM, V273, P19294, DOI 10.1074/jbc.273.30.19294; Hilton TL, 2003, J BIOL CHEM, V278, P12992, DOI 10.1074/jbc.M300412200; ICELY PL, 1991, J BIOL CHEM, V266, P16073; Kaczynski J, 2003, GENOME BIOL, V4, DOI 10.1186/gb-2003-4-2-206; Kawakami Y, 2004, DEVELOPMENT, V131, P4763, DOI 10.1242/dev.01331; Kennett SB, 1997, NUCLEIC ACIDS RES, V25, P3110, DOI 10.1093/nar/25.15.3110; Kuhen KL, 1996, GENOMICS, V36, P197, DOI 10.1006/geno.1996.0446; Kuhen KL, 1997, VIROLOGY, V227, P119, DOI 10.1006/viro.1996.8306; Kuhen KL, 1999, VIROLOGY, V254, P182, DOI 10.1006/viro.1998.9536; Kuhen KL, 1998, J VIROL, V72, P9934, DOI 10.1128/JVI.72.12.9934-9939.1998; KUMAR A, 1994, P NATL ACAD SCI USA, V91, P6288, DOI 10.1073/pnas.91.14.6288; Li L, 2004, BIOCHEM CELL BIOL, V82, P460, DOI 10.1139/O04-045; Look DC, 1995, J BIOL CHEM, V270, P30264, DOI 10.1074/jbc.270.51.30264; LUTHMAN H, 1983, NUCLEIC ACIDS RES, V11, P1295, DOI 10.1093/nar/11.5.1295; Meraz MA, 1996, CELL, V84, P431, DOI 10.1016/S0092-8674(00)81288-X; PESTKA S, 1987, ANNU REV BIOCHEM, V56, P727, DOI 10.1146/annurev.biochem.56.1.727; Platanias LC, 2005, NAT REV IMMUNOL, V5, P375, DOI 10.1038/nri1604; Rodig SJ, 1998, CELL, V93, P373, DOI 10.1016/S0092-8674(00)81166-6; Samuel C E, 1981, Methods Enzymol, V79, P168; Samuel CE, 2001, CLIN MICROBIOL REV, V14, P778, DOI 10.1128/CMR.14.4.778-809.2001; SAMUEL CE, 1979, P NATL ACAD SCI USA, V76, P600, DOI 10.1073/pnas.76.2.600; SAMUEL CE, 1982, J BIOL CHEM, V257, P1791; SAMUEL CE, 1991, VIROLOGY, V183, P1, DOI 10.1016/0042-6822(91)90112-O; SAMUEL CE, 1984, J BIOL CHEM, V259, P3451; SAMUEL CE, 1983, VIROLOGY, V130, P474, DOI 10.1016/0042-6822(83)90101-0; SANTORO C, 1988, NATURE, V334, P218, DOI 10.1038/334218a0; Sapetschnig A, 2004, J BIOL CHEM, V279, P42095, DOI 10.1074/jbc.M404989200; Shtrichman R, 2002, INFECT IMMUN, V70, P5579, DOI 10.1128/IAI.70.10.5579-5588.2002; SMALE ST, 1990, P NATL ACAD SCI USA, V87, P4509, DOI 10.1073/pnas.87.12.4509; Suske G, 1999, GENE, V238, P291, DOI 10.1016/S0378-1119(99)00357-1; Suske G, 2005, GENOMICS, V85, P551, DOI 10.1016/j.ygeno.2005.01.005; TANAKA H, 1994, P NATL ACAD SCI USA, V91, P7995, DOI 10.1073/pnas.91.17.7995; UDVADIA AJ, 1995, P NATL ACAD SCI USA, V92, P3953, DOI 10.1073/pnas.92.9.3953; Wang J, 2005, J NEUROCHEM, V93, P474, DOI 10.1111/j.1471-4159.2005.03051.x; Ward SV, 2003, VIROLOGY, V313, P553, DOI 10.1016/S0042-6822(03)00347-7; Ward SV, 2002, VIROLOGY, V296, P136, DOI 10.1006/viro.2002.1356; WILLIAMS BRG, 1995, SEMIN VIROL, V6, P191, DOI 10.1006/smvy.1995.0024; Williams BRG, 1999, ONCOGENE, V18, P6112, DOI 10.1038/sj.onc.1203127; Yu B, 2003, NUCLEIC ACIDS RES, V31, P5368, DOI 10.1093/nar/gkg706; Zhang XH, 2003, AM J PHYSIOL-RENAL, V284, pF82, DOI 10.1152/ajprenal.00200.2002	55	36	37	1	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 10	2006	281	6					3244	3253		10.1074/jbc.M510612200	http://dx.doi.org/10.1074/jbc.M510612200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	009QV	16339759	hybrid			2022-12-25	WOS:000235128200029
J	Hinek, A; Pshezhetsky, AV; von Itzstein, M; Starcher, B				Hinek, A; Pshezhetsky, AV; von Itzstein, M; Starcher, B			Lysosomal sialidase (neuraminidase-1) is targeted to the cell surface in a multiprotein complex that facilitates elastic fiber assembly	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LAMININ-BINDING-PROTEIN; BETA-GALACTOSIDASE; PROTECTIVE PROTEIN; MOLECULAR-CLONING; FUNCTIONAL DOMAINS; GENE; GALACTOSIALIDOSIS; EXPRESSION; DEFICIENCY; MUTATIONS	We have established previously that the 67-kDa elastin-binding protein (EBP), identical to the spliced variant of beta-galactosidase, acts as a recyclable chaperone that facilitates secretion of tropoelastin. (Hinek, A., Keeley, F. W., and Callahan, J. W. (1995) Exp. Cell Res. 220, 312-324). We now demonstrate that EBP also forms a cell surface-targeted molecular complex with protective protein/cathepsin A and sialidase (neuraminidase-1), and provide evidence that this sialidase activity is a prerequisite for the subsequent release of tropoelastin. We found that treatment with sialidase inhibitors repressed assembly of elastic fibers in cultures of human skin fibroblasts, aortic smooth muscle cells, and ear cartilage chondrocytes and caused impaired elastogenesis in developing chick embryos. Fibroblasts derived from patients with congenital sialidosis (primary deficiency of neuraminidase-1) and galactosialidosis (secondary deficiency of neuraminidase-1) demonstrated impaired elastogenesis, which could be reversed after their transduction with neuraminidase-1 cDNA or after treatment with bacterial sialidase, which has a similar substrate specificity to human neuraminidase-1. We postulate that neuraminidase-1 catalyzes removal of the terminal sialic acids from carbohydrate chains of microfibrillar glycoproteins and other adjacent matrix glycoconjugates, unmasking their penultimate galactosugars. In turn, the exposed galactosugars interact with the galectin domain of EBP, thereby inducing the release of transported tropoelastin molecules and facilitating their subsequent assembly into elastic fibers.	Hosp Sick Children, Cardiovasc Res Program, Toronto, ON M5G 1X8, Canada; Univ Toronto, Dept Lab Med & Pathobiol, Toronto, ON M5G 1X8, Canada; Univ Montreal, Dept Med Genet, St Justine Hosp, Montreal, PQ H3T 1C5, Canada; Univ Montreal, Dept Pediat, Montreal, PQ H3T 1C5, Canada; Univ Montreal, Dept Biochem, Montreal, PQ H3T 1C5, Canada; Univ Texas Hlth Ctr, Tyler, TX 75708 USA	University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Toronto; Universite de Montreal; Centre Hospitalier Universitaire Sainte-Justine; Universite de Montreal; Universite de Montreal	Hinek, A (corresponding author), Hosp Sick Children, Cardiovasc Res Program, 555 Univ Ave, Toronto, ON M5G 1X8, Canada.	alek.hinek@sickkids.ca	von Itzstein, Mark/E-4823-2010; Hinek, Aleksander/V-8790-2019	A, Pshezhetsky/0000-0002-6612-1062				Achyuthan KE, 2001, COMP BIOCHEM PHYS B, V129, P29, DOI 10.1016/S1096-4959(01)00372-4; AKIMOTO S, 1994, BIOCHEM BIOPH RES CO, V203, P914, DOI 10.1006/bbrc.1994.2269; Arai Y, 1999, ULTRASTRUCT PATHOL, V23, P369, DOI 10.1080/019131299281338; BACCARANICONTRI M, 1990, EUR J CELL BIOL, V53, P305; Bonten E, 1996, GENE DEV, V10, P3156, DOI 10.1101/gad.10.24.3156; Bonten EJ, 2000, J BIOL CHEM, V275, P37657, DOI 10.1074/jbc.M007380200; BONTEN EJ, 1995, J BIOL CHEM, V270, P26441, DOI 10.1074/jbc.270.44.26441; Bonten EJ, 2000, HUM MOL GENET, V9, P2715, DOI 10.1093/hmg/9.18.2715; BrownAugsburger P, 1996, BIOCHEM J, V318, P149, DOI 10.1042/bj3180149; Caciotti A, 2005, HUM MUTAT, V25, P285, DOI 10.1002/humu.20147; Chen XP, 1997, J IMMUNOL, V158, P3070; CHRISTIANO AM, 1994, J INVEST DERMATOL, V103, pS53, DOI 10.1111/1523-1747.ep12399044; CROSS AS, 1991, J CLIN INVEST, V88, P2067, DOI 10.1172/JCI115536; Csiszar K, 2001, PROG NUCLEIC ACID RE, V70, P1, DOI 10.1016/S0079-6603(01)70012-8; d'Azzo A., 2001, METABOLIC MOL BASES, V3, P3811; DAGROSA RM, 1992, BIOCHEM J, V285, P833, DOI 10.1042/bj2850833; Davis EC, 1998, J CELL BIOL, V140, P295, DOI 10.1083/jcb.140.2.295; de Geest N, 2002, HUM MOL GENET, V11, P1455, DOI 10.1093/hmg/11.12.1455; Debelle L, 1999, INT J BIOCHEM CELL B, V31, P261, DOI 10.1016/S1357-2725(98)00098-3; Debret R, 2005, ARTERIOSCL THROM VAS, V25, P1353, DOI 10.1161/01.ATV.0000168412.50855.9f; Florio P, 1999, BIOORG MED CHEM LETT, V9, P2065, DOI 10.1016/S0960-894X(99)00331-5; Gibson MA, 1996, J BIOL CHEM, V271, P1096, DOI 10.1074/jbc.271.2.1096; GILLESPIE W, 1993, J BIOL CHEM, V268, P3801; Hinek A, 2000, AM J HUM GENET, V66, P859, DOI 10.1086/302829; Hinek A, 2000, AM J PATHOL, V156, P925, DOI 10.1016/S0002-9440(10)64961-9; HINEK A, 1994, CELL ADHES COMMUN, V2, P185, DOI 10.3109/15419069409004436; HINEK A, 1992, EXP CELL RES, V203, P344, DOI 10.1016/0014-4827(92)90008-V; HINEK A, 1991, J CLIN INVEST, V88, P2083, DOI 10.1172/JCI115538; HINEK A, 1995, EXP CELL RES, V220, P312, DOI 10.1006/excr.1995.1321; HINEK A, 1994, J CELL BIOL, V126, P563, DOI 10.1083/jcb.126.2.563; Hinek A, 2005, J DERMATOL SCI, V39, P155, DOI 10.1016/j.jdermsci.2005.04.002; HINEK A, 1988, SCIENCE, V239, P1539, DOI 10.1126/science.2832941; HINEK A, 1993, J CLIN INVEST, V91, P1198, DOI 10.1172/JCI116280; Hinek A, 1996, BIOL CHEM, V377, P471; HOLZER CT, 1993, GLYCOCONJUGATE J, V10, P40, DOI 10.1007/BF00731185; Hou YM, 1998, J BIOL CHEM, V273, P21386, DOI 10.1074/jbc.273.33.21386; Igdoura SA, 1998, HUM MOL GENET, V7, P115, DOI 10.1093/hmg/7.1.115; Kielty CM, 2002, PHILOS T R SOC B, V357, P207, DOI 10.1098/rstb.2001.1029; Kielty CM, 2002, J CELL SCI, V115, P2817; KNIBBS RN, 1993, J BIOL CHEM, V268, P18524; LANDOLFI NF, 1986, MOL IMMUNOL, V23, P297, DOI 10.1016/0161-5890(86)90057-X; Lukong KE, 2001, J BIOL CHEM, V276, P46172, DOI 10.1074/jbc.M104547200; Lukong KE, 1999, BIOCHEMISTRY-US, V38, P73, DOI 10.1021/bi981324r; Malvagia S, 2004, MOL GENET METAB, V82, P48, DOI 10.1016/j.ymgme.2004.02.007; Mann MC, 2004, BIOORG MED CHEM LETT, V14, P5555, DOI 10.1016/j.bmcl.2004.08.064; MECHAM RP, 1988, BIOCHEM BIOPH RES CO, V151, P822, DOI 10.1016/S0006-291X(88)80355-3; MECHAM RP, 1991, J CELL BIOL, V113, P187, DOI 10.1083/jcb.113.1.187; MECHAM RP, 1989, BIOCHEMISTRY-US, V28, P3716, DOI 10.1021/bi00435a014; Miyagi T, 1999, J BIOL CHEM, V274, P5004, DOI 10.1074/jbc.274.8.5004; MIYAGI T, 1993, GLYCOCONJUGATE J, V10, P45, DOI 10.1007/BF00731186; Mochizuki S, 2002, J BIOL CHEM, V277, P44854, DOI 10.1074/jbc.M205630200; Monti E, 1999, GLYCOBIOLOGY, V9, P1313, DOI 10.1093/glycob/9.12.1313; Monti E, 2000, BIOCHEM J, V349, P343, DOI 10.1042/0264-6021:3490343; Monti E, 2004, GENOMICS, V83, P445, DOI 10.1016/j.ygeno.2003.08.019; Monti E, 1999, GENOMICS, V57, P137, DOI 10.1006/geno.1999.5749; Monti E, 2002, NEUROCHEM RES, V27, P649, DOI 10.1023/A:1020276000901; MORREAU H, 1989, J BIOL CHEM, V264, P20655; MORREAU H, 1992, J BIOL CHEM, V267, P17949; Morrone A, 2000, HUM MUTAT, V15, P354, DOI 10.1002/(SICI)1098-1004(200004)15:4<354::AID-HUMU8>3.3.CO;2-C; Nakamura T, 2002, NATURE, V415, P171, DOI 10.1038/415171a; OBRIEN JS, 1980, CLIN GENET, V17, P35; PASQUALIRONCHETTI I, 1984, EXP MOL PATHOL, V40, P235, DOI 10.1016/0014-4800(84)90080-7; Patel MS, 1999, AM J MED GENET, V85, P38, DOI 10.1002/(SICI)1096-8628(19990702)85:1<38::AID-AJMG8>3.3.CO;2-V; Pattison S, 2004, HUM MUTAT, V23, P32, DOI 10.1002/humu.10278; POTIER M, 1979, ANAL BIOCHEM, V94, P287, DOI 10.1016/0003-2697(79)90362-2; Privitera S, 1998, J BIOL CHEM, V273, P6319, DOI 10.1074/jbc.273.11.6319; PROSSER IW, 1991, CONNECT TISSUE RES, V25, P265, DOI 10.3109/03008209109029162; Pshezhetsky AV, 1997, NAT GENET, V15, P316, DOI 10.1038/ng0397-316; PSHEZHETSKY AV, 1995, ANAL BIOCHEM, V230, P303, DOI 10.1006/abio.1995.1478; ROARK EF, 1995, J HISTOCHEM CYTOCHEM, V43, P401, DOI 10.1177/43.4.7534784; Rock MJ, 2004, J BIOL CHEM, V279, P23748, DOI 10.1074/jbc.M400212200; Saito N., 1995, BIOL SIALIC ACIDS, P261; SAKURABA H, 1982, CLIN CHIM ACTA, V125, P275; SATO K, 1995, GLYCOBIOLOGY, V5, P511, DOI 10.1093/glycob/5.5.511; Seyrantepe V, 2003, HUM MUTAT, V22, P343, DOI 10.1002/humu.10268; Sherratt MJ, 2001, MICRON, V32, P185, DOI 10.1016/S0968-4328(99)00082-7; Starcher B, 1999, J INVEST DERMATOL, V112, P450, DOI 10.1046/j.1523-1747.1999.00553.x; Trask BC, 2000, MOL BIOL CELL, V11, P1499, DOI 10.1091/mbc.11.5.1499; Uitto J, 1995, CIBA F SYMP, V192, P237; van der Spoel A, 1998, EMBO J, V17, P1588, DOI 10.1093/emboj/17.6.1588; Vinogradova MV, 1998, BIOCHEM J, V330, P641; Vleurick L, 1999, J CELL BIOCHEM, V72, P349, DOI 10.1002/(SICI)1097-4644(19990301)72:3<349::AID-JCB4>3.0.CO;2-H; VONITZSTEIN M, 1994, CARBOHYD RES, V259, P301, DOI 10.1016/0008-6215(94)84065-2; Vrhovski B, 1998, EUR J BIOCHEM, V258, P1, DOI 10.1046/j.1432-1327.1998.2580001.x; Wada T, 1999, BIOCHEM BIOPH RES CO, V261, P21, DOI 10.1006/bbrc.1999.0973; WRENN DS, 1988, J BIOL CHEM, V263, P2280; Yamaguchi K, 2005, BIOCHEM J, V390, P85, DOI 10.1042/BJ20050017; ZHU L, 1994, J CLIN INVEST, V94, P1163, DOI 10.1172/JCI117432	88	127	133	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 10	2006	281	6					3698	3710		10.1074/jbc.M508736200	http://dx.doi.org/10.1074/jbc.M508736200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	009QV	16314420	hybrid			2022-12-25	WOS:000235128200082
J	Kim, SG; Manes, NP; El-Maghrabi, MR; Lee, YH				Kim, SG; Manes, NP; El-Maghrabi, MR; Lee, YH			Crystal structure of the hypoxia-inducible form of 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase (PFKFB3) - A possible new target for cancer therapy	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE; FRUCTOSE 2,6-BISPHOSPHATE; BIFUNCTIONAL ENZYME; 6-PHOSPHOFRUCTO-2-KINASE; FRUCTOSE-2,6-BISPHOSPHATASE; GLYCOLYSIS; ACTIVATION; EXPRESSION; GENE; PHOSPHORYLATION	The hypoxia-inducible form of 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase (PFKFB3) plays a crucial role in the progression of cancerous cells by enabling their glycolytic pathways even under severe hypoxic conditions. To understand its structural architecture and to provide a molecular scaffold for the design of new cancer therapeutics, the crystal structure of the human form was determined. The structure at 2.1 angstrom resolution shows that the overall folding and functional dimerization are very similar to those of the liver (PFKFB1) and testis (PFKFB4) forms, as expected from sequence homology. However, in this structure, the N-terminal regulatory domain is revealed for the first time among the PFKFB isoforms. With a beta-hairpin structure, the N terminus interacts with the 2-Pase domain to secure binding of fructose-6-phosphate to the active pocket, slowing down the release of fructose-6-phosphate from the phosphoenzyme intermediate product complex. The C-terminal regulatory domain is mostly disordered, leaving the active pocket of the fructose-2,6-bisphosphatase domain wide open. The active pocket of the 6-phosphofructo-2-kinase domain has a more rigid conformation, allowing independent bindings of substrates, fructose-6-phosphate and ATP, with higher affinities than other isoforms. Intriguingly, the structure shows an EDTA molecule bound to the fructose-6-phosphate site of the 6-phosphofructo-2-kinase active pocket despite its unfavorable liganding concentration, suggesting a high affinity. EDTA is not removable from the site with fructose-6-P alone but is with both ATP and fructose-6-P or with fructose-2,6-bisphosphate. This finding suggests that a molecule in which EDTA is covalently linked to ADP is a good starting molecule for the development of new cancer-therapeutic molecules.	Louisiana State Univ, Dept Biol Sci, Baton Rouge, LA 70803 USA; SUNY Stony Brook, Dept Physiol & Biophys, Stony Brook, NY 11794 USA	Louisiana State University System; Louisiana State University; State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook	Lee, YH (corresponding author), Louisiana State Univ, Dept Biol Sci, 202 Life Sci Bldg, Baton Rouge, LA 70803 USA.	yhlee@lsu.edu	Manes, Nathan P/E-2817-2012	Manes, Nathan P/0000-0001-6701-3314	NCI NIH HHS [R01 CA124758] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA124758] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Atsumi T, 2002, CANCER RES, V62, P5881; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; BAZAN JF, 1989, P NATL ACAD SCI USA, V86, P9642, DOI 10.1073/pnas.86.24.9642; Bertrand L, 1999, J BIOL CHEM, V274, P30927, DOI 10.1074/jbc.274.43.30927; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Chesney J, 2005, BIOCHEM BIOPH RES CO, V331, P139, DOI 10.1016/j.bbrc.2005.02.193; Chesney J, 1999, P NATL ACAD SCI USA, V96, P3047, DOI 10.1073/pnas.96.6.3047; El-Maghrabi MR, 2001, CURR OPIN CLIN NUTR, V4, P411, DOI 10.1097/00075197-200109000-00012; Esnouf RM, 1999, ACTA CRYSTALLOGR D, V55, P938, DOI 10.1107/S0907444998017363; Fukasawa M, 2004, J BIOCHEM, V136, P273, DOI 10.1093/jb/mvh137; Goren N, 2000, MOL BRAIN RES, V75, P138, DOI 10.1016/S0169-328X(99)00319-8; Hasemann CA, 1996, STRUCTURE, V4, P1017, DOI 10.1016/S0969-2126(96)00109-8; Heine-Suner D, 1998, EUR J BIOCHEM, V254, P103, DOI 10.1046/j.1432-1327.1998.2540103.x; Hirata T, 2000, BIOSCI BIOTECH BIOCH, V64, P2047, DOI 10.1271/bbb.64.2047; Hue L, 2002, J MOL CELL CARDIOL, V34, P1091, DOI 10.1006/jmcc.2002.2063; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Koshland DE, 1998, NAT MED, V4, P1112, DOI 10.1038/2605; Lee YH, 1997, NAT STRUCT BIOL, V4, P615, DOI 10.1038/nsb0897-615; Lee YH, 1996, BIOCHEMISTRY-US, V35, P6010, DOI 10.1021/bi9600613; Lee YH, 2003, J BIOL CHEM, V278, P523, DOI 10.1074/jbc.M209105200; LI L, 1992, J BIOL CHEM, V267, P21588; LI L, 1992, J BIOL CHEM, V267, P16669; LIN K, 1992, J BIOL CHEM, V267, P6556; LIN K, 1994, J BIOL CHEM, V269, P16953; Manes NP, 2005, ARCH BIOCHEM BIOPHYS, V438, P125, DOI 10.1016/j.abb.2005.04.011; Manzano A, 1999, GENE, V229, P83, DOI 10.1016/S0378-1119(99)00037-2; Marsin AS, 2000, CURR BIOL, V10, P1247, DOI 10.1016/S0960-9822(00)00742-9; Marsin AS, 2002, J BIOL CHEM, V277, P30778, DOI 10.1074/jbc.M205213200; MERRITT EA, 1994, ACTA CRYSTALLOGR D, V50, P869, DOI 10.1107/S0907444994006396; Minchenko A, 2002, J BIOL CHEM, V277, P6183, DOI 10.1074/jbc.M110978200; Minchenko O, 2004, FEBS LETT, V576, P14, DOI 10.1016/j.febslet.2004.08.053; Minchenko OH, 2005, BIOCHIMIE, V87, P1005, DOI 10.1016/j.biochi.2005.04.007; NAVAZA J, 1993, ACTA CRYSTALLOGR D, V49, P588, DOI 10.1107/S0907444993005141; Okamura N, 1998, BIOSCI BIOTECH BIOCH, V62, P2039, DOI 10.1271/bbb.62.2039; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; PILKIS SJ, 1984, J BIOL CHEM, V259, P949; PILKIS SJ, 1988, ADV SEC MESS PHOSPH, V22, P175; PILKIS SJ, 1995, ANNU REV BIOCHEM, V64, P799, DOI 10.1146/annurev.bi.64.070195.004055; PILKIS SJ, 1981, J BIOL CHEM, V256, P3171; Sakakibara R, 1997, J BIOCHEM-TOKYO, V122, P122; Sakakibara R, 1999, BIOCHEM BIOPH RES CO, V257, P177, DOI 10.1006/bbrc.1999.0429; Semenza GL, 2002, BIOCHEM PHARMACOL, V64, P993, DOI 10.1016/S0006-2952(02)01168-1; STEWART HB, 1986, J BIOL CHEM, V261, P8793; UYEDA K, 1981, J BIOL CHEM, V256, P8679; WARBURG O, 1956, SCIENCE, V123, P309, DOI 10.1126/science.123.3191.309; Yuen MH, 1999, BIOCHEMISTRY-US, V38, P12333, DOI 10.1021/bi991268+	46	36	43	2	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 3	2006	281	5					2939	2944		10.1074/jbc.M511019200	http://dx.doi.org/10.1074/jbc.M511019200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	006XT	16316985	hybrid			2022-12-25	WOS:000234931800063
J	Roes, S; Mumm, F; Seydel, U; Gutsmann, T				Roes, S; Mumm, F; Seydel, U; Gutsmann, T			Localization of the lipopolysaccharide-binding protein in phospholipid membranes by atomic force microscopy	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							(LPS)-BINDING PROTEIN; LPS; CELLS; NEUTRALIZATION; DIFFUSION; ENDOTOXIN; RESPONSES; SURFACES; RELEASE; CD14	Lipopolysaccharides (LPS; endotoxin) activate immunocompetent cells of the host via a transmembrane signaling process. In this study, we investigated the function of the LPS-binding protein (LBP) in this process. The cytoplasmic membrane of the cells was mimicked by lipid liposomes adsorbed on mica, and the lateral organization of LBP in these membranes and its interaction with LPS aggregates were characterized by atomic force microscopy. Using cantilever tips functionalized with anti-LBP antibodies, single LBP molecules were localized in the membrane at low concentrations. At higher concentrations, LBP formed clusters of several molecules and caused cross-linking of lipid bilayers. The addition of LPS to LBP-containing liposomes led to the formation of LPS domains in the membranes, which could be inhibited by anti-LBP antibodies. Thus, LBP mediates the fusion of lipid membranes and LPS aggregates.	Leibniz Ctr Med & Biol Sci, Div Biophys, Res Ctr Borstel, D-23845 Borstel, Germany	Forschungszentrum Borstel	Gutsmann, T (corresponding author), Leibniz Ctr Med & Biol Sci, Div Biophys, Res Ctr Borstel, Parkallee 10, D-23845 Borstel, Germany.	tguts@fz-borstel.de	Gutsmann, Thomas/E-6100-2011					ALVAREZ E, 1993, MECH AGEING DEV, V71, P1, DOI 10.1016/0047-6374(93)90030-U; Beamer LJ, 1998, PROTEIN SCI, V7, P906; BINNIG G, 1986, PHYS REV LETT, V56, P930, DOI 10.1103/PhysRevLett.56.930; Brass DM, 2004, J ALLERGY CLIN IMMUN, V114, P586, DOI 10.1016/j.jaci.2004.04.043; Cai XE, 2002, BIOPHYS J, V82, P357, DOI 10.1016/S0006-3495(02)75400-3; DENTENER MA, 1993, J IMMUNOL, V151, P4258; Dunzendorfer S, 2004, FASEB J, V18, P1117, DOI 10.1096/fj.03-1263fje; Dunzendorfer S, 2004, J IMMUNOL, V173, P1166, DOI 10.4049/jimmunol.173.2.1166; GALANOS C, 1969, EUR J BIOCHEM, V9, P245, DOI 10.1111/j.1432-1033.1969.tb00601.x; GEGNER JA, 1995, J BIOL CHEM, V270, P5320, DOI 10.1074/jbc.270.10.5320; Grandbois M, 2000, J HISTOCHEM CYTOCHEM, V48, P719, DOI 10.1177/002215540004800516; Grandbois M, 1999, SCIENCE, V283, P1727, DOI 10.1126/science.283.5408.1727; Gutsmann T, 2001, BIOL CHEM, V382, P425, DOI 10.1515/BC.2001.052; Gutsmann T, 2001, INFECT IMMUN, V69, P6942, DOI 10.1128/IAI.69.11.6942-6950.2001; Hinterdorfer P, 1996, P NATL ACAD SCI USA, V93, P3477, DOI 10.1073/pnas.93.8.3477; Jares-Erijman EA, 2003, NAT BIOTECHNOL, V21, P1387, DOI 10.1038/nbt896; Kato A, 2004, J IMMUNOL, V172, P6185, DOI 10.4049/jimmunol.172.10.6185; Kienberger F, 2004, EMBO REP, V5, P579, DOI 10.1038/sj.embor.7400149; KRONER EE, 1981, J BIOL CHEM, V256, P3690; Lamping N, 1998, J CLIN INVEST, V101, P2065, DOI 10.1172/JCI2338; Mueller M, 2004, J BIOL CHEM, V279, P26307, DOI 10.1074/jbc.M401231200; Muller DJ, 1999, J MOL BIOL, V285, P1347, DOI 10.1006/jmbi.1998.2359; Muller M., 2004, Immunobiology, V209, P325; NOLLERT P, 1995, BIOPHYS J, V69, P1447, DOI 10.1016/S0006-3495(95)80014-7; Post DMB, 2005, J BIOL CHEM, V280, P38383, DOI 10.1074/jbc.M508063200; Pralle A, 2000, J CELL BIOL, V148, P997, DOI 10.1083/jcb.148.5.997; Raab A, 1999, NAT BIOTECHNOL, V17, P902, DOI 10.1038/12898; RAMADORI G, 1990, PATHOBIOLOGY, V58, P89, DOI 10.1159/000163569; SCHABERT FA, 1995, SCIENCE, V268, P92, DOI 10.1126/science.7701347; Schmidt T, 1996, P NATL ACAD SCI USA, V93, P2926, DOI 10.1073/pnas.93.7.2926; Schromm AB, 1996, FEBS LETT, V399, P267, DOI 10.1016/S0014-5793(96)01338-5; SCHUMANN RR, 1990, SCIENCE, V249, P1429, DOI 10.1126/science.2402637; Schutz GJ, 1997, BIOPHYS J, V73, P1073, DOI 10.1016/S0006-3495(97)78139-6; Seydel U, 2000, EUR J BIOCHEM, V267, P3032; Stroh C, 2004, P NATL ACAD SCI USA, V101, P12503, DOI 10.1073/pnas.0403538101; Tapping RI, 1999, J IMMUNOL, V162, P5483; THEOFAN G, 1994, J IMMUNOL, V152, P3623; Thompson PA, 2003, J BIOL CHEM, V278, P28367, DOI 10.1074/jbc.M302921200; Vesy CJ, 2000, INFECT IMMUN, V68, P2410, DOI 10.1128/IAI.68.5.2410-2417.2000; Vreugdenhil ACE, 1999, J IMMUNOL, V163, P2792; Wiese A, 1998, J MEMBRANE BIOL, V162, P127, DOI 10.1007/s002329900350; WURFEL MM, 1994, J EXP MED, V180, P1025, DOI 10.1084/jem.180.3.1025	42	25	28	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 3	2006	281	5					2757	2763		10.1074/jbc.M507634200	http://dx.doi.org/10.1074/jbc.M507634200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	006XT	16303759	hybrid			2022-12-25	WOS:000234931800042
J	Alarcon-Vargas, D; Zhang, Z; Agarwal, B; Challagulla, K; Mani, S; Kalpana, GV				Alarcon-Vargas, D; Zhang, Z; Agarwal, B; Challagulla, K; Mani, S; Kalpana, GV			Targeting cyclin D1, a downstream effector of INI1/hSNF5, in rhabdoid tumors	ONCOGENE			English	Article						rhabdoid; cyclin D1; 4-HPR; tamoxifen; cell cycle and apoptosis	BREAST-CANCER CELLS; ATYPICAL TERATOID/RHABDOID TUMOR; CENTRAL-NERVOUS-SYSTEM; IN-VITRO; TAMOXIFEN; EXPRESSION; N-(4-HYDROXYPHENYL)RETINAMIDE; FENRETINIDE; APOPTOSIS; RECEPTOR	Rhabdoid tumors (RTs) are aggressive and currently incurable pediatric malignancies. INI1/hSNF5 is a tumor suppressor biallelically inactivated in RTs. Our previous studies have indicated that cyclin D1 is a key downstream target of INI1/hSNF5 and genesis and/or survival of RTs in vivo is critically dependent on the presence of cyclin D1. In this report, we have tested the hypothesis that therapeutic targeting of cyclin D1 is an effective means of treating RTs. We found that RNA interference of cyclin D1 in rhabdoid cells was sufficient to induce G1 arrest and apoptosis. Furthermore, we found that pharmacological intervention with low micromolar concentrations of N-(4-hydroxyphenyl) retinamide (4-HPR), which downmodulates cyclin D1, induced G1 arrest and apoptosis in rhabdoid cell lines. 4-HPR in combination with 4-hydroxy-tamoxifen (4OH-Tam), synergistically inhibited survival as well as anchorage-dependent and -independent growth of rhabdoid cells and caused synergistic induction of cell cycle arrest and apoptosis. 4-HPR and tamoxifen exhibited synergistic growth inhibition of RTs in xenograft models in vivo. The effects of combination of drugs were correlated to the depletion of cyclin D1 levels both in in vitro and in vivo tumor models. These results demonstrate that 4-HPR and tamoxifen are effective chemotherapeutic agents for RTs. We propose that downmodulation of cyclin D1 is a novel and effective therapeutic strategy for RTs.	Yeshiva Univ Albert Einstein Coll Med, Dept Mol Genet, Bronx, NY 10461 USA; Yeshiva Univ Albert Einstein Coll Med, Dept Med, Bronx, NY 10461 USA	Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine	Mani, S (corresponding author), Yeshiva Univ Albert Einstein Coll Med, Dept Mol Genet, 1300 Morris Pk Ave,Ullman 821, Bronx, NY 10461 USA.	smani@montefiore.org; kalpana@aecom.yu.edu		Kalpana, Ganjam/0000-0003-4111-0604	NATIONAL CANCER INSTITUTE [P30CA013330] Funding Source: NIH RePORTER; NCI NIH HHS [P30 CA13330] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Ae K, 2002, ONCOGENE, V21, P3112, DOI 10.1038/sj.onc.1205414; Aoyama Yuko, 2002, Kurume Medical Journal, V49, P27; Appierto V, 2001, BRIT J CANCER, V84, P1528, DOI 10.1054/bjoc.2001.1826; Argiris A, 2004, CLIN CANCER RES, V10, P1409, DOI 10.1158/1078-0432.CCR-1060-02; Betz BL, 2002, ONCOGENE, V21, P5193, DOI 10.1038/sj.onc.1205706; Biegel JA, 1999, CANCER RES, V59, P74; Biegel Jaclyn A., 2002, Cancer Research, V62, P323; Brockdorff BL, 2003, ENDOCR-RELAT CANCER, V10, P579, DOI 10.1677/erc.0.0100579; DiPietrantonio AM, 1998, INT J CANCER, V78, P53, DOI 10.1002/(SICI)1097-0215(19980925)78:1<53::AID-IJC10>3.0.CO;2-6; Dragnev KH, 2004, CLIN CANCER RES, V10, P2570, DOI 10.1158/1078-0432.CCR-03-0271; Erdreich-Epstein A, 2002, J BIOL CHEM, V277, P49531, DOI 10.1074/jbc.M209962200; Favoni RE, 1998, BRIT J CANCER, V77, P2138, DOI 10.1038/bjc.1998.358; Fu MF, 2004, ENDOCRINOLOGY, V145, P5439, DOI 10.1210/en.2004-0959; Hilden JM, 2004, J CLIN ONCOL, V22, P2877, DOI 10.1200/jco.2004.07.073; Jang TJ, 2001, CANCER LETT, V170, P109, DOI 10.1016/S0304-3835(01)00593-6; Koshida S, 2002, JPN J CANCER RES, V93, P1351, DOI 10.1111/j.1349-7006.2002.tb01244.x; Le Marchand L, 2003, JAMA-J AM MED ASSOC, V290, P2843, DOI 10.1001/jama.290.21.2843; Lee D, 1999, NATURE, V399, P487, DOI 10.1038/20966; Lee TH, 1999, ONCOGENE, V18, P4269, DOI 10.1038/sj.onc.1202755; Li WW, 2001, CLIN CANCER RES, V7, P2908; Maurer BJ, 2000, JNCI-J NATL CANCER I, V92, P1897, DOI 10.1093/jnci/92.23.1897; Mitsiades CS, 2003, J ENDOCRINOL, V178, P205, DOI 10.1677/joe.0.1780205; Packer RJ, 2002, J PEDIAT HEMATOL ONC, V24, P337, DOI 10.1097/00043426-200206000-00004; Panigone S, 2000, ONCOGENE, V19, P4035, DOI 10.1038/sj.onc.1203743; Pirkmaier A, 2003, CLIN CANCER RES, V9, P1877; Pollack IF, 1997, CLIN CANCER RES, V3, P1109; Reynolds C P, 2000, Curr Oncol Rep, V2, P511, DOI 10.1007/s11912-000-0104-y; Reynolds CP, 2001, HEMATOL ONCOL CLIN N, V15, P867, DOI 10.1016/S0889-8588(05)70256-2; Riedeout D, 1991, ENCY HUMAN BIOL, V2, P371; Rousseau C, 2003, J STEROID BIOCHEM, V86, P1, DOI 10.1016/S0960-0760(03)00255-3; Simeone AM, 2002, MOL CANCER THER, V1, P1009; Singletary SE, 2002, CLIN CANCER RES, V8, P2835; Tsikitis M, 2005, P NATL ACAD SCI USA, V102, P12129, DOI 10.1073/pnas.0505300102; Versteege I, 2002, ONCOGENE, V21, P6403, DOI 10.1038/sj.onc.1205841; Versteege I, 1998, NATURE, V394, P203, DOI 10.1038/28212; Vries RGJ, 2005, GENE DEV, V19, P665, DOI 10.1101/gad.335805; Wang HT, 2003, UROLOGY, V61, P1047, DOI 10.1016/S0090-4295(02)02511-6; Wu KM, 2002, MOL CANCER THER, V1, P695; Zeisig R, 2004, BREAST CANCER RES TR, V87, P245, DOI 10.1007/s10549-004-8699-6; Zhang ZK, 2002, MOL CELL BIOL, V22, P5975, DOI 10.1128/MCB.22.16.5975-5988.2002	40	57	58	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB	2006	25	5					722	734		10.1038/sj.onc.1209112	http://dx.doi.org/10.1038/sj.onc.1209112			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	008VM	16302003				2022-12-25	WOS:000235068800008
J	Calvo, E; Mans, BJ; Andersen, JF; Ribeiro, JMC				Calvo, E; Mans, BJ; Andersen, JF; Ribeiro, JMC			Function and evolution of a mosquito salivary protein family	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADULT FEMALE MOSQUITO; BINDING PROTEIN; GLAND; NITROPHORIN-2; TRANSCRIPTOME; SEROTONIN; SIALOME; PURIFICATION; INHIBITOR; LIPOCALIN	Saliva of blood-sucking arthropods contains a complex and diverse mixture of antihemostatic, antiinflammatory, and immunomodulatory compounds. The D7 salivary family of proteins is abundantly expressed in blood-feeding Diptera and is distantly related to the odorant-binding protein superfamily. In mosquitoes, two subfamilies exist, the long and short D7 proteins. Ticks and kissing bugs evolved salivary lipocalins that act as efficient scavengers of biogenic amines, and a similar function was postulated for the D7 proteins. Accordingly, we expressed the five members of the small D7 family of the African malaria vector Anopheles gambiae and a D7 long form from Aedes aegypti and showed by isothermal microcalorimetry, a modified and very sensitive non-equilibrium chromatography/ spectrum distortion method, and by smooth muscle bioassay that four of these five short D7 proteins and the D7 long form bind serotonin with high affinity, as well as histamine and norepinephrine. The nonbinding D7 protein is poorly expressed in the salivary glands and appears to be on the path to becoming a pseudogene. Scavenging of host amines would antagonize their vasoconstrictor, platelet-aggregating, and pain-inducing properties. It appears that counteracting biogenic amines is of strong adaptive value in the convergent evolution of arthropods to hematophagy. This adaptation has been solved independently in ticks, bugs, and mosquitoes by co-option of either member of the lipocalin or, as shown here, by the odorant-binding protein families.	NIAID, LMVR, Sect Vector Biol, NIH, Rockville, MD 20852 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID)	Ribeiro, JMC (corresponding author), NIAID, LMVR, Sect Vector Biol, NIH, 12735 Twinbrook Pkwy,Rm 2E32D, Rockville, MD 20852 USA.	jribeiro@niaid.nih.gov	Mans, Ben J./M-2427-2017; Calvo, Eric/ABB-4935-2021	Mans, Ben J./0000-0002-0177-0029; Calvo, Eric/0000-0001-7880-2730; Ribeiro, Jose/0000-0002-9107-0818	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [ZIAAI000810, Z01AI000810] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ABRAMSON DI, 1989, HDB EXP PHARM, V87, P89; Aguilera A, 2005, CURR OPIN CELL BIOL, V17, P242, DOI 10.1016/j.ceb.2005.03.001; Andersen JF, 2004, BIOCHEMISTRY-US, V43, P6987, DOI 10.1021/bi049655t; Andersen JF, 2005, ARCH INSECT BIOCHEM, V58, P97, DOI 10.1002/arch.20032; Andersen JF, 2003, J BIOL CHEM, V278, P4611, DOI 10.1074/jbc.M211438200; Arca B, 2002, INSECT MOL BIOL, V11, P47, DOI 10.1046/j.0962-1075.2001.00309.x; Arca B, 2005, J EXP BIOL, V208, P3971, DOI 10.1242/jeb.01849; BARNETT DB, 1985, ADV EXP MED BIOL, V192, P97; Calvo E, 2004, INSECT MOL BIOL, V13, P73, DOI 10.1111/j.1365-2583.2004.00463.x; Campbell CL, 2005, INSECT MOL BIOL, V14, P121, DOI 10.1111/j.1365-2583.2004.00537.x; DEGIUSTI DL, 1973, NATURE, V242, P50, DOI 10.1038/242050a0; Francischetti IMB, 2002, J EXP BIOL, V205, P2429; GADDUM JH, 1949, J PHYSIOL-LONDON, V108, P240; Gudderra NP, 2005, J BIOL CHEM, V280, P25022, DOI 10.1074/jbc.M504386200; Hekmat-Scafe DS, 2000, GENETICS, V155, P117; Hochscheid S, 2002, PHYSIOL BIOCHEM ZOOL, V75, P66, DOI 10.1086/339050; Holt RA, 2002, SCIENCE, V298, P129, DOI 10.1126/science.1076181; HUMPHREY JH, 1954, J PHYSIOL-LONDON, V124, P305, DOI 10.1113/jphysiol.1954.sp005109; ISAWA H, 2002, J BIOL CHEM, V13, P13; JAMES AA, 1991, MOL BIOCHEM PARASIT, V44, P245, DOI 10.1016/0166-6851(91)90010-4; Jutel M, 2005, INT ARCH ALLERGY IMM, V137, P82, DOI 10.1159/000085108; Kondrashov FA, 2002, GENOME BIOL, V3, DOI 10.1186/gb-2002-3-2-research0008; MARINOTTI O, 1990, J INSECT PHYSIOL, V36, P545, DOI 10.1016/0022-1910(90)90021-7; Maurer-Spurej E, 2005, CELL MOL LIFE SCI, V62, P1881, DOI 10.1007/s00018-005-5149-5; Millan MJ, 1999, PROG NEUROBIOL, V57, P1, DOI 10.1016/S0301-0082(98)00048-3; Moro O, 1997, J BIOL CHEM, V272, P966, DOI 10.1074/jbc.272.2.966; Nascimento EP, 2000, ARCH INSECT BIOCHEM, V43, P9, DOI 10.1002/(SICI)1520-6327(200001)43:1&lt;9::AID-ARCH2&gt;3.0.CO;2-2; Rai KS, 1999, ADV GENET, V41, P1, DOI 10.1016/S0065-2660(08)60149-2; RIBEIRO JMC, 1987, ANNU REV ENTOMOL, V32, P463, DOI 10.1146/annurev.en.32.010187.002335; Ribeiro JMC, 2004, INSECT BIOCHEM MOLEC, V34, P543, DOI 10.1016/j.ibmb.2004.02.008; RIBEIRO JMC, 1995, BIOCHEM J, V308, P243, DOI 10.1042/bj3080243; Ribeiro JMC, 2003, ANNU REV ENTOMOL, V48, P73, DOI 10.1146/annurev.ento.48.060402.102812; RIBEIRO JMC, 1995, INFECT AGENT DIS, V4, P143; RIBEIRO JMC, 1985, J INSECT PHYSL, V9, P551; Sangamnatdej S, 2002, INSECT MOL BIOL, V11, P79, DOI 10.1046/j.0962-1075.2001.00311.x; Sankoff D, 2001, CURR OPIN GENET DEV, V11, P681, DOI 10.1016/S0959-437X(00)00253-7; SCHLUTER H, 1993, J CHROMATOGR, V639, P17, DOI 10.1016/0021-9673(93)83083-5; SMITH EN, 1976, AM J PHYSIOL, V230, P1205, DOI 10.1152/ajplegacy.1976.230.5.1205; Valenzuela JG, 2003, INSECT BIOCHEM MOLEC, V33, P717, DOI 10.1016/S0965-1748(03)00067-5; Valenzuela JG, 2002, INSECT MOL BIOL, V11, P149, DOI 10.1046/j.1365-2583.2002.00319.x; Valenzuela JG, 2002, INSECT BIOCHEM MOLEC, V32, P1101, DOI 10.1016/S0965-1748(02)00047-4; VANNUETEN JM, 1985, PHARMACOL RES COMMUN, V17, P585, DOI 10.1016/0031-6989(85)90067-0; WEATHERS WW, 1971, AM J PHYSIOL, V221, P704, DOI 10.1152/ajplegacy.1971.221.3.704; WEBSTER ME, 1970, METHOD ENZYMOL, V19, P681; Zhang Y, 1998, BIOCHEMISTRY-US, V37, P10681, DOI 10.1021/bi973050y	45	168	180	0	38	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 27	2006	281	4					1935	1942		10.1074/jbc.M510359200	http://dx.doi.org/10.1074/jbc.M510359200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	004NV	16301315	hybrid			2022-12-25	WOS:000234760400012
J	Holinstat, M; Knezevic, N; Broman, M; Samarel, AM; Malik, AB; Mehta, D				Holinstat, M; Knezevic, N; Broman, M; Samarel, AM; Malik, AB; Mehta, D			Suppression of RhoA activity by focal adhesion kinase-induced activation of p190RhoGAP - Role in regulation of endothelial permeability	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STIMULATES TYROSINE PHOSPHORYLATION; SMOOTH-MUSCLE-CELLS; BARRIER FUNCTION; GROWTH-FACTOR; ENDOGENOUS INHIBITOR; DEPENDENT MECHANISM; PROTEIN; FAK; THROMBIN; CYTOSKELETON	The interaction of endothelial cells with extracellular matrix proteins at focal adhesions sites contributes to the integrity of vascular endothelial barrier. Although focal adhesion kinase (FAK) activation is required for the recovery of the barrier function after increased endothelial junctional permeability, the basis for the recovery remains unclear. We tested the hypothesis that FAK activates p190RhoGAP and, thus, negatively regulates RhoA activity and promotes endothelial barrier restoration in response to the permeability-increasing mediator thrombin. We observed that thrombin caused a transient activation of RhoA but a more prolonged FAK activation temporally coupled to the recovery of barrier function. Thrombin also induced tyrosine phosphorylation of p190RhoGAP, which coincided with decrease in RhoA activity. We further showed that FAK was associated with p190RhoGAP, and importantly, recombinant FAK phosphorylated p190RhoGAP in vitro. Inhibition of FAK by adenoviral expression of FRNK (a dominant negative FAK construct) in monolayers prevented p190RhoGAP phosphorylation, increased RhoA activity, induced actin stress fiber formation, and produced an irreversible increase in endothelial permeability in response to thrombin. We also observed that p190RhoGAP was unable to attenuate RhoA activation in the absence of FAK activation induced by FRNK. The inhibition of RhoA by the C3 toxin (Clostridium botulinum toxin) restored endothelial barrier function in the FRNK-expressing cells. These findings in endothelial cells were recapitulated in the lung microcirculation in which FRNK expression in microvessel endothelia increased vascular permeability. Our studies demonstrate that FAK-induced down-modulation of RhoA activity via p190RhoGAP is a crucial step in signaling endothelial barrier restoration after increased endothelial permeability.	Univ Illinois, Coll Med, Dept Pharmacol, Chicago, IL 60612 USA; Univ Illinois, Coll Med, Ctr Lung & Vasc Biol, Chicago, IL 60612 USA; Loyola Univ, Med Ctr, Cardiovasc Inst, Maywood, IL 60153 USA	University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; Loyola University Chicago	Mehta, D (corresponding author), Univ Illinois, Coll Med, Dept Pharmacol, 835 S Wolcott Ave, Chicago, IL 60612 USA.	dmehta@uic.edu	Samarel, Allen/Q-9810-2019; Knezevic, Nebojsa Nick/H-9921-2019	Knezevic, Nebojsa Nick/0000-0001-8028-1495; Samarel, Allen/0000-0001-8765-9884; Malik, Asrar/0000-0002-8205-7128	NHLBI NIH HHS [R01 HL071794, T32 HL 07829, HL 71794] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL071794, T32HL007829] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Abedi H, 1997, J BIOL CHEM, V272, P15442, DOI 10.1074/jbc.272.24.15442; Adamson RH, 2002, J PHYSIOL-LONDON, V539, P295, DOI 10.1113/jphysiol.2001.013117; Amerongen GPV, 2000, CIRC RES, V87, P335, DOI 10.1161/01.RES.87.4.335; Amerongen GPV, 2004, CIRC RES, V94, P1041, DOI 10.1161/01.RES.0000125627.77235.0C; Arthur WT, 2000, CURR BIOL, V10, P719, DOI 10.1016/S0960-9822(00)00537-6; BOUTON AH, 1991, MOL CELL BIOL, V11, P945, DOI 10.1128/MCB.11.2.945; Burridge K, 1996, ANNU REV CELL DEV BI, V12, P463, DOI 10.1146/annurev.cellbio.12.1.463; Carbajal JM, 2000, AM J PHYSIOL-CELL PH, V279, pC195; Carbajal JM, 1999, AM J PHYSIOL-CELL PH, V277, pC955, DOI 10.1152/ajpcell.1999.277.5.C955; CHANG JH, 1995, J CELL BIOL, V130, P355, DOI 10.1083/jcb.130.2.355; Chen HC, 1996, J BIOL CHEM, V271, P26329, DOI 10.1074/jbc.271.42.26329; Dudek SM, 2001, J APPL PHYSIOL, V91, P1487, DOI 10.1152/jappl.2001.91.4.1487; Essler M, 1998, J BIOL CHEM, V273, P21867, DOI 10.1074/jbc.273.34.21867; Gao XP, 2000, AM J PHYSIOL-LUNG C, V279, pL1218, DOI 10.1152/ajplung.2000.279.6.L1218; Gebb S, 2004, MICROVASC RES, V68, P1, DOI 10.1016/j.mvr.2004.02.002; Harrington EO, 2005, EXP CELL RES, V308, P407, DOI 10.1016/j.yexcr.2005.05.005; Hauck CR, 2002, EMBO J, V21, P6289, DOI 10.1093/emboj/cdf631; Heidkamp MC, 2002, CIRC RES, V90, P1282, DOI 10.1161/01.RES.0000023201.41774.EA; HILDEBRAND JD, 1993, J CELL BIOL, V123, P993, DOI 10.1083/jcb.123.4.993; Holinstat M, 2003, J BIOL CHEM, V278, P28793, DOI 10.1074/jbc.M303900200; Kolosova IA, 2004, AM J PHYSIOL-LUNG C, V287, pL970, DOI 10.1152/ajplung.00398.2003; Kouklis P, 2004, CIRC RES, V94, P159, DOI 10.1161/01.RES.0000110418.38500.31; LAMPUGNANI MG, 1991, J CELL BIOL, V112, P479, DOI 10.1083/jcb.112.3.479; LUM H, 1994, AM J PHYSIOL, V267, P223; Maa MC, 1998, BIOCHEM BIOPH RES CO, V251, P344, DOI 10.1006/bbrc.1998.9464; Martin KH, 2002, CELL MOTIL CYTOSKEL, V51, P76, DOI 10.1002/cm.10018; Masiero L, 1999, J CELL SCI, V112, P3205; Mehta D, 2003, J BIOL CHEM, V278, P33492, DOI 10.1074/jbc.M302401200; Mehta D, 2002, J PHYSIOL-LONDON, V539, P779, DOI 10.1113/jphysiol.2001.013289; Mehta D, 2001, J BIOL CHEM, V276, P22614, DOI 10.1074/jbc.M101927200; Melendez J, 2002, J BIOL CHEM, V277, P45203, DOI 10.1074/jbc.M204886200; Moy AB, 1996, J CLIN INVEST, V97, P1020, DOI 10.1172/JCI118493; Parsons JT, 2003, J CELL SCI, V116, P1409, DOI 10.1242/jcs.00373; Quadri SK, 2003, J BIOL CHEM, V278, P13342, DOI 10.1074/jbc.M209922200; Ren XD, 2000, J CELL SCI, V113, P3673; Ren XD, 1999, EMBO J, V18, P578, DOI 10.1093/emboj/18.3.578; Ruest PJ, 2000, CELL GROWTH DIFFER, V11, P41; Schlaepfer DD, 2004, CURR OPIN GENET DEV, V14, P92, DOI 10.1016/j.gde.2003.12.002; SETTLEMAN J, 1992, NATURE, V359, P153, DOI 10.1038/359153a0; Shen TL, 2005, J CELL BIOL, V169, P941, DOI 10.1083/jcb.200411155; Sieg DJ, 1998, EMBO J, V17, P5933, DOI 10.1093/emboj/17.20.5933; Sundberg LJ, 2003, J BIOL CHEM, V278, P29783, DOI 10.1074/jbc.M303771200; Takai Y, 2001, PHYSIOL REV, V81, P153, DOI 10.1152/physrev.2001.81.1.153; Taylor JM, 2001, MOL CELL BIOL, V21, P1565, DOI 10.1128/MCB.21.5.1565-1572.2001; TIRUPPATHI C, 1992, P NATL ACAD SCI USA, V89, P7919, DOI 10.1073/pnas.89.17.7919; Vepa S, 1999, AM J PHYSIOL-LUNG C, V277, pL150, DOI 10.1152/ajplung.1999.277.1.L150; Wojciak-Stothard B, 2001, J CELL SCI, V114, P1343; Wu MH, 2003, J PHYSIOL-LONDON, V552, P691, DOI 10.1113/jphysiol.2003.048405; Zhou MY, 1998, J CLIN INVEST, V101, P2427, DOI 10.1172/JCI407	49	124	131	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 27	2006	281	4					2296	2305		10.1074/jbc.M511248200	http://dx.doi.org/10.1074/jbc.M511248200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	004NV	16308318	hybrid			2022-12-25	WOS:000234760400055
J	Salsi, V; Zappavigna, V				Salsi, V; Zappavigna, V			Hoxd13 and Hoxa13 directly control the expression of the EphA7 ephrin tyrosine kinase receptor in developing limbs	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA-BINDING; IN-VIVO; CELL-MIGRATION; GENES; MISEXPRESSION; DOWNSTREAM; PROTEINS; HOXD-13; IDENTIFICATION; MORPHOGENESIS	Hoxa and Hoxd genes, related to the Drosophila Abd-B gene, display regionally restricted expression patterns and are necessary for the formation of the limb skeletal elements. Hox genes encode transcription factors, which are supposed to control the expression of a series of downstream target genes, whose nature has remained largely elusive. Several genes were identified that are differentially expressed in relation to Hox gene activity; few studies, however, explored their direct regulation by Hox proteins. Ephrin tyrosine kinase receptors and ephrins have been proposed as Hox targets, and recently, evidence was gained for their role in limb development. The expression of the EphA7 gene in developing limbs was shown to correlate with the expression of Hoxa13 and Hoxd13; however, its direct regulation by these genes has never been assessed. We have characterized the EphA7 promoter region and show that it contains multiple binding sites for paralog group 13 Hox proteins. We found that one of these sites is bound in vivo by HOXA13 and HOXD13 and by endogenous Hoxd13 in developing mouse limbs. Moreover, we show that HOXD13 and HOXA13 activate transcription from the EphA7 promoter and that a mutation of the HOXA13/HOXD13 binding site was sufficient to abolish activation. Conversely, the HOXD13(147L) mutation, identified in patients displaying a novel brachydactyly-polydactyly syndrome, does not bind to in vivo, and fails to transactivate the EphA7 promoter. These results establish that EphA7 is a direct downstream target of Hoxd13 and Hoxa13 during limb development, thus providing further insight into the regulatory networks that control limb patterning.	Univ Modena & Reggio Emilia, Dept Anim Biol, I-41100 Modena, Italy; Cornell Univ, Weill Med Sch, Dept Cell & Dev Biol, New York, NY 10021 USA	Universita di Modena e Reggio Emilia; Cornell University	Zappavigna, V (corresponding author), Univ Modena & Reggio Emilia, Dept Anim Biol, Via G Campi 213-D, I-41100 Modena, Italy.	zappavigna.vincenzo@unimore.it	Zappavigna, Vincenzo/D-3899-2015	Zappavigna, Vincenzo/0000-0002-7384-3207; SALSI, Valentina/0000-0002-7133-0360				BENSON GV, 1995, MOL CELL BIOL, V15, P1591; Biggin MD, 1997, DEVELOPMENT, V124, P4425; Bruhl T, 2004, CIRC RES, V94, P743, DOI 10.1161/01.RES.0000120861.27064.09; Caronia G, 2003, DEVELOPMENT, V130, P1701, DOI 10.1242/dev.00396; Carr A, 1999, EMBO J, V18, P1598, DOI 10.1093/emboj/18.6.1598; Cartharius K, 2005, BIOINFORMATICS, V21, P2933, DOI 10.1093/bioinformatics/bti473; Chen J, 1998, J BIOL CHEM, V273, P24670, DOI 10.1074/jbc.273.38.24670; Cobb J, 2005, DEVELOPMENT, V132, P3055, DOI 10.1242/dev.01885; Compagni A, 2003, DEV CELL, V5, P217, DOI 10.1016/S1534-5807(03)00198-9; DINOCERA PP, 1983, P NATL ACAD SCI-BIOL, V80, P7095; DOLLE P, 1991, MECH DEVELOP, V36, P3, DOI 10.1016/0925-4773(91)90067-G; DOLLE P, 1993, CELL, V75, P431, DOI 10.1016/0092-8674(93)90378-4; DUBOULE D, 1994, TRENDS GENET, V10, P358, DOI 10.1016/0168-9525(94)90132-5; Elkon R, 2003, GENOME RES, V13, P773, DOI 10.1101/gr.947203; Favier B, 1997, MOL HUM REPROD, V3, P115, DOI 10.1093/molehr/3.2.115; Frisen J, 1999, EMBO J, V18, P5159, DOI 10.1093/emboj/18.19.5159; FromentalRamain C, 1996, DEVELOPMENT, V122, P2997; Goff DJ, 1997, DEVELOPMENT, V124, P627; Graba Y, 1997, BIOESSAYS, V19, P379, DOI 10.1002/bies.950190505; Kent WJ, 2002, GENOME RES, V12, P996, DOI 10.1101/gr.229102; Kinsella TM, 1996, HUM GENE THER, V7, P1405, DOI 10.1089/hum.1996.7.12-1405; Knosp WM, 2004, DEVELOPMENT, V131, P4581, DOI 10.1242/dev.01327; Kodadek T, 1998, TRENDS BIOCHEM SCI, V23, P79, DOI 10.1016/S0968-0004(97)01165-1; KRUMLAUF R, 1994, CELL, V78, P191, DOI 10.1016/0092-8674(94)90290-9; Lei HY, 2005, P NATL ACAD SCI USA, V102, P2420, DOI 10.1073/pnas.0409700102; MORGAN BA, 1992, NATURE, V358, P236, DOI 10.1038/358236a0; Morgan EA, 2003, DEVELOPMENT, V130, P3095, DOI 10.1242/dev.00530; Nelson CE, 1996, DEVELOPMENT, V122, P1449; Orlando V, 2000, TRENDS BIOCHEM SCI, V25, P99, DOI 10.1016/S0968-0004(99)01535-2; Orlando V, 1997, METHODS, V11, P205, DOI 10.1006/meth.1996.0407; Palmer A, 2003, GENE DEV, V17, P1429, DOI 10.1101/gad.1093703; Poliakov A, 2004, DEV CELL, V7, P465, DOI 10.1016/j.devcel.2004.09.006; Quandt K, 1995, NUCLEIC ACIDS RES, V23, P4878, DOI 10.1093/nar/23.23.4878; Rijli FM, 1997, CURR OPIN GENET DEV, V7, P481, DOI 10.1016/S0959-437X(97)80074-3; Shen WF, 1997, J BIOL CHEM, V272, P8198, DOI 10.1074/jbc.272.13.8198; Stadler HS, 2001, DEVELOPMENT, V128, P4177; Stormo GD, 2000, BIOINFORMATICS, V16, P16, DOI 10.1093/bioinformatics/16.1.16; TOTH J, 2000, NUCL ACIDS RES 2000, pE4; Valerius AT, 2002, MECH DEVELOP, V112, P217; Wada N, 2003, DEV BIOL, V264, P550, DOI 10.1016/j.ydbio.2003.08.019; WALTER J, 1994, GENE DEV, V8, P1678, DOI 10.1101/gad.8.14.1678; Williams TM, 2005, DEV BIOL, V279, P462, DOI 10.1016/j.ydbio.2004.12.015; YOKOUCHI Y, 1995, GENE DEV, V9, P2509, DOI 10.1101/gad.9.20.2509; Zakany J, 1999, CELL TISSUE RES, V296, P19, DOI 10.1007/s004410051262; ZAPPAVIGNA V, 1994, GENE DEV, V8, P732, DOI 10.1101/gad.8.6.732	45	50	54	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 27	2006	281	4					1992	1999		10.1074/jbc.M510900200	http://dx.doi.org/10.1074/jbc.M510900200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	004NV	16314414	hybrid			2022-12-25	WOS:000234760400019
J	Urano, Y; Iiduka, M; Sugiyama, A; Akiyama, H; Uzawa, K; Matsumoto, G; Kawasaki, Y; Tashiro, F				Urano, Y; Iiduka, M; Sugiyama, A; Akiyama, H; Uzawa, K; Matsumoto, G; Kawasaki, Y; Tashiro, F			Involvement of the mouse Prp19 gene in neuronal/astroglial cell fate decisions	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EMBRYONAL CARCINOMA-CELLS; LEUKEMIA INHIBITORY FACTOR; MAMMALIAN ACHAETE-SCUTE; CENTRAL-NERVOUS-SYSTEM; LOOP-HELIX GENES; PROMOTES NEURONAL DIFFERENTIATION; RETINOIC ACID; GLIAL-CELLS; STEM-CELLS; P19 CELLS	The molecular mechanisms involved in neuronal/astroglial cell fate decisions during the development of the mammalian central nervous system are poorly understood. Here, we report that PRP19 beta, a splice variant of mouse PRP19 alpha corresponding to the yeast PRP19 protein, can function as a neuron-astroglial switch during the retinoic acid-primed neural differentiation of P19 cells. The beta-variant possesses an additional 19 amino acid residues in-frame in the N-terminal region of the alpha-variant. The forced expression of the alpha-variant RNA caused the down-regulation of oct-3/4 and nanog mRNA expression during the 12 - 48 h of the late-early stages of neural differentiation and was sufficient to convert P19 cells into neurons ( but not glial cells) when the cells were cultured in aggregated form without retinoic acid. In contrast, the forced expression of the alpha-variant RNA suppressed neuronal differentiation and conversely stimulated astroglial cell differentiation in retinoic acid-primed P19 cells. Based on yeast two-hybrid screening, cyclophilin A was identified as a specific binding partner of the beta-variant. Luciferase reporter assay mediated by the oct-3/4 promoter revealed that cyclophilin A could act as a transcriptional activator and that its activity was suppressed by the beta-variant, suggesting that cyclophilin A takes part in the induction of oct-3/4 gene expression, which might lead to neuroectodermal otx2 expression within 12 h of the immediate-early stages of retinoic acid-primed neural differentiation. These results show that the alpha-variant gene plays a pivotal role in neural differentiation and that the beta-variant participates in neuronal/astroglial cell fate decisions.	Tokyo Univ Sci, Fac Ind Sci & Technol, Dept Biol Sci & Technol, Noda, Chiba 2708510, Japan	Tokyo University of Science	Tashiro, F (corresponding author), Tokyo Univ Sci, Fac Ind Sci & Technol, Dept Biol Sci & Technol, Noda, Chiba 2708510, Japan.	ftashir@rs.noda.tus.ac.jp	TASHIRO, Yumiko/AAV-2054-2020	Tashiro, Yumiko/0000-0002-8328-2634				Ajuh P, 2000, EMBO J, V19, P6569, DOI 10.1093/emboj/19.23.6569; Akiyama H, 2003, DEV BRAIN RES, V140, P45, DOI 10.1016/S0165-3806(02)00574-6; Akiyama H, 2003, J BIOL CHEM, V278, P10752, DOI 10.1074/jbc.M209856200; Akiyama Y, 1996, P NATL ACAD SCI USA, V93, P14912, DOI 10.1073/pnas.93.25.14912; Altshuller Y, 1996, FEBS LETT, V393, P201, DOI 10.1016/0014-5793(96)00890-3; Anson-Cartwright L, 2000, NAT GENET, V25, P311, DOI 10.1038/77076; BAIN G, 1994, BIOESSAYS, V16, P343, DOI 10.1002/bies.950160509; Basyuk E, 1999, DEV DYNAM, V214, P303, DOI 10.1002/(SICI)1097-0177(199904)214:4<303::AID-AJA3>3.3.CO;2-2; BENEZRA R, 1990, CELL, V61, P49, DOI 10.1016/0092-8674(90)90214-Y; BENSHUSHAN E, 1995, MOL CELL BIOL, V15, P1034; Bonni A, 1997, SCIENCE, V278, P477, DOI 10.1126/science.278.5337.477; Boudjelal M, 1997, GENE DEV, V11, P2052, DOI 10.1101/gad.11.16.2052; Bugga L, 1998, J NEUROBIOL, V36, P509, DOI 10.1002/(SICI)1097-4695(19980915)36:4<509::AID-NEU5>3.0.CO;2-#; Cai L, 2000, DEVELOPMENT, V127, P3021; Chambers I, 2003, CELL, V113, P643, DOI 10.1016/S0092-8674(03)00392-1; CHENG SC, 1993, MOL CELL BIOL, V13, P1876, DOI 10.1128/MCB.13.3.1876; DELAMO FF, 1993, BIOCHIM BIOPHYS ACTA, V1171, P323, DOI 10.1016/0167-4781(93)90076-P; Duncan MK, 1997, DEV DYNAM, V208, P107, DOI 10.1002/(SICI)1097-0177(199701)208:1<107::AID-AJA10>3.0.CO;2-3; FORT P, 1985, NUCLEIC ACIDS RES, V13, P1431, DOI 10.1093/nar/13.5.1431; Ge WH, 2002, J NEUROSCI RES, V69, P848, DOI 10.1002/jnr.10364; Goldner FM, 1996, J COMP NEUROL, V372, P283; Gunther T, 2000, NATURE, V406, P199, DOI 10.1038/35018111; Hardy RJ, 1998, J NEUROSCI RES, V54, P46, DOI 10.1002/(SICI)1097-4547(19981001)54:1<46::AID-JNR6>3.0.CO;2-H; HASEL KW, 1990, NUCLEIC ACIDS RES, V18, P4019, DOI 10.1093/nar/18.13.4019; He F, 2005, NAT NEUROSCI, V8, P616, DOI 10.1038/nn1440; Hirabayashi Y, 2004, DEVELOPMENT, V131, P2791, DOI 10.1242/dev.01165; HOSOYA T, 1995, CELL, V82, P1025, DOI 10.1016/0092-8674(95)90281-3; Iwasaki Y, 2003, DEVELOPMENT, V130, P6027, DOI 10.1242/dev.00822; JOH T, 1992, CELL GROWTH DIFFER, V3, P315; Johe KK, 1996, GENE DEV, V10, P3129, DOI 10.1101/gad.10.24.3129; JOHNSON JE, 1992, DEVELOPMENT, V114, P75; JONESVILLENEUVE EMV, 1982, J CELL BIOL, V94, P253, DOI 10.1083/jcb.94.2.253; Kamakura S, 2004, NAT CELL BIOL, V6, P547, DOI 10.1038/ncb1138; Kammerer M, 1999, CYTOGENET CELL GENET, V84, P43, DOI 10.1159/000015210; Kanemura Y, 1999, FEBS LETT, V442, P151, DOI 10.1016/S0014-5793(98)01650-0; Kim J, 2003, NEURON, V38, P17, DOI 10.1016/S0896-6273(03)00163-6; Kim JS, 1998, P NATL ACAD SCI USA, V95, P12364, DOI 10.1073/pnas.95.21.12364; Koblar SA, 1998, P NATL ACAD SCI USA, V95, P3178, DOI 10.1073/pnas.95.6.3178; Lee JE, 1997, CURR OPIN NEUROBIOL, V7, P13, DOI 10.1016/S0959-4388(97)80115-8; Makarov EM, 2002, SCIENCE, V298, P2205, DOI 10.1126/science.1077783; Massari ME, 2000, MOL CELL BIOL, V20, P429, DOI 10.1128/MCB.20.2.429-440.2000; McCormick MB, 1996, MOL CELL BIOL, V16, P5792; Mitsui K, 2003, CELL, V113, P631, DOI 10.1016/S0092-8674(03)00393-3; Mukobata Shigeki, 2000, Research Communications in Biochemistry and Cell and Molecular Biology, V4, P221; Nakashima K, 1999, J NEUROSCI, V19, P5429; Nakashima K, 1999, SCIENCE, V284, P479, DOI 10.1126/science.284.5413.479; Nieto M, 2001, NEURON, V29, P401, DOI 10.1016/S0896-6273(01)00214-8; Niwa H, 2000, NAT GENET, V24, P372, DOI 10.1038/74199; OKAMOTO K, 1990, CELL, V60, P461, DOI 10.1016/0092-8674(90)90597-8; PIKARSKY E, 1994, MOL CELL BIOL, V14, P1026, DOI 10.1128/MCB.14.2.1026; SCHMIDT JW, 1992, J CELL BIOL, V116, P1019, DOI 10.1083/jcb.116.4.1019; Schreiber J, 2000, MOL CELL BIOL, V20, P2466, DOI 10.1128/MCB.20.7.2466-2474.2000; SHIMAZAKI T, 1993, EMBO J, V12, P4489, DOI 10.1002/j.1460-2075.1993.tb06138.x; Shimozaki K, 2003, DEVELOPMENT, V130, P2505, DOI 10.1242/dev.00476; SIMEONE A, 1992, NATURE, V358, P687, DOI 10.1038/358687a0; Song J, 2004, J BIOL CHEM, V279, P24414, DOI 10.1074/jbc.M311406200; Song MR, 2004, NAT NEUROSCI, V7, P229, DOI 10.1038/nn1192; Stolt CC, 2003, GENE DEV, V17, P1677, DOI 10.1101/gad.259003; Strausberg RL, 2002, P NATL ACAD SCI USA, V99, P16899, DOI 10.1073/pnas.242603899; Sugiyama A, 2003, CARCINOGENESIS, V24, P1549, DOI 10.1093/carcin/bgg113; Sun Y, 2001, CELL, V104, P365, DOI 10.1016/S0092-8674(01)00224-0; Takahashi J, 1999, J NEUROBIOL, V38, P65, DOI 10.1002/(SICI)1097-4695(199901)38:1<65::AID-NEU5>3.3.CO;2-H; Tang K, 2002, BIOCHEM BIOPH RES CO, V293, P167, DOI 10.1016/S0006-291X(02)00215-2; Teramoto S, 2005, ONCOL REP, V14, P1231; Tomita K, 2000, EMBO J, V19, P5460, DOI 10.1093/emboj/19.20.5460; Vincent S, 1996, DEVELOPMENT, V122, P131; Viti J, 2003, J NEUROSCI, V23, P3385; WILLIAMS RK, 1985, J CELL BIOL, V101, P36, DOI 10.1083/jcb.101.1.36; ZELENT A, 1991, EMBO J, V10, P71, DOI 10.1002/j.1460-2075.1991.tb07922.x	69	28	32	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 17	2006	281	11					7498	7514		10.1074/jbc.M510881200	http://dx.doi.org/10.1074/jbc.M510881200			17	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	022BY	16352598	hybrid			2022-12-25	WOS:000236030900072
J	Delettre, C; Yuste, VJ; Moubarak, RS; Bras, M; Lesbordes-Brion, JC; Petres, S; Bellalou, J; Susin, SA				Delettre, C; Yuste, VJ; Moubarak, RS; Bras, M; Lesbordes-Brion, JC; Petres, S; Bellalou, J; Susin, SA			AIFsh, a novel apoptosis-inducing factor (AIF) pro-apoptotic isoform with potential pathological relevance in human cancer	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROGRAMMED CELL-DEATH; DNA-DEGRADATION; RELEASE; ACTIVATION; INDUCTION; CLEAVAGE; FRAGMENTATION; TRANSLOCATION; MITOCHONDRIA; DEFICIENCY	AIF is a main mediator of caspase-independent cell death. It is encoded by a single gene located on chromosome X, region q25 - 26 and A6 in humans and mice, respectively. Previous studies established that AIF codes for two isoforms of the protein, AIF and AIF-exB. Here, we identify a third AIF isoform resulting from an alternate transcriptional start site located at intron 9 of AIF. The resulting mRNA encodes a cytosolic protein that corresponds to the C-terminal domain of AIF ( amino acids 353 - 613). We named this new isoform AIFshort (AIFsh). AIFsh overexpression in HeLa cells results in nuclear translocation and caspase-independent cell death. Once in the nucleus, AIFsh provokes the same effects than AIF, namely chromatin condensation and large scale ( 50 kb) DNA fragmentation. In contrast, these apoptogenic effects are not precluded by the AIF-inhibiting protein Hsp70. These findings identify AIFsh as a new pro-apoptotic isoform of AIF, and also reveal that the first N-terminal 352 amino acids of AIF are not required for its apoptotic activity. In addition, we demonstrate that AIFsh is strongly down-regulated in tumor cells derived from kidney, vulva, skin, thyroid, and pancreas, whereas, gamma-irradiation treatment provokes AIFsh up-regulation. Overall, our results identify a novel member of the AIF-dependent pathway and shed new light on the role of caspase-independent cell death in tumor formation/suppression.	Inst Pasteur, CNRS, URA 1961, F-75015 Paris, France	Centre National de la Recherche Scientifique (CNRS); Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris	Susin, SA (corresponding author), Inst Pasteur, CNRS, URA 1961, 25 Rue Dr Roux, F-75015 Paris, France.	susin@pasteur.fr	Yuste, Victor J./C-7071-2008; Susin, Santos A/Q-6754-2017; Delettre, Cécile/AAC-3096-2020	Yuste, Victor J./0000-0001-5322-9261; Susin, Santos A/0000-0002-3366-1628; Delettre, Cécile/0000-0003-3269-2155; petres, stephane/0000-0002-4716-565X; Moubarak, Rana/0000-0003-2096-1258				Blagosklonny MV, 2004, ONCOGENE, V23, P2967, DOI 10.1038/sj.onc.1207520; BROWN DG, 1993, J BIOL CHEM, V268, P3037; Brown JM, 2005, NAT REV CANCER, V5, P231, DOI 10.1038/nrc1560; Cande C, 2004, ONCOGENE, V23, P1514, DOI 10.1038/sj.onc.1207279; Corbiere C, 2004, CELL RES, V14, P188, DOI 10.1038/sj.cr.7290219; Cregan SP, 2002, J CELL BIOL, V158, P507, DOI 10.1083/jcb.200202130; Furre IE, 2005, CANCER RES, V65, P11051, DOI 10.1158/0008-5472.CAN-05-0510; Gallego MA, 2004, ONCOGENE, V23, P6282, DOI 10.1038/sj.onc.1207835; Ghosh A, 2004, MOL CELL BIOL, V24, P7987, DOI 10.1128/MCB.24.18.7987-7997.2004; Glinsky GV, 2004, J CLIN INVEST, V113, P913, DOI 10.1172/JCI200420032; Glinsky GV, 1997, CANCER LETT, V115, P185, DOI 10.1016/S0304-3835(97)04738-1; Good PI, 2004, STAT MED, V23, P857, DOI 10.1002/sim.1738; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Hengartner MO, 2000, NATURE, V407, P770, DOI 10.1038/35037710; Hu W, 2003, LANCET ONCOL, V4, P721, DOI 10.1016/S1470-2045(03)01277-4; Jaattela M, 2004, ONCOGENE, V23, P2746, DOI 10.1038/sj.onc.1207513; Jaattela M, 2002, ANN MED, V34, P480, DOI 10.1080/078538902321012423; Jiang ZH, 1999, P SOC EXP BIOL MED, V220, P64, DOI 10.1046/j.1525-1373.1999.d01-11.x; Jolly C, 2000, JNCI-J NATL CANCER I, V92, P1564, DOI 10.1093/jnci/92.19.1564; Joza N, 2001, NATURE, V410, P549, DOI 10.1038/35069004; Kang YH, 2004, CANCER RES, V64, P8960, DOI 10.1158/0008-5472.CAN-04-1830; Klein JA, 2002, NATURE, V419, P367, DOI 10.1038/nature01034; KOZAK M, 1991, J CELL BIOL, V115, P887, DOI 10.1083/jcb.115.4.887; Landry JR, 2001, GENOMICS, V76, P110, DOI 10.1006/geno.2001.6604; Li WL, 2005, CANCER RES, V65, P2592, DOI 10.1158/0008-5472.CAN-04-1532; Liu T, 2004, ONCOGENE, V23, P39, DOI 10.1038/sj.onc.1206978; Loeffler M, 2001, FASEB J, V15, P758, DOI 10.1096/fj.00-0388com; Lorenzo HK, 2004, FEBS LETT, V557, P14, DOI 10.1016/S0014-5793(03)01464-9; Mate MJ, 2002, NAT STRUCT BIOL, V9, P442, DOI 10.1038/nsb793; Miramar MD, 2001, J BIOL CHEM, V276, P16391, DOI 10.1074/jbc.M010498200; Nomura M, 2004, J CELL PHYSIOL, V201, P374, DOI 10.1002/jcp.20090; Otera H, 2005, EMBO J, V24, P1375, DOI 10.1038/sj.emboj.7600614; Park YC, 2005, LIFE SCI, V77, P2059, DOI 10.1016/j.lfs.2005.04.021; Polster BM, 2005, J BIOL CHEM, V280, P6447, DOI 10.1074/jbc.M413269200; Ravagnan L, 2001, NAT CELL BIOL, V3, P839, DOI 10.1038/ncb0901-839; Sakahira H, 1998, NATURE, V391, P96, DOI 10.1038/34214; Schmitt E, 2003, CANCER RES, V63, P8233; Schultz DR, 2003, SEMIN ARTHRITIS RHEU, V32, P345, DOI 10.1053/sarh.2003.50005; Schwerk C, 2005, MOL CELL, V19, P1, DOI 10.1016/j.molcel.2005.05.026; Susin SA, 2000, J EXP MED, V192, P571, DOI 10.1084/jem.192.4.571; Susin SA, 1999, NATURE, V397, P441, DOI 10.1038/17135; Susin SA, 1996, J EXP MED, V184, P1331, DOI 10.1084/jem.184.4.1331; THOMPSON CB, 1995, SCIENCE, V267, P1456, DOI 10.1126/science.7878464; Urbano A, 2005, EMBO J, V24, P2815, DOI 10.1038/sj.emboj.7600746; Vahsen N, 2004, EMBO J, V23, P4679, DOI 10.1038/sj.emboj.7600461; Wang HM, 2004, J NEUROSCI, V24, P10963, DOI 10.1523/JNEUROSCI.3461-04.2004; Wang XC, 2002, SCIENCE, V298, P1587, DOI 10.1126/science.1076194; Ye H, 2002, NAT STRUCT BIOL, V9, P680, DOI 10.1038/nsb836; Yu SW, 2002, SCIENCE, V297, P259, DOI 10.1126/science.1072221; Yuste VJ, 2005, J BIOL CHEM, V280, P35670, DOI 10.1074/jbc.M504015200; Yuste VJ, 2005, CELL DEATH DIFFER, V12, P1445, DOI 10.1038/sj.cdd.4401687	51	68	74	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 10	2006	281	10					6413	6427		10.1074/jbc.M509884200	http://dx.doi.org/10.1074/jbc.M509884200			15	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	022BX	16365034	Green Submitted, hybrid			2022-12-25	WOS:000236030800035
J	Wang, B; Sun, JS; Kitamoto, S; Yang, M; Grubb, A; Chapman, HA; Kalluri, R; Shi, GP				Wang, B; Sun, JS; Kitamoto, S; Yang, M; Grubb, A; Chapman, HA; Kalluri, R; Shi, GP			Cathepsin S controls angiogenesis and tumor growth via matrix-derived angiogenic factors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LAMININ-5 GAMMA-2 CHAIN; ENDOTHELIAL-CELL PROLIFERATION; FACTOR-BETA; CYSTATIN-C; GENETIC-HETEROGENEITY; CYSTEINE PROTEASES; CANCER-CELLS; INTEGRIN; COLLAGEN; PROTEOLYSIS	The cysteine protease cathepsin S is highly expressed in malignant tissues. By using a mouse model of multistage murine pancreatic islet cell carcinogenesis in which cysteine cathepsin activity has been functionally implicated, we demonstrated that selective cathepsin S deficiency impaired angiogenesis and tumor cell proliferation, thereby impairing angiogenic islet formation and the growth of solid tumors, whereas the absence of its endogenous inhibitor cystatin C resulted in opposite phenotypes. Although mitogenic vascular endothelial growth factor, transforming growth factor-beta 1, and the anti-angiogenic endostatin levels in either serum or carcinoma tissue extracts did not change in cathepsin S- or cystatin C-null mice, tumor tissue basic fibroblast growth factor and serum type 1 insulin growth factor levels were higher in cystatin C-null mice, and serum type 1 insulin growth factor levels were also increased in cathepsin S-null mice. Furthermore, cathepsin S affected the production of type IV collagen-derived anti-angiogenic peptides and the generation of bioactive pro-angiogenic gamma 2 fragments from laminin-5, revealing a functional role for cathepsin S in angiogenesis and neoplastic progression.	Brigham & Womens Hosp, Dept Med, Boston, MA 02115 USA; Harvard Univ, Sch Med, Boston, MA 02115 USA; So Med Univ, Dept Nephrol, Nanfang Hosp, Guangzhou 510515, Peoples R China; Univ Lund Hosp, Dept Clin Chem, S-22185 Lund, Sweden; Univ Calif San Francisco, Dept Med, San Francisco, CA 94143 USA; Beth Israel Deaconess Med Ctr, Ctr Matrix Biol, Boston, MA 02115 USA	Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School; Southern Medical University - China; Lund University; Skane University Hospital; University of California System; University of California San Francisco; Harvard University; Beth Israel Deaconess Medical Center	Shi, GP (corresponding author), NRB-7,77 Ave Louis Pasteur, Boston, MA 02115 USA.	gshi@rics.bwh.harvard.edu	Kalluri, Raghu/E-2677-2015	Kalluri, Raghu/0000-0002-2190-547X; Grubb, Anders/0000-0002-0125-3662	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL067283, R01HL060942] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK062987] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL 48621, HL 60942, HL 67283] Funding Source: Medline; NIDDK NIH HHS [DK 62987] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Amano S, 2000, J BIOL CHEM, V275, P22728, DOI 10.1074/jbc.M002345200; Bergers G, 2000, NAT CELL BIOL, V2, P737, DOI 10.1038/35036374; Buczek-Thomas JA, 2004, AM J RESP CELL MOL, V31, P344, DOI 10.1165/rcmb.2003-0420OC; Colorado PC, 2000, CANCER RES, V60, P2520; Fang KC, 1996, J CLIN INVEST, V97, P1589, DOI 10.1172/JCI118583; Felbor U, 2000, EMBO J, V19, P1187, DOI 10.1093/emboj/19.6.1187; Ferreras M, 2000, FEBS LETT, V486, P247, DOI 10.1016/S0014-5793(00)02249-3; FOLKMAN J, 1971, NEW ENGL J MED, V285, P1182; FOLKMAN J, 1995, NAT MED, V1, P27, DOI 10.1038/nm0195-27; Fowlkes JL, 2002, CYTOKINE GROWTH F R, V13, P277, DOI 10.1016/S1359-6101(02)00005-9; Giannelli G, 1997, SCIENCE, V277, P225, DOI 10.1126/science.277.5323.225; Gondi CS, 2004, ONCOGENE, V23, P8486, DOI 10.1038/sj.onc.1207879; Gonzales M, 1999, MOL BIOL CELL, V10, P259, DOI 10.1091/mbc.10.2.259; Guo M, 2002, J BIOL CHEM, V277, P14829, DOI 10.1074/jbc.M108180200; Hall A, 1998, BIOCHEMISTRY-US, V37, P4071, DOI 10.1021/bi971197j; Hamano Y, 2003, CANCER CELL, V3, P589, DOI 10.1016/S1535-6108(03)00133-8; He GA, 2003, BIOCHEM BIOPH RES CO, V312, P801, DOI 10.1016/j.bbrc.2003.11.003; Hershberg RM, 1997, J CLIN INVEST, V100, P204, DOI 10.1172/JCI119514; Jedeszko C, 2004, BIOL CHEM, V385, P1017, DOI 10.1515/BC.2004.132; Joyce JA, 2004, CANCER CELL, V5, P443, DOI 10.1016/S1535-6108(04)00111-4; Kamphaus GD, 2000, J BIOL CHEM, V275, P1209, DOI 10.1074/jbc.275.2.1209; Kato T, 2001, FEBS LETT, V508, P187, DOI 10.1016/S0014-5793(01)02897-6; KOBAYASHI H, 1991, J BIOL CHEM, V266, P5147; Koshikawa N, 2003, FASEB J, V17, P364, DOI 10.1096/fj.03-0584fje; Lakka SS, 2004, ONCOGENE, V23, P4681, DOI 10.1038/sj.onc.1207616; Lee CY, 1996, ENDOCRINOLOGY, V137, P2051, DOI 10.1210/en.137.5.2051; Lin HC, 2001, INVEST OPHTH VIS SCI, V42, P2517; LIU J, 2006, IN PRESS ATHEROSCLER; Lohi J, 2001, INT J CANCER, V94, P763, DOI 10.1002/ijc.1539; Maeshima Y, 2001, J BIOL CHEM, V276, P31959, DOI 10.1074/jbc.M103024200; Maeshima Y, 2001, J BIOL CHEM, V276, P15240, DOI 10.1074/jbc.M007764200; MARINKOVICH MP, 1992, J BIOL CHEM, V267, P17900; Martin KJ, 1998, MOL MED, V4, P602, DOI 10.1007/BF03401760; Martineau I, 2004, BIOMATERIALS, V25, P4489, DOI 10.1016/j.biomaterials.2003.11.013; Meara JP, 1996, J MED CHEM, V39, P3357, DOI 10.1021/jm950445b; Mook ORF, 2004, BBA-REV CANCER, V1705, P69, DOI 10.1016/j.bbcan.2004.09.006; Pasco S, 2004, EXP CELL RES, V301, P251, DOI 10.1016/j.yexcr.2004.07.036; Pepper MS, 2001, THROMB HAEMOSTASIS, V86, P346; Rohan RM, 2000, FASEB J, V14, P871, DOI 10.1096/fasebj.14.7.871; Sasaki T, 2001, J MOL BIOL, V314, P751, DOI 10.1006/jmbi.2001.5176; Seftor REB, 2001, CANCER RES, V61, P6322; Shaked Y, 2005, CANCER CELL, V7, P101, DOI 10.1016/j.ccr.2004.11.023; Shi GP, 2000, J EXP MED, V191, P1177, DOI 10.1084/jem.191.7.1177; Shi GP, 2003, CIRC RES, V92, P493, DOI 10.1161/01.RES.0000060485.20318.96; Siler U, 2002, BRIT J HAEMATOL, V119, P212, DOI 10.1046/j.1365-2141.2002.03800.x; SLOANE BF, 1981, SCIENCE, V212, P1151, DOI 10.1126/science.7233209; Sokol JP, 2005, BREAST CANCER RES, V7, pR844, DOI 10.1186/bcr1312; Sokol JP, 2004, MOL CANCER RES, V2, P183; Somanna A, 2002, J BIOL CHEM, V277, P25305, DOI 10.1074/jbc.M203034200; Sukhova GK, 2005, CIRC RES, V96, P368, DOI 10.1161/01.RES.0000155964.34150.F7; Vigneswaran N, 2005, INT J ONCOL, V26, P103; WEITZMAN JB, 1993, J BIOL CHEM, V268, P8651; Wen W, 1999, CANCER RES, V59, P6052; Wild R, 2000, MICROVASC RES, V59, P368, DOI 10.1006/mvre.1999.2233; Yanamandra N, 2004, ONCOGENE, V23, P2224, DOI 10.1038/sj.onc.1207338; Zent R, 2001, DEV BIOL, V238, P289, DOI 10.1006/dbio.2001.0391	56	209	233	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 3	2006	281	9					6020	6029		10.1074/jbc.M509134200	http://dx.doi.org/10.1074/jbc.M509134200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	015RQ	16365041	Green Published, hybrid			2022-12-25	WOS:000235568900083
J	Huo, JS; McEachin, RC; Cui, TX; Duggal, NK; Hai, T; States, DJ; Schwartz, J				Huo, JS; McEachin, RC; Cui, TX; Duggal, NK; Hai, T; States, DJ; Schwartz, J			Profiles of growth hormone (GH)-regulated genes reveal time-dependent responses and identify a mechanism for regulation of activating transcription factor 3 by GH	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BINDING-PROTEIN-BETA; INSULIN-RECEPTOR SUBSTRATE-1; TERNARY COMPLEX FACTORS; RAT ADIPOSE-TISSUE; C-FOS; FACTOR-I; PHOSPHOINOSITIDE 3-KINASE; SIGNAL-TRANSDUCTION; P85-ALPHA SUBUNIT; MESSENGER-RNA	In examination of mechanisms regulating metabolic responses to growth hormone (GH), microarray analysis identified 561 probe sets showing time-dependent patterns of expression in GH-treated 3T3-F442A adipocytes. Biological functions significantly over-represented among GH-regulated genes include regulators of transcription at early times, and lipid biosynthesis, cholesterol biosynthesis, and mediators of immune responses at later times ( 48 h). One novel GH-induced gene encodes activating transcription factor 3 (ATF3). Atf3 mRNA expression and promoter activity were stimulated by GH. Genes for ATF3 and growth arrest and DNA damage-inducible gene 45 gamma (GADD45 gamma) showed similar time-dependent patterns of responses to GH, suggesting similar regulatory mechanisms. A conserved sequence in the promoters of the Atf3 and Gadd45 gamma genes contains a CCAAT/enhancer-binding protein (C/EBP) site previously observed in the Gadd45 gamma promoter, suggesting a novel corresponding C/EBP site in the Atf3 promoter. C/EBP beta was found to bind to the predicted Atf3 C/EBP site, and C/EBP beta enhanced the activation of the wild-type Atf3 promoter. Mutation of the predicted Atf3 C/EBP site disrupted Atf3 promoter activation not only by C/EBP beta but also by GH. These findings suggest that GH regulates transcription of Atf3 through a mechanism utilizing factors, such as C/EBP beta, which bind to a novel C/EBP site.	Univ Michigan, Dept Mol & Integrat Physiol, Ann Arbor, MI 48109 USA; Univ Michigan, Dept Human Genet, Ann Arbor, MI 48109 USA; Univ Michigan, Bioinformat Program, Ann Arbor, MI 48109 USA; Univ Michigan, Program Mol & Cellular Biol, Ann Arbor, MI 48109 USA; Ohio State Univ, Dept Mol & Cellular Biochem, Columbus, OH 43210 USA	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University System of Ohio; Ohio State University	Schwartz, J (corresponding author), Univ Michigan, Dept Mol & Integrat Physiol, 6815 Med Sci 2,1301 Catherine St, Ann Arbor, MI 48109 USA.	jeschwar@umich.edu	Hai, Tsonwin/E-3185-2011; Hai, Tsonwin/H-4480-2011	Hai, Tsonwin/0000-0003-4510-0315; Hai, Tsonwin/0000-0003-4510-0315; Huo, Jeffrey/0000-0002-0057-9118	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK046072, R01DK059605] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007315] Funding Source: NIH RePORTER; NATIONAL LIBRARY OF MEDICINE [R01LM008106] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK58771, DK59605, DK46072] Funding Source: Medline; NIGMS NIH HHS [T32-GM07315] Funding Source: Medline; NLM NIH HHS [LM008106] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL LIBRARY OF MEDICINE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Library of Medicine (NLM)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NLM NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Library of Medicine (NLM))		Adams TE, 1998, J BIOL CHEM, V273, P1285, DOI 10.1074/jbc.273.3.1285; Allen-Jennings AE, 2002, J BIOL CHEM, V277, P20020, DOI 10.1074/jbc.M200727200; Allen-Jennings AE, 2001, J BIOL CHEM, V276, P29507, DOI 10.1074/jbc.M100986200; Ashburner M, 2000, NAT GENET, V25, P25, DOI 10.1038/75556; Assa-Kunik E, 2003, J IMMUNOL, V171, P2945, DOI 10.4049/jimmunol.171.6.2945; Barbour LA, 2004, ENDOCRINOLOGY, V145, P1144, DOI 10.1210/en.2003-1297; BICHELL DP, 1992, MOL ENDOCRINOL, V6, P1899, DOI 10.1210/me.6.11.1899; Cai Y, 2000, BLOOD, V96, P2140, DOI 10.1182/blood.V96.6.2140.h8002140_2140_2148; Chefalo PJ, 2003, J IMMUNOL, V170, P5825, DOI 10.4049/jimmunol.170.12.5825; Cheng J, 2004, BIOINFORMATICS, V20, P1462, DOI 10.1093/bioinformatics/bth087; Clarkson RWE, 1999, MOL ENDOCRINOL, V13, P619, DOI 10.1210/me.13.4.619; CLARKSON RWE, 1995, MOL ENDOCRINOL, V9, P108, DOI 10.1210/me.9.1.108; Clemmons David Robert, 2002, Pituitary, V5, P181, DOI 10.1023/A:1023321421760; Coleman RA, 2002, J NUTR, V132, P2123, DOI 10.1093/jn/132.8.2123; Cui TX, 2005, MOL ENDOCRINOL, V19, P2175, DOI 10.1210/me.2004-0502; DAVIDSON MB, 1987, ENDOCR REV, V8, P115, DOI 10.1210/edrv-8-2-115; de Hoon MJL, 2004, BIOINFORMATICS, V20, P1453, DOI 10.1093/bioinformatics/bth078; DIMITRIADIS G, 1994, EUR J CLIN INVEST, V24, P161, DOI 10.1111/j.1365-2362.1994.tb00982.x; DOGLIO A, 1989, P NATL ACAD SCI USA, V86, P1148, DOI 10.1073/pnas.86.4.1148; Doniger SW, 2003, GENOME BIOL, V4, DOI 10.1186/gb-2003-4-1-r7; Eickelberg O, 1999, J BIOL CHEM, V274, P12933, DOI 10.1074/jbc.274.18.12933; Eisen MB, 1998, P NATL ACAD SCI USA, V95, P14863, DOI 10.1073/pnas.95.25.14863; Fasshauer M, 2004, FEBS LETT, V558, P27, DOI 10.1016/S0014-5793(03)01525-4; Fasshauer M, 2004, J ENDOCRINOL, V181, P129, DOI 10.1677/joe.0.1810129; FEHLING HJ, 1994, SCIENCE, V265, P1234, DOI 10.1126/science.8066463; FOSTER CM, 1988, ENDOCRINOLOGY, V123, P1082, DOI 10.1210/endo-123-2-1082; Gong TWL, 1998, ENDOCRINOLOGY, V139, P1863, DOI 10.1210/en.139.4.1863; Greenhalgh CJ, 2004, GROWTH HORM IGF RES, V14, P200, DOI 10.1016/j.ghir.2003.12.011; GURLAND G, 1990, ENDOCRINOLOGY, V127, P3187, DOI 10.1210/endo-127-6-3187; Hai T, 2001, GENE, V273, P1, DOI 10.1016/S0378-1119(01)00551-0; Hartman MG, 2004, MOL CELL BIOL, V24, P5721, DOI 10.1128/MCB.24.13.5721-5732.2004; Hettiarachchi M, 1996, DIABETES, V45, P415, DOI 10.2337/diabetes.45.4.415; Horton JD, 2002, J CLIN INVEST, V109, P1125, DOI 10.1172/JCI200215593; Jung N, 2000, EUR J BIOCHEM, V267, P6180, DOI 10.1046/j.1432-1327.2000.01692.x; Karlsson M, 2004, EUR J BIOCHEM, V271, P2471, DOI 10.1111/j.1432-1033.2004.04177.x; Karolchik D, 2003, NUCLEIC ACIDS RES, V31, P51, DOI 10.1093/nar/gkg129; LaFleur AM, 2004, MEDIAT INFLAMM, V13, P349, DOI 10.1080/09629350400014172; LECAM A, 1994, J BIOL CHEM, V269, P21532; LeCouter J, 2003, ENDOCRINOLOGY, V144, P2606, DOI 10.1210/en.2002-0146; Leung KC, 1997, J CLIN ENDOCR METAB, V82, P4208, DOI 10.1210/jc.82.12.4208; Lewin TM, 2001, J BIOL CHEM, V276, P24674, DOI 10.1074/jbc.M102036200; Liao J, 1999, J BIOL CHEM, V274, P31597, DOI 10.1074/jbc.274.44.31597; Liao JF, 1997, J BIOL CHEM, V272, P25951, DOI 10.1074/jbc.272.41.25951; Mauvais-Jarvis F, 2002, J CLIN INVEST, V109, P141, DOI 10.1172/JCI200213305; Mohamadzadeh M, 1996, J IMMUNOL, V156, P3102; MOLLER C, 1992, J BIOL CHEM, V267, P23403; Moller N, 2003, GROWTH HORM IGF RES, V13, pS18, DOI 10.1016/S1096-6374(03)00048-0; Mootha VK, 2003, NAT GENET, V34, P267, DOI 10.1038/ng1180; Moraes RC, 2003, ENDOCRINOLOGY, V144, P4773, DOI 10.1210/en.2003-0456; NORDEEN SK, 1988, BIOTECHNIQUES, V6, P454; Olsson B, 2003, AM J PHYSIOL-ENDOC M, V285, pE504, DOI 10.1152/ajpendo.00444.2002; Ooi GT, 1997, MOL ENDOCRINOL, V11, P997, DOI 10.1210/me.11.7.997; Ozcan U, 2004, SCIENCE, V306, P457, DOI 10.1126/science.1103160; Parpal S, 2001, J BIOL CHEM, V276, P9670, DOI 10.1074/jbc.M007454200; Piwien-Pilipuk G, 2002, J PEDIATR ENDOCR MET, V15, P771; Piwien-Pilipuk G, 2002, J BIOL CHEM, V277, P44557, DOI 10.1074/jbc.M206886200; Piwien-Pilipuk G, 2001, J BIOL CHEM, V276, P19664, DOI 10.1074/jbc.M010193200; Ramalingam TS, 1997, MOL BIOL CELL, V8, P2463, DOI 10.1091/mbc.8.12.2463; Rowland JE, 2005, MOL CELL BIOL, V25, P66, DOI 10.1128/MCB.25.1.66-77.2005; Ruan H, 2004, CURR OPIN LIPIDOL, V15, P297, DOI 10.1097/00041433-200406000-00009; Ruan H, 2002, DIABETES, V51, P3176, DOI 10.2337/diabetes.51.11.3176; Sartipy P, 2003, P NATL ACAD SCI USA, V100, P7265, DOI 10.1073/pnas.1133870100; SCHWARTZ J, 1984, BIOCHEM BIOPH RES CO, V125, P237, DOI 10.1016/S0006-291X(84)80359-9; SLOOTWEG MC, 1991, J MOL ENDOCRINOL, V6, P179, DOI 10.1677/jme.0.0060179; Stahlberg Nina, 2005, BMC Physiol, V5, P8, DOI 10.1186/1472-6793-5-8; Suzuki H, 1999, SCIENCE, V283, P390, DOI 10.1126/science.283.5400.390; Takekawa M, 1998, CELL, V95, P521, DOI 10.1016/S0092-8674(00)81619-0; Terauchi Y, 1999, NAT GENET, V21, P230, DOI 10.1038/6023; Thompson BJL, 2000, ENDOCRINOLOGY, V141, P4321, DOI 10.1210/en.141.11.4321; Thompson W, 2003, NUCLEIC ACIDS RES, V31, P3580, DOI 10.1093/nar/gkg608; Tollet-Egnell P, 1999, ENDOCRINOLOGY, V140, P3693, DOI 10.1210/en.140.8.3693; Tollet-Egnell P, 2004, PHYSIOL GENOMICS, V16, P261, DOI 10.1152/physiolgenomics.00093.2002; VIKMAN K, 1991, ENDOCRINOLOGY, V129, P1155, DOI 10.1210/endo-129-3-1155; VIKMAN K, 1991, J ENDOCRINOL, V131, P139, DOI 10.1677/joe.0.1310139; Wang Y, 2005, J BIOL CHEM, V280, P10955, DOI 10.1074/jbc.M412808200; Wasserman WW, 2004, NAT REV GENET, V5, P276, DOI 10.1038/nrg1315; Weisberg SP, 2003, J CLIN INVEST, V112, P1796, DOI 10.1172/JCI200319246; Woelfle J, 2003, J BIOL CHEM, V278, P51261, DOI 10.1074/jbc.M309486200; Wright DE, 2004, J PERIPHER NERV SYST, V9, P242, DOI 10.1111/j.1085-9489.2004.09404.x; Xu HY, 2003, J CLIN INVEST, V112, P1821, DOI 10.1172/JCI200319451; Xu XQ, 2005, J BIOL CHEM, V280, P23987, DOI 10.1074/jbc.M503869200; YOUN BS, 1995, J IMMUNOL, V155, P2661; Zerbini LF, 2004, P NATL ACAD SCI USA, V101, P13618, DOI 10.1073/pnas.0402069101; Zhang W, 1999, ONCOGENE, V18, P4899, DOI 10.1038/sj.onc.1202885	84	40	40	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 17	2006	281	7					4132	4141		10.1074/jbc.M508492200	http://dx.doi.org/10.1074/jbc.M508492200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	011NN	16326703	hybrid			2022-12-25	WOS:000235275300044
J	Nakanishi-Matsui, M; Kashiwagi, S; Hosokawa, H; Cipriano, DJ; Dunn, SD; Wada, Y; Futai, M				Nakanishi-Matsui, M; Kashiwagi, S; Hosokawa, H; Cipriano, DJ; Dunn, SD; Wada, Y; Futai, M			Stochastic high-speed rotation of Escherichia coli ATP synthase F-1 sector - The epsilon subunit-sensitive rotation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GAMMA-SUBUNIT; BETA-SUBUNIT; ADENOSINE-TRIPHOSPHATASE; CATALYTIC MECHANISM; NUCLEOTIDE-BINDING; TORQUE GENERATION; ROTARY MOTOR; NA+-ATPASE; F-ATPASE; C-RING	The gamma subunit of the ATP synthase F-1 sector rotates at the center of the alpha(3)beta(3) hexamer during ATP hydrolysis. A gold bead (40-200 nm diameter) was attached to the gamma subunit of Escherichia coli F1, and then its ATP hydrolysis-dependent rotation was studied. The rotation speeds were variable, showing stochastic fluctuation. The high-speed rates of 40- and 60-nm beads were essentially similar: 721 and 671 rps (revolutions/s), respectively. The average rate of 60-nm beads was 381 rps, which is similar to 13-fold faster than that expected from the steady-state ATPase turnover number. These results indicate that the F1 sector rotates much faster than expected from the bulk of ATPase activity, and that similar to 10% of the F1 molecules are active on the millisecond time scale. Furthermore, the real ATP turnover number ( number of ATP molecules converted to ADP and phosphate/s), as a single molecule, is variable during a short period. The epsilon subunit inhibited rotation and ATPase, whereas epsilon fused through its carboxyl terminus to cytochrome b(562) showed no effect. The epsilon subunit significantly increased the pausing time during rotation. Stochastic fluctuation of catalysis may be a general property of an enzyme, although its understanding requires combining studies of steady-state kinetics and single molecule observation.	Japan Sci & Technol Agcy, Microbial Chem Res Fdn, Futai Special Lab, Microbial Chem Res Ctr,CREST, Tokyo 1410021, Japan; Univ Tokyo, Grad Sch Pharmaceut Sci, Bunkyo Ku, Tokyo 1130033, Japan; Univ Western Ontario, Dept Biochem, London, ON N6A 5C2, Canada; Osaka Univ, ISIR, Dept Biol Sci, Osaka 5670041, Japan	Japan Science & Technology Agency (JST); University of Tokyo; Western University (University of Western Ontario); Osaka University	Futai, M (corresponding author), Japan Sci & Technol Agcy, Microbial Chem Res Fdn, Futai Special Lab, Microbial Chem Res Ctr,CREST, Tokyo 1410021, Japan.	mfutai-fsl@bikaken.or.jp	Dunn, Stanley/D-3418-2013					ABRAHAMS JP, 1994, NATURE, V370, P621, DOI 10.1038/370621a0; Adachi K, 2000, P NATL ACAD SCI USA, V97, P7243, DOI 10.1073/pnas.120174297; AlShawi MK, 1997, J BIOL CHEM, V272, P2300; Boyer PD, 1997, ANNU REV BIOCHEM, V66, P717, DOI 10.1146/annurev.biochem.66.1.717; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Cipriano DJ, 2002, J BIOL CHEM, V277, P16782, DOI 10.1074/jbc.M201349200; Diez M, 2004, NAT STRUCT MOL BIOL, V11, P135, DOI 10.1038/nsmb718; DUNCAN TM, 1995, P NATL ACAD SCI USA, V92, P10964, DOI 10.1073/pnas.92.24.10964; DUNN SD, 1982, J BIOL CHEM, V257, P7354; DUNN SD, 1986, ANAL BIOCHEM, V159, P35, DOI 10.1016/0003-2697(86)90304-0; Fillingame RH, 2003, FEBS LETT, V555, P29, DOI 10.1016/S0014-5793(03)01101-3; FUTAI M, 1974, P NATL ACAD SCI USA, V71, P2725, DOI 10.1073/pnas.71.7.2725; Futai M., 2004, HDB ATPASES BIOCH CE, P237; GOGOL EP, 1990, P NATL ACAD SCI USA, V87, P9585, DOI 10.1073/pnas.87.24.9585; Hosokawa H, 2005, J BIOL CHEM, V280, P23797, DOI 10.1074/jbc.M502650200; Hutcheon ML, 2001, P NATL ACAD SCI USA, V98, P8519, DOI 10.1073/pnas.151236798; HYNDMAN DJ, 1994, J BIOL CHEM, V269, P28871; Iko Y, 2001, J BIOL CHEM, V276, P47508, DOI 10.1074/jbc.M108803200; Jones PC, 2000, J BIOL CHEM, V275, P31340, DOI 10.1074/jbc.M003687200; Junge W, 1997, TRENDS BIOCHEM SCI, V22, P420, DOI 10.1016/S0968-0004(97)01129-8; Kaim G, 2002, FEBS LETT, V525, P156, DOI 10.1016/S0014-5793(02)03097-1; Kato-Yamada Y, 1998, J BIOL CHEM, V273, P19375, DOI 10.1074/jbc.273.31.19375; LOTSCHER HR, 1984, BIOCHEMISTRY-US, V23, P4140, DOI 10.1021/bi00313a020; Meier T, 2005, SCIENCE, V308, P659, DOI 10.1126/science.1111199; MORIYAMA Y, 1991, J BIOL CHEM, V266, P22141; Murata T, 2005, SCIENCE, V308, P654, DOI 10.1126/science.1110064; Nishio K, 2002, P NATL ACAD SCI USA, V99, P13448, DOI 10.1073/pnas.202149599; Noji H, 1997, NATURE, V386, P299, DOI 10.1038/386299a0; OMOTE H, 1995, J BIOL CHEM, V270, P25656, DOI 10.1074/jbc.270.43.25656; Omote H, 1999, P NATL ACAD SCI USA, V96, P7780, DOI 10.1073/pnas.96.14.7780; Panke O, 2000, FEBS LETT, V472, P34, DOI 10.1016/S0014-5793(00)01436-8; Rodgers AJW, 2000, NAT STRUCT BIOL, V7, P1051; Sabbert D, 1996, NATURE, V381, P623, DOI 10.1038/381623a0; Sambongi Y, 1999, SCIENCE, V286, P1722, DOI 10.1126/science.286.5445.1722; STERNWEIS PC, 1980, BIOCHEMISTRY-US, V19, P526, DOI 10.1021/bi00544a021; Stock D, 1999, SCIENCE, V286, P1700, DOI 10.1126/science.286.5445.1700; Stock D, 2000, CURR OPIN STRUC BIOL, V10, P672, DOI 10.1016/S0959-440X(00)00147-0; Tanabe M, 2001, J BIOL CHEM, V276, P15269, DOI 10.1074/jbc.M100289200; Tsunoda SP, 2001, P NATL ACAD SCI USA, V98, P6560, DOI 10.1073/pnas.111128098; Ueno H, 2005, P NATL ACAD SCI USA, V102, P1333, DOI 10.1073/pnas.0407857102; Wada Y, 2000, BBA-BIOENERGETICS, V1459, P499, DOI 10.1016/S0005-2728(00)00189-4; Weber J, 1997, BBA-BIOENERGETICS, V1319, P19, DOI 10.1016/S0005-2728(96)00121-1; Weber J, 1999, J BIOL CHEM, V274, P19124, DOI 10.1074/jbc.274.27.19124; Yasuda R, 2001, NATURE, V410, P898, DOI 10.1038/35073513; Zimmermann B, 2005, EMBO J, V24, P2053, DOI 10.1038/sj.emboj.7600682	45	60	60	3	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 17	2006	281	7					4126	4131		10.1074/jbc.M510090200	http://dx.doi.org/10.1074/jbc.M510090200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	011NN	16352612	hybrid			2022-12-25	WOS:000235275300043
J	Okumura, AJ; Hatsuzawa, K; Tamura, T; Nagaya, H; Saeki, K; Okumura, F; Nagao, K; Nishikawa, M; Yoshimura, A; Wada, I				Okumura, AJ; Hatsuzawa, K; Tamura, T; Nagaya, H; Saeki, K; Okumura, F; Nagao, K; Nishikawa, M; Yoshimura, A; Wada, I			Involvement of a novel Q-SNARE, D12, in quality control of the endomembrane system	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENDOPLASMIC-RETICULUM; MEMBRANE-FUSION; INTERMEDIATE COMPARTMENT; FLUORESCENT PROTEIN; MAMMALIAN-CELLS; GOLGI TRANSPORT; YEAST; ER; LIPOFUSCIN; APOPTOSIS	The cellular endomembrane system requires the proper kinetic balance of synthesis and degradation of its individual components, which is maintained in part by a specific membrane fusion apparatus. In this study, we describe the molecular properties of D12, which was identified from a mouse expression library. This C-terminal anchored membrane protein has sequence similarity to both a yeast soluble N-ethylmaleimide-sensitive factor attachment protein (SNAP) receptor (SNARE), Use1p/Slt1p, and a recently identified human syntaxin 18-binding protein, p31. D12 formed a tight complex with syntaxin 18 as well as Sec22b and bound to alpha-SNAP, indicating that D12 is a SNARE protein. Although the majority of D12 is located in the endoplasmic reticulum and endoplasmic reticulum-Golgi intermediate compartments at steady state, overexpression or knockdown of D12 had no obvious effects on membrane trafficking in the early secretory pathway. However, suppression of D12 expression caused rapid appearance of lipofuscin granules, accompanied by apoptotic cell death without the apparent activation of the unfolded protein response. The typical cause of lipofuscin formation is the impaired degradation of mitochondria by lysosomal degradative enzymes, and, consistent with this, we found that proper post-Golgi maturation of cathepsin D was impaired in D12-deficient cells. This unexpected observation was supported by evidence that D12 associates with VAMP7, a SNARE in the endosomal-lysosomal pathway. Hence, we suggest that D12 participates in the degradative function of lysosomes.	Fukushima Med Univ, Sch Med, Inst Biomed Sci, Dept Cell Sci, Fukushima 9601295, Japan; Kyushu Univ, Med Inst Bioregulat, Div Mol & Cellular Immunol, Higashi Ku, Fukuoka 8128582, Japan; Kirin Brewery Pharmaceut Res Labs, Takasaki, Gumma 3701295, Japan	Fukushima Medical University; Kyushu University	Wada, I (corresponding author), Fukushima Med Univ, Sch Med, Inst Biomed Sci, Dept Cell Sci, Fukushima 9601295, Japan.	iwada@fmu.ac.jp	Yoshimura, Akihiko/K-5515-2013	Wada, Ikuo/0000-0001-5668-6994; Tamura, Taku/0000-0001-6074-9273				Antonin W, 2000, EMBO J, V19, P6453, DOI 10.1093/emboj/19.23.6453; BENNETT MK, 1993, P NATL ACAD SCI USA, V90, P2559, DOI 10.1073/pnas.90.7.2559; Blumenthal R, 2003, CHEM REV, V103, P53, DOI 10.1021/cr000036+; Bogdanovic A, 2002, BIOCHEM J, V368, P29, DOI 10.1042/BJ20020845; Braun V, 2004, EMBO J, V23, P4166, DOI 10.1038/sj.emboj.7600427; Brunk UT, 2002, EUR J BIOCHEM, V269, P1996, DOI 10.1046/j.1432-1033.2002.02869.x; Burri L, 2003, P NATL ACAD SCI USA, V100, P9873, DOI 10.1073/pnas.1734000100; Campbell RE, 2002, P NATL ACAD SCI USA, V99, P7877, DOI 10.1073/pnas.082243699; Chen YA, 2001, NAT REV MOL CELL BIO, V2, P98, DOI 10.1038/35052017; Cory S, 2002, NAT REV CANCER, V2, P647, DOI 10.1038/nrc883; Desagher S, 1999, J CELL BIOL, V144, P891, DOI 10.1083/jcb.144.5.891; Dilcher M, 2003, EMBO J, V22, P3664, DOI 10.1093/emboj/cdg339; Haralampus-Grynaviski NM, 2003, P NATL ACAD SCI USA, V100, P3179, DOI 10.1073/pnas.0630280100; Hatsuzawa K, 2000, J BIOL CHEM, V275, P13713, DOI 10.1074/jbc.275.18.13713; Hay JC, 1997, CELL, V89, P149, DOI 10.1016/S0092-8674(00)80191-9; Hirose H, 2004, EMBO J, V23, P1267, DOI 10.1038/sj.emboj.7600135; Ihara Y, 1999, MOL CELL, V4, P331, DOI 10.1016/S1097-2765(00)80335-4; Ishidoh K, 2002, BIOL CHEM, V383, P1827, DOI 10.1515/BC.2002.206; IVY GO, 1989, ADV EXP MED BIOL, V266, P31; IVY GO, 1984, SCIENCE, V226, P985, DOI 10.1126/science.6505679; Jahn R, 2003, CELL, V112, P519, DOI 10.1016/S0092-8674(03)00112-0; Kamada A, 2004, J BIOL CHEM, V279, P21533, DOI 10.1074/jbc.M401403200; Kaufman RJ, 2004, TRENDS BIOCHEM SCI, V29, P152, DOI 10.1016/j.tibs.2004.01.004; Kim DH, 2004, NAT BIOTECHNOL, V22, P321, DOI 10.1038/nbt940; Korotkov KV, 2001, J BIOL CHEM, V276, P15330, DOI 10.1074/jbc.M009861200; Lowe SL, 1997, NATURE, V389, P881, DOI 10.1038/39923; LUPAS A, 1991, SCIENCE, V252, P1162, DOI 10.1126/science.252.5009.1162; Masuhara M, 1997, BIOCHEM BIOPH RES CO, V239, P439, DOI 10.1006/bbrc.1997.7484; McNew JA, 2000, J CELL BIOL, V150, P105, DOI 10.1083/jcb.150.1.105; McNew JA, 1999, MOL CELL, V4, P415, DOI 10.1016/S1097-2765(00)80343-3; Misawa K, 2000, P NATL ACAD SCI USA, V97, P3062, DOI 10.1073/pnas.060489597; Mori K, 2000, CELL, V101, P451, DOI 10.1016/S0092-8674(00)80855-7; Mori K, 2002, ARCH HISTOL CYTOL, V65, P359, DOI 10.1679/aohc.65.359; Morita S, 2000, GENE THER, V7, P1063, DOI 10.1038/sj.gt.3301206; Nagahama M, 1996, J CELL BIOL, V133, P507, DOI 10.1083/jcb.133.3.507; Nagahama M, 2003, MOL BIOL CELL, V14, P262, DOI 10.1091/mbc.02-07-0115; Nagaya H, 2002, MOL BIOL CELL, V13, P302, DOI 10.1091/mbc.01-05-0255; Nakajima K, 2004, EMBO J, V23, P3216, DOI 10.1038/sj.emboj.7600333; Nakanishi H, 2003, AGEING RES REV, V2, P367, DOI 10.1016/S1568-1637(03)00027-8; Nosaka T, 1999, EMBO J, V18, P4754, DOI 10.1093/emboj/18.17.4754; OKAZAKI I, 1992, J BIOCHEM, V111, P763, DOI 10.1093/oxfordjournals.jbchem.a123833; Paek I, 1997, J CELL BIOL, V137, P1017, DOI 10.1083/jcb.137.5.1017; Pelham HRB, 1999, EXP CELL RES, V247, P1, DOI 10.1006/excr.1998.4356; Powell SR, 2005, FREE RADICAL BIO MED, V38, P1093, DOI 10.1016/j.freeradbiomed.2005.01.003; Prekeris R, 1999, MOL BIOL CELL, V10, P3891, DOI 10.1091/mbc.10.11.3891; Pryor PR, 2004, EMBO REP, V5, P590, DOI 10.1038/sj.embor.7400150; Rayner JC, 1997, EMBO J, V16, P1832, DOI 10.1093/emboj/16.8.1832; Saeki K, 2003, EMBO J, V22, P3015, DOI 10.1093/emboj/cdg293; Sasaki A, 2003, J BIOL CHEM, V278, P2432, DOI 10.1074/jbc.C200608200; Subramaniam VN, 1996, SCIENCE, V272, P1161, DOI 10.1126/science.272.5265.1161; Tang BL, 1998, BIOCHEM BIOPH RES CO, V243, P885, DOI 10.1006/bbrc.1998.8194; Terman A, 2004, INT J BIOCHEM CELL B, V36, P1400, DOI 10.1016/j.biocel.2003.08.009; Ungar D, 2003, ANNU REV CELL DEV BI, V19, P493, DOI 10.1146/annurev.cellbio.19.110701.155609; Watson RT, 2001, AM J PHYSIOL-CELL PH, V281, pC215, DOI 10.1152/ajpcell.2001.281.1.C215; Xu Y, 1997, J BIOL CHEM, V272, P20162, DOI 10.1074/jbc.272.32.20162; Zhang KZ, 2004, J BIOL CHEM, V279, P25935, DOI 10.1074/jbc.R400008200; Zhang T, 1999, MOL BIOL CELL, V10, P435, DOI 10.1091/mbc.10.2.435	57	24	24	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 17	2006	281	7					4495	4506		10.1074/jbc.M509715200	http://dx.doi.org/10.1074/jbc.M509715200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	011NN	16354670	hybrid			2022-12-25	WOS:000235275300085
J	Kittiworakarn, J; Lecoq, A; Moine, G; Thai, R; Lajeunesse, E; Drevet, P; Vidaud, C; Menez, A; Leonetti, M				Kittiworakarn, J; Lecoq, A; Moine, G; Thai, R; Lajeunesse, E; Drevet, P; Vidaud, C; Menez, A; Leonetti, M			HIV-1 tat raises an adjuvant-free humoral immune response controlled by its core region and its ability to form cysteine-mediated oligomers	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IMMUNODEFICIENCY-VIRUS TYPE-1; FIBROBLAST-GROWTH-FACTOR; HEPARAN-SULFATE PROTEOGLYCANS; VASCULAR ENDOTHELIAL-CELLS; DENDRITIC CELLS; BASIC DOMAIN; T-CELLS; TRANSACTIVATOR GENE; ANTIBODY-RESPONSE; KAPOSIS-SARCOMA	Proteins are poor immunogens that require an adjuvant to raise an immune response. Here we show that the human immunodeficiency virus, type 1 Tat protein possesses an autoadjuvant property, and we have identified the determinants and the molecular events that are associated with this unusual property. Using a series of chemically synthesized Tat101 derivatives, we show that the core region controls the autoadjuvant phenomenon independently of the B-cell recognition and T-cell stimulation that are associated with epitopes respectively located on the N-terminal region and the cysteine-rich region. We also show that cysteine-mediated oligomerization is a key molecular event of the adjuvant-free antibody response. In particular, a Tat dimer formed by the oxidation of two cysteine residues, at position 34 only, raises an adjuvant-free antibody response that is comparable with that observed with the wildtype protein. Unlike the parent protein, the Tat dimer has no transactivating activity and remains homogeneous for several weeks in solution. This construct might be of value for the design of an adjuvant-free Tat-based vaccine. Furthermore, we suggest that the specific autoadjuvanticity determinant of Tat could be used to provide other proteins with adjuvant-free immunogenicity.	CEA Saclay, Dept Ingn & Etudes Prot, F-91191 Gif Sur Yvette, France; CEA, VALRHO, Serv Biochim Post Gen & Toxicol Nucl, F-30207 Bagnols Sur Ceze, France	CEA; UDICE-French Research Universities; Universite Paris Saclay; CEA	Leonetti, M (corresponding author), CEA Saclay, Dept Ingn & Etudes Prot, Batiment 152, F-91191 Gif Sur Yvette, France.	michel.leonetti@cea.fr	VIDAUD, Claude/AGX-9878-2022	Thai, Robert/0000-0001-9438-4225				Albini A, 1996, ONCOGENE, V12, P289; Albini A, 1998, P NATL ACAD SCI USA, V95, P13153, DOI 10.1073/pnas.95.22.13153; Albini A, 1996, NAT MED, V2, P1371, DOI 10.1038/nm1296-1371; Albini A, 1998, J BIOL CHEM, V273, P15895, DOI 10.1074/jbc.273.26.15895; Bairoch A, 2000, NUCLEIC ACIDS RES, V28, P45, DOI 10.1093/nar/28.1.45; BARILLARI G, 1993, P NATL ACAD SCI USA, V90, P7941, DOI 10.1073/pnas.90.17.7941; Barillari G, 2002, CLIN MICROBIOL REV, V15, P310, DOI 10.1128/CMR.15.2.310-326.2002; BATTAGLIA PA, 1994, BIOCHEM BIOPH RES CO, V201, P701, DOI 10.1006/bbrc.1994.1757; Betti M, 2001, VACCINE, V19, P3408, DOI 10.1016/S0264-410X(01)00067-6; BOGERD HP, 1993, J VIROL, V67, P5030, DOI 10.1128/JVI.67.8.5030-5034.1993; Bomford R, 1998, DEV BIOL STAND, V92, P13; Boykins RA, 1999, J IMMUNOL, V163, P15; BRAKE DA, 1990, J CELL BIOL, V111, P1275, DOI 10.1083/jcb.111.3.1275; BUONAGURO L, 1992, J VIROL, V66, P7159, DOI 10.1128/JVI.66.12.7159-7167.1992; Cafaro A, 1999, NAT MED, V5, P643, DOI 10.1038/9488; Caputo A, 1996, GENE THER, V3, P235; Chang HC, 1997, AIDS, V11, P1421, DOI 10.1097/00002030-199712000-00006; Cohen SS, 1999, P NATL ACAD SCI USA, V96, P10842, DOI 10.1073/pnas.96.19.10842; Davis JC, 1999, BIOCHEM J, V341, P613, DOI 10.1042/0264-6021:3410613; DAYTON AI, 1986, CELL, V44, P941, DOI 10.1016/0092-8674(86)90017-6; DiGabriele AD, 1998, NATURE, V393, P812, DOI 10.1038/31741; ENSOLI B, 1994, NATURE, V371, P674, DOI 10.1038/371674a0; ENSOLI B, 1993, J VIROL, V67, P277, DOI 10.1128/JVI.67.1.277-287.1993; Fanales-Belasio E, 2002, J IMMUNOL, V168, P197, DOI 10.4049/jimmunol.168.1.197; FISHER AG, 1986, NATURE, V320, P367, DOI 10.1038/320367a0; FRANKEL AD, 1988, SCIENCE, V240, P70, DOI 10.1126/science.2832944; FROEBEL KS, 1994, AIDS RES HUM RETROV, V2, P83; GREGORIADIS G, 1990, IMMUNOL TODAY, V11, P89, DOI 10.1016/0167-5699(90)90034-7; GROENINK M, 1991, J VIROL, V65, P1968, DOI 10.1128/JVI.65.4.1968-1975.1991; GUTHEIL WG, 1994, P NATL ACAD SCI USA, V91, P6594, DOI 10.1073/pnas.91.14.6594; HAUBER J, 1989, J VIROL, V63, P1181, DOI 10.1128/JVI.63.3.1181-1187.1989; Izmailova E, 2003, NAT MED, V9, P191, DOI 10.1038/nm822; Kuschel Meike, 2002, J Biomol Tech, V13, P172; LASCELLES AK, 1989, VET IMMUNOL IMMUNOP, V22, P15, DOI 10.1016/0165-2427(89)90160-8; MEYAARD L, 1992, EUR J IMMUNOL, V22, P2729, DOI 10.1002/eji.1830221038; MITCHISON N A, 1971, European Journal of Immunology, V1, P18, DOI 10.1002/eji.1830010104; Mitola S, 2000, J VIROL, V74, P344, DOI 10.1128/JVI.74.1.344-353.2000; Pauza CD, 2000, P NATL ACAD SCI USA, V97, P3515, DOI 10.1073/pnas.070049797; PHILIPPON V, 1994, VIROLOGY, V205, P519, DOI 10.1006/viro.1994.1673; Poggi A, 2004, BLOOD, V103, P2205, DOI 10.1182/blood-2003-08-2928; Proudfoot AEI, 2003, P NATL ACAD SCI USA, V100, P1885, DOI 10.1073/pnas.0334864100; REISS P, 1990, J MED VIROL, V30, P163, DOI 10.1002/jmv.1890300303; Rothel JS, 1998, VET IMMUNOL IMMUNOP, V63, P167, DOI 10.1016/S0165-2427(98)00093-2; SABATIER JM, 1991, J VIROL, V65, P961, DOI 10.1128/JVI.65.2.961-967.1991; Safran M, 2000, BIOCHEM J, V345, P107, DOI 10.1042/0264-6021:3450107; Schijns VEJC, 2000, CURR OPIN IMMUNOL, V12, P456, DOI 10.1016/S0952-7915(00)00120-5; STEMMER WPC, 1995, GENE, V164, P49, DOI 10.1016/0378-1119(95)00511-4; SUBRAMANYAM M, 1993, J IMMUNOL, V150, P2544; Tosi G, 2000, EUR J IMMUNOL, V30, P1120, DOI 10.1002/(SICI)1521-4141(200004)30:4<1120::AID-IMMU1120>3.0.CO;2-4; Tyagi M, 2001, J BIOL CHEM, V276, P3254, DOI 10.1074/jbc.M006701200; vanBaalen CA, 1997, J GEN VIROL, V78, P1913, DOI 10.1099/0022-1317-78-8-1913; VISCIDI RP, 1989, SCIENCE, V246, P1606, DOI 10.1126/science.2556795; Vives E, 1997, J BIOL CHEM, V272, P16010, DOI 10.1074/jbc.272.25.16010; Vogel FR, 1998, DEV BIOL STAND, V92, P241; WESTENDORP MO, 1995, NATURE, V375, P497, DOI 10.1038/375497a0; Wrenger S, 1997, J BIOL CHEM, V272, P30283, DOI 10.1074/jbc.272.48.30283; Xiao H, 2000, P NATL ACAD SCI USA, V97, P11466, DOI 10.1073/pnas.97.21.11466; Zagury J F, 1998, J Hum Virol, V1, P282; ZAULI G, 1995, BLOOD, V86, P3823, DOI 10.1182/blood.V86.10.3823.bloodjournal86103823; Zocchi MR, 1997, AIDS, V11, P1227, DOI 10.1097/00002030-199710000-00005	60	27	32	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 10	2006	281	6					3105	3115		10.1074/jbc.M509899200	http://dx.doi.org/10.1074/jbc.M509899200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	009QV	16321975	hybrid			2022-12-25	WOS:000235128200013
J	Li, FY; Jeffrey, PD; Yu, JW; Shi, YG				Li, FY; Jeffrey, PD; Yu, JW; Shi, YG			Crystal structure of a viral FLIP - Insights into FLIP-mediated inhibition of death receptor signaling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DOMAIN-CONTAINING PROTEIN; EFFECTOR DOMAIN; CELL-DEATH; NMR STRUCTURE; APOPTOSIS; FAS; FADD; CASPASE-8; COMPLEX; ACTIVATION	Death receptor signaling is initiated by the assembly of the death-inducing signaling complex, which culminates in the activation of the initiator caspase, either caspase-8 or caspase-10. A family of viral and cellular proteins, known as FLIP, plays an essential role in the regulation of death receptor signaling. Viral FLIP (v-FLIP) and short cellular FLIP (c-FLIPS) inhibit apoptosis by interfering with death receptor signaling. The structure and mechanisms of v-FLIP and c-FLIPS remain largely unknown. Here we report a high resolution crystal structure of MC159, a v-FLIP derived from the molluscum contagiosum virus, which is a member of the human poxvirus family. Unexpectedly, the two tandem death effector domains (DEDs) of MC159 rigidly associate with each other through a hydrophobic interface. Structure-based sequence analysis suggests that this interface is conserved in the tandem DEDs from other v-FLIP, c-FLIPS, and caspase-8 and -10. Strikingly, the overall packing arrangement between the two DEDs of MC159 resembles that between the caspase recruitment domains of Apaf-1 and caspase-9. In addition, each DED of MC159 contains a highly conserved binding motif on the surface, to which loss-of-function mutations in MC159 map. These observations, in conjunction with published evidence, reveal significant insights into the function of v-FLIP and suggest a mechanism by which v-FLIP and c-FLIPS inhibit death receptor signaling.	Princeton Univ, Dept Mol Biol, Lewis Thomas Lab, Princeton, NJ 08544 USA	Princeton University	Shi, YG (corresponding author), Princeton Univ, Dept Mol Biol, Lewis Thomas Lab, Washington Rd, Princeton, NJ 08544 USA.	yshi@molbio.princeton.edu		Jeffrey, Philip/0000-0002-4351-5341; Shi, Yigong/0000-0003-2030-168X				Berglund H, 2000, J MOL BIOL, V302, P171, DOI 10.1006/jmbi.2000.4011; Bertin J, 1997, P NATL ACAD SCI USA, V94, P1172, DOI 10.1073/pnas.94.4.1172; BOLDIN MP, 1995, J BIOL CHEM, V270, P7795, DOI 10.1074/jbc.270.14.7795; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Chai JJ, 2001, CELL, V104, P769, DOI 10.1016/S0092-8674(02)02034-2; Chang DW, 2002, EMBO J, V21, P3704, DOI 10.1093/emboj/cdf356; CHINNAIYAN AM, 1995, CELL, V81, P505, DOI 10.1016/0092-8674(95)90071-3; Danial NN, 2004, CELL, V116, P205, DOI 10.1016/S0092-8674(04)00046-7; Djerbi M, 1999, J EXP MED, V190, P1025, DOI 10.1084/jem.190.7.1025; Eberstadt M, 1998, NATURE, V392, P941, DOI 10.1038/31972; Fesik SW, 2000, CELL, V103, P273, DOI 10.1016/S0092-8674(00)00119-7; Garvey TL, 2002, J VIROL, V76, P697, DOI 10.1128/JVI.76.2.697-706.2002; Green DR, 2002, CANCER CELL, V1, P19, DOI 10.1016/S1535-6108(02)00024-7; Han DKM, 1997, P NATL ACAD SCI USA, V94, P11333, DOI 10.1073/pnas.94.21.11333; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Hay BA, 2004, NAT REV GENET, V5, P911, DOI 10.1038/nrg1491; Hill JM, 2002, EMBO J, V21, P6494, DOI 10.1093/emboj/cdf641; Holler N, 2003, MOL CELL BIOL, V23, P1428, DOI 10.1128/MCB.23.4.1428-1440.2003; HOLM L, 1993, J MOL BIOL, V233, P123, DOI 10.1006/jmbi.1993.1489; Horvitz HR, 2003, CHEMBIOCHEM, V4, P697, DOI 10.1002/cbic.200300614; Hu SM, 1997, J BIOL CHEM, V272, P9621; Huang BH, 1996, NATURE, V384, P638, DOI 10.1038/384638a0; Inohara N, 1997, P NATL ACAD SCI USA, V94, P10717, DOI 10.1073/pnas.94.20.10717; Irmler M, 1997, NATURE, V388, P190, DOI 10.1038/40657; Jeong EJ, 1999, J BIOL CHEM, V274, P16337, DOI 10.1074/jbc.274.23.16337; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Kischkel FC, 2001, J BIOL CHEM, V276, P46639, DOI 10.1074/jbc.M105102200; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; Li WY, 2002, NAT STRUCT BIOL, V9, P436, DOI 10.1038/nsb795; Muzio M, 1996, CELL, V85, P817, DOI 10.1016/S0092-8674(00)81266-0; Nagata S, 1999, ANNU REV GENET, V33, P29, DOI 10.1146/annurev.genet.33.1.29; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Ozoren N, 2003, SEMIN CANCER BIOL, V13, P135, DOI 10.1016/S1044-579X(02)00131-1; Perrakis A, 1999, NAT STRUCT BIOL, V6, P458, DOI 10.1038/8263; Peter ME, 2003, CELL DEATH DIFFER, V10, P26, DOI 10.1038/sj.cdd.4401186; Qin HX, 1999, NATURE, V399, P549, DOI 10.1038/21124; Rasper DM, 1998, CELL DEATH DIFFER, V5, P271, DOI 10.1038/sj.cdd.4400370; Rathmell JC, 2002, CELL, V109, pS97, DOI 10.1016/S0092-8674(02)00704-3; Riedl SJ, 2004, NAT REV MOL CELL BIO, V5, P897, DOI 10.1038/nrm1496; SHELDRICK GM, 1990, ACTA CRYSTALLOGR A, V46, P467, DOI 10.1107/S0108767390000277; Shisler JL, 2001, VIROLOGY, V282, P14, DOI 10.1006/viro.2001.0834; Shu HB, 1997, IMMUNITY, V6, P751, DOI 10.1016/S1074-7613(00)80450-1; Siegel RM, 1998, J CELL BIOL, V141, P1243, DOI 10.1083/jcb.141.5.1243; Srinivasula SM, 1997, J BIOL CHEM, V272, P18542, DOI 10.1074/jbc.272.30.18542; Thome M, 2001, NAT REV IMMUNOL, V1, P50, DOI 10.1038/35095508; Thome M, 1997, NATURE, V386, P517, DOI 10.1038/386517a0; THOMPSON CB, 1995, SCIENCE, V267, P1456, DOI 10.1126/science.7878464; Thornberry NA, 1998, SCIENCE, V281, P1312, DOI 10.1126/science.281.5381.1312; Vaux DL, 2000, CURR OPIN IMMUNOL, V12, P719, DOI 10.1016/S0952-7915(00)00168-0; Wang GH, 1997, J VIROL, V71, P8928, DOI 10.1128/JVI.71.11.8928-8932.1997; Wang L, 2001, P NATL ACAD SCI USA, V98, P13884, DOI 10.1073/pnas.241358198; Wang XD, 2001, GENE DEV, V15, P2922; Xiao T, 1999, CELL, V99, P545, DOI 10.1016/S0092-8674(00)81542-1; Yuan JY, 2000, NATURE, V407, P802, DOI 10.1038/35037739	55	71	72	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 3	2006	281	5					2960	2968		10.1074/jbc.M511074200	http://dx.doi.org/10.1074/jbc.M511074200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	006XT	16317000	hybrid			2022-12-25	WOS:000234931800066
J	Moiseyev, G; Takahashi, Y; Chen, Y; Gentleman, S; Redmond, TM; Crouch, RK; Ma, JX				Moiseyev, G; Takahashi, Y; Chen, Y; Gentleman, S; Redmond, TM; Crouch, RK; Ma, JX			RPE65 is an iron(II)-dependent isomerohydrolase in the retinoid visual cycle	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-CAROTENE; IRON; EXPRESSION; MUTATIONS; PROTEINS; GENE; IDENTIFICATION; METABOLISM; SUBSTRATE; CLONING	The isomerization of all-trans-retinyl ester to 11-cis-retinol in the retinal pigment epithelium (RPE) is a critical step in the visual cycle and is essential for normal vision. Recently, we have established that protein RPE65 is the isomerohydrolase catalyzing this reaction. The present study investigated if metal ions are required for the isomerohydrolase activity of RPE65. The conversion of all-trans-[H-3] retinol to 11-cis-[H-3]retinol was used as the measure for isomerohydrolase activity. Metal chelators 2,2'-bipyridine and 1,10-phenanthroline both showed dose-dependent inhibitions of the isomerohydrolase activity in bovine RPE microsomes, with IC50 values of 0.5 and 0.2 mM, respectively. In the same reaction systems, however, lecithin-retinol acyltransferase (LRAT) activity was not affected by these metal chelators. The isomerohydrolase activity inhibited by the metal chelators was restored by FeSO4 but not by CuSO4, ZnCl2, or MgCl2. Moreover, addition of Fe(III) citrate or FeCl3 did not restore the activity, indicating that Fe2+ is the metal ion essential for the isomerohydrolase activity. To confirm this result in recombinant RPE65, we expressed RPE65 in a 293A cell line stably expressing LRAT. In vitro activity assay showed that both metal chelators inhibited isomerohydrolase activity of recombinant RPE65. The addition of FeSO4 restored the enzymatic activity of the recombinant RPE65. Further, two specific iron-staining methods showed that purified RPE65 contains endogenous iron. Inductively coupled plasma mass spectrometry measurements showed that bovine RPE65 binds iron ion with a stoichiometry of 0.8 +/- 0.1. These results indicate that RPE65 is an iron-dependent isomerohydrolase in the visual cycle.	Univ Oklahoma, Hlth Sci Ctr, Dept Cell Biol, Dept Med, Oklahoma City, OK 73104 USA; NEI, NIH, Bethesda, MD 20892 USA; Med Univ S Carolina, Dept Ophthalmol, Charleston, SC 29425 USA; Med Univ S Carolina, Dept Biochem, Charleston, SC 29425 USA	University of Oklahoma System; University of Oklahoma Health Sciences Center; National Institutes of Health (NIH) - USA; NIH National Eye Institute (NEI); Medical University of South Carolina; Medical University of South Carolina	Ma, JX (corresponding author), 941 Stanton L Young Blvd,BSEB 328B, Oklahoma City, OK 73104 USA.	jian-xing-ma@ouhsc.edu		Redmond, T. Michael/0000-0002-1813-5291	NATIONAL EYE INSTITUTE [R24EY014793, R01EY012231, Z01EY000260, R21EY015650, ZIAEY000260, R33EY015650, R01EY004939] Funding Source: NIH RePORTER; NEI NIH HHS [EY14793, EY012231, EY15650, EY04939] Funding Source: Medline	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		Acland GM, 2001, NAT GENET, V28, P92, DOI 10.1038/88327; Baker HM, 2003, P NATL ACAD SCI USA, V100, P3579, DOI 10.1073/pnas.0637295100; BAVIK CO, 1992, J BIOL CHEM, V267, P23035; Crabb JW, 1998, METH MOL B, V89, P91; Dejneka NS, 2004, MOL THER, V9, P182, DOI 10.1016/j.ymthe.2003.11.013; Gollapalli DR, 2003, BIOCHEMISTRY-US, V42, P5809, DOI 10.1021/bi0341004; GOODMAN DS, 1967, J BIOL CHEM, V242, P3543; HAMEL CP, 1993, J BIOL CHEM, V268, P15751; Jin MH, 2005, CELL, V122, P449, DOI 10.1016/j.cell.2005.06.042; Kloer DP, 2005, SCIENCE, V308, P267, DOI 10.1126/science.1108965; KUO CF, 1988, ANAL BIOCHEM, V170, P183, DOI 10.1016/0003-2697(88)90106-6; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lai Chooi-May, 2004, Genet Vaccines Ther, V2, P3, DOI 10.1186/1479-0556-2-3; Lange SJ, 1998, CURR OPIN CHEM BIOL, V2, P159, DOI 10.1016/S1367-5931(98)80057-4; LEONG LM, 1992, ANAL BIOCHEM, V207, P317, DOI 10.1016/0003-2697(92)90018-3; Lindqvist A, 2002, J BIOL CHEM, V277, P23942, DOI 10.1074/jbc.M202756200; Ma JX, 2001, INVEST OPHTH VIS SCI, V42, P1429; Marlhens F, 1997, NAT GENET, V17, P139, DOI 10.1038/ng1097-139; McBee JK, 2001, PROG RETIN EYE RES, V20, P469, DOI 10.1016/S1350-9462(01)00002-7; Moiseyev G, 2005, P NATL ACAD SCI USA, V102, P12413, DOI 10.1073/pnas.0503460102; Moiseyev G, 2003, BIOCHEMISTRY-US, V42, P2229, DOI 10.1021/bi026911y; Morimura H, 1998, P NATL ACAD SCI USA, V95, P3088, DOI 10.1073/pnas.95.6.3088; Petrat F, 2003, J BIOL CHEM, V278, P46403, DOI 10.1074/jbc.M305291200; POLIAKOV E, 2005, IN PRESS J BIOL CHEM; Rando RR, 2001, CHEM REV, V101, P1881, DOI 10.1021/cr960141c; RANDO RR, 1991, BIOCHEMISTRY-US, V30, P595, DOI 10.1021/bi00217a001; Redmond TM, 1998, NAT GENET, V20, P344, DOI 10.1038/3813; Redmond TM, 2005, P NATL ACAD SCI USA, V102, P13658, DOI 10.1073/pnas.0504167102; Redmond TM, 2001, J BIOL CHEM, V276, P6560, DOI 10.1074/jbc.M009030200; Stecher H, 1999, J BIOL CHEM, V274, P8577, DOI 10.1074/jbc.274.13.8577; Takahashi Y, 2005, FEBS LETT, V579, P5414, DOI 10.1016/j.febslet.2005.09.002; Thompson DA, 2003, DEV OPHTHALMOL, V37, P141; Thompson DA, 2000, INVEST OPHTH VIS SCI, V41, P4293; von Lintig J, 2000, J BIOL CHEM, V275, P11915, DOI 10.1074/jbc.275.16.11915; Winston A, 1998, BIOCHEMISTRY-US, V37, P2044, DOI 10.1021/bi971908d; Yan WM, 2001, GENOMICS, V72, P193, DOI 10.1006/geno.2000.6476	36	93	94	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 3	2006	281	5					2835	2840		10.1074/jbc.M508903200	http://dx.doi.org/10.1074/jbc.M508903200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	006XT	16319067	hybrid			2022-12-25	WOS:000234931800051
J	Hanley, WD; Napier, SL; Burdick, MM; Schnaar, RL; Sackstein, R; Konstantopoulos, K				Hanley, William D.; Napier, Susan L.; Burdick, Monica M.; Schnaar, Ronald L.; Sackstein, Robert; Konstantopoulos, Konstantinos			Variant isoforms of CD44 are P- and L-selectin ligands on colon carcinoma cells	FASEB JOURNAL			English	Article									[Hanley, William D.; Napier, Susan L.; Konstantopoulos, Konstantinos] Johns Hopkins Univ, Dept Chem & Biomol Engn, Baltimore, MD 21205 USA; [Konstantopoulos, Konstantinos] Johns Hopkins Univ, Dept Biomed Engn, Baltimore, MD USA; [Schnaar, Ronald L.] Johns Hopkins Univ, Sch Med, Dept Pharmacol, Baltimore, MD 21205 USA; [Burdick, Monica M.; Sackstein, Robert] Brigham & Womens Hosp, Dept Dermatol, Boston, MA 02115 USA; [Sackstein, Robert] Brigham & Womens Hosp, Dept Med, Boston, MA 02115 USA; [Burdick, Monica M.; Sackstein, Robert] Harvard Univ, Sch Med, Harvard Skin Dis Res Ctr, Boston, MA USA; [Sackstein, Robert] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA	Johns Hopkins University; Johns Hopkins University; Johns Hopkins University; Harvard University; Brigham & Women's Hospital; Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School; Harvard University; Dana-Farber Cancer Institute	Konstantopoulos, K (corresponding author), Johns Hopkins Univ, Dept Chem & Biomol Engn, Baltimore, MD 21205 USA.	rsackstein@rics.bwh.harvard.edu; kkonsta1@jhu.edu	Thomas, Susan/B-4592-2016; Schnaar, Ronald L/S-8967-2016; Thomas, Susan/A-9947-2009; Konstantopoulos, Konstantinos/A-7045-2011	Schnaar, Ronald L/0000-0002-7701-5484; Thomas, Susan/0000-0003-4651-232X; Burdick, Monica/0000-0003-3168-0072	NCI NIH HHS [R01 CA 101135] Funding Source: Medline; NHLBI NIH HHS [R01 HL60528, R01 HL073714] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA101135] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL073714, R01HL060528] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))			0	96	105	0	11	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	FEB	2006	20	2					337	339		10.1096/fj.05-4574fje	http://dx.doi.org/10.1096/fj.05-4574fje			3	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	V17CJ	16352650				2022-12-25	WOS:000207915000013
J	Asensio, JG; Maia, C; Ferrer, NL; Barilone, N; Laval, F; Soto, CY; Winter, N; Daffe, M; Gicquel, B; Martin, C; Jackson, M				Asensio, JG; Maia, C; Ferrer, NL; Barilone, N; Laval, F; Soto, CY; Winter, N; Daffe, M; Gicquel, B; Martin, C; Jackson, M			The virulence-associated twocomponent PhoP-PhoR system controls the biosynthesis of polyketide-derived lipids in Mycobacterium tuberculosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUBERCLE BACILLUS; FATTY-ACIDS; GENE; TREHALOSE; STRAINS; ACYLTREHALOSES; DEFICIENCY; SELECTION; H37RV; CELLS	Two-component regulatory signal transduction systems are important elements of the adaptative response of prokaryotes to a variety of environmental stimuli. Disruption of PhoP-PhoR in Mycobacterium tuberculosis dramatically attenuates virulence, implying that this system directly and/or indirectly coordinates the expression of important virulence factors whose identity remains to be established. Interestingly, in knocking-out the PhoP-PhoR two-component system in M. tuberculosis Mt103, dramatic changes in the colonial morphology, cording properties, and reactivity of the mutant strain to the basic dye neutral red, all intrinsic properties of tubercle bacilli known to correlate with virulence, were noted. Because deficiencies in the ability of the mutant to form serpentine cords and stain with the dye are likely the results of alterations of its cell envelope composition, we undertook to analyze the lipid content of phoP and phoP-phoR mutants constructed in two different strains of M. tuberculosis. Our results indicate that PhoP coordinately and positively regulates the synthesis of methyl-branched fatty acid-containing acyltrehaloses known to be restricted to pathogenic species of the M. tuberculosis complex, namely diacyltrehaloses, polyacyltrehaloses, and sulfolipids. Evidence is also provided that PhoP but not PhoR is required for the production of these lipids. This work represents an important step toward the functional characterization of PhoP-PhoR and the understanding of complex lipid synthesis in M. tuberculosis.	Univ Zaragoza, Dept Microbiol Med Prevent & Salud Publ, E-50009 Zaragoza, Spain; Inst Pasteur, Unite Genet Mycobacterienne, F-75724 Paris 15, France; Univ Toulouse 3, Dept Mecan Mol Infect Mycobacteriennes, Inst Pharmacol Biol Struct, UMR 5089,CNRS, F-31077 Toulouse, France	University of Zaragoza; Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Universite de Toulouse; Universite Toulouse III - Paul Sabatier	Jackson, M (corresponding author), Univ Zaragoza, Dept Microbiol Med Prevent & Salud Publ, C Domingo Miral Sin Numero, E-50009 Zaragoza, Spain.	mjackson@pasteur.fr	LAUZERAL-VIZCAINO, Françoise/W-8898-2019; Martin, Carlos/A-7283-2008; Gonzalo-Asensio, Jesús/E-4122-2013; Winter, Nathalie/U-2690-2018; Jackson, Mary/D-5345-2017	LAUZERAL-VIZCAINO, Françoise/0000-0002-9741-3252; Martin, Carlos/0000-0003-2993-5478; Gonzalo-Asensio, Jesús/0000-0001-8841-6593; Winter, Nathalie/0000-0003-0994-7834; Jackson, Mary/0000-0002-9212-0258; Maia, Catarina/0000-0002-3010-6178; Soto Ospina, Carlos Yesid/0000-0001-8694-7489				BESRA GS, 1992, BIOCHEMISTRY-US, V31, P9832, DOI 10.1021/bi00155a040; CASON J, 1956, J BIOL CHEM, V220, P893; Converse SE, 2003, P NATL ACAD SCI USA, V100, P6121, DOI 10.1073/pnas.1030024100; DAFFE M, 1988, EUR J BIOCHEM, V172, P579, DOI 10.1111/j.1432-1033.1988.tb13928.x; Domenech P, 2004, J BIOL CHEM, V279, P21257, DOI 10.1074/jbc.M400324200; Dubey VS, 2002, MOL MICROBIOL, V45, P1451, DOI 10.1046/j.1365-2958.2002.03119.x; DUBOS RJ, 1948, AM REV TUBERC PULM, V58, P698; Fontan PA, 2004, CURR SCI INDIA, V86, P122; Gao LY, 2003, MOL MICROBIOL, V49, P1547, DOI 10.1046/j.1365-2958.2003.03667.x; Gao Q, 2004, TUBERCULOSIS, V84, P188, DOI 10.1016/j.tube.2003.12.013; Gilleron M, 2004, J EXP MED, V199, P649, DOI 10.1084/jem.20031097; Glickman MS, 2000, MOL CELL, V5, P717, DOI 10.1016/S1097-2765(00)80250-6; Goren M. B., 1979, TUBERCULOSIS, P63; GOREN MB, 1990, HDB LIPID RES, V6, P363; Graham JE, 1999, P NATL ACAD SCI USA, V96, P11554, DOI 10.1073/pnas.96.20.11554; Groisman EA, 2001, J BACTERIOL, V183, P1835, DOI 10.1128/JB.183.6.1835-1842.2001; Himpens S, 2000, MICROBIOL-SGM, V146, P3091, DOI 10.1099/00221287-146-12-3091; HOWARD NS, 1995, GENE, V166, P181, DOI 10.1016/0378-1119(95)00597-X; Jackson M, 2001, Methods Mol Med, V54, P59, DOI 10.1385/1-59259-147-7:059; Jackson M, 1999, MOL MICROBIOL, V31, P1573, DOI 10.1046/j.1365-2958.1999.01310.x; Laval F, 2001, ANAL CHEM, V73, P4537, DOI 10.1021/ac0105181; LEMASSU A, 1991, FEMS MICROBIOL LETT, V78, P171, DOI 10.1016/0378-1097(91)90153-2; Lesley JA, 2003, J BACTERIOL, V185, P2563, DOI 10.1128/JB.185.8.2563-2570.2003; Ludwiczak P, 2002, MICROBIOL-SGM, V148, P3029, DOI 10.1099/00221287-148-10-3029; Martin JF, 2004, J BACTERIOL, V186, P5197, DOI 10.1128/JB.186.16.5197-5201.2004; MIDDLEBROOK G, 1947, J EXP MED, V86, P175, DOI 10.1084/jem.86.2.175; MIDDLEBROOK G, 1959, P NATL ACAD SCI USA, V45, P1801, DOI 10.1073/pnas.45.12.1801; MINNIKIN DE, 1985, J GEN MICROBIOL, V131, P1369; MINNIKIN DE, 1982, BIOL MYCOBACTERIA, V1, P95; Perez E, 2001, MOL MICROBIOL, V41, P179, DOI 10.1046/j.1365-2958.2001.02500.x; Reed MB, 2004, NATURE, V431, P84, DOI 10.1038/nature02837; Rousseau C, 2003, INFECT IMMUN, V71, P4684, DOI 10.1128/IAI.71.8.4684-4690.2003; Rousseau C, 2003, CELL MICROBIOL, V5, P405, DOI 10.1046/j.1462-5822.2003.00289.x; Sirakova TD, 2001, J BIOL CHEM, V276, P16833, DOI 10.1074/jbc.M011468200; Sola-Landa A, 2003, P NATL ACAD SCI USA, V100, P6133, DOI 10.1073/pnas.0931429100; Soto CY, 2004, J CLIN MICROBIOL, V42, P212, DOI 10.1128/JCM.42.1.212-219.2004; Soto CY, 2002, J CLIN MICROBIOL, V40, P3021, DOI 10.1128/JCM.40.8.3021-3024.2002	37	157	166	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 20	2006	281	3					1313	1316		10.1074/jbc.C500388200	http://dx.doi.org/10.1074/jbc.C500388200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	002ZS	16326699	Green Published, hybrid			2022-12-25	WOS:000234652000004
J	Hill, M; Pereira, V; Chauveau, C; Zagani, R; Remy, S; Tesson, L; Mazal, D; Ubillos, L; Brion, R; Ashgar, K; Mashreghi, MF; Kotsch, K; Moffett, J; Doebis, C; Seifert, M; Boczkowski, J; Osinaga, E; Anegon, I				Hill, M; Pereira, V; Chauveau, C; Zagani, R; Remy, S; Tesson, L; Mazal, D; Ubillos, L; Brion, R; Ashgar, K; Mashreghi, MF; Kotsch, K; Moffett, J; Doebis, C; Seifert, M; Boczkowski, J; Osinaga, E; Anegon, I			Heme oxygenase-1 inhibits rat and human breast cancer cell proliferation: mutual cross inhibition with indoleamine 2,3-dioxygenase	FASEB JOURNAL			English	Article						HO-1; IDO; breast cancer; apoptosis; proliferation	NITRIC-OXIDE SYNTHASE; SMOOTH-MUSCLE CELLS; DENDRITIC CELLS; TRYPTOPHAN DEGRADATION; EPITHELIAL-CELLS; GENE-TRANSFER; SOLID TUMOR; T-CELLS; EXPRESSION; APOPTOSIS	Heme oxygenase-1 (HO-1) is the rate limiting enzyme of heme catabolism whereas indoleamine 2,3 dioxygenase (IDO) catabolizes tryptophan through the kynurenine pathway. We analyzed the expression and biological effects of these enzymes in rat and human breast cancer cell lines. We show that rat (NMU and 13762) but not human cells (MCF-7 and T47D) express HO-1. When overexpressed, we found this enzyme to have anti-proliferative and proapoptotic effects by antioxidant mechanisms in these four cell lines. We show that IDO is expressed by rat and human breast cancer cells. IDO inhibition with 1-MT and siRNA leads to diminished proliferation in rat cells. In contrast, HO-1 negative human cell lines increase proliferation upon IDO inhibition. Since we also demonstrate that IDO inhibits the anti-proliferative HO-1, we propose that IDO has opposite effects on proliferation depending on the coexpression or not of HO-1. We also describe that HO-1 inhibits IDO at the post-translational level through heme starvation. In vivo, we show that rat normal breast expresses HO-1 and IDO. In contrast, N-nitrosomethylurea-induced breast adenocarcinomas only express IDO. In conclusion, we show that HO-1/IDO cross-regulation modulates apoptosis and proliferation in rat and human breast cancer cells.	INSERM, U643, ITERT, F-44093 Nantes 1, France; Fac Med, Dept Bioquim, Lab Oncol Basica & Biol Mol, Montevideo, Uruguay; Charite Hosp, Inst Med Immunol, Berlin, Germany; Uniformed Serv Univ Hlth Sci, Dept Anat, Bethesda, MD 20814 USA; INSERM, U408, Fac Med Xavier Bichat, Paris, France	Institut National de la Sante et de la Recherche Medicale (Inserm); Universidad de la Republica, Uruguay; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Uniformed Services University of the Health Sciences - USA; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Bichat-Claude Bernard - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite	Anegon, I (corresponding author), INSERM, U643, ITERT, 30 Bv Jean Monnet, F-44093 Nantes 1, France.	ianegon@nantes.inserm.fr	Anegon, Ignacio/I-7760-2018; Kotsch, Katja/AAG-2597-2021; Boczkowski, Jorge/S-7474-2018; Mashreghi, Mir-Farzin/S-2911-2019	Boczkowski, Jorge/0000-0001-6619-5785; Mashreghi, Mir-Farzin/0000-0002-8015-6907; Hill, Marcelo/0000-0002-1589-0320				BLOXAM DL, 1974, ANAL BIOCHEM, V60, P621, DOI 10.1016/0003-2697(74)90275-9; Brouard S, 2000, J EXP MED, V192, P1015, DOI 10.1084/jem.192.7.1015; Brown NS, 2001, BREAST CANCER RES, V3, P323, DOI 10.1186/bcr315; Burdick AD, 2003, CANCER RES, V63, P7825; CADY SG, 1991, ARCH BIOCHEM BIOPHYS, V291, P326, DOI 10.1016/0003-9861(91)90142-6; Chauveau C, 2002, AM J TRANSPLANT, V2, P581, DOI 10.1034/j.1600-6143.2002.20702.x; Chen GG, 2004, J CELL BIOCHEM, V92, P1246, DOI 10.1002/jcb.20157; CHOI SY, 1996, J PARODONTOL IMPLANT, V15, P19; COHEN LA, 1982, IN VITRO CELL DEV B, V18, P565; DRUMMOND GS, 1981, P NATL ACAD SCI-BIOL, V78, P6466, DOI 10.1073/pnas.78.10.6466; Duckers HJ, 2001, NAT MED, V7, P693, DOI 10.1038/89068; Evan GI, 2001, NATURE, V411, P342, DOI 10.1038/35077213; Fallarino F, 2002, INT IMMUNOL, V14, P65, DOI 10.1093/intimm/14.1.65; Fang J, 2003, CANCER RES, V63, P3567; Follenzi A, 2000, NAT GENET, V25, P217, DOI 10.1038/76095; Haider A, 2002, J PHARMACOL EXP THER, V300, P188, DOI 10.1124/jpet.300.1.188; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Hill M, 2004, BREAST CANCER RES TR, V84, P107, DOI 10.1023/B:BREA.0000018407.47909.78; Hwu P, 2000, J IMMUNOL, V164, P3596, DOI 10.4049/jimmunol.164.7.3596; Kampa M, 2004, BREAST CANCER RES, V6, pR63, DOI 10.1186/bcr752; Kaufmann SH, 2003, ONCOGENE, V22, P7414, DOI 10.1038/sj.onc.1206945; Khong HT, 2002, NAT IMMUNOL, V3, P999, DOI 10.1038/ni1102-999; Kudo Y, 2004, HUM REPROD, V19, P1222, DOI 10.1093/humrep/deh218; Lala PK, 2001, LANCET ONCOL, V2, P149, DOI 10.1016/S1470-2045(00)00256-4; Liu XM, 2002, CIRCULATION, V105, P79, DOI 10.1161/hc0102.101369; Liu ZM, 2004, ONCOGENE, V23, P503, DOI 10.1038/sj.onc.1207173; Maines MD, 1997, ANNU REV PHARMACOL, V37, P517, DOI 10.1146/annurev.pharmtox.37.1.517; Mayerhofer M, 2004, CANCER RES, V64, P3148, DOI 10.1158/0008-5472.CAN-03-1200; McDaid J, 2005, FASEB J, V19, P458, DOI 10.1096/fj.04-2217fje; MOFFETT JR, 1993, BRAIN RES, V623, P337, DOI 10.1016/0006-8993(93)91450-7; Munn DH, 2005, IMMUNITY, V22, P633, DOI 10.1016/j.immuni.2005.03.013; Munn DH, 2004, J CLIN INVEST, V114, P280, DOI 10.1172/JCI200421583; Oh GS, 2004, BIOCHEM BIOPH RES CO, V320, P1156, DOI 10.1016/j.bbrc.2004.06.061; Otterbein LE, 2003, TRENDS IMMUNOL, V24, P449, DOI 10.1016/S1471-4906(03)00181-9; Ozawa N, 2002, J CLIN INVEST, V109, P457, DOI [10.1172/JCI0213190, 10.1172/JCI200213190]; Policastro L, 2004, MOL CARCINOGEN, V39, P103, DOI 10.1002/mc.20001; Pozo-Guisado E, 2002, BIOCHEM PHARMACOL, V64, P1375, DOI 10.1016/S0006-2952(02)01296-0; Santen RJ, 2002, J STEROID BIOCHEM, V80, P239, DOI 10.1016/S0960-0760(01)00189-3; Shilkaitis A, 2000, CARCINOGENESIS, V21, P227, DOI 10.1093/carcin/21.2.227; SHIMIZU S, 1988, BIOCHIM BIOPHYS ACTA, V967, P255, DOI 10.1016/0304-4165(88)90017-7; SHIMIZU T, 1978, J BIOL CHEM, V253, P4700; SONG R, 2004, J BIOL CHEM, V279, P4423; SONO M, 1980, J BIOL CHEM, V255, P1339; Sunamura Makoto, 2003, Angiogenesis, V6, P15, DOI 10.1023/A:1025803600840; Taille C, 2004, J BIOL CHEM, V279, P28681, DOI 10.1074/jbc.M310661200; Taille C, 2003, J BIOL CHEM, V278, P27160, DOI 10.1074/jbc.M300364200; TAKIKAWA O, 1988, J BIOL CHEM, V263, P2041; Tanaka S, 2003, BRIT J CANCER, V88, P902, DOI 10.1038/sj.bjc.6600830; Thomas SR, 2001, J IMMUNOL, V166, P6332, DOI 10.4049/jimmunol.166.10.6332; Turcanu V, 1998, RES IMMUNOL, V149, P741, DOI 10.1016/S0923-2494(99)80050-9; Turcanu V, 1998, TRANSPL P, V30, P4184, DOI 10.1016/S0041-1345(98)01385-2; Uyttenhove C, 2003, NAT MED, V9, P1269, DOI 10.1038/nm934; WERNERFELMAYER G, 1989, BIOCHIM BIOPHYS ACTA, V1012, P140, DOI 10.1016/0167-4889(89)90087-6; Xiao BG, 2004, STEROIDS, V69, P653, DOI 10.1016/j.steroids.2004.05.019; Yanagawa T, 2004, ORAL ONCOL, V40, P21, DOI 10.1016/S1368-8375(03)00128-3; YOSHINAGA T, 1982, J BIOL CHEM, V257, P7778; Zhang M, 2002, CELL RES, V12, P123, DOI 10.1038/sj.cr.7290118	57	136	141	0	14	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	DEC	2005	19	14					1957	1968		10.1096/fj.05-3875com	http://dx.doi.org/10.1096/fj.05-3875com			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	999QR	16319139				2022-12-25	WOS:000234405500006
J	Thon, L; Mohlig, H; Mathieu, S; Lange, A; Bulanova, E; Winoto-Morbach, S; Schutze, S; Bulfone-Paus, S; Adam, D				Thon, L; Mohlig, H; Mathieu, S; Lange, A; Bulanova, E; Winoto-Morbach, S; Schutze, S; Bulfone-Paus, S; Adam, D			Ceramide mediates caspase-independent programmed cell death	FASEB JOURNAL			English	Article						tumor necrosis factor; RIP1; mitochondria	TUMOR-NECROSIS-FACTOR; NF-KAPPA-B; INDUCED APOPTOSIS; T-LYMPHOCYTES; INHIBITION; FAS; SPHINGOMYELINASE; CYTOTOXICITY; ACTIVATION; MITOCHONDRIA	Although numerous studies have implicated the sphingolipid ceramide in the induction of cell death, a causative function of ceramide in caspase-dependent apoptosis remains a highly debated issue. Here, we show that ceramide is a key mediator of a distinct route to programmed cell death (PCD), i.e., caspase-independent PCD. Under conditions where apoptosis is either not initiated or actively inhibited, TNF induces caspase-independent PCD in L929 fibrosarcoma cells, NIH3T3 fibroblasts, human leukemic Jurkat T cells, and lung fibroblasts by increasing intracellular ceramide levels prior to the onset of cell death. Survival is significantly enhanced when ceramide accumulation is prevented, as demonstrated in fibroblasts genetically deficient for acid sphingomyelinase, in L929 cells overexpressing acid ceramidase, by pharmacological intervention, or by RNA interference. Jurkat cells deficient for receptor-interacting protein 1 (RIP1) do not accumulate ceramide and therefore are fully resistant to caspase-independent PCD whereas Jurkat cells overexpressing the mitochondrial protein Bcl-2 are partially protected, implicating RIP1 and mitochondria as components of the ceramide death pathway. Our data point to a role of caspases (but not cathepsins) in suppressing the ceramide death pathway under physiological conditions. Moreover, clonogenic survival of tumor cells is clearly reduced by induction of the ceramide death pathway, promising additional options for the development of novel tumor therapies.	Univ Klinikum Schleswig Holstein, Inst Immunol, Kiel, Germany; Forschungszentrum Borstel, Abt Immunol & Zellbiol, Borstel, Germany	University of Kiel; Schleswig Holstein University Hospital; Forschungszentrum Borstel	Adam, D (corresponding author), Univ Klinikum Schleswig Holstein, Inst Immunol, Campus Kiel, Kiel, Germany.	dadam@email.uni-kiel.de	Adam, Dieter/E-9763-2010; Schütze, Stefan/C-8596-2011	Adam, Dieter/0000-0002-5668-5032; 				Armstrong RC, 1996, J BIOL CHEM, V271, P16850, DOI 10.1074/jbc.271.28.16850; Cauwels A, 2003, NAT IMMUNOL, V4, P387, DOI 10.1038/ni914; Dbaibo GS, 2001, FEBS LETT, V503, P7, DOI 10.1016/S0014-5793(01)02625-4; De Maria R, 1998, J EXP MED, V187, P897, DOI 10.1084/jem.187.6.897; Denecker G, 2001, CELL DEATH DIFFER, V8, P829, DOI 10.1038/sj.cdd.4400883; DRESSLER KA, 1990, J BIOL CHEM, V265, P14917; Foghsgaard L, 2001, J CELL BIOL, V153, P999, DOI 10.1083/jcb.153.5.999; Garcia-Calvo M, 1998, J BIOL CHEM, V273, P32608, DOI 10.1074/jbc.273.49.32608; Ghafourifar P, 1999, J BIOL CHEM, V274, P6080, DOI 10.1074/jbc.274.10.6080; Grassme H, 2000, SCIENCE, V290, P527, DOI 10.1126/science.290.5491.527; HENNET T, 1993, CANCER RES, V53, P1456; Hofmann K, 1998, TRENDS BIOCHEM SCI, V23, P374, DOI 10.1016/S0968-0004(98)01289-4; Holland GN, 2000, OCUL IMMUNOL INFLAMM, V8, P1, DOI 10.1076/0927-3948(200003)8:1;1-S;FT001; HURWITZ R, 1994, BIOL CHEM H-S, V375, P447, DOI 10.1515/bchm3.1994.375.7.447; Jaattela M, 2003, NAT IMMUNOL, V4, P416, DOI 10.1038/ni0503-416; Jensen JM, 1999, J CLIN INVEST, V104, P1761, DOI 10.1172/JCI5307; Johnstone RW, 2002, CELL, V108, P153, DOI 10.1016/S0092-8674(02)00625-6; Jones BE, 1999, HEPATOLOGY, V30, P215, DOI 10.1002/hep.510300146; Juo P, 1999, CELL GROWTH DIFFER, V10, P797; Kolesnick R, 2002, J CLIN INVEST, V110, P3, DOI 10.1172/JCI200216127; Kolesnick R, 1999, TRENDS BIOCHEM SCI, V24, P224, DOI 10.1016/S0968-0004(99)01408-5; Kolesnick RN, 1998, ANNU REV PHYSIOL, V60, P643, DOI 10.1146/annurev.physiol.60.1.643; Koonin EV, 2002, CELL DEATH DIFFER, V9, P394, DOI 10.1038/sj.cdd.4400991; Leist M, 2001, NAT REV MOL CELL BIO, V2, P589, DOI 10.1038/35085008; Luschen S, 2000, J BIOL CHEM, V275, P24670, DOI 10.1074/jbc.M003280200; Maurer BJ, 2000, JNCI-J NATL CANCER I, V92, P1897, DOI 10.1093/jnci/92.23.1897; Mengubas K, 1999, EXP CELL RES, V249, P116, DOI 10.1006/excr.1999.4474; Metkar SS, 2000, EXP CELL RES, V255, P18, DOI 10.1006/excr.1999.4773; Perry DK, 1999, TRENDS BIOCHEM SCI, V24, P226, DOI 10.1016/S0968-0004(99)01407-3; Pettus BJ, 2002, BBA-MOL CELL BIOL L, V1585, P114, DOI 10.1016/S1388-1981(02)00331-1; Pirianov G, 2001, MOL CELL ENDOCRINOL, V172, P69, DOI 10.1016/S0303-7207(00)00380-4; Ramos B, 2003, MOL PHARMACOL, V64, P502, DOI 10.1124/mol.64.2.502; Reynolds CP, 2004, CANCER LETT, V206, P169, DOI 10.1016/j.canlet.2003.08.034; Sanchenkov A, 2001, JNCI-J NATL CANCER I, V93, P347, DOI 10.1093/jnci/93.5.347; Santana P, 1996, CELL, V86, P189, DOI 10.1016/S0092-8674(00)80091-4; SCHUERMANN M, 1990, NUCLEIC ACIDS RES, V18, P4945, DOI 10.1093/nar/18.16.4945; SCHUTZE S, 1992, CELL, V71, P765, DOI 10.1016/0092-8674(92)90553-O; Strelow A, 2000, J EXP MED, V192, P601, DOI 10.1084/jem.192.5.601; Tanaka M, 1997, J AM CHEM SOC, V119, P7871, DOI 10.1021/ja9713385; Ting AT, 1996, EMBO J, V15, P6189, DOI 10.1002/j.1460-2075.1996.tb01007.x; Vanden Berghe T, 2004, J BIOL CHEM, V279, P7925, DOI 10.1074/jbc.M307807200; Vanden Berghe T, 2003, J BIOL CHEM, V278, P5622, DOI 10.1074/jbc.M208925200; Vercammen D, 1998, J EXP MED, V187, P1477, DOI 10.1084/jem.187.9.1477; WANG E, 1991, J BIOL CHEM, V266, P14486; WIEGMANN K, 1994, CELL, V78, P1005, DOI 10.1016/0092-8674(94)90275-5; Yu L, 2004, SCIENCE, V304, P1500, DOI 10.1126/science.1096645; Zhao S, 2004, J CELL PHYSIOL, V199, P47, DOI 10.1002/jcp.10453	47	107	113	0	8	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	DEC	2005	19	14					1945	1956		10.1096/fj.05-3726com	http://dx.doi.org/10.1096/fj.05-3726com			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	999QR	16319138				2022-12-25	WOS:000234405500005
J	Gandhi, M; Medvedovic, M; Stringer, JR; Nikiforov, YE				Gandhi, M; Medvedovic, M; Stringer, JR; Nikiforov, YE			Interphase chromosome folding determines spatial proximity of genes participating in carcinogenic RET/PTC rearrangements	ONCOGENE			English	Article						chromosomal rearrangements; thyroid cancer; RET/ PTC; nuclear architecture	PAPILLARY THYROID CARCINOMAS; NUCLEAR ARCHITECTURE; RET PROTOONCOGENE; HUMAN-CELLS; CANCER; RADIATION; MODEL; ACTIVATION; FUSION; LOOPS	Recurrent chromosomal rearrangements are common in cancer cells and may be influenced by nonrandom positioning of recombination-prone genetic loci in the nucleus. However, the mechanism responsible for spatial proximity of specific loci is unknown. In this study, we use an 18Mb region on 10q11.2-21 containing the RET gene and its recombination partners, the H4 and NCOA4 (ELE1) genes, as a model chromosomal region frequently involved in RET/PTC rearrangements in thyroid cancer. RET/PTC is particularly common in tumors from children exposed to ionizing radiation. Using fluorescence in situ hybridization and three-dimensional microscopy, the locations of. five different loci in this region were mapped in interphase nuclei of normal human thyroid cells. We show that RET and NCOA4 are much closer to each other than expected based on their genomic separation. Modeling of chromosome folding in this region suggests the presence of chromosome coiling with coils of similar to 8Mb in length, which positions the RET gene close to both, the NCOA4 and H4, loci. There was no significant variation in gene proximity between adult and pediatric thyroid cells. This study provides evidence for large-scale chromosome folding of the 10q11.2-21 region that offers a structural basis for nonrandom positioning and spatial proximity of potentially recombinogenic intrachromosomal loci.	Univ Cincinnati, Coll Med, Dept Pathol & Lab Med, Cincinnati, OH 45267 USA; Univ Cincinnati, Coll Med, Ctr Biostat Serv, Cincinnati, OH 45267 USA; Univ Cincinnati, Coll Med, Dept Mol Genet, Cincinnati, OH 45267 USA; Childrens Hosp Res Fdn, Div Biomed Informat, Cincinnati, OH 45229 USA	University System of Ohio; University of Cincinnati; University System of Ohio; University of Cincinnati; University System of Ohio; University of Cincinnati; Cincinnati Children's Hospital Medical Center; Cincinnati Children's Hospital Research Foundation	Nikiforov, YE (corresponding author), Univ Cincinnati, Dept Pathol, 231 Albert Sabin Way, Cincinnati, OH 45267 USA.	Yuri.Nikiforov@uc.edu			NCI NIH HHS [CA88041] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA088041] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BELMONT AS, 1994, J CELL BIOL, V127, P287, DOI 10.1083/jcb.127.2.287; BONGARZONE I, 1994, CANCER RES, V54, P2979; Ciampi R, 2005, J CLIN INVEST, V115, P94, DOI 10.1172/JCI200523237; Cornforth MN, 2002, J CELL BIOL, V159, P237, DOI 10.1083/jcb.200206009; Cremer C, 1996, MUTAT RES-REV GENET, V366, P97, DOI 10.1016/S0165-1110(96)90031-7; Cremer T, 2001, NAT REV GENET, V2, P292, DOI 10.1038/35066075; Futreal PA, 2004, NAT REV CANCER, V4, P177, DOI 10.1038/nrc1299; GRIECO M, 1990, CELL, V60, P557, DOI 10.1016/0092-8674(90)90659-3; Kozubek S, 1997, BLOOD, V89, P4537, DOI 10.1182/blood.V89.12.4537; MANTON I, 1950, BIOL REV, V25, P486, DOI 10.1111/j.1469-185X.1950.tb00770.x; MANUELIDIS L, 1990, CYTOMETRY, V11, P8, DOI 10.1002/cyto.990110104; MANUELIDIS L, 1990, SCIENCE, V250, P1533, DOI 10.1126/science.2274784; Munkel C, 1999, J MOL BIOL, V285, P1053, DOI 10.1006/jmbi.1998.2361; Nikiforov YE, 2002, ENDOCR PATHOL, V13, P3, DOI 10.1385/EP:13:1:03; Nikiforova MN, 2000, SCIENCE, V290, P138, DOI 10.1126/science.290.5489.138; ONHUKI Y, 1965, NATURE, V208, P916; Parada LA, 2002, CURR BIOL, V12, P1692, DOI 10.1016/S0960-9822(02)01166-1; Rabes HM, 2000, CLIN CANCER RES, V6, P1093; RATTNER JB, 1985, CELL, V42, P291, DOI 10.1016/S0092-8674(85)80124-0; Roccato E, 2005, CANCER RES, V65, P2572, DOI 10.1158/0008-5472.CAN-04-4294; Roix JJ, 2003, NAT GENET, V34, P287, DOI 10.1038/ng1177; RON E, 1995, RADIAT RES, V141, P259, DOI 10.2307/3579003; SACHS RK, 1995, P NATL ACAD SCI USA, V92, P2710, DOI 10.1073/pnas.92.7.2710; SANTORO M, 1994, ONCOGENE, V9, P509; SHORE RE, 1992, RADIAT RES, V131, P98, DOI 10.2307/3578322; SUMNER AT, 1991, CHROMOSOMA, V100, P410, DOI 10.1007/BF00337519; YOKOTA H, 1995, J CELL BIOL, V130, P1239, DOI 10.1083/jcb.130.6.1239	27	55	57	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 13	2006	25	16					2360	2366		10.1038/sj.onc.1209268	http://dx.doi.org/10.1038/sj.onc.1209268			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	032HC	16331264				2022-12-25	WOS:000236764300008
J	Sridhar, SC; Miranti, CK				Sridhar, SC; Miranti, CK			Tetraspanin KAI1/CD82 suppresses invasion by inhibiting integrin-dependent crosstalk with c-Met receptor and Src kinases	ONCOGENE			English	Review						tetraspanin; integrin; c-Met; HGF; metastasis	HEPATOCYTE GROWTH-FACTOR; PROSTATE-CANCER CELLS; FOCAL ADHESION KINASE; FREQUENT DOWN-REGULATION; METASTASIS-SUPPRESSOR; TRANSMEMBRANE-4 SUPERFAMILY; GENE-EXPRESSION; EGF RECEPTOR; LUNG-CANCER; ALPHA-6-BETA-4 INTEGRIN	KAI1/CD82, a tetraspanin protein, was. first identified as a metastasis suppressor in prostate cancer. How loss of CD82 expression promotes cancer metastasis is unknown. Restoration of CD82 expression to physiological levels in the metastatic prostate cell line PC3 inhibits integrinmediated cell migration and invasion, but does not affect integrin expression. Integrin-dependent activation of the receptor kinase c-Met is dramatically reduced in CD82expressing cells, as is c-Met activation by its ligand HGF/SF. CD82 expression also reduced integrin-induced activation and phosphorylation of the cytoplasmic tyrosine kinase Src, and its downstream substrates p130Cas and FAK Y861. Inhibition of c-Met expression or Src kinase function reduced matrigel invasion of PC3 cells to the same extent as CD82 expression. These data indicate that CD82 functions to suppress integrin-induced invasion by regulating signaling to c-Met and Src kinases, and suggests that CD82 loss may promote metastasis by removing a negative regulator of c-Met and Src signaling.	Van Andel Res Inst, Lab Integrin Signaling & Tumorigenesis, Grand Rapids, MI 49503 USA	Van Andel Institute	Miranti, CK (corresponding author), Van Andel Res Inst, Lab Integrin Signaling & Tumorigenesis, 333 Bostwick Ave NE, Grand Rapids, MI 49503 USA.	cindy.miranti@vai.org	Miranti, Cindy/AAJ-3783-2020					Adachi M, 1996, CANCER RES, V56, P1751; Berditchevski F, 1999, J CELL BIOL, V146, P477, DOI 10.1083/jcb.146.2.477; Berditchevski F, 2001, J CELL SCI, V114, P4143; Bill HM, 2004, MOL CELL BIOL, V24, P8586, DOI 10.1128/MCB.24.19.8586-8599.2004; Birchmeier C, 2003, NAT REV MOL CELL BIO, V4, P915, DOI 10.1038/nrm1261; Birchmeier W, 1997, CIBA F SYMP, V212, P230; Blake RA, 2000, MOL CELL BIOL, V20, P9018, DOI 10.1128/MCB.20.23.9018-9027.2000; Bouchard P, 2001, ORG DIVERS EVOL, V1, P17, DOI 10.1078/1439-6092-00003; Boucheix C, 2001, CELL MOL LIFE SCI, V58, P1189, DOI 10.1007/PL00000933; Brader S, 2004, TUMORI J, V90, P2, DOI 10.1177/030089160409000102; Brunton VG, 2005, CANCER RES, V65, P1335, DOI 10.1158/0008-5472.CAN-04-1949; Cannon KS, 2001, EMBO J, V20, P2443, DOI 10.1093/emboj/20.10.2443; Cary LA, 1998, J CELL BIOL, V140, P211, DOI 10.1083/jcb.140.1.211; Chung J, 2004, J BIOL CHEM, V279, P32287, DOI 10.1074/jbc.M403809200; Clezardin P, 1998, CELL MOL LIFE SCI, V54, P541, DOI 10.1007/s000180050182; Danilkovitch-Miagkova A, 2000, J BIOL CHEM, V275, P14783, DOI 10.1074/jbc.C000028200; Davies G, 2004, PROSTATE, V60, P317, DOI 10.1002/pros.20068; Davis TL, 2001, PROSTATE, V46, P240; De Miguel MP, 1999, CYTOKINE, V11, P722, DOI 10.1006/cyto.1998.0443; Di Lorenzo D, 2002, ENDOCRINOLOGY, V143, P4544, DOI 10.1210/en.2002-220448; Dong Jin-Tang, 1997, Current Opinion in Oncology, V9, P101; DONG JT, 1995, SCIENCE, V268, P884, DOI 10.1126/science.7754374; Dong JT, 1996, CANCER RES, V56, P4387; FIXMAN ED, 1995, ONCOGENE, V10, P237; Frame MC, 2004, J CELL SCI, V117, P989, DOI 10.1242/jcs.01111; Guo XZ, 1996, CANCER RES, V56, P4876; Hammond C, 1998, J IMMUNOL, V161, P3282; Hauck CR, 2002, EMBO J, V21, P6289, DOI 10.1093/emboj/cdf631; Hay RV, 2003, CLIN CANCER RES, V9, p3839S; He B, 2005, J BIOL CHEM, V280, P3346, DOI 10.1074/jbc.M406680200; Hemler ME, 2001, J CELL BIOL, V155, P1103, DOI 10.1083/jcb.200108061; Hemler ME, 1998, CURR OPIN CELL BIOL, V10, P578, DOI 10.1016/S0955-0674(98)80032-X; Hemler ME, 2003, ANNU REV CELL DEV BI, V19, P397, DOI 10.1146/annurev.cellbio.19.111301.153609; HIGASHIYAMA M, 1995, CANCER RES, V55, P6040; Hsia DA, 2003, J CELL BIOL, V160, P753, DOI 10.1083/jcb.200212114; Huang CI, 1998, AM J PATHOL, V153, P973, DOI 10.1016/S0002-9440(10)65639-8; HUMPHREY PA, 1995, AM J PATHOL, V147, P386; IMAI T, 1995, J IMMUNOL, V155, P1229; Jee B, 2003, EXP MOL MED, V35, P30, DOI 10.1038/emm.2003.5; Kim SJ, 2003, CLIN CANCER RES, V9, P5161; Klemke RL, 1998, J CELL BIOL, V140, P961, DOI 10.1083/jcb.140.4.961; Knudsen BS, 2004, ADV CANCER RES, V91, P31, DOI 10.1016/S0065-230X(04)91002-0; Knudsen BS, 2002, UROLOGY, V60, P1113, DOI 10.1016/S0090-4295(02)01954-4; Lagaudriere-Gesbert C, 1998, EUR J IMMUNOL, V28, P4332, DOI 10.1002/(SICI)1521-4141(199812)28:12<4332::AID-IMMU4332>3.0.CO;2-8; Lee CC, 2004, ONCOGENE, V23, P5193, DOI 10.1038/sj.onc.1207646; Lee JH, 2004, CANCER RES, V64, P4235, DOI 10.1158/0008-5472.CAN-04-0275; LIPSICH LA, 1983, J VIROL, V48, P352, DOI 10.1128/JVI.48.2.352-360.1983; Liu FS, 2000, GYNECOL ONCOL, V78, P10, DOI 10.1006/gyno.2000.5801; Liu FS, 2001, AM J PATHOL, V159, P1629, DOI 10.1016/S0002-9440(10)63009-X; Liu L, 2003, WORLD J GASTROENTERO, V9, P1231, DOI 10.3748/wjg.v9.i6.1231; Lombardi DP, 1999, CANCER RES, V59, P5724; Maecker HT, 1997, FASEB J, V11, P428, DOI 10.1096/fasebj.11.6.9194523; Maggiora P, 1997, J CELL PHYSIOL, V173, P183, DOI 10.1002/(SICI)1097-4652(199711)173:2<183::AID-JCP18>3.3.CO;2-Y; Mannion BA, 1996, J IMMUNOL, V157, P2039; MAYGARDEN SJ, 1992, ARCH PATHOL LAB MED, V116, P269; Miranti CK, 2002, METHOD CELL BIOL, V69, P359, DOI 10.1016/S0091-679X(02)69023-5; Miranti CK, 2002, NAT CELL BIOL, V4, pE83, DOI 10.1038/ncb0402-e83; Miyazaki T, 2000, CANCER-AM CANCER SOC, V89, P955, DOI 10.1002/1097-0142(20000901)89:5<955::AID-CNCR3>3.0.CO;2-Z; Mora LB, 2002, CANCER RES, V62, P6659; Moro L, 1998, EMBO J, V17, P6622, DOI 10.1093/emboj/17.22.6622; Moro L, 2002, J BIOL CHEM, V277, P9405, DOI 10.1074/jbc.M109101200; Nakaigawa N, 2000, ONCOGENE, V19, P2996, DOI 10.1038/sj.onc.1203628; Nakashiro K, 2003, ONCOL REP, V10, P1149; Nishimura K, 1999, PROSTATE, V41, P145; Nishimura K, 1998, Int J Urol, V5, P276, DOI 10.1111/j.1442-2042.1998.tb00603.x; Odintsova E, 2000, CURR BIOL, V10, P1009, DOI 10.1016/S0960-9822(00)00652-7; Odintsova E, 2003, J CELL SCI, V116, P4557, DOI 10.1242/jcs.00793; Ono M, 2000, BIOCHEM BIOPH RES CO, V279, P744, DOI 10.1006/bbrc.2000.4030; Owens DM, 2001, CANCER RES, V61, P5248; Perlino E, 2000, AM J PATHOL, V157, P1727, DOI 10.1016/S0002-9440(10)64809-2; PISTERS LL, 1995, J UROLOGY, V154, P293, DOI 10.1016/S0022-5347(01)67297-5; PONZETTO C, 1994, CELL, V77, P261, DOI 10.1016/0092-8674(94)90318-2; RADFORD KJ, 1995, INT J CANCER, V62, P631, DOI 10.1002/ijc.2910620523; Rahimi N, 1998, J BIOL CHEM, V273, P33714, DOI 10.1074/jbc.273.50.33714; RONG S, 1992, MOL CELL BIOL, V12, P5152, DOI 10.1128/MCB.12.11.5152; Schmelz M, 2002, NEOPLASIA, V4, P243, DOI 10.1038/sj.neo.7900223; Schoenfeld N, 2004, FASEB J, V18, P158, DOI 10.1096/fj.03-0420fje; Shinomiya N, 2004, CANCER RES, V64, P7962, DOI 10.1158/0008-5472.CAN-04-1043; Sieg DJ, 2000, NAT CELL BIOL, V2, P249, DOI 10.1038/35010517; Skacel M, 2001, HUM PATHOL, V32, P1392, DOI 10.1053/hupa.2001.29676; SRIDHAR SC, 2005, IN PRESS; Sundberg C, 1996, J CELL BIOL, V132, P741, DOI 10.1083/jcb.132.4.741; Takaoka A, 1998, ONCOGENE, V16, P1443, DOI 10.1038/sj.onc.1201648; Tamura M, 1999, JNCI-J NATL CANCER I, V91, P1820, DOI 10.1093/jnci/91.21.1820; Testa JE, 1999, CANCER RES, V59, P3812; Timpson P, 2001, CURR BIOL, V11, P1836, DOI 10.1016/S0960-9822(01)00583-8; Tokuhara T, 2001, CLIN CANCER RES, V7, P4109; Trusolino L, 2001, CELL, V107, P643, DOI 10.1016/S0092-8674(01)00567-0; Uchida S, 1999, BRIT J CANCER, V79, P1168, DOI 10.1038/sj.bjc.6690186; van Leenders G, 2002, PROSTATE, V51, P98, DOI 10.1002/pros.10073; Vogt AB, 2002, IMMUNOL REV, V189, P136, DOI 10.1034/j.1600-065X.2002.18912.x; Vuori K, 1996, MOL CELL BIOL, V16, P2606; Wang R, 1996, P NATL ACAD SCI USA, V93, P8425, DOI 10.1073/pnas.93.16.8425; Wang R, 2001, J CELL BIOL, V153, P1023, DOI 10.1083/jcb.153.5.1023; Westhoff MA, 2004, MOL CELL BIOL, V24, P8113, DOI 10.1128/MCB.24.18.8113-8133.2004; White A, 1998, ONCOGENE, V16, P3143, DOI 10.1038/sj.onc.1201852; Wu De-hua, 2003, Di Yi Jun Yi Da Xue Xue Bao, V23, P714; Yu Y, 1997, CLIN CANCER RES, V3, P1045; Yunta M, 2003, CELL SIGNAL, V15, P559, DOI 10.1016/S0898-6568(02)00147-X; Zhang XA, 2003, CANCER RES, V63, P2665; Zhang XA, 2003, J BIOL CHEM, V278, P27319, DOI 10.1074/jbc.M303039200; Zhang XA, 2001, J BIOL CHEM, V276, P25005, DOI 10.1074/jbc.M102156200	102	130	140	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 13	2006	25	16					2367	2378		10.1038/sj.onc.1209269	http://dx.doi.org/10.1038/sj.onc.1209269			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	032HC	16331263				2022-12-25	WOS:000236764300009
J	Lahne, HU; Kloster, MM; Lefdal, S; Blomhoff, HK; Naderi, S				Lahne, HU; Kloster, MM; Lefdal, S; Blomhoff, HK; Naderi, S			Degradation of cyclin D3 independent of Thr-283 phosphorylation	ONCOGENE			English	Article						okadaic acid; cyclin D3; degradation; phosphorylation	PHOSPHATIDYLINOSITOL 3-KINASE; RETINOBLASTOMA PROTEIN; DEPENDENT DEGRADATION; DOWN-REGULATION; CDK INHIBITORS; D1 EXPRESSION; OKADAIC ACID; PROGRESSION; PATHWAY; ARREST	Cyclin D3 has been shown to play a major role in the regulation of cell cycle progression in lymphocytes. It is therefore important to understand the mechanisms involved in the regulation of this protein. We have previously shown that both basal and cAMP-induced degradation of cyclin D3 in Reh cells is dependent on Thr-283 phosphorylation by glycogen synthase kinase-3 beta (GSK-3 beta). We now provide evidence of an alternative mechanism being involved in the regulation of cyclin D3 degradation. Treatment of lymphoid cells with okadaic acid (OA), an inhibitor of protein phosphatases 1 and 2A (PP1 and PP2A), induces rapid phosphorylation and proteasomal degradation of cyclin D3. This degradation is not inhibited by the GSK-3 beta inhibitors lithium or Kenpaullone, or by substitution of Thr-283 with Ala on cyclin D3, indicating that cyclin D3 can be degraded independently of Thr-283 phosphorylation and GSK-3 beta activity. Interestingly, in vitro experiments revealed that PP1, but not PP2A, was able to dephosphorylate cyclin D3 efficiently, and PP1 was found to associate with His-tagged cyclin D3. These results support the hypothesis that PP1 constitutively keeps cyclin D3 in a stable, dephosphorylated state, and that treatment of cells with OA leads to phosphorylation and degradation of cyclin D3 through inhibition of PP1.	Univ Oslo, Inst Basic Med Sci, Dept Biochem, N-0317 Oslo, Norway	University of Oslo	Naderi, S (corresponding author), Univ Oslo, Inst Basic Med Sci, Dept Biochem, POB 1112, N-0317 Oslo, Norway.	soheil.naderi@basalmed.uio.no						Aktas H, 1997, MOL CELL BIOL, V17, P3850, DOI 10.1128/MCB.17.7.3850; ANDO K, 1993, P NATL ACAD SCI USA, V90, P9571, DOI 10.1073/pnas.90.20.9571; Bakiri L, 2000, EMBO J, V19, P2056, DOI 10.1093/emboj/19.9.2056; BALDIN V, 1993, GENE DEV, V7, P812, DOI 10.1101/gad.7.5.812; Bartkova J, 1998, ONCOGENE, V17, P1027, DOI 10.1038/sj.onc.1202016; Bergsagel PL, 2005, BLOOD, V106, P296, DOI 10.1182/blood-2005-01-0034; BIALOJAN C, 1988, BIOCHEM J, V256, P283, DOI 10.1042/bj2560283; Bollen M, 2002, TRENDS CELL BIOL, V12, P138, DOI 10.1016/S0962-8924(01)02247-4; Boonen GJJC, 1999, J BIOL CHEM, V274, P34676, DOI 10.1074/jbc.274.49.34676; Brown K, 1997, MOL CELL BIOL, V17, P3021, DOI 10.1128/MCB.17.6.3021; Casanovas O, 2004, ONCOGENE, V23, P7537, DOI 10.1038/sj.onc.1208040; COHEN P, 1990, TRENDS BIOCHEM SCI, V15, P98, DOI 10.1016/0968-0004(90)90192-E; Deng XB, 2003, J BIOL CHEM, V278, P41347, DOI 10.1074/jbc.M306780200; Diehl JA, 1997, GENE DEV, V11, P957, DOI 10.1101/gad.11.8.957; FERNANDEZ A, 1992, J CELL BIOL, V116, P1421, DOI 10.1083/jcb.116.6.1421; Filipits M, 2002, CLIN CANCER RES, V8, P729; Germain D, 2000, J BIOL CHEM, V275, P12074, DOI 10.1074/jbc.275.16.12074; Gutzkow KB, 2003, CELL SIGNAL, V15, P871, DOI 10.1016/S0898-6568(03)00038-X; Hall M, 1996, ADV CANCER RES, V68, P67, DOI 10.1016/S0065-230X(08)60352-8; Hu XT, 2002, J BIOL CHEM, V277, P16528, DOI 10.1074/jbc.M109929200; Kornitzer D, 2000, J CELL PHYSIOL, V182, P1, DOI 10.1002/(SICI)1097-4652(200001)182:1<1::AID-JCP1>3.0.CO;2-V; Ma Y, 2005, CANCER RES, V65, P6476, DOI 10.1158/0008-5472.CAN-05-0370; MATSUSHIME H, 1992, CELL, V71, P323, DOI 10.1016/0092-8674(92)90360-O; MIYATAKE S, 1995, J EXP MED, V182, P401, DOI 10.1084/jem.182.2.401; Muise-Helmericks RC, 1998, J BIOL CHEM, V273, P29864, DOI 10.1074/jbc.273.45.29864; Naderi S, 2000, EUR J IMMUNOL, V30, P1757, DOI 10.1002/1521-4141(200006)30:6<1757::AID-IMMU1757>3.0.CO;2-N; Naderi S, 2004, J CELL SCI, V117, P3769, DOI 10.1242/jcs.01210; Oliver C.J., 1998, FRONT BIOSCI, V3, P961; QUELLE DE, 1993, GENE DEV, V7, P1559, DOI 10.1101/gad.7.8.1559; Rechsteiner M, 1996, TRENDS BIOCHEM SCI, V21, P267, DOI 10.1016/S0968-0004(96)10031-1; ROGERS S, 1986, SCIENCE, V234, P364, DOI 10.1126/science.2876518; SHERR CJ, 1993, CELL, V73, P1059, DOI 10.1016/0092-8674(93)90636-5; Sherr CJ, 1999, GENE DEV, V13, P1501, DOI 10.1101/gad.13.12.1501; SHERR CJ, 1994, CELL, V79, P551, DOI 10.1016/0092-8674(94)90540-1; Shtutman M, 1999, P NATL ACAD SCI USA, V96, P5522, DOI 10.1073/pnas.96.10.5522; Singer JD, 1999, GENE DEV, V13, P2375, DOI 10.1101/gad.13.18.2375; Takuwa N, 1999, MOL CELL BIOL, V19, P1346; Tao GZ, 2002, J BIOL CHEM, V277, P19295, DOI 10.1074/jbc.M109654200; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; Won KA, 1996, EMBO J, V15, P4182, DOI 10.1002/j.1460-2075.1996.tb00793.x; Yan Y, 1999, J BIOL CHEM, V274, P31917, DOI 10.1074/jbc.274.45.31917; Zou YL, 2004, J BIOL CHEM, V279, P27790, DOI 10.1074/jbc.M403042200	42	8	8	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR	2006	25	17					2468	2476		10.1038/sj.onc.1209278	http://dx.doi.org/10.1038/sj.onc.1209278			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	034RJ	16331257				2022-12-25	WOS:000236948000005
J	Fu, ZJ; Runquist, JA; Forouhar, F; Hussain, M; Hunt, JF; Miziorko, HM; Kim, JJP				Fu, ZJ; Runquist, JA; Forouhar, F; Hussain, M; Hunt, JF; Miziorko, HM; Kim, JJP			Crystal structure of human 3-hydroxy-3-methylglutaryl-CoA lyase - Insights into catalysis and the molecular basis for hydroxymethylglutaric aciduria	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COENZYME-A LYASE; POINT MUTATIONS; ACETYL-COENZYME; MALATE SYNTHASE; ENZYME; DEFICIENCY; IDENTIFICATION; SENSITIVITY; MECHANISM; PRODUCE	3-Hydroxy-3-methylglutaryl-CoA (HMG-CoA) lyase is a key enzyme in the ketogenic pathway that supplies metabolic fuel to extrahepatic tissues. Enzyme deficiency may be due to a variety of human mutations and can be fatal. Diminished activity has been explained based on analyses of recombinant human mutant proteins or, more recently, in the context of structural models for the enzyme. We report the experimental determination of a crystal structure at 2.1 angstrom resolution of the recombinant human mitochondrial HMG-CoA lyase containing a bound activator cation and the dicarboxylic acid 3-hydroxyglutarate. The enzyme adopts a (beta alpha)(8) barrel fold, and the N-terminal barrel end is occluded. The structure of a physiologically relevant dimer suggests that substrate access to the active site involves binding across the cavity located at the C-terminal end of the barrel. An alternative hypothesis that involves substrate insertion through a pore proposed to extend through the barrel is not compatible with the observed structure. The activator cation ligands included Asn(275), Asp(42), His(233), and His(235); the latter three residues had been implicated previously as contributing to metal binding or enzyme activity. Arg(41), previously shown to have a major effect on catalytic efficiency, is also located at the active site. In the observed structure, this residue interacts with a carboxyl group of 3-hydroxyglutarate, the hydrolysis product of the competitive inhibitor 3-hydroxyglutaryl-CoA required for crystallization of human enzyme. The structure provides a rationale for the decrease in enzyme activity due to clinical mutations, including H233R, R41Q, D42H, and D204N, that compromise active site function or enzyme stability.	Med Coll Wisconsin, Dept Biochem, Milwaukee, WI 53226 USA; Columbia Univ, Dept Biol Sci, New York, NY 10027 USA; Univ Missouri, Sch Biol Sci, Div Mol Biol & Biochem, Kansas City, MO 64110 USA	Medical College of Wisconsin; Columbia University; University of Missouri System; University of Missouri Kansas City	Kim, JJP (corresponding author), Med Coll Wisconsin, Dept Biochem, 8701 Watertown Plank Rd, Milwaukee, WI 53226 USA.	jjkim@mcw.edu			NCRR NIH HHS [S10 RR 017929, RR 07707] Funding Source: Medline; NIDDK NIH HHS [DK 21491] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [S10RR017929] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK021491, R01DK021491] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Anstrom DM, 2003, PROTEIN SCI, V12, P1822, DOI 10.1110/ps.03174303; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; BANNER DW, 1975, NATURE, V255, P609, DOI 10.1038/255609a0; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Casals N, 2003, J BIOL CHEM, V278, P29016, DOI 10.1074/jbc.M304276200; COON MJ, 1955, AMINO ACID METABOLIS, P431; Forouhar F, 2006, J BIOL CHEM, V281, P7533, DOI 10.1074/jbc.M507996200; GIBSON KM, 1988, EUR J PEDIATR, V148, P180, DOI 10.1007/BF00441397; HIGGINS MJP, 1972, ENZYMES, V2, P407; HRUZ PW, 1992, BIOCHEMISTRY-US, V31, P6842, DOI 10.1021/bi00144a026; HRUZ PW, 1992, PROTEIN SCI, V1, P1144, DOI 10.1002/pro.5560010908; Koon N, 2004, P NATL ACAD SCI USA, V101, P8295, DOI 10.1073/pnas.0400820101; KRAMER PR, 1980, J BIOL CHEM, V255, P1023; KRAMER PR, 1983, BIOCHEMISTRY-US, V22, P2353, DOI 10.1021/bi00279a008; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Mancia F, 1996, STRUCTURE, V4, P339, DOI 10.1016/S0969-2126(96)00037-8; Manjasetty BA, 2003, P NATL ACAD SCI USA, V100, P6992, DOI 10.1073/pnas.1236794100; MATTHEWS BW, 1968, J MOL BIOL, V33, P491, DOI 10.1016/0022-2836(68)90205-2; MITCHELL GA, 1993, J BIOL CHEM, V268, P4376; Mitchell GA, 1998, BIOCHEM SOC T, V26, P136, DOI 10.1042/bst0260136; Mitchell GA, 1998, AM J HUM GENET, V62, P295, DOI 10.1086/301730; Muroi J, 2000, HUM GENET, V107, P320, DOI 10.1007/s004390000363; NICHOLLS A, 1993, BIOPHYS J, V64, pA166; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; REMINGTON S, 1982, J MOL BIOL, V158, P111, DOI 10.1016/0022-2836(82)90452-1; Roberts JR, 1997, BIOCHEMISTRY-US, V36, P7594, DOI 10.1021/bi970207d; ROBERTS JR, 1994, J BIOL CHEM, V269, P17841; Roberts JR, 1996, J BIOL CHEM, V271, P24604, DOI 10.1074/jbc.271.40.24604; ROBERTS JR, 1995, J BIOL CHEM, V270, P17311, DOI 10.1074/jbc.270.29.17311; ROBINSON AM, 1980, PHYSIOL REV, V60, P143, DOI 10.1152/physrev.1980.60.1.143; ROUSSEL A, 1999, TURBOFRODO VERSION O; Smith CV, 2003, J BIOL CHEM, V278, P1735, DOI 10.1074/jbc.M209248200; STEGINK LD, 1968, J BIOL CHEM, V243, P5272; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; Tuinstra RL, 2004, BIOCHEMISTRY-US, V43, P5287, DOI 10.1021/bi0499765; Tuinstra RL, 2003, J BIOL CHEM, V278, P37092, DOI 10.1074/jbc.M304472200; Tuinstra RL, 2002, ARCH BIOCHEM BIOPHYS, V408, P286, DOI 10.1016/S0003-9861(02)00584-2; XIA ZX, 1987, P NATL ACAD SCI USA, V84, P2629, DOI 10.1073/pnas.84.9.2629; Zapater N, 1998, ARCH BIOCHEM BIOPHYS, V358, P197, DOI 10.1006/abbi.1998.0788	42	26	27	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 17	2006	281	11					7526	7532		10.1074/jbc.M506880200	http://dx.doi.org/10.1074/jbc.M506880200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	022BY	16330550	hybrid			2022-12-25	WOS:000236030900074
J	Yehezkel, G; Hadad, N; Zaid, H; Sivan, S; Shoshan-Barmatz, V				Yehezkel, G; Hadad, N; Zaid, H; Sivan, S; Shoshan-Barmatz, V			Nucleotide-binding sites in the voltage-dependent anion channel - Characterization and localization	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PERMEABILITY TRANSITION PORE; MITOCHONDRIAL OUTER-MEMBRANE; RAT-HEART MITOCHONDRIA; VDAC CHANNELS; CELL-DEATH; MAMMALIAN PORIN; HIGH-AFFINITY; ATP BINDING; TRANSPORT; MODULATION	In this study, we addressed the presence and location of nucleotide-binding sites in the voltage-dependent anion channel (VDAC). VDAC bound to reactive red 120-agarose, from which it was eluted by ATP, less effectively by ADP and AMP, but not by NADH. The photoreactive ATP analog, benzoyl-benzoyl-ATP (BzATP), was used to identify and characterize the ATP-binding sites in VDAC. [alpha-P-32] BzATP bound to purified VDAC at two or more binding sites with apparent high and low binding affinities. Matrix-assisted laser desorption ionization time-of-flight (MALDI-TOF) analysis of BzATP-labeled VDAC confirmed the binding of at least two BzATP molecules to VDAC. The VDAC BzATP-binding sites showed higher specificity for purine than for pyrimidine nucleotides and higher affinity for negatively charged nucleotide species. VDAC treatment with the lysyl residue modifying reagent, fluorescein 5'-isothiocyanate, markedly inhibited VDAC labeling with BzATP. The VDAC nucleotide-binding sites were localized using chemical and enzymatic cleavage. Digestion of [alpha-P-32] BzATP-labeled VDAC with CNBr or V8 protease resulted in the appearance of similar to 17- and similar to 14-kDa labeled fragments. Further digestion, high performance liquid chromatography separation, and sequencing of the selected V8 peptides suggested that the labeled fragments originated from two different regions of the VDAC molecule. MALDI-TOF analysis of BzATP-labeled, tryptic VDAC fragments indicated and localized three nucleotide binding sites, two of which were at the N and C termini of VDAC. Thus, the presence of two or more nucleotide-binding sites in VDAC is suggested, and their possible function in the control of VDAC activity, and, thereby, of outer mitochondrial membrane permeability is discussed.	Ben Gurion Univ Negev, Dept Life Sci, IL-84105 Beer Sheva, Israel	Ben Gurion University	Shoshan-Barmatz, V (corresponding author), Ben Gurion Univ Negev, Dept Life Sci, IL-84105 Beer Sheva, Israel.	vardasb@bgu.ac.il						ADAMS V, 1991, BIOCHEM MED METAB B, V45, P271, DOI 10.1016/0885-4505(91)90032-G; Azoulay-Zohar H, 2004, BIOCHEM J, V377, P347, DOI 10.1042/BJ20031465; BATHORI G, 1993, BIOCHIM BIOPHYS ACTA, V1145, P168, DOI 10.1016/0005-2736(93)90394-F; BENZ R, 1988, FEBS LETT, V231, P75, DOI 10.1016/0014-5793(88)80706-3; BERA AK, 1995, BIOCHEM BIOPH RES CO, V209, P213, DOI 10.1006/bbrc.1995.1491; Beutner G, 1998, BBA-BIOMEMBRANES, V1368, P7, DOI 10.1016/S0005-2736(97)00175-2; BLACHLYDYSON E, 1990, SCIENCE, V247, P1233, DOI 10.1126/science.1690454; BRDICZKA D, 1994, BBA-BIOENERGETICS, V1187, P264, DOI 10.1016/0005-2728(94)90124-4; BROWN GC, 1992, BIOCHEM J, V284, P1; Casadio R, 2002, FEBS LETT, V520, P1, DOI 10.1016/S0014-5793(02)02758-8; CLEVELAND DW, 1977, J BIOL CHEM, V252, P1102; COLL RJ, 1984, J BIOL CHEM, V259, P4249; Colombini M, 2004, MOL CELL BIOCHEM, V256, P107, DOI 10.1023/B:MCBI.0000009862.17396.8d; Crompton M, 1999, BIOCHEM J, V341, P233, DOI 10.1042/0264-6021:3410233; Crompton M, 1998, EUR J BIOCHEM, V258, P729, DOI 10.1046/j.1432-1327.1998.2580729.x; Dawson R. M. C., 1986, DATA BIOCH RES, V3rd; FLORKE H, 1994, BIOL CHEM H-S, V375, P513, DOI 10.1515/bchm3.1994.375.8.513; GARLID KD, 1980, J BIOL CHEM, V255, P1273; Halestrap AP, 1998, BBA-BIOENERGETICS, V1366, P79, DOI 10.1016/S0005-2728(98)00122-4; Haworth RA, 2000, J BIOENERG BIOMEMBR, V32, P91, DOI 10.1023/A:1005568630151; Heiden MGV, 2001, J BIOL CHEM, V276, P19414, DOI 10.1074/jbc.M101590200; Hishida T, 1999, J BIOL CHEM, V274, P25335, DOI 10.1074/jbc.274.36.25335; Hou YX, 2000, J BIOL CHEM, V275, P20280, DOI 10.1074/jbc.M001109200; Huizing M, 1998, J BIOENERG BIOMEMBR, V30, P277, DOI 10.1023/A:1020501021222; Imagawa T, 2003, ANN NY ACAD SCI, V986, P240, DOI 10.1111/j.1749-6632.2003.tb07170.x; Johnson  D., 1967, METHOD ENZYMOL, V10, P94, DOI DOI 10.1016/0076-6879(67)10018-9; KLINGENBERG M, 1980, J MEMBRANE BIOL, V56, P97, DOI 10.1007/BF01875961; Kroemer G, 2000, NAT MED, V6, P513, DOI 10.1038/74994; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Landry F, 2000, ANAL BIOCHEM, V279, P1, DOI 10.1006/abio.1999.4468; LAPIDUS RG, 1994, J BIOL CHEM, V269, P18931; Lee AC, 1996, J BIOL CHEM, V271, P26724, DOI 10.1074/jbc.271.43.26724; Liberatori S, 2004, PROTEOMICS, V4, P1335, DOI 10.1002/pmic.200300734; LIU MY, 1992, BIOCHIM BIOPHYS ACTA, V1098, P255, DOI 10.1016/S0005-2728(05)80344-5; Majima E, 2001, J BIOL CHEM, V276, P9792, DOI 10.1074/jbc.M007222200; NOVGORODOV SA, 1994, ARCH BIOCHEM BIOPHYS, V311, P219, DOI 10.1006/abbi.1994.1230; REYMANN S, 1995, BIOCHEM MOL MED, V54, P75, DOI 10.1006/bmme.1995.1011; Rodriguez-Zavala JS, 1998, J BIOL CHEM, V273, P7850, DOI 10.1074/jbc.273.14.7850; Rostovtseva T, 1997, BIOPHYS J, V72, P1954, DOI 10.1016/S0006-3495(97)78841-6; Rostovtseva TK, 1998, BIOPHYS J, V74, P2365, DOI 10.1016/S0006-3495(98)77945-7; Rostovtseva TK, 2002, BIOPHYS J, V82, P193, DOI 10.1016/S0006-3495(02)75386-1; Rudel T, 1996, CELL, V85, P391, DOI 10.1016/S0092-8674(00)81117-4; RUTTER GA, 1990, BIOCHEM J, V271, P627, DOI 10.1042/bj2710627; Shoshan-Barmatz V, 2005, J MEMBRANE BIOL, V204, P57, DOI 10.1007/s00232-005-0749-4; Shoshan-Barmatz V, 2003, CELL BIOCHEM BIOPHYS, V39, P279, DOI 10.1385/CBB:39:3:279; Song JM, 1996, J BIOENERG BIOMEMBR, V28, P153, DOI 10.1007/BF02110646; TRAUT TW, 1994, MOL CELL BIOCHEM, V140, P1, DOI 10.1007/BF00928361; WALKER JE, 1982, EMBO J, V1, P945, DOI 10.1002/j.1460-2075.1982.tb01276.x; WILLIAMS N, 1982, J BIOL CHEM, V257, P2834; ZIZI M, 1994, J BIOL CHEM, V269, P1614; ZORATTI M, 1995, BBA-REV BIOMEMBRANES, V1241, P139, DOI 10.1016/0304-4157(95)00003-A	51	49	49	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 3	2006	281	9					5938	5946		10.1074/jbc.M510104200	http://dx.doi.org/10.1074/jbc.M510104200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	015RQ	16354668	hybrid			2022-12-25	WOS:000235568900074
J	Bernard, D; Gil, J; Dumont, P; Rizzo, S; Monte, D; Quatannens, B; Hudson, D; Visakorpi, T; Fuks, F; de Launoit, Y				Bernard, D; Gil, J; Dumont, P; Rizzo, S; Monte, D; Quatannens, B; Hudson, D; Visakorpi, T; Fuks, F; de Launoit, Y			The methyl-CpG- binding protein MECP2 is required for prostate cancer cell growth	ONCOGENE			English	Article						methyl-CpG-binding protein; epigenetic; cancer; prostate; growth	ANDROGEN DEPRIVATION THERAPY; HISTONE DEACETYLASE COMPLEX; DNA METHYLATION; NEUROENDOCRINE DIFFERENTIATION; MOLECULAR-GENETICS; C-MYC; EXPRESSION; CARCINOMA; RECEPTOR; METHYLTRANSFERASE	The incidence of prostate cancer is increasing in western countries because of population aging. Prostate cancer begins as an androgen-dependent disease, but it can become androgen independent at a later stage or in tumors recurring after an antihormonal treatment. Although many genetic events have been described to be involved in androgen-dependent and/or -independent prostate cancer growth, little is known about the contribution of epigenetic events. Here we have examined the possibility that the methyl-CpG-binding protein MECP2 might play a role in controlling the growth of prostate cancer cells. Inhibition of MECP2 expression by stable short hairpin RNA stopped the growth of both normal and cancer human prostate cells. In addition, ectopic expression of the MECP2 conferred a growth advantage to human prostate cancer cells. More importantly, this expression allowed androgen-dependent cells to grow independently of androgen stimulation and to retain tumorigenic properties in androgen-depleted conditions. Analysis of signaling pathways showed that this effect is independent of androgen receptor signaling. Instead, MECP2 appears to act by maintaining a constant c-myc level during antihormonal treatment. We further show that MECP2-expressing cells possess a functional p53 pathway and are still responsive to chemotherapeutic drugs.	ULB, Fac Med, Lab Virol Mol, B-1070 Brussels, Belgium; Imperial Coll Sch Med, MRC Clin Sci Ctr, London, England; Univ Sci & Technol, CNRS, UMR 8117, Inst Pasteur Lille,Inst Biol, Lille, France; Inst Canc Res, Prostate Stem Cell Lab, Sutton, Surrey, England; Tampere Univ Hosp, Tampere, Finland	Universite Libre de Bruxelles; Imperial College London; Centre National de la Recherche Scientifique (CNRS); Le Reseau International des Instituts Pasteur (RIIP); Universite de Lille - ISITE; Institut Pasteur Lille; Universite de Lille; University of London; Institute of Cancer Research - UK; Tampere University; Tampere University Hospital	Bernard, D (corresponding author), ULB, Fac Med, Lab Virol Mol, CP 614,808 Route Lennik, B-1070 Brussels, Belgium.	dbernard@ulb.ac.be	Gil, Jesus/C-7739-2012; Bernard, David/D-6265-2018	Gil, Jesus/0000-0002-4303-6260; Bernard, David/0000-0002-1557-2074; monte, didier/0000-0002-0613-6203; Visakorpi, Tapio/0000-0002-5004-0364	Medical Research Council [MC_U120085810] Funding Source: Medline; MRC [MC_U120085810] Funding Source: UKRI	Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))		Abate-Shen C, 2000, GENE DEV, V14, P2410, DOI 10.1101/gad.819500; ABRAHAMSSON PA, 1989, PATHOL RES PRACT, V185, P373, DOI 10.1016/S0344-0338(89)80016-0; Ahlgren G, 2000, PROSTATE, V42, P274, DOI 10.1002/(SICI)1097-0045(20000301)42:4<274::AID-PROS4>3.0.CO;2-R; Baylin SB, 2000, TRENDS GENET, V16, P168, DOI 10.1016/S0168-9525(99)01971-X; Bernard D, 2003, J CLIN INVEST, V112, P1724; Bernard D, 2001, CANCER RES, V61, P2656; Burgers WA, 2002, TRENDS GENET, V18, P275, DOI 10.1016/S0168-9525(02)02667-7; Carlson CA, 2000, RADIAT RES, V154, P590, DOI 10.1667/0033-7587(2000)154[0590:LORPCW]2.0.CO;2; CARROLL AG, 1993, PROSTATE, V23, P123, DOI 10.1002/pros.2990230206; Chen L, 2004, NEW ASTRON, V10, P39, DOI 10.1016/j.newast.2004.04.008; Cheng JC, 2004, CANCER CELL, V6, P151, DOI 10.1016/j.ccr.2004.06.023; COHEN RJ, 1990, BRIT J UROL, V66, P405, DOI 10.1111/j.1464-410X.1990.tb14963.x; Denmeade SR, 2002, NAT REV CANCER, V2, P389, DOI 10.1038/nrc801; Dobosy JR, 2001, CELL MOL LIFE SCI, V58, P721, DOI 10.1007/PL00000895; Feldman BJ, 2001, NAT REV CANCER, V1, P34, DOI 10.1038/35094009; Fojo T, 2003, ONCOGENE, V22, P7512, DOI 10.1038/sj.onc.1206951; Fuks F, 2003, J BIOL CHEM, V278, P4035, DOI 10.1074/jbc.M210256200; Futreal PA, 2004, NAT REV CANCER, V4, P177, DOI 10.1038/nrc1299; Goffin J, 2002, ANN ONCOL, V13, P1699, DOI 10.1093/annonc/mdf314; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; He TC, 1998, SCIENCE, V281, P1509, DOI 10.1126/science.281.5382.1509; Hirano D, 2004, EUR UROL, V45, P586, DOI 10.1016/j.eururo.2003.11.032; Hudson David L, 2003, Methods Mol Med, V81, P59; Jones PA, 2002, ONCOGENE, V21, P5358, DOI 10.1038/sj.onc.1205597; Kasibhatla S, 1998, MOL CELL, V1, P543, DOI 10.1016/S1097-2765(00)80054-4; KELLEN JA, 1994, ANTICANCER RES, V14, P433; Kimura H, 2003, J BIOL CHEM, V278, P4806, DOI 10.1074/jbc.M209923200; Kongkanuntn R, 1999, ONCOGENE, V18, P7219, DOI 10.1038/sj.onc.1203181; Kudo S, 2001, BRAIN DEV-JPN, V23, pS165, DOI 10.1016/S0387-7604(01)00345-X; Li LC, 2004, BBA-REV CANCER, V1704, P87, DOI 10.1016/j.bbcan.2004.06.001; Lund AH, 2004, CURR OPIN CELL BIOL, V16, P239, DOI 10.1016/j.ceb.2004.03.010; Miyoshi Y, 2001, BJU INT, V88, P982, DOI 10.1046/j.1464-4096.2001.00936.x; Nan X., 1998, NOVART FDN SYMP, V214, P16, DOI DOI 10.1002/9780470515501.CH2; Nan XS, 1998, CIBA F SYMP, V214, P6; Nan XS, 1998, NATURE, V393, P386, DOI 10.1038/30764; Nelson WG, 2003, NEW ENGL J MED, V349, P366, DOI 10.1056/NEJMra021562; Ng HH, 1999, NAT GENET, V23, P58, DOI 10.1038/12659; Porkka KP, 2004, EUR UROL, V45, P683, DOI 10.1016/j.eururo.2004.01.012; Sansom OJ, 2003, NAT GENET, V34, P145, DOI 10.1038/ng1155; Sears RC, 2004, CELL CYCLE, V3, P1133, DOI 10.4161/cc.3.9.1145; Shah RB, 2004, CANCER RES, V64, P9209, DOI 10.1158/0008-5472.CAN-04-2442; Taplin ME, 2004, J CELL BIOCHEM, V91, P483, DOI 10.1002/jcb.10653; TETU B, 1987, CANCER, V59, P1803, DOI 10.1002/1097-0142(19870515)59:10<1803::AID-CNCR2820591019>3.0.CO;2-X; Valkov NI, 2003, DRUG RESIST UPDATE, V6, P27, DOI 10.1016/S1368-7646(02)00143-7; Visakorpi T, 2003, UROLOGY, V62, P3, DOI 10.1016/S0090-4295(03)00776-3; Wang J, 1998, GENE DEV, V12, P1769, DOI 10.1101/gad.12.12.1769; WOLF DA, 1992, MOL ENDOCRINOL, V6, P753, DOI 10.1210/me.6.5.753; Wright ME, 2003, MOL ENDOCRINOL, V17, P1726, DOI 10.1210/me.2003-0031; Yeap BB, 1999, ENDOCRINOLOGY, V140, P3282, DOI 10.1210/en.140.7.3282; Yoshida M, 2001, CANCER CHEMOTH PHARM, V48, pS20, DOI 10.1007/s002800100300; Zhu Wei-Guo, 2003, Current Medicinal Chemistry - Anti-Cancer Agents, V3, P187, DOI 10.2174/1568011033482440	51	44	55	1	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 2	2006	25	9					1358	1366		10.1038/sj.onc.1209179	http://dx.doi.org/10.1038/sj.onc.1209179			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	017QN	16331274				2022-12-25	WOS:000235708200009
J	Rubio, MF; Werbajh, S; Cafferata, EGA; Quaglino, A; Colo, GP; Nojek, IM; Kordon, EC; Nahmod, VE; Costas, MA				Rubio, MF; Werbajh, S; Cafferata, EGA; Quaglino, A; Colo, GP; Nojek, IM; Kordon, EC; Nahmod, VE; Costas, MA			TNF-alpha enhances estrogen-induced cell proliferation of estrogen-dependent breast tumor cells through a complex containing nuclear factor-kappa B	ONCOGENE			English	Article						NF-kB; nuclear receptor coactivators; breast tumor; TNF-alpha; estrogen receptor	CYCLIN D1 EXPRESSION; CANCER CELLS; CROSS-TALK; RECEPTOR; ACTIVATION; GROWTH; AIB1; PROGRESSION; INDUCTION; MECHANISM	Breast tumors are usually classified according to their response to estrogens as hormone-dependent or -independent. In this work, we investigated the role of the proinflammatory cytokine TNF-alpha on the estrogen-receptor-positive T47D breast ductal tumor cells. We have found that TNF-alpha exerts a mitogenic effect, inducing cyclin D1 expression and activation of the transcription factor NF-kappa B. Importantly, activation of NF-kappa B was required for estrogen-induced proliferation and cyclin D1 expression. TNF-alpha enhanced the estrogen response by increasing the levels and availability of NF-kappa B. Chromatin immunoprecipitation analysis suggested that the action of estrogens is mediated by a protein complex that contains the activated estrogen receptor, the nuclear receptor coactivator RAC3 and a member of the NF-kappa B family. Finally, our results demonstrate that activation of this transcription factor could be one of the key signals for estrogen-mediated response.	Univ Buenos Aires, CONICET, IDIM, Dept Sustancias Vasoact,Fac Med,Lab Biol Mol & Ap, Buenos Aires, DF, Argentina; FIL, ANLIS, Ctr Genet Med, Buenos Aires, DF, Argentina; Consejo Nacl Invest Cient & Tecn, Div Med, Inst Invest Hematol, Acad Nacl Med, Buenos Aires, DF, Argentina	Consejo Nacional de Investigaciones Cientificas y Tecnicas (CONICET); University of Buenos Aires; Buenos Aires National Academy of Medicine; IIHEMA - Instituto de Investigaciones Hematologicas; Consejo Nacional de Investigaciones Cientificas y Tecnicas (CONICET)	Costas, MA (corresponding author), Univ Buenos Aires, CONICET, IDIM, Dept Sustancias Vasoact,Fac Med,Lab Biol Mol & Ap, Combatients Malvinas 3150, Buenos Aires, DF, Argentina.	mcostas@lanari.fmed.uba.ar		Costas, Monica/0000-0002-4773-3389; Cafferata, Eduardo G/0000-0001-5089-3757				Anzick SL, 1997, SCIENCE, V277, P965, DOI 10.1126/science.277.5328.965; Beg AA, 1996, SCIENCE, V274, P782, DOI 10.1126/science.274.5288.782; Biswas DK, 2000, P NATL ACAD SCI USA, V97, P8542, DOI 10.1073/pnas.97.15.8542; Biswas DK, 2001, P NATL ACAD SCI USA, V98, P10386, DOI 10.1073/pnas.151257998; Cafferata EGA, 2001, J BIOL CHEM, V276, P15441, DOI 10.1074/jbc.M010061200; Cao YX, 2001, CELL, V107, P763, DOI 10.1016/S0092-8674(01)00599-2; Castoria G, 2001, EMBO J, V20, P6050, DOI 10.1093/emboj/20.21.6050; Castro-Rivera E, 2001, J BIOL CHEM, V276, P30853, DOI 10.1074/jbc.M103339200; Chen F, 2001, AM J PATHOL, V159, P387, DOI 10.1016/S0002-9440(10)61708-7; Chouchane L, 1997, CANCER, V80, P1489, DOI 10.1002/(SICI)1097-0142(19971015)80:8<1489::AID-CNCR17>3.0.CO;2-1; Cogswell PC, 2000, ONCOGENE, V19, P1123, DOI 10.1038/sj.onc.1203412; Costas M, 1996, J CLIN INVEST, V98, P1409, DOI 10.1172/JCI118928; Costas MA, 2000, BBA-MOL CELL RES, V1499, P122, DOI 10.1016/S0167-4889(00)00113-0; Evans MJ, 2001, CIRC RES, V89, P823, DOI 10.1161/hh2101.098543; Franco D, 2002, CELL DEATH DIFFER, V9, P1090, DOI 10.1038/sj.cdd.4401074; Ghosh S, 2002, CELL, V109, pS81, DOI 10.1016/S0092-8674(02)00703-1; Guttridge DC, 1999, MOL CELL BIOL, V19, P5785; Hamelers IHL, 2003, ENDOCR-RELAT CANCER, V10, P331, DOI 10.1677/erc.0.0100331; Hengartner MO, 2000, NATURE, V407, P770, DOI 10.1038/35037710; Hinz M, 1999, MOL CELL BIOL, V19, P2690; HSU HL, 1995, CELL, V81, P495, DOI 10.1016/0092-8674(95)90070-5; Hsu HL, 1996, IMMUNITY, V4, P387, DOI 10.1016/S1074-7613(00)80252-6; Hsu HL, 1996, CELL, V84, P299, DOI 10.1016/S0092-8674(00)80984-8; Hsu SM, 2000, BIOCHEM BIOPH RES CO, V279, P47, DOI 10.1006/bbrc.2000.3891; Joyce D, 2001, CYTOKINE GROWTH F R, V12, P73, DOI 10.1016/S1359-6101(00)00018-6; Kato S, 2000, GENES CELLS, V5, P593, DOI 10.1046/j.1365-2443.2000.00354.x; Klinge CM, 2000, STEROIDS, V65, P227, DOI 10.1016/S0039-128X(99)00107-5; LARRICK JW, 1990, FASEB J, V4, P3215, DOI 10.1096/fasebj.4.14.2172061; Lin A, 2003, SEMIN CANCER BIOL, V13, P107, DOI 10.1016/S1044-579X(02)00128-1; List HJ, 2001, J BIOL CHEM, V276, P23763, DOI 10.1074/jbc.M102397200; Liu ZG, 1996, CELL, V87, P565, DOI 10.1016/S0092-8674(00)81375-6; McKenna NJ, 1999, ENDOCR REV, V20, P321, DOI 10.1210/er.20.3.321; Migliaccio A, 1998, EMBO J, V17, P2008, DOI 10.1093/emboj/17.7.2008; MORA JF, 2000, MOL CELL BIOL, V20, P5041; Nakshatri H, 1997, MOL CELL BIOL, V17, P3629, DOI 10.1128/MCB.17.7.3629; PARTANEN R, 1995, OCCUP ENVIRON MED, V52, P316, DOI 10.1136/oem.52.5.316; Planas-Silva MD, 2001, CANCER RES, V61, P3858; Pratt MAC, 2003, MOL CELL BIOL, V23, P6887, DOI 10.1128/MCB.23.19.6887-6900.2003; Sheppard KA, 1999, MOL CELL BIOL, V19, P6367; Speir E, 2000, CIRC RES, V87, P1006, DOI 10.1161/01.RES.87.11.1006; Tsai EM, 2001, CANCER RES, V61, P8390; Valentine JE, 2000, J BIOL CHEM, V275, P25322, DOI 10.1074/jbc.M002497200; Wahl C, 1998, J CLIN INVEST, V101, P1163, DOI 10.1172/JCI992; Wang CY, 1998, SCIENCE, V281, P1680, DOI 10.1126/science.281.5383.1680; Webb P, 1998, MOL ENDOCRINOL, V12, P1605, DOI 10.1210/me.12.10.1605; Werbajh S, 2000, FEBS LETT, V485, P195, DOI 10.1016/S0014-5793(00)02223-7; Westerheide SD, 2001, MOL CELL BIOL, V21, P8428, DOI 10.1128/MCB.21.24.8428-8436.2001; Wu RC, 2002, MOL CELL BIOL, V22, P3549, DOI 10.1128/MCB.22.10.3549-3561.2002; Zornig M., 2001, BIOCHIM BIOPHYS ACTA, V1551, P1; ZYAD A, 1994, CANCER RES, V54, P825	50	75	83	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 2	2006	25	9					1367	1377		10.1038/sj.onc.1209176	http://dx.doi.org/10.1038/sj.onc.1209176			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	017QN	16331275				2022-12-25	WOS:000235708200010
J	Ohtsuka, T; Liu, XF; Koga, Y; Kitajima, Y; Nakafusa, Y; Ha, CW; Lee, SW; Miyazaki, K				Ohtsuka, T; Liu, XF; Koga, Y; Kitajima, Y; Nakafusa, Y; Ha, CW; Lee, SW; Miyazaki, K			Methylation-induced silencing of ASC and the effect of expressed ASC on p53-mediated chemosensitivity in colorectal cancer	ONCOGENE			English	Article						ASC; p53; methylation; chemosensitivity; colorectal cancer	RECRUITMENT DOMAIN PROTEIN; APOPTOTIC RESPONSE; HUMAN BREAST; P53; GENE; CELLS; BAX; ACTIVATION; MUTATIONS; ASC/TMS1	Tumor suppressor p53 is known to play a crucial role in chemosensitivity in colorectal cancer. We previously demonstrated that an apoptosis-associated speck-like protein, ASC, is a p53-target gene which regulates p53-Bax mitochondrial apoptotic pathway. ASC is also known to be a target of methylation-induced gene silencing. An inactivation of ASC might thus cause resistance to chemotherapy, and if this is the case, then the expression of ASC would restore the chemosensitivity. The aim of this study was to clarify this hypothesis. ASC was methylated in 25% of all resected specimens in patients with colorectal cancer; however, ASC methylation did not always correspond to a lack of ASC protein. When expressed in colon cancer cells, in which ASC is absent due to methylation, ASC was found to enhance the chemosensitivity in a p53-dependent manner. In p53-null cells, ASC increased the p53-mediated cell death induced by p53-expressing adenovirus infection. Our data suggest that the methylation-induced silencing of ASC might cause resistance to p53-mediated chemosensitivity in colorectal cancer. The gene introduction of ASC may thus restore such chemosensitivity, and this modality may therefore be a useful new treatment strategy for colorectal cancer.	Saga Univ, Fac Med, Dept Surg, Saga 8498501, Japan; Sungkyunkwan Univ, Sch Med, Samsung Med Ctr, Dept Orthoped Surg, Seoul, South Korea; Massachusetts Gen Hosp, Cutaneuos Biol Res Ctr, Charlestown, MA USA; Harvard Univ, Sch Med, Charlestown, MA USA	Saga University; Sungkyunkwan University (SKKU); Samsung Medical Center; Harvard University; Massachusetts General Hospital; Harvard University	Ohtsuka, T (corresponding author), Saga Univ, Fac Med, Dept Surg, Saga 8498501, Japan.	ootsuka4@cc.saga-u.ac.jp	Ha, C/GZL-9046-2022	HA, Chul-Won/0000-0001-5123-6513	NCI NIH HHS [CA80058-06, CA078356-05] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA078356] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Bunz F, 1999, J CLIN INVEST, V104, P263, DOI 10.1172/JCI6863; Conway KE, 2000, CANCER RES, V60, P6236; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Green DR, 1998, SCIENCE, V281, P1309, DOI 10.1126/science.281.5381.1309; Guan X, 2003, INT J CANCER, V107, P202, DOI 10.1002/ijc.11376; Herman JG, 1996, P NATL ACAD SCI USA, V93, P9821, DOI 10.1073/pnas.93.18.9821; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; Hwang PM, 2001, NAT MED, V7, P1111, DOI 10.1038/nm1001-1111; LOWE SW, 1994, SCIENCE, V266, P807, DOI 10.1126/science.7973635; Mariathasan S, 2004, NATURE, V430, P213, DOI 10.1038/nature02664; Masumoto J, 1999, J BIOL CHEM, V274, P33835, DOI 10.1074/jbc.274.48.33835; MIYASHITA T, 1995, CELL, V80, P293; Moriai R, 2002, ANTICANCER RES, V22, P4163; Oda E, 2000, SCIENCE, V288, P1053, DOI 10.1126/science.288.5468.1053; Ohtsuka T, 2004, NAT CELL BIOL, V6, P121, DOI 10.1038/ncb1087; SCARPA A, 1993, AM J PATHOL, V142, P1534; Stehlik C, 2002, J EXP MED, V196, P1605, DOI 10.1084/jem.20021552; Vogelstein B, 2000, NATURE, V408, P307, DOI 10.1038/35042675; Yokoyama T, 2003, CANCER LETT, V202, P101, DOI 10.1016/j.canlet.2003.08.027; Yu J, 2003, P NATL ACAD SCI USA, V100, P1931, DOI 10.1073/pnas.2627984100; Zhang L, 2000, SCIENCE, V290, P989, DOI 10.1126/science.290.5493.989	21	25	30	1	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR	2006	25	12					1807	1811		10.1038/sj.onc.1209204	http://dx.doi.org/10.1038/sj.onc.1209204			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	021VJ	16331272				2022-12-25	WOS:000236013700012
J	Hers, I; Wherlock, M; Homma, Y; Yagisawa, H; Tavare, J				Hers, I; Wherlock, M; Homma, Y; Yagisawa, H; Tavare, J			Identification of p122RhoGAP (deleted in liver cancer-1) serine 322 as a substrate for protein kinase B and ribosomal S6 kinase in insulin-stimulated cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GTPASE-ACTIVATING PROTEIN; TUMOR-SUPPRESSOR GENE; AKT SUBSTRATE; PLC-DELTA(1)-BINDING PROTEIN; GLUCOSE-TRANSPORT; MAPKAP KINASE-1; RAT ADIPOCYTES; PHOSPHORYLATION; DLC-1; MEDIATOR	Protein kinase B (PKB or Akt) plays an essential role in the actions of insulin, cytokines, and growth factors, although the substrates for PKB that are relevant to many of its actions require identification. In this study, we have reported the identification of p122RhoGAP, a GTPase-activating protein selective for RhoA and rodent homologue of the tumor suppressor deleted in liver cancer (DLC1) as a novel insulin-stimulated phosphoprotein in primary rat adipocytes. We have demonstrated that Ser-322 is phosphorylated upon insulin stimulation of intact cells and that this site is directly phosphorylated in vitro by PKB and ribosomal S6 kinase, members of the AGC (protein kinases A, G, and C) family of insulin-stimulated protein kinases. Furthermore, expression of constitutively active mutants of PKB or mitogen-activated protein kinase/extracellular signal-regulated kinase kinase (MEK) stimulates Ser-322 phosphorylation in intact cells, demonstrating that activation of the PKB or MEK pathway is sufficient for Ser-322 phosphorylation in vivo. Indeed, in primary adipocytes, insulin-stimulated Ser-322 phosphorylation was almost exclusively regulated by the phosphatidylinositol 3-kinase/PKB pathway, whereas in immortalized cells, insulin-stimulated phosphorylation was predominantly regulated by the MEK/extracellular signal-regulated kinase/ribosomal S6 kinase pathway, with the phosphatidylinositol 3-kinase/PKB pathway playing a minor role. These results demonstrate that p122RhoGAP Ser-322 acts as an integrator of signal transduction in a manner dependent on the cellular context.	Univ Bristol, Sch Med Sci, Dept Biochem, Bristol BS8 1TD, Avon, England; Fukushima Med Univ, Sch Med, Inst Biomed Sci, Dept Biomol Res, Fukushima 9601295, Japan; Univ Hyogo, Grad Sch Life Sci, Harima, Hyogo 6781297, Japan	University of Bristol; Fukushima Medical University; University of Hyogo	Hers, I (corresponding author), Univ Bristol, Sch Med Sci, Bristol BS6 7TP, Avon, England.	i.hers@bris.ac.uk	Hers, Ingeborg/ABG-3357-2020; Yagisawa, Hitoshi/C-9305-2012	Yagisawa, Hitoshi/0000-0002-5365-4513; Hers, Ingeborg/0000-0002-6467-5715	Medical Research Council [G7708269] Funding Source: Medline; MRC [G7708269] Funding Source: UKRI	Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))		Alessi DR, 1997, CURR BIOL, V7, P261, DOI 10.1016/S0960-9822(06)00122-9; Alessi DR, 1996, FEBS LETT, V399, P333, DOI 10.1016/S0014-5793(96)01370-1; Auld GC, 2005, BIOCHEM J, V389, P775, DOI 10.1042/BJ20050733; Basu S, 2003, MOL CELL, V11, P11, DOI 10.1016/S1097-2765(02)00776-1; Berwick DC, 2004, J CELL SCI, V117, P5985, DOI 10.1242/jcs.01517; Berwick DC, 2002, J BIOL CHEM, V277, P33895, DOI 10.1074/jbc.M204681200; Brazil DP, 2004, TRENDS BIOCHEM SCI, V29, P233, DOI 10.1016/j.tibs.2004.03.006; Cartlidge RA, 2005, EMBO J, V24, P1696, DOI 10.1038/sj.emboj.7600648; Cho H, 2001, SCIENCE, V292, P1728, DOI 10.1126/science.292.5522.1728; De Mesquita DD, 2001, FEBS LETT, V502, P84, DOI 10.1016/S0014-5793(01)02669-2; Deak M, 1998, EMBO J, V17, P4426, DOI 10.1093/emboj/17.15.4426; Feng JH, 2004, J BIOL CHEM, V279, P41189, DOI 10.1074/jbc.M406731200; Garami A, 2003, MOL CELL, V11, P1457, DOI 10.1016/S1097-2765(03)00220-X; Gridley S, 2005, CELL SIGNAL, V17, P59, DOI 10.1016/j.cellsig.2004.05.013; Hers I, 2002, BIOCHEM J, V368, P875, DOI 10.1042/BJ20020903; HOMMA Y, 1995, EMBO J, V14, P286, DOI 10.1002/j.1460-2075.1995.tb07002.x; Inoki K, 2002, NAT CELL BIOL, V4, P648, DOI 10.1038/ncb839; Jiang ZY, 2005, J BIOL CHEM, V280, P21622, DOI 10.1074/jbc.m414464200; Kane S, 2002, J BIOL CHEM, V277, P22115, DOI 10.1074/jbc.C200198200; Karlsson HKR, 2005, DIABETES, V54, P1692, DOI 10.2337/diabetes.54.6.1692; Karnam P, 1997, J BIOL CHEM, V272, P6136, DOI 10.1074/jbc.272.10.6136; Kawai K, 2004, BIOCHEM SOC T, V32, P1107, DOI 10.1042/BST0321107; Kovacina KS, 2003, J BIOL CHEM, V278, P10189, DOI 10.1074/jbc.M210837200; Lawlor MA, 2001, J CELL SCI, V114, P2903; LEIGHTON IA, 1995, FEBS LETT, V375, P289, DOI 10.1016/0014-5793(95)01170-J; Li Y, 2004, TRENDS BIOCHEM SCI, V29, P32, DOI 10.1016/j.tibs.2003.11.007; Manning BD, 2002, MOL CELL, V10, P151, DOI 10.1016/S1097-2765(02)00568-3; Manning BD, 2003, TRENDS BIOCHEM SCI, V28, P573, DOI 10.1016/j.tibs.2003.09.003; MIINEA CP, 2005, BIOCH J; Ng IOL, 2000, CANCER RES, V60, P6581; Obata T, 2000, J BIOL CHEM, V275, P36108, DOI 10.1074/jbc.M005497200; Persad S, 2001, J BIOL CHEM, V276, P27462, DOI 10.1074/jbc.M102940200; Plaumann M, 2003, J CANCER RES CLIN, V129, P349, DOI 10.1007/s00432-003-0440-z; Potter CJ, 2002, NAT CELL BIOL, V4, P658, DOI 10.1038/ncb840; Roux PP, 2004, P NATL ACAD SCI USA, V101, P13489, DOI 10.1073/pnas.0405659101; Sano H, 2003, J BIOL CHEM, V278, P14599, DOI 10.1074/jbc.C300063200; Sarbassov DD, 2005, SCIENCE, V307, P1098, DOI 10.1126/science.1106148; Schmid G, 1998, N-S ARCH PHARMACOL, V357, P385, DOI 10.1007/PL00005183; Sekimata M, 1999, J BIOL CHEM, V274, P17757, DOI 10.1074/jbc.274.25.17757; Shaw M, 1999, FEBS LETT, V461, P120, DOI 10.1016/S0014-5793(99)01434-9; Standaert M, 1998, J BIOL CHEM, V273, P7470, DOI 10.1074/jbc.273.13.7470; Tee AR, 2003, CURR BIOL, V13, P1259, DOI 10.1016/S0960-9822(03)00506-2; Todaka M, 1996, BIOCHEM J, V315, P875, DOI 10.1042/bj3150875; vandenBerghe N, 1996, BIOCHEM BIOPH RES CO, V229, P430, DOI 10.1006/bbrc.1996.1821; Viniegra JG, 2005, J BIOL CHEM, V280, P4029, DOI 10.1074/jbc.M410344200; Watson RT, 2004, ENDOCR REV, V25, P177, DOI 10.1210/er.2003-0011; Yamaga M, 2004, GENES CELLS, V9, P25, DOI 10.1111/j.1356-9597.2004.00698.x; Yuan BZ, 1998, CANCER RES, V58, P2196; Yuan BZ, 2004, ONCOGENE, V23, P1405, DOI 10.1038/sj.onc.1207291; Zhao ZS, 2005, BIOCHEM J, V386, P201, DOI 10.1042/BJ20041638; Zhou QL, 2004, BIOCHEM SOC T, V32, P817, DOI 10.1042/BST0320817	51	26	28	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 24	2006	281	8					4762	4770		10.1074/jbc.M511008200	http://dx.doi.org/10.1074/jbc.M511008200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	013RF	16338927	hybrid			2022-12-25	WOS:000235426200026
J	Krusong, K; Carpenter, EP; Bellamy, SRW; Savva, R; Baldwin, GS				Krusong, K; Carpenter, EP; Bellamy, SRW; Savva, R; Baldwin, GS			A comparative study of uracil-DNA glycosylases from human and herpes simplex virus type 1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BASE-EXCISION-REPAIR; ECORV RESTRICTION-ENDONUCLEASE; ESCHERICHIA-COLI; FLUORESCENCE POLARIZATION; DEAMINATED CYTOSINE; CRYSTAL-STRUCTURES; STRUCTURAL BASIS; MECHANISM; SUBSTRATE; RECOGNITION	Uracil-DNA glycosylase (UNG) is the key enzyme responsible for initiation of base excision repair. We have used both kinetic and binding assays for comparative analysis of UNG enzymes from humans and herpes simplex virus type 1 (HSV-1). Steady-state fluorescence assays showed that hUNG has a much higher specificity constant (k(cat)/K-m) compared with the viral enzyme due to a lower Km. The binding of UNG to DNA was also studied using a catalytically inactive mutant of UNG and non-cleavable substrate analogs (2'-deoxypseudouridine and 2'-alpha-fluoro-2'-deoxyuridine). Equilibrium DNA binding revealed that both human and HSV-1 UNG enzymes bind to abasic DNA and both substrate analogs more weakly than to uracil-containing DNA. Structure determination of HSV-1 D88N/H210N UNG in complex with uracil revealed detailed information on substrate binding. Together, these results suggest that a significant proportion of the binding energy is provided by specific interactions with the target uracil. The kinetic parameters for human UNG indicate that it is likely to have activity against both U(.)A and U(.)G mismatches in vivo. Weak binding to abasic DNA also suggests that UNG activity is unlikely to be coupled to the subsequent common steps of base excision repair.	Univ London Imperial Coll Sci Technol & Med, Div Mol Biosci, London SW7 2AZ, England; Univ London Imperial Coll Sci Technol & Med, Ctr Struct Biol, London SW7 2AZ, England; Univ Bristol, Dept Biochem, Bristol BS8 1TD, Avon, England; Univ London Birkbeck Coll, Sch Crystallog, London WC1E 7HX, England	Imperial College London; Imperial College London; University of London; Institute of Cancer Research - UK; University of Bristol; University of London; Birkbeck University London	Baldwin, GS (corresponding author), Univ London Imperial Coll Sci Technol & Med, Div Mol Biosci, Sir Alexander Fleming Bldg, London SW7 2AZ, England.	g.baldwin@imperial.ac.uk		Carpenter, Liz/0000-0001-9138-2937; Baldwin, Geoffrey/0000-0003-4800-023X; Savva, Renos/0000-0001-7375-2340				An Q, 2005, EMBO J, V24, P2205, DOI 10.1038/sj.emboj.7600689; BALDWIN GS, 1995, BIOCHEMISTRY-US, V34, P705, DOI 10.1021/bi00002a038; BARZILAY G, 1995, BIOESSAYS, V17, P713, DOI 10.1002/bies.950170808; Bellamy SRW, 2001, NUCLEIC ACIDS RES, V29, P3857, DOI 10.1093/nar/29.18.3857; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Cornish-Bowden A, 2001, FUNDAMENTALS ENZYME; Drohat AC, 1999, BIOCHEMISTRY-US, V38, P11866, DOI 10.1021/bi9910878; FAZAKERLEY GV, 1985, FEBS LETT, V182, P365, DOI 10.1016/0014-5793(85)80334-3; Fischer JA, 2004, DNA REPAIR, V3, P505, DOI 10.1016/j.dnarep.2004.01.012; Haushalter KA, 1999, CURR BIOL, V9, P174, DOI 10.1016/S0960-9822(99)80087-6; Jiang YL, 2002, BIOCHEMISTRY-US, V41, P7116, DOI 10.1021/bi025694y; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Kavli B, 2002, J BIOL CHEM, V277, P39926, DOI 10.1074/jbc.M207107200; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Law SM, 1996, BIOCHEMISTRY-US, V35, P12329, DOI 10.1021/bi9614545; LINDAHL T, 1974, P NATL ACAD SCI USA, V71, P3649, DOI 10.1073/pnas.71.9.3649; LINDAHL T, 1993, NATURE, V362, P709, DOI 10.1038/362709a0; LIPNICK RL, 1981, BIOCHEMISTRY-US, V20, P7319, DOI 10.1021/bi00528a042; MARCK C, 1982, J MOL STRUCT, V82, P77, DOI 10.1016/0022-2860(82)85236-8; MOL CD, 1995, CELL, V80, P869, DOI 10.1016/0092-8674(95)90290-2; Nilsen H, 2000, MOL CELL, V5, P1059, DOI 10.1016/S1097-2765(00)80271-3; Nilsen H, 2001, EMBO J, V20, P4278, DOI 10.1093/emboj/20.15.4278; O'Neill RJ, 2003, J BIOL CHEM, V278, P20526, DOI 10.1074/jbc.M210860200; Otterlei M, 1999, EMBO J, V18, P3834, DOI 10.1093/emboj/18.13.3834; Panayotou G, 1998, J BIOL CHEM, V273, P45, DOI 10.1074/jbc.273.1.45; Parikh SS, 2000, P NATL ACAD SCI USA, V97, P5083, DOI 10.1073/pnas.97.10.5083; Parikh SS, 1998, EMBO J, V17, P5214, DOI 10.1093/emboj/17.17.5214; Perrakis A, 1997, ACTA CRYSTALLOGR D, V53, P448, DOI 10.1107/S0907444997005696; Powell LM, 1998, J MOL BIOL, V283, P947, DOI 10.1006/jmbi.1998.2142; Reid SL, 2001, BIOCHEMISTRY-US, V40, P2484, DOI 10.1021/bi001956p; Sambrook J., 1989, MOL CLONING LAB MANU, V2; SAVVA R, 1995, NATURE, V373, P487, DOI 10.1038/373487a0; SEEBERG E, 1995, TRENDS BIOCHEM SCI, V20, P391, DOI 10.1016/S0968-0004(00)89086-6; Sekino Y, 2000, J BIOL CHEM, V275, P36506, DOI 10.1074/jbc.C000585200; Slupphaug G, 1996, NATURE, V384, P87, DOI 10.1038/384087a0; SLUPPHAUG G, 1995, BIOCHEMISTRY-US, V34, P128, DOI 10.1021/bi00001a016; Stivers JT, 1998, NUCLEIC ACIDS RES, V26, P3837, DOI 10.1093/nar/26.16.3837; Stivers JT, 1999, BIOCHEMISTRY-US, V38, P952, DOI 10.1021/bi9818669; UESUGI S, 1979, TETRAHEDRON LETT, V42, P4073; Vagin A, 1997, J APPL CRYSTALLOGR, V30, P1022, DOI 10.1107/S0021889897006766; VRIEND G, 1990, J MOL GRAPHICS, V8, P52, DOI 10.1016/0263-7855(90)80070-V; WILLIAMS DM, 1991, BIOCHEMISTRY-US, V30, P4001, DOI 10.1021/bi00230a027; Xiao GY, 1999, PROTEINS, V35, P13	43	46	49	1	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 24	2006	281	8					4983	4992		10.1074/jbc.M509137200	http://dx.doi.org/10.1074/jbc.M509137200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	013RF	16306042	hybrid, Green Accepted			2022-12-25	WOS:000235426200050
J	Orlichenko, L; Huang, B; Krueger, E; McNiven, MA				Orlichenko, L; Huang, B; Krueger, E; McNiven, MA			Epithelial growth factor-induced phosphorylation of caveolin 1 at tyrosine 14 stimulates caveolae formation in epithelial cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; FACTOR RECEPTOR; ELECTROPHORETIC TRANSFER; POLYACRYLAMIDE-GELS; PHOSPHOLIPASE D1; BETA-CATENIN; E-CADHERIN; ENDOCYTOSIS; INTERNALIZATION; MEMBRANE	Caveolae are flask-shaped endocytic structures composed primarily of caveolin-1 (Cav1) and caveolin-2 (Cav2) proteins. Interestingly, a cytoplasmic accumulation of Cav1 protein does not always result in a large number of assembled caveolae organelles, suggesting a regulatory mechanism that controls caveolae assembly. In this study we report that stimulation of epithelial cells with epithelial growth factor (EGF) results in a profound increase in the number of caveolar structures at the plasma membrane. Human pancreatic tumor cells (PANC-1) and normal rat kidney cells (NRK), as a control, were treated with 30 ng/ml EGF for 0, 5, and 20 min before fixation and viewing by electron microscopy. Cells fixed without EGF treatment exhibited modest numbers of plasma membrane-associated caveolae. Cells treated with EGF for 5 or 20 min showed an 8-10-fold increase in caveolar structures, some forming long, pronounced caveolar "towers" at the cell-cell borders. It is known that Cav1 is Src-phosphorylated on tyrosine 14 in response to EGF treatment, although the significance of this modification is unknown. We postulated that phosphorylation could provide the stimulus for caveolae assembly. To this end, we transfected cells with mutant forms of Cav1 that could not be phosphorylated (Cav1Y14F) and tested if this altered protein reduced the number of EGF-induced caveolae. We observed that EGF-stimulated PANC-1 cells expressing the mutant Cav1Y14F protein exhibited a 90-95% reduction in caveolae number compared with cells expressing wild type Cav1. This study provides novel insights into how cells regulate caveolae formation and implicates EGF-based signaling cascades in the phosphorylation of Cav1 as a stimulus for caveolae assembly.	Mayo Clin, Dept Biochem & Mol Biol, Rochester, MN 55905 USA; Mayo Clin, Ctr Basic Res Digest Dis, Rochester, MN 55905 USA	Mayo Clinic; Mayo Clinic	McNiven, MA (corresponding author), Mayo Clin, Dept Biochem & Mol Biol, Guggenheim 1637,200 1st St SW, Rochester, MN 55905 USA.	mcniven.mark@mayo.edu						Aoki T, 1999, EXP CELL RES, V253, P629, DOI 10.1006/excr.1999.4652; Beardsley A, 2005, J BIOL CHEM, V280, P3541, DOI 10.1074/jbc.M409040200; BEHRENS J, 1993, J CELL BIOL, V120, P757, DOI 10.1083/jcb.120.3.757; BURNETTE WN, 1981, ANAL BIOCHEM, V112, P195, DOI 10.1016/0003-2697(81)90281-5; Cao HM, 2002, J BIOL CHEM, V277, P8771, DOI 10.1074/jbc.C100661200; Crescioli C, 2002, PROSTATE, V50, P15, DOI 10.1002/pros.10028; Drab M, 2001, SCIENCE, V293, P2449, DOI 10.1126/science.1062688; Gonzalez-Cabrera J, 2003, INSECT BIOCHEM MOLEC, V33, P929, DOI 10.1016/S0965-1748(03)00099-7; Henley JR, 1996, J CELL BIOL, V133, P761, DOI 10.1083/jcb.133.4.761; Henley JR, 1998, J CELL BIOL, V141, P85, DOI 10.1083/jcb.141.1.85; Ishizaka N, 1998, HYPERTENSION, V32, P459, DOI 10.1161/01.HYP.32.3.459; Kim Y, 1999, BBA-MOL CELL BIOL L, V1436, P319, DOI 10.1016/S0005-2760(98)00120-9; Kim Y, 2000, J BIOL CHEM, V275, P13621, DOI 10.1074/jbc.275.18.13621; Kim YN, 2002, EXP CELL RES, V280, P134, DOI 10.1006/excr.2002.5623; KORC M, 1986, P NATL ACAD SCI USA, V83, P5141, DOI 10.1073/pnas.83.14.5141; Labrecque L, 2004, J BIOL CHEM, V279, P52132, DOI 10.1074/jbc.M409617200; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lahtinen U, 2003, FEBS LETT, V538, P85, DOI 10.1016/S0014-5793(03)00135-2; Lamb ME, 2001, BIOCHEM J, V355, P741, DOI 10.1042/bj3550741; Li SW, 1996, J BIOL CHEM, V271, P3863; LIEBER M, 1975, INT J CANCER, V15, P741, DOI 10.1002/ijc.2910150505; Liou W, 1996, HISTOCHEM CELL BIOL, V106, P41, DOI 10.1007/BF02473201; Lu ZM, 2003, CANCER CELL, V4, P499, DOI 10.1016/S1535-6108(03)00304-0; Mineo C, 1999, J BIOL CHEM, V274, P30636, DOI 10.1074/jbc.274.43.30636; Navarro A, 2004, FASEB J, V18, P1801, DOI 10.1096/fj.04-2516rev; Nichols B, 2003, J CELL SCI, V116, P4707, DOI 10.1242/jcs.00840; Nomura R, 1999, MOL BIOL CELL, V10, P975, DOI 10.1091/mbc.10.4.975; Okamoto Y, 2000, J BIOL CHEM, V275, P6439, DOI 10.1074/jbc.275.9.6439; Orth JD, 2002, P NATL ACAD SCI USA, V99, P167, DOI 10.1073/pnas.012607899; Parat MO, 2003, MOL BIOL CELL, V14, P3156, DOI 10.1091/mbc.e02-11-0761; PARTON RG, 1994, J CELL BIOL, V127, P1199, DOI 10.1083/jcb.127.5.1199; Pawson AJ, 2003, ENDOCRINOLOGY, V144, P3860, DOI 10.1210/en.2003-0028; Pelkmans L, 2002, SCIENCE, V296, P535, DOI 10.1126/science.1069784; Pelkmans L, 2002, TRAFFIC, V3, P311, DOI 10.1034/j.1600-0854.2002.30501.x; Razani B, 2002, MOL CELL BIOL, V22, P2329, DOI 10.1128/MCB.22.7.2329-2344.2002; Razani B, 2001, BIOCHEM SOC T, V29, P494, DOI 10.1042/BST0290494; Razani B, 2001, J CLIN INVEST, V108, P1553, DOI 10.1172/JCI14611; Remacle A, 2003, J CELL SCI, V116, P3905, DOI 10.1242/jcs.00710; SARGIACOMO M, 1995, P NATL ACAD SCI USA, V92, P9407, DOI 10.1073/pnas.92.20.9407; Scheiffele P, 1998, J CELL BIOL, V140, P795, DOI 10.1083/jcb.140.4.795; SCHERER PE, 1995, J BIOL CHEM, V270, P16395, DOI 10.1074/jbc.270.27.16395; Shajahan AN, 2004, J BIOL CHEM, V279, P20392, DOI 10.1074/jbc.M308710200; Sharma DK, 2004, MOL BIOL CELL, V15, P3114, DOI 10.1091/mbc.E04-03-0189; Sigismund S, 2005, P NATL ACAD SCI USA, V102, P2760, DOI 10.1073/pnas.0409817102; SLOT JW, 1991, J CELL BIOL, V113, P123, DOI 10.1083/jcb.113.1.123; Sotgia F, 2000, J BIOL CHEM, V275, P38048, DOI 10.1074/jbc.M005321200; Sowa G, 2003, P NATL ACAD SCI USA, V100, P6511, DOI 10.1073/pnas.1031672100; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; Williams TM, 2005, AM J PHYSIOL-CELL PH, V288, pC494, DOI 10.1152/ajpcell.00458.2004; Yamamoto M, 1999, EXP CELL RES, V247, P380, DOI 10.1006/excr.1998.4379	50	93	94	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 24	2006	281	8					4570	4579		10.1074/jbc.M512088200	http://dx.doi.org/10.1074/jbc.M512088200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	013RF	16332692	hybrid			2022-12-25	WOS:000235426200004
J	Subramanian, VS; Marchant, JS; Said, HM				Subramanian, VS; Marchant, JS; Said, HM			Targeting and trafficking of the human thiamine transporter-2 in epithelial cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							REDUCED FOLATE CARRIER; APICAL SORTING SIGNAL; CANINE KIDNEY-CELLS; INTRACELLULAR TRAFFICKING; TRANSMEMBRANE DOMAIN; CYTOPLASMIC TAIL; MEMBRANE; EXPRESSION; MUTATIONS; MECHANISM	Humans lack biochemical pathways for thiamine synthesis, so cellular requirements are met via specific carrier-mediated uptake pathways. Two proteins from the solute carrier SLC19A gene family have been identified as human thiamine transporters (hTHTRs), SLC19A1 (hTHTR1) and SLC19A2 (hTHTR2). Both of these transporters are co-expressed but are differentially targeted in polarized cell types that mediate vectorial thiamine transport ( e. g. renal and intestinal epithelia). It is important to understand the domain structure of these proteins, namely which regions within the polypeptide sequence are important for physiological delivery to the cell surface, in order to understand the impact of clinically relevant mutations on thiamine transport. Here we have characterized the mechanisms regulating hTHTR2 distribution by using live cell imaging methods that resolve the targeting and trafficking dynamics of full-length hTHTR2, a series of hTHTR2 truncation mutants, as well as chimeras comprising the hTHTR1 and hTHTR2 sequence. We showed the following: (i) that the cytoplasmic COOH-tail of hTHTR2 is not essential for apical targeting in polarized cells; (ii) that delivery of hTHTR2 to the cell surface is critically dependent on the integrity of the transmembrane backbone of the polypeptide so that minimal truncations abrogate cell surface expression of hTHTR2; and (iii) video rate images of hTHTR2-containing intracellular vesicles displayed rapid bi-directional trafficking events to and from the cell surface impaired by microtubule-disrupting but not microfilament-disrupting agents as well as by overexpression of the dynactin subunit dynamitin (p50). Finally, we compared the behavior of hTHTR2 with that of hTHTR1 and the human reduced folate carrier (SLC19A1) to underscore commonalities in the cell surface targeting mechanisms of the entire SLC19A gene family.	Univ Calif Irvine, Dept Med, Irvine, CA 92697 USA; Univ Calif Irvine, Dept Physiol, Irvine, CA 92697 USA; Univ Calif Irvine, Dept Biophys, Irvine, CA 92697 USA; Univ Minnesota, Sch Med, Dept Pharmacol, Minneapolis, MN 55455 USA; Dept Vet Affairs Med Ctr, Long Beach, CA 90822 USA	University of California System; University of California Irvine; University of California System; University of California Irvine; University of California System; University of California Irvine; University of Minnesota System; University of Minnesota Twin Cities; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Long Beach Healthcare System	Said, HM (corresponding author), Dept Vet Affairs Med Ctr 151, Long Beach, CA 90822 USA.	hmsaid@uci.edu	MARCHANT, Jonathan/B-8051-2009; Marchant, Jonathan/Q-5484-2019	MARCHANT, Jonathan/0000-0001-6592-0877; Marchant, Jonathan/0000-0001-6592-0877	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [F32DK063750, R01DK056061, R01DK058057, R37DK056061] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS046783] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK-63750, DK-58057, DK-56061] Funding Source: Medline; NINDS NIH HHS [NS-046783] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Abramson J, 2003, SCIENCE, V301, P610, DOI 10.1126/science.1088196; Altschuler Y, 2003, CURR OPIN CELL BIOL, V15, P423, DOI 10.1016/S0955-0674(03)00084-X; AXELROD D, 1989, METHOD CELL BIOL, V30, P245; BACALLAO R, 1989, J CELL BIOL, V109, P2817, DOI 10.1083/jcb.109.6.2817; Berdanier CD, 1998, ADV NUTR MICRONUTRIE, P80; Boulware MJ, 2003, BIOCHEM J, V376, P43, DOI 10.1042/BJ20031220; Burkhardt JK, 1997, J CELL BIOL, V139, P469, DOI 10.1083/jcb.139.2.469; Callamaras N, 1999, CELL CALCIUM, V26, P271, DOI 10.1054/ceca.1999.0085; Cheng CL, 2002, J NEUROSCI, V22, P10643; Chuang JZ, 1998, J CELL BIOL, V142, P1245, DOI 10.1083/jcb.142.5.1245; Deacon SW, 2003, J CELL BIOL, V160, P297, DOI 10.1083/jcb.200210066; Diaz GA, 1999, NAT GENET, V22, P309, DOI 10.1038/10385; Dudeja PK, 2001, AM J PHYSIOL-CELL PH, V281, pC786, DOI 10.1152/ajpcell.2001.281.3.C786; Dunbar LA, 2000, J CELL BIOL, V148, P769, DOI 10.1083/jcb.148.4.769; Dutta B, 1999, J BIOL CHEM, V274, P31925, DOI 10.1074/jbc.274.45.31925; Echeverri CJ, 1996, J CELL BIOL, V132, P617, DOI 10.1083/jcb.132.4.617; Eudy JD, 2000, MOL GENET METAB, V71, P581, DOI 10.1006/mgme.2000.3112; Fleming JC, 1999, NAT GENET, V22, P305, DOI 10.1038/10379; Gastaldi G, 2000, KIDNEY INT, V57, P2043, DOI 10.1046/j.1523-1755.2000.00053.x; GOLDSCHMIDT RB, 1989, BRAIN RES, V486, P133, DOI 10.1016/0006-8993(89)91285-7; Hirai T, 2002, NAT STRUCT BIOL, V9, P597, DOI 10.1038/nsb821; Hirokawa N, 1998, SCIENCE, V279, P519, DOI 10.1126/science.279.5350.519; Hou ZJ, 2005, J BIOL CHEM, V280, P36206, DOI 10.1074/jbc.M507295200; Huang YF, 2003, SCIENCE, V301, P616, DOI 10.1126/science.1087619; Karim-Jimenez Z, 2000, P NATL ACAD SCI USA, V97, P2916, DOI 10.1073/pnas.97.6.2916; King SJ, 2003, MOL BIOL CELL, V14, P5089, DOI 10.1091/mbc.E03-01-0025; Kreitzer G, 2003, NAT CELL BIOL, V5, P126, DOI 10.1038/ncb917; Kundu A, 1996, J VIROL, V70, P6508, DOI 10.1128/JVI.70.9.6508-6515.1996; Labay V, 1999, NAT GENET, V22, P300, DOI 10.1038/10372; LAFONT F, 1994, NATURE, V372, P801; Lin SS, 1998, J CELL BIOL, V142, P51, DOI 10.1083/jcb.142.1.51; Marchant JS, 2002, J BIOL CHEM, V277, P33325, DOI 10.1074/jbc.M205955200; Matherly LH, 2001, PROG NUCLEIC ACID RE, V67, P131, DOI 10.1016/S0079-6603(01)67027-2; MEADS T, 1995, CELL MOTIL CYTOSKEL, V32, P273, DOI 10.1002/cm.970320404; Muth TR, 1998, J BIOL CHEM, V273, P25616, DOI 10.1074/jbc.273.40.25616; Neufeld EJ, 2001, BLOOD CELL MOL DIS, V27, P135, DOI 10.1006/bcmd.2000.0356; Reidling JC, 2002, BBA-BIOMEMBRANES, V1561, P180, DOI 10.1016/S0005-2736(02)00341-3; Said HM, 2004, AM J PHYSIOL-GASTR L, V286, pG491, DOI 10.1152/ajpgi.00361.2003; Said HM, 2001, AM J PHYSIOL-GASTR L, V281, pG144, DOI 10.1152/ajpgi.2001.281.1.G144; Schroer TA, 2004, ANNU REV CELL DEV BI, V20, P759, DOI 10.1146/annurev.cellbio.20.012103.094623; Subramanian VS, 2004, J BIOL CHEM, V279, P27719, DOI 10.1074/jbc.M400876200; Subramanian VS, 2003, J BIOL CHEM, V278, P3976, DOI 10.1074/jbc.M210717200; Subramanian VS, 2001, AM J PHYSIOL-GASTR L, V281, pG1477, DOI 10.1152/ajpgi.2001.281.6.G1477; Sun AQ, 2001, J BIOL CHEM, V276, P6825, DOI 10.1074/jbc.M008797200; Suzuki T, 2001, EUR J CELL BIOL, V80, P765, DOI 10.1078/0171-9335-00204; Tai AW, 2001, J CELL BIOL, V153, P1499, DOI 10.1083/jcb.153.7.1499; Tamura N, 2001, J BIOL CHEM, V276, P20330, DOI 10.1074/jbc.M007993200; Toomre D, 2001, TRENDS CELL BIOL, V11, P298, DOI 10.1016/S0962-8924(01)02027-X; Trinczek B, 1999, J CELL SCI, V112, P2355; Valetti C, 1999, MOL BIOL CELL, V10, P4107, DOI 10.1091/mbc.10.12.4107; VICTOR M, 1989, WERNICKEKORSAKOFF SY; Wang YR, 2003, J CELL SCI, V116, P2051, DOI 10.1242/jcs.00398; Welte MA, 2004, CURR BIOL, V14, pR525, DOI 10.1016/j.cub.2004.06.045; Zeng WQ, 2005, AM J HUM GENET, V77, P16, DOI 10.1086/431216	54	29	30	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 24	2006	281	8					5233	5245		10.1074/jbc.M512765200	http://dx.doi.org/10.1074/jbc.M512765200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	013RF	16371350				2022-12-25	WOS:000235426200078
J	Kamimoto, T; Shoji, S; Hidvegi, T; Mizushima, N; Umebayashi, K; Perlmutter, DH; Yoshimori, T				Kamimoto, T; Shoji, S; Hidvegi, T; Mizushima, N; Umebayashi, K; Perlmutter, DH; Yoshimori, T			Intracellular inclusions containing mutant alpha(1)-antitrypsin Z are propagated in the absence of autophagic activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENDOPLASMIC-RETICULUM; CONJUGATION SYSTEM; QUALITY-CONTROL; LIVER-DISEASE; DEGRADATION; PROTEIN; AGGRESOMES; MATURATION; INHIBITORS; RETENTION	Mutant alpha(1)-antitrypsin Z (alpha(1)-ATZ) protein, which has a tendency to form aggregated polymers as it accumulates within the endoplasmic reticulum of the liver cells, is associated with the development of chronic liver injury and hepatocellular carcinoma in hereditary alpha(1)-antitrypsin (alpha(1)-AT) deficiency. Previous studies have suggested that efficient intracellular degradation of alpha(1)-ATZ is correlated with protection from liver disease in alpha(1)-AT deficiency and that the ubiquitinproteasome system accounts for a major route, but not the sole route, of alpha(1)-ATZ disposal. Yet another intracellular degradation system, autophagy, has also been implicated in the pathophysiology of alpha(1)-AT deficiency. To provide genetic evidence for autophagymediated disposal of alpha(1)-ATZ, here we used cell lines deleted for the Atg5 gene that is necessary for initiation of autophagy. In the absence of autophagy, the degradation of alpha(1)-ATZ was retarded, and the characteristic cellular inclusions of alpha(1)-ATZ accumulated. In wild-type cells, colocalization of the autophagosomal membrane marker GFP-LC3 and alpha(1)-ATZ was observed, and this colocalization was enhanced when clearance of autophagosomes was prevented by inhibiting fusion between autophagosome and lysosome. By using a transgenic mouse with liver-specific inducible expression of alpha(1)-ATZ mated to the GFP-LC3 mouse, we also found that expression of alpha(1)-ATZ in the liver in vivo is sufficient to induce autophagy. These data provide definitive evidence that autophagy can participate in the quality control/degradative pathway for alpha(1)-ATZ and suggest that autophagic degradation plays a fundamental role in preventing toxic accumulation of alpha(1)-ATZ.	Natl Inst Genet, Dept Cell Genet, Shizuoka 4558540, Japan; Grad Univ Adv Studies, Dept Genet, Mishima, Shizuoka 4558540, Japan; Natl Inst Basic Biol, Dept Cell Biol, Okazaki, Aichi 4448585, Japan; Univ Pittsburgh, Sch Med, Childrens Hosp Pittsburgh, Dept Pediat Cell Biol & Physiol, Pittsburgh, PA 15213 USA; Tokyo Metropolitan Inst Med Sci, Dept Bioregulat & Metab, Tokyo 1138613, Japan; Japan Sci & Technol Agcy, PRESTO, Kawaguchi 3320012, Japan; Japan Sci & Technol Agcy, CREST, Kawaguchi 3320012, Japan	Research Organization of Information & Systems (ROIS); National Institute of Genetics (NIG) - Japan; Graduate University for Advanced Studies - Japan; National Institutes of Natural Sciences (NINS) - Japan; National Institute for Basic Biology (NIBB); Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Tokyo Metropolitan Institute of Medical Science; Japan Science & Technology Agency (JST); Japan Science & Technology Agency (JST)	Yoshimori, T (corresponding author), Natl Inst Genet, Dept Cell Genet, Yata 1111 Mishima, Shizuoka 4558540, Japan.	tamyoshi@lab.nig.ac.jp	Shoji, Shisako/C-3690-2017; Hidvegi, Tunda/A-8041-2008; Mizushima, Noboru/C-3635-2009; Shoji, Shisako/AAJ-2654-2020	Shoji, Shisako/0000-0001-8787-2159; Mizushima, Noboru/0000-0002-6258-6444; Shoji, Shisako/0000-0001-8787-2159	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL037784] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK061760] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL037784] Funding Source: Medline; NIDDK NIH HHS [DK061760, DK52565] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BOLENDER RP, 1973, J CELL BIOL, V56, P746, DOI 10.1083/jcb.56.3.746; Cabral CM, 2000, J BIOL CHEM, V275, P25015, DOI 10.1074/jbc.M910172199; Dantuma NP, 2000, NAT BIOTECHNOL, V18, P538, DOI 10.1038/75406; Ellgaard L, 2003, NAT REV MOL CELL BIO, V4, P181, DOI 10.1038/nrm1052; Gutierrez MG, 2004, J CELL SCI, V117, P2687, DOI 10.1242/jcs.01114; Hidvegi T, 2005, J BIOL CHEM, V280, P39002, DOI 10.1074/jbc.M508652200; Jager S, 2004, J CELL SCI, V117, P4837, DOI 10.1242/jcs.01370; Johnston JA, 1998, J CELL BIOL, V143, P1883, DOI 10.1083/jcb.143.7.1883; Kabeya Y, 2000, EMBO J, V19, P5720, DOI 10.1093/emboj/19.21.5720; Kabeya Y, 2004, J CELL SCI, V117, P2805, DOI 10.1242/jcs.01131; Kamhi-Nesher S, 2001, MOL BIOL CELL, V12, P1711, DOI 10.1091/mbc.12.6.1711; Komatsu M, 2005, J CELL BIOL, V169, P425, DOI 10.1083/jcb.200412022; Kopito RR, 2000, EMBO REP, V1, P225, DOI 10.1093/embo-reports/kvd052; Kuma A, 2004, NATURE, V432, P1032, DOI 10.1038/nature03029; LE AQ, 1992, J BIOL CHEM, V267, P1072; Levine B, 2004, DEV CELL, V6, P463, DOI 10.1016/S1534-5807(04)00099-1; Lin L, 2001, J BIOL CHEM, V276, P33893, DOI 10.1074/jbc.M105226200; Lomas DA, 2002, J CLIN INVEST, V110, P1585, DOI 10.1172/JCI200216782; Marcus NY, 2000, J BIOL CHEM, V275, P1987, DOI 10.1074/jbc.275.3.1987; MASAKI R, 1987, J CELL BIOL, V104, P1207, DOI 10.1083/jcb.104.5.1207; Mizushima N, 1998, NATURE, V395, P395, DOI 10.1038/26506; Mizushima N, 2003, INT J BIOCHEM CELL B, V35, P553, DOI 10.1016/S1357-2725(02)00343-6; Mizushima N, 2001, J CELL BIOL, V152, P657, DOI 10.1083/jcb.152.4.657; Mizushima N, 2004, MOL BIOL CELL, V15, P1101, DOI 10.1091/mbc.E03-09-0704; MOLMENTI EP, 1993, J CLIN INVEST, V92, P2022, DOI 10.1172/JCI116797; Nakagawa I, 2004, SCIENCE, V306, P1037, DOI 10.1126/science.1103966; Okiyoneda T, 2004, MOL BIOL CELL, V15, P563, DOI 10.1091/mbc.E03-06-0379; Perlmutter DH, 2002, J CLIN INVEST, V110, P1579, DOI 10.1172/JCI200216787; Qu DF, 1996, J BIOL CHEM, V271, P22791, DOI 10.1074/jbc.271.37.22791; Rudnick DA, 2005, HEPATOLOGY, V42, P1001, DOI 10.1002/hep.20931; Rudnick DA, 2004, HEPATOLOGY, V39, P1048, DOI 10.1002/hep.20118; Sivasothy P, 2000, J BIOL CHEM, V275, P33663, DOI 10.1074/jbc.M004054200; Teckman JH, 2000, AM J PHYSIOL-GASTR L, V279, pG961, DOI 10.1152/ajpgi.2000.279.5.G961; Teckman JH, 2004, AM J PHYSIOL-GASTR L, V286, pG851, DOI 10.1152/ajpgi.00175.2003; Teckman JH, 2002, AM J PHYSIOL-GASTR L, V283, pG1156, DOI 10.1152/ajpgi.00041.2002; Teckman JH, 1996, HEPATOLOGY, V24, P1504, DOI 10.1002/hep.510240635; Teckman JH, 2000, AM J PHYSIOL-GASTR L, V278, pG39, DOI 10.1152/ajpgi.2000.278.1.G39; Teckman JH, 2001, J BIOL CHEM, V276, P44865, DOI 10.1074/jbc.M103703200; WU Y, 1994, P NATL ACAD SCI USA, V91, P9014, DOI 10.1073/pnas.91.19.9014; Yamamoto A, 1998, CELL STRUCT FUNCT, V23, P33, DOI 10.1247/csf.23.33; Yoshida Y, 2003, J BIOCHEM, V134, P183, DOI 10.1093/jb/mvg128; Yoshimori T, 2004, BIOCHEM BIOPH RES CO, V313, P453, DOI 10.1016/j.bbrc.2003.07.023	42	205	214	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 17	2006	281	7					4467	4476		10.1074/jbc.M509409200	http://dx.doi.org/10.1074/jbc.M509409200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	011NN	16365039	hybrid			2022-12-25	WOS:000235275300082
J	Kihara, A; Anada, Y; Igarashi, Y				Kihara, A; Anada, Y; Igarashi, Y			Mouse sphingosine kinase isoforms SPHK1a and SPHK1b differ in enzymatic traits including stability, localization, modification, and oligomerization	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FUNCTIONAL-CHARACTERIZATION; CALCIUM MOBILIZATION; MOLECULAR-CLONING; SPHINGOSINE-1-PHOSPHATE; PROTEIN; IDENTIFICATION; 1-PHOSPHATE; RECEPTOR; PHOSPHORYLATION; MEMBRANE	Sphingosine kinases catalyze the production of the bioactive lipid molecule sphingosine 1-phosphate. Mice have two isoforms of sphingosine kinase type 1, SPHK1a and SPHK1b. In addition to the previously reported difference in their enzyme activities, we have found that these isoforms differ in several enzymatic characteristics. First, SPHK1b is unstable, whereas SPHK1a is highly stable. Degradation of SPHK1b occurs at the membrane and is inhibited by a proteasome inhibitor. Second, only SPHK1b exhibits abnormal mobility on SDS-PAGE, probably due to its SDS-resistant structure. Third, SPHK1a and SPHK1b are predominantly detected in the soluble and membrane fractions, respectively, when their degradation is inhibited. Fourth, only SPHK1b is modified with lipid, on its unique Cys residues (Cys-4 and Cys-5). Site-directed mutagenesis at these Cys residues resulted in increased sphingosine kinase activity, suggesting that the modification is inhibitory to the enzyme. Finally, SPHK1b tends to form homo-oligomers, whereas most SPHK1a is presented as monomers. We have also determined that the lipid modification of SPHK1b is involved in its homo-oligomerization. Thus, although these two proteins differ only in a few N-terminal amino acid residues, their enzymatic traits are extremely different.	Hokkaido Univ, Grad Sch Pharmaceut Sci, Dept Biomembrane & Biofunct Chem, Kita Ku, Sapporo, Hokkaido 0600812, Japan	Hokkaido University	Kihara, A (corresponding author), Hokkaido Univ, Grad Sch Pharmaceut Sci, Dept Biomembrane & Biofunct Chem, Kita Ku, Kita 12-Jo,Nishi 6-Choume, Sapporo, Hokkaido 0600812, Japan.	kihara@pharm.hokudai.ac.jp	KIHARA, AKIO/A-3802-2012	KIHARA, AKIO/0000-0001-5889-0788				Allende ML, 2004, J BIOL CHEM, V279, P52487, DOI 10.1074/jbc.M406512200; Allende ML, 2004, J BIOL CHEM, V279, P15396, DOI 10.1074/jbc.M314291200; Billich A, 2003, J BIOL CHEM, V278, P47408, DOI 10.1074/jbc.M307687200; Blakey D, 2002, BIOCHEM J, V364, P527, DOI 10.1042/BJ20011761; Borgnia MJ, 1999, J MOL BIOL, V291, P1169, DOI 10.1006/jmbi.1999.3032; Brinkmann V, 2002, J BIOL CHEM, V277, P21453, DOI 10.1074/jbc.C200176200; Choi OH, 1996, NATURE, V380, P634; Fukata M, 2004, NEURON, V44, P987, DOI 10.1016/j.neuron.2004.12.005; Fukuda Y, 2004, BBA-MOL CELL BIOL L, V1636, P12, DOI 10.1016/j.bbalip.2003.11.006; Fukuda Y, 2003, BIOCHEM BIOPH RES CO, V309, P155, DOI 10.1016/S0006-291X(03)01551-1; Gaillard I, 1996, BIOCHEMISTRY-US, V35, P6150, DOI 10.1021/bi953005v; Hayashi S, 2002, J BIOL CHEM, V277, P33319, DOI 10.1074/jbc.M201442200; Heginbotham L, 1997, BIOCHEMISTRY-US, V36, P10335, DOI 10.1021/bi970988i; Hirschman JE, 1999, MOL CELL BIOL, V19, P7705; Hla T, 2004, SEMIN CELL DEV BIOL, V15, P513, DOI 10.1016/j.semcdb.2004.05.002; Imai S, 2002, J BIOL CHEM, V277, P35323, DOI 10.1074/jbc.M202035200; Imamura T, 2004, J VET MED SCI, V66, P1387, DOI 10.1292/jvms.66.1387; Imamura T, 2001, GENOMICS, V76, P117, DOI 10.1006/geno.2001.6607; Johnson KR, 2002, J BIOL CHEM, V277, P35257, DOI 10.1074/jbc.M203033200; Kharel Y, 2005, J BIOL CHEM, V280, P36865, DOI 10.1074/jbc.M506293200; Kihara A, 2005, MOL CELL BIOL, V25, P9189, DOI 10.1128/MCB.25.21.9189-9197.2005; Kihara A, 2003, J BIOL CHEM, V278, P14578, DOI 10.1074/jbc.M211416200; Kohama T, 1998, J BIOL CHEM, V273, P23722, DOI 10.1074/jbc.273.37.23722; Lacana E, 2002, J BIOL CHEM, V277, P32947, DOI 10.1074/jbc.M202841200; Liu H, 2000, J BIOL CHEM, V275, P19513, DOI 10.1074/jbc.M002759200; Liu YJ, 2000, J CLIN INVEST, V106, P951, DOI 10.1172/JCI10905; Lu W, 2001, J BIOL CHEM, V276, P47993, DOI 10.1074/jbc.M109674200; Maceyka M, 2004, FEBS LETT, V568, P30, DOI 10.1016/j.febslet.2004.04.093; Mandala S, 2002, SCIENCE, V296, P346, DOI 10.1126/science.1070238; Matloubian M, 2004, NATURE, V427, P355, DOI 10.1038/nature02284; MAZUREK N, 1994, BIOCHEM BIOPH RES CO, V198, P1, DOI 10.1006/bbrc.1994.1001; Melendez A, 1998, J BIOL CHEM, V273, P9393, DOI 10.1074/jbc.273.16.9393; Ogawa C, 2003, J BIOL CHEM, V278, P1268, DOI 10.1074/jbc.M209514200; Olivera A, 1998, J BIOL CHEM, V273, P12576, DOI 10.1074/jbc.273.20.12576; OLIVERA A, 1993, NATURE, V365, P557, DOI 10.1038/365557a0; Pitson SM, 2003, EMBO J, V22, P5491, DOI 10.1093/emboj/cdg540; Pitson SM, 2002, J BIOL CHEM, V277, P49545, DOI 10.1074/jbc.M206687200; Pyne S, 2000, BIOCHEM J, V349, P385, DOI 10.1042/0264-6021:3490385; Resh MD, 1999, BBA-MOL CELL RES, V1451, P1, DOI 10.1016/S0167-4889(99)00075-0; Smotrys JE, 2004, ANNU REV BIOCHEM, V73, P559, DOI 10.1146/annurev.biochem.73.011303.073954; Spiegel S, 2003, NAT REV MOL CELL BIO, V4, P397, DOI 10.1038/nrm1103; Taha TA, 2004, BBA-MOL CELL BIOL L, V1682, P48, DOI 10.1016/S1388-1981(04)00023-X; Xia P, 1998, P NATL ACAD SCI USA, V95, P14196, DOI 10.1073/pnas.95.24.14196; Xia P, 2002, J BIOL CHEM, V277, P7996, DOI 10.1074/jbc.M111423200; Yatomi Y, 1997, J BIOCHEM, V121, P969; Yokota S, 2004, FEBS LETT, V578, P106, DOI 10.1016/j.febslet.2004.10.081	46	77	78	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 17	2006	281	7					4532	4539		10.1074/jbc.M510308200	http://dx.doi.org/10.1074/jbc.M510308200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	011NN	16368679	hybrid			2022-12-25	WOS:000235275300089
J	Lindermayr, C; Saalbach, G; Bahnweg, G; Durner, J				Lindermayr, C; Saalbach, G; Bahnweg, G; Durner, J			Differential inhibition of Arabidopsis methionine adenosyltransferases by protein S-nitrosylation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLANT NITRATE REDUCTASE; ACTIVE-SITE LOOP; NITRIC-OXIDE; ADENOSYLMETHIONINE SYNTHETASE; IN-VITRO; CRYSTAL-STRUCTURE; ABSCISIC-ACID; NO; IDENTIFICATION; SIGNAL	In animals, protein S-nitrosylation, the covalent attachment of NO to the thiol group of cysteine residues, is an intensively investigated posttranslational modification, which regulates many different processes. A growing body of evidence suggests that this type of redox-based regulation mechanism plays a pivotal role in plants, too. Here we report the molecular mechanism for S-nitrosylation of methionine adenosyltransferase (MAT) of Arabidopsis thaliana, thereby presenting the first detailed characterization of S-nitrosylation in plants. We cloned three MAT isoforms of Arabidopsis and tested the effect of NO on the activity of the purified, recombinant proteins. Our data showed that incubation with GSNO resulted in blunt, reversible inhibition of MAT1, whereas MAT2 and MAT3 were not significantly affected. Cys-114 of MAT1 was identified as the most promising target of NO-induced inhibition of MAT1, because this residue is absent in MAT2 and MAT3. Structural analysis of MAT1 revealed that Cys-114 is located nearby the putative substrate binding site of this enzyme. Furthermore, Cys-114 is flanked by S-nitrosylation-promoting amino acids. The inhibitory effect of GSNO was drastically reduced when Cys-114 of MAT1 was replaced by arginine, and mass spectrometric analyses of Cys-114-containing peptides obtained after chymotryptic digestion demonstrated that Cys-114 of MAT1 is indeed S-nitrosylated. Because MAT catalyzes the synthesis of the ethylene precursor S-adenosylmethionine and NO is known to influence ethylene production in plants, this enzyme probably mediates the cross-talk between ethylene and NO signaling.	GSF Munich, Natl Res Ctr Environm & Hlth, Inst Biochem Plant Pathol, D-85764 Munich, Germany; Riso Natl Lab, Plant Res Dept, DK-4000 Roskilde, Denmark	Helmholtz Association; Helmholtz-Center Munich - German Research Center for Environmental Health; University of Munich; Technical University of Denmark	Durner, J (corresponding author), GSF Munich, Natl Res Ctr Environm & Hlth, Inst Biochem Plant Pathol, Ingolstadter Landstr 1, D-85764 Munich, Germany.	durner@gsf.de	Lindermayr, Christian/M-7338-2014	Lindermayr, Christian/0000-0002-9343-4996				Akhand AK, 1999, J BIOL CHEM, V274, P25821, DOI 10.1074/jbc.274.36.25821; Avila MA, 1997, HEPATOLOGY, V25, P391; Beligni MV, 2002, PLANT PHYSIOL, V129, P1642, DOI 10.1104/pp.002337; Bethke PC, 2004, PLANT CELL, V16, P332, DOI 10.1105/tpc.017822; Brandish PE, 1998, BIOCHEMISTRY-US, V37, P16898, DOI 10.1021/bi9814989; Castro C, 1999, FEBS LETT, V459, P319, DOI 10.1016/S0014-5793(99)01267-3; Corrales FJ, 2002, J NUTR, V132, p2377S, DOI 10.1093/jn/132.8.2377S; Delledonne M, 1998, NATURE, V394, P585, DOI 10.1038/29087; Durner J, 1998, P NATL ACAD SCI USA, V95, P10328, DOI 10.1073/pnas.95.17.10328; Eu JP, 2000, CELL, V102, P499, DOI 10.1016/S0092-8674(00)00054-4; Feechan A, 2005, P NATL ACAD SCI USA, V102, P8054, DOI 10.1073/pnas.0501456102; Garcia-Mata C, 2003, TRENDS PLANT SCI, V8, P20, DOI 10.1016/S1360-1385(02)00009-2; Gaston Benjamin M, 2003, Mol Interv, V3, P253, DOI 10.1124/mi.3.5.253; Graziano M, 2005, TRENDS PLANT SCI, V10, P4, DOI 10.1016/j.tplants.2004.12.004; Graziano M, 2002, PLANT PHYSIOL, V130, P1852, DOI 10.1104/pp.009076; Guex N, 1997, ELECTROPHORESIS, V18, P2714, DOI 10.1002/elps.1150181505; Guo FQ, 2003, SCIENCE, V302, P100, DOI 10.1126/science.1086770; Haendeler J, 2002, NAT CELL BIOL, V4, P743, DOI 10.1038/ncb851; Hao G, 2004, J BIOL CHEM, V279, P36192, DOI 10.1074/jbc.M404866200; Hess DT, 2005, NAT REV MOL CELL BIO, V6, P150, DOI 10.1038/nrm1569; Huang JY, 2001, NUCLEIC ACIDS RES, V29, P202, DOI 10.1093/nar/29.1.202; Kim SO, 2002, CELL, V109, P383, DOI 10.1016/S0092-8674(02)00723-7; Komoto J, 2004, BIOCHEMISTRY-US, V43, P1821, DOI 10.1021/bi035611t; Lamattina L, 2003, ANNU REV PLANT BIOL, V54, P109, DOI 10.1146/annurev.arplant.54.031902.134752; LANDY A, 1989, ANNU REV BIOCHEM, V58, P913, DOI 10.1146/annurev.biochem.58.1.913; Leshem YY, 1998, PLANT PHYSIOL BIOCH, V36, P825, DOI 10.1016/S0981-9428(99)80020-5; Leshem YY, 1996, J PLANT PHYSIOL, V148, P258, DOI 10.1016/S0176-1617(96)80251-3; Leshem YY, 2000, NITRIC OXIDE PLANTS; Lindermayr C, 2005, PLANT PHYSIOL, V137, P921, DOI 10.1104/pp.104.058719; Lindermayr C, 2003, J BIOL CHEM, V278, P2781, DOI 10.1074/jbc.M202632200; Liu LM, 2001, NATURE, V410, P490, DOI 10.1038/35068596; Mannick JB, 2004, FREE RADICAL RES, V38, P1, DOI 10.1080/10715760310001629065; Martinez-Ruiz A, 2004, CARDIOVASC RES, V62, P43, DOI 10.1016/j.cardiores.2004.01.013; MATO JM, 1994, ADV EXP MED BIOL, V368, P113; Matsumoto A, 2003, SCIENCE, V301, P657, DOI 10.1126/science.1079319; Neill SJ, 2002, PLANT PHYSIOL, V128, P13, DOI 10.1104/pp.010707; Perazzolli M, 2004, PLANT CELL, V16, P2785, DOI 10.1105/tpc.104.025379; Perez-Mato I, 1999, J BIOL CHEM, V274, P17075, DOI 10.1074/jbc.274.24.17075; Rockel P, 2002, J EXP BOT, V53, P103, DOI 10.1093/jexbot/53.366.103; Ruiz F, 1998, HEPATOLOGY, V28, P1051, DOI 10.1002/hep.510280420; Russwurm M, 2004, EMBO J, V23, P4443, DOI 10.1038/sj.emboj.7600422; Sanchez-Perez GF, 2004, J MOL BIOL, V335, P693, DOI 10.1016/j.jmb.2003.11.022; Shen B, 2002, PLANT J, V29, P371, DOI 10.1046/j.1365-313X.2002.01221.x; Sokolovski S, 2004, PLANT PHYSIOL, V136, P4275, DOI 10.1104/pp.104.050344; STAMLER JS, 1992, P NATL ACAD SCI USA, V89, P7674, DOI 10.1073/pnas.89.16.7674; Stamler JS, 1997, NEURON, V18, P691, DOI 10.1016/S0896-6273(00)80310-4; Stohr C, 2001, PLANTA, V212, P835, DOI 10.1007/s004250000447; Takusagawa F, 1996, J BIOL CHEM, V271, P136, DOI 10.1074/jbc.271.1.136; Takusagawa F, 1996, BIOCHEMISTRY-US, V35, P2586, DOI 10.1021/bi952604z; Taylor JC, 2003, ARCH BIOCHEM BIOPHYS, V415, P164, DOI 10.1016/S0003-9861(03)00277-7; Taylor JC, 2002, BIOCHEMISTRY-US, V41, P9358, DOI 10.1021/bi025851t; Tedeschi G, 2005, PROTEOMICS, V5, P2422, DOI 10.1002/pmic.200401208; Tuomainen J, 1997, PLANT J, V12, P1151, DOI 10.1046/j.1365-313X.1997.12051151.x; Wang KLC, 2002, PLANT CELL, V14, pS131, DOI 10.1105/tpc.001768; Wendehenne D, 2004, CURR OPIN PLANT BIOL, V7, P449, DOI 10.1016/j.pbi.2004.04.002; Yamasaki H, 2000, FEBS LETT, V468, P89, DOI 10.1016/S0014-5793(00)01203-5; Zeidler D, 2004, P NATL ACAD SCI USA, V101, P15811, DOI 10.1073/pnas.0404536101	57	191	213	0	19	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 17	2006	281	7					4285	4291		10.1074/jbc.M511635200	http://dx.doi.org/10.1074/jbc.M511635200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	011NN	16365035	hybrid			2022-12-25	WOS:000235275300062
J	Twiddy, D; Cohen, GM; MacFarlane, M; Cain, K				Twiddy, D; Cohen, GM; MacFarlane, M; Cain, K			Caspase-7 is directly activated by the similar to 700-kDa apoptosome complex and is released as a stable XIAP-caspase-7 similar to 200-kDa complex	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTERLEUKIN-1-BETA CONVERTING-ENZYME; INHIBITOR-INDUCED APOPTOSIS; CHEMICAL-INDUCED APOPTOSIS; BREAST-CANCER CELLS; CYTOCHROME-C; APAF-1 APOPTOSOME; DEATH; PROTEASOME; MECHANISM; MODEL	MCF-7 cells lack caspase-3 but undergo mitochondrial-dependent apoptosis via caspase-7 activation. It is assumed that the Apaf-1-caspase-9 apoptosome processes caspase-7 in an analogous manner to that described for caspase-3. However, this has not been validated experimentally, and we have now characterized the caspase-7 activating apoptosome complex in MCF-7 cell lysates activated with dATP/cytochrome c. Apaf-1 oligomerizes to produce similar to 1.4-MDa and similar to 700-kDa apoptosome complexes, and the latter complex directly cleaves/activates procaspase-7. This similar to 700-kDa apoptosome complex, which is also formed in apoptotic MCF-7 cells, is assembled by rapid oligomerization of Apaf-1 and followed by a slower process of procaspase-9 recruitment and cleavage to form the p35/34 forms. However, procaspase-9 recruitment and processing are accelerated in lysates supplemented with caspase-3. In lysates containing very low levels of Smac and Omi/HtrA2, XIAP (X-linked inhibitor of apoptosis) binds tightly to caspase-9 in the apoptosome complex, and as a result caspase-7 processing is abrogated. In contrast, in MCF-7 lysates containing Smac and Omi/HtrA2, active caspase-7 is released from the apoptosome and forms a stable similar to 200-kDa XIAP-caspase-7 complex, which apparently does not contain cIAP1 or cIAP2. Thus, in comparison to caspase-3-containing cells, XIAP appears to have a more significant antiapoptotic role in MCF-7 cells because it directly inhibits caspase-7 activation by the apoptosome and also forms a stable similar to 200-kDa complex with active caspase-7.	Univ Leicester, MRC, Toxicol Unit, Leicester LE1 9HN, Leics, England	University of Leicester	Cain, K (corresponding author), Univ Leicester, MRC, Toxicol Unit, Lancaster Rd, Leicester LE1 9HN, Leics, England.	kc5@le.ac.uk	Cohen, Gerald M/A-1687-2008		Medical Research Council [MC_U132685863] Funding Source: Medline; MRC [MC_U132685863] Funding Source: UKRI	Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))		Adrain C, 2001, TRENDS BIOCHEM SCI, V26, P390, DOI 10.1016/S0968-0004(01)01844-8; Almond JB, 2001, LEUKEMIA, V15, P1388, DOI 10.1038/sj.leu.2402201; Boatright KM, 2003, MOL CELL, V11, P529, DOI 10.1016/S1097-2765(03)00051-0; Bratton SB, 2000, EXP CELL RES, V256, P27, DOI 10.1006/excr.2000.4835; Bratton SB, 2001, CELL DEATH DIFFER, V8, P425, DOI 10.1038/sj.cdd.4400834; Bratton SB, 2001, EMBO J, V20, P998, DOI 10.1093/emboj/20.5.998; Cain K, 2002, BIOCHIMIE, V84, P203, DOI 10.1016/S0300-9084(02)01376-7; Cain K, 2003, DRUG METAB REV, V35, P337, DOI 10.1081/DMR-120026497; Cain K, 2000, J BIOL CHEM, V275, P6067, DOI 10.1074/jbc.275.9.6067; Cain K, 1999, J BIOL CHEM, V274, P22686, DOI 10.1074/jbc.274.32.22686; Chai JJ, 2001, CELL, V107, P399, DOI 10.1016/S0092-8674(01)00544-X; Chandler JM, 1998, J BIOL CHEM, V273, P10815, DOI 10.1074/jbc.273.18.10815; Cohen GM, 1997, BIOCHEM J, V326, P1, DOI 10.1042/bj3260001; Denault JB, 2003, J BIOL CHEM, V278, P34042, DOI 10.1074/jbc.M305110200; Devarajan E, 2002, ONCOGENE, V21, P8843, DOI 10.1038/sj.onc.1206044; Dewson G, 2003, ONCOGENE, V22, P2643, DOI 10.1038/sj.onc.1206326; Earnshaw WC, 1999, ANNU REV BIOCHEM, V68, P383, DOI 10.1146/annurev.biochem.68.1.383; Fuentes-Prior P, 2004, BIOCHEM J, V384, P201, DOI 10.1042/BJ20041142; Garcia-Calvo M, 1999, CELL DEATH DIFFER, V6, P362, DOI 10.1038/sj.cdd.4400497; Goyal L, 2000, EMBO J, V19, P589, DOI 10.1093/emboj/19.4.589; Harlin H, 2001, MOL CELL BIOL, V21, P3604, DOI 10.1128/MCB.21.10.3604-3608.2001; Hengartner M, 1998, SCIENCE, V281, P1298, DOI 10.1126/science.281.5381.1298; Hill MM, 2004, EMBO J, V23, P2134, DOI 10.1038/sj.emboj.7600210; Janicke RU, 1998, J BIOL CHEM, V273, P9357, DOI 10.1074/jbc.273.16.9357; Janicke RU, 1998, J BIOL CHEM, V273, P15540, DOI 10.1074/jbc.273.25.15540; Kurokawa H, 1999, ONCOL REP, V6, P33; Li P, 1997, CELL, V91, P479, DOI 10.1016/S0092-8674(00)80434-1; Liu XS, 1996, CELL, V86, P147, DOI 10.1016/S0092-8674(00)80085-9; MacFarlane M, 2000, J CELL BIOL, V148, P1239, DOI 10.1083/jcb.148.6.1239; MacFarlane M, 1997, J CELL BIOL, V137, P469, DOI 10.1083/jcb.137.2.469; Renatus M, 2001, P NATL ACAD SCI USA, V98, P14250, DOI 10.1073/pnas.231465798; Riedl SJ, 2001, P NATL ACAD SCI USA, V98, P14790, DOI 10.1073/pnas.221580098; Rodriguez J, 1999, GENE DEV, V13, P3179, DOI 10.1101/gad.13.24.3179; Rotonda J, 1996, NAT STRUCT BIOL, V3, P619, DOI 10.1038/nsb0796-619; Salvesen GS, 1999, P NATL ACAD SCI USA, V96, P10964, DOI 10.1073/pnas.96.20.10964; Salvesen GS, 2002, NAT REV MOL CELL BIO, V3, P401, DOI 10.1038/nrm830; Salvesen GS, 2004, ONCOGENE, V23, P2774, DOI 10.1038/sj.onc.1207522; Scott FL, 2005, EMBO J, V24, P645, DOI 10.1038/sj.emboj.7600544; Simstein R, 2003, EXP BIOL MED, V228, P995, DOI 10.1177/153537020322800903; Slee EA, 1999, J CELL BIOL, V144, P281, DOI 10.1083/jcb.144.2.281; Srinivasula SM, 2001, NATURE, V410, P112, DOI 10.1038/35065125; Stennicke HR, 1999, J BIOL CHEM, V274, P8359, DOI 10.1074/jbc.274.13.8359; Sun XM, 2004, MOL CELL, V14, P81, DOI 10.1016/S1097-2765(04)00156-X; Sun XM, 1999, J BIOL CHEM, V274, P5053, DOI 10.1074/jbc.274.8.5053; Tang DM, 2000, J BIOL CHEM, V275, P9303, DOI 10.1074/jbc.275.13.9303; Tenev T, 2005, NAT CELL BIOL, V7, P70, DOI 10.1038/ncb1204; Twiddy D, 2004, J BIOL CHEM, V279, P19665, DOI 10.1074/jbc.M311388200; Wei YY, 2000, CHEM BIOL, V7, P423, DOI 10.1016/S1074-5521(00)00123-X; WILSON KP, 1994, NATURE, V370, P270, DOI 10.1038/370270a0; Yang XH, 2001, CANCER RES, V61, P348; Yang XH, 1998, J BIOL CHEM, V273, P34278, DOI 10.1074/jbc.273.51.34278; Zhivotovsky B, 1999, CELL DEATH DIFFER, V6, P644, DOI 10.1038/sj.cdd.4400536; Zou H, 1997, CELL, V90, P405, DOI 10.1016/S0092-8674(00)80501-2	53	41	44	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 17	2006	281	7					3876	3888		10.1074/jbc.M507393200	http://dx.doi.org/10.1074/jbc.M507393200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	011NN	16352606	hybrid			2022-12-25	WOS:000235275300015
J	Letts, JA; Rose, NL; Fang, YR; Barry, CH; Borisova, SN; Seto, NOL; Palcic, MM; Evans, SV				Letts, JA; Rose, NL; Fang, YR; Barry, CH; Borisova, SN; Seto, NOL; Palcic, MM; Evans, SV			Differential recognition of the type I and IIH antigen acceptors by the human ABO(H) blood group A and B glycosyltransferases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GENE-SPECIFIED GLYCOSYLTRANSFERASES; ANALOGS; ALPHA-L-FUCP-(1->2)-BETA-D-GALP-OR; BIOSYNTHESIS; SYSTEM	The human ABO( H) blood group A and B antigens are generated by the homologous glycosyltransferases A (GTA) and B (GTB), which add the monosaccharides GalNAc and Gal, respectively, to the cell-surface H antigens. In the first comprehensive structural study of the recognition by a glycosyltransferase of a panel of substrates corresponding to acceptor fragments, 14 high resolution crystal structures of GTA and GTB have been determined in the presence of oligosaccharides corresponding to different segments of the type I (alpha-L-Fucp-(1 -> 2)-beta-D-Galp-(1 -> 3)-beta-D-GlcNAcp-OR, where R is a glycoprotein or glycolipid in natural acceptors) and type II (alpha-L-Fucp-(1 -> 2)-beta-D-Galp-(1 -> 4)-beta-D-GlcNAcp-OR) H antigen trisaccharides. GTA and GTB differ in only four '' critical '' amino acid residues (Arg/Gly-176, Gly/Ser-235, Leu/Met-266, and Gly/Ala-268). As these enzymes both utilize the H antigen acceptors, the four critical residues had been thought to be involved strictly in donor recognition; however, we now report that acceptor binding and subsequent transfer are significantly influenced by two of these residues: Gly/Ser-235 and Leu/Met-266. Furthermore, these structures show that acceptor recognition is dominated by the central Gal residue despite the fact that the L-Fuc residue is required for efficient catalysis and give direct insight into the design of model inhibitors for GTA and GTB.	Univ Victoria, Dept Biochem & Microbiol, Victoria, BC V8W 3P6, Canada; Univ Alberta, Dept Chem, Edmonton, AB T6G 2G2, Canada	University of Victoria; University of Alberta	Evans, SV (corresponding author), Univ Victoria, Dept Biochem & Microbiol, POB 3055 STN SCS, Victoria, BC V8W 3P6, Canada.	svevans@uvic.ca	Letts, James Anthony/AAN-6632-2020	Letts, James Anthony/0000-0002-9864-3586; Evans, Stephen/0000-0002-0366-4027				Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; CLAUSEN H, 1989, VOX SANG, V56, P1, DOI 10.1111/j.1423-0410.1989.tb03040.x; Coutinho PM, 2003, J MOL BIOL, V328, P307, DOI 10.1016/S0022-2836(03)00307-3; EVANS SV, 1993, J MOL GRAPHICS, V11, P134, DOI 10.1016/0263-7855(93)87009-T; Hakomori S, 1999, BBA-GEN SUBJECTS, V1473, P247, DOI 10.1016/S0304-4165(99)00183-X; Lazar K, 2002, CURR OPIN CHEM BIOL, V6, P786, DOI 10.1016/S1367-5931(02)00355-1; Liu Jianhua, 2001, Current Drug Targets - Infectious Disorders, V1, P159, DOI 10.2174/1568005014606107; LOWARY TL, 1993, CARBOHYD RES, V249, P163, DOI 10.1016/0008-6215(93)84068-H; LOWARY TL, 1994, CARBOHYD RES, V251, P33, DOI 10.1016/0008-6215(94)84275-2; Marcus SL, 2003, J BIOL CHEM, V278, P12403, DOI 10.1074/jbc.M212002200; Nguyen HP, 2003, J BIOL CHEM, V278, P49191, DOI 10.1074/jbc.M308770200; Patenaude SI, 2002, NAT STRUCT BIOL, V9, P685, DOI 10.1038/nsb832; Pflugrath JW, 1999, ACTA CRYSTALLOGR D, V55, P1718, DOI 10.1107/S090744499900935X; SCHWYZER M, 1977, J BIOL CHEM, V252, P2346; Seto NOL, 1999, EUR J BIOCHEM, V259, P770, DOI 10.1046/j.1432-1327.1999.00086.x; Seto NOL, 2000, CARBOHYD RES, V324, P161, DOI 10.1016/S0008-6215(99)00297-9; Somsak L, 2003, CURR PHARM DESIGN, V9, P1177, DOI 10.2174/1381612033454919; YAMAMOTO F, 1990, NATURE, V345, P229, DOI 10.1038/345229a0; YAMAMOTO F, 1992, BIOCHEM BIOPH RES CO, V187, P366, DOI 10.1016/S0006-291X(05)81502-5	19	32	33	1	14	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 10	2006	281	6					3625	3632		10.1074/jbc.M507620200	http://dx.doi.org/10.1074/jbc.M507620200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	009QV	16326711	hybrid			2022-12-25	WOS:000235128200074
J	Mareninova, OA; Sung, KF; Hong, P; Lugea, A; Pandol, SJ; Gukovsky, I; Gukovskaya, AS				Mareninova, OA; Sung, KF; Hong, P; Lugea, A; Pandol, SJ; Gukovsky, I; Gukovskaya, AS			Cell death in pancreatitis - Caspases protect from necrotizing pancreatitis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECEPTOR-INTERACTING PROTEIN; ACINAR-CELLS; APAF-1 APOPTOSOME; CYTOCHROME-C; KINASE RIP; ACTIVATION; NECROSIS; MITOCHONDRIAL; INHIBITION; NEUTROPHILS	Mechanisms of cell death in pancreatitis remain unknown. Parenchymal necrosis is a major complication of pancreatitis; also, the severity of experimental pancreatitis correlates directly with necrosis and inversely with apoptosis. Thus, shifting death responses from necrosis to apoptosis may have a therapeutic value. To determine cell death pathways in pancreatitis and the possibility of necrosis/apoptosis switch, we utilized the differences between the rat model of cerulein pancreatitis, with relatively high apoptosis and low necrosis, and the mouse model, with little apoptosis and high necrosis. We found that caspases were greatly activated during cerulein pancreatitis in the rat but not mouse. Endogenous caspase inhibitor X-linked inhibitor of apoptosis protein (XIAP) underwent complete degradation in the rat but remained intact in the mouse model. Furthermore, XIAP inhibition with embelin triggered caspase activation in the mouse model, implicating XIAP in caspase blockade in pancreatitis. Caspase inhibitors decreased apoptosis and markedly stimulated necrosis in the rat model, worsening pancreatitis parameters. Conversely, caspase induction with embelin stimulated apoptosis and decreased necrosis in mouse model. Thus, caspases not only mediate apoptosis but also protect from necrosis in pancreatitis. One protective mechanism is through degradation of receptor-interacting protein (RIP), a key mediator of "programmed" necrosis. We found that RIP was cleaved (i.e. inactivated) in the rat but not the mouse model. Caspase inhibition restored RIP levels; conversely, caspase induction with embelin triggered RIP cleavage. Our results indicate key roles for caspases, XIAP, and RIP in the regulation of cell death in pancreatitis. Manipulating these signals to change the pattern of death responses presents a therapeutic strategy for treatment of pancreatitis.	Univ Calif Los Angeles, Vet Affairs Greater Los Angeles Healthcare Syst, W Los Angeles Vet Affairs Med Ctr, Los Angeles, CA 90073 USA; Univ Calif Los Angeles, David Geffen Sch Med, Dept Med, Los Angeles, CA 90073 USA; Chang Gung Mem Hosp, Dept HepatoGastroenterol, Taipei 333, Taiwan	University of California System; University of California Los Angeles; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Greater Los Angeles Healthcare System; West Los Angeles VA Medical Center; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; Chang Gung Memorial Hospital	Gukovskaya, AS (corresponding author), Univ Calif Los Angeles, Vet Affairs Greater Los Angeles Healthcare Syst, W Los Angeles Vet Affairs Med Ctr, 11301 Wilshire Blvd,Bldg 258,Rm 340, Los Angeles, CA 90073 USA.	agukovsk@ucla.edu		Gukovskaya, Anna/0000-0003-3737-5335	NIDDK NIH HHS [DK59936] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK059936] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Adams JM, 2003, GENE DEV, V17, P2481, DOI 10.1101/gad.1126903; Alvarado-Kristensson M, 2005, J BIOL CHEM, V280, P6238, DOI 10.1074/jbc.M409718200; Bassi C, 2003, PANCREATOLOGY, V3, P128, DOI 10.1159/000070080; Bhatia M, 2000, J PATHOL, V190, P117; Bhatia M, 2004, AM J PHYSIOL-GASTR L, V286, pG189, DOI 10.1152/ajpgi.00304.2003; Bhatia M, 1998, BIOCHEM BIOPH RES CO, V246, P476, DOI 10.1006/bbrc.1998.8519; Blinman TA, 2000, AM J PHYSIOL-CELL PH, V279, pC1993, DOI 10.1152/ajpcell.2000.279.6.C1993; Bratton SB, 2002, CELL DEATH DIFFER, V9, P881, DOI 10.1038/sj.cdd.4401069; Bratton SB, 2001, EMBO J, V20, P998, DOI 10.1093/emboj/20.5.998; Caserta TM, 2003, APOPTOSIS, V8, P345, DOI 10.1023/A:1024116916932; Chan FKM, 2003, J BIOL CHEM, V278, P51613, DOI 10.1074/jbc.M305633200; Chen XQ, 2002, GASTROENTEROLOGY, V122, P448, DOI 10.1053/gast.2002.31060; CHITRA M, 1994, CHEMOTHERAPY, V40, P109, DOI 10.1159/000239181; Connor S, 2004, WORLD J GASTROENTERO, V10, P1697; Du CY, 2000, CELL, V102, P33, DOI 10.1016/S0092-8674(00)00008-8; Edinger AL, 2004, CURR OPIN CELL BIOL, V16, P663, DOI 10.1016/j.ceb.2004.09.011; Ekert PG, 1999, CELL DEATH DIFFER, V6, P1081, DOI 10.1038/sj.cdd.4400594; Fiers W, 1999, ONCOGENE, V18, P7719, DOI 10.1038/sj.onc.1203249; GORELICK PS, 1993, PANCREAS BIOL PATHOL, P64; Guimaraes CA, 2004, EUR J BIOCHEM, V271, P1638, DOI 10.1111/j.1432-1033.2004.04084.x; Gukovsaya AS, 1996, GASTROENTEROLOGY, V110, P875, DOI 10.1053/gast.1996.v110.pm8608898; Gukovskaya AS, 2002, J BIOL CHEM, V277, P22595, DOI 10.1074/jbc.M202929200; Gukovskaya AS, 1997, J CLIN INVEST, V100, P1853, DOI 10.1172/JCI119714; Gukovskaya AS, 2004, PANCREATOLOGY, V4, P567, DOI 10.1159/000082182; Gukovskaya AS, 2002, GASTROENTEROLOGY, V122, P974, DOI 10.1053/gast.2002.32409; Gukovsky I, 1998, AM J PHYSIOL-GASTR L, V275, pG1402, DOI 10.1152/ajpgi.1998.275.6.G1402; GUPTA S, 1989, CONTRACEPTION, V39, P307, DOI 10.1016/0010-7824(89)90063-2; Harlin H, 2001, MOL CELL BIOL, V21, P3604, DOI 10.1128/MCB.21.10.3604-3608.2001; Hayakawa K, 2003, CIRCULATION, V108, P104, DOI 10.1161/01.CIR.0000074225.62168.68; Hegyi P, 2004, WORLD J GASTROENTERO, V10, P2003, DOI 10.3748/wjg.v10.i14.2003; Henson PM, 2001, NAT REV MOL CELL BIO, V2, P627, DOI 10.1038/35085094; Holler N, 2000, NAT IMMUNOL, V1, P489, DOI 10.1038/82732; Jaattela M, 2003, NAT IMMUNOL, V4, P416, DOI 10.1038/ni0503-416; JENSEN RT, 1989, TRENDS PHARMACOL SCI, V10, P418, DOI 10.1016/0165-6147(89)90192-2; Johnson CR, 2004, APOPTOSIS, V9, P423, DOI 10.1023/B:APPT.0000031457.90890.13; KAISER AM, 1995, AM J PHYSIOL-CELL PH, V269, pC1295, DOI 10.1152/ajpcell.1995.269.5.C1295; Kakimura J, 2001, EUR J PHARMACOL, V417, P59, DOI 10.1016/S0014-2999(01)00902-5; Kasahara Y, 2000, J CLIN INVEST, V106, P1311, DOI 10.1172/JCI10259; Kim JW, 2000, ONCOGENE, V19, P4491, DOI 10.1038/sj.onc.1203796; Krieser RJ, 2002, CURR OPIN CELL BIOL, V14, P734, DOI 10.1016/S0955-0674(02)00390-3; Krueger A, 2001, J BIOL CHEM, V276, P20633, DOI 10.1074/jbc.M101780200; Kuida K, 1996, NATURE, V384, P368, DOI 10.1038/384368a0; Lee HC, 2000, J BIOMED SCI, V7, P2, DOI 10.1007/BF02255913; Leist M, 2001, NAT REV MOL CELL BIO, V2, P589, DOI 10.1038/35085008; LERCH MM, 1994, INT J PANCREATOL, V15, P159; Lin Y, 2004, J BIOL CHEM, V279, P10822, DOI 10.1074/jbc.M313141200; Lin Y, 1999, GENE DEV, V13, P2514, DOI 10.1101/gad.13.19.2514; LUTHEN R, 1995, AM J PHYSIOL-GASTR L, V268, pG592, DOI 10.1152/ajpgi.1995.268.4.G592; LUTHEN RE, 1995, PANCREAS, V11, P141; MacFarlane M, 2002, J BIOL CHEM, V277, P36611, DOI 10.1074/jbc.M200317200; Martin DA, 1998, J BIOL CHEM, V273, P4345, DOI 10.1074/jbc.273.8.4345; Melnikov VY, 2002, J CLIN INVEST, V110, P1083, DOI 10.1172/JCI200215623; Nikolovska-Coleska Z, 2004, J MED CHEM, V47, P2430, DOI 10.1021/jm030420+; Norman J, 1998, AM J SURG, V175, P76, DOI 10.1016/S0002-9610(97)00240-7; Norman JG, 1999, DIGESTION, V60, P57, DOI 10.1159/000051455; Peter Marcus E, 2004, Biochem J, V382, pe1; Proskuryakov SY, 2003, EXP CELL RES, V283, P1, DOI 10.1016/S0014-4827(02)00027-7; Raraty Michael G T, 2004, Curr Gastroenterol Rep, V6, P99, DOI 10.1007/s11894-004-0035-0; Reed J. C., 2004, SCI STKE, V2004, pre9, DOI DOI 10.1126/STKE.2392004RE9; Reed JC, 2005, BLOOD, V106, P408, DOI 10.1182/blood-2004-07-2761; Saluja A, 1996, BIOCHEM BIOPH RES CO, V220, P875, DOI 10.1006/bbrc.1996.0498; Salvesen GS, 2002, NAT REV MOL CELL BIO, V3, P401, DOI 10.1038/nrm830; Sandoval D, 1996, GASTROENTEROLOGY, V111, P1081, DOI 10.1016/S0016-5085(96)70077-X; Scaffidi C, 1997, J BIOL CHEM, V272, P26953, DOI 10.1074/jbc.272.43.26953; Scaffidi C, 1998, EMBO J, V17, P1675, DOI 10.1093/emboj/17.6.1675; Schotte P, 1999, FEBS LETT, V442, P117, DOI 10.1016/S0014-5793(98)01640-8; Slee EA, 2001, J BIOL CHEM, V276, P7320, DOI 10.1074/jbc.M008363200; Soares RV, 2002, ARCH ORAL BIOL, V47, P591, DOI 10.1016/S0003-9969(02)00047-X; Steer ML, 1999, BEST PRACT RES CL GA, V13, P213, DOI 10.1053/bega.1999.0020; Sumino M, 2002, CHEM PHARM BULL, V50, P1484, DOI 10.1248/cpb.50.1484; Sun XM, 1999, J BIOL CHEM, V274, P5053, DOI 10.1074/jbc.274.8.5053; Tang DM, 2000, J BIOL CHEM, V275, P9303, DOI 10.1074/jbc.275.13.9303; Tashiro M, 2001, GUT, V49, P241, DOI 10.1136/gut.49.2.241; Thome M, 2001, NAT REV IMMUNOL, V1, P50, DOI 10.1038/35095508; Vaquero EC, 2003, GASTROENTEROLOGY, V125, P1188, DOI 10.1016/S0016-5085(03)01203-4; Vercammen D, 1998, J EXP MED, V187, P1477, DOI 10.1084/jem.187.9.1477; von Harsdorf R, 2004, CIRC RES, V95, P554, DOI 10.1161/01.RES.0000143717.70275.8f; Wolf BB, 1999, J BIOL CHEM, V274, P20049, DOI 10.1074/jbc.274.29.20049	78	228	248	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 10	2006	281	6					3370	3381		10.1074/jbc.M511276200	http://dx.doi.org/10.1074/jbc.M511276200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	009QV	16339139	hybrid			2022-12-25	WOS:000235128200045
J	Pavlovic, S; Du, B; Sakamoto, K; Khan, KMF; Natarajan, C; Breyer, RM; Dannenberg, AJ; Falcone, DJ				Pavlovic, S; Du, B; Sakamoto, K; Khan, KMF; Natarajan, C; Breyer, RM; Dannenberg, AJ; Falcone, DJ			Targeting prostaglandin E-2 receptors as an alternative strategy to block cyclooxygenase-2-dependent extracellular matrix-induced matrix metalloproteinase-9 expression by macrophages	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-KINASE; SMOOTH-MUSCLE-CELLS; HMG-COA REDUCTASE; PROSTANOID RECEPTORS; ATHEROSCLEROTIC PLAQUES; PHOSPHATIDYLINOSITOL 3-KINASE; TYROSINE PHOSPHORYLATION; PLASMINOGEN ACTIVATION; MMP-9 SECRETION; MESSENGER-RNA	COX-2-dependent prostaglandin (PG) E-2 synthesis regulates macrophage MMP expression, which is thought to destabilize atherosclerotic plaques. However, the administration of selective COX-2 inhibitors paradoxically increases the frequency of adverse cardiovascular events potentially through the loss of anti-inflammatory prostanoids and/or disturbance in the balance of pro-and anti-thrombotic prostanoids. To avoid these collateral effects of COX-2 inhibition, a strategy to identify and block specific prostanoid-receptor interactions may be required. We previously reported that macrophage engagement of vascular extracellular matrix (ECM) triggers proteinase expression through a MAPK(erk1/2)-dependent increase in COX-2 expression and PGE(2) synthesis. Here we demonstrate that elicited macrophages express the PGE(2) receptors EP1-4. When plated on ECM, their expression of EP2 and EP4, receptors linked to PGE(2)-induced activation of adenylyl cyclase, is strongly stimulated. Forskolin and dibutryl cyclic-AMP stimulate macrophage matrix metalloproteinase (MMP)-9 expression in a dose-dependent manner. However, an EP2 agonist (butaprost) has no effect on MMP-9 expression, and macrophages from EP2 null mice exhibited enhanced COX-2 and MMP-9 expression when plated on ECM. In contrast, the EP4 agonist (PGE(1)-OH) stimulated macrophage MMP-9 expression, which was inhibited by the EP4 antagonist ONO-AE3-208. When compared with COX-2 silencing by small interfering RNA or inhibition by celecoxib, the EP4 antagonist was as effective in inhibiting ECM-induced proteinase expression. In addition, ECM-induced MMP-9 expression was blocked in macrophages in which EP4 was silenced by small interfering RNA. Thus, COX-2-dependent ECM-induced proteinase expression is effectively blocked by selective inhibition of EP4, a member of the PGE(2) family of receptors.	Cornell Univ, Joan & Sanford I Weill Med Coll, Dept Pathol & Lab Med, New York, NY 10021 USA; Cornell Univ, Joan & Sanford I Weill Med Coll, Vasc Biol Ctr, New York, NY 10021 USA; Cornell Univ, Joan & Sanford I Weill Med Coll, Dept Cell & Dev Biol, New York, NY 10021 USA; Cornell Univ, Joan & Sanford I Weill Med Coll, Dept Med, New York, NY 10021 USA; Vanderbilt Univ, Sch Med, Dept Med, Nashville, TN 37232 USA; Vanderbilt Univ, Sch Med, Dept Pharmacol, Nashville, TN 37232 USA	Cornell University; Cornell University; Cornell University; Cornell University; Vanderbilt University; Vanderbilt University	Falcone, DJ (corresponding author), Cornell Univ, Joan & Sanford I Weill Med Coll, Dept Pathol & Lab Med, Rm A678,1300 York Ave, New York, NY 10021 USA.	dfalcone@med.cornell.edu			NCI NIH HHS [CA089578] Funding Source: Medline; NHLBI NIH HHS [R01 HL073375, HL073375] Funding Source: Medline; NIGMS NIH HHS [GM15431, P50 GM015431] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA089578] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL073375] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [P01GM015431, P50GM015431] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Abramovitz M, 2000, BBA-MOL CELL BIOL L, V1483, P285, DOI 10.1016/S1388-1981(99)00164-X; Akaogi J, 2004, J LEUKOCYTE BIOL, V76, P227, DOI 10.1189/jlb.1203627; Baker CSR, 1999, ARTERIOSCL THROM VAS, V19, P646, DOI 10.1161/01.ATV.19.3.646; Bayston T, 2003, J VASC SURG, V38, P354, DOI 10.1016/S0741-5214(03)00339-2; Bellosta S, 1998, ARTERIOSCL THROM VAS, V18, P1671, DOI 10.1161/01.ATV.18.11.1671; Belton O, 2000, CIRCULATION, V102, P840; Boie Y, 1997, EUR J PHARMACOL, V340, P227, DOI 10.1016/S0014-2999(97)01383-6; Breyer RM, 2002, ADV EXP MED BIOL, V507, P321; Breyer RM, 2001, ANNU REV PHARMACOL, V41, P661, DOI 10.1146/annurev.pharmtox.41.1.661; Burleigh ME, 2002, CIRCULATION, V105, P1816, DOI 10.1161/01.CIR.0000014927.74465.7F; Chen BC, 1999, IMMUNOLOGY, V97, P124, DOI 10.1046/j.1365-2567.1999.00747.x; Cheng Y, 2002, SCIENCE, V296, P539, DOI 10.1126/science.1068711; Cipollone F, 2005, ARTERIOSCL THROM VAS, V25, P1925, DOI 10.1161/01.ATV.0000177814.41505.41; Cipollone F, 2004, ARTERIOSCL THROM VAS, V24, P1259, DOI 10.1161/01.ATV.0000133192.39901.be; Cipollone F, 2004, JAMA-J AM MED ASSOC, V291, P2221, DOI 10.1001/jama.291.18.2221; Cipollone F, 2003, CIRCULATION, V107, P1479, DOI 10.1161/01.CIR.0000056530.03783.81; Cipollone F, 2001, CIRCULATION, V104, P921, DOI 10.1161/hc3401.093152; CORCORAN ML, 1994, ARCH BIOCHEM BIOPHYS, V310, P481, DOI 10.1006/abbi.1994.1196; CORCORAN ML, 1995, J BIOL CHEM, V270, P10365, DOI 10.1074/jbc.270.18.10365; de Fougerolles AR, 2000, IMMUNITY, V13, P749, DOI 10.1016/S1074-7613(00)00073-X; de Gaetano G, 2003, TRENDS PHARMACOL SCI, V24, P245, DOI 10.1016/S0165-6147(03)00077-4; Dohadwala M, 2002, J BIOL CHEM, V277, P50828, DOI 10.1074/jbc.M210707200; EDELSON PJ, 1976, IN VITRO METHODS CEL, P333; FALCONE DJ, 1993, J BIOL CHEM, V268, P11951; FALCONE DJ, 1988, J CELL PHYSIOL, V135, P387, DOI 10.1002/jcp.1041350305; Faour WH, 2001, J BIOL CHEM, V276, P31720, DOI 10.1074/jbc.M104036200; Fujino H, 2003, TRENDS PHARMACOL SCI, V24, P335, DOI 10.1016/S0165-6147(03)00162-7; Fujino H, 2003, J BIOL CHEM, V278, P12151, DOI 10.1074/jbc.M212665200; GALIS ZS, 1994, J CLIN INVEST, V94, P2493, DOI 10.1172/JCI117619; GALIS ZS, 1995, P NATL ACAD SCI USA, V92, P402, DOI 10.1073/pnas.92.2.402; Ganne F, 2000, THROMB HAEMOSTASIS, V84, P680, DOI 10.1055/s-0037-1614087; Hansson GK, 2005, NEW ENGL J MED, V352, P1685, DOI 10.1056/NEJMra043430; Hata AN, 2004, PHARMACOL THERAPEUT, V103, P147, DOI 10.1016/j.pharmthera.2004.06.003; Hernandez-Presa MA, 2002, ATHEROSCLEROSIS, V160, P49, DOI 10.1016/S0021-9150(01)00547-0; Hla T, 1999, INT J BIOCHEM CELL B, V31, P551, DOI 10.1016/S1357-2725(98)00152-6; Holmes DR, 1996, J SURG RES, V63, P305, DOI 10.1006/jsre.1996.0265; Hubbard NE, 2001, PROSTAG LEUKOTR ESS, V65, P287, DOI 10.1054/plef.2001.0327; Hwang Daniel H., 2002, Neoplasia (New York), V4, P91, DOI 10.1038/sj.neo.7900226; Ikegami R, 2001, J IMMUNOL, V166, P4689, DOI 10.4049/jimmunol.166.7.4689; Kennedy CRJ, 1999, NAT MED, V5, P217, DOI 10.1038/5583; Khan KMF, 2004, J BIOL CHEM, V279, P22039, DOI 10.1074/jbc.M312735200; Khan KMF, 1997, J BIOL CHEM, V272, P8270, DOI 10.1074/jbc.272.13.8270; Kiriyama M, 1997, BRIT J PHARMACOL, V122, P217, DOI 10.1038/sj.bjp.0701367; Kobayashi T, 2002, PROSTAG OTH LIPID M, V68-9, P557, DOI 10.1016/S0090-6980(02)00055-2; LIN TH, 1994, J CELL BIOL, V126, P1585, DOI 10.1083/jcb.126.6.1585; LIN TH, 1995, J BIOL CHEM, V270, P16189, DOI 10.1074/jbc.270.27.16189; Ma WY, 2003, EXP NEUROL, V183, P581, DOI 10.1016/S0014-4886(03)00182-1; McAdam BF, 1999, P NATL ACAD SCI USA, V96, P272, DOI 10.1073/pnas.96.1.272; McCoy JM, 2002, J CLIN INVEST, V110, P651, DOI 10.1172/JCI200215528; McGeer PL, 2002, EXP GERONTOL, V37, P925, DOI 10.1016/S0531-5565(02)00028-1; MORENO PR, 1994, CIRCULATION, V90, P775, DOI 10.1161/01.CIR.90.2.775; Mukherjee D, 2001, JAMA-J AM MED ASSOC, V286, P954, DOI 10.1001/jama.286.8.954; Narumiya S, 2003, LIFE SCI, V74, P391, DOI 10.1016/j.lfs.2003.09.025; Ottino P, 2001, CURR EYE RES, V23, P77, DOI 10.1076/ceyr.23.2.77.5471; RASCHKE WC, 1978, CELL, V15, P261, DOI 10.1016/0092-8674(78)90101-0; Ray WA, 2002, LANCET, V360, P1071, DOI 10.1016/S0140-6736(02)11131-7; Regan JW, 2003, LIFE SCI, V74, P143, DOI 10.1016/j.lfs.2003.09.031; Robbie L, 2001, ANN NY ACAD SCI, V947, P167; Schonbeck U, 1999, AM J PATHOL, V155, P1281, DOI 10.1016/S0002-9440(10)65230-3; SHAH PK, 1995, CIRCULATION, V92, P1565; Shankavaram UT, 1997, J CELL PHYSIOL, V173, P327, DOI 10.1002/(SICI)1097-4652(199712)173:3<327::AID-JCP4>3.3.CO;2-R; Smith WL, 2001, J CLIN INVEST, V107, P1491, DOI 10.1172/JCI13271; Stemme V, 2000, EUR J VASC ENDOVASC, V20, P146, DOI 10.1053/ejvs.2000.1145; Takayama K, 2002, J BIOL CHEM, V277, P44147, DOI 10.1074/jbc.M204810200; Tanabe T, 2002, PROSTAG OTH LIPID M, V68-9, P95, DOI 10.1016/S0090-6980(02)00024-2; Tani K, 2001, BIOORG MED CHEM LETT, V11, P2025, DOI 10.1016/S0960-894X(01)00359-6; Treffkorn L, 2004, PROSTAG OTH LIPID M, V74, P113, DOI 10.1016/j.prostaglandins.2004.07.005; Wang DZ, 2005, CANCER RES, V65, P1822, DOI 10.1158/0008-5472.CAN-04-3671	68	84	86	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 10	2006	281	6					3321	3328		10.1074/jbc.M506846200	http://dx.doi.org/10.1074/jbc.M506846200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	009QV	16338931	hybrid			2022-12-25	WOS:000235128200039
J	Seo, DW; Li, HM; Qu, CK; Oh, J; Kim, YS; Diaz, T; Wei, BY; Han, JW; Stetler-Stevenson, WG				Seo, DW; Li, HM; Qu, CK; Oh, J; Kim, YS; Diaz, T; Wei, BY; Han, JW; Stetler-Stevenson, WG			Shp-1 mediates the antiproliferative activity of tissue inhibitor of metalloproteinase-2 in human microvascular endothelial cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TYROSINE-PHOSPHATASE SHP-1; DIFFERENTIAL REGULATION; MOTH-EATEN; P27(KIP1); INTEGRIN; ANGIOGENESIS; PROTEIN; GROWTH; CYCLE; EXPRESSION	The tissue inhibitors of metalloproteinases (TIMPs) regulate matrix metalloproteinase activity required for cell migration/invasion associated with cancer progression and angiogenesis. TIMPs also modulate cell proliferation in vitro and angiogenesis in vivo independent of their matrix metalloproteinase inhibitory activity. Here, we show that TIMP-2 mediates G(1) growth arrest in human endothelial cells through de novo synthesis of the cyclin-dependent kinase inhibitor p27(Kip1). TIMP-2-mediated inhibition of Cdk4 and Cdk2 activity is associated with increased binding of p27(Kip1) to these complexes in vivo. Protein-tyrosine phosphatase inhibitors or expression of a dominant negative Shp-1 mutant ablates TIMP-2 induction of p27(Kip1). Finally, angiogenic responses to fibroblast growth factor-2 and vascular endothelial growth factor-A in '' motheaten viable '' Shp-1-deficient mice are resistant to TIMP-2 inhibition, demonstrating that Shp-1 is an important negative regulator of angiogenesis in vivo.	NCI, NIH, Cell & Canc Biol Branch, Ctr Canc Res, Bethesda, MD 20892 USA; Univ Maryland, Sch Med, Dept Pathol, Rockville, MD 20855 USA; Sungkyunkwan Univ, Coll Pharm, Dept Biochem & Mol Biol, Suwon 440746, South Korea	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Sungkyunkwan University (SKKU)	Stetler-Stevenson, WG (corresponding author), NCI, NIH, Cell & Canc Biol Branch, Ctr Canc Res, Bldg 37,Rm 1062B, Bethesda, MD 20892 USA.	sstevenw@mail.nih.gov	Stetler-Stevenson, William/AAE-3501-2020; Stetler-Stevenson, William G/H-6956-2012	Stetler-Stevenson, William/0000-0002-5500-5808; Stetler-Stevenson, William G/0000-0002-5500-5808; Seo, Dong-Wan/0000-0003-4971-834X	Intramural NIH HHS [Z01 SC009179] Funding Source: Medline; NCI NIH HHS [Z01 SC009179-17] Funding Source: Medline; NATIONAL CANCER INSTITUTE [Z01SC009179] Funding Source: NIH RePORTER	Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Akahane T, 2004, EXP CELL RES, V301, P158, DOI 10.1016/j.yexcr.2004.08.002; Belkin AM, 1998, J BIOL CHEM, V273, P15234, DOI 10.1074/jbc.273.24.15234; Berrier AL, 2000, J CELL BIOL, V151, P1549, DOI 10.1083/jcb.151.7.1549; Boehm M, 2002, EMBO J, V21, P3390, DOI 10.1093/emboj/cdf343; Carmeliet P, 2000, NAT MED, V6, P389, DOI 10.1038/74651; Carrano AC, 1999, NAT CELL BIOL, V1, P193, DOI 10.1038/12013; Chang C, 2001, TRENDS CELL BIOL, V11, pS37, DOI 10.1016/S0962-8924(01)82222-4; Chen F, 2005, CELL SIGNAL, V17, P809, DOI 10.1016/j.cellsig.2004.11.002; Ezhevsky SA, 2001, MOL CELL BIOL, V21, P4773, DOI 10.1128/MCB.21.14.4773-4784.2001; Fernandez CA, 2003, J BIOL CHEM, V278, P40989, DOI 10.1074/jbc.M306176200; Fornaro M, 1999, J CLIN INVEST, V103, P321, DOI 10.1172/JCI4585; Guedez L, 2003, AM J PATHOL, V162, P1431, DOI 10.1016/S0002-9440(10)64276-9; Guedez L, 1998, J CLIN INVEST, V102, P2002, DOI 10.1172/JCI2881; Guedez L, 2001, AM J PATHOL, V158, P1207, DOI 10.1016/S0002-9440(10)64070-9; Hoegy SE, 2001, J BIOL CHEM, V276, P3203, DOI 10.1074/jbc.M008157200; Kalluri R, 2003, NAT REV CANCER, V3, P422, DOI 10.1038/nrc1094; KATO JY, 1994, CELL, V79, P487, DOI 10.1016/0092-8674(94)90257-7; Kim CH, 1999, J EXP MED, V190, P681, DOI 10.1084/jem.190.5.681; KOZLOWSKI M, 1993, J EXP MED, V178, P2157, DOI 10.1084/jem.178.6.2157; Liu XW, 2003, J BIOL CHEM, V278, P40364, DOI 10.1074/jbc.M302999200; Malumbres M, 2001, NAT REV CANCER, V1, P222, DOI 10.1038/35106065; Mattila E, 2005, NAT CELL BIOL, V7, P78, DOI 10.1038/ncb1209; Meredith JE, 1999, J BIOL CHEM, V274, P8111, DOI 10.1074/jbc.274.12.8111; MURPHY AN, 1993, J CELL PHYSIOL, V157, P351, DOI 10.1002/jcp.1041570219; Nakagami H, 2002, ARTERIOSCL THROM VAS, V22, P238, DOI 10.1161/hq0202.104001; Neel BG, 2003, TRENDS BIOCHEM SCI, V28, P284, DOI 10.1016/S0968-0004(03)00091-4; Oh J, 2004, CANCER RES, V64, P9062, DOI 10.1158/0008-5472.CAN-04-1981; Qi JH, 2003, NAT MED, V9, P407, DOI 10.1038/nm846; Roach TIA, 1998, CURR BIOL, V8, P1035, DOI 10.1016/S0960-9822(07)00426-5; Rodier G, 2001, EMBO J, V20, P6672, DOI 10.1093/emboj/20.23.6672; Seo DW, 2003, CELL, V114, P171, DOI 10.1016/S0092-8674(03)00551-8; Servant MJ, 2000, J CELL BIOL, V148, P543, DOI 10.1083/jcb.148.3.543; VARNER JA, 1995, MOL BIOL CELL, V6, P725, DOI 10.1091/mbc.6.6.725; Vidal A, 2000, GENE, V247, P1, DOI 10.1016/S0378-1119(00)00092-5; Viglietto G, 2002, NAT MED, V8, P1136, DOI 10.1038/nm762; Visse R, 2003, CIRC RES, V92, P827, DOI 10.1161/01.RES.0000070112.80711.3D; Wingfield PT, 1999, J BIOL CHEM, V274, P21362, DOI 10.1074/jbc.274.30.21362	37	108	113	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 10	2006	281	6					3711	3721		10.1074/jbc.M509932200	http://dx.doi.org/10.1074/jbc.M509932200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	009QV	16326706	hybrid, Green Accepted			2022-12-25	WOS:000235128200083
J	Todeschini, AL; Condon, C; Benard, L				Todeschini, AL; Condon, C; Benard, L			Sodium-induced GCN4 expression controls the accumulation of the 5 ' to 3 ' RNA degradation inhibitor, 3 '-phosphoadenosine 5 '-phosphate	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SACCHAROMYCES-CEREVISIAE; SALT TOLERANCE; GENE-EXPRESSION; MESSENGER-RNAS; PROCESSING ENZYMES; STRESS CONDITIONS; MASTER REGULATOR; KINASE GCN2; YEAST; PROTEIN	Most cytoplasmic mRNAs are decapped and digested by the 5'-3'-exonuclease Xrn1p in Saccharomyces cerevisiae. The activity of Xrn1p is naturally inhibited in the presence of 3'-phosphoadenosine 5'-phosphate (pAp), a metabolite produced during sulfate assimilation that is quickly metabolized to AMP by the enzymatic activity of Hal2p. However, pAp accumulates and 5'-3' degradation decreases in the presence of ions known to inhibit Hal2p activity, such as sodium or lithium. We have shown that yeast cells can better adapt to the presence of sodium than lithium because of their ability to reduce pAp accumulation by activating HAL2 expression in a Gcn4p-dependent response, a regulatory loop that is likely to be conserved in different yeast species. We have thus identified a new role for the transcriptional activity of Gcn4p in maintaining an active mRNA degradation pathway under conditions of sodium stress. Since deregulation of proteins involved in different metabolic pathways is observed in xrn1 Delta mutants, the maintenance of mRNA degradation capacity is likely to be important for the accurate and rapid adaptation of gene expression to salt stress.	Univ Paris 07, Inst Biol Physicochim, UPR 9073, CNRS, F-75005 Paris, France	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Cite	Benard, L (corresponding author), Univ Paris 07, Inst Biol Physicochim, UPR 9073, CNRS, 13,Rue Pierre & Marie Curie, F-75005 Paris, France.	lionel.benard@ibpc.fr	BENARD, LIONEL/E-4057-2019; Condon, Ciaran/F-6798-2011	BENARD, LIONEL/0000-0003-1745-1361; Condon, Ciaran/0000-0002-2199-9621				Adams A, 1997, METHODS YEAST GENETI; Albert A, 2000, J MOL BIOL, V295, P927, DOI 10.1006/jmbi.1999.3408; Albig AR, 2001, MOL BIOL CELL, V12, P3428, DOI 10.1091/mbc.12.11.3428; Anderson JSJ, 1998, EMBO J, V17, P1497, DOI 10.1093/emboj/17.5.1497; ARNDT K, 1986, P NATL ACAD SCI USA, V83, P8516, DOI 10.1073/pnas.83.22.8516; BAUDIN A, 1993, NUCLEIC ACIDS RES, V21, P3329, DOI 10.1093/nar/21.14.3329; Benard L, 2004, RNA, V10, P458, DOI 10.1261/rna.5183804; Benard L, 1998, MOL CELL BIOL, V18, P2688, DOI 10.1128/MCB.18.5.2688; CAPONIGRO G, 1995, GENE DEV, V9, P2421, DOI 10.1101/gad.9.19.2421; CHEREST H, 1971, Journal of Bacteriology, V106, P758; Crespo JL, 2002, MICROBIOL MOL BIOL R, V66, P579, DOI 10.1128/MMBR.66.4.579-591.2002; DECKER CJ, 1994, TRENDS BIOCHEM SCI, V19, P336, DOI 10.1016/0968-0004(94)90073-6; Dichtl B, 1997, EMBO J, V16, P7184, DOI 10.1093/emboj/16.23.7184; Dong JS, 2000, MOL CELL, V6, P269, DOI 10.1016/S1097-2765(00)00028-9; GAXIOLA R, 1992, EMBO J, V11, P3157, DOI 10.1002/j.1460-2075.1992.tb05392.x; GLASER HU, 1993, EMBO J, V12, P3105, DOI 10.1002/j.1460-2075.1993.tb05979.x; Goossens A, 2001, J BIOL CHEM, V276, P30753, DOI 10.1074/jbc.M102960200; HARO R, 1991, FEBS LETT, V291, P189, DOI 10.1016/0014-5793(91)81280-L; HE F, 1993, P NATL ACAD SCI USA, V90, P7034, DOI 10.1073/pnas.90.15.7034; HINNEBUSCH AG, 1985, MOL CELL BIOL, V5, P2349, DOI 10.1128/MCB.5.9.2349; Hinnebusch AG, 2002, EUKARYOT CELL, V1, P22, DOI 10.1128/EC.01.1.22-32.2002; HINNEBUSCH AG, 1992, MOL CELLULAR BIOL YE, V2, P409; HOPE IA, 1986, CELL, V46, P885, DOI 10.1016/0092-8674(86)90070-X; JOHNSON AW, 1995, MOL CELL BIOL, V15, P2719; Johnson AW, 1997, MOL CELL BIOL, V17, P6122, DOI 10.1128/MCB.17.10.6122; Kearsey S, 1991, Trends Cell Biol, V1, P110, DOI 10.1016/0962-8924(91)90101-E; KUO MS, 1986, CARBOHYD RES, V156, P173, DOI 10.1016/S0008-6215(00)90109-5; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LARIMER FW, 1992, GENE, V120, P51, DOI 10.1016/0378-1119(92)90008-D; LIM CK, 1989, J CHROMATOGR, V461, P259, DOI 10.1016/S0021-9673(00)94291-2; Mendizabal I, 1998, FEBS LETT, V425, P323, DOI 10.1016/S0014-5793(98)00249-X; MOUNTAIN HA, 1993, MOL MICROBIOL, V9, P221, DOI 10.1111/j.1365-2958.1993.tb01684.x; MUHLRAD D, 1994, GENE DEV, V8, P855, DOI 10.1101/gad.8.7.855; MUHLRAD D, 1994, NATURE, V370, P578, DOI 10.1038/370578a0; MURGUIA JR, 1995, SCIENCE, V267, P232; Murguia JR, 1996, J BIOL CHEM, V271, P29029, DOI 10.1074/jbc.271.46.29029; Narasimhan J, 2004, J BIOL CHEM, V279, P22820, DOI 10.1074/jbc.M402228200; Natarajan K, 2001, MOL CELL BIOL, V21, P4347, DOI 10.1128/MCB.21.13.4347-4368.2001; OCONNELL KF, 1995, MOL CELL BIOL, V15, P1879; Parker R, 2004, NAT STRUCT MOL BIOL, V11, P121, DOI 10.1038/nsmb724; Pascual-Ahuir M, 2001, MOL CELL BIOL, V21, P16, DOI 10.1128/MCB.21.1.16-25.2001; Rios G, 1997, YEAST, V13, P515, DOI 10.1002/(SICI)1097-0061(199705)13:6<515::AID-YEA102>3.0.CO;2-X; ROLFES RJ, 1993, MOL CELL BIOL, V13, P5099, DOI 10.1128/MCB.13.8.5099; Ros R, 1998, J BACTERIOL, V180, P3131, DOI 10.1128/JB.180.12.3131-3136.1998; ROSE M, 1983, METHOD ENZYMOL, V101, P167; Ross PL, 2004, MOL CELL PROTEOMICS, V3, P1154, DOI 10.1074/mcp.M400129-MCP200; Sambrook J., 1989, MOL CLONING LAB MANU, V2; Serrano R, 1999, J EXP BOT, V50, P1023, DOI 10.1093/jexbot/50.suppl_1.1023; Serrano R, 1996, INT REV CYTOL, V165, P1, DOI 10.1016/S0074-7696(08)62219-6; Shim J, 2002, MOL CELLS, V14, P323; STEVENS A, 1991, J BACTERIOL, V173, P7024, DOI 10.1128/jb.173.21.7024-7028.1991; THOMAS D, 1989, MOL CELL BIOL, V9, P3292, DOI 10.1128/MCB.9.8.3292; Thomas D, 1997, MICROBIOL MOL BIOL R, V61, P503, DOI 10.1128/.61.4.503-532.1997; Torchet C, 2002, MOL CELL, V9, P1285, DOI 10.1016/S1097-2765(02)00544-0; Vasudevan S, 2001, MOL CELL, V7, P1191, DOI 10.1016/S1097-2765(01)00279-9; WIELAND J, 1995, EMBO J, V14, P3870, DOI 10.1002/j.1460-2075.1995.tb00059.x; Wilusz CJ, 2004, TRENDS GENET, V20, P491, DOI 10.1016/j.tig.2004.07.011; Yale J, 2001, J BIOL CHEM, V276, P15996, DOI 10.1074/jbc.M008209200	58	15	16	1	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 10	2006	281	6					3276	3282		10.1074/jbc.M511688200	http://dx.doi.org/10.1074/jbc.M511688200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	009QV	16352596	hybrid			2022-12-25	WOS:000235128200033
J	Olivera, A; Urtz, N; Mizugishi, K; Yamashita, Y; Gilfillan, AM; Furumoto, Y; Gu, HH; Proia, RL; Baumruker, T; Rivera, J				Olivera, A; Urtz, N; Mizugishi, K; Yamashita, Y; Gilfillan, AM; Furumoto, Y; Gu, HH; Proia, RL; Baumruker, T; Rivera, J			IgE-dependent activation of sphingosine kinases 1 and 2 and secretion of sphingosine 1-phosphate requires Fyn kinase and contributes to mast cell responses	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FC-EPSILON-RI; PROTEIN-COUPLED RECEPTORS; STRESS FIBER FORMATION; ALLERGIC RESPONSE; FUNCTIONAL-CHARACTERIZATION; CALCIUM MOBILIZATION; MOLECULAR-CLONING; PLASMA-MEMBRANE; SPHINGOSINE-1-PHOSPHATE; SIGNALS	Engagement of the high affinity receptor for IgE (Fc epsilon RI) on mast cells results in the production and secretion of sphingosine 1-phosphate (S1P), a lipid metabolite present in the lungs of allergen-challenged asthmatics. Herein we report that two isoforms of sphingosine kinase (SphK1 and SphK2) are expressed and activated upon Fc epsilon RI engagement of bone marrow-derived mast cells (BMMC). Fyn kinase is required for Fc epsilon RI coupling to SphK1 and -2 and for subsequent S1P production. Normal activation of SphK1 and -2 was restored by expression of wild type Fyn but only partly with a kinase-defective Fyn, indicating that induction of SphK1 and SphK2 depended on both catalytic and noncatalytic properties of Fyn. Downstream of Fyn, the requirements for SphK1 activation differed from that of SphK2. Whereas SphK1 was considerably dependent on the adapter Grb2-associated binder 2 and phosphatidylinositol 3-OH kinase, SphK2 showed minimal dependence on these molecules. Fyn-deficient BMMC were defective in chemotaxis and, as previously reported, in degranulation. These functional responses were partly reconstituted by the addition of exogenous S1P to Fc epsilon RI-stimulated cells. Taken together with our previous study, which demonstrated delayed SphK activation in Lyn-deficient BMMC, we propose a cooperative role between Fyn and Lyn kinases in the activation of SphKs, which contributes to mast cell responses.	NIAMS, NIH, Mol Inflammat Sect, Mol Immunol & Inflammat Branch, Bethesda, MD 20892 USA; NIAID, Lab Allerg Dis, NIH, Bethesda, MD 20892 USA; NIDDK, Gen Dev & Dis Branch, Bethesda, MD 20892 USA; Novartis Inst Biomed Res Vienna, A-1235 Vienna, Austria; Harvard Univ, Sch Med, Boston, MA 02115 USA; Beth Israel Deaconess Med Ctr, Canc Biol Program, Div Hematol & Oncol, Boston, MA 02115 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS); National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK); Novartis; Harvard University; Harvard Medical School; Harvard University; Beth Israel Deaconess Medical Center	Olivera, A (corresponding author), NIAMS, NIH, Mol Inflammat Sect, Mol Immunol & Inflammat Branch, Bldg 10,Rm 9N228, Bethesda, MD 20892 USA.	oliveraa@mail.nih.gov; juan_rivera@nih.gov	Proia, Richard L/A-7908-2012	Proia, Richard/0000-0003-0456-1270	NIAID NIH HHS [AI51612] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI051612, Z01AI000850] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [Z01AR041155, Z01AR041101] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [Z01DK056000, Z01DK056015] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Ali K, 2004, NATURE, V431, P1007, DOI 10.1038/nature02991; Allende ML, 2004, J BIOL CHEM, V279, P52487, DOI 10.1074/jbc.M406512200; Burton EA, 1997, J BIOL CHEM, V272, P16189, DOI 10.1074/jbc.272.26.16189; Choi OH, 1996, NATURE, V380, P634; Edsall L, 2000, METHOD ENZYMOL, V312, P9; Gordon JR, 2000, CELL IMMUNOL, V205, P128, DOI 10.1006/cimm.2000.1714; Gu HH, 2001, NATURE, V412, P186, DOI 10.1038/35084076; Hait NC, 2005, J BIOL CHEM, V280, P29462, DOI 10.1074/jbc.M502922200; Hanna AN, 2001, MOL BIOL CELL, V12, P3618, DOI 10.1091/mbc.12.11.3618; Hobson JP, 2001, SCIENCE, V291, P1800, DOI 10.1126/science.1057559; Johnson KR, 2002, J BIOL CHEM, V277, P35257, DOI 10.1074/jbc.M203033200; Jolly PS, 2004, J EXP MED, V199, P959, DOI 10.1084/jem.20030680; Kawakami Y, 2000, J IMMUNOL, V165, P1210, DOI 10.4049/jimmunol.165.3.1210; Kirshenbaum AS, 1999, BLOOD, V94, P2333, DOI 10.1182/blood.V94.7.2333.419k30_2333_2342; Kohama T, 1998, J BIOL CHEM, V273, P23722, DOI 10.1074/jbc.273.37.23722; Liu H, 2000, J BIOL CHEM, V275, P19513, DOI 10.1074/jbc.M002759200; Liu H, 2002, PROG NUCLEIC ACID RE, V71, P493, DOI 10.1016/S0079-6603(02)71049-0; Melendez A, 1998, J BIOL CHEM, V273, P9393, DOI 10.1074/jbc.273.16.9393; Melendez AJ, 2002, J BIOL CHEM, V277, P17255, DOI 10.1074/jbc.M110944200; Olivera A, 2001, PROSTAG OTH LIPID M, V64, P123, DOI 10.1016/S0090-6980(01)00108-3; Olivera A, 1998, J BIOL CHEM, V273, P12576, DOI 10.1074/jbc.273.20.12576; OLIVERA A, 1993, NATURE, V365, P557, DOI 10.1038/365557a0; Olivera A, 2005, J IMMUNOL, V174, P1153, DOI 10.4049/jimmunol.174.3.1153; Olivera A, 2003, J BIOL CHEM, V278, P46452, DOI 10.1074/jbc.M308749200; OLIVERA A, 1994, ANAL BIOCHEM, V223, P306, DOI 10.1006/abio.1994.1589; Olivera A, 1996, J CELL BIOCHEM, V60, P529, DOI 10.1002/(SICI)1097-4644(19960315)60:4<529::AID-JCB9>3.0.CO;2-U; Parravicini V, 2002, NAT IMMUNOL, V3, P741, DOI 10.1038/ni817; Pitson SM, 2003, EMBO J, V22, P5491, DOI 10.1093/emboj/cdg540; Prieschl EE, 1999, J EXP MED, V190, P1, DOI 10.1084/jem.190.1.1; Rivera J, 2002, CURR OPIN IMMUNOL, V14, P688, DOI 10.1016/S0952-7915(02)00396-5; Saba JD, 2004, CIRC RES, V94, P724, DOI 10.1161/01.RES.0000122383.60368.24; Saitoh S, 2000, IMMUNITY, V12, P525, DOI 10.1016/S1074-7613(00)80204-6; Sanchez T, 2004, J CELL BIOCHEM, V92, P913, DOI 10.1002/jcb.20127; Smith RE, 2003, BLOOD, V102, P2532, DOI 10.1182/blood-2002-11-3596; Spiegel S, 2003, NAT REV MOL CELL BIO, V4, P397, DOI 10.1038/nrm1103; Spiegel S, 2000, ANN NY ACAD SCI, V905, P54; Tan BL, 2003, BLOOD, V101, P4725, DOI 10.1182/blood-2002-08-2521; Timokhina I, 1998, EMBO J, V17, P6250, DOI 10.1093/emboj/17.21.6250; Urtz N, 2004, MOL CELL BIOL, V24, P8765, DOI 10.1128/MCB.24.19.8765-8777.2004; Xia P, 2002, J BIOL CHEM, V277, P7996, DOI 10.1074/jbc.M111423200; Yoshimoto T, 2003, J IMMUNOL, V171, P1352, DOI 10.4049/jimmunol.171.3.1352; Young KW, 2003, CELL CALCIUM, V33, P119, DOI 10.1016/S0143-4160(02)00205-1	42	117	117	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 3	2006	281	5					2515	2525		10.1074/jbc.M508931200	http://dx.doi.org/10.1074/jbc.M508931200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	006XT	16316995	hybrid			2022-12-25	WOS:000234931800014
J	Xie, Y; Hong, Y; Ma, XY; Ren, XR; Ackerman, S; Mei, L; Xiong, WC				Xie, Y; Hong, Y; Ma, XY; Ren, XR; Ackerman, S; Mei, L; Xiong, WC			DCC-dependent phospholipase C signaling in netrin-1-induced neurite elongation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FOCAL ADHESION KINASE; COLORECTAL-CANCER; AXON OUTGROWTH; SHORT-RANGE; LONG-RANGE; GUIDANCE; GROWTH; RECEPTORS; NETRINS; ENCODES	Netrins, a family of secreted molecules, play important roles in axon pathfinding during nervous system development. Although phosphatidylinositol signaling has been implicated in this event, how netrin-1 regulates phosphatidylinositol signaling remains poorly understood. Here we provide evidence that netrin-1 stimulates phosphatidylinositol bisphosphate hydrolysis in cortical neurons. This event appears to be mediated by DCC (deleted in colorectal cancer), but not neogenin or Unc5h2. Netrin-1 induces phospholipase C gamma (PLC gamma) tyrosine phosphorylation. Inhibition of PLC activity attenuates netrin-1-induced cortical neurite outgrowth. These results suggest that netrin-1 regulates phosphatidylinositol turnover and demonstrate a crucial role of PLC signaling in netrin-1-induced neurite elongation.	Med Coll Georgia, Dept Neurol, Augusta, GA 30809 USA; Med Coll Georgia, Inst Mol Med & Genom, Augusta, GA 30809 USA; Univ Alabama Birmingham, Dept Pathol, Birmingham, AL 35294 USA; Howard Hughes Med Inst, Bar Harbor, ME 04609 USA; Jackson Lab, Bar Harbor, ME 04609 USA	University System of Georgia; Augusta University; University System of Georgia; Augusta University; University of Alabama System; University of Alabama Birmingham; Howard Hughes Medical Institute; Jackson Laboratory	Xiong, WC (corresponding author), Med Coll Georgia, Inst Mol Med & Genom, Augusta, GA 30912 USA.	wxiong@mcg.edu	Mei, Lin/G-8755-2012		NIAMS NIH HHS [AR48120] Funding Source: Medline; NIGMS NIH HHS [GM63861] Funding Source: Medline; NINDS NIH HHS [NS44521, NS045710, NS40480, R01 NS060648] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR048120] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM063861] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS040480, R01NS045710, R01NS044521] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Ackerman SL, 1997, NATURE, V386, P838, DOI 10.1038/386838a0; Brose K, 2000, CURR OPIN NEUROBIOL, V10, P95, DOI 10.1016/S0959-4388(99)00066-5; Chan SSY, 1996, CELL, V87, P187, DOI 10.1016/S0092-8674(00)81337-9; Colavita A, 1998, DEV BIOL, V194, P72, DOI 10.1006/dbio.1997.8790; Cremona O, 2001, J CELL SCI, V114, P1041; Culotti JG, 1998, CURR OPIN CELL BIOL, V10, P609, DOI 10.1016/S0955-0674(98)80036-7; DeCamilli P, 1996, NEURON, V16, P481, DOI 10.1016/S0896-6273(00)80068-9; Di Paolo G, 2004, NATURE, V431, P415, DOI 10.1038/nature02896; Fazeli A, 1997, NATURE, V386, P796, DOI 10.1038/386796a0; Finger JH, 2002, J NEUROSCI, V22, P10346; Forcet C, 2002, NATURE, V417, P443, DOI 10.1038/nature748; Graef IA, 2003, CELL, V113, P657, DOI 10.1016/S0092-8674(03)00390-8; Hara S, 1997, J BIOL CHEM, V272, P14908, DOI 10.1074/jbc.272.23.14908; HEDGECOCK EM, 1990, NEURON, V4, P61, DOI 10.1016/0896-6273(90)90444-K; Hilpela P, 2004, CURR TOP MICROBIOL, V282, P117; Hiramoto M, 2000, NATURE, V406, P886, DOI 10.1038/35022571; Hong KS, 1999, CELL, V97, P927, DOI 10.1016/S0092-8674(00)80804-1; KeinoMasu K, 1996, CELL, V87, P175, DOI 10.1016/S0092-8674(00)81336-7; Keleman K, 2001, NEURON, V32, P605, DOI 10.1016/S0896-6273(01)00505-0; KENNEDY TE, 1994, CELL, V78, P425, DOI 10.1016/0092-8674(94)90421-9; Kennedy TE, 2000, BIOCHEM CELL BIOL, V78, P569, DOI 10.1139/bcb-78-5-569; Kolodziej PA, 1996, CELL, V87, P197, DOI 10.1016/S0092-8674(00)81338-0; Leonardo ED, 1997, NATURE, V386, P833, DOI 10.1038/386833a0; Li HS, 1999, CELL, V96, P807, DOI 10.1016/S0092-8674(00)80591-7; Li WQ, 2004, NAT NEUROSCI, V7, P1213, DOI 10.1038/nn1329; Li XD, 2002, J BIOL CHEM, V277, P15207, DOI 10.1074/jbc.M109913200; Liu GF, 2004, NAT NEUROSCI, V7, P1222, DOI 10.1038/nn1331; Livesey FJ, 1999, CELL MOL LIFE SCI, V56, P62, DOI 10.1007/s000180050006; Meriane M, 2004, J CELL BIOL, V167, P687, DOI 10.1083/jcb.200405053; Metin C, 1997, DEVELOPMENT, V124, P5063; Ming GI, 1999, NEURON, V23, P139, DOI 10.1016/S0896-6273(00)80760-6; Ming GL, 2002, NATURE, V417, P411, DOI 10.1038/nature745; Rajagopalan S, 2004, NAT CELL BIOL, V6, P756, DOI 10.1038/ncb1156; Ren XR, 2004, NAT NEUROSCI, V7, P1204, DOI 10.1038/nn1330; Ren XR, 2001, J CELL BIOL, V152, P971, DOI 10.1083/jcb.152.5.971; Richards LJ, 1997, J NEUROSCI, V17, P2445; SERAFINI T, 1994, CELL, V78, P409, DOI 10.1016/0092-8674(94)90420-0; Stein E, 2001, SCIENCE, V291, P1976, DOI 10.1126/science.1059391; Stein E, 2001, SCIENCE, V291, P1928, DOI 10.1126/science.1058445; Takei K, 1998, SCIENCE, V282, P1705, DOI 10.1126/science.282.5394.1705; Wenk MR, 2004, P NATL ACAD SCI USA, V101, P8262, DOI 10.1073/pnas.0401874101; Xie Y, 2005, NAT CELL BIOL, V7, P1124, DOI 10.1038/ncb1321; Xiong WC, 1997, J CELL BIOL, V139, P529, DOI 10.1083/jcb.139.2.529; Yin HL, 2003, ANNU REV PHYSIOL, V65, P761, DOI 10.1146/annurev.physiol.65.092101.142517	44	46	50	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 3	2006	281	5					2605	2611		10.1074/jbc.M512767200	http://dx.doi.org/10.1074/jbc.M512767200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	006XT	16321979	hybrid			2022-12-25	WOS:000234931800024
J	Ali, FY; Davidson, SJ; Moraes, LA; Traves, SL; Paul-Clark, M; Bishop-Bailey, D; Warner, TD; Mitchell, JA				Ali, Ferhana Y.; Davidson, Simon J.; Moraes, Leonardo A.; Traves, Suzanne L.; Paul-Clark, Mark; Bishop-Bailey, David; Warner, Timothy D.; Mitchell, Jane A.			Role of nuclear receptor signaling in platelets: antithrombotic effects of PPAR beta	FASEB JOURNAL			English	Article									[Moraes, Leonardo A.; Warner, Timothy D.] Queen Marys Sch Med, William Harvey Res Inst, London, England; [Ali, Ferhana Y.; Davidson, Simon J.; Traves, Suzanne L.; Paul-Clark, Mark; Bishop-Bailey, David; Mitchell, Jane A.] Univ London Imperial Coll Sci Technol & Med, Natl Heart & Lung Inst, Unit Crit Care Med, London, England	University of London; Queen Mary University London; Imperial College London	Mitchell, JA (corresponding author), Imperial Coll Sch Med, Unit Crit Care Med, Natl Heart & Lung Inst, Dovehouse St, London SW3 6LY, England.	j.a.mitchell@ic.ac.uk	Warner, Timothy D/A-1980-2009; Davidson, Simon/AGX-8916-2022; Mitchell, Jane A/A-1991-2009	Warner, Timothy D/0000-0003-3988-4408; Bishop-Bailey, David/0000-0003-2455-596X					0	97	97	0	3	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	FEB	2006	20	2					326	328		10.1096/fj.05-4395fje	http://dx.doi.org/10.1096/fj.05-4395fje			3	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	V17CJ	16368717				2022-12-25	WOS:000207915000009
J	Kartikasari, AER; Georgiou, NA; Visseren, FLJ; van Kats-Renaud, H; van Asbeck, BS; Marx, JJM				Kartikasari, Apriliana E. R.; Georgiou, Niki A.; Visseren, Frank L. J.; van Kats-Renaud, Henny; van Asbeck, B. Sweder; Marx, Joannes J. M.			Endothelial activation and induction of monocyte adhesion by nontransferrin-bound iron present in human sera	FASEB JOURNAL			English	Article									[Kartikasari, Apriliana E. R.; Georgiou, Niki A.; Visseren, Frank L. J.; van Kats-Renaud, Henny; van Asbeck, B. Sweder; Marx, Joannes J. M.] Univ Med Ctr Utrecht, Eijkman Winkler Ctr Med Microbiol Infect Dis & In, NL-3584 CX Utrecht, Netherlands; [Kartikasari, Apriliana E. R.; Georgiou, Niki A.; Visseren, Frank L. J.; van Kats-Renaud, Henny; van Asbeck, B. Sweder; Marx, Joannes J. M.] Univ Med Ctr Utrecht, Eijkman Grad Sch Immunol & Infect Dis, NL-3584 CX Utrecht, Netherlands; [Visseren, Frank L. J.] Univ Med Ctr Utrecht, Dept Vasc Med, NL-3584 CX Utrecht, Netherlands; [van Asbeck, B. Sweder] Univ Med Ctr Utrecht, Dept Internal Med, NL-3584 CX Utrecht, Netherlands	Utrecht University; Utrecht University Medical Center; Utrecht University; Utrecht University Medical Center; Utrecht University; Utrecht University Medical Center; Utrecht University; Utrecht University Medical Center	Marx, JJM (corresponding author), Univ Med Ctr Utrecht, Eijkman Winkler Ctr Med Microbiol Infect Dis & In, 100 Heidelberglaan,G04-614, NL-3584 CX Utrecht, Netherlands.	jmarx@azu.nl	Marx, Joannes/AAS-9268-2020; Kartikasari, Apriliana E. R./AAN-4594-2020; Visseren, Frank LJ/I-4855-2013	kartikasari, april/0000-0002-8115-4866; Visseren, Frank/0000-0003-3951-5223					0	56	59	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	FEB	2006	20	2					353	355		10.1096/fj.05-4700fje	http://dx.doi.org/10.1096/fj.05-4700fje			3	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	V17CJ	16368718				2022-12-25	WOS:000207915000019
J	Noyan-Ashraf, MH; Wu, LY; Wang, R; Juurlink, BHJ				Noyan-Ashraf, Mohammad Hossein; Wu, Lingyun; Wang, Rui; Juurlink, Bernhard H. J.			Dietary approaches to positively influence fetal determinants of adult health	FASEB JOURNAL			English	Article									[Noyan-Ashraf, Mohammad Hossein; Juurlink, Bernhard H. J.] Univ Saskatchewan, Coll Med, Dept Anat & Cell Biol, Saskatoon, SK S7N 5E5, Canada; [Wu, Lingyun] Univ Saskatchewan, Coll Med, Dept Pharmacol, Saskatoon, SK S7N 5E5, Canada; [Wang, Rui] Univ Saskatchewan, Coll Med, Dept Physiol, Saskatoon, SK S7N 5E5, Canada	University of Saskatchewan; University of Saskatchewan; University of Saskatchewan	Juurlink, BHJ (corresponding author), Univ Saskatchewan, Coll Med, Dept Anat & Cell Biol, 107 Wiggins Rd, Saskatoon, SK S7N 5E5, Canada.	juurlink@duke.usask.ca	Wang, Rui/C-7824-2012	Wang, Rui/0000-0003-3825-3620					0	42	42	0	3	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	FEB	2006	20	2					371	373		10.1096/fj.05-4889fje	http://dx.doi.org/10.1096/fj.05-4889fje			3	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	V17CJ	16354723				2022-12-25	WOS:000207915000025
J	Sexton, A; Drake, PM; Mahmood, N; Harman, SJ; Shattock, RJ; Ma, JKC				Sexton, Amy; Drake, Pascal M.; Mahmood, Naheed; Harman, Sarah J.; Shattock, Robin J.; Ma, Julian K-C.			Transgenic plant production of Cyanovirin-N, an HIV microbicide	FASEB JOURNAL			English	Article									[Sexton, Amy; Drake, Pascal M.; Mahmood, Naheed; Harman, Sarah J.; Shattock, Robin J.; Ma, Julian K-C.] St Georges Univ London, Dept Cellular & Mol Med, Ctr Infect, London SW17 0RE, England	St Georges University London	Sexton, A (corresponding author), St Georges Univ London, Dept Cellular & Mol Med, Ctr Infect, London SW17 0RE, England.	a.sexton@sgul.ac.uk		Drake, Pascal/0000-0002-6181-0600; Harman, Sarah/0000-0001-6443-0614; Ma, Julian/0000-0003-0767-0042					0	64	71	0	6	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	FEB	2006	20	2					356	358		10.1096/fj.05-4742fje	http://dx.doi.org/10.1096/fj.05-4742fje			3	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	V17CJ	16354721				2022-12-25	WOS:000207915000020
J	Zang, H; Irimia, A; Choi, JY; Angel, KC; Loukachevitch, LV; Egli, M; Guengerich, FP				Zang, H; Irimia, A; Choi, JY; Angel, KC; Loukachevitch, LV; Egli, M; Guengerich, FP			Efficient and high fidelity incorporation of dCTP opposite 7,8-dihydro-8-oxodeoxyguanosine by Sulfolobus solfataricus DNA polymerase Dpo4	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STATE KINETIC-ANALYSIS; HIV-1 REVERSE-TRANSCRIPTASE; SYN THYMINE DIMER; STEADY-STATE; NUCLEOTIDE INCORPORATION; CRYSTAL-STRUCTURE; STRUCTURAL BASIS; URINARY 8-HYDROXY-2'-DEOXYGUANOSINE; ESCHERICHIA-COLI; ERROR-PRONE	DNA polymerases insert dATP opposite the oxidative damage product 7,8-dihydro-8-oxodeoxyguanosine (8-oxoG) instead of dCTP, to the extent of > 90% with some polymerases. Steady-state kinetics with the Y-family Sulfolobus solfataricus DNA polymerase IV (Dpo4) showed 90-fold higher incorporation efficiency of dCTP > dATP opposite 8-oxoG and 4-fold higher efficiency of extension beyond an 8-oxoG: C pair than an 8-oxoG: A pair. The catalytic efficiency for these events (with dCTP or C) was similar for G and 8-oxoG templates. Mass spectral analysis of extended DNA primers showed >= 95% incorporation of dCTP > dATP opposite 8-oxoG. Pre-steady-state kinetics showed faster rates of dCTP incorporation opposite 8-oxoG than G. The measured K-d,K-dCTP was 15-fold lower for an oligonucleotide containing 8-oxoG than with G. Extension beyond an 8-oxoG: C pair was similar to G: C and faster than for an 8-oxoG: A pair, in contrast to other polymerases. The Ea for dCTP insertion opposite 8-oxoG was lower than for opposite G. Crystal structures of Dpo4 complexes with oligonucleotides were solved with C, A, and G nucleoside triphosphates placed opposite 8-oxoG. With ddCTP, dCTP, and dATP the phosphodiester bonds were formed even in the presence of Ca2+. The 8-oxoG: C pair showed classic Watson-Crick geometry; the 8-oxoG: A pair was in the syn:anti configuration, with the A hybridized in a Hoogsteen pair with 8-oxoG. With dGTP placed opposite 8-oxoG, pairing was not to the 8-oxoG but to the 5' C (and in classic Watson-Crick geometry), consistent with the low frequency of this frameshift event observed in the catalytic assays.	Vanderbilt Univ, Sch Med, Dept Biochem, Nashville, TN 37232 USA; Vanderbilt Univ, Sch Med, Ctr Mol Toxicol, Nashville, TN 37232 USA	Vanderbilt University; Vanderbilt University	Guengerich, FP (corresponding author), 638 Robinson Res Bldg,23rd & Pierce Aves, Nashville, TN 37232 USA.	f.guengerich@vanderbilt.edu			NIEHS NIH HHS [R01 ES 010375, P30 ES 000267] Funding Source: Medline; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES010375, P30ES000267] Funding Source: NIH RePORTER	NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Abu Al-Soud W, 1998, APPL ENVIRON MICROB, V64, P3748; AMES BN, 1979, SCIENCE, V204, P587, DOI 10.1126/science.373122; Bauer KH, 1928, MUTATIONSTHEORIE GES; Brieba LG, 2004, EMBO J, V23, P3452, DOI 10.1038/sj.emboj.7600354; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Carlson KD, 2005, MOL CELL BIOL, V25, P2169, DOI 10.1128/MCB.25.6.2169-2176.2005; Choi JY, 2004, J BIOL CHEM, V279, P19217, DOI 10.1074/jbc.M313759200; CULP SJ, 1989, CHEM RES TOXICOL, V2, P416, DOI 10.1021/tx00012a010; DEGAN P, 1991, CARCINOGENESIS, V12, P865, DOI 10.1093/carcin/12.5.865; DeLano WL, 2002, PYMOL USERS MANUAL; Einolf HJ, 2000, J BIOL CHEM, V275, P16316, DOI 10.1074/jbc.M001291200; Einolf HJ, 2001, J BIOL CHEM, V276, P3764, DOI 10.1074/jbc.M006696200; Einolf HJ, 1998, BIOCHEMISTRY-US, V37, P13300, DOI 10.1021/bi981346d; Fiala KA, 2004, BIOCHEMISTRY-US, V43, P2116, DOI 10.1021/bi035746z; Fiala KA, 2004, BIOCHEMISTRY-US, V43, P2106, DOI 10.1021/bi0357457; FRAGA CG, 1991, P NATL ACAD SCI USA, V88, P11003, DOI 10.1073/pnas.88.24.11003; FRAGA CG, 1990, P NATL ACAD SCI USA, V87, P4533, DOI 10.1073/pnas.87.12.4533; Freisinger E, 2004, EMBO J, V23, P1494, DOI 10.1038/sj.emboj.7600158; FRENCH S, 1978, ACTA CRYSTALLOGR A, V34, P517, DOI 10.1107/S0567739478001114; FRIEDBERG EC, 1995, DNA REPAIR MUTAGENES; Furge LL, 1998, BIOCHEMISTRY-US, V37, P3567, DOI 10.1021/bi9722094; Furge LL, 1997, BIOCHEMISTRY-US, V36, P6475, DOI 10.1021/bi9627267; Guengerich FP, 2001, MUTAT RES-REV MUTAT, V488, P195, DOI 10.1016/S1383-5742(01)00059-X; Hailer MK, 2005, CHEM RES TOXICOL, V18, P1378, DOI 10.1021/tx0501379; Haracska L, 2000, NAT GENET, V25, P458, DOI 10.1038/78169; Henderson PT, 2003, BIOCHEMISTRY-US, V42, P9257, DOI 10.1021/bi0347252; Hogg M, 2005, CURR OPIN STRUC BIOL, V15, P86, DOI 10.1016/j.sbi.2005.01.014; HOWARD AJ, 2000, CRYSTALLOGRAPHIC COM, V7; Hsu GW, 2004, NATURE, V431, P217, DOI 10.1038/nature02908; JOHNSON KA, 1993, ANNU REV BIOCHEM, V62, P685, DOI 10.1146/annurev.bi.62.070193.003345; JOHNSON KA, 1995, METHOD ENZYMOL, V249, P38; JOHNSON MD, 1992, PHYSICIAN SPORTSMED, V20, P61; Johnson RE, 2005, P NATL ACAD SCI USA, V102, P12359, DOI 10.1073/pnas.0504380102; KABSCH W, 1988, J APPL CRYSTALLOGR, V21, P916, DOI 10.1107/S0021889888007903; Kornberg A., 1992, DNA REPLICATION; KOUCHAKDJIAN M, 1991, BIOCHEMISTRY-US, V30, P1403, DOI 10.1021/bi00219a034; Krahn JM, 2003, STRUCTURE, V11, P121, DOI 10.1016/S0969-2126(02)00930-9; LASKOWSKI LA, 1999, J APPL CRYSTALLOGR, V26, P283; Ling H, 2001, CELL, V107, P91, DOI 10.1016/S0092-8674(01)00515-3; Ling H, 2004, MOL CELL, V13, P751, DOI 10.1016/S1097-2765(04)00101-7; Ling H, 2004, P NATL ACAD SCI USA, V101, P2265, DOI 10.1073/pnas.0308332100; Ling H, 2003, NATURE, V424, P1083, DOI 10.1038/nature01919; LIPSCOMB LA, 1995, P NATL ACAD SCI USA, V92, P719, DOI 10.1073/pnas.92.3.719; Lowe LG, 1996, BIOCHEMISTRY-US, V35, P9840, DOI 10.1021/bi960485x; MALINS DC, 1991, CANCER RES, V51, P5430; MCAULEYHECHT KE, 1994, BIOCHEMISTRY-US, V33, P10266, DOI 10.1021/bi00200a006; McCoy AJ, 2005, ACTA CRYSTALLOGR D, V61, P458, DOI 10.1107/S0907444905001617; Miller H, 2000, BIOCHEMISTRY-US, V39, P1029, DOI 10.1021/bi991789x; Miller JA, 1998, DRUG METAB REV, V30, P645, DOI 10.3109/03602539808996326; Neeley WL, 2004, J BIOL CHEM, V279, P43568, DOI 10.1074/jbc.M407117200; Pelletier H, 1996, BIOCHEMISTRY-US, V35, P12778, DOI 10.1021/bi960790i; Pelletier H, 1996, BIOCHEMISTRY-US, V35, P12762, DOI 10.1021/bi9529566; Ravanat JL, 1998, ANAL BIOCHEM, V260, P30, DOI 10.1006/abio.1998.2685; Rechkunova NI, 2000, BIOCHEMISTRY-MOSCOW+, V65, P609; SHIBUTANI S, 1991, NATURE, V349, P431, DOI 10.1038/349431a0; SHIGENAGA MK, 1989, P NATL ACAD SCI USA, V86, P9697, DOI 10.1073/pnas.86.24.9697; Shimizu M, 2003, EMBO REP, V4, P269, DOI 10.1038/sj.embor.embor765; SHIMODA R, 1994, CANCER RES, V54, P3171; Vaisman A, 2005, EMBO J, V24, P2957, DOI 10.1038/sj.emboj.7600786; Vellieux FMD, 1997, J APPL CRYSTALLOGR, V30, P396, DOI 10.1107/S0021889896012551; Woodside AM, 2002, BIOCHEMISTRY-US, V41, P1039, DOI 10.1021/bi011496f; Zang H, 2005, J BIOL CHEM, V280, P29750, DOI 10.1074/jbc.M504756200; Zang H, 2005, J BIOL CHEM, V280, P1165, DOI 10.1074/jbc.M405996200; ZINNEN S, 1994, J BIOL CHEM, V269, P24195	64	107	108	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 27	2006	281	4					2358	2372		10.1074/jbc.M510889200	http://dx.doi.org/10.1074/jbc.M510889200			15	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	004NV	16306039	hybrid			2022-12-25	WOS:000234760400061
J	Carapito, R; Chesnel, L; Vernet, T; Zapun, A				Carapito, R; Chesnel, L; Vernet, T; Zapun, A			Pneumococcal beta-lactam resistance due to a conformational change in penicillin-binding protein 2x	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STREPTOCOCCUS-PNEUMONIAE; CRYSTAL-STRUCTURE; CLINICAL ISOLATE; ACTIVE-SITE; ANTIBIOTICS; PBP2X; MUTATIONS; SUSCEPTIBILITY; DEACYLATION; MECHANISM	Streptococcus pneumoniae is a life-threatening human pathogen that is increasingly resistant to a wide array of drugs. Resistance to beta-lactams, the most widely used antibiotics, is correlated with tens of amino acid substitutions in their targets; that is, the penicillin-binding proteins (PBPs), resulting from multiple events of recombination. To discriminate relevant substitutions from those that are incidental to the recombination process, we report the exhaustive characterization of all the mutations in the transpeptidase domain of PBP2x from the highly resistant strain 5204. A semi-automated method combining biochemical and microbiological approaches singled out 6 mutations of 41 (15%) that are essential for high level resistance. The hitherto uncharacterized I371T, R384G, M400T, and N605T together with the previously studied T338M and M339F account for nearly all the loss of affinity of PBP2x for beta-lactams. Most interestingly, I371T and R384G cause the conformational change of a loop that borders the entrance of the active site cavity, hampering antibiotic binding. For the first time all the mutations of a PBP relevant to beta-lactam resistance have been identified, providing new mechanistic insights. Most notable is the relationship between the decreased susceptibility to beta-lactams and the dynamic behavior of a loop.	Univ Grenoble 1, CEA, CNRS, Lab Ingn Macromol,Inst Biol Struct,UMR 5075, F-38027 Grenoble, France	Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); UDICE-French Research Universities; Communaute Universite Grenoble Alpes; Universite Grenoble Alpes (UGA); CEA	Vernet, T (corresponding author), Univ Grenoble 1, CEA, CNRS, Lab Ingn Macromol,Inst Biol Struct,UMR 5075, 41 Rue Jules Horowitz, F-38027 Grenoble, France.	thierry.vernet@ibs.fr	Carapito, Raphael/ABG-5061-2020; Vernet, Thierry/G-1118-2012; Carapito, Raphael/O-5317-2016	Carapito, Raphael/0000-0002-7036-442X; Carapito, Raphael/0000-0002-7036-442X; Zapun, Andre/0000-0001-8953-4399; chesnel, laurent/0000-0002-4947-5029				Asahi Y, 1999, ANTIMICROB AGENTS CH, V43, P1252, DOI 10.1128/AAC.43.5.1252; Chesnel L, 2005, ANTIMICROB AGENTS CH, V49, P2895, DOI 10.1128/AAC.49.7.2895-2902.2005; Chesnel L, 2003, J BIOL CHEM, V278, P44448, DOI 10.1074/jbc.M305948200; Chesnel L, 2002, EUR J BIOCHEM, V269, P1678, DOI 10.1046/j.1432-1327.2002.02815.x; CLAVERYS JP, 1986, MICROBIOL REV, V50, P133, DOI 10.1128/MMBR.50.2.133-165.1986; Dessen A, 2001, J BIOL CHEM, V276, P45106, DOI 10.1074/jbc.M107608200; Dowson Christopher G., 1994, Trends in Microbiology, V2, P361, DOI 10.1016/0966-842X(94)90612-2; FRERE JM, 1975, EUR J BIOCHEM, V57, P343, DOI 10.1111/j.1432-1033.1975.tb02307.x; Gordon E, 2000, J MOL BIOL, V299, P477, DOI 10.1006/jmbi.2000.3740; Grebe T, 1996, ANTIMICROB AGENTS CH, V40, P829, DOI 10.1128/AAC.40.4.829; Hakenbeck R, 1999, MICROB DRUG RESIST, V5, P91, DOI 10.1089/mdr.1999.5.91; JAMIN M, 1993, FEBS LETT, V331, P101, DOI 10.1016/0014-5793(93)80305-E; Krauss J, 1996, MICROB DRUG RESIST, V2, P183, DOI 10.1089/mdr.1996.2.183; KUNKEL TA, 1991, METHOD ENZYMOL, V204, P125; LAIBLE G, 1991, MOL MICROBIOL, V5, P1993, DOI 10.1111/j.1365-2958.1991.tb00821.x; Lu WP, 2001, J BIOL CHEM, V276, P31494, DOI 10.1074/jbc.M102499200; Macheboeuf P, 2005, P NATL ACAD SCI USA, V102, P577, DOI 10.1073/pnas.0407186102; Mouz N, 1998, P NATL ACAD SCI USA, V95, P13403, DOI 10.1073/pnas.95.23.13403; Mouz N, 1999, J BIOL CHEM, V274, P19175, DOI 10.1074/jbc.274.27.19175; NIKAIDO H, 1994, SCIENCE, V264, P382, DOI 10.1126/science.8153625; Pares S, 1996, NAT STRUCT BIOL, V3, P284, DOI 10.1038/nsb0396-284; Pernot L, 2004, J BIOL CHEM, V279, P16463, DOI 10.1074/jbc.M313492200; Studier FW, 2005, PROTEIN EXPRES PURIF, V41, P207, DOI 10.1016/j.pep.2005.01.016; WAXMAN DJ, 1983, ANNU REV BIOCHEM, V52, P825, DOI 10.1146/annurev.bi.52.070183.004141; Wilke MS, 2005, CURR OPIN MICROBIOL, V8, P525, DOI 10.1016/j.mib.2005.08.016	25	53	54	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 20	2006	281	3					1771	1777		10.1074/jbc.M511506200	http://dx.doi.org/10.1074/jbc.M511506200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	002ZS	16303769	Green Published, hybrid			2022-12-25	WOS:000234652000058
J	Kulp, MS; Frickel, EM; Ellgaard, L; Weissman, JS				Kulp, MS; Frickel, EM; Ellgaard, L; Weissman, JS			Domain architecture of protein-disulfide isomerase facilitates its dual role as an oxidase and an isomerase in Ero1p-mediated disulfide formation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BOVINE PANCREATIC RIBONUCLEASE; ENDOPLASMIC-RETICULUM; BOND FORMATION; FUNCTIONAL-PROPERTIES; ACTIVE-SITES; LIVING CELLS; ER STRESS; IN-VITRO; YEAST; ERP57	Native disulfide bond formation in eukaryotes is dependent on protein-disulfide isomerase (PDI) and its homologs, which contain varying combinations of catalytically active and inactive thioredoxin domains. However, the specific contribution of PDI to the formation of new disulfides versus reduction/rearrangement of non-native disulfides is poorly understood. We analyzed the role of individual PDI domains in disulfide bond formation in a reaction driven by their natural oxidant, Ero1p. We found that Ero1p oxidizes the isolated PDI catalytic thioredoxin domains, A and A' at the same rate. In contrast, we found that in the context of full-length PDI, there is an asymmetry in the rate of oxidation of the two active sites. This asymmetry is the result of a dual effect: an enhanced rate of oxidation of the second catalytic (A') domain and the substrate-mediated inhibition of oxidation of the first catalytic (A) domain. The specific order of thioredoxin domains in PDI is important in establishing the asymmetry in the rate of oxidation of the two active sites thus allowing A and A', two thioredoxin domains that are similar in sequence and structure, to serve opposing functional roles as a disulfide isomerase and disulfide oxidase, respectively. These findings reveal how native disulfide folding is accomplished in the endoplasmic reticulum and provide a context for understanding the proliferation of PDI homologs with combinatorial arrangements of thioredoxin domains.	Univ Calif San Francisco, Dept Cellular & Mol Pharmacol, Howard Hughes Med Inst, San Francisco, CA 94158 USA; ETH, Inst Biochem, CH-8093 Zurich, Switzerland	Howard Hughes Medical Institute; University of California System; University of California San Francisco; Swiss Federal Institutes of Technology Domain; ETH Zurich	Weissman, JS (corresponding author), Univ Calif San Francisco, Dept Cellular & Mol Pharmacol, Howard Hughes Med Inst, 1700 4th St, San Francisco, CA 94158 USA.	weissman@cmp.ucsf.edu	Ellgaard, Lars/I-9034-2014	Ellgaard, Lars/0000-0002-7018-0137; Weissman, Jonathan/0000-0003-2445-670X				Cabibbo A, 2000, J BIOL CHEM, V275, P4827, DOI 10.1074/jbc.275.7.4827; Collet JF, 2002, MOL MICROBIOL, V44, P1, DOI 10.1046/j.1365-2958.2002.02851.x; Cunnea PM, 2003, J BIOL CHEM, V278, P1059, DOI 10.1074/jbc.M206995200; Cuozzo JW, 1999, NAT CELL BIOL, V1, P130, DOI 10.1038/11047; Ellgaard L, 2005, EMBO REP, V6, P28, DOI 10.1038/sj.embor.7400311; FARQUHAR R, 1991, GENE, V108, P81, DOI 10.1016/0378-1119(91)90490-3; Frand AR, 1999, MOL CELL, V4, P469, DOI 10.1016/S1097-2765(00)80198-7; Frand AR, 1998, MOL CELL, V1, P161, DOI 10.1016/S1097-2765(00)80017-9; Freedman RB, 2002, EMBO REP, V3, P136, DOI 10.1093/embo-reports/kvf035; Frickel EM, 2004, J BIOL CHEM, V279, P18277, DOI 10.1074/jbc.M314089200; GOLDBERGER RF, 1963, J BIOL CHEM, V238, P628; Gross E, 2004, CELL, V117, P601, DOI 10.1016/S0092-8674(04)00418-0; Holst B, 1997, J CELL BIOL, V138, P1229, DOI 10.1083/jcb.138.6.1229; Hosoda A, 2003, J BIOL CHEM, V278, P2669, DOI 10.1074/jbc.M208346200; Kemmink J, 1997, CURR BIOL, V7, P239, DOI 10.1016/S0960-9822(06)00119-9; Klappa P, 1998, EMBO J, V17, P927, DOI 10.1093/emboj/17.4.927; LABOISSIERE MCA, 1995, J BIOL CHEM, V270, P28006; LYLES MM, 1991, BIOCHEMISTRY-US, V30, P613, DOI 10.1021/bi00217a004; Meunier L, 2002, MOL BIOL CELL, V13, P4456, DOI 10.1091/mbc.E02-05-0311; Mezghrani A, 2001, EMBO J, V20, P6288, DOI 10.1093/emboj/20.22.6288; Molinari M, 1999, NATURE, V402, P90, DOI 10.1038/47062; Molteni SN, 2004, J BIOL CHEM, V279, P32667, DOI 10.1074/jbc.M404992200; Mossner E, 1998, PROTEIN SCI, V7, P1233; Norgaard P, 2001, J CELL BIOL, V152, P553, DOI 10.1083/jcb.152.3.553; Oliver JD, 1999, MOL BIOL CELL, V10, P2573, DOI 10.1091/mbc.10.8.2573; Oliver JD, 1997, SCIENCE, V275, P86, DOI 10.1126/science.275.5296.86; Pagani M, 2000, J BIOL CHEM, V275, P23685, DOI 10.1074/jbc.M003061200; Pollard MG, 1998, MOL CELL, V1, P171, DOI 10.1016/S1097-2765(00)80018-0; Pollock S, 2004, EMBO J, V23, P1020, DOI 10.1038/sj.emboj.7600119; Ritz D, 2001, ANNU REV MICROBIOL, V55, P21, DOI 10.1146/annurev.micro.55.1.21; Sevier CS, 2002, NAT REV MOL CELL BIO, V3, P836, DOI 10.1038/nrm954; Shen Y, 2002, J BIOL CHEM, V277, P15947, DOI 10.1074/jbc.M112214200; Shin HC, 2000, J MOL BIOL, V300, P995, DOI 10.1006/jmbi.2000.3928; Silvennoinen L, 2004, J BIOL CHEM, V279, P13607, DOI 10.1074/jbc.M313054200; TACHIBANA C, 1992, MOL CELL BIOL, V12, P4601, DOI 10.1128/MCB.12.10.4601; Tachikawa H, 1997, BIOCHEM BIOPH RES CO, V239, P710, DOI 10.1006/bbrc.1997.7426; TACHIKAWA H, 1995, FEBS LETT, V369, P212, DOI 10.1016/0014-5793(95)00750-4; Tsai M, 2002, J CELL BIOL, V159, P207, DOI 10.1083/jcb.200207120; Tu BP, 2000, SCIENCE, V290, P1571, DOI 10.1126/science.290.5496.1571; Tu BP, 2004, J CELL BIOL, V164, P341, DOI 10.1083/jcb.200311055; Tu BP, 2002, MOL CELL, V10, P983, DOI 10.1016/S1097-2765(02)00696-2; Wang QQ, 1999, EMBO J, V18, P5972, DOI 10.1093/emboj/18.21.5972; Westphal V, 1999, J MOL BIOL, V286, P1229, DOI 10.1006/jmbi.1999.2560; Wright SK, 1998, ANAL BIOCHEM, V265, P8, DOI 10.1006/abio.1998.2858; Xiao RY, 2004, J BIOL CHEM, V279, P49780, DOI 10.1074/jbc.M409210200; Zapun A, 1998, J BIOL CHEM, V273, P6009, DOI 10.1074/jbc.273.11.6009	46	64	66	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 13	2006	281	2					876	884		10.1074/jbc.M511764200	http://dx.doi.org/10.1074/jbc.M511764200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	000FV	16368681	hybrid, Green Published			2022-12-25	WOS:000234447200026
J	Wedhas, N; Klamut, HJ; Dogra, C; Srivastava, AK; Mohan, S; Kumar, A				Wedhas, N; Klamut, HJ; Dogra, C; Srivastava, AK; Mohan, S; Kumar, A			Inhibition of mechanosensitive cation channels inhibits myogenic differentiation by suppressing the expression of myogenic regulatory factors and caspase-3 activity	FASEB JOURNAL			English	Article						mechanosensitive cation channels; gadolinium; myogenesis; C2C12; caspase-3; apoptosis	ACTIVATED PROTEIN-KINASE; SERUM RESPONSE FACTOR; SKELETAL-MUSCLE; ION CHANNELS; GROWTH-FACTOR; MECHANICAL STRETCH; INTRACELLULAR CA2+; BINDING PROTEIN; APOPTOSIS; CALCIUM	Mechanosensitive cation channels (MSC) are ubiquitous in eukaryotic cell types. However, the physiological functions of MSC in several tissues remain in question. In this study we have investigated the role of MSC in skeletal myogenesis. Treatment of C2C12 myoblasts with gadolinium ions ( MSC blocker) inhibited myotube formation and the myogenic index in differentiation medium (DM). The enzymatic activity of creatine kinase (CK) and the expression of myosin heavy chain-fast twitch (MyHCf) in C2C12 cultures were also blocked in response to gadolinium. Treatment of C2C12 myoblasts with gadolinium ions did not affect the expression of either cyclin A or cyclin D1 in DM. Other inhibitors of MSC such as streptomycin and GsTMx-4 also suppressed the expression of CK and MyHCf in C2C12 cultures. The inhibitory effect of gadolinium ions on myogenic differentiation was reversible and independent of myogenic cell type. Real-time-polymerase chain reaction analysis revealed that inhibition of MSC decreases the expression of myogenic transcription factors MyoD, myogenin, and Myf-5. Furthermore, the activity of skeletal alpha-actin promoter was suppressed on MSC blockade. Treatment of C2C12 myoblasts with gadolinium ions prevented differentiation-associated cell death and inhibited the cleavage of poly (ADP-ribose) polymerase and activation of caspase-3. On the other hand, delivery of active caspase-3 protein to C2C12 myoblasts reversed the inhibitory effect of gadolinium ions on myogenesis. Our data suggest that inhibition of MSC suppresses myogenic differentiation by inhibiting the caspase-3 activity and the expression of myogenic regulatory factors.	Jerry L Pettis Mem Vet Adm Med Ctr, Div Mol Genet, Musculoskeletal Dis Ctr, Loma Linda, CA 92354 USA; Loma Linda Univ, Dept Med, Loma Linda, CA 92350 USA; Loma Linda Univ, Dept Biochem, Loma Linda, CA 92350 USA	Loma Linda University; Loma Linda University	Kumar, A (corresponding author), Jerry L Pettis Mem Vet Adm Med Ctr, Div Mol Genet, Musculoskeletal Dis Ctr, 11201 Benton St,151, Loma Linda, CA 92354 USA.	Ashok.Kumar2@med.va.gov		Kumar, Ashok/0000-0001-8571-2848				Amthor H, 1998, CURR BIOL, V8, P642, DOI 10.1016/S0960-9822(98)70251-9; Amthor H, 1999, DEVELOPMENT, V126, P1041; Caldwell RA, 1998, AM J PHYSIOL-CELL PH, V275, pC619, DOI 10.1152/ajpcell.1998.275.2.C619; CAMPBELL JS, 1995, P NATL ACAD SCI USA, V92, P870, DOI 10.1073/pnas.92.3.870; Charge SBP, 2004, PHYSIOL REV, V84, P209, DOI 10.1152/physrev.00019.2003; Chen AE, 2005, NATURE, V433, P317, DOI 10.1038/nature03126; Corey DP, 2003, NEURON, V39, P585, DOI 10.1016/S0896-6273(03)00505-1; Delling U, 2000, MOL CELL BIOL, V20, P6600, DOI 10.1128/MCB.20.17.6600-6611.2000; Fernando P, 2002, P NATL ACAD SCI USA, V99, P11025, DOI 10.1073/pnas.162172899; Formigli L, 2005, J CELL SCI, V118, P1161, DOI 10.1242/jcs.01695; FRANCO A, 1990, J PHYSIOL-LONDON, V427, P361, DOI 10.1113/jphysiol.1990.sp018176; Franco-Obregon A, 2002, J PHYSIOL-LONDON, V539, P391, DOI 10.1113/jphysiol.2001.013043; FRANCOOBREGON A, 1994, J PHYSIOL-LONDON, V481, P299, DOI 10.1113/jphysiol.1994.sp020440; GLUCKSMANN A, 1951, BIOL REV, V26, P59, DOI 10.1111/j.1469-185X.1951.tb00774.x; Gonzalez I, 2004, MOL CELL BIOL, V24, P3607, DOI 10.1128/MCB.24.9.3607-3622.2004; Gottlieb PA, 2004, CNS NEUROL DISORD-DR, V3, P287, DOI 10.2174/1568007043337283; GUHARAY F, 1985, J PHYSIOL-LONDON, V363, P119, DOI 10.1113/jphysiol.1985.sp015699; GUHARAY F, 1984, J PHYSIOL-LONDON, V352, P685, DOI 10.1113/jphysiol.1984.sp015317; Hamill OP, 2001, PHYSIOL REV, V81, P685, DOI 10.1152/physrev.2001.81.2.685; Hamill OP, 1996, PHARMACOL REV, V48, P231; Inoh H, 2002, FASEB J, V16, P405, DOI 10.1096/fj.01-0354fje; Juin P, 1998, J BIOL CHEM, V273, P17559, DOI 10.1074/jbc.273.28.17559; Kamradt MC, 2002, J BIOL CHEM, V277, P38731, DOI 10.1074/jbc.M201770200; Kuida K, 1996, NATURE, V384, P368, DOI 10.1038/384368a0; Kumar A, 2004, FASEB J, V18, P1524, DOI 10.1096/fj.04-2414com; Kumar A, 2004, FASEB J, V18, P102, DOI 10.1096/fj.03-0453com; Kumar A, 2003, FASEB J, V17, P386, DOI 10.1096/fj.02-0542com; Kumar A, 2003, J BIOL CHEM, V278, P18868, DOI 10.1074/jbc.M212777200; Kumar A, 2002, J BIOL CHEM, V277, P46493, DOI 10.1074/jbc.M203654200; Langen RCJ, 2004, FASEB J, V18, P227, DOI 10.1096/fj.03-0251com; Langen RCJ, 2001, FASEB J, V15, P1169, DOI 10.1096/fj.00-0463; LANSMAN JB, 1990, J GEN PHYSIOL, V95, P679, DOI 10.1085/jgp.95.4.679; Li YP, 2003, AM J PHYSIOL-CELL PH, V285, pC370, DOI 10.1152/ajpcell.00453.2002; Lluis F, 2005, EMBO J, V24, P974, DOI 10.1038/sj.emboj.7600528; MACLELLAN WR, 1994, J BIOL CHEM, V269, P16754; Martinac B, 2004, J CELL SCI, V117, P2449, DOI 10.1242/jcs.01232; Miller AL, 1998, J PHYSIOL-LONDON, V508, P793, DOI 10.1111/j.1469-7793.1998.793bp.x; Miyakoshi N, 2001, J CLIN INVEST, V107, P73, DOI 10.1172/JCI10459; Oswald RE, 2002, J BIOL CHEM, V277, P34443, DOI 10.1074/jbc.M202715200; Park JY, 2002, BIOCHEM BIOPH RES CO, V290, P1176, DOI 10.1006/bbrc.2001.6323; Perry RLS, 2000, FRONT BIOSCI, V5, pD750, DOI 10.2741/Perry; Schulz RA, 2004, DEV BIOL, V266, P1, DOI 10.1016/j.ydbio.2003.10.008; Seale P, 2000, DEV BIOL, V218, P115, DOI 10.1006/dbio.1999.9565; Shin KS, 1997, J BIOL CHEM, V272, P21227, DOI 10.1074/jbc.272.34.21227; Shin KS, 1996, DEV BIOL, V175, P14, DOI 10.1006/dbio.1996.0091; Sitcheran R, 2003, GENE DEV, V17, P2368, DOI 10.1101/gad.1114503; SMITH TH, 1993, DEVELOPMENT, V117, P1125; Soderling TR, 2001, CHEM REV, V101, P2341, DOI 10.1021/cr0002386; Stull JT, 2001, J BIOL CHEM, V276, P2311, DOI 10.1074/jbc.R000030200; Suchyna TM, 2004, NATURE, V430, P235, DOI 10.1038/nature02743; Suchyna TM, 2000, J GEN PHYSIOL, V115, P583, DOI 10.1085/jgp.115.5.583; Temm-Grove CJ, 1999, EXP CELL RES, V247, P293, DOI 10.1006/excr.1998.4362; Tureckova J, 2001, J BIOL CHEM, V276, P39264, DOI 10.1074/jbc.M104991200; Wang J, 1996, SCIENCE, V273, P359, DOI 10.1126/science.273.5273.359; Wang J, 1997, CANCER RES, V57, P351; Wei L, 1998, J BIOL CHEM, V273, P30287, DOI 10.1074/jbc.273.46.30287; Wilson EM, 2004, MOL BIOL CELL, V15, P497, DOI 10.1091/mbc.E03-05-0351; Wu ZG, 2000, MOL CELL BIOL, V20, P3951, DOI 10.1128/MCB.20.11.3951-3964.2000; Yamazaki T, 1998, CIRC RES, V82, P430, DOI 10.1161/01.RES.82.4.430; Yang SH, 1999, MOL CELL BIOL, V19, P4028; YANG XC, 1989, SCIENCE, V243, P1068, DOI 10.1126/science.2466333; Yun KS, 1996, CURR OPIN CELL BIOL, V8, P877, DOI 10.1016/S0955-0674(96)80091-3	62	30	31	0	9	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	DEC	2005	19	14					1986	1997		10.1096/fj.05-4198com	http://dx.doi.org/10.1096/fj.05-4198com			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	999QR	16319142				2022-12-25	WOS:000234405500009
J	Yao, H; Dashner, EJ; van Golen, CM; van Golen, KL				Yao, H; Dashner, EJ; van Golen, CM; van Golen, KL			RhoC GTPase is required for PC-3 prostate cancer cell invasion but not motility	ONCOGENE			English	Article						RhoC GTPase; Rac1 GTPase; insulin-like growth factor-1; collagen 1	INFLAMMATORY BREAST-CANCER; GROWTH-FACTOR-I; ACTIVATED PROTEIN-KINASE; ACTIN STRESS FIBERS; BINDING PROTEINS; BOTULINUM ADP-RIBOSYLTRANSFERASE-C3; METASTATIC VARIANTS; CYCLE PROGRESSION; GENE-EXPRESSION; FACTOR RECEPTOR	It is projected that in 2005, approximately 220 900 men will be newly diagnosed with carcinoma of the prostate (CaP). Men who are diagnosed with locally advanced or metastatic disease undergo androgen ablation therapy and most will relapse and progress within 18 months. Metastasis to bone is the major clinical concern during CaP progression, as it is associated with intractable pain, bone fracture and paralysis resulting from spinal cord compression. Therefore, an understanding of the key mechanisms involved in CaP cell bone metastasis is vital to development of novel treatments. The Rho GTPases are molecular switches involved in cell survival, motility and invasion. Increased expression of RhoC GTPase is linked to enhanced metastatic potential in multiple cancers; however, the role of RhoC GTPase in CaP metastasis has not been addressed. In the current study, we demonstrate that RhoC GTPase is expressed and active in PC-3 CaP cells. RhoC inhibition, either pharmacologically with C3 exotransferase or molecularly through expression of a dominant-negative RhoC, promotes IGF-I stimulated random motility but decreases in vitro invasion and experimental metastases. Inhibition of RhoC activity results in drastic morphologic changes and alterations in the expression and distribution of focal adhesion-related proteins. These data suggest that RhoC inhibition leads to activation of other GTPases involved in nondirected motility and that expression of active RhoC is required for the invasive phenotype of PC-3 cells.	Univ Michigan, Ctr Comprehens Canc, Dept Internal Med, Div Hematol Oncol, Ann Arbor, MI 48109 USA; Univ Michigan, Sch Med, Dept Neurol, Ann Arbor, MI 48109 USA	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan	van Golen, KL (corresponding author), Univ Michigan, Ctr Canc, Dept Internal Med, 200 Zina Pitcher Pl,R-4048A Kresge 2, Ann Arbor, MI 48109 USA.	Kgolen@umich.edu			NATIONAL CANCER INSTITUTE [P50CA069568, P30CA046592] Funding Source: NIH RePORTER; NCI NIH HHS [P50 CA69568, 5 P30 CA46592] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Abate-Shen C, 2000, GENE DEV, V14, P2410, DOI 10.1101/gad.819500; AKTORIES K, 1989, TRENDS PHARMACOL SCI, V10, P415, DOI 10.1016/0165-6147(89)90191-0; AKTORIES K, 1989, BIOCHEM BIOPH RES CO, V158, P209, DOI 10.1016/S0006-291X(89)80199-8; Aktories K, 1997, TRENDS MICROBIOL, V5, P282, DOI 10.1016/S0966-842X(97)01067-6; ALBRECHTBUEHLER G, 1977, CELL, V11, P395, DOI 10.1016/0092-8674(77)90057-5; Alcover J, 1994, Actas Urol Esp, V18 Suppl, P409; Bockhorn M, 2004, CANCER RES, V64, P2469, DOI 10.1158/0008-5472.CAN-03-0256; Carr KM, 2003, ONCOGENE, V22, P3076, DOI 10.1038/sj.onc.1206448; Chang FM, 2003, INT J ONCOL, V22, P469; Chung LWK, 2005, J UROLOGY, V173, P10, DOI 10.1097/01.ju.0000141582.15218.10; Clark EA, 2000, NATURE, V406, P532, DOI 10.1038/35020106; Cooper CR, 2000, PROSTATE CANCER P D, V3, P6, DOI 10.1038/sj.pcan.4500387; Danen EHJ, 2000, J CELL BIOL, V151, P1413, DOI 10.1083/jcb.151.7.1413; del Peso L, 1997, ONCOGENE, V15, P3047; DIEKMANN D, 1995, METHOD ENZYMOL, V256, P207; Edlund S, 2002, MOL BIOL CELL, V13, P902, DOI 10.1091/mbc.01-08-0398; Evers EE, 2000, METHOD ENZYMOL, V325, P403; Fritz G, 1999, INT J CANCER, V81, P682, DOI 10.1002/(SICI)1097-0215(19990531)81:5<682::AID-IJC2>3.0.CO;2-B; Garber K, 2005, J NATL CANCER I, V97, P790, DOI 10.1093/jnci/97.11.790; Geyer M, 1997, CURR OPIN STRUC BIOL, V7, P786, DOI 10.1016/S0959-440X(97)80147-9; Greenberg DL, 2003, BIOCHEMISTRY-US, V42, P702, DOI 10.1021/bi027100x; Hall A, 1998, SCIENCE, V279, P509, DOI 10.1126/science.279.5350.509; HALL A, 1990, SCIENCE, V249, P635, DOI 10.1126/science.2116664; Hellawell GO, 2002, CANCER RES, V62, P2942; HENDRIX MJC, 1987, CANCER LETT, V38, P137, DOI 10.1016/0304-3835(87)90209-6; Hodge JC, 2003, CANCER RES, V63, P1359; Horiuchi A, 2003, LAB INVEST, V83, P861, DOI 10.1097/01.LAB.0000073128.16098.31; Imamura F, 1999, CLIN EXP METASTAS, V17, P141, DOI 10.1023/A:1006598531238; IWAMURA M, 1993, PROSTATE, V22, P243, DOI 10.1002/pros.2990220307; Jackson JG, 2001, ONCOGENE, V20, P7318, DOI 10.1038/sj.onc.1204920; Jaffe AB, 2002, ADV CANCER RES, V84, P57, DOI 10.1016/S0065-230X(02)84003-9; Kamai T, 2003, CLIN CANCER RES, V9, P2632; Kaverina I, 2002, INT J BIOCHEM CELL B, V34, P746, DOI 10.1016/S1357-2725(01)00171-6; Keely P, 1998, TRENDS CELL BIOL, V8, P101, DOI 10.1016/S0962-8924(97)01219-1; Kiefer JA, 2001, MATRIX BIOL, V20, P429, DOI 10.1016/S0945-053X(01)00159-7; Kimura G, 1996, Int J Urol, V3, P39; Kjoller L, 1999, EXP CELL RES, V253, P166, DOI 10.1006/excr.1999.4674; Kleer CG, 2002, AM J PATHOL, V160, P579, DOI 10.1016/S0002-9440(10)64877-8; Kondo T, 2004, PATHOBIOLOGY, V71, P19, DOI 10.1159/000072958; Kwon T, 2000, J BIOL CHEM, V275, P423, DOI 10.1074/jbc.275.1.423; Lopez T, 2002, CANCER CELL, V1, P339, DOI 10.1016/S1535-6108(02)00055-7; Marionnet C, 2003, ONCOGENE, V22, P3500, DOI 10.1038/sj.onc.1206571; Meyer GE, 2001, ONCOGENE, V20, P7542, DOI 10.1038/sj.onc.1204927; Mitsiades CS, 2005, EXPERT REV ANTICANC, V5, P487, DOI 10.1586/14737140.5.3.487; Moorman JP, 1999, ONCOGENE, V18, P47, DOI 10.1038/sj.onc.1202262; MOSCOW JA, 1994, ONCOGENE, V9, P189; NOBES CD, 1995, CELL, V81, P53, DOI 10.1016/0092-8674(95)90370-4; Olson MF, 1996, J MOL MED-JMM, V74, P563, DOI 10.1007/s001090050060; PIENTA KJ, 1999, CANC MANAGEMENT MULT, P193; Price LS, 2001, SEMIN CANCER BIOL, V11, P167, DOI 10.1006/scbi.2000.0367; RIDLEY AJ, 1992, COLD SPRING HARB SYM, V57, P661, DOI 10.1101/SQB.1992.057.01.072; RIDLEY AJ, 1992, CELL, V70, P401, DOI 10.1016/0092-8674(92)90164-8; Ridley AJ, 2001, J CELL SCI, V114, P2713; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; Rubin J, 2004, PROSTATE, V58, P41, DOI 10.1002/pros.10299; Sahai E, 2002, NAT REV CANCER, V2, P133, DOI 10.1038/nrc725; Sander EE, 1999, J CELL BIOL, V147, P1009, DOI 10.1083/jcb.147.5.1009; Shinto Eiji, 2003, Nihon Rinsho, V61 Suppl 7, P215; Somlyo AV, 2003, FASEB J, V17, P223, DOI 10.1096/fj.02-0655com; Somlyo AV, 2000, BIOCHEM BIOPH RES CO, V269, P652, DOI 10.1006/bbrc.2000.2343; Suwa H, 1998, BRIT J CANCER, V77, P147, DOI 10.1038/bjc.1998.23; Takai Y, 2001, PHYSIOL REV, V81, P153, DOI 10.1152/physrev.2001.81.1.153; Tanno S, 2001, CANCER RES, V61, P589; Thalmann GN, 2000, PROSTATE, V44, P91; Turner CE, 2000, J CELL SCI, V113, P4139; van Golen KL, 1999, CLIN CANCER RES, V5, P2511; van Golen KL, 2000, CANCER RES, V60, P5832; van Golen KL, 2003, BREAST CANCER RES, V5, P174, DOI 10.1186/bcr598; van Golen KL, 2002, MOL CANCER THER, V1, P575; van Golen KL, 2002, CLIN EXP METASTAS, V19, P301, DOI 10.1023/A:1015518114931; van Golen KL, 2000, NEOPLASIA, V2, P418, DOI 10.1038/sj.neo.7900115; Wang W, 2003, WORLD J GASTROENTERO, V9, P1950, DOI 10.3748/wjg.v9.i9.1950; WEST K, 2004, J CELL BIOL, V154, P161, DOI DOI 10.1083/JCB.200101039; Yin JJ, 2005, CELL RES, V15, P57, DOI 10.1038/sj.cr.7290266; Zaidel-Bar R, 2003, J CELL SCI, V116, P4605, DOI 10.1242/jcs.00792; Zhang H, 2004, EXPERT OPIN INV DRUG, V13, P1569, DOI 10.1517/13543784.13.12.1569; Zondag GCM, 2000, J CELL BIOL, V149, P775, DOI 10.1083/jcb.149.4.775; 1999, CANC MANAGEMENT MULT	78	53	66	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 13	2006	25	16					2285	2296		10.1038/sj.onc.1209260	http://dx.doi.org/10.1038/sj.onc.1209260			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	032HC	16314838				2022-12-25	WOS:000236764300001
J	Yi, MK; Tong, X; Skelton, A; Chase, R; Chen, T; Prongay, A; Bogen, SL; Saksena, AK; Njoroge, FG; Veselenak, RL; Pyles, RB; Bourne, N; Malcolm, BA; Lemon, SM				Yi, MK; Tong, X; Skelton, A; Chase, R; Chen, T; Prongay, A; Bogen, SL; Saksena, AK; Njoroge, FG; Veselenak, RL; Pyles, RB; Bourne, N; Malcolm, BA; Lemon, SM			Mutations conferring resistance to SCH6, a novel hepatitis C virus NS3/4A protease inhibitor - Reduced rna replication fitness and partial rescue by second-site mutations	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADAPTER PROTEIN; VIRAL FITNESS; ACTIVE-SITE; IN-VIVO; EXPRESSION; TYPE-1; VARIANTS; GAG	Drug resistance is a major issue in the development and use of specific antiviral therapies. Here we report the isolation and characterization of hepatitis C virus RNA replicons resistant to a novel ketoamide inhibitor of the NS3/4A protease, SCH6 ( originally SCH446211). Resistant replicon RNAs were generated by G418 selection in the presence of SCH6 in a dose-dependent fashion, with the emergence of resistance reduced at higher SCH6 concentrations. Sequencing demonstrated remarkable consistency in the mutations conferring SCH6 resistance in genotype 1b replicons derived from two different strains of hepatitis C virus, A156T/ A156V and R109K. R109K, a novel mutation not reported previously to cause resistance to NS3/4A inhibitors, conferred moderate resistance only to SCH6. Structural analysis indicated that this reflects unique interactions of SCH6 with P'-side residues in the protease active site. In contrast, A156T conferred high level resistance to SCH6 and a related ketoamide, SCH503034, as well as BILN 2061 and VX-950. Unlike R109K, which had minimal impact on NS3/4A enzymatic function, A156T significantly reduced NS3/4A catalytic efficiency, polyprotein processing, and replicon fitness. However, three separate second-site mutations, P89L, Q86R, and G162R, were capable of partially reversing A156T-associated defects in polyprotein processing and/or replicon fitness, without significantly reducing resistance to the protease inhibitor.	Schering Plough Corp, Res Inst, Dept Virol, Kenilworth, NJ 07033 USA; Univ Texas, Med Branch, Inst Human Infect & Immun, Ctr Hepatitis Res, Galveston, TX 77555 USA; Univ Texas, Med Branch, Dept Microbiol & Immunol, Galveston, TX 77555 USA; Univ Texas, Med Branch, Dept Pediat, Galveston, TX 77555 USA; Schering Plough Corp, Res Inst, Dept Struct Chem, Kenilworth, NJ 07033 USA; Schering Plough Corp, Res Inst, Dept Med Chem, Kenilworth, NJ 07033 USA	Merck & Company; Schering Plough Corporation; University of Texas System; University of Texas Medical Branch Galveston; University of Texas System; University of Texas Medical Branch Galveston; University of Texas System; University of Texas Medical Branch Galveston; Merck & Company; Schering Plough Corporation; Merck & Company; Schering Plough Corporation	Tong, X (corresponding author), Schering Plough Corp, Res Inst, Dept Virol, Kenilworth, NJ 07033 USA.	xiao.tong@spcorp.com; smlemon@utmb.edu			NIAID NIH HHS [N01-AI25488, R21-AI063451, U19-AI40035] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R21AI063451, U19AI040035] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Arasappan A, 2005, BIOORG MED CHEM LETT, V15, P4180, DOI 10.1016/j.bmcl.2005.06.091; Back SH, 2000, PROTEIN EXPRES PURIF, V20, P196, DOI 10.1006/prep.2000.1301; BERGER A, 1970, PHILOS T R SOC B, V257, P249, DOI 10.1098/rstb.1970.0024; Blight KJ, 2000, SCIENCE, V290, P1972, DOI 10.1126/science.290.5498.1972; Bourne N, 2005, ANTIVIR RES, V67, P76, DOI 10.1016/j.antiviral.2005.03.006; Cabot B, 2001, J VIROL, V75, P12005, DOI 10.1128/JVI.75.24.12005-12013.2001; Croteau G, 1997, J VIROL, V71, P1089, DOI 10.1128/JVI.71.2.1089-1096.1997; CRUMPACKER C, 2001, FIELDS VIROLOGY, P393; Farci P, 2002, P NATL ACAD SCI USA, V99, P3081, DOI 10.1073/pnas.052712599; Foy E, 2003, SCIENCE, V300, P1145, DOI 10.1126/science.1082604; Johnson Victoria A, 2004, Top HIV Med, V12, P119; Kolykhalov AA, 2000, J VIROL, V74, P2046, DOI 10.1128/JVI.74.4.2046-2051.2000; Krieger N, 2001, J VIROL, V75, P4614, DOI 10.1128/JVI.75.10.4614-4624.2001; Kuzmic P, 2000, ANAL BIOCHEM, V281, P62, DOI 10.1006/abio.2000.4501; Lamarre D, 2003, NATURE, V426, P186, DOI 10.1038/nature02099; Li K, 2005, P NATL ACAD SCI USA, V102, P2992, DOI 10.1073/pnas.0408824102; Li XD, 2005, P NATL ACAD SCI USA, V102, P17717, DOI 10.1073/pnas.0508531102; Lin C, 2004, J BIOL CHEM, V279, P17508, DOI 10.1074/jbc.M313020200; Lohmann V, 1999, SCIENCE, V285, P110, DOI 10.1126/science.285.5424.110; Lu LJ, 2004, ANTIMICROB AGENTS CH, V48, P2260, DOI 10.1128/AAC.48.6.2260-2266.2004; Maguire MF, 2002, J VIROL, V76, P7398, DOI 10.1128/JVI.76.15.7398-7406.2002; Mammano F, 1998, J VIROL, V72, P7632, DOI 10.1128/JVI.72.9.7632-7637.1998; MARTELL M, 1992, J VIROL, V66, P3225, DOI 10.1128/JVI.66.5.3225-3229.1992; Meylan E, 2005, NATURE, V437, P1167, DOI 10.1038/nature04193; MORRISON JF, 1988, ADV ENZYMOL RAMB, V61, P201; NAKABAYASHI H, 1982, CANCER RES, V42, P3858; Nijhuis M, 2001, CURR OPIN INFECT DIS, V14, P23, DOI 10.1097/00001432-200102000-00005; Reed KE, 2000, CURR TOP MICROBIOL, V242, P55; REESINK HW, 2005, 36 ANN DIG DIS WEEK; Taremi SS, 1998, PROTEIN SCI, V7, P2143, DOI 10.1002/pro.5560071011; Trozzi C, 2003, J VIROL, V77, P3669, DOI 10.1128/JVI.77.6.3669-3679.2003; Wang WY, 2004, J VIROL, V78, P700, DOI 10.1128/JVI.78.2.700-709.2004; Yao NH, 1999, STRUCTURE, V7, P1353, DOI 10.1016/S0969-2126(00)80025-8; Yi MK, 2004, J VIROL, V78, P7904, DOI 10.1128/JVI.78.15.7904-7915.2004; Yi MK, 2002, VIROLOGY, V304, P197, DOI 10.1006/viro.2002.1652; Yusa K, 2004, CURR PHARM DESIGN, V10, P4055, DOI 10.2174/1381612043382477; Zhang RM, 1999, ANAL BIOCHEM, V270, P268, DOI 10.1006/abio.1999.4109	37	89	94	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 24	2006	281	12					8205	8215		10.1074/jbc.M510246200	http://dx.doi.org/10.1074/jbc.M510246200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	022BZ	16352601	hybrid			2022-12-25	WOS:000236031000060
J	Bergeron, A; Jorquera, R; Orejuela, D; Tanguay, RM				Bergeron, A; Jorquera, R; Orejuela, D; Tanguay, RM			Involvement of endoplasmic reticulum stress in hereditary tyrosinemia type I	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							UNFOLDED PROTEIN RESPONSE; INDUCED GENE-EXPRESSION; CELL-DEATH PROGRAM; FUMARYLACETOACETATE; APOPTOSIS; ACTIVATION; INDUCTION; MOUSE; LIVER; ER	Hereditary tyrosinemia type I ( HTI) is the most severe disease of the tyrosine degradation pathway. HTI is caused by a deficiency of fumarylacetoacetate hydrolase ( FAH), the enzyme responsible for the hydrolysis of fumarylacetoacetate ( FAA). As a result, there is an accumulation of metabolites such as maleylacetoacetate, succinylacetone, and FAA. The latter was shown to display mutagenic, cytostatic, and apoptogenic activities and to cause chromosomal instability. Herein, we demonstrate that FAA also causes a cellular insult leading to the endoplasmic reticulum ( ER) stress signaling. Treatment of V79 Chinese hamster lung cells with an apoptogenic dose of FAA ( 100 mu M) causes an early induction of the ER resident chaperone GRP78/BiP and a simultaneous phosphorylation of the eIF2 alpha. FAA treatment also causes a subsequent induction of the proapoptotic CHOP ( CEBP homologous protein) transcription factor as well as a late activation of caspase-12. Data obtained from fah(-)/ - mice taken off the therapeutic 2-(2-nitro-4-trifluoromethylbenzoyl)1,3 cyclohexanedione drug are similar. However, in this mouse model, there is also an increase in proteasome activity indicative of ER-associated degradation. This difference observed between the two models may be due to the fact that the murine model measures the effects of all metabolites accumulating in hereditary tyrosinemia type I as opposed to the cellular model that only measures the effects of exogenous FAA.	Univ Laval, Ctr Rech Fonct Struct & Ingn Prot, Dept Med, Lab Cell & Dev Genet, Ste Foy, PQ G1K 7P4, Canada	Laval University	Tanguay, RM (corresponding author), Univ Laval, Ctr Rech Fonct Struct & Ingn Prot, Dept Med, Lab Cell & Dev Genet, Pavillon Marchand, Ste Foy, PQ G1K 7P4, Canada.	robert.tanguay@rsvs.ulaval.ca						BARTLETT JD, 1992, J BIOL CHEM, V267, P20465; BERGER R, 1987, PEDIATR RES, V22, P394, DOI 10.1203/00006450-198710000-00005; Bloom D, 2002, ONCOGENE, V21, P2191, DOI 10.1038/sj.onc.1205288; Castano JG, 1996, BIOCHEMISTRY-US, V35, P3782, DOI 10.1021/bi952540s; Chang JY, 1996, EXP NEUROL, V137, P201, DOI 10.1006/exnr.1996.0019; Dieter MZ, 2003, FREE RADICAL BIO MED, V35, P351, DOI 10.1016/S0891-5849(03)00273-9; EDWARDS SW, 1955, METHOD ENZYMOL, V2, P292; Ellgaard L, 2005, EMBO REP, V6, P28, DOI 10.1038/sj.embor.7400311; FALLSTROM SP, 1979, PEDIATR RES, V13, P78, DOI 10.1203/00006450-197901000-00056; Filippin L, 2003, J BIOL CHEM, V278, P39224, DOI 10.1074/jbc.M302301200; Friedlander R, 2000, NAT CELL BIOL, V2, P379, DOI 10.1038/35017001; Garrido C, 2003, CELL CYCLE, V2, P579, DOI 10.4161/cc.2.6.521; GROMPE M, 1993, GENE DEV, V7, P2298, DOI 10.1101/gad.7.12a.2298; Harding HP, 2000, MOL CELL, V6, P1099, DOI 10.1016/S1097-2765(00)00108-8; Harding HP, 2003, MOL CELL, V11, P619, DOI 10.1016/S1097-2765(03)00105-9; Hayes JD, 2000, BIOCHEM SOC T, V28, P33, DOI 10.1042/bst0280033; Ito H, 2005, J CELL BIOCHEM, V95, P932, DOI 10.1002/jcb.20445; Jorquera R, 1999, FASEB J, V13, P2284, DOI 10.1096/fasebj.13.15.2284; Jorquera R, 1997, BIOCHEM BIOPH RES CO, V232, P42, DOI 10.1006/bbrc.1997.6220; Jorquera R, 2001, HUM MOL GENET, V10, P1741, DOI 10.1093/hmg/10.17.1741; Kato K, 2002, FASEB J, V16, P1432, DOI 10.1096/fj.02-0129fje; Kaufman RJ, 1999, GENE DEV, V13, P1211, DOI 10.1101/gad.13.10.1211; KVITTINGEN EA, 1981, CLIN CHIM ACTA, V115, P311, DOI 10.1016/0009-8981(81)90244-8; Lee AH, 2003, MOL CELL BIOL, V23, P7448, DOI 10.1128/MCB.23.21.7448-7459.2003; LINDBLAD B, 1977, P NATL ACAD SCI USA, V74, P4641, DOI 10.1073/pnas.74.10.4641; Liu XM, 2005, J BIOL CHEM, V280, P872, DOI 10.1074/jbc.M410413200; Luijerink MC, 2003, J HEPATOL, V39, P901, DOI 10.1016/S0168-8278(03)00433-1; Ma YJ, 2004, J BIOL CHEM, V279, P13792, DOI 10.1074/jbc.M313724200; McCullough KD, 2001, MOL CELL BIOL, V21, P1249, DOI 10.1128/MCB.21.4.1249-1259.2001; Moinova HR, 1999, BIOCHEM BIOPH RES CO, V261, P661, DOI 10.1006/bbrc.1999.1109; Morishima N, 2002, J BIOL CHEM, V277, P34287, DOI 10.1074/jbc.M204973200; Nakagawa T, 2000, J CELL BIOL, V150, P887, DOI 10.1083/jcb.150.4.887; Novoa I, 2003, EMBO J, V22, P1180, DOI 10.1093/emboj/cdg112; Parcellier A, 2003, MOL CELL BIOL, V23, P5790, DOI 10.1128/MCB.23.16.5790-5802.2003; PEREZSALA D, 1995, J CELL PHYSIOL, V163, P523, DOI 10.1002/jcp.1041630312; Rao RV, 2002, J BIOL CHEM, V277, P21836, DOI 10.1074/jbc.M202726200; Rao RV, 2001, J BIOL CHEM, V276, P33869, DOI 10.1074/jbc.M102225200; RICE WR, 1989, EVOLUTION, V43, P223, DOI 10.1111/j.1558-5646.1989.tb04220.x; Rutkowski DT, 2004, TRENDS CELL BIOL, V14, P20, DOI 10.1016/j.tcb.2003.11.001; Sokal R.R, 1995, BIOMETRY PRINCIPLES, P392; Szegezdi E, 2003, ANN NY ACAD SCI, V1010, P186, DOI 10.1196/annals.1299.032; Tanguay RM, 1996, ACTA BIOCHIM POL, V43, P209; TANGUAY RM, 1993, DEV GENET, V14, P112, DOI 10.1002/dvg.1020140205; TANGUAY RM, 1984, ADV GENE TECHNOLOGY, P256; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; Tu BP, 2004, J CELL BIOL, V164, P341, DOI 10.1083/jcb.200311055; Venugopal R, 1998, ONCOGENE, V17, P3145, DOI 10.1038/sj.onc.1202237; Vogel A, 2004, HEPATOLOGY, V39, P433, DOI 10.1002/hep.20077; Yan LJ, 2005, ANTIOXID REDOX SIGN, V7, P465, DOI 10.1089/ars.2005.7.465; Yoneda T, 2001, J BIOL CHEM, V276, P13935, DOI 10.1074/jbc.M010677200; Yoshida H, 1998, J BIOL CHEM, V273, P33741, DOI 10.1074/jbc.273.50.33741; ZAR JH, 1984, BIOSTAT ANAL, P122; Zhang KZ, 2004, J BIOL CHEM, V279, P25935, DOI 10.1074/jbc.R400008200	53	29	29	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 3	2006	281	9					5329	5334		10.1074/jbc.M506804200	http://dx.doi.org/10.1074/jbc.M506804200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	015RQ	16317004	hybrid			2022-12-25	WOS:000235568900002
J	Gibbs, GM; Scanlon, MJ; Swarbrick, J; Curtis, S; Gallant, E; Dulhunty, AF; O'Bryan, MK				Gibbs, GM; Scanlon, MJ; Swarbrick, J; Curtis, S; Gallant, E; Dulhunty, AF; O'Bryan, MK			The cysteine-rich secretory protein domain of Tpx-1 is related to ion channel toxins and regulates ryanodine receptor Ca2+ signaling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PATHOGENESIS-RELATED PROTEIN; TESTIS-SPECIFIC GENE; TORSION ANGLE DYNAMICS; II-III-LOOP; CRISP FAMILY; SNAKE-VENOM; DIHYDROPYRIDINE RECEPTOR; SARCOPLASMIC-RETICULUM; CRYSTAL-STRUCTURE; LIZARD VENOM	The cysteine-rich secretory proteins (Crisp) are predominantly found in the mammalian male reproductive tract as well as in the venom of reptiles. Crisps are two domain proteins with a structurally similar yet evolutionary diverse N-terminal domain and a characteristic cysteine- rich C-terminal domain, which we refer to as the Crisp domain. We presented the NMR solution structure of the Crisp domain of mouse Tpx-1, and we showed that it contains two subdomains, one of which has a similar fold to the ion channel regulators BgK and ShK. Furthermore, we have demonstrated for the first time that the ion channel regulatory activity of Crisp proteins is attributed to the Crisp domain. Specifically, the Tpx-1 Crisp domain inhibited cardiac ryanodine receptor (RyR) 2 with an IC50 between 0.5 and 1.0 mu M and activated the skeletal RyR1 with an AC(50) between 1 and 10 mu M when added to the cytoplasmic domain of the receptor. This activity was nonvoltage-dependent and weakly voltage-dependent, respectively. Furthermore, the Tpx-1 Crisp domain activated both RyR forms at negative bilayer potentials and showed no effect at positive bilayer potentials when added to the luminal domain of the receptor. These data show that the Tpx-1 Crisp domain on its own can regulate ion channel activity and provide compelling evidence for a role for Tpx-1 in the regulation of Ca2+ fluxes observed during sperm capacitation.	Monash Univ, Monash Inst Med Res, Clayton, Vic 3168, Australia; Monash Univ, Australian Res Council, Ctr Excellence Biotechnol & Dev, Clayton, Vic 3168, Australia; Monash Univ, Dept Med Chem, Clayton, Vic 3168, Australia; Australian Natl Univ, John Curtin Sch Med Res, Canberra, ACT 2601, Australia	Monash University; Monash University; Monash University; Australian National University; John Curtin School of Medical Research	O'Bryan, MK (corresponding author), Monash Univ, Monash Inst Med Res, 27-31 Wright St, Clayton, Vic 3168, Australia.	Moira.OBryan@med.monash.edu.au	Dulhunty, Angela/AAO-5421-2020; O'Bryan, Moira K/F-8256-2012	O'Bryan, Moira K/0000-0001-7298-4940; Dulhunty, Angela/0000-0001-9493-4944; Scanlon, Martin/0000-0002-9230-7506				BRAUNSCHWEILER L, 1983, J MAGN RESON, V53, P521, DOI 10.1016/0022-2364(83)90226-3; Brown RL, 2003, J GEN PHYSIOL, V122, P749, DOI 10.1085/jgp.200308823; Busso D, 2003, CELL MOL BIOL, V49, P407; Chang TY, 1997, TOXICON, V35, P879, DOI 10.1016/S0041-0101(96)00192-4; Chiarella P, 2004, J CELL SCI, V117, P4127, DOI 10.1242/jcs.01283; Cohen DJ, 2001, BIOL REPROD, V65, P1000, DOI 10.1095/biolreprod65.4.1000; CRAIK DJ, 2000, ENCY ANAL CHEM, P12390; Dauplais M, 1997, J BIOL CHEM, V272, P4302, DOI 10.1074/jbc.272.7.4302; Dulhunty A, 2001, J BIOL CHEM, V276, P3319, DOI 10.1074/jbc.M007874200; Dulhunty AF, 2004, BIOCHEM J, V379, P161, DOI 10.1042/BJ20031096; Dulhunty AF, 2004, J BIOL CHEM, V279, P11853, DOI 10.1074/jbc.M310466200; EBERSPAECHER U, 1995, MOL REPROD DEV, V42, P157, DOI 10.1002/mrd.1080420205; Feng W, 2002, J BIOL CHEM, V277, P44722, DOI 10.1074/jbc.M207675200; Fernandez C, 1997, J MOL BIOL, V266, P576, DOI 10.1006/jmbi.1996.0772; Foster JA, 1996, MOL REPROD DEV, V44, P221, DOI 10.1002/(SICI)1098-2795(199606)44:2&lt;221::AID-MRD11&gt;3.0.CO;2-5; GIANNINI G, 1995, J CELL BIOL, V128, P893, DOI 10.1083/jcb.128.5.893; Giese A, 2002, GENE, V299, P101, DOI 10.1016/S0378-1119(02)01018-1; Goddard T. D., 1999, SPARKY 3; Guo M, 2005, J BIOL CHEM, V280, P12405, DOI 10.1074/jbc.M413566200; Haarmann CS, 2003, BIOCHEM J, V372, P305, DOI 10.1042/BJ20021763; HAENDLER B, 1993, ENDOCRINOLOGY, V133, P192, DOI 10.1210/en.133.1.192; Harper CV, 2004, J BIOL CHEM, V279, P46315, DOI 10.1074/jbc.M401194200; Henriksen A, 2001, PROTEINS, V45, P438, DOI 10.1002/prot.1160; Herrmann T, 2002, J MOL BIOL, V319, P209, DOI 10.1016/S0022-2836(02)00241-3; Holm L, 1998, NUCLEIC ACIDS RES, V26, P316, DOI 10.1093/nar/26.1.316; Jalkanen J, 2005, BIOL REPROD, V72, P1268, DOI 10.1095/biolreprod.104.035758; JEENER J, 1979, J CHEM PHYS, V71, P4546, DOI 10.1063/1.438208; Jin Y, 2003, TOXICON, V42, P539, DOI 10.1016/S0041-0101(03)00234-4; KASAHARA M, 1989, IMMUNOGENETICS, V29, P61, DOI 10.1007/BF02341616; KASAHARA M, 1989, GENOMICS, V5, P527, DOI 10.1016/0888-7543(89)90019-0; KAY LE, 1989, J MAGN RESON, V84, P72, DOI 10.1016/0022-2364(89)90006-1; KING TP, 1978, BIOCHEMISTRY-US, V17, P5165, DOI 10.1021/bi00617a016; Kitajima S, 1999, J BIOCHEM, V125, P1, DOI 10.1093/oxfordjournals.jbchem.a022244; KLAUS W, 1993, J MOL BIOL, V232, P897, DOI 10.1006/jmbi.1993.1438; Kratzschmar J, 1996, EUR J BIOCHEM, V236, P827, DOI 10.1111/j.1432-1033.1996.t01-1-00827.x; Maeda T, 1999, DEV GROWTH DIFFER, V41, P715; MARION D, 1983, BIOCHEM BIOPH RES CO, V113, P967, DOI 10.1016/0006-291X(83)91093-8; Marley J, 2001, J BIOMOL NMR, V20, P71, DOI 10.1023/A:1011254402785; MOCHCAMORALES J, 1990, TOXICON, V28, P299, DOI 10.1016/0041-0101(90)90065-F; MORRISSETTE J, 1995, BIOPHYS J, V68, P2280, DOI 10.1016/S0006-3495(95)80410-8; MURPHY EV, 1995, GENE, V159, P131, DOI 10.1016/0378-1119(95)00061-A; NIXON B, 2005, BIOL REPROD; NOBILE M, 1994, J MEMBRANE BIOL, V139, P49; Nobile M, 1996, EXP BRAIN RES, V110, P15; O'Bryan MK, 1998, MOL REPROD DEV, V50, P313, DOI 10.1002/(SICI)1098-2795(199807)50:3&lt;313::AID-MRD7&gt;3.0.CO;2-M; O'Bryan MK, 2001, MOL REPROD DEV, V58, P116, DOI 10.1002/1098-2795(200101)58:1&lt;116::AID-MRD14&gt;3.0.CO;2-8; O'Leary JM, 2004, J BIOL CHEM, V279, P53857, DOI 10.1074/jbc.M409225200; OTSU K, 1990, J BIOL CHEM, V265, P13472; RICE LM, 1994, PROTEINS, V19, P277, DOI 10.1002/prot.340190403; Roberts KP, 2003, BIOL REPROD, V69, P572, DOI 10.1095/biolreprod.102.013771; Rosengren KJ, 2001, BIOCHEMISTRY-US, V40, P4601, DOI 10.1021/bi002623v; Schambony A, 2003, MECH DEVELOP, V120, P937, DOI 10.1016/S0925-4773(03)00162-X; Schreiber MC, 1997, GENE, V191, P135, DOI 10.1016/S0378-1119(97)00010-3; Schwieters CD, 2003, J MAGN RESON, V160, P65, DOI 10.1016/S1090-7807(02)00014-9; Serrano RL, 2004, J MOL BIOL, V339, P173, DOI 10.1016/j.jmb.2004.03.015; Shikamoto Y, 2005, J MOL BIOL, V350, P735, DOI 10.1016/j.jmb.2005.05.020; Sleight SB, 2005, BIOL REPROD, V73, P721, DOI 10.1095/biolreprod.105.041533; Trevino CL, 1998, ZYGOTE, V6, P159, DOI 10.1017/S0967199498000094; Tudor JE, 1996, NAT STRUCT BIOL, V3, P317, DOI 10.1038/nsb0496-317; Udby L, 2004, BIOCHEMISTRY-US, V43, P12877, DOI 10.1021/bi048823e; Udby L, 2002, J LEUKOCYTE BIOL, V72, P462; Westhoff JH, 2003, CELL CALCIUM, V34, P261, DOI 10.1016/S0143-4160(03)00112-X; Yamazaki Y, 2004, TOXICON, V44, P227, DOI 10.1016/j.toxicon.2004.05.023; Yamazaki Y, 2003, ARCH BIOCHEM BIOPHYS, V412, P133, DOI 10.1016/S0003-9861(03)00028-6; Yamazaki Y, 2002, EUR J BIOCHEM, V269, P2708, DOI 10.1046/j.1432-1033.2002.02940.x; Yamazaki Y, 2002, BIOCHEMISTRY-US, V41, P11331, DOI 10.1021/bi026132h	66	107	114	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 17	2006	281	7					4156	4163		10.1074/jbc.M506849200	http://dx.doi.org/10.1074/jbc.M506849200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	011NN	16339766	hybrid			2022-12-25	WOS:000235275300047
J	Gross, CH; Abdul-Manan, N; Fulghum, J; Lippke, J; Liu, X; Prabhakar, P; Brennan, D; Willis, MS; Faerman, C; Connelly, P; Raybuck, S; Moore, J				Gross, CH; Abdul-Manan, N; Fulghum, J; Lippke, J; Liu, X; Prabhakar, P; Brennan, D; Willis, MS; Faerman, C; Connelly, P; Raybuck, S; Moore, J			Nucleotide-binding domains of cystic fibrosis transmembrane conductance regulator, an ABC transporter, catalyze adenylate kinase activity but not ATP hydrolysis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							R-DOMAIN; CFTR; 2ND; PROTEIN; CHANNELS; SEQUENCE; COMPLEX; FOLD; HETERODIMER; MUTATIONS	The cystic fibrosis transmembrane conductance regulator (CFTR) is an anion channel in the ATP-binding cassette (ABC) transporter family. CFTR consists of two transmembrane domains, two nucleotide-binding domains (NBD1 and NBD2), and a regulatory domain. Previous biochemical reports suggest NBD1 is a site of stable nucleotide interaction with low ATPase activity, whereas NBD2 is the site of active ATP hydrolysis. It has also been reported that NBD2 additionally possessed adenylate kinase (AK) activity. Knowledge about the intrinsic biochemical activities of the NBDs is essential to understanding the Cl- ion gating mechanism. We find that purified mouse NBD1, human NBD1, and human NBD2 function as adenylate kinases but not as ATPases. AK activity is strictly dependent on the addition of the adenosine monophosphate ( AMP) substrate. No liberation of [P-33] phosphate is observed from the gamma-P-33-labeled ATP substrate in the presence or absence of AMP. AK activity is intrinsic to both human NBDs, as the Walker A box lysine mutations abolish this activity. At low protein concentration, the NBDs display an initial slower nonlinear phase in AK activity, suggesting that the activity results from homodimerization. Interestingly, the G551D gating mutation has an exaggerated nonlinear phase compared with the wild type and may indicate this mutation affects the ability of NBD1 to dimerize. hNBD1 and hNBD2 mixing experiments resulted in an 8-57-fold synergistic enhancement in AK activity suggesting heterodimer formation, which supports a common theme in ABC transporter models. A CFTR gating mechanism model based on adenylate kinase activity is proposed.	Vertex Pharmaceut Inc, Cambridge, MA 02139 USA	Vertex Pharmaceuticals	Gross, CH (corresponding author), Vertex Pharmaceut Inc, 130 Waverly St, Cambridge, MA 02139 USA.	Christian_Gross@vrtx.com	Willis, Monte S/J-9994-2015	Willis, Monte S/0000-0002-0769-5816; Moore, Jonathan/0000-0001-8633-3313				ALBERTY RA, 1992, BIOCHEMISTRY-US, V31, P10610, DOI 10.1021/bi00158a025; Aleksandrov L, 2002, J BIOL CHEM, V277, P15419, DOI 10.1074/jbc.M111713200; Annereau JP, 2003, BIOCHEM J, V371, P451, DOI 10.1042/BJ20021318; Balakrishnan L, 2004, J BIOL CHEM, V279, P11273, DOI 10.1074/jbc.M308494200; Berger AL, 2005, P NATL ACAD SCI USA, V102, P455, DOI 10.1073/pnas.0408575102; Berry MB, 1998, PROTEINS, V32, P276, DOI 10.1002/(SICI)1097-0134(19980815)32:3<276::AID-PROT3>3.0.CO;2-G; Callebaut I, 2004, CELL MOL LIFE SCI, V61, P230, DOI 10.1007/s00018-003-3386-z; Chappe V, 2005, EMBO J, V24, P2730, DOI 10.1038/sj.emboj.7600747; Chen JH, 2002, J MEMBRANE BIOL, V188, P55, DOI 10.1007/s00232-001-0174-2; CUTTING GR, 1990, NATURE, V346, P366, DOI 10.1038/346366a0; ElvirMairena JR, 1996, J BIOL CHEM, V271, P31903, DOI 10.1074/jbc.271.50.31903; Gadsby D. C., 1999, PHYSIOL REV, V79, pS77; GILL SC, 1989, ANAL BIOCHEM, V182, P319, DOI 10.1016/0003-2697(89)90602-7; Holland IB, 1999, J MOL BIOL, V293, P381, DOI 10.1006/jmbi.1999.2993; Howell LD, 2004, BIOCHEM J, V378, P151, DOI 10.1042/BJ20021428; HYDE SC, 1990, NATURE, V346, P362, DOI 10.1038/346362a0; Kidd JF, 2004, J BIOL CHEM, V279, P41664, DOI 10.1074/jbc.M407666200; Krishnamurthy H, 2005, PROTEINS, V58, P88, DOI 10.1002/prot.20301; Lewis HA, 2004, EMBO J, V23, P282, DOI 10.1038/sj.emboj.7600040; LIENHARD GE, 1973, J BIOL CHEM, V248, P1121; Lu NT, 2000, ARCH BIOCHEM BIOPHYS, V375, P7, DOI 10.1006/abbi.1999.1656; Mossessova E, 2000, MOL CELL, V5, P865, DOI 10.1016/S1097-2765(00)80326-3; Ostedgaard LS, 2001, J BIOL CHEM, V276, P7689, DOI 10.1074/jbc.R100001200; Ramaen O, 2005, BIOCHEM J, V391, P481, DOI 10.1042/BJ20050897; Ramjeesingh M, 1997, BIOCHEM J, V327, P17, DOI 10.1042/bj3270017; Ramjeesingh M, 2003, BIOCHEM J, V375, P633, DOI 10.1042/BJ20030774; Ramjeesingh M, 2001, BIOCHEMISTRY-US, V40, P10700, DOI 10.1021/bi0108195; Randak C, 1997, FEBS LETT, V410, P180, DOI 10.1016/S0014-5793(97)00574-7; Randak C, 2003, CELL, V115, P837, DOI 10.1016/S0092-8674(03)00983-8; Randak C, 1999, BIOCHEM J, V340, P227, DOI 10.1042/0264-6021:3400227; Randak CO, 2005, J BIOL CHEM, V280, P34385, DOI 10.1074/jbc.R500009200; Randak CO, 2005, P NATL ACAD SCI USA, V102, P2216, DOI 10.1073/pnas.0409787102; RICH DP, 1991, SCIENCE, V253, P205, DOI 10.1126/science.1712985; SHEPPARD DN, 1993, NATURE, V362, P160, DOI 10.1038/362160a0; SHUTZGESHWENDER A, 2004, LICOR BIOSCIENCES; Stefkova J, 2004, PHYSIOL RES, V53, P235; SWOPE MW, 2005, PROTEIN SCI, V14, P1818; Verdon G, 2003, J MOL BIOL, V334, P255, DOI 10.1016/j.jmb.2003.08.065; Vonrhein C, 1998, J MOL BIOL, V282, P167, DOI 10.1006/jmbi.1998.2003; Wang WL, 2002, AM J PHYSIOL-CELL PH, V282, pC1170, DOI 10.1152/ajpcell.00337.2001; WELSH MJ, 1993, CELL, V73, P1251, DOI 10.1016/0092-8674(93)90353-R; Winter MC, 1997, NATURE, V389, P294, DOI 10.1038/38514; Zimmermann H, 1996, PROG NEUROBIOL, V49, P589, DOI 10.1016/0301-0082(96)00026-3	43	21	21	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 17	2006	281	7					4058	4068		10.1074/jbc.M511113200	http://dx.doi.org/10.1074/jbc.M511113200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	011NN	16361259	hybrid			2022-12-25	WOS:000235275300035
J	Knauf, JA; Ouyang, B; Knudsen, ES; Fukasawa, K; Babcock, G; Fagin, JA				Knauf, JA; Ouyang, B; Knudsen, ES; Fukasawa, K; Babcock, G; Fagin, JA			Oncogenic RAS induces accelerated transition through G(2)/M and promotes defects in the G(2) DNA damage and mitotic spindle checkpoints	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							THYROID PCCL3 CELLS; SIGNAL-REGULATED KINASE; GENOMIC INSTABILITY; MAP KINASE; HA-RAS; GENETIC INSTABILITY; METASTATIC ABILITY; MUTATOR PHENOTYPE; PATHWAY; PROTEIN	Activating mutations of RAS are prevalent in thyroid follicular neoplasms, which commonly have chromosomal losses and gains. In thyroid cells, acute expression of HRAS(V12) increases the frequency of chromosomal abnormalities within one or two cell cycles, suggesting that RAS oncoproteins may interfere with cell cycle checkpoints required for maintenance of a stable genome. To explore this, PCCL3 thyroid cells with conditional expression of HRAS(V12) or HRAS(V12) effector mutants were presynchronized at the G(1)/S boundary, followed by activation of expression of RAS mutants and release from the cell cycle block. Expression of HRAS(V12) accelerated the G(2)/M phase by similar to 4 h and promoted bypass of the G(2) DNA damage and mitotic spindle checkpoints. Accelerated passage through G(2)/M and bypass of the G(2) DNA damage checkpoint, but not bypass of the mitotic spindle checkpoint, required activation of mitogen-activated protein kinase (MAPK). However, selective activation of the MAPK pathway was not sufficient to disrupt the G(2) DNA damage checkpoint, because cells arrested appropriately in G(2) despite conditional expression of HRAS(V12,S35) or BRAF(V600E). By contrast to the MAPK requirement for radiation-induced G(2) arrest, RAS-induced bypass of the mitotic spindle checkpoint was not prevented by pretreatment with MEK inhibitors. These data support a direct role for the MAPK pathway in control of G(2) progression and regulation of the G(2) DNA damage checkpoint. We propose that oncogenic RAS activation may predispose cells to genomic instability through both MAPK-dependent and independent pathways that affect critical checkpoints in G(2)/M.	Univ Cincinnati, Coll Med, Div Endocrinol & Metab, Cincinnati, OH 45267 USA; Univ Cincinnati, Coll Med, Dept Cell Biol Neurobiol & Anat, Cincinnati, OH 45267 USA; Univ Cincinnati, Coll Med, Shriners Burns Inst, Div Burn Surg, Cincinnati, OH 45267 USA	University System of Ohio; University of Cincinnati; University System of Ohio; University of Cincinnati; University System of Ohio; University of Cincinnati	Fagin, JA (corresponding author), Univ Cincinnati, Coll Med, Div Endocrinol & Metab, 231 Bethesda Ave,Rm 5564, Cincinnati, OH 45267 USA.	James.Fagin@uc.edu		Knauf, Jeffrey/0000-0003-4456-8792	NCI NIH HHS [CA72597] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA072597] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Abbott DW, 1999, J BIOL CHEM, V274, P2732, DOI 10.1074/jbc.274.5.2732; AESCHIMANN S, 1993, J CLIN ENDOCR METAB, V77, P846, DOI 10.1210/jc.77.3.846; Agapova LS, 2004, J BIOL CHEM, V279, P36382, DOI 10.1074/jbc.M405007200; Agapova LS, 1999, ONCOGENE, V18, P3135, DOI 10.1038/sj.onc.1202386; BARBACID M, 1990, EUR J CLIN INVEST, V20, P225, DOI 10.1111/j.1365-2362.1990.tb01848.x; Bartkova J, 2005, NATURE, V434, P864, DOI 10.1038/nature03482; BOS JL, 1989, CANCER RES, V49, P4682; Cahill DP, 1998, NATURE, V392, P300, DOI 10.1038/32688; Campbell PM, 2004, SEMIN CANCER BIOL, V14, P105, DOI 10.1016/j.semcancer.2003.09.015; Cha HJ, 2001, J CELL BIOL, V153, P1355, DOI 10.1083/jcb.153.7.1355; Chen CR, 1999, P NATL ACAD SCI USA, V96, P517, DOI 10.1073/pnas.96.2.517; DENKO N, 1995, SOMAT CELL MOLEC GEN, V21, P241, DOI 10.1007/BF02255779; DENKO NC, 1994, P NATL ACAD SCI USA, V91, P5124, DOI 10.1073/pnas.91.11.5124; DEVRIES JE, 1993, CANCER GENET CYTOGEN, V67, P35, DOI 10.1016/0165-4608(93)90041-J; Downward J, 1998, CURR OPIN GENET DEV, V8, P49, DOI 10.1016/S0959-437X(98)80061-0; Esapa CT, 1999, CLIN ENDOCRINOL, V50, P529, DOI 10.1046/j.1365-2265.1999.00704.x; FEY MF, 1992, J CLIN INVEST, V89, P1438, DOI 10.1172/JCI115733; FINNEY RE, 1993, SCIENCE, V260, P1524, DOI 10.1126/science.8502998; Gorgoulis VG, 2005, NATURE, V434, P907, DOI 10.1038/nature03485; GOTOH Y, 1991, NATURE, V349, P251, DOI 10.1038/349251a0; ICHIKAWA T, 1990, CANCER RES, V50, P6349; ICHIKAWA T, 1991, PROSTATE, V18, P163, DOI 10.1002/pros.2990180209; Jesch SA, 2001, MOL BIOL CELL, V12, P1811, DOI 10.1091/mbc.12.6.1811; Kandel ES, 2002, MOL CELL BIOL, V22, P7831, DOI 10.1128/MCB.22.22.7831-7841.2002; KARGA H, 1991, J CLIN ENDOCR METAB, V73, P832, DOI 10.1210/jcem-73-4-832; Knauf JA, 1999, J BIOL CHEM, V274, P23414, DOI 10.1074/jbc.274.33.23414; Kranenburg O, 2004, BBA-REV CANCER, V1654, P23, DOI 10.1016/j.bbcan.2003.09.004; Lavoie JN, 1996, J BIOL CHEM, V271, P20608, DOI 10.1074/jbc.271.34.20608; LEMOINE NR, 1989, ONCOGENE, V4, P159; LEMOINE NR, 1988, CANCER RES, V48, P4459; Li YC, 2000, GENETICS, V156, P995; Liu X, 2004, ONCOGENE, V23, P763, DOI 10.1038/sj.onc.1207188; LOEB LA, 1991, CANCER RES, V51, P3075; Loeb LA, 1998, ADV CANCER RES, V72, P25, DOI 10.1016/S0065-230X(08)60699-5; Malumbres M, 2001, NAT REV CANCER, V1, P222, DOI 10.1038/35106065; Mitsutake N, 2005, CANCER RES, V65, P2465, DOI 10.1158/0008-5472.CAN-04-3314; NAMBA H, 1990, J CLIN INVEST, V86, P120, DOI 10.1172/JCI114673; NAMBA H, 1990, MOL ENDOCRINOL, V4, P1474, DOI 10.1210/mend-4-10-1474; Norppa H, 2003, MUTAGENESIS, V18, P221, DOI 10.1093/mutage/18.3.221; OLLER AR, 1989, MUTAT RES, V216, P149, DOI 10.1016/0165-1161(89)90001-0; Panta GR, 2004, MOL CELL BIOL, V24, P1823, DOI 10.1128/MCB.24.5.1823-1835.2004; Roberts EC, 2002, MOL CELL BIOL, V22, P7226, DOI 10.1128/MCB.22.20.7226-7241.2002; RodriguezViciana P, 1997, CELL, V89, P457, DOI 10.1016/S0092-8674(00)80226-3; Saavedra HI, 2000, ONCOGENE, V19, P3948, DOI 10.1038/sj.onc.1203723; Saavedra HI, 1999, J BIOL CHEM, V274, P38083, DOI 10.1074/jbc.274.53.38083; Sebolt-Leopold JS, 2004, CURR PHARM DESIGN, V10, P1907, DOI 10.2174/1381612043384439; Segal M, 2001, BIOESSAYS, V23, P307, DOI 10.1002/bies.1044; Shapiro PS, 1998, J CELL BIOL, V142, P1533, DOI 10.1083/jcb.142.6.1533; Shiloh Y, 2003, NAT REV CANCER, V3, P155, DOI 10.1038/nrc1011; Shiloh Y, 2001, ADV CANCER RES, V83, P209, DOI 10.1016/S0065-230X(01)83007-4; Shirokawa JM, 2000, MOL ENDOCRINOL, V14, P1725, DOI 10.1210/me.14.11.1725; SUAREZ HG, 1990, ONCOGENE, V5, P565; Tang DM, 2002, J BIOL CHEM, V277, P12710, DOI 10.1074/jbc.M111598200; Taylor SS, 1997, CELL, V89, P727, DOI 10.1016/S0092-8674(00)80255-X; THACKER J, 1985, MUTAT RES, V150, P431, DOI 10.1016/0027-5107(85)90140-X; Wang JW, 2003, MOL ENDOCRINOL, V17, P1425, DOI 10.1210/me.2003-0041; WANI MA, 1994, CANCER RES, V54, P2504; Wright JH, 1999, P NATL ACAD SCI USA, V96, P11335, DOI 10.1073/pnas.96.20.11335; Zecevic M, 1998, J CELL BIOL, V142, P1547, DOI 10.1083/jcb.142.6.1547	59	75	75	1	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 17	2006	281	7					3800	3809		10.1074/jbc.M511690200	http://dx.doi.org/10.1074/jbc.M511690200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	011NN	16316983	hybrid			2022-12-25	WOS:000235275300008
J	El-Guindy, AS; Paek, SY; Countryman, J; Miller, G				El-Guindy, AS; Paek, SY; Countryman, J; Miller, G			Identification of constitutive phosphorylation sites on the Epstein-Barr virus ZEBRA protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CASEIN KINASE-II; CREB-BINDING-PROTEIN; LYTIC CYCLE GENES; NF-KAPPA-B; DNA-BINDING; C-JUN; TRANSCRIPTION FACTOR; PRODUCTIVE CYCLE; BZLF1 PROTEIN; CELL-CYCLE	ZEBRA, the product of the Epstein-Barr virus gene bzlf1, and a member of the AP-1 subfamily of basic zipper ( bZIP) transcription factors, is necessary and sufficient to disrupt viral latency and to initiate the viral lytic cycle. Two serine residues of ZEBRA, Ser(167) and Ser(173), are substrates for casein kinase 2 ( CK2) and are constitutively phosphorylated in vivo. Phosphorylation of ZEBRA at its CK2 sites is required for proper temporal regulation of viral gene expression. Phosphopeptide analysis indicated that ZEBRA contains additional constitutive phosphorylation sites. Here we employed a co-migration strategy to map these sites in vivo. The cornerstone of this strategy was to correlate the migration of P-32- and S-35- labeled tryptic peptides of ZEBRA. The identity of the peptides was revealed by mutagenesis of methionine and cysteine residues present in each peptide. Phosphorylation sites within the peptide were identified by mutagenesis of serines and threonines. ZEBRA was shown to be phosphorylated at serine and threonine residues, but not tyrosine. Two previously unrecognized phosphorylation sites of ZEBRA were identified in the NH2-terminal region of the transactivation domain: a cluster of weak phosphorylation sites at Ser(6), Thr(7), and Ser(8) and a strong phosphorylation site at Thr(14). Thr(14) was embedded in a MAP kinase consensus sequence and could be phosphorylated in vitro by JNK, despite the absence of a canonical JNK docking site. Thus ZEBRA is now known to be constitutively phosphorylated at three distinct sites.	Yale Univ, Sch Med, Dept Mol Biophys & Biochem, New Haven, CT 06520 USA; Yale Univ, Sch Med, Dept Pediat, New Haven, CT 06520 USA; Yale Univ, Sch Med, Dept Epidemiol & Publ Hlth, New Haven, CT 06520 USA	Yale University; Yale University; Yale University	Miller, G (corresponding author), Rm 420 LSOG,333 Cedar St,POB 208064, New Haven, CT 06520 USA.	George.Miller@yale.edu		Paek, So Yeon/0000-0002-1598-5928	NCI NIH HHS [CA12055, CA16038] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA012055, R37CA012055, P01CA016038] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Adamson AL, 1999, J VIROL, V73, P6551, DOI 10.1128/JVI.73.8.6551-6558.1999; Adamson AL, 2000, J VIROL, V74, P1224, DOI 10.1128/JVI.74.3.1224-1233.2000; Adamson AL, 2001, J VIROL, V75, P2388, DOI 10.1128/JVI.75.5.2388-2399.2001; ADLER V, 1992, P NATL ACAD SCI USA, V89, P5341, DOI 10.1073/pnas.89.12.5341; ARIAS J, 1994, NATURE, V370, P226, DOI 10.1038/370226a0; Bannister AJ, 1995, ONCOGENE, V11, P2509; Baumann M, 1998, J VIROL, V72, P8105, DOI 10.1128/JVI.72.10.8105-8114.1998; Baumann M, 1999, EMBO J, V18, P6095, DOI 10.1093/emboj/18.21.6095; BERBERICH SJ, 1992, GENE DEV, V6, P166, DOI 10.1101/gad.6.2.166; Bhende PM, 2004, NAT GENET, V36, P1099, DOI 10.1038/ng1424; Cayrol C, 1996, EMBO J, V15, P2748, DOI 10.1002/j.1460-2075.1996.tb00635.x; CHANG YN, 1990, J VIROL, V64, P3358, DOI 10.1128/JVI.64.7.3358-3369.1990; CHI TH, 1993, MOL CELL BIOL, V13, P7045, DOI 10.1128/MCB.13.11.7045; COUNTRYMAN J, 1985, P NATL ACAD SCI USA, V82, P4085, DOI 10.1073/pnas.82.12.4085; DAI TN, 1995, ONCOGENE, V10, P849; DAIBATA M, 1992, VIROLOGY, V188, P916, DOI 10.1016/0042-6822(92)90553-2; Darnell JE, 1996, RECENT PROG HORM RES, V51, P391; DAVIS MG, 1988, BIOTECHNOL APPL BIOC, V10, P6; Deng Z, 2003, MOL CELL BIOL, V23, P2633, DOI 10.1128/MCB.23.8.2633-2644.2003; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; El-Guindy AS, 2004, J VIROL, V78, P7634, DOI 10.1128/JVI.78.14.7634-7644.2004; El-Guindy AS, 2002, J VIROL, V76, P11199, DOI 10.1128/JVI.76.22.11199-11208.2002; ELGUINDY A, 2003, THESIS YALE U NEW HA; Fantz DA, 2001, J BIOL CHEM, V276, P27256, DOI 10.1074/jbc.M102512200; FARRELL PJ, 1989, EMBO J, V8, P127, DOI 10.1002/j.1460-2075.1989.tb03356.x; Feederle R, 2004, J VIROL, V78, P12082, DOI 10.1128/JVI.78.21.12082-12084.2004; FIXMAN ED, 1992, J VIROL, V66, P5030, DOI 10.1128/JVI.66.8.5030-5039.1992; FLEMINGTON E, 1990, J VIROL, V64, P1227, DOI 10.1128/JVI.64.3.1227-1232.1990; FLEMINGTON E, 1990, P NATL ACAD SCI USA, V87, P9459, DOI 10.1073/pnas.87.23.9459; FLEMINGTON EK, 1992, J VIROL, V66, P922, DOI 10.1128/JVI.66.2.922-929.1992; Flemington EK, 2001, J VIROL, V75, P4475, DOI 10.1128/JVI.75.10.4475-4481.2001; Francis A, 1999, J VIROL, V73, P4543, DOI 10.1128/JVI.73.6.4543-4551.1999; Francis AL, 1997, J VIROL, V71, P3054, DOI 10.1128/JVI.71.4.3054-3061.1997; Gao ZG, 1998, J VIROL, V72, P8559, DOI 10.1128/JVI.72.11.8559-8567.1998; HAMMERSCHMIDT W, 1988, CELL, V55, P427, DOI 10.1016/0092-8674(88)90028-1; HESTON L, 1982, NATURE, V295, P160, DOI 10.1038/295160a0; HOLLEYGUTHRIE EA, 1990, J VIROL, V64, P3753, DOI 10.1128/JVI.64.8.3753-3759.1990; HUPP TR, 1994, COLD SPRING HARB SYM, V59, P195, DOI 10.1101/SQB.1994.059.01.024; HUPP TR, 1992, CELL, V71, P875, DOI 10.1016/0092-8674(92)90562-Q; Jacobs D, 1999, GENE DEV, V13, P163, DOI 10.1101/gad.13.2.163; JOHNSON PF, 1993, MOL CELL BIOL, V13, P6919, DOI 10.1128/MCB.13.11.6919; Kallunki T, 1996, CELL, V87, P929, DOI 10.1016/S0092-8674(00)81999-6; KOLMAN JL, 1993, P NATL ACAD SCI USA, V90, P10115, DOI 10.1073/pnas.90.21.10115; Kolman JL, 1996, J VIROL, V70, P1493, DOI 10.1128/JVI.70.3.1493-1504.1996; KOUZARIDES T, 1991, ONCOGENE, V6, P195; LeRoux F, 1996, J GEN VIROL, V77, P501, DOI 10.1099/0022-1317-77-3-501; LIEBERMAN PM, 1990, J VIROL, V64, P1143, DOI 10.1128/JVI.64.3.1143-1155.1990; LIN AN, 1992, CELL, V70, P777, DOI 10.1016/0092-8674(92)90311-Y; LUSCHER B, 1990, NATURE, V344, P517, DOI 10.1038/344517a0; Morrison TE, 2001, IMMUNITY, V15, P787, DOI 10.1016/S1074-7613(01)00226-6; Muller S, 2000, J BIOL CHEM, V275, P13321, DOI 10.1074/jbc.275.18.13321; Musti AM, 1997, SCIENCE, V275, P400, DOI 10.1126/science.275.5298.400; Pearson G, 2001, ENDOCR REV, V22, P153, DOI 10.1210/er.22.2.153; Ragoczy T, 1999, J VIROL, V73, P9858, DOI 10.1128/JVI.73.12.9858-9866.1999; ROONEY CM, 1989, J VIROL, V63, P3109, DOI 10.1128/JVI.63.7.3109-3116.1989; SCHEPERS A, 1993, J VIROL, V67, P4237, DOI 10.1128/JVI.67.7.4237-4245.1993; SCHEPERS A, 1993, EMBO J, V12, P3921, DOI 10.1002/j.1460-2075.1993.tb06070.x; SINCLAIR AJ, 1991, J VIROL, V65, P2237, DOI 10.1128/JVI.65.5.2237-2244.1991; TAYLOR N, 1991, J VIROL, V65, P4033, DOI 10.1128/JVI.65.8.4033-4041.1991; TAYLOR N, 1989, J VIROL, V63, P1721, DOI 10.1128/JVI.63.4.1721-1728.1989; URIER G, 1989, EMBO J, V8, P1447, DOI 10.1002/j.1460-2075.1989.tb03527.x; Viatour P, 2005, TRENDS BIOCHEM SCI, V30, P43, DOI 10.1016/j.tibs.2004.11.009; WANG Y, 1995, NATURE, V376, P88, DOI 10.1038/376088a0; Wu FY, 2003, J VIROL, V77, P1481, DOI 10.1128/JVI.77.2.1481-1500.2003; Zerby D, 1999, MOL CELL BIOL, V19, P1617; Zhang Q, 1996, J VIROL, V70, P5131, DOI 10.1128/JVI.70.8.5131-5142.1996; Zhong HH, 1998, MOL CELL, V1, P661, DOI 10.1016/S1097-2765(00)80066-0	67	24	24	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 10	2006	281	6					3085	3095		10.1074/jbc.M506076200	http://dx.doi.org/10.1074/jbc.M506076200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	009QV	16321978	hybrid			2022-12-25	WOS:000235128200011
J	Gonzalez, E; Kou, RQ; Michel, T				Gonzalez, E; Kou, RQ; Michel, T			Rac1 modulates sphingosine 1-phosphate-mediated activation of phosphoinositide 3-kinase/Akt signaling pathways in vascular endothelial cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-COUPLED RECEPTOR; NITRIC-OXIDE SYNTHASE; DIFFERENTIAL REGULATION; LYSOPHOSPHATIDIC ACID; BINDING-PROTEINS; KINASE; EDG-1; AKT; RHO; PHOSPHORYLATION	Sphingosine 1-phosphate (S1P) is a platelet-derived sphingolipid that activates G protein-coupled S1P receptors and initiates a broad range of responses in vascular endothelial cells. The small GTPase Rac1 is implicated in diverse S1P-modulated cellular responses in endothelial cells, yet the molecular mechanisms involved in S1P-mediated Rac1 activation are incompletely understood. We studied the pathways involved in S1P-mediated Rac1 activation in bovine aortic endothelial cells (BAEC) and found that S1P-induced Rac1 activation is impaired following chelation of G protein beta gamma subunits by transfection of beta ARKct. Treatment with the Src tyrosine kinase inhibitor PP2 completely attenuated S1P-mediated Rac1 activation; however, pretreatment of BAEC with wortmannin, an inhibitor of phosphoinositide (PI) 3-kinase, had no effect on Rac1 activation while completely blocking S1P-induced Akt phosphorylation. We used Rac1-specific small interfering RNA (siRNA) duplexes to "knock down" endogenous Rac1 expression and found that siRNA-mediated Rac1 knockdown significantly impaired basal as well as S1P-induced phosphorylation of protein kinase Akt, as well as several downstream targets of Akt including endothelial nitric-oxide synthase and glycogen synthase kinase 3 beta. By contrast, S1P-induced phosphorylation of the mitogen-activated protein kinases ERK1/2 was unperturbed by siRNA-mediated Rac1 knockdown. We found that overexpression of the Rac1 guanine nucleotide exchange factor (GEF) Tiam1 markedly enhanced Rac1 activity, whereas a dominant negative Tiam1 mutant significantly attenuated S1P-mediated Rac1 activation. Taken together, these studies identify G protein beta gamma subunits, Src kinase and the GEF Tiam1 as upstream modulators of S1P-mediated Rac1 activation, and establish a central role for Rac1 in S1P- mediated activation of PI3-kinase/Akt/endothelial nitric-oxide synthase signaling in vascular endothelial cells.	Harvard Univ, Div Cardiovasc, Brigham & Womens Hosp, Sch Med, Boston, MA 02115 USA; Vet Affairs Boston Healthcare Syst, Boston, MA 02132 USA	Harvard University; Brigham & Women's Hospital; Harvard Medical School; US Department of Veterans Affairs; Veterans Health Administration (VHA); Harvard University; VA Boston Healthcare System	Michel, T (corresponding author), Harvard Univ, Div Cardiovasc, Brigham & Womens Hosp, Sch Med, 75 Francis St, Boston, MA 02115 USA.	tmichel@research.bwh.harvard.edu			NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL046457, R29HL046457] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM036259, R37GM036259] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL46457] Funding Source: Medline; NIGMS NIH HHS [GM36259] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Brazil DP, 2002, CELL, V111, P293, DOI 10.1016/S0092-8674(02)01083-8; Burridge K, 2004, CELL, V116, P167, DOI 10.1016/S0092-8674(04)00003-0; Chan ASL, 2004, CELL SIGNAL, V16, P823, DOI 10.1016/j.cellsig.2003.12.007; Dantas APV, 2003, AM J PHYSIOL-HEART C, V284, pH2045, DOI 10.1152/ajpheart.01089.2002; Ehler E, 1997, MOL CELL NEUROSCI, V9, P1, DOI 10.1006/mcne.1997.0602; English D, 2000, FASEB J, V14, P2255, DOI 10.1096/fj.00-0134com; Erickson JW, 2004, BIOCHEMISTRY-US, V43, P837, DOI 10.1021/bi036026v; Eriksson A, 2003, CIRCULATION, V107, P1532, DOI 10.1161/01.CIR.0000055324.34758.32; Garcia JGN, 2001, J CLIN INVEST, V108, P689, DOI 10.1172/JCI12450; Gonzalez E, 2004, J BIOL CHEM, V279, P40659, DOI 10.1074/jbc.M407051200; Higuchi M, 2001, CURR BIOL, V11, P1958, DOI 10.1016/S0960-9822(01)00599-1; HLA T, 1990, J BIOL CHEM, V265, P9308; Hla T, 2001, SCIENCE, V294, P1875, DOI 10.1126/science.1065323; Igarashi J, 2001, J BIOL CHEM, V276, P12420, DOI 10.1074/jbc.M008375200; Igarashi J, 2001, J BIOL CHEM, V276, P36281, DOI 10.1074/jbc.M105628200; Igarashi J, 2000, J BIOL CHEM, V275, P32363, DOI 10.1074/jbc.M003075200; KINSELLA BT, 1991, J BIOL CHEM, V266, P9786; Kiyokawa E, 1998, GENE DEV, V12, P3331, DOI 10.1101/gad.12.21.3331; Kiyono M, 2000, J BIOL CHEM, V275, P5441, DOI 10.1074/jbc.275.8.5441; KOCH WJ, 1994, J BIOL CHEM, V269, P6193; Kou RQ, 2005, BIOCHEMISTRY-US, V44, P15064, DOI 10.1021/bi0509898; Lee H, 2000, AM J PHYSIOL-CELL PH, V278, pC612, DOI 10.1152/ajpcell.2000.278.3.C612; Lee MJ, 1996, J BIOL CHEM, V271, P11272, DOI 10.1074/jbc.271.19.11272; Lee MJ, 1999, CELL, V99, P301, DOI 10.1016/S0092-8674(00)81661-X; Lee MJ, 2001, MOL CELL, V8, P693, DOI 10.1016/S1097-2765(01)00324-0; Liu YJ, 2000, J CLIN INVEST, V106, P951, DOI 10.1172/JCI10905; Mehta D, 2005, J BIOL CHEM, V280, P17320, DOI 10.1074/jbc.M411674200; MICHIELS F, 1995, NATURE, V375, P338, DOI 10.1038/375338a0; RIDLEY AJ, 1992, CELL, V70, P401, DOI 10.1016/0092-8674(92)90164-8; Rossman KL, 2005, NAT REV MOL CELL BIO, V6, P167, DOI 10.1038/nrm1587; Sanchez T, 2004, J CELL BIOCHEM, V92, P913, DOI 10.1002/jcb.20127; Singleton PA, 2005, FASEB J, V19, P1646, DOI 10.1096/fj.05-3928com; Tanimoto T, 2002, J BIOL CHEM, V277, P42997, DOI 10.1074/jbc.M204764200; Tolias KF, 2005, NEURON, V45, P525, DOI 10.1016/j.neuron.2005.01.024; TOLIAS KF, 1995, J BIOL CHEM, V270, P17656, DOI 10.1074/jbc.270.30.17656; Turner M, 2002, NAT REV IMMUNOL, V2, P476, DOI 10.1038/nri840; van Leeuwen FN, 2003, J BIOL CHEM, V278, P400, DOI 10.1074/jbc.M210151200; vanLeeuwen FN, 1997, J CELL BIOL, V139, P797, DOI 10.1083/jcb.139.3.797	38	80	80	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 10	2006	281	6					3210	3216		10.1074/jbc.M510434200	http://dx.doi.org/10.1074/jbc.M510434200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	009QV	16339142	hybrid			2022-12-25	WOS:000235128200025
J	Hoe, HS; Pocivavsek, A; Chakraborty, G; Fu, ZY; Vicini, S; Ehlers, MD; Rebeck, GW				Hoe, HS; Pocivavsek, A; Chakraborty, G; Fu, ZY; Vicini, S; Ehlers, MD; Rebeck, GW			Apolipoprotein E receptor 2 interactions with the N-methyl-D-aspartate receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN; PSD-95; MICE; NEURONS; REELIN; FAMILY	In our previous studies we showed that apoE treatment of neurons activated ERK 1/2 signaling, and activation was blocked by treatment with inhibitors of the low density lipoprotein receptor family, the N-methyl-D-aspartate (NMDA) receptor antagonist MK 801, and calcium channel blockers. We hypothesized an interaction between the low density lipoprotein receptor family members and the NMDA receptor. In the present study, we confirmed through co-immunoprecipitation experiments an interaction between the apoE receptor, ApoEr2, and NMDAR1 through their extracellular domains. We also found that the PDZ1 domain of PSD95, a postsynaptic scaffolding protein, interacted with the C terminus of ApoEr2 via an alternatively spliced, intracellular exon. This interaction between ApoEr2 and PSD95 in neurons was modulated by NMDA receptor activation and an ApoEr2 ligand. We also found that the PDZ2 domain of PSD95 interacted with the NR2A and NR2B subunits of NMDA receptors. Full-length PSD95 increased cell surface levels of ApoEr2 and its cleavage, resulting in increases in secreted ApoEr2 and C-terminal fragments of ApoEr2. These studies suggest that ApoEr2 can form a multiprotein complex with NMDA receptor subunits and PSD95.	Georgetown Univ, Med Ctr, Dept Neurosci, Washington, DC 20057 USA; Georgetown Univ, Med Ctr, Dept Physiol & Biophys, Washington, DC 20057 USA; Duke Univ, Med Ctr, Dept Neurobiol, Durham, NC 27710 USA	Georgetown University; Georgetown University; Duke University	Rebeck, GW (corresponding author), Georgetown Univ, Med Ctr, Dept Neurosci, Washington, DC 20057 USA.	gwr2@georgetown.edu	Pocivavsek, Ana/AAW-8923-2020; Rebeck, George William/J-2192-2012	Rebeck, George William/0000-0001-6276-248X; Vicini, Stefano/0000-0001-8671-5194; Pocivavsek, Ana/0000-0002-3817-3201				Bacskai BJ, 2000, P NATL ACAD SCI USA, V97, P11551, DOI 10.1073/pnas.200238297; Beffert U, 2005, NEURON, V47, P567, DOI 10.1016/j.neuron.2005.07.007; Beffert U, 2004, J LIPID RES, V45, P403, DOI 10.1194/jlr.R300017-JLR200; Brandes C, 2001, J BIOL CHEM, V276, P22160, DOI 10.1074/jbc.M102662200; Dulabon L, 2000, NEURON, V27, P33, DOI 10.1016/S0896-6273(00)00007-6; El-Hussein AE, 2000, SCIENCE, V290, P1364; Gotthardt M, 2000, J BIOL CHEM, V275, P25616, DOI 10.1074/jbc.M000955200; Grootendorst J, 2005, BEHAV BRAIN RES, V159, P1, DOI 10.1016/j.bbr.2004.09.019; Hoe HS, 2005, MOL CELL BIOL, V25, P9259, DOI 10.1128/MCB.25.21.9259-9268.2005; Hoe HS, 2005, MOL BRAIN RES, V137, P31, DOI 10.1016/j.molbrainres.2005.02.013; Hoe HS, 2005, J NEUROCHEM, V93, P145, DOI 10.1111/j.1471-4159.2004.03007.x; Li YH, 2001, MOL NEUROBIOL, V23, P53; May P, 2004, MOL CELL BIOL, V24, P8872, DOI 10.1128/MCB.24.20.8872-8883.2004; McGee AW, 2001, MOL CELL, V8, P1291, DOI 10.1016/S1097-2765(01)00411-7; Migaud M, 1998, NATURE, V396, P433, DOI 10.1038/24790; Niethammer M, 1996, J NEUROSCI, V16, P2157; Ohkubo N, 2001, J BIOL CHEM, V276, P3046, DOI 10.1074/jbc.M005070200; Qiu ZH, 2002, J BIOL CHEM, V277, P14458, DOI 10.1074/jbc.M112066200; QUI Z, 2004, J BIOL CHEM, V279, P34948; QUI Z, 2003, NEUROSCIENCE, V122, P291; Sala C, 2001, NEURON, V31, P115, DOI 10.1016/S0896-6273(01)00339-7; Tavares GA, 2001, MOL CELL, V8, P1313, DOI 10.1016/S1097-2765(01)00416-6; Trommer BL, 2004, NEUROREPORT, V15, P2655, DOI 10.1097/00001756-200412030-00020; Watson PG, 1998, RAT BRAIN STEREOTAXI; Weeber EJ, 2002, J BIOL CHEM, V277, P39944, DOI 10.1074/jbc.M205147200; Wenthold RJ, 2003, ANNU REV PHARMACOL, V43, P335, DOI 10.1146/annurev.pharmtox.43.100901.135803	26	69	75	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 10	2006	281	6					3425	3431		10.1074/jbc.M509380200	http://dx.doi.org/10.1074/jbc.M509380200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	009QV	16332682	hybrid			2022-12-25	WOS:000235128200051
J	Khalil, IA; Kogure, K; Futaki, S; Harashima, H				Khalil, IA; Kogure, K; Futaki, S; Harashima, H			High density of octaarginine stimulates macropinocytosis leading to efficient intracellular trafficking for gene expression	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-PENETRATING PEPTIDES; ARGININE-RICH PEPTIDES; TAT-FUSION PROTEINS; TRANSDUCTION DOMAINS; MODIFIED LIPOSOMES; MAMMALIAN-CELLS; MEDIATED UPTAKE; DRUG-DELIVERY; IN-VIVO; ENDOCYTOSIS	The mechanism of the arginine-rich peptide-mediated cellular uptake is currently a controversial issue. Several factors, including the type of peptide, the nature of the cargo, and the linker between them, appear to affect uptake. One of the less studied factors, which may affect the uptake mechanism, is the effect of peptide density on the surface of the cargo. Here, we examined the mechanism of cellular uptake and intracellular trafficking of liposomes modified with different densities of the octaarginine (R8) peptide. Liposomes modified with a low R8 density were taken up mainly through clathrin- mediated endocytosis, leading to extensive lysosomal degradation, whereas those modified with a high R8 density were taken up mainly through macropinocytosis and were less subject to lysosomal degradation. Furthermore, the high density R8-liposomes were able to stimulate the macropinocytosis- mediated uptake of other particles. When plasmid DNA was condensed and encapsulated in R8-liposomes, the levels of gene expression were three orders of magnitude higher for the high density liposomes. The enhanced gene expression by the high density R8- liposomes was highly impaired by blocking uptake through macropinocytosis. The different extents of gene expression from different densities of the R8 peptide on the liposomes could be explained principally by the existence of an intracellular trafficking route, but not by the uptake amount, of internalized liposomes. These results show that the density of the R8 peptide on liposomes determines the uptake mechanism and that this is directly linked to intracellular trafficking, resulting in different levels of gene expression.	Hokkaido Univ, Grad Sch Pharmaceut Sci, Kita Ku, Sapporo, Hokkaido 0600812, Japan; Japan Sci & Technol Agcy, Core Res Evolut Sci & Technol, Shibuya Ku, Tokyo 1500002, Japan; Japan Sci & Technol Agcy, Precursory Res Embryon Sci & Technol, Shibuya Ku, Tokyo 1500002, Japan; Kyoto Univ, Inst Chem Res, Uji, Kyoto 6110011, Japan	Hokkaido University; Japan Science & Technology Agency (JST); Japan Science & Technology Agency (JST); Kyoto University	Harashima, H (corresponding author), Hokkaido Univ, Grad Sch Pharmaceut Sci, Kita Ku, Kita 12,Nishi 6, Sapporo, Hokkaido 0600812, Japan.	harasima@pharm.hokudai.ac.jp	Harashima, Hideyoshi/D-8390-2012; khalil, ikramy A./T-7523-2019	khalil, ikramy A./0000-0001-9417-7437; Futaki, Shiroh/0000-0002-0124-4002				Akita H, 2004, MOL THER, V9, P443, DOI 10.1016/j.ymthe.2004.01.005; Almofti MR, 2003, ARCH BIOCHEM BIOPHYS, V410, P246, DOI 10.1016/S0003-9861(02)00725-7; Brooks H, 2005, ADV DRUG DELIVER REV, V57, P559, DOI 10.1016/j.addr.2004.12.001; Conner SD, 2003, NATURE, V422, P37, DOI 10.1038/nature01451; Console S, 2003, J BIOL CHEM, V278, P35109, DOI 10.1074/jbc.M301726200; Derossi D, 1996, J BIOL CHEM, V271, P18188, DOI 10.1074/jbc.271.30.18188; Drin G, 2003, J BIOL CHEM, V278, P31192, DOI 10.1074/jbc.M303938200; Eguchi A, 2001, J BIOL CHEM, V276, P26204, DOI 10.1074/jbc.M010625200; FARHOOD H, 1995, BBA-BIOMEMBRANES, V1235, P289, DOI 10.1016/0005-2736(95)80016-9; Ferrari A, 2003, MOL THER, V8, P284, DOI 10.1016/S1525-0016(03)00122-9; Fittipaldi A, 2003, J BIOL CHEM, V278, P34141, DOI 10.1074/jbc.M303045200; Fretz MM, 2004, BBA-BIOMEMBRANES, V1665, P48, DOI 10.1016/j.bbamem.2004.06.022; Futaki S, 2001, BIOCONJUGATE CHEM, V12, P1005, DOI 10.1021/bc015508l; Futaki S, 2001, J BIOL CHEM, V276, P5836, DOI 10.1074/jbc.M007540200; Futaki S, 2002, INT J PHARM, V245, P1, DOI 10.1016/S0378-5173(02)00337-X; Hafez IM, 2000, BBA-BIOMEMBRANES, V1463, P107, DOI 10.1016/S0005-2736(99)00186-8; Kaplan IM, 2005, J CONTROL RELEASE, V102, P247, DOI 10.1016/j.jconrel.2004.10.018; Khalil IA, 2004, GENE THER, V11, P636, DOI 10.1038/sj.gt.3302128; Kogure K, 2004, J CONTROL RELEASE, V98, P317, DOI 10.1016/j.jconrel.2004.04.024; Kopatz I, 2004, J GENE MED, V6, P769, DOI 10.1002/jgm.558; LAMAZE C, 1995, CURR OPIN CELL BIOL, V7, P573, DOI 10.1016/0955-0674(95)80015-8; Lindgren M, 2000, TRENDS PHARMACOL SCI, V21, P99, DOI 10.1016/S0165-6147(00)01447-4; Lundberg M, 2003, MOL THER, V8, P143, DOI 10.1016/S1525-0016(03)00135-7; Marty C, 2004, CELL MOL LIFE SCI, V61, P1785, DOI 10.1007/s00018-004-4166-0; Meier O, 2002, J CELL BIOL, V158, P1119, DOI 10.1083/jcb.200112067; Nakase I, 2004, MOL THER, V10, P1011, DOI 10.1016/j.ymthe.2004.08.010; Parton RG, 2003, NAT REV MOL CELL BIO, V4, P162, DOI 10.1038/nrm1017; Richard JP, 2005, J BIOL CHEM, V280, P15300, DOI 10.1074/jbc.M401604200; Richard JP, 2003, J BIOL CHEM, V278, P585, DOI 10.1074/jbc.M209548200; Schwarze SR, 2000, TRENDS CELL BIOL, V10, P290, DOI 10.1016/S0962-8924(00)01771-2; Schwarze SR, 1999, SCIENCE, V285, P1569, DOI 10.1126/science.285.5433.1569; Singh M, 1999, CURR PHARM DESIGN, V5, P443; Snyder EL, 2004, PHARM RES-DORDR, V21, P389, DOI 10.1023/B:PHAM.0000019289.61978.f5; Suzuki T, 2002, J BIOL CHEM, V277, P2437, DOI 10.1074/jbc.M110017200; SWANSON JA, 1995, TRENDS CELL BIOL, V5, P424, DOI 10.1016/S0962-8924(00)89101-1; Torchilin VP, 2003, P NATL ACAD SCI USA, V100, P1972, DOI 10.1073/pnas.0435906100; Torchilin VP, 2001, P NATL ACAD SCI USA, V98, P8786, DOI 10.1073/pnas.151247498; Trehin R, 2004, EUR J PHARM BIOPHARM, V58, P209, DOI 10.1016/j.ejpb.2004.02.018; Vives E, 1997, J BIOL CHEM, V272, P16010, DOI 10.1074/jbc.272.25.16010; Wadia JS, 2004, NAT MED, V10, P310, DOI 10.1038/nm996; Yoneda A, 2003, MATRIX BIOL, V22, P25, DOI 10.1016/S0945-053X(03)00010-6; Zuhorn IS, 2002, J BIOL CHEM, V277, P18021, DOI 10.1074/jbc.M111257200	42	325	334	3	35	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 10	2006	281	6					3544	3551		10.1074/jbc.M503202200	http://dx.doi.org/10.1074/jbc.M503202200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	009QV	16326716	hybrid			2022-12-25	WOS:000235128200065
J	Stanitsa, ES; Arps, L; Traktman, P				Stanitsa, ES; Arps, L; Traktman, P			Vaccinia virus uracil DNA glycosylase interacts with the A20 protein to form a heterodimeric processivity factor for the viral DNA polymerase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TEMPERATURE-SENSITIVE MUTANTS; TO-ALANINE MUTAGENESIS; BASE EXCISION-REPAIR; CRYSTAL-STRUCTURE; ESCHERICHIA-COLI; GENETIC-ANALYSIS; BINDING PROTEIN; III HOLOENZYME; REPLICATION; UL42	The vaccinia virus E9 protein, the catalytic subunit of the DNA polymerase holoenzyme, is inherently distributive under physiological conditions, although infected cells contain a highly processive form of the enzyme. The viral A20 protein was previously characterized as a stoichiometric component of the processivity factor, and an interaction between A20 and E9 was documented in vivo. A20 has been shown to interact with D4, the virally encoded uracil DNA glycosylase (UDG), by yeast-two hybrid and in vitro analysis. Here we confirm that UDG and A20 interact in vivo and show that temperature-sensitive viruses with lesions in the D4R gene show a profound defect in DNA synthesis at the non-permissive temperature. Moreover, cytoplasmic extracts prepared from these infections lack processive polymerase activity in vitro, implicating D4 in the assembly or activity of the processive polymerase. Upon overexpression of 3 x FLAG-UDG, A20, and E9 in various combinations, we purified dimeric and trimeric UDG-A20 and UDG-A20-polymerase complexes, respectively. These complexes are stable in 750 mM NaCl and can be further purified by Mono Q chromatography. Notably, the trimeric complex displays robust processive polymerase activity, and the dimeric complex can confer processivity on purified E9. Consistent with previous reports that the catalytic activity of UDG is dispensable for virus replication in tissue culture, we find that the role of UDG role in the polymerase complex is not diminished by mutations targeting residues involved in uracil recognition or excision. Our cumulative data support the conclusion that A20 and UDG form a heterodimeric processivity factor that associates with E9 to comprise the processive polymerase holoenzyme.	Med Coll Wisconsin, Dept Microbiol & Mol Genet, Milwaukee, WI 53226 USA	Medical College of Wisconsin	Traktman, P (corresponding author), Med Coll Wisconsin, Dept Microbiol & Mol Genet, 8701 Watertown Plank Rd,BSB-273, Milwaukee, WI 53226 USA.	ptrakt@mcw.edu		Traktman, Paula/0000-0002-6517-0225	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI021758] Funding Source: NIH RePORTER; NIAID NIH HHS [R01-AI-21758] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Akbari M, 2004, NUCLEIC ACIDS RES, V32, P5486, DOI 10.1093/nar/gkh872; Appleton BA, 2004, MOL CELL, V15, P233, DOI 10.1016/j.molcel.2004.06.018; Beaud G, 1995, BIOCHIMIE, V77, P774, DOI 10.1016/0300-9084(96)88195-8; BRUCKI, 2001, GENOME BIOL; Chaudhuri M, 2002, J VIROL, V76, P10270, DOI 10.1128/JVI.76.20.10270-10281.2002; De Silva FS, 2003, J VIROL, V77, P159, DOI 10.1128/JVI.77.1.159-166.2003; DeMasi J, 2000, J VIROL, V74, P2393, DOI 10.1128/JVI.74.5.2393-2405.2000; EVANS E, 1987, J VIROL, V61, P3152, DOI 10.1128/JVI.61.10.3152-3162.1987; FRANKE CA, 1985, MOL CELL BIOL, V5, P1918, DOI 10.1128/MCB.5.8.1918; Garcia AD, 2000, P NATL ACAD SCI USA, V97, P8926, DOI 10.1073/pnas.150238697; Grubisha O, 2003, J VIROL, V77, P10929, DOI 10.1128/JVI.77.20.10929-10942.2003; Ishii K, 2002, VIROLOGY, V303, P232, DOI 10.1006/viro.2002.1721; Ishii K, 2001, J VIROL, V75, P1656, DOI 10.1128/JVI.75.4.1656-1663.2001; Johnson DE, 2003, J BIOL CHEM, V278, P23762, DOI 10.1074/jbc.M301366200; Kelman Z, 1998, STRUCTURE, V6, P121, DOI 10.1016/S0969-2126(98)00014-8; Klemperer N, 2001, J VIROL, V75, P12298, DOI 10.1128/JVI.75.24.12298-12307.2001; KONG XP, 1992, CELL, V69, P425, DOI 10.1016/0092-8674(92)90445-I; KRISHNA TSR, 1994, CELL, V79, P1233, DOI 10.1016/0092-8674(94)90014-0; Lackner CA, 2003, VIROLOGY, V305, P240, DOI 10.1006/viro.2002.1745; McConnell M, 1996, BIOCHEMISTRY-US, V35, P8268, DOI 10.1021/bi9530649; McCraith S, 2000, P NATL ACAD SCI USA, V97, P4879, DOI 10.1073/pnas.080078197; McDonald WF, 1997, VIROLOGY, V234, P168, DOI 10.1006/viro.1997.8639; MCDONALD WF, 1994, PROTEIN EXPRES PURIF, V5, P409, DOI 10.1006/prep.1994.1059; MCDONALD WF, 1994, J BIOL CHEM, V269, P31190; MCFADDEN G, 1980, VIROLOGY, V103, P68, DOI 10.1016/0042-6822(80)90126-9; McIntosh AAG, 1996, J VIROL, V70, P272, DOI 10.1128/JVI.70.1.272-281.1996; MILLNS AK, 1994, VIROLOGY, V198, P504, DOI 10.1006/viro.1994.1061; Moarefi I, 2000, J MOL BIOL, V296, P1215, DOI 10.1006/jmbi.1999.3511; Otterlei M, 1999, EMBO J, V18, P3834, DOI 10.1093/emboj/18.13.3834; Parikh SS, 1998, EMBO J, V17, P5214, DOI 10.1093/emboj/17.17.5214; Parikh SS, 2000, MUTAT RES-DNA REPAIR, V460, P183, DOI 10.1016/S0921-8777(00)00026-4; Prichard MN, 2005, VIROL J, V2, DOI 10.1186/1743-422X-2-55; Prichard MN, 1996, J VIROL, V70, P3018, DOI 10.1128/JVI.70.5.3018-3025.1996; Punjabi A, 2005, J VIROL, V79, P2171, DOI 10.1128/JVI.79.4.2171-2190.2005; Punjabi A, 2001, J VIROL, V75, P12308, DOI 10.1128/JVI.75.24.12308-12318.2001; Randell JC, 2001, MOL CELL, V8, P911, DOI 10.1016/S1097-2765(01)00355-0; Randell JCW, 2005, J VIROL, V79, P12025, DOI 10.1128/JVI.79.18.12025-12034.2005; STUART DT, 1993, J VIROL, V67, P2503, DOI 10.1128/JVI.67.5.2503-2512.1993; STUKENBERG PT, 1991, J BIOL CHEM, V266, P11328; Thornton KE, 2000, VIROLOGY, V275, P373, DOI 10.1006/viro.2000.0506; Trakselis MA, 2001, STRUCTURE, V9, P999, DOI 10.1016/S0969-2126(01)00676-1; TRAKTMAN P, 1996, POXVIRUS DNA REPLICA, P775; Traktman Paula, 2004, Methods Mol Biol, V269, P169; Trego KS, 2005, NUCLEIC ACIDS RES, V33, P536, DOI 10.1093/nar/gki196; UPTON C, 1993, P NATL ACAD SCI USA, V90, P4518, DOI 10.1073/pnas.90.10.4518; Weisshart K, 1999, J VIROL, V73, P55, DOI 10.1128/JVI.73.1.55-66.1999; Yao N, 1996, GENES CELLS, V1, P101, DOI 10.1046/j.1365-2443.1996.07007.x; Zuccola HJ, 2000, MOL CELL, V5, P267, DOI 10.1016/S1097-2765(00)80422-0	48	73	82	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 10	2006	281	6					3439	3451		10.1074/jbc.M511239200	http://dx.doi.org/10.1074/jbc.M511239200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	009QV	16326701	hybrid			2022-12-25	WOS:000235128200053
J	Bernier, M; Kwon, YK; Pandey, SK; Zhu, TN; Zhao, RJ; Maciuk, A; He, HJ; DeCabo, R; Kole, S				Bernier, M; Kwon, YK; Pandey, SK; Zhu, TN; Zhao, RJ; Maciuk, A; He, HJ; DeCabo, R; Kole, S			Binding of manumycin A inhibits I kappa B kinase beta activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MICE LACKING; ACTIVATION; IKK; COMPLEX; ALPHA; ANGIOGENESIS; SUBUNIT; TNF; INFLAMMATION; ASSOCIATION	I kappa B kinase (IKK) catalytic subunits play a key role in cytokine-mediated nuclear factor (NF)-kappa B signaling, and a loss of NF-kappa B function appears to inhibit inflammation and oncogenesis. Manumycin A is a potent and selective farnesyltransferase inhibitor with antitumor activity. We found that manumycin A caused a rapid and potent inhibition of IKK activity induced by tumor necrosis factor alpha in a number of cell types. Most unexpectedly, other classes of farnesyltransferase inhibitors had no inhibitory effect. To identify the molecular mechanisms of manumycin A action, cultured human HepG2 hepatoma cells were transiently transfected with various IKK alpha and IKK beta constructs, and a striking difference in manumycin A sensitivity was observed. Furthermore, cells expressing wild-type IKK beta and IKK beta mutated in the activation loop at Cys-179 exhibited covalent homotypic dimerization of IKK beta in response to manumycin A, whereas substitution of Cys-662 and -716 conferred protection against dimer formation. Direct inhibition of IKK activity and formation of stable IKK beta dimers were observed in the presence of manumycin A that could be blocked by dithiothreitol. IKK interaction with the adaptor protein IKK gamma/NEMO was disrupted in manumycin A-treated cells. Most importantly, administration of manumycin A to mice xenografted with murine B16F10 tumors caused potent IKK-suppressive effects. Thus, manumycin A with its epoxyquinoid moieties plays an important regulatory function in IKK signaling through pathways distinct from its role as a protein farnesylation inhibitor.	NIA, Diabet Sect, NIH, Baltimore, MD 21224 USA; NIA, Bioanalyt Chem & Drug Discovery Sect, Lab Clin Invest, Baltimore, MD 21224 USA; NIA, Bioanalyt Chem & Drug Discovery Sect, Lab Clin Invest, NIH, Baltimore, MD 21224 USA; NIA, Lab Expt Gerontol, NIH, Baltimore, MD 21224 USA; Johns Hopkins Univ, Sch Med, Dept Neurol, Baltimore, MD 21205 USA	National Institutes of Health (NIH) - USA; NIH National Institute on Aging (NIA); National Institutes of Health (NIH) - USA; NIH National Institute on Aging (NIA); National Institutes of Health (NIH) - USA; NIH National Institute on Aging (NIA); National Institutes of Health (NIH) - USA; NIH National Institute on Aging (NIA); Johns Hopkins University	Bernier, M (corresponding author), NIA, Diabet Sect, NIH, Box 23,5600 Nathan Shock Dr, Baltimore, MD 21224 USA.	Bernierm@grc.nia.nih.gov	de Cabo, Rafael Carlos/J-5230-2016; de Cabo, Rafael/E-7996-2010; Bernier, Michel/AAO-3983-2021; Bernier, Michel/Y-7139-2019; de Cabo, Rafael/J-5230-2016; Maciuk, Alexandre/J-2270-2018	de Cabo, Rafael Carlos/0000-0003-2830-5693; de Cabo, Rafael/0000-0003-2830-5693; Bernier, Michel/0000-0002-5948-368X; de Cabo, Rafael/0000-0002-3354-2442; Maciuk, Alexandre/0000-0003-1436-6436	NATIONAL INSTITUTE ON AGING [ZIAAG000368, Z01AG000368, ZIAAG000302, Z01AG000302, Z01AG000886] Funding Source: NIH RePORTER; Intramural NIH HHS Funding Source: Medline	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)		Auer J, 2002, CURR MED CHEM, V9, P1831, DOI 10.2174/0929867023369024; Baldwin AS, 1996, ANNU REV IMMUNOL, V14, P649, DOI 10.1146/annurev.immunol.14.1.649; Carcamo JM, 2004, MOL CELL BIOL, V24, P6645, DOI 10.1128/mcb.24.15.6645-6652.2004; Carter RS, 2003, J BIOL CHEM, V278, P48903, DOI 10.1074/jbc.M310686200; Chen GQ, 2002, MOL CELL, V9, P401, DOI 10.1016/S1097-2765(02)00450-1; de Cabo R, 2003, EXP GERONTOL, V38, P631, DOI 10.1016/S0531-5565(03)00055-X; Finder JD, 2001, AM J PHYSIOL-LUNG C, V281, pL816, DOI 10.1152/ajplung.2001.281.4.L816; Fritz G, 2001, J BIOL CHEM, V276, P3115, DOI 10.1074/jbc.M005058200; Fu DX, 2003, J BIOL CHEM, V278, P1487, DOI 10.1074/jbc.M210631200; Gnad R, 2001, EXP CELL RES, V264, P244, DOI 10.1006/excr.2001.5165; Goalstone ML, 2001, J BIOL CHEM, V276, P12805, DOI 10.1074/jbc.M009443200; HARA M, 1995, P NATL ACAD SCI USA, V92, P3333, DOI 10.1073/pnas.92.8.3333; Higuchi Y, 2003, J BIOL CHEM, V278, P20770, DOI 10.1074/jbc.M213203200; Hu YB, 2001, ORG LETT, V3, P1649, DOI 10.1021/ol0159367; Hu YL, 1999, SCIENCE, V284, P316, DOI 10.1126/science.284.5412.316; Ito T, 1996, JPN J CANCER RES, V87, P113, DOI 10.1111/j.1349-7006.1996.tb03146.x; Jeon KI, 2000, J IMMUNOL, V164, P5981, DOI 10.4049/jimmunol.164.11.5981; Johnson LN, 1996, CELL, V85, P149, DOI 10.1016/S0092-8674(00)81092-2; Kapahi P, 2000, J BIOL CHEM, V275, P36062, DOI 10.1074/jbc.M007204200; Klein S, 2002, MOL CELL BIOL, V22, P5912, DOI 10.1128/MCB.22.16.5912-5922.2002; Knaus UG, 2000, IMMUNOL RES, V21, P103, DOI 10.1385/IR:21:2-3:103; Kwok BHB, 2001, CHEM BIOL, V8, P759, DOI 10.1016/S1074-5521(01)00049-7; Kyriakis JM, 1996, BIOESSAYS, V18, P567, DOI 10.1002/bies.950180708; Lee FS, 1997, CELL, V88, P213, DOI 10.1016/S0092-8674(00)81842-5; Leonardi A, 2000, P NATL ACAD SCI USA, V97, P10494, DOI 10.1073/pnas.190245697; Li CM, 2002, ORG LETT, V4, P3267, DOI 10.1021/ol026513n; Li CM, 2001, J AM CHEM SOC, V123, P11308, DOI 10.1021/ja0169769; Li ZW, 1999, J EXP MED, V189, P1839, DOI 10.1084/jem.189.11.1839; Liang MC, 2003, MOL PHARMACOL, V64, P123, DOI 10.1124/mol.64.1.123; Lin X, 1998, MOL CELL BIOL, V18, P5899, DOI 10.1128/MCB.18.10.5899; Malinin NL, 1997, NATURE, V385, P540, DOI 10.1038/385540a0; Matsuzaki J, 2000, J NUTR, V130, P111; Mayo MW, 2001, METHOD ENZYMOL, V333, P73; Nakano H, 1998, P NATL ACAD SCI USA, V95, P3537, DOI 10.1073/pnas.95.7.3537; Pandey SK, 2002, ENDOCRINOLOGY, V143, P375, DOI 10.1210/en.143.2.375; Park KJ, 2003, J BIOL CHEM, V278, P35272, DOI 10.1074/jbc.M305095200; Poyet JL, 2000, J BIOL CHEM, V275, P37966, DOI 10.1074/jbc.M006643200; Prajapati S, 2002, J BIOL CHEM, V277, P24331, DOI 10.1074/jbc.M201393200; Prajapati S, 2004, J BIOL CHEM, V279, P1739, DOI 10.1074/jbc.M306273200; Reddy SAG, 2000, J IMMUNOL, V164, P1355, DOI 10.4049/jimmunol.164.3.1355; Rossi A, 2000, NATURE, V403, P103, DOI 10.1038/47520; Rothwarf DM, 1998, NATURE, V395, P297, DOI 10.1038/26261; Segain JP, 2003, GASTROENTEROLOGY, V124, P1180, DOI 10.1016/S0016-5085(03)00283-X; Takeda K, 1999, SCIENCE, V284, P313, DOI 10.1126/science.284.5412.313; Tang ED, 2003, J BIOL CHEM, V278, P38566, DOI 10.1074/jbc.M304374200; Tojima Y, 2000, NATURE, V404, P778, DOI 10.1038/35008109; Umezawa K, 2000, ANTI-CANCER DRUG DES, V15, P239; Werner N, 2002, BASIC RES CARDIOL, V97, P105, DOI 10.1007/s003950200000; Wipf P, 1998, BIOORG MED CHEM LETT, V8, P351, DOI 10.1016/S0960-894X(98)00026-2; Woronicz JD, 1997, SCIENCE, V278, P866, DOI 10.1126/science.278.5339.866; Wurzer G, 2001, J CELL BIOCHEM, P1; Xu GP, 2001, J CLIN ENDOCR METAB, V86, P1769, DOI 10.1210/jc.86.4.1769; Yamamoto Y, 1999, J BIOL CHEM, V274, P27307, DOI 10.1074/jbc.274.38.27307; Yamaoka S, 1998, CELL, V93, P1231, DOI 10.1016/S0092-8674(00)81466-X; Yin MJ, 1998, NATURE, V396, P77, DOI 10.1038/23948; Zandi E, 1999, MOL CELL BIOL, V19, P4547; Zhao DZ, 2003, AM J PHYSIOL-CELL PH, V284, pC1397, DOI 10.1152/ajpcell.00328.2002; Zhou JM, 2003, INT J MOL MED, V12, P955	58	41	42	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 3	2006	281	5					2551	2561		10.1074/jbc.M511878200	http://dx.doi.org/10.1074/jbc.M511878200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	006XT	16319058	hybrid			2022-12-25	WOS:000234931800018
J	Lee, JY; Ristow, M; Lin, XY; White, MF; Magnuson, MA; Hennighausen, L				Lee, JY; Ristow, M; Lin, XY; White, MF; Magnuson, MA; Hennighausen, L			RIP-Cre revisited, evidence for impairments of pancreatic beta-cell function	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INSULIN-RECEPTOR SUBSTRATE-2; TETRACYCLINE-RESPONSIVE PROMOTER; TISSUE-SPECIFIC KNOCKOUT; ALTERED GENE-EXPRESSION; GLUCOSE-HOMEOSTASIS; TEMPORAL CONTROL; TRANSGENIC MICE; SECRETION; RECOMBINASE; LEADS	The Cre/loxP recombinase system for performing conditional gene targeting experiments has been very useful in exploring genetic pathways that control both the development and function of pancreatic beta-cells. One particular line of transgenic mice (B6.Cg-Tg(Ins2-cre)25Mgn/J), commonly called RIP-Cre, in which expression of Cre recombinase is controlled by a short fragment of the rat insulin II gene promoter has been used in at least 21 studies on at least 17 genes. In most of these studies inactivation of the gene of interest was associated with either glucose intolerance or frank diabetes. Experimental evidence has been gradually emerging to suggest that RIP-Cre mice alone display glucose intolerance. In this study experiments from three laboratories demonstrate that RIP-Cre mice, in the absence of genes targeted by loxP sites, are glucose intolerant, possibly due to impaired insulin secretion. In addition, we review the use of RIP-Cre mice and discuss possible molecular underpinnings and ramifications of our findings.	NIDDK, Lab Genet & Physiol, NIH, Bethesda, MD 20892 USA; Univ Jena, Dept Human Nutr, D-07743 Jena, Germany; German Inst Human Potsdam Rehbruecke, Potsdam, Germany; Harvard Univ, Sch Med, Childrens Hosp, Howard Hughes Med Inst, Boston, MA 02115 USA; Vanderbilt Univ, Sch Med, Dept Mol Physiol & Biophys, Nashville, TN 37232 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK); Friedrich Schiller University of Jena; Harvard University; Boston Children's Hospital; Harvard Medical School; Howard Hughes Medical Institute; Vanderbilt University	Magnuson, MA (corresponding author), NIDDK, Lab Genet & Physiol, NIH, 8 Ctr Dr,Rm 101, Bethesda, MD 20892 USA.	mark.magnuson@vanderbilt.edu	Magnuson, Mark/AAY-7172-2021; Magnuson, Mark A/B-1335-2009; Ristow, Michael/O-9858-2014	Magnuson, Mark/0000-0002-8824-6499; Magnuson, Mark A/0000-0002-8824-6499; Ristow, Michael/0000-0003-2109-2453; Hennighausen, Lothar/0000-0001-8319-9841	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [ZIADK061000, Z01DK061000] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Bardoux P, 2005, DIABETES, V54, P1357, DOI 10.2337/diabetes.54.5.1357; Biondi CA, 2004, MOL CELL BIOL, V24, P3125, DOI 10.1128/MCB.24.8.3125-3131.2004; Choudhury AI, 2005, J CLIN INVEST, V115, P940; Crabtree JS, 2003, MOL CELL BIOL, V23, P6075, DOI 10.1128/MCB.23.17.6075-6085.2003; Cui YX, 2004, MOL CELL BIOL, V24, P258, DOI 10.1128/MCB.24.1.258-269.2004; Dai CS, 2005, AM J PATHOL, V167, P429, DOI 10.1016/S0002-9440(10)62987-2; de Alboran IM, 2001, IMMUNITY, V14, P45, DOI 10.1016/S1074-7613(01)00088-7; FURTH PA, 1994, P NATL ACAD SCI USA, V91, P9302, DOI 10.1073/pnas.91.20.9302; Gannon M, 2000, GENESIS, V26, P139, DOI 10.1002/(SICI)1526-968X(200002)26:2<139::AID-GENE12>3.0.CO;2-7; Gesina E, 2004, DIABETES, V53, P2322, DOI 10.2337/diabetes.53.9.2322; Glaser S, 2005, NAT GENET, V37, P1187, DOI 10.1038/ng1668; Gorogawa S, 2004, BIOCHEM BIOPH RES CO, V319, P1159, DOI 10.1016/j.bbrc.2004.05.095; Gunton JE, 2005, CELL, V122, P337, DOI 10.1016/j.cell.2005.05.027; Gupta RK, 2005, J CLIN INVEST, V115, P1006, DOI 10.1172/JCI22365; Hashimoto N, 2005, J CLIN INVEST, V115, P138, DOI 10.1172/JCI200522232; Kubota N, 2004, J CLIN INVEST, V114, P917, DOI 10.1172/JCI200421484; Kulkarni RN, 2002, NAT GENET, V31, P111, DOI 10.1038/ng872; Kulkarni RN, 1999, CELL, V96, P329, DOI 10.1016/S0092-8674(00)80546-2; Lammert E, 2003, CURR BIOL, V13, P1070, DOI 10.1016/S0960-9822(03)00378-6; Lee JY, 2005, BIOCHEM BIOPH RES CO, V334, P764, DOI 10.1016/j.bbrc.2005.06.162; Lin XY, 2004, J CLIN INVEST, V114, P908, DOI [10.1172/JCI22217, 10.1172/JCI200422217]; Loonstra A, 2001, P NATL ACAD SCI USA, V98, P9209, DOI 10.1073/pnas.161269798; Postic C, 1999, J BIOL CHEM, V274, P305, DOI 10.1074/jbc.274.1.305; Ristow M, 2003, J CLIN INVEST, V112, P527, DOI 10.1172/JCI200318107; Rosen ED, 2003, MOL CELL BIOL, V23, P7222, DOI 10.1128/MCB.23.20.7222-7229.2003; Schmidt EE, 2000, P NATL ACAD SCI USA, V97, P13702, DOI 10.1073/pnas.240471297; Schulla V, 2003, EMBO J, V22, P3844, DOI 10.1093/emboj/cdg389; Silva JP, 2000, NAT GENET, V26, P336, DOI 10.1038/81649; Silver DP, 2001, MOL CELL, V8, P233, DOI 10.1016/S1097-2765(01)00295-7; StOnge L, 1996, NUCLEIC ACIDS RES, V24, P3875, DOI 10.1093/nar/24.19.3875; Sund NJ, 2001, GENE DEV, V15, P1706, DOI 10.1101/gad.901601; Thyagarajan B, 2000, GENE, V244, P47, DOI 10.1016/S0378-1119(00)00008-1; Wang L, 2004, ENDOCRINOLOGY, V145, P3941, DOI 10.1210/en.2004-0281; Wang XP, 2005, FEBS LETT, V579, P3107, DOI 10.1016/j.febslet.2005.04.069	34	187	192	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 3	2006	281	5					2649	2653		10.1074/jbc.M512373200	http://dx.doi.org/10.1074/jbc.M512373200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	006XT	16326700	hybrid			2022-12-25	WOS:000234931800029
J	NcNally, LM; Yee, L; McNally, MT				NcNally, LM; Yee, L; McNally, MT			Heterogeneous nuclear ribonucleoprotein h is required for optimal U11 small nuclear ribonucleoprotein binding to a retroviral RNA-processing control element - Implications for U12-dependent RNA splicing	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PRE-MESSENGER-RNA; VIRUS NEGATIVE REGULATOR; HNRNP-H; IN-VIVO; INHIBITOR ELEMENT; DISTINCT PROTEINS; U6ATAC SNRNA; SR PROTEINS; MINOR CLASS; SITE	An RNA-processing element from Rous sarcoma virus, the negative regulator of splicing (NRS), represses splicing to generate unspliced RNA that serves as mRNA and as genomic RNA for progeny virions and also promotes polyadenylation of the unspliced RNA. Integral to NRS function is the binding of U1 small nuclear ribonucleoprotein (snRNP), but its binding is controlled by U11 snRNP that binds to an overlapping site. U11 snRNP, the U1 counterpart for splicing of U12-dependent introns, binds the NRS remarkably well and requires G-rich elements just downstream of the consensus U11 binding site. We present evidence that heterogeneous nuclear ribonucleoprotein (hnRNP) H binds to the NRS G-rich elements and that hnRNP H is required for optimal U11 binding in vitro. It is further shown that hnRNP H (but not hnRNP F) can promote U11 binding and splicing from the NRS in vivo when tethered to the RNA as an MS2 fusion protein. Interestingly, 17% of the naturally occurring U12-dependent introns have at least two potential hnRNP H binding sites positioned similarly to the NRS. For two such introns from the SCN4A and P120 genes, we show that hnRNP H binds to each in a G-tract-dependent manner, that G-tract mutations strongly reduce splicing of minigene RNA, and that tethered hnRNP H restores splicing to mutant RNA. In support of a role for hnRNP H in both splicing pathways, hnRNP H antibodies co-precipitate U1 and U11 small nuclear ribonucleoproteins. These results indicate that hnRNP H is an auxiliary factor for U11 binding to the NRS and that, more generally, hnRNP H is a splicing factor for a subset of U12-dependent introns that harbor G- rich elements.	Med Coll Wisconsin, Dept Microbiol & Mol Genet, Milwaukee, WI 53226 USA	Medical College of Wisconsin	McNally, MT (corresponding author), Med Coll Wisconsin, Dept Microbiol & Mol Genet, 8701 Watertown Plank Rd, Milwaukee, WI 53226 USA.	mtm@mcw.edu			NATIONAL CANCER INSTITUTE [R01CA078709] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA078709-07, R01 CA78709, R01 CA078709] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ARRIGO S, 1988, MOL CELL BIOL, V8, P4858, DOI 10.1128/MCB.8.11.4858; Black DL, 2003, ANNU REV BIOCHEM, V72, P291, DOI 10.1146/annurev.biochem.72.121801.161720; Buratti E, 2004, NUCLEIC ACIDS RES, V32, P4224, DOI 10.1093/nar/gkh752; Burge C. B., 1999, RNA WORLD; Caputi M, 1999, EMBO J, V18, P4060, DOI 10.1093/emboj/18.14.4060; Caputi M, 2002, EMBO J, V21, P845, DOI 10.1093/emboj/21.4.845; Caputi M, 2001, J BIOL CHEM, V276, P43850, DOI 10.1074/jbc.M102861200; Chen CD, 1999, GENE DEV, V13, P593, DOI 10.1101/gad.13.5.593; Chou MY, 1999, MOL CELL BIOL, V19, P69; Cook CR, 1998, VIROLOGY, V242, P211, DOI 10.1006/viro.1997.8983; Cook CR, 1999, J VIROL, V73, P2394, DOI 10.1128/JVI.73.3.2394-2400.1999; Dietrich RC, 2001, RNA, V7, P1378; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; Fogel BL, 2000, J BIOL CHEM, V275, P32371, DOI 10.1074/jbc.M005000200; Fogel BL, 2002, NUCLEIC ACIDS RES, V30, P810, DOI 10.1093/nar/30.3.810; Frilander MJ, 2001, MOL CELL, V7, P217, DOI 10.1016/S1097-2765(01)00169-1; Garneau D, 2005, J BIOL CHEM, V280, P22641, DOI 10.1074/jbc.M501070200; Giles KE, 2005, MOL CELL BIOL, V25, P4397, DOI 10.1128/MCB.25.11.4397-4405.2005; GONTAREK RR, 1993, GENE DEV, V7, P1926, DOI 10.1101/gad.7.10.1926; HALL SL, 1994, J MOL BIOL, V239, P357, DOI 10.1006/jmbi.1994.1377; Hall SL, 1996, SCIENCE, V271, P1716, DOI 10.1126/science.271.5256.1716; Han K, 2005, PLOS BIOL, V3, P843, DOI 10.1371/journal.pbio.0030158; Hastings ML, 2001, CURR OPIN CELL BIOL, V13, P302, DOI 10.1016/S0955-0674(00)00212-X; Hastings ML, 2001, RNA, V7, P859, DOI 10.1017/S1355838201002084; Hastings ML, 2001, RNA, V7, P471, DOI 10.1017/S1355838201002552; Hibbert CS, 1999, RNA, V5, P333, DOI 10.1017/S1355838299981347; Honore B, 2004, EXP CELL RES, V294, P199, DOI 10.1016/j.yexcr.2003.11.011; HONORE B, 1995, J BIOL CHEM, V270, P28780; Incorvaia R, 1998, RNA, V4, P709, DOI 10.1017/S1355838298980207; Jacquenet S, 2001, J BIOL CHEM, V276, P40464, DOI 10.1074/jbc.M104070200; Kolossova I, 1997, RNA, V3, P227; Krecic AM, 1999, CURR OPIN CELL BIOL, V11, P363, DOI 10.1016/S0955-0674(99)80051-9; Levine A, 2001, NUCLEIC ACIDS RES, V29, P4006, DOI 10.1093/nar/29.19.4006; Luo HBR, 1999, RNA, V5, P893, DOI 10.1017/S1355838299990520; McCullough AJ, 1997, MOL CELL BIOL, V17, P4562, DOI 10.1128/MCB.17.8.4562; McNally LM, 1996, J VIROL, V70, P1163, DOI 10.1128/JVI.70.2.1163-1172.1996; McNally LM, 2004, J BIOL CHEM, V279, P38201, DOI 10.1074/jbc.M407073200; McNally LM, 1999, J VIROL, V73, P2385, DOI 10.1128/JVI.73.3.2385-2393.1999; McNally LM, 1998, MOL CELL BIOL, V18, P3103, DOI 10.1128/MCB.18.6.3103; MERIC C, 1986, J VIROL, V60, P450; MIN HS, 1995, GENE DEV, V9, P2659, DOI 10.1101/gad.9.21.2659; MONTZKA KA, 1988, P NATL ACAD SCI USA, V85, P8885, DOI 10.1073/pnas.85.23.8885; Nilsen TW, 2002, MOL CELL, V9, P8, DOI 10.1016/S1097-2765(02)00430-6; O'Sullivan CT, 2002, VIROLOGY, V302, P405, DOI 10.1006/viro.2002.1616; Patel AA, 2003, NAT REV MOL CELL BIO, V4, P960, DOI 10.1038/nrm1259; Romano M, 2002, J BIOL CHEM, V277, P43821, DOI 10.1074/jbc.M208107200; Scamborova P, 2004, MOL CELL BIOL, V24, P1855, DOI 10.1128/MCB.24.5.1855-1869.2004; Schneider C, 2002, MOL CELL BIOL, V22, P3219, DOI 10.1128/MCB.22.10.3219-3229.2002; SCHWARTZ DE, 1983, CELL, V32, P853, DOI 10.1016/0092-8674(83)90071-5; Sharp PA, 1997, CELL, V91, P875, DOI 10.1016/S0092-8674(00)80479-1; Shukla GC, 1999, RNA, V5, P525, DOI 10.1017/S1355838299982213; Shukla GC, 2001, RNA, V7, P94, DOI 10.1017/S1355838201000218; Stevens SW, 2002, MOL CELL, V9, P31, DOI 10.1016/S1097-2765(02)00436-7; STOLTZFUS CM, 1989, J VIROL, V63, P1669, DOI 10.1128/JVI.63.4.1669-1676.1989; Tarn WY, 1996, SCIENCE, V273, P1824, DOI 10.1126/science.273.5283.1824; Tarn WY, 1996, CELL, V84, P801, DOI 10.1016/S0092-8674(00)81057-0; WASSARMAN KM, 1992, MOL CELL BIOL, V12, P1276, DOI 10.1128/MCB.12.3.1276; Will CL, 2004, RNA, V10, P929, DOI 10.1261/rna.7320604; Will CL, 1999, SCIENCE, V284, P2003, DOI 10.1126/science.284.5422.2003; XU YZ, 2004, EMBO J; Yu YT, 1997, P NATL ACAD SCI USA, V94, P6030, DOI 10.1073/pnas.94.12.6030	61	21	21	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 3	2006	281	5					2478	2488		10.1074/jbc.M511215200	http://dx.doi.org/10.1074/jbc.M511215200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	006XT	16308319	hybrid			2022-12-25	WOS:000234931800010
J	Aricha, R; Feferman, T; Souroujon, MC; Fuchs, S				Aricha, Revital; Feferman, Tali; Souroujon, Miriam C.; Fuchs, Sara			Overexpression of phosphodiesterases in experimental autoimmune myasthenia gravis: suppression of disease by a phosphodiesterase inhibitor	FASEB JOURNAL			English	Article									[Aricha, Revital; Feferman, Tali; Souroujon, Miriam C.; Fuchs, Sara] Weizmann Inst Sci, Dept Immunol, IL-76100 Rehovot, Israel; [Souroujon, Miriam C.] Open Univ Israel, Raanana, Israel	Weizmann Institute of Science; Open University Israel	Fuchs, S (corresponding author), Weizmann Inst Sci, Dept Immunol, IL-76100 Rehovot, Israel.	sara.fuchs@weizmann.ac.il	, Tali/AAC-9642-2020	, Tali/0000-0002-4072-341X					0	36	37	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	FEB	2006	20	2					374	376		10.1096/fj.05-4909fje	http://dx.doi.org/10.1096/fj.05-4909fje			3	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	V17CJ	16365386				2022-12-25	WOS:000207915000026
J	Zhang, SX; Wang, JJ; Gao, GQ; Shao, CK; Mott, R; Ma, JX				Zhang, Sarah X.; Wang, Joshua J.; Gao, Guoquan; Shao, Chunkui; Mott, Robert; Ma, Jian-xing			Pigment epithelium-derived factor (PEDF) is an endogenous antiinflammatory factor	FASEB JOURNAL			English	Article									[Zhang, Sarah X.; Wang, Joshua J.; Mott, Robert; Ma, Jian-xing] Univ Oklahoma, Hlth Sci Ctr, Dept Cell Biol, Dept Med Endocrinol, Oklahoma City, OK USA; [Gao, Guoquan; Shao, Chunkui] Zhongshan Univ, Dept Biochem, Guangzhou, Guangdong, Peoples R China	University of Oklahoma System; University of Oklahoma Health Sciences Center; Sun Yat Sen University	Ma, JX (corresponding author), 941 Stanton L Young Blvd,BSEB 328B, Oklahoma City, OK 73104 USA.	jian-xing-ma@ouhsc.edu			NATIONAL EYE INSTITUTE [R01EY012231, R33EY015650, R21EY015650] Funding Source: NIH RePORTER; NEI NIH HHS [EY015650, EY12231] Funding Source: Medline	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))			0	246	270	1	12	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	FEB	2006	20	2					323	325		10.1096/fj.05-4313fje	http://dx.doi.org/10.1096/fj.05-4313fje			3	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	V17CJ	16368716				2022-12-25	WOS:000207915000008
J	Kim, TW; Brieba, LG; Ellenberger, T; Kool, ET				Kim, TW; Brieba, LG; Ellenberger, T; Kool, ET			Functional evidence for a small and rigid active site in a high fidelity DNA polymerase - Probing T7 DNA polymerase with variably sized base pairs	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI THIOREDOXIN; DEOXYRIBONUCLEIC-ACID; BACTERIOPHAGE-T7 DNA; CRYSTAL-STRUCTURES; REPLICATION; TIGHTNESS; SEQUENCE; ANALOGS; FIT	Hypotheses on the origins of high fidelity in replicative DNA polymerases have recently focused on the importance of geometric or steric effects in this selectivity. Here we reported a systematic study of the effects of base pair size in T7 DNA polymerase (pol), the replicative enzyme for bacteriophage T7. We varied base pair size in very small (0.25 angstrom) increments by use of a series of nonpolar thymidine shape mimics having gradually increasing size. Steady-state kinetics were evaluated for the 5A7A exonuclease-deficient mutant in a 1: 1 complex with thioredoxin. For T7 pol, we studied insertion of natural nucleotides opposite variably sized T analogs in the template and, conversely, for variably sized dTTP analogs opposite natural template bases. The enzyme displayed extremely high selectivity for a specific base pair size, with drops in efficiency of as much as 280-fold for increases of 0.4 angstrom beyond an optimum size approximating the size of a natural pair. The enzyme also strongly rejected pairs that were smaller than the optimum by as little as 0.3 angstrom. The size preferences with T7 DNA pol were generally smaller, and the steric rejection was greater than DNA pol I Klenow fragment, correlating with the higher fidelity of the former. The hypothetical effects of varied active site size and rigidity are discussed. The data lend direct support to the concept that active site tightness is a chief determinant of high fidelity of replicative polymerases and that a less rigid ( looser) and larger active site can lead to lower fidelity.	Stanford Univ, Dept Chem, Stanford, CA 94305 USA; Harvard Univ, Sch Med, Dept Biol Chem & Mol Pharmacol, Boston, MA 02115 USA	Stanford University; Harvard University; Harvard Medical School	Kool, ET (corresponding author), Stanford Univ, Dept Chem, Stanford, CA 94305 USA.	kool@stanford.edu	Brieba, Luis/I-8447-2016	Brieba, Luis/0000-0002-6073-5207; Kool, Eric/0000-0002-7310-2935	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM072705, R01GM055390] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM 55390, GM 072705] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Beard WA, 1998, CHEM BIOL, V5, pR7, DOI 10.1016/S1074-5521(98)90081-3; Cavaluzzi MJ, 2004, NUCLEIC ACIDS RES, V32, DOI 10.1093/nar/gnh015; Doublie S, 1998, NATURE, V391, P251, DOI 10.1038/34593; Doublie S, 1999, STRUCTURE, V7, pR31, DOI 10.1016/S0969-2126(99)80017-3; DUNN JJ, 1983, J MOL BIOL, V166, P477, DOI 10.1016/S0022-2836(83)80282-4; ECHOLS H, 1991, ANNU REV BIOCHEM, V60, P477, DOI 10.1146/annurev.biochem.60.1.477; ENGLER MJ, 1983, J BIOL CHEM, V258, P1197; GAO JL, 1994, BIOPHYS CHEM, V51, P253, DOI 10.1016/0301-4622(94)00046-8; GOODMAN MF, 1993, CRIT REV BIOCHEM MOL, V28, P83, DOI 10.3109/10409239309086792; Harris D, 1998, J BIOL CHEM, V273, P33624, DOI 10.1074/jbc.273.50.33624; Johnson SJ, 2004, CELL, V116, P803, DOI 10.1016/S0092-8674(04)00252-1; JUNG G, 1987, P NATL ACAD SCI USA, V84, P8287, DOI 10.1073/pnas.84.23.8287; Kim TW, 2005, P NATL ACAD SCI USA, V102, P15803, DOI 10.1073/pnas.0505113102; Kim TW, 2005, J ORG CHEM, V70, P2048, DOI 10.1021/jo048061t; Kim TW, 2004, ORG LETT, V6, P3949, DOI 10.1021/ol048487u; Kool ET, 2002, ANNU REV BIOCHEM, V71, P191, DOI 10.1146/annurev.biochem.71.110601.135453; Kunkel TA, 2000, ANNU REV BIOCHEM, V69, P497, DOI 10.1146/annurev.biochem.69.1.497; Li Y, 1998, EMBO J, V17, P7514, DOI 10.1093/emboj/17.24.7514; MARK DF, 1976, P NATL ACAD SCI USA, V73, P780, DOI 10.1073/pnas.73.3.780; Moran S, 1997, P NATL ACAD SCI USA, V94, P10506, DOI 10.1073/pnas.94.20.10506; Moran S, 1997, J AM CHEM SOC, V119, P2056, DOI 10.1021/ja963718g; PATEL SS, 1991, BIOCHEMISTRY-US, V30, P511, DOI 10.1021/bi00216a029; RICHARDSON CC, 1983, CELL, V33, P315, DOI 10.1016/0092-8674(83)90411-7; Sambrook J., 2001, MOL CLONING, V2; SCHWEITZER BA, 1994, J ORG CHEM, V59, P7238, DOI 10.1021/jo00103a013; TABOR S, 1987, J BIOL CHEM, V262, P16212; WONG I, 1991, BIOCHEMISTRY-US, V30, P526, DOI 10.1021/bi00216a030; Yang W, 2005, FEBS LETT, V579, P868, DOI 10.1016/j.febslet.2004.11.047; Zang H, 2005, J BIOL CHEM, V280, P29750, DOI 10.1074/jbc.M504756200	29	57	57	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 27	2006	281	4					2289	2295		10.1074/jbc.M510744200	http://dx.doi.org/10.1074/jbc.M510744200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	004NV	16311403	hybrid			2022-12-25	WOS:000234760400054
J	Chen, SY; Crawford, M; Day, RM; Briones, VR; Leader, JE; Jose, PA; Lechleider, RJ				Chen, SY; Crawford, M; Day, RM; Briones, VR; Leader, JE; Jose, PA; Lechleider, RJ			RhoA modulates smad signaling during transforming growth factor-beta-induced smooth muscle differentiation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TGF-BETA; DEPENDENT MECHANISM; MARKER GENES; CELLS; EXPRESSION; KINASE; ACTIVATION; INDUCTION; MIGRATION; FEATURES	We recently reported that transforming growth factor (TGF)-beta induced the neural crest stem cell line Monc-1 to differentiate into a spindle-like contractile smooth muscle cell (SMC) phenotype and that Smad signaling played an important role in this phenomenon. In addition to Smad signaling, other pathways such as mitogen-activated protein kinase (MAPK), phosphoinositol-3 kinase, and RhoA have also been shown to mediate TGF-beta actions. The objectives of this study were to examine whether these signaling pathways contribute to TGF-beta-induced SMC development and to test whether Smad signaling cross-talks with other pathway(s) during SMC differentiation induced by TGF-beta. We demonstrate here that RhoA signaling is critical to TGF-beta-induced SMC differentiation. RhoA kinase ( ROCK) inhibitor Y27632 significantly blocks the expression of multiple SMC markers such as smooth muscle alpha-actin, SM22 alpha, and calponin in TGF-beta-treated Monc-1 cells. In addition, Y27632 reversed the cell morphology and abolished the contractility of TGF-beta-treated cells. RhoA signaling was activated as early as 5 min following TGF-beta addition. Dominant negative RhoA blocked nuclear translocation of Smad2 and Smad3 because of the inhibition of phosphorylation of both Smads and inhibited Smad-dependent SBE promoter activity, whereas constitutively active RhoA significantly enhanced SBE promoter activity. Consistent with these results, C3 exotoxin, an inhibitor of RhoA activation, significantly attenuated SBE promoter activity and inhibited Smad nuclear translocation. Taken together, these data point to a new role for RhoA as a modulator of Smad activation while regulating TGF-beta-induced SMC differentiation.	Georgetown Univ, Dept Pediat, Sch Med, Washington, DC 20057 USA; Georgetown Univ, Dept Cell Biol, Sch Med, Washington, DC 20057 USA; Uniformed Serv Univ Hlth Sci, Dept Pharmacol, Bethesda, MD 20814 USA	Georgetown University; Georgetown University; Uniformed Services University of the Health Sciences - USA	Chen, SY (corresponding author), Georgetown Univ, Dept Pediat, Sch Med, Bldg D Rm 63,4000 Reservoir Rd NW, Washington, DC 20057 USA.	sc229@Georgetown.edu			NCI NIH HHS [T32 CA009686] Funding Source: Medline; NHLBI NIH HHS [R01 HL065681, R01HL65681, R01HL073929-01, R01 HL073929-02, R01 HL073929] Funding Source: Medline; NATIONAL CANCER INSTITUTE [T32CA009686] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL073929, R01HL065681] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Bhowmick NA, 2001, MOL BIOL CELL, V12, P27, DOI 10.1091/mbc.12.1.27; Bi D, 2005, CIRC RES, V96, P890, DOI 10.1161/01.RES.0000163018.66460.85; Blindt R, 2004, CARDIOVASC RES, V62, P212, DOI 10.1016/j.cardiores.2004.01.004; Bostrom K, 2000, J CELL BIOCHEM, V78, P210, DOI 10.1002/(SICI)1097-4644(20000801)78:2<210::AID-JCB4>3.0.CO;2-Z; Chen SY, 2004, CIRC RES, V94, P1195, DOI 10.1161/01.RES.0000126897.41658.81; Chen SY, 2003, NUCLEIC ACIDS RES, V31, P1302, DOI 10.1093/nar/gkg224; Christiansen JH, 2000, CURR OPIN CELL BIOL, V12, P719, DOI 10.1016/S0955-0674(00)00158-7; Deaton RA, 2005, J BIOL CHEM, V280, P31172, DOI 10.1074/jbc.M504774200; Derynck R, 2003, NATURE, V425, P577, DOI 10.1038/nature02006; Desai LP, 2004, AM J PHYSIOL-LUNG C, V287, pL1134, DOI 10.1152/ajplung.00022.2004; Edlund S, 2004, J CELL SCI, V117, P1835, DOI 10.1242/jcs.01036; Edlund S, 2002, MOL BIOL CELL, V13, P902, DOI 10.1091/mbc.01-08-0398; Goumans MJ, 2000, INT J DEV BIOL, V44, P253; Hirschi KK, 1998, J CELL BIOL, V141, P805, DOI 10.1083/jcb.141.3.805; Hungerford JE, 1999, J VASC RES, V36, P2, DOI 10.1159/000025622; Ishizaki T, 2000, MOL PHARMACOL, V57, P976; Jain MK, 1998, J BIOL CHEM, V273, P5993, DOI 10.1074/jbc.273.11.5993; Kamaraju SK, 2005, J BIOL CHEM, V280, P1024, DOI 10.1074/jbc.M403960200; Klesse LJ, 1998, J NEUROSCI, V18, P10420; KOCHER O, 1991, LAB INVEST, V65, P459; KOCHER O, 1986, HUM PATHOL, V17, P875, DOI 10.1016/S0046-8177(86)80637-2; Liu YL, 2004, CIRC RES, V95, P579, DOI 10.1161/01.RES.0000141428.53262.a4; Lu J, 2001, DEV BIOL, V240, P404, DOI 10.1006/dbio.2001.0403; Mack CP, 2001, J BIOL CHEM, V276, P341, DOI 10.1074/jbc.M005505200; Massague J, 2000, EMBO J, V19, P1745, DOI 10.1093/emboj/19.8.1745; Mulder KM, 2000, CYTOKINE GROWTH F R, V11, P23, DOI 10.1016/S1359-6101(99)00026-X; Nawshad A, 2004, ARCH ORAL BIOL, V49, P675, DOI 10.1016/j.archoralbio.2004.05.007; Piek E, 1999, FASEB J, V13, P2105, DOI 10.1096/fasebj.13.15.2105; ROSS R, 1993, NATURE, V362, P801, DOI 10.1038/362801a0; Sauzeau V, 2003, CIRC RES, V93, P630, DOI 10.1161/01.RES.0000093220.90027.D9; Shen X, 2001, J BIOL CHEM, V276, P15362, DOI 10.1074/jbc.M009534200; Wamhoff BR, 2004, CIRC RES, V95, P406, DOI 10.1161/01.RES.0000138582.36921.9e; Watts KL, 2004, AM J PHYSIOL-LUNG C, V287, pL1323, DOI 10.1152/ajplung.00447.2003; Worth NF, 2001, ANN NY ACAD SCI, V947, P316	34	117	121	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 20	2006	281	3					1765	1770		10.1074/jbc.M507771200	http://dx.doi.org/10.1074/jbc.M507771200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	002ZS	16317010	Green Accepted, hybrid			2022-12-25	WOS:000234652000057
J	Monraats, PS; Pireso, NMM; Schepers, A; Agema, WRP; Boesten, LSM; de Vries, MR; Zwinderman, AH; de Maat, MPM; Doevendans, PAFM; de Winter, RJ; Tio, RA; Waltenberger, J; 't Hart, LM; Frants, RR; Quax, PHA; van Vlijmen, BJM; Havekes, LM; van der Laarse, A; van der Wall, EE; Jukema, JW				Monraats, PS; Pireso, NMM; Schepers, A; Agema, WRP; Boesten, LSM; de Vries, MR; Zwinderman, AH; de Maat, MPM; Doevendans, PAFM; de Winter, RJ; Tio, RA; Waltenberger, J; 't Hart, LM; Frants, RR; Quax, PHA; van Vlijmen, BJM; Havekes, LM; van der Laarse, A; van der Wall, EE; Jukema, JW			Tumor necrosis factor-alpha plays an important role in restenosis development	FASEB JOURNAL			English	Article						TNF alpha; inflammation; transgenic mice; haplotype	TNF-ALPHA; TRANSGENIC MICE; CORONARY ANGIOPLASTY; MULTIPLE-SCLEROSIS; STENT ERA; GENE; POLYMORPHISMS; ARTERY; PROGRESSION; DISEASE	Genetic factors appear to be important in the restenotic process after percutaneous coronary intervention (PCI), as well as in inflammation, a pivotal factor in restenosis. TNF alpha, a key regulator of inflammatory responses, may exert critical influence on the development of restenosis after PCI. The GENetic DEterminants of Restenosis (GENDER) project included 3104 patients who underwent a successful PCI. Systematic genotyping for six polymorphisms in the TNF alpha gene was performed. The role of TNF alpha in restenosis was also assessed in ApoE*3-Leiden mice, TNF alpha knockout mice, and by local delivery of a TNF alpha biosynthesis inhibitor, thalidomide. The -238G-1031T haplotype of the TNF alpha gene increased clinical and angiographic risk of restenosis (P = 0.02 and P = 0.002, respectively). In a mouse model of reactive stenosis, arterial TNF alpha mRNA was significantly time-dependently up-regulated. Mice lacking TNF alpha or treated locally with thalidomide showed a reduction in reactive stenosis (P = 0.01 and P = 0.005, respectively). Clinical and preclinical data indicate that TNF alpha plays an important role in restenosis. Therefore, TNF alpha genotype may be used as a risk marker for restenosis and may contribute to individual patient screening prior to PCI in clinical practice. Inhibition of TNF alpha may be an anti-restenotic target strategy.	Leiden Univ, Med Ctr, Dept Cardiol, NL-2300 RC Leiden, Netherlands; Leiden Univ, Med Ctr, Dept Surg, NL-2300 RC Leiden, Netherlands; Leiden Univ, Med Ctr, Dept Mol Cell Biol, NL-2300 RC Leiden, Netherlands; Leiden Univ, Med Ctr, Dept Human Genet, Ctr Human & Clin Genet, NL-2300 RC Leiden, Netherlands; Leiden Univ, Med Ctr, Dept Gen Internal Med, NL-2300 RC Leiden, Netherlands; Interuniv Cardiol Inst Netherlands, Utrecht, Netherlands; TNO Qual Life, Gaubius Lab, Leiden, Netherlands; Univ Amsterdam, Acad Med Ctr, Dept Med Stat, NL-1105 AZ Amsterdam, Netherlands; Erasmus Univ, Med Ctr, Dept Hematol, NL-3000 DR Rotterdam, Netherlands; Univ Utrecht, Med Ctr, Dept Cardiol, NL-3508 TC Utrecht, Netherlands; Univ Amsterdam, Acad Med Ctr, Dept Cardiol, NL-1105 AZ Amsterdam, Netherlands; Acad Hosp, Dept Cardiol, Groningen, Netherlands; Univ Limburg, Acad Hosp Maastricht, Dept Cardiol, Maastricht, Netherlands	Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC; Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC; Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC; Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC; Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC; Interuniversity Cardiology Institute of the Netherlands; Utrecht University; Netherlands Organization Applied Science Research; University of Amsterdam; Academic Medical Center Amsterdam; Erasmus University Rotterdam; Erasmus MC; Utrecht University; University of Amsterdam; Academic Medical Center Amsterdam; University of Groningen; Hasselt University; Maastricht University; Maastricht University Medical Centre (MUMC)	Jukema, JW (corresponding author), Leiden Univ, Med Ctr, Dept Cardiol, 5-P,POB 9600, NL-2300 RC Leiden, Netherlands.	j.w.jukema@lumc.nl	't Hart, Leen/ABG-3185-2021; Jukema, J. Wouter/ABD-6503-2021; Quax, Paul/ABD-5294-2020; Tio, Rene/ABG-2820-2020; Quax, Paul/W-8520-2019; Waltenberger, Johannes/I-1813-2013	't Hart, Leen/0000-0003-4401-2938; Jukema, J. Wouter/0000-0002-3246-8359; Quax, Paul/0000-0002-6853-5760; Pires, Nuno/0000-0001-5244-8550; Schepers, Abbey/0000-0003-0504-3491; Waltenberger, Johannes/0000-0002-2417-9880				Agema WRP, 2004, EUR HEART J, V25, P1163, DOI 10.1016/j.ehj.2004.05.006; Barcellos LF, 2004, ANN NEUROL, V55, P793, DOI 10.1002/ana.20092; Boesten LSM, 2005, CARDIOVASC RES, V66, P179, DOI 10.1016/j.cardiores.2005.01.001; Cheng S, 1999, GENOME RES, V9, P936, DOI 10.1101/gr.9.10.936; FONG CLW, 1994, NUCLEIC ACIDS RES, V22, P1108, DOI 10.1093/nar/22.6.1108; Hojo Y, 2001, ATHEROSCLEROSIS, V156, P165, DOI 10.1016/S0021-9150(00)00611-0; Huizinga TWJ, 1997, J NEUROIMMUNOL, V72, P149, DOI 10.1016/S0165-5728(96)00182-8; JUKEMA JW, 1995, CIRCULATION, V91, P2528, DOI 10.1161/01.CIR.91.10.2528; Kaluza W, 2000, J INVEST DERMATOL, V114, P1180, DOI 10.1046/j.1523-1747.2000.00001.x; Koch W, 2003, CYTOKINE, V24, P161, DOI 10.1016/j.cyto.2003.08.004; Lardenoye JHP, 2000, CIRC RES, V87, P248, DOI 10.1161/01.RES.87.3.248; Li WT, 2001, GENET EPIDEMIOL, V21, pS272, DOI 10.1002/gepi.2001.21.s1.s272; LIBBY P, 1992, CIRCULATION, V86, P47; Livak KJ, 1999, GENET ANAL-BIOMOL E, V14, P143, DOI 10.1016/S1050-3862(98)00019-9; Mehilli J, 2003, EUR HEART J, V24, P1523, DOI 10.1016/S0195-668X(03)00320-8; Park SJ, 2004, ARTERIOSCL THROM VAS, V24, P885, DOI 10.1161/01.ATV.0000124924.21961.c3; Pires NMM, 2005, BIOMATERIALS, V26, P5386, DOI 10.1016/j.biomaterials.2005.01.063; Saia F, 2003, CIRCULATION, V108, P1927, DOI 10.1161/01.CIR.0000096053.87580.CD; Schomig A, 1997, CIRCULATION, V96, P3880; Serrano CV, 1997, J AM COLL CARDIOL, V29, P1276, DOI 10.1016/S0735-1097(97)00070-3; Simmonds MJ, 2004, GENES IMMUN, V5, P267, DOI 10.1038/sj.gene.6364066; Skoog T, 1999, HUM MOL GENET, V8, P1443, DOI 10.1093/hmg/8.8.1443; Tanck MWT, 2003, ANN HUM GENET, V67, P175, DOI 10.1046/j.1469-1809.2003.00021.x; VANDENMAAGDENBERG AMJM, 1993, J BIOL CHEM, V268, P10540; Waldron-Lynch F, 2001, GENES IMMUN, V2, P82, DOI 10.1038/sj.gene.6363738; Welt FGP, 2002, ARTERIOSCL THROM VAS, V22, P1769, DOI 10.1161/01.ATV.0000037100.44766.5B; Wilson AG, 1997, P NATL ACAD SCI USA, V94, P3195, DOI 10.1073/pnas.94.7.3195	27	70	75	0	5	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	DEC	2005	19	14					1998	2004		10.1096/fj.05-4634com	http://dx.doi.org/10.1096/fj.05-4634com			7	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	999QR	16319143				2022-12-25	WOS:000234405500010
J	Rouget-Quermalet, V; Giustiniani, J; Marie-Cardine, A; Beaud, G; Besnard, F; Loyaux, D; Ferrara, P; Leroy, K; Shimizu, N; Gaulard, P; Bensussan, A; Schmitt, C				Rouget-Quermalet, V; Giustiniani, J; Marie-Cardine, A; Beaud, G; Besnard, F; Loyaux, D; Ferrara, P; Leroy, K; Shimizu, N; Gaulard, P; Bensussan, A; Schmitt, C			Protocadherin 15 (PCDH15): a new secreted isoformand a potential marker for NK/T cell lymphomas	ONCOGENE			English	Article						NK/T lymphomas; isoforms; PCDH15; RT-PCR	T-CELL; EXPRESSION; RECEPTORS; MUTANT; LINES; GENE	Natural killer cells are well known to play an important role in immune defense against tumor development and viral infections. To further characterize new functionally relevant structures in these cells, we studied a series of monoclonal antibodies that we have raised against the NK cell line YT. One of these antibodies previously described as AY19, recognizes a 85 kD surface glycoprotein. Here we report the identification of a new secreted isoform of protocadherin 15, PCDH15C, which represents a potential associated protein for p85. Importantly, whereas protocadherins are absent from the surface of normal hematopoietic cells, we describe, for the first time, that PCDH15 is expressed in cytotoxic tumor-derived T- and NK-cell lines as well as in biopsies of nasal NK/T-cell lymphomas.	INSERM, Fac Med, U659, F-94010 Creteil, France; Sanofi Aventis, Rueil Malmaison, France; Sanofi Aventis, Labege, France; CHU Henri Mondor, Dept Pathol, INSERM, U 617,AP HP, F-94010 Creteil, France; Med Res Inst, Dept Virol, Tokyo, Japan	Institut National de la Sante et de la Recherche Medicale (Inserm); Universite Paris-Est-Creteil-Val-de-Marne (UPEC); Sanofi-Aventis; Sanofi-Aventis; Assistance Publique Hopitaux Paris (APHP); Universite Paris-Est-Creteil-Val-de-Marne (UPEC); Hopital Universitaire Henri-Mondor - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm)	Schmitt, C (corresponding author), INSERM, Fac Med, U659, 8 Rue Gen Sarrail, F-94010 Creteil, France.	christian.schmitt@im3.inserm.fr	Bensussan, Armand/E-5434-2017; Leroy, Karen/E-9235-2011	Leroy, Karen/0000-0002-4379-0140; Bensussan, Armand/0000-0002-0409-2497; Giustiniani, Jerome/0000-0002-4612-0759				Ahmed ZM, 2003, HUM MOL GENET, V12, P3215, DOI 10.1093/hmg/ddg358; Ahmed ZM, 2001, AM J HUM GENET, V69, P25, DOI 10.1086/321277; Alagramam KN, 2001, NAT GENET, V27, P99, DOI 10.1038/83837; Chen MW, 2002, ONCOGENE, V21, P7861, DOI 10.1038/sj.onc.1205991; Frank M, 2002, CURR OPIN CELL BIOL, V14, P557, DOI 10.1016/S0955-0674(02)00365-4; Kanavaros P, 2000, LEUKEMIA LYMPHOMA, V38, P317, DOI 10.3109/10428190009087022; Lanier LL, 2005, ANNU REV IMMUNOL, V23, P225, DOI 10.1146/annurev.immunol.23.021704.115526; Le Bouteiller P, 2002, P NATL ACAD SCI USA, V99, P16963, DOI 10.1073/pnas.012681099; MANSUR IG, 1993, HUM IMMUNOL, V37, P31, DOI 10.1016/0198-8859(93)90140-V; Moretta L, 2004, EMBO J, V23, P255, DOI 10.1038/sj.emboj.7600019; Nagata H, 2001, BLOOD, V97, P708, DOI 10.1182/blood.V97.3.708; Nava VE, 2005, ADV ANAT PATHOL, V12, P27, DOI 10.1097/01.pap.0000151318.34752.80; Sherwood DR, 2005, CELL, V121, P951, DOI 10.1016/j.cell.2005.03.031; VILMER E, 1988, BLOOD, V72, P841; YING L, 2005, ONCOGENE, DOI DOI 10.1038	15	21	23	2	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 4	2006	25	19					2807	2811		10.1038/sj.onc.1209301	http://dx.doi.org/10.1038/sj.onc.1209301			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	039AW	16369489				2022-12-25	WOS:000237272900012
J	Haupt, M; Bramkamp, M; Heller, M; Coles, M; Deckers-Hebestreit, G; Herkenhoff-Hesselmann, B; Altendorf, K; Kessler, H				Haupt, M; Bramkamp, M; Heller, M; Coles, M; Deckers-Hebestreit, G; Herkenhoff-Hesselmann, B; Altendorf, K; Kessler, H			The Holo-form of the nucleotide binding domain of the KdpFABC complex from Escherichia coli reveals a new binding mode	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SARCOPLASMIC-RETICULUM CA2+-ATPASE; AMINO-ACID SUBSTITUTIONS; P-TYPE ATPASES; KDP-ATPASE; CALCIUM-PUMP; N-DOMAIN; BACKBONE DYNAMICS; CRYSTAL-STRUCTURE; NMR-SPECTROSCOPY; CHEMICAL-SHIFT	P-type ATPases are ubiquitously abundant enzymes involved in active transport of charged residues across biological membranes. The KdpB subunit of the prokaryotic Kdp-ATPase (KdpFABC complex) shares characteristic regions of homology with class II - IV P-type ATPases and has been shown previously to be misgrouped as a class IA P-type ATPase. Here, we present the NMR structure of the AMP-PNP-bound nucleotide binding domain KdpBN of the Escherichia coli Kdp-ATPase at high resolution. The aromatic moiety of the nucleotide is clipped into the binding pocket by Phe(377) and Lys(395) via a pi-pi stacking and a cation-pi interaction, respectively. Charged residues at the outer rim of the binding pocket (Arg(317), Arg(382), Asp(399), and Glu(348)) stabilize and direct the triphosphate group via electrostatic attraction and repulsion toward the phosphorylation domain. The nucleotide binding mode was corroborated by the replacement of critical residues. The conservative mutation F377Y produced a high residual nucleotide binding capacity, whereas replacement by alanine resulted in low nucleotide binding capacities and a considerable loss of ATPase activity. Similarly, mutation K395A resulted in loss of ATPase activity and nucleotide binding affinity, even though the protein was properly folded. We present a schematic model of the nucleotide binding mode that allows for both high selectivity and a low nucleotide binding constant, necessary for the fast and effective turnover rate realized in the reaction cycle of the Kdp-ATPase.	Tech Univ Munich, Dept Chem, D-85747 Garching, Germany; Univ Osnabruck, Fachbereich Biol Chem, Abt Mikrobiol, D-49069 Osnabruck, Germany	Technical University of Munich; University Osnabruck	Kessler, H (corresponding author), Tech Univ Munich, Dept Chem, Lichtenbergstr 4, D-85747 Garching, Germany.	horst.kessler@ch.tum.de	Kessler, Horst/C-1178-2010	Bramkamp, Marc/0000-0002-7704-3266				Abu-Abed M, 2002, BIOCHEMISTRY-US, V41, P1156, DOI 10.1021/bi015703n; Altendorf K, 1998, ACTA PHYSIOL SCAND, V163, P137; ALTENDORF K, 1996, BIOMEMBR, V5, P403; Axelsen KB, 1998, J MOL EVOL, V46, P84, DOI 10.1007/PL00006286; Bertrand J, 2004, J BACTERIOL, V186, P5519, DOI 10.1128/JB.186.16.5519-5522.2004; Bramkamp M, 2005, BIOCHEMISTRY-US, V44, P8260, DOI 10.1021/bi050135n; Bramkamp M, 2004, BIOCHEMISTRY-US, V43, P12289, DOI 10.1021/bi048727d; Bramkamp M, 2004, BIOCHEMISTRY-US, V43, P4559, DOI 10.1021/bi030198a; BRUNGER AT, 1992, XPLOR SYSTEM XRAY CR; Clausen JD, 2003, J BIOL CHEM, V278, P20245, DOI 10.1074/jbc.M301122200; CLORE GM, 1990, J AM CHEM SOC, V112, P4989, DOI 10.1021/ja00168a070; Cole R, 2003, J BIOMOL NMR, V26, P203, DOI 10.1023/A:1023808801134; Cornilescu G, 1999, J BIOMOL NMR, V13, P289, DOI 10.1023/A:1008392405740; Dalvit C, 2001, J BIOMOL NMR, V21, P349, DOI 10.1023/A:1013302231549; Delano W. L., 2003, PYMOL MOL GENETICS G; Diercks T, 1999, J BIOMOL NMR, V15, P177, DOI 10.1023/A:1008367912535; Dorus S, 2001, J BIOL CHEM, V276, P9590, DOI 10.1074/jbc.M009365200; EPSTEIN W, 1971, J BACTERIOL, V108, P639, DOI 10.1128/JB.108.2.639-644.1971; FARROW NA, 1994, BIOCHEMISTRY-US, V33, P5984, DOI 10.1021/bi00185a040; Hakansson KO, 2003, J MOL BIOL, V332, P1175, DOI 10.1016/j.jmb.2003.07.012; Haupt M, 2005, J MOL MICROB BIOTECH, V10, P120, DOI 10.1159/000091559; Haupt M, 2004, J MOL BIOL, V342, P1547, DOI 10.1016/j.jmb.2004.07.060; Haupt M, 2004, J BIOMOL NMR, V29, P437, DOI 10.1023/B:JNMR.0000032512.08757.8b; HENKEL RD, 1988, ANAL BIOCHEM, V169, P312, DOI 10.1016/0003-2697(88)90290-4; Kuhlbrandt W, 2004, NAT REV MOL CELL BIO, V5, P282, DOI 10.1038/nrm1354; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; LIPARI G, 1982, J AM CHEM SOC, V104, P4546, DOI 10.1021/ja00381a009; Loria JP, 1999, J AM CHEM SOC, V121, P2331, DOI 10.1021/ja983961a; LUTSENKO S, 1995, BIOCHEMISTRY-US, V34, P15607, DOI 10.1021/bi00048a001; MANDEL AM, 1995, J MOL BIOL, V246, P144, DOI 10.1006/jmbi.1994.0073; Mayer M, 2001, J AM CHEM SOC, V123, P6108, DOI 10.1021/ja0100120; McIntosh DB, 2003, ANN NY ACAD SCI, V986, P101, DOI 10.1111/j.1749-6632.2003.tb07145.x; Meyer B, 2003, ANGEW CHEM INT EDIT, V42, P864, DOI 10.1002/anie.200390233; Mulder FAA, 2002, J AM CHEM SOC, V124, P1443, DOI 10.1021/ja0119806; Sambrock J, 1989, MOL CLONING LAB MANU; Skrynnikov NR, 2001, J AM CHEM SOC, V123, P4556, DOI 10.1021/ja004179p; Sorensen TLM, 2004, SCIENCE, V304, P1672, DOI 10.1126/science.1099366; Tollinger M, 2001, J AM CHEM SOC, V123, P11341, DOI 10.1021/ja011300z; Toyoshima C, 2004, NATURE, V430, P529, DOI 10.1038/nature02680; Toyoshima C, 2000, NATURE, V405, P647, DOI 10.1038/35015017; Toyoshima C, 2002, NATURE, V418, P605, DOI 10.1038/nature00944; Truffault V, 2001, J MOL BIOL, V309, P949, DOI 10.1006/jmbi.2001.4683; van der Laan M, 2002, J BACTERIOL, V184, P5491, DOI 10.1128/JB.184.19.5491-5494.2002; WISHART DS, 1994, J BIOMOL NMR, V4, P171	44	19	20	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 7	2006	281	14					9641	9649		10.1074/jbc.M508290200	http://dx.doi.org/10.1074/jbc.M508290200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	027HB	16354672	hybrid			2022-12-25	WOS:000236404700076
J	Aung, PP; Oue, N; Mitani, Y; Nakayama, H; Yoshida, K; Noguchi, T; Bosserhoff, AK; Yasui, W				Aung, PP; Oue, N; Mitani, Y; Nakayama, H; Yoshida, K; Noguchi, T; Bosserhoff, AK; Yasui, W			Systematic search for gastric cancer-specific genes based on SAGE data: melanoma inhibitory activity and matrix metalloproteinase-10 are novel prognostic factors in patients with gastric cancer	ONCOGENE			English	Article						gastric cancer; MIA; MMP10; DKK4; SAGE; tumor serum marker	SQUAMOUS-CELL CARCINOMA; CLINICAL-IMPLICATIONS; MALIGNANT-MELANOMA; METASTATIC CANCER; TISSUE INHIBITORS; SERIAL ANALYSIS; FUNCTIONAL-ROLE; PHASE-I; EXPRESSION; PROTEIN	Gastric cancer ( GC) is one of the most common malignancies worldwide. Genes expressed only in cancer tissue will be useful molecular markers for diagnosis and may also be good therapeutic targets. However, little is known about cancer-specific genes, at least in GC. In this study, we searched for GC-specific genes by serial analysis of gene expression ( SAGE) data analysis and quantitative reverse transcription (RT)-PCR. Comparing GC SAGE libraries with those of various normal tissues in the SAGEmap database, we identified 54 candidate GC-specific genes. Quantitative RT-PCR analysis of these candidates revealed that APin protein (APIN), taxol resistance-associated gene 3 (TRAG3), cytochrome P450, family 2, subfamily W, polypeptide 1 (CYP2W1), melanoma inhibitory activity (MIA), matrix metalloproteinase-10 (MMP-10), dickkopf homolog 4 (DKK4), GW112, regenerating islet-derived family, member 4 (REGIV), and HORMA domain-containing 1 (HOR-MAD1) were expressed much more highly in GC than in 14 kinds of normal tissues. Immunohistochemical staining for MIA, MMP-10, and DKK4 was found in 47 (31.1%), 68 (45.0%), and two (1.3%) of 151 GCs, respectively, and staining for both MIA and MMP-10 was correlated with poor prognosis in advanced GC (P = 0.0001 and 0.0141, respectively). Moreover, enzyme-linked immunosorbent assay showed high levels of MMP-10 (65/69, 94.2%) in serum samples from patients with GC. Levels of MIA were raised in a small proportion of serum samples from patients with GC (4/69, 5.8%). In Boyden chamber invasion assays, MIA-transfected GC cells were up to three times more invasive than cells transfected with empty vector. Taken together, these results suggest that MMP-10 is a good marker for the detection of GC and that MIA and MMP-10 are prognostic factors for GC. As expression of MIA and MMP-10 is narrowly restricted in cancer, these two molecules may be good therapeutic targets for GC.	Hiroshima Univ, Grad Sch Biomed Sci, Dept Mol Pathol, Minami Ku, Hiroshima 7348551, Japan; Hiroshima Univ, Res Inst Radiat Biol & Med, Dept Surg Oncol, Hiroshima, Japan; Oita Univ, Fac Med, Dept Oncol Sci, Oita, Japan; Univ Regensburg, Inst Pathol, Regensburg, Germany	Hiroshima University; Hiroshima University; Oita University; University of Regensburg	Yasui, W (corresponding author), Hiroshima Univ, Grad Sch Biomed Sci, Dept Mol Pathol, Minami Ku, 1-2-3 Kasumi, Hiroshima 7348551, Japan.	wyasui@hiroshima-u.ac.jp	Bosserhoff, Anja/GNH-4801-2022; Mitani, Yoshitsugu/ABA-2736-2021	Mitani, Yoshitsugu/0000-0002-8661-4702; Aung, Phyu/0000-0002-3398-0573; Bosserhoff, Anja/0000-0001-8147-394X				ALLEY MC, 1988, CANCER RES, V48, P589; Amatschek S, 2004, CANCER RES, V64, P844, DOI 10.1158/0008-5472.CAN-03-2361; Bando E, 1999, AM J SURG, V178, P256, DOI 10.1016/S0002-9610(99)00162-2; Beachy PA, 2004, NATURE, V432, P324, DOI 10.1038/nature03100; BLESCH A, 1994, CANCER RES, V54, P5695; Bodey B, 2000, ANTICANCER RES, V20, P4585; Bosserhoff AK, 1999, J PATHOL, V187, P446, DOI 10.1002/(SICI)1096-9896(199903)187:4<446::AID-PATH267>3.0.CO;2-Y; Bosserhoff AK, 1997, CANCER RES, V57, P3149; Bosserhoff AK, 2001, MELANOMA RES, V11, P417, DOI 10.1097/00008390-200108000-00013; Buckhaults P, 2001, CANCER RES, V61, P6996; Clark HF, 2003, GENOME RES, V13, P2265, DOI 10.1101/gr.1293003; Dietz UH, 1996, J BIOL CHEM, V271, P3311, DOI 10.1074/jbc.271.6.3311; El Fitori J, 2005, CANCER CELL INT, V5, DOI 10.1186/1475-2867-5-3; Hau P, 2004, ONCOL REP, V12, P1355; Hau P, 2002, ANTICANCER RES, V22, P577; HEMBRY RM, 1995, ANN RHEUM DIS, V54, P25, DOI 10.1136/ard.54.1.25; Hohenberger P, 2003, LANCET, V362, P305, DOI 10.1016/S0140-6736(03)13975-X; Kevorkian L, 2004, ARTHRITIS RHEUM-US, V50, P131, DOI 10.1002/art.11433; KOGA T, 1987, JPN J SURG, V17, P342, DOI 10.1007/BF02470632; Kondo T, 2004, CANCER RES, V64, P523, DOI 10.1158/0008-5472.CAN-03-1196; Krupnik VE, 1999, GENE, V238, P301, DOI 10.1016/S0378-1119(99)00365-0; Lal A, 1999, CANCER RES, V59, P5403; LAUREN P, 1965, ACTA PATHOL MIC SC, V64, P31, DOI 10.1111/apm.1965.64.1.31; MANTEL NATHAN, 1966, CANCERCHEMOTHERAP REP, V50, P163; Mao BY, 2003, GENE, V302, P179, DOI 10.1016/S0378-1119(02)01106-X; Mathew R, 2002, CANCER DETECT PREV, V26, P222, DOI 10.1016/S0361-090X(02)00035-1; MOLNAR IG, 1976, GASTROENTEROLOGY, V70, P513; MULLER D, 1991, INT J CANCER, V48, P550, DOI 10.1002/ijc.2910480412; Nakamura H, 1998, EUR J BIOCHEM, V253, P67, DOI 10.1046/j.1432-1327.1998.2530067.x; Nelson AR, 2000, J CLIN ONCOL, V18, P1135, DOI 10.1200/JCO.2000.18.5.1135; Nomura H, 1996, INT J CANCER, V69, P9, DOI 10.1002/(SICI)1097-0215(19960220)69:1<9::AID-IJC3>3.0.CO;2-8; OHGAKI H, 2003, WORLD CANC REPORT, P197; Oue N, 2005, J PATHOL, V207, P185, DOI 10.1002/path.1827; Oue N, 2004, CANCER RES, V64, P2397, DOI 10.1158/0008-5472.CAN-03-3514; Poser I, 2004, ONCOGENE, V23, P6115, DOI 10.1038/sj.onc.1207797; Ramos MC, 2004, BIOL CHEM, V385, P75, DOI 10.1515/BC.2004.010; Rizvi NA, 2004, CLIN CANCER RES, V10, P1963, DOI 10.1158/1078-0432.CCR-1183-02; Rudek MA, 2001, J CLIN ONCOL, V19, P584, DOI 10.1200/JCO.2001.19.2.584; Saghizadeh M, 2001, AM J PATHOL, V158, P723, DOI 10.1016/S0002-9440(10)64015-1; Sharma R, 2004, ONCOLOGY-BASEL, V67, P300, DOI 10.1159/000081331; SHIMIZU N, 1987, ONCOLOGY, V44, P240, DOI 10.1159/000226486; SOBIN LH, 2002, TNM CLASSIFICATION M, P65; Solomon A, 2003, J LAB CLIN MED, V142, P348, DOI 10.1016/S0022-2143(03)00149-5; Thorns V, 2003, ANTICANCER RES, V23, P3937; Ushijima T, 2004, CANCER CELL, V5, P121, DOI 10.1016/S1535-6108(04)00033-9; Visse R, 2003, CIRC RES, V92, P827, DOI 10.1161/01.RES.0000070112.80711.3D; Yamashita K, 1998, INT J CANCER, V79, P187; Yasui W, 2004, CANCER SCI, V95, P385, DOI 10.1111/j.1349-7006.2004.tb03220.x; Yasui Wataru, 2000, Journal of Gastroenterology, V35, P111; Zhang XW, 2004, CANCER RES, V64, P2474, DOI 10.1158/0008-5472.CAN-03-3443; Zucker S, 1999, ANN NY ACAD SCI, V878, P212, DOI 10.1111/j.1749-6632.1999.tb07687.x	51	137	153	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR	2006	25	17					2546	2557		10.1038/sj.onc.1209279	http://dx.doi.org/10.1038/sj.onc.1209279			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	034RJ	16331256				2022-12-25	WOS:000236948000013
J	Chattopadhyay, A; Tate, SA; Beswick, RW; Wagner, SD; Ferrigno, PK				Chattopadhyay, A; Tate, SA; Beswick, RW; Wagner, SD; Ferrigno, PK			A peptide aptamer to antagonize BCL-6 function	ONCOGENE			English	Article						peptide aptamer; BCL-6; B-cell lymphoma	GERMINAL-CENTER FORMATION; FINGER PROTEIN; POZ DOMAIN; BTB DOMAIN; TRANSCRIPTION; DIFFERENTIATION; IDENTIFICATION; INFLAMMATION; COREPRESSOR; RECRUITMENT	BCL-6 is a transcription factor essential for germinal centre B-cell development. The BCL-6 gene is involved in diffuse large-cell lymphoma and overexpressed in other types of non-Hodgkin's lymphoma and in high-grade breast cancer. BCL-6 is a transcriptional repressor whose N-terminal POZ domain mediates protein-protein interactions to exert its effects. Reasoning that disruption of POZ domain-mediated interactions may be an effective route to antagonizing the effects of BCL-6 in lymphoma, we screened a library for peptide aptamers that specifically bind to BCL-6 POZ and not the POZ domains of related proteins and describe here the first of these reagents, Apt48. Apt 48 binds BCL-6 POZ in a manner distinct from the transcriptional corepressor SMRT, yet was found to prevent BCL-6-mediated repression of a luciferase reporter gene. Apt48 also reproduced several previously validated effects of BCL-6 inhibition. Not ably, expression of the differentiation markers CD69, Blimp-1 and cyclin D2 was increased in B-cell lines when Apt48 was expressed. W e also show that expression of Apt48 restores cytokine-mediated growth arrest to BCL-6 over-expressing cells. Thus, we have identified a peptide aptamer that affects a function of BCL-6 that is required to prevent differentiation of proliferating B cells.	Hammersmith Hosp, Imperial Coll London, Div Invest Sci, Dept Haematol, London W12 0NN, England; MRC, Canc Cell Unit, Hutchison MRC Res Ctr, Cambridge, England; Univ Cambridge, Canc Res UK, Dept Oncol, Hutchison MRC Res Ctr, Cambridge, England	Imperial College London; Cancer Research UK; CRUK Cambridge Institute; University of Cambridge	Wagner, SD (corresponding author), Hammersmith Hosp, Imperial Coll London, Div Invest Sci, Dept Haematol, Du Cane Rd, London W12 0NN, England.	simon.wagner@imperial.ac.uk; pkf@hutchison-mrc.cam.ac.uk		Wagner, Simon/0000-0002-8914-0370; Ko Ferrigno, Paul/0000-0002-5922-4100	MRC [MC_U105359876] Funding Source: UKRI; Medical Research Council [MC_U105359876] Funding Source: Medline	MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))		Ahmad KF, 1998, P NATL ACAD SCI USA, V95, P12123, DOI 10.1073/pnas.95.21.12123; Ahmad KF, 2003, MOL CELL, V12, P1551, DOI 10.1016/S1097-2765(03)00454-4; BARDWELL VJ, 1994, GENE DEV, V8, P1664, DOI 10.1101/gad.8.14.1664; BARON BW, 1993, P NATL ACAD SCI USA, V90, P5262, DOI 10.1073/pnas.90.11.5262; CATTORETTI G, 1995, BLOOD, V86, P45, DOI 10.1182/blood.V86.1.45.bloodjournal86145; Chang CC, 1996, P NATL ACAD SCI USA, V93, P6947, DOI 10.1073/pnas.93.14.6947; Chevallier N, 2004, BLOOD, V103, P1454, DOI 10.1182/blood-2003-06-2081; Colas P, 1996, NATURE, V380, P548, DOI 10.1038/380548a0; Crawford Margaret, 2003, Briefings in Functional Genomics & Proteomics, V2, P72, DOI 10.1093/bfgp/2.1.72; Davies JM, 1999, ONCOGENE, V18, P365, DOI 10.1038/sj.onc.1202332; Deltour S, 1999, P NATL ACAD SCI USA, V96, P14831, DOI 10.1073/pnas.96.26.14831; Dent AL, 1997, SCIENCE, V276, P589, DOI 10.1126/science.276.5312.589; Dhordain P, 1998, NUCLEIC ACIDS RES, V26, P4645, DOI 10.1093/nar/26.20.4645; Dhordain P, 2000, ONCOGENE, V19, P6240, DOI 10.1038/sj.onc.1203976; Fujita N, 2004, CELL, V119, P75, DOI 10.1016/j.cell.2004.09.014; Fukuda T, 1997, J EXP MED, V186, P439, DOI 10.1084/jem.186.3.439; GOLEMIS EA, 1999, CURRENT PROTOCOS MOL; GYURIS J, 1993, CELL, V75, P791, DOI 10.1016/0092-8674(93)90498-F; Harris MB, 1999, MOL CELL BIOL, V19, P7264; Huynh KD, 1998, ONCOGENE, V17, P2473, DOI 10.1038/sj.onc.1202197; Logarajah S, 2003, ONCOGENE, V22, P5572, DOI 10.1038/sj.onc.1206689; Melnick A, 2000, MOL CELL BIOL, V20, P6550, DOI 10.1128/MCB.20.17.6550-6567.2000; Melnick A, 2002, MOL CELL BIOL, V22, P1804, DOI 10.1128/MCB.22.6.1804-1818.2002; Muto A, 1998, EMBO J, V17, P5734, DOI 10.1093/emboj/17.19.5734; Niu HF, 1998, GENE DEV, V12, P1953, DOI 10.1101/gad.12.13.1953; Okabe S, 1998, MOL CELL BIOL, V18, P4235, DOI 10.1128/MCB.18.7.4235; ONIZUKA T, 1995, BLOOD, V86, P28, DOI 10.1182/blood.V86.1.28.bloodjournal86128; Polo JM, 2004, NAT MED, V10, P1329, DOI 10.1038/nm1134; Reljic R, 2000, J EXP MED, V192, P1841, DOI 10.1084/jem.192.12.1841; Rose MD., 1990, METHODS YEAST GENETI; Sambrook J, 2001, MOL CLONING LAB MANU; Shaffer AL, 2000, IMMUNITY, V13, P199, DOI 10.1016/S1074-7613(00)00020-0; TURNER CA, 1994, CELL, V77, P297, DOI 10.1016/0092-8674(94)90321-2; Ye BH, 1997, NAT GENET, V16, P161, DOI 10.1038/ng0697-161; YE BHH, 1993, CANCER RES, V53, P2732	35	41	46	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR	2006	25	15					2223	2233		10.1038/sj.onc.1209252	http://dx.doi.org/10.1038/sj.onc.1209252			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	029RD	16331266				2022-12-25	WOS:000236581200009
J	Cenas, N; Prast, S; Nivinskas, H; Sarlauskas, J; Arner, ESJ				Cenas, N; Prast, S; Nivinskas, H; Sarlauskas, J; Arner, ESJ			Interactions of nitroaromatic compounds with the mammalian selenoprotein thioredoxin reductase and the relation to induction of apoptosis in human cancer cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CONGOLENSE TRYPANOTHIONE REDUCTASE; EARLY EMBRYONIC LETHALITY; GLUTATHIONE-REDUCTASE; LIPOAMIDE DEHYDROGENASE; ELECTRON-TRANSFER; ESCHERICHIA-COLI; OXIDATIVE STRESS; HUMAN PLACENTA; MECHANISM; SELENOCYSTEINE	Here we described novel interactions of the mammalian selenoprotein thioredoxin reductase (TrxR) with nitroaromatic environmental pollutants and drugs. We found that TrxR could catalyze nitroreductase reactions with either one- or two-electron reduction, using its selenocysteine-containing active site and another redox active center, presumably the FAD. Tetryl and p-dinitrobenzene were the most efficient nitroaromatic substrates with a k(cat) of 1.8 and 2.8 s(-1), respectively, at pH 7.0 and 25 degrees C using 50 mu M NADPH. As a nitroreductase, TrxR cycled between four- and two-electron-reduced states. The one- electron reactions led to superoxide formation as detected by cytochrome c reduction and, interestingly, reductive N-denitration of tetryl or 2,4-dinitrophenyl-N-methylnitramine, resulting in the release of nitrite. Most nitroaromatics were uncompetitive and noncompetitive inhibitors with regard to NADPH and the disulfide substrate 5,5'-dithiobis(2-nitrobenzoic acid), respectively. Tetryl and 4,6-dinitrobenzofuroxan were, however, competitive inhibitors with respect to 5,5'-dithiobis( 2-nitrobenzoic acid) and were clearly substrates for the selenolthiol motif of the enzyme. Furthermore, tetryl and 4,6-dinitrobenzofuroxan efficiently inactivated TrxR, likely by alkylation of the selenolthiol motif as in the inhibition of TrxR by 1-chloro-2,4-dinitrobenzene/ dinitrochlorobenzene ( DNCB) or juglone. The latter compounds were the most efficient inhibitors of TrxR activity in a cellular context. DNCB, juglone, and tetryl were highly cytotoxic and induced caspase-3/7 activation in HeLa cells. Furthermore, DNCB and juglone were potent inducers of apoptosis also in Bcl2 overexpressing HeLa cells or in A549 cells. Based on these findings, we suggested that targeting of intracellular TrxR by alkylating nitroaromatic or quinone compounds may contribute to the induction of apoptosis in exposed human cancer cells.	Inst Biochem, LT-08662 Vilnius, Lithuania; Karolinska Inst, Med Nobel Inst Biochem, Dept Med Biochem & Biophys, SE-17177 Stockholm, Sweden	Vilnius University; Karolinska Institutet	Cenas, N (corresponding author), Inst Biochem, Mokslininku 12, LT-08662 Vilnius, Lithuania.	ncenas@bchi.lt; Elias.Arner@ki.se	Arnér, Elias S.J./J-5832-2012; Prast-Nielsen, Stefanie/W-6946-2019; Sarlauskas, Jonas/ACX-5314-2022; Arnér, Elias/K-6737-2019	Arnér, Elias S.J./0000-0002-4807-6114; Prast-Nielsen, Stefanie/0000-0001-5877-7988; Arnér, Elias/0000-0002-4807-6114; Sarlauskas, Jonas/0000-0003-4268-1716				Anestal K, 2003, J BIOL CHEM, V278, P15966, DOI 10.1074/jbc.M210733200; Arner ESJ, 2000, EUR J BIOCHEM, V267, P6102, DOI 10.1046/j.1432-1327.2000.01701.x; Arner ESJ, 2001, FREE RADICAL BIO MED, V31, P1170, DOI 10.1016/S0891-5849(01)00698-0; ARNER ESJ, 2000, CURRENT PROTOCOLS TO; Arscott LD, 1997, P NATL ACAD SCI USA, V94, P3621, DOI 10.1073/pnas.94.8.3621; Bauer H, 2003, J BIOL CHEM, V278, P33020, DOI 10.1074/jbc.M303762200; Becker K, 2000, EUR J BIOCHEM, V267, P6118, DOI 10.1046/j.1432-1327.2000.01703.x; Becker K, 2001, J MED CHEM, V44, P2784, DOI 10.1021/jm001014i; BEREZIN IV, 1976, PRACTICAL COURSE CHE; BIRONAITE DA, 1991, BIOCHIM BIOPHYS ACTA, V1060, P203, DOI 10.1016/S0005-2728(09)91008-8; Biterova EI, 2005, P NATL ACAD SCI USA, V102, P15018, DOI 10.1073/pnas.0504218102; Blumenstiel K, 1999, BIOCHEM PHARMACOL, V58, P1791, DOI 10.1016/S0006-2952(99)00264-6; CARLBERG I, 1985, METHOD ENZYMOL, V113, P484; Cenas N, 2004, J BIOL CHEM, V279, P2583, DOI 10.1074/jbc.M310292200; Cenas N, 2001, BBA-GEN SUBJECTS, V1528, P31, DOI 10.1016/S0304-4165(01)00169-6; CENAS N, 1994, BIOCHEM BIOPH RES CO, V204, P224, DOI 10.1006/bbrc.1994.2448; CENAS N, 1994, ARCH BIOCHEM BIOPHYS, V315, P400, DOI 10.1006/abbi.1994.1517; CENAS N, 2006, ECOTOXICOLOGY EXPLOS; CENAS NK, 1994, BIOCHEMISTRY-US, V33, P2509, DOI 10.1021/bi00175a021; CENAS NK, 1989, BIOCHIM BIOPHYS ACTA, V973, P399, DOI 10.1016/S0005-2728(89)80381-0; Conrad M, 2004, MOL CELL BIOL, V24, P9414, DOI 10.1128/MCB.24.21.9414-9423.2004; Cory S, 2002, NAT REV CANCER, V2, P647, DOI 10.1038/nrc883; Gladyshev VN, 1996, P NATL ACAD SCI USA, V93, P6146, DOI 10.1073/pnas.93.12.6146; Grellier P, 2001, ARCH BIOCHEM BIOPHYS, V393, P199, DOI 10.1006/abbi.2001.2487; Gromer S, 2003, P NATL ACAD SCI USA, V100, P12618, DOI 10.1073/pnas.2134510100; Gromer S, 2004, MED RES REV, V24, P40, DOI 10.1002/med.10051; Gromer S, 1998, J BIOL CHEM, V273, P20096, DOI 10.1074/jbc.273.32.20096; Gromer S, 1997, FEBS LETT, V412, P318, DOI 10.1016/S0014-5793(97)00816-8; Jakupoglu C, 2005, MOL CELL BIOL, V25, P1980, DOI 10.1128/MCB.25.5.1980-1988.2005; Jiang XJ, 2004, ANNU REV BIOCHEM, V73, P87, DOI 10.1146/annurev.biochem.73.011303.073706; Johansson L, 2004, NAT METHODS, V1, P61, DOI 10.1038/NMETH707; Johansson L, 2005, BBA-GEN SUBJECTS, V1726, P1, DOI 10.1016/j.bbagen.2005.05.010; Knox RJ, 2004, METHOD ENZYMOL, V382, P194; Koder RL, 1998, BBA-PROTEIN STRUCT M, V1387, P395, DOI 10.1016/S0167-4838(98)00151-4; Maroziene A, 2001, Z NATURFORSCH C, V56, P1157; Matsui M, 1996, DEV BIOL, V178, P179, DOI 10.1006/dbio.1996.0208; Maurice MM, 1999, ARTHRITIS RHEUM, V42, P2430, DOI 10.1002/1529-0131(199911)42:11<2430::AID-ANR22>3.0.CO;2-6; Miskiniene V, 1999, CANCER LETT, V146, P217, DOI 10.1016/S0304-3835(99)00271-2; Miskiniene V, 1998, BBA-BIOENERGETICS, V1366, P275, DOI 10.1016/S0005-2728(98)00128-5; Nemeikaie-Ceniene A, 2004, ACTA BIOCHIM POL, V51, P1081; Nikitovic D, 1996, J BIOL CHEM, V271, P19180, DOI 10.1074/jbc.271.32.19180; Nonn L, 2003, MOL CELL BIOL, V23, P916, DOI 10.1128/MCB.23.3.916-922.2003; Nordberg J, 1998, J BIOL CHEM, V273, P10835, DOI 10.1074/jbc.273.18.10835; Nordberg J, 2001, FREE RADICAL BIO MED, V31, P1287, DOI 10.1016/S0891-5849(01)00724-9; Paul C, 2000, EXP GERONTOL, V35, P757, DOI 10.1016/S0531-5565(00)00150-9; Perkins C, 2000, BLOOD, V95, P1014, DOI 10.1182/blood.V95.3.1014.003k04_1014_1022; Purohit V, 2000, CHEM RES TOXICOL, V13, P673, DOI 10.1021/tx000002x; Rengby O, 2004, APPL ENVIRON MICROB, V70, P5159, DOI 10.1128/AEM.70.9.5159-5167.2004; Riefler RG, 2002, APPL ENVIRON MICROB, V68, P1690, DOI 10.1128/AEM.68.4.1690-1696.2002; Rossa MM, 2003, PHARMACOL RES, V48, P369, DOI 10.1016/S1043-6618(03)00183-X; Rundlof AK, 2004, ANTIOXID REDOX SIGN, V6, P41, DOI 10.1089/152308604771978336; Sandalova T, 2001, P NATL ACAD SCI USA, V98, P9533, DOI 10.1073/pnas.171178698; Sasada T, 1999, FREE RADICAL BIO MED, V27, P504, DOI 10.1016/S0891-5849(99)00101-X; Seo T, 2005, ANTICANCER RES, V25, P991; SPAIN JC, 1995, ANNU REV MICROBIOL, V49, P523, DOI 10.1146/annurev.mi.49.100195.002515; Tchounwou Paul B, 2003, Rev Environ Health, V18, P203; Tocher JH, 1997, GEN PHARMACOL, V28, P485, DOI 10.1016/S0306-3623(96)00283-2; Viode C, 1999, BIOCHEM PHARMACOL, V57, P549, DOI 10.1016/S0006-2952(98)00324-4; WARDMAN P, 1990, FREE RADICAL RES COM, V8, P219, DOI 10.3109/10715769009053355; WARDMAN P, 1989, J PHYS CHEM REF DATA, V18, P1637, DOI 10.1063/1.555843; Wardman P, 2001, CURR MED CHEM, V8, P739, DOI 10.2174/0929867013372959; Wardman P, 1995, BIOCHEM SOC SYMP, P171, DOI 10.1042/bss0610171; Watanabe N, 2002, AM J PHYSIOL-LUNG C, V283, pL726, DOI 10.1152/ajplung.00025.2002; Witte AB, 2005, FREE RADICAL BIO MED, V39, P696, DOI 10.1016/j.freeradbiomed.2005.04.025; Xia L, 2003, J BIOL CHEM, V278, P2141, DOI 10.1074/jbc.M210456200; Zhon LW, 1998, J BIOL CHEM, V273, P8581, DOI 10.1074/jbc.273.15.8581; Zhong LW, 2000, P NATL ACAD SCI USA, V97, P5854, DOI 10.1073/pnas.100114897	67	102	106	2	19	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 3	2006	281	9					5593	5603		10.1074/jbc.M511972200	http://dx.doi.org/10.1074/jbc.M511972200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	015RQ	16354662	hybrid			2022-12-25	WOS:000235568900035
J	Do, AT; Smeds, E; Spillmann, D; Kusche-Gullberg, M				Do, AT; Smeds, E; Spillmann, D; Kusche-Gullberg, M			Overexpression of heparan sulfate 6-O-sulfotransferases in human embryonic kidney 293 cells results in increased N-acetylglucosaminyl 6-O-sulfation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							D-GLUCOSAMINYL 3-O-SULFOTRANSFERASE; SUBSTRATE-SPECIFICITY; O-SULFOTRANSFERASES; EXPRESSION PATTERNS; MOLECULAR-CLONING; IDURONIC ACID; HUMAN CDNAS; MOUSE; ISOFORMS; 2-O-SULFATION	Heparan sulfate (HS) interacts with a variety of proteins and thus mediates numerous complex biological processes. These interactions critically depend on the patterns of O-sulfate groups within the HS chains that determine binding sites for proteins. In particular the distribution of 6-O-sulfated glucosamine residues influences binding and activity of HS-dependent signaling molecules. The protein binding domains of HS show large structural variability, potentially because of differential expression patterns of HS biosynthetic enzymes along with differences in substrate specificity. To investigate whether different isoforms of HS glucosaminyl 6-O-sulfotransferase (6-OST) give rise to differently sulfated domains, we have introduced mouse 6-OST1, 6-OST2, and 6-OST3 in human embryonic kidney 293 cells and compared the effects of overexpression on HS structure. High expression of any one of the 6-OST enzymes resulted in appreciably increased 6-O-sulfation of N-sulfated as well as N-acetylated glucosamine units. The increased 6-O-sulfation was accompanied by a decrease in nonsulfated as well as in iduronic acid 2-O-sulfated disaccharide structures. Furthermore, overexpression led to an altered HS domain structure, the most striking effect was the formation of extended 6-O-sulfated predominantly N-acetylated HS domains. Although the effect was most noticeable in 6-OST3-expressing cells, these results were largely independent of the particular 6-OST isoform expressed and mainly influenced by the level of overexpression.	Uppsala Univ, Biomed Ctr, Dept Med Biochem & Microbiol, SE-75123 Uppsala, Sweden; Univ Bergen, Dept Biomed, Div Physiol, N-5009 Bergen, Norway	Uppsala University; University of Bergen	Kusche-Gullberg, M (corresponding author), Uppsala Univ, Biomed Ctr, Dept Med Biochem & Microbiol, POB 582, SE-75123 Uppsala, Sweden.	Marion.Kusche@biomed.uib.no	Kusche-Gullberg, Marion/P-4466-2016	Kusche-Gullberg, Marion/0000-0002-5636-1695				Ai XB, 2003, J CELL BIOL, V162, P341, DOI 10.1083/jcb.200212083; Bai XM, 1997, J BIOL CHEM, V272, P23172, DOI 10.1074/jbc.272.37.23172; Bernfield M, 1999, ANNU REV BIOCHEM, V68, P729, DOI 10.1146/annurev.biochem.68.1.729; Bink RJ, 2003, J BIOL CHEM, V278, P31118, DOI 10.1074/jbc.M213124200; BITTER T, 1962, ANAL BIOCHEM, V4, P330, DOI 10.1016/0003-2697(62)90095-7; Bulow HE, 2004, NEURON, V41, P723, DOI 10.1016/S0896-6273(04)00084-4; Chen E, 2005, DEV BIOL, V284, P364, DOI 10.1016/j.ydbio.2005.05.032; Cheung WF, 1996, BIOCHEMISTRY-US, V35, P5250, DOI 10.1021/bi952325b; Crawford BE, 2001, J BIOL CHEM, V276, P21538, DOI 10.1074/jbc.M100880200; Dhoot GK, 2001, SCIENCE, V293, P1663, DOI 10.1126/science.293.5535.1663; Esko JD, 2002, ANNU REV BIOCHEM, V71, P435, DOI 10.1146/annurev.biochem.71.110601.135458; Esko JD, 2001, J CLIN INVEST, V108, P169, DOI 10.1172/JCI200113530; Ford-Perriss M, 2002, GLYCOBIOLOGY, V12, P721, DOI 10.1093/glycob/cwf072; Grobe K, 2002, BBA-GEN SUBJECTS, V1573, P209, DOI 10.1016/S0304-4165(02)00386-0; Habuchi H, 2003, BIOCHEM J, V371, P131, DOI 10.1042/BJ20021259; Habuchi H, 2000, J BIOL CHEM, V275, P2859, DOI 10.1074/jbc.275.4.2859; Holmborn K, 2004, J BIOL CHEM, V279, P42355, DOI 10.1074/jbc.C400373200; Irie A, 2002, DEVELOPMENT, V129, P61; Jemth P, 2003, J BIOL CHEM, V278, P24371, DOI 10.1074/jbc.M212155200; Kamimura K, 2001, J BIOL CHEM, V276, P17014, DOI 10.1074/jbc.M011354200; Kobayashi M, 1997, J BIOL CHEM, V272, P13980, DOI 10.1074/jbc.272.21.13980; Ledin J, 2004, J BIOL CHEM, V279, P42732, DOI 10.1074/jbc.M405382200; Li JP, 2003, J BIOL CHEM, V278, P28363, DOI 10.1074/jbc.C300219200; Li JP, 2001, J BIOL CHEM, V276, P20069, DOI 10.1074/jbc.M011783200; Lindahl U, 1998, J BIOL CHEM, V273, P24979, DOI 10.1074/jbc.273.39.24979; LYON M, 1991, BIOCHEM J, V273, P415, DOI 10.1042/bj2730415; Maccarana M, 1996, J BIOL CHEM, V271, P17804, DOI 10.1074/jbc.271.30.17804; Merry CLR, 2001, J BIOL CHEM, V276, P35429, DOI 10.1074/jbc.M100379200; Morimoto-Tomita M, 2002, J BIOL CHEM, V277, P49175, DOI 10.1074/jbc.M205131200; Nogami K, 2004, J BIOL CHEM, V279, P8219, DOI 10.1074/jbc.M307304200; Pikas DS, 2000, BIOCHEMISTRY-US, V39, P4552, DOI 10.1021/bi992524l; Rong JH, 2001, BIOCHEMISTRY-US, V40, P5548, DOI 10.1021/bi002926p; Rong JH, 2000, BIOCHEM J, V346, P463, DOI 10.1042/0264-6021:3460463; Safaiyan F, 2000, BIOCHEMISTRY-US, V39, P10823, DOI 10.1021/bi000411s; Salmivirta M, 1996, FASEB J, V10, P1270, DOI 10.1096/fasebj.10.11.8836040; SANDERSON PN, 1983, BIOCHEM J, V211, P677, DOI 10.1042/bj2110677; Sedita J, 2004, DEV DYNAM, V231, P782, DOI 10.1002/dvdy.20173; SHAKLEE PN, 1984, BIOCHEM J, V217, P187, DOI 10.1042/bj2170187; SHIVELY JE, 1976, BIOCHEMISTRY-US, V15, P3932, DOI 10.1021/bi00663a005; Shworak NW, 1997, J BIOL CHEM, V272, P28008, DOI 10.1074/jbc.272.44.28008; Shworak NW, 1999, J BIOL CHEM, V274, P5170, DOI 10.1074/jbc.274.8.5170; Smeds E, 2003, BIOCHEM J, V372, P371, DOI 10.1042/BJ20021665; Turnbull J, 2003, BIOCHEM SOC T, V31, P343, DOI 10.1042/BST0310343; Viviano BL, 2004, J BIOL CHEM, V279, P5604, DOI 10.1074/jbc.M310691200; WLAD H, 1994, J BIOL CHEM, V269, P24538; Xia GQ, 2002, J BIOL CHEM, V277, P37912, DOI 10.1074/jbc.M204209200	46	9	10	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 3	2006	281	9					5348	5356		10.1074/jbc.M509584200	http://dx.doi.org/10.1074/jbc.M509584200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	015RQ	16326709	hybrid			2022-12-25	WOS:000235568900005
J	Tirosh, B; Iwakoshi, NN; Glimcher, LH; Ploegh, HL				Tirosh, B; Iwakoshi, NN; Glimcher, LH; Ploegh, HL			Rapid turnover of unspliced Xbp-1 as a factor that modulates the unfolded protein response	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							I MEMBRANE-PROTEIN; KAPPA-B-ALPHA; ENDOPLASMIC-RETICULUM; MESSENGER-RNA; PROTEASOMAL DEGRADATION; TRANSCRIPTION FACTOR; STRESS; US11; INDUCTION; DOMAIN	The mammalian and yeast unfolded protein responses (UPR) share the characteristic of rapid elimination of unspliced Xbp-1 (Xbp-1u) and unspliced Hac1p, respectively. These polypeptides derive from mRNAs, whose splicing is induced upon onset of the UPR, so as to allow synthesis of transcription factors essential for execution of the UPR itself. Whereas in yeast translation of unspliced Hac1p is blocked, mammalian Xbp-1u is synthesized constitutively and eliminated by rapid proteasomal degradation. Here we show that the rate of Xbp-1u degradation approaches its rate of synthesis. The C terminus of XBP-1u ensures its trafficking to the cytoplasm, and is sufficient to impose rapid degradation. Degradation of XBP-1u involves both ubiquitin-dependent and ubiquitin-independent mechanisms, which might explain its unusually rapid turnover. Xbp-1(-/-) mouse embryonic fibroblasts reconstituted with mutants of XBP-1u that show improved stability differentially activate UPR target genes. Unexpectedly, we found that one of the mutants activates transcription of both Xbp-1-specific and non-Xbp-1-dependent UPR targets in response to tunicamycin treatment, even more potently than does wild type Xbp-1. We suggest that the degradation of Xbp-1u is required to prevent uncontrolled activation of the UPR while allowing short dwell times for initiation of this response.	Harvard Univ, Sch Publ Hlth, Whitehead Inst Biomed Res, Boston, MA 02115 USA; Harvard Univ, Sch Publ Hlth, Dept Immunol & Infect Dis, Boston, MA 02115 USA	Harvard University; Harvard T.H. Chan School of Public Health; Massachusetts Institute of Technology (MIT); Whitehead Institute; Harvard University; Harvard T.H. Chan School of Public Health	Ploegh, HL (corresponding author), 9 Cambridge Ctr, Cambridge, MA 02142 USA.	ploegh@wi.mit.edu	Longo, Kenneth A/A-5631-2010		NIAID NIH HHS [AI 32412, 5R37 AI 33456] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI032412, R37AI033456] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Asher G, 2005, MOL CELL, V17, P645, DOI 10.1016/j.molcel.2005.01.020; Asher G, 2002, P NATL ACAD SCI USA, V99, P13125, DOI 10.1073/pnas.202480499; Baumeister P, 2005, MOL CELL BIOL, V25, P4529, DOI 10.1128/MCB.25.11.4529-4540.2005; Beauparlant P, 1996, J BIOL CHEM, V271, P10690, DOI 10.1074/jbc.271.18.10690; Calfon M, 2002, NATURE, V415, P92, DOI 10.1038/415092a; Dantuma NP, 2000, NAT BIOTECHNOL, V18, P538, DOI 10.1038/75406; Ellgaard L, 2001, CURR OPIN CELL BIOL, V13, P431, DOI 10.1016/S0955-0674(00)00233-7; FAIRWELL T, 1984, FEBS LETT, V170, P281, DOI 10.1016/0014-5793(84)81329-0; Furman MH, 2003, J BIOL CHEM, V278, P34804, DOI 10.1074/jbc.M300913200; Iwakoshi NN, 2003, IMMUNOL REV, V194, P29, DOI 10.1034/j.1600-065X.2003.00057.x; KULKA RG, 1988, J BIOL CHEM, V263, P15726; Lee AH, 2003, MOL CELL BIOL, V23, P7448, DOI 10.1128/MCB.23.21.7448-7459.2003; Lee AH, 2003, P NATL ACAD SCI USA, V100, P9946, DOI 10.1073/pnas.1334037100; Ma YJ, 2004, J BIOL CHEM, V279, P13792, DOI 10.1074/jbc.M313724200; Papa FR, 2003, SCIENCE, V302, P1533, DOI 10.1126/science.1090031; Rehm A, 2001, EMBO J, V20, P1573, DOI 10.1093/emboj/20.7.1573; Ruegsegger U, 2001, CELL, V107, P103, DOI 10.1016/S0092-8674(01)00505-0; Schroder M, 2005, ANNU REV BIOCHEM, V74, P739, DOI 10.1146/annurev.biochem.73.011303.074134; Shen XH, 2005, PLOS GENET, V1, P355, DOI 10.1371/journal.pgen.0010037; Sidrauski C, 1997, CELL, V90, P1031, DOI 10.1016/S0092-8674(00)80369-4; Tirosh B, 2005, J VIROL, V79, P2768, DOI 10.1128/JVI.79.5.2768-2779.2005; Travers KJ, 2000, CELL, V101, P249, DOI 10.1016/S0092-8674(00)80835-1; Wiertz EJHJ, 1996, CELL, V84, P769, DOI 10.1016/S0092-8674(00)81054-5; Wiertz EJHJ, 1996, NATURE, V384, P432, DOI 10.1038/384432a0; Yaron A, 1998, NATURE, V396, P590, DOI 10.1038/25159; Yoshida H, 2001, CELL, V107, P881, DOI 10.1016/S0092-8674(01)00611-0	26	92	99	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 3	2006	281	9					5852	5860		10.1074/jbc.M509061200	http://dx.doi.org/10.1074/jbc.M509061200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	015RQ	16332684	hybrid			2022-12-25	WOS:000235568900065
J	Torrents, E; Trevisiol, C; Rotte, C; Hellman, U; Martin, W; Reichard, P				Torrents, E; Trevisiol, C; Rotte, C; Hellman, U; Martin, W; Reichard, P			Euglena gracilis ribonucleotide reductase - The eukaryote class II enzyme and the possible antiquity of eukaryote B12 dependence	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							METHYLMALONYL-COA MUTASE; ESCHERICHIA-COLI; LACTOBACILLUS-LEICHMANNII; EVOLUTION; ADENOSYLCOBALAMIN; MECHANISM; VITAMIN-B-12; EXPRESSION; PROTEIN; ASSAY	Ribonucleotide reductases provide the building blocks for DNA synthesis. Three classes of enzymes are known, differing widely in amino acid sequence but with similar structural motives and allosteric regulation. Class I occurs in eukaryotes and aerobic prokaryotes, class II occurs in aerobic and anaerobic prokaryotes, and class III occurs in anaerobic prokaryotes. The eukaryote Euglena gracilis contains a class II enzyme ( Gleason, F. K., and Hogenkamp, H. P. ( 1970) J. Biol. Chem. 245, 4894 - 4899) and, thus, forms an exception. Class II enzymes depend on vitamin B-12 for their activity. We purified the reductase from Euglena cells, determined partial peptide sequences, identified its cDNA, and purified the recombinant enzyme. Its amino acid sequence and general properties, including its allosteric behavior, were similar to the class II reductase from Lactobacillus leichmannii. Both enzymes belong to a distinct small group of reductases that unlike all other homodimeric reductases are monomeric. They compensate the loss of the second polypeptide of dimeric enzymes by a large insertion in the monomeric chain. Data base searching and sequence comparison revealed a homolog from the eukaryote Dictyostelium discoideum as the closest relative to the Euglena reductase, suggesting that the class II enzyme was present in a common, B-12-dependent, eukaryote ancestor.	Univ Padua, Dept Biol, I-35131 Padua, Italy; Stockholm Univ, Arrhenius Labs Nat Sci, Dept Mol Biol & Funct Genom, SE-10691 Stockholm, Sweden; Univ Dusseldorf, Inst Bot 3, DE-40225 Dusseldorf, Germany; Ludwig Inst Canc Res, Ctr Biomed, SE-75124 Uppsala, Sweden; Karolinska Inst, Dept Biochem, S-17177 Stockholm, Sweden	University of Padua; Stockholm University; Heinrich Heine University Dusseldorf; Ludwig Institute for Cancer Research; Karolinska Institutet	Reichard, P (corresponding author), Univ Padua, Dept Biol, I-35131 Padua, Italy.	reichard@mail.bio.unipd.it	Martin, William F./O-5446-2015; Torrents, Eduard/C-7184-2008; Trevisiol, Chiara/AAX-5369-2020; Trevisiol, Chiara/AAB-9554-2020; Martin, William/C-5680-2008	Martin, William F./0000-0003-1478-6449; Torrents, Eduard/0000-0002-3010-1609; Trevisiol, Chiara/0000-0002-6063-7930; 				Bapteste E, 2002, P NATL ACAD SCI USA, V99, P1414, DOI 10.1073/pnas.032662799; BOOKER S, 1993, P NATL ACAD SCI USA, V90, P8352, DOI 10.1073/pnas.90.18.8352; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Bryant D, 2004, MOL BIOL EVOL, V21, P255, DOI 10.1093/molbev/msh018; CARELL EF, 1980, BIOCHEM J, V188, P573, DOI 10.1042/bj1880573; Croft MT, 2005, NATURE, V438, P90, DOI 10.1038/nature04056; Eklund H, 2001, PROG BIOPHYS MOL BIO, V77, P177, DOI 10.1016/S0079-6107(01)00014-1; Eliasson R, 1999, J BIOL CHEM, V274, P7182, DOI 10.1074/jbc.274.11.7182; Gleason FK, 2002, J BACTERIOL, V184, P6544, DOI 10.1128/JB.184.23.6544-6550.2002; GLEASON FK, 1970, J BIOL CHEM, V245, P4894; HAMILTON FD, 1974, J BIOL CHEM, V249, P4428; HELLMAN U, 1995, ANAL BIOCHEM, V224, P451, DOI 10.1006/abio.1995.1070; Hoffmeister M, 2005, J BIOL CHEM, V280, P4329, DOI 10.1074/jbc.M411010200; Hoffmeister M, 2004, J BIOL CHEM, V279, P22422, DOI 10.1074/jbc.M400913200; HOLMGREN A, 1989, J BIOL CHEM, V264, P13963; HUNTER SH, 1964, ANNU REV PLANT PHYS, V15, P37, DOI DOI 10.1146/ANNUREV.PP.15.060164.000345; Huson DH, 1998, BIOINFORMATICS, V14, P68, DOI 10.1093/bioinformatics/14.1.68; Jordan A, 1998, ANNU REV BIOCHEM, V67, P71, DOI 10.1146/annurev.biochem.67.1.71; Larsson KM, 2004, NAT STRUCT MOL BIOL, V11, P1142, DOI 10.1038/nsmb838; Lawrence CC, 1998, CURR OPIN CHEM BIOL, V2, P650, DOI 10.1016/S1367-5931(98)80097-5; LOCKHART PJ, 1994, MOL BIOL EVOL, V11, P605; MOLLIN DL, 1976, CLIN HAEMATOL, V5, P521; Parle-McDermott A, 2003, MOL GENET METAB, V80, P463, DOI 10.1016/j.ymgme.2003.09.009; POSTON JM, 1977, SCIENCE, V195, P301, DOI 10.1126/science.195.4275.301; PRINGSHEIM EG, 1962, NATURE, V195, P604, DOI 10.1038/195604a0; REICHARD P, 1993, J BIOL CHEM, V268, P8383; Reichard P, 2002, ARCH BIOCHEM BIOPHYS, V397, P149, DOI 10.1006/abbi.2001.2637; REICHARD P, 1993, SCIENCE, V260, P1773, DOI 10.1126/science.8511586; Richards TA, 2005, NATURE, V436, P1113, DOI 10.1038/nature03949; Roth JR, 1996, ANNU REV MICROBIOL, V50, P137, DOI 10.1146/annurev.micro.50.1.137; Sintchak MD, 2002, NAT STRUCT BIOL, V9, P293, DOI 10.1038/nsb774; Sjoberg BM, 1997, STRUCT BOND, V88, P139; SJOBERG BM, 1978, J BIOL CHEM, V253, P6863; Stubble J, 2003, CURR OPIN CHEM BIOL, V7, P183, DOI 10.1016/S1367-5931(03)00025-5; STUTZENBERGER F, 1973, ANAL BIOCHEM, V56, P294, DOI 10.1016/0003-2697(73)90193-0; Thelander L, 1978, Methods Enzymol, V51, P227; Thollesson M, 2004, BIOINFORMATICS, V20, P416, DOI 10.1093/bioinformatics/btg422; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; Torrents E, 2002, J MOL EVOL, V55, P138, DOI 10.1007/s00239-002-2311-7; Torrents E, 2001, J BIOL CHEM, V276, P33488, DOI 10.1074/jbc.M103743200; Watanabe F, 1996, MICROBIOL-SGM, V142, P2631, DOI 10.1099/00221287-142-9-2631; WOLKEN JJ, 1967, EUGLENA, P174	42	20	21	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 3	2006	281	9					5604	5611		10.1074/jbc.M512962200	http://dx.doi.org/10.1074/jbc.M512962200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	015RQ	16368684	hybrid			2022-12-25	WOS:000235568900036
J	Leonard, R; Rendic, D; Rabouille, C; Wilson, IBH; Preat, T; Altmann, F				Leonard, R; Rendic, D; Rabouille, C; Wilson, IBH; Preat, T; Altmann, F			The Drosophila fused lobes gene encodes an N-acetylglucosaminidase involved in N-glycan processing	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ASPARAGINE-LINKED OLIGOSACCHARIDES; ACETYL-D-GLUCOSAMINIDASE; ALPHA-MANNOSIDASE-II; BOMBYX-MORI LARVAE; INSECT CELLS; CAENORHABDITIS-ELEGANS; MOLECULAR-CLONING; FUNCTIONAL-CHARACTERIZATION; GLYCOPROTEIN-BIOSYNTHESIS; SPODOPTERA-FRUGIPERDA	Most processed, e. g. fucosylated, N-glycans on insect glycoproteins terminate in mannose, yet the relevant modifying enzymes require the prior action of N-acetylglucosaminyltransferase I. This led to the hypothesis that a hexosaminidase acts during the course of N-glycan maturation. To determine whether the Drosophila melanogaster genome indeed encodes such an enzyme, a cDNAcorresponding to fused lobes (fdl), a putative beta-N-acetylglucosaminidase with a potential transmembrane domain, was cloned. When expressed in Pichia pastoris, the enzyme exhibited a substrate specificity similar to that previously described for a hexosaminidase activity from Sf-9 cells, i.e. it hydrolyzed exclusively the GlcNAc residue attached to the alpha 1,3-linked mannose of the core pentasaccharide of N-glycans. It also hydrolyzed p-nitrophenyl-N-acetyl-beta-glucosaminide, but not chitooligosaccharides; in contrast, Drosophila HEXO1 and HEXO2 expressed in Pichia cleaved both these substrates but not N-glycans. The localization of recombinant FDL tagged with green fluorescent protein in Drosophila S2 cells by immunoelectron microscopy showed that this enzyme transits through the Golgi, is present on the plasma membrane and in multivesicular bodies, and is secreted. Finally, the N-glycans of two lines of fdl mutant flies were analyzed by mass spectrometry and reversed-phase high-performance liquid chromatography. The ratio of structures with terminal GlcNAc over those without (i.e. paucimannosidic N-glycans) was drastically increased in the fdl-deficient flies. Therefore, we conclude that the fdl gene encodes a novel hexosaminidase responsible for the occurrence of paucimannosidic N-glycans in Drosophila.	Univ Nat Resources & Appl Life Sci, Dept Chem, Glycobiol Grp, A-1190 Vienna, Austria; Univ Utrecht, Med Ctr, Dept Cell Biol, NL-3584 CX Utrecht, Netherlands; Univ Utrecht, Med Ctr, Inst Biomembranes, NL-3584 CX Utrecht, Netherlands; CNRS, F-91190 Gif Sur Yvette, France	University of Natural Resources & Life Sciences, Vienna; Utrecht University; Utrecht University; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Saclay	Leonard, R (corresponding author), Univ Nat Resources & Appl Life Sci, Dept Chem, Glycobiol Grp, Muthgasse 18, A-1190 Vienna, Austria.	renaud.leonard@boku.ac.at	Wilson, Iain/B-3326-2009; Rendic, Dubravko/A-9368-2010	Wilson, Iain/0000-0001-8996-1518; Leonard, Renaud/0000-0001-5023-1032; Altmann, Friedrich/0000-0002-0112-7877; Preat, Thomas/0000-0001-9976-1763				Ailor E, 2000, GLYCOBIOLOGY, V10, P837, DOI 10.1093/glycob/10.8.837; ALTMANN F, 1995, J BIOL CHEM, V270, P17344, DOI 10.1074/jbc.270.29.17344; Altmann F, 2001, BIOCHIMIE, V83, P703, DOI 10.1016/S0300-9084(01)01297-4; Altmann F, 1999, GLYCOCONJUGATE J, V16, P109, DOI 10.1023/A:1026488408951; ALTMANN F, 1993, GLYCOBIOLOGY, V3, P619, DOI 10.1093/glycob/3.6.619; ALTMANN F, 1995, GLYCOCONJUGATE J, V12, P150, DOI 10.1007/BF00731359; Ayyar S, 2003, DEVELOPMENT, V130, P2841, DOI 10.1242/dev.00513; Bencurova M, 2003, BIOCHIMIE, V85, P413, DOI 10.1016/S0300-9084(03)00072-5; Boisson M, 2001, EMBO J, V20, P1010, DOI 10.1093/emboj/20.5.1010; Boquet I, 2000, J NEUROBIOL, V42, P33; Bruckner K, 2000, NATURE, V406, P411, DOI 10.1038/35019075; Cattaneo F, 2002, INSECT BIOCHEM MOLEC, V32, P929, DOI 10.1016/S0965-1748(02)00031-0; CORPET F, 1988, NUCLEIC ACIDS RES, V16, P10881, DOI 10.1093/nar/16.22.10881; Ding HB, 2003, PROTEIN EXPRES PURIF, V31, P34, DOI 10.1016/S1046-5928(03)00138-4; Donaldson M, 1999, BIOTECHNOL PROGR, V15, P168, DOI 10.1021/bp9900211; Fabini G, 2001, J BIOL CHEM, V276, P28058, DOI 10.1074/jbc.M100573200; Fitchette-Laine AC, 1997, PLANT J, V12, P1411, DOI 10.1046/j.1365-313x.1997.12061411.x; Haines N, 2005, GLYCOBIOLOGY, V15, P335, DOI 10.1093/glycob/cwi017; Haslam SM, 2003, BIOCHIMIE, V85, P25, DOI 10.1016/S0300-9084(03)00041-5; HENRISSAT B, 1993, BIOCHEM J, V293, P781, DOI 10.1042/bj2930781; Hollister J, 2002, BIOCHEMISTRY-US, V41, P15093, DOI 10.1021/bi026455d; Hollister JR, 1998, GLYCOBIOLOGY, V8, P473, DOI 10.1093/glycob/8.5.473; Hsu TA, 1997, J BIOL CHEM, V272, P9062; Kawar Z, 2001, J BIOL CHEM, V276, P16335, DOI 10.1074/jbc.M100119200; Kim YK, 2005, BIOTECHNOL BIOENG, V92, P452, DOI 10.1002/bit.20605; Koles K, 2004, J BIOL CHEM, V279, P4346, DOI 10.1074/jbc.M309912200; KUBELKA V, 1993, EUR J BIOCHEM, V213, P1193, DOI 10.1111/j.1432-1033.1993.tb17870.x; Landis G, 2001, GENETICS, V158, P1167; Lerouge P, 1998, PLANT MOL BIOL, V38, P31, DOI 10.1023/A:1006012005654; Liou W, 1996, HISTOCHEM CELL BIOL, V106, P41, DOI 10.1007/BF02473201; Mahuran DJ, 1999, BBA-MOL BASIS DIS, V1455, P105, DOI 10.1016/S0925-4439(99)00074-5; Marchal I, 1999, GLYCOBIOLOGY, V9, P645, DOI 10.1093/glycob/9.7.645; Marchal I, 2001, BIOL CHEM, V382, P151, DOI 10.1515/BC.2001.023; Matsuo I, 2003, BIOSCI BIOTECH BIOCH, V67, P646, DOI 10.1271/bbb.67.646; Misaki R, 2003, BIOCHEM BIOPH RES CO, V311, P979, DOI 10.1016/j.bbrc.2003.10.094; Morton CL, 2000, MOL BIOTECHNOL, V16, P193, DOI 10.1385/MB:16:3:193; Munro S, 2000, CURR BIOL, V10, P813, DOI 10.1016/S0960-9822(00)00578-9; NAGAMATSU Y, 1995, BIOSCI BIOTECH BIOCH, V59, P219, DOI 10.1271/bbb.59.219; OGONAH OW, 1995, BIOCHEM SOC T, V23, pS100, DOI 10.1042/bst023100s; Paschinger K, 2004, J BIOL CHEM, V279, P49588, DOI 10.1074/jbc.M408978200; Paschinger K, 2005, GLYCOBIOLOGY, V15, P463, DOI 10.1093/glycob/cwi028; Rabouille C, 1999, J CELL SCI, V112, P3319; RABOUILLE C, 1995, J CELL SCI, V108, P1617; Sarkar M, 2001, BIOL CHEM, V382, P209, DOI 10.1515/BC.2001.028; SCHACHTER H, 1986, BIOCHEM CELL BIOL, V64, P163, DOI 10.1139/o86-026; SOMMER U, 1991, ARCH INSECT BIOCHEM, V17, P3, DOI 10.1002/arch.940170103; SOMMER U, 1991, ARCH INSECT BIOCHEM, V18, P45, DOI 10.1002/arch.940180105; Staudacher E, 1998, GLYCOCONJUGATE J, V15, P355, DOI 10.1023/A:1006969701231; Tan J, 1996, AM J HUM GENET, V59, P810; TOMIYA N, 1991, ANAL BIOCHEM, V193, P90, DOI 10.1016/0003-2697(91)90047-W; Tomiya N, 2003, ACCOUNTS CHEM RES, V36, P613, DOI 10.1021/ar020202v; TRETTER V, 1993, INT ARCH ALLERGY IMM, V102, P259, DOI 10.1159/000236534; Vadaie N, 2004, J BIOL CHEM, V279, P33501, DOI 10.1074/jbc.M404925200; Vadaie N, 2002, GLYCOBIOLOGY, V12, P589, DOI 10.1093/glycob/cwf074; VITALE A, 1984, J CELL BIOL, V99, P133, DOI 10.1083/jcb.99.1.133; Wagner R, 1996, GLYCOBIOLOGY, V6, P165, DOI 10.1093/glycob/6.2.165; Wagner R, 1996, J VIROL, V70, P4103, DOI 10.1128/JVI.70.6.4103-4109.1996; WANG AM, 1990, J BIOL CHEM, V265, P21859; Wang Y, 2002, BBA-GEN SUBJECTS, V1573, P301, DOI 10.1016/S0304-4165(02)00397-5; Watanabe S, 2002, J BIOL CHEM, V277, P5090, DOI 10.1074/jbc.M110548200; WILLIAMS PJ, 1991, BIOCHIM BIOPHYS ACTA, V1075, P146, DOI 10.1016/0304-4165(91)90245-C; YAMAMOTO S, 1989, J BIOCHEM-TOKYO, V105, P547, DOI 10.1093/oxfordjournals.jbchem.a122703; Zhang WL, 2003, BIOCHEM J, V372, P53, DOI 10.1042/BJ20021931; [No title captured]	64	122	128	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 24	2006	281	8					4867	4875		10.1074/jbc.M511023200	http://dx.doi.org/10.1074/jbc.M511023200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	013RF	16339150	hybrid			2022-12-25	WOS:000235426200037
J	Tang, HB; Veldman, MB; Goldman, D				Tang, HB; Veldman, MB; Goldman, D			Characterization of a muscle-specific enhancer in human MuSK promoter reveals the essential role of myogenin in controlling activity-dependent gene regulation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NICOTINIC ACETYLCHOLINE-RECEPTOR; DELTA-SUBUNIT PROMOTER; ELECTRICAL-ACTIVITY; NEUROMUSCULAR-JUNCTION; SKELETAL-MUSCLE; IN-VIVO; EXPRESSION; TRANSCRIPTION; PATHWAY; SYNAPSE	Neuromuscular synaptogenesis is initiated by the release of agrin from motor neurons and the activation of the receptor tyrosine kinase, MuSK, in the postsynaptic membrane. MuSK gene expression is regulated by nerve-derived agrin and muscle activity. Agrin stimulates synapse-specific MuSK gene expression by activating GABP(alpha beta) transcription factors in endplate-associated myonuclei. In contrast, the mechanism by which muscle activity regulates MuSK gene expression is not known. We report on a 60-bp MuSK enhancer that confers promoter regulation by muscle differentiation, changes in intracellular calcium, and muscle activity. Within this enhancer, we identified a single E-box that is essential for this regulation. This E-box binds myogenin, and we showed that myogenin is necessary for not only MuSK but also nAChR gene regulation by muscle activity. Surprisingly, the same E-box functions in vivo to mediate muscle-specific and differentiation-dependent gene induction in zebrafish, suggesting an evolutionary conserved mechanism of regulation of synaptic protein gene expression.	Univ Michigan, Mol & Behav Neurosci Inst, Ann Arbor, MI 48109 USA; Univ Michigan, Dept Biol Chem, Ann Arbor, MI 48109 USA	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan	Goldman, D (corresponding author), Univ Michigan, Mol & Behav Neurosci Inst, 205 Zina Pitcher Pl, Ann Arbor, MI 48109 USA.	neuroman@umich.edu			NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS025153] Funding Source: NIH RePORTER; NINDS NIH HHS [R01 NS25153] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Adams L, 1998, J NEUROBIOL, V35, P245, DOI 10.1002/(SICI)1097-4695(19980605)35:3<245::AID-NEU2>3.0.CO;2-Z; Altiok N, 1997, EMBO J, V16, P717, DOI 10.1093/emboj/16.4.717; BESSEREAU JL, 1994, P NATL ACAD SCI USA, V91, P1304, DOI 10.1073/pnas.91.4.1304; Bessereau JL, 1998, J BIOL CHEM, V273, P12786, DOI 10.1074/jbc.273.21.12786; Biesiada E, 1999, MOL CELL BIOL, V19, P2577; Bowen DC, 1998, DEV BIOL, V199, P309, DOI 10.1006/dbio.1998.8936; BRAUN T, 1995, EMBO J, V14, P1176, DOI 10.1002/j.1460-2075.1995.tb07101.x; CHAHINE KG, 1992, DEVELOPMENT, V115, P213; Fromm L, 1998, GENE DEV, V12, P3074, DOI 10.1101/gad.12.19.3074; GILMOUR BP, 1995, DEV BIOL, V168, P416, DOI 10.1006/dbio.1995.1091; Goldman D, 2001, TRANSGENIC RES, V10, P21, DOI 10.1023/A:1008998832552; HASTY P, 1993, NATURE, V364, P501, DOI 10.1038/364501a0; Kim CH, 2005, MOL CELL BIOL, V25, P5329, DOI 10.1128/MCB.25.13.5329-5338.2005; Kim CH, 2003, J BIOL CHEM, V278, P38522, DOI 10.1074/jbc.M305058200; Lacazette E, 2003, J CELL BIOL, V161, P727, DOI 10.1083/jcb.200210156; Liu SH, 2000, J BIOL CHEM, V275, P41364, DOI 10.1074/jbc.M004172200; Macpherson P, 2002, J BIOL CHEM, V277, P15638, DOI 10.1074/jbc.M109864200; Macpherson PCD, 2004, J CELL BIOCHEM, V91, P821, DOI 10.1002/jcb.10784; Sanes JR, 2001, NAT REV NEUROSCI, V2, P791, DOI 10.1038/35097557; Schaeffer L, 1998, EMBO J, V17, P3078, DOI 10.1093/emboj/17.11.3078; SMALE ST, 1989, CELL, V57, P103, DOI 10.1016/0092-8674(89)90176-1; Steinke JW, 2000, NUCLEIC ACIDS RES, V28, P2726, DOI 10.1093/nar/28.14.2726; SU CT, 1995, FEBS LETT, V366, P131, DOI 10.1016/0014-5793(95)00496-V; Sunesen M, 2003, J NEUROCYTOL, V32, P677, DOI 10.1023/B:NEUR.0000020616.53664.80; Tang HB, 2004, CELL SIGNAL, V16, P551, DOI 10.1016/j.cellsig.2003.09.006; Tang HB, 2001, J BIOL CHEM, V276, P26057, DOI 10.1074/jbc.M101670200; TANG JC, 1994, DEVELOPMENT, V120, P1799; Tansey MG, 1996, J CELL BIOL, V134, P465, DOI 10.1083/jcb.134.2.465; Tzahar E, 1996, MOL CELL BIOL, V16, P5276; Walke W, 1996, J NEUROSCI, V16, P3641; Wang ZZ, 2003, J NEUROSCI, V23, P5161	31	21	21	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 17	2006	281	7					3943	3953		10.1074/jbc.M511317200	http://dx.doi.org/10.1074/jbc.M511317200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	011NN	16361705	hybrid			2022-12-25	WOS:000235275300022
J	Hirao, J; Arakawa, S; Watanabe, K; Ito, K; Furukawa, T				Hirao, J; Arakawa, S; Watanabe, K; Ito, K; Furukawa, T			Effects of restricted feeding on daily fluctuations of hepatic functions including P450 monooxygenase activities in rats	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							O-DEALKYLASE ACTIVITIES; SUPRACHIASMATIC NUCLEUS; GROWTH-HORMONE; CIRCADIAN OSCILLATORS; PERIPHERAL-TISSUES; LIVER-MICROSOMES; METABOLISM; GHRELIN; 7-ALKOXYCOUMARIN; RHYTHM	Hepatic P450 monooxygenase activities, assessed by measurement of 7-alkoxycoumarin O-dealkylase ( ACD) activities, show obvious daily fluctuations in male rats with high values during the dark period and low values during the light period. We have already confirmed that the ACD activities are controlled by the suprachiasmatic nucleus ( SCN), which is well known as the oscillator of circadian rhythm. Recently, it is reported that circadian oscillators exist not only in the SCN but also in peripheral organs. To date, it is unclear which circadian oscillators predominantly drive the daily fluctuations of hepatic ACD activities. To address this question, we examined the effects of restricted feeding, which uncouples the circadian oscillators in the liver from the central pacemaker in the SCN, on the daily fluctuations in hepatic ACD activities in male rats. Here we show that restricted feeding inverts the oscillation phase of the daily fluctuations in hepatic ACD activities. Regarding the hepatic P450 content, there were no fluctuations between the light and dark periods under ad libitum and restricted feeding conditions. Therefore, it is considered that the daily fluctuations in hepatic ACD activities are predominantly driven by the circadian factors in peripheral organs rather than by the oscillator in the SCN directly.	Sankyo Co Ltd, Med Safety Res Labs, Shizuoka 4370065, Japan	Daiichi Sankyo Company Limited	Hirao, J (corresponding author), Sankyo Co Ltd, Med Safety Res Labs, 717,Horikoshi, Shizuoka 4370065, Japan.	jhirao@sankyo.co.jp						Balsalobre A, 1998, CELL, V93, P929, DOI 10.1016/S0092-8674(00)81199-X; Damiola F, 2000, GENE DEV, V14, P2950, DOI 10.1101/gad.183500; Davis RA, 2002, J LIPID RES, V43, P533; Dunlap JC, 1999, CELL, V96, P271, DOI 10.1016/S0092-8674(00)80566-8; Furukawa T, 1999, TOXICOL LETT, V108, P11, DOI 10.1016/S0378-4274(99)00065-X; Furukawa T, 1999, ARCH TOXICOL, V73, P367, DOI 10.1007/s002040050675; Furukawa T, 1999, TOXICOL APPL PHARM, V161, P219, DOI 10.1006/taap.1999.8808; Gibson UEM, 1996, GENOME RES, V6, P995, DOI 10.1101/gr.6.10.995; Heid CA, 1996, GENOME RES, V6, P986, DOI 10.1101/gr.6.10.986; Hirota T, 2004, ZOOL SCI, V21, P359, DOI 10.2108/zsj.21.359; Honkakoski P, 2003, ANN MED, V35, P172, DOI 10.1080/07853890310008224; INOUYE SIT, 1994, NEUROSCI RES, V20, P109, DOI 10.1016/0168-0102(94)90029-9; Kojima M, 1999, NATURE, V402, P656, DOI 10.1038/45230; Lewis DFV, 2004, PHARMACOGENOMICS, V5, P305, DOI 10.1517/phgs.5.3.305.29827; LopezMolina L, 1997, EMBO J, V16, P6762, DOI 10.1093/emboj/16.22.6762; LOWRY OH, 1951, J BIOL CHEM, V193, P265; LU AYH, 1969, J BIOL CHEM, V244, P3714; Lu SC, 1999, FASEB J, V13, P1169, DOI 10.1096/fasebj.13.10.1169; MATSUBARA T, 1983, JPN J PHARMACOL, V33, P41, DOI 10.1254/jjp.33.41; Meier U, 2004, CLIN CHEM, V50, P1511, DOI 10.1373/clinchem.2004.032482; Mugford CA, 1998, DRUG METAB REV, V30, P441, DOI 10.3109/03602539808996322; Nakazato M, 2001, NATURE, V409, P194, DOI 10.1038/35051587; NOSHIRO M, 1990, J BIOL CHEM, V265, P10036; Noshiro M, 2004, GENES CELLS, V9, P317, DOI 10.1111/j.1356-9597.2004.00722.x; OKUNO H, 1989, JPN J PHARMACOL, V50, P1, DOI 10.1254/jjp.50.1; OMURA T, 1964, J BIOL CHEM, V239, P2379; RALPH MR, 1990, SCIENCE, V247, P975, DOI 10.1126/science.2305266; Reppert SM, 2002, NATURE, V418, P935, DOI 10.1038/nature00965; RUSAK B, 1979, PHYSIOL REV, V59, P449, DOI 10.1152/physrev.1979.59.3.449; Rutter J, 2002, ANNU REV BIOCHEM, V71, P307, DOI 10.1146/annurev.biochem.71.090501.142857; Schibler U, 2002, CELL, V111, P919, DOI 10.1016/S0092-8674(02)01225-4; SHARMA C, 1963, J BIOL CHEM, V238, P3840; Smid M, 2003, BIOINFORMATICS, V19, P2065, DOI 10.1093/bioinformatics/btg282; SOUCEK P, 1992, XENOBIOTICA, V22, P83; St Pierre DH, 2003, NEWS PHYSIOL SCI, V18, P242; Stokkan KA, 2001, SCIENCE, V291, P490, DOI 10.1126/science.291.5503.490; Turek FW, 2005, SCIENCE, V308, P1043, DOI 10.1126/science.1108750; Van Schaftingen E, 2002, BIOCHEM J, V362, P513, DOI 10.1042/0264-6021:3620513; VanSchaftingen E, 1997, BIOCHEM SOC T, V25, P136, DOI 10.1042/bst0250136; Yabe D, 2003, P NATL ACAD SCI USA, V100, P3155, DOI 10.1073/pnas.0130116100; Yamazaki S, 2000, SCIENCE, V288, P682, DOI 10.1126/science.288.5466.682; YOSHIMURA J, 1987, STAT ANAL TOXICITY D, P28	42	23	25	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 10	2006	281	6					3165	3171		10.1074/jbc.M511194200	http://dx.doi.org/10.1074/jbc.M511194200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	009QV	16332680	hybrid			2022-12-25	WOS:000235128200019
J	Harikumar, KG; Hosohata, K; Pinon, DI; Miller, LJ				Harikumar, KG; Hosohata, K; Pinon, DI; Miller, LJ			Use of probes with fluorescence indicator distributed throughout the pharmacophore to examine the peptide agonist-binding environment of the family B G protein-coupled secretin receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VASOACTIVE INTESTINAL POLYPEPTIDE; AMINO-TERMINAL TAIL; SPATIAL APPROXIMATION; CHOLECYSTOKININ RECEPTOR; MOLECULAR PHARMACOLOGY; CONFORMATIONAL-CHANGES; TRANSMEMBRANE HELICES; EXTRACELLULAR DOMAIN; CALCITONIN RECEPTOR; DISULFIDE PATTERN	Fluorescence techniques can provide insight into the environment of fluorescence indicators situated at distinct sites within a ligand as it is bound to its receptor. Here, we have developed a series of analogues of the 27-amino acid hormone, secretin, that incorporate a fluorescent Alexa Fluor 488 into the amino terminus, the carboxyl terminus, and positions 13 and 22. Each probe bound with high affinity and was biologically active, stimulating full cAMP responses in receptor-bearing Chinese hamster ovary-SecR cells. Treatment with 10 mu M guanosine 5'-(beta, gamma-imido) triphosphate (GppNHp) shifted the agonist-bound receptor into a G protein-uncoupled low affinity state. Fluorescence spectra for the probes in solution and bound to the receptor demonstrated maximal emission at 521 nm after excitation at 481 nm. Collisional quenching of fluorescence with potassium iodide revealed that Alexa at the amino terminus of secretin was more accessible than at the other three positions within the probes. Of note, quenching constants for each probe were higher when bound in the active state than in the G protein-uncoupled, low affinity state of the receptor, with the most marked changes occurring for the two midregion probes. Anisotropy values and fluorescence lifetimes confirmed this, with higher anisotropy and longer lifetimes observed for position 13 and 22 probes bound to the receptor in its uncoupled state than in its active state. These observations suggest that the amino terminus of secretin as docked to the receptor is most exposed to the hydrophilic aqueous milieu, and that the major changes in conformation and exposure to the medium occur in the midregion of secretin. Photoaffinity labeling studies have demonstrated approximation of each of these ligand residues with distinct receptor residues. Combining the fluorescence data with photoaffinity labeling data provides insights into the conformation and dynamics of a natural peptide ligand docked to a Family B G protein-coupled receptor.	Mayo Clin, Ctr Canc, Scottsdale, AZ 85259 USA; Mayo Clin, Dept Mol Pharmacol & Expt Therapeut, Scottsdale, AZ 85259 USA	Mayo Clinic; Mayo Clinic Phoenix; Mayo Clinic; Mayo Clinic Phoenix	Miller, LJ (corresponding author), 13400 E Shea Blvd, Scottsdale, AZ 85259 USA.	miller@mayo.edu			NIDDK NIH HHS [DK46577] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK046577] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Altenbach C, 2001, BIOCHEMISTRY-US, V40, P15493, DOI 10.1021/bi011545o; Asmann YW, 2000, MOL PHARMACOL, V58, P911, DOI 10.1124/mol.58.5.911; Bazarsuren A, 2002, BIOPHYS CHEM, V96, P305, DOI 10.1016/S0301-4622(02)00023-6; Dong MQ, 2000, J BIOL CHEM, V275, P26032, DOI 10.1074/jbc.M000612200; Dong MQ, 2004, J BIOL CHEM, V279, P2894, DOI 10.1074/jbc.M310407200; Dong MQ, 2003, J BIOL CHEM, V278, P48300, DOI 10.1074/jbc.M309166200; Dong MQ, 1999, J BIOL CHEM, V274, P19161, DOI 10.1074/jbc.274.27.19161; Dong MQ, 2002, MOL ENDOCRINOL, V16, P2490, DOI 10.1210/me.2002-0111; Dong MQ, 2002, RECEPTOR CHANNEL, V8, P189, DOI 10.1080/10606820213686; Dong MQ, 2000, ANN NY ACAD SCI, V921, P381; Dong MQ, 1999, J BIOL CHEM, V274, P903, DOI 10.1074/jbc.274.2.903; Donnelly D, 1997, FEBS LETT, V409, P431, DOI 10.1016/S0014-5793(97)00546-2; Farrens DL, 1996, SCIENCE, V274, P768, DOI 10.1126/science.274.5288.768; Gether U, 1997, EMBO J, V16, P6737, DOI 10.1093/emboj/16.22.6737; Ghanouni P, 2001, P NATL ACAD SCI USA, V98, P5997, DOI 10.1073/pnas.101126198; Grace CRR, 2004, P NATL ACAD SCI USA, V101, P12836, DOI 10.1073/pnas.0404702101; Grauschopf U, 2000, BIOCHEMISTRY-US, V39, P8878, DOI 10.1021/bi0001426; Harikumar KG, 2005, J BIOL CHEM, V280, P1044, DOI 10.1074/jbc.M409480200; Harikumar KG, 2004, MOL PHARMACOL, V65, P28, DOI 10.1124/mol.65.1.28; Harikumar KG, 2002, J BIOL CHEM, V277, P18552, DOI 10.1074/jbc.M201164200; Holtmann MH, 1996, J PHARMACOL EXP THER, V279, P555; Holtmann MH, 1996, J BIOL CHEM, V271, P14944, DOI 10.1074/jbc.271.25.14944; HOLTMANN MH, 1995, J BIOL CHEM, V270, P14394, DOI 10.1074/jbc.270.24.14394; ISHIHARA T, 1991, EMBO J, V10, P1635, DOI 10.1002/j.1460-2075.1991.tb07686.x; Ji TH, 1998, J BIOL CHEM, V273, P17299, DOI 10.1074/jbc.273.28.17299; Kobilka B, 2004, MOL PHARMACOL, V65, P1060, DOI 10.1124/mol.65.5.1060; Laburthe M, 1996, ANN NY ACAD SCI, V805, P94; Laburthe M, 2002, RECEPTOR CHANNEL, V8, P137, DOI 10.1080/10606820290005191; Lisenbee CS, 2005, J BIOL CHEM, V280, P12330, DOI 10.1074/jbc.M414016200; MUNSON PJ, 1980, ANAL BIOCHEM, V107, P220, DOI 10.1016/0003-2697(80)90515-1; Palczewski K, 2000, SCIENCE, V289, P739, DOI 10.1126/science.289.5480.739; Perrin MH, 2001, J BIOL CHEM, V276, P31528, DOI 10.1074/jbc.M101838200; Pham V, 2005, J BIOL CHEM, V280, P28610, DOI 10.1074/jbc.M503272200; Purdue BW, 2002, RECEPTOR CHANNEL, V8, P243, DOI 10.1080/10606820213681; Qi LJ, 1997, BIOCHEMISTRY-US, V36, P12442, DOI 10.1021/bi970997r; ULRICH CD, 1993, GASTROENTEROLOGY, V105, P1534, DOI 10.1016/0016-5085(93)90162-6; Ulrich CD, 1998, GASTROENTEROLOGY, V114, P382, DOI 10.1016/S0016-5085(98)70491-3; ULRICH CD, 1993, BIOCHEM BIOPH RES CO, V193, P204, DOI 10.1006/bbrc.1993.1610; Zang MW, 2003, MOL PHARMACOL, V63, P993, DOI 10.1124/mol.63.5.993	39	22	22	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 3	2006	281	5					2543	2550		10.1074/jbc.M509197200	http://dx.doi.org/10.1074/jbc.M509197200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	006XT	16319066	hybrid			2022-12-25	WOS:000234931800017
J	Polevoda, B; Span, L; Sherman, F				Polevoda, B; Span, L; Sherman, F			The yeast translation release factors Mrf1p and Sup45p (eRF1) are methylated, respectively, by the methyltransferases Mtq1p and Mtq2p	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PEPTIDE-CHAIN TERMINATION; ESCHERICHIA-COLI; GGQ MOTIF; SACCHAROMYCES-CEREVISIAE; PROTEIN METHYLATION; SEQUENCE MOTIFS; GTPASE ACTIVITY; MUTANT LACKING; IN-VIVO; GENE	The translation release factors (RFs) RF1 and RF2 of Escherichia coli are methylated at the N-5-glutamine of the GGQ motif by PrmC methyltransferase. This motif is conserved in organisms from bacteria to higher eukaryotes. The Saccharomyces cerevisiae RFs, mitochondrial Mrf1p and cytoplasmic Sup45p (eRF1), have sequence similarities to the bacterial RFs, including the potential site of glutamine methylation in the GGQ motif. A computational analysis revealed two yeast proteins, Mtq1p and Mtq2p, that have strong sequence similarity to PrmC. Mass spectrometric analysis demonstrated that Mtq1p and Mtq2p methylate Mrf1p and Sup45p, respectively, in vivo. A tryptic peptide of Mrf1p, GGQHVNTTD-SAVR, containing the GGQ motif was found to be similar to 50% methylated at the glutamine residue in the normal strain but completely unmodified in the peptide from mtq1-Delta. Moreover, Mtq1p methyltransferase activity was observed in an in vitro assay. In similar experiments, it was determined that Mtq2p methylates Sup45p. The Sup45p methylation by Mtq2p was recently confirmed independently (Heurgue-Hamard, V., Champ, S., Mora, L., Merkulova-Rainon, T., Kisselev, L. L., and Buckingham, R. H. (2005) J. Biol. Chem. 280, 2439 - 2445). Analysis of the deletion mutants showed that although mtq1-Delta had only moderate growth defects on nonfermentable carbon sources, the mtq2-Delta had multiple phenotypes, including cold sensitivity and sensitivity to translation fidelity antibiotics paromomycin and geneticin, to high salt and calcium concentrations, to polymyxin B, and to caffeine. Also, the mitochondrial mit(-) mutation, cox2-V25, containing a premature stop mutation, was suppressed by mtq1-Delta. Most interestingly, the mtq2-Delta was significantly more resistant to the anti-microtubule drugs thiabendazole and benomyl, suggesting that Mtq2p may also methylate certain microtubule-related proteins.	Univ Rochester, Med Ctr, Dept Biochem & Biophys, Rochester, NY 14642 USA	University of Rochester	Sherman, F (corresponding author), Univ Rochester, Med Ctr, Dept Biochem & Biophys, 601 Elmwood Ave, Rochester, NY 14642 USA.	Fred_Sherman@urmc.rochester.edu	Polevoda, Bogdan/A-4880-2008		NIGMS NIH HHS [GM12702] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Askarian-Amiri ME, 2000, J BIOL CHEM, V275, P17241, DOI 10.1074/jbc.M910448199; BEAUDET AL, 1971, P NATL ACAD SCI USA, V68, P619, DOI 10.1073/pnas.68.3.619; BOGUSLAWSKI G, 1985, MOL GEN GENET, V199, P401, DOI 10.1007/BF00330749; BOGUTA M, 1986, J GEN MICROBIOL, V132, P2087; Bonnefoy N, 2000, MOL GEN GENET, V262, P1036, DOI 10.1007/PL00008646; Borchsenius AS, 2000, CURR GENET, V37, P285, DOI 10.1007/s002940050529; Clarke S, 2002, P NATL ACAD SCI USA, V99, P1104, DOI 10.1073/pnas.042004099; CONDEELIS J, 1995, TRENDS BIOCHEM SCI, V20, P169, DOI 10.1016/S0968-0004(00)88998-7; Dincbas-Renqvist V, 2000, EMBO J, V19, P6900, DOI 10.1093/emboj/19.24.6900; Freistroffer DV, 1997, EMBO J, V16, P4126, DOI 10.1093/emboj/16.13.4126; FROLOVA L, 1994, NATURE, V372, P701, DOI 10.1038/372701a0; Frolova LY, 2000, RNA, V6, P381, DOI 10.1017/S135583820099143X; Grant PA, 2001, GENOME BIOL, V2; Heurgue-Hamard V, 2005, J BIOL CHEM, V280, P2439, DOI 10.1074/jbc.M407252200; Heurgue-Hamard V, 2002, EMBO J, V21, P769, DOI 10.1093/emboj/21.4.769; Huh WK, 2003, NATURE, V425, P686, DOI 10.1038/nature02026; Inge-Vechtomov S, 2003, BIOL CELL, V95, P195, DOI 10.1016/S0248-4900(03)00035-2; JUKES TH, 1993, COMP BIOCHEM PHYS B, V106, P489, DOI 10.1016/0305-0491(93)90122-L; KAGAN RM, 1994, ARCH BIOCHEM BIOPHYS, V310, P417, DOI 10.1006/abbi.1994.1187; Kim C, 2001, J MOL BIOL, V307, P119, DOI 10.1006/jmbi.2000.4389; Kisselev LL, 2000, TRENDS BIOCHEM SCI, V25, P561, DOI 10.1016/S0968-0004(00)01669-8; LHOEST J, 1981, EUR J BIOCHEM, V121, P33, DOI 10.1111/j.1432-1033.1981.tb06425.x; LHOEST J, 1984, EUR J BIOCHEM, V141, P585, DOI 10.1111/j.1432-1033.1984.tb08233.x; LHOEST J, 1977, MOL GEN GENET, V154, P175, DOI 10.1007/BF00330833; LHOEST J, 1990, PROTEIN METHYLATION, P61; MALONE T, 1995, J MOL BIOL, V253, P618, DOI 10.1006/jmbi.1995.0577; McBride AE, 2001, CELL, V106, P5, DOI 10.1016/S0092-8674(01)00423-8; MILMAN G, 1969, P NATL ACAD SCI USA, V63, P183, DOI 10.1073/pnas.63.1.183; Mora L, 2003, MOL MICROBIOL, V47, P267, DOI 10.1046/j.1365-2958.2003.03301.x; Nakahigashi K, 2002, P NATL ACAD SCI USA, V99, P1473, DOI 10.1073/pnas.032488499; PAIK WK, 1990, PROTEIN METHYLATION, P1; PEL HJ, 1992, NUCLEIC ACIDS RES, V20, P6339, DOI 10.1093/nar/20.23.6339; Polevoda B, 2003, J BIOL CHEM, V278, P30686, DOI 10.1074/jbc.M304690200; Rigaut G, 1999, NAT BIOTECHNOL, V17, P1030, DOI 10.1038/13732; Schubert HL, 2003, BIOCHEMISTRY-US, V42, P5592, DOI 10.1021/bi034026p; SCOLNICK E, 1968, P NATL ACAD SCI USA, V61, P768, DOI 10.1073/pnas.61.2.768; Sherman F, 2002, METHOD ENZYMOL, V350, P3, DOI 10.1016/S0076-6879(02)50954-X; Shi YJ, 2004, CELL, V119, P941, DOI 10.1016/j.cell.2004.12.012; Song HW, 2000, CELL, V100, P311, DOI 10.1016/S0092-8674(00)80667-4; STANSFIELD I, 1995, TRENDS BIOCHEM SCI, V20, P489, DOI 10.1016/S0968-0004(00)89113-6; STANSFIELD I, 1995, EMBO J, V14, P4365, DOI 10.1002/j.1460-2075.1995.tb00111.x; Tate WP, 1996, PROG NUCLEIC ACID RE, V52, P293, DOI 10.1016/S0079-6603(08)60970-8; Tolstykh T, 2000, EMBO J, V19, P5682, DOI 10.1093/emboj/19.21.5682; Towpik J, 2004, J BIOL CHEM, V279, P14096, DOI 10.1074/jbc.M312856200; Valouev IA, 2004, MOL MICROBIOL, V53, P687, DOI 10.1111/j.1365-2958.2004.04157.x; Valouev IA, 2002, CELL MOTIL CYTOSKEL, V52, P161, DOI 10.1002/cm.10040; Yang Z, 2004, J MOL BIOL, V340, P695, DOI 10.1016/j.jmb.2004.05.019; Zavialov AV, 2002, MOL CELL, V10, P789, DOI 10.1016/S1097-2765(02)00691-3; Zavialov AV, 2001, CELL, V107, P115, DOI 10.1016/S0092-8674(01)00508-6; Zhang YL, 1998, BBA-GENE STRUCT EXPR, V1443, P245, DOI 10.1016/S0167-4781(98)00223-1; ZHOURAVLEVA G, 1995, EMBO J, V14, P4065, DOI 10.1002/j.1460-2075.1995.tb00078.x	51	43	49	1	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 3	2006	281	5					2562	2571		10.1074/jbc.M507651200	http://dx.doi.org/10.1074/jbc.M507651200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	006XT	16321977	hybrid			2022-12-25	WOS:000234931800019
J	Cai, ZW; Taddei, A; Sheppard, DN				Cai, ZW; Taddei, A; Sheppard, DN			Differential sensitivity of the cystic fibrosis (CF)-associated mutants G551D and G1349D to potentiators of the cystic fibrosis transmembrane conductance regulator (CFTR) Cl- channel	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEOTIDE-BINDING DOMAINS; WILD-TYPE; ATP; CHLORIDE; PYROPHOSPHATE; INHIBITION; ACTIVATION; GENISTEIN	The genetic disease cystic fibrosis (CF) is caused by loss of function of the cystic fibrosis transmembrane conductance regulator (CFTR) Cl- channel. Two CF mutants, G551D and G1349D, affect equivalent residues in the highly conserved LSGGQ motifs that are essential components of the ATP-binding sites of CFTR. Both mutants severely disrupt CFTR channel gating by decreasing mean burst duration (MBD) and prolonging greatly the interburst interval (IBI). To identify small molecules that rescue the gating defects of G551D- and G1349D-CFTR and understand better how these agents work, we used the patch clamp technique to study the effects on G551D- and G1349D-CFTR of phloxine B, pyrophosphate (PPi), and 2'-deoxy ATP (2'-dATP), three agents that strongly enhance CFTR channel gating. Phloxine B (5 mu M) potentiated robustly G551D-CFTR Cl- channels by altering both MBD and IBI. In contrast, phloxine B (5 mu M) decreased the IBI of G1349D-CFTR, but this effect was insufficient to rescue G1349D-CFTR channel gating. PPi (5mM) potentiated weakly G551D-CFTR and was without effect on the G1349D-CFTR Cl- channel. However, by altering both MBD and IBI, albeit with different efficacies, 2(')-dATP (1mM) potentiated both G551D- and G1349D-CFTR Cl- channels. Using the ATP-driven nucleotide-binding domain dimerization model of CFTR channel gating, we suggest that phloxine B, PPi and 2'-dATP alter channel gating by distinct mechanisms. We conclude that G551D and G1349D-CFTR have distinct pharmacological profiles and speculate that drug therapy for CF is likely to be mutation-specific.	Univ Bristol, Sch Med Sci, Dept Physiol, Bristol BS8 1TD, Avon, England; Ist Giannina Gaslini, Genet Mol Lab, I-16148 Genoa, Italy	University of Bristol; University of Genoa; IRCCS Istituto Giannina Gaslini	Sheppard, DN (corresponding author), Univ Bristol, Sch Med Sci, Dept Physiol, Univ Walk, Bristol BS8 1TD, Avon, England.	D.N.Sheppard@bristol.ac.uk	Sheppard, David N/AAV-4187-2021	Sheppard, David N/0000-0001-5533-9130				Ai T, 2004, MOL PHARMACOL, V65, P1415, DOI 10.1124/mol.65.6.1415; Aleksandrov AA, 2002, FEBS LETT, V518, P183, DOI 10.1016/S0014-5793(02)02698-4; ANDERSON MP, 1992, SCIENCE, V257, P1701, DOI 10.1126/science.1382316; Cai ZW, 2003, J GEN PHYSIOL, V122, P605, DOI 10.1085/jgp.200308921; Cai ZW, 2002, J BIOL CHEM, V277, P19546, DOI 10.1074/jbc.M108023200; Callebaut I, 2004, CELL MOL LIFE SCI, V61, P230, DOI 10.1007/s00018-003-3386-z; CARSON MR, 1995, J BIOL CHEM, V270, P20466, DOI 10.1074/jbc.270.35.20466; CARSON MR, 1995, J BIOL CHEM, V270, P1711, DOI 10.1074/jbc.270.4.1711; GABRIEL SE, 1994, SCIENCE, V266, P107, DOI 10.1126/science.7524148; GUNDERSON KL, 1994, J BIOL CHEM, V269, P19349; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; Lansdell KA, 2000, J PHYSIOL-LONDON, V524, P317, DOI 10.1111/j.1469-7793.2000.t01-1-00317.x; Lansdell KA, 1998, J PHYSIOL-LONDON, V508, P379, DOI 10.1111/j.1469-7793.1998.379bq.x; Lewis HA, 2004, EMBO J, V23, P282, DOI 10.1038/sj.emboj.7600040; Li CH, 1996, J BIOL CHEM, V271, P28463, DOI 10.1074/jbc.271.45.28463; LOGAN J, 1994, J CLIN INVEST, V94, P228, DOI 10.1172/JCI117311; Moran O, 2005, CELL MOL LIFE SCI, V62, P446, DOI 10.1007/s00018-004-4422-3; Ostedgaard LS, 2000, P NATL ACAD SCI USA, V97, P5657, DOI 10.1073/pnas.100588797; Qin F, 2004, BIOPHYS J, V87, P1657, DOI 10.1529/biophysj.103.037531; Riordan JR, 2005, ANNU REV PHYSIOL, V67, P701, DOI 10.1146/annurev.physiol.67.032003.154107; RIORDAN JR, 1989, SCIENCE, V245, P1066; Sheppard DN, 2004, J GEN PHYSIOL, V124, P109, DOI 10.1085/JGP.200409135; Sheppard DN, 1997, J PHYSIOL-LONDON, V503, P333, DOI 10.1111/j.1469-7793.1997.333bh.x; Sheppard DN, 1999, PHYSIOL REV, V79, P23; SMIT LS, 1993, P NATL ACAD SCI USA, V90, P9963, DOI 10.1073/pnas.90.21.9963; Sullivan LP, 1998, J AM SOC NEPHROL, V9, P903; VENGLARIK CJ, 1994, J GEN PHYSIOL, V104, P123, DOI 10.1085/jgp.104.1.123; Vergani P, 2003, J GEN PHYSIOL, V121, P17, DOI 10.1085/jgp.20028673; Vergani P, 2005, NATURE, V433, P876, DOI 10.1038/nature03313; Welsh MJ, 2001, METABOLIC MOL BASES, P5121; WINTER MC, 1994, BIOPHYS J, V66, P1398, DOI 10.1016/S0006-3495(94)80930-0; Zegarra-Moran O, 2002, BRIT J PHARMACOL, V137, P504, DOI 10.1038/sj.bjp.0704882	32	74	76	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 27	2006	281	4					1970	1977		10.1074/jbc.M510576200	http://dx.doi.org/10.1074/jbc.M510576200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	004NV	16311240	hybrid			2022-12-25	WOS:000234760400016
J	Li, L; Li, ZG; Howley, PM; Sacks, DB				Li, L; Li, ZG; Howley, PM; Sacks, DB			E6AP and calmodulin reciprocally regulate estrogen receptor stability	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTIONAL ACTIVITY; PROTEIN; PROTEASOME; ESTRADIOL; ASSOCIATION; CANCER; INHIBITION; FAMILY; ALPHA; E6-AP	Estrogen promotes the proliferation of human breast epithelial cells by interacting with the estrogen receptor ( ER). Physiological responses of cells to estrogen are regulated in part by degradation of the ER. Previous studies revealed that calmodulin binds directly to the ER, thereby enhancing its stability. Consistent with these findings, cell-permeable calmodulin antagonists dramatically reduced the number of ER in MCF-7 human breast epithelial cells. Here we investigated the molecular mechanism by which calmodulin attenuates ER degradation. MG132 and lactacystin, inhibitors of the ubiquitin-proteasome pathway, prevented the calmodulin antagonist CGS9343B from reducing the amount of ER in MCF-7 cells. In contrast, protease inhibitors afforded no protection. Moreover, CGS9343B enhanced ER ubiquitination. A point mutant ER construct that is unable to bind calmodulin, termed ER Delta CaM, is ubiquitinated to a greater extent than wild type ER. The ubiquitin-protein isopeptide ligase E6-associated protein (E6AP) associated with and promoted the degradation of ER. The possible convergence of calmodulin and E6AP on ER degradation was examined. ER Delta CaM bound E6AP with higher affinity than that of wild type ER. Moreover, calmodulin attenuated the in vitro interaction between ER and E6AP in a Ca2+-dependent manner. Collectively, our data reveal that E6AP is a component of ER degradation via the ubiquitin-proteasome pathway and that Ca2+/calmodulin modulates this degradation mechanism. These results have potential implications for the development of selectively targeted therapeutic agents for breast cancer.	Brigham & Womens Hosp, Dept Pathol, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Pathol, Boston, MA 02115 USA	Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School	Sacks, DB (corresponding author), Brigham & Womens Hosp, Dept Pathol, Thom 530,75 Francis St, Boston, MA 02115 USA.	dsacks@rics.bwh.harvard.edu		Sacks, David/0000-0003-3100-0735; Howley, Peter/0000-0002-8668-9579	NATIONAL CANCER INSTITUTE [R01CA093645, R37CA064888] Funding Source: NIH RePORTER; NCI NIH HHS [R37 CA 64888, CA 93645] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Adams J, 2002, TRENDS MOL MED, V8, pS49, DOI 10.1016/S1471-4914(02)02315-8; Adams J, 2004, NAT REV CANCER, V4, P349, DOI 10.1038/nrc1361; Alarid ET, 1999, MOL ENDOCRINOL, V13, P1522, DOI 10.1210/me.13.9.1522; Arbeit JM, 1996, P NATL ACAD SCI USA, V93, P2930, DOI 10.1073/pnas.93.7.2930; Bai C, 1996, CELL, V86, P263, DOI 10.1016/S0092-8674(00)80098-7; Biswas DK, 1998, J BIOL CHEM, V273, P33817, DOI 10.1074/jbc.273.50.33817; BOUHOUTE A, 1995, BIOCHEM BIOPH RES CO, V208, P748, DOI 10.1006/bbrc.1995.1401; BOUHOUTE A, 1992, BIOCHEM BIOPH RES CO, V184, P1432, DOI 10.1016/S0006-291X(05)80043-9; BOUHOUTE A, 1994, BIOCHEM PHARMACOL, V47, P748, DOI 10.1016/0006-2952(94)90140-6; Brake T, 2005, P NATL ACAD SCI USA, V102, P2490, DOI 10.1073/pnas.0409883102; CASTORIA G, 1988, MOL ENDOCRINOL, V2, P167, DOI 10.1210/mend-2-2-167; Cohen P, 1988, CALMODULIN; Das SK, 2000, J BIOL CHEM, V275, P28834, DOI 10.1074/jbc.M003827200; Dickson R B, 2000, J Natl Cancer Inst Monogr, P135; El Khissiin A, 1999, FEBS LETT, V448, P160, DOI 10.1016/S0014-5793(99)00343-9; Glickman MH, 2002, PHYSIOL REV, V82, P373, DOI 10.1152/physrev.00027.2001; Hall JM, 2001, J BIOL CHEM, V276, P36869, DOI 10.1074/jbc.R100029200; Hatakeyama S, 1997, J BIOL CHEM, V272, P15085, DOI 10.1074/jbc.272.24.15085; Hochstrasser M, 1996, ANNU REV GENET, V30, P405, DOI 10.1146/annurev.genet.30.1.405; HORIGOME T, 1988, ENDOCRINOLOGY, V123, P2540, DOI 10.1210/endo-123-5-2540; HUIBREGTSE JM, 1993, MOL CELL BIOL, V13, P4918, DOI 10.1128/MCB.13.8.4918; HUIBREGTSE JM, 1995, P NATL ACAD SCI USA, V92, P2563, DOI 10.1073/pnas.92.7.2563; Kim SH, 2000, J BIOL CHEM, V275, P36999, DOI 10.1074/jbc.M003430200; Kumar S, 1997, J BIOL CHEM, V272, P13548, DOI 10.1074/jbc.272.21.13548; Li L, 2005, J BIOL CHEM, V280, P13097, DOI 10.1074/jbc.M410642200; Li L, 2003, J BIOL CHEM, V278, P1195, DOI 10.1074/jbc.M210708200; Li ZG, 2001, J BIOL CHEM, V276, P17354, DOI 10.1074/jbc.M010238200; Magnifico A, 2003, J BIOL CHEM, V278, P43169, DOI 10.1074/jbc.M308009200; McKenna NJ, 2002, CELL, V108, P465, DOI 10.1016/S0092-8674(02)00641-4; MIGLIACCIO A, 1984, P NATL ACAD SCI-BIOL, V81, P5921, DOI 10.1073/pnas.81.19.5921; Moggs JG, 2001, EMBO REP, V2, P775, DOI 10.1093/embo-reports/kve185; MURAYAMA A, 1984, J BIOCHEM-TOKYO, V95, P1697, DOI 10.1093/oxfordjournals.jbchem.a134783; Nawaz Z, 1999, P NATL ACAD SCI USA, V96, P1858, DOI 10.1073/pnas.96.5.1858; Nawaz Z, 1999, MOL CELL BIOL, V19, P1182; Newton CJ, 2000, J STEROID BIOCHEM, V73, P29, DOI 10.1016/S0960-0760(00)00047-9; NORMAN JA, 1987, MOL PHARMACOL, V31, P535; Oda H, 1999, P NATL ACAD SCI USA, V96, P9557, DOI 10.1073/pnas.96.17.9557; Pedrero JMG, 2002, MOL ENDOCRINOL, V16, P947; Shao WL, 2004, P NATL ACAD SCI USA, V101, P11599, DOI 10.1073/pnas.0402997101; SINGER AL, 1976, CANCER RES, V36, P60; STROBL JS, 1992, J PHARMACOL EXP THER, V263, P186; Talis AL, 1998, J BIOL CHEM, V273, P6439, DOI 10.1074/jbc.273.11.6439; TREIER M, 1994, CELL, V78, P787, DOI 10.1016/S0092-8674(94)90502-9; WEI JW, 1983, CANCER CHEMOTH PHARM, V11, P86; Wijayaratne AL, 2001, J BIOL CHEM, V276, P35684, DOI 10.1074/jbc.M101097200; zur Hausen H, 2002, NAT REV CANCER, V2, P342, DOI 10.1038/nrc798	46	71	72	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 27	2006	281	4					1978	1985		10.1074/jbc.M508545200	http://dx.doi.org/10.1074/jbc.M508545200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	004NV	16314411	hybrid			2022-12-25	WOS:000234760400017
J	Kato, Y; Ying, H; Zhao, L; Furuya, F; Araki, O; Willingham, MC; Cheng, SY				Kato, Y; Ying, H; Zhao, L; Furuya, F; Araki, O; Willingham, MC; Cheng, SY			PPAR gamma insufficiency promotes follicular thyroid carcinogenesis via activation of the nuclear factor-kappa B signaling pathway	ONCOGENE			English	Article						thyroid cancer; mutant thyroid hormone receptor; PPAR gamma; NF-kappa B; mouse model; apoptosis	HORMONE RECEPTOR-BETA; HUMAN PROSTATE-CANCER; INHIBITS CELL-GROWTH; MOUSE MODEL; TRANSCRIPTIONAL ACTIVITY; GENERALIZED RESISTANCE; LIPOPROTEIN-LIPASE; TARGETED MUTATION; CARCINOMA CELLS; TRANSGENIC MICE	The molecular genetic events underlying thyroid carcinogenesis are poorly understood. Mice harboring a knock-in dominantly negative mutant thyroid hormone receptor beta (TR beta(PV/PV) mouse) spontaneously develop follicular thyroid carcinoma similar to human thyroid cancer. Using this mutant mouse, we tested the hypothesis that the peroxisome proliferator-activated receptor gamma (PPAR gamma) could function as a tumor suppressor in thyroid cancer in vivo. Using the offspring from the cross of TR beta(PV/+) and PPAR gamma(+/-) mice, we found that thyroid carcinogenesis progressed significantly faster in TRbPV/PV mice with PPAR gamma insufficiency from increased cell proliferation and reduced apoptosis. Reduced PPAR gamma protein abundance led to the activation of the nuclear factor-kappa B signaling pathway, resulting in the activation of cyclin D1 and repression of critical genes involved in apoptosis. Treatment of TR beta PV/PV mice with a PPAR gamma agonist, rosiglitazone, delayed the progression of thyroid carcinogenesis by decreasing cell proliferation and activation of apoptosis. These results suggest that PPAR gamma is a critical modi. er in thyroid carcinogenesis and could be tested as a therapeutic target in thyroid follicular carcinoma.	NCI, Mol Biol Lab, Canc Res Ctr, NIH, Bethesda, MD 20892 USA; Wake Forest Univ, Sch Med, Dept Pathol, Winston Salem, NC 27109 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Wake Forest University	Cheng, SY (corresponding author), NCI, Mol Biol Lab, Canc Res Ctr, NIH, 37 Convent Dr,Room 5128, Bethesda, MD 20892 USA.	chengs@mail.nih.gov			Intramural NIH HHS Funding Source: Medline; NATIONAL CANCER INSTITUTE [Z01BC008752, ZIABC008752] Funding Source: NIH RePORTER	Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Akiyama TE, 2002, MOL CELL BIOL, V22, P2607, DOI 10.1128/MCB.22.8.2607-2619.2002; Asou H, 1999, INT J ONCOL, V15, P1027; Baud V, 2001, TRENDS CELL BIOL, V11, P372, DOI 10.1016/S0962-8924(01)02064-5; Biswas DK, 2000, P NATL ACAD SCI USA, V97, P8542, DOI 10.1073/pnas.97.15.8542; Cheung L, 2003, J CLIN ENDOCR METAB, V88, P354, DOI 10.1210/jc.2002-021020; Chevillard S, 2004, CLIN CANCER RES, V10, P6586, DOI 10.1158/1078-0432.CCR-04-0053; COOPER DS, 1981, J CLIN ENDOCR METAB, V52, P294, DOI 10.1210/jcem-52-2-294; Demetri GD, 1999, P NATL ACAD SCI USA, V96, P3951, DOI 10.1073/pnas.96.7.3951; Fan WQ, 2005, ENDOCRINOLOGY, V146, P85, DOI 10.1210/en.2004-1046; FLEISS JL, 1981, STAT METHODS RATES; Furumoto H, 2005, MOL CELL BIOL, V25, P124, DOI 10.1128/MCB.25.1.124-135.2005; Goldberg IJ, 2001, FRONT BIOSCI-LANDMRK, V6, pD388, DOI 10.2741/Goldberg; Guan You-Fei, 1999, Neoplasia (New York), V1, P330, DOI 10.1038/sj.neo.7900050; Gustafson KS, 2003, AM J CLIN PATHOL, V120, P175, DOI 10.1309/2E6QGJRGGETVT8K9; Hinz M, 1999, MOL CELL BIOL, V19, P2690; Jeker LT, 1999, BIOCHEM BIOPH RES CO, V257, P511, DOI 10.1006/bbrc.1999.0468; Joyce D, 1999, J BIOL CHEM, V274, P25245, DOI 10.1074/jbc.274.36.25245; Kaneshige M, 2000, P NATL ACAD SCI USA, V97, P13209, DOI 10.1073/pnas.230285997; Kato Y, 2004, ENDOCRINOLOGY, V145, P4430, DOI 10.1210/en.2004-0612; Keelan JA, 1999, BIOCHEM BIOPH RES CO, V262, P579, DOI 10.1006/bbrc.1999.1257; Klopper JP, 2004, MOL CANCER THER, V3, P1011; Kroll TG, 2000, SCIENCE, V289, P1357, DOI 10.1126/science.289.5483.1357; Kubota T, 1998, CANCER RES, V58, P3344; LEDENT C, 1992, EMBO J, V11, P537, DOI 10.1002/j.1460-2075.1992.tb05084.x; Lee E, 2013, STAT METHODS SURVIVA; MAZZAFERRI EL, 1993, NEW ENGL J MED, V328, P553; MEIER CA, 1992, MOL ENDOCRINOL, V6, P248, DOI 10.1210/me.6.2.248; Michalik L, 2004, NAT REV CANCER, V4, P61, DOI 10.1038/nrc1254; MICHIELS FM, 1994, P NATL ACAD SCI USA, V91, P10488, DOI 10.1073/pnas.91.22.10488; Motomura W, 2000, CANCER RES, V60, P5558; Mueller E, 2000, P NATL ACAD SCI USA, V97, P10990, DOI 10.1073/pnas.180329197; Nikiforova MN, 2002, AM J SURG PATHOL, V26, P1016, DOI 10.1097/00000478-200208000-00006; Nishida K, 2002, BRIT J CANCER, V86, P1303, DOI 10.1038/sj.bjc.6600241; Ohta K, 2001, J CLIN ENDOCR METAB, V86, P2170, DOI 10.1210/jc.86.5.2170; ONO S, 1991, J CLIN ENDOCR METAB, V73, P990, DOI 10.1210/jcem-73-5-990; Park JW, 2005, THYROID, V15, P222, DOI 10.1089/thy.2005.15.222; PARRILLA R, 1991, J CLIN INVEST, V88, P2123, DOI 10.1172/JCI115542; Rivas M, 2003, MOL CELL ENDOCRINOL, V213, P31, DOI 10.1016/j.mce.2003.10.029; Sarraf P, 1998, NAT MED, V4, P1046, DOI 10.1038/2030; Schoonjans K, 1996, EMBO J, V15, P5336, DOI 10.1002/j.1460-2075.1996.tb00918.x; Setoguchi K, 2001, J CLIN INVEST, V108, P1667; Suh J, 2004, J CELL BIOCHEM, V91, P100, DOI 10.1002/jcb.10729; Suzuki H, 2003, MOL ENDOCRINOL, V17, P1647, DOI 10.1210/me.2003-0114; Suzuki H, 2003, MOL ENDOCRINOL, V17, P895, DOI 10.1210/me.2002-0326; Suzuki H, 2002, THYROID, V12, P963, DOI 10.1089/105072502320908295; SYLVIA L, 2004, MOL BASIS THYROID CA, P23; Takahashi N, 1999, FEBS LETT, V455, P135, DOI 10.1016/S0014-5793(99)00871-6; Tsubouchi Y, 2000, BIOCHEM BIOPH RES CO, V270, P400, DOI 10.1006/bbrc.2000.2436; Wang NP, 2002, J BIOL CHEM, V277, P34176, DOI 10.1074/jbc.M203436200; Yen PM, 2003, TRENDS ENDOCRIN MET, V14, P327, DOI 10.1016/S1043-2760(03)00114-0; Ying H, 2003, CANCER RES, V63, P5274; Ying H, 2003, CARCINOGENESIS, V24, P1467, DOI 10.1093/carcin/bgg111; Zeiger MA, 1997, ENDOCRINOLOGY, V138, P3133, DOI 10.1210/en.138.8.3133	53	85	90	1	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 4	2006	25	19					2736	2747		10.1038/sj.onc.1209299	http://dx.doi.org/10.1038/sj.onc.1209299			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	039AW	16314832				2022-12-25	WOS:000237272900005
J	Lajus, S; Vacher, P; Huber, D; Dubois, M; Benassy, MN; Ushkaryov, Y; Lang, JC				Lajus, S; Vacher, P; Huber, D; Dubois, M; Benassy, MN; Ushkaryov, Y; Lang, JC			alpha-Latrotoxin induces exocytosis by inhibition of voltage-dependent K+ channels and by stimulation of l-type Ca2+ channels via latrophilin in beta-cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; CALCIUM-INDEPENDENT RECEPTOR; INSULIN-SECRETION; TRANSMITTER RELEASE; INTRACELLULAR CA2+; COUPLED RECEPTORS; XENOPUS-OOCYTES; MEMBRANE PORES; GLUCOSE; FAMILY	The spider venom alpha-latrotoxin (alpha-LTX) induces massive exocytosis after binding to surface receptors, and its mechanism is not fully understood. We have investigated its action using toxin-sensitive MIN6 beta-cells, which express endogenously the alpha-LTX receptor latrophilin (LPH), and toxin-insensitive HIT-T15 beta-cells, which lack endogenous LPH. alpha-LTX evoked insulin exocytosis in HIT-T15 cells only upon expression of full-length LPH but not of LPH truncated after the first transmembrane domain (LPH-TD1). In HIT-T15 cells expressing full-length LPH and in native MIN6 cells, alpha-LTX first induced membrane depolarization by inhibition of repolarizing K+ channels followed by the appearance of Ca2+ transients. In a second phase, the toxin induced a large inward current and a prominent increase in intracellular calcium ([Ca2+](i)) reflecting pore formation. Upon expression of LPH-TD1 in HIT-T15 cells just this second phase was observed. Moreover, the mutated toxin LTXN4C, which is devoid of pore formation, only evoked oscillations of membrane potential by reversible inhibition of iberiotoxin-sensitive K+ channels via phospholipase C, activated L-type Ca2+ channels independently from its effect on membrane potential, and induced an inositol 1,4,5-trisphosphate receptor-dependent release of intracellular calcium in MIN6 cells. The combined effects evoked transient increases in [Ca2+](i) in these cells, which were sensitive to inhibitors of phospholipase C, protein kinase C, or L-type Ca2+ channels. The latter agents also reduced toxin-induced insulin exocytosis. In conclusion, alpha-LTX induces signaling distinct from pore formation via full-length LPH and phospholipase C to regulate physiologically important K+ and Ca2+ channels as novel targets of its secretory activity.	Inst Europeen Chim & Biol, JE 2390, F-33607 Pessac, France; INSERM, E347, F-33607 Pessac, France; Univ Geneva, Ctr Med Univ, CH-1211 Geneva, Switzerland; Univ London Imperial Coll Sci Technol & Med, Dept Biol Sci, London SW7 2AY, England	Institut National de la Sante et de la Recherche Medicale (Inserm); University of Geneva; Imperial College London	Lang, JC (corresponding author), Inst Europeen Chim & Biol, JE 2390, 2 Rue Robert Escarpit, F-33607 Pessac, France.	j.lang@iecb.u-bordeaux.fr	Vacher, Pierre/N-2243-2018; Lang, Jochen/F-5782-2014; Lang, Jochen/B-1215-2010; Ushkaryov, Yuri/AAQ-2985-2020	Lang, Jochen/0000-0001-6847-5641; Lang, Jochen/0000-0001-6847-5641; Ushkaryov, Yuri/0000-0002-5712-8297; VACHER, Pierre/0000-0003-3503-7981	Biotechnology and Biological Sciences Research Council [BB/D523078/1] Funding Source: Medline; Wellcome Trust [074359] Funding Source: Medline	Biotechnology and Biological Sciences Research Council(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC)); Wellcome Trust(Wellcome TrustEuropean Commission)		Ashton AC, 2001, J BIOL CHEM, V276, P44695, DOI 10.1074/jbc.M108088200; Bittner MA, 2000, J BIOL CHEM, V275, P25351, DOI 10.1074/jbc.M004884200; Boal F, 2004, BIOCHEMISTRY-US, V43, P16212, DOI 10.1021/bi048612+; Bourinet E, 2004, J CLIN INVEST, V113, P1382, DOI 10.1172/JCI200421815; Capogna M, 2003, J NEUROSCI, V23, P4044; Davies SP, 2000, BIOCHEM J, V351, P95, DOI 10.1042/0264-6021:3510095; Davletov BA, 1996, J BIOL CHEM, V271, P23239, DOI 10.1074/jbc.271.38.23239; Dukes ID, 1996, DIABETES, V45, P845, DOI 10.2337/diabetes.45.7.845; EDDLESTONE GT, 1989, J MEMBRANE BIOL, V109, P123, DOI 10.1007/BF01870851; FILIPPOV AK, 1994, NEUROSCIENCE, V61, P179, DOI 10.1016/0306-4522(94)90070-1; Fujiwara K, 2005, AM J PHYSIOL-ENDOC M, V289, pE670, DOI 10.1152/ajpendo.00035.2005; Gerber SH, 2002, DIABETES, V51, pS3, DOI 10.2337/diabetes.51.2007.S3; GRASSO A, 1982, TOXICON, V20, P149, DOI 10.1016/0041-0101(82)90184-2; Gschwendt M, 1996, FEBS LETT, V392, P77, DOI 10.1016/0014-5793(96)00785-5; Henquin JC, 2000, DIABETES, V49, P1751, DOI 10.2337/diabetes.49.11.1751; HENQUIN JC, 1990, PFLUG ARCH EUR J PHY, V416, P568, DOI 10.1007/BF00382691; Hlubek MD, 2000, MOL PHARMACOL, V57, P519, DOI 10.1124/mol.57.3.519; Hu H, 2001, J NEUROSCI, V21, P9585, DOI 10.1523/JNEUROSCI.21-24-09585.2001; HURLBUT WP, 1994, J MEMBRANE BIOL, V138, P91, DOI 10.1007/BF00211072; Ichtchenko K, 1999, J BIOL CHEM, V274, P5491, DOI 10.1074/jbc.274.9.5491; Jing XJ, 2005, J CLIN INVEST, V115, P146, DOI 10.1172/JCI200522518; Krasnoperov V, 2002, J BIOL CHEM, V277, P35887, DOI 10.1074/jbc.M205478200; Krasnoperov V, 1999, J BIOL CHEM, V274, P3590, DOI 10.1074/jbc.274.6.3590; Krasnoperov VG, 1997, NEURON, V18, P925, DOI 10.1016/S0896-6273(00)80332-3; Lang JC, 1997, EMBO J, V16, P5837, DOI 10.1093/emboj/16.19.5837; LANGNER CG, 1999, P OFFSH TECHN C, V3, P17; Lelianova VG, 1997, J BIOL CHEM, V272, P21504, DOI 10.1074/jbc.272.34.21504; Liu J, 2005, TRAFFIC, V6, P756, DOI 10.1111/j.1600-0854.2005.00313.x; Liu J, 1998, J NEUROSCI, V18, P6113; MacDonald PE, 2003, J BIOL CHEM, V278, P52446, DOI 10.1074/jbc.M307612200; MacDonald PE, 2002, J BIOL CHEM, V277, P44938, DOI 10.1074/jbc.M205532200; MacDonald PE, 2001, MOL ENDOCRINOL, V15, P1423, DOI 10.1210/me.15.8.1423; Machado JD, 2001, MOL PHARMACOL, V60, P514; Michelena P, 1997, J PHYSIOL-LONDON, V502, P481, DOI 10.1111/j.1469-7793.1997.481bj.x; Minami K, 2000, AM J PHYSIOL-ENDOC M, V279, pE773, DOI 10.1152/ajpendo.2000.279.4.E773; Orlova EV, 2000, NAT STRUCT BIOL, V7, P48, DOI 10.1038/71247; Rorsman P, 1997, DIABETOLOGIA, V40, P487, DOI 10.1007/s001250050706; Sekine N, 1996, ENDOCRINOLOGY, V137, P1841, DOI 10.1210/en.137.5.1841; Sheu L, 2003, J BIOL CHEM, V278, P27556, DOI 10.1074/jbc.M303203200; Silva AM, 2005, J PHYSIOL-LONDON, V565, P783, DOI 10.1113/jphysiol.2005.082586; Sorin B, 1998, J BIOL CHEM, V273, P28461, DOI 10.1074/jbc.273.43.28461; Sudhof TC, 2001, ANNU REV NEUROSCI, V24, P933, DOI 10.1146/annurev.neuro.24.1.933; Sugita S, 1998, J BIOL CHEM, V273, P32715, DOI 10.1074/jbc.273.49.32715; Terrillon S, 2004, EMBO REP, V5, P30, DOI 10.1038/sj.embor.7400052; Trimmer JS, 2004, ANNU REV PHYSIOL, V66, P477, DOI 10.1146/annurev.physiol.66.032102.113328; Tsang CW, 2000, J NEUROSCI, V20, P8685; Tse FW, 1999, ENDOCRINOLOGY, V140, P3025, DOI 10.1210/en.140.7.3025; Tsuboi T, 2003, BIOCHEM J, V369, P287, DOI 10.1042/BJ20021288; Ushkaryov YA, 2004, TOXICON, V43, P527, DOI 10.1016/j.toxicon.2004.02.008; Van Renterghem C, 2000, EUR J NEUROSCI, V12, P3953, DOI 10.1046/j.1460-9568.2000.00282.x; Volynski KE, 2004, EMBO J, V23, P4423, DOI 10.1038/sj.emboj.7600443; Volynski KE, 2003, J BIOL CHEM, V278, P31058, DOI 10.1074/jbc.M210395200; Volynski KE, 2000, J BIOL CHEM, V275, P41175, DOI 10.1074/jbc.M005857200; Wang ZW, 2001, NEURON, V32, P867, DOI 10.1016/S0896-6273(01)00522-0; Weiss S, 2004, J BIOL CHEM, V279, P12503, DOI 10.1074/jbc.M310196200; Willson J, 2004, CURR BIOL, V14, P1374, DOI 10.1016/j.cub.2004.07.056; Wiser O, 1999, P NATL ACAD SCI USA, V96, P248, DOI 10.1073/pnas.96.1.248; Yang L, 2005, J BIOL CHEM, V280, P207, DOI 10.1074/jbc.M410509200; Yang SN, 2005, AM J PHYSIOL-ENDOC M, V288, pE16, DOI 10.1152/ajpendo.00042.2004; Yang Y, 2004, J GEN PHYSIOL, V124, P641, DOI 10.1085/jgp.200409081; Zhang H, 1999, J CELL SCI, V112, P1345	61	26	29	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 3	2006	281	9					5522	5531		10.1074/jbc.M510528200	http://dx.doi.org/10.1074/jbc.M510528200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	015RQ	16301314	hybrid			2022-12-25	WOS:000235568900026
J	Williamson, EA; Wolf, I; O'Kelly, J; Bose, S; Tanosaki, S; Koeffler, HP				Williamson, EA; Wolf, I; O'Kelly, J; Bose, S; Tanosaki, S; Koeffler, HP			BRCA1 and FOXA1 proteins coregulate the expression of the cell cycle-dependent kinase inhibitor p27(Kip1)	ONCOGENE			English	Article						FOXA1; BRCA1; cell cycle regulation	TRANSCRIPTION FACTOR HNF3; GENE-EXPRESSION; FORK-HEAD; BREAST-CANCER; MAMMARY-GLAND; MOUSE EMBRYO; IN-VIVO; BINDING; HELIX; DNA	We have previously shown that the breast cancer susceptibility gene, BRCA1, can transcriptionally activate the p27(Kip1) promoter. The BRCA1-responsive element was defined as a 35 bp region from position -545 to -511. We next determined that within this region is also a potential binding site for the transcription factor Forkhead box (FOX)A1. RNA and protein analysis as well as immunohistochemistry showed that expression of FOXA1 correlated with the expression of the estrogen receptor in a panel of breast cancer cell lines and tissues. In transient transfection reporter assays, FOXA1 could activate the p27(Kip1) promoter. Cotransfection of BRCA1 and FOXA1 resulted in a synergistic activation of the p27(Kip1) promoter. Mutation of the FOXA1 DNA-binding site in the p27(Kip1) promoter-luciferase construct significantly diminished the activity of FOXA1 alone or in combination with BRCA1. Cotransfection of FOXA1 and BRCA1 resulted in a greater amount of each protein compared to transfection of each expression vector alone. The half-life of FOXA1 was increased when coexpressed with BRCA1. Electrophoretic mobility shift assay analysis demonstrated that FOXA1 could bind to a wild-type oligonucleotide containing the FOXA1 binding site in the p27(Kip1) promoter, but this binding was lost upon mutation of this FOXA1 binding site. The protein-DNA binding complex could be supershifted with an antibody directed against FOXA1. The activity of the p27(Kip1) promoter as well as FOXA1 expression was reduced in cells treated with BRCA1 siRNA, thus silencing the expression of BRCA1 protein. In summary, we identified a FOXA1 binding site within the BRCA1-responsive element of the p27(Kip1) promoter and showed that FOXA1 activated the promoter alone and in conjunction with BRCA1. Furthermore, we identified high expression of FOXA1 in breast cancer cell lines and tissues, discovered a role for BRCA1 in the regulation of p27(Kip1) transcription and a possible interaction with BRCA1.	Univ Calif Los Angeles, Sch Med, Cedars Sinai Med Ctr, Dept Med Hematol Oncol, Los Angeles, CA USA; Univ Calif Los Angeles, Sch Med, Cedars Sinai Med Ctr, Dept Pathol, Los Angeles, CA USA	Cedars Sinai Medical Center; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; Cedars Sinai Medical Center; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA	Williamson, EA (corresponding author), Univ New Mexico, Canc Res Facil, 1UNM MSCO8 4630,Room 117, Albuquerque, NM 87131 USA.	ewilliamson@salud.unm.edu						Brodie SG, 2001, ONCOGENE, V20, P7514, DOI 10.1038/sj.onc.1204929; Cable PL, 2003, MOL CARCINOGEN, V38, P85, DOI 10.1002/mc.10148; Castrillon DH, 2003, SCIENCE, V301, P215, DOI 10.1126/science.1086336; Catzavelos C, 1997, NAT MED, V3, P227, DOI 10.1038/nm0297-227; Ciaparrone M, 1998, CANCER RES, V58, P114; Cirillo LA, 2002, MOL CELL, V9, P279, DOI 10.1016/S1097-2765(02)00459-8; Cirillo LA, 1998, EMBO J, V17, P244, DOI 10.1093/emboj/17.1.244; CLARK KL, 1993, NATURE, V364, P412, DOI 10.1038/364412a0; Cordon-Cardo C, 1998, JNCI-J NATL CANCER I, V90, P1284, DOI 10.1093/jnci/90.17.1284; COSTA RH, 2001, CELL MOL PHYSL, V280, pL823; Crowe AJ, 1999, J BIOL CHEM, V274, P25113, DOI 10.1074/jbc.274.35.25113; Cunningham MA, 2004, MOL ENDOCRINOL, V18, P1756, DOI 10.1210/me.2004-0071; Deans AJ, 2004, ONCOGENE, V23, P6136, DOI 10.1038/sj.onc.1207805; Fan SJ, 2001, ONCOGENE, V20, P8215, DOI 10.1038/sj.onc.1205033; Ganesan S, 2002, CELL, V111, P393, DOI 10.1016/S0092-8674(02)01052-8; Houvras Y, 2000, J BIOL CHEM, V275, P36230, DOI 10.1074/jbc.M002539200; JACKSON DA, 1993, MOL CELL BIOL, V13, P2401, DOI 10.1128/MCB.13.4.2401; Jin GS, 2004, ACTA MED OKAYAMA, V58, P197; Kaestner KH, 2000, GENE DEV, V14, P142; Kaestner KH, 1999, GENE DEV, V13, P495, DOI 10.1101/gad.13.4.495; Kaufmann E, 1996, MECH DEVELOP, V57, P3, DOI 10.1016/0925-4773(96)00539-4; LAI E, 1991, GENE DEV, V5, P416, DOI 10.1101/gad.5.3.416; Masciullo V, 1999, CANCER RES, V59, P3790; Medema RH, 2000, NATURE, V404, P782, DOI 10.1038/35008115; Ouchi T, 2000, P NATL ACAD SCI USA, V97, P5208, DOI 10.1073/pnas.080469697; Ouchi T, 1998, P NATL ACAD SCI USA, V95, P2302, DOI 10.1073/pnas.95.5.2302; OVERDIER DG, 1994, MOL CELL BIOL, V14, P2755, DOI 10.1128/MCB.14.4.2755; Robyr D, 2000, J BIOL CHEM, V275, P28291; SASAKI H, 1993, DEVELOPMENT, V118, P47; Shim EY, 1998, GENE DEV, V12, P5, DOI 10.1101/gad.12.1.5; Somasundaram K, 1997, NATURE, V389, P187, DOI 10.1038/38291; van't Veer LJ, 2002, NATURE, V415, P530, DOI 10.1038/415530a; Verbeek W, 1999, BLOOD, V93, P3327, DOI 10.1182/blood.V93.10.3327; Wang Q, 1998, ONCOGENE, V17, P1939, DOI 10.1038/sj.onc.1202403; WEINSTEIN DC, 1994, CELL, V78, P575, DOI 10.1016/0092-8674(94)90523-1; West M, 2001, P NATL ACAD SCI USA, V98, P11462, DOI 10.1073/pnas.201162998; Williamson EA, 2002, ONCOGENE, V21, P3199, DOI 10.1038/sj.onc.1205461; Wolfrum C, 2003, P NATL ACAD SCI USA, V100, P11624, DOI 10.1073/pnas.1931483100; Xia Y, 2003, J BIOL CHEM, V278, P5255, DOI 10.1074/jbc.M204591200; Yu X, 1998, J BIOL CHEM, V273, P25388, DOI 10.1074/jbc.273.39.25388; Zaret K, 1999, DEV BIOL, V209, P1, DOI 10.1006/dbio.1999.9228; Zhang HB, 1998, ONCOGENE, V16, P1713, DOI 10.1038/sj.onc.1201932	42	60	69	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR 2	2006	25	9					1391	1399		10.1038/sj.onc.1209170	http://dx.doi.org/10.1038/sj.onc.1209170			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	017QN	16331276				2022-12-25	WOS:000235708200012
J	Lalle, M; Salzano, AM; Crescenzi, M; Pozio, E				Lalle, M; Salzano, AM; Crescenzi, M; Pozio, E			The Giardia duodenalis 14-3-3 protein is post-translationally modified by phosphorylation and polyglycylation of the C-terminal tail	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-TUBULIN; SUBCELLULAR-LOCALIZATION; FUNCTIONAL SPECIFICITY; 14-3-3-PROTEIN FAMILY; AMPHIPATHIC GROOVE; TOXOPLASMA-GONDII; CRYSTAL-STRUCTURE; ALPHA-TUBULIN; LAMBLIA; ISOFORM	The flagellated protozoan Giardia duodenalis (syn. lamblia or intestinalis) has been chosen as a model parasite to further investigate the multifunctional 14-3-3s, a family of highly conserved eukaryotic proteins involved in many cellular processes, such as cell cycle, differentiation, apoptosis, and signal transduction pathways. We confirmed the presence of a single 14-3-3 homolog gene (g14-3-3) by an in silico screening of the complete genome of Giardia, and we demonstrated its constitutive transcription throughout the life stages of the parasite. We cloned and expressed the g14-3-3 in bacteria, and by protein-protein interaction assays we demonstrated that it is a functional 14-3-3. Using an anti-peptide antibody raised against a unique 18-amino acid sequence at the N terminus, we observed variations both in the intracellular localization and in the molecular size of the native g14-3-3 during the conversion of Giardia from trophozoites to the cyst stage. An affinity chromatography, based on the 14-3-3 binding to the polypeptide difopein, was set to purify the native g14-3-3. By matrix-assisted laser desorption ionization mass spectroscopy analysis, we showed that polyglycylation, an unusual post-translational modification described only for tubulin, occurred at the extreme C terminus of the native g14-3-3 on Glu(246), Glu(247), or both and that the Thr(214), located in the loop between helices 8 and 9, is phosphorylated. We propose that the addition of the polyglycine chain can promote the binding of g14-3-3 to alternative ligands and that the differential rate of polyglycylation/deglycylation during the encystation process can act as a novel mechanism to regulate the intracellular localization of g14-3-3.	Ist Super Sanita, Dept Infect Parasit & Immunomediated Dis, I-00161 Rome, Italy; Ist Super Sanita, Dept Environm & Primary Prevent, I-00161 Rome, Italy	Istituto Superiore di Sanita (ISS); Istituto Superiore di Sanita (ISS)	Lalle, M (corresponding author), Ist Super Sanita, Dept Infect Parasit & Immunomediated Dis, Viale Regina Elena 299, I-00161 Rome, Italy.	marco.lalle@iss.it	Salzano, Anna Maria/C-7139-2012; Crescenzi, Marco/J-3603-2018; Lalle, Marco/O-2287-2015	Salzano, Anna Maria/0000-0001-7192-8760; Crescenzi, Marco/0000-0003-0156-1494; Lalle, Marco/0000-0001-5168-2150				Aducci P, 2002, IUBMB LIFE, V53, P49, DOI 10.1080/15216540210813; Aitken A, 2002, PLANT MOL BIOL, V50, P993, DOI 10.1023/A:1021261931561; Al-Khedery B, 1999, MOL BIOCHEM PARASIT, V102, P117, DOI 10.1016/S0166-6851(99)00090-0; Assossou O, 2003, FEMS MICROBIOL LETT, V224, P161, DOI 10.1016/S0378-1097(03)00479-8; Athwal GS, 2002, PLANT J, V29, P119, DOI 10.1046/j.0960-7412.2001.01200.x; Benzinger A, 2005, CELL RES, V15, P219, DOI 10.1038/sj.cr.7290290; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Bre MH, 1996, J CELL SCI, V109, P727; Campanati L, 1999, BIOL CELL, V91, P499, DOI 10.1016/S0248-4900(00)88206-4; Ellis JG, 2003, J BIOL CHEM, V278, P1936, DOI 10.1074/jbc.M209274200; Hedges SB, 2004, BMC EVOL BIOL, V4, DOI 10.1186/1471-2148-4-2; ICHIMURA T, 1987, FEBS LETT, V219, P79, DOI 10.1016/0014-5793(87)81194-8; Jin J, 2004, CURR BIOL, V14, P1436, DOI 10.1016/j.cub.2004.07.051; KANE AV, 1991, J PARASITOL, V77, P974, DOI 10.2307/3282752; Kjellstrom S, 2004, ANAL CHEM, V76, P5109, DOI 10.1021/ac0400257; Koyama T, 2001, VET PARASITOL, V96, P65, DOI 10.1016/S0304-4017(00)00424-6; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lalle M, 2005, PLANT MOL BIOL, V59, P713, DOI 10.1007/s11103-005-0862-x; Lally NC, 1996, MOL BIOCHEM PARASIT, V75, P169, DOI 10.1016/0166-6851(95)02530-8; LIU D, 1995, NATURE, V376, P191, DOI 10.1038/376191a0; Lloyd D, 2002, TRENDS MICROBIOL, V10, P122, DOI 10.1016/S0966-842X(02)02306-5; Masters SC, 2001, J BIOL CHEM, V276, P45193, DOI 10.1074/jbc.M105971200; McArthur AG, 2000, FEMS MICROBIOL LETT, V189, P271, DOI 10.1111/j.1574-6968.2000.tb09242.x; Moorhead G, 1999, PLANT J, V18, P1, DOI 10.1046/j.1365-313X.1999.00417.x; MOSS DM, 1990, J CLIN MICROBIOL, V28, P254, DOI 10.1128/JCM.28.2.254-257.1990; Muslin AJ, 2000, CELL SIGNAL, V12, P703, DOI 10.1016/S0898-6568(00)00131-5; Pan SQ, 1999, PLANT CELL, V11, P1591, DOI 10.1105/tpc.11.8.1591; Petosa C, 1998, J BIOL CHEM, V273, P16305, DOI 10.1074/jbc.273.26.16305; Redeker V, 2005, J BIOL CHEM, V280, P596, DOI 10.1074/jbc.M408324200; REDEKER V, 1994, SCIENCE, V266, P1688, DOI 10.1126/science.7992051; Rosenquist M, 2000, J MOL EVOL, V51, P446, DOI 10.1007/s002390010107; Rubio MP, 2004, BIOCHEM J, V379, P395, DOI 10.1042/bj20031797; Sambrook J., 1989, MOL CLONING LAB MANU, V2; Shevchenko A, 1996, ANAL CHEM, V68, P850, DOI 10.1021/ac950914h; Siles-Lucas MD, 2003, TRENDS PARASITOL, V19, P575, DOI 10.1016/j.pt.2003.10.003; Slavin I, 2002, MOL BIOCHEM PARASIT, V122, P95, DOI 10.1016/S0166-6851(02)00065-8; SOGIN ML, 1989, SCIENCE, V243, P75, DOI 10.1126/science.2911720; Testerink C, 2002, PLANT MOL BIOL, V50, P535, DOI 10.1023/A:1019869900285; Thazhath R, 2002, NAT CELL BIOL, V4, P256, DOI 10.1038/ncb764; Thompson RCA, 2000, INT J PARASITOL, V30, P1259, DOI 10.1016/S0020-7519(00)00127-2; van Hemert MJ, 2004, J CELL SCI, V117, P1411, DOI 10.1242/jcs.00990; Vinh J, 1999, BIOCHEMISTRY-US, V38, P3133, DOI 10.1021/bi982304s; Wakui H, 1997, J BIOL CHEM, V272, P8153, DOI 10.1074/jbc.272.13.8153; Wang HN, 1998, J BIOL CHEM, V273, P16297, DOI 10.1074/jbc.273.26.16297; Wang WF, 1996, J MOL EVOL, V43, P384; Weber K, 1997, FEBS LETT, V419, P87, DOI 10.1016/S0014-5793(97)01436-1; Westermann S, 2003, NAT REV MOL CELL BIO, V4, P938, DOI 10.1038/nrm1260; Wurtele M, 2003, EMBO J, V22, P987, DOI 10.1093/emboj/cdg104; Xia L, 2000, J CELL BIOL, V149, P1097, DOI 10.1083/jcb.149.5.1097; Xiao Bing, 1995, Nature (London), V376, P188, DOI 10.1038/376188a0; Yaffe MB, 1997, CELL, V91, P961, DOI 10.1016/S0092-8674(00)80487-0; Yang H, 2003, MOL BIOCHEM PARASIT, V128, P167, DOI 10.1016/S0166-6851(03)00072-0	52	42	45	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 24	2006	281	8					5137	5148		10.1074/jbc.M509673200	http://dx.doi.org/10.1074/jbc.M509673200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	013RF	16368691	hybrid			2022-12-25	WOS:000235426200068
J	Vos, MD; Dallol, A; Eckfeld, K; Allen, NPC; Donninger, H; Hesson, LB; Calvisi, D; Latif, F; Clark, GJ				Vos, MD; Dallol, A; Eckfeld, K; Allen, NPC; Donninger, H; Hesson, LB; Calvisi, D; Latif, F; Clark, GJ			The RASSF1A tumor suppressor activates Bax via MOAP-1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EPIGENETIC INACTIVATION; RAS; FAMILY; PROTEIN; BREAST; NORE1; GENE; IDENTIFICATION; EFFECTOR; KINASE	The novel tumor suppressor RASSF1A is frequently inactivated during human tumorigenesis by promoter methylation. RASSF1A may serve as a node in the integration of signaling pathways controlling a range of critical cellular functions including cell cycle, genomic instability, and apoptosis. The mechanism of action of RASSF1A remains under investigation. We now identify a novel pathway connecting RASSF1A to Bax via the Bax binding protein MOAP-1. RASSF1A and MOAP-1 interact directly, and this interaction is enhanced by the presence of activated K-Ras. RASSF1A can activate Bax via MOAP-1. Moreover, activated K-Ras, RASSF1A, and MOAP-1 synergize to induce Bax activation and cell death. Analysis of a tumor-derived point mutant of RASSF1A showed that the mutant was defective for the MOAP-1 interaction and for Bax activation. Moreover, inhibition of RASSF1A by shRNA impaired the ability of K-Ras to activate Bax. Thus, we identify a novel pro-apoptotic pathway linking K-Ras, RASSF1A and Bax that is specifically impaired in some human tumors.	NCI, Dept Cell & Canc Biol, Rockville, MD 20850 USA; Univ Sassari, Dept Biomed Sci, I-07110 Sassari, Italy; Univ Birmingham, Div Reprod & Child Hlth, Sect Med & Mol Genet, Birmingham B15 2TT, W Midlands, England	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); University of Sassari; University of Birmingham	Clark, GJ (corresponding author), NCI, Dept Cell & Canc Biol, 9610 Med Ctr Dr, Rockville, MD 20850 USA.	gclark@mail.nih.gov	Donninger, Howard/I-9874-2019; Dallol, Ashraf/H-8661-2012	Donninger, Howard/0000-0002-8589-1660; Dallol, Ashraf/0000-0002-8803-228X				Agathanggelou A, 2005, CANCER RES, V65, P3497, DOI 10.1158/0008-5472.CAN-04-4088; Agathanggelou A, 2001, ONCOGENE, V20, P1509, DOI 10.1038/sj.onc.1204175; BRTVA TR, 1995, J BIOL CHEM, V270, P9809, DOI 10.1074/jbc.270.17.9809; Burbee DG, 2001, JNCI-J NATL CANCER I, V93, P691, DOI 10.1093/jnci/93.9.691; Chan EH, 2005, ONCOGENE, V24, P2076, DOI 10.1038/sj.onc.1208445; Chen JD, 2003, CANCER CELL, V4, P405, DOI 10.1016/S1535-6108(03)00269-1; Choi JA, 2004, ONCOGENE, V23, P9, DOI 10.1038/sj.onc.1206982; Clark GJ, 1997, J BIOL CHEM, V272, P20990, DOI 10.1074/jbc.272.34.20990; Dallol A, 2004, CANCER RES, V64, P4112, DOI 10.1158/0008-5472.CAN-04-0267; Dammann R, 2001, CANCER RES, V61, P3105; Dammann R, 2000, NAT GENET, V25, P315, DOI 10.1038/77083; Eckfeld K, 2004, CANCER RES, V64, P8688, DOI 10.1158/0008-5472.CAN-04-2065; Fenton SL, 2004, CANCER RES, V64, P102, DOI 10.1158/0008-5472.CAN-03-2622; Harada K, 2002, ONCOGENE, V21, P4345, DOI 10.1038/sj.onc.1205446; Ke HN, 2004, EXP CELL RES, V298, P329, DOI 10.1016/j.yexcr.2004.04.031; Khokhlatchev A, 2002, CURR BIOL, V12, P253, DOI 10.1016/S0960-9822(02)00683-8; Kiel C, 2005, J MOL BIOL, V348, P759, DOI 10.1016/j.jmb.2005.02.046; Kuzmin I, 2002, CANCER RES, V62, P3498; Kveiborg M, 2005, CANCER RES, V65, P4754, DOI 10.1158/0008-5472.CAN-05-0262; Liu LM, 2003, ONCOGENE, V22, P8125, DOI 10.1038/sj.onc.1206984; Luo ZJ, 1997, MOL CELL BIOL, V17, P46, DOI 10.1128/MCB.17.1.46; McPherson RA, 1999, ONCOGENE, V18, P3862, DOI 10.1038/sj.onc.1202730; Ponting CP, 1996, TRENDS BIOCHEM SCI, V21, P422, DOI 10.1016/S0968-0004(96)30038-8; Praskova M, 2004, BIOCHEM J, V381, P453, DOI 10.1042/BJ20040025; Rabizadeh S, 2004, J BIOL CHEM, V279, P29247, DOI 10.1074/jbc.M401699200; Rodriguez-Viciana P, 2004, MOL CELL BIOL, V24, P4943, DOI 10.1128/MCB.24.11.4943-4954.2004; Rong R, 2004, ONCOGENE, V23, P8216, DOI 10.1038/sj.onc.1207901; Sharpe JC, 2004, BBA-MOL CELL RES, V1644, P107, DOI 10.1016/j.bbamcr.2003.10.016; Shivakumar L, 2002, MOL CELL BIOL, V22, P4309, DOI 10.1128/MCB.22.12.4309-4318.2002; Song MS, 2004, NAT CELL BIOL, V6, P129, DOI 10.1038/ncb1091; Tan KO, 2001, J BIOL CHEM, V276, P2802, DOI 10.1074/jbc.M008955200; Tommasi S, 2005, CANCER RES, V65, P92; Vavvas D, 1998, J BIOL CHEM, V273, P5439, DOI 10.1074/jbc.273.10.5439; Vos MD, 2003, J BIOL CHEM, V278, P21938, DOI 10.1074/jbc.M211019200; Vos MD, 2003, J BIOL CHEM, V278, P28045, DOI 10.1074/jbc.M300554200; Vos MD, 2004, CANCER RES, V64, P4244, DOI 10.1158/0008-5472.CAN-04-0339; Vos MD, 2000, J BIOL CHEM, V275, P35669, DOI 10.1074/jbc.C000463200; Wolter KG, 1997, J CELL BIOL, V139, P1281, DOI 10.1083/jcb.139.5.1281; Xia H, 2002, ONCOGENE, V21, P1233, DOI 10.1038/sj.onc.1205174	39	101	105	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 24	2006	281	8					4557	4563		10.1074/jbc.M512128200	http://dx.doi.org/10.1074/jbc.M512128200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	013RF	16344548	hybrid			2022-12-25	WOS:000235426200002
J	Brown, L; Benchimol, S				Brown, L; Benchimol, S			The involvement of MAPK signaling pathways in determining the cellular response to p53 activation - Cell cycle arrest or apoptosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FOCUS-FORMING VIRUS; RECEPTOR TYROSINE KINASE; P53-MEDIATED APOPTOSIS; PROTEIN-KINASE; GROWTH ARREST; FRIEND-VIRUS; PHOSPHATIDYLINOSITOL 3-KINASE; P53-DEPENDENT APOPTOSIS; CONSTITUTIVE ACTIVATION; ERYTHROPOIETIN RECEPTOR	The effect of ERK, p38, and JNK signaling on p53-dependent apoptosis and cell cycle arrest was investigated using a Friend murine erythroleukemia virus (FVP)-transformed cell line that expresses a temperature-sensitive p53 allele, DP16.1/p53ts. In response to p53 activation at 32 degrees C, DP16.1/p53ts cells undergo p53-dependent G(1) cell cycle arrest and apoptosis. As a result of viral transformation, these cells express the spleen focus forming env-related glycoprotein gp55, which can bind to the erythropoietin receptor (EPO-R) and mimics many aspects of EPO-induced EPO-R signaling. We demonstrate that ERK, p38 and JNK mitogen-activated protein kinases (MAPKs) are constitutively active in DP16.1/p53ts cells. Constitutive MEK activity contributes to p53-dependent apoptosis and phosphorylation of p53 on serine residue 15. The pro-apoptotic effect of this MAPK kinase signal likely reflects an aberrant Ras proliferative signal arising from FVP-induced viral transformation. Inhibition of MEK alters the p53-dependent cellular response of DP16.1/p53ts from apoptosis to G(1) cell cycle arrest, with a concomitant increase in p21(WAF1), suggesting that the Ras/MEK pathway may influence the cellular response to p53 activation. p38 and JNK activity in DP16.1/p53ts cells is anti-apoptotic and capable of limiting p53-dependent apoptosis at 32 degrees C. Moreover, JNK facilitates p53 protein turnover, which could account for the enhanced apoptotic effects of inhibiting this MAPK pathway in DP16.1/p53ts cells. Overall, these data show that intrinsic MAPK signaling pathways, active in transformed cells, can both positively and negatively influence p53-dependent apoptosis, and illustrate their potential to affect cancer therapies aimed at reconstituting or activating p53 function.	Ontario Canc Inst, Toronto, ON M5G 2M9, Canada; Univ Toronto, Dept Med Biophys, Toronto, ON M5G 2M9, Canada	University of Toronto; University Toronto Affiliates; University Health Network Toronto; University of Toronto	Benchimol, S (corresponding author), Ontario Canc Inst, 610 Univ Ave, Toronto, ON M5G 2M9, Canada.	benchimo@uhnres.utoronto.ca		Benchimol, Samuel/0000-0003-3433-890X				ABRAHAMSON JLA, 1995, MOL CELL BIOL, V15, P6953; Ashcroft M, 1999, MOL CELL BIOL, V19, P1751; Bates S, 1999, CELL MOL LIFE SCI, V55, P28, DOI 10.1007/s000180050267; Benchimol S, 2001, CELL DEATH DIFFER, V8, P1049, DOI 10.1038/sj.cdd.4400918; Bergmann A, 2002, DEV CELL, V2, P159, DOI 10.1016/S1534-5807(02)00116-8; CANMAN CE, 1995, GENE DEV, V9, P600, DOI 10.1101/gad.9.5.600; CHIOU SK, 1994, MOL CELL BIOL, V14, P2556, DOI 10.1128/MCB.14.4.2556; Cory S, 2002, NAT REV CANCER, V2, P647, DOI 10.1038/nrc883; Datta SR, 1997, CELL, V91, P231, DOI 10.1016/S0092-8674(00)80405-5; Davis RJ, 2000, CELL, V103, P239, DOI 10.1016/S0092-8674(00)00116-1; Evan G, 1998, SCIENCE, V281, P1317, DOI 10.1126/science.281.5381.1317; Finkelstein LD, 2002, ONCOGENE, V21, P3562, DOI 10.1038/sj.onc.1205442; Fuchs SY, 1998, GENE DEV, V12, P2658, DOI 10.1101/gad.12.17.2658; Fuchs SY, 1998, P NATL ACAD SCI USA, V95, P10541, DOI 10.1073/pnas.95.18.10541; FUKUNAGAJOHNSON N, 1995, CARCINOGENESIS, V16, P1761, DOI 10.1093/carcin/16.8.1761; Gardner AM, 1996, J BIOL CHEM, V271, P14560, DOI 10.1074/jbc.271.24.14560; Gorospe M, 1997, ONCOGENE, V14, P929, DOI 10.1038/sj.onc.1200897; Heinrichs S, 2003, ONCOGENE, V22, P555, DOI 10.1038/sj.onc.1206138; JOHNSON P, 1993, MOL CELL BIOL, V13, P1456, DOI 10.1128/MCB.13.3.1456; JOHNSON P, 1992, CANCER SURV, V12, P137; Kamijo T, 1998, P NATL ACAD SCI USA, V95, P8292, DOI 10.1073/pnas.95.14.8292; KauffmanZeh A, 1997, NATURE, V385, P544, DOI 10.1038/385544a0; LI JP, 1990, NATURE, V343, P762, DOI 10.1038/343762a0; Lin A, 2003, BIOESSAYS, V25, P17, DOI 10.1002/bies.10204; Lin YP, 2002, BLOOD, V100, P3990, DOI 10.1182/blood-2002-02-0504; LIN YP, 1995, MOL CELL BIOL, V15, P6045; Lotem J, 1999, APOPTOSIS, V4, P187, DOI 10.1023/A:1009614723237; Martin-Blanco E, 2000, BIOESSAYS, V22, P637, DOI 10.1002/1521-1878(200007)22:7<637::AID-BIES6>3.0.CO;2-E; MOREAUGACHELIN F, 1988, NATURE, V331, P277, DOI 10.1038/331277a0; MOWAT M, 1985, NATURE, V314, P633, DOI 10.1038/314633a0; Muszynski KW, 1998, J VIROL, V72, P919, DOI 10.1128/JVI.72.2.919-925.1998; Muszynski KW, 2000, J VIROL, V74, P8444, DOI 10.1128/JVI.74.18.8444-8451.2000; Nagata Y, 1997, BLOOD, V89, P2664, DOI 10.1182/blood.V89.8.2664; Nagata Y, 1998, BLOOD, V92, P1859, DOI 10.1182/blood.V92.6.1859.418k37_1859_1869; Ney PA, 2000, BLOOD, V96, P3675, DOI 10.1182/blood.V96.12.3675.h8003675_3675_3680; Nishigaki K, 2001, J VIROL, V75, P7893, DOI 10.1128/JVI.75.17.7893-7903.2001; Nishigaki K, 2000, J VIROL, V74, P3037, DOI 10.1128/JVI.74.7.3037-3045.2000; Oldham SM, 1996, P NATL ACAD SCI USA, V93, P6924, DOI 10.1073/pnas.93.14.6924; Parrizas M, 1997, J BIOL CHEM, V272, P154; Persons DA, 1999, NAT GENET, V23, P159, DOI 10.1038/13787; Persons DL, 2000, J BIOL CHEM, V275, P35778, DOI 10.1074/jbc.M004267200; Polyak K, 1996, GENE DEV, V10, P1945, DOI 10.1101/gad.10.15.1945; Pomerantz J, 1998, CELL, V92, P713, DOI 10.1016/S0092-8674(00)81400-2; Quelle FW, 1998, GENE DEV, V12, P1099, DOI 10.1101/gad.12.8.1099; Ruscetti SK, 1999, INT J BIOCHEM CELL B, V31, P1089, DOI 10.1016/S1357-2725(99)00074-6; Sabbatini P, 1999, J BIOL CHEM, V274, P24263, DOI 10.1074/jbc.274.34.24263; SALE EM, 1995, EMBO J, V14, P674, DOI 10.1002/j.1460-2075.1995.tb07046.x; Schmitt CA, 1999, J PATHOL, V187, P127; SCHOTT AF, 1995, ONCOGENE, V11, P1389; Serrano M, 1997, CELL, V88, P593, DOI 10.1016/S0092-8674(00)81902-9; She QB, 2000, J BIOL CHEM, V275, P20444, DOI 10.1074/jbc.M001020200; Thompson T, 2004, J BIOL CHEM, V279, P53015, DOI 10.1074/jbc.M410233200; Tian H, 2000, CANCER RES, V60, P679; Unger T, 1999, ONCOGENE, V18, P3205, DOI 10.1038/sj.onc.1202656; Vousden KH, 2000, CELL, V103, P691, DOI 10.1016/S0092-8674(00)00171-9; Waldman T, 1997, NAT MED, V3, P1034, DOI 10.1038/nm0997-1034; Waldman T, 1996, NATURE, V381, P713, DOI 10.1038/381713a0; Wang SW, 2001, CARCINOGENESIS, V22, P757, DOI 10.1093/carcin/22.5.757; Wang YA, 1997, P NATL ACAD SCI USA, V94, P14590, DOI 10.1073/pnas.94.26.14590; WANG YS, 1995, CELL GROWTH DIFFER, V6, P1071; Wojchowski DM, 1999, EXP CELL RES, V253, P143, DOI 10.1006/excr.1999.4673; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326; YONISHROUACH E, 1991, NATURE, V352, P345, DOI 10.1038/352345a0; Zanke BW, 1996, J BIOL CHEM, V271, P29876, DOI 10.1074/jbc.271.47.29876; Zha JP, 1996, CELL, V87, P619, DOI 10.1016/S0092-8674(00)81382-3; Zhang S, 2004, BRIT J CANCER, V91, P178, DOI 10.1038/sj.bjc.6601902	66	67	70	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 17	2006	281	7					3832	3840		10.1074/jbc.M507951200	http://dx.doi.org/10.1074/jbc.M507951200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	011NN	16330547	hybrid			2022-12-25	WOS:000235275300011
J	Cai, CL; Li, H; Rivera, C; Keinanen, K				Cai, CL; Li, H; Rivera, C; Keinanen, K			Interaction between SAP97 and PSD-95, two Maguk proteins involved in synaptic trafficking of AMPA receptors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LONG-TERM POTENTIATION; POSTSYNAPTIC DENSITY; EXCITATORY SYNAPSES; DISTINCT MECHANISMS; PDZ DOMAINS; MYOSIN-VI; PLASTICITY; SUBUNIT; L27; ORGANIZATION	Synapse-associated protein 97 (SAP97) and postsynaptic density 95 (PSD-95) are closely related membrane-associated guanylate kinase homologs (Maguks) implicated in the synaptic targeting and anchoring of alpha-amino-5-methyl-3-hydroxy-4-isoxazolepropionic acid (AMPA)-selective glutamate receptors. Prompted by accumulating evidence for an oligomeric nature of Maguks, we examined the potential of SAP97 and PSD-95 to form heteromeric complexes. SAP97 and PSD-95 coimmunoprecipitated from rat brain detergent extracts and subsequent glutathione S-transferase pull-down and immunoprecipitation experiments showed that the interaction is mediated by binding of the N-terminal segment of SAP97 (SAP97(NTD)) to the Src homology 3 domain of PSD-95 (PSD-95(SH3)). In cultured hippocampal neurons, expression of green fluorescent protein-tagged PSD-95 triggered accumulation of SAP97 in synaptic spines, which was totally inhibited by coexpression of PSD95(SH3). Furthermore, overexpression of green fluorescent proteinPSD-95 induced dendritic clustering of GluR-A subunit-containing AMPA receptors, which was strongly inhibited by cotransfection with SAP97(NTD) and PSD-95(SH3) constructs. Our results demonstrated a direct interaction between SAP97 and PSD-95 and suggested that this association may play a functional role in the trafficking and clustering of AMPA receptors.	Univ Helsinki, Viikki Bioctr, Dept Biol & Environm Sci, FI-00014 Helsinki, Finland; Univ Helsinki, Viikki Bioctr, Div Biochem, FI-00014 Helsinki, Finland; Univ Helsinki, Viikki Bioctr, Div Physiol, FI-00014 Helsinki, Finland; Univ Helsinki, Viikki Bioctr, Inst Biotechnol, FI-00014 Helsinki, Finland	University of Helsinki; University of Helsinki; University of Helsinki; University of Helsinki	Keinanen, K (corresponding author), Univ Helsinki, Viikki Bioctr, Dept Biol & Environm Sci, POB 56, FI-00014 Helsinki, Finland.	kari.keinanen@helsinki.fi	Keinanen, Kari/E-9122-2010; Rivera, Claudio/ABE-2499-2021	Rivera, Claudio/0000-0003-2462-6561				Bredt DS, 2003, NEURON, V40, P361, DOI 10.1016/S0896-6273(03)00640-8; Cai C, 2002, J BIOL CHEM, V277, P31484, DOI 10.1074/jbc.M204354200; Chen L, 2000, NATURE, V408, P936, DOI 10.1038/35050030; Chetkovich DM, 2002, J NEUROSCI, V22, P6415; Christopherson KS, 2003, J CELL SCI, V116, P3213, DOI 10.1242/jcs.00617; Contro N, 2002, ARCH PEDIAT ADOL MED, V156, P14, DOI 10.1001/archpedi.156.1.14; Doerks T, 2000, TRENDS BIOCHEM SCI, V25, P317, DOI 10.1016/S0968-0004(00)01599-1; Ehrlich I, 2004, J NEUROSCI, V24, P916, DOI 10.1523/JNEUROSCI.4733-03.2004; El-Hussein AE, 2000, SCIENCE, V290, P1364; Feng W, 2004, NAT STRUCT MOL BIOL, V11, P475, DOI 10.1038/nsmb751; Garner CC, 2000, TRENDS CELL BIOL, V10, P274, DOI 10.1016/S0962-8924(00)01783-9; Hata Y, 1999, CELL MOL LIFE SCI, V56, P461, DOI 10.1007/s000180050445; Hayashi Y, 2000, SCIENCE, V287, P2262, DOI 10.1126/science.287.5461.2262; Hsueh YP, 1997, NEURON, V18, P803, DOI 10.1016/S0896-6273(00)80319-0; Kim E, 1996, NEURON, V17, P103, DOI 10.1016/S0896-6273(00)80284-6; Kim EJ, 2004, NAT REV NEUROSCI, V5, P771, DOI 10.1038/nrn1517; Lee S, 2002, MOL CELL BIOL, V22, P1778, DOI 10.1128/MCB.22.6.1778-1791.2002; Leonard AS, 1998, J BIOL CHEM, V273, P19518, DOI 10.1074/jbc.273.31.19518; Li YH, 2004, EMBO J, V23, P2723, DOI 10.1038/sj.emboj.7600294; Malinow R, 2002, ANNU REV NEUROSCI, V25, P103, DOI 10.1146/annurev.neuro.25.112701.142758; Marfatia SM, 2000, J BIOL CHEM, V275, P13759, DOI 10.1074/jbc.275.18.13759; Masuko N, 1999, J BIOL CHEM, V274, P5782, DOI 10.1074/jbc.274.9.5782; Mauceri D, 2004, J BIOL CHEM, V279, P23813, DOI 10.1074/jbc.M402796200; McGee AW, 2003, CURR OPIN NEUROBIOL, V13, P111, DOI 10.1016/S0959-4388(03)00008-4; McGee AW, 2001, MOL CELL, V8, P1291, DOI 10.1016/S1097-2765(01)00411-7; McLaughlin M, 2002, J BIOL CHEM, V277, P6406, DOI 10.1074/jbc.M108724200; Mehta S, 2001, J BIOL CHEM, V276, P16092, DOI 10.1074/jbc.M100643200; Montgomery JM, 2004, CELL MOL LIFE SCI, V61, P911, DOI 10.1007/s00018-003-3364-5; Nakagawa T, 2004, NEURON, V44, P453, DOI 10.1016/j.neuron.2004.10.012; Osterweil E, 2005, J CELL BIOL, V168, P329, DOI 10.1083/jcb.200410091; Passafaro M, 2001, NAT NEUROSCI, V4, P917, DOI 10.1038/nn0901-917; Piccini A, 2002, J NEUROSCI, V22, P5387; Rumbaugh G, 2003, J NEUROSCI, V23, P4567; Sans N, 2001, J NEUROSCI, V21, P7506, DOI 10.1523/JNEUROSCI.21-19-07506.2001; Schnell E, 2002, P NATL ACAD SCI USA, V99, P13902, DOI 10.1073/pnas.172511199; Sheng M, 2001, ANNU REV NEUROSCI, V24, P1, DOI 10.1146/annurev.neuro.24.1.1; Sheng M, 2003, NEUROSCI RES, V46, P127, DOI 10.1016/S0168-0102(03)00040-3; Shi SH, 2001, CELL, V105, P331, DOI 10.1016/S0092-8674(01)00321-X; Stein V, 2003, J NEUROSCI, V23, P5503; Tavares GA, 2001, MOL CELL, V8, P1313, DOI 10.1016/S1097-2765(01)00416-6; Tomita S, 2003, J CELL BIOL, V161, P805, DOI 10.1083/jcb.200212116; Valtschanoff JG, 2000, EUR J NEUROSCI, V12, P3605, DOI 10.1046/j.1460-9568.2000.00256.x; Vinade L, 2003, J NEUROCHEM, V87, P1255, DOI 10.1046/j.1471-4159.2003.02091.x; Wu HJ, 2000, EMBO J, V19, P5740, DOI 10.1093/emboj/19.21.5740; Wu HJ, 2002, J BIOL CHEM, V277, P30928, DOI 10.1074/jbc.M203735200	45	39	39	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 17	2006	281	7					4267	4273		10.1074/jbc.M505886200	http://dx.doi.org/10.1074/jbc.M505886200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	011NN	16332687	hybrid			2022-12-25	WOS:000235275300060
J	Field, MS; Szebenyi, DME; Stover, PJ				Field, MS; Szebenyi, DME; Stover, PJ			Regulation of de novo purine biosynthesis by methenyltetrahydrofolate synthetase in neuroblastoma	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							5,10-METHENYLTETRAHYDROFOLATE SYNTHETASE; SERINE HYDROXYMETHYLTRANSFERASE; RABBIT LIVER; BINDING-SITE; FOLATE; 5-FORMYLTETRAHYDROFOLATE; PURIFICATION; HOMOCYSTEINE; INHIBITION; HYDROLYSIS	5-Formyltetrahydrofolate (5-formylTHF) is the only folate derivative that does not serve as a cofactor in folate-dependent one-carbon metabolism. Two metabolic roles have been ascribed to this folate derivative. It has been proposed to 1) serve as a storage form of folate because it is chemically stable and accumulates in seeds and spores and 2) regulate folate-dependent one-carbon metabolism by inhibiting folate-dependent enzymes, specifically targeting folate-dependent de novo purine biosynthesis. Methenyltetrahydrofolate synthetase (MTHFS) is the only enzyme that metabolizes 5-formylTHF and catalyzes its ATP-dependent conversion to 5,10-methenylTHF. This reaction determines intracellular 5-formylTHF concentrations and converts 5-formylTHF into an enzyme cofactor. The regulation and metabolic role of MTHFS in one-carbon metabolism was investigated in vitro and in human neuroblastoma cells. Steady-state kinetic studies revealed that 10-formylTHF, which exists in chemical equilibrium with 5,10-methenylTHF, acts as a tight binding inhibitor of mouse MTHFS. [6R]-10-formylTHF inhibited MTHFS with a K-i of 150 nM, and [6R, S]-10-formylTHF triglutamate inhibited MTHFS with a Ki of 30 nM. MTHFS is the first identified 10-formylTHF tight-binding protein. Isotope tracer studies in neuroblastoma demonstrate that MTHFS enhances de novo purine biosynthesis, indicating that MTHFS-bound 10-formylTHF facilitates de novo purine biosynthesis. Feedback metabolic regulation of MTHFS by 10-formylTHF indicates that 5-formylTHF can only accumulate in the presence of 10-formylTHF, providing the first evidence that 5-formylTHF is a storage form of excess formylated folates in mammalian cells. The sequestration of 10-formylTHF by MTHFS may explain why de novo purine biosynthesis is protected from common disruptions in the folate-dependent one-carbon network.	Cornell Univ, Div Nutr Sci, Ithaca, NY 14853 USA; Cornell Univ, Grad Field Biochem Mol & Cell Biol, Ithaca, NY 14853 USA; Cornell Univ, Cornell High Energy Synchrotron Source, Ithaca, NY 14853 USA	Cornell University; Cornell University; Cornell University	Stover, PJ (corresponding author), Cornell Univ, Div Nutr Sci, 127 Savage Hall, Ithaca, NY 14853 USA.	pjs13@cornell.edu	Szebenyi, Marian/GMX-2709-2022	Field, Martha/0000-0001-7547-5180	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD035687] Funding Source: NIH RePORTER; NICHD NIH HHS [HD35687] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; Anguera MC, 2004, PROTEIN EXPRES PURIF, V35, P276, DOI 10.1016/j.pep.2004.02.010; Anguera MC, 2003, J BIOL CHEM, V278, P29856, DOI 10.1074/jbc.M302883200; Bailey LB, 1999, J NUTR, V129, P919, DOI 10.1093/jn/129.5.919; BERTRAND R, 1987, BIOCHIM BIOPHYS ACTA, V911, P154, DOI 10.1016/0167-4838(87)90004-5; BERTRAND R, 1989, J BIOL CHEM, V264, P8843; Boeckmann B, 2003, NUCLEIC ACIDS RES, V31, P365, DOI 10.1093/nar/gkg095; Chen SF, 2005, PROTEINS, V61, P433, DOI 10.1002/prot.20591; Chen SF, 2004, PROTEINS, V56, P839, DOI 10.1002/prot.20214; Clarke S, 2001, HOMOCYSTEINE IN HEALTH AND DISEASE, P63; Finkelstein JD, 2000, SEMIN THROMB HEMOST, V26, P219, DOI 10.1055/s-2000-8466; Finkelstein JD, 2000, NUTR REV, V58, P193, DOI 10.1111/j.1753-4887.2000.tb01862.x; Friso S, 2002, ANAL CHEM, V74, P4526, DOI 10.1021/ac020050h; Fu TF, 1999, ARCH BIOCHEM BIOPHYS, V367, P161, DOI 10.1006/abbi.1999.1262; Girgis S, 1997, J BIOL CHEM, V272, P4729, DOI 10.1074/jbc.272.8.4729; Herbig K, 2002, J BIOL CHEM, V277, P38381, DOI 10.1074/jbc.M205000200; Higgins DG, 1996, METHOD ENZYMOL, V266, P383; Holmes WB, 2002, J BIOL CHEM, V277, P20205, DOI 10.1074/jbc.M201242200; HOPKINS S, 1984, J BIOL CHEM, V259, P5618; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Kisliuk RL, 2003, CURR PHARM DESIGN, V9, P2615, DOI 10.2174/1381612033453695; Kisliuk RL, 2000, PHARMACOL THERAPEUT, V85, P183, DOI 10.1016/S0163-7258(99)00056-X; Koradi R, 1996, J MOL GRAPHICS, V14, P29; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; KRUSCHWITZ HL, 1994, J BIOL CHEM, V269, P28757; MARAS B, 1994, J BIOL CHEM, V269, P18429; Marsilje TH, 2002, BIOORGAN MED CHEM, V10, P2739, DOI 10.1016/S0968-0896(02)00102-5; McGuire JJ, 2003, CURR PHARM DESIGN, V9, P2593, DOI 10.2174/1381612033453712; Merritt EA, 1997, METHOD ENZYMOL, V277, P505, DOI 10.1016/S0076-6879(97)77028-9; MORAN RG, 1986, METHOD ENZYMOL, V122, P309; Moran RG, 1999, SEMIN ONCOL, V26, P24; Roje S, 2002, J BIOL CHEM, V277, P42748, DOI 10.1074/jbc.M205632200; SCHIRCH V, 1989, ARCH BIOCHEM BIOPHYS, V269, P371, DOI 10.1016/0003-9861(89)90120-3; Schwede T, 2003, NUCLEIC ACIDS RES, V31, P3381, DOI 10.1093/nar/gkg520; Shane B., 1995, FOLATE HLTH DIS, V2, P1; STOVER P, 1993, TRENDS BIOCHEM SCI, V18, P102, DOI 10.1016/0968-0004(93)90162-G; STOVER P, 1992, ANAL BIOCHEM, V202, P82, DOI 10.1016/0003-2697(92)90210-X; STOVER P, 1992, BIOCHEMISTRY-US, V31, P2148, DOI 10.1021/bi00122a036; STOVER P, 1992, BIOCHEMISTRY-US, V31, P2155, DOI 10.1021/bi00122a037; STOVER P, 1990, J BIOL CHEM, V265, P14227; Stover PJ, 2004, NUTR REV, V62, pS3, DOI 10.1111/j.1753-4887.2004.tb00070.x; Suh JR, 2001, ANNU REV NUTR, V21, P255, DOI 10.1146/annurev.nutr.21.1.255; Wagner C, 1995, FOLATE HLTH DIS, P23; Yeo EJ, 1999, J BIOL CHEM, V274, P37559, DOI 10.1074/jbc.274.53.37559; Zhao RB, 2003, ONCOGENE, V22, P7431, DOI 10.1038/sj.onc.1206946	45	41	42	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 17	2006	281	7					4215	4221		10.1074/jbc.M510624200	http://dx.doi.org/10.1074/jbc.M510624200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	011NN	16365037	hybrid			2022-12-25	WOS:000235275300054
J	Okamoto, M; Yoko-o, T; Umemura, M; Nakayama, K; Jigami, Y				Okamoto, M; Yoko-o, T; Umemura, M; Nakayama, K; Jigami, Y			Glycosylphosphatidylinositol-anchored proteins are required for the transport of detergent-resistant microdomain-associated membrane proteins Tat2p and Fur4p	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							YEAST URACIL PERMEASE; SACCHAROMYCES-CEREVISIAE; PLASMA-MEMBRANE; TRYPTOPHAN PERMEASE; CELL-WALL; INOSITOL ACYLATION; LIPID RAFTS; STRUCTURAL-CHARACTERIZATION; MAMMALIAN-CELLS; HIGH-PRESSURE	In eukaryotic cells many cell surface proteins are attached to the membrane via the glycosylphosphatidylinositol (GPI) moiety. In yeast, GPI also plays important roles in the production of manno-protein in the cell wall. We previously isolated gwt1 mutants and found that GWT1 is required for inositol acylation in the GPI bio-synthetic pathway. In this study we isolated a new gwt1 mutant allele, gwt1-10, that shows not only high temperature sensitivity but also low temperature sensitivity. The gwt1-10 cells show impaired acyltransferase activity and attachment of GPI to proteins even at the permissive temperature. We identified TAT2, which encodes a high affinity tryptophan permease, as a multicopy suppressor of cold sensitivity in gwt1-10 cells. The gwt1-10 cells were also defective in the import of tryptophan, and a lack of tryptophan caused low temperature sensitivity. Microscopic observation revealed that Tat2p is not transported to the plasma membrane but is retained in the endoplasmic reticulum in gwt1-10 cells grown under tryptophan-poor conditions. We found that Tat2p was not associated with detergent-resistant membranes (DRMs), which are required for the recruitment of Tat2p to the plasma membrane. A similar result was obtained for Fur4p, a uracil permease localized in the DRMs of the plasma membrane. These results indicate that GPI-anchored proteins are required for the recruitment of membrane proteins Tat2p and Fur4p to the plasma membrane via DRMs, suggesting that some membrane proteins are redistributed in the cell in response to environmental and nutritional conditions due to an association with DRMs that is dependent on GPI-anchored proteins.	AIST, Res Ctr Glycosci, Tsukuba, Ibaraki 3058566, Japan	National Institute of Advanced Industrial Science & Technology (AIST)	Jigami, Y (corresponding author), AIST, Res Ctr Glycosci, Tsukuba Cent 6,1-1-1 Higashi, Tsukuba, Ibaraki 3058566, Japan.	jigami.yoshi@aist.go.jp	Yoko-o, Takehiko/L-7093-2018	Yoko-o, Takehiko/0000-0003-0291-8299; Okamoto, michiyo/0000-0003-4280-6048				Abe F, 2000, MOL CELL BIOL, V20, P8093, DOI 10.1128/MCB.20.21.8093-8102.2000; Bagnat M, 2000, P NATL ACAD SCI USA, V97, P3254, DOI 10.1073/pnas.060034697; Bagnat M, 2001, MOL BIOL CELL, V12, P4129, DOI 10.1091/mbc.12.12.4129; Beck T, 1999, J CELL BIOL, V146, P1227, DOI 10.1083/jcb.146.6.1227; Benachour A, 1999, J BIOL CHEM, V274, P15251, DOI 10.1074/jbc.274.21.15251; BENGHEZAL M, 1995, J CELL BIOL, V130, P1333, DOI 10.1083/jcb.130.6.1333; Blondel MO, 2004, MOL BIOL CELL, V15, P883, DOI 10.1091/mbc.E03-04-0202; BROWN DA, 1992, CELL, V68, P533, DOI 10.1016/0092-8674(92)90189-J; Campbell RE, 2002, P NATL ACAD SCI USA, V99, P7877, DOI 10.1073/pnas.082243699; CHVATCHKO Y, 1986, CELL, V46, P355, DOI 10.1016/0092-8674(86)90656-2; CONZELMANN A, 1990, EMBO J, V9, P653, DOI 10.1002/j.1460-2075.1990.tb08157.x; COSTELLO LC, 1992, J BIOL CHEM, V267, P8599; Dupre S, 2003, TRAFFIC, V4, P83, DOI 10.1034/j.1600-0854.2003.40204.x; Eisen A, 2001, J BIOL CHEM, V276, P3484, DOI 10.1074/jbc.M008159200; ENGLUND PT, 1993, ANNU REV BIOCHEM, V62, P121, DOI 10.1146/annurev.bi.62.070193.001005; FIEDLER K, 1993, BIOCHEMISTRY-US, V32, P6365, DOI 10.1021/bi00076a009; Fujita M, 2004, J BIOL CHEM, V279, P51869, DOI 10.1074/jbc.M405232200; GABER RF, 1989, MOL CELL BIOL, V9, P3447, DOI 10.1128/MCB.9.8.3447; Galan JM, 1996, J BIOL CHEM, V271, P10946, DOI 10.1074/jbc.271.18.10946; HAMBURGER D, 1995, J CELL BIOL, V129, P629, DOI 10.1083/jcb.129.3.629; Hearn JD, 2003, J BIOL CHEM, V278, P3679, DOI 10.1074/jbc.M209170200; HEITMAN J, 1993, MOL CELL BIOL, V13, P5010, DOI 10.1128/MCB.13.8.5010; HIROSE S, 1992, J BIOL CHEM, V267, P16968; HOMANS SW, 1988, NATURE, V333, P269, DOI 10.1038/333269a0; HORVATH A, 1994, EMBO J, V13, P3687, DOI 10.1002/j.1460-2075.1994.tb06678.x; KAMITANI T, 1992, J BIOL CHEM, V267, P24611; Kapteyn JC, 1999, BBA-GEN SUBJECTS, V1426, P373, DOI 10.1016/S0304-4165(98)00137-8; Keller P, 1998, J CELL BIOL, V140, P1357, DOI 10.1083/jcb.140.6.1357; KLIS FM, 1994, YEAST, V10, P851, DOI 10.1002/yea.320100702; Lafont F, 1998, J CELL BIOL, V142, P1413, DOI 10.1083/jcb.142.6.1413; Lafont F, 2001, P NATL ACAD SCI USA, V98, P3180, DOI 10.1073/pnas.051003498; Ledesma MD, 1998, P NATL ACAD SCI USA, V95, P3966, DOI 10.1073/pnas.95.7.3966; LEIDICH SD, 1994, J BIOL CHEM, V269, P10193; LEIDICH SD, 1995, J BIOL CHEM, V270, P13029, DOI 10.1074/jbc.270.22.13029; LISANTI MP, 1990, J MEMBRANE BIOL, V117, P1, DOI 10.1007/BF01871561; Longtine MS, 1998, YEAST, V14, P953, DOI 10.1002/(SICI)1097-0061(199807)14:10<953::AID-YEA293>3.3.CO;2-L; Malinska K, 2004, J CELL SCI, V117, P6031, DOI 10.1242/jcs.01493; Malinska K, 2003, MOL BIOL CELL, V14, P4427, DOI 10.1091/mbc.E03-04-0221; MCCONVILLE MJ, 1993, BIOCHEM J, V294, P305, DOI 10.1042/bj2940305; Muniz M, 2001, CELL, V104, P313, DOI 10.1016/S0092-8674(01)00215-X; Muniz M, 2000, EMBO J, V19, P10, DOI 10.1093/emboj/19.1.10; Murakami Y, 2003, MOL BIOL CELL, V14, P4285, DOI 10.1091/mbc.E03-03-0193; Nagayama A, 2004, EXTREMOPHILES, V8, P143, DOI 10.1007/s00792-003-0373-0; NOVICK P, 1980, CELL, V21, P205, DOI 10.1016/0092-8674(80)90128-2; Papa FR, 1999, MOL BIOL CELL, V10, P741, DOI 10.1091/mbc.10.3.741; Pfund C, 1998, EMBO J, V17, P3981, DOI 10.1093/emboj/17.14.3981; PUOTI A, 1992, J BIOL CHEM, V267, P22673; Reggiori F, 1997, EMBO J, V16, P3506, DOI 10.1093/emboj/16.12.3506; ROBERTS WL, 1988, J BIOL CHEM, V263, P18776; SCHMIDT A, 1994, MOL CELL BIOL, V14, P6597, DOI 10.1128/MCB.14.10.6597; SHERMAN F, 1991, METHOD ENZYMOL, V194, P3; Sievi E, 2001, TRAFFIC, V2, P896, DOI 10.1034/j.1600-0854.2001.21205.x; Simons K, 2000, NAT REV MOL CELL BIO, V1, P31, DOI 10.1038/35036052; Simons K, 1997, NATURE, V387, P569, DOI 10.1038/42408; SIPOS G, 1994, EMBO J, V13, P2789, DOI 10.1002/j.1460-2075.1994.tb06572.x; Sutterlin C, 1997, J CELL SCI, V110, P2703; Tsukahara K, 2003, MOL MICROBIOL, V48, P1029, DOI 10.1046/j.1365-2958.2003.03481.x; Umebayashi K, 2003, J CELL BIOL, V161, P1117, DOI 10.1083/jcb.200303088; Umemura M, 2003, J BIOL CHEM, V278, P23639, DOI 10.1074/jbc.M301044200; VOSSEN JH, 1995, BBA-GEN SUBJECTS, V1243, P549, DOI 10.1016/0304-4165(95)00002-S; Watanabe R, 2002, J BIOL CHEM, V277, P49538, DOI 10.1074/jbc.M206209200; Yashiroda H, 1998, GENE, V225, P39, DOI 10.1016/S0378-1119(98)00535-6	62	39	40	1	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 17	2006	281	7					4013	4023		10.1074/jbc.M504684200	http://dx.doi.org/10.1074/jbc.M504684200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	011NN	16361252	hybrid			2022-12-25	WOS:000235275300030
J	Saerens, SMG; Verstrepen, KJ; Van Laere, SDM; Voet, ARD; Van Dijck, P; Delvaux, FR; Thevelein, JM				Saerens, SMG; Verstrepen, KJ; Van Laere, SDM; Voet, ARD; Van Dijck, P; Delvaux, FR; Thevelein, JM			The Saccharomyces cerevisiae EHT1 and EEB1 genes encode novel enzymes with medium-chain fatty acid ethyl ester synthesis and hydrolysis capacity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HYDROLASE; GENOME; GENTHREADER; EFFICIENT; SEQUENCE; CELLS	Fatty acid ethyl esters are secondary metabolites produced by Saccharomyces cerevisiae and many other fungi. Their natural physiological role is not known but in fermentations of alcoholic beverages and other food products they play a key role as flavor compounds. Information about the metabolic pathways and enzymology of fatty acid ethyl ester biosynthesis, however, is very limited. In this work, we have investigated the role of a three-member S. cerevisiae gene family with moderately divergent sequences (YBR177c/EHT1,YPL095c/EEB1, and YMR210w). We demonstrate that two family members encode an acyl-coenzymeA: ethanol O-acyltransferase, an enzyme required for the synthesis of medium-chain fatty acid ethyl esters. Deletion of either one or both of these genes resulted in severely reduced medium-chain fatty acid ethyl ester production. Purified glutathione S-transferase-tagged Eht1 and Eeb1 proteins both exhibited acyl-coenzymeA: ethanol O-acyltransferase activity in vitro, as well as esterase activity. Overexpression of Eht1 and Eeb1 did not enhance medium-chain fatty acid ethyl ester content, which is probably due to the bifunctional synthesis and hydrolysis activity. Molecular modeling of Eht1 and Eeb1 revealed the presence of a alpha/beta-hydrolase fold, which is generally present in the substrate-binding site of esterase enzymes. Hence, our results identify Eht1 and Eeb1 as novel acyl- coenzymeA: ethanol O-acyltransferases/esterases, whereas the third family member, Ymr210w, does not seem to play an important role in medium-chain fatty acid ethyl ester formation.	Katholieke Univ Leuven, Inst Bot & Microbiol, Mol Cell Biol Lab, B-3001 Heverlee, Belgium; Flemish Interuniv Inst Biotechnol, Dept Mol Microbiol, B-3001 Heverlee, Belgium; Katholieke Univ Leuven, Dept Microbial & Mol Syst, Ctr Food & Microbial Technol, B-3001 Heverlee, Belgium; Harvard Univ, Bauer Ctr Genom Res, Cambridge, MA 02138 USA; Katholieke Univ Leuven, Dept Chem, Lab Biomol Modeling, B-3001 Heverlee, Belgium	KU Leuven; KU Leuven; Harvard University; KU Leuven	Thevelein, JM (corresponding author), Katholieke Univ Leuven, Inst Bot & Microbiol, Mol Cell Biol Lab, Kastellpk Arenberg 31, B-3001 Heverlee, Belgium.	Johan.Thevelein@bio.kuleuven.be	Thevelein, Johan M./AAK-4203-2021; Thevelein, Johan M./A-7897-2013; Verstrepen, Kevin/AAA-4343-2021; voet, arnout/O-5248-2014	Thevelein, Johan M./0000-0002-2626-0180; Verstrepen, Kevin/0000-0002-3077-6219; voet, arnout/0000-0002-3329-2703				ANSARI GAS, 1995, TOXICOL LETT, V75, P1, DOI 10.1016/0378-4274(94)03171-3; Athenstaedt K, 1999, J BACTERIOL, V181, P6441, DOI 10.1128/JB.181.20.6441-6448.1999; Ausubel FM, 1994, CURRENT PROTOCOLS MO; Balakrishnan R, 2005, NUCLEIC ACIDS RES, V33, pD374, DOI 10.1093/nar/gki023; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Criddle DN, 2004, P NATL ACAD SCI USA, V101, P10738, DOI 10.1073/pnas.0403431101; DELHAISE P, 1984, J MOL GRAPHICS, V2, P103, DOI 10.1016/0263-7855(84)80002-8; DESMET J, 1992, NATURE, V356, P539, DOI 10.1038/356539a0; Diczfalusy MA, 2001, J LIPID RES, V42, P1025; Dietrich FS, 2004, SCIENCE, V304, P304, DOI 10.1126/science.1095781; Dujon B, 2004, NATURE, V430, P35, DOI 10.1038/nature02579; Fushinobu S, 2005, BIOSCI BIOTECH BIOCH, V69, P491, DOI 10.1271/bbb.69.491; GIETZ RD, 1995, YEAST, V11, P355, DOI 10.1002/yea.320110408; Gilham D, 2005, METHODS, V36, P139, DOI 10.1016/j.ymeth.2004.11.003; Guldener U, 1996, NUCLEIC ACIDS RES, V24, P2519, DOI 10.1093/nar/24.13.2519; Holmquist M, 2000, CURR PROTEIN PEPT SC, V1, P209, DOI 10.2174/1389203003381405; Jones DT, 1999, J MOL BIOL, V287, P797, DOI 10.1006/jmbi.1999.2583; Jones T, 2004, P NATL ACAD SCI USA, V101, P7329, DOI 10.1073/pnas.0401648101; Laposata M, 1998, PROG LIPID RES, V37, P307, DOI 10.1016/S0163-7827(98)00013-7; Lilly M, 2000, APPL ENVIRON MICROB, V66, P744, DOI 10.1128/AEM.66.2.744-753.2000; Liu SQ, 2004, INT DAIRY J, V14, P923, DOI 10.1016/j.idairyj.2004.02.010; MALCORPS P, 1992, EUR J BIOCHEM, V210, P1015, DOI 10.1111/j.1432-1033.1992.tb17507.x; Manolis K., 2004, NATURE, V428, P617; Mason AB, 2000, YEAST, V16, P1287, DOI 10.1002/1097-0061(200010)16:14<1287::AID-YEA613>3.0.CO;2-I; McGuffin LJ, 2003, BIOINFORMATICS, V19, P874, DOI 10.1093/bioinformatics/btg097; Nandhagopal N, 1997, P JPN ACAD B-PHYS, V73, P154, DOI 10.2183/pjab.73.154; Page RDM, 1996, COMPUT APPL BIOSCI, V12, P357; SHERMAN F, 1991, METHODS YEAST GENETI; Soderberg BL, 2003, AM J CLIN PATHOL, V119, P94; Stratford M, 1996, FEMS MICROBIOL LETT, V142, P53, DOI 10.1016/0378-1097(96)00242-X; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; Verstrepen KJ, 2004, YEAST, V21, P367, DOI 10.1002/yea.1100; Verstrepen KJ, 2003, J BIOSCI BIOENG, V96, P110, DOI 10.1016/S1389-1723(03)90112-5; Verstrepen KJ, 2003, APPL ENVIRON MICROB, V69, P5228, DOI 10.1128/AEM.69.9.5228-5237.2003; WAKIL SJ, 1983, ANNU REV BIOCHEM, V52, P537, DOI 10.1146/annurev.bi.52.070183.002541	35	192	216	11	71	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 17	2006	281	7					4446	4456		10.1074/jbc.M512028200	http://dx.doi.org/10.1074/jbc.M512028200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	011NN	16361250	hybrid, Green Published			2022-12-25	WOS:000235275300080
J	Zhao, LJ; Subramanian, T; Zhou, Y; Chinnadurai, G				Zhao, LJ; Subramanian, T; Zhou, Y; Chinnadurai, G			Acetylation by p300 regulates nuclear localization and function of the transcriptional corepressor CtBP2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TERMINAL-BINDING-PROTEIN; ADENOVIRUS E1A; MOLECULAR-CLONING; CO-REPRESSOR; CELLULAR PHOSPHOPROTEIN; NEGATIVE MODULATION; MEMBRANE FISSION; SYNAPTIC RIBBONS; DROSOPHILA CTBP; INTERACTS	CtBP family members, CtBP1 and CtBP2, are unique transcriptional regulators that adapt a metabolic enzyme fold, and their activities are regulated by NAD(H)- binding. CtBP1 is both cytoplasmic and nuclear, and its subcellular localization is regulated by sumoylation, phosphorylation, and binding to a PDZ protein. In contrast, we showed that CtBP2 is exclusively nuclear. CtBP1 and CtBP2 are highly similar, but differ at the N-terminal 20 amino acid region. Substitution of the N-terminal domain of CtBP1 with the corresponding CtBP2 domain confers a dominant nuclear localization pattern to CtBP1. The N-terminal domain of CtBP2 contains three Lys residues. Our results show that these Lys residues are acetylated by the nuclear acetylase p300. Although all three Lys residues of CtBP2 (Lys-6, Lys-8, and Lys-10) appear to be acetylated, acetylation of Lys-10 is critical for nuclear localization. CtBP2 with a single amino acid substitution at Lys-10 (K10R) is predominantly localized in the cytoplasm. The cytoplasmic localization of the K10R mutant is correlated with enhanced nuclear export that is inhibited by leptomycin B. Furthermore, lack of acetylation at Lys-10 renders CtBP2 to be more efficient in repression of the E-cadherin promoter. Our studies have revealed the important roles of acetylation in regulating subcellular localization and transcriptional activity of CtBP2.	St Louis Univ, Hlth Sci Ctr, Inst Mol Virol, St Louis, MO 63110 USA	Saint Louis University	Chinnadurai, G (corresponding author), St Louis Univ, Hlth Sci Ctr, Inst Mol Virol, 3681 Pk Ave, St Louis, MO 63110 USA.	chinnag@slu.edu			NCI NIH HHS [CA-84941] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA084941] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Balasubramanian P, 2003, FEBS LETT, V537, P157, DOI 10.1016/S0014-5793(03)00119-4; Barnes CJ, 2003, NAT STRUCT BIOL, V10, P622, DOI 10.1038/nsb957; Bonazzi M, 2005, NAT CELL BIOL, V7, P570, DOI 10.1038/ncb1260; BOYD JM, 1993, EMBO J, V12, P469, DOI 10.1002/j.1460-2075.1993.tb05679.x; Brannon M, 1999, DEVELOPMENT, V126, P3159; Carcedo CH, 2004, SCIENCE, V305, P93, DOI 10.1126/science.1097775; Chinnadurai G, 2003, BIOESSAYS, V25, P9, DOI 10.1002/bies.10212; Chinnadurai G, 2002, MOL CELL, V9, P213, DOI 10.1016/S1097-2765(02)00443-4; Comijn J, 2001, MOL CELL, V7, P1267, DOI 10.1016/S1097-2765(01)00260-X; Criqui-Filipe P, 1999, EMBO J, V18, P3392, DOI 10.1093/emboj/18.12.3392; Dahiya A, 2001, MOL CELL, V8, P557, DOI 10.1016/S1097-2765(01)00346-X; Dieck ST, 2005, J CELL BIOL, V168, P825, DOI 10.1083/jcb.200408157; ECKNER R, 1994, GENE DEV, V8, P869, DOI 10.1101/gad.8.8.869; Fjeld CC, 2003, P NATL ACAD SCI USA, V100, P9202, DOI 10.1073/pnas.1633591100; Fornerod M, 1997, CELL, V90, P1051, DOI 10.1016/S0092-8674(00)80371-2; Gallop JL, 2005, NATURE, V438, P675, DOI 10.1038/nature04136; Grooteclaes M, 2003, P NATL ACAD SCI USA, V100, P4568, DOI 10.1073/pnas.0830998100; Grooteclaes ML, 2000, ONCOGENE, V19, P3823, DOI 10.1038/sj.onc.1203721; Hamada F, 2004, DEV CELL, V7, P677, DOI 10.1016/j.devcel.2004.08.022; Hildebrand JD, 2002, MOL CELL BIOL, V22, P5296, DOI 10.1128/MCB.22.15.5296-5307.2002; Kagey MH, 2003, CELL, V113, P127, DOI 10.1016/S0092-8674(03)00159-4; Kamine J, 1996, VIROLOGY, V216, P357, DOI 10.1006/viro.1996.0071; Katsanis N, 1998, GENOMICS, V47, P294, DOI 10.1006/geno.1997.5115; Kim JH, 2005, NAT STRUCT MOL BIOL, V12, P423, DOI 10.1038/nsmb924; Kumar V, 2002, MOL CELL, V10, P857, DOI 10.1016/S1097-2765(02)00650-0; Lin X, 2003, MOL CELL, V11, P1389, DOI 10.1016/S1097-2765(03)00175-8; Meloni AR, 2005, MOL CANCER RES, V3, P575, DOI 10.1158/1541-7786.MCR-05-0088; Nardini M, 2003, EMBO J, V22, P3122, DOI 10.1093/emboj/cdg283; Nibu Y, 1998, SCIENCE, V280, P101, DOI 10.1126/science.280.5360.101; Pollard VW, 1998, ANNU REV MICROBIOL, V52, P491, DOI 10.1146/annurev.micro.52.1.491; Poortinga G, 1998, EMBO J, V17, P2067, DOI 10.1093/emboj/17.7.2067; Postigo AA, 1999, P NATL ACAD SCI USA, V96, P6683, DOI 10.1073/pnas.96.12.6683; Riefler GM, 2001, J BIOL CHEM, V276, P48262, DOI 10.1074/jbc.M106503200; SCHAEPER U, 1995, P NATL ACAD SCI USA, V92, P10467, DOI 10.1073/pnas.92.23.10467; Schmitz F, 2000, NEURON, V28, P857, DOI 10.1016/S0896-6273(00)00159-8; Senyuk V, 2005, ARCH BIOCHEM BIOPHYS, V441, P168, DOI 10.1016/j.abb.2005.06.024; Sewalt RGAB, 1999, MOL CELL BIOL, V19, P777; Shi YJ, 2004, CELL, V119, P941, DOI 10.1016/j.cell.2004.12.012; Shi YJ, 2003, NATURE, V422, P735, DOI 10.1038/nature01550; Sollerbrant K, 1996, NUCLEIC ACIDS RES, V24, P2578, DOI 10.1093/nar/24.13.2578; Spanfo S, 1999, J BIOL CHEM, V274, P17705, DOI 10.1074/jbc.274.25.17705; Subramanian T, 2003, FEBS LETT, V540, P255, DOI 10.1016/S0014-5793(03)00275-8; Sundqvist A, 1998, FEBS LETT, V429, P183, DOI 10.1016/S0014-5793(98)00588-2; Sutrias-Grau M, 2004, MOL CELL BIOL, V24, P5953, DOI 10.1128/MCB.24.13.5953-5966.2004; Turner J, 1998, EMBO J, V17, P5129, DOI 10.1093/emboj/17.17.5129; Turner J, 2001, BIOESSAYS, V23, P683, DOI 10.1002/bies.1097; Weigert R, 1999, NATURE, V402, P429, DOI 10.1038/46587; Xu WT, 1998, MOL CELL BIOL, V18, P5659, DOI 10.1128/MCB.18.10.5659; Zenisek D, 2004, J NEUROSCI, V24, P9752, DOI 10.1523/JNEUROSCI.2886-04.2004; Zhang OH, 2003, CELL, V115, P177, DOI 10.1016/S0092-8674(03)00802-X; Zhang QH, 2002, SCIENCE, V295, P1895	51	63	67	1	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 17	2006	281	7					4183	4189		10.1074/jbc.M509051200	http://dx.doi.org/10.1074/jbc.M509051200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	011NN	16356938	hybrid			2022-12-25	WOS:000235275300050
J	Barros, MH; Myers, AM; Van Driesche, S; Tzagoloff, A				Barros, MH; Myers, AM; Van Driesche, S; Tzagoloff, A			COX24 codes for a mitochondrial protein required for processing of the COX1 transcript	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYTOCHROME-C-OXIDASE; GROUP-I INTRON; PRE-MESSENGER RNA; SACCHAROMYCES-CEREVISIAE; MEMBRANE SYSTEM; YEAST MITOCHONDRIA; CBP2 PROTEIN; BOX PROTEIN; B GENE; MATURASE	In most strains of Saccharomyces cerevisiae the mitochondrial gene COX1, for subunit 1 of cytochrome oxidase, contains multiple exons and introns. Processing of COX1 primary transcript requires accessory proteins factors, some of which are encoded by nuclear genes and others by reading frames residing in some of the introns of the COX1 and COB genes. Here we show that the low molecular weight protein product of open reading frame YLR204W, for which we propose the name COX24, is also involved in processing of COX1 RNA intermediates. The growth defect of cox24 mutants is partially rescued in strains harboring mitochondrial DNA lacking introns. Northern blot analyses of mitochondrial transcripts indicate cox24 null mutants to be blocked in processing of introns aI2 and aI3. The dependence of intron aI3 excision on Cox24p is also supported by the growth properties of the cox24 mutant harboring mitochondrial DNA with different intron compositions. The intermediate phenotype of the cox24 mutant in the background of intronless mitochondrial DNA, however, suggests that in addition to its role in splicing of the COX1 pre-mRNA, Cox24p still has another function. Based on the analysis of a cox14-cox24 double mutant, we propose that the other function of Cox24p is related to translation of the COX1 mRNA.	Columbia Univ, Dept Biol Sci, New York, NY 10027 USA	Columbia University	Tzagoloff, A (corresponding author), Columbia Univ, Dept Biol Sci, New York, NY 10027 USA.	spud@cubpet2.bio.columbia.edu	Barros, Mario H/B-8118-2012; Barros, Mario/Q-6358-2019	Barros, Mario/0000-0003-2977-9815; Myers, Alan/0000-0002-9619-4692	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM045952, R01GM050187] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM45952, R01 GM050187] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Barrientos A, 2002, GENE, V286, P53, DOI 10.1016/S0378-1119(01)00803-4; Barrientos A, 2004, EMBO J, V23, P3472, DOI 10.1038/sj.emboj.7600358; Barros MH, 2002, J BIOL CHEM, V277, P9997, DOI 10.1074/jbc.M112025200; BEGGS JD, 1978, NATURE, V275, P104, DOI 10.1038/275104a0; BONITZ SG, 1980, J BIOL CHEM, V255, P1927; BOUSQUET I, 1990, CURR GENET, V18, P117, DOI 10.1007/BF00312599; BROACH JR, 1979, GENE, V8, P121, DOI 10.1016/0378-1119(79)90012-X; Chenna R, 2003, NUCLEIC ACIDS RES, V31, P3497, DOI 10.1093/nar/gkg500; CONDE J, 1976, P NATL ACAD SCI USA, V73, P3651, DOI 10.1073/pnas.73.10.3651; COSTANZO MC, 1988, P NATL ACAD SCI USA, V85, P2677, DOI 10.1073/pnas.85.8.2677; DECOSTER E, 1993, J MOL BIOL, V232, P79, DOI 10.1006/jmbi.1993.1371; DUJON B, 1989, GENE, V82, P91, DOI 10.1016/0378-1119(89)90034-6; FAYE G, 1974, J MOL BIOL, V88, P105, DOI 10.1016/0022-2836(74)90304-0; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; GAMPEL A, 1989, MOL CELL BIOL, V9, P5424, DOI 10.1128/MCB.9.12.5424; GAMPEL A, 1991, GENE DEV, V5, P1870, DOI 10.1101/gad.5.10.1870; Glerum DM, 1996, J BIOL CHEM, V271, P20531, DOI 10.1074/jbc.271.34.20531; Glick BS, 1995, METHOD ENZYMOL, V260, P224, DOI 10.1016/0076-6879(95)60140-6; Glick BS, 1995, METHOD ENZYMOL, V260, P213, DOI 10.1016/0076-6879(95)60139-2; Golik P, 2004, FEMS YEAST RES, V4, P477, DOI 10.1016/S1567-1356(03)00160-0; GUO WW, 1995, J BIOL CHEM, V270, P15563, DOI 10.1074/jbc.270.26.15563; HERBERT CJ, 1988, EMBO J, V7, P473, DOI 10.1002/j.1460-2075.1988.tb02835.x; HILL J, 1985, J BIOL CHEM, V260, P3235; HILL JE, 1986, YEAST, V2, P163, DOI 10.1002/yea.320020304; Hiser L, 2000, J BIOL CHEM, V275, P619, DOI 10.1074/jbc.275.1.619; Huang HR, 2005, P NATL ACAD SCI USA, V102, P163, DOI 10.1073/pnas.0407896101; KENNELL JC, 1993, CELL, V73, P133, DOI 10.1016/0092-8674(93)90166-N; Krause K, 2004, MOL BIOL CELL, V15, P2674, DOI 10.1091/mbc.E04-02-0126; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LABOUESSE M, 1983, EMBO J, V2, P269, DOI 10.1002/j.1460-2075.1983.tb01416.x; LABOUESSE M, 1990, MOL GEN GENET, V224, P209, DOI 10.1007/BF00271554; LAZOWSKA J, 1989, J MOL BIOL, V205, P275, DOI 10.1016/0022-2836(89)90341-0; LAZOWSKA J, 1980, CELL, V22, P333, DOI 10.1016/0092-8674(80)90344-X; LAZOWSKA J, 1994, EMBO J, V13, P4963, DOI 10.1002/j.1460-2075.1994.tb06823.x; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MANON S, 1989, BIOCHIM BIOPHYS ACTA, V985, P127, DOI 10.1016/0005-2736(89)90356-8; MANTHEY GM, 1995, EMBO J, V14, P4031, DOI 10.1002/j.1460-2075.1995.tb00074.x; Margossian SP, 1996, CELL, V84, P199, DOI 10.1016/S0092-8674(00)80975-7; MAXAM AM, 1980, METHOD ENZYMOL, V65, P49; MCEWEN JE, 1986, J BIOL CHEM, V261, P1872; MCGRAW P, 1983, J BIOL CHEM, V258, P9459; MULERO JJ, 1993, MOL BIOL CELL, V4, P1327, DOI 10.1091/mbc.4.12.1327; MUROFF I, 1990, EMBO J, V9, P2765, DOI 10.1002/j.1460-2075.1990.tb07464.x; Naithani S, 2003, MOL BIOL CELL, V14, P324, DOI 10.1091/mbc.E02-08-0490; PEL HJ, 1992, CURR GENET, V21, P139, DOI 10.1007/BF00318473; ROTHSTEIN RJ, 1983, METHOD ENZYMOL, V101, P202; Sambrook J., 1989, MOL CLONING LAB MANU, V2; SERAPHIN B, 1988, EMBO J, V7, P1455, DOI 10.1002/j.1460-2075.1988.tb02963.x; SERAPHIN B, 1987, P NATL ACAD SCI USA, V84, P6810, DOI 10.1073/pnas.84.19.6810; SERAPHIN B, 1992, GENE, V113, P1, DOI 10.1016/0378-1119(92)90663-A; SIMON M, 1992, YEAST, V8, P559, DOI 10.1002/yea.320080707; STEPIEN PP, 1992, P NATL ACAD SCI USA, V89, P6813, DOI 10.1073/pnas.89.15.6813; SZCZEPANEK T, 1994, GENE, V139, P1, DOI 10.1016/0378-1119(94)90516-9; ten Berge A M, 1974, Mol Gen Genet, V131, P113; TZAGOLOFF A, 1990, MICROBIOL REV, V54, P211, DOI 10.1128/MMBR.54.3.211-225.1990; TZAGOLOFF A, 1976, FEBS LETT, V65, P391, DOI 10.1016/0014-5793(76)80154-8; TZAGOLOFF A, 1975, J BIOL CHEM, V250, P8228; VALENCIK ML, 1989, EMBO J, V8, P3899, DOI 10.1002/j.1460-2075.1989.tb08569.x; WENZLAU JM, 1989, CELL, V56, P421, DOI 10.1016/0092-8674(89)90245-6	59	19	21	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 10	2006	281	6					3743	3751		10.1074/jbc.M510778200	http://dx.doi.org/10.1074/jbc.M510778200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	009QV	16339141	hybrid			2022-12-25	WOS:000235128200087
J	Korzeniewski, B				Korzeniewski, B			AMP deamination delays muscle acidification during heavy exercise and hypoxia	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN SKELETAL-MUSCLE; OXIDATIVE-PHOSPHORYLATION; ADENINE-NUCLEOTIDE; EXHAUSTIVE EXERCISE; AMMONIA METABOLISM; PROTON LEAK; ATP; CONTRACTION; HUMANS; KINETICS	In silico studies carried out by using a computer model of oxidative phosphorylation and anaerobic glycolysis in skeletal muscle demonstrated that deamination of AMP to IMP during heavy short term exercise and/or hypoxia lessens the acidification of myocytes. The concerted action of adenylate kinase and AMP deaminase, leading to a decrease in the total adenine nucleotide pool, constitutes an additional process consuming ADP and producing ATP. It diminishes the amount of ADP that must be converted to ATP by other processes in order to meet the rate of ADP production by ATPases ( because the adenylate kinase + AMP deaminase system produces only 1 ATP per 2 ADPs used, ATP consumption is not matched by ATP production, and the reduction of the total adenine nucleotide pool occurs mostly at the cost of [ ATP]). As a result, the rate of ADP consumption by other processes may be lowered. This effect concerns mostly ADP consumption by anaerobic glycolysis that is inhibited by AMP deamination-induced decrease in [ ADP] and [ AMP], and not oxidative phosphorylation, because during heavy exercise and/or hypoxia [ ADP] is significantly greater than the K-m value of this process for ADP. The resultant reduction of proton production by anaerobic glycolysis enables us to delay the termination of exercise because of fatigue and/or to diminish cell damage.	Jagiellonian Univ, Fac Biotechnol, PL-30387 Krakow, Poland	Jagiellonian University	Korzeniewski, B (corresponding author), Jagiellonian Univ, Fac Biotechnol, Ul Gronostajowa 7, PL-30387 Krakow, Poland.	benio@mol.uj.edu.pl						ANDERSEN P, 1985, J PHYSIOL-LONDON, V366, P233, DOI 10.1113/jphysiol.1985.sp015794; BANGSBO J, 1992, J PHYSIOL-LONDON, V451, P205, DOI 10.1113/jphysiol.1992.sp019161; Blomstrand E, 1997, J PHYSIOL-LONDON, V501, P455, DOI 10.1111/j.1469-7793.1997.455bn.x; BRINDLE KM, 1989, BIOCHEMISTRY-US, V28, P4887, DOI 10.1021/bi00437a054; BRINDLE KM, 1987, BIOCHIM BIOPHYS ACTA, V928, P45, DOI 10.1016/0167-4889(87)90084-X; BROBERG S, 1989, J APPL PHYSIOL, V67, P116, DOI 10.1152/jappl.1989.67.1.116; DUDLEY GA, 1985, AM J PHYSIOL, V248, pC37, DOI 10.1152/ajpcell.1985.248.1.C37; Garnier A, 1996, J MOL CELL CARDIOL, V28, P1671, DOI 10.1006/jmcc.1996.0157; GRAHAM TE, 1990, AM J PHYSIOL, V259, pE170, DOI 10.1152/ajpendo.1990.259.2.E170; Hancock CR, 2005, AM J PHYSIOL-CELL PH, V288, pC1298, DOI 10.1152/ajpcell.00621.2004; HARRIS RC, 1991, EUR J APPL PHYSIOL O, V62, P235, DOI 10.1007/BF00571546; Hellsten Y, 1999, J PHYSIOL-LONDON, V520, P909, DOI 10.1111/j.1469-7793.1999.00909.x; KATZ A, 1986, AM J PHYSIOL, V250, pC834, DOI 10.1152/ajpcell.1986.250.6.C834; Kay L, 1997, J MOL CELL CARDIOL, V29, P3399, DOI 10.1006/jmcc.1997.0564; Kobara M, 1996, J MOL CELL CARDIOL, V28, P417, DOI 10.1006/jmcc.1996.0038; Korzeniewski B, 2003, BIOCHEM J, V375, P799, DOI 10.1042/BJ20030882; Korzeniewski B, 1998, BIOCHEM J, V330, P1189, DOI 10.1042/bj3301189; Korzeniewski B, 2001, BIOPHYS CHEM, V92, P17, DOI 10.1016/S0301-4622(01)00184-3; Korzeniewski B, 2004, BIOPHYS CHEM, V110, P147, DOI 10.1016/j.bpc.2004.01.011; Kushmerick MJ, 1997, AM J PHYSIOL-CELL PH, V272, pC1739, DOI 10.1152/ajpcell.1997.272.5.C1739; Lambeth MJ, 2002, ANN BIOMED ENG, V30, P808, DOI 10.1114/1.1492813; LOWENBRAUN S, 1990, REM SPEC EDUC, V11, P37, DOI 10.1177/074193259001100408; REN JM, 1992, J APPL PHYSIOL, V73, P2713, DOI 10.1152/jappl.1992.73.6.2713; Rolfe DFS, 1996, BBA-BIOENERGETICS, V1276, P45, DOI 10.1016/0005-2728(96)00029-1; Rolfe DFS, 1999, AM J PHYSIOL-CELL PH, V276, pC692, DOI 10.1152/ajpcell.1999.276.3.C692; SABINA RL, 1984, J CLIN INVEST, V73, P720, DOI 10.1172/JCI111265; SAHLIN K, 1990, INT J SPORTS MED, V11, pS62, DOI 10.1055/s-2007-1024856; SAHLIN K, 1978, PFLUG ARCH EUR J PHY, V374, P193, DOI 10.1007/BF00581301; SAHLIN K, 1992, MED SPORTS SCI, V43, P54; SALTIN B, 1985, AM J CARDIOL, V55, pD42, DOI 10.1016/0002-9149(85)91054-9; SIEMANKOWSKI RF, 1984, J BIOL CHEM, V259, P5045; SODERLUND K, 1991, AM J PHYSIOL, V261, pE737, DOI 10.1152/ajpendo.1991.261.6.E737; Tonkonogi M, 1997, ACTA PHYSIOL SCAND, V161, P345, DOI 10.1046/j.1365-201X.1997.00222.x; Tullson P C, 1991, Exerc Sport Sci Rev, V19, P507; TULLSON PC, 1995, J APPL PHYSIOL, V78, P146, DOI 10.1152/jappl.1995.78.1.146; Tullson PC, 1998, AM J PHYSIOL-CELL PH, V274, pC1411, DOI 10.1152/ajpcell.1998.274.5.C1411; TULLSON PC, 1990, INT J SPORTS MED, V11, pS47, DOI 10.1055/s-2007-1024854; Turner D, 1999, PHYSL DETERMINANTS E, P29; WHIPP BJ, 1969, J APPL PHYSIOL, V26, P644, DOI 10.1152/jappl.1969.26.5.644; Zhao S, 2000, J APPL PHYSIOL, V88, P1513, DOI 10.1152/jappl.2000.88.5.1513	40	34	34	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 10	2006	281	6					3057	3066		10.1074/jbc.M510418200	http://dx.doi.org/10.1074/jbc.M510418200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	009QV	16314416	hybrid			2022-12-25	WOS:000235128200008
J	McGuire, JR; Rong, J; Li, SH; Li, XJ				McGuire, JR; Rong, J; Li, SH; Li, XJ			Interaction of huntingtin-associated protein-1 with kinesin light chain - Implications in intracellular trafficking in neurons	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMYLOID PRECURSOR PROTEIN; BOVINE BRAIN KINESIN; AXONAL-TRANSPORT; ACTIN CYTOSKELETON; MUTANT HUNTINGTIN; IN-VITRO; DISEASE; HAP1; CELLS; IDENTIFICATION	Huntingtin-associated protein-1 ( HAP1) was initially identified as an interacting partner of huntingtin, the Huntington disease protein. Unlike huntingtin that is ubiquitously expressed throughout the brain and body, HAP1 is enriched in neurons, suggesting that its dysfunction could contribute to Huntington disease neuropathology. Growing evidence has demonstrated that HAP1 and huntingtin are anterogradely transported in axons and that the abnormal interaction between mutant huntingtin and HAP1 may impair axonal transport. However, the exact role of HAP1 in anterograde transport remains unclear. Here we report that HAP1 interacts with kinesin light chain, a subunit of the kinesin motor complex that drives anterograde transport along microtubules in neuronal processes. The interaction of HAP1 with kinesin light chain is demonstrated via a yeast two-hybrid assay, glutathione S-transferase pull down, and coimmunoprecipitation. Furthermore, HAP1 is colocalized with kinesin in growth cones of neuronal cells. We also demonstrated that knocking down HAP1 via small interfering RNA suppresses neurite outgrowth of PC12 cells. Analysis of live neuronal cells with fluorescence microscopy and fluorescence recovery after photobleaching demonstrates that suppressing the expression of HAP1 or deleting the HAP1 gene inhibits the kinesin- dependent transport of amyloid precursor protein vesicles. These studies provide amolecular basis for the participation of HAP1 in anterograde transport in neuronal cells.	Emory Clin, Sch Med, Dept Human Genet, Atlanta, GA 30322 USA	Emory University	Li, XJ (corresponding author), Emory Clin, Sch Med, Dept Human Genet, 615 Michael St, Atlanta, GA 30322 USA.	xiaoli@genetics.emory.edu						Apodaca G, 2001, TRAFFIC, V2, P149, DOI 10.1034/j.1600-0854.2001.020301.x; Bananis E, 2004, MOL BIOL CELL, V15, P3688, DOI 10.1091/mbc.E04-04-0278; BlockGalarza J, 1997, NEUROREPORT, V8, P2247, DOI 10.1097/00001756-199707070-00031; BLOOM GS, 1988, BIOCHEMISTRY-US, V27, P3409, DOI 10.1021/bi00409a043; Buxbaum JD, 1998, J NEUROSCI, V18, P9629; Cha BY, 2004, J CELL SCI, V117, P3353, DOI 10.1242/jcs.01180; Chan EYW, 2002, HUM MOL GENET, V11, P945, DOI 10.1093/hmg/11.8.945; DRAGATSIS I, 2004, HUM MOL GENET, V20, P20; Engelender S, 1997, HUM MOL GENET, V6, P2205, DOI 10.1093/hmg/6.13.2205; FEIGUIN F, 1994, J CELL BIOL, V127, P1021, DOI 10.1083/jcb.127.4.1021; Gauthier LR, 2004, CELL, V118, P127, DOI 10.1016/j.cell.2004.06.018; Gunawardena S, 2003, NEURON, V40, P25, DOI 10.1016/S0896-6273(03)00594-4; Gutekunst CA, 1998, J NEUROSCI, V18, P7674, DOI 10.1523/jneurosci.18-19-07674.1998; Hames RS, 2005, MOL BIOL CELL, V16, P1711, DOI 10.1091/mbc.E04-08-0688; Harjes P, 2003, TRENDS BIOCHEM SCI, V28, P425, DOI 10.1016/S0968-0004(03)00168-3; HIROKAWA N, 1991, J CELL BIOL, V114, P295, DOI 10.1083/jcb.114.2.295; Kaether C, 2000, MOL BIOL CELL, V11, P1213, DOI 10.1091/mbc.11.4.1213; Kamal A, 2000, NEURON, V28, P449, DOI 10.1016/S0896-6273(00)00124-0; Kittler JT, 2004, P NATL ACAD SCI USA, V101, P12736, DOI 10.1073/pnas.0401860101; KOO EH, 1990, P NATL ACAD SCI USA, V87, P1561, DOI 10.1073/pnas.87.4.1561; KREMER HPH, 1990, J NEUROPATH EXP NEUR, V49, P371, DOI 10.1097/00005072-199007000-00002; KUZNETSOV SA, 1988, EMBO J, V7, P353, DOI 10.1002/j.1460-2075.1988.tb02820.x; Lazarov O, 2005, J NEUROSCI, V25, P2386, DOI 10.1523/JNEUROSCI.3089-04.2005; Li H, 2001, J NEUROSCI, V21, P8473, DOI 10.1523/JNEUROSCI.21-21-08473.2001; Li SH, 2004, TRENDS GENET, V20, P146, DOI 10.1016/j.tig.2004.01.008; Li SH, 2003, J NEUROSCI, V23, P6956; Li SH, 1998, J NEUROCHEM, V71, P2178; Li SH, 1998, J NEUROSCI, V18, P1261, DOI 10.1523/jneurosci.18-04-01261.1998; Li SH, 2000, MOL CELL NEUROSCI, V16, P168, DOI 10.1006/mcne.2000.0858; LI XJ, 1995, NATURE, V378, P398, DOI 10.1038/378398a0; Li XJ, 2005, TRENDS PHARMACOL SCI, V26, P1, DOI 10.1016/j.tips.2004.11.001; Li YK, 2002, J BIOL CHEM, V277, P28212, DOI 10.1074/jbc.M111612200; Lin SX, 2002, MOL BIOL CELL, V13, P96, DOI 10.1091/mbc.01-05-0224; Martin EJ, 1999, J COMP NEUROL, V403, P421; McGuire JR, 2005, CURR GENOMICS, V6, P189, DOI 10.2174/1389202053971938; Meyvis TKL, 1999, PHARM RES-DORDR, V16, P1153, DOI 10.1023/A:1011924909138; Morfini G, 1997, J CELL BIOL, V138, P657, DOI 10.1083/jcb.138.3.657; Muller U, 2002, TRENDS MOL MED, V8, P152, DOI 10.1016/S1471-4914(02)02320-1; Niu TK, 2005, MOL BIOL CELL, V16, P1213, DOI 10.1091/mbc.E04-07-0599; Perutz MF, 1999, TRENDS BIOCHEM SCI, V24, P58, DOI 10.1016/S0968-0004(98)01350-4; PFISTER KK, 1989, J CELL BIOL, V108, P1453, DOI 10.1083/jcb.108.4.1453; Rahman A, 1998, J BIOL CHEM, V273, P15395, DOI 10.1074/jbc.273.25.15395; Satpute-Krishnan P, 2003, AGING CELL, V2, P305, DOI 10.1046/j.1474-9728.2003.00069.x; Schmidt K, 2004, BMC CELL BIOL, V5, DOI 10.1186/1471-2121-5-43; SCHOLEY JM, 1989, NATURE, V338, P355, DOI 10.1038/338355a0; SISODIA SS, 1993, J NEUROSCI, V13, P3136; Stamer K, 2002, J CELL BIOL, V156, P1051, DOI 10.1083/jcb.200108057; Tang TS, 2004, EUR J NEUROSCI, V20, P1779, DOI 10.1111/j.1460-9568.2004.03633.x; Tang TS, 2003, NEURON, V39, P227, DOI 10.1016/S0896-6273(03)00366-0; Trushina E, 2004, MOL CELL BIOL, V24, P8195, DOI 10.1128/MCB.24.18.8195-8209.2004; Vale RD, 2003, CELL, V112, P467, DOI 10.1016/S0092-8674(03)00111-9; WatermanStorer CM, 1997, P NATL ACAD SCI USA, V94, P12180, DOI 10.1073/pnas.94.22.12180; YANG JT, 1990, SCIENCE, V249, P42, DOI 10.1126/science.2142332; Zhang HL, 2001, NEURON, V31, P261, DOI 10.1016/S0896-6273(01)00357-9	54	198	208	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 10	2006	281	6					3552	3559		10.1074/jbc.M509806200	http://dx.doi.org/10.1074/jbc.M509806200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	009QV	16339760	hybrid			2022-12-25	WOS:000235128200066
J	Moreau, K; Dizin, E; Ray, H; Luquain, C; Lefai, E; Foufelle, F; Billaud, M; Lenoir, GM; Dalla Venezia, N				Moreau, K; Dizin, E; Ray, H; Luquain, C; Lefai, E; Foufelle, F; Billaud, M; Lenoir, GM; Dalla Venezia, N			BRCA1 affects lipid synthesis through its interaction with acetyl-CoA carboxylase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-KINASE; FATTY-ACID SYNTHASE; BREAST-CANCER; DNA-DAMAGE; SYNTHESIS PATHWAY; PROSTATE-CANCER; ALPHA-GENE; CELL-CYCLE; PHOSPHORYLATION; SUSCEPTIBILITY	Germ line alterations in BRCA1 ( breast cancer susceptibility gene 1) are associated with an increased susceptibility to breast and ovarian cancer. BRCA1 acts as a scaffold protein implicated in multiple cellular functions, such as transcription, DNA repair, and ubiquitination. However, the molecular mechanisms responsible for tumorigenesis are not yet fully understood. We have recently demonstrated that BRCA1 interacts in vivo with acetyl coenzyme A carboxylase alpha (ACCA) through its tandem of BRCA1 C terminus (BRCT) domains. To understand the biological function of the BRCA1 center dot ACCA complex, we sought to determine whether BRCA1 is a regulator of lipogenesis through its interaction with ACCA. We showed here that RNA inhibition-mediated down-regulation of BRCA1 expression induced a marked increase in the fatty acid synthesis. We then delineated the biochemical characteristics of the complex and found that BRCA1 interacts solely with the phosphorylated and inactive form of ACCA (P-ACCA). Finally, we demonstrated that BRCA1 affects lipid synthesis by preventing P-ACCA dephosphorylation. These results suggest that BRCA1 affects lipogenesis through binding to P-ACCA, providing a new mechanism by which BRCA1 may exert a tumor suppressor function.	CNRS, UMR 5201, Genet Mol Lab, Fac Med Rockefeller, F-69373 Lyon 08, France; Fac Med Laennec, INSERM, U449, INRA 1235, F-69372 Lyon 08, France; Univ Paris 06, INSERM, U671, Ctr Biomed Cordeliers, F-75270 Paris 06, France; Inst Gustave Roussy, CNRS, UMR 8125, Lab Genet Oncol, F-94805 Villejuif, France	Centre National de la Recherche Scientifique (CNRS); INRAE; Institut National de la Sante et de la Recherche Medicale (Inserm); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Sorbonne Universite; Universite Paris Cite; Centre National de la Recherche Scientifique (CNRS); UNICANCER; Gustave Roussy	Dalla Venezia, N (corresponding author), CNRS, UMR 5201, Genet Mol Lab, Fac Med Rockefeller, 8 Ave Rockefeller, F-69373 Lyon 08, France.	dalla@rockefeller.univ-lyon1.fr	Lefai, Etienne/L-7961-2019; Lefai, Etienne/E-9615-2019; Billaud, Marc N/M-6954-2013; VENEZIA, Nicole DALLA/C-6542-2017; Moreau, Karen L/L-9903-2014	Lefai, Etienne/0000-0002-3042-7801; Lefai, Etienne/0000-0002-3042-7801; VENEZIA, Nicole DALLA/0000-0002-4553-3535; Moreau, Karen L/0000-0001-6297-3543; FOUFELLE, Fabienne/0000-0002-0752-622X				Alli PM, 2005, ONCOGENE, V24, P39, DOI 10.1038/sj.onc.1208174; Bork P, 1997, FASEB J, V11, P68, DOI 10.1096/fasebj.11.1.9034168; Brusselmans K, 2005, CANCER RES, V65, P6719, DOI 10.1158/0008-5472.CAN-05-0571; Calle EE, 2004, NAT REV CANCER, V4, P579, DOI 10.1038/nrc1408; CALLEBAUT L, 1997, FEBS LETT, V400, P25; CORTON JM, 1995, EUR J BIOCHEM, V229, P558, DOI 10.1111/j.1432-1033.1995.0558k.x; Couch FJ, 1996, HUM MUTAT, V8, P8, DOI 10.1002/humu.1380080102; DAVIES SP, 1990, EUR J BIOCHEM, V187, P183, DOI 10.1111/j.1432-1033.1990.tb15293.x; De Schrijver E, 2003, CANCER RES, V63, P3799; Debnath J, 2003, METHODS, V30, P256, DOI 10.1016/S1046-2023(03)00032-X; Eberle D, 2004, BIOCHIMIE, V86, P839, DOI 10.1016/j.biochi.2004.09.018; FOLCH J, 1957, J BIOL CHEM, V226, P497; FORD D, 1994, LANCET, V343, P692, DOI 10.1016/S0140-6736(94)91578-4; Gosmain Y, 2005, J LIPID RES, V46, P697, DOI 10.1194/jlr.M400261-JLR200; HA J, 1994, J BIOL CHEM, V269, P22162; Huyton T, 2000, MUTAT RES-DNA REPAIR, V460, P319, DOI 10.1016/S0921-8777(00)00034-3; Kim KS, 1997, BIOCHEM SOC T, V25, P1211, DOI 10.1042/bst0251211; Koonin EV, 1996, NAT GENET, V13, P266, DOI 10.1038/ng0796-266; Kuhajda FP, 2000, NUTRITION, V16, P202, DOI 10.1016/S0899-9007(99)00266-X; Li AC, 2004, J LIPID RES, V45, P2161, DOI 10.1194/jlr.R400010-JLR200; Magdinier F, 1998, ONCOGENE, V17, P3169, DOI 10.1038/sj.onc.1202248; Magnard C, 2002, ONCOGENE, V21, P6729, DOI 10.1038/sj.onc.1205915; Manke IA, 2003, SCIENCE, V302, P636, DOI 10.1126/science.1088877; MIKI Y, 1994, SCIENCE, V266, P66, DOI 10.1126/science.7545954; Milgraum LZ, 1997, CLIN CANCER RES, V3, P2115; Pizer ES, 1996, CANCER RES, V56, P2745; Ribieras S, 1997, INT J CANCER, V73, P715, DOI 10.1002/(SICI)1097-0215(19971127)73:5<715::AID-IJC17>3.0.CO;2-4; Rodriguez M, 2003, J BIOL CHEM, V278, P52914, DOI 10.1074/jbc.C300407200; Scully R, 1997, CELL, V90, P425, DOI 10.1016/S0092-8674(00)80503-6; Sinilnikova OM, 2004, CARCINOGENESIS, V25, P2417, DOI 10.1093/carcin/bgh273; Starita LM, 2003, CURR OPIN CELL BIOL, V15, P345, DOI 10.1016/S0955-0674(03)00042-5; Swinnen JV, 2000, INT J CANCER, V88, P176, DOI 10.1002/1097-0215(20001015)88:2<176::AID-IJC5>3.0.CO;2-3; Venkitaraman AR, 2002, CELL, V108, P171, DOI 10.1016/S0092-8674(02)00615-3; Winder WW, 1997, J APPL PHYSIOL, V82, P219, DOI 10.1152/jappl.1997.82.1.219; Yoshida K, 2004, CANCER SCI, V95, P866, DOI 10.1111/j.1349-7006.2004.tb02195.x; Yu XC, 2003, SCIENCE, V302, P639, DOI 10.1126/science.1088753; Zhou WB, 2003, CANCER RES, V63, P7330	37	93	100	0	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 10	2006	281	6					3172	3181		10.1074/jbc.M504652200	http://dx.doi.org/10.1074/jbc.M504652200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	009QV	16326698	hybrid			2022-12-25	WOS:000235128200020
J	Roberts, MT; Phelan, R; Erlichman, BS; Pillai, RN; Ma, L; Lopreato, GF; Mihic, SJ				Roberts, MT; Phelan, R; Erlichman, BS; Pillai, RN; Ma, L; Lopreato, GF; Mihic, SJ			Occupancy of a single anesthetic binding pocket is sufficient to enhance glycine receptor function	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GATED ION CHANNELS; GENERAL-ANESTHETICS; ALCOHOLS; GABA(A); ETHANOL; MUTANT; SITES; MECHANISM; MICE	Alcohols and volatile anesthetics enhance the function of inhibitory glycine receptors (GlyRs). This is hypothesized to occur by their binding to a pocket formed between the transmembrane domains of individual alpha 1 GlyR subunits. Because GlyRs are pentameric, it follows that each GlyR contains up to five alcohol/anesthetic binding sites, with one in each subunit. We asked how many subunits per pentamer need be bound by drug in order to enhance receptor-mediated currents. A cysteine mutation was introduced at amino acid serine 267 (S267C) in the transmembrane 2 domain as a tool to block GlyR potentiation by some anesthetic drugs and to provide a means for covalent binding by the small, anesthetic-like thiol reagent propyl methanethiosulfonate. Xenopus laevis oocytes were co-injected with various ratios of wild-type (wt) to S267C alpha 1 GlyR cDNAs in order to express heteromeric receptors with a range of wt: mutant subunit stoichiometries. The enhancement of GlyR currents by 200 mM ethanol and 1.5 mM chloroform was positively correlated with the number of wt subunits found in heteromeric receptors. Furthermore, currents from oocytes injected with high ratios of wt to S267C cDNAs (up to 200:1) were significantly and irreversibly enhanced following propyl methanethiosulfonate labeling and washout, demonstrating that drug binding to a single subunit in the receptor pentamer is sufficient to induce enhancement of GlyR currents.	Univ Texas, Univ Stn 1, Waggoner Ctr Alcohol & Addict Res, Sect Neurobiol,Inst Neurosci, Austin, TX 78712 USA; Univ Texas, Inst Cell & Mol Biol, Waggoner Ctr Alcohol & Addict Res, Neurobiol Sect, Austin, TX 78712 USA	University of Texas System; University of Texas Austin; University of Texas System; University of Texas Austin	Mihic, SJ (corresponding author), Univ Texas, Univ Stn 1, Waggoner Ctr Alcohol & Addict Res, Sect Neurobiol,Inst Neurosci, A4800, Austin, TX 78712 USA.	mihic@mail.utexas.edu		Roberts, Michael/0000-0003-2835-8752	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [P01GM047818] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM [R01AA011525, F31AA014454] Funding Source: NIH RePORTER; NIAAA NIH HHS [R01 AA11525, F31 AA14454] Funding Source: Medline; NIGMS NIH HHS [P01 GM47818] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA)); NIAAA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Aguayo Luis G., 2002, Current Topics in Medicinal Chemistry, V2, P869, DOI 10.2174/1568026023393426; Beato M, 2004, J NEUROSCI, V24, P895, DOI 10.1523/JNEUROSCI.4420-03.2004; Beckstead MJ, 2000, MOL PHARMACOL, V57, P1199; Beckstead MJ, 2001, J BIOL CHEM, V276, P24959, DOI 10.1074/jbc.M011627200; Bhattacharya AA, 2000, J BIOL CHEM, V275, P38731, DOI 10.1074/jbc.M005460200; Breitinger HG, 2002, NEUROSCI LETT, V331, P21, DOI 10.1016/S0304-3940(02)00773-5; Burzomato V, 2004, J NEUROSCI, V24, P10924, DOI 10.1523/JNEUROSCI.3424-04.2004; Changeux JP, 1998, NEURON, V21, P959, DOI 10.1016/S0896-6273(00)80616-9; Daniels S, 1998, TOXICOL LETT, V101, P71, DOI 10.1016/S0378-4274(98)00167-2; Downie DL, 1996, BRIT J PHARMACOL, V118, P493, DOI 10.1111/j.1476-5381.1996.tb15430.x; Eger EI, 1999, ANESTH ANALG, V88, P867, DOI 10.1097/00000539-199904000-00035; Findlay GS, 2003, J NEUROSCI, V23, P8051; Findlay GS, 2002, J PHARMACOL EXP THER, V300, P526, DOI 10.1124/jpet.300.2.526; Franks NP, 1998, BIOPHYS J, V75, P2205, DOI 10.1016/S0006-3495(98)77664-7; Griffon N, 1999, EMBO J, V18, P4711, DOI 10.1093/emboj/18.17.4711; Kash TL, 2003, NATURE, V421, P272, DOI 10.1038/nature01280; Kruse SW, 2003, NAT STRUCT BIOL, V10, P694, DOI 10.1038/nsb960; LANGOSCH D, 1988, P NATL ACAD SCI USA, V85, P7394, DOI 10.1073/pnas.85.19.7394; Legendre P, 2001, CELL MOL LIFE SCI, V58, P760, DOI 10.1007/PL00000899; Lobo IA, 2004, J BIOL CHEM, V279, P33919, DOI 10.1074/jbc.M313941200; Lynch JW, 2004, PHYSIOL REV, V84, P1051, DOI 10.1152/physrev.00042.2003; Mascia MP, 2000, P NATL ACAD SCI USA, V97, P9305, DOI 10.1073/pnas.160128797; Mascia MP, 1996, BRIT J PHARMACOL, V119, P1331, DOI 10.1111/j.1476-5381.1996.tb16042.x; Mascia MP, 1998, BRIT J PHARMACOL, V125, P263; Mihic SJ, 1999, NEUROCHEM INT, V35, P115, DOI 10.1016/S0197-0186(99)00053-4; Mihic SJ, 1997, NATURE, V389, P385, DOI 10.1038/38738; Miller KW, 2002, BRIT J ANAESTH, V89, P17, DOI 10.1093/bja/aef167; Miyazawa A, 2003, NATURE, V423, P949, DOI 10.1038/nature01748; Rudolph U, 2004, NAT REV NEUROSCI, V5, P709, DOI 10.1038/nrn1496; Ye Q, 1998, J BIOL CHEM, V273, P3314, DOI 10.1074/jbc.273.6.3314; Zhang Y, 2003, ANESTH ANALG, V96, P97, DOI 10.1097/00000539-200301000-00021	31	15	15	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 10	2006	281	6					3305	3311		10.1074/jbc.M502000200	http://dx.doi.org/10.1074/jbc.M502000200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	009QV	16361257	hybrid			2022-12-25	WOS:000235128200037
J	Deb, S; Zhou, JF; Amin, SA; Gonca, IA; Bertan, YM; Zihong, L; Bulun, SE				Deb, S; Zhou, JF; Amin, SA; Gonca, IA; Bertan, YM; Zihong, L; Bulun, SE			A novel role of sodium butyrate in the regulation of cancer-associated aromatase promoters I.3 and II by disrupting a transcriptional complex in breast adipose fibroblasts	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYTOCHROME-P450 GENE-EXPRESSION; POLYMERASE-CHAIN-REACTION; TISSUE STROMAL CELLS; ESTROGEN BIOSYNTHESIS; POSTMENOPAUSAL WOMEN; BINDING-PROTEIN; ADIPOCYTE DIFFERENTIATION; ALTERNATIVE PROMOTERS; ABERRANT EXPRESSION; SILENCER ELEMENT	The aromatase gene encodes the key enzyme for estrogen formation. Aromatase enzyme inhibitors eliminate total body estrogen production and are highly effective therapeutics for postmenopausal breast cancer. A distal promoter (I.4) regulates low levels of aromatase expression in tumor-free breast adipose tissue. Two proximal promoters (I.3/II) strikingly induce in vivo aromatase expression in breast fibroblasts surrounding malignant cells. Treatment of breast fibroblasts with medium conditioned with malignant breast epithelial cells (MCM) or a surrogate hormonal mixture (dibutyryl (Bt(2)) cAMP plus phorbol diacetate (PDA)) induces promoters I.3/II. The mechanism of promoter-selective expression, however, is not clear. Here we reported that sodium butyrate profoundly decreased MCM- or Bt(2)cAMP + PDA-induced promoter I.3/II-specific aromatase mRNA. MCM, Bt(2)cAMP + PDA, or sodium butyrate regulated aromatase mRNA or activity only via promoters I.3/II but not promoters I.1 or I.4 in breast, ovarian, placental, and hepatic cells. Mechanistically, recruitment of phosphorylated ATF-2 by a CRE (-211/-199, promoter I.3/II) conferred inductions by MCM or Bt(2)cAMP + PDA. Chromatin immunoprecipitation-PCR and immunoprecipitation-immunoblotting assays indicated that MCM or Bt(2)cAMP + PDA stabilized a complex composed of phosphorylated ATF-2, C/EBP beta, and cAMP-response element-binding protein (CREB)-binding protein in the common regulatory region of promoters I.3/II. Overall, histone acetylation patterns of promoters I.3/II did not correlate with sodium butyrate-dependent silencing of promoters I.3/II. Sodium butyrate, however, consistently disrupted the activating complex composed of phosphorylated ATF-2, C/EBP beta, and CREB-binding protein. This was mediated, in part, by decreased ATF-2 phosphorylation. Together, these findings represent a novel mechanism of sodium butyrate action and provide evidence that aromatase activity can be ablated in a signaling pathway- and cell-specific fashion.	Northwestern Univ, Div Reprod Biol Res, Feinberg Sch Med, Chicago, IL 60611 USA	Northwestern University; Feinberg School of Medicine	Bulun, SE (corresponding author), Northwestern Univ, Div Reprod Biol Res, Feinberg Sch Med, 303 Super St,Ste 4-123, Chicago, IL 60611 USA.	s-bulun@northwestern.edu	yilmaz, bertan/G-8633-2018	yilmaz, bertan/0000-0001-5558-3299				ACKERMAN GE, 1981, J CLIN ENDOCR METAB, V53, P412, DOI 10.1210/jcem-53-2-412; Agarwal VR, 1996, J CLIN ENDOCR METAB, V81, P3843, DOI 10.1210/jc.81.11.3843; Baum M, 2002, LANCET, V359, P2131; BOFFA LC, 1981, J BIOL CHEM, V256, P9612; Bulun SE, 2005, PHARMACOL REV, V57, P359, DOI 10.1124/pr.57.3.6; BULUN SE, 1993, J CLIN ENDOCR METAB, V77, P1622, DOI 10.1210/jc.77.6.1622; BULUN SE, 1993, J CLIN ENDOCR METAB, V77, P1616, DOI 10.1210/jc.77.6.1616; Cardinaux JR, 2000, MOL CELL BIOL, V20, P1546, DOI 10.1128/MCB.20.5.1546-1552.2000; CLELAND WH, 1983, ENDOCRINOLOGY, V113, P2155, DOI 10.1210/endo-113-6-2155; Coombes RC, 2004, NEW ENGL J MED, V350, P1081, DOI 10.1056/NEJMoa040331; Cosma MP, 1999, CELL, V97, P299, DOI 10.1016/S0092-8674(00)80740-0; Cuisset L, 1998, BIOCHEM BIOPH RES CO, V246, P760, DOI 10.1006/bbrc.1998.8698; Cuisset L, 1997, J BIOL CHEM, V272, P24148, DOI 10.1074/jbc.272.39.24148; Ellis MJ, 2003, J STEROID BIOCHEM, V86, P301, DOI 10.1016/S0960-0760(03)00371-6; Geisler H, 2003, J STEROID BIOCHEM, V86, P245, DOI 10.1016/S0960-0760(03)00364-9; Goss PE, 2003, NEW ENGL J MED, V349, P1793, DOI 10.1056/NEJMoa032312; Gurates B, 2003, MOL CELL ENDOCRINOL, V208, P61, DOI 10.1016/S0303-7207(03)00198-9; Harada N, 1997, J STEROID BIOCHEM, V61, P175; Harada N, 1998, BREAST CANCER RES TR, V49, pS15, DOI 10.1023/A:1006076101178; Hecht A, 1996, NATURE, V383, P92, DOI 10.1038/383092a0; HEMSELL DL, 1974, J CLIN ENDOCR METAB, V38, P476, DOI 10.1210/jcem-38-3-476; JAMES VHT, 1990, ANN NY ACAD SCI, V595, P227, DOI 10.1111/j.1749-6632.1990.tb34296.x; Jin TR, 2000, BREAST CANCER RES TR, V62, P151, DOI 10.1023/A:1006481228794; Jung JW, 2005, CANCER LETT, V225, P199, DOI 10.1016/j.canlet.2004.11.029; Lee MY, 2001, BIOCHEM BIOPH RES CO, V281, P1241, DOI 10.1006/bbrc.2001.4494; MAEKAWA T, 1989, EMBO J, V8, P2023, DOI 10.1002/j.1460-2075.1989.tb03610.x; MAHENDROO MS, 1993, J BIOL CHEM, V268, P19463; MCINTYRE A, 1991, GASTROENTEROLOGY, V101, P1274, DOI 10.1016/0016-5085(91)90077-X; MCNATTY KP, 1976, J ENDOCRINOL, V71, P77, DOI 10.1677/joe.0.0710077; Meng L, 2001, CANCER RES, V61, P2250; Michael MD, 1997, MOL CELL ENDOCRINOL, V134, P147, DOI 10.1016/S0303-7207(97)00178-0; Miller WR, 2001, J STEROID BIOCHEM, V79, P93, DOI 10.1016/S0960-0760(01)00148-0; Miller WR, 2003, J STEROID BIOCHEM, V86, P413, DOI 10.1016/S0960-0760(03)00352-2; Mink S, 1997, MOL CELL BIOL, V17, P6609, DOI 10.1128/MCB.17.11.6609; Montminy M, 1997, ANNU REV BIOCHEM, V66, P807, DOI 10.1146/annurev.biochem.66.1.807; NICHOLS JE, 1995, J SOC GYNECOL INVEST, V2, P45, DOI 10.1016/1071-5576(94)00047-5; ONEILL JS, 1988, BRIT MED J, V296, P741, DOI 10.1136/bmj.296.6624.741; Orchel A, 2005, DIGEST DIS SCI, V50, P490, DOI 10.1007/s10620-005-2463-6; Paridaens R, 2003, ANN ONCOL, V14, P1391, DOI 10.1093/annonc/mdg362; PRICE T, 1992, J CLIN ENDOCR METAB, V74, P1247, DOI 10.1210/jc.74.6.1247; Schwartz B, 1998, MOL CELL BIOCHEM, V188, P21, DOI 10.1023/A:1006831330340; Shaywitz AJ, 1999, ANNU REV BIOCHEM, V68, P821, DOI 10.1146/annurev.biochem.68.1.821; Shozu M, 2003, NEW ENGL J MED, V348, P1855, DOI 10.1056/NEJMoa021559; Shuman JD, 1997, J BIOL CHEM, V272, P12793, DOI 10.1074/jbc.272.19.12793; SIMPSON ER, 1994, ENDOCR REV, V15, P342, DOI 10.1210/er.15.3.342; Simpson ER, 2001, ANN NY ACAD SCI, V949, P58; Sowa Yoshihiro, 2003, Nihon Eiseigaku Zasshi, V58, P267; STEINKAMPF MP, 1987, MOL ENDOCRINOL, V1, P465, DOI 10.1210/mend-1-7-465; Vernia P, 2000, DIGEST DIS SCI, V45, P976, DOI 10.1023/A:1005537411244; Weidle UH, 2000, ANTICANCER RES, V20, P1471; Yue W, 1998, CANCER RES, V58, P927; ZHAO Y, 1995, MOL ENDOCRINOL, V9, P340, DOI 10.1210/me.9.3.340; ZHAO Y, 1995, J BIOL CHEM, V270, P16449, DOI 10.1074/jbc.270.27.16449; Zhao Y, 1996, ENDOCRINOLOGY, V137, P5739, DOI 10.1210/en.137.12.5739; Zhou CB, 1996, J STEROID BIOCHEM, V59, P163, DOI 10.1016/S0960-0760(96)00100-8; Zhou DJ, 1999, ARCH BIOCHEM BIOPHYS, V371, P179, DOI 10.1006/abbi.1999.1454; Zhou DJ, 1998, ARCH BIOCHEM BIOPHYS, V353, P213, DOI 10.1006/abbi.1998.0641; Zhou JF, 2001, CANCER RES, V61, P2328	58	41	41	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 3	2006	281	5					2585	2597		10.1074/jbc.M508498200	http://dx.doi.org/10.1074/jbc.M508498200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	006XT	16303757	hybrid			2022-12-25	WOS:000234931800022
J	Li, Y; Asuri, S; Rebhun, JF; Castro, AF; Paranavitana, NC; Quilliam, LA				Li, Y; Asuri, S; Rebhun, JF; Castro, AF; Paranavitana, NC; Quilliam, LA			The RAP1 guanine nucleotide exchange factor Epac2 couples cyclic AMP and Ras signals at the plasma membrane	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-ADHESION; DISSOCIATION STIMULATOR; BIOCHEMICAL-ANALYSIS; PHOSPHOLIPASE-C; BINDING PROTEIN; FAMILY GTPASES; GOLGI-COMPLEX; R-RAS; ACTIVATION; CAMP	Epac-1 and -2 ( exchange proteins directly activated by cyclic AMP) are guanine-nucleotide exchange factors for the GTPases Rap1 and -2. Epac2 but not Epac1 was found to possess a RA (Ras association) domain similar to that found in the Ras effector Ral-GDS. This domain specifically bound Ras-GTP, enabling oncogenic Ras to translocate Epac2 from the cytosol to the plasma membrane. Consequently, a small pool of plasma membrane-bound Rap1 was activated at the expense of bulk Rap1 located on intracellular organelles. Whereas translocation of Epac2 was not mimicked by challenge with epidermal growth factor alone, costimulation with forskolin, prostaglandin E-2, or an Epac-selective cyclic AMP analog-induced rapid relocation of GFP-Epac2 but not -Epac1 to the plasma membrane in a Ras-dependent manner. Deletion of the cyclic AMP-binding domain overcame the need for nucleotide, suggesting that this domain normally masked the RA domain in the resting GEF. Thus, Epac2 can respond to costimulation by agonists that jointly elevate Ras-GTP and cyclic AMP levels, activating a specific pool of Rap1 at the plasma membrane. Therefore, despite its previous description as a Ras antagonist or independently functioning GTPase, Rap1/Krev-1 may additionally act downstream of Ras in cells that express the cyclic AMP-regulated GEF, Epac2.	Indiana Univ, Sch Med, Dept Biochem & Mol Biol, Indianapolis, IN 46202 USA; Walther Canc Inst, Indianapolis, IN 46202 USA	Indiana University System; Indiana University-Purdue University Indianapolis; Walther Cancer Institute	Quilliam, LA (corresponding author), 635 Barnhill Dr,MS-4053, Indianapolis, IN 46202 USA.	lquillia@iupui.edu	Quilliam, Lawrence/B-6447-2015; Rebhun, John F/H-7235-2019; Quilliam, Lawrence/Q-4987-2019	Rebhun, John F/0000-0002-0764-5210; 	NATIONAL CANCER INSTITUTE [R01CA108647] Funding Source: NIH RePORTER; NCI NIH HHS [CA108647, R01 CA108647-02, R01 CA108647] Funding Source: Medline; PHS HHS [T32-H07774] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		BERANGER F, 1991, P NATL ACAD SCI USA, V88, P1606, DOI 10.1073/pnas.88.5.1606; Bivona TG, 2004, J CELL BIOL, V164, P461, DOI 10.1083/jcb.200311093; Boettner B, 2000, P NATL ACAD SCI USA, V97, P9064, DOI 10.1073/pnas.97.16.9064; Bos JL, 1998, EMBO J, V17, P6776, DOI 10.1093/emboj/17.23.6776; Bos JL, 2001, NAT REV MOL CELL BIO, V2, P369, DOI 10.1038/35073073; Bos JL, 2005, CURR OPIN CELL BIOL, V17, P123, DOI 10.1016/j.ceb.2005.02.009; Caloca MJ, 2004, J BIOL CHEM, V279, P20435, DOI 10.1074/jbc.M313013200; Campbell SL, 1998, ONCOGENE, V17, P1395, DOI 10.1038/sj.onc.1202174; Caron E, 2003, J CELL SCI, V116, P435, DOI 10.1242/jcs.00238; Choy E, 1999, CELL, V98, P69, DOI 10.1016/S0092-8674(00)80607-8; de Hoog CL, 2001, MOL CELL BIOL, V21, P2107, DOI 10.1128/MCB.21.6.2107-2117.2001; de Rooij J, 2000, J BIOL CHEM, V275, P20829, DOI 10.1074/jbc.M001113200; de Rooij J, 1998, NATURE, V396, P474, DOI 10.1038/24884; de Rooij J, 1999, J BIOL CHEM, V274, P38125, DOI 10.1074/jbc.274.53.38125; DSilva NJ, 1997, J HISTOCHEM CYTOCHEM, V45, P965, DOI 10.1177/002215549704500706; Elmendorf Jeffrey S, 2003, Methods Mol Med, V83, P105; Enserink JM, 2002, NAT CELL BIOL, V4, P901, DOI 10.1038/ncb874; Gao XL, 2001, J BIOL CHEM, V276, P42219, DOI 10.1074/jbc.M105760200; Gonzalez-Robayna IJ, 2000, MOL ENDOCRINOL, V14, P1283, DOI 10.1210/me.14.8.1283; HOFER F, 1994, P NATL ACAD SCI USA, V91, P11089, DOI 10.1073/pnas.91.23.11089; Holz GG, 2004, DIABETES, V53, P5, DOI 10.2337/diabetes.53.1.5; Huang L, 1998, NAT STRUCT BIOL, V5, P422, DOI 10.1038/nsb0698-422; Ichiba T, 1999, FEBS LETT, V457, P85, DOI 10.1016/S0014-5793(99)01012-1; KAPLON T, 1995, J BIOL CHEM, V270, P20742, DOI 10.1074/jbc.270.35.20742; Kashima Y, 2001, J BIOL CHEM, V276, P46046, DOI 10.1074/jbc.M108378200; Katagiri K, 2003, NAT IMMUNOL, V4, P741, DOI 10.1038/ni950; Kawasaki H, 1998, SCIENCE, V282, P2275, DOI 10.1126/science.282.5397.2275; Kelley GG, 2001, EMBO J, V20, P743, DOI 10.1093/emboj/20.4.743; Kishida S, 1997, ONCOGENE, V15, P2899, DOI 10.1038/sj.onc.1201473; KITAYAMA H, 1989, CELL, V56, P77, DOI 10.1016/0092-8674(89)90985-9; Kiyokawa E, 1997, CRIT REV ONCOGENESIS, V8, P329, DOI 10.1615/CritRevOncog.v8.i4.30; Knox AL, 2002, SCIENCE, V295, P1285, DOI 10.1126/science.1067549; Kopito RR, 2000, TRENDS CELL BIOL, V10, P524, DOI 10.1016/S0962-8924(00)01852-3; Kuiperij HB, 2003, BBA-MOL CELL RES, V1593, P141, DOI 10.1016/S0167-4889(02)00365-8; Kuriyama M, 1996, J BIOL CHEM, V271, P607, DOI 10.1074/jbc.271.2.607; Laroche-Joubert N, 2002, J BIOL CHEM, V277, P18598, DOI 10.1074/jbc.M201868200; LEEVERS SJ, 1994, NATURE, V369, P411, DOI 10.1038/369411a0; Liao YH, 2001, J BIOL CHEM, V276, P28478, DOI 10.1074/jbc.M101737200; Margarit SM, 2003, CELL, V112, P685, DOI 10.1016/S0092-8674(03)00149-1; Matsubara K, 1999, ONCOGENE, V18, P1303, DOI 10.1038/sj.onc.1202425; Mochizuki N, 2001, NATURE, V411, P1065, DOI 10.1038/35082594; NASSAR M, 1995, NATURE, V375, P554, DOI 10.1038/375554a0; Nielsen KH, 1997, MOL CELL BIOL, V17, P7132, DOI 10.1128/MCB.17.12.7132; Pacold ME, 2000, CELL, V103, P931, DOI 10.1016/S0092-8674(00)00196-3; Pfleger CM, 2000, GENE DEV, V14, P655; Pham N, 2001, J BIOL CHEM, V276, P46995, DOI 10.1074/jbc.M108373200; PIZON V, 1994, J CELL SCI, V107, P1661; Qiao JB, 2002, J BIOL CHEM, V277, P26581, DOI 10.1074/jbc.M203571200; Quilliam LA, 2002, PROG NUCLEIC ACID RE, V71, P391, DOI 10.1016/S0079-6603(02)71047-7; Quilliam LA, 2001, METHOD ENZYMOL, V333, P187; Rangarajan S, 2003, J CELL BIOL, V160, P487, DOI 10.1083/jcb.200209105; Rebhun JF, 2000, J BIOL CHEM, V275, P34901, DOI 10.1074/jbc.M005327200; Rehmann H, 2003, J BIOL CHEM, V278, P23508, DOI 10.1074/jbc.M301680200; Rehmann H, 2003, J BIOL CHEM, V278, P38548, DOI 10.1074/jbc.M306292200; Rodriguez-Viciana P, 2004, MOL CELL BIOL, V24, P4943, DOI 10.1128/MCB.24.11.4943-4954.2004; Schmidt M, 2001, NAT CELL BIOL, V3, P1020, DOI 10.1038/ncb1101-1020; Shibasaki T, 2004, J BIOL CHEM, V279, P7956, DOI 10.1074/jbc.M309068200; SPAARGAREN M, 1994, P NATL ACAD SCI USA, V91, P12609, DOI 10.1073/pnas.91.26.12609; STOKOE D, 1994, SCIENCE, V264, P1463, DOI 10.1126/science.7811320; Stork PJS, 2003, TRENDS BIOCHEM SCI, V28, P267, DOI 10.1016/S0968-0004(03)00087-2; Urano T, 1996, EMBO J, V15, P810, DOI 10.1002/j.1460-2075.1996.tb00416.x; Vavvas D, 1998, J BIOL CHEM, V273, P5439, DOI 10.1074/jbc.273.10.5439; Vetter IR, 1999, FEBS LETT, V451, P175, DOI 10.1016/S0014-5793(99)00555-4; Wohlgemuth S, 2005, J MOL BIOL, V348, P741, DOI 10.1016/j.jmb.2005.02.048; Wu CB, 2001, J NEUROSCI, V21, P5406, DOI 10.1523/JNEUROSCI.21-15-05406.2001; Yamashita S, 2000, J BIOL CHEM, V275, P25488, DOI 10.1074/jbc.M003414200; York RD, 2000, MOL CELL BIOL, V20, P8069, DOI 10.1128/MCB.20.21.8069-8083.2000	67	81	83	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 3	2006	281	5					2506	2514		10.1074/jbc.M508165200	http://dx.doi.org/10.1074/jbc.M508165200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	006XT	16316996	hybrid			2022-12-25	WOS:000234931800013
J	Valentin, G; Schwob, E; Della Seta, F				Valentin, G; Schwob, E; Della Seta, F			Dual role of the Cdc7-regulatory protein Dbf4 during yeast meiosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PREMEIOTIC DNA-REPLICATION; KINASE REGULATORY SUBUNIT; MEIOTIC S PHASE; SACCHAROMYCES-CEREVISIAE; CDC7 KINASE; CELL-CYCLE; CHROMOSOME SEGREGATION; FISSION YEAST; CHECKPOINT; INITIATION	The Dbf4-dependent Cdc7 kinase (DDK) is essential for chromosome duplication in all eukaryotes, but was proposed to be dispensable for yeast pre-meiotic DNA replication. This discrepancy led us to investigate the role of the unstable Cdc7-regulatory protein Dbf4 in meiosis. We show that, when Dbf4 is depleted at the time of meiotic induction, cells enter the meiotic program but do not replicate their chromosomes. Surprisingly when Dbf4 is depleted after the initiation of DNA synthesis, S phase goes to completion, but most cells arrest before anaphase I. Deletion of the cohesin Rec8 suppresses this phenotype, suggesting a distinct role of DDK for meiotic chromosome segregation. As after Cdc5 depletion, a fraction of cells undergo a single equational division suggesting a failure to mono-orient sister kinetochores. Our results demonstrate that Dbf4 is essential for DNA replication during meiosis like in vegetative cells and provide evidence for an additional role in setting up the reductional division of meiosis I.	Inst Mol Genet, F-34293 Montpellier 5, France; Univ Montpellier 2, CNRS, UMR5535, F-34293 Montpellier 5, France	Universite de Montpellier; Centre National de la Recherche Scientifique (CNRS); Universite de Montpellier	Schwob, E (corresponding author), Inst Mol Genet, 1919,Route Mende, F-34293 Montpellier 5, France.	etienne.schwob@igmm.cnrs.fr; flavio.dellaseta@igmm.fr	Valentin, Guillaume/AAL-9185-2020; Schwob, Etienne/H-4678-2015; Schwob, Etienne/AAC-3050-2020	Schwob, Etienne/0000-0002-9369-6419; Valentin, Guillaume/0000-0003-4596-6282				Bailis JM, 2003, NAT CELL BIOL, V5, P1111, DOI 10.1038/ncb1069; Benjamin KR, 2003, GENE DEV, V17, P1524, DOI 10.1101/gad.1101503; Bousset K, 1998, GENE DEV, V12, P480, DOI 10.1101/gad.12.4.480; Brott BK, 2005, DEV CELL, V8, P703, DOI 10.1016/j.devcel.2005.02.012; Buonomo SBC, 2000, CELL, V103, P387, DOI 10.1016/S0092-8674(00)00131-8; Cha RS, 2000, GENE DEV, V14, P493; Clyne RK, 2003, NAT CELL BIOL, V5, P480, DOI 10.1038/ncb977; COLLINS I, 1994, MOL CELL BIOL, V14, P3524, DOI 10.1128/MCB.14.5.3524; Costanzo V, 2003, MOL CELL, V11, P203, DOI 10.1016/S1097-2765(02)00799-2; CROSS FR, 1991, CELL, V65, P875, DOI 10.1016/0092-8674(91)90394-E; Dirick L, 1998, SCIENCE, V281, P1854, DOI 10.1126/science.281.5384.1854; Donaldson AD, 1998, GENE DEV, V12, P491, DOI 10.1101/gad.12.4.491; DOWELL SJ, 1994, SCIENCE, V265, P1243, DOI 10.1126/science.8066465; Duncker BP, 2003, MUTAT RES-FUND MOL M, V532, P21, DOI 10.1016/j.mrfmmm.2003.08.007; Elia AEH, 2003, CELL, V115, P83, DOI 10.1016/S0092-8674(03)00725-6; Forsburg SL, 2000, NAT GENET, V25, P263, DOI 10.1038/77015; Guttmann-Raviv N, 2001, GENETICS, V159, P1547; HOLLINGSWORTH RE, 1993, CHROMOSOMA, V102, P415, DOI 10.1007/BF00360406; Honigberg SM, 2004, J CELL BIOCHEM, V92, P1025, DOI 10.1002/jcb.20131; Keeney S, 2001, CURR TOP DEV BIOL, V52, P1, DOI 10.1016/S0070-2153(01)52008-6; KLAPHOLZ S, 1985, GENETICS, V110, P187; Klein F, 1999, CELL, V98, P91, DOI 10.1016/S0092-8674(00)80609-1; Lee BH, 2003, SCIENCE, V300, P482, DOI 10.1126/science.1081846; Lengronne A, 2001, NUCLEIC ACIDS RES, V29, P1433, DOI 10.1093/nar/29.7.1433; Lindner K, 2002, MOL BIOL CELL, V13, P435, DOI 10.1091/mbc.01-11-0537; Marston AL, 2004, NAT REV MOL CELL BIO, V5, P983, DOI 10.1038/nrm1526; Masai H, 2002, J CELL PHYSIOL, V190, P287, DOI 10.1002/jcp.10070; Montagnoli A, 2002, EMBO J, V21, P3171, DOI 10.1093/emboj/cdf290; Murakami H, 2001, NAT GENET, V28, P290, DOI 10.1038/90142; Nakamura T, 2002, MOL CELL BIOL, V22, P309, DOI 10.1128/MCB.22.1.309-320.2002; Nougarede R, 2000, MOL CELL BIOL, V20, P3795, DOI 10.1128/MCB.20.11.3795-3806.2000; Ofir Y, 2004, MOL BIOL CELL, V15, P2230, DOI 10.1091/mbc.E03-08-0617; Pasero P, 1999, GENE DEV, V13, P2159, DOI 10.1101/gad.13.16.2159; SCHILD D, 1978, CHROMOSOMA, V70, P109, DOI 10.1007/BF00292220; Shonn MA, 2000, SCIENCE, V289, P300, DOI 10.1126/science.289.5477.300; SIMCHEN G, 1974, GENETICS, V76, P745; Snaith HA, 2000, MOL CELL BIOL, V20, P7922, DOI 10.1128/MCB.20.21.7922-7932.2000; Stuart D, 1998, GENE DEV, V12, P2698, DOI 10.1101/gad.12.17.2698; Weinreich M, 1999, EMBO J, V18, P5334, DOI 10.1093/emboj/18.19.5334; Woo RA, 2003, CELL CYCLE, V2, P316, DOI 10.4161/cc.2.4.468; XU LZ, 1995, MOL CELL BIOL, V15, P6572; Yanow SK, 2003, J BIOL CHEM, V278, P41083, DOI 10.1074/jbc.M307144200; Yoshizawa-Sugata N, 2005, J BIOL CHEM, V280, P13062, DOI 10.1074/jbc.M411653200	43	24	26	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 3	2006	281	5					2828	2834		10.1074/jbc.M510626200	http://dx.doi.org/10.1074/jbc.M510626200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	006XT	16319063	Green Published, hybrid			2022-12-25	WOS:000234931800050
J	Mason, AJ; Martinez, A; Glaubitz, C; Danos, O; Kichler, A; Bechinger, B				Mason, A. James; Martinez, Amelie; Glaubitz, Clemens; Danos, Olivier; Kichler, Antoine; Bechinger, Burkhard			The antibiotic and DNA-transfecting peptide LAH4 selectively associates with, and disorders, anionic lipids in mixed membranes	FASEB JOURNAL			English	Article						(31)P MAS and (2)H solid-state NMR; phosphatidylserine asymmetry; gene transfer	PHOSPHOLIPID-BILAYER MEMBRANES; LACTOFERRIN-DERIVED PEPTIDES; STATE NMR-SPECTROSCOPY; ANTIMICROBIAL PEPTIDE; MAGNETIC-RESONANCE; LYTIC PEPTIDES; BETA-PEPTIDE; GRAMICIDIN-S; TUMOR-CELLS; PHOSPHATIDYLSERINE	The histidine-rich amphipathic peptide LAH4 has antibiotic and DNA delivery capabilities. The peptide has a strong affinity for anionic lipids found in the outer membrane of bacterial membranes. A role for anionic lipids in release of cationic plasmid-containing complexes has been proposed previously, and disruption of membrane asymmetry and presentation of phosphatidylserine (PS) in the membrane outer leaflet is a general feature observed in diseased mammalian cells. Therefore, to understand the peptide-lipid interactions in more detail, solidstate NMR experiments on model membranes have been performed. (31)P MAS NMR on mixed phosphatidylcholine (PC)/PS and PC/phosphatidylglycerol (PG) membranes has been used to demonstrate a strong interaction between LAH4 and anionic lipids. By using deuterated lipids and wide-line (2)H NMR when probing lipid chain order, it is demonstrated that LAH4 preferentially interacts with PS over PC and effectively disorders the anionic PS lipid fatty acyl chains. In addition, we demonstrate that the efficiency of gene transfer in vitro to different cell lines is closely related to the degree of disruption of PS acyl chains for four isomers of LAH4. This work suggests a mechanism of selective destabilization by LAH4 of anionic lipids in the membranes of cells during transfection with implications for nucleic acid delivery in vivo.	[Mason, A. James; Bechinger, Burkhard] Univ Strasbourg 1, Inst Bel, Fac Chim, CNRS UMR717 LC3, Strasbourg, France; [Martinez, Amelie; Glaubitz, Clemens; Danos, Olivier; Kichler, Antoine] Genethon CNRS UMR8115, Evry, France; [Mason, A. James] Goethe Univ Frankfurt, Ctr Biomol Magnet Resonance, Frankfurt, Germany; [Mason, A. James] Goethe Univ Frankfurt, Inst Biophys Chem, Frankfurt, Germany	UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg; Centre National de la Recherche Scientifique (CNRS); Goethe University Frankfurt; Goethe University Frankfurt	Mason, AJ (corresponding author), Inst Isis, 8 Rue Gaspard Monge, F-67000 Strasbourg, France.	jmason@chimie.u-strasbg.fr	Glaubitz, Clemens/D-5714-2011; Mason, James/J-2273-2012	Glaubitz, Clemens/0000-0002-3554-6586; Mason, James/0000-0003-0411-602X; Kichler, Antoine/0000-0003-0593-2424				Andersen JF, 2004, BIOCHEMISTRY-US, V43, P6987, DOI 10.1021/bi049655t; Andreu D, 1998, BIOPOLYMERS, V47, P415, DOI 10.1002/(SICI)1097-0282(1998)47:6<415::AID-BIP2>3.0.CO;2-D; Bechinger B, 1996, J MOL BIOL, V263, P768, DOI 10.1006/jmbi.1996.0614; Bechinger B, 1999, BBA-BIOMEMBRANES, V1462, P157, DOI 10.1016/S0005-2736(99)00205-9; Bechinger B, 2005, BBA-BIOMEMBRANES, V1712, P101, DOI 10.1016/j.bbamem.2005.03.003; Bechinger B, 2004, CRIT REV PLANT SCI, V23, P271, DOI 10.1080/07352680490452825; Bechinger B, 1997, J MEMBRANE BIOL, V156, P197, DOI 10.1007/s002329900201; Blazyk J, 2001, J BIOL CHEM, V276, P27899, DOI 10.1074/jbc.M102865200; Bonev B, 2001, PHYS CHEM CHEM PHYS, V3, P2904, DOI 10.1039/b103352m; Buffy JJ, 2004, BIOCHEMISTRY-US, V43, P9800, DOI 10.1021/bi036243w; Callahan MK, 2003, J IMMUNOL, V170, P4840, DOI 10.4049/jimmunol.170.9.4840; Chen HM, 1997, BBA-GEN SUBJECTS, V1336, P171, DOI 10.1016/S0304-4165(97)00024-X; CRUCIANI RA, 1991, P NATL ACAD SCI USA, V88, P3792, DOI 10.1073/pnas.88.9.3792; DAVIS JH, 1983, BIOCHIM BIOPHYS ACTA, V737, P117, DOI 10.1016/0304-4157(83)90015-1; Epand RF, 2003, EUR J BIOCHEM, V270, P1240, DOI 10.1046/j.1432-1033.2003.03484.x; Gidalevitz D, 2003, P NATL ACAD SCI USA, V100, P6302, DOI 10.1073/pnas.0934731100; HUSCHTSCHA LI, 1983, J CELL SCI, V63, P77; Kichler A, 2003, M S-MED SCI, V19, P1046, DOI 10.1051/medsci/200319111046; Kichler A, 2003, P NATL ACAD SCI USA, V100, P1564, DOI 10.1073/pnas.0337677100; Kol MA, 2003, BIOCHEMISTRY-US, V42, P231, DOI 10.1021/bi0268403; KOOPMAN G, 1994, BLOOD, V84, P1415, DOI 10.1182/blood.V84.5.1415.1415; Lakowicz J.R., 2010, PRINCIPLE FLUORESCEN, DOI 10.1007/978-0-387-46312-4/COVER; Lewis RNAH, 2003, BIOCHEMISTRY-US, V42, P440, DOI 10.1021/bi026707a; Ludtke SJ, 1996, BIOCHEMISTRY-US, V35, P13723, DOI 10.1021/bi9620621; Mason AJ, 2005, BBA-BIOMEMBRANES, V1714, P1, DOI 10.1016/j.bbamem.2005.06.003; Nieh MP, 2004, LANGMUIR, V20, P7893, DOI 10.1021/la048641l; Nieh MP, 2002, BIOPHYS J, V82, P2487, DOI 10.1016/S0006-3495(02)75591-4; Prenner EJ, 2001, BBA-BIOMEMBRANES, V1510, P83, DOI 10.1016/S0005-2736(00)00337-0; Ran S, 2002, CANCER RES, V62, P6132; Rinaldi AC, 2002, BIOCHEM J, V368, P91, DOI 10.1042/BJ20020806; SCHAFER H, 1995, J MAGN RESON SER A, V116, P145, DOI 10.1006/jmra.1995.0002; SEELIG A, 1974, BIOCHEMISTRY-US, V13, P4839, DOI 10.1021/bi00720a024; SEELIG J, 1978, BIOCHIM BIOPHYS ACTA, V515, P105, DOI 10.1016/0304-4157(78)90001-1; Shai Y, 1999, BBA-BIOMEMBRANES, V1462, P55, DOI 10.1016/S0005-2736(99)00200-X; Shin SY, 2001, J PEPT RES, V58, P504, DOI 10.1034/j.1399-3011.2001.00934.x; STERNIN E, 1983, J MAGN RESON, V55, P274, DOI 10.1016/0022-2364(83)90239-1; TURNER GL, 1986, J MAGN RESON, V70, P408, DOI 10.1016/0022-2364(86)90129-0; UTSUGI T, 1991, CANCER RES, V51, P3062; Vogt TCB, 1999, J BIOL CHEM, V274, P29115, DOI 10.1074/jbc.274.41.29115; Wieprecht T, 1997, BIOCHEMISTRY-US, V36, P12869, DOI 10.1021/bi971398n; Yang N, 2004, J PEPT SCI, V10, P37, DOI 10.1002/psc.470; Yang N, 2002, J PEPT RES, V60, P187, DOI 10.1034/j.1399-3011.2002.21008.x; Zelphati O, 1996, P NATL ACAD SCI USA, V93, P11493, DOI 10.1073/pnas.93.21.11493	43	79	79	1	17	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	FEB	2006	20	2					320	322		10.1096/fj.05-4293fje	http://dx.doi.org/10.1096/fj.05-4293fje			3	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	V17CJ	16352649				2022-12-25	WOS:000207915000007
J	Wendt, J; Radetzki, S; von Haefen, C; Hemmati, PG; Guner, D; Schulze-Osthoff, K; Dorken, B; Daniel, PT				Wendt, J; Radetzki, S; von Haefen, C; Hemmati, PG; Guner, D; Schulze-Osthoff, K; Dorken, B; Daniel, PT			Induction of p21(CIP/WAF-1) and G2 arrest by ionizing irradiation impedes caspase-3-mediated apoptosis in human carcinoma cells	ONCOGENE			English	Article						ionizing irradiation; DNA damage; G2 cell cycle arrest; apoptosis; resistance	DRUG-INDUCED APOPTOSIS; CYCLE ARREST; MITOTIC CATASTROPHE; CD95/FAS RECEPTOR; MITOCHONDRIAL; BAX; DEATH; ACTIVATION; CANCER; P53	There is an ongoing controversy regarding the relevance of apoptosis induction by ionizing irradiation as compared with other end points including transient or permanent cell cycle arrest of damaged cells. Here, we show that such permanent cell cycle arrest and apoptosis represent two sides of the same coin. MCF-7 cells fail to express procaspase-3, which results in resistance to apoptosis induced by anticancer drugs. Conversely, restoration of procaspase-3 sensitizes MCF- 7 cells to chemotherapeutics including epirubicine, etoposide and taxol. In contrast, irradiation does not trigger apoptotic cell death but results in prolonged arrest in the G2 phase of the cell division cycle regardless of procaspase-3 expression. This suggested that the propensity of MCF-7 cells to arrest at the G2 checkpoint results in resistance to apoptosis upon gamma-irradiation. This G2 arrest was associated with upregulation of p21(CIP/WAF-1). Inhibition of DNA-damage-induced stress kinases and p21(CIP/WAF-1) expression by caffeine abrogated G2 arrest and induced apoptosis of the irradiated cells in a caspase-3-dependent manner. Inhibition of cell cycle progression by adenoviral expression of the cyclin dependent kinase inhibitor p21(CIP/WAF-1) prevented apoptosis upon caffeine treatment indicating that cell cycle progression, that is, G2-release, is required for induction of apoptosis. Likewise, cells homozygously deleted for p21(CIP/WAF-1) (HCT116 p21(-/-)) display enhanced irradiation-induced apoptosis via a caspase-3-dependent mechanism. These data indicate that the disruption of G2 checkpoint control overcomes cell cycle arrest and resistance to gamma-irradiation-induced cell death. Thus, DNA damage may trigger a permanent G2 arrest as an initial inactivation step of tumor cells where the phenomenon of apoptosis is hidden unless cell cycle arrest is overcome. The efficient induction of apoptosis upon G2 release thereby depends on the propensity to activate the key executioner caspase-3. This finding is of crucial importance for the understanding of molecular steps underlying the efficacy of ionizing radiation to delete tumor cells.	Humboldt Univ, Med Ctr Charite, Dept Hematol Oncol & Tumor Immunol, D-13125 Berlin, Germany; Univ Dusseldorf, Inst Mol Med, D-4000 Dusseldorf, Germany	Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Heinrich Heine University Dusseldorf	Daniel, PT (corresponding author), Humboldt Univ, Med Ctr Charite, Dept Hematol Oncol & Tumor Immunol, Lindenberger Weg 80,Campus Berlin Buch, D-13125 Berlin, Germany.	pdaniel@mdc-berlin.de	Schulze-Osthoff, Klaus/N-9025-2013	Schulze-Osthoff, Klaus/0000-0003-1443-2720				Bhonde MR, 2005, ONCOGENE, V24, P148, DOI 10.1038/sj.onc.1207842; Bunz F, 1998, SCIENCE, V282, P1497, DOI 10.1126/science.282.5393.1497; Chan TA, 1999, NATURE, V401, P616, DOI 10.1038/44188; Chartier C, 1996, J VIROL, V70, P4805, DOI 10.1128/JVI.70.7.4805-4810.1996; Chu K, 2004, RADIAT RES, V162, P270, DOI 10.1667/RR3221; Daniel PT, 1999, ANAL BIOCHEM, V266, P110, DOI 10.1006/abio.1998.2929; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Essmann F, 2000, BIOCHEM J, V346, P777, DOI 10.1042/0264-6021:3460777; Friedrich K, 2001, ONCOGENE, V20, P2749, DOI 10.1038/sj.onc.1204342; Gillissen B, 2003, EMBO J, V22, P3580, DOI 10.1093/emboj/cdg343; Guner Dilek, 2003, Curr Med Chem Anticancer Agents, V3, P319, DOI 10.2174/1568011033482369; Hasenjager A, 2004, ONCOGENE, V23, P4523, DOI 10.1038/sj.onc.1207594; He TC, 1998, P NATL ACAD SCI USA, V95, P2509, DOI 10.1073/pnas.95.5.2509; Heid CA, 1996, GENOME RES, V6, P986, DOI 10.1101/gr.6.10.986; Hemmati PG, 2005, ONCOGENE, V24, P4114, DOI 10.1038/sj.onc.1208579; Hemmati PG, 2002, ONCOGENE, V21, P3149, DOI 10.1038/sj.onc.1205458; Janicke RU, 2001, ONCOGENE, V20, P5043, DOI 10.1038/sj.onc.1204659; Janicke RU, 1998, J BIOL CHEM, V273, P15540, DOI 10.1074/jbc.273.25.15540; Javelaud D, 2002, J BIOL CHEM, V277, P37949, DOI 10.1074/jbc.M204497200; Kastan MB, 2000, NAT REV MOL CELL BIO, V1, P179, DOI 10.1038/35043058; Klopfer A, 2004, ONCOGENE, V23, P9408, DOI 10.1038/sj.onc.1207975; Kroemer G, 2000, NAT MED, V6, P513, DOI 10.1038/74994; Motwani M, 1999, CLIN CANCER RES, V5, P1876; Mrozek A, 2003, CELL DEATH DIFFER, V10, P461, DOI 10.1038/sj.cdd.4401193; Normand G, 2005, J BIOL CHEM, V280, P7118, DOI 10.1074/jbc.M412330200; Prokop A, 2003, ONCOGENE, V22, P9107, DOI 10.1038/sj.onc.1207196; Prokop A, 2000, LEUKEMIA, V14, P1606, DOI 10.1038/sj.leu.2401866; Radetzki S, 2002, ONCOGENE, V21, P227, DOI 10.1038/sj/onc/1205010; Rau B, 2003, J CLIN ONCOL, V21, P3391, DOI 10.1200/JCO.2003.07.077; Rudner J, 2001, J CELL SCI, V114, P4161; Sarkaria JN, 1999, CANCER RES, V59, P4375; Sturm I, 2001, J CLIN ONCOL, V19, P2272, DOI 10.1200/JCO.2001.19.8.2272; Sturm I, 1999, J CLIN ONCOL, V17, P1364, DOI 10.1200/JCO.1999.17.5.1364; Taylor WR, 2001, ONCOGENE, V20, P1803, DOI 10.1038/sj.onc.1204252; von Haefen C, 2003, ONCOGENE, V22, P2236, DOI 10.1038/sj.onc.1206280; von Haefen C, 2004, ONCOGENE, V23, P8320, DOI 10.1038/sj.onc.1207971; von Haefen C, 2002, ONCOGENE, V21, P4009, DOI 10.1038/sj.onc.1205497; Waldman T, 1996, NATURE, V381, P713, DOI 10.1038/381713a0; Wieder T, 2001, BLOOD, V97, P1378, DOI 10.1182/blood.V97.5.1378; Xaus J, 1999, IMMUNITY, V11, P103, DOI 10.1016/S1074-7613(00)80085-0; Zhou BBS, 2000, J BIOL CHEM, V275, P10342, DOI 10.1074/jbc.275.14.10342	41	62	63	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB	2006	25	7					972	980		10.1038/sj.onc.1209031	http://dx.doi.org/10.1038/sj.onc.1209031			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	012SX	16331277				2022-12-25	WOS:000235361000002
J	McCormick, F				McCormick, F			Future prospects for oncolytic therapy	ONCOGENE			English	Review						oncolytic viruses; adenovirus; targeted therapy; oncology	AGENTS; POTENT	Viruses have been engineered to replicate selectively in cancer cells, based on a number of innovative principles. Several of these viruses have entered clinical trials and have proven relatively safe, and have shown evidence of efficacy. However, further research is required to enable these agents to function systemically. This might involve attempts to suppress immune responses to virus antigens, and re-targeting of viruses to favor tumor infection and increased potency. When these barriers are overcome, oncolytic viruses could enter the mainstream of clinical oncology.	Univ Calif San Francisco, Canc Res Inst, San Francisco, CA 94115 USA	University of California System; University of California San Francisco	McCormick, F (corresponding author), Univ Calif San Francisco, Canc Res Inst, 2340 Sutter St, San Francisco, CA 94115 USA.	mccormick@cc.ucsf.edu						Aghi M, 2005, ONCOGENE, V24, P7802, DOI 10.1038/sj.onc.1209037; Fueyo J, 2003, J NATL CANCER I, V95, P652, DOI 10.1093/jnci/95.9.652; Heise C, 2000, NAT MED, V6, P1134, DOI 10.1038/80474; Johnson L, 2002, CANCER CELL, V1, P325, DOI 10.1016/S1535-6108(02)00060-0; Ko D, 2005, ONCOGENE, V24, P7763, DOI 10.1038/sj.onc.1209048; McCormick F, 2001, NAT REV CANCER, V1, P130, DOI 10.1038/35101008; Nemunaitis J, 2002, CANCER GENE THER, V9, P987, DOI 10.1038/sj.cgt.7700547; O'Shea CC, 2004, CANCER CELL, V6, P611, DOI 10.1016/j.ccr.2004.11.012; Reid T, 2001, GENE THER, V8, P1618, DOI 10.1038/sj.gt.3301512; Reid T, 2002, CANCER GENE THER, V9, P979, DOI 10.1038/sj.cgt.7700539; YU C, 2001, CANCER RES, V61, P5453	11	35	36	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 21	2005	24	52					7817	7819		10.1038/sj.onc.1209064	http://dx.doi.org/10.1038/sj.onc.1209064			3	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	985JD	16299540	Bronze			2022-12-25	WOS:000233372600016
J	Wang, RA; Zhang, H; Balasenthil, S; Medina, D; Kumar, R				Wang, R-A; Zhang, H.; Balasenthil, S.; Medina, D.; Kumar, R.			PAK1 hyperactivation is sufficient for mammary gland tumor formation	ONCOGENE			English	Article						PAK1; transgenic mice; mammary tumors; breast cancer	P21-ACTIVATED-KINASE-1; KINASES; EXPRESSION; PHOSPHORYLATES; ORGANIZATION; HYPERPLASIA; ONCOGENE; REGION; ALPHA; CDC42	Emerging data suggest that p21- activated kinase 1 ( Pak1), a downstream signaling molecule of the small GTPases, growth factors, and lipid signaling, is upregulated or hyperactivated in human breast cancer. Until now, however, no direct causative role had been found for Pak1 in mammary tumor formation. We therefore sought to identify the role that Pak1 plays in mammary gland tumorigenesis. Our results showed that in a transgenic mouse model, overexpression of catalytically active Pak1 leads to the development of malignant mammary tumors and to a variety of other breast lesions, including focal solid nodules, ductal hyperplasia, and mini- intraductal neoplasm and adenoma. We also found that Pak1 hyperactivation increases the stimulation of downstream proliferative signaling effectors MEK1/ 2 and p38- MAPK in mammary tumor epithelial cells. Moreover, in our study, we detected expression of estrogen receptor- alpha expression and progesterone receptor expression during early stages of the lesions, but their expression was lost during the cells' transition to malignant invasive tumors. Finally, we found that consistent with a role in breast tumor progression, Pak1 expression and its nuclear accumulation was increased progressively during the transition from ductal hyperplasia to ductal carcinoma in situ to adenocarcinoma in widely used multistep polyoma- middle T- antigen transgenic mice. Together, these findings provide the first direct evidence that Pak1 deregulation may be sufficient for the formation of mammary gland tumors.	Univ Texas, MD Anderson Canc Ctr, Dept Mol & Cellular Oncol, Houston, TX 77030 USA; Baylor Coll Med, Dept Mol & Cellular Biol, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center; Baylor College of Medicine	Kumar, R (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Mol & Cellular Oncol, 1515 Holcombe Blvd, Houston, TX 77030 USA.	rkumar@mdanderson.org	Wang, Brian/HGA-9535-2022		NCI NIH HHS [CA 65746, CA 90970] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA065746, R01CA090970, U01CA065746] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Adam L, 1998, J BIOL CHEM, V273, P28238, DOI 10.1074/jbc.273.43.28238; Balasenthil S, 2004, J BIOL CHEM, V279, P1422, DOI 10.1074/jbc.M309937200; BARKAN D, 2004, MOUSE MODELS HUMAN C, P103; Bekri S, 1997, CYTOGENET CELL GENET, V79, P125, DOI 10.1159/000134699; Bocchinfuso WP, 1999, CANCER RES, V59, P1869; GUY CT, 1992, MOL CELL BIOL, V12, P954, DOI 10.1128/MCB.12.3.954; Knowles HJ, 2001, ANTICANCER RES, V21, P2305; Kumar R, 2002, MICROSC RES TECHNIQ, V59, P49, DOI 10.1002/jemt.10176; Kumar R, 2002, J CELL PHYSIOL, V193, P133, DOI 10.1002/jcp.10167; Li F, 2002, EMBO REP, V3, P767, DOI 10.1093/embo-reports/kvf157; Lin EY, 2003, AM J PATHOL, V163, P2113, DOI 10.1016/S0002-9440(10)63568-7; Manser E, 1998, MOL CELL, V1, P183, DOI 10.1016/S1097-2765(00)80019-2; MANSER E, 1994, NATURE, V367, P40, DOI 10.1038/367040a0; Medina D, 2003, CANCER RES, V63, P1067; Medina D, 2000, METHODS MAMMARY GLAN, P101; Salh B, 2002, INT J CANCER, V98, P148, DOI 10.1002/ijc.10147; Schraml P, 2003, AM J PATHOL, V163, P985, DOI 10.1016/S0002-9440(10)63458-X; Sells MA, 1997, CURR BIOL, V7, P202, DOI 10.1016/S0960-9822(97)70091-5; Sells MA, 1999, J CELL BIOL, V145, P837, DOI 10.1083/jcb.145.4.837; Singh RR, 2005, J BIOL CHEM, V280, P18130, DOI 10.1074/jbc.M412607200; Vadlamudi RK, 2000, J BIOL CHEM, V275, P36238, DOI 10.1074/jbc.M002138200; Wang RA, 2003, J CELL BIOL, V161, P583, DOI 10.1083/JCB.200212066; Wang RA, 2002, EMBO J, V21, P5437, DOI 10.1093/emboj/cdf543; Zhao ZS, 1998, MOL CELL BIOL, V18, P2153, DOI 10.1128/MCB.18.4.2153	24	98	102	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY	2006	25	20					2931	2936		10.1038/sj.onc.1209309	http://dx.doi.org/10.1038/sj.onc.1209309			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	041IN	16331248				2022-12-25	WOS:000237448200011
J	Baars, L; Ytterberg, AJ; Drew, D; Wagner, S; Thilo, C; van Wijk, KJ; de Gier, JW				Baars, L; Ytterberg, AJ; Drew, D; Wagner, S; Thilo, C; van Wijk, KJ; de Gier, JW			Defining the role of the Escherichia coli chaperone SecB using comparative proteomics	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIGNAL RECOGNITION PARTICLE; HEAT-SHOCK RESPONSE; OUTER-MEMBRANE; PROTEIN-TRANSLOCATION; SALMONELLA-TYPHIMURIUM; MOLECULAR CHAPERONE; CRYSTAL-STRUCTURE; PLASMA-MEMBRANE; BINDING PROTEIN; FLOW-CYTOMETRY	To improve understanding and identify novel substrates of the cytoplasmic chaperone SecB in Escherichia coli, we analyzed a secB null mutant using comparative proteomics. The secB null mutation did not affect cell growth but caused significant differences at the proteome level. In the absence of SecB, dynamic protein aggregates containing predominantly secretory proteins accumulated in the cytoplasm. Unprocessed secretory proteins were detected in radiolabeled whole cell lysates. Furthermore, the assembly of a large fraction of the outer membrane proteome was slowed down, whereas its steady state composition was hardly affected. In response to aggregation and delayed sorting of secretory proteins, cytoplasmic chaperones DnaK, GroEL/ES, ClpB, IbpA/B, and HslU were up-regulated severalfold, most likely to stabilize secretory proteins during their delayed translocation and/or rescue aggregated secretory proteins. The SecB/A dependence of 12 secretory proteins affected by the secB null mutation ( DegP, FhuA, FkpA, OmpT, OmpX, OppA, TolB, TolC, YbgF, YcgK, YgiW, and YncE) was confirmed by "classical" pulse-labeling experiments. Our study more than triples the number of known SecB-dependent secretory proteins and shows that the primary role of SecB is to facilitate the targeting of secretory proteins to the Sec-translocase.	Stockholm Univ, Arrhenius Labs, Dept Biochem & Biophys, SE-10691 Stockholm, Sweden; Cornell Univ, Dept Plant Biol, Ithaca, NY 14853 USA; Karolinska Univ Hosp Huddinge, Karolinska Inst, Ctr Infect Dis, SE-14186 Stockholm, Sweden	Stockholm University; Cornell University; Karolinska Institutet; Karolinska University Hospital	de Gier, JW (corresponding author), Stockholm Univ, Arrhenius Labs, Dept Biochem & Biophys, SE-10691 Stockholm, Sweden.	degier@dbb.su.se	Drew, David/D-3243-2018; Ytterberg, Anders/E-1773-2016; Drew, David/AAY-3455-2020	Ytterberg, Anders/0000-0002-1485-2314; Drew, David/0000-0001-8866-6349; Wagner, Claudia/0000-0002-7311-2236				Arsene F, 2000, INT J FOOD MICROBIOL, V55, P3, DOI 10.1016/S0168-1605(00)00206-3; Berven FS, 2003, ELECTROPHORESIS, V24, P757, DOI 10.1002/elps.200390091; Carrio MM, 2003, FEBS LETT, V537, P215, DOI 10.1016/S0014-5793(03)00126-1; Darwin AJ, 2005, MOL MICROBIOL, V57, P621, DOI 10.1111/j.1365-2958.2005.04694.x; Davey HM, 1996, MICROBIOL REV, V60, P641, DOI 10.1128/MMBR.60.4.641-696.1996; Dekker C, 2003, J STRUCT BIOL, V144, P313, DOI 10.1016/j.jsb.2003.09.012; Deuerling E, 2003, MOL MICROBIOL, V47, P1317, DOI 10.1046/j.1365-2958.2003.03370.x; Duguay AR, 2004, BBA-MOL CELL RES, V1694, P121, DOI 10.1016/j.bbamcr.2004.04.012; FEKKES P, 1995, BIOCHEMISTRY-US, V34, P10078, DOI 10.1021/bi00031a032; Fekkes P, 1997, EMBO J, V16, P6105, DOI 10.1093/emboj/16.20.6105; Fekkes P, 1999, MICROBIOL MOL BIOL R, V63, P161, DOI 10.1128/MMBR.63.1.161-173.1999; Field HI, 2002, PROTEOMICS, V2, P36, DOI 10.1002/1615-9861(200201)2:1<36::AID-PROT36>3.0.CO;2-W; Friso G, 2004, PLANT CELL, V16, P478, DOI 10.1105/tpc.017814; Froderberg L, 2004, J BIOL CHEM, V279, P31026, DOI 10.1074/jbc.M403229200; Froderberg L, 2003, MOL MICROBIOL, V47, P1015, DOI 10.1046/j.1365-2958.2003.03346.x; Froderberg L, 2001, FEBS LETT, V498, P52, DOI 10.1016/S0014-5793(01)02494-2; HARTL FU, 1990, CELL, V63, P269, DOI 10.1016/0092-8674(90)90160-G; Hewitt CJ, 2004, ADV BIOCHEM ENG BIOT, V89, P197; Kerner MJ, 2005, CELL, V122, P209, DOI 10.1016/j.cell.2005.05.028; Knoblauch NTM, 1999, J BIOL CHEM, V274, P34219, DOI 10.1074/jbc.274.48.34219; KUMAMOTO CA, 1985, J BACTERIOL, V163, P267, DOI 10.1128/JB.163.1.267-274.1985; LAMINET AA, 1991, MOL MICROBIOL, V5, P117, DOI 10.1111/j.1365-2958.1991.tb01832.x; Manting EH, 2000, MOL MICROBIOL, V37, P226, DOI 10.1046/j.1365-2958.2000.01980.x; Mogk A, 2003, MOL MICROBIOL, V50, P585, DOI 10.1046/j.1365-2958.2003.03710.x; Molloy MP, 2000, EUR J BIOCHEM, V267, P2871, DOI 10.1046/j.1432-1327.2000.01296.x; Mori H, 2001, TRENDS MICROBIOL, V9, P494, DOI 10.1016/S0966-842X(01)02174-6; OAKLEY BR, 1980, ANAL BIOCHEM, V105, P361, DOI 10.1016/0003-2697(80)90470-4; OSBORN MJ, 1972, J BIOL CHEM, V247, P3962; OSBORN MJ, 1972, J BIOL CHEM, V247, P3973; Peltier JB, 2000, PLANT CELL, V12, P319, DOI 10.1105/tpc.12.3.319; Peltier JB, 2002, PLANT CELL, V14, P211, DOI 10.1105/tpc.010304; Peterson JH, 2003, J BIOL CHEM, V278, P46155, DOI 10.1074/jbc.M309082200; POWERS EL, 1995, J BACTERIOL, V177, P1906, DOI 10.1128/jb.177.7.1906-1907.1995; Randall LL, 2002, CELL MOL LIFE SCI, V59, P1617, DOI 10.1007/PL00012488; Rosen R, 2002, MASS SPECTROM REV, V21, P244, DOI 10.1002/mas.10031; Ruiz N, 2005, CELL, V121, P307, DOI 10.1016/j.cell.2005.02.014; SCHAGGER H, 1988, ANAL BIOCHEM, V173, P201, DOI 10.1016/0003-2697(88)90179-0; Schierle CF, 2003, J BACTERIOL, V185, P5706, DOI 10.1128/JB.185.19.5706-5713.2003; Seol JH, 1997, EUR J BIOCHEM, V247, P1143, DOI 10.1111/j.1432-1033.1997.01143.x; Seong IS, 2000, FEBS LETT, V477, P224, DOI 10.1016/S0014-5793(00)01808-1; Shimizu H, 1997, MOL MICROBIOL, V26, P1013, DOI 10.1046/j.1365-2958.1997.6392003.x; Sijbrandi R, 2003, J BIOL CHEM, V278, P4654, DOI 10.1074/jbc.M211630200; Smith VF, 1997, PROTEIN SCI, V6, P1746, DOI 10.1002/pro.5560060815; Tomoyasu T, 2001, MOL MICROBIOL, V40, P397, DOI 10.1046/j.1365-2958.2001.02383.x; Traxler B, 1996, J BIOL CHEM, V271, P12394, DOI 10.1074/jbc.271.21.12394; Ullers RS, 2004, P NATL ACAD SCI USA, V101, P7583, DOI 10.1073/pnas.0402398101; van den Berg B, 2004, NATURE, V427, P36, DOI 10.1038/nature02218; VanBogelen RA, 1999, METH MOL B, V112, P21; Vorderwulbecke S, 2004, FEBS LETT, V559, P181, DOI 10.1016/S0014-5793(04)00052-3; Weibezahn J, 2004, CELL, V119, P653, DOI 10.1016/j.cell.2004.11.027; WICKNER W, 1991, ANNU REV BIOCHEM, V60, P101, DOI 10.1146/annurev.bi.60.070191.000533; WILD J, 1993, J BACTERIOL, V175, P3992, DOI 10.1128/JB.175.13.3992-3997.1993; Wu T, 2005, CELL, V121, P235, DOI 10.1016/j.cell.2005.02.015; Xu ZH, 2000, NAT STRUCT BIOL, V7, P1172, DOI 10.1038/82040; Zhang WZ, 2000, ANAL CHEM, V72, P2482, DOI 10.1021/ac991363o	55	65	71	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 14	2006	281	15					10024	10034		10.1074/jbc.M509929200	http://dx.doi.org/10.1074/jbc.M509929200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	029WE	16352602	hybrid			2022-12-25	WOS:000236594300026
J	Ahsan, MK; Masutani, H; Yamaguchi, Y; Kim, YC; Nosaka, K; Matsuoka, M; Nishinaka, Y; Maeda, M; Yodoi, J				Ahsan, MK; Masutani, H; Yamaguchi, Y; Kim, YC; Nosaka, K; Matsuoka, M; Nishinaka, Y; Maeda, M; Yodoi, J			Loss of interleukin-2-dependency in HTLV-I-infected T cells on gene silencing of thioredoxin-binding protein-2	ONCOGENE			English	Article						HTLV-I; ATL; TBP-2/ VDUP1; DNA-methylation; histone deacetylation; interleukin-2	UP-REGULATED PROTEIN-1; VIRUS TYPE-I; LEUKEMIA; CANCER; GROWTH; LINES; D-3; IDENTIFICATION; TRANSFORMATION; METHYLATION	The transition from interleukin-2 (IL-2)-dependent to IL-2-independent growth is considered one of the key steps in the transformation of human T-cell leukemia virus type-I (HTLV-I)-infected T cells. The expression of thioredoxin-binding protein-2 (TBP-2) is lost during the transition of HTLV-I-infected T-cell lines. Here, we analysed the mechanism of loss of TBP-2 expression and the role of TBP-2 in IL-2-dependent growth in the in vitro model to investigate multistep transformation of HTLV-I. CpGs in the TBP-2 gene are methylated in IL-2-independent but not in IL-2-dependent cells. Sequential treatment with 5-aza-2'-deoxycytidine and a histone deacetylase inhibitor augmented histone acetylation and TBP-2 expression, suggesting that loss of TBP-2 expression is due to DNA methylation and histone deacetylation. In IL-2-dependent cells, a basal level of TBP-2 expression was maintained by IL-2 associated with cellular growth, whereas TBP-2 expression was upregulated on deprivation of IL-2 associated with growth suppression. Overexpression of TBP-2 in IL-2-independent cells suppressed the growth and partially restored responsiveness to IL-2. Knockdown of TBP-2 caused the IL-2-dependent cells to show partial growth without IL- 2. These results suggested that epigenetic silencing of the TBP-2 gene results in a loss of responsiveness to IL- 2, contributing to uncontrolled IL- 2- independent growth in HTLV-I-infected T-cell lines.	Kyoto Univ, Inst Virus Res, Dept Biol Responses, Sakyo Ku, Kyoto 6068507, Japan; Kyoto Univ, Inst Virus Res, Res Ctr Acquired Immunofef Syndrome, Sakyo Ku, Kyoto, Japan	Kyoto University; Kyoto University	Masutani, H (corresponding author), Kyoto Univ, Inst Virus Res, Dept Biol Responses, Sakyo Ku, 53 Shogoin, Kyoto 6068507, Japan.	hmasutan@virus.kyoto-u.ac.jp	Masutani, Hiroshi/B-5114-2014	Masutani, Hiroshi/0000-0001-7633-2827; Matsuoka, Masao/0000-0002-0473-754X				Butler LM, 2002, P NATL ACAD SCI USA, V99, P11700, DOI 10.1073/pnas.182372299; Cameron EE, 1999, NAT GENET, V21, P103, DOI 10.1038/5047; CHEN KS, 1994, BBA-GENE STRUCT EXPR, V1219, P26, DOI 10.1016/0167-4781(94)90242-9; Coombes MM, 2003, ONCOGENE, V22, P8902, DOI 10.1038/sj.onc.1207050; GARDINERGARDEN M, 1987, J MOL BIOL, V196, P261, DOI 10.1016/0022-2836(87)90689-9; Goldberg SF, 2003, CANCER RES, V63, P432; Han SH, 2003, ONCOGENE, V22, P4035, DOI 10.1038/sj.onc.1206610; HOLMGREN A, 1985, ANNU REV BIOCHEM, V54, P237, DOI 10.1146/annurev.bi.54.070185.001321; Jeang KT, 2004, J BIOL CHEM, V279, P31991, DOI 10.1074/jbc.R400009200; Maeda M, 1992, Hum Cell, V5, P70; MAEDA M, 1985, J EXP MED, V162, P2169, DOI 10.1084/jem.162.6.2169; MAKINO S, 1992, IMMUNOLOGY, V76, P578; Masutani H, 2002, METHOD ENZYMOL, V347, P279; Matsuoka M, 2003, ONCOGENE, V22, P5131, DOI 10.1038/sj.onc.1206551; MIGONE TS, 1995, SCIENCE, V269, P79, DOI 10.1126/science.7604283; MORGAN DA, 1976, SCIENCE, V193, P1007, DOI 10.1126/science.181845; Nishinaka Y, 2004, J BIOL CHEM, V279, P37559, DOI 10.1074/jbc.M405473200; Nishinaka Y, 2004, CANCER RES, V64, P1287, DOI 10.1158/0008-5472.CAN-03-0908; Nishiyama A, 1999, J BIOL CHEM, V274, P21645, DOI 10.1074/jbc.274.31.21645; Nosaka K, 2000, CANCER RES, V60, P1043; OKAMOTO T, 1989, JPN J CANCER RES, V80, P191; Satoh A, 2003, CANCER RES, V63, P8606; Spencer VA, 2003, METHODS, V31, P67, DOI 10.1016/S1046-2023(03)00089-6; TAGAYA Y, 1989, EMBO J, V13, P2244; UCHIYAMA T, 1977, BLOOD, V50, P481, DOI 10.1182/blood.V50.3.481.481; Ushijima T, 2005, CANCER SCI, V96, P206, DOI 10.1111/j.1349-7006.2005.00035.x; Yasunaga J, 2004, CANCER RES, V64, P6002, DOI 10.1158/0008-5472.CAN-04-1422; YODOI J, 1974, NEW ENGL J MED, V290, P572; YOSHIDA M, 1982, P NATL ACAD SCI-BIOL, V79, P2031, DOI 10.1073/pnas.79.6.2031	29	51	53	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR	2006	25	15					2181	2191		10.1038/sj.onc.1209256	http://dx.doi.org/10.1038/sj.onc.1209256			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	029RD	16314839				2022-12-25	WOS:000236581200005
J	Abdi, KM; Mohler, PJ; Davis, JQ; Bennett, V				Abdi, KM; Mohler, PJ; Davis, JQ; Bennett, V			Isoform specificity of ankyrin-B - A site in the divergent C-terminal domain is required for intramolecular association	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INOSITOL 1,4,5-TRISPHOSPHATE; NEONATAL CARDIOMYOCYTES; CARDIAC-ARRHYTHMIA; REGULATORY DOMAIN; MEMBRANE SKELETON; CRYSTAL-STRUCTURE; BINDING; PROTEINS; SPECTRIN; LOCALIZATION	Ankyrins contain significant amino acid identity and are co-expressed in many cell types yet maintain unique functions in vivo. Recent studies have identified the highly divergent C-terminal domain in ankyrin-B as the key domain for driving ankyrin-B-specific functions in cardiomyocytes. Here we identify an intramolecular interaction between the C-terminal domain and the membrane-binding domain of ankyrin- B using pure proteins in solution and the yeast two-hybrid assay. Through extensive deletion and alanine-scanning mutagenesis we have mapped key residues for interaction in both domains. Amino acids (EED1599)-E-1597 located in the ankyrin- B C-terminal domain and amino acids Arg(37)/Arg(40) located in ANK repeat 1 are necessary for inter-domain interactions in yeast two-hybrid assays. Furthermore, conversion of amino acids EED1597 to AAA(1597) leads to a loss of function in the localization of inositol 1,4,5-trisphosphate receptors in ankyrin- B mutant cardiomyocytes. Physical properties of the ankyrin- B C-terminal domain determined by circular dichroism spectroscopy and hydrodynamic parameters reveal it is unstructured and highly extended in solution. Similar structural studies performed on full-length 220-kDa ankyrin- B harboring alanine substitutions, (1597)AAA(1599), reveal a more extended conformation compared with wild-type ankyrin- B. Taken together these results suggest a model of an extended and unstructured C-terminal domain folding back to bind and potentially regulate the membrane-binding domain of ankyrin- B.	Duke Univ, Med Ctr, Dept Cell Biol, Durham, NC 27710 USA; Duke Univ, Med Ctr, Dept Biochem, Durham, NC 27710 USA; Duke Univ, Med Ctr, Dept Neurosci, Durham, NC 27710 USA; Duke Univ, Howard Hughes Med Inst, Durham, NC 27710 USA; Vanderbilt Univ, Med Ctr, Dept Pathol, Nashville, TN 37232 USA	Duke University; Duke University; Duke University; Duke University; Howard Hughes Medical Institute; Vanderbilt University	Bennett, V (corresponding author), Duke Univ, Med Ctr, Dept Cell Biol, 355 CARL Bldg, Durham, NC 27710 USA.	v.bennett@cellbio.duke.edu						Bennett V, 2001, PHYSIOL REV, V81, P1353, DOI 10.1152/physrev.2001.81.3.1353; CHAN W, 1993, J CELL BIOL, V123, P1463, DOI 10.1083/jcb.123.6.1463; Chang SH, 2003, J BIOL CHEM, V278, P6879, DOI 10.1074/jbc.M211137200; DAVIS J, 1983, J BIOL CHEM, V258, P7757; DAVIS LH, 1992, J BIOL CHEM, V267, P18966; Eber S, 2004, SEMIN HEMATOL, V41, P118, DOI 10.1053/j.seminhematol.2004.01.002; Garver TD, 1997, J CELL BIOL, V137, P703, DOI 10.1083/jcb.137.3.703; HALL TG, 1987, J BIOL CHEM, V262, P10537; Jenkins SM, 2001, J CELL BIOL, V155, P739, DOI 10.1083/jcb.200109026; Kontrogianni-Konstantopoulos A, 2003, MOL BIOL CELL, V14, P1138, DOI 10.1091/mbc.E02-07-0411; MARTIN RG, 1961, J BIOL CHEM, V236, P1372; Michaely P, 2002, EMBO J, V21, P6387, DOI 10.1093/emboj/cdf651; Mohler PJ, 2004, P NATL ACAD SCI USA, V101, P17533, DOI 10.1073/pnas.0403711101; Mohler PJ, 2004, P NATL ACAD SCI USA, V101, P9137, DOI 10.1073/pnas.0402546101; Mohler PJ, 2004, J BIOL CHEM, V279, P25798, DOI 10.1074/jbc.M401296200; Mohler PJ, 2004, J BIOL CHEM, V279, P12980, DOI 10.1074/jbc.M313979200; Mohler PJ, 2003, NATURE, V421, P634, DOI 10.1038/nature01335; Mohler PJ, 2002, J BIOL CHEM, V277, P10599, DOI 10.1074/jbc.M110958200; Pearson MA, 2000, CELL, V101, P259, DOI 10.1016/S0092-8674(00)80836-3; PETERS LL, 1995, J CELL BIOL, V130, P313, DOI 10.1083/jcb.130.2.313; Tompa P, 2002, TRENDS BIOCHEM SCI, V27, P527, DOI 10.1016/S0968-0004(02)02169-2; Tuvia S, 1999, J CELL BIOL, V147, P995, DOI 10.1083/jcb.147.5.995; Xiao T, 1999, CELL, V99, P545, DOI 10.1016/S0092-8674(00)81542-1; Zhang X, 1998, J BIOL CHEM, V273, P30785, DOI 10.1074/jbc.273.46.30785	24	49	50	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 3	2006	281	9					5741	5749		10.1074/jbc.M506697200	http://dx.doi.org/10.1074/jbc.M506697200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	015RQ	16368689	hybrid			2022-12-25	WOS:000235568900052
J	Schonichen, A; Alexander, M; Gasteier, JE; Cuesta, FE; Fackler, OT; Geyer, M				Schonichen, A; Alexander, M; Gasteier, JE; Cuesta, FE; Fackler, OT; Geyer, M			Biochemical characterization of the diaphanous autoregulatory interaction in the formin homology protein FHOD1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SERUM RESPONSE FACTOR; SRC TYROSINE KINASE; ACTIN NUCLEATION; FH2 DOMAIN; CYTOSKELETAL CONTROL; STRUCTURAL BASIS; BINDING PROTEIN; RHO-GTPASE; F-ACTIN; MDIA1	Diaphanous related formins ( DRFs) are cytoskeleton remodeling proteins that mediate specific upstream GTPase signals to regulate cellular processes such as cytokinesis, cell polarity, and organelle motility. Previous work on the Rho-interacting DRF mDia has established that the biological activity of DRFs is regulated by an autoinhibitory interaction of a C-terminal diaphanous autoregulatory domain ( DAD) with the DRFN terminus. This autoinhibition is released upon competitive binding of an activated GTPase to the N terminus of the DRF. Analyzing autoregulation of the Rac1-interacting DRF FHOD1, we utilized in vitro binding studies to identify a 60-amino acid DAD at the protein C terminus that recognizes an N-terminal formin homology ( FH) 3 domain. Importantly, the FH3 domain of FHOD1 does not overlap with the proposed Rac1-binding domain. The FHOD1 DAD was found to contain one functional hydrophobic autoregulatory motif, while a previously uncharacterized basic cluster that is conserved in all DRF family DADs also contributed to the FH3-DAD interaction. Simultaneous mutation of both motifs efficiently released autoinhibition of FHOD1 in NIH3T3 cells resulting in the formation of actin stress fibers and increased serum response element transcription. A second putative hydrophobic autoregulatory motif N-terminal of the DAD belongs to a unique FHOD subdomain of yet undefined function. NMR structural analysis and size exclusion chromatography experiments revealed that the FHOD1 DAD is intrinsically unstructured with a tendency for a helical conformation in the hydrophobic autoregulation motif. Together, these data suggest that in FHOD1, DAD acts as signal sequence for binding to the well folded and monomeric FH3 domain and imply an activation mechanism that differs from competitive binding of Rac1 and DAD to one interaction site.	Max Planck Inst Mol Physiol, Phys Biochem Abt, D-44227 Dortmund, Germany; Univ Heidelberg, Dept Virol, D-69120 Heidelberg, Germany	Max Planck Society; Ruprecht Karls University Heidelberg	Geyer, M (corresponding author), Max Planck Inst Mol Physiol, Phys Biochem Abt, Otto Hahn Str 11, D-44227 Dortmund, Germany.	matthias.geyer@mpi-dortmund.mpg.de		Fackler, Oliver Till/0000-0003-2982-4209; Geyer, Matthias/0000-0002-7718-5002				Alberts AS, 2001, J BIOL CHEM, V276, P2824, DOI 10.1074/jbc.M006205200; Copeland JW, 2004, J BIOL CHEM, V279, P50250, DOI 10.1074/jbc.M404429200; Copeland JW, 2002, MOL BIOL CELL, V13, P4088, DOI 10.1091/mbc.02-06-0092; Evangelista M, 1997, SCIENCE, V276, P118, DOI 10.1126/science.276.5309.118; Gasman S, 2003, NAT CELL BIOL, V5, P195, DOI 10.1038/ncb935; Gasteier JE, 2005, EXP CELL RES, V306, P192, DOI 10.1016/j.yexcr.2005.02.006; Gasteier JE, 2003, J BIOL CHEM, V278, P38902, DOI 10.1074/jbc.M306229200; Geyer M, 1999, J MOL BIOL, V289, P123, DOI 10.1006/jmbi.1999.2740; Habas R, 2001, CELL, V107, P843, DOI 10.1016/S0092-8674(01)00614-6; Higashida C, 2004, SCIENCE, V303, P2007, DOI 10.1126/science.1093923; Higgs HN, 2005, MOL BIOL CELL, V16, P1, DOI 10.1091/mbc.E04-07-0565; Huber AH, 2001, CELL, V105, P391, DOI 10.1016/S0092-8674(01)00330-0; Kanaya H, 2005, GENES CELLS, V10, P665, DOI 10.1111/j.1365-2443.2005.00867.x; Kohno H, 1996, EMBO J, V15, P6060, DOI 10.1002/j.1460-2075.1996.tb00994.x; Koka S, 2003, J CELL SCI, V116, P1745, DOI 10.1242/jcs.00386; Li F, 2005, J BIOL CHEM, V280, P6986, DOI 10.1074/jbc.M411605200; Li F, 2003, CURR BIOL, V13, P1335, DOI 10.1016/S0960-9822(03)00540-2; Madrid R, 2005, FEBS LETT, V579, P441, DOI 10.1016/j.febslet.2004.12.009; Miralles F, 2003, CELL, V113, P329, DOI 10.1016/S0092-8674(03)00278-2; Moseley JB, 2004, MOL BIOL CELL, V15, P896, DOI 10.1091/mbc.E03-08-0621; NEIDIG KP, 1995, J BIOMOL NMR, V6, P255, DOI 10.1007/BF00197807; Otomo T, 2005, NATURE, V433, P488, DOI 10.1038/nature03251; Otomo T, 2005, MOL CELL, V18, P273, DOI 10.1016/j.molcel.2005.04.002; Petersen J, 1998, J CELL BIOL, V141, P1217, DOI 10.1083/jcb.141.5.1217; Posern G, 2002, MOL BIOL CELL, V13, P4167, DOI 10.1091/mbc.02-05-0068; Pring M, 2003, BIOCHEMISTRY-US, V42, P486, DOI 10.1021/bi026520j; Pruyne D, 2002, SCIENCE, V297, P612, DOI 10.1126/science.1072309; Romero S, 2004, CELL, V119, P419, DOI 10.1016/j.cell.2004.09.039; Rose R, 2005, NATURE, V435, P513, DOI 10.1038/nature03604; Sagot I, 2002, NAT CELL BIOL, V4, P626, DOI 10.1038/ncb834; Schulte A, 2005, J BIOL CHEM, V280, P24968, DOI 10.1074/jbc.M501431200; Shimada A, 2004, MOL CELL, V13, P511, DOI 10.1016/S1097-2765(04)00059-0; Sotiropoulos A, 1999, CELL, V98, P159, DOI 10.1016/S0092-8674(00)81011-9; Takeya R, 2003, J CELL SCI, V116, P4567, DOI 10.1242/jcs.00769; Tanaka K, 2000, BIOCHEM BIOPH RES CO, V267, P479, DOI 10.1006/bbrc.1999.1707; Tominaga T, 2000, MOL CELL, V5, P13, DOI 10.1016/S1097-2765(00)80399-8; Wallar BJ, 2003, TRENDS CELL BIOL, V13, P435, DOI 10.1016/S0962-8924(03)00153-3; Watanabe N, 2004, EXP CELL RES, V301, P16, DOI 10.1016/j.yexcr.2004.08.020; Watanabe N, 1999, NAT CELL BIOL, V1, P136, DOI 10.1038/11056; Westendorf JJ, 1999, GENE, V232, P173, DOI 10.1016/S0378-1119(99)00127-4; Westendorf JJ, 2001, J BIOL CHEM, V276, P46453, DOI 10.1074/jbc.M105162200; Xu YW, 2004, CELL, V116, P711, DOI 10.1016/S0092-8674(04)00210-7; Zigmond SH, 2004, CURR OPIN CELL BIOL, V16, P99, DOI 10.1016/j.ceb.2003.10.019	43	38	40	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 24	2006	281	8					5084	5093		10.1074/jbc.M509226200	http://dx.doi.org/10.1074/jbc.M509226200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	013RF	16361249	hybrid			2022-12-25	WOS:000235426200063
J	Takahashi, E; Wraight, CA				Takahashi, E; Wraight, CA			Small weak acids reactivate proton transfer in reaction centers from Rhodobacter sphaeroides mutated at Asp(L210) and Asp(M17)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BACTERIAL REACTION CENTERS; PHOTOSYNTHETIC REACTION CENTERS; ACCEPTOR QUINONE COMPLEX; SITE-DIRECTED MUTANTS; 2 IONIZABLE RESIDUES; INDUCED H+ BINDING; ELECTRON-TRANSFER; SECONDARY QUINONE; MEMBRANE-PROTEINS; TRANSFER PATHWAYS	In reaction centers of Rhodobacter sphaeroides, site-directed mutagenesis has implicated several acidic residues in the delivery of protons to the secondary quinone (Q(B)) during reduction to quinol. In a double mutant (Asp(L210) -> Asn + Asp(M17) -> Asn) that is severely impaired in proton transfer capability over a wide pH range, proton transfer was "rescued" by added weak acids. For low pK(a) acids the total concentration of salt required near neutral pH was high. The ionic strength effect of added salts stimulated the rate of proton-coupled electron transfer at pH < 7, but decreased it at pH > 7.5, indicating an effective isoelectric point between these limits. In this region, a substantial rate enhancement by weak acids was clearly evident. A Bronsted plot of activity versus pK(a) of the rescuing acids was linear, with a slope of -1, and extrapolated to a diffusion-limited rate at pK(a)(app) approximate to 1. However, the maximum rate at saturating concentrations of acid did not correlate with pKa, indicating that the acid and anion species compete for binding, both with weak affinity. This model predicts that pK(a)(app) corresponds to a true pK(a) = 4-5, similar to that for a carboxylic acid or Q(B)(-), itself. Only rather small, neutral acids were active, indicating a need to access a small internal volume, suggested to be a proton channel to theQB domain. However, the on-rates were near the diffusion limit. The implications for intraprotein proton transfer pathway design are discussed.	Univ Illinois, Ctr Biophys & Computat Biol, Urbana, IL 61801 USA; Univ Illinois, Dept Biochem, Urbana, IL 61801 USA	University of Illinois System; University of Illinois Urbana-Champaign; University of Illinois System; University of Illinois Urbana-Champaign	Wraight, CA (corresponding author), Univ Illinois, Ctr Biophys & Computat Biol, MC-147,607 S Mathews Ave, Urbana, IL 61801 USA.	cwraight@uiuc.edu						Abresch EC, 1998, PHOTOSYNTH RES, V55, P119, DOI 10.1023/A:1006047519260; Adelroth P, 2000, P NATL ACAD SCI USA, V97, P13086, DOI 10.1073/pnas.230439597; Adelroth P, 2001, BIOCHEMISTRY-US, V40, P14538, DOI 10.1021/bi011585s; Alexov E, 2000, BIOCHEMISTRY-US, V39, P5940, DOI 10.1021/bi9929498; Alexov EG, 1999, BIOCHEMISTRY-US, V38, P8253, DOI 10.1021/bi982700a; Axelrod HL, 2000, P NATL ACAD SCI USA, V97, P1542, DOI 10.1073/pnas.97.4.1542; BEROZA P, 1995, BIOPHYS J, V68, P2233, DOI 10.1016/S0006-3495(95)80406-6; BUDIL DE, 1987, ANNU REV PHYS CHEM, V38, P561, DOI 10.1146/annurev.pc.38.100187.003021; Chelikani P, 2003, J BIOL CHEM, V278, P31290, DOI 10.1074/jbc.M304076200; Cherepanov DA, 2000, BBA-BIOENERGETICS, V1459, P10, DOI 10.1016/S0005-2728(00)00110-9; CROFTS AR, 1983, BIOCHIM BIOPHYS ACTA, V726, P149, DOI 10.1016/0304-4173(83)90004-6; Deisenhofer J., 1993, PHOTOSYNTHETIC REACT, VII, P49; FEHER G, 1989, NATURE, V339, P111, DOI 10.1038/339111a0; Gerencser L, 2001, BIOCHEMISTRY-US, V40, P1850, DOI 10.1021/bi0021636; Graige MS, 1999, BIOCHEMISTRY-US, V38, P11465, DOI 10.1021/bi990708u; Graige MS, 1996, J AM CHEM SOC, V118, P9005, DOI 10.1021/ja960056m; Graige MS, 1998, P NATL ACAD SCI USA, V95, P11679, DOI 10.1073/pnas.95.20.11679; HANSON DK, 1993, P NATL ACAD SCI USA, V90, P8929, DOI 10.1073/pnas.90.19.8929; Jenkins HDB, 1999, INORG CHEM, V38, P3609, DOI 10.1021/ic9812961; KEMPSTER CJ, 1972, ACTA CRYSTALLOGR B, V28, P3674, DOI 10.1107/S056774087200857X; KRISHTALIK LI, 1995, FEBS LETT, V369, P140, DOI 10.1016/0014-5793(95)00756-Y; Lancaster CRD, 1995, PHOTOSYNTHESIS: FROM LIGHT TO BIOSPHERE, VOL I, P903; LEE JK, 1989, J BACTERIOL, V171, P3391, DOI 10.1128/jb.171.6.3391-3405.1989; Li JL, 1998, BIOCHEMISTRY-US, V37, P2818, DOI 10.1021/bi971699x; Maniatis T., 1982, MOL CLONING LAB MANU; MAROTI P, 1994, P NATL ACAD SCI USA, V91, P5617, DOI 10.1073/pnas.91.12.5617; MAROTI P, 1995, NAT STRUCT BIOL, V2, P1057, DOI 10.1038/nsb1295-1057; MAROTI P, 1988, BIOCHIM BIOPHYS ACTA, V934, P329, DOI 10.1016/0005-2728(88)90092-8; Maroti P, 1997, BIOPHYS J, V73, P367, DOI 10.1016/S0006-3495(97)78077-9; MAROTI P, 1988, BIOCHIM BIOPHYS ACTA, V934, P314, DOI 10.1016/0005-2728(88)90091-6; MCPHERSON PH, 1988, BIOCHIM BIOPHYS ACTA, V934, P348, DOI 10.1016/0005-2728(88)90093-X; Miksovska J, 1997, BIOCHEMISTRY-US, V36, P12216, DOI 10.1021/bi970442w; MITCHELL P, 1979, SCIENCE, V206, P1148, DOI 10.1126/science.388618; Moser CC, 2003, ADV PROTEIN CHEM, V63, P71; NAIR HK, 1994, BIOCHEMISTRY-US, V33, P8566, DOI 10.1021/bi00194a023; Nicholls P, 2001, ADV INORG CHEM, V51, P51; Okamura MY, 2000, BBA-BIOENERGETICS, V1458, P148, DOI 10.1016/S0005-2728(00)00065-7; Paddock M, 2004, BIOPHYS J, V86, p11A; PADDOCK ML, 1995, BIOCHEMISTRY-US, V34, P15742, DOI 10.1021/bi00048a019; Paddock ML, 2003, FEBS LETT, V555, P45, DOI 10.1016/S0014-5793(03)01149-9; Paddock ML, 2003, BIOCHEMISTRY-US, V42, P9626, DOI 10.1021/bi0346648; Paddock ML, 1998, PHOTOSYNTH RES, V55, P281, DOI 10.1023/A:1005953615604; Paddock ML, 1999, P NATL ACAD SCI USA, V96, P6183, DOI 10.1073/pnas.96.11.6183; PADDOCK ML, 1990, P NATL ACAD SCI USA, V87, P6803, DOI 10.1073/pnas.87.17.6803; Paddock ML, 2000, P NATL ACAD SCI USA, V97, P1548, DOI 10.1073/pnas.97.4.1548; Paddock ML, 2002, BIOCHEMISTRY-US, V41, P14716, DOI 10.1021/bi020419x; PADDOCK ML, 1989, P NATL ACAD SCI USA, V86, P6602, DOI 10.1073/pnas.86.17.6602; Paddock ML, 2001, BIOCHEMISTRY-US, V40, P6893, DOI 10.1021/bi010280a; PRINCE RC, 1974, BIOCH BIOPHYS ACTA, V347; RADIC Z, 1992, BIOCHEMISTRY-US, V31, P9760, DOI 10.1021/bi00155a032; RONGEY SH, 1993, P NATL ACAD SCI USA, V90, P1325, DOI 10.1073/pnas.90.4.1325; SEBBAN P, 1995, BIOCHEMISTRY-US, V34, P8390, DOI 10.1021/bi00026a021; Shinkarev VP, 1993, PHOTOSYNTHETIC REACT, V1, P193; SISTROM WR, 1962, J GEN MICROBIOL, V28, P607, DOI 10.1099/00221287-28-4-607; TAKAHASHI E, 1990, BIOCHIM BIOPHYS ACTA, V1020, P107, DOI 10.1016/0005-2728(90)90100-I; TAKAHASHI E, 1992, BIOCHEMISTRY-US, V31, P855, DOI 10.1021/bi00118a031; TAKAHASHI E, 1991, FEBS LETT, V283, P140, DOI 10.1016/0014-5793(91)80572-K; Takahashi E., 1990, CURRENT RES PHOTOSYN, V1, P169; TAKAHASHI E, 1992, ELECT PROTON TRANSFE, V78, P219; Utschig LM, 1998, BIOCHEMISTRY-US, V37, P8278, DOI 10.1021/bi980395n; Utschig LM, 2000, BIOCHEMISTRY-US, V39, P2961, DOI 10.1021/bi991800t; VONHEIJNE G, 1986, EMBO J, V5, P3021, DOI 10.1002/j.1460-2075.1986.tb04601.x; Woodbury NW, 1995, ANOXYGENIC PHOTOSYNT, P527, DOI [DOI 10.1007/0-306-47954-0_24, 10.1007/0-306-47954-0_24]; Wraight CA, 2004, FRONT BIOSCI-LANDMRK, V9, P309, DOI 10.2741/1236; WRAIGHT CA, 1982, FUNCTION QUINONES EN, P11; Zhou HX, 1996, J AM CHEM SOC, V118, P13069, DOI 10.1021/ja963134e; Zhu ZY, 2005, BIOCHEMISTRY-US, V44, P82, DOI 10.1021/bi048348k	67	24	25	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 17	2006	281	7					4413	4422		10.1074/jbc.M511359200	http://dx.doi.org/10.1074/jbc.M511359200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	011NN	16354664	hybrid			2022-12-25	WOS:000235275300077
J	Bylund, J; Burgess, LA; Cescutti, P; Ernst, RK; Speert, DP				Bylund, J; Burgess, LA; Cescutti, P; Ernst, RK; Speert, DP			Exopolysaccharides from Burkholderia cenocepacia inhibit neutrophil chemotaxis and scavenge reactive oxygen species	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MUCOID PSEUDOMONAS-AERUGINOSA; CHRONIC GRANULOMATOUS-DISEASE; CYSTIC-FIBROSIS; MOUSE MODEL; MICROBIAL PATHOGENESIS; RESPIRATORY BURST; CLINICAL ISOLATE; CEPACIA COMPLEX; LIPOPOLYSACCHARIDE; ALGINATE	Bacteria belonging to the Burkholderia cepacia complex are important opportunistic pathogens in compromised hosts, particularly patients with cystic fibrosis or chronic granulomatous disease. Isolates of B. cepacia complex may produce large amounts of exopolysaccharides (EPS) that endow the bacteria with a mucoid phenotype and appear to facilitate bacterial persistence during infection. We showed that EPS from a clinical B. cenocepacia isolate interfered with the function of human neutrophils in vitro; it inhibited chemotaxis and production of reactive oxygen species (ROS), both essential components of innate neutrophil-mediated host defenses. These inhibitory effects were not due to cytotoxicity or interference with intracellular calcium signaling. EPS also inhibited enzymatic generation of ROS in cell-free systems, indicating that it scavenges these bactericidal products. B. cenocepacia EPS is structurally distinct from Pseudomonas aeruginosa alginate, yet they share the capacity to scavenge ROS and inhibit chemotaxis. These properties could explain why the two bacterial species resist clearance from the infected cystic fibrosis lung.	Univ British Columbia, Dept Paediat, Child & Family Res Inst, Vancouver, BC V5Z 4H4, Canada; Univ Washington, Dept Med, Seattle, WA 98195 USA; Univ Trieste, Dept Biochem Biophys & Macromol Chem, I-34127 Trieste, Italy	Child & Family Research Institute; University of British Columbia; University of Washington; University of Washington Seattle; University of Trieste	Speert, DP (corresponding author), Univ British Columbia, Dept Paediat, Child & Family Res Inst, Rm 377,950 W 238th Ave, Vancouver, BC V5Z 4H4, Canada.	dspeert@cw.bc.ca		Ernst, Robert/0000-0001-5016-8694; Cescutti, Paola/0000-0003-3744-2198	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [U54AI057141] Funding Source: NIH RePORTER; NIAID NIH HHS [U54AI057141] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Aaron SD, 2000, AM J RESP CRIT CARE, V161, P1206, DOI 10.1164/ajrccm.161.4.9907147; BIGNOLD LP, 1991, INFECT IMMUN, V59, P4255, DOI 10.1128/IAI.59.11.4255-4258.1991; Borges F, 2002, CURR MED CHEM, V9, P195, DOI 10.2174/0929867023371229; Boucher JC, 1997, INFECT IMMUN, V65, P3838, DOI 10.1128/IAI.65.9.3838-3846.1997; BOYUM A, 1991, SCAND J IMMUNOL, V34, P697, DOI 10.1111/j.1365-3083.1991.tb01594.x; BURKHOLDER WH, 1950, PHYTOPATHOLOGY, V40, P115; Bylund J, 2002, INFECT IMMUN, V70, P2908, DOI 10.1128/IAI.70.6.2908-2914.2002; Bylund J, 2005, ADV EXP MED BIOL, V568, P67; Bylund J, 2005, J IMMUNOL, V174, P3562, DOI 10.4049/jimmunol.174.6.3562; Cerantola S, 1999, EUR J BIOCHEM, V260, P373, DOI 10.1046/j.1432-1327.1999.00171.x; Cerantola S, 1996, CARBOHYD RES, V285, P59, DOI 10.1016/0008-6215(96)00014-6; Cerantola S, 2000, FEMS MICROBIOL LETT, V185, P243, DOI 10.1016/S0378-1097(00)00099-9; Cescutti P, 2000, BIOCHEM BIOPH RES CO, V273, P1088, DOI 10.1006/bbrc.2000.3059; Clark RA, 1999, J INFECT DIS, V179, pS309, DOI 10.1086/513849; Conway BAD, 2004, J INFECT DIS, V190, P957, DOI 10.1086/423141; Cunha MV, 2004, J CLIN MICROBIOL, V42, P3052, DOI 10.1128/JCM.42.7.3052-3058.2004; Cunha MV, 2003, J CLIN MICROBIOL, V41, P4113, DOI 10.1128/JCM.41.9.4113-4120.2003; Dahlgren C, 1999, J IMMUNOL METHODS, V232, P3, DOI 10.1016/S0022-1759(99)00146-5; Eberl L, 2004, INT J MED MICROBIOL, V294, P123, DOI 10.1016/j.ijmm.2004.06.022; Fan J, 2003, NAT MED, V9, P315, DOI 10.1038/nm832; Govan JRW, 1996, MICROBIOL REV, V60, P539, DOI 10.1128/MMBR.60.3.539-574.1996; Gudmundsson GH, 1999, J IMMUNOL METHODS, V232, P45, DOI 10.1016/S0022-1759(99)00152-0; GUTHRIE LA, 1984, J EXP MED, V160, P1656, DOI 10.1084/jem.160.6.1656; HANCOCK REW, 1983, INFECT IMMUN, V42, P170, DOI 10.1128/IAI.42.1.170-177.1983; Hirschfeld M, 2000, J IMMUNOL, V165, P618, DOI 10.4049/jimmunol.165.2.618; Hoffmann N, 2005, INFECT IMMUN, V73, P2504, DOI 10.1128/IAI.73.4.2504-2514.2005; Hudson VM, 2001, FREE RADICAL BIO MED, V30, P1440, DOI 10.1016/S0891-5849(01)00530-5; Hughes JE, 1997, INFECT IMMUN, V65, P4281, DOI 10.1128/IAI.65.10.4281-4287.1997; ISLES A, 1984, J PEDIATR-US, V104, P206, DOI 10.1016/S0022-3476(84)80993-2; Karlsson A, 2002, ANTIOXID REDOX SIGN, V4, P49, DOI 10.1089/152308602753625852; KONIG B, 1992, INT ARCH ALLERGY IMM, V99, P98, DOI 10.1159/000236341; Krause KH, 2004, JPN J INFECT DIS, V57, pS28; Lagatolla C, 2002, FEMS MICROBIOL LETT, V209, P99, DOI 10.1111/j.1574-6968.2002.tb11116.x; LEARN DB, 1987, INFECT IMMUN, V55, P1813, DOI 10.1128/IAI.55.8.1813-1818.1987; LEW PD, 1990, AM REV RESPIR DIS, V141, pS127, DOI 10.1164/ajrccm/141.3_Pt_2.S127; Linker A, 2001, CARBOHYD RES, V335, P45, DOI 10.1016/S0008-6215(01)00205-1; LIPUMA JJ, 1990, LANCET, V336, P1094, DOI 10.1016/0140-6736(90)92571-X; MRSNY RJ, 1994, PULM PHARMACOL, V7, P357, DOI 10.1006/pulp.1994.1042; Pasquier C, 1997, FEMS MICROBIOL LETT, V147, P195, DOI 10.1016/S0378-1097(96)00523-X; PEDERSEN SS, 1990, INFECT IMMUN, V58, P3363, DOI 10.1128/IAI.58.10.3363-3368.1990; Richau JA, 2000, J CLIN MICROBIOL, V38, P1651, DOI 10.1128/JCM.38.4.1651-1655.2000; ROMMENS JM, 1989, SCIENCE, V245, P1059, DOI 10.1126/science.2772657; Roos D, 2003, MICROBES INFECT, V5, P1307, DOI 10.1016/j.micinf.2003.09.009; SHERBROCKCOX V, 1984, CARBOHYD RES, V135, P147, DOI 10.1016/0008-6215(84)85012-0; Shimomura H, 2003, INFECT IMMUN, V71, P5225, DOI 10.1128/IAI.71.9.5225-5230.2003; SIMPSON JA, 1989, FREE RADICAL BIO MED, V6, P347, DOI 10.1016/0891-5849(89)90078-6; Sist P, 2003, CARBOHYD RES, V338, P1861, DOI 10.1016/S0008-6215(03)00306-9; Speert David Paul, 2002, Paediatr Respir Rev, V3, P230, DOI 10.1016/S1526-0542(02)00185-9; SPEERT DP, 1994, J INFECT DIS, V170, P1524, DOI 10.1093/infdis/170.6.1524; STOKES DC, 1989, J INFECT DIS, V160, P52, DOI 10.1093/infdis/160.1.52; Yu H, 1998, INFECT IMMUN, V66, P280, DOI 10.1128/IAI.66.1.280-288.1998	51	106	107	1	11	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 3	2006	281	5					2526	2532		10.1074/jbc.M510692200	http://dx.doi.org/10.1074/jbc.M510692200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	006XT	16316987	hybrid			2022-12-25	WOS:000234931800015
J	D'Souza, I; Schellenberg, GD				D'Souza, I; Schellenberg, GD			Arginine/serine-rich protein interaction domain-dependent modulation of a tau Exon 10 splicing enhancer - Altered interactions and mechanisms for functionally antagonistic FTDP-17 mutations Delta 280K and N279K	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FRONTOTEMPORAL DEMENTIA; GENE-MUTATIONS; FACTOR U2AF(35); TRA2 PROTEINS; A/B PROTEINS; SR PROTEINS; HNRNP A1; RNA; EXPRESSION; SEQUENCE	Tau exon 10 splicing is altered by autosomal dominant mutations that cause frontotemporal dementia with parkinsonism chromosome 17-type and by unknown mechanisms in other related neurodegenerative disorders. Identifying cis- and trans-regulators of tau exon 10 splicing is therefore crucial for understanding disease mechanisms. We previously identified several splicing enhancers and silencers within exon 10 and intron 10. Here, we show that splicing factors SF2/ASF, Tra2 beta, and a 50-kDa nuclear protein bind in vitro to the polypurine enhancer at the 5' end of exon 10. Disease splicing mutations N279K and Delta 280K disrupt the enhancer and alter associations with these factors. N279K targets robustly bind Tra2 beta compared with the normal enhancer, which may explain why N279K enhances exon 10 splicing in vivo. In contrast, factor associations with Delta 280K targets are nearly undetectable, explaining why Delta 280K almost abolishes exon 10 splicing in vivo. Small interfering RNA-mediated suppression of endogenous SF2/ASF and Tra2 beta significantly reduces exon 10 splicing. Exogenous SF2/ASF dramatically enhances normal exon 10 splicing and efficiently rescues the Delta 280K splicing defect. Domain deletion analyses show that the C-terminal RS domains of SF2/ASF and Tra2 beta are required for normal exon 10 splicing in vivo. In contrast to Tra2 beta, the SF2/ASF RS domain remains essential in the presence of a strengthened enhancer or when either weak splice site is strengthened. The data suggest that SF2/ASF has both essential and regulatory roles, whereas Tra2 beta has a supporting role in exon 10 splicing.	GRECC, VAPSHCS, Seattle Div, Seattle, WA 98108 USA; Univ Washington, Dept Pharmacol, Seattle, WA 98195 USA; Univ Washington, Dept Neurol, Seattle, WA 98195 USA; Univ Washington, Dept Med, Div Gerontol & Geriatr Med, Seattle, WA 98195 USA	Geriatric Research Education & Clinical Center; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle	D'Souza, I (corresponding author), GRECC, VAPSHCS, Seattle Div, 182B,1660 S Columbian Way, Seattle, WA 98108 USA.	iands@u.washington.edu			NATIONAL INSTITUTE ON AGING [R01AG011762] Funding Source: NIH RePORTER; NIA NIH HHS [R01 AG11762] Funding Source: Medline	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		AMREIN H, 1994, CELL, V76, P735, DOI 10.1016/0092-8674(94)90512-6; ANDREADIS A, 1992, BIOCHEMISTRY-US, V31, P10626, DOI 10.1021/bi00158a027; BERGET SM, 1995, J BIOL CHEM, V270, P2411, DOI 10.1074/jbc.270.6.2411; Blencowe BJ, 2000, TRENDS BIOCHEM SCI, V25, P106, DOI 10.1016/S0968-0004(00)01549-8; Cao WH, 1997, RNA, V3, P1456; Caputi M, 1999, EMBO J, V18, P4060, DOI 10.1093/emboj/18.14.4060; Cartegni L, 2003, NUCLEIC ACIDS RES, V31, P3568, DOI 10.1093/nar/gkg616; Chew SL, 1999, P NATL ACAD SCI USA, V96, P10655, DOI 10.1073/pnas.96.19.10655; D'Souza I, 2000, J BIOL CHEM, V275, P17700, DOI 10.1074/jbc.M909470199; D'Souza I, 2005, BBA-MOL BASIS DIS, V1739, P104, DOI 10.1016/j.bbadis.2004.08.009; D'Souza I, 2002, J BIOL CHEM, V277, P26587, DOI 10.1074/jbc.M203794200; D'Souza I, 1999, P NATL ACAD SCI USA, V96, P5598, DOI 10.1073/pnas.96.10.5598; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; Dorsett Y, 2004, NAT REV DRUG DISCOV, V3, P318, DOI 10.1038/nrd1345; Ebneth A, 1998, J CELL BIOL, V143, P777, DOI 10.1083/jcb.143.3.777; Eperon IC, 2000, MOL CELL BIOL, V20, P8303, DOI 10.1128/MCB.20.22.8303-8318.2000; Foster NL, 1997, ANN NEUROL, V41, P706, DOI 10.1002/ana.410410606; GOEDERT M, 1989, EMBO J, V8, P393, DOI 10.1002/j.1460-2075.1989.tb03390.x; GOEDERT M, 1988, P NATL ACAD SCI USA, V85, P4051, DOI 10.1073/pnas.85.11.4051; Graveley BR, 1998, EMBO J, V17, P6747, DOI 10.1093/emboj/17.22.6747; Graveley BR, 2000, RNA, V6, P1197, DOI 10.1017/S1355838200000960; Grover A, 1999, J BIOL CHEM, V274, P15134, DOI 10.1074/jbc.274.21.15134; Grover A, 2002, NEUROSCI LETT, V323, P33, DOI 10.1016/S0304-3940(02)00124-6; Guil S, 2003, MOL CELL BIOL, V23, P2927, DOI 10.1128/MCB.23.8.2927-2941.2003; Guth S, 1999, MOL CELL BIOL, V19, P8263; Hanamura A, 1998, RNA, V4, P430; Hertel KJ, 1998, MOL CELL, V1, P449, DOI 10.1016/S1097-2765(00)80045-3; Hofmann Y, 2002, HUM MOL GENET, V11, P2037, DOI 10.1093/hmg/11.17.2037; Hutton M, 1998, NATURE, V393, P702, DOI 10.1038/31508; Ingram EM, 2002, TRENDS MOL MED, V8, P555, DOI 10.1016/S1471-4914(02)02440-1; Janke C, 1999, MOL BRAIN RES, V68, P119, DOI 10.1016/S0169-328X(99)00079-0; Jiang ZH, 2003, J BIOL CHEM, V278, P18997, DOI 10.1074/jbc.M301800200; Kan JLC, 1999, GENE DEV, V13, P462, DOI 10.1101/gad.13.4.462; Kondo S, 2004, GENES CELLS, V9, P121, DOI 10.1111/j.1356-9597.2004.00709.x; KOSIK KS, 1989, NEURON, V2, P1389, DOI 10.1016/0896-6273(89)90077-9; Lee VMY, 2001, ANNU REV NEUROSCI, V24, P1121, DOI 10.1146/annurev.neuro.24.1.1121; Liu HX, 1998, GENE DEV, V12, P1998, DOI 10.1101/gad.12.13.1998; Lynch KW, 1996, GENE DEV, V10, P2089, DOI 10.1101/gad.10.16.2089; Poorkaj P, 1998, ANN NEUROL, V43, P815, DOI 10.1002/ana.410430617; Poorkaj P, 2001, MAMM GENOME, V12, P700, DOI 10.1007/s00335-001-2044-8; Reed R, 2000, CURR OPIN CELL BIOL, V12, P340, DOI 10.1016/S0955-0674(00)00097-1; Shen HH, 2004, MOL CELL, V13, P367, DOI 10.1016/S1097-2765(04)00025-5; Spillantini MG, 1998, P NATL ACAD SCI USA, V95, P7737, DOI 10.1073/pnas.95.13.7737; Spillantini MG, 2000, ANN NEUROL, V48, P939; Stanford PM, 2003, BRAIN, V126, P814, DOI 10.1093/brain/awg090; Tacke R, 1999, P SOC EXP BIOL MED, V220, P59, DOI 10.1046/j.1525-1373.1999.d01-10.x; Tacke R, 1998, CELL, V93, P139, DOI 10.1016/S0092-8674(00)81153-8; Wang JN, 2004, J NEUROCHEM, V88, P1078, DOI 10.1046/j.1471-4159.2003.02232.x; Wang YZ, 2005, J BIOL CHEM, V280, P14230, DOI 10.1074/jbc.M413846200; Xiao SH, 1997, GENE DEV, V11, P334, DOI 10.1101/gad.11.3.334; Yoshida H, 2002, J NEUROCHEM, V80, P548, DOI 10.1046/j.0022-3042.2001.00729.x; Zahler AM, 2004, J BIOL CHEM, V279, P10077, DOI 10.1074/jbc.M312743200; ZAHLER AM, 1992, GENE DEV, V6, P837, DOI 10.1101/gad.6.5.837; Zhu J, 2001, MOL CELL, V8, P1351, DOI 10.1016/S1097-2765(01)00409-9; Zhu J, 2000, GENE DEV, V14, P3166, DOI 10.1101/gad.189500; Zuo P, 1996, GENE DEV, V10, P1356, DOI 10.1101/gad.10.11.1356	56	39	40	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 3	2006	281	5					2460	2469		10.1074/jbc.M505809200	http://dx.doi.org/10.1074/jbc.M505809200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	006XT	16308321	hybrid			2022-12-25	WOS:000234931800008
J	Mangoura, D; Sun, Y; Li, C; Singh, D; Gutmann, DH; Flores, A; Ahmed, M; Vallianatos, G				Mangoura, D; Sun, Y; Li, C; Singh, D; Gutmann, DH; Flores, A; Ahmed, M; Vallianatos, G			Phosphorylation of neurofibromin by PKC is a possible molecular switch in EGF receptor signaling in neural cells	ONCOGENE			English	Article						neurofibromin; tumor suppressor; EGF signaling; PKC	NF1 GENE-PRODUCT; PROTEIN-KINASE; TYPE-1 GENE; TARGETED DISRUPTION; F-ACTIN; RAS; ACTIVATION; DOMAIN; GAP; EXPRESSION	Children with neurofibromatosis (NF1) typically develop central nervous system (CNS) abnormalities, including aberrant proliferation of astrocytes and formation of benign astrocytomas. The NF1 gene encodes neurofibromin, a Ras-GAP, highly expressed in developing neural cells; the mechanism of regulation of neurofibromin as a Ras-GAP, remains however unknown. We now show that, in response to EGF, neurofibromin is in vivo phosphorylated on serine residues by PKC-alpha, in human, rat, and avian CNS cells and cell lines. EGF-induced PKC phosphorylation was prominent in the cysteine/serine-rich domain (CSRD) of neurofibromin, which lies in the N-terminus and upstream of the Ras-GAP domain (GRD), and this modification significantly increased the association of neurofibromin with actin in co-immunoprecipitations. In addition, we show that Ras activation in response to EGF was significantly lowered when C62B cells overexpressed a construct encoding both CSRD+GRD. Moreover, when PKC-alpha was downregulated, the Ras-GAP activity of CSRD+GRD was significantly diminished, whereas overexpressed GRD alone acted as a weaker GAP and in a PKC-independent manner. Most importantly, functional Ras inhibition and EGF signaling shifts were established at the single cell level in C6-derived cell lines stably overexpressing CSRD+GRD, when transient co-overexpression of Ras and PKC-depletion prior to stimulation with EGF-induced mitosis. Taken together, these data provide the first evidence of a functional, allosteric regulation of GRD by CSRD, which requires neurofibromin phosphorylation by PKC and association with the actin cytoskeleton. Our data may suggest a novel mechanism for regulating biological responses to EGF and provide a new aspect for the understanding of the aberrant proliferation seen in the CNS of children with NF1.	Inst Biomed Res, Div Neurosci, GR-11527 Athens, Greece; Univ Chicago, Dept Pediat, Chicago, IL 60637 USA; Washington Univ, Dept Neurol, St Louis, MO USA	University of Chicago; Washington University (WUSTL)	Mangoura, D (corresponding author), Inst Biomed Res, Div Neurosci, 4 Soranou Efesiou, GR-11527 Athens, Greece.	mangoura@bioacademy.gr	Vallianatos, George/AAF-2973-2019	Gutmann, David/0000-0002-3127-5045	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [P01HD009402] Funding Source: NIH RePORTER; NICHD NIH HHS [HD09402] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		BRANNAN CI, 1994, GENE DEV, V8, P1019, DOI 10.1101/gad.8.9.1019; Brodie C, 1998, J BIOL CHEM, V273, P30713, DOI 10.1074/jbc.273.46.30713; Burrows RC, 1997, NEURON, V19, P251, DOI 10.1016/S0896-6273(00)80937-X; CAWTHON RM, 1990, CELL, V62, P193, DOI 10.1016/0092-8674(90)90253-B; Chen JS, 2004, J BIOL CHEM, V279, P22076, DOI 10.1074/jbc.M311033200; Chen P, 1996, MOL BIOL CELL, V7, P871, DOI 10.1091/mbc.7.6.871; Cheng Y, 2000, J BIOL CHEM, V275, P23326, DOI 10.1074/jbc.M001837200; Cheng Y, 2000, J CELL SCI, V113, P3161; Chidiac P, 1999, J BIOL CHEM, V274, P19639, DOI 10.1074/jbc.274.28.19639; Chiu VK, 2002, NAT CELL BIOL, V4, P343, DOI 10.1038/ncb783; Chodniewicz D, 2004, J BIOL CHEM, V279, P24460, DOI 10.1074/jbc.M312764200; CLARK GJ, 1993, P NATL ACAD SCI USA, V90, P4887, DOI 10.1073/pnas.90.11.4887; Clark GJ, 1997, J BIOL CHEM, V272, P1677, DOI 10.1074/jbc.272.3.1677; Corbit KC, 1999, MOL CELL BIOL, V19, P4209; Crespo NC, 2002, CELL DEATH DIFFER, V9, P702, DOI 10.1038/sj.cdd.4401023; deRooij J, 1997, ONCOGENE, V14, P623, DOI 10.1038/sj.onc.1201005; Drugan JK, 2000, J BIOL CHEM, V275, P35021, DOI 10.1074/jbc.M004386200; Duchek P, 2001, SCIENCE, V291, P131, DOI 10.1126/science.291.5501.131; Edamatsu H, 1998, FEBS LETT, V440, P231, DOI 10.1016/S0014-5793(98)01457-4; Fahsold R, 2000, AM J HUM GENET, V66, P790, DOI 10.1086/302809; Faul C, 2005, J CELL BIOL, V169, P415, DOI 10.1083/jcb.200411169; Frazier JA, 1997, CURR BIOL, V7, pR414, DOI 10.1016/S0960-9822(06)00205-3; Fricker-Gates RA, 2000, EXP NEUROL, V165, P237, DOI 10.1006/exnr.2000.7482; Goya L, 1996, INT J DEV NEUROSCI, V14, P409, DOI 10.1016/S0736-5748(96)00026-3; Gutmann DH, 1995, PROG BRAIN RES, V105, P327; Hiatt KK, 2001, J BIOL CHEM, V276, P7240, DOI 10.1074/jbc.M009202200; Koehler JA, 2001, BIOCHEM BIOPH RES CO, V283, P888, DOI 10.1006/bbrc.2001.4889; Kornblum HI, 1999, EUR J NEUROSCI, V11, P3236, DOI 10.1046/j.1460-9568.1999.00744.x; Kuroda S, 1996, J BIOL CHEM, V271, P23363, DOI 10.1074/jbc.271.38.23363; Li CJ, 2001, DEV BRAIN RES, V130, P231, DOI 10.1016/S0165-3806(01)00190-0; Mangoura D, 1998, J NEUROCHEM, V70, P130; Mangoura D, 1997, J NEUROSCI RES, V50, P391, DOI 10.1002/(SICI)1097-4547(19971101)50:3<391::AID-JNR5>3.0.CO;2-D; MANGOURA D, 1993, P NATL ACAD SCI USA, V90, P2915, DOI 10.1073/pnas.90.7.2915; MARCHUK DA, 1991, GENOMICS, V11, P931, DOI 10.1016/0888-7543(91)90017-9; MARTIN GA, 1990, CELL, V63, P843, DOI 10.1016/0092-8674(90)90150-D; MARTIN GA, 1992, SCIENCE, V255, P192, DOI 10.1126/science.1553544; Miralles F, 2003, CELL, V113, P329, DOI 10.1016/S0092-8674(03)00278-2; Raucher D, 1999, J CELL BIOL, V144, P497, DOI 10.1083/jcb.144.3.497; Represa A, 2001, EUR J NEUROSCI, V14, P452, DOI 10.1046/j.0953-816x.2001.01660.x; Riccardi VM, 1999, NEUROFIBROMATOSIS PH; Rose SD, 2001, J BIOL CHEM, V276, P36757, DOI 10.1074/jbc.M006518200; SCHWEIGHOFFER F, 1992, SCIENCE, V256, P825, DOI 10.1126/science.1317056; Shiraha H, 2002, MOL CELL BIOL, V22, P2716, DOI 10.1128/MCB.22.8.2716-2727.2002; Sibilia M, 1998, EMBO J, V17, P719, DOI 10.1093/emboj/17.3.719; THREADGILL DW, 1995, SCIENCE, V269, P230, DOI 10.1126/science.7618084; Tong JY, 2002, NAT NEUROSCI, V5, P95, DOI 10.1038/nn792; Vandenbroucke I, 2004, FEBS LETT, V560, P98, DOI 10.1016/S0014-5793(04)00078-X; WALLACE MR, 1990, SCIENCE, V249, P181, DOI 10.1126/science.2134734; WU J, 1993, SCIENCE, V262, P1065, DOI 10.1126/science.7694366; Xie H, 1998, J CELL SCI, V111, P615; Yamashiro S, 2003, MOL BIOL CELL, V14, P1745, DOI 10.1091/mbc.E02-07-0427; YAN N, 1995, CANCER RES, V55, P3569	52	57	61	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB	2006	25	5					735	745		10.1038/sj.onc.1209113	http://dx.doi.org/10.1038/sj.onc.1209113			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	008VM	16314845				2022-12-25	WOS:000235068800009
J	Hu, KB; Yang, JW; Tanaka, S; Gonias, SL; Mars, WM; Liu, YH				Hu, KB; Yang, JW; Tanaka, S; Gonias, SL; Mars, WM; Liu, YH			Tissue-type plasminogen activator acts as a cytokine that triggers intracellular signal transduction and induces matrix metalloproteinase-9 gene expression	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECEPTOR-RELATED PROTEIN; RENAL INTERSTITIAL FIBROSIS; HEPATOCYTE GROWTH-FACTOR; IN-VIVO; TYROSINE PHOSPHORYLATION; MYOFIBROBLAST TRANSITION; OBSTRUCTIVE NEPHROPATHY; MESENCHYMAL TRANSITION; CORECEPTOR FUNCTION; CYTOPLASMIC DOMAIN	Tissue-type plasminogen activator (tPA), a serine protease well known for generating plasmin, has been demonstrated to induce matrix metalloproteinase-9 (MMP-9) gene expression and protein secretion in renal interstitial fibroblasts. However, exactly how tPA transduces its signal into the nucleus to control gene expression is unknown. This study investigated the mechanism by which tPA induces MMP-9 gene expression. Both wild-type and non-enzymatic mutant tPA were found to induce MMP-9 expression in rat kidney interstitial fibroblasts (NRK-49F), indicating that the actions of tPA are independent of its proteolytic activity. tPA bound to the low density lipoprotein receptor-related protein-1 (LRP-1) in NRK-49F cells, and this binding was competitively abrogated by the LRP-1 antagonist, the receptor-associated protein. In mouse embryonic fibroblasts (PEA-13) lacking LRP-1, tPA failed to induce MMP-9 expression. Furthermore, tPA induced rapid tyrosine phosphorylation on the beta subunit of LRP-1, which was followed by the activation of Mek1 and its downstream Erk-1 and -2. Blockade of Erk-1/2 activation by the Mek1 inhibitor abolished MMP-9 induction by tPA in NRK-49F cells. Conversely, overexpression of constitutively activated Mek1 induced Erk-1/2 phosphorylation and MMP-9 expression. In mouse obstructed kidney, tPA, LRP-1, and MMP-9 were concomitantly induced in the renal interstitium. Collectively, these results suggest that besides its classical proteolytic activity, tPA acts as a cytokine that binds to the cell membrane receptor LRP-1, induces its tyrosine phosphorylation, and triggers intracellular signal transduction, thereby inducing specific gene expression in renal interstitial fibroblasts.	Univ Pittsburgh, Dept Pathol, Sch Med, Pittsburgh, PA 15261 USA; Nanjing Med Univ, Jiangsu Prov Hosp, Dept Med, Nanjing 210008, Peoples R China; Univ Tokyo, Fac Med, Dept Orthopaed Surg, Tokyo, Japan; Univ Calif San Diego, Dept Pathol, La Jolla, CA 92093 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Nanjing Medical University; University of Tokyo; University of California System; University of California San Diego	Liu, YH (corresponding author), Univ Pittsburgh, Dept Pathol, Sch Med, S-405 Biomed Sci Tower,200 Lothrop St, Pittsburgh, PA 15261 USA.	liuy@upmc.edu	Hu, Kebin/AAT-7840-2021; Tanaka, Sakae/Y-3061-2019	Tanaka, Sakae/0000-0001-9210-9414; Liu, Youhua/0000-0002-4740-805X; Hu, Kebin/0000-0002-0829-4256	NIDDK NIH HHS [DK 071040, DK 064005, DK 061408, DK 054922] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK061408, R01DK064005, R01DK054922, R01DK071040] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Barnes H, 2003, ONCOGENE, V22, P3589, DOI 10.1038/sj.onc.1206504; Barnes H, 2001, J BIOL CHEM, V276, P19119, DOI 10.1074/jbc.M011437200; Boucher P, 2002, J BIOL CHEM, V277, P15507, DOI 10.1074/jbc.M200428200; Brivanlou AH, 2002, SCIENCE, V295, P813, DOI 10.1126/science.1066355; BU GJ, 1992, P NATL ACAD SCI USA, V89, P7427, DOI 10.1073/pnas.89.16.7427; Degryse B, 2004, J BIOL CHEM, V279, P22595, DOI 10.1074/jbc.M313004200; DONATE LE, 1994, PROTEIN SCI, V3, P2378, DOI 10.1002/pro.5560031222; Downward J, 2001, NATURE, V411, P759, DOI 10.1038/35081138; Eddy AA, 2000, PEDIATR NEPHROL, V15, P290, DOI 10.1007/s004670000461; Edgtton KL, 2004, KIDNEY INT, V66, P68, DOI 10.1111/j.1523-1755.2004.00707.x; Fernandez-Monreal M, 2004, MOL CELL NEUROSCI, V25, P594, DOI 10.1016/j.mcn.2003.11.002; Flavin MP, 2000, GLIA, V29, P347, DOI 10.1002/(SICI)1098-1136(20000215)29:4<347::AID-GLIA5>3.3.CO;2-#; Gao RP, 2003, HEPATOL RES, V27, P214, DOI 10.1016/S1386-6346(03)00241-9; Gherardi E, 1997, CIBA F SYMP, V212, P24; Herz J, 2001, J CLIN INVEST, V108, P779, DOI 10.1172/JCI200113992; Hussain MM, 2001, FRONT BIOSCI, V6, pD417, DOI 10.2741/Hussain1; Kalluri R, 2003, J CLIN INVEST, V112, P1776, DOI 10.1172/JCI200320530; Kitching AR, 1997, J EXP MED, V185, P963, DOI 10.1084/jem.185.5.963; Leonard EJ, 1997, CIBA F SYMP, V212, P183; LEONARD EJ, 1997, CIBA F SYMP, V212, P192; Liu YH, 2004, J AM SOC NEPHROL, V15, P1, DOI 10.1097/01.ASN.0000106015.29070.E7; Liu YH, 2004, AM J PHYSIOL-RENAL, V287, pF7, DOI 10.1152/ajprenal.00451.2003; Loukinova E, 2002, J BIOL CHEM, V277, P15499, DOI 10.1074/jbc.M200427200; Makarova A, 2003, J BIOL CHEM, V278, P50250, DOI 10.1074/jbc.M309150200; MARS WM, 1993, AM J PATHOL, V143, P949; Miyazaki T, 2000, J CELL BIOL, V148, P333, DOI 10.1083/jcb.148.2.333; MIZUNO K, 1993, HEPATOCYTE GROWTH FA, P1; Nagai N, 2001, J CEREBR BLOOD F MET, V21, P631, DOI 10.1097/00004647-200106000-00001; NARITA M, 1995, J CLIN INVEST, V96, P1164, DOI 10.1172/JCI118105; Nassar T, 2004, BLOOD, V103, P897, DOI 10.1182/blood-2003-05-1685; Newton CS, 2005, J BIOL CHEM, V280, P27872, DOI 10.1074/jbc.M505410200; Olson ST, 2001, BIOCHEMISTRY-US, V40, P11742, DOI 10.1021/bi0107290; ORTH K, 1994, J BIOL CHEM, V269, P21117; Segarini PR, 2001, J BIOL CHEM, V276, P40659, DOI 10.1074/jbc.M105180200; Strickland DK, 2003, J THROMB HAEMOST, V1, P1663, DOI 10.1046/j.1538-7836.2003.00330.x; Thery C, 1996, ACTA ANAT, V156, P162; Van Valckenborgh E, 2004, AM J PATHOL, V165, P869, DOI 10.1016/S0002-9440(10)63349-4; Wang XY, 2003, NAT MED, V9, P1313, DOI 10.1038/nm926; Wang XY, 1999, NEUROSCI LETT, V274, P79, DOI 10.1016/S0304-3940(99)00682-5; Welling TH, 1996, J SURG RES, V66, P36, DOI 10.1006/jsre.1996.0369; Werner F, 1999, J BIOL CHEM, V274, P21555, DOI 10.1074/jbc.274.31.21555; WILLNOW TE, 1995, P NATL ACAD SCI USA, V92, P4537, DOI 10.1073/pnas.92.10.4537; Yang JW, 2002, J CLIN INVEST, V110, P1525, DOI 10.1172/JC1200216219; Yang JW, 2002, J AM SOC NEPHROL, V13, P96, DOI 10.1681/ASN.V13196; Yang JW, 2001, AM J PATHOL, V159, P1465, DOI 10.1016/S0002-9440(10)62533-3; Yang M, 2004, FASEB J, V18, P1920, DOI 10.1096/fj.04-2357fje; YEE JA, 1993, J CELL PHYSIOL, V157, P528, DOI 10.1002/jcp.1041570312; Yepes M, 2003, J CLIN INVEST, V112, P1533, DOI 10.1172/JCI200319212; Yepes M, 2002, J CLIN INVEST, V109, P1571, DOI 10.1172/JCI200214308; Zhang GQ, 2003, J AM SOC NEPHROL, V14, P1254, DOI 10.1097/01.ASN.0000064292.37793.FB; Zhuo M, 2000, J NEUROSCI, V20, P542, DOI 10.1523/JNEUROSCI.20-02-00542.2000	51	155	165	1	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 27	2006	281	4					2120	2127		10.1074/jbc.M504988200	http://dx.doi.org/10.1074/jbc.M504988200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	004NV	16303771	hybrid			2022-12-25	WOS:000234760400034
J	Manna, T; Thrower, D; Miller, HP; Curmi, P; Wilson, L				Manna, T; Thrower, D; Miller, HP; Curmi, P; Wilson, L			Stathmin strongly increases the minus end catastrophe frequency and induces rapid treadmilling of bovine brain microtubules at steady state in vitro	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							KINESIN-RELATED PROTEIN; STAGE-SPECIFIC EXPRESSION; DYNAMIC INSTABILITY; INTRACELLULAR PH; ONCOPROTEIN 18; PHOSPHOPROTEIN P19; LIGHT-MICROSCOPY; MITOTIC SPINDLES; TUBULIN; OP18/STATHMIN	Stathmin is a ubiquitous microtubule destabilizing protein that is believed to play an important role linking cell signaling to the regulation of microtubule dynamics. Here we show that stathmin strongly destabilizes microtubule minus ends in vitro at steady state, conditions in which the soluble tubulin and microtubule levels remain constant. Stathmin increased the minus end catastrophe frequency similar to 13-fold at a stathmin: tubulin molar ratio of 1:5. Stathmin steady-state catastrophe-promoting activity was considerably stronger at the minus ends than at the plus ends. Consistent with its ability to destabilize minus ends, stathmin strongly increased the treadmilling rate of bovine brain microtubules. By immunofluorescence microscopy, we also found that stathmin binds to purified microtubules along their lengths in vitro. Co-sedimentation of purified microtubules polymerized in the presence of a 1: 5 initial molar ratio of stathmin to tubulin yielded a binding stoichiometry of 1 mol of stathmin per similar to 14.7 mol of tubulin in the microtubules. The results firmly establish that stathmin can increase the steady-state catastrophe frequency by a direct action on microtubules, and furthermore, they indicate that an important regulatory action of stathmin in cells may be to destabilize microtubule minus ends.	Univ Calif Santa Barbara, Dept Mol Cellular & Dev Biol, Santa Barbara, CA 93106 USA; Univ Evry Val Essonne, Lab Struct & Reconnaissance Biomol, EA3637, F-91025 Evry, France	University of California System; University of California Santa Barbara; UDICE-French Research Universities; Universite Paris Saclay	Wilson, L (corresponding author), Univ Calif Santa Barbara, Dept Mol Cellular & Dev Biol, Santa Barbara, CA 93106 USA.	Wilson@lifesci.ucsb.edu		CURMI, Patrick A./0000-0001-5045-8501; Manna, Tapas/0000-0002-2213-6246	NINDS NIH HHS [NS 13560] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS013560] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		AMAT JA, 1991, DEV BRAIN RES, V60, P205, DOI 10.1016/0165-3806(91)90049-O; Arnal I, 2000, J CELL BIOL, V149, P767, DOI 10.1083/jcb.149.4.767; Belmont LD, 1996, CELL, V84, P623, DOI 10.1016/S0092-8674(00)81037-5; Bieche I, 2003, GENOMICS, V81, P400, DOI 10.1016/S0888-7543(03)00031-4; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BUCKLER KJ, 1990, PFLUG ARCH EUR J PHY, V417, P234, DOI 10.1007/BF00370705; Cassimeris L, 2002, CURR OPIN CELL BIOL, V14, P18, DOI 10.1016/S0955-0674(01)00289-7; CHAILLET JR, 1986, P NATL ACAD SCI USA, V83, P522, DOI 10.1073/pnas.83.2.522; Chen W, 2004, NAT CELL BIOL, V6, P227, DOI 10.1038/ncb1104; Curmi PA, 1997, J BIOL CHEM, V272, P25029, DOI 10.1074/jbc.272.40.25029; CURMI PA, 1994, BIOCHEM J, V300, P331, DOI 10.1042/bj3000331; Dammermann A, 2003, CURR BIOL, V13, pR614, DOI 10.1016/S0960-9822(03)00530-X; Derry WB, 1998, CANCER RES, V58, P1177; Desai A, 1999, CELL, V96, P69, DOI 10.1016/S0092-8674(00)80960-5; DOYE V, 1989, J BIOL CHEM, V264, P12134; FARRELL KW, 1987, J CELL BIOL, V104, P1035, DOI 10.1083/jcb.104.4.1035; GAMBLIN TC, 1995, ANAL BIOCHEM, V232, P43; Gavet O, 1998, J CELL SCI, V111, P3333; GELFAND VI, 1991, ANNU REV CELL BIOL, V7, P93, DOI 10.1146/annurev.cb.07.110191.000521; GERBOTH GD, 1993, AM J PHYSIOL, V264, pL448, DOI 10.1152/ajplung.1993.264.5.L448; Gigant B, 2000, CELL, V102, P809, DOI 10.1016/S0092-8674(00)00069-6; Gradin HM, 1998, J CELL BIOL, V140, P131, DOI 10.1083/jcb.140.1.131; Grego S, 2001, BIOPHYS J, V81, P66, DOI 10.1016/S0006-3495(01)75680-9; Holmfeldt P, 2001, MOL BIOL CELL, V12, P73, DOI 10.1091/mbc.12.1.73; Howell B, 1999, J CELL SCI, V112, P3713; Howell B, 1999, MOL BIOL CELL, V10, P105, DOI 10.1091/mbc.10.1.105; Hunter AW, 2003, MOL CELL, V11, P445, DOI 10.1016/S1097-2765(03)00049-2; Keating TJ, 1997, P NATL ACAD SCI USA, V94, P5078, DOI 10.1073/pnas.94.10.5078; Kuntziger T, 2001, J BIOL CHEM, V276, P22979, DOI 10.1074/jbc.M101466200; Larsson N, 1999, J CELL BIOL, V146, P1289, DOI 10.1083/jcb.146.6.1289; Leem CH, 1999, J PHYSIOL-LONDON, V517, P159, DOI 10.1111/j.1469-7793.1999.0159z.x; MALINOWSKA I, 2002, MED SCI MONITOR, V8, P441; MARGOLIS RL, 1981, NATURE, V293, P705, DOI 10.1038/293705a0; Marklund U, 1996, EMBO J, V15, P5290, DOI 10.1002/j.1460-2075.1996.tb00914.x; MCBEATH E, 1990, EUR J CELL BIOL, V52, P1; MITCHISON T, 1984, NATURE, V312, P237, DOI 10.1038/312237a0; MITCHISON TJ, 1988, ANNU REV CELL BIOL, V4, P527, DOI 10.1146/annurev.cellbio.4.1.527; MITCHISON TJ, 1989, J CELL BIOL, V109, P637, DOI 10.1083/jcb.109.2.637; Muller-Borer BJ, 1998, AM J PHYSIOL-HEART C, V275, pH1937, DOI 10.1152/ajpheart.1998.275.6.H1937; Newton CN, 2004, FEBS LETT, V572, P80, DOI 10.1016/j.febslet.2004.06.093; Ozon S, 2002, MOL BIOL CELL, V13, P698, DOI 10.1091/mbc.01-07-0362; Panda D, 1996, J BIOL CHEM, V271, P29807, DOI 10.1074/jbc.271.47.29807; Panda D, 2000, BIOCHEMISTRY-US, V39, P5075, DOI 10.1021/bi992217f; Panda D, 1999, P NATL ACAD SCI USA, V96, P12459, DOI 10.1073/pnas.96.22.12459; Panda D, 2003, P NATL ACAD SCI USA, V100, P9548, DOI 10.1073/pnas.1633508100; Popov AV, 2002, CURR BIOL, V12, P1326, DOI 10.1016/S0960-9822(02)01033-3; Ravelli RBG, 2004, NATURE, V428, P198, DOI 10.1038/nature02393; Rodionov V, 1999, P NATL ACAD SCI USA, V96, P115, DOI 10.1073/pnas.96.1.115; Rodionov VI, 1997, SCIENCE, V275, P215, DOI 10.1126/science.275.5297.215; Rogers GC, 2005, J CELL SCI, V118, P1105, DOI 10.1242/jcs.02284; Rogers GC, 2004, NATURE, V427, P364, DOI 10.1038/nature02256; ROOS G, 1993, LEUKEMIA, V7, P1538; SAWIN KE, 1991, J CELL BIOL, V112, P941, DOI 10.1083/jcb.112.5.941; SCHUBART UK, 1992, DIFFERENTIATION, V51, P21, DOI 10.1111/j.1432-0436.1992.tb00676.x; SEKSEK O, 1991, ANAL BIOCHEM, V193, P49, DOI 10.1016/0003-2697(91)90042-R; Shaw SL, 2003, SCIENCE, V300, P1715, DOI 10.1126/science.1083529; SOBEL A, 1991, TRENDS BIOCHEM SCI, V16, P301, DOI 10.1016/0968-0004(91)90123-D; Srivastava A, 1997, ANAL BIOCHEM, V249, P140, DOI 10.1006/abio.1997.2164; Steinmetz MO, 2000, EMBO J, V19, P572, DOI 10.1093/emboj/19.4.572; Stewart AK, 1999, J PHYSIOL-LONDON, V516, P209, DOI 10.1111/j.1469-7793.1999.209aa.x; TANAKA E, 1995, J CELL BIOL, V128, P139, DOI 10.1083/jcb.128.1.139; TANAKA EM, 1991, J CELL BIOL, V115, P345, DOI 10.1083/jcb.115.2.345; TOSO RJ, 1993, BIOCHEMISTRY-US, V32, P1285, DOI 10.1021/bi00056a013; Trzaskawka E, 2000, EUR J ORAL SCI, V108, P54, DOI 10.1034/j.1600-0722.2000.00670.x; Vorobjev IA, 1997, J CELL SCI, V110, P2635; Vorobjev IA, 1999, J CELL SCI, V112, P2277; Walczak CE, 1996, CELL, V84, P37, DOI 10.1016/S0092-8674(00)80991-5; WALKER RA, 1988, J CELL BIOL, V107, P1437, DOI 10.1083/jcb.107.4.1437; WatermanStorer CM, 1997, J CELL BIOL, V139, P417, DOI 10.1083/jcb.139.2.417; Wilson L, 1999, CELL STRUCT FUNCT, V24, P329, DOI 10.1247/csf.24.329; Wittmann T, 2004, J BIOL CHEM, V279, P6196, DOI 10.1074/jbc.M307261200; Wittmann T, 2001, J CELL SCI, V114, P3795; Wong P, 2002, BRIT J CANCER, V87, P238, DOI 10.1038/sj.bjc.6600424; WORDEMAN L, 1995, J CELL BIOL, V128, P95, DOI 10.1083/jcb.128.1.95	74	38	40	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 27	2006	281	4					2071	2078		10.1074/jbc.M510661200	http://dx.doi.org/10.1074/jbc.M510661200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	004NV	16317007	hybrid			2022-12-25	WOS:000234760400028
J	Prabu, SK; Anandatheerthavarada, HK; Raza, H; Srinivasan, S; Spear, JF; Avadhani, NG				Prabu, SK; Anandatheerthavarada, HK; Raza, H; Srinivasan, S; Spear, JF; Avadhani, NG			Protein kinase A-mediated phosphorylation modulates cytochrome c oxidase function and augments hypoxia and myocardial ischemia-related injury	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CATALYTIC-ACTIVITY; GENE-EXPRESSION; NITRIC-OXIDE; ELECTRON-TRANSPORT; SMOOTH-MUSCLE; OXYGEN; NUCLEAR; INHIBITION; COMPLEX; HEART	We have investigated the effects of hypoxia and myocardial ischemia/reperfusion on the structure and function of cytochrome c oxidase (CcO). Hypoxia (0.1% O-2 for 10 h) and cAMP-mediated inhibition of CcO activity were accompanied by hyperphosphorylation of subunits I, IVi1, and Vb and markedly increased reactive O2 species production by the enzyme complex in an in vitro system that uses reduced cytochrome c as an electron donor. Both subunit phosphorylation and enzyme activity were effectively reversed by 50 nM H89 or 50 nM myristoylated peptide inhibitor (MPI), specific inhibitors of protein kinase A, but not by inhibitors of protein kinase C. In rabbit hearts subjected to global and focal ischemia, CcO activity was inhibited in a time-dependent manner and was accompanied by hyperphosphorylation as in hypoxia. Additionally, CcO activity and subunit phosphorylation in the ischemic heart were nearly completely reversed by H89 or MPI added to the perfusion medium. Hyperphosphorylation of subunits I, IVi1, and Vb was accompanied by reduced subunit contents of the immunoprecipitated CcO complex. Most interestingly, both H89 and MPI added to the perfusion medium dramatically reduced the ischemia/reperfusion injury to the myocardial tissue. Our results pointed to an exciting possibility of using CcO activity modulators for controlling myocardial injury associated with ischemia and oxidative stress conditions.	Univ Penn, Sch Vet Med, Dept Anim Biol, Philadelphia, PA 19104 USA	University of Pennsylvania	Avadhani, NG (corresponding author), Univ Penn, Sch Vet Med, Dept Anim Biol, 3800 Spruce St, Philadelphia, PA 19104 USA.	narayan@vet.upenn.edu		Raza, Haider/0000-0001-9680-5388	NIGMS NIH HHS [GM 49683, R01 GM049683] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM049683] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Arnold S, 1999, FEBS LETT, V443, P105, DOI 10.1016/S0014-5793(98)01694-9; Barman SA, 2003, AM J PHYSIOL-LUNG C, V284, pL1004, DOI 10.1152/ajplung.00295.2002; Bender E, 2000, FEBS LETT, V466, P130, DOI 10.1016/S0014-5793(99)01773-1; BHAT NK, 1982, BIOCHEMISTRY-US, V21, P2452, DOI 10.1021/bi00539a026; Birch-Machin MA, 2001, METHOD CELL BIOL, V65, P97, DOI 10.1016/S0091-679X(01)65006-4; Boopathi E, 2004, J BIOL CHEM, V279, P35242, DOI 10.1074/jbc.M403160200; Borutaite V, 2005, SHOCK, V23, P319, DOI 10.1097/01.shk.0000156672.36439.2d; BUGE U, 1986, EUR J BIOCHEM, V161, P383, DOI 10.1111/j.1432-1033.1986.tb10457.x; Burke PV, 1998, J EXP BIOL, V201, P1163; CAPALDI RA, 1990, ANNU REV BIOCHEM, V59, P569, DOI 10.1146/annurev.bi.59.070190.003033; CASEY RP, 1982, EUR J BIOCHEM, V122, P313, DOI 10.1111/j.1432-1033.1982.tb05882.x; CHANDEL N, 1995, AM J PHYSIOL-LUNG C, V268, pL918, DOI 10.1152/ajplung.1995.268.6.L918; Chandel NS, 1996, J BIOL CHEM, V271, P18672, DOI 10.1074/jbc.271.31.18672; Chandel NS, 1997, J BIOL CHEM, V272, P18808, DOI 10.1074/jbc.272.30.18808; Chandel NS, 2000, J APPL PHYSIOL, V88, P1880, DOI 10.1152/jappl.2000.88.5.1880; Chen Q, 2003, J BIOL CHEM, V278, P36027, DOI 10.1074/jbc.M304854200; CHRZANOWSKALIGHTOWLERS ZMA, 1993, ANAL BIOCHEM, V214, P45, DOI 10.1006/abio.1993.1454; CORNWELL TL, 1994, AM J PHYSIOL-CELL PH, V267, pC1405, DOI 10.1152/ajpcell.1994.267.5.C1405; Dagsgaard C, 2001, J BIOL CHEM, V276, P7593, DOI 10.1074/jbc.M009180200; FULLER SD, 1982, BIOCHEMISTRY-US, V21, P2525, DOI 10.1021/bi00539a036; Giordano FJ, 2005, J CLIN INVEST, V115, P500, DOI 10.1172/JCI200524408; Hu KL, 1996, CIRC RES, V78, P492, DOI 10.1161/01.RES.78.3.492; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lasley RD, 1997, J MOL CELL CARDIOL, V29, P3345, DOI 10.1006/jmcc.1997.0559; LEBEL CP, 1990, TOXICOL APPL PHARM, V104, P17, DOI 10.1016/0041-008X(90)90278-3; Lee I, 2002, MOL CELL BIOCHEM, V234, P63, DOI 10.1023/A:1015921513720; Lesnefsky EJ, 2004, J BIOL CHEM, V279, P47961, DOI 10.1074/jbc.M409720200; Lesnefsky EJ, 2003, ARCH BIOCHEM BIOPHYS, V420, P287, DOI 10.1016/j.abb.2003.09.046; Lesnefsky EJ, 1997, AM J PHYSIOL-HEART C, V273, pH1544, DOI 10.1152/ajpheart.1997.273.3.H1544; Li YB, 1998, J BIOL CHEM, V273, P2015, DOI 10.1074/jbc.273.4.2015; Maejima Y, 2003, CARDIOVASC RES, V59, P308, DOI 10.1016/S0008-6363(03)00425-5; Meldrum DR, 1996, AM J PHYSIOL-REG I, V271, pR718, DOI 10.1152/ajpregu.1996.271.3.R718; MERLE P, 1982, EUR J BIOCHEM, V125, P239, DOI 10.1111/j.1432-1033.1982.tb06674.x; MURRY CE, 1986, CIRCULATION, V74, P1124, DOI 10.1161/01.CIR.74.5.1124; Napiwotzki J, 1998, BIOL CHEM, V379, P335, DOI 10.1515/bchm.1998.379.3.335; Nisoli E, 2003, SCIENCE, V299, P896, DOI 10.1126/science.1079368; Paradies G, 2000, FEBS LETT, V466, P323, DOI 10.1016/S0014-5793(00)01082-6; Poyton RO, 2000, ADV EXP MED BIOL, V475, P177; Raza H, 2004, DIABETES, V53, P185, DOI 10.2337/diabetes.53.1.185; Sanada S, 2001, CIRCULATION, V104, P705, DOI 10.1161/hc3201.092216; Sardanelli AM, 1996, FEBS LETT, V396, P276, DOI 10.1016/0014-5793(96)01112-X; Scacco S, 2000, J BIOL CHEM, V275, P17578, DOI 10.1074/jbc.M001174200; Shiva S, 2005, FREE RADICAL BIO MED, V38, P297, DOI 10.1016/j.freeradbiomed.2004.10.037; Spear JF, 2002, J CARDIOVASC PHARM, V39, P761, DOI 10.1097/00005344-200205000-00018; Stamm C, 2001, CARDIOVASC RES, V51, P108, DOI 10.1016/S0008-6363(01)00249-8; Tomai F, 1999, CIRCULATION, V100, P559, DOI 10.1161/01.CIR.100.5.559; Turcotte ML, 2002, BRIT J CANCER, V86, P619, DOI 10.1038/sj.bjc.6600087; Turrens JF, 2003, J PHYSIOL-LONDON, V552, P335, DOI 10.1113/jphysiol.2003.049478; VandenHoek TL, 1997, J MOL CELL CARDIOL, V29, P2571, DOI 10.1006/jmcc.1997.0497; Vijayasarathy C, 1998, BBA-BIOMEMBRANES, V1371, P71, DOI 10.1016/S0005-2736(97)00278-2; Vijayasarathy C, 2003, EUR J BIOCHEM, V270, P871, DOI 10.1046/j.1432-1033.2003.03447.x; Vijayasarathy C, 1999, EUR J BIOCHEM, V266, P191, DOI 10.1046/j.1432-1327.1999.00843.x	52	152	153	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 27	2006	281	4					2061	2070		10.1074/jbc.M507741200	http://dx.doi.org/10.1074/jbc.M507741200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	004NV	16303765	Green Accepted, hybrid			2022-12-25	WOS:000234760400027
J	Ivanov, VN; Ronai, Z; Hei, TK				Ivanov, VN; Ronai, Z; Hei, TK			Opposite roles of FAP-1 and dynamin in the regulation of Fas (CD95) translocation to the cell surface and susceptibility to fas ligand-mediated apoptosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; PROTEIN-TYROSINE-PHOSPHATASE; EPIDERMAL-GROWTH-FACTOR; HUMAN-MELANOMA; DEATH RECEPTORS; KINASE COMPLEX; CANCER-CELLS; EXPRESSION; ACTIVATION; PHOSPHORYLATION	Human melanoma is the most aggressive form of skin cancer and is extremely resistant to radiation and chemotherapy. One of the critical parameters of this resistance is down-regulation of Fas (CD95) cell-surface expression. Using TIG3 normal human fibroblasts and human melanoma cell lines, we investigated transcriptional regulation of FAP-1, a regulator of Fas translocation in the cell. Protein-tyrosine phosphatase FAP-1 (PTPN13, PTP-BAS) interacts with human Fas protein and prevents its export from the cytoplasm to the cell surface. In contrast, dynamin-2 facilitates Fas protein translocation from the Golgi apparatus via the trans-Golgi network to the cell surface. Suppression of dynamin functions by dominant negative dynamin K44A blocks Fas export, whereas the down-regulation of FAP-1 expression by specific RNA interference restores Fas export (a phenomenon that could still be down-regulated in the presence of dominant-negative dynamin). Based on the FAP-1- and dynamin-dependent regulation of Fas translocation, we have created human melanoma lines with different levels of surface expression of Fas. Treatment of these melanoma lines with soluble Fas ligand resulted in programmed cell death that was proportional to the pre-existing levels of surface Fas. Taking into consideration the well known observations that FAP-1 expression is often up-regulated in metastatic tumors, we have established a causal connection between high basal NF-kappa B transcription factor activity ( which is a hallmark of many types of metastatic tumors) and NF-kappa B-dependent transcriptional regulation of FAP-1 gene expression that finally restricts Fas protein trafficking, thereby, facilitating the survival of cancer cells.	Columbia Univ, Ctr Radiol Res, Coll Phys & Surg, New York, NY 10032 USA; Columbia Univ, Dept Environm Hlth, Mailman Sch Publ Hlth, New York, NY 10032 USA; Burnham Inst, Signal Transduct Program, La Jolla, CA 92037 USA	Columbia University; Columbia University; Sanford Burnham Prebys Medical Discovery Institute	Ivanov, VN (corresponding author), Columbia Univ, Ctr Radiol Res, Coll Phys & Surg, VC11-204,630 W 168th St, New York, NY 10032 USA.	vni3@columbia.edu	Ivanov, Vladimir N/A-3081-2008	Ivanov, Vladimir N/0000-0003-3091-9774; RONAI, ZEEV/0000-0002-3859-0400	NIEHS NIH HHS [P30 ES 09089, R01 ES011804, P30 ES009089, P42 ES010349, ES 11804, P42 ES 10349] Funding Source: Medline; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES011804, P42ES010349, P30ES009089] Funding Source: NIH RePORTER	NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Abaan OD, 2005, ONCOGENE, V24, P2715, DOI 10.1038/sj.onc.1208247; Ahn S, 2002, J BIOL CHEM, V277, P26642, DOI 10.1074/jbc.M201499200; Ahn S, 1999, J BIOL CHEM, V274, P1185, DOI 10.1074/jbc.274.3.1185; Altschuler Y, 1998, J CELL BIOL, V143, P1871, DOI 10.1083/jcb.143.7.1871; Aoki K, 2000, MOL THER, V1, P555, DOI 10.1006/mthe.2000.0076; Arai H, 1997, P NATL ACAD SCI USA, V94, P13862, DOI 10.1073/pnas.94.25.13862; Berking C, 2001, CANCER RES, V61, P8306; BROCKMAN JA, 1995, MOL CELL BIOL, V15, P2809; Cao H, 2000, J CELL SCI, V113, P1993; Cao H, 2005, NAT CELL BIOL, V7, P483, DOI 10.1038/ncb1246; Chan H, 1999, MOL CELL BIOL, V19, P2098, DOI 10.1128/mcb.19.3.2098; Conner SD, 2003, NATURE, V422, P37, DOI 10.1038/nature01451; Cuppen E, 2000, EUR J CELL BIOL, V79, P283, DOI 10.1078/S0171-9335(04)70031-X; Damke H, 2001, MOL BIOL CELL, V12, P2578, DOI 10.1091/mbc.12.9.2578; Debatin KM, 2004, ONCOGENE, V23, P2950, DOI 10.1038/sj.onc.1207558; Dorrie J, 2002, CYTOKINE, V18, P98, DOI 10.1006/cyto.2002.1030; Eramo A, 2004, EUR J IMMUNOL, V34, P1930, DOI 10.1002/eji.200324786; Erdmann KS, 2003, EUR J BIOCHEM, V270, P4789, DOI 10.1046/j.1432-1033.2003.03895.x; Gingras AC, 2001, GENE DEV, V15, P807, DOI 10.1101/gad.887201; Gonzalez-Gaitan Marcos, 2003, Cell, V115, P513, DOI 10.1016/S0092-8674(03)00932-2; Haynes AP, 2002, BRIT J HAEMATOL, V118, P488, DOI 10.1046/j.1365-2141.2002.03643.x; Houston A, 2004, CURR OPIN PHARMACOL, V4, P321, DOI 10.1016/j.coph.2004.03.008; Irie S, 2001, DNA SEQUENCE, V11, P519, DOI 10.3109/10425170109041336; ITOH N, 1991, CELL, V66, P233, DOI 10.1016/0092-8674(91)90614-5; IVANOV V, 1994, J IMMUNOL, V153, P2394; Ivanov VN, 2001, MOL CELL, V7, P517, DOI 10.1016/S1097-2765(01)00199-X; Ivanov VN, 2003, ONCOGENE, V22, P3152, DOI 10.1038/sj.onc.1206456; Ivanov VN, 2000, ONCOGENE, V19, P3003, DOI 10.1038/sj.onc.1203602; Ivanov VN, 2003, MOL CELL BIOL, V23, P3623, DOI 10.1128/MCB.23.10.3623-3635.2003; Karin M, 2002, NAT REV CANCER, V2, P301, DOI 10.1038/nrc780; Karin M, 2002, NAT IMMUNOL, V3, P221, DOI 10.1038/ni0302-221; Kassel O, 2004, GENE DEV, V18, P2518, DOI 10.1101/gad.322404; KATO Y, 1992, P NATL ACAD SCI USA, V89, P8507, DOI 10.1073/pnas.89.18.8507; Kumar A, 2004, J MOL MED, V82, P434, DOI 10.1007/s00109-004-0555-y; Lee FS, 1997, CELL, V88, P213, DOI 10.1016/S0092-8674(00)81842-5; Li G, 2003, ONCOGENE, V22, P6891, DOI 10.1038/sj.onc.1206819; Li G, 2001, CANCER RES, V61, P3819; Maecker HL, 2002, CANCER CELL, V2, P139, DOI 10.1016/S1535-6108(02)00095-8; Meinhold-Heerlein I, 2001, AM J PATHOL, V158, P1335, DOI 10.1016/S0002-9440(10)64084-9; MINDEN A, 1994, SCIENCE, V266, P1719, DOI 10.1126/science.7992057; MYKLEBUST AT, 1994, J NEURO-ONCOL, V21, P215, DOI 10.1007/BF01063770; Nagata S, 1999, ANNU REV GENET, V33, P29, DOI 10.1146/annurev.genet.33.1.29; NICOLETTI I, 1991, J IMMUNOL METHODS, V139, P271, DOI 10.1016/0022-1759(91)90198-O; Orlowski RZ, 2002, TRENDS MOL MED, V8, P385, DOI 10.1016/S1471-4914(02)02375-4; Peter ME, 2005, BBA-REV CANCER, V1755, P25, DOI 10.1016/j.bbcan.2005.01.001; Praefcke GJK, 2004, NAT REV MOL CELL BIO, V5, P133, DOI 10.1038/nrm1313; Reinehr R, 2003, FASEB J, V17, P731, DOI 10.1096/fj.02-0915fje; SATO T, 1995, SCIENCE, V268, P411, DOI 10.1126/science.7536343; SATYAMOORTHY K, 1997, MELANOMA RES S2, V7, P35; Schulze-Bergkamen H, 2004, SEMIN ONCOL, V31, P90, DOI 10.1053/j.seminoncol.2003.11.006; Shajahan AN, 2004, J BIOL CHEM, V279, P20392, DOI 10.1074/jbc.M308710200; Ungefroren H, 2001, J CELL SCI, V114, P2735; van Dam H, 1998, GENE DEV, V12, P1227, DOI 10.1101/gad.12.8.1227; Villa F, 2005, J BIOL CHEM, V280, P8180, DOI 10.1074/jbc.M412211200; Yao H, 2004, BRIT J CANCER, V91, P1718, DOI 10.1038/sj.bjc.6602136; Yoshida S, 2002, J HUM GENET, V47, P614, DOI 10.1007/s100380200094; Zandi E, 1997, CELL, V91, P243, DOI 10.1016/S0092-8674(00)80406-7; Zheng Y, 2001, J IMMUNOL, V166, P4949, DOI 10.4049/jimmunol.166.8.4949	58	53	57	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 20	2006	281	3					1840	1852		10.1074/jbc.M509866200	http://dx.doi.org/10.1074/jbc.M509866200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	002ZS	16306044	Green Accepted, Green Published, hybrid			2022-12-25	WOS:000234652000065
J	Snider, J; Gutsche, I; Lin, M; Baby, S; Cox, B; Butland, G; Greenblatt, J; Emili, A; Houry, WA				Snider, J; Gutsche, I; Lin, M; Baby, S; Cox, B; Butland, G; Greenblatt, J; Emili, A; Houry, WA			Formation of a distinctive complex between the inducible bacterial lysine decarboxylase and a novel AAA plus ATPase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI K-12; NITRIC-OXIDE REDUCTASE; VESICLE GENE-CLUSTER; PARACOCCUS-DENITRIFICANS; ELECTRON-MICROSCOPY; LOCATED DOWNSTREAM; PROTEIN COMPLEXES; ACID TOLERANCE; COG DATABASE; CAD OPERON	AAA+ ATPases are ubiquitous proteins that employ the energy obtained from ATP hydrolysis to remodel proteins, DNA, or RNA. The MoxR family of AAA+ proteins is widespread throughout bacteria and archaea but is largely uncharacterized. Limited work with specific members has suggested a potential role as molecular chaperones involved in the assembly of protein complexes. As part of an effort aimed at determining the function of novel AAA+ chaperones in Escherichia coli, we report the characterization of a representative member of the MoxR family, YieN, which we have renamed RavA (regulatory ATPase variant A). We show that the ravA gene exists on an operon with another gene encoding a protein, YieM, of unknown function containing a Von Willebrand Factor Type A domain. RavA expression is under the control of the sigma(S) transcription factor, and its levels increase toward late log/early stationary phase, consistent with its possible role as a general stress-response protein. RavA functions as an ATPase and forms hexameric oligomers. Importantly, we demonstrate that RavA interacts strongly with inducible lysine decarboxylase (LdcI or CadA) forming a large cage-like structure consisting of two LdcI decamers linked by a maximum of five RavA oligomers. Surprisingly, the activity of LdcI does not appear to be affected by binding to RavA in a number of in vitro and in vivo assays, however, complex formation results in the stimulation of RavA ATPase activity. Data obtained suggest that the RavA-LdcI interaction may be important for the regulation of RavA activity against its targets.	Univ Toronto, Dept Biochem, Toronto, ON M5S 1A8, Canada; Univ Toronto, Mt Sinai Hosp, Samuel Lunenfeld Res Inst, Toronto, ON M5S 1A8, Canada; Univ Toronto, Dept Med Genet & Microbiol, Toronto, ON M5S 1A8, Canada; Univ Toronto, Banting & Best Dept Med Res, Toronto, ON M5S 1A8, Canada; Univ Toronto, Dept Med Genet & Microbiol, Toronto, ON M5S 1A8, Canada; Inst Natl Rech Agronom, CNRS, UMR 2472 1157, Lab Virol Mol & Struct, F-91198 Gif Sur Yvette, France	University of Toronto; University of Toronto; University Toronto Affiliates; Sinai Health System Toronto; Lunenfeld Tanenbaum Research Institute; University of Toronto; University of Toronto; University of Toronto; Centre National de la Recherche Scientifique (CNRS); Communaute Universite Grenoble Alpes; UDICE-French Research Universities; Universite Grenoble Alpes (UGA); INRAE; Universite Paris Saclay	Gutsche, I (corresponding author), Univ Toronto, Dept Biochem, Toronto, ON M5S 1A8, Canada.	gutsche@embl-grenoble.fr						ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; AUGER EA, 1989, ARCH MICROBIOL, V151, P466, DOI 10.1007/BF00416608; AUSTIN S, 1992, EMBO J, V11, P2219, DOI 10.1002/j.1460-2075.1992.tb05281.x; Baker TS, 1996, J STRUCT BIOL, V116, P120, DOI 10.1006/jsbi.1996.0020; Bartnikas TB, 1997, J BACTERIOL, V179, P3534, DOI 10.1128/jb.179.11.3534-3540.1997; Beyer A, 1997, PROTEIN SCI, V6, P2043; Blattner FR, 1997, SCIENCE, V277, P1453, DOI 10.1126/science.277.5331.1453; Butland G, 2005, NATURE, V433, P531, DOI 10.1038/nature03239; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CLARK DP, 1989, FEMS MICROBIOL LETT, V63, P223, DOI 10.1111/j.1574-6968.1989.tb03398.x; DASSARMA S, 1994, J BACTERIOL, V176, P7646, DOI 10.1128/JB.176.24.7646-7652.1994; Datsenko KA, 2000, P NATL ACAD SCI USA, V97, P6640, DOI 10.1073/pnas.120163297; DeBoer APN, 1996, EUR J BIOCHEM, V242, P592, DOI 10.1111/j.1432-1033.1996.0592r.x; ENGLERT C, 1992, MOL MICROBIOL, V6, P3543, DOI 10.1111/j.1365-2958.1992.tb01789.x; Felsenstein J, 1996, METHOD ENZYMOL, V266, P418; Fodje MN, 2001, J MOL BIOL, V311, P111, DOI 10.1006/jmbi.2001.4834; Frickey T, 2004, J STRUCT BIOL, V146, P2, DOI 10.1016/j.jsb.2003.11.020; Hanson PI, 2005, NAT REV MOL CELL BIO, V6, P519, DOI 10.1038/nrm1684; Hayashi NR, 1999, BIOCHEM BIOPH RES CO, V265, P177, DOI 10.1006/bbrc.1999.1103; Hayashi NR, 1997, BIOCHEM BIOPH RES CO, V241, P565, DOI 10.1006/bbrc.1997.7853; HEGERL R, 1982, ULTRAMICROSCOPY, V9, P109, DOI 10.1016/0304-3991(82)90233-9; Hegerl R, 1996, J STRUCT BIOL, V116, P30, DOI 10.1006/jsbi.1996.0006; Heymann JB, 2001, J STRUCT BIOL, V133, P156, DOI 10.1006/jsbi.2001.4339; Iyer LM, 2004, J STRUCT BIOL, V146, P11, DOI 10.1016/j.jsb.2003.10.010; Iyer R, 2003, J BACTERIOL, V185, P6556, DOI 10.1128/JB.185.22.6556-6561.2003; JUNGST A, 1992, FEBS LETT, V314, P308, DOI 10.1016/0014-5793(92)81495-8; Kachlany SC, 2000, J BACTERIOL, V182, P6169, DOI 10.1128/JB.182.21.6169-6176.2000; Katerov V, 2000, CURR MICROBIOL, V40, P149, DOI 10.1007/s002849910031; Kikuchi Y, 1997, J BACTERIOL, V179, P4486, DOI 10.1128/jb.179.14.4486-4492.1997; KUNAU WH, 1993, BIOCHIMIE, V75, P209, DOI 10.1016/0300-9084(93)90079-8; LANZETTA PA, 1979, ANAL BIOCHEM, V100, P95, DOI 10.1016/0003-2697(79)90115-5; Lee JE, 2000, RES MICROBIOL, V151, P605; LEMIRE BD, 1986, METHOD ENZYMOL, V126, P377; Lemonnier M, 1998, MICROBIOL-SGM, V144, P751, DOI 10.1099/00221287-144-3-751; Ludtke SJ, 1999, J STRUCT BIOL, V128, P82, DOI 10.1006/jsbi.1999.4174; MENG SY, 1992, J BACTERIOL, V174, P2659, DOI 10.1128/jb.174.8.2659-2669.1992; Merrell DS, 1999, MOL MICROBIOL, V34, P836, DOI 10.1046/j.1365-2958.1999.01650.x; Mlouka A, 2004, J BACTERIOL, V186, P2355, DOI 10.1128/JB.186.8.2355-2365.2004; Neuwald AF, 1999, GENOME RES, V9, P27; Offner S, 1996, J BACTERIOL, V178, P2071, DOI 10.1128/jb.178.7.2071-2078.1996; Ogura T, 2001, GENES CELLS, V6, P575, DOI 10.1046/j.1365-2443.2001.00447.x; Park YK, 1996, MOL MICROBIOL, V20, P605, DOI 10.1046/j.1365-2958.1996.5441070.x; Patel S, 1998, TRENDS CELL BIOL, V8, P65, DOI 10.1016/S0962-8924(97)01212-9; PHAN APH, 1982, ANAL BIOCHEM, V120, P193, DOI 10.1016/0003-2697(82)90336-0; Rigaut G, 1999, NAT BIOTECHNOL, V17, P1030, DOI 10.1038/13732; SABO DL, 1974, BIOCHEMISTRY-US, V13, P662, DOI 10.1021/bi00701a005; SABO DL, 1974, BIOCHEMISTRY-US, V13, P670, DOI 10.1021/bi00701a006; Shevchenko A, 1996, ANAL CHEM, V68, P850, DOI 10.1021/ac950914h; Soksawatmaekhin W, 2004, MOL MICROBIOL, V51, P1401, DOI 10.1046/j.1365-2958.2003.03913.x; Starkova NN, 1998, FEBS LETT, V422, P218, DOI 10.1016/S0014-5793(98)00012-X; STERNBERG NL, 1991, METHOD ENZYMOL, V204, P18; Tatusov RL, 2003, BMC BIOINFORMATICS, V4, DOI 10.1186/1471-2105-4-41; Tatusov RL, 2000, NUCLEIC ACIDS RES, V28, P33, DOI 10.1093/nar/28.1.33; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; VANSPANNING RJM, 1991, J BACTERIOL, V173, P6948, DOI 10.1128/jb.173.21.6948-6961.1991; Veerassamy S, 2003, J COMPUT BIOL, V10, P997, DOI 10.1089/106652703322756195; WATSON N, 1992, J BACTERIOL, V174, P530, DOI 10.1128/jb.174.2.530-540.1992; Weber H, 2005, J BACTERIOL, V187, P1591, DOI 10.1128/JB.187.5.1591-1603.2005; Wheeler DL, 2005, NUCLEIC ACIDS RES, V33, pD39, DOI 10.1093/nar/gki062; Whittaker CA, 2002, MOL BIOL CELL, V13, P3369, DOI 10.1091/mbc.E02-05-0259; Willows RD, 2003, NAT PROD REP, V20, P327, DOI 10.1039/b110549n; Wolf YI, 2001, GENOME RES, V11, P356, DOI 10.1101/gr.GR-1619R; Xiong JP, 2002, SCIENCE, V296, P151, DOI 10.1126/science.1069040; Yoo SJ, 1996, J BIOL CHEM, V271, P14035, DOI 10.1074/jbc.271.24.14035; Yu DG, 2000, P NATL ACAD SCI USA, V97, P5978, DOI 10.1073/pnas.100127597; Zhang RG, 2001, STRUCTURE, V9, P1095, DOI 10.1016/S0969-2126(01)00675-X	66	43	46	1	16	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 20	2006	281	3					1532	1546		10.1074/jbc.M511172200	http://dx.doi.org/10.1074/jbc.M511172200			15	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	002ZS	16301313	Green Published, hybrid			2022-12-25	WOS:000234652000031
J	Haase, H; Alvarez, J; Petzhold, D; Doller, A; Behlke, J; Erdmann, J; Hetzer, R; Regitz-Zagrosek, V; Vassort, G; Morano, I				Haase, H; Alvarez, J; Petzhold, D; Doller, A; Behlke, J; Erdmann, J; Hetzer, R; Regitz-Zagrosek, V; Vassort, G; Morano, I			Ahnak is critical for cardiac Ca(v)1.2 calcium channel function and its beta-adrenergic regulation	FASEB JOURNAL			English	Article							CA2+ CHANNEL; PROTEIN-KINASE; RAT-HEART; SUBUNIT; PHOSPHORYLATION; MEMBRANE; MODULATION; GENE; PKA; IDENTIFICATION	Defective L-type Ca2+ channel (I-CaL) regulation is one major cause for contractile dysfunction in the heart. The I-CaL is enhanced by sympathetic nervous stimulation: via the activation of beta-adrenergic receptors, PKA phosphorylates the alpha 1C(Ca(V)1.2)- and beta 2-channel subunits and ahnak, an associated 5643-amino acid (aa) protein. In this study, we examined the role of a naturally occurring, genetic variant Ile5236Thr-ahnak on I-CaL. Binding experiments with ahnak fragments (wild-type, Ile5236Thr mutated) and patch clamp recordings revealed that Ile5236Thr-ahnak critically affected both beta 2 subunit interaction and I-CaL regulation. Binding affinity between ahnak-C1 (aa 4646-5288) and beta 2 subunit decreased by approximate to 50% after PKA phosphorylation or in the presence of Ile5236Thr-ahnak peptide. On native cardiomyocytes, intracellular application of this mutated ahnak peptide mimicked the PKA-effects on I-CaL increasing the amplitude by approximate to 60% and slowing its inactivation together with a leftward shift of its voltage dependency. Both mutated Ile5236Thr-peptide and Ile5236Thr-fragment (aa 5215-5288) prevented specifically the further up-regulation of I-CaL by isoprenaline. Hence, we suggest the ahnak-C1 domain serves as physiological brake on I-CaL. Relief from this inhibition is proposed as common pathway used by sympathetic signaling and Ile5236Thr- ahnak fragments to increase I-CaL. This genetic ahnak variant might cause individual differences in I-CaL regulation upon physiological challenges or therapeutic interventions.	Max Delbruck Ctr Mol Med, MDC, D-13092 Berlin, Germany; Inst Cardiol, Havana, Cuba; Univ Med, Charite, Cardiovasc Res Ctr, Berlin, Germany; Deutsch Herzzentrum Berlin, Berlin, Germany; INSERM, U637, Montpellier 5, France; Univ Med, Charite, Johannes Muller Inst Physiol, Berlin, Germany	Helmholtz Association; Max Delbruck Center for Molecular Medicine; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; German Heart Center Berlin; Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Montpellier; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin	Haase, H (corresponding author), Robert Rossle Str 10, D-13092 Berlin, Germany.	haase@mdc-berlin.de	Erdmann, Jeanette/P-7513-2014; Erdmann, Jeanette/A-4417-2009	Erdmann, Jeanette/0000-0002-4486-6231; Regitz-Zagrosek, Vera/0000-0002-3566-3467				Aimond F, 1999, CARDIOVASC RES, V42, P402, DOI 10.1016/S0008-6363(99)00070-X; Alvarez J, 2004, J BIOL CHEM, V279, P12456, DOI 10.1074/jbc.M312177200; Behlke J, 1997, BIOCHEMISTRY-US, V36, P5149, DOI 10.1021/bi962755h; Benaud C, 2004, J CELL BIOL, V164, P133, DOI 10.1083/jcb.200307098; Bunemann M, 1999, J BIOL CHEM, V274, P33851, DOI 10.1074/jbc.274.48.33851; Catterall WA, 2000, ANNU REV CELL DEV BI, V16, P521, DOI 10.1146/annurev.cellbio.16.1.521; Charnet P, 1995, BIOCHIMIE, V77, P957, DOI 10.1016/0300-9084(95)80008-5; Colecraft HM, 2002, J PHYSIOL-LONDON, V541, P435, DOI 10.1113/jphysiol.2002.018515; Erdmann J, 2001, J AM COLL CARDIOL, V38, P322, DOI 10.1016/S0735-1097(01)01387-0; Gao TY, 1997, NEURON, V19, P185, DOI 10.1016/S0896-6273(00)80358-X; Gentil BJ, 2003, J HISTOCHEM CYTOCHEM, V51, P339, DOI 10.1177/002215540305100309; Gerhardstein BL, 1999, BIOCHEMISTRY-US, V38, P10361, DOI 10.1021/bi990896o; Haase H, 2004, FASEB J, V18, P839, DOI 10.1096/fj.03-0446fje; HAASE H, 1993, FEBS LETT, V335, P217, DOI 10.1016/0014-5793(93)80733-B; Haase H, 1999, FASEB J, V13, P2161, DOI 10.1096/fasebj.13.15.2161; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; HASHIMOTO T, 1995, EXP CELL RES, V217, P258, DOI 10.1006/excr.1995.1085; HESCHELER J, 1986, PFLUG ARCH EUR J PHY, V407, P182, DOI 10.1007/BF00580674; Hohaus A, 2002, FASEB J, V16, DOI 10.1096/fj.01-0855com; Hohaus A, 2000, BIOCHEM J, V348, P657, DOI 10.1042/0264-6021:3480657; HULLIN R, 1992, EMBO J, V11, P885, DOI 10.1002/j.1460-2075.1992.tb05126.x; Hulme JT, 2003, P NATL ACAD SCI USA, V100, P13093, DOI 10.1073/pnas.2135335100; Kamp TJ, 1996, J PHYSIOL-LONDON, V492, P89, DOI 10.1113/jphysiol.1996.sp021291; Kobrinsky E, 2004, BIOPHYS J, V87, P844, DOI 10.1529/biophysj.104.041152; Komuro A, 2004, P NATL ACAD SCI USA, V101, P4053, DOI 10.1073/pnas.0308619101; LUO WS, 1994, CIRC RES, V75, P401, DOI 10.1161/01.RES.75.3.401; Marx SO, 2000, CELL, V101, P365, DOI 10.1016/S0092-8674(00)80847-8; Muth JN, 1999, J BIOL CHEM, V274, P21503, DOI 10.1074/jbc.274.31.21503; Restituito S, 2000, J NEUROSCI, V20, P9046; Schroder F, 1998, CIRCULATION, V98, P969, DOI 10.1161/01.CIR.98.10.969; Sekiya F, 1999, J BIOL CHEM, V274, P13900, DOI 10.1074/jbc.274.20.13900; Shistik E, 1998, J BIOL CHEM, V273, P17901, DOI 10.1074/jbc.273.28.17901; SHISTIK E, 1995, J PHYSIOL-LONDON, V489, P55, DOI 10.1113/jphysiol.1995.sp021029; SHTIVELMAN E, 1993, J CELL BIOL, V120, P625, DOI 10.1083/jcb.120.3.625; SHTIVELMAN E, 1992, P NATL ACAD SCI USA, V89, P5472, DOI 10.1073/pnas.89.12.5472; Splawski I, 2004, CELL, V119, P19, DOI 10.1016/j.cell.2004.09.011; Straub BK, 2003, J CELL SCI, V116, P4985, DOI 10.1242/jcs.00815; Sussman J, 2001, J CELL BIOL, V154, P1019, DOI 10.1083/jcb.200105121; TRAUTWEIN W, 1990, ANNU REV PHYSIOL, V52, P257, DOI 10.1146/annurev.ph.52.030190.001353; Van Wagoner DR, 2000, J MOL CELL CARDIOL, V32, P1101, DOI 10.1006/jmcc.2000.1147; WEI XY, 1994, J BIOL CHEM, V269, P1635	41	60	61	0	6	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	DEC	2005	19	14					1969	1977		10.1096/fj.05-3997com	http://dx.doi.org/10.1096/fj.05-3997com			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	999QR	16319140				2022-12-25	WOS:000234405500007
J	Lu, Z; Lam, KS; Wang, N; Xu, X; Cortes, M; Andersen, B				Lu, Z.; Lam, K. S.; Wang, N.; Xu, X.; Cortes, M.; Andersen, B.			LMO4 can interact with Smad proteins and modulate transforming growth factor-beta signaling in epithelial cells	ONCOGENE			English	Article						LMO4; transforming growth factor-beta; Smads; mammary gland epithelial cells; cellular proliferation	LIM-ONLY PROTEIN; HOMEODOMAIN TRANSCRIPTION FACTORS; DOMAIN-BINDING-PROTEIN; NEURAL-TUBE CLOSURE; ACTIVITY IN-VIVO; ADULT-MOUSE; PLASMINOGEN-ACTIVATOR; MAMMARY-GLAND; KNOCKOUT MICE; BREAST-CANCER	LIM- only protein 4 ( LMO4) plays critical roles in mammalian development, and has been proposed to play roles in epithelial oncogenesis, including breast cancer. As LMO4 is highly expressed in the epithelial compartments at locations of active mesenchymal - epithelial interactions, we reasoned that LMO4 might act by modulating signaling pathways involved in mesenchymal - epithelial signaling. One such candidate signal is the transforming growth factor- beta ( TGF beta) cytokine pathway, which plays important roles both in development and cancer. We show here that the transcriptional response to TGFb in epithelial cells is sensitive to LMO4 levels; both up- and downregulation of LMO4 can enhance TGF beta signaling as assessed by a TGF beta- responsive reporter gene. Furthermore, LMO4 can interact with the MH1 and linker domains of receptor- mediated Smad proteins, and associate with the endogenous TGF beta- responsive Plasminogen Activator Inhibitor- 1 gene promoter in a TGF beta- dependent manner, suggesting that such interactions may mediate the effects of LMO4 on TGFb signaling. When introduced into mammary epithelial cells, LMO4 potentiated the growth- inhibitory effects of TGF beta in those cells. These results de. ne a new function for LMO4 as a coactivator in TGFb signaling, and provide a potential novel mechanism for LMO4- mediated regulation in development and oncogenesis.	Univ Calif Irvine, Dept Med, Div Endocrinol, Irvine, CA 92697 USA; Univ Calif Irvine, Dept Biol Chem, Irvine, CA 92717 USA	University of California System; University of California Irvine; University of California System; University of California Irvine	Andersen, B (corresponding author), Univ Calif Irvine, Dept Med, Div Endocrinol, Sprague Hall,Room 206, Irvine, CA 92697 USA.	bogi@uci.edu	Lu, ZX/G-4586-2010		NIAMS NIH HHS [AR44882] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR044882] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Agulnick AD, 1996, NATURE, V384, P270, DOI 10.1038/384270a0; Aoyama M, 2005, CANCER RES, V65, P4587, DOI 10.1158/0008-5472.CAN-04-4630; Arias AM, 2001, CELL, V105, P425, DOI 10.1016/S0092-8674(01)00365-8; Bach I, 1999, NAT GENET, V22, P394, DOI 10.1038/11970; Bach I, 2000, MECH DEVELOP, V91, P5, DOI 10.1016/S0925-4773(99)00314-7; Bach I, 1997, GENE DEV, V11, P1370, DOI 10.1101/gad.11.11.1370; Berk M, 1997, GENE DEV, V11, P2029, DOI 10.1101/gad.11.16.2029; Chang H, 1999, DEVELOPMENT, V126, P1631; Chen YG, 1997, EMBO J, V16, P3866, DOI 10.1093/emboj/16.13.3866; Colland F, 2004, GENOME RES, V14, P1324, DOI 10.1101/gr.2334104; de la Calle-Mustienes E, 2003, DEV BIOL, V264, P564, DOI 10.1016/j.ydbio.2003.09.002; Dennler S, 1998, EMBO J, V17, P3091, DOI 10.1093/emboj/17.11.3091; Derynck R, 2001, NAT GENET, V29, P117, DOI 10.1038/ng1001-117; Derynck R, 2003, NATURE, V425, P577, DOI 10.1038/nature02006; Dong-Le Bourhis X, 1998, BRIT J CANCER, V77, P396, DOI 10.1038/bjc.1998.63; Grutz G, 1998, ONCOGENE, V17, P2799, DOI 10.1038/sj.onc.1202502; Hahm KM, 2004, MOL CELL BIOL, V24, P2074, DOI 10.1128/MCB.24.5.2074-2082.2004; Hata A, 1997, NATURE, V388, P82, DOI 10.1038/40424; Hermanson O, 1999, CELL MOL BIOL, V45, P677; Hinks GL, 1997, J NEUROSCI, V17, P5549; Jurata LW, 1996, P NATL ACAD SCI USA, V93, P11693, DOI 10.1073/pnas.93.21.11693; Kenny DA, 1998, P NATL ACAD SCI USA, V95, P11257, DOI 10.1073/pnas.95.19.11257; Kudryavtseva EI, 2003, DEV DYNAM, V226, P604, DOI 10.1002/dvdy.10255; Kurisaki K, 2003, MOL CELL BIOL, V23, P4494, DOI 10.1128/MCB.23.13.4494-4510.2003; Lee K, 2004, J IMMUNOL, V172, P6539, DOI 10.4049/jimmunol.172.11.6539; Lee SK, 2003, NEURON, V38, P731, DOI 10.1016/S0896-6273(03)00296-4; Lee SK, 2005, MOL CELL NEUROSCI, V28, P205, DOI 10.1016/j.mcn.2004.04.010; Lin KK, 2004, P NATL ACAD SCI USA, V101, P15955, DOI 10.1073/pnas.0407114101; LUO G, 1995, GENE DEV, V9, P2808, DOI 10.1101/gad.9.22.2808; Manetopoulos C, 2003, BIOCHEM BIOPH RES CO, V307, P891, DOI 10.1016/S0006-291X(03)01298-1; Massague J, 2000, EMBO J, V19, P1745, DOI 10.1093/emboj/19.8.1745; Matsuda K, 2002, CANCER RES, V62, P5611; Matthews JM, 2003, EMBO REP, V4, P1132, DOI 10.1038/sj.embor.7400030; McMahon JA, 1998, GENE DEV, V12, P1438, DOI 10.1101/gad.12.10.1438; Milan M, 1999, MOL CELL, V4, P267, DOI 10.1016/S1097-2765(00)80374-3; Milan M, 1998, GENE DEV, V12, P2912, DOI 10.1101/gad.12.18.2912; Milan M, 2000, DEVELOPMENT, V127, P3069; Mizunuma H, 2003, BRIT J CANCER, V88, P1543, DOI 10.1038/sj.bjc.6600952; Mousses S, 2002, CANCER RES, V62, P1256; Puig O, 2001, METHODS, V24, P218, DOI 10.1006/meth.2001.1183; Rabbitts TH, 1998, GENE DEV, V12, P2651, DOI 10.1101/gad.12.17.2651; Racevskis J, 1999, BBA-GENE STRUCT EXPR, V1445, P148, DOI 10.1016/S0167-4781(99)00037-8; Ramain P, 2000, MOL CELL, V6, P781, DOI 10.1016/S1097-2765(05)00079-1; Sanford LP, 1997, DEVELOPMENT, V124, P2659; Sugihara TM, 2001, J BIOL CHEM, V276, P33036, DOI 10.1074/jbc.M103000200; Sugihara TM, 1998, P NATL ACAD SCI USA, V95, P15418, DOI 10.1073/pnas.95.26.15418; Sum EYM, 2005, P NATL ACAD SCI USA, V102, P7659, DOI 10.1073/pnas.0502990102; Sum EYM, 2005, J HISTOCHEM CYTOCHEM, V53, P475, DOI 10.1369/jhc.4A6553.2005; Sum EYM, 2005, ONCOGENE, V24, P4820, DOI 10.1038/sj.onc.1208638; Sum EYM, 2002, J BIOL CHEM, V277, P7849, DOI 10.1074/jbc.M110603200; Thaler JP, 2002, CELL, V110, P237, DOI 10.1016/S0092-8674(02)00823-1; Torigoi E, 2000, P NATL ACAD SCI USA, V97, P2686, DOI 10.1073/pnas.050586397; Tse E, 2004, MOL CELL BIOL, V24, P2063, DOI 10.1128/MCB.24.5.2063-2073.2004; van Meyel DJ, 1999, MOL CELL, V4, P259, DOI 10.1016/S1097-2765(00)80373-1; Visvader JE, 1997, P NATL ACAD SCI USA, V94, P13707, DOI 10.1073/pnas.94.25.13707; Visvader JE, 2001, P NATL ACAD SCI USA, V98, P14452, DOI 10.1073/pnas.251547698; WADMAN I, 1994, EMBO J, V13, P4831, DOI 10.1002/j.1460-2075.1994.tb06809.x; Wadman IA, 1997, EMBO J, V16, P3145, DOI 10.1093/emboj/16.11.3145; Waite KA, 2003, NAT REV GENET, V4, P763, DOI 10.1038/nrg1178; Wang N, 2004, ONCOGENE, V23, P1507, DOI 10.1038/sj.onc.1207288; WIESER R, 1995, EMBO J, V14, P2199, DOI 10.1002/j.1460-2075.1995.tb07214.x; Yamada Y, 1998, P NATL ACAD SCI USA, V95, P3890, DOI 10.1073/pnas.95.7.3890; Zeng CY, 1998, P NATL ACAD SCI USA, V95, P10637, DOI 10.1073/pnas.95.18.10637	63	35	37	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY	2006	25	20					2920	2930		10.1038/sj.onc.1209318	http://dx.doi.org/10.1038/sj.onc.1209318			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	041IN	16331278				2022-12-25	WOS:000237448200010
J	Su, ZZ; Lebedeva, IV; Sarkar, D; Emdad, L; Gupta, P; Kitada, S; Dent, P; Reed, JC; Fisher, PB				Su, ZZ; Lebedeva, IV; Sarkar, D; Emdad, L; Gupta, P; Kitada, S; Dent, P; Reed, JC; Fisher, PB			Ionizing radiation enhances therapeutic activity of mda-7/IL-24: overcoming radiation- and mda-7/IL-24-resistance in prostate cancer cells overexpressing the antiapoptotic proteins bcl-x(L) or bcl-2	ONCOGENE			English	Article						mda-7/1L-24; prostate cancer; ionizing radiation; apoptosis; bcl-family	DIFFERENTIATION-ASSOCIATED GENE-7; IN-VITRO; IMMUNOHISTOCHEMICAL ANALYSIS; INHIBITS GROWTH; GAMMA-RADIATION; APOPTOSIS; DEATH; RADIOSENSITIVITY; ACTIVATION; EXPRESSION	Subtraction hybridization applied to terminally differentiating human melanoma cells identified mda-7/IL-24, a cytokine belonging to the IL-10 gene superfamily. Adenoviral-mediated delivery of mda-7/IL-24 (Ad. mda7) provokes apoptosis selectively in a wide spectrum of cancers in vitro in cell culture, in vivo in human tumor xenograft animal models and in patients with advanced carcinomas and melanomas. In human prostate cancer cells, a role for mitochondrial dysfunction and induction of reactive oxygen species in the apoptotic process has been established. Ectopic overexpression of bcl-x(L) and bcl-2 prevents these changes including apoptosis induction in prostate tumor cells by Ad.mda-7. We now document that this resistance to apoptosis can be reversed by treating bcl-2 family overexpressing prostate tumor cells with ionizing radiation in combination with Ad.mda-7 or purified GSTMDA-7 protein. Additionally, radiation augments apoptosis induction by mda-7/IL-24 in parental and neomycin-resistant prostate tumor cells. Radiosensitization to mda7/IL-24 is dependent on JNK signaling, as treatment with the JNK 1/2/3 inhibitor SP600125 abolishes this effect. Considering that elevated expression of bcl-x(L) and bcl-2 are frequent events in prostate cancer development and progression, the present studies support the use of ionizing radiation in combination with mda-7/IL-24 as a means of augmenting the therapeutic benefit of this gene in prostate cancer, particularly in the context of tumors displaying resistance to radiation therapy owing to bcl-2family member overexpression.	Columbia Univ Coll Phys & Surg, Dept Pathol, Herbert Irving Comprehens Canc Ctr, Med Ctr, New York, NY 10032 USA; Burnham Inst, La Jolla, CA 92037 USA; Virginia Commonwealth Univ, Dept Radiat Oncol, Richmond, VA USA; Columbia Univ Coll Phys & Surg, Dept Urol, Herbert Irving Comprehens Canc Ctr, Med Ctr, New York, NY 10032 USA; Columbia Univ Coll Phys & Surg, Dept Neurosurg, Herbert Irving Comprehens Canc Ctr, Med Ctr, New York, NY 10032 USA	Columbia University; Sanford Burnham Prebys Medical Discovery Institute; Virginia Commonwealth University; Columbia University; Columbia University	Fisher, PB (corresponding author), Columbia Univ Coll Phys & Surg, Dept Pathol, Herbert Irving Comprehens Canc Ctr, Med Ctr, 630 W 168th St, New York, NY 10032 USA.	pbf1@columbia.edu	Lebedeva, Irina V/A-3156-2008	Lebedeva, Irina V/0000-0002-1693-9392	NATIONAL CANCER INSTITUTE [R01CA098712, R01CA097318, R01CA088906, P01CA104177] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM060554] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA88906, R01 CA72955, P01 CA104177, R01 CA097318, R01 CA098712] Funding Source: Medline; NIDDK NIH HHS [DK52585] Funding Source: Medline; NIGMS NIH HHS [GM60554] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BAE VL, 1994, INT J CANCER, V58, P721, DOI 10.1002/ijc.2910580517; Bai XZ, 1999, INT J ONCOL, V14, P785; Bauer JJ, 1996, J UROLOGY, V156, P1511, DOI 10.1016/S0022-5347(01)65641-6; Catz SD, 2003, APOPTOSIS, V8, P29, DOI 10.1023/A:1021692801278; Chada S, 2004, MOL THER, V10, P1085, DOI 10.1016/j.ymthe.2004.08.020; Chaudhary KS, 1999, ENVIRON HEALTH PERSP, V107, P49, DOI 10.2307/3434471; Chen YR, 1996, J BIOL CHEM, V271, P631, DOI 10.1074/jbc.271.2.631; COLOMBEL M, 1993, AM J PATHOL, V143, P390; Cooperberg MR, 2004, ONCOLOGY-NY, V18, P1239; Dent P, 2003, ONCOGENE, V22, P5885, DOI 10.1038/sj.onc.1206701; Dent P, 2003, RADIAT RES, V159, P283, DOI 10.1667/0033-7587(2003)159[0283:SARIAO]2.0.CO;2; Fisher PB, 2003, CANCER BIOL THER, V2, pS23; FISHER PB, 2005, IN PRESS CANC RES; Gopalkrishnan RV, 2001, J CELL PHYSIOL, V189, P245, DOI 10.1002/jcp.10023; GUPTA P, 2005, IN PRESS PHARM THER; Kajiwara T, 1999, INT J UROL, V6, P520, DOI 10.1046/j.1442-2042.1999.00102.x; Karin M, 1998, ANN NY ACAD SCI, V851, P139, DOI 10.1111/j.1749-6632.1998.tb08987.x; Kawabe S, 2002, MOL THER, V6, P637, DOI 10.1006/mthe.2002.0714; Keshgegian AA, 1998, AM J CLIN PATHOL, V110, P443; Kharbanda S, 2000, J BIOL CHEM, V275, P322, DOI 10.1074/jbc.275.1.322; Krajewska M, 1996, AM J PATHOL, V148, P1567; KRAJEWSKI S, 1994, CANCER RES, V54, P5501; Lebedeva I, 2000, CANCER RES, V60, P6052; Lebedeva IV, 2003, ONCOGENE, V22, P8758, DOI 10.1038/sj.onc.1206891; Lebedeva IV, 2005, MOL THER, V11, P4, DOI 10.1016/j.ymthe.2004.08.012; Lebedeva IV, 2002, ONCOGENE, V21, P708, DOI 10.1038/sj.onc.1205116; Li XY, 2001, CANCER RES, V61, P1699; Liu QY, 1997, CLIN CANCER RES, V3, P2039; Mabjeesh NJ, 2002, ENDOCR-RELAT CANCER, V9, DOI 10.1677/erc.0.0090115; Maundrell K, 1997, J BIOL CHEM, V272, P25238, DOI 10.1074/jbc.272.40.25238; MCDONNELL TJ, 1992, CANCER RES, V52, P6940; Reed JC, 1996, J CELL BIOCHEM, V60, P23, DOI 10.1002/(SICI)1097-4644(19960101)60:1<23::AID-JCB5>3.3.CO;2-3; Saito Y, 2005, CANCER GENE THER, V12, P238, DOI 10.1038/sj.cgt.7700780; Sarkar D, 2005, P NATL ACAD SCI USA, V102, P14034, DOI 10.1073/pnas.0506837102; Sauane M, 2004, ONCOGENE, V23, P7679, DOI 10.1038/sj.onc.1207958; Srivastava RK, 1999, MOL CELL BIOL, V19, P5659; Su ZZ, 2001, P NATL ACAD SCI USA, V98, P10332, DOI 10.1073/pnas.171315198; Su ZZ, 2003, ONCOGENE, V22, P1164, DOI 10.1038/sj.onc.1206062; Su ZZ, 1998, P NATL ACAD SCI USA, V95, P14400, DOI 10.1073/pnas.95.24.14400; SU ZZ, 2005, ONCOGENE, V24; Yacoub A, 2004, CANCER BIOL THER, V3, P739, DOI 10.4161/cbt.3.8.968; Yacoub A, 2003, CANCER BIOL THER, V2, P347, DOI 10.4161/cbt.2.4.422; Yacoub A, 2003, CLIN CANCER RES, V9, P3272; Yacoub A, 2003, MOL CANCER THER, V2, P623	44	70	80	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 13	2006	25	16					2339	2348		10.1038/sj.onc.1209271	http://dx.doi.org/10.1038/sj.onc.1209271			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	032HC	16331261				2022-12-25	WOS:000236764300006
J	Chen, KQ; Iribarren, P; Hu, JY; Chen, JH; Gong, WH; Cho, EH; Lockett, S; Dunlop, NM; Wang, JM				Chen, KQ; Iribarren, P; Hu, JY; Chen, JH; Gong, WH; Cho, EH; Lockett, S; Dunlop, NM; Wang, JM			Activation of toll-like receptor 2 on microglia promotes cell uptake of Alzheimer disease-associated amyloid beta peptide	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TOLL-LIKE RECEPTOR-2; CENTRAL-NERVOUS-SYSTEM; STAPHYLOCOCCUS-AUREUS; IMMUNE-RESPONSES; PROTEIN; INFLAMMATION; MECHANISMS; EXPRESSION; BRAIN; PHAGOCYTOSIS	The human G-protein-coupled formyl peptide receptor-like 1 (FPRL1) and its mouse homologue mFPR2 mediate the chemotactic activity of a variety of polypeptides associated with inflammation and bacterial infection, including the 42-amino acid form of amyloid beta peptide (A beta(42)), a pathogenic factor in Alzheimer disease. Because mFPR2 was inducible in mouse microglial cells by proinflammatory stimulants, such as bacterial lipopolysaccharide, a ligand for the Toll-like receptor 4 (TLR4), we investigated the role of TLR2 in the regulation of mFPR2. We found that a TLR2 agonist, peptidoglycan (PGN) derived from Gram-positive bacterium Staphylococcus aureus, induced considerable mFpr2 mRNA expression in a mouse microglial cell line and primary microglial cells. This was associated with a markedly increased chemotaxis of the cells in response to mFPR2 agonist peptides. In addition, activation of TLR2 markedly enhanced mFPR2-mediated uptake of A beta(42) by microglia. Studies of the mechanistic basis showed that PGN activates MAPK and I kappa Ba, and the effect of PGN on induction of mFPR2 was dependent on signaling pathways via ERK1/2 and p38 MAPKs. The use of TLR2 on microglial cells by PGN was supported by the fact that N9 cells transfected with short interfering RNA targeting mouse TLR2 failed to show increased expression of functional mFPR2 after stimulation with PGN. Our results demonstrated a potentially important role for TLR2 in microglial cells of promoting cell responses to chemoattractants produced in lesions of inflammatory and neurodegenerative diseases in the brain.	NCI, Lab Mol Immunoregulat, Ctr Canc Res, NIH, Frederick, MD 21702 USA; NCI, Image Anal Lab, SAIC, NIH, Frederick, MD 21702 USA; NCI, Basic Res Program, SAIC, NIH, Frederick, MD 21702 USA; Shanghai Jiao Tong Univ, Sch Agr & Biol, Shanghai 201101, Peoples R China	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick; Shanghai Jiao Tong University	Wang, JM (corresponding author), NCI, Lab Mol Immunoregulat, Ctr Canc Res, NIH, Bldg 560,Rm 31-40, Frederick, MD 21702 USA.	wangji@mail.ncifcrf.gov	Cho, Edward/B-3727-2012	Cho, Edward/0000-0002-0278-334X	NATIONAL CANCER INSTITUTE [ZIABC010015, Z01BC010015, Z01BC010723] Funding Source: NIH RePORTER	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Akiyama H, 2000, NEUROBIOL AGING, V21, P383, DOI 10.1016/S0197-4580(00)00124-X; Ard MD, 1996, J NEUROSCI RES, V43, P190, DOI 10.1002/(SICI)1097-4547(19960115)43:2<190::AID-JNR7>3.0.CO;2-B; Bsibsi M, 2002, J NEUROPATH EXP NEUR, V61, P1013, DOI 10.1093/jnen/61.11.1013; Carl VS, 2002, J BIOL CHEM, V277, P17448, DOI 10.1074/jbc.M111847200; Cotter RL, 1999, J LEUKOCYTE BIOL, V65, P416, DOI 10.1002/jlb.65.4.416; Cui YH, 2002, J LEUKOCYTE BIOL, V72, P628; Cui YH, 2002, NEUROBIOL DIS, V10, P366, DOI 10.1006/nbdi.2002.0517; Cui YH, 2002, J IMMUNOL, V168, P434, DOI 10.4049/jimmunol.168.1.434; Eikelenboom P, 1998, EXP NEUROL, V154, P89, DOI 10.1006/exnr.1998.6920; ElKhoury J, 1996, NATURE, V382, P716; FRACKOWIAK J, 1992, ACTA NEUROPATHOL, V84, P225; Frautschy SA, 1998, AM J PATHOL, V152, P307; FRAUTSCHY SA, 1992, AM J PATHOL, V140, P1389; Giulian D, 1999, AM J HUM GENET, V65, P13, DOI 10.1086/302477; Grabiec A, 2004, J BIOL CHEM, V279, P48004, DOI 10.1074/jbc.M405311200; Hirsch EC, 2003, ANN NY ACAD SCI, V991, P214; Iribarren P, 2003, J IMMUNOL, V171, P5482, DOI 10.4049/jimmunol.171.10.5482; Iribarren P, 2005, IMMUNOL RES, V31, P165, DOI 10.1385/IR:31:3:165; Kalaria R N, 1999, Curr Opin Hematol, V6, P15, DOI 10.1097/00062752-199901000-00004; Karin M, 1999, ONCOGENE, V18, P6867, DOI 10.1038/sj.onc.1203219; Kielian T, 2005, INFECT IMMUN, V73, P7428, DOI 10.1128/IAI.73.11.7428-7435.2005; Kielian T, 2002, J NEUROIMMUNOL, V130, P86, DOI 10.1016/S0165-5728(02)00216-3; Kielian T, 2004, J NEUROINFLAMM, V1, DOI 10.1186/1742-2094-1-16; Laflamme N, 2003, EUR J IMMUNOL, V33, P1127, DOI 10.1002/eji.200323821; Le YY, 2002, TRENDS IMMUNOL, V23, P541, DOI 10.1016/S1471-4906(02)02316-5; Le YY, 2001, J NEUROSCI, V21, DOI 10.1523/JNEUROSCI.21-02-j0003.2001; Lombardo JA, 2003, J NEUROSCI, V23, P10879, DOI 10.1523/jneurosci.23-34-10879.2003; McGeer PL, 1999, J LEUKOCYTE BIOL, V65, P409, DOI 10.1002/jlb.65.4.409; Minagar A, 2002, J NEUROL SCI, V202, P13, DOI 10.1016/S0022-510X(02)00207-1; Monsonego A, 2003, SCIENCE, V302, P834, DOI 10.1126/science.1088469; Morgan C, 2004, PROG NEUROBIOL, V74, P323, DOI 10.1016/j.pneurobio.2004.10.004; Olson JK, 2004, J IMMUNOL, V173, P3916, DOI 10.4049/jimmunol.173.6.3916; Oppenheim JJ, 2005, CURR OPIN IMMUNOL, V17, P359, DOI 10.1016/j.coi.2005.06.002; Pocock JM, 2002, E SCHERING RES FDN W, V39, P105; Rock RB, 2004, CLIN MICROBIOL REV, V17, P942, DOI 10.1128/CMR.17.4.942-964.2004; Rogers J, 2002, GLIA, V40, P260, DOI 10.1002/glia.10153; Rogers J, 2002, E SCHERING RES FDN W, V39, P25; Rogers J, 2001, NEUROCHEM INT, V39, P333, DOI 10.1016/S0197-0186(01)00040-7; Schenk D, 1999, NATURE, V400, P173, DOI 10.1038/22124; SHIGEMATSU K, 1992, J NEUROSCI RES, V31, P443, DOI 10.1002/jnr.490310306; Tiffany HL, 2001, J BIOL CHEM, V276, P23645, DOI 10.1074/jbc.M101031200; Tsan MF, 2004, J LEUKOCYTE BIOL, V76, P514, DOI 10.1189/jlb.0304127; Vabulas RM, 2002, J BIOL CHEM, V277, P15107, DOI 10.1074/jbc.M111204200; Vabulas RM, 2002, J BIOL CHEM, V277, P20847, DOI 10.1074/jbc.M200425200; Vabulas RM, 2001, J BIOL CHEM, V276, P31332, DOI 10.1074/jbc.M103217200; Wegiel J, 2000, ACTA NEUROPATHOL, V100, P356, DOI 10.1007/s004010000199; Weldon DT, 1998, J NEUROSCI, V18, P2161; Wilcock DM, 2003, J NEUROSCI, V23, P3745, DOI 10.1523/jneurosci.23-09-03745.2003; WISNIEWSKI HM, 1994, NEUROPATH APPL NEURO, V20, P192; Yan SD, 1996, NATURE, V382, P685, DOI 10.1038/382685a0; Yazawa H, 2001, FASEB J, V15, P2454, DOI 10.1096/fj.01-0251com; Ying GG, 2004, J IMMUNOL, V172, P7078, DOI 10.4049/jimmunol.172.11.7078; Zekki H, 2002, BRAIN PATHOL, V12, P308	53	180	182	0	16	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 10	2006	281	6					3651	3659		10.1074/jbc.M508125200	http://dx.doi.org/10.1074/jbc.M508125200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	009QV	16339765	hybrid			2022-12-25	WOS:000235128200077
J	Natesampillai, S; Zapico, ME; Urrutia, R; Veldhuis, JD				Natesampillai, S; Zapico, ME; Urrutia, R; Veldhuis, JD			A novel functional interaction between the Sp1-like protein KLF13 and SREBP-Sp1 activation complex underlies regulation of low density lipoprotein receptor promoter function	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ELEMENT-BINDING PROTEIN; SWINE GRANULOSA-CELLS; FOLLICLE-STIMULATING-HORMONE; BOVINE CYP11A GENE; TRANSCRIPTION FACTOR; CHOLESTEROL-METABOLISM; HISTONE DEACETYLASE; 3 FINGERS; SP1; KRUPPEL	Cholesterol homeostasis is regulated by a family of transcription factors designated sterol regulatory element-binding proteins ( SREBPs). Precise control of SREBP-targeted genes requires additional interactions with co-regulatory transcription factors. In the case of the low density lipoprotein receptor ( LDLR), SREBP cooperates with the specificity protein Sp1 to activate the promoter. In this report, we describe a novel pathway in LDLR transcriptional regulation distinct from the SREBP-Sp1 activation complex involving the Sp1-like protein Krueppel-like factor 13 ( KLF13). Using a combination of RNA interference, electrophoretic mobility shift, chromatin immunoprecipitation, and reporter assays, deletion, and site-directed mutagenesis, we demonstrated that KLF13 mediates repression in a DNA context-selective manner. KLF13 repression of LDLR promoter activity appears to be needed to keep the receptor silent, a state that can be antagonized by Sp1, SREBP, and inhibitors of histone deacetylase activity. Chromatin immunoprecipitation assay confirmed that KLF13 binds proximal LDLR DNA sequences in vivo and that exogenous oxysterol up-regulates such binding. Together these studies identify a novel regulatory pathway in which gene repression by KLF13 must be overcome by the Sp1-SREBP complex to activate the LDLR promoter. Therefore, these data should replace a pre-existent and more simple paradigm that takes into consideration only the induction of the activator proteins Sp1-SREBP as necessary for LDLR promoter drive without including default repression, such as that by KLF13, of the LDLR gene.	Mayo Clin Rochester, Coll Med, Endocrine Res Unit, Rochester, MN 55905 USA; Mayo Clin Rochester, Coll Med, Gastroenterol Res Unit, Dept Internal Med,Mayo Sch Grad Med Educ, Rochester, MN 55905 USA	Mayo Clinic; Mayo Clinic	Veldhuis, JD (corresponding author), Mayo Clin Rochester, Coll Med, Endocrine Res Unit, Rochester, MN 55905 USA.	veldhuis.johannes@mayo.edu			EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD016393] Funding Source: NIH RePORTER; NATIONAL CANCER INSTITUTE [P50CA102701] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK056620, R01DK052913] Funding Source: NIH RePORTER; NCI NIH HHS [P50-CA102701, P50 CA102701] Funding Source: Medline; NICHD NIH HHS [R01 HD016393, R01 HD16393] Funding Source: Medline; NIDDK NIH HHS [R01 DK56620, R01 DK052913-09, R01 DK056620, R01 DK052913, R01 DK52913] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Ahlgren R, 1999, J BIOL CHEM, V274, P19422, DOI 10.1074/jbc.274.27.19422; Ammanamanchi S, 2003, J BIOL CHEM, V278, P35775, DOI 10.1074/jbc.M305961200; Athanikar JN, 1997, MOL CELL BIOL, V17, P5193, DOI 10.1128/MCB.17.9.5193; Bieker JJ, 2001, J BIOL CHEM, V276, P34355, DOI 10.1074/jbc.R100043200; Borroni R, 1997, ENDOCRINOLOGY, V138, P2011, DOI 10.1210/en.138.5.2011; BRANNIAN JD, 1993, ENDOCRINOLOGY, V132, P591, DOI 10.1210/en.132.2.591; Braun H, 2001, NUCLEIC ACIDS RES, V29, P4994, DOI 10.1093/nar/29.24.4994; Brown MS, 1997, CELL, V89, P331, DOI 10.1016/S0092-8674(00)80213-5; CHANG CY, 1992, MOL ENDOCRINOL, V6, P1362, DOI 10.1210/me.6.9.1362; Chatterjee S, 2001, ANN NEUROL, V49, P345, DOI 10.1002/ana.71.abs; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DYNAN WS, 1983, CELL, V35, P79, DOI 10.1016/0092-8674(83)90210-6; Fernandez-Zapico ME, 2003, EMBO J, V22, P4748, DOI 10.1093/emboj/cdg470; Ge YB, 2002, BBA-GENE STRUCT EXPR, V1579, P73, DOI 10.1016/S0167-4781(02)00509-2; GWYNNE JT, 1982, ENDOCR REV, V3, P299, DOI 10.1210/edrv-3-3-299; Jansen E, 2004, MOL ENDOCRINOL, V18, P3050, DOI 10.1210/me.2004-0074; Jo MS, 2004, ENDOCRINOLOGY, V145, P5384, DOI 10.1210/en.2004-0407; Kaczynski J, 2001, J BIOL CHEM, V276, P36749, DOI 10.1074/jbc.M105831200; Kaczynski J, 2003, GENOME BIOL, V4, DOI 10.1186/gb-2003-4-2-206; Kuehl R.C, 1994, STAT PRINCIPLES RES; LaVoie HA, 1999, ENDOCRINOLOGY, V140, P178, DOI 10.1210/en.140.1.178; Nakamura T, 2004, J BIOL CHEM, V279, P626, DOI 10.1074/jbc.M307502200; NATESAMPILLAI S, 2004, AM J PHYSIOL, V287, pE128; NATESAMPILLAI S, 2001, ENDOCRINOLOGY, V142, P2921; Nicolas M, 2003, BIOCHEM J, V371, P265, DOI 10.1042/BJ20021166; Pandya K, 2002, J BIOL CHEM, V277, P16304, DOI 10.1074/jbc.M200866200; Pena P, 1999, MOL ENDOCRINOL, V13, P1402, DOI 10.1210/me.13.8.1402; Philipsen S, 1999, NUCLEIC ACIDS RES, V27, P2991, DOI 10.1093/nar/27.15.2991; PREISS A, 1985, NATURE, V313, P27, DOI 10.1038/313027a0; Sadate-Ngatchou PI, 2004, MOL ENDOCRINOL, V18, P2805, DOI 10.1210/me.2003-0203; SANCHEZ HB, 1995, J BIOL CHEM, V270, P1161, DOI 10.1074/jbc.270.3.1161; Scohy S, 2000, GENOMICS, V70, P93, DOI 10.1006/geno.2000.6362; Song CZ, 2003, J MOL BIOL, V329, P207, DOI 10.1016/S0022-2836(03)00429-7; Song CZ, 2002, J BIOL CHEM, V277, P7029, DOI 10.1074/jbc.M108826200; Sowa Y, 1999, CANCER RES, V59, P4266; STOPECK AT, 1993, J BIOL CHEM, V268, P17489; Sugawara T, 2000, ENDOCRINOLOGY, V141, P2895, DOI 10.1210/en.141.8.2895; TAKAGI K, 1989, J BIOL CHEM, V264, P12352; VAN LC, 1996, GENE EXPRESSION, V5, P245; VELDHUIS JD, 1985, ENDOCRINOLOGY, V117, P1067, DOI 10.1210/endo-117-3-1067; VELDHUIS JD, 1985, ENDOCRINOLOGY, V117, P1321, DOI 10.1210/endo-117-4-1321; VELDHUIS JD, 1986, ENDOCRINOLOGY, V118, P2242, DOI 10.1210/endo-118-6-2242; VENEPALLY P, 1995, J BIOL CHEM, V270, P25402, DOI 10.1074/jbc.270.43.25402; Yamamoto J, 2004, J BIOL CHEM, V279, P16954, DOI 10.1074/jbc.M312079200; Yang WS, 1998, J LIPID RES, V39, P2054; YIEH L, 1995, P NATL ACAD SCI USA, V92, P6102, DOI 10.1073/pnas.92.13.6102; YOSHIDA M, 1990, J BIOL CHEM, V265, P17174; Zhang GQ, 2004, ENDOCRINOLOGY, V145, P2760, DOI 10.1210/en.2003-1545; Zhang JS, 2001, MOL CELL BIOL, V21, P5041, DOI 10.1128/MCB.21.15.5041-5049.2001; Zhang XL, 2003, J BIOL CHEM, V278, P21474, DOI 10.1074/jbc.M212098200	50	26	28	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 10	2006	281	6					3040	3047		10.1074/jbc.M509417200	http://dx.doi.org/10.1074/jbc.M509417200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	009QV	16303770	hybrid			2022-12-25	WOS:000235128200006
J	He, JQ; Bellini, M; Inuzuka, H; Xu, JG; Xiong, Y; Yang, XM; Castleberry, AM; Hall, RA				He, JQ; Bellini, M; Inuzuka, H; Xu, JG; Xiong, Y; Yang, XM; Castleberry, AM; Hall, RA			Proteomic analysis of beta(1)-adrenergic receptor interactions with PDZ scaffold proteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EXCHANGER REGULATORY FACTOR; BETA-ADRENERGIC-RECEPTORS; RAT VENTRICULAR MYOCYTES; BETA(2)-ADRENERGIC RECEPTOR; BETA-1-ADRENERGIC RECEPTOR; CARDIAC MYOCYTES; GUANYLATE KINASE; BETA-2-ADRENERGIC RECEPTORS; BINDING; INTERNALIZATION	Many G protein-coupled receptors possess carboxyl-terminal motifs ideal for interaction with PDZ scaffold proteins, which can control receptor trafficking and signaling in a cell-specific manner. To gain a panoramic view of beta(1)-adrenergic receptor (beta(1)AR) interactions with PDZ scaffolds, the beta 1AR carboxyl terminus was screened against a newly developed proteomic array of PDZ domains. These screens confirmed beta(1)AR associations with several previously identified PDZ partners, such as PSD-95, MAGI-2, GIPC, and CAL. Moreover, two novel beta(1)AR- interacting proteins, SAP97 and MAGI-3, were also identified. The beta(1)AR carboxyl terminus was found to bind specifically to the first PDZ domain of MAGI-3, with the last four amino acids (E-S-K-V) of beta(1)AR being the key determinants of the interaction. Full-length beta(1)AR robustly associated with full-length MAGI-3 in cells, and this association was abolished by mutation of the beta(1)AR terminal valine residue to alanine (V477A), as determined by co-immunoprecipitation experiments and immunofluorescence co-localization studies. MAGI-3 co-expression with beta(1)AR profoundly impaired beta(1)AR-mediated ERK1/2 activation but had no apparent effect on beta(1)AR-mediated cyclic AMP generation or agonist-promoted beta(1)AR internalization. These findings revealed that the interaction of MAGI-3 with beta(1)AR can selectively regulate specific aspects of receptor signaling. Moreover, the screens of the PDZ domain proteomic array provide a comprehensive view of beta(1)AR interactions with PDZ scaffolds, thereby shedding light on the molecular mechanisms by which beta(1)AR signaling and trafficking can be regulated in a cell-specific manner.	Emory Univ, Sch Med, Dept Pharmacol, Rollins Res Ctr 5113, Atlanta, GA 30322 USA; Capital Univ Med Sci, Dept Biochem & Mol Biol, Beijing 100054, Peoples R China	Emory University; Capital Medical University	Hall, RA (corresponding author), Emory Univ, Sch Med, Dept Pharmacol, Rollins Res Ctr 5113, 1510 Clifton Rd, Atlanta, GA 30322 USA.	rhall@pharm.emory.edu		Hall, Randy/0000-0002-8318-8728				Adamsky K, 2003, J CELL SCI, V116, P1279, DOI 10.1242/jcs.00302; Balasubramanian S, 2004, J BIOL CHEM, V279, P18840, DOI 10.1074/jbc.M313470200; Balda MS, 2000, EMBO J, V19, P2024, DOI 10.1093/emboj/19.9.2024; Cao TT, 1999, NATURE, V401, P286, DOI 10.1038/45816; Cesetti T, 2003, J NEUROSCI, V23, P73; Chesley A, 2000, CIRC RES, V87, P1172, DOI 10.1161/01.RES.87.12.1172; Communal C, 1999, CIRCULATION, V100, P2210, DOI 10.1161/01.CIR.100.22.2210; Devic E, 2001, MOL PHARMACOL, V60, P577; Fam SR, 2005, P NATL ACAD SCI USA, V102, P8042, DOI 10.1073/pnas.0408818102; GREEN SA, 1994, J BIOL CHEM, V269, P26215; Hall RA, 1998, NATURE, V392, P626, DOI 10.1038/33458; Hall RA, 2004, SEMIN CELL DEV BIOL, V15, P281, DOI 10.1016/j.semcdb.2003.12.017; Hall RA, 1998, P NATL ACAD SCI USA, V95, P8496, DOI 10.1073/pnas.95.15.8496; He JQ, 2004, J BIOL CHEM, V279, P50190, DOI 10.1074/jbc.M404876200; Hsueh YP, 2000, NATURE, V404, P298, DOI 10.1038/35005118; Hu LA, 2002, J BIOL CHEM, V277, P1607, DOI 10.1074/jbc.M107297200; Hu LYA, 2000, J BIOL CHEM, V275, P38659, DOI 10.1074/jbc.M005938200; Hu LYA, 2003, J BIOL CHEM, V278, P26295, DOI 10.1074/jbc.M212352200; Hung AY, 2002, J BIOL CHEM, V277, P5699, DOI 10.1074/jbc.R100065200; Kanai F, 2000, EMBO J, V19, P6778, DOI 10.1093/emboj/19.24.6778; Pak Y, 2002, MOL CELL BIOL, V22, P7942, DOI 10.1128/MCB.22.22.7942-7952.2002; Shiina T, 2000, J BIOL CHEM, V275, P29082, DOI 10.1074/jbc.M909757199; Shizukuda Y, 2002, J MOL CELL CARDIOL, V34, P823, DOI 10.1006/jmcc.2002.2020; SUZUKI T, 1992, MOL PHARMACOL, V41, P542; Tang YT, 1999, P NATL ACAD SCI USA, V96, P12559, DOI 10.1073/pnas.96.22.12559; Wang GS, 2004, NEURON, V42, P113, DOI 10.1016/S0896-6273(04)00139-4; Wu Y, 2000, J BIOL CHEM, V275, P21477, DOI 10.1074/jbc.M909741199; Xiang Y, 2002, J BIOL CHEM, V277, P33783, DOI 10.1074/jbc.M204136200; XIAO RP, 1994, J BIOL CHEM, V269, P19151; XIAO RP, 1993, CIRC RES, V73, P286, DOI 10.1161/01.RES.73.2.286; Xu JG, 2001, J BIOL CHEM, V276, P41310, DOI 10.1074/jbc.M107480200; Zaugg M, 2000, CIRCULATION, V102, P344	32	97	105	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 3	2006	281	5					2820	2827		10.1074/jbc.M509503200	http://dx.doi.org/10.1074/jbc.M509503200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	006XT	16316992	hybrid			2022-12-25	WOS:000234931800049
J	Taylor, J; Grote, SK; Xia, JR; Vandelft, M; Graczyk, J; Ellerby, LM; La Spada, AR; Truant, R				Taylor, J; Grote, SK; Xia, JR; Vandelft, M; Graczyk, J; Ellerby, LM; La Spada, AR; Truant, R			Ataxin-7 can export from the nucleus via a conserved exportin-dependent signal	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HISTONE ACETYLTRANSFERASE ACTIVITY; DOMINANT CEREBELLAR-ATAXIA; TATA-BINDING PROTEIN; EXPANDED POLYGLUTAMINE; RETINAL DEGENERATION; CELLULAR TOXICITY; ANDROGEN RECEPTOR; MUTANT ATAXIN-7; BETA-ARRESTINS; MESSENGER-RNA	Spinocerebellar ataxia type 7 is a progressive neurodegenerative disorder caused by a CAG DNA triplet repeat expansion leading to an expanded polyglutamine tract in the ataxin-7 protein. Ataxin-7 appears to be a transcription factor and a component of the STAGA transcription coactivator complex. Here, using live cell imaging and inverted fluorescence recovery after photobleaching, we demonstrate that ataxin-7 has the ability to export from the nucleus via the CRM-1/exportin pathway and that ataxin-7 contains a classic leucine-type nuclear export signal (NES). We have precisely defined the location of this NES in ataxin-7 and found it to be fully conserved in all vertebrate species. Polyglutamine expansion was seen to reduce the nuclear export rate of mutant ataxin-7 relative to wildtype ataxin-7. Subtle point mutation of the NES in polyglutamine expanded ataxin-7 increased toxicity in primary cerebellar neurons in a polyglutamine length-dependent manner in the context of full-length ataxin-7. Our results add ataxin-7 to a growing list of polyglutamine disease proteins that are capable of nuclear shuttling, and we define an activity of ataxin-7 in the STAGA complex of trafficking between the nucleus and cytoplasm.	McMaster Univ, Dept Biochem & Biomed Sci, Hamilton, ON L8N 3Z5, Canada; Univ Washington, Med Ctr, Dept Lab Med Med & Neurol, Seattle, WA 98195 USA; Univ Washington, Med Ctr, Ctr Neurogenet & Neurotherapeut, Seattle, WA 98195 USA; Buck Inst Age Res, Novato, CA 94945 USA	McMaster University; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; Buck Institute for Research on Aging	Truant, R (corresponding author), McMaster Univ, Dept Biochem & Biomed Sci, HSC4H45, Hamilton, ON L8N 3Z5, Canada.	truantr@mcmaster.ca	La Spada, Albert/AAG-8809-2020	Achenbach, Jillian/0000-0002-1054-3784; van Delft, Mark/0000-0002-3866-4318	NEI NIH HHS [EY14061] Funding Source: Medline; NINDS NIH HHS [NS40251A] Funding Source: Medline; NATIONAL EYE INSTITUTE [R01EY014061] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS040251] Funding Source: NIH RePORTER	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Abdullah AAR, 1998, HUM MOL GENET, V7, P379, DOI 10.1093/hmg/7.3.379; Arrasate M, 2004, NATURE, V431, P805, DOI 10.1038/nature02998; Bogerd HP, 1996, MOL CELL BIOL, V16, P4207; Bowman AB, 2005, HUM MOL GENET, V14, P679, DOI 10.1093/hmg/ddi064; Brand M, 1999, J BIOL CHEM, V274, P18285, DOI 10.1074/jbc.274.26.18285; Cancel G, 2000, BRAIN, V123, P2519, DOI 10.1093/brain/123.12.2519; Chai YH, 2002, P NATL ACAD SCI USA, V99, P9310, DOI 10.1073/pnas.152101299; Chen LF, 2003, J MOL MED, V81, P549, DOI 10.1007/s00109-003-0469-0; Chen SM, 2004, HUM MOL GENET, V13, P53, DOI 10.1093/hmg/ddh005; Cummings CJ, 2000, HUM MOL GENET, V9, P909, DOI 10.1093/hmg/9.6.909; David G, 1997, NAT GENET, V17, P65, DOI 10.1038/ng0997-65; ENEVOLDSON TP, 1994, BRAIN, V117, P445, DOI 10.1093/brain/117.3.445; Fornerod M, 1997, CELL, V90, P1051, DOI 10.1016/S0092-8674(00)80371-2; Fornerod Maarten, 2002, Results Probl Cell Differ, V35, P67; GAO WQ, 1991, NEURON, V6, P705, DOI 10.1016/0896-6273(91)90168-Y; Garden GA, 2002, J NEUROSCI, V22, P4897, DOI 10.1523/JNEUROSCI.22-12-04897.2002; Grote SK, 2003, CYTOGENET GENOME RES, V100, P164, DOI 10.1159/000072851; Helmlinger D, 2004, HUM MOL GENET, V13, P1257, DOI 10.1093/hmg/ddh139; Henderson BR, 2002, EMBO REP, V3, P834, DOI 10.1093/embo-reports/kvf181; Howell JL, 2002, BIOTECHNIQUES, V32, P80, DOI 10.2144/02321st04; Irwin S, 2005, J CELL SCI, V118, P233, DOI 10.1242/jcs.01611; Jacob AL, 2001, J BIOL CHEM, V276, P37659, DOI 10.1074/jbc.M104427200; JACQ X, 1994, CELL, V79, P107, DOI 10.1016/0092-8674(94)90404-9; Johnson C, 1999, EMBO J, V18, P6682, DOI 10.1093/emboj/18.23.6682; Kaytor MD, 1999, HUM MOL GENET, V8, P1657, DOI 10.1093/hmg/8.9.1657; Kim S, 2002, NAT CELL BIOL, V4, P826, DOI 10.1038/ncb863; la Cour T, 2003, NUCLEIC ACIDS RES, V31, P393, DOI 10.1093/nar/gkg101; La Spada AR, 2001, NEURON, V31, P913, DOI 10.1016/S0896-6273(01)00422-6; Lebre AS, 2003, CYTOGENET GENOME RES, V100, P154, DOI 10.1159/000072850; Lee JH, 2003, MOL CELLS, V16, P78; Martinez E, 2001, MOL CELL BIOL, V21, P6782, DOI 10.1128/MCB.21.20.6782-6795.2001; Matilla A, 2001, HUM MOL GENET, V10, P2821, DOI 10.1093/hmg/10.24.2821; Mauger C, 1999, MOL BRAIN RES, V74, P35, DOI 10.1016/S0169-328X(99)00256-9; McMahon SJ, 2005, P NATL ACAD SCI USA, V102, P8478, DOI 10.1073/pnas.0503493102; Mushegian AR, 2000, BIOCHEMISTRY-US, V39, P6809, DOI 10.1021/bi992694y; Nakamura K, 2001, HUM MOL GENET, V10, P1441, DOI 10.1093/hmg/10.14.1441; Nucifora FC, 2003, J BIOL CHEM, V278, P13047, DOI 10.1074/jbc.M211224200; Palhan VB, 2005, P NATL ACAD SCI USA, V102, P8472, DOI 10.1073/pnas.0503505102; Ralser M, 2005, J MOL BIOL, V346, P203, DOI 10.1016/j.jmb.2004.11.024; Rashevsky-Finkel A, 2001, J BIOL CHEM, V276, P44963, DOI 10.1074/jbc.M106112200; Ross CA, 1997, NEURON, V19, P1147, DOI 10.1016/S0896-6273(00)80405-5; Saporita AJ, 2003, J BIOL CHEM, V278, P41998, DOI 10.1074/jbc.M302460200; Schaffar G, 2004, MOL CELL, V15, P95, DOI 10.1016/j.molcel.2004.06.029; Scott MGH, 2002, J BIOL CHEM, V277, P37693, DOI 10.1074/jbc.M207552200; Slow EJ, 2005, CLIN GENET, V67, P228, DOI 10.1111/j.1399-0004.2005.00416.x; Stenoien DL, 2002, NAT CELL BIOL, V4, P806, DOI 10.1038/ncb859; TO KW, 1993, OPHTHALMOLOGY, V100, P15; Truant R, 2003, CLIN NEUROSCI RES, V3, P157, DOI 10.1016/S1566-2772(03)00058-6; Turpin P, 1999, FEBS LETT, V452, P82, DOI 10.1016/S0014-5793(99)00533-5; Voss TC, 2005, BIOTECHNIQUES, V38, P413, DOI 10.2144/05383RV01; Wang P, 2003, J BIOL CHEM, V278, P11648, DOI 10.1074/jbc.M208109200; Wolff B, 1997, CHEM BIOL, V4, P139, DOI 10.1016/S1074-5521(97)90257-X; Xia JR, 2003, HUM MOL GENET, V12, P1393, DOI 10.1093/hmg/ddg156; Yoo SY, 2003, NEURON, V37, P383, DOI 10.1016/S0896-6273(02)01190-X; Yvert G, 2001, HUM MOL GENET, V10, P1679, DOI 10.1093/hmg/10.16.1679; Zander C, 2001, HUM MOL GENET, V10, P2569, DOI 10.1093/hmg/10.22.2569	56	34	36	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 3	2006	281	5					2730	2739		10.1074/jbc.M506751200	http://dx.doi.org/10.1074/jbc.M506751200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	006XT	16314424	hybrid			2022-12-25	WOS:000234931800039
J	Wagner, TM; Mullally, JE; Fitzpatrick, FA				Wagner, TM; Mullally, JE; Fitzpatrick, FA			Reactive lipid species from cyclooxygenase-2 inactivate tumor suppressor LKB1/STK11 - Cyclopentenone prostaglandins and 4-hydroxy-2-nonenal covalently modify and inhibit the AMP-kinase kinase that modulates cellular energy homeostasis and protein translation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PEUTZ-JEGHERS-SYNDROME; KAPPA-B KINASE; WILD-TYPE P53; ELECTROPHILIC PROSTAGLANDINS; HAMARTOMATOUS POLYPS; MOLECULAR TARGET; IN-VIVO; LKB1; CANCER; GENES	LKB1, a unique serine/threonine kinase tumor suppressor, modulates anabolic and catabolic homeostasis, cell proliferation, and organ polarity. Chemically reactive lipids, e. g. cyclopentenone prostaglandins, formed a covalent adduct with LKB1 in MCF-7 and RKO cells. Site-directed mutagenesis implicated Cys(210) in the LKB1 activation loop as the residue modified. Notably, ERK, JNK, and AKT serine/threonine kinases with leucine or methionine, instead of cysteine, in their activation loop did not form a covalent lipid adduct. 4-Hydroxy-2-nonenal, 4-oxo-2-nonenal, and cyclopentenone prostaglandin A and J, which all contain alpha,beta-unsaturated carbonyls, inhibited the AMP-kinase kinase activity of cellular LKB1. In turn, this attenuated signals throughout the LKB1 3 AMP kinase pathway and disrupted its restraint of ribosomal S6 kinases. The electrophilic beta-carbon in these lipids appears to be critical for inhibition because unreactive lipids, e. g. PGB(1), PGE(2), PGF(2)alpha, and TxB(2), did not inhibit LKB1 activity (p > 0.05). Ectopic expression of cyclooxygenase-2 and endogenous biosynthesis of eicosanoids also inhibited LKB1 activity in MCF-7 cells. Our results suggested a molecular mechanism whereby chronic inflammation or oxidative stress may confer risk for hypertrophic or neoplastic diseases. Moreover, chemical inactivation of LKB1 may interfere with its physiological antagonism of signals from growth factors, insulin, and oncogenes.	Univ Utah, Dee Glenn & Ida W Smith Chair Canc Res, Huntsman Canc Inst, Dept Med Chem, Salt Lake City, UT 84112 USA	Huntsman Cancer Institute; Utah System of Higher Education; University of Utah	Fitzpatrick, FA (corresponding author), Univ Utah, Dee Glenn & Ida W Smith Chair Canc Res, Huntsman Canc Inst, Dept Med Chem, 2000 Circle Hope, Salt Lake City, UT 84112 USA.	frank.fitzpatrick@hci.utah.edu			NCI NIH HHS [P01 CA73992] Funding Source: Medline; NIAID NIH HHS [R01 AI26730] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA073992] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI026730] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Alderton AL, 2003, BIOCHEMISTRY-US, V42, P4398, DOI 10.1021/bi0271695; Avizienyte E, 1999, AM J PATHOL, V154, P677, DOI 10.1016/S0002-9440(10)65314-X; Brugarolas J, 2004, CANCER CELL, V6, P7, DOI 10.1016/j.ccr.2004.06.020; Cernuda-Morollon E, 2001, J BIOL CHEM, V276, P35530, DOI 10.1074/jbc.M104518200; Chen Y, 1999, J BIOL CHEM, V274, P10863, DOI 10.1074/jbc.274.16.10863; Chen Y, 1999, BBA-MOL CELL BIOL L, V1436, P550, DOI 10.1016/S0005-2760(98)00168-4; Cook WD, 2000, ONCOGENE, V19, P3434, DOI 10.1038/sj.onc.1203653; CORTON JM, 1995, EUR J BIOCHEM, V229, P558, DOI 10.1111/j.1432-1033.1995.0558k.x; Crabb JW, 2002, PROTEIN SCI, V11, P831, DOI 10.1110/ps.4400102; de Leng WWJ, 2003, CLIN CANCER RES, V9, P3065; Entius MM, 2001, J CLIN PATHOL, V54, P126, DOI 10.1136/jcp.54.2.126; Esteller M, 2000, ONCOGENE, V19, P164, DOI 10.1038/sj.onc.1203227; ESTERBAUER H, 1990, MUTAT RES, V238, P223, DOI 10.1016/0165-1110(90)90014-3; Fero ML, 1998, NATURE, V396, P177, DOI 10.1038/24179; Fitzpatrick FA, 2001, INT IMMUNOPHARMACOL, V1, P1651, DOI 10.1016/S1567-5769(01)00102-3; Ghaffar H, 2003, CLIN CANCER RES, V9, P2998; GIARDIELLO FM, 1987, NEW ENGL J MED, V316, P1511, DOI 10.1056/NEJM198706113162404; HANSEN MF, 1988, CELL, V53, P172, DOI 10.1016/0092-8674(88)90376-5; Hardie DG, 2004, J CELL SCI, V117, P5479, DOI 10.1242/jcs.01540; Hemminki A, 1998, NATURE, V391, P184, DOI 10.1038/34432; Hortelano S, 2000, J IMMUNOL, V165, P6525, DOI 10.4049/jimmunol.165.11.6525; Jenne DE, 1998, NAT GENET, V18, P38, DOI 10.1038/ng0198-38; Ji C, 2001, J BIOL CHEM, V276, P18223, DOI 10.1074/jbc.M101266200; Jones PA, 1999, NAT GENET, V21, P163, DOI 10.1038/5947; KNUDSON AG, 1971, P NATL ACAD SCI USA, V68, P820, DOI 10.1073/pnas.68.4.820; Knudson AG, 2002, AM J MED GENET, V111, P96, DOI 10.1002/ajmg.10320; Kwabi-Addo B, 2001, P NATL ACAD SCI USA, V98, P11563, DOI 10.1073/pnas.201167798; KYRIAKIS JM, 2003, J BIOL, V2; Lawrence T, 2002, NAT REV IMMUNOL, V2, P787, DOI 10.1038/nri915; Levonen AL, 2004, BIOCHEM J, V378, P373, DOI 10.1042/BJ20031049; Liu XH, 1996, CANCER RES, V56, P5125; Lizcano JM, 2004, EMBO J, V23, P833, DOI 10.1038/sj.emboj.7600110; Moos PJ, 2000, P NATL ACAD SCI USA, V97, P9215, DOI 10.1073/pnas.160241897; Moos PJ, 2003, J BIOL CHEM, V278, P745, DOI 10.1074/jbc.M211134200; Paige AJW, 2003, CELL MOL LIFE SCI, V60, P2147, DOI 10.1007/s00018-003-3027-6; Rossi A, 2000, NATURE, V403, P103, DOI 10.1038/47520; Santarosa M, 2004, BBA-REV CANCER, V1654, P105, DOI 10.1016/j.bbcan.2004.01.001; Shaw RJ, 2004, P NATL ACAD SCI USA, V101, P3329, DOI 10.1073/pnas.0308061100; Shen Z, 2002, CLIN CANCER RES, V8, P2085; Shibata T, 2002, J BIOL CHEM, V277, P10459, DOI 10.1074/jbc.M110314200; Shibata T, 2003, J BIOL CHEM, V278, P26046, DOI 10.1074/jbc.M303690200; Straus DS, 2000, P NATL ACAD SCI USA, V97, P4844, DOI 10.1073/pnas.97.9.4844; Tee AR, 2005, SEMIN CELL DEV BIOL, V16, P29, DOI 10.1016/j.semcdb.2004.11.005; Thun Michael J, 2004, Novartis Found Symp, V256, P6; Venkatachalam S, 1998, EMBO J, V17, P4657, DOI 10.1093/emboj/17.16.4657; Vogelstein B, 2004, NAT MED, V10, P789, DOI 10.1038/nm1087; Wang ZJ, 1999, J PATHOL, V188, P9, DOI 10.1002/(SICI)1096-9896(199905)188:1<9::AID-PATH326>3.0.CO;2-E; Watkins SJ, 2002, BRIT J CANCER, V86, P1023, DOI 10.1038/sj/bjc/6600222; Wei CJ, 2003, J HISTOCHEM CYTOCHEM, V51, P1665, DOI 10.1177/002215540305101210; Woods A, 2003, CURR BIOL, V13, P2004, DOI 10.1016/j.cub.2003.10.031	50	58	59	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 3	2006	281	5					2598	2604		10.1074/jbc.M509723200	http://dx.doi.org/10.1074/jbc.M509723200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	006XT	16311241	hybrid			2022-12-25	WOS:000234931800023
J	Smith, JP; Drewes, LR				Smith, JP; Drewes, LR			Modulation of monocarboxylic acid transporter-1 kinetic function by the cAMP signaling pathway in rat brain endothelial cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTRACELLULAR PH INDICATOR; DEPENDENT PROTEIN-KINASE; XENOPUS-LAEVIS OOCYTES; INHIBITOR SPECIFICITY; LACTATE TRANSPORTER; NA/H EXCHANGER; EXPRESSION; SUBSTRATE; GLUCOSE; FAMILY	MCT1 ( monocarboxylic acid transporter 1) facilitates bidirectional monocarboxylic acid transport across membranes. MCT1 function and regulation have not been characterized previously in cerebral endothelial cells but may be important during normal cerebral energy metabolism and during brain diseases such as stroke. Here, by using the cytoplasmic pH indicator 2',7'-bis-(2-carboxyethyl)-5-(and-6)-carboxyfluorescein-acetoxymethyl ester, the initial rates of monocarboxylate-dependent cytoplasmic acidification were measured as an indication of MCT1 kinetic function in vitro using the rat brain endothelial cell (RBE4) model of blood-brain transport. The initial rate of L-lactate-dependent acidification was significantly inhibited by 5-10-min incubations with agonists of intracellular cAMP-dependent cell signaling pathways as follows: dibutyryl cAMP, forskolin, and isoproterenol. Isoproterenol reduced V-max but did not affect K-m values. The effects of forskolin were completely reversed by the protein kinase A inhibitor H89, whereas H89 alone increased transport rates. Cytoplasmic cAMP levels, measured by radioimmunoassay, were increased by forskolin or isoproterenol, and the effect of isoproterenol was inhibited by propranolol. MCT1-independent intracellular pH control mechanisms did not contribute to the forskolin or H89 effects on MCT1 kinetic function as determined with amiloride, monocarboxylate-independent acid loading, or the transport inhibitor alpha-cyano-4-hydroxycinnamate. The data demonstrate the direct modulation of MCT1 kinetic function in cerebral endothelial cells by agents known to affect the beta-adrenergic receptor/adenylyl cyclase/cAMP/protein kinase A intracellular signaling pathway.	Univ Minnesota, Sch Med, Dept Biochem & Mol Biol, Duluth, MN 55812 USA	University of Minnesota System; University of Minnesota Duluth	Drewes, LR (corresponding author), Univ Minnesota, Sch Med, Dept Biochem & Mol Biol, 1035 Univ Dr, Duluth, MN 55812 USA.	ldrewes@d.umn.edu	Drewes, Lester R/X-9794-2018	Drewes, Lester R/0000-0002-7440-0387	NINDS NIH HHS [NS 37764] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS037764] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		AZARANI A, 1995, J BIOL CHEM, V270, P23166, DOI 10.1074/jbc.270.39.23166; BORON WF, 1992, KIDNEY, V2, P219; Broer S, 1999, BIOCHEM J, V341, P529, DOI 10.1042/0264-6021:3410529; Broer S, 1998, BIOCHEM J, V333, P167, DOI 10.1042/bj3330167; Buyse M, 2002, J BIOL CHEM, V277, P28182, DOI 10.1074/jbc.M203281200; CARPENTER L, 1994, BIOCHEM J, V304, P751, DOI 10.1042/bj3040751; CASNOCHA SA, 1989, J APPL PHYSIOL, V67, P1997, DOI 10.1152/jappl.1989.67.5.1997; Cloherty EK, 1996, BIOCHEMISTRY-US, V35, P13231, DOI 10.1021/bi961208t; DREWES LR, 1973, J BIOL CHEM, V248, P2489; Drewes LR, 1999, ALFRED BENZON SYMP S, V45, P285; Enerson BE, 2003, J PHARM SCI-US, V92, P1531, DOI 10.1002/jps.10389; Fan J, 1996, P NATL ACAD SCI USA, V93, P5527, DOI 10.1073/pnas.93.11.5527; Fanelli A, 2003, AM J PHYSIOL-ENDOC M, V285, pE1223, DOI 10.1152/ajpendo.00172.2003; Gerhart DZ, 1997, AM J PHYSIOL-ENDOC M, V273, pE207, DOI 10.1152/ajpendo.1997.273.1.E207; Gerhart DZ, 1998, GLIA, V22, P272; Halestrap AP, 1999, BIOCHEM J, V343, P281, DOI 10.1042/0264-6021:3430281; Halestrap AP, 2004, PFLUG ARCH EUR J PHY, V447, P619, DOI 10.1007/s00424-003-1067-2; Heard KS, 2000, BIOCHEMISTRY-US, V39, P3005, DOI 10.1021/bi991931u; Jackson VN, 1996, J BIOL CHEM, V271, P861, DOI 10.1074/jbc.271.2.861; Kurashima K, 1997, J BIOL CHEM, V272, P28672, DOI 10.1074/jbc.272.45.28672; Leino RL, 1999, DEV BRAIN RES, V113, P47, DOI 10.1016/S0165-3806(98)00188-6; Lum H, 1999, AM J PHYSIOL-CELL PH, V277, pC580, DOI 10.1152/ajpcell.1999.277.3.C580; MARTIN RL, 1994, TRENDS NEUROSCI, V17, P251, DOI 10.1016/0166-2236(94)90008-6; Montminy M, 1997, ANNU REV BIOCHEM, V66, P807, DOI 10.1146/annurev.biochem.66.1.807; ORLOWSKI J, 1993, J BIOL CHEM, V268, P16369; Pierre K, 2005, J NEUROCHEM, V94, P1, DOI 10.1111/j.1471-4159.2005.03168.x; Pierre K, 2002, J CEREBR BLOOD F MET, V22, P586, DOI 10.1097/00004647-200205000-00010; POOLE RC, 1993, AM J PHYSIOL, V264, pC761, DOI 10.1152/ajpcell.1993.264.4.C761; ROUX F, 1994, J CELL PHYSIOL, V159, P101, DOI 10.1002/jcp.1041590114; Tasken K, 1997, ADV SEC MESS PHOSPH, V31, P191; Tasken K, 2004, PHYSIOL REV, V84, P137, DOI 10.1152/physrev.00021.2003; TAYLOR SS, 1993, PHILOS T ROY SOC B, V340, P315, DOI 10.1098/rstb.1993.0073; THOMAS JA, 1979, BIOCHEMISTRY-US, V18, P2210, DOI 10.1021/bi00578a012; Wain HM, 2002, GENOMICS, V79, P464, DOI 10.1006/geno.2002.6748; WANG XM, 1994, AM J PHYSIOL-HEART C, V267, pH1759, DOI 10.1152/ajpheart.1994.267.5.H1759; Zhao H, 1999, J BIOL CHEM, V274, P3978, DOI 10.1074/jbc.274.7.3978; ZINK S, 1995, AM J PHYSIOL-CELL PH, V269, pC1209, DOI 10.1152/ajpcell.1995.269.5.C1209	37	28	28	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 27	2006	281	4					2053	2060		10.1074/jbc.M511577200	http://dx.doi.org/10.1074/jbc.M511577200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	004NV	16301311	hybrid			2022-12-25	WOS:000234760400026
J	Wang, Z; Rong, YP; Malone, MH; Davis, MC; Zhong, F; Distelhorst, CW				Wang, Z; Rong, YP; Malone, MH; Davis, MC; Zhong, F; Distelhorst, CW			Thioredoxin-interacting protein (txnip) is a glucocorticoid-regulated primary response gene involved in mediating glucocorticoid-induced apoptosis	ONCOGENE			English	Article						glucocorticoid; apoptosis; lymphoma; dexamethasone-induced gene; thioredoxin-interacting protein; txnip	LEUKEMIC-CELLS; OXIDATIVE STRESS; T-CELLS; IN-VIVO; RECEPTOR; EXPRESSION; ACTIVATION; DEATH; IDENTIFICATION; DEXAMETHASONE	Glucocorticoid hormones induce apoptosis in lymphoid cells. This process is transcriptionally regulated and requires de novo RNA/protein synthesis. However, the full spectrum of glucocorticoid-regulated genes mediating this cell death process is unknown. Through gene expression pro. ling we discovered that the expression of thioredoxin-intereacting protein (txnip) mRNA is significantly induced by the glucocorticoid hormone dexamethasone not only in the murine T-cell lymphoma line WEHI7.2, but also in normal mouse thymocytes. This result was confirmed by Northern blot analysis in multiple models of dexamethasone-induced apoptosis. The induction of txnip mRNA by dexamethasone appears to be mediated through the glucocorticoid receptor as it is blocked in the presence of RU486, a glucocorticoid receptor antagonist. Deletion and mutation analysis of the txnip promoter identified a functional glucocorticoid response element in the txnip promoter. Reporter assays demonstrated that this glucocorticoid response element was necessary and sufficient for induction of txnip by dexamethasone. Expression of a GFP-TXNIP fusion protein was sufficient to induce apoptosis in WEHI7.2 cells, and repression of endogenous txnip by RNA interference inhibited dexamethasone-induced apoptosis in WEHI7.2 cells. Together, these findings indicate that txnip is a novel glucocorticoid-induced primary target gene involved in mediating glucocorticoid- induced apoptosis.	Case Western Reserve Univ, Sch Med, Ctr Comprehens Canc, Dept Med, Cleveland, OH 44106 USA; Case Western Reserve Univ, Sch Med, Ctr Comprehens Canc, Dept Pharmacol, Cleveland, OH 44106 USA; Univ Hosp Cleveland, Cleveland, OH 44106 USA	Case Western Reserve University; Case Western Reserve University; University Hospitals of Cleveland	Distelhorst, CW (corresponding author), Case Western Reserve Univ, Sch Med, Ctr Comprehens Canc, Dept Med, WRB 3-133,10900 Euclid Ave, Cleveland, OH 44106 USA.	cwd@case.edu	Davis, Michael C/L-8920-2013	Davis, Michael C/0000-0003-2293-5694	NCI NIH HHS [CP30 CA43703, T32 CA59366, R01 CA42755] Funding Source: Medline; NHLBI NIH HHS [T32 HL07147] Funding Source: Medline; NATIONAL CANCER INSTITUTE [T32CA059366, P30CA043703, R01CA042755] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [T32HL007147] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Ashwell JD, 2000, ANNU REV IMMUNOL, V18, P309, DOI 10.1146/annurev.immunol.18.1.309; Baker A, 1997, CANCER RES, V57, P5162; Butler LM, 2002, P NATL ACAD SCI USA, V99, P11700, DOI 10.1073/pnas.182372299; CAIRNS C, 1991, MOL ENDOCRINOL, V5, P598, DOI 10.1210/mend-5-4-598; Chapman MS, 1996, MOL ENDOCRINOL, V10, P967, DOI 10.1210/me.10.8.967; Chauhan D, 2002, ONCOGENE, V21, P1346, DOI 10.1038/sj.onc.1205205; CHEN KS, 1994, BBA-GENE STRUCT EXPR, V1219, P26, DOI 10.1016/0167-4781(94)90242-9; COHEN JJ, 1984, J IMMUNOL, V132, P38; DIEKEN ES, 1992, MOL CELL BIOL, V12, P589, DOI 10.1128/MCB.12.2.589; Han SH, 2003, ONCOGENE, V22, P4035, DOI 10.1038/sj.onc.1206610; HARMON JM, 1979, J CELL PHYSIOL, V98, P267, DOI 10.1002/jcp.1040980203; HELMBERG A, 1995, EMBO J, V14, P452, DOI 10.1002/j.1460-2075.1995.tb07021.x; Jondal M, 2004, TRENDS IMMUNOL, V25, P595, DOI 10.1016/j.it.2004.09.003; Junn E, 2000, J IMMUNOL, V164, P6287, DOI 10.4049/jimmunol.164.12.6287; Kim KY, 2004, BIOCHEM BIOPH RES CO, V315, P369, DOI 10.1016/j.bbrc.2004.01.047; Malone MH, 2004, J BIOL CHEM, V279, P52850, DOI 10.1074/jbc.M408040200; Minn AH, 2005, ENDOCRINOLOGY, V146, P2397, DOI 10.1210/en.2004-1378; Mullick J, 2001, J BIOL CHEM, V276, P18007, DOI 10.1074/jbc.M100671200; Nishinaka Y, 2001, REDOX REP, V6, P289, DOI 10.1179/135100001101536427; Nishiyama A, 1999, J BIOL CHEM, V274, P21645, DOI 10.1074/jbc.274.31.21645; NORDEEN SK, 1990, MOL ENDOCRINOL, V4, P1866, DOI 10.1210/mend-4-12-1866; Oberg HH, 2004, CELL DEATH DIFFER, V11, P674, DOI 10.1038/sj.cdd.4401407; Park CG, 1996, IMMUNITY, V4, P583, DOI 10.1016/S1074-7613(00)80484-7; Planey SL, 2003, CANCER RES, V63, P172; Powis G, 2001, ANNU REV BIOPH BIOM, V30, P421, DOI 10.1146/annurev.biophys.30.1.421; Prefontaine GG, 1998, MOL CELL BIOL, V18, P3416, DOI 10.1128/MCB.18.6.3416; Qian N, 1997, HUM MOL GENET, V6, P2021, DOI 10.1093/hmg/6.12.2021; Ramdas J, 1998, ENDOCRINOLOGY, V139, P3813, DOI 10.1210/en.139.9.3813; Reichardt HM, 1998, CELL, V93, P531, DOI 10.1016/S0092-8674(00)81183-6; Rho J, 2001, MOL CELL BIOL, V21, P8365, DOI 10.1128/MCB.21.24.8365-8370.2001; Saitoh T, 2001, J NEUROCHEM, V78, P1267, DOI 10.1046/j.1471-4159.2001.00505.x; Schmidt S, 2004, CELL DEATH DIFFER, V11, pS45, DOI 10.1038/sj.cdd.4401456; Schoneveld OJLM, 2004, BBA-GENE STRUCT EXPR, V1680, P114, DOI 10.1016/j.bbaexp.2004.09.004; Thompson EB, 1998, STEROIDS, V63, P368, DOI 10.1016/S0039-128X(98)00045-2; Tome ME, 2001, CANCER RES, V61, P2766; Tonomura N, 2003, J IMMUNOL, V170, P2469, DOI 10.4049/jimmunol.170.5.2469; Torres-Roca JF, 2000, J IMMUNOL, V165, P4822, DOI 10.4049/jimmunol.165.9.4822; TRUSS M, 1990, P NATL ACAD SCI USA, V87, P7180, DOI 10.1073/pnas.87.18.7180; Wang RX, 1998, J IMMUNOL, V161, P2201; Wang YL, 2002, J BIOL CHEM, V277, P26496, DOI 10.1074/jbc.M202133200; Wang ZQ, 2003, J BIOL CHEM, V278, P23861, DOI 10.1074/jbc.M301843200; Wang ZQ, 2003, J BIOL CHEM, V278, P27053, DOI 10.1074/jbc.M303723200; Webb MS, 2003, J STEROID BIOCHEM, V85, P183, DOI 10.1016/S0960-0760(03)00194-8; WYLLIE AH, 1984, J PATHOL, V142, P67, DOI 10.1002/path.1711420112; WYLLIE AH, 1980, NATURE, V284, P555, DOI 10.1038/284555a0; Yamawaki H, 2005, J CLIN INVEST, V115, P733, DOI 10.1172/JCI200523001	46	87	87	1	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 23	2006	25	13					1903	1913		10.1038/sj.onc.1209218	http://dx.doi.org/10.1038/sj.onc.1209218			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	024VQ	16301999				2022-12-25	WOS:000236224800007
J	Proia, DA; Nannenga, BW; Donehower, LA; Weigel, NL				Proia, DA; Nannenga, BW; Donehower, LA; Weigel, NL			Dual roles for the phosphatase PPM1D in regulating progesterone receptor function	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-KINASE; LIGAND-INDEPENDENT ACTIVATION; PHOSPHORYLATION SITES; ANDROGEN RECEPTOR; WIP1; TRANSCRIPTION; COACTIVATOR; HORMONE; P38; PROMOTER	Although protein phosphatase magnesium-dependent 1 delta (PPM1D) was initially characterized as a p53-regulated phosphatase responsible for inactivation of p38 MAPK and consequent inactivation of p53, its overexpression and amplification in human breast cancers led us to assess its role in steroid hormone action. We found that PPM1D stimulated the activity of several nuclear receptors including the progesterone receptor ( PR) and estrogen receptor. Although p38 MAPK inhibited PR activity, PPM1D stimulation of PR activity was greater than that achieved by a chemical inhibitor of p38 MAPK, SB202190. This suggests an additional novel function for PPM1D. Consistent with this, the transcriptional activity of endogenous PR in MCF-7 breast cancer cells was preferentially inhibited by small interfering RNA for PPM1D; SB202190 failed to reverse the inhibition. Although PPM1D phosphatase activity was required for stimulation of transcriptional activity, the activity of a PR phosphorylation site null mutant was enhanced by PPM1D, indicating that PR is not the direct target. Additional studies revealed that PPM1D enhanced the intrinsic activity of p160 coactivators such as steroid receptor coactivator-1 and promoted the interaction between PR and steroid receptor coactivator-1 in a mammalian two-hybrid assay. Neither activity was induced by SB202190. Although PPM1D stimulated PR activity in part through inhibition of p38 MAPK, its primary action is novel and independent of p38 MAPK. Thus, we speculate that PPM1D promotes breast tumor growth both by inhibiting p53 activity and by enhancing steroid hormone receptor action.	Baylor Coll Med, Dept Mol & Cellular Biol, Houston, TX 77030 USA; Baylor Coll Med, Dept Microbiol & Virol, Houston, TX 77030 USA	Baylor College of Medicine; Baylor College of Medicine	Weigel, NL (corresponding author), Baylor Coll Med, Dept Mol & Cellular Biol, 1 Baylor Plaza, Houston, TX 77030 USA.	nweigel@bcm.tmc.edu			EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [T32HD007165] Funding Source: NIH RePORTER; NATIONAL CANCER INSTITUTE [R01CA057539, R55CA057539, R01CA100420] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA 100420, CA 57539] Funding Source: Medline; NICHD NIH HHS [T32 HD 07165] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		Agoulnik IU, 2003, J BIOL CHEM, V278, P31136, DOI 10.1074/jbc.M305153200; ARCHER TK, 1992, SCIENCE, V255, P1573, DOI 10.1126/science.1347958; Bai WL, 1996, J BIOL CHEM, V271, P12801, DOI 10.1074/jbc.271.22.12801; BECK CA, 1992, MOL ENDOCRINOL, V6, P607, DOI 10.1210/me.6.4.607; Belova GI, 2005, CANCER BIOL THER, V4, P1154, DOI 10.4161/cbt.4.10.2204; BROU C, 1993, EMBO J, V12, P489, DOI 10.1002/j.1460-2075.1993.tb05681.x; Bulavin DV, 2004, NAT GENET, V36, P343, DOI 10.1038/ng1317; Bulavin DV, 2002, NAT GENET, V31, P210, DOI 10.1038/ng894; Bulavin DV, 2002, CURR OPIN GENET DEV, V12, P92, DOI 10.1016/S0959-437X(01)00270-2; Bulavin DV, 2001, NATURE, V411, P102, DOI 10.1038/35075107; Cheng SW, 2000, COMB OPT (SER), V6, P137; Choi J, 2000, GENOMICS, V64, P298, DOI 10.1006/geno.2000.6134; Choi J, 2002, MOL CELL BIOL, V22, P1094, DOI 10.1128/MCB.22.4.1094-1105.2002; Connor JH, 1998, J BIOL CHEM, V273, P27716, DOI 10.1074/jbc.273.42.27716; Fiscella M, 1997, P NATL ACAD SCI USA, V94, P6048, DOI 10.1073/pnas.94.12.6048; KASTNER P, 1990, J BIOL CHEM, V265, P12163; KASTNER P, 1990, EMBO J, V9, P1603, DOI 10.1002/j.1460-2075.1990.tb08280.x; Knotts TA, 2001, J BIOL CHEM, V276, P8475, DOI 10.1074/jbc.M009805200; Lange CA, 2000, P NATL ACAD SCI USA, V97, P1032, DOI 10.1073/pnas.97.3.1032; Li J, 2002, NAT GENET, V31, P133, DOI 10.1038/ng888; Lonard DM, 2000, MOL CELL, V5, P939, DOI 10.1016/S1097-2765(00)80259-2; Lopez GN, 2001, J BIOL CHEM, V276, P22177, DOI 10.1074/jbc.M010718200; Lu Q, 2003, J BIOL CHEM, V278, P4639, DOI 10.1074/jbc.M210949200; Lu XB, 2005, GENE DEV, V19, P1162, DOI 10.1101/gad.1291305; Lu XB, 2004, MOL CELL, V15, P621, DOI 10.1016/j.molcel.2004.08.007; Ma ZQ, 2001, MOL CELL BIOL, V21, P8056, DOI 10.1128/MCB.21.23.8056-8067.2001; McKenna NJ, 2002, ENDOCRINOLOGY, V143, P2461, DOI 10.1210/endo.143.7.8892; MEYER ME, 1992, J BIOL CHEM, V267, P10882; Mulac-Jericevic B, 2000, SCIENCE, V289, P1751, DOI 10.1126/science.289.5485.1751; Mulac-Jericevic B, 2003, P NATL ACAD SCI USA, V100, P9744, DOI 10.1073/pnas.1732707100; Narayanan R, 2005, MOL CELL BIOL, V25, P2885, DOI 10.1128/MCB.25.8.2885-2898.2005; Narayanan R, 2005, MOL CELL BIOL, V25, P264, DOI 10.1128/MCB.25.1.264-277.2005; Nawaz Z, 1999, P NATL ACAD SCI USA, V96, P1858, DOI 10.1073/pnas.96.5.1858; Nazareth LV, 1996, J BIOL CHEM, V271, P19900, DOI 10.1074/jbc.271.33.19900; Onate SA, 1998, J BIOL CHEM, V273, P12101, DOI 10.1074/jbc.273.20.12101; Pramanik R, 2003, J BIOL CHEM, V278, P4831, DOI 10.1074/jbc.M207732200; Rowan BG, 2000, MOL CELL BIOL, V20, P8720, DOI 10.1128/MCB.20.23.8720-8730.2000; Rowan BG, 2000, J BIOL CHEM, V275, P4475, DOI 10.1074/jbc.275.6.4475; Stallcup MR, 2003, J STEROID BIOCHEM, V85, P139, DOI 10.1016/S0960-0760(03)00222-X; Takekawa M, 2000, EMBO J, V19, P6517, DOI 10.1093/emboj/19.23.6517; Tetel MJ, 1999, MOL ENDOCRINOL, V13, P910, DOI 10.1210/me.13.6.910; VEGETO E, 1993, MOL ENDOCRINOL, V7, P1244, DOI 10.1210/me.7.10.1244; Weigel NL, 1998, J MOL MED, V76, P469, DOI 10.1007/s001090050241; Weigel NL, 1996, BIOCHEM J, V319, P657, DOI 10.1042/bj3190657; Wu RC, 2004, MOL CELL, V15, P937, DOI 10.1016/j.molcel.2004.08.019; Yamaguchi H, 2005, BIOCHEMISTRY-US, V44, P5285, DOI 10.1021/bi0476634; Yang WB, 2001, J BIOL CHEM, V276, P38341, DOI 10.1074/jbc.C100316200; Yeh SY, 2002, P NATL ACAD SCI USA, V99, P13498, DOI 10.1073/pnas.212474399; ZHANG YX, 1994, MOL ENDOCRINOL, V8, P577, DOI 10.1210/me.8.5.577; Zhang YX, 1997, MOL ENDOCRINOL, V11, P823, DOI 10.1210/me.11.6.823; Zou AH, 1997, J BIOL CHEM, V272, P19027, DOI 10.1074/jbc.272.30.19027; Zuo Z, 1999, BIOCHEMISTRY-US, V38, P8849, DOI 10.1021/bi990842e	52	23	25	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 17	2006	281	11					7089	7101		10.1074/jbc.M511839200	http://dx.doi.org/10.1074/jbc.M511839200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	022BY	16352595	hybrid			2022-12-25	WOS:000236030900023
J	Baechle, D; Flad, T; Cansier, A; Steffen, H; Schittek, B; Tolson, J; Herrmann, T; Dihazi, H; Beck, A; Mueller, GA; Mueller, M; Stevanovic, S; Garbe, C; Mueller, CA; Kalbacher, H				Baechle, D; Flad, T; Cansier, A; Steffen, H; Schittek, B; Tolson, J; Herrmann, T; Dihazi, H; Beck, A; Mueller, GA; Mueller, M; Stevanovic, S; Garbe, C; Mueller, CA; Kalbacher, H			Cathepsin D is present in human eccrine sweat and involved in the postsecretory processing of the antimicrobial peptide DCD-1L	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYSTATIN M/E EXPRESSION; HUMAN SKIN; ATOPIC-DERMATITIS; INNATE DEFENSE; GLANDS; KERATINOCYTES; CATHELICIDINS; INFECTION; DERMCIDIN; PURIFICATION	The protein pattern of healthy human eccrine sweat was investigated and 10 major proteins were detected from which apolipoprotein D, lipophilin B, and cathepsin D ( CatD) were identified for the first time in human eccrine sweat. We focused our studies on the function of the aspartate protease CatD in sweat. In vitro digestion experiments using a specific fluorescent CatD substrate showed that CatD is enzymatically active in human sweat. To identify potential substrates of CatD in human eccrine sweat LL-37 and DCD-1L, two antimicrobial peptides present in sweat, were digested in vitro with purified CatD. LL-37 was not significantly digested by CatD, whereas DCD-1L was cleaved between Leu(44) and Asp(45) and between Leu(29) and Glu(30) almost completely. The DCD-1L-derived peptides generated in vitro by CatD were also found in vivo in human sweat as determined by surface-enhanced laser desorption/ ionization (SELDI) mass spectrometry. Furthermore, besides the CatD-processed peptides we identified additionally DCD-1L-derived peptides that are generated upon cleavage with a 1,10-phenanthroline- sensitive carboxypeptidase and an endoprotease. Taken together, proteolytic processing generates 12 DCD-1L-derived peptides. To elucidate the functional significance of postsecretory processing the antimicrobial activity of three CatD-processed DCD-1L peptides was tested. Whereas two of these peptides showed no activity against Gram-positive and Gram-negative bacteria, one DCD-1L-derived peptide showed an even higher activity against Escherichia coli than DCD-1L. Functional analysis indicated that proteolytic processing of DCD-1L by CatD in human sweat modulates the innate immune defense of human skin.	Univ Tubingen, Med & Nat Sci Res Ctr, D-72074 Tubingen, Germany; Univ Tubingen, Sect Transplantat Immunol & Immunohematol, D-72072 Tubingen, Germany; Univ Tubingen, Dept Dermatol, D-72076 Tubingen, Germany; Univ Tubingen, Dept Immunol, D-72076 Tubingen, Germany; Univ Hosp Gottingen, Dept Nephrol & Rheumatol, D-37075 Gottingen, Germany; Univ Tubingen Hosp, Dept Internal Med 4, Div Clin Chem, D-72076 Tubingen, Germany	Eberhard Karls University of Tubingen; Eberhard Karls University of Tubingen; Eberhard Karls University of Tubingen; Eberhard Karls University Hospital; Eberhard Karls University of Tubingen; University of Gottingen; Eberhard Karls University of Tubingen; Eberhard Karls University Hospital	Kalbacher, H (corresponding author), Ob Himmelreich 7, D-72074 Tubingen, Germany.	kalbacher@uni-tuebingen.de	Garbe, Claus/ABH-2128-2021	Garbe, Claus/0000-0001-8530-780X; Schittek, Birgit/0000-0003-0081-2001				Algermissen B, 1996, ARCH DERMATOL RES, V288, P426, DOI 10.1007/BF02505229; Ali RS, 2001, J INVEST DERMATOL, V117, P106; Baechle D, 2005, J PEPT SCI, V11, P166, DOI 10.1002/psc.607; Chen SH, 2000, FASEB J, V14, P565, DOI 10.1096/fasebj.14.3.565; DAHER KA, 1988, P NATL ACAD SCI USA, V85, P7327, DOI 10.1073/pnas.85.19.7327; FIELDS C G, 1991, Peptide Research, V4, P95; Flad T, 2002, J IMMUNOL METHODS, V270, P53, DOI 10.1016/S0022-1759(02)00229-6; Frohm M, 1997, J BIOL CHEM, V272, P15258, DOI 10.1074/jbc.272.24.15258; Glaser R, 2005, NAT IMMUNOL, V6, P57, DOI 10.1038/ni1142; Harder J, 1997, NATURE, V387, P861, DOI 10.1038/43088; HIBINO T, 1994, J INVEST DERMATOL, V102, P214, DOI 10.1111/1523-1747.ep12371765; HORIE N, 1986, AM J PHYSIOL, V250, pR691, DOI 10.1152/ajpregu.1986.250.4.R691; Kishi T, 2004, CLIN CHEM, V50, P709, DOI 10.1373/clinchem.2003.029538; Langbein L, 2005, J INVEST DERMATOL, V125, P428, DOI 10.1111/j.0022-202X.2005.23860.x; Lopez-Garcia B, 2005, J INVEST DERMATOL, V125, P108, DOI 10.1111/j.0022-202X.2005.23713.x; Miranda E, 2003, J SURG ONCOL, V83, P99, DOI 10.1002/jso.10245; Murakami M, 2002, J INVEST DERMATOL, V119, P1090, DOI 10.1046/j.1523-1747.2002.19507.x; Murakami M, 2004, J IMMUNOL, V172, P3070, DOI 10.4049/jimmunol.172.5.3070; MYAL Y, 1991, MOL CELL ENDOCRINOL, V80, P165, DOI 10.1016/0303-7207(91)90153-J; NAKAYASHIKI N, 1990, TOHOKU J EXP MED, V161, P25, DOI 10.1620/tjem.161.25; Nizet V, 2001, NATURE, V414, P454, DOI 10.1038/35106587; Ong PY, 2002, NEW ENGL J MED, V347, P1151, DOI 10.1056/NEJMoa021481; Perkins DN, 1999, ELECTROPHORESIS, V20, P3551, DOI 10.1002/(SICI)1522-2683(19991201)20:18<3551::AID-ELPS3551>3.0.CO;2-2; PETERSON LM, 1976, BIOCHEMISTRY-US, V15, P2501, DOI 10.1021/bi00657a001; Rieg S, 2005, J IMMUNOL, V174, P8003, DOI 10.4049/jimmunol.174.12.8003; Rieg S, 2004, BRIT J DERMATOL, V151, P534, DOI 10.1111/j.1365-2133.2004.06081.x; Schittek B, 2001, NAT IMMUNOL, V2, P1133, DOI 10.1038/ni732; Sorensen OE, 2001, BLOOD, V97, P3951, DOI 10.1182/blood.V97.12.3951; TADA T, 1991, J HISTOCHEM CYTOCHEM, V39, P1221, DOI 10.1177/39.9.1918940; VALORE EV, 1992, BLOOD, V79, P1538; Valore EV, 1998, J CLIN INVEST, V101, P1633, DOI 10.1172/JCI1861; VANNOORT JM, 1989, J BIOL CHEM, V264, P14159; Wright George L Jr, 2002, Expert Rev Mol Diagn, V2, P549, DOI 10.1586/14737159.2.6.549; YOKOZEKI H, 1987, AM J PHYSIOL, V252, pR1119; ZANETTI M, 1995, FEBS LETT, V374, P1, DOI 10.1016/0014-5793(95)01050-O; Zeeuwen PLJM, 2002, BRIT J DERMATOL, V147, P87, DOI 10.1046/j.1365-2133.2002.04785.x; Zeeuwen PLJM, 2001, J INVEST DERMATOL, V116, P693, DOI 10.1046/j.1523-1747.2001.01309.x	37	74	82	2	19	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 3	2006	281	9					5406	5415		10.1074/jbc.M504670200	http://dx.doi.org/10.1074/jbc.M504670200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	015RQ	16354654	hybrid			2022-12-25	WOS:000235568900012
J	Ferrara, C; Stuart, F; Sondermann, P; Brukner, P; Umana, P				Ferrara, C; Stuart, F; Sondermann, P; Brukner, P; Umana, P			The carbohydrate at Fc gamma RIIIa Asn-162 - an element required for high affinity binding to non-fucosylated IgG glycoforms	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEPENDENT CELLULAR CYTOTOXICITY; EFFECTOR FUNCTIONS; INTERACTION SITES; RECEPTOR; ANTIBODY; OLIGOSACCHARIDES; GLYCOSYLATION; POLYMORPHISM; SPECIFICITY; EXPRESSION	Fc gamma RIIIa plays a prominent role in the elimination of tumor cells by antibody-based cancer therapies. Non-fucosylated bisected IgGs bind this receptor with increased affinity and trigger Fc gamma RIII-mediated effector functions more efficiently than native, fucosylated antibodies. In this study the contribution of the carbohydrates of both binding partners to the strength of the complex was analyzed. Glycoengineering of the antibody increased affinity for two polymorphic forms of soluble human Fc gamma RIIIa ( by up to 50-fold) but did not affect binding to the inhibitory Fc gamma RIIb receptor. While the absence of carbohydrate at Fc gamma RIIIa's Asn-162 increased affinity for native IgG, presumably due to the removal of steric hindrance caused by the bulky sugars, it unexpectedly reduced affinity for glycoengineered ( GE) antibodies by over one order of magnitude, bringing the affinity down to the same level as for native IgG. We conclude that the high affinity between GE antibodies and Fc gamma RIII is mediated by productive interactions formed between the receptor carbohydrate attached at Asn-162 and regions of the Fc that are only accessible when it is nonfucosylated. As Fc gamma RIIIa and Fc gamma RIIIb are the only human Fc gamma receptors glycosylated at this position, the proposed interactions explain the observed selective affinity increase of GE antibodies for only these receptors. Furthermore, we predict from our structural model that only one of the two Fc-fucose residues needs to be absent for increased binding affinity toward Fc gamma RIII. This information can be exploited for the design of new antibodies with altered Fc receptor binding affinity and enhanced therapeutic potential.	GLYCART Bioterchnol aG, Roche Grp, CH-8952 Schlieren, Switzerland; ETH, Dept Biotechnol, CH-8093 Zurich, Switzerland	Roche Holding; Swiss Federal Institutes of Technology Domain; ETH Zurich	Umana, P (corresponding author), GLYCART Bioterchnol aG, Roche Grp, Wagistr 18, CH-8952 Schlieren, Switzerland.	pablo.umana@roche.com						BRAAKMAN E, 1992, CELL IMMUNOL, V143, P97, DOI 10.1016/0008-8749(92)90008-D; Cartron G, 2002, BLOOD, V99, P754, DOI 10.1182/blood.V99.3.754; Clynes RA, 2000, NAT MED, V6, P443, DOI 10.1038/74704; Deo YM, 1997, IMMUNOL TODAY, V18, P127, DOI 10.1016/S0167-5699(97)01007-4; Drescher B, 2003, IMMUNOLOGY, V110, P335, DOI 10.1046/j.1365-2567.2003.01743.x; Edberg JC, 1997, J IMMUNOL, V159, P3849; FERRARA C, 2006, IN PRESS BIOTECHNOL; HUBER R, 1976, NATURE, V264, P415, DOI 10.1038/264415a0; Jefferis R, 1998, IMMUNOL REV, V163, P59, DOI 10.1111/j.1600-065X.1998.tb01188.x; Jordan M, 1996, NUCLEIC ACIDS RES, V24, P596, DOI 10.1093/nar/24.4.596; Koene HR, 1997, BLOOD, V90, P1109, DOI 10.1182/blood.V90.3.1109.1109_1109_1114; Mechetina LV, 2002, IMMUNOGENETICS, V54, P463, DOI 10.1007/s00251-002-0486-0; Mimura Y, 2001, J BIOL CHEM, V276, P45539, DOI 10.1074/jbc.M107478200; Nimmerjahn F, 2005, IMMUNITY, V23, P41, DOI 10.1016/j.immuni.2005.05.010; Okazaki A, 2004, J MOL BIOL, V336, P1239, DOI 10.1016/j.jmb.2004.01.007; Papac DI, 1998, GLYCOBIOLOGY, V8, P445, DOI 10.1093/glycob/8.5.445; RAVETCH JV, 1989, J EXP MED, V170, P481, DOI 10.1084/jem.170.2.481; SARMAY G, 1992, MOL IMMUNOL, V29, P633, DOI 10.1016/0161-5890(92)90200-H; Shields RL, 2002, J BIOL CHEM, V277, P26733, DOI 10.1074/jbc.M202069200; Shields RL, 2001, J BIOL CHEM, V276, P6591, DOI 10.1074/jbc.M009483200; Shinkawa T, 2003, J BIOL CHEM, V278, P3466, DOI 10.1074/jbc.M210665200; Sondermann P, 1999, BIOL CHEM, V380, P717, DOI 10.1515/BC.1999.090; Sondermann P, 2000, NATURE, V406, P267, DOI 10.1038/35018508; TAO MH, 1989, J IMMUNOL, V143, P2595; Umana P, 1999, NAT BIOTECHNOL, V17, P176, DOI 10.1038/6179; Weng WK, 2004, J CLIN ONCOL, V22, P4717, DOI 10.1200/JCO.2004.06.003; WRIGHT A, 1994, J EXP MED, V180, P1087, DOI 10.1084/jem.180.3.1087	27	269	303	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 24	2006	281	8					5032	5036		10.1074/jbc.M510171200	http://dx.doi.org/10.1074/jbc.M510171200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	013RF	16330541	hybrid			2022-12-25	WOS:000235426200056
J	Segarra, J; Balenci, L; Drenth, T; Maina, F; Lamballe, F				Segarra, J; Balenci, L; Drenth, T; Maina, F; Lamballe, F			Combined signaling through ERK, PI3K/AKT, and RAC1/p38 is required for Met-triggered cortical neuron migration	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEPATOCYTE GROWTH-FACTOR; ACTIVATED PROTEIN-KINASE; RECEPTOR TYROSINE KINASE; MUSCLE-CELL-MIGRATION; FACTOR SCATTER FACTOR; PHOSPHATIDYLINOSITOL 3-KINASE; FACTOR/SCATTER FACTOR; ACTIN REORGANIZATION; ENDOTHELIAL-CELLS; MAMMALIAN TARGET	Cell migration is a complex biological process playing a key role in physiological and pathological conditions. During central nervous system development, positioning and function of cortical neurons is tightly regulated by cell migration. Recently, signaling events involving the urokinase-type plasminogen activator receptor, which is a key regulator for the activation of hepatocyte growth factor (HGF), have been implicated in modulating cortical neuron migration. However, the intracellular pathways controlling neuronal migration triggered by the HGF receptor Met have not been elucidated. By combining pharmacological and genetic approaches, we show here that the Ras/ERK pathway and phosphatidylinositol 3-kinase (PI3K) are both required for cortical neuron migration. By dissecting the downstream signals necessary for this event, we found that Rac1/p38 and Akt are required, whereas the c-Jun N-terminal kinase (JNK) and mTOR/p70(s6k) pathways are dispensable. This study demonstrates that concomitant activation of the Ras/ERK, PI3K/Akt, and Rac1/p38 pathways is required to achieve full capacity of cortical neurons to migrate upon HGF stimulation.	Univ Mediterranee, CNRS, UMR623, Dev Biol Inst Marseille,INSERM, F-13288 Marseille 09, France	Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Aix-Marseille Universite	Lamballe, F (corresponding author), Univ Mediterranee, CNRS, UMR623, Dev Biol Inst Marseille,INSERM, Campus Luminy,Case 907, F-13288 Marseille 09, France.	lamballe@ibdm.univ-mrs.fr	Maina, Flavio/J-9962-2019; Lamballe, Fabienne/GLT-0820-2022; Lamballe, Fabienne/P-4293-2017	Maina, Flavio/0000-0001-6100-4695; Lamballe, Fabienne/0000-0001-7631-942X; 				Akhmanova A, 2001, CELL, V104, P923, DOI 10.1016/S0092-8674(01)00288-4; ALASEK P, 2005, DEVELOPMENT CAMB, V132, P447; Allen MP, 2002, MOL CELL BIOL, V22, P599, DOI 10.1128/MCB.22.2.599-613.2002; Asnaghi L, 2004, PHARMACOL RES, V50, P545, DOI 10.1016/j.phrs.2004.03.007; Berven LA, 2000, IMMUNOL CELL BIOL, V78, P447, DOI 10.1046/j.1440-1711.2000.00928.x; Bielas S, 2004, ANNU REV CELL DEV BI, V20, P593, DOI 10.1146/annurev.cellbio.20.082503.103047; Birchmeier C, 2003, NAT REV MOL CELL BIO, V4, P915, DOI 10.1038/nrm1261; BLADT F, 1995, NATURE, V376, P768, DOI 10.1038/376768a0; Brunstrom JE, 1997, NEURON, V18, P505, DOI 10.1016/S0896-6273(00)81250-7; Burridge K, 2004, CELL, V116, P167, DOI 10.1016/S0092-8674(04)00003-0; Cacci E, 2003, J NEUROSCI RES, V74, P760, DOI 10.1002/jnr.10799; Coltella N, 2003, FASEB J, V17, P1162, DOI 10.1096/fj.02-0576fje; COSO OA, 1995, CELL, V81, P1137, DOI 10.1016/S0092-8674(05)80018-2; CROSS DAE, 1995, NATURE, V378, P785, DOI 10.1038/378785a0; del Pozo MA, 2000, EMBO J, V19, P2008, DOI 10.1093/emboj/19.9.2008; Delehedde M, 2001, EUR J BIOCHEM, V268, P4423, DOI 10.1046/j.1432-1327.2001.02363.x; Dono R, 1998, EMBO J, V17, P4213, DOI 10.1093/emboj/17.15.4213; Dubrulle J, 2001, CELL, V106, P219, DOI 10.1016/S0092-8674(01)00437-8; Dudek H, 1997, SCIENCE, V275, P661, DOI 10.1126/science.275.5300.661; Ebens A, 1996, NEURON, V17, P1157, DOI 10.1016/S0896-6273(00)80247-0; Franke TF, 2003, ONCOGENE, V22, P8983, DOI 10.1038/sj.onc.1207115; Furge KA, 2000, ONCOGENE, V19, P5582, DOI 10.1038/sj.onc.1203859; Gomez-Cambronero J, 2003, J IMMUNOL, V171, P6846, DOI 10.4049/jimmunol.171.12.6846; Gomez-Cambronero J, 2003, FEBS LETT, V550, P94, DOI 10.1016/S0014-5793(03)00828-7; Guay J, 1997, J CELL SCI, V110, P357; HAN JW, 1995, J BIOL CHEM, V270, P21396, DOI 10.1074/jbc.270.36.21396; Helmbacher F, 2003, NEURON, V39, P767, DOI 10.1016/S0896-6273(03)00493-8; Huang SL, 2003, CANCER BIOL THER, V2, P222, DOI 10.4161/cbt.2.3.360; Huot J, 1997, CIRC RES, V80, P383, DOI 10.1161/01.RES.80.3.383; JUN T, 1999, SCI STKE, V13, pPE1; Kandel ES, 1999, EXP CELL RES, V253, P210, DOI 10.1006/excr.1999.4690; Kawamura K, 2004, J BIOL CHEM, V279, P54862, DOI 10.1074/jbc.M408057200; Kawauchi T, 2003, EMBO J, V22, P4190, DOI 10.1093/emboj/cdg413; Kermorgant S, 2004, EMBO J, V23, P3721, DOI 10.1038/sj.emboj.7600396; Khwaja A, 1998, J BIOL CHEM, V273, P18793, DOI 10.1074/jbc.273.30.18793; Kodama A, 2000, MOL BIOL CELL, V11, P2565, DOI 10.1091/mbc.11.8.2565; Konno D, 2005, J BIOL CHEM, V280, P5082, DOI 10.1074/jbc.M408251200; Lambert JM, 2002, NAT CELL BIOL, V4, P621, DOI 10.1038/ncb833; Maina F, 1999, NAT NEUROSCI, V2, P213, DOI 10.1038/6310; Maina F, 1997, GENE DEV, V11, P3341, DOI 10.1101/gad.11.24.3341; Maina F, 1998, NEURON, V20, P835, DOI 10.1016/S0896-6273(00)80466-3; Maina F, 2001, MOL CELL, V7, P1293, DOI 10.1016/S1097-2765(01)00261-1; Maina F, 1996, CELL, V87, P531, DOI 10.1016/S0092-8674(00)81372-0; Marin O, 2003, ANNU REV NEUROSCI, V26, P441, DOI 10.1146/annurev.neuro.26.041002.131058; Medina DL, 2004, EMBO J, V23, P3803, DOI 10.1038/sj.emboj.7600399; Morales-Ruiz M, 2000, CIRC RES, V86, P892, DOI 10.1161/01.RES.86.8.892; NOBES CD, 1995, J CELL SCI, V108, P225; PONZETTO C, 1994, CELL, V77, P261, DOI 10.1016/0092-8674(94)90318-2; Powell EM, 2003, J NEUROSCI, V23, P622, DOI 10.1523/JNEUROSCI.23-02-00622.2003; Powell EM, 2001, NEURON, V30, P79, DOI 10.1016/S0896-6273(01)00264-1; Qian Y, 2005, ONCOGENE, V24, P3154, DOI 10.1038/sj.onc.1208525; Qian Y, 2004, AM J PHYSIOL-CELL PH, V286, pC153, DOI 10.1152/ajpcell.00142.2003; Rahimi N, 1998, J BIOL CHEM, V273, P33714, DOI 10.1074/jbc.273.50.33714; Reif K, 1996, CURR BIOL, V6, P1445, DOI 10.1016/S0960-9822(96)00749-X; Rice DS, 1999, GENE DEV, V13, P2758, DOI 10.1101/gad.13.21.2758; RIDLEY AJ, 1995, MOL CELL BIOL, V15, P1110; Rommel C, 1998, CURR OPIN GENET DEV, V8, P412, DOI 10.1016/S0959-437X(98)80111-1; Rosario M, 2003, TRENDS CELL BIOL, V13, P328, DOI 10.1016/S0962-8924(03)00104-1; Ross ME, 2001, ANNU REV NEUROSCI, V24, P1041, DOI 10.1146/annurev.neuro.24.1.1041; Rousseau S, 1997, ONCOGENE, V15, P2169, DOI 10.1038/sj.onc.1201380; ROYAL I, 1995, J BIOL CHEM, V270, P27780, DOI 10.1074/jbc.270.46.27780; Scott PH, 1998, P NATL ACAD SCI USA, V95, P7772, DOI 10.1073/pnas.95.13.7772; Sharma GD, 2003, J BIOL CHEM, V278, P21989, DOI 10.1074/jbc.M302650200; Song G, 2005, J CELL MOL MED, V9, P59, DOI 10.1111/j.1582-4934.2005.tb00337.x; Sun YX, 2003, MICROW OPT TECHN LET, V36, P48, DOI 10.1002/mop.10667; Taher TEI, 2002, BIOCHEM BIOPH RES CO, V298, P80, DOI 10.1016/S0006-291X(02)02397-5; Tai YT, 2003, BLOOD, V101, P2762, DOI 10.1182/blood-2002-09-2813; Takeda K, 2002, GENES CELLS, V7, P1099, DOI 10.1046/j.1365-2443.2002.00591.x; Tanski WJ, 2005, J VASC SURG, V41, P91, DOI 10.1016/j.jvs.2004.08.058; Thompson J, 2004, MOL CELL NEUROSCI, V27, P441, DOI 10.1016/j.mcn.2004.07.007; Tokumaru S, 2005, BIOCHEM BIOPH RES CO, V327, P100, DOI 10.1016/j.bbrc.2004.11.145; Vivanco I, 2002, NAT REV CANCER, V2, P489, DOI 10.1038/nrc839; Xia Y, 2004, TRENDS CELL BIOL, V14, P94, DOI 10.1016/j.tcb.2003.12.005; Yamamoto Y, 1997, DEVELOPMENT, V124, P2903; Yang XM, 1998, J NEUROSCI, V18, P8369; Zhang YW, 2003, J CELL BIOCHEM, V88, P408, DOI 10.1002/jcb.10358	76	94	96	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 24	2006	281	8					4771	4778		10.1074/jbc.M508298200	http://dx.doi.org/10.1074/jbc.M508298200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	013RF	16361255	hybrid			2022-12-25	WOS:000235426200027
J	Fan, JS; Matsumoto, Y; Wilson, DM				Fan, JS; Matsumoto, Y; Wilson, DM			Nucleotide sequence and DNA secondary structure, as well as replication protein A, modulate the single-stranded abasic endonuclease activity of APE1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BASE EXCISION-REPAIR; HUMAN APURINIC/APYRIMIDINIC ENDONUCLEASE; HUMAN APURINIC ENDONUCLEASE; ANTIGEN-DEPENDENT REPAIR; DAMAGE-RECOGNITION; MAJOR HUMAN; FUNCTIONAL-CHARACTERIZATION; OXIDATIVE DAMAGE; BINDING-PROTEIN; T7 ENDONUCLEASE	A major role of the multifunctional human Ape1 protein is to incise at apurinic/apyrimidinic (AP) sites in DNA via site-specific endonuclease activity. This nuclease function has been well characterized on double-stranded (ds) DNA substrates, where the complementary strand provides a template for subsequent base excision repair events. Recently, Ape1 was found to incise efficiently at AP sites positioned within the single-stranded (ss) regions of various biologically relevant DNA configurations. The studies within indicated that the ss endonuclease activity of Ape1 is poorly active on ss AP site-containing polyadenine or polythymine oligonucleotides, suggesting a requirement for some form of DNA secondary structure for efficient cleavage. Computational, footprinting, and biochemical analyses indicated that the nature of the secondary structure and the proximity of the AP site influence Ape1 incision efficiency significantly. Replication protein A (RPA), the major ssDNA-binding protein in mammalian cells, was found to bind ss AP-DNA with similar affinity as unmodified ssDNA and ds AP-DNA with lower affinity. Consistent with their known relative DNA binding affinities, RPA blocks/inhibits the ss, but not ds, AP endonuclease function of Ape1. Moreover, RPA inactivates Ape1 incision activity at an AP site within the ss region of a fork duplex, but not a transcription-like bubble intermediate. The data herein suggested a model whereby RPA selectively suppresses the nontemplated ss cleavage activity of Ape1 in vivo, particularly at sites of ongoing replication/recombination, by coating the ssDNA.	NIA, Lab Mol Gerontol, NIH, GRC, Baltimore, MD 21224 USA; Fox Chase Canc Ctr, Div Med Sci, Philadelphia, PA 19111 USA	National Institutes of Health (NIH) - USA; NIH National Institute on Aging (NIA); Fox Chase Cancer Center	Wilson, DM (corresponding author), NIA, Lab Mol Gerontol, NIH, GRC, 2D-13,5600 Nathan Shock Dr, Baltimore, MD 21224 USA.	wilsonda@grc.nia.nih.gov	Wilson, David M/AAK-5409-2021	Wilson, David M/0000-0002-8945-0395; Matsumoto, Yoshihiro/0000-0001-6580-7188	NATIONAL INSTITUTE ON AGING [ZIAAG000743, Z01AG000743] Funding Source: NIH RePORTER; Intramural NIH HHS Funding Source: Medline	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)		BARZILAY G, 1995, NAT STRUCT BIOL, V2, P561, DOI 10.1038/nsb0795-561; Beard BC, 2003, P NATL ACAD SCI USA, V100, P7465, DOI 10.1073/pnas.1330328100; Beloglazova NG, 2004, NUCLEIC ACIDS RES, V32, P5134, DOI 10.1093/nar/gkh846; BLACKWELL LJ, 1994, MOL CELL BIOL, V14, P3993, DOI 10.1128/MCB.14.6.3993; Bochkareva E, 2001, EMBO J, V20, P612, DOI 10.1093/emboj/20.3.612; Bochkareva E, 2002, EMBO J, V21, P1855, DOI 10.1093/emboj/21.7.1855; Burns JL, 1996, J BIOL CHEM, V271, P11607, DOI 10.1074/jbc.271.20.11607; CLUGSTON CK, 1992, CANCER RES, V52, P6375; Declais AC, 2003, EMBO J, V22, P1398, DOI 10.1093/emboj/cdg132; DeMott MS, 1998, J BIOL CHEM, V273, P27492, DOI 10.1074/jbc.273.42.27492; DEMPLE B, 1994, ANNU REV BIOCHEM, V63, P915, DOI 10.1146/annurev.biochem.63.1.915; Dianov GL, 1999, BIOCHEMISTRY-US, V38, P11021, DOI 10.1021/bi9908890; Erzberger JP, 1999, J MOL BIOL, V290, P447, DOI 10.1006/jmbi.1999.2888; Erzberger JP, 1998, NUCLEIC ACIDS RES, V26, P2771, DOI 10.1093/nar/26.11.2771; FAIRMAN MP, 1988, EMBO J, V7, P1211, DOI 10.1002/j.1460-2075.1988.tb02933.x; Fortini P, 2003, BIOCHIMIE, V85, P1053, DOI 10.1016/j.biochi.2003.11.003; Fung H, 2005, MOL CELL, V17, P463, DOI 10.1016/j.molcel.2004.12.029; GEORGAKI A, 1992, FEBS LETT, V308, P240, DOI 10.1016/0014-5793(92)81283-R; GEORGAKI A, 1993, NUCLEIC ACIDS RES, V21, P3659, DOI 10.1093/nar/21.16.3659; Hadi MZ, 2000, NUCLEIC ACIDS RES, V28, P3871, DOI 10.1093/nar/28.20.3871; Hadi MZ, 2002, J MOL BIOL, V316, P853, DOI 10.1006/jmbi.2001.5382; HE ZG, 1995, NATURE, V374, P566, DOI 10.1038/374566a0; HENRICKSEN LA, 1994, J BIOL CHEM, V269, P11121; Hey T, 2001, BIOCHEMISTRY-US, V40, P2901, DOI 10.1021/bi002166i; Hofacker IL, 2003, NUCLEIC ACIDS RES, V31, P3429, DOI 10.1093/nar/gkg599; Huamani J, 2004, MOL CELL BIOL, V24, P8145, DOI 10.1128/MCB.24.18.8145-8153.2004; Iftode C, 1999, CRIT REV BIOCHEM MOL, V34, P141, DOI 10.1080/10409239991209255; Izumi T, 2005, P NATL ACAD SCI USA, V102, P5739, DOI 10.1073/pnas.0500986102; KENNY M K, 1990, Journal of Biological Chemistry, V265, P7693; KIM CS, 1994, BIOCHEMISTRY-US, V33, P14197, DOI 10.1021/bi00251a031; KIM CS, 1992, MOL CELL BIOL, V12, P3050, DOI 10.1128/MCB.12.7.3050; Lao Y, 2000, BIOCHEMISTRY-US, V39, P850, DOI 10.1021/bi991704s; Larson ED, 2005, MOL CELL, V20, P367, DOI 10.1016/j.molcel.2005.09.018; LINDAHL T, 1993, NATURE, V362, P709, DOI 10.1038/362709a0; Liu YY, 2005, BIOCHEM J, V385, P519, DOI 10.1042/BJ20041151; LOEB LA, 1986, ANNU REV GENET, V20, P201, DOI 10.1146/annurev.ge.20.120186.001221; Marenstein DR, 2004, DNA REPAIR, V3, P527, DOI 10.1016/j.dnarep.2004.01.010; Matsumoto Y, 1999, J BIOL CHEM, V274, P33703, DOI 10.1074/jbc.274.47.33703; Meira LB, 2001, CANCER RES, V61, P5552; Morland I, 2002, NUCLEIC ACIDS RES, V30, P4926, DOI 10.1093/nar/gkf618; Nguyen LH, 2000, J MOL BIOL, V298, P447, DOI 10.1006/jmbi.2000.3653; Nilsen H, 2002, EMBO J, V21, P5943, DOI 10.1093/emboj/cdf581; Opresko PL, 2005, NUCLEIC ACIDS RES, V33, P1230, DOI 10.1093/nar/gki273; Otterlei M, 1999, EMBO J, V18, P3834, DOI 10.1093/emboj/18.13.3834; Parker A, 2001, J BIOL CHEM, V276, P5547, DOI 10.1074/jbc.M008463200; Parkinson MJ, 1997, J MOL BIOL, V270, P169, DOI 10.1006/jmbi.1997.1128; Parsian AJ, 2002, MUTAT RES-FUND MOL M, V501, P105, DOI 10.1016/S0027-5107(02)00016-7; Patrick SM, 1998, BIOCHEMISTRY-US, V37, P8808, DOI 10.1021/bi9730590; Patrick SM, 2001, J BIOL CHEM, V276, P22630, DOI 10.1074/jbc.M010314200; Ranalli TA, 2002, J BIOL CHEM, V277, P1719, DOI 10.1074/jbc.M109053200; Stivers JT, 2003, CHEM REV, V103, P2729, DOI 10.1021/cr010219b; Strauss PR, 1997, J BIOL CHEM, V272, P1302, DOI 10.1074/jbc.272.2.1302; TAKESHITA M, 1987, J BIOL CHEM, V262, P10171; Thoma BS, 2003, MOL CARCINOGEN, V38, P1, DOI 10.1002/mc.10143; Treuner K, 1996, J MOL BIOL, V259, P104, DOI 10.1006/jmbi.1996.0305; Wilson DM, 2001, MUTAT RES-DNA REPAIR, V485, P283, DOI 10.1016/S0921-8777(01)00063-5; Wilson DM, 2005, J MOL BIOL, V345, P1003, DOI 10.1016/j.jmb.2004.11.028; WILSON DM, 1995, J BIOL CHEM, V270, P16002, DOI 10.1074/jbc.270.27.16002; Wilson DM, 1997, NUCLEIC ACIDS RES, V25, P933, DOI 10.1093/nar/25.5.933; WOBBE CR, 1987, P NATL ACAD SCI USA, V84, P1834, DOI 10.1073/pnas.84.7.1834; Wold MS, 1997, ANNU REV BIOCHEM, V66, P61, DOI 10.1146/annurev.biochem.66.1.61; WOLD MS, 1988, P NATL ACAD SCI USA, V85, P2523, DOI 10.1073/pnas.85.8.2523	62	26	28	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 17	2006	281	7					3889	3898		10.1074/jbc.M511004200	http://dx.doi.org/10.1074/jbc.M511004200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	011NN	16356936	hybrid			2022-12-25	WOS:000235275300016
J	Goetz, JA; Singh, S; Suber, LM; Kull, FJ; Robbins, DJ				Goetz, JA; Singh, S; Suber, LM; Kull, FJ; Robbins, DJ			A highly conserved amino-terminal region of sonic hedgehog is required for the formation of its freely diffusible multimeric form	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOTOR-NEURON INDUCTION; SCLEROTOME INDUCTION; CLEAVAGE PRODUCT; FLOOR PLATE; PROTEIN; ACYLTRANSFERASE; PALMITOYLATION; ASSOCIATION; ECTODERM; COMPLEX	Although members of the Hedgehog (Hh) family were initially described as morphogens, many of these early conclusions were based on experiments that used non-physiologically relevant forms of Hh. Native Hh is modified by cholesterol (HhNp) and palmitate. These hydrophobic modifications are responsible for the ability of Hh to associate with cellular membranes, a property that initially appeared inconsistent with its ability to act far from its site of synthesis. Although it is now clear that Hh family members are capable of acting directly in long-range signaling, the form of Hh capable of this activity remains controversial. We have previously provided evidence for a freely diffusible multimeric form of Sonic Hedgehog (Shh) termed s-ShhNp, which is capable of accumulating in a gradient fashion through a morphogenic field. Here, we provide further evidence that s-ShhNp is the physiologically relevant form of Shh. We show that the biological activity of freely diffusible ShhNp resides in its multimeric form and that this multimeric form is exceedingly stable, even to high concentrations of salt and detergent. Furthermore, we now validate the Shh-Shh interactions previously observed in the crystal structure of human Shh, showing that a highly conserved amino-terminal domain of Shh is important for the formation of s-ShhNp. We also conclusively show that palmi-toylation is required for s-ShhNp formation. Thus, our results identify both protein-protein and protein-lipid interactions that are required for s-ShhNp formation, and provide the first structural analyses supporting the existence of Shh multimers.	Dartmouth Coll, Sch Med, Dept Pharmacol & Toxicol, Hanover, NH 03755 USA; Dartmouth Coll, Hitchcock Med Ctr, Norris Cotton Canc Ctr, Lebanon, NH 03756 USA; Dartmouth Coll, Dept Chem, Hanover, NH 03755 USA; Univ Cincinnati, Coll Med, Dept Mol Genet, Cincinnati, OH 45249 USA	Dartmouth College; Dartmouth College; Norris Cotton Cancer Center; Dartmouth College; University System of Ohio; University of Cincinnati	Robbins, DJ (corresponding author), Dartmouth Coll, Sch Med, Dept Pharmacol & Toxicol, Hanover, NH 03755 USA.	David.J.Robbins@Dartmouth.edu	Singh, Samer/H-8468-2013	Singh, Samer/0000-0002-0921-1686	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM064011] Funding Source: NIH RePORTER; NIGMS NIH HHS [R01-GM64011] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Amanai K, 2001, DEVELOPMENT, V128, P5119; Beachy PA, 2004, NATURE, V432, P324, DOI 10.1038/nature03100; BUMCROT DA, 1995, MOL CELL BIOL, V15, P2294; Chamoun Z, 2001, SCIENCE, V293, P2080, DOI 10.1126/science.1064437; Chen MH, 2004, GENE DEV, V18, P641, DOI 10.1101/gad.1185804; DeLano WL, 2002, PYMOL USERS MANUAL; FAN CM, 1994, CELL, V79, P1175, DOI 10.1016/0092-8674(94)90009-4; FAN CM, 1995, CELL, V81, P457, DOI 10.1016/0092-8674(95)90398-4; Feng J, 2004, DEVELOPMENT, V131, P4357, DOI 10.1242/dev.01301; FIETZ MJ, 1995, CURR BIOL, V5, P643, DOI 10.1016/S0960-9822(95)00129-1; Fuse N, 1999, P NATL ACAD SCI USA, V96, P10992, DOI 10.1073/pnas.96.20.10992; Goetz JA, 2002, BIOESSAYS, V24, P157, DOI 10.1002/bies.10056; HALL TMT, 1995, NATURE, V378, P212, DOI 10.1038/378212a0; Herr AB, 1997, J BIOL CHEM, V272, P16382, DOI 10.1074/jbc.272.26.16382; Ingham PW, 2001, GENE DEV, V15, P3059, DOI 10.1101/gad.938601; LAI CJ, 1995, DEVELOPMENT, V121, P2349; Lee JD, 2001, CURR BIOL, V11, P1147, DOI 10.1016/S0960-9822(01)00323-2; LEE JJ, 1994, SCIENCE, V266, P1528, DOI 10.1126/science.7985023; MARTI E, 1995, NATURE, V375, P322, DOI 10.1038/375322a0; Micchelli CA, 2002, DEVELOPMENT, V129, P843; Pepinsky RB, 2000, J BIOL CHEM, V275, P10995, DOI 10.1074/jbc.275.15.10995; Pepinsky RB, 1998, J BIOL CHEM, V273, P14037, DOI 10.1074/jbc.273.22.14037; PORTER JA, 1995, NATURE, V374, P363, DOI 10.1038/374363a0; Porter JA, 1996, SCIENCE, V274, P255, DOI 10.1126/science.274.5285.255; Porter JA, 1996, CELL, V86, P21, DOI 10.1016/S0092-8674(00)80074-4; Rietveld A, 1999, J BIOL CHEM, V274, P12049, DOI 10.1074/jbc.274.17.12049; Robbins DJ, 2005, CURR CANCER THER REV, V1, P277, DOI 10.2174/157339405774574243; Robbins DJ, 1997, CELL, V90, P225, DOI 10.1016/S0092-8674(00)80331-1; ROELINK H, 1995, CELL, V81, P445, DOI 10.1016/0092-8674(95)90397-6; ROELINK H, 1994, CELL, V76, P761, DOI 10.1016/0092-8674(94)90514-2; Rubin JB, 2002, DEVELOPMENT, V129, P2223; Sanchez P, 2005, CANCER RES, V65, P2990, DOI 10.1158/0008-5472.CAN-05-0439; Taipale J, 2000, NATURE, V406, P1005, DOI 10.1038/35023008; Taylor FR, 2001, BIOCHEMISTRY-US, V40, P4359, DOI 10.1021/bi002487u; Torroja C, 2005, J NEUROBIOL, V64, P334, DOI 10.1002/neu.20168; Zeng X, 2001, NATURE, V411, P716, DOI 10.1038/35079648	36	107	111	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 17	2006	281	7					4087	4093		10.1074/jbc.M511427200	http://dx.doi.org/10.1074/jbc.M511427200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	011NN	16339763	hybrid			2022-12-25	WOS:000235275300038
J	Yamaguchi, Y; Takatsuka, Y; Matsufuji, S; Murakami, Y; Kamio, Y				Yamaguchi, Y; Takatsuka, Y; Matsufuji, S; Murakami, Y; Kamio, Y			Characterization of a counterpart to mammalian ornithine decarboxylase antizyme in prokaryotes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COMPLETE GENOME SEQUENCE; RUMINANTIUM LYSINE DECARBOXYLASE; SELENOMONAS-RUMINANTIUM; ESCHERICHIA-COLI; VEILLONELLA-ALCALESCENS; OVERLAP EXTENSION; CELL-GROWTH; PEPTIDOGLYCAN; CADAVERINE; PROTEIN	The degradation of mammalian ornithine decarboxylase (ODC) (EC 4.1.1.17) by 26 S proteasome, is accelerated by the ODC antizyme (AZ), a trigger protein involved in the specific degradation of eukaryotic ODC. In prokaryotes, AZ has not been found. Previously, we found that in Selenomonas ruminantium, a strictly anaerobic and Gram-negative bacterium, a drastic degradation of lysine decarboxylase (LDC; EC 4.1.1.18), which has decarboxylase activities toward both L-lysine and L-ornithine with similar K-m values, occurs upon entry into the stationary phase of cell growth by protease together with a protein of 22 kDa (P22). Here, we show that P22 is a direct counterpart of eukaryotic AZ by the following evidence. (i) P22 synthesis is induced by putrescine but not cadaverine. (ii) P22 enhances the degradation of both mouse ODC and S. ruminantium LDC by a 26 S proteasome. (iii) S. ruminantium LDC degradation is also enhanced by mouse AZ replacing P22 in a cell-free extract from S. ruminantium. (iv) Both P22 and mouse AZ bind to S. ruminantium LDC but not to the LDC mutated in its binding site for P22 and AZ. In this report, we also show that P22 is a ribosomal protein of S. ruminantium.	Tohoku Univ, Grad Sch Agr Sci, Dept Microbial Biotechnol, Appl Microbiol Lab,Aoba Ku, Sendai, Miyagi 9818555, Japan; Jikei Univ, Sch Med, Dept Biochem 2, Minato Ku, Tokyo 1058461, Japan	Tohoku University; Jikei University	Kamio, Y (corresponding author), Tohoku Univ, Grad Sch Agr Sci, Dept Microbial Biotechnol, Appl Microbiol Lab,Aoba Ku, 1-1 Tsutsumi Dori, Sendai, Miyagi 9818555, Japan.	ykamio@biochem.tohoku.ac.jp		Yamaguchi, Yoshihiro/0000-0003-4663-6963				Blattner FR, 1997, SCIENCE, V277, P1453, DOI 10.1126/science.277.5331.1453; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Coffino P, 2001, NAT REV MOL CELL BIO, V2, P188, DOI 10.1038/35056508; GHODA L, 1989, SCIENCE, V243, P1493, DOI 10.1126/science.2928784; Hayashi S, 1996, TRENDS BIOCHEM SCI, V21, P27, DOI 10.1016/0968-0004(96)80882-6; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; Holden MTG, 2004, P NATL ACAD SCI USA, V101, P9786, DOI 10.1073/pnas.0402521101; HORTON RM, 1989, GENE, V77, P61, DOI 10.1016/0378-1119(89)90359-4; Ivanov IP, 1998, MOL MICROBIOL, V29, P1521, DOI 10.1046/j.1365-2958.1998.01032.x; KAMIO Y, 1986, J BIOL CHEM, V261, P6585; KAMIO Y, 1981, J BACTERIOL, V146, P49, DOI 10.1128/JB.146.1.49-53.1981; KAMIO Y, 1987, J BACTERIOL, V169, P4837, DOI 10.1128/jb.169.10.4837-4840.1987; KAMIO Y, 1982, J BIOL CHEM, V257, P3326; KAMIO Y, 1987, J BACTERIOL, V169, P2881, DOI 10.1128/jb.169.6.2881-2884.1987; KAMIO Y, 1983, J BACTERIOL, V153, P658, DOI 10.1128/JB.153.2.658-664.1983; KANEGASAKI S, 1967, J BACTERIOL, V93, P456, DOI 10.1128/JB.93.1.456-463.1967; KASHIWAGI K, 1987, BIOCHIM BIOPHYS ACTA, V911, P180, DOI 10.1016/0167-4838(87)90007-0; Kern AD, 1999, STRUCTURE, V7, P567, DOI 10.1016/S0969-2126(99)80073-2; KITANI T, 1984, J BIOL CHEM, V259, P36; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LINEHAN B, 1978, APPL ENVIRON MICROB, V35, P317, DOI 10.1128/AEM.35.2.317-322.1978; Murakami Y, 2000, BIOCHEM BIOPH RES CO, V267, P1, DOI 10.1006/bbrc.1999.1706; Newman RM, 2004, J BIOL CHEM, V279, P41504, DOI 10.1074/jbc.M407349200; PANAGIOTIDIS CA, 1984, J BIOL CHEM, V259, P5025; Persson L, 2003, BIOCHEM SOC T, V31, P411, DOI 10.1042/BST0310411; PHAN APH, 1982, ANAL BIOCHEM, V120, P193, DOI 10.1016/0003-2697(82)90336-0; POSO H, 1984, BIOCHEM BIOPH RES CO, V125, P205, DOI 10.1016/S0006-291X(84)80355-1; POST LE, 1979, P NATL ACAD SCI USA, V76, P1697, DOI 10.1073/pnas.76.4.1697; Saito T, 2000, BIOCHEM J, V345, P99, DOI 10.1042/0264-6021:3450099; Shimizu T, 2002, P NATL ACAD SCI USA, V99, P996, DOI 10.1073/pnas.022493799; Takami H, 2000, NUCLEIC ACIDS RES, V28, P4317, DOI 10.1093/nar/28.21.4317; Takatsuka Y, 1999, BIOSCI BIOTECH BIOCH, V63, P1063, DOI 10.1271/bbb.63.1063; Takatsuka Y, 2000, J BACTERIOL, V182, P6732, DOI 10.1128/JB.182.23.6732-6741.2000; Welch RA, 2002, P NATL ACAD SCI USA, V99, P17020, DOI 10.1073/pnas.252529799; Yamaguchi Y, 2002, BIOSCI BIOTECH BIOCH, V66, P1431, DOI 10.1271/bbb.66.1431; Zhang MS, 2003, EMBO J, V22, P1488, DOI 10.1093/emboj/cdg158	36	13	15	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 17	2006	281	7					3995	4001		10.1074/jbc.M507545200	http://dx.doi.org/10.1074/jbc.M507545200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	011NN	16354653	hybrid			2022-12-25	WOS:000235275300028
J	Bhanumathy, CD; Nakao, SK; Joseph, SK				Bhanumathy, CD; Nakao, SK; Joseph, SK			Mechanism of proteasomal degradation of inositol trisphosphate receptors in CHO-K1 cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RETICULUM-ASSOCIATED DEGRADATION; INDUCED DOWN-REGULATION; LIVER EPITHELIAL-CELLS; 1,4,5-TRISPHOSPHATE RECEPTOR; LIGAND-BINDING; MAMMALIAN UBC7; MOUSE OOCYTES; EARLY EMBRYOS; ACTIVATION; UBIQUITINATION	myo-Inositol 1,4,5-trisphosphate receptor (IP3R) degradation occurs in response to carbachol (Cch) stimulation of CHO-K1 cells. The response was mediated by endogenous muscarinic receptors and was blocked by atropine or proteasomal inhibitors. We have used these cells to identify the sites of ubiquitination on IP(3)Rs and study the role of Ca2+ and substrate recognition properties of the degradation system using exogenously expressed IP3R constructs. Employing caspase-3 for IP3R cleavage, we show that Cch promotes polyubiquitination in the N-terminal domain and monoubiquitination in the C-terminal domain. The addition of extracellular Ca2+ to Ca2+-depleted Chinese hamster ovary (CHO) cells initiates IP3R degradation provided Cch is present. This effect is inhibited by thapsigargin. The data suggest that both a sustained elevation of IP3 and a minimal content of Ca2+ in the endoplasmic reticulum lumen is required to initiate IP3R degradation. Transient transfection of IP3R constructs into CHO cells indicated the selective degradation of only the SI(+) splice variant of the type I IP3R. This was also the splice form present endogenously in these cells. A pore-defective, nonfunctional SI(+) IP3R mutant (D2550A) was also degraded in Cch-stimulated cells. The Cch-mediated response in CHO cells provides a convenient model system to further analyze the Ca2+ dependence and structural requirements of the IP3R proteasomal degradation pathway.	Thomas Jefferson Univ, Dept Pathol, Sch Med, Philadelphia, PA 19107 USA	Jefferson University	Joseph, SK (corresponding author), Thomas Jefferson Univ, Dept Pathol Anat & Cell Biol, Rm 230A,JAH,1020 Locust St, Philadelphia, PA 19107 USA.	suresh.joseph@mail.tju.edu			NIDDK NIH HHS [DK34804] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK034804] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Alzayady KJ, 2005, BIOCHEM J, V392, P601, DOI 10.1042/BJ20050949; Berridge MJ, 2003, NAT REV MOL CELL BIO, V4, P517, DOI 10.1038/nrm1155; Boehning D, 2000, J BIOL CHEM, V275, P21492, DOI 10.1074/jbc.M001724200; Boehning D, 2000, EMBO J, V19, P5450, DOI 10.1093/emboj/19.20.5450; Bokkala S, 1999, ALCOHOL CLIN EXP RES, V23, P1875, DOI 10.1097/00000374-199912000-00004; Bokkala S, 1997, J BIOL CHEM, V272, P12454, DOI 10.1074/jbc.272.19.12454; Brind S, 2000, DEV BIOL, V223, P251, DOI 10.1006/dbio.2000.9728; Haglund K, 2003, TRENDS BIOCHEM SCI, V28, P598, DOI 10.1016/j.tibs.2003.09.005; Hamada K, 2003, J BIOL CHEM, V278, P52881, DOI 10.1074/jbc.M309743200; Hang LS, 2000, J NEUROCHEM, V75, P1852; Hirota J, 1999, J BIOL CHEM, V274, P34433, DOI 10.1074/jbc.274.48.34433; Jellerette T, 2000, DEV BIOL, V223, P238, DOI 10.1006/dbio.2000.9675; Joseph SK, 2006, BIOCHEM J, V393, P575, DOI 10.1042/BJ20050889; JOSEPH SK, 1993, J BIOL CHEM, V268, P6477; Khan MT, 2003, BIOCHEM J, V375, P603, DOI 10.1042/BJ20030828; Kim BW, 2003, MOL ENDOCRINOL, V17, P2603, DOI 10.1210/me.2003-0082; Kume S, 2000, DEV GROWTH DIFFER, V42, P327; Lee B, 2001, ENDOCRINOLOGY, V142, P1744, DOI 10.1210/en.142.5.1744; McArdle CA, 2002, J ENDOCRINOL, V173, P1, DOI 10.1677/joe.0.1730001; MIGNERY GA, 1990, J BIOL CHEM, V265, P12679; MIGNERY GA, 1989, NATURE, V342, P192, DOI 10.1038/342192a0; NAKAGAWA T, 1991, P NATL ACAD SCI USA, V88, P6244, DOI 10.1073/pnas.88.14.6244; NEWTON CL, 1994, J BIOL CHEM, V269, P28613; Oberdorf J, 1999, BIOCHEM J, V339, P453, DOI 10.1042/0264-6021:3390453; Parrington J, 1998, DEV BIOL, V203, P451, DOI 10.1006/dbio.1998.9071; Patel S, 1999, CELL CALCIUM, V25, P247, DOI 10.1054/ceca.1999.0021; Ramos-Franco J, 1998, BIOPHYS J, V75, P2783, DOI 10.1016/S0006-3495(98)77721-5; Regan MR, 2005, PROTEINS, V59, P312, DOI 10.1002/prot.20225; ROONEY TA, 1989, J BIOL CHEM, V264, P17131; Sharma K, 1997, J BIOL CHEM, V272, P14617, DOI 10.1074/jbc.272.23.14617; Sipma H, 1998, CELL CALCIUM, V23, P11, DOI 10.1016/S0143-4160(98)90070-7; Tiwari S, 2001, J BIOL CHEM, V276, P16193, DOI 10.1074/jbc.M007640200; Tovey SC, 2001, J CELL SCI, V114, P3979; Walter BN, 1998, J BIOL CHEM, V273, P28733, DOI 10.1074/jbc.273.44.28733; WANG SZ, 1995, EUR J PHARM-MOLEC PH, V291, pR1; Webster JM, 2003, J BIOL CHEM, V278, P38238, DOI 10.1074/jbc.M305600200; Willars GB, 2001, J BIOL CHEM, V276, P3123, DOI 10.1074/jbc.M008916200; WOJCIKIEWICZ RJH, 1992, J NEUROCHEM, V59, P383, DOI 10.1111/j.1471-4159.1992.tb08916.x; Wojcikiewicz RJH, 1999, GASTROENTEROLOGY, V116, P1194, DOI 10.1016/S0016-5085(99)70023-5; Wojcikiewicz RJH, 2003, J BIOL CHEM, V278, P940, DOI 10.1074/jbc.M206607200; WOJCIKIEWICZ RJH, 1994, J BIOL CHEM, V269, P7963; Yoshikawa F, 1999, J BIOL CHEM, V274, P316, DOI 10.1074/jbc.274.1.316; Young KW, 2003, J BIOL CHEM, V278, P20753, DOI 10.1074/jbc.M211555200; Zhu CC, 1999, J BIOL CHEM, V274, P3476, DOI 10.1074/jbc.274.6.3476; Zhu CC, 2000, BIOCHEM J, V348, P551, DOI 10.1042/0264-6021:3480551	45	21	22	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 10	2006	281	6					3722	3730		10.1074/jbc.M509966200	http://dx.doi.org/10.1074/jbc.M509966200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	009QV	16316991	hybrid			2022-12-25	WOS:000235128200084
J	Handy, DE; Hang, GZ; Scolaro, J; Metes, N; Razaq, N; Yang, Y; Loscalzo, J				Handy, DE; Hang, GZ; Scolaro, J; Metes, N; Razaq, N; Yang, Y; Loscalzo, J			Aminoglycosides decrease glutathione peroxidase-1 activity by interfering with selenocysteine incorporation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MAMMALIAN THIOREDOXIN REDUCTASE; NONSENSE-MEDIATED DECAY; MESSENGER-RNA; INSERTION-SEQUENCE; GENE-EXPRESSION; SELENOPROTEIN SYNTHESIS; BINDING PROTEIN; STOP MUTATIONS; FUNCTIONAL-CHARACTERIZATION; GENTAMICIN-NEPHROTOXICITY	Cellular glutathione peroxidase is a key intracellular antioxidant enzyme that contains a selenocysteine residue at its active site. Selenium, a selenocysteine incorporation sequence in the 3'-untranslated region of the glutathione peroxidase mRNA, and other translational cofactors are necessary for "read-through" of a UGA stop codon that specifies selenocysteine incorporation. Aminoglycoside antibiotics facilitate read-through of premature stop codons in prokayotes and eukaryotes. We studied the effects of G418, an aminoglycoside, on cellular glutathione peroxidase expression and function in mammalian cells. Insertion of a selenocysteine incorporation element along with a UGA codon into a reporter construct allows for read-through only in the presence of selenium. G418 increased read-through in selenium-replete cells as well as in the absence of selenium. G418 treatment increased immunodetectable endogenous or recombinant glutathione peroxidase but reduced the specific activity of the enzyme. Tandem mass spectrometry experiments indicated that G418 caused a substitution of L-arginine for selenocysteine. These data show that G418 can affect the biosynthesis of this key antioxidant enzyme by promoting substitution at the UGA codon.	Brigham & Womens Hosp, Dept Med, Boston, MA 02115 USA; Harvard Univ, Sch Med, Boston, MA 02115 USA	Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School	Handy, DE (corresponding author), Brigham & Womens Hosp, Dept Med, HMS-NRB 0630,77 Ave Louis Pasteur, Boston, MA 02115 USA.	dhandy@rics.bwh.harvard.edu	Loscalzo, Joseph/ABD-8980-2021; Yang, Yi/C-1297-2013	Yang, Yi/0000-0001-7896-1184; Sutton, Nadia/0000-0002-0968-3085; Handy, Diane/0000-0002-4310-8527	NHLBI NIH HHS [P50 HL055993, N01 HV028178, N01 HV28178, P01 HL81587, R01 HL058976, HL61795, R01 HL59876] Funding Source: Medline; DIVISION OF HEART AND VASCULAR DISEASES [N01HV028178] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL081587, R37HL061795, R01HL058976, R01HL061795, P50HL055993] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); DIVISION OF HEART AND VASCULAR DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Ali BH, 2003, FOOD CHEM TOXICOL, V41, P1447, DOI 10.1016/S0278-6915(03)00186-8; Atessahin A, 2003, PHARMACOL RES, V48, P637, DOI 10.1016/S1043-6618(03)00227-5; Barton-Davis ER, 1999, J CLIN INVEST, V104, P375, DOI 10.1172/JCI7866; Behne D, 2001, ANNU REV NUTR, V21, P453, DOI 10.1146/annurev.nutr.21.1.453; BERRY MJ, 1992, ENDOCRINOLOGY, V131, P1848, DOI 10.1210/en.131.4.1848; BERRY MJ, 1994, NUCLEIC ACIDS RES, V22, P3753, DOI 10.1093/nar/22.18.3753; BERRY MJ, 1993, EMBO J, V12, P3315, DOI 10.1002/j.1460-2075.1993.tb06001.x; CHADA S, 1989, BLOOD, V74, P2535; Copeland PR, 2003, GENE, V312, P17, DOI 10.1016/S0378-1119(03)00588-2; Copeland PR, 1999, J BIOL CHEM, V274, P25447, DOI 10.1074/jbc.274.36.25447; Cuzzocrea S, 2002, EUR J PHARMACOL, V450, P67, DOI 10.1016/S0014-2999(02)01749-1; DAVIES J, 1965, MOL PHARMACOL, V1, P93; Driscoll DM, 2003, ANNU REV NUTR, V23, P17, DOI 10.1146/annurev.nutr.23.011702.073318; Erdem A, 2000, NEPHROL DIAL TRANSPL, V15, P1175, DOI 10.1093/ndt/15.8.1175; Ferraiuolo MA, 2004, P NATL ACAD SCI USA, V101, P4118, DOI 10.1073/pnas.0400933101; Fletcher JE, 2001, RNA, V7, P1442; Gasdaska JR, 1999, J BIOL CHEM, V274, P25379, DOI 10.1074/jbc.274.36.25379; GORINI L, 1964, P NATL ACAD SCI USA, V51, P995, DOI 10.1073/pnas.51.6.995; Grundner-Culemann E, 2001, J MOL BIOL, V310, P699, DOI 10.1006/jmbi.2001.4809; Handy DE, 2005, J BIOL CHEM, V280, P15518, DOI 10.1074/jbc.M501452200; Hoppe G, 2003, ARCH BIOCHEM BIOPHYS, V414, P19, DOI 10.1016/S0003-9861(03)00144-9; Howard M, 1996, NAT MED, V2, P467, DOI 10.1038/nm0496-467; Howard MT, 2004, ANN NEUROL, V55, P422, DOI 10.1002/ana.20052; Keeling KM, 2001, HUM MOL GENET, V10, P291, DOI 10.1093/hmg/10.3.291; Kisselev L, 2003, EMBO J, V22, P175, DOI 10.1093/emboj/cdg017; Kotra LP, 2000, ANTIMICROB AGENTS CH, V44, P3249, DOI 10.1128/AAC.44.12.3249-3256.2000; Kuiper GGJM, 2003, ENDOCRINOLOGY, V144, P2505, DOI 10.1210/en.2003-0084; Lee SR, 2000, P NATL ACAD SCI USA, V97, P2521, DOI 10.1073/pnas.050579797; LEINFELDER W, 1988, NATURE, V331, P723, DOI 10.1038/331723a0; Leonard JL, 1996, J CELL BIOCHEM, V61, P410, DOI 10.1002/(SICI)1097-4644(19960601)61:3<410::AID-JCB8>3.0.CO;2-W; Lesoon A, 1997, MOL CELL BIOL, V17, P1977, DOI 10.1128/MCB.17.4.1977; Lin CL, 2002, ELECTROPHORESIS, V23, P513, DOI 10.1002/1522-2683(200202)23:4<513::AID-ELPS513>3.0.CO;2-J; LOW SC, 1995, J BIOL CHEM, V270, P21659, DOI 10.1074/jbc.270.37.21659; Maiorino M, 1998, Z ERNAHRUNGSWISS, V37, P118; Manuvakhova M, 2000, RNA, V6, P1044, DOI 10.1017/S1355838200000716; MARTIN R, 1989, MOL GEN GENET, V217, P411, DOI 10.1007/BF02464911; MCCAUGHAN KK, 1995, P NATL ACAD SCI USA, V92, P5431, DOI 10.1073/pnas.92.12.5431; Mehta A, 2004, J BIOL CHEM, V279, P37852, DOI 10.1074/jbc.M404639200; Moriarty PM, 1998, MOL CELL BIOL, V18, P2932, DOI 10.1128/MCB.18.5.2932; Namy O, 2004, MOL CELL, V13, P157, DOI 10.1016/S1097-2765(04)00031-0; Ozawa Y, 2002, GENE, V300, P79, DOI 10.1016/S0378-1119(02)01042-9; Pedraza-Chaverri J, 2000, FREE RADICAL BIO MED, V29, P602, DOI 10.1016/S0891-5849(00)00354-3; Sachdev SW, 2001, BIOCHEM J, V357, P851; Schulz A, 2002, J CLIN ENDOCR METAB, V87, P5247, DOI 10.1210/jc.2002-020286; Shen QC, 1998, J BIOL CHEM, V273, P5443, DOI 10.1074/jbc.273.10.5443; SINGH A, 1979, NATURE, V277, P146, DOI 10.1038/277146a0; Soejima A, 1998, NEPHRON, V80, P331, DOI 10.1159/000045194; Stadtman TC, 2000, ANN NY ACAD SCI, V899, P399, DOI 10.1111/j.1749-6632.2000.tb06203.x; Sun XL, 2000, EMBO J, V19, P4734, DOI 10.1093/emboj/19.17.4734; Tujebajeva RM, 2000, EMBO REP, V1, P158, DOI 10.1093/embo-reports/kvd033; URSINI F, 1995, METHOD ENZYMOL, V252, P38; Weiss N, 2001, P NATL ACAD SCI USA, V98, P12503, DOI 10.1073/pnas.231428998; Wilschanski M, 2003, NEW ENGL J MED, V349, P1433, DOI 10.1056/NEJMoa022170; Wingler K, 1999, EUR J BIOCHEM, V259, P149, DOI 10.1046/j.1432-1327.1999.00012.x; Wu WJ, 2002, AUDIOL NEURO-OTOL, V7, P171, DOI 10.1159/000058305; Yazar E, 2003, CAN J VET RES, V67, P239; Zavacki AM, 2003, MOL CELL, V11, P773, DOI 10.1016/S1097-2765(03)00064-9; Zhong LW, 2000, J BIOL CHEM, V275, P18121, DOI 10.1074/jbc.M000690200; Zsembery A, 2002, HEPATOLOGY, V35, P95, DOI 10.1053/jhep.2002.30423	59	31	31	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 10	2006	281	6					3382	3388		10.1074/jbc.M511295200	http://dx.doi.org/10.1074/jbc.M511295200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	009QV	16354666	Green Published, hybrid, Green Accepted			2022-12-25	WOS:000235128200046
J	Jurkuvenaite, A; Varga, K; Nowotarski, K; Kirk, KL; Sorscher, EJ; Li, Y; Clancy, JP; Bebok, Z; Collawn, JF				Jurkuvenaite, A; Varga, K; Nowotarski, K; Kirk, KL; Sorscher, EJ; Li, Y; Clancy, JP; Bebok, Z; Collawn, JF			Mutations in the amino terminus of the cystic fibrosis transmembrane conductance regulator enhance endocytosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTERNALIZATION SEQUENCE; CHLORIDE CHANNELS; CFTR; DOMAIN; PROTEIN; IDENTIFICATION; DETERMINANT; DEGRADATION; MEMBRANE; SIGNALS	Efficient endocytosis of the cystic fibrosis transmembrane conductance regulator (CFTR) is mediated by a tyrosine-based internalization signal in the CFTR carboxyl-terminal tail (YDSI1427)-Y-1424. In the present studies, two naturally occurring cystic fibrosis mutations in the amino terminus of CFTR, R31C, and R31L were examined. To determine the defect that these mutations cause, the Arg-31 mutants were expressed in COS-7 cells and their biogenesis and trafficking to the cell surface tested in metabolic pulse-chase and surface biotinylation assays, respectively. The results indicated that both Arg-31 mutants were processed to band C at similar to 50% the efficiency of the wild-type protein. However, once processed and delivered to the cell surface, their half-lives were the same as wildtype protein. Interestingly, indirect immunofluorescence and cell surface biotinylation indicated that the surface pool was much smaller than could be accounted for based on the biogenesis defect alone. Therefore, the Arg-31 mutants were tested in internalization assays and found to be internalized at 2x the rate of the wild-type protein. Patch clamp and 6-methoxy-N-(3-sulfopropyl) quinolinium analysis confirmed reduced amounts of functional Arg-31 channels at the cell surface. Together, the results suggest that both R31C and R31L mutations compromise biogenesis and enhance internalization of CFTR. These two additive effects contribute to the loss of surface expression and the associated defect in chloride conductance that is consistent with a disease phenotype.	Univ Alabama Birmingham, Dept Cell Biol, Birmingham, AL 35294 USA; Univ Alabama Birmingham, Dept Physiol & Biophys, Birmingham, AL 35294 USA; Univ Alabama Birmingham, Dept Med, Birmingham, AL 35294 USA; Univ Alabama Birmingham, Dept Pediat, Birmingham, AL 35294 USA; Univ Alabama Birmingham, Gregory Fleming James Cyst Fibrosis Ctr, Birmingham, AL 35294 USA	University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham	Collawn, JF (corresponding author), Univ Alabama Birmingham, Dept Cell Biol, 1918 Univ Blvd,MCLM 350, Birmingham, AL 35294 USA.	jcollawn@uab.edu		Jurkuvenaite, Asta/0000-0002-9193-5797; Sorscher, Eric J./0000-0001-9341-3354; Collawn, James/0000-0002-2528-2759	NHLBI NIH HHS [HL076587] Funding Source: Medline; NIDDK NIH HHS [DK60065] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL076587] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK060065] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Bebok Z, 2002, J BIOL CHEM, V277, P43041, DOI 10.1074/jbc.M203154200; BIWERSI J, 1994, AM J PHYSIOL, V266, pC149, DOI 10.1152/ajpcell.1994.266.1.C149; BRADBURY NA, 1994, J BIOL CHEM, V269, P8296; CHENG SH, 1990, CELL, V63, P827, DOI 10.1016/0092-8674(90)90148-8; CHENG SH, 1991, CELL, V66, P1027, DOI 10.1016/0092-8674(91)90446-6; Clancy JP, 1998, BIOCHEMISTRY-US, V37, P15222, DOI 10.1021/bi980436f; COLLAWN JF, 1990, CELL, V63, P1061, DOI 10.1016/0092-8674(90)90509-D; Cormet-Boyaka E, 2004, P NATL ACAD SCI USA, V101, P8221, DOI 10.1073/pnas.0400459101; DEMOLOMBE S, 1994, EUR J CELL BIOL, V65, P214; DENNING GM, 1992, NATURE, V358, P761, DOI 10.1038/358761a0; Gentzsch M, 2004, MOL BIOL CELL, V15, P2684, DOI 10.1091/mbc.E04-03-0176; Hu W, 2001, BIOCHEM J, V354, P561, DOI 10.1042/0264-6021:3540561; Lukacs GL, 1997, BIOCHEM J, V328, P353; LUKACS GL, 1992, J BIOL CHEM, V267, P14568; Naren AP, 1999, SCIENCE, V286, P544, DOI 10.1126/science.286.5439.544; Naren AP, 1998, P NATL ACAD SCI USA, V95, P10972, DOI 10.1073/pnas.95.18.10972; Peter K, 2002, J BIOL CHEM, V277, P49952, DOI 10.1074/jbc.M209275200; Prince LS, 1999, J BIOL CHEM, V274, P3602, DOI 10.1074/jbc.274.6.3602; PRINCE LS, 1993, AM J PHYSIOL, V264, pC491, DOI 10.1152/ajpcell.1993.264.2.C491; PRINCE LS, 1994, P NATL ACAD SCI USA, V91, P5192, DOI 10.1073/pnas.91.11.5192; Rowntree RK, 2003, ANN HUM GENET, V67, P471, DOI 10.1046/j.1469-1809.2003.00028.x; Schultz BD, 1996, AM J PHYSIOL-LUNG C, V271, pL192, DOI 10.1152/ajplung.1996.271.2.L192; Sharma M, 2004, J CELL BIOL, V164, P923, DOI 10.1083/jcb.200312018; Silvis MR, 2003, J BIOL CHEM, V278, P11554, DOI 10.1074/jbc.M212843200; Straley KS, 1998, MOL BIOL CELL, V9, P1683, DOI 10.1091/mbc.9.7.1683; Swiatecka-Urban A, 2005, J BIOL CHEM, V280, P36762, DOI 10.1074/jbc.M508944200; Varga K, 2004, J BIOL CHEM, V279, P22578, DOI 10.1074/jbc.M401522200; Wang W, 2005, J BIOL CHEM, V280, P23622, DOI 10.1074/jbc.M503118200; WARD CL, 1995, CELL, V83, P121, DOI 10.1016/0092-8674(95)90240-6; WEBSTER P, 1994, AM J PHYSIOL, V267, pC340, DOI 10.1152/ajpcell.1994.267.2.C340; Weixel KM, 2001, PFLUG ARCH EUR J PHY, V443, pS70; Weixel KM, 2001, J BIOL CHEM, V276, P46251, DOI 10.1074/jbc.M104545200; Weixel KM, 2000, J BIOL CHEM, V275, P3655, DOI 10.1074/jbc.275.5.3655; ZIELENSKI J, 1995, HUM MUTAT, V5, P43, DOI 10.1002/humu.1380050106	34	30	33	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 10	2006	281	6					3329	3334		10.1074/jbc.M508131200	http://dx.doi.org/10.1074/jbc.M508131200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	009QV	16339147	hybrid			2022-12-25	WOS:000235128200040
J	Kwon, G; Marshall, CA; Liu, H; Pappan, KL; Remedi, MS; McDaniel, ML				Kwon, G; Marshall, CA; Liu, H; Pappan, KL; Remedi, MS; McDaniel, ML			Glucose-stimulated DNA synthesis through mammalian target of rapamycin (mTOR) is regulated by K-ATP channels - Effects on cell cycle progression in rodent islets	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PANCREATIC BETA-CELLS; METABOLIC-REGULATION; SIGNALING PATHWAY; IN-VIVO; MASS; PROLIFERATION; MITOCHONDRIA; ACTIVATION; DIAZOXIDE; APOPTOSIS	The aim of this study was to define metabolic signaling pathways that mediate DNA synthesis and cell cycle progression in adult rodent islets to devise strategies to enhance survival, growth, and proliferation. Since previous studies indicated that glucose-stimulated activation of mammalian target of rapamycin (mTOR) leads to [H-3]thymidine incorporation and that mTOR activation is mediated, in part, through the K-ATP channel and changes in cytosolic Ca2+, we determined whether glyburide, an inhibitor of KATP channels that stimulates Ca2+ influx, modulates [H-3]thymidine incorporation. Glyburide (10-100 nM) at basal glucose stimulated [H-3]thymidine incorporation to the same magnitude as elevated glucose and further enhanced the ability of elevated glucose to increase [H-3]thymidine incorporation. Diazoxide (250 mu M), an activator of KATP channels, paradoxically potentiated glucose-stimulated [H-3]thymidine incorporation 2-4-fold above elevated glucose alone. Cell cycle analysis demonstrated that chronic exposure of islets to basal glucose resulted in a typical cell cycle progression pattern that is consistent with a low level of proliferation. In contrast, chronic exposure to elevated glucose or glyburide resulted in progression from G(0)/G(1) to an accumulation in S phase and a reduction in G(2)/M phase. Rapamycin (100 nM) resulted in an similar to 62% reduction of S phase accumulation. The enhanced [H-3]thymidine incorporation with chronic elevated glucose or glyburide therefore appears to be associated with S phase accumulation. Since diazoxide significantly enhanced [H-3]thymidine incorporation without altering S phase accumulation under chronic elevated glucose, this increase in DNA synthesis also appears to be primarily related to an arrest in S phase and not cell proliferation.	Washington Univ, Sch Med, Dept Pathol & Immunol, St Louis, MO 63110 USA; Washington Univ, Sch Med, Dept Cell Biol & Physiol, St Louis, MO 63110 USA; So Illinois Univ, Sch Pharm, Edwardsville, IL 62026 USA	Washington University (WUSTL); Washington University (WUSTL); Southern Illinois University System; Southern Illinois University Edwardsville	McDaniel, ML (corresponding author), Washington Univ, Sch Med, Dept Pathol & Immunol, Campus Box 8118,660 S Euclid Ave, St Louis, MO 63110 USA.	mmcdaniel@wustl.edu	Pappan, Kirk/AAV-5946-2021	Pappan, Kirk/0000-0002-2341-8798	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R56DK006181, R01DK006181] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK-06181] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Belanger S, 2005, GYNECOL ONCOL, V97, P796, DOI 10.1016/j.ygyno.2005.02.018; Bjorklund A, 2000, DIABETES, V49, P1840, DOI 10.2337/diabetes.49.11.1840; BRADLEY LM, 1980, SELECTED METHODS CEL, P156; Briaud I, 2005, J BIOL CHEM, V280, P2282, DOI 10.1074/jbc.M412179200; Briaud I, 2003, DIABETES, V52, P974, DOI 10.2337/diabetes.52.4.974; Conus NM, 1998, J BIOL CHEM, V273, P4776, DOI 10.1074/jbc.273.8.4776; Dor Y, 2004, NATURE, V429, P41, DOI 10.1038/nature02520; Fikaris AJ, 2005, J BIOL CHEM, V280, P32107, DOI 10.1074/jbc.M504432200; Grimmsmann T, 1998, BRIT J PHARMACOL, V123, P781, DOI 10.1038/sj.bjp.0701663; GUIOT Y, 1994, EUR J PHARMACOL, V261, P157, DOI 10.1016/0014-2999(94)90314-X; Hannan KM, 2003, BIOCHEM J, V370, P469, DOI 10.1042/BJ20021709; Harris Thurl E, 2003, Sci STKE, V2003, pre15; Hay N, 2004, GENE DEV, V18, P1926, DOI 10.1101/gad.1212704; Holmuhamedov E, 2002, FASEB J, V16, P1010, DOI 10.1096/fj.01-0996com; Holmuhamedov EL, 1999, J PHYSIOL-LONDON, V519, P347, DOI 10.1111/j.1469-7793.1999.0347m.x; Kullin M, 2003, DIABETOLOGIA, V46, P80, DOI 10.1007/s00125-002-0997-0; Kwon G, 2004, DIABETES, V53, pS225, DOI 10.2337/diabetes.53.suppl_3.S225; Laybutt DR, 2003, J BIOL CHEM, V278, P2997, DOI 10.1074/jbc.M210581200; Laybutt DR, 2002, DIABETES, V51, P413, DOI 10.2337/diabetes.51.2.413; Lipsett M, 2002, DIABETES, V51, P1834, DOI 10.2337/diabetes.51.6.1834; Maedler K, 2005, J CLIN ENDOCR METAB, V90, P501, DOI 10.1210/jc.2004-0699; Maedler K, 2001, DIABETES, V50, P1683, DOI 10.2337/diabetes.50.8.1683; MCDANIEL ML, 1983, METHOD ENZYMOL, V98, P182; McDaniel ML, 2002, DIABETES, V51, P2877, DOI 10.2337/diabetes.51.10.2877; Montanya E, 2000, DIABETES, V49, P1341, DOI 10.2337/diabetes.49.8.1341; Namkung Y, 2001, J CLIN INVEST, V108, P1015, DOI 10.1172/JCI13310; Ozcan C, 2001, J THORAC CARDIOV SUR, V121, P298, DOI 10.1067/mtc.2001.111421; PARDEE AB, 1989, SCIENCE, V246, P603, DOI 10.1126/science.2683075; Paris M, 2003, ENDOCRINOLOGY, V144, P2717, DOI 10.1210/en.2002-221112; Rhodes CJ, 2005, SCIENCE, V307, P380, DOI 10.1126/science.1104345; Rother KI, 2004, J CLIN INVEST, V114, P877, DOI 10.1172/JC1200423235; Steil GM, 2001, AM J PHYSIOL-ENDOC M, V280, pE788, DOI 10.1152/ajpendo.2001.280.5.E788; Xu G, 2001, DIABETES, V50, P353, DOI 10.2337/diabetes.50.2.353; Xu G, 1998, J BIOL CHEM, V273, P28178, DOI 10.1074/jbc.273.43.28178; Yarosh DB, 2002, METHODS, V28, P55, DOI 10.1016/S1046-2023(02)00209-8; Yoshikawa H, 2004, AM J PHYSIOL-ENDOC M, V287, pE1202, DOI 10.1152/ajpendo.00255.2004	36	51	53	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 10	2006	281	6					3261	3267		10.1074/jbc.M508821200	http://dx.doi.org/10.1074/jbc.M508821200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	009QV	16344552	hybrid			2022-12-25	WOS:000235128200031
J	Sanderson-Smith, M; Batzloff, M; Sriprakash, KS; Dowton, M; Ranson, M; Walker, MJ				Sanderson-Smith, M; Batzloff, M; Sriprakash, KS; Dowton, M; Ranson, M; Walker, MJ			Divergence in the plasminogen-binding group A streptococcal M protein family - Functional conservation of binding site and potential role for immune selection of variants	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POPULATION GENETIC-STRUCTURE; BACTERIAL SURFACE PROTEIN; ESCHERICHIA-COLI; KRINGLE-2 DOMAIN; ALPHA-ENOLASE; PYOGENES; PAM; EVOLUTION; REGION; STREPTOKINASE	Group A streptococci ( GAS) display receptors for the human zymogen plasminogen on the cell surface, one of which is the plasminogen-binding group A streptococcal M protein (PAM). Characterization of PAM genes from 12 GAS isolates showed significant variation within the plasminogen-binding repeat motifs (a1/a2) of this protein. To determine the impact of sequence variation on protein function, recombinant proteins representing five naturally occurring variants of PAM, together with a recombinant M1 protein, were expressed and purified. Equilibrium dissociation constants for the interaction of PAM variants with biotinylated Glu-plasminogen ranged from 1.58 to 4.99 nM. Effective concentrations of prototype PAM required for 50% inhibition of plasminogen binding to immobilized PAM variants ranged from 0.68 to 22.06 nM. These results suggest that although variation in the a1/a2 region of the PAM protein does affect the comparative affinity of PAM variants, the functional capacity to bind plasminogen is conserved. Additionally, a potential role for the a1 region of PAM in eliciting a protective immune response was investigated by using a mouse model for GAS infection. The a1 region of PAM was found to protect immunized mice challenged with a PAM-positive GAS strain. These data suggest a link between selective immune pressure against the plasminogen-binding repeats and the functional conservation of the binding domain in PAM variants.	Univ Wollongong, Sch Biol Sci, Wollongong, NSW 2522, Australia; Queensland Inst Med Res, Herston, Qld 4006, Australia	University of Wollongong; QIMR Berghofer Medical Research Institute	Walker, MJ (corresponding author), Univ Wollongong, Sch Biol Sci, Wollongong, NSW 2522, Australia.	mwalker@uow.edu.au	Dowton, Mark/A-7766-2012; Ranson, Marie/A-6324-2008; Sanderson-Smith, Martina/O-9387-2019; Sanderson-Smith, Martina L/H-9614-2013; Ranson, Marie/GRO-5792-2022; Walker, Mark J./F-6940-2011; Ranson, Marie/AAC-4468-2019	Dowton, Mark/0000-0003-3180-2922; Ranson, Marie/0000-0002-5570-9645; Sanderson-Smith, Martina L/0000-0002-6366-4993; Ranson, Marie/0000-0002-5570-9645; Ranson, Marie/0000-0002-5570-9645; Walker, Mark/0000-0001-7423-2769				Andronicos NM, 1997, BBA-PROTEIN STRUCT M, V1337, P27, DOI 10.1016/S0167-4838(96)00146-X; BEACHEY EH, 1977, J EXP MED, V145, P1469, DOI 10.1084/jem.145.6.1469; BEACHEY EH, 1979, J EXP MED, V150, P862, DOI 10.1084/jem.150.4.862; BENNASR A, 1994, EUR J BIOCHEM, V222, P267, DOI 10.1111/j.1432-1033.1994.tb18865.x; Beres SB, 2004, P NATL ACAD SCI USA, V101, P11833, DOI 10.1073/pnas.0404163101; BERGE A, 1993, J BIOL CHEM, V268, P25417; Bessen DE, 1996, J INFECT DIS, V173, P896, DOI 10.1093/infdis/173.4.896; Brandt ER, 1996, IMMUNOLOGY, V89, P331, DOI 10.1046/j.1365-2567.1996.d01-754.x; Cedervall T, 1997, BIOCHEMISTRY-US, V36, P4987, DOI 10.1021/bi962971q; Cunningham MW, 2000, CLIN MICROBIOL REV, V13, P470, DOI 10.1128/CMR.13.3.470-511.2000; DANO K, 1985, ADV CANCER RES, V44, P139, DOI 10.1016/S0065-230X(08)60028-7; HARBAUGH MP, 1993, MOL MICROBIOL, V8, P981, DOI 10.1111/j.1365-2958.1993.tb01642.x; Hayman WA, 1997, INT IMMUNOL, V9, P1723, DOI 10.1093/intimm/9.11.1723; HOLLINGSHEAD SK, 1993, MOL MICROBIOL, V8, P707, DOI 10.1111/j.1365-2958.1993.tb01614.x; Huelsenbeck JP, 2001, SCIENCE, V294, P2310, DOI 10.1126/science.1065889; HUNTER WM, 1962, NATURE, V194, P495, DOI 10.1038/194495a0; JONES KF, 1988, P NATL ACAD SCI USA, V85, P8271, DOI 10.1073/pnas.85.21.8271; Kalia A, 2004, J BACTERIOL, V186, P110, DOI 10.1128/JB.186.1.110-121.2004; Kalia A, 2002, INFECT IMMUN, V70, P1971, DOI 10.1128/IAI.70.4.1971-1983.2002; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lahteenmaki K, 2001, FEMS MICROBIOL REV, V25, P531, DOI 10.1111/j.1574-6976.2001.tb00590.x; LOTTENBERG R, 1992, J INFECT DIS, V166, P436, DOI 10.1093/infdis/166.2.436; LOTTENBERG R, 1992, J BACTERIOL, V174, P5204, DOI 10.1128/JB.174.16.5204-5210.1992; McKay FC, 2004, INFECT IMMUN, V72, P364, DOI 10.1128/IAI.72.1.364-370.2004; Olive C, 2002, INFECT IMMUN, V70, P2734, DOI 10.1128/IAI.70.5.2734-2738.2002; Pancholi V, 1998, J BIOL CHEM, V273, P14503, DOI 10.1074/jbc.273.23.14503; PANCHOLI V, 1992, J EXP MED, V176, P415, DOI 10.1084/jem.176.2.415; PONTING CP, 1992, BLOOD COAGUL FIBRIN, V3, P605, DOI 10.1097/00001721-199210000-00012; Ramachandran V, 2004, J BACTERIOL, V186, P7601, DOI 10.1128/JB.186.22.7601-7609.2004; RELF WA, 1994, GENE, V144, P25, DOI 10.1016/0378-1119(94)90198-8; Ringdahl U, 1998, J BIOL CHEM, V273, P6424, DOI 10.1074/jbc.273.11.6424; Rios-Steiner JL, 2001, J MOL BIOL, V308, P705, DOI 10.1006/jmbi.2001.4646; Ronquist F, 2003, BIOINFORMATICS, V19, P1572, DOI 10.1093/bioinformatics/btg180; Sambrook J., 1989, MOL CLONING LAB MANU, P74; Schenone MM, 2000, J PEPT RES, V56, P438, DOI 10.1034/j.1399-3011.2000.00810.x; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; Sun HM, 2004, SCIENCE, V305, P1283, DOI 10.1126/science.1101245; Svensson MD, 1999, INFECT IMMUN, V67, P3915, DOI 10.1128/IAI.67.8.3915-3920.1999; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; Walker MJ, 2005, TRENDS MICROBIOL, V13, P308, DOI 10.1016/j.tim.2005.05.006; WHATMORE AM, 1994, MOL MICROBIOL, V14, P619, DOI 10.1111/j.1365-2958.1994.tb01301.x; Whelan S, 2001, MOL BIOL EVOL, V18, P691, DOI 10.1093/oxfordjournals.molbev.a003851; WISTEDT AC, 1995, MOL MICROBIOL, V18, P569, DOI 10.1111/j.1365-2958.1995.mmi_18030569.x; Wistedt AC, 1998, J BIOL CHEM, V273, P24420, DOI 10.1074/jbc.273.38.24420	44	34	35	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 10	2006	281	6					3217	3226		10.1074/jbc.M508758200	http://dx.doi.org/10.1074/jbc.M508758200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	009QV	16319056	hybrid			2022-12-25	WOS:000235128200026
J	Sou, Y; Tanida, I; Komatsu, M; Ueno, T; Kominami, E				Sou, Y; Tanida, I; Komatsu, M; Ueno, T; Kominami, E			Phosphatidylserine in addition to phosphatidylethanolamine is an in vitro target of the mammalian Atg8 modifiers, LC3, GABARAP, and GATE-16	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CRYSTAL-STRUCTURE; UBIQUITIN SYSTEM; PROTEIN; AUTOPHAGY; CONJUGATION; HOMOLOG; PATHWAY; REVERSE; MAP-LC3; FAMILY	In yeast, phosphatidylethanolamine is a target of the Atg8 modifier in ubiquitylation-like reactions essential for autophagy. Three human Atg8 ( hAtg8) homologs, LC3, GABARAP, and GATE-16, have been characterized as modifiers in reactions mediated by hAtg7 ( an E1-like enzyme) and hAtg3 ( an E2-like enzyme) as in yeast Atg8 lipidation, but their final targets have not been identified. The results of a recent study in which COS7 cells were incubated with [ C-14] ethanolamine for 48 h suggested that phosphatidylethanolamine is a target of LC3. However, these results were not conclusive because of the long incubation time. To identify the phospholipid targets of Atg8 homologs, we reconstituted conjugation systems for mammalian Atg8 homologs in vitro using purified recombinant Atg proteins and liposomes. Each purified mutant Atg8 homolog with an exposed C-terminal Gly formed an E1-substrate intermediate with hAtg7 via a thioester bond in an ATP-dependent manner and formed an E2-substrate intermediate with hAtg3 via a thioester bond dependent on ATP and hAtg7. A conjugated form of each Atg8 homolog was observed in the presence of hAtg7, hAtg3, ATP, and liposomes. In addition to phosphatidylethanolamine, in vitro conjugation experiments using synthetic phospholipid liposomes showed that phosphatidylserine is also a target of LC3, GABARAP, and GATE-16. In contrast, thin layer chromatography of phospholipids released on hAtg4B-digestion from endogenous LC3-phospholipid conjugate revealed that phosphatidylethanolamine, but not phosphatidylserine, is the predominant target phospholipid of LC3 in vivo. The discrepancy between in vitro and in vivo reactions suggested that there may be selective factor( s) involved in the endogenous LC3 conjugation system.	Juntendo Univ, Dept Biochem, Sch Med, Bunkyo Ku, Tokyo 1138421, Japan	Juntendo University	Kominami, E (corresponding author), Juntendo Univ, Dept Biochem, Sch Med, Bunkyo Ku, 2-1-1,Hongo, Tokyo 1138421, Japan.	kominami@med.juntendo.ac.jp	Kominami, Eiki/D-3802-2009; Komatsu, Masaaki/B-8321-2011; Tanida, Isei/C-8277-2009	Komatsu, Masaaki/0000-0001-7672-7722; Tanida, Isei/0000-0001-8999-3990; Sou, Yu-shin/0000-0002-7219-9106				Bavro VN, 2002, EMBO REP, V3, P183, DOI 10.1093/embo-reports/kvf026; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; Bonifacino JS, 1998, ANNU REV CELL DEV BI, V14, P19, DOI 10.1146/annurev.cellbio.14.1.19; Duzgunes N, 2003, METHOD ENZYMOL, V367, P23; Glickman MH, 2002, PHYSIOL REV, V82, P373, DOI 10.1152/physrev.00027.2001; Hershko A, 1998, ANNU REV BIOCHEM, V67, P425, DOI 10.1146/annurev.biochem.67.1.425; Hochstrasser M, 2000, SCIENCE, V289, P563, DOI 10.1126/science.289.5479.563; HOPE MJ, 1986, CHEM PHYS LIPIDS, V40, P89, DOI 10.1016/0009-3084(86)90065-4; Ichimura Y, 2000, NATURE, V408, P488, DOI 10.1038/35044114; Ichimura Y, 2004, J BIOL CHEM, V279, P40584, DOI 10.1074/jbc.M405860200; Jentsch S, 2000, TRENDS CELL BIOL, V10, P335, DOI 10.1016/S0962-8924(00)01785-2; Johnson ES, 1997, EMBO J, V16, P5509, DOI 10.1093/emboj/16.18.5509; Kabeya Y, 2000, EMBO J, V19, P5720, DOI 10.1093/emboj/19.21.5720; Kabeya Y, 2004, J CELL SCI, V117, P2805, DOI 10.1242/jcs.01131; Kirisako T, 2000, J CELL BIOL, V151, P263, DOI 10.1083/jcb.151.2.263; Komatsu M, 2005, J CELL BIOL, V169, P425, DOI 10.1083/jcb.200412022; Komatsu M, 2004, EMBO J, V23, P1977, DOI 10.1038/sj.emboj.7600205; Ohsumi Y, 2001, NAT REV MOL CELL BIO, V2, P211, DOI 10.1038/35056522; Paz Y, 2000, J BIOL CHEM, V275, P25445, DOI 10.1074/jbc.C000307200; Pickart CM, 2001, ANNU REV BIOCHEM, V70, P503, DOI 10.1146/annurev.biochem.70.1.503; Schwartz DC, 2003, TRENDS BIOCHEM SCI, V28, P321, DOI 10.1016/S0968-0004(03)00113-0; Sugawara K, 2004, GENES CELLS, V9, P611, DOI 10.1111/j.1356-9597.2004.00750.x; Tanida I, 2004, J BIOL CHEM, V279, P36268, DOI 10.1074/jbc.M401461200; Tanida I, 2003, BIOCHEM BIOPH RES CO, V300, P637, DOI 10.1016/S0006-291X(02)02907-8; Tanida I, 2002, J BIOL CHEM, V277, P13739, DOI 10.1074/jbc.M200385200; Tanida I, 2001, J BIOL CHEM, V276, P1701, DOI 10.1074/jbc.C000752200; Tanida I, 2004, INT J BIOCHEM CELL B, V36, P2503, DOI 10.1016/j.biocel.2004.05.009; Varshavsky A, 1997, TRENDS BIOCHEM SCI, V22, P383, DOI 10.1016/S0968-0004(97)01122-5; Wing SS, 2003, INT J BIOCHEM CELL B, V35, P590, DOI 10.1016/S1357-2725(02)00392-8; WRIGHT RS, 1971, J CHROMATOGR, V59, P220, DOI 10.1016/S0021-9673(01)80033-9	30	169	178	0	14	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 10	2006	281	6					3017	3024		10.1074/jbc.M505888200	http://dx.doi.org/10.1074/jbc.M505888200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	009QV	16303767	hybrid			2022-12-25	WOS:000235128200003
J	Gross-Langenhoff, M; Hofbauer, K; Weber, J; Schultz, A; Schultz, JE				Gross-Langenhoff, M; Hofbauer, K; Weber, J; Schultz, A; Schultz, JE			cAMP is a ligand for the tandem GAF domain of human phosphodiesterase 10 and cGMP for the tandem GAF domain of phosphodiesterase 11	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYCLIC-NUCLEOTIDE PHOSPHODIESTERASES; PROSTATIC STROMAL CELLS; ADENYLYL-CYCLASE; EVOLUTIONARY RELATEDNESS; GENOMIC ORGANIZATION; GENE FAMILY; A DOMAIN; BINDING; PDE11A; DIMERIZATION	N-terminal tandem GAF domains are present in 5 out of 11 mammalian phosphodiesterase (PDE) families. The ligand for the GAF domains of PDEs 2, 5, and 6 is cGMP, whereas those for PDEs 10 and 11 remained enigmatic for years. Here we used the cyanobacterial cyaB1 adenylyl cyclase, which has an N-terminal tandem GAF domain closely related to those of the mammalian PDEs, as an assay system to identify the ligands for the human PDEs 10 and 11 GAF domains. We report that a chimera between the PDE10 GAF domain and the cyanobacterial cyclase was 9-fold stimulated by cAMP (EC50 = 19.8 mu M), whereas cGMP had only low activity. cAMP increased V-max in a non-cooperative manner and did not affect the Km for ATP of 27 mu M. In an analogous chimeric construct with the tandem GAF domain of human PDE11A4, cGMP was identified as an allosteric activator (EC50 = 72.5 mu M) that increased V-max of the cyclase non-cooperatively 4-fold. GAF-B of PDE10 and GAF-A of PDE11A4 contain an invariant NKFDE motif present in all mammalian PDE GAF ensembles. We mutated the aspartates within this motif in both regions and found that intramolecular signaling was considerably reduced or abolished. This was in line with all data concerning GAF domains with an NKFDE motif as far as they have been tested. The data appeared to define those GAF domains as a distinct subclass within the > 3100 annotated GAF domains for which we propose a tentative classification scheme.	Univ Tubingen, Abt Pharmazeut Biochem, Fak Chem & Pharm, D-72076 Tubingen, Germany	Eberhard Karls University of Tubingen	Schultz, JE (corresponding author), Univ Tubingen, Abt Pharmazeut Biochem, Fak Chem & Pharm, Morgenstelle 8, D-72076 Tubingen, Germany.	joachim.schultz@uni-tuebingen.de						Aravind L, 1997, TRENDS BIOCHEM SCI, V22, P458, DOI 10.1016/S0968-0004(97)01148-1; BEAVO JA, 1994, MOL PHARMACOL, V46, P399; Beavo JA, 2002, NAT REV MOL CELL BIO, V3, P710, DOI 10.1038/nrm911; BEAVO JA, 1995, PHYSIOL REV, V75, P725, DOI 10.1152/physrev.1995.75.4.725; Bruder S, 2005, P NATL ACAD SCI USA, V102, P3088, DOI 10.1073/pnas.0409917102; Cook ALM, 2004, CELL SIGNAL, V16, P253, DOI 10.1016/S0898-6568(03)00134-7; Cook ALM, 2002, CELL SIGNAL, V14, P1023, DOI 10.1016/S0898-6568(02)00050-5; Corbin JD, 2000, EUR J BIOCHEM, V267, P2760, DOI 10.1046/j.1432-1327.2000.01297.x; ERNEUX C, 1981, EUR J BIOCHEM, V115, P503; Fawcett L, 2000, P NATL ACAD SCI USA, V97, P3702, DOI 10.1073/pnas.050585197; Francis SH, 2001, PROG NUCLEIC ACID RE, V65, P1; Fujishige K, 2000, EUR J BIOCHEM, V267, P5943, DOI 10.1046/j.1432-1327.2000.01661.x; Hetman JM, 2000, P NATL ACAD SCI USA, V97, P12891, DOI 10.1073/pnas.200355397; Houslay MD, 2003, BIOCHEM J, V370, P1, DOI 10.1042/BJ20021698; HURLEY JH, 2003, SCI STKE, pPE1; Kanacher T, 2002, EMBO J, V21, P3672, DOI 10.1093/emboj/cdf375; Karniol B, 2005, BIOCHEM J, V392, P103, DOI 10.1042/BJ20050826; Laxman S, 2005, J BIOL CHEM, V280, P3771, DOI 10.1074/jbc.M408111200; Little R, 2003, J BIOL CHEM, V278, P28711, DOI 10.1074/jbc.M301992200; Loughney K, 2005, INT J IMPOT RES, V17, P320, DOI 10.1038/sj.ijir.3901317; Martinez SE, 2005, P NATL ACAD SCI USA, V102, P3082, DOI 10.1073/pnas.0409913102; Martinez SE, 2002, P NATL ACAD SCI USA, V99, P13260, DOI 10.1073/pnas.192374899; Martinez Sergio E, 2002, Mol Interv, V2, P317, DOI 10.1124/mi.2.5.317; Mou HM, 2001, J BIOL CHEM, V276, P27527, DOI 10.1074/jbc.M103316200; Mullershausen F, 2003, J CELL BIOL, V160, P719, DOI 10.1083/jcb.200211041; Rascon A, 2002, P NATL ACAD SCI USA, V99, P4714, DOI 10.1073/pnas.002031599; Rybalkin SD, 2003, EMBO J, V22, P469, DOI 10.1093/emboj/cdg051; SALOMON Y, 1974, ANAL BIOCHEM, V58, P541, DOI 10.1016/0003-2697(74)90222-X; Schultz J, 1998, P NATL ACAD SCI USA, V95, P5857, DOI 10.1073/pnas.95.11.5857; Seeger TF, 2003, BRAIN RES, V985, P113, DOI 10.1016/S0006-8993(03)02754-9; Soderling SH, 1999, P NATL ACAD SCI USA, V96, P7071, DOI 10.1073/pnas.96.12.7071; Soderling SH, 2000, CURR OPIN CELL BIOL, V12, P174, DOI 10.1016/S0955-0674(99)00073-3; Sopory S, 2003, FEBS LETT, V539, P161, DOI 10.1016/S0014-5793(03)00219-9; Wayman C, 2005, INT J IMPOT RES, V17, P216, DOI 10.1038/sj.ijir.3901307; Wu AY, 2004, J BIOL CHEM, V279, P37928, DOI 10.1074/jbc.M404287200; Yuasa K, 2000, J BIOL CHEM, V275, P31469, DOI 10.1074/jbc.M003041200; Yuasa K, 2001, EUR J BIOCHEM, V268, P4440, DOI 10.1046/j.1432-1327.2001.02366.x; Yuasa K, 2001, EUR J BIOCHEM, V268, P168, DOI 10.1046/j.1432-1327.2001.01866.x; Zoraghi R, 2004, MOL PHARMACOL, V65, P267, DOI 10.1124/mol.65.2.267; Zoraghi R, 2005, J BIOL CHEM, V280, P12051, DOI 10.1074/jbc.M413611200	40	86	96	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 3	2006	281	5					2841	2846		10.1074/jbc.M511468200	http://dx.doi.org/10.1074/jbc.M511468200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	006XT	16330539	hybrid			2022-12-25	WOS:000234931800052
J	Lin, YW; MacMullen, C; Ganguly, A; Stanley, CA; Shyng, SL				Lin, YW; MacMullen, C; Ganguly, A; Stanley, CA; Shyng, SL			A novel KCNJ11 mutation associated with congenital hyperinsulinism reduces the intrinsic open probability of beta-cell ATP-sensitive potassium channels	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SULFONYLUREA RECEPTOR GENE; COENZYME-A ESTERS; ACYL-COA ESTERS; FAMILIAL HYPERINSULINISM; PHOSPHATIDYLINOSITOL 4,5-BISPHOSPHATE; INSULIN-SECRETION; K+ CHANNELS; KIR6.2; HYPOGLYCEMIA; INHIBITION	The beta-cell ATP-sensitive potassium (KATP) channel controls insulin secretion by linking glucose metabolism to membrane excitability. Loss of K-ATP channel function due to mutations in ABCC8 or KCNJ11, genes that encode the sulfonylurea receptor 1 or the inward rectifier Kir6.2 subunit of the channel, is a major cause of congenital hyperinsulinism. Here, we report identification of a novel KCNJ11 mutation associated with the disease that renders a missense mutation, F55L, in the Kir6.2 protein. Mutant channels reconstituted in COS cells exhibited a wild-type-like surface expression level and normal sensitivity to ATP, MgADP, and diazoxide. However, the intrinsic open probability of the mutant channel was greatly reduced, by similar to 10-fold. This low open probability defect could be reversed by application of phosphatidylinositol 4,5-bisphosphates or oleoyl-CoA to the cytoplasmic face of the channel, indicating that reduced channel response to membrane phospholipids and/or long chain acyl-CoAs underlies the low intrinsic open probability in the mutant. Our findings reveal a novel molecular mechanism for loss of K-ATP channel function and congenital hyperinsulinism and support the importance of phospholipids and/or long chain acyl-CoAs in setting the physiological activity of beta-cell K-ATP channels. The F55L mutation is located in the slide helix of Kir6.2. Several permanent neonatal diabetes-associated mutations found in the same structure have the opposite effect of increasing intrinsic channel open probability. Our results also highlight the critical role of the Kir6.2 slide helix in determining the intrinsic open probability of K-ATP channels.	Oregon Hlth & Sci Univ, Ctr Res Occupat & Environm Toxicol, Portland, OR 97239 USA; Childrens Hosp Philadelphia, Div Endocrinol Diabet, Philadelphia, PA 19104 USA	Oregon Health & Science University; University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of Philadelphia	Stanley, CA (corresponding author), Childrens Hosp Philadelphia, Div Endocrinol Diabet, 34th St & Civ Ctr Blvd, Philadelphia, PA 19104 USA.	stanleyc@email.chop.edu; shyngs@ohsu.edu		STANLEY, CHARLES/0000-0003-4881-9392	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK066485, R01DK057699] Funding Source: NIH RePORTER; NCRR NIH HHS [M01 RR000240] Funding Source: Medline; NIDDK NIH HHS [R01 DK057699, R01 DK066485, R01 DK056268] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Aguilar-Bryan L, 1999, ENDOCR REV, V20, P101, DOI 10.1210/er.20.2.101; Aguilar-Bryan L, 2001, RECENT PROG HORM RES, V56, P47, DOI 10.1210/rp.56.1.47; Ashcroft FM, 1999, DIABETOLOGIA, V42, P903, DOI 10.1007/s001250051247; ASHCROFT FM, 1988, ANNU REV NEUROSCI, V11, P97, DOI 10.1146/annurev.neuro.11.1.97; Babenko AP, 1999, J BIOL CHEM, V274, P11587, DOI 10.1074/jbc.274.17.11587; Baukrowitz T, 1998, SCIENCE, V282, P1141, DOI 10.1126/science.282.5391.1141; Branstrom R, 2004, DIABETOLOGIA, V47, P277, DOI 10.1007/s00125-003-1299-x; Branstrom R, 1998, J BIOL CHEM, V273, P31395, DOI 10.1074/jbc.273.47.31395; Clement JP, 1997, NEURON, V18, P827, DOI 10.1016/S0896-6273(00)80321-9; COLLINS JE, 1990, ARCH DIS CHILD, V65, P1118, DOI 10.1136/adc.65.10.1118; COLLINS JE, 1984, LANCET, V2, P311; COOK DL, 1988, DIABETES, V37, P495, DOI 10.2337/diabetes.37.5.495; Crane A, 2004, J BIOL CHEM, V279, P9080, DOI 10.1074/jbc.M311079200; Cukras CA, 2002, J GEN PHYSIOL, V120, P437, DOI 10.1085/jgp.20028621; Drain P, 1998, P NATL ACAD SCI USA, V95, P13953, DOI 10.1073/pnas.95.23.13953; Dunne MJ, 2004, PHYSIOL REV, V84, P239, DOI 10.1152/physrev.00022.2003; Enkvetchakul D, 2000, BIOPHYS J, V78, P2334, DOI 10.1016/S0006-3495(00)76779-8; Fox JEM, 2004, MOL ENDOCRINOL, V18, P679, DOI 10.1210/me.2003-0431; Glaser B, 2000, SEMIN PERINATOL, V24, P150, DOI 10.1053/sp.2000.6365; Gribble FM, 1998, J BIOL CHEM, V273, P26383, DOI 10.1074/jbc.273.41.26383; Henwood MJ, 2005, J CLIN ENDOCR METAB, V90, P789, DOI 10.1210/jc.2004-1604; Huopio H, 2002, AM J PHYSIOL-ENDOC M, V283, pE207, DOI 10.1152/ajpendo.00047.2002; Inagaki N, 1997, FEBS LETT, V409, P232, DOI 10.1016/S0014-5793(97)00488-2; John SA, 2001, J GEN PHYSIOL, V118, P391, DOI 10.1085/jgp.118.4.391; Kuo AL, 2003, SCIENCE, V300, P1922, DOI 10.1126/science.1085028; Larsson O, 2000, DIABETES, V49, P1409, DOI 10.2337/diabetes.49.9.1409; Lin CW, 2005, DIABETES, V54, P2852, DOI 10.2337/diabetes.54.10.2852; Lin YW, 2003, J GEN PHYSIOL, V122, P225, DOI 10.1085/jgp.200308822; Magge SN, 2004, J CLIN ENDOCR METAB, V89, P4450, DOI 10.1210/jc.2004-0441; Matsuo M, 2000, J BIOL CHEM, V275, P41184, DOI 10.1074/jbc.M006503200; NEHER E, 1977, ANNU REV BIOPHYS BIO, V6, P345, DOI 10.1146/annurev.bb.06.060177.002021; Nestorowicz A, 1996, HUM MOL GENET, V5, P1813, DOI 10.1093/hmg/5.11.1813; Nestorowicz A, 1998, HUM MOL GENET, V7, P1119, DOI 10.1093/hmg/7.7.1119; Nestorowicz A, 1997, DIABETES, V46, P1743, DOI 10.2337/diabetes.46.11.1743; Nichols CG, 1996, SCIENCE, V272, P1785, DOI 10.1126/science.272.5269.1785; Proks P, 2005, EMBO REP, V6, P470, DOI 10.1038/sj.embor.7400393; Proks P, 2001, J GEN PHYSIOL, V118, P341, DOI 10.1085/jgp.118.4.341; Proks P, 2004, P NATL ACAD SCI USA, V101, P17539, DOI 10.1073/pnas.0404756101; Riedel MJ, 2005, DIABETES, V54, P2070, DOI 10.2337/diabetes.54.7.2070; Riedel MJ, 2003, DIABETES, V52, P2630, DOI 10.2337/diabetes.52.10.2630; Riedel MJ, 2005, HUM GENET, V116, P133, DOI 10.1007/s00439-004-1216-5; Schulze D, 2003, J BIOL CHEM, V278, P10500, DOI 10.1074/jbc.M208413200; Schulze D, 2003, J PHYSIOL-LONDON, V552, P357, DOI 10.1113/jphysiol.2003.047035; Sharma N, 2000, KIDNEY INT, V57, P803, DOI 10.1046/j.1523-1755.2000.00918.x; Shyng SL, 2000, J GEN PHYSIOL, V116, P599, DOI 10.1085/jgp.116.5.599; Shyng SL, 1997, J GEN PHYSIOL, V110, P141, DOI 10.1085/jgp.110.2.141; Shyng SL, 1998, DIABETES, V47, P1145, DOI 10.2337/diabetes.47.7.1145; Shyng SL, 1997, J GEN PHYSIOL, V110, P655, DOI 10.1085/jgp.110.6.655; Shyng SL, 1998, SCIENCE, V282, P1138, DOI 10.1126/science.282.5391.1138; SIGWORTH FJ, 1980, J PHYSIOL-LONDON, V307, P97, DOI 10.1113/jphysiol.1980.sp013426; Stanley CA, 2002, J CLIN ENDOCR METAB, V87, P4857, DOI 10.1210/jc.2002-021403; Tarasov A, 2004, DIABETES, V53, pS113, DOI 10.2337/diabetes.53.suppl_3.S113; Taschenberger G, 2002, J BIOL CHEM, V277, P17139, DOI 10.1074/jbc.M200363200; THOMAS PM, 1995, SCIENCE, V268, P426, DOI 10.1126/science.7716548	54	59	62	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 3	2006	281	5					3006	3012		10.1074/jbc.M511875200	http://dx.doi.org/10.1074/jbc.M511875200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	006XT	16332676	Green Accepted, hybrid			2022-12-25	WOS:000234931800071
J	Stephens, FB; Constantin-Teodosiu, D; Laithwaite, D; Simpson, EJ; Greenhaff, PL				Stephens, Francis B.; Constantin-Teodosiu, Dumitru; Laithwaite, David; Simpson, Elizabeth J.; Greenhaff, Paul L.			Insulin stimulates L-carnitine accumulation in human skeletal muscle	FASEB JOURNAL			English	Article									[Stephens, Francis B.; Constantin-Teodosiu, Dumitru; Laithwaite, David; Simpson, Elizabeth J.; Greenhaff, Paul L.] Univ Nottingham, Queens Med Ctr, Sch Biomed Sci, Ctr Integrated Syst Biol & Med, Nottingham NG7 2UH, England	University of Nottingham	Stephens, FB (corresponding author), Univ Nottingham, Queens Med Ctr, Sch Biomed Sci, Sch Med, Nottingham NG7 2UH, England.	mbxfbs@nottingham.ac.uk	, Liz/M-7432-2019	, Liz/0000-0001-9353-6258; Constantin-Teodosiu, Dumitru/0000-0002-8448-5564; Greenhaff, Paul/0000-0003-4403-0490; Stephens, Francis/0000-0001-6312-5351					0	73	75	0	11	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	FEB	2006	20	2					377	379		10.1096/fj.05-4985fje	http://dx.doi.org/10.1096/fj.05-4985fje			3	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	V17CJ	16368715				2022-12-25	WOS:000207915000027
J	Cavard, C; Terris, B; Grimber, G; Christa, L; Audard, V; Bussiere, BR; Simon, MT; Renard, CA; Buendia, MA; Perret, C				Cavard, C; Terris, B; Grimber, G; Christa, L; Audard, V; Bussiere, BR; Simon, MT; Renard, CA; Buendia, MA; Perret, C			Overexpression of regenerating islet-derived 1 alpha and 3 alpha genes in human primaryliver tumors with beta-catenin mutations	ONCOGENE			English	Article						beta-catenin; REG1A; REG3A; hepatocellular; carcinoma; hepatoblastoma; Wnt signaling	PANCREATITIS-ASSOCIATED PROTEIN; HUMAN HEPATOCELLULAR CARCINOMAS; REG-I; CHILDHOOD HEPATOBLASTOMA; LIVER-REGENERATION; CANCER-CELLS; EXPRESSION; ADENOMAS; GROWTH; CHOLANGIOCARCINOMA	The Wnt/beta-catenin signaling pathways activated in many human hepatocellular carcinomas (HCC). We tried to identify the genes involved in carcinogenesis and progression of HCC with beta-catenin mutations. We used PCR-based subtractive hybridization to compare gene expression between malignant and benign components of a human HCC occurring in pre-existing adenoma activated for beta-catenin. Two of the genes identified belong to the Regenerating gene (REG) family. They encode the Regenerating islet-derived 3 alpha (REG3A/HIP/PAP/ REG-III) and 1 alpha (REG1A) proteins, both involved in liver and pancreatic regeneration and proliferation. Using siRNA directed against beta-catenin, we demonstrated that REG3A is a target of beta-catenin signaling in Huh7 hepatoma cells. The upregulation of REG3A and REG1A expression is significantly correlated to the beta-catenin status in 42 HCC and 28 hepatoblastomas characterized for their b-catenin status. Thus, we report strong evidence that both genes are downstream targets of the Wnt pathway during liver tumorigenesis.	Univ Paris 05, INSERM, U567, CNRS,UMR 8104,Inst Cochin,Dept GDPM, F-75014 Paris, France; Univ Paris 05, Hop Cochin, Serv Anat Pathol, F-75014 Paris, France; Univ Paris 05, Inst Necker Pasteur, INSERM, U370, F-75014 Paris, France; Inst Pasteur, INSERM, U579, Unite Oncogenese & Virol Mol, F-75724 Paris, France	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Cochin - APHP; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Cochin - APHP; UDICE-French Research Universities; Universite Paris Cite; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Institut National de la Sante et de la Recherche Medicale (Inserm); Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris	Cavard, C (corresponding author), Univ Paris 05, INSERM, U567, CNRS,UMR 8104,Inst Cochin,Dept GDPM, 24 Rue Faubourg St Jacques, F-75014 Paris, France.	cavard@cochin.inserm.fr	Terris, Benoit/P-1497-2017; Perret-Mayeux, Christine/L-3297-2017	perret, christine/0000-0003-4710-7051				Andreu P, 2005, DEVELOPMENT, V132, P1443, DOI 10.1242/dev.01700; Bernard-Perrone FR, 1999, J HISTOCHEM CYTOCHEM, V47, P863, DOI 10.1177/002215549904700703; Bioulac-Sage P, 2003, HEPATOLOGY, V37, P480, DOI 10.1053/jhep.2003.50058; Bluteau O, 2002, NAT GENET, V32, P312, DOI 10.1038/ng1001; Bruix J, 2004, CANCER CELL, V5, P215, DOI 10.1016/S1535-6108(04)00058-3; Buckhaults P, 2001, CANCER RES, V61, P6996; Buendia MA, 2002, MED PEDIATR ONCOL, V39, P530, DOI 10.1002/mpo.10180; Buendia MA, 2000, SEMIN CANCER BIOL, V10, P185; Cadoret A, 2002, ONCOGENE, V21, P8293, DOI 10.1038/sj.onc.1206118; Chen YW, 2002, HEPATOLOGY, V36, P927, DOI 10.1053/jhep.2002.36126; Christa L, 1999, AM J PATHOL, V155, P1525, DOI 10.1016/S0002-9440(10)65468-5; de La Coste A, 1998, P NATL ACAD SCI USA, V95, P8847; Dhar DK, 2004, CANCER-AM CANCER SOC, V100, P1130, DOI 10.1002/cncr.20097; DUSETTI NJ, 1994, GENOMICS, V19, P108, DOI 10.1006/geno.1994.1019; El-Serag HB, 2002, HEPATOLOGY, V36, pS74, DOI 10.1053/jhep.2002.36807; Fukui H, 2004, DIGESTION, V69, P177, DOI 10.1159/000078762; Giles RH, 2003, BBA-REV CANCER, V1653, P1, DOI 10.1016/S0304-419X(03)00005-2; Harada K, 2001, HEPATOLOGY, V33, P1036, DOI 10.1053/jhep.2001.24168; IOVANNA J, 1991, J BIOL CHEM, V266, P24664; LASSERRE C, 1992, CANCER RES, V52, P5089; Laurent-Puig P, 2001, GASTROENTEROLOGY, V120, P1763, DOI 10.1053/gast.2001.24798; Levy L, 2002, J BIOL CHEM, V277, P42386, DOI 10.1074/jbc.M207418200; Macadam RCA, 2000, BRIT J CANCER, V83, P188; Malka D, 2000, GASTROENTEROLOGY, V119, P816, DOI 10.1053/gast.2000.16491; Ortiz EM, 1998, GASTROENTEROLOGY, V114, P808, DOI 10.1016/S0016-5085(98)70595-5; Ovejero C, 2004, HEPATOLOGY, V40, P167, DOI 10.1002/hep.20286; Parkin DM, 2001, EUR J CANCER, V37, pS4, DOI 10.1016/S0959-8049(01)00267-2; Perilongo G, 2004, EUR J CANCER, V40, P411, DOI 10.1016/j.ejca.2003.06.003; Polakis P, 2000, GENE DEV, V14, P1837; Rechreche H, 1999, INT J CANCER, V81, P688, DOI 10.1002/(SICI)1097-0215(19990531)81:5<688::AID-IJC3>3.0.CO;2-R; Satoh S, 2000, NAT GENET, V24, P245, DOI 10.1038/73448; Simon MT, 2003, FASEB J, V17, P1441, DOI 10.1096/fj.02-1013com; Stambolic V, 1996, CURR BIOL, V6, P1664, DOI 10.1016/S0960-9822(02)70790-2; Takayasu H, 2002, HUM PATHOL, V33, P852, DOI 10.1053/hupa.2002.125771; Takayasu H, 2001, CLIN CANCER RES, V7, P901; Taniguchi K, 2002, ONCOGENE, V21, P4863, DOI 10.1038/sj.onc.1205591; TERAZONO K, 1988, J BIOL CHEM, V263, P2111; Terris B, 1999, ONCOGENE, V18, P6583, DOI 10.1038/sj.onc.1203051; Thorgeirsson SS, 2002, NAT GENET, V31, P339, DOI 10.1038/ng0802-339; Verma UN, 2003, CLIN CANCER RES, V9, P1291; WATANABE T, 1994, P NATL ACAD SCI USA, V91, P3589, DOI 10.1073/pnas.91.9.3589; White P, 2005, J BIOL CHEM, V280, P3715, DOI 10.1074/jbc.M410844200; Yamamoto Y, 2003, HEPATOLOGY, V37, P528, DOI 10.1053/jhep.2003.50029; Yamaoka T, 2000, BIOCHEM BIOPH RES CO, V278, P368, DOI 10.1006/bbrc.2000.3813; Yuan RH, 2005, CLIN CANCER RES, V11, P2568, DOI 10.1158/1078-0432.CCR-04-2039; Zhang YW, 2003, WORLD J GASTROENTERO, V9, P2635; ZUCMANROSSI J, UNPUB COMP EVALUATIO	47	74	77	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN	2006	25	4					599	608		10.1038/sj.onc.1208860	http://dx.doi.org/10.1038/sj.onc.1208860			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	006KW	16314847				2022-12-25	WOS:000234897400011
J	Li, ZH; Zhao, RJ; Wu, XH; Sun, Y; Yao, M; Li, JJ; Xu, YH; Gu, JR				Li, ZH; Zhao, RJ; Wu, XH; Sun, Y; Yao, M; Li, JJ; Xu, YH; Gu, JR			Identification and characterization of a novel peptide ligand of epidermal growth factor receptor for targeted delivery of therapeutics	FASEB JOURNAL			English	Article						EGFR; peptide synthesis; peptide ligand	EFFICIENT GENE-TRANSFER; IN-VITRO; FORMULATIONS; LIPIDS	Epidermal growth factor receptor (ErbB1, EGFR) is overexpressed in a variety of human cancer cells. It has been considered as a rational target for drug delivery. To identify novel ligands with specific binding capabilities to EGFR, we screened a phage display peptide library and found an enriched phage clone encoding the amino acid sequence YHWYGYT-PQNVI (designated as GE11). Competitive binding assay and Scatchard analysis revealed that GE11 peptide bound specifically and efficiently to EGFR with a dissociation constant of similar to 22 nM, but with much lower mitogenic activity than with EGF. We showed that the peptides were internalized preferentially into EGFR highly expressing cells, and they accumulated in EGFR overexpressing tumor xenografts after i.v. delivery in vivo. In gene delivery studies, GE11-conjugated polyethylenimine (PEI) vectors were less mitogenic, but still quite efficient at transfecting genes into EGFR highly expressing cells and tumor xenografts. Taken together, GE11 is a potentially safe and efficient targeting moiety for selective drug delivery systems mediated through EGFR.	Shanghai Jiao Tong Univ, Natl Lab Oncogenes & Related Genes, Coll Med, Shanghai Canc Inst, Shanghai 200032, Peoples R China; Shanghai Jiao Tong Univ, Sch Pharm, Shanghai 200032, Peoples R China; Fudan Univ, Coll Med, Shanghai 200433, Peoples R China	Shanghai Jiao Tong University; Shanghai Jiao Tong University; Fudan University	Xu, YH (corresponding author), Shanghai Jiao Tong Univ, Natl Lab Oncogenes & Related Genes, Coll Med, Shanghai Canc Inst, 25-2200,Xietu Rd, Shanghai 200032, Peoples R China.	yhxu@sjtu.edu.cn	Xu, Yuhong/E-4247-2012	Li, Zonghai/0000-0003-2448-3636				Balasubramaniam RP, 1996, GENE THER, V3, P163; Binetruy-Tournaire R, 2000, EMBO J, V19, P1525, DOI 10.1093/emboj/19.7.1525; Blessing T, 2001, BIOCONJUGATE CHEM, V12, P529, DOI 10.1021/bc0001488; Chiu SH, 2004, J CONTROL RELEASE, V97, P357, DOI 10.1016/j.jconrel.2004.03.019; Gorman CM, 1997, GENE THER, V4, P983, DOI 10.1038/sj.gt.3300473; Gosselin MA, 2001, BIOCONJUGATE CHEM, V12, P989, DOI 10.1021/bc0100455; Gosselin MA, 2002, BIOCONJUGATE CHEM, V13, P1044, DOI 10.1021/bc025512c; Halin C, 2003, CANCER RES, V63, P3202; HANSEN MB, 1989, J IMMUNOL METHODS, V119, P203, DOI 10.1016/0022-1759(89)90397-9; Jong M, 2003, EUR J NUCL MED MOL I, V30, P463, DOI 10.1007/s00259-002-1107-8; Kunath K, 2003, J GENE MED, V5, P588, DOI 10.1002/jgm.382; Kursa M, 2003, BIOCONJUGATE CHEM, V14, P222, DOI 10.1021/bc0256087; Langer M., 2001, Current Medicinal Chemistry - Anti-Cancer Agents, V1, P71, DOI 10.2174/1568011013354877; Lee ER, 1996, HUM GENE THER, V7, P1701, DOI 10.1089/hum.1996.7.14-1701; Li S, 2000, AM J PHYSIOL-LUNG C, V278, pL504, DOI 10.1152/ajplung.2000.278.3.L504; LIN CR, 1986, CELL, V44, P839, DOI 10.1016/0092-8674(86)90006-1; Mamot C, 2003, CANCER RES, V63, P3154; MICHAEL SI, 1995, GENE THER, V2, P660; Ogiso H, 2002, CELL, V110, P775, DOI 10.1016/S0092-8674(02)00963-7; OPRESKO LK, 1995, J BIOL CHEM, V270, P4325, DOI 10.1074/jbc.270.9.4325; Rajotte D, 1999, J BIOL CHEM, V274, P11593, DOI 10.1074/jbc.274.17.11593; SafiejkoMroczka B, 1996, J HISTOCHEM CYTOCHEM, V44, P641, DOI 10.1177/44.6.8666749; SALOMON DS, 1995, CRIT REV ONCOL HEMAT, V19, P183, DOI 10.1016/1040-8428(94)00144-I; SOLODIN I, 1995, BIOCHEMISTRY-US, V34, P13537, DOI 10.1021/bi00041a033; White SJ, 2001, HYPERTENSION, V37, P449, DOI 10.1161/01.HYP.37.2.449; Wolschek MF, 2002, HEPATOLOGY, V36, P1106, DOI 10.1053/jhep.2002.36372; Woodburn JR, 1999, PHARMACOL THERAPEUT, V82, P241, DOI 10.1016/S0163-7258(98)00045-X; Zou YY, 2000, CANCER GENE THER, V7, P683, DOI 10.1038/sj.cgt.7700156	28	309	340	6	121	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	DEC	2005	19	14					1978	1985		10.1096/fj.05-4058com	http://dx.doi.org/10.1096/fj.05-4058com			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	999QR	16319141				2022-12-25	WOS:000234405500008
J	O'Shea, CC				O'Shea, CC			Viruses: tools for tumor target discovery, and agents for oncolytic therapies - an introduction	ONCOGENE			English	Editorial Material						oncolytic; virus; cancer therapy; transformation	REPLICATION		Univ Calif San Francisco, Canc Res Inst, San Francisco, CA 94115 USA	University of California System; University of California San Francisco	O'Shea, CC (corresponding author), Univ Calif San Francisco, Canc Res Inst, 2340 Sutter St,N315, San Francisco, CA 94115 USA.	coshea@cc.ucsf.edu						Aghi M, 2005, ONCOGENE, V24, P7802, DOI 10.1038/sj.onc.1209037; Ahuja D, 2005, ONCOGENE, V24, P7729, DOI 10.1038/sj.onc.1209046; Arroyo JD, 2005, ONCOGENE, V24, P7746, DOI 10.1038/sj.onc.1209038; Barber GN, 2005, ONCOGENE, V24, P7710, DOI 10.1038/sj.onc.1209042; Berk AJ, 2005, ONCOGENE, V24, P7673, DOI 10.1038/sj.onc.1209040; Freeman-Cook LL, 2005, ONCOGENE, V24, P7756, DOI 10.1038/sj.onc.1209039; Ko D, 2005, ONCOGENE, V24, P7763, DOI 10.1038/sj.onc.1209048; Mathis JM, 2005, ONCOGENE, V24, P7775, DOI 10.1038/sj.onc.1209044; McCormick F, 2005, ONCOGENE, V24, P7817, DOI 10.1038/sj.onc.1209064; Mohr I, 2005, ONCOGENE, V24, P7697, DOI 10.1038/sj.onc.1209053; O'Shea CC, 2005, ONCOGENE, V24, P7640, DOI 10.1038/sj.onc.1209047; Shmulevitz M, 2005, ONCOGENE, V24, P7720, DOI 10.1038/sj.onc.1209041; Uren AG, 2005, ONCOGENE, V24, P7656, DOI 10.1038/sj.onc.1209043; Weitzman MD, 2005, ONCOGENE, V24, P7686, DOI 10.1038/sj.onc.1209063; Working PK, 2005, ONCOGENE, V24, P7792, DOI 10.1038/sj.onc.1209045	15	8	9	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 21	2005	24	52					7636	7639		10.1038/sj.onc.1209035	http://dx.doi.org/10.1038/sj.onc.1209035			4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	985JD	16299525				2022-12-25	WOS:000233372600001
J	Louhelainen, JP; Hurst, CD; Pitt, E; Nishiyama, H; Pickett, HA; Knowles, MA				Louhelainen, JP; Hurst, CD; Pitt, E; Nishiyama, H; Pickett, HA; Knowles, MA			DBC1 re-expression alters the expression of multiple components of the plasminogen pathway	ONCOGENE			English	Article						DBC1; bladder cancer; tumour suppressor gene; expression microarray	TUMOR-SUPPRESSOR REGION; BLADDER-CANCER; HOMOZYGOUS DELETION; IN-VITRO; CELL; METALLOTHIONEIN; ACTIVATOR; UROKINASE; IDENTIFICATION; RECEPTOR	Deleted in bladder cancer 1 (DBC1) is a candidate gene for the bladder tumour suppressor locus at 9q33.1. The function of the gene is currently unknown but a cross-species sequence comparison suggests an important role, as it is highly evolutionarily conserved. Here, we transfected a nonexpressing human bladder cancer cell line with a set of human DBC1 cDNA constructs. The effect on global expression patterns was assessed using cDNA microarrays. The cell clone with the lowest level of DBC1 expression showed induced expression of 26 genes including plasminogen activator inhibitor 2 (SERPINB5; 4.6-fold), heparin-binding EGF-like growth factor precursor ( DTR; 4.2-fold), small proline-rich protein 2B (SPRR2B; 3.6-fold), metallothionein 1 isoforms (MT1B/ MT1A/MT-1F; from 2.9- to 3.2-fold), tissue-type plasminogen activator precursor ( PLAT; 2.8-fold) and urokinasetype plasminogen activator precursor (PLAU; 2.7fold). In clustering analysis, both PLAT and PLAU clustered with the functionally related urokinase plasminogen activator surface receptor (PLAUR; 1.9-fold). Furthermore, 14 human bladder tumours were analysed by real-time quantitative PCR using gene-specific primers for selected (n = 20) genes. The expression levels of SERPINB5, PLAU, PLAUR and MT1 correlated with the DBC1 levels, suggesting previously unknown involvement of DBC1 in the urokinase-plasminogen pathway.	St James Univ Hosp, Canc Res UK, Ctr Clin, Leeds LS9 7TF, W Yorkshire, England	Cancer Research UK; Saint James's University Hospital	Knowles, MA (corresponding author), St James Univ Hosp, Canc Res UK, Ctr Clin, Beckett St, Leeds LS9 7TF, W Yorkshire, England.	margaret.knowles@cancer.org.uk		Knowles, Margaret/0000-0002-9363-8657; Louhelainen, Jari/0000-0001-8680-8614	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		BACHMANN F, 1995, THROMB HAEMOSTASIS, V74, P172; Barradas M, 2002, EXP CELL RES, V273, P127, DOI 10.1006/excr.2001.5434; Champelovier P, 2002, UROL RES, V30, P301, DOI 10.1007/s00240-002-0270-5; COHEN RL, 1989, J BIOL CHEM, V264, P8375; ELLER MS, 1995, J CELL SCI, V108, P2741; FOUCRE D, 1991, BRIT J CANCER, V64, P926, DOI 10.1038/bjc.1991.428; Fujiwara H, 2001, J HUM GENET, V46, P372, DOI 10.1007/s100380170056; Fujiyama C, 2001, BRIT J CANCER, V84, P558, DOI 10.1054/bjoc.2000.1641; Habuchi T, 1998, GENOMICS, V48, P277, DOI 10.1006/geno.1997.5165; Habuchi T, 1997, HUM MOL GENET, V6, P913, DOI 10.1093/hmg/6.6.913; Habuchi T, 2001, ONCOGENE, V20, P531, DOI 10.1038/sj.onc.1204122; Hamada T, 1996, BIOCHEM BIOPH RES CO, V219, P829, DOI 10.1006/bbrc.1996.0318; Hasui Y, 1997, J NATL CANCER I, V89, P678, DOI 10.1093/jnci/89.10.678; Hudson MA, 1997, J NATL CANCER I, V89, P709, DOI 10.1093/jnci/89.10.709; Hurst CD, 2004, ONCOGENE, V23, P2250, DOI 10.1038/sj.onc.1207260; Hurst RE, 1999, ADV EXP MED BIOL, V462, P449; Ioachim EE, 2001, ANTICANCER RES, V21, P1757; JENSEN PH, 1994, BRIT J CANCER, V70, P834, DOI 10.1038/bjc.1994.407; Kawano H, 2004, MOL BRAIN RES, V125, P60, DOI 10.1016/j.molbrainres.2004.04.001; Knowles MA, 1999, ELECTROPHORESIS, V20, P269, DOI 10.1002/(SICI)1522-2683(19990201)20:2<269::AID-ELPS269>3.3.CO;2-Z; KONDO Y, 1994, J PHARMACOL EXP THER, V270, P1313; MARVIN KW, 1992, P NATL ACAD SCI USA, V89, P11026, DOI 10.1073/pnas.89.22.11026; Mouton RE, 2000, MECH AGEING DEV, V113, P169, DOI 10.1016/S0047-6374(99)00105-0; Nishiyama H, 1999, GENE CHROMOSOME CANC, V26, P171, DOI 10.1002/(SICI)1098-2264(199910)26:2<171::AID-GCC10>3.3.CO;2-2; Nishiyama H, 2001, ONCOGENE, V20, P2956, DOI 10.1038/sj.onc.1204432; Sens MA, 2000, ENVIRON HEALTH PERSP, V108, P413; Serakinci N, 2004, ONCOGENE, V23, P5095, DOI 10.1038/sj.onc.1207651; Shelton DN, 1999, CURR BIOL, V9, P939, DOI 10.1016/S0960-9822(99)80420-5; Simpkins CO, 2000, CELL MOL BIOL, V46, P465; Stadler WM, 2001, CLIN CANCER RES, V7, P1676; Toshiyuki N, 2004, MOL BRAIN RES, V125, P47, DOI 10.1016/j.molbrainres.2004.03.017; Tsangaris GT, 1998, ANTICANCER RES, V18, P2423; Vandesompele J, 2002, GENOME BIOL, V3, DOI 10.1186/gb-2002-3-7-research0034; Williams SV, 2002, GENE CHROMOSOME CANC, V34, P86, DOI 10.1002/gcc.10050; Wright KO, 2004, ONCOGENE, V23, P82, DOI 10.1038/sj.onc.1206642; Wright KO, 2002, J UROLOGY, V168, P2645, DOI 10.1016/S0022-5347(05)64236-X; Yu J, 2003, CELL RES, V13, P319, DOI 10.1038/sj.cr.7290177	37	17	18	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 13	2006	25	16					2409	2419		10.1038/sj.onc.1209228	http://dx.doi.org/10.1038/sj.onc.1209228			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	032HC	16369496				2022-12-25	WOS:000236764300012
J	Li, R; Wang, H; Bekele, BN; Yin, Z; Caraway, NP; Katz, RL; Stass, SA; Jiang, F				Li, R; Wang, H; Bekele, BN; Yin, Z; Caraway, NP; Katz, RL; Stass, SA; Jiang, F			Identification of putative oncogenes in lung adenocarcinoma by a comprehensive functional genomic approach	ONCOGENE			English	Article						lung cancer; microarrays; proteomics; tissue microarray	CANCER TISSUES; EXPRESSION; PROTEIN; HYBRIDIZATION; DNA; AMPLIFICATION; PROFILES; CELLS	Amplification and overexpression of putative oncogenes confer growth advantages for tumor development. We used a functional genomic approach that integrated simultaneous genomic and transcript microarray, proteomics, and tissue microarray analyses to directly identify putative oncogenes in lung adenocarcinoma. We first identified 183 genes with increases in both genomic copy number and transcript in six lung adenocarcinoma cell lines. Next, we used two-dimensional polyacrylamide gel electrophoresis and mass spectrometry to identify 42 proteins that were overexpressed in the cancer cells relative to normal cells. Comparing the 183 genes with the 42 proteins, we identified four genes - PRDX1, EEF1A2, CALR, and KCIP-1-in which elevated protein expression correlated with both increased DNA copy number and increased transcript levels ( all r > 0.84, two-sided P < 0.05). These findings were validated by Southern, Northern, and Western blotting. Specific inhibition of EEF1A2 and KCIP-1 expression with siRNA in the four cell lines tested suppressed proliferation and induced apoptosis. Parallel fluorescence in situ hybridization and immunohistochemical analyses of EEF1A2 and KCIP-1 in tissue microarrays from patients with lung adenocarcinoma showed that gene amplification was associated with high protein expression for both genes and that protein overexpression was related to tumor grade, disease stage, Ki-67 expression, and a shorter survival of patients. The amplification of EEF1A2 and KCIP-1 and the presence of overexpressed protein in tumor samples strongly suggest that these genes could be oncogenes and hence potential targets for diagnosis and therapy in lung adenocarcinoma.	Univ Maryland, Sch Med, Dept Pathol, Baltimore, MD 21201 USA; Univ Texas, MD Anderson Canc Ctr, Dept Pathol, Houston, TX 77030 USA; Univ Texas, MD Anderson Canc Ctr, Dept Biostat & Appl Math, Houston, TX 77030 USA; Univ Texas, Sch Med, Dept Internal Med, Houston, TX 77030 USA	University System of Maryland; University of Maryland Baltimore; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Texas System	Jiang, F (corresponding author), Univ Maryland, Sch Med, Dept Pathol, 10 S Pine St,MSTF 7th Floor, Baltimore, MD 21201 USA.	fjiang@som.umaryland.edu			NCI NIH HHS [CA113707-01, P50 CA70907] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R21CA113707, P50CA070907] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Anand N, 2002, NAT GENET, V31, P301, DOI 10.1038/ng904; Barrett MT, 2004, P NATL ACAD SCI USA, V101, P17765, DOI 10.1073/pnas.0407979101; Chen GA, 2002, MOL CELL PROTEOMICS, V1, P304, DOI 10.1074/mcp.M200008-MCP200; Feng J, 2004, NEOPLASIA, V6, P623, DOI 10.1593/neo.04142; Hyman E, 2002, CANCER RES, V62, P6240; Jiang F, 2005, ONCOGENE, V24, P3409, DOI 10.1038/sj.onc.1208459; Jiang F, 2002, J MOL DIAGN, V4, P144, DOI 10.1016/S1525-1578(10)60695-2; Kim HJ, 2003, CELL BIOL TOXICOL, V19, P285, DOI 10.1023/B:CBTO.0000004952.07979.3d; Lee Jonathan M, 2003, Reprod Biol Endocrinol, V1, P69, DOI 10.1186/1477-7827-1-69; Luk C, 2001, CANCER GENET CYTOGEN, V125, P87, DOI 10.1016/S0165-4608(00)00363-0; Martin B, 2004, BRIT J CANCER, V91, P2018, DOI 10.1038/sj.bjc.6602233; Oates J, 2000, HISTOPATHOLOGY, V36, P341; Pollack JR, 2002, P NATL ACAD SCI USA, V99, P12963, DOI 10.1073/pnas.162471999; Qi WQ, 2005, INT J CANCER, V113, P359, DOI 10.1002/ijc.20492; Ross JS, 1999, SEMIN CANCER BIOL, V9, P125, DOI 10.1006/scbi.1998.0083; Shen JJ, 2004, CANCER RES, V64, P9018, DOI 10.1158/0008-5472.CAN-04-3262; Thomas D, 2005, CURR TOP DEV BIOL, V67, P285, DOI 10.1016/S0070-2153(05)67009-3; Tonon G, 2005, P NATL ACAD SCI USA, V102, P9625, DOI 10.1073/pnas.0504126102; Wang HJ, 2005, INT J CANCER, V116, P285, DOI 10.1002/ijc.21035	19	98	111	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR	2006	25	18					2628	2635		10.1038/sj.onc.1209289	http://dx.doi.org/10.1038/sj.onc.1209289			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	036TU	16369491				2022-12-25	WOS:000237099400006
J	Zhang, L; Wang, C				Zhang, L; Wang, C			F-box protein Skp2: a novel transcriptional target of E2F	ONCOGENE			English	Article						transcription; SCFskp2; E2F; cell cycle	SCFSKP2 UBIQUITIN LIGASE; CELL-CYCLE; IN-VITRO; CHROMATIN IMMUNOPRECIPITATION; S-PHASE; C-MYC; DEGRADATION; EXPRESSION; COMPLEX; PROTEOLYSIS	The F-box-containing protein Skp2 plays a critical role in coordinating the G1/S transition and progression through the S phase of the mammalian cell cycle. Skp2 is overexpressed in a broad spectrum of human cancers and the expression level correlates with tumor malignancy. However, the Skp2 gene is neither amplified nor rearranged in most human cancers and the underlying mechanism of Skp2 overexpression remains poorly understood. We show here that the Skp2 gene contains a functional E2F response element ( hSRE2). Ectopic expression of E2F1 induces expression of the endogenous Skp2 gene in human fibroblast cells, whereas antisense-mediated knockdown of E2F1 in human tumor cell lines reduces expression of endogenous Skp2 gene. The hSRE2 element not only participates in activation of Skp2 promoter function during normal cell cycle progression into S phase, it is also required for the high-level Skp2 gene expression in many human tumor cell lines. These results reveal Skp2 as a novel target for E2F regulation that is disrupted in several human tumor cell lines.	Univ Illinois, Ctr Mol Biol Oral Dis, Chicago, IL 60612 USA	University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital	Wang, C (corresponding author), Univ Illinois, Ctr Mol Biol Oral Dis, 801 S Paulina St,Room 530E,M-C 860, Chicago, IL 60612 USA.	chiayeng@uic.edu			NATIONAL CANCER INSTITUTE [R29CA074907, R01CA074907] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA074907, R29 CA074907, CA074907] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Amati B, 2004, P NATL ACAD SCI USA, V101, P8843, DOI 10.1073/pnas.0403046101; Ausubel F, 1990, CURRENT PROTOCOLS MO, V1; Bai C, 1996, CELL, V86, P263, DOI 10.1016/S0092-8674(00)80098-7; Bashir T, 2004, NATURE, V428, P190, DOI 10.1038/nature02330; Bashir T, 2004, CELL CYCLE, V3, P850; Bhattacharya S, 2003, ONCOGENE, V22, P2443, DOI 10.1038/sj.onc.1206339; BLIN N, 1976, NUCLEIC ACIDS RES, V3, P2303, DOI 10.1093/nar/3.9.2303; Bloom J, 2003, SEMIN CANCER BIOL, V13, P41, DOI 10.1016/S1044-579X(02)00098-6; Bornstein G, 2003, J BIOL CHEM, V278, P25752, DOI 10.1074/jbc.M301774200; Cao Y, 2000, J BIOL CHEM, V275, P9854, DOI 10.1074/jbc.275.13.9854; Carrano AC, 1999, NAT CELL BIOL, V1, P193, DOI 10.1038/12013; Carrano AC, 2001, J CELL BIOL, V153, P1381, DOI 10.1083/jcb.153.7.1381; Ciechanover A, 2004, BBA-MOL CELL RES, V1695, P3, DOI 10.1016/j.bbamcr.2004.09.018; Coe BR, 2005, GENE CHROMOSOME CANC, V42, P308, DOI 10.1002/gcc.20137; Deshaies RJ, 1999, ANNU REV CELL DEV BI, V15, P435, DOI 10.1146/annurev.cellbio.15.1.435; DEVOTO SH, 1992, CELL, V68, P167, DOI 10.1016/0092-8674(92)90215-X; Dow R, 2001, J BIOL CHEM, V276, P45945, DOI 10.1074/jbc.M103593200; Dowen SE, 2003, ONCOGENE, V22, P2531, DOI 10.1038/sj.onc.1206296; Dyson N, 1998, GENE DEV, V12, P2245, DOI 10.1101/gad.12.15.2245; Frolov MV, 2004, J CELL SCI, V117, P2173, DOI 10.1242/jcs.01227; Gstaiger M, 2001, P NATL ACAD SCI USA, V98, P5043, DOI 10.1073/pnas.081474898; HELIN K, 1993, MOL CELL BIOL, V13, P6501, DOI 10.1128/MCB.13.10.6501; Hershko A, 1998, ANNU REV BIOCHEM, V67, P425, DOI 10.1146/annurev.biochem.67.1.425; Imaki H, 2003, CANCER RES, V63, P4607; Jin JP, 2003, CANCER CELL, V3, P517, DOI 10.1016/S1535-6108(03)00145-4; Kamura T, 2003, P NATL ACAD SCI USA, V100, P10231, DOI 10.1073/pnas.1831009100; Kel AE, 2001, J MOL BIOL, V309, P99, DOI 10.1006/jmbi.2001.4650; Kim SY, 2003, MOL CELL, V11, P1177, DOI 10.1016/S1097-2765(03)00173-4; Kipreos ET, 2000, GENOME BIOL, V1, DOI 10.1186/gb-2000-1-5-reviews3002; Koepp DM, 1999, CELL, V97, P431, DOI 10.1016/S0092-8674(00)80753-9; Koga H, 2003, HEPATOLOGY, V37, P1086, DOI 10.1053/jhep.2003.50186; Koziczak M, 2000, MOL CELL BIOL, V20, P2014, DOI 10.1128/MCB.20.6.2014-2022.2000; Kurland JF, 2004, CANCER CELL, V5, P305, DOI 10.1016/S1535-6108(04)00091-1; Latres E, 2001, P NATL ACAD SCI USA, V98, P2515, DOI 10.1073/pnas.041475098; LEES E, 1992, GENE DEV, V6, P1874, DOI 10.1101/gad.6.10.1874; Li XH, 2003, J BIOL CHEM, V278, P30854, DOI 10.1074/jbc.C300251200; Marti A, 1999, NAT CELL BIOL, V1, P14, DOI 10.1038/8984; Mendez J, 2002, MOL CELL, V9, P481, DOI 10.1016/S1097-2765(02)00467-7; MERCOLA M, 1985, SCIENCE, V227, P266, DOI 10.1126/science.3917575; Muller H, 2001, GENE DEV, V15, P267, DOI 10.1101/gad.864201; Nakayama K, 2000, EMBO J, V19, P2069, DOI 10.1093/emboj/19.9.2069; Nakayama K, 2004, DEV CELL, V6, P661, DOI 10.1016/S1534-5807(04)00131-5; Ohta T, 2001, CANCER RES, V61, P1347; Oliveira AM, 2003, J CLIN ONCOL, V21, P722, DOI 10.1200/JCO.2003.05.112; Pickart CM, 2004, BBA-MOL CELL RES, V1695, P55, DOI 10.1016/j.bbamcr.2004.09.019; QIN XQ, 1995, MOL CELL BIOL, V15, P742; Ren B, 2002, GENE DEV, V16, P245, DOI 10.1101/gad.949802; Ross JF, 2001, GENE DEV, V15, P392, DOI 10.1101/gad.858501; Simile MM, 2004, CARCINOGENESIS, V25, P333, DOI 10.1093/carcin/bgh014; Smith EJ, 1996, MOL CELL BIOL, V16, P6965; Sutterluty H, 1999, NAT CELL BIOL, V1, P207, DOI 10.1038/12027; Tedesco D, 2002, GENE DEV, V16, P2946, DOI 10.1101/gad.1011202; Tsvetkov LM, 1999, CURR BIOL, V9, P661, DOI 10.1016/S0960-9822(99)80290-5; Vernell R, 2003, J BIOL CHEM, V278, P46124, DOI 10.1074/jbc.M304930200; von der Lehr N, 2003, MOL CELL, V11, P1189, DOI 10.1016/S1097-2765(03)00193-X; Wei W, 2004, NATURE, V428, P194, DOI 10.1038/nature02381; Weinmann AS, 2002, GENE DEV, V16, P235, DOI 10.1101/gad.943102; Weinmann AS, 2001, MOL CELL BIOL, V21, P6820, DOI 10.1128/MCB.21.20.6820-6832.2001; Wells J, 2002, P NATL ACAD SCI USA, V99, P3890, DOI 10.1073/pnas.062047499; Willems AR, 2004, BBA-MOL CELL RES, V1695, P133, DOI 10.1016/j.bbamcr.2004.09.027; Wirbelauer C, 2000, EMBO J, V19, P5362, DOI 10.1093/emboj/19.20.5362; Yeh KH, 2001, BIOCHEM BIOPH RES CO, V281, P884, DOI 10.1006/bbrc.2001.4442; Yokoi S, 2004, AM J PATHOL, V165, P175, DOI 10.1016/S0002-9440(10)63286-5; ZHANG H, 1995, CELL, V82, P915, DOI 10.1016/0092-8674(95)90271-6; Zheng N, 2002, NATURE, V416, P703, DOI 10.1038/416703a	65	104	107	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR	2006	25	18					2615	2627		10.1038/sj.onc.1209286	http://dx.doi.org/10.1038/sj.onc.1209286			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	036TU	16331253	Green Accepted			2022-12-25	WOS:000237099400005
J	Najmudin, S; Guerreiro, CIPD; Carvalho, AL; Prates, JAM; Correia, MAS; Alves, VD; Ferreira, LMA; Romao, MJ; Gilbert, HJ; Bolam, DN; Fontes, CMGA				Najmudin, S; Guerreiro, CIPD; Carvalho, AL; Prates, JAM; Correia, MAS; Alves, VD; Ferreira, LMA; Romao, MJ; Gilbert, HJ; Bolam, DN; Fontes, CMGA			Xyloglucan is recognized by carbohydrate-binding modules that interact with beta-glucan chains	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELLULOMONAS-FIMI; LIGAND-BINDING; CRYSTAL-STRUCTURE; AFFINITY ELECTROPHORESIS; DOMAIN; FAMILY; CELLULASE; COMPLEX; IDENTIFICATION; SPECIFICITY	Enzyme systems that attack the plant cell wall contain noncatalytic carbohydrate-binding modules (CBMs) that mediate attachment to this composite structure and play a pivotal role in maximizing the hydrolytic process. Although xyloglucan, which includes a backbone of beta-1,4-glucan decorated primarily with xylose residues, is a key component of the plant cell wall, CBMs that bind to this polymer have not been identified. Here we showed that the C-terminal domain of the modular Clostridium thermocellum enzyme CtCel9D-Cel44A (formerly known as CelJ) comprises a novel CBM (designated CBM44) that binds with equal affinity to cellulose and xyloglucan. We also showed that accommodation of xyloglucan side chains is a general feature of CBMs that bind to single cellulose chains. The crystal structures of CBM44 and the other CBM (CBM30) in CtCel9D-Cel44A display a beta-sandwich fold. The concave face of both CBMs contains a hydrophobic platform comprising three tryptophan residues that can accommodate up to five glucose residues. The orientation of these aromatic residues is such that the bound ligand would adopt the twisted conformation displayed by cello-oligosaccharides in solution. Mutagenesis studies confirmed that the hydrophobic platform located on the concave face of both CBMs mediates ligand recognition. In contrast to other CBMs that bind to single polysaccharide chains, the polar residues in the binding cleft of CBM44 play only a minor role in ligand recognition. The mechanism by which these proteins are able to recognize linear and decorated beta-1,4-glucans is discussed based on the structures of CBM44 and the other CBMs that bind single cellulose chains.	Newcastle Univ, Inst Cell & Mol Biosci, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England; Univ Nova Lisboa, Fac Ciencias & Tecnol, Dept Quim, REQUIMTE CQFB, P-2829516 Caparica, Portugal; Univ Tecn Lisboa, Fac Med Vet, CIISA, P-1300477 Lisbon, Portugal	Newcastle University - UK; Universidade Nova de Lisboa; Universidade de Lisboa	Bolam, DN (corresponding author), Newcastle Univ, Inst Cell & Mol Biosci, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England.	D.N.Bolam@newcastle.ac.uk; cafontes@fmv.utl.pt	Correia, Márcia/D-2077-2013; Romao, Maria J/A-4115-2013; Prates, José A M/K-9934-2013; Carvalho, Ana Luísa/G-5638-2011; UCIBIO, U Cienc Biom Apl/F-7948-2017	Correia, Márcia/0000-0003-0636-8095; Romao, Maria J/0000-0002-3004-0543; Prates, José A M/0000-0003-1032-5987; Carvalho, Ana Luísa/0000-0002-3824-0240; UCIBIO, U Cienc Biom Apl/0000-0002-3004-0543; Alves, Victor Diogo/0000-0002-8430-4380; Bolam, David/0000-0003-0314-3122; Najmudin, Shabir/0000-0002-0429-5454; Ferreira, Luis/0000-0002-3543-9166; Fontes, Carlos/0000-0002-1219-9753	Biotechnology and Biological Sciences Research Council [BB/C005074/1] Funding Source: Medline	Biotechnology and Biological Sciences Research Council(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC))		Abou-Hachem M, 2002, BIOCHEMISTRY-US, V41, P5720, DOI 10.1021/bi012094a; Ahsan MM, 1996, J BACTERIOL, V178, P5732, DOI 10.1128/jb.178.19.5732-5740.1996; Arai T, 2003, J BACTERIOL, V185, P504, DOI 10.1128/JB.185.2.504-512.2003; ATKINS EDT, 1992, 3 DIMENSIONAL STRUCT; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; BESKROVNAYA OI, 2000, HUM MOL GENET, V9, P1641, DOI DOI 10.1093/HMG/9.11.1641; Bolam DN, 2004, J BIOL CHEM, V279, P22953, DOI 10.1074/jbc.M313317200; Bolam DN, 1998, BIOCHEM J, V331, P775, DOI 10.1042/bj3310775; Boraston AB, 2003, STRUCTURE, V11, P665, DOI 10.1016/S0969-2126(03)00100-X; Boraston AB, 2002, J MOL BIOL, V319, P1143, DOI 10.1016/S0022-2836(02)00374-1; Boraston AB, 2002, BIOCHEM J, V361, P35, DOI 10.1042/0264-6021:3610035; Boraston AB, 2004, BIOCHEM J, V382, P769, DOI 10.1042/BJ20040892; Boraston AB, 2000, BIOCHEMISTRY-US, V39, P11129, DOI 10.1021/bi0007728; BUEREN AL, 2005, J BIOL CHEM, V280, P530; Bycroft M, 1999, EMBO J, V18, P297, DOI 10.1093/emboj/18.2.297; Carvalho AL, 2004, J BIOL CHEM, V279, P34785, DOI 10.1074/jbc.M405867200; Charnock SJ, 2002, P NATL ACAD SCI USA, V99, P14077, DOI 10.1073/pnas.212516199; Charnock SJ, 2000, BIOCHEMISTRY-US, V39, P5013, DOI 10.1021/bi992821q; COUGHLAN MP, 1985, BIOTECHNOL GENET ENG, V3, P39, DOI 10.1080/02648725.1985.10647809; Coutinho PM, 1999, ROY SOC CH, P3; Czjzek M, 2001, J BIOL CHEM, V276, P48580, DOI 10.1074/jbc.M109142200; Dias FMV, 2004, J BIOL CHEM, V279, P25517, DOI 10.1074/jbc.M401647200; Flint J, 2005, J BIOL CHEM, V280, P23718, DOI 10.1074/jbc.M501551200; Flint J, 2004, J MOL BIOL, V337, P417, DOI 10.1016/j.jmb.2003.12.081; Gill J, 1999, BIOCHEM J, V342, P473, DOI 10.1042/0264-6021:3420473; Henrissat B, 1998, BIOCHEM SOC T, V26, P153, DOI 10.1042/bst0260153; Henshaw JL, 2004, J BIOL CHEM, V279, P21552, DOI 10.1074/jbc.M401620200; Jamal-Talabani S, 2004, STRUCTURE, V12, P1177, DOI 10.1016/j.str.2004.04.022; Johnson PE, 1996, BIOCHEMISTRY-US, V35, P13895, DOI 10.1021/bi961186a; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KABSCH W, 1988, J APPL CRYSTALLOGR, V21, P67, DOI 10.1107/S0021889887009737; Kormos J, 2000, BIOCHEMISTRY-US, V39, P8844, DOI 10.1021/bi000607s; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; KRAULIS PJ, 1989, BIOCHEMISTRY-US, V28, P7241, DOI 10.1021/bi00444a016; Leslie AGW, 1992, PROTEIN CRYSTALLOGR, V26, P27; MATTHEWS BW, 1968, J MOL BIOL, V33, P491, DOI 10.1016/0022-2836(68)90205-2; McLean BW, 2000, PROTEIN ENG, V13, P801, DOI 10.1093/protein/13.11.801; Merritt EA, 1997, METHOD ENZYMOL, V277, P505, DOI 10.1016/S0076-6879(97)77028-9; Murshudov GN, 1997, ACTA CRYSTALLOGR D, V53, P240, DOI 10.1107/S0907444996012255; Najmudin S, 2005, ACTA CRYSTALLOGR F, V61, P1043, DOI 10.1107/S1744309105035670; Notenboom V, 2001, J MOL BIOL, V314, P797, DOI 10.1006/jmbi.2001.5153; Orikoshi H, 2005, J APPL MICROBIOL, V99, P551, DOI 10.1111/j.1365-2672.2005.02630.x; Pell G, 2003, BIOCHEMISTRY-US, V42, P9316, DOI 10.1021/bi0347510; Perrakis A, 1999, NAT STRUCT BIOL, V6, P458, DOI 10.1038/8263; Pires VMR, 2004, J BIOL CHEM, V279, P21560, DOI 10.1074/jbc.M401599200; Raghothama S, 2000, BIOCHEMISTRY-US, V39, P978, DOI 10.1021/bi992163+; ROUSSEL A, 1991, TURBO FRODO SILICON, P86; Sheldrick GM, 1997, METHOD ENZYMOL, V277, P319, DOI 10.1016/S0076-6879(97)77018-6; SOMOGYI M, 1945, J BIOL CHEM, V160, P69; Szabo L, 2001, J BIOL CHEM, V276, P49061, DOI 10.1074/jbc.M109558200; TAKEO K, 1984, ELECTROPHORESIS, V5, P187, DOI 10.1002/elps.1150050402; Terwilliger TC, 1999, ACTA CRYSTALLOGR D, V55, P849, DOI 10.1107/S0907444999000839; Tomme P, 2000, ENZYME MICROB TECH, V27, P453, DOI 10.1016/S0141-0229(00)00246-5; Tormo J, 1996, EMBO J, V15, P5739, DOI 10.1002/j.1460-2075.1996.tb00960.x; Tunnicliffe RB, 2005, J MOL BIOL, V347, P287, DOI 10.1016/j.jmb.2005.01.038; Vagin A, 1997, J APPL CRYSTALLOGR, V30, P1022, DOI 10.1107/S0021889897006766; WOOD TM, 1988, METHOD ENZYMOL, V160, P19; Xie HF, 2001, BIOCHEMISTRY-US, V40, P5700, DOI 10.1021/bi010034z; Xie HF, 2001, BIOCHEMISTRY-US, V40, P9167, DOI 10.1021/bi0106742; XU GY, 1995, BIOCHEMISTRY-US, V34, P6993, DOI 10.1021/bi00021a011	60	94	94	2	31	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 31	2006	281	13					8815	8828		10.1074/jbc.M510559200	http://dx.doi.org/10.1074/jbc.M510559200			14	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	025EC	16314409	Green Published, hybrid			2022-12-25	WOS:000236247100061
J	Villa-Morales, M; Santos, J; Fernandez-Piqueras, J				Villa-Morales, M; Santos, J; Fernandez-Piqueras, J			Functional Fas (Cd95/Apo-1) promoter polymorphisms in inbred mouse strains exhibiting different susceptibility to gamma-radiation-induced thymic lymphoma	ONCOGENE			English	Article						Fas (Apo-1/CD95); functional polymorphisms; cancer-genetic-susceptibility; thymic lymphoma	TUMOR-SUPPRESSOR GENE; NF-KAPPA-B; SELECTION IN-VIVO; NEGATIVE SELECTION; TRANSCRIPTIONAL REGULATION; INDUCED APOPTOSIS; T-CELLS; THYMOCYTES; EXPRESSION; LIGAND	The Fas death receptor is a cell surface molecule involved in apoptosis as well as in proliferative or activating signals of many cells types, including T lymphocytes. Using quantitative real-time reverse transcription - PCR analysis, we confirm that expression of this gene is scarcely perceptible in thymic lymphomas induced by c-irradiation in C57BL/6J mice. Notably, we also demonstrate for the first time that Fas expression is significantly upregulated in vivo both after single high dose of radiation and in thymic lymphoma-free mice. In addition, we determined its levels of expression in five mouse strains exhibiting different degrees of susceptibility (SPRET/Ei, SEG/Pas, BALB/cJ, C57BL/6J and RF/J). Interestingly, we found the highest levels of expression in SPRET/Ei and SEG/Pas strains ( both derived from the Mus spretus species), which are known to have the most resistant phenotype, and the lowest levels in the most susceptible strains C57BL/6J and RF/J. DNA sequencing of the Fas promoter in all five strains showed many polymorphisms that can be classified into three functional haplotypes by using luciferase assays: (1) C57BL/6J and RF/J, ( 2) BALB/cJ and ( 3) SPRET/Ei and SEG/Pas. Promoter activities in response to single high doses of radiation correlated well with the levels of Fas expression and are consistent with the degree of strain susceptibility.	Univ Autonoma Madrid, Dept Biol, Lab Genet Mol Humana, E-28049 Madrid, Spain	Autonomous University of Madrid	Fernandez-Piqueras, J (corresponding author), Univ Autonoma Madrid, Dept Biol, Lab Genet Mol Humana, E-28049 Madrid, Spain.	jf.piqueras@uam.es	VILLA-MORALES, MARIA C./H-8797-2015; Santos, Javier/ABF-5755-2021	VILLA-MORALES, MARIA C./0000-0001-7906-0169; Santos, Javier/0000-0002-4168-6251				Adachi M, 1996, P NATL ACAD SCI USA, V93, P2131, DOI 10.1073/pnas.93.5.2131; Booker JK, 1998, J IMMUNOL, V161, P4536; Castro JE, 1996, IMMUNITY, V5, P617, DOI 10.1016/S1074-7613(00)80275-7; Chan H, 1999, MOL CELL BIOL, V19, P2098, DOI 10.1128/mcb.19.3.2098; DeRyckere D, 2003, J IMMUNOL, V171, P802, DOI 10.4049/jimmunol.171.2.802; Feuk L, 2003, HUM MUTAT, V21, P53, DOI 10.1002/humu.10148; Fleck M, 1998, J IMMUNOL, V160, P3766; Hettmann T, 2000, J IMMUNOL, V165, P5004, DOI 10.4049/jimmunol.165.9.5004; Hettmann T, 1999, J EXP MED, V189, P145, DOI 10.1084/jem.189.1.145; Hoogendoorn B, 2003, HUM MOL GENET, V12, P2249, DOI 10.1093/hmg/ddg246; Kishimoto H, 1998, J EXP MED, V187, P1427, DOI 10.1084/jem.187.9.1427; Krammer PH, 2000, NATURE, V407, P789, DOI 10.1038/35037728; Kurasawa K, 1999, CELL IMMUNOL, V194, P127, DOI 10.1006/cimm.1999.1502; Lai HC, 2003, INT J CANCER, V103, P221, DOI 10.1002/ijc.10800; Maas K, 2005, ARTHRITIS RHEUM-US, V52, P1047, DOI 10.1002/art.20931; Melendez B, 1999, ONCOGENE, V18, P4166, DOI 10.1038/sj.onc.1202826; Muschen M, 2000, J MOL MED-JMM, V78, P312, DOI 10.1007/s001090000112; NAGATA S, 1995, IMMUNOL TODAY, V16, P39, DOI 10.1016/0167-5699(95)80069-7; NISHIMURA Y, 1995, J IMMUNOL, V154, P4395; OGASAWARA J, 1995, J EXP MED, V181, P485, DOI 10.1084/jem.181.2.485; Oukka M, 1998, IMMUNITY, V9, P295, DOI 10.1016/S1074-7613(00)80612-3; Pinkoski MJ, 1999, CELL DEATH DIFFER, V6, P1174, DOI 10.1038/sj.cdd.4400611; RATHMELL JC, 2002, CELL S, V109, P97; Reap EA, 1997, P NATL ACAD SCI USA, V94, P5750, DOI 10.1073/pnas.94.11.5750; Santos J, 1996, ONCOGENE, V12, P669; Santos J, 2002, ONCOGENE, V21, P6680, DOI 10.1038/sj.onc.1205846; Santos J, 2001, ONCOGENE, V20, P2186, DOI 10.1038/sj.onc.1204297; Schmitz I, 2003, INT IMMUNOL, V15, P1237, DOI 10.1093/intimm/dxg125; Sibley K, 2003, CANCER RES, V63, P4327; Siegel RM, 2000, NAT IMMUNOL, V1, P469, DOI 10.1038/82712; Zheng Y, 2001, J IMMUNOL, V166, P4949, DOI 10.4049/jimmunol.166.8.4949	31	21	21	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR	2006	25	14					2022	2029		10.1038/sj.onc.1209234	http://dx.doi.org/10.1038/sj.onc.1209234			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	026RL	16301997				2022-12-25	WOS:000236359700005
J	Flemming, PK; Dedman, AM; Xu, SZ; Li, J; Zeng, FN; Naylor, J; Benham, CD; Bateson, AN; Muraki, K; Beech, DJ				Flemming, PK; Dedman, AM; Xu, SZ; Li, J; Zeng, FN; Naylor, J; Benham, CD; Bateson, AN; Muraki, K; Beech, DJ			Sensing of lysophospholipids by TRPC5 calcium channel	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MULTIFUNCTIONAL CATION CHANNELS; SMOOTH-MUSCLE; RECEPTOR; LYSOPHOSPHATIDYLCHOLINE; ENTRY; IDENTIFICATION; ACTIVATION; MECHANISM; PATHWAY; INFLUX	TRPC calcium channels are emerging as a ubiquitous feature of vertebrate cells, but understanding of them is hampered by limited knowledge of the mechanisms of activation and identity of endogenous regulators. We have revealed that one of the TRPC channels, TRPC5, is strongly activated by common endogenous lysophospholipids including lysophosphatidylcholine ( LPC) but, by contrast, not arachidonic acid. Although TRPC5 was stimulated by agonists at G-protein-coupled receptors, TRPC5 activation by LPC occurred downstream and independently of G-protein signaling. The effect was not due to the generation of reactive oxygen species or because of a detergent effect of LPC. LPC activated TRPC5 when applied to excised membrane patches and thus has a relatively direct action on the channel structure, either because of a phospholipid binding site on the channel or because of sensitivity of the channel to perturbation of the bilayer by certain lipids. Activation showed dependence on side-chain length and the chemical head-group. The data revealed a previously unrecognized lysophospholipid-sensing capability of TRPC5 that confers the property of a lipid ionotropic receptor.	Univ Leeds, Inst Membrane & Syst Biol, Leeds LS2 9JT, W Yorkshire, England; Aichi Gakuin Univ, Sch Pharm, Chikusa Ku, Nagoya, Aichi 4678650, Japan; GlaxoSmithKline Res & Dev Ltd, Neurol & GI Ctr Excellence Drug Discovery, Harlow CM19 5AW, Essex, England	University of Leeds; Aichi Gakuin University; GlaxoSmithKline	Beech, DJ (corresponding author), Univ Leeds, Inst Membrane & Syst Biol, Leeds LS2 9JT, W Yorkshire, England.	d.j.beech@leeds.ac.uk	Xu, Shang-Zhong/P-2807-2015	Xu, Shang-Zhong/0000-0002-7295-9347; Beech, David/0000-0002-7683-9422	Wellcome Trust [060988] Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		Beech DJ, 2004, J PHYSIOL-LONDON, V559, P685, DOI 10.1113/jphysiol.2004.068734; Bezzerides VJ, 2004, NAT CELL BIOL, V6, P709, DOI 10.1038/ncb1150; Caterina MJ, 2001, ANNU REV NEUROSCI, V24, P487, DOI 10.1146/annurev.neuro.24.1.487; Facemire CS, 2004, AM J PHYSIOL-RENAL, V286, pF546, DOI 10.1152/ajprenal.00338.2003; FELDER CC, 1990, J PHARMACOL EXP THER, V255, P1140; Freichel M, 2005, J PHYSIOL-LONDON, V567, P59, DOI 10.1113/jphysiol.2005.092999; Hara Y, 2002, MOL CELL, V9, P163, DOI 10.1016/S1097-2765(01)00438-5; Ishii I, 2004, ANNU REV BIOCHEM, V73, P321, DOI 10.1146/annurev.biochem.73.011303.073731; Jordt SE, 2004, NATURE, V427, P260, DOI 10.1038/nature02282; McHugh D, 2003, J BIOL CHEM, V278, P11002, DOI 10.1074/jbc.M210810200; Nilius B, 2005, PFLUG ARCH EUR J PHY, V451, P1, DOI 10.1007/s00424-005-1462-y; Obukhov AG, 2005, J NEUROSCI, V25, P1234, DOI 10.1523/JNEUROSCI.4451-04.2005; Okita M, 1997, INT J CANCER, V71, P31, DOI 10.1002/(SICI)1097-0215(19970328)71:1<31::AID-IJC7>3.0.CO;2-4; Ordaz B, 2005, J BIOL CHEM, V280, P30788, DOI 10.1074/jbc.M504745200; Peier AM, 2002, CELL, V108, P705, DOI 10.1016/S0092-8674(02)00652-9; Philipp S, 1998, EMBO J, V17, P4274, DOI 10.1093/emboj/17.15.4274; Plant TD, 2003, CELL CALCIUM, V33, P441, DOI 10.1016/S0143-4160(03)00055-1; Putney JW, 2004, TRENDS CELL BIOL, V14, P282, DOI 10.1016/j.tcb.2004.04.002; Schaefer M, 2000, J BIOL CHEM, V275, P17517, DOI 10.1074/jbc.275.23.17517; Smani T, 2004, NAT CELL BIOL, V6, P113, DOI 10.1038/ncb1089; Strubing C, 2001, NEURON, V29, P645, DOI 10.1016/S0896-6273(01)00240-9; Takeshita S, 2000, J Atheroscler Thromb, V7, P238; Thukkani AK, 2003, CIRCULATION, V108, P3128, DOI 10.1161/01.CIR.0000104564.01539.6A; Watanabe H, 2003, NATURE, V424, P434, DOI 10.1038/nature01807; Wolf MJ, 1997, J BIOL CHEM, V272, P1522, DOI 10.1074/jbc.272.3.1522; Wu XY, 2000, AM J PHYSIOL-CELL PH, V278, pC526, DOI 10.1152/ajpcell.2000.278.3.C526; Yan JJ, 2004, NAT MED, V10, P161, DOI 10.1038/nm989; ZENG F, 2004, J PHYSIOL-LONDON, V15, P739; Zitt C, 2002, PROG NEUROBIOL, V66, P243, DOI 10.1016/S0301-0082(02)00002-3	29	100	106	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 24	2006	281	8					4977	4982		10.1074/jbc.M510301200	http://dx.doi.org/10.1074/jbc.M510301200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	013RF	16368680	hybrid			2022-12-25	WOS:000235426200049
J	Kambara, T; Ikebe, M				Kambara, T; Ikebe, M			A unique ATP hydrolysis mechanism of single-headed processive myosin, myosin IX	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SMOOTH-MUSCLE MYOSIN; PHOSPHORYLATION-DEPENDENT REGULATION; ACTIN-BINDING LOOP; KINETIC MECHANISM; MOTOR DOMAIN; CHIMERIC SUBSTITUTIONS; CONFORMATIONAL-CHANGES; NUCLEOTIDE-BINDING; FREE-ENERGY; TRYPTOPHAN	Recent studies have revealed that myosin IX is a single-headed processive myosin, yet it is unclear how myosin IX can achieve the processive movement. Here we studied the mechanism of ATP hydrolysis cycle of actomyosin IXb. We found that myosin IXb has a rate-limiting ATP hydrolysis step unlike other known myosins, thus populating the prehydrolysis intermediate (M(.)ATP). M(.)ATP has a high affinity for actin, and, unlike other myosins, the dissociation of M(.)ATP from actin was extremely slow, thus preventing myosin from dissociating away from actin. The ADP dissociation step was 10-fold faster than the overall ATP hydrolysis cycle rate and thus not rate-limiting. We propose the following model for single-headed processive myosin. Upon the formation of the M(.)ATP intermediate, the tight binding of actomyosin IX at the interface is weakened. However, the head is kept in close proximity to actin due to the tethering role of loop 2/large unique insertion of myosin IX. There is enough freedom for the myosin head to find the next location of the binding site along with the actin filament before complete dissociation from the filament. After ATP hydrolysis, P-i is quickly released to form a strong actin binding form, and a power stroke takes place.	Univ Massachusetts, Sch Med, Dept Physiol, Worcester, MA 01655 USA	University of Massachusetts System; University of Massachusetts Worcester	Ikebe, M (corresponding author), Univ Massachusetts, Sch Med, Dept Physiol, 55 Lake Ave N, Worcester, MA 01655 USA.	mitsuo.ikebe@umassmed.edu			NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR048898, R01AR048526, R01AR041653] Funding Source: NIH RePORTER; NIAMS NIH HHS [AR 41653, AR 048898, AR 048526] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Batra R, 1999, BIOL CHEM, V380, P1017, DOI 10.1515/BC.1999.126; BERGER CL, 1991, BIOCHEMISTRY-US, V30, P11036, DOI 10.1021/bi00110a005; De La Cruz EM, 1999, P NATL ACAD SCI USA, V96, P13726, DOI 10.1073/pnas.96.24.13726; De la Cruz EM, 2001, J BIOL CHEM, V276, P32373, DOI 10.1074/jbc.M104136200; El Mezgueldi M, 2002, J BIOL CHEM, V277, P21514, DOI 10.1074/jbc.M200713200; FISHER AJ, 1995, BIOCHEMISTRY-US, V34, P8960, DOI 10.1021/bi00028a004; Forkey JN, 2003, NATURE, V422, P399, DOI 10.1038/nature01529; Furch M, 1998, BIOCHEMISTRY-US, V37, P6317, DOI 10.1021/bi972851y; Homma K, 2005, J BIOL CHEM, V280, P29381, DOI 10.1074/jbc.M504779200; IKEBE M, 1985, J BIOL CHEM, V260, P3146; Ikebe M, 1998, J BIOL CHEM, V273, P17702, DOI 10.1074/jbc.273.28.17702; Inoue A, 2002, NAT CELL BIOL, V4, P302, DOI 10.1038/ncb774; Kambara T, 1999, J BIOL CHEM, V274, P16400, DOI 10.1074/jbc.274.23.16400; Knetsch MLW, 1999, J BIOL CHEM, V274, P20133, DOI 10.1074/jbc.274.29.20133; KONRAD M, 1982, EUR J BIOCHEM, V128, P547; Kovacs M, 2002, J BIOL CHEM, V277, P28459, DOI 10.1074/jbc.M202180200; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Malnasi-Csizmadia A, 2000, BIOCHEMISTRY-US, V39, P16135, DOI 10.1021/bi001125j; MARUTA H, 1981, J BIOL CHEM, V256, P499; Murphy CT, 1999, BIOCHEMISTRY-US, V38, P3785, DOI 10.1021/bi9826815; Nalavadi V, 2005, J BIOL CHEM, V280, P38957, DOI 10.1074/jbc.M507161200; O'Connell CB, 2003, NAT CELL BIOL, V5, P171, DOI 10.1038/ncb924; Park S, 1997, BIOCHEMISTRY-US, V36, P3368, DOI 10.1021/bi9624999; Post PL, 1998, J CELL SCI, V111, P941; Post PL, 2002, J BIOL CHEM, V277, P11679, DOI 10.1074/jbc.M111173200; REINHARD J, 1995, EMBO J, V14, P697, DOI 10.1002/j.1460-2075.1995.tb07048.x; Resetar AM, 1995, BIOCHEMISTRY-US, V34, P16039, DOI 10.1021/bi00049a018; ROTH K, 1991, MAGNET RESON MED, V22, P505, DOI 10.1002/mrm.1910220258; Rovner AS, 1998, J BIOL CHEM, V273, P27939, DOI 10.1074/jbc.273.43.27939; Rovner AS, 1995, J BIOL CHEM, V270, P30260, DOI 10.1074/jbc.270.51.30260; Saeki N, 2005, J BIOL CHEM, V280, P10128, DOI 10.1074/jbc.M413415200; Sato O, 2004, J BIOL CHEM, V279, P28844, DOI 10.1074/jbc.M314332200; SPUDICH JA, 1971, J BIOL CHEM, V246, P4866; Trybus KM, 1999, J BIOL CHEM, V274, P27448, DOI 10.1074/jbc.274.39.27448; UYEDA TQP, 1994, NATURE, V368, P567, DOI 10.1038/368567a0; WHITE HD, 1993, J BIOL CHEM, V268, P10039; White HD, 1997, BIOCHEMISTRY-US, V36, P11828, DOI 10.1021/bi970540h; Yengo CM, 2000, J BIOL CHEM, V275, P25481, DOI 10.1074/jbc.M002910200; Yengo CM, 2002, J BIOL CHEM, V277, P24114, DOI 10.1074/jbc.M111253200; Yengo CM, 1999, BIOCHEMISTRY-US, V38, P14515, DOI 10.1021/bi991226l; Yengo CM, 1998, P NATL ACAD SCI USA, V95, P12944, DOI 10.1073/pnas.95.22.12944; Yengo CM, 2002, BIOCHEMISTRY-US, V41, P8508, DOI 10.1021/bi015969u; Yildiz A, 2003, SCIENCE, V300, P2061, DOI 10.1126/science.1084398; Yoshimura M, 2001, J BIOL CHEM, V276, P39600, DOI 10.1074/jbc.M105080200	44	24	24	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 24	2006	281	8					4949	4957		10.1074/jbc.M509141200	http://dx.doi.org/10.1074/jbc.M509141200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	013RF	16338935	hybrid			2022-12-25	WOS:000235426200046
J	Westerberg, R; Mansson, JE; Golozoubova, V; Shabalina, IG; Backlund, EC; Tvrdik, P; Retterstol, K; Capecchi, MR; Jacobsson, A				Westerberg, R; Mansson, JE; Golozoubova, V; Shabalina, IG; Backlund, EC; Tvrdik, P; Retterstol, K; Capecchi, MR; Jacobsson, A			ELOVL3 is an important component for early onset of lipid recruitment in brown adipose tissue	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MITOCHONDRIAL UNCOUPLING PROTEIN; FATTY-ACIDS; NONSHIVERING THERMOGENESIS; COLD-ACCLIMATION; CHAIN ELONGATION; IDENTIFICATION; ADIPOCYTES; ADAPTATION; EXPRESSION; REGULATORS	During the recruitment process of brown adipose tissue, the mRNA level of the fatty acyl chain elongase Elovl3 is elevated more than 200-fold in cold-stressed mice. We have obtained Elovl3-ablated mice and report here that, although cold-acclimated Elovl3-ablated mice experienced an increased heat loss due to impaired skin barrier, they were unable to hyperrecruit their brown adipose tissue. Instead, they used muscle shivering in order to maintain body temperature. Lack of Elovl3 resulted in a transient decrease in the capacity to elongate saturated fatty acyl-CoAs into very long chain fatty acids, concomitantly with the occurrence of reduced levels of arachidic acid (C20:0) and behenic acid (C22:0) in brown adipose tissue during the initial cold stress. This effect on very long chain fatty acid synthesis could be illustrated as a decrease in the condensation activity of the elongation enzyme. In addition, warm-acclimated Elovl3-ablated mice showed diminished ability to accumulate fat and reduced metabolic capacity within the brown fat cells. This points to ELOVL3 as an important regulator of endogenous synthesis of saturated very long chain fatty acids and triglyceride formation in brown adipose tissue during the early phase of the tissue recruitment.	Stockholm Univ, Arrhenius Labs F3, Wenner Gren Inst, SE-10691 Stockholm, Sweden; Sahlgrens Univ Hosp, Lab Med Clin Chem, SE-43180 Molndal, Sweden; Univ Utah, Howard Hughes Med Inst, Salt Lake City, UT 84112 USA; Univ Oslo, Rikshosp, Inst Clin Biochem, N-0027 Oslo, Norway	Stockholm University; Sahlgrenska University Hospital; Howard Hughes Medical Institute; Utah System of Higher Education; University of Utah; University of Oslo; National Hospital Norway	Jacobsson, A (corresponding author), Stockholm Univ, Arrhenius Labs F3, Wenner Gren Inst, SE-10691 Stockholm, Sweden.	anders.jacobsson@wgi.su.se	Shabalina, Irina/AAC-3720-2019; Shabalina, Irina G/A-4225-2011; Tvrdik, Petr/AAK-4398-2021	Shabalina, Irina/0000-0002-2915-6450; Shabalina, Irina G/0000-0002-2915-6450; Tvrdik, Petr/0000-0002-8750-9672				ALBERTS P, 2005, CURRENT PROTOCOLS PH; BAHT HS, 1989, BIOCHEM J, V258, P369, DOI 10.1042/bj2580369; BERNERT JT, 1979, J NEUROCHEM, V32, P85, DOI 10.1111/j.1471-4159.1979.tb04513.x; BERNERT JT, 1977, J BIOL CHEM, V252, P6736; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BROOKS BJ, 1983, BIOSCIENCE REP, V3, P263, DOI 10.1007/BF01122458; BUKOWIECKI L, 1982, AM J PHYSIOL, V242, pE353, DOI 10.1152/ajpendo.1982.242.6.E353; CAMERON IL, 1964, J CELL BIOL, V23, P89, DOI 10.1083/jcb.23.1.89; Cannon B, 1996, INT J OBESITY, V20, pS36; Cannon B, 2004, PHYSIOL REV, V84, P277, DOI 10.1152/physrev.00015.2003; Cannon B, 2000, METH MOL B, V155, P295; CANNON B, 1975, ARCH BIOCHEM BIOPHYS, V167, P505, DOI 10.1016/0003-9861(75)90493-2; CARNEHEIM C, 1989, AM J PHYSIOL, V256, pR146, DOI 10.1152/ajpregu.1989.256.1.R146; DICKER A, 1995, AM J PHYSIOL-REG I, V269, pR767, DOI 10.1152/ajpregu.1995.269.4.R767; Enerback S, 1997, NATURE, V387, P90, DOI 10.1038/387090a0; Fluhr JW, 2003, J INVEST DERMATOL, V120, P728, DOI 10.1046/j.1523-1747.2003.12134.x; FOSTER DO, 1979, CAN J PHYSIOL PHARM, V57, P257, DOI 10.1139/y79-039; GELOEN A, 1988, AM J PHYSIOL, V254, pC175, DOI 10.1152/ajpcell.1988.254.1.C175; Golozoubova V, 2001, FASEB J, V15, P2048, DOI 10.1096/fj.00-0536fje; HOHTOLA E, 1982, COMP BIOCHEM PHYS A, V73, P159, DOI 10.1016/0300-9629(82)90049-4; Inagaki K, 2002, BIOSCI BIOTECH BIOCH, V66, P613, DOI 10.1271/bbb.66.613; JACOBSSON A, 1994, AM J PHYSIOL-REG I, V267, pR999, DOI 10.1152/ajpregu.1994.267.4.R999; JACOBSSON A, 1985, J BIOL CHEM, V260, P6250; Jakobsson A, 2005, AM J PHYSIOL-ENDOC M, V289, pE517, DOI 10.1152/ajpendo.00045.2005; JANSKY L, 1973, BIOL REV, V48, P85; Leonard AE, 2000, BIOCHEM J, V350, P765, DOI 10.1042/0264-6021:3500765; Leonard AE, 2002, LIPIDS, V37, P733, DOI 10.1007/s11745-002-0955-6; Moon YA, 2001, J BIOL CHEM, V276, P45358, DOI 10.1074/jbc.M108413200; NEDERGAARD J, 1992, NEW COMPREHENSIVE BI, V23, P385; NUGTEREN DH, 1965, BIOCHIM BIOPHYS ACTA, V106, P280, DOI 10.1016/0005-2760(65)90036-6; OGAWA K, 1992, JPN J PHYSIOL, V42, P63, DOI 10.2170/jjphysiol.42.63; OGAWA K, 1987, JPN J PHYSIOL, V37, P783, DOI 10.2170/jjphysiol.37.783; Raclot T, 2003, PROG LIPID RES, V42, P257, DOI 10.1016/S0163-7827(02)00066-8; REHNMARK S, 1989, EXP CELL RES, V180, P574, DOI 10.1016/0014-4827(89)90086-4; RICQUIER D, 1979, CAN J BIOCHEM CELL B, V57, P1262, DOI 10.1139/o79-167; SENAULT C, 1975, ANN NUTR ALIMENT, V29, P67; Shabalina IG, 2004, J BIOL CHEM, V279, P38236, DOI 10.1074/jbc.M402375200; Silve S, 1996, MOL CELL BIOL, V16, P2719; SMITH RE, 1969, PHYSIOL REV, V49, P330, DOI 10.1152/physrev.1969.49.2.330; SMITH S, 1994, FASEB J, V8, P1248, DOI 10.1096/fasebj.8.15.8001737; SUNEJA SK, 1991, J NEUROCHEM, V57, P140, DOI 10.1111/j.1471-4159.1991.tb02108.x; SVENNERHOLM L, 1980, BIOCHIM BIOPHYS ACTA, V617, P97, DOI 10.1016/0005-2760(80)90227-1; TRAYHURN P, 1987, P NUTR SOC, V46, P135, DOI 10.1079/PNS19870017; Trayhurn P., 1986, BROWN ADIPOSE TISSUE, P299; TRVDIK P, 2000, J CELL BIOL, V149, P707; Tvrdik P, 1997, J BIOL CHEM, V272, P31738, DOI 10.1074/jbc.272.50.31738; UDENFRIEND S, 1972, SCIENCE, V178, P871, DOI 10.1126/science.178.4063.871; Westerberg R, 2004, J BIOL CHEM, V279, P5621, DOI 10.1074/jbc.M310529200; Zhang K, 2001, NAT GENET, V27, P89, DOI 10.1038/83817; [No title captured]	51	100	103	0	14	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 24	2006	281	8					4958	4968		10.1074/jbc.M511588200	http://dx.doi.org/10.1074/jbc.M511588200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	013RF	16326704	hybrid			2022-12-25	WOS:000235426200047
J	Liu, LJ; Song, X; He, DD; Komma, C; Kita, A; Virbasius, JV; Huang, GQ; Bellamy, HD; Miki, K; Czech, MP; Zhou, GW				Liu, LJ; Song, X; He, DD; Komma, C; Kita, A; Virbasius, JV; Huang, GQ; Bellamy, HD; Miki, K; Czech, MP; Zhou, GW			Crystal structure of the C2 domain of class II phosphatidylinositide 3-kinase C2 alpha	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN PHOSPHOINOSITIDE 3-KINASE; KINASE-C; SIGNAL-TRANSDUCTION; ALPHA-ISOFORM; CDNA CLONING; BINDING; PROTEIN; SYNAPTOTAGMIN; CALCIUM; DIMERIZATION	Phosphatidylinositide (PtdIns) 3-kinase catalyzes the addition of a phosphate group to the 3'-position of phosphatidyl inositol. Accumulated evidence shows that PtdIns 3-kinase can provide a critical signal for cell proliferation, cell survival, membrane trafficking, glucose transport, and membrane ruffling. Mammalian PtdIns 3-kinases are divided into three classes based on structure and substrate specificity. A unique characteristic of class II PtdIns 3-kinases is the presence of both a phox homolog domain and a C2 domain at the C terminus. The biological function of the C2 domain of the class II PtdIns 3-kinases remains to be determined. We have determined the crystal structure of the mCPK-C2 domain, which is the first three-dimensional structural model of a C2 domain of class II PtdIns 3-kinases. Structural studies reveal that the mCPK-C2 domain has a typical anti-parallel beta-sandwich fold. Scrutiny of the surface of this C2 domain has identified three small, shallow sulfate-binding sites. On the basis of the structural features of these sulfate-binding sites, we have studied the lipid binding properties of the mCPK-C2 domain by site-directed mutagenesis. Our results show that this C2 domain binds specifically to PtdIns(3,4)P-2 and PtdIns(4,5)P-2 and that three lysine residues at SBS I site, Lys-1420, Lys-1432, and Lys-1434, are responsible for the phospholipid binding affinity.	Louisiana State Univ, Dept Sci Biol, Baton Rouge, LA 70803 USA; Kyoto Univ, Grad Sch Sci, Dept Chem, Sakyo Ku, Kyoto 6068502, Japan; Univ Massachusetts, Sch Med, Program Mol Med, Worcester, MA 01605 USA; Louisiana State Univ, Ctr Adv Microstruct & Devices, Baton Rouge, LA 70806 USA	Louisiana State University System; Louisiana State University; Kyoto University; University of Massachusetts System; University of Massachusetts Worcester; Louisiana State University System; Louisiana State University	Zhou, GW (corresponding author), Louisiana State Univ, Dept Sci Biol, Baton Rouge, LA 70803 USA.	zhouw@lsu.edu		Virbasius, Joseph/0000-0003-1784-6793				Anderson KE, 2003, INT J BIOCHEM CELL B, V35, P1028, DOI 10.1016/S1357-2725(02)00270-4; Arcaro A, 1998, J BIOL CHEM, V273, P33082, DOI 10.1074/jbc.273.49.33082; Bravo J, 2001, MOL CELL, V8, P829, DOI 10.1016/S1097-2765(01)00372-0; Brown RA, 1999, J BIOL CHEM, V274, P14529, DOI 10.1074/jbc.274.21.14529; Brown RA, 1997, BIOCHEM BIOPH RES CO, V233, P537, DOI 10.1006/bbrc.1997.6495; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Cantley LC, 2002, SCIENCE, V296, P1655, DOI 10.1126/science.296.5573.1655; Chapman ER, 1996, J BIOL CHEM, V271, P5844, DOI 10.1074/jbc.271.10.5844; Collaborative Computational Project, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI DOI 10.1107/S0907444994003112; Corbalan-Garcia S, 2003, BIOCHEMISTRY-US, V42, P11661, DOI 10.1021/bi034850d; Czech MP, 2000, CELL, V100, P603, DOI 10.1016/S0092-8674(00)80696-0; DAVLETOV BA, 1993, J BIOL CHEM, V268, P26386; Didichenko SA, 2001, J BIOL CHEM, V276, P48135, DOI 10.1074/jbc.M104610200; Domin J, 1997, BIOCHEM J, V326, P139, DOI 10.1042/bj3260139; Domin J, 1997, FEBS LETT, V410, P91, DOI 10.1016/S0014-5793(97)00617-0; Fruman DA, 1998, ANNU REV BIOCHEM, V67, P481, DOI 10.1146/annurev.biochem.67.1.481; Gaidarov I, 2001, MOL CELL, V7, P443, DOI 10.1016/S1097-2765(01)00191-5; Garcia-Garcia J, 1999, BIOCHEMISTRY-US, V38, P9667, DOI 10.1021/bi9905765; Hurley JH, 2000, ANNU REV BIOPH BIOM, V29, P49, DOI 10.1146/annurev.biophys.29.1.49; Jimenez JL, 2003, J MOL BIOL, V333, P621, DOI 10.1016/j.jmb.2003.08.052; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Klemm JD, 1998, ANNU REV IMMUNOL, V16, P569, DOI 10.1146/annurev.immunol.16.1.569; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LAWRENCE MC, 2000, J APPL CRYSTALLOGR, V33, P990; Layton MJ, 1998, J BIOL CHEM, V273, P33379, DOI 10.1074/jbc.273.50.33379; Macdougall LK, 1995, CURR BIOL, V5, P1404, DOI 10.1016/S0960-9822(95)00278-8; Merritt EA, 1997, METHOD ENZYMOL, V277, P505, DOI 10.1016/S0076-6879(97)77028-9; Misra S, 2001, CELL, V107, P559, DOI 10.1016/S0092-8674(01)00594-3; Molz L, 1996, J BIOL CHEM, V271, P13892, DOI 10.1074/jbc.271.23.13892; Murray D, 2002, MOL CELL, V9, P145, DOI 10.1016/S1097-2765(01)00426-9; Nalefski EA, 1996, PROTEIN SCI, V5, P2375, DOI 10.1002/pro.5560051201; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Pepio AM, 1998, BIOCHEMISTRY-US, V37, P1256, DOI 10.1021/bi971841u; Rozycka M, 1998, GENOMICS, V54, P569, DOI 10.1006/geno.1998.5621; Song X, 2001, BIOCHEMISTRY-US, V40, P8940, DOI 10.1021/bi0155100; Sutton RB, 1998, STRUCTURE, V6, P1395, DOI 10.1016/S0969-2126(98)00139-7; Sutton RB, 1999, J CELL BIOL, V147, P589, DOI 10.1083/jcb.147.3.589; SUTTON RB, 1995, CELL, V80, P929, DOI 10.1016/0092-8674(95)90296-1; Turner SJ, 1998, J BIOL CHEM, V273, P25987, DOI 10.1074/jbc.273.40.25987; Urso B, 1999, FEBS LETT, V460, P423, DOI 10.1016/S0014-5793(99)01388-5; Verdaguer N, 1999, EMBO J, V18, P6329, DOI 10.1093/emboj/18.22.6329; Virbasius JV, 1996, J BIOL CHEM, V271, P13304, DOI 10.1074/jbc.271.23.13304; Zhan Y, 2002, J BIOL CHEM, V277, P4512, DOI 10.1074/jbc.M109520200; Zhang J, 1998, J BIOL CHEM, V273, P14081, DOI 10.1074/jbc.273.23.14081; [No title captured]	45	28	29	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 17	2006	281	7					4254	4260		10.1074/jbc.M510791200	http://dx.doi.org/10.1074/jbc.M510791200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	011NN	16338929	hybrid			2022-12-25	WOS:000235275300058
J	van Oevelen, CJC; van Teeffelen, HAAM; van Werven, FJ; Timmers, HTM				van Oevelen, CJC; van Teeffelen, HAAM; van Werven, FJ; Timmers, HTM			Snf1p-dependent Spt-Ada-Gcn5-acetyltransferase (SAGA) recruitment and chromatin remodeling activities on the HXT2 and HXT4 promoters	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLOBAL TRANSCRIPTIONAL REGULATORS; IN-VIVO; GLUCOSE REPRESSION; HISTONE ACETYLTRANSFERASE; TBP RECRUITMENT; MIG1 REPRESSOR; YEAST GCN5P; SWI-SNF; GENE; PROTEIN	We previously showed that the Spt-Ada-Gcn5-acetyltransferase ( SAGA) complex is recruited to the activated HXT2 and HXT4 genes and plays a role in the association of TBP-associated factors. Using the HXT2 and HXT4 genes, we now present evidence for a functional link between Snf1p-dependent activation, recruitment of the SAGA complex, histone H3 removal, and H3 acetylation. Recruitment of the SAGA complex is dependent on the release of Ssn6p-Tup1p repression by Snf1p. In addition, we found that the Gcn5p subunit of the SAGA complex preferentially acetylates histone H3K18 on the HXT2 and HXT4 promoters and that Gcn5p activity is required for removal of histone H3 from the HXT4 promoter TATA region. In contrast, histone H3 removal from the HXT2 promoter does not require Gcn5p. In conclusion, although similar protein complexes are involved, induction of HXT2 and HXT4 displays important mechanistic differences.	Univ Utrecht, Ctr Med, Dept Physiol Chem, Div Biomed Genet, NL-3584 CG Utrecht, Netherlands	Utrecht University	Timmers, HTM (corresponding author), Univ Utrecht, Ctr Med, Dept Physiol Chem, Div Biomed Genet, Universiteitsweg 100, NL-3584 CG Utrecht, Netherlands.	h.t.m.timmers@med.uu.nl		van Werven, Folkert/0000-0002-6685-2084				Andrau JC, 2002, EMBO J, V21, P5173, DOI 10.1093/emboj/cdf485; Bai Y, 1997, MOL CELL BIOL, V17, P3081, DOI 10.1128/MCB.17.6.3081; Bhaumik SR, 2001, GENE DEV, V15, P1935, DOI 10.1101/gad.911401; Bone JR, 2001, J BIOL CHEM, V276, P1808, DOI 10.1074/jbc.M008668200; Brown CE, 2001, SCIENCE, V292, P2333, DOI 10.1126/science.1060214; Brownell JE, 1996, CELL, V84, P843, DOI 10.1016/S0092-8674(00)81063-6; BURKE D, METHODS YEAST GENETI; Carlson M, 1999, CURR OPIN MICROBIOL, V2, P202, DOI 10.1016/S1369-5274(99)80035-6; Carlson M, 1997, ANNU REV CELL DEV BI, V13, P1, DOI 10.1146/annurev.cellbio.13.1.1; CELENZA JL, 1984, MOL CELL BIOL, V4, P49, DOI 10.1128/MCB.4.1.49; CELENZA JL, 1986, SCIENCE, V233, P1175, DOI 10.1126/science.3526554; COOPER JP, 1994, GENE DEV, V8, P1400, DOI 10.1101/gad.8.12.1400; Davie JK, 2003, J BIOL CHEM, V278, P50158, DOI 10.1074/jbc.M309753200; Davie JK, 2002, MOL CELL BIOL, V22, P693, DOI 10.1128/MCB.22.3.693-703.2002; Diderich JA, 1999, J BIOL CHEM, V274, P15350, DOI 10.1074/jbc.274.22.15350; Ducker CE, 2000, EMBO J, V19, P400, DOI 10.1093/emboj/19.3.400; Dudley AM, 1999, GENE DEV, V13, P2940, DOI 10.1101/gad.13.22.2940; Edmondson DG, 1996, GENE DEV, V10, P1247, DOI 10.1101/gad.10.10.1247; EISENMANN DM, 1994, GENETICS, V137, P647; EISENMANN DM, 1992, GENE DEV, V6, P1319, DOI 10.1101/gad.6.7.1319; Fleming AB, 2001, EMBO J, V20, P5219, DOI 10.1093/emboj/20.18.5219; Gavin IM, 1997, EMBO J, V16, P6263, DOI 10.1093/emboj/16.20.6263; Grant PA, 1997, GENE DEV, V11, P1640, DOI 10.1101/gad.11.13.1640; Grant PA, 1999, J BIOL CHEM, V274, P5895, DOI 10.1074/jbc.274.9.5895; Grant PA, 1998, TRENDS CELL BIOL, V8, P193, DOI 10.1016/S0962-8924(98)01263-X; Kuchin S, 1998, MOL CELL BIOL, V18, P1163, DOI 10.1128/MCB.18.3.1163; Kuo MH, 1998, GENE DEV, V12, P627, DOI 10.1101/gad.12.5.627; Kuras L, 2000, SCIENCE, V288, P1244, DOI 10.1126/science.288.5469.1244; Kuras L, 1999, NATURE, V399, P609, DOI 10.1038/21239; Larschan E, 2001, GENE DEV, V15, P1946, DOI 10.1101/gad.911501; Li B, 2001, J BIOL CHEM, V276, P33788, DOI 10.1074/jbc.M104220200; Lo WS, 2000, MOL CELL, V5, P917, DOI 10.1016/S1097-2765(00)80257-9; Lo WS, 2005, EMBO J, V24, P997, DOI 10.1038/sj.emboj.7600577; Ozcan S, 1996, MOL CELL BIOL, V16, P5536; Ozcan S, 1999, MICROBIOL MOL BIOL R, V63, P554; OZCAN S, 1995, MOL CELL BIOL, V15, P1564; Papamichos-Chronakis M, 2004, EMBO REP, V5, P368, DOI 10.1038/sj.embor.7400120; Papamichos-Chronakis M, 2002, MOL CELL, V9, P1297, DOI 10.1016/S1097-2765(02)00545-2; POON D, 1994, J BIOL CHEM, V269, P23135; Proft M, 2002, MOL CELL, V9, P1307, DOI 10.1016/S1097-2765(02)00557-9; Reid RJD, 2002, METHOD ENZYMOL, V350, P258; Rolland F, 2002, FEMS YEAST RES, V2, P183, DOI 10.1111/j.1567-1364.2002.tb00084.x; Smith RL, 2000, TRENDS BIOCHEM SCI, V25, P325, DOI 10.1016/S0968-0004(00)01592-9; Sterner DE, 1999, MOL CELL BIOL, V19, P86; Suka N, 2001, MOL CELL, V8, P473, DOI 10.1016/S1097-2765(01)00301-X; Syntichaki P, 2000, NATURE, V404, P414, DOI 10.1038/35006136; Timmers HTM, 2005, TRENDS BIOCHEM SCI, V30, P7, DOI 10.1016/j.tibs.2004.11.007; Topalidou I, 2004, EMBO J, V23, P1943, DOI 10.1038/sj.emboj.7600199; Treitel MA, 1998, MOL CELL BIOL, V18, P6273, DOI 10.1128/MCB.18.11.6273; TREITEL MA, 1995, P NATL ACAD SCI USA, V92, P3132, DOI 10.1073/pnas.92.8.3132; TZAMARIAS D, 1994, NATURE, V369, P758, DOI 10.1038/369758a0; VALLIER LG, 1994, GENETICS, V137, P49; van Oevelen CJC, 2005, MOL CELL BIOL, V25, P4863, DOI 10.1128/MCB.25.12.4863-4872.2005; WAHI M, 1995, GENETICS, V140, P79; Watson AD, 2000, GENE DEV, V14, P2737, DOI 10.1101/gad.829100; Wu JS, 2001, MOL CELL, V7, P117, DOI 10.1016/S1097-2765(01)00160-5; Wu PYJ, 2004, MOL CELL, V15, P199, DOI 10.1016/j.molcel.2004.06.005	57	20	21	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 17	2006	281	7					4523	4531		10.1074/jbc.M509330200	http://dx.doi.org/10.1074/jbc.M509330200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	011NN	16368692	hybrid			2022-12-25	WOS:000235275300088
J	Dementiev, A; Dobo, J; Gettins, PGW				Dementiev, A; Dobo, J; Gettins, PGW			Active site distortion is sufficient for proteinase inhibition by serpins - Structure of the covalent complex of alpha(1)-proteinase inhibitor with porcine pancreatic elastase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEASE COMPLEX; TERNARY COMPLEX; MECHANISM; ANTITHROMBIN; PITTSBURGH; REVEALS; HEPARIN; TRYPSIN; NMR; STABILIZATION	We report here the x-ray structure of a covalent serpin-proteinase complex, alpha(1)-proteinase inhibitor (alpha 1PI) with porcine pancreatic elastase (PPE), which differs from the only other x-ray structure of such a complex, that of alpha 1PI with trypsin, in showing nearly complete definition of the proteinase. alpha 1PI complexes with trypsin, PPE, and human neutrophil elastase (HNE) showed similar rates of deacylation and enhanced susceptibility to proteolysis by exogenous proteinases in solution. The differences between the two x-ray structures therefore cannot arise from intrinsic differences in the inhibition mechanism. However, self-proteolysis of purified complex resulted in rapid cleavage of the trypsin complex, slower cleavage of the PPE complex, and only minimal cleavage of the HNE complex. This suggests that the earlier alpha 1PI-trypsin complex may have been proteolyzed and that the present structure is more likely to be representative of serpin-proteinase complexes. The present structure shows that active site distortion alone is sufficient for inhibition and suggests that enhanced proteolysis is not necessarily exploited in vivo.	Univ Illinois, Dept Biochem & Mol Genet, M-C 669,900 S Ashland, Chicago, IL 60607 USA	University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital	Gettins, PGW (corresponding author), Univ Illinois, Dept Biochem & Mol Genet, M-C 669,900 S Ashland, Chicago, IL 60607 USA.	pgettins@uic.edu	Dobo, Jozsef/C-7331-2014	Dobo, Jozsef/0000-0001-9187-8502	NHLBI NIH HHS [P01HL64013, R37HL49234] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL064013, R01HL049234, R37HL049234] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Backovic M, 2002, PROTEIN SCI, V11, P1182, DOI 10.1110/ps.4320102; Baglin TP, 2002, P NATL ACAD SCI USA, V99, P11079, DOI 10.1073/pnas.162232399; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Calugaru SV, 2001, J BIOL CHEM, V276, P32446, DOI 10.1074/jbc.M104731200; COOPERMAN BS, 1993, J BIOL CHEM, V268, P23616; Dementiev A, 2003, J BIOL CHEM, V278, P37881, DOI 10.1074/jbc.M305195200; Dementiev A, 2004, NAT STRUCT MOL BIOL, V11, P863, DOI 10.1038/nsmb810; Dobo J, 2004, J BIOL CHEM, V279, P9264, DOI 10.1074/jbc.M311731200; Egelund R, 2001, EUR J BIOCHEM, V268, P673, DOI 10.1046/j.1432-1327.2001.01921.x; Fa M, 2000, STRUCT FOLD DES, V8, P397, DOI 10.1016/S0969-2126(00)00121-0; FISH WW, 1979, EUR J BIOCHEM, V101, P39, DOI 10.1111/j.1432-1033.1979.tb04213.x; Futamura A, 1998, BIOCHEMISTRY-US, V37, P13110, DOI 10.1021/bi981234m; Gettins PGW, 2002, FEBS LETT, V523, P2, DOI 10.1016/S0014-5793(02)02924-1; Gettins PGW, 2002, CHEM REV, V102, P4751, DOI 10.1021/cr010170+; HERVE M, 1991, ARCH BIOCHEM BIOPHYS, V285, P142, DOI 10.1016/0003-9861(91)90341-F; Huntington JA, 2000, NATURE, V407, P923, DOI 10.1038/35038119; KASLIK G, 1995, FEBS LETT, V370, P179, DOI 10.1016/0014-5793(95)00816-R; Kaslik G, 1997, BIOCHEMISTRY-US, V36, P5455, DOI 10.1021/bi962931m; LAWRENCE DA, 1995, J BIOL CHEM, V270, P25309, DOI 10.1074/jbc.270.43.25309; Lee FT, 1996, ACAD RADIOL, V3, pS500, DOI 10.1016/S1076-6332(05)80366-6; Li W, 2004, NAT STRUCT MOL BIOL, V11, P857, DOI 10.1038/nsmb811; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Peterson FC, 2000, BIOCHEMISTRY-US, V39, P11884, DOI 10.1021/bi001152+; Peterson FC, 2001, BIOCHEMISTRY-US, V40, P6284, DOI 10.1021/bi010100x; Stavridi ES, 1996, BIOCHEMISTRY-US, V35, P10608, DOI 10.1021/bi9605806; Stratikos E, 1998, J BIOL CHEM, V273, P15582, DOI 10.1074/jbc.273.25.15582; Stratikos E, 1999, P NATL ACAD SCI USA, V96, P4808, DOI 10.1073/pnas.96.9.4808; Ye S, 2001, NAT STRUCT BIOL, V8, P979, DOI 10.1038/nsb1101-979	28	110	113	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 10	2006	281	6					3452	3457		10.1074/jbc.M510564200	http://dx.doi.org/10.1074/jbc.M510564200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	009QV	16321984	hybrid			2022-12-25	WOS:000235128200054
J	Dode, L; Andersen, JP; Vanoevelen, J; Raeymaekers, L; Missiaen, L; Vilsen, B; Wuytack, F				Dode, L; Andersen, JP; Vanoevelen, J; Raeymaekers, L; Missiaen, L; Vilsen, B; Wuytack, F			Dissection of the functional differences between human secretory pathway Ca2+/Mn2+-ATPase (SPCA) 1 and 2 isoenzymes by steady-state and transient kinetic analyses	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SARCOPLASMIC-RETICULUM CA2+-ATPASE; HAILEY-HAILEY-DISEASE; CA2&-DEPENDENT ATP HYDROLYSIS; ALKALI-METAL SALTS; SKELETAL-MUSCLE; CALCIUM-PUMP; CA2+ PUMP; ADENOSINE-TRIPHOSPHATASE; REACTION-MECHANISM; CRYSTAL-STRUCTURE	Human secretory pathway Ca2+/Mn2+-ATPase (SPCA) 2 encoded by ATP2C2 is only expressed in a limited number of tissues, unlike the ubiquitously expressed SPCA1 pump (encoded by ATP2C1, the gene defective in Hailey-Hailey disease). It has not been determined whether there are significant functional differences between SPCA1 and SPCA2 pump enzymes. Therefore, steady-state and transient kinetic approaches were used to characterize the overall and partial reactions of the Ca2+ transport cycle mediated by the human SPCA2 enzyme upon heterologous expression in HEK-293 cells. The catalytic turnover rate of SPCA2 was found enhanced relative to SPCA1 pumps. SPCA2 displayed a very high apparent affinity for cytosolic Ca2+ (K-0.(5) = 0.025 mu M) in activation of the phosphorylation activity but still 2.5- fold lower than that of SPCA1d. Our kinetic analysis traced both differences to the increased rate characterizing the E-1 similar to P(Ca) to E-2-P transition of SPCA2. Moreover, the reduced rate of the E-2 to E-1 transition seems to contribute in determining the lower apparent Ca2+ affinity and the increased sensitivity to thapsigargin inhibition, relative to SPCA1d. SPCA2 also displayed a reduced apparent affinity for inorganic phosphate, which could be explained by the observed enhanced rate of the E-2-P dephosphorylation. The insensitivity to modulation by pH and K+ concentration of the constitutively enhanced E-2-P dephosphorylation of SPCA2 is similar to SPCA1d and possibly represents a novel SPCA-specific feature, which is not shared by sarco(endo) plasmic reticulum Ca2+-ATPases.	Univ Aarhus, Dept Physiol, Inst Physiol & Biophys, DK-8000 Aarhus C, Denmark; Catholic Univ Louvain, Physiol Lab, B-3000 Louvain, Belgium	Aarhus University; Universite Catholique Louvain	Andersen, JP (corresponding author), Univ Aarhus, Dept Physiol, Inst Physiol & Biophys, Ole Worms Alle 160, DK-8000 Aarhus C, Denmark.	jpa@fi.au.dk	Vanoevelen, Jo M/F-2686-2013	Vanoevelen, Jo M/0000-0003-1830-8858; Vilsen, Bente/0000-0002-4727-9382; Andersen, Jens Peter/0000-0003-0654-4300				Andersen JP, 1995, BIOSCIENCE REP, V15, P243, DOI 10.1007/BF01788358; Andersen JP, 2001, J BIOL CHEM, V276, P23312, DOI 10.1074/jbc.M102384200; ANTEBI A, 1992, MOL BIOL CELL, V3, P633, DOI 10.1091/mbc.3.6.633; BRANDL CJ, 1987, J BIOL CHEM, V262, P3768; CLARKE DM, 1989, NATURE, V339, P476, DOI 10.1038/339476a0; DEMEIS L, 1980, BIOCHEMISTRY-US, V19, P4252, DOI 10.1021/bi00559a017; DEMEIS L, 1979, ANNU REV BIOCHEM, V48, P275; Dode L, 2005, J BIOL CHEM, V280, P39124, DOI 10.1074/jbc.M506181200; Dode L, 2003, J BIOL CHEM, V278, P47877, DOI 10.1074/jbc.M306784200; Dode L, 2002, J BIOL CHEM, V277, P45579, DOI 10.1074/jbc.M207778200; Fairclough RJ, 2003, J BIOL CHEM, V278, P24721, DOI 10.1074/jbc.M300509200; GUNTESKIHAMBLIN AM, 1992, BIOCHEMISTRY-US, V31, P7600, DOI 10.1021/bi00148a023; Hu ZL, 2000, NAT GENET, V24, P61, DOI 10.1038/71701; MARUYAMA K, 1988, P NATL ACAD SCI USA, V85, P3314, DOI 10.1073/pnas.85.10.3314; Obara K, 2005, P NATL ACAD SCI USA, V102, P14489, DOI 10.1073/pnas.0506222102; PETITHORY JR, 1988, BIOCHEMISTRY-US, V27, P5553, DOI 10.1021/bi00415a025; RUDOLPH HK, 1989, CELL, V58, P133, DOI 10.1016/0092-8674(89)90410-8; Sakuntabhai A, 1999, NAT GENET, V21, P271, DOI 10.1038/6784; SHIGEKAWA M, 1978, J BIOL CHEM, V253, P1442; SHIGEKAWA M, 1978, J BIOL CHEM, V253, P1451; Sorensen TLM, 2004, J BIOL CHEM, V279, P46355, DOI 10.1074/jbc.C400414200; Sorensen TLM, 2000, J BIOL CHEM, V275, P5400, DOI 10.1074/jbc.275.8.5400; Sorin A, 1997, J BIOL CHEM, V272, P9895; Sudbrak R, 2000, HUM MOL GENET, V9, P1131, DOI 10.1093/hmg/9.7.1131; Sugita Y, 2005, J AM CHEM SOC, V127, P6150, DOI 10.1021/ja0427505; Ton VK, 2004, AM J PHYSIOL-CELL PH, V287, pC580, DOI 10.1152/ajpcell.00135.2004; Toyoshima C, 2000, NATURE, V405, P647, DOI 10.1038/35015017; Van Baelen K, 2004, BBA-MOL CELL RES, V1742, P103, DOI 10.1016/j.bbamcr.2004.08.018; Van Baelen K, 2001, J BIOL CHEM, V276, P10683, DOI 10.1074/jbc.M010553200; Vanoevelen J, 2005, J BIOL CHEM, V280, P22800, DOI 10.1074/jbc.M501026200; WAKABAYASHI S, 1987, J BIOL CHEM, V262, P9121; Xiang MH, 2005, J BIOL CHEM, V280, P11608, DOI 10.1074/jbc.M413116200; Zhang ZS, 2000, BIOCHEMISTRY-US, V39, P8758, DOI 10.1021/bi000185m	33	40	42	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 10	2006	281	6					3182	3189		10.1074/jbc.M511547200	http://dx.doi.org/10.1074/jbc.M511547200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	009QV	16332677	hybrid			2022-12-25	WOS:000235128200021
J	Wicher, D; Agricola, HJ; Schonherr, R; Heinemann, SH; Derst, C				Wicher, D; Agricola, HJ; Schonherr, R; Heinemann, SH; Derst, C			TRP gamma channels are inhibited by cAMP and contribute to pacemaking in neurosecretory insect neurons	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CAPACITATIVE CA2+ ENTRY; PERIPLANETA-AMERICANA; CALCIUM-ENTRY; DROSOPHILA; COCKROACH; RELEASE; CELLS; CURRENTS	From a neuronal cDNA library of the cockroach Periplaneta americana we isolated a 3585-bp cDNA sequence encoding Periplaneta transient receptor potential gamma (pTRP gamma), a protein of 1194 amino acids showing 65% identity to the orthologous Drosophila channel protein dTRP gamma. Heterologous expression of pTRP gamma in HEK293 cells produced a constitutively active, non-selective cation channel with a Ca2(+):Na+ permeability ratio of 2. In contrast to dTRP gamma-mediated currents, pTRP gamma currents were partially inhibited by 8-bromo-cAMP, and this effect was not mediated by protein kinase A (PKA) activation. pTRP gamma b, a truncated pTRP gamma splice variant missing most of the C terminus, was insensitive to 8-bromo-cAMP. Thus, the critical cAMP-binding site seems to be located in the C-terminal part of pTRP gamma, although there is no common cAMP-binding consensus sequence. While dTRP gamma is only expressed in the photoreceptors, pTRP gamma is expressed throughout the nervous system. In particular it is expressed in dorsal unpaired median (DUM) neurons. In these octopamine-releasing, neurosecretory cells a Ca2+ background current contributing to pacemaker activity was found to be up-regulated by the reduction of cAMP level. In addition, the Ca2+ background current was inhibited by LOE-908, 2-APB, and La3+, which similarly affected the pTRP gamma current. We thus propose that the pTRP gamma protein is involved in forming the channel passing the Ca2+ pakemaking background current in DUM neurons.	Saxon Acad Sci, Dept Neurohormones, D-07743 Jena, Germany; Univ Jena, Inst Zool, D-6900 Jena, Germany; Univ Jena, Inst Mol Cell Biol, D-6900 Jena, Germany; Charite, Ctr Anat, Berlin, Germany	Friedrich Schiller University of Jena; Friedrich Schiller University of Jena; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin	Wicher, D (corresponding author), Max Planck Inst Chem Ecol, Hans Knoll Str 8, D-07745 Jena, Germany.	dwicher@ice.mpg.de	Schönherr, Roland/K-8713-2013	Schönherr, Roland/0000-0003-0633-0775; Heinemann, Stefan H./0000-0002-4144-0251				Achenbach H, 1997, NEUROREPORT, V8, P3737, DOI 10.1097/00001756-199712010-00016; BAUMANN E, 1984, BIOMED BIOCHIM ACTA, V43, P13; Bezzerides VJ, 2004, NAT CELL BIOL, V6, P709, DOI 10.1038/ncb1150; Bugaj V, 2005, J BIOL CHEM, V280, P16790, DOI 10.1074/jbc.M500192200; Clapham DE, 2003, PHARMACOL REV, V55, P591, DOI 10.1124/pr.55.4.6; Clapham DE, 2003, NATURE, V426, P517, DOI 10.1038/nature02196; Clapham DE, 2001, NAT REV NEUROSCI, V2, P387, DOI 10.1038/35077544; Derst C, 2003, EUR J NEUROSCI, V17, P1197, DOI 10.1046/j.1460-9568.2003.02550.x; Dunne MJ, 1999, TRENDS ENDOCRIN MET, V10, P146, DOI 10.1016/S1043-2760(98)00135-0; Grolleau F, 2000, J EXP BIOL, V203, P1633; Heine M, 1998, NEUROREPORT, V9, P3309, DOI 10.1097/00001756-199810050-00029; Hille B., 2001, ION CHANNELS EXCITAB, V3rd Edn; MERRITT JE, 1990, BIOCHEM J, V271, P515, DOI 10.1042/bj2710515; Messutat S, 2001, CELL CALCIUM, V30, P199, DOI 10.1054/ceca.2001.0227; MINKE B, 1977, BIOPHYS STRUCT MECH, V3, P59, DOI 10.1007/BF00536455; Moneer Z, 2002, BIOCHEM J, V362, P13, DOI 10.1042/0264-6021:3620013; Montell C, 1999, ANNU REV CELL DEV BI, V15, P231, DOI 10.1146/annurev.cellbio.15.1.231; Montell Craig, 2005, Sci STKE, V2005, pre3, DOI 10.1126/stke.2722005re3; Predel R, 2004, EUR J NEUROSCI, V20, P1499, DOI 10.1111/j.1460-9568.2004.03598.x; Shuttleworth TJ, 1996, BIOCHEM J, V316, P819, DOI 10.1042/bj3160819; WICHER D, 1994, J COMP PHYSIOL A, V174, P507; Wicher D, 2006, J NEUROPHYSIOL, V95, P311, DOI 10.1152/jn.00904.2005; Wicher D, 2004, J BIOL CHEM, V279, P50410, DOI 10.1074/jbc.M405800200; Xu XZS, 2000, NEURON, V26, P647, DOI 10.1016/S0896-6273(00)81201-5; Zagranichnaya TK, 2005, J BIOL CHEM, V280, P29559, DOI 10.1074/jbc.M505842200	25	23	23	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 10	2006	281	6					3227	3236		10.1074/jbc.M511741200	http://dx.doi.org/10.1074/jbc.M511741200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	009QV	16319060	hybrid			2022-12-25	WOS:000235128200027
J	Chen, B; Nelson, DM; Sadovsky, Y				Chen, B; Nelson, DM; Sadovsky, Y			N-Myc down-regulated gene 1 modulates the response of term human trophoblasts to hypoxic injury	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; VASCULAR ENDOTHELIAL-CELLS; EMBRYONIC STEM-CELLS; TRANSFORMING GROWTH-FACTOR-BETA-1; CALORIE RESTRICTION; IN-VITRO; EXPRESSION; DIFFERENTIATION; GROWTH; PROTEIN	The placenta is susceptible to diverse insults during human pregnancy. The expression of the protein N-myc down-regulated gene 1 (NDRG1) is regulated during cell proliferation, differentiation, and in response to stress. Nevertheless, the function of this protein in humans remains unknown. We tested the hypothesis that NDRG1 is up-regulated in hypoxic primary human trophoblasts and that NDRG1 modulates trophoblast response to hypoxia. We initially demonstrated that the expression of NDRG1 is enhanced in primary human trophoblasts exposed to hypoxia. Importantly, we found a similar increase in NDRG1 expression in placental samples derived from either singleton gestations complicated by intrauterine growth restriction or from dizygotic twin gestation where one twin exhibited growth restriction. Having established efficient lentivirus-mediated transfection of primary human trophoblasts, we overexpressed NDRG1 in trophoblasts, which resulted in enhanced trophoblast differentiation. In contrast, lentivirus-driven short interfering RNA-mediated silencing of NDRG1 diminished trophoblast viability and differentiation. Consistent with these results, NDRG1 reduced the expression level of p53 in trophoblasts cultured in standard or hypoxic conditions. Furthermore, NDRG1 expression was regulated by the activity of SIRT1 (Sir2 like protein 1), which promotes cell survival. Together, our data indicate that NDRG1 interacts with SIRT1/p53 signaling to attenuate hypoxic injury in human trophoblasts.	Washington Univ, Sch Med, Dept Obstet & Gynecol, St Louis, MO 63110 USA; Washington Univ, Sch Med, Dept Cell Biol & Physiol, St Louis, MO 63110 USA	Washington University (WUSTL); Washington University (WUSTL)	Sadovsky, Y (corresponding author), Washington Univ, Sch Med, Dept Obstet & Gynecol, Campus Box 8064,4566 Scott Ave, St Louis, MO 63110 USA.	ysadovsky@wustl.edu		Sadovsky, Yoel/0000-0003-2969-6737				Ahmed A, 2000, PLACENTA, V21, pS16, DOI 10.1053/plac.1999.0524; Alarcon R, 1999, CANCER RES, V59, P6046; Alcendor RR, 2004, CIRC RES, V95, P971, DOI 10.1161/01.RES.0000147557.75257.ff; Alsat E, 1996, J CELL PHYSIOL, V168, P346, DOI 10.1002/(SICI)1097-4652(199608)168:2<346::AID-JCP13>3.0.CO;2-1; Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; Araki T, 2004, SCIENCE, V305, P1010, DOI 10.1126/science.1098014; Bandyopadhyay S, 2003, CANCER RES, V63, P1731; BENIRSCHKE K, 2000, PATHOLOGY HUMAN PLAC, P452; Blattner C, 2002, MOL CELL BIOL, V22, P6170, DOI 10.1128/MCB.22.17.6170-6182.2002; Bordone L, 2005, NAT REV MOL CELL BIO, V6, P298, DOI 10.1038/nrm1616; Budhraja V, 2003, BMC BIOL, V1, DOI 10.1186/1741-7007-1-1; BURNS DPW, 1993, J VIROL, V67, P4104, DOI 10.1128/JVI.67.7.4104-4113.1993; Caniggia I, 2002, PLACENTA, V23, pS47, DOI 10.1053/plac.2002.0815; Chen LH, 1997, J BIOL CHEM, V272, P22966, DOI 10.1074/jbc.272.36.22966; Di Santo S, 2003, PLACENTA, V24, P882, DOI 10.1016/S0143-4004(03)00142-5; Dong YS, 2001, J IMMUNOL, V167, P311, DOI 10.4049/jimmunol.167.1.311; DOUGLAS GC, 1990, J CELL SCI, V96, P131; Esterman A, 1996, PLACENTA, V17, P217, DOI 10.1016/S0143-4004(96)90041-7; Follenzi A, 2000, NAT GENET, V25, P217, DOI 10.1038/76095; Frye RA, 2000, BIOCHEM BIOPH RES CO, V273, P793, DOI 10.1006/bbrc.2000.3000; Genbacev O, 1997, SCIENCE, V277, P1669, DOI 10.1126/science.277.5332.1669; Graham CH, 2000, PLACENTA, V21, P443, DOI 10.1053/plac.2000.0543; Gratton RJ, 2004, PLACENTA, V25, P62, DOI 10.1016/S0143-4004(03)00216-9; Gropp M, 2003, MOL THER, V7, P281, DOI 10.1016/S1525-0016(02)00047-3; Guang RJ, 2000, CANCER RES, V60, P749; Guarente L, 2005, CELL, V120, P473, DOI 10.1016/j.cell.2005.01.029; Kalaydjieva L, 2000, AM J HUM GENET, V67, P47, DOI 10.1086/302978; Kale VP, 2004, STEM CELLS DEV, V13, P536, DOI 10.1089/1547328042417390; Kilani RT, 1997, J VIROL, V71, P6359, DOI 10.1128/JVI.71.9.6359-6372.1997; Kilani RT, 2003, PLACENTA, V24, P826, DOI 10.1016/S0143-4004(03)00129-2; KLIMAN HJ, 1986, ENDOCRINOLOGY, V118, P1567, DOI 10.1210/endo-118-4-1567; Klimatcheva E, 1999, FRONT BIOSCI-LANDMRK, V4, P481; Kokame K, 1996, J BIOL CHEM, V271, P29659, DOI 10.1074/jbc.271.47.29659; Kordower JH, 1999, EXP NEUROL, V160, P1, DOI 10.1006/exnr.1999.7178; Korin YD, 1999, J VIROL, V73, P6526, DOI 10.1128/JVI.73.8.6526-6532.1999; Kudo Y, 2003, BBA-MOL BASIS DIS, V1638, P63, DOI 10.1016/S0925-4439(03)00043-7; Kurdistani SK, 1998, CANCER RES, V58, P4439; Lachat P, 2002, HISTOCHEM CELL BIOL, V118, P399, DOI 10.1007/s00418-002-0460-9; Levy R, 2002, AM J OBSTET GYNECOL, V186, P1056, DOI 10.1067/mob.2002.122250; Levy R, 2000, AM J PHYSIOL-CELL PH, V278, pC982, DOI 10.1152/ajpcell.2000.278.5.C982; LEWIS P, 1992, EMBO J, V11, P3053, DOI 10.1002/j.1460-2075.1992.tb05376.x; LEWIS PF, 1994, J VIROL, V68, P510, DOI 10.1128/JVI.68.1.510-516.1994; Lin TM, 1997, P NATL ACAD SCI USA, V94, P4988, DOI 10.1073/pnas.94.10.4988; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; Luo JY, 2001, CELL, V107, P137, DOI 10.1016/S0092-8674(01)00524-4; Ma Y, 2003, STEM CELLS, V21, P111, DOI 10.1634/stemcells.21-1-111; MARTIN AW, 1992, HUM PATHOL, V23, P411, DOI 10.1016/0046-8177(92)90088-K; MATTERN CFT, 1992, PEDIATRICS, V89, P207; Maynard SE, 2003, J CLIN INVEST, V111, P649, DOI 10.1172/JCI200317189; Mi S, 2000, NATURE, V403, P785, DOI 10.1038/35001608; Morrish DW, 2001, CURR PROTEIN PEPT SC, V2, P245, DOI 10.2174/1389203013381116; Murray JT, 2004, BIOCHEM J, V384, P477, DOI 10.1042/BJ20041057; Nagata M, 2003, J GENE MED, V5, P921, DOI 10.1002/jgm.431; Nelson DM, 1999, AM J OBSTET GYNECOL, V180, P896, DOI 10.1016/S0002-9378(99)70661-7; Okuda T, 2004, MOL CELL BIOL, V24, P3949, DOI 10.1128/MCB.24.9.3949-3956.2004; OMURA T, 1995, J STEROID BIOCHEM, V53, P19, DOI 10.1016/0960-0760(95)00036-Y; Park H, 2000, BIOCHEM BIOPH RES CO, V276, P321, DOI 10.1006/bbrc.2000.3475; Piquemal D, 1999, BBA-MOL CELL RES, V1450, P364, DOI 10.1016/S0167-4889(99)00056-7; Piret JP, 2004, EXP CELL RES, V295, P340, DOI 10.1016/j.yexcr.2004.01.024; Qu XH, 2002, MOL CELL BIOCHEM, V229, P35, DOI 10.1023/A:1017934810825; Resnik R, 2002, OBSTET GYNECOL, V99, P490, DOI 10.1016/S0029-7844(01)01780-X; Roh CR, 2005, PLACENTA, V26, P319, DOI 10.1016/j.placenta.2004.06.013; Salnikow K, 2000, CANCER RES, V60, P5630; Salnikow K, 1999, TOXICOL APPL PHARM, V160, P127, DOI 10.1006/taap.1999.8759; Sato N, 1998, J BIOCHEM-TOKYO, V123, P1119; Schmid T, 2004, J CELL MOL MED, V8, P423, DOI 10.1111/j.1582-4934.2004.tb00467.x; Shaw E, 2002, PROTEINS, V47, P163, DOI 10.1002/prot.10083; Shimono A, 1999, MECH DEVELOP, V83, P39, DOI 10.1016/S0925-4773(99)00025-8; Stein S, 2004, J BIOL CHEM, V279, P48930, DOI 10.1074/jbc.M400386200; Sugiki T, 2004, BIOL PHARM BULL, V27, P628, DOI 10.1248/bpb.27.628; Takahashi Masayo, 2004, Methods Mol Biol, V246, P439; TANG SB, 1995, J VIROL, V69, P5659, DOI 10.1128/JVI.69.9.5659-5665.1995; Taylor CM, 1997, PLACENTA, V18, P451, DOI 10.1016/S0143-4004(97)80047-1; Totsugawa T, 2003, ASAIO J, V49, P635, DOI 10.1097/01.MAT.0000093747.89681.4C; Ulrix W, 1999, FEBS LETT, V455, P23, DOI 10.1016/S0014-5793(99)00845-5; vanBelzen N, 1997, LAB INVEST, V77, P85; Vidricaire G, 2003, J BIOL CHEM, V278, P15832, DOI 10.1074/jbc.M210470200; WHEELER T, 1995, PLACENTA, V16, P289, DOI 10.1016/0143-4004(95)90115-9; Xu B, 1999, BIOL REPROD, V61, P681, DOI 10.1095/biolreprod61.3.681; Zhang G, 2003, J NEUROSCI RES, V72, P33, DOI 10.1002/jnr.10559; Zhou DJ, 1998, CANCER RES, V58, P2182; Zhou RH, 2001, GENOMICS, V73, P86, DOI 10.1006/geno.2000.6496; Zou H, 2003, J BIOL CHEM, V278, P8091, DOI 10.1074/jbc.M204783200	83	113	119	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 3	2006	281	5					2764	2772		10.1074/jbc.M507330200	http://dx.doi.org/10.1074/jbc.M507330200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	006XT	16314423	hybrid			2022-12-25	WOS:000234931800043
J	Di Sano, F; Ferraro, E; Tufi, R; Achsel, T; Piacentini, M; Cecconi, F				Di Sano, F; Ferraro, E; Tufi, R; Achsel, T; Piacentini, M; Cecconi, F			Endoplasmic reticulum stress induces apoptosis by an apoptosome-dependent but caspase 12-independent mechanism	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-DEATH PROGRAM; UNFOLDED PROTEIN RESPONSE; ER STRESS; MITOCHONDRIAL RELEASE; ACTIVATION; APAF1; PATHWAYS; CED-4	The endoplasmic reticulum (ER) is the cellular site of polypeptide folding and modification. When these processes are hampered, an unfolded protein response (UPR) is activated. If the damage is too broad, the mammalian UPR launches the apoptotic program. As a consequence, mobilization of ER calcium stores sensitizes mitochondria to direct proapoptotic stimuli. We make use of a mouse Apaf1-deficient cell system of proneural origin to understand the roles played in this context by the apoptosome, the most studied apoptotic machinery along the mitochondrial pathway of death. We show here that in the absence of the apoptosome ER stress induces cytochrome c release from the mitochondria but that apoptosis cannot occur. Under these circumstances, Grp78/BiP and GADD153/CHOP, both hallmarks of UPR, are canonically up-regulated, and calcium is properly released from ER stores. We also demonstrate that caspase 12, a protease until now believed to play a central role in the initiation of ER stress-induced cell death in the mouse system, is dispensable for the mitochondrial pathway of death to take place.	Univ Roma Tor Vergata, Dulbecco Telethon Inst, Dept Biol, I-00133 Rome, Italy; Fdn Santa Lucia, IRCCS, I-00100 Rome, Italy; IRCCS L Spallanzani, Natl Inst Infect Dis, I-00100 Rome, Italy	Fondazione Telethon; Dulbecco Telethon Institute (DTI); University of Rome Tor Vergata; IRCCS Santa Lucia; IRCCS Lazzaro Spallanzani	Cecconi, F (corresponding author), Univ Roma Tor Vergata, Dulbecco Telethon Inst, Dept Biol, Via Ric Sci, I-00133 Rome, Italy.	fcecconi@dti.telethon.it	Ferraro, Elisabetta/AAS-4975-2020; Cecconi, Francesco/K-3969-2016; Piacentini, Mauro/I-2411-2016; ferraro, elisabetta/K-3904-2016	Cecconi, Francesco/0000-0002-5614-4359; Piacentini, Mauro/0000-0003-2919-1296; ferraro, elisabetta/0000-0002-9596-4624; Di Sano, Federica/0000-0002-5048-3966	Telethon [TCP99038] Funding Source: Medline	Telethon(Fondazione Telethon)		Arnoult D, 2003, EMBO J, V22, P4385, DOI 10.1093/emboj/cdg423; Arnoult D, 2003, CELL DEATH DIFFER, V10, P845, DOI 10.1038/sj.cdd.4401240; Berridge MJ, 2000, NAT REV MOL CELL BIO, V1, P11, DOI 10.1038/35036035; Berridge MJ, 2002, CELL CALCIUM, V32, P235, DOI 10.1016/S0143416002001823; Breckenridge DG, 2003, ONCOGENE, V22, P8608, DOI 10.1038/sj.onc.1207108; Cecconi F, 1998, CELL, V94, P727, DOI 10.1016/S0092-8674(00)81732-8; Cecconi F, 2001, CELL MOL LIFE SCI, V58, P1688, DOI 10.1007/PL00000806; Chen LZ, 2002, NEUROCHEM RES, V27, P891, DOI 10.1023/A:1020387414086; Cozzolino M, 2004, CELL DEATH DIFFER, V11, P1179, DOI 10.1038/sj.cdd.4401476; Fujita E, 2002, CELL DEATH DIFFER, V9, P1108, DOI 10.1038/sj.cdd.4401080; Lu T, 2002, BBA-MOL CELL RES, V1590, P16, DOI 10.1016/S0167-4889(02)00193-3; Morishima N, 2002, J BIOL CHEM, V277, P34287, DOI 10.1074/jbc.M204973200; Nakagawa T, 2000, NATURE, V403, P98, DOI 10.1038/47513; Nakamura K, 2000, J CELL BIOL, V150, P731, DOI 10.1083/jcb.150.4.731; Obeng EA, 2005, J BIOL CHEM, V280, P29578, DOI 10.1074/jbc.M502685200; Patil C, 2001, CURR OPIN CELL BIOL, V13, P349, DOI 10.1016/S0955-0674(00)00219-2; POZZAN T, 1994, PHYSIOL REV, V74, P595, DOI 10.1152/physrev.1994.74.3.595; Rao RV, 2004, CELL DEATH DIFFER, V11, P372, DOI 10.1038/sj.cdd.4401378; Rao RV, 2002, J BIOL CHEM, V277, P21836, DOI 10.1074/jbc.M202726200; Rao RV, 2001, J BIOL CHEM, V276, P33869, DOI 10.1074/jbc.M102225200; Saleh M, 2004, NATURE, V429, P75, DOI 10.1038/nature02451; Salvesen GS, 2002, DEV CELL, V2, P256, DOI 10.1016/S1534-5807(02)00137-5; Schroder M, 2005, MUTAT RES-FUND MOL M, V569, P29, DOI 10.1016/j.mrfmmm.2004.06.056; Stennicke HR, 1998, BBA-PROTEIN STRUCT M, V1387, P17, DOI 10.1016/S0167-4838(98)00133-2; Wang XZ, 1998, EMBO J, V17, P5708, DOI 10.1093/emboj/17.19.5708; Yoneda T, 2001, J BIOL CHEM, V276, P13935, DOI 10.1074/jbc.M010677200; Yoshida H, 1998, CELL, V94, P739, DOI 10.1016/S0092-8674(00)81733-X; Zou H, 1997, CELL, V90, P405, DOI 10.1016/S0092-8674(00)80501-2	28	108	110	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 3	2006	281	5					2693	2700		10.1074/jbc.M509110200	http://dx.doi.org/10.1074/jbc.M509110200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	006XT	16317003	hybrid, Green Published			2022-12-25	WOS:000234931800035
J	Ogasawara, J; Sanpei, M; Rahman, N; Sakurai, T; Kizaki, T; Hitomi, Y; Ohno, H; Izawa, T				Ogasawara, Junetsu; Sanpei, Minori; Rahman, Nazibur; Sakurai, Tomonobu; Kizaki, Takako; Hitomi, Yoshiaki; Ohno, Hideki; Izawa, Tetsuya			beta-Adrenergic receptor trafficking by exercise in rat adipocytes: roles of G-protein-coupled receptor kinase-2, beta-arrestin-2, and the ubiquitin-proteasome pathway	FASEB JOURNAL			English	Article									[Ogasawara, Junetsu; Sanpei, Minori; Rahman, Nazibur; Sakurai, Tomonobu; Izawa, Tetsuya] Tokyo Metropolitan Univ, Grad Sch Sci, Dept Kinesiol, Tokyo 1920397, Japan; [Kizaki, Takako; Hitomi, Yoshiaki; Ohno, Hideki] Kyorin Univ, Sch Med, Dept Mol Predict Med & Sport Sci, Tokyo, Japan	Tokyo Metropolitan University; Kyorin University	Izawa, T (corresponding author), Tokyo Metropolitan Univ, Grad Sch Sci, Dept Kinesiol, 1-1 Minami Ohsawa, Tokyo 1920397, Japan.	izawa@comp.metro-u.ac.jp		Izawa, Tetsuya/0000-0001-5197-9085					0	10	10	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	FEB	2006	20	2					350	352		10.1096/fj.05-4688fje	http://dx.doi.org/10.1096/fj.05-4688fje			3	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	V17CJ	16368719				2022-12-25	WOS:000207915000018
J	Sonawane, ND; Hu, J; Muanprasat, C; Verkman, AS				Sonawane, ND; Hu, J; Muanprasat, C; Verkman, AS			Luminally active, nonabsorbable CFTR inhibitors as potential therapy to reduce intestinal fluid loss in cholera	FASEB JOURNAL			English	Article						diarrhea; cystic fibrosis; chloride channel; drug discovery	ORAL REHYDRATION SOLUTION; BLIND CLINICAL-TRIAL; CHLORIDE SECRETION; DIARRHEAL DISEASE; CELL-LINE; EFFICACY; TOXIN; MECHANISM; CHANNEL; PORE	Enterotoxin-mediated secretory diarrheas such as cholera involve chloride secretion by enterocytes into the intestinal lumen by the cystic fibrosis transmembrane conductance regulator (CFTR) chloride channel. We previously identified glycine hydrazide CFTR blockers that by electrophysiological studies appeared to block the CFTR anion pore at its lumen-facing surface. Here, we synthesize highly water-soluble, nonabsorbable malondihydrazides by coupling 2,4-disulfobenzaldehyde, 4-sulfophenylisothiocyante, and polyethylene glycol (PEG) moieties to 2-naphthalenylamino-[(3,5- dibromo-2,4-dihydroxyphenyl) methylene] propanedioic acid dihydrazide, and aminoacethydrazides by coupling PEG to [(N-2-naphthalenyl)-2-(2hydroxyethyl)]-glycine- 2-[(3,5-dibromo-2,4-dihydroxyphenyl) methylene] hydrazide. Compounds rapidly, fully and reversibly blocked CFTR-mediated chloride current with K-i of 2-8 mu M when added to the apical surface of epithelial cell monolayers. Compounds did not pass across Caco-2 monolayers, and were absorbed by < 2%/hr in mouse intestine. Luminally added compounds blocked by > 90% cholera toxin-induced fluid secretion in mouse intestinal loops, without inhibiting intestinal fluid absorption. These orally administered, nonabsorbable, nontoxic CFTR inhibitors may reduce intestinal fluid losses in cholera.	Univ Calif San Francisco, Dept Med, Cardiovasc Res Inst, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Physiol, Cardiovasc Res Inst, San Francisco, CA 94143 USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco	Verkman, AS (corresponding author), Univ Calif San Francisco, Dept Med, Cardiovasc Res Inst, 1246 Hlth Sci E Tower, San Francisco, CA 94143 USA.	verkman@itsa.ucsf.edu			NEI NIH HHS [EY-13574] Funding Source: Medline; NHLBI NIH HHS [HL-73854] Funding Source: Medline; NIAID NIH HHS [AI-062530] Funding Source: Medline; NIBIB NIH HHS [EB-00415] Funding Source: Medline; NIDDK NIH HHS [DK-43840, DK35124, DK-72517] Funding Source: Medline; NATIONAL EYE INSTITUTE [R01EY013574] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERING [R37EB000415, R01EB000415] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK043840, R37DK035124, P30DK072517, R01DK035124] Funding Source: NIH RePORTER	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIBIB NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Biomedical Imaging & Bioengineering (NIBIB)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Biomedical Imaging & Bioengineering (NIBIB)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Alam NH, 2003, GUT, V52, P1419, DOI 10.1136/gut.52.10.1419; Alam NH, 2001, PEDIATRICS, V107, P613, DOI 10.1542/peds.107.4.613; Barrett KE, 2000, ANNU REV PHYSIOL, V62, P535, DOI 10.1146/annurev.physiol.62.1.535; BERN C, 1992, B WORLD HEALTH ORGAN, V70, P705; Boedeker EC, 2005, CURR OPIN GASTROEN, V21, P15; CHAO AC, 1994, EMBO J, V13, P1065, DOI 10.1002/j.1460-2075.1994.tb06355.x; Currid A, 2004, J PHYSIOL-LONDON, V555, P241, DOI 10.1113/jphysiol.2003.059295; Dawson David C., 1999, Physiological Reviews, V79, pS47; GABRIEL SE, 1994, SCIENCE, V266, P107, DOI 10.1126/science.7524148; Guerrant RL, 2003, CLIN INFECT DIS, V37, P398, DOI 10.1086/376619; Guiraldes E, 1995, J DIARRHOEAL DIS RES, V13, P207; Khan WA, 2002, LANCET, V360, P1722, DOI 10.1016/S0140-6736(02)11680-1; Kosek M, 2003, B WORLD HEALTH ORGAN, V81, P197; Kunzelmann K, 1999, Rev Physiol Biochem Pharmacol, V137, P1; Kunzelmann K, 2002, PHYSIOL REV, V82, P245, DOI 10.1152/physrev.00026.2001; Ma TH, 2002, J CLIN INVEST, V110, P1651, DOI 10.1172/JCI200216112; McCarty NA, 2000, J EXP BIOL, V203, P1947; Muanprasat C, 2004, J GEN PHYSIOL, V124, P125, DOI 10.1085/jgp.200409059; Pickens JC, 2004, CHEM BIOL, V11, P1205, DOI 10.1016/j.chembiol.2004.06.008; Santosham M, 1996, J PEDIATR-US, V128, P45, DOI 10.1016/S0022-3476(96)70426-2; Sears CL, 1996, MICROBIOL REV, V60, P167, DOI 10.1128/MMBR.60.1.167-215.1996; Sheppard DN, 1997, J PHYSIOL-LONDON, V503, P333, DOI 10.1111/j.1469-7793.1997.333bh.x; Sonawane ND, 2005, J PHARM SCI-US, V94, P134, DOI 10.1002/jps.20228; Svennerholm AM, 2004, BEST PRACT RES CL GA, V18, P421, DOI 10.1016/j.bpg.2003.11.004; Taddei A, 2004, FEBS LETT, V558, P52, DOI 10.1016/S0014-5793(04)00011-0; Thiagarajah JR, 2005, TRENDS PHARMACOL SCI, V26, P172, DOI 10.1016/j.tips.2005.02.003; Thiagarajah JR, 2004, GASTROENTEROLOGY, V126, P511, DOI 10.1053/j.gastro.2003.11.005; THIAGARAJAH JR, 2002, J PHYSL, V536, P541; Zhou Z, 2002, J GEN PHYSIOL, V120, P647, DOI 10.1085/jgp.20028685	29	45	56	0	4	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	NOV	2005	19	13					130	+		10.1096/fj.05-4818fje	http://dx.doi.org/10.1096/fj.05-4818fje			18	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	994TC	16317066				2022-12-25	WOS:000234053100004
J	Ito, S; Ito, Y; Senga, T; Hattori, S; Matsuo, S; Hamaguchi, M				Ito, S; Ito, Y; Senga, T; Hattori, S; Matsuo, S; Hamaguchi, M			v-Src requires Ras signaling for the suppression of gap junctional intercellular communication	ONCOGENE			English	Article						v-Src; Ras; gap junction; cell-cell communication; Connexin43	TYROSINE PHOSPHORYLATION; PROTEIN; CONNEXIN-43; INHIBITION; TRANSFORMATION; PERMEABILITY; MUTANT; STAT3	Cell transformation by v-Src causes suppression of gap junctional intercellular communication (GJIC). Although tyrosine phosphorylation of connexin43 (Cx43), a gap junctional component, appears to be necessary for the suppression, involvement of other signaling remains unclear. We investigated the role of Ras signaling in the suppression of GJIC by v-Src. Conditional expression of either S17N Ras or mtGap1m dramatically recovered GJIC in v-Src-transformed cells. Although expression of S17N Ras or mtGap1m substantially decreased the levels of active Ras, tyrosine phosphorylation of cellular proteins including Cx43 remained unchanged. Similarly, treatment of v-Src-transfomed cells with a Ras farnesyltransferase inhibitor, manumycin A, restored GJIC, whereas tyrosine phosphorylation of Cx43 remained unchanged. Thus, these results strongly suggest that, in addition to Cx43 phosphorylation, constitutive activation of Ras signaling is required for the suppression of GJIC by v-Src.	Nagoya Univ, Grad Sch Med, Div Canc Biol, Showa Ku, Nagoya, Aichi 4668550, Japan; Nagoya Univ, Grad Sch Med, Dept Internal Med, Div Clin Immunol,Showa Ku, Nagoya, Aichi 4668550, Japan; Univ Tokyo, Inst Med Sci, Div Cellular Genome Prote, Minato Ku, Tokyo, Japan	Nagoya University; Nagoya University; University of Tokyo	Hamaguchi, M (corresponding author), Nagoya Univ, Grad Sch Med, Div Canc Biol, Showa Ku, 65 Tsurumai Cho, Nagoya, Aichi 4668550, Japan.	mhamagu@med.nagoya-u.ac.jp						ATKINSON M, 1984, J CELL BIOL, V99, pA401; ATKINSON MM, 1981, J CELL BIOL, V91, P573, DOI 10.1083/jcb.91.2.573; Bromberg JF, 1998, MOL CELL BIOL, V18, P2553, DOI 10.1128/MCB.18.5.2553; Cameron SJ, 2003, J BIOL CHEM, V278, P18682, DOI 10.1074/jbc.M213283200; Campbell SL, 1998, ONCOGENE, V17, P1395, DOI 10.1038/sj.onc.1202174; Cao XM, 1996, MOL CELL BIOL, V16, P1595; Cottrell GT, 2003, AM J PHYSIOL-CELL PH, V284, pC511, DOI 10.1152/ajpcell.00214.2002; DECLUE JE, 1991, MOL CELL BIOL, V11, P2819, DOI 10.1128/MCB.11.5.2819; EGAN SE, 1993, NATURE, V365, P781, DOI 10.1038/365781a0; Evans WH, 2002, MOL MEMBR BIOL, V19, P121, DOI 10.1080/09687680210139839; FEIG LA, 1988, MOL CELL BIOL, V8, P3235, DOI 10.1128/MCB.8.8.3235; Goodenough DA, 1996, ANNU REV BIOCHEM, V65, P475, DOI 10.1146/annurev.bi.65.070196.002355; HAMAGUCHI M, 1993, EMBO J, V12, P307, DOI 10.1002/j.1460-2075.1993.tb05658.x; HARA M, 1993, P NATL ACAD SCI USA, V90, P2281, DOI 10.1073/pnas.90.6.2281; Lampe PD, 2004, INT J BIOCHEM CELL B, V36, P1171, DOI 10.1016/S1357-2725(03)00264-4; Lin R, 2001, J CELL BIOL, V154, P815, DOI 10.1083/jcb.200102027; LOEWENSTEIN WR, 1981, PHYSIOL REV, V61, P829, DOI 10.1152/physrev.1981.61.4.829; MAEKAWA M, 1994, MOL CELL BIOL, V14, P6879, DOI 10.1128/MCB.14.10.6879; NORI M, 1991, MOL CELL BIOL, V11, P2812, DOI 10.1128/MCB.11.5.2812; Saez JC, 2003, PHYSIOL REV, V83, P1359, DOI 10.1152/physrev.00007.2003; SMITH MR, 1986, NATURE, V320, P540, DOI 10.1038/320540a0; SWENSON KI, 1990, CELL REGUL, V1, P989, DOI 10.1091/mbc.1.13.989; Turkson J, 1999, MOL CELL BIOL, V19, P7519; VANHAMME L, 1989, EXP CELL RES, V180, P297, DOI 10.1016/0014-4827(89)90234-6; Warn-Cramer BJ, 2004, BBA-BIOMEMBRANES, V1662, P81, DOI 10.1016/j.bbamem.2003.10.018; WarnCramer BJ, 1996, J BIOL CHEM, V271, P3779; YU CL, 1995, SCIENCE, V269, P81, DOI 10.1126/science.7541555; Zhou L, 1999, J CELL BIOL, V144, P1033, DOI 10.1083/jcb.144.5.1033	28	15	15	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 13	2006	25	16					2420	2424		10.1038/sj.onc.1209263	http://dx.doi.org/10.1038/sj.onc.1209263			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	032HC	16301992				2022-12-25	WOS:000236764300013
J	Bian, D; Mahanivong, C; Yu, J; Frisch, SM; Pan, ZK; Ye, RD; Huang, S				Bian, D; Mahanivong, C; Yu, J; Frisch, SM; Pan, ZK; Ye, RD; Huang, S			The G(12/13)-RhoA signaling pathway contributes to efficient lysophosphatidic acid-stimulated cell migration	ONCOGENE			English	Article						LPA; FAK; cell migration	OVARIAN-CANCER CELLS; FOCAL ADHESION KINASE; GROWTH-FACTOR; TYROSINE PHOSPHORYLATION; PHOSPHOLIPASE-D; RAC ACTIVATION; RHO-GTPASES; EXPRESSION; LPA; RECEPTORS	The membrane redistribution and phosphorylation of focal adhesion kinase (FAK) have been reported to be important for cell migration. We previously showed that Lysophosphatidic acid (LPA) induced FAK membrane redistribution and autophosphorylation in ovarian cancer SK-OV3 cells and the signaling pathway consisting of G(i)-Ras-MEKK1 mediated LPA-induced FAK membrane redistribution but not FAK autophosphorylation. We also showed that the disruption of the Gi-Ras-MEKK1 pathway led to a significant reduction in LPA-stimulated cell migration. These findings raised the question of whether LPA-induced FAK autophosphorylation was required for LPA-stimulated cell migration and what signaling mechanism was involved in LPA-induced FAK autophosphorylation. In this study, we expressed the membrane anchored wild-type FAK (CD2-FAK) in SK-OV3 cells and found that the expression of CD2-FAK greatly rescued LPA-stimulated cell migration in G(i) or Ras-inhibited cells. However, Gi inhibitor pertussis toxin or dominant-negative H-Ras still significantly inhibited LPA-stimulated cell migration in cells expressing the membrane anchored FAK containing a mutation in the autophosphorylation site [CD2-FAK(Y397A)]. These results suggest that FAK autophosphorylation plays a role in LPA-stimulated cell migration. With the aid of p115Rho-GEF-RGS, G(12) and G(13) minigenes to inhibit G12/13, we found that the G12/13 pathway was required for LPA-induced FAK autophosphorylation and efficient cell migration. Moreover, LPA activated RhoA and Rho kinase (ROCK) in a G(12/13)-dependent manner and their activities were required for LPA-induced FAK autophosphorylation. However, Rho or ROCK inhibitors displayed no effect on LPA-induced FAK membrane redistribution although they abolished LPA-induced cytoskeleton reorganization. Our studies show that the G(12/13)-RhoA-ROCK signaling pathway mediates LPA-induced FAK autophosphorylation and contributes to LPA-stimulated cell migration.	Scripps Res Inst, Dept Immunol, La Jolla, CA 92037 USA; W Virginia Univ, Sch Med, Morgantown, WV USA; Med Coll Ohio, Dept Med Microbiol & Immunol, Toledo, OH USA; Univ Illinois, Coll Med, Dept Pharmacol, Chicago, IL USA	Scripps Research Institute; West Virginia University; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital	Huang, S (corresponding author), Scripps Res Inst, Dept Immunol, IMM19,10550 N Torrey Pines Rd, La Jolla, CA 92037 USA.	shuang@scripps.edu	Ye, Richard/O-5223-2016; Ye, Richard/ABF-2413-2020	Ye, Richard/0000-0002-2164-5620; Ye, Richard/0000-0002-2164-5620	NCI NIH HHS [R01 CA93926] Funding Source: Medline; NIAID NIH HHS [R01 AI043524, R01 AI043524-11] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA093926] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI043524] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Bian DF, 2004, CANCER RES, V64, P4209, DOI 10.1158/0008-5472.CAN-04-0060; Bourguignon LYW, 2003, J BIOL CHEM, V278, P29420, DOI 10.1074/jbc.M301885200; BUHL AM, 1995, J BIOL CHEM, V270, P24631, DOI 10.1074/jbc.270.42.24631; Cary LA, 1998, J CELL BIOL, V140, P211, DOI 10.1083/jcb.140.1.211; CHAN PY, 1994, J BIOL CHEM, V269, P20567; Daaka Y, 2002, BBA-MOL CELL BIOL L, V1582, P265, DOI 10.1016/S1388-1981(02)00180-4; Dutt P, 2002, FEBS LETT, V531, P565, DOI 10.1016/S0014-5793(02)03625-6; Eder AM, 2000, CLIN CANCER RES, V6, P2482; Etienne-Manneville S, 2002, NATURE, V420, P629, DOI 10.1038/nature01148; Fang XJ, 2004, J BIOL CHEM, V279, P9653, DOI 10.1074/jbc.M306662200; Fang XJ, 2000, ANN NY ACAD SCI, V905, P188; Fishman DA, 2001, CANCER RES, V61, P3194; Frankel A, 1996, CLIN CANCER RES, V2, P1307; Frisch SM, 1996, J CELL BIOL, V134, P793, DOI 10.1083/jcb.134.3.793; Fujita T, 2003, CANCER LETT, V192, P161, DOI 10.1016/S0304-3835(02)00713-9; Gschwind A, 2002, CANCER RES, V62, P6329; Han DC, 1999, J BIOL CHEM, V274, P24425, DOI 10.1074/jbc.274.34.24425; Han QW, 2002, J BIOL CHEM, V277, P48379, DOI 10.1074/jbc.M209542200; Holinstat M, 2003, J BIOL CHEM, V278, P28793, DOI 10.1074/jbc.M303900200; Hu YL, 2001, J NATL CANCER I, V93, P762, DOI 10.1093/jnci/93.10.762; Hunger-Glaser I, 2003, J BIOL CHEM, V278, P22631, DOI 10.1074/jbc.M210876200; Ilic Dusko, 1995, Nature (London), V377, P539, DOI 10.1038/377539a0; Ishibe S, 2004, MOL CELL, V16, P257, DOI 10.1016/j.molcel.2004.10.006; Khyrul WAKM, 2004, J BIOL CHEM, V279, P54131, DOI 10.1074/jbc.M410051200; Kitayama J, 2004, BREAST CANCER RES, V6, pR640, DOI 10.1186/bcr935; KOZASA T, 2004, G PROTEIN SIGNALING, P153; Kranenburg O, 1999, MOL BIOL CELL, V10, P1851, DOI 10.1091/mbc.10.6.1851; Li HB, 2005, J BIOL CHEM, V280, P10564, DOI 10.1074/jbc.M412152200; Linseman DA, 2000, J NEUROCHEM, V74, P2010, DOI 10.1046/j.1471-4159.2000.0742010.x; Luquain C, 2003, J LIPID RES, V44, P1963, DOI 10.1194/jlr.M300188-JLR200; MARTELLI AM, 1992, NATURE, V358, P242, DOI 10.1038/358242a0; Moolenaar WH, 1999, EXP CELL RES, V253, P230, DOI 10.1006/excr.1999.4702; Moolenaar WH, 2004, BIOESSAYS, V26, P870, DOI 10.1002/bies.20081; Mukai M, 1999, INT J CANCER, V81, P918, DOI 10.1002/(SICI)1097-0215(19990611)81:6<918::AID-IJC13>3.0.CO;2-E; Needham LK, 1998, J BIOL CHEM, V273, P14626, DOI 10.1074/jbc.273.23.14626; Panetti TS, 2000, ARTERIOSCL THROM VAS, V20, P1013, DOI 10.1161/01.ATV.20.4.1013; Pustilnik TB, 1999, CLIN CANCER RES, V5, P3704; Raftopoulou M, 2004, DEV BIOL, V265, P23, DOI 10.1016/j.ydbio.2003.06.003; Riento K, 2003, NAT REV MOL CELL BIO, V4, P446, DOI 10.1038/nrm1128; Sah VP, 2000, ANNU REV PHARMACOL, V40, P459, DOI 10.1146/annurev.pharmtox.40.1.459; Sawada K, 2002, GYNECOL ONCOL, V87, P252, DOI 10.1006/gyno.2002.6831; Sawada K, 2002, CANCER RES, V62, P6015; SCHALLER MD, 2003, BIOCHIM BIOPHYS ACTA, V1540, P1; Schwartz BM, 2001, GYNECOL ONCOL, V81, P291, DOI 10.1006/gyno.2001.6124; Sengupta S, 2004, SEMIN CELL DEV BIOL, V15, P503, DOI 10.1016/j.semcdb.2004.05.003; Shen ZZ, 1998, GYNECOL ONCOL, V71, P364, DOI 10.1006/gyno.1998.5193; Shida D, 2004, LAB INVEST, V84, P1352, DOI 10.1038/labinvest.3700146; Sieg DJ, 2000, NAT CELL BIOL, V2, P249, DOI 10.1038/35010517; Stahle M, 2003, J CELL SCI, V116, P3835, DOI 10.1242/jcs.00679; Sundberg LJ, 2003, J BIOL CHEM, V278, P29783, DOI 10.1074/jbc.M303771200; Symowicz J, 2005, CANCER RES, V65, P2234, DOI 10.1158/0008.5472.CAN-04-2781; Tanyi JL, 2003, CANCER RES, V63, P1073; van Leeuwen FN, 2003, BIOCHEM SOC T, V31, P1209; van Leeuwen FN, 2003, J BIOL CHEM, V278, P400, DOI 10.1074/jbc.M210151200; Wang F, 1997, BIOCHEM J, V324, P481, DOI 10.1042/bj3240481; Webb DJ, 2004, NAT CELL BIOL, V6, P154, DOI 10.1038/ncb1094; Xie YH, 2002, BBA-MOL CELL BIOL L, V1582, P270, DOI 10.1016/S1388-1981(02)00181-6; XU Y, 1995, BIOCHEM J, V309, P933, DOI 10.1042/bj3090933; Xu Y, 1995, CLIN CANCER RES, V1, P1223; Yuan JZ, 2003, J BIOL CHEM, V278, P4882, DOI 10.1074/jbc.M211175200; Zeng HY, 2002, J BIOL CHEM, V277, P46791, DOI 10.1074/jbc.M206133200	61	91	94	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR	2006	25	15					2234	2244		10.1038/sj.onc.1209261	http://dx.doi.org/10.1038/sj.onc.1209261			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	029RD	16301993				2022-12-25	WOS:000236581200010
J	Matei, D; Emerson, RE; Lai, YC; Baldridge, LA; Rao, J; Yiannoutsos, C; Donner, DB				Matei, D; Emerson, RE; Lai, YC; Baldridge, LA; Rao, J; Yiannoutsos, C; Donner, DB			Autocrine activation of PDGFR alpha promotes the progression of ovarian cancer	ONCOGENE			English	Article						ovarian epithelial cancer; platelet-derived growth factor receptor; autocrine	GROWTH-FACTOR-RECEPTOR; PROGNOSTIC-SIGNIFICANCE; GENE-EXPRESSION; PHOSPHATIDYLINOSITOL-3 KINASE; C-KIT; BETA; CARCINOMA; CELLS; MUTATIONS; RECURRENT	Platelet-derived growth factor receptor ( PDGFR) a expression was found in ovarian cancer cells and tumors by microarray hybridization. This led us to test whether ovarian cancers also produce ligands for this receptor, as this would demonstrate that such malignancies support their own growth and spread through autocrine activation. We assayed the expression of ligands for the PDGFR in ovarian tumors, cell lines and peritoneal fluid using RT-PCR, immunohistochemistry (IHC) and ELISA. We detected strong mRNA expression for the PDGFR alpha ligands in most ovarian tumors. Receptor and ligand expressions (PDGFR alpha and PDGF AB) were also detected by IHC in, respectively, 34 and 32 of 47 ovarian tumors. The stainings for PDGFR alpha and PDGF AB were strongly correlated (P-value = 0.014), suggesting that an autocrine loop is functional in ovarian cancer. PDGF AA and BB were quantified in peritoneal fluid by ELISA. Both ligands are secreted at higher levels in ovarian cancer ascites specimens (n = 54) than in fluid from nonmalignant disorders (n = 8). PDGF was detected in media conditioned by ovarian cancer cells. Such conditioned media induced activation of the PDGFR, Akt and MAPK and stimulated cell proliferation. A neutralizing PDGF antibody blocked these effects. Specific PDGFR inhibition by siRNA or a neutralizing antibody to the receptor inhibited PDGF-stimulated receptor activation and cell proliferation, suggesting that receptor targeting has a role in ovarian cancer treatment.	Indiana Univ, Sch Med, Div Hematol Oncol, Dept Med, Indianapolis, IN 46202 USA; Indiana Univ, Sch Med, Dept Obstet & Gynecol, Indianapolis, IN 46202 USA; Indiana Univ, Sch Med, Ctr Canc, Indianapolis, IN USA; Indiana Univ, Sch Med, Walther Oncol Ctr, Indianapolis, IN USA; Indiana Univ, Sch Med, Dept Pathol & Lab Med, Indianapolis, IN USA; Univ Calif Los Angeles, David Geffen Sch Med, Jonsson Comprehens Canc Ctr, Los Angeles, CA USA; Univ Calif Los Angeles, David Geffen Sch Med, Dept Pathol, Los Angeles, CA USA; Indiana Univ, Sch Med, Dept Biostat, Indianapolis, IN USA; Indiana Univ, Sch Med, Dept Microbiol & Immunol, Indianapolis, IN 46202 USA	Indiana University System; Indiana University-Purdue University Indianapolis; Indiana University System; Indiana University-Purdue University Indianapolis; Indiana University System; Indiana University-Purdue University Indianapolis; Indiana University System; Indiana University-Purdue University Indianapolis; Walther Cancer Institute; Indiana University System; Indiana University-Purdue University Indianapolis; UCLA Jonsson Comprehensive Cancer Center; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; Indiana University System; Indiana University-Purdue University Indianapolis; Indiana University System; Indiana University-Purdue University Indianapolis	Matei, D (corresponding author), Indiana Univ, Sch Med, Div Hematol Oncol, Dept Med, RT-457,535 Barnhill Dr, Indianapolis, IN 46202 USA.	dmatei@iupui.edu		Matei, Daniela/0000-0003-2169-5035				Aase K, 2002, MECH DEVELOP, V110, P187, DOI 10.1016/S0925-4773(01)00560-3; Bookman MA, 2003, J CLIN ONCOL, V21, P283, DOI 10.1200/JCO.2003.10.104; Dong JY, 2004, EMBO J, V23, P2800, DOI 10.1038/sj.emboj.7600289; ERIKSSON A, 1992, EMBO J, V11, P543, DOI 10.1002/j.1460-2075.1992.tb05085.x; FRANKLIN WA, 1990, CANCER RES, V50, P6344; Gillan L, 2002, CANCER RES, V62, P5358; Gordon AN, 2001, J CLIN ONCOL, V19, P3312, DOI 10.1200/JCO.2001.19.14.3312; GREENHALGH DG, 1990, AM J PATHOL, V136, P1235; Greenlee RT, 2000, CA-CANCER J CLIN, V50, P7, DOI 10.3322/canjclin.50.1.7; HART CE, 1988, SCIENCE, V240, P1529, DOI 10.1126/science.2836952; Heinrich MC, 2003, SCIENCE, V299, P708, DOI 10.1126/science.1079666; Heldin CH, 1998, BIOCHIM BIOPHYS ACTA, V1378, P79; HENRIKSEN R, 1993, CANCER RES, V53, P4550; Hu YH, 1998, FASEB J, V12, P1135, DOI 10.1096/fasebj.12.12.1135; HUANG JS, 1984, CELL, V39, P79, DOI 10.1016/0092-8674(84)90193-4; Ikeda K, 2003, INT J GYNECOL CANCER, V13, P776, DOI 10.1111/j.1525-1438.2003.13381.x; Ismail RS, 2000, CANCER RES, V60, P6744; JENSEN RA, 1992, BIOCHEMISTRY-US, V31, P10887, DOI 10.1021/bi00159a032; KARLAN BY, 1995, GYNECOL ONCOL, V59, P67, DOI 10.1006/gyno.1995.1269; LaRochelle WJ, 2001, NAT CELL BIOL, V3, P517, DOI 10.1038/35074593; Lassus H, 2004, BRIT J CANCER, V91, P2048, DOI 10.1038/sj.bjc.6602252; Li XR, 2000, NAT CELL BIOL, V2, P302, DOI 10.1038/35010579; Loizos N, 2005, MOL CANCER THER, V4, P369; Lokker NA, 2002, CANCER RES, V62, P3729; Matei D, 2004, CLIN CANCER RES, V10, P681, DOI 10.1158/1078-0432.CCR-0754-03; Matei D, 2002, ONCOGENE, V21, P6289, DOI 10.1038/sj.onc.1205785; MATSUI T, 1989, SCIENCE, V243, P800, DOI 10.1126/science.2536956; OZOLS RF, 1997, CANC PRINCIPLES PRAC, V1, P1502; Pietras K, 2002, CANCER RES, V62, P5476; Schmandt RE, 2003, CANCER-AM CANCER SOC, V98, P758, DOI 10.1002/cncr.11561; Sihto H, 2005, J CLIN ONCOL, V23, P49, DOI 10.1200/JCO.2005.02.093; Spentzos D, 2004, J CLIN ONCOL, V22, P4700, DOI 10.1200/JCO.2004.04.070; UREN A, 1994, BIOCHEM BIOPH RES CO, V204, P628, DOI 10.1006/bbrc.1994.2505; VALIUS M, 1993, CELL, V73, P321, DOI 10.1016/0092-8674(93)90232-F; VERSNEL MA, 1994, CANCER GENET CYTOGEN, V73, P60, DOI 10.1016/0165-4608(94)90183-X; Wilczynski SP, 2005, HUM PATHOL, V36, P242, DOI 10.1016/j.humpath.2004.11.009; YAO RJ, 1995, SCIENCE, V267, P2003, DOI 10.1126/science.7701324; YU JC, 1994, J BIOL CHEM, V269, P10668; Yu JH, 2001, BIOCHEM BIOPH RES CO, V282, P697, DOI 10.1006/bbrc.2001.4622; Zwerner JP, 2001, ONCOGENE, V20, P626, DOI 10.1038/sj.onc.1204133	40	95	102	0	5	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR	2006	25	14					2060	2069		10.1038/sj.onc.1209232	http://dx.doi.org/10.1038/sj.onc.1209232			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	026RL	16331269				2022-12-25	WOS:000236359700009
J	Raynal, N; Hamaia, SW; Siljander, PRM; Maddox, B; Peachey, AR; Fernandez, R; Foley, LJ; Slatter, DA; Jarvis, GE; Farndale, RW				Raynal, N; Hamaia, SW; Siljander, PRM; Maddox, B; Peachey, AR; Fernandez, R; Foley, LJ; Slatter, DA; Jarvis, GE; Farndale, RW			Use of synthetic peptides to locate novel integrin alpha(2)beta(1)-binding motifs in human collagen III	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRIPLE-HELICAL PEPTIDES; ALPHA-2 VWFA DOMAIN; PLATELET-ADHESION; GLYCOPROTEIN-VI; BINDING-SITE; I-DOMAIN; IDENTIFICATION; SEQUENCE; RECOGNITION; ACTIVATION	A set of 57 synthetic peptides encompassing the entire triple-helical domain of human collagen III was used to locate binding sites for the collagen-binding integrin alpha(2)beta(1). The capacity of the peptides to support Mg2+-dependent binding of several integrin preparations was examined. Wild-type integrins (recombinant alpha(2) I-domain, alpha(2)beta(1) purified from platelet membranes, and recombinant soluble alpha(2)beta(1) expressed as an alpha(2)-Fos/beta(1)-Jun heterodimer) bound well to only three peptides, two containing GXX'GER motifs (GROGER and GMOGER, where O is hydroxyproline) and one containing two adjacent GXX'GEN motifs (GLKGEN and GLOGEN). Two mutant alpha(2) I-domains were tested: the inactive T221A mutant, which recognized no peptides, and the constitutively active E318W mutant, which bound a larger subset of peptides. Adhesion of activated human platelets to GER-containing peptides was greater than that of resting platelets, and HT1080 cells bound well to more of the peptides compared with platelets. Binding of cells and recombinant proteins was abolished by anti-alpha(2) monoclonal antibody 6F1 and by chelation of Mg2+. We describe two novel high affinity integrin-binding motifs in human collagen III (GROGER and GLOGEN) and a third motif (GLKGEN) that displays intermediate activity. Each motif was verified using shorter synthetic peptides.	Univ Cambridge, Dept Biochem, Cambridge CB2 1QW, England	University of Cambridge	Farndale, RW (corresponding author), Univ Cambridge, Dept Biochem, Bldg O,Dowling Site, Cambridge CB2 1QW, England.	rwf10@cam.ac.uk	Slatter, David/AAW-6938-2021; Jarvis, Gavin/A-1903-2013; Slatter, David/AAV-5771-2020	Siljander, Pia/0000-0003-2326-5821; Jarvis, Gavin/0000-0003-4362-1133	Medical Research Council [G0400701, G0601378] Funding Source: Medline; MRC [G0400701] Funding Source: UKRI	Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))		Aquilina A, 2002, EUR J BIOCHEM, V269, P1136, DOI 10.1046/j.0014-2956.2001.02740.x; Bella J, 2000, STRUCTURE, V8, pR121, DOI 10.1016/S0969-2126(00)00153-2; Clemetson JM, 1999, J BIOL CHEM, V274, P29019, DOI 10.1074/jbc.274.41.29019; Clemetson KJ, 2001, THROMB HAEMOSTASIS, V86, P189; COLLER BS, 1989, BLOOD, V74, P182; Eble JA, 1998, BIOCHEMISTRY-US, V37, P10945, DOI 10.1021/bi980175+; Emsley J, 1997, J BIOL CHEM, V272, P28512, DOI 10.1074/jbc.272.45.28512; Emsley J, 2000, CELL, V101, P47, DOI 10.1016/S0092-8674(00)80622-4; Farndale RW, 2004, J THROMB HAEMOST, V2, P561, DOI 10.1111/j.1538-7836.2004.00665.x; Glattauer V, 1997, BIOCHEM J, V323, P45, DOI 10.1042/bj3230045; Humphries MJ, 2000, BIOCHEM SOC T, V28, P311, DOI 10.1042/0300-5127:0280311; Jin M, 2004, STRUCTURE, V12, P2137, DOI 10.1016/j.str.2004.10.005; Jung SM, 2000, J BIOL CHEM, V275, P8016, DOI 10.1074/jbc.275.11.8016; Kapyla J, 2004, J BIOL CHEM, V279, P51677, DOI 10.1074/jbc.M409412200; Kim JK, 2005, J BIOL CHEM, V280, P32512, DOI 10.1074/jbc.M502431200; Knight CG, 2000, J BIOL CHEM, V275, P35, DOI 10.1074/jbc.275.1.35; Knight CG, 1998, J BIOL CHEM, V273, P33287, DOI 10.1074/jbc.273.50.33287; Luque A, 1996, J BIOL CHEM, V271, P11067, DOI 10.1074/jbc.271.19.11067; MORTON LF, 1994, BIOCHEM J, V299, P791, DOI 10.1042/bj2990791; Onley DJ, 2000, J BIOL CHEM, V275, P24560, DOI 10.1074/jbc.M004111200; Ramshaw JAM, 1998, J STRUCT BIOL, V122, P86, DOI 10.1006/jsbi.1998.3977; SAELMAN EUM, 1994, BLOOD, V83, P1244; Shah NK, 1996, BIOCHEMISTRY-US, V35, P10262, DOI 10.1021/bi960046y; Siljander PRM, 2004, J BIOL CHEM, V279, P47763, DOI 10.1074/jbc.M404685200; Siljander PRM, 2004, BLOOD, V103, P1333, DOI 10.1182/blood-2003-03-00869; SILJANDER PRM, 2002, PLATELETS THROMBOTIC, P158; Smethurst PA, 2004, BLOOD, V103, P903, DOI 10.1182/blood-2003-01-0308; STAATZ WD, 1991, J BIOL CHEM, V266, P7363; TUCKWELL D, 1995, J CELL SCI, V108, P1629; Tuckwell DS, 2000, BIOCHEM J, V350, P485, DOI 10.1042/0264-6021:3500485; VANZANTEN GH, 1994, J CLIN INVEST, V93, P615, DOI 10.1172/JCI117014; Xu Y, 2000, J BIOL CHEM, V275, P38981, DOI 10.1074/jbc.M007668200; Zhang WM, 2003, J BIOL CHEM, V278, P7270, DOI 10.1074/jbc.M210313200	33	142	150	0	17	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 17	2006	281	7					3821	3831		10.1074/jbc.M509818200	http://dx.doi.org/10.1074/jbc.M509818200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	011NN	16326707	hybrid			2022-12-25	WOS:000235275300010
J	Li, LW; Sampat, K; Hu, N; Zakari, J; Yuspa, SH				Li, LW; Sampat, K; Hu, N; Zakari, J; Yuspa, SH			Protein kinase C negatively regulates Akt activity and modifies UVC-induced apoptosis in mouse keratinocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-FACTOR-I; INDUCED ACTIVATION; PHOSPHATASE 2A; HUMAN SKIN; B AKT; PHOSPHORYLATION; DIFFERENTIATION; INHIBITION; DELTA; EXPRESSION	Skin keratinocytes are subject to frequent chemical and physical injury and have developed elaborate cell survival mechanisms to compensate. Among these, the Akt/protein kinase B (PKB) pathway protects keratinocytes from the toxic effects of ultraviolet light (UV). In contrast, the protein kinase C (PKC) family is involved in several keratinocyte death pathways. During an examination of potential interactions among these two pathways, we found that the insulin-like growth factor (IGF-1) activates both the PKC and the Akt signaling pathways in cultured primary mouse keratinocytes as indicated by increased phospho-PKC and phospho-Ser-473-Akt. IGF-1 also selectively induced translocation of PKC delta and PKC delta from soluble to particulate fractions in mouse keratinocytes. Furthermore, the PKC-specific inhibitor, GF109203X, increased IGF-1-induced phospho-Ser-473-Akt and Akt kinase activity and enhanced IGF-1 protection from UVC-induced apoptosis. Selective activation of PKC by 12-O-tetradecanoylphorbol-13-acetate (TPA) reduced phospho-Ser-473-Akt, suggesting that activation of PKC inhibits Akt activity. TPA also attenuated IGF-1 and epidermal growth factor-induced phospho-Ser-473-Akt, reduced Akt kinase activity, and blocked IGF-1 protection from UVC-induced apoptosis. The inhibition of Akt activity by TPA was reduced by inhibitors of protein phosphatase 2A, and TPA stimulated the association of phosphatase 2A with Akt. Individual PKC isoforms were overexpressed in cultured keratinocytes by transduction with adenoviral vectors or inhibited with PKC-selective inhibitors. These studies indicated that PKC alpha and PKC epsilon were selectively potent at causing dephosphorylation of Akt and modifying cell survival, whereas PKC alpha enhanced phosphorylation of Akt on Ser-473. Our results suggested that activation of PKC delta and PKC epsilon provide a negative regulation for Akt phosphorylation and kinase activity in mouse keratinocytes and serve as modulators of cell survival pathways in response to external stimuli.	NCI, Lab Cellular Carcinogenesis & Tumor Promot, Canc Res Ctr, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Li, LW (corresponding author), NCI, Lab Cellular Carcinogenesis & Tumor Promot, Canc Res Ctr, NIH, Bldg 37,Rm 4600,37 Convent Dr, Bethesda, MD 20892 USA.	lilu@mail.nih.gov			NATIONAL CANCER INSTITUTE [ZIABC004504, Z01BC004504] Funding Source: NIH RePORTER	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Andjelkovic M, 1996, P NATL ACAD SCI USA, V93, P5699, DOI 10.1073/pnas.93.12.5699; Andjelkovic M, 1997, J BIOL CHEM, V272, P31515, DOI 10.1074/jbc.272.50.31515; Berwick DC, 2002, J BIOL CHEM, V277, P33895, DOI 10.1074/jbc.M204681200; BLUMBERG PM, 1980, CRC CR REV TOXICOL, V8, P153, DOI 10.3109/10408448009037493; BURGERING BMT, 1995, NATURE, V376, P599, DOI 10.1038/376599a0; Cardone MH, 1998, SCIENCE, V282, P1318, DOI 10.1126/science.282.5392.1318; Chen NY, 1999, J BIOL CHEM, V274, P15389, DOI 10.1074/jbc.274.22.15389; Cooper SJ, 2003, MOL CANCER RES, V1, P848; Datta SR, 1997, CELL, V91, P231, DOI 10.1016/S0092-8674(00)80405-5; Denning MF, 1998, J BIOL CHEM, V273, P29995, DOI 10.1074/jbc.273.45.29995; DENNING MF, 1993, J BIOL CHEM, V268, P26079; DENNING MF, 1995, CELL GROWTH DIFFER, V6, P149; Dent P, 2003, RADIAT RES, V159, P283, DOI 10.1667/0033-7587(2003)159[0283:SARIAO]2.0.CO;2; DiGiovanni J, 2000, CANCER RES, V60, P1561; DLUGOSZ AA, 1993, J CELL BIOL, V120, P217, DOI 10.1083/jcb.120.1.217; DLUGOSZ AA, 1994, CANCER RES, V54, P6413; Doornbos RP, 1999, J BIOL CHEM, V274, P8589, DOI 10.1074/jbc.274.13.8589; FARESE RV, 1989, BIOCHEM J, V261, P927, DOI 10.1042/bj2610927; FISHER GJ, 1993, J INVEST DERMATOL, V101, P553, DOI 10.1111/1523-1747.ep12365967; Fujita N, 2002, J BIOL CHEM, V277, P28706, DOI 10.1074/jbc.M203668200; Gliki G, 2002, CELL BIOL INT, V26, P751, DOI 10.1016/S1065-6995(02)90926-1; Graff JR, 2000, J BIOL CHEM, V275, P24500, DOI 10.1074/jbc.M003145200; GSCHWENDT M, 1994, BIOCHEM BIOPH RES CO, V199, P93, DOI 10.1006/bbrc.1994.1199; Gschwendt M, 1998, FEBS LETT, V421, P165, DOI 10.1016/S0014-5793(97)01530-5; Gschwendt M, 1996, FEBS LETT, V392, P77, DOI 10.1016/0014-5793(96)00785-5; Hill MM, 2002, PHARMACOL THERAPEUT, V93, P243, DOI 10.1016/S0163-7258(02)00193-6; Huang CS, 1997, J BIOL CHEM, V272, P4187, DOI 10.1074/jbc.272.7.4187; Huang CS, 2001, J BIOL CHEM, V276, P40234, DOI 10.1074/jbc.M103684200; Itoh N, 2002, CANCER, V94, P3127, DOI 10.1002/cncr.10591; Ivaska J, 2002, MOL CELL BIOL, V22, P1352, DOI 10.1128/MCB.22.5.1352-1359.2002; Jansen AP, 2001, INT J CANCER, V93, P635, DOI 10.1002/ijc.1395; Kampfer S, 1998, ADV ENZYME REGUL, V38, P35, DOI 10.1016/S0065-2571(97)00005-8; KOIZUMI H, 1993, J INVEST DERMATOL, V101, P858, DOI 10.1111/1523-1747.ep12371707; KOJIMA I, 1993, J BIOL CHEM, V268, P10003; Kroner C, 2000, J BIOL CHEM, V275, P27790, DOI 10.1074/jbc.M000540200; Letiges M, 2002, MOL ENDOCRINOL, V16, P847, DOI 10.1210/me.16.4.847; Li LW, 1999, MOL CELL BIOL, V19, P8547; LI LW, 1995, CELL GROWTH DIFFER, V6, P1171; Matsumoto M, 2001, J BIOL CHEM, V276, P14400, DOI 10.1074/jbc.M011093200; Mayo LD, 2001, P NATL ACAD SCI USA, V98, P11598, DOI 10.1073/pnas.181181198; Millward TA, 1999, TRENDS BIOCHEM SCI, V24, P186, DOI 10.1016/S0968-0004(99)01375-4; Miyata Y, 2004, MOL CANCER THER, V3, P839; NERI LM, 1994, FEBS LETT, V347, P63, DOI 10.1016/0014-5793(94)00508-7; Newton AC, 2003, BIOCHEM J, V370, P361, DOI 10.1042/BJ20021626; Ohba M, 1998, MOL CELL BIOL, V18, P5199, DOI 10.1128/MCB.18.9.5199; Paramio JM, 2001, MOL CELL BIOL, V21, P7449, DOI 10.1128/MCB.21.21.7449-7459.2001; Powers CJ, 2000, ENDOCR-RELAT CANCER, V7, P165, DOI 10.1677/erc.0.0070165; Resjo S, 2002, CELL SIGNAL, V14, P231, DOI 10.1016/S0898-6568(01)00238-8; Schwartz MA, 1999, CURR OPIN CELL BIOL, V11, P197, DOI 10.1016/S0955-0674(99)80026-X; Segrelles C, 2002, ONCOGENE, V21, P53, DOI 10.1038/sj.onc.1205032; Shin I, 2002, NAT MED, V8, P1145, DOI 10.1038/nm759; Simpson L, 2001, EXP CELL RES, V264, P29, DOI 10.1006/excr.2000.5130; Stork PJS, 2002, TRENDS CELL BIOL, V12, P258, DOI 10.1016/S0962-8924(02)02294-8; STRICKLAND JE, 1988, CANCER RES, V48, P165; Suzuki A, 2003, CANCER RES, V63, P674; Testa JR, 2001, P NATL ACAD SCI USA, V98, P10983, DOI 10.1073/pnas.211430998; TRANQUE PA, 1992, ENDOCRINOLOGY, V131, P1948, DOI 10.1210/en.131.4.1948; Viglietto G, 2002, NAT MED, V8, P1136, DOI 10.1038/nm762; Vincent AM, 2002, GROWTH HORM IGF RES, V12, P193, DOI 10.1016/S1096-6374(02)00017-5; Waite KA, 2002, AM J HUM GENET, V70, P829, DOI 10.1086/340026; Wen HC, 2003, CELL SIGNAL, V15, P37, DOI 10.1016/S0898-6568(02)00047-5; WENZELSEIFERT K, 1994, BIOCHEM BIOPH RES CO, V200, P1536, DOI 10.1006/bbrc.1994.1625; Xu WP, 2003, CANCER RES, V63, P7777; Yang J, 2002, MOL CELL, V9, P1227, DOI 10.1016/S1097-2765(02)00550-6; Yellaturu CR, 2002, J BIOL CHEM, V277, P40148, DOI 10.1074/jbc.M206376200; Zheng WH, 2000, J BIOL CHEM, V275, P13377, DOI 10.1074/jbc.275.18.13377; Zheng WH, 2002, MOL PHARMACOL, V62, P225, DOI 10.1124/mol.62.2.225; Zhou XM, 2000, J BIOL CHEM, V275, P25046, DOI 10.1074/jbc.M002526200	68	88	92	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 10	2006	281	6					3237	3243		10.1074/jbc.M512167200	http://dx.doi.org/10.1074/jbc.M512167200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	009QV	16338928	hybrid			2022-12-25	WOS:000235128200028
J	Lu, S; Yao, Y; Cheng, XY; Mitchell, S; Leng, SY; Meng, SM; Gallagher, JW; Shelness, GS; Morris, GS; Mahan, J; Frase, S; Mansbach, CM; Weinberg, RB; Black, DD				Lu, S; Yao, Y; Cheng, XY; Mitchell, S; Leng, SY; Meng, SM; Gallagher, JW; Shelness, GS; Morris, GS; Mahan, J; Frase, S; Mansbach, CM; Weinberg, RB; Black, DD			Overexpression of apolipoprotein A-IV enhances lipid secretion in IPEC-1 cells by increasing chylomicron size	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTESTINAL EPITHELIAL-CELLS; NEWBORN SWINE; INTERFACIAL PROPERTIES; FEEDING-BEHAVIOR; FATTY-ACIDS; C-III; CHOLESTEROL; EXPRESSION; RAT; ABSORPTION	Intestinal apolipoprotein A- IV expression is highly regulated by dietary lipid in newborn swine, suggesting a role in lipid absorption. Constitutive overexpression of apoA- IV in newborn swine enterocytes enhances basolateral secretion of triacylglycerol ( TG) in TG-rich lipoproteins 4.9- fold ( Lu, S., Yao, Y., Meng, S., Cheng, X., and Black, D. D. ( 2002) J. Biol. Chem. 277, 31929 - 31937). To investigate the mechanism of this enhancement, IPEC- 1 cells were transfected with a tetracycline- regulatable expression system ( Tet- On). In cells incubated with oleic acid, a dose response relationship was observed between medium doxycycline concentration and basolateral apoA- IV and TG secretion. Similarly regulated expression of apoA- I did not enhance lipid secretion. The mean diameter of TG-rich lipoproteins secreted from doxycycline- treated cells was larger than from untreated cells ( 87.0 nm versus 53.4 nm). Basolateral apoB secretion decreased. Using the same expression system, full-length human apoA-IV ( 376 amino acids); a " pig- like" human apoA-IV, lacking the C- terminal EQQQ repeats ( 361 amino acids); and a " chicken- like" apoA- IV, further truncated to 343 amino acids, were expressed in IPEC- 1 cells. With increasing protein secretion, cells expressing the full- length human apoA- IV displayed a 2- fold increase in TG secretion; in sharp contrast, cells expressing the piglike human apoA- IV displayed a 25- fold increase in TG secretion and a 27- fold increase in lipoprotein diameter. When human apoA- IV was further truncated to yield a chicken- like protein, TG secretion was inhibited. We conclude that overexpression of swine apoA- IV enhances basolateral TG secretion in a dose- dependent manner by increasing the size of secreted lipoproteins. These data suggest that the region in the human apoA- IV protein from residues 344 to 354 is critical to its ability to enhance lipid secretion, perhaps by enabling the packaging of additional core TG into chylomicron particles. The EQQQ- rich region may play an inhibitory or modulatory role in chylomicron packaging in humans.	Lebonheur Childrens Hosp & Med Ctr, Childrens Fdn Res Ctr, Memphis, TN 38103 USA; Univ Tennessee, Hlth Sci Ctr, Dept Paediat, Memphis, TN 38103 USA; Univ Tennessee, Hlth Sci Ctr, Dept Med, Memphis, TN 38103 USA; Wake Forest Univ, Sch Med, Dept Internal Med, Winston Salem, NC 27157 USA; Wake Forest Univ, Sch Med, Dept Pathol, Winston Salem, NC 27157 USA; Wake Forest Univ, Sch Med, Dept Physiol, Winston Salem, NC 27157 USA; Wake Forest Univ, Sch Med, Dept Pharmacol, Winston Salem, NC 27157 USA; Vet Adm Med Ctr, Memphis, TN 38104 USA; Univ Memphis, Integrated Microscopy Ctr, Memphis, TN 38152 USA	University of Tennessee System; University of Tennessee Health Science Center; University of Tennessee System; University of Tennessee Health Science Center; Wake Forest University; Wake Forest University; Wake Forest University; Wake Forest University; US Department of Veterans Affairs; Veterans Health Administration (VHA); Memphis VA Medical Center; University of Memphis	Black, DD (corresponding author), Lebonheur Childrens Hosp & Med Ctr, Childrens Fdn Res Ctr, Rm 401,W Patient Tower ,50 N Dunlap, Memphis, TN 38103 USA.	dblack@utmem.edu	Black, Dennis/AAD-9809-2020		NHLBI NIH HHS [R01 HL030897, HL30897, HL49373, R01 HL030897-23] Funding Source: Medline; NICHD NIH HHS [R01 HD022551-14A1, R01 HD022551-17, R01 HD022551-11, R01 HD022551-09A1, R01 HD022551-08, R01 HD022551-16, R01 HD022551-12, R01 HD022551, R01 HD022551-13, R01 HD022551-15, R01 HD022551-18, HD22551] Funding Source: Medline; NIDDK NIH HHS [DK38760] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD022551, R23HD022551, R29HD022551] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL049373, R23HL030897, R01HL030897] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK038760] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AALTOSETALA K, 1994, J CLIN INVEST, V93, P1776, DOI 10.1172/JCI117163; APFELBAUM TF, 1987, AM J PHYSIOL, V252, pG662, DOI 10.1152/ajpgi.1987.252.5.G662; BLACK DD, 1990, J LIPID RES, V31, P497; BLACK DD, 1989, J LIPID RES, V30, P207; Black DD, 1996, BIOCHEM BIOPH RES CO, V221, P619, DOI 10.1006/bbrc.1996.0645; Chauhan V, 1998, BIOCHEMISTRY-US, V37, P3735, DOI 10.1021/bi9718853; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P159; Cohen RD, 1997, J CLIN INVEST, V99, P1906, DOI 10.1172/JCI119358; Davis RA, 1999, BBA-MOL CELL BIOL L, V1440, P1, DOI 10.1016/S1388-1981(99)00083-9; Duverger N, 1996, SCIENCE, V273, P966, DOI 10.1126/science.273.5277.966; DVORIN E, 1986, J BIOL CHEM, V261, P5714; Ee LC, 2000, AM J PHYSIOL-GASTR L, V279, pG325, DOI 10.1152/ajpgi.2000.279.2.G325; ELSHOURBAGY NA, 1987, J BIOL CHEM, V262, P7973; EMMANUEL F, 1994, J BIOL CHEM, V269, P29883; FUJIMOTO K, 1992, AM J PHYSIOL, V262, pG1002, DOI 10.1152/ajpgi.1992.262.6.G1002; FUJIMOTO K, 1993, J CLIN INVEST, V91, P1830, DOI 10.1172/JCI116395; Gallagher JW, 2004, J LIPID RES, V45, P1826, DOI 10.1194/jlr.M400188-JLR200; GonzalezVallina R, 1996, AM J PHYSIOL-GASTR L, V271, pG249, DOI 10.1152/ajpgi.1996.271.2.G249; GREEN PHR, 1980, J CLIN INVEST, V65, P911, DOI 10.1172/JCI109745; HADDAD IA, 1986, J BIOL CHEM, V261, P3268; INNIS SM, 1993, J NUTR, V123, P386, DOI 10.1093/jn/123.suppl_2.386; Kalogeris TJ, 1997, J NUTR, V127, pS537, DOI 10.1093/jn/127.3.537S; Kumar NS, 1999, AM J PHYSIOL-GASTR L, V276, pG378, DOI 10.1152/ajpgi.1999.276.2.G378; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lu S, 2002, J BIOL CHEM, V277, P31929, DOI 10.1074/jbc.M201418200; MURTHY S, 1992, ARTERIOSCLER THROMB, V12, P691, DOI 10.1161/01.ATV.12.6.691; Navarro MA, 2004, GENE, V325, P157, DOI 10.1016/j.gene.2003.10.007; Pearson K, 2005, J BIOL CHEM, V280, P38576, DOI 10.1074/jbc.M506802200; Pearson K, 2004, BIOCHEMISTRY-US, V43, P10719, DOI 10.1021/bi048978m; Phillips ML, 1997, J LIPID RES, V38, P1170; Qin XF, 1998, AM J PHYSIOL-HEART C, V274, pH1836, DOI 10.1152/ajpheart.1998.274.5.H1836; SMITH MW, 1988, COMP BIOCHEM PHYS A, V90, P577, DOI 10.1016/0300-9629(88)90670-6; STEIN O, 1986, BIOCHIM BIOPHYS ACTA, V878, P7, DOI 10.1016/0005-2760(86)90337-1; Steinmetz A, 1998, J BIOL CHEM, V273, P10543, DOI 10.1074/jbc.273.17.10543; Vowinkel T, 2004, J CLIN INVEST, V114, P260, DOI 10.1172/JCI200421233; Wang H, 1999, AM J PHYSIOL-GASTR L, V276, pG353, DOI 10.1152/ajpgi.1999.276.2.G353; Wang H, 2001, AM J PHYSIOL-GASTR L, V280, pG1137, DOI 10.1152/ajpgi.2001.280.6.G1137; Wang H, 1997, AM J PHYSIOL-GASTR L, V272, pG935, DOI 10.1152/ajpgi.1997.272.5.G935; WEINBERG RB, 1990, J BIOL CHEM, V265, P18372; Weinberg RB, 2002, J BIOL CHEM, V277, P21549, DOI 10.1074/jbc.M202197200; Weinberg RB, 2000, J LIPID RES, V41, P2035; Weinberg RB, 2000, J LIPID RES, V41, P1419; Weinberg RB, 2000, J LIPID RES, V41, P1410; Weinstock PH, 1997, J LIPID RES, V38, P1782	44	67	68	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 10	2006	281	6					3473	3483		10.1074/jbc.M502501200	http://dx.doi.org/10.1074/jbc.M502501200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	009QV	16338933	hybrid			2022-12-25	WOS:000235128200057
J	Morten, KJ; Ackrell, BAC; Melov, S				Morten, KJ; Ackrell, BAC; Melov, S			Mitochondrial reactive oxygen species in mice lacking superoxide dismutase 2 - Attenuation via antioxidant treatment	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MANGANESE SUPEROXIDE-DISMUTASE; ELECTRON-TRANSPORT CHAIN; DEVELOPMENTAL-CHANGES; ENERGY-METABOLISM; DILATED CARDIOMYOPATHY; HEART-MITOCHONDRIA; HYDROGEN-PEROXIDE; ALZHEIMER-DISEASE; OXIDATIVE STRESS; CYTOCHROME-C	Mice that lack the mitochondrial form of superoxide dismutase (SOD2) incur severe pathologies and mitochondrial deficiencies, including major depletion of complex II, as a consequence of buildup of endogenous reactive oxygen species (Melov, S., Coskun, P., Patel, M., Tuinstra, R., Cottrell, B., Jun, A. S., Zastawny, T. H., Dizdaroglu, M., Goodman, S. I., Huang, T. T., Miziorko, H., Epstein, C. J., and Wallace, D. C. (1999) Proc. Natl. Acad. Sci. U. S. A. 96, 846-851 and Li, Y., Huang, T. T., Carlson, E. J., Melov, S., Ursell, P. C., Olson, J. L., Noble, L. J., Yoshimura, M. P., Berger, C., Chan, P. H., Wallace, D. C., and Epstein, C. J. (1995) Nat. Genet. 11, 376-381). These problems can be greatly attenuated or rescued by synthetic antioxidant treatment, such as with the catalytic antioxidant EUK189 (Hinerfeld, D., Traini, M. D., Weinberger, R. P., Cochran, B., Doctrow, S. R., Harry, J., and Melov, S. (2004) J. Neurochem. 88, 657-667). We have used heart mitochondria from sod2 null mice to better understand mitochondrial reactive oxygen species production both in the absence of SOD2 and following in vivo antioxidant treatment. Isolated heart mitochondria from 5-day-old sod2 null animals respiring on the complex II substrate succinate exhibited statistically significant higher levels of mitochondrial O-2(.). (157%, p < 0.01) but significantly less H2O2 (33%, p < 0.001) than wild type littermates. Treatment of sod2 nullizygous mice with EUK189 proportionately increased the levels of complex II and H2O2. Increased production of O-2(.). resulting from complex II normalization had no effect on steady state levels due to the rapid conversion to H2O2, a process presumably aided by the presence of the EUK189, an SOD mimetic.	Buck Inst Age Res, Novato, CA 94945 USA	Buck Institute for Research on Aging	Melov, S (corresponding author), Buck Inst Age Res, 8001 Redwood Blvd, Novato, CA 94945 USA.	smelov@buckinstitute.org	Melov, Simon/AAC-9469-2020; MORTEN, Karl/GXM-6291-2022	Morten, Karl/0000-0001-6926-6550; Melov, Simon/0000-0001-8554-2834	NIA NIH HHS [AG18679] Funding Source: Medline; NATIONAL INSTITUTE ON AGING [R01AG018679] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Bass A, 2001, PHYSIOL RES, V50, P237; Baysal BE, 2000, SCIENCE, V287, P848, DOI 10.1126/science.287.5454.848; Beal MF, 2004, J BIOENERG BIOMEMBR, V36, P381, DOI 10.1023/B:JOBB.0000041772.74810.92; Benov L, 1998, FREE RADICAL BIO MED, V25, P826, DOI 10.1016/S0891-5849(98)00163-4; BOVERIS A, 1984, METHOD ENZYMOL, V105, P429; CARLSSON LM, 1995, P NATL ACAD SCI USA, V92, P6264, DOI 10.1073/pnas.92.14.6264; DOCTROW SR, 2002, CRITCAL REV OXIDATIV, P1324; DOCTROW SR, 2005, MED INORGANIC CHEM, P301; Drahota Z, 2004, PHYSIOL RES, V53, P119; ELCHURI S, 2004, ONCOGENE; Fink B, 2004, AM J PHYSIOL-CELL PH, V287, pC895, DOI 10.1152/ajpcell.00028.2004; Friedman JS, 2004, BLOOD, V104, P2565, DOI 10.1182/blood-2003-11-3858; Friedman JS, 2001, J EXP MED, V193, P925, DOI 10.1084/jem.193.8.925; GOLDEN TR, 2005, RADIC BIOL MED, V39, P162; Han D, 2001, BIOCHEM J, V353, P411, DOI 10.1042/0264-6021:3530411; Hansford RG, 1997, J BIOENERG BIOMEMBR, V29, P89, DOI 10.1023/A:1022420007908; Hinerfeld D, 2004, J NEUROCHEM, V88, P657, DOI 10.1046/j.1471-4159.2003.02195.x; Huang TT, 2001, FREE RADICAL BIO MED, V31, P1101, DOI 10.1016/S0891-5849(01)00694-3; HUET O, 1992, CYTOMETRY, V13, P532, DOI 10.1002/cyto.990130513; Kalous M, 2001, PHYSIOL RES, V50, P315; Kushnareva Y, 2002, BIOCHEM J, V368, P545, DOI 10.1042/BJ20021121; LI YB, 1995, NAT GENET, V11, P376, DOI 10.1038/ng1295-376; Liu YB, 2002, J NEUROCHEM, V80, P780, DOI 10.1046/j.0022-3042.2002.00744.x; Maier CM, 2002, NEUROBIOL DIS, V11, P28, DOI 10.1006/nbdi.2002.0513; Melov S, 2000, SCIENCE, V289, P1567, DOI 10.1126/science.289.5484.1567; Melov S, 1999, P NATL ACAD SCI USA, V96, P846, DOI 10.1073/pnas.96.3.846; Melov S, 2005, FREE RADICAL BIO MED, V38, P258, DOI 10.1016/j.freeradbiomed.2004.10.023; Melov S, 2001, J NEUROSCI, V21, P8348, DOI 10.1523/JNEUROSCI.21-21-08348.2001; Melov S, 1998, NAT GENET, V18, P159, DOI 10.1038/ng0298-159; Miwa S, 2003, FREE RADICAL BIO MED, V35, P938, DOI 10.1016/S0891-5849(03)00464-7; Mootha VK, 2003, CELL, V115, P629, DOI 10.1016/S0092-8674(03)00926-7; Muller FL, 2004, J BIOL CHEM, V279, P49064, DOI 10.1074/jbc.M407715200; Nakai A, 2000, DEV BRAIN RES, V121, P67, DOI 10.1016/S0165-3806(00)00025-0; Polyak K, 1998, NAT GENET, V20, P291, DOI 10.1038/3108; Qi XP, 2003, INVEST OPHTH VIS SCI, V44, P1088, DOI 10.1167/iovs.02-0864; Raha S, 2000, FREE RADICAL BIO MED, V29, P170, DOI 10.1016/S0891-5849(00)00338-5; Rapoport SI, 1996, NEURODEGENERATION, V5, P473, DOI 10.1006/neur.1996.0065; Reaume AG, 1996, NAT GENET, V13, P43, DOI 10.1038/ng0596-43; Samper E, 2003, AGING CELL, V2, P277, DOI 10.1046/j.1474-9728.2003.00062.x; SCHNEIDER SH, 1984, DIABETOLOGIA, V26, P355, DOI 10.1007/BF00266036; St-Pierre J, 2002, J BIOL CHEM, V277, P44784, DOI 10.1074/jbc.M207217200; Strassburger M, 2005, FREE RADICAL BIO MED, V38, P1458, DOI 10.1016/j.freeradbiomed.2005.02.009; STURTZ LA, 2001, J BIOL CHEM, V10, P10; Tiivel T, 2000, MOL CELL BIOCHEM, V208, P119, DOI 10.1023/A:1007002323492; TURRENS JF, 1980, BIOCHEM J, V191, P421, DOI 10.1042/bj1910421; Valente EM, 2004, SCIENCE, V304, P1158, DOI 10.1126/science.1096284; Van Remmen H, 2003, PHYSIOL GENOMICS, V16, P29, DOI 10.1152/physiolgenomics.00122.2003; Votyakova TV, 2001, J NEUROCHEM, V79, P266, DOI 10.1046/j.1471-4159.2001.00548.x; Zhao HT, 2003, FREE RADICAL BIO MED, V34, P1359, DOI 10.1016/S0891-5849(03)00142-4	49	52	56	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 10	2006	281	6					3354	3359		10.1074/jbc.M509261200	http://dx.doi.org/10.1074/jbc.M509261200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	009QV	16326710	hybrid			2022-12-25	WOS:000235128200043
J	Picard, M; Toyoshima, C; Champeil, P				Picard, M; Toyoshima, C; Champeil, P			Effects of inhibitors on luminal opening of Ca2+ binding sites in an E2P-like complex of sarcoplasmic reticulum Ca2+-ATPase with Be2+-fluoride	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INSENSITIVE PHOSPHOENZYME INTERMEDIATE; CALCIUM-PUMP; TRANSPORT SITES; ADENOSINE-TRIPHOSPHATASE; CONFORMATIONAL-CHANGES; INORGANIC-PHOSPHATE; CRYSTAL-STRUCTURE; STRUCTURAL BASIS; HYDROGEN-ION; LOW-AFFINITY	We document here the intrinsic fluorescence and Ca-45(2+) binding properties of putative "E2P-related" complexes of Ca2+-free ATPase with fluoride, formed in the presence of magnesium, aluminum, or beryllium. Intrinsic fluorescence measurements suggest that in the absence of inhibitors, the ATPase complex with beryllium fluoride ( but not those with magnesium or aluminum fluoride) does constitute an appropriate analog of the "ADP-insensitive" phosphorylated form of Ca2+-ATPase, the so-called "E2P" state. Ca-45(2+) binding measurements, performed in the presence of 100 mM KCl, 5 mM Mg2+, and 20% Me2SO at pH 8, demonstrate that this ATPase complex with beryllium fluoride ( but again not those with magnesium or aluminum fluoride) has its Ca2+ binding sites accessible for rapid, low affinity (submillimolar) binding of Ca2+ from the luminal side of SR. In addition, we specifically demonstrate that in this E2P-like form of ATPase, the presence of thapsigargin, 2,5-ditertbutyl-1,4-dihydroxybenzene, or cyclopiazonic acid prevents Ca-45(2+) binding (i.e. presumably prevents opening of the Ca-45(2+) binding sites on the SR luminal side). Since crystals of E2P-related forms of ATPase have up to now been described in the presence of thapsigargin only, these results suggest that crystallizing an inhibitor-free E2P-like form of ATPase ( like its complex with beryllium fluoride) would be highly desirable, to unambiguously confirm previous predictions about the exit pathway from the ATPase transmembrane Ca2+ binding sites to the SR luminal medium.	CEA Saclay, CNRS, URA 2096, Serv Biophys Fonct Membranaires,CEA, F-91191 Gif Sur Yvette, France; Univ Paris Sud, Dept Biol Joliot Curie, CEA Saclay, Inst Federat Rech 46, F-91191 Gif Sur Yvette, France; Univ Tokyo, Inst Mol & Cellular Biosci, Bunkyo Ku, Tokyo 1130032, Japan	CEA; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Saclay; CEA; UDICE-French Research Universities; Universite Paris Saclay; University of Tokyo	Champeil, P (corresponding author), CEA Saclay, CNRS, URA 2096, Serv Biophys Fonct Membranaires,CEA, F-91191 Gif Sur Yvette, France.	champeil@dsvidf.cea.fr	Picard, Martin/A-3236-2016; Toyoshima, Chikashi/R-4153-2019	Picard, Martin/0000-0002-6518-8900; Toyoshima, Chikashi/0000-0001-9640-0778				BONNET JP, 1978, ARCH BIOCHEM BIOPHYS, V191, P32, DOI 10.1016/0003-9861(78)90064-4; CHAMPEIL P, 1985, BIOCHEMISTRY-US, V24, P69, DOI 10.1021/bi00322a012; CHAMPEIL P, 1986, FEBS LETT, V206, P93, DOI 10.1016/0014-5793(86)81347-3; Champeil P., 1996, BIOMEMBR, V5, P43; CUENDA A, 1994, BBA-BIOMEMBRANES, V1194, P35, DOI 10.1016/0005-2736(94)90200-3; Danko S, 2004, J BIOL CHEM, V279, P14991, DOI 10.1074/jbc.M313363200; Danko S, 2001, FEBS LETT, V489, P277, DOI 10.1016/S0014-5793(01)02111-1; Davidson GA, 1996, BBA-GEN SUBJECTS, V1289, P187, DOI 10.1016/0304-4165(95)00155-7; DEFORESTA B, 1990, EUR J BIOCHEM, V194, P383; DEMEIS L, 1980, BIOCHEMISTRY-US, V19, P4252, DOI 10.1021/bi00559a017; DEMEIS L, 1979, ANNU REV BIOCHEM, V48, P275; FERNANDEZBELDA F, 1985, BIOCHIM BIOPHYS ACTA, V854, P257; GOOD NE, 1966, BIOCHEMISTRY-US, V5, P467, DOI 10.1021/bi00866a011; GUILLAIN F, 1982, J BIOL CHEM, V257, P7366; HASSELBACH W, 1983, Z NATURFORSCH C, V38, P1015; HASSELBACH W, 1978, BIOCHIM BIOPHYS ACTA, V515, P23, DOI 10.1016/0304-4157(78)90007-2; INESI G, 1980, J BIOL CHEM, V255, P3025; JENCKS WP, 1989, J BIOL CHEM, V264, P18855; KHAN YM, 1995, BIOCHEMISTRY-US, V34, P14385, DOI 10.1021/bi00044a015; KIJIMA Y, 1991, J BIOL CHEM, V266, P22912; KUBOTA T, 1993, BIOCHIM BIOPHYS ACTA, V1163, P131, DOI 10.1016/0167-4838(93)90174-P; Kuhlbrandt W, 2004, NAT REV MOL CELL BIO, V5, P282, DOI 10.1038/nrm1354; LACAPERE JJ, 1981, J BIOL CHEM, V256, P2302; Logan-Smith MJ, 2002, BIOCHEMISTRY-US, V41, P2869, DOI 10.1021/bi011938n; LUND S, 1989, J BIOL CHEM, V264, P4907; MAKINOSE M, 1972, FEBS LETT, V25, P113, DOI 10.1016/0014-5793(72)80466-6; Moller JV, 2005, CURR OPIN STRUC BIOL, V15, P387, DOI 10.1016/j.sbi.2005.06.005; Moller JV, 2002, J BIOL CHEM, V277, P38647, DOI 10.1074/jbc.M204603200; MURPHY AJ, 1993, J BIOL CHEM, V268, P23307; MURPHY AJ, 1992, J BIOL CHEM, V267, P16990; MYUNG J, 1994, BIOCHEMISTRY-US, V33, P8775, DOI 10.1021/bi00195a020; Obara K, 2005, P NATL ACAD SCI USA, V102, P14489, DOI 10.1073/pnas.0506222102; Ogawa H, 2002, P NATL ACAD SCI USA, V99, P15977, DOI 10.1073/pnas.202622299; Olesen C, 2004, SCIENCE, V306, P2251, DOI 10.1126/science.1106289; ORLOWSKI S, 1991, BIOCHEMISTRY-US, V30, P352, DOI 10.1021/bi00216a007; Picard M, 2005, J BIOL CHEM, V280, P18745, DOI 10.1074/jbc.M501596200; SAGARA Y, 1991, J BIOL CHEM, V266, P13503; SAGARA Y, 1992, J BIOL CHEM, V267, P1286; SAGARA Y, 1992, J BIOL CHEM, V267, P12606; SCALES DJ, 1984, Z NATURFORSCH C, V39, P177; Seekoe T, 2001, J BIOL CHEM, V276, P46737, DOI 10.1074/jbc.M106320200; Sorensen TLM, 2004, SCIENCE, V304, P1672, DOI 10.1126/science.1099366; Toyoshima C, 2004, NATURE, V430, P529, DOI 10.1038/nature02680; Toyoshima C, 2004, ANNU REV BIOCHEM, V73, P269, DOI 10.1146/annurev.biochem.73.011303.073700; Toyoshima C, 2004, NATURE, V432, P361, DOI 10.1038/nature02981; Toyoshima C, 2003, FEBS LETT, V555, P106, DOI 10.1016/S0014-5793(03)01086-X; Toyoshima C, 2000, NATURE, V405, P647, DOI 10.1038/35015017; Toyoshima C, 2002, NATURE, V418, P605, DOI 10.1038/nature00944; TROULLIER A, 1992, J BIOL CHEM, V267, P22821; VERJOVSKIALMEIDA S, 1977, BIOCHEMISTRY-US, V16, P329, DOI 10.1021/bi00621a026; VIEYRA A, 2005, BIOCHIM BIOPHYS ACTA, V1667, P103; Webb RJ, 2000, J BIOL CHEM, V275, P977, DOI 10.1074/jbc.275.2.977; WICTOME M, 1992, FEBS LETT, V304, P109, DOI 10.1016/0014-5793(92)80599-C; WICTOME M, 1995, BIOCHEM J, V310, P859, DOI 10.1042/bj3100859; WICTOME M, 1992, BIOCHEM J, V283, P525, DOI 10.1042/bj2830525; Xu C, 2004, J BIOL CHEM, V279, P17973, DOI 10.1074/jbc.M313263200; Yamasaki K, 2002, J BIOL CHEM, V277, P13615, DOI 10.1074/jbc.M200625200; Young HS, 2001, J MOL BIOL, V308, P231, DOI 10.1006/jmbi.2001.4558; Zhong L, 1998, J BIOL CHEM, V273, P12994, DOI 10.1074/jbc.273.21.12994	59	29	29	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 10	2006	281	6					3360	3369		10.1074/jbc.M511385200	http://dx.doi.org/10.1074/jbc.M511385200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	009QV	16332689	hybrid			2022-12-25	WOS:000235128200044
J	Yang, CK; Kim, JH; Li, HW; Stallcup, MR				Yang, CK; Kim, JH; Li, HW; Stallcup, MR			Differential use of functional domains by coiled-coil coactivator in its synergistic coactivator function with beta-catenin or GRIP1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEAR RECEPTOR COACTIVATOR; ARYL-HYDROCARBON RECEPTOR; ANDROGEN RECEPTOR; TRANSCRIPTIONAL ACTIVATION; GENE-EXPRESSION; ARGININE METHYLTRANSFERASE; MUSCLE DIFFERENTIATION; PROSTATE-CANCER; CARCINOMA-CELLS; CYCLIN D1	beta-Catenin, a pivotal component of the Wnt-signaling pathway, binds to and serves as a transcriptional coactivator for the T-cell factor/lymphoid enhancer factor (TCF/LEF) family of transcriptional activator proteins and for the androgen receptor (AR), a nuclear receptor. Three components of the p160 nuclear receptor coactivator complex, including CARM1, p300/CBP, and GRIP1 (one of the p160 coactivators), bind to and cooperate with beta-catenin to enhance transcriptional activation by TCF/LEF and AR. Here we report that another component of the p160 nuclear receptor coactivator complex, the coiled-coil coactivator (CoCoA), directly binds to and cooperates synergistically with beta-catenin as a coactivator for AR and TCF/LEF. CoCoA uses different domains to bind GRIP1 and beta-catenin, and it uses different domains to transmit the activating signal to the transcription machinery, depending on whether it is bound to GRIP1 or beta-catenin. CoCoA associated specifically with the promoters of transiently transfected and endogenous target genes of TCF/LEF, and reduction of the endogenous CoCoA level decreased the ability of TCF/LEF and beta-catenin to activate transcription of transient and endogenous target genes. Thus, CoCoA uses different combinations of functional domains to serve as a physiologically relevant component of the Wnt/beta-catenin signaling pathway and the androgen signaling pathway.	Univ So Calif, Dept Pathol, Los Angeles, CA 90089 USA; Univ So Calif, Dept Biochem & Mol Biol, Los Angeles, CA 90089 USA	University of Southern California; University of Southern California	Stallcup, MR (corresponding author), Univ So Calif, Dept Pathol, HMR 301,2011 Zonal Ave, Los Angeles, CA 90089 USA.	stallcup@usc.edu			NIDDK NIH HHS [R01 DK043093, DK43093] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK043093] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		An W, 2004, CELL, V117, P735, DOI 10.1016/j.cell.2004.05.009; Barker N, 2000, BIOESSAYS, V22, P961; Barker N, 2001, EMBO J, V20, P4935, DOI 10.1093/emboj/20.17.4935; Beischlag TV, 2002, MOL CELL BIOL, V22, P4319, DOI 10.1128/MCB.22.12.4319-4333.2002; Belandia B, 2000, J BIOL CHEM, V275, P30801, DOI 10.1074/jbc.C000484200; Billin AN, 2000, MOL CELL BIOL, V20, P6882, DOI 10.1128/MCB.20.18.6882-6890.2000; Brannon M, 1999, DEVELOPMENT, V126, P3159; Cavallo RA, 1998, NATURE, V395, P604, DOI 10.1038/26982; Chen DG, 1999, SCIENCE, V284, P2174, DOI 10.1126/science.284.5423.2174; Chen HW, 1997, CELL, V90, P569, DOI 10.1016/S0092-8674(00)80516-4; Chen SL, 2000, GENE DEV, V14, P1209; Chen SL, 2002, J BIOL CHEM, V277, P4324, DOI 10.1074/jbc.M109835200; Chesire DR, 2002, ONCOGENE, V21, P8453, DOI 10.1038/sj.onc.1206049; Glass CK, 2000, GENE DEV, V14, P121; HAEGEL H, 1995, DEVELOPMENT, V121, P3529; Harada N, 1999, EMBO J, V18, P5931, DOI 10.1093/emboj/18.21.5931; Hecht A, 2000, EMBO J, V19, P1839, DOI 10.1093/emboj/19.8.1839; Heinlein CA, 2002, ENDOCR REV, V23, P175, DOI 10.1210/er.23.2.175; Jenster G, 1999, SEMIN ONCOL, V26, P407; Kamei Y, 1996, CELL, V85, P403, DOI 10.1016/S0092-8674(00)81118-6; Kim JH, 2004, J BIOL CHEM, V279, P49842, DOI 10.1074/jbc.M408535200; Kim JH, 2003, MOL CELL, V12, P1537, DOI 10.1016/S1097-2765(03)00450-7; Kizu R, 2003, ARCH TOXICOL, V77, P335, DOI 10.1007/s00204-003-0454-y; Koh SS, 2002, J BIOL CHEM, V277, P26031, DOI 10.1074/jbc.M110865200; Lee SK, 1998, J BIOL CHEM, V273, P16651, DOI 10.1074/jbc.273.27.16651; Li HW, 2004, J BIOL CHEM, V279, P4212, DOI 10.1074/jbc.M311374200; Liu T, 2001, SCIENCE, V292, P1718, DOI 10.1126/science.1060100; Ma H, 1999, MOL CELL BIOL, V19, P6164; McKenna NJ, 2002, CELL, V108, P465, DOI 10.1016/S0092-8674(02)00641-4; MEYER ME, 1989, CELL, V57, P433, DOI 10.1016/0092-8674(89)90918-5; MILLER JR, 2001, GENOME BIOL; Morin PJ, 1999, BIOESSAYS, V21, P1021, DOI 10.1002/(SICI)1521-1878(199912)22:1<1021::AID-BIES6>3.0.CO;2-P; Morrow D, 2004, J STEROID BIOCHEM, V88, P27, DOI 10.1016/j.jsbmb.2003.10.005; Mulholland DJ, 2003, ONCOGENE, V22, P5602, DOI 10.1038/sj.onc.1206802; Rogatsky I, 2002, P NATL ACAD SCI USA, V99, P16701, DOI 10.1073/pnas.262671599; Romagnolo B, 1999, CANCER RES, V59, P3875; Sheppard KA, 1999, MOL CELL BIOL, V19, P6367; Shtutman M, 1999, P NATL ACAD SCI USA, V96, P5522, DOI 10.1073/pnas.96.10.5522; Song LN, 2003, MOL CELL BIOL, V23, P1674, DOI 10.1128/MCB.23.5.1674-1687.2003; Soutoglou E, 2000, J BIOL CHEM, V275, P12515, DOI 10.1074/jbc.275.17.12515; Stallcup MR, 2003, J STEROID BIOCHEM, V85, P139, DOI 10.1016/S0960-0760(03)00222-X; Stallcup MR, 2000, BIOCHEM SOC T, V28, P415, DOI 10.1042/0300-5127:0280415; Sun YN, 2000, P NATL ACAD SCI USA, V97, P12613, DOI 10.1073/pnas.220158597; Takemaru KI, 2000, J CELL BIOL, V149, P249, DOI 10.1083/jcb.149.2.249; Tetsu O, 1999, NATURE, V398, P422, DOI 10.1038/18884; Torchia J, 1997, NATURE, V387, P677, DOI 10.1038/42652; Truica CI, 2000, CANCER RES, V60, P4709; Verma UN, 2003, CLIN CANCER RES, V9, P1291; Vo N, 2001, J BIOL CHEM, V276, P13505, DOI 10.1074/jbc.R000025200; Xu JM, 2003, MOL ENDOCRINOL, V17, P1681, DOI 10.1210/me.2003-0116; Yao TP, 1996, P NATL ACAD SCI USA, V93, P10626, DOI 10.1073/pnas.93.20.10626	51	30	32	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 10	2006	281	6					3389	3397		10.1074/jbc.M510403200	http://dx.doi.org/10.1074/jbc.M510403200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	009QV	16344550	Green Accepted, hybrid			2022-12-25	WOS:000235128200047
J	Liu, BF; Liang, JJN				Liu, BF; Liang, JJN			Domain interaction sites of human lens beta b2-crystallin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-PROTEIN INTERACTIONS; CRYSTALLIN; DIMERIZATION; TRYPTOPHAN	beta B2- crystallin, the major component of beta-crystallin, is a dimer at low concentrations but can form oligomers under physiological conditions. The interaction domains have been speculated to be the beta-sheets, each of which is formed by two or more beta-strands. beta B2-crystallin consists of 16 beta-strands, 8 in the N-terminal domain and 8 in the C-terminal domain. Domain interaction sites may be removed by destroying the beta-strands, which can be done by site-specific mutations, substituting the beta-formers (Val, Phe, Leu) with Glu or Asn, strong beta-breakers. We have cloned the following beta-strand-deleted mutants, I20E, L34E, V54E, V60E, V73E, L97E, I109E, I124E, V144E, V152E, L162E, L165E, and V187E and their corresponding X -> Asn mutants. We also made two mutants, V46E and V129E, that were not on the beta-strand as controls. Disruption of protein-protein interactions was screened by a mammalian two-hybrid system assay. Protein-protein interactions decreased for all beta-strand-deleted mutants except I20E, L34E, and L162E mutants; this effect was not seen in the two mutant controls, V46E and V129E. The sequences around Val-54, Val-60, Val-73, and Leu-97 in the N-terminal region and Ile-109, Ile-124, Val-144, Val-152, Leu-165, and Val-187 in the C-terminal region that formed beta-strands appear to be important in dimerization. Some selected mutant proteins that showed strong ( V46E and V129E) and reduced ( V60E, V144E, V60N, and V144N) interactions were expressed in bacterial culture and were studied with spectroscopy and chromatography. The V60E and V144E mutants were found to be partially unfolded and incapable of forming a complete dimer.	Brigham & Womens Hosp, Ctr Ophthalm Res Surg, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Ophthalmol, Boston, MA 02115 USA	Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School	Liang, JJN (corresponding author), Brigham & Womens Hosp, Ctr Ophthalm Res Surg, 221 Longwood Ave, Boston, MA 02115 USA.	jliang@rics.bwh.harvard.edu			NATIONAL EYE INSTITUTE [R01EY013968] Funding Source: NIH RePORTER; NEI NIH HHS [EY13968] Funding Source: Medline	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		BAX B, 1989, J MOL BIOL, V208, P715, DOI 10.1016/0022-2836(89)90162-9; BAX B, 1990, NATURE, V347, P776, DOI 10.1038/347776a0; CHOU PY, 1978, ANNU REV BIOCHEM, V47, P251, DOI 10.1146/annurev.bi.47.070178.001343; CHOU PY, 1989, PREDICTION PROTEIN S, P549; DRIESSEN HPC, 1991, ACTA CRYSTALLOGR B, V47, P987, DOI 10.1107/S0108768191009163; Fu L, 2003, INVEST OPHTH VIS SCI, V44, P1155, DOI 10.1167/iovs.02-0950; Fu L, 2002, J BIOL CHEM, V277, P4255, DOI 10.1074/jbc.M110027200; Fu L, 2001, MOL VIS, V7, P178; Ghosh JG, 2005, PROTEIN SCI, V14, P684, DOI 10.1110/ps.041152805; Hejtmancik JF, 2004, EXP EYE RES, V79, P377, DOI 10.1016/j.exer.2004.06.011; Kosinski-Collins MS, 2004, PROTEIN SCI, V13, P2223, DOI 10.1110/ps.04627004; Koteiche HA, 1999, J MOL BIOL, V294, P561, DOI 10.1006/jmbi.1999.3242; Kumaraswamy VS, 1996, ACTA CRYSTALLOGR D, V52, P611, DOI 10.1107/S0907444995014302; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lampi KJ, 1997, J BIOL CHEM, V272, P2268; Liu BF, 2005, MOL VIS, V11, P321; MACH H, 1992, ANAL BIOCHEM, V200, P74, DOI 10.1016/0003-2697(92)90279-G; NALINI V, 1994, J MOL BIOL, V236, P1250, DOI 10.1016/0022-2836(94)90025-6; ROST B, 1993, J MOL BIOL, V232, P584, DOI 10.1006/jmbi.1993.1413; Sergeev YV, 2004, BIOCHEMISTRY-US, V43, P415, DOI 10.1021/bi034617f; Sreelakshmi Y, 2004, BIOCHEMISTRY-US, V43, P15785, DOI 10.1021/bi048151s; TRINKL S, 1994, PROTEIN SCI, V3, P1392, DOI 10.1002/pro.5560030905	22	21	23	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 3	2006	281	5					2624	2630		10.1074/jbc.M509017200	http://dx.doi.org/10.1074/jbc.M509017200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	006XT	16319073	hybrid			2022-12-25	WOS:000234931800026
J	Rastogi, S; Joshi, B; Fusaro, G; Chellappan, S				Rastogi, S; Joshi, B; Fusaro, G; Chellappan, S			Camptothecin induces nuclear export of prohibitin preferentially in transformed cells through a CRM-1-dependent mechanism	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESTROGEN-RECEPTOR ACTIVITY; NUCLEOCYTOPLASMIC TRANSPORT; REPRESSES TRANSCRIPTION; MITOCHONDRIAL PROTEINS; 3'-UNTRANSLATED REGION; POTENTIAL ROLE; P53; RB; TARGET; CANCER	Prohibitin is a growth-suppressive protein that has multiple functions in the nucleus and the mitochondria. Our earlier studies had shown that prohibitin represses the activity of E2F transcription factors while enhancing p53-mediated transcription. At the same time, prohibitin has been implicated in mediating the proper folding of mitochondrial proteins. We had found that treatment of cells with camptothecin, a topoisomerase 1 inhibitor, led to the export of prohibitin and p53 from the nucleus to the mitochondria. Here we show that the camptothecin-induced export of prohibitin occurs preferentially in transformed cell lines, but not in untransformed or primary cells. Cells that did not display the translocation of prohibitin were refractive to the apoptotic effects of camptothecin. The translocation was mediated by a putative nuclear export signal at the C-terminal region of prohibitin; fusion of the nuclear export signal (NES) of prohibitin to green fluorescence protein led to its export from the nucleus. Leptomycin B could inhibit the nuclear export of prohibitin showing that it was a CRM-1-dependent event driven by Ran GTPase. Confirming this, prohibitin was found to physically interact with CRM-1, and this interaction was significantly higher in transformed cells. Delivery of a peptide corresponding to the NES of prohibitin prevented the export of prohibitin to cytoplasm and protected cells from apoptosis. These results suggest that the regulated translocation of prohibitin from the nucleus to the mitochondria facilitates its pleiotropic functions and might contribute to its anti-proliferative and tumor suppressive properties.	Univ S Florida, H Lee Moffitt Canc Ctr & Res Inst, Dept Interdisciplinary Oncol, Drug Discovery Program, Tampa, FL 33612 USA	H Lee Moffitt Cancer Center & Research Institute; State University System of Florida; University of South Florida	Chellappan, S (corresponding author), Univ S Florida, H Lee Moffitt Canc Ctr & Res Inst, Dept Interdisciplinary Oncol, Drug Discovery Program, 12902 Magnolia Dr, Tampa, FL 33612 USA.	Chellasp@moffitt.usf.edu	Rastogi, Shipra/L-1209-2015; Rastogi, Shipra/F-5109-2012	Rastogi, Shipra/0000-0003-3296-4405; 	NCI NIH HHS [CA77301] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA077301] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Bednenko J, 2003, TRAFFIC, V4, P127, DOI 10.1034/j.1600-0854.2003.00109.x; Berger KH, 1998, MOL CELL BIOL, V18, P4043, DOI 10.1128/MCB.18.7.4043; Brehm A, 1998, NATURE, V391, P597, DOI 10.1038/35404; Chau BN, 2003, NAT REV CANCER, V3, P130, DOI 10.1038/nrc993; CHELLAPPAN SP, 1991, CELL, V65, P1053, DOI 10.1016/0092-8674(91)90557-F; Chipuk JE, 2004, CELL CYCLE, V3, P429; Coates PJ, 1997, CURR BIOL, V7, P607, DOI 10.1016/S0960-9822(06)00261-2; Crosby ME, 2004, CANCER BIOL THER, V3, P1208, DOI 10.4161/cbt.3.12.1494; Dahiya A, 2001, MOL CELL, V8, P557, DOI 10.1016/S1097-2765(01)00346-X; DEROSSI D, 1994, J BIOL CHEM, V269, P10444; Duriez PJ, 1997, BIOCHEM CELL BIOL, V75, P337, DOI 10.1139/bcb-75-4-337; Fabbro M, 2003, EXP CELL RES, V282, P59, DOI 10.1016/S0014-4827(02)00019-8; Fahrenkrog B, 2003, NAT REV MOL CELL BIO, V4, P757, DOI 10.1038/nrm1230; FISCHER U, 1995, CELL, V82, P475, DOI 10.1016/0092-8674(95)90436-0; Fornerod M, 1997, CELL, V90, P1051, DOI 10.1016/S0092-8674(00)80371-2; Fukuda M, 1997, NATURE, V390, P308, DOI 10.1038/36894; Fusaro G, 2002, ONCOGENE, V21, P4539, DOI 10.1038/sj.onc.1205551; Fusaro G, 2003, J BIOL CHEM, V278, P47853, DOI 10.1074/jbc.M305171200; Gamble SC, 2004, ONCOGENE, V23, P2996, DOI 10.1038/sj.onc.1207444; Gasiorowski JZ, 2003, ADV DRUG DELIVER REV, V55, P703, DOI 10.1016/S0169-409X(03)00048-6; Gorlich D, 1998, EMBO J, V17, P2721, DOI 10.1093/emboj/17.10.2721; Harbour JW, 2000, NAT CELL BIOL, V2, pE65, DOI 10.1038/35008695; Harel A, 2004, MOL CELL, V16, P319, DOI 10.1016/S1097-2765(04)00647-1; Henderson BR, 2000, EXP CELL RES, V256, P213, DOI 10.1006/excr.2000.4825; Hipfner DR, 2004, NAT REV MOL CELL BIO, V5, P805, DOI 10.1038/nrm1491; Joseph TW, 2003, FASEB J, V17, P1622, DOI 10.1096/fj.02-0931com; Joshi B, 2003, BIOCHEM BIOPH RES CO, V312, P459, DOI 10.1016/j.bbrc.2003.10.148; Jupe ER, 2001, LANCET, V357, P1588, DOI 10.1016/S0140-6736(00)04747-4; Jupe ER, 1996, CELL GROWTH DIFFER, V7, P871; Kau TR, 2004, NAT REV CANCER, V4, P106, DOI 10.1038/nrc1274; Koster M, 2003, EXP CELL RES, V286, P321, DOI 10.1016/S0014-4827(03)00100-9; Kurtev V, 2004, J BIOL CHEM, V279, P24834, DOI 10.1074/jbc.M312300200; Li CP, 2004, PHARM RES-DORDR, V21, P93, DOI 10.1023/B:PHAM.0000012166.44521.1f; Lohrum MAE, 2001, MOL CELL BIOL, V21, P8521, DOI 10.1128/MCB.21.24.8521-8532.2001; Magnaghi-Jaulin L, 1998, NATURE, V391, P601, DOI 10.1038/35410; Manjeshwar S, 2003, CANCER RES, V63, P5251; Marchenko ND, 2000, J BIOL CHEM, V275, P16202, DOI 10.1074/jbc.275.21.16202; Matsuyama S, 1997, J VET MED SCI, V59, P201, DOI 10.1292/jvms.59.201; MCCLUNG JK, 1995, EXP GERONTOL, V30, P99, DOI 10.1016/0531-5565(94)00069-7; Mihara M, 2003, MOL CELL, V11, P577, DOI 10.1016/S1097-2765(03)00050-9; Mundle SD, 2003, FASEB J, V17, P569, DOI 10.1096/fj.02-0431rev; Nijtmans LGJ, 2000, EMBO J, V19, P2444, DOI 10.1093/emboj/19.11.2444; Okada H, 2004, NAT REV CANCER, V4, P592, DOI 10.1038/nrc1412; Ossareh-Nazari B, 1999, EXP CELL RES, V252, P236, DOI 10.1006/excr.1999.4599; OssarehNazari B, 1997, SCIENCE, V278, P141, DOI 10.1126/science.278.5335.141; Park SE, 2005, MOL CELL BIOL, V25, P1989, DOI 10.1128/MCB.25.5.1989-1999.2005; Pemberton LF, 2005, TRAFFIC, V6, P187, DOI 10.1111/j.1600-0854.2005.00270.x; Robertson KD, 2000, NAT GENET, V25, P338, DOI 10.1038/77124; Santamaria E, 2003, P NATL ACAD SCI USA, V100, P3065, DOI 10.1073/pnas.0536625100; SATO T, 1992, CANCER RES, V52, P1643; Sebolt-Leopold JS, 2004, NAT REV CANCER, V4, P937, DOI 10.1038/nrc1503; Spurdle AB, 2002, LANCET, V360, P925, DOI 10.1016/S0140-6736(02)11043-9; Stevens C, 2003, ARCH BIOCHEM BIOPHYS, V412, P157, DOI 10.1016/S0003-9861(03)00054-7; Stutz F, 1998, GENE DEV, V12, P3303, DOI 10.1101/gad.12.21.3303; Sun LG, 2004, J CELL SCI, V117, P3021, DOI 10.1242/jcs.01142; Thompson WE, 2004, BIOL REPROD, V71, P282, DOI 10.1095/biolreprod.103.024125; Trouche D, 1997, P NATL ACAD SCI USA, V94, P11268, DOI 10.1073/pnas.94.21.11268; Vander Heiden MG, 2002, J BIOL CHEM, V277, P44870, DOI 10.1074/jbc.M204888200; Wang S, 2002, EMBO J, V21, P3019, DOI 10.1093/emboj/cdf302; Wang S, 1999, MOL CELL BIOL, V19, P7447; Wang S, 1999, ONCOGENE, V18, P3501, DOI 10.1038/sj.onc.1202684; Wang S, 2004, EMBO J, V23, P2293, DOI 10.1038/sj.emboj.7600231; Wang S, 2002, ONCOGENE, V21, P8388, DOI 10.1038/sj.onc.1205944; Weis K, 2002, CURR OPIN CELL BIOL, V14, P328, DOI 10.1016/S0955-0674(02)00337-X; Yamasaki Lili, 2003, Cancer Treat Res, V115, P209; Yashiroda Y, 2003, CURR MED CHEM, V10, P741, DOI 10.2174/0929867033457791; Yoneda Y, 1999, CELL STRUCT FUNCT, V24, P425, DOI 10.1247/csf.24.425; Zhang YP, 2001, SCIENCE, V292, P1910, DOI 10.1126/science.1058637	68	62	70	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 3	2006	281	5					2951	2959		10.1074/jbc.M508669200	http://dx.doi.org/10.1074/jbc.M508669200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	006XT	16319068	hybrid			2022-12-25	WOS:000234931800065
J	Sheehan, JH; Bunick, CG; Hu, HT; Fagan, PA; Meyn, SM; Chazin, WJ				Sheehan, JH; Bunick, CG; Hu, HT; Fagan, PA; Meyn, SM; Chazin, WJ			Structure of the N-terminal calcium sensor domain of centrin reveals the biochemical basis for domain-specific function	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SPINDLE POLE BODY; NUCLEOTIDE EXCISION-REPAIR; EF-HAND DOMAIN; YEAST CENTRIN; BINDING-SITES; CALMODULIN; DYNAMICS; CDC31P; KAR1P; NMR	Centrin is an essential component of microtubule-organizing centers in organisms ranging from algae and yeast to humans. It is an EF-hand calcium-binding protein with homology to calmodulin but distinct calcium binding properties. In a previously proposed model, the C-terminal domain of centrin serves as a constitutive anchor to target proteins, and the N-terminal domain serves as the sensor of calcium signals. The three-dimensional structure of the N-terminal domain of Chlamydomonas rheinhardtii centrin has been determined in the presence of calcium by solution NMR spectroscopy. The domain is found to occupy an open conformation typical of EF-hand calcium sensors. Comparison of the N- and C-terminal domains of centrin reveals a structural and biochemical basis for the domain specificity of interactions with its cellular targets and the distinct nature of centrin relative to other EF-hand proteins. An NMR titration of the centrin N-terminal domain with a fragment of the known centrin target Sfi1 reveals binding of the peptide to a discrete site on the protein, which supports the proposal that the N-terminal domain serves as a calcium sensor in centrin.	Vanderbilt Univ, Dept Biochem, Nashville, TN 37232 USA; Vanderbilt Univ, Dept Phys, Nashville, TN 37232 USA; Vanderbilt Univ, Ctr Struct Biol, Nashville, TN 37232 USA; Scripps Res Inst, Dept Mol Biol, La Jolla, CA 92307 USA	Vanderbilt University; Vanderbilt University; Vanderbilt University; Scripps Research Institute	Chazin, WJ (corresponding author), Vanderbilt Univ, Dept Biochem, 221 Kirkland Hall, Nashville, TN 37232 USA.	walter.chazin@vanderbilt.edu	Bunick, Christopher/AAD-3842-2021	Bunick, Christopher/0000-0002-4011-8308; Sheehan, Jonathan/0000-0002-9641-7577; Hu, Haitao/0000-0002-0312-1954; Meyn, Susan/0000-0002-0894-0721	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P30ES000267] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM040120, T32GM008320, R01GM065484] Funding Source: NIH RePORTER; NIEHS NIH HHS [P30 ES0000267] Funding Source: Medline; NIGMS NIH HHS [GM-65484, R01 GM-40120, T32 GM008320] Funding Source: Medline	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AKKE M, 1993, BIOCHEMISTRY-US, V32, P9832, DOI 10.1021/bi00088a039; Araki M, 2001, J BIOL CHEM, V276, P18665, DOI 10.1074/jbc.M100855200; BAUM P, 1986, P NATL ACAD SCI USA, V83, P5512, DOI 10.1073/pnas.83.15.5512; Bhattacharya S, 2004, BBA-MOL CELL RES, V1742, P69, DOI 10.1016/j.bbamcr.2004.09.002; BIGGINS S, 1994, J CELL BIOL, V125, P843, DOI 10.1083/jcb.125.4.843; Cavanagh J., 1996, PROTEIN NMR SPECTROS; Cornilescu G, 1999, J BIOMOL NMR, V13, P289, DOI 10.1023/A:1008392405740; Duggan BM, 2001, J BIOMOL NMR, V19, P321, DOI 10.1023/A:1011227824104; Durussel I, 2000, FEBS LETT, V472, P208, DOI 10.1016/S0014-5793(00)01452-6; Fischer T, 2004, NAT CELL BIOL, V6, P840, DOI 10.1038/ncb1163; Geier BM, 1996, J BIOL CHEM, V271, P28366, DOI 10.1074/jbc.271.45.28366; Guntert P, 1997, J MOL BIOL, V273, P283, DOI 10.1006/jmbi.1997.1284; Hoeflich KP, 2002, CELL, V108, P739, DOI 10.1016/S0092-8674(02)00682-7; Hu HT, 2004, J BIOL CHEM, V279, P50895, DOI 10.1074/jbc.M404233200; Hu HT, 2003, J MOL BIOL, V330, P473, DOI 10.1016/S0022-2836(03)00619-3; IKURA M, 1992, SCIENCE, V256, P632, DOI 10.1126/science.1585175; Ivanovska I, 2001, GENETICS, V157, P503; Jasperson SL, 2002, J CELL BIOL, V159, P945, DOI 10.1083/jcb.200208169; Kilmartin JV, 2003, J CELL BIOL, V162, P1211, DOI 10.1083/jcb.200307064; Koradi R, 1996, J MOL GRAPHICS, V14, P29; Laskowski RA, 1996, J BIOMOL NMR, V8, P477, DOI 10.1007/BF00228148; LINSE S, 1991, J BIOL CHEM, V266, P8050; Matei E, 2003, BIOCHEMISTRY-US, V42, P1439, DOI 10.1021/bi0269714; Molinier J, 2004, PLANT CELL, V16, P1633, DOI 10.1105/tpc.021378; Nelson MR, 2002, PROTEIN SCI, V11, P198, DOI 10.1110/ps.33302; NERI D, 1989, BIOCHEMISTRY-US, V28, P7510, DOI 10.1021/bi00445a003; ONEIL KT, 1990, TRENDS BIOCHEM SCI, V15, P59, DOI 10.1016/0968-0004(90)90177-D; Ortiz M, 2005, BIOCHEMISTRY-US, V44, P2409, DOI 10.1021/bi0484419; PEARLMAN DA, 1995, COMPUT PHYS COMMUN, V91, P1, DOI 10.1016/0010-4655(95)00041-D; Popescu A, 2003, J BIOL CHEM, V278, P40252, DOI 10.1074/jbc.M302546200; Salisbury JL, 2004, CURR BIOL, V14, pR27, DOI 10.1016/j.cub.2003.12.019; SALISBURY JL, 1995, CURR OPIN CELL BIOL, V7, P39; SANDERS MA, 1994, J CELL BIOL, V124, P795, DOI 10.1083/jcb.124.5.795; SCHIEBEL E, 1995, TRENDS CELL BIOL, V5, P197, DOI 10.1016/S0962-8924(00)88999-0; Schwede T, 2003, NUCLEIC ACIDS RES, V31, P3381, DOI 10.1093/nar/gkg520; SMITH JA, 1996, MAGN RESON CHEM, V34, P147; SPANG A, 1995, J CELL BIOL, V128, P863, DOI 10.1083/jcb.128.5.863; Sullivan DS, 1998, J CELL BIOL, V143, P751, DOI 10.1083/jcb.143.3.751; TAILLON BE, 1992, J CELL BIOL, V119, P1613, DOI 10.1083/jcb.119.6.1613; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; Tourbez M, 2004, J BIOL CHEM, V279, P47672, DOI 10.1074/jbc.M404996200; Veeraraghavan S, 2002, J BIOL CHEM, V277, P28564, DOI 10.1074/jbc.M112232200; WEBER C, 1994, J BIOL CHEM, V269, P15795; Yuan T, 1999, PROTEIN SCI, V8, P113	44	34	35	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 3	2006	281	5					2876	2881		10.1074/jbc.M509886200	http://dx.doi.org/10.1074/jbc.M509886200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	006XT	16317001	hybrid			2022-12-25	WOS:000234931800056
J	Wang, JD; He, H; Yu, LF; Xia, HHX; Lin, MCM; Gu, Q; Li, M; Zou, B; An, XM; Jiang, B; Kung, HF; Wong, BCY				Wang, JD; He, H; Yu, LF; Xia, HHX; Lin, MCM; Gu, Q; Li, M; Zou, B; An, XM; Jiang, B; Kung, HF; Wong, BCY			HSF1 down-regulates XAF1 through transcriptional regulation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEAT-SHOCK PROTEINS; XIAP-ASSOCIATED FACTOR-1; HYDROGEN-PEROXIDE; HYPOOSMOTIC STRESS; OXIDATIVE STRESS; REDOX REGULATION; CELL-DEATH; ACTIVATION; GENE; EXPRESSION	Studies have indicated the role of HSF1 (heat-shock transcription factor 1) in repressing the transcription of some nonheat shock genes. XAF1 (XIAP-associated factor 1) was an inhibitor of apoptosis-interacting protein with the effect of antagonizing the cytoprotective role of XIAP. XAF1 expression was lower in gastrointestinal cancers than in normal tissues with the mechanism unclear. Here we showed that gastrointestinal cancer tissues expressed higher levels of HSF1 than matched normal tissues. The expression of XAF1 and HSF1 was negatively correlated in gastrointestinal cancer cell lines. Stress stimuli, including heat, hypo-osmolarity, and H2O2, significantly suppressed the expression of XAF1, whereas the alteration of HSF1 expression negatively correlated with XAF1 expression. We cloned varying lengths of the 5'-flanking region of the XAF1 gene into luciferase reporter vectors, and we evaluated their promoter activities. A transcription silencer was found between the -592- and -1414-nucleotide region that was rich in nGAAn/nT-TCn elements (where n indicates G, A, T, or C). A high affinity and functional HSF1-binding element within the -862/-821-nucleotide region was determined by electrophoretic mobility shift assay and chromatin immunoprecipitation assay. Inactivation of this "heat-shock element" by either site-directed mutation or an HSF1 inhibitor, pifithrin-alpha, restored the promoter activity of the silencer structure. Moreover, pretreatment with antioxidants suppressed HSF1 binding activity and increased the transcriptional activity and expression of XAF1. These findings suggested that endogenous stress pressure in cancer cells sustained the high level expression of HSF1 and subsequently suppressed XAF1 expression, implicating the synergized effect of two anti-apoptotic protein families, HSP and inhibitors of apoptosis, in cytoprotection under stress circumstances.	Univ Hong Kong, Dept Med, Hong Kong, Hong Kong, Peoples R China; Univ Hong Kong, Inst Mol Biol, Hong Kong, Hong Kong, Peoples R China; So Med Univ, Nanfang Hosp, Inst Digest Med, Guangzhou, Peoples R China	University of Hong Kong; University of Hong Kong; Southern Medical University - China	Wong, BCY (corresponding author), Univ Hong Kong, Dept Med, Queen Mary Hosp, Hong Kong, Hong Kong, Peoples R China.	bcywong@hku.hk	li, ming/F-3495-2013; Wong, Benjamin Chun Yu/ABB-1962-2020; Wong, Benjamin Chun Yu/C-4436-2009	Li, Ming/0000-0002-2540-1738; He, Hua/0000-0002-7756-1039				Ahn SG, 2003, GENE DEV, V17, P516, DOI 10.1101/gad.1044503; Arnt CR, 2002, J BIOL CHEM, V277, P44236, DOI 10.1074/jbc.M207578200; Bittinger F, 1998, MELANOMA RES, V8, P381, DOI 10.1097/00008390-199810000-00001; BRUCE JL, 1993, CANCER RES, V53, P12; Byun DS, 2003, CANCER RES, V63, P7068; Cahill CM, 1996, J BIOL CHEM, V271, P24874; CARPER SW, 1987, CANCER RES, V47, P5249; Caruccio L, 1997, BIOCHEM J, V327, P341, DOI 10.1042/bj3270341; Cen H, 2004, WORLD J GASTROENTERO, V10, P3122; Feder ME, 1999, ANNU REV PHYSIOL, V61, P243, DOI 10.1146/annurev.physiol.61.1.243; Fong WG, 2000, GENOMICS, V70, P113, DOI 10.1006/geno.2000.6364; Fortugno P, 2003, P NATL ACAD SCI USA, V100, P13791, DOI 10.1073/pnas.2434345100; Franek WR, 2001, J BIOL CHEM, V276, P569, DOI 10.1074/jbc.M004716200; Garrido C, 2001, BIOCHEM BIOPH RES CO, V286, P433, DOI 10.1006/bbrc.2001.5427; Garrido C, 1998, CANCER RES, V58, P5495; Hatayama T, 1997, BIOL PHARM BULL, V20, P605; Hay BA, 2000, CELL DEATH DIFFER, V7, P1045, DOI 10.1038/sj.cdd.4400765; Hileman EO, 2004, CANCER CHEMOTH PHARM, V53, P209, DOI 10.1007/s00280-003-0726-5; HUANG LE, 1995, BIOCHEM J, V307, P347, DOI 10.1042/bj3070347; Kim DK, 2001, J CELL SCI, V114, P4329; Komarova EA, 2003, J BIOL CHEM, V278, P15465, DOI 10.1074/jbc.C300011200; KROEGER PE, 1994, MOL CELL BIOL, V14, P7592, DOI 10.1128/MCB.14.11.7592; Leaman DW, 2002, J BIOL CHEM, V277, P28504, DOI 10.1074/jbc.M204851200; Lee BR, 1999, EXP CELL RES, V248, P430, DOI 10.1006/excr.1999.4409; Liao Q, 2003, GASTROENTEROLOGY, V124, P1830, DOI 10.1016/S0016-5085(03)00398-6; Liston P, 2001, NAT CELL BIOL, V3, P128, DOI 10.1038/35055027; MIVECHI NF, 1995, J CELL BIOCHEM, V59, P266, DOI 10.1002/jcb.240590215; Munkholm P, 2003, ALIMENT PHARM THER, V18, P1, DOI 10.1046/j.1365-2036.18.s2.2.x; Muzio G, 1999, LIPIDS, V34, P705, DOI 10.1007/s11745-999-0416-2; Nishizawa J, 1999, CIRCULATION, V99, P934, DOI 10.1161/01.CIR.99.7.934; Ozaki M, 2000, J BIOL CHEM, V275, P35377, DOI 10.1074/jbc.M005287200; Pirkkala L, 2001, FASEB J, V15, P1118, DOI 10.1096/fj00-0294rev; Sarto C, 2000, ELECTROPHORESIS, V21, P1218, DOI 10.1002/(SICI)1522-2683(20000401)21:6<1218::AID-ELPS1218>3.3.CO;2-8; Singh IS, 2002, J BIOL CHEM, V277, P4981, DOI 10.1074/jbc.M108154200; Syagailo YV, 2002, GENE, V294, P259, DOI 10.1016/S0378-1119(02)00798-9; SZATROWSKI TP, 1991, CANCER RES, V51, P794; Tanaka T, 2004, ONCOGENE, V23, P3980, DOI 10.1038/sj.onc.1207555; Trautinger F, 1996, J PHOTOCH PHOTOBIO B, V35, P141, DOI 10.1016/S1011-1344(96)07344-7; Wang D, 1998, MUTAT RES-FUND MOL M, V400, P99, DOI 10.1016/S0027-5107(98)00066-9; WANG Y, 1994, NUCLEIC ACIDS RES, V22, P3113, DOI 10.1093/nar/22.15.3113; WEI H, 1992, MED HYPOTHESES, V39, P267, DOI 10.1016/0306-9877(92)90120-2; Wong BCY, 2004, GASTROENTEROLOGY, V126, P136, DOI 10.1053/j.gastro.2003.10.063; WU BJ, 1986, P NATL ACAD SCI USA, V83, P629, DOI 10.1073/pnas.83.3.629; Xie Y, 2003, J BIOL CHEM, V278, P4687, DOI 10.1074/jbc.M210189200	44	52	60	1	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 3	2006	281	5					2451	2459		10.1074/jbc.M505890200	http://dx.doi.org/10.1074/jbc.M505890200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	006XT	16303760	hybrid			2022-12-25	WOS:000234931800007
J	Bloquel, C; Bejjani, R; Bigey, P; Bedioui, F; Doat, M; BenEzra, D; Scherman, D; Behar-Cohen, F				Bloquel, C.; Bejjani, R.; Bigey, P.; Bedioui, F.; Doat, M.; BenEzra, D.; Scherman, D.; Behar-Cohen, F.			Plasmid electrotransfer of eye ciliary muscle: principles and therapeutic efficacy using hTNF-alpha soluble receptor in uveitis	FASEB JOURNAL			English	Article									[Bloquel, C.; Bigey, P.; Bedioui, F.; Scherman, D.] Univ Paris 05, INSERM,Ecole Normale Super Chem Paris, CNRS,Fac Sci Pharmaceut & Biol,U640, Chem & Genet Pharmacol Lab,UMR8151, F-75270 Paris, France; [Bejjani, R.; Doat, M.; BenEzra, D.; Behar-Cohen, F.] Univ Paris 05, INSERM, U598, F-75270 Paris, France; [BenEzra, D.] Hadassah Hebrew Univ Hosp, Jerusalem, Israel; [Behar-Cohen, F.] Rothschild Fdn, Lab Innovat Therapeut, Paris, France	Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Hebrew University of Jerusalem; Hadassah University Medical Center	Scherman, D (corresponding author), Univ Paris 05, INSERM,Ecole Normale Super Chem Paris, CNRS,Fac Sci Pharmaceut & Biol,U640, Chem & Genet Pharmacol Lab,UMR8151, 4 Ave Observ, F-75270 Paris, France.	daniel.scherman@univ-paris5.fr	Bedioui, Fethi/N-3507-2014	Bedioui, Fethi/0000-0002-0063-4412; Scherman, Daniel/0000-0003-1207-1298; bigey, pascal/0000-0002-6795-8569					0	45	52	0	2	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	FEB	2006	20	2					389	391		10.1096/fj.05-4737fje	http://dx.doi.org/10.1096/fj.05-4737fje			3	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	V17CJ	16352651				2022-12-25	WOS:000207915000031
J	Takenaka, K; Ogi, T; Okada, T; Sonoda, E; Guo, CX; Friedberg, EC; Takeda, S				Takenaka, K; Ogi, T; Okada, T; Sonoda, E; Guo, CX; Friedberg, EC; Takeda, S			Involvement of vertebrate Pol kappa in translesion DNA synthesis across DNA monoalkylation damage	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							THYMINE DIMER BYPASS; HUMAN DINB1 GENE; POLYMERASE-KAPPA; REV1 PROTEIN; POSTREPLICATION REPAIR; MAMMALIAN-CELLS; MULTIPLE ROLES; ETA; REPLICATION; FIDELITY	DNA lesions that escape excision repair pathways can cause arrested DNA replication. This replication block can be processed by translesion DNA synthesis (TLS), which is carried out by a number of specialized DNA polymerases. A sequential lesion bypass model has been proposed; one of the lesion-specific polymerases inserts nucleotide(s) opposite the damaged template, followed by extension from the inserted nucleotide by the same or another polymerase. Pol zeta and Pol kappa have been proposed as candidates for executing the extension step in eukaryotic cells. We previously disrupted separately Rev3, the catalytic subunit of Pol zeta, and Pol kappa in chicken B lymphocyte DT40 cells. We found that each cell line showed significant UV sensitivity, implying that both contribute to UV radiation damage repair. In the present studies we generated REV3 -/-POLK/- double knock-out cells to determine whether they participate in the same or different pathways. The double mutant was viable and proliferated with the same kinetics as parental REV3(-/-) cells. The cells showed the same sensitivity as REV3(-/-) cells to UV, ionizing radiation, and chemical cross-linking agents. In contrast, they were more sensitive than REV3(-/-) cells to monofunctional alkylating agents, even though POLK/- cells barely exhibited increased sensitivity to those. Moreover Polk-deficient mouse embryonic stem and fibroblast cells, both of which have previously been shown to be sensitive to UV radiation, also showed moderate sensitivity to methyl methanesulfonate, a monofunctional alkylating agent. These data imply that Pol kappa has a function in TLS past alkylated base adducts as well as UV radiation DNA damage in vertebrates.	Kyoto Univ, Grad Sch Med, Dept Radiat Genet, Kyoto 6068501, Japan; Kyoto Univ, Inst Virus Res, Kyoto 6068507, Japan; Univ Sussex, Genome Damage & Stabil Ctr, Brighton BN1 9RQ, E Sussex, England; Univ Texas, SW Med Ctr, Lab Mol Pathol, Dept Pathol, Dallas, TX 75390 USA	Kyoto University; Kyoto University; University of Sussex; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Takeda, S (corresponding author), Kyoto Univ, Grad Sch Med, Dept Radiat Genet, Kyoto 6068501, Japan.	stakeda@rg.med.kyoto-u.ac.jp		Takeda, Shunichi/0000-0002-7924-7991; Ogi, Tomoo/0000-0002-5492-9072	Medical Research Council [G0300662B] Funding Source: researchfish	Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission)		Bi XH, 2005, J BIOL CHEM, V280, P22343, DOI 10.1074/jbc.M501562200; Friedberg EC, 2002, SCIENCE, V296, P1627, DOI 10.1126/science.1070236; FRIEDBERG EC, 1995, DNA REPAIR MUTAGENES; Fujimori A, 2001, EMBO J, V20, P5513, DOI 10.1093/emboj/20.19.5513; Gerlach VL, 2001, J BIOL CHEM, V276, P92, DOI 10.1074/jbc.M004413200; Gibbs PEM, 2005, GENETICS, V169, P575, DOI 10.1534/genetics.104.034611; Guo CX, 2003, EMBO J, V22, P6621, DOI 10.1093/emboj/cdg626; Haracska L, 2002, P NATL ACAD SCI USA, V99, P16000, DOI 10.1073/pnas.252524999; Johnson RE, 2000, P NATL ACAD SCI USA, V97, P3838, DOI 10.1073/pnas.97.8.3838; Lawrence CW, 2002, DNA REPAIR, V1, P425, DOI 10.1016/S1568-7864(02)00038-1; Lehmann AR, 2002, MUTAT RES-FUND MOL M, V509, P23, DOI 10.1016/S0027-5107(02)00227-0; Lin WS, 1999, NUCLEIC ACIDS RES, V27, P4468, DOI 10.1093/nar/27.22.4468; Masutani C, 2000, EMBO J, V19, P3100, DOI 10.1093/emboj/19.12.3100; McCulloch SD, 2004, NATURE, V428, P97, DOI 10.1038/nature02352; Murakumo Y, 2001, J BIOL CHEM, V276, P35644, DOI 10.1074/jbc.M102051200; Nelson JR, 1996, SCIENCE, V272, P1646, DOI 10.1126/science.272.5268.1646; Ogi T, 2002, P NATL ACAD SCI USA, V99, P15548, DOI 10.1073/pnas.222377899; Ohashi E, 2000, GENE DEV, V14, P1589; Ohashi E, 2004, GENES CELLS, V9, P523, DOI 10.1111/j.1356-9597.2004.00747.x; Ohmori H, 2004, ADV PROTEIN CHEM, V69, P265; Okada T, 2005, MOL CELL BIOL, V25, P6103, DOI 10.1128/MCB.25.14.6103-6111.2005; Okada T, 2002, J BIOL CHEM, V277, P48690, DOI 10.1074/jbc.M207957200; Prakash S, 2002, GENE DEV, V16, P1872, DOI 10.1101/gad.1009802; Simpson LJ, 2003, EMBO J, V22, P1654, DOI 10.1093/emboj/cdg161; Sonoda E, 2003, EMBO J, V22, P3188, DOI 10.1093/emboj/cdg308; Suzuki N, 2001, BIOCHEMISTRY-US, V40, P15176, DOI 10.1021/bi010702g; Tissier A, 2004, DNA REPAIR, V3, P1503, DOI 10.1016/j.dnarep.2004.06.015; Washington MT, 2002, P NATL ACAD SCI USA, V99, P1910, DOI 10.1073/pnas.032594399; Zhang YB, 2000, NUCLEIC ACIDS RES, V28, P4138, DOI 10.1093/nar/28.21.4138; Zhang YB, 2000, NUCLEIC ACIDS RES, V28, P4147, DOI 10.1093/nar/28.21.4147	30	33	33	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 27	2006	281	4					2000	2004		10.1074/jbc.M506153200	http://dx.doi.org/10.1074/jbc.M506153200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	004NV	16308320	hybrid			2022-12-25	WOS:000234760400020
J	Campbell, MR; Wang, Y; Andrew, SE; Liu, Y				Campbell, MR; Wang, Y; Andrew, SE; Liu, Y			Msh2 deficiency leads to chromosomal abnormalities, centrosome amplification, and telomere capping defect	ONCOGENE			English	Article						mismatch repair; centrosome amplification; telomere capping; chromosomal abnormalities	DNA MISMATCH REPAIR; CANCER-CELLS; GENE; SUSCEPTIBILITY; PROLIFERATION; RECOMBINATION; ABERRATIONS; MUTATION; MOUSE; MICE	Msh2 is a key mammalian DNA mismatch repair (MMR) gene and mutations or deficiencies in mammalian Msh2 gene result in microsatellite instability (MSI+) and the development of cancer. Here, we report that primary mouse embryonic fibroblasts (MEFs) deficient in the murine MMR gene Msh2 (Msh2(-/-)) showed a significant increase in chromosome aneuploidy, centrosome amplification, and defective mitotic spindle organization and unequal chromosome segregation. Although Msh2(-/-) mouse tissues or primary MEFs had no apparent change in telomerase activity, telomere length, or recombination at telomeres, Msh2(-/-) MEFs showed an increase in chromosome end-to-end fusions or chromosome ends without detectable telomeric DNA. These data suggest that MSH2 helps to maintain genomic stability through the regulation of the centrosome and normal telomere capping in vivo and that defects in MMR can contribute to oncogenesis through multiple pathways.	Oak Ridge Natl Lab, Div Life Sci, Oak Ridge, TN 37831 USA; Univ Alberta, Dept Med Genet, Edmonton, AB, Canada	United States Department of Energy (DOE); Oak Ridge National Laboratory; University of Alberta	Liu, Y (corresponding author), Oak Ridge Natl Lab, Div Life Sci, Oak Ridge, TN 37831 USA.	liuy3@ornl.gov						Artandi SE, 2000, CURR OPIN GENET DEV, V10, P39, DOI 10.1016/S0959-437X(99)00047-7; Bailey SM, 2004, NUCLEIC ACIDS RES, V32, P3743, DOI 10.1093/nar/gkh691; Bechter OE, 2004, CANCER RES, V64, P3444, DOI 10.1158/0008-5472.CAN-04-0323; Bellacosa A, 2001, CELL DEATH DIFFER, V8, P1076, DOI 10.1038/sj.cdd.4400948; Buermeyer AB, 1999, ANNU REV GENET, V33, P533, DOI 10.1146/annurev.genet.33.1.533; DEWIND N, 1995, CELL, V82, P321, DOI 10.1016/0092-8674(95)90319-4; Doxsey S, 2005, TRENDS CELL BIOL, V15, P303, DOI 10.1016/j.tcb.2005.04.008; Edelmann W, 1997, CELL, V91, P467, DOI 10.1016/S0092-8674(00)80433-X; ELANGE T, 2002, ONCOGENE, V21, P532; Ghadimi BM, 2000, GENE CHROMOSOME CANC, V27, P183, DOI 10.1002/(SICI)1098-2264(200002)27:2<183::AID-GCC10>3.0.CO;2-P; Greider CW, 1998, P NATL ACAD SCI USA, V95, P90, DOI 10.1073/pnas.95.1.90; Kim NW, 1997, NUCLEIC ACIDS RES, V25, P2595, DOI 10.1093/nar/25.13.2595; Nigg EA, 2002, NAT REV CANCER, V2, P815, DOI 10.1038/nrc924; Pickett HA, 2004, ONCOGENE, V23, P3434, DOI 10.1038/sj.onc.1207477; Prolla TA, 1998, NAT GENET, V18, P276, DOI 10.1038/ng0398-276; REITMAIR AH, 1995, NAT GENET, V11, P64, DOI 10.1038/ng0995-64; Rizki A, 2001, NATURE, V411, P713, DOI 10.1038/35079641; Rufer N, 1998, NAT BIOTECHNOL, V16, P743, DOI 10.1038/nbt0898-743; Saunders W, 2005, SEMIN CANCER BIOL, V15, P25, DOI 10.1016/j.semcancer.2004.09.003; Zijlmans JMJM, 1997, P NATL ACAD SCI USA, V94, P7423, DOI 10.1073/pnas.94.14.7423	20	36	36	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR	2006	25	17					2531	2536		10.1038/sj.onc.1209277	http://dx.doi.org/10.1038/sj.onc.1209277			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	034RJ	16331258				2022-12-25	WOS:000236948000011
J	Larsen, E; Reite, K; Nesse, G; Gran, C; Seeberg, E; Klungland, A				Larsen, E; Reite, K; Nesse, G; Gran, C; Seeberg, E; Klungland, A			Repair and mutagenesis at oxidized DNA lesions in the developing brain of wild-type and Ogg1(-/-) mice	ONCOGENE			English	Article						OGG1; DNA damage; mouse; brain; mutagenesis; DNA repair	BASE EXCISION-REPAIR; MUTATIONAL SPECTRUM; MMH/OGG1 GENE; DAMAGE; HOGG1; OGG1; 8-HYDROXYGUANINE; CANCER; ENZYME; POLYMORPHISM	OGG1 (8-oxoguanine DNA glycosylase-1) is one of the main DNA glycosylases present in mammalian cells. The enzyme removes 7,8-dihydro-8-oxoguanine (8-oxoG) lesions, believed to be the most important oxidized lesions due to their relatively high incidence and their miscoding properties. This study shows that in prenatal mice brains the repair capacity for 8-oxoG is 5-10-fold higher than in adult mice brains. Western blot analysis and repair activity in extracts from Ogg1(-/-) mice revealed that OGG1 was responsible for the efficient 8-oxoG removal from prenatal mice. To investigate how OGG1 protects against oxidative stress-induced mutagenesis, pregnant Big Blue/wild-type and Big Blue/Ogg1(-/-) mice were exposed to nontoxic doses of gamma radiation. A 2.5-fold increase in the mutation frequency in Ogg1(-/-) mouse brains was obtained by exposure to 3.5 Gy at day 19 postfertilization. This was largely due to GC to TA transversions, believed to originate from 8-oxoG mispairing with A during replication. Furthermore, rapid cell divisions seemed to be required for fixation of mutations, as a similar dose of radiation did not increase the mutation frequency, or the frequency of GC to TA transversion, in the adult brain.	Univ Oslo, Natl Hosp, Ctr Mol Biol & Neurosci, N-0027 Oslo, Norway; Univ Oslo, Natl Hosp, Inst Med Microbiol, Oslo, Norway; Univ Oslo, Inst Basic Med Sci, Dept Nutr, Oslo, Norway	University of Oslo; National Hospital Norway; University of Oslo; National Hospital Norway; University of Oslo	Larsen, E (corresponding author), Univ Oslo, Natl Hosp, Ctr Mol Biol & Neurosci, N-0027 Oslo, Norway.	elisabeth.larsen@medisin.uio.no	Klungland, Arne/X-1233-2019	Klungland, Arne/0000-0001-7274-3661				Aburatani H, 1997, CANCER RES, V57, P2151; Achanta G, 2004, CANCER RES, V64, P6233, DOI 10.1158/0008-5472.CAN-04-0494; AMES BN, 1989, MUTAT RES, V214, P41, DOI 10.1016/0027-5107(89)90196-6; Andrew SE, 1997, ONCOGENE, V15, P123, DOI 10.1038/sj.onc.1201180; Andrew SE, 1998, P NATL ACAD SCI USA, V95, P1126, DOI 10.1073/pnas.95.3.1126; Arai T, 2003, CANCER RES, V63, P4287; Audebert M, 2000, CANCER RES, V60, P4740; Bjelland S, 2003, MUTAT RES-FUND MOL M, V531, P37, DOI 10.1016/j.mrfmmm.2003.07.002; Bjoras M, 1997, EMBO J, V16, P6314, DOI 10.1093/emboj/16.20.6314; Bohr VA, 2002, FREE RADICAL BIO MED, V32, P804, DOI 10.1016/S0891-5849(02)00787-6; BREEN AP, 1995, FREE RADICAL BIO MED, V18, P1033, DOI 10.1016/0891-5849(94)00209-3; Dianov GL, 2001, PROG NUCLEIC ACID RE, V68, P285; Dou H, 2003, J BIOL CHEM, V278, P49679, DOI 10.1074/jbc.M308658200; Elahi A, 2002, CARCINOGENESIS, V23, P1229, DOI 10.1093/carcin/23.7.1229; FRANKS LM, 1974, GERONTOLOGY, V20, P21, DOI 10.1159/000211994; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; Hyun JW, 2000, ONCOGENE, V19, P4476, DOI 10.1038/sj.onc.1203787; Ishida T, 1999, INT J CANCER, V80, P18; Karahalil B, 2002, FASEB J, V16, P1895, DOI 10.1096/fj.02-0463com; Kasai H, 1997, MUTAT RES-REV MUTAT, V387, P147, DOI 10.1016/S1383-5742(97)00035-5; KASAI H, 1984, NUCLEIC ACIDS RES, V12, P2137, DOI 10.1093/nar/12.4.2137; Klungland A, 1999, P NATL ACAD SCI USA, V96, P13300, DOI 10.1073/pnas.96.23.13300; Klungland A, 1997, EMBO J, V16, P3341, DOI 10.1093/emboj/16.11.3341; KOHLER SW, 1991, ENVIRON MOL MUTAGEN, V18, P316, DOI 10.1002/em.2850180421; Korr H, 1980, Adv Anat Embryol Cell Biol, V61, P1; Kubota Y, 1996, EMBO J, V15, P6662, DOI 10.1002/j.1460-2075.1996.tb01056.x; Kucherlapati M, 2002, P NATL ACAD SCI USA, V99, P9924, DOI 10.1073/pnas.152321699; Larsen E, 2003, MOL CELL BIOL, V23, P5346, DOI 10.1128/MCB.23.15.5346-5353.2003; Le Marchand L, 2002, CANCER EPIDEM BIOMAR, V11, P409; Lin LH, 2000, J NEUROCHEM, V74, P1098; Lipton L, 2003, CANCER RES, V63, P7595; Lovell MA, 2000, BRAIN RES, V855, P116, DOI 10.1016/S0006-8993(99)02335-5; Lovell MA, 1999, J NEUROCHEM, V72, P771, DOI 10.1046/j.1471-4159.1999.0720771.x; Ludwig DL, 1998, MUTAT RES-DNA REPAIR, V409, P17, DOI 10.1016/S0921-8777(98)00039-1; MICHAELS ML, 1992, P NATL ACAD SCI USA, V89, P7022, DOI 10.1073/pnas.89.15.7022; MICHAELS ML, 1992, J BACTERIOL, V174, P6321, DOI 10.1128/JB.174.20.6321-6325.1992; MICHAELS ML, 1991, NUCLEIC ACIDS RES, V19, P3629, DOI 10.1093/nar/19.13.3629; Minowa O, 2000, P NATL ACAD SCI USA, V97, P4156, DOI 10.1073/pnas.050404497; Morland I, 2002, NUCLEIC ACIDS RES, V30, P4926, DOI 10.1093/nar/gkf618; Nishino H, 1996, MUTAT RES-FUND MOL M, V372, P97, DOI 10.1016/S0027-5107(96)00172-8; Prolla TA, 1998, NAT GENET, V18, P276, DOI 10.1038/ng0398-276; Radicella JP, 1997, P NATL ACAD SCI USA, V94, P8010, DOI 10.1073/pnas.94.15.8010; RoldanArjona T, 1997, P NATL ACAD SCI USA, V94, P8016, DOI 10.1073/pnas.94.15.8016; Rosenquist TA, 2003, DNA REPAIR, V2, P581, DOI 10.1016/S1568-7864(03)00025-9; Sakumi K, 2003, CANCER RES, V63, P902; Shinmura K, 1998, JPN J CANCER RES, V89, P825, DOI 10.1111/j.1349-7006.1998.tb00635.x; Sieber OM, 2003, NEW ENGL J MED, V348, P791, DOI 10.1056/NEJMoa025283; Stuart GR, 2000, GENETICS, V154, P1291; Sugo N, 2000, EMBO J, V19, P1397, DOI 10.1093/emboj/19.6.1397; Tebbs RS, 1999, DEV BIOL, V208, P513, DOI 10.1006/dbio.1999.9232; VERJAT T, 2000, MUTAT RES, V25, P127; Wikman H, 2000, INT J CANCER, V88, P932, DOI 10.1002/1097-0215(20001215)88:6<932::AID-IJC15>3.0.CO;2-P; Xie YL, 2004, CANCER RES, V64, P3096, DOI 10.1158/0008-5472.CAN-03-3834	53	43	43	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR	2006	25	17					2425	2432		10.1038/sj.onc.1209284	http://dx.doi.org/10.1038/sj.onc.1209284			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	034RJ	16369492				2022-12-25	WOS:000236948000001
J	Soyombo, AA; Tjon-Kon-Sang, S; Rbaibi, Y; Bashllari, E; Bisceglia, J; Muallem, S; Kiselyov, K				Soyombo, AA; Tjon-Kon-Sang, S; Rbaibi, Y; Bashllari, E; Bisceglia, J; Muallem, S; Kiselyov, K			TRP-ML1 regulates lysosomal pH and acidic lysosomal lipid hydrolytic activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MUCOLIPIDOSIS TYPE-IV; ABNORMAL TRANSPORT; IDENTIFICATION; PROTEIN; CELLS; PHOSPHOLIPIDS; ACCUMULATION; COMPARTMENT; CURRENTS; CALCIUM	Mucolipidosis type IV (MLIV) is caused by mutations in the ion channel mucolipin 1 (TRP-ML1). MLIV is typified by accumulation of lipids and membranous materials in intracellular organelles, which was hypothesized to be caused by the altered membrane fusion and fission events. How mutations in TRP-ML1 lead to aberrant lipolysis is not known. Here we present evidence that MLIV is a metabolic disorder that is not associated with aberrant membrane fusion/ fission events. Thus, measurement of lysosomal pH revealed that the lysosomes in TRP-ML1(-/-) cells obtained from the patients with MLIV are over-acidified. TRP-ML1 can function as a H+ channel, and the increased lysosomal acidification in TRP-ML1(-/-) cells is likely caused by the loss of TRP-ML1-mediated H+ leak. Measurement of lipase activity using several substrates revealed a marked reduction in lipid hydrolysis in TRP-ML1(-/-) cells, which was rescued by the expression of TRP-ML1. Cell fractionation indicated specific loss of acidic lipase activity in TRP-ML1(-/-) cells. Furthermore, dissipation of the acidic lysosomal pH of TRP-ML1(-/-) cells by nigericin or chloroquine reversed the lysosomal storage disease phenotype. These findings provide a new mechanism to account for the pathogenesis of MLIV.	Univ Texas, SW Med Ctr, Dept Physiol, Dallas, TX 75390 USA; Univ Pittsburgh, Dept Biol Sci, Pittsburgh, PA 15260 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Muallem, S (corresponding author), Univ Texas, SW Med Ctr, Dept Physiol, 5323 Harry Hines Blvd, Dallas, TX 75390 USA.	shmuel.muallem@utsouthwestern.edu	Dembowski, Jill/Y-2500-2019	Dembowski, Jill/0000-0002-0309-8053; Kiselyov, Kirill/0000-0001-6683-2895; Soyombo, Abigail/0000-0003-0850-2593	NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [R01DE012309] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK038938] Funding Source: NIH RePORTER; NIDCR NIH HHS [DE 12309] Funding Source: Medline; NIDDK NIH HHS [DK 38938] Funding Source: Medline	NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BACH G, 1979, BIOCHEM BIOPH RES CO, V90, P1341, DOI 10.1016/0006-291X(79)91183-5; Bach G, 1999, CLIN CHIM ACTA, V280, P173, DOI 10.1016/S0009-8981(98)00183-1; Bach G, 2001, MOL GENET METAB, V73, P197, DOI 10.1006/mgme.2001.3195; Bach G, 2005, PFLUG ARCH EUR J PHY, V451, P313, DOI 10.1007/s00424-004-1361-7; BACH G, 1988, ENZYME, V40, P40, DOI 10.1159/000469140; Bargal R, 1997, J INHERIT METAB DIS, V20, P625, DOI 10.1023/A:1005362123443; BARGAL R, 1989, CLIN CHIM ACTA, V181, P167, DOI 10.1016/0009-8981(89)90184-8; Bassi MT, 2000, AM J HUM GENET, V67, P1110, DOI 10.1016/S0002-9297(07)62941-3; BERGE RK, 1979, EUR J BIOCHEM, V96, P393, DOI 10.1111/j.1432-1033.1979.tb13051.x; BURTON BK, 1980, CLIN CHIM ACTA, V101, P25, DOI 10.1016/0009-8981(80)90052-2; Chen CS, 1998, P NATL ACAD SCI USA, V95, P6373, DOI 10.1073/pnas.95.11.6373; DeCoursey TE, 1996, BIOPHYS J, V71, P182, DOI 10.1016/S0006-3495(96)79215-9; DECOURSEY TE, 1991, BIOPHYS J, V60, P1243, DOI 10.1016/S0006-3495(91)82158-0; DeCoursey TE, 1998, FRONT BIOSCI, V3, P477; Duncan JA, 1996, J BIOL CHEM, V271, P23594, DOI 10.1074/jbc.271.38.23594; Fares H, 2001, NAT GENET, V28, P64, DOI 10.1038/ng0501-64; Goldin E, 1999, P NATL ACAD SCI USA, V96, P8562, DOI 10.1073/pnas.96.15.8562; Haller T, 1996, CELL CALCIUM, V19, P157, DOI 10.1016/S0143-4160(96)90084-6; Kim J J, 2001, Results Probl Cell Differ, V33, P39; Kiselyov K, 2005, J BIOL CHEM, V280, P43218, DOI 10.1074/jbc.M508210200; LAKE JR, 1987, GASTROENTEROLOGY, V92, P1251, DOI 10.1016/S0016-5085(87)91085-7; LaPlante JM, 2002, FEBS LETT, V532, P183, DOI 10.1016/S0014-5793(02)03670-0; LaPlante JM, 2004, BIOCHEM BIOPH RES CO, V322, P1384, DOI 10.1016/j.bbrc.2004.08.045; Luzio JP, 2005, BIOCHEM SOC SYMP, V72, P77, DOI 10.1042/bss0720077; Luzio JP, 2003, MOL MEMBR BIOL, V20, P141, DOI 10.1080/0968768031000089546; Manzoni M, 2004, FEBS LETT, V567, P219, DOI 10.1016/j.febslet.2004.04.080; Morgan D, 2003, FRONT BIOSCI, V8, pS1266, DOI 10.2741/1191; Mullins C, 2001, BIOESSAYS, V23, P333, DOI 10.1002/bies.1048; Ostrowska H, 2003, CELL MOL BIOL LETT, V8, P19; Pillay CS, 2002, BIOCHEM J, V363, P417, DOI 10.1042/0264-6021:3630417; Piper RC, 2004, TRENDS CELL BIOL, V14, P471, DOI 10.1016/j.tcb.2004.07.010; Pshezhetsky AV, 2001, PROG NUCLEIC ACID RE, V69, P81, DOI 10.1016/S0079-6603(01)69045-7; Raychowdhury MK, 2004, HUM MOL GENET, V13, P617, DOI 10.1093/hmg/ddh067; Slaugenhaupt Susan A., 2002, Current Molecular Medicine (Hilversum), V2, P445, DOI 10.2174/1566524023362276; Srinivas SP, 2002, INVEST OPHTH VIS SCI, V43, P2341; Treusch S, 2004, P NATL ACAD SCI USA, V101, P4483, DOI 10.1073/pnas.0400709101; Tzagoloff A, 2004, J BIOL CHEM, V279, P19775, DOI 10.1074/jbc.M401506200; Yuan JP, 2003, CELL, V114, P777, DOI 10.1016/S0092-8674(03)00716-5; ZEIGLER M, 1992, PRENATAL DIAG, V12, P1037, DOI 10.1002/pd.1970121209	39	174	178	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 17	2006	281	11					7294	7301		10.1074/jbc.M508211200	http://dx.doi.org/10.1074/jbc.M508211200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	022BY	16361256	hybrid			2022-12-25	WOS:000236030900047
J	Liu, JY; Timm, DE; Hurley, TD				Liu, JY; Timm, DE; Hurley, TD			Pyrithiamine as a substrate for thiamine pyrophosphokinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CRYSTAL-STRUCTURE; RAT-TISSUES; TRIPHOSPHATE; METABOLISM; ANTAGONISTS; DEFICIENCY; BRAIN	Thiamine pyrophosphokinase transfers a pyrophosphate group from a nucleoside triphosphate, such as ATP, to the hydroxyl group of thiamine to produce thiamine pyrophosphate. Deficiencies in thiamine can result in the development of the neurological disorder Wernicke-Korsakoff Syndrome as well as the potentially fatal cardiovascular disease wet beriberi. Pyrithiamine is an inhibitor of thiamine metabolism that induces neurological symptoms similar to that of Wernicke-Korsakoff Syndrome in animals. However, the mechanism by which pyrithiamine interferes with cellular thiamine phosphoester homeostasis is not entirely clear. We used kinetic assays coupled with mass spectrometry of the reaction products and x-ray crystallography of an equilibrium reaction mixture of thiamine pyrophosphokinase, pyrithiamine, and Mg2+/ATP to elucidate the mechanism by which pyrithiamine inhibits the enzymatic production of thiamine pyrophosphate. Three lines of evidence support the ability of thiamine pyrophosphokinase to form pyrithiamine pyrophosphate. First, a coupled enzyme assay clearly demonstrated the ability of thiamine pyrophosphokinase to produce AMP when pyrithiamine was used as substrate. Second, an analysis of the reaction mixture by mass spectrometry directly identified pyrithiamine pyrophosphate in the reaction mixture. Last, the structure of thiamine pyrophosphokinase crystallized from an equilibrium substrate/product mixture shows clear electron density for pyrithiamine pyrophosphate bound in the enzyme active site. This structure also provides the first clear picture of the binding pocket for the nucleoside triphosphate and permits the first detailed understanding of the catalytic requirements for catalysis in this enzyme.	Indiana Univ, Sch Med, Dept Biochem & Mol Biol, Indianapolis, IN 46202 USA; Eli Lilly & Co, Indianapolis, IN 46285 USA	Indiana University System; Indiana University-Purdue University Indianapolis; Eli Lilly	Hurley, TD (corresponding author), Indiana Univ, Sch Med, Dept Biochem & Mol Biol, 635 Barnhill Dr, Indianapolis, IN 46202 USA.	thurley@iupui.edu		HURLEY, THOMAS/0000-0002-5942-1163				Bergmeyer H.U., 1974, METHODS ENZYMATIC AN, P2127; BETTENDORFF L, 1993, J NEUROCHEM, V60, P423, DOI 10.1111/j.1471-4159.1993.tb03168.x; Blaszczyk J, 2000, STRUCTURE, V8, P1049, DOI 10.1016/S0969-2126(00)00502-5; Brunger AT, 1997, NAT STRUCT BIOL, V4, P862; D'Amour ML, 2000, ADDICT BIOL, V5, P71, DOI 10.1080/13556210071298; Gasteiger J., 1990, TETRAHEDRON COMPUT M, V3, P537, DOI DOI 10.1016/0898-5529(90)90156-3; GUBLER CJ, 1982, J NUTR SCI VITAMINOL, V28, P217, DOI 10.3177/jnsv.28.217; GUBLER CJ, 1961, J BIOL CHEM, V236, P3112; Hennig M, 1999, J MOL BIOL, V287, P211, DOI 10.1006/jmbi.1999.2623; Homewood J, 1999, ALCOHOL, V19, P75, DOI 10.1016/S0741-8329(99)00027-0; IWASHIMA A, 1976, J BIOCHEM-TOKYO, V79, P845, DOI 10.1093/oxfordjournals.jbchem.a131138; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Lakaye B, 2004, J BIOL CHEM, V279, P17142, DOI 10.1074/jbc.M313569200; Lakaye B, 2002, J BIOL CHEM, V277, P13771, DOI 10.1074/jbc.M111241200; LIU JY, 2002, THIAMINE CATALYTIC M, P29; MACHLIN LJ, 1991, HDB VITAMINS, P233; Makarchikov AF, 2003, CELL MOL LIFE SCI, V60, P1477, DOI 10.1007/s00018-003-3098-4; Nghiem HO, 2000, FASEB J, V14, P543, DOI 10.1096/fasebj.14.3.543; NOSAKA K, 1993, J BIOL CHEM, V268, P17440; NOSAKA K, 1989, FEMS MICROBIOL LETT, V51, P55; Onozuka M, 2003, J NUTR SCI VITAMINOL, V49, P156, DOI 10.3177/jnsv.49.156; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; PLETCHER J, 1972, J AM CHEM SOC, V94, P3998, DOI 10.1021/ja00766a058; Rindi G, 2003, METAB BRAIN DIS, V18, P245, DOI 10.1023/B:MEBR.0000020187.98238.58; RINDI G, 1963, J NUTR, V81, P47; SADOWSKI J, 1992, ANAL CHIM ACTA, V265, P233, DOI 10.1016/0003-2670(92)85029-6; Schellenberger A, 1998, BBA-PROTEIN STRUCT M, V1385, P177, DOI 10.1016/S0167-4838(98)00067-3; SHIKATA H, 1989, BIOCHEM INT, V18, P943; Timm DE, 2001, J MOL BIOL, V310, P195, DOI 10.1006/jmbi.2001.4727; VOSKOBOYEV AI, 1982, ANN NY ACAD SCI, V378, P161, DOI 10.1111/j.1749-6632.1982.tb31195.x; 1994, ACTA CRYSTALLOGR D, V50, P60	31	38	41	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 10	2006	281	10					6601	6607		10.1074/jbc.M510951200	http://dx.doi.org/10.1074/jbc.M510951200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	022BX	16365036	hybrid			2022-12-25	WOS:000236030800056
J	Britschgi, C; Rizzi, M; Grob, TJ; Tschan, MP; Hugli, B; Reddy, VA; Andres, AC; Torbett, BE; Tobler, A; Fey, MF				Britschgi, C; Rizzi, M; Grob, TJ; Tschan, MP; Hugli, B; Reddy, VA; Andres, AC; Torbett, BE; Tobler, A; Fey, MF			Identification of the p53 family-responsive element in the promoter region of the tumor suppressor gene hypermethylated in cancer 1	ONCOGENE			English	Article						HIC1; p53; transcriptional target; HIC1.PRE; p73	HUMAN BREAST-CANCER; DNA-BINDING; COLORECTAL-CANCER; HIC-1; P73; EXPRESSION; CELLS; SITE; PCR; TUMORIGENESIS	The tumor suppressor gene hypermethylated in cancer 1 (HIC1), located on human chromosome 17p13.3, is frequently silenced in cancer by epigenetic mechanisms. Hypermethylated in cancer 1 belongs to the bric a brac/ poxviruses and zinc-finger family of transcription factors and acts by repressing target gene expression. It has been shown that enforced p53 expression leads to increased HIC1 mRNA, and recent data suggest that p53 and Hic1 cooperate in tumorigenesis. In order to elucidate the regulation of HIC1 expression, we have analysed the HIC1 promoter region for p53-dependent induction of gene expression. Using progressively truncated luciferase reporter gene constructs, we have identified a p53-responsive element (PRE) 500 bp upstream of the TATA-box containing promoter P0 of HIC1, which is sequence specifically bound by p53 in vitro as assessed by electrophoretic mobility shift assays. We demonstrate that this HIC1 p53-responsive element ( HIC1. PRE) is necessary and sufficient to mediate induction of transcription by p53. This result is supported by the observation that abolishing endogenous wild-type p53 function prevents HIC1 mRNA induction in response to UV-induced DNA damage. Other members of the p53 family, notably TAp73 beta and Delta Np63 alpha, can also act through this HIC1. PRE to induce transcription of HIC1, and finally, hypermethylation of the HIC1 promoter attenuates inducibility by p53.	Inselspital Bern, CH-3010 Bern, Switzerland; Univ Bern, Dept Clin Res, Bern, Switzerland; Scripps Res Inst, Dept Mol & Expt Med, La Jolla, CA USA; Univ Bern, Dept Clin Res, Tiefenau Labs, Bern, Switzerland	University of Bern; Scripps Research Institute; University of Bern	Fey, MF (corresponding author), Inselspital Bern, CH-3010 Bern, Switzerland.	martin.fey@insel.ch	Rizzi, Mattia/ABE-3996-2021; Rizzi, Mattia/AHE-4168-2022	Rizzi, Mattia/0000-0001-6987-0678; Grob, Tobias/0000-0002-6298-9796; Tschan, Mario P./0000-0001-5897-3647; Britschgi, Christian/0000-0001-8831-1564	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI049165] Funding Source: NIH RePORTER; NIAID NIH HHS [AI49165] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Ahuja N, 1997, CANCER RES, V57, P3370; Arnold CN, 2003, INT J CANCER, V106, P66, DOI 10.1002/ijc.11176; Bahia H, 2002, INT J ONCOL, V20, P489; Beillard E, 2003, LEUKEMIA, V17, P2474, DOI 10.1038/sj.leu.2403136; Benard J, 2003, HUM MUTAT, V21, P182, DOI 10.1002/humu.10172; Bunz F, 1998, SCIENCE, V282, P1497, DOI 10.1126/science.282.5393.1497; CHEN W, 2005, P AM ASSOC CANC RES, V46, P114; Chen WY, 2003, NAT GENET, V33, P197, DOI 10.1038/ng1077; Chen WY, 2004, CANCER CELL, V6, P387, DOI 10.1016/j.ccr.2004.08.030; de Almodovar CR, 2004, J BIOL CHEM, V279, P4093, DOI 10.1074/jbc.M311243200; Deltour S, 1999, P NATL ACAD SCI USA, V96, P14831, DOI 10.1073/pnas.96.26.14831; Di Como CJ, 1999, MOL CELL BIOL, V19, P1438; ELDEIRY WS, 1992, NAT GENET, V1, P45, DOI 10.1038/ng0492-45; Fontemaggi G, 2002, J BIOL CHEM, V277, P43359, DOI 10.1074/jbc.M205573200; Fujii H, 1998, ONCOGENE, V16, P2159, DOI 10.1038/sj.onc.1201976; Galimi F, 2002, BLOOD, V100, P2732, DOI 10.1182/blood-2002-04-1245; Grob TJ, 2001, CELL DEATH DIFFER, V8, P1213, DOI 10.1038/sj.cdd.4400962; Guerardel C, 2001, J BIOL CHEM, V276, P3078, DOI 10.1074/jbc.M008690200; Issa JPJ, 1997, CANCER RES, V57, P1678; Jones PA, 2002, NAT REV GENET, V3, P415, DOI 10.1038/nrg816; Liu G, 2004, MOL CELL BIOL, V24, P487, DOI 10.1128/MCB.24.2.487-501.2004; Liu XG, 2004, CANCER RES, V64, P5078, DOI 10.1158/0008-5472.CAN-04-1195; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; Luo JY, 2001, CELL, V107, P137, DOI 10.1016/S0092-8674(01)00524-4; MARCHUK D, 1991, NUCLEIC ACIDS RES, V19, P1154, DOI 10.1093/nar/19.5.1154; Marin MC, 1998, MOL CELL BIOL, V18, P6316, DOI 10.1128/MCB.18.11.6316; Melino G, 2002, NAT REV CANCER, V2, P605, DOI 10.1038/nrc861; Moll UM, 2004, MOL CANCER RES, V2, P371; Nakano K, 2001, MOL CELL, V7, P683, DOI 10.1016/S1097-2765(01)00214-3; Nemoto S, 2004, SCIENCE, V306, P2105, DOI 10.1126/science.1101731; Nicoll G, 2001, BRIT J CANCER, V85, P1878, DOI 10.1054/bjoc.2001.2163; Obad S, 2004, ONCOGENE, V23, P4050, DOI 10.1038/sj.onc.1207524; Pinte S, 2004, J BIOL CHEM, V279, P38313, DOI 10.1074/jbc.M401610200; Pinte S, 2004, ONCOGENE, V23, P4023, DOI 10.1038/sj.onc.1207504; Qian H, 2002, ONCOGENE, V21, P7901, DOI 10.1038/sj.onc.1205974; Sun PQ, 1998, SCIENCE, V282, P2270, DOI 10.1126/science.282.5397.2270; Tschan MP, 2003, J BIOL CHEM, V278, P42750, DOI 10.1074/jbc.M307067200; Vaziri H, 2001, CELL, V107, P149, DOI 10.1016/S0092-8674(01)00527-X; Voorhoeve PM, 2003, CANCER CELL, V4, P311, DOI 10.1016/S1535-6108(03)00223-X; WALES MM, 1995, NAT MED, V1, P570, DOI 10.1038/nm0695-570; Wolcke J, 2003, J BIOL CHEM, V278, P32587, DOI 10.1074/jbc.M303615200; Wu GJ, 2005, CANCER RES, V65, P758	42	44	45	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR	2006	25	14					2030	2039		10.1038/sj.onc.1209240	http://dx.doi.org/10.1038/sj.onc.1209240			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	026RL	16301995				2022-12-25	WOS:000236359700006
J	Baum, J; Richard, D; Healer, J; Rug, M; Krnajski, Z; Gilberger, TW; Green, JL; Holder, AA; Cowman, AF				Baum, J; Richard, D; Healer, J; Rug, M; Krnajski, Z; Gilberger, TW; Green, JL; Holder, AA; Cowman, AF			A conserved molecular motor drives cell invasion and gliding motility across malaria life cycle stages and other apicomplexan parasites	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLASMODIUM-FALCIPARUM MEROZOITES; TOXOPLASMA-GONDII; ANONYMOUS PROTEIN; DIVERSIFYING SELECTION; CRYPTOSPORIDIUM-PARVUM; ERYTHROCYTE INVASION; GENOME SEQUENCE; THEILERIA-PARVA; HOST-CELLS; MYOSIN-A	Apicomplexan parasites constitute one of the most significant groups of pathogens infecting humans and animals. The liver stage sporozoites of Plasmodium spp. and tachyzoites of Toxoplasma gondii, the causative agents of malaria and toxoplasmosis, respectively, use a unique mode of locomotion termed gliding motility to invade host cells and cross cell substrates. This amoeboid-like movement uses a parasite adhesin from the thrombospondin-related anonymous protein (TRAP) family and a set of proteins linking the extracellular adhesin, via an actin-myosin motor, to the inner membrane complex. The Plasmodium blood stage merozoite, however, does not exhibit gliding motility. Here we show that homologues of the key proteins that make up the motor complex, including the recently identified glideosome-associated proteins 45 and 50 (GAP40 and GAP50), are present in P. falciparum merozoites and appear to function in erythrocyte invasion. Furthermore, we identify a merozoite TRAP homologue, termed MTRAP, a micronemal protein that shares key features with TRAP, including a thrombospondin repeat domain, a putative rhomboid-protease cleavage site, and a cytoplasmic tail that, in vitro, binds the actin-binding protein aldolase. Analysis of other parasite genomes shows that the components of this motor complex are conserved across diverse Apicomplexan genera. Conservation of the motor complex suggests that a common molecular mechanism underlies all Apicomplexan motility, which, given its unique properties, highlights a number of novel targets for drug intervention to treat major diseases of humans and livestock.	Walter & Eliza Hall Inst Med Res, Div Infect & Immun, Parkville, Vic 3050, Australia; Bernhard Nocht Inst Trop Med, D-20359 Hamburg, Germany; Natl Inst Med Res, London NW7 1AA, England	Walter & Eliza Hall Institute; Bernhard Nocht Institut fur Tropenmedizin; MRC National Institute for Medical Research	Cowman, AF (corresponding author), Walter & Eliza Hall Inst Med Res, Div Infect & Immun, Parkville, Vic 3050, Australia.	cowman@wehi.edu.au	Rug, Melanie/A-9504-2011; Holder, Anthony A/A-7554-2013; Rug, Melanie/B-5417-2015; Cowman, Alan F/C-7642-2013	Holder, Anthony A/0000-0002-8490-6058; Cowman, Alan F/0000-0001-5145-9004; Baum, Jake/0000-0002-0275-352X; Green, Judith/0000-0001-6825-9404; Gilberger, Tim-Wolf/0000-0002-7965-8272	Medical Research Council [MC_U117532067] Funding Source: Medline; Wellcome Trust Funding Source: Medline; MRC [MC_U117532067] Funding Source: UKRI	Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Wellcome Trust(Wellcome Trust); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))		Abrahamsen MS, 2004, SCIENCE, V304, P441, DOI 10.1126/science.1094786; Adams JH, 2001, TRENDS PARASITOL, V17, P297, DOI 10.1016/S1471-4922(01)01948-1; Alexander DL, 2005, PLOS PATHOG, V1, P137, DOI 10.1371/journal.ppat.0010017; Baldi DL, 2000, EMBO J, V19, P2435, DOI 10.1093/emboj/19.11.2435; Baldi DL, 2002, INFECT IMMUN, V70, P5236, DOI 10.1128/IAI.70.9.5236-5245.2002; Baum J, 2003, GENETICS, V163, P1327; Bergman LW, 2003, J CELL SCI, V116, P39, DOI 10.1242/jcs.00194; Bozdech Z, 2003, PLOS BIOL, V1, P85, DOI 10.1371/journal.pbio.0000005; Brossier F, 2005, INT J BIOCHEM CELL B, V37, P2266, DOI 10.1016/j.biocel.2005.06.006; Brossier F, 2005, P NATL ACAD SCI USA, V102, P4146, DOI 10.1073/pnas.0407918102; Buscaglia CA, 2003, MOL BIOL CELL, V14, P4947, DOI 10.1091/mbc.E03-06-0355; Carreno RA, 1999, PARASITOL RES, V85, P899, DOI 10.1007/s004360050655; Carruthers VB, 1997, EUR J CELL BIOL, V73, P114; Chattopadhyay R, 2003, J BIOL CHEM, V278, P25977, DOI 10.1074/jbc.M300865200; Dowse TJ, 2005, INT J PARASITOL, V35, P747, DOI 10.1016/j.ijpara.2005.04.001; Duraisingh MT, 2003, EMBO J, V22, P1047, DOI 10.1093/emboj/cdg096; Duraisingh MT, 2002, INT J PARASITOL, V32, P81, DOI 10.1016/S0020-7519(01)00345-9; FIELD SJ, 1993, CELL MOTIL CYTOSKEL, V25, P43, DOI 10.1002/cm.970250106; Gantt S, 2000, INFECT IMMUN, V68, P3667, DOI 10.1128/IAI.68.6.3667-3673.2000; Gardner MJ, 2002, NATURE, V419, P498, DOI 10.1038/nature01097; Gaskins E, 2004, J CELL BIOL, V165, P383, DOI 10.1083/jcb.200311137; Gilberger TW, 2003, J CELL BIOL, V162, P317, DOI 10.1083/jcb.200301046; Healer J, 2002, INFECT IMMUN, V70, P5751, DOI 10.1128/IAI.70.10.5751-5758.2002; Herm-Gotz A, 2002, EMBO J, V21, P2149, DOI 10.1093/emboj/21.9.2149; Hettmann C, 2000, MOL BIOL CELL, V11, P1385, DOI 10.1091/mbc.11.4.1385; Huynh MH, 2004, CELL MICROBIOL, V6, P771, DOI 10.1111/j.1462-5822.2004.00403.x; Huynh MH, 2003, EMBO J, V22, P2082, DOI 10.1093/emboj/cdg217; Jewett TJ, 2003, MOL CELL, V11, P885, DOI 10.1016/S1097-2765(03)00113-8; Kappe S, 1999, J CELL BIOL, V147, P937, DOI 10.1083/jcb.147.5.937; LAMBROS C, 1979, J PARASITOL, V65, P418, DOI 10.2307/3280287; Lebrun M, 2005, CELL MICROBIOL, V7, P1823, DOI 10.1111/j.1462-5822.2005.00646.x; Lew AE, 2002, CELL MOTIL CYTOSKEL, V52, P202, DOI 10.1002/cm.10046; Margos G, 2004, PARASITOLOGY, V129, P273, DOI 10.1017/S0031182004005657; MCDONALD JH, 1991, NATURE, V351, P652, DOI 10.1038/351652a0; Menard R, 1997, NATURE, V385, P336, DOI 10.1038/385336a0; Menard R, 2001, CELL MICROBIOL, V3, P63, DOI 10.1046/j.1462-5822.2001.00097.x; Morrissette NS, 2002, MICROBIOL MOL BIOL R, V66, P21, DOI 10.1128/MMBR.66.1.21-38.2002; MULLER HM, 1993, EMBO J, V12, P2881, DOI 10.1002/j.1460-2075.1993.tb05950.x; NARUM DL, 1994, MOL BIOCHEM PARASIT, V67, P59, DOI 10.1016/0166-6851(94)90096-5; Opitz C, 2002, EMBO J, V21, P1577, DOI 10.1093/emboj/21.7.1577; Pain A, 2005, SCIENCE, V309, P131, DOI 10.1126/science.1110418; Pinder JC, 1998, J CELL SCI, V111, P1831; Polley SD, 2001, GENETICS, V158, P1505; Rabenau KE, 2001, MOL MICROBIOL, V41, P537, DOI 10.1046/j.1365-2958.2001.02513.x; ROBSON KJH, 1988, NATURE, V335, P79, DOI 10.1038/335079a0; Rug M, 2004, INFECT IMMUN, V72, P6095, DOI 10.1128/IAI.72.10.6095-6105.2004; SCHOFIELD L, 1986, MOL BIOCHEM PARASIT, V18, P183, DOI 10.1016/0166-6851(86)90037-X; Shaw MK, 1999, EXP PARASITOL, V92, P24, DOI 10.1006/expr.1998.4393; Snow RW, 2005, NATURE, V434, P214, DOI 10.1038/nature03342; Soldati D, 2004, TRENDS PARASITOL, V20, P567, DOI 10.1016/j.pt.2004.09.009; Sultan AA, 1997, CELL, V90, P511, DOI 10.1016/S0092-8674(00)80511-5; Tan KM, 2002, J CELL BIOL, V159, P373, DOI 10.1083/jcb.200206062; Thompson J, 2004, MOL BIOCHEM PARASIT, V134, P225, DOI 10.1016/j.molbiopara.2003.12.003; Tonkin CJ, 2004, MOL BIOCHEM PARASIT, V137, P13, DOI 10.1016/j.molbiopara.2004.05.009; TRAGER W, 1976, SCIENCE, V193, P673, DOI 10.1126/science.781840; Triglia T, 2000, MOL MICROBIOL, V38, P706, DOI 10.1046/j.1365-2958.2000.02175.x; Trottein F, 1995, MOL BIOCHEM PARASIT, V74, P129, DOI 10.1016/0166-6851(95)02489-1; Urban S, 2003, MOL CELL, V11, P1425, DOI 10.1016/S1097-2765(03)00181-3; van Dooren GG, 2005, MOL MICROBIOL, V57, P405, DOI 10.1111/j.1365-2958.2005.04699.x; Wetzel DM, 2005, INFECT IMMUN, V73, P5379, DOI 10.1128/IAI.73.9.5379-5387.2005; Yuda M, 1999, J EXP MED, V190, P1711, DOI 10.1084/jem.190.11.1711; Zhou XW, 2004, MOL CELL PROTEOMICS, V3, P565, DOI 10.1074/mcp.M300123-MCP200	62	263	282	0	35	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 24	2006	281	8					5197	5208		10.1074/jbc.M509807200	http://dx.doi.org/10.1074/jbc.M509807200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	013RF	16321976	hybrid			2022-12-25	WOS:000235426200074
J	Panadero, J; Pallotti, C; Rodriguez-Vargas, S; Randez-Gil, F; Prieto, JA				Panadero, J; Pallotti, C; Rodriguez-Vargas, S; Randez-Gil, F; Prieto, JA			A downshift in temperature activates the high osmolarity glycerol (HOG) pathway, which determines freeze tolerance in Saccharomyces cerevisiae	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE PATHWAY; ABC-TRANSPORT-SYSTEM; HEAT-SHOCK RESPONSE; MEMBRANE-FLUIDITY; OSMOTIC-STRESS; PHYSICAL STATE; YEAST-CELLS; COLD-SHOCK; SIGNAL-TRANSDUCTION; GENE	The molecular mechanisms that enable yeast cells to detect and transmit cold signals and their physiological significance in the adaptive response to low temperatures are unknown. Here, we have demonstrated that the MAPK Hog1p is specifically activated in response to cold. Phosphorylation of Hog1p was dependent on Pbs2p, the MAPK kinase ( MAPKK) of the high osmolarity glycerol (HOG) pathway, and Ssk1p, the response regulator of the two-component system Sln1p-Ypd1p. However, Sho1p was not required. Interestingly, phosphorylation of Hog1p was stimulated at 30 degrees C in cells exposed to the membrane rigidifier agent dimethyl sulfoxide. Moreover, Hog1p activation occurred specifically through the Sln1 branch. This suggests that Sln1p monitors changes in membrane fluidity caused by cold. Quite remarkably, activation of Hog1p at low temperatures affected the transcriptional response to cold shock. Indeed, the absence of Hog1p impaired the cold-instigated expression of genes for trehalose- and glycerol-synthesizing enzymes and small chaperones. Moreover, a downward transfer to 12 or 4 degrees C stimulated the overproduction of glycerol in a Hog1p-dependent manner. However, hog1 Delta mutant cells showed no growth defects at 12 degrees C as compared with the wild type. On the contrary, deletion of HOG1 or GPD1 decreased tolerance to freezing of wildtype cells preincubated at a low temperature, whereas no differences could be detected in cells shifted directly from 30 to -20 degrees C. Thus, exposure to low temperatures triggered a Hog1p-dependent accumulation of glycerol, which is essential for freeze protection.	CSIC, Inst Agroquim & Tecnol Alimentos, Dept Biotechnol, E-46100 Burjassot, Spain	Consejo Superior de Investigaciones Cientificas (CSIC); Instituto de Agroquimica y Tecnologia de los Alimentos (IATA)	Prieto, JA (corresponding author), CSIC, Inst Agroquim & Tecnol Alimentos, Dept Biotechnol, POB 73, E-46100 Burjassot, Spain.	prieto@iata.csic.es	Prieto, Jose A/H-4646-2012; Randez-Gil, Francisca/H-2868-2012; pallotti, claudia/F-5489-2016	Prieto, Jose A/0000-0001-9677-0023; Randez-Gil, Francisca/0000-0001-8217-3156; pallotti, claudia/0000-0002-5231-4285; Panadero, Joaquin/0000-0002-8039-6505				Aguilar PS, 2001, EMBO J, V20, P1681, DOI 10.1093/emboj/20.7.1681; Aguilera J, 2005, MOL MICROBIOL, V56, P228, DOI 10.1111/j.1365-2958.2005.04533.x; ALBERTYN J, 1994, MOL CELL BIOL, V14, P4135, DOI 10.1128/MCB.14.6.4135; Alepuz PM, 2003, EMBO J, V22, P2433, DOI 10.1093/emboj/cdg243; Alepuz PM, 2001, MOL CELL, V7, P767, DOI 10.1016/S1097-2765(01)00221-0; BELL W, 1992, EUR J BIOCHEM, V209, P951, DOI 10.1111/j.1432-1033.1992.tb17368.x; BOLARD J, 1986, BIOCHIM BIOPHYS ACTA, V864, P257, DOI 10.1016/0304-4157(86)90002-X; Browse J, 2001, CURR OPIN PLANT BIOL, V4, P241, DOI 10.1016/S1369-5266(00)00167-9; Carratu L, 1996, P NATL ACAD SCI USA, V93, P3870, DOI 10.1073/pnas.93.9.3870; CVRCKOVA F, 1995, GENE DEV, V9, P1817, DOI 10.1101/gad.9.15.1817; de Nadal E, 2002, EMBO REP, V3, P735, DOI 10.1093/embo-reports/kvf158; Estruch F, 2000, FEMS MICROBIOL REV, V24, P469, DOI 10.1016/S0168-6445(00)00035-8; Gacto M, 2003, INT MICROBIOL, V6, P211, DOI 10.1007/s10123-003-0136-x; Garcia-Rodriguez LJ, 2000, J BACTERIOL, V182, P2428, DOI 10.1128/JB.182.9.2428-2437.2000; Gustin MC, 1998, MICROBIOL MOL BIOL R, V62, P1264, DOI 10.1128/MMBR.62.4.1264-1300.1998; Hohmann S, 2002, MICROBIOL MOL BIOL R, V66, P300, DOI 10.1128/MMBR.66.2.300-372.2002; Horvath I, 1998, P NATL ACAD SCI USA, V95, P3513, DOI 10.1073/pnas.95.7.3513; Inaba M, 2003, J BIOL CHEM, V278, P12191, DOI 10.1074/jbc.M212204200; Inoue Y, 1996, J BIOL CHEM, V271, P25958, DOI 10.1074/jbc.271.42.25958; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; Izawa S, 2004, APPL MICROBIOL BIOT, V66, P303, DOI 10.1007/s00253-004-1688-1; Kandror O, 2004, MOL CELL, V13, P771, DOI 10.1016/S1097-2765(04)00148-0; KONDO K, 1991, J BIOL CHEM, V266, P17537; KONDO K, 1992, J BIOL CHEM, V267, P16252; KOWALSKI LRZ, 1995, MOL MICROBIOL, V15, P341, DOI 10.1111/j.1365-2958.1995.tb02248.x; Laroche C, 2001, APPL MICROBIOL BIOT, V56, P249, DOI 10.1007/s002530000583; Lawrence CL, 2004, MOL CELL BIOL, V24, P3307, DOI 10.1128/MCB.24.8.3307-3323.2004; Lopez CS, 2000, INT J FOOD MICROBIOL, V55, P137, DOI 10.1016/S0168-1605(00)00171-9; Los DA, 2004, BBA-BIOMEMBRANES, V1666, P142, DOI 10.1016/j.bbamem.2004.08.002; LUYTEN K, 1995, EMBO J, V14, P1360, DOI 10.1002/j.1460-2075.1995.tb07122.x; MAEDA T, 1994, NATURE, V369, P242, DOI 10.1038/369242a0; McKemy DD, 2002, NATURE, V416, P52, DOI 10.1038/nature719; Mikami K, 2002, MOL MICROBIOL, V46, P905, DOI 10.1046/j.1365-2958.2002.03202.x; MILLAR JBA, 1995, GENE DEV, V9, P2117, DOI 10.1101/gad.9.17.2117; Murata N, 1997, PLANT PHYSIOL, V115, P875, DOI 10.1104/pp.115.3.875; O'Rourke SM, 2002, MOL CELL BIOL, V22, P4739, DOI 10.1128/MCB.22.13.4739-4749.2002; Ohsaka Y, 2002, CELL PHYSIOL BIOCHEM, V12, P111, DOI 10.1159/000063787; Orvar BL, 2000, PLANT J, V23, P785, DOI 10.1046/j.1365-313x.2000.00845.x; Perraud AL, 1999, TRENDS MICROBIOL, V7, P115, DOI 10.1016/S0966-842X(99)01458-4; PRAEKELT UM, 1990, MOL GEN GENET, V223, P97, DOI 10.1007/BF00315801; Randez-Gil F, 2003, TOP CURR GENET, V2, P57; Reiser V, 2003, J CELL BIOL, V161, P1035, DOI 10.1083/jcb.200301099; Reiser V, 1999, MOL BIOL CELL, V10, P1147, DOI 10.1091/mbc.10.4.1147; Rep M, 2000, J BIOL CHEM, V275, P8290, DOI 10.1074/jbc.275.12.8290; Reynolds TB, 1998, J CELL BIOL, V143, P935, DOI 10.1083/jcb.143.4.935; Sahara T, 2002, J BIOL CHEM, V277, P50015, DOI 10.1074/jbc.M209258200; Sangwan V, 2002, PLANT J, V31, P629, DOI 10.1046/j.1365-313X.2002.01384.x; Sherman F., 1986, METHODS YEAST GENETI; Soto T, 2002, EUR J BIOCHEM, V269, P5056, DOI 10.1046/j.1432-1033.2002.03214.x; STUKEY JE, 1990, J BIOL CHEM, V265, P20144; Suzuki I, 2001, MOL MICROBIOL, V40, P235, DOI 10.1046/j.1365-2958.2001.02379.x; Suzuki I, 2000, EMBO J, V19, P1327, DOI 10.1093/emboj/19.6.1327; Szalontai B, 2000, BBA-BIOMEMBRANES, V1509, P409, DOI 10.1016/S0005-2736(00)00323-0; Tamas MJ, 1999, MOL MICROBIOL, V31, P1087, DOI 10.1046/j.1365-2958.1999.01248.x; Thieringer HA, 1998, BIOESSAYS, V20, P49; THOMAS BJ, 1989, CELL, V56, P619, DOI 10.1016/0092-8674(89)90584-9; TOKISHITA S, 1994, MOL MICROBIOL, V13, P435, DOI 10.1111/j.1365-2958.1994.tb00438.x; van der Heide T, 2000, P NATL ACAD SCI USA, V97, P7102, DOI 10.1073/pnas.97.13.7102; van der Heide T, 2001, EMBO J, V20, P7022, DOI 10.1093/emboj/20.24.7022; Van Wuytswinkel O, 2000, MOL MICROBIOL, V37, P382, DOI 10.1046/j.1365-2958.2000.02002.x; Vigh L, 1998, TRENDS BIOCHEM SCI, V23, P369, DOI 10.1016/S0968-0004(98)01279-1; Westfall PJ, 2004, SCIENCE, V306, P1511, DOI 10.1126/science.1104879; Winkler A, 2002, EUKARYOT CELL, V1, P163, DOI 10.1128/EC.1.2.163-173.2002; Wolfe J, 1999, CRYOBIOLOGY, V39, P103, DOI 10.1006/cryo.1999.2195; Zhang L, 2001, BIOCHEM BIOPH RES CO, V283, P531, DOI 10.1006/bbrc.2001.4776	65	140	155	0	22	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 24	2006	281	8					4638	4645		10.1074/jbc.M512736200	http://dx.doi.org/10.1074/jbc.M512736200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	013RF	16371351	Green Submitted, hybrid			2022-12-25	WOS:000235426200011
J	Babu, GJ; Bhupathy, P; Petrashevskaya, NN; Wang, HL; Raman, S; Wheeler, D; Jagatheesan, G; Wieczorek, D; Schwartz, A; Janssen, PML; Ziolo, MT; Periasamy, M				Babu, GJ; Bhupathy, P; Petrashevskaya, NN; Wang, HL; Raman, S; Wheeler, D; Jagatheesan, G; Wieczorek, D; Schwartz, A; Janssen, PML; Ziolo, MT; Periasamy, M			Targeted overexpression of sarcolipin in the mouse heart decreases sarcoplasmic reticulum calcium transport and cardiac contractility	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MESSENGER-RNA; PHOSPHOLAMBAN; SERCA; CA2+-ATPASE; EXPRESSION; ATPASE; RYANODINE; MYOCYTES; INCREASE; PUMPS	The role of sarcolipin (SLN) in cardiac physiology was critically evaluated by generating a transgenic (TG) mouse model in which the SLN to sarco(endoplasmic) reticulum (SR) Ca2+ ATPase (SERCA) ratio was increased in the ventricle. Overexpression of SLN decreases SR calcium transport function and results in decreased calcium transient amplitude and rate of relaxation. SLN TG hearts exhibit a significant decrease in rates of contraction and relaxation when assessed by ex vivo work-performing heart preparations. Similar results were also observed with muscle preparations and myocytes from SLN TG ventricles. Interestingly, the inhibitory effect of SLN was partially relieved upon high dose of isoproterenol treatment and stimulation at high frequency. Biochemical analyses show that an increase in SLN level does not affect PLB levels, monomer to pentamer ratio, or its phosphorylation status. No compensatory changes were seen in the expression of other calcium-handling proteins. These studies suggest that the SLN effect on SERCA pump is direct and is not mediated through increased monomerization of PLB or by a change in PLB phosphorylation status. We conclude that SLN is a novel regulator of SERCA pump activity, and its inhibitory effect can be reversed by beta-adrenergic agonists.	Ohio State Univ, Coll Med & Publ Hlth, Dept Physiol & Cell Biol, Columbus, OH 43210 USA; Univ Cincinnati, Coll Med, Dept Surg, Cincinnati, OH 45267 USA; Univ Cincinnati, Coll Med, Dept Mol Genet & Biochem, Cincinnati, OH 45267 USA	University System of Ohio; Ohio State University; University System of Ohio; University of Cincinnati; University System of Ohio; University of Cincinnati	Periasamy, M (corresponding author), Ohio State Univ, Coll Med & Publ Hlth, Dept Physiol & Cell Biol, 304 Hamilton Hall,1645 Neil Ave, Columbus, OH 43210 USA.	periasamy.1@osu.edu	Janssen, Paul ML/E-3307-2011; Babu, Gopal/AAB-7787-2021; Ziolo, Mark/E-4371-2011	Babu, Gopal/0000-0001-7833-5300; Periasamy, Muthu/0000-0001-8834-5975; Janssen, Paul/0000-0002-9682-3014	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL064140] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-64140] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Asahi M, 2004, P NATL ACAD SCI USA, V101, P9199, DOI 10.1073/pnas.0402596101; Asahi M, 2003, TRENDS CARDIOVAS MED, V13, P152, DOI 10.1016/S1050-1738(03)00037-9; Asahi M, 2003, P NATL ACAD SCI USA, V100, P5040, DOI 10.1073/pnas.0330962100; Asahi M, 2002, J BIOL CHEM, V277, P26725, DOI 10.1074/jbc.C200269200; Babu GJ, 2005, CARDIOVASC RES, V65, P177, DOI 10.1016/j.cardiores.2004.08.012; BERS DM, 1987, AM J PHYSIOL, V253, pC408, DOI 10.1152/ajpcell.1987.253.3.C408; Bers DR, 1999, CARDIOVASC RES, V42, P339, DOI 10.1016/S0008-6363(99)00038-3; Frank KF, 2003, CARDIOVASC RES, V57, P20, DOI 10.1016/S0008-6363(02)00694-6; Gayan-Ramirez G, 2000, J PHYSIOL-LONDON, V524, P387, DOI 10.1111/j.1469-7793.2000.t01-2-00387.x; Greene AL, 2000, J BIOL CHEM, V275, P24722, DOI 10.1074/jbc.M001783200; GRUPP IL, 1993, AM J PHYSIOL, V265, pH1401, DOI 10.1152/ajpheart.1993.265.4.H1401; Hellstern S, 2001, J BIOL CHEM, V276, P30845, DOI 10.1074/jbc.M102495200; Ji Y, 1999, ANAL BIOCHEM, V269, P236, DOI 10.1006/abio.1999.4059; Kimura Y, 1996, J BIOL CHEM, V271, P21726, DOI 10.1074/jbc.271.36.21726; Li L, 1998, AM J PHYSIOL-HEART C, V274, pH1335, DOI 10.1152/ajpheart.1998.274.4.H1335; Luss I, 1999, J MOL CELL CARDIOL, V31, P1299, DOI 10.1006/jmcc.1999.0962; MacLennan DH, 2003, ANN NY ACAD SCI, V986, P472, DOI 10.1111/j.1749-6632.2003.tb07231.x; MacLennan DH, 2003, NAT REV MOL CELL BIO, V4, P566, DOI 10.1038/nrm1151; MacLennan DH, 2002, J MOL CELL CARDIOL, V34, P897, DOI 10.1006/jmcc.2002.2031; Minamisawa S, 2003, J BIOL CHEM, V278, P9570, DOI 10.1074/jbc.M213132200; Odermatt A, 1997, GENOMICS, V45, P541, DOI 10.1006/geno.1997.4967; Odermatt A, 1998, J BIOL CHEM, V273, P12360, DOI 10.1074/jbc.273.20.12360; Pan BS, 1999, J MOL CELL CARDIOL, V31, P159, DOI 10.1006/jmcc.1998.0854; Pashmforoush M, 2004, CELL, V117, P373, DOI 10.1016/S0092-8674(04)00405-2; Periasamy M, 2001, J MOL CELL CARDIOL, V33, P1053, DOI 10.1006/jmcc.2001.1366; Reed TD, 2000, J MOL CELL CARDIOL, V32, P453, DOI 10.1006/jmcc.1999.1095; Stokes DL, 2000, EUR J BIOCHEM, V267, P5274, DOI 10.1046/j.1432-1327.2000.01569.x; Stull LB, 2002, J MOL CELL CARDIOL, V34, P1367, DOI 10.1006/jmcc.2002.2065; Uemura N, 2004, EUR J CLIN INVEST, V34, P723, DOI 10.1111/j.1365-2362.2004.01422.x; Valverde CA, 2005, J PHYSIOL-LONDON, V562, P801, DOI 10.1113/jphysiol.2004.075432; Ziolo MT, 2005, CIRC RES, V96, P815, DOI 10.1161/01.RES.0000163981.97262.3b	31	57	58	0	15	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 17	2006	281	7					3972	3979		10.1074/jbc.M508998200	http://dx.doi.org/10.1074/jbc.M508998200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	011NN	16365042	hybrid			2022-12-25	WOS:000235275300025
J	Zou, WG; Zhang, DE				Zou, WG; Zhang, DE			The interferon-inducible ubiquitin-protein isopeptide ligase (E3) EFP also functions as an ISG15 E3 ligase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RING-FINGER PROTEIN; SIGNALING PROTEINS; CRYSTAL-STRUCTURE; BINDING-PROTEINS; CELLS; E2; ISGYLATION; EXPRESSION; PATHWAYS; TARGETS	The expression of the ubiquitin-like protein ISG15 and protein modification by ISG15 (ISGylation) are strongly activated by interferons. Accordingly, ISG15 expression and protein ISGylation are strongly activated upon viral and bacterial infections and during other stress conditions, suggesting important roles for the ISG15 system in innate immune responses. Here, we report the identification of the ubiquitin-protein isopeptide ligase (E3) EFP (estrogen-responsive finger protein) as the ISG15 E3 ligase for 14-3-3 sigma protein. Like other known components of the protein ISGylation system (ISG15, UBE1L, UBP43, and UBC8), EFP is also an interferon-inducible protein. Expression of EFP small interfering RNA decreased the ISGylation of 14-3-3 sigma in the 293T cell ISGylation system as well as in MCF-7 cells upon interferon treatment. Furthermore, the ISGylation enzyme activity of EFP was RING domain-dependent. These findings indicate that EFP is an ISG15 E3 ligase for 14-3-3 sigma in vivo. The fact that both UBC8 and EFP are common components in the ubiquitin and ISG15 conjugation pathways suggests a mechanism whereby a limited set of enzymes accomplishes diverse post-translational modifications of their substrates in response to changes in environmental stimulations.	Scripps Res Inst, Dept Mol & Expt Med, La Jolla, CA 92037 USA	Scripps Research Institute	Zhang, DE (corresponding author), Scripps Res Inst, Dept Mol & Expt Med, Mail Drop MEM-L51,10550 N Torrey Pines Rd, La Jolla, CA 92037 USA.	dzhang@scripps.edu			NCI NIH HHS [CA079849] Funding Source: Medline; NIGMS NIH HHS [GM066955] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA079849] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM066955] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Borden KLB, 2000, J MOL BIOL, V295, P1103, DOI 10.1006/jmbi.1999.3429; Bridges D, 2004, SCI STKE, pre10; Brummelkamp TR, 2002, SCIENCE, V296, P550, DOI 10.1126/science.1068999; Chin LS, 2002, J BIOL CHEM, V277, P35071, DOI 10.1074/jbc.M203300200; Dao CT, 2005, FRONT BIOSCI-LANDMRK, V10, P2701, DOI 10.2741/1730; DARNELL JE, 1994, SCIENCE, V264, P1415, DOI 10.1126/science.8197455; FARRELL PJ, 1979, NATURE, V279, P523, DOI 10.1038/279523a0; Fujii Y, 1999, EMBO J, V18, P5028, DOI 10.1093/emboj/18.18.5028; Giannakopoulos NV, 2005, BIOCHEM BIOPH RES CO, V336, P496, DOI 10.1016/j.bbrc.2005.08.132; HAAS AL, 1987, J BIOL CHEM, V262, P11315; Hamerman JA, 2002, J IMMUNOL, V168, P2415, DOI 10.4049/jimmunol.168.5.2415; Hicke L, 1999, TRENDS CELL BIOL, V9, P107, DOI 10.1016/S0962-8924(98)01491-3; Hochstrasser M, 2000, NAT CELL BIOL, V2, pE153, DOI 10.1038/35019643; Hu SM, 2003, J BIOL CHEM, V278, P10055, DOI 10.1074/jbc.M207197200; Ikeda K, 1997, BIOCHEM BIOPH RES CO, V236, P765, DOI 10.1006/bbrc.1997.7046; Imai Y, 2000, J BIOL CHEM, V275, P35661, DOI 10.1074/jbc.C000447200; INOUE S, 1993, P NATL ACAD SCI USA, V90, P11117, DOI 10.1073/pnas.90.23.11117; Kim KI, 2004, MOL CELL BIOL, V24, P9592, DOI 10.1128/MCB.24.21.9592-9600.2004; Kim KI, 2006, MOL CELL BIOL, V26, P472, DOI 10.1128/MCB.26.2.472-479.2006; Kim KI, 2003, BIOCHEM BIOPH RES CO, V307, P431, DOI 10.1016/S0006-291X(03)01216-6; Kim KI, 2005, J IMMUNOL, V175, P847, DOI 10.4049/jimmunol.175.2.847; KOK K, 1993, P NATL ACAD SCI USA, V90, P6071, DOI 10.1073/pnas.90.13.6071; KORANT BD, 1984, J BIOL CHEM, V259, P4835; Kramer OH, 2003, EMBO J, V22, P3411, DOI 10.1093/emboj/cdg315; Kumar S, 1997, J BIOL CHEM, V272, P13548, DOI 10.1074/jbc.272.21.13548; Leaman DW, 2003, J INTERF CYTOK RES, V23, P745, DOI 10.1089/107999003772084860; Liu LQ, 1999, MOL CELL BIOL, V19, P3029; LOEB KR, 1992, J BIOL CHEM, V267, P7806; Malakhov MP, 2002, J BIOL CHEM, V277, P9976, DOI 10.1074/jbc.M109078200; Malakhov MP, 2003, J BIOL CHEM, V278, P16608, DOI 10.1074/jbc.M208435200; Malakhova OA, 2003, GENE DEV, V17, P455, DOI 10.1101/gad.1056303; MORRISON D, 1994, SCIENCE, V266, P56, DOI 10.1126/science.7939645; Moynihan TP, 1999, J BIOL CHEM, V274, P30963, DOI 10.1074/jbc.274.43.30963; Narasimhan J, 2005, J BIOL CHEM, V280, P27356, DOI 10.1074/jbc.M502814200; Niwa J, 2001, BIOCHEM BIOPH RES CO, V281, P706, DOI 10.1006/bbrc.2001.4414; Osiak A, 2005, MOL CELL BIOL, V25, P6338, DOI 10.1128/MCB.25.15.6338-6345.2005; Pickart CM, 2001, ANNU REV BIOCHEM, V70, P503, DOI 10.1146/annurev.biochem.70.1.503; Ritchie KJ, 2004, SEMIN CELL DEV BIOL, V15, P237, DOI 10.1016/j.semcdb.2003.12.005; Schnell JD, 2003, J BIOL CHEM, V278, P35857, DOI 10.1074/jbc.R300018200; Schwartz DC, 2003, TRENDS BIOCHEM SCI, V28, P321, DOI 10.1016/S0968-0004(03)00113-0; Shimada N, 2004, MOL CELL ENDOCRINOL, V218, P147, DOI 10.1016/j.mce.2003.12.008; Urano T, 2002, NATURE, V417, P871, DOI 10.1038/nature00826; Weissman AM, 2001, NAT REV MOL CELL BIO, V2, P169, DOI 10.1038/35056563; Wilkinson KD, 2004, CELL, V119, P741, DOI 10.1016/S0092-8674(04)01154-7; Xiao Bing, 1995, Nature (London), V376, P188, DOI 10.1038/376188a0; Yuan WM, 2001, EMBO J, V20, P362, DOI 10.1093/emboj/20.3.362; ZHANG DE, 1994, MOL CELL BIOL, V14, P373, DOI 10.1128/MCB.14.1.373; Zhao C, 2004, P NATL ACAD SCI USA, V101, P7578, DOI 10.1073/pnas.0402528101; Zhao C, 2005, P NATL ACAD SCI USA, V102, P10200, DOI 10.1073/pnas.0504754102; Zou WG, 2005, BIOCHEM BIOPH RES CO, V336, P61, DOI 10.1016/j.bbrc.2005.08.038	50	194	206	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 17	2006	281	7					3989	3994		10.1074/jbc.M510787200	http://dx.doi.org/10.1074/jbc.M510787200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	011NN	16352599	hybrid			2022-12-25	WOS:000235275300027
J	Mackintosh, SG; Lu, JZQ; Jordan, JB; Harrison, MK; Sikora, B; Sharma, SD; Cameron, CE; Raney, KD; Sakon, J				Mackintosh, SG; Lu, JZQ; Jordan, JB; Harrison, MK; Sikora, B; Sharma, SD; Cameron, CE; Raney, KD; Sakon, J			Structural and biological identification of residues on the surface of NS3 helicase required for optimal replication of the hepatitis C virus	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEPENDENT RNA-POLYMERASE; CRYSTAL-STRUCTURE; DNA HELICASE; NONSTRUCTURAL PROTEIN-3; MACROMOLECULAR MACHINES; ENDOPLASMIC-RETICULUM; PROTEASE DOMAIN; STEP-SIZE; MECHANISMS; MEMBRANE	The hepatitis C virus (HCV) nonstructural protein 3 (NS3) is a multifunctional enzyme with serine protease and DEXH/ D-box helicase domains. A crystal structure of the NS3 helicase domain (NS3h) was generated in the presence of a single-stranded oligonucleotide long enough to accommodate binding of two molecules of enzyme. Several amino acid residues at the interface of the two NS3h molecules were identified that appear to mediate a protein-protein interaction between domains 2 and 3 of adjacent molecules. Mutations were introduced into domain 3 to disrupt the putative interface and subsequently examined using an HCV subgenomic replicon, resulting in significant reduction in replication capacity. The mutations in domain 3 were then examined using recombinant NS3h in biochemical assays. The mutant enzyme showed RNA binding and RNA- stimulated ATPase activity that mirrored wild type NS3h. In DNA unwinding assays under single turnover conditions, the mutant NS3h exhibited a similar unwinding rate and only similar to 2-fold lower processivity than wild type NS3h. Overall biochemical activities of the mutant NS3h were similar to the wild type enzyme, which was not reflective of the large reduction in HCV replicative capacity observed in the biological experiment. Hence, the biological results suggest that the known biochemical properties associated with the helicase activity of NS3h do not reveal all of the likely biological roles of NS3 during HCV replication. Domain 3 of NS3 is implicated in protein-protein interactions that are necessary for HCV replication.	Univ Arkansas Med Sci, Dept Biochem & Mol Biol, Little Rock, AR 72205 USA; Univ Arkansas, Dept Chem & Biochem, Fayetteville, AR 72701 USA; Penn State Univ, Dept Biochem & Mol Biol, University Pk, PA 16802 USA	University of Arkansas System; University of Arkansas Medical Sciences; University of Arkansas System; University of Arkansas Fayetteville; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Pennsylvania State University - University Park	Raney, KD (corresponding author), Univ Arkansas Med Sci, Dept Biochem & Mol Biol, Little Rock, AR 72205 USA.	raneykevind@uams.edu; jsakon@uark.edu	SHARMA, Suresh D./AAD-7723-2022; SHARMA, Suresh/C-4431-2008; Sakon, Joshua/N-2289-2014	SHARMA, Suresh D./0000-0002-8633-4145; SHARMA, Suresh/0000-0002-8633-4145; Sakon, Joshua/0000-0002-8373-969X	NATIONAL CENTER FOR RESEARCH RESOURCES [P20RR015569, P20RR016460] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI060563] Funding Source: NIH RePORTER; NCRR NIH HHS [P20 RR15569, P20 RR016460] Funding Source: Medline; NIAID NIH HHS [R01 AI60563] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Ali JA, 1997, SCIENCE, V275, P377, DOI 10.1126/science.275.5298.377; BARTENSCHLAGER R, 1993, J VIROL, V67, P3835, DOI 10.1128/JVI.67.7.3835-3844.1993; Behrens SE, 1996, EMBO J, V15, P12, DOI 10.1002/j.1460-2075.1996.tb00329.x; Blight KJ, 2000, SCIENCE, V290, P1972, DOI 10.1126/science.290.5498.1972; Blight KJ, 1998, ANTIVIR THER, V3, P71; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Cheng W, 2002, P NATL ACAD SCI USA, V99, P16006, DOI 10.1073/pnas.242479399; Cho HS, 1998, J BIOL CHEM, V273, P15045, DOI 10.1074/jbc.273.24.15045; De Francesco Raffaele, 2003, Clin Liver Dis, V7, P211, DOI 10.1016/S1089-3261(02)00069-7; Delagoutte E, 2003, Q REV BIOPHYS, V36, P1, DOI 10.1017/S0033583502003864; Delagoutte E, 2002, Q REV BIOPHYS, V35, P431, DOI 10.1017/S0033583502003852; ENOMOTO N, 1995, J CLIN INVEST, V96, P224, DOI 10.1172/JCI118025; FAILLA C, 1994, J VIROL, V68, P3753, DOI 10.1128/JVI.68.6.3753-3760.1994; Frick DN, 2004, J BIOL CHEM, V279, P1269, DOI 10.1074/jbc.M310630200; Galletto R, 2004, J MOL BIOL, V343, P83, DOI 10.1016/j.jmb.2004.07.055; Gallinari P, 1998, J VIROL, V72, P6758, DOI 10.1128/JVI.72.8.6758-6769.1998; Giannini C, 2003, CELL DEATH DIFFER, V10, pS27, DOI 10.1038/sj.cdd.4401121; Hall MC, 1999, MOL MICROBIOL, V34, P867, DOI 10.1046/j.1365-2958.1999.01659.x; HELLER T, 2005, P NATL ACAD SCI US; Hooft RWW, 1996, NATURE, V381, P272, DOI 10.1038/381272a0; Hugle T, 2001, VIROLOGY, V284, P70, DOI 10.1006/viro.2001.0873; KIM DW, 1995, BIOCHEM BIOPH RES CO, V215, P160, DOI 10.1006/bbrc.1995.2447; Kim JL, 1996, CELL, V87, P343, DOI 10.1016/S0092-8674(00)81351-3; Kim JL, 1998, STRUCTURE, V6, P89, DOI 10.1016/S0969-2126(98)00010-0; Levin MK, 1999, J BIOL CHEM, V274, P31839, DOI 10.1074/jbc.274.45.31839; Levin MK, 2004, J BIOL CHEM, V279, P26005, DOI 10.1074/jbc.M403257200; Levin MK, 2003, J BIOL CHEM, V278, P23311, DOI 10.1074/jbc.M301283200; Levin MK, 2002, J BIOL CHEM, V277, P29377, DOI 10.1074/jbc.M112315200; LIN C, 1995, J VIROL, V69, P4373, DOI 10.1128/JVI.69.7.4373-4380.1995; Locatelli GA, 2002, BIOCHEMISTRY-US, V41, P10332, DOI 10.1021/bi026082g; Lohmann V, 1999, SCIENCE, V285, P110, DOI 10.1126/science.285.5424.110; Lucius AL, 2003, BIOPHYS J, V85, P2224, DOI 10.1016/S0006-3495(03)74648-7; McRee DE, 1999, J STRUCT BIOL, V125, P156, DOI 10.1006/jsbi.1999.4094; Mottola G, 2002, VIROLOGY, V293, P31, DOI 10.1006/viro.2001.1229; Navaza J, 2001, ACTA CRYSTALLOGR D, V57, P1367, DOI 10.1107/S0907444901012422; Pang PS, 2002, EMBO J, V21, P1168, DOI 10.1093/emboj/21.5.1168; Parkinson G, 1996, ACTA CRYSTALLOGR D, V52, P57, DOI 10.1107/S0907444995011115; Penin F, 2004, HEPATOLOGY, V39, P5, DOI 10.1002/hep.20032; Piccininni S, 2002, J BIOL CHEM, V277, P45670, DOI 10.1074/jbc.M204124200; Qin WP, 2002, J BIOL CHEM, V277, P2132, DOI 10.1074/jbc.M106880200; REED KE, 1995, J VIROL, V69, P4127, DOI 10.1128/JVI.69.7.4127-4136.1995; Serebrov V, 2004, NATURE, V430, P476, DOI 10.1038/nature02704; Shi ST, 2003, J VIROL, V77, P4160, DOI 10.1128/JVI.77.7.4160-4168.2003; Singleton MR, 2002, J BACTERIOL, V184, P1819, DOI 10.1128/JB.184.7.1819-1826.2002; Tackett AJ, 2005, J BIOL CHEM, V280, P10797, DOI 10.1074/jbc.M407971200; Tan SL, 2002, NAT REV DRUG DISCOV, V1, P867, DOI 10.1038/nrd937; Velankar SS, 1999, CELL, V97, P75, DOI 10.1016/S0092-8674(00)80716-3; VRIEND G, 1990, J MOL GRAPHICS, V8, P52, DOI 10.1016/0263-7855(90)80070-V; Wolk B, 2000, J VIROL, V74, P2293, DOI 10.1128/JVI.74.5.2293-2304.2000; Yao NH, 1999, STRUCTURE, V7, P1353, DOI 10.1016/S0969-2126(00)80025-8	50	59	60	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 10	2006	281	6					3528	3535		10.1074/jbc.M512100200	http://dx.doi.org/10.1074/jbc.M512100200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	009QV	16306038	hybrid, Green Published			2022-12-25	WOS:000235128200063
J	McGee, DJ; Kumar, S; Viator, RJ; Bolland, JR; Ruiz, J; Spadafora, D; Testerman, TL; Kelly, DJ; Pannell, LK; Windle, HJ				McGee, DJ; Kumar, S; Viator, RJ; Bolland, JR; Ruiz, J; Spadafora, D; Testerman, TL; Kelly, DJ; Pannell, LK; Windle, HJ			Helicobacter pylori thioredoxin is an arginase chaperone and guardian against oxidative and nitrosative stresses	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NITRIC-OXIDE; GNOTOBIOTIC PIGLETS; UREASE ACTIVITY; SYSTEM; COLONIZATION; PATHOGENESIS; PATHWAYS; SEQUENCE; ARTICLE; ACID	The gastric human pathogen Helicobacter pylori faces formidable challenges in the stomach including reactive oxygen and nitrogen intermediates. Here we demonstrate that arginase activity, which inhibits host nitric oxide production, is post-translationally stimulated by H. pylori thioredoxin (Trx) 1 but not the homologous Trx2. Trx1 has chaperone activity that renatures urea- or heat-denatured arginase back to the catalytically active state. Most reactive oxygen and nitrogen intermediates inhibit arginase activity; this damage is reversed by Trx1, but not Trx2. Trx1 and arginase equip H. pylori with a "renox guardian" to overcome abundant nitrosative and oxidative stresses encountered during the persistence of the bacterium in the hostile gastric environment.	Univ S Alabama, Coll Med, Inst Canc Res, Dept Microbiol & Immunol, Mobile, AL 36688 USA; Univ S Alabama, Coll Med, Inst Canc Res, Dept Biol Sci, Mobile, AL 36688 USA; Univ S Alabama, Coll Med, Inst Canc Res, Prote & Mass Spectrometry Res Facil, Mobile, AL 36688 USA; Univ Sheffield, Dept Mol Biol & Biotechnol, Sheffield S10 2TN, S Yorkshire, England; St Jamess Univ Hosp, Trinity Coll, Trinity Ctr Hlth Sci, Dept Clin Med, Dublin 8, Ireland	University of South Alabama; University of South Alabama; University of South Alabama; University of Sheffield; Trinity College Dublin	McGee, DJ (corresponding author), Louisiana State Univ, Hlth Sci Ctr, Dept Microbiol & Immunol, 1501 Kings Highway, Shreveport, LA 71130 USA.	dmcgee@lsuhsc.edu	Testerman, Traci L/AAI-1506-2020	Testerman, Traci L/0000-0002-3883-6407; McGee, David/0000-0003-0592-7836	NATIONAL CANCER INSTITUTE [R01CA101931] Funding Source: NIH RePORTER; NCI NIH HHS [CA101931] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Alm RA, 1999, NATURE, V397, P176, DOI 10.1038/16495; Baker LMS, 2001, J BACTERIOL, V183, P1961, DOI 10.1128/JB.183.6.1961-1973.2001; Bauerfeind P, 1997, GUT, V40, P25, DOI 10.1136/gut.40.1.25; Comtois SL, 2003, MICROBIOL-SGM, V149, P121, DOI 10.1099/mic.0.25896-0; EATON KA, 1992, J MED MICROBIOL, V37, P123, DOI 10.1099/00222615-37-2-123; EATON KA, 1991, INFECT IMMUN, V59, P2470, DOI 10.1128/IAI.59.7.2470-2475.1991; Ernst P, 1999, ALIMENT PHARM THER, V13, P13, DOI 10.1046/j.1365-2036.1999.00003.x; Gobert AP, 2001, P NATL ACAD SCI USA, V98, P13844, DOI 10.1073/pnas.241443798; Kern R, 2003, BIOCHEM J, V371, P965, DOI 10.1042/BJ20030093; MARSHALL BJ, 1990, GASTROENTEROLOGY, V99, P697, DOI 10.1016/0016-5085(90)90957-3; McGee DJ, 2004, EUR J BIOCHEM, V271, P1952, DOI 10.1111/j.1432-1033.2004.04105.x; McGee DJ, 1999, J BACTERIOL, V181, P2477, DOI 10.1128/JB.181.8.2477-2484.1999; McGee DJ, 1999, J BACTERIOL, V181, P7314, DOI 10.1128/JB.181.23.7314-7322.1999; Nardone G, 2004, ALIMENT PHARM THER, V20, P261, DOI 10.1111/j.1365-2036.2004.02075.x; Ritz D, 2001, ANNU REV MICROBIOL, V55, P21, DOI 10.1146/annurev.micro.55.1.21; Satriano J, 2004, AMINO ACIDS, V26, P321, DOI 10.1007/s00726-004-0078-4; Slonczewski JL, 2000, HELICOBACTER, V5, P240, DOI 10.1046/j.1523-5378.2000.00037.x; STAMLER JS, 1992, SCIENCE, V258, P1898, DOI 10.1126/science.1281928; Tomb JF, 1997, NATURE, V388, P539, DOI 10.1038/41483; Windle HJ, 2000, J BIOL CHEM, V275, P5081, DOI 10.1074/jbc.275.7.5081; Zabaleta J, 2004, J IMMUNOL, V173, P586, DOI 10.4049/jimmunol.173.1.586	21	31	37	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 10	2006	281	6					3290	3296		10.1074/jbc.M506139200	http://dx.doi.org/10.1074/jbc.M506139200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	009QV	16354674	hybrid			2022-12-25	WOS:000235128200035
J	Friedman, JE; Watson, JA; Lam, DWH; Rokita, SE				Friedman, JE; Watson, JA; Lam, DWH; Rokita, SE			Iodotyrosine deiodinase is the first mammalian member of the NADH oxidase/flavin reductase superfamily	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							I IODOTHYRONINE DEIODINASE; TETRACHLOROHYDROQUINONE DEHALOGENASE; THERMUS-THERMOPHILUS; PROTEIN STRUCTURES; IODINE-METABOLISM; MONO-IODOTYROSINE; CRYSTAL-STRUCTURE; FLAVIN REDUCTASE; DI-IODOTYROSINE; REDUCED FLAVIN	The enzyme responsible for iodide salvage in the thyroid, iodotyrosine deiodinase, was solubilized from porcine thyroid microsomes by limited proteolysis with trypsin. The resulting protein retained deiodinase activity and was purified using anion exchange, dye, and hydrophobic chromatography successively. Peptide sequencing of the final isolate identified the gene responsible for the deiodinase. The amino acid sequence of the porcine enzyme is highly homologous to corresponding genes in a variety of mammals including humans, and the mouse gene was expressed in human embryonic kidney 293 cells to confirm its identity. The amino acid sequence of the deiodinase suggests the presence of three domains. The N-terminal domain provides a membrane anchor. The intermediate domain contains the highest sequence variability and lacks homology to structural motifs available in the common databases. The C-terminal domain is highly conserved and resembles bacterial enzymes of the NADH oxidase/flavin reductase superfamily. A three-dimensional model of the deiodinase based on the coordinates of the minor nitroreductase of Escherichia coli indicates that a Cys common to all of the mammal sequences is located adjacent to bound FMN. However, the deiodinase is not structurally related to other known flavoproteins containing redox-active cysteines or the iodothyronine deiodinases containing an active site selenocysteine.	Univ Maryland, Dept Chem & Biochem, College Pk, MD 20742 USA	University System of Maryland; University of Maryland College Park	Rokita, SE (corresponding author), Univ Maryland, Dept Chem & Biochem, College Pk, MD 20742 USA.	rokita@umd.edu	Rokita, Steven E/C-4793-2009					Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; Bendtsen JD, 2004, J MOL BIOL, V340, P783, DOI 10.1016/j.jmb.2004.05.028; BERRY MJ, 1991, NATURE, V349, P438, DOI 10.1038/349438a0; Bianco AC, 2002, ENDOCR REV, V23, P38, DOI 10.1210/er.23.1.38; Callebaut I, 2003, J BIOL CHEM, V278, P36887, DOI 10.1074/jbc.M305725200; Cavalieri RR, 1997, THYROID, V7, P177, DOI 10.1089/thy.1997.7.177; COLOVOS C, 1993, PROTEIN SCI, V2, P1511, DOI 10.1002/pro.5560020916; Copley S.D., 1999, COMPREHENSIVE NATURA, P401, DOI 10.1016/b978-0-08-091283-7.00122-3; Copley SD, 2003, CURR OPIN CHEM BIOL, V7, P265, DOI 10.1016/S1367-5931(03)00032-2; Coppock DL, 1998, GENOMICS, V54, P460, DOI 10.1006/geno.1998.5605; Dunn CR, 1996, NAT STRUCT BIOL, V3, P912, DOI 10.1038/nsb1196-912; Dunn JT, 2001, THYROID, V11, P407, DOI 10.1089/105072501300176363; Dym O, 2001, PROTEIN SCI, V10, P1712, DOI 10.1110/ps.12801; Fetzner S, 1998, APPL MICROBIOL BIOT, V50, P633, DOI 10.1007/s002530051346; Fischer D, 1999, PROTEINS, P209; Gnidehou S, 2004, FASEB J, V18, P1574, DOI 10.1096/fj.04-2023fje; GOSWAMI A, 1977, ENDOCRINOLOGY, V101, P331, DOI 10.1210/endo-101-2-331; GOSWAMI A, 1979, J BIOL CHEM, V254, P2326; Gouet P, 1999, BIOINFORMATICS, V15, P305, DOI 10.1093/bioinformatics/15.4.305; GREEN WL, 1968, ENDOCRINOLOGY, V83, P336, DOI 10.1210/endo-83-2-336; Gross E, 2002, NAT STRUCT BIOL, V9, P61, DOI 10.1038/nsb740; HECHT HJ, 1995, NAT STRUCT BIOL, V2, P1109, DOI 10.1038/nsb1295-1109; Hoober KL, 1999, J BIOL CHEM, V274, P31759, DOI 10.1074/jbc.274.45.31759; Hooft RWW, 1996, NATURE, V381, P272, DOI 10.1038/381272a0; JANSSEN DB, 1994, ANNU REV MICROBIOL, V48, P163, DOI 10.1146/annurev.mi.48.100194.001115; Jeffers CE, 2001, BIOCHEMISTRY-US, V40, P1749, DOI 10.1021/bi0024310; Kiefer PM, 2002, BIOCHEMISTRY-US, V41, P1308, DOI 10.1021/bi0117495; Kiefer PM, 2002, BIOCHEMISTRY-US, V41, P1315, DOI 10.1021/bi0117504; Koder RL, 2002, BIOCHEMISTRY-US, V41, P14197, DOI 10.1021/bi025805t; Krogh A, 2001, J MOL BIOL, V305, P567, DOI 10.1006/jmbi.2000.4315; Kuiper GGJM, 2005, J MOL ENDOCRINOL, V34, P865, DOI 10.1677/jme.1.01770; Kunishima M, 1999, J AM CHEM SOC, V121, P4722, DOI 10.1021/ja990693n; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Lei BF, 2005, BIOCHEMISTRY-US, V44, P261, DOI 10.1021/bi047952s; LUTHY R, 1992, NATURE, V356, P83, DOI 10.1038/356083a0; McCarthy DL, 1996, BIOCHEMISTRY-US, V35, P14634, DOI 10.1021/bi961730f; MILLER H, 1995, BIOCHEMISTRY-US, V34, P5180, DOI 10.1021/bi00015a032; Moreno JC, 2003, TRENDS ENDOCRIN MET, V14, P318, DOI 10.1016/S1043-2760(03)00137-1; Moreno JC, 2002, J ENDOCRINOL INVE S7, V25, P23; NOVOA WB, 1959, J BIOL CHEM, V234, P1143; PARK HJ, 1992, EUR J BIOCHEM, V205, P881, DOI 10.1111/j.1432-1033.1992.tb16853.x; Parkinson GN, 2000, J MED CHEM, V43, P3624, DOI 10.1021/jm000159m; Parry RJ, 1997, ARCH BIOCHEM BIOPHYS, V339, P47, DOI 10.1006/abbi.1996.9857; PESCE A, 1967, J BIOL CHEM, V242, P2151; Poelarends GJ, 2004, BIOORG CHEM, V32, P376, DOI 10.1016/j.bioorg.2004.05.006; Pontius J, 1996, J MOL BIOL, V264, P121, DOI 10.1006/jmbi.1996.0628; ROSENBERG IN, 1984, METHOD ENZYMOL, V107, P488; ROSENBERG IN, 1979, J BIOL CHEM, V254, P2318; SALI A, 1993, J MOL BIOL, V234, P779, DOI 10.1006/jmbi.1993.1626; SALI A, 1994, PROTEIN STRUCTURE BY DISTANCE ANALYSIS, P64; Solis-S JC, 2004, J ENDOCRINOL, V181, P385, DOI 10.1677/joe.0.1810385; STANBURY JB, 1956, J CLIN ENDOCR METAB, V16, P735, DOI 10.1210/jcem-16-6-735; STANBURY JB, 1957, J BIOL CHEM, V228, P801; STANBURY JB, 1956, J CLIN ENDOCR METAB, V16, P848, DOI 10.1210/jcem-16-7-848; STOSCHECK CM, 1990, METHOD ENZYMOL, V182, P50; Sun BC, 1997, ENDOCRINOLOGY, V138, P5452, DOI 10.1210/en.138.12.5452; Tanner JJ, 1996, BIOCHEMISTRY-US, V35, P13531, DOI 10.1021/bi961400v; Taurog AM, 2000, WERNER INGBARS THYRO, P61; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; Tu SC, 2001, ANTIOXID REDOX SIGN, V3, P881, DOI 10.1089/15230860152665046; Valverde-R C, 2004, INT REV CYTOL, V234, P143, DOI 10.1016/S0074-7696(04)34004-0; Vasil'ev AA, 1998, J ORG CHEM, V63, P3911, DOI 10.1021/jo972240b; Wackett LP, 2004, J BIOL CHEM, V279, P41259, DOI 10.1074/jbc.R400014200; Wang SC, 2003, J AM CHEM SOC, V125, P14282, DOI 10.1021/ja0370948; WHITAKER JR, 1994, FOOD SCI TECHNOL, V61, P521; Williams Jr C. H., 1992, CHEM BIOCH FLAVOENZY, P121; Zenno S, 1996, J BACTERIOL, V178, P4508, DOI 10.1128/jb.178.15.4508-4514.1996	68	47	47	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 3	2006	281	5					2812	2819		10.1074/jbc.M510365200	http://dx.doi.org/10.1074/jbc.M510365200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	006XT	16316988	hybrid			2022-12-25	WOS:000234931800048
J	Nawrocki, AR; Rajala, MW; Tomas, E; Pajvani, UB; Saha, AK; Trumbauer, ME; Pang, Z; Chen, AS; Ruderman, NB; Chen, H; Rossetti, L; Scherer, PE				Nawrocki, AR; Rajala, MW; Tomas, E; Pajvani, UB; Saha, AK; Trumbauer, ME; Pang, Z; Chen, AS; Ruderman, NB; Chen, H; Rossetti, L; Scherer, PE			Mice lacking adiponectin show decreased hepatic insulin sensitivity and reduced responsiveness to peroxisome proliferator-activated receptor gamma agonists	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACETYL-COA CARBOXYLASE; ADIPOSE-TISSUE; PROTEIN-KINASE; RESISTANCE; OXIDATION; MUSCLE; MOUSE; LIVER; MECHANISMS; EXPRESSION	The adipose tissue-derived hormone adiponectin improves insulin sensitivity and its circulating levels are decreased in obesity-induced insulin resistance. Here, we report the generation of a mouse line with a genomic disruption of the adiponectin locus. We aimed to identify whether these mice develop insulin resistance and which are the primary target tissues affected in this model. Using euglycemic/insulin clamp studies, we demonstrate that these mice display severe hepatic but not peripheral insulin resistance. Furthermore, we wanted to test whether the lack of adiponectin magnifies the impairments of glucose homeostasis in the context of a dietary challenge. When exposed to high fat diet, adiponectin null mice rapidly develop glucose intolerance. Specific PPAR gamma agonists such as thiazolidinediones (TZDs) improve insulin sensitivity by mechanisms largely unknown. Circulating adiponectin levels are significantly up-regulated in vivo upon activation of PPAR gamma. Both TZDs and adiponectin have been shown to activate AMP-activated protein kinase (AMPK) in the same target tissues. We wanted to address whether the ability of TZDs to improve glucose tolerance is dependent on adiponectin and whether this improvement involved AMPK activation. We demonstrate that the ability of PPAR gamma agonists to improve glucose tolerance in ob/ob mice lacking adiponectin is diminished. Adiponectin is required for the activation of AMPK upon TZD administration in both liver and muscle. In summary, adiponectin is an important contributor to PPAR gamma-mediated improvements in glucose tolerance through mechanisms that involve the activation of the AMPK pathway.	Albert Einstein Coll Med, Dept Cell Biol, Bronx, NY 10461 USA; Albert Einstein Coll Med, Dept Mol Pharmacol, Bronx, NY 10461 USA; Albert Einstein Coll Med, Dept Med, Div Endocrinol, Bronx, NY 10461 USA; Albert Einstein Coll Med, Ctr Diabet Res & Training, Bronx, NY 10461 USA; Boston Univ, Med Ctr, Dept Physiol & Med Biophys, Boston, MA 02118 USA; Boston Univ, Med Ctr, Diabet Unit, Boston, MA 02118 USA; Merck Res Labs, Rahway, NJ 07065 USA	Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine; Boston University; Boston University; Merck & Company	Scherer, PE (corresponding author), Albert Einstein Coll Med, Dept Cell Biol, 1300 Morris Pk Ave, Bronx, NY 10461 USA.	scherer@aecom.yu.edu	Scherer, Philipp E/K-7819-2012	Scherer, Philipp E/0000-0003-0680-3392; Ruderman, Neil/0000-0002-6589-6587; Saha, Asish/0000-0003-1001-5110	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL073163, P01HL068758] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK019514, R01DK049147, R01DK055758] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007288] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL68758, R01-HL073163-01] Funding Source: Medline; NIDDK NIH HHS [R01-DK55758, DK 19514, DK 49147] Funding Source: Medline; NIGMS NIH HHS [T32-GM07288] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Arita Y, 1999, BIOCHEM BIOPH RES CO, V257, P79, DOI 10.1006/bbrc.1999.0255; Berg AH, 2001, NAT MED, V7, P947, DOI 10.1038/90992; Berger J, 2002, ANNU REV MED, V53, P409, DOI 10.1146/annurev.med.53.082901.104018; Berger J, 1996, ENDOCRINOLOGY, V137, P4189, DOI 10.1210/en.137.10.4189; Boden G, 2002, EUR J CLIN INVEST, V32, P14, DOI 10.1046/j.1365-2362.32.s3.3.x; Chao L, 2000, J CLIN INVEST, V106, P1221, DOI 10.1172/JCI11245; Combs TP, 2001, J CLIN INVEST, V108, P1875, DOI 10.1172/JCI200114120; Combs TP, 2004, ENDOCRINOLOGY, V145, P367, DOI 10.1210/en.2003-1068; Combs TP, 2002, ENDOCRINOLOGY, V143, P998, DOI 10.1210/endo.143.3.8662; Fajas L, 1997, J BIOL CHEM, V272, P18779, DOI 10.1074/jbc.272.30.18779; Fasshauer M, 2002, BIOCHEM BIOPH RES CO, V290, P1084, DOI 10.1006/bbrc.2001.6307; Hardie DG, 1998, ANNU REV BIOCHEM, V67, P821, DOI 10.1146/annurev.biochem.67.1.821; Kim JK, 2003, DIABETES, V52, P1311, DOI 10.2337/diabetes.52.6.1311; Kubota N, 2002, J BIOL CHEM, V277, P25863, DOI 10.1074/jbc.C200251200; Lee CH, 2003, ENDOCRINOLOGY, V144, P2201, DOI 10.1210/en.2003-0288; Ma K, 2002, J BIOL CHEM, V277, P34658, DOI 10.1074/jbc.C200362200; Maeda N, 2002, NAT MED, V8, P731, DOI 10.1038/nm724; Namae M, 1998, LAB ANIM SCI, V48, P103; Pajvani UB, 2005, NAT MED, V11, P797, DOI 10.1038/nm1262; Pajvani UB, 2003, J BIOL CHEM, V278, P9073, DOI 10.1074/jbc.M207198200; Pajvani Utpal B, 2003, Curr Diab Rep, V3, P207, DOI 10.1007/s11892-003-0065-2; Rajala MW, 2003, J CLIN INVEST, V111, P225, DOI 10.1172/JCI200316521; Rangwala SM, 2004, TRENDS PHARMACOL SCI, V25, P331, DOI 10.1016/j.tips.2004.03.012; Ruderman NB, 2003, ACTA PHYSIOL SCAND, V178, P435, DOI 10.1046/j.1365-201X.2003.01164.x; Saha AK, 2004, BIOCHEM BIOPH RES CO, V314, P580, DOI 10.1016/j.bbrc.2003.12.120; Steppan CM, 2001, NATURE, V409, P307, DOI 10.1038/35053000; Tomas E, 2002, P NATL ACAD SCI USA, V99, P16309, DOI 10.1073/pnas.222657499; Vavvas D, 1997, J BIOL CHEM, V272, P13255, DOI 10.1074/jbc.272.20.13255; Vincent MF, 1996, DIABETOLOGIA, V39, P1148, DOI 10.1007/BF02658500; Wellen KE, 2004, ENDOCRINOLOGY, V145, P2214, DOI 10.1210/en.2003-1580; Wilson-Fritch L, 2003, MOL CELL BIOL, V23, P1085, DOI 10.1128/MCB.23.3.1085-1094.2003; Winder WW, 1999, AM J PHYSIOL-ENDOC M, V277, pE1, DOI 10.1152/ajpendo.1999.277.1.E1; Yamauchi T, 2002, NAT MED, V8, P1288, DOI 10.1038/nm788; Yamauchi T, 2001, J BIOL CHEM, V276, P41245, DOI 10.1074/jbc.M103241200; Yang WS, 2001, J CLIN ENDOCR METAB, V86, P3815, DOI 10.1210/jc.86.8.3815	35	495	514	1	22	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 3	2006	281	5					2654	2660		10.1074/jbc.M505311200	http://dx.doi.org/10.1074/jbc.M505311200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	006XT	16326714	hybrid			2022-12-25	WOS:000234931800030
J	Vetting, MW; Yu, M; Rendle, PM; Blanchard, JS				Vetting, MW; Yu, M; Rendle, PM; Blanchard, JS			The substrate-induced conformational change of Mycobacterium tuberculosis mycothiol synthase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SMEGMATIS MUTANTS; GNAT SUPERFAMILY; ACETYLTRANSFERASES; THIOLS	The structure of the ternary complex of mycothiol synthase from Mycobacterium tuberculosis with bound desacetylmycothiol and CoA was determined to 1.8 angstrom resolution. The structure of the acety-lCoA-binary complex had shown an active site groove that was several times larger than its substrate. The structure of the ternary complex reveals that mycothiol synthase undergoes a large conformational change in which the two acetyltransferase domains are brought together through shared interactions with the functional groups of desacetylmycothiol, thereby decreasing the size of this large central groove. A comparison of the binary and ternary structures illustrates many of the features that promote catalysis. Desacetylmycothiol is positioned with its primary amine in close proximity and in the proper orientation for direct nucleophilic attack on the si-face of the acetyl group of acetyl-CoA. Glu-234 and Tyr-294 are positioned to act as a general base and general acid to promote acetyl transfer. In addition, this structure provides further evidence that the N-terminal acetyltransferase domain no longer has enzymatic activity and is vestigial in nature.	Albert Einstein Coll Med, Dept Biochem, Bronx, NY 10461 USA; Ind Res Ltd, Carbohydrate Chem, Lower Hutt, New Zealand	Yeshiva University; Albert Einstein College of Medicine; Callaghan Innovation	Blanchard, JS (corresponding author), Albert Einstein Coll Med, Dept Biochem, 1300 Morris Pk Ave, Bronx, NY 10461 USA.	blanchar@aecom.yu.edu		Rendle, Phillip/0000-0002-2825-8746	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI033696, T32AI007501, R01AI060899] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007288] Funding Source: NIH RePORTER; NIAID NIH HHS [T32 AI07501, AI60899, AI33696] Funding Source: Medline; NIGMS NIH HHS [T32 GM07288] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Burk DL, 2003, PROTEIN SCI, V12, P426, DOI 10.1110/ps.0233503; DELANO WL, 2002, PYMOL 0 97; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Knapp S, 2002, ORG LETT, V4, P4337, DOI 10.1021/ol0269796; Koledin T, 2002, ARCH MICROBIOL, V178, P331, DOI 10.1007/s00203-002-0462-y; NAVAZA J, 1994, ACTA CRYSTALLOGR A, V50, P157, DOI 10.1107/S0108767393007597; NEWTON GL, 1995, EUR J BIOCHEM, V230, P821; Newton GL, 1996, J BACTERIOL, V178, P1990, DOI 10.1128/jb.178.7.1990-1995.1996; NEWTON GL, 1993, J BACTERIOL, V175, P2734, DOI 10.1128/JB.175.9.2734-2742.1993; Newton GL, 1999, BIOCHEM BIOPH RES CO, V255, P239, DOI 10.1006/bbrc.1999.0156; Newton GL, 2000, BIOCHEMISTRY-US, V39, P10739, DOI 10.1021/bi000356n; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Patel MP, 2001, BIOCHEMISTRY-US, V40, P5119, DOI 10.1021/bi0029144; Rawat M, 2002, ANTIMICROB AGENTS CH, V46, P3348, DOI 10.1128/AAC.46.11.3348-3355.2002; SWEENEY AM, 2002, J APPL CRYSTALLOGR, V36, P165; Vetting MW, 2005, J BIOL CHEM, V280, P22108, DOI 10.1074/jbc.M502401200; Vetting MW, 2005, ARCH BIOCHEM BIOPHYS, V433, P212, DOI 10.1016/j.abb.2004.09.003; Vetting MW, 2003, PROTEIN SCI, V12, P1954, DOI 10.1110/ps.03153703	19	20	24	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 3	2006	281	5					2795	2802		10.1074/jbc.M510798200	http://dx.doi.org/10.1074/jbc.M510798200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	006XT	16326705	hybrid			2022-12-25	WOS:000234931800046
J	Lee, YH; Naider, F; Becker, JM				Lee, YH; Naider, F; Becker, JM			Interacting residues in an activated state of a G protein-coupled receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALPHA-FACTOR RECEPTOR; CEREVISIAE TRIDECAPEPTIDE PHEROMONE; MUSCARINIC ACETYLCHOLINE-RECEPTOR; DOMINANT-NEGATIVE MUTATIONS; TRANSMEMBRANE DOMAINS III; DISULFIDE CROSS-LINKING; SACCHAROMYCES-CEREVISIAE; CONFORMATIONAL-CHANGES; LIGAND SPECIFICITY; EXTRACELLULAR ENDS	Ste2p, the G protein-coupled receptor ( GPCR) for the tridecapeptide pheromone alpha- factor of Saccharomyces cerevisiae, was used as a model GPCR to investigate the role of specific residues in the resting and activated states of the receptor. Using a series of biological and biochemical analyses of wild-type and site-directed mutant receptors, we identified Asn(205) as a potential interacting partner with the Tyr(266) residue. An N205H/Y266H double mutant showed pH-dependent functional activity, whereas the N205H receptor was non-functional and the Y266H receptor was partially active indicating that the histidine 205 and 266 residues interact in an activated state of the receptor. The introduction of N205K or Y266D mutations into the P258L/S259L constitutively active receptor suppressed the constitutive activity; in contrast, the N205K/ Y266D/P258L/S259L quadruple mutant was fully constitutively active, again indicating an interaction between residues at the 205 and 206 positions in the receptor-active state. To further test this interaction, we introduced the N205C/Y266C, F204C/Y266C, and N205C/A265C double mutations into wild-type and P258L/S259L constitutively active receptors. After trypsin digestion, we found that a disulfide-cross-linked product, with the molecular weight expected for a receptor fragment with a cross-link between N205C and Y266C, formed only in the N205C/ Y266C constitutively activated receptor. This study represents the first experimental demonstration of an interaction between specific residues in an active state, but not the resting state, of Ste2p. The information gained from this study should contribute to an understanding of the conformational differences between resting and active states in GPCRs.	Univ Tennessee, Dept Microbiol, Knoxville, TN 37996 USA; Univ Tennessee, Grad Sch Genome Sci & Technol, Knoxville, TN 37996 USA; CUNY Coll Staten Isl, Dept Chem, Staten Isl, NY 10314 USA; CUNY Coll Staten Isl, Macromol Assemblies Inst, Staten Isl, NY 10314 USA; CUNY Grad Sch & Univ Ctr, Staten Isl, NY 10314 USA	University of Tennessee System; University of Tennessee Knoxville; University of Tennessee System; University of Tennessee Knoxville; City University of New York (CUNY) System; College of Staten Island (CUNY); City University of New York (CUNY) System; College of Staten Island (CUNY); City University of New York (CUNY) System; City University of New York (CUNY) Graduate School	Becker, JM (corresponding author), Univ Tennessee, Dept Microbiol, Knoxville, TN 37996 USA.	jbecker@utk.edu			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R56GM022087, R56GM022086, R01GM022086, R01GM022087] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM 22086, GM 22087] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Abel MG, 1998, BBA-MOL CELL RES, V1448, P12, DOI 10.1016/S0167-4889(98)00109-8; Abel MG, 1998, J PEPT RES, V52, P95; BLUMER KJ, 1990, P NATL ACAD SCI USA, V87, P4363, DOI 10.1073/pnas.87.11.4363; Cai KW, 1997, P NATL ACAD SCI USA, V94, P14267, DOI 10.1073/pnas.94.26.14267; Chen QJ, 1996, MOL CELL BIOL, V16, P247; CHENG Y, 1973, BIOCHEM PHARMACOL, V22, P3099; Ding FX, 2002, J PEPT RES, V60, P65, DOI 10.1034/j.1399-3011.2002.21004.x; Ding FX, 2001, BIOCHEMISTRY-US, V40, P1102, DOI 10.1021/bi0021535; DOHLMAN HG, 1991, ANNU REV BIOCHEM, V60, P653, DOI 10.1146/annurev.biochem.60.1.653; Dosil M, 2000, MOL CELL BIOL, V20, P5321, DOI 10.1128/MCB.20.14.5321-5329.2000; Dosil M, 1998, MOL CELL BIOL, V18, P5981, DOI 10.1128/MCB.18.10.5981; Dube P, 1998, MOL CELL BIOL, V18, P7205, DOI 10.1128/MCB.18.12.7205; Dube P, 2000, J BIOL CHEM, V275, P26492, DOI 10.1074/jbc.M002767200; Eilers M, 2005, BIOCHEMISTRY-US, V44, P8959, DOI 10.1021/bi047316u; Elling CE, 1999, P NATL ACAD SCI USA, V96, P12322, DOI 10.1073/pnas.96.22.12322; Farrens DL, 1996, SCIENCE, V274, P768, DOI 10.1126/science.274.5288.768; Gether U, 1997, EMBO J, V16, P6737, DOI 10.1093/emboj/16.22.6737; GUARENTE L, 1983, METHOD ENZYMOL, V101, P181; Han SJ, 2005, J BIOL CHEM, V280, P34849, DOI 10.1074/jbc.M506711200; Han SJ, 2005, J BIOL CHEM, V280, P24870, DOI 10.1074/jbc.M500379200; Henry LK, 2002, BIOCHEMISTRY-US, V41, P6128, DOI 10.1021/bi015863z; Holst B, 2000, MOL PHARMACOL, V58, P263, DOI 10.1124/mol.58.2.263; Hunyady L, 2003, TRENDS PHARMACOL SCI, V24, P81, DOI 10.1016/S0165-6147(02)00050-0; JENNESS DD, 1986, MOL CELL BIOL, V6, P318, DOI 10.1128/MCB.6.1.318; Karnik SS, 2003, TRENDS ENDOCRIN MET, V14, P431, DOI 10.1016/j.tem.2003.09.007; KIPPERT F, 1995, FEMS MICROBIOL LETT, V128, P201, DOI 10.1016/0378-1097(95)00113-J; Klabunde T, 2002, CHEMBIOCHEM, V3, P929, DOI 10.1002/1439-7633(20021004)3:10<928::AID-CBIC928>3.0.CO;2-5; Klco JM, 2005, NAT STRUCT MOL BIOL, V12, P320, DOI 10.1038/nsmb913; Konopka JB, 1996, P NATL ACAD SCI USA, V93, P6764, DOI 10.1073/pnas.93.13.6764; Kristiansen K, 2004, PHARMACOL THERAPEUT, V103, P21, DOI 10.1016/j.pharmthera.2004.05.002; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; Leavitt LM, 1999, MOL GEN GENET, V261, P917, DOI 10.1007/s004380051039; Lee BK, 2002, BIOCHEMISTRY-US, V41, P13681, DOI 10.1021/bi026100u; Lee BK, 2001, J BIOL CHEM, V276, P37950; LEFF P, 1995, TRENDS PHARMACOL SCI, V16, P89, DOI 10.1016/S0165-6147(00)88989-0; LEFKOWITZ RJ, 1993, TRENDS PHARMACOL SCI, V14, P303, DOI 10.1016/0165-6147(93)90048-O; Lin JC, 2004, MOL CELL BIOL, V24, P2041, DOI 10.1128/MCB.24.5.2041-2051.2004; Lin JC, 2003, BIOCHEMISTRY-US, V42, P293, DOI 10.1021/bi026766o; Overton MC, 2003, J BIOL CHEM, V278, P49369, DOI 10.1074/jbc.M308654200; Palczewski K, 2000, SCIENCE, V289, P739, DOI 10.1126/science.289.5480.739; Parrish W, 2002, GENETICS, V160, P429; RATHS SK, 1988, J BIOL CHEM, V263, P17333; Schwede T, 2003, NUCLEIC ACIDS RES, V31, P3381, DOI 10.1093/nar/gkg520; SEN M, 1994, J BIOL CHEM, V269, P968; Sen M, 1997, CURR GENET, V31, P235, DOI 10.1007/s002940050200; Shah A, 1996, BIOCHEM BIOPH RES CO, V226, P242, DOI 10.1006/bbrc.1996.1340; Shapiro DA, 2002, J BIOL CHEM, V277, P11441, DOI 10.1074/jbc.M111675200; Sommers CM, 1997, J MOL BIOL, V266, P559, DOI 10.1006/jmbi.1996.0816; STEFAN CJ, 1994, MOL CELL BIOL, V14, P3339, DOI 10.1128/MCB.14.5.3339; Stefan CJ, 1998, MOL BIOL CELL, V9, P885, DOI 10.1091/mbc.9.4.885; Swaminath G, 2004, J BIOL CHEM, V279, P686, DOI 10.1074/jbc.M310888200; Swaminath G, 2003, J BIOL CHEM, V278, P352, DOI 10.1074/jbc.M206424200; VIEIRA J, 1987, METHOD ENZYMOL, V153, P3; Ward SDC, 2002, J BIOL CHEM, V277, P2247, DOI 10.1074/jbc.M107647200; Yu BM, 2004, J BIOL CHEM, V279, P40972, DOI 10.1074/jbc.M405300200; Yu HB, 1999, BIOCHEMISTRY-US, V38, P12028, DOI 10.1021/bi990948+; Zhang YL, 1997, J PEPT RES, V50, P319	57	24	25	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 27	2006	281	4					2263	2272		10.1074/jbc.M509987200	http://dx.doi.org/10.1074/jbc.M509987200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	004NV	16314417	hybrid			2022-12-25	WOS:000234760400051
J	Akasaki, Y; Liu, GT; Matundan, HH; Ng, HS; Yuan, XP; Zeng, ZH; Black, KL; Yu, JS				Akasaki, Y; Liu, GT; Matundan, HH; Ng, HS; Yuan, XP; Zeng, ZH; Black, KL; Yu, JS			A peroxisome proliferator-activated receptor-gamma agonist, troglitazone, facilitates caspase-8 and-9 activities by increasing the enzymatic activity of protein-tyrosine phosphatase-1B on human glioma cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MEDIATED APOPTOSIS; GLIOBLASTOMA CELLS; CYTOCHROME-C; INDUCTION; KINASE; RESISTANCE; INHIBITION; GROWTH; THIAZOLIDINEDIONES; EXPRESSION	Despite dramatic advances in adjuvant therapies, patients with malignant glioma face a bleak prognosis. Because many adjuvant therapies seek to induce glioma apoptosis, strategies that lower thresholds for the induction of apoptosis may improve patient outcomes. Therefore, elucidation of the biological mechanisms that underlie resistance to current therapies is needed to develop new therapeutic strategies. Here we proposed a novel mechanism of proapoptotic effect induced by a pharmacological peroxisome proliferator-activated receptor-gamma (PPAR gamma) agonist, troglitazone, that facilitates caspase signaling in human glioma cells. Troglitazone activates protein-tyrosine phosphatase (PTP)-1B, which subsequently reduces phosphotyrosine 705 STAT3 (pY705-STAT3) via a PPAR gamma-independent pathway. Reduction of pY705-STAT3 in glioma cells caused down-regulation of FLIP (FADD-like IL-1 beta-converting enzyme-inhibitory protein) and Bcl-2. Furthermore, troglitazone induced Ser-392 phosphorylation of p53 via a PPAR gamma-dependent pathway and up-regulation of Bax in a p53 wild-type glioma. When given with tumor necrosis factor-related apoptosis-inducing ligand or caspase-dependent chemotherapeutic agents, such as etoposide and paclitaxel, troglitazone exhibited a synergistic effect by facilitating caspase-8/9 activities. A PPAR gamma antagonist, GW9662, did not block this effect, although a PTP inhibitor abrogated it. Knockdown of STAT3 by STAT3-small interfering RNA negated the inhibitory effect of PTP inhibitor on troglitazone, indicating that troglitazone uses a STAT3 inactivation mechanism that makes caspase-8/9 activities susceptible to cytotoxic agents in glioma cells and that PTP1B plays a critical role in the down-regulation of activated STAT3, as well as FLIP and Bcl-2. When taken with caspase-dependent anti-neoplastic agents, troglitazone may be a promising drug for use against malignant gliomas because it facilitates the caspase cascade, thereby lowering thresholds for the apoptosis induction of glioma cells.	Cedars Sinai Med Ctr, Maxine Dunitz Neurosurg Inst, Los Angeles, CA 90048 USA	Cedars Sinai Medical Center	Yu, JS (corresponding author), Cedars Sinai Med Ctr, Maxine Dunitz Neurosurg Inst, 800 E,8631 W 3rd St, Los Angeles, CA 90048 USA.	yuj@cshs.org		Yu, John/0000-0003-1230-8494; Black, Keith/0000-0002-0546-4934				Adams JM, 1998, SCIENCE, V281, P1322, DOI 10.1126/science.281.5381.1322; Akasaki Y, 2004, J IMMUNOL, V173, P4352, DOI 10.4049/jimmunol.173.7.4352; Andersen JN, 2001, MOL CELL BIOL, V21, P7117, DOI 10.1128/MCB.21.21.7117-7136.2001; Arabaci G, 1999, J AM CHEM SOC, V121, P5085, DOI 10.1021/ja9906756; Ashkenazi A, 1999, J CLIN INVEST, V104, P155, DOI 10.1172/JCI6926; Bobola MS, 2004, CLIN CANCER RES, V10, P7875, DOI 10.1158/1078-0432.CCR-04-1161; Bousquet C, 1999, J CLIN INVEST, V104, P1277, DOI 10.1172/JCI7924; Chakravarti A, 2004, ONCOGENE, V23, P7494, DOI 10.1038/sj.onc.1208049; Charest A, 2003, P NATL ACAD SCI USA, V100, P916, DOI 10.1073/pnas.242741799; Chen CW, 2003, J IMMUNOL, V171, P979, DOI 10.4049/jimmunol.171.2.979; FRANGIONI JV, 1992, CELL, V68, P545, DOI 10.1016/0092-8674(92)90190-N; FRANGIONI JV, 1993, EMBO J, V12, P4843, DOI 10.1002/j.1460-2075.1993.tb06174.x; Haga S, 2003, J CLIN INVEST, V112, P989, DOI 10.1172/JCI200317970; Hao CH, 2001, CANCER RES, V61, P1162; Hsu S, 2003, CELL SIGNAL, V15, P1149, DOI 10.1016/S0898-6568(03)00088-3; Hunter T, 2000, CELL, V100, P113, DOI 10.1016/S0092-8674(00)81688-8; Kaszubska W, 2002, MOL CELL ENDOCRINOL, V195, P109, DOI 10.1016/S0303-7207(02)00178-8; Kim Y, 2002, J BIOL CHEM, V277, P22320, DOI 10.1074/jbc.M202458200; Knight MJ, 2001, ONCOGENE, V20, P5789, DOI 10.1038/sj.onc.1204810; Koeffler HP, 2003, CLIN CANCER RES, V9, P1; Kohn KW, 1999, MOL BIOL CELL, V10, P2703, DOI 10.1091/mbc.10.8.2703; Konnikova L, 2003, BMC CANCER, V3, DOI 10.1186/1471-2407-3-23; Krueger A, 2001, MOL CELL BIOL, V21, P8247, DOI 10.1128/MCB.21.24.8247-8254.2001; Kuwana T, 1998, J BIOL CHEM, V273, P16589, DOI 10.1074/jbc.273.26.16589; Lefebvre AM, 1998, NAT MED, V4, P1053, DOI 10.1038/2036; Li B, 2003, CANCER RES, V63, P7443; Li P, 1997, CELL, V91, P479, DOI 10.1016/S0092-8674(00)80434-1; Lin CF, 2004, J BIOL CHEM, V279, P40755, DOI 10.1074/jbc.M404726200; Liu GT, 2004, EUR J IMMUNOL, V34, P1680, DOI 10.1002/eji.200425081; Nikitakis NG, 2002, BRIT J CANCER, V87, P1396, DOI 10.1038/sj.bjc.6600618; Ostman A, 2001, TRENDS CELL BIOL, V11, P258, DOI 10.1016/S0962-8924(01)01990-0; Palakurthi SS, 2001, CANCER RES, V61, P6213; Park EJ, 2003, J BIOL CHEM, V278, P14747, DOI 10.1074/jbc.M210819200; Park SJ, 2004, J BIOL CHEM, V279, P51057, DOI 10.1074/jbc.M406543200; Perkins CL, 2000, CANCER RES, V60, P1645; Reed John C., 1999, Current Opinion in Oncology, V11, P68, DOI 10.1097/00001622-199901000-00014; Rippo MR, 2004, ONCOGENE, V23, P7753, DOI 10.1038/sj.onc.1208051; Saez E, 1998, NAT MED, V4, P1058, DOI 10.1038/2042; Schaefer LK, 2002, ONCOGENE, V21, P2058, DOI 10.1038/sj.onc.1205263; Shiau CW, 2005, CANCER RES, V65, P1561, DOI 10.1158/0008-5472.CAN-04-1677; Shimizu S, 1999, NATURE, V399, P483, DOI 10.1038/20959; Teixeira JE, 2002, INFECT IMMUN, V70, P1816, DOI 10.1128/IAI.70.4.1816-1823.2002; Thomas CY, 2003, INT J CANCER, V104, P19, DOI 10.1002/ijc.10880; Thomas LR, 2004, J BIOL CHEM, V279, P32780, DOI 10.1074/jbc.M401680200; VAN MEIR EG, 1994, CANCER RES, V54, P649; Weissenberger J, 2004, ONCOGENE, V23, P3308, DOI 10.1038/sj.onc.1207455; Wolf BB, 1999, J BIOL CHEM, V274, P30651, DOI 10.1074/jbc.274.43.30651; Yoon G, 2002, J NEURO-ONCOL, V60, P135, DOI 10.1023/A:1020604705831; Zabolotny JM, 2002, DEV CELL, V2, P489, DOI 10.1016/S1534-5807(02)00148-X; Zhang XP, 2004, CANCER RES, V64, P7086, DOI 10.1158/0008-5472.CAN-04-1498	50	63	65	1	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 10	2006	281	10					6165	6174		10.1074/jbc.M505266200	http://dx.doi.org/10.1074/jbc.M505266200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	022BX	16319070	hybrid			2022-12-25	WOS:000236030800008
J	Yamada, HY; Gorbsky, GJ				Yamada, HY; Gorbsky, GJ			Tumor suppressor candidate TSSC5 is regulated by UbcH6 and a novel ubiquitin ligase RING105	ONCOGENE			English	Article						TSSC5; protease associated; RING finger; ubiquitin ligase; UbcH6; 11p15.5	RETICULUM-ASSOCIATED DEGRADATION; CHROMOSOME 11P15.5; POLYSPECIFIC TRANSPORTER; IMPRINTED GENE; PROTEIN; IDENTIFICATION; KINETOCHORES; ASSOCIATION; PROTEOLYSIS; MUTATIONS	The region of human chromosome 11p15.5 is linked with Beckwith-Wiedemann syndrome that is associated with susceptibility to Wilms' tumor, rhabdomyosarcoma and hepatoblastoma. TSSC5 (tumor-suppressing subchromo-somal transferable fragment cDNA; also known as ORCTL2/IMPT1/BWR1A/SLC22A1L) is located in the region. The expression of TSSC5 and other genes in the region is regulated through paternal imprinting. Mutations and/or reduced expression of TSSC5 have been found in certain tumors. TSSC5 encodes an efflux transporter-like protein with 10 transmembrane domains, whose regulation may affect drug sensitivity, cellular metabolism and growth. Here, we present evidences indicating that RING105, a novel conserved RING-finger protein with a PA (protease-associated) domain and a PEST sequence, is a ubiquitin ligase for TSSC5 that can function in concert with the ubiquitin-conjugating enzyme UbcH6. The polyubiquitin target site on TSSC5 was mapped to a region in the 6th hydrophilic loop. Ectopic expression of RING105 in HeLa cells caused an accumulation of cells during G1 that was not observed with the expression of a form of RING105 in which a residue within the RING finger was mutated to inactivate its ligase activity. UbcH6-RING105 may de. ne a novel ubiquitin-proteasome pathway that targets TSSC5 in mammalian cells.	OMRF, Mol Cell & Dev Biol Res Program, Oklahoma City, OK 73104 USA	Oklahoma Medical Research Foundation	Yamada, HY (corresponding author), OMRF, Mol Cell & Dev Biol Res Program, 825 NE 13th St MS48, Oklahoma City, OK 73104 USA.	Hiroshi-yamada@omrf.ouhsc.edu		Yamada, Hiroshi/0000-0002-0536-5581; Gorbsky, Gary/0000-0003-3076-4725	NIGMS NIH HHS [R01-GM50412, R01 GM050412, R01 GM050412-07] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM050412] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Albrecht S, 2004, INT J CANCER, V111, P627, DOI 10.1002/ijc.20280; Almond JB, 2002, LEUKEMIA, V16, P433, DOI 10.1038/sj.leu.2402417; Biederer T, 1997, SCIENCE, V278, P1806, DOI 10.1126/science.278.5344.1806; Bonifacino JS, 1998, ANNU REV CELL DEV BI, V14, P19, DOI 10.1146/annurev.cellbio.14.1.19; Cooper PR, 1998, GENOMICS, V49, P38, DOI 10.1006/geno.1998.5221; Cui HM, 2003, SCIENCE, V299, P1753, DOI 10.1126/science.1080902; Dao D, 1998, HUM MOL GENET, V7, P597, DOI 10.1093/hmg/7.4.597; Feinberg AP, 1999, CANCER RES, V59, p1743S; FEINBERG AP, 1994, J CELL SCI, P7; Gilon T, 2000, MOL CELL BIOL, V20, P7214, DOI 10.1128/MCB.20.19.7214-7219.2000; Hampton RY, 2002, CURR OPIN CELL BIOL, V14, P476, DOI 10.1016/S0955-0674(02)00358-7; Hershko A, 1997, CURR OPIN CELL BIOL, V9, P788, DOI 10.1016/S0955-0674(97)80079-8; Hershko A, 1998, ANNU REV BIOCHEM, V67, P425, DOI 10.1146/annurev.biochem.67.1.425; Hirsch C, 2004, BBA-MOL CELL RES, V1695, P215, DOI 10.1016/j.bbamcr.2004.10.006; Jordan MA, 2004, NAT REV CANCER, V4, P253, DOI 10.1038/nrc1317; Kallio M, 1998, J CELL BIOL, V141, P1393, DOI 10.1083/jcb.141.6.1393; Kallio MJ, 2002, J CELL BIOL, V158, P841, DOI 10.1083/jcb.200201135; Kang DM, 2002, J CELL BIOL, V156, P249, DOI 10.1083/jcb.200108016; KOI M, 1993, SCIENCE, V260, P361, DOI 10.1126/science.8469989; Lee MP, 1998, CANCER RES, V58, P4155; Lewis A, 2004, CURR BIOL, V14, pR284, DOI 10.1016/j.cub.2004.03.026; Li TK, 2001, ANNU REV PHARMACOL, V41, P53, DOI 10.1146/annurev.pharmtox.41.1.53; LOVERING R, 1993, P NATL ACAD SCI USA, V90, P2112, DOI 10.1073/pnas.90.6.2112; Mahon P, 2000, PROTEIN SCI, V9, P1930, DOI 10.1110/ps.9.10.1930; McCracken AA, 2003, BIOESSAYS, V25, P868, DOI 10.1002/bies.10320; Pagano M, 1997, FASEB J, V11, P1067, DOI 10.1096/fasebj.11.13.9367342; Paulsen M, 1998, HUM MOL GENET, V7, P1149, DOI 10.1093/hmg/7.7.1149; Poirier K, 2003, J PATHOL, V201, P473, DOI 10.1002/path.1477; Ptak C, 2001, MOL CELL BIOL, V21, P6537, DOI 10.1128/MCB.21.19.6537-6548.2001; Ravenel JD, 2001, JNCI-J NATL CANCER I, V93, P1698, DOI 10.1093/jnci/93.22.1698; Rechsteiner M, 1996, TRENDS BIOCHEM SCI, V21, P267, DOI 10.1016/S0968-0004(96)10031-1; Reece M, 1998, FEBS LETT, V433, P245, DOI 10.1016/S0014-5793(98)00907-7; Romisch K, 2005, ANNU REV CELL DEV BI, V21, P435, DOI 10.1146/annurev.cellbio.21.012704.133250; Sagne C, 1996, BIOCHEM J, V316, P825, DOI 10.1042/bj3160825; Schwienbacher C, 1998, P NATL ACAD SCI USA, V95, P3873, DOI 10.1073/pnas.95.7.3873; Schwienbacher C, 2000, P NATL ACAD SCI USA, V97, P5445, DOI 10.1073/pnas.090087497; Topper LM, 2001, J CELL BIOL, V154, P707, DOI 10.1083/jcb.200104130	37	28	35	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 2	2006	25	9					1330	1339		10.1038/sj.onc.1209167	http://dx.doi.org/10.1038/sj.onc.1209167			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	017QN	16314844	Green Accepted			2022-12-25	WOS:000235708200006
J	Bienert, R; Baier, K; Volkmer, R; Lockau, W; Heinemann, U				Bienert, R; Baier, K; Volkmer, R; Lockau, W; Heinemann, U			Crystal structure of NblA from Anabaena sp PCC 7120, a small protein playing a key role in phycobilisome degradation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; MACROMOLECULAR STRUCTURES; CYANOBACTERIUM ANABAENA; SPIRULINA-PLATENSIS; DIFFRACTION DATA; STRAIN PCC-6803; PHYCOCYANIN; EXPRESSION; NITROGEN; REFINEMENT	Cyanobacterial light-harvesting complexes, the phycobilisomes, are proteolytically degraded when the organisms are starved for combined nitrogen, a process referred to as chlorosis or bleaching. Gene nblA, present in all phycobilisome-containing organisms, encodes a protein of about 7 kDa that plays a key role in phycobilisome degradation. The mode of action of NblA in this degradation process is poorly understood. Here we presented the 1.8-angstrom crystal structure of NblA from Anabaena sp. PCC 7120. In the crystal, NblA is present as a four-helix bundle formed by dimers, the basic structural units. By using pull-down assays with immobilized NblA and peptide scanning, we showed that NblA specifically binds to the alpha-subunits of phycocyanin and phycoerythrocyanin, the main building blocks of the phycobilisome rod structure. By site-directed mutagenesis, we identified amino acid residues in NblA that are involved in phycobilisome binding. The results provided evidence that NblA is directly involved in phycobilisome degradation, and the results allowed us to present a model that gives insight into the interaction of this small protein with the phycobilisomes.	Max Delbruck Ctr Mol Med, Crystallog Grp, D-13125 Berlin, Germany; Humboldt Univ, Inst Biol, D-10115 Berlin, Germany; CCM Univ Med Berlin, Mol Lib, Inst Med Immunol, D-10115 Berlin, Germany; Free Univ Berlin, Inst Chem Crystallog, D-14195 Berlin, Germany	Helmholtz Association; Max Delbruck Center for Molecular Medicine; Humboldt University of Berlin; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Free University of Berlin	Baier, K (corresponding author), Max Delbruck Ctr Mol Med, Crystallog Grp, FG Kristallog,Robert Rossle Str 10, D-13125 Berlin, Germany.	kerstin.baier@biologie.hu-berlin.de	Heinemann, Udo/S-3379-2016; Heinemann, Udo/AAH-4766-2019	Heinemann, Udo/0000-0002-8191-3850; Heinemann, Udo/0000-0002-8191-3850; Volkmer, Rudolf/0000-0003-4710-1143				ALLEN MM, 1969, ARCH MIKROBIOL, V69, P114, DOI 10.1007/BF00409755; Baier K, 2004, MICROBIOL-SGM, V150, P2739, DOI 10.1099/mic.0.27153-0; Baier K, 2001, FEMS MICROBIOL LETT, V195, P35, DOI 10.1111/j.1574-6968.2001.tb10494.x; Boisguerin P, 2004, CHEM BIOL, V11, P449, DOI 10.1016/j.chembiol.2004.03.010; BOUSSIBA S, 1980, ARCH MICROBIOL, V125, P143, DOI 10.1007/BF00403211; BUDISA N, 1995, EUR J BIOCHEM, V230, P788; COLLIER JL, 1994, EMBO J, V13, P1039, DOI 10.1002/j.1460-2075.1994.tb06352.x; Combet C, 2000, TRENDS BIOCHEM SCI, V25, P147, DOI 10.1016/S0968-0004(99)01540-6; Diederichs K, 1997, NAT STRUCT BIOL, V4, P269, DOI 10.1038/nsb0497-269; Dolganov N, 1999, J BACTERIOL, V181, P610, DOI 10.1128/JB.181.2.610-617.1999; DUERRING M, 1990, J MOL BIOL, V211, P633, DOI 10.1016/0022-2836(90)90270-V; ENGH RA, 1991, ACTA CRYSTALLOGR A, V47, P392, DOI 10.1107/S0108767391001071; FOULDS IJ, 1977, FEMS MICROBIOL LETT, V2, P117; GLAZER AN, 1982, ANNU REV MICROBIOL, V36, P173, DOI 10.1146/annurev.mi.36.100182.001133; Grossman AR, 2001, J BIOL CHEM, V276, P11449, DOI 10.1074/jbc.R100003200; Hooft RWW, 1996, NATURE, V381, P272, DOI 10.1038/381272a0; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KABSCH W, 1976, ACTA CRYSTALLOGR A, V32, P922, DOI 10.1107/S0567739476001873; KABSCH W, 1993, J APPL CRYSTALLOGR, V26, P795, DOI 10.1107/S0021889893005588; Koradi R, 1996, J MOL GRAPHICS, V14, P51, DOI 10.1016/0263-7855(96)00009-4; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Landgraf C, 2004, PLOS BIOL, V2, P94, DOI 10.1371/journal.pbio.0020014; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Li H, 2002, ARCH MICROBIOL, V178, P256, DOI 10.1007/s00203-002-0446-y; LOCKAU W, 1988, EUR J BIOCHEM, V172, P433, DOI 10.1111/j.1432-1033.1988.tb13906.x; Luque I, 2003, MOL MICROBIOL, V50, P1043, DOI 10.1046/j.1365-2958.2003.03768.x; MALDENER I, 1991, MOL GEN GENET, V225, P113, DOI 10.1007/BF00282649; MATTHEWS BW, 1968, J MOL BIOL, V33, P491, DOI 10.1016/0022-2836(68)90205-2; Muffler A, 1996, EMBO J, V15, P1333, DOI 10.1002/j.1460-2075.1996.tb00475.x; Murshudov GN, 1997, ACTA CRYSTALLOGR D, V53, P240, DOI 10.1107/S0907444996012255; Nanni B, 2001, MICROBIOL RES, V156, P259, DOI 10.1078/0944-5013-00110; Perrakis A, 2001, ACTA CRYSTALLOGR D, V57, P1445, DOI 10.1107/S0907444901014007; Piven I, 2005, J BIOL CHEM, V280, P21667, DOI 10.1074/jbc.m412967200; Ramachandran G N, 1968, Adv Protein Chem, V23, P283, DOI 10.1016/S0065-3233(08)60402-7; Reineke U, 2001, CURR OPIN BIOTECH, V12, P59, DOI 10.1016/S0958-1669(00)00178-6; Richaud C, 2001, J BACTERIOL, V183, P2989, DOI 10.1128/JB.183.10.2989-2994.2001; Romero P, 2001, PROTEINS, V42, P38, DOI 10.1002/1097-0134(20010101)42:1<38::AID-PROT50>3.0.CO;2-3; ROST B, 1993, J MOL BIOL, V232, P584, DOI 10.1006/jmbi.1993.1413; Rost B, 1996, METHOD ENZYMOL, V266, P525; Strauss H, 2002, EUR J BIOCHEM, V269, P4617, DOI 10.1046/j.1432-1033.2002.03161.x; Studemann A, 2003, EMBO J, V22, P4111, DOI 10.1093/emboj/cdg411; Terwilliger TC, 1999, ACTA CRYSTALLOGR D, V55, P849, DOI 10.1107/S0907444999000839; Terwilliger TC, 2003, ACTA CRYSTALLOGR D, V59, P38, DOI 10.1107/S0907444902018036; Terwilliger TC, 2000, ACTA CRYSTALLOGR D, V56, P965, DOI 10.1107/S0907444900005072; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; Toole CM, 1998, MOL MICROBIOL, V30, P475, DOI 10.1046/j.1365-2958.1998.01082.x; Weiser AA, 2005, ANAL BIOCHEM, V342, P300, DOI 10.1016/j.ab.2005.04.033; Winn MD, 2001, ACTA CRYSTALLOGR D, V57, P122, DOI 10.1107/S0907444900014736; WOOD NB, 1979, LTD PROTEOLYSIS MICR, P159	49	38	40	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 24	2006	281	8					5216	5223		10.1074/jbc.M507243200	http://dx.doi.org/10.1074/jbc.M507243200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	013RF	16356935	hybrid			2022-12-25	WOS:000235426200076
J	Song, G; Lazar, GA; Kortemme, T; Shimaoka, M; Desjarlais, JR; Baker, D; Springer, TA				Song, G; Lazar, GA; Kortemme, T; Shimaoka, M; Desjarlais, JR; Baker, D; Springer, TA			Rational design of intercellular adhesion molecule-1 (ICAM-1) variants for antagonizing integrin lymphocyte function-associated antigen-1-dependent adhesion	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-PROTEIN COMPLEXES; HIGH-LEVEL EXPRESSION; I-LIKE DOMAIN; CONFORMATIONAL REGULATION; COMPUTATIONAL DESIGN; BINDING-ENERGY; HIGH-AFFINITY; SUBUNIT; RECOGNITION; PREDICTION	The interaction between integrin lymphocyte function-associated antigen-1 ( LFA-1) and its ligand intercellular adhesion molecule-1 ( ICAM-1) is critical in immunological and inflammatory reactions but, like other adhesive interactions, is of low affinity. Here, multiple rational design methods were used to engineer ICAM-1 mutants with enhanced affinity for LFA-1. Five amino acid substitutions 1) enhance the hydrophobicity and packing of residues surrounding Glu-34 of ICAM-1, which coordinates to a Mg2+ in the LFA-1 I domain, and 2) alter associations at the edges of the binding interface. The affinity of the most improved ICAM-1 mutant for intermediate-and high-affinity LFA-1 I domains was increased by 19-fold and 22-fold, respectively, relative to wild type. Moreover, potency was similarly enhanced for inhibition of LFA-1-dependent ligand binding and cell adhesion. Thus, rational design can be used to engineer novel adhesion molecules with high monomeric affinity; furthermore, the ICAM-1 mutant holds promise for targeting LFA-1-ICAM-1 interaction for biological studies and therapeutic purposes.	Harvard Univ, Sch Med, CBR Inst Biochem Res, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Pathol, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Anesthesia, Boston, MA 02115 USA; Xencor, Monrovia, CA 91016 USA; Univ Washington, Howard Hughes Med Inst, Seattle, WA 98195 USA; Univ Washington, Dept Biochem, Seattle, WA 98195 USA	Harvard University; Boston Children's Hospital; Program in Cellular & Molecular Medicine (PCMM); Harvard Medical School; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; Howard Hughes Medical Institute; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle	Springer, TA (corresponding author), Harvard Univ, Sch Med, CBR Inst Biochem Res, 200 Longwood Ave, Boston, MA 02115 USA.	springeroffice@cbr.med.harvard.edu	Kortemme, Tanja/AAN-3180-2021; Baker, David/K-8941-2012	Baker, David/0000-0001-7896-6217; Kortemme, Tanja/0000-0002-8494-680X; Lazar, Greg/0000-0003-2169-8703	NCI NIH HHS [R01 CA031798, CA31798, R37 CA031798] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R37CA031798, R01CA031798] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Altman JD, 1996, SCIENCE, V274, P94, DOI 10.1126/science.274.5284.94; Carson M, 1997, METHOD ENZYMOL, V277, P493, DOI 10.1016/S0076-6879(97)77027-7; CLACKSON T, 1995, SCIENCE, V267, P383, DOI 10.1126/science.7529940; Clackson T, 1998, J MOL BIOL, V277, P1111, DOI 10.1006/jmbi.1998.1669; Crawford F, 1998, IMMUNITY, V8, P675, DOI 10.1016/S1074-7613(00)80572-5; Curley GP, 1999, CELL MOL LIFE SCI, V56, P427, DOI 10.1007/s000180050443; Dahiyat BI, 1996, PROTEIN SCI, V5, P895, DOI 10.1002/pro.5560050511; Dahiyat BI, 1997, SCIENCE, V278, P82, DOI 10.1126/science.278.5335.82; Dunbrack RL, 1997, PROTEIN SCI, V6, P1661, DOI 10.1002/pro.5560060807; DUSTIN ML, 1999, GUIDEBOOK EXTRACELLU, P216; Huang CC, 2000, J BIOL CHEM, V275, P21514, DOI 10.1074/jbc.M002286200; Jun CD, 2001, P NATL ACAD SCI USA, V98, P6830, DOI 10.1073/pnas.121186998; Kim M, 2004, J CELL BIOL, V167, P1241, DOI 10.1083/jcb.200404160; Kim M, 2003, SCIENCE, V301, P1720, DOI 10.1126/science.1084174; Kortemme T, 2004, CURR OPIN CHEM BIOL, V8, P91, DOI 10.1016/j.cbpa.2003.12.008; Kortemme T, 2003, J MOL BIOL, V326, P1239, DOI 10.1016/S0022-2836(03)00021-4; Kortemme T, 2002, P NATL ACAD SCI USA, V99, P14116, DOI 10.1073/pnas.202485799; Kuhlman B, 2000, P NATL ACAD SCI USA, V97, P10383, DOI 10.1073/pnas.97.19.10383; Lazar GA, 2003, CURR OPIN STRUC BIOL, V13, P513, DOI 10.1016/S0959-440X(03)00104-0; Lu CF, 1998, J BIOL CHEM, V273, P15138, DOI 10.1074/jbc.273.24.15138; Lu CF, 1997, J IMMUNOL, V159, P268; Luo P, 2002, PROTEIN SCI, V11, P1218, DOI 10.1110/ps.4580102; Marshall SA, 2003, DRUG DISCOV TODAY, V8, P212, DOI 10.1016/S1359-6446(03)02610-2; Martin L, 2003, NAT BIOTECHNOL, V21, P71, DOI 10.1038/nbt768; Mendes J, 1999, PROTEINS, V37, P530; Parkos CA, 1996, MOL MED, V2, P489, DOI 10.1007/BF03401908; Raha K, 2000, PROTEIN SCI, V9, P1106, DOI 10.1110/ps.9.6.1106; Reeves PJ, 2002, P NATL ACAD SCI USA, V99, P13413, DOI 10.1073/pnas.212519199; Reeves PJ, 2002, P NATL ACAD SCI USA, V99, P13419, DOI 10.1073/pnas.212519299; Sarkar CA, 2002, NAT BIOTECHNOL, V20, P908, DOI 10.1038/nbt725; SCHATZ PJ, 1993, BIO-TECHNOL, V11, P1138, DOI 10.1038/nbt1093-1138; Selzer T, 2000, NAT STRUCT BIOL, V7, P537; Selzer T, 1999, J MOL BIOL, V287, P409, DOI 10.1006/jmbi.1999.2615; Shimaoka M, 2001, P NATL ACAD SCI USA, V98, P6009, DOI 10.1073/pnas.101130498; Shimaoka M, 2003, IMMUNITY, V19, P391, DOI 10.1016/S1074-7613(03)00238-3; Shimaoka M, 2003, NAT REV DRUG DISCOV, V2, P703, DOI 10.1038/nrd1174; Shimaoka M, 2003, CELL, V112, P99, DOI 10.1016/S0092-8674(02)01257-6; Shimaoka M, 2002, ANNU REV BIOPH BIOM, V31, P485, DOI 10.1146/annurev.biophys.31.101101.140922; Shimaoka M, 2000, NAT STRUCT BIOL, V7, P674, DOI 10.1038/77978; Song G, 2005, P NATL ACAD SCI USA, V102, P3366, DOI 10.1073/pnas.0500200102; SPRINGER TA, 1990, NATURE, V346, P425, DOI 10.1038/346425a0; SPRINGER TA, 1994, CELL, V76, P301, DOI 10.1016/0092-8674(94)90337-9; STAUNTON DE, 1990, CELL, V61, P243, DOI 10.1016/0092-8674(90)90805-O; Tamada A, 1998, NEUROSCI LETT, V240, P163, DOI 10.1016/S0304-3940(97)00951-8; Tian L, 1997, J IMMUNOL, V158, P928; Wang JH, 2002, TRENDS BIOCHEM SCI, V27, P122, DOI 10.1016/S0968-0004(01)02038-2; Wu LC, 2002, NATURE, V418, P552, DOI 10.1038/nature00920	47	42	43	1	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 24	2006	281	8					5042	5049		10.1074/jbc.M510454200	http://dx.doi.org/10.1074/jbc.M510454200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	013RF	16354667	hybrid, Green Accepted			2022-12-25	WOS:000235426200058
J	Bauman, AT; Yukl, ET; Alkevich, K; McCormack, AL; Blackburn, NJ				Bauman, AT; Yukl, ET; Alkevich, K; McCormack, AL; Blackburn, NJ			The hydrogen peroxide reactivity of peptidylglycine monooxygenase supports a Cu(II)-superoxo catalytic intermediate	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALPHA-HYDROXYLATING MONOOXYGENASE; BINUCLEAR COPPER SITE; AMIDATING ENZYME; OXYGEN ACTIVATION; ELECTRON-TRANSFER; MONONUCLEAR COPPER; PEPTIDE AMIDATION; ACTIVE-SITE; MECHANISM; MUTAGENESIS	We have investigated the reaction of peptidylglycine monooxygenase with hydrogen peroxide to determine whether Cu(II)-peroxo is a likely intermediate. When the oxidized enzyme was reacted with the dansyl-YVG substrate and H2O2, the alpha-hydroxyglycine product was formed. The reaction was catalytic and did not require the presence of additional reductant. When O-18-labeled H2O2 was reacted with peptidylglycine monooxygenase and substrate anaerobically, oxygen in the product was labeled with O-18 and must therefore be derived from H2O2. However, when the reaction was carried out with H-2 O-16(2) in the presence of O-18(2), 60% of the product contained the O-18 label. Therefore, the reaction must proceed via an intermediate that can react directly with dioxygen and thus scramble the label. Under strictly anaerobic conditions ( in the presence of glucose and glucose oxidase, where no oxygen was released into the medium from nonenzymatic peroxide decomposition), product formation and peroxide consumption were tightly coupled, and the rate of product formation was identical to that measured under aerobic conditions. Peroxide reactivity was eliminated by amutation at the Cu-H center, which should not be involved in the peroxide shunt. Our data lend support to recent proposals that Cu(II)-superoxide is the active species.	Oregon Hlth Sci Univ, OGI Sch Sci & Engn, Dept Environm & Biomol Syst, Beaverton, OR 97006 USA; Oregon Hlth Sci Univ, Mass Spectrometry Lab, Vaccine & Gene Therapy Inst, Beaverton, OR 97006 USA	Oregon Health & Science University; Oregon Health & Science University	Blackburn, NJ (corresponding author), Oregon Hlth Sci Univ, OGI Sch Sci & Engn, Dept Environm & Biomol Syst, 20000 NW Walker Rd, Beaverton, OR 97006 USA.	ninian@ebs.ogi.edu		Yukl, Erik/0000-0001-6519-6938	NINDS NIH HHS [NS-27583] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS027583] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Bell J, 2003, BIOCHEMISTRY-US, V42, P7133, DOI 10.1021/bi034247v; Blackburn NJ, 2000, J BIOL INORG CHEM, V5, P341, DOI 10.1007/PL00010663; Boswell JS, 1996, BIOCHEMISTRY-US, V35, P12241, DOI 10.1021/bi960742y; Chen P, 2004, P NATL ACAD SCI USA, V101, P13105, DOI 10.1073/pnas.0402114101; Chen P, 2004, J AM CHEM SOC, V126, P4991, DOI 10.1021/ja031564g; Chen P, 2004, BIOCHEMISTRY-US, V43, P5735, DOI 10.1021/bi0362830; Davydov R, 2001, J AM CHEM SOC, V123, P1403, DOI 10.1021/ja003583l; EIPPER BA, 1995, BIOCHEMISTRY-US, V34, P2857, DOI 10.1021/bi00009a016; Evans JP, 2003, J BIOL CHEM, V278, P49691, DOI 10.1074/jbc.M300797200; Francisco WA, 2004, J AM CHEM SOC, V126, P13168, DOI 10.1021/ja046888z; Francisco WA, 2002, J AM CHEM SOC, V124, P8194, DOI 10.1021/ja025758s; Francisco WA, 1998, BIOCHEMISTRY-US, V37, P8244, DOI 10.1021/bi973004y; FREEMAN JC, 1993, J AM CHEM SOC, V115, P4923, DOI 10.1021/ja00064a077; FROLAND WA, 1992, J BIOL CHEM, V267, P17588; HRYCAY EG, 1976, EUR J BIOCHEM, V61, P43, DOI 10.1111/j.1432-1033.1976.tb09995.x; Jaron S, 2002, BIOCHEMISTRY-US, V41, P13274, DOI 10.1021/bi020404z; Jaron S, 1999, BIOCHEMISTRY-US, V38, P15086, DOI 10.1021/bi991341w; Klinman JP, 1996, CHEM REV, V96, P2541, DOI 10.1021/cr950047g; KULATHILA R, 1994, ARCH BIOCHEM BIOPHYS, V311, P191, DOI 10.1006/abbi.1994.1225; LI CZ, 1994, BIOCHEM J, V300, P31, DOI 10.1042/bj3000031; MERKLER DJ, 1992, BIOCHEMISTRY-US, V31, P7282, DOI 10.1021/bi00147a011; Prigge ST, 2004, SCIENCE, V304, P864, DOI 10.1126/science.1094583; Prigge ST, 1999, NAT STRUCT BIOL, V6, P976; Prigge ST, 1997, SCIENCE, V278, P1300, DOI 10.1126/science.278.5341.1300; Prigge ST, 2000, CELL MOL LIFE SCI, V57, P1236, DOI 10.1007/PL00000763; Su QJ, 1999, BIOCHEMISTRY-US, V38, P8572, DOI 10.1021/bi990044o; Wolfe MD, 2003, J BIOL CHEM, V278, P829, DOI 10.1074/jbc.M209604200	27	44	45	1	17	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 17	2006	281	7					4190	4198		10.1074/jbc.M511199200	http://dx.doi.org/10.1074/jbc.M511199200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	011NN	16330540	hybrid			2022-12-25	WOS:000235275300051
J	Klumpp, K; Leveque, V; Le Pogam, S; Ma, H; Jiang, WR; Kang, HS; Granycome, C; Singer, M; Laxton, C; Hang, JQ; Sarma, K; Smith, DB; Heindl, D; Hobbs, CJ; Merrett, JH; Symons, J; Cammack, N; Martin, JA; Devos, R; Najera, I				Klumpp, K; Leveque, V; Le Pogam, S; Ma, H; Jiang, WR; Kang, HS; Granycome, C; Singer, M; Laxton, C; Hang, JQ; Sarma, K; Smith, DB; Heindl, D; Hobbs, CJ; Merrett, JH; Symons, J; Cammack, N; Martin, JA; Devos, R; Najera, I			The novel nucleoside analog R1479 (4 '-azidocytidine) is a potent inhibitor of NS5B-dependent RNA synthesis and hepatitis C virus replication in cell culture	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALPHA-2A PLUS RIBAVIRIN; SPECTRUM ANTIVIRAL ACTIVITY; REPLICON	Hepatitis C virus (HCV) polymerase activity is essential for HCV replication. Targeted screening of nucleoside analogs identified R1479 (4'-azidocytidine) as a specific inhibitor of HCV replication in the HCV subgenomic replicon system (IC50 = 1.28 mu M) with similar potency compared with 2'-C-methylcytidine (IC50 = 1.13 mu M). R1479 showed no effect on cell viability or proliferation of HCV replicon or Huh-7 cells at concentrations up to 2 mM. HCV replicon RNA could be fully cleared from replicon cells after prolonged incubation with R1479. The corresponding 5'-triphosphate derivative (R1479-TP) is a potent inhibitor of native HCV replicase isolated from replicon cells and of recombinant HCV polymerase (NS5B)-mediated RNA synthesis activity. R1479-TP inhibited RNA synthesis as a CTP-competitive inhibitor with a K-i of 40 nM. On an HCV RNA-derived template substrate (complementary internal ribosome entry site), R1479-TP showed similar potency of NS5B inhibition compared with 3'-dCTP. R1479-TP was incorporated into nascent RNA by HCV polymerase and reduced further elongation with similar efficiency compared with 3'-dCTP under the reaction conditions. The S282T point mutation in the coding sequence of NS5B confers resistance to inhibition by 2'-C-MeATP and other 2'-methyl-nucleotides. In contrast, the S282T mutation did not confer cross-resistance to R1479.	Roche Palo Alto LLC, Palo Alto, CA 94304 USA; Roche Diagnost GmbH, D-82377 Penzberg, Germany	Roche Holding; Roche Holding	Klumpp, K (corresponding author), Roche Palo Alto LLC, 3431 Hillview Ave, Palo Alto, CA 94304 USA.	klaus.klumpp@roche.com						[Anonymous], 1998, MMWR Recomm Rep, V47, P1; Beaulieu Pierre L, 2004, Curr Opin Investig Drugs, V5, P838; Carroll SS, 2003, J BIOL CHEM, V278, P11979, DOI 10.1074/jbc.M210914200; Chung RT, 2004, NEW ENGL J MED, V351, P451, DOI 10.1056/NEJMoa032653; Crotty S, 2000, NAT MED, V6, P1375, DOI 10.1038/82191; Eldrup AB, 2004, J MED CHEM, V47, P5284, DOI 10.1021/jm040068f; Ferrari E, 1999, J VIROL, V73, P1649, DOI 10.1128/JVI.73.2.1649-1654.1999; Frese M, 2002, HEPATOLOGY, V35, P694, DOI 10.1053/jhep.2002.31770; Fried MW, 2002, NEW ENGL J MED, V347, P975, DOI 10.1056/NEJMoa020047; Krieger N, 2001, J VIROL, V75, P4614, DOI 10.1128/JVI.75.10.4614-4624.2001; Lau JYN, 2002, HEPATOLOGY, V35, P1002, DOI 10.1053/jhep.2002.32672; Lohmann V, 2003, J VIROL, V77, P3007, DOI 10.1128/JVI.77.5.3007-3019.2003; Ma H, 2005, VIROLOGY, V332, P8, DOI 10.1016/j.virol.2004.11.024; Manns MP, 2001, LANCET, V358, P958, DOI 10.1016/S0140-6736(01)06102-5; Migliaccio G, 2003, J BIOL CHEM, V278, P49164, DOI 10.1074/jbc.M305041200; Moradpour D, 2003, ANTIVIR RES, V60, P103, DOI 10.1016/j.antiviral.2003.08.017; Olsen DB, 2004, ANTIMICROB AGENTS CH, V48, P3944, DOI 10.1128/AAC.48.10.3944-3953.2004; Pawlotsky JM, 2004, NEW ENGL J MED, V351, P422, DOI 10.1056/NEJMp048068; Pietschmann T, 2001, J VIROL, V75, P1252, DOI 10.1128/JVI.75.3.1252-1264.2001; Shim J, 2003, ANTIVIR RES, V58, P243, DOI 10.1016/S0166-3542(03)00007-X; SIDWELL RW, 1972, SCIENCE, V177, P705, DOI 10.1126/science.177.4050.705; Stuyver LJ, 2004, ANTIMICROB AGENTS CH, V48, P651, DOI 10.1128/AAC.48.2.651-654.2004; Thomson BJ, 2005, CLIN MICROBIOL INFEC, V11, P86, DOI 10.1111/j.1469-0691.2004.01061.x; TISDALE M, 1995, ANTIMICROB AGENTS CH, V39, P2454, DOI 10.1128/AAC.39.11.2454; Torriani FJ, 2004, NEW ENGL J MED, V351, P438, DOI 10.1056/NEJMoa040842; Vrolijk JM, 2003, J VIROL METHODS, V110, P201, DOI 10.1016/S0166-0934(03)00134-4; WITKOWSKI JT, 1972, J MED CHEM, V15, P1150, DOI 10.1021/jm00281a014	27	175	220	1	9	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 17	2006	281	7					3793	3799		10.1074/jbc.M510195200	http://dx.doi.org/10.1074/jbc.M510195200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	011NN	16316989	hybrid			2022-12-25	WOS:000235275300007
J	Huang, IC; Bosch, BJ; Li, F; Li, WH; Lee, KH; Ghiran, S; Vasilieva, N; Dermody, TS; Harrison, SC; Dormitzer, PR; Farzan, M; Rottier, PJM; Choe, H				Huang, IC; Bosch, BJ; Li, F; Li, WH; Lee, KH; Ghiran, S; Vasilieva, N; Dermody, TS; Harrison, SC; Dormitzer, PR; Farzan, M; Rottier, PJM; Choe, H			SARS coronavirus, but not human coronavirus NL63, utilizes cathepsin L to infect ACE2-expressing cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACUTE-RESPIRATORY-SYNDROME; ANGIOTENSIN-CONVERTING ENZYME-2; SPIKE GLYCOPROTEIN; RECEPTOR SPECIFICITY; FUNCTIONAL RECEPTOR; TISSUE DISTRIBUTION; REOVIRUS INFECTION; AMINOPEPTIDASE-N; YOUNG-CHILDREN; TRACT DISEASE	Viruses require specific cellular receptors to infect their target cells. Angiotensin-converting enzyme 2 ( ACE2) is a cellular receptor for two divergent coronaviruses, SARS coronavirus (SARS-CoV) and human coronavirus NL63 (HCoV-NL63). In addition to host-cell receptors, lysosomal cysteine proteases are required for productive infection by some viruses. Here we show that SARS-CoV, but not HCoV-NL63, utilizes the enzymatic activity of the cysteine protease cathepsin L to infect ACE2-expressing cells. Inhibitors of cathepsin L blocked infection by SARS-CoV and by a retrovirus pseudotyped with the SARS-CoV spike ( S) protein but not infection by HCoV-NL63 or a retrovirus pseudotyped with the HCoV-NL63 S protein. Expression of exogenous cathepsin L substantially enhanced infection mediated by the SARS-CoV S protein and by filovirus GP proteins but not by the HCoV-NL63 S protein or the vesicular stomatitis virus G protein. Finally, an inhibitor of endosomal acidification had substantially less effect on infection mediated by the HCoV-NL63 S protein than on that mediated by the SARS-CoV S protein. Our data indicate that two coronaviruses that utilize a common receptor nonetheless enter cells through distinct mechanisms.	Univ Utrecht, Div Virol, Dept Infect Dis & Immunol, Fac Vet Med, NL-3584 CL Utrecht, Netherlands; Univ Utrecht, Biomembrane Inst, NL-3584 CL Utrecht, Netherlands; Harvard Univ, Sch Med, Div Pulm, Childrens Hosp, Boston, MA 02115 USA; Harvard Univ, Sch Med, Childrens Hosp, Mol Med Lab, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Microbiol & Mol Genet, New England Reg Primate Res Ctr, Southborough, MA 01772 USA; Vanderbilt Univ, Sch Med, Dept Microbiol & Immunol, Elizabeth B Lamb Ctr Pediat Res, Nashville, TN 37232 USA	Utrecht University; Utrecht University; Harvard University; Boston Children's Hospital; Harvard Medical School; Harvard University; Boston Children's Hospital; Harvard Medical School; Harvard University; Vanderbilt University	Rottier, PJM (corresponding author), Univ Utrecht, Div Virol, Dept Infect Dis & Immunol, Fac Vet Med, Yalelaan 1, NL-3584 CL Utrecht, Netherlands.	p.j.m.rottier@vet.uu.nl; hyeryun.choe@childrens.harvard.edu	Bosch, Berend/ABD-8740-2021	Li, Wenhui/0000-0003-1305-7404; Farzan, Michael/0000-0002-2990-5319	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI043891] Funding Source: NIH RePORTER; NIAID NIH HHS [AI43891, AI0616101] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Arden KE, 2005, J MED VIROL, V75, P455, DOI 10.1002/jmv.20288; Baer GS, 1999, J VIROL, V73, P9532, DOI 10.1128/JVI.73.11.9532-9543.1999; Bastien N, 2005, J INFECT DIS, V191, P503, DOI 10.1086/426869; Bonavia A, 2003, J VIROL, V77, P2530, DOI 10.1128/JVI.77.4.2530-2538.2003; Chandran K, 2005, SCIENCE, V308, P1643, DOI 10.1126/science.1110656; Chandran K, 2003, J VIROL, V77, P13361, DOI 10.1128/JVI.77.24.13361-13375.2003; Chandran K, 2002, J VIROL, V76, P9920, DOI 10.1128/JVI.76.19.9920-9933.2002; Chiu SS, 2005, CLIN INFECT DIS, V40, P1721, DOI 10.1086/430301; Dimitrov DS, 2004, NAT REV MICROBIOL, V2, P109, DOI 10.1038/nrmicro817; Ding YQ, 2004, J PATHOL, V203, P622, DOI 10.1002/path.1560; Drosten C, 2003, NEW ENGL J MED, V348, P1967, DOI 10.1056/NEJMoa030747; Ebert DH, 2002, J BIOL CHEM, V277, P24609, DOI 10.1074/jbc.M201107200; Ebihara T, 2005, J MED VIROL, V75, P463, DOI 10.1002/jmv.20289; Esper F, 2005, J INFECT DIS, V191, P492, DOI 10.1086/428138; Fouchier RAM, 2004, P NATL ACAD SCI USA, V101, P6212, DOI 10.1073/pnas.0400762101; Fouchier RAM, 2003, NATURE, V423, P240, DOI 10.1038/423240a; Gallagher TM, 2001, VIROLOGY, V279, P371, DOI 10.1006/viro.2000.0757; Golden JW, 2004, J BIOL CHEM, V279, P8547, DOI 10.1074/jbc.M309758200; Golden JW, 2002, J VIROL, V76, P7430, DOI 10.1128/JVI.76.15.7430-7443.2002; Guan Y, 2004, LANCET, V363, P99, DOI 10.1016/S0140-6736(03)15259-2; Hamming I, 2004, J PATHOL, V203, P631, DOI 10.1002/path.1570; Hofmann H, 2005, P NATL ACAD SCI USA, V102, P7988, DOI 10.1073/pnas.0409465102; HOLMES KV, 1993, ADV EXP MED BIOL, V342, P261; Hsieh CS, 2002, J IMMUNOL, V168, P2618, DOI 10.4049/jimmunol.168.6.2618; Jane-Valbuena J, 2002, J VIROL, V76, P5184, DOI 10.1128/JVI.76.10.5184-5197.2002; Ksiazek TG, 2003, NEW ENGL J MED, V348, P1953, DOI 10.1056/NEJMoa030781; Kuba K, 2005, NAT MED, V11, P875, DOI 10.1038/nm1267; KUBO H, 1994, J VIROL, V68, P5403, DOI 10.1128/JVI.68.9.5403-5410.1994; Kuiken T, 2003, LANCET, V362, P263, DOI 10.1016/S0140-6736(03)13967-0; Li WH, 2003, NATURE, V426, P450, DOI 10.1038/nature02145; Li WH, 2005, EMBO J, V24, P1634, DOI 10.1038/sj.emboj.7600640; Mirzabekov T, 1999, J BIOL CHEM, V274, P28745, DOI 10.1074/jbc.274.40.28745; Moes E, 2005, BMC INFECT DIS, V5, DOI 10.1186/1471-2334-5-6; Moore MJ, 2004, J VIROL, V78, P10628, DOI 10.1128/JVI.78.19.10628-10635.2004; Odegard AL, 2003, J VIROL, V77, P5389, DOI 10.1128/JVI.77.9.5389-5400.2003; Simmons G, 2004, P NATL ACAD SCI USA, V101, P4240, DOI 10.1073/pnas.0306446101; Snijder EJ, 2003, J MOL BIOL, V331, P991, DOI 10.1016/S0022-2836(03)00865-9; STURZENBECKER LJ, 1987, J VIROL, V61, P2351, DOI 10.1128/JVI.61.8.2351-2361.1987; To KF, 2004, J PATHOL, V203, P740, DOI 10.1002/path.1597; Tresnan DB, 1998, ADV EXP MED BIOL, V440, P69; Tsai JC, 2003, J VIROL, V77, P841, DOI 10.1128/JVI.77.2.841-850.2003; Turk V, 2001, EMBO J, V20, P4629, DOI 10.1093/emboj/20.17.4629; Urbich C, 2005, NAT MED, V11, P206, DOI 10.1038/nm1182; van der Hoek L, 2004, NAT MED, V10, P368, DOI 10.1038/nm1024; Wei BDL, 2005, J VIROL, V79, P5705, DOI 10.1128/JVI.79.9.5705-5712.2005; Wong SK, 2004, J BIOL CHEM, V279, P3197, DOI 10.1074/jbc.C300520200; Woo PCY, 2005, J VIROL, V79, P884, DOI 10.1128/JVI.79.2.884-895.2005; Xiao X, 2004, CELL MOL LIFE SCI, V61, P2428, DOI 10.1007/s00018-004-4257-y; YEAGER CL, 1992, NATURE, V357, P420, DOI 10.1038/357420a0	49	245	258	0	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 10	2006	281	6					3198	3203		10.1074/jbc.M508381200	http://dx.doi.org/10.1074/jbc.M508381200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	009QV	16339146	Green Published, hybrid			2022-12-25	WOS:000235128200023
J	Krones-Herzig, A; Mesaros, A; Metzger, D; Ziegler, A; Lemke, U; Bruning, JC; Herzig, S				Krones-Herzig, A; Mesaros, A; Metzger, D; Ziegler, A; Lemke, U; Bruning, JC; Herzig, S			Signal-dependent control of gluconeogenic key enzyme genes through coactivator-associated arginine methyltransferase 1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHOENOLPYRUVATE CARBOXYKINASE GENE; CCAAT/ENHANCER-BINDING PROTEIN; CAMP RESPONSE ELEMENT; TRANSCRIPTIONAL REGULATION; PROMOTER; EXPRESSION; CARM1; GLUCOCORTICOIDS; IDENTIFICATION; METHYLATION	Together with impaired glucose uptake in skeletal muscle, elevated hepatic gluconeogenesis is largely responsible for the hyperglycemic phenotype in type II diabetic patients. Intracellular glucocorticoid and cyclic adenosine monophosphate ( cAMP)/protein kinase A-dependent signaling pathways contribute to aberrant hepatic glucose production through the induction of gluconeogenic enzyme gene expression. Here we show that the coactivator-associated arginine methyltransferase 1 ( CARM1) is required for cAMP-mediated activation of rate-limiting gluconeogenic phosphoenolpyruvate carboxykinase ( PEPCK; EC 4.1.1.32) and glucose-6-phosphatase genes. Mutational analysis showed that CARM1 mediates its effect via the cAMP-responsive element within the PEPCK promoter, which is identified here as a CARM1 target in vivo. In hepatocytes, endogenous CARM1 physically interacts with cAMP-responsive element binding factor CREB and is recruited to the PEPCK and glucose-6-phosphatase promoters in a cAMP-dependent manner associated with increased promoter methylation. CARM1 might, therefore, represent a critical component of cAMP-dependent glucose metabolism in the liver.	German Canc Res Ctr, Dept Mol Metab Control, D-69120 Heidelberg, Germany; Univ Cologne, Dept Mouse Genet & Metab, Inst Genet, D-50674 Cologne, Germany; Univ Cologne, Ctr Mol Med, D-50674 Cologne, Germany	Helmholtz Association; German Cancer Research Center (DKFZ); University of Cologne; University of Cologne	Herzig, S (corresponding author), German Canc Res Ctr, Dept Mol Metab Control, A170,Neuenheimer Feld 280, D-69120 Heidelberg, Germany.	s.herzig@dkfz.de		Herzig, Stephan/0000-0003-3950-3652				Amos AF, 1997, DIABETIC MED, V14, pS7, DOI 10.1002/(SICI)1096-9136(199712)14:5+<S7::AID-DIA522>3.3.CO;2-I; An W, 2004, CELL, V117, P735, DOI 10.1016/j.cell.2004.05.009; Barthel A, 2003, AM J PHYSIOL-ENDOC M, V285, pE685, DOI 10.1152/ajpendo.00253.2003; Bauer UM, 2002, EMBO REP, V3, P39, DOI 10.1093/embo-reports/kvf013; Canettieri G, 2003, NAT STRUCT BIOL, V10, P175, DOI 10.1038/nsb895; Chakravarty K, 2005, CRIT REV BIOCHEM MOL, V40, P129, DOI 10.1080/10409230590935479; Chen DG, 1999, SCIENCE, V284, P2174, DOI 10.1126/science.284.5423.2174; Chen SL, 2002, J BIOL CHEM, V277, P4324, DOI 10.1074/jbc.M109835200; Chevillard-Briet M, 2002, EMBO J, V21, P5457, DOI 10.1093/emboj/cdf548; Covic M, 2005, EMBO J, V24, P85, DOI 10.1038/sj.emboj.7600500; Croniger C, 1998, J BIOL CHEM, V273, P31629, DOI 10.1074/jbc.273.48.31629; Crosson SM, 2000, J BIOL CHEM, V275, P5804, DOI 10.1074/jbc.275.8.5804; Friedman JE, 1997, J BIOL CHEM, V272, P31475, DOI 10.1074/jbc.272.50.31475; Gautier-Stein A, 2005, MOL ENDOCRINOL, V19, P163, DOI 10.1210/me.2004-0105; HABER BA, 1995, J CLIN INVEST, V95, P832, DOI 10.1172/JCI117733; Hanson RW, 1997, ANNU REV BIOCHEM, V66, P581, DOI 10.1146/annurev.biochem.66.1.581; Herzig S, 2000, J BIOL CHEM, V275, P27989; Herzig S, 2001, NATURE, V413, P179, DOI 10.1038/35093131; IMAI E, 1993, J BIOL CHEM, V268, P5353; Koh SS, 2002, J BIOL CHEM, V277, P26031, DOI 10.1074/jbc.M110865200; Koh SS, 2001, J BIOL CHEM, V276, P1089, DOI 10.1074/jbc.M004228200; Kopelman PG, 1998, LANCET, V352, P5; Lee YH, 2002, MOL CELL BIOL, V22, P3621, DOI 10.1128/MCB.22.11.3621-3632.2002; LIU JS, 1991, J BIOL CHEM, V266, P19095; Mayr B, 2001, NAT REV MOL CELL BIO, V2, P599, DOI 10.1038/35085068; Michael MD, 2000, MOL CELL, V6, P87, DOI 10.1016/S1097-2765(00)00010-1; ORELLANA SA, 1992, P NATL ACAD SCI USA, V89, P4726, DOI 10.1073/pnas.89.10.4726; Postic C, 2004, DIABETES METAB, V30, P398, DOI 10.1016/S1262-3636(07)70133-7; Roesler WJ, 2000, MOL CELL ENDOCRINOL, V162, P1, DOI 10.1016/S0303-7207(00)00198-2; Roesler WJ, 1996, J BIOL CHEM, V271, P8068, DOI 10.1074/jbc.271.14.8068; Roesler WJ, 1998, J BIOL CHEM, V273, P14950, DOI 10.1074/jbc.273.24.14950; Saltiel AR, 2001, CELL, V104, P517, DOI 10.1016/S0092-8674(01)00239-2; Saltiel AR, 2001, NATURE, V414, P799, DOI 10.1038/414799a; Schmoll D, 1999, BIOCHEM J, V338, P457, DOI 10.1042/0264-6021:3380457; SHORT JM, 1986, J BIOL CHEM, V261, P9721; Wang XHL, 2004, J BIOL CHEM, V279, P34191, DOI 10.1074/jbc.M403455200; Wilson HL, 2002, J BIOL CHEM, V277, P43895, DOI 10.1074/jbc.M203169200; XING LP, 1993, MOL ENDOCRINOL, V7, P1484, DOI 10.1210/me.7.11.1484; Xu W, 2001, SCIENCE, V294, P2507, DOI 10.1126/science.1065961; Yadav N, 2003, P NATL ACAD SCI USA, V100, P6464, DOI 10.1073/pnas.1232272100	40	35	36	1	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 10	2006	281	6					3025	3029		10.1074/jbc.M509770200	http://dx.doi.org/10.1074/jbc.M509770200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	009QV	16330542	hybrid			2022-12-25	WOS:000235128200004
J	Tu, SL; Sughrue, W; Britt, RD; Lagarias, JC				Tu, SL; Sughrue, W; Britt, RD; Lagarias, JC			A conserved histidine-aspartate pair is required for exovinyl reduction of biliverdin by a cyanobacterial phycocyanobilin : ferredoxin oxidoreductase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ANABAENA PCC 7119; ELECTRON-TRANSFER; BINDING; BIOSYNTHESIS; SURFACE; COMPLEX	Phycocyanobilin: ferredoxin oxidoreductase is a member of the ferredoxin-dependent bilin reductase family and catalyzes two vinyl reductions of biliverdin IX alpha to produce phycocyanobilin, the pigment precursor of both phytochrome and phycobiliprotein chromophores in cyanobacteria. Atypically for ferredoxin-dependent enzymes, phycocyanobilin: ferredoxin oxidoreductase mediates direct electron transfers from reduced ferredoxin to its tetrapyrrole substrate without metal ion or organic cofactors. We previously showed that bound bilin radical intermediates could be detected by low temperature electron paramagnetic resonance and absorption spectroscopies ( Tu, S., Gunn, A., Toney, M. D., Britt, R. D., and Lagarias, J. C. ( 2004) J. Am. Chem. Soc. 126, 8682 - 8693). On the basis of these studies, a mechanism involving sequential electron-coupled proton transfers to protonated bilin substrates buried within the phycocyanobilin: ferredoxin oxidoreductase protein scaffold was proposed. The present investigation was undertaken to identify catalytic residues in phycocyanobilin: ferredoxin oxidoreductase from the cyanobacterium Nostoc sp. PCC7120 through site-specific chemical modification and mutagenesis of candidate proton-donating residues. These studies identified conserved histidine and aspartate residues essential for the catalytic activity of phycocyanobilin: ferredoxin oxidoreductase. Spectroscopic evidence for the formation of stable enzyme-bound biliverdin radicals for the H85Q and D102N mutants support their role as a "coupled" protondonating pair during the reduction of the biliverdin exovinyl group.	Univ Calif Davis, Coll Biol Sci, Sect Mol & Cellular Biol, Davis, CA 95616 USA; Univ Calif Davis, Dept Chem, Davis, CA 95616 USA	University of California System; University of California Davis; University of California System; University of California Davis	Lagarias, JC (corresponding author), Univ Calif Davis, Coll Biol Sci, Sect Mol & Cellular Biol, Davis, CA 95616 USA.	jclagarias@ucdavis.edu	Lagarias, John Clark/L-3139-2013; Tu, Shih-Long/ABF-5446-2021	Lagarias, John Clark/0000-0002-2093-0403; Tu, Shih-Long/0000-0001-9436-278X				Akashi T, 1999, J BIOL CHEM, V274, P29399, DOI 10.1074/jbc.274.41.29399; BEALE SI, 1993, CHEM REV, V93, P785, DOI 10.1021/cr00018a008; DEPASCALIS AR, 1993, PROTEIN SCI, V2, P1126, DOI 10.1002/pro.5560020707; Dose MM, 1997, PLANT PHYSIOL, V114, P1047, DOI 10.1104/pp.114.3.1047; ELICH TD, 1989, J BIOL CHEM, V264, P183; Frankenberg N, 2003, J BIOL CHEM, V278, P9219, DOI 10.1074/jbc.M211643200; Frankenberg N, 2001, PLANT CELL, V13, P965, DOI 10.1105/tpc.13.4.965; Frankenberg N., 2003, PORPHYRIN HDB, P211; Glazer A. N., 1999, CHEM MICROALGAE, P261; GOMI T, 1983, BIOCHEMISTRY-US, V22, P137, DOI 10.1021/bi00270a020; Kurisu G, 2001, NAT STRUCT BIOL, V8, P117, DOI 10.1038/84097; Lundblad RL., 2005, CHEM REAGENTS PROTEI; Martinez-Julvez M, 1998, BIOCHEMISTRY-US, V37, P17680, DOI 10.1021/bi981718i; McDowell MT, 2001, PLANT PHYSIOL, V126, P1546, DOI 10.1104/pp.126.4.1546; Medina M, 1998, BIOCHEMISTRY-US, V37, P2715, DOI 10.1021/bi971795y; Prisner T, 2001, ANNU REV PHYS CHEM, V52, P279, DOI 10.1146/annurev.physchem.52.1.279; SCHLUCHTER WM, 1994, THESIS PENNSYLVANIA; Tu SL, 2004, J AM CHEM SOC, V126, P8682, DOI 10.1021/ja049280z	18	22	22	0	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 10	2006	281	6					3127	3136		10.1074/jbc.M510126200	http://dx.doi.org/10.1074/jbc.M510126200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	009QV	16327013	hybrid			2022-12-25	WOS:000235128200015
J	Mishra, DP; Pal, R; Shaha, C				Mishra, DP; Pal, R; Shaha, C			Changes in cytosolic Ca2+ levels regulate Bcl-xS and Bcl-xL expression in spermatogenic cells during apoptotic death	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TESTICULAR GERM-CELLS; IN-VIVO; BAX EXPRESSION; RAT; CALCIUM; PATHWAY; INVOLVEMENT; PROTEINS; CHANNELS; GROWTH	Bcl-x exists in two isoforms, the anti-apoptotic form Bcl-xL and the proapoptotic form Bcl-xS. The critical balance between the two forms appears to be important for cell survival; however, it is still not clear exactly how the vital balance is maintained. Using an in vitro spermatogenic cell apoptosis model, this study provides a new insight into the possible role of Ca2+ in regulating the Bcl-xS and Bcl-xL expression. 2,5-Hexanedione, a metabolite of the common industrial solvent n-hexane, caused a significant increase in reactive oxygen species followed by an enhancement of intracellular Ca2+ through the T-type Ca2+ channels. Consequent to the above changes, expression of Bcl-xS increased with a concomitant drop in Bcl-xL expression, thus altering the ratio of the two proteins. Impediment of Ca2+ influx by using a T-type Ca2+ channel blocker pimozide resulted in a decrease in Bcl-xS and an increase in Bcl-xL expression. This caused prevention of mitochondrial potential loss, reduction of caspase-3 activity, inhibition of DNA fragmentation, and increase in cell survival. Alternatively, Ca2+ ionophores caused an increase of Bcl-xS encoding isoform over the Bcl-xL-encoding isoform. Therefore, this study proposes a role for Ca2+ in regulation of Bcl-xS and Bcl-xL expression and ultimately cell fate.	Natl Inst Immunol, New Delhi 110067, India	Department of Biotechnology (DBT) India; National Institute of Immunology (NII)	Shaha, C (corresponding author), Natl Inst Immunol, Aruna Asaf Ali Marg, New Delhi 110067, India.	cshaha@nii.res.in						Akingbemi BT, 2001, ANN MED, V33, P391, DOI 10.3109/07853890108995952; BENOFF S, 1998, FRONT BIOSCI, V3, P1220; Boekelheide K, 2003, ANNU REV PHARMACOL, V43, P125, DOI 10.1146/annurev.pharmtox.43.100901.135930; BOEKELHEIDE K, 2005, J NATL CANC I MONOGR, V34, P6, DOI DOI 10.1093/JNCIMONOGRAPHS/LGI006; Brookes PS, 2004, AM J PHYSIOL-CELL PH, V287, pC817, DOI 10.1152/ajpcell.00139.2004; Chami M, 2004, J BIOL CHEM, V279, P54581, DOI 10.1074/jbc.M409663200; Chiu CT, 2003, DIGEST DIS SCI, V48, P670, DOI 10.1023/A:1022816204831; Grad JM, 2000, CURR OPIN ONCOL, V12, P543, DOI 10.1097/00001622-200011000-00006; Han JH, 1996, GENE DEV, V10, P461, DOI 10.1101/gad.10.4.461; Hengartner MO, 2000, NATURE, V407, P770, DOI 10.1038/35037710; Hikim APS, 2003, J STEROID BIOCHEM, V85, P175, DOI 10.1016/S0960-0760(03)00193-6; Holdcraft RW, 2004, INT J ANDROL, V27, P335, DOI 10.1111/j.1365-2605.2004.00502.x; Kasai S, 2003, DEV BIOL, V264, P202, DOI 10.1016/S0012-1606(03)00400-7; Kim BC, 2002, J BIOL CHEM, V277, P31381, DOI 10.1074/jbc.M203465200; Kim SK, 2004, ARCH ANDROLOGY, V50, P427, DOI 10.1080/01485010490475093; KNUDSON CM, 1995, SCIENCE, V270, P96, DOI 10.1126/science.270.5233.96; Koji T, 2001, BIOL REPROD, V64, P946, DOI 10.1095/biolreprod64.3.946; Korsmeyer SJ, 1999, CANCER RES, V59, p1693S; KRAJEWSKI S, 1994, CANCER RES, V54, P5501; Lemasters JJ, 2002, ANTIOXID REDOX SIGN, V4, P769, DOI 10.1089/152308602760598918; Li C, 2002, P NATL ACAD SCI USA, V99, P9830, DOI 10.1073/pnas.152571899; Lievano A, 1996, FEBS LETT, V388, P150, DOI 10.1016/0014-5793(96)00515-7; Mattson MP, 2003, NAT CELL BIOL, V5, P1041, DOI 10.1038/ncb1203-1041; Mishra DP, 2005, J BIOL CHEM, V280, P6181, DOI 10.1074/jbc.M405970200; Miyake H, 1999, J UROLOGY, V162, P916, DOI 10.1097/00005392-199909010-00090; Mizuno N, 1998, ENDOCRINOLOGY, V139, P1429, DOI 10.1210/en.139.3.1429; Nair R, 2003, J BIOL CHEM, V278, P6470, DOI 10.1074/jbc.M209319200; OLTVAI ZN, 1993, CELL, V74, P609, DOI 10.1016/0092-8674(93)90509-O; Parborell F, 2002, BIOL REPROD, V67, P481, DOI 10.1095/biolreprod67.2.481; Parks JE, 2003, THERIOGENOLOGY, V59, P73, DOI 10.1016/S0093-691X(02)01275-X; Pecci A, 1997, J BIOL CHEM, V272, P11791, DOI 10.1074/jbc.272.18.11791; Pollock AS, 2003, FASEB J, V17, P203, DOI 10.1096/fj.02-0602com; Rao AVSK, 2000, FREE RADICAL BIO MED, V29, P1015, DOI 10.1016/S0891-5849(00)00408-1; Reed JC, 1997, NATURE, V387, P773, DOI 10.1038/42867; Richburg JH, 2000, ENDOCRINOLOGY, V141, P787, DOI 10.1210/en.141.2.787; Rohrbach S, 2005, J MOL CELL CARDIOL, V38, P485, DOI 10.1016/j.yjmcc.2004.12.013; Russell LD, 2002, BIOL REPROD, V66, P950, DOI 10.1095/biolreprod66.4.950; Santi CM, 1996, AM J PHYSIOL-CELL PH, V271, pC1583, DOI 10.1152/ajpcell.1996.271.5.C1583; Schlegel RA, 2000, ANN NY ACAD SCI, V926, P217; Staub C, 2001, J ANDROL, V22, P911; Waring P, 2005, ARCH BIOCHEM BIOPHYS, V434, P33, DOI 10.1016/j.abb.2004.08.001; Woolveridge I, 1998, PROSTATE, V36, P23; Yamaguchi H, 2002, LEUKEMIA RES, V26, P1119, DOI 10.1016/S0145-2126(02)00061-9; Yan W, 2000, MOL CELL ENDOCRINOL, V165, P115, DOI 10.1016/S0303-7207(00)00257-4	44	49	51	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 27	2006	281	4					2133	2143		10.1074/jbc.M508648200	http://dx.doi.org/10.1074/jbc.M508648200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	004NV	16301318	hybrid			2022-12-25	WOS:000234760400036
J	Neumann, S; Schobel, S; Jager, S; Trautwein, A; Haass, C; Pietrzik, CU; Lichtenthaler, SF				Neumann, S; Schobel, S; Jager, S; Trautwein, A; Haass, C; Pietrzik, CU; Lichtenthaler, SF			Amyloid precursor-like protein 1 influences endocytosis and proteolytic processing of the amyloid precursor protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECEPTOR-RELATED PROTEIN; HUMAN NEUROBLASTOMA-CELLS; ALZHEIMERS-DISEASE; BETA-PROTEIN; CYTOPLASMIC DOMAIN; BINDING PROTEIN; TRANSGENIC MICE; FAMILY-MEMBERS; RETINOIC ACID; FE65 PROTEIN	Ectodomain shedding of the amyloid precursor protein (APP) is a key regulatory step in the generation of the Alzheimer disease amyloid beta peptide (A beta). The molecular mechanisms underlying the control of APP shedding remain little understood but are in part dependent on the low density lipoprotein receptor-related protein (LRP), which is involved in APP endocytosis. Here, we show that the APP homolog APLP1 (amyloid precursor-like protein 1) influences APP shedding. In human embryonic kidney 293 cells expression of APLP1 strongly activated APP shedding by alpha-secretase and slightly reduced beta-secretase cleavage. As revealed by domain deletion analysis, the increase in APP shedding required the NPTY amino acid motif within the cytoplasmic domain of APLP1. This motif is conserved in APP and is essential for the endocytosis of APP and APLP1. Unrelated membrane proteins containing similar endocytic motifs did not affect APP shedding, showing that the increase in APP shedding was specific to APLP1. In LRP-deficient cells APLP1 no longer induced APP shedding, suggesting that in wild-type cells APLP1 interferes with the LRP-dependent endocytosis of APP and thereby increases APP alpha-cleavage. In fact, an antibody uptake assay revealed that expression of APLP1 reduced the rate of APP endocytosis. In summary, our study provides a novel mechanism for APP shedding, in which APLP1 affects the endocytosis of APP and makes more APP available for alpha-secretase cleavage.	Univ Munich, Adolf Butenandt Inst, D-80336 Munich, Germany; Johannes Gutenberg Univ Mainz, Inst Physiol Chem & Pathobiochem, D-55128 Mainz, Germany	University of Munich; Johannes Gutenberg University of Mainz	Lichtenthaler, SF (corresponding author), Univ Munich, Adolf Butenandt Inst, Schillerstr 44, D-80336 Munich, Germany.	Stefan.Lichtenthaler@med.uni-muenchen.de	Lichtenthaler, Stefan F/B-6587-2016	Lichtenthaler, Stefan F/0000-0003-2211-2575				Adlerz L, 2003, MOL BRAIN RES, V119, P62, DOI 10.1016/j.molbrainres.2003.08.014; Allinson TMJ, 2003, J NEUROSCI RES, V74, P342, DOI 10.1002/jnr.10737; Araki Y, 2003, J BIOL CHEM, V278, P49448, DOI 10.1074/jbc.M306024200; Bayer TA, 1999, MOL PSYCHIATR, V4, P524, DOI 10.1038/sj.mp.4000552; Bayer TA, 1997, ACTA NEUROPATHOL, V94, P519, DOI 10.1007/s004010050745; Beckman M, 1997, NEUROSCI LETT, V221, P73, DOI 10.1016/S0304-3940(96)13292-4; Blobel CP, 2000, CURR OPIN CELL BIOL, V12, P606, DOI 10.1016/S0955-0674(00)00139-3; Bonifacino JS, 2003, ANNU REV BIOCHEM, V72, P395, DOI 10.1146/annurev.biochem.72.121801.161800; Borg JP, 1996, MOL CELL BIOL, V16, P6229; Borg JP, 1998, J BIOL CHEM, V273, P14761, DOI 10.1074/jbc.273.24.14761; Bressler SL, 1996, HUM MOL GENET, V5, P1589, DOI 10.1093/hmg/5.10.1589; Cam JA, 2004, J BIOL CHEM, V279, P29639, DOI 10.1074/jbc.M313893200; Cao XW, 2001, SCIENCE, V293, P115, DOI 10.1126/science.1058783; Cao XW, 2004, J BIOL CHEM, V279, P24601, DOI 10.1074/jbc.M402248200; Chyung JH, 2003, J BIOL CHEM, V278, P51035, DOI 10.1074/jbc.M304989200; Citron M, 2004, TRENDS PHARMACOL SCI, V25, P92, DOI 10.1016/j.tips.2003.12.004; Dovey HF, 2001, J NEUROCHEM, V76, P173, DOI 10.1046/j.1471-4159.2001.00012.x; Duilio A, 1998, BIOCHEM J, V330, P513, DOI 10.1042/bj3300513; Eggert S, 2004, J BIOL CHEM, V279, P18146, DOI 10.1074/jbc.M311601200; Guenette SY, 1999, J NEUROCHEM, V73, P985, DOI 10.1046/j.1471-4159.1999.0730985.x; Haass C, 2004, EMBO J, V23, P483, DOI 10.1038/sj.emboj.7600061; HAASS C, 1992, NATURE, V357, P500, DOI 10.1038/357500a0; Herz J, 2001, J CLIN INVEST, V108, P779, DOI 10.1172/JCI200113992; Homayouni R, 1999, J NEUROSCI, V19, P7507, DOI 10.1523/JNEUROSCI.19-17-07507.1999; Hooper NM, 1997, BIOCHEM J, V321, P265, DOI 10.1042/bj3210265; Ida N, 1996, J BIOL CHEM, V271, P22908, DOI 10.1074/jbc.271.37.22908; Kaether C, 2002, J CELL BIOL, V158, P551, DOI 10.1083/jcb.200201123; King GD, 2004, EXP NEUROL, V185, P208, DOI 10.1016/j.expneurol.2003.10.011; Kinoshita A, 2001, J NEUROSCI, V21, P8354, DOI 10.1523/JNEUROSCI.21-21-08354.2001; KOO EH, 1994, J BIOL CHEM, V269, P17386; Kummer C, 2002, EXP CELL RES, V280, P222, DOI 10.1006/excr.2002.5631; Lee JH, 2004, J BIOL CHEM, V279, P49099, DOI 10.1074/jbc.M405602200; Li QM, 2004, J BIOL CHEM, V279, P10542, DOI 10.1074/jbc.M310001200; Lichtenthaler SF, 2003, J BIOL CHEM, V278, P48713, DOI 10.1074/jbc.M303861200; Perez RG, 1999, J BIOL CHEM, V274, P18851, DOI 10.1074/jbc.274.27.18851; Pietrzik CU, 2002, EMBO J, V21, P5691, DOI 10.1093/emboj/cdf568; Pietrzik CU, 2004, J NEUROSCI, V24, P4259, DOI 10.1523/JNEUROSCI.5451-03.2004; Rebeck GW, 2001, MOL BRAIN RES, V87, P238, DOI 10.1016/S0169-328X(01)00006-7; Russo C, 2005, BRAIN RES REV, V48, P257, DOI 10.1016/j.brainresrev.2004.12.016; Sabo SL, 2003, J NEUROSCI, V23, P5407; Sabo SL, 2001, J CELL BIOL, V153, P1403, DOI 10.1083/jcb.153.7.1403; Sabo SL, 1999, J BIOL CHEM, V274, P7952, DOI 10.1074/jbc.274.12.7952; Santiard-Baron D, 2005, J NEUROCHEM, V93, P330, DOI 10.1111/j.1471-4159.2005.03026.x; Sastre M, 1998, J BIOL CHEM, V273, P22351, DOI 10.1074/jbc.273.35.22351; Scheinfeld MH, 2002, J BIOL CHEM, V277, P44195, DOI 10.1074/jbc.M208110200; Selkoe DJ, 2003, ANNU REV PHARMACOL, V43, P545, DOI 10.1146/annurev.pharmtox.43.100901.140248; SEUBERT P, 1993, NATURE, V361, P260, DOI 10.1038/361260a0; SISODIA SS, 1992, P NATL ACAD SCI USA, V89, P6075, DOI 10.1073/pnas.89.13.6075; Steiner H, 2000, NAT CELL BIOL, V2, P848, DOI 10.1038/35041097; Taru H, 2002, J BIOL CHEM, V277, P27567, DOI 10.1074/jbc.M203713200; Ting Adrian, 2005, Novartis Found Symp, V267, P219; Trommsdorff R, 1998, J BIOL CHEM, V273, P33556, DOI 10.1074/jbc.273.50.33556; Ulery PG, 2000, J BIOL CHEM, V275, P7410, DOI 10.1074/jbc.275.10.7410; Walsh DM, 2003, BIOCHEMISTRY-US, V42, P6664, DOI 10.1021/bi027375c; Xie ZC, 2005, J BIOL CHEM, V280, P15413, DOI 10.1074/jbc.M414353200	55	44	47	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 17	2006	281	11					7583	7594		10.1074/jbc.M508340200	http://dx.doi.org/10.1074/jbc.M508340200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	022BY	16344553				2022-12-25	WOS:000236030900080
J	Horman, S; Vertommen, D; Heath, R; Neumann, D; Mouton, V; Woods, A; Schlattner, U; Walliman, T; Carling, D; Hue, L; Rider, MH				Horman, S; Vertommen, D; Heath, R; Neumann, D; Mouton, V; Woods, A; Schlattner, U; Walliman, T; Carling, D; Hue, L; Rider, MH			Insulin antagonizes ischemia-induced Thr(172) phosphorylation of AMP-activated protein kinase alpha-subunits in heart via hierarchical phosphorylation of Ser(485/491)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MYOCARDIAL-ISCHEMIA; GLUCOSE-UPTAKE; INHIBITION; COMPLEXES; SUBFAMILY; ISOFORMS; GLUT-4; ROLES; SNF1; LKB1	Previous studies showed that insulin antagonizes AMP-activated protein kinase activation by ischemia and that protein kinase B might be implicated. Here we investigated whether the direct phosphorylation of AMP-activated protein kinase by protein kinase B might participate in this effect. Protein kinase B phosphorylated recombinant bacterially expressed AMP-activated protein kinase heterotrimers at Ser(485) of the alpha 1-subunits. In perfused rat hearts, phosphorylation of the alpha 1/alpha 2 AMP-activated protein kinase subunits on Ser(485)/Ser(491) was increased by insulin and insulin pretreatment decreased the phosphorylation of the alpha-subunits at Thr(172) in a subsequent ischemic episode. It is proposed that the effect of insulin to antagonize AMP-activated protein kinase activation involves a hierarchical mechanism whereby Ser(485)/Ser(491) phosphorylation by protein kinase B reduces subsequent phosphorylation of Thr(172) by LKB1 and the resulting activation of AMP-activated protein kinase.	Christian de Duve Inst Cellular Pathol, Hormone & Metab Res Unit, B-1200 Brussels, Belgium; Catholic Univ Louvain, B-1200 Brussels, Belgium; Hammersmith Hosp, Imperial Coll, Cellular Stress Grp, MRC,Clin Sci Ctr, London W12 0NN, England; ETH, Inst Cell Biol, CH-8093 Zurich, Switzerland	Universite Catholique Louvain; Imperial College London; Swiss Federal Institutes of Technology Domain; ETH Zurich	Horman, S (corresponding author), Christian de Duve Inst Cellular Pathol, Hormone & Metab Res Unit, Ave Hippocrate 75, B-1200 Brussels, Belgium.	sandrine.horman@horm.ucl.ac.be	Wallimann, Theo/C-6047-2008; Schlattner, Uwe/D-1267-2009; Carling, David/F-1943-2014	Wallimann, Theo/0000-0003-4957-5836; Schlattner, Uwe/0000-0003-1159-5911; Carling, David/0000-0002-2316-1830; Vertommen, Didier/0000-0001-7648-8282; Neumann, Dietbert/0000-0002-4316-684X	Medical Research Council [MC_U120027537] Funding Source: Medline	Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))		Altarejos JY, 2005, J BIOL CHEM, V280, P183, DOI 10.1074/jbc.M411810200; Apfeld J, 2004, GENE DEV, V18, P3004, DOI 10.1101/gad.1255404; Baron SJ, 2005, CIRC RES, V96, P337, DOI 10.1161/01.RES.0000155723.53868.d2; Beauloye C, 2001, FEBS LETT, V505, P348, DOI 10.1016/S0014-5793(01)02788-0; Beauloye C, 2001, CIRC RES, V88, P513, DOI 10.1161/01.RES.88.5.513; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Browne GJ, 2002, EUR J BIOCHEM, V269, P5360, DOI 10.1046/j.1432-1033.2002.03290.x; Casamayor A, 1999, CURR BIOL, V9, P186, DOI 10.1016/S0960-9822(99)80088-8; Cheung PCF, 2000, BIOCHEM J, V346, P659, DOI 10.1042/0264-6021:3460659; Clark H, 2004, EUR J BIOCHEM, V271, P2215, DOI 10.1111/j.1432-1033.2004.04151.x; DeGnore JP, 1998, J AM SOC MASS SPECTR, V9, P1175, DOI 10.1016/S1044-0305(98)00088-9; Deprez J, 2000, BIOCHEM J, V347, P305, DOI 10.1042/0264-6021:3470305; Gao F, 2002, CIRCULATION, V105, P1497, DOI 10.1161/01.CIR.0000012529.00367.0F; Hardie DG, 1998, ANNU REV BIOCHEM, V67, P821, DOI 10.1146/annurev.biochem.67.1.821; Hawley Simon A, 2003, J Biol, V2, P28, DOI 10.1186/1475-4924-2-28; Hong SP, 2003, P NATL ACAD SCI USA, V100, P8839, DOI 10.1073/pnas.1533136100; Horman S, 2002, CURR BIOL, V12, P1419, DOI 10.1016/S0960-9822(02)01077-1; Horman S, 2003, J BIOL CHEM, V278, P41970, DOI 10.1074/jbc.M302403200; Jessen N, 2003, J APPL PHYSIOL, V94, P1373, DOI 10.1152/japplphysiol.00250.2002; Kovacic S, 2003, J BIOL CHEM, V278, P39422, DOI 10.1074/jbc.M305371200; Krause U, 2002, EUR J BIOCHEM, V269, P3742, DOI 10.1046/j.1432-1033.2002.03069.x; Lefebvre V, 1996, J BIOL CHEM, V271, P22289, DOI 10.1074/jbc.271.37.22289; Lizcano JM, 2004, EMBO J, V23, P833, DOI 10.1038/sj.emboj.7600110; Marsin AS, 2000, CURR BIOL, V10, P1247, DOI 10.1016/S0960-9822(00)00742-9; Nagata D, 2003, J BIOL CHEM, V278, P31000, DOI 10.1074/jbc.M300643200; Neumann D, 2003, PROTEIN EXPRES PURIF, V30, P230, DOI 10.1016/S1046-5928(03)00126-8; Russell RR, 1999, AM J PHYSIOL-HEART C, V277, pH643, DOI 10.1152/ajpheart.1999.277.2.H643; Salt I, 1998, BIOCHEM J, V334, P177, DOI 10.1042/bj3340177; Stapleton D, 1996, J BIOL CHEM, V271, P611, DOI 10.1074/jbc.271.2.611; Sugden C, 1999, PLANT J, V19, P433, DOI 10.1046/j.1365-313X.1999.00532.x; Sutherland CM, 2003, CURR BIOL, V13, P1299, DOI 10.1016/S0960-9822(03)00459-7; WITTERS LA, 1992, J BIOL CHEM, V267, P2864; Woods A, 2003, CURR BIOL, V13, P2004, DOI 10.1016/j.cub.2003.10.031; Woods A, 1996, FEBS LETT, V397, P347, DOI 10.1016/S0014-5793(96)01209-4; Woods A, 2003, J BIOL CHEM, V278, P28434, DOI 10.1074/jbc.M303946200; Yin W, 2003, J BIOL CHEM, V278, P43074, DOI 10.1074/jbc.M308484200	36	272	278	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 3	2006	281	9					5335	5340		10.1074/jbc.M506850200	http://dx.doi.org/10.1074/jbc.M506850200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	015RQ	16340011	hybrid			2022-12-25	WOS:000235568900003
J	Chang, PC; Chi, CW; Chau, GY; Li, FY; Tsai, YH; Wu, JC; Lee, YHW				Chang, PC; Chi, CW; Chau, GY; Li, FY; Tsai, YH; Wu, JC; Lee, YHW			DDX3, a DEAD box RNA helicase, is deregulated in hepatitis virus-associated hepatocellular carcinoma and is involved in cell growth control	ONCOGENE			English	Article						DDX3; hepatocellular carcinoma; small interfering RNA; p21(WAF1); proliferation; apoptosis	CYCLIN D1 OVEREXPRESSION; CORE PROTEIN INTERACTS; C-MYC; DECREASED EXPRESSION; GENETIC ALTERATIONS; TUMOR PROGRESSION; P53 MUTATION; CANCER; PATHOGENESIS; RECEPTOR	Hepatocellular carcinoma (HCC) is one of the leading causes of cancer deaths worldwide and is highly correlated with hepatitis virus infection. Our previous report shows that a DEAD box RNA helicase, DDX3, is targeted and regulated by hepatitis C virus (HCV) core protein, which implicates the involvement of DDX3 in HCV-related HCC development. In this study, the potential role of DDX3 in hepatocarcinogenesis is investigated by examining its expression in surgically excised human HCC specimens. Here we report the differential deregulation of DDX3 expression in hepatitis virus-associated HCC. A significant downregulation of DDX3 expression is found in HCCs from hepatitis B virus (HBV)-positive patients, but not from HCV-positive ones, compared to the corresponding nontumor tissues. The expression of DDX3 is differentially regulated by the gender and, moreover, there is a tendency that the downregulation of DDX3 expression in HCCs is more frequent in males than in females. Genetic knockdown of DDX3 with small interfering RNAs (siRNA) in a nontransformed mouse fibroblast cell line, NIH-3T3, results in a premature entry to S phase and an enhancement of cell growth. This enhanced cell cycle progression is linked to the upregulation of cyclin D1 and the downregulation of p21(WAF1) in the DDX3 knockdown cells. In addition, constitutive reduction of DDX3 expression increases the resistance of NIH-3T3 cells to serum depletion-induced apoptosis and enhances the ras-induced anchorage-independent growth, indicating the involvement of DDX3 in cell growth control. These findings together with the previous study suggest that the deregulation of DDX3, a DEAD box RNA helicase with cell growth-regulatory functions, is involved in HBV- and HCV-associated pathogenesis.	Natl Yang Ming Univ, Inst Biochem & Mol Biol, Taipei 112, Taiwan; Natl Yang Ming Univ, Inst Pharmacol, Taipei, Taiwan; Taipei Vet Gen Hosp, Dept Surg, Taipei, Taiwan; Natl Yang Ming Univ, Dept Pathol, Taipei, Taiwan; Natl Yang Ming Univ, Inst Clin Med, Taipei, Taiwan	National Yang Ming Chiao Tung University; National Yang Ming Chiao Tung University; Taipei Veterans General Hospital; National Yang Ming Chiao Tung University; National Yang Ming Chiao Tung University	Lee, YHW (corresponding author), Natl Yang Ming Univ, Inst Biochem & Mol Biol, Taipei 112, Taiwan.	yhwulee@ym.edu.tw		Lee Wu, Yan-Hwa/0000-0001-7299-7354				Ahn J, 2004, DM-DIS MON, V50, P556, DOI 10.1016/j.disamonth.2004.10.001; Alarcon-Vargas D, 2002, CANCER BIOL THER, V1, P237, DOI 10.4161/cbt.74; Albertson DG, 2003, NAT GENET, V34, P369, DOI 10.1038/ng1215; Brechot C, 2004, GASTROENTEROLOGY, V127, pS56, DOI 10.1053/j.gastro.2004.09.016; Brechot C, 2000, SEMIN CANCER BIOL, V10, P211, DOI 10.1006/scbi.2000.0321; Brooks CL, 2003, CURR OPIN CELL BIOL, V15, P164, DOI 10.1016/S0955-0674(03)00003-6; Buendia MA, 2000, SEMIN CANCER BIOL, V10, P185; Causevic M, 2001, ONCOGENE, V20, P7734, DOI 10.1038/sj.onc.1204976; Chen CJ, 2002, JPN J CLIN ONCOL, V32, pS66, DOI 10.1093/jjco/hye138; De Petro G, 1998, CANCER RES, V58, P2234; Deane NG, 2001, CANCER RES, V61, P5389; El-Serag H, 2003, ANN INTERN MED, V139, P817, DOI 10.7326/0003-4819-139-10-200311180-00009; El-Serag HB, 2004, GASTROENTEROLOGY, V127, pS27, DOI 10.1053/j.gastro.2004.09.013; Endo K, 2000, LIVER, V20, P209, DOI 10.1034/j.1600-0676.2000.020003209.x; Fu MF, 2004, ENDOCRINOLOGY, V145, P5439, DOI 10.1210/en.2004-0959; Fukushima K, 2001, HEPATOL RES, V20, P52, DOI 10.1016/S1386-6346(00)00122-4; Furutani M, 1997, CANCER LETT, V111, P191, DOI 10.1016/S0304-3835(96)04509-0; Godbout R, 1998, J BIOL CHEM, V273, P21161, DOI 10.1074/jbc.273.33.21161; Gregory RI, 2005, CANCER RES, V65, P3509, DOI 10.1158/0008-5472.CAN-05-0298; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Hsu HC, 1997, CANCER RES, V57, P5179; Huang JS, 2004, BIOCHEM BIOPH RES CO, V315, P950, DOI 10.1016/j.bbrc.2004.01.151; Hui AM, 2000, CANCER LETT, V154, P93, DOI 10.1016/S0304-3835(00)00385-2; Hui AM, 1997, HEPATOLOGY, V25, P575, DOI 10.1002/hep.510250314; Huynh H, 2004, CARCINOGENESIS, V25, P1485, DOI 10.1093/carcin/bgh154; Joo M, 2001, LIVER, V21, P89, DOI 10.1034/j.1600-0676.2001.021002089.x; Jung YJ, 2001, CANCER LETT, V168, P57, DOI 10.1016/S0304-3835(01)00403-7; Kahlina K, 2004, J BIOL CHEM, V279, P44872, DOI 10.1074/jbc.M402467200; Kawate S, 1999, ONCOLOGY-BASEL, V57, P157, DOI 10.1159/000012024; Kim YS, 2001, MOL CELLS, V12, P209; Kobayashi T, 2002, AM J GASTROENTEROL, V97, P3166; Kobayashi Y, 2000, J HEPATOL, V32, P612, DOI 10.1016/S0168-8278(00)80223-8; Lahn BT, 1997, SCIENCE, V278, P675, DOI 10.1126/science.278.5338.675; Lee JO, 2005, ONCOGENE, V24, P6617, DOI 10.1038/sj.onc.1208827; Liang TJ, 2004, GASTROENTEROLOGY, V127, pS62, DOI 10.1053/j.gastro.2004.09.017; LINDER P, 1989, NATURE, V337, P121, DOI 10.1038/337121a0; Lukas J, 1997, AM J PATHOL, V150, P167; Luking A, 1998, CRIT REV BIOCHEM MOL, V33, P259, DOI 10.1080/10409239891204233; Macaluso M, 2003, ONCOGENE, V22, P6472, DOI 10.1038/sj.onc.1206955; Mamiya N, 1999, J BIOL CHEM, V274, P15751, DOI 10.1074/jbc.274.22.15751; Marchetti A, 1996, ONCOGENE, V12, P1319; Masaki T, 2003, HEPATOLOGY, V37, P534, DOI 10.1053/jhep.2003.50112; Matsushita K, 1996, INT J CANCER, V69, P259, DOI 10.1002/(SICI)1097-0215(19960822)69:4<259::AID-IJC3>3.3.CO;2-D; MURAKAMI Y, 1991, CANCER RES, V51, P5520; Nagano H, 2003, ONCOGENE, V22, P4656, DOI 10.1038/sj.onc.1206588; Nakagawa Y, 1999, BRIT J CANCER, V80, P914, DOI 10.1038/sj.bjc.6690441; NISHIDA N, 1993, CANCER RES, V53, P368; OGATA N, 1991, HEPATOLOGY, V13, P31, DOI 10.1002/hep.1840130106; Owsianka AM, 1999, VIROLOGY, V257, P330, DOI 10.1006/viro.1999.9659; Paik SY, 2003, MODERN PATHOL, V16, P86, DOI 10.1097/01.MP.0000047308.03300.9C; Pang R, 2004, ONCOGENE, V23, P4182, DOI 10.1038/sj.onc.1207493; Park SH, 1998, CYTOGENET CELL GENET, V81, P178, DOI 10.1159/000015022; Parkin DM, 2001, INT J CANCER, V94, P153, DOI 10.1002/ijc.1440; Parkin DM, 2001, EUR J CANCER, V37, pS4, DOI 10.1016/S0959-8049(01)00267-2; Qin LF, 1998, INT J CANCER, V79, P424, DOI 10.1002/(SICI)1097-0215(19980821)79:4<424::AID-IJC19>3.0.CO;2-4; Rashid A, 1999, BRIT J CANCER, V80, P59, DOI 10.1038/sj.bjc.6690321; Rocak S, 2004, NAT REV MOL CELL BIO, V5, P232, DOI 10.1038/nrm1335; SAITO I, 1990, P NATL ACAD SCI USA, V87, P6547, DOI 10.1073/pnas.87.17.6547; Sato Y, 1999, J GASTROENTEROL, V34, P486, DOI 10.1007/s005350050301; Shackelford J, 2004, MOL CELL BIOL, V24, P5089, DOI 10.1128/MCB.24.12.5089-5093.2004; Shi YZ, 2000, BRIT J CANCER, V83, P50; Stevenson RJ, 1998, J PATHOL, V184, P351, DOI 10.1002/(SICI)1096-9896(199804)184:4<351::AID-PATH1235>3.0.CO;2-C; Suriawinata A, 2004, SEMIN LIVER DIS, V24, P77; TANAKA S, 1993, CANCER RES, V53, P2884; Tannapfel A, 2000, INT J CANCER, V89, P350, DOI 10.1002/1097-0215(20000720)89:4<350::AID-IJC6>3.0.CO;2-3; Tannapfel A, 2002, VIRCHOWS ARCH, V440, P345, DOI 10.1007/s00428-002-0617-x; TaylorRobinson SD, 1997, LANCET, V350, P1142, DOI 10.1016/S0140-6736(05)63789-0; Thorgeirsson SS, 2002, NAT GENET, V31, P339, DOI 10.1038/ng0802-339; Torbenson M, 2002, HUM PATHOL, V33, P871, DOI 10.1053/hupa.2002.128061; Tron VA, 1996, AM J PATHOL, V149, P1139; Ueki T, 1997, HEPATOLOGY, V25, P862, DOI 10.1002/hep.510250413; Wei Y, 2002, HEPATOLOGY, V36, P692, DOI 10.1053/jhep.2002.35342; Xie HL, 2004, WORLD J GASTROENTERO, V10, P1125; Yan J, 2004, ONCOGENE, V23, P1939, DOI 10.1038/sj.onc.1207306; Yedavalli VSRK, 2004, CELL, V119, P381, DOI 10.1016/j.cell.2004.09.029; You LR, 1999, J VIROL, V73, P2841, DOI 10.1128/JVI.73.4.2841-2853.1999; Yu MC, 2004, GASTROENTEROLOGY, V127, pS72, DOI 10.1016/j.gastro.2004.09.018; Yuen MF, 2001, CANCER, V91, P106, DOI 10.1002/1097-0142(20010101)91:1<106::AID-CNCR14>3.0.CO;2-2; Zhang J, 2004, WORLD J GASTROENTERO, V10, P830; ZHANG XK, 1990, ONCOGENE, V5, P909; Zhou ZL, 2002, NATURE, V419, P182, DOI 10.1038/nature01031	81	119	124	1	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR	2006	25	14					1991	2003		10.1038/sj.onc.1209239	http://dx.doi.org/10.1038/sj.onc.1209239			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	026RL	16301996				2022-12-25	WOS:000236359700002
J	Franco, MC; Arciuch, VGA; Peralta, JG; Galli, S; Levisman, D; Lopez, LM; Romorini, L; Poderoso, JJ; Carreras, MC				Franco, MC; Arciuch, VGA; Peralta, JG; Galli, S; Levisman, D; Lopez, LM; Romorini, L; Poderoso, JJ; Carreras, MC			Hypothyroid phenotype is contributed by mitochondrial complex I inactivation due to translocated neuronal nitric-oxide synthase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							THYROID-HORMONE; SPATIAL CONFINEMENT; RADICAL PRODUCTION; PROTEIN COMPLEXES; LIVER; OXYGEN; MODULATION; IDENTIFICATION; PROLIFERATION; INHIBITION	Although transcriptional effects of thyroid hormones have substantial influence on oxidative metabolism, how thyroid sets basal metabolic rate remains obscure. Compartmental localization of nitric-oxide synthases is important for nitric oxide signaling. We therefore examined liver neuronal nitric-oxide synthase-alpha( nNOS) subcellular distribution as a putative mechanism for thyroid effects on rat metabolic rate. At low 3,3',5-triiodo-L-thyronine levels, nNOS mRNA increased by 3-fold, protein expression by one-fold, and nNOS was selectively translocated to mitochondria without changes in other isoforms. In contrast, under thyroid hormone administration, mRNA level did not change and nNOS remained predominantly localized in cytosol. In hypothyroidism, nNOS translocation resulted in enhanced mitochondrial nitric-oxide synthase activity with low O-2 uptake. In this context, NO utilization increased active O-2 species and peroxynitrite yields and tyrosine nitration of complex I proteins that reduced complex activity. Hypothyroidism was also associated to high phospho-p38 mitogen-activated protein kinase and decreased phospho-extracellular signal-regulated kinase 1/2 and cyclin D1 levels. Similarly to thyroid hormones, but without changing thyroid status, nitric-oxide synthase inhibitor N-omega-nitro-L-arginine methyl ester increased basal metabolic rate, prevented mitochondrial nitration and complex I derangement, and turned mitogen-activated protein kinase signaling and cyclin D1 expression back to control pattern. We surmise that nNOS spatial confinement in mitochondria is a significant downstream effector of thyroid hormone and hypothyroid phenotype.	Univ Buenos Aires, Univ Hosp, Lab Oxygen Metab, RA-1120 Buenos Aires, DF, Argentina; Univ Buenos Aires, Fac Med, Inst Biol Celular & Neurociencia Prof Eduardo Rob, RA-1120 Buenos Aires, DF, Argentina; Univ Buenos Aires, Fac Ciencias Exactas & Nat, Dept Quim Biol, RA-1120 Buenos Aires, DF, Argentina; Univ Buenos Aires, Fac Farm & Bioquim, Dept Bioquim Clin, RA-1120 Buenos Aires, DF, Argentina	University of Buenos Aires; University of Buenos Aires; University of Buenos Aires; University of Buenos Aires	Carreras, MC (corresponding author), Univ Buenos Aires, Univ Hosp, Lab Oxygen Metab, Cordoba 2351, RA-1120 Buenos Aires, DF, Argentina.	ccarreras@hospitaldeclinicas.uba.ar	Franco, Maria/O-7862-2015					Alvarez MJ, 2000, ANAL BIOCHEM, V287, P87, DOI 10.1006/abio.2000.4823; Barouch LA, 2002, NATURE, V416, P337, DOI 10.1038/416337a; Barrientos A, 1999, J BIOL CHEM, V274, P16188, DOI 10.1074/jbc.274.23.16188; BERRY MN, 1969, J CELL BIOL, V43, P506, DOI 10.1083/jcb.43.3.506; Bianchi MS, 2004, NEUROENDOCRINOLOGY, V80, P129, DOI 10.1159/000082527; Brookes PS, 2003, J BIOL CHEM, V278, P31603, DOI 10.1074/jbc.M211784200; Carreras Maria C., 2004, Molecular Aspects of Medicine, V25, P125, DOI 10.1016/j.mam.2004.02.014; Carreras MC, 2004, HEPATOLOGY, V40, P157, DOI 10.1002/hep.20255; Carreras MC, 2001, AM J PHYSIOL-HEART C, V281, pH2282, DOI 10.1152/ajpheart.2001.281.6.H2282; Cymeryng CB, 2002, ENDOCRINOLOGY, V143, P1235, DOI 10.1210/en.143.4.1235; Das K, 2001, BBA-MOL BASIS DIS, V1537, P1, DOI 10.1016/S0925-4439(01)00048-5; Dougherty CJ, 2004, FASEB J, V18, P1060, DOI 10.1096/fj.04-1505com; Elfering SL, 2004, AM J PHYSIOL-HEART C, V286, pH22, DOI 10.1152/ajpheart.00766.2003; Fulton D, 2004, J BIOL CHEM, V279, P30349, DOI 10.1074/jbc.M402155200; Ghafourifar P, 1999, J BIOL CHEM, V274, P31185, DOI 10.1074/jbc.274.44.31185; Ghafourifar P, 2005, TRENDS PHARMACOL SCI, V26, P190, DOI 10.1016/j.tips.2005.02.005; Giulivi C, 1998, J BIOL CHEM, V273, P11038, DOI 10.1074/jbc.273.18.11038; Hare JM, 2004, LANCET, V363, P1338, DOI 10.1016/S0140-6736(04)16083-2; Jiang JH, 2003, J BIOL CHEM, V278, P49332, DOI 10.1074/jbc.M304738200; Jope RS, 2000, ARCH BIOCHEM BIOPHYS, V376, P365, DOI 10.1006/abbi.2000.1728; Kanai AJ, 2001, P NATL ACAD SCI USA, V98, P14126, DOI 10.1073/pnas.241380298; Koeck T, 2004, J BIOL CHEM, V279, P27257, DOI 10.1074/jbc.M401586200; Liggett SB, 2004, NAT MED, V10, P582, DOI 10.1038/nm0604-582; LIU JW, 1995, BIOCHEMISTRY-US, V34, P12333, DOI 10.1021/bi00038a029; Lopez-Figueroa MO, 2000, BIOCHEM BIOPH RES CO, V272, P129, DOI 10.1006/bbrc.2000.2748; Lopez-Torres M, 2000, MOL CELL ENDOCRINOL, V168, P127, DOI 10.1016/S0303-7207(00)00302-6; Moro L, 2004, ENDOCRINOLOGY, V145, P5121, DOI 10.1210/en.2004-0909; Myhre O, 2003, BIOCHEM PHARMACOL, V65, P1575, DOI 10.1016/S0006-2952(03)00083-2; Nisoli E, 2003, SCIENCE, V299, P896, DOI 10.1126/science.1079368; OGILVIE P, 1995, FASEB J, V9, P799, DOI 10.1096/fasebj.9.9.7541381; Peralta JG, 2003, AM J PHYSIOL-HEART C, V284, pH2375, DOI 10.1152/ajpheart.00785.2002; Persichini T, 2005, NEUROSCI LETT, V384, P254, DOI 10.1016/j.neulet.2005.04.085; Pibiri M, 2001, FASEB J, V15, P1006, DOI 10.1096/fj.00-0416com; Pillar TM, 1997, EUR J ENDOCRINOL, V136, P231, DOI 10.1530/eje.0.1360231; Poderoso JJ, 1996, ARCH BIOCHEM BIOPHYS, V328, P85, DOI 10.1006/abbi.1996.0146; Poderoso JJ, 1999, J BIOL CHEM, V274, P37709, DOI 10.1074/jbc.274.53.37709; Riobo NA, 2002, J BIOL CHEM, V277, P42447, DOI 10.1074/jbc.M204580200; Riobo NA, 2001, BIOCHEM J, V359, P139, DOI 10.1042/0264-6021:3590139; Sato Y, 2004, J BIOL CHEM, V279, P8827, DOI 10.1074/jbc.M310327200; Scanlan TS, 2004, NAT MED, V10, P638, DOI 10.1038/nm1051; Schagger H, 2001, METHOD CELL BIOL, V65, P231, DOI 10.1016/S0091-679X(01)65014-3; SCHAGGER H, 1991, ANAL BIOCHEM, V199, P223, DOI 10.1016/0003-2697(91)90094-A; Souza JM, 2000, ARCH BIOCHEM BIOPHYS, V380, P360, DOI 10.1006/abbi.2000.1940; Valdez Laura B., 2004, Molecular Aspects of Medicine, V25, P49, DOI 10.1016/j.mam.2004.02.008; Valdez LB, 2005, METHOD ENZYMOL, V396, P444, DOI 10.1016/S0076-6879(05)96037-0; Venditti P, 2003, MOL CELL ENDOCRINOL, V205, P185, DOI 10.1016/S0303-7207(02)00332-5; Venkatraman A, 2004, HEPATOLOGY, V40, P565, DOI 10.1002/hep.20326; Zhang JL, 2005, AM J PHYSIOL-CELL PH, V288, pC840, DOI 10.1152/ajpcell.00325.2004	48	65	69	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 24	2006	281	8					4779	4786		10.1074/jbc.M512080200	http://dx.doi.org/10.1074/jbc.M512080200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	013RF	16361261	hybrid, Green Published			2022-12-25	WOS:000235426200028
J	Osibow, K; Malli, R; Kostner, GM; Graier, WF				Osibow, K; Malli, R; Kostner, GM; Graier, WF			A new type of non-Ca2+-buffering Apo(a)-based fluorescent indicator for intraluminal Ca2+ in the endoplasmic reticulum	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CALCIUM; MITOCHONDRIA; PROTEINS; CALRETICULIN; DYNAMICS; RELEASE; ENTRY	Genetically encoded Ca2+ indicators are outstanding tools for the assessment of intracellular/organelle Ca2+ dynamics. Basically, most indicators contain the Ca2+-binding site of a ( mutated) cytosolic protein that interacts with its natural ( mutated) interaction partner upon binding of Ca2+. Consequently, a change in the structure of the sensor occurs that, in turn, alters the fluorescent properties of the sensor. Herein, we present a new type of genetically encoded Ca2+ indicator for the endoplasmic reticulum ( ER) ( apoK1-er ( W. F. Graier, K. Osibow, R. Malli, and G. M. Kostner, patent application number 05450006.1 at the European patent office)) that is based on a single kringle domain from apolipoprotein( a), which is flanked by yellow and cyan fluorescent protein at the 3'- and 5'- ends, respectively. Notably, apoK1-er does not interact with Ca2+ itself but serves as a substrate for calreticulin, the main constitutive Ca2+-binding protein in the ER. ApoK1- er assembles with calreticulin and the protein disulfide isomerase ERp57 and undergoes a conformational shift in a Ca2+-dependent manner that allows fluorescence resonance energy transfer between the two fluorophores. This construct primarily offers three major advantages compared with the already existing probes: ( i) it resolves perfectly the physiological range of the free Ca2+ concentration in the ER, ( ii) expression of apoK1-er does not affect the Ca2+ buffering capacity of the ER, and ( iii) apoK1-er is not inactivated by binding of constitutive interaction partners that prevent Ca2+-dependent conformational changes. These unique characteristics of apoK1-er make this sensor particularly attractive for studies on ER Ca2+ signaling and dynamics in which alteration of Ca2+ fluctuations by expression of any additional Ca2+ buffer essentially has to be avoided.	Med Univ Graz, Ctr Mol Med, Inst Mol Biol & Biochem, A-8010 Graz, Austria	Medical University of Graz	Graier, WF (corresponding author), Med Univ Graz, Ctr Mol Med, Inst Mol Biol & Biochem, Harrachgasse 21-3, A-8010 Graz, Austria.	wolfgang.graier@meduni-graz.at	Malli, Roland/B-7369-2008; Graier, Wolfgang F./B-7052-2008	Graier, Wolfgang F./0000-0003-1871-3298; Osibow, Karin/0000-0002-9703-595X; Malli, Roland/0000-0001-6327-8729	Austrian Science Fund FWF [P 16860] Funding Source: Medline	Austrian Science Fund FWF(Austrian Science Fund (FWF))		Arnaudeau S, 2002, J BIOL CHEM, V277, P46696, DOI 10.1074/jbc.M202395200; Arnaudeau S, 2001, J BIOL CHEM, V276, P29430, DOI 10.1074/jbc.M103274200; Corbett EF, 2000, J BIOL CHEM, V275, P27177; Corbett EF, 2000, TRENDS BIOCHEM SCI, V25, P307, DOI 10.1016/S0968-0004(00)01588-7; Demaurex N, 2003, CELL CALCIUM, V34, P109, DOI 10.1016/S0143-4160(03)00081-2; DOLOR RJ, 1992, AM J PHYSIOL, V262, pC171, DOI 10.1152/ajpcell.1992.262.1.C171; Frickel EM, 2004, J BIOL CHEM, V279, P18277, DOI 10.1074/jbc.M314089200; Frieden M, 2000, J PHYSIOL-LONDON, V524, P715, DOI 10.1111/j.1469-7793.2000.00715.x; Frieden M, 2002, J PHYSIOL-LONDON, V540, P73, DOI 10.1113/jphysiol.2002.017053; Graier WF, 1997, HORM METAB RES, V29, P622, DOI 10.1055/s-2007-979113; Graier WF, 1995, EUR J PHARMACOL, V294, P221; Heim N, 2004, J BIOL CHEM, V279, P14280, DOI 10.1074/jbc.M312751200; Helenius A, 2001, SCIENCE, V291, P2364, DOI 10.1126/science.291.5512.2364; Helenius A, 2004, ANNU REV BIOCHEM, V73, P1019, DOI 10.1146/annurev.biochem.73.011303.073752; Kostner GM, 1999, J LIPID RES, V40, P2255; Lippincott-Schwartz J, 2001, NAT REV MOL CELL BIO, V2, P444, DOI 10.1038/35073068; Malli R, 2005, J BIOL CHEM, V280, P12114, DOI 10.1074/jbc.M409353200; Malli R, 2003, J BIOL CHEM, V278, P10807, DOI 10.1074/jbc.M212971200; Malli R, 2003, J BIOL CHEM, V278, P44769, DOI 10.1074/jbc.M302511200; Miyakawa T, 1999, EMBO J, V18, P1303, DOI 10.1093/emboj/18.5.1303; Miyawaki A, 1999, P NATL ACAD SCI USA, V96, P2135, DOI 10.1073/pnas.96.5.2135; Miyawaki A, 1997, NATURE, V388, P882, DOI 10.1038/42264; MONTERO M, 1995, EMBO J, V14, P5467, DOI 10.1002/j.1460-2075.1995.tb00233.x; Nagai T, 2001, P NATL ACAD SCI USA, V98, P3197, DOI 10.1073/pnas.051636098; Nilius B, 2003, CELL CALCIUM, V33, P293, DOI 10.1016/S0143-4160(03)00042-3; Nilius B, 2003, ENDOTHELIUM-J ENDOTH, V10, P5, DOI 10.1080/10623320303356; Nilius B, 1993, EXS, V66, P269; Palmer AE, 2004, P NATL ACAD SCI USA, V101, P17404, DOI 10.1073/pnas.0408030101; Paltauf-Doburzynska J, 2000, J PHYSIOL-LONDON, V524, P701, DOI 10.1111/j.1469-7793.2000.00701.x; Paltauf-Doburzynska J, 2004, J CARDIOVASC PHARM, V44, P423, DOI 10.1097/01.fjc.0000139449.64337.1b; Persechini A, 1997, CELL CALCIUM, V22, P209, DOI 10.1016/S0143-4160(97)90014-2; Rizzuto R, 1998, SCIENCE, V280, P1763, DOI 10.1126/science.280.5370.1763; Romoser VA, 1997, J BIOL CHEM, V272, P13270, DOI 10.1074/jbc.272.20.13270; SOMMER A, 1991, BIOCHEMISTRY-US, V30, P11245, DOI 10.1021/bi00111a008; Szabadkai G, 2004, FEBS LETT, V567, P111, DOI 10.1016/j.febslet.2004.04.059; TSE A, 1994, J PHYSIOL-LONDON, V477, P511, DOI 10.1113/jphysiol.1994.sp020212; White AL, 1997, J BIOL CHEM, V272, P5048, DOI 10.1074/jbc.272.8.5048; Zoratti C, 2003, BRIT J PHARMACOL, V140, P1351, DOI 10.1038/sj.bjp.0705529	38	26	26	2	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 24	2006	281	8					5017	5025		10.1074/jbc.M508583200	http://dx.doi.org/10.1074/jbc.M508583200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	013RF	16368693	Green Accepted, hybrid			2022-12-25	WOS:000235426200054
J	Xu, LJ; Deng, XM				Xu, LJ; Deng, XM			Protein kinase C iota promotes nicotine-induced migration and invasion of cancer cells via phosphorylation of mu- and m-calpains	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EPIDERMAL-GROWTH-FACTOR; PULMONARY NEUROENDOCRINE CELLS; DRUG-INDUCED APOPTOSIS; LUNG-CARCINOMA CELLS; ACETYLCHOLINE-RECEPTOR; CIGARETTE-SMOKING; SURVIVAL FUNCTION; ACTIVATION; METASTASIS; MOTILITY	Nicotine is a major component in cigarette smoke that activates the growth-promoting pathways to facilitate the development of lung cancer. However, it is not clear whether nicotine affects cell motility to facilitate tumor metastasis. Here we discovered that nicotine potently induces phosphorylation of both mu- and m-calpains via activation of protein kinase C iota( PKC iota), which is associated with accelerated migration and invasion of human lung cancer cells. Purified PKC iota directly phosphorylates mu- and m-calpains in vitro. Overexpression of PKC iota results in increased phosphorylation of both mu- and m-calpains in vivo. Nicotine also induces activation of c-Src, which is a known PKC iota upstream kinase. Treatment of cells with the alpha(7) nicotinic acetylcholine receptor inhibitor alpha-bungarotoxin can block nicotine-induced calpain phosphorylation with suppression of calpain activity, wound healing, cell migration, and invasion, indicating that nicotine-induced calpain phosphorylation occurs, at least in part, through a signaling pathway involving the upstream alpha(7) nicotinic acetylcholine receptor. Intriguingly, depletion of PKC iota by RNA interference suppresses nicotine-induced calpain phosphorylation, calpain activity, cell migration, and invasion, indicating that PKC iota is a necessary component in nicotine-mediated cell motility signaling. Importantly, nicotine potently induces secretion of mu- and m-calpains from lung cancer cells into culture medium, which may have potential to cleave substrates in the extracellular matrix. These findings reveal a novel role for PKC iota as a nicotine-activated, physiological calpain kinase that directly phosphorylates and activates calpains, leading to enhanced migration and invasion of human lung cancer cells.	Univ Florida, Shands Canc Ctr, Dept Med, Gainesville, FL 32610 USA; Univ Florida, Shands Canc Ctr, Dept Anat & Cell Biol, Gainesville, FL 32610 USA	State University System of Florida; University of Florida; State University System of Florida; University of Florida	Deng, XM (corresponding author), Univ Florida, Shands Canc Ctr, Dept Med, 1600 SW Archer Rd,Acad Res Bldg,R4-216,POB 100232, Gainesville, FL 32610 USA.	xdeng@ufscc.ufl.edu			NCI NIH HHS [R01CA112183-01] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA112183] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALBERT RK, 2004, CLIN RESPIRATORY MED, P519; BECKERLE MC, 1987, CELL, V51, P569, DOI 10.1016/0092-8674(87)90126-7; BENOWITZ NL, 1988, NEW ENGL J MED, V319, P1318; Bhatt A, 2002, J CELL SCI, V115, P3415; Carragher NO, 2004, NEOPLASIA, V6, P53, DOI 10.1016/S1476-5586(04)80053-8; Deng XM, 2000, P NATL ACAD SCI USA, V97, P1578, DOI 10.1073/pnas.97.4.1578; Dourdin N, 2001, J BIOL CHEM, V276, P48382, DOI 10.1074/jbc.M108893200; DUMONT JA, 1994, BIOCHEM BIOPH RES CO, V204, P264, DOI 10.1006/bbrc.1994.2454; Glading A, 2000, J BIOL CHEM, V275, P2390, DOI 10.1074/jbc.275.4.2390; Glading A, 2004, MOL CELL BIOL, V24, P2499, DOI 10.1128/MCB.24.6.2499-2512.2004; Glading A, 2001, J BIOL CHEM, V276, P23341, DOI 10.1074/jbc.M008847200; Gomez DE, 1999, ONCOL REP, V6, P1363; GOPALAKRISHNA R, 1994, P NATL ACAD SCI USA, V91, P12233, DOI 10.1073/pnas.91.25.12233; Hecht SS, 1999, JNCI-J NATL CANCER I, V91, P1194, DOI 10.1093/jnci/91.14.1194; Heino J, 2002, CELL INVASION MED IN, P1; Horwitz AR, 1999, SCIENCE, V286, P1102, DOI 10.1126/science.286.5442.1102; Huttenlocher A, 1997, J BIOL CHEM, V272, P32719, DOI 10.1074/jbc.272.52.32719; IKONEN E, 1995, FEBS LETT, V358, P273, DOI 10.1016/0014-5793(94)01444-6; Itier V, 2001, FEBS LETT, V504, P118, DOI 10.1016/S0014-5793(01)02702-8; Jamieson L, 1999, J BIOL CHEM, V274, P3927, DOI 10.1074/jbc.274.7.3927; Jeong HW, 2005, CANCER RES, V65, P507; Jin ZJ, 2005, J BIOL CHEM, V280, P16045, DOI 10.1074/jbc.M413488200; Jull BA, 2001, J CANCER RES CLIN, V127, P707; Krajewska M, 1997, CANCER RES, V57, P1605; Lopez MG, 1998, P NATL ACAD SCI USA, V95, P14184, DOI 10.1073/pnas.95.24.14184; Mamoune A, 2003, CANCER RES, V63, P4632; Mellor H, 1998, BIOCHEM J, V332, P281, DOI 10.1042/bj3320281; Mihara M, 2003, MOL CELL, V11, P577, DOI 10.1016/S1097-2765(03)00050-9; Minna JD, 2003, J CLIN INVEST, V111, P31, DOI 10.1172/JCI200317492; Murin S, 2001, CHEST, V119, P1635, DOI 10.1378/chest.119.6.1635; Murray NR, 1997, J BIOL CHEM, V272, P27521, DOI 10.1074/jbc.272.44.27521; NEWTON AC, 1995, J BIOL CHEM, V270, P28495, DOI 10.1074/jbc.270.48.28495; Nishihara H, 2001, BIOCHEM BIOPH RES CO, V285, P845, DOI 10.1006/bbrc.2001.5242; Palecek SP, 1998, J CELL SCI, V111, P929; Sahai E, 2005, CURR OPIN GENET DEV, V15, P87, DOI 10.1016/j.gde.2004.12.002; SALVATERRA PM, 1976, J BIOL CHEM, V251, P6327; Schuller HM, 2003, ANAT REC PART A, V270A, P51, DOI 10.1002/ar.a.10019; SELBIE LA, 1993, J BIOL CHEM, V268, P24296; Shiraha H, 2002, MOL CELL BIOL, V22, P2716, DOI 10.1128/MCB.22.8.2716-2727.2002; Shopland DR, 1995, ENVIRON HEALTH PERSP, V103, P131, DOI 10.2307/3432300; Smith SD, 2003, FEBS LETT, V542, P115, DOI 10.1016/S0014-5793(03)00361-2; Spitaler M, 2000, J BIOL CHEM, V275, P33289, DOI 10.1074/jbc.M002742200; STOSSEL TP, 1993, SCIENCE, V260, P1086, DOI 10.1126/science.8493552; Wells A, 2002, ACTA ONCOL, V41, P124, DOI 10.1080/028418602753669481; Witkowski JM, 2002, BLOOD, V100, P1802, DOI 10.1182/blood-2001-11-0073; Wooten MW, 2001, MOL CELL BIOL, V21, P8414, DOI 10.1128/MCB.21.24.8414-8427.2001; Xu LJ, 2004, J BIOL CHEM, V279, P53683, DOI 10.1074/jbc.M409889200	47	102	108	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 17	2006	281	7					4457	4466		10.1074/jbc.M510721200	http://dx.doi.org/10.1074/jbc.M510721200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	011NN	16361262	hybrid			2022-12-25	WOS:000235275300081
J	Gasser, A; Glassmeier, G; Fliegert, R; Langhorst, MF; Meinke, S; Hein, D; Kruger, S; Weber, K; Heiner, I; Oppenheimer, N; Schwarz, JR; Guse, AH				Gasser, A; Glassmeier, G; Fliegert, R; Langhorst, MF; Meinke, S; Hein, D; Kruger, S; Weber, K; Heiner, I; Oppenheimer, N; Schwarz, JR; Guse, AH			Activation of T cell calcium influx by the second messenger ADP-ribose	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HYDROGEN-PEROXIDE; NAD GLYCOHYDROLASE; REVERSED-PHASE; CA2+ RELEASE; CHANNEL; TRPM2; LTRPC2; LYMPHOCYTES; INHIBITOR; APOPTOSIS	Stimulation of Jurkat T cells by high concentrations of concanavalin A (ConA) induced an elevation of the endogenous adenosine diphosphoribose (ADPR) concentration and an inward current significantly different from the Ca2+ release-activated Ca2+ current (I-CRAC). Electrophysiological characterization and activation of a similar current by infusion of ADPR indicated that the ConA-induced current is carried by TRPM2. Expression of TRPM2 in the plasma membrane of Jurkat T cells was demonstrated by reverse transcription-PCR, Western blot, and immunofluorescence. Inhibition of ADPR formation reduced ConA-mediated, but not store-operated, Ca2+ entry and prevented ConA-induced cell death of Jurkat cells. Moreover, gene silencing of TRPM2 abolished the ADPR- and ConA-mediated inward current. Thus, ADPR is a novel second messenger significantly involved in ConA-mediated cell death in T cells.	Univ Hamburg, Med Ctr, Ctr Med Expt, Inst Biochem & Mol Biol 1, D-20246 Hamburg, Germany; Inst Appl Physiol, D-20246 Hamburg, Germany; Univ Hosp Aachen, Rhein Westfal TH Aachen, Inst Physiol, D-52057 Aachen, Germany; Univ Calif San Francisco, Dept Pharmaceut Chem, San Francisco, CA 94143 USA	University of Hamburg; RWTH Aachen University; RWTH Aachen University Hospital; University of California System; University of California San Francisco	Guse, AH (corresponding author), Univ Hamburg, Med Ctr, Ctr Med Expt, Inst Biochem & Mol Biol 1, Martinistr 52, D-20246 Hamburg, Germany.	guse@uke.uni-hamburg.de		Meinke, Stephan/0000-0003-4489-9727	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		Ayub K, 2004, FASEB J, V18, P1335, DOI 10.1096/fj.04-1888hyp; Bastide B, 2002, BIOCHEM BIOPH RES CO, V296, P1267, DOI 10.1016/S0006-291X(02)02073-9; BEHL B, 1987, BIOCHEM BIOPH RES CO, V144, P1303, DOI 10.1016/0006-291X(87)91452-5; Berridge MJ, 2003, NAT REV MOL CELL BIO, V4, P517, DOI 10.1038/nrm1155; Clapham DE, 2003, NATURE, V426, P517, DOI 10.1038/nature02196; da Silva CP, 1998, J CHROMATOGR B, V707, P43, DOI 10.1016/S0378-4347(97)00622-1; De Flora A, 2000, CHEM IMMUNOL, V75, P79; Fonfria E, 2005, J NEUROCHEM, V95, P715, DOI 10.1111/j.1471-4159.2005.03396.x; Fonfria E, 2004, BRIT J PHARMACOL, V143, P186, DOI 10.1038/sj.bjp.0705914; Gasser A, 2005, J CHROMATOGR B, V821, P181, DOI 10.1016/j.jchromb.2005.05.002; Ghanshani S, 2000, J BIOL CHEM, V275, P37137, DOI 10.1074/jbc.M003941200; Guse AH, 1998, CRIT REV IMMUNOL, V18, P419, DOI 10.1615/CritRevImmunol.v18.i5.20; Guse AH, 1997, J BIOL CHEM, V272, P8546, DOI 10.1074/jbc.272.13.8546; Guse AH, 1999, NATURE, V398, P70, DOI 10.1038/18024; GUSE AH, 1995, J IMMUNOL, V155, P3353; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; Hanke JH, 1996, J BIOL CHEM, V271, P695, DOI 10.1074/jbc.271.2.695; Hara Y, 2002, MOL CELL, V9, P163, DOI 10.1016/S1097-2765(01)00438-5; HORN R, 1988, J GEN PHYSIOL, V92, P145, DOI 10.1085/jgp.92.2.145; HOTH M, 1995, PFLUG ARCH EUR J PHY, V430, P315, DOI 10.1007/BF00373905; Huang D, 2003, J CHROMATOGR B, V784, P101, DOI 10.1016/S1570-0232(02)00780-8; KIM UH, 1993, BIOCHIM BIOPHYS ACTA, V1178, P121, DOI 10.1016/0167-4889(93)90001-6; Kolisek M, 2005, MOL CELL, V18, P61, DOI 10.1016/j.molcel.2005.02.033; Kuhn FJP, 2004, J BIOL CHEM, V279, P46431, DOI 10.1074/jbc.M407263200; Kunerth S, 2004, J CELL SCI, V117, P2141, DOI 10.1242/jcs.01063; Kunerth S, 2003, CELL SIGNAL, V15, P783, DOI 10.1016/S0898-6568(03)00015-9; Langhorst MF, 2004, CELL SIGNAL, V16, P1283, DOI 10.1016/j.cellsig.2004.03.013; LEWIS RS, 1989, CELL REGUL, V1, P99, DOI 10.1091/mbc.1.1.99; Li PL, 2002, AM J PHYSIOL-HEART C, V282, pH1229, DOI 10.1152/ajpheart.00736.2001; McHugh D, 2003, J BIOL CHEM, V278, P11002, DOI 10.1074/jbc.M210810200; Montell C, 2002, MOL CELL, V9, P229, DOI 10.1016/S1097-2765(02)00448-3; MULLERSTEFFNER HM, 1992, J BIOL CHEM, V267, P9606; Nagase F, 1998, MICROBIOL IMMUNOL, V42, P567, DOI 10.1111/j.1348-0421.1998.tb02325.x; Perraud AL, 2004, MOL IMMUNOL, V41, P657, DOI 10.1016/j.molimm.2004.04.013; Perraud AL, 2003, CELL CALCIUM, V33, P519, DOI 10.1016/S0143-4160(03)00057-5; Perraud AL, 2001, NATURE, V411, P595, DOI 10.1038/35079100; ROSS PE, 1995, J GEN PHYSIOL, V106, P415, DOI 10.1085/jgp.106.3.415; Sano Y, 2001, SCIENCE, V293, P1327, DOI 10.1126/science.1062473; Schuber F, 2004, CURR MOL MED, V4, P249, DOI 10.2174/1566524043360708; Suen YK, 2000, APOPTOSIS, V5, P369, DOI 10.1023/A:1009691727077; Treiman M, 1998, TRENDS PHARMACOL SCI, V19, P131, DOI 10.1016/S0165-6147(98)01184-5; Uemura T, 2005, BIOCHEM BIOPH RES CO, V328, P1232, DOI 10.1016/j.bbrc.2005.01.086; Wehage E, 2002, J BIOL CHEM, V277, P23150, DOI 10.1074/jbc.M112096200; WERNER A, 1993, J CHROMATOGR-BIOMED, V618, P3, DOI 10.1016/0378-4347(93)80024-X; YOST DA, 1981, J BIOL CHEM, V256, P3647; ZWEIFACH A, 1993, P NATL ACAD SCI USA, V90, P6295, DOI 10.1073/pnas.90.13.6295	46	95	101	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 3	2006	281	5					2489	2496		10.1074/jbc.M506525200	http://dx.doi.org/10.1074/jbc.M506525200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	006XT	16316998	hybrid			2022-12-25	WOS:000234931800011
J	Horcajada, C; Guinovart, JJ; Fita, I; Ferrer, JC				Horcajada, C; Guinovart, JJ; Fita, I; Ferrer, JC			Crystal structure of an archaeal glycogen synthase - Insights into oligomerization and substrate binding of eukaryotic glycogen synthases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHORYLASE; CLASSIFICATION; IDENTIFICATION; PURIFICATION; METABOLISM; MECHANISM; RESIDUES; MUSCLE	Glycogen and starch synthases are retaining glycosyltransferases that catalyze the transfer of glucosyl residues to the non-reducing end of a growing alpha-1,4-glucan chain, a central process of the carbon/energy metabolism present in almost all living organisms. The crystal structure of the glycogen synthase from Pyrococcus abyssi, the smallest known member of this family of enzymes, revealed that its subunits possess a fold common to other glycosyltransferases, a pair of beta/alpha/beta Rossmann fold-type domains with the catalytic site at their interface. Nevertheless, the archaeal enzyme presents an unprecedented homotrimeric molecular arrangement both in solution, as determined by analytical ultracentrifugation, and in the crystal. The C-domains are not involved in intersubunit interactions of the trimeric molecule, thus allowing for movements, likely required for catalysis, across the narrow hinge that connects the Nand C-domains. The radial disposition of the subunits confers on the molecule a distinct triangular shape, clearly visible with negative staining electron microscopy, in which the upper and lower faces present a sharp asymmetry. Comparison of bacterial and eukaryotic glycogen synthases, which use, respectively, ADP or UDP glucose as donor substrates, with the archaeal enzyme, which can utilize both molecules, allowed us to propose the residues that determine glucosyl donor specificity.	Univ Barcelona, Dept Bioquim & Biol Mol, E-08028 Barcelona, Spain; Univ Barcelona, Inst Recerca Biomed, E-08028 Barcelona, Spain; CSIC, Inst Biol Mol Barcelona, E-08028 Barcelona, Spain	University of Barcelona; Barcelona Institute of Science & Technology; Institute for Research in Biomedicine - IRB Barcelona; University of Barcelona; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Instituto de Biologia Molecular de Barcelona (IBMB)	Ferrer, JC (corresponding author), Univ Barcelona, Dept Bioquim & Biol Mol, Av Diagonal 645, E-08028 Barcelona, Spain.	ferrer@bq.ub.es	Fita, Ignasi/R-4515-2019; Ferrer, Joan C./AAP-2145-2021	Fita, Ignasi/0000-0002-7521-2679; Ferrer, Joan C./0000-0003-1212-5161				BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; BROWN NE, 1971, BIOCHIM BIOPHYS ACTA, V242, P69, DOI 10.1016/0005-2744(71)90088-X; Buschiazzo A, 2004, EMBO J, V23, P3196, DOI 10.1038/sj.emboj.7600324; Campbell JA, 1997, BIOCHEM J, V326, P929, DOI 10.1042/bj3260929u; Cid E, 2000, J BIOL CHEM, V275, P33614, DOI 10.1074/jbc.M005358200; Cid E, 2002, FEBS LETT, V528, P5, DOI 10.1016/S0014-5793(02)03313-6; Coutinho PM, 2003, J MOL BIOL, V328, P307, DOI 10.1016/S0022-2836(03)00307-3; Geremia S, 2002, J MOL BIOL, V322, P413, DOI 10.1016/S0022-2836(02)00771-4; Gibson RP, 2002, CHEM BIOL, V9, P1337, DOI 10.1016/S1074-5521(02)00292-2; Gouet P, 1999, BIOINFORMATICS, V15, P305, DOI 10.1093/bioinformatics/15.4.305; Gruyer S, 2002, CURR MICROBIOL, V44, P206, DOI 10.1007/s00284-001-0029-1; Henrissat B, 2002, TRENDS GENET, V18, P437, DOI 10.1016/S0168-9525(02)02734-8; Horcajada C, 2003, ACTA CRYSTALLOGR D, V59, P2322, DOI 10.1107/S0907444903021279; JETT MF, 1979, J BIOL CHEM, V254, P6739; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; LIN DC, 1973, J BIOL CHEM, V248, P7007; Mitchell EP, 1996, BIOCHEMISTRY-US, V35, P7341, DOI 10.1021/bi960072w; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Pederson BA, 2000, J BIOL CHEM, V275, P27753; Prats C, 2005, J BIOL CHEM, V280, P23165, DOI 10.1074/jbc.M502713200; Schwarz A, 2005, BIOCHEM J, V387, P437, DOI 10.1042/BJ20041593; TAKAHARA H, 1978, BIOCHIM BIOPHYS ACTA, V522, P363, DOI 10.1016/0005-2744(78)90070-0; TAKEDA Y, 1975, J BIOL CHEM, V250, P8943; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; Tong L, 1997, METHOD ENZYMOL, V276, P594, DOI 10.1016/S0076-6879(97)76080-4; Watson KA, 1999, EMBO J, V18, P4619, DOI 10.1093/emboj/18.17.4619; WITITSUWANNAKUL D, 1977, J BIOL CHEM, V252, P7812; WOESE CR, 1990, P NATL ACAD SCI USA, V87, P4576, DOI 10.1073/pnas.87.12.4576; Zea CJ, 2003, J AM CHEM SOC, V125, P13666, DOI 10.1021/ja037298o	30	55	55	1	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 3	2006	281	5					2923	2931		10.1074/jbc.M507394200	http://dx.doi.org/10.1074/jbc.M507394200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	006XT	16319074	hybrid			2022-12-25	WOS:000234931800061
J	Marion, S; Oakley, RH; Kim, KM; Caron, MG; Barak, LS				Marion, S; Oakley, RH; Kim, KM; Caron, MG; Barak, LS			A beta-arrestin binding determinant common to the second intracellular loops of rhodopsin family G protein-coupled receptors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MU-OPIOID RECEPTOR; BETA(2)-ADRENERGIC RECEPTOR; CONSTITUTIVE ACTIVATION; VASOPRESSIN RECEPTOR; ADRENERGIC-RECEPTOR; 48-KDA PROTEIN; DESENSITIZATION; PHOSPHORYLATION; LIGHT; MUTANTS	beta-Arrestins have been shown to inhibit competitively G protein-dependent signaling and to mediate endocytosis for many of the hundreds of nonvisual rhodopsin family G protein-coupled receptors ( GPCR). An open question of fundamental importance concerning the regulation of signal transduction of several hundred rhodopsin-like GPCRs is how these receptors of limited sequence homology, when considered in toto, can all recruit and activate the two highly conserved beta-arrestin proteins as part of their signaling/desensitization process. Although the serine and threonine residues that form GPCR kinase phosphorylation sites are common beta-arrestin-associated receptor determinants regulating receptor desensitization and internalization, the agonist-activated conformation of a GPCR probably reveals the most fundamental determinant mediating the GPCR and arrestin interaction. Here we identified a beta-arrestin binding determinant common to the rhodopsin family GPCRs formed from the proximal 10 residues of the second intracellular loop. We demonstrated by both gain and loss of function studies for the serotonin 2C, beta(2)-adrenergic, alpha(2a)-adrenergic, and neuropeptide Y type 2 receptors that the highly conserved amino acids, proline and alanine, naturally occurring in rhodopsin family receptors six residues distal to the highly conserved second loop DRY motif regulate beta-arrestin binding and beta-arrestin-mediated internalization. In particular, as demonstrated for the beta(2)AR, this occurs independently of changes in GPCR kinase phosphorylation. These results suggest that a GPCR conformation directed by the second intracellular loop, likely using the loop itself as a binding patch, may function as a switch for transitioning beta-arrestin from its inactive form to its active receptor-binding state.	Duke Univ, Med Ctr, Dept Cell Biol, Durham, NC 27710 USA	Duke University	Caron, MG (corresponding author), Duke Univ, Med Ctr, Dept Cell Biol, Durham, NC 27710 USA.	caron002@mc.duke.edu; l.barak@cellbio.duke.edu		Marion, Sebastien/0000-0002-3302-3845	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL061635] Funding Source: NIH RePORTER	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Barak LS, 2003, ASSAY DRUG DEV TECHN, V1, P339, DOI 10.1089/15406580360545152; BARAK LS, 1994, J BIOL CHEM, V269, P2790; Barak LS, 1997, J BIOL CHEM, V272, P27497, DOI 10.1074/jbc.272.44.27497; Barak LS, 2001, P NATL ACAD SCI USA, V98, P93, DOI 10.1073/pnas.011303698; Berglund MM, 2003, J PHARMACOL EXP THER, V306, P147, DOI 10.1124/jpet.103.051227; Burns CM, 1997, NATURE, V387, P303, DOI 10.1038/387303a0; Celver JP, 2001, J BIOL CHEM, V276, P4894, DOI 10.1074/jbc.M007437200; CHANG MS, 2000, SCI STKE 2000, pPL1; Chung DA, 2002, BIOCHEMISTRY-US, V41, P3596, DOI 10.1021/bi015811+; Daunt DA, 1997, MOL PHARMACOL, V51, P711, DOI 10.1124/mol.51.5.711; DeGraff JL, 1999, J BIOL CHEM, V274, P11253, DOI 10.1074/jbc.274.16.11253; Demene H, 2003, BIOCHEMISTRY-US, V42, P8204, DOI 10.1021/bi027358n; FERGUSON SSG, 1995, J BIOL CHEM, V270, P24782, DOI 10.1074/jbc.270.42.24782; Filipek S, 2004, PHOTOCH PHOTOBIO SCI, V3, P628, DOI 10.1039/b315661c; Filipek S, 2005, J MOL MODEL, V11, P385, DOI 10.1007/s00894-005-0268-3; Fotiadis D, 2003, NATURE, V421, P127, DOI 10.1038/421127a; Gether U, 1997, EMBO J, V16, P6737, DOI 10.1093/emboj/16.22.6737; Gibson SK, 2000, BIOCHEMISTRY-US, V39, P5738, DOI 10.1021/bi991857f; GUEX N, 2001, DEEP VIEW SWISS PDBV; GUREVICH VV, 1993, J BIOL CHEM, V268, P11628; Gurevich VV, 2004, TRENDS PHARMACOL SCI, V25, P105, DOI 10.1016/j.tips.2003.12.008; Gurevich VV, 1997, J BIOL CHEM, V272, P28849, DOI 10.1074/jbc.272.46.28849; KRUPNICK JG, 1994, J BIOL CHEM, V269, P3226; KUHN H, 1984, FEBS LETT, V176, P473, DOI 10.1016/0014-5793(84)81221-1; Li J, 2001, BIOCHEMISTRY-US, V40, P12039, DOI 10.1021/bi0100945; Liu Y, 1999, J BIOL CHEM, V274, P18351, DOI 10.1074/jbc.274.26.18351; Luttrell LM, 2002, J CELL SCI, V115, P455; Marion S, 2004, J BIOL CHEM, V279, P2945, DOI 10.1074/jbc.M308742200; MORO O, 1993, J BIOL CHEM, V268, P22273; Nakamura K, 1998, J BIOL CHEM, V273, P24346, DOI 10.1074/jbc.273.38.24346; Niswender CM, 1999, J BIOL CHEM, V274, P9472, DOI 10.1074/jbc.274.14.9472; Niswender CM, 1998, ANN NY ACAD SCI, V861, P38, DOI 10.1111/j.1749-6632.1998.tb10171.x; Oakley RH, 2001, J BIOL CHEM, V276, P19452, DOI 10.1074/jbc.M101450200; Oakley RH, 1999, J BIOL CHEM, V274, P32248, DOI 10.1074/jbc.274.45.32248; Okada T, 2004, J MOL BIOL, V342, P571, DOI 10.1016/j.jmb.2004.07.044; Parker SL, 2001, EUR J BIOCHEM, V268, P877, DOI 10.1046/j.1432-1327.2001.01966.x; Price RD, 2001, J BIOL CHEM, V276, P44663, DOI 10.1074/jbc.M106745200; Raman D, 1999, BIOCHEMISTRY-US, V38, P5117, DOI 10.1021/bi9824588; Raman D, 2003, J NEUROCHEM, V84, P1040, DOI 10.1046/j.1471-4159.2003.01598.x; Rasmussen SGF, 1999, MOL PHARMACOL, V56, P175, DOI 10.1124/mol.56.1.175; Scheer A, 2000, MOL PHARMACOL, V57, P219; SCHLEICHER A, 1989, BIOCHEMISTRY-US, V28, P1770, DOI 10.1021/bi00430a052; Seibold A, 2000, MOL PHARMACOL, V58, P1162, DOI 10.1124/mol.58.5.1162; Sheikh SP, 1999, J BIOL CHEM, V274, P17033, DOI 10.1074/jbc.274.24.17033; Sheikh SP, 1996, NATURE, V383, P347, DOI 10.1038/383347a0; Shi W, 1998, BIOCHEMISTRY-US, V37, P4869, DOI 10.1021/bi9731100; Teller DC, 2001, BIOCHEMISTRY-US, V40, P7761, DOI 10.1021/bi0155091; Wilbanks AM, 2002, BIOCHEMISTRY-US, V41, P11981, DOI 10.1021/bi020275m	48	85	89	1	2	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 3	2006	281	5					2932	2938		10.1074/jbc.M508074200	http://dx.doi.org/10.1074/jbc.M508074200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	006XT	16319069	hybrid			2022-12-25	WOS:000234931800062
J	Watanabe, S; Kodak, T; Makino, K				Watanabe, S; Kodak, T; Makino, K			Cloning, expression, and characterization of bacterial L-arabinose 1-dehydrogenase involved in an alternative pathway of L-arabinose metabolism	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLUCOSE-FRUCTOSE OXIDOREDUCTASE; D-GALACTOSE DEHYDROGENASE; L-XYLULOSE REDUCTASE; ZYMOMONAS-MOBILIS; 2-KETO-3-DEOXYGLUCONATE ALDOLASE; PSEUDOMONAS-FLUORESCENS; SULFOLOBUS-SOLFATARICUS; CATABOLIC PATHWAY; ASPERGILLUS-NIGER; GENE	Azospirillum brasiliense converts L-arabinose to alpha-ketoglutarate via five hypothetical enzymatic steps. We purified and characterized L-arabinose 1-dehydrogenase (EC 1.1.1.46), catalyzing the conversion of L-arabinose to L-arabino-gamma-lactone as an enzyme responsible for the first step of this alternative pathway of L-arabinose metabolism. The purified enzyme preferred NADP(+) to NAD(+) as a coenzyme. Kinetic analysis revealed that the enzyme had high catalytic efficiency for both L-arabinose and D-galactose. The gene encoding L-arabinose 1-dehydrogenase was cloned using a partial peptide sequence of the purified enzyme and was overexpressed in Escherichia coli as a fully active enzyme. The enzyme consists of 308 amino acids and has a calculated molecular mass of 33,663.92 Da. The deduced amino acid sequence had some similarity to glucose-fructose oxidoreductase, D-xylose 1-dehydrogenase, and D-galactose 1-dehydrogenase. Site-directed mutagenesis revealed that the enzyme possesses unique catalytic amino acid residues. Northern blot analysis showed that this gene was induced by L-arabinose but not by D-galactose. Furthermore, a disruptant of the L-arabinose 1-dehydrogenase gene did not grow on L-arabinose but grew on D-galactose at the same growth rate as the wild-type strain. There was a partial gene for L-arabinose transport in the flanking region of the L-arabinose 1-dehydrogenase gene. These results indicated that the enzyme is involved in the metabolism of L-arabinose but not D-galactose. This is the first identification of a gene involved in an alternative pathway of L-arabinose metabolism in bacterium.	Kyoto Univ, Inst Adv Energy, Uji, Kyoto 6110011, Japan; Kyoto Univ, Fac Engn, Saikyo Ku, Kyoto 6158530, Japan; Japan Sci & Technol Agcy, CREST, Uji, Kyoto 6110011, Japan; Kyoto Univ, Int Innovat Ctr, Sakyo Ku, Kyoto 6068501, Japan	Kyoto University; Kyoto University; Japan Science & Technology Agency (JST); Kyoto University	Makino, K (corresponding author), Kyoto Univ, Inst Adv Energy, Uji, Kyoto 6110011, Japan.	kmak@iae.kyoto-u.ac.jp						Angelov A, 2005, FEBS J, V272, P1054, DOI 10.1111/j.1742-4658.2004.04539.x; Aoki S, 2001, CHEM-BIOL INTERACT, V130, P775, DOI 10.1016/S0009-2797(00)00307-0; Arimitsu E, 1999, BIOCHEM J, V342, P721, DOI 10.1042/0264-6021:3420721; Asada Y, 2000, BIOCHEM BIOPH RES CO, V278, P333, DOI 10.1006/bbrc.2000.3796; BLACHNITZKY EO, 1974, EUR J BIOCHEM, V47, P235, DOI 10.1111/j.1432-1033.1974.tb03687.x; Bonete MJ, 1996, FEBS LETT, V383, P227, DOI 10.1016/0014-5793(96)00235-9; Cosgrove MS, 1998, BIOCHEMISTRY-US, V37, P2759, DOI 10.1021/bi972069y; Cosgrove MS, 2000, BIOCHEMISTRY-US, V39, P15002, DOI 10.1021/bi0014608; DAGLEY S, 1965, BIOCHEM J, V95, P48, DOI 10.1042/bj0950048; DAHMS AS, 1969, BIOCHEM BIOPH RES CO, V36, P809, DOI 10.1016/0006-291X(69)90681-0; DUNCAN MJ, 1979, J GEN MICROBIOL, V113, P177, DOI 10.1099/00221287-113-1-177; DUNCAN MJ, 1979, J BACTERIOL, V137, P415, DOI 10.1128/JB.137.1.415-419.1979; Edwards KJ, 1996, ARCH BIOCHEM BIOPHYS, V328, P173, DOI 10.1006/abbi.1996.0158; Elshafei AM, 2001, ENZYME MICROB TECH, V29, P76, DOI 10.1016/S0141-0229(01)00346-5; ELZAINY TA, 1973, J BACTERIOL, V114, P457, DOI 10.1128/JB.114.1.457-459.1973; Galbraith MP, 1998, MICROBIOL-SGM, V144, P2915, DOI 10.1099/00221287-144-10-2915; GENNADY PM, 2002, HDB DETECTION ENZYME, P27; Gros E., 1967, METHOD ENZYMOL, V11, P238; Johnsen U, 2004, J BACTERIOL, V186, P6198, DOI 10.1128/JB.186.18.6198-6207.2004; Kemner JM, 1997, J BACTERIOL, V179, P2452, DOI 10.1128/jb.179.7.2452-2458.1997; Kim ST, 1998, BBA-PROTEIN STRUCT M, V1429, P29, DOI 10.1016/S0167-4838(98)00217-9; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lamble FJ, 2004, FEBS LETT, V576, P133, DOI 10.1016/j.febslet.2004.08.074; Lamble HJ, 2003, J BIOL CHEM, V278, P34066, DOI 10.1074/jbc.M305818200; Lott JS, 2000, J MOL BIOL, V304, P575, DOI 10.1006/jmbi.2000.4245; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MATHIAS AL, 1989, J BACTERIOL, V171, P5206, DOI 10.1128/jb.171.9.5206-5209.1989; Moore RA, 2004, INFECT IMMUN, V72, P4172, DOI 10.1128/IAI.72.7.4172-4187.2004; Moore S, 1940, J BIOL CHEM, V133, P293; NOVICK NJ, 1982, J BACTERIOL, V149, P364, DOI 10.1128/JB.149.1.364-367.1982; Nurizzo D, 2001, BIOCHEMISTRY-US, V40, P13857, DOI 10.1021/bi011355d; PEDROSA FO, 1974, J BACTERIOL, V119, P336, DOI 10.1128/JB.119.1.336-338.1974; Penning TM, 2001, CHEM REV, V101, P3027, DOI 10.1021/cr000049n; Richard P, 2002, BIOCHEMISTRY-US, V41, P6432, DOI 10.1021/bi025529i; Richard P, 2001, J BIOL CHEM, V276, P40631, DOI 10.1074/jbc.M104022200; Rossman M.G., 1975, ENZYMES, V11, P61, DOI 10.1016/S1874-6047(08)60210-3; Sambrook J, 2001, MOL CLONING LAB MANU; Selig M, 1997, ARCH MICROBIOL, V167, P217, DOI 10.1007/BF03356097; SIMON R, 1983, BIO-TECHNOL, V1, P784, DOI 10.1038/nbt1183-784; SPERKA S, 1989, NUCLEIC ACIDS RES, V17, P5402, DOI 10.1093/nar/17.13.5402; STRYER L, 1988, BIOCHEMISTRY-US, P805; TARRAND JJ, 1978, CAN J MICROBIOL, V24, P967, DOI 10.1139/m78-160; Theodossis A, 2004, J BIOL CHEM, V279, P43886, DOI 10.1074/jbc.M407702200; Van Bastelaere E, 1999, MOL MICROBIOL, V32, P703, DOI 10.1046/j.1365-2958.1999.01384.x; Verho R, 2004, J BIOL CHEM, V279, P14746, DOI 10.1074/jbc.M312533200; WELMBERG R, 1961, J BIOL CHEM, V236, P629; WELMBERG R, 1955, J BIOL CHEM, V217, P607; WENGENMA.F, 1973, EUR J BIOCHEM, V40, P49, DOI 10.1111/j.1432-1033.1973.tb03168.x; Wiegert T, 1997, J BIOL CHEM, V272, P13126, DOI 10.1074/jbc.272.20.13126; WIERENGA RK, 1985, BIOCHEMISTRY-US, V24, P1346, DOI 10.1021/bi00327a012; ZACHARIOU M, 1986, J BACTERIOL, V167, P863, DOI 10.1128/jb.167.3.863-869.1986; Zaldivar J, 2001, APPL MICROBIOL BIOT, V56, P17, DOI 10.1007/s002530100624	52	61	68	0	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 3	2006	281	5					2612	2623		10.1074/jbc.M506477200	http://dx.doi.org/10.1074/jbc.M506477200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	006XT	16326697	hybrid			2022-12-25	WOS:000234931800025
J	Wegrzyn, RD; Hofmann, D; Merz, F; Nikolay, R; Rauch, T; Graf, C; Deuerling, E				Wegrzyn, RD; Hofmann, D; Merz, F; Nikolay, R; Rauch, T; Graf, C; Deuerling, E			A conserved motif is prerequisite for the interaction of NAC with ribosomal protein L23 and nascent chains	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POLYPEPTIDE-ASSOCIATED COMPLEX; SIGNAL RECOGNITION PARTICLE; MULTIPLE SEQUENCE ALIGNMENT; NEWLY SYNTHESIZED PROTEINS; COLI TRIGGER FACTOR; ESCHERICHIA-COLI; IN-VIVO; SACCHAROMYCES-CEREVISIAE; MOLECULAR CHAPERONES; FUNCTIONAL DISSECTION	In eukaryotes, newly synthesized proteins interact co-translationally with a multitude of different ribosome-bound factors and chaperones including the conserved heterodimeric nascent polypeptide-associated complex (NAC) and a Hsp40/70-based chaperone system. These factors are thought to play an important role in protein folding and targeting, yet their specific ribosomal localizations, which are prerequisite for their functions, remain elusive. This study describes the ribosomal localization of NAC and the molecular details by which NAC is able to contact the ribosome and gain access to nascent polypeptides. We identified a conserved RRK(X)(n)KK ribosome binding motif within the beta-subunit of NAC that is essential for the entire NAC complex to attach to ribosomes and allow for its interaction with nascent polypeptide chains. The motif localizes within a potential loop region between two predicted alpha-helices in the N terminus of beta NAC. This N-terminal beta NAC ribosome-binding domain was completely portable and sufficient to target an otherwise cytosolic protein to the ribosome. NAC modified with a UV-activatable cross-linker within its ribosome binding motif specifically cross-linked to L23 ribosomal protein family members at the exit site of the ribosome, providing the first evidence of NAC-L23 interaction in the context of the ribosome. Mutations of L23 reduced NAC ribosome binding in vivo and in vitro, whereas other eukaryotic ribosome-associated factors such as the Hsp70/40 chaperones Ssb or Zuotin were unaffected. We conclude that NAC employs a conserved ribosome binding domain to position itself on the L23 ribosomal protein adjacent to the nascent polypeptide exit site.	Univ Heidelberg, Zentrum Mol Biol, D-69120 Heidelberg, Germany	Ruprecht Karls University Heidelberg	Deuerling, E (corresponding author), Univ Heidelberg, Zentrum Mol Biol, Neuenheimer Feld 282, D-69120 Heidelberg, Germany.	e.deuerling@zmbh.uni-heidelberg.de		Nikolay, Rainer/0000-0003-4713-2548				AMANN E, 1988, GENE, V69, P3001; Baram D, 2005, P NATL ACAD SCI USA, V102, P12017, DOI 10.1073/pnas.0505581102; Beatrix B, 2000, J BIOL CHEM, V275, P37838, DOI 10.1074/jbc.M006368200; Beckmann R, 2001, CELL, V107, P361, DOI 10.1016/S0092-8674(01)00541-4; Bloss TA, 2003, NATURE, V424, P1066, DOI 10.1038/nature01920; Bukau B, 2000, CELL, V101, P119, DOI 10.1016/S0092-8674(00)80806-5; Cheng ZL, 2005, J CELL BIOL, V168, P67, DOI 10.1083/jcb.200408188; Chenna R, 2003, NUCLEIC ACIDS RES, V31, P3497, DOI 10.1093/nar/gkg500; Clamp M, 2004, BIOINFORMATICS, V20, P426, DOI 10.1093/bioinformatics/btg430; Cuff JA, 2000, PROTEINS, V40, P502, DOI 10.1002/1097-0134(20000815)40:3<502::AID-PROT170>3.0.CO;2-Q; Cyr DM, 2002, TRENDS BIOCHEM SCI, V27, P368, DOI 10.1016/S0968-0004(02)02125-4; DENG JM, 1995, TRANSGENIC RES, V4, P264, DOI 10.1007/BF01969120; Deuerling E, 2003, MOL MICROBIOL, V47, P1317, DOI 10.1046/j.1365-2958.2003.03370.x; Deuerling E, 1999, NATURE, V400, P693, DOI 10.1038/23301; Ferbitz L, 2004, NATURE, V431, P590, DOI 10.1038/nature02899; Franke J, 2001, J CELL SCI, V114, P2641; Frydman J, 2001, ANNU REV BIOCHEM, V70, P603, DOI 10.1146/annurev.biochem.70.1.603; Funfschilling U, 1999, MOL BIOL CELL, V10, P3289, DOI 10.1091/mbc.10.10.3289; Gautschi M, 2001, P NATL ACAD SCI USA, V98, P3762, DOI 10.1073/pnas.071057198; Gautschi M, 2003, MOL CELL BIOL, V23, P7403, DOI 10.1128/MCB.23.20.7403-7414.2003; George R, 1998, P NATL ACAD SCI USA, V95, P2296, DOI 10.1073/pnas.95.5.2296; GRALLATH S, 2005, EMBO REPORTS; Gu SQ, 2003, RNA, V9, P566, DOI 10.1261/rna.2196403; GUTHRIE C, 2004, METHODS ENZYMOLOGY G, V194; Halic M, 2004, NATURE, V427, P808, DOI 10.1038/nature02342; Hartl FU, 2002, SCIENCE, V295, P1852, DOI 10.1126/science.1068408; Hesterkamp T, 1997, J BIOL CHEM, V272, P21865, DOI 10.1074/jbc.272.35.21865; Hundley H, 2002, P NATL ACAD SCI USA, V99, P4203, DOI 10.1073/pnas.062048399; Hundley HA, 2005, SCIENCE, V308, P1032, DOI 10.1126/science.1109247; Hurt E, 1999, J CELL BIOL, V144, P389, DOI 10.1083/jcb.144.3.389; Kramer G, 2004, J BACTERIOL, V186, P3777, DOI 10.1128/JB.186.12.3777-3784.2004; Kramer G, 2002, NATURE, V419, P171, DOI 10.1038/nature01047; Kristensen O, 2003, STRUCTURE, V11, P1547, DOI 10.1016/j.str.2003.11.003; Laufen T, 1999, P NATL ACAD SCI USA, V96, P5452, DOI 10.1073/pnas.96.10.5452; LAURING B, 1995, P NATL ACAD SCI USA, V92, P5411, DOI 10.1073/pnas.92.12.5411; Longtine MS, 1998, YEAST, V14, P953, DOI 10.1002/(SICI)1097-0061(199807)14:10<953::AID-YEA293>3.3.CO;2-L; Markesich DC, 2000, DEVELOPMENT, V127, P559; Moller I, 1998, FEBS LETT, V441, P1, DOI 10.1016/S0014-5793(98)01440-9; Nakatogawa H, 2002, CELL, V108, P629, DOI 10.1016/S0092-8674(02)00649-9; Nikolay R, 2004, J BIOL CHEM, V279, P2673, DOI 10.1074/jbc.M311112200; Otto H, 2005, P NATL ACAD SCI USA, V102, P10064, DOI 10.1073/pnas.0504400102; Pool MR, 2002, SCIENCE, V297, P1345, DOI 10.1126/science.1072366; Powers T, 1996, CURR BIOL, V6, P331, DOI 10.1016/S0960-9822(02)00484-0; Rauch T, 2005, MOL MICROBIOL, V57, P357, DOI 10.1111/j.1365-2958.2005.04690.x; Reimann B, 1999, YEAST, V15, P397, DOI 10.1002/(SICI)1097-0061(19990330)15:5<397::AID-YEA384>3.3.CO;2-L; Rist W, 2005, ANAL BIOCHEM, V342, P160, DOI 10.1016/j.ab.2004.11.043; Rospert S, 2002, CELL MOL LIFE SCI, V59, P1632, DOI 10.1007/PL00012490; Schaffitzel E, 2001, BIOL CHEM, V382, P1235, DOI 10.1515/BC.2001.154; Schlunzen F, 2005, STRUCTURE, V13, P1685, DOI 10.1016/j.str.2005.08.007; SIKORSKI RS, 1989, GENETICS, V122, P19; Spreter T, 2005, J BIOL CHEM, V280, P15849, DOI 10.1074/jbc.M500160200; Wegrzyn RD, 2005, CELL MOL LIFE SCI, V62, P2727, DOI 10.1007/s00018-005-5292-z; WIEDMANN B, 1994, NATURE, V370, P434, DOI 10.1038/370434a0	53	61	61	1	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 3	2006	281	5					2847	2857		10.1074/jbc.M511420200	http://dx.doi.org/10.1074/jbc.M511420200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	006XT	16316984	hybrid			2022-12-25	WOS:000234931800053
J	Xiao, YJ; Cai, YB; Bommineni, YR; Fernando, SC; Prakash, O; Gilliland, SE; Zhang, GL				Xiao, YJ; Cai, YB; Bommineni, YR; Fernando, SC; Prakash, O; Gilliland, SE; Zhang, GL			Identification and functional characterization of three chicken cathelicidins with potent antimicrobial activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INNATE IMMUNITY; HOST-DEFENSE; PEPTIDE PROTECTS; RAPID METHOD; EXPRESSION; INFECTION; SKIN; SEQUENCES; EVOLUTION; ALIGNMENT	Cathelicidins comprise a family of antimicrobial peptides sharing a highly conserved cathelin domain. Here we report that the entire chicken genome encodes three cathelicidins, namely fowlicidin-1 to -3, which are densely clustered within a 7.5-kb distance at the proximal end of chromosome 2p. Each fowlicidin gene adopts a four-exon, three-intron structure, typical for a mammalian cathelicidin. Phylogenetic analysis revealed that fowlicidins and a group of distantly related mammalian cathelicidins known as neutrophilic granule proteins are likely to originate from a common ancestral gene prior to the separation of birds from mammals, whereas other classic mammalian cathelicidins may have been duplicated from the primordial gene for neutrophilic granule proteins after mammals and birds are diverged. Similar to ovine cathelicidin SMAP-29, putatively mature fowlicidins displayed potent and salt-independent activities against a range of Gram-negative and Gram-positive bacteria, including antibiotic-resistant strains, with minimum inhibitory concentrations in the range of 0.4-2.0 mu M for most strains. Fowlicidin-1 and -2 also showed cytotoxicity, with 50% killing of mammalian erythrocytes or epithelial cells in the range of 6-40 mu M. In addition, two fowlicidins demonstrated a strong positive cooperativity in binding lipopolysaccharide (LPS), resulting in nearly complete blockage of LPS-mediated proinflammatory gene expression in RAW264.7 cells. Taken together, fowlicidin-1 and -2 are clearly among the most potent cathelicidins that have been reported. Their broad spectrum and salt-insensitive antibacterial activities, coupled with their potent LPS-neutralizing activity, make fowlicidins excellent candidates for novel antimicrobial and antisepsis agents.	Oklahoma State Univ, Dept Anim Sci, Stillwater, OK 74078 USA; Kansas State Univ, Dept Biochem, Manhattan, KS 66506 USA	Oklahoma State University System; Oklahoma State University - Stillwater; Kansas State University	Zhang, GL (corresponding author), Oklahoma State Univ, Dept Anim Sci, Stillwater, OK 74078 USA.	zguolon@okstate.edu	Zhang, Guolong/AAU-8197-2020; Zhang, Guolong/HCI-5587-2022	Zhang, Guolong/0000-0003-4781-5816; 				ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; Bals R, 1999, J CLIN INVEST, V103, P1113, DOI 10.1172/JCI6570; Bals R, 1999, INFECT IMMUN, V67, P6084, DOI 10.1128/IAI.67.11.6084-6089.1999; Bartlett KH, 2003, ANTIMICROB AGENTS CH, V47, P3901, DOI 10.1128/AAC.47.12.3901-3906.2003; Brogden KA, 2003, INT J ANTIMICROB AG, V22, P465, DOI 10.1016/S0924-8579(03)00180-8; Carretero M, 2004, FASEB J, V18, P1931, DOI 10.1096/fj.04-1515fje; Ganz T, 2003, NAT REV IMMUNOL, V3, P710, DOI 10.1038/nri1180; Harmon BG, 1998, POULTRY SCI, V77, P972, DOI 10.1093/ps/77.7.972; Hettinger AM, 2001, BIOL REPROD, V65, P507, DOI 10.1095/biolreprod65.2.507; Iimura M, 2005, J IMMUNOL, V174, P4901, DOI 10.4049/jimmunol.174.8.4901; Kobayashi KS, 2005, SCIENCE, V307, P731, DOI 10.1126/science.1104911; LARRICK JW, 1995, INFECT IMMUN, V63, P1291, DOI 10.1128/IAI.63.4.1291-1297.1995; Lee PHA, 2005, P NATL ACAD SCI USA, V102, P3750, DOI 10.1073/pnas.0500268102; Lehrer RI, 2004, NAT REV MICROBIOL, V2, P727, DOI 10.1038/nrmicro976; LEVY O, 1993, J BIOL CHEM, V268, P6058; Lynn DJ, 2004, IMMUNOGENETICS, V56, P170, DOI 10.1007/s00251-004-0675-0; Moscinski LC, 1995, J CELL BIOCHEM, V59, P431, DOI 10.1002/jcb.240590404; MUNROE DJ, 1994, GENOMICS, V19, P506, DOI 10.1006/geno.1994.1100; Nizet V, 2001, NATURE, V414, P454, DOI 10.1038/35106587; Nociari MM, 1998, J IMMUNOL METHODS, V213, P157, DOI 10.1016/S0022-1759(98)00028-3; Ong PY, 2002, NEW ENGL J MED, V347, P1151, DOI 10.1056/NEJMoa021481; Panyutich A, 1997, INFECT IMMUN, V65, P978, DOI 10.1128/IAI.65.3.978-985.1997; Patil A, 2004, PHYSIOL GENOMICS, V20, P1, DOI 10.1152/physiolgenomics.00150.2004; Patil AA, 2005, PHYSIOL GENOMICS, V23, P5, DOI 10.1152/physiolgenomics.00104.2005; Patthy L, 1999, GENE, V238, P103, DOI 10.1016/S0378-1119(99)00228-0; Putsep K, 2002, LANCET, V360, P1144, DOI 10.1016/S0140-6736(02)11201-3; RILEY J, 1990, NUCLEIC ACIDS RES, V18, P2887, DOI 10.1093/nar/18.10.2887; SAITOU N, 1987, MOL BIOL EVOL, V4, P406, DOI 10.1093/oxfordjournals.molbev.a040454; SCOCCHI M, 1992, EUR J BIOCHEM, V209, P589, DOI 10.1111/j.1432-1033.1992.tb17324.x; Scott MG, 2000, CRIT REV IMMUNOL, V20, P407; Shai Y, 2002, CURR PHARM DESIGN, V8, P715, DOI 10.2174/1381612023395367; Shi JS, 1999, INFECT IMMUN, V67, P3121, DOI 10.1128/IAI.67.6.3121-3127.1999; Shin SY, 2001, BIOCHEM BIOPH RES CO, V285, P1046, DOI 10.1006/bbrc.2001.5280; Smith JJ, 1996, CELL, V85, P229, DOI 10.1016/S0092-8674(00)81099-5; Tack BF, 2002, EUR J BIOCHEM, V269, P1181, DOI 10.1046/j.0014-2956.2002.02751.x; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; Travis SM, 2000, INFECT IMMUN, V68, P2748, DOI 10.1128/IAI.68.5.2748-2755.2000; Turner J, 1998, ANTIMICROB AGENTS CH, V42, P2206, DOI 10.1128/AAC.42.9.2206; Uzzell T, 2003, PEPTIDES, V24, P1655, DOI 10.1016/j.peptides.2003.08.024; van Dijk A, 2005, VET IMMUNOL IMMUNOP, V106, P321, DOI 10.1016/j.vetimm.2005.03.003; Wehkamp Jan, 2005, V86, P42, DOI 10.1159/000086672; Xiao YJ, 2004, BMC GENOMICS, V5, DOI 10.1186/1471-2164-5-56; Yang D, 2004, ANNU REV IMMUNOL, V22, P181, DOI 10.1146/annurev.immunol.22.012703.104603; Yeh RF, 2001, GENOME RES, V11, P803, DOI 10.1101/gr.175701; Yu K, 2002, J PEPT RES, V60, P1, DOI 10.1034/j.1399-3011.2002.01968.x; Zaiou M, 2003, J INVEST DERMATOL, V120, P810, DOI 10.1046/j.1523-1747.2003.12132.x; Zaiou M, 2002, J MOL MED, V80, P549, DOI 10.1007/s00109-002-0350-6; Zanetti M, 2002, CURR PHARM DESIGN, V8, P779, DOI 10.2174/1381612023395457; Zanetti M, 2004, J LEUKOCYTE BIOL, V75, P39, DOI 10.1189/jlb.0403147; Zarember KA, 2002, INFECT IMMUN, V70, P569, DOI 10.1128/IAI.70.2.569-576.2002; Zasloff M, 2002, NATURE, V415, P389, DOI 10.1038/415389a	51	179	203	0	16	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 3	2006	281	5					2858	2867		10.1074/jbc.M507180200	http://dx.doi.org/10.1074/jbc.M507180200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	006XT	16326712	hybrid			2022-12-25	WOS:000234931800054
J	Belleudi, F; Leone, L; Aimati, L; Stirparo, MG; Cardinali, G; Marchese, C; Frati, L; Picardo, M; Torrisi, MR				Belleudi, Francesca; Leone, Laura; Aimati, Laura; Stirparo, Maria Giovanna; Cardinali, Giorgia; Marchese, Cinzia; Frati, Luigi; Picardo, Mauro; Torrisi, Maria Rosaria			Endocytic pathways and biological effects induced by UVB-dependent or ligand-dependent activation of the keratinocyte growth factor receptor	FASEB JOURNAL			English	Article									[Belleudi, Francesca; Leone, Laura; Stirparo, Maria Giovanna; Marchese, Cinzia; Frati, Luigi; Torrisi, Maria Rosaria] Univ Roma La Sapienza, Dipartimento Med Sperimentale & Patol, Rome, Italy; [Aimati, Laura; Torrisi, Maria Rosaria] Azienda Osped St Andrea, Rome, Italy; [Cardinali, Giorgia; Picardo, Mauro] Ist Dermatol S Maria & S Gallicano, Rome, Italy; [Torrisi, Maria Rosaria] Ist Neurol Mediterraneo Neuromed, Pozzilli, Italy	Sapienza University Rome; Sapienza University Rome; Azienda Ospedaliera Sant'Andrea; IRCCS Istituti Fisioterapici Ospitalieri (IFO); IRCCS San Gallicano Dermatological Institute (ISG); IRCCS Neuromed	Torrisi, MR (corresponding author), Dip Med Sperimentale & Patol, Viale Regina Elena 324, I-00161 Rome, Italy.	mara.torrisi@uniroma1.it	Picardo, Mauro/A-6978-2011; Frati, Luigi/ABI-7437-2020; Marchese, Cinzia/J-1323-2018; Cardinali, Giorgia/H-1814-2016	Picardo, Mauro/0000-0003-4899-6639; Cardinali, Giorgia/0000-0002-7527-9451; MARCHESE, CINZIA/0000-0002-9280-8917					0	31	33	0	0	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	FEB	2006	20	2					395	397		10.1096/fj.05-3934fje	http://dx.doi.org/10.1096/fj.05-3934fje			3	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	V17CJ	16354720	Green Published			2022-12-25	WOS:000207915000033
J	Pintucci, G; Saunders, PC; Gulkarov, I; Sharony, R; Kadian-Dodov, DL; Bohmann, K; Baumann, FG; Galloway, AC; Mignatti, P				Pintucci, Giuseppe; Saunders, Paul C.; Gulkarov, Iosif; Sharony, Ram; Kadian-Dodov, Daniella L.; Bohmann, Katja; Baumann, F. Gregory; Galloway, Aubrey C.; Mignatti, Paolo			Anti-proliferative and anti-inflammatory effects of topical MAPK inhibition in arterialized vein grafts	FASEB JOURNAL			English	Article									[Pintucci, Giuseppe; Saunders, Paul C.; Gulkarov, Iosif; Sharony, Ram; Kadian-Dodov, Daniella L.; Bohmann, Katja; Baumann, F. Gregory; Galloway, Aubrey C.; Mignatti, Paolo] NYU, Sch Med, Dept Cardiothorac Surg, Seymour Cohn Cardiovasc Surg Res Lab, New York, NY 10016 USA; [Mignatti, Paolo] NYU, Sch Med, Dept Cell Biol, New York, NY 10016 USA	New York University; New York University	Pintucci, G (corresponding author), NYU, Sch Med, Dept Cardiothorac Surg, Seymour Cohn Cardiovasc Surg Res Lab, 530 1st Ave,NB 15W16, New York, NY 10016 USA.	pintug01@med.nyu.edu		Mignatti, Paolo/0000-0002-8157-457X; Galoway, Aubrey/0000-0001-5461-3820	NHLBI NIH HHS [5 R01 HL70203-01] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL070203] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))			0	19	27	0	0	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	FEB	2006	20	2					398	400		10.1096/fj.05-4114fje	http://dx.doi.org/10.1096/fj.05-4114fje			3	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	V17CJ	16303874				2022-12-25	WOS:000207915000034
J	Lee, SJ; Kim, DC; Choi, BH; Ha, HJ; Kim, KT				Lee, SJ; Kim, DC; Choi, BH; Ha, HJ; Kim, KT			Regulation of p53 by activated protein kinase C-delta during nitric oxide-induced dopaminergic cell death	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INDUCED APOPTOSIS; TYROSINE NITRATION; OXIDATIVE STRESS; INDUCED PHOSPHORYLATION; PROTEOLYTIC ACTIVATION; ALPHA; INHIBITION; PEROXYNITRITE; TRANSLOCATION; MECHANISM	Selective cell death of dopaminergic neurons in the substantia nigra is the major cause of Parkinson disease. Current evidence suggests that this cell death could be mediated by nitric oxide by-products such as nitrate and peroxynitrite. Because protein kinase C (PKC)-delta is implicated in apoptosis of various cell types, we studied its roles and activation mechanisms in nitric oxide (NO)-induced apoptosis of SN4741 dopaminergic cells. When cells were treated with sodium nitroprusside (SNP), a NO donor, endogenous PKC-delta was nitrated and activated. Immunoprecipitation revealed that p53 co-immunoprecipitated with PKC-delta and was phosphorylated at the 15th serine residue in SNP-treated cells. An in vitro kinase assay revealed that p53 was directly phosphorylated by SNP-activated PKC-delta. The p53 Ser-15 phosphorylation was suppressed in SNP-treated cells when the NO-mediated activation of PKC-delta was inhibited by rottlerin or (-)-epigallocatechin gallate. Within 3 h of p53 phosphorylation, its protein levels increased because of decreased ubiquitin-dependent proteosomal proteolysis, whereas the protein levels of MDM2, ubiquitin-protein isopeptide ligase, were down-regulated in a p53 phosphorylation-dependent fashion. Taken together, these results demonstrate that nitration-mediated activation of PKC-delta induces the phosphorylation of the Ser-15 residue in p53, which increases its protein stability, thereby contributing to the nitric oxide-mediated apoptosis-like cell death pathway. These findings may be expanded to provide new insight into the cellular mechanisms of Parkinson disease.	POSTECH, Dept Life Sci, Div Mol & Life Sci, Syst BioDynam NCRC, Pohang 790784, South Korea; Chungbuk Natl Univ, Sch Life Sci, Dept Biochem, Cheongju 361763, South Korea	Pohang University of Science & Technology (POSTECH); Chungbuk National University	Kim, KT (corresponding author), POSTECH, Dept Life Sci, Div Mol & Life Sci, Syst BioDynam NCRC, Pohang 790784, South Korea.	ktk@postech.ac.kr		KIM, KYONG-TAI/0000-0001-7292-2627				Achanta G, 2001, CANCER RES, V61, P8723; Appella E, 2001, EUR J BIOCHEM, V268, P2764, DOI 10.1046/j.1432-1327.2001.02225.x; Bal-Price A, 2000, J NEUROCHEM, V75, P1455, DOI 10.1046/j.1471-4159.2000.0751455.x; Balafanova Z, 2002, J BIOL CHEM, V277, P15021, DOI 10.1074/jbc.M112451200; BASHIR M, 2002, J BIOL CHEM, V277, P2330; Basu A, 2001, CELL DEATH DIFFER, V8, P899, DOI 10.1038/sj.cdd.4400885; Bharti A, 1998, MOL CELL BIOL, V18, P6719, DOI 10.1128/MCB.18.11.6719; Brooks CL, 2003, CURR OPIN CELL BIOL, V15, P164, DOI 10.1016/S0955-0674(03)00003-6; Chakraborti T, 2005, BIOCHEMISTRY-US, V44, P5246, DOI 10.1021/bi0477889; Chan P, 1998, NEUROLOGY, V50, P513, DOI 10.1212/WNL.50.2.513; Chen NY, 1999, J BIOL CHEM, V274, P15389, DOI 10.1074/jbc.274.22.15389; Chernov MV, 1998, P NATL ACAD SCI USA, V95, P2284, DOI 10.1073/pnas.95.5.2284; Choi BH, 2004, J NEUROCHEM, V90, P442, DOI 10.1111/j.1471-4159.2004.02495.x; Choi SH, 2003, J NEUROSCI, V23, P5877; de Bernardo S, 2004, J NEUROCHEM, V91, P667, DOI 10.1111/j.1471-4159.2004.02744.x; DeVries TA, 2004, J BIOL CHEM, V279, P45603, DOI 10.1074/jbc.M407448200; El-Remessy AB, 2005, J CELL SCI, V118, P243, DOI 10.1242/jcs.01612; Emoto Y, 1996, BLOOD, V87, P1990; Emoto Y, 1995, EMBO J, V14, P6148, DOI 10.1002/j.1460-2075.1995.tb00305.x; FERNANDESALNEMRI T, 1994, J BIOL CHEM, V269, P30761; Fridman JS, 2003, ONCOGENE, V22, P9030, DOI 10.1038/sj.onc.1207116; Gorell JM, 1999, NEUROTOXICOLOGY, V20, P239; Gorell JM, 1997, NEUROLOGY, V48, P650, DOI 10.1212/WNL.48.3.650; Gu ZZ, 2002, SCIENCE, V297, P1186, DOI 10.1126/science.1073634; Hodara R, 2004, J BIOL CHEM, V279, P47746, DOI 10.1074/jbc.M408906200; Hofseth LJ, 2004, TRENDS PHARMACOL SCI, V25, P177, DOI 10.1016/j.tips.2004.02.009; Ito K, 2004, CANCER RES, V64, P1071, DOI 10.1158/0008-5472.CAN-03-1670; Kajimoto T, 2001, MOL CELL BIOL, V21, P1769, DOI 10.1128/MCB.21.5.1769-1783.2001; Kim DC, 2005, BIOCHEM BIOPH RES CO, V337, P110, DOI 10.1016/j.bbrc.2005.09.009; Kim SJ, 2002, J BIOL CHEM, V277, P33501, DOI 10.1074/jbc.M202862200; Kim SJ, 2002, J BIOL CHEM, V277, P1332, DOI 10.1074/jbc.M107231200; Kim SJ, 2002, J BIOL CHEM, V277, P30375, DOI 10.1074/jbc.M205193200; Knapp LT, 2001, BIOCHEM BIOPH RES CO, V286, P764, DOI 10.1006/bbrc.2001.5448; Le Good JA, 1998, SCIENCE, V281, P2042, DOI 10.1126/science.281.5385.2042; Leist M, 1999, EXP CELL RES, V249, P396, DOI 10.1006/excr.1999.4514; Li BJ, 2004, GENE DEV, V18, P1824, DOI 10.1101/gad.1223504; Li L, 2004, J BIOL CHEM, V279, P4058, DOI 10.1074/jbc.M310415200; Liu YB, 1997, J NEUROCHEM, V69, P581, DOI 10.1046/j.1471-4159.1997.69020581.x; MacMillan-Crow LA, 2000, ARCH BIOCHEM BIOPHYS, V377, P350, DOI 10.1006/abbi.2000.1799; Matassa A, 2003, CELL DEATH DIFFER, V10, P269, DOI 10.1038/sj.cdd.4401149; Mouradian MM, 2002, NEUROLOGY, V58, P179, DOI 10.1212/WNL.58.2.179; Murphy S, 2000, GLIA, V29, P1, DOI 10.1002/(SICI)1098-1136(20000101)29:1<1::AID-GLIA1>3.0.CO;2-N; Murriel CL, 2004, J BIOL CHEM, V279, P47985, DOI 10.1074/jbc.M405071200; NEWTON AC, 1995, CURR BIOL, V5, P973, DOI 10.1016/S0960-9822(95)00191-6; Oh-hashi K, 1999, BIOCHEM BIOPH RES CO, V263, P504, DOI 10.1006/bbrc.1999.1237; Polymeropoulos MH, 1997, SCIENCE, V276, P2045, DOI 10.1126/science.276.5321.2045; Rogoff HA, 2002, MOL CELL BIOL, V22, P5308, DOI 10.1128/MCB.22.15.5308-5318.2002; Shieh SY, 1997, CELL, V91, P325, DOI 10.1016/S0092-8674(00)80416-X; TAKENAKA I, 1995, J BIOL CHEM, V270, P5405, DOI 10.1074/jbc.270.10.5405; Tang Y, 1999, IMMUNOLOGY, V96, P171; Vaughan JR, 2001, ANN HUM GENET, V65, P111, DOI 10.1017/S0003480001008557; Wang JY, 2003, J NEUROSCI RES, V72, P508, DOI 10.1002/jnr.10597; Wang X, 2003, CELL DEATH DIFFER, V10, P468, DOI 10.1038/sj.cdd.4401181; Wang XJ, 2002, J BIOL CHEM, V277, P15697, DOI 10.1074/jbc.M112068200; Waterman MJF, 1998, NAT GENET, V19, P175, DOI 10.1038/542; Xie SQ, 2001, J BIOL CHEM, V276, P36194, DOI 10.1074/jbc.M104157200; Youmell M, 1998, BIOCHEM BIOPH RES CO, V245, P514, DOI 10.1006/bbrc.1998.8471; Zhang YM, 2004, J NEUROSCI, V24, P10616, DOI 10.1523/JNEUROSCI.2469-04.2004	58	56	60	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 27	2006	281	4					2215	2224		10.1074/jbc.M509509200	http://dx.doi.org/10.1074/jbc.M509509200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	004NV	16314418	hybrid			2022-12-25	WOS:000234760400045
J	Supangat, S; Seo, KH; Choi, YK; Park, YS; Son, D; Han, CD; Lee, KH				Supangat, S; Seo, KH; Choi, YK; Park, YS; Son, D; Han, CD; Lee, KH			Structure of Chlorobium tepidum sepiapterin reductase complex reveals the novel substrate binding mode for stereospecific production of L-threo-tetrahydrobiopterin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							2 TROPINONE REDUCTASES; DICTYOSTELIUM-DISCOIDEUM; CRYSTAL-STRUCTURE; BIOSYNTHESIS; HYPERPHENYLALANINEMIA; TETRAHYDROPTERIN; DEHYDROGENASE; DIFFRACTION; CARBONYL; DENSITY	Sepiapterin reductase (SR) is involved in the last step of tetrahydrobiopterin (BH4) biosynthesis by reducing the di-keto group of 6-pyruvoyl tetrahydropterin. Chlorobium tepidum SR (cSR) generates a distinctBH(4) product, L-threo- BH4 (6R-(1'S, 2'S)- 5,6,7,8- BH4), whereas animal enzymes produce L-erythro-BH4 (6R-( 1'R, 2'S)5,6,7,8- BH4) although it has high amino acid sequence similarities to the other animal enzymes. To elucidate the structural basis for the different reaction stereospecificities, we have determined the three-dimensional structures of cSR alone and complexed with NADP and sepiapterin at 2.1 and 1.7 angstrom resolution, respectively. The overall folding of the cSR, the binding site for the cofactor NADP(H), and the positions of active site residues were quite similar to the mouse and the human SR. However, significant differences were found in the substrate binding region of the cSR. In comparison to the mouse SR complex, the sepiapterin in the cSR is rotated about 180 around the active site and bound between two aromatic side chains of Trp-196 and Phe-99 so that its pterin ring is shifted to the opposite side, but its side chain position is not changed. The swiveled sepiapterin binding results in the conversion of the side chain configuration, exposing the opposite face for hydride transfer from NADPH. The different sepiapterin binding mode within the conserved catalytic architecture presents a novel strategy of switching the reaction stereospecificities in the same protein fold.	Gyeongsang Natl Univ, Div Appl Life Sci, Jinju 660701, South Korea; Gyeongsang Natl Univ, Environm Biotechnol Natl Core Res Ctr, Jinju 660701, South Korea; Gyeongsang Natl Univ, Plant Mol Biol & Biotechnol Res Ctr, Jinju 660701, South Korea; Inje Univ, Sch Biotechnol & Biomed Sci, Kimhae 621749, South Korea	Gyeongsang National University; Gyeongsang National University; Gyeongsang National University; Inje University	Lee, KH (corresponding author), Gyeongsang Natl Univ, Div Appl Life Sci, Jinju 660701, South Korea.	lkh@gsnu.ac.kr	, supangat/ABA-9734-2020; Park, Young Shik/S-1978-2019	, supangat/0000-0003-4915-9218; 				Auerbach G, 1997, EMBO J, V16, P7219, DOI 10.1093/emboj/16.24.7219; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Blau N, 2001, MOL GENET METAB, V74, P172, DOI 10.1006/mgme.2001.3213; Bonafe L, 2001, AM J HUM GENET, V69, P269, DOI 10.1086/321970; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Cho SH, 1999, BIOCHEM J, V340, P497, DOI 10.1042/0264-6021:3400497; Cho SH, 1998, BBA-GEN SUBJECTS, V1379, P53, DOI 10.1016/S0304-4165(97)00081-0; Choi YK, 2005, FEBS LETT, V579, P3085, DOI 10.1016/j.febslet.2005.04.064; Choi YK, 2005, FEMS MICROBIOL LETT, V242, P95, DOI 10.1016/j.femsle.2004.10.044; Delano W. L., 2001, PYMOL MOL GRAPHICS S; Fujimoto K, 2001, CHEM-BIOL INTERACT, V130, P825, DOI 10.1016/S0009-2797(00)00238-6; GHOSH D, 1994, STRUCTURE, V2, P629, DOI 10.1016/S0969-2126(00)00064-2; Gouet P, 1999, BIOINFORMATICS, V15, P305, DOI 10.1093/bioinformatics/15.4.305; HENDRICKSON WA, 1991, SCIENCE, V254, P51, DOI 10.1126/science.1925561; HOLM L, 1995, TRENDS BIOCHEM SCI, V20, P478, DOI 10.1016/S0968-0004(00)89105-7; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; JORVANALL H, 1995, BIOCHEMISTRY-US, V34, P6003; KABSCH W, 1983, BIOPOLYMERS, V22, P2577, DOI 10.1002/bip.360221211; KATOH S, 1984, BIOCHEM BIOPH RES CO, V118, P859, DOI 10.1016/0006-291X(84)91474-8; KATOH S, 1988, J BIOCHEM-TOKYO, V103, P286, DOI 10.1093/oxfordjournals.jbchem.a122262; KATOH S, 1987, J BIOCHEM-TOKYO, V101, P275, DOI 10.1093/oxfordjournals.jbchem.a121901; KAUFMAN S, 1993, ANNU REV NUTR, V13, P261, DOI 10.1146/annurev.nu.13.070193.001401; Kim YA, 2000, MOL CELLS, V10, P405; KLEIN R, 1990, EUR J BIOCHEM, V187, P665, DOI 10.1111/j.1432-1033.1990.tb15351.x; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; MARLETTA MA, 1994, CELL, V78, P927, DOI 10.1016/0092-8674(94)90268-2; Michael G., 1975, ENZYMES, V11, P61, DOI 10.1016/S1874-6047(08)60210-3; MILSTIEN S, 1989, BIOCHEM BIOPH RES CO, V165, P845, DOI 10.1016/S0006-291X(89)80043-9; Nakajima K, 1999, J BIOL CHEM, V274, P16563, DOI 10.1074/jbc.274.23.16563; Nakajima K, 1998, P NATL ACAD SCI USA, V95, P4876, DOI 10.1073/pnas.95.9.4876; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; PARK YS, 1991, BIOCHEM BIOPH RES CO, V175, P738, DOI 10.1016/0006-291X(91)91628-P; Supangat S, 2005, ACTA CRYSTALLOGR F, V61, P202, DOI [10.1107/S174430910403444X, 10.1007/S174330910403444X]; Tanaka N, 1996, STRUCTURE, V4, P33, DOI 10.1016/S0969-2126(96)00007-X; Terwilliger TC, 1999, ACTA CRYSTALLOGR D, V55, P1872, DOI 10.1107/S090744499901029X; Thompson JD, 1997, NUCLEIC ACIDS RES, V25, P4876, DOI 10.1093/nar/25.24.4876; Thony B, 2000, BIOCHEM J, V347, P1, DOI 10.1042/0264-6021:3470001; Werner-Felmayer G, 2002, CURR DRUG METAB, V3, P159, DOI 10.2174/1389200024605073	38	15	16	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 27	2006	281	4					2249	2256		10.1074/jbc.M509343200	http://dx.doi.org/10.1074/jbc.M509343200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	004NV	16308317	hybrid			2022-12-25	WOS:000234760400049
J	Dewilde, S; Ebner, B; Vinck, E; Gilany, K; Hankeln, T; Burmester, T; Kreiling, J; Reinisch, C; Vanfleteren, JR; Kiger, L; Marden, MC; Hundahl, C; Fago, A; Van Doorslaer, S; Moens, L				Dewilde, S; Ebner, B; Vinck, E; Gilany, K; Hankeln, T; Burmester, T; Kreiling, J; Reinisch, C; Vanfleteren, JR; Kiger, L; Marden, MC; Hundahl, C; Fago, A; Van Doorslaer, S; Moens, L			The nerve hemoglobin of the bivalve mollusc Spisula solidissima - Molecular cloning, ligand binding studies, and phylogenetic analysis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CEREBRO-VISCERAL CONNECTIVES; VERTEBRATE GLOBIN FAMILY; HIGH-PRESSURE; TEMPERATURE-DEPENDENCE; HUMAN NEUROGLOBIN; HEME ENVIRONMENT; OXYGEN-AFFINITY; CYTOGLOBIN; BRAIN; PROTEIN	Members of the hemoglobin (Hb) superfamily are present in nerve tissue of several vertebrate and invertebrate species. In vertebrates they display hexacoordinate heme iron atoms and are typically expressed at low levels (mu M). Their function is still a matter of debate. In invertebrates they have a hexa- or pentacoordinate heme iron, are mostly expressed at high levels ( mM), and have been suggested to have a myoglobin-like function. The native Hb of the surf clam, Spisula solidissima, composed of 162 amino acids, does not show specific deviations from the globin templates. UV-visible and resonance Raman spectroscopy demonstrate a hexacoordinate heme iron. Based on the sequence analogy, the histidine E7 is proposed as a sixth ligand. Kinetic and equilibrium measurements show amoderate oxygen affinity (P-50 similar to 0.6 torr) and no cooperativity. The histidine binding affinity is 100-fold lower than in neuroglobin. Phylogenetic analysis demonstrates a clustering of the S. solidissima nerve Hb with mollusc Hbs and myoglobins, but not with the vertebrate neuroglobins. We conclude that invertebrate nerve Hbs expressed at high levels are, despite the hexacoordinate nature of their heme iron, not essentially different from other intracellular Hbs. They most likely fulfill a myoglobin-like function and enhance oxygen supply to the neurons.	Univ Antwerp, Dept Biomed Sci, B-2610 Antwerp, Belgium; Univ Antwerp, Dept Phys, B-2610 Antwerp, Belgium; Johannes Gutenberg Univ Mainz, Inst Mol Genet, D-55099 Mainz, Germany; Johannes Gutenberg Univ Mainz, Inst Zool, D-55099 Mainz, Germany; Marine Biol Lab, Woods Hole, MA 02543 USA; Univ Ghent, Dept Biol, B-9000 Ghent, Belgium; INSERM, U779, F-94276 Le Kremlin Bicetre, France; Aarhus Univ, Inst Biol Sci, DK-8000 Aarhus C, Denmark	University of Antwerp; University of Antwerp; Johannes Gutenberg University of Mainz; Johannes Gutenberg University of Mainz; Marine Biological Laboratory - Woods Hole; Ghent University; Institut National de la Sante et de la Recherche Medicale (Inserm); Aarhus University	Moens, L (corresponding author), Univ Antwerp, Dept Biomed Sci, Campus Drie Eiken,Univ Pl 1, B-2610 Antwerp, Belgium.	luc.moens@ua.ac.be	Marden, Michael/AAA-5923-2020; Kiger, Laurent/Q-1686-2018; Hundahl, Christian Ansgar/H-3938-2015; Van Doorslaer, Sabine/E-5050-2017; Gilany, Kambiz/F-3271-2017; Fago, Angela/J-5946-2013; Burmester, Thorsten/I-7225-2013; Marden, Michael C/G-3139-2012	Van Doorslaer, Sabine/0000-0002-1685-9202; Gilany, Kambiz/0000-0003-2916-7245; Fago, Angela/0000-0001-7315-2628; Burmester, Thorsten/0000-0002-5772-7863; Marden, Michael C/0000-0002-5254-6385; Kreiling, Jill/0000-0003-4440-2039; Vinck, Evi/0000-0001-6167-1068; Gilany, Kambiz/0000-0002-6729-5566				ALDEN RG, 1989, J BIOL CHEM, V264, P1933; [Anonymous], 2005, PHYLIP PHYLOGENY INF; Antonini E., 1971, HEMOGLOBIN MYOGLOBIN; ArredondoPeter R, 1997, PLANT PHYSIOL, V115, P1259, DOI 10.1104/pp.115.3.1259; ARVANITAKI A., 1960, BULL INST OCEANOGR [MONACO], V1164, P1; BASHFORD D, 1987, J MOL BIOL, V196, P199, DOI 10.1016/0022-2836(87)90521-3; BOISSEL JP, 1985, P NATL ACAD SCI USA, V82, P8448, DOI 10.1073/pnas.82.24.8448; Burmester T, 2002, MOL BIOL EVOL, V19, P416, DOI 10.1093/oxfordjournals.molbev.a004096; Burmester T, 2000, NATURE, V407, P520, DOI 10.1038/35035093; Burmester T, 2004, IUBMB LIFE, V56, P703, DOI 10.1080/15216540500037257; CHALAZON.N, 1966, CR SOC BIOL, V160, P1020; Couture M, 2001, J BIOL CHEM, V276, P36377, DOI 10.1074/jbc.M103907200; Das TK, 1999, J BIOL CHEM, V274, P4207, DOI 10.1074/jbc.274.7.4207; Das TK, 2000, BIOCHEMISTRY-US, V39, P14330, DOI 10.1021/bi001681d; Dayhoff M. O., 1978, ATLAS PROTEIN SEQ S3, V5, P345; Dewilde S, 2001, J BIOL CHEM, V276, P38949, DOI 10.1074/jbc.M106438200; Dewilde S, 1996, J BIOL CHEM, V271, P19865, DOI 10.1074/jbc.271.33.19865; DOELLER JE, 1988, BIOL BULL, V174, P67, DOI 10.2307/1541760; Duff SMG, 1997, J BIOL CHEM, V272, P16746, DOI 10.1074/jbc.272.27.16746; Ebner B, 2003, MOL BIOL EVOL, V20, P1521, DOI 10.1093/molbev/msg164; Fago A, 2004, J BIOL CHEM, V279, P44417, DOI 10.1074/jbc.M407126200; FELSENSTEIN J, 1985, EVOLUTION, V39, P783, DOI 10.1111/j.1558-5646.1985.tb00420.x; Geuens E, 2003, J BIOL CHEM, V278, P30417, DOI 10.1074/jbc.C300203200; Hamdane D, 2005, J BIOL CHEM, V280, P36809, DOI 10.1074/jbc.M506253200; Hamdane D, 2004, MICRON, V35, P59, DOI 10.1016/j.micron.2003.10.019; Hankeln T, 2005, J INORG BIOCHEM, V99, P110, DOI 10.1016/j.jinorgbio.2004.11.009; Huelsenbeck JP, 2001, BIOINFORMATICS, V17, P754, DOI 10.1093/bioinformatics/17.8.754; KEILIN J, 1949, BIOCHEM J, V45, P440, DOI 10.1042/bj0450440; Kiger L, 2004, IUBMB LIFE, V56, P709, DOI 10.1080/15216540500037711; KRAUS DW, 1986, SCIENCE, V232, P90, DOI 10.1126/science.232.4746.90; KRAUS DW, 1988, BIOL BULL, V174, P346, DOI 10.2307/1541960; KRAUS DW, 1988, BIOL BULL, V174, P54, DOI 10.2307/1541759; Kumar S, 2001, BIOINFORMATICS, V17, P1244, DOI 10.1093/bioinformatics/17.12.1244; Lacan P, 2002, AM J HEMATOL, V69, P214, DOI 10.1002/ajh.10051; LANKESTER ER, 1872, ADV COMP ENV PHYSL, V21, P70; Laufs TL, 2004, NEUROSCI LETT, V362, P83, DOI 10.1016/j.neulet.2004.02.072; Lee JM, 2000, J CLIN INVEST, V106, P723, DOI 10.1172/JCI11003; Moens L, 2000, NATURE, V407, P461, DOI 10.1038/35035181; MORISHIMA I, 1980, BIOCHEMISTRY-US, V19, P1569, DOI 10.1021/bi00549a006; Pesce A, 2003, STRUCTURE, V11, P1087, DOI 10.1016/S0969-2126(03)00166-7; Pesce A, 2002, EMBO REP, V3, P1146, DOI 10.1093/embo-reports/kvf248; Polevoda B, 2000, J BIOL CHEM, V275, P36479, DOI 10.1074/jbc.R000023200; Reuss S, 2002, NEUROSCIENCE, V115, P645, DOI 10.1016/S0306-4522(02)00536-5; Roesner A, 2005, MOL BIOL EVOL, V22, P12, DOI 10.1093/molbev/msh258; SAGE JT, 1991, BIOCHEMISTRY-US, V30, P1227, DOI 10.1021/bi00219a010; SAITOU N, 1987, MOL BIOL EVOL, V4, P406, DOI 10.1093/oxfordjournals.molbev.a040454; Sawai H, 2003, BIOCHEMISTRY-US, V42, P5133, DOI 10.1021/bi027067e; SCHINDELMEISER I, 1979, COMP BIOCHEM PHYS B, V64, P149, DOI 10.1016/0305-0491(79)90153-6; SCHMIDT ER, 1980, CHROMOSOMA, V76, P35, DOI 10.1007/BF00292224; Schmidt M, 2003, J BIOL CHEM, V278, P1932, DOI 10.1074/jbc.M209909200; Strimmer K, 1996, MOL BIOL EVOL, V13, P964, DOI 10.1093/oxfordjournals.molbev.a025664; STRITTMATTER P, 1963, BIOCHIM BIOPHYS ACTA, V78, P562, DOI 10.1016/0006-3002(63)90928-4; Sun YJ, 2001, P NATL ACAD SCI USA, V98, P15306, DOI 10.1073/pnas.251466698; Sun YJ, 2003, P NATL ACAD SCI USA, V100, P3497, DOI 10.1073/pnas.0637726100; Uzan J, 2004, BIOPHYS J, V87, P1196, DOI 10.1529/biophysj.104.042168; Vandergon TL, 1998, J BIOL CHEM, V273, P16998, DOI 10.1074/jbc.273.27.16998; Weber RE, 2001, PHYSIOL REV, V81, P569, DOI 10.1152/physrev.2001.81.2.569; Whelan S, 2001, MOL BIOL EVOL, V18, P691, DOI 10.1093/oxfordjournals.molbev.a003851; WITTENBERG BA, 1965, BIOCHEM J, V96, P363, DOI 10.1042/bj0960363; WITTENBERG JB, 1992, ADV COMP ENV PHYSL, P59; Wystub S, 2003, NEUROSCI LETT, V346, P114, DOI 10.1016/S0304-3940(03)00563-9	61	24	26	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 3	2006	281	9					5364	5372		10.1074/jbc.M509486200	http://dx.doi.org/10.1074/jbc.M509486200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	015RQ	16352603	Green Published, hybrid			2022-12-25	WOS:000235568900007
J	Montalibet, J; Skorey, K; McKay, D; Scapin, G; Asante-Appiah, E; Kennedy, BP				Montalibet, J; Skorey, K; McKay, D; Scapin, G; Asante-Appiah, E; Kennedy, BP			Residues distant from the active site influence protein-tyrosine phosphatase 1B inhibitor binding	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MAMMALIAN PHOSPHODIESTERASE; PTP-1B INHIBITORS; POTENT; DESIGN; YEAST; SPECIFICITY; IDENTIFICATION; SELECTIVITY; SUBSTRATE; SCREEN	Regions of protein-tyrosine phosphatase (PTP) 1B that are distant from the active site yet affect inhibitor binding were identified by a novel library screen. This screen was based on the observation that expression of v-Src in yeast leads to lethality, which can be rescued by the coexpression of PTP1B. However, this rescue is lost when yeast are grown in the presence of PTP1B inhibitors. To identify regions of PTP1B (amino acids 1-400, catalytic domain plus 80-amino acid C-terminal tail) that can affect the binding of the difluoromethyl phosphonate (DFMP) inhibitor 7-bromo-6-difluoromethyl phosphonate 3-naphthalenenitrile, a library coexpressing PTP1B mutants and v-Src was generated, and the ability of yeast to grow in the presence of the inhibitor was evaluated. PTP1B inhibitor-resistant mutations were found to concentrate on helix alpha 7 and its surrounding region, but not in the active site. No resistant amino acid substitutions were found to occur in the C-terminal tail, suggesting that this region has little effect on active-site inhibitor binding. An in-depth characterization of a resistant substitution localizing to region alpha 7 (S295F) revealed that this change minimally affected enzyme catalytic activity, but significantly reduced the potency of a panel of structurally diverse DFMP PTP1B inhibitors. This loss of inhibitor potency was found to be due to the difluoro moiety of these inhibitors because only the difluoro inhibitors were shifted. For example, the inhibitor potency of a monofluorinated or non-fluorinated analog of one of these DFMP inhibitors was only minimally affected. Using this type of library screen, which can scan the nearly full-length PTP1B sequence (catalytic domain and C-terminal tail) for effects on inhibitor binding, we have been able to identify novel regions of PTP1B that specifically affect the binding of DFMP inhibitors.	Merck Frosst Ctr Therapeut Res, Dept Biochem & Mol Biol, Pointe Claire, PQ H9R 4P8, Canada; Merck Frosst Ctr Therapeut Res, Dept Chem, Pointe Claire, PQ H9R 4P8, Canada; Concordia Univ, Dept Chem & Biochem, Montreal, PQ H4B 1R6, Canada; Merck Res Labs, Dept Med Chem, Rahway, NJ 07065 USA	Merck & Company; Merck & Company; Concordia University - Canada; Merck & Company	Kennedy, BP (corresponding author), Merck Frosst Ctr Therapeut Res, Dept Biochem & Mol Biol, POB 1005,16711 Trans Canada Hwy, Pointe Claire, PQ H9R 4P8, Canada.	brian_kennedy@merck.com						Asante-Appiah E, 2001, J BIOL CHEM, V276, P26036, DOI 10.1074/jbc.M011697200; Atienza JM, 1999, J BIOL CHEM, V274, P4839, DOI 10.1074/jbc.274.8.4839; Burke TR, 2003, ACCOUNTS CHEM RES, V36, P426, DOI 10.1021/ar020127o; Burke TR, 1996, BIOCHEMISTRY-US, V35, P15989, DOI 10.1021/bi961256d; BURKE TR, 1994, BIOCHEM BIOPH RES CO, V204, P129, DOI 10.1006/bbrc.1994.2435; CHEN L, 1995, BIOCHEM BIOPH RES CO, V216, P976, DOI 10.1006/bbrc.1995.2716; Cornish-Bowden A., 1995, FUNDAMENTALS ENZYME; Desmarais S, 1999, BIOCHEM J, V337, P219, DOI 10.1042/0264-6021:3370219; Dufresne C, 2004, BIOORG MED CHEM LETT, V14, P1039, DOI 10.1016/j.bmcl.2003.11.048; FRANGIONI JV, 1992, CELL, V68, P545, DOI 10.1016/0092-8674(92)90190-N; Gietz RD, 2002, METHOD ENZYMOL, V350, P87; Goldstein Barry J., 2001, Current Drug Targets - Immune Endocrine and Metabolic Disorders, V1, P265, DOI 10.2174/1568008013341163; Guo XL, 2002, J BIOL CHEM, V277, P41014, DOI 10.1074/jbc.M207347200; Jones TA, 1997, METHOD ENZYMOL, V277, P173, DOI 10.1016/S0076-6879(97)77012-5; Lau CK, 2004, BIOORG MED CHEM LETT, V14, P1043, DOI 10.1016/j.bmcl.2003.11.076; Leslie AGW, 1990, CRYSTALLOGRAPHIC COM; Montalibet J, 2005, METHODS, V35, P2, DOI 10.1016/j.ymeth.2004.07.002; Montalibet J, 2004, BIOCHEM PHARMACOL, V68, P1807, DOI 10.1016/j.bcp.2004.06.024; Montalibet J., 2005, DRUG DISCOV TODAY TH, V2, P129, DOI DOI 10.1016/J.DDSTR.2005.05.002; NELSON Z, 2004, F HUTCHINSON CANC RE; Ohtaka H, 2004, INT J BIOCHEM CELL B, V36, P1787, DOI 10.1016/j.biocel.2004.02.021; PILLAI R, 1993, P NATL ACAD SCI USA, V90, P11970, DOI 10.1073/pnas.90.24.11970; Prejdova Jana, 2004, Current Drug Targets - Infectious Disorders, V4, P137, DOI 10.2174/1568005043340984; Puius YA, 1997, P NATL ACAD SCI USA, V94, P13420, DOI 10.1073/pnas.94.25.13420; Rossmann MG, 1999, ACTA CRYSTALLOGR D, V55, P1631, DOI 10.1107/S0907444999008379; Scapin G, 2003, BIOCHEMISTRY-US, V42, P11451, DOI 10.1021/bi035098j; SupertiFurga G, 1996, NAT BIOTECHNOL, V14, P600, DOI 10.1038/nbt0596-600; Taylor SD, 2004, EXPERT OPIN INV DRUG, V13, P199, DOI 10.1517/eoid.13.3.199.27347; Wang QP, 1998, BIOORG MED CHEM LETT, V8, P345, DOI 10.1016/S0960-894X(98)00027-4; Wiesmann C, 2004, NAT STRUCT MOL BIOL, V11, P730, DOI 10.1038/nsmb803; Xu RX, 2004, J MOL BIOL, V337, P355, DOI 10.1016/j.jmb.2004.01.040; Zhang ZY, 2002, ANNU REV PHARMACOL, V42, P209, DOI 10.1146/annurev.pharmtox.42.083001.144616	32	52	58	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 24	2006	281	8					5258	5266		10.1074/jbc.M511546200	http://dx.doi.org/10.1074/jbc.M511546200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	013RF	16332678	hybrid			2022-12-25	WOS:000235426200080
J	Yoshida, R; Umezawa, T; Mizoguchi, T; Takahashi, S; Takahashi, F; Shinozaki, K				Yoshida, R; Umezawa, T; Mizoguchi, T; Takahashi, S; Takahashi, F; Shinozaki, K			The regulatory domain of SRK2E/OST1/SnRK2.6 interacts with ABI1 and integrates abscisic acid (ABA) and osmotic stress signals controlling stomatal closure in Arabidopsis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN PHOSPHATASE 2C; HYPEROSMOTIC STRESS; DROUGHT TOLERANCE; GENE-EXPRESSION; KINASE; ACTIVATION; CHANNELS; TRANSDUCTION; RESPONSES; UPSTREAM	ABI1 and ABI2 encode PP2C-type protein phosphatases and are thought to negatively regulate many aspects of abscisic acid (ABA) signaling, including stomatal closure in Arabidopsis. In contrast, SRK2E/OST1/SnRK2.6 encodes an Arabidopsis SnRK2 protein kinase and acts as a positive regulator in the ABA-induced stomatal closure. SRK2E/OST1 is activated by osmotic stress as well as by ABA, but the independence of the two activation processes has not yet been determined. Additionally, interaction between SRK2E/OST1 and PP2C-type phosphatases (ABI1 and ABI2) is not understood. In the present study, we demonstrated that the abi1-1 mutation, but not the abi2-1 mutation, strongly inhibited ABA-dependent SRK2E/OST1 activation. In contrast, osmotic stress activated SRK2E/OST1 even in abi1-1 and aba2-1 plants. The C-terminal regulatory domain of SRK2E/OST1 was required for its activation by both ABA and osmotic stress in Arabidopsis. The C-terminal domain was functionally divided into Domains I and II. Domain II was required only for the ABA-dependent activation of SRK2E/OST1, whereas Domain I was responsible for the ABA-independent activation. Full-length SRK2E/OST1 completely complemented the wilty phenotype of the srk2e mutant, but SRK2E/OST1 lacking Domain II did not. Domain II interacted with the ABI1 protein in a yeast two-hybrid assay. Our results suggested that the direct interaction between SRK2E/OST1 and ABI1 through Domain II plays a critical role in the control of stomatal closure.	RIKEN, Tsukuba Inst, Plant Mol Biol Lab, Tsukuba, Ibaraki 3050074, Japan; RIKEN, Genom Sci Ctr, Plant Mutat Explorat Team, Plant Funct Genom Res Grp,Tsurumi Ku, Yokohama, Kanagawa 2300045, Japan; Univ Tsukuba, Inst Biol Sci, Tsukuba, Ibaraki 3058572, Japan; RIKEN, Plant Sci Ctr, Gene Discovery Res Grp, Tsurumi Ku, Yokohama, Kanagawa 2300045, Japan	RIKEN; RIKEN; University of Tsukuba; RIKEN	Shinozaki, K (corresponding author), RIKEN, Tsukuba Inst, Plant Mol Biol Lab, 3-1-1,Koyadai, Tsukuba, Ibaraki 3050074, Japan.	sinozaki@rtc.riken.jp	Umezawa, Taishi/E-3028-2010; Shinozaki, Kazuo/G-4202-2013; Takahashi, Seiji/AAE-1509-2019; Takahashi, Fuminori/D-6200-2017	Umezawa, Taishi/0000-0003-3750-0503; Shinozaki, Kazuo/0000-0002-6317-9867; Takahashi, Seiji/0000-0002-2288-4340; Takahashi, Fuminori/0000-0001-8817-8652				ANDERBERG RJ, 1992, P NATL ACAD SCI USA, V89, P10183, DOI 10.1073/pnas.89.21.10183; Bonetta D, 1998, TRENDS PLANT SCI, V3, P231, DOI 10.1016/S1360-1385(98)01241-2; Boudsocq M, 2004, J BIOL CHEM, V279, P41758, DOI 10.1074/jbc.M405259200; Bray EA, 1997, TRENDS PLANT SCI, V2, P48, DOI 10.1016/S1360-1385(97)82562-9; Finkelstein Ruth R., 2002, Plant Cell, V14, pS15; Gosti F, 1999, PLANT CELL, V11, P1897, DOI 10.1105/tpc.11.10.1897; Guo Y, 2002, DEV CELL, V3, P233, DOI 10.1016/S1534-5807(02)00229-0; Halford NG, 2000, ADV BOT RES, V32, P405, DOI 10.1016/S0065-2296(00)32031-6; Himmelbach A, 2002, EMBO J, V21, P3029, DOI 10.1093/emboj/cdf316; Hong SP, 2003, P NATL ACAD SCI USA, V100, P8839, DOI 10.1073/pnas.1533136100; Hrabak EM, 2003, PLANT PHYSIOL, V132, P666, DOI 10.1104/pp.102.011999; Iuchi S, 2001, PLANT J, V27, P325, DOI 10.1046/j.1365-313x.2001.01096.x; Kelner A, 2004, PLANT PHYSIOL, V136, P3255, DOI 10.1104/pp.104.046151; Kobayashi Y, 2004, PLANT CELL, V16, P1163, DOI 10.1105/tpc.019943; Lemichez E, 2001, GENE DEV, V15, P1808, DOI 10.1101/gad.900401; Leung J, 1997, PLANT CELL, V9, P759, DOI 10.1105/tpc.9.5.759; LEUNG J, 1994, SCIENCE, V264, P1448, DOI 10.1126/science.7910981; Li JX, 2000, SCIENCE, V287, P300, DOI 10.1126/science.287.5451.300; Liu K, 1998, PLANT CELL, V10, P1957, DOI 10.1105/tpc.10.11.1957; Luan S, 2002, PLANT CELL ENVIRON, V25, P229, DOI 10.1046/j.1365-3040.2002.00758.x; Mikolajczyk M, 2000, PLANT CELL, V12, P165, DOI 10.1105/tpc.12.1.165; Mitsuhara I, 1996, PLANT CELL PHYSIOL, V37, P49, DOI 10.1093/oxfordjournals.pcp.a028913; Monks DE, 2001, PLANT CELL, V13, P1205, DOI 10.1105/tpc.13.5.1205; Mustilli AC, 2002, PLANT CELL, V14, P3089, DOI 10.1105/tpc.007906; Nath N, 2003, MOL CELL BIOL, V23, P3909, DOI 10.1128/MCB.23.11.3909-3917.2003; Ohta M, 2003, P NATL ACAD SCI USA, V100, P11771, DOI 10.1073/pnas.2034853100; Pei ZM, 2000, NATURE, V406, P731, DOI 10.1038/35021067; Seo M, 2002, TRENDS PLANT SCI, V7, P41, DOI 10.1016/S1360-1385(01)02187-2; Shinozaki K, 2003, CURR OPIN PLANT BIOL, V6, P410, DOI 10.1016/S1369-5266(03)00092-X; Taji T, 2002, PLANT J, V29, P417, DOI 10.1046/j.0960-7412.2001.01227.x; Umezawa T, 2004, P NATL ACAD SCI USA, V101, P17306, DOI 10.1073/pnas.0407758101; VALVEKENS D, 1988, P NATL ACAD SCI USA, V85, P5536, DOI 10.1073/pnas.85.15.5536; Wang XQ, 2001, SCIENCE, V292, P2070, DOI 10.1126/science.1059046; Woods A, 2003, CURR BIOL, V13, P2004, DOI 10.1016/j.cub.2003.10.031; Yamaguchi-Shinozaki K, 2005, TRENDS PLANT SCI, V10, P88, DOI 10.1016/j.tplants.2004.12.012; Yoshida R, 2002, PLANT CELL PHYSIOL, V43, P1473, DOI 10.1093/pcp/pcf188; Zhang WH, 2004, P NATL ACAD SCI USA, V101, P9508, DOI 10.1073/pnas.0402112101; Zhu JK, 2002, ANNU REV PLANT BIOL, V53, P247, DOI 10.1146/annurev.arplant.53.091401.143329	38	381	437	8	99	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 24	2006	281	8					5310	5318		10.1074/jbc.M509820200	http://dx.doi.org/10.1074/jbc.M509820200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	013RF	16365038	hybrid			2022-12-25	WOS:000235426200085
J	Iwata, J; Ezaki, J; Komatsu, M; Yokota, S; Ueno, T; Tanida, I; Chiba, T; Tanaka, K; Kominami, E				Iwata, J; Ezaki, J; Komatsu, M; Yokota, S; Ueno, T; Tanida, I; Chiba, T; Tanaka, K; Kominami, E			Excess peroxisomes are degraded by autophagic machinery in mammals	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-ACTIVATING ENZYME; VACUOLE TARGETING PATHWAY; SACCHAROMYCES-CEREVISIAE; SELECTIVE DEGRADATION; PICHIA-PASTORIS; RAT-LIVER; BIOGENESIS; PROLIFERATORS; PEXOPHAGY; CYTOPLASM	Peroxisomes are degraded by autophagic machinery termed "pexophagy" in yeast; however, whether this is essential for peroxisome degradation in mammals remains unknown. Here we have shown that Atg7, an essential gene for autophagy, plays a pivotal role in the degradation of excess peroxisomes in mammals. Following induction of peroxisomes by a 2-week treatment with phthalate esters in control and Atg7-deficient livers, peroxisomal degradation was monitored within 1 week after discontinuation of phthalate esters. Although most of the excess peroxisomes in the control liver were selectively degraded within 1 week, this rapid removal was exclusively impaired in the mutant liver. Furthermore, morphological analysis revealed that surplus peroxisomes, but not mutant hepatocytes, were surrounded by autophagosomes in the control. Our results indicated that the autophagic machinery is essential for the selective clearance of excess peroxisomes in mammals. This is the first direct evidence for the contribution of autophagic machinery in peroxisomal degradation in mammals.	Juntendo Univ, Sch Med, Dept Biochem, Bunkyo Ku, Tokyo 1138421, Japan; Tokyo Metropolitan Inst Med Sci, Dept Mol Oncol, Tokyo 1138613, Japan; Univ Yamanashi, Interdisciplinary Grad Sch Med & Engn, Biol Lab, Tamaho, Yamanashi 40938, Japan	Juntendo University; Tokyo Metropolitan Institute of Medical Science; University of Yamanashi	Kominami, E (corresponding author), Juntendo Univ, Sch Med, Dept Biochem, Bunkyo Ku, 2-1-1 Hongo, Tokyo 1138421, Japan.	komilabo@med.juntendo.ac.jp	Kominami, Eiki/D-3802-2009; Komatsu, Masaaki/B-8321-2011; Tanida, Isei/C-8277-2009	Komatsu, Masaaki/0000-0001-7672-7722; Tanida, Isei/0000-0001-8999-3990				Ano Y, 2005, MOL BIOL CELL, V16, P446, DOI 10.1091/mbc.E04-09-0842; Asanuma K, 2003, FASEB J, V17, P1165, DOI 10.1096/fj.02-0580fje; Bellu AR, 2003, MICROSC RES TECHNIQ, V61, P161, DOI 10.1002/jemt.10325; Bellu AR, 2001, J BIOL CHEM, V276, P44570, DOI 10.1074/jbc.M107599200; DUVE CD, 1955, BIOCHEM J, V60, P604, DOI 10.1042/bj0600604; EZAKI J, 1995, J NEUROCHEM, V64, P733; Farre JC, 2004, TRENDS CELL BIOL, V14, P515, DOI 10.1016/j.tcb.2004.07.014; Heiland I, 2005, FEBS J, V272, P2362, DOI 10.1111/j.1742-4658.2005.04690.x; Ichimura Y, 2000, NATURE, V408, P488, DOI 10.1038/35044114; Kabeya Y, 2000, EMBO J, V19, P5720, DOI 10.1093/emboj/19.21.5720; Kim J, 2000, ANNU REV BIOCHEM, V69, P303, DOI 10.1146/annurev.biochem.69.1.303; Kim J, 2001, J CELL BIOL, V153, P381, DOI 10.1083/jcb.153.2.381; Kissova I, 2004, J BIOL CHEM, V279, P39068, DOI 10.1074/jbc.M406960200; Klionsky DT, 1999, ANNU REV CELL DEV BI, V15, P1, DOI 10.1146/annurev.cellbio.15.1.1; Komatsu M, 2005, J CELL BIOL, V169, P425, DOI 10.1083/jcb.200412022; LAZAROW PB, 1985, ANNU REV CELL BIOL, V1, P489, DOI 10.1146/annurev.cb.01.110185.002421; Lemasters JJ, 2005, REJUV RES, V8, P3, DOI 10.1089/rej.2005.8.3; Mizushima N, 1998, NATURE, V395, P395, DOI 10.1038/26506; Nakagawa I, 2004, SCIENCE, V306, P1037, DOI 10.1126/science.1103966; NICHOLLSGRZEMSK.FA, 1992, BIOCHEM PHARMACOL, V7, P1395; Onodera J, 2004, J BIOL CHEM, V279, P16071, DOI 10.1074/jbc.M312706200; REDDY JK, 1983, CRC CR REV TOXICOL, V12, P1, DOI 10.3109/10408448309029317; REDDY JK, 1980, NATURE, V283, P397, DOI 10.1038/283397a0; Shintani T, 2004, J BIOL CHEM, V279, P29889, DOI 10.1074/jbc.M404399200; Stromhaug PE, 2001, J BIOL CHEM, V276, P42422, DOI 10.1074/jbc.M104087200; Subramani S, 1998, PHYSIOL REV, V78, P171, DOI 10.1152/physrev.1998.78.1.171; Tanida I, 1999, MOL BIOL CELL, V10, P1367, DOI 10.1091/mbc.10.5.1367; Tanida I, 2002, BIOCHEM BIOPH RES CO, V292, P256, DOI 10.1006/bbrc.2002.6645; Tanida I, 2002, J BIOL CHEM, V277, P13739, DOI 10.1074/jbc.M200385200; Tanida I, 2001, J BIOL CHEM, V276, P1701, DOI 10.1074/jbc.C000752200; Tanida I, 2005, AUTOPHAGY, V1, P84, DOI 10.4161/auto.1.2.1697; TSUKAMOTO T, 1990, J CELL BIOL, V110, P651, DOI 10.1083/jcb.110.3.651; USUDA N, 1991, J HISTOCHEM CYTOCHEM, V39, P95, DOI 10.1177/39.1.1670581; Vanden Heuvel JP, 1999, TOXICOL SCI, V47, P1, DOI 10.1093/toxsci/47.1.1; YOKOTA S, 1993, EUR J CELL BIOL, V61, P67; Yokota S, 2003, MICROSC RES TECHNIQ, V61, P151, DOI 10.1002/jemt.10324; Yokota S, 2001, J HISTOCHEM CYTOCHEM, V49, P613, DOI 10.1177/002215540104900508; Yuan WP, 1999, MOL BIOL CELL, V10, P1353, DOI 10.1091/mbc.10.5.1353	38	184	195	0	14	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 17	2006	281	7					4035	4041		10.1074/jbc.M512283200	http://dx.doi.org/10.1074/jbc.M512283200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	011NN	16332691	hybrid			2022-12-25	WOS:000235275300032
J	Karten, B; Campenot, RB; Vance, DE; Vance, JE				Karten, B; Campenot, RB; Vance, DE; Vance, JE			Expression of ABCG1, but not ABCA1, correlates with cholesterol release by cerebellar astroglia	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CENTRAL-NERVOUS-SYSTEM; APOLIPOPROTEIN-E; CELLULAR CHOLESTEROL; CONTAINING LIPOPROTEINS; ASTROCYTES SYNTHESIZE; DENSITY-LIPOPROTEIN; CEREBROSPINAL-FLUID; LIPID EFFLUX; WILD-TYPE; IN-VITRO	Central nervous system lipoproteins mediate the exchange of cholesterol between cells and support synaptogenesis and neuronal growth. The primary source of lipoproteins in the brain is astroglia cells that synthesize and secrete apolipoprotein (apo) E in high density lipoprotein-like particles. Small quantities of apoA1, derived from the peripheral circulation, are also present in the brain. In addition to the direct secretion of apoE-containing lipoproteins from astroglia, glia-derived lipoproteins are thought to be formed by cholesterol efflux to extracellular apolipoproteins via ATP-binding cassette (ABC) transporters. We used cultured cerebellar murine astroglia to investigate the relationship among cholesterol availability, apoE secretion, expression of ABCA1 and ABCG1, and cholesterol efflux. In many cell types, cholesterol content, ABCA1 expression, and cholesterol efflux are closely correlated. In contrast, cholesterol enrichment of glia failed to increase ABCA1 expression, although ABCG1 expression and cholesterol efflux to apoA1 were increased. Moreover, the liver X receptor (LXR) agonist TO901317 up-regulated ABCA1 and ABCG1 expression in glia without stimulating cholesterol efflux. Larger lipoproteins were generated when glia were enriched with cholesterol, whereas treatment with the LXR agonist produced smaller particles that were eliminated when the glia were loaded with cholesterol. We also used glia from ApoE(-/-) mice to distinguish between direct lipoprotein secretion and the extracellular generation of lipoproteins. Our observations indicate that partially lipidated apoE, secreted directly by glia, is likely to be the major extracellular acceptor of cholesterol released from glia in a process mediated by ABCG1.	Univ Alberta, Canadian Inst Hlth Res, Res Grp Mol & Cell Biol Lipids, Edmonton, AB T6G 2S2, Canada; Univ Alberta, Dept Med, Edmonton, AB T6G 2S2, Canada; Univ Alberta, Dept Biochem, Edmonton, AB T6G 2S2, Canada; Univ Alberta, Dept Cell Biol, Edmonton, AB T6G 2S2, Canada	Institute for Work & Health; University of Alberta; University of Alberta; University of Alberta; University of Alberta	Vance, JE (corresponding author), Univ Alberta, Canadian Inst Hlth Res, Res Grp Mol & Cell Biol Lipids, 328 Heritage Med Res Ctr, Edmonton, AB T6G 2S2, Canada.	jean.vance@ualberta.ca		Karten, Barbara/0000-0003-2395-3333				Choi HY, 2003, J BIOL CHEM, V278, P32569, DOI 10.1074/jbc.M304553200; Costet P, 2000, J BIOL CHEM, V275, P28240; DeMattos RB, 2001, NEUROCHEM INT, V39, P415, DOI 10.1016/S0197-0186(01)00049-3; Dietschy JM, 2001, CURR OPIN LIPIDOL, V12, P105, DOI 10.1097/00041433-200104000-00003; Fagan AM, 1999, J BIOL CHEM, V274, P30001, DOI 10.1074/jbc.274.42.30001; Hayashi H, 2004, J BIOL CHEM, V279, P14009, DOI 10.1074/jbc.M313828200; Hirsch-Reinshagen V, 2004, J BIOL CHEM, V279, P41197, DOI 10.1074/jbc.M407962200; Ito T, 2003, DRUG NEWS PERSPECT, V16, P490, DOI 10.1358/dnp.2003.16.8.829346; Karten B, 2005, BIOCHEM J, V387, P779, DOI 10.1042/BJ20041694; Kennedy MA, 2005, CELL METAB, V1, P121, DOI 10.1016/j.cmet.2005.01.002; Klucken J, 2000, P NATL ACAD SCI USA, V97, P817, DOI 10.1073/pnas.97.2.817; Koch S, 2001, J LIPID RES, V42, P1143; Koudinov AR, 2005, J NEUROL SCI, V229, P233, DOI 10.1016/j.jns.2004.11.036; Krimbou L, 2004, J LIPID RES, V45, P839, DOI 10.1194/jlr.M300418-JLR200; LaDu MJ, 2000, J BIOL CHEM, V275, P33974, DOI 10.1074/jbc.M000602200; LaDu MJ, 1998, J NEUROCHEM, V70, P2070; Langmann T, 2003, CLIN CHEM, V49, P230, DOI 10.1373/49.2.230; Langmann T, 1999, BIOCHEM BIOPH RES CO, V257, P29, DOI 10.1006/bbrc.1999.0406; Lee JY, 2005, CURR OPIN LIPIDOL, V16, P19, DOI 10.1097/00041433-200502000-00005; Lordkipanidze T, 2005, GLIA, V51, P229, DOI 10.1002/glia.20200; Lund EG, 2003, J BIOL CHEM, V278, P22980, DOI 10.1074/jbc.M303415200; Lutjohann D, 1996, P NATL ACAD SCI USA, V93, P9799, DOI 10.1073/pnas.93.18.9799; MAHLEY RW, 1988, SCIENCE, V240, P622, DOI 10.1126/science.3283935; Mauch DH, 2001, SCIENCE, V294, P1354, DOI 10.1126/science.294.5545.1354; MOCKEL B, 1994, J NEUROCHEM, V62, P788; Nagler K, 2001, J PHYSIOL-LONDON, V533, P665, DOI 10.1111/j.1469-7793.2001.00665.x; Nakamura K, 2004, J BIOL CHEM, V279, P45980, DOI 10.1074/jbc.M408652200; Oram JF, 2003, ARTERIOSCL THROM VAS, V23, P720, DOI 10.1161/01.ATV.0000054662.44688.9A; Oram JF, 2001, J LIPID RES, V42, P1173; Panzenboeck U, 2002, J BIOL CHEM, V277, P42781, DOI 10.1074/jbc.M207601200; PATEL SC, 1995, NEUROREPORT, V6, P653, DOI 10.1097/00001756-199503000-00017; PITAS RE, 1987, BIOCHIM BIOPHYS ACTA, V917, P148, DOI 10.1016/0005-2760(87)90295-5; PITAS RE, 1987, J BIOL CHEM, V262, P14352; Remaley AT, 2001, BIOCHEM BIOPH RES CO, V280, P818, DOI 10.1006/bbrc.2000.4219; Schmitz G, 2001, J LIPID RES, V42, P1513; Schwartz K, 2000, BIOCHEM BIOPH RES CO, V274, P794, DOI 10.1006/bbrc.2000.3243; Sparrow CP, 2002, J BIOL CHEM, V277, P10021, DOI 10.1074/jbc.M108225200; STITT TN, 1991, ANN NY ACAD SCI, V633, P113; Turley SD, 1996, J LIPID RES, V37, P1953; Ullian EM, 2001, SCIENCE, V291, P657, DOI 10.1126/science.291.5504.657; Vance JE, 2005, SEMIN CELL DEV BIOL, V16, P193, DOI 10.1016/j.semcdb.2005.01.005; Venkateswaran A, 2000, P NATL ACAD SCI USA, V97, P12097, DOI 10.1073/pnas.200367697; Wahrle SE, 2004, J BIOL CHEM, V279, P40987, DOI 10.1074/jbc.M407963200; Wang N, 2004, P NATL ACAD SCI USA, V101, P9774, DOI 10.1073/pnas.0403506101; Yamada Keiko, 2002, Anatomical Science International, V77, P94, DOI 10.1046/j.0022-7722.2002.00021.x	45	100	101	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 17	2006	281	7					4049	4057		10.1074/jbc.M508915200	http://dx.doi.org/10.1074/jbc.M508915200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	011NN	16352604	hybrid			2022-12-25	WOS:000235275300034
J	Ma, JL; Lee, SJ; Duong, JK; Stern, DF				Ma, JL; Lee, SJ; Duong, JK; Stern, DF			Activation of the checkpoint kinase Rad53 by the phosphatidyl inositol kinase-like kinase Mec1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA-DAMAGE CHECKPOINT; DOUBLE-STRAND BREAKS; CHK2 PROTEIN-KINASE; BUDDING YEAST RAD9; SACCHAROMYCES-CEREVISIAE; S-PHASE; REPLICATION STRESS; MRE11 COMPLEX; PHOSPHORYLATION; PATHWAYS	Saccharomyces cerevisiae Rad53, the ortholog of mammalian Chk2, is an essential protein kinase in DNA damage and DNA replication checkpoint pathways. Consecutive phosphatidyl inositol kinase-like kinase (PIKK)-dependent and PIKK-independent steps in activation of Rad53 are key steps for controlling and transmitting diverse downstream responses to DNA damage. However, these activities have not been demonstrated in vitro in defined systems. Here, we have shown that enzymatically dephosphorylated purified Rad53 autoactivates in vitro through a phosphorylation-dependent mechanism. Kinetic analysis demonstrated that autophosphorylation results in a more than 9-fold increase in protein kinase activity. Autophosphorylation was Rad53 concentration-dependent, indicating that the reaction follows an intermolecular mechanism. DNA damage induced oligomerization of a subset of Rad53 molecules in vivo. At low concentrations of Rad53, preincubation of Rad53 with immune complexes containing the Mec1/Ddc2 complex can activate Rad53 kinase activity. Our findings showed that Mec1/Ddc2 complexes can directly activate Rad53 through a phosphorylation-dependent mechanism, and more generally, supported the hypothesis that PIKKs regulate Chk2 orthologs through phosphorylation. Moreover, this work has substantiated a model for PIKK-independent amplification of Rad53 activation (and by extension, activation of other Chk2 orthologs) mediated by inter-Rad53 phosphorylation.	Yale Univ, Sch Med, Dept Pathol, New Haven, CT 06510 USA	Yale University	Stern, DF (corresponding author), Yale Univ, Sch Med, Dept Pathol, New Haven, CT 06510 USA.	DF.Stern@yale.edu	Ma, Nianhan/AAB-9869-2020	Ma, Nianhan/0000-0003-1800-2306	NATIONAL CANCER INSTITUTE [R01CA082257] Funding Source: NIH RePORTER; NCI NIH HHS [R01CA82257] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Ahn J, 2004, DNA REPAIR, V3, P1039, DOI 10.1016/j.dnarep.2004.03.033; Ahn J, 2002, J BIOL CHEM, V277, P48418, DOI 10.1074/jbc.M208321200; AHN JY, 2002, J BIOL CHEM, V18, P18; Alcasabas AA, 2001, NAT CELL BIOL, V3, P958, DOI 10.1038/ncb1101-958; D'Amours D, 2002, NAT REV MOL CELL BIO, V3, P317, DOI 10.1038/nrm805; D'Amours D, 2001, GENE DEV, V15, P2238, DOI 10.1101/gad.208701; de la Torre-Ruiz MA, 1998, EMBO J, V17, P2687, DOI 10.1093/emboj/17.9.2687; Duncker BP, 2002, P NATL ACAD SCI USA, V99, P16087, DOI 10.1073/pnas.252093999; Durocher D, 2001, CURR OPIN CELL BIOL, V13, P225, DOI 10.1016/S0955-0674(00)00201-5; Emili A, 1998, MOL CELL, V2, P183, DOI 10.1016/S1097-2765(00)80128-8; Gardner R, 1999, EMBO J, V18, P3173, DOI 10.1093/emboj/18.11.3173; Gilbert CS, 2003, EMBO REP, V4, P953, DOI 10.1038/sj.embor.embor935; Gilbert CS, 2001, MOL CELL, V8, P129, DOI 10.1016/S1097-2765(01)00267-2; Grenon M, 2001, NAT CELL BIOL, V3, P844, DOI 10.1038/ncb0901-844; Huang MX, 1998, CELL, V94, P595, DOI 10.1016/S0092-8674(00)81601-3; Katou Y, 2003, NATURE, V424, P1078, DOI 10.1038/nature01900; Kim ST, 1999, J BIOL CHEM, V274, P37538, DOI 10.1074/jbc.274.53.37538; Kondo T, 2001, SCIENCE, V294, P867, DOI 10.1126/science.1063827; Lee CH, 2001, J BIOL CHEM, V276, P30537, DOI 10.1074/jbc.M104414200; Lee SJ, 2004, MOL BIOL CELL, V15, P5443, DOI 10.1091/mbc.E04-07-0608; Lee SJ, 2003, MOL CELL BIOL, V23, P6300, DOI 10.1128/MCB.23.17.6300-6314.2003; Leroy C, 2003, MOL CELL, V11, P827, DOI 10.1016/S1097-2765(03)00058-3; Lisby M, 2004, CELL, V118, P699, DOI 10.1016/j.cell.2004.08.015; Lisby M, 2004, CURR OPIN CELL BIOL, V16, P328, DOI 10.1016/j.ceb.2004.03.011; Matsuoka S, 2000, P NATL ACAD SCI USA, V97, P10389, DOI 10.1073/pnas.190030497; Melo J, 2002, CURR OPIN CELL BIOL, V14, P237, DOI 10.1016/S0955-0674(02)00312-5; Mochida S, 2004, EMBO J, V23, P418, DOI 10.1038/sj.emboj.7600018; Motoyama N, 2004, CURR OPIN GENET DEV, V14, P11, DOI 10.1016/j.gde.2003.12.003; Naiki T, 2004, MOL CELL BIOL, V24, P3277, DOI 10.1128/MCB.24.8.3277-3285.2004; Nyberg KA, 2002, ANNU REV GENET, V36, P617, DOI 10.1146/annurev.genet.36.060402.113540; Osborn AJ, 2003, GENE DEV, V17, P1755, DOI 10.1101/gad.1098303; Pellicioli A, 1999, EMBO J, V18, P6561, DOI 10.1093/emboj/18.22.6561; Pellicioli A, 2005, CURR BIOL, V15, pR769, DOI 10.1016/j.cub.2005.08.057; Ruiz MAD, 2000, FEBS LETT, V485, P205, DOI 10.1016/S0014-5793(00)02198-0; Sanchez Y, 1996, SCIENCE, V271, P357, DOI 10.1126/science.271.5247.357; Sanchez Y, 1999, SCIENCE, V286, P1166, DOI 10.1126/science.286.5442.1166; Schwartz MF, 2003, CELL CYCLE, V2, P384, DOI 10.4161/cc.2.4.457; Schwartz MF, 2002, MOL CELL, V9, P1055, DOI 10.1016/S1097-2765(02)00532-4; Schwarz JK, 2003, MOL CANCER RES, V1, P598; Smolka MB, 2005, MOL CELL PROTEOMICS, V4, P1358, DOI 10.1074/mcp.M500115-MCP200; Soulier J, 1999, CURR BIOL, V9, P551, DOI 10.1016/S0960-9822(99)80242-5; Sun ZX, 1996, GENE DEV, V10, P395, DOI 10.1101/gad.10.4.395; Sun ZX, 1998, SCIENCE, V281, P272, DOI 10.1126/science.281.5374.272; Sweeney FD, 2005, CURR BIOL, V15, P1364, DOI 10.1016/j.cub.2005.06.063; Usui T, 2001, MOL CELL, V7, P1255, DOI 10.1016/S1097-2765(01)00270-2; Weinreich M, 1999, EMBO J, V18, P5334, DOI 10.1093/emboj/18.19.5334; Xu XZ, 2002, MOL CELL BIOL, V22, P4419, DOI 10.1128/MCB.22.12.4419-4432.2002; Zhao H, 2002, P NATL ACAD SCI USA, V99, P14795, DOI 10.1073/pnas.182557299; Zhao XL, 2001, EMBO J, V20, P3544, DOI 10.1093/emboj/20.13.3544; ZHENG P, 1993, MOL CELL BIOL, V13, P5829, DOI 10.1128/MCB.13.9.5829	50	37	42	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 17	2006	281	7					3954	3963		10.1074/jbc.M507508200	http://dx.doi.org/10.1074/jbc.M507508200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	011NN	16365046	hybrid			2022-12-25	WOS:000235275300023
J	Macauley, MS; Errington, WJ; Scharpf, M; Mackereth, CD; Blaszczak, AG; Graves, BJ; McIntosh, LP				Macauley, MS; Errington, WJ; Scharpf, M; Mackereth, CD; Blaszczak, AG; Graves, BJ; McIntosh, LP			Beads-on-a-string, characterization of Ets-1 sumoylated within its flexible N-terminal sequence	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTIONAL REPRESSION; SUMO-1 MODIFICATION; BACKBONE DYNAMICS; CRYSTAL-STRUCTURE; POINTED DOMAIN; DNA-BINDING; PROTEIN; IDENTIFICATION; MOTIF; SITE	Sumoylation regulates the activities of several members of the ETS transcription factor family. To provide a molecular framework for understanding this regulation, we have characterized the conjugation of Ets-1 with SUMO-1. Ets-1 is modified in vivo predominantly at a consensus sumoylation motif containing Lys-15. This lysine is located within the unstructured N-terminal segment of Ets-1 preceding its PNT domain. Using NMR spectroscopy, we demonstrate that the Ets-1 sumoylation motif associates with the substrate binding site on the SUMO-conjugating enzyme UBC9 (K-d similar to 400 mu M) and that the PNT domain is not involved in this interaction. Ets-1 with Lys-15 mutated to an arginine still binds UBC9 with an affinity similar to the wild type protein, but is no longer sumoylated. NMR chemical shift and relaxation measurements reveal that the covalent attachment of mature SUMO-1, via its flexible C-terminal Gly-97, to Lys-15 of Ets-1 does not perturb the structure or dynamic properties of either protein. Therefore sumoylated Ets-1 behaves as "beads-on-a-string" with the two proteins tethered by flexible polypeptide segments containing the isopeptide linkage. Accordingly, SUMO-1 may mediate interactions of Ets-1 with signaling or transcriptional regulatory macromolecules by acting as a structurally independent docking module, rather than through the induction of a conformational change in either protein upon their covalent linkage. We also hypothesize that the flexibility of the linking polypeptide sequence may be a general feature contributing to the recognition of SUMO-modified proteins by their downstream effectors.	Univ British Columbia, Dept Biochem & Mol Biol, Vancouver, BC V6T 1Z3, Canada; Univ British Columbia, Dept Chem, Vancouver, BC V6T 1Z3, Canada; Univ British Columbia, Michael Smith Labs, Vancouver, BC V6T 1Z3, Canada; Univ Utah, Dept Oncol Sci, Huntsman Canc Inst, Salt Lake City, UT 84112 USA	University of British Columbia; University of British Columbia; University of British Columbia; Huntsman Cancer Institute; Utah System of Higher Education; University of Utah	McIntosh, LP (corresponding author), Univ British Columbia, Dept Biochem & Mol Biol, 2350 Hlth Sci Mall, Vancouver, BC V6T 1Z3, Canada.	mcintosh@chem.ubc.ca	Mackereth, Cameron D./F-7946-2013	Mackereth, Cameron D./0000-0002-0776-7947; Macauley, Matthew/0000-0003-4579-1048	NATIONAL CANCER INSTITUTE [P30CA042014] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM038663] Funding Source: NIH RePORTER; NIGMS NIH HHS [R01 GM038663] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Baba D, 2005, NATURE, V435, P979, DOI 10.1038/nature03634; Bayer P, 1998, J MOL BIOL, V280, P275, DOI 10.1006/jmbi.1998.1839; Bencsath KP, 2002, J BIOL CHEM, V277, P47938, DOI 10.1074/jbc.M207442200; Bernier-Villamor V, 2002, CELL, V108, P345, DOI 10.1016/S0092-8674(02)00630-X; Best JL, 2002, MOL CELL, V10, P843, DOI 10.1016/S1097-2765(02)00699-8; Borden KLB, 2002, MOL CELL BIOL, V22, P5259, DOI 10.1128/MCB.22.15.5259-5269.2002; Bossis G, 2005, MOL CELL BIOL, V25, P6964, DOI 10.1128/MCB.25.16.6964-6979.2005; Chakrabarti SR, 2000, P NATL ACAD SCI USA, V97, P13281, DOI 10.1073/pnas.240315897; Chakrabarti SR, 1999, P NATL ACAD SCI USA, V96, P7467, DOI 10.1073/pnas.96.13.7467; Chang CC, 2005, J BIOL CHEM, V280, P10164, DOI 10.1074/jbc.M409161200; Cowley DO, 2000, GENE DEV, V14, P366; Degerny C, 2005, J BIOL CHEM, V280, P24330, DOI 10.1074/jbc.M411250200; DELAGLIO F, 1995, J BIOMOL NMR, V6, P277, DOI 10.1007/BF00197809; Desterro JMP, 1998, MOL CELL, V2, P233, DOI 10.1016/S1097-2765(00)80133-1; Eskiw CH, 2002, BIOCHEM CELL BIOL, V80, P301, DOI 10.1139/O02-079; FARROW NA, 1994, BIOCHEMISTRY-US, V33, P5984, DOI 10.1021/bi00185a040; Foulds CE, 2004, MOL CELL BIOL, V24, P10954, DOI 10.1128/MCB.24.24.10954-10964.2004; Gasteiger E, 2003, NUCLEIC ACIDS RES, V31, P3784, DOI 10.1093/nar/gkg563; Gill G, 2005, CURR OPIN GENET DEV, V15, P536, DOI 10.1016/j.gde.2005.07.004; Girdwood D, 2003, MOL CELL, V11, P1043, DOI 10.1016/S1097-2765(03)00141-2; Girdwood DWH, 2004, SEMIN CELL DEV BIOL, V15, P201, DOI 10.1016/j.semcdb.2003.12.001; Gocke CB, 2005, J BIOL CHEM, V280, P5004, DOI 10.1074/jbc.M411718200; Goddard T. D., 1999, SPARKY 3; GUNTHER CV, 1994, MOL CELL BIOL, V14, P7569, DOI 10.1128/MCB.14.11.7569; Hahn SL, 1997, ONCOGENE, V15, P1489, DOI 10.1038/sj.onc.1201301; Hannich JT, 2005, J BIOL CHEM, V280, P4102, DOI 10.1074/jbc.M413209200; Hay RT, 2005, MOL CELL, V18, P1, DOI 10.1016/j.molcel.2005.03.012; Hilgarth RS, 2004, J BIOL CHEM, V279, P53899, DOI 10.1074/jbc.R400021200; Hong YL, 2001, J BIOL CHEM, V276, P40263, DOI 10.1074/jbc.M104714200; Iniguez-Lluhi JA, 2000, MOL CELL BIOL, V20, P6040, DOI 10.1128/MCB.20.16.6040-6050.2000; Jin CW, 2001, INT J BIOL MACROMOL, V28, P227, DOI 10.1016/S0141-8130(00)00169-0; Johnson ES, 2004, ANNU REV BIOCHEM, V73, P355, DOI 10.1146/annurev.biochem.73.011303.074118; Johnson PE, 1996, BIOCHEMISTRY-US, V35, P13895, DOI 10.1021/bi961186a; KAY LE, 1989, BIOCHEMISTRY-US, V28, P8972, DOI 10.1021/bi00449a003; Kim CA, 2001, EMBO J, V20, P4173, DOI 10.1093/emboj/20.15.4173; Lee GM, 2005, J BIOL CHEM, V280, P7088, DOI 10.1074/jbc.M410722200; Leight ER, 2005, DEVELOPMENT, V132, P1047, DOI 10.1242/dev.01664; Lin DH, 2002, J BIOL CHEM, V277, P21740, DOI 10.1074/jbc.M108418200; Lin X, 2003, J BIOL CHEM, V278, P31043, DOI 10.1074/jbc.C300112200; Liu Q, 1999, J BIOL CHEM, V274, P16979, DOI 10.1074/jbc.274.24.16979; Macauley MS, 2004, J BIOL CHEM, V279, P49131, DOI 10.1074/jbc.M408705200; Matunis MJ, 1998, J CELL BIOL, V140, P499, DOI 10.1083/jcb.140.3.499; Melchior F, 2003, TRENDS BIOCHEM SCI, V28, P612, DOI 10.1016/j.tibs.2003.09.002; Mossessova E, 2000, MOL CELL, V5, P865, DOI 10.1016/S1097-2765(00)80326-3; Muller S, 2004, ONCOGENE, V23, P1998, DOI 10.1038/sj.onc.1207415; Pichler A, 2005, NAT STRUCT MOL BIOL, V12, P264, DOI 10.1038/nsmb903; Reverter D, 2005, NATURE, V435, P687, DOI 10.1038/nature03588; Rodriguez MS, 2001, J BIOL CHEM, V276, P12654, DOI 10.1074/jbc.M009476200; Salinas S, 2004, J CELL BIOL, V165, P767, DOI 10.1083/jcb.200310136; Seidel JJ, 2002, GENE DEV, V16, P127, DOI 10.1101/gad.950902; Slupsky CM, 1998, P NATL ACAD SCI USA, V95, P12129, DOI 10.1073/pnas.95.21.12129; Song J, 2004, P NATL ACAD SCI USA, V101, P14373, DOI 10.1073/pnas.0403498101; Subramanian L, 2003, J BIOL CHEM, V278, P9134, DOI 10.1074/jbc.M210440200; Tatham MH, 2003, BIOCHEMISTRY-US, V42, P9959, DOI 10.1021/bi0345283; Verger A, 2003, EMBO REP, V4, P137, DOI 10.1038/sj.embor.embor738; Wasylyk C, 2005, ONCOGENE, V24, P820, DOI 10.1038/sj.onc.1208226; Wohlschlegel JA, 2004, J BIOL CHEM, V279, P45662, DOI 10.1074/jbc.M409203200; Wood LD, 2003, P NATL ACAD SCI USA, V100, P3257, DOI 10.1073/pnas.0637114100; Wykoff DD, 2005, MOL CELL PROTEOMICS, V4, P73, DOI 10.1074/mcp.M400166-MCP200; Yang SH, 2004, MOL CELL, V13, P611, DOI 10.1016/S1097-2765(04)00060-7; Yang SH, 2003, MOL CELL, V12, P63, DOI 10.1016/S1097-2765(03)00265-X; Zuiderweg ERP, 2002, BIOCHEMISTRY-US, V41, P1, DOI 10.1021/bi011870b	62	31	31	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 17	2006	281	7					4164	4172		10.1074/jbc.M510488200	http://dx.doi.org/10.1074/jbc.M510488200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	011NN	16319071	hybrid			2022-12-25	WOS:000235275300048
J	Swift, S; Leger, AJ; Talavera, J; Lei, Z; Bohm, A; Kuliopulos, A				Swift, S; Leger, AJ; Talavera, J; Lei, Z; Bohm, A; Kuliopulos, A			Role of the PAR1 receptor 8th helix in signaling - The 7-8-1 receptor activation mechanism	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-COUPLED RECEPTOR; LIGHT-DEPENDENT CHANGES; 4TH CYTOPLASMIC LOOP; THROMBIN-RECEPTOR; INTRACELLULAR TRAFFICKING; ENDOTHELIAL-CELLS; CRYSTAL-STRUCTURE; RHODOPSIN; BINDING; TRANSDUCIN	The protease-activated receptors are tethered ligand G protein-coupled receptors that are activated by proteolytic cleavage of the extracellular domain of the receptor. The archetypic protease-activated receptor PAR1 strongly activates G(q) signaling pathways, but very little is known regarding the mechanism of signal transference between receptor and internally located G protein. The recent x-ray structure of rhodopsin revealed the presence of a highly conserved amphipathic 8th helix that is likely to be physically interposed between receptor and G protein. We found that the analogous 8th helix region of PAR1 was critical for activation of Gq-dependent signaling. Engineering an 8th helix alpha-aneurysm with a downwards-directed alanine residue markedly interfered with signal transference to Gq. The 8th helix-anchoring cysteine palmitoylation sites were important for the affinity of ligand-dependent G protein coupling but did not affect the maximal signal. A network of H-bond and ionic interactions was found to connect the N-terminal portion of the 8th helix to the nearby NPXXY motif on transmembrane helix 7 and also to the adjacent intracellular loop-1. Disruption of these pairwise interactions caused additive defects in coupling to G protein, indicating that the transmembrane 7-8th helix-i1 loop may move in a coordinated manner to transfer the signal from PAR1 to G protein. This "7-8-1" interaction network was found to be prevalent in G protein-coupled receptors involved in endothelial signaling and angiogenesis.	Tufts Univ, New England Med Ctr, Mol Oncol Res Inst, Boston, MA 02111 USA; Tufts Univ, New England Med Ctr, Div Hematol & Oncol, Boston, MA 02111 USA; Tufts Univ, Sch Med, Dept Biochem, Boston, MA 02111 USA	Tufts Medical Center; Tufts University; Tufts Medical Center; Tufts University; Tufts University	Kuliopulos, A (corresponding author), Tufts Univ, New England Med Ctr, Mol Oncol Res Inst, Box 7510,750 Washington St, Boston, MA 02111 USA.	athan.kuliopulos@tufts.edu		Swift, Steven/0000-0002-3840-4401	NHLBI NIH HHS [F32HL10296, R01-HL57905, R01-HL64701] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [F32HL010296, R01HL057905, R01HL064701] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AKTORIES K, 1984, EUR J BIOCHEM, V145, P333, DOI 10.1111/j.1432-1033.1984.tb08558.x; Al-Ani B, 2004, MOL PHARMACOL, V65, P149, DOI 10.1124/mol.65.1.149; Al-Ani B, 1999, BRIT J PHARMACOL, V128, P1105, DOI 10.1038/sj.bjp.0702834; Altenbach C, 2001, BIOCHEMISTRY-US, V40, P15493, DOI 10.1021/bi011545o; Altenbach C, 2001, BIOCHEMISTRY-US, V40, P15483, DOI 10.1021/bi011546g; BARAK LS, 1995, BIOCHEMISTRY-US, V34, P15407, DOI 10.1021/bi00047a003; Barr AJ, 1997, J BIOL CHEM, V272, P2223; Blackhart BD, 2000, MOL PHARMACOL, V58, P1178, DOI 10.1124/mol.58.6.1178; Boire A, 2005, CELL, V120, P303, DOI 10.1016/j.cell.2004.12.018; Cenac N, 2002, AM J PATHOL, V161, P1903, DOI 10.1016/S0002-9440(10)64466-5; Compton SJ, 2000, J BIOL CHEM, V275, P39207, DOI 10.1074/jbc.M007215200; Coughlin SR, 2000, NATURE, V407, P258, DOI 10.1038/35025229; Covic L, 2002, P NATL ACAD SCI USA, V99, P643, DOI 10.1073/pnas.022460899; Covic L, 2002, NAT MED, V8, P1161, DOI 10.1038/nm760; DeFea KA, 2000, J CELL BIOL, V148, P1267, DOI 10.1083/jcb.148.6.1267; Ernst OP, 2000, J BIOL CHEM, V275, P1937, DOI 10.1074/jbc.275.3.1937; Fritze O, 2003, P NATL ACAD SCI USA, V100, P2290, DOI 10.1073/pnas.0435715100; Goldman LA, 1996, BIOTECHNIQUES, V21, P1013; Griffin CT, 2001, SCIENCE, V293, P1666, DOI 10.1126/science.1061259; Hammes SR, 1999, BIOCHEMISTRY-US, V38, P9308, DOI 10.1021/bi9902236; HARRISON CJ, 1994, SCIENCE, V263, P224, DOI 10.1126/science.8284672; HUNG DT, 1992, J BIOL CHEM, V267, P20831; Imamoto Y, 2000, BIOCHEMISTRY-US, V39, P15225, DOI 10.1021/bi0018685; ISHII K, 1994, J BIOL CHEM, V269, P1125; Kaneider NC, 2005, NAT MED, V11, P661, DOI 10.1038/nm1245; KEEFE LJ, 1993, P NATL ACAD SCI USA, V90, P3275, DOI 10.1073/pnas.90.8.3275; Krishna AG, 2002, BIOCHEMISTRY-US, V41, P8298, DOI 10.1021/bi025534m; Kuliopulos A, 1999, BIOCHEMISTRY-US, V38, P4572, DOI 10.1021/bi9824792; Li J, 2004, J MOL BIOL, V343, P1409, DOI 10.1016/j.jmb.2004.08.090; Marin EP, 2000, J BIOL CHEM, V275, P1930, DOI 10.1074/jbc.275.3.1930; McLaughlin JN, 2005, J BIOL CHEM, V280, P25048, DOI 10.1074/jbc.M414090200; MILDVAN AS, 1992, ARCH BIOCHEM BIOPHYS, V294, P327, DOI 10.1016/0003-9861(92)90692-P; Natochin M, 2003, J BIOL CHEM, V278, P37574, DOI 10.1074/jbc.M305136200; O'Brien PJ, 2000, J BIOL CHEM, V275, P13502, DOI 10.1074/jbc.275.18.13502; OFFERMANNS S, 1994, P NATL ACAD SCI USA, V91, P504, DOI 10.1073/pnas.91.2.504; Offermanns S, 1997, NATURE, V389, P183, DOI 10.1038/38284; Okuno T, 2003, J BIOL CHEM, V278, P41500, DOI 10.1074/jbc.M307335200; Paing MM, 2004, J BIOL CHEM, V279, P21938, DOI 10.1074/jbc.M401672200; Palczewski K, 2000, SCIENCE, V289, P739, DOI 10.1126/science.289.5480.739; PHILLIPS WJ, 1992, J BIOL CHEM, V267, P17032; Prioleau C, 2002, J BIOL CHEM, V277, P36577, DOI 10.1074/jbc.M206223200; Qanbar R, 2003, PHARMACOL THERAPEUT, V97, P1, DOI 10.1016/S0163-7258(02)00300-5; Riewald M, 2002, SCIENCE, V296, P1880, DOI 10.1126/science.1071699; Seeley S, 2003, CHEM BIOL, V10, P1033, DOI 10.1016/j.chembiol.2003.10.014; Shapiro MJ, 1998, J BIOL CHEM, V273, P29009, DOI 10.1074/jbc.273.44.29009; Shapiro MJ, 1996, J BIOL CHEM, V271, P32874, DOI 10.1074/jbc.271.51.32874; SHORTLE D, 1995, CURR OPIN BIOTECH, V6, P387, DOI 10.1016/0958-1669(95)80067-0; Swift S, 2000, J BIOL CHEM, V275, P2627, DOI 10.1074/jbc.275.4.2627; Teller DC, 2001, BIOCHEMISTRY-US, V40, P7761, DOI 10.1021/bi0155091; Trejo J, 1998, P NATL ACAD SCI USA, V95, P13698, DOI 10.1073/pnas.95.23.13698; Verrall S, 1997, J BIOL CHEM, V272, P6898, DOI 10.1074/jbc.272.11.6898; VOURETCRAVIARI V, 1992, MOL BIOL CELL, V3, P95, DOI 10.1091/mbc.3.1.95; VU TKH, 1991, CELL, V64, P1057, DOI 10.1016/0092-8674(91)90261-V; Woulfe D, 2004, J CLIN INVEST, V113, P441, DOI 10.1172/JCI200420267; Zain J, 2000, BLOOD, V95, P3133	55	76	82	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 17	2006	281	7					4109	4116		10.1074/jbc.M509525200	http://dx.doi.org/10.1074/jbc.M509525200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	011NN	16354660	hybrid			2022-12-25	WOS:000235275300041
J	Veit, G; Kobbe, B; Keene, DR; Paulsson, M; Koch, M; Wagener, R				Veit, G; Kobbe, B; Keene, DR; Paulsson, M; Koch, M; Wagener, R			Collagen XXVIII, a novel von Willebrand factor A domain-containing protein with many imperfections in the collagenous domain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINO-ACID-SEQUENCE; CRYSTAL-STRUCTURE; PROCOLLAGEN-VII; SCHWANN-CELLS; C5 DOMAIN; BINDING; IDENTIFICATION; EXPRESSION; PREDICTION; MUTATIONS	Here we describe a novel collagen belonging to the class of von Willebrand factor A ( VWA) domain- containing proteins. This novel protein was identified by screening the EST data base and was subsequently recombinantly expressed and characterized as an authentic tissue component. The COL28A1 gene on human chromosome 7p21.3 and on mouse chromosome 6A1 encodes a novel protein that structurally resembles the beaded filament- forming collagens. The collagenous domain contains several very short interruptions arranged in a repeat pattern. As shown for other novel minor collagens, the expression of collagen XXVIII protein in mouse is very restricted. In addition to small amounts in skin and calvaria, the major signals were in dorsal root ganglia and peripheral nerves. By immunoelectron microscopy, collagen XXVIII was detected in the sciatic nerve, at the basement membrane of certain Schwann cells surrounding the nerve fibers. Even though the protein is present in the adult sciatic nerve, collagen XXVIII mRNA was only detected in sciatic nerve of newborn mice, indicating that the protein persists for an extended period after synthesis.	Univ Cologne, Inst Biochem 2, Fac Med, Ctr Biochem, D-50931 Cologne, Germany; Univ Cologne, Ctr Mol Med, Fac Med, D-50931 Cologne, Germany; Univ Cologne, Dept Dermatol, Fac Med, D-50931 Cologne, Germany; Shriners Hosp Crippled Children, Childrens Res Ctr, Portland, OR 97239 USA	University of Cologne; University of Cologne; University of Cologne	Wagener, R (corresponding author), Univ Cologne, Inst Biochem 2, Fac Med, Ctr Biochem, Joseph Stelzmann Str 52, D-50931 Cologne, Germany.	raimund.wagener@uni-koeln.de	Veit, Guido/C-9596-2009; Koch, Manuel/AAG-9914-2021	Veit, Guido/0000-0002-6758-2696; Koch, Manuel/0000-0002-2962-7814				Abril JF, 2005, GENOME RES, V15, P111, DOI 10.1101/gr.3108805; Aigner T, 2002, BIOCHEM BIOPH RES CO, V290, P743, DOI 10.1006/bbrc.2001.6227; Bendtsen JD, 2004, J MOL BIOL, V340, P783, DOI 10.1016/j.jmb.2004.05.028; Bienkowska J, 1997, J BIOL CHEM, V272, P25162, DOI 10.1074/jbc.272.40.25162; BONALDO P, 1990, BIOCHEMISTRY-US, V29, P1245, DOI 10.1021/bi00457a021; BRUCKNERTUDERMAN L, 1995, J CELL BIOL, V131, P551, DOI 10.1083/jcb.131.2.551; CHU ML, 1988, J BIOL CHEM, V263, P18601; Dumas JJ, 2004, J BIOL CHEM, V279, P23327, DOI 10.1074/jbc.M401659200; Farrer T, 2002, NUCLEIC ACIDS RES, V30, P3360, DOI 10.1093/nar/gkf465; Feltri ML, 2005, J PERIPHER NERV SYST, V10, P128, DOI 10.1111/j.1085-9489.2005.0010204.x; Knupp C, 2001, EMBO J, V20, P372, DOI 10.1093/emboj/20.3.372; Ko YP, 2004, MOL CELL BIOL, V24, P1691, DOI 10.1128/MCB.24.4.1691-1699.2004; Kohfeldt E, 1996, EUR J BIOCHEM, V238, P333, DOI 10.1111/j.1432-1033.1996.0333z.x; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEE JO, 1995, CELL, V80, P631, DOI 10.1016/0092-8674(95)90517-0; LI K, 1993, GENOMICS, V16, P733, DOI 10.1006/geno.1993.1255; Myllyharju J, 2004, TRENDS GENET, V20, P33, DOI 10.1016/j.tig.2003.11.004; Nanda A, 2004, CANCER RES, V64, P817, DOI 10.1158/0008-5472.CAN-03-2408; Nolte M, 1999, FEBS LETT, V452, P379, DOI 10.1016/S0014-5793(99)00666-3; PERKINS SJ, 1994, J MOL BIOL, V238, P104, DOI 10.1006/jmbi.1994.1271; Persikov AV, 2005, J BIOL CHEM, V280, P19343, DOI 10.1074/jbc.M501657200; Persikov AV, 2005, BIOCHEMISTRY-US, V44, P1414, DOI 10.1021/bi048216r; POSCHL E, 1994, EMBO J, V13, P3741, DOI 10.1002/j.1460-2075.1994.tb06683.x; Rattenholl A, 2002, J BIOL CHEM, V277, P26372, DOI 10.1074/jbc.M203247200; Ries A, 2001, EUR J BIOCHEM, V268, P5119, DOI 10.1046/j.0014-2956.2001.02437.x; Rothblum K, 2004, J BIOL CHEM, V279, P51282, DOI 10.1074/jbc.M408837200; Sengle G, 2003, J BIOL CHEM, V278, P50240, DOI 10.1074/jbc.M307794200; SIBLEY MH, 1993, J CELL BIOL, V123, P255, DOI 10.1083/jcb.123.1.255; Smyth N, 2000, METH MOL B, V139, P49; TRYGGVASON K, 1990, ANN NY ACAD SCI, V580, P97, DOI 10.1111/j.1749-6632.1990.tb17922.x; Uschkureit T, 2000, J NEUROSCI, V20, P5225, DOI 10.1523/JNEUROSCI.20-14-05225.2000; Whittaker CA, 2002, MOL BIOL CELL, V13, P3369, DOI 10.1091/mbc.E02-05-0259	32	130	142	1	19	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 10	2006	281	6					3494	3504		10.1074/jbc.M509333200	http://dx.doi.org/10.1074/jbc.M509333200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	009QV	16330543	hybrid			2022-12-25	WOS:000235128200059
J	Kawamori, T; Osta, W; Johnson, KR; Pettus, BJ; Bielawski, J; Tanaka, T; Wargovich, MJ; Reddy, BS; Hannun, YA; Obeid, LM; Zhou, DH				Kawamori, Toshihiko; Osta, Walid; Johnson, Korey R.; Pettus, Benjamin J.; Bielawski, Jacek; Tanaka, Takuji; Wargovich, Michael J.; Reddy, Bandaru S.; Hannun, Yusuf A.; Obeid, Lina M.; Zhou, Daohong			Sphingosine kinase 1 is up-regulated in colon carcinogenesis	FASEB JOURNAL			English	Article									[Kawamori, Toshihiko; Zhou, Daohong] Med Univ S Carolina, Dept Pathol & Lab Med, Charleston, SC 29425 USA; [Osta, Walid] Med Univ S Carolina, Dept Surg, Charleston, SC 29425 USA; [Johnson, Korey R.] Med Univ S Carolina, Dept Med, Charleston, SC 29425 USA; [Pettus, Benjamin J.; Bielawski, Jacek; Hannun, Yusuf A.; Obeid, Lina M.] Med Univ S Carolina, Dept Biochem & Mol Biol, Charleston, SC 29425 USA; [Tanaka, Takuji] Kanazawa Med Univ, Dept Pathol, Kanazawa, Ishikawa, Japan; [Wargovich, Michael J.] Univ S Carolina, Dept Pathol, S Carolina Canc Ctr, Columbia, SC 29208 USA; [Reddy, Bandaru S.] Inst Canc Prevent, Chemoprevent & Nutr Carcinogenesis Program, Valhalla, NY USA	Medical University of South Carolina; Medical University of South Carolina; Medical University of South Carolina; Medical University of South Carolina; Kanazawa Medical University; University of South Carolina; University of South Carolina System; University of South Carolina Columbia	Kawamori, T (corresponding author), Med Univ S Carolina, Dept Pathol & Lab Med, 165 Ashley Ave,Suite 309, Charleston, SC 29425 USA.	kawamori@musc.edu; zhoud@musc.edu	Kawamori, Toshihiko/G-7636-2012; Tanaka, Takuji/G-5246-2010		NATIONAL CANCER INSTITUTE [P01CA097132, R01CA102558] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [P20RR017677] Funding Source: NIH RePORTER; NCI NIH HHS [CA102558, CA86688, P01CA097132] Funding Source: Medline; NCRR NIH HHS [P20RR017677] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))			0	154	171	0	4	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	FEB	2006	20	2					386	388		10.1096/fj.05-4331fje	http://dx.doi.org/10.1096/fj.05-4331fje			3	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	V17CJ	16319132				2022-12-25	WOS:000207915000030
J	Incassati, A; Patel, D; McCance, DJ				Incassati, A; Patel, D; McCance, DJ			Induction of tetraploidy through loss of p53 and upregulation of Plk1 by human papillomavirus type-16 E6	ONCOGENE			English	Article						HPV-16; E6 and E7; tetraploidy; Plk1	POLO-LIKE KINASE-1; HUMAN KERATINOCYTES; SPINDLE CHECKPOINT; GROWTH ARREST; CANCER; CELLS; E7; DEGRADATION; EXPRESSION; ONCOPROTEIN	Cancer cells are insensitive to many signals that inhibit growth of untransformed cells. Here, we show that primary human epithelial cells expressing human papillomavirus (HPV) type-16 E6/E7 bypass arrest caused by the DNA-damaging drug adriamycin and become tetraploid. To determine the contribution of E6 in the context of E7 to the resistance of arrest and induction of tetraploidy, we used an E6 mutant unable to degrade p53 or RNAi targeting p53 for knockdown. The E6 mutant fails to generate tetraploidy; however, the presence of E7 is sufficient to bypass arrest while the p53 RNAi permits both arrest insensitivity and tetraploidy. We published previously that polo-like kinase 1(Plk1) is upregulated in E6/E7-expressing cells. We observe here that abnormal expression of Plk1 protein correlates with tetraploidy. Using the p53 binding-defective mutant of E6 and p53 RNAi, we show that p53 represses Plk1, suggesting that loss of p53 results in tetraploidy through upregulation of Plk1. Consistent with this hypothesis, overexpression of Plk1 in cells generates tetraploidy but does not confer resistance to arrest. These results support a model for transformation caused by HPV-16 where bypass of arrest and tetraploidy are separable consequences of p53 loss with Plk1 required only for the latter effect.	Univ Rochester, Dept Microbiol & Immunol, Rochester, NY 14642 USA; Univ Rochester, Dept Biomed Genet, Rochester, NY USA; Univ Rochester, James P Wilmot Canc Ctr, Rochester, NY USA	University of Rochester; University of Rochester; University of Rochester	McCance, DJ (corresponding author), Univ Rochester, Dept Microbiol & Immunol, Box 672, Rochester, NY 14642 USA.	dennis_mccance@urmc.rochester.edu			NIDCR NIH HHS [DE13526, T32-DE07165] Funding Source: Medline; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [T32DE007165, R01DE013526] Funding Source: NIH RePORTER	NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		Brummelkamp TR, 2002, SCIENCE, V296, P550, DOI 10.1126/science.1068999; Burd EM, 2003, CLIN MICROBIOL REV, V16, P1, DOI 10.1128/CMR.16.1.1-17.2003; Cahill DP, 1998, NATURE, V392, P300, DOI 10.1038/32688; CROSS SM, 1995, SCIENCE, V267, P1353, DOI 10.1126/science.7871434; Demers GW, 1996, J VIROL, V70, P6862, DOI 10.1128/JVI.70.10.6862-6869.1996; DYSON N, 1989, SCIENCE, V243, P934, DOI 10.1126/science.2537532; Eichten A, 2002, VIROLOGY, V295, P74, DOI 10.1006/viro.2002.1375; Flatt PM, 1998, CELL GROWTH DIFFER, V9, P535; FOSTER SA, 1994, J VIROL, V68, P5698, DOI 10.1128/JVI.68.9.5698-5705.1994; Galipeau PC, 1996, P NATL ACAD SCI USA, V93, P7081, DOI 10.1073/pnas.93.14.7081; Guan R, 2005, CANCER RES, V65, P2698, DOI 10.1158/0008-5472.CAN-04-2131; Hanks S, 2004, NAT GENET, V36, P1159, DOI 10.1038/ng1449; HAWLEYNELSON P, 1989, EMBO J, V8, P3905, DOI 10.1002/j.1460-2075.1989.tb08570.x; Jackson MW, 2005, J CELL SCI, V118, P1821, DOI 10.1242/jcs.02307; Kho PS, 2004, J BIOL CHEM, V279, P21183, DOI 10.1074/jbc.M311912200; Knecht R, 1999, CANCER RES, V59, P2794; Lanni JS, 1998, MOL CELL BIOL, V18, P1055, DOI 10.1128/MCB.18.2.1055; McMurray HR, 2004, J VIROL, V78, P5698, DOI 10.1128/JVI.78.11.5698-5706.2004; Meraldi P, 2002, EMBO J, V21, P483, DOI 10.1093/emboj/21.4.483; Michel L, 2004, P NATL ACAD SCI USA, V101, P4459, DOI 10.1073/pnas.0306069101; MORGENSTERN JP, 1990, NUCLEIC ACIDS RES, V18, P3587, DOI 10.1093/nar/18.12.3587; Mundt KE, 1997, BIOCHEM BIOPH RES CO, V239, P377, DOI 10.1006/bbrc.1997.7378; MUNGER K, 1989, J VIROL, V63, P4417; Nigg EA, 2001, NAT REV MOL CELL BIO, V2, P21, DOI 10.1038/35048096; Patel D, 2004, CANCER RES, V64, P1299, DOI 10.1158/0008-5472.CAN-03-2917; SCHEFFNER M, 1990, CELL, V63, P1129, DOI 10.1016/0092-8674(90)90409-8; Smits VAJ, 2000, NAT CELL BIOL, V2, P672, DOI 10.1038/35023629; Southern SA, 2004, BRIT J CANCER, V90, P1949, DOI 10.1038/sj.bjc.6601827; Spankuch-Schmitt B, 2002, JNCI-J NATL CANCER I, V94, P1863, DOI 10.1093/jnci/94.24.1863; Storchova Z, 2004, NAT REV MOL CELL BIO, V5, P45, DOI 10.1038/nrm1276; Thomas JT, 1998, J VIROL, V72, P1131, DOI 10.1128/JVI.72.2.1131-1137.1998; Thompson DA, 1997, ONCOGENE, V15, P3025, DOI 10.1038/sj.onc.1201495; Weichert W, 2005, VIRCHOWS ARCH, V446, P442, DOI 10.1007/s00428-005-1212-8; Weichert W, 2004, BRIT J CANCER, V90, P815, DOI 10.1038/sj.bjc.6601610; WERNESS BA, 1990, SCIENCE, V248, P76, DOI 10.1126/science.2157286; zur Hausen H, 2000, JNCI-J NATL CANCER I, V92, P690, DOI 10.1093/jnci/92.9.690	36	67	70	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR	2006	25	17					2444	2451		10.1038/sj.onc.1209276	http://dx.doi.org/10.1038/sj.onc.1209276			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	034RJ	16369493				2022-12-25	WOS:000236948000003
J	Suzuki, M; Yamada, T; Kihara-Negishi, F; Sakurai, T; Hara, E; Tenen, DG; Hozumi, N; Oikawa, T				Suzuki, M; Yamada, T; Kihara-Negishi, F; Sakurai, T; Hara, E; Tenen, DG; Hozumi, N; Oikawa, T			Site-specific DNA methylation by a complex of PU.1 and Dnmt3a/b	ONCOGENE			English	Article						PU.1; DNA methyltransferase; epigenetic transcriptional repression; p16(INK4a)	TRANSCRIPTION FACTOR PU.1; ETS FAMILY; EXPRESSION; DNMT1; DIFFERENTIATION; ASSOCIATION; PROTEINS; BINDS; METHYLTRANSFERASES; LOCALIZATION	The Ets transcription factor PU.1 is a hematopoietic master regulator essential for the development of myeloid and B-cell lineages. As we previously reported, PU.1 sometimes represses transcription on forming a complex with mSin3A-histone deacetyl transferase-MeCP2. Here, we show an interaction between PU.1 and DNA methyltransferases, DNA methyltransferase (Dnmt)3a and Dnmt3b (Dnmt3s). Glutathione-S-transferase pulldown assay revealed that PU.1 directly interacted with the ATRX domain of Dnmt3s through the ETS domain. Dnmt3s repressed the transcriptional activity of PU.1 on a reporter construct with trimerized PU.1-binding sites. The repression was recovered by addition of 5-aza-deoxycitidine, a DNA methyltransferase inhibitor, but not trichostatin A, a histone deacetylase inhibitor. Bisulfite sequence analysis revealed that several CpG sites in the promoter region neighboring the PU.1-binding sites were methylated when Dnmt3s were coexpressed with PU.1. We also showed that the CpG sites in the p16(INK4A) promoter were methylated by overexpression of PU.1 in NIH3T3 cells, accompanied by a downregulation of p16(INK4A) gene expression. These results suggest that PU.1 may downregulate its target genes through an epigenetic modi. cation such as DNA methylation.	Sasaki Inst, Dept Cell Genet, Chiyoda Ku, Tokyo 1010062, Japan; Tokyo Univ Sci, Res Inst Biol Sci, Chiba, Japan; Univ Tokushima, Inst Genome Res, Tokushima, Japan; Beth Israel Hosp, Boston, MA 02215 USA; Harvard Univ, Sch Med, Boston, MA USA	Tokyo University of Science; Tokushima University; Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Harvard Medical School	Oikawa, T (corresponding author), Sasaki Inst, Dept Cell Genet, Chiyoda Ku, 2-2 Kanda Surugadai, Tokyo 1010062, Japan.	oikawa@sasaki.or.jp		Tenen, Daniel/0000-0002-6423-3888				Bachman KE, 2001, J BIOL CHEM, V276, P32282, DOI 10.1074/jbc.M104661200; BASSUK AG, 1995, IMMUNITY, V3, P223, DOI 10.1016/1074-7613(95)90092-6; BESTOR T, 1988, J MOL BIOL, V203, P971, DOI 10.1016/0022-2836(88)90122-2; Bird AP, 1999, CELL, V99, P451, DOI 10.1016/S0092-8674(00)81532-9; Datta J, 2003, J CELL BIOCHEM, V88, P855, DOI 10.1002/jcb.10457; Di Croce L, 2002, SCIENCE, V295, P1079, DOI 10.1126/science.1065173; EISENBEIS CF, 1995, GENE DEV, V9, P1377, DOI 10.1101/gad.9.11.1377; Fuks F, 2001, EMBO J, V20, P2536, DOI 10.1093/emboj/20.10.2536; Hara E, 1996, MOL CELL BIOL, V16, P859; Herman JG, 1996, P NATL ACAD SCI USA, V93, P9821, DOI 10.1073/pnas.93.18.9821; Hwang CK, 2004, J BIOL CHEM, V279, P19764, DOI 10.1074/jbc.M400755200; Jenuwein T, 2001, SCIENCE, V293, P1074, DOI 10.1126/science.1063127; Kihara-Negishi F, 2001, ONCOGENE, V20, P6039, DOI 10.1038/sj.onc.1204756; KLEMSZ MJ, 1990, CELL, V61, P113, DOI 10.1016/0092-8674(90)90219-5; Konishi Y, 1999, ONCOGENE, V18, P6795, DOI 10.1038/sj.onc.1203118; Linderson Y, 2004, EMBO REP, V5, P291, DOI 10.1038/sj.embor.7400089; Majumder S, 2002, J BIOL CHEM, V277, P16048, DOI 10.1074/jbc.M111662200; MoreauGachelin F, 1996, MOL CELL BIOL, V16, P2453; MOREAUGACHELIN F, 1989, ONCOGENE, V4, P1449; MOREAUGACHELIN F, 1997, BIOCHIM BIOPHYS ACTA, V1198, P149; Mueller BU, 2002, BLOOD, V100, P998, DOI 10.1182/blood.V100.3.998; NAGULAPALLI S, 1995, J IMMUNOL, V155, P4330; Ng HH, 1999, CURR OPIN GENET DEV, V9, P158, DOI 10.1016/S0959-437X(99)80024-0; Oelgeschlager M, 1996, MOL CELL BIOL, V16, P4717; Ohtani N, 2001, NATURE, V409, P1067, DOI 10.1038/35059131; Oikawa T, 2003, GENE, V303, P11, DOI 10.1016/S0378-1119(02)01156-3; Oikawa T, 1999, CELL DEATH DIFFER, V6, P599, DOI 10.1038/sj.cdd.4400534; Okano M, 1998, NAT GENET, V19, P219, DOI 10.1038/890; Pongubala JMR, 1997, P NATL ACAD SCI USA, V94, P127, DOI 10.1073/pnas.94.1.127; Rao G, 1997, ONCOGENE, V14, P123, DOI 10.1038/sj.onc.1200807; Robertson KD, 2000, NAT GENET, V25, P338, DOI 10.1038/77124; Robertson KD, 2001, ONCOGENE, V20, P3139, DOI 10.1038/sj.onc.1204341; Robertson KD, 2002, ONCOGENE, V21, P5361, DOI 10.1038/sj.onc.1205609; Rosenbauer F, 2004, NAT GENET, V36, P624, DOI 10.1038/ng1361; Rountree MR, 2000, NAT GENET, V25, P269, DOI 10.1038/77023; Singal R, 1999, BLOOD, V93, P4059, DOI 10.1182/blood.V93.12.4059; Suzuki M, 2003, ONCOGENE, V22, P8688, DOI 10.1038/sj.onc.1207182; Tatematsu K, 2000, GENES CELLS, V5, P677, DOI 10.1046/j.1365-2443.2000.00359.x; Tenen DG, 1997, BLOOD, V90, P489, DOI 10.1182/blood.V90.2.489.489_489_519; Vangala RK, 2003, BLOOD, V101, P270, DOI 10.1182/blood-2002-04-1288; Walsh CP, 1999, GENE DEV, V13, P26, DOI 10.1101/gad.13.1.26; Yamada T, 1997, BLOOD, V89, P1383, DOI 10.1182/blood.V89.4.1383; Yamamoto H, 1999, ONCOGENE, V18, P1495, DOI 10.1038/sj.onc.1202427; ZHANG DE, 1994, MOL CELL BIOL, V14, P373, DOI 10.1128/MCB.14.1.373	44	95	100	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR	2006	25	17					2477	2488		10.1038/sj.onc.1209272	http://dx.doi.org/10.1038/sj.onc.1209272			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	034RJ	16331260				2022-12-25	WOS:000236948000006
J	Waters, D; Greene, CM; Fernandez, ML				Waters, D; Greene, CM; Fernandez, ML			Plasma responses to cholesterol, lutein and alpha-tocopherol from eggs in postmenopausal women are related	FASEB JOURNAL			English	Meeting Abstract	Experimental Biology 2006 Meeting	APR 01-05, 2006	San Francisco, CA	Amer Assoc Anatomists, Amer Physiol Soc, Amer Soc Biochem & Mol Biol, Amer Soc Investigat Pathol, Amer Soc Nutr, Amer Soc Pharmacol & Expt Therapeut					Univ Connecticut, Dept Nutr Sci, Storrs, CT 06269 USA	University of Connecticut				Pyne, Susan/0000-0002-6608-9584; Pyne, Nigel/0000-0002-5657-4578	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL071152, R01HL079396, R01HL061469] Funding Source: NIH RePORTER; NCI NIH HHS [CA-92160] Funding Source: Medline; NHLBI NIH HHS [R01 HL-71152/, R01 HL-79396, HL-61469] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))			0	71	72	0	0	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	MAR 7	2006	20	5	2				A1058	A1058						1	Biochemistry & Molecular Biology; Biology; Cell Biology	Conference Proceedings Citation Index - Science (CPCI-S); Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	026GA	16319133				2022-12-25	WOS:000236326202087
J	Covarrubias, AS; Bergfors, T; Jones, TA; Hogbom, M				Covarrubias, AS; Bergfors, T; Jones, TA; Hogbom, M			Structural mechanics of the pH-dependent activity of beta-carbonic anhydrase from Mycobacterium tuberculosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CRYSTAL-STRUCTURE; ESCHERICHIA-COLI; METHANOBACTERIUM-THERMOAUTOTROPHICUM; ALCOHOL-DEHYDROGENASE; STRUCTURE REFINEMENT; TERNARY COMPLEX; ANCIENT ENZYME; PISUM-SATIVUM; CO2 HYDRATION; CATALYSIS	Carbonic anhydrases catalyze the reversible hydration of carbon dioxide to form bicarbonate, a reaction required for many functions, including carbon assimilation and pH homeostasis. Carbonic anhydrases are divided into at least three classes and are believed to share a zinc-hydroxide mechanism for carbon dioxide hydration. beta-carbonic anhydrases are broadly spread among the domains of life, and existing structures from different organisms show two distinct active site setups, one with three protein coordinations to the zinc ( accessible) and the other with four ( blocked). The latter is believed to be inconsistent with the zinc-hydroxide mechanism. The Mycobacterium tuberculosis Rv3588c gene, shown to be required for in vivo growth of the pathogen, encodes a beta-carbonic anhydrase with a steep pH dependence of its activity, being active at pH 8.4 but not at pH 7.5. We have recently solved the structure of this protein, which was a dimeric protein with a blocked active site. Here we present the structure of the thiocyanate complexed protein in a different crystal form. The protein now forms distinct tetramers and shows large structural changes, including a carboxylate shift yielding the accessible active site. This structure demonstrated for the first time that a beta-carbonic anhydrase can switch between the two states. A pH-dependent dimer to tetramer equilibrium was also demonstrated by dynamic light scattering measurements. The data presented here, therefore, suggest a carboxylate shift on/off switch for the enzyme, which may, in turn, be controlled by a dimer-to-tetramer equilibrium.	Uppsala Univ, Ctr Biomed, Dept Cell & Mol Biol, S-75124 Uppsala, Sweden	Uppsala University	Hogbom, M (corresponding author), Uppsala Univ, Ctr Biomed, Dept Cell & Mol Biol, Box 596, S-75124 Uppsala, Sweden.	hogbom@xray.bmc.uu.se		Hogbom, Martin/0000-0001-5574-9383				BADGER MR, 1994, ANNU REV PLANT PHYS, V45, P369, DOI 10.1146/annurev.pp.45.060194.002101; Berman HM, 2000, NUCLEIC ACIDS RES, V28, P235, DOI 10.1093/nar/28.1.235; BRUNGER AT, 1992, NATURE, V355, P472, DOI 10.1038/355472a0; Chegwidden W. R., 2000, CARBONIC ANHYDRASES, DOI [10.1007/978-3-0348-8446-4_9, DOI 10.1007/978-3-0348-8446-4_9]; Christianson DW, 1999, ANNU REV BIOCHEM, V68, P33, DOI 10.1146/annurev.biochem.68.1.33; Cole ST, 1998, NATURE, V393, P537, DOI 10.1038/31159; Covarrubias AS, 2005, J BIOL CHEM, V280, P18782, DOI 10.1074/jbc.M414348200; Cox EH, 2000, BIOCHEMISTRY-US, V39, P12128, DOI 10.1021/bi001416s; Cronk JD, 2001, PROTEIN SCI, V10, P911, DOI 10.1110/ps.46301; Ducruix A, 1999, CRYSTALLIZATION NUCL; ENGH RA, 1991, ACTA CRYSTALLOGR A, V47, P392, DOI 10.1107/S0108767391001071; Esposito L, 2003, BIOCHEMISTRY-US, V42, P14397, DOI 10.1021/bi035271b; Flynn JL, 2003, CURR OPIN IMMUNOL, V15, P450, DOI 10.1016/S0952-7915(03)00075-X; Flynn JL, 2001, ANNU REV IMMUNOL, V19, P93, DOI 10.1146/annurev.immunol.19.1.93; Frieden TR, 2003, LANCET, V362, P887, DOI 10.1016/S0140-6736(03)14333-4; FUKUZAWA H, 1992, P NATL ACAD SCI USA, V89, P4437, DOI 10.1073/pnas.89.10.4437; GUILLOTON MB, 1992, J BIOL CHEM, V267, P3731; GUILLOTON MB, 1993, J BACTERIOL, V175, P1443, DOI 10.1128/JB.175.5.1443-1451.1993; Harris M, 2001, ACTA CRYSTALLOGR D, V57, P1201, DOI 10.1107/S0907444901007697; HewettEmmett D, 1996, MOL PHYLOGENET EVOL, V5, P50, DOI 10.1006/mpev.1996.0006; Hiltonen T, 1998, PLANT PHYSIOL, V117, P1341, DOI 10.1104/pp.117.4.1341; Hogbom M, 2001, J BIOL INORG CHEM, V6, P315, DOI 10.1007/s007750000205; JOHANSSON IM, 1993, EUR J BIOCHEM, V218, P439, DOI 10.1111/j.1432-1033.1993.tb18394.x; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KANDEL M, 1978, J BIOL CHEM, V253, P679; Karlsson A, 2003, CHEM-BIOL INTERACT, V143, P239, DOI 10.1016/S0009-2797(02)00222-3; Kimber MS, 2000, EMBO J, V19, P1407, DOI 10.1093/emboj/19.7.1407; KISIEL W, 1972, PHYTOCHEMISTRY, V11, P113, DOI 10.1016/S0031-9422(00)89975-6; Kisker C, 1996, EMBO J, V15, P2323, DOI 10.1002/j.1460-2075.1996.tb00588.x; Kleywegt GJ, 1996, STRUCTURE, V4, P1395, DOI 10.1016/S0969-2126(96)00147-5; Kleywegt GJ, 2004, ACTA CRYSTALLOGR D, V60, P2240, DOI 10.1107/S0907444904013253; LINDSKOG S, 1993, CURR OPIN STRUC BIOL, V3, P915, DOI 10.1016/0959-440X(93)90156-F; MELDRUM N. IT., 1933, JOUR PHYSIOL, V80, P113; Mitsuhashi S, 2000, J BIOL CHEM, V275, P5521, DOI 10.1074/jbc.275.8.5521; Murshudov GN, 1997, ACTA CRYSTALLOGR D, V53, P240, DOI 10.1107/S0907444996012255; O'Neill JW, 2001, ACTA CRYSTALLOGR D, V57, P480, DOI 10.1107/S0907444901000373; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Perrakis A, 1999, NAT STRUCT BIOL, V6, P458, DOI 10.1038/8263; Perrin CL, 1997, ANNU REV PHYS CHEM, V48, P511, DOI 10.1146/annurev.physchem.48.1.511; Roberts SB, 1997, J PHYCOL, V33, P845, DOI 10.1111/j.0022-3646.1997.00845.x; Rowlett RS, 2004, ARCH BIOCHEM BIOPHYS, V425, P25, DOI 10.1016/j.abb.2004.02.033; ROWLETT RS, 1994, BIOCHEMISTRY-US, V33, P13967, DOI 10.1021/bi00251a003; Rumeau D, 1996, PLANTA, V199, P79, DOI 10.1007/BF00196884; Sanghani PC, 2002, BIOCHEMISTRY-US, V41, P15189, DOI 10.1021/bi026705q; Sassetti CM, 2003, P NATL ACAD SCI USA, V100, P12989, DOI 10.1073/pnas.2134250100; Smith KS, 2002, J BACTERIOL, V184, P4240, DOI 10.1128/JB.184.15.4240-4245.2002; Smith KS, 1999, J BACTERIOL, V181, P6247, DOI 10.1128/JB.181.20.6247-6253.1999; Smith KS, 1999, P NATL ACAD SCI USA, V96, P15184, DOI 10.1073/pnas.96.26.15184; Smith KS, 2000, J BACTERIOL, V182, P6605, DOI 10.1128/JB.182.23.6605-6613.2000; Smith KS, 2000, FEMS MICROBIOL REV, V24, P335, DOI 10.1016/S0168-6445(00)00030-9; Solomon EI, 2000, CHEM REV, V100, P235, DOI 10.1021/cr9900275; SoltesRak E, 1997, J BACTERIOL, V179, P769, DOI 10.1128/jb.179.3.769-774.1997; Stadie WC, 1933, J BIOL CHEM, V103, P521; Storoni LC, 2004, ACTA CRYSTALLOGR D, V60, P432, DOI 10.1107/S0907444903028956; Strop P, 2001, J BIOL CHEM, V276, P10299, DOI 10.1074/jbc.M009182200; TOBIN AJ, 1970, J BIOL CHEM, V245, P2656; Tripp BC, 2001, J BIOL CHEM, V276, P48615, DOI 10.1074/jbc.R100045200	57	114	119	0	15	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 24	2006	281	8					4993	4999		10.1074/jbc.M510756200	http://dx.doi.org/10.1074/jbc.M510756200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	013RF	16321983	hybrid			2022-12-25	WOS:000235426200051
J	Cai, J; Jiang, WG; Grant, MB; Boulton, M				Cai, J; Jiang, WG; Grant, MB; Boulton, M			Pigment epithelium-derived factor inhibits angiogenesis via regulated intracellular proteolysis of vascular endothelial growth factor receptor 1 (Withdrawn Publication. See vol. 298, 2021)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article; Withdrawn Publication							TYROSINE KINASE; GAMMA-SECRETASE; EXPRESSION; CLEAVAGE; PRESENILIN; PROTEIN; CELLS; TRAFFICKING; DEFICIENCY; ACTIVATION	Pigment epithelium-derived factor ( PEDF) has been identified as one of the most potent of endogenous negative regulators of blood vessel growth in the body. Here we report that PEDF is able to inhibit growth factor-induced angiogenesis in microvascular endothelial cells through a novel pathway requiring cleavage and intracellular translocation of the transmembrane domain of the VEGFR-1. Analysis of the subcellular distribution of VEGFR-1 revealed the appearance of an 80-kDa C-terminal domain in the cytosol of cells treated with VEGF and PEDF that correlated with a decrease of the full-length receptor in the nuclear and cytoskeletal fractions. This regulated intramembrane proteolysis is dependent on gamma-secretase because inhibition of gamma-secretase abolished the inhibitory effect of PEDF on VEGF-induced angiogenesis as well as VEGFR-1 cleavage. The addition of PEDF to microvascular endothelial cells significantly increases gamma-secretase activity even in the absence of VEGF, showing that VEGF binding to VEGF-R1 is essential for substrate availability. This increase in activity was associated with translocation of presenilin 1 from the perinuclear region to the cell membrane. PEDF was also able to inhibit VEGF-induced phosphorylation of VEGFR-1. Taken together we have identified two novel pathways by which PEDF inhibits VEGF-induced angiogenesis: regulated intramembrane proteolysis and inhibition of phosphorylation. This confirms the importance of PEDF and VEGFR-1 in the negative regulation of angiogenesis.	Cardiff Univ, Cell & Mol Biol Grp, Sch Optometry & Vis Sci, Cardiff CF10 3NB, Wales; Cardiff Univ, Dept Surg, Metastasis Res Grp, Cardiff CF10 3NB, Wales; Cardiff Univ, Cardiff Inst Tissue Engn & Repair, Cardiff CF10 3NB, Wales; Univ Florida, Coll Med, Dept Pharmacol & Therapeut, Gainesville, FL 32610 USA	Cardiff University; Cardiff University; Cardiff University; State University System of Florida; University of Florida	Boulton, M (corresponding author), Cardiff Univ, Cell & Mol Biol Grp, Sch Optometry & Vis Sci, Cardiff CF10 3NB, Wales.	boultonm@cardiff.ac.uk	jiang, wen/GYI-9662-2022; Jiang, Wen G./AAF-1876-2020; Jiang, Wen G/B-1293-2010	Jiang, Wen G./0000-0002-3283-1111; Jiang, Wen G/0000-0002-3283-1111				Aymerich MS, 2001, INVEST OPHTH VIS SCI, V42, P3287; Blat Y, 2002, BIOCHEM BIOPH RES CO, V299, P569, DOI 10.1016/S0006-291X(02)02705-5; Bocci G, 2001, MOL HUM REPROD, V7, P771, DOI 10.1093/molehr/7.8.771; Bouck N, 2002, TRENDS MOL MED, V8, P330, DOI 10.1016/S1471-4914(02)02362-6; Brou C, 2000, MOL CELL, V5, P207, DOI 10.1016/S1097-2765(00)80417-7; Brunkan AL, 2005, J NEUROCHEM, V93, P769, DOI 10.1111/j.1471-4159.2005.03099.x; Bussolati B, 2001, AM J PATHOL, V159, P993, DOI 10.1016/S0002-9440(10)61775-0; Cai J, 1999, BIOCHEM BIOPH RES CO, V258, P113, DOI 10.1006/bbrc.1999.0596; Cai J, 2003, DIABETES, V52, P2959, DOI 10.2337/diabetes.52.12.2959; Carmeliet P, 2001, NAT MED, V7, P575, DOI 10.1038/87904; Chan CK, 2005, LAB INVEST, V85, P721, DOI 10.1038/labinvest.3700277; Dawson DW, 1999, SCIENCE, V285, P245, DOI 10.1126/science.285.5425.245; DE SB, 1999, NATURE, V398, P518; De Strooper B, 1998, NATURE, V391, P387, DOI 10.1038/34910; Ferrara N, 1999, J MOL MED, V77, P527, DOI 10.1007/s001099900019; FONG GH, 1995, NATURE, V376, P66, DOI 10.1038/376066a0; Fortini ME, 2002, NAT REV MOL CELL BIO, V3, P673, DOI 10.1038/nrm910; Haas IG, 2005, J BIOL CHEM, V280, P9313, DOI 10.1074/jbc.M412909200; Hiratsuka S, 1998, P NATL ACAD SCI USA, V95, P9349, DOI 10.1073/pnas.95.16.9349; Hiratsuka S, 2001, CANCER RES, V61, P1207; Ilan N, 2003, LAB INVEST, V83, P1105, DOI 10.1097/01.LAB.0000083531.84403.8B; Itokawa T, 2002, MOL CANCER THER, V1, P295; Kaiser S, 2001, J VASC RES, V38, P133, DOI 10.1159/000051040; KENDALL RL, 1993, P NATL ACAD SCI USA, V90, P10705, DOI 10.1073/pnas.90.22.10705; Kimberly WT, 2003, P NATL ACAD SCI USA, V100, P6382, DOI 10.1073/pnas.1037392100; LARA L, 2003, INVESTIG OPTHALMOL V, V44; Liao YF, 2004, J BIOL CHEM, V279, P49523, DOI 10.1074/jbc.M402034200; Liu H, 2004, P NATL ACAD SCI USA, V101, P6605, DOI 10.1073/pnas.0308342101; Myers JM, 2003, J CELL BIOCHEM, V88, P1273, DOI 10.1002/jcb.10476; Naruse S, 1998, NEURON, V21, P1213, DOI 10.1016/S0896-6273(00)80637-6; Ni CY, 2001, SCIENCE, V294, P2179, DOI 10.1126/science.1065412; Ogata N, 2002, AM J OPHTHALMOL, V133, P851, DOI 10.1016/S0002-9394(02)01406-X; Rahimi N, 2000, J BIOL CHEM, V275, P16986, DOI 10.1074/jbc.M000528200; Roberts DM, 2004, AM J PATHOL, V164, P1531, DOI 10.1016/S0002-9440(10)63711-X; Ruggeri B, 2003, CANCER RES, V63, P5978; SEETHARAM L, 1995, ONCOGENE, V10, P135; Shalaby F, 1997, CELL, V89, P981, DOI 10.1016/S0092-8674(00)80283-4; SHIBUYA M, 1990, ONCOGENE, V5, P519; STEELE FR, 1993, P NATL ACAD SCI USA, V90, P1526, DOI 10.1073/pnas.90.4.1526; Stellmach V, 2001, P NATL ACAD SCI USA, V98, P2593, DOI 10.1073/pnas.031252398; Struhl G, 1999, NATURE, V398, P522, DOI 10.1038/19091; Takahashi T, 2001, EMBO J, V20, P2768, DOI 10.1093/emboj/20.11.2768; Thinakaran G, 1996, NEURON, V17, P181, DOI 10.1016/S0896-6273(00)80291-3; Tombran-Tink J, 1996, Mol Vis, V2, P11; TOMBRANTINK J, 1989, INVEST OPHTH VIS SCI, V30, P1700; Tonnesen MG, 2000, J INVEST DERM SYMP P, V5, P40, DOI 10.1046/j.1087-0024.2000.00014.x; Zeng HY, 2001, J BIOL CHEM, V276, P26969, DOI 10.1074/jbc.M103213200	47	202	212	0	18	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 10	2006	281	6					3604	3613		10.1074/jbc.M507401200	http://dx.doi.org/10.1074/jbc.M507401200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	009QV	16339148	hybrid			2022-12-25	WOS:000235128200072
J	Cheong, R; Bergmann, A; Werner, SL; Regal, J; Hoffmann, A; Levchenko, A				Cheong, R; Bergmann, A; Werner, SL; Regal, J; Hoffmann, A; Levchenko, A			Transient I kappa B kinase activity mediates temporal NF-kappa B dynamics in response to a wide range of tumor necrosis factor-alpha doses	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TNF-ALPHA; ESCHERICHIA-COLI; IKK-BETA; ACTIVATION; TRANSCRIPTION; MACROPHAGES; APOPTOSIS; NETWORK; MODULE; PHOSPHORYLATION	Dynamic properties of signaling pathways control their behavior and function. We undertook an iterative computational and experimental investigation of the dynamic properties of tumor necrosis factor (TNF)alpha-mediated activation of the transcription factor NF-kappa B. Surprisingly, we found that the temporal profile of the NF-kappa B activity is invariant to the TNF alpha dose. We reverse engineered a computational model of the signaling pathway to identify mechanisms that impart this important response characteristic, thus predicting that the IKK activity profile must transiently peak at all TNF alpha doses to generate the observed NF-kappa B dynamics. Experimental confirmation of this prediction emphasizes the importance of mechanisms that rapidly down-regulate IKK following TNF alpha activation. A refined computational model further revealed signaling characteristics that ensure robust TNF alpha-mediated cell-cell communication over considerable distances, allowing for fidelity of cellular inflammatory responses in infected tissue.	Johns Hopkins Univ, Dept Biomed Engn, Baltimore, MD 21218 USA; Univ Calif San Diego, Dept Chem & Biochem, Signaling Syst Lab, La Jolla, CA 92093 USA	Johns Hopkins University; University of California System; University of California San Diego	Levchenko, A (corresponding author), Johns Hopkins Univ, Dept Biomed Engn, 208C Clark Hall,3400 N Charles St, Baltimore, MD 21218 USA.	alev@jhu.edu			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R21GM069013, R33GM069013, R01GM072024] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM072024-01, GM69013-01/B270JA] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALON R, 1994, J IMMUNOL, V152, P1304; Aupperle KR, 1999, J IMMUNOL, V163, P427; Baer M, 1998, MOL CELL BIOL, V18, P5678, DOI 10.1128/MCB.18.10.5678; Banzhaf W., 1998, GENETIC PROGRAMMING; Barken D, 2005, SCIENCE, V308, DOI 10.1126/science.1107904; BEUTLER BA, 1985, J IMMUNOL, V135, P3972; Bhalla US, 2002, SCIENCE, V297, P1018, DOI 10.1126/science.1068873; Blander JM, 2004, SCIENCE, V304, P1014, DOI 10.1126/science.1096158; Brummelkamp TR, 2003, NATURE, V424, P797, DOI 10.1038/nature01811; Cheng H, 2005, MOL CELL BIOL, V25, P44, DOI 10.1128/MCB.25.1.44-59.2005; CHEONG R, 2005, ENCY MOL CELL BIOL M, V14, P437; Delhase M, 1999, SCIENCE, V284, P309, DOI 10.1126/science.284.5412.309; DiDonato JA, 1997, NATURE, V388, P548, DOI 10.1038/41493; Ferrell JE, 1998, SCIENCE, V280, P895, DOI 10.1126/science.280.5365.895; Francis K, 1997, P NATL ACAD SCI USA, V94, P12258, DOI 10.1073/pnas.94.23.12258; Fu DX, 2003, J BIOL CHEM, V278, P1487, DOI 10.1074/jbc.M210631200; Ghosh S, 2002, CELL, V109, pS81, DOI 10.1016/S0092-8674(02)00703-1; Goodhill GJ, 1997, EUR J NEUROSCI, V9, P1414, DOI 10.1111/j.1460-9568.1997.tb01496.x; Hartwell LH, 1999, NATURE, V402, pC47, DOI 10.1038/35011540; Hoffmann A, 2003, EMBO J, V22, P5530, DOI 10.1093/emboj/cdg534; Hoffmann A, 2002, SCIENCE, V298, P1241, DOI 10.1126/science.1071914; Klein DE, 2004, NATURE, V430, P1040, DOI 10.1038/nature02840; Klein RD, 2000, J SURG RES, V94, P159, DOI 10.1006/jsre.2000.5975; Kovalenko A, 2003, NATURE, V424, P801, DOI 10.1038/nature01802; Lee EG, 2000, SCIENCE, V289, P2350, DOI 10.1126/science.289.5488.2350; Lipniacki T, 2004, J THEOR BIOL, V228, P195, DOI 10.1016/j.jtbi.2004.01.001; Matzinger P, 1998, SEMIN IMMUNOL, V10, P399, DOI 10.1006/smim.1998.0143; Ozbudak EM, 2004, NATURE, V427, P737, DOI 10.1038/nature02298; Prajapati S, 2004, J BIOL CHEM, V279, P1739, DOI 10.1074/jbc.M306273200; Ran RQ, 2004, GENE DEV, V18, P1466, DOI 10.1101/gad.1188204; REEVES R, 1990, PROG NUCLEIC ACID RE, V38, P241; Sasagawa S, 2005, NAT CELL BIOL, V7, P365, DOI 10.1038/ncb1233; Shapiro BE, 2003, BIOINFORMATICS, V19, P677, DOI 10.1093/bioinformatics/btg042; Stoecklin G, 2003, MOL CELL BIOL, V23, P3506, DOI 10.1128/MCB.23.10.3506-3515.2003; Swameye I, 2003, P NATL ACAD SCI USA, V100, P1028, DOI 10.1073/pnas.0237333100; TRACEY KJ, 1992, P SOC EXP BIOL MED, V200, P233; Trompouki E, 2003, NATURE, V424, P793, DOI 10.1038/nature01803; von Dassow G, 2000, NATURE, V406, P188, DOI 10.1038/35018085; Wajant H, 2003, CELL DEATH DIFFER, V10, P45, DOI 10.1038/sj.cdd.4401189; Werner SL, 2005, SCIENCE, V309, P1857, DOI 10.1126/science.1113319; Wertz IE, 2004, NATURE, V430, P694, DOI 10.1038/nature02794; Xaus J, 2000, BLOOD, V95, P3823; Zandi E, 1997, CELL, V91, P243, DOI 10.1016/S0092-8674(00)80406-7; Zhou A, 2003, ONCOGENE, V22, P2054, DOI 10.1038/sj.onc.1206262	44	99	101	2	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 3	2006	281	5					2945	2950		10.1074/jbc.M510085200	http://dx.doi.org/10.1074/jbc.M510085200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	006XT	16321974	hybrid			2022-12-25	WOS:000234931800064
J	O'Hayre, M; Taylor, L; Andratsch, M; Feifel, E; Gstraunthaler, G; Curthoys, NP				O'Hayre, M; Taylor, L; Andratsch, M; Feifel, E; Gstraunthaler, G; Curthoys, NP			Effects of constitutively active and dominant negative MAPK kinase (MKK) 3 and MKK6 on the pH-responsive increase in phosphoenolpyruvate carboxykinase mRNA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACID-BASE-BALANCE; GENE-EXPRESSION; LLC-PK1-FBPASE(+) CELLS; GLUTAMINE-METABOLISM; RENAL GLUTAMINASE; MAMMALIAN-CELLS; PROTEIN-KINASES; RAT; PATHWAYS; GLUCONEOGENESIS	Metabolic acidosis is partially compensated by a pronounced increase in renal catabolism of glutamine. This adaptive response is sustained, in part, through increased expression of phosphoenolpyruvate carboxykinase ( PEPCK). Previous inhibitor studies suggested that the pH-responsive increase in PEPCK mRNA in LLCPK1-FBPase(+) cells is mediated by a p38 mitogen-activated protein kinase ( MAPK). These cells express high levels of the upstream kinase MAPK kinase (MKK) 3 but relatively low levels of the alternative upstream kinase MKK6. To firmly establish the role of the p38 MAPK signaling pathway, clonal lines of LLC-PK1-FBPase(+) cells that express constitutively active (ca) and dominant negative (dn) forms of MKK3 and MKK6 from a tetracycline-responsive promoter were developed. Western blot analyses confirmed that 0.5 mu g/ml doxycycline was sufficient to block transcription and that removal of doxycycline led to pronounced and sustained expression of the caMKKs and dnMKKs. Expression of caMKK6 ( but not caMKK3) caused an increase in phosphorylation of p38 MAPK and an increase in the level of PEPCK mRNA that closely mimicked the effect of treatment with acidic medium (pH 6.9, 10 mM HCO3-). Only caMKK6 activated transcription of a PEPCK-luciferase reporter construct. Co-expression of both dnMKKs blocked the increases in phosphorylation of p38 MAPK and PEPCK mRNA. The latter effect closely mimicked that of the p38 MAPK inhibitor SB203580. The expression of either dnMKK3 or dnMKK6 was less effective than co-expression of both dnMKKs. Thus, the pH-responsive increase in PEPCK mRNA in the kidney is mediated by the p38 MAPK signaling pathway and involves activation of MKK3 and/or MKK6.	Colorado State Univ, Dept Biochem & Mol Biol, Ft Collins, CO 80523 USA; Innsbruck Med Univ, Dept Phys & Med Phys, A-6010 Innsbruck, Austria	Colorado State University; Medical University of Innsbruck	Curthoys, NP (corresponding author), Colorado State Univ, Dept Biochem & Mol Biol, Ft Collins, CO 80523 USA.	Norman.Curthoys@ColoState.edu			NIDDK NIH HHS [DK-43704, DK-37124] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK043704, R01DK037124] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BROSNAN JT, 1987, CAN J PHYSIOL PHARM, V65, P489, DOI 10.1139/y87-084; BURCH HB, 1978, AM J PHYSIOL, V235, pF246, DOI 10.1152/ajprenal.1978.235.3.F246; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; Cheong J, 1998, J BIOL CHEM, V273, P22714, DOI 10.1074/jbc.273.35.22714; Cowan KJ, 2003, J EXP BIOL, V206, P1107, DOI 10.1242/jeb.00220; Curthoys NP, 2001, AM J PHYSIOL-RENAL, V281, pF381, DOI 10.1152/ajprenal.2001.281.3.F381; DALESSIO JM, 1981, BIOCHEMISTRY-US, V20, P3822, DOI 10.1021/bi00516a024; DAVIS RJ, 1994, TRENDS BIOCHEM SCI, V19, P470, DOI 10.1016/0968-0004(94)90132-5; Dean JLE, 2004, CELL SIGNAL, V16, P1113, DOI 10.1016/j.cellsig.2004.04.006; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; DHAKRAS PS, 2006, IN PRESS AM J PHYSL; Enslen H, 1998, J BIOL CHEM, V273, P1741, DOI 10.1074/jbc.273.3.1741; Feifel E, 2002, AM J PHYSIOL-RENAL, V283, pF678, DOI 10.1152/ajprenal.00097.2002; Gerich JE, 2001, DIABETES CARE, V24, P382, DOI 10.2337/diacare.24.2.382; Gstraunthaler G, 2000, AM J PHYSIOL-RENAL, V278, pF227, DOI 10.1152/ajprenal.2000.278.2.F227; GSTRAUNTHALER G, 1987, AM J PHYSIOL, V252, pC232, DOI 10.1152/ajpcell.1987.252.2.C232; Hajarnis S, 2005, J BIOL CHEM, V280, P28272, DOI 10.1074/jbc.M501204200; HALPERIN ML, 1993, CLIN INVEST MED, V16, P294; Hansen WR, 1996, AM J PHYSIOL-RENAL, V271, pF126, DOI 10.1152/ajprenal.1996.271.1.F126; HOLCOMB T, 1995, AM J PHYSIOL-CELL PH, V268, pC449, DOI 10.1152/ajpcell.1995.268.2.C449; HWANG JJ, 1991, J BIOL CHEM, V266, P9392; HWANG JJ, 1991, BIOCHEMISTRY-US, V30, P7522, DOI 10.1021/bi00244a022; IYNEDJIAN PB, 1975, J BIOL CHEM, V250, P5596; Johnson GL, 2002, SCIENCE, V298, P1911, DOI 10.1126/science.1072682; Liu NS, 1996, J BIOL CHEM, V271, P355, DOI 10.1074/jbc.271.1.355; Loflin PT, 1999, METHODS, V17, P11, DOI 10.1006/meth.1998.0702; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Morel C, 2005, J BIOL CHEM, V280, P21384, DOI 10.1074/jbc.M408851200; Morrison DK, 2003, ANNU REV CELL DEV BI, V19, P91, DOI 10.1146/annurev.cellbio.19.111401.091942; Platanias LC, 2005, NAT REV IMMUNOL, V5, P375, DOI 10.1038/nri1604; Raingeaud J, 1996, MOL CELL BIOL, V16, P1247; SCHOOLWERTH AC, 1994, AM J PHYSIOL, V267, pF400, DOI 10.1152/ajprenal.1994.267.3.F400; SCHROEDER JM, 2006, IN PRESS AM J PHYSL; TANNEN RL, 1990, MINER ELECTROL METAB, V16, P249; Taylor L, 2004, BIOCHEM MOL BIOL EDU, V32, P291, DOI 10.1002/bmb.2004.494032050388; YOOWARREN H, 1983, P NATL ACAD SCI-BIOL, V80, P3656, DOI 10.1073/pnas.80.12.3656	36	8	8	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 3	2006	281	5					2982	2988		10.1074/jbc.M510084200	http://dx.doi.org/10.1074/jbc.M510084200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	006XT	16319064	hybrid			2022-12-25	WOS:000234931800068
J	Hourcade, DE				Hourcade, DE			The role of properdin in the assembly of the alternative pathway C3 convertases of complement	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEMOLYTIC-UREMIC SYNDROME; FACTOR-H POLYMORPHISM; MACULAR DEGENERATION; 3RD COMPONENT; FACTOR-B; BINDING; C-3; DEFICIENCY; ACTIVATION; MUTATIONS	Complement is a powerful host defense system that contributes to both innate and acquired immunity. There are three pathways of complement activation, the classical pathway, lectin pathway, and alternative pathway. Each generates a C3 convertase, a serine protease that cleaves the central complement protein, C3. Nearly all the biological consequences of complement are dependent on the resulting cleavage products. Properdin is a positive regulator of complement activation that stabilizes the alternative pathway convertases (C3bBb). Properdin is composed of multiple identical protein subunits, with each subunit carrying a separate ligand-binding site. Previous reports suggest that properdin function depends on multiple interactions between its subunits with its ligands. In this study I used surface plasmon resonance assays to examine properdin interactions with C3b and factor B. I demonstrated that properdin promotes the association of C3b with factor B and provides a focal point for the assembly of C3bBb on a surface. I also found that properdin binds to preformed alternative pathway C3 convertases. These findings support a model in which properdin, bound to a target surface via C3b, iC3b, or other ligands, can use its unoccupied C3b-binding sites as receptors for nascent C3b, bystander C3b, or pre-formed C3bB and C3bBb complexes. New C3bP and C3bBP intermediates can lead to in situ assembly of C3bBbP. The full stabilizing effect of properdin on C3bBb would be attained as properdin binds more than one ligand at a time, forming a lattice of properdin: ligand interactions bound to a surface scaffold.	Washington Univ, Sch Med, Div Rheumatol, Dept Med, St Louis, MO 63110 USA	Washington University (WUSTL)	Hourcade, DE (corresponding author), Washington Univ, Sch Med, Div Rheumatol, Dept Med, 660 S Euclid Ave,Box 8045, St Louis, MO 63110 USA.	dhourcad@im.wustl.edu			NIAID NIH HHS [R01 AI 051436] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI051436] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BERGER M, 1998, HUMAN COMPLEMENT SYS, P285; BRACONIER JH, 1983, SCAND J INFECT DIS, V15, P339, DOI 10.3109/inf.1983.15.issue-4.04; DENSEN P, 1987, NEW ENGL J MED, V316, P922, DOI 10.1056/NEJM198704093161506; DISCIPIO RG, 1981, BIOCHEM J, V199, P485, DOI 10.1042/bj1990485; Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189; FARRIES TC, 1988, BIOCHEM J, V252, P47, DOI 10.1042/bj2520047; FARRIES TC, 1988, BIOCHEM J, V253, P667, DOI 10.1042/bj2530667; FEARON DT, 1975, J EXP MED, V142, P856, DOI 10.1084/jem.142.4.856; Goodship THJ, 2004, TRENDS MOL MED, V10, P226, DOI 10.1016/j.molmed.2004.03.006; Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359; Harris CL, 2005, J BIOL CHEM, V280, P2569, DOI 10.1074/jbc.M410179200; HOLT GD, 1990, J BIOL CHEM, V265, P2852; HOURCADE D, 1989, ADV IMMUNOL, V45, P381, DOI 10.1016/S0065-2776(08)60697-5; HOURCADE DE, 1995, J BIOL CHEM, V270, P19716, DOI 10.1074/jbc.270.34.19716; Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557; Kolble K, 1993, Int Rev Immunol, V10, P17, DOI 10.3109/08830189309051169; LAMBRIS JD, 1984, BIOCHEM J, V217, P323, DOI 10.1042/bj2170323; Liszewski M.K., 1998, HUMAN COMPLEMENT SYS, P149; Mastellos D, 2002, TRENDS IMMUNOL, V23, P485, DOI 10.1016/S1471-4906(02)02287-1; MEDICUS RG, 1976, J EXP MED, V144, P1076, DOI 10.1084/jem.144.4.1076; Myszka DG, 2000, METHOD ENZYMOL, V323, P325; PILLEMER L, 1954, SCIENCE, V120, P279, DOI 10.1126/science.120.3112.279; Richards A, 2001, AM J HUM GENET, V68, P485, DOI 10.1086/318203; Riley-Vargas RC, 2004, TRENDS IMMUNOL, V25, P496, DOI 10.1016/j.it.2004.07.004; Schwaeble WJ, 1999, IMMUNOL TODAY, V20, P17, DOI 10.1016/S0167-5699(98)01376-0; SIM RB, 1981, BIOCHEM J, V193, P115, DOI 10.1042/bj1930115; SMITH CA, 1984, J BIOL CHEM, V259, P4582; Volanakis JE, 2002, CURR TOP MICROBIOL, V266, P41; Volanakis JE, 1998, HUMAN COMPLEMENT SYS, V20, P9, DOI DOI 10.1201/B14212-3; Vuagnat BB, 2000, MOL IMMUNOL, V37, P467, DOI 10.1016/S0161-5890(00)00069-9; Zipfel PF, 2001, INT IMMUNOPHARMACOL, V1, P461, DOI 10.1016/S1567-5769(00)00047-3	31	175	178	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 27	2006	281	4					2128	2132		10.1074/jbc.M508928200	http://dx.doi.org/10.1074/jbc.M508928200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	004NV	16301317	hybrid			2022-12-25	WOS:000234760400035
J	Pandhare, J; Cooper, SK; Phang, JM				Pandhare, J; Cooper, SK; Phang, JM			Proline oxidase, a proapoptotic gene, is induced by troglitazone - Evidence for both peroxisome proliferator-activated receptor gamma-dependent and -independent mechanisms	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIGAND-INDUCED APOPTOSIS; PPAR-GAMMA; COLON-CANCER; SIGNAL-TRANSDUCTION; INHIBIT GROWTH; IN-VITRO; OXYGEN; DIFFERENTIATION; CELLS; EXPRESSION	Proline oxidase ( POX) is a redox enzyme localized in the mitochondrial inner membrane. We and others have shown that POX is a p53-induced gene that can mediate apoptosis through generation of reactive oxygen species (ROS). The peroxisome proliferator-activated receptor gamma(PPAR gamma) ligand troglitazone was found to activate the POX promoter in colon cancer cells. PPAR gamma ligands have been reported to induce apoptosis in a variety of cancer cells. In HCT116 cells expressing a wild-type PPAR gamma, troglitazone enhanced the binding of PPAR gamma to PPAR-responsive element in the POX promoter and increased endogenous POX expression. Blocking of PPAR gamma activation either by antagonist GW9662 or deletion of PPAR-responsive element in the POX promoter only partially decreased the POX promoter activation in response to troglitazone, indicating also the involvement of PPAR gamma-independent mechanisms. Further, troglitazone also induced p53 protein expression in HCT116 cells, which may be the possible mechanism for PPAR gamma-independent POX activation, since POX has been shown to be a downstream mediator in p53-induced apoptosis. In HCT15 cells, with both mutant p53 and mutant PPAR gamma, there was no effect of troglitazone on POX activation, whereas in HT29 cells, with a mutant p53 and wild type PPAR gamma, increased activation was observed by ligand stimulation, indicating that both PPAR gamma-dependent and gamma-independent mechanisms are involved in the troglitazone-induced POX expression. A time- and dose-dependent increase in POX catalytic activity was obtained in HCT116 cells treated with troglitazone with a concomitant increase in the production of intracellular ROS. Our results suggest that the induction of apoptosis by troglitazone may, at least in part, be mediated by targeting POX gene expression for generation of ROS by POX both by PPAR gamma-dependent and gamma-independent mechanisms.	NCI, NIH, Metab & Canc Susceptibil Sect, Lab Comparat Carcinogenesis,Ctr Canc Res, Ft Detrick, MD 21702 USA; SAIC Frederick Inc, Basic Res Program, Ft Detrick, MD 21702 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick	Phang, JM (corresponding author), NCI, NIH, Metab & Canc Susceptibil Sect, Lab Comparat Carcinogenesis,Ctr Canc Res, Bldg 538,Rm 144, Ft Detrick, MD 21702 USA.	phang@ncifcrf.gov		Pandhare, Jui/0000-0002-0356-064X	Intramural NIH HHS Funding Source: Medline; NCI NIH HHS [N01 CO 12400] Funding Source: Medline; NATIONAL CANCER INSTITUTE [Z01BC010744] Funding Source: NIH RePORTER	Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Bae MA, 2003, TOXICOL LETT, V139, P67, DOI 10.1016/S0378-4274(02)00468-X; Brockman JA, 1998, GASTROENTEROLOGY, V115, P1049, DOI 10.1016/S0016-5085(98)70072-1; Chen YC, 2005, BBA-MOL CELL RES, V1743, P291, DOI 10.1016/j.bbamcr.2004.10.016; Desvergne B, 1999, ENDOCR REV, V20, P649, DOI 10.1210/er.20.5.649; Donald SP, 2001, CANCER RES, V61, P1810; Elstner E, 1998, P NATL ACAD SCI USA, V95, P8806, DOI 10.1073/pnas.95.15.8806; Evans RM, 2004, NAT MED, V10, P355, DOI 10.1038/nm1025; Ferri KF, 2001, NAT CELL BIOL, V3, pE255, DOI 10.1038/ncb1101-e255; Finkel T, 1999, J LEUKOCYTE BIOL, V65, P337, DOI 10.1002/jlb.65.3.337; Fleury C, 2002, BIOCHIMIE, V84, P131, DOI 10.1016/S0300-9084(02)01369-X; Grommes C, 2004, LANCET ONCOL, V5, P419, DOI 10.1016/S1470-2045(04)01509-8; Gupta RA, 2001, J BIOL CHEM, V276, P29681, DOI 10.1074/jbc.M103779200; Gupta RA, 2003, J BIOL CHEM, V278, P22669, DOI 10.1074/jbc.M300637200; HAGEDORN CH, 1986, ARCH BIOCHEM BIOPHYS, V248, P166, DOI 10.1016/0003-9861(86)90413-3; HAGEDORN CH, 1983, ARCH BIOCHEM BIOPHYS, V225, P95, DOI 10.1016/0003-9861(83)90010-3; Hammerman PS, 2004, TRENDS BIOCHEM SCI, V29, P586, DOI 10.1016/j.tibs.2004.09.008; Han C, 2003, HEPATOLOGY, V38, P167, DOI 10.1053/jhep.2003.50296; He GB, 2004, J INVEST DERMATOL, V123, P1110, DOI 10.1111/j.0022-202X.2004.23465.x; HU CAA, 2001, P AM ASSOC CANC RES, V42, P1211; Kato M, 2004, J CANCER RES CLIN, V130, P73, DOI 10.1007/s00432-003-0510-2; Kersten S, 2000, NATURE, V405, P421, DOI 10.1038/35013000; Keshamouni VG, 2004, ONCOGENE, V23, P100, DOI 10.1038/sj.onc.1206885; Kitamura S, 1999, JPN J CANCER RES, V90, P75, DOI 10.1111/j.1349-7006.1999.tb00668.x; Kondo M, 2001, J BIOL CHEM, V276, P12076, DOI 10.1074/jbc.M009630200; Kubota T, 1998, CANCER RES, V58, P3344; Lee HC, 2000, J BIOMED SCI, V7, P2, DOI 10.1007/BF02255913; Leesnitzer LM, 2002, BIOCHEMISTRY-US, V41, P6640, DOI 10.1021/bi0159581; Li LY, 2001, J BIOL CHEM, V276, P38152; Liu YM, 2005, CARCINOGENESIS, V26, P1335, DOI 10.1093/carcin/bgi083; Maxwell SA, 2000, P NATL ACAD SCI USA, V97, P13009, DOI 10.1073/pnas.230445997; Maxwell SA, 2003, J BIOL CHEM, V278, P9784, DOI 10.1074/jbc.M210012200; MERRILL MJ, 1989, J BIOL CHEM, V264, P9352; Michalik L, 2004, NAT REV CANCER, V4, P61, DOI 10.1038/nrc1254; Nagamine M, 2003, CANCER SCI, V94, P338, DOI 10.1111/j.1349-7006.2003.tb01443.x; Okura T, 2000, EUR J PHARMACOL, V407, P227, DOI 10.1016/S0014-2999(00)00758-5; Perez-Ortiz JM, 2004, J BIOL CHEM, V279, P8976, DOI 10.1074/jbc.M308518200; PHANG JM, 1985, CURR TOP CELL REGUL, V25, P91; Polyak K, 1997, NATURE, V389, P300, DOI 10.1038/38525; Rosen ED, 2001, J BIOL CHEM, V276, P37731, DOI 10.1074/jbc.R100034200; Sarraf P, 1998, NAT MED, V4, P1046, DOI 10.1038/2030; Sarraf P, 1999, MOL CELL, V3, P799, DOI 10.1016/S1097-2765(01)80012-5; Shimada T, 2002, GUT, V50, P658, DOI 10.1136/gut.50.5.658; Theocharis S, 2004, CANCER TREAT REV, V30, P545, DOI 10.1016/j.ctrv.2004.04.004; Tsujie M, 2003, EXP CELL RES, V289, P143, DOI 10.1016/S0014-4827(03)00263-5; Turturro F, 2004, CLIN CANCER RES, V10, P7022, DOI 10.1158/1078-0432.CCR-04-0879; Willson TM, 2000, J MED CHEM, V43, P527, DOI 10.1021/jm990554g; Yang WL, 2001, CARCINOGENESIS, V22, P1379, DOI 10.1093/carcin/22.9.1379; YEH GC, 1988, J BIOL CHEM, V263, P13083	48	90	93	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 27	2006	281	4					2044	2052		10.1074/jbc.M507867200	http://dx.doi.org/10.1074/jbc.M507867200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	004NV	16303758	hybrid			2022-12-25	WOS:000234760400025
J	Dang, LH; Chen, F; Ying, C; Chun, S; Knock, SA; Appelman, HD; Dang, DT				Dang, LH; Chen, F; Ying, C; Chun, S; Knock, SA; Appelman, HD; Dang, DT			CDX2 has tumorigenic potential in the human colon cancer cell lines LOVO and SW48	ONCOGENE			English	Article						CDX2; colon cancer; tumorigenesis; LOVO; SW48	HOMEOBOX GENE CDX2; COLORECTAL-CANCER; DOWN-REGULATION; PROTEIN EXPRESSION; RNA EXPRESSION; PROLIFERATION; ADENOCARCINOMA; APOPTOSIS; TUMORS; BCL-2	CDX2 is a Drosophila caudal-related homeo box transcription factor that is important for the establishment and maintenance of intestinal epithelial cells. CDX2 is a marker of colon cancer, with strong staining in up to 90% of colonic adenocarcinomas. CDX2 heterozygous-null mice develop colonic neoplasms, which have suggested that CDX2 is a tumor suppressor. However, CDX2 has not been reported to affect xenograft growth. Furthermore, CDX2 is rarely mutated in colon cancer, which has led to suggestions that it may play only a minor role as a tumor suppressor in colon cancer. To understand the functional contributions of CDX2 to colon cancer, we disrupted CDX2 in LOVO and SW48 human colon cancer cell lines by targeted homologous recombination. Consistent with the literature, disruption of CDX2 enhanced anchorage-dependent cell proliferation. However, homozygous loss of CDX2 led to significant inhibition of anchorage-independent growth in LOVO cells, and cell lethality in SW48 cells. Further analyses revealed that disruption of CDX2 led to anchorage-independent G1 to S growth arrest and anoikis. In vivo xenograft studies confirmed that disruption of CDX2 inhibited LOVO tumor growth. These data demonstrate that CDX2 mediates anchorage-independent growth and survival. Thus, CDX2 has tumorigenic potential in the human colon cancer cell lines LOVO and SW48.	Univ Michigan, Dept Internal Med, Div Hematol Oncol, Ann Arbor, MI 48109 USA; Univ Michigan, Div Anat Pathol, Dept Pathol, Ann Arbor, MI USA; Univ Michigan, Dept Internal Med, Div Gastroenterol, Ann Arbor, MI USA; Univ Michigan, Ctr Comprehens Canc, Ann Arbor, MI USA	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan	Dang, DT (corresponding author), Univ Michigan, Dept Internal Med, Div Hematol Oncol, 1150 W Med Ctr Dr,MSRB I,Room 6514, Ann Arbor, MI 48109 USA.	dangd@umich.edu						Abate-Shen C, 2002, NAT REV CANCER, V2, P777, DOI 10.1038/nrc907; Aoki K, 2003, NAT GENET, V35, P323, DOI 10.1038/ng1265; Bai YQ, 2003, ONCOGENE, V22, P7942, DOI 10.1038/sj.onc.1206634; Beck F, 2002, GUT, V51, P450, DOI 10.1136/gut.51.3.450; Bonhomme C, 2003, GUT, V52, P1465, DOI 10.1136/gut.52.10.1465; Brabletz T, 2004, CANCER RES, V64, P6973, DOI 10.1158/0008-5472.CAN-04-1132; Chan TA, 2002, P NATL ACAD SCI USA, V99, P8265, DOI 10.1073/pnas.082240999; Chawengsaksophak K, 2004, P NATL ACAD SCI USA, V101, P7641, DOI 10.1073/pnas.0401654101; Chawengsaksophak K, 1997, NATURE, V386, P84, DOI 10.1038/386084a0; Cummins JM, 2004, CANCER RES, V64, P3006, DOI 10.1158/0008-5472.CAN-04-0046; CUMMINS JM, 2004, NATURE, V428, P486, DOI [DOI 10.1038/NATURE02501, 10.1038/nature02501]; da Costa LT, 1999, ONCOGENE, V18, P5010, DOI 10.1038/sj.onc.1202872; Dang DT, 2001, ONCOGENE, V20, P4884, DOI 10.1038/sj.onc.1204645; DANG DT, 2005, CANCER RES, V65, P1; Dang LH, 2001, P NATL ACAD SCI USA, V98, P15155, DOI 10.1073/pnas.251543698; Dang LH, 2004, CANCER BIOL THER, V3, P326, DOI 10.4161/cbt.3.3.704; DANG LH, 2006, IN PRESS ONCOGENE; DONG Z, 2002, SCI STKE, pPL7; DREWINKO B, 1976, CANCER RES, V36, P467; EE HC, 1995, AM J PATHOL, V147, P586; Evan GI, 2001, NATURE, V411, P342, DOI 10.1038/35077213; Freund JN, 1998, BIOCHEM CELL BIOL, V76, P957, DOI 10.1139/bcb-76-6-957; Guo RJ, 2004, CANCER BIOL THER, V3, P593, DOI 10.4161/cbt.3.7.913; Guo RJ, 2004, J BIOL CHEM, V279, P36865, DOI 10.1074/jbc.M405213200; Hahn WC, 2002, NAT REV CANCER, V2, P331, DOI 10.1038/nrc795; Heckman CA, 2000, J BIOL CHEM, V275, P6499, DOI 10.1074/jbc.275.9.6499; Hinoi T, 2001, AM J PATHOL, V159, P2239, DOI 10.1016/S0002-9440(10)63074-X; Hinoi T, 2003, J BIOL CHEM, V278, P44608, DOI 10.1074/jbc.M307435200; Hinoi T, 2005, GASTROENTEROLOGY, V128, P946, DOI 10.1053/j.gastro.2005.01.003; Hinoi T, 2002, GASTROENTEROLOGY, V123, P1565, DOI 10.1053/gast.2002.36598; Hwang PM, 2001, NAT MED, V7, P1111, DOI 10.1038/nm1001-1111; Igney FH, 2002, NAT REV CANCER, V2, P277, DOI 10.1038/nrc776; JACOBSON MD, 1995, NATURE, V374, P814, DOI 10.1038/374814a0; JAMES R, 1994, J BIOL CHEM, V269, P15229; KAIMAKTCHIEV V, 2004, MOD PATHOL; Keller MS, 2004, AM J PHYSIOL-GASTR L, V287, pG104, DOI 10.1152/ajpgi.00484.2003; Kohli M, 2004, NUCLEIC ACIDS RES, V32, DOI 10.1093/nar/gnh009; Koo HM, 1996, CANCER RES, V56, P5211; LEIBOVITZ A, 1976, CANCER RES, V36, P4562; Ling YH, 1998, J BIOL CHEM, V273, P18984, DOI 10.1074/jbc.273.30.18984; Lynch J, 2003, ONCOGENE, V22, P6395, DOI 10.1038/sj.onc.1206770; Lynch J, 2000, J BIOL CHEM, V275, P4499, DOI 10.1074/jbc.275.6.4499; Mallo GV, 1998, J BIOL CHEM, V273, P14030, DOI 10.1074/jbc.273.22.14030; Mallo GV, 1997, INT J CANCER, V74, P35, DOI 10.1002/(SICI)1097-0215(19970220)74:1<35::AID-IJC7>3.0.CO;2-1; McLean GW, 2004, GENE DEV, V18, P2998, DOI 10.1101/gad.316304; Moskaluk CA, 2003, MODERN PATHOL, V16, P913, DOI 10.1097/01.MP.0000086073.92773.55; Pfaffl MW, 2001, NUCLEIC ACIDS RES, V29, DOI 10.1093/nar/29.9.e45; Rawat VPS, 2004, P NATL ACAD SCI USA, V101, P817, DOI 10.1073/pnas.0305555101; Rowan AJ, 2000, P NATL ACAD SCI USA, V97, P3352, DOI 10.1073/pnas.97.7.3352; Rozek LS, 2005, CANCER RES, V65, P5488, DOI 10.1158/0008-5472.CAN-04-3645; Russo P, 2002, INT J CANCER, V100, P266, DOI 10.1002/ijc.10461; Sebolt-Leopold JS, 2004, NAT REV CANCER, V4, P937, DOI 10.1038/nrc1503; Sugao Y, 1997, HISTOPATHOLOGY, V31, P123, DOI 10.1046/j.1365-2559.1997.2320843.x; Suh E, 1996, MOL CELL BIOL, V16, P619; Tamai Y, 1999, CANCER RES, V59, P2965; Wicking C, 1998, ONCOGENE, V17, P657, DOI 10.1038/sj.onc.1201971; Woodford-Richens KL, 2001, BRIT J CANCER, V84, P1314, DOI 10.1054/bjoc.2001.1800; Yagi OK, 1999, BRIT J CANCER, V79, P440, DOI 10.1038/sj.bjc.6690068	58	43	50	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR	2006	25	15					2264	2272		10.1038/sj.onc.1209247	http://dx.doi.org/10.1038/sj.onc.1209247			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	029RD	16314840				2022-12-25	WOS:000236581200013
J	White, PC; Shore, AM; Clement, M; McLaren, J; Soeiro, I; Lam, EWF; Brennan, P				White, PC; Shore, AM; Clement, M; McLaren, J; Soeiro, I; Lam, EWF; Brennan, P			Regulation of cyclin D2 and the cyclin D2 promoter by protein kinase A and CREB in lymphocytes	ONCOGENE			English	Article						cyclin D2; phosphatidylinositol 3-kinase; CREB; interelukin-2; Epstein-Barr virus	ANTIGEN RECEPTOR; B-LYMPHOCYTES; PHOSPHATIDYLINOSITOL 3-KINASE; GENE-EXPRESSION; TRANSGENIC MICE; CELL; PROLIFERATION; TRANSCRIPTION; ACTIVATION; COOPERATE	Lymphocyte proliferation is key to the regulation of the immune system. Cyclin D2 is the first cell cycle protein induced following stimulation through the T-cell receptor, the B-cell receptor or cytokines. The promoter of this cyclin integrates a diverse range of signals. Through investigating the regulation of this promoter by interleukin-2 and phosphatidylinositol 3-kinase, we have identified a role for the transcription factor CREB, cAMP response element-binding protein. Mutation of the CREB-binding site reduced cyclin D2 promoter activity 5-10-fold. CREB-1 is phosphorylated at serine 133, a critical site for activity, in both T cells and Epstein Barr virus immortalized B cells. The introduction of an S133A mutant of CREB-1 reduces IL-2 induction of cyclin D2 promoter activity, demonstrating a role for this phosphorylation site in promoter activity. Two inhibitors of protein kinase A reduce lymphocyte proliferation and CREB-1 phosphorylation. This study demonstrates that the cyclin D2 promoter is capable of being regulated by PI3K and CREB and identifies CREB-1 and protein kinase A as potential targets for altering lymphocyte proliferation.	Cardiff Univ, Cardiff CF14 4XX, Wales; Canc Res UK Labs, London, England; Hammersmith Hosp, Imperial Coll Sch Med, Sect Canc Cell Biol, London, England	Cardiff University; Cancer Research UK; Imperial College London	Brennan, P (corresponding author), Cardiff Univ, Henry Wellcome Res Bldg,Heath Pk, Cardiff CF14 4XX, Wales.	brennanp@cf.ac.uk	Brennan, Paul/ABB-9196-2021; Lam, Eric W-F/AAW-8566-2020; Brennan, Paul/B-9210-2009	Brennan, Paul/0000-0001-8792-0499; Lam, Eric W-F/0000-0003-1274-3576; Brennan, Paul/0000-0001-8792-0499; McLaren, James/0000-0002-7021-5934				AJCHENBAUM F, 1993, J BIOL CHEM, V268, P4113; Appleman LJ, 2000, J IMMUNOL, V164, P144, DOI 10.4049/jimmunol.164.1.144; Banerji L, 2001, ONCOGENE, V20, P7352, DOI 10.1038/sj.onc.1204951; Barton K, 1996, NATURE, V379, P81, DOI 10.1038/379081a0; BEADLING C, 1994, EMBO J, V13, P5605, DOI 10.1002/j.1460-2075.1994.tb06898.x; Belkowski SM, 1998, J IMMUNOL, V161, P659; Brennan P, 1997, IMMUNITY, V7, P679, DOI 10.1016/S1074-7613(00)80388-X; Brennan P, 1996, BIOCHEM SOC T, V24, pS3, DOI 10.1042/bst024003s; Brennan P, 2002, ONCOGENE, V21, P1263, DOI 10.1038/sj.onc.1205182; Breslin EM, 2005, BRIT J PHARMACOL, V144, P791, DOI 10.1038/sj.bjp.0706061; Brooks AR, 1996, J BIOL CHEM, V271, P9090, DOI 10.1074/jbc.271.15.9090; DELMER A, 1995, BLOOD, V85, P2870, DOI 10.1182/blood.V85.10.2870.bloodjournal85102870; FEUERSTEIN N, 1995, J BIOL CHEM, V270, P9454, DOI 10.1074/jbc.270.16.9454; FEUERSTEIN N, 1995, J IMMUNOL, V154, P68; Frissora F, 2003, EUR J IMMUNOL, V33, P907, DOI 10.1002/eji.200323657; Fruman DA, 2002, P NATL ACAD SCI USA, V99, P359, DOI 10.1073/pnas.012605099; HORI T, 1987, BLOOD, V70, P1069; Huang YP, 2001, ONCOGENE, V20, P1094, DOI 10.1038/sj.onc.1204198; Lam EWF, 2000, J BIOL CHEM, V275, P3479, DOI 10.1074/jbc.275.5.3479; Martino A, 2001, J IMMUNOL, V166, P1723, DOI 10.4049/jimmunol.166.3.1723; Mayr B, 2001, NAT REV MOL CELL BIO, V2, P599, DOI 10.1038/35085068; Mehl AM, 2001, J BIOL CHEM, V276, P984, DOI 10.1074/jbc.M003758200; Moriggl R, 1999, IMMUNITY, V11, P225, DOI 10.1016/S1074-7613(00)80097-7; PALMERO I, 1993, ONCOGENE, V8, P1049; Rudolph D, 1998, P NATL ACAD SCI USA, V95, P4481, DOI 10.1073/pnas.95.8.4481; SAMPLE J, 1990, J VIROL, V64, P1667, DOI 10.1128/JVI.64.4.1667-1674.1990; Schmidt M, 2002, MOL CELL BIOL, V22, P7842, DOI 10.1128/MCB.22.22.7842-7852.2002; Sherr CJ, 1996, SCIENCE, V274, P1672, DOI 10.1126/science.274.5293.1672; SINCLAIR AJ, 1994, EMBO J, V13, P3321, DOI 10.1002/j.1460-2075.1994.tb06634.x; Solvason N, 2000, INT IMMUNOL, V12, P631, DOI 10.1093/intimm/12.5.631; Spender LC, 2001, J VIROL, V75, P3537, DOI 10.1128/JVI.75.8.3537-3546.2001; Takano Y, 1999, J PATHOL, V189, P194; Teramoto N, 1999, INT J CANCER, V81, P543, DOI 10.1002/(SICI)1097-0215(19990517)81:4<543::AID-IJC7>3.3.CO;2-V; VLAHOS CJ, 1994, J BIOL CHEM, V269, P5241; Waltereit R, 2003, MOL NEUROBIOL, V27, P99, DOI 10.1385/MN:27:1:99; XIE HJ, 1995, J IMMUNOL, V154, P1717; Yu CT, 2001, J IMMUNOL, V166, P284, DOI 10.4049/jimmunol.166.1.284; Zhang CY, 2002, J BIOL CHEM, V277, P48359, DOI 10.1074/jbc.M209329200	38	40	43	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR	2006	25	15					2170	2180		10.1038/sj.onc.1209255	http://dx.doi.org/10.1038/sj.onc.1209255			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	029RD	16301994				2022-12-25	WOS:000236581200004
J	Mazzochi, C; Bubien, JK; Smith, PR; Benos, DJ				Mazzochi, C; Bubien, JK; Smith, PR; Benos, DJ			The carboxyl terminus of the alpha-subunit of the amiloride-sensitive epithelial sodium channel binds to F-actin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NA+ CHANNELS; APICAL MEMBRANE; ENAC SUBUNITS; ION-TRANSPORT; MDCK CELLS; EXPRESSION; LOCALIZATION; CYTOSKELETON; AQUAPORIN-2; SECRETION	The activity of the amiloride-sensitive epithelial sodium channel (ENaC) is modulated by F-actin. However, it is unknown if there is a direct interaction between alpha-ENaC and actin. We have investigated the hypothesis that the actin cytoskeleton directly binds to the carboxyl terminus of alpha-ENaC using a combination of confocal microscopy, co-immunoprecipitation, and protein binding studies. Confocal microscopy of Madin-Darby canine kidney cell monolayers stably transfected with wild type, rat isoforms of alpha-, beta-, and gamma-ENaC revealed co-localization of alpha-ENaC with the cortical F-actin cytoskeleton both at the apical membrane and within the subapical cytoplasm. F-actin was found to co-immunoprecipitate with alpha-ENaC from whole cell lysates of this cell line. Gel overlay assays demonstrated that F-actin specifically binds to the carboxyl terminus of alpha-ENaC. A direct interaction between F-actin and the COOH terminus of alpha-ENaC was further corroborated by F-actin co-sedimentation studies. This is the first study to report a direct and specific biochemical interaction between F-actin and ENaC.	Univ Alabama Birmingham, Dept Physiol & Biophys, Birmingham, AL 35294 USA; Univ Alabama Birmingham, Dept Cell Biol, Birmingham, AL 35294 USA	University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham	Benos, DJ (corresponding author), Univ Alabama Birmingham, Dept Physiol & Biophys, MCLM 704,1918 Univ Blvd, Birmingham, AL 35294 USA.	benos@physiology.uab.edu			NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R56DK037206, R01DK037206] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK37206] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		*AM BIOSC, 2005, GST GEN FUS SYST, P26; Berdiev BK, 2001, BIOPHYS J, V80, P2176, DOI 10.1016/S0006-3495(01)76190-5; Berdiev BK, 1996, J BIOL CHEM, V271, P17704, DOI 10.1074/jbc.271.30.17704; BERNSTEIN BW, 1989, NEURON, V3, P257, DOI 10.1016/0896-6273(89)90039-1; Berryman M, 2004, J BIOL CHEM, V279, P34794, DOI 10.1074/jbc.M402835200; Blazer-Yost BL, 2003, AM J PHYSIOL-CELL PH, V284, pC1645, DOI 10.1152/ajpcell.00372.2002; Blazer-Yost BL, 2001, AM J PHYSIOL-CELL PH, V281, pC624, DOI 10.1152/ajpcell.2001.281.2.C624; BlazerYost BL, 1997, AM J PHYSIOL-CELL PH, V272, pC761, DOI 10.1152/ajpcell.1997.272.3.C761; Brown D, 2003, AM J PHYSIOL-RENAL, V284, pF893, DOI 10.1152/ajprenal.00387.2002; Bubien JK, 2001, J BIOL CHEM, V276, P8557, DOI 10.1074/jbc.M008886200; CANTIELLO HF, 1991, AM J PHYSIOL, V261, pC882, DOI 10.1152/ajpcell.1991.261.5.C882; Chasan B, 2002, EUR BIOPHYS J BIOPHY, V30, P617, DOI 10.1007/s00249-001-0188-9; Copeland SJ, 2001, AM J PHYSIOL-CELL PH, V281, pC231, DOI 10.1152/ajpcell.2001.281.1.C231; de la Rosa DA, 2002, J GEN PHYSIOL, V119, P427, DOI 10.1085/jgp.20028559; DENHARTIGH JC, 1992, J CELL BIOL, V119, P349, DOI 10.1083/jcb.119.2.349; Denker SP, 2002, CURR OPIN CELL BIOL, V14, P214, DOI 10.1016/S0955-0674(02)00304-6; DING G, 1991, AM J PHYSIOL, V260, pC9, DOI 10.1152/ajpcell.1991.260.1.C9; Ehre C, 2005, AM J PHYSIOL-CELL PH, V288, pC46, DOI 10.1152/ajpcell.00397.2004; FECHHEIMER M, 1979, MOL IMMUNOL, V16, P881, DOI 10.1016/0161-5890(79)90086-5; Firsov D, 1996, P NATL ACAD SCI USA, V93, P15370, DOI 10.1073/pnas.93.26.15370; Hager H, 2001, AM J PHYSIOL-RENAL, V280, pF1093, DOI 10.1152/ajprenal.2001.280.6.F1093; Hitt AL, 2002, ANAL BIOCHEM, V310, P67, DOI 10.1016/S0003-2697(02)00280-4; Ishikawa T, 1998, J GEN PHYSIOL, V111, P825, DOI 10.1085/jgp.111.6.825; Ismailov II, 1997, AM J PHYSIOL-CELL PH, V272, pC1077, DOI 10.1152/ajpcell.1997.272.4.C1077; Jovov B, 1999, J BIOL CHEM, V274, P37845, DOI 10.1074/jbc.274.53.37845; Kanzaki M, 2001, J BIOL CHEM, V276, P42436, DOI 10.1074/jbc.M108297200; Khurana S, 2000, J MEMBRANE BIOL, V178, P73, DOI 10.1007/s002320010016; Loffing J, 2000, AM J PHYSIOL-RENAL, V278, pF530, DOI 10.1152/ajprenal.2000.278.4.F530; Loffing J, 2001, AM J PHYSIOL-RENAL, V280, pF675, DOI 10.1152/ajprenal.2001.280.4.F675; Loffing J, 2000, AM J PHYSIOL-RENAL, V279, pF252, DOI 10.1152/ajprenal.2000.279.2.F252; Morris RG, 2002, J GEN PHYSIOL, V120, P71, DOI 10.1085/jgp.20018547; Noda Y, 2004, BIOCHEM BIOPH RES CO, V322, P740, DOI 10.1016/j.bbrc.2004.07.195; PEARL M, 1983, AM J PHYSIOL, V245, pC28, DOI 10.1152/ajpcell.1983.245.1.C28; PRAT AG, 1993, AM J PHYSIOL, V265, pC224, DOI 10.1152/ajpcell.1993.265.1.C224; ROTIN D, 1994, EMBO J, V13, P4440, DOI 10.1002/j.1460-2075.1994.tb06766.x; Short DB, 1998, J BIOL CHEM, V273, P19797, DOI 10.1074/jbc.273.31.19797; SMITH PR, 1991, P NATL ACAD SCI USA, V88, P6971, DOI 10.1073/pnas.88.16.6971; Szaszi K, 2000, CELL PHYSIOL BIOCHEM, V10, P265, DOI 10.1159/000016358; Valentijn KM, 1999, J CELL SCI, V112, P81; VITALE ML, 1991, J CELL BIOL, V113, P1057, DOI 10.1083/jcb.113.5.1057; Weisz OA, 2000, J BIOL CHEM, V275, P39886, DOI 10.1074/jbc.M003822200	41	88	90	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 10	2006	281	10					6528	6538		10.1074/jbc.M509386200	http://dx.doi.org/10.1074/jbc.M509386200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	022BX	16356937	hybrid			2022-12-25	WOS:000236030800048
J	Bark-Jones, SJ; Webb, HM; West, MJ				Bark-Jones, SJ; Webb, HM; West, MJ			EBV EBNA 2 stimulates CDK9-dependent transcription and RNA polymerase II phosphorylation on serine 5	ONCOGENE			English	Article						CDK9; CTD; EBNA 2; phosphorylation; serine 5; serine 2	EPSTEIN-BARR-VIRUS; CARBOXYL-TERMINAL DOMAIN; DEPENDENT KINASE INHIBITOR; SIGNAL-BINDING-PROTEIN; LYMPHOCYTE GROWTH TRANSFORMATION; NUCLEAR-PROTEIN-2 ACIDIC DOMAIN; LATENT MEMBRANE-PROTEIN; HUMAN LEUKEMIA-CELLS; FACTOR P-TEFB; RBP-J-KAPPA	EBNA 2 is one of only. v e viral genes essential for the infection and immortalization of human B cells by the cancer-associated virus Epstein-Barr virus (EBV). EBNA 2 activates cellular and viral transcription and associates with components of the basal transcription apparatus and a number of coactivators. We provide the first evidence to show that the mechanism of transcriptional activation by EBNA 2 also involves phosphorylation of the C-terminal domain (CTD) of RNA polymerase II (pol II). We found that transcriptional activation by EBNA 2 was inhibited by a dominant-negative mutant of the pol II CTD kinase, CDK9, and by low concentrations of the CDK9 inhibitor 5, 6-dichloro-1-beta-D-ribofuranosylbenzimidazole. Moreover, using chromatin immunoprecipitation assays we demonstrated that EBNA 2 stimulates both pol II recruitment and pol II phosphorylation on serine 5 of the CTD in vivo. These results identify a new step in the transcription cycle that is subject to regulation by a key EBV-encoded transcription factor and highlight CDK9 inhibitors as potential anti-EBV agents.	Univ Sussex, Sch Life Sci, Dept Biochem, Brighton BN1 9QG, E Sussex, England	University of Sussex	West, MJ (corresponding author), Univ Sussex, Sch Life Sci, Dept Biochem, Brighton BN1 9QG, E Sussex, England.	m.j.west@sussex.ac.uk		West, Michelle/0000-0002-9497-9365	Wellcome Trust [064014] Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		ABBOT SD, 1990, J VIROL, V64, P2126, DOI 10.1128/JVI.64.5.2126-2134.1990; Alazard N, 2003, J VIROL, V77, P8166, DOI 10.1128/JVI.77.14.8166-8172.2003; ALFIERI C, 1991, VIROLOGY, V181, P595, DOI 10.1016/0042-6822(91)90893-G; ALLDAY MJ, 1989, J GEN VIROL, V70, P1755, DOI 10.1099/0022-1317-70-7-1755; Andersson Jan, 2000, Herpes, V7, P76; Chao SH, 2000, J BIOL CHEM, V275, P28345, DOI 10.1074/jbc.C000446200; Chao SH, 2001, J BIOL CHEM, V276, P31793, DOI 10.1074/jbc.M102306200; COHEN JI, 1991, J VIROL, V65, P5880, DOI 10.1128/JVI.65.11.5880-5885.1991; COHEN JI, 1989, P NATL ACAD SCI USA, V86, P9558, DOI 10.1073/pnas.86.23.9558; COHEN JI, 1992, P NATL ACAD SCI USA, V89, P8030, DOI 10.1073/pnas.89.17.8030; Decker RH, 2001, CELL DEATH DIFFER, V8, P715, DOI 10.1038/sj.cdd.4400868; Deng Z, 2003, J VIROL, V77, P11992, DOI 10.1128/JVI.77.22.11992-12001.2003; DUBOIS MF, 1994, J BIOL CHEM, V269, P13331; Eberhardy SR, 2002, J BIOL CHEM, V277, P40156, DOI 10.1074/jbc.M207441200; Gold MO, 1998, J VIROL, V72, P4448, DOI 10.1128/JVI.72.5.4448-4453.1998; Gold MO, 1996, NUCLEIC ACIDS RES, V24, P3771, DOI 10.1093/nar/24.19.3771; GROSSMAN SR, 1994, P NATL ACAD SCI USA, V91, P7568, DOI 10.1073/pnas.91.16.7568; HENKEL T, 1994, SCIENCE, V265, P92, DOI 10.1126/science.8016657; Herrmann CH, 1996, NUCLEIC ACIDS RES, V24, P501, DOI 10.1093/nar/24.3.501; Isel C, 1999, J MOL BIOL, V290, P929, DOI 10.1006/jmbi.1999.2933; JOHANNSEN E, 1995, J VIROL, V69, P253, DOI 10.1128/JVI.69.1.253-262.1995; KAYE KM, 1993, P NATL ACAD SCI USA, V90, P9150, DOI 10.1073/pnas.90.19.9150; KEMPKES B, 1995, EMBO J, V14, P88, DOI 10.1002/j.1460-2075.1995.tb06978.x; Kim YK, 2002, MOL CELL BIOL, V22, P4622, DOI 10.1128/MCB.22.13.4622-4637.2002; Komarnitsky P, 2000, GENE DEV, V14, P2452, DOI 10.1101/gad.824700; Lee DK, 2001, J BIOL CHEM, V276, P9978, DOI 10.1074/jbc.M002285200; Lee MA, 1999, J VIROL, V73, P2974, DOI 10.1128/JVI.73.4.2974-2982.1999; LING PD, 1993, P NATL ACAD SCI USA, V90, P9237, DOI 10.1073/pnas.90.20.9237; Litz J, 2003, CLIN CANCER RES, V9, P4586; Ma YH, 2003, MOL CANCER THER, V2, P73; MAKELA TP, 1994, NATURE, V371, P254, DOI 10.1038/371254a0; Marshall NF, 1996, J BIOL CHEM, V271, P27176, DOI 10.1074/jbc.271.43.27176; Nelson PJ, 2003, J ANTIMICROB CHEMOTH, V51, P921, DOI 10.1093/jac/dkg175; Palancade B, 2003, EUR J BIOCHEM, V270, P3859, DOI 10.1046/j.1432-1033.2003.03794.x; Patel V, 1998, J CLIN INVEST, V102, P1674, DOI 10.1172/JCI3661; Ping YH, 1999, J BIOL CHEM, V274, P7399, DOI 10.1074/jbc.274.11.7399; Ramanathan Y, 2001, J BIOL CHEM, V276, P10913, DOI 10.1074/jbc.M010975200; Sadaie AR, 2004, ANTIVIR RES, V61, P1, DOI 10.1016/j.antiviral.2003.09.004; Sedlacek HH, 2001, CRIT REV ONCOL HEMAT, V38, P139, DOI 10.1016/S1040-8428(00)00124-4; SJOBLOM A, 1995, J GEN VIROL, V76, P2679, DOI 10.1099/0022-1317-76-11-2679; SKARE J, 1985, J VIROL, V55, P286, DOI 10.1128/JVI.55.2.286-297.1985; Spilianakis C, 2003, EMBO J, V22, P5125, DOI 10.1093/emboj/cdg496; Swaminathan S, 1996, VIROLOGY, V217, P532, DOI 10.1006/viro.1996.0148; Tian YN, 2003, J BIOL CHEM, V278, P44041, DOI 10.1074/jbc.M306443200; TOMKINSON B, 1993, J VIROL, V67, P2014, DOI 10.1128/JVI.67.4.2014-2025.1993; TONG X, 1995, J VIROL, V69, P585, DOI 10.1128/JVI.69.1.585-588.1995; TONG X, 1995, MOL CELL BIOL, V15, P4735; TONG X, 1995, P NATL ACAD SCI USA, V92, P3259, DOI 10.1073/pnas.92.8.3259; TSANG SF, 1991, J VIROL, V65, P6765, DOI 10.1128/JVI.65.12.6765-6771.1991; Van Veldhuizen PJ, 2005, CANCER CHEMOTH PHARM, V56, P39, DOI 10.1007/s00280-004-0969-9; WALTZER L, 1994, EMBO J, V13, P5633, DOI 10.1002/j.1460-2075.1994.tb06901.x; WANG F, 1990, J VIROL, V64, P3407, DOI 10.1128/JVI.64.7.3407-3416.1990; Wang L, 2000, P NATL ACAD SCI USA, V97, P430, DOI 10.1073/pnas.97.1.430; Wendtner CM, 2004, SEMIN HEMATOL, V41, P224, DOI 10.1053/j.seminhematol.2004.05.004; West MJ, 2004, J VIROL, V78, P9431, DOI 10.1128/JVI.78.17.9431-9445.2004; West MJ, 1999, EMBO J, V18, P1378, DOI 10.1093/emboj/18.5.1378; WOISETSCHLAEGER M, 1991, P NATL ACAD SCI USA, V88, P3942, DOI 10.1073/pnas.88.9.3942; Wu DY, 1996, J VIROL, V70, P6020, DOI 10.1128/JVI.70.9.6020-6028.1996; Yu CR, 2002, CLIN CANCER RES, V8, P2976; Yue W, 2005, J VIROL, V79, P5880, DOI 10.1128/JVI.79.9.5880-5885.2005; Yue W, 2004, J VIROL, V78, P3542, DOI 10.1128/JVI.78.7.3542-3552.2004; Zhou MS, 2000, MOL CELL BIOL, V20, P5077, DOI 10.1128/MCB.20.14.5077-5086.2000; Zhu YR, 1997, GENE DEV, V11, P2622, DOI 10.1101/gad.11.20.2622; ZIMBERSTROBL U, 1994, EMBO J, V13, P4973, DOI 10.1002/j.1460-2075.1994.tb06824.x	64	48	69	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR	2006	25	12					1775	1785		10.1038/sj.onc.1209205	http://dx.doi.org/10.1038/sj.onc.1209205			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	021VJ	16314842				2022-12-25	WOS:000236013700009
J	Sheldon, AL; Gonzalez, MI; Robinson, MB				Sheldon, AL; Gonzalez, MI; Robinson, MB			A carboxyl-terminal determinant of the neuronal glutamate transporter, EAAC1, is required for platelet-derived growth factor-dependent trafficking	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-SURFACE EXPRESSION; PROTEIN-KINASE-C; PERINUCLEAR STORAGE COMPARTMENT; TRAUMATIC BRAIN-INJURY; GABA SYNTHESIS; AMINO; ACTIVATION; SUBTYPE; GLUT4; EXCITOTOXICITY	The neuronal glutamate transporter, EAAC1 ( excitatory amino acid carrier 1), undergoes rapid regulation after treatment with platelet-derived growth factor (PDGF) or phorbol ester in C6 glioma cells and neurons. A large intracellular pool of EAAC1 exists, from which transporters are redistributed to the cell surface in response to these signals. Here we show that PDGF had no effect on subcellular localization of the glial glutamate transporter, GLT-1, after transfection into C6 glioma cells. Chimeras consisting of domains from EAAC1 or GLT-1 were used to investigate structural motifs involved in PDGF-dependent redistribution of EAAC1. PDGF did not induce trafficking of an EAAC1 chimera containing the carboxyl- terminal domain of GLT-1; however, it did induce trafficking of a GLT-1 chimera containing the carboxyl- terminal domain of EAAC1. A truncated mutant of EAAC1 lacking 10 carboxyl-terminal amino acids was responsive to PDGF, whereas a mutant lacking 20 residues was not. Alanine substitution mutagenesis in this region revealed a short motif, (YVN504)-Y-502, necessary for regulated trafficking. This motif was also involved in protein kinase C-dependent trafficking, as mutant transporters exhibited an attenuated response to phorbol ester. Interestingly, the presence of YVN in the homologous region of a nonresponsive chimera was not sufficient to confer regulated trafficking; however, the presence of a 12-amino acid motif starting at this Tyr residue was sufficient to confer responsiveness to PDGF. These studies identify a novel motif within the carboxyl terminus of EAAC1 which is required for regulated trafficking. The possibility that this motif targets EAAC1 to an intracellular, "regulated pool" is discussed.	Univ Penn, Childrens Hosp Philadelphia, Dept Pediat, Philadelphia, PA 19104 USA; Univ Penn, Childrens Hosp Philadelphia, Dept Pharmacol, Philadelphia, PA 19104 USA; Univ Penn, Childrens Hosp Philadelphia, Dept Neurosci, Philadelphia, PA 19104 USA	University of Pennsylvania; Childrens Hospital of Philadelphia; University of Pennsylvania; Childrens Hospital of Philadelphia; University of Pennsylvania; Childrens Hospital of Philadelphia	Robinson, MB (corresponding author), Dept Pediat, 502N Abramson Pediat Res Bldg,3615 Civ Ctr Blvd, Philadelphia, PA 19104 USA.	Robinson@pharm.med.upenn.edu			NICHD NIH HHS [P30-HD29679] Funding Source: Medline; NIGMS NIH HHS [5-T32-GM07517] Funding Source: Medline; NIMH NIH HHS [1-F31-MH1071008-01] Funding Source: Medline; NINDS NIH HHS [NS39011, NS29868] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R13HD029679] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS039011, R01NS029868] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BECKMANN ML, 2005, NEUROPHARMACOL C, V15; Cheng CL, 2002, J NEUROSCI, V22, P10643; CHOI DW, 1992, J NEUROBIOL, V23, P1261, DOI 10.1002/neu.480230915; Conti F, 1998, CEREB CORTEX, V8, P108, DOI 10.1093/cercor/8.2.108; Danbolt NC, 2001, PROG NEUROBIOL, V65, P1, DOI 10.1016/S0301-0082(00)00067-8; Davis KE, 1998, J NEUROSCI, V18, P2475; Diamond JS, 2001, J NEUROSCI, V21, P8328, DOI 10.1523/JNEUROSCI.21-21-08328.2001; Dowd LA, 1996, J NEUROCHEM, V67, P508, DOI 10.1046/j.1471-4159.1996.67020508.x; Fournier KM, 2004, J BIOL CHEM, V279, P34505, DOI 10.1074/jbc.M404032200; Gonzalez MI, 2002, MOL PHARMACOL, V62, P901, DOI 10.1124/mol.62.4.901; Haugeto O, 1996, J BIOL CHEM, V271, P27715, DOI 10.1074/jbc.271.44.27715; He Y, 2000, J COMP NEUROL, V418, P255; Kalandadze A, 2002, J BIOL CHEM, V277, P45741, DOI 10.1074/jbc.M203771200; Levenson J, 2002, NAT NEUROSCI, V5, P155, DOI 10.1038/nn791; Martinez-Arca S, 2000, J CELL SCI, V113, P1705; Mathews GC, 2003, J NEUROSCI, V23, P2040; Melvin DR, 1999, BIOCHEMISTRY-US, V38, P1456, DOI 10.1021/bi980988y; MONAGHAN DT, 1989, ANNU REV PHARMACOL, V29, P365, DOI 10.1146/annurev.pa.29.040189.002053; Nilsson P, 1996, J CEREBR BLOOD F MET, V16, P262, DOI 10.1097/00004647-199603000-00011; Palacios S, 2001, J BIOL CHEM, V276, P3371, DOI 10.1074/jbc.M006739200; PALMER AM, 1993, J NEUROCHEM, V61, P2015, DOI 10.1111/j.1471-4159.1993.tb07437.x; Robinson MB, 1998, NEUROCHEM INT, V33, P479, DOI 10.1016/S0197-0186(98)00055-2; ROTHSTEIN JD, 1994, NEURON, V13, P713, DOI 10.1016/0896-6273(94)90038-8; Rothstein JD, 1996, NEURON, V16, P675, DOI 10.1016/S0896-6273(00)80086-0; Sepkuty JP, 2002, J NEUROSCI, V22, P6372; Shewan AM, 2000, BIOCHEM J, V350, P99, DOI 10.1042/0264-6021:3500099; Sims KD, 1999, CRIT REV NEUROBIOL, V13, P169, DOI 10.1615/CritRevNeurobiol.v13.i2.30; Sims KD, 2000, J BIOL CHEM, V275, P5228, DOI 10.1074/jbc.275.7.5228; Tsvetkov E, 2004, NEURON, V41, P139, DOI 10.1016/S0896-6273(03)00800-6; Watson RT, 2004, ENDOCR REV, V25, P177, DOI 10.1210/er.2003-0011; Whitworth TL, 2001, J BIOL CHEM, V276, P42932, DOI 10.1074/jbc.M107638200; Yernool D, 2004, NATURE, V431, P811, DOI 10.1038/nature03018	32	38	39	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 24	2006	281	8					4876	4886		10.1074/jbc.M504983200	http://dx.doi.org/10.1074/jbc.M504983200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	013RF	16368696	hybrid			2022-12-25	WOS:000235426200038
J	Daus, ML; Landmesser, H; Schlosser, A; Muller, P; Herrmann, A; Schneider, E				Daus, ML; Landmesser, H; Schlosser, A; Muller, P; Herrmann, A; Schneider, E			ATP induces conformational changes of periplasmic loop regions of the maltose ATP-binding cassette transporter	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYTOPLASMIC MEMBRANE-PROTEIN; LARGE-SCALE PURIFICATION; RETRACTED ARTICLE. SEE; HUMAN P-GLYCOPROTEIN; ABC TRANSPORTER; ESCHERICHIA-COLI; SALMONELLA-TYPHIMURIUM; SUBUNIT INTERACTIONS; CRYSTAL-STRUCTURE; TRANSITION-STATE	We have studied cofactor-induced conformational changes of the maltose ATP-binding cassette transporter by employing limited proteolysis in detergent solution. The transport complex consists of one copy each of the transmembrane subunits, MalF and MalG, and of two copies of the nucleotide-binding subunit, MalK. Transport activity further requires the periplasmic maltose-binding protein, MalE. Binding of ATP to the MalK subunits increased the susceptibility of two tryptic cleavage sites in the periplasmic loops P2 of MalF and P1 of MalG, respectively. Lys(262) of MalF and Arg(73) of MalG were identified as probable cleavage sites, resulting in two N-terminal peptide fragments of 29 and 8 kDa, respectively. Trapping the complex in the transition state by vanadate further stabilized the fragments. In contrast, the tryptic cleavage profile of MalK remained largely unchanged. ATP-induced conformational changes of MalF-P2 and MalG-P1 were supported by fluorescence spectroscopy of complex variants labeled with 2-(4'-maleimidoanilino)naphthalene-6-sulfonic acid. Limited proteolysis was subsequently used as a tool to study the consequences of mutations on the transport cycle. The results suggest that complex variants exhibiting a binding protein-independent phenotype (MalF500) or containing a mutation that affects the "catalytic carboxylate" (MalKE159Q) reside in a transition state-like conformation. A similar conclusion was drawn for a complex containing a replacement of MalKQ140 in the signature sequence by leucine, whereas substitution of lysine for Gln(140) appears to lock the transport complex in the ground state. Together, our data provide the first evidence for conformational changes of the transmembrane subunits of an ATP-binding cassette import system upon binding of ATP.	Humboldt Univ, Inst Biol Bakterienphysiol, D-10115 Berlin, Germany; Charite Univ Med Berlin, Inst Med Immunol, D-10115 Berlin, Germany; Humboldt Univ, Inst Biol Biophys, D-10115 Berlin, Germany	Humboldt University of Berlin; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Humboldt University of Berlin	Schneider, E (corresponding author), Humboldt Univ, Inst Biol Bakterienphysiol, Chausseestr 117, D-10115 Berlin, Germany.	erwin.schneider@rz.hu-berlin.de						Austermuhle MI, 2004, J BIOL CHEM, V279, P28243, DOI 10.1074/jbc.M403508200; Chang G, 2001, SCIENCE, V293, P1793, DOI 10.1126/science.293.5536.1793; Chang G, 2003, J MOL BIOL, V330, P419, DOI 10.1016/S0022-2836(03)00587-4; Chen J, 2003, MOL CELL, V12, P651, DOI 10.1016/j.molcel.2003.08.004; Chen J, 2001, P NATL ACAD SCI USA, V98, P1525, DOI 10.1073/pnas.041542498; COVITZ KMY, 1994, EMBO J, V13, P1752, DOI 10.1002/j.1460-2075.1994.tb06439.x; DASSA E, 1993, MOL MICROBIOL, V7, P39, DOI 10.1111/j.1365-2958.1993.tb01095.x; DASSA E, 1993, MOL MICROBIOL, V7, P29, DOI 10.1111/j.1365-2958.1993.tb01094.x; Dassa E., 2003, ABC PROTEINS BACTERI, P3; Davidson AL, 2004, ANNU REV BIOCHEM, V73, P241, DOI 10.1146/annurev.biochem.73.011303.073626; DAVIDSON AL, 1991, J BIOL CHEM, V266, P8946; DAVIDSON AL, 1992, P NATL ACAD SCI USA, V89, P2360, DOI 10.1073/pnas.89.6.2360; Ehrmann M, 1998, MOL MICROBIOL, V29, P685, DOI 10.1046/j.1365-2958.1998.00915.x; Fetsch EE, 2002, P NATL ACAD SCI USA, V99, P9685, DOI 10.1073/pnas.152204499; FROSHAUER S, 1988, J MOL BIOL, V200, P501, DOI 10.1016/0022-2836(88)90539-6; HOLLAND EB, 2003, ABC PROTEINS BACTERI; Hopfner KP, 2000, CELL, V101, P789, DOI 10.1016/S0092-8674(00)80890-9; Horlacher R, 1998, J BACTERIOL, V180, P680, DOI 10.1128/JB.180.3.680-689.1998; Hulsmann A, 2000, J BACTERIOL, V182, P6292, DOI 10.1128/JB.182.22.6292-6301.2000; Hung LW, 1998, NATURE, V396, P703, DOI 10.1038/25393; Hunke S, 1999, FEBS LETT, V448, P131, DOI 10.1016/S0014-5793(99)00356-7; Hunke S, 2000, J BIOL CHEM, V275, P15526, DOI 10.1074/jbc.275.20.15526; Hunke S, 2000, J BACTERIOL, V182, P1432, DOI 10.1128/JB.182.5.1432-1436.2000; HUNKE S, 1995, BIOCHEM BIOPH RES CO, V216, P589, DOI 10.1006/bbrc.1995.2663; Janas E, 2003, J BIOL CHEM, V278, P26862, DOI 10.1074/jbc.M301227200; Jones PM, 2004, CELL MOL LIFE SCI, V61, P682, DOI 10.1007/s00018-003-3336-9; Julien M, 2000, BIOCHEMISTRY-US, V39, P4559, DOI 10.1021/bi992744z; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Landmesser H, 2002, BBA-BIOMEMBRANES, V1565, P64, DOI 10.1016/S0005-2736(02)00506-0; Locher KP, 2002, SCIENCE, V296, P1091, DOI 10.1126/science.1071142; Loo TW, 2003, J BIOL CHEM, V278, P1575, DOI 10.1074/jbc.M211307200; Loo TW, 2002, J BIOL CHEM, V277, P41303, DOI 10.1074/jbc.C200484200; Mannering DE, 2001, J BIOL CHEM, V276, P12362, DOI 10.1074/jbc.M011686200; MARTINEZ E, 1988, GENE, V68, P159, DOI 10.1016/0378-1119(88)90608-7; Moody JE, 2002, J BIOL CHEM, V277, P21111, DOI 10.1074/jbc.C200228200; Mourez M, 1997, MOL MICROBIOL, V26, P821, DOI 10.1046/j.1365-2958.1997.6271992.x; Mourez M, 1998, MOL MICROBIOL, V30, P353, DOI 10.1046/j.1365-2958.1998.01070.x; Mourez M, 1997, EMBO J, V16, P3066, DOI 10.1093/emboj/16.11.3066; Nelson BD, 1998, J BACTERIOL, V180, P2507, DOI 10.1128/JB.180.9.2507-2514.1998; Nikaido K, 1997, J BIOL CHEM, V272, P27745, DOI 10.1074/jbc.272.44.27745; Reyes CL, 2005, SCIENCE, V308, P1028, DOI 10.1126/science.1107733; Scheffel F, 2005, FEBS LETT, V579, P2953, DOI 10.1016/j.febslet.2005.04.017; Schmees G, 1999, EUR J BIOCHEM, V266, P420, DOI 10.1046/j.1432-1327.1999.00871.x; Schmitt L, 2002, CURR OPIN STRUC BIOL, V12, P754, DOI 10.1016/S0959-440X(02)00399-8; Schneider E, 2001, RES MICROBIOL, V152, P303, DOI 10.1016/S0923-2508(01)01201-3; SCHNEIDER E, 1994, J BIOL CHEM, V269, P20456; Schneider E, 1998, FEMS MICROBIOL REV, V22, P1; SCHNEIDER E, 2003, ABC PROTEINS BACTERI, P157; Sharma S, 2000, J BACTERIOL, V182, P6570, DOI 10.1128/JB.182.23.6570-6576.2000; Sharom FJ., 2003, ABC PROTEINS BACTERI, P107; Smith PC, 2002, MOL CELL, V10, P139, DOI 10.1016/S1097-2765(02)00576-2; Steinke A, 2001, J BACTERIOL, V183, P375, DOI 10.1128/JB.183.1.375-381.2001; Tapia MI, 1999, J BACTERIOL, V181, P2267, DOI 10.1128/JB.181.7.2267-2272.1999; TREPTOW NA, 1985, J BACTERIOL, V163, P654, DOI 10.1128/JB.163.2.654-660.1985; Urbatsch IL, 2000, BIOCHEMISTRY-US, V39, P14138, DOI 10.1021/bi001128w; WALTER C, 1992, FEBS LETT, V303, P41, DOI 10.1016/0014-5793(92)80473-T; WALTER C, 1992, J BIOL CHEM, V267, P8863; Wang GC, 1997, BIOCHEM J, V328, P897, DOI 10.1042/bj3280897; Yuan YR, 2001, J BIOL CHEM, V276, P32313, DOI 10.1074/jbc.M100758200	59	40	41	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 17	2006	281	7					3856	3865		10.1074/jbc.M511953200	http://dx.doi.org/10.1074/jbc.M511953200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	011NN	16352608	hybrid			2022-12-25	WOS:000235275300013
J	Mitchell, MS; Tozser, J; Princler, G; Lloyd, PA; Auth, A; Derse, D				Mitchell, MS; Tozser, J; Princler, G; Lloyd, PA; Auth, A; Derse, D			Synthesis, processing, and composition of the virion-associated HTLV-1 reverse transcriptase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL LEUKEMIA-VIRUS; MAMMARY-TUMOR VIRUS; COMPLETE NUCLEOTIDE-SEQUENCE; AQUATICUS DNA-POLYMERASE; PFIZER MONKEY VIRUS; POL-GENE-PRODUCTS; SUBSTRATE-SPECIFICITY; CLEAVAGE SITE; MESSENGER-RNA; TYPE-1	It is not known whether the low infectivity and low virion-associated polymerase activity of human T-cell lymphotropic virus type-1 (HTLV-1) are due to the quantity or quality of the reverse transcriptase (RT), because the protein has not yet been fully characterized. We have developed anti-RT antibodies and constructed HTLV-1 expression plasmids that express truncated or hemagglutinin-tagged Pol polyproteins to examine the maturation and composition of HTLV-1 RT. We detected virion-associated proteins corresponding to RT-integrase (IN) (pr98) and RT (p62) as well as smaller proteins containing the polymerase (p49) or RNase H domains. We have identified the amino acid sequences in the Pol polyprotein that are cleaved by HTLV-1 protease to yield RT and IN. We have also identified the cleavage sites within RT that give rise to the p49 polymerase fragment. Immunoprecipitation of an epitope-tagged p62 subunit coprecipitated p49, indicating that the HTLV-1 RT complex can exist as a p62/p49 heterodimer analogous to the RT of HIV-1 (p66/p51).	NCI, HIV Drug Resistance Program, Frederick, MD 21702 USA; Univ Debrecen, Dept Biochem, H-4012 Debrecen, Hungary; SAIC Frederick, Basic Res Program, Frederick, MD 21702 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); University of Debrecen; Science Applications International Corporation (SAIC); SAIC-Frederick	Derse, D (corresponding author), NCI, HIV Drug Resistance Program, POB B,Bldg 535-134, Frederick, MD 21702 USA.	derse@ncifcrf.gov	Tozser, Jozsef/A-7840-2008	Tozser, Jozsef/0000-0003-0274-0056; Tozser, Jozsef/0000-0001-5076-8729	NATIONAL CANCER INSTITUTE [ZIABC010003, Z01BC010003] Funding Source: NIH RePORTER	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Abram ME, 2005, J VIROL, V79, P11952, DOI 10.1128/JVI.79.18.11952-11961.2005; Agbuya PG, 2001, ARCH BIOCHEM BIOPHYS, V392, P93, DOI 10.1006/abbi.2001.2432; BARBER AM, 1990, AIDS RES HUM RETROV, V6, P1061, DOI 10.1089/aid.1990.6.1061; Bukovsky A, 1996, J VIROL, V70, P6820, DOI 10.1128/JVI.70.10.6820-6825.1996; Das D, 2004, STRUCTURE, V12, P819, DOI 10.1016/j.str.2004.02.032; Derse D, 2001, J VIROL, V75, P8461, DOI 10.1128/JVI.75.18.8461-8468.2001; DICKSON C, 1979, CELL, V17, P1003, DOI 10.1016/0092-8674(79)90339-8; DICKSON C, 1983, CURR TOP MICROBIOL, V106, P1; Entin-Meer M, 2003, VIROLOGY, V310, P157, DOI 10.1016/S0042-6822(03)00113-2; Heidecker G, 2002, J VIROL, V76, P13101, DOI 10.1128/JVI.76.24.13101-13105.2002; HOSTOMSKY Z, 1992, J VIROL, V66, P3179, DOI 10.1128/JVI.66.5.3179-3182.1992; HRUSKOVAHEIDINGSFELDOVA O, 1995, J BIOL CHEM, V270, P15053, DOI 10.1074/jbc.270.25.15053; JACKS T, 1987, P NATL ACAD SCI USA, V84, P4298, DOI 10.1073/pnas.84.12.4298; JACKS T, 1985, SCIENCE, V230, P1237, DOI 10.1126/science.2416054; JACKS T, 1988, NATURE, V331, P280, DOI 10.1038/331280a0; JOHNSON MS, 1986, P NATL ACAD SCI USA, V83, P7648, DOI 10.1073/pnas.83.20.7648; JONES MD, 1989, NUCLEIC ACIDS RES, V17, P8387, DOI 10.1093/nar/17.20.8387; JUPP RA, 1991, FEBS LETT, V283, P180, DOI 10.1016/0014-5793(91)80583-O; Kadas J, 2004, J BIOL CHEM, V279, P27148, DOI 10.1074/jbc.M401868200; LEDERER H, 1992, EMBO J, V11, P1131, DOI 10.1002/j.1460-2075.1992.tb05153.x; LEGRICE SFJ, 1991, EMBO J, V10, P3905, DOI 10.1002/j.1460-2075.1991.tb04960.x; Louis JM, 1999, J BIOL CHEM, V274, P6660, DOI 10.1074/jbc.274.10.6660; MADOR N, 1989, J VIROL, V63, P2400, DOI 10.1128/JVI.63.5.2400-2404.1989; Mariani VL, 2003, BIOCHEM BIOPH RES CO, V300, P268, DOI 10.1016/S0006-291X(02)02848-6; MOORE R, 1987, J VIROL, V61, P480, DOI 10.1128/JVI.61.2.480-490.1987; NAM SH, 1993, J VIROL, V67, P196, DOI 10.1128/JVI.67.1.196-203.1993; NAM SH, 1988, J VIROL, V62, P3718, DOI 10.1128/JVI.62.10.3718-3728.1988; Navarro JM, 2001, VIROLOGY, V290, P300, DOI 10.1006/viro.2001.1188; Owen SM, 1998, J VIROL, V72, P5279, DOI 10.1128/JVI.72.6.5279-5284.1998; POWER MD, 1986, SCIENCE, V231, P1567, DOI 10.1126/science.3006247; Princler GL, 2003, VIROLOGY, V317, P136, DOI 10.1016/j.virol.2003.09.010; Quillent C, 1996, VIROLOGY, V219, P29, DOI 10.1006/viro.1996.0219; RHO HM, 1981, VIROLOGY, V112, P355, DOI 10.1016/0042-6822(81)90642-5; RICE NR, 1985, VIROLOGY, V142, P357, DOI 10.1016/0042-6822(85)90344-7; RODGERS DW, 1995, P NATL ACAD SCI USA, V92, P1222, DOI 10.1073/pnas.92.4.1222; ROTH MJ, 1985, J BIOL CHEM, V260, P9326; SAGATA N, 1985, P NATL ACAD SCI USA, V82, P677, DOI 10.1073/pnas.82.3.677; SCHECHTER I, 1967, BIOCHEM BIOPH RES CO, V27, P157, DOI 10.1016/S0006-291X(67)80055-X; SEIKI M, 1983, P NATL ACAD SCI-BIOL, V80, P3618, DOI 10.1073/pnas.80.12.3618; SHAFFER AL, 1990, ANAL BIOCHEM, V190, P292, DOI 10.1016/0003-2697(90)90196-G; SONIGO P, 1986, CELL, V45, P375, DOI 10.1016/0092-8674(86)90323-5; Telesnitsky A., 1997, P121; TOZSER J, 1993, BIOCHEMISTRY-US, V32, P3347, DOI 10.1021/bi00064a018; Tozser J, 2000, EUR J BIOCHEM, V267, P6287, DOI 10.1046/j.1432-1327.2000.01714.x; Trentin B, 1998, J VIROL, V72, P6504, DOI 10.1128/JVI.72.8.6504-6510.1998; Werner S, 2000, J VIROL, V74, P3245, DOI 10.1128/JVI.74.7.3245-3252.2000; Wlodawer A, 2000, BBA-PROTEIN STRUCT M, V1477, P16, DOI 10.1016/S0167-4838(99)00267-8	47	10	11	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 17	2006	281	7					3964	3971		10.1074/jbc.M507660200	http://dx.doi.org/10.1074/jbc.M507660200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	011NN	16368688	hybrid			2022-12-25	WOS:000235275300024
J	Sun, MJ; Finnemann, SC; Febbraio, M; Shan, L; Annangudi, SP; Podrez, EA; Hoppe, G; Darrow, R; Organisciak, DT; Salomon, RG; Silverstein, RL; Hazen, SL				Sun, MJ; Finnemann, SC; Febbraio, M; Shan, L; Annangudi, SP; Podrez, EA; Hoppe, G; Darrow, R; Organisciak, DT; Salomon, RG; Silverstein, RL; Hazen, SL			Light-induced oxidation of photoreceptor outer segment phospholipids generates ligands for CD36-mediated phagocytosis by retinal pigment epithelium - A potential mechanism for modulating outer segment phagocytosis under oxidant stress conditons	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SCAVENGER RECEPTOR CD36; NITRIC-OXIDE; RCS RAT; ALPHA-V-BETA-5 INTEGRIN; OXIDIZED PHOSPHOLIPIDS; MACULAR DEGENERATION; RPE CELLS; IN-VITRO; DYSTROPHY; BINDING	Clearance by the retinal pigment epithelium (RPE) of shed photoreceptor outer segments (OSs), a tissue with one of the highest turnover rates in the body, is critical to the maintenance and normal function of the retina. We hypothesized that there is a potential role for photo-oxidation in OS uptake by RPE via scavenger receptor-mediated recognition of structurally defined lipid peroxidation products. We now demonstrate that specific structurally defined oxidized species derived from arachidonyl, linoleoyl, and docosahexanoyl phosphatidylcholine may serve as endogenous ligands on OSs for uptake by RPE via the scavenger receptor CD36. Mass spectrometry studies of retinal lipids recovered from dark-adapted rats following physiological light exposure demonstrate in vivo formation of specific oxidized phosphatidylcholine molecular species possessing a CD36 recognition motif, an oxidatively truncated sn-2 acyl group with a terminal gamma-hydroxy(or oxo)-alpha,beta-unsaturated carbonyl. Cellular studies using RPE isolated from wild-type versus CD36 null mice suggest that CD36 plays a role in engulfment, but not initial binding, of OSs via these oxidized phospholipids. Parallel increases in OS protein-bound nitrotyrosine, a post-translational modification by nitric oxide (NO)-derived oxidants, were also observed, suggesting a possible role for light-induced generation of NO-derived oxidants in the initiation of OS lipid peroxidation. Collectively, these studies suggest that intense light exposure promotes "oxidative tagging" of photoreceptor outer segments with structurally defined choline glycerophospholipids that may serve as a physiological signal for CD36-mediated phagocytosis under oxidant stress conditions.	Cleveland Clin Fdn, Ctr Cardiovas Diagnost & Prevent, Cleveland, OH 44195 USA; Case Western Reserve Univ, Dept Chem, Cleveland, OH 44106 USA; Cleveland Clin Fdn, Dept Cell Biol, Cleveland, OH 44195 USA; Cleveland Clin Fdn, Dept Cardiovasc Med, Cleveland, OH 44195 USA; Cornell Univ, Weill Med Coll, Dyson Vis Res Inst, Dept Ophthalmol,Dept Cell & Dev Biol, New York, NY 10021 USA; Cornell Univ, Weill Med Coll, Dept Phys & Biophys, New York, NY 10021 USA; Cleveland Clin Fdn, Cole Eye Inst, Cleveland, OH 44195 USA; Wright State Univ, Sch Med, Dept Biochem & Mol Biol, Dayton, OH 45401 USA	Cleveland Clinic Foundation; Case Western Reserve University; Cleveland Clinic Foundation; Cleveland Clinic Foundation; Cornell University; Dyson; Cornell University; Cleveland Clinic Foundation; University System of Ohio; Wright State University Dayton	Hazen, SL (corresponding author), Cleveland Clin Fdn, Ctr Cardiovas Diagnost & Prevent, 9500 Euclid Ave,NE-10, Cleveland, OH 44195 USA.	hazens@ccf.org	Annangudi, Suresh/AAD-6408-2020; Hazen, Stanley L/ABD-5845-2021; Salomon, Robert G/C-3463-2008	Salomon, Robert/0000-0001-9456-3557	NCRR NIH HHS [M01 RR018390] Funding Source: Medline; NEI NIH HHS [EY01959, R01 EY001959, EY13295, EY10967, R01 EY013295] Funding Source: Medline; NHLBI NIH HHS [HL46403, R01 HL061878, P01 HL046403, R01 HL070621, HL70621, P01 HL076491, P50 HL077107, HL61878, P01 HL77107] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR018390] Funding Source: NIH RePORTER; NATIONAL EYE INSTITUTE [R01EY001959, R01EY010967, R01EY013295] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL070621, P01HL046403, R01HL061878, P50HL077107, P01HL076491] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BECKMAN JS, 1990, P NATL ACAD SCI USA, V87, P1620, DOI 10.1073/pnas.87.4.1620; Benssasson R.V., 1993, EXCITED STATES FREE, P128; BLANKS JC, 1992, INVEST OPHTH VIS SCI, V33, P2814; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; BOYLE D, 1991, INVEST OPHTH VIS SCI, V32, P1464; CHAITIN MH, 1983, INVEST OPHTH VIS SCI, V24, P812; Daviet L, 1997, THROMB HAEMOSTASIS, V78, P65; DELMELLE M, 1975, EXP EYE RES, V21, P369, DOI 10.1016/0014-4835(75)90047-0; Deng YH, 1998, J ORG CHEM, V63, P7789, DOI 10.1021/jo980861e; Dillon J, 1996, PHOTOCHEM PHOTOBIOL, V63, P680, DOI 10.1111/j.1751-1097.1996.tb05673.x; Donovan M, 2001, J BIOL CHEM, V276, P23000, DOI 10.1074/jbc.M005359200; EDWARDS RB, 1977, SCIENCE, V197, P1001, DOI 10.1126/science.560718; Febbraio M, 1999, J BIOL CHEM, V274, P19055, DOI 10.1074/jbc.274.27.19055; Febbraio M, 2001, J CLIN INVEST, V108, P785, DOI 10.1172/JCI200114006; Finneman SC, 2001, J EXP MED, V194, P1289, DOI 10.1084/jem.194.9.1289; Finnemann SC, 1997, P NATL ACAD SCI USA, V94, P12932, DOI 10.1073/pnas.94.24.12932; Finnemann SC, 2003, EMBO J, V22, P4143, DOI 10.1093/emboj/cdg416; FLIESLER SJ, 1983, PROG LIPID RES, V22, P79; GAILLARD ER, 1995, PHOTOCHEM PHOTOBIOL, V61, P448, DOI 10.1111/j.1751-1097.1995.tb02343.x; Gal A, 2000, NAT GENET, V26, P270, DOI 10.1038/81555; GOUREAU O, 1993, NEUROREPORT, V5, P233, DOI 10.1097/00001756-199312000-00012; Grimm C, 2000, NAT GENET, V25, P63, DOI 10.1038/75614; Gu XR, 2003, J BIOL CHEM, V278, P42027, DOI 10.1074/jbc.M305460200; Gu XR, 2003, J ORG CHEM, V68, P3749, DOI 10.1021/jo026721t; HALL MO, 1987, EXP EYE RES, V45, P907, DOI 10.1016/S0014-4835(87)80105-7; Hall MO, 2002, EXP EYE RES, V75, P391, DOI 10.1006/exer.2002.2030; Hall MO, 2001, EXP EYE RES, V73, P509, DOI 10.1006/exer.2001.1062; ISCHIROPOULOS H, 1992, ARCH BIOCHEM BIOPHYS, V298, P431, DOI 10.1016/0003-9861(92)90431-U; Jimenez B, 2000, NAT MED, V6, P41, DOI 10.1038/71517; LAVAIL MM, 1976, SCIENCE, V194, P1071, DOI 10.1126/science.982063; LI S, 1995, ARCH OPHTHALMOL-CHIC, V113, P521, DOI 10.1001/archopht.1995.01100040143041; Miyagi M, 2002, MOL CELL PROTEOMICS, V1, P293, DOI 10.1074/mcp.M100034-MCP200; MULLEN RJ, 1976, SCIENCE, V192, P799, DOI 10.1126/science.1265483; NABI IR, 1993, J CELL SCI, V104, P37; Nandrot EE, 2004, J EXP MED, V200, P1539, DOI 10.1084/jem.20041447; Nicholls SJ, 2005, METHOD ENZYMOL, V396, P245, DOI 10.1016/S0076-6879(05)96022-9; NOZAKI S, 1995, J CLIN INVEST, V96, P1859, DOI 10.1172/JCI118231; ORGANISCIAK DT, 1985, INVEST OPHTH VIS SCI, V26, P1580; ORGANISCIAK DT, 1994, PROG RETIN EYE RES, V13, P1, DOI 10.1016/1350-9462(94)90003-5; Organisciak DT, 2000, INVEST OPHTH VIS SCI, V41, P3694; PALMER RMJ, 1988, NATURE, V333, P664, DOI 10.1038/333664a0; PAUTLER EL, 1994, CURR EYE RES, V13, P687, DOI 10.3109/02713689408999905; Podrez EA, 2000, J CLIN INVEST, V105, P1095, DOI 10.1172/JCI8574; Podrez EA, 2002, J BIOL CHEM, V277, P38517, DOI 10.1074/jbc.M205924200; Podrez EA, 2002, J BIOL CHEM, V277, P38503, DOI 10.1074/jbc.M203318200; Pravenec M, 2003, PHYSIOL RES, V52, P681; Rozanowska M, 1998, FREE RADICAL BIO MED, V24, P1107, DOI 10.1016/S0891-5849(97)00395-X; ROZANOWSKA M, 1995, J BIOL CHEM, V270, P18825, DOI 10.1074/jbc.270.32.18825; Ryeom SW, 1996, J CELL SCI, V109, P387; Ryeom SW, 1996, J BIOL CHEM, V271, P20536, DOI 10.1074/jbc.271.34.20536; Scott RS, 2001, NATURE, V411, P207, DOI 10.1038/35075603; Silverstein RL, 2000, CURR OPIN LIPIDOL, V11, P483, DOI 10.1097/00041433-200010000-00006; SUN M, 2003, THESIS CASE W RESERV, P262; Sun MJ, 2002, J ORG CHEM, V67, P3575, DOI 10.1021/jo0105383; Vollrath D, 2001, P NATL ACAD SCI USA, V98, P12584, DOI 10.1073/pnas.221364198; Watson CL, 1997, CIRC RES, V81, P387, DOI 10.1161/01.RES.81.3.387; YOUNG RW, 1969, J CELL BIOL, V42, P392, DOI 10.1083/jcb.42.2.392; Zarbin MA, 2004, ARCH OPHTHALMOL-CHIC, V122, P598, DOI 10.1001/archopht.122.4.598	58	117	121	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 17	2006	281	7					4222	4230		10.1074/jbc.M509769200	http://dx.doi.org/10.1074/jbc.M509769200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	011NN	16354659	Green Accepted, hybrid			2022-12-25	WOS:000235275300055
J	Wallar, BJ; Stropich, BN; Schoenherr, JA; Holman, HA; Kitchen, SM; Alberts, AS				Wallar, BJ; Stropich, BN; Schoenherr, JA; Holman, HA; Kitchen, SM; Alberts, AS			The basic region of the diaphanous-autoregulatory domain (DAD) is required for autoregulatory interactions with the diaphanous-related formin inhibitory domain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIN NUCLEATION; MOUSE FORMIN; RHO-GTPASE; PROTEIN; MDIA1; MECHANISM; DYNAMICS; REVEALS; ROCK; BNI1	(M) under bar ammalian (dia) under bar phanous-related (mDia) formins act as Rho GTPase effectors during cytoskeletal remodeling. Rho binding to mDia amino-terminal (G) under bar TPase-(b) under bar inding (b) under bar omains (GBDs) causes the adjacent (D) under bar ia-(i) under bar nhibitory (d) under bar omain (DID) to release the carboxyl-terminal (D) under bar ia-(a) under bar utoregulatory (DAD) domain that flanks the formin (h) under bar omology-2 (FH2) domain. The release of DAD allows the FH2 domain to then nucleate and elongate nonbranched actin filaments. DAD, initially discovered as a region of homology shared between a phylogenetically divergent set of formin proteins, is comprised of a core motif, MDXLLXL, and an adjacent region is comprised of numerous basic residues, typically RRKR in the mDia family. Here, we show that these specific amino acids within the basic region of DAD contribute to the binding of DID and therefore the maintenance of the mDia autoregulatory mechanism. In addition, expression of full-length versions of mDia2 containing amino acid substitutions in either the DAD core or basic regions causes profound changes in the F-actin architecture, including the formation of filopodia-like structures that rapidly elongate from the cell edge. These studies further refine our understanding of the molecular contribution of DAD to mDia control and the role of mDia2 in the assembly of membrane protrusions.	Grand Valley State Univ, Dept Chem, Allendale, MI 49401 USA; Grand Valley State Univ, Cell & Mol Biol Program, Allendale, MI 49401 USA; Van Andel Res Inst, Lab Cell Struct & Signal Integrat, Grand Rapids, MI 49503 USA	Grand Valley State University; Grand Valley State University; Van Andel Institute	Alberts, AS (corresponding author), 333 Bostwick Ave, Grand Rapids, MI 49503 USA.	art.alberts@vai.org			NATIONAL CANCER INSTITUTE [R21CA107529] Funding Source: NIH RePORTER; NCI NIH HHS [R21 CA107529] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Alberts AS, 2005, J BIOL CHEM, V280, P12152, DOI 10.1074/jbc.M405073200; Alberts AS, 2001, J BIOL CHEM, V276, P2824, DOI 10.1074/jbc.M006205200; Alberts AS, 1998, J BIOL CHEM, V273, P8616, DOI 10.1074/jbc.273.15.8616; Dong YQ, 2003, J CELL BIOL, V161, P1081, DOI 10.1083/jcb.200212040; Gasman S, 2003, NAT CELL BIOL, V5, P195, DOI 10.1038/ncb935; Harris ES, 2004, J BIOL CHEM, V279, P20076, DOI 10.1074/jbc.M312718200; Higgs HN, 2005, MOL BIOL CELL, V16, P1, DOI 10.1091/mbc.E04-07-0565; Kovar DR, 2004, NAT CELL BIOL, V6, P1158, DOI 10.1038/ncb1204-1158; Li F, 2005, J BIOL CHEM, V280, P6986, DOI 10.1074/jbc.M411605200; Li F, 2003, CURR BIOL, V13, P1335, DOI 10.1016/S0960-9822(03)00540-2; Miralles F, 2003, CELL, V113, P329, DOI 10.1016/S0092-8674(03)00278-2; Moseley JB, 2004, MOL BIOL CELL, V15, P896, DOI 10.1091/mbc.E03-08-0621; Nakano K, 1999, MOL BIOL CELL, V10, P2481, DOI 10.1091/mbc.10.8.2481; Otomo T, 2005, MOL CELL, V18, P273, DOI 10.1016/j.molcel.2005.04.002; Palazzo AF, 2001, NAT CELL BIOL, V3, P723, DOI 10.1038/35087035; Pellegrin S, 2005, CURR BIOL, V15, P129, DOI 10.1016/j.cub.2005.01.011; Peng J, 2003, CURR BIOL, V13, P534, DOI 10.1016/S0960-9822(03)00170-2; Posern G, 2004, EMBO J, V23, P3973, DOI 10.1038/sj.emboj.7600404; Pruyne D, 2002, SCIENCE, V297, P612, DOI 10.1126/science.1072309; Rose R, 2005, NATURE, V435, P513, DOI 10.1038/nature03604; Sagot I, 2002, NAT CELL BIOL, V4, P626, DOI 10.1038/ncb834; Schirenbeck A, 2005, NAT CELL BIOL, V7, P619, DOI 10.1038/ncb1266; Shimada A, 2004, MOL CELL, V13, P511, DOI 10.1016/S1097-2765(04)00059-0; Tominaga T, 2000, MOL CELL, V5, P13, DOI 10.1016/S1097-2765(00)80399-8; Wallar BJ, 2003, TRENDS CELL BIOL, V13, P435, DOI 10.1016/S0962-8924(03)00153-3; Watanabe N, 1997, EMBO J, V16, P3044, DOI 10.1093/emboj/16.11.3044; Watanabe N, 1999, NAT CELL BIOL, V1, P136, DOI 10.1038/11056; Wen Y, 2004, NAT CELL BIOL, V6, P820, DOI 10.1038/ncb1160; Xu YW, 2004, CELL, V116, P711, DOI 10.1016/S0092-8674(04)00210-7; Yasuda S, 2004, NATURE, V428, P767, DOI 10.1038/nature02452	30	77	80	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 17	2006	281	7					4300	4307		10.1074/jbc.M510277200	http://dx.doi.org/10.1074/jbc.M510277200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	011NN	16361707	hybrid			2022-12-25	WOS:000235275300064
J	Juarez-Diaz, JA; McClure, B; Vazquez-Santana, S; Guevara-Garcia, A; Leon-Mejia, P; Marquez-Guzman, J; Cruz-Garcia, F				Juarez-Diaz, JA; McClure, B; Vazquez-Santana, S; Guevara-Garcia, A; Leon-Mejia, P; Marquez-Guzman, J; Cruz-Garcia, F			A novel thioredoxin h is secreted in Nicotiana alata and reduces S-RNase in vitro	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LOCUS RECEPTOR KINASE; SELF-INCOMPATIBILITY; ESCHERICHIA-COLI; PLANT THIOREDOXINS; PROTEINS; GENE; SEQUENCE; REDUCTASE; SYSTEM; IDENTIFICATION	Thioredoxins type h are classified into three subgroups. The subgroup II includes thioredoxins containing an N-terminal extension, the role of which is still unclear. Although thioredoxin secretion has been observed in animal cells, there is no evidence suggesting that any thioredoxin h is secreted in plants. In this study, we report that a thioredoxin h, subgroup II, from Nicotiana alata (NaTrxh) is secreted into the extracellular matrix of the stylar transmitting tract tissue. Fractionation studies showed that NaTrxh is extracted along with well characterized secretion proteins such as S-RNases and NaTTS (N. alata transmitting tissue-specific protein). Moreover, an NaTrxh-green fluorescent fusion protein transiently expressed in Nicotiana benthamiana and Arabidopsis thaliana leaves was also secreted, showing that NaTrxh has the required information for its secretion. We performed reduction assays in vitro to identify potential extracellular targets of NaTrxh. We found that S-RNase is one of the several potential substrates of the NaTrxh in the extracellular matrix. In addition, we proved by affinity chromatography that NaTrxh specifically interacts with S-RNase. Our findings showed that NaTrxh is a new thioredoxin h in Nicotiana that is secreted as well as in animal systems. Because NaTrxh is localized in the extracellular matrix of the stylar transmitting tract and its specific interaction with S-RNase to reduce it in vitro, we suggest that this thioredoxin h may be involved either in general pollen-pistil interaction processes or particularly in S-RNase-based self-incompatibility.	Univ Nacl Autonoma Mexico, Fac Quim, Dept Bioquim & Biol Mol Plantas, Mexico City 04510, DF, Mexico; Life Sci Ctr, Div Biochem, Columbia, MO 65211 USA; Univ Nacl Autonoma Mexico, Fac Ciencias, Dept Biol Comparada, Mexico City 04510, DF, Mexico; Univ Nacl Autonoma Mexico, Inst Biotecnol, Dept Biol Mol Plantas, Cuernavaca 62250, Morelos, Mexico	Universidad Nacional Autonoma de Mexico; Universidad Nacional Autonoma de Mexico; Universidad Nacional Autonoma de Mexico	Cruz-Garcia, F (corresponding author), Univ Nacl Autonoma Mexico, Fac Quim, Dept Bioquim & Biol Mol Plantas, Mexico City 04510, DF, Mexico.	fcg@servidor.unam.mx	Cruz-Garcia, Felipe/A-5817-2008; Juárez-Díaz, Javier Andrés/AAD-6398-2021	Juarez-Diaz, Javier Andres/0000-0001-9238-8564				Arner ESJ, 2000, EUR J BIOCHEM, V267, P6102, DOI 10.1046/j.1432-1327.2000.01701.x; Baumann U, 2002, CELL MOL LIFE SCI, V59, P1042, DOI 10.1007/s00018-002-8485-8; Bendtsen JD, 2004, PROTEIN ENG DES SEL, V17, P349, DOI 10.1093/protein/gzh037; Bendtsen JD, 2004, J MOL BIOL, V340, P783, DOI 10.1016/j.jmb.2004.05.028; Bosch M, 2001, PLANT PHYSIOL, V125, P2180, DOI 10.1104/pp.125.4.2180; Bower MS, 1996, PLANT CELL, V8, P1641, DOI 10.1105/tpc.8.9.1641; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRUGIDOU C, 1993, MOL GEN GENET, V238, P285, DOI 10.1007/BF00279557; Cabrillac D, 2001, NATURE, V410, P220, DOI 10.1038/35065626; Cruz-Garcia F, 2005, PLANT J, V42, P295, DOI 10.1111/j.1365-313X.2005.02375.x; DEBLAERE R, 1985, NUCLEIC ACIDS RES, V13, P4777, DOI 10.1093/nar/13.13.4777; EKLUND H, 1991, PROTEINS, V11, P13, DOI 10.1002/prot.340110103; FLORENCIO FJ, 1988, ARCH BIOCHEM BIOPHYS, V266, P496, DOI 10.1016/0003-9861(88)90282-2; Gelhaye E, 2004, P NATL ACAD SCI USA, V101, P14545, DOI 10.1073/pnas.0405282101; Gelhaye E, 2004, PLANT PHYSIOL BIOCH, V42, P265, DOI 10.1016/j.plaphy.2004.03.002; HARTMAN H, 1990, MOL BIOL EVOL, V7, P247; HODGES M, 1994, PLANT MOL BIOL, V26, P225, DOI 10.1007/BF00039534; HOLMGREN A, 1985, ANNU REV BIOCHEM, V54, P237, DOI 10.1146/annurev.bi.54.070185.001321; HOLMGREN A, 1979, J BIOL CHEM, V254, P9627; HOOG JO, 1984, BIOSCIENCE REP, V4, P917, DOI 10.1007/BF01116889; Ishiwatari Y, 1998, PLANTA, V205, P12, DOI 10.1007/s004250050291; ISHIWATARI Y, 1995, PLANTA, V195, P456, DOI 10.1007/BF00202605; Jefferson RA., 1988, GENETIC ENG GENETIC, V10, P247, DOI DOI 10.1007/978-1-4615-7081-3_13; JOHNSON TC, 1987, PLANTA, V171, P321, DOI 10.1007/BF00398677; KALEF E, 1993, ANAL BIOCHEM, V212, P325, DOI 10.1006/abio.1993.1337; KALLIS GB, 1980, J BIOL CHEM, V255, P261; Kumar S, 2001, BIOINFORMATICS, V17, P1244, DOI 10.1093/bioinformatics/17.12.1244; Laloi C, 2001, P NATL ACAD SCI USA, V98, P14144, DOI 10.1073/pnas.241340898; Lind JL, 1996, SEX PLANT REPROD, V9, P75, DOI 10.1007/BF02153054; Llave C, 2000, P NATL ACAD SCI USA, V97, P13401, DOI 10.1073/pnas.230334397; Marchand C, 2004, PROTEOMICS, V4, P2696, DOI 10.1002/pmic.200400805; Mazzurco M, 2001, PLANT MOL BIOL, V45, P365, DOI 10.1023/A:1006412329934; MCCLURE BA, 1989, NATURE, V342, P955, DOI 10.1038/342955a0; Meyer Y, 1999, TRENDS PLANT SCI, V4, P388, DOI 10.1016/S1360-1385(99)01475-2; Meyer Y, 2002, METHOD ENZYMOL, V347, P394; MURFETT J, 1995, PLANT MOL BIOL, V29, P201, DOI 10.1007/BF00043646; Murfett J, 1996, PLANT CELL, V8, P943, DOI 10.1105/tpc.8.6.943; Oxley D, 1996, EUR J BIOCHEM, V242, P75, DOI 10.1111/j.1432-1033.1996.0075r.x; RIVERAMADRID R, 1995, P NATL ACAD SCI USA, V92, P5620, DOI 10.1073/pnas.92.12.5620; SAITOU N, 1987, MOL BIOL EVOL, V4, P406, DOI 10.1093/oxfordjournals.molbev.a040454; SANFORD JC, 1990, PHYSIOL PLANTARUM, V79, P206, DOI 10.1111/j.1399-3054.1990.tb05888.x; Schob H, 1997, MOL GEN GENET, V256, P581, DOI 10.1007/s004380050604; Schopfer CR, 1999, SCIENCE, V286, P1697, DOI 10.1126/science.286.5445.1697; SHEEN J, 1995, PLANT J, V8, P777, DOI 10.1046/j.1365-313X.1995.08050777.x; Sijacic P, 2004, NATURE, V429, P302, DOI 10.1038/nature02523; Soderberg A, 2000, CANCER RES, V60, P2281; Tanudji M, 2003, AM J PHYSIOL-CELL PH, V284, pC1272, DOI 10.1152/ajpcell.00521.2002; Thompson JD, 1997, NUCLEIC ACIDS RES, V25, P4876, DOI 10.1093/nar/25.24.4876; Wu HM, 2000, PLANT J, V22, P165, DOI 10.1046/j.1365-313x.2000.00731.x; WYNN R, 1995, BIOCHEMISTRY-US, V34, P11807, DOI 10.1021/bi00037a019; Yano H, 2001, P NATL ACAD SCI USA, V98, P4794, DOI 10.1073/pnas.071041998; Zurek DM, 1997, PLANT J, V11, P797, DOI 10.1046/j.1365-313X.1997.11040797.x	52	45	50	1	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 10	2006	281	6					3418	3424		10.1074/jbc.M511687200	http://dx.doi.org/10.1074/jbc.M511687200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	009QV	16354655	hybrid			2022-12-25	WOS:000235128200050
J	Majumdar, G; Harrington, A; Hungerford, J; Martinez-Hernandez, A; Gerling, IC; Raghow, R; Solomon, S				Majumdar, G; Harrington, A; Hungerford, J; Martinez-Hernandez, A; Gerling, IC; Raghow, R; Solomon, S			Insulin dynamically regulates calmodulin gene expression by sequential O-glycosylation and phosphorylation of Sp1 and its subcellular compartmentalization in liver cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTION FACTOR; NUCLEOCYTOPLASMIC PROTEINS; GLCNAC; NUCLEAR; INTERPLAY; BETA; HYPERGLYCEMIA; INHIBITION; ACTIVATION; MECHANISMS	O-Glycosylation and phosphorylation of Sp1 are thought to modulate the expression of a number of genes in normal and diabetic state. Sp1 is an obligatory transcription factor for constitutive and insulin responsive expression of the calmodulin gene(Majumdar, G., Harmon, A., Candelaria, R., Martinez-Hernandez, A., Raghow, R., and Solomon, S. S. (2003) Am. J. Physiol. 285, E584-E591). Here we report the temporal dynamics of accumulation of total, O-GlcNAc-modified, and phosphorylated Sp1 in H-411E hepatoma cells by immunohistochemistry with monospecific antibodies, confocal microscopy, and matrix-assisted laser desorption and ionization-time of flight mass spectrometry. Insulin elicited sequential and reciprocal post-translational modifications of Sp1. The O-glycosylation of Sp1 and its nuclear accumulation induced by insulin peaked early (similar to 30 min), followed by a steady decline of O-GlcNAc-modified Sp1 to negligible levels by 240 min. The accumulation of phosphorylated Sp1 in the nuclei of insulin-treated cells showed an opposite pattern, increasing steadily until reaching a maximum around 240 min after treatment. Analyses of the total, O-GlcNAc-modified, or phosphorylated Sp1 by Western blot and mass spectrometry corroborated the sequential and reciprocal control of post-translational modifications of Sp1 in response to insulin. Treatment of cells with streptozotocin ( a potent inhibitor of O-GlcNAcase) led to hyperglycosylation of Sp1 that failed to be significantly phosphorylated. The mass spectrometry data indicated that a number of common serine residues of Sp1 undergo time-dependent, reciprocal O-glycosylation and phosphorylation, paralleling its rapid translocation from cytoplasm to the nucleus. Later, changes in the steady state levels of phosphorylated Sp1 mimicked the enhanced steady state levels of calmodulin mRNA seen after insulin treatment. Thus, O-glycosylation of Sp1 appears to be critical for its localization into the nucleus, where it undergoes obligatory phosphorylation that is needed for Sp1 to activate calmodulin gene expression.	VAMC, Res Serv, Memphis, TN 38104 USA; VAMC, Med Serv, Memphis, TN 38104 USA; VAMC, Pathol Serv, Memphis, TN 38104 USA; Univ Tennessee, Hlth Sci Ctr, Dept Med, Memphis, TN 38104 USA; Univ Tennessee, Hlth Sci Ctr, Dept Pathol, Memphis, TN 38104 USA; Univ Tennessee, Hlth Sci Ctr, Dept Pharmacol, Memphis, TN 38104 USA	US Department of Veterans Affairs; Veterans Health Administration (VHA); Memphis VA Medical Center; US Department of Veterans Affairs; Veterans Health Administration (VHA); Memphis VA Medical Center; US Department of Veterans Affairs; Veterans Health Administration (VHA); Memphis VA Medical Center; University of Tennessee System; University of Tennessee Health Science Center; University of Tennessee System; University of Tennessee Health Science Center; University of Tennessee System; University of Tennessee Health Science Center	Solomon, S (corresponding author), VAMC, Res Serv, 151,1030 Jefferson Ave, Memphis, TN 38104 USA.	ssolomon@utmem.edu						Cheng XG, 2001, J BIOL CHEM, V276, P10570, DOI 10.1074/jbc.M010411200; Comer FI, 2000, J BIOL CHEM, V275, P29179, DOI 10.1074/jbc.R000010200; Haltiwanger RS, 1998, J BIOL CHEM, V273, P3611, DOI 10.1074/jbc.273.6.3611; Hart GW, 1997, ANNU REV BIOCHEM, V66, P315, DOI 10.1146/annurev.biochem.66.1.315; JACKSON SP, 1988, CELL, V55, P125, DOI 10.1016/0092-8674(88)90015-3; JACKSON SP, 1990, CELL, V63, P155, DOI 10.1016/0092-8674(90)90296-Q; Kamemura K, 2003, PROG NUCLEIC ACID RE, V73, P107, DOI 10.1016/S0079-6603(03)01004-3; Keembiyehetty CN, 2002, ENDOCRINOLOGY, V143, P1512, DOI 10.1210/en.143.4.1512; Lefebvre T, 2003, BBA-GEN SUBJECTS, V1619, P167, DOI 10.1016/S0304-4165(02)00477-4; Li T, 2003, CIRC RES, V93, P1202, DOI 10.1161/01.RES.0000104085.76261.02; Liu F, 2004, P NATL ACAD SCI USA, V101, P10804, DOI 10.1073/pnas.0400348101; Majumdar G, 2004, DIABETES, V53, P3184, DOI 10.2337/diabetes.53.12.3184; Majumdar G, 2003, AM J PHYSIOL-ENDOC M, V285, pE584, DOI 10.1152/ajpendo.00140.2003; Murphy PR, 2001, ENDOCRINOLOGY, V142, P81, DOI 10.1210/en.142.1.81; O'Donnell N, 2004, MOL CELL BIOL, V24, P1680, DOI 10.1128/MCB.24.4.1680-1690.2004; Pan XL, 2000, J LAB CLIN MED, V136, P157, DOI 10.1067/mlc.2000.108149; Pan XL, 2001, ENDOCRINOLOGY, V142, P1635, DOI 10.1210/en.142.4.1635; Parker G, 2004, J BIOL CHEM, V279, P20636, DOI 10.1074/jbc.M312139200; Samson SLA, 2002, J MOL ENDOCRINOL, V29, P265, DOI 10.1677/jme.0.0290265; Slawson C, 2005, J BIOL CHEM, V280, P32944, DOI 10.1074/jbc.M503396200; Slawson C, 2003, CURR OPIN STRUC BIOL, V13, P631, DOI 10.1016/j.sbi.2003.08.003; SOLOMON SS, 1994, J LAB CLIN MED, V124, P348; SOLOMON SS, 1995, BIOCHEM BIOPH RES CO, V210, P921, DOI 10.1006/bbrc.1995.1745; Solomon SS, 1997, P ASSOC AM PHYSICIAN, V109, P470; Solomon SS, 1997, ENDOCRINOLOGY, V138, P5052, DOI 10.1210/en.138.11.5052; SOLOMON SS, 1990, BIOCHEM BIOPH RES CO, V168, P1007, DOI 10.1016/0006-291X(90)91129-G; Solomon SS, 2005, J LAB CLIN MED, V145, P275, DOI 10.1016/j.lab.2005.02.013; SOLOMON SS, 2002, RRD ENDOCRINOL 1, V3, P79; Tannu NS, 2004, ANAL BIOCHEM, V327, P222, DOI 10.1016/j.ab.2004.01.033; Villafuerte BC, 2005, J BIOL CHEM, V280, P20010, DOI 10.1074/jbc.M410817200; Vosseller K, 2002, P NATL ACAD SCI USA, V99, P5313, DOI 10.1073/pnas.072072399; Wang GY, 2004, ENDOCRINOLOGY, V145, P659, DOI 10.1210/en.2003-0770; Wells L, 2001, SCIENCE, V291, P2376, DOI 10.1126/science.1058714; WHITE MF, 1994, J BIOL CHEM, V269, P1; Wu J, 2005, ELECTROPHORESIS, V26, P225, DOI 10.1002/elps.200406176; Ye XB, 2002, J BIOL CHEM, V277, P31863, DOI 10.1074/jbc.M205544200; Zachara NE, 2002, CHEM REV, V102, P431, DOI 10.1021/cr000406u; Zhang FX, 2003, CELL, V115, P715, DOI 10.1016/S0092-8674(03)00974-7; Zhao M, 2001, FEBS LETT, V509, P405, DOI 10.1016/S0014-5793(01)03185-4	39	76	79	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 10	2006	281	6					3642	3650		10.1074/jbc.M511223200	http://dx.doi.org/10.1074/jbc.M511223200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	009QV	16332679	hybrid			2022-12-25	WOS:000235128200076
J	Ogura, K; Nobuhisa, I; Yuzawa, S; Takeya, R; Torikai, S; Saikawa, K; Sumimoto, H; Inagaki, F				Ogura, K; Nobuhisa, I; Yuzawa, S; Takeya, R; Torikai, S; Saikawa, K; Sumimoto, H; Inagaki, F			NMR solution structure of the tandem Src homology 3 domains of p47(phox) complexed with a p22(phox)-derived proline-rich peptide	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHAGOCYTE NADPH OXIDASE; CHRONIC GRANULOMATOUS-DISEASE; RESPIRATORY BURST OXIDASE; SRC HOMOLOGY-3 DOMAINS; PHOSPHORYLATION-INDUCED ACTIVATION; RESIDUAL DIPOLAR COUPLINGS; PROTEIN-KINASE-C; SH3 DOMAINS; BINDING; RECOGNITION	The phagocyte NADPH oxidase plays a crucial role in host defense against microbial infections by generating reactive oxygen species. It is a multisubunit enzyme composed of membrane-bound flavocytochrome b(558) as well as cytosolic components, including p47(phox), which is essential for assembly of the complex. When phagocytes are activated, the cytosolic components of the NADPH oxidase translocate to flavocytochrome b558 due to binding of the tandem Src homology 3 (SH3) domains of p47(phox) to a proline-rich region in p22(phox), a subunit of flavocytochrome b558. Using NMR titration, we first identified the proline-rich region of p22(phox) that is essential for binding to the tandem SH3 domains of p47(phox). We subsequently determined the solution structure of the p47(phox) tandem SH3 domains complexed with the proline-rich peptide of p22(phox) using NMR spectroscopy. In contrast to the intertwined dimer reported for the crystal state, the solution structure is a monomer. The central region of the p22phox peptide forms a polyproline type II helix that is sandwiched by the N- and C-terminal SH3 domains, as was observed in the crystal structure, whereas the C-terminal region of the peptide takes on a short alpha-helical conformation that provides an additional binding site with the N- terminal SH3 domain. Thus, the C-terminal alpha-helical region of the p22(phox) peptide increases the binding affinity for the tandem SH3 domains of p47(phox) more than 10-fold.	Hokkaido Univ, Dept Biol Struct, Grad Sch Pharmaceut Sci, Kita Ku, Sapporo, Hokkaido 0600812, Japan; Kyushu Univ, Med Inst Bioregulat, Higashi Ku, Fukuoka 8128582, Japan; Japan Sci & Technol Agcy, CREST, Kawaguchi, Saitama 3320012, Japan	Hokkaido University; Kyushu University; Japan Science & Technology Agency (JST)	Inagaki, F (corresponding author), Hokkaido Univ, Dept Biol Struct, Grad Sch Pharmaceut Sci, Kita Ku, N-12,W-6, Sapporo, Hokkaido 0600812, Japan.	finagaki@pharm.hokudai.ac.jp		Yuzawa, Satoru/0000-0002-1031-5781				Ago T, 1999, J BIOL CHEM, V274, P33644, DOI 10.1074/jbc.274.47.33644; Babior BM, 1999, BLOOD, V93, P1464, DOI 10.1182/blood.V93.5.1464.405a32_1464_1476; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; CAVANAGH J, 1995, PROTEIN NMR SPECTROS, P478; Cornilescu G, 1999, J BIOMOL NMR, V13, P289, DOI 10.1023/A:1008392405740; Dahan I, 2002, J BIOL CHEM, V277, P8421, DOI 10.1074/jbc.M109778200; DELAGLIO F, 1995, J BIOMOL NMR, V6, P277, DOI 10.1007/BF00197809; DINAUER MC, 1992, ANNU REV MED, V43, P117, DOI 10.1146/annurev.med.43.1.117; ElBenna J, 1996, J BIOL CHEM, V271, P6374; ELBENNA J, 1994, J BIOL CHEM, V269, P23431; FARROW NA, 1994, BIOCHEMISTRY-US, V33, P5984, DOI 10.1021/bi00185a040; Fischer MWF, 1999, BIOCHEMISTRY-US, V38, P9013, DOI 10.1021/bi9905213; Fontayne A, 2002, BIOCHEMISTRY-US, V41, P7743, DOI 10.1021/bi011953s; Groemping Y, 2003, CELL, V113, P343, DOI 10.1016/S0092-8674(03)00314-3; GRZESIEK S, 1993, J MAGN RESON SER B, V101, P114, DOI 10.1006/jmrb.1993.1019; Guinier A., 1955, SMALL ANGLE SCATTERI; Heyworth PG, 2003, CURR OPIN IMMUNOL, V15, P578, DOI 10.1016/S0952-7915(03)00109-2; Hoyal CR, 2003, P NATL ACAD SCI USA, V100, P5130, DOI 10.1073/pnas.1031526100; Huang J, 1999, J BIOL CHEM, V274, P19731, DOI 10.1074/jbc.274.28.19731; Kanelis V, 2000, J BIOMOL NMR, V16, P253, DOI 10.1023/A:1008355012528; KATAOKA M, 1989, P NATL ACAD SCI USA, V86, P6944, DOI 10.1073/pnas.86.18.6944; Lambeth JD, 2000, J BIOCHEM MOL BIOL, V33, P427; Lapouge K, 2002, J BIOL CHEM, V277, P10121, DOI 10.1074/jbc.M112065200; Laskowski RA, 1996, J BIOMOL NMR, V8, P477, DOI 10.1007/BF00228148; LETO TL, 1994, P NATL ACAD SCI USA, V91, P10650, DOI 10.1073/pnas.91.22.10650; Linge JP, 2001, METHOD ENZYMOL, V339, P71, DOI 10.1016/S0076-6879(01)39310-2; Mal TK, 2002, BIOCHEMISTRY-US, V41, P12899, DOI 10.1021/bi0264162; MUSACCHIO A, 1994, NAT STRUCT BIOL, V1, P546, DOI 10.1038/nsb0894-546; Nauseef WM, 1999, P ASSOC AM PHYSICIAN, V111, P373, DOI 10.1111/paa.1999.111.5.373; OLEJNICZAK ET, 1992, J BIOMOL NMR, V2, P655, DOI 10.1007/BF02192854; Ottiger M, 1998, J MAGN RESON, V131, P373, DOI 10.1006/jmre.1998.1361; Ottiger M, 1998, J BIOMOL NMR, V12, P361, DOI 10.1023/A:1008366116644; Roos D, 2003, MICROBES INFECT, V5, P1307, DOI 10.1016/j.micinf.2003.09.009; Ruckert M, 2000, J AM CHEM SOC, V122, P7793, DOI 10.1021/ja001068h; Segal BH, 2000, MEDICINE, V79, P170, DOI 10.1097/00005792-200005000-00004; Skrynnikov NR, 2000, J MOL BIOL, V295, P1265, DOI 10.1006/jmbi.1999.3430; SUMIMOTO H, 1994, P NATL ACAD SCI USA, V91, P5345, DOI 10.1073/pnas.91.12.5345; Sumimoto H, 2005, BIOCHEM BIOPH RES CO, V338, P677, DOI 10.1016/j.bbrc.2005.08.210; Sumimoto H, 1996, J BIOL CHEM, V271, P22152, DOI 10.1074/jbc.271.36.22152; SVERGUN DI, 1992, J APPL CRYSTALLOGR, V25, P495, DOI 10.1107/S0021889892001663; THRASHER AJ, 1994, BBA-MOL BASIS DIS, V1227, P1, DOI 10.1016/0925-4439(94)90100-7; UEKI T, 1985, BIOPHYS CHEM, V23, P115, DOI 10.1016/0301-4622(85)80069-7; Ulmer TS, 2002, STRUCTURE, V10, P901, DOI 10.1016/S0969-2126(02)00781-5; Wiesner S, 2002, J MOL BIOL, V324, P807, DOI 10.1016/S0022-2836(02)01145-2; WITTEKIND M, 1993, J MAGN RESON SER B, V101, P201, DOI 10.1006/jmrb.1993.1033; YU HT, 1994, CELL, V76, P933, DOI 10.1016/0092-8674(94)90367-0; Yuzawa S, 2004, J BIOL CHEM, V279, P29752, DOI 10.1074/jbc.M401457200; Yuzawa S, 2004, GENES CELLS, V9, P443, DOI 10.1111/j.1356-9597.2004.00733.x; Yuzawa S, 2001, J MOL BIOL, V306, P527, DOI 10.1006/jmbi.2000.4396	49	59	64	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 10	2006	281	6					3660	3668		10.1074/jbc.M505193200	http://dx.doi.org/10.1074/jbc.M505193200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	009QV	16326715	hybrid			2022-12-25	WOS:000235128200078
J	Takeshita, J; Byun, J; Nhan, TQ; Pritchard, DK; Pennathur, S; Schwartz, SM; Chait, A; Heinecke, JW				Takeshita, J; Byun, J; Nhan, TQ; Pritchard, DK; Pennathur, S; Schwartz, SM; Chait, A; Heinecke, JW			Myeloperoxidase generates 5-chlorouracil in human atherosclerotic tissue - A potential pathway for somatic mutagenesis by macrophages	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LOW-DENSITY-LIPOPROTEIN; SMOOTH-MUSCLE-CELLS; SENESCENCE-LIKE PHENOMENON; PEROXIDE-CHLORIDE SYSTEM; ACUTE CORONARY SYNDROMES; OXIDATIVE DNA-DAMAGE; HYPOCHLOROUS ACID; HYDROGEN-PEROXIDE; MASS-SPECTROMETRY; GAS-CHROMATOGRAPHY	Somatic mutations induced by oxidative damage of DNA might play important roles in atherogenesis. However, the underlying mechanisms remain poorly understood. Myeloperoxidase, a heme protein expressed by select populations of artery wall macrophages, initiates one potentially mutagenic pathway by generating hypochlorous acid. This potent chlorinating agent reacts rapidly with primary amines to yield long-lived, selectively reactive N-chloramines. In the current studies, we demonstrate that myeloperoxidase produced by human macrophages differentiated in the presence of granulocyte macrophage colony-stimulating factor generates 5-chlorouracil, a mutagenic thymine analog. The primary amine taurine fails to block the reaction, suggesting that N-haloamines produced by macrophages might oxidize uracil. Model system studies demonstrated that N-chloramines convert uracil to 5-chlorouracil. Interestingly, the tertiary amine nicotine dramatically enhances uracil chlorination, suggesting that cigarette smoke might promote nucleobase oxidation by N-chloramines. To look for evidence that myeloperoxidase promotes uracil oxidation in vivo, we measured 5-chlorouracil levels in human aortic tissue, using isotope dilution gas chromatography-mass spectrometry. The level of 5-chlorouracil was 10-fold higher in atherosclerotic aortic tissue obtained during vascular surgery than in normal aortic tissue, suggesting that halogenated nucleobases produced by macrophages might contribute to atherogenesis. Because 5-chlorouracil can be incorporated into nuclear DNA, our observations raise the possibility that halogenation reactions initiated by phagocytes provide one pathway for mutagenesis, phenotypic modulation, and cytotoxicity during atherogenesis.	Washington Univ, Sch Med, Dept Med, St Louis, MO 63110 USA; Univ Washington, Dept Pathol, Seattle, WA 98195 USA; Univ Washington, Dept Med, Seattle, WA 98195 USA	Washington University (WUSTL); University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle	Heinecke, JW (corresponding author), Univ Washington, Div Metab, Box 356426, Seattle, WA 98195 USA.	heinecke@u.washington.edu			NHLBI NIH HHS [P01HL030086] Funding Source: Medline; NIA NIH HHS [AG19309, AG02119] Funding Source: Medline; NIDDK NIH HHS [P30DK017047] Funding Source: Medline; NIEHS NIH HHS [P30ES07083] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL030086] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK017047] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG019309] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Anderson MM, 1997, J CLIN INVEST, V99, P424, DOI 10.1172/JCI119176; Andreassi MG, 2003, CELL CYCLE, V2, P224, DOI 10.4161/cc.2.3.403; Andreassi MG, 2003, MUTAT RES-REV MUTAT, V543, P67, DOI 10.1016/S1383-5742(02)00089-3; Baldus S, 2001, J CLIN INVEST, V108, P1759; Baldus S, 2003, CIRCULATION, V108, P1440, DOI 10.1161/01.CIR.0000090690.67322.51; BENDITT EP, 1973, P NATL ACAD SCI USA, V70, P1753, DOI 10.1073/pnas.70.6.1753; BENOWITZ NL, 1984, CLIN PHARMACOL THER, V36, P74, DOI 10.1038/clpt.1984.142; Bergt C, 2004, P NATL ACAD SCI USA, V101, P13032, DOI 10.1073/pnas.0405292101; BOOTHMAN DA, 1987, CANCER RES, V47, P2354; Brennan ML, 2001, J CLIN INVEST, V107, P419, DOI 10.1172/JCI8797; Byun J, 2003, ANAL BIOCHEM, V317, P201, DOI 10.1016/S0003-2697(03)00093-9; Carr AC, 2001, FREE RADICAL BIO MED, V30, P526, DOI 10.1016/S0891-5849(00)00495-0; CHAIT A, 1982, METABOLISM, V31, P721, DOI 10.1016/0026-0495(82)90204-9; Chen HJC, 2002, CHEM RES TOXICOL, V15, P262, DOI 10.1021/tx015578g; DAUGHERTY A, 1994, J CLIN INVEST, V94, P437, DOI 10.1172/JCI117342; Eiserich JP, 2002, SCIENCE, V296, P2391, DOI 10.1126/science.1106830; ELLIS AJ, 1954, J CHEM SOC, P1750, DOI 10.1039/jr9540001750; FALK E, 1992, CIRCULATION, V86, P30; Flynn PD, 1997, BLOOD, V89, P4378, DOI 10.1182/blood.V89.12.4378; FRENKEL K, 1986, J CELL BIOCHEM, V30, P181, DOI 10.1002/jcb.240300302; GENG YJ, 1995, AM J PATHOL, V147, P251; Giese RW, 1996, METHOD ENZYMOL, V271, P504; Gottardi W, 2002, ARCH PHARM, V335, P411, DOI 10.1002/1521-4184(200212)335:9<411::AID-ARDP411>3.0.CO;2-D; GOTTO AM, 1969, CANCER RES, V29, P807; GRISHAM MB, 1984, J BIOL CHEM, V259, P404; Hale JT, 2002, BIOCHEM PHARMACOL, V64, P1493, DOI 10.1016/S0006-2952(02)01413-2; HARRISON JE, 1976, J BIOL CHEM, V251, P1371; HAZELL LJ, 1993, BIOCHEM J, V290, P165, DOI 10.1042/bj2900165; Hazen SL, 1997, J CLIN INVEST, V99, P2075, DOI 10.1172/JCI119379; HEARTLEIN MW, 1983, MUTAT RES, V107, P103, DOI 10.1016/0027-5107(83)90081-7; Heinecke J W, 1996, Curr Opin Lipidol, V7, pU131, DOI 10.1097/00041433-199608000-00020; HEINECKE JW, 1986, J CLIN INVEST, V77, P757, DOI 10.1172/JCI112371; HEINECKE JW, 1993, J CLIN INVEST, V91, P2866, DOI 10.1172/JCI116531; Heinecke JW, 1999, METHOD ENZYMOL, V300, P124; Heller JI, 2000, J BIOL CHEM, V275, P9957, DOI 10.1074/jbc.275.14.9957; Henderson JP, 1999, J BIOL CHEM, V274, P33440, DOI 10.1074/jbc.274.47.33440; Henderson JP, 1999, REDOX REP, V4, P319, DOI 10.1179/135100099101535025; Henderson JP, 2003, J BIOL CHEM, V278, P23522, DOI 10.1074/jbc.M303928200; Henderson JP, 2001, J BIOL CHEM, V276, P7867, DOI 10.1074/jbc.M005379200; Henderson JP, 2001, P NATL ACAD SCI USA, V98, P1631, DOI 10.1073/pnas.041146998; Henderson JP, 2001, BIOCHEMISTRY-US, V40, P2052, DOI 10.1021/bi002015f; HIGUCHI T, 1969, J CHEM SOC B, P626, DOI 10.1039/j29690000626; IARC Working Group on the Evaluation of Carcinogenic Risks to Humans, 1986, IARC MON EV CARC RIS, V38; Jiang Q, 2003, J BIOL CHEM, V278, P32834, DOI 10.1074/jbc.M304021200; KETTLE AJ, 1994, METHOD ENZYMOL, V233, P502; Kiyohara C, 2002, LUNG CANCER, V37, P241, DOI 10.1016/S0169-5002(02)00107-1; Klebanoff SJ., 1988, INFLAMMATION BASIC P, P391; KOEFFLER HP, 1985, BLOOD, V65, P484; KOK RM, 1985, J CHROMATOGR, V343, P59, DOI 10.1016/S0378-4347(00)84568-5; KRISS JP, 1963, CANCER RES, V23, P260; LEARN DB, 1990, J LEUKOCYTE BIOL, V48, P174, DOI 10.1002/jlb.48.2.174; Leeuwenburgh C, 1997, J BIOL CHEM, V272, P1433, DOI 10.1074/jbc.272.3.1433; Leeuwenburgh C, 1997, J BIOL CHEM, V272, P3520, DOI 10.1074/jbc.272.6.3520; LINDER M, 1992, NUTR BIOCH METABOLIS, P98; Martinet W, 2002, CIRCULATION, V106, P927, DOI 10.1161/01.CIR.0000026393.47805.21; Masuda M, 2001, J BIOL CHEM, V276, P40486, DOI 10.1074/jbc.M102700200; McMillen TS, 2005, CIRCULATION, V111, P2798, DOI 10.1161/CIRCULATIONAHA.104.516278; Michishita E, 2002, EXP GERONTOL, V37, P885, DOI 10.1016/S0531-5565(02)00033-5; Michishita E, 2002, BIOSCI BIOTECH BIOCH, V66, P877, DOI 10.1271/bbb.66.877; MORITA Y, 1986, J BIOCHEM-TOKYO, V99, P761, DOI 10.1093/oxfordjournals.jbchem.a135535; MORRIS JC, 1966, J PHYS CHEM-US, V70, P3798, DOI 10.1021/j100884a007; MORRIS SM, 1993, MUTAT RES, V297, P39, DOI 10.1016/0165-1110(93)90006-9; MORRIS SM, 1991, MUTAT RES, V258, P161, DOI 10.1016/0165-1110(91)90007-I; NELSON DP, 1972, ANAL BIOCHEM, V49, P474, DOI 10.1016/0003-2697(72)90451-4; Nikpoor B, 2001, AM HEART J, V142, P336, DOI 10.1067/mhj.2001.116769; O'Neill J P, 1984, Basic Life Sci, V29 Pt A, P59; Ohshima H, 2003, ARCH BIOCHEM BIOPHYS, V417, P3, DOI 10.1016/S0003-9861(03)00283-2; ONEILL JP, 1983, MUTAT RES, V109, P259, DOI 10.1016/0027-5107(83)90051-9; PAL BC, 1981, MUTAT RES, V91, P395, DOI 10.1016/0165-7992(81)90021-X; Pennathur S, 2004, J BIOL CHEM, V279, P42977, DOI 10.1074/jbc.M406762200; Pennathur S, 2001, J CLIN INVEST, V107, P853, DOI 10.1172/JCI11194; Peskin AV, 2001, FREE RADICAL BIO MED, V30, P572, DOI 10.1016/S0891-5849(00)00506-2; Prutz WA, 2001, ARCH BIOCHEM BIOPHYS, V393, P297, DOI 10.1006/abbi.2001.2503; Prutz WA, 1998, ARCH BIOCHEM BIOPHYS, V357, P265, DOI 10.1006/abbi.1998.0822; RAKITA RM, 1990, BIOCHEMISTRY-US, V29, P1075, DOI 10.1021/bi00456a033; REDDY VY, 1994, J BIOL CHEM, V269, P4683; Ross R, 1999, NEW ENGL J MED, V340, P115, DOI 10.1056/NEJM199901143400207; Schaub FJ, 2000, NAT MED, V6, P790, DOI 10.1038/77521; SHECHTER Y, 1975, BIOCHEMISTRY-US, V14, P4497, DOI 10.1021/bi00691a025; Sugimura T, 2004, CANCER SCI, V95, P290, DOI 10.1111/j.1349-7006.2004.tb03205.x; Sugiyama S, 2001, AM J PATHOL, V158, P879, DOI 10.1016/S0002-9440(10)64036-9; Suzuki T, 2002, NUCLEIC ACIDS RES, V30, P2555, DOI 10.1093/nar/30.11.2555; Suzuki T, 2002, FEBS LETT, V516, P67, DOI 10.1016/S0014-5793(02)02503-6; TAPSCOTT SJ, 1989, SCIENCE, V245, P532, DOI 10.1126/science.2547249; Thomas E L, 1986, Methods Enzymol, V132, P569; WEISS SJ, 1982, J CLIN INVEST, V70, P598, DOI 10.1172/JCI110652; Whiteman M, 1997, CHEM RES TOXICOL, V10, P1240, DOI 10.1021/tx970086i; Winterbourn CC, 2004, JPN J INFECT DIS, V57, pS31; WITZTUM JL, 1991, J CLIN INVEST, V88, P1785, DOI 10.1172/JCI115499; Wu Xifeng, 2003, Methods Mol Med, V75, P121; YU H, 1993, J BIOL CHEM, V268, P15935; ZGLICZYNSKI JM, 1971, BIOCHIM BIOPHYS ACTA, V235, P419, DOI 10.1016/0005-2744(71)90281-6; Zhang ZL, 2001, JAMA-J AM MED ASSOC, V286, P2136, DOI 10.1001/jama.286.17.2136	93	77	81	0	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 10	2006	281	6					3096	3104		10.1074/jbc.M509236200	http://dx.doi.org/10.1074/jbc.M509236200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	009QV	16326702	hybrid			2022-12-25	WOS:000235128200012
J	Helton, ES; Zhu, JH; Chen, XB				Helton, ES; Zhu, JH; Chen, XB			The unique NH2-terminally deleted (Delta N) residues, the PXXP motif, and the PPXY motif are required for the transcriptional activity of the Delta N variant of p63	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							P53 TARGET GENES; DIFFERENTIAL REGULATION; FUNCTIONAL DOMAINS; GROWTH SUPPRESSION; INDUCED APOPTOSIS; DNA-DAMAGE; P73; PROTEIN; EXPRESSION; CANCER	p63, a member of the p53 family of transcription factors, is known to be involved in epithelial development. However, its role in tumorigenesis is unclear. Contributing to this uncertainty, the TP63 locus can express multiple gene products from two different promoters. Utilization of the upstream promoter results in expression of the TAp63 variant with an activation domain similar to p53. In contrast, the NH2-terminally deleted (Delta N) p63 variant, transcribed from a cryptic promoter in intron 3, lacks such an activation domain. Thus, the TAp63 and Delta Np63 variants possess a wide ranging ability to up-regulate p53 target genes. Consequentially, the disparity in transactivation potential between p63 variants has given rise to the hypothesis that the Delta Np63 variant can serve as oncoprotein by opposing the activity of the TAp63 variant and p53. However, recent studies have revealed a transcriptional activity for Delta Np63. This study was undertaken to address the transcriptional activity of the Delta Np63 variant. Here, we showed that all NH2-terminally deleted p63 isoforms retain a potential in transactivation and growth suppression. Interestingly, Delta Np63 beta possesses a remarkable ability to suppress cell proliferation and transactivate target genes, which is consistently higher than that seen with Delta Np63 alpha. In contrast, Delta Np63 gamma has a weak or undetectable activity dependent upon the cell lines used. We also demonstrate that an intact DNA-binding domain is required for Delta Np63 function. In addition, we found that the novel activation domain for the Delta Np63 variant is composed of the 14 unique Delta N residues along with the adjacent region, including a PXXP motif. Finally, we demonstrated that a PPXY motif shared by Delta Np63 alpha and Delta Np63 beta is required for optimal transactivation of target gene promoters, suggesting that the PPXY motif is requisite for Delta Np63 function.	Univ Alabama, Dept Cell Biol, Birmingham, AL 35294 USA	University of Alabama System; University of Alabama Birmingham	Chen, XB (corresponding author), MCLM 660,1530 3rd Ave S, Birmingham, AL 35294 USA.	xchen@uab.edu			NCI NIH HHS [R01 CA102188] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA102188] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Amiel J, 2001, EUR J HUM GENET, V9, P642, DOI 10.1038/sj.ejhg.5200676; Aqeilan RI, 2004, P NATL ACAD SCI USA, V101, P4401, DOI 10.1073/pnas.0400805101; Brunner HG, 2002, J MED GENET, V39, P377, DOI 10.1136/jmg.39.6.377; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; Chen XB, 1996, GENE DEV, V10, P2438, DOI 10.1101/gad.10.19.2438; Chen XB, 2003, CANCER BIOL THER, V2, P55; Chinery R, 1997, NAT MED, V3, P1233, DOI 10.1038/nm1197-1233; COHEN GB, 1995, CELL, V80, P237, DOI 10.1016/0092-8674(95)90406-9; Di Como CJ, 2002, CLIN CANCER RES, V8, P494; Dohn M, 2001, ONCOGENE, V20, P3193, DOI 10.1038/sj.onc.1204427; Duijf PHG, 2002, HUM MOL GENET, V11, P799, DOI 10.1093/hmg/11.7.799; Flores ER, 2002, NATURE, V416, P560, DOI 10.1038/416560a; Flores ER, 2005, CANCER CELL, V7, P363, DOI 10.1016/j.ccr.2005.02.019; Ghioni P, 2002, MOL CELL BIOL, V22, P8659, DOI 10.1128/MCB.22.24.8659-8668.2002; Harmes DC, 2003, ONCOGENE, V22, P7607, DOI 10.1038/sj.onc.1207129; Hibi K, 2000, P NATL ACAD SCI USA, V97, P5462, DOI 10.1073/pnas.97.10.5462; Kaghad M, 1997, CELL, V90, P809, DOI 10.1016/S0092-8674(00)80540-1; King KE, 2003, ONCOGENE, V22, P3635, DOI 10.1038/sj.onc.1206536; Koga F, 2003, CLIN CANCER RES, V9, P5501; Liefer KM, 2000, CANCER RES, V60, P4016; LIN JY, 1994, GENE DEV, V8, P1235, DOI 10.1101/gad.8.10.1235; Liu G, 2004, MOL CELL BIOL, V24, P487, DOI 10.1128/MCB.24.2.487-501.2004; Liu G, 2002, ONCOGENE, V21, P7195, DOI 10.1038/sj.onc.1205862; Liu G, 2003, J BIOL CHEM, V278, P17557, DOI 10.1074/jbc.M210696200; Massion PP, 2003, CANCER RES, V63, P7113; Miyazaki K, 2003, BIOCHEM BIOPH RES CO, V308, P106, DOI 10.1016/S0006-291X(03)01347-0; Nozell S, 2003, ONCOGENE, V22, P4333, DOI 10.1038/sj.onc.1206470; Osada M, 1998, NAT MED, V4, P839, DOI 10.1038/nm0798-839; Park BJ, 2000, CANCER RES, V60, P3370; Rossi M, 2005, EMBO J, V24, P836, DOI 10.1038/sj.emboj.7600444; Serber Z, 2002, MOL CELL BIOL, V22, P8601, DOI 10.1128/MCB.22.24.8601-8611.2002; Shimada A, 1999, CANCER RES, V59, P2781; Strano S, 2001, J BIOL CHEM, V276, P15164, DOI 10.1074/jbc.M010484200; Strano S, 2000, J BIOL CHEM, V275, P29503, DOI 10.1074/jbc.M003360200; Urist MJ, 2002, AM J PATHOL, V161, P1199, DOI 10.1016/S0002-9440(10)64396-9; Wang Xiaojuan, 2002, Breast Cancer, V9, P216, DOI 10.1007/BF02967592; Wu GJ, 2005, CANCER RES, V65, P758; Yang A, 2002, TRENDS GENET, V18, P90, DOI 10.1016/S0168-9525(02)02595-7; Yang AN, 1998, MOL CELL, V2, P305, DOI 10.1016/S1097-2765(00)80275-0; Zhu JH, 1998, J BIOL CHEM, V273, P13030, DOI 10.1074/jbc.273.21.13030; Zhu JH, 1999, ONCOGENE, V18, P2149, DOI 10.1038/sj.onc.1202533; Zhu JH, 1998, CANCER RES, V58, P5061	42	87	89	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 3	2006	281	5					2533	2542		10.1074/jbc.M507964200	http://dx.doi.org/10.1074/jbc.M507964200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	006XT	16319057	hybrid			2022-12-25	WOS:000234931800016
J	Kurschat, P; Bielenberg, D; Rossignol-Tallandier, M; Stahl, A; Klagsbrun, M				Kurschat, P; Bielenberg, D; Rossignol-Tallandier, M; Stahl, A; Klagsbrun, M			Neuron restrictive silencer factor NRSF/REST is a transcriptional repressor of neuropilin-1 and diminishes the ability of semaphorin 3A to inhibit keratinocyte migration	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENDOTHELIAL GROWTH-FACTOR; TARGET GENES; HISTONE DEACETYLASE; IN-VIVO; VESSEL DEVELOPMENT; AXON GUIDANCE; TUMOR-CELLS; EXPRESSION; RECEPTORS; ANGIOGENESIS	Neuropilin-1 (NRP1) is expressed by endothelial cells and neurons and serves as a receptor for both vascular endothelial growth factor (VEGF), an angiogenesis factor, and semaphorin 3A (Sema3A), a mediator of axonal guidance. We show here that NRP1 is also expressed in keratinocytes in vitro and in vivo. However, nothing has been reported about the regulation or function of keratinocyte NRP1. Using NRP1 promoter constructs in HaCaT cells, a keratinocyte cell line, we could demonstrate that a neuron restrictive silencer element (NRSE) was implicated in transcriptional repression of the NRP1 gene. Electrophoretic mobility shift assays demonstrated that the neuron restrictive silencer factor (NRSF) binds to NRSE. Overexpression of NRSF in HaCaT cells decreased NRP1 RNA and protein, whereas a dominant negative NRSF increased NRP1. Furthermore, the histone deacetylase inhibitor trichostatin A, an inhibitor of NRSF silencing activity, also increased NRP1 levels. NRP2 expression was not affected. Epidermal growth factor (EGF) and heparin-binding EGF-like growth factor (HB-EGF) strongly up-regulated NRP1 expression, concomitant with downregulation of NRSF. Other keratinocyte mitogens such as keratinocyte growth factor (KGF) had no effect. To address function, HaCaT cells were exposed to two NRP1 ligands, VEGF(165) and Sema3A. Neither had an effect on proliferation, whereas Sema3A, but not VEGF(165), inhibited cell migration. Down-regulation of NRP1 by NRSF overexpression reduced Sema3A activity. It was concluded that NRSF is a transcription factor that silences NRP1 expression and thereby diminishes the Sema3A mediated inhibition of HaCaT keratinocyte migration.	Childrens Hosp, Vasc Biol Program, Dept Pathol, Boston, MA 02115 USA; Childrens Hosp, Dept Surg, Boston, MA 02115 USA	Harvard University; Boston Children's Hospital; Harvard University; Boston Children's Hospital	Klagsbrun, M (corresponding author), Childrens Hosp, Vasc Biol Program, Dept Pathol, Karp Bldg 12210,300 Longwood Ave, Boston, MA 02115 USA.	michael.klagsbrun@childrens.harvard.edu			NCI NIH HHS [CA37392, CA45548] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R37CA037392, R01CA037392, R56CA037392, P01CA045548] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Bagri A, 2002, ADV EXP MED BIOL, V515, P13; BISMUTH G, 2002, SCI STKE, pRE4; BOUKAMP P, 1988, J CELL BIOL, V106, P761, DOI 10.1083/jcb.106.3.761; Chen CY, 2005, WORLD J SURG, V29, P271, DOI 10.1007/s00268-004-7818-1; Chen ZF, 1998, NAT GENET, V20, P136, DOI 10.1038/2431; CHONG JHA, 1995, CELL, V80, P949, DOI 10.1016/0092-8674(95)90298-8; Deroanne CF, 2002, ONCOGENE, V21, P427, DOI 10.1038/sj.onc.1205108; Gagnon ML, 2000, P NATL ACAD SCI USA, V97, P2573, DOI 10.1073/pnas.040337597; Giraudo E, 1998, J BIOL CHEM, V273, P22128, DOI 10.1074/jbc.273.34.22128; Goishi K, 2004, CURR TOP DEV BIOL, V62, P127; Gu CH, 2005, SCIENCE, V307, P265, DOI 10.1126/science.1105416; He Zhigang, 2002, Sci STKE, V2002, pre1, DOI 10.1126/stke.2002.119.re1; Herzog Y, 2001, MECH DEVELOP, V109, P115, DOI 10.1016/S0925-4773(01)00518-4; Hong YK, 2002, DEV DYNAM, V225, P351, DOI 10.1002/dvdy.10163; Huang YF, 1999, NAT NEUROSCI, V2, P867, DOI 10.1038/13165; Jones FS, 1999, BIOESSAYS, V21, P372, DOI 10.1002/(SICI)1521-1878(199905)21:5<372::AID-BIES3>3.0.CO;2-3; Kawasaki T, 1999, DEVELOPMENT, V126, P4895; Kitsukawa T, 1997, NEURON, V19, P995, DOI 10.1016/S0896-6273(00)80392-X; Klagsbrun M, 2002, ADV EXP MED BIOL, V515, P33; Kuwahara K, 2003, EMBO J, V22, P6310, DOI 10.1093/emboj/cdg601; Kwei S, 2004, AM J PATHOL, V164, P81, DOI 10.1016/S0002-9440(10)63099-4; le Noble F, 2004, DEVELOPMENT, V131, P361, DOI 10.1242/dev.00929; Lohela M, 2003, THROMB HAEMOSTASIS, V90, P167, DOI 10.1160/TH03-04-0200; MARIKOVSKY M, 1993, P NATL ACAD SCI USA, V90, P3889, DOI 10.1073/pnas.90.9.3889; Miao HQ, 2000, FASEB J, V14, P2532, DOI 10.1096/fj.00-0250com; Miao HQ, 1999, J CELL BIOL, V146, P233, DOI 10.1083/jcb.146.1.233; Mukouyama YS, 2005, DEVELOPMENT, V132, P941, DOI 10.1242/dev.01675; Naruse Y, 1999, P NATL ACAD SCI USA, V96, P13691, DOI 10.1073/pnas.96.24.13691; Neufeld G, 2002, TRENDS CARDIOVAS MED, V12, P13, DOI 10.1016/S1050-1738(01)00140-2; Neufeld G, 2005, FRONT BIOSCI-LANDMRK, V10, P751, DOI 10.2741/1569; Neufeld G, 2002, ADV EXP MED BIOL, V515, P81; Parikh AA, 2004, AM J PATHOL, V164, P2139, DOI 10.1016/S0002-9440(10)63772-8; PAYA CV, 1992, P NATL ACAD SCI USA, V89, P7826, DOI 10.1073/pnas.89.16.7826; Puschel AW, 2002, ADV EXP MED BIOL, V515, P71; Rossignol M, 2003, J CELL BIOCHEM, V88, P744, DOI 10.1002/jcb.10384; SCHOENHERR CJ, 1995, SCIENCE, V267, P1360, DOI 10.1126/science.7871435; Schoenherr CJ, 1996, P NATL ACAD SCI USA, V93, P9881, DOI 10.1073/pnas.93.18.9881; Shimojo M, 2001, J BIOL CHEM, V276, P13121, DOI 10.1074/jbc.M011193200; Soker S, 1998, CELL, V92, P735, DOI 10.1016/S0092-8674(00)81402-6; Su XH, 2004, MOL CELL BIOL, V24, P8018, DOI 10.1128/MCB.24.18.8018-8025.2004; Watanabe D, 2004, AM J PATHOL, V164, P1827, DOI 10.1016/S0002-9440(10)63741-8; Werner S, 1998, CYTOKINE GROWTH F R, V9, P153, DOI 10.1016/S1359-6101(98)00010-0; Westbrook TF, 2005, CELL, V121, P837, DOI 10.1016/j.cell.2005.03.033; Woodside KJ, 2003, AM J SURG, V186, P561, DOI 10.1016/j.amjsurg.2003.07.023; Yoo JY, 2001, BIOCHEM BIOPH RES CO, V283, P928, DOI 10.1006/bbrc.2001.4857; Yoshida M, 2003, CURR MED CHEM, V10, P2351, DOI 10.2174/0929867033456602; You LR, 2005, NATURE, V435, P98, DOI 10.1038/nature03511; Yuan L, 2002, DEVELOPMENT, V129, P4797	48	55	60	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 3	2006	281	5					2721	2729		10.1074/jbc.M507860200	http://dx.doi.org/10.1074/jbc.M507860200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	006XT	16330548	hybrid			2022-12-25	WOS:000234931800038
J	Bearzatto, B; Servais, L; Roussel, C; Gall, D; Baba-Aissa, F; Schurmans, S; d'Exaerde, AD; Cheron, G; Schiffmann, SN				Bearzatto, Bertrand; Servais, Laurent; Roussel, Celine; Gall, David; Baba-Aissa, Fawzia; Schurmans, Stephane; d'Exaerde, Alban de Kerchove; Cheron, Guy; Schiffmann, Serge N.			Targeted calretinin expression in granule cells of calretinin-null mice restores normal cerebellar functions	FASEB JOURNAL			English	Article									[Bearzatto, Bertrand; Servais, Laurent; Roussel, Celine; Gall, David; Baba-Aissa, Fawzia; d'Exaerde, Alban de Kerchove; Schiffmann, Serge N.] Univ Libre Bruxelles, Neurophysiol Lab, B-1070 Brussels, Belgium; [Schurmans, Stephane] Univ Libre Bruxelles, IRIBHM, IBMM, B-1070 Brussels, Belgium; [Cheron, Guy] Univ Libre Bruxelles, Lab Movement Biomech, B-1070 Brussels, Belgium; [Cheron, Guy] Univ Mons, Lab Electrophysiol, B-7000 Mons, Belgium	Universite Libre de Bruxelles; Universite Libre de Bruxelles; Universite Libre de Bruxelles; University of Mons	Schiffmann, SN (corresponding author), Univ Libre Bruxelles, Lab Neurophysiol CP601, Route de Lennik 808, B-1070 Brussels, Belgium.	sschiffm@ulb.ac.be	Servais, Laurent/AAL-7384-2020; de Kerchove d'Exaerde, Alban/R-6984-2019; Baba-Aissa, Fawzia/AAD-7811-2020	de Kerchove d'Exaerde, Alban/0000-0002-0682-5877; Schiffmann, Serge/0000-0002-0118-9816; Servais, Laurent/0000-0001-9270-4061					0	46	46	0	0	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	FEB	2006	20	2					380	382		10.1096/fj.05-3785fje	http://dx.doi.org/10.1096/fj.05-3785fje			3	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	V17CJ	16352645				2022-12-25	WOS:000207915000028
J	Togashi, Y; Kobayashi, T; Momose, S; Ueda, M; Okimoto, K; Hino, O				Togashi, Y.; Kobayashi, T.; Momose, S.; Ueda, M.; Okimoto, K.; Hino, O.			Transgenic rescue from embryonic lethality and renal carcinogenesis in the Nihon rat model by introduction of a wild-type Bhd gene	ONCOGENE			English	Article						renal carcinoma; Bhd gene; Nihon rat; transgenic rescue	EKER RAT; PREDISPOSING GENE; CARCINOMA; MUTATIONS; INSERTION; TUMORS; RISE	We recently reported that a germline insertion of a single nucleotide in the rat homologue of the human Birt - Hogg Dube ' gene ( BHD) gives rise to dominantly inherited cancer in the Nihon rat model. In this study, we constructed transgenic Nihon rats with introduction of a wild- type Bhd gene to ascertain whether suppression of the Nihon phenotype is possible. Rescue from embryonic lethality of mutant homozygotes ( Nihon/ Nihon) and suppression of renal carcinogenesis in heterozygotes ( Nihon/ +) were both observed, de. ning the germline Bhd mutation in the Nihon rat as an embryonal lethal and tumor predisposing mutation. This transgenic rescue system will be useful to analyse Bhd gene function, its relation to tumorigenesis in vivo, and genetic - environmental interactions in carcinogenesis.	Juntendo Univ, Sch Med, Dept Pathol, Bunkyo Ku, Tokyo 1138421, Japan; YS Inst Inc, Utsunomiya, Tochigi, Japan; Dainippon Pharmaceut Co Ltd, Toxicol Grp, Safety Res Labs, Suita, Osaka 564, Japan	Juntendo University; Dainippon Sumitomo Pharmaceutical Company	Hino, O (corresponding author), Juntendo Univ, Sch Med, Dept Pathol, Bunkyo Ku, Tokyo 1138421, Japan.	ohino@med.juntendo.ac.jp						BIRT AR, 1977, ARCH DERMATOL, V113, P1674, DOI 10.1001/archderm.113.12.1674; EKER R, 1961, NATURE, V189, P858, DOI 10.1038/189858b0; HINO O, 1993, P NATL ACAD SCI USA, V90, P327, DOI 10.1073/pnas.90.1.327; HINO O, 1994, BIOCHEM BIOPH RES CO, V203, P1302, DOI 10.1006/bbrc.1994.2324; Hino O, 2001, JPN J CANCER RES, V92, P1147, DOI 10.1111/j.1349-7006.2001.tb02133.x; Kobayashi T, 1997, P NATL ACAD SCI USA, V94, P3990, DOI 10.1073/pnas.94.8.3990; KOBAYASHI T, 1995, NAT GENET, V9, P70, DOI 10.1038/ng0195-70; Majima S, 2000, JPN J CANCER RES, V91, P869, DOI 10.1111/j.1349-7006.2000.tb01027.x; Momose S, 2002, HUM MOL GENET, V11, P2997, DOI 10.1093/hmg/11.24.2997; Nickerson ML, 2002, CANCER CELL, V2, P157, DOI 10.1016/S1535-6108(02)00104-6; Okimoto K, 2004, CURR MOL MED, V4, P887, DOI 10.2174/1566524043359737; Okimoto K, 2004, P NATL ACAD SCI USA, V101, P2023, DOI 10.1073/pnas.0308071100; Okimoto K, 2000, JPN J CANCER RES, V91, P1096, DOI 10.1111/j.1349-7006.2000.tb00890.x; Satake N, 1999, CANCER RES, V59, P849; YEUNG RS, 1994, P NATL ACAD SCI USA, V91, P11413, DOI 10.1073/pnas.91.24.11413	15	10	10	0	1	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY	2006	25	20					2885	2889		10.1038/sj.onc.1209317	http://dx.doi.org/10.1038/sj.onc.1209317			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	041IN	16369488				2022-12-25	WOS:000237448200006
J	Copland, JA; Marlow, LA; Kurakata, S; Fujiwara, K; Wong, AKC; Kreinest, PA; Williams, SF; Haugen, BR; Klopper, JP; Smallridge, RC				Copland, JA; Marlow, LA; Kurakata, S; Fujiwara, K; Wong, AKC; Kreinest, PA; Williams, SF; Haugen, BR; Klopper, JP; Smallridge, RC			Novel high-affinity PPAR gamma agonist alone and in combination with paclitaxel inhibits human anaplastic thyroid carcinoma tumor growth via p21(WAF1/CIP1)	ONCOGENE			English	Article						peroxisome proliferator-activated receptor gamma; paclitaxel; anaplastic thyroid carcinoma; RS5444; p21(WAF1/CIP1); combinatorial therapy; thiazolidinedione	ACTIVATED-RECEPTOR-GAMMA; PANCREATIC-CANCER CELLS; IN-VITRO; DIFFERENTIATION MARKERS; INDEPENDENT GROWTH; PROSTATE-CANCER; GENE-EXPRESSION; CYCLE ARREST; APOPTOSIS; LIGANDS	Peroxisome proliferator-activated receptor gamma (PPARc) agonists demonstrate antitumor activity likely through transactivating genes that regulate cell proliferation, apoptosis, and differentiation. The PAX8/PPARc fusion oncogene, which is common in human follicular thyroid carcinomas appears to act via dominant negative suppression of wild-type PPARc, suggesting that it may be a tumor suppressor gene in thyroid cells. We have identified a novel high-affinity PPARc agonist (RS5444) that is dependent upon PPARc for its biological activity. This is the first report of this molecule and its antitumor activity. In vitro, the IC50 for growth inhibition is similar to 0.8 nM while anaplastic thyroid carcinoma (ATC) tumor growth was inhibited three-to fourfold in nude mice. siRNA against PPARc and a pharmacological antagonist demonstrated that functional PPARc was required for growth inhibitory activity of RS5444. RS5444 upregulated the cell cycle kinase inhibitor, p21(WAF1/CIP1). Silencing p21(WAF1CIP1) rendered cells insensitive to RS5444. RS5444 plus paclitaxel demonstrated additive antiproliferative activity in cell culture and minimal ATC tumor growth in vivo. RS5444 did not induce apoptosis but combined with paclitaxel, doubled the apoptotic index compared to that of paclitaxel. Our data indicate that functional PPARc is a molecular target for therapy in ATC. We demonstrated that RS5444, a thiazolidinedione (Tzd) derivative, alone or in combination with paclitaxel, may provide therapeutic benefit to patients diagnosed with ATC.	Mayo Clin, Coll Med, Dept Canc Biol, Ctr Comprehens Canc, Jacksonville, FL 33224 USA; Sankyo Pharma Res Inst, La Jolla, CA USA; Sankyo Co Ltd, Shinagawa Ku, Tokyo 140, Japan; Sankyo Pharma Res Inst, La Jolla, CA USA; Mayo Clin, Coll Med, Dept Internal Med, Div Endocrinol, Jacksonville, FL 33224 USA; Univ Colorado, Ctr Canc, Dept Med, Div Endocrinol Diabet & Metab, Denver, CO 80262 USA; Hlth Sci Ctr, Aurora, CO USA	Mayo Clinic; Daiichi Sankyo Company Limited; Mayo Clinic; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver	Copland, JA (corresponding author), Mayo Clin, Coll Med, Dept Canc Biol, Ctr Comprehens Canc, 4500 San Pablo Rd, Jacksonville, FL 33224 USA.	copland.john@mayo.edu		Marlow, Laura/0000-0002-4726-9889	NCI NIH HHS [P30CA15083, CA100560] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA015083, R01CA100560] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Ain KB, 1996, J CLIN ENDOCR METAB, V81, P3650, DOI 10.1210/jc.81.10.3650; Ain KB, 2000, THYROID, V10, P587, DOI 10.1089/thy.2000.10.587; Aldred MA, 2003, ONCOGENE, V22, P3412, DOI 10.1038/sj.onc.1206400; Barboule N, 1997, ONCOGENE, V15, P2867, DOI 10.1038/sj.onc.1201469; Bauer AJ, 2002, THYROID, V12, P953, DOI 10.1089/105072502320908286; Belletti B, 1999, ONCOGENE, V18, P4860, DOI 10.1038/sj.onc.1202869; Brockman JA, 1998, GASTROENTEROLOGY, V115, P1049, DOI 10.1016/S0016-5085(98)70072-1; Castrillo A, 2001, J BIOL CHEM, V276, P34082, DOI 10.1074/jbc.M102472200; Chang TH, 2000, CANCER RES, V60, P1129; Chang TH, 2002, CLIN CANCER RES, V8, P1206; Chen F, 2005, CELL SIGNAL, V17, P809, DOI 10.1016/j.cellsig.2004.11.002; Chung SH, 2002, JPN J CANCER RES, V93, P1358, DOI 10.1111/j.1349-7006.2002.tb01245.x; Davies GF, 2002, J PHARMACOL EXP THER, V300, P72, DOI 10.1124/jpet.300.1.72; de la Lastra CA, 2004, CURR PHARM DESIGN, V10, P3505; Debril MB, 2001, J MOL MED, V79, P30, DOI 10.1007/s001090000145; Dwight T, 2003, J CLIN ENDOCR METAB, V88, P4440, DOI 10.1210/jc.2002-021690; Eibl G, 2001, BIOCHEM BIOPH RES CO, V287, P522, DOI 10.1006/bbrc.2001.5619; Elnemr A, 2000, INT J ONCOL, V17, P1157; Elstner E, 1998, P NATL ACAD SCI USA, V95, P8806, DOI 10.1073/pnas.95.15.8806; Fan SJ, 1997, ONCOGENE, V14, P2127, DOI 10.1038/sj.onc.1201052; Fujiwara T, 2000, LIFE SCI, V67, P2405, DOI 10.1016/S0024-3205(00)00829-8; Fujiwara T, 1998, LIFE SCI, V63, P2039, DOI 10.1016/S0024-3205(98)00482-2; Galli A, 2004, GUT, V53, P1688, DOI 10.1136/gut.2003.031997; Girnun GD, 2003, GASTROENTEROLOGY, V124, P564, DOI 10.1053/gast.2003.50070; Guan You-Fei, 1999, Neoplasia (New York), V1, P330, DOI 10.1038/sj.neo.7900050; Han SW, 2004, CLIN CANCER RES, V10, P1911, DOI 10.1158/1078-0432.CCR-03-0985; Hayashi N, 2004, INT J ONCOL, V24, P89; Hong J, 2004, ENDOCRINOLOGY, V145, P5774, DOI 10.1210/en.2004-0686; Huang JW, 2005, MOL PHARMACOL, V67, P1342, DOI 10.1124/mol.104.007732; Itami A, 2001, INT J CANCER, V94, P370, DOI 10.1002/ijc.1488; Kawa S, 2002, PANCREAS, V24, P1, DOI 10.1097/00006676-200201000-00001; Kim S, 2005, MOL CANCER THER, V4, P632, DOI 10.1158/1535-7163.MCT-04-0293; Kitamura S, 1999, JPN J CANCER RES, V90, P75, DOI 10.1111/j.1349-7006.1999.tb00668.x; Klopper JP, 2004, MOL CANCER THER, V3, P1011; Koeffler HP, 2003, CLIN CANCER RES, V9, P1; Koga H, 2001, HEPATOLOGY, V33, P1087, DOI 10.1053/jhep.2001.24024; Kroll TG, 2000, SCIENCE, V289, P1357, DOI 10.1126/science.289.5483.1357; Kubota T, 1998, CANCER RES, V58, P3344; Li WW, 1999, MOL PHARMACOL, V55, P1088, DOI 10.1124/mol.55.6.1088; Lovekamp-Swan T, 2005, MOL CELL ENDOCRINOL, V233, P15, DOI 10.1016/j.mce.2005.01.011; Lu ML, 2005, J BIOL CHEM, V280, P6742, DOI 10.1074/jbc.M411519200; Lui WO, 2005, ONCOGENE, V24, P1467, DOI 10.1038/sj.onc.1208135; Margeli A., 2003, Angiogenesis, V6, P165, DOI 10.1023/B:AGEN.0000021377.13669.c0; Martelli ML, 2002, J CLIN ENDOCR METAB, V87, P4728, DOI 10.1210/jc.2001-012054; McIver Bryan, 2004, Current Drug Targets - Immune Endocrine and Metabolic Disorders, V4, P221, DOI 10.2174/1568008043339802; Motomura W, 2000, CANCER RES, V60, P5558; Nakajima A, 2001, GASTROENTEROLOGY, V120, P460, DOI 10.1053/gast.2001.21191; Nakashiro K, 2001, AM J PATHOL, V159, P591, DOI 10.1016/S0002-9440(10)61730-0; Palakurthi SS, 2001, CANCER RES, V61, P6213; Panigrahy D, 2003, EXPERT OPIN INV DRUG, V12, P1925, DOI 10.1517/13543784.12.12.1925; Panigrahy D, 2002, J CLIN INVEST, V110, P923, DOI 10.1172/JCI200215634; Pei XH, 2005, ONCOGENE, V24, P2787, DOI 10.1038/sj.onc.1208611; Perez-Ortiz JM, 2004, J BIOL CHEM, V279, P8976, DOI 10.1074/jbc.M308518200; Place AE, 2003, CLIN CANCER RES, V9, P2798; Powell JG, 2004, ONCOGENE, V23, P3634, DOI 10.1038/sj.onc.1207399; Rosen ED, 2001, J BIOL CHEM, V276, P37731, DOI 10.1074/jbc.R100034200; Rumi MAK, 2004, GENES CELLS, V9, P1113, DOI 10.1111/j.1365-2443.2004.00793.x; Sato K, 2001, ENDOCR J, V48, P635, DOI 10.1507/endocrj.48.635; Schmidt M, 2000, ONCOGENE, V19, P2423, DOI 10.1038/sj.onc.1203546; Sherman SI, 2003, LANCET, V361, P501, DOI 10.1016/S0140-6736(03)12488-9; Shiau CW, 2005, CANCER RES, V65, P1561, DOI 10.1158/0008-5472.CAN-04-1677; Smith WM, 2001, HUM GENET, V109, P146, DOI 10.1007/s004390100563; TAKASHIMA T, 2001, TRENDS MOL MED, V7, P395; Tsubouchi Y, 2000, BIOCHEM BIOPH RES CO, V270, P400, DOI 10.1006/bbrc.2000.2436; Turturro F, 2004, CLIN CANCER RES, V10, P7022, DOI 10.1158/1078-0432.CCR-04-0879; Vogt T, 2003, CANCER, V98, P2251, DOI 10.1002/cncr.11775; Wahl AF, 1996, NAT MED, V2, P72, DOI 10.1038/nm0196-72; Xin XH, 1999, J BIOL CHEM, V274, P9116, DOI 10.1074/jbc.274.13.9116; Xu GP, 2001, J CLIN ENDOCR METAB, V86, P1769, DOI 10.1210/jc.86.4.1769; Yang HL, 2003, J CLIN ENDOCR METAB, V88, P763, DOI 10.1210/jc.2002-020992; Yang WC, 2005, AM J PATHOL, V166, P1239, DOI 10.1016/S0002-9440(10)62342-5; Yang WL, 2001, CARCINOGENESIS, V22, P1379, DOI 10.1093/carcin/22.9.1379; Yeung SCJ, 2000, CANCER RES, V60, P650; Yin F, 2001, BIOCHEM BIOPH RES CO, V286, P916, DOI 10.1006/bbrc.2001.5491; Yin F, 2004, ONCOGENE, V23, P4614, DOI 10.1038/sj.onc.1207598; Yki-Jarvinen H, 2004, NEW ENGL J MED, V351, P1106, DOI 10.1056/NEJMra041001; Yuan JY, 2005, UROLOGY, V65, P594, DOI 10.1016/j.urology.2004.10.019	77	120	128	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 13	2006	25	16					2304	2317		10.1038/sj.onc.1209267	http://dx.doi.org/10.1038/sj.onc.1209267			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	032HC	16331265				2022-12-25	WOS:000236764300003
J	Carmagnat, M; Drenou, B; Chahal, H; Lord, JM; Charron, D; Estaquier, J; Mooney, NA				Carmagnat, M; Drenou, B; Chahal, H; Lord, JM; Charron, D; Estaquier, J; Mooney, NA			Dissociation of caspase-mediated events and programmed cell death induced via HLA-DR in follicular lymphoma	ONCOGENE			English	Article						MHC class II; apoptosis; signalling	PROTEIN-KINASE-C; LYMPHOCYTIC-LEUKEMIA CELLS; INDUCED APOPTOSIS; PROTEOLYTIC ACTIVATION; MONOCLONAL-ANTIBODIES; CROSS-LINKING; IN-VITRO; B-CELLS; DELTA; TRANSLOCATION	Human leukocyte antigens (HLA) class II antigen-mediated apoptosis has been documented in antigenpresenting cells and B lymphoproliferations. Characteristics of the apoptosis include rapidity and selectivity for mature cells. Follicular lymphomas are particularly refractory to apoptosis. The B-cell lymphoma Ramos shares characteristics of this subgroup and is insensitive to apoptosis via simple HLA-DR engagement. However, oligomerization of HLA-DR antigens induced caspase activation followed byphosphatidylserine externalization, activation of PKC-delta and cleavage of nuclear lamin B. Mitochondrial injury was also detected. However, inhibition of caspase activation simply delayed the apoptotic phenotype but neither protected against cell death nor prevented mitochondrial injury. The data in this report demonstrate that the requirements for the initiating signal ( oligomerization versus engagement) as well as the molecular pathways varies between different B lymphoproliferations despite their common expression of HLADR. Finally, blockade of caspase activation in parallel with HLA-DR mAb stimulation could provide a potent autovaccination stimulus by leading to necrotic death of B-cell lymphomas.	Inst Univ Hematol, Hop St Louis, INSERM U662, F-75010 Paris, France; Hop St Louis, AP HP, Serv Immunol & Histocompatibil, Paris, France; CHU Rennes, Hop Pontchaillou, Lab Hematol, Rennes, France; Univ Birmingham, Sch Med, Dept Immunol, Birmingham, W Midlands, England; Inst Pasteur, Unite Physiopathol Infect Lentivirales, Paris, France; Univ Paris 06, Fac Med, Inst Hematol, Ctr Hayem, Paris, France	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Louis - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Louis - APHP; UDICE-French Research Universities; Universite Paris Cite; CHU Rennes; University of Birmingham; Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; UDICE-French Research Universities; Sorbonne Universite; Universite Paris Cite	Mooney, NA (corresponding author), Inst Univ Hematol, Hop St Louis, INSERM U662, F-75010 Paris, France.	nuala.mooney@histo.chu-stlouis.fr	, ESTAQUIER/AAR-7799-2020	, ESTAQUIER/0000-0002-9432-8044; Lord, Janet/0000-0003-1030-6786; Mooney, Nuala/0000-0002-3516-6882	Medical Research Council [G9818340B] Funding Source: researchfish	Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission)		Besnault L, 2001, J IMMUNOL, V167, P733, DOI 10.4049/jimmunol.167.2.733; BRICKGHANNAM C, 1991, J BIOL CHEM, V266, P24169; BRICKGHANNAM C, 1994, HUM IMMUNOL, V41, P216, DOI 10.1016/0198-8859(94)90039-6; CHAOUCHI N, 1995, J IMMUNOL, V154, P3096; Cross T, 2000, ONCOGENE, V19, P2331, DOI 10.1038/sj.onc.1203555; Drenou B, 1999, J IMMUNOL, V163, P4115; Edinger AL, 2004, CURR OPIN CELL BIOL, V16, P663, DOI 10.1016/j.ceb.2004.09.011; Emoto Y, 1995, EMBO J, V14, P6148, DOI 10.1002/j.1460-2075.1995.tb00305.x; Funakoshi S, 1997, BLOOD, V90, P3160, DOI 10.1182/blood.V90.8.3160; Ghayur T, 1996, J EXP MED, V184, P2399, DOI 10.1084/jem.184.6.2399; GREEN DR, 1994, CURR OPIN IMMUNOL, V6, P476, DOI 10.1016/0952-7915(94)90130-9; Huby RDJ, 1999, J BIOL CHEM, V274, P22591, DOI 10.1074/jbc.274.32.22591; Inman GJ, 2000, J IMMUNOL, V165, P2500, DOI 10.4049/jimmunol.165.5.2500; LAZEBNIK YA, 1993, J CELL BIOL, V123, P7, DOI 10.1083/jcb.123.1.7; Leveille C, 1999, INT IMMUNOL, V11, P719, DOI 10.1093/intimm/11.5.719; Leverkus M, 2003, INT IMMUNOL, V15, P993, DOI 10.1093/intimm/dxg099; Majumder PK, 2000, J BIOL CHEM, V275, P21793, DOI 10.1074/jbc.C000048200; McLellan AD, 2000, CELL DEATH DIFFER, V7, P933, DOI 10.1038/sj.cdd.4400734; Mecklenbrauker I, 2002, NATURE, V416, P860, DOI 10.1038/416860a; Medema JP, 1997, EMBO J, V16, P2794, DOI 10.1093/emboj/16.10.2794; Miyamoto A, 2002, NATURE, V416, P865, DOI 10.1038/416865a; Mone AP, 2004, BLOOD, V103, P1846, DOI 10.1182/blood-2003-08-2836; Nagy ZA, 2002, NAT MED, V8, P801, DOI 10.1038/nm736; Pedersen IM, 2002, BLOOD, V99, P1314, DOI 10.1182/blood.V99.4.1314; Rich T, 1997, J IMMUNOL, V159, P3792; Scheel-Toellner D, 1999, EUR J IMMUNOL, V29, P2603, DOI 10.1002/(SICI)1521-4141(199908)29:08<2603::AID-IMMU2603>3.0.CO;2-L; Setterblad N, 2004, J LEUKOCYTE BIOL, V75, P1036, DOI 10.1189/jlb.0703356; Truman JP, 1996, EXP HEMATOL, V24, P1409; Webb PR, 2000, APOPTOSIS, V5, P451, DOI 10.1023/A:1009601220552; Wieder T, 2001, BLOOD, V97, P1378, DOI 10.1182/blood.V97.5.1378	30	7	8	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 23	2006	25	13					1914	1921		10.1038/sj.onc.1209222	http://dx.doi.org/10.1038/sj.onc.1209222			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	024VQ	16301998				2022-12-25	WOS:000236224800008
J	Rosengren, KJ; Lin, F; Bathgate, RAD; Tregear, GW; Daly, NL; Wade, JD; Craik, DJ				Rosengren, KJ; Lin, F; Bathgate, RAD; Tregear, GW; Daly, NL; Wade, JD; Craik, DJ			Solution structure and novel insights into the determinants of the receptor specificity of human relaxin-3	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DISULFIDE BOND ISOMERIZATION; HUMAN INSULIN MUTANT; NUCLEUS INCERTUS; PEPTIDE FAMILY; H3 RELAXIN; LIGAND; FIELD; LGR8; IDENTIFICATION; ACTIVATION	Relaxin- 3 is the most recently discovered member of the relaxin family of peptide hormones. In contrast to relaxin- 1 and - 2, whose main functions are associated with pregnancy, relaxin- 3 is involved in neuropeptide signaling in the brain. Here, we report the solution structure of human relaxin- 3, the first structure of a relaxin family member to be solved by NMR methods. Overall, relaxin- 3 adopts an insulin- like fold, but the structure differs crucially from the crystal structure of human relaxin- 2 near the B- chain terminus. In particular, the B- chain C terminus folds back, allowing Trp(B27) to interact with the hydrophobic-core. This interaction partly blocks the conserved RXXXRXXI motif identified as a determinant for the interaction with the relaxin receptor LGR7 and may account for the lower affinity of relaxin- 3 relative to relaxin for this receptor. This structural feature is likely important for the activation of its endogenous receptor, GPCR135.	Univ Queensland, Inst Mol Biosci, Brisbane, Qld 4072, Australia; Univ Melbourne, Howard Florey Inst, Melbourne, Vic 3010, Australia; Univ Kalmar, Dept Chem & Biomed Sci, SE-39281 Kalmar, Sweden	University of Queensland; Florey Institute of Neuroscience & Mental Health; University of Melbourne; Linnaeus University; University of Kalmar	Craik, DJ (corresponding author), Univ Queensland, Inst Mol Biosci, Brisbane, Qld 4072, Australia.	d.craik@imb.uq.edu.au	Craik, David/B-1695-2010; Daly, Norelle L/D-4302-2013; Rosengren, K. Johan/P-4450-2016; Bathgate, Ross/ABE-6471-2020	Craik, David/0000-0003-0007-6796; Daly, Norelle L/0000-0002-4697-6602; Rosengren, K. Johan/0000-0002-5007-8434; Bathgate, Ross/0000-0001-6301-861X; Wade, John/0000-0002-1352-6568				ALTIERI AS, 1995, J AM CHEM SOC, V117, P7566, DOI 10.1021/ja00133a039; BAKER EN, 1988, PHILOS T ROY SOC B, V319, P369, DOI 10.1098/rstb.1988.0058; BALSCHMIDT P, 1992, DIABETOLOGIA, V35, pA4; Bani D, 1997, GEN PHARMACOL-VASC S, V28, P13, DOI 10.1016/S0306-3623(96)00171-1; Bathgate RAD, 2002, J BIOL CHEM, V277, P1148, DOI 10.1074/jbc.M107882200; BLUNDELL TL, 1971, NATURE, V231, P506, DOI 10.1038/231506a0; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Bullesbach EE, 2005, J BIOL CHEM, V280, P14586, DOI 10.1074/jbc.M414443200; Bullesbach EE, 1999, BIOCHEMISTRY-US, V38, P3073, DOI 10.1021/bi982687u; Burazin TCD, 2002, J NEUROCHEM, V82, P1553, DOI 10.1046/j.1471-4159.2002.01114.x; Clausen R, 2002, EUR J ENDOCRINOL, V147, P227, DOI 10.1530/eje.0.1470227; DEREWENDA U, 1989, NATURE, V338, P594, DOI 10.1038/338594a0; DEREWENDA U, 1991, J MOL BIOL, V220, P425, DOI 10.1016/0022-2836(91)90022-X; EIGENBROT C, 1991, J MOL BIOL, V221, P15, DOI 10.1016/0022-2836(91)90796-9; Garber SL, 2001, KIDNEY INT, V59, P876, DOI 10.1046/j.1523-1755.2001.059003876.x; Goto M, 2001, J COMP NEUROL, V438, P86, DOI 10.1002/cne.1303; Grey MJ, 2003, J AM CHEM SOC, V125, P14324, DOI 10.1021/ja0367389; Higgins K A, 1988, Drug Des Deliv, V3, P159; Hsu SY, 2002, SCIENCE, V295, P671, DOI 10.1126/science.1065654; HUDSON P, 1984, EMBO J, V3, P2333, DOI 10.1002/j.1460-2075.1984.tb02135.x; HUDSON P, 1983, NATURE, V301, P628, DOI 10.1038/301628a0; Jorgensen AMM, 1996, J MOL BIOL, V257, P684, DOI 10.1006/jmbi.1996.0194; Keller D, 2001, BIOCHEMISTRY-US, V40, P10732, DOI 10.1021/bi0108150; Kumagai J, 2002, J BIOL CHEM, V277, P31283, DOI 10.1074/jbc.C200398200; Lin F, 2004, J PEPT SCI, V10, P257, DOI 10.1002/psc.521; Linge JP, 1999, J BIOMOL NMR, V13, P51, DOI 10.1023/A:1008365802830; Liu CL, 2005, J BIOL CHEM, V280, P292, DOI 10.1074/jbc.M409916200; Liu CL, 2003, J BIOL CHEM, V278, P50765, DOI 10.1074/jbc.M308996200; Liu CL, 2003, J BIOL CHEM, V278, P50754, DOI 10.1074/jbc.M308995200; McGowan BMC, 2005, ENDOCRINOLOGY, V146, P3295, DOI 10.1210/en.2004-1532; OTTING G, 1993, BIOCHEMISTRY-US, V32, P3571, DOI 10.1021/bi00065a008; Sherwood O. David, 1994, P861; SMITH GD, 1984, P NATL ACAD SCI-BIOL, V81, P7093, DOI 10.1073/pnas.81.22.7093; Sudo S, 2003, J BIOL CHEM, V278, P7855, DOI 10.1074/jbc.M212457200; Tanaka M, 2005, EUR J NEUROSCI, V21, P1659, DOI 10.1111/j.1460-9568.2005.03980.x; UNEMORI EN, 1990, J BIOL CHEM, V265, P10681; Van Der Westhuizen ET, 2005, ANN NY ACAD SCI, V1041, P332, DOI 10.1196/annals.1282.053; Wilkins DK, 1999, BIOCHEMISTRY-US, V38, P16424, DOI 10.1021/bi991765q; Wilkinson TN, 2005, BMC EVOL BIOL, V5, DOI 10.1186/1471-2148-5-14; Williams EJ, 2001, GUT, V49, P577, DOI 10.1136/gut.49.4.577	40	75	78	1	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 3	2006	281	9					5845	5851		10.1074/jbc.M511210200	http://dx.doi.org/10.1074/jbc.M511210200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	015RQ	16365033	hybrid			2022-12-25	WOS:000235568900064
J	Eckstein, TM; Chandrasekaran, S; Mahapatra, S; McNeil, MR; Chatterjee, D; Rithner, CD; Ryan, PW; Belisle, JT; Inamine, JM				Eckstein, TM; Chandrasekaran, S; Mahapatra, S; McNeil, MR; Chatterjee, D; Rithner, CD; Ryan, PW; Belisle, JT; Inamine, JM			A major cell wall lipopeptide of Mycobacterium avium subspecies paratuberculosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAPID SERODIAGNOSIS; SYNTHETASE; GLYCOPEPTIDOLIPIDS; ANTIGENS; ANTIBODY	Mycobacterium avium subspecies paratuberculosis (MAP), the causative agent of Johne disease in cattle and other ruminants, is proposed to be at least one of the causes of Crohn disease in humans. MAP and Mycobacterium avium subspecies avium, a closely related opportunistic environmental bacterium, share 95% of their genes and exhibit homologies of more than 99% between these genes. The identification of molecules specific for MAP is essential for understanding its pathogenicity and for development of useful diagnostic tools. The application of gas chromatography, mass spectrometry, and nuclear magnetic resonance led to the structural identification of a major cell wall lipopeptide of MAP, termed Para-LP-01, defined as C20 fatty acyl-D-Phe-N-Me-L-Val-L-Ile-L-Phe-L-Ala methyl ester. Variations of this lipopeptide with different fatty acyl moieties (C16 fatty acyl through C17, C18, C19, C21 to C22) were also identified. Besides the specificity of this lipopeptide for MAP, the presence of an N-Me-L-valine represents the first reported N-methylated amino acid within an immunogenic lipopeptide of mycobacteria. Sera from animals with Johne disease, but not sera from uninfected cattle, reacted with this lipopeptide, indicating potential biological importance.	Colorado State Univ, Dept Microbiol Immunol & Pathol, Ft Collins, CO 80523 USA; Colorado State Univ, Macromol Res Facil, Ft Collins, CO 80523 USA; Colorado State Univ, Dept Chem, Ft Collins, CO 80523 USA	Colorado State University; Colorado State University; Colorado State University	Inamine, JM (corresponding author), Colorado State Univ, Dept Microbiol Immunol & Pathol, 1682 Campus Delivery, Ft Collins, CO 80523 USA.	jinamine@colostate.edu	Belisle, John T/B-8944-2017; Mahapatra, Sebabrata/D-6033-2017; McNeil, Michael/G-3325-2019	Belisle, John T/0000-0002-2539-2798; 	NIAID NIH HHS [R01 AI-51283] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI051283] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BARBER M, 1965, BIOCHEM BIOPH RES CO, V18, P469, DOI 10.1016/0006-291X(65)90775-8; BARROW WW, 1982, INFECT IMMUN, V36, P678, DOI 10.1128/IAI.36.2.678-684.1982; BARTOS M, 2005, J MICROBIOL METHODS; Behr M, 2004, PATHOGENIC MYCOBACTE, P39; BELISLE JT, 1993, J BIOL CHEM, V268, P10510; BILLICH A, 1987, BIOL CHEM H-S, V368, P521, DOI 10.1515/bchm3.1987.368.1.521; Chacon O, 2004, ANNU REV MICROBIOL, V58, P329, DOI 10.1146/annurev.micro.58.030603.123726; Chatterjee D, 2001, CELL MOL LIFE SCI, V58, P2018, DOI 10.1007/PL00000834; CIUCANU I, 1984, CARBOHYD RES, V131, P209, DOI 10.1016/0008-6215(84)85242-8; DALEINE G, 1995, TUBERCLE LUNG DIS, V76, P234, DOI 10.1016/S0962-8479(05)80011-5; deCrecyLagard V, 1997, ANTIMICROB AGENTS CH, V41, P1904, DOI 10.1128/AAC.41.9.1904; Hacker C, 2000, J BIOL CHEM, V275, P30826, DOI 10.1074/jbc.M002614200; HUSEK P, 1975, J CHROMATOGR, V113, P139, DOI 10.1016/S0021-9673(00)86962-9; LEE BY, 1991, J CLIN MICROBIOL, V29, P1026, DOI 10.1128/JCM.29.5.1026-1029.1991; Li LL, 2005, P NATL ACAD SCI USA, V102, P12344, DOI 10.1073/pnas.0505662102; Maekura R, 2001, J CLIN MICROBIOL, V39, P3603, DOI 10.1128/JCM.39.10.3603-3608.2001; Marahiel MA, 1997, CHEM REV, V97, P2651, DOI 10.1021/cr960029e; Moody DB, 2004, SCIENCE, V303, P527, DOI 10.1126/science.1089353; Okuda Y, 2004, J CLIN MICROBIOL, V42, P1136, DOI 10.1128/JCM.42.3.1136-1141.2004; Primm TP, 2004, CLIN MICROBIOL REV, V17, P98, DOI 10.1128/CMR.17.1.98-106.2004; Riviere M, 1996, EUR J BIOCHEM, V241, P682, DOI 10.1111/j.1432-1033.1996.00682.x; Rojas-Espinosa O, 2003, Acta Leprol, V12, P112; Schauwecker F, 2000, CHEM BIOL, V7, P287, DOI 10.1016/S1074-5521(00)00103-4; Sieber SA, 2005, CHEM REV, V105, P715, DOI 10.1021/cr0301191; Stabel JR, 2005, J CLIN MICROBIOL, V43, P4744, DOI 10.1128/JCM.43.9.4744-4750.2005; Thern B, 2002, ANGEW CHEM INT EDIT, V41, P2307, DOI 10.1002/1521-3773(20020703)41:13&lt;2307::AID-ANIE2307&gt;3.0.CO;2-Y; VITOUX B, 1986, INT J PEPT PROT RES, V27, P617; vonDohren H, 1997, CHEM REV, V97, P2675, DOI 10.1021/cr9600262	28	27	30	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 24	2006	281	8					5209	5215		10.1074/jbc.M512465200	http://dx.doi.org/10.1074/jbc.M512465200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	013RF	16339155	hybrid			2022-12-25	WOS:000235426200075
J	Nikrodhanond, AA; Ortiga-Carvalho, TM; Shibusawa, N; Hashimoto, K; Liao, XH; Refetoff, S; Yamada, M; Mori, M; Wondisford, FE				Nikrodhanond, AA; Ortiga-Carvalho, TM; Shibusawa, N; Hashimoto, K; Liao, XH; Refetoff, S; Yamada, M; Mori, M; Wondisford, FE			Dominant role of thyrotropin-releasing hormone in the hypothalamic-pituitary-thyroid axis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECEPTOR-BETA; TRANSCRIPTIONAL REGULATION; PARAVENTRICULAR NUCLEUS; TERTIARY HYPOTHYROIDISM; POSTNATAL-DEVELOPMENT; STIMULATING HORMONE; GENE-EXPRESSION; SUBUNIT GENES; ALPHA-GENE; NULL MICE	Hypothalamic thyrotropin-releasing hormone (TRH) stimulates thyroid-stimulating hormone (TSH) secretion from the anterior pituitary. TSH then initiates thyroid hormone (TH) synthesis and release from the thyroid gland. Although opposing TRH and TH inputs regulate the hypothalamic-pituitary-thyroid axis, TH negative feedback is thought to be the primary regulator. This hypothesis, however, has yet to be proven in vivo. To elucidate the relative importance of TRH and TH in regulating the hypothalamic-pituitary-thyroid axis, we have generated mice that lack either TRH, the beta isoforms of TH receptors ( TR beta KO), or both ( double KO). TR beta knock-out ( KO) mice have significantly higher TH and TSH levels compared with wild-type mice, in contrast to double KO mice, which have reduced TH and TSH levels. Unexpectedly, hypothyroid double KO mice also failed to mount a significant rise in serum TSH levels, and pituitary TSH immunostaining was markedly reduced compared with all other hypothyroid mouse genotypes. This impaired TSH response, however, was not due to a reduced number of pituitary thyrotrophs because thyrotroph cell number, as assessed by counting TSH immunopositive cells, was restored after chronic TRH treatment. Thus, TRH is absolutely required for both TSH and TH synthesis but is not necessary for thyrotroph cell development.	Johns Hopkins Med Inst, Dept Med, Baltimore, MD 21287 USA; Univ Chicago, Dept Med, Chicago, IL 60637 USA; Univ Chicago, Comm Mol Metab & Nutr, Pritzker Sch Med, Chicago, IL 60637 USA; Univ Fed Rio de Janeiro, Inst Biofis Carlos Chagas Filho, BR-21000000 Rio De Janeiro, Brazil; Gunma Univ, Dept Med & Mol Sci, Grad Sch Med, Maebashi, Gumma 33922, Japan	Johns Hopkins University; Johns Hopkins Medicine; University of Chicago; University of Chicago; Universidade Federal do Rio de Janeiro; Gunma University	Wondisford, FE (corresponding author), Johns Hopkins Med Inst, Div Metab, Dept Pediat, Baltimore, MD 21287 USA.	fwondisford@jhmi.edu	Ortiga-Carvalho, Tania/F-7178-2014; Ortiga-Carvalho, Tania M/D-5093-2011; Refetoff, Samuel/ABB-1263-2021	Ortiga-Carvalho, Tania/0000-0002-0225-1132; Ortiga-Carvalho, Tania M/0000-0002-0225-1132; Refetoff, Samuel/0000-0003-0164-8231	NIDDK NIH HHS [DK20595, DK49126, DK53036] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK049126, P60DK020595, R01DK053036] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Abel ED, 1999, J CLIN INVEST, V104, P291, DOI 10.1172/JCI6397; Abel ED, 2003, MOL ENDOCRINOL, V17, P1767, DOI 10.1210/me.2003-0109; Abel ED, 2001, J CLIN INVEST, V107, P1017, DOI 10.1172/JCI10858; Bassett JHD, 2003, MOL CELL ENDOCRINOL, V213, P1, DOI 10.1016/j.mce.2003.10.033; BECKPECCOZ P, 1985, NEW ENGL J MED, V312, P1085, DOI 10.1056/NEJM198504253121703; BRADLEY DJ, 1994, P NATL ACAD SCI USA, V91, P439, DOI 10.1073/pnas.91.2.439; COHEN RN, 2005, WERNER INGBARS THYRO, P159; DANGELO SA, 1972, NEUROENDOCRINOLOGY, V9, P197, DOI 10.1159/000122050; DELEAN A, 1977, ENDOCRINOLOGY, V100, P1496, DOI 10.1210/endo-100-6-1496; Dupre SM, 2004, ENDOCRINOLOGY, V145, P2337, DOI 10.1210/en.2003-1209; DYESS EM, 1988, ENDOCRINOLOGY, V123, P2291, DOI 10.1210/endo-123-5-2291; Flamant F, 2003, TRENDS ENDOCRIN MET, V14, P85, DOI 10.1016/S1043-2760(02)00043-7; Forrest D, 1996, NAT GENET, V13, P354, DOI 10.1038/ng0796-354; Fraichard A, 1997, EMBO J, V16, P4412, DOI 10.1093/emboj/16.14.4412; Gauthier K, 1999, EMBO J, V18, P623, DOI 10.1093/emboj/18.3.623; HARRIS ARC, 1978, J CLIN INVEST, V61, P441, DOI 10.1172/JCI108955; HINKLE PM, 1982, ENDOCRINOLOGY, V110, P1725, DOI 10.1210/endo-110-5-1725; HODIN RA, 1989, SCIENCE, V244, P76, DOI 10.1126/science.2539642; KOJIMA A, 1974, ENDOCRINOLOGY, V94, P1133, DOI 10.1210/endo-94-4-1133; Lado-Abeal J, 2005, J CLIN ENDOCR METAB, V90, P1760, DOI 10.1210/jc.2004-1488; Lazar MA, 2003, J CLIN INVEST, V112, P497, DOI 10.1172/JCI200319479; LECHAN RM, 1994, ENDOCRINOLOGY, V135, P92, DOI 10.1210/en.135.1.92; Macchia PE, 2001, P NATL ACAD SCI USA, V98, P349, DOI 10.1073/pnas.011306998; Moeller LC, 2003, MOL ENDOCRINOL, V17, P2295, DOI 10.1210/me.2003-0175; Ng L, 2001, HUM MOL GENET, V10, P2701, DOI 10.1093/hmg/10.23.2701; PERRET J, 1990, BIOCHEM BIOPH RES CO, V171, P1044, DOI 10.1016/0006-291X(90)90789-P; Persani L, 2000, J CLIN ENDOCR METAB, V85, P3631, DOI 10.1210/jc.85.10.3631; Pohlenz J, 1999, THYROID, V9, P1265, DOI 10.1089/thy.1999.9.1265; SCALAN TS, 2004, NAT MED, V6, P638; SEGERSON TP, 1987, SCIENCE, V238, P78, DOI 10.1126/science.3116669; Shibusawa N, 2003, J CLIN INVEST, V112, P588, DOI 10.1172/JCI200318377; Shibusawa N, 2000, MOL ENDOCRINOL, V14, P137, DOI 10.1210/me.14.1.137; Shupnik M A, 2000, Rev Endocr Metab Disord, V1, P35, DOI 10.1023/A:1010008318961; SHUPNIK MA, 1986, J BIOL CHEM, V261, P2675; SHUPNIK MA, 1985, J BIOL CHEM, V260, P2900; SIMMONS DM, 1989, J HISTOTECHNOL, V12, P169; STEINFELDER HJ, 1991, P NATL ACAD SCI USA, V88, P3130, DOI 10.1073/pnas.88.8.3130; TAYLOR T, 1989, ENDOCRINOLOGY, V125, P2198; Weiss RE, 1997, ENDOCRINOLOGY, V138, P3624, DOI 10.1210/en.138.9.3624; Wikstrom L, 1998, EMBO J, V17, P455, DOI 10.1093/emboj/17.2.455; Yamada M, 1997, P NATL ACAD SCI USA, V94, P10862, DOI 10.1073/pnas.94.20.10862	41	66	68	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 24	2006	281	8					5000	5007		10.1074/jbc.M511530200	http://dx.doi.org/10.1074/jbc.M511530200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	013RF	16339138	hybrid			2022-12-25	WOS:000235426200052
J	Fellin, T; Pozzan, T; Carmignoto, G				Fellin, T; Pozzan, T; Carmignoto, G			Purinergic receptors mediate two distinct glutamate release pathways in hippocampal astrocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							P2X RECEPTORS; RAT HIPPOCAMPUS; SYNAPTIC-TRANSMISSION; EXTRACELLULAR CALCIUM; NUCLEOTIDE RECEPTORS; MOLECULAR PHYSIOLOGY; CULTURED ASTROCYTES; NEURONAL-ACTIVITY; NERVOUS-SYSTEM; GLIAL-CELLS	The purinergic P2X(7) receptor (P2X(7)R) can mediate glutamate release from cultured astrocytes. Using patch clamp recordings, we investigated whether P2X(7)Rs have the same action in hippocampal astrocytes in situ. We found that 2- and 3-O-(4-benzoylbenzoyl) ATP (BzATP), a potent, although unselective P2X(7)R agonist, triggers two different glutamate-mediated responses in CA1 pyramidal neurons; they are transient inward currents, which have the kinetic and pharmacological properties of previously described slow inward currents (SICs) due to Ca2+-dependent glutamate release from astrocytes, and a sustained tonic current. Although SICs were unaffected by P2X(7)Rs antagonists, the tonic current was inhibited, was amplified in low extracellular Ca2+, and was insensitive to glutamate transporter and hemichannel inhibitors. BzATP triggered in astrocytes a large depolarization that was inhibited by P2X(7)R antagonists and amplified in low Ca2+. In low Ca2+ BzATP also induced lucifer yellow uptake into a subpopulation of astrocytes and CA3 neurons. Our results demonstrate that purinergic receptors other than the P2X(7)R mediate glutamate release that evokes SICs, whereas activation of a receptor that has features similar to the P2X(7)R, mediates a sustained glutamate efflux that generates a tonic current in CA1 neurons. This sustained glutamate efflux, which is potentiated under non-physiological conditions, may have important pathological actions in the brain.	Univ Padua, CNR, Ist Neurosci, I-35121 Padua, Italy; Univ Padua, Dipartimento Sci Biomed Sperimentali, I-35121 Padua, Italy	Consiglio Nazionale delle Ricerche (CNR); University of Padua; University of Padua	Carmignoto, G (corresponding author), Univ Padua, CNR, Ist Neurosci, Viale G Colombo 3, I-35121 Padua, Italy.	gcarmi@bio.unipd.it	Carmignoto, Giorgio/A-8375-2018	Carmignoto, Giorgio/0000-0003-3063-6774				Angulo MC, 2004, J NEUROSCI, V24, P6920, DOI 10.1523/JNEUROSCI.0473-04.2004; Armstrong JN, 2002, J NEUROSCI, V22, P5938; Atkinson L, 2004, NEUROSCIENCE, V123, P761, DOI 10.1016/j.neuroscience.2003.08.065; Bezzi P, 2004, NAT NEUROSCI, V7, P613, DOI 10.1038/nn1246; Bezzi P, 1998, NATURE, V391, P281, DOI 10.1038/34651; Bianchi BR, 1999, EUR J PHARMACOL, V376, P127, DOI 10.1016/S0014-2999(99)00350-7; Bowser DN, 2004, J NEUROSCI, V24, P8606, DOI 10.1523/JNEUROSCI.2660-04.2004; Burgo A, 2003, J PHYSIOL-LONDON, V549, P537, DOI 10.1113/jphysiol.2003.041871; Cavaliere F, 2004, J CEREBR BLOOD F MET, V24, P392, DOI 10.1097/00004647-200404000-00004; Chen NS, 2000, J NEUROPHYSIOL, V84, P693, DOI 10.1152/jn.2000.84.2.693; CHOI DW, 1988, NEURON, V1, P623, DOI 10.1016/0896-6273(88)90162-6; CHOI DW, 1990, ANNU REV NEUROSCI, V13, P171, DOI 10.1146/annurev.ne.13.030190.001131; CHOI ESH, 1990, DEV BIOL, V142, P169, DOI 10.1016/0012-1606(90)90160-K; Coco S, 2003, J BIOL CHEM, V278, P1354, DOI 10.1074/jbc.M209454200; Deuchars SA, 2001, J NEUROSCI, V21, P7143, DOI 10.1523/JNEUROSCI.21-18-07143.2001; Di Virgilio F, 2001, BLOOD, V97, P587, DOI 10.1182/blood.V97.3.587; DIVIRGILIO F, 1995, IMMUNOL TODAY, V16, P524, DOI 10.1016/0167-5699(95)80045-X; Duan SM, 2003, J NEUROSCI, V23, P1320, DOI 10.1523/JNEUROSCI.23-04-01320.2003; EDWARDS FA, 1989, PFLUG ARCH EUR J PHY, V414, P600, DOI 10.1007/BF00580998; Evanko DS, 2004, GLIA, V47, P233, DOI 10.1002/glia.20050; Fellin T, 2004, NEURON, V43, P729, DOI 10.1016/j.neuron.2004.08.011; Fiacco TA, 2004, J NEUROSCI, V24, P722, DOI 10.1523/JNEUROSCI.2859-03.2004; Fields RD, 2000, TRENDS NEUROSCI, V23, P625, DOI 10.1016/S0166-2236(00)01674-X; Fumagalli M, 2003, GLIA, V43, P218, DOI 10.1002/glia.10248; GERBER U, 1989, J PHYSIOL-LONDON, V417, P567, DOI 10.1113/jphysiol.1989.sp017819; GORTER JA, 1995, NEUROSCI LETT, V194, P209, DOI 10.1016/0304-3940(95)11748-L; Jeremic A, 2001, J NEUROCHEM, V77, P664, DOI 10.1046/j.1471-4159.2001.00272.x; Jiang LH, 2000, MOL PHARMACOL, V58, P82, DOI 10.1124/mol.58.1.82; Kamermans M, 2001, SCIENCE, V292, P1178, DOI 10.1126/science.1060101; Kang J, 1998, NAT NEUROSCI, V1, P683, DOI 10.1038/3684; Khakh BS, 2001, NAT REV NEUROSCI, V2, P165, DOI 10.1038/35058521; Khakh BS, 1999, NAT NEUROSCI, V2, P322, DOI 10.1038/7233; Kreft M, 2004, GLIA, V46, P437, DOI 10.1002/glia.20018; Kukley M, 2004, J NEUROSCI, V24, P7128, DOI 10.1523/JNEUROSCI.2093-04.2004; Kukley M, 2001, GLIA, V36, P11, DOI 10.1002/glia.1091; Lambrecht G, 2000, N-S ARCH PHARMACOL, V362, P340, DOI 10.1007/s002100000312; Liu QS, 2004, P NATL ACAD SCI USA, V101, P3172, DOI 10.1073/pnas.0306731101; Matthias K, 2003, J NEUROSCI, V23, P1750; Mulligan SJ, 2004, NATURE, V431, P195, DOI 10.1038/nature02827; MURGIA M, 1993, J BIOL CHEM, V268, P8199; Newman EA, 1998, J NEUROSCI, V18, P4022; North RA, 2000, ANNU REV PHARMACOL, V40, P563, DOI 10.1146/annurev.pharmtox.40.1.563; North RA, 1997, CURR OPIN NEUROBIOL, V7, P346, DOI 10.1016/S0959-4388(97)80062-1; North RA, 2002, PHYSIOL REV, V82, P1013, DOI 10.1152/physrev.00015.2002; Pankratov Y, 1998, EUR J NEUROSCI, V10, P3898, DOI 10.1046/j.1460-9568.1998.00419.x; PARPURA V, 1994, NATURE, V369, P744, DOI 10.1038/369744a0; Pasti L, 1997, J NEUROSCI, V17, P7817; Peters O, 2003, J NEUROSCI, V23, P9888; Ralevic V, 1998, PHARMACOL REV, V50, P413; Shimamoto K, 1998, MOL PHARMACOL, V53, P195, DOI 10.1124/mol.53.2.195; Sim JA, 2004, J NEUROSCI, V24, P6307, DOI 10.1523/JNEUROSCI.1469-04.2004; Sperlagh B, 2002, J NEUROCHEM, V81, P1196, DOI 10.1046/j.1471-4159.2002.00920.x; Ventura R, 1999, J NEUROSCI, V19, P6897, DOI 10.1523/JNEUROSCI.19-16-06897.1999; Virginio C, 1999, NAT NEUROSCI, V2, P315, DOI 10.1038/7225; Wang XH, 2004, NAT MED, V10, P821, DOI 10.1038/nm1082; Ye ZC, 2003, J NEUROSCI, V23, P3588, DOI 10.1523/jneurosci.23-09-03588.2003; Zhang JM, 2003, NEURON, V40, P971, DOI 10.1016/S0896-6273(03)00717-7	57	117	124	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 17	2006	281	7					4274	4284		10.1074/jbc.M510679200	http://dx.doi.org/10.1074/jbc.M510679200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	011NN	16338906	hybrid			2022-12-25	WOS:000235275300061
J	Hashikawa, N; Mizukami, Y; Imazu, H; Sakurai, H				Hashikawa, N; Mizukami, Y; Imazu, H; Sakurai, H			Mutated yeast heat shock transcription factor activates transcription independently of hyperphosphorylation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA-BINDING DOMAIN; METALLOTHIONEIN GENE-EXPRESSION; SACCHAROMYCES-CEREVISIAE; PROTEIN-KINASE; GLUCOSE STARVATION; FACTOR CONTAINS; IN-VITRO; PHOSPHORYLATION; DROSOPHILA; ELEMENT	The homotrimeric heat shock transcription factor (HSF) binds to the heat shock element of target genes and regulates transcription in response to various stresses. The Hsf1 protein of Saccharomyces cerevisiae is extensively phosphorylated upon heat shock; a modification that is under positive regulation by its C-terminal regulatory domain (CTM). Hyperphosphorylation has been implicated in gene-specific transcriptional activation. Here, we surveyed genes whose heat shock response is reduced by a CTM mutation. The CTM is indispensable for transcription via heat shock elements bound by a single Hsf1 trimer but is dispensable for transcription via heat shock elements bound by Hsf1 trimers in a cooperative manner. Intragenic mutations located within or near the wing region of the winged helix-turn-helix DNA-binding domain suppress the temperature-sensitive growth phenotype associated with the CTM mutation and enable Hsf1 to activate transcription independently of hyperphosphorylation. Deletion of the wing partially restores the transcriptional defects of the unphosphorylated Hsf1. These results demonstrate a functional link between hyperphosphorylation and the wing region and suggest that this modification is involved in a conformational change of a single Hsf1 trimer to an active form.	Kanazawa Univ, Grad Sch Med Sci, Div Hlth Sci, Kanazawa, Ishikawa 920094, Japan	Kanazawa University	Sakurai, H (corresponding author), Kanazawa Univ, Grad Sch Med Sci, Div Hlth Sci, 5-11-80 Kodatsuno, Kanazawa, Ishikawa 920094, Japan.	sakurai@kenroku.kanazawa-u.ac.jp		Sakurai, Hiroshi/0000-0002-0336-2301; Hashikawa, Naoya/0000-0001-8192-6881				Ahn SG, 2001, GENE DEV, V15, P2134, DOI 10.1101/gad.894801; AMIN J, 1988, MOL CELL BIOL, V8, P3761, DOI 10.1128/MCB.8.9.3761; AMIN J, 1994, J BIOL CHEM, V269, P4804; BONNER JJ, 1994, MOL CELL BIOL, V14, P501, DOI 10.1128/MCB.14.1.501; BONNER JJ, 1992, MOL CELL BIOL, V12, P1021, DOI 10.1128/MCB.12.3.1021; Bulman AL, 2001, J BIOL CHEM, V276, P40254, DOI 10.1074/jbc.M106301200; Chen TX, 2002, P NATL ACAD SCI USA, V99, P1200, DOI 10.1073/pnas.032681299; Chen ZD, 1998, NUCLEIC ACIDS RES, V26, P1126, DOI 10.1093/nar/26.4.1126; Cicero MP, 2001, NUCLEIC ACIDS RES, V29, P1715, DOI 10.1093/nar/29.8.1715; Cotto JJ, 1996, J BIOL CHEM, V271, P3355; DAMBERGER FF, 1994, PROTEIN SCI, V3, P1806, DOI 10.1002/pro.5560031020; Ferguson SB, 2005, GENETICS, V169, P1203, DOI 10.1534/genetics.104.034256; FERNANDES M, 1994, NUCLEIC ACIDS RES, V22, P167, DOI 10.1093/nar/22.2.167; Fernandes M, 1995, NUCLEIC ACIDS RES, V23, P4799, DOI 10.1093/nar/23.23.4799; GIETZ RD, 1988, GENE, V74, P527, DOI 10.1016/0378-1119(88)90185-0; GUARENTE L, 1981, P NATL ACAD SCI-BIOL, V78, P2199, DOI 10.1073/pnas.78.4.2199; Guettouche Toumy, 2005, BMC Biochemistry, V6, DOI 10.1186/1471-2091-6-4; Hahn JS, 2004, J BIOL CHEM, V279, P5169, DOI 10.1074/jbc.M311005200; Hahn JS, 2004, MOL CELL BIOL, V24, P5249, DOI 10.1128/MCB.24.12.5249-5256.2004; Hardy JA, 2000, J MOL BIOL, V295, P393, DOI 10.1006/jmbi.1999.3357; HARRISON CJ, 1994, SCIENCE, V263, P224, DOI 10.1126/science.8284672; Hashikawa N, 2004, MOL CELL BIOL, V24, P3648, DOI 10.1128/MCB.24.9.3648-3659.2004; HOJ A, 1994, EMBO J, V13, P2617; Holmberg CI, 2002, TRENDS BIOCHEM SCI, V27, P619, DOI 10.1016/S0968-0004(02)02207-7; Imazu H, 2005, EUKARYOT CELL, V4, P1050, DOI 10.1128/EC.4.6.1050-1056.2005; JAKOBSEN BK, 1991, EMBO J, V10, P369, DOI 10.1002/j.1460-2075.1991.tb07958.x; KROEGER PE, 1994, MOL CELL BIOL, V14, P7592, DOI 10.1128/MCB.14.11.7592; Lee S, 2000, MOL BIOL CELL, V11, P1753, DOI 10.1091/mbc.11.5.1753; Littlefield O, 1999, NAT STRUCT BIOL, V6, P464; Liu Xiao-Dong, 1996, Genes and Development, V10, P592, DOI 10.1101/gad.10.5.592; McMillan DR, 1998, J BIOL CHEM, V273, P7523, DOI 10.1074/jbc.273.13.7523; Morimoto RI, 1998, GENE DEV, V12, P3788, DOI 10.1101/gad.12.24.3788; NIETOSOTELO J, 1990, CELL, V62, P807, DOI 10.1016/0092-8674(90)90124-W; PERISIC O, 1989, CELL, V59, P797, DOI 10.1016/0092-8674(89)90603-X; Pirkkala L, 2001, FASEB J, V15, P1118, DOI 10.1096/fj00-0294rev; PTASHNE M, 1990, NATURE, V346, P329, DOI 10.1038/346329a0; Sakurai H, 2003, GENES CELLS, V8, P951, DOI 10.1046/j.1356-9597.2003.00689.x; Sakurai H, 2001, BIOCHEM BIOPH RES CO, V285, P696, DOI 10.1006/bbrc.2001.5234; SARGE KD, 1993, MOL CELL BIOL, V13, P1392, DOI 10.1128/MCB.13.3.1392; SEWELL AK, 1995, J BIOL CHEM, V270, P25079, DOI 10.1074/jbc.270.42.25079; SORGER PK, 1987, NATURE, V329, P81, DOI 10.1038/329081a0; SORGER PK, 1988, CELL, V54, P855, DOI 10.1016/S0092-8674(88)91219-6; Tachibana T, 2002, J BIOL CHEM, V277, P22140, DOI 10.1074/jbc.M201267200; TAMAI KT, 1994, MOL CELL BIOL, V14, P8155, DOI 10.1128/MCB.14.12.8155; TORRES FAG, 1995, MOL CELL BIOL, V15, P5063; Trinklein ND, 2004, MOL BIOL CELL, V15, P1254, DOI 10.1091/mbc.E03-10-0738; Wu C, 1995, ANNU REV CELL DEV BI, V11, P441, DOI 10.1146/annurev.cellbio.11.1.441; Xia WL, 1997, J BIOL CHEM, V272, P4094, DOI 10.1074/jbc.272.7.4094; XIAO H, 1991, CELL, V64, P585, DOI 10.1016/0092-8674(91)90242-Q; Xiao XZ, 1999, EMBO J, V18, P5943, DOI 10.1093/emboj/18.21.5943; Yamamoto A, 2005, J BIOL CHEM, V280, P11911, DOI 10.1074/jbc.M411256200; YANG WM, 1991, MOL CELL BIOL, V11, P3676, DOI 10.1128/MCB.11.7.3676	52	31	32	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 17	2006	281	7					3936	3942		10.1074/jbc.M510827200	http://dx.doi.org/10.1074/jbc.M510827200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	011NN	16361698	hybrid			2022-12-25	WOS:000235275300021
J	Oh, TJ; Daniel, J; Kim, HJ; Sirakova, TD; Kolattukudy, PE				Oh, TJ; Daniel, J; Kim, HJ; Sirakova, TD; Kolattukudy, PE			Identification and characterization of Rv3281 as a novel subunit of a biotin-dependent Acyl-CoA carboxylase in Mycobacterium tuberculosis H37Rv	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COENZYME-A CARBOXYLASE; PURIFICATION; EXPRESSION; GROWTH; DOMAIN; GENES; ACIDS	Mycobacterium tuberculosis produces a large number of structurally diverse lipids generated from the carboxylation products of acetyl-CoA and propionyl-CoA. A biotin-dependent acyl-CoA carboxylase was purified from M. tuberculosis H37Rv by avidin affinity chromatography, and the three major protein components were determined by N-terminal sequencing to be the 63-kDa alpha 3-subunit (AccA3, Rv3285), the 59-kDa beta 5-subunit (AccD5, Rv3280), and the 56-kDa beta 4-subunit (AccD4, Rv3799). A minor protein of about 24 kDa that co-purified with the above subunits was identified by matrix-assisted laser desorption/ionization-time of flight mass spectrometry to be the product of Rv3281 that is located immediately downstream of the open reading frame encoding the beta 5-subunit. This protein displays identity over a short stretch of amino acids with the recently discovered epsilon-subunits of Streptomyces coelicolor, suggesting that it might be an epsilon-subunit of the mycobacterial acyl-CoA carboxylase. To test this hypothesis, the carboxylase subunits were expressed in Escherichia coli and purified. Acyl-CoA carboxylase activity was successfully reconstituted for the first time from purified subunits of the acyl-CoA carboxylase of M. tuberculosis. The reconstituted alpha 3-beta 5 showed higher activity with propionyl-CoA than with acetyl-CoA, and the addition of the epsilon-subunit stimulated the carboxylation by 3.2- and 6.3-fold, respectively. The alpha 3-beta 4 showed very low activity with the above substrates but carboxylated long chain acyl-CoA. This epsilon-subunit contains five sets of tandem repeats at the N terminus that are required for maximal enhancement of carboxylase activity. The Rv3281 open reading frame is co-transcribed with Rv3280 in the mycobacterial cell, and the level of epsilon-protein was highest during the log phase and decreased during the stationary phase.	Univ Cent Florida, Burnett Coll Biomed Sci, Orlando, FL 32816 USA	State University System of Florida; University of Central Florida	Kolattukudy, PE (corresponding author), Univ Cent Florida, Burnett Coll Biomed Sci, BMS 136,4000 Cent Florida Blvd, Orlando, FL 32816 USA.	pk@mail.ucf.edu	kolattukudy, pappachan e/A-1350-2012	Kim, Hwa-Jung/0000-0002-1127-0909	NIAID NIH HHS [AI46582, AI35272, R01 AI046582, R01 AI035272] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI046582, R01AI035272] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Attwood PV, 2002, ACCOUNTS CHEM RES, V35, P113, DOI 10.1021/ar000049+; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHAPMANSMITH A, 1994, BIOCHEM J, V302, P881, DOI 10.1042/bj3020881; Cole ST, 2001, NATURE, V409, P1007, DOI 10.1038/35059006; Cole ST, 1998, NATURE, V393, P537, DOI 10.1038/31159; Cronan JE, 2002, PROG LIPID RES, V41, P407, DOI 10.1016/S0163-7827(02)00007-3; Diacovich L, 2002, J BIOL CHEM, V277, P31228, DOI 10.1074/jbc.M203263200; Gande R, 2004, J BIOL CHEM, V279, P44847, DOI 10.1074/jbc.M408648200; HASSE FC, 1982, J BIOL CHEM, V257, P11994; HENRIKSON KP, 1979, J BIOL CHEM, V254, P5888; HUNAITI AR, 1982, ARCH BIOCHEM BIOPHYS, V216, P362, DOI 10.1016/0003-9861(82)90222-3; LAEMMLI UK, 1970, NATURE, V227, P685; Portevin D, 2005, J BIOL CHEM, V280, P8862, DOI 10.1074/jbc.M408578200; RAINWATER DL, 1982, J BACTERIOL, V151, P905, DOI 10.1128/JB.151.2.905-911.1982; Rodriguez E, 2001, APPL ENVIRON MICROB, V67, P4166, DOI 10.1128/AEM.67.9.4166-4176.2001; Sambrook J., 1989, MOL CLONING LAB MANU, V2; Sassetti CM, 2003, MOL MICROBIOL, V48, P77, DOI 10.1046/j.1365-2958.2003.03425.x; STUDIER FW, 1986, J MOL BIOL, V189, P113, DOI 10.1016/0022-2836(86)90385-2; Zhang HL, 2004, P NATL ACAD SCI USA, V101, P5910, DOI 10.1073/pnas.0400891101	19	39	43	1	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 17	2006	281	7					3899	3908		10.1074/jbc.M511761200	http://dx.doi.org/10.1074/jbc.M511761200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	011NN	16354663	hybrid, Green Accepted, Green Published			2022-12-25	WOS:000235275300017
J	Shimizu, N; Imamoto, Y; Harigai, M; Kamikubo, H; Yamazaki, Y; Kataoka, M				Shimizu, N; Imamoto, Y; Harigai, M; Kamikubo, H; Yamazaki, Y; Kataoka, M			pH-dependent equilibrium between long lived near-UV intermediates of photoactive yellow protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							E46Q MUTANT; ECTOTHIORHODOSPIRA-HALOPHILA; STRUCTURAL-CHANGES; COUMARIC ACID; PHOTOCYCLE; CHROMOPHORE; PHOTOREACTION; KINETICS; I-1; DEPROTONATION	The long lived intermediate (signaling state) of photoactive yellow protein (PYPM), which is formed in the photocycle, was characterized at various pHs. PYPM at neutral pH was in equilibrium between two spectroscopically distinct states. Absorption maxima of the acidic form (PYPMacid) and alkaline form (PYPMalkali) were located at 367 and 356 nm, respectively. Equilibrium was represented by the Henderson-Hasselbalch equation, in which apparent pK(a) was 6.4. Content of alpha- and/or beta-structure of PYPMacid was significantly greater than PYPMalkali as demonstrated by the molar ellipticity at 222 nm. In addition, changes in amide I and II modes of beta-structure in the difference Fourier transform infrared spectra for formation of PYPM acid was smaller than that of PYPMalkali. The vibrational mode at 1747 cm(-1) of protonated Glu-46 was found as a small band for PYPMacid but not for PYPMalkali, suggesting that Glu-46 remains partially protonated in PYPMacid, whereas it is fully deprotonated in PYPMalkali. Small angle x-ray scattering measurements demonstrated that the radius of gyration of PYPMacid was 15.7 angstrom, whereas for PYPMalkali it was 16.2 angstrom. These results indicate that PYPMacid assumes a more ordered and compact structure than PYPMalkali. Binding of citrate shifts this equilibrium toward PYPMalkali. UV-visible absorption spectra and difference infrared spectra of the long lived intermediate formed from E46Q mutant was consistent with those of PYPMacid, indicating that the mutation shifts this equilibrium toward PYPMacid. Alterations in the nature of PYPM by pH, citrate, and mutation of Glu-46 are consistently explained by the shift of the equilibrium between PYPMacid and PYPMalkali.	Nara Inst Sci & Technol, Grad Sch Mat Sci, Ikoma, Nara 6300192, Japan	Nara Institute of Science & Technology	Imamoto, Y (corresponding author), Nara Inst Sci & Technol, Grad Sch Mat Sci, Ikoma, Nara 6300192, Japan.	imamoto@ms.naist.jp	Kataoka, Mikio/H-4402-2011					Anderson S, 2004, STRUCTURE, V12, P1039, DOI 10.1016/j.str.2004.04.008; BACA M, 1994, BIOCHEMISTRY-US, V33, P14369, DOI 10.1021/bi00252a001; Borucki B, 2003, BIOCHEMISTRY-US, V42, P8780, DOI 10.1021/bi034315d; Brudler R, 2001, NAT STRUCT BIOL, V8, P265, DOI 10.1038/85021; Chen EF, 2003, BIOCHEMISTRY-US, V42, P2062, DOI 10.1021/bi020577o; Craven CJ, 2000, BIOCHEMISTRY-US, V39, P14392, DOI 10.1021/bi001628p; Cusanovich MA, 2003, BIOCHEMISTRY-US, V42, P4759, DOI 10.1021/bi020690e; Derix NM, 2003, BIOCHEMISTRY-US, V42, P14501, DOI 10.1021/bi034877x; Genick UK, 1997, BIOCHEMISTRY-US, V36, P8, DOI 10.1021/bi9622884; Glatter O., 1982, SMALL ANGLE X RAY SC; Guinier A, 1955, SMALL ANGLE XRAY SCA; HARIGAI M, 2003, BIOCHEMISTRY-US, V42, P13901; Hendriks J, 1999, J BIOL CHEM, V274, P17655, DOI 10.1074/jbc.274.25.17655; Hendriks J, 2003, BIOPHYS J, V84, P1180, DOI 10.1016/S0006-3495(03)74932-7; HOFF WD, 1994, BIOCHEMISTRY-US, V33, P13959, DOI 10.1021/bi00251a001; HOFF WD, 1994, BIOPHYS J, V67, P1691, DOI 10.1016/S0006-3495(94)80643-5; Hoff WD, 1999, BIOCHEMISTRY-US, V38, P1009, DOI 10.1021/bi980504y; Ihee H, 2005, P NATL ACAD SCI USA, V102, P7145, DOI 10.1073/pnas.0409035102; IMAMOTO Y, 1995, FEBS LETT, V374, P157, DOI 10.1016/0014-5793(95)01096-W; Imamoto Y, 1997, J BIOL CHEM, V272, P12905, DOI 10.1074/jbc.272.20.12905; Imamoto Y, 1996, BIOCHEMISTRY-US, V35, P14047, DOI 10.1021/bi961342d; Imamoto Y, 2004, FEBS LETT, V577, P75, DOI 10.1016/j.febslet.2004.09.065; Imamoto Y, 2002, BIOCHEMISTRY-US, V41, P13595, DOI 10.1021/bi0264768; Imamoto Y, 2001, BIOCHEMISTRY-US, V40, P14336, DOI 10.1021/bi010468u; Imamoto Y, 2001, BIOCHEMISTRY-US, V40, P6047, DOI 10.1021/bi002437p; Imamoto Y, 2001, BIOCHEMISTRY-US, V40, P8997, DOI 10.1021/bi010021l; Imamoto Y, 2001, BIOCHEMISTRY-US, V40, P4679, DOI 10.1021/bi002291u; Joshi CP, 2005, BIOCHEMISTRY-US, V44, P656, DOI 10.1021/bi0481141; Kandori H, 2000, BIOCHEMISTRY-US, V39, P7902, DOI 10.1021/bi000357f; Kort R, 1996, FEBS LETT, V382, P73, DOI 10.1016/0014-5793(96)00149-4; MEYER TE, 1985, BIOCHIM BIOPHYS ACTA, V806, P175, DOI 10.1016/0005-2728(85)90094-5; Mihara K, 1997, J BIOCHEM, V121, P876; Ohishi S, 2001, BIOCHEMISTRY-US, V40, P2854, DOI 10.1021/bi001846i; Pan DH, 2004, BIOPHYS J, V86, P2374, DOI 10.1016/S0006-3495(04)74294-0; Pellequer JL, 1998, P NATL ACAD SCI USA, V95, P5884, DOI 10.1073/pnas.95.11.5884; Rajagopal S, 2005, STRUCTURE, V13, P55, DOI 10.1016/j.str.2004.10.016; Shimizu N, 2002, J BIOCHEM, V132, P257, DOI 10.1093/oxfordjournals.jbchem.a003219; SPRENGER WW, 1993, J BACTERIOL, V175, P3096, DOI 10.1128/JB.175.10.3096-3104.1993; Svergun D, 1995, J APPL CRYSTALLOGR, V28, P768, DOI 10.1107/S0021889895007047; Ujj L, 1998, BIOPHYS J, V75, P406, DOI 10.1016/S0006-3495(98)77525-3; Xie AH, 2001, BIOCHEMISTRY-US, V40, P1510, DOI 10.1021/bi002449a; Zhou Y, 2001, J PHYS CHEM A, V105, P5719, DOI 10.1021/jp004575u	42	27	29	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 17	2006	281	7					4318	4325		10.1074/jbc.M506403200	http://dx.doi.org/10.1074/jbc.M506403200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	011NN	16368695	hybrid			2022-12-25	WOS:000235275300066
J	Szczesna-Skorupa, E; Kemper, B				Szczesna-Skorupa, E; Kemper, B			BAP31 is involved in the retention of cytochrome P4502C2 in the endoplasmic reticulum	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BIMOLECULAR FLUORESCENCE COMPLEMENTATION; CASPASE CLEAVAGE PRODUCT; LIVING CELLS; MOLECULAR-INTERACTIONS; MEMBRANE-PROTEINS; GOLGI-APPARATUS; TRANSMEMBRANE; 2E1; OVERPRODUCTION; DEGRADATION	Microsomal cytochrome P450 2C2 is an integral endoplasmic reticulum ( ER) membrane protein that is directly retained in the ER and excluded from transport vesicles. We have used bimolecular fluorescence complementation and co-immunoprecipitation to show that a ubiquitous ER membrane protein (BAP31) interacts with P450 2C2 in transfected COS-1 cells. A chimera containing only the N-terminal signal anchor of P450 2C1 ( P450 2C1-(1-29)) also interacted with BAP31, which is consistent with interaction of the two proteins via their transmembrane domains. Down-regulation of BAP31 expression with small interfering RNA resulted in redistribution of green fluorescent protein-tagged P450 2C2 or P450 2C1-(1-29) from the ER into the nuclear membrane and compact perinuclear compartment structures as well as the cell surface in a small fraction of the cells. In Bap31-null embryonic stem cells, a significant fraction of P450 2C2 or P450 2C1-(1-29) was detected at the cell surface and nuclear envelope, but was redistributed to the ER by expression of BAP31. The expression level of P450 2C2 was significantly increased in COS-1 cells with repressed levels of BAP31. Formation of the pro-apoptotic p20 fragment of BAP31 was detected in transfected COS-1 cells expressing P450 2C2, and annexin V staining was consistent with the activation of an apoptotic pathway in these cells. Down-regulation of BAP31 with small interfering RNA partially reversed the apoptosis. These results suggest that interaction of P450 2C2 with BAP31 is important for its ER retention and expression level and that BAP31 may be involved in the regulation of apoptosis induced by the ER overload response to increased expression of P450.	Univ Illinois, Dept Mol & Integrat Physiol, Urbana, IL 61801 USA; Univ Illinois, Dept Cell & Dev Biol, Urbana, IL 61801 USA	University of Illinois System; University of Illinois Urbana-Champaign; University of Illinois System; University of Illinois Urbana-Champaign	Kemper, B (corresponding author), Univ Illinois, Dept Mol & Integrat Physiol, 407 S Goodwin Ave, Urbana, IL 61801 USA.	byronkem@life.uiuc.edu			NIGMS NIH HHS [GM35897] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM035897] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Adachi T, 1996, EMBO J, V15, P1534, DOI 10.1002/j.1460-2075.1996.tb00497.x; AHN KS, 1993, J BIOL CHEM, V268, P18726; Annaert WG, 1997, J CELL BIOL, V139, P1397, DOI 10.1083/jcb.139.6.1397; Backes WL, 2003, PHARMACOL THERAPEUT, V98, P221, DOI 10.1016/S0163-7258(03)00031-7; BALCH WE, 1994, CELL, V76, P841, DOI 10.1016/0092-8674(94)90359-X; Breckenridge DG, 2003, J CELL BIOL, V160, P1115, DOI 10.1083/jcb.200212059; Breckenridge DG, 2002, P NATL ACAD SCI USA, V99, P4331, DOI 10.1073/pnas.072088099; Correia MA, 2005, ANNU REV PHARMACOL, V45, P439, DOI 10.1146/annurev.pharmtox.45.120403.100127; Correia MA, 2003, DRUG METAB REV, V35, P107, DOI 10.1081/DMR-120023683; Ducret A, 2003, EUR J BIOCHEM, V270, P342, DOI 10.1046/j.1432-1033.2003.03395.x; Eliasson E, 1996, MOL PHARMACOL, V50, P573; Farinha CA, 2005, MOL CELL BIOL, V25, P5242, DOI 10.1128/MCB.25.12.5242-5252.2005; Hu CD, 2002, MOL CELL, V9, P789, DOI 10.1016/S1097-2765(02)00496-3; Huan JY, 2004, TOXICOL APPL PHARM, V199, P332, DOI 10.1016/j.taap.2003.12.019; Kamhi-Nesher S, 2001, MOL BIOL CELL, V12, P1711, DOI 10.1091/mbc.12.6.1711; Lambert G, 2001, J BIOL CHEM, V276, P20340, DOI 10.1074/jbc.M011209200; Lee MCS, 2004, ANNU REV CELL DEV BI, V20, P87, DOI 10.1146/annurev.cellbio.20.010403.105307; Mancias JD, 2005, TRAFFIC, V6, P278, DOI 10.1111/j.1600-0854.2005.00279.x; Manley HA, 2001, J HISTOCHEM CYTOCHEM, V49, P1235, DOI 10.1177/002215540104901005; MARTIN SJ, 1995, J EXP MED, V182, P1545, DOI 10.1084/jem.182.5.1545; Menzel R, 1997, YEAST, V13, P1211, DOI 10.1002/(SICI)1097-0061(199710)13:13<1211::AID-YEA168>3.0.CO;2-8; MURAKAMI K, 1994, J BIOCHEM, V116, P164, DOI 10.1093/oxfordjournals.jbchem.a124489; Nelson DS, 1998, J CELL BIOL, V143, P319, DOI 10.1083/jcb.143.2.319; Neve EPA, 1996, ARCH BIOCHEM BIOPHYS, V333, P459, DOI 10.1006/abbi.1996.0415; Ng FWH, 1997, J CELL BIOL, V139, P327, DOI 10.1083/jcb.139.2.327; Nguyen M, 2000, MOL CELL BIOL, V20, P6731, DOI 10.1128/MCB.20.18.6731-6740.2000; OHKUMA M, 1995, BBA-BIOMEMBRANES, V1236, P163, DOI 10.1016/0005-2736(95)00040-A; Ozalp C, 2005, DRUG METAB DISPOS, V33, P1382, DOI 10.1124/dmd.105.005538; Paquet ME, 2004, J IMMUNOL, V172, P7548, DOI 10.4049/jimmunol.172.12.7548; Schamel WWA, 2003, P NATL ACAD SCI USA, V100, P9861, DOI 10.1073/pnas.1633363100; Stojanovic M, 2005, J BIOL CHEM, V280, P30018, DOI 10.1074/jbc.M501306200; Szczesna-Skorupa E, 2003, J BIOL CHEM, V278, P31269, DOI 10.1074/jbc.M301489200; Szczesna-Skorupa E, 2000, J BIOL CHEM, V275, P19409, DOI 10.1074/jbc.M002394200; Szczesna-Skorupa E, 1998, P NATL ACAD SCI USA, V95, P14793, DOI 10.1073/pnas.95.25.14793; Szczesna-Skorupa E, 2004, J BIOL CHEM, V279, P13953, DOI 10.1074/jbc.M312170200; SZCZESNASKORUPA E, 1995, J BIOL CHEM, V270, P24327, DOI 10.1074/jbc.270.41.24327; SZCZESNASKORUPA E, 1993, J BIOL CHEM, V268, P1757; Takewaka T, 1999, J BIOCHEM-TOKYO, V125, P507, DOI 10.1093/oxfordjournals.jbchem.a022314; Teasdale RD, 1996, ANNU REV CELL DEV BI, V12, P27, DOI 10.1146/annurev.cellbio.12.1.27; Wang B, 2004, MOL CELL BIOL, V24, P2767, DOI 10.1128/MCB.24.7.2767-2778.2004; Wang B, 2003, J BIOL CHEM, V278, P14461, DOI 10.1074/jbc.M209684200; Zen K, 2004, J BIOL CHEM, V279, P44924, DOI 10.1074/jbc.M402115200; Zuppini A, 2002, BIOCHEMISTRY-US, V41, P2850, DOI 10.1021/bi015967+	43	40	40	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 17	2006	281	7					4142	4148		10.1074/jbc.M509522200	http://dx.doi.org/10.1074/jbc.M509522200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	011NN	16332681	hybrid			2022-12-25	WOS:000235275300045
J	Wang, DS; Mangin, JM; Moonen, G; Rigo, JM; Legendre, P				Wang, DS; Mangin, JM; Moonen, G; Rigo, JM; Legendre, P			Mechanisms for picrotoxin block of alpha(2) homomeric glycine receptors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-SUBUNIT; CHLORIDE CHANNELS; CONFORMATIONAL-CHANGE; CRAYFISH MUSCLE; NEURONS; BINDING; GABA; ZEBRAFISH; RESIDUE; RAT	It is well known that the convulsant alkaloid picrotoxin (PTX) can inhibit neuronal gamma-aminobutyric acid ( GABA) and homomeric glycine receptors (GlyR). However, the mechanism for PTX block of alpha(2) homomeric GlyR is still unclear compared with that of alpha(1) homomeric GlyR, GABA(A), and GABA(C) receptors. Furthermore, PTX effects on GlyR kinetics have been poorly explored at the single-channel level. Hence, we used the patch-clamp technique in the outside-out configuration to investigate the mechanism of PTX suppression of currents carried by alpha(2) homomeric GlyRs stably transfected into Chinese hamster ovary cells. PTX inhibited the alpha(2) homomeric GlyR current elicited by glycine in a concentration-dependent and voltage-independent manner. Both competitive and noncompetitive mechanisms were observed. PTX decreased the mean open time of the GlyR channel in a concentration-dependent manner, suggesting that PTX can block channel openings and bind to the receptor in the open channel conformation. When PTX and glycine were co-applied, a small rebound current was observed during drug washout. Application of PTX during the deactivation phase of glycine-induced currents eliminated the rebound current and accelerated the deactivation time course in a concentration-dependent manner. PTX could not bind to the unbound conformation of GlyR, but could be trapped at its binding site when the channel closed during glycine dissociation. Based on these observations, we propose a kinetic Markov model in which PTX binds to the alpha(2) homomeric GlyR in both the open channel state and the fully liganded closed state. Our data suggest a new allosteric mechanism for PTX inhibition of wild-type homomeric alpha(2) GlyR.	Univ Paris 06, CNRS, Unite Mixte Rech 7102, F-75252 Paris 05, France; Fac Med, Ctr Rech Neurobiol Cellulaire & Mol, B-4020 Liege 2, Belgium; Univ Hasselt, Ctr Biomed Res, B-3590 Diepenbeek, Belgium; Fourth Mil Med Univ, Dept Anat, Xian 710032, Peoples R China	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Sorbonne Universite; Hasselt University; Air Force Military Medical University	Legendre, P (corresponding author), Univ Paris 06, CNRS, Unite Mixte Rech 7102, 9 Quai St Bernard, F-75252 Paris 05, France.	pascal.legendre@snv.jussieu.fr	Rigo, Jean-Michel/E-3456-2010	Rigo, Jean-Michel/0000-0002-0031-526X; Mangin, Jean-Marie/0000-0002-7804-0251				Adelsberger H, 1998, EUR J NEUROSCI, V10, P179, DOI 10.1046/j.1460-9568.1998.00038.x; ALDRICH RW, 1983, NATURE, V306, P436, DOI 10.1038/306436a0; Buhr A, 2001, J BIOL CHEM, V276, P7775, DOI 10.1074/jbc.M008907200; Burzomato V, 2004, J NEUROSCI, V24, P10924, DOI 10.1523/JNEUROSCI.3424-04.2004; CLEMENTS JD, 1991, NEURON, V7, P605, DOI 10.1016/0896-6273(91)90373-8; Colquhoun D, 2004, TRENDS NEUROSCI, V27, P337, DOI 10.1016/j.tins.2004.04.010; Colquhoun David, 1995, P397; Das P, 2005, J PHARMACOL EXP THER, V314, P320, DOI 10.1124/jpet.104.080325; Dibas MI, 2002, J BIOL CHEM, V277, P9112, DOI 10.1074/jbc.M111356200; Etter A, 1999, J NEUROCHEM, V72, P318, DOI 10.1111/jnc.1999.72.1.318; FFRENCHCONSTANT RH, 1993, NATURE, V363, P449, DOI 10.1038/363449a0; Flint AC, 1998, NEURON, V20, P43, DOI 10.1016/S0896-6273(00)80433-X; FRANKE C, 1987, NEUROSCI LETT, V77, P199, DOI 10.1016/0304-3940(87)90586-6; Gentet LJ, 2002, J PHYSIOL-LONDON, V544, P97, DOI 10.1113/jphysiol.2001.015321; Grudzinska J, 2005, NEURON, V45, P727, DOI 10.1016/j.neuron.2005.01.028; GURLEY D, 1995, RECEPTOR CHANNEL, V3, P13; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; Harvey RJ, 2000, EUR J NEUROSCI, V12, P994, DOI 10.1046/j.1460-9568.2000.00993.x; Hawthorne R, 2005, J BIOL CHEM, V280, P35836, DOI 10.1074/jbc.M506645200; INOUE M, 1988, NEUROSCI RES, V5, P380, DOI 10.1016/0168-0102(88)90024-7; KUHSE J, 1991, FEBS LETT, V283, P73, DOI 10.1016/0014-5793(91)80557-J; Legendre P, 1997, J NEUROPHYSIOL, V77, P2400, DOI 10.1152/jn.1997.77.5.2400; Legendre P, 1998, J NEUROSCI, V18, P2856; Legendre P, 2000, J NEUROSCI, V20, P140, DOI 10.1523/JNEUROSCI.20-01-00140.2000; Legendre P, 2001, CELL MOL LIFE SCI, V58, P760, DOI 10.1007/PL00000899; LYNCH JW, 1995, J BIOL CHEM, V270, P13799, DOI 10.1074/jbc.270.23.13799; Lynch JW, 2004, PHYSIOL REV, V84, P1051, DOI 10.1152/physrev.00042.2003; MACONOCHIE DJ, 1995, J GEN PHYSIOL, V106, P113, DOI 10.1085/jgp.106.1.113; Mangin JA, 2003, J PHYSIOL-LONDON, V553, P369, DOI 10.1113/jphysiol.2003.052142; Mangin JM, 2005, MOL PHARMACOL, V67, P1783, DOI 10.1124/mol.104.007435; NEWLAND CF, 1992, J PHYSIOL-LONDON, V447, P191, DOI 10.1113/jphysiol.1992.sp018998; PRIBILLA I, 1992, EMBO J, V11, P4305, DOI 10.1002/j.1460-2075.1992.tb05529.x; Qian HH, 2005, MOL PHARMACOL, V67, P470, DOI 10.1124/mol.104.003996; RUNDSTROM N, 1994, P NATL ACAD SCI USA, V91, P8950, DOI 10.1073/pnas.91.19.8950; Shan Q, 2001, J NEUROCHEM, V76, P1109, DOI 10.1046/j.1471-4159.2001.00124.x; SIGWORTH FJ, 1987, BIOPHYS J, V52, P1047, DOI 10.1016/S0006-3495(87)83298-8; TRILLER A, 1990, New Biologist, V2, P637; Xu M, 1995, BIOPHYS J, V69, P1858, DOI 10.1016/S0006-3495(95)80056-1; Yoon KW, 1998, NEUROSCIENCE, V87, P807, DOI 10.1016/S0306-4522(98)00158-4; ZHANG DX, 1995, P NATL ACAD SCI USA, V92, P11756, DOI 10.1073/pnas.92.25.11756; Zhorov BS, 2000, BIOPHYS J, V78, P1786, DOI 10.1016/S0006-3495(00)76729-4	41	35	35	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 17	2006	281	7					3841	3855		10.1074/jbc.M511022200	http://dx.doi.org/10.1074/jbc.M511022200			15	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	011NN	16344549	hybrid, Green Submitted			2022-12-25	WOS:000235275300012
J	Xie, Y; Newberry, EP; Young, SG; Robine, S; Hamilton, RL; Wong, JS; Luo, JY; Kennedy, S; Davidson, NO				Xie, Y; Newberry, EP; Young, SG; Robine, S; Hamilton, RL; Wong, JS; Luo, JY; Kennedy, S; Davidson, NO			Compensatory increase in hepatic lipogenesis in mice with conditional intestine-specific Mttp deficiency	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRIGLYCERIDE TRANSFER PROTEIN; LOW-DENSITY LIPOPROTEINS; APOLIPOPROTEIN-B; CHOLESTEROL ABSORPTION; EMBRYONIC LETHALITY; APOBEC-1(-/-) MICE; APO-B; SECRETION; LIVER; GENE	Microsomal TG transfer protein (MTTP) is required for the assembly and secretion of TG (TG)-rich lipoproteins from both enterocytes and hepatocytes. Liver-specific deletion of Mttp produced a dramatic reduction in plasma very low density lipoprotein-TG and virtually eliminated apolipoprotein B100 (apoB100) secretion yet caused only modest reductions in plasma apoB48 and apoB48 secretion from primary hepatocytes. These observations prompted us to examine the phenotype following intestine-specific Mttp deletion because murine, like human enterocytes, secrete virtually exclusively apoB48. We generated mice with conditional Mttp deletion in villus enterocytes (Mttp-IKO), using a tamoxifen-inducible, intestine-specific Cre transgene. Villus enterocytes from chow-fed Mttp-IKO mice contained large cytoplasmic TG droplets and no chylomicron-sized particles within the secretory pathway. Chow-fed, Mttp-IKO mice manifested steatorrhea, growth arrest, and decreased cholesterol absorption, features that collectively recapitulate the phenotype associated with abetalipoproteinemia. Chylomicron secretion was reduced dramatically in vivo, in conjunction with an similar to 80% decrease in apoB48 secretion from primary enterocytes. Additionally, although plasma and hepatic cholesterol and TG content were decreased, Mttp-IKO mice demonstrated a paradoxical increase in both hepatic lipogenesis and very low density lipoprotein secretion. These findings establish distinctive features for MTTP involvement in intestinal chylomicron assembly and secretion and suggest that hepatic lipogenesis undergoes compensatory induction in the face of defective intestinal TG secretion.	Washington Univ, Sch Med, Dept Med, Div Gastroenterol, St Louis, MO 63110 USA; Washington Univ, Sch Med, Dept Mol Biol & Pharmacol, St Louis, MO 63110 USA; Inst Curie, F-75248 Paris 05, France; Univ Calif Los Angeles, Dept Med, Los Angeles, CA 90095 USA; Univ Calif San Francisco, Cardiovasc Res Inst, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Anat, San Francisco, CA 94143 USA	Washington University (WUSTL); Washington University (WUSTL); UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; University of California System; University of California Los Angeles; University of California System; University of California San Francisco; University of California System; University of California San Francisco	Davidson, NO (corresponding author), Washington Univ, Sch Med, Dept Med, Div Gastroenterol, Box 8124,660 S Euclid Ave, St Louis, MO 63110 USA.	nod@wustl.edu		Young, Stephen/0000-0001-7270-3176	NCI NIH HHS [CA103999, CA099506] Funding Source: Medline; NHLBI NIH HHS [HL-38180, R01 HL038180] Funding Source: Medline; NIAMS NIH HHS [AR050200] Funding Source: Medline; NIDDK NIH HHS [P30 DK056341, DK-56260, P30 DK056341-05S2, R01 DK056260, DK-52574, P30 DK056341-06] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R21CA103999, R01CA099506] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R37HL038180, R01HL038180] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR050200] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK052574, P30DK056341, R01DK056260] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Berriot-Varoqueaux N, 2000, ANNU REV NUTR, V20, P663, DOI 10.1146/annurev.nutr.20.1.663; Bjorkegren J, 2002, J BIOL CHEM, V277, P5476, DOI 10.1074/jbc.M108514200; Blanc V, 2003, J BIOL CHEM, V278, P1395, DOI 10.1074/jbc.R200024200; Chang BHJ, 1999, J BIOL CHEM, V274, P6051, DOI 10.1074/jbc.274.10.6051; Davidson NO, 2000, ANNU REV NUTR, V20, P169, DOI 10.1146/annurev.nutr.20.1.169; El Marjou F, 2004, GENESIS, V39, P186, DOI 10.1002/gene.20042; FARESE RV, 1995, P NATL ACAD SCI USA, V92, P1774, DOI 10.1073/pnas.92.5.1774; Finck BN, 2005, CELL METAB, V1, P133, DOI 10.1016/j.cmet.2005.01.006; Gianturco S H, 1986, Methods Enzymol, V129, P319; Hamilton RL, 1998, J LIPID RES, V39, P1543; HUANG LS, 1995, J CLIN INVEST, V96, P2152, DOI 10.1172/JCI118269; Iqbal J, 2005, J LIPID RES, V46, P1491, DOI 10.1194/jlr.M500023-JLR200; Iqbal J, 2003, J BIOL CHEM, V278, P31610, DOI 10.1074/jbc.M301177200; Jones B, 2003, NAT GENET, V34, P29, DOI 10.1038/ng1145; Jung HR, 1999, BIOCHEM J, V343, P473, DOI 10.1042/0264-6021:3430473; Kulinski A, 2002, J BIOL CHEM, V277, P31516, DOI 10.1074/jbc.M202015200; Kuriyama H, 2005, CELL METAB, V1, P41, DOI 10.1016/j.cmet.2004.11.004; Leung GK, 2000, J BIOL CHEM, V275, P7515, DOI 10.1074/jbc.275.11.7515; Lieu HD, 2003, CIRCULATION, V107, P1315, DOI 10.1161/01.CIR.0000054781.50889.0C; LINTON MF, 1993, J LIPID RES, V34, P521; Nassir F, 2004, J LIPID RES, V45, P1649, DOI 10.1194/jlr.M300505-JLR200; Newberry EP, 2003, J BIOL CHEM, V278, P51664, DOI 10.1074/jbc.M309377200; Raabe M, 1999, J CLIN INVEST, V103, P1287, DOI 10.1172/JCI6576; Saam JR, 1999, J BIOL CHEM, V274, P38071, DOI 10.1074/jbc.274.53.38071; SCANU AM, 1974, J CLIN INVEST, V53, P440, DOI 10.1172/JCI107578; Shoulders CC, 2005, CURR TOP MED CHEM, V5, P283, DOI 10.2174/1568026053544560; Wang DQH, 2001, J LIPID RES, V42, P1820; Wang YW, 1997, J BIOL CHEM, V272, P12272, DOI 10.1074/jbc.272.19.12272; Xie Y, 2003, AM J PHYSIOL-GASTR L, V285, pG735, DOI 10.1152/ajpgi.00202.2003; Young SG, 1995, J CLIN INVEST, V96, P2932, DOI 10.1172/JCI118365; YOUNG SG, 1990, CIRCULATION, V82, P1574, DOI 10.1161/01.CIR.82.5.1574	31	95	97	1	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 17	2006	281	7					4075	4086		10.1074/jbc.M510622200	http://dx.doi.org/10.1074/jbc.M510622200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	011NN	16354657	hybrid			2022-12-25	WOS:000235275300037
J	Yang, Z; Cool, BH; Martin, GM; Hu, QB				Yang, Z; Cool, BH; Martin, GM; Hu, QB			A dominant role for FE65 (APBB1) in nuclear signaling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMYLOID PRECURSOR PROTEIN; ALZHEIMERS-DISEASE; INTRACELLULAR DOMAIN; ADAPTER PROTEIN; TIP60; TRANSCRIPTION; GAMMA; TRANSDUCTION; PRESENILINS; ACTIVATION	FE65 has been described as an adaptor protein; its partners include the beta-amyloid precursor protein (APP) and Tip60 ( a histone acetyltransferase). Recent evidence suggests that APP may function in a nuclear signaling pathway via formation of APP-FE65-Tip60 complexes. The evidence is largely based on experiments in which APP/Tip60 is fused to the DNA binding domain of a yeast transcriptional factor Gal4 (Gal4DB) that can activate a reporter gene only when FE65 is coexpressed. One interpretation of published experiments has not yet been tested; however, there is the possibility that FE65 itself is the dominant transcriptional activator, whereas APP and Tip60 serve merely as positive/negative modulators or bridges for connecting FE65 to Gal4DB. To test this possibility, we fused Gal4DB directly to either end of FE65 and assessed their nuclear signaling in the presence or absence of exogenous APP/Tip60 or after knockdown of endogenous APP/ Tip60. We found that FE65-Gal4DB by itself was able to trigger robust reporter activities. Increasing levels of APP could not further augment the reporter activity, but knocking down endogenous APP or interrupting FE65-APP binding reduced the signaling by up to 2-fold. The magnitudes of the reporter activities did not correlate with relative FE65 affinities for APP. Both overexpression and knockdown experiments showed that Tip60 plays a negative role. The results are consistent with the notion that FE65 is the key agent of Gal4DB-mediated transcriptional transactivation, whereas Tip60 is an FE65-associated repressor. Although APP may have modest stimulating effects, apparently there is no absolute requirement for that molecule for the nuclear signaling pathway.	Univ Washington, Dept Pathol, Seattle, WA 98195 USA	University of Washington; University of Washington Seattle	Hu, QB (corresponding author), Univ Washington, Dept Pathol, 1959 NE Pacific St, Seattle, WA 98195 USA.	qhu@u.washington.edu			NATIONAL INSTITUTE ON AGING [R01AG019711, T32AG000057] Funding Source: NIH RePORTER; NIA NIH HHS [T32 AG00057, AG19711] Funding Source: Medline	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Annaert W, 1999, TRENDS NEUROSCI, V22, P439, DOI 10.1016/S0166-2236(99)01455-1; Bothwell M, 2000, CELL, V102, P271, DOI 10.1016/S0092-8674(00)00032-5; Bressler SL, 1996, HUM MOL GENET, V5, P1589, DOI 10.1093/hmg/5.10.1589; Brown MS, 2000, CELL, V100, P391, DOI 10.1016/S0092-8674(00)80675-3; Cao XW, 2001, SCIENCE, V293, P115, DOI 10.1126/science.1058783; Cao XW, 2004, J BIOL CHEM, V279, P24601, DOI 10.1074/jbc.M402248200; Chang Y, 2003, J BIOL CHEM, V278, P51100, DOI 10.1074/jbc.M309561200; Dickson DW, 1997, NEUROBIOL AGING, V18, pS21, DOI 10.1016/S0197-4580(97)00065-1; Duilio A, 1998, BIOCHEM J, V330, P513, DOI 10.1042/bj3300513; Ebinu JO, 2002, NEURON, V34, P499, DOI 10.1016/S0896-6273(02)00704-3; Fiore F, 1995, J BIOL CHEM, V270, P30853, DOI 10.1074/jbc.270.52.30853; Gaughan L, 2001, J BIOL CHEM, V276, P46841, DOI 10.1074/jbc.M103710200; Gavaravarapu S, 2000, BIOCHEM BIOPH RES CO, V269, P758, DOI 10.1006/bbrc.2000.2358; Green MR, 2005, MOL CELL, V18, P399, DOI 10.1016/j.molcel.2005.04.017; GUENETTE S, 2006, IN PRESS EMBO J; Guenette SY, 1996, P NATL ACAD SCI USA, V93, P10832, DOI 10.1073/pnas.93.20.10832; Hardy J, 1997, TRENDS NEUROSCI, V20, P154, DOI 10.1016/S0166-2236(96)01030-2; Hass MR, 2005, J BIOL CHEM, V280, P36895, DOI 10.1074/jbc.M502861200; Hill K, 2003, J BIOL CHEM, V278, P36032, DOI 10.1074/jbc.M301632200; Hlubek F, 2001, J BIOCHEM-TOKYO, V129, P635, DOI 10.1093/oxfordjournals.jbchem.a002901; Hu QB, 2005, J BIOL CHEM, V280, P12548, DOI 10.1074/jbc.M411855200; Hu QB, 1999, J NEUROSCI RES, V58, P632, DOI 10.1002/(SICI)1097-4547(19991201)58:5<632::AID-JNR4>3.0.CO;2-P; Hu QB, 2002, HUM MOL GENET, V11, P465, DOI 10.1093/hmg/11.4.465; Kim JH, 2005, NATURE, V434, P921, DOI 10.1038/nature03452; Kimberly WT, 2005, J NEUROSCI, V25, P5533, DOI 10.1523/JNEUROSCI.4883-04.2005; King GD, 2004, EXP NEUROL, V185, P208, DOI 10.1016/j.expneurol.2003.10.011; Kinoshita A, 2003, J BIOL CHEM, V278, P41182, DOI 10.1074/jbc.M306403200; Kusch T, 2004, SCIENCE, V306, P2084, DOI 10.1126/science.1103455; Legube G, 2004, J BIOL CHEM, V279, P44825, DOI 10.1074/jbc.M407478200; Lu DC, 2003, J NEUROCHEM, V87, P733, DOI 10.1046/j.1471-4159.2003.02059.x; Martin GM, 2005, CELL, V120, P523, DOI 10.1016/j.cell.2005.01.031; Mattson MP, 1997, PHYSIOL REV, V77, P1081, DOI 10.1152/physrev.1997.77.4.1081; Minopoli G, 2001, J BIOL CHEM, V276, P6545, DOI 10.1074/jbc.M007340200; Perkinton MS, 2004, J BIOL CHEM, V279, P22084, DOI 10.1074/jbc.M311479200; Philpott A, 2000, SEMIN CELL DEV BIOL, V11, P7, DOI 10.1006/scdb.1999.0346; Price DL, 1998, ANNU REV NEUROSCI, V21, P479, DOI 10.1146/annurev.neuro.21.1.479; Russo T, 1998, FEBS LETT, V434, P1, DOI 10.1016/S0014-5793(98)00941-7; Sabo SL, 2003, J NEUROSCI, V23, P5407; Sabo SL, 2001, J CELL BIOL, V153, P1403, DOI 10.1083/jcb.153.7.1403; Santiard-Baron D, 2005, J NEUROCHEM, V93, P330, DOI 10.1111/j.1471-4159.2005.03026.x; Scheinfeld MH, 2002, J BIOL CHEM, V277, P44195, DOI 10.1074/jbc.M208110200; Scheinfeld MH, 2003, P NATL ACAD SCI USA, V100, P1729, DOI 10.1073/pnas.0437908100; Schroeter EH, 1998, NATURE, V393, P382, DOI 10.1038/30756; Selkoe DJ, 2001, P NATL ACAD SCI USA, V98, P11039, DOI 10.1073/pnas.211352598; Sterner DE, 2000, MICROBIOL MOL BIOL R, V64, P435, DOI 10.1128/MMBR.64.2.435-459.2000; Sudol M, 2001, FEBS LETT, V490, P190, DOI 10.1016/S0014-5793(01)02122-6; Telese F, 2005, EMBO REP, V6, P77, DOI 10.1038/sj.embor.7400309; Wang BP, 2004, J NEUROSCI RES, V75, P12, DOI 10.1002/jnr.10834; Wolfe MS, 2001, J BIOL CHEM, V276, P5413, DOI 10.1074/jbc.R000026200; Xiao H, 2003, J BIOL CHEM, V278, P11197, DOI 10.1074/jbc.M210816200; Zhao Q, 2003, BIOCHEMISTRY-US, V42, P3627, DOI 10.1021/bi027117f	51	45	50	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 17	2006	281	7					4207	4214		10.1074/jbc.M508445200	http://dx.doi.org/10.1074/jbc.M508445200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	011NN	16332686	hybrid			2022-12-25	WOS:000235275300053
J	Chia, DJ; Ono, M; Woelfle, J; Schlesinger-Massart, M; Jiang, HL; Rotwein, P				Chia, DJ; Ono, M; Woelfle, J; Schlesinger-Massart, M; Jiang, HL; Rotwein, P			Characterization of distinct Stat5b binding sites that mediate growth hormone-stimulated IGF-I gene transcription	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MESSENGER-RIBONUCLEIC-ACID; DNA-BINDING; INSULIN; PROTEINS; EXPRESSION; PROMOTER; RECEPTOR; SOCS-3; ALPHA; IDENTIFICATION	A key agent in the anabolic actions of growth hormone (GH) is insulin-like growth factor-I (IGF-I), a 70-amino acid secreted protein with direct effects on somatic growth and tissue maintenance and repair. GH rapidly and potently stimulates IGF-I gene transcription by mechanisms independent of new protein synthesis, and recent studies have linked the transcription factor Stat5b to a regulatory network connecting the activated GH receptor on the cell membrane to the IGF-I gene in the nucleus. Here we analyze two distinct conserved GH response elements in the rat IGF-I locus that contain paired Stat5b sites. Each response element binds Stat5b in vivo in a GH-dependent way, as assessed by chromatin immunoprecipitation assays, and consists of one high affinity and one lower affinity Stat5b site, as determined by both qualitative and quantitative protein-DNA binding studies. In biochemical reconstitution experiments, both response elements are able to mediate GH-stimulated and Stat5b-dependent transcription when fused to a reporter gene containing either the major IGF-I promoter or a minimal neutral promoter, although the paired Stat5b sites located in the second IGF-I intron were more than twice as effective as the response element that mapped similar to 73 kb 5' to the IGF-I exon 1. Taken together, our results define the initial molecular architecture of a complicated GH-regulated transcriptional pathway, and suggest that apparently redundant hormone response elements provide a mechanism for amplifying GH action at a physiologically important target gene.	OR Hlth & Sci Univ, Dept Biochem & Mol Biol, Portland, OR 97239 USA; Virginia Polytech Inst & State Univ, Dept Anim & Poultry Sci, Blacksburg, VA 24061 USA	Oregon Health & Science University; Virginia Polytechnic Institute & State University	Rotwein, P (corresponding author), OR Hlth & Sci Univ, Dept Biochem & Mol Biol, 3181 SW Sam Jackson Rd,Mail Code L224, Portland, OR 97239 USA.	rotweinp@ohsu.edu	Woellfe, joachim F/E-9406-2014; Rotwein, Peter/R-5783-2019; Massart, Mylynda/ABC-6861-2021	Massart, Mylynda/0000-0002-8835-7957; Rotwein, Peter/0000-0002-9505-1817; , Honglin/0000-0001-9540-5788; , Joachim/0000-0002-9132-6174	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [K12HD057588] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [F32DK070447, R01DK069703, R01DK063073, R01DK067961] Funding Source: NIH RePORTER; NICHD NIH HHS [K12 HD057588] Funding Source: Medline; NIDDK NIH HHS [R01 DK069703, R01 DK67961, F32 DK70447, R01 DK063073] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Adams TE, 1998, J BIOL CHEM, V273, P1285, DOI 10.1074/jbc.273.3.1285; Bartke A, 2005, ENDOCRINOLOGY, V146, P3718, DOI 10.1210/en.2005-0411; Bergad PL, 2000, J BIOL CHEM, V275, P8114, DOI 10.1074/jbc.275.11.8114; BICHELL DP, 1992, MOL ENDOCRINOL, V6, P1899, DOI 10.1210/me.6.11.1899; Boulikas Teni, 1994, Critical Reviews in Eukaryotic Gene Expression, V4, P117; Carter D, 2002, NAT GENET, V32, P623, DOI 10.1038/ng1051; Cella N, 1998, MOL CELL BIOL, V18, P1783, DOI 10.1128/MCB.18.4.1783; DAUGHADAY WH, 1989, ENDOCR REV, V10, P68, DOI 10.1210/edrv-10-1-68; Davey HW, 1999, MOL CELL ENDOCRINOL, V158, P111, DOI 10.1016/S0303-7207(99)00175-6; DERCOLE AJ, 1984, P NATL ACAD SCI-BIOL, V81, P935, DOI 10.1073/pnas.81.3.935; Ehret GB, 2001, J BIOL CHEM, V276, P6675, DOI 10.1074/jbc.M001748200; GRONOWSKI AM, 1994, J BIOL CHEM, V269, P7874; GULER HP, 1988, P NATL ACAD SCI USA, V85, P4889, DOI 10.1073/pnas.85.13.4889; Herrington J, 2001, TRENDS ENDOCRIN MET, V12, P252, DOI 10.1016/S1043-2760(01)00423-4; Herrington J, 2000, ONCOGENE, V19, P2585, DOI 10.1038/sj.onc.1203526; Horvath CM, 2000, TRENDS BIOCHEM SCI, V25, P496, DOI 10.1016/S0968-0004(00)01624-8; JARMAN AP, 1991, MOL CELL BIOL, V11, P4679, DOI 10.1128/MCB.11.9.4679; Jolivet G, 1996, FEBS LETT, V389, P257, DOI 10.1016/0014-5793(96)00598-4; JONES JI, 1995, ENDOCR REV, V16, P3, DOI 10.1210/er.16.1.3; Katic M, 2005, CELL MOL LIFE SCI, V62, P320, DOI 10.1007/s00018-004-4297-y; Kofoed EM, 2003, NEW ENGL J MED, V349, P1139, DOI 10.1056/NEJMoa022926; Lahuna O, 2000, MOL ENDOCRINOL, V14, P285, DOI 10.1210/me.14.2.285; Le Roith D, 2001, ENDOCR REV, V22, P53, DOI 10.1210/er.22.1.53; Levy DE, 2002, NAT REV MOL CELL BIO, V3, P651, DOI 10.1038/nrm909; Litterst CM, 2003, J BIOL CHEM, V278, P45340, DOI 10.1074/jbc.M303644200; LIU XW, 1995, P NATL ACAD SCI USA, V92, P8831, DOI 10.1073/pnas.92.19.8831; Lupu F, 2001, DEV BIOL, V229, P141, DOI 10.1006/dbio.2000.9975; Murrell A, 2004, NAT GENET, V36, P889, DOI 10.1038/ng1402; Nobrega MA, 2003, SCIENCE, V302, P413, DOI 10.1126/science.1088328; Ooi GT, 1998, MOL ENDOCRINOL, V12, P675, DOI 10.1210/me.12.5.675; Ooi GT, 1997, MOL ENDOCRINOL, V11, P997, DOI 10.1210/me.11.7.997; Paul C, 2000, EUR J BIOCHEM, V267, P5849, DOI 10.1046/j.1432-1327.2000.01395.x; Pfitzner E, 1998, MOL ENDOCRINOL, V12, P1582, DOI 10.1210/mend.12.10.0180; Pollak M, 2000, GROWTH HORM IGF RES, V10, pS6, DOI 10.1016/S1096-6374(00)90002-9; Rotwein P, 1999, CONT ENDOCRINOL, V17, P19; ROTWEIN P, 1997, J ANIM SCI, V75, P11; SALMON WD, 1957, J LAB CLIN MED, V49, P825; SCHOENLE E, 1982, NATURE, V296, P252, DOI 10.1038/296252a0; Shang YF, 2000, CELL, V103, P843, DOI 10.1016/S0092-8674(00)00188-4; Soldaini E, 2000, MOL CELL BIOL, V20, P389, DOI 10.1128/MCB.20.1.389-401.2000; Tatar M, 2003, SCIENCE, V299, P1346, DOI 10.1126/science.1081447; Teglund S, 1998, CELL, V93, P841, DOI 10.1016/S0092-8674(00)81444-0; Tollet-Egnell P, 1999, ENDOCRINOLOGY, V140, P3693, DOI 10.1210/en.140.8.3693; Udy GB, 1997, P NATL ACAD SCI USA, V94, P7239, DOI 10.1073/pnas.94.14.7239; Verdier F, 1998, MOL CELL BIOL, V18, P5852, DOI 10.1128/MCB.18.10.5852; Vinkemeier U, 1996, EMBO J, V15, P5616, DOI 10.1002/j.1460-2075.1996.tb00946.x; Wang Y, 2005, J BIOL CHEM, V280, P10955, DOI 10.1074/jbc.M412808200; Woelfle J, 2004, AM J PHYSIOL-ENDOC M, V286, pE393, DOI 10.1152/ajpendo.00389.2003; Woelfle J, 2003, J BIOL CHEM, V278, P51261, DOI 10.1074/jbc.M309486200; Woelfle J, 2003, J BIOL CHEM, V278, P22696, DOI 10.1074/jbc.M301362200; Zhu MH, 1999, CELL, V96, P121, DOI 10.1016/S0092-8674(00)80965-4	51	66	69	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 10	2006	281	6					3190	3197		10.1074/jbc.M510204200	http://dx.doi.org/10.1074/jbc.M510204200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	009QV	16339156	hybrid			2022-12-25	WOS:000235128200022
J	Hao, W; Takano, T; Guillemette, J; Papillon, J; Ren, GH; Cybulsky, AV				Hao, W; Takano, T; Guillemette, J; Papillon, J; Ren, GH; Cybulsky, AV			Induction of apoptosis by the Ste20-like kinase SLK, a germinal center kinase that activates apoptosis signal-regulating kinase and p38	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLOMERULAR EPITHELIAL-CELLS; MESSENGER-RNA STABILITY; PROTEIN-KINASE; ENDOPLASMIC-RETICULUM; STRESS-RESPONSE; STE20-RELATED KINASE; OXIDANT STRESS; PATHWAYS; DEATH; ASK1	Expression and activity of the germinal center kinase, Ste20-like kinase ( SLK), are increased during kidney development and recovery from ischemic acute renal failure. In this study, we characterize the activation and functional role of SLK. SLK underwent dimerization via the C-terminal domain, and dimerization enhanced SLK activity. In contrast, the C-terminal domain of SLK did not dimerize with a related kinase, Mst1, and did not affect Mst1 activity. Phosphorylation/ dephosphorylation of SLK were not associated with changes in kinase activity. SLK induced phosphorylation of apoptosis signal-regulating kinase-1 ( ASK1) and increased ASK1 activity, indicating that ASK1 is a substrate of SLK. Moreover, SLK stimulated phosphorylation of p38 mitogen-activated protein kinase via ASK1, but not c-Jun N-terminal kinase nor extracellular signal-regulated kinase. Chemical anoxia and recovery during re-exposure to glucose ( ischemia-reperfusion injury in cell culture) stimulated SLK activity. Overexpression of SLK enhanced anoxia/recovery-induced apoptosis, release of cytochrome c, and activities of caspase-8 and -9, and apoptosis was reduced significantly with p38 and caspase-9 inhibitors. Induction of the endoplasmic reticulum stress response by anoxia/recovery or tunicamycin ( monitored by induction of Bip or Grp94 expression, phosphorylation of eukaryotic translation initiation factor 2 alpha subunit, expression of CHOP, and activation of caspase-12) was attenuated in cells that overexpress SLK. Thus, SLK is an anoxia/recovery-dependent kinase that is activated via homodimerization and that signals via ASK1 and p38 to promote apoptosis. Attenuation of the protective aspects of the endoplasmic reticulum stress response by SLK may contribute to its proapoptotic effect.	McGill Univ, Ctr Hlth, Dept Med, Montreal, PQ H3A 1A1, Canada	McGill University	Cybulsky, AV (corresponding author), Royal Victoria Hosp, Div Nephrol, 687 Pine Ave W, Montreal, PQ H3A 1A1, Canada.	andrey.cybulsky@mcgill.ca	Cybulsky, Andrey V./AAG-8238-2020; Ren, Guohui/E-5388-2018	Cybulsky, Andrey V./0000-0003-4348-2348; 				ATWATER JA, 1990, ANNU REV GENET, V24, P519; BERNSTEIN P, 1989, TRENDS BIOCHEM SCI, V14, P373, DOI 10.1016/0968-0004(89)90011-X; Bijian K, 2004, AM J PHYSIOL-RENAL, V286, pF255, DOI 10.1152/ajprenal.00259.2003; Boyce M, 2005, SCIENCE, V307, P935, DOI 10.1126/science.1101902; Brinkworth RI, 2003, P NATL ACAD SCI USA, V100, P74, DOI 10.1073/pnas.0134224100; Buse P, 1999, J BIOL CHEM, V274, P7253, DOI 10.1074/jbc.274.11.7253; Coers W, 1996, EXP NEPHROL, V4, P184; Cybulsky AV, 2004, AM J PHYSIOL-RENAL, V286, pF16, DOI 10.1152/ajprenal.00144.2003; Cybulsky AV, 2002, J BIOL CHEM, V277, P41342, DOI 10.1074/jbc.M204694200; CYBULSKY AV, 1995, AM J PHYSIOL-RENAL, V269, pF739, DOI 10.1152/ajprenal.1995.269.5.F739; Dan I, 2001, TRENDS CELL BIOL, V11, P220, DOI 10.1016/S0962-8924(01)01980-8; Demaurex N, 2003, SCIENCE, V300, P65, DOI 10.1126/science.1083628; Donze O, 2004, EMBO J, V23, P564, DOI 10.1038/sj.emboj.7600078; Ellinger-Ziegelbauer H, 2000, GENES CELLS, V5, P491, DOI 10.1046/j.1365-2443.2000.00337.x; Galvan V, 2003, J BIOL CHEM, V278, P13325, DOI 10.1074/jbc.M211398200; Graves JD, 1998, EMBO J, V17, P2224, DOI 10.1093/emboj/17.8.2224; Green DR, 1998, SCIENCE, V281, P1309, DOI 10.1126/science.281.5381.1309; Ichijo H, 1997, SCIENCE, V275, P90, DOI 10.1126/science.275.5296.90; Kaufman RJ, 2002, J CLIN INVEST, V110, P1389, DOI 10.1172/JC1200216886; Kebache S, 2004, J BIOL CHEM, V279, P9662, DOI 10.1074/jbc.M310535200; KOSEKI C, 1992, J CELL BIOL, V119, P1327, DOI 10.1083/jcb.119.5.1327; Kroemer G, 2000, NAT MED, V6, P513, DOI 10.1038/74994; Kuramochi S, 1997, J BIOL CHEM, V272, P22679, DOI 10.1074/jbc.272.36.22679; Kyriakis JM, 1999, J BIOL CHEM, V274, P5259, DOI 10.1074/jbc.274.9.5259; Kyriakis JM, 2001, PHYSIOL REV, V81, P807, DOI 10.1152/physrev.2001.81.2.807; Kyriakis JM, 1996, BIOESSAYS, V18, P567, DOI 10.1002/bies.950180708; Lavoie JN, 1996, J BIOL CHEM, V271, P20608, DOI 10.1074/jbc.271.34.20608; Letunic I, 2004, NUCLEIC ACIDS RES, V32, pD142, DOI 10.1093/nar/gkh088; Liu JH, 2001, BIOCHEM J, V353, P79, DOI 10.1042/bj3530079; LUPAS A, 1991, SCIENCE, V252, P1162, DOI 10.1126/science.252.5009.1162; Matsukawa J, 2004, J BIOCHEM, V136, P261, DOI 10.1093/jb/mvh134; Park KM, 2001, J BIOL CHEM, V276, P11870, DOI 10.1074/jbc.M007518200; Pombo CM, 1997, J BIOL CHEM, V272, P29372, DOI 10.1074/jbc.272.46.29372; Pombo CM, 1996, EMBO J, V15, P4537, DOI 10.1002/j.1460-2075.1996.tb00831.x; Reed JC, 2000, AM J PATHOL, V157, P1415, DOI 10.1016/S0002-9440(10)64779-7; Ron D, 2002, J CLIN INVEST, V110, P1383, DOI 10.1172/JCI200216784; Sabourin LA, 2000, MOL CELL BIOL, V20, P684, DOI 10.1128/MCB.20.2.684-696.2000; Sabourin LA, 1999, ONCOGENE, V18, P7566, DOI 10.1038/sj.onc.1203119; Saikumar P, 1998, ONCOGENE, V17, P3401, DOI 10.1038/sj.onc.1202590; Savill J, 1999, KIDNEY INT, V56, P1216, DOI 10.1046/j.1523-1755.1999.00707.x; SHAW G, 1986, CELL, V46, P659, DOI 10.1016/0092-8674(86)90341-7; Sherr CJ, 2004, GENE DEV, V18, P2699, DOI 10.1101/gad.1256504; Sivaraman VS, 1997, J CLIN INVEST, V99, P1478, DOI 10.1172/JCI119309; Song JJ, 2004, J CELL BIOCHEM, V92, P1257, DOI 10.1002/jcb.20155; SOROKIN L, 1992, KIDNEY INT, V41, P657, DOI 10.1038/ki.1992.101; Takeda K, 2003, CELL STRUCT FUNCT, V28, P23; Thadhani R, 1996, NEW ENGL J MED, V334, P1448, DOI 10.1056/NEJM199605303342207; Van Laethem A, 2004, FASEB J, V18, P1946, DOI 10.1096/fj.04-2285fje; Wilkinson MG, 2000, FASEB J, V14, P2147, DOI 10.1096/fj.00-0102rev; Yamada E, 2000, BBA-MOL CELL RES, V1495, P250, DOI 10.1016/S0167-4889(99)00164-0; Yuan ZQ, 2003, J BIOL CHEM, V278, P23432, DOI 10.1074/jbc.M302674200; Zong WX, 2003, J CELL BIOL, V162, P59, DOI 10.1083/jcb.200302084	52	55	59	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 10	2006	281	6					3075	3084		10.1074/jbc.M511744200	http://dx.doi.org/10.1074/jbc.M511744200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	009QV	16316999	hybrid			2022-12-25	WOS:000235128200010
J	Henage, LG; Exton, JH; Brown, HA				Henage, LG; Exton, JH; Brown, HA			Kinetic analysis of a mammalian phospholipase D - Allosteric modulation by monomeric GTPases, protein kinase C, and polyphosphoinositides	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADP-RIBOSYLATION-FACTOR; PHOSPHATIDYLINOSITOL 4,5-BISPHOSPHATE; MEDIATED ACTIVATION; INTERACTION SITES; BINDING; RHO; MECHANISM; IDENTIFICATION; ENZYMES; FAMILY	In mammalian cells, phospholipase D activity is tightly regulated by diverse cellular signals, including hormones, neurotransmitters, and growth factors. Multiple signaling pathways converge upon phospholipase D to modulate cellular actions, such as cell growth, shape, and secretion. We examined the kinetics of protein kinase C and G-protein regulation of mammalian phospholipase D1 (PLD1) in order to better understand interactions between PLD1 and its regulators. Activation by Arf-1, RhoA, Rac1, Cdc42, protein kinase C alpha, and phosphatidylinositol 4,5-bisphosphate displayed surface dilution kinetics, but these effectors modulated different kinetic parameters. PKC alpha activation of PLD1 involves N- and C-terminal PLD domains. Rho GTPases were binding activators, enhancing the catalytic efficiency of a purified PLD1 catalytic domain via effects on K-m. Arf-1, a catalytic activator, stimulated PLD1 by enhancing the catalytic constant, k(cat). A kinetic description of PLD1 activation by multiple modulators reveals a mechanism for apparent synergy between activators. Synergy was observed only when PLD1 was simultaneously stimulated by a binding activator and a catalytic activator. Surprisingly, synergistic activation was steeply dependent on phosphatidylinositol 4,5-bisphosphate and phosphatidylcholine. Together, these findings suggest a role for PLD1 as a signaling node, in which integration of convergent signals occurs within discrete locales of the cellular membrane.	Vanderbilt Univ, Dept Pharmacol, Inst Biol Chem, Nashville, TN 37232 USA; Vanderbilt Univ, Vanderbilt Ingram Canc Ctr, Nashville, TN 37232 USA	Vanderbilt University; Vanderbilt University	Brown, HA (corresponding author), Vanderbilt Univ, Dept Pharmacol, Inst Biol Chem, Nashville, TN 37232 USA.	alex.brown@vanderbilt.edu			NIGMS NIH HHS [GM58516, R01 GM058516] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM058516] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Andresen BT, 2002, FEBS LETT, V531, P65, DOI 10.1016/S0014-5793(02)03483-X; BROWN HA, 1993, CELL, V75, P1137, DOI 10.1016/0092-8674(93)90323-I; BROWN HA, 1995, METHOD ENZYMOL, V257, P313; Buchanan FG, 2005, P NATL ACAD SCI USA, V102, P1638, DOI 10.1073/pnas.0406698102; Buser CA, 1998, METH MOL B, V84, P267; Cai SM, 2001, BIOCHEM J, V355, P779, DOI 10.1042/bj3550779; CARMAN GM, 1995, J BIOL CHEM, V270, P18711, DOI 10.1074/jbc.270.32.18711; Chalifa-Caspi V, 1998, NEUROCHEM RES, V23, P589, DOI 10.1023/A:1022422418388; Du GW, 2003, J CELL BIOL, V162, P305, DOI 10.1083/jcb.200302033; Du GW, 2000, MOL BIOL CELL, V11, P4359, DOI 10.1091/mbc.11.12.4359; Dubois T, 2005, NAT CELL BIOL, V7, P353, DOI 10.1038/ncb1244; Elias M, 2002, BMC GENOMICS, V3, DOI 10.1186/1471-2164-3-2; Erickson JW, 1996, J BIOL CHEM, V271, P26850, DOI 10.1074/jbc.271.43.26850; Exton JH, 2002, REV PHYSIOL BIOCH P, V144, P1, DOI 10.1007/BFb0116585; Foster DA, 2003, MOL CANCER RES, V1, P789; Ge MT, 2001, BIOPHYS J, V81, P994, DOI 10.1016/S0006-3495(01)75757-8; Hammond SM, 1997, J BIOL CHEM, V272, P3860, DOI 10.1074/jbc.272.6.3860; Hiroyama M, 2005, J CELL BIOCHEM, V95, P149, DOI 10.1002/jcb.20351; Hodgkin MN, 2000, CURR BIOL, V10, P43, DOI 10.1016/S0960-9822(99)00264-X; Hoer A, 2000, BBA-PROTEIN STRUCT M, V1481, P189, DOI 10.1016/S0167-4838(00)00108-4; *IUPAC IUBMB, 1982, EUR J BIOCHEM, V128, P281; Jiang XJ, 2002, METHOD ENZYMOL, V345, P328; Kook S, 2005, CELL SIGNAL, V17, P1423, DOI 10.1016/j.cellsig.2005.03.003; KTISTAKIS NT, 1995, P NATL ACAD SCI USA, V92, P4952, DOI 10.1073/pnas.92.11.4952; LEE MH, 1991, BIOCHEMISTRY-US, V30, P1041, DOI 10.1021/bi00218a023; Leiros I, 2004, J MOL BIOL, V339, P805, DOI 10.1016/j.jmb.2004.04.003; LISCOVITCH M, 1994, J BIOL CHEM, V269, P21403; Matas OB, 2004, TRAFFIC, V5, P838, DOI 10.1111/j.1600-0854.2004.00225.x; McDermott M, 2004, BIOCHEM CELL BIOL, V82, P225, DOI 10.1139/o03-079; Min DS, 1998, J BIOL CHEM, V273, P7044, DOI 10.1074/jbc.273.12.7044; Miura K, 2002, MOL CELL, V9, P109, DOI 10.1016/S1097-2765(02)00428-8; Nakamura SI, 1996, P NATL ACAD SCI USA, V93, P4300, DOI 10.1073/pnas.93.9.4300; Park SK, 1998, BIOCHEM BIOPH RES CO, V244, P364, DOI 10.1006/bbrc.1998.8275; Park SK, 1997, J BIOL CHEM, V272, P29263, DOI 10.1074/jbc.272.46.29263; Ponting CP, 1996, PROTEIN SCI, V5, P914; Qin CB, 2002, J BIOL CHEM, V277, P49685, DOI 10.1074/jbc.M209598200; Roth MG, 2004, PHYSIOL REV, V84, P699, DOI 10.1152/physrev.00033.2003; RUMENAPP U, 1995, EUR J BIOCHEM, V234, P240, DOI 10.1111/j.1432-1033.1995.240_c.x; Sciorra VA, 2001, BIOCHEMISTRY-US, V40, P2640, DOI 10.1021/bi002528m; Sciorra VA, 1999, EMBO J, V18, P5911, DOI 10.1093/emboj/18.21.5911; SINGER WD, 1995, J BIOL CHEM, V270, P14944, DOI 10.1074/jbc.270.25.14944; Singer WD, 1996, J BIOL CHEM, V271, P4504; Stahelin RV, 2004, J BIOL CHEM, V279, P54918, DOI 10.1074/jbc.M407798200; Stuckey JA, 1999, NAT STRUCT BIOL, V6, P278; Sung TC, 1997, EMBO J, V16, P4519, DOI 10.1093/emboj/16.15.4519; Sung TC, 1999, J BIOL CHEM, V274, P3659, DOI 10.1074/jbc.274.6.3659; TERUI T, 1994, J BIOL CHEM, V269, P28130; Waite M, 1999, BBA-MOL CELL BIOL L, V1439, P187, DOI 10.1016/S1388-1981(99)00094-3; Walker SJ, 2000, J BIOL CHEM, V275, P15665, DOI 10.1074/jbc.M000076200; Walker SJ, 2002, J BIOL CHEM, V277, P26260, DOI 10.1074/jbc.M201811200; Walker Stephanie J., 2003, V237, P89; Weernink PAO, 2004, EUR J PHARMACOL, V500, P87, DOI 10.1016/j.ejphar.2004.07.014; Westermann P, 1996, BIOCHEM J, V320, P651, DOI 10.1042/bj3200651; Yang HY, 2003, PROTEIN SCI, V12, P2087, DOI 10.1110/ps.03192503; Zheng L, 2002, BIOCHEMISTRY-US, V41, P4546, DOI 10.1021/bi0158775; Zheng Y, 1996, J BIOL CHEM, V271, P23815, DOI 10.1074/jbc.271.39.23815	56	48	51	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 10	2006	281	6					3408	3417		10.1074/jbc.M508800200	http://dx.doi.org/10.1074/jbc.M508800200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	009QV	16339153	Green Accepted, hybrid			2022-12-25	WOS:000235128200049
J	Kramlinger, VM; Hiasa, H				Kramlinger, VM; Hiasa, H			The "GyrA-box" is required for the ability of DNA gyrase to wrap DNA and catalyze the supercoiling reaction	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							C-TERMINAL DOMAIN; REPLICATION IN-VITRO; ESCHERICHIA-COLI; TOPOISOMERASE-IV; A-PROTEIN; ENZYME; RECONSTITUTION; PURIFICATION; MECHANISM; SUBUNITS	DNA gyrase is the only topoisomerase that can introduce negative supercoils into DNA. It is thought that the binding of conventional type II topoisomerases, including topoisomerase IV, to DNA takes place at the catalytic domain across the DNA gate, whereas DNA gyrase binds to DNA not only at the amino-terminal catalytic domain but also at the carboxyl-terminal domain (CTD) of the GyrA subunit. The binding of the GyrA CTD to DNA allows gyrase to wrap DNA around itself and catalyze the supercoiling reaction. Recent structural studies, however, have revealed striking similarities between the GyrA CTD and the ParC CTD, as well as the ability of the ParC CTD to bind and bend DNA. Thus, the molecular basis of gyrase-mediated wrapping of DNA needs to be reexamined. Here, we have conducted a mutational analysis to determine the role of the '' GyrA-box,'' a 7-amino acid-long motif unique to the GyrA CTD, in determining the DNA binding mode of gyrase. Either a deletion of the entire GyrA-box or substitution of the GyrA-box with 7 Ala residues abolishes the ability of gyrase to wrap DNA around itself and catalyze the supercoiling reaction. However, these mutations do not affect the relaxation and decatenation activities of gyrase. Thus, the presence of a GyrA-box allows gyrase to wrap DNA and catalyze the supercoiling reaction. The consequence of the loss of the GyrA-box during evolution of bacterial type II topoisomerases is discussed.	Univ Minnesota, Sch Med, Dept Pharmacol, Minneapolis, MN 55455 USA	University of Minnesota System; University of Minnesota Twin Cities	Hiasa, H (corresponding author), 6-120 Jackson Hall,321 Church St SE, Minneapolis, MN 55455 USA.	hiasa001@umn.edu						ADAMS DE, 1992, CELL, V71, P277, DOI 10.1016/0092-8674(92)90356-H; Bergerat A, 1997, NATURE, V386, P414, DOI 10.1038/386414a0; Buhler C, 1998, NUCLEIC ACIDS RES, V26, P5157, DOI 10.1093/nar/26.22.5157; Champoux JJ, 2001, ANNU REV BIOCHEM, V70, P369, DOI 10.1146/annurev.biochem.70.1.369; Charvin G, 2005, BIOPHYS J, V89, P384, DOI 10.1529/biophysj.105.060202; Corbett KD, 2005, J MOL BIOL, V351, P545, DOI 10.1016/j.jmb.2005.06.029; Corbett KD, 2004, P NATL ACAD SCI USA, V101, P7293, DOI 10.1073/pnas.0401595101; Hiasa H, 2000, J BIOL CHEM, V275, P34780, DOI 10.1074/jbc.M001608200; HIASA H, 1994, J BIOL CHEM, V269, P2093; HIGGINS NP, 1978, P NATL ACAD SCI USA, V75, P1773, DOI 10.1073/pnas.75.4.1773; Hsieh TJ, 2004, J BIOL CHEM, V279, P55587, DOI 10.1074/jbc.M408934200; Kampranis SC, 1996, P NATL ACAD SCI USA, V93, P14416, DOI 10.1073/pnas.93.25.14416; KATO J, 1990, CELL, V63, P393, DOI 10.1016/0092-8674(90)90172-B; Knight SW, 1999, EMBO J, V18, P4875, DOI 10.1093/emboj/18.17.4875; LIU LF, 1978, CELL, V15, P979, DOI 10.1016/0092-8674(78)90281-7; LIU LF, 1978, P NATL ACAD SCI USA, V75, P2098, DOI 10.1073/pnas.75.5.2098; MIZUUCHI K, 1978, P NATL ACAD SCI USA, V75, P5960, DOI 10.1073/pnas.75.12.5960; MORTON RM, 1993, METHOD ENZYMOL, V217, P270; PENG H, 1993, P NATL ACAD SCI USA, V90, P8571, DOI 10.1073/pnas.90.18.8571; PENG H, 1995, J BIOL CHEM, V270, P25286, DOI 10.1074/jbc.270.42.25286; Qi Y, 2002, PROTEINS, V47, P258, DOI 10.1002/prot.10090; REECE RJ, 1989, J BIOL CHEM, V264, P19648; REECE RJ, 1991, J BIOL CHEM, V266, P3540; Ruthenburg AJ, 2005, J BIOL CHEM, V280, P26177, DOI 10.1074/jbc.M502838200; Shea ME, 2000, J BIOL CHEM, V275, P14649, DOI 10.1074/jbc.275.19.14649; STUDIER WF, 1990, METHOD ENZYMOL, V185, P60, DOI DOI 10.1016/0076-6879(90)85008-C; SUGINO A, 1977, P NATL ACAD SCI USA, V74, P4767, DOI 10.1073/pnas.74.11.4767; Wang JC, 1996, ANNU REV BIOCHEM, V65, P635, DOI 10.1146/annurev.bi.65.070196.003223; Ward D, 1997, MOL MICROBIOL, V26, P897, DOI 10.1046/j.1365-2958.1997.6242005.x	29	38	41	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 10	2006	281	6					3738	3742		10.1074/jbc.M511160200	http://dx.doi.org/10.1074/jbc.M511160200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	009QV	16332690	hybrid			2022-12-25	WOS:000235128200086
J	Krueger, S; Hundertmark, T; Kalinski, T; Peitz, U; Wex, T; Malfertheiner, P; Naumann, M; Roessner, A				Krueger, S; Hundertmark, T; Kalinski, T; Peitz, U; Wex, T; Malfertheiner, P; Naumann, M; Roessner, A			Helicobacter pylori encoding the pathogenicity island activates matrix metalloproteinase 1 in gastric epithelial cells via JNK and ERK	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FACTOR-KAPPA-B; MATRIX-METALLOPROTEINASE SECRETION; INTERSTITIAL COLLAGENASE; PROSTAGLANDIN E-2; PROTEIN-KINASES; GENE-EXPRESSION; RHO GTPASES; IN-VITRO; INFECTION; CANCER	Helicobacter pylori colonizes the human gastric epithelium and induces an inflammatory response that is a trigger for gastric carcinogenesis. Matrix metalloproteinases ( MMPs) have recently been shown to be up-regulated in gastric epithelial cells infected with H. pylori and might contribute to the pathogenesis of peptic ulcer. The aim of this study was to extend the knowledge about the effect of H. pylori infection on MMP-1 expression by gastric epithelial cells, the kinetics of induction, the pathogenetic properties of the bacterium, and the intracellular signaling pathways required for MMP-1 up-regulation. Expression of MMP-1 was induced more than 10-fold by co-culture of AGS cells with H. pylori strains carrying the pathogenicity island (PAI(+)). H. pylori strains with mutations in the PAI and a defective type IV secretion system had no effect on MMP-1. Double immunofluorescence revealed strong MMP-1 staining in epithelial cells of gastric biopsies at sites of bacterial attachment. In vitro, MMP-1 is up-regulated by interleukin-1 beta and tumor necrosis factor-alpha, but these regulatory mechanisms are not operating in H. pylori infection as shown by inhibitory antibodies. Specific inhibitors of JNK kinase and ERK1/2 kinase were found to suppress the H. pylori-induced MMP-1 expression and activity. AGS cells treated with antisense MMP-1 showed a significantly reduced potential to degrade reconstituted basement membrane. Our results suggest that in gastric epithelial cells, H. pylori up-regulate sMMP-1 in a type IV secretion system-dependent manner via JNK and ERK1/2. Induction of MMP-1 is further implicated in complex processes induced by H. pylori, resulting in tissue degradation and remodeling of the gastric mucosa.	Otto Von Guericke Univ, Inst Pathol, D-39120 Magdeburg, Germany; Otto Von Guericke Univ, Dept Gastroenterol Hepatol & Infect Dis, D-39120 Magdeburg, Germany; Otto Von Guericke Univ, Inst Expt Internal Med, D-39120 Magdeburg, Germany	Otto von Guericke University; Otto von Guericke University; Otto von Guericke University	Krueger, S (corresponding author), Otto Von Guericke Univ, Inst Pathol, Leipziger Str 44, D-39120 Magdeburg, Germany.	sabine.krueger@medizin.uni-magdeburg.de	Naumann, Michael/B-5285-2011	Naumann, Michael/0000-0002-8060-2313				Al-Ghoul L, 2004, BIOCHEM BIOPH RES CO, V322, P860, DOI 10.1016/j.bbrc.2004.07.199; Bebb JR, 2003, GUT, V52, P1408, DOI 10.1136/gut.52.10.1408; Bergin PJ, 2004, HELICOBACTER, V9, P201, DOI 10.1111/j.1083-4389.2004.00232.x; BLASER MJ, 1995, CANCER RES, V55, P2111; Brauchle M, 2000, EXP CELL RES, V258, P135, DOI 10.1006/excr.2000.4913; Churin Y, 2003, J CELL BIOL, V161, P249, DOI 10.1083/jcb.200208039; Churin Y, 2001, MOL MICROBIOL, V40, P815, DOI 10.1046/j.1365-2958.2001.02443.x; Cover TL, 1999, GASTROENTEROLOGY, V117, P257, DOI 10.1016/S0016-5085(99)70575-5; Crawford HC, 2003, GASTROENTEROLOGY, V125, P1125, DOI 10.1016/S0016-5085(03)01206-X; Crowe SE, 2005, CURR OPIN GASTROEN, V21, P32; Deroanne CF, 2005, J CELL SCI, V118, P1173, DOI 10.1242/jcs.01707; Gooz M, 2003, GUT, V52, P1250, DOI 10.1136/gut.52.9.1250; Gooz M, 2001, AM J PHYSIOL-GASTR L, V281, pG823, DOI 10.1152/ajpgi.2001.281.3.G823; Ho LJ, 2005, BIOCHEM PHARMACOL, V70, P200, DOI 10.1016/j.bcp.2005.04.039; Huntington JT, 2004, J BIOL CHEM, V279, P33168, DOI 10.1074/jbc.M405102200; Inoue T, 1999, INT J MOL MED, V4, P73; Keates S, 1999, J IMMUNOL, V163, P5552; Keates S, 1997, GASTROENTEROLOGY, V113, P1099, DOI 10.1053/gast.1997.v113.pm9322504; Kida Y, 2005, CYTOKINE, V29, P159, DOI 10.1016/j.cyto.2004.10.009; Koyama S, 2004, SCAND J GASTROENTERO, V39, P1046, DOI 10.1080/00365520410003245; Krueger S, 2001, CANCER GENE THER, V8, P522, DOI 10.1038/sj.cgt.7700341; Kruger S, 1999, CANCER RES, V59, P6010; Lai WC, 2003, J IMMUNOL, V170, P6244, DOI 10.4049/jimmunol.170.12.6244; Lynch CC, 2002, DIFFERENTIATION, V70, P561, DOI 10.1046/j.1432-0436.2002.700909.x; Malfertheiner P, 2005, AM J GASTROENTEROL, V100, P2100, DOI 10.1111/j.1572-0241.2005.41688.x; Menges M, 2000, Z GASTROENTEROL, V38, P887, DOI 10.1055/s-2000-10300; Mori N, 2003, GASTROENTEROLOGY, V124, P983, DOI 10.1053/gast.2003.50152; Mott JD, 2004, CURR OPIN CELL BIOL, V16, P558, DOI 10.1016/j.ceb.2004.07.010; Munzenmaier A, 1997, J IMMUNOL, V159, P6140; Murray GI, 1998, GUT, V43, P791, DOI 10.1136/gut.43.6.791; Naumann M, 2005, INT J MED MICROBIOL, V295, P335, DOI 10.1016/j.ijmm.2005.06.007; Naumann M, 2004, TRENDS MICROBIOL, V12, P29, DOI 10.1016/j.tim.2003.11.005; Naumann M, 1999, J BIOL CHEM, V274, P31655, DOI 10.1074/jbc.274.44.31655; OTANI Y, 1994, J GASTROENTEROL, V29, P391, DOI 10.1007/BF02361233; Otani Y, 1997, J CLIN GASTROENTEROL, V25, pS101, DOI 10.1097/00004836-199700001-00017; Pardo A, 2005, INT J BIOCHEM CELL B, V37, P283, DOI 10.1016/j.biocel.2004.06.017; Parsonnet J, 1997, GUT, V40, P297, DOI 10.1136/gut.40.3.297; Peek RM, 2002, NAT REV CANCER, V2, P28, DOI 10.1038/nrc703; Pillinger MH, 2005, J BIOL CHEM, V280, P9973, DOI 10.1074/jbc.M413522200; Pomorski T, 2001, J BIOL CHEM, V276, P804, DOI 10.1074/jbc.M003819200; Reunanen N, 2002, J BIOL CHEM, V277, P32360, DOI 10.1074/jbc.M204296200; Ridley AJ, 2001, J CELL SCI, V114, P2713; Sharma SA, 1998, J IMMUNOL, V160, P2401; Sossey-Alaoui K, 2005, EXP CELL RES, V308, P135, DOI 10.1016/j.yexcr.2005.04.011; Stoicov C, 2004, GENE, V341, P1, DOI 10.1016/j.gene.2004.07.023; Suerbaum S, 2002, NEW ENGL J MED, V347, P1175, DOI 10.1056/NEJMra020542; Wessler S, 2000, J BIOL CHEM, V275, P3629, DOI 10.1074/jbc.275.5.3629; Wroblewski LE, 2003, J CELL SCI, V116, P3017, DOI 10.1242/jcs.00518; Yokoyama T, 2000, ALIMENT PHARM THERAP, V14, P193, DOI 10.1046/j.1365-2036.2000.014s1193.x; Zucker S, 2003, CURR TOP DEV BIOL, V54, P1, DOI 10.1016/S0070-2153(03)54004-2	50	39	42	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 3	2006	281	5					2868	2875		10.1074/jbc.m511053200	http://dx.doi.org/10.1074/jbc.m511053200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	006XT	16321971	hybrid			2022-12-25	WOS:000234931800055
J	Flanagan, JJ; Barlowe, C				Flanagan, JJ; Barlowe, C			Cysteine-disulfide cross-linking to monitor SNARE complex assembly during endoplasmic reticulum-Golgi transport	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTRACELLULAR MEMBRANE-FUSION; BIOCHEMICAL REQUIREMENTS; SACCHAROMYCES-CEREVISIAE; SECRETORY PATHWAY; PROTEIN-TRANSPORT; CRYSTAL-STRUCTURE; COPII VESICLES; SWISS-MODEL; ER; BIOSYNTHESIS	Assembly of cognate SNARE proteins into SNARE complexes is required for many intracellular membrane fusion reactions. However, the mechanisms that govern SNARE complex assembly and disassembly during fusion are not well understood. We have devised a new in vitro cross-linking assay to monitor SNARE complex assembly during fusion of endoplasmic reticulum (ER)-derived vesicles with Golgi-acceptor membranes. In Saccharomyces cerevisiae, anterograde ER-Golgi transport requires four SNARE proteins: Sec22p, Bos1p, Bet1p, and Sed5p. After tethering of ER-derived vesicles to Golgi-acceptor membranes, SNARE proteins are thought to assemble into a four-helix coiled-coil bundle analogous to the structurally characterized neuronal and endosomal SNARE complexes. Molecular modeling was used to generate a structure of the four-helix ER-Golgi SNARE complex. Based on this structure, cysteine residues were introduced into adjacent SNARE proteins such that disulfide bonds would form if assembled into a SNARE complex. Our initial studies focused on disulfide bond formation between the SNARE motifs of Bet1p and Sec22p. Expression of SNARE cysteine derivatives in the same strain produced a cross-linked heterodimer of Bet1p and Sec22p under oxidizing conditions. Moreover, this Bet1p-Sec22p heterodimer formed during in vitro transport reactions when ER-derived vesicles containing the Bet1p derivative fused with Golgi membranes containing the Sec22p derivative. Using this disulfide cross-linking assay, we show that inhibition of transport with anti-Sly1p antibodies blocked formation of the Bet1p-Sec22p heterodimer. In contrast, chelation of divalent cations did not inhibit formation of the Bet1p-Sec22p heterodimer during in vitro transport but potently inhibited Golgi-specific carbohydrate modification of glyco-pro-alpha factor. This data suggests that Ca2+ is not directly required for membrane fusion between ER-derived vesicles and Golgi-acceptor membranes.	Dartmouth Coll, Sch Med, Dept Biochem, Hanover, NH 03755 USA	Dartmouth College	Barlowe, C (corresponding author), Dartmouth Coll, Sch Med, Dept Biochem, Hanover, NH 03755 USA.	barlowe@dartmouth.edu			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM052549, F32GM070096, R37GM052549] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM 52549, GM 070096] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Antonin W, 2002, NAT STRUCT BIOL, V9, P107, DOI 10.1038/nsb746; BAKER D, 1990, P NATL ACAD SCI USA, V87, P355, DOI 10.1073/pnas.87.1.355; BAKER D, 1988, CELL, V54, P335, DOI 10.1016/0092-8674(88)90196-1; Barlowe C, 1997, J CELL BIOL, V139, P1097, DOI 10.1083/jcb.139.5.1097; BECKERS CJM, 1989, J CELL BIOL, V108, P1245, DOI 10.1083/jcb.108.4.1245; Bock JB, 2001, NATURE, V409, P839, DOI 10.1038/35057024; Cao XC, 2000, J CELL BIOL, V149, P55, DOI 10.1083/jcb.149.1.55; Cao XC, 1998, EMBO J, V17, P2156, DOI 10.1093/emboj/17.8.2156; Dani VS, 2003, PROTEIN ENG, V16, P187, DOI 10.1093/proeng/gzg024; Dascher C, 1996, J BIOL CHEM, V271, P15866, DOI 10.1074/jbc.271.27.15866; ELBLE R, 1992, BIOTECHNIQUES, V13, P18; FALKE JJ, 1987, SCIENCE, V237, P1596, DOI 10.1126/science.2820061; Fasshauer D, 1998, P NATL ACAD SCI USA, V95, P15781, DOI 10.1073/pnas.95.26.15781; Gillingham AK, 2003, BBA-MOL CELL RES, V1641, P71, DOI 10.1016/S0167-4889(03)00088-0; Giraudo CG, 2005, J CELL BIOL, V170, P249, DOI 10.1083/jcb.200501093; Guex N, 1997, ELECTROPHORESIS, V18, P2714, DOI 10.1002/elps.1150181505; Guo W, 2003, J BIOL CHEM, V278, P4385, DOI 10.1074/jbc.C200679200; Guthrie C, 1991, METHOD ENZYMOL, V194, P3; Han X, 2004, SCIENCE, V304, P289, DOI 10.1126/science.1095801; Hanson PI, 1997, CELL, V90, P523, DOI 10.1016/S0092-8674(00)80512-7; HARDWICK KG, 1992, J CELL BIOL, V119, P513, DOI 10.1083/jcb.119.3.513; HARLOW E, 1988, ANTIBODIES LABORATOR, P312; Hooft RWW, 1996, NATURE, V381, P272, DOI 10.1038/381272a0; Jahn R, 2000, NEURON, V27, P201, DOI 10.1016/S0896-6273(00)00029-5; Jahn R, 2003, CELL, V112, P519, DOI 10.1016/S0092-8674(03)00112-0; KAISER CA, 1990, CELL, V61, P723, DOI 10.1016/0092-8674(90)90483-U; KOBASHI K, 1968, BIOCHIM BIOPHYS ACTA, V158, P239, DOI 10.1016/0304-4165(68)90136-0; Liu YT, 2004, J BIOL CHEM, V279, P27225, DOI 10.1074/jbc.M312122200; Liu YT, 2002, MOL BIOL CELL, V13, P3314, DOI 10.1091/mbc.E02-04-0204; LOUKIN S, 1995, J CELL BIOL, V131, P1025, DOI 10.1083/jcb.131.4.1025; Lupashin VV, 1996, J CELL BIOL, V132, P277, DOI 10.1083/jcb.132.3.277; McNew JA, 2000, NATURE, V407, P153, DOI 10.1038/35025000; MIZUTA K, 1994, MOL CELL BIOL, V14, P2493, DOI 10.1128/MCB.14.4.2493; NAKAJIMA T, 1975, P NATL ACAD SCI USA, V72, P3912, DOI 10.1073/pnas.72.10.3912; NEWMAN AP, 1990, MOL CELL BIOL, V10, P3405, DOI 10.1128/MCB.10.7.3405; Nickel W, 1999, P NATL ACAD SCI USA, V96, P12571, DOI 10.1073/pnas.96.22.12571; Otte S, 2001, J CELL BIOL, V152, P503, DOI 10.1083/jcb.152.3.503; Parlati F, 2000, NATURE, V407, P194, DOI 10.1038/35025076; Parlati F, 1999, P NATL ACAD SCI USA, V96, P12565, DOI 10.1073/pnas.96.22.12565; PARODI AJ, 1979, J BIOL CHEM, V254, P8343; Peng RW, 2002, J CELL BIOL, V157, P645, DOI 10.1083/jcb.200202006; Peters C, 1998, NATURE, V396, P575, DOI 10.1038/25133; Porat A, 2000, J BIOL CHEM, V275, P29233, DOI 10.1074/jbc.M005316200; Pryor PR, 2000, J CELL BIOL, V149, P1053, DOI 10.1083/jcb.149.5.1053; Reese C, 2005, NATURE, V436, P410, DOI 10.1038/nature03722; REXACH MF, 1991, J CELL BIOL, V114, P219, DOI 10.1083/jcb.114.2.219; Schwede T, 2003, NUCLEIC ACIDS RES, V31, P3381, DOI 10.1093/nar/gkg520; SHARMA CB, 1974, EUR J BIOCHEM, V46, P35, DOI 10.1111/j.1432-1033.1974.tb03594.x; SIKORSKI RS, 1989, GENETICS, V122, P19; SOLLNER T, 1993, NATURE, V362, P318, DOI 10.1038/362318a0; SOWDHAMINI R, 1989, PROTEIN ENG, V3, P95, DOI 10.1093/protein/3.2.95; Sutton RB, 1998, NATURE, V395, P347, DOI 10.1038/26412; Tamm LK, 2003, CURR OPIN STRUC BIOL, V13, P453, DOI 10.1016/S0959-440X(03)00107-6; Tsui MMK, 2001, MOL BIOL CELL, V12, P521, DOI 10.1091/mbc.12.3.521; Ungermann C, 2005, J CELL SCI, V118, P3819, DOI 10.1242/jcs.02561; VRIEND G, 1990, J MOL GRAPHICS, V8, P52, DOI 10.1016/0263-7855(90)80070-V; Weber T, 1998, CELL, V92, P759, DOI 10.1016/S0092-8674(00)81404-X; Weimbs T, 1997, P NATL ACAD SCI USA, V94, P3046, DOI 10.1073/pnas.94.7.3046; WUESTEHUBE LJ, 1992, METHOD ENZYMOL, V219, P124; Zerial M, 2001, NAT REV MOL CELL BIO, V2, P107, DOI 10.1038/35052055	60	17	19	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 27	2006	281	4					2281	2288		10.1074/jbc.M511695200	http://dx.doi.org/10.1074/jbc.M511695200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	004NV	16303754	hybrid			2022-12-25	WOS:000234760400053
J	Li, N; Li, H; Cherukuri, P; Farzan, S; Harmes, DC; DiRenzo, J				Li, N; Li, H; Cherukuri, P; Farzan, S; Harmes, DC; DiRenzo, J			TA-p63-gamma regulates expression of Delta N-p63 in a manner that is sensitive to p53	ONCOGENE			English	Article						p63; p53; mammary gland; progenitor; self-renewal	EPITHELIAL STEM-CELLS; P63 GENE-MUTATIONS; BREAST-CANCER; DIFFERENTIAL REGULATION; DEVELOPMENTAL SYNDROMES; PROTEIN-DEGRADATION; MAMMARY-GLAND; TARGET GENES; SELF-RENEWAL; EEC-SYNDROME	Geneticanalysis indicates that TP63 is required for establishment and preservation of self-renewing progenitors within the basal layer of several epithelial structures, however, the specific contributions of transactivating ( TAp63) and dominant-negative (DN-p63) isoforms remain largely undemned. Recent studies have suggested a model in which TA-p63 plays an important role in the establishment of progenitor populations in which expression of Delta Np63 contributes to the preservation of self-renewing capacity. Our previous studies indicate that Delta N-p63 is a transcriptional target of p53, however, the absence of overt epithelial deficiencies in p53-/- mice and reports of increased expression of Delta N-p63 in p53-/- mice suggest p53-independent mechanisms also contribute to expression of DN-p63. Here, we present data indicating that, prolonged loss of p53 leads to the activation of a p53-independent mechanism for transcriptional regulation of DN-p63. This p53-independent mechanism is sensitive to ectopic p53 but not to a p53 mutant that lacks the transactivation domain. We further show that in cells in which p53 is expressed TA-p63-gamma protein is destabilized in a manner that is p53 dependent and sensitive to pharmacologic inhibition of the 26S proteosome. Consistent with this observation, we demonstrate that loss of p53 leads to the stabilization of TA-p63-gamma that is reversible by ectopic p53. Finally, we present evidence that disruption of TA-p63-gamma expression leads to decreased expression of Delta N-p63 and that overexpression of TA-p63c was sufficient to enhance the activity of the Delta N-p63 promoter. Taken together, our studies indicate that TAp63 gamma is capable of activating expression of Delta N-p63 and that this mechanism may account for p53-independent expression of DN-p63.	Dartmouth Coll, Sch Med, Dept Pharmacol & Toxicol, Hanover, NH 03755 USA	Dartmouth College	DiRenzo, J (corresponding author), Dartmouth Coll, Sch Med, Dept Pharmacol & Toxicol, 7650 Remsen, Hanover, NH 03755 USA.	james.direnzo@dartmouth.edu			NATIONAL CANCER INSTITUTE [R01CA108539] Funding Source: NIH RePORTER; NCI NIH HHS [1R01 CA108539] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Al-Hajj M, 2003, P NATL ACAD SCI USA, V100, P3983, DOI 10.1073/pnas.0530291100; Brunner HG, 2002, AM J MED GENET, V112, P284, DOI 10.1002/ajmg.10778; Celli J, 1999, CELL, V99, P143, DOI 10.1016/S0092-8674(00)81646-3; Chepko G, 1999, J MAMMARY GLAND BIOL, V4, P35, DOI 10.1023/A:1018752519356; Clarke RB, 2003, CELL PROLIFERAT, V36, P1, DOI 10.1046/j.1365-2184.36.s.1.1.x; Di Como CJ, 2002, CLIN CANCER RES, V8, P494; Dick J E, 1996, Semin Immunol, V8, P197, DOI 10.1006/smim.1996.0025; DiRenzo J, 2002, CANCER RES, V62, P89; Dohn M, 2001, ONCOGENE, V20, P3193, DOI 10.1038/sj.onc.1204427; Dontu G, 2003, GENE DEV, V17, P1253, DOI 10.1101/gad.1061803; Harmes DC, 2003, ONCOGENE, V22, P7607, DOI 10.1038/sj.onc.1207129; Hope KJ, 2004, NAT IMMUNOL, V5, P738, DOI 10.1038/ni1080; Jerry DJ, 2000, ONCOGENE, V19, P1052, DOI 10.1038/sj.onc.1203270; Jerry DJ, 1999, J MAMMARY GLAND BIOL, V4, P177, DOI 10.1023/A:1018777224808; Kaelin WG, 1999, ONCOGENE, V18, P7701, DOI 10.1038/sj.onc.1202955; Koster MI, 2004, GENE DEV, V18, P126, DOI 10.1101/gad.1165104; Koster MI, 2002, J INVEST DERM SYMP P, V7, P41, DOI 10.1046/j.1523-1747.2002.19639.x; Kussie PH, 1996, SCIENCE, V274, P948, DOI 10.1126/science.274.5289.948; Mills AA, 1999, NATURE, V398, P708, DOI 10.1038/19531; Molofsky AV, 2003, NATURE, V425, P962, DOI 10.1038/nature02060; Nylander K, 2002, J PATHOL, V198, P417, DOI 10.1002/path.1231; Nylander K, 2000, INT J CANCER, V87, P368, DOI 10.1002/1097-0215(20000801)87:3<368::AID-IJC9>3.3.CO;2-A; Pardal R, 2003, NAT REV CANCER, V3, P895, DOI 10.1038/nrc1232; Parsa R, 1999, J INVEST DERMATOL, V113, P1099, DOI 10.1046/j.1523-1747.1999.00780.x; Pellegrini G, 2001, P NATL ACAD SCI USA, V98, P3156, DOI 10.1073/pnas.061032098; Ratovitski EA, 2001, P NATL ACAD SCI USA, V98, P1817, DOI 10.1073/pnas.98.4.1817; ROSNER B, 1994, AM J EPIDEMIOL, V139, P819, DOI 10.1093/oxfordjournals.aje.a117079; Smalley M, 2003, NAT REV CANCER, V3, P832, DOI 10.1038/nrc1212; Smith GH, 2001, MICROSC RES TECHNIQ, V52, P190, DOI 10.1002/1097-0029(20010115)52:2<190::AID-JEMT1005>3.0.CO;2-O; Suliman Y, 2001, CANCER RES, V61, P6467; Trosko JE, 2003, ONCOL RES, V13, P353; van Bokhoven H, 2001, AM J HUM GENET, V69, P481, DOI 10.1086/323123; van Bokhoven H, 2002, TRENDS MOL MED, V8, P133, DOI 10.1016/S1471-4914(01)02260-2; Waltermann A, 2003, ONCOGENE, V22, P5686, DOI 10.1038/sj.onc.1206859; Welm AL, 2005, P NATL ACAD SCI USA, V102, P4324, DOI 10.1073/pnas.0500470102; Welm B, 2003, CELL PROLIFERAT, V36, P17, DOI 10.1046/j.1365-2184.36.s.1.3.x; Wu GJ, 2003, CANCER RES, V63, P2351; Yang A, 1999, NATURE, V398, P714, DOI 10.1038/19539; Yang AN, 1998, MOL CELL, V2, P305, DOI 10.1016/S1097-2765(00)80275-0; Ying HQ, 2005, MOL CELL BIOL, V25, P6154, DOI 10.1128/MCB.25.14.6154-6164.2005	40	22	24	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 13	2006	25	16					2349	2359		10.1038/sj.onc.1209270	http://dx.doi.org/10.1038/sj.onc.1209270			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	032HC	16331262				2022-12-25	WOS:000236764300007
J	Zhou, YT; Guy, GR; Low, BC				Zhou, YT; Guy, GR; Low, BC			BNIP-S alpha induces cell rounding and apoptosis by displacing p50RhoGAP and facilitating RhoA activation via its unique motifs in the BNIP-2 and Cdc42GAP homology domain	ONCOGENE			English	Article						BNIP-S; RhoA; BCH domain; p50RhoGAP/Cdc42GAP; cell rounding; apoptosis	AKT PHOSPHORYLATION; BCL-2 EXPRESSION; FAMILY PROTEINS; F-ACTIN; GTPASES; KINASE; GROWTH; TRANSLOCATION; BINDING; HOMOLOGY/SEC14P-LIKE	Changes in cell morphology are linked to many cellular events including cytokinesis, differentiation, migration and apoptosis. We recently showed that BNIP-S alpha induced cell rounding that leads to apoptosis via its BNIP-2 and Cdc42GAP Homology (BCH) domain, but the underlying mechanism has not been determined. Here, we have identified a unique region (amino acid 133-177) of the BNIP-S alpha BCH domain that targets RhoA, but not Cdc42 or Rac1 and only the dominant-negative form of RhoA could prevent the resultant cell rounding and apoptotic effect. The RhoA-binding region consists of two parts; one region (residues 133-147) that shows some homology to part of the RhoA switch I region and an adjacent sequence (residues 148-177) that resembles the REM class I RhoA-binding motif. The sequence 133-147 is also necessary for its heterophilic interaction with the BCH domain of the Rho GTPase-activating protein, p50RhoGAP/Cdc42GAP. These overlapping motifs allow tripartite competition such that overexpression of BNIP-S alpha could reduce p50RhoGAP binding to RhoA and restore RhoA activation. Furthermore, BNIP-Sa mutants lacking the RhoA-binding motif completely failed to induce cell rounding and apoptosis. Therefore, via unique binding motifs within its BCH domain, BNIP-S alpha could interact and activate RhoA while preventing its inhibition by p50RhoGAP. This concerted mechanism could allow effective propagation of the RhoA pathway for cell rounding and apoptosis.	Natl Univ Singapore, Dept Biol Sci, Cell Signaling & Dev Biol Lab, Singapore 117548, Singapore; Natl Univ Singapore, Inst Mol & Cell Biol, Signal Transduct Lab, Singapore 117548, Singapore	National University of Singapore; Agency for Science Technology & Research (A*STAR); A*STAR - Institute of Molecular & Cell Biology (IMCB); National University of Singapore	Low, BC (corresponding author), Natl Univ Singapore, Dept Biol Sci, Cell Signaling & Dev Biol Lab, 14 Sci Dr 4, Singapore 117548, Singapore.	dbslowbc@nus.edu.sg	Low, Boon Chuan/H-8049-2012; Low, Boon Chuan/AAU-7685-2021	Low, Boon Chuan/0000-0003-0756-096X; Low, Boon Chuan/0000-0003-0756-096X; Zhou, Yi-Ting/0000-0003-4543-3099				Aspenstrom P, 1999, EXP CELL RES, V246, P20, DOI 10.1006/excr.1998.4300; Aznar S, 2001, CANCER LETT, V165, P1, DOI 10.1016/S0304-3835(01)00412-8; Bando M, 2002, BIOCHEM BIOPH RES CO, V290, P268, DOI 10.1006/bbrc.2001.6199; Bayless KJ, 2004, J BIOL CHEM, V279, P11686, DOI 10.1074/jbc.M308373200; Bishop AL, 2000, BIOCHEM J, V348, P241, DOI 10.1042/0264-6021:3480241; Bobak D, 1997, ONCOGENE, V15, P2179, DOI 10.1038/sj.onc.1201396; BOYD JM, 1994, CELL, V79, P341, DOI 10.1016/0092-8674(94)90202-X; Chua BT, 2003, NAT CELL BIOL, V5, P1083, DOI 10.1038/ncb1070; Coleman ML, 2002, CELL DEATH DIFFER, V9, P493, DOI 10.1038/sj.cdd.4400987; Collard JG, 2004, NATURE, V428, P705, DOI 10.1038/428705a; Combet C, 2000, TRENDS BIOCHEM SCI, V25, P147, DOI 10.1016/S0968-0004(99)01540-6; Croft DR, 2005, J CELL BIOL, V168, P245, DOI 10.1083/jcb.200409049; Dubreuil CI, 2003, J CELL BIOL, V162, P233, DOI 10.1083/jcb.200301080; Dvorsky R, 2004, EMBO REP, V5, P1130, DOI 10.1038/sj.embor.7400293; Fiorentini C, 1998, EXP CELL RES, V242, P341, DOI 10.1006/excr.1998.4057; Fiorentini C, 1998, INFECT IMMUN, V66, P2660, DOI 10.1128/IAI.66.6.2660-2665.1998; Flusberg DA, 2001, MOL BIOL CELL, V12, P3087, DOI 10.1091/mbc.12.10.3087; Frisch SM, 2001, CURR OPIN CELL BIOL, V13, P555, DOI 10.1016/S0955-0674(00)00251-9; Gourlay CW, 2005, J CELL SCI, V118, P2119, DOI 10.1242/jcs.02337; Hall A, 1998, SCIENCE, V279, P509, DOI 10.1126/science.279.5350.509; Huot J, 1998, J CELL BIOL, V143, P1361, DOI 10.1083/jcb.143.5.1361; Jenna S, 2002, J BIOL CHEM, V277, P6366, DOI 10.1074/jbc.M105516200; Kaufmann SH, 2001, TRENDS CELL BIOL, V11, P526, DOI 10.1016/S0962-8924(01)02173-0; Kim O, 2002, J BIOL CHEM, V277, P30066, DOI 10.1074/jbc.M201713200; Kim SJ, 2003, J BIOL CHEM, V278, P42448, DOI 10.1074/jbc.M304887200; Korichneva I, 1999, J CELL SCI, V112, P2521; Lim J, 2000, J BIOL CHEM, V275, P32837, DOI 10.1074/jbc.M002156200; Lockshin RA, 2004, ONCOGENE, V23, P2766, DOI 10.1038/sj.onc.1207514; Low BC, 1999, J BIOL CHEM, V274, P33123, DOI 10.1074/jbc.274.46.33123; Low BC, 2000, J BIOL CHEM, V275, P14415, DOI 10.1074/jbc.275.19.14415; Low BC, 2000, J BIOL CHEM, V275, P37742, DOI 10.1074/jbc.M004897200; Lua BL, 2004, MOL BIOL CELL, V15, P2873, DOI 10.1091/mbc.E04-02-0141; Melamed I, 1999, CELL IMMUNOL, V194, P136, DOI 10.1006/cimm.1999.1506; Mills JC, 1999, J CELL BIOL, V146, P703, DOI 10.1083/jcb.146.4.703; Moon SY, 2003, TRENDS CELL BIOL, V13, P13, DOI 10.1016/S0962-8924(02)00004-1; Posey SC, 1999, J BIOL CHEM, V274, P4259, DOI 10.1074/jbc.274.7.4259; Qin WX, 2003, BIOCHEM BIOPH RES CO, V308, P379, DOI 10.1016/S0006-291X(03)01387-1; Reuveny M, 2004, FEBS LETT, V569, P129, DOI 10.1016/j.febslet.2004.05.035; Ridley AJ, 2001, TRENDS CELL BIOL, V11, P471, DOI 10.1016/S0962-8924(01)02153-5; Saeki N, 2005, J BIOL CHEM, V280, P10128, DOI 10.1074/jbc.M413415200; Sahai E, 2002, NAT REV CANCER, V2, P133, DOI 10.1038/nrc725; Shang X, 2003, J BIOL CHEM, V278, P45903, DOI 10.1074/jbc.M304514200; Song YH, 2002, EXP CELL RES, V278, P45, DOI 10.1006/excr.2002.5565; Spector D. L., 1998, CELLS LAB MANUAL; Subauste MC, 2000, J BIOL CHEM, V275, P9725, DOI 10.1074/jbc.275.13.9725; Suria H, 1999, LIFE SCI, V65, P2697, DOI 10.1016/S0024-3205(99)00538-X; Surks HK, 2003, J BIOL CHEM, V278, P51484, DOI 10.1074/jbc.M305622200; Takahashi K, 1997, J BIOL CHEM, V272, P23371, DOI 10.1074/jbc.272.37.23371; Tosello-Trampont AC, 2003, J BIOL CHEM, V278, P49911, DOI 10.1074/jbc.M306079200; Ueda H, 2004, EXP CELL RES, V298, P207, DOI 10.1016/j.yexcr.2004.04.015; Wang L, 2006, BLOOD, V107, P98, DOI 10.1182/blood-2005-05-2171; Wang L, 2005, P NATL ACAD SCI USA, V102, P13484, DOI 10.1073/pnas.0504420102; Wennerberg K, 2003, CURR BIOL, V13, P1106, DOI 10.1016/S0960-9822(03)00418-4; White SR, 2001, AM J RESP CELL MOL, V24, P282, DOI 10.1165/ajrcmb.24.3.3995; Yamashita T, 2003, NAT NEUROSCI, V6, P461, DOI 10.1038/nn1045; Zhou XL, 2004, ONCOGENE, V23, P1308, DOI 10.1038/sj.onc.1207246; Zhou Yi Ting, 2005, Experimental Cell Research, V303, P263, DOI 10.1016/j.yexcr.2004.08.044; Zhou YT, 2002, J BIOL CHEM, V277, P7483, DOI 10.1074/jbc.M109459200	58	18	18	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 13	2006	25	16					2393	2408		10.1038/sj.onc.1209274	http://dx.doi.org/10.1038/sj.onc.1209274			16	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	032HC	16331259				2022-12-25	WOS:000236764300011
J	Chia, DJ; Subbian, E; Buck, TM; Hwa, V; Rosenfeld, RG; Skach, WR; Shinde, U; Rotwein, P				Chia, DJ; Subbian, E; Buck, TM; Hwa, V; Rosenfeld, RG; Skach, WR; Shinde, U; Rotwein, P			Aberrant folding of a mutant Stat5b causes growth hormone insensitivity and proteasomal dysfunction	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FACTOR-I GENE; HYPOPHYSECTOMIZED RATS; AGGRESOME FORMATION; STIMULATES GROWTH; BODY FORMATION; DNA-BINDING; PROTEIN; TRANSCRIPTION; DEGRADATION; RECEPTOR	A predicted alanine to proline substitution in Stat5b that results in profound short stature, growth hormone insensitivity, and immunodeficiency represents the first natural mutation of this transcription factor in a human. To understand the mechanisms responsible for these pathophysiological abnormalities, we have studied the biochemical and biophysical properties of the mutant Stat5b molecule. In a cellular reconstitution model growth hormone robustly stimulated tyrosine phosphorylation and transcriptional activity of wild-type Stat5b while Stat5b(A630P) was minimally modified and did not promote reporter gene expression. Steady state levels of Stat5b(WT) were similar to 3-fold higher than Stat5b(A630P) in cell extracts prepared with nonionic detergents. Although initial rates of biosynthesis of both proteins were similar, pulse-chase experiments established that the apparent half-life of newly synthesized soluble Stat5b(A630P) was < 15% of Stat5b(WT) (3.5 h versus > 24 h). Stat5b(A630P) accumulated in cells primarily in cytoplasmic inclusion bodies. Structural analysis of the isolated SH2 domain containing the A630P mutation showed that it resembled the wild-type SH2 segment but that it exhibited reduced thermodynamic stability and slower folding kinetics, displayed an increased hydrophobic surface, and was prone to aggregation in solution. Our results are compatible with a model in which Stat5bA630P is an inactive transcription factor by virtue of its aberrant folding and diminished solubility triggered by amisfolded SH2 domain. The potential for aggregation and formation of cytoplasmic inclusions raises the possibility that Stat5b(A630P) could produce additional defects through inhibition of proteasome function.	Oregon Hlth & Sci Univ, Dept Biochem & Mol Biol, Portland, OR 97239 USA; Oregon Hlth & Sci Univ, Dept Pediat, Portland, OR 97239 USA	Oregon Health & Science University; Oregon Health & Science University	Rotwein, P (corresponding author), Oregon Hlth & Sci Univ, Dept Biochem & Mol Biol, 3181 SW Sam Jackson Rd, Portland, OR 97239 USA.	rotweinp@ohsu.edu	Rotwein, Peter/R-5783-2019	Rotwein, Peter/0000-0002-9505-1817; Buck, Teresa/0000-0002-9013-9756	NCI NIH HHS [R01 CA85110] Funding Source: Medline; NICHD NIH HHS [K12 HD057588] Funding Source: Medline; NIDDK NIH HHS [F32 DK070447, R01 DK063073, R01 DK069703] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [K12HD057588] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK069703, R01DK063073, F32DK070447] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Abu Hatoum O, 1998, MOL CELL BIOL, V18, P5670, DOI 10.1128/MCB.18.10.5670; Abuzzahab MJ, 2003, NEW ENGL J MED, V349, P2211, DOI 10.1056/NEJMoa010107; Bence NF, 2001, SCIENCE, V292, P1552, DOI 10.1126/science.292.5521.1552; Bennett EJ, 2005, MOL CELL, V17, P351, DOI 10.1016/j.molcel.2004.12.021; Bonapace G, 2003, J MED GENET, V40, P913, DOI 10.1136/jmg.40.12.913; Castro-Fernandez C, 2005, ENDOCR REV, V26, P479, DOI 10.1210/er.2004-0010; Chen XM, 1998, CELL, V93, P827, DOI 10.1016/S0092-8674(00)81443-9; Cohen FE, 2003, NATURE, V426, P905, DOI 10.1038/nature02265; Darnell JE, 1997, SCIENCE, V277, P1630, DOI 10.1126/science.277.5332.1630; DAUGHADAY WH, 1989, ENDOCR REV, V10, P68, DOI 10.1210/edrv-10-1-68; Dobson CM, 2004, SEMIN CELL DEV BIOL, V15, P3, DOI 10.1016/j.semcdb.2003.12.008; Goldberg AL, 2003, NATURE, V426, P895, DOI 10.1038/nature02263; GULER HP, 1988, P NATL ACAD SCI USA, V85, P4889, DOI 10.1073/pnas.85.13.4889; Haan S, 1999, J BIOL CHEM, V274, P1342, DOI 10.1074/jbc.274.3.1342; Herrington J, 2001, TRENDS ENDOCRIN MET, V12, P252, DOI 10.1016/S1043-2760(01)00423-4; Horvath CM, 2000, TRENDS BIOCHEM SCI, V25, P496, DOI 10.1016/S0968-0004(00)01624-8; Hwa V, 2005, J CLIN ENDOCR METAB, V90, P4260, DOI 10.1210/jc.2005-0515; Illing ME, 2002, J BIOL CHEM, V277, P34150, DOI 10.1074/jbc.M204955200; Johnston JA, 1998, J CELL BIOL, V143, P1883, DOI 10.1083/jcb.143.7.1883; Kawaguchi Y, 2003, CELL, V115, P727, DOI 10.1016/S0092-8674(03)00939-5; Kofoed EM, 2003, NEW ENGL J MED, V349, P1139, DOI 10.1056/NEJMoa022926; Le Roith D, 2001, ENDOCR REV, V22, P53, DOI 10.1210/er.22.1.53; Levy DE, 2002, NAT REV MOL CELL BIO, V3, P651, DOI 10.1038/nrm909; Lin JX, 1996, J BIOL CHEM, V271, P10738, DOI 10.1074/jbc.271.18.10738; Lopez-Bermejo A, 2000, TRENDS ENDOCRIN MET, V11, P39, DOI 10.1016/S1043-2760(99)00226-X; Olanow CW, 2004, LANCET NEUROL, V3, P496, DOI 10.1016/S1474-4422(04)00827-0; Ptashne M, 2005, TRENDS BIOCHEM SCI, V30, P275, DOI 10.1016/j.tibs.2005.04.003; Rosenbloom AL, 1997, PEDIATR CLIN N AM, V44, P423, DOI 10.1016/S0031-3955(05)70484-3; ROSENFELD RG, 1994, ENDOCR REV, V15, P369, DOI 10.1210/er.15.3.369; Ross CA, 2004, NAT MED, V10, pS10, DOI 10.1038/nm1066; Ross CA, 2002, NEURON, V35, P819, DOI 10.1016/S0896-6273(02)00872-3; Saliba RS, 2002, J CELL SCI, V115, P2907; SCHOENLE E, 1982, NATURE, V296, P252, DOI 10.1038/296252a0; Sharp ZD, 2004, J CELL BIOCHEM, V92, P664, DOI 10.1002/jcb.20028; Stenoien DL, 1999, HUM MOL GENET, V8, P731, DOI 10.1093/hmg/8.5.731; Subbian E, 2004, BIOCHEMISTRY-US, V43, P14348, DOI 10.1021/bi048397x; Taylor JP, 2003, HUM MOL GENET, V12, P749, DOI 10.1093/hmg/ddg074; Teglund S, 1998, CELL, V93, P841, DOI 10.1016/S0092-8674(00)81444-0; Udy GB, 1997, P NATL ACAD SCI USA, V94, P7239, DOI 10.1073/pnas.94.14.7239; Woelfle J, 2003, J BIOL CHEM, V278, P51261, DOI 10.1074/jbc.M309486200; Woelfle J, 2003, J BIOL CHEM, V278, P22696, DOI 10.1074/jbc.M301362200; Woods KA, 1996, NEW ENGL J MED, V335, P1363, DOI 10.1056/NEJM199610313351805; Woods KA, 1997, J CLIN ENDOCR METAB, V82, P3529, DOI 10.1210/jc.82.11.3529	43	23	25	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 10	2006	281	10					6552	6558		10.1074/jbc.M510903200	http://dx.doi.org/10.1074/jbc.M510903200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	022BX	16303763	hybrid			2022-12-25	WOS:000236030800051
J	Jadlowiec, JA; Zhang, XY; Li, JH; Campbell, PG; Sfeir, C				Jadlowiec, JA; Zhang, XY; Li, JH; Campbell, PG; Sfeir, C			Extracellular matrix-mediated signaling by dentin phosphophoryn involves activation of the smad pathway independent of bone morphogenetic protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MESENCHYMAL STEM-CELLS; GENE-EXPRESSION; RAT INCISOR; NEURAL INDUCTION; MAPK PATHWAYS; BMP; DIFFERENTIATION; BETA; PHOSPHOPROTEIN; INTEGRATION	Cells have ingenious mechanisms for interpreting complex signals from their external microenvironment. Previously, we have shown that phosphophoryn (PP) regulates the expression of bone/ dentin marker genes via the integrin/MAPK signaling pathway (Jadlowiec, J., Koch, H., Zhang, X., Campbell, P. G., Seyedain, M., and Sfeir, C. ( 2004) J. Biol. Chem. 279, 53323 - 53330). We hypothesize that other signaling pathways important for mineralized tissue morphogenesis such as the Smad pathway could be involved in PP signaling. We determined activation of the Smad pathway in human adult mesenchymal stem cells following treatment with recombinant PP (rPP). We observed that PP enhanced phosphorylation of Smad1 within 30 min and Smad1 translocation to the nucleus within 1 h. PP up-regulated the expression of Smad1 target genes, Smad6, Dlx5, and Runx2. The timing of PP activation of Smad1 implies this is a direct effect; however, we also investigated the possible involvement of bone morphogenetic proteins in PP stimulation of the Smad pathway. PP was shown to up-regulate Bmp-2 gene expression 12 h post-treatment with PP, which is much later than initial detection of Smad1 phosphorylation at 30 min. Furthermore, addition of Noggin did not block Smad1 phosphorylation by PP. We propose that PP could signal via the Smad pathway by either directly stimulating the phosphorylation of Smad1 via integrins or other mechanisms. These might include integrin/bone morphogenetic protein receptor interactions or involvement of PP with other growth factors leading to the modulation of intracellular signaling. It is noteworthy that a non-transforming growth factor-beta family member activates the Smad pathway. The role of PP in regulating the Smad pathway raises very interesting questions regarding the role of PP during bone and tooth development.	Univ Pittsburgh, Sch Dent Med, Dept Oral Med & Pathol, Pittsburgh, PA 15261 USA; Carnegie Mellon Univ, Dept Biol Sci, Pittsburgh, PA 15213 USA; Carnegie Mellon Univ, Inst Complex Engineered Syst, Pittsburgh, PA 15213 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Carnegie Mellon University; Carnegie Mellon University	Sfeir, C (corresponding author), Univ Pittsburgh, Sch Dent Med, Dept Oral Med & Pathol, 693A Salk Hall,3501 Terrace St, Pittsburgh, PA 15261 USA.	csfeir@pitt.edu			NIDCR NIH HHS [DE 016123-01] Funding Source: Medline; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [R01DE016123] Funding Source: NIH RePORTER	NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		AHRENS M, 1993, DNA CELL BIOL, V12, P871, DOI 10.1089/dna.1993.12.871; *APPL BIOS, 2001, US B APPL BIOS, V2; Aubin J, 2004, GENE DEV, V18, P1482, DOI 10.1101/gad.1202604; Celil AB, 2005, J CELL BIOCHEM, V95, P518, DOI 10.1002/jcb.20429; De Robertis EM, 2000, NAT REV GENET, V1, P171, DOI 10.1038/35042039; DEVRIES IG, 1989, HISTOCHEMISTRY, V91, P69, DOI 10.1007/BF00501914; Diefenderfer DL, 2003, CONNECT TISSUE RES, V44, P305, DOI 10.1080/03008200390181825; Ebara S, 2002, SPINE, V27, pS10, DOI 10.1097/00007632-200208151-00004; Elefteriou F, 2005, NATURE, V434, P514, DOI 10.1038/nature03398; Fisher LW, 2003, CONNECT TISSUE RES, V44, P33, DOI 10.1080/03008200390152061; Gallea S, 2001, BONE, V28, P491, DOI 10.1016/S8756-3282(01)00415-X; Ganan Y, 1996, DEVELOPMENT, V122, P2349; Giancotti FG, 1999, SCIENCE, V285, P1028, DOI 10.1126/science.285.5430.1028; Guha U, 2002, DEV BIOL, V249, P108, DOI 10.1006/dbio.2002.0752; Jadlowiec J, 2005, ENDOCRINOLOGY, V146, P3765, DOI 10.1210/en.2004-1351; Jadlowiec J, 2004, J BIOL CHEM, V279, P53323, DOI 10.1074/jbc.M404934200; Kawakami Y, 1996, DEVELOPMENT, V122, P3557; Kimura N, 2000, J BIOL CHEM, V275, P17647, DOI 10.1074/jbc.M908622199; KOCH H, 2005, IN PRESS STEM CELL D; Kretzschmar M, 1997, NATURE, V389, P618, DOI 10.1038/39348; Lai CF, 2002, J BIOL CHEM, V277, P15514, DOI 10.1074/jbc.M200794200; LINDE A, 1980, J BIOL CHEM, V255, P5931; MACDOUGALL M, 1985, BIOCHEM J, V232, P493, DOI 10.1042/bj2320493; Massague J, 2000, EMBO J, V19, P1745, DOI 10.1093/emboj/19.8.1745; Massague J, 2003, GENE DEV, V17, P2993, DOI 10.1101/gad.1167003; Nohe A, 2002, J BIOL CHEM, V277, P5330, DOI 10.1074/jbc.M102750200; Pera EM, 2003, GENE DEV, V17, P3023, DOI 10.1101/gad.1153603; Qin C, 2002, J DENT RES, V81, P392, DOI 10.1177/154405910208100607; Raftery LA, 2003, TRENDS GENET, V19, P701, DOI 10.1016/j.tig.2003.10.009; RICHARDSON WS, 1978, J BIOL CHEM, V253, P8042; Seki K, 2004, J BIOL CHEM, V279, P18544, DOI 10.1074/jbc.M311592200; Sfeir C, 1996, CONNECT TISSUE RES, V35, P215, DOI 10.3109/03008209609029194; SFEIR C, 1995, J BONE MINER RES, V10, P607; Shi YG, 2003, CELL, V113, P685, DOI 10.1016/S0092-8674(03)00432-X; Souchelnytskyi S, 2002, TRENDS CELL BIOL, V12, P304, DOI 10.1016/S0962-8924(02)02300-0; Tamura Y, 2001, J BONE MINER RES, V16, P1772, DOI 10.1359/jbmr.2001.16.10.1772; URIST MARSHALL R., 1967, CLIN ORTHOP RELATED RESIN COMPLICATIONS OF ORTHOPAEDIC SURGERY, V53, P243; URIST MR, 1965, SCIENCE, V150, P893, DOI 10.1126/science.150.3698.893; Veis A, 1998, EUR J ORAL SCI, V106, P234, DOI 10.1111/j.1600-0722.1998.tb02181.x; von Bubnoff A, 2001, DEV BIOL, V239, P1, DOI 10.1006/dbio.2001.0388; Weinstein DC, 1999, ANNU REV CELL DEV BI, V15, P411, DOI 10.1146/annurev.cellbio.15.1.411; WEINSTOCK M, 1973, J CELL BIOL, V56, P838, DOI 10.1083/jcb.56.3.838; Wrana JL, 2000, CYTOKINE GROWTH F R, V11, P5, DOI 10.1016/S1359-6101(99)00024-6; Xiao GZ, 2000, J BIOL CHEM, V275, P4453, DOI 10.1074/jbc.275.6.4453; Xiao GZ, 2002, J BONE MINER RES, V17, P101, DOI 10.1359/jbmr.2002.17.1.101; Xiao GZ, 2005, J BIOL CHEM, V280, P30689, DOI 10.1074/jbc.M500750200; Yang XG, 2004, CELL, V117, P387, DOI 10.1016/S0092-8674(04)00344-7; Zaidi SK, 2002, P NATL ACAD SCI USA, V99, P8048, DOI 10.1073/pnas.112664499; Zhang W, 2002, J CELL PHYSIOL, V193, P233, DOI 10.1002/jcp.10168	49	59	59	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 3	2006	281	9					5341	5347		10.1074/jbc.M506158200	http://dx.doi.org/10.1074/jbc.M506158200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	015RQ	16326713	hybrid			2022-12-25	WOS:000235568900004
J	Romero, C; Desai, P; DeLillo, N; Vancura, A				Romero, C; Desai, P; DeLillo, N; Vancura, A			Expression of FLR1 transporter requires phospholipase C and is repressed by mediator	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RNA-POLYMERASE-II; OF-FUNCTION ALLELE; SACCHAROMYCES-CEREVISIAE; BUDDING YEAST; INOSITOL PYROPHOSPHATES; MICROTUBULE FUNCTION; TRANSCRIPTIONAL ACTIVATION; DIAZABORINE RESISTANCE; DEPENDENT BINDING; PLEIOTROPIC DRUG	In budding yeast, phosphoinositide-specific phospholipase C (Plc1p encoded by PLC1 gene) is important for function of kinetochores. Deletion of PLC1 results in benomyl sensitivity, alterations in chromatin structure of centromeres, mitotic delay, and a higher frequency of chromosome loss. Here we intended to utilize benomyl sensitivity as a phenotype that would allow us to identify genes that are important for kinetochore function and are downstream of Plc1p. However, our screen identified SIN4, encoding a component of the Mediator complex of RNA polymerase II. Deletion of SIN4 gene (sin4 Delta) does not suppress benomyl sensitivity of plc1 Delta cells by improving the function of kinetochores. Instead, benomyl sensitivity of plc1 Delta cells is caused by a defect in expression of FLR1, and the suppression of benomyl sensitivity in plc1 Delta sin4 Delta cells occurs by derepression of FLR1 transcription. FLR1 encodes a plasma membrane transporter that mediates resistance to benomyl. Several other mutations in the Mediator complex also result in significant derepression of FLR1 and greatly increased resistance to benomyl. Thus, benomyl sensitivity is not a phenotype exclusively associated with mitotic spindle defect. These results demonstrate that in addition to promoter-specific transcription factors that are components of the pleiotropic drug resistance network, expression of the membrane transporters can be regulated by Plc1p, a component of a signal transduction pathway, and by Mediator, a general transcription factor. The results thus suggest another layer of complexity in regulation of pleiotropic drug resistance.	St Johns Univ, Dept Biol Sci, Queens, NY 11439 USA	Saint John's University	Vancura, A (corresponding author), St Johns Univ, Dept Biol Sci, 8000 Utopia Pkwy, Queens, NY 11439 USA.	vancuraa@stjohns.edu		Vancura, Ales/0000-0002-5895-1218	NIGMS NIH HHS [GM 62183] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R15GM062183] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Asturias FJ, 1999, SCIENCE, V283, P985, DOI 10.1126/science.283.5404.985; Balciunas D, 1999, P NATL ACAD SCI USA, V96, P376, DOI 10.1073/pnas.96.2.376; BALCIUNAS D, 1995, NUCLEIC ACIDS RES, V23, P4421, DOI 10.1093/nar/23.21.4421; BALZI E, 1994, BBA-BIOENERGETICS, V1187, P152, DOI 10.1016/0005-2728(94)90102-3; Bauer BE, 1999, BBA-BIOMEMBRANES, V1461, P217, DOI 10.1016/S0005-2736(99)00160-1; Bhoite LT, 2001, GENE DEV, V15, P2457, DOI 10.1101/gad.921601; Broco N, 1999, YEAST, V15, P1595; Cardenas ME, 1999, CLIN MICROBIOL REV, V12, P583, DOI 10.1128/CMR.12.4.583; Cosma MP, 2001, MOL CELL, V7, P1213, DOI 10.1016/S1097-2765(01)00266-0; COVITZ PA, 1994, GENETICS, V138, P577; DeLillo N, 2003, MOL GENET GENOMICS, V269, P261, DOI 10.1007/s00438-003-0832-4; DIVECHA N, 1995, CELL, V80, P269, DOI 10.1016/0092-8674(95)90409-3; Dotson MR, 2000, P NATL ACAD SCI USA, V97, P14307, DOI 10.1073/pnas.260489497; FLICK JS, 1993, MOL CELL BIOL, V13, P5861, DOI 10.1128/MCB.13.9.5861; Gromoller A, 2000, EMBO J, V19, P6845, DOI 10.1093/emboj/19.24.6845; Hampsey M, 1997, YEAST, V13, P1099, DOI 10.1002/(SICI)1097-0061(19970930)13:12<1099::AID-YEA177>3.3.CO;2-Z; Hengartner CJ, 1998, MOL CELL, V2, P43, DOI 10.1016/S1097-2765(00)80112-4; Holstege FCP, 1998, CELL, V95, P717, DOI 10.1016/S0092-8674(00)81641-4; HOYT MA, 1991, CELL, V66, P507, DOI 10.1016/0092-8674(81)90014-3; Iyer V, 1996, P NATL ACAD SCI USA, V93, P5208, DOI 10.1073/pnas.93.11.5208; JIANG YW, 1992, MOL CELL BIOL, V12, P4503, DOI 10.1128/MCB.12.10.4503; JIANG YW, 1995, GENETICS, V140, P47; Jungwirth H, 2000, EUR J BIOCHEM, V267, P4809, DOI 10.1046/j.1432-1327.2000.01537.x; KINGSBURY J, 1991, CELL, V66, P483, DOI 10.1016/0092-8674(81)90012-X; KINGSBURY J, 1993, MOL BIOL CELL, V4, P859, DOI 10.1091/mbc.4.8.859; Koh SS, 1998, MOL CELL, V1, P895, DOI 10.1016/S1097-2765(00)80088-X; KOSHLAND D, 1987, CELL, V48, P801, DOI 10.1016/0092-8674(87)90077-8; Le Crom S, 2002, MOL CELL BIOL, V22, P2642, DOI 10.1128/MCB.22.8.2642-2649.2002; LEE SB, 1995, CURR OPIN CELL BIOL, V7, P183, DOI 10.1016/0955-0674(95)80026-3; LI R, 1991, CELL, V66, P519, DOI 10.1016/0092-8674(81)90015-5; Lin H, 2002, MOL GENET GENOMICS, V267, P313, DOI 10.1007/s00438-002-0647-8; Lin HY, 2000, MOL CELL BIOL, V20, P3597, DOI 10.1128/MCB.20.10.3597-3607.2000; Luo HBR, 2002, BIOCHEMISTRY-US, V41, P2509, DOI 10.1021/bi0118153; Macatee T, 1997, NUCLEIC ACIDS RES, V25, P1240, DOI 10.1093/nar/25.6.1240; Martin TFJ, 1998, ANNU REV CELL DEV BI, V14, P231, DOI 10.1146/annurev.cellbio.14.1.231; MELUH PB, 1995, MOL BIOL CELL, V6, P793, DOI 10.1091/mbc.6.7.793; Myers LC, 1999, P NATL ACAD SCI USA, V96, P67, DOI 10.1073/pnas.96.1.67; Nelissen B, 1997, FEMS MICROBIOL REV, V21, P113, DOI 10.1111/j.1574-6976.1997.tb00347.x; Nguyen DT, 2001, J BIOL CHEM, V276, P1138, DOI 10.1074/jbc.M008377200; Odom AR, 2000, SCIENCE, V287, P2026, DOI 10.1126/science.287.5460.2026; Pangilinan F, 1996, MOL BIOL CELL, V7, P1195, DOI 10.1091/mbc.7.8.1195; Papamichos-Chronakis M, 2000, J BIOL CHEM, V275, P8397, DOI 10.1074/jbc.275.12.8397; Park JM, 2000, MOL CELL BIOL, V20, P8709, DOI 10.1128/MCB.20.23.8709-8719.2000; Proft M, 1999, MOL CELL BIOL, V19, P537; REIJO RA, 1993, GENETICS, V135, P955; Saiardi A, 2005, P NATL ACAD SCI USA, V102, P1911, DOI 10.1073/pnas.0409322102; Saiardi A, 2004, SCIENCE, V306, P2101, DOI 10.1126/science.1103344; Schuller J, 2003, J MOL MICROB BIOTECH, V5, P199, DOI 10.1159/000071071; Shen XT, 2003, SCIENCE, V299, P112, DOI 10.1126/science.1078068; SHERMAN F, 1991, METHOD ENZYMOL, V194, P3; Song WJ, 1996, MOL CELL BIOL, V16, P115; SPENCER F, 1992, P NATL ACAD SCI USA, V89, P8908, DOI 10.1073/pnas.89.19.8908; STEARNS T, 1990, GENETICS, V124, P251; Steger DJ, 2003, SCIENCE, V299, P114, DOI 10.1126/science.1078062; Tenreiro S, 2001, BIOCHEM BIOPH RES CO, V280, P216, DOI 10.1006/bbrc.2000.4100; THOMAS JH, 1985, GENETICS, V111, P715; Wehrschutz-Sigl E, 2004, EUR J BIOCHEM, V271, P1145, DOI 10.1111/j.1432-1033.2004.04018.x; York JD, 1999, SCIENCE, V285, P96, DOI 10.1126/science.285.5424.96; York SJ, 2005, J BIOL CHEM, V280, P4264, DOI 10.1074/jbc.M412070200; Yu YX, 2003, MOL CELL BIOL, V23, P1910, DOI 10.1128/MCB.23.6.1910-1921.2003; Zaman Z, 2001, P NATL ACAD SCI USA, V98, P2550, DOI 10.1073/pnas.041611198; Zhang F, 2004, MOL CELL BIOL, V24, P6871, DOI 10.1128/mcb.24.15.6871-6886.2004; Zhao KJ, 1998, CELL, V95, P625, DOI 10.1016/S0092-8674(00)81633-5	63	8	8	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 3	2006	281	9					5677	5685		10.1074/jbc.M506728200	http://dx.doi.org/10.1074/jbc.M506728200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	015RQ	16352614	hybrid			2022-12-25	WOS:000235568900044
J	Bowers, K; Piper, SC; Edeling, MA; Gray, SR; Owen, DJ; Lehner, PJ; Luzio, JP				Bowers, K; Piper, SC; Edeling, MA; Gray, SR; Owen, DJ; Lehner, PJ; Luzio, JP			Degradation of endocytosed epidermal growth factor and virally ubiquitinated major histocompatibility complex class I is independent of mammalian ESCRTII	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MULTIVESICULAR BODY PATHWAY; RECEPTOR DOWN-REGULATION; SORTING COMPLEX; PROTEIN; YEAST; TRAFFICKING; TRANSPORT; ENDOSOMES; MUTANTS; ATPASE	Models for protein sorting at multivesicular bodies in the endocytic pathway of mammalian cells have relied largely on data obtained from yeast. These data suggest the essential role of four ESCRT complexes in multivesicular body protein sorting. However, the putative mammalian ESCRTII complex (hVps25p, hVps22p, and hVps36p) has no proven functional role in endosomal transport. We have characterized the human ESCRTII complex and investigated its function in endosomal trafficking. The human ESCRTII proteins interact with one another, with hVps20p (a component of ESCRTIII), and with their yeast homologues. Our interaction data from yeast two-hybrid studies along with experiments with purified proteins suggest an essential role for the N-terminal domain of hVps22p in the formation of a heterotetrameric ESCRTII complex. Although human ESCRTII is found in the cytoplasm and in the nucleus, it can be recruited to endosomes upon overexpression of dominant-negative hVps4Bp. Interestingly, we find that small interference RNA depletion of mammalian ESCRTII does not affect degradation of epidermal growth factor, a known cargo of the multivesicular body protein sorting pathway. We also show that depletion of the deubiquitinating enzymes AMSH (associated molecule with the SH3 domain of STAM (signal transducing adaptor molecule)) and UBPY (ubiquitin isopeptidase Y) have opposite effects on epidermal growth factor degradation, with UBPY depletion causing dramatic swelling of endosomes. Down-regulation of another cargo, the major histocompatibility complex class I in cells expressing the Kaposi sarcoma-associated herpesvirus protein K3, is unaffected in ESCRTII-depleted cells. Our data suggest that mammalian ESCRTII may be redundant, cargo-specific, or not required for protein sorting at the multivesicular body.	Univ Cambridge, Addenbrookes Hosp, Cambridge Inst Med Res, Dept Clin Biochem, Cambridge CB2 2XY, England; Univ Cambridge, Addenbrookes Hosp, Cambridge Inst Med Res, Dept Med, Cambridge CB2 2XY, England	Cambridge University Hospitals NHS Foundation Trust; Addenbrooke's Hospital; University of Cambridge; Cambridge University Hospitals NHS Foundation Trust; Addenbrooke's Hospital; University of Cambridge	Bowers, K (corresponding author), Univ Cambridge, Addenbrookes Hosp, Cambridge Inst Med Res, Dept Clin Biochem, Wellcome Trust MRC Bldg,Hills Rd, Cambridge CB2 2XY, England.	kb123@cam.ac.uk	Bowers, Katherine/U-2013-2019	Bowers, Katherine/0000-0001-5085-5208; Lehner, Paul Joseph/0000-0001-9383-1054	Medical Research Council [G9310915, G0600823] Funding Source: Medline; Wellcome Trust [066438] Funding Source: Medline	Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Wellcome Trust(Wellcome Trust)		Alam SL, 2004, EMBO J, V23, P1411, DOI 10.1038/sj.emboj.7600114; Amerik AY, 2000, MOL BIOL CELL, V11, P3365, DOI 10.1091/mbc.11.10.3365; Amit I, 2004, GENE DEV, V18, P1737, DOI 10.1101/gad.294904; Babst M, 1998, EMBO J, V17, P2982, DOI 10.1093/emboj/17.11.2982; Babst M, 2002, DEV CELL, V3, P283, DOI 10.1016/S1534-5807(02)00219-8; Babst M, 2005, TRAFFIC, V6, P2, DOI 10.1111/j.1600-0854.2004.00246.x; Babst M, 2002, DEV CELL, V3, P271, DOI 10.1016/S1534-5807(02)00220-4; Babst M, 2000, TRAFFIC, V1, P248, DOI 10.1034/j.1600-0854.2000.010307.x; Babst M, 1997, EMBO J, V16, P1820, DOI 10.1093/emboj/16.8.1820; Bache KG, 2004, MOL BIOL CELL, V15, P4337, DOI 10.1091/mbc.E04-03-0250; BANTA LM, 1988, J CELL BIOL, V107, P1369, DOI 10.1083/jcb.107.4.1369; Benmerah A, 2004, CURR BIOL, V14, pR314, DOI 10.1016/j.cub.2004.03.053; Bilodeau PS, 2003, J CELL BIOL, V163, P237, DOI 10.1083/jcb.200305007; Bilodeau PS, 2002, NAT CELL BIOL, V4, P534, DOI 10.1038/ncb815; Bishop N, 2002, J CELL BIOL, V157, P91, DOI 10.1083/jcb.200112080; Bishop N, 2000, MOL BIOL CELL, V11, P227, DOI 10.1091/mbc.11.1.227; Bishop N, 2001, J BIOL CHEM, V276, P11735, DOI 10.1074/jbc.M009863200; Bowers K, 2004, TRAFFIC, V5, P194, DOI 10.1111/j.1600-0854.2004.00169.x; Bowers K, 2005, BBA-MOL CELL RES, V1744, P438, DOI 10.1016/j.bbamcr.2005.04.004; Bowers K, 2000, MOL BIOL CELL, V11, P4277, DOI 10.1091/mbc.11.12.4277; Burke D., 2000, METHODS YEAST GENETI; Cabezas A, 2005, J CELL SCI, V118, P2625, DOI 10.1242/jcs.02382; Coscoy L, 2001, J CELL BIOL, V155, P1265, DOI 10.1083/jcb.200111010; Dupre S, 2001, MOL CELL BIOL, V21, P4482, DOI 10.1128/MCB.21.14.4482-4494.2001; Eastman SW, 2005, J BIOL CHEM, V280, P628, DOI 10.1074/jbc.M410384200; Fujita H, 2003, J CELL SCI, V116, P401, DOI 10.1242/jcs.00213; Futter CE, 1996, J CELL BIOL, V132, P1011, DOI 10.1083/jcb.132.6.1011; Garrus JE, 2001, CELL, V107, P55, DOI 10.1016/S0092-8674(01)00506-2; Haglund K, 2003, NAT CELL BIOL, V5, P461, DOI 10.1038/ncb983; Hewitt EW, 2002, EMBO J, V21, P2418, DOI 10.1093/emboj/21.10.2418; Hierro A, 2004, NATURE, V431, P221, DOI 10.1038/nature02914; Hittelman AB, 1999, EMBO J, V18, P5380, DOI 10.1093/emboj/18.19.5380; Hyman J, 2000, J CELL BIOL, V149, P537, DOI 10.1083/jcb.149.3.537; James P, 1996, GENETICS, V144, P1425; Kamura T, 2001, J BIOL CHEM, V276, P16528, DOI 10.1074/jbc.M010142200; Katoh K, 2003, J BIOL CHEM, V278, P39104, DOI 10.1074/jbc.M301604200; Katzmann DJ, 2001, CELL, V106, P145, DOI 10.1016/S0092-8674(01)00434-2; Katzmann DJ, 2003, J CELL BIOL, V162, P413, DOI 10.1083/jcb.200302136; Lloyd TE, 2002, CELL, V108, P261, DOI 10.1016/S0092-8674(02)00611-6; Luhtala N, 2004, J CELL BIOL, V166, P717, DOI 10.1083/jcb.200403139; Martin-Serrano J, 2003, P NATL ACAD SCI USA, V100, P12414, DOI 10.1073/pnas.2133846100; Matsuo H, 2004, SCIENCE, V303, P531, DOI 10.1126/science.1092425; McCullough J, 2004, J CELL BIOL, V166, P487, DOI 10.1083/jcb.200401141; Miaczynska M, 2004, CELL, V116, P445, DOI 10.1016/S0092-8674(04)00117-5; Mizuno E, 2005, MOL BIOL CELL, V16, P5163, DOI 10.1091/mbc.E05-06-0560; Moberg KH, 2005, DEV CELL, V9, P699, DOI 10.1016/j.devcel.2005.09.018; Morita E, 2004, ANNU REV CELL DEV BI, V20, P395, DOI 10.1146/annurev.cellbio.20.010403.102350; Motley A, 2003, J CELL BIOL, V162, P909, DOI 10.1083/jcb.200305145; Mullock BM, 2000, MOL BIOL CELL, V11, P3137, DOI 10.1091/mbc.11.9.3137; Naviglio S, 1998, EMBO J, V17, P3241, DOI 10.1093/emboj/17.12.3241; PARHAM P, 1979, J IMMUNOL, V123, P342; Peck JW, 2004, BIOCHEM J, V377, P693, DOI 10.1042/bj20031347; Pelchen-Matthews A, 2004, TRENDS MICROBIOL, V12, P310, DOI 10.1016/j.tim.2004.05.004; Poupon V, 2002, J BIOL CHEM, V277, P8941, DOI 10.1074/jbc.M108385200; Raiborg C, 2003, CURR OPIN CELL BIOL, V15, P446, DOI 10.1016/S0955-0674(03)00080-2; RAYMOND CK, 1992, MOL BIOL CELL, V3, P1389, DOI 10.1091/mbc.3.12.1389; Reaves BJ, 1996, J CELL SCI, V109, P749; Reggiori F, 2001, EMBO J, V20, P5176, DOI 10.1093/emboj/20.18.5176; Rice P, 2000, TRENDS GENET, V16, P276, DOI 10.1016/S0168-9525(00)02024-2; ROBINSON JS, 1988, MOL CELL BIOL, V8, P4936, DOI 10.1128/MCB.8.11.4936; ROTHMAN JH, 1989, EMBO J, V8, P2057, DOI 10.1002/j.1460-2075.1989.tb03614.x; ROTHMAN JH, 1986, CELL, V47, P1041, DOI 10.1016/0092-8674(86)90819-6; Roudier N, 2005, TRAFFIC, V6, P695, DOI 10.1111/j.1600-0854.2005.00309.x; Schmidt AE, 1999, J BIOL CHEM, V274, P21981, DOI 10.1074/jbc.274.31.21981; Schmidt MHH, 2004, MOL CELL BIOL, V24, P8981, DOI 10.1128/MCB.24.20.8981-8993.2004; Scott MGH, 2002, J BIOL CHEM, V277, P37693, DOI 10.1074/jbc.M207552200; Sevrioukov EA, 2005, MOL BIOL CELL, V16, P2301, DOI 10.1091/mbc.E04-11-1013; Shih SC, 2002, NAT CELL BIOL, V4, P389, DOI 10.1038/ncb790; Shilatifard A, 1996, SCIENCE, V271, P1873, DOI 10.1126/science.271.5257.1873; Shilatifard A, 1997, J BIOL CHEM, V272, P22355, DOI 10.1074/jbc.272.35.22355; Sigismund S, 2005, P NATL ACAD SCI USA, V102, P2760, DOI 10.1073/pnas.0409817102; SLAGSVOLD T, 2005, J BIOL CHEM; Stauffer DR, 2001, J CELL SCI, V114, P2383; Strack B, 2003, CELL, V114, P689, DOI 10.1016/S0092-8674(03)00653-6; Thompson BJ, 2005, DEV CELL, V9, P711, DOI 10.1016/j.devcel.2005.09.020; Urbanowski JL, 2001, TRAFFIC, V2, P622, DOI 10.1034/j.1600-0854.2001.20905.x; Vaccari T, 2005, DEV CELL, V9, P687, DOI 10.1016/j.devcel.2005.09.019; Vecchi M, 2001, J CELL BIOL, V153, P1511, DOI 10.1083/jcb.153.7.1511; von Schwedler UK, 2003, CELL, V114, P701, DOI 10.1016/S0092-8674(03)00714-1; White IJ, 2006, EMBO J, V25, P1, DOI 10.1038/sj.emboj.7600759; Whitley P, 2003, J BIOL CHEM, V278, P38786, DOI 10.1074/jbc.M306864200; Yorikawa C, 2005, BIOCHEM J, V387, P17, DOI 10.1042/BJ20041227	82	140	141	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 24	2006	281	8					5094	5105		10.1074/jbc.M508632200	http://dx.doi.org/10.1074/jbc.M508632200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	013RF	16371348	hybrid			2022-12-25	WOS:000235426200064
J	Mas-Droux, C; Biou, V; Dumas, R				Mas-Droux, C; Biou, V; Dumas, R			Allosteric threonine synthase - Reorganization of the pyridoxal phosphate site upon asymmetric activation through S-adenosylmethionine binding to a novel site	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CRYSTAL-STRUCTURE; 3-DIMENSIONAL STRUCTURE; ROTATION; PROGRAM; MODEL	Threonine synthase (TS) is a fold-type II pyridoxal phosphate (PLP)-dependent enzyme that catalyzes the ultimate step of threonine synthesis in plants and microorganisms. Unlike the enzyme from microorganisms, plant TS is activated by S-adenosylmethionine ( AdoMet). The mechanism of activation has remained unknown up to now. We report here the crystallographic structures of Arabidopsis thaliana TS in complex with PLP (aTS) and with PLP and AdoMet (aTS-AdoMet), which show with atomic detail how AdoMet activates TS. The aTS structure reveals a PLP orientation never previously observed for a type II PLP-dependent enzyme and explains the low activity of plant TS in the absence of its allosteric activator. The aTS-AdoMet structure shows that activation of the enzyme upon AdoMet binding triggers a large reorganization of active site loops in one monomer of the structural dimer and allows the displacement of PLP to its active conformation. Comparison with other TS structures shows that activation of the second monomer may be triggered by substrate binding. This structure also discloses a novel fold for two AdoMet binding sites located at the dimer interface, each site containing two AdoMet effectors bound in tandem. Moreover, aTS-AdoMet is the first structure of an enzyme that uses AdoMet as an allosteric effector.	CNRS, Lab Enzymol & Biochim Struct, F-91198 Gif Sur Yvette, France; CNRS, Commissariat Energie Atom, Physiol Cellulaire Vegetale Lab, Dept Reponse & Dynam Cellulaires, F-38054 Grenoble, France	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Saclay; UDICE-French Research Universities; Communaute Universite Grenoble Alpes; Universite Grenoble Alpes (UGA); CEA; Centre National de la Recherche Scientifique (CNRS)	Dumas, R (corresponding author), CNRS, Lab Enzymol & Biochim Struct, Ave Terrasse, F-91198 Gif Sur Yvette, France.	rdumas@cea.fr	Dumas, Renaud/E-1835-2011					Berkovitch F, 2004, SCIENCE, V303, P76, DOI 10.1126/science.1088493; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Burkhard P, 1998, J MOL BIOL, V283, P121, DOI 10.1006/jmbi.1998.2037; Curien G, 1996, FEBS LETT, V390, P85, DOI 10.1016/0014-5793(96)00633-3; Curien G, 1998, BIOCHEMISTRY-US, V37, P13212, DOI 10.1021/bi980068f; Curien G, 2003, EUR J BIOCHEM, V270, P4615, DOI 10.1046/j.1432-1033.2003.03851.x; Evans P. R., 1997, RECENT ADV PHASING, P97; Gallagher DT, 1998, STRUCTURE, V6, P465, DOI 10.1016/S0969-2126(98)00048-3; Garrido-Franco M, 2002, J BIOL CHEM, V277, P12396, DOI 10.1074/jbc.M108734200; HYDE CC, 1988, J BIOL CHEM, V263, P17857; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KABSCH W, 1976, ACTA CRYSTALLOGR A, V32, P922, DOI 10.1107/S0567739476001873; KABSCH W, 1993, J APPL CRYSTALLOGR, V26, P795, DOI 10.1107/S0021889893005588; Kleywegt GJ, 1997, METHOD ENZYMOL, V277, P525, DOI 10.1016/S0076-6879(97)77029-0; LABER B, 1994, BIOCHEMISTRY-US, V33, P3413, DOI 10.1021/bi00177a035; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Layer G, 2003, EMBO J, V22, P6214, DOI 10.1093/emboj/cdg598; LEE B, 1971, J MOL BIOL, V55, P379, DOI 10.1016/0022-2836(71)90324-X; Leslie AGW, 1992, JOINT CCP4 ESF EAMCB, V26; Martin JL, 2002, CURR OPIN STRUC BIOL, V12, P783, DOI 10.1016/S0959-440X(02)00391-3; Murshudov GN, 1997, ACTA CRYSTALLOGR D, V53, P240, DOI 10.1107/S0907444996012255; Omi R, 2003, J BIOL CHEM, V278, P46035, DOI 10.1074/jbc.M308065200; Schneider G, 2000, STRUCT FOLD DES, V8, pR1, DOI 10.1016/S0969-2126(00)00085-X; SOMERS WS, 1992, NATURE, V359, P387, DOI 10.1038/359387a0; Thomazeau K, 2001, PROTEIN SCI, V10, P638, DOI 10.1110/ps.44301; Vagin A, 1997, J APPL CRYSTALLOGR, V30, P1022, DOI 10.1107/S0021889897006766; WALLACE AC, 1995, PROTEIN ENG, V8, P127, DOI 10.1093/protein/8.2.127; Winn MD, 2001, ACTA CRYSTALLOGR D, V57, P122, DOI 10.1107/S0907444900014736	28	32	33	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 24	2006	281	8					5188	5196		10.1074/jbc.M509798200	http://dx.doi.org/10.1074/jbc.M509798200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	013RF	16319072	hybrid, Green Published			2022-12-25	WOS:000235426200073
J	Thiel, A; Heinonen, M; Rintahaka, J; Hallikainen, T; Hemmes, A; Dixon, DA; Haglund, C; Ristimaki, A				Thiel, A; Heinonen, M; Rintahaka, J; Hallikainen, T; Hemmes, A; Dixon, DA; Haglund, C; Ristimaki, A			Expression of cyclooxygenase-2 is regulated by glycogen synthase kinase-3 beta in gastric cancer cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MESSENGER-RNA STABILITY; GROWTH-FACTOR; PHOSPHATIDYLINOSITOL 3-KINASE; POSTTRANSCRIPTIONAL CONTROL; GENE-EXPRESSION; KINASE; INTERLEUKIN-1-BETA; INHIBITION; ACTIVATION; PREVENTION	Cyclooxygenase-2 (COX-2) expression is a marker of poor prognosis in gastric cancer patients, and its inhibition suppresses gastric tumorigenesis in experimental animal models. The mechanism that leads to COX-2 overexpression in this tumor type is unknown. We have now shown that inhibition of phosphatidylinositol 3-kinase by LY294002 suppresses both basal and phorbol myristate acetate-induced COX-2 expression in TMK-1 and MKN-28 gastric cancer cells. Furthermore, inhibition of glycogen synthase kinase-3 beta (GSK-3 beta) by SB415286 induced expression of COX-2 mRNA and protein as well as the enzyme activity in the gastric cancer cells. The effect of SB415286 was confirmed by the use of two additional GSK-3 beta inhibitors, lithium chloride and SB216763. SB415286 had a modest 1.6-fold stimulatory effect on a 2-kb COX-2 promoter reporter construct, but more importantly, it was shown to block the decay of COX-2 mRNA. In contrast to modulation of phosphatidylinositol 3-kinase/Akt/GSK-3 beta pathway, inhibitors of mitogen-activated protein kinases (MEK 1/2, p38, JNK) or the mammalian target of rapamycin did not alter COX-2 expression in gastric cancer cells. Our data show that inhibition of GSK-3 beta stimulates COX-2 expression in gastric cancer cells, which seems to be primarily facilitated via an increase in mRNA stability and to a lesser extent through enhanced transcription.	Univ Helsinki, Mol & Canc Biol Res Program, Biomedicum, FIN-00014 Helsinki, Finland; Univ Helsinki, Cent Hosp, Dept Pathol, FIN-00014 Helsinki, Finland; Univ S Carolina, Dept Biol Sci, Columbia, SC 29203 USA; Univ Helsinki, Cent Hosp, Dept Surg, FIN-00014 Helsinki, Finland	University of Helsinki; University of Helsinki; Helsinki University Central Hospital; University of South Carolina; University of South Carolina System; University of South Carolina Columbia; University of Helsinki; Helsinki University Central Hospital	Ristimaki, A (corresponding author), Univ Helsinki, Mol & Canc Biol Res Program, Biomedicum, Rm B512B,POB 63,Haartmaninkatu 8, FIN-00014 Helsinki, Finland.	Ari.Ristimaki@hus.fi	Haglund, Caj/N-1240-2019					Brunn GJ, 1996, EMBO J, V15, P5256, DOI 10.1002/j.1460-2075.1996.tb00911.x; Chun KS, 2004, BIOCHEM PHARMACOL, V68, P1089, DOI 10.1016/j.bcp.2004.05.031; Dannenberg AJ, 2001, LANCET ONCOL, V2, P544, DOI 10.1016/S1470-2045(01)00488-0; Dannenberg AJ, 2005, J CLIN ONCOL, V23, P254, DOI 10.1200/JCO.2005.09.112; Dixon DA, 2000, J BIOL CHEM, V275, P11750, DOI 10.1074/jbc.275.16.11750; Dixon DA, 2004, CURR PHARM DESIGN, V10, P635, DOI 10.2174/1381612043453171; Fan XM, 2001, J GASTROEN HEPATOL, V16, P1098, DOI 10.1046/j.1440-1746.2001.02593.x; Gupta RA, 2001, NAT REV CANCER, V1, P11, DOI 10.1038/35094017; HORI T, 1993, FEBS LETT, V334, P331, DOI 10.1016/0014-5793(93)80705-Y; Hu PJ, 2004, GUT, V53, P195, DOI 10.1136/gut.2003.021477; Jang BC, 2000, J BIOL CHEM, V275, P39507, DOI 10.1074/jbc.M003224200; Jang TJ, 2004, VIRCHOWS ARCH, V445, P564, DOI 10.1007/s00428-004-1104-3; Kutchera W, 1996, P NATL ACAD SCI USA, V93, P4816, DOI 10.1073/pnas.93.10.4816; Liu WV, 2003, CANCER RES, V63, P3632; Monick MM, 2002, J BIOL CHEM, V277, P32992, DOI 10.1074/jbc.M203218200; Mrena J, 2005, CLIN CANCER RES, V11, P7362, DOI 10.1158/1078-0432.CCR-05-0764; Murakami M, 2004, PROG LIPID RES, V43, P3, DOI 10.1016/S0163-7827(03)00037-7; Oshima H, 2004, EMBO J, V23, P1669, DOI 10.1038/sj.emboj.7600170; Parkin DM, 2005, CA-CANCER J CLIN, V55, P74, DOI 10.3322/canjclin.55.2.74; Pfaffl MW, 2001, NUCLEIC ACIDS RES, V29, DOI 10.1093/nar/29.9.e45; Rao R, 2005, AM J PHYSIOL-RENAL, V288, pF642, DOI 10.1152/ajprenal.00287.2004; Rao R, 2004, J BIOL CHEM, V279, P3949, DOI 10.1074/jbc.M309325200; RIGAS B, 1993, J LAB CLIN MED, V122, P518; Ristimaki A, 1997, CANCER RES, V57, P1276; RISTIMAKI A, 1994, J BIOL CHEM, V269, P11769; Saukkonen K, 2003, CANCER RES, V63, P3032; Saukkonen K, 2003, APMIS, V111, P915, DOI 10.1034/j.1600-0463.2003.1111001.x; Shao JY, 2000, J BIOL CHEM, V275, P33951, DOI 10.1074/jbc.M002324200; Sheng HM, 2001, CANCER RES, V61, P2670; Shi H, 2003, WORLD J GASTROENTERO, V9, P1421, DOI 10.3748/wjg.v9.i7.1421; Simmons DL, 2004, PHARMACOL REV, V56, P387, DOI 10.1124/pr.56.3.3; Takada Y, 2004, J BIOL CHEM, V279, P39541, DOI 10.1074/jbc.M403449200; Tang QB, 2001, CANCER RES, V61, P4329; Thun MJ, 2002, JNCI-J NATL CANCER I, V94, P252, DOI 10.1093/jnci/94.4.252; Ushijima T, 2004, CANCER CELL, V5, P121, DOI 10.1016/S1535-6108(04)00033-9; van Rees BP, 2003, INT J CANCER, V107, P551, DOI 10.1002/ijc.11422; Wang Q, 2006, ONCOGENE, V25, P43, DOI 10.1038/sj.onc.1209004; Weaver SA, 2001, GASTROENTEROLOGY, V120, P1117, DOI 10.1053/gast.2001.23257; Yokozaki H, 2000, PATHOL INT, V50, P767, DOI 10.1046/j.1440-1827.2000.01117.x; Zheng Leizhen, 2004, Gastric Cancer, V7, P61	40	47	57	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 24	2006	281	8					4564	4569		10.1074/jbc.M512722200	http://dx.doi.org/10.1074/jbc.M512722200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	013RF	16371352	hybrid			2022-12-25	WOS:000235426200003
J	Boissier, F; Bardou, F; Guillet, VR; Uttenweiler-Joseph, S; Daffe, M; Quemard, A; Mourey, L				Boissier, F; Bardou, F; Guillet, VR; Uttenweiler-Joseph, S; Daffe, M; Quemard, A; Mourey, L			Further insight into S-adenosylmethionine-dependent methyltransferases - Structural characterization of Hma, an enzyme essential for the biosynthesis of oxygenated mycolic acids in Mycobacterium tuberculosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FATTY-ACIDS; CELL-WALL; CYCLOPROPANE SYNTHETASE; ISONIAZID INHIBITION; ENVELOPE; SEQUENCE; SYNTHASE; GENE; BCG; BICARBONATE	Mycolic acids are major and specific components of the cell envelope of Mycobacteria that include Mycobacterium tuberculosis, the causative agent of tuberculosis. Their metabolism is the target of the most efficient antitubercular drug currently used in therapy, and the enzymes that are involved in the production of mycolic acids represent important targets for the development of new drugs effective against multidrug-resistant strains. Among these are the S-adenosylmethionine-dependent methyltransferases (SAM-MTs) that catalyze the introduction of key chemical modifications in defined positions of mycolic acids. Some of these subtle structural variations are known to be crucial for both the virulence of the tubercle bacillus and the permeability of the mycobacterial cell envelope. We report here the structural characterization of the enzyme Hma (MmaA4), a SAM-MT that is unique in catalyzing the introduction of a methyl branch together with an adjacent hydroxyl group essential for the formation of both keto- and methoxymycolates in M. tuberculosis. Despite the high propensity of Hma to proteolytic degradation, the enzyme was produced and crystallized, and its three-dimensional structure in the apo-form and in complex with S-adenosylmethionine was solved to about 2 angstrom.. The structures show the important role played by the modifications found within mycolic acid SAM- MTs, especially the alpha 2-alpha 3motif and the chemical environment of the active site. Essential information with respect to cofactor and substrate binding, selectivity and specificity, and about the mechanism of catalytic reaction were derived.	CNRS, UMR 5089, IPBS, Dept Mecan Mol Infect Mycobacteriennes, F-31077 Toulouse 04, France; CNRS, Inst Pharmacol & Biol Struct, Dept Proteome & Cibles Therapeut, F-31077 Toulouse 04, France; CNRS, Inst Pharmacol & Biol Struct, Dept Plate Forme Prot, F-31077 Toulouse 04, France; Univ Toulouse 3, F-31077 Toulouse 04, France	Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Universite de Toulouse; Universite Toulouse III - Paul Sabatier; Centre National de la Recherche Scientifique (CNRS); Universite de Toulouse; Universite Toulouse III - Paul Sabatier; Centre National de la Recherche Scientifique (CNRS); Universite de Toulouse; Universite Toulouse III - Paul Sabatier	Mourey, L (corresponding author), CNRS, UMR 5089, IPBS, Dept Mecan Mol Infect Mycobacteriennes, 205 Route Narbonne, F-31077 Toulouse 04, France.	lionel.mourey@ipbs.fr	Mourey, Lionel/B-5662-2009	Mourey, Lionel/0000-0002-8259-1259; Uttenweiler, Sandrine/0000-0001-9019-4766; Quemard, Annaik/0000-0002-5545-3424				Asselineau C, 2002, PROG LIPID RES, V41, P501, DOI 10.1016/S0163-7827(02)00008-5; Behr MA, 2000, J BACTERIOL, V182, P3394, DOI 10.1128/JB.182.12.3394-3399.2000; Bloch K, 1977, Adv Enzymol Relat Areas Mol Biol, V45, P1; BRENNAN PJ, 1995, ANNU REV BIOCHEM, V64, P29, DOI 10.1146/annurev.bi.64.070195.000333; Chang YY, 2000, J BACTERIOL, V182, P4288, DOI 10.1128/JB.182.15.4288-4294.2000; Claverol S, 2003, MOL CELL PROTEOMICS, V2, P483, DOI 10.1074/mcp.T300003-MCP200; Cole ST, 1998, NATURE, V393, P537, DOI 10.1038/31159; Collaborative Computational Project, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI DOI 10.1107/S0907444994003112; Courtois F, 2005, BIOCHEMISTRY-US, V44, P13583, DOI 10.1021/bi051159x; DAFFE M, 1983, ANN INST PASTEUR MIC, VB134, P241, DOI 10.1016/S0769-2609(83)80037-4; Daffe M, 1998, ADV MICROB PHYSIOL, V39, P131; DAVIDSON LA, 1979, ANTIMICROB AGENTS CH, V16, P104, DOI 10.1128/AAC.16.1.104; DeLano W.L., 2002, PYMOL MOL GRAPHICS S; Dinadayala P, 2003, J BIOL CHEM, V278, P7310, DOI 10.1074/jbc.M210501200; Dubnau E, 1998, MOL MICROBIOL, V29, P1526; Dubnau E, 1997, MOL MICROBIOL, V23, P313, DOI 10.1046/j.1365-2958.1997.2301589.x; Dubnau E, 2000, MOL MICROBIOL, V36, P630, DOI 10.1046/j.1365-2958.2000.01882.x; ESNOUSF BM, 1997, J MOL GRAPHICS, V15, P138; Evans P. R., 1993, P CCP4 STUD WEEK DAT, P114; Frishman D, 1995, PROTEINS, V23, P566, DOI 10.1002/prot.340230412; Gao LY, 2003, MOL MICROBIOL, V49, P1547, DOI 10.1046/j.1365-2958.2003.03667.x; GEORGE KM, 1995, J BIOL CHEM, V270, P27292, DOI 10.1074/jbc.270.45.27292; Glickman MS, 2000, MOL CELL, V5, P717, DOI 10.1016/S1097-2765(00)80250-6; Glickman MS, 2003, J BIOL CHEM, V278, P7844, DOI 10.1074/jbc.M212458200; Glickman MS, 2001, J BIOL CHEM, V276, P2228, DOI 10.1074/jbc.C000652200; Goren M. B., 1979, TUBERCULOSIS, P63; Gouet P, 1999, BIOINFORMATICS, V15, P305, DOI 10.1093/bioinformatics/15.4.305; Grogan DW, 1997, MICROBIOL MOL BIOL R, V61, P429, DOI 10.1128/.61.4.429-441.1997; Huang CC, 2002, J BIOL CHEM, V277, P11559, DOI 10.1074/jbc.M111698200; Iwig DF, 2005, J AM CHEM SOC, V127, P11612, DOI 10.1021/ja053899z; Jackson M, 1999, MOL MICROBIOL, V31, P1573, DOI 10.1046/j.1365-2958.1999.01310.x; KURTH J, 1990, BIOL CHEM H-S, V371, P675, DOI 10.1515/bchm3.1990.371.2.675; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Laval F, 2001, ANAL CHEM, V73, P4537, DOI 10.1021/ac0105181; LESLIE AGW, 1987, P CCP4 STUD WEEK SER, P39; Liu J, 1996, J BIOL CHEM, V271, P29545, DOI 10.1074/jbc.271.47.29545; Martin JL, 2002, CURR OPIN STRUC BIOL, V12, P783, DOI 10.1016/S0959-440X(02)00391-3; MERRITT EA, 1994, ACTA CRYSTALLOGR D, V50, P869, DOI 10.1107/S0907444994006396; MINNIKIN DE, 1984, ARCH MICROBIOL, V139, P225, DOI 10.1007/BF00402005; Murshudov GN, 1997, ACTA CRYSTALLOGR D, V53, P240, DOI 10.1107/S0907444996012255; Perrakis A, 1999, NAT STRUCT BIOL, V6, P458, DOI 10.1038/8263; Perrakis A, 1997, ACTA CRYSTALLOGR D, V53, P448, DOI 10.1107/S0907444997005696; Potterton E, 2003, ACTA CRYSTALLOGR D, V59, P1131, DOI 10.1107/S0907444903008126; QUEMARD A, 1991, ANTIMICROB AGENTS CH, V35, P1035, DOI 10.1128/AAC.35.6.1035; Quemard A, 1997, EUR J BIOCHEM, V250, P758, DOI 10.1111/j.1432-1033.1997.00758.x; QURESHI N, 1984, J BACTERIOL, V157, P46, DOI 10.1128/JB.157.1.46-52.1984; Rao V, 2005, J EXP MED, V201, P535, DOI 10.1084/jem.20041668; Rawlings ND, 2004, NUCLEIC ACIDS RES, V32, pD160, DOI 10.1093/nar/gkp971; READ RJ, 1986, ACTA CRYSTALLOGR A, V42, P140, DOI 10.1107/S0108767386099622; Rozwarski DA, 1998, SCIENCE, V279, P98, DOI 10.1126/science.279.5347.98; Storoni LC, 2004, ACTA CRYSTALLOGR D, V60, P432, DOI 10.1107/S0907444903028956; STOVER CK, 1991, NATURE, V351, P456, DOI 10.1038/351456a0; Takayama K, 2005, CLIN MICROBIOL REV, V18, P81, DOI 10.1128/CMR.18.1.81-101.2005; TAKAYAMA K, 1972, ANTIMICROB AGENTS CH, V2, P29, DOI 10.1128/AAC.2.1.29; WINDER F G, 1970, Journal of General Microbiology, V63, P41; Wong HC, 2002, J BIOL CHEM, V277, P15874, DOI 10.1074/jbc.M112300200; Yuan Y, 1998, MOL MICROBIOL, V29, P1449, DOI 10.1046/j.1365-2958.1998.01026.x; Yuan Y, 1996, P NATL ACAD SCI USA, V93, P12828, DOI 10.1073/pnas.93.23.12828	58	58	64	0	20	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 17	2006	281	7					4434	4445		10.1074/jbc.M510250200	http://dx.doi.org/10.1074/jbc.M510250200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	011NN	16356931	hybrid, Green Published			2022-12-25	WOS:000235275300079
J	Masin, M; Kerschensteiner, D; Dumke, K; Rubio, ME; Soto, F				Masin, M; Kerschensteiner, D; Dumke, K; Rubio, ME; Soto, F			Fe65 interacts with P2X(2) subunits at excitatory synapses and modulates receptor function	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMYLOID PRECURSOR PROTEIN; PHOSPHOTYROSINE-BINDING DOMAIN; PROLINE-RICH MOTIFS; GATED ION CHANNELS; ADAPTER PROTEIN; C-TERMINUS; IONOTROPIC RECEPTOR; CYTOPLASMIC DOMAIN; SIGNALING PROTEINS; ATP RECEPTOR	Ionotropic receptors in the neuronal plasmamembrane are organized in macromolecular complexes, which assure their proper localization and regulate signal transduction. P2X receptors, the ionotropic receptors activated by extracellular ATP, have been shown to influence synaptic transmission. Using a yeast two-hybrid approach with the P2X(2) subunit C-terminal domain as bait we isolated the beta-amyloid precursor protein-binding proteins Fe65 and Fe65-like 1 as the first identified proteins interacting with neuronal P2X receptors. We confirmed the direct interaction of Fe65 and the P2X(2) C-terminal domain by glutathione S-transferase pull-down experiments. No interaction was observed between Fe65 and the naturally occurring P2X(2) splice variant P2X(2(b)), indicating that alternative splicing can regulate the receptor complex assembly. We generated two antibodies to Fe65 to determine its subcellular localization using postembedding immunogold labeling electron microscopy. We found labeling for Fe65 at the pre- and postsynaptic specialization of CA1 hippocampal pyramidal cell/Schaffer collateral synapses. By double immunogold labeling, we determined that Fe65 colocalizes with P2X(2) subunits at the postsynaptic specialization of excitatory synapses. Moreover, P2X(2) and Fe65 could be coimmunoprecipitated from brain membrane extracts, demonstrating that the interaction occurs in vivo. The assembly with Fe65 regulates the functional properties of P2X(2) receptors. Thus, the time- and activation-dependent change in ionic selectivity of P2X(2) receptors was inhibited by coexpression of Fe65, suggesting a novel role for Fe65 in regulating P2X receptor function and ATP-mediated synaptic transmission.	Max Planck Inst Expt Med, Dept Mol Biol Neuronal Signals, D-37075 Gottingen, Germany; UCL, Dept Pharmacol, Mol Pharmacol Lab, London WC1E 6BT, England; Univ Connecticut, Dept Physiol & Neurobiol, Storrs, CT 06269 USA	Max Planck Society; University of London; University College London; University of Connecticut	Soto, F (corresponding author), St Louis Univ, Sch Med, Dept Pharmacol & Physiol Sci, 1402 S Grand Blvd, St Louis, MO 63104 USA.	sotof@slu.edu						Bo XN, 2003, MOL PHARMACOL, V63, P1407, DOI 10.1124/mol.63.6.1407; Boue-Grabot E, 2004, J BIOL CHEM, V279, P6967, DOI 10.1074/jbc.M307772200; Boue-Grabot E, 2003, J NEUROSCI, V23, P1246, DOI 10.1523/JNEUROSCI.23-04-01246.2003; BRAKE AJ, 1994, NATURE, V371, P519, DOI 10.1038/371519a0; Brandle U, 1997, FEBS LETT, V404, P294, DOI 10.1016/S0014-5793(97)00128-2; Cao XW, 2001, SCIENCE, V293, P115, DOI 10.1126/science.1058783; Chaumont S, 2004, J BIOL CHEM, V279, P29628, DOI 10.1074/jbc.M403940200; Denlinger LC, 2003, J IMMUNOL, V171, P1304, DOI 10.4049/jimmunol.171.3.1304; DUILIO A, 1991, NUCLEIC ACIDS RES, V19, P5269, DOI 10.1093/nar/19.19.5269; Duttweiler HM, 1996, TRENDS GENET, V12, P340, DOI 10.1016/S0168-9525(96)80008-4; Eickhorst AN, 2002, J GEN PHYSIOL, V120, P119, DOI 10.1085/jgp.20028535; Ermekova KS, 1997, J BIOL CHEM, V272, P32869, DOI 10.1074/jbc.272.52.32869; Fiore F, 1995, J BIOL CHEM, V270, P30853, DOI 10.1074/jbc.270.52.30853; Fisher JA, 2004, J NEUROSCI, V24, P10475, DOI 10.1523/JNEUROSCI.3250-04.2004; Fujiwara Y, 2004, J PHYSIOL-LONDON, V558, P31, DOI 10.1113/jphysiol.2004.064568; Gendreau S, 2003, J CHROMATOGR B, V786, P311, DOI 10.1016/S1570-0232(02)00743-2; Gietz RD, 2002, METHOD ENZYMOL, V350, P87; Guenette SY, 1996, P NATL ACAD SCI USA, V93, P10832, DOI 10.1073/pnas.93.20.10832; Kanjhan R, 1999, J COMP NEUROL, V407, P11; Kay BK, 2000, FASEB J, V14, P231, DOI 10.1096/fasebj.14.2.231; Kesavapany S, 2002, NEUROSCIENCE, V115, P951, DOI 10.1016/S0306-4522(02)00422-0; Khakh BS, 2005, J BIOL CHEM, V280, P6118, DOI 10.1074/jbc.M411324200; Khakh BS, 1999, NAT NEUROSCI, V2, P322, DOI 10.1038/7233; Kim M, 2001, EMBO J, V20, P6347, DOI 10.1093/emboj/20.22.6347; King GD, 2004, EXP NEUROL, V185, P208, DOI 10.1016/j.expneurol.2003.10.011; Koshimizu T, 1999, J BIOL CHEM, V274, P37651, DOI 10.1074/jbc.274.53.37651; McLoughlin DM, 1996, FEBS LETT, V397, P197; North RA, 2002, PHYSIOL REV, V82, P1013, DOI 10.1152/physrev.00015.2002; Okamoto M, 1997, J BIOL CHEM, V272, P31459, DOI 10.1074/jbc.272.50.31459; Paukert M, 2001, J BIOL CHEM, V276, P21077, DOI 10.1074/jbc.M101465200; Pietrzik CU, 2004, J NEUROSCI, V24, P4259, DOI 10.1523/JNEUROSCI.5451-03.2004; Rassendren F, 1997, J BIOL CHEM, V272, P5482, DOI 10.1074/jbc.272.9.5482; Royle SJ, 2002, J BIOL CHEM, V277, P35378, DOI 10.1074/jbc.M204844200; Rubio ME, 2001, J NEUROSCI, V21, P641, DOI 10.1523/JNEUROSCI.21-02-00641.2001; Ruppelt A, 2001, J NEUROCHEM, V77, P1256, DOI 10.1046/j.1471-4159.2001.00348.x; Sabo SL, 2003, J NEUROSCI, V23, P5407; Sabo SL, 2001, J CELL BIOL, V153, P1403, DOI 10.1083/jcb.153.7.1403; Sabo SL, 1999, J BIOL CHEM, V274, P7952, DOI 10.1074/jbc.274.12.7952; Schild L, 2004, REV PHYSIOL BIOCH P, V151, P93, DOI 10.1007/s10254-004-0023-7; Sheng M, 2000, ANNU REV PHYSIOL, V62, P755, DOI 10.1146/annurev.physiol.62.1.755; Simon J, 1997, MOL PHARMACOL, V52, P237, DOI 10.1124/mol.52.2.237; Smith FM, 1999, J PHYSIOL-LONDON, V520, P91, DOI 10.1111/j.1469-7793.1999.00091.x; Soto F, 1996, P NATL ACAD SCI USA, V93, P3684, DOI 10.1073/pnas.93.8.3684; Soto F, 1997, J MEMBRANE BIOL, V160, P91, DOI 10.1007/s002329900298; Surprenant A, 1996, SCIENCE, V272, P735, DOI 10.1126/science.272.5262.735; Virginio C, 1999, NAT NEUROSCI, V2, P315, DOI 10.1038/7225; Werner P, 1996, P NATL ACAD SCI USA, V93, P15485, DOI 10.1073/pnas.93.26.15485; Wilson HL, 2002, J BIOL CHEM, V277, P34017, DOI 10.1074/jbc.M205120200; Zambrano N, 1998, J BIOL CHEM, V273, P20128, DOI 10.1074/jbc.273.32.20128	49	37	37	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 17	2006	281	7					4100	4108		10.1074/jbc.M507735200	http://dx.doi.org/10.1074/jbc.M507735200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	011NN	16330549	hybrid			2022-12-25	WOS:000235275300040
J	Zheng, Z; Cai, CM; Omwancha, J; Chen, SY; Baslan, T; Shemshedini, L				Zheng, Z; Cai, CM; Omwancha, J; Chen, SY; Baslan, T; Shemshedini, L			SUMO-3 enhances androgen receptor transcriptional activity through a sumoylation-independent mechanism in prostate cancer cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINO-TERMINAL DOMAIN; C-JUN; PROTEIN INHIBITOR; NUCLEAR RECEPTORS; DEPENDENT TRANSCRIPTION; INDUCED TRANSACTIVATION; MOLECULAR-GENETICS; CODON-877 MUTATION; COACTIVATOR SRC-1; BINDING PROTEIN	Androgens are important for male sexual development, which depend on the cognate receptor, the androgen receptor. The transcriptional activity of the androgen receptor, like other nuclear receptors, is regulated by accessory proteins that can have either positive or negative effects. Through a yeast functional screen, we have identified SUMO-3 as a regulator of androgen receptor activity in prostate cancer cells. SUMO-3 is one of three eukaryotic proteins that become post-translationally conjugated to their target proteins in a manner analogous to the attachment of ubiquitin. In primary prostate epithelial cells, PrEC, and the prostate cancer cells, PC-3, SUMO-3 has a weak negative effect on androgen receptor transcriptional activity. In contrast, SUMO-3 and it close relative SUMO-2 strongly enhance transactivation by endogenous androgen receptor in LNCaP cells. This positive effect is observed in both androgen-dependent and androgen-independent LNCaP cells. Interestingly, SUMO-1, unlike SUMO-3 and SUMO-2, can inhibit, but not stimulate, androgen receptor activity. Mutational analysis of the androgen receptor and SUMO-3 demonstrates that the SUMO-3-positive activity does not depend on either the sumoylation sites of the androgen receptor or the sumoylation function of SUMO-3. Stable overexpression of SUMO-3 in LNCaP cells significantly enhances the androgen-dependent proliferation of these cells. Additionally, siRNA-mediated repression of SUMO-2 significantly inhibits the growth of both androgen-dependent and androgen-independent LNCaP cells. Collectively, these results suggest (i) a novel mechanism for elevating AR activity through the switch of SUMO-3 from a weak negative regulator in normal prostate cells to a strong positive regulator in prostate cancer cells and (ii) a proliferative role for SUMO-3 and SUMO-2 in the growth of prostate cancer cells that is independent of sumoylation of the androgen receptor.	Univ Toledo, Dept Biol Sci, Toledo, OH 43606 USA	University System of Ohio; University of Toledo	Shemshedini, L (corresponding author), Univ Toledo, Dept Biol Sci, 2801 W Bancroft St, Toledo, OH 43606 USA.	lshemsh@uoft02.utoledo.edu	Cai, Changmeng/AAE-6835-2020; CHEN, Shaoyong/ABF-3357-2021	Cai, Changmeng/0000-0002-8701-2586	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R29DK051274] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK51274] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Aarnisalo P, 1998, P NATL ACAD SCI USA, V95, P2122, DOI 10.1073/pnas.95.5.2122; Abate-Shen C, 2000, GENE DEV, V14, P2410, DOI 10.1101/gad.819500; Alen P, 1999, MOL CELL BIOL, V19, P6085; AUSUBEL FM, 1998, CURRENT PROTOCOLS MO, V2; BEATO M, 1995, CELL, V83, P851, DOI 10.1016/0092-8674(95)90201-5; Berrevoets CA, 1998, MOL ENDOCRINOL, V12, P1172, DOI 10.1210/me.12.8.1172; Bubulya A, 2001, J BIOL CHEM, V276, P44704, DOI 10.1074/jbc.M107346200; Bubulya A, 1996, J BIOL CHEM, V271, P24583, DOI 10.1074/jbc.271.40.24583; Bubulya A, 2000, ENDOCRINE, V13, P55, DOI 10.1385/ENDO:13:1:55; CHASMAN DI, 1989, MOL CELL BIOL, V9, P4746, DOI 10.1128/MCB.9.11.4746; Chauchereau A, 2003, J BIOL CHEM, V278, P12335, DOI 10.1074/jbc.M207148200; CHEN SY, 2002, THESIS U TOLEDO TOLE; Culig Z, 2003, UROLOGY, V62, P21, DOI 10.1016/S0090-4295(03)00698-8; Fu MF, 2002, MOL CELL BIOL, V22, P3373, DOI 10.1128/MCB.22.10.3373-3388.2002; Fu MF, 2000, J BIOL CHEM, V275, P20853, DOI 10.1074/jbc.M000660200; Fujimoto N, 2001, UROLOGY, V58, P289, DOI 10.1016/S0090-4295(01)01117-7; GADDIPATI JP, 1994, CANCER RES, V54, P2861; Gregory CW, 2001, CANCER RES, V61, P4315; Gross M, 2001, ONCOGENE, V20, P3880, DOI 10.1038/sj.onc.1204489; GYURIS J, 1993, CELL, V75, P791, DOI 10.1016/0092-8674(93)90498-F; Hay RT, 2001, TRENDS BIOCHEM SCI, V26, P332, DOI 10.1016/S0968-0004(01)01849-7; Heinlein CA, 2002, ENDOCR REV, V23, P175, DOI 10.1210/er.23.2.175; HERSHKO A, 1992, ANNU REV BIOCHEM, V61, P761, DOI 10.1146/annurev.bi.61.070192.003553; Hochstrasser M, 2001, CELL, V107, P5, DOI 10.1016/S0092-8674(01)00519-0; HOWELL BW, 1991, MOL CELL BIOL, V11, P568, DOI 10.1128/MCB.11.1.568; Hsiao PW, 1999, J BIOL CHEM, V274, P22373, DOI 10.1074/jbc.274.32.22373; Igawa T, 2002, PROSTATE, V50, P222, DOI 10.1002/pros.10054; Iniguez-Lluhi JA, 2000, MOL CELL BIOL, V20, P6040, DOI 10.1128/MCB.20.16.6040-6050.2000; Jarrard DF, 1998, CANCER RES, V58, P5310; JENSTER G, 1995, J BIOL CHEM, V270, P7341, DOI 10.1074/jbc.270.13.7341; JENTSCH S, 1992, ANNU REV GENET, V26, P179, DOI 10.1146/annurev.ge.26.120192.001143; Johnson ES, 2004, ANNU REV BIOCHEM, V73, P355, DOI 10.1146/annurev.biochem.73.011303.074118; Junicho A, 2000, BIOCHEM BIOPH RES CO, V278, P9, DOI 10.1006/bbrc.2000.3753; Kagey MH, 2003, CELL, V113, P127, DOI 10.1016/S0092-8674(03)00159-4; Kahyo T, 2001, MOL CELL, V8, P713, DOI 10.1016/S1097-2765(01)00349-5; KASTNER P, 1995, CELL, V83, P859, DOI 10.1016/0092-8674(95)90202-3; Kokontis JM, 1999, VITAM HORM, V55, P219; Kotaja N, 2000, MOL ENDOCRINOL, V14, P1986, DOI 10.1210/me.14.12.1986; Kotaja N, 2002, J BIOL CHEM, V277, P30283, DOI 10.1074/jbc.M204768200; Le Drean Y, 2002, ENDOCRINOLOGY, V143, P3482, DOI 10.1210/en.2002-220135; Li YH, 2003, P NATL ACAD SCI USA, V100, P259, DOI 10.1073/pnas.0235361100; LINZEY J, 1994, VITAM HORM, V49, P383; MANGELSDORF DJ, 1995, CELL, V83, P841, DOI 10.1016/0092-8674(95)90200-7; MANGELSDORF DJ, 1995, CELL, V83, P835, DOI 10.1016/0092-8674(95)90199-X; Marcelli M, 2000, CANCER RES, V60, P944; McEwan IJ, 1997, P NATL ACAD SCI USA, V94, P8485, DOI 10.1073/pnas.94.16.8485; Melchior F, 2000, ANNU REV CELL DEV BI, V16, P591, DOI 10.1146/annurev.cellbio.16.1.591; Moilanen AM, 1999, J BIOL CHEM, V274, P3700, DOI 10.1074/jbc.274.6.3700; Muller S, 2000, J BIOL CHEM, V275, P13321, DOI 10.1074/jbc.275.18.13321; Muller S, 2001, NAT REV MOL CELL BIO, V2, P202, DOI 10.1038/35056591; Nishida T, 2002, J BIOL CHEM, V277, P41311, DOI 10.1074/jbc.M206741200; Pichler A, 2002, CELL, V108, P109, DOI 10.1016/S0092-8674(01)00633-X; Poukka H, 1999, J BIOL CHEM, V274, P19441, DOI 10.1074/jbc.274.27.19441; Poukka H, 2000, P NATL ACAD SCI USA, V97, P14145, DOI 10.1073/pnas.97.26.14145; QUIGLEY CA, 1995, ENDOCR REV, V16, P271, DOI 10.1210/er.16.3.271; Rosendorff A, 2004, J VIROL, V78, P367, DOI 10.1128/JVI.78.1.367-377.2004; Rowan BG, 2000, J BIOL CHEM, V275, P4475, DOI 10.1074/jbc.275.6.4475; Sachdev S, 2001, GENE DEV, V15, P3088, DOI 10.1101/gad.944801; Saitoh H, 1998, CURR BIOL, V8, P121, DOI 10.1016/S0960-9822(98)70044-2; SANCHEZ ER, 1994, MOL ENDOCRINOL, V8, P408, DOI 10.1210/me.8.4.408; Savarese DM, 2001, J CLIN ONCOL, V19, P2509, DOI 10.1200/JCO.2001.19.9.2509; Seeler JS, 2003, NAT REV MOL CELL BIO, V4, P690, DOI 10.1038/nrm1200; Shang YF, 2002, MOL CELL, V9, P601, DOI 10.1016/S1097-2765(02)00471-9; SHEMSHEDINI L, 1991, EMBO J, V10, P3839, DOI 10.1002/j.1460-2075.1991.tb04953.x; Shen XQ, 1999, ENDOCRINE, V10, P281, DOI 10.1007/BF02738627; Shenk JL, 2001, J BIOL CHEM, V276, P38472, DOI 10.1074/jbc.M103652200; Shuai K, 2000, ONCOGENE, V19, P2638, DOI 10.1038/sj.onc.1203522; Steffan JS, 2004, SCIENCE, V304, P100, DOI 10.1126/science.1092194; Suzuki H, 2003, ENDOCR-RELAT CANCER, V10, P209, DOI 10.1677/erc.0.0100209; Suzuki H, 1996, PROSTATE, V29, P153, DOI 10.1002/1097-0045(199609)29:3<153::AID-PROS2990290303>3.0.CO;2-5; SUZUKI H, 1993, J STEROID BIOCHEM, V46, P759, DOI 10.1016/0960-0760(93)90316-O; Tan JA, 2000, MOL ENDOCRINOL, V14, P14, DOI 10.1210/me.14.1.14; Taplin ME, 1999, CANCER RES, V59, P2511; Taplin ME, 2004, J CELL BIOCHEM, V91, P483, DOI 10.1002/jcb.10653; TAPLIN ME, 1995, NEW ENGL J MED, V332, P1393, DOI 10.1056/NEJM199505253322101; THIGPEN AE, 1992, J CLIN INVEST, V90, P799, DOI 10.1172/JCI115954; THUMMEL C, 1995, CELL, V83, P571; Tran CP, 2002, MOL CANCER RES, V1, P113; Verger A, 2003, EMBO REP, V4, P137, DOI 10.1038/sj.embor.embor738; Verrijzer CP, 1996, TRENDS BIOCHEM SCI, V21, P338, DOI 10.1016/0968-0004(96)10044-X; Voegel JJ, 1996, EMBO J, V15, P3667, DOI 10.1002/j.1460-2075.1996.tb00736.x; Weissman AM, 2001, NAT REV MOL CELL BIO, V2, P169, DOI 10.1038/35056563; Wen Y, 2000, CANCER RES, V60, P6841; Yao TP, 1996, P NATL ACAD SCI USA, V93, P10626, DOI 10.1073/pnas.93.20.10626; Yeh SY, 1996, P NATL ACAD SCI USA, V93, P5517, DOI 10.1073/pnas.93.11.5517; YUAN SX, 1993, CANCER RES, V53, P1304	86	36	36	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 17	2006	281	7					4002	4012		10.1074/jbc.M509260200	http://dx.doi.org/10.1074/jbc.M509260200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	011NN	16361251	hybrid			2022-12-25	WOS:000235275300029
J	Cheng, CY; Chang, CH; Wu, YJ; Li, YK				Cheng, CY; Chang, CH; Wu, YJ; Li, YK			Exploration of glycosyl hydrolase family 75, a chitosanase from Aspergillus fumigatus	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STREPTOMYCES SP N174; CRYSTAL-STRUCTURE; GLYCOSIDE HYDROLASE; ACTIVE-SITE; PURIFICATION; CHITINASE; GENE; IDENTIFICATION; RESIDUES; SPECIFICITY	A powerful endo-chitosanase ( CSN) previously described for a large scale preparation of chito-oligosaccharides ( Cheng, C.-Y., and Li, Y.-K. ( 2000) Biotechnol. Appl. Biochem. 32, 197 - 203) was cloned from Aspergillus fumigatus and further identified as a member of glycosyl hydrolase family 75. We report here a study of gene expression, functional characterization, and mutation analysis of this enzyme. Gene cloning was accomplished by reverse transcription-PCR and inverse PCR. Within the 1382-bp Aspergillus gene ( Gen-Bank (TM) accession number AY190324), two introns ( 67 and 82 bp) and an open reading frame encoding a 238-residue protein containing a 17-residue signal peptide were characterized. The recombinant mature protein was overexpressed as an inclusion body in Escherichia coli, rescued by treatment with 5 M urea, and subsequently purified by cation exchange chromatography. A time course H-1 NMR study on the enzymatic formation of chito-oligosaccharides confirmed that this A. fumigatus CSN is an inverting enzyme. Tandem mass spectrum analysis of the enzymatic hydrolysate revealed that the recombinant CSN can cleave linkages of GlcNAc-GlcN and GlcN-GlcN in its substrate, suggesting that it is a subclass I chitosanase. In addition, an extensive site-directed mutagenesis study on 10 conserved carboxylic amino acids of glycosyl hydrolase family 75 was performed. This showed that among these various mutants, D160N and E169Q lost nearly all activity. Further investigation using circular dichroism measurements of D160N, E169Q, wild-type CSN, and other active mutants showed similar spectra, indicating that the loss of enzymatic activity in D160N and E169Q was not because of changes in protein structure but was caused by loss of the catalytic essential residue. We conclude that Asp(160) and Glu(169) are the essential residues for the action of A. fumigatus endo-chitosanase.	Natl Chiao Tung Univ, Dept Appl Chem, Decatur, GA 30030 USA; Natl Chiao Tung Univ, Ctr Interdisciplinary Mol Sci, Decatur, GA 30030 USA		Li, YK (corresponding author), Natl Chiao Tung Univ, Dept Appl Chem, 1001 Ta Hseh Rd, Decatur, GA 30030 USA.	ykl@cc.nctu.edu.tw	cheng, chih-yu/A-1129-2013; Cheng, Chih-yu/AAA-6921-2021	cheng, chih-yu/0000-0002-7274-416X; Cheng, Chih-yu/0000-0002-7274-416X				Adachi W, 2004, J MOL BIOL, V343, P785, DOI 10.1016/j.jmb.2004.08.028; Ak O, 1998, BIOCHEM ARCH, V14, P221; Boucher I, 1995, J BIOL CHEM, V270, P31077, DOI 10.1074/jbc.270.52.31077; Bravman T, 2003, J BIOL CHEM, V278, P26742, DOI 10.1074/jbc.M304144200; Cheng CY, 2000, BIOTECHNOL APPL BIOC, V32, P197, DOI 10.1042/BA20000063; Chiang CL, 2003, ENZYME MICROB TECH, V32, P260, DOI 10.1016/S0141-0229(02)00275-2; Chir J, 2002, BIOCHEM J, V365, P857, DOI 10.1042/BJ20020186; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Collins T, 2002, J BIOL CHEM, V277, P35133, DOI 10.1074/jbc.M204517200; FINK D, 1991, BIOTECHNOL LETT, V13, P945; Forsyth WR, 2002, PROTEINS, V48, P388, DOI 10.1002/prot.10174; FUKAMIZO T, 1995, BIOCHEM J, V311, P377, DOI 10.1042/bj3110377; FUKAMIZO T, 1994, BBA-PROTEIN STRUCT M, V1205, P183, DOI 10.1016/0167-4838(94)90232-1; Fukamizo T, 2000, CURR PROTEIN PEPT SC, V1, P105, DOI 10.2174/1389203003381450; GEBLER J, 1992, J BIOL CHEM, V267, P12559; Henrissat B, 1996, BIOCHEM J, V316, P695, DOI 10.1042/bj3160695; Hidaka M, 2002, J MOL BIOL, V322, P79, DOI 10.1016/S0022-2836(02)00746-5; Honda Y, 1998, BBA-PROTEIN STRUCT M, V1388, P53, DOI 10.1016/S0167-4838(98)00153-8; Jeon YJ, 2001, CARBOHYD POLYM, V44, P71, DOI 10.1016/S0144-8617(00)00200-9; Juffer AH, 1998, BIOCHEM CELL BIOL, V76, P198, DOI 10.1139/bcb-76-2-3-198; Kim S.J., 1998, KOREAN J FOOD SCI TE, V30, P693; MARCOTTE E, 1993, J MOL BIOL, V232, P995, DOI 10.1006/jmbi.1993.1447; MILLER GL, 1959, ANAL CHEM, V31, P426, DOI 10.1021/ac60147a030; Miyanaga A, 2004, J BIOL CHEM, V279, P44907, DOI 10.1074/jbc.M405390200; MUZZARELLI RAA, 1985, CHITIN NATURE TECHNO, P209; Nishimura T, 2001, FEBS LETT, V499, P187, DOI 10.1016/S0014-5793(01)02551-0; No HK, 2002, J FOOD SCI, V67, P1511, DOI 10.1111/j.1365-2621.2002.tb10314.x; OCHMAN H, 1988, GENETICS, V120, P621; OSSWALD WF, 1994, PLANT CELL PHYSIOL, V35, P811, DOI 10.1093/oxfordjournals.pcp.a078662; Park JK, 1999, J BACTERIOL, V181, P6642, DOI 10.1128/JB.181.21.6642-6649.1999; Puchart V, 2004, BBA-GEN SUBJECTS, V1674, P239, DOI 10.1016/j.bbagen.2004.06.022; Seo WG, 2000, CANCER LETT, V159, P189, DOI 10.1016/S0304-3835(00)00551-6; Seth D, 2003, J BIOCHEM BIOPH METH, V55, P53, DOI 10.1016/S0165-022X(02)00177-X; Shahidi F, 1999, TRENDS FOOD SCI TECH, V10, P37, DOI 10.1016/S0924-2244(99)00017-5; Shimosaka M, 1996, J FERMENT BIOENG, V82, P426, DOI 10.1016/S0922-338X(97)86977-2; Somashekar D, 1996, BIORESOURCE TECHNOL, V55, P35, DOI 10.1016/0960-8524(95)00144-1; Sun LW, 1999, VIROLOGY, V263, P376, DOI 10.1006/viro.1999.9958; SUZUKI K, 1986, CARBOHYD RES, V151, P403, DOI 10.1016/S0008-6215(00)90359-8; Synstad B, 2004, EUR J BIOCHEM, V271, P253, DOI 10.1046/j.1432-1033.2003.03923.x; Tang Chuan Yi, 2003, J Bioinform Comput Biol, V1, P267, DOI 10.1142/S0219720003000095; Tsai YT, 2004, BIOINFORMATICS, V20, P2309, DOI 10.1093/bioinformatics/bth220; WANG QP, 1993, J BIOL CHEM, V268, P14096; Yun CS, 2005, APPL ENVIRON MICROB, V71, P5138, DOI 10.1128/AEM.71.9.5138-5144.2005; Zhang XY, 2000, BIOSCI BIOTECH BIOCH, V64, P1896, DOI 10.1271/bbb.64.1896; ZIKAKIS JP, 1984, CHITIN CHITOSAN RELA, P119	45	50	55	0	27	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 10	2006	281	6					3137	3144		10.1074/jbc.M512506200	http://dx.doi.org/10.1074/jbc.M512506200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	009QV	16330537	hybrid			2022-12-25	WOS:000235128200016
J	Dassler, K; Zydek, M; Wandzik, K; Kaup, M; Fuchs, H				Dassler, K; Zydek, M; Wandzik, K; Kaup, M; Fuchs, H			Release of the soluble transferrin receptor is directly regulated by binding of its ligand ferritransferrin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NECROSIS-FACTOR-ALPHA; LEUKEMIC HL60 CELLS; HEREDITARY HEMOCHROMATOSIS; IRON-ABSORPTION; HYPOTRANSFERRINEMIC MICE; HFE PROTEIN; BODY IRON; ECTODOMAIN; ERYTHROPOIESIS; ASSOCIATION	The human transferrin receptor (TfR) is shed by an integral metalloprotease releasing a soluble form (sTfR) into serum. The sTfR reflects the iron demand of the body and is postulated as a regulator of iron homeostasis via binding to the hereditary hemochromatosis protein HFE. To study the role of transferrin in this process, we investigated TfR shedding in HL60 cells and TfR-deficient Chinese hamster ovary cells transfected with human TfR. Independent of TfR expression, sTfR release decreases with increasing ferritransferrin concentrations, whereas apo-transferrin exhibits no inhibitory effect. To investigate the underlying mechanism, we generated several TfR mutants with different binding affinities for transferrin. Shedding of TfR mutants in transfected cells correlates exactly with their binding affinity, implying that the effect of ferritransferrin on TfR shedding is mediated by a direct molecular interaction. Analysis of sTfR release from purified microsomal membranes revealed that the regulation is independent from intracellular trafficking or cellular signaling events. Our results clearly demonstrated that sTfR does not only reflect the iron demand of the cells but also the iron availability in the bloodstream, mirrored by iron saturation of transferrin, corroborating the important potential function of sTfR as a regulator of iron homeostasis.	Univ Med Berlin, Charite, Inst Klin Chem & Pathobiochem, D-12200 Berlin, Germany	Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin	Fuchs, H (corresponding author), Univ Med Berlin, Charite, Inst Klin Chem & Pathobiochem, Campus Benjamin Franklin,Hindenburgdamm 30, D-12200 Berlin, Germany.	hendrik.fuchs@charite.de	Fuchs, Hendrik/AAE-7379-2019	Fuchs, Hendrik/0000-0001-9153-9594				Althoff K, 2000, EUR J BIOCHEM, V267, P2624, DOI 10.1046/j.1432-1327.2000.01278.x; Arribas J, 2002, CHEM REV, V102, P4627, DOI 10.1021/cr010202t; BAYNES RD, 1995, P SOC EXP BIOL MED, V209, P286; BAYNES RD, 1993, P SOC EXP BIOL MED, V204, P65; Beguin Y, 2003, CLIN CHIM ACTA, V329, P9, DOI 10.1016/S0009-8981(03)00005-6; Blobel CP, 2002, INFLAMM RES, V51, P83, DOI 10.1007/BF02684007; Brandao M, 2005, HAEMATOLOGICA, V90, P31; Buchegger F, 1996, EUR J BIOCHEM, V235, P9, DOI 10.1111/j.1432-1033.1996.0009u.x; BUYS SS, 1991, BLOOD, V78, P3288; Bzowska M, 2004, EUR J BIOCHEM, V271, P2808, DOI 10.1111/j.1432-1033.2004.04215.x; Cazzola M, 1999, BRIT J HAEMATOL, V106, P752, DOI 10.1046/j.1365-2141.1999.01600.x; Cheng Y, 2004, CELL, V116, P565, DOI 10.1016/S0092-8674(04)00130-8; CHITAMBAR CR, 1990, J LAB CLIN MED, V116, P345; CHITAMBAR CR, 1989, BLOOD, V74, P602; COOK JD, 1990, BRIT J HAEMATOL, V75, P603, DOI 10.1111/j.1365-2141.1990.tb07806.x; COOK JD, 1993, ANNU REV MED, V44, P63, DOI 10.1146/annurev.med.44.1.63; Cook JD, 2003, BLOOD, V101, P3359, DOI 10.1182/blood-2002-10-3071; Dassler K, 2003, FEBS LETT, V536, P25, DOI 10.1016/S0014-5793(03)00004-8; Davies PS, 2004, J BIOL CHEM, V279, P25085, DOI 10.1074/jbc.M400537200; Lima Gisélia Aparecida Freire Maia de, 2003, Sao Paulo Med. J., V121, P90; Dello Sbarba P, 2002, BIOL CHEM, V383, P69; Drakesmith H, 2002, P NATL ACAD SCI USA, V99, P15602, DOI 10.1073/pnas.242614699; Dubljevic V, 1999, BIOCHEM J, V341, P11, DOI 10.1042/0264-6021:3410011; FINCH C, 1994, BLOOD, V84, P1697; Frazer DM, 2003, BLOOD CELL MOL DIS, V30, P288, DOI 10.1016/S1079-9796(03)00039-1; Fuchs H, 1998, STRUCTURE, V6, P1235, DOI 10.1016/S0969-2126(98)00124-5; Fuchs H, 2002, BBA-GEN SUBJECTS, V1570, P19, DOI 10.1016/S0304-4165(02)00146-0; Fuchs H, 2001, BIOTECHNIQUES, V31, P584, DOI 10.2144/01313rr03; Fuchs H, 1995, J IMMUNOL METHODS, V188, P197, DOI 10.1016/0022-1759(95)00202-2; Giannetti AM, 2003, PLOS BIOL, V1, P341, DOI 10.1371/journal.pbio.0000051; Gross CN, 1998, J BIOL CHEM, V273, P22068, DOI 10.1074/jbc.273.34.22068; Gutwein P, 2002, FASEB J, V16, P292, DOI 10.1096/fj.02-0430fje; Hall DR, 2002, ACTA CRYSTALLOGR D, V58, P70, DOI 10.1107/S0907444901017309; Hentze MW, 2004, CELL, V117, P285, DOI 10.1016/S0092-8674(04)00343-5; Hooper NM, 1997, BIOCHEM J, V321, P265, DOI 10.1042/bj3210265; HUEBERS HA, 1990, BLOOD, V75, P102; Kang TB, 2004, EXP CELL RES, V298, P285, DOI 10.1016/j.yexcr.2004.04.022; Kaup M, 2002, J BIOL CHEM, V277, P38494, DOI 10.1074/jbc.M203461200; Kaup M, 2002, BIOL CHEM, V383, P1011, DOI 10.1515/BC.2002.108; KOHGO Y, 1987, CELL BIOL INT REP, V11, P871; Lawrence CM, 1999, SCIENCE, V286, P779, DOI 10.1126/science.286.5440.779; LILIOM K, 1991, J IMMUNOL METHODS, V143, P119, DOI 10.1016/0022-1759(91)90280-S; Liu RT, 2003, BIOCHEMISTRY-US, V42, P12447, DOI 10.1021/bi0352973; MacGillivray RTA, 1998, BIOCHEMISTRY-US, V37, P7919, DOI 10.1021/bi980355j; Maes M, 1997, SCAND J CLIN LAB INV, V57, P31, DOI 10.3109/00365519709057816; Montosi G, 2000, BLOOD, V96, P1125, DOI 10.1182/blood.V96.3.1125.015k19_1125_1129; Moss ML, 2002, ESSAYS BIOCHEM, V38, P141, DOI 10.1042/bse0380141; Nemeth E, 2004, SCIENCE, V306, P2090, DOI 10.1126/science.1104742; Osenkowski P, 2004, J CELL PHYSIOL, V200, P2, DOI 10.1002/jcp.20064; Parkkila S, 1997, P NATL ACAD SCI USA, V94, P13198, DOI 10.1073/pnas.94.24.13198; Raja KB, 1999, BLOOD, V94, P3185, DOI 10.1182/blood.V94.9.3185.421a20_3185_3192; Rutledge EA, 1996, J CELL PHYSIOL, V168, P284, DOI 10.1002/(SICI)1097-4652(199608)168:2<284::AID-JCP7>3.0.CO;2-L; SHIH YJ, 1990, J BIOL CHEM, V265, P19077; SKIKNE BS, 1990, BLOOD, V75, P1870; Thomas L., 2005, LABOR DIAGNOSE; Townsend A, 2002, LANCET, V359, P786, DOI 10.1016/S0140-6736(02)07885-6; Waheed A, 1999, P NATL ACAD SCI USA, V96, P1579, DOI 10.1073/pnas.96.4.1579; Weatherall DJ, 1998, BAILLIERE CLIN HAEM, V11, P127, DOI 10.1016/S0950-3536(98)80072-3; West AP, 2001, J MOL BIOL, V313, P385, DOI 10.1006/jmbi.2001.5048	59	16	18	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 10	2006	281	6					3297	3304		10.1074/jbc.M511341200	http://dx.doi.org/10.1074/jbc.M511341200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	009QV	16354665	hybrid			2022-12-25	WOS:000235128200036
J	Lepesheva, GI; Zaitseva, NG; Nes, WD; Zhou, WX; Arase, M; Liu, J; Hill, GC; Waterman, MR				Lepesheva, GI; Zaitseva, NG; Nes, WD; Zhou, WX; Arase, M; Liu, J; Hill, GC; Waterman, MR			Cyp51 from Trypanosoma cruzi - A phyla-specific residue in the B ' helix defines substrate preferences of sterol 14 alpha-demethylase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							OBTUSIFOLIOL 14-ALPHA-DEMETHYLASE; STRUCTURAL REQUIREMENTS; EXPRESSION; BIOSYNTHESIS; DEMETHYLASE; INHIBITORS; P-45014DM; PROTEIN; GENOME; PLANTS	A potential drug target for treatment of Chagas disease, sterol 14 alpha- demethylase from Trypanosoma cruzi (TCCYP51), was found to be catalytically closely related to animal/fungi-like CYP51. Contrary to the ortholog from Trypanosoma brucei ( TB), which like plant CYP51 requires C4-monomethylated sterol substrates, TCCYP51 prefers C4-dimethylsterols. Sixty-six CYP51 sequences are known from bacteria to human, their sequence homology ranging from similar to 25% between phyla to similar to 80% within a phylum. TC versus TB is the first example of two organisms from the same phylum, in which CYP51s (83% amino acid identity) have such profound differences in substrate specificity. Substitution of animal/fungi- like Ile(105) in the B' helix to Phe, the residue found in this position in all plant and the other six CYP51 sequences from Trypanosomatidae, dramatically alters substrate preferences of TCCYP51, converting it into a more plant-like enzyme. The rates of 14 alpha- demethylation of obtusifoliol and its 24- demethyl analog 4 alpha, 4 alpha- dimethylcholesta-8,24- dien-3 beta-ol( norlanosterol) increase 60- and 150- fold, respectively. Turnover of the three 4,4- dimethylated sterol substrates is reduced similar to 3.5- fold. These catalytic properties correlate with the sterol binding parameters, suggesting that Phe in this position provides necessary interactions with C4-monomethylated substrates, which Ile cannot. The CYP51 substrate preferences imply differences in the post- squalene portion of sterol biosynthesis in TC and TB. The phyla-specific residue can be used to predict preferred substrates of new CYP51 sequences and subsequently for the development of new artificial substrate analogs, which might serve as highly specific inhibitors able to kill human parasites.	Vanderbilt Univ, Dept Biochem, Sch Med, Nashville, TN 37232 USA; Vanderbilt Univ, Dept Microbiol, Sch Med, Nashville, TN 37232 USA; Texas Tech Univ, Dept Chem & Biochem, Lubbock, TX 79409 USA	Vanderbilt University; Vanderbilt University; Texas Tech University System; Texas Tech University	Lepesheva, GI (corresponding author), Vanderbilt Univ, Dept Biochem, Sch Med, Nashville, TN 37232 USA.	galina.i.lepesheva@vanderbilt.edu	Zhou, Wenxu/T-6917-2019		NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P30ES000267] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM067871, R01GM063477] Funding Source: NIH RePORTER; NIEHS NIH HHS [ES00267-32] Funding Source: Medline; NIGMS NIH HHS [GM067871, GM63477] Funding Source: Medline	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AOYAMA Y, 1991, BIOCHEM BIOPH RES CO, V178, P1064, DOI 10.1016/0006-291X(91)91000-3; AOYAMA Y, 1987, BIOCHIM BIOPHYS ACTA, V922, P270; Araujo MSS, 2000, J ANTIMICROB CHEMOTH, V45, P819, DOI 10.1093/jac/45.6.819; Baddley JW, 2004, CLIN LAB MED, V24, P721, DOI 10.1016/j.cll.2004.05.003; BARNES HJ, 1991, P NATL ACAD SCI USA, V88, P5597, DOI 10.1073/pnas.88.13.5597; BEACH DH, 1988, MOL BIOCHEM PARASIT, V31, P149, DOI 10.1016/0166-6851(88)90166-1; Berriman M, 2005, SCIENCE, V309, P416, DOI 10.1126/science.1112642; Braga MV, 2004, INT J ANTIMICROB AG, V24, P72, DOI 10.1016/j.ijantimicag.2003.12.009; Buckner F, 2003, P NATL ACAD SCI USA, V100, P15149, DOI 10.1073/pnas.2535442100; Buckner FS, 2001, ANTIMICROB AGENTS CH, V45, P1210, DOI 10.1128/AAC.45.4.1210-1215.2001; BURTON PM, 1995, BIOCHEM PHARMACOL, V50, P529, DOI 10.1016/0006-2952(95)00152-P; Cabello-Hurtado F, 1999, EUR J BIOCHEM, V262, P435, DOI 10.1046/j.1432-1327.1999.00376.x; COOPER AB, 1989, J CHEM SOC CHEM COMM, P898, DOI 10.1039/c39890000898; Coura JR, 2002, MEM I OSWALDO CRUZ, V97, P3, DOI 10.1590/S0074-02762002000100001; DEMONTELLANO PRO, 1995, CYTOCHROME P450 STRU, P305; El-Sayed NM, 2005, SCIENCE, V309, P404, DOI 10.1126/science.1112181; El-Sayed NM, 2005, SCIENCE, V309, P409, DOI 10.1126/science.1112631; Frye LL, 1999, CRIT REV BIOCHEM MOL, V34, P123, DOI 10.1080/10409239991209246; Garzoni LR, 2004, INT J ANTIMICROB AG, V23, P273, DOI 10.1016/j.ijantimicag.2003.07.020; GOAD LJ, 1985, MOL BIOCHEM PARASIT, V15, P257, DOI 10.1016/0166-6851(85)90089-1; GOTOH O, 1992, J BIOL CHEM, V267, P83; Kahn RA, 1996, J BIOL CHEM, V271, P32944, DOI 10.1074/jbc.271.51.32944; Kale P, 2005, DRUG TODAY, V41, P91, DOI 10.1358/dot.2005.41.2.882661; KREIER T, 1992, PARASITIC PROTOZOA; Kuksis A, 2001, J CHROMATOGR A, V935, P203, DOI 10.1016/S0021-9673(01)01226-2; Lamb DC, 1998, FEBS LETT, V425, P263, DOI 10.1016/S0014-5793(98)00247-6; Lepesheva GI, 2003, BIOCHEMISTRY-US, V42, P9091, DOI 10.1021/bi034663f; Lepesheva GI, 2004, MOL CELL ENDOCRINOL, V215, P165, DOI 10.1016/j.mce.2003.11.016; Lepesheva GI, 2004, BIOCHEMISTRY-US, V43, P10789, DOI 10.1021/bi048967t; Lepesheva GI, 2001, J BIOL CHEM, V276, P28413, DOI 10.1074/jbc.M102767200; Liendo A, 1999, MOL BIOCHEM PARASIT, V104, P81, DOI 10.1016/S0166-6851(99)00129-2; LINDBERG RLP, 1989, NATURE, V339, P632, DOI 10.1038/339632a0; Lorente SO, 2004, ANTIMICROB AGENTS CH, V48, P2937, DOI 10.1128/AAC.48.8.2937-2950.2004; Morel CM, 2003, NAT REV MICROBIOL, V1, P14, DOI 10.1038/nrmicro735; MORISAKI M, 1986, J BIOCHEM-TOKYO, V99, P597, DOI 10.1093/oxfordjournals.jbchem.a135516; NES WR, 1977, BIOCH STEROIDS OTHER, P229; O'Brien M, 2005, PLANT PHYSIOL, V139, P734, DOI 10.1104/pp.105.066639; Podust LM, 2004, STRUCTURE, V12, P1937, DOI 10.1016/j.str.2004.08.009; Quinones W, 2004, EXP PARASITOL, V106, P135, DOI 10.1016/j.exppara.2004.03.006; Roberts CW, 2003, MOL BIOCHEM PARASIT, V126, P129, DOI 10.1016/S0166-6851(02)00280-3; Rodrigues CO, 2001, J EUKARYOT MICROBIOL, V48, P588, DOI 10.1111/j.1550-7408.2001.tb00195.x; Schaller H, 2003, PROG LIPID RES, V42, P163, DOI 10.1016/S0163-7827(02)00047-4; SONODA Y, 1992, CHEM PHARM BULL, V40, P2796, DOI 10.1248/cpb.40.2796; TATON M, 1991, BIOCHEM J, V277, P483, DOI 10.1042/bj2770483; TRZASKOS JM, 1995, BIOCHEMISTRY-US, V34, P9677, DOI 10.1021/bi00030a004; TRZASKOS JM, 1987, J BIOL CHEM, V262, P12261; Urbina JA, 1996, SCIENCE, V273, P969, DOI 10.1126/science.273.5277.969; Urbina JA, 2001, CURR OPIN INFECT DIS, V14, P733, DOI 10.1097/00001432-200112000-00012; Venkatramesh M, 1996, BBA-LIPID LIPID MET, V1299, P313, DOI 10.1016/0005-2760(95)00218-9; Von Wachenfeldt C, 1995, CYTOCHROME P450 STRU, P183; Waterman MR, 2005, BIOCHEM BIOPH RES CO, V338, P418, DOI 10.1016/j.bbrc.2005.08.118; Zhang WJ, 2002, DRUG METAB DISPOS, V30, P314, DOI 10.1124/dmd.30.3.314	52	111	116	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 10	2006	281	6					3577	3585		10.1074/jbc.M510317200	http://dx.doi.org/10.1074/jbc.M510317200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	009QV	16321980	hybrid			2022-12-25	WOS:000235128200069
J	Lise, MF; Wong, TP; Trinh, A; Hines, RM; Liu, LD; Kang, RJ; Hines, DJ; Lu, J; Goldenring, JR; Wang, YT; El-Husseini, A				Lise, MF; Wong, TP; Trinh, A; Hines, RM; Liu, LD; Kang, RJ; Hines, DJ; Lu, J; Goldenring, JR; Wang, YT; El-Husseini, A			Involvement of myosin Vb in glutamate receptor trafficking	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMPA RECEPTORS; PROTEIN COMPLEX; INTERACTING PROTEIN-2; NMDA RECEPTOR; RAB GTPASES; VA; MOTOR; IDENTIFICATION; TRANSPORT; FAMILY	Myosin V motors mediate cargo transport; however, the identity of neuronal molecules transported by these proteins remains unknown. Here we show that myosin Vb is expressed in several neuronal populations and associates with the alpha-amino-3-hydroxy-5-methyl-4-isoxazole propionate-type glutamate receptor subunit GluR1. In developing hippocampal neurons, expression of the tail domain of myosin Vb, but not myosin Va, enhanced GluR1 accumulation in the soma and reduced its surface expression. These changes were accompanied by reduced GluR1 clustering and diminished frequency of excitatory but not inhibitory synaptic currents. Similar effects were observed upon expression of full-length myosin Vb lacking a C-terminal region required for binding to the small GTPase Rab11. In contrast, mutant myosin Vb did not change the localization of several other neurotransmitter receptors, including the glutamate receptor subunit NR1. These results reveal a novel mechanism for the transport of a specific glutamate receptor subunit in neurons mediated by a member of the myosin V family.	Univ British Columbia, Dept Psychiat, Brain Res Ctr, Vancouver, BC V6T 1Z3, Canada; Univ British Columbia, Dept Med, Brain Res Ctr, Vancouver, BC V6T 1Z3, Canada; Vanderbilt Univ, Sch Med, Dept Surg, Nashville, TN 37232 USA	University of British Columbia; University of British Columbia; Vanderbilt University	El-Husseini, A (corresponding author), Univ British Columbia, Dept Psychiat, Brain Res Ctr, Vancouver, BC V6T 1Z3, Canada.	alaa@interchange.ubc.ca	Hines, Dustin/AAC-6394-2021; Hines, Rochelle/AAE-3784-2020; Wang, Yu Tian/J-8255-2015; Wang, Yu Tian/A-4729-2008	Liu, Lidong/0000-0002-7026-690X; Hines, Dustin/0000-0003-2952-9824; Wong, Tak Pan/0000-0001-8611-4911; Hines, Rochelle/0000-0002-0459-7911	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK048370] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK48370] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Bahadoran P, 2001, J CELL BIOL, V152, P843, DOI 10.1083/jcb.152.4.843; Braithwaite SP, 2000, NEUROPHARMACOLOGY, V39, P919, DOI 10.1016/S0028-3908(99)00171-9; Bredt DS, 2003, NEURON, V40, P361, DOI 10.1016/S0896-6273(03)00640-8; BREWER GJ, 1993, J NEUROSCI RES, V35, P567, DOI 10.1002/jnr.490350513; Bridgman PC, 1999, J CELL BIOL, V146, P1045, DOI 10.1083/jcb.146.5.1045; Chen L, 2000, NATURE, V408, P936, DOI 10.1038/35050030; El-Husseini AE, 1999, J BIOL CHEM, V274, P19771, DOI 10.1074/jbc.274.28.19771; Fan GH, 2004, MOL BIOL CELL, V15, P2456, DOI 10.1091/mbc.E03-09-0706; Fleisig H, 2004, NEUROSCIENCE, V127, P91, DOI 10.1016/j.neuroscience.2004.04.060; Fukata Y, 2005, J CELL BIOL, V169, P399, DOI 10.1083/jcb.200501121; Fukuda M, 2002, J BIOL CHEM, V277, P12432, DOI 10.1074/jbc.C200005200; Guillaud L, 2003, J NEUROSCI, V23, P131; Hales CM, 2001, J BIOL CHEM, V276, P39067, DOI 10.1074/jbc.M104831200; Hales CM, 2002, J BIOL CHEM, V277, P50415, DOI 10.1074/jbc.M209270200; Hammer JA, 2002, CURR OPIN CELL BIOL, V14, P69, DOI 10.1016/S0955-0674(01)00296-4; Hirokawa N, 2005, NAT REV NEUROSCI, V6, P201, DOI 10.1038/nrn1624; Jiang M, 2004, GENE THER, V11, P1303, DOI 10.1038/sj.gt.3302305; Karcher RL, 2002, TRENDS CELL BIOL, V12, P21, DOI 10.1016/S0962-8924(01)02184-5; Kim E, 1997, J CELL BIOL, V136, P669, DOI 10.1083/jcb.136.3.669; Kim EJ, 2004, NAT REV NEUROSCI, V5, P771, DOI 10.1038/nrn1517; Langford GM, 2002, TRAFFIC, V3, P859, DOI 10.1034/j.1600-0854.2002.31202.x; Lapierre LA, 2001, MOL BIOL CELL, V12, P1843, DOI 10.1091/mbc.12.6.1843; Lee SH, 2004, NEURON, V43, P221, DOI 10.1016/j.neuron.2004.06.015; Lee SH, 2001, NEUROPHARMACOLOGY, V41, P680, DOI 10.1016/S0028-3908(01)00124-1; Malenka RC, 2003, ANN NY ACAD SCI, V1003, P1, DOI 10.1196/annals.1300.001; Man HY, 2000, CELL MOL LIFE SCI, V57, P1526, DOI 10.1007/PL00000637; MERCER JA, 1991, NATURE, V349, P709, DOI 10.1038/349709a0; Naisbitt S, 2000, J NEUROSCI, V20, P4524, DOI 10.1523/JNEUROSCI.20-12-04524.2000; Osterweil E, 2005, J CELL BIOL, V168, P329, DOI 10.1083/jcb.200410091; Park M, 2004, SCIENCE, V305, P1972, DOI 10.1126/science.1102026; Passafaro M, 2001, NAT NEUROSCI, V4, P917, DOI 10.1038/nn0901-917; Petralia RS, 2001, EUR J NEUROSCI, V13, P1722, DOI 10.1046/j.0953-816x.2001.01553.x; Prange O, 2004, P NATL ACAD SCI USA, V101, P13915, DOI 10.1073/pnas.0405939101; Provance DW, 2002, TRAFFIC, V3, P124, DOI 10.1034/j.1600-0854.2002.030205.x; Rodriguez OC, 2002, J CELL SCI, V115, P991; Sans N, 2003, NAT CELL BIOL, V5, P520, DOI 10.1038/ncb990; Schnell E, 2001, J NEUROPHYSIOL, V85, P1498, DOI 10.1152/jn.2001.85.4.1498; Seabra MC, 2004, TRAFFIC, V5, P393, DOI 10.1111/j.1398-9219.2004.00190.x; Setou M, 2002, NATURE, V417, P83, DOI 10.1038/nature743; Setou M, 2000, SCIENCE, V288, P1796, DOI 10.1126/science.288.5472.1796; Shi SH, 2001, CELL, V105, P331, DOI 10.1016/S0092-8674(01)00321-X; Swayze RD, 2004, NEUROPHARMACOLOGY, V47, P764, DOI 10.1016/j.neuropharm.2004.07.014; Takagishi Y, 1996, NEUROSCI LETT, V215, P169, DOI 10.1016/S0304-3940(96)12967-0; Thiagarajan TC, 2005, NEURON, V47, P725, DOI 10.1016/j.neuron.2005.06.037; Tilelli CQ, 2003, NEUROSCIENCE, V121, P573, DOI 10.1016/S0306-4522(03)00546-3; Vandenberghe W, 2004, CURR OPIN CELL BIOL, V16, P134, DOI 10.1016/j.ceb.2004.01.003; Volpicelli LA, 2002, J NEUROSCI, V22, P9776, DOI 10.1523/jneurosci.22-22-09776.2002; Wakabayashi Y, 2005, P NATL ACAD SCI USA, V102, P15087, DOI 10.1073/pnas.0503702102; Walikonis RS, 2000, J NEUROSCI, V20, P4069; Wenthold RJ, 2003, ANNU REV PHARMACOL, V43, P335, DOI 10.1146/annurev.pharmtox.43.100901.135803; Wenthold RJ, 1996, J NEUROSCI, V16, P1982; Wu XF, 1998, CELL MOTIL CYTOSKEL, V40, P286, DOI 10.1002/(SICI)1097-0169(1998)40:3<286::AID-CM7>3.0.CO;2-B; Wu XF, 1998, J CELL BIOL, V143, P1899, DOI 10.1083/jcb.143.7.1899; Wu XF, 2001, J CELL SCI, V114, P1091; Wu XFS, 2002, NAT CELL BIOL, V4, P271, DOI 10.1038/ncb760; Yan Q, 2005, MOL BIOL CELL, V16, P2470, DOI 10.1091/mbc.e04-11-1014; Zhao LP, 1996, P NATL ACAD SCI USA, V93, P10826, DOI 10.1073/pnas.93.20.10826	57	98	102	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 10	2006	281	6					3669	3678		10.1074/jbc.M511725200	http://dx.doi.org/10.1074/jbc.M511725200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	009QV	16338934	hybrid			2022-12-25	WOS:000235128200079
J	Patel, JH; McMahon, SB				Patel, JH; McMahon, SB			Targeting of Miz-1 is essential for Myc-mediated apoptosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CDK INHIBITOR P15(INK4B); C-MYC; TRANSCRIPTIONAL REPRESSION; ESSENTIAL COFACTOR; GENE-REGULATION; DNA-DAMAGE; PROTEIN; ASSOCIATION; PROMOTER; SUPPRESSION	The c-Myc oncoprotein plays a central role in human cancer via its ability to either activate or repress the transcription of essential downstream targets. For many of the repressed target genes, downregulation by c-Myc relies on its ability to bind and inactivate the transcription factor Miz-1. Although Miz-1 inactivation is suspected to be essential for at least some of the biological activities of c-Myc, it has been difficult to demonstrate this requirement experimentally. Using a combination of short hairpin RNA-mediated knockdown and a previously characterized mutant of c-Myc that is defective for Miz-1 inactivation, we examined whether this inactivation is critical for three of the most central biological functions of c-Myc, cell cycle progression, transformation, and apoptosis. The results of this analysis demonstrated that in the in vitro assays utilized here, Miz-1 inactivation is dispensable for c-Myc-induced cell cycle progression and transformation. In marked contrast, the ability of c-Myc to induce apoptosis in primary diploid human fibroblasts in response to growth factor withdrawal is entirely dependent on its ability to inactivate Miz-1. These data have a significant impact on our understanding of the biochemical mechanisms dictating how c-Myc mediates opposing biological functions, such as transformation and apoptosis, and demonstrate the first requirement for Miz-1 inactivation in any of the biological functions of c-Myc.	Wistar Inst Anat & Biol, Philadelphia, PA 19104 USA	The Wistar Institute	McMahon, SB (corresponding author), Wistar Inst Anat & Biol, 3601 Spruce St, Philadelphia, PA 19104 USA.	smcmahon@jwistar.org		McMahon, Steven/0000-0002-3405-1768	NCI NIH HHS [CA090465] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA090465] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Barsyte-Lovejoy D, 2004, ONCOGENE, V23, P3481, DOI 10.1038/sj.onc.1207487; Bowen H, 2002, J BIOL CHEM, V277, P34997, DOI 10.1074/jbc.M204232200; Brenner C, 2005, EMBO J, V24, P336, DOI 10.1038/sj.emboj.7600509; Cheng SWG, 1999, NAT GENET, V22, P102, DOI 10.1038/8811; EILERS M, 1989, NATURE, V340, P66, DOI 10.1038/340066a0; Eischen CM, 2001, ONCOGENE, V20, P6983, DOI 10.1038/sj.onc.1204892; Eischen CM, 2001, MOL CELL BIOL, V21, P5063, DOI 10.1128/MCB.21.15.5063-5070.2001; Etard C, 2005, MECH DEVELOP, V122, P545, DOI 10.1016/j.mod.2004.11.010; EVAN GI, 1992, CELL, V69, P119, DOI 10.1016/0092-8674(92)90123-T; Felsher DW, 1999, P NATL ACAD SCI USA, V96, P3940, DOI 10.1073/pnas.96.7.3940; Feng XH, 2002, MOL CELL, V9, P133, DOI 10.1016/S1097-2765(01)00430-0; Gartel AL, 2001, P NATL ACAD SCI USA, V98, P4510, DOI 10.1073/pnas.081074898; Herold S, 2002, MOL CELL, V10, P509, DOI 10.1016/S1097-2765(02)00633-0; Izumi H, 2001, J CELL SCI, V114, P1533; Kim SY, 2003, MOL CELL, V11, P1177, DOI 10.1016/S1097-2765(03)00173-4; Kime L, 2003, BIOCHEM J, V370, P291, DOI 10.1042/BJ20021679; LANDAU NR, 1992, J VIROL, V66, P5110, DOI 10.1128/JVI.66.8.5110-5113.1992; Lapham AS, 2004, BIOCHEM SOC T, V32, P1084, DOI 10.1042/BST0321084; Lee LA, 1996, J CLIN INVEST, V97, P1687, DOI 10.1172/JCI118595; LI LH, 1994, EMBO J, V13, P4070, DOI 10.1002/j.1460-2075.1994.tb06724.x; LITTLEWOOD TD, 1995, NUCLEIC ACIDS RES, V23, P1686, DOI 10.1093/nar/23.10.1686; Mao DYL, 2004, NUCLEIC ACIDS RES, V32, P3462, DOI 10.1093/nar/gkh669; Mateyak MK, 1997, CELL GROWTH DIFFER, V8, P1039; McMahon SB, 1998, CELL, V94, P363, DOI 10.1016/S0092-8674(00)81479-8; McMahon SB, 2000, MOL CELL BIOL, V20, P556, DOI 10.1128/MCB.20.2.556-562.2000; Nesbit CE, 1999, ONCOGENE, V18, P3004, DOI 10.1038/sj.onc.1202746; Nilsson JA, 2003, ONCOGENE, V22, P9007, DOI 10.1038/sj.onc.1207261; Patel JH, 2004, NAT REV CANCER, V4, P562, DOI 10.1038/nrc1393; Pelengaris S, 2002, NAT REV CANCER, V2, P764, DOI 10.1038/nrc904; Pelengaris S, 2002, CELL, V109, P321, DOI 10.1016/S0092-8674(02)00738-9; Peukert K, 1997, EMBO J, V16, P5672, DOI 10.1093/emboj/16.18.5672; ROY AL, 1993, NATURE, V365, P359, DOI 10.1038/365359a0; Schneider A, 1997, CURR TOP MICROBIOL, V224, P137; SCHREIBERAGUS N, 1995, CELL, V80, P777, DOI 10.1016/0092-8674(95)90356-9; Seoane J, 2002, NATURE, V419, P729, DOI 10.1038/nature01119; Seoane J, 2001, NAT CELL BIOL, V3, P400, DOI 10.1038/35070086; SHRIVASTAVA A, 1993, SCIENCE, V262, P1889, DOI 10.1126/science.8266081; Staller P, 2001, NAT CELL BIOL, V3, P392, DOI 10.1038/35070076; Vaque JP, 2005, J BIOL CHEM, V280, P1112, DOI 10.1074/jbc.M409503200; Vervoorts J, 2003, EMBO REP, V4, P484, DOI 10.1038/sj.embor.embor821; von der Lehr N, 2003, MOL CELL, V11, P1189, DOI 10.1016/S1097-2765(03)00193-X; Wanzel M, 2005, NAT CELL BIOL, V7, P30, DOI 10.1038/ncb1202; Wu SQ, 2003, ONCOGENE, V22, P351, DOI 10.1038/sj.onc.1206145; Xiao QR, 1998, GENE DEV, V12, P3803, DOI 10.1101/gad.12.24.3803; Yang W, 2001, ONCOGENE, V20, P1688, DOI 10.1038/sj.onc.1204245; Zhang XY, 2005, P NATL ACAD SCI USA, V102, P13968, DOI 10.1073/pnas.0502330102; Ziegelbauer J, 2004, P NATL ACAD SCI USA, V101, P458, DOI 10.1073/pnas.0307562100	47	34	36	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 10	2006	281	6					3283	3289		10.1074/jbc.M513038200	http://dx.doi.org/10.1074/jbc.M513038200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	009QV	16352593	hybrid			2022-12-25	WOS:000235128200034
J	Sewell, R; Backstrom, M; Dalziel, M; Gschmeissner, S; Karlsson, H; Noll, T; Gatgens, J; Clausen, H; Hansson, GC; Burchell, J; Taylor-Papadimitriou, J				Sewell, R; Backstrom, M; Dalziel, M; Gschmeissner, S; Karlsson, H; Noll, T; Gatgens, J; Clausen, H; Hansson, GC; Burchell, J; Taylor-Papadimitriou, J			The ST6GalNAc-I sialyltransferase localizes throughout the golgi and is responsible for the synthesis of the tumor-associated Sialyl-Tn O-glycan in human breast cancer	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POLYMORPHIC EPITHELIAL MUCIN; SIALOSYL-TN; LINKED GLYCOSYLATION; MAMMARY-GLAND; CHO-K1 CELLS; EXPRESSION; ANTIGEN; ADJUVANT; TRANSFERASES; INITIATION	The functional properties of glycoproteins are strongly influenced by their profile of glycosylation, and changes in this profile are seen in malignancy. In mucin-typeO- linked glycosylation these changes can result in the production of mucins such as MUC1, carrying shorter sialylated O-glycans, and with different site occupancy. Of the tumor-associated sialylated-O-glycans, the disaccharide, sialyl-Tn (sialic acid alpha 2,6GalNAc), is expressed by 30% of breast carcinomas and is the most tumor-specific. The ST6GalNAc-I glycosyltransferase, which can catalyze the transfer of sialic acid to GalNAc, shows a highly restricted pattern of expression in normal adult tissues, being largely limited to the gastrointestinal tract and absent in mammary gland. In breast carcinomas, however, a complete correlation between the expression of RNA-encoding ST6GalNAc-I and the expression of sialyl-Tn is evident, demonstrating that the expression of sialyl-Tn results from switching on expression of hST6GalNAc-I. Endogenous or exogenous expression of hST6GalNAc-I ( but not ST6GalNAc-II) always results in the expression of sialyl-Tn. This ability to override core 1/ core 2 pathways of O-linked glycosylation is explained by the localization of ST6GalNAc-I, which is found throughout the Golgi stacks. The development of a Chinese hamster ovary (CHO) cell line expressing MUC1 and ST6GalNAc-I allowed the large scale production of MUC1 carrying 83% sialyl-Tn O-glycans. The presence of ST6GalNAc-I in the CHO cells reduced the number of O-glycosylation sites occupied in MUC1, from an average of 4.3 to 3.8 per tandem repeat. The availability of large quantities of this MUC1 glycoform will allow the evaluation of its efficacy as an immunogen for immunotherapy of MUC1/ STn- expressing tumors.	Guys Hosp, Canc Res UK Breast Canc Biol Grp, London SE1 9RT, England; Gothenburg Univ, Dept Biochem Med, S-41390 Gothenburg, Sweden; Canc Res UK London Inst, Electron Microscopy Unit, London WC2A 3PX, England; Juelich GmbH, Inst Biochem Res Ctr, D-52425 Julich, Germany; Univ Copenhagen, Dept Biochem Med, DK-2200 Copenhagen, Denmark; Univ Copenhagen, Genet Hlth Sci Fac, DK-2200 Copenhagen, Denmark	Guy's & St Thomas' NHS Foundation Trust; University of Gothenburg; Cancer Research UK; Helmholtz Association; Research Center Julich; University of Copenhagen; University of Copenhagen	Taylor-Papadimitriou, J (corresponding author), Guys Hosp, Canc Res UK Breast Canc Biol Grp, 3rd Floor, London SE1 9RT, England.	joyce.taylor-papadimitriou@cancer.org.uk	Noll, Thomas/A-3539-2012; Burchell, Joy/G-4560-2012; clausen, henrik/AAD-8016-2021; Hansson, Gunnar C/A-1236-2009; Hansson, Gunnar C./AAF-7324-2019	Noll, Thomas/0000-0003-0748-3423; Hansson, Gunnar C/0000-0002-1900-1869; Hansson, Gunnar C./0000-0002-1900-1869; Burchell, Joy/0000-0003-0413-3823; Dalziel, Martin/0000-0002-8967-6378; Clausen, Henrik/0000-0002-0915-5055				Backstrom M, 2003, BIOCHEM J, V376, P677, DOI 10.1042/BJ20031130; BARTEK J, 1991, P NATL ACAD SCI USA, V88, P3520, DOI 10.1073/pnas.88.9.3520; BROCKHAUSEN I, 1995, EUR J BIOCHEM, V233, P607, DOI 10.1111/j.1432-1033.1995.607_2.x; Brockhausen I, 2001, BIOL CHEM, V382, P219; Burchell J, 1999, GLYCOBIOLOGY, V9, P1307, DOI 10.1093/glycob/9.12.1307; BURCHELL J, 1993, CANCER SURV, V18, P135; Burchell JM, 2001, J MAMMARY GLAND BIOL, V6, P355, DOI 10.1023/A:1011331809881; Cao Y, 1996, HISTOCHEM CELL BIOL, V106, P197, DOI 10.1007/BF02484401; Cao Y, 1999, VIRCHOWS ARCH, V434, P503, DOI 10.1007/s004280050375; Clausen H, 1996, GLYCOBIOLOGY, V6, P635, DOI 10.1093/glycob/6.6.635; Corfield AP, 1999, GLYCOCONJUGATE J, V16, P307, DOI 10.1023/A:1007026314792; Dalziel M, 2001, J BIOL CHEM, V276, P11007, DOI 10.1074/jbc.M006523200; Hakomori S, 2002, P NATL ACAD SCI USA, V99, P10231, DOI 10.1073/pnas.172380699; Hakomori S, 2004, ARCH BIOCHEM BIOPHYS, V426, P173, DOI 10.1016/j.abb.2004.02.032; HANISCH FG, 1989, J BIOL CHEM, V264, P872; Hassan H, 2000, J BIOL CHEM, V275, P38197, DOI 10.1074/jbc.M005783200; Hull S R, 1989, Cancer Commun, V1, P261; Ikehara Y, 1999, GLYCOBIOLOGY, V9, P1213, DOI 10.1093/glycob/9.11.1213; Imai J, 2001, ANTICANCER RES, V21, P1327; ITZKOWITZ SH, 1989, CANCER RES, V49, P197; ITZKOWITZ SH, 1990, CANCER-AM CANCER SOC, V66, P1960, DOI 10.1002/1097-0142(19901101)66:9<1960::AID-CNCR2820660919>3.0.CO;2-X; JASS JR, 1995, J PATHOL, V176, P143, DOI 10.1002/path.1711760207; Johnson TK, 2002, CANCER, V94, P1240, DOI 10.1002/cncr.10292; Kinney AY, 1997, CANCER-AM CANCER SOC, V80, P2240, DOI 10.1002/(SICI)1097-0142(19971215)80:12<2240::AID-CNCR4>3.0.CO;2-Y; KJELDSEN T, 1988, CANCER RES, V48, P2214; Kono M, 2000, BIOCHEM BIOPH RES CO, V272, P94, DOI 10.1006/bbrc.2000.2745; Leivonen M, 2001, ONCOLOGY-BASEL, V61, P299, DOI 10.1159/000055337; Link T, 2004, J BIOTECHNOL, V110, P51, DOI 10.1016/j.jbiotec.2003.12.008; Lloyd KO, 1996, J BIOL CHEM, V271, P33325, DOI 10.1074/jbc.271.52.33325; LONGENECKER BM, 1993, ANN NY ACAD SCI, V690, P276; Lowe JB, 2003, ANNU REV BIOCHEM, V72, P643, DOI 10.1146/annurev.biochem.72.121801.161809; MACLEAN GD, 1993, CANCER IMMUNOL IMMUN, V36, P215, DOI 10.1007/BF01740902; Marcos NT, 2004, CANCER RES, V64, P7050, DOI 10.1158/0008-5472.CAN-04-1921; Miles David, 2003, Clin Breast Cancer, V3 Suppl 4, pS134, DOI 10.3816/CBC.2003.s.002; MILES DW, 1994, BRIT J CANCER, V70, P1272, DOI 10.1038/bjc.1994.486; Miles DW, 1996, BRIT J CANCER, V74, P1292, DOI 10.1038/bjc.1996.532; MILES DW, 1995, BRIT J CANCER, V71, P1074, DOI 10.1038/bjc.1995.207; Muller S, 2002, J BIOL CHEM, V277, P26103, DOI 10.1074/jbc.M202921200; Mungul A, 2004, INT J ONCOL, V25, P937; Ogata S, 1998, GLYCOCONJUGATE J, V15, P29, DOI 10.1023/A:1006935331756; Olson FJ, 2005, GLYCOBIOLOGY, V15, P177, DOI 10.1093/glycob/cwh158; PEAT N, 1992, CANCER RES, V52, P1954; Rottger S, 1998, J CELL SCI, V111, P45; Samyn-Petit B, 2000, BBA-GEN SUBJECTS, V1474, P201, DOI 10.1016/S0304-4165(00)00020-9; TAYLORPAPADIMITRIOU J, 1993, ANN NY ACAD SCI, V690, P69; THOR A, 1986, CANCER RES, V46, P3118; Vazquez-Martin C, 2004, ONCOLOGY-BASEL, V67, P159, DOI 10.1159/000081003; VITIELLO A, 1991, J EXP MED, V173, P1007, DOI 10.1084/jem.173.4.1007; Wells L, 2003, BIOCHEM BIOPH RES CO, V302, P435, DOI 10.1016/S0006-291X(03)00175-X; Whitehouse C, 1997, J CELL BIOL, V137, P1229, DOI 10.1083/jcb.137.6.1229	50	165	177	0	20	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 10	2006	281	6					3586	3594		10.1074/jbc.M511826200	http://dx.doi.org/10.1074/jbc.M511826200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	009QV	16319059	hybrid			2022-12-25	WOS:000235128200070
J	Dash, C; Marino, JP; Le Grice, SFJ				Dash, C; Marino, JP; Le Grice, SFJ			Examining Ty3 polypurine tract structure and function by nucleoside analog interference	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HIV-1 REVERSE-TRANSCRIPTASE; HUMAN-IMMUNODEFICIENCY-VIRUS; COLI RIBONUCLEASE HI; STRAND DNA-SYNTHESIS; RNASE-H; ESCHERICHIA-COLI; CRYSTAL-STRUCTURE; TEMPLATE-PRIMER; RETROTRANSPOSON TY3; ANGSTROM RESOLUTION	We have combined nucleoside analog interference with chemical footprinting, thermal denaturation, NMR spectroscopy, and biochemical studies to understand recognition of the polypurine tract (PPT) primer of the Saccharomyces cerevisiae long terminal repeatcontaining retrotransposon Ty3 by its cognate reverse transcriptase. Locked nucleic acid analogs, which constrain sugar ring geometry, were introduced pairwise throughout the PPT (-)-DNA template, whereas abasic tetrahydrofuran linkages, which lack the nucleobase but preserve the sugar phosphate backbone, were introduced throughout the (-)-strand DNA template and (+)-strand RNA primer. Collectively, our data suggest that both the 5'- and 3'-portions of the PPT-containing RNA/DNA hybrid are sensitive to nucleoside analog substitution, whereas the intervening region can be modified without altering cleavage specificity. These two regions most likely correspond to portions of the PPT that make close contact with the Ty3 reverse transcriptase thumb subdomain and RNase H catalytic center, respectively. Achieving a similar phenotype with nucleoside analogs that have different effects on duplex geometry reveals structural features that are important mediators of Ty3 PPT recognition. Finally, the results from introducing tetrahydrofuran lesions around the scissile PPT/unique 3'-sequence junction indicate that template nucleobase -1 is dispensable for catalysis.	NCI, Resistance Mech Lab, HIV Drug Resistance Program, NIH, Frederick, MD 21702 USA; Univ Maryland, Ctr Adv Res Biotechnol, Inst Biotechnol, Rockville, MD 20850 USA; Natl Inst Stand & Technol, Rockville, MD 20850 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); University System of Maryland; University of Maryland Baltimore; National Institute of Standards & Technology (NIST) - USA	Le Grice, SFJ (corresponding author), NCI, Resistance Mech Lab, HIV Drug Resistance Program, NIH, Frederick, MD 21702 USA.	slegrice@ncifcrf.gov		Dash, Chandravanu/0000-0003-4466-8355	Intramural NIH HHS Funding Source: Medline; NIDA NIH HHS [K99 DA024558] Funding Source: Medline; NIGMS NIH HHS [GM59107] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM059107] Funding Source: NIH RePORTER	Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Arosio D, 2004, J BIOL CHEM, V279, P42826, DOI 10.1074/jbc.M406529200; Ayadi L, 1999, J BIOMOL STRUCT DYN, V17, P245, DOI 10.1080/07391102.1999.10508357; Ayadi L, 2000, J BIOMOL STRUCT DYN, V17, P645, DOI 10.1080/07391102.2000.10506555; Barsky D, 2000, NUCLEIC ACIDS RES, V28, P2613, DOI 10.1093/nar/28.13.2613; Bebenek K, 1999, MUTAT RES-FUND MOL M, V429, P149, DOI 10.1016/S0027-5107(99)00119-0; Bibillo A, 2005, J BIOL CHEM, V280, P30282, DOI 10.1074/jbc.M502457200; BIBLILLO A, 2005, NUCLEIC ACIDS RES, V33, P171; Bondensgaard K, 2000, CHEM-EUR J, V6, P2687, DOI 10.1002/1521-3765(20000804)6:15<2687::AID-CHEM2687>3.0.CO;2-U; Dash C, 2004, J BIOL CHEM, V279, P37095, DOI 10.1074/jbc.M403306200; Dash C, 2004, NUCLEIC ACIDS RES, V32, P1539, DOI 10.1093/nar/gkh307; Ding JP, 1998, J MOL BIOL, V284, P1095, DOI 10.1006/jmbi.1998.2208; Ding JP, 1997, BIOPOLYMERS, V44, P125, DOI 10.1002/(SICI)1097-0282(1997)44:2&lt;125::AID-BIP2&gt;3.0.CO;2-X; Farah JA, 1997, J MOL BIOL, V272, P699, DOI 10.1006/jmbi.1997.1259; Gabus C, 1998, EMBO J, V17, P4873, DOI 10.1093/emboj/17.16.4873; Haruki M, 2000, BIOCHEMISTRY-US, V39, P13939, DOI 10.1021/bi001469+; HEYDUK T, 1989, BIOCHEMISTRY-US, V28, P6914, DOI 10.1021/bi00443a021; HEYMAN T, 1995, J MOL BIOL, V253, P291, DOI 10.1006/jmbi.1995.0553; Huang HF, 1998, SCIENCE, V282, P1669, DOI 10.1126/science.282.5394.1669; IWAI S, 1995, FEBS LETT, V368, P315, DOI 10.1016/0014-5793(95)00683-Z; JACOBOMOLINA A, 1993, P NATL ACAD SCI USA, V90, P6320, DOI 10.1073/pnas.90.13.6320; Kamtekar S, 2004, MOL CELL, V16, P609, DOI 10.1016/j.molcel.2004.10.019; Ke N, 1999, RNA, V5, P929, DOI 10.1017/S1355838299990015; Kopka ML, 2003, J MOL BIOL, V334, P653, DOI 10.1016/j.jmb.2003.09.057; Kvaratskhelia M, 2002, J BIOL CHEM, V277, P16689, DOI 10.1074/jbc.M109914200; Latham GJ, 2000, J BIOL CHEM, V275, P15025, DOI 10.1074/jbc.M000279200; Lener D, 2003, J BIOL CHEM, V278, P26526, DOI 10.1074/jbc.M302374200; LEVIN HL, 1995, MOL CELL BIOL, V15, P3310; Lhomme J, 1999, BIOPOLYMERS, V52, P65, DOI 10.1002/1097-0282(1999)52:2<65::AID-BIP1>3.0.CO;2-U; MCCARTHY JG, 1990, BIOCHEMISTRY-US, V29, P6071, DOI 10.1021/bi00477a027; NAKAMURA H, 1991, P NATL ACAD SCI USA, V88, P11535, DOI 10.1073/pnas.88.24.11535; Nielsen KE, 2005, J AM CHEM SOC, V127, P15273, DOI 10.1021/ja051026z; Nowotny M, 2005, CELL, V121, P1005, DOI 10.1016/j.cell.2005.04.024; Petersen M, 2002, J AM CHEM SOC, V124, P5974, DOI 10.1021/ja012288d; Petersen M, 2000, J MOL RECOGNIT, V13, P44, DOI 10.1002/(SICI)1099-1352(200001/02)13:1<44::AID-JMR486>3.0.CO;2-6; Powell MD, 1999, J BIOL CHEM, V274, P19885, DOI 10.1074/jbc.274.28.19885; RATTRAY AJ, 1989, J MOL BIOL, V208, P445, DOI 10.1016/0022-2836(89)90508-1; Rausch JW, 2004, INT J BIOCHEM CELL B, V36, P1752, DOI 10.1016/j.biocel.2004.02.016; Rausch JW, 2003, P NATL ACAD SCI USA, V100, P11279, DOI 10.1073/pnas.1932546100; Rausch JW, 2000, J BIOL CHEM, V275, P13879, DOI 10.1074/jbc.275.18.13879; Reddy YVR, 2000, J MOL BIOL, V298, P597, DOI 10.1006/jmbi.2000.3673; Sarafianos SG, 2001, EMBO J, V20, P1449, DOI 10.1093/emboj/20.6.1449; UCHIYAMA Y, 1994, J MOL BIOL, V243, P782, DOI 10.1016/0022-2836(94)90047-7; Vogel SK, 2002, NUCLEIC ACIDS RES, V30, P4094, DOI 10.1093/nar/gkf519; Wilhelm FX, 2003, J BIOL CHEM, V278, P47678, DOI 10.1074/jbc.M305162200; Wilhelm M, 1999, NUCLEIC ACIDS RES, V27, P4547, DOI 10.1093/nar/27.23.4547; Wilhelm M, 2000, BIOCHEM J, V348, P337, DOI 10.1042/0264-6021:3480337; Yi-Brunozzi HY, 2005, J AM CHEM SOC, V127, P16344, DOI 10.1021/ja0534203; Yi-Brunozzi HY, 2005, J BIOL CHEM, V280, P20154, DOI 10.1074/jbc.M411228200; Zou Y, 1999, EMBO J, V18, P4889, DOI 10.1093/emboj/18.17.4889	49	9	10	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 3	2006	281	5					2773	2783		10.1074/jbc.M510369200	http://dx.doi.org/10.1074/jbc.M510369200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	006XT	16306041	hybrid			2022-12-25	WOS:000234931800044
J	Gareus, R; Di Nardo, A; Rybin, V; Witke, W				Gareus, R; Di Nardo, A; Rybin, V; Witke, W			Mouse profilin 2 regulates endocytosis and competes with SH3 ligand binding to dynamin 1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CLATHRIN-MEDIATED ENDOCYTOSIS; ACTIN NUCLEOTIDE EXCHANGE; PROLINE-RICH DOMAIN; GTPASE DYNAMIN; F-ACTIN; PROTEIN; IDENTIFICATION; CYTOSKELETON; ISOFORMS; DISTINCT	Mammalian profilins are abundantly expressed actin monomerbinding proteins, highly conserved with respect to their affinities for G-actin, poly-L-proline, and phosphoinositides. Profilins associate with a large number of proline-rich proteins; the physiological significance and regulation of which is poorly understood. Here we show that profilin 2 associates with dynamin 1 via the C-terminal proline-rich domain of dynamin and thereby competes with the binding of SH3 ligands such as endophilin, amphiphysin, and Grb2, thus interfering with the assembly of the endocytic machinery. We also present a novel role for the brain-specific mouse profilin 2 as a regulator of membrane trafficking. Overexpression of profilin 2 inhibits endocytosis, whereas lack of profilin 2 in neurons results in an increase in endocytosis and membrane recycling. Phosphatidylinositol 4,5-bisphosphate releases profilin 2 from the profilin 2-dynamin 1 complex as well as from the profilin 2-actin complex, suggesting that profilin 2 is diverging the phosphoinositide signaling pathway to actin polymerization as well as endocytosis.	European Mol Biol Lab, Mouse Biol Unit, I-00016 Monterotondo, Italy; EMBL, D-69117 Heidelberg, Germany	European Molecular Biology Laboratory (EMBL); European Molecular Biology Laboratory (EMBL)	Witke, W (corresponding author), European Mol Biol Lab, Mouse Biol Unit, Campus Adriano Buzzati Traverso, I-00016 Monterotondo, Italy.	witke@embl-monterotondo.it						BJORKEGREN C, 1993, FEBS LETT, V333, P123, DOI 10.1016/0014-5793(93)80388-B; Di Nardo A, 2000, J CELL SCI, V113, P3795; Diefenbach TJ, 1999, J NEUROSCI, V19, P9436; Dong JX, 2000, BBA-MOL CELL RES, V1497, P253, DOI 10.1016/S0167-4889(00)00056-2; Engqvist-Goldstein AEY, 2004, MOL BIOL CELL, V15, P1666, DOI 10.1091/mbc.E03-09-0639; Fabian-Fine R, 2003, J NEUROSCI, V23, P10732; Finger FP, 1997, MOL BIOL CELL, V8, P647, DOI 10.1091/mbc.8.4.647; GIESELMANN R, 1995, EUR J BIOCHEM, V229, P621, DOI 10.1111/j.1432-1033.1995.tb20506.x; Giesemann T, 2003, J NEUROSCI, V23, P8330; GOLDSCHMIDTCLERMONT PJ, 1990, SCIENCE, V247, P1575, DOI 10.1126/science.2157283; Gomez TS, 2005, NAT IMMUNOL, V6, P261, DOI 10.1038/ni1168; GOUT I, 1993, CELL, V75, P25, DOI 10.1016/0092-8674(93)90676-H; Grabs D, 1997, J BIOL CHEM, V272, P13419, DOI 10.1074/jbc.272.20.13419; HERSKOVITS JS, 1993, J CELL BIOL, V122, P565, DOI 10.1083/jcb.122.3.565; Hill E, 2001, J CELL BIOL, V152, P309, DOI 10.1083/jcb.152.2.309; HONORE B, 1993, FEBS LETT, V330, P151, DOI 10.1016/0014-5793(93)80262-S; Hu ED, 2001, EXP NEPHROL, V9, P265; Jonckheere V, 1999, FEBS LETT, V447, P257, DOI 10.1016/S0014-5793(99)00293-8; Karakesisoglou I, 1999, J CELL BIOL, V145, P167, DOI 10.1083/jcb.145.1.167; Kay BK, 2000, FASEB J, V14, P231, DOI 10.1096/fasebj.14.2.231; Kessels MM, 2001, J CELL BIOL, V153, P351, DOI 10.1083/jcb.153.2.351; KWIATKOWSKI DJ, 1990, AM J HUM GENET, V46, P559; Lambrechts A, 1997, EMBO J, V16, P484, DOI 10.1093/emboj/16.3.484; Lambrechts A, 2000, J BIOL CHEM, V275, P36143, DOI 10.1074/jbc.M006274200; LASSING I, 1985, NATURE, V314, P472, DOI 10.1038/314472a0; Lu J, 2001, MOL BIOL CELL, V12, P1161, DOI 10.1091/mbc.12.4.1161; MACHESKY LM, 1994, BIOCHEMISTRY-US, V33, P10815, DOI 10.1021/bi00201a032; Mahoney NM, 1999, NAT STRUCT BIOL, V6, P666, DOI 10.1038/10722; MALM B, 1983, J MUSCLE RES CELL M, V4, P569, DOI 10.1007/BF00712116; McNiven MA, 2000, J CELL BIOL, V151, P187, DOI 10.1083/jcb.151.1.187; Merrifield CJ, 2002, NAT CELL BIOL, V4, P691, DOI 10.1038/ncb837; Nyman T, 2002, J BIOL CHEM, V277, P15828, DOI 10.1074/jbc.M112195200; Obermann H, 2005, MOL HUM REPROD, V11, P53, DOI 10.1093/molehr/gah132; Ochoa GC, 2000, J CELL BIOL, V150, P377, DOI 10.1083/jcb.150.2.377; Okamoto PM, 1997, J BIOL CHEM, V272, P11629; Orth JD, 2002, P NATL ACAD SCI USA, V99, P167, DOI 10.1073/pnas.012607899; Ostrander DB, 1999, EUR J BIOCHEM, V262, P26, DOI 10.1046/j.1432-1327.1999.00354.x; Pearson AM, 2003, MICROBES INFECT, V5, P815, DOI 10.1016/S1286-4579(03)00157-6; Pollard TD, 2000, ANNU REV BIOPH BIOM, V29, P545, DOI 10.1146/annurev.biophys.29.1.545; Qualmann B, 2000, J CELL BIOL, V148, P1047, DOI 10.1083/jcb.148.5.1047; REINHARD M, 1995, EMBO J, V14, P1583, DOI 10.1002/j.1460-2075.1995.tb07146.x; Schluter K, 1997, BBA-MOL CELL RES, V1359, P97, DOI 10.1016/S0167-4889(97)00100-6; Schmidt A, 1999, NATURE, V401, P133, DOI 10.1038/43613; Schuck P, 2000, BIOPHYS J, V78, P1606, DOI 10.1016/S0006-3495(00)76713-0; SCHUTT CE, 1993, NATURE, V365, P810, DOI 10.1038/365810a0; Slepnev VI, 1998, SCIENCE, V281, P821, DOI 10.1126/science.281.5378.821; SPUDICH JA, 1971, J BIOL CHEM, V246, P4866; Sweitzer SM, 1998, CELL, V93, P1021, DOI 10.1016/S0092-8674(00)81207-6; Takei K, 1999, NAT CELL BIOL, V1, P33, DOI 10.1038/9004; Takenawa T, 2001, BBA-MOL CELL BIOL L, V1533, P190, DOI 10.1016/S1388-1981(01)00165-2; Temesvari L, 2000, MOL BIOL CELL, V11, P2019, DOI 10.1091/mbc.11.6.2019; Thery C, 2001, J IMMUNOL, V166, P7309, DOI 10.4049/jimmunol.166.12.7309; VANDERBLIEK AM, 1993, J CELL BIOL, V122, P533; WARNOCK DE, 1995, EMBO J, V14, P1322, DOI 10.1002/j.1460-2075.1995.tb07118.x; Witke W, 2004, TRENDS CELL BIOL, V14, P461, DOI 10.1016/j.tcb.2004.07.003; Witke W, 1998, EMBO J, V17, P967, DOI 10.1093/emboj/17.4.967; Wittenmayer N, 2000, EUR J BIOCHEM, V267, P5247, DOI 10.1046/j.1432-1327.2000.01600.x; Wolven AK, 2000, J CELL BIOL, V150, P895, DOI 10.1083/jcb.150.4.895; Yarar D, 2005, MOL BIOL CELL, V16, P964, DOI 10.1091/mbc.e04-09-0774; Zheng J, 1996, J MOL BIOL, V255, P14, DOI 10.1006/jmbi.1996.0002	60	48	52	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 3	2006	281	5					2803	2811		10.1074/jbc.M503528200	http://dx.doi.org/10.1074/jbc.M503528200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	006XT	16319076	hybrid			2022-12-25	WOS:000234931800047
J	Kelley, GG; Kaproth-Joslin, KA; Reks, SE; Smrcka, AV; Wojcikiewicz, RJH				Kelley, GG; Kaproth-Joslin, KA; Reks, SE; Smrcka, AV; Wojcikiewicz, RJH			G-protein-coupled receptor agonists activate endogenous phospholipase C epsilon and phospholipase C beta 3 in a temporally distinct manner	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INOSITOL 1,4,5-TRISPHOSPHATE RECEPTORS; VASCULAR SMOOTH-MUSCLE; RAT-1 FIBROBLASTS; DOWN-REGULATION; ANGIOTENSIN-II; EGF RECEPTOR; INS(1,4,5)P3 FORMATION; LYSOPHOSPHATIDIC-ACID; SIGNAL-TRANSDUCTION; CYCLIC-AMP	Phospholipase C epsilon (PLC epsilon) is one of the newest members of the phosphatidylinositol-specific phospholipase C (PLC) family. Previous studies have suggested that G-protein-coupled receptors (GPCRs) stimulate phosphoinositide (PI) hydrolysis by activating PLC beta isoforms through G(q) family G proteins and G beta gamma subunits. Using RNA interference to knock down PLC isoforms, we demonstrate that the GPCR agonists endothelin (ET-1), lysophosphatidic acid (LPA), and thrombin, acting through endogenous receptors, couple to both endogenous PLC epsilon and the PLC beta isoform, PLC beta 3, in Rat-1 fibroblasts. Examination of the temporal activation of these PLC isoforms, however, reveals agonist- and isoform-specific profiles. PLC beta 3 is activated acutely within the first minute of ET-1, LPA, or thrombin stimulation but does not contribute to sustained PI hydrolysis induced by LPA or thrombin and accounts for only part of ET-1 sustained stimulation. PLC epsilon, on the other hand, predominantly accounts for sustained PI hydrolysis. Consistent with this observation, reconstitution of PLC epsilon in knockdown cells dose-dependently increases sustained, but not acute, agonist- stimulated PI hydrolysis. Furthermore, combined knockdown of both PLC epsilon and PLC beta 3 additively inhibits PI hydrolysis, suggesting independent regulation of each isoform. Importantly, ubiquitination of inositol 1,4,5-trisphosphate receptors correlates with sustained, but not acute, activation of PLC epsilon or PLC beta 3. In conclusion, GPCR agonists ET-1, LPA, and thrombin activate endogenous PLC epsilon and PLC beta 3 in Rat-1 fibroblasts. Activation of these PLC isoforms displays agonist- specific temporal profiles; however, PLC beta 3 is predominantly involved in acute and PLC epsilon in sustained PI hydrolysis.	SUNY Upstate Med, Dept Med, Syracuse, NY 13210 USA; SUNY Upstate Med, Dept Pharmacol, Syracuse, NY 13210 USA; Univ Rochester, Sch Med & Dent, Dept Pharmacol, Rochester, NY 14642 USA	State University of New York (SUNY) System; State University of New York (SUNY) Upstate Medical Center; State University of New York (SUNY) System; State University of New York (SUNY) Upstate Medical Center; University of Rochester	Kelley, GG (corresponding author), SUNY Upstate Med, Dept Med, Syracuse, NY 13210 USA.	kelleyg@upstate.edu			NIDDK NIH HHS [DK56294, R29 DK049194, R01 DK056294, DK49194, R01 DK049194] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK056294, R29DK049194, R01DK049194] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Alzayady KJ, 2005, J BIOL CHEM, V280, P34530, DOI 10.1074/jbc.M508890200; ALZAYADY KJ, 2005, BIOCH J; BANNO Y, 1994, J BIOL CHEM, V269, P15846; Berk BC, 1997, CIRC RES, V80, P607, DOI 10.1161/01.RES.80.5.607; Berridge MJ, 2003, NAT REV MOL CELL BIO, V4, P517, DOI 10.1038/nrm1155; Bokkala S, 1997, J BIOL CHEM, V272, P12454, DOI 10.1074/jbc.272.19.12454; Brind S, 2000, DEV BIOL, V223, P251, DOI 10.1006/dbio.2000.9728; Brummelkamp TR, 2002, SCIENCE, V296, P550, DOI 10.1126/science.1068999; Cadwallader K, 1997, BIOCHEM J, V321, P795, DOI 10.1042/bj3210795; CHALLISS RAJ, 1991, J NEUROCHEM, V57, P1042, DOI 10.1111/j.1471-4159.1991.tb08255.x; Chun J, 2002, PHARMACOL REV, V54, P265, DOI 10.1124/pr.54.2.265; Daub H, 1996, NATURE, V379, P557, DOI 10.1038/379557a0; Daub H, 1997, EMBO J, V16, P7032, DOI 10.1093/emboj/16.23.7032; Duale H, 2005, EXP PHYSIOL, V90, P71, DOI 10.1113/expphysiol.2004.029173; Evellin S, 2002, J BIOL CHEM, V277, P16805, DOI 10.1074/jbc.M112024200; GUO Y, 2004, J BIOL CHEM; Hodgkin MN, 1998, TRENDS BIOCHEM SCI, V23, P200, DOI 10.1016/S0968-0004(98)01200-6; Jellerette T, 2000, DEV BIOL, V223, P238, DOI 10.1006/dbio.2000.9675; Kelley GG, 2004, BIOCHEM J, V378, P129, DOI 10.1042/BJ20031370; Kelley GG, 2001, EMBO J, V20, P743, DOI 10.1093/emboj/20.4.743; KELLEY GG, 2005, AFCS NATURE MOL PAGE, DOI DOI 10.1038/MP.A000046.000001; Kim YH, 1999, J BIOL CHEM, V274, P26127, DOI 10.1074/jbc.274.37.26127; KOUCHI Z, 2003, J BIOL CHEM; Kranenburg O, 2001, ONCOGENE, V20, P1540, DOI 10.1038/sj.onc.1204187; Lopez I, 2001, J BIOL CHEM, V276, P2758, DOI 10.1074/jbc.M008119200; Macfarlane SR, 2001, PHARMACOL REV, V53, P245; MACNULTY EE, 1990, BIOCHEM J, V272, P761, DOI 10.1042/bj2720761; MULDOON LL, 1989, J BIOL CHEM, V264, P8529; MULDOON LL, 1991, AM J PHYSIOL, V260, pC1273, DOI 10.1152/ajpcell.1991.260.6.C1273; MULDOON LL, 1988, J BIOL CHEM, V263, P18834; Oberdorf J, 1999, BIOCHEM J, V339, P453, DOI 10.1042/0264-6021:3390453; PLEVIN R, 1991, BIOCHEM J, V280, P609, DOI 10.1042/bj2800609; PLEVIN R, 1991, BIOCHEM SOC T, V19, pS100, DOI 10.1042/bst019100s; Prenzel N, 1999, NATURE, V402, P884, DOI 10.1038/47260; Rhee SG, 2001, ANNU REV BIOCHEM, V70, P281, DOI 10.1146/annurev.biochem.70.1.281; Riobo NA, 2005, TRENDS PHARMACOL SCI, V26, P146, DOI 10.1016/j.tips.2005.01.007; Sah VP, 2000, ANNU REV PHARMACOL, V40, P459, DOI 10.1146/annurev.pharmtox.40.1.459; Schmidt M, 2001, NAT CELL BIOL, V3, P1020, DOI 10.1038/ncb1101-1020; SEIFERT JP, 2004, J BIOL CHEM; Shears SB, 2004, BIOCHEM J, V377, P265, DOI 10.1042/BJ20031428; Song C, 2001, J BIOL CHEM, V276, P2752, DOI 10.1074/jbc.M008324200; Song CH, 2002, ONCOGENE, V21, P8105, DOI 10.1038/sj.onc.1206003; Sugden PH, 2003, J MOL CELL CARDIOL, V35, P871, DOI 10.1016/S0022-2828(03)00153-6; Ushio-Fukai M, 1998, J BIOL CHEM, V273, P19772, DOI 10.1074/jbc.273.31.19772; VANCORVEN EJ, 1993, P NATL ACAD SCI USA, V90, P1257, DOI 10.1073/pnas.90.4.1257; Vogt S, 2003, J BIOL CHEM, V278, P28743, DOI 10.1074/jbc.M304570200; Wing MR, 2001, J BIOL CHEM, V276, P48257, DOI 10.1074/jbc.C100574200; Wojcikiewicz RJH, 2004, TRENDS PHARMACOL SCI, V25, P35, DOI 10.1016/j.tips.2003.11.008; Wojcikiewicz RJH, 2003, J BIOL CHEM, V278, P940, DOI 10.1074/jbc.M206607200; WOJCIKIEWICZ RJH, 1994, J BIOL CHEM, V269, P7963; WOJCIKIEWICZ RJH, 1991, J BIOL CHEM, V266, P22234; Zhang JW, 1999, BIOCHEM J, V343, P541, DOI 10.1042/0264-6021:3430541; Zhu CC, 2000, BIOCHEM J, V348, P551, DOI 10.1042/0264-6021:3480551	53	64	69	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 3	2006	281	5					2639	2648		10.1074/jbc.M507681200	http://dx.doi.org/10.1074/jbc.M507681200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	006XT	16314422	hybrid, Green Accepted			2022-12-25	WOS:000234931800028
J	Rodriguez, M; Zoecklein, L; Gamez, JD; Pavelko, KD; Papke, LM; Nakane, S; Howe, C; Radhakrishnan, S; Hansen, MJ; David, CS; Warrington, AE; Pease, LR				Rodriguez, Moses; Zoecklein, Laurie; Gamez, Jeffrey D.; Pavelko, Kevin D.; Papke, Louisa M.; Nakane, Shunya; Howe, Charles; Radhakrishnan, Suresh; Hansen, Michael J.; David, Chella S.; Warrington, Arthur E.; Pease, Larry R.			STAT4-and STAT6-signaling molecules in a murine model of multiple sclerosis	FASEB JOURNAL			English	Article									[Rodriguez, Moses; Zoecklein, Laurie; Gamez, Jeffrey D.; Pavelko, Kevin D.; Papke, Louisa M.; Nakane, Shunya; Howe, Charles; Warrington, Arthur E.] Mayo Clin, Dept Neurol, Rochester, MN 55905 USA; [Rodriguez, Moses; Radhakrishnan, Suresh; Hansen, Michael J.; David, Chella S.; Pease, Larry R.] Mayo Clin, Dept Immunol, Rochester, MN 55905 USA	Mayo Clinic; Mayo Clinic	Rodriguez, M (corresponding author), Mayo Clin, Dept Neurol, 200 1st St SW, Rochester, MN 55905 USA.	rodriguez.moses@mayo.edu	Nakane, Shunya/AAF-3715-2022; Nakane, Shunya/AFB-9194-2022; Pavelko, Kevin D/K-7072-2019	Pavelko, Kevin D/0000-0001-7555-1315; Rodriguez, Moses/0000-0001-6328-6497; Howe, Charles/0000-0002-3889-8739	NINDS NIH HHS [R01-NS-32129, R01-NS-24180, P01-NS-38468] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS032129, R01NS024180, P01NS038468] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))			0	10	10	0	8	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	FEB	2006	20	2					343	345		10.1096/fj.05-4650fje	http://dx.doi.org/10.1096/fj.05-4650fje			3	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	V17CJ	16352646				2022-12-25	WOS:000207915000015
J	Mayeenuddin, LH; McIntire, WE; Garrison, JC				Mayeenuddin, LH; McIntire, WE; Garrison, JC			Differential sensitivity of P-Rex1 to isoforms of G protein beta gamma dimers	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEOTIDE EXCHANGE FACTOR; HETEROTRIMERIC G-PROTEINS; PHOSPHOINOSITIDE 3-KINASE; SUBUNIT COMPOSITION; TISSUE DISTRIBUTION; P115 RHOGEF; RECEPTOR; ACTIVATION; ADENOSINE; INHIBITION	P-Rex1 is a specific guanine nucleotide exchange factor (GEF) for Rac, which is present in high abundance in brain and hematopoietic cells. P-Rex1 is dually regulated by phosphatidylinositol ( 3,4,5)trisphosphate and the G beta gamma subunits of heterotrimeric G proteins. We examined which of the multiple G protein alpha and beta gamma subunits activate P-Rex1-mediated Rac guanine nucleotide exchange using pure, recombinant proteins reconstituted into synthetic lipid vesicles. AlF4- activated G(s), G(i), G(q), G(12), orG(13) alpha subunits were unable to activate P-Rex1. G beta gamma dimers containing G beta(1-4) complexed with gamma(2) stimulated P-Rex1 activity with EC50 values ranging from 10 to 20 nM. G beta(5)gamma(2) was not able to stimulate P-Rex1 GEF activity. Dimers containing the beta(1) subunit complexed with a panel of different G gamma subunits varied in their ability to stimulate P-Rex1. The beta 1 gamma 3,beta 1 gamma 7, beta 1 gamma(10), and beta 1 gamma(13HA) dimers all activated P-Rex1 with EC50 values ranging from 20 to 38 nM. Dimers composed of beta(1)gamma(12) had lower EC50 values (similar to 112 nM). The farnesylated gamma(11) subunit is highly expressed in hematopoietic cells; surprisingly, dimers containing this subunit (beta(1)gamma(11)) were also less effective at activating P-Rex1. These findings suggest that the composition of the G beta gamma dimer released by receptor activation may differentially activate P-Rex1.	Univ Virginia, Hlth Syst, Dept Pharmacol, Charlottesville, VA 22908 USA	University of Virginia	Mayeenuddin, LH (corresponding author), POB 800735, Charlottesville, VA 22908 USA.	lhm4n@virginia.edu			NCI NIH HHS [CA 40042] Funding Source: Medline; NIDDK NIH HHS [DK 19952] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK019952] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Akgoz M, 2002, J BIOL CHEM, V277, P19573, DOI 10.1074/jbc.M201546200; Bayewitch ML, 1998, J BIOL CHEM, V273, P2273, DOI 10.1074/jbc.273.4.2273; Blake BL, 2001, J BIOL CHEM, V276, P49267, DOI 10.1074/jbc.M106565200; Brock C, 2003, J CELL BIOL, V160, P89, DOI 10.1083/jcb.200210115; Cabrera-Vera TM, 2003, ENDOCR REV, V24, P765, DOI 10.1210/er.2000-0026; Cantley LC, 2002, SCIENCE, V296, P1655, DOI 10.1126/science.296.5573.1655; Clapham DE, 1997, ANNU REV PHARMACOL, V37, P167, DOI 10.1146/annurev.pharmtox.37.1.167; Diverse-Pierluissi M, 2000, J BIOL CHEM, V275, P28380, DOI 10.1074/jbc.M003571200; Donald S, 2004, FEBS LETT, V572, P172, DOI 10.1016/j.febslet.2004.06.096; Downes GB, 1999, GENOMICS, V62, P544, DOI 10.1006/geno.1999.5992; Fenteany G, 2004, CURR OPIN HEMATOL, V11, P15, DOI 10.1097/00062752-200401000-00004; Fletcher JE, 1998, J BIOL CHEM, V273, P636, DOI 10.1074/jbc.273.1.636; Fogg VC, 2001, J BIOL CHEM, V276, P41797, DOI 10.1074/jbc.M107661200; Fukuhara S, 2000, FEBS LETT, V485, P183, DOI 10.1016/S0014-5793(00)02224-9; Fukuhara S, 1999, J BIOL CHEM, V274, P5868, DOI 10.1074/jbc.274.9.5868; GRABER SG, 1992, J BIOL CHEM, V267, P1271; GRABER SG, 1992, J BIOL CHEM, V267, P13123; GRABER SG, 1996, METH NEUROSCI, V29, P207; GRUSSENMEYER T, 1985, P NATL ACAD SCI USA, V82, P7952, DOI 10.1073/pnas.82.23.7952; Hart MJ, 1998, SCIENCE, V280, P2112, DOI 10.1126/science.280.5372.2112; Hill K, 2005, J BIOL CHEM, V280, P4166, DOI 10.1074/jbc.M411262200; Hou YM, 2001, J BIOL CHEM, V276, P19982, DOI 10.1074/jbc.M010424200; Jones PG, 1998, BBA-MOL CELL RES, V1402, P288, DOI 10.1016/S0167-4889(98)00017-2; Kerchner KR, 2004, J BIOL CHEM, V279, P44554, DOI 10.1074/jbc.M406071200; Kozasa T, 1998, SCIENCE, V280, P2109, DOI 10.1126/science.280.5372.2109; KOZASA T, 1999, CRC METH SIG TRANS, P23; Krugmann S, 2002, BIOCHEM J, V362, P725, DOI 10.1042/0264-6021:3620725; Lei QB, 2000, P NATL ACAD SCI USA, V97, P9771, DOI 10.1073/pnas.97.17.9771; Leopoldt D, 1998, J BIOL CHEM, V273, P7024, DOI 10.1074/jbc.273.12.7024; Lim WK, 2001, BIOCHEMISTRY-US, V40, P10532, DOI 10.1021/bi010950c; Linden J, 2001, ANNU REV PHARMACOL, V41, P775, DOI 10.1146/annurev.pharmtox.41.1.775; Lindorfer MA, 1996, J BIOL CHEM, V271, P18582, DOI 10.1074/jbc.271.31.18582; Lindorfer MA, 1998, J BIOL CHEM, V273, P34429, DOI 10.1074/jbc.273.51.34429; Locati M, 1999, ANNU REV MED, V50, P425, DOI 10.1146/annurev.med.50.1.425; Maier U, 2000, J BIOL CHEM, V275, P13746, DOI 10.1074/jbc.275.18.13746; Maier U, 1999, J BIOL CHEM, V274, P29311, DOI 10.1074/jbc.274.41.29311; Mayeenuddin LH, 2006, J BIOL CHEM, V281, P1921, DOI 10.1074/jbc.M506035200; McIntire WE, 2001, J BIOL CHEM, V276, P15801, DOI 10.1074/jbc.M011233200; Morishita R, 1998, FEBS LETT, V428, P85, DOI 10.1016/S0014-5793(98)00498-0; MOTULSKY HJ, 1987, FASEB J, V1, P365, DOI 10.1096/fasebj.1.5.3315805; Myung CS, 1999, J BIOL CHEM, V274, P16595, DOI 10.1074/jbc.274.23.16595; Procko E, 2005, BIOESSAYS, V27, P153, DOI 10.1002/bies.20157; RAY K, 1995, J BIOL CHEM, V270, P21765, DOI 10.1074/jbc.270.37.21765; Richardson M, 1999, J BIOL CHEM, V274, P13525, DOI 10.1074/jbc.274.19.13525; Ridley AJ, 2001, FEBS LETT, V498, P168, DOI 10.1016/S0014-5793(01)02481-4; Rosenfeldt H, 2004, FEBS LETT, V572, P167, DOI 10.1016/j.febslet.2004.06.097; Schmidt A, 1998, ANNU REV CELL DEV BI, V14, P305, DOI 10.1146/annurev.cellbio.14.1.305; Siderovski DP, 1999, CRIT REV BIOCHEM MOL, V34, P215, DOI 10.1080/10409239991209273; Snow BE, 1998, P NATL ACAD SCI USA, V95, P13307, DOI 10.1073/pnas.95.22.13307; Snow BE, 1999, P NATL ACAD SCI USA, V96, P6489, DOI 10.1073/pnas.96.11.6489; Stephens LR, 1997, CELL, V89, P105, DOI 10.1016/S0092-8674(00)80187-7; Sullivan GW, 2001, BRIT J PHARMACOL, V132, P1017, DOI 10.1038/sj.bjp.0703893; Takai Y, 2001, PHYSIOL REV, V81, P153, DOI 10.1152/physrev.2001.81.1.153; Vanhaesebroeck B, 1999, EXP CELL RES, V253, P239, DOI 10.1006/excr.1999.4701; Weiner OD, 2002, CURR BIOL, V12, pR429, DOI 10.1016/S0960-9822(02)00917-X; Welch HCE, 2003, FEBS LETT, V546, P93, DOI 10.1016/S0014-5793(03)00454-X; Welch HCE, 2002, CELL, V108, P809, DOI 10.1016/S0092-8674(02)00663-3; Wenzel-Seifert K, 1999, J BIOL CHEM, V274, P33259, DOI 10.1074/jbc.274.47.33259; Wolfe JT, 2003, NATURE, V424, P209, DOI 10.1038/nature01772; Yasuda H, 1998, J BIOL CHEM, V273, P21958, DOI 10.1074/jbc.273.34.21958	60	33	33	0	1	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 27	2006	281	4					1913	1920		10.1074/jbc.M506034200	http://dx.doi.org/10.1074/jbc.M506034200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	004NV	16301321	hybrid			2022-12-25	WOS:000234760400009
J	Chen, SC; Chang, YC; Lin, CH; Lin, CH; Liaw, SH				Chen, SC; Chang, YC; Lin, CH; Lin, CH; Liaw, SH			Crystal structure of a bifunctional deaminase and reductase from Bacillus subtilis involved in riboflavin biosynthesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYTIDINE DEAMINASE; ESCHERICHIA-COLI; SACCHAROMYCES-CEREVISIAE; DIHYDROFOLATE-REDUCTASE; INSIGHTS; RESISTANCE; MECHANISM; SEQUENCE; PROGRAM; MUTANT	Bacterial RibG is an attractive candidate for development of antimicrobial drugs because of its involvement in the riboflavin biosynthesis. The crystal structure of Bacillus subtilis RibG at 2.41-angstrom resolution displayed a tetrameric ring-like structure with an extensive interface of similar to 2400 angstrom(2)/monomer. The N-terminal deaminase domain belongs to the cytidine deaminase superfamily. A structure-based sequence alignment of a variety of nucleotide deaminases reveals not only the unique signatures in each family member for gene annotation but also putative substrate-interacting residues for RNA-editing deaminases. The strong structural conservation between the C-terminal reductase domain and the pharmaceutically important dihydrofolate reductase suggests that the two reductases involved in the riboflavin and folate biosyntheses evolved from a single ancestral gene. Together with the binding of the essential cofactors, zinc ion and NADPH, the structural comparison assists substrate modeling into the active-site cavities allowing identification of specific substrate recognition. Finally, the present structure reveals that the deaminase and the reductase are separate functional domains and that domain fusion is crucial for the enzyme activities through formation of a stable tetrameric structure.	Natl Yang Ming Univ, Fac Life Sci, Taipei 11221, Taiwan; Natl Yang Ming Univ, Struct Biol Program, Taipei 11221, Taiwan; Natl Yang Ming Univ, Inst Biochem, Taipei 11221, Taiwan; Acad Sinica, Inst Biol Chem, Taipei 11529, Taiwan; Vet Gen Hosp, Dept Med Res & Educ, Taipei 11217, Taiwan	National Yang Ming Chiao Tung University; National Yang Ming Chiao Tung University; National Yang Ming Chiao Tung University; Academia Sinica - Taiwan	Liaw, SH (corresponding author), Natl Yang Ming Univ, Fac Life Sci, Taipei 11221, Taiwan.	shliaw@ym.edu.tw						Almog R, 2004, BIOCHEMISTRY-US, V43, P13715, DOI 10.1021/bi048928h; Bacher A, 2000, ANNU REV NUTR, V20, P153, DOI 10.1146/annurev.nutr.20.1.153; BAUR A, 1993, YEAST, V9, P289, DOI 10.1002/yea.320090308; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; BURROWS RB, 1978, J BACTERIOL, V136, P657, DOI 10.1128/JB.136.2.657-667.1978; Chenna R, 2003, NUCLEIC ACIDS RES, V31, P3497, DOI 10.1093/nar/gkg500; Dams T, 2000, J MOL BIOL, V297, P659, DOI 10.1006/jmbi.2000.3570; Dietmann S, 2001, NUCLEIC ACIDS RES, V29, P55, DOI 10.1093/nar/29.1.55; Elias Y, 2005, BIOCHEMISTRY-US, V44, P12057, DOI 10.1021/bi050499f; Esnouf RM, 1999, ACTA CRYSTALLOGR D, V55, P938, DOI 10.1107/S0907444998017363; FIERKE CA, 1987, BIOCHEMISTRY-US, V26, P4085, DOI 10.1021/bi00387a052; Fisher N, 2004, J BIOL CHEM, V279, P12951, DOI 10.1074/jbc.M313866200; Graupner M, 2002, J BACTERIOL, V184, P1952, DOI 10.1128/JB.184.7.1952-1957.2002; Harris RS, 2004, NAT REV IMMUNOL, V4, P868, DOI 10.1038/nri1489; Johansson E, 2002, BIOCHEMISTRY-US, V41, P2563, DOI 10.1021/bi011849a; Keegan LP, 2004, GENOME BIOL, V5, DOI 10.1186/gb-2004-5-2-209; Kelley LA, 2000, J MOL BIOL, V299, P499, DOI 10.1006/jmbi.2000.3741; Ko TP, 2003, J BIOL CHEM, V278, P19111, DOI 10.1074/jbc.M300874200; Kompis IM, 2005, CHEM REV, V105, P593, DOI 10.1021/cr0301144; Kuratani M, 2005, J BIOL CHEM, V280, P16002, DOI 10.1074/jbc.M414541200; Liaw SH, 2004, J BIOL CHEM, V279, P35479, DOI 10.1074/jbc.M405304200; Merritt EA, 1997, METHOD ENZYMOL, V277, P505, DOI 10.1016/S0076-6879(97)77028-9; Navaratnam N, 1998, J MOL BIOL, V275, P695, DOI 10.1006/jmbi.1997.1506; OLTMANNS O, 1972, J BACTERIOL, V110, P818, DOI 10.1128/JB.110.3.818-822.1972; Richter G, 1997, J BACTERIOL, V179, P2022, DOI 10.1128/jb.179.6.2022-2028.1997; ROUSSEL A, 1991, SILICON GRAPHICS GEO; Schaffer AA, 2001, NUCLEIC ACIDS RES, V29, P2994, DOI 10.1093/nar/29.14.2994; Schnell JR, 2004, ANNU REV BIOPH BIOM, V33, P119, DOI 10.1146/annurev.biophys.33.110502.133613; Schuck P, 2002, BIOPHYS J, V82, P1096, DOI 10.1016/S0006-3495(02)75469-6; Ta VT, 2003, NAT IMMUNOL, V4, P843, DOI 10.1038/ni964; Terwilliger TC, 2003, METHOD ENZYMOL, V374, P22, DOI 10.1016/S0076-6879(03)74002-6; WALLACE AC, 1995, PROTEIN ENG, V8, P127, DOI 10.1093/protein/8.2.127; Wang JW, 2004, ACTA CRYSTALLOGR D, V60, P1244, DOI 10.1107/S0907444904010674; Wolan DW, 2002, BIOCHEMISTRY-US, V41, P15505, DOI 10.1021/bi020505x; Xu HZ, 2004, P NATL ACAD SCI USA, V101, P5652, DOI 10.1073/pnas.0400830101; Yuvaniyama J, 2003, NAT STRUCT BIOL, V10, P357, DOI 10.1038/nsb921	36	27	28	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 17	2006	281	11					7605	7613		10.1074/jbc.M510254200	http://dx.doi.org/10.1074/jbc.M510254200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	022BY	16308316	hybrid, Green Submitted			2022-12-25	WOS:000236030900082
J	Balza, RO; Misra, RP				Balza, RO; Misra, RP			Role of the serum response factor in regulating contractile apparatus gene expression and sarcomeric integrity in cardiomyocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEAVY-CHAIN GENE; ALPHA-ACTIN GENE; SMOOTH-MUSCLE DIFFERENTIATION; EMBRYONIC STEM-CELLS; A/T-RICH ELEMENT; SKELETAL-MUSCLE; DILATED CARDIOMYOPATHY; MYOCARDIAL-INFARCTION; TRANSCRIPTION FACTORS; MOUSE EMBRYOGENESIS	The serum response factor (SRF) is a transcriptional regulator required for mesodermal development, including heart formation and function. Previous studies have described the role of SRF in controlling expression of structural genes involved in conferring the myogenic phenotype. Recent studies by us and others have demonstrated embryonic lethal cardiovascular phenotypes in SRF-null animals, but have not directly addressed the mechanistic role of SRF in controlling broad regulatory programs in cardiac cells. In this study, we used a loss-of-function approach to delineate the role of SRF in cardiomyocyte gene expression and function. In SRF-null neonatal cardiomyocytes, we observed severe defects in the contractile apparatus, including Z-disc and stress fiber formation, as well as mislocalization and/or attenuation of sarcomeric proteins. Consistent with this, gene array and reverse transcription-PCR analyses showed down-regulation of genes encoding key cardiac transcriptional regulatory factors and proteins required for the maintenance of sarcomeric structure, function, and regulation. Chromatin immunoprecipitation analysis revealed that at least a subset of these proteins are likely regulated directly by SRF. The results presented here indicate that SRF is an essential coordinator of cardiomyocyte function due to its ability to regulate expression of numerous genes ( some previously identified and at least 28 targets newly identified in this study) that are involved in multiple and disparate levels of sarcomeric function and assembly.	Med Coll Wisconsin, Dept Biochem, Milwaukee, WI 53226 USA	Medical College of Wisconsin	Misra, RP (corresponding author), Med Coll Wisconsin, Dept Biochem, 3701 W Watertown Plank Rd, Milwaukee, WI 53226 USA.	rmisra@mcw.edu			NHLBI NIH HHS [HL-62572] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL062572] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Alsan BH, 2002, DEVELOPMENT, V129, P1935; Arsenian S, 1998, EMBO J, V17, P6289, DOI 10.1093/emboj/17.21.6289; Baker DL, 1998, NUCLEIC ACIDS RES, V26, P1092, DOI 10.1093/nar/26.4.1092; Barron MR, 2005, J BIOL CHEM, V280, P11816, DOI 10.1074/jbc.M412408200; Belaguli NS, 2000, MOL CELL BIOL, V20, P7550, DOI 10.1128/MCB.20.20.7550-7558.2000; BERGSMA DJ, 1986, MOL CELL BIOL, V6, P2462, DOI 10.1128/MCB.6.7.2462; Brancaccio M, 2003, NAT MED, V9, P68, DOI 10.1038/nm805; Chang DF, 2003, DEV CELL, V4, P107, DOI 10.1016/S1534-5807(02)00396-9; Charron F, 1999, MOL CELL BIOL, V19, P4355; Charron F, 1999, SEMIN CELL DEV BIOL, V10, P85, DOI 10.1006/scdb.1998.0281; Chen CY, 1996, MOL CELL BIOL, V16, P6372; Chen JY, 2002, J MOL CELL CARDIOL, V34, P1345, DOI 10.1006/jmcc.2002.2086; Cheng GM, 1999, J BIOL CHEM, V274, P12819, DOI 10.1074/jbc.274.18.12819; Cripps RM, 2002, DEV BIOL, V246, P14, DOI 10.1006/dbio.2002.0666; Dabiri GA, 1997, P NATL ACAD SCI USA, V94, P9493, DOI 10.1073/pnas.94.17.9493; Eigenthaler M, 2003, AM J PHYSIOL-HEART C, V285, pH2471, DOI 10.1152/ajpheart.00362.2003; Ferrari S, 1997, CELL GROWTH DIFFER, V8, P23; Finsen AV, 2004, PHYSIOL GENOMICS, V16, P301, DOI 10.1152/physiolgenomics.00144.2002; Fisher SA, 1996, J MOL CELL CARDIOL, V28, P113, DOI 10.1006/jmcc.1996.0011; FOSTER DN, 1992, J BIOL CHEM, V267, P11995; GILGENKRANTZ H, 1992, J BIOL CHEM, V267, P10823; Heicklen-Klein A, 2004, DEV BIOL, V267, P490, DOI 10.1016/j.ydbio.2003.09.042; HEIM R, 1994, P NATL ACAD SCI USA, V91, P12501, DOI 10.1073/pnas.91.26.12501; HEIN J, 1990, METHOD ENZYMOL, V183, P626; Heineke J, 2005, P NATL ACAD SCI USA, V102, P1655, DOI 10.1073/pnas.0405488102; Hillis GS, 1998, HEART, V79, P429, DOI 10.1136/hrt.79.5.429; Hiroi Y, 2001, NAT GENET, V28, P276, DOI 10.1038/90123; Huang WY, 2000, NAT MED, V6, P482, DOI 10.1038/74914; Huang WY, 1997, BIOCHEM J, V327, P507, DOI 10.1042/bj3270507; JOHANSEN FE, 1995, BBA-REV CANCER, V1242, P1, DOI 10.1016/0304-419X(94)00014-S; Kim SJ, 1999, AM J PHYSIOL-HEART C, V276, pH1780, DOI 10.1152/ajpheart.1999.276.5.H1780; Kuisk IR, 1996, DEV BIOL, V174, P1, DOI 10.1006/dbio.1996.0046; Kumar A, 1997, P NATL ACAD SCI USA, V94, P4406, DOI 10.1073/pnas.94.9.4406; Landerholm TE, 1999, DEVELOPMENT, V126, P2053; Lange S, 2005, J MOL BIOL, V345, P289, DOI 10.1016/j.jmb.2004.10.040; Li SJ, 2005, P NATL ACAD SCI USA, V102, P1082, DOI 10.1073/pnas.0409103102; Lilly B, 2001, DEV BIOL, V240, P531, DOI 10.1006/dbio.2001.0507; Mericskay M, 2000, DEV BIOL, V226, P192, DOI 10.1006/dbio.2000.9865; Miano JM, 2004, P NATL ACAD SCI USA, V101, P17132, DOI 10.1073/pnas.0406041101; Miano JM, 2003, J MOL CELL CARDIOL, V35, P577, DOI 10.1016/S0022-2828(03)00110-X; Milner DJ, 1996, J CELL BIOL, V134, P1255, DOI 10.1083/jcb.134.5.1255; MINTY A, 1986, MOL CELL BIOL, V6, P2125, DOI 10.1128/MCB.6.6.2125; MISRA RP, 1991, MOL CELL BIOL, V11, P4545, DOI 10.1128/MCB.11.9.4545; Molkentin JD, 1996, J MOL CELL CARDIOL, V28, P1211, DOI 10.1006/jmcc.1996.0112; MOLKENTIN JD, 1994, MOL CELL BIOL, V14, P5056, DOI 10.1128/MCB.14.8.5056; MONCMAN CL, 1995, CELL MOTIL CYTOSKEL, V32, P205, DOI 10.1002/cm.970320305; Morkin E, 2000, MICROSC RES TECHNIQ, V50, P522, DOI 10.1002/1097-0029(20000915)50:6<522::AID-JEMT9>3.0.CO;2-U; MUTHUCHAMY M, 1993, MOL CELL BIOL, V13, P3311, DOI 10.1128/MCB.13.6.3311; Muthuchamy M, 1995, J BIOL CHEM, V270, P30593, DOI 10.1074/jbc.270.51.30593; Nakamura M, 2001, J BIOL CHEM, V276, P18313, DOI 10.1074/jbc.M101127200; Nelson TJ, 2005, J MOL CELL CARDIOL, V39, P479, DOI 10.1016/j.yjmcc.2005.05.004; Niu Z, 2005, J BIOL CHEM, V280, P32531, DOI 10.1074/jbc.M501372200; Parlakian A, 2004, MOL CELL BIOL, V24, P5281, DOI 10.1128/MCB.24.12.5281-5289.2004; PARMACEK MS, 1989, J BIOL CHEM, V264, P13217; Philippar U, 2004, MOL CELL, V16, P867, DOI 10.1016/j.molcel.2004.11.039; Ramanan N, 2005, NAT NEUROSCI, V8, P759, DOI 10.1038/nn1462; Reinhold MI, 2004, J BIOL CHEM, V279, P38209, DOI 10.1074/jbc.M404855200; Schratt G, 2002, J CELL BIOL, V156, P737, DOI 10.1083/jcb.200106008; Schratt G, 2001, MOL CELL BIOL, V21, P2933, DOI 10.1128/MCB.21.8.2933-2943.2001; Selvaraj A, 2004, BMC MOL BIOL, V5, DOI 10.1186/1471-2199-5-13; Shin CH, 2002, CELL, V110, P725, DOI 10.1016/S0092-8674(02)00933-9; Skerjanc IS, 1998, J BIOL CHEM, V273, P34904, DOI 10.1074/jbc.273.52.34904; SOLWAY J, 1995, J BIOL CHEM, V270, P13460, DOI 10.1074/jbc.270.22.13460; Soonpaa MH, 1998, CIRC RES, V83, P15, DOI 10.1161/01.RES.83.1.15; Spencer JA, 1996, J BIOL CHEM, V271, P16535, DOI 10.1074/jbc.271.28.16535; SPRENKLE AB, 1995, CIRC RES, V77, P1060, DOI 10.1161/01.RES.77.6.1060; Sugiura S, 1998, JPN J PHYSIOL, V48, P173, DOI 10.2170/jjphysiol.48.173; Sun GF, 2004, J CELL BIOCHEM, V92, P189, DOI 10.1002/jcb.20039; THUERAUF DJ, 1994, J BIOL CHEM, V269, P17772; TREISMAN R, 1995, EMBO J, V14, P4905, DOI 10.1002/j.1460-2075.1995.tb00173.x; Vickers ER, 2004, MOL CELL BIOL, V24, P10340, DOI 10.1128/MCB.24.23.10340-10351.2004; Vyas DR, 1999, J BIOL CHEM, V274, P30832, DOI 10.1074/jbc.274.43.30832; Wang DZ, 2001, CELL, V105, P851, DOI 10.1016/S0092-8674(01)00404-4; Watson DK, 1997, ONCOGENE, V14, P213, DOI 10.1038/sj.onc.1200839; Watt AJ, 2004, P NATL ACAD SCI USA, V101, P12573, DOI 10.1073/pnas.0400752101; Zhang JCL, 2001, MOL CELL BIOL, V21, P1336, DOI 10.1128/MCB.2001.21.4.1336-1344.2001; Zhang SX, 2005, J BIOL CHEM, V280, P19115, DOI 10.1074/jbc.M413793200; Zhang XM, 2001, AM J PHYSIOL-HEART C, V280, pH1782, DOI 10.1152/ajpheart.2001.280.4.H1782; Zhu XL, 2003, ANAT REC PART A, V271A, P315, DOI 10.1002/ar.a.10032	79	78	80	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 10	2006	281	10					6498	6510		10.1074/jbc.M509487200	http://dx.doi.org/10.1074/jbc.M509487200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	022BX	16368687	hybrid			2022-12-25	WOS:000236030800045
J	Lu, XF; Wang, MH; Qi, J; Wang, HT; Li, XN; Gupta, D; Dziarski, R				Lu, XF; Wang, MH; Qi, J; Wang, HT; Li, XN; Gupta, D; Dziarski, R			Peptidoglycan recognition proteins are a new class of human bactericidal proteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GRAM-POSITIVE BACTERIA; L-ALANINE AMIDASE; ANTIMICROBIAL PEPTIDES; HUMAN SKIN; STAPHYLOCOCCUS-AUREUS; INNATE IMMUNITY; DROSOPHILA-MELANOGASTER; ESCHERICHIA-COLI; INFECTION; RECEPTOR	Skin and mucous membranes come in contact with external environment and protect tissues from infections by producing antimicrobial peptides. We report that human peptidoglycan recognition proteins 3 and 4 (PGLYRP3 and PGLYRP4) are secreted as 89-115-kDa disulfide-linked homo- and heterodimers and are bactericidal against several pathogenic and nonpathogenic transient, but not normal flora, Gram-positive bacteria. PGLYRP3 and PGLYRP4 are also bacteriostatic toward all other tested bacteria, which include Gram-negative bacteria and normal flora Gram-positive bacteria. PGLYRP3 and PGLYRP4 are also active in vivo and protect mice against experimental lung infection. In contrast to antimicrobial peptides, PGLYRPs kill bacteria by interacting with their cell wall peptidoglycan, rather than permeabilizing their membranes. PGLYRP3 and PGLYRP4 are expressed in the skin, eyes, salivary glands, throat, tongue, esophagus, stomach, and intestine. Thus, we have identified the function of mammalian PGLYRP3 and PGLYRP4, and show that they are a new class of bactericidal and bacteriostatic proteins that have different structures, mechanism of actions, and expression patterns than antimicrobial peptides.	Indiana Univ, Sch Med NW, Gary, IN 46408 USA	Indiana University System; Indiana University Northwest	Dziarski, R (corresponding author), Indiana Univ, Sch Med NW, Gary, IN 46408 USA.	rdziar@iun.edu			NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [U01AI056395] Funding Source: NIH RePORTER; NIAID NIH HHS [AI 2879, AI 56395] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Bischoff V, 2004, NAT IMMUNOL, V5, P1175, DOI 10.1038/ni1123; Brogden KA, 2005, NAT REV MICROBIOL, V3, P238, DOI 10.1038/nrmicro1098; Brotz H, 1997, EUR J BIOCHEM, V246, P193, DOI 10.1111/j.1432-1033.1997.t01-1-00193.x; Chang CI, 2004, PLOS BIOL, V2, P1293, DOI 10.1371/journal.pbio.0020277; CHEN HC, 1988, FEBS LETT, V236, P462, DOI 10.1016/0014-5793(88)80077-2; Cho JH, 2005, BLOOD, V106, P2551, DOI 10.1182/blood-2005-02-0530; Choe KM, 2002, SCIENCE, V296, P359, DOI 10.1126/science.1070216; Christophides GK, 2002, SCIENCE, V298, P159, DOI 10.1126/science.1077136; Dziarski R, 2005, INFECT IMMUN, V73, P5212, DOI 10.1128/IAI.73.8.5212-5216.2005; Dziarski R, 2003, BLOOD, V102, P689, DOI 10.1182/blood-2002-12-3853; Dziarski R, 2004, MOL IMMUNOL, V40, P877, DOI 10.1016/j.molimm.2003.10.011; ERLANDSEN SL, 1974, J HISTOCHEM CYTOCHEM, V22, P401, DOI 10.1177/22.6.401; Ganz T, 2003, NAT REV IMMUNOL, V3, P710, DOI 10.1038/nri1180; Gelius E, 2003, BIOCHEM BIOPH RES CO, V306, P988, DOI 10.1016/S0006-291X(03)01096-9; Glaser R, 2005, NAT IMMUNOL, V6, P57, DOI 10.1038/ni1142; Gottar M, 2002, NATURE, V416, P640, DOI 10.1038/nature734; GOTZ F, 1981, J BACTERIOL, V145, P74; Guan RJ, 2004, P NATL ACAD SCI USA, V101, P17168, DOI 10.1073/pnas.0407856101; Harder J, 2002, J BIOL CHEM, V277, P46779, DOI 10.1074/jbc.M207587200; Harder J, 2001, J BIOL CHEM, V276, P5707, DOI 10.1074/jbc.M008557200; Harder J, 1997, NATURE, V387, P861, DOI 10.1038/43088; HARWIG SSL, 1995, J CLIN INVEST, V95, P603, DOI 10.1172/JCI117704; Hornef MW, 2004, NAT IMMUNOL, V5, P836, DOI 10.1038/ni1094; JACOBSON ED, 1975, J BACTERIOL, V124, P445, DOI 10.1128/JB.124.1.445-448.1975; Kang DW, 1998, P NATL ACAD SCI USA, V95, P10078, DOI 10.1073/pnas.95.17.10078; Kim MS, 2003, NAT IMMUNOL, V4, P787, DOI 10.1038/ni952; Lehrer RI, 2004, NAT REV MICROBIOL, V2, P727, DOI 10.1038/nrmicro976; Leulier F, 2003, NAT IMMUNOL, V4, P478, DOI 10.1038/ni922; Liu C, 2000, J BIOL CHEM, V275, P24490, DOI 10.1074/jbc.M001239200; Liu C, 2001, J BIOL CHEM, V276, P34686, DOI 10.1074/jbc.M105566200; Mathur P, 2004, GENOMICS, V83, P1151, DOI 10.1016/j.ygeno.2004.01.003; Mellroth P, 2003, J BIOL CHEM, V278, P7059, DOI 10.1074/jbc.M208900200; Michel T, 2001, NATURE, V414, P756, DOI 10.1038/414756a; Nekhotiaeva N, 2003, FASEB J, V17, P394, DOI 10.1096/fj.03-0449fje; Nizet V, 2001, NATURE, V414, P454, DOI 10.1038/35106587; Ramet M, 2002, NATURE, V416, P644, DOI 10.1038/nature735; ROSENTHAL RS, 1994, METHOD ENZYMOL, V235, P253; SCHAEFFER P, 1965, P NATL ACAD SCI USA, V54, P704, DOI 10.1073/pnas.54.3.704; Schittek B, 2001, NAT IMMUNOL, V2, P1133, DOI 10.1038/ni732; SINHA RK, 1968, J BACTERIOL, V96, P374, DOI 10.1128/JB.96.2.374-382.1968; Takehana A, 2004, EMBO J, V23, P4690, DOI 10.1038/sj.emboj.7600466; Tydell CC, 2002, J BIOL CHEM, V277, P19658, DOI 10.1074/jbc.M200659200; Wang ZM, 2000, J BIOL CHEM, V275, P20260, DOI 10.1074/jbc.M909168199; Wang ZM, 2003, J BIOL CHEM, V278, P49044, DOI 10.1074/jbc.M307758200; Werner T, 2000, P NATL ACAD SCI USA, V97, P13772, DOI 10.1073/pnas.97.25.13772; Wiedow O, 1998, BIOCHEM BIOPH RES CO, V248, P904, DOI 10.1006/bbrc.1998.9069; Wingens M, 1998, J INVEST DERMATOL, V111, P996, DOI 10.1046/j.1523-1747.1998.00425.x; Yoshida H, 1996, J BIOL CHEM, V271, P13854, DOI 10.1074/jbc.271.23.13854; Zasloff M, 2002, NATURE, V415, P389, DOI 10.1038/415389a; ZEIGER AR, 1982, INFECT IMMUN, V37, P1112, DOI 10.1128/IAI.37.3.1112-1118.1982; Zhang YO, 2005, BBA-PROTEINS PROTEOM, V1752, P34, DOI 10.1016/j.bbapap.2005.07.001	51	169	201	0	16	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 3	2006	281	9					5895	5907		10.1074/jbc.M511631200	http://dx.doi.org/10.1074/jbc.M511631200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	015RQ	16354652	hybrid			2022-12-25	WOS:000235568900070
J	Mitchell, JE; Cvetanovic, M; Tibrewal, N; Patel, V; Colamonici, OR; Li, MO; Flavell, RA; Levine, JS; Birge, RB; Ucker, DS				Mitchell, JE; Cvetanovic, M; Tibrewal, N; Patel, V; Colamonici, OR; Li, MO; Flavell, RA; Levine, JS; Birge, RB; Ucker, DS			The presumptive phosphatidylserine receptor is dispensable for innate anti-inflammatory recognition and clearance of apoptotic cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MICE LACKING; C-ELEGANS; PHAGOCYTOSIS; ENGULFMENT; ACTIVATION; REMOVAL; CORPSES; PROTEIN; LYMPHOCYTES; MACROPHAGES	The role of the presumptive phosphatidylserine receptor (PSR) in the recognition and engulfment of apoptotic cells, and the antiinflammatory response they exert, has been of great interest. Genetic deficiency of PSR in the mouse is lethal perinatally, and results to date have been ambiguous with regard to the phagocytic and inflammatory phenotypes associated with that deficiency. Recently, we found that the specific functional recognition of apoptotic cells is a ubiquitous property of virtually all cell types, including mouse embryo fibroblasts, and reflects an innate immunity that discriminates live from effete cells. Taking advantage of this property of fibroblasts, we generated PSR+/+, PSR+/-, and PSR-/- fibroblast cell lines to examine definitively the involvement of PSR in apoptotic recognition and inflammatory modulation. Our data demonstrate that PSR-deficient cells are fully competent to recognize, engulf, and respond to apoptotic cells. Signal transduction in the responder cells, including the activation of Akt and Rac1, is unimpaired in the absence of PSR. We confirm as well that PSR is localized predominantly to the nucleus. However, it does not play a role in pro-inflammatory transcription or in the anti-inflammatory modulation of that transcriptional response triggered by apoptotic cells. We conclude that PSR is not involved generally in either specific innate recognition or engulfment of apoptotic cells.	Univ Illinois, Coll Med, Dept Microbiol & Immunol, Chicago, IL 60612 USA; Univ Illinois, Coll Med, Dept Med, Nephrol Sect, Chicago, IL 60612 USA; Univ Illinois, Coll Med, Dept Pharmacol, Chicago, IL 60612 USA; Univ Med & Dent New Jersey, New Jersey Med Sch, Dept Biochem & Mol Biol, Newark, NJ 07214 USA; Yale Univ, Sch Med, Howard Hughes Med Inst, Immunobiol Sect, New Haven, CT 06520 USA	University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; Rutgers State University New Brunswick; Rutgers State University Medical Center; Howard Hughes Medical Institute; Yale University	Ucker, DS (corresponding author), Univ Illinois, Coll Med, Dept Microbiol & Immunol MC 790, 835 S Wolcott, Chicago, IL 60612 USA.	duck@uic.edu	Cvetanovic, Marija/B-8907-2016	li, ming/0000-0002-1383-0535	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK059793] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R21AG024234] Funding Source: NIH RePORTER; NIA NIH HHS [AG 024234] Funding Source: Medline; NIDDK NIH HHS [DK 59793] Funding Source: Medline; NIGMS NIH HHS [GM 55760] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Akakura S, 2004, EXP CELL RES, V292, P403, DOI 10.1016/j.yexcr.2003.09.011; Albert ML, 2000, NAT CELL BIOL, V2, P899, DOI 10.1038/35046549; AUSTYN JM, 1981, EUR J IMMUNOL, V11, P805, DOI 10.1002/eji.1830111013; BOSE J, 2004, J BIOL LONDON, V3, pNIL5; Chang SH, 2002, EXP CELL RES, V277, P15, DOI 10.1006/excr.2002.5539; Chung SB, 2000, NAT CELL BIOL, V2, P931, DOI 10.1038/35046585; Cikala M, 2004, BMC CELL BIOL, V5, DOI 10.1186/1471-2121-5-26; Clissold PM, 2001, TRENDS BIOCHEM SCI, V26, P7, DOI 10.1016/S0968-0004(00)01700-X; Cocco RE, 2001, MOL BIOL CELL, V12, P919, DOI 10.1091/mbc.12.4.919; Cohen PL, 2002, J EXP MED, V196, P135, DOI 10.1084/jem.20012094; Cui P, 2004, EXP CELL RES, V293, P154, DOI 10.1016/j.yexcr.2003.09.023; Cvetanovic M, 2004, J IMMUNOL, V172, P880, DOI 10.4049/jimmunol.172.2.880; ELLIS RE, 1991, GENETICS, V129, P79; Fadok VA, 2000, NATURE, V405, P85, DOI 10.1038/35011084; FADOK VA, 1992, J IMMUNOL, V148, P2207; Fadok VA, 1998, J IMMUNOL, V161, P6250; Gumienny TL, 2001, CELL DEATH DIFFER, V8, P564, DOI 10.1038/sj.cdd.4400850; Hanayama R, 2004, SCIENCE, V304, P1147, DOI 10.1126/science.1094359; Harvey KJ, 2001, CYTOMETRY, V43, P273, DOI 10.1002/1097-0320(20010401)43:4<273::AID-CYTO1059>3.0.CO;2-3; Hoffmann PR, 2001, J CELL BIOL, V155, P649, DOI 10.1083/jcb.200108080; Hogue MJ, 1919, J EXP MED, V30, P617, DOI 10.1084/jem.30.6.617; Hong JR, 2004, DEVELOPMENT, V131, P5417, DOI 10.1242/dev.01409; KERR JFR, 1972, BRIT J CANCER, V26, P239, DOI 10.1038/bjc.1972.33; Kinchen JM, 2005, NATURE, V434, P93, DOI 10.1038/nature03263; Kunisaki Y, 2004, BLOOD, V103, P3362, DOI 10.1182/blood-2003-09-3245; Li MO, 2003, SCIENCE, V302, P1560, DOI 10.1126/science.1087621; MCEVOY L, 1986, P NATL ACAD SCI USA, V83, P3311, DOI 10.1073/pnas.83.10.3311; Patel VA, 2006, J BIOL CHEM, V281, P4663, DOI 10.1074/jbc.M508342200; Pradhan D, 1997, MOL BIOL CELL, V8, P767, DOI 10.1091/mbc.8.5.767; Reddien PW, 2000, NAT CELL BIOL, V2, P131, DOI 10.1038/35004000; Reddy SM, 2002, J IMMUNOL, V169, P702, DOI 10.4049/jimmunol.169.2.702; SCHROIT AJ, 1985, J BIOL CHEM, V260, P5131; TODARO GJ, 1963, J CELL BIOL, V17, P299, DOI 10.1083/jcb.17.2.299; Wang XC, 2003, SCIENCE, V302, P1563, DOI 10.1126/science.1087641	34	54	57	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 3	2006	281	9					5718	5725		10.1074/jbc.M509775200	http://dx.doi.org/10.1074/jbc.M509775200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	015RQ	16317002	hybrid			2022-12-25	WOS:000235568900049
J	Patel, A; Shuman, S; Mondragon, A				Patel, A; Shuman, S; Mondragon, A			Crystal structure of a bacterial type IB DNA topoisomerase reveals a preassembled active site in the absence of DNA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FUNCTION PHASE REFINEMENT; VACCINIA TOPOISOMERASE; CATALYTIC MECHANISM; MUTATIONAL ANALYSIS; COVALENT CATALYSIS; RECOMBINATION SYNAPSE; LAMBDA-INTEGRASE; DIFFRACTION DATA; PROTEIN CLAMP; SV40 DNA	Type IB DNA topoisomerases are found in all eukarya, two families of eukaryotic viruses (poxviruses and mimivirus), and many genera of bacteria. They alter DNA topology by cleaving and resealing one strand of duplex DNA via a covalent DNA-(3-phosphotyrosyl)enzyme intermediate. Bacterial type IB enzymes were discovered recently and are described as poxvirus-like with respect to their small size, primary structures, and bipartite domain organization. Here we report the 1.75-angstrom crystal structure of Deinococcus radiodurans topoisomerase IB (DraTopIB), a prototype of the bacterial clade. DraTopIB consists of an amino-terminal (N) beta-sheet domain (amino acids 1-90) and a predominantly alpha-helical carboxyl-terminal (C) domain (amino acids 91-346) that closely resemble the corresponding domains of vaccinia virus topoisomerase IB. The five amino acids of DraTopIB that comprise the catalytic pentad (Arg-137, Lys-174, Arg-239, Asn-280, and Tyr-289) are preassembled into the active site in the absence of DNA in a manner nearly identical to the pentad configuration in human topoisomerase I bound to DNA. This contrasts with the apoenzyme of vaccinia topoisomerase, in which three of the active site constituents are either displaced or disordered. The N and C domains of DraTopIB are splayed apart in an "open" conformation, in which the surface of the catalytic domain containing the active site is exposed for DNA binding. A comparison with the human topoisomerase I-DNA cocrystal structure suggests how viral and bacterial topoisomerase IB enzymes might bind DNA circumferentially via movement of the N domain into the major groove and clamping of a disordered loop of the C domain around the helix.	Northwestern Univ, Dept Biochem Mol Biol & Cell Biol, Evanston, IL 60208 USA; Sloan Kettering Inst, Program Mol Biol, New York, NY 10021 USA	Northwestern University; Memorial Sloan Kettering Cancer Center	Mondragon, A (corresponding author), Northwestern Univ, Dept Biochem Mol Biol & Cell Biol, 2205 Tech Dr, Evanston, IL 60208 USA.	a-mondragon@northwestern.edu			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM051350] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM 51350, R01 GM051350] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Abrahams JP, 1996, ACTA CRYSTALLOGR D, V52, P30, DOI 10.1107/S0907444995008754; Aihara H, 2003, MOL CELL, V12, P187, DOI 10.1016/S1097-2765(03)00268-5; BEEN MD, 1984, NUCLEIC ACIDS RES, V12, P3097, DOI 10.1093/nar/12.7.3097; Benarroch D, 2006, J VIROL, V80, P314, DOI 10.1128/JVI.80.1.314-321.2006; Carey JF, 2003, P NATL ACAD SCI USA, V100, P5640, DOI 10.1073/pnas.1031537100; Champoux JJ, 2001, ANNU REV BIOCHEM, V70, P369, DOI 10.1146/annurev.biochem.70.1.369; Cheng CH, 1998, CELL, V92, P841, DOI 10.1016/S0092-8674(00)81411-7; Cheng CH, 1998, J BIOL CHEM, V273, P11589, DOI 10.1074/jbc.273.19.11589; Cheng CH, 1997, J BIOL CHEM, V272, P8263, DOI 10.1074/jbc.272.13.8263; Chrencik JE, 2004, J MOL BIOL, V339, P773, DOI 10.1016/j.jmb.2004.03.007; Collaborative Computational Project, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI DOI 10.1107/S0907444994003112; Corbett KD, 2004, ANNU REV BIOPH BIOM, V33, P95, DOI 10.1146/annurev.biophys.33.110502.140357; Cowtan K., 1994, JOINT CCP4 ESF EACBM, V31, P34; delaFortelle E, 1997, METHOD ENZYMOL, V276, P472, DOI 10.1016/S0076-6879(97)76073-7; DeLano WL, 2002, PYMOL USERS MANUAL; DETITTA GT, 1994, ACTA CRYSTALLOGR A, V50, P203, DOI 10.1107/S0108767393008980; Diederichs K, 1997, NAT STRUCT BIOL, V4, P269, DOI 10.1038/nsb0497-269; EDWARDS KA, 1982, NUCLEIC ACIDS RES, V10, P2565, DOI 10.1093/nar/10.8.2565; Gopaul DN, 1998, EMBO J, V17, P4175, DOI 10.1093/emboj/17.14.4175; Guo F, 1999, P NATL ACAD SCI USA, V96, P7143, DOI 10.1073/pnas.96.13.7143; Guo F, 1997, NATURE, V389, P40, DOI 10.1038/37925; Hickman AB, 1997, CELL, V89, P227, DOI 10.1016/S0092-8674(00)80202-0; HOLM L, 1993, J MOL BIOL, V233, P123, DOI 10.1006/jmbi.1993.1489; Interthal H, 2004, J BIOL CHEM, V279, P2984, DOI 10.1074/jbc.M309959200; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KABSCH W, 1993, J APPL CRYSTALLOGR, V26, P795, DOI 10.1107/S0021889893005588; Koster DA, 2005, NATURE, V434, P671, DOI 10.1038/nature03395; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; Krissinel E, 2004, ACTA CRYSTALLOGR D, V60, P2256, DOI 10.1107/S0907444904026460; Krogh BO, 2000, MOL CELL, V5, P1035, DOI 10.1016/S1097-2765(00)80268-3; Krogh BO, 2002, P NATL ACAD SCI USA, V99, P1853, DOI 10.1073/pnas.032613199; Krogh BO, 2002, J BIOL CHEM, V277, P5711, DOI 10.1074/jbc.C100681200; Krogh BO, 2001, J BIOL CHEM, V276, P36091, DOI 10.1074/jbc.M102609200; Kwon HJ, 1997, SCIENCE, V276, P126, DOI 10.1126/science.276.5309.126; MERRITT EA, 1994, ACTA CRYSTALLOGR D, V50, P869, DOI 10.1107/S0907444994006396; MORHAM SG, 1992, J BIOL CHEM, V267, P15984; Murshudov GN, 1997, ACTA CRYSTALLOGR D, V53, P240, DOI 10.1107/S0907444996012255; MURZIN AG, 1995, J MOL BIOL, V247, P536, DOI 10.1006/jmbi.1995.0159; Perrakis A, 1999, NAT STRUCT BIOL, V6, P458, DOI 10.1038/8263; Petersen BO, 1997, J BIOL CHEM, V272, P3891, DOI 10.1074/jbc.272.7.3891; Redinbo Matthew R., 1999, Current Opinion in Structural Biology, V9, P29, DOI 10.1016/S0959-440X(99)80005-0; Redinbo MR, 1998, SCIENCE, V279, P1504, DOI 10.1126/science.279.5356.1504; Redinbo MR, 2000, BIOCHEMISTRY-US, V39, P6832, DOI 10.1021/bi992690t; SEKIGUCHI J, 1994, NUCLEIC ACIDS RES, V22, P5360, DOI 10.1093/nar/22.24.5360; Sekiguchi J, 1996, EMBO J, V15, P3448, DOI 10.1002/j.1460-2075.1996.tb00711.x; SEKIGUCHI J, 1995, J BIOL CHEM, V270, P11636, DOI 10.1074/jbc.270.19.11636; SEKIGUCHI J, 1994, J BIOL CHEM, V269, P31731; Sekiguchi J, 1997, NUCLEIC ACIDS RES, V25, P3649, DOI 10.1093/nar/25.18.3649; SHARMA A, 1994, STRUCTURE, V2, P767, DOI 10.1016/S0969-2126(94)00077-8; Shuman S, 1998, BBA-GENE STRUCT EXPR, V1400, P321, DOI 10.1016/S0167-4781(98)00144-4; SHUMAN S, 1990, J BIOL CHEM, V265, P17826; Staker BL, 2005, J MED CHEM, V48, P2336, DOI 10.1021/jm049146p; Stivers JT, 2000, BIOCHEMISTRY-US, V39, P5561, DOI 10.1021/bi992429c; STIVERS JT, 1994, BIOCHEMISTRY-US, V33, P327, DOI 10.1021/bi00167a043; Subramanya HS, 1997, EMBO J, V16, P5178, DOI 10.1093/emboj/16.17.5178; Tian LG, 2005, STRUCTURE, V13, P513, DOI 10.1016/j.str.2005.02.001; Tian LG, 2004, J BIOL CHEM, V279, P39718, DOI 10.1074/jbc.M407376200; Tian LG, 2004, STRUCTURE, V12, P31, DOI 10.1016/j.str.2003.11.025; Tian LG, 2003, MOL CELL, V12, P199, DOI 10.1016/S1097-2765(03)00263-6; VANDUYNE GD, 1993, J MOL BIOL, V229, P105, DOI 10.1006/jmbi.1993.1012; WEEKS CM, 1994, ACTA CRYSTALLOGR A, V50, P210, DOI 10.1107/S0108767393008992; WITTSCHIEBEN J, 1994, J BIOL CHEM, V269, P29978; Wittschieben J, 1997, NUCLEIC ACIDS RES, V25, P3001, DOI 10.1093/nar/25.15.3001; Woo MH, 2003, P NATL ACAD SCI USA, V100, P13767, DOI 10.1073/pnas.2235886100; Yang Z, 2001, J BIOL CHEM, V276, P677, DOI 10.1074/jbc.M007593200; Zhang HL, 2001, P NATL ACAD SCI USA, V98, P10608, DOI 10.1073/pnas.191321998	66	22	23	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 3	2006	281	9					6030	6037		10.1074/jbc.M512332200	http://dx.doi.org/10.1074/jbc.M512332200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	015RQ	16368685	hybrid			2022-12-25	WOS:000235568900084
J	von Wronski, MA; Raju, N; Pillai, R; Bogdan, NJ; Marinelli, ER; Nanjappan, P; Ramalingam, K; Arunachalam, T; Eaton, S; Linder, KE; Yan, F; Pochon, S; Tweedle, MF; Nunn, AD				von Wronski, MA; Raju, N; Pillai, R; Bogdan, NJ; Marinelli, ER; Nanjappan, P; Ramalingam, K; Arunachalam, T; Eaton, S; Linder, KE; Yan, F; Pochon, S; Tweedle, MF; Nunn, AD			Tuftsin binds neuropilin-1 through a sequence similar to that encoded by exon 8 of vascular endothelial growth factor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FACTOR VEGF; TUMOR-CELLS; 7-ENCODED DOMAIN; IN-VIVO; RECEPTORS; VEGF(165); PEPTIDE; EXPRESSION; ANGIOGENESIS; REGENERATION	Tuftsin, Thr-Lys-Pro-Arg (TKPR), is an immunostimulatory peptide with reported nervous system effects as well. We unexpectedly found that tuftsin and a higher affinity antagonist, TKPPR, bind selectively to neuropilin- 1 and block vascular endothelial growth factor ( VEGF) binding to that receptor. Dimeric and tetrameric forms of TKPPR had greatly increased affinity for neuropilin-1 based on competition binding experiments. On endothelial cells tetrameric TKPPR inhibited the VEGF(165)-induced autophosphorylation of vascular endothelial growth factor receptor-2 (VEGFR-2) even though it did not directly inhibit VEGF binding to VEGFR-2. Homology between exon 8 of VEGF and TKPPR suggests that the sequence coded for by exon 8 may stabilize VEGF binding to neuropilin- 1 to facilitate signaling through VEGFR-2. Given the overlap between processes involving neuropilin- 1 and tuftsin, we propose that at least some of the previously reported effects of tuftsin are mediated through neuropilin- 1.	Bracco Res USA, Ernst Felder Labs, Princeton, NJ 08540 USA; Bracco Res SA, CH-1228 Geneva, Switzerland	Bracco; Bracco	von Wronski, MA (corresponding author), Bracco Res USA, Ernst Felder Labs, 305 Coll Rd E, Princeton, NJ 08540 USA.	mvonwron@bru.bracco.com	Tweedle, Michael/E-4221-2011					Akimov SS, 2001, BLOOD, V98, P1567, DOI 10.1182/blood.V98.5.1567; Barr MP, 2005, BRIT J CANCER, V92, P328, DOI 10.1038/sj.bjc.6602308; Bates DO, 2002, CANCER RES, V62, P4123; Beck LH, 2004, DIFFERENTIATION, V72, P162, DOI 10.1111/j.1432-0436.2004.07204004.x; BIKFALVI A, 1991, J CELL PHYSIOL, V149, P50, DOI 10.1002/jcp.1041490108; Castro-Rivera E, 2004, P NATL ACAD SCI USA, V101, P11432, DOI 10.1073/pnas.0403969101; Caveliers V, 2001, J NUCL MED, V42, P154; Fesus L, 2002, TRENDS BIOCHEM SCI, V27, P534, DOI 10.1016/S0968-0004(02)02182-5; Fukahi K, 2004, CLIN CANCER RES, V10, P581, DOI 10.1158/1078-0432.CCR-0930-03; Gavazzi I, 2001, CELL TISSUE RES, V305, P275, DOI 10.1007/s004410100365; Gluzman-Poltorak Z, 2000, J BIOL CHEM, V275, P18040, DOI 10.1074/jbc.M909259199; GOLDMAN R, 1983, ANN NY ACAD SCI, V419, P143, DOI 10.1111/j.1749-6632.1983.tb37099.x; HERMAN ZS, 1981, EXPERIENTIA, V37, P76, DOI 10.1007/BF01965580; Ikeda M, 2000, J PATHOL, V191, P426; Keyt BA, 1996, J BIOL CHEM, V271, P7788, DOI 10.1074/jbc.271.13.7788; LIAW L, 1993, ARTERIOSCLER THROMB, V13, P985, DOI 10.1161/01.ATV.13.7.985; Ma X, 2004, INVEST OPHTH VIS SCI, V45, P2915, DOI 10.1167/iovs.04-0128; MOORE RN, 1989, J IMMUNOL, V142, P2689; NAJJAR VA, 1989, FEBS LETT, V253, P129, DOI 10.1016/0014-5793(89)80944-5; NAJJAR VA, 1970, NATURE, V228, P672, DOI 10.1038/228672a0; Neufeld G, 1999, FASEB J, V13, P9, DOI 10.1096/fasebj.13.1.9; OLIVER SJ, 1995, CELL IMMUNOL, V166, P196, DOI 10.1006/cimm.1995.9978; Raju N, 2005, TETRAHEDRON LETT, V46, P1463, DOI 10.1016/j.tetlet.2005.01.026; ROBEY FA, 1987, J BIOL CHEM, V262, P7053; Shrivastava A, 2005, PROTEIN ENG DES SEL, V18, P417, DOI 10.1093/protein/gzi049; Siemion IZ, 1999, PEPTIDES, V20, P645, DOI 10.1016/S0196-9781(99)00019-4; Soker S, 1997, J BIOL CHEM, V272, P31582, DOI 10.1074/jbc.272.50.31582; Soker S, 1998, CELL, V92, P735, DOI 10.1016/S0092-8674(00)81402-6; Soker S, 1996, J BIOL CHEM, V271, P5761, DOI 10.1074/jbc.271.10.5761; Storgard CM, 1999, J CLIN INVEST, V103, P47, DOI 10.1172/JCI3756; THANOS S, 1993, J NEUROSCI, V13, P455; Tordjman R, 2002, NAT IMMUNOL, V3, P477, DOI 10.1038/ni789; Wang L, 2003, J BIOL CHEM, V278, P48848, DOI 10.1074/jbc.M310047200; Whitaker GB, 2001, J BIOL CHEM, V276, P25520, DOI 10.1074/jbc.M102315200; Wise LM, 1999, P NATL ACAD SCI USA, V96, P3071, DOI 10.1073/pnas.96.6.3071	35	99	104	1	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 3	2006	281	9					5702	5710		10.1074/jbc.M511941200	http://dx.doi.org/10.1074/jbc.M511941200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	015RQ	16371354	hybrid			2022-12-25	WOS:000235568900047
J	Jarvinen, A; Keinanen, TA; Grigorenko, NA; Khomutov, AR; Uimari, A; Vepsalainen, J; Narvanen, A; Alhonen, L; Janne, J				Jarvinen, A; Keinanen, TA; Grigorenko, NA; Khomutov, AR; Uimari, A; Vepsalainen, J; Narvanen, A; Alhonen, L; Janne, J			Guide molecule-driven stereospecific degradation of alpha-methylpolyamines by polyamine oxidase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ORNITHINE-DECARBOXYLASE; RAT-LIVER; DERIVATIVES; SPERMIDINE; INHIBITION; ANALOGS; PURIFICATION; SPECIFICITY; METABOLISM; SPECTRA	FAD-dependent polyamine oxidase (PAO; EC 1.5.3.11) is one of the key enzymes in the catabolism of polyamines spermidine and spermine. The natural substrates for the enzyme are N-1-acetylspermidine, N-1-acetylspermine, and N-1, N-12-diacetylspermine. Here we report that PAO, which normally metabolizes achiral substrates, oxidized (R)-isomer of 1-amino-8-acetamido-5-azanonane and N-1-acetylspermidine as efficiently while (S)-1-amino-8-acetamido-5-azanonane was a much less preferred substrate. It has been shown that in the presence of certain aldehydes, the substrate specificity of PAO and the kinetics of the reaction are changed to favor spermine and spermidine as substrates. Therefore, we examined the effect of several aldehydes on the ability of PAO to oxidize different enantiomers of alpha-methylated polyamines. PAO supplemented with benzaldehyde predominantly catalyzed the cleavage of (R)-isomer of alpha-methylspermidine, whereas in the presence of pyridoxal the (S)-alpha-methylspermidine was preferred. PAO displayed the same stereospecificity with both singly and doubly alpha-methylated spermine derivatives when supplemented with the same aldehydes. Structurally related ketones proved to be ineffective. This is the first time that the stereospecificity of FAD-dependent oxidase has been successfully regulated by changing the supplementary aldehyde. These findings might facilitate the chemical regulation of stereospecificity of the enzymes.	Univ Kuopio, AI Virtanen Inst Mol Sci, Dept Biotechnol & Mol Med, FI-70211 Kuopio, Finland; Univ Kuopio, Dept Chem, FI-70211 Kuopio, Finland; Russian Acad Sci, Engelhardt Inst Mol Biol, Moscow 119991, Russia	University of Eastern Finland; University of Eastern Finland; Russian Academy of Sciences; Engelhardt Institute of Molecular Biology, RAS	Jarvinen, A (corresponding author), Univ Kuopio, AI Virtanen Inst Mol Sci, Dept Biotechnol & Mol Med, POB 1627, FI-70211 Kuopio, Finland.	Juhani.Janne@uku.fi	Khomutov, Alex/G-2128-2015; Keinänen, Tuomo/AAC-5630-2019; Narvanen, Ale/A-6002-2009	Khomutov, Alex/0000-0001-6833-7855				BEY P, 1978, J MED CHEM, V21, P50, DOI 10.1021/jm00199a009; Binda C, 2001, BIOCHEMISTRY-US, V40, P2766, DOI 10.1021/bi002751j; BOLKENIUS FN, 1981, INT J BIOCHEM, V13, P287, DOI 10.1016/0020-711X(81)90080-X; CASERO RA, 1993, FASEB J, V7, P653, DOI 10.1096/fasebj.7.8.8500690; DELLARAGIONE F, 1983, BIOCHEM J, V213, P701, DOI 10.1042/bj2130701; FOSTER RJ, 1961, J BIOL CHEM, V236, P2461; Gerner EW, 2004, NAT REV CANCER, V4, P781, DOI 10.1038/nrc1454; Grigorenko N. A., 2005, Bioorganicheskaya Khimiya, V31, P200; Grigorenko N. A., 2004, Bioorganicheskaya Khimiya, V30, P441; Grigorenko NA, 2005, MENDELEEV COMMUN, V15, P142, DOI 10.1070/MC2005v015n04ABEH002120; HOLTTA E, 1977, BIOCHEMISTRY-US, V16, P91, DOI 10.1021/bi00620a015; HYVONEN T, 1992, J CHROMATOGR-BIOMED, V574, P17, DOI 10.1016/0378-4347(92)80093-6; Igarashi K, 2000, BIOCHEM BIOPH RES CO, V271, P559, DOI 10.1006/bbrc.2000.2601; Janne J, 2004, EUR J BIOCHEM, V271, P877, DOI 10.1111/j.1432-1033.2004.04009.x; Jarvinen A, 2005, J BIOL CHEM, V280, P6595, DOI 10.1074/jbc.M412788200; KEINANEN TA, 1993, ANAL BIOCHEM, V208, P35, DOI 10.1006/abio.1993.1005; Khomutov AR, 2001, TETRAHEDRON LETT, V42, P2887, DOI 10.1016/S0040-4039(01)00315-X; Khomutov AR, 1996, TETRAHEDRON, V52, P13751, DOI 10.1016/0040-4020(96)00836-8; Klibanov AM, 2001, NATURE, V409, P241, DOI 10.1038/35051719; LEDBETTER JW, 1982, J PHYS CHEM-US, V86, P2449, DOI 10.1021/j100210a041; MarkovicHousley Z, 1996, EUR J BIOCHEM, V236, P1025, DOI 10.1111/j.1432-1033.1996.01025.x; MCQUATE RS, 1975, J AM CHEM SOC, V97, P5117, DOI 10.1021/ja00851a016; METCALF BW, 1978, J AM CHEM SOC, V100, P2551, DOI 10.1021/ja00476a050; METZLER CM, 1980, J AM CHEM SOC, V102, P6075, DOI 10.1021/ja00539a017; Niiranen K, 2002, J BIOL CHEM, V277, P25323, DOI 10.1074/jbc.M203599200; Oredsson SM, 2003, BIOCHEM SOC T, V31, P366, DOI 10.1042/BST0310366; Perez-Cano FJ, 2003, CELL IMMUNOL, V226, P86, DOI 10.1016/j.cellimm.2003.09.009; PORTER CW, 1985, CANCER RES, V45, P2050; Qu N, 2003, BIOCHEM J, V375, P465, DOI 10.1042/BJ20030382; Rasanen TL, 2002, J BIOL CHEM, V277, P39867, DOI 10.1074/jbc.M205967200; REHSE K, 1990, ARCH PHARM, V323, P287, DOI 10.1002/ardp.19903230507; Royo M, 2005, BIOCHEMISTRY-US, V44, P7079, DOI 10.1021/bi050347k; Seiler N, 2004, AMINO ACIDS, V26, P217, DOI 10.1007/s00726-004-0070-z; TABOR H, 1983, METHOD ENZYMOL, V94, P420; Thomas T, 2003, J CELL MOL MED, V7, P113, DOI 10.1111/j.1582-4934.2003.tb00210.x; TSUKADA T, 1988, INT J BIOCHEM, V20, P695, DOI 10.1016/0020-711X(88)90164-4; Vujcic S, 2003, BIOCHEM J, V370, P19, DOI 10.1042/BJ20021779; WEITKAMP ELC, 1991, BIOCHEM J, V277, P643, DOI 10.1042/bj2770643; Williams K, 1997, CELL SIGNAL, V9, P1, DOI 10.1016/S0898-6568(96)00089-7; Wu TY, 2003, J BIOL CHEM, V278, P20514, DOI 10.1074/jbc.M302149200; Yoshida M, 2004, J BIOL CHEM, V279, P46008, DOI 10.1074/jbc.M404393200	41	19	20	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 24	2006	281	8					4589	4595		10.1074/jbc.M509959200	http://dx.doi.org/10.1074/jbc.M509959200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	013RF	16354669	Green Published, hybrid			2022-12-25	WOS:000235426200006
J	Vergauwen, B; De Vos, D; Van Beeumen, JJ				Vergauwen, B; De Vos, D; Van Beeumen, JJ			Characterization of the bifunctional gamma-glutamate-cysteine ligase/glutathione synthetase (GshF) of Pasteurella multocida	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI K-12; GLYCEROL PHOSPHATE SYNTHASE; HAEMOPHILUS-INFLUENZAE RD; GLUTAMYLCYSTEINE SYNTHETASE; GLUTATHIONE SYNTHETASE; TRYPTOPHAN SYNTHASE; CRYSTAL-STRUCTURE; DIHYDROFOLATE-REDUCTASE; 3-DIMENSIONAL STRUCTURE; THYMIDYLATE SYNTHASE	Glutamate-cysteine ligase (gamma-ECL) and glutathione synthetase (GS) are the two unrelated ligases that constitute the glutathione biosynthesis pathway in most eukaryotes, purple bacteria, and cyanobacteria. gamma-ECL is a member of the glutamine synthetase family, whereas GS enzymes group together with highly diverse carboxyltoamine/thiol ligases, all characterized by the so-called two-domain ATP-grasp fold. This generalized scheme toward the formation of glutathione, however, is incomplete, as functional steady-state levels of intracellular glutathione may also accumulate solely by import, as has been reported for the Pasteurellaceae member Haemophilus influenzae, as well as for certain Gram-positive enterococci and streptococci, or by the action of a bifunctional fusion protein (termed GshF), as has been reported recently for the Gram-positive firmicutes Streptococcus agalactiae and Listeria monocytogenes. Here, we show that yet another member of the Pasteurellaceae family, Pasteurella multocida, acquires glutathione both by import and GshF-driven biosynthesis. Domain architecture analysis shows that this P. multocida GshF bifunctional ligase contains an N-terminal gamma-proteobacterial gamma-ECL-like domain followed by a typical ATP-grasp domain, which most closely resembles that of cyanophycin synthetases, although it has no significant homology with known GS ligases. Recombinant P. multocida GshF overexpresses as an similar to 85-kDa protein, which, on the basis of gel-sizing chromatography, forms dimers in solution. The gamma-ECL activity of GshF is regulated by an allosteric type of glutathione feedback inhibition (K-i = 13.6 mM). Furthermore, steady-state kinetics, on the basis of which we present a novel variant of half-of-the-sites reactivity, indicate intimate domain-domain interactions, which may explain the bifunctionality of GshF proteins.	Univ Ghent, Lab Prot Biochem & Prot Engn, B-9000 Ghent, Belgium	Ghent University	Van Beeumen, JJ (corresponding author), Univ Ghent, Lab Prot Biochem & Prot Engn, KL Ledeganckstr 35, B-9000 Ghent, Belgium.	Jozef.Vanbeeumen@Ugent.be						Abbott JJ, 2001, J BIOL CHEM, V276, P42099, DOI 10.1074/jbc.M104672200; Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; ANDERSON KS, 1991, J BIOL CHEM, V266, P8020; APONTOWEIL P, 1975, BIOCHIM BIOPHYS ACTA, V399, P1, DOI 10.1016/0304-4165(75)90205-6; BELDA FF, 1982, REV ESP FISIOL, V38, P327; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BROWN CM, 1972, J APPL CHEM BIOTECHN, V22, P363, DOI 10.1002/jctb.5020220307; Chaudhuri BN, 2001, STRUCTURE, V9, P987, DOI 10.1016/S0969-2126(01)00661-X; Copley SD, 2002, GENOME BIOL, V3; Datsenko KA, 2000, P NATL ACAD SCI USA, V97, P6640, DOI 10.1073/pnas.120163297; EASTERBY JS, 1981, BIOCHEM J, V199, P155, DOI 10.1042/bj1990155; FAHEY RC, 1984, SCIENCE, V224, P70, DOI 10.1126/science.6322306; FAHEY RC, 1978, J BACTERIOL, V133, P1126, DOI 10.1128/JB.133.3.1126-1129.1978; FAN C, 1994, SCIENCE, V266, P439, DOI 10.1126/science.7939684; Ferguson GP, 1998, J BACTERIOL, V180, P4314, DOI 10.1128/JB.180.16.4314-4318.1998; Galperin MY, 1997, PROTEIN SCI, V6, P2639; Gogos A, 2002, STRUCTURE, V10, P1669, DOI 10.1016/S0969-2126(02)00906-1; Gopal S, 2005, J BACTERIOL, V187, P3839, DOI 10.1128/JB.187.11.3839-3847.2005; Griffith OW, 1999, FREE RADICAL BIO MED, V27, P922, DOI 10.1016/S0891-5849(99)00176-8; HERRIOTT RM, 1970, J BACTERIOL, V101, P513, DOI 10.1128/JB.101.2.513-516.1970; Hibi T, 2004, P NATL ACAD SCI USA, V101, P15052, DOI 10.1073/pnas.0403277101; HUANG CS, 1993, J BIOL CHEM, V268, P19675; HUANG CS, 1993, J BIOL CHEM, V268, P20578; Huang XY, 2001, ANNU REV BIOCHEM, V70, P149, DOI 10.1146/annurev.biochem.70.1.149; HYDE CC, 1990, BIO-TECHNOL, V8, P27, DOI 10.1038/nbt0190-27; HYDE CC, 1988, J BIOL CHEM, V263, P17857; Jahoor F, 1999, AM J PHYSIOL-ENDOC M, V276, pE205, DOI 10.1152/ajpendo.1999.276.1.E205; Janowiak BE, 2005, J BIOL CHEM, V280, P11829, DOI 10.1074/jbc.M414326200; Joyce MA, 1999, BIOCHEMISTRY-US, V38, P7273, DOI 10.1021/bi990527s; KATO H, 1994, BIOCHEMISTRY-US, V33, P4995, DOI 10.1021/bi00183a001; Kelly BS, 2002, J BIOL CHEM, V277, P50, DOI 10.1074/jbc.M107961200; KNIGHTON DR, 1994, NAT STRUCT BIOL, V1, P186, DOI 10.1038/nsb0394-186; Koshland DE, 1996, CURR OPIN STRUC BIOL, V6, P757, DOI 10.1016/S0959-440X(96)80004-2; Krehenbrink M, 2004, MICROBIOL-SGM, V150, P2599, DOI 10.1099/mic.0.27140-0; Kunishima N, 2005, J MOL BIOL, V352, P212, DOI 10.1016/j.jmb.2005.07.008; Levert KL, 2000, BIOCHEMISTRY-US, V39, P4122, DOI 10.1021/bi992662a; Liang PH, 1998, BIOCHEMISTRY-US, V37, P12195, DOI 10.1021/bi9803168; Luo JL, 2000, BIOCHEM BIOPH RES CO, V275, P577, DOI 10.1006/bbrc.2000.3337; Lyons J, 2000, P NATL ACAD SCI USA, V97, P5071, DOI 10.1073/pnas.090083297; Matsuda K, 1996, PROTEIN ENG, V9, P1083, DOI 10.1093/protein/9.12.1083; May BJ, 2001, P NATL ACAD SCI USA, V98, P3460, DOI 10.1073/pnas.051634598; McGuffin LJ, 2000, BIOINFORMATICS, V16, P404, DOI 10.1093/bioinformatics/16.4.404; MEISTER A, 1983, ANNU REV BIOCHEM, V52, P711, DOI 10.1146/annurev.bi.52.070183.003431; Misra I, 1998, PROTEIN EXPRES PURIF, V13, P268, DOI 10.1006/prep.1998.0897; MURATA K, 1982, APPL ENVIRON MICROB, V44, P1444, DOI 10.1128/AEM.44.6.1444-1448.1982; Myers RS, 2003, BIOCHEMISTRY-US, V42, P7013, DOI 10.1021/bi034314l; Nagradova N, 2003, IUBMB LIFE, V55, P459, DOI 10.1080/15216540310001602805; Newton GL, 1996, J BACTERIOL, V178, P1990, DOI 10.1128/jb.178.7.1990-1995.1996; Notredame C, 2000, J MOL BIOL, V302, P205, DOI 10.1006/jmbi.2000.4042; Oppermann-Sanio FB, 2002, NATURWISSENSCHAFTEN, V89, P11, DOI 10.1007/s00114-001-0280-0; Pauwels F, 2004, J BIOL CHEM, V279, P12163, DOI 10.1074/jbc.M312037200; Pauwels F, 2003, J BIOL CHEM, V278, P16658, DOI 10.1074/jbc.M300157200; Polekhina G, 1999, EMBO J, V18, P3204, DOI 10.1093/emboj/18.12.3204; SAKUDA S, 1994, BIOSCI BIOTECH BIOCH, V58, P1347, DOI 10.1271/bbb.58.1347; Sambrook J., 1989, MOL CLONING LAB MANU, V2; Silva MS, 2005, FEBS J, V272, P2388, DOI 10.1111/j.1742-4658.2005.04632.x; Spivey HO, 1999, METHODS, V19, P306, DOI 10.1006/meth.1999.0858; STALLCUP WB, 1972, BIOCHEM BIOPH RES CO, V49, P1108, DOI 10.1016/0006-291X(72)90327-0; SUZUKI H, 1993, J BACTERIOL, V175, P6038, DOI 10.1128/JB.175.18.6038-6040.1993; Thoden JB, 1997, BIOCHEMISTRY-US, V36, P6305, DOI 10.1021/bi970503q; TIETZE F, 1969, ANAL BIOCHEM, V27, P502, DOI 10.1016/0003-2697(69)90064-5; Tu ZH, 1998, ARCH BIOCHEM BIOPHYS, V354, P247, DOI 10.1006/abbi.1998.0676; van den Heuvel RHH, 2003, J MOL BIOL, V330, P113, DOI 10.1016/S0022-2836(03)00522-9; Vergauwen B, 2003, J BACTERIOL, V185, P5555, DOI 10.1128/JB.185.18.5555-5562.2003; Vergauwen B, 2003, J BACTERIOL, V185, P1572, DOI 10.1128/JB.185.5.1572-1581.2003; WIEDERHOLT KM, 1994, J DAIRY SCI, V77, P1183, DOI 10.3168/jds.S0022-0302(94)77056-9; WOLODKO WT, 1981, P NATL ACAD SCI-BIOL, V78, P2140, DOI 10.1073/pnas.78.4.2140; YAMAGUCHI H, 1993, J MOL BIOL, V229, P1083, DOI 10.1006/jmbi.1993.1106; YAQUB S, 2004, TIDSSKR NOR LAEGEFOR, V214, P3194	69	47	54	1	26	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 17	2006	281	7					4380	4394		10.1074/jbc.M509517200	http://dx.doi.org/10.1074/jbc.M509517200			15	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	011NN	16339152	hybrid			2022-12-25	WOS:000235275300074
J	Chen, YL; Law, PY; Loh, HH				Chen, YL; Law, PY; Loh, HH			Sustained activation of phosphatidylinositol 3-kinase/Akt/nuclear factor kappa B signaling mediates G protein-coupled delta-opioid receptor gene expression	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NERVE GROWTH-FACTOR; TRANSCRIPTION FACTOR; PC12 CELLS; MORPHINE-TOLERANCE; PHEOCHROMOCYTOMA CELLS; KINASE ACTIVITY; MESSENGER-RNAS; TRK RECEPTORS; PC-12 CELLS; RAT-BRAIN	Expression of the delta-opioid receptor gene ( dor) is tightly controlled during neuronal differentiation and developmental stages. Such distinct temporal and spatial expression of dor during development suggests a role for the delta-opioid receptor in early developmental events. However, little is known about intracellular signaling pathways that control dor expression. A well established cell line model for the study of gene expression during neuronal differentiation is the rat adrenal pheochromocytoma PC12 cell line. Here we found that the constitutively activated TrkA/phosphatidylinositol 3-kinase/Akt ( protein kinase B)/NF-kappa B survival cascade mediates dor expression during nerve growth factor ( NGF)-induced differentiation of PC12h cells. Biochemical experiments showed that constitutive phosphorylation of Akt and I kappa B alpha correlates with NGF-induced dor expression. Overexpression of the transcriptional activator NF-kappa B/p65 increased dor promoter activity. Overexpression of the NF-kappa B signaling super inhibitor mutant I kappa B alpha ( S32A/ S36A) abolished the effect of p65 and blocked NGF-induced activation of NF-kappa B signaling, resulting in a significant reduction in dor promoter activity. Treatment with SN50, an NF-kappa B-specific nuclear translocation peptide inhibitor, inhibited the translocation of NF-kappa B, resulting in a reduction of dor mRNA. The gel shift assay supported the fact that there exists an NF-kappa B-binding site on the dor promoter. RNA interference experiments using NF-kappa B/p65 small interfering RNA confirmed that NF-kappa B signaling is required for dor expression. Our findings not only provide a new mechanistic explanation for NGF-induced dor expression but also shed some light on the molecular mechanism of the temporal and spatial expression of dor and the roles of the delta-opioid receptor during neuronal differentiation.	Univ Minnesota, Sch Med, Dept Pharmacol, Minneapolis, MN 55455 USA	University of Minnesota System; University of Minnesota Twin Cities	Chen, YL (corresponding author), Univ Minnesota, Sch Med, Dept Pharmacol, 6-120 Jackson Hall,321 Church St SE, Minneapolis, MN 55455 USA.	chenx112@tc.umn.edu		Law, Ping-Yee/0000-0002-5364-1093	NATIONAL INSTITUTE ON DRUG ABUSE [R37DA001583, R01DA001583, R01DA000564, P50DA011806, K05DA070554, K05DA000513, R56DA000564] Funding Source: NIH RePORTER; NIDA NIH HHS [DA-000564, DA-001583, K05-DA00513, DA-011806, K05-DA-70554] Funding Source: Medline	NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission); NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA))		ABDELHAMID EE, 1991, J PHARMACOL EXP THER, V258, P299; ABOOD ME, 1995, J PHARMACOL EXP THER, V274, P1566; Agalioti T, 2000, CELL, V103, P667, DOI 10.1016/S0092-8674(00)00169-0; AUGUSTIN LB, 1995, BIOCHEM BIOPH RES CO, V207, P111, DOI 10.1006/bbrc.1995.1160; AUSUBEL FM, 1993, CURRENT PROTOCOLS MO, V2; Baeuerle PA, 1996, CELL, V87, P13, DOI 10.1016/S0092-8674(00)81318-5; BAEUERLE PA, 1988, SCIENCE, V242, P540, DOI 10.1126/science.3140380; Borlongan CV, 2004, FRONT BIOSCI-LANDMRK, V9, P3392, DOI 10.2741/1490; Brunet A, 2001, CURR OPIN NEUROBIOL, V11, P297, DOI 10.1016/S0959-4388(00)00211-7; Bui NT, 2001, J CELL BIOL, V152, P753, DOI 10.1083/jcb.152.4.753; Chang JH, 2003, J BIOL CHEM, V278, P42877, DOI 10.1074/jbc.M308155200; Chang SF, 2001, NEUROSCI LETT, V314, P29, DOI 10.1016/S0304-3940(01)02280-7; CHAO MV, 1995, TRENDS NEUROSCI, V18, P321, DOI 10.1016/0166-2236(95)93922-K; Chen LF, 2004, NAT REV MOL CELL BIO, V5, P392, DOI 10.1038/nrm1368; Chen YL, 2004, CANCER RES, V64, P8723, DOI 10.1158/0008-5472.CAN-03-3091; Dermitzaki E, 2000, J NEUROCHEM, V74, P960, DOI 10.1046/j.1471-4159.2000.0740960.x; DUDLEY DT, 1995, P NATL ACAD SCI USA, V92, P7689; Fernyhough P, 2005, J NEUROSCI, V25, P1682, DOI 10.1523/JNEUROSCI.3127-04.2005; Georges F, 1998, DEV BRAIN RES, V109, P187, DOI 10.1016/S0165-3806(98)00082-0; GREENE LA, 1976, P NATL ACAD SCI USA, V73, P2424, DOI 10.1073/pnas.73.7.2424; Grumont RJ, 2002, MOL CELL, V10, P1283, DOI 10.1016/S1097-2765(02)00779-7; Gustin JA, 2004, J BIOL CHEM, V279, P1615, DOI 10.1074/jbc.M306976200; Hoffmann A, 2002, SCIENCE, V298, P1241, DOI 10.1126/science.1071914; INOUE N, 1982, J BIOL CHEM, V257, P9238; IP NY, 1993, NEURON, V10, P137, DOI 10.1016/0896-6273(93)90306-C; Jamen F, 2002, J NEUROCHEM, V82, P1199, DOI 10.1046/j.1471-4159.2002.01124.x; Kim SS, 2005, MOL PHARMACOL, V68, P729, DOI 10.1124/mol.105.012245; KUNSCH C, 1992, MOL CELL BIOL, V12, P4412, DOI 10.1128/MCB.12.10.4412; Law PY, 2004, NEUROPHARMACOLOGY, V47, P300, DOI 10.1016/j.neuropharm.2004.07.013; Lee NH, 1998, J BIOL CHEM, V273, P22317, DOI 10.1074/jbc.273.35.22317; LEE NH, 1995, P NATL ACAD SCI USA, V92, P8303, DOI 10.1073/pnas.92.18.8303; LEVI A, 1988, MOL NEUROBIOL, V2, P201, DOI 10.1007/BF02935346; Li QT, 2002, NAT REV IMMUNOL, V2, P725, DOI 10.1038/nri910; LIN YZ, 1995, J BIOL CHEM, V270, P14255, DOI 10.1074/jbc.270.24.14255; Liu HC, 1999, J BIOL CHEM, V274, P23617, DOI 10.1074/jbc.274.33.23617; Maggirwar SB, 1998, J NEUROSCI, V18, P10356; Malek RL, 1999, J BIOL CHEM, V274, P35499, DOI 10.1074/jbc.274.50.35499; Mattson MP, 2003, NAT NEUROSCI, V6, P105, DOI 10.1038/nn0203-105; Meffert MK, 2005, TRENDS NEUROSCI, V28, P37, DOI 10.1016/j.tins.2004.11.002; Meffert MK, 2003, NAT NEUROSCI, V6, P1072, DOI 10.1038/nn1110; Middleton G, 2001, DEVELOPMENT, V128, P447; Nickols JC, 2003, NAT NEUROSCI, V6, P161, DOI 10.1038/nn995; Nie ZZ, 1999, MOL PHARMACOL, V56, P947, DOI 10.1124/mol.56.5.947; Numan S, 1998, J NEUROSCI, V18, P10700; ONeill LAJ, 1997, TRENDS NEUROSCI, V20, P252, DOI 10.1016/S0166-2236(96)01035-1; PANG L, 1995, J BIOL CHEM, V270, P13585, DOI 10.1074/jbc.270.23.13585; Patapoutian A, 2001, CURR OPIN NEUROBIOL, V11, P272, DOI 10.1016/S0959-4388(00)00208-7; Polakiewicz RD, 1998, J BIOL CHEM, V273, P23534, DOI 10.1074/jbc.273.36.23534; Pomerantz JL, 2002, MOL CELL, V10, P693, DOI 10.1016/S1097-2765(02)00697-4; Rojo AI, 2004, J NEUROSCI, V24, P7324, DOI 10.1523/JNEUROSCI.2111-04.2004; Roy S, 2005, J NEUROSCI, V25, P3229, DOI 10.1523/JNEUROSCI.0332-05.2005; Saccani S, 2003, MOL CELL, V11, P1563, DOI 10.1016/S1097-2765(03)00227-2; Smith DJ, 2003, NEUROSCI LETT, V340, P103, DOI 10.1016/S0304-3940(03)00084-3; Sofroniew MV, 2001, ANNU REV NEUROSCI, V24, P1217, DOI 10.1146/annurev.neuro.24.1.1217; TAPLEY P, 1992, ONCOGENE, V7, P371; Tenconi B, 1996, DEV BRAIN RES, V94, P175, DOI 10.1016/0165-3806(96)00047-8; TSOULFAS P, 1993, NEURON, V10, P975, DOI 10.1016/0896-6273(93)90212-A; VLAHOS CJ, 1994, J BIOL CHEM, V269, P5241; Wittert G, 1996, BIOCHEM BIOPH RES CO, V218, P877, DOI 10.1006/bbrc.1996.0156; YAN Q, 1989, J COMP NEUROL, V290, P585, DOI 10.1002/cne.902900411; Yuan JY, 2000, NATURE, V407, P802, DOI 10.1038/35037739; Zhu YX, 1999, NEURON, V24, P243, DOI 10.1016/S0896-6273(00)80836-3; Zhu YX, 1998, J NEUROSCI, V18, P2538	64	36	39	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 10	2006	281	6					3067	3074		10.1074/jbc.M506721200	http://dx.doi.org/10.1074/jbc.M506721200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	009QV	16316997	hybrid			2022-12-25	WOS:000235128200009
J	Arlander, SJH; Felts, SJ; Wagner, JM; Stensgard, B; Toft, DO; Karnitz, LM				Arlander, SJH; Felts, SJ; Wagner, JM; Stensgard, B; Toft, DO; Karnitz, LM			Chaperoning checkpoint kinase 1 (Chk1), an Hsp90 client, with purified chaperones	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEAT-SHOCK-PROTEIN; VIRUS TRANSFORMING PROTEIN; 2 CELLULAR PHOSPHOPROTEINS; GLUCOCORTICOID-RECEPTOR; PROGESTERONE-RECEPTOR; RADIOSENSITIZING AGENT; REVERSE-TRANSCRIPTASE; MOLECULAR CHAPERONE; STEROID-RECEPTORS; TYROSINE KINASES	Checkpoint kinase 1 ( Chk1), a serine/threonine kinase that regulates DNA damage checkpoints, is destabilized when heat shock protein 90 (Hsp90) is inhibited, suggesting that Chk1 is an Hsp90 client. In the present work we examined the interplay between Chk1 and Hsp90 in intact cells, identified a source of unchaperoned Chk1, and report the in vitro chaperoning of Chk1 in reticulocyte lysates and with purified chaperones and co-chaperones. We find that bacterially expressed Chk1 is post-translationally chaperoned to an active kinase. This reaction minimally requires Hsp90, Hsp70, Hsp40, Cdc37, and the protein kinase CK2. The co-chaperone Hop, although not essential for the activation of Chk1 in vitro, enhanced the chaperoning process, whereas the co-chaperone p23 did not stimulate the chaperoning reaction. Additionally, we found that the C-terminal regulatory domain of Chk1 affects the association of Chk1 with Hsp90. Collectively these results provide new insights into Hsp90-dependent chaperoning of a client kinase and identify a novel, biochemically tractable model system that will be useful to further dissect the Hsp90-dependent chaperoning of this important and ubiquitous class of Hsp90 clients.	Mayo Clin & Mayo Fdn, Coll Med, Div Dev Oncol Res, Rochester, MN 55905 USA; Mayo Clin & Mayo Fdn, Coll Med, Dept Radiat Oncol, Rochester, MN 55905 USA; Mayo Clin & Mayo Grad Sch Med, Dept Mol Pharmacol & Expt Therapeut, Rochester, MN 55905 USA; Mayo Clin & Mayo Grad Sch Med, Dept Biochem & Mol Biol, Rochester, MN 55905 USA	Mayo Clinic; Mayo Clinic; Mayo Clinic; Mayo Clinic	Karnitz, LM (corresponding author), Mayo Clin & Mayo Fdn, Coll Med, Div Dev Oncol Res, Guggenheim 13,200 1st St SW, Rochester, MN 55905 USA.	karnitz.larry@mayo.edu			NATIONAL CANCER INSTITUTE [R01CA104378] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK046249] Funding Source: NIH RePORTER; NCI NIH HHS [CA104378] Funding Source: Medline; NIDDK NIH HHS [DK46249] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ADKINS B, 1982, J VIROL, V43, P448, DOI 10.1128/JVI.43.2.448-455.1982; ALNEMRI ES, 1993, BIOCHEMISTRY-US, V32, P5387, DOI 10.1021/bi00071a014; Arlander SJH, 2003, J BIOL CHEM, V278, P52572, DOI 10.1074/jbc.M309054200; Barent RL, 1998, MOL ENDOCRINOL, V12, P342, DOI 10.1210/me.12.3.342; Basso AD, 2002, J BIOL CHEM, V277, P39858, DOI 10.1074/jbc.M206322200; Bohen SP, 1998, MOL CELL BIOL, V18, P3330, DOI 10.1128/MCB.18.6.3330; BRUGGE J, 1983, MOL CELL BIOL, V3, P9, DOI 10.1128/MCB.3.1.9; BRUGGE JS, 1981, CELL, V25, P363, DOI 10.1016/0092-8674(81)90055-6; Busby EC, 2000, CANCER RES, V60, P2108; CAPLAN AJ, 1992, J BIOL CHEM, V267, P18890; Chen P, 2000, CELL, V100, P681, DOI 10.1016/S0092-8674(00)80704-7; Chen SY, 1996, MOL ENDOCRINOL, V10, P682, DOI 10.1210/me.10.6.682; Dittmar KD, 1997, J BIOL CHEM, V272, P13047, DOI 10.1074/jbc.272.20.13047; Dittmar KD, 1998, J BIOL CHEM, V273, P7358, DOI 10.1074/jbc.273.13.7358; Dittmar KD, 1997, J BIOL CHEM, V272, P21213, DOI 10.1074/jbc.272.34.21213; Donze O, 1999, MOL CELL BIOL, V19, P8422, DOI 10.1128/mcb.19.12.8422; Egorin MJ, 1998, CANCER RES, V58, P2385; Fang YF, 1998, MOL CELL BIOL, V18, P3727, DOI 10.1128/MCB.18.7.3727; Farrell A, 2000, MOL CELL BIOL, V20, P749, DOI 10.1128/MCB.20.3.749-754.2000; Felts SJ, 2003, CELL STRESS CHAPERON, V8, P108, DOI 10.1379/1466-1268(2003)008<0108:PASPWC>2.0.CO;2; Goetz MP, 2003, ANN ONCOL, V14, P1169, DOI 10.1093/annonc/mdg316; Hartson SD, 2000, BIOCHEMISTRY-US, V39, P7631, DOI 10.1021/bi000315r; Hartson SD, 1998, J BIOL CHEM, V273, P8475, DOI 10.1074/jbc.273.14.8475; HARTSON SD, 1994, BIOCHEMISTRY-US, V33, P8912, DOI 10.1021/bi00196a008; Hernandez MP, 2002, J BIOL CHEM, V277, P11873, DOI 10.1074/jbc.M111445200; Holt SE, 1999, GENE DEV, V13, P817, DOI 10.1101/gad.13.7.817; Hu JM, 2004, J VIROL, V78, P13122, DOI 10.1128/JVI.78.23.13122-13131.2004; Hu JM, 2002, J VIROL, V76, P269, DOI 10.1128/JVI.76.1.269-279.2002; Hunter T, 1997, TRENDS CELL BIOL, V7, P157, DOI 10.1016/S0962-8924(97)01027-1; IBA H, 1985, MOL CELL BIOL, V5, P1058, DOI 10.1128/MCB.5.5.1058; Isaacs JS, 2003, CANCER CELL, V3, P213, DOI 10.1016/S1535-6108(03)00029-1; JOAB I, 1984, NATURE, V308, P850, DOI 10.1038/308850a0; JOHNSON JL, 1994, J BIOL CHEM, V269, P24989; Katsuragi Y, 2004, MOL BIOL CELL, V15, P1680, DOI 10.1091/mbc.E03-12-0874; King FW, 2001, EMBO J, V20, P6297, DOI 10.1093/emboj/20.22.6297; Kosano H, 1998, J BIOL CHEM, V273, P32973, DOI 10.1074/jbc.273.49.32973; Lee P, 2004, MOL BIOL CELL, V15, P1785, DOI 10.1091/mbc.E03-07-0480; Miyata Y, 2004, MOL CELL BIOL, V24, P4065, DOI 10.1128/MCB.24.9.4065-4074.2004; Morishima Y, 2000, J BIOL CHEM, V275, P18054, DOI 10.1074/jbc.M000434200; Neckers L, 2002, TRENDS MOL MED, V8, pS55, DOI 10.1016/S1471-4914(02)02316-X; Nollen EAA, 2002, J CELL SCI, V115, P2809; Odunuga OO, 2004, BIOESSAYS, V26, P1058, DOI 10.1002/bies.20107; Oe T, 2001, DEV BIOL, V229, P250, DOI 10.1006/dbio.2000.9968; Pratt WB, 2003, EXP BIOL MED, V228, P111, DOI 10.1177/153537020322800201; Sakagami M, 1999, CELL STRESS CHAPERON, V4, P19, DOI 10.1054/csac.1998.0115; SANCHEZ ER, 1985, J BIOL CHEM, V260, P2398; Sanchez Y, 1997, SCIENCE, V277, P1497, DOI 10.1126/science.277.5331.1497; Sarkaria JN, 1999, CANCER RES, V59, P4375; Scholz GM, 2001, CELL GROWTH DIFFER, V12, P409; SCHUH S, 1985, J BIOL CHEM, V260, P4292; Schulte TW, 1996, MOL CELL BIOL, V16, P5839; SCHULTE TW, 1995, J BIOL CHEM, V270, P24585, DOI 10.1074/jbc.270.41.24585; Schumacher RJ, 1996, BIOCHEMISTRY-US, V35, P14889, DOI 10.1021/bi961825h; SCHUMACHER RJ, 1994, J BIOL CHEM, V269, P9493; Shao JY, 2003, J BIOL CHEM, V278, P38117, DOI 10.1074/jbc.C300330200; SMITH DF, 1993, MOL CELL BIOL, V13, P869, DOI 10.1128/MCB.13.2.869; STANCATO LF, 1994, J BIOL CHEM, V269, P22157; STANCATO LF, 1993, J BIOL CHEM, V268, P21711; Sullivan W, 1997, J BIOL CHEM, V272, P8007, DOI 10.1074/jbc.272.12.8007; Uma S, 1997, J BIOL CHEM, V272, P11648; VELDSCHOLTE J, 1992, BIOCHEMISTRY-US, V31, P742, DOI 10.1021/bi00147a029; WARTMANN M, 1994, J BIOL CHEM, V269, P6695; WHITESELL L, 1994, P NATL ACAD SCI USA, V91, P8324, DOI 10.1073/pnas.91.18.8324; Yorgin PD, 2000, J IMMUNOL, V164, P2915, DOI 10.4049/jimmunol.164.6.2915	64	74	75	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 3	2006	281	5					2989	2998		10.1074/jbc.M508687200	http://dx.doi.org/10.1074/jbc.M508687200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	006XT	16330544	hybrid			2022-12-25	WOS:000234931800069
J	Ji, YB; Neverova, I; Van Eyk, JE; Bennett, BM				Ji, YB; Neverova, I; Van Eyk, JE; Bennett, BM			Nitration of tyrosine 92 mediates the activation of rat microsomal glutathione S-transferase by peroxynitrite	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SULFHYDRYL OXIDATION; INACTIVATION; HYDROXYLASE; BINDING	There is increasing evidence that protein function can be modified by nitration of tyrosine residue(s), a reaction catalyzed by proteins with peroxidase activity, or that occurs by interaction with peroxynitrite, a highly reactive oxidant formed by the reaction of nitric oxide with superoxide. Although there are numerous reports describing loss of function after treatment of proteins with peroxynitrite, we recently demonstrated that the microsomal glutathione S-transferase 1 is activated rather than inactivated by peroxynitrite and suggested that this could be attributed to nitration of tyrosine residues rather than to other effects of peroxynitrite. In this report, the nitrated tyrosine residues of peroxynitrite-treated microsomal glutathione S-transferase 1 were characterized by mass spectrometry and their functional significance determined. Of the seven tyrosine residues present in the protein, only those at positions 92 and 153 were nitrated after treatment with peroxynitrite. Three mutants (Y92F, Y153F, and Y92F, Y153F) were created using site-directed mutagenesis and expressed in LLC-PK1 cells. Treatment of the microsomal fractions of these cells with peroxynitrite resulted in an similar to 2-fold increase in enzyme activity in cells expressing the wild type microsomal glutathione S-transferase 1 or the Y153F mutant, whereas the enzyme activity of Y92F and double site mutant was unaffected. These results indicate that activation of microsomal glutathione S-transferase 1 by peroxynitrite is mediated by nitration of tyrosine residue 92 and represents one of the few examples in which a gain in function has been associated with nitration of a specific tyrosine residue.	Queens Univ, Fac Hlth Sci, Dept Pharmacol & Toxicol, Kingston, ON K7L 3N6, Canada; Queens Univ, Fac Hlth Sci, Dept Physiol, Kingston, ON K7L 3N6, Canada; Johns Hopkins Univ, Dept Med, Baltimore, MD 21224 USA	Queens University - Canada; Queens University - Canada; Johns Hopkins University	Bennett, BM (corresponding author), Queens Univ, Fac Hlth Sci, Dept Pharmacol & Toxicol, Kingston, ON K7L 3N6, Canada.	brian.bennett@queensu.ca			NHLBI NIH HHS [P01 HL081427-040003, P01 HL077180-050001, P01 HL077180-020001, P01 HL081427-030003, P01 HL077180-010001, P50 HL084946-029003, P01 HL081427, P50 HL084946, P01 HL081427-010003, P50 HL084946-039003, P01 HL081427-020003, P01 HL077180-030001, P01 HL077180-040001, P01 HL077180, P50 HL084946-019003, P01 HL081427-050003] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL081427, P50HL084946, P01HL077180] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ANDERSSON C, 1994, BBA-PROTEIN STRUCT M, V1204, P298, DOI 10.1016/0167-4838(94)90021-3; ANIYA Y, 1989, J BIOL CHEM, V264, P1998; ANIYA Y, 1992, ARCH BIOCHEM BIOPHYS, V296, P611, DOI 10.1016/0003-9861(92)90617-6; BECKMAN JS, 1994, METHOD ENZYMOL, V233, P229; Busenlehner LS, 2004, BIOCHEMISTRY-US, V43, P11145, DOI 10.1021/bi048716k; CROW JP, 1995, BIOCHEMISTRY-US, V34, P3544, DOI 10.1021/bi00011a008; Francescutti D, 1996, PROTEIN ENG, V9, P189, DOI 10.1093/protein/9.2.189; Grzelak A, 2000, SCAND J CLIN LAB INV, V60, P253, DOI 10.1080/003655100750046413; HABIG WH, 1974, J BIOL CHEM, V249, P7130; Holm PJ, 2002, BBA-PROTEIN STRUCT M, V1594, P276, DOI 10.1016/S0167-4838(01)00311-9; ISCHIROPOULOS H, 1992, ARCH BIOCHEM BIOPHYS, V298, P431, DOI 10.1016/0003-9861(92)90431-U; Jakobsson PJ, 1999, PROTEIN SCI, V8, P689, DOI 10.1110/ps.8.3.689; Ji YB, 2002, BIOCHEM PHARMACOL, V63, P1397, DOI 10.1016/S0006-2952(02)00879-1; Ji YB, 2003, MOL PHARMACOL, V63, P136, DOI 10.1124/mol.63.1.136; Kocis JM, 2002, FRONT BIOSCI-LANDMRK, V7, pA175, DOI 10.2741/kocis; Kuhn DM, 1999, J NEUROSCI, V19, P10289; Kuhn DM, 1999, J BIOL CHEM, V274, P29726, DOI 10.1074/jbc.274.42.29726; LUNDQVIST G, 1992, BIOCHEM PHARMACOL, V43, P1725, DOI 10.1016/0006-2952(92)90702-K; MOSIALOU E, 1989, ARCH BIOCHEM BIOPHYS, V275, P289, DOI 10.1016/0003-9861(89)90375-5; Padmaja S, 1998, ARCH BIOCHEM BIOPHYS, V349, P1, DOI 10.1006/abbi.1997.0407; Shi Q, 2005, PHARMACOL RES, V51, P303, DOI 10.1016/j.phrs.2004.10.001; Sun TH, 1997, BIOCHEM J, V326, P193, DOI 10.1042/bj3260193; Svensson R, 2004, BIOCHEMISTRY-US, V43, P8869, DOI 10.1021/bi0492511; Svensson R, 2000, BIOCHEMISTRY-US, V39, P15144, DOI 10.1021/bi001764u; Takakura K, 1999, ARCH BIOCHEM BIOPHYS, V369, P197, DOI 10.1006/abbi.1999.1374; Wong PSY, 2001, ARCH BIOCHEM BIOPHYS, V394, P216, DOI 10.1006/abbi.2001.2532; Zou MH, 2002, J CLIN INVEST, V109, P817, DOI 10.1172/JCI200214442	27	56	60	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 27	2006	281	4					1986	1991		10.1074/jbc.M509480200	http://dx.doi.org/10.1074/jbc.M509480200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	004NV	16314419	hybrid			2022-12-25	WOS:000234760400018
J	Schultz, SJ; Zhang, MH; Champoux, JJ				Schultz, SJ; Zhang, MH; Champoux, JJ			Sequence, distance, and accessibility are determinants of 5 '-end-directed cleavages by retroviral RNases H	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; MURINE LEUKEMIA-VIRUS; HIV-1 REVERSE-TRANSCRIPTASE; STRAND DNA-SYNTHESIS; POLYPURINE TRACT; RIBONUCLEASE-H; CRYSTAL-STRUCTURE; AVIAN-MYELOBLASTOSIS; PRIMED INITIATION; TYPE-1	The RNase H activity of reverse transcriptase is essential for retroviral replication. RNA5'-end-directed cleavages represent a form of RNase H activity that is carried out on RNA/DNA hybrids that contain a recessed RNA 5'-end. Previously, the distance from the RNA 5'-end has been considered the primary determinant for the location of these cleavages. Employing model hybrid substrates and the HIV-1 and Moloney murine leukemia virus reverse transcriptases, we demonstrate that cleavage sites correlate with specific sequences and that the distance from the RNA 5'-end determines the extent of cleavage. An alignment of sequences flanking multiple RNA 5'-end-directed cleavage sites reveals that both enzymes strongly prefer A or U at the +1 position and C or G at the -2 position, and additionally for HIV-1, A is disfavored at the -4 position. For both enzymes, 5'-end-directed cleavages occurred when sites were positioned between the 13th and 20th nucleotides from the RNA 5'-end, a distance termed the cleavage window. In examining the importance of accessibility to the RNA5'-end, it was found that the extent of 5'-end-directed cleavages observed in substrates containing a free recessed RNA5'-end was most comparable to substrates with a gap of two or three bases between the upstream and downstream RNAs. Together these finding demonstrate that the selection of 5'-end-directed cleavage sites by retroviral RNases H results from a combination of nucleotide sequence, permissible distance, and accessibility to the RNA 5'-end.	Univ Washington, Sch Med, Dept Microbiol, Seattle, WA 98195 USA	University of Washington; University of Washington Seattle	Champoux, JJ (corresponding author), Univ Washington, Sch Med, Dept Microbiol, Box 357242, Seattle, WA 98195 USA.	champoux@u.washington.edu			NCI NIH HHS [R01 CA051605, R37 CA051605, CA 51605] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA051605, R37CA051605] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Arts EJ, 1998, PROG NUCLEIC ACID RE, V58, P339; BENARTZI H, 1993, J BIOL CHEM, V268, P16465; CAPRANICO G, 1990, NUCLEIC ACIDS RES, V18, P6611, DOI 10.1093/nar/18.22.6611; CHAMPOUX JJ, 1993, REVERSE TRANSCRIPTAS, P103; Coffin J, 1997, RETROVIRUSES; DESTEFANO JJ, 1991, J BIOL CHEM, V266, P7423; DESTEFANO JJ, 1994, NUCLEIC ACIDS RES, V22, P3793, DOI 10.1093/nar/22.18.3793; DESTEFANO JJ, 1995, NUCLEIC ACIDS RES, V23, P3901, DOI 10.1093/nar/23.19.3901; DESTEFANO JJ, 1993, NUCLEIC ACIDS RES, V21, P4330, DOI 10.1093/nar/21.18.4330; FINSTON WI, 1984, J VIROL, V51, P26, DOI 10.1128/JVI.51.1.26-33.1984; FU TB, 1992, J VIROL, V66, P4271, DOI 10.1128/JVI.66.7.4271-4278.1992; FUENTES GM, 1995, J BIOL CHEM, V270, P28169, DOI 10.1074/jbc.270.47.28169; Fuentes GM, 1996, NUCLEIC ACIDS RES, V24, P1719, DOI 10.1093/nar/24.9.1719; FURFINE ES, 1991, BIOCHEMISTRY-US, V30, P7041, DOI 10.1021/bi00243a001; FURFINE ES, 1991, J BIOL CHEM, V266, P406; Gao GX, 1998, J VIROL, V72, P5905, DOI 10.1128/JVI.72.7.5905-5911.1998; Gao GX, 1997, P NATL ACAD SCI USA, V94, P407, DOI 10.1073/pnas.94.2.407; Gao HQ, 2001, J VIROL, V75, P11874, DOI 10.1128/JVI.75.23.11874-11880.2001; GOPALAKRISHNAN V, 1992, P NATL ACAD SCI USA, V89, P10763, DOI 10.1073/pnas.89.22.10763; GOTTE M, 1995, EMBO J, V14, P833, DOI 10.1002/j.1460-2075.1995.tb07061.x; Gotte M, 1999, J BIOL CHEM, V274, P11159, DOI 10.1074/jbc.274.16.11159; GUO JH, 1995, BIOCHEMISTRY-US, V34, P5018, DOI 10.1021/bi00015a013; Han GW, 2003, P NATL ACAD SCI USA, V100, P9214, DOI 10.1073/pnas.1533326100; Hang JQ, 2004, BIOCHEM BIOPH RES CO, V317, P321, DOI 10.1016/j.bbrc.2004.03.061; Huang HF, 1998, SCIENCE, V282, P1669, DOI 10.1126/science.282.5394.1669; HUBER HE, 1990, J BIOL CHEM, V265, P10565; JACOBOMOLINA A, 1993, P NATL ACAD SCI USA, V90, P6320, DOI 10.1073/pnas.90.13.6320; KATI WM, 1992, J BIOL CHEM, V267, P25988; Kelleher CD, 2000, J BIOL CHEM, V275, P13061, DOI 10.1074/jbc.275.17.13061; Kopka ML, 2003, J MOL BIOL, V334, P653, DOI 10.1016/j.jmb.2003.09.057; LUO GX, 1990, J VIROL, V64, P592, DOI 10.1128/JVI.64.2.592-597.1990; Misra HS, 1998, J BIOL CHEM, V273, P9785, DOI 10.1074/jbc.273.16.9785; Nowotny M, 2005, CELL, V121, P1005, DOI 10.1016/j.cell.2005.04.024; Palaniappan C, 1997, J BIOL CHEM, V272, P11157, DOI 10.1074/jbc.272.17.11157; Palaniappan C, 1998, J BIOL CHEM, V273, P3808, DOI 10.1074/jbc.273.7.3808; Palaniappan C, 1996, J BIOL CHEM, V271, P2063, DOI 10.1074/jbc.271.47.29605; Powell MD, 1996, J VIROL, V70, P5288, DOI 10.1128/JVI.70.8.5288-5296.1996; PULLEN KA, 1992, J VIROL, V66, P367, DOI 10.1128/JVI.66.1.367-373.1992; PULLEN KA, 1990, J VIROL, V64, P6274, DOI 10.1128/JVI.64.12.6274-6277.1990; RATTRAY AJ, 1987, J VIROL, V61, P2843, DOI 10.1128/JVI.61.9.2843-2851.1987; Rausch JW, 2004, INT J BIOCHEM CELL B, V36, P1752, DOI 10.1016/j.biocel.2004.02.016; Sarafianos SG, 2001, EMBO J, V20, P1449, DOI 10.1093/emboj/20.6.1449; SCHATZ O, 1990, EMBO J, V9, P1171, DOI 10.1002/j.1460-2075.1990.tb08224.x; SCHULTZ SJ, 1995, J BIOL CHEM, V270, P24135, DOI 10.1074/jbc.270.41.24135; Schultz SJ, 2004, J MOL BIOL, V344, P635, DOI 10.1016/j.jmb.2004.09.081; Schultz SJ, 1999, J BIOL CHEM, V274, P34547, DOI 10.1074/jbc.274.49.34547; Schultz SJ, 2003, J VIROL, V77, P5275, DOI 10.1128/JVI.77.9.5275-5285.2003; SHINNICK TM, 1981, NATURE, V293, P543, DOI 10.1038/293543a0; SMITH JS, 1992, J BIOL CHEM, V267, P15071; TELESNITSKY A, 1993, P NATL ACAD SCI USA, V90, P1276, DOI 10.1073/pnas.90.4.1276; VERONESE FD, 1986, SCIENCE, V231, P1289, DOI 10.1126/science.2418504; Wisniewski M, 2000, J BIOL CHEM, V275, P37664, DOI 10.1074/jbc.M007381200; Wisniewski M, 2000, P NATL ACAD SCI USA, V97, P11978, DOI 10.1073/pnas.210392297; Wisniewski M, 2002, J BIOL CHEM, V277, P28400, DOI 10.1074/jbc.M201645200; WOHRL BM, 1990, BIOCHEMISTRY-US, V29, P10141, DOI 10.1021/bi00496a001	55	27	30	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 27	2006	281	4					1943	1955		10.1074/jbc.M510504200	http://dx.doi.org/10.1074/jbc.M510504200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	004NV	16306040	Green Accepted, hybrid			2022-12-25	WOS:000234760400013
J	Shigi, N; Suzuki, T; Terada, T; Shirouzu, M; Yokoyama, S; Watanabe, K				Shigi, N; Suzuki, T; Terada, T; Shirouzu, M; Yokoyama, S; Watanabe, K			Temperature-dependent biosynthesis of 2-thioribothymidine of Thermus thermophilus tRNA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							THIOLATED NUCLEOSIDES PRESENT; IN-VITRO BIOSYNTHESIS; FE-S CLUSTER; EXTREME THERMOPHILE; MIAB PROTEIN; 4-THIOURIDINE; ISCS; ENZYME; THII; RESIDUES	2-Thioribothymidine (s(2)T) is a modified nucleoside of U, specifically found at position 54 of tRNAs from extreme thermophilic microorganisms. The function of the 2-thiocarbonyl group of s(2)T54 is thermostabilization of the three-dimensional structure of tRNA; however, its biosynthesis has not been clarified until now. Using an in vivo tRNA labeling experiment, we demonstrate that the sulfur atom of s(2)T in tRNA is derived from cysteine or sulfate. We attempted to reconstitute 2-thiolation of s(2)T in vitro, using a cell extract of Thermus thermophilus. Specific 2-thiolation of ribothymidine, at position 54, was observed in vitro, in the presence of ATP. Using this assay, we found a strong temperature dependence of the 2-thiolation reaction in vitro as well as expression of 2-thiolation enzymes in vivo. These results suggest that the variable content of s(2)T in vivo at different temperatures may be explained by the above characteristics of the enzymes responsible for the 2-thiolation reaction. Furthermore, we found that another posttranscriptionally modified nucleoside, 1-methyladenosine at position 58, is required for the efficient 2-thiolation of ribothymidine 54 both in vivo and in vitro.	Natl Inst Adv Ind Sci & Technol, Bio Informat Res Ctr, Koto Ku, Tokyo 1350064, Japan; Univ Tokyo, Grad Sch Engn, Dept Chem & Biotechnol, Bunkyo Ku, Tokyo 1138656, Japan; RIKEN, Genom Sci Ctr, Yokohama, Kanagawa 2300045, Japan; RIKEN, Harima Inst, SPring 8, Sayo, Hyogo 6795148, Japan; Univ Tokyo, Grad Sch Sci, Dept Biophys & Biochem, Bunkyo Ku, Tokyo 110033, Japan	National Institute of Advanced Industrial Science & Technology (AIST); University of Tokyo; RIKEN; Japan Synchrotron Radiation Research Institute; RIKEN; University of Tokyo	Watanabe, K (corresponding author), Natl Inst Adv Ind Sci & Technol, Bio Informat Res Ctr, Koto Ku, 2-42 Aomi, Tokyo 1350064, Japan.	kwatanab@jbirc.aist.go.jp	Shigi, Naoki/L-7135-2018; Yokoyama, Shigeyuki/N-6911-2015; Shirouzu, Mikako/A-6521-2016; Suzuki, Tsutomu/J-1776-2015	Shigi, Naoki/0000-0003-4452-8264; Yokoyama, Shigeyuki/0000-0003-3133-7338; Suzuki, Tsutomu/0000-0002-9731-1731				Curran J. F., 1998, MODIFICATION EDITING, P493; DONISKELLER H, 1980, NUCLEIC ACIDS RES, V8, P3133, DOI 10.1093/nar/8.14.3133; Droogmans L, 2003, NUCLEIC ACIDS RES, V31, P2148, DOI 10.1093/nar/gkg314; HAUSNER TP, 1990, GENE DEV, V4, P2146, DOI 10.1101/gad.4.12a.2146; Hoseki J, 1999, J BIOCHEM-TOKYO, V126, P951, DOI 10.1093/oxfordjournals.jbchem.a022539; IGLOI GL, 1988, BIOCHEMISTRY-US, V27, P3842, DOI 10.1021/bi00410a048; Ikeuchi Y, 2005, MOL CELL, V19, P235, DOI 10.1016/j.molcel.2005.06.007; Jager G, 2004, J BACTERIOL, V186, P750, DOI 10.1128/JB.186.3.750-757.2004; Kambampati R, 2000, J BIOL CHEM, V275, P10727, DOI 10.1074/jbc.275.15.10727; Kambampati R, 2003, BIOCHEMISTRY-US, V42, P1109, DOI 10.1021/bi026536+; Kambampati R, 1999, BIOCHEMISTRY-US, V38, P16561, DOI 10.1021/bi991119r; Kaneko T, 2003, EMBO J, V22, P657, DOI 10.1093/emboj/cdg066; KOWALAK JA, 1994, BIOCHEMISTRY-US, V33, P7869, DOI 10.1021/bi00191a014; KOYAMA Y, 1986, J BACTERIOL, V166, P338, DOI 10.1128/jb.166.1.338-340.1986; KUMAGAI I, 1980, P NATL ACAD SCI-BIOL, V77, P1922, DOI 10.1073/pnas.77.4.1922; KUMAGAI I, 1982, J BIOL CHEM, V257, P7388; Lauhon CT, 2004, J BIOL CHEM, V279, P19551, DOI 10.1074/jbc.M401261200; Lauhon CT, 2002, J BACTERIOL, V184, P6820, DOI 10.1128/JB.184.24.6820-6829.2002; Leipuviene R, 2004, J BACTERIOL, V186, P758, DOI 10.1128/JB.186.3.758-766.2004; Mihara H, 2002, APPL MICROBIOL BIOT, V60, P12, DOI 10.1007/s00253-002-1107-4; MILLIGAN JF, 1989, METHOD ENZYMOL, V180, P51; Mueller EG, 2001, J BIOL CHEM, V276, P33588, DOI 10.1074/jbc.M104067200; Mueller EG, 1998, NUCLEIC ACIDS RES, V26, P2606, DOI 10.1093/nar/26.11.2606; Mueller EG, 1999, PROTEIN SCI, V8, P2424; Nilsson K, 2002, J BACTERIOL, V184, P6830, DOI 10.1128/JB.184.24.6830-6835.2002; OSHIMA T, 1971, J GEN APPL MICROBIOL, V17, P513, DOI 10.2323/jgam.17.513; Outten FW, 2004, MOL MICROBIOL, V52, P861, DOI 10.1111/j.1365-2958.2004.04025.x; Palenchar PM, 2000, J BIOL CHEM, V275, P8283, DOI 10.1074/jbc.275.12.8283; Pierrel F, 2003, J BIOL CHEM, V278, P29515, DOI 10.1074/jbc.M301518200; Pierrel F, 2004, J BIOL CHEM, V279, P47555, DOI 10.1074/jbc.M408562200; Pierrel F, 2002, J BIOL CHEM, V277, P13367, DOI 10.1074/jbc.C100609200; SCHNEIDER A, 1994, NUCLEIC ACIDS RES, V22, P3699, DOI 10.1093/nar/22.18.3699; Shigi N, 2002, J BIOL CHEM, V277, P39128, DOI 10.1074/jbc.M207323200; Soma A, 2003, MOL CELL, V12, P689, DOI 10.1016/S1097-2765(03)00346-0; Sprinzl M, 2005, NUCLEIC ACIDS RES, V33, pD139, DOI 10.1093/nar/gki012; TAKADA T, 1993, APPL ENVIRON MICROB, V59, P2737, DOI 10.1128/AEM.59.8.2737-2739.1993; Takahashi Y, 2002, J BIOL CHEM, V277, P28380, DOI 10.1074/jbc.C200365200; Tomari Y, 2000, GENES CELLS, V5, P689, DOI 10.1046/j.1365-2443.2000.00360.x; WATANABE K, 1976, BIOCHEM BIOPH RES CO, V72, P1137, DOI 10.1016/S0006-291X(76)80250-1; WATANABE K, 1974, FEBS LETT, V43, P59, DOI 10.1016/0014-5793(74)81105-1; Wolfe MD, 2004, J BIOL CHEM, V279, P1801, DOI 10.1074/jbc.M310442200; YANISCHPERRON C, 1985, GENE, V33, P103, DOI 10.1016/0378-1119(85)90120-9; Yokoyama S, 1987, Adv Biophys, V23, P115, DOI 10.1016/0065-227X(87)90006-2	43	60	62	3	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 27	2006	281	4					2104	2113		10.1074/jbc.M510771200	http://dx.doi.org/10.1074/jbc.M510771200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	004NV	16317006	hybrid			2022-12-25	WOS:000234760400032
J	Wang, YQ; Dohlman, HG				Wang, YQ; Dohlman, HG			Pheromone-regulated sumoylation of transcription factors that mediate the invasive to mating developmental switch in yeast	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIGNALING SPECIFICITY; FILAMENTOUS-GROWTH; DIFFERENTIAL REGULATION; SUMO-1 MODIFICATION; GLOBAL ANALYSIS; KINASE CASCADE; MAPK; UBIQUITINATION; KSS1; PHOSPHORYLATION	A fundamental question in biology is how different signaling pathways use common signaling proteins to attain different developmental outcomes. The yeast transcription factor Ste12 is required in at least two distinct signaling processes, each regulated by many of the same protein kinases. Whereas Ste12-Ste12 homodimers promote transcription of genes required for mating, Ste12-Tec1 heterodimers activate genes required for invasive growth. We report that Ste12 and Tec1 undergo covalent modification by the ubiquitin-related modifier SUMO. Stimulation by mating pheromone promotes sumoylation of Ste12 and diminishes the sumoylation of Tec1. In the absence of sumoylation Tec1 is more rapidly degraded. We propose that pheromone-regulated sumoylation of Ste12 and Tec1 promotes a developmental switch from the invasive to the mating differentiation program.	Univ N Carolina, Dept Biochem & Biophys, Chapel Hill, NC 27599 USA	University of North Carolina; University of North Carolina Chapel Hill	Dohlman, HG (corresponding author), Univ N Carolina, Dept Biochem & Biophys, Chapel Hill, NC 27599 USA.	hdohlman@med.unc.edu		Dohlman, Henrik/0000-0003-2443-0729	NIGMS NIH HHS [GM 059167, GM 055316, R01 GM059167, R01 GM055316] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM059167, R29GM055316, R01GM055316] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Bao MZ, 2004, CELL, V119, P991, DOI 10.1016/j.cell.2004.11.052; Bardwell L, 1998, P NATL ACAD SCI USA, V95, P15400, DOI 10.1073/pnas.95.26.15400; Bardwell L, 1998, GENE DEV, V12, P2887, DOI 10.1101/gad.12.18.2887; Baur M, 1997, MOL CELL BIOL, V17, P4330, DOI 10.1128/MCB.17.8.4330; Bhalla US, 2002, SCIENCE, V297, P1018, DOI 10.1126/science.1068873; Breitkreutz A, 2003, GENETICS, V165, P997; Breitkreutz A, 2001, CURR BIOL, V11, P1266, DOI 10.1016/S0960-9822(01)00370-0; Bruckner S, 2004, CURR GENET, V46, P331, DOI 10.1007/s00294-004-0545-1; Chou S, 2004, CELL, V119, P981, DOI 10.1016/j.cell.2004.11.053; Cook JG, 1997, NATURE, V390, P85, DOI 10.1038/36355; Cook JG, 1996, GENE DEV, V10, P2831, DOI 10.1101/gad.10.22.2831; Desterro JMP, 1998, MOL CELL, V2, P233, DOI 10.1016/S1097-2765(00)80133-1; DOLAN JW, 1989, P NATL ACAD SCI USA, V86, P5703, DOI 10.1073/pnas.86.15.5703; Elion EA, 2005, SCIENCE, V307, P687, DOI 10.1126/science.1109500; ELION EA, 1993, MOL BIOL CELL, V4, P495, DOI 10.1091/mbc.4.5.495; ELLISON MJ, 1991, J BIOL CHEM, V266, P21150; Erdman S, 2001, GENETICS, V159, P919; GARTNER A, 1992, GENE DEV, V6, P1280, DOI 10.1101/gad.6.7.1280; Gavrias V, 1996, MOL MICROBIOL, V19, P1255, DOI 10.1111/j.1365-2958.1996.tb02470.x; Ghaemmaghami S, 2003, NATURE, V425, P737, DOI 10.1038/nature02046; HAGEN DC, 1991, MOL CELL BIOL, V11, P2952, DOI 10.1128/MCB.11.6.2952; Hao N, 2003, J BIOL CHEM, V278, P46506, DOI 10.1074/jbc.M308432200; Hicke L, 1996, CELL, V84, P277, DOI 10.1016/S0092-8674(00)80982-4; Hochstrasser M, 2000, NAT CELL BIOL, V2, pE153, DOI 10.1038/35019643; Hoege C, 2002, NATURE, V419, P135, DOI 10.1038/nature00991; Hoffman GA, 2002, METHOD ENZYMOL, V344, P617; Hung W, 1997, EUR J BIOCHEM, V245, P241, DOI 10.1111/j.1432-1033.1997.00241.x; Johnson ES, 1999, J CELL BIOL, V147, P981, DOI 10.1083/jcb.147.5.981; Johnson ES, 1997, J BIOL CHEM, V272, P26799, DOI 10.1074/jbc.272.43.26799; LALOUX I, 1994, NUCLEIC ACIDS RES, V22, P999, DOI 10.1093/nar/22.6.999; LIU HP, 1993, SCIENCE, V262, P1741, DOI 10.1126/science.8259520; Long JY, 2004, BIOCHEM J, V379, P23, DOI 10.1042/BJ20031867; Madhani HD, 1999, P NATL ACAD SCI USA, V96, P12530, DOI 10.1073/pnas.96.22.12530; Madhani HD, 1997, SCIENCE, V275, P1314, DOI 10.1126/science.275.5304.1314; MADURA K, 1994, SCIENCE, V265, P1454, DOI 10.1126/science.8073290; Marotti LA, 2002, BIOCHEMISTRY-US, V41, P5067, DOI 10.1021/bi015940q; Nelson C, 2003, NATURE, V421, P187, DOI 10.1038/nature01243; Oehlen LJWM, 1998, J BIOL CHEM, V273, P25089, DOI 10.1074/jbc.273.39.25089; Pawson T, 1997, SCIENCE, V278, P2075, DOI 10.1126/science.278.5346.2075; Roberts CJ, 2000, SCIENCE, V287, P873, DOI 10.1126/science.287.5454.873; ROBERTS RL, 1994, GENE DEV, V8, P2974, DOI 10.1101/gad.8.24.2974; Ross S, 2002, MOL CELL, V10, P831, DOI 10.1016/S1097-2765(02)00682-2; Roth AF, 1996, J CELL BIOL, V134, P661, DOI 10.1083/jcb.134.3.661; Sabbagh W, 2001, MOL CELL, V8, P683, DOI 10.1016/S1097-2765(01)00322-7; Seeler JS, 2003, NAT REV MOL CELL BIO, V4, P690, DOI 10.1038/nrm1200; SENGUPTA P, 1990, MOL CELL BIOL, V10, P6809, DOI 10.1128/MCB.10.12.6809; SONG OK, 1991, GENE DEV, V5, P741, DOI 10.1101/gad.5.5.741; Tedford K, 1997, CURR BIOL, V7, P228, DOI 10.1016/S0960-9822(06)00118-7; Wang YQ, 2003, J BIOL CHEM, V278, P22284, DOI 10.1074/jbc.M301272200; Wang YQ, 2002, J BIOL CHEM, V277, P15766, DOI 10.1074/jbc.M111733200; Wohlschlegel JA, 2004, J BIOL CHEM, V279, P45662, DOI 10.1074/jbc.M409203200; Yang SH, 2003, MOL CELL, V12, P63, DOI 10.1016/S1097-2765(03)00265-X; Zeitlinger J, 2003, CELL, V113, P395, DOI 10.1016/S0092-8674(03)00301-5	53	20	21	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 27	2006	281	4					1964	1969		10.1074/jbc.M508985200	http://dx.doi.org/10.1074/jbc.M508985200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	004NV	16306045	hybrid, Green Published			2022-12-25	WOS:000234760400015
J	Honda, Y; Kitaoka, M				Honda, Y; Kitaoka, M			The first glycosynthase derived from an inverting glycoside hydrolase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BACILLUS-HALODURANS C-125; D-GLUCOSYL FLUORIDE; ACID-SEQUENCE SIMILARITIES; BETA-CELLOBIOSYL FLUORIDES; ALPHA-D-GLUCOSYL; EXO-OLIGOXYLANASE; OLIGOSACCHARIDE SYNTHESIS; CATALYTIC VERSATILITY; CARBOHYDRASE ACTION; EFFICIENT SYNTHESIS	Reducing end xylose-releasing exooligoxylanase (Rex, EC 3.2.1.156) is an inverting GH that hydrolyzes xylooligosaccharides (>= X-3) to release X-1 at their reducing end. The wild-type enzyme exhibited the Hehre resynthesis hydrolysis mechanism, in which alpha-X2F was hydrolyzed to X-2 and HF in the presence of X-1 as an acceptor molecule. However, the transglycosidation product (X-3) was not detectable in the reaction. To convert reducing end xylose-releasing exooligoxylanase to glycosynthase, derivatives with mutations in the catalytic base (Asp-263) were constructed by saturation random mutagenesis. Nine amino acid residue mutants (Asp-263 to Gly, Ala, Val, Thr, Leu, Asn, Cys, Pro, or Ser) were found to possess glycosynthase activity forming X-3 from alpha-X2F and X-1. Among them, D263C showed the highest level of X-3 production, and D263N exhibited the fastest consumption of alpha-X2F. The D263C mutant showed 10-fold lower hydrolytic activity than D263N, resulting in the highest yield of X-3. X-2 was formed from the early stage of the reaction of the D263C mutant, indicating that a portion of the X-3 formed by condensation was hydrolyzed before its release from the enzyme. To acquire glycosynthase activity from inverting enzymes, it is important to minimize the decrease in F--releasing activity while maximizing the decrease in the hydrolytic activity. The present study expands the possibility of conversion of glycosynthases from inverting enzymes.	Natl Food Res Inst, Tsukuba, Ibaraki 3058642, Japan	National Agriculture & Food Research Organization - Japan; National Food Research Institute - Japan	Kitaoka, M (corresponding author), Natl Food Res Inst, 2-1-12,Kannondai, Tsukuba, Ibaraki 3058642, Japan.	mkitaoka@nfri.affrc.go.jp	Kitaoka, Motomitsu/R-1536-2019	Kitaoka, Motomitsu/0000-0002-0083-1838				Becker D, 2000, BIOCHEM J, V345, P315, DOI 10.1042/0264-6021:3450315; DAVIES G, 1995, STRUCTURE, V3, P853, DOI 10.1016/S0969-2126(01)00220-9; Drone J, 2005, EUR J ORG CHEM, V2005, P1977, DOI 10.1002/ejoc.200500014; Ducros VMA, 2003, CHEM BIOL, V10, P619, DOI 10.1016/S1074-5521(03)00143-1; Fort S, 2000, J AM CHEM SOC, V122, P5429, DOI 10.1021/ja9936520; Fushinobu S, 2005, J BIOL CHEM, V280, P17180, DOI 10.1074/jbc.M413693200; HAYASHI M, 1984, CHEM LETT, P1747, DOI 10.1246/cl.1984.1747; HEHRE EJ, 1979, J BIOL CHEM, V254, P5942; Hehre EJ, 2000, ADV CARBOHYD CHEM BI, V55, P265, DOI 10.1016/S0065-2318(00)55007-0; HEHRE EJ, 1982, BIOCHEMISTRY-US, V21, P3090, DOI 10.1021/bi00256a009; Henrissat B, 1996, BIOCHEM J, V316, P695, DOI 10.1042/bj3160695; HENRISSAT B, 1991, BIOCHEM J, V280, P309, DOI 10.1042/bj2800309; HENRISSAT B, 1993, BIOCHEM J, V293, P781, DOI 10.1042/bj2930781; HIGUCHI R, 1988, NUCLEIC ACIDS RES, V16, P7351, DOI 10.1093/nar/16.15.7351; Honda Y, 2005, ACTA CRYSTALLOGR F, V61, P291, DOI 10.1107/S1744309105003635; Honda Y, 2004, J BIOL CHEM, V279, P55097, DOI 10.1074/jbc.M409832200; Hrmova M, 2002, J BIOL CHEM, V277, P30102, DOI 10.1074/jbc.M203971200; KASUMI T, 1987, BIOCHEMISTRY-US, V26, P3010, DOI 10.1021/bi00385a009; KASUMI T, 1986, CARBOHYD RES, V146, P39, DOI 10.1016/0008-6215(86)85022-4; KITAHATA S, 1981, J BIOL CHEM, V256, P6017; KONSTANTINIDIS AK, 1993, BIOCHEM J, V291, P883, DOI 10.1042/bj2910883; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Ly HD, 1999, ANNU REV BIOCHEM, V68, P487, DOI 10.1146/annurev.biochem.68.1.487; Mackenzie LF, 1998, J AM CHEM SOC, V120, P5583, DOI 10.1021/ja980833d; Malet C, 1998, FEBS LETT, V440, P208, DOI 10.1016/S0014-5793(98)01448-3; Mayer C, 2000, FEBS LETT, V466, P40, DOI 10.1016/S0014-5793(99)01751-2; Mayer C, 2001, CHEM BIOL, V8, P437, DOI 10.1016/S1074-5521(01)00022-9; Nashiru O, 2001, ANGEW CHEM INT EDIT, V40, P417, DOI 10.1002/1521-3773(20010119)40:2<417::AID-ANIE417>3.0.CO;2-V; Okuyama M, 2002, BIOSCI BIOTECH BIOCH, V66, P928, DOI 10.1271/bbb.66.928; PACE CN, 1995, PROTEIN SCI, V4, P2411, DOI 10.1002/pro.5560041120; Sambrook J., 1989, MOL CLONING LAB MANU, V2; SINNOTT ML, 1990, CHEM REV, V90, P1171, DOI 10.1021/cr00105a006; Trincone A, 2000, BIOORG MED CHEM LETT, V10, P365, DOI 10.1016/S0960-894X(99)00700-3; Van Lieshout J., 2004, Archaea, V1, P285, DOI 10.1155/2004/731548; Williams SJ, 2000, CARBOHYD RES, V327, P27, DOI 10.1016/S0008-6215(00)00041-0; Yokoyama M, 2000, CARBOHYD RES, V327, P5, DOI 10.1016/S0008-6215(99)00324-9	36	69	74	1	24	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 20	2006	281	3					1426	1431		10.1074/jbc.M511202200	http://dx.doi.org/10.1074/jbc.M511202200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	002ZS	16301312	hybrid			2022-12-25	WOS:000234652000019
J	Munoz-Najar, UM; Neurath, KM; Vumbaca, F; Claffey, KP				Munoz-Najar, UM; Neurath, KM; Vumbaca, F; Claffey, KP			Hypoxia stimulates breast carcinoma cell invasion through MT1-MMP and MMP-2 activation	ONCOGENE			English	Article						breast cancer; hypoxia; invasion; MT1-MMP; RhoA	TYPE-1 MATRIX-METALLOPROTEINASE; MESSENGER-RNA EXPRESSION; EXTRACELLULAR-MATRIX; 1-MATRIX METALLOPROTEINASE; TISSUE INHIBITOR; UP-REGULATION; GELATINASE-A; SURFACE; CANCER; TRAFFICKING	The process of cancer cell invasion involves degradation of the extracellular matrix (ECM) by proteases, integrin adhesion and cell motility. The role of ECM degrading proteases on the hypoxia-induced invasion of breast carcinoma cells was investigated. Hypoxia markedly increased the invasion capacity of MDA-MB-231and MDA-MB-435 breast carcinoma cell lines. Matrix metalloproteinase (MMP) inhibitors blocked the hypoxia-induced invasion, whereas other protease inhibitors had no effect. Antibodies or siRNAs blocking either membrane type-1MMP (MT1-MMP) or MMP-2 were effective in reducing the hypoxia-induced invasion. Serum-free reconstitution experiments confirmed the involvement of the MT1-MMP/ MMP-2/tissue inhibitor of metalloproteinase-2 complex in this hypoxia-induced response. Overexpression of MT1-MMP in a poorly invasive breast cancer cell line, T47-D, promoted hypoxia-induced invasion and MMP-2 activation. Cell surface accumulation and activation of MT1-MMP without apparent regulation at the mRNA or protein levels indicated a post-translational adaptive response to hypoxia. Inhibition of the small GTPase RhoA eliminated the hypoxia-induced invasion and blocked the localization of MT1-MMP to the plasma membrane. Zymographic and molecular analysis of human breast tumors showed a strong correlation between hypoxic microenvironments and MMP-2 activation without changes in MT1-MMP expression. Our studies suggest that hypoxic tumor microenvironments promote breast cancer invasion through an MT1-MMP-dependent mechanism.	Univ Connecticut, Ctr Hlth, Ctr Vasc Biol, Farmington, CT 06030 USA	University of Connecticut	Claffey, KP (corresponding author), Univ Connecticut, Ctr Hlth, Ctr Vasc Biol, EM028,263 Farmington Ave, Farmington, CT 06030 USA.	claffey@nso2.uchc.edu			NCI NIH HHS [CA64436] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA064436, R29CA064436] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Annabi B, 2003, STEM CELLS, V21, P337, DOI 10.1634/stemcells.21-3-337; AZZAM HS, 1993, J NATL CANCER I, V85, P1758, DOI 10.1093/jnci/85.21.1758; Bailly K, 2004, CIRC RES, V94, P1383, DOI 10.1161/01.RES.0000128405.83582.2e; Bartolome RA, 2004, CANCER RES, V64, P2534, DOI 10.1158/0008-5472.CAN-03-3398; Ben-Yosef Y, 2002, CIRC RES, V90, P784, DOI 10.1161/01.RES.0000015588.70132.DC; Brat DJ, 2004, CANCER RES, V64, P920, DOI 10.1158/0008-5472.CAN-03-2073; Brinckerhoff CE, 2002, NAT REV MOL CELL BIO, V3, P207, DOI 10.1038/nrm763; Burke B, 2003, AM J PATHOL, V163, P1233, DOI 10.1016/S0002-9440(10)63483-9; Canning MT, 2001, EXP CELL RES, V267, P88, DOI 10.1006/excr.2001.5243; CAO J, 1995, J BIOL CHEM, V270, P801, DOI 10.1074/jbc.270.2.801; Chang C, 2001, TRENDS CELL BIOL, V11, pS37, DOI 10.1016/S0962-8924(01)82222-4; Claffey KP, 1996, CANCER RES, V56, P172; d'Ortho MP, 1997, EUR J BIOCHEM, V250, P751, DOI 10.1111/j.1432-1033.1997.00751.x; DeClerck YA, 2004, AM J PATHOL, V164, P1131, DOI 10.1016/S0002-9440(10)63200-2; Deschamps AM, 2005, CIRCULATION, V111, P1166, DOI 10.1161/01.CIR.0000157149.71297.3A; Duffy MJ, 2000, BREAST CANCER RES, V2, P252, DOI 10.1186/bcr65; Edwards DR, 1998, NATURE, V394, P527, DOI 10.1038/28961; Egeblad M, 2002, NAT REV CANCER, V2, P161, DOI 10.1038/nrc745; Fahling M, 2004, COMP BIOCHEM PHYS C, V139, P119, DOI 10.1016/j.cca.2004.09.013; Freije JMP, 2003, ADV EXP MED BIOL, V532, P91; Fritz G, 1999, INT J CANCER, V81, P682, DOI 10.1002/(SICI)1097-0215(19990531)81:5<682::AID-IJC2>3.0.CO;2-B; Giannelli G, 2002, INT J CANCER, V97, P425, DOI 10.1002/ijc.1635; Graham CH, 1999, INT J CANCER, V80, P617, DOI 10.1002/(SICI)1097-0215(19990209)80:4<617::AID-IJC22>3.0.CO;2-C; Hewitt R, 1996, ENZYME PROTEIN, V49, P163, DOI 10.1159/000468623; HOFMANN UB, 2005, ARCH DERMATOL RES, V4, P1; Ishigaki S, 1999, JPN J CANCER RES, V90, P516, DOI 10.1111/j.1349-7006.1999.tb00778.x; Itoh Y, 2001, EMBO J, V20, P4782, DOI 10.1093/emboj/20.17.4782; Jiang AX, 2001, P NATL ACAD SCI USA, V98, P13693, DOI 10.1073/pnas.241293698; Jones JL, 1999, J PATHOL, V189, P161, DOI 10.1002/(SICI)1096-9896(199910)189:2<161::AID-PATH406>3.0.CO;2-2; Kalman D, 1999, MOL BIOL CELL, V10, P1665, DOI 10.1091/mbc.10.5.1665; Kinoshita T, 1996, CANCER RES, V56, P2535; Krishnamachary B, 2003, CANCER RES, V63, P1138; Lambert E, 2004, CRIT REV ONCOL HEMAT, V49, P187, DOI 10.1016/j.critrevonc.2003.09.008; Lehti K, 1998, BIOCHEM J, V334, P345, DOI 10.1042/bj3340345; Leufgen H, 2005, J CELL PHYSIOL, V204, P146, DOI 10.1002/jcp.20289; Liu WH, 2002, BIOCHEM BIOPH RES CO, V294, P347, DOI 10.1016/S0006-291X(02)00478-3; Lolmede K, 2003, INT J OBESITY, V27, P1187, DOI 10.1038/sj.ijo.0802407; Mimori K, 2001, ONCOL REP, V8, P401; Mori H, 2002, EMBO J, V21, P3949, DOI 10.1093/emboj/cdf411; Nagase H, 1999, J BIOL CHEM, V274, P21491, DOI 10.1074/jbc.274.31.21491; Nelson AR, 2000, J CLIN ONCOL, V18, P1135, DOI 10.1200/JCO.2000.18.5.1135; Nelson WJ, 2003, NATURE, V422, P766, DOI 10.1038/nature01602; Ottino P, 2004, MOL VIS, V10, P341; Oxford G, 2003, CANCER LETT, V189, P117, DOI 10.1016/S0304-3835(02)00510-4; Paik JH, 2001, J BIOL CHEM, V276, P11830, DOI 10.1074/jbc.M009422200; Petrella BL, 2005, ONCOGENE, V24, P1043, DOI 10.1038/sj.onc.1208305; Remacle A, 2003, J CELL SCI, V116, P3905, DOI 10.1242/jcs.00710; Ridgway PF, 2005, J SURG RES, V124, P180, DOI 10.1016/j.jss.2004.10.020; Rozanov DV, 2004, EXP CELL RES, V293, P81, DOI 10.1016/j.yexcr.2003.10.006; Saad S, 2002, CANCER RES, V62, P283; Sameshima T, 2000, CANCER LETT, V157, P177, DOI 10.1016/S0304-3835(00)00485-7; SATO H, 1994, NATURE, V370, P61, DOI 10.1038/370061a0; Sato Y, 2003, ENDOTHELIUM-J ENDOTH, V10, P287, DOI 10.1080/10623320390272334; Seiki M, 2002, CURR OPIN CELL BIOL, V14, P624, DOI 10.1016/S0955-0674(02)00363-0; Semenza GL, 2002, TRENDS MOL MED, V8, pS62, DOI 10.1016/S1471-4914(02)02317-1; SLOANE JP, 1981, CANCER, V47, P1786, DOI 10.1002/1097-0142(19810401)47:7<1786::AID-CNCR2820470711>3.0.CO;2-8; Stetler-Stevenson WG, 2001, SEMIN CANCER BIOL, V11, P143, DOI 10.1006/scbi.2000.0365; Subarsky P, 2003, CLIN EXP METASTAS, V20, P237, DOI 10.1023/A:1022939318102; Symons M, 2003, CURR BIOL, V13, pR409, DOI 10.1016/S0960-9822(03)00324-5; Takino T, 2003, BIOCHEM BIOPH RES CO, V304, P160, DOI 10.1016/S0006-291X(03)00544-8; Turcotte S, 2003, J CELL SCI, V116, P2247, DOI 10.1242/jcs.00427; Turcotte S, 2004, AM J PHYSIOL-RENAL, V286, pF338, DOI 10.1152/ajprenal.00254.2003; Udayakumar TS, 2003, CANCER RES, V63, P2292; Ueno H, 1997, CANCER RES, V57, P2055; Vaupel P, 2004, ONCOLOGIST, V9, P10, DOI 10.1634/theoncologist.9-90005-10; Wang X, 2004, J BIOL CHEM, V279, P9331, DOI 10.1074/jbc.M312369200; Wang ZP, 2000, J BIOL CHEM, V275, P26411, DOI 10.1074/jbc.M001270200; Yamanaka M, 2000, J DERMATOL SCI, V24, P99, DOI 10.1016/S0923-1811(00)00086-4; Yoon SO, 2003, J BIOCHEM MOL BIOL, V36, P128; Yoon SO, 2005, CANCER RES, V65, P2761, DOI 10.1158/0008-5472.CAN-04-4122; Yu M, 1997, CANCER RES, V57, P5028; Zhai YL, 2005, CANCER RES, V65, P6543, DOI 10.1158/0008-5472.CAN-05-0231; Zucker S, 2004, EXP CELL RES, V293, P164, DOI 10.1016/j.yexcr.2003.10.007; Zucker S, 2002, LAB INVEST, V82, P1673, DOI 10.1097/01.LAB.0000041713.74852.2A; Zucker S, 1998, J BIOL CHEM, V273, P1216, DOI 10.1074/jbc.273.2.1216	75	149	165	2	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 13	2006	25	16					2379	2392		10.1038/sj.onc.1209273	http://dx.doi.org/10.1038/sj.onc.1209273			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	032HC	16369494				2022-12-25	WOS:000236764300010
J	Jermy, AJ; Willer, M; Davis, E; Wilkinson, BM; Stirling, CJ				Jermy, AJ; Willer, M; Davis, E; Wilkinson, BM; Stirling, CJ			The Brl domain in Sec63p is required for assembly of functional endoplasmic reticulum translocons	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-CONDUCTING CHANNEL; ER MEMBRANE; SACCHAROMYCES-CEREVISIAE; YEAST; COMPLEX; BIP; TRANSPORT; SECYEG; IDENTIFICATION; PRECURSORS	Protein translocation into the endoplasmic reticulum occurs at pore-forming structures known as translocons. In yeast, two different targeting pathways converge at a translocation pore formed by the Sec61 complex. The signal recognition particle-dependent pathway targets nascent precursors co-translationally, whereas the Sec62p-dependent pathway targets polypeptides post-translationally. In addition to the Sec61 complex, both pathways also require Sec63p, an integral membrane protein of the Hsp40 family, and Kar2p, a soluble Hsp70 located in the ER lumen. Using a series of mutant alleles, we demonstrate that a conserved Brl (Brr2-like) domain in the COOH-terminal cytosolic region of Sec63p is essential for function both in vivo and in vitro. We further demonstrate that this domain is required for assembly of two oligomeric complexes of 350 and 380 kDa, respectively. The larger of these corresponds to the heptameric "SEC complex" required for post-translational translocation. However, the 350-kDa complex represents a newly defined hexameric SEC' complex comprising Sec61p, Sss1p, Sbh1p, Sec63p, Sec71p, and Sec72p. Our data indicate that the SEC' complex is required for co-translational protein translocation across the yeast ER membrane.	Univ Manchester, Fac Life Sci, Manchester M13 9PT, Lancs, England	University of Manchester	Stirling, CJ (corresponding author), Univ Manchester, Fac Life Sci, Michael Smith Bldg,Oxford Rd, Manchester M13 9PT, Lancs, England.	colin.stirling@manchester.ac.uk		Jermy, Andrew/0000-0002-7454-0670	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		Alder NN, 2005, J CELL BIOL, V168, P389, DOI 10.1083/jcb.200409174; Beckmann R, 2001, CELL, V107, P361, DOI 10.1016/S0092-8674(01)00541-4; Beckmann R, 1997, SCIENCE, V278, P2123, DOI 10.1126/science.278.5346.2123; Bessonneau P, 2002, EMBO J, V21, P995, DOI 10.1093/emboj/21.5.995; Breyton C, 2002, NATURE, V418, P662, DOI 10.1038/nature00827; BRODSKY JL, 1993, J CELL BIOL, V123, P1355, DOI 10.1083/jcb.123.6.1355; Craven RA, 1996, EMBO J, V15, P2640, DOI 10.1002/j.1460-2075.1996.tb00624.x; DESHAIES RJ, 1991, NATURE, V349, P806, DOI 10.1038/349806a0; Dudek J, 2002, EMBO J, V21, P2958, DOI 10.1093/emboj/cdf315; ESNAULT Y, 1993, EMBO J, V12, P4083, DOI 10.1002/j.1460-2075.1993.tb06092.x; FELDHEIM D, 1992, MOL CELL BIOL, V12, P3288, DOI 10.1128/MCB.12.7.3288; GORLICH D, 1993, CELL, V75, P615, DOI 10.1016/0092-8674(93)90483-7; GREEN N, 1992, J CELL BIOL, V116, P597, DOI 10.1083/jcb.116.3.597; Haigh NG, 2002, J CELL BIOL, V156, P261, DOI 10.1083/jcb.200110074; Hamman BD, 1998, CELL, V92, P747, DOI 10.1016/S0092-8674(00)81403-8; Hanein D, 1996, CELL, V87, P721, DOI 10.1016/S0092-8674(00)81391-4; Johnson AE, 1999, ANNU REV CELL DEV BI, V15, P799, DOI 10.1146/annurev.cellbio.15.1.799; Longtine MS, 1998, YEAST, V14, P953, DOI 10.1002/(SICI)1097-0061(199807)14:10<953::AID-YEA293>3.3.CO;2-L; Manting EH, 2000, EMBO J, V19, P852, DOI 10.1093/emboj/19.5.852; Matlack KES, 1999, CELL, V97, P553, DOI 10.1016/S0092-8674(00)80767-9; Menetret JF, 2000, MOL CELL, V6, P1219, DOI 10.1016/S1097-2765(00)00118-0; Meyer HA, 2000, J BIOL CHEM, V275, P14550, DOI 10.1074/jbc.275.19.14550; Misselwitz E, 1999, J BIOL CHEM, V274, P20110, DOI 10.1074/jbc.274.29.20110; Mitra K, 2005, NATURE, V438, P318, DOI 10.1038/nature04133; Noble SM, 1996, GENETICS, V143, P67; PANZNER S, 1995, CELL, V81, P561, DOI 10.1016/0092-8674(95)90077-2; Plath K, 2000, J CELL BIOL, V151, P167, DOI 10.1083/jcb.151.1.167; Ponting CP, 2000, BIOCHEM J, V351, P527, DOI 10.1042/0264-6021:3510527; SCHAGGER H, 1991, ANAL BIOCHEM, V199, P223, DOI 10.1016/0003-2697(91)90094-A; THOMAS BJ, 1989, CELL, V56, P619, DOI 10.1016/0092-8674(89)90584-9; Tyedmers J, 2000, P NATL ACAD SCI USA, V97, P7214, DOI 10.1073/pnas.97.13.7214; Tyson JR, 2000, EMBO J, V19, P6440, DOI 10.1093/emboj/19.23.6440; van den Berg B, 2004, NATURE, V427, P36, DOI 10.1038/nature02218; van Nues RW, 2001, GENETICS, V157, P1451; VOGEL JP, 1990, J CELL BIOL, V110, P1885, DOI 10.1083/jcb.110.6.1885; Wang L, 1999, FEBS LETT, V457, P316, DOI 10.1016/S0014-5793(99)01075-3; Wang X, 2005, J CELL SCI, V118, P723, DOI 10.1242/jcs.01671; Wilkinson BM, 1997, J MEMBRANE BIOL, V155, P189, DOI 10.1007/s002329900171; Willer M, 2003, BIOCHEMISTRY-US, V42, P7171, DOI 10.1021/bi034395l; Willer M, 2003, YEAST, V20, P133, DOI 10.1002/yea.954; Wittke S, 2000, MOL BIOL CELL, V11, P3859, DOI 10.1091/mbc.11.11.3859; Young BP, 2001, EMBO J, V20, P262, DOI 10.1093/emboj/20.1.262	42	40	40	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 24	2006	281	12					7899	7906		10.1074/jbc.M511402200	http://dx.doi.org/10.1074/jbc.M511402200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	022BZ	16368690	hybrid			2022-12-25	WOS:000236031000025
J	Agirre, X; Roman-Gomez, J; Jimenez-Velasco, A; Garate, L; Montiel-Duarte, C; Navarro, G; Vazquez, I; Zalacain, M; Calasanz, MJ; Heiniger, A; Torres, A; Minna, JD; Prosper, F				Agirre, X; Roman-Gomez, J; Jimenez-Velasco, A; Garate, L; Montiel-Duarte, C; Navarro, G; Vazquez, I; Zalacain, M; Calasanz, MJ; Heiniger, A; Torres, A; Minna, JD; Prosper, F			ASPP1, a common activator of TP53, is inactivated by aberrant methylation of its promoter in acute lymphoblastic leukemia	ONCOGENE			English	Article						ASPP; TP53; methylation; MSP	P53-INTERACTING PROTEIN 53BP2; MESSENGER-RNA EXPRESSION; GEL-ELECTROPHORESIS; WILD-TYPE; HYPERMETHYLATION; CANCER; CHILDREN; GENES; CHEMOTHERAPY; MUTATIONS	We have analyzed the regulation and expression of ASPP members, genes implicated in the regulation of the apoptotic function of the TP53 tumor-suppressor gene, in acute lymphoblastic leukemia ( ALL). Expression of ASPP1 was significantly reduced in ALL and was dependent on hypermethylation of the ASPP1 gene promoter. Abnormal ASPP1 expression was associated with normal function of the tumor-suppressor gene TP53 in ALL. The analyses of 180 patients with ALL at diagnosis showed that the ASPP1 promoter was hypermethylated in 25% of cases with decreased mRNA expression. Methylation was significantly higher in adult ALL vs childhood ALL ( 32 vs 17%, P = 0.03) and T-ALL vs B-ALL ( 50 vs 9%, P = 0.001). Relapse rate ( 62 vs 44%, P = 0.05) and mortality ( 59 vs 43%, P = 0.05) were significantly higher in patients with methylated ASPP1. DFS and OS were 32.8 and 33.7% for patients with unmethylated ASPP1 and 6.1 and 9.9% for methylated patients ( P < 0.001 y P < 0.02, respectively). On the multivariate analysis, methylation of the ASPP1 gene promoter was an independent poor prognosis factor in ALL patients. Our results demonstrate that decreased expression of ASPP1 in patients with ALL is due to an abnormal methylation of its promoter and is associated with a poor prognosis.	Univ Navarra, Clin Univ, Fdn Appl Med Res, Div Canc & Area Cell Therapy, Navarra 31008, Spain; Univ Navarra, Clin Univ, Serv Hematol, Navarra 31008, Spain; Hosp Reina Sofia, Dept Hematol, Cordoba, Spain; Univ Navarra, Clin Univ, Dept Pediat, Navarra 31008, Spain; Hosp Carlos Haya, Dept Hematol, Malaga, Spain; Univ Navarra, Dept Genet, Sch Sci, Navarra 31008, Spain; Univ Texas, SW Med Ctr, Hamon Ctr Therapeut Oncol Res, Dallas, TX 75230 USA; Univ Texas, SW Med Ctr, Dept Internal Med, Dallas, TX 75230 USA; Univ Texas, SW Med Ctr, Dept Pharmacol, Dallas, TX 75230 USA	University of Navarra; University of Navarra; Hospital Universitario Reina Sofia - Cordoba; University of Navarra; Hospital Carlos Haya; University of Navarra; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Prosper, F (corresponding author), Univ Navarra, Clin Univ, Fdn Appl Med Res, Div Canc & Area Cell Therapy, Avda Pio 12 36, Navarra 31008, Spain.	fprosper@unav.es	Prosper, Felipe/H-6859-2017; Agirre, Xabier/ABE-4110-2020; Calasanz, MJ/R-5813-2016; Montiel-Duarte, Cristina/AAB-3758-2019	Prosper, Felipe/0000-0001-6115-8790; Calasanz, MJ/0000-0002-0374-3008; Montiel-Duarte, Cristina/0000-0002-9144-8809				Agirre X, 2003, ONCOGENE, V22, P1070, DOI 10.1038/sj.onc.1206236; Agirre X, 2002, BIOTECHNIQUES, V32, P1064, DOI 10.2144/02325rr01; Ao Y, 2001, ONCOGENE, V20, P2720, DOI 10.1038/sj.onc.1204352; Bergamaschi D, 2004, MOL CELL BIOL, V24, P1341, DOI 10.1128/MCB.24.3.1341-1350.2004; Bergamaschi D, 2003, NAT GENET, V33, P162, DOI 10.1038/ng1070; Bird A, 2002, GENE DEV, V16, P6, DOI 10.1101/gad.947102; BORRESEN AL, 1991, P NATL ACAD SCI USA, V88, P8405, DOI 10.1073/pnas.88.19.8405; DEFROMENTEL CC, 1992, GENE CHROMOSOME CANC, V4, P1; Esteller M, 2002, ONCOGENE, V21, P5427, DOI 10.1038/sj.onc.1205600; Gorina S, 1996, SCIENCE, V274, P1001, DOI 10.1126/science.274.5289.1001; HAMELIN R, 1993, ONCOGENE, V8, P2213; HOLLSTEIN M, 1994, NUCLEIC ACIDS RES, V22, P3551; IWABUCHI K, 1994, P NATL ACAD SCI USA, V91, P6098, DOI 10.1073/pnas.91.13.6098; Iwabuchi K, 1998, J BIOL CHEM, V273, P26061, DOI 10.1074/jbc.273.40.26061; Liu ZJ, 2005, FEBS LETT, V579, P1587, DOI 10.1016/j.febslet.2005.01.069; Liu ZJ, 2004, LEUKEMIA, V18, P880, DOI 10.1038/sj.leu.2403300; Lopez CD, 2000, MOL CELL BIOL, V20, P8018, DOI 10.1128/MCB.20.21.8018-8025.2000; Mori T, 2000, FEBS LETT, V465, P124, DOI 10.1016/S0014-5793(99)01726-3; Naumovski L, 1996, MOL CELL BIOL, V16, P3884; Ortega JJ, 2001, HAEMATOLOGICA, V86, P586; Ribera JM, 2002, HAEMATOLOGICA, V87, P154; Ribera JM, 1998, HAEMATOLOGICA, V83, P222; Roman-Gomez J, 2004, BLOOD, V104, P2492, DOI 10.1182/blood-2004-03-0954; Roman-Gomez J, 2004, BRIT J CANCER, V91, P707, DOI 10.1038/sj.bjc.6602008; Roman-Gomez J, 2004, LEUKEMIA, V18, P362, DOI 10.1038/sj.leu.2403223; Rossi D, 2004, HAEMATOLOGICA, V89, P154; Samuels-Lev Y, 2001, MOL CELL, V8, P781, DOI 10.1016/S1097-2765(01)00367-7; Slee EA, 2003, TOXICOL LETT, V139, P81, DOI 10.1016/S0378-4274(02)00421-6; Smith M, 1996, J CLIN ONCOL, V14, P18, DOI 10.1200/JCO.1996.14.1.18; SOUSSI T, 1994, INT J CANCER, V57, P1, DOI 10.1002/ijc.2910570102; Zhang XW, 2005, LEUKEMIA RES, V29, P179, DOI 10.1016/j.leukres.2004.07.001	31	56	63	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 23	2006	25	13					1862	1870		10.1038/sj.onc.1209236	http://dx.doi.org/10.1038/sj.onc.1209236			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	024VQ	16314841	Green Published			2022-12-25	WOS:000236224800003
J	Rowland, P; Blaney, FE; Smyth, MG; Jones, JJ; Leydon, VR; Oxbrow, AK; Lewis, CJ; Tennant, MG; Modi, S; Eggleston, DS; Chenery, RJ; Bridges, AM				Rowland, P; Blaney, FE; Smyth, MG; Jones, JJ; Leydon, VR; Oxbrow, AK; Lewis, CJ; Tennant, MG; Modi, S; Eggleston, DS; Chenery, RJ; Bridges, AM			Crystal structure of human cytochrome P450 2D6	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVE-SITE; ESCHERICHIA-COLI; SUBSTRATE-SPECIFICITY; GENETIC-POLYMORPHISM; PHARMACOPHORE MODEL; ENZYMATIC-ACTIVITY; COMBINED PROTEIN; DRUG-METABOLISM; CYP2D ISOFORMS; AMINO-ACID	Cytochrome P450 2D6 is a heme-containing enzyme that is responsible for the metabolism of at least 20% of known drugs. Substrates of 2D6 typically contain a basic nitrogen and a planar aromatic ring. The crystal structure of human 2D6 has been solved and refined to 3.0 angstrom resolution. The structure shows the characteristic P450 fold as seen in other members of the family, with the lengths and orientations of the individual secondary structural elements being very similar to those seen in 2C9. There are, however, several important differences, the most notable involving the F helix, the F-G loop, the B' helix, beta sheet 4, and part of beta sheet 1, all of which are situated on the distal face of the protein. The 2D6 structure has a well defined active site cavity above the heme group, containing many important residues that have been implicated in substrate recognition and binding, including Asp-301, Glu-216, Phe-483, and Phe-120. The crystal structure helps to explain how Asp-301, Glu-216, and Phe-483 can act as substrate binding residues and suggests that the role of Phe-120 is to control the orientation of the aromatic ring found in most substrates with respect to the heme. The structure has been compared with published homology models and has been used to explain much of the reported site-directed mutagenesis data and help understand the metabolism of several compounds.	GlaxoSmithKline, Dept Discovery Res, Harlow CM19 5AW, Essex, England	GlaxoSmithKline	Rowland, P (corresponding author), GlaxoSmithKline, Dept Discovery Res, New Frontiers Sci Pk,3rd Ave, Harlow CM19 5AW, Essex, England.	Paul_2_Rowland@gsk.com		Tennant, Mike/0000-0001-6083-3109				ABAGYAN R, 1994, J COMPUT CHEM, V15, P488, DOI 10.1002/jcc.540150503; *ACC INC, 1999, QUANTA98 VERS 98 111; Allorge D, 2005, PROTEINS, V59, P339, DOI 10.1002/prot.20399; Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; BARNES HJ, 1991, P NATL ACAD SCI USA, V88, P5597, DOI 10.1073/pnas.88.13.5597; Bathelt CM, 2004, ORG BIOMOL CHEM, V2, P2998, DOI 10.1039/b410729b; Bertz RJ, 1997, CLIN PHARMACOKINET, V32, P210, DOI 10.2165/00003088-199732030-00004; BROOKS BR, 1983, J COMPUT CHEM, V4, P187, DOI 10.1002/jcc.540040211; Chowdry J, 2002, BRIT J CLIN PHARMACO, V53, p443P; DALY AK, 1995, HUM GENET, V95, P337; de Graaf C, 2005, J MED CHEM, V48, P2725, DOI 10.1021/jm040180d; de Groot MJ, 1999, J MED CHEM, V42, P4062, DOI 10.1021/jm991058v; de Groot MJ, 1999, J MED CHEM, V42, P1515, DOI 10.1021/jm981118h; De Rienzo F, 2000, J COMPUT AID MOL DES, V14, P93, DOI 10.1023/A:1008187802746; deGroot MJ, 1996, CHEM RES TOXICOL, V9, P1079, DOI 10.1021/tx960003i; DeLano W.L., 2002, PYMOL MOL GRAPHICS S; Eddy SR, 1996, CURR OPIN STRUC BIOL, V6, P361, DOI 10.1016/S0959-440X(96)80056-X; ELLIS SW, 1995, J BIOL CHEM, V270, P29055, DOI 10.1074/jbc.270.49.29055; Ellis SW, 1996, BIOCHEM J, V316, P647, DOI 10.1042/bj3160647; Ellis SW, 2002, BRIT J CLIN PHARMACO, V53, p444P; Ellis SW, 2000, BIOCHEM J, V345, P565, DOI 10.1042/0264-6021:3450565; Emsley P, 2004, ACTA CRYSTALLOGR D, V60, P2126, DOI 10.1107/S0907444904019158; Flanagan JU, 2004, BIOCHEM J, V380, P353, DOI 10.1042/BJ20040062; GILLAM EMJ, 1993, ARCH BIOCHEM BIOPHYS, V305, P123, DOI 10.1006/abbi.1993.1401; GONZALEZ FJ, 1988, NATURE, V331, P442, DOI 10.1038/331442a0; GOTOH O, 1992, J BIOL CHEM, V267, P83; GOUGH AC, 1990, NATURE, V347, P773, DOI 10.1038/347773a0; Guengerich FP, 2001, CHEM RES TOXICOL, V14, P611, DOI 10.1021/tx0002583; Guengerich FP, 2003, BIOCHEMISTRY-US, V42, P1245, DOI 10.1021/bi027085w; Hanna IH, 2001, ARCH BIOCHEM BIOPHYS, V393, P255, DOI 10.1006/abbi.2001.2510; Hayhurst GP, 2001, BIOCHEM J, V355, P373, DOI 10.1042/0264-6021:3550373; Hiroi T, 2002, DRUG METAB DISPOS, V30, P970, DOI 10.1124/dmd.30.9.970; Keizers PHJ, 2004, BIOCHEM PHARMACOL, V68, P2263, DOI 10.1016/j.bcp.2004.08.013; Kirton SB, 2002, PROTEINS, V49, P216, DOI 10.1002/prot.10192; KLEYWEGT GJ, 1994, ACTA CRYSTALLOGR D, V50, P178, DOI 10.1107/S0907444993011333; Kleywegt GJ, 1996, ACTA CRYSTALLOGR D, V52, P842, DOI 10.1107/S0907444995016477; KOYMANS L, 1992, CHEM RES TOXICOL, V5, P211, DOI 10.1021/tx00026a010; KOYMANS LMH, 1993, J COMPUT AID MOL DES, V7, P281, DOI 10.1007/BF00125503; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; LENNARD MS, 1990, PHARMACOL TOXICOL, V67, P273, DOI 10.1111/j.1600-0773.1990.tb00830.x; Lewis D. F. V., 2002, Xenobiotica, V32, P305, DOI 10.1080/00498250110112015; Lewis DFV, 1997, XENOBIOTICA, V27, P319, DOI 10.1080/004982597240497; LEWIS DFV, 1995, XENOBIOTICA, V25, P333, DOI 10.3109/00498259509061857; Lightfoot T, 2000, XENOBIOTICA, V30, P219, DOI 10.1080/004982500237622; Lussenburg BMA, 2005, BIOCHEM PHARMACOL, V70, P1253, DOI 10.1016/j.bcp.2005.07.002; McLaughlin LA, 2005, J BIOL CHEM, V280, P38617, DOI 10.1074/jbc.M505974200; MEYER UA, 1990, PHARMACOL THERAPEUT, V46, P297, DOI 10.1016/0163-7258(90)90096-K; Modi S, 1996, BIOCHEMISTRY-US, V35, P4540, DOI 10.1021/bi952742o; Murshudov GN, 1997, ACTA CRYSTALLOGR D, V53, P240, DOI 10.1107/S0907444996012255; OMURA T, 1964, J BIOL CHEM, V239, P2379; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Paine MJI, 2003, J BIOL CHEM, V278, P4021, DOI 10.1074/jbc.M209519200; Pritchard MP, 1997, ARCH BIOCHEM BIOPHYS, V345, P342, DOI 10.1006/abbi.1997.0265; RAVICHANDRAN KG, 1993, SCIENCE, V261, P731, DOI 10.1126/science.8342039; RICHARDSON TH, 1993, ARCH BIOCHEM BIOPHYS, V300, P510, DOI 10.1006/abbi.1993.1069; Schleinkofer K, 2005, EMBO REP, V6, P584, DOI 10.1038/sj.embor.7400420; Schlichting I, 2000, SCIENCE, V287, P1615, DOI 10.1126/science.287.5458.1615; Schoch GA, 2004, J BIOL CHEM, V279, P9497, DOI 10.1074/jbc.M312516200; Smith DA, 1997, DRUG DISCOV TODAY, V2, P406, DOI 10.1016/S1359-6446(97)01081-7; Snyder R, 2002, QUANT STRUCT-ACT REL, V21, P357, DOI 10.1002/1521-3838(200210)21:4<357::AID-QSAR357>3.0.CO;2-D; Storoni LC, 2004, ACTA CRYSTALLOGR D, V60, P432, DOI 10.1107/S0907444903028956; SZCZESNASKORUPA E, 1993, ARCH BIOCHEM BIOPHYS, V304, P170, DOI 10.1006/abbi.1993.1335; Venhorst J, 2000, DRUG METAB DISPOS, V28, P1524; Venhorst J, 2003, J MED CHEM, V46, P74, DOI 10.1021/jm0209578; vonWachenfeldt C, 1997, ARCH BIOCHEM BIOPHYS, V339, P107, DOI 10.1006/abbi.1996.9859; *WAV INC, 1999, SPARTAN SGI VERS 5 1; Wester MR, 2004, J BIOL CHEM, V279, P35630, DOI 10.1074/jbc.M405427200; Williams D, 2000, PERFORM RES, V5, P131; Williams PA, 2003, NATURE, V424, P464, DOI 10.1038/nature01862; Williams PA, 2004, SCIENCE, V305, P683, DOI 10.1126/science.1099736; Winn MD, 2001, ACTA CRYSTALLOGR D, V57, P122, DOI 10.1107/S0907444900014736; Yano JK, 2005, NAT STRUCT MOL BIOL, V12, P822, DOI 10.1038/nsmb971; Yano JK, 2004, J BIOL CHEM, V279, P38091, DOI 10.1074/jbc.C400293200; Zhang YQ, 1999, BIOCHEM BIOPH RES CO, V258, P32, DOI 10.1006/bbrc.1999.0569	75	359	374	2	35	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 17	2006	281	11					7614	7622		10.1074/jbc.M511232200	http://dx.doi.org/10.1074/jbc.M511232200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	022BY	16352597	hybrid			2022-12-25	WOS:000236030900083
J	Mahfoud, M; Sukumaran, S; Hulsmann, P; Grieger, K; Niederweis, M				Mahfoud, M; Sukumaran, S; Hulsmann, P; Grieger, K; Niederweis, M			Topology of the porin MspA in the outer membrane of Mycobacterium smegmatis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-LACTAM ANTIBIOTICS; CELL-WALL PERMEABILITY; FREEZE-SUBSTITUTION; BACTERIAL PORINS; PROTEIN; ULTRASTRUCTURE; ACID; TUBERCULOSIS; CHELONAE; BARRIER	MspA is the major porin of Mycobacterium smegmatis mediating the exchange of hydrophilic solutes across the outer membrane (OM). It is the prototype of a new family of octameric porins with a single central channel of 9.6 nm in length and consists of two hydrophobic beta-barrels of 3.7 nm in length and a more hydrophilic, globular rim domain. The length of the hydrophobic domain of MspA does not match the thicknesses of mycobacterial OMs of 5-12 nm as derived from electron micrographs. Further, the membrane topology of MspA is unknown as it is for any other mycobacterial OM protein. We used MspA as a molecular ruler to define the boundaries of the OM of M. smegmatis by surface labeling of single cysteine mutants. Seventeen mutants covered the surface of the rim domain and were biotinylated with a membrane-impermeable reagent. The label efficiencies in vitro were remarkably similar to the predicted accessibilities of the cysteines. By contrast, six of these mutants were protected from biotinylation in M. smegmatis cells. Tryptophan 21 defines a horizontal plane that dissects the surface-exposed versus the membrane-protected residues of MspA. The 8 phenylalanines at position 99 form a ring at the periplasmic end of the hydrophobic beta-barrel domain. These results indicated that (i) the membrane boundaries of MspA are defined by aromatic girdles as in porins of Gram-negative bacteria and (ii) loops and a 3.4-nm-long part of the hydrophilic rim domain are embedded into the OM of M. smegmatis. This is the first report suggesting that elements other than hydrophobic alpha-helices or beta-sheets are integrated into a lipid membrane.	Univ Erlangen Nurnberg, Lehrstuhl Mikrobiol, D-91058 Erlangen, Germany; Univ Alabama, Dept Microbiol, Birmingham, AL 35294 USA	University of Erlangen Nuremberg; University of Alabama System; University of Alabama Birmingham	Niederweis, M (corresponding author), Univ Erlangen Nurnberg, Lehrstuhl Mikrobiol, Staudtstr 5, D-91058 Erlangen, Germany.	mnieder@uab.edu						Bi WL, 1998, ANAL BIOCHEM, V256, P137, DOI 10.1006/abio.1997.2516; BRENNAN PJ, 1995, ANNU REV BIOCHEM, V64, P29, DOI 10.1146/annurev.bi.64.070195.000333; Camacho LR, 2001, J BIOL CHEM, V276, P19845, DOI 10.1074/jbc.M100662200; CHAMBERS HF, 1995, ANTIMICROB AGENTS CH, V39, P2620, DOI 10.1128/AAC.39.12.2620; Chatterjee D, 2001, CELL MOL LIFE SCI, V58, P2018, DOI 10.1007/PL00000834; COWAN SW, 1992, NATURE, V358, P727, DOI 10.1038/358727a0; Diederichs K, 1998, PROTEIN SCI, V7, P2413, DOI 10.1002/pro.5560071119; Engelhardt H, 2002, J BIOL CHEM, V277, P37567, DOI 10.1074/jbc.M206983200; Etienne G, 2002, MICROBIOL-SGM, V148, P3089, DOI 10.1099/00221287-148-10-3089; Faller M, 2004, SCIENCE, V303, P1189, DOI 10.1126/science.1094114; Heinz C, 2000, ANAL BIOCHEM, V285, P113, DOI 10.1006/abio.2000.4728; Heinz C, 2003, J BIOL CHEM, V278, P8678, DOI 10.1074/jbc.M212280200; Heinze M, 2004, BIOCHEMISTRY-US, V43, P931, DOI 10.1021/bi030175w; JARLIER V, 1991, ANTIMICROB AGENTS CH, V35, P1937, DOI 10.1128/AAC.35.9.1937; JARLIER V, 1990, J BACTERIOL, V172, P1418, DOI 10.1128/jb.172.3.1418-1423.1990; Kaback HR, 2001, NAT REV MOL CELL BIO, V2, P610, DOI 10.1038/35085077; Kaps I, 2001, GENE, V278, P115, DOI 10.1016/S0378-1119(01)00712-0; Killian JA, 1996, BIOCHEMISTRY-US, V35, P1037, DOI 10.1021/bi9519258; Koebnik R, 2000, MOL MICROBIOL, V37, P239, DOI 10.1046/j.1365-2958.2000.01983.x; KREUSCH A, 1994, J MOL BIOL, V243, P891, DOI 10.1006/jmbi.1994.1690; Liu J, 1996, J BIOL CHEM, V271, P29545, DOI 10.1074/jbc.271.47.29545; LIU J, 1995, P NATL ACAD SCI USA, V92, P11254, DOI 10.1073/pnas.92.24.11254; Minnikin D. E., 1982, BIOL MYCOBACTERIA, P95; Minnikin DE, 2002, CHEM BIOL, V9, P545, DOI 10.1016/S1074-5521(02)00142-4; Molloy MP, 2000, EUR J BIOCHEM, V267, P2871, DOI 10.1046/j.1432-1327.2000.01296.x; Niederweis M, 1999, MOL MICROBIOL, V33, P933, DOI 10.1046/j.1365-2958.1999.01472.x; Niederweis M, 2003, MOL MICROBIOL, V49, P1167, DOI 10.1046/j.1365-2958.2003.03662.x; Nikaido H, 2003, MICROBIOL MOL BIOL R, V67, P593, DOI 10.1128/MMBR.67.4.593-656.2003; NIKAIDO H, 1993, MOL MICROBIOL, V8, P1025, DOI 10.1111/j.1365-2958.1993.tb01647.x; PAUL TR, 1993, ZBL BAKT-INT J MED M, V279, P450; PAUL TR, 1994, INFECT IMMUN, V62, P1542, DOI 10.1128/IAI.62.5.1542-1550.1994; PAUL TR, 1992, J BACTERIOL, V174, P6508, DOI 10.1128/JB.174.20.6508-6517.1992; RAUCH G, 1994, BIOCHEM BIOPH RES CO, V200, P908, DOI 10.1006/bbrc.1994.1536; Russell DG, 2002, J CELL BIOL, V158, P421, DOI 10.1083/jcb.200205034; Sander P, 1996, MOL MICROBIOL, V22, P841, DOI 10.1046/j.1365-2958.1996.01532.x; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; Schulz GE, 1993, CURR OPIN CELL BIOL, V5, P701, DOI 10.1016/0955-0674(93)90143-E; Stahl C, 2001, MOL MICROBIOL, V40, P451, DOI 10.1046/j.1365-2958.2001.02394.x; Stephan J, 2005, MOL MICROBIOL, V58, P714, DOI 10.1111/j.1365-2958.2005.04878.x; Tieleman DP, 1998, BIOPHYS J, V74, P2786, DOI 10.1016/S0006-3495(98)77986-X; TRIAS J, 1992, SCIENCE, V258, P1479, DOI 10.1126/science.1279810; Ulmschneider MB, 2001, BBA-BIOMEMBRANES, V1512, P1, DOI 10.1016/S0005-2736(01)00299-1; URRY DW, 1994, BIOPOLYMERS, V34, P889, DOI 10.1002/bip.360340708; White SH, 2001, J BIOL CHEM, V276, P32395, DOI 10.1074/jbc.R100008200; White SH, 1999, ANNU REV BIOPH BIOM, V28, P319, DOI 10.1146/annurev.biophys.28.1.319; Wimley WC, 1996, BIOCHEMISTRY-US, V35, P5109, DOI 10.1021/bi9600153; Zachariae U, 2002, PROTEIN SCI, V11, P1309, DOI 10.1110/ps.4910102	47	36	51	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 3	2006	281	9					5908	5915		10.1074/jbc.M511642200	http://dx.doi.org/10.1074/jbc.M511642200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	015RQ	16352610	hybrid			2022-12-25	WOS:000235568900071
J	von Otte, S; Paletta, JRJ; Becker, S; Konig, S; Fobker, M; Greb, RR; Kiesel, L; Assmann, G; Diedrich, K; Nofer, JR				von Otte, S; Paletta, JRJ; Becker, S; Konig, S; Fobker, M; Greb, RR; Kiesel, L; Assmann, G; Diedrich, K; Nofer, JR			Follicular fluid high density lipoprotein-associated sphingosine 1-phosphate is a novel mediator of ovarian angiogenesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENDOTHELIAL GROWTH-FACTOR; HUMAN SKIN FIBROBLASTS; HUMAN GRANULOSA-CELLS; CORPUS-LUTEUM; PLASMA-LIPOPROTEINS; PROTEIN; CHOLESTEROL; RAT; HDL; SPHINGOSINE-1-PHOSPHATE	Angiogenesis plays an important role in the development of the ovarian follicle and its subsequent transition into the corpus luteum. Accordingly, follicular fluid is a rich source of mitogenic and angiogenic factors such as basic fibroblast growth factor and vascular endothelial growth factor secreted by granulosa cells. In the present study, we show that follicular fluid deprived of basic fibroblast growth factor or vascular endothelial growth factor by means of thermal denaturation or antibody neutralization retains its capacity to stimulate endothelial proliferation and angiogenesis. Mass spectrometric analysis of chromatographic fractions stimulating endothelial growth obtained from follicular fluid revealed that the heat-stable mitogenic activity is identical with the subfraction alpha of high density lipoproteins purified from follicular fluid (FF-HDL). Further investigations demonstrated that sphingosine 1-phosphate (S1P), one of the lysophospholipids associated with HDL, accounts for the capacity of this lipoprotein to stimulate endothelial growth and the formation of new vessels. Activation of mitogen-activated protein kinase (p42/44(ERK1/2)), protein kinase C, and protein kinase Akt represent signaling pathways utilized by FF-HDL and S1P to induce endothelial proliferation and angiogenesis. We conclude that FF-HDL represents a novel mitogenic and angiogenic factor present in follicular fluid and that S1P is one of the FF-HDL lipid components accounting for this activity.	Univ Klinikum Schleswig Holstein, Klin Frauenheilkunde & Geburtshilfe, D-23538 Lubeck, Germany; Univ Munster, Klin & Poliklin Unfall Hand & Wiederherstellungsc, D-48149 Munster, Germany; Univ Munster, Inst Klin Chem & Lab Med, D-48149 Munster, Germany; Univ Munster, Klin & Poliklin Frauenheilkunde & Geburtshilfe, D-48149 Munster, Germany; Univ Munster, Fak Med, Interdisziplinares Zentrum Klin Forsch, D-48149 Munster, Germany; Univ Munster, Leibniz Inst Arterioskleroseforsch, D-48149 Munster, Germany	University of Kiel; Schleswig Holstein University Hospital; University of Munster; University of Munster; University of Hamburg; University Medical Center Hamburg-Eppendorf; University of Munster; University of Munster; University of Munster	von Otte, S (corresponding author), Univ Klinikum Schleswig Holstein, Klin Frauenheilkunde & Geburtshilfe, Campus Lubeck,Ratzeburger Allee 160, D-23538 Lubeck, Germany.	svonotte@gmx.de	König, Simone/B-6504-2008; Kiesel, Ludwig/ABC-5333-2020	König, Simone/0000-0003-0672-7246; Kiesel, Ludwig/0000-0002-7247-9247				Abulafia O, 2000, AM J OBSTET GYNECOL, V182, P240, DOI 10.1016/S0002-9378(00)70519-9; Anliker B, 2004, J BIOL CHEM, V279, P20555, DOI 10.1074/jbc.R400013200; Augustin HG, 2000, BEST PRACT RES CL OB, V14, P867, DOI 10.1053/beog.2000.0132; Azhar S, 1998, J CLIN ENDOCR METAB, V83, P983, DOI 10.1210/jc.83.3.983; Bagavandoss P, 1998, J HISTOCHEM CYTOCHEM, V46, P1043, DOI 10.1177/002215549804600908; BRYANT SM, 1988, AM J OBSTET GYNECOL, V158, P1207, DOI 10.1016/0002-9378(88)90256-6; Chandras C, 2004, MOL CELL ENDOCRINOL, V222, P1, DOI 10.1016/j.mce.2004.05.008; Deeg MA, 1997, ARTERIOSCL THROM VAS, V17, P1667, DOI 10.1161/01.ATV.17.9.1667; FREDERICK JL, 1984, SCIENCE, V224, P389, DOI 10.1126/science.6200930; GOSPODAROWICZ D, 1985, ENDOCRINOLOGY, V117, P2383, DOI 10.1210/endo-117-6-2383; Hammadeh ME, 2004, AM J REPROD IMMUNOL, V51, P81, DOI 10.1046/j.8755-8920.2003.00121.x; HAVEL RJ, 1955, J CLIN INVEST, V34, P1345, DOI 10.1172/JCI103182; Hayashi KG, 2003, BIOL REPROD, V69, P2078, DOI 10.1095/biolreprod.103.017152; Hla T, 2004, SEMIN CELL DEV BIOL, V15, P513, DOI 10.1016/j.semcdb.2004.05.002; JAFFE EA, 1973, J CLIN INVEST, V52, P2745, DOI 10.1172/JCI107470; Jaspard B, 1997, ARTERIOSCL THROM VAS, V17, P1605, DOI 10.1161/01.ATV.17.8.1605; KAMAT BR, 1995, AM J PATHOL, V146, P157; Kimura T, 2003, ARTERIOSCL THROM VAS, V23, P1283, DOI 10.1161/01.ATV.0000079011.67194.5A; Kimura T, 2001, J BIOL CHEM, V276, P31780, DOI 10.1074/jbc.M104353200; Kon J, 1999, J BIOL CHEM, V274, P23940, DOI 10.1074/jbc.274.34.23940; KOOS RD, 1986, ENDOCRINOLOGY, V119, P481, DOI 10.1210/endo-119-2-481; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Manau D, 2000, HUM REPROD, V15, P1295, DOI 10.1093/humrep/15.6.1295; MENDEZ AJ, 1991, J BIOL CHEM, V266, P10104; MEYER GT, 1988, ANAT REC, V222, P18, DOI 10.1002/ar.1092220105; Miura S, 2003, ARTERIOSCL THROM VAS, V23, P802, DOI 10.1161/01.ATV.0000066134.79956.58; MOLLERS C, 1995, CELL SIGNAL, V7, P695, DOI 10.1016/0898-6568(95)00041-M; Morita Y, 2000, NAT MED, V6, P1109, DOI 10.1038/80442; Murata N, 2000, BIOCHEM J, V352, P809, DOI 10.1042/0264-6021:3520809; Nofer JR, 2005, TRENDS CARDIOVAS MED, V15, P265, DOI 10.1016/j.tcm.2005.08.005; Nofer JR, 2001, J BIOL CHEM, V276, P34480, DOI 10.1074/jbc.M103782200; Nofer JR, 2004, J CLIN INVEST, V113, P569, DOI 10.1172/JCI200418004; Nofer JR, 2001, THROMB HAEMOSTASIS, V85, P730; Nofer JR, 2000, BIOCHEMISTRY-US, V39, P15199, DOI 10.1021/bi001162a; Paletta JRJ, 2003, HUM REPROD, V18, P125; PHILLIPS HS, 1990, ENDOCRINOLOGY, V127, P965, DOI 10.1210/endo-127-2-965; Reynolds LP, 1998, J ANIM SCI, V76, P1671; REYNOLDS LP, 1992, FASEB J, V6, P886, DOI 10.1096/fasebj.6.3.1371260; Risau W, 1997, NATURE, V386, P671, DOI 10.1038/386671a0; ROY R, 1992, ENDOCRINOLOGY, V131, P1390, DOI 10.1210/en.131.3.1390; Ruwisch L, 2001, N-S ARCH PHARMACOL, V363, P358, DOI 10.1007/s002100000365; Seli E, 1998, FERTIL STERIL, V69, P1145, DOI 10.1016/S0015-0282(98)00074-0; Shevchenko A, 1996, ANAL CHEM, V68, P850, DOI 10.1021/ac950914h; SIMPSON ER, 1980, J CLIN ENDOCR METAB, V51, P1469, DOI 10.1210/jcem-51-6-1469; Svensson PA, 1999, ENDOCRINOLOGY, V140, P2494, DOI 10.1210/en.140.6.2494; Therien I, 2001, BIOL REPROD, V65, P41, DOI 10.1095/biolreprod65.1.41; Tilly JL, 2002, BBA-MOL CELL BIOL L, V1585, P135, DOI 10.1016/S1388-1981(02)00333-5; VanBlerkom J, 1997, HUM REPROD, V12, P1047; Watterson K, 2003, PROG LIPID RES, V42, P344, DOI 10.1016/S0163-7827(03)00015-8	49	59	61	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 3	2006	281	9					5398	5405		10.1074/jbc.M508759200	http://dx.doi.org/10.1074/jbc.M508759200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	015RQ	16365044	hybrid			2022-12-25	WOS:000235568900011
J	Lee, HH; Yoon, JY; Kim, HS; Kang, JY; Kim, KH; Kim, DJ; Ha, JY; Mikami, B; Yoon, HJ; Suh, SW				Lee, HH; Yoon, JY; Kim, HS; Kang, JY; Kim, KH; Kim, DJ; Ha, JY; Mikami, B; Yoon, HJ; Suh, SW			Crystal structure of a metal ion-bound IS200 transposase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INSERTION SEQUENCES; BINDING PROTEINS; DNA; DOMAIN; RECOGNITION; ALIGNMENT; ELEMENTS; ORIGIN; MOTIFS; SITE	IS200 transposases, present in many bacteria and Archaea, appear to be distinct from other groups of transposases. To provide a structural basis for understanding the action of IS200 transposases, we have determined the crystal structure of the SSO1474 protein from Sulfolobus solfataricus, a member of the IS200 family, in both Mn2+-bound and Mn2+-free forms. Its monomer fold is distinct from other classes of structurally characterized transposases. Two monomers form a tight dimer by exchanging the C-terminal alpha-helix and by merging the two central beta-sheets into a large beta-sheet. Glu(55), His(62), and four water molecules provide the direct coordination sphere of the catalytically essential metal ion in the Mn2+-bound structure. His(16), Asp(59), and His(60) also play important roles in maintaining the metal binding site. The catalytic site is formed at the interface between monomers. The candidate nucleophile in the transposition mechanism, strictly conserved Tyr(121) coming from the other monomer, is turned away from the active site, suggesting that a conformational change is likely to occur during the catalytic cycle.	Seoul Natl Univ, Coll Nat Sci, Dept Chem, Seoul 151742, South Korea; Kyoto Univ, Grad Sch Agr, Div Agron & Hort Sci, Lab Qual Design & Exploitat, Uji, Kyoto 6110011, Japan	Seoul National University (SNU); Kyoto University	Suh, SW (corresponding author), Seoul Natl Univ, Coll Nat Sci, Dept Chem, Seoul 151742, South Korea.	sewonsuh@snu.ac.kr	Suh, Won/H-8306-2013; Kim, Do Jin/I-7675-2014	Suh, Won/0000-0002-1768-4635; 				Banci L, 2002, J MOL BIOL, V323, P883, DOI 10.1016/S0022-2836(02)01007-0; Bao TH, 2005, EMBO J, V24, P3325, DOI 10.1038/sj.emboj.7600787; Beuzon CR, 2004, INT MICROBIOL, V7, P3; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; BURD CG, 1994, SCIENCE, V265, P615, DOI 10.1126/science.8036511; Curcio MJ, 2003, NAT REV MOL CELL BIO, V4, P865, DOI 10.1038/nrm1241; Datta S, 2003, STRUCTURE, V11, P1369, DOI 10.1016/j.str.2003.10.001; Davies DR, 2000, SCIENCE, V289, P77, DOI 10.1126/science.289.5476.77; Devalckenaere A, 1999, FEMS MICROBIOL LETT, V176, P229, DOI 10.1111/j.1574-6968.1999.tb13666.x; DYDA F, 1994, SCIENCE, V266, P1981, DOI 10.1126/science.7801124; Gitschier J, 1998, NAT STRUCT BIOL, V5, P47, DOI 10.1038/nsb0198-47; Guasch A, 2003, NAT STRUCT BIOL, V10, P1002, DOI 10.1038/nsb1017; Hickman AB, 2002, MOL CELL, V10, P327, DOI 10.1016/S1097-2765(02)00592-0; HOLM L, 1993, J MOL BIOL, V233, P123, DOI 10.1006/jmbi.1993.1489; Hutchinson EG, 1996, PROTEIN SCI, V5, P212; ILYINA TV, 1992, NUCLEIC ACIDS RES, V20, P3279, DOI 10.1093/nar/20.13.3279; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; LAM S, 1983, CELL, V34, P951, DOI 10.1016/0092-8674(83)90552-4; Mahillon J, 1998, MICROBIOL MOL BIOL R, V62, P725, DOI 10.1128/MMBR.62.3.725-774.1998; NEVERS P, 1977, NATURE, V268, P109, DOI 10.1038/268109a0; Nicholas K.B., 1997, EMBNEW NEWS, V4, P14, DOI DOI 10.11118/ACTAUN201361041061; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; RICE P, 1995, CELL, V82, P209, DOI 10.1016/0092-8674(95)90308-9; Ronning DR, 2005, MOL CELL, V20, P143, DOI 10.1016/j.molcel.2005.07.026; Terwilliger TC, 1999, ACTA CRYSTALLOGR D, V55, P849, DOI 10.1107/S0907444999000839; Terwilliger TC, 2000, ACTA CRYSTALLOGR D, V56, P965, DOI 10.1107/S0907444900005072; Thompson JD, 1997, NUCLEIC ACIDS RES, V25, P4876, DOI 10.1093/nar/25.24.4876	27	8	9	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 17	2006	281	7					4261	4266		10.1074/jbc.M511567200	http://dx.doi.org/10.1074/jbc.M511567200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	011NN	16340015	hybrid			2022-12-25	WOS:000235275300059
J	Mouilleron, S; Badet-Denisot, MA; Golinelli-Pimpaneau, B				Mouilleron, S; Badet-Denisot, MA; Golinelli-Pimpaneau, B			Glutamine binding opens the ammonia channel and activates glucosamine-6P synthase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ANGSTROM CRYSTAL-STRUCTURE; ESCHERICHIA-COLI; 6-PHOSPHATE SYNTHASE; INSULIN-RESISTANCE; AMIDOTRANSFERASE; REFINEMENT; MECHANISM; ENZYME; DOMAIN; SITE	Glucosamine-6P synthase catalyzes the synthesis of glucosamine-6P from fructose-6P and glutamine and uses a channel to transfer ammonia from its glutaminase to its synthase active site. X-ray structures of glucosamine-6P synthase have been determined at 2.05 angstrom resolution in the presence of fructose-6P and at 2.35 angstrom resolution in the presence of fructose-6P and 6-diazo-5-oxo-L-norleucine, a glutamine affinity analog that covalently modifies the N-terminal catalytic cysteine, therefore mimicking the gamma-glutamylthioester intermediate formed during hydrolysis of glutamine. The fixation of the glutamine analog activates the enzyme through several major structural changes: 1) the closure of a loop to shield the glutaminase site accompanied by significant domain hinging, 2) the activation of catalytic residues involved in glutamine hydrolysis, i.e. the alpha-amino group of Cys-1 and Asn-98 that is positioned to form the oxyanion hole, and 3) a 75 degrees rotation of the Trp-74 indole group that opens the ammonia channel.	Lab Enzymol & Biochim Struct, Unite Propre Rech 9063, F-91198 Gif Sur Yvette, France; CNRS, Unite Propre Rech 2301, Inst Chim Subst Nat, F-91198 Gif Sur Yvette, France	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Saclay	Golinelli-Pimpaneau, B (corresponding author), Lab Enzymol & Biochim Struct, Unite Propre Rech 9063, Batiment 34, F-91198 Gif Sur Yvette, France.	beatrice.golinelli@lebs.cnrs-gif.fr	Golinelli, Beatrice/ABB-8347-2021	Golinelli, Beatrice/0000-0001-8248-4704; badet-denisot, marie-ange/0000-0003-3417-6330; mouilleron, stephane/0000-0001-7977-6298				Adams PD, 1997, P NATL ACAD SCI USA, V94, P5018, DOI 10.1073/pnas.94.10.5018; BADET B, 1987, BIOCHEMISTRY-US, V26, P1940, DOI 10.1021/bi00381a023; BADET B, 1988, BIOCHEMISTRY-US, V27, P2282, DOI 10.1021/bi00407a006; BRANNIGAN JA, 1995, NATURE, V378, P416, DOI 10.1038/378416a0; DENISOT MA, 1991, ARCH BIOCHEM BIOPHYS, V288, P225, DOI 10.1016/0003-9861(91)90188-O; Hebert LF, 1996, J CLIN INVEST, V98, P930, DOI 10.1172/JCI118876; Huang XY, 2001, ANNU REV BIOCHEM, V70, P149, DOI 10.1146/annurev.biochem.70.1.149; Isupov MN, 1996, STRUCTURE, V4, P801, DOI 10.1016/S0969-2126(96)00087-1; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Krahn JM, 1997, BIOCHEMISTRY-US, V36, P11061, DOI 10.1021/bi9714114; Leriche C, 1996, J AM CHEM SOC, V118, P1797, DOI 10.1021/ja953614q; MARQUES S, 1992, EUR J BIOCHEM, V206, P69, DOI 10.1111/j.1432-1033.1992.tb16902.x; Massiere F, 1998, CELL MOL LIFE SCI, V54, P205, DOI 10.1007/s000180050145; Murshudov GN, 1999, ACTA CRYSTALLOGR D, V55, P247, DOI 10.1107/S090744499801405X; NAVAZA J, 1994, ACTA CRYSTALLOGR A, V50, P157, DOI 10.1107/S0108767393007597; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Raushel FM, 1999, BIOCHEMISTRY-US, V38, P7891, DOI 10.1021/bi990871p; Smith JL, 1998, CURR OPIN STRUC BIOL, V8, P686, DOI 10.1016/S0959-440X(98)80087-0; Teplyakov A, 2002, NAT PROD REP, V19, P60, DOI 10.1039/b103713g; Teplyakov A, 2001, J MOL BIOL, V313, P1093, DOI 10.1006/jmbi.2001.5094; Teplyakov A, 1998, STRUCTURE, V6, P1047, DOI 10.1016/S0969-2126(98)00105-1; Teplyakov A, 1999, PROTEIN SCI, V8, P596; van den Heuvel RHH, 2003, J MOL BIOL, V330, P113, DOI 10.1016/S0022-2836(03)00522-9; van den Heuvel RHH, 2004, CELL MOL LIFE SCI, V61, P669, DOI 10.1007/s00018-003-3316-0; Wells L, 2003, CELL MOL LIFE SCI, V60, P222, DOI 10.1007/s000180300017; Winn MD, 2001, ACTA CRYSTALLOGR D, V57, P122, DOI 10.1107/S0907444900014736; Zalkin H, 1998, ADV ENZYMOL RAMB, V72, P87	27	68	70	0	15	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 17	2006	281	7					4404	4412		10.1074/jbc.M511689200	http://dx.doi.org/10.1074/jbc.M511689200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	011NN	16339762	hybrid			2022-12-25	WOS:000235275300076
J	Koide, T; Asada, S; Takahara, Y; Nishikawa, Y; Nagata, K; Kitagawa, K				Koide, T; Asada, S; Takahara, Y; Nishikawa, Y; Nagata, K; Kitagawa, K			Specific recognition of the collagen triple helix by chaperone HSP47 - Minimal structural requirement and spatial molecular orientation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STRESS-PROTEIN HSP47; PEPTIDES; SITES; PROCOLLAGEN	The unique folding of procollagens in the endoplasmic reticulum is achieved with the assistance of procollagen-specific molecular chaperones. Heat-shock protein 47 (HSP47) is an endoplasmic reticulum-resident chaperone that plays an essential role in normal procollagen folding, although its molecular function has not yet been clarified. Recent advances in studies on the binding specificity of HSP47 have revealed that Arg residues at Yaa positions in collagenous Gly-Xaa-Yaa repeats are critical for its interactions (Koide, T., Takahara, Y., Asada, S., and Nagata, K. (2002) J. Biol. Chem. 277, 6178-6182; Tasab, M., Jenkinson, L., and Bulleid, N. J. (2002) J. Biol. Chem. 277, 35007-35012). In the present study, we further examined the client recognition mechanism of HSP47 by taking advantage of systems employing engineered collagen model peptides. First, in vitro binding studies using conformationally constrained collagen-like peptides revealed that HSP47 only recognized correctly folded triple helices and that the interaction with the corresponding single-chain polypeptides was negligible. Second, a binding study using heterotrimeric model clients for HSP47 demonstrated a minimal requirement for the number of Arg residues in the triple helix. Finally, a cross-linking study using photoreactive collagenous peptides provided information about the spatial orientation of an HSP47 molecule in the chaperone-collagen complex. The obtained results led to the development of a new model of HSP47-collagen complexes that differs completely from the previously proposed "flying capstan model" (Dafforn, T. R., Della, M., and Miller, A. D. ( 2001) J. Biol. Chem. 276, 49310-49319).	Niigata Univ Pharm & Appl Life Sci, Fac Pharmaceut Sci, Niigata 9502081, Japan; Univ Tokushima, Fac Engn, Tokushima 7708506, Japan; Kyoto Univ, Inst Frontier Med Sci, Kyoto 6068397, Japan	Niigata University; Tokushima University; Kyoto University	Koide, T (corresponding author), Niigata Univ Pharm & Appl Life Sci, Fac Pharmaceut Sci, Niigata 9502081, Japan.	koi@niigata-pharm.ac.jp						BACHINGER HP, 1980, EUR J BIOCHEM, V106, P619, DOI 10.1111/j.1432-1033.1980.tb04610.x; BACHINGER HP, 1978, EUR J BIOCHEM, V90, P605, DOI 10.1111/j.1432-1033.1978.tb12641.x; Dafforn TR, 2001, J BIOL CHEM, V276, P49310, DOI 10.1074/jbc.M108896200; Hatanaka Y, 1998, J AM CHEM SOC, V120, P453, DOI 10.1021/ja973056a; Kanamori T, 1997, P NATL ACAD SCI USA, V94, P485, DOI 10.1073/pnas.94.2.485; KAUER JC, 1986, J BIOL CHEM, V261, P695; Koide T, 1999, J BIOL CHEM, V274, P34523, DOI 10.1074/jbc.274.49.34523; Koide T, 2005, TOP CURR CHEM, V247, P85, DOI 10.1007/b103820; Koide T, 2004, BIOORG MED CHEM LETT, V14, P125, DOI 10.1016/j.bmcl.2003.10.005; Koide T, 2002, J BIOL CHEM, V277, P6178, DOI 10.1074/jbc.M106497200; Koide T, 2000, J BIOL CHEM, V275, P27957; Kramer RZ, 1999, NAT STRUCT BIOL, V6, P454; Macdonald JR, 2001, J BIOL CHEM, V276, P25399, DOI 10.1074/jbc.M102471200; Marutani T, 2004, J CELL SCI, V117, P5913, DOI 10.1242/jcs.01514; Myllyharju J, 2005, TOP CURR CHEM, V247, P115, DOI 10.1007/b103821; Nagai N, 2000, J CELL BIOL, V150, P1499, DOI 10.1083/jcb.150.6.1499; NAKAI A, 1992, J CELL BIOL, V117, P903, DOI 10.1083/jcb.117.4.903; NATSUME T, 1994, J BIOL CHEM, V269, P31224; Ottl J, 2000, CHEM BIOL, V7, P119, DOI 10.1016/S1074-5521(00)00077-6; Renner C, 2004, BIOPOLYMERS, V76, P34, DOI 10.1002/bip.10569; Sacca B, 2002, CHEMBIOCHEM, V3, P904, DOI 10.1002/1439-7633(20020902)3:9<904::AID-CBIC904>3.0.CO;2-I; Sacca B, 2002, J PEPT SCI, V8, P192, DOI 10.1002/psc.385; SAGA S, 1987, J CELL BIOL, V105, P517, DOI 10.1083/jcb.105.1.517; Satoh M, 1996, J CELL BIOL, V133, P469, DOI 10.1083/jcb.133.2.469; SAUK JJ, 1994, J BIOL CHEM, V269, P3941; Tasab M, 2000, EMBO J, V19, P2204, DOI 10.1093/emboj/19.10.2204; Tasab M, 2002, J BIOL CHEM, V277, P35007, DOI 10.1074/jbc.M202782200; Thomson CA, 2003, PROTEIN SCI, V12, P1792, DOI 10.1110/ps.0236903; Walmsley AR, 1999, J BIOL CHEM, V274, P14884, DOI 10.1074/jbc.274.21.14884; Yokota SI, 2003, BIOCHEM BIOPH RES CO, V303, P413, DOI 10.1016/S0006-291X(03)00352-8	30	51	57	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 10	2006	281	6					3432	3438		10.1074/jbc.M509707200	http://dx.doi.org/10.1074/jbc.M509707200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	009QV	16326708				2022-12-25	WOS:000235128200052
J	Tsukahara, T; Tsukahara, R; Yasuda, S; Makarova, N; Valentine, WJ; Allison, P; Yuan, HB; Baker, DL; Li, ZG; Bittman, R; Parrill, A; Tigyi, G				Tsukahara, T; Tsukahara, R; Yasuda, S; Makarova, N; Valentine, WJ; Allison, P; Yuan, HB; Baker, DL; Li, ZG; Bittman, R; Parrill, A; Tigyi, G			Different residues mediate recognition of 1-O-oleyl-lysophosphatidic acid and rosiglitazone in the ligand binding domain of peroxisome proliferator-activated receptor gamma	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CORONARY-ARTERY-DISEASE; LOW-DENSITY-LIPOPROTEIN; RABBIT CEREBRAL-CORTEX; LYSOPHOSPHATIDIC ACID; PPAR-GAMMA; NEURONAL NUCLEI; ADIPOCYTE DIFFERENTIATION; ATHEROSCLEROTIC LESIONS; AUTOMATED DOCKING; GENE-EXPRESSION	Here we showed that a naturally occurring ether analog of lysophosphatidic acid, 1-O-octadecenyl-2-hydroxy-sn-glycero-3-phosphate (AGP), is a high affinity partial agonist of the peroxisome proliferator-activated receptor gamma (PPAR gamma). Binding studies using the PPAR gamma ligand binding domain showed that [P-32]AGP and [H-3]rosiglitazone (Rosi) both specifically bind to PPAR gamma and compete with each other. [P-32]AGP bound PPAR gamma with an affinity (K-d(app) 60 nM) similar to that of Rosi. However, AGP displaced similar to 40% of bound [H-3]Rosi even when applied at a 2000-fold excess. Activation of PPAR gamma reporter gene expression by AGP and Rosi showed similar potency, yet AGP-mediated activation was similar to 40% that of Rosi. A complex between AGP and PPAR gamma was generated using molecular modeling based on a PPAR gamma crystal structure. AGP-interacting residues were compared with Rosi-interacting residues identified within the Rosi-PPAR gamma co-crystal complex. These comparisons showed that the two ligands occupy partially overlapping positions but make different hydrogen bonding and ion pairing interactions. Site-specific mutants of PPAR gamma were prepared to examine individual ligand binding. H323A and H449A mutants showed reduced binding of Rosi but maintained binding of AGP. In contrast, the R288A showed reduced AGP binding but maintained Rosi binding. Finally, alanine replacement of Tyr-473 abolished binding and activation by Rosi and AGP. These observations indicate that the endogenous lipid mediator AGP is a high affinity ligand of PPAR gamma but that it binds via interactions distinct from those involved in Rosi binding. These distinct interactions are likely responsible for the partial PPAR gamma agonism of AGP.	Univ Tennessee, Ctr Hlth Sci, Dept Physiol, Memphis, TN 38163 USA; Univ Tennessee, Ctr Hlth Sci, Dept Pharmaceut Sci, Memphis, TN 38163 USA; Univ Memphis, Dept Chem, Memphis, TN 38152 USA; Univ Memphis, Computat Res Inst Mat, Memphis, TN 38152 USA; Univ Tennessee, Hlth Sci Ctr, Univ Tennessee Canc Inst, Dept Med, Memphis, TN 38152 USA; Univ Tennessee, Hlth Sci Ctr, Univ Tennessee Canc Inst, Vasc Biol Ctr Excellence, Memphis, TN 38152 USA; Univ Tennessee, Hlth Sci Ctr, Univ Tennessee Canc Inst, Genom & Bioinformat Ctr Excellence, Memphis, TN 38152 USA; CUNY Queens Coll, Dept Chem & Biochem, Flushing, NY 11367 USA	University of Tennessee System; University of Tennessee Health Science Center; University of Tennessee System; University of Tennessee Health Science Center; University of Memphis; University of Memphis; University of Tennessee System; University of Tennessee Health Science Center; University of Tennessee System; University of Tennessee Health Science Center; University of Tennessee System; University of Tennessee Health Science Center; City University of New York (CUNY) System; Queens College NY (CUNY)	Tigyi, G (corresponding author), Univ Tennessee, Ctr Hlth Sci, Dept Physiol, 894 Union Ave, Memphis, TN 38163 USA.	gtigyi@physio1.utmem.edu		YASUDA, Satoshi/0000-0002-1011-0815; Baker, Daniel/0000-0003-1482-0416; Parrill, Abby/0000-0003-1658-8497; Tsukahara, Tamotsu/0000-0001-6469-920X	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL061469, R24HL083187, R01HL079004, T32HL007641] Funding Source: NIH RePORTER; NCI NIH HHS [CA92160] Funding Source: Medline; NHLBI NIH HHS [T32 HL007641, HL083187, HL79004, HL61469] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Angeli W, 2003, J IMMUNOL, V170, P5295, DOI 10.4049/jimmunol.170.10.5295; Asami-Miyagishi R, 2004, BIOCHEM BIOPH RES CO, V315, P497, DOI 10.1016/j.bbrc.2004.01.074; BAKER RR, 1988, BIOCHIM BIOPHYS ACTA, V960, P390, DOI 10.1016/0005-2760(88)90047-1; Baker RR, 1998, BBA-LIPID LIPID MET, V1392, P351, DOI 10.1016/S0005-2760(98)00050-2; BAKER RR, 1990, BIOCHEM CELL BIOL, V68, P641, DOI 10.1139/o90-091; Baker RR, 2000, BBA-MOL CELL BIOL L, V1483, P58, DOI 10.1016/S1388-1981(99)00185-7; Baker RR, 1999, MOL CELL BIOCHEM, V198, P47, DOI 10.1023/A:1006933625802; Bandoh K, 2000, FEBS LETT, V478, P159, DOI 10.1016/S0014-5793(00)01827-5; Berger JP, 2005, INT J OBESITY, V29, pS3, DOI 10.1038/sj.ijo.0802904; Berger JP, 2003, MOL ENDOCRINOL, V17, P662, DOI 10.1210/me.2002-0217; BOCOS C, 1995, J STEROID BIOCHEM, V53, P467, DOI 10.1016/0960-0760(95)00093-F; Brivanlou AH, 2002, SCIENCE, V295, P813, DOI 10.1126/science.1066355; *CHEM COMP GROUP, 2003, MOE VERS 2003 02; Davies SS, 2001, J BIOL CHEM, V276, P16015, DOI 10.1074/jbc.M100878200; Desvergne B, 1999, ENDOCR REV, V20, P649, DOI 10.1210/er.20.5.649; Duval C, 2002, TRENDS MOL MED, V8, P422, DOI 10.1016/S1471-4914(02)02385-7; FORMAN BM, 1995, CELL, V83, P803, DOI 10.1016/0092-8674(95)90193-0; Fujiwara Y, 2005, J BIOL CHEM, V280, P35038, DOI 10.1074/jbc.M504351200; Gaits F, 1997, FEBS LETT, V410, P54, DOI 10.1016/S0014-5793(97)00411-0; Gampe RT, 2000, MOL CELL, V5, P545, DOI 10.1016/S1097-2765(00)80448-7; GOODSELL DS, 1990, PROTEINS, V8, P195, DOI 10.1002/prot.340080302; Huang JT, 1999, NATURE, V400, P378, DOI 10.1038/22572; Ishii I, 2000, MOL PHARMACOL, V58, P895, DOI 10.1124/mol.58.5.895; Jiang WG, 2000, PROSTAG LEUKOTR ESS, V62, P119, DOI 10.1054/plef.1999.0131; Kelly D, 2004, NAT IMMUNOL, V5, P104, DOI 10.1038/ni1018; Kiec-Wilk B, 2005, J PHYSIOL PHARMACOL, V56, P149; KLIEWER SA, 1994, P NATL ACAD SCI USA, V91, P7355, DOI 10.1073/pnas.91.15.7355; KLIEWER SA, 1995, CELL, V83, P813, DOI 10.1016/0092-8674(95)90194-9; Knouff C, 2004, ENDOCR REV, V25, P899, DOI 10.1210/er.2003-0036; Krey G, 1997, MOL ENDOCRINOL, V11, P779, DOI 10.1210/me.11.6.779; Lautamaki R, 2005, DIABETES, V54, P2787, DOI 10.2337/diabetes.54.9.2787; Lebovitz HE, 2002, DIABETES-METAB RES, V18, pS23, DOI 10.1002/dmrr.252; LEHMANN JM, 1995, J BIOL CHEM, V270, P12953, DOI 10.1074/jbc.270.22.12953; LENZ ML, 1990, J LIPID RES, V31, P1043; LI Z, 2005, IN PRESS J ORG CHEM; Liu K, 2005, J MED CHEM, V48, P2262, DOI 10.1021/jm048993p; Llodra J, 2004, P NATL ACAD SCI USA, V101, P11779, DOI 10.1073/pnas.0403259101; MANGELSDORF DJ, 1995, CELL, V83, P835, DOI 10.1016/0092-8674(95)90199-X; McIntyre TM, 2003, P NATL ACAD SCI USA, V100, P131, DOI 10.1073/pnas.0135855100; McKenna NJ, 1999, ENDOCR REV, V20, P321, DOI 10.1210/er.20.3.321; Medina-Gomez G, 2005, DIABETES, V54, P1706, DOI 10.2337/diabetes.54.6.1706; Minamikawa J, 1998, J CLIN ENDOCR METAB, V83, P1818, DOI 10.1210/jc.83.5.1818; Morris GM, 1998, J COMPUT CHEM, V19, P1639, DOI 10.1002/(SICI)1096-987X(19981115)19:14<1639::AID-JCC10>3.0.CO;2-B; Nakane S, 2001, LIPIDS, V36, P413, DOI 10.1007/s11745-001-0737-1; Negro R, 2005, DIABETES RES CLIN PR, V70, P20, DOI 10.1016/j.diabres.2005.02.012; Nicholson AC, 2004, TRENDS CARDIOVAS MED, V14, P8, DOI 10.1016/j.tcm.2003.09.004; Noguchi K, 2003, J BIOL CHEM, V278, P25600, DOI 10.1074/jbc.M302648200; Nolte RT, 1998, NATURE, V395, P137, DOI 10.1038/25931; Oberfield JL, 1999, P NATL ACAD SCI USA, V96, P6102, DOI 10.1073/pnas.96.11.6102; Rodway HA, 2004, BIOCHEM J, V382, P83, DOI 10.1042/BJ20040107; Rother E, 2003, CIRCULATION, V108, P741, DOI 10.1161/01.CIR.0000083715.37658.C4; Santini E, 2004, DIABETES, V53, pS79, DOI 10.2337/diabetes.53.suppl_3.S79; Sarafidis PA, 2005, METABOLISM, V54, P1236, DOI 10.1016/j.metabol.2005.04.010; Sarraf P, 1999, MOL CELL, V3, P799, DOI 10.1016/S1097-2765(01)80012-5; Schopfer FJ, 2005, P NATL ACAD SCI USA, V102, P2340, DOI 10.1073/pnas.0408384102; Shao DL, 1998, NATURE, V396, P377, DOI 10.1038/24634; Siess W, 1999, P NATL ACAD SCI USA, V96, P6931, DOI 10.1073/pnas.96.12.6931; Simon MF, 2002, J BIOL CHEM, V277, P23131, DOI 10.1074/jbc.M201530200; Sugiura T, 1999, BBA-MOL CELL BIOL L, V1440, P194, DOI 10.1016/S1388-1981(99)00127-4; Sugiura T, 2002, J LIPID RES, V43, P2049, DOI 10.1194/jlr.M200242-JLR200; TOKUMURA A, 1992, J BIOL CHEM, V267, P7275; TONTONOZ P, 1994, GENE DEV, V8, P1224, DOI 10.1101/gad.8.10.1224; Tontonoz P, 1998, CELL, V93, P241, DOI 10.1016/S0092-8674(00)81575-5; Wang G, 2005, METABOLISM, V54, P590, DOI 10.1016/j.metabol.2004.11.017; Way JM, 2001, ENDOCRINOLOGY, V142, P1269, DOI 10.1210/en.142.3.1269; Weatherman RV, 1999, ANNU REV BIOCHEM, V68, P559, DOI 10.1146/annurev.biochem.68.1.559; Xiao YJ, 2001, ANAL BIOCHEM, V290, P302, DOI 10.1006/abio.2001.5000; Xu HE, 2001, P NATL ACAD SCI USA, V98, P13919, DOI 10.1073/pnas.241410198; Zhang CX, 2004, J EXP MED, V199, P763, DOI 10.1084/jem.20031619	69	69	73	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 10	2006	281	6					3398	3407		10.1074/jbc.M510843200	http://dx.doi.org/10.1074/jbc.M510843200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	009QV	16321982	hybrid			2022-12-25	WOS:000235128200048
J	Imamura, S; Tanaka, K; Shirai, M; Asayama, M				Imamura, S; Tanaka, K; Shirai, M; Asayama, M			Growth phase-dependent activation of nitrogen-related genes by a control network of group 1 and group 2 sigma factors in a cyanobacterium	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SYNECHOCYSTIS SP PCC-6803; II SIGNAL-TRANSDUCTION; STRAIN PCC 7002; RNA-POLYMERASE; ESCHERICHIA-COLI; RESPONSE REGULATOR; TRANSCRIPTION; EXPRESSION; PROMOTER; IDENTIFICATION	It has been reported that an RNA polymerase sigma factor, SigC, mainly contributes to specific transcription from the promoter PglnB-54,-53 under nitrogen-deprived conditions during the stationary phase of cell growth in the cyanobacterium Synechocystis sp. strain PCC 6803 (Asayama, M., Imamura, S., Yoshihara, S., Miyazaki, A., Yoshida, N., Sazuka, T., Kaneko, T., Ohara, O., Tabata, S., Osanai, T., Tanaka, K., Takahashi, H., and Shirai, M. ( 2004) Bio-sci. Biotechnol. Biochem. 68, 477 - 487). In this study, we further examined the functions of group 2 sigma factors of RNA polymerase in NtcA-dependent nitrogen-related gene expression in PCC 6803. Results indicated that SigB and SigC contribute to the transcription from PglnB-54,-53 with a sigma factor replaced in a growth phase-dependent manner. We also confirmed the contribution of SigB and SigC to the transcription of other NtcA- dependent genes, glnA, sigE, and amt1, as in the case of glnB. On the other hand, the transcription of glnN was dependent on SigB and SigE. In the SigB and SigC-based regulation, the level of SigB increased, but that of SigC was constant under conditions of nitrogen deprivation. Furthermore, it was found that SigC negatively and positively regulates the level of SigB in the log and stationary phase, respectively. SigC also had a positive effect on the level of sigB transcript during the stationary phase. In contrast, SigB acts positively on SigC levels in both growth phases. These results and previous findings indicated that multiple group 2 sigma factors take part in the control of NtcA- dependent nitrogen-related gene expression in cooperation with a group 1 sigma factor, SigA.	Ibaraki Univ, Coll Agr, Mol Genet Lab, Ibaraki 3000393, Japan; Univ Tokyo, Inst Mol & Cellular Biosci, Bunkyo Ku, Tokyo 1130032, Japan	Ibaraki University; University of Tokyo	Asayama, M (corresponding author), Ibaraki Univ, Coll Agr, Mol Genet Lab, 3-21-1 Ami, Ibaraki 3000393, Japan.	asam@mx.ibaraki.ac.jp	Imamura, Sousuke/D-3638-2015; Imamura, Sousuke/N-6703-2019; Tanaka, Kan/E-3724-2015	Imamura, Sousuke/0000-0002-3040-4757; Tanaka, Kan/0000-0001-7560-7884				Alfonso M, 2001, PLANT PHYSIOL, V125, P969, DOI 10.1104/pp.125.2.969; Allakhverdiev SI, 2000, PLANT PHYSIOL, V123, P1047, DOI 10.1104/pp.123.3.1047; ALLEN MM, 1969, ARCH MIKROBIOL, V69, P114, DOI 10.1007/BF00409755; Aoki S, 2002, J MICROBIOL METH, V49, P265, DOI 10.1016/S0167-7012(01)00376-1; Arcondeguy T, 2001, MICROBIOL MOL BIOL R, V65, P80, DOI 10.1128/MMBR.65.1.80-105.2001; Asayama M, 1996, GENE, V181, P213, DOI 10.1016/S0378-1119(96)00517-3; Asayama M, 2004, BIOSCI BIOTECH BIOCH, V68, P477, DOI 10.1271/bbb.68.477; Asayama M, 1999, J BIOCHEM, V125, P460, DOI 10.1093/oxfordjournals.jbchem.a022309; BRAHAMSHA B, 1992, J BACTERIOL, V174, P7273, DOI 10.1128/jb.174.22.7273-7282.1992; Caslake LF, 1997, MICROBIOL-SGM, V143, P3807, DOI 10.1099/00221287-143-12-3807; Farewell A, 1998, MOL MICROBIOL, V29, P1039, DOI 10.1046/j.1365-2958.1998.00990.x; Forchhammer K, 2004, FEMS MICROBIOL REV, V28, P319, DOI 10.1016/j.femsre.2003.11.001; Garcia-Dominguez M, 2000, MOL MICROBIOL, V35, P1192, DOI 10.1046/j.1365-2958.2000.01789.x; GOLDEN SS, 1987, METHOD ENZYMOL, V153, P215; Gruber TM, 1998, ARCH MICROBIOL, V169, P211, DOI 10.1007/s002030050563; Herrero A, 2001, J BACTERIOL, V183, P411, DOI 10.1128/JB.183.2.411-425.2001; Imamura S, 2004, GENES CELLS, V9, P1175, DOI 10.1111/j.1365-2443.2004.00808.x; Imamura S, 2003, FEBS LETT, V554, P357, DOI 10.1016/S0014-5793(03)01188-8; Imamura S, 2003, J MOL BIOL, V325, P857, DOI 10.1016/S0022-2836(02)01242-1; ISHIHAMA A, 1993, J BACTERIOL, V175, P2483, DOI 10.1128/JB.175.9.2483-2489.1993; Ito Y, 2003, BIOSCI BIOTECH BIOCH, V67, P1382, DOI 10.1271/bbb.67.1382; Jishage M, 1999, J BACTERIOL, V181, P3768, DOI 10.1128/JB.181.12.3768-3776.1999; Jishage M, 2002, GENE DEV, V16, P1260, DOI 10.1101/gad.227902; Jishage M, 2001, J BACTERIOL, V183, P2952, DOI 10.1128/JB.183.9.2952-2956.2001; Kaneko T, 1996, DNA Res, V3, P109; Khudyakov IY, 2001, J BACTERIOL, V183, P6667, DOI 10.1128/JB.183.22.6667-6675.2001; Klein G, 2003, MOL MICROBIOL, V48, P269, DOI 10.1046/j.1365-2958.2003.03449.x; Lemeille S, 2005, NUCLEIC ACIDS RES, V33, P3381, DOI 10.1093/nar/gki654; LONETTO M, 1992, J BACTERIOL, V174, P3843, DOI 10.1128/jb.174.12.3843-3849.1992; Maeda H, 2000, NUCLEIC ACIDS RES, V28, P3497, DOI 10.1093/nar/28.18.3497; Marin K, 2003, P NATL ACAD SCI USA, V100, P9061, DOI 10.1073/pnas.1532302100; MERRICK MJ, 1995, MICROBIOL REV, V59, P604, DOI 10.1128/MMBR.59.4.604-622.1995; Muffler A, 1997, J BACTERIOL, V179, P445; Muro-Pastor AM, 2001, J BACTERIOL, V183, P1090, DOI 10.1128/JB.183.3.1090-1095.2001; Nakamoto H, 2000, FEBS LETT, V483, P169, DOI 10.1016/S0014-5793(00)02097-4; Osanai T, 2005, J BIOL CHEM, V280, P30653, DOI 10.1074/jbc.M505043200; REITZER LJ, 1986, CELL, V45, P785, DOI 10.1016/0092-8674(86)90553-2; Reyes JC, 1997, J BACTERIOL, V179, P2678, DOI 10.1128/jb.179.8.2678-2689.1997; RIPPKA R, 1988, METHOD ENZYMOL, V167, P3; Schwarz R, 1998, P NATL ACAD SCI USA, V95, P11008, DOI 10.1073/pnas.95.18.11008; Shibato J, 1998, BBA-GENE STRUCT EXPR, V1442, P296, DOI 10.1016/S0167-4781(98)00149-3; Shibato J, 2002, MOL GENET GENOMICS, V267, P684, DOI 10.1007/s00438-002-0704-3; STANIER RY, 1977, ANNU REV MICROBIOL, V31, P225, DOI 10.1146/annurev.mi.31.100177.001301; Tanigawa R, 2002, P NATL ACAD SCI USA, V99, P4251, DOI 10.1073/pnas.072587199; Vazquez-Bermudez MF, 2002, FEBS LETT, V512, P71, DOI 10.1016/S0014-5793(02)02219-6; Zhou YN, 2001, GENE DEV, V15, P627, DOI 10.1101/gad.864401	46	41	47	1	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 3	2006	281	5					2668	2675		10.1074/jbc.M509639200	http://dx.doi.org/10.1074/jbc.M509639200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	006XT	16303755	hybrid			2022-12-25	WOS:000234931800032
J	Bocharova, OV; Makarava, N; Breydo, L; Anderson, M; Salnikov, VV; Baskakov, IV				Bocharova, OV; Makarava, N; Breydo, L; Anderson, M; Salnikov, VV; Baskakov, IV			Annealing prion protein amyloid fibrils at high temperature results in extension of a proteinase K-resistant core	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IN-VITRO; CONVERSION; DOMAIN; PRPSC; CONFORMATION; AGGREGATION; MECHANISM; DISEASE; INDUCE; URE2P	Amyloids are highly ordered, rigid beta-sheet-rich structures that appear to have minimal dynamic flexibility in individual polypeptide chains. Here, we demonstrate that substantial conformational rearrangements occur within mature amyloid fibrils produced from full-length mammalian prion protein. The rearrangement results in a substantial extension of a proteinase K-resistant core and is accompanied by an increase in the beta-sheet-rich conformation. The conformational rearrangement was induced in the presence of low concentrations of Triton X-100 either by brief exposure to 80 degrees C or, with less efficacy, by prolonged incubation at 37 degrees C at pH 7.5 and is referred to here as "annealing." Upon annealing, amyloid fibrils acquired a proteinase K-resistant core identical to that found in bovine spongiform encephalopathy-specific scrapie-associated prion protein. Annealing was also observed when amyloid fibrils were exposed to high temperatures in the absence of detergent but in the presence of brain homogenate. These findings suggest that the amyloid fibrils exist in two conformationally distinct states that are separated by a high energy barrier and that yet unknown cellular cofactors may facilitate transition of the fibrils into thermodynamically more stable state. Our studies provide new insight into the complex behavior of prion polymerization and highlight the annealing process, a previously unknown step in the evolution of amyloid structures.	Univ Maryland, Inst Biotechnol, Ctr Med Biotechnol, 725 W Lombard St, Baltimore, MD 21201 USA; Univ Maryland, Sch Med, Dept Biochem & Mol Biol, Baltimore, MD 21201 USA; Russian Acad Sci, Kazan Inst Biochem & Biophys, Kazan 420111, Russia	University System of Maryland; University of Maryland Baltimore; University System of Maryland; University of Maryland Baltimore; Russian Academy of Sciences; Kazan Scientific Centre of the Russian Academy of Sciences; Kazan Institute of Biochemistry & Biophysics	Baskakov, IV (corresponding author), Univ Maryland, Inst Biotechnol, Ctr Med Biotechnol, 725 W Lombard St, Baltimore, MD 21201 USA.	Baskakov@umbi.umd.edu	Breydo, Leonid/E-6119-2010; Breydo, Leo/AAJ-7996-2020; Bocharova, Olga V./J-8284-2018	Bocharova, Olga V./0000-0002-5056-1506; Vadim, Salnikov/0000-0002-2367-672X; Breydo, Leonid/0000-0003-4666-2301	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS045585] Funding Source: NIH RePORTER; NINDS NIH HHS [NS 045585] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Adler V, 2003, J MOL BIOL, V332, P47, DOI 10.1016/S0022-2836(03)00919-7; Baxa U, 2004, J MOL BIOL, V339, P259, DOI 10.1016/j.jmb.2004.03.033; Berson JF, 2003, J CELL BIOL, V161, P521, DOI 10.1083/jcb.200302072; Bitan G, 2003, P NATL ACAD SCI USA, V100, P330, DOI 10.1073/pnas.222681699; Bocharova OV, 2005, PROTEIN SCI, V14, P1222, DOI 10.1110/ps.041186605; Bocharova OV, 2005, J MOL BIOL, V346, P645, DOI 10.1016/j.jmb.2004.11.068; Bousset L, 2003, J STRUCT BIOL, V141, P132, DOI 10.1016/S1047-8477(02)00606-8; Breydo L, 2005, BIOCHEMISTRY-US, V44, P15534, DOI 10.1021/bi051369+; Bucciantini M, 2002, NATURE, V416, P507, DOI 10.1038/416507a; Carrell RW, 1997, LANCET, V350, P134, DOI 10.1016/S0140-6736(97)02073-4; Castilla J, 2005, CELL, V121, P195, DOI 10.1016/j.cell.2005.02.011; Caughey B, 1997, J VIROL, V71, P4107, DOI 10.1128/JVI.71.5.4107-4110.1997; Caughey B, 1995, CHEM BIOL, V2, P807, DOI 10.1016/1074-5521(95)90087-X; Chapman MR, 2002, SCIENCE, V295, P851, DOI 10.1126/science.1067484; Chatani E, 2005, J MOL BIOL, V352, P941, DOI 10.1016/j.jmb.2005.07.043; Chiti F, 1999, P NATL ACAD SCI USA, V96, P3590, DOI 10.1073/pnas.96.7.3590; Cohen FE, 2003, NATURE, V426, P905, DOI 10.1038/nature02265; Cordeiro Y, 2004, J BIOL CHEM, V279, P32354, DOI 10.1074/jbc.M404295200; Cordeiro Y, 2001, J BIOL CHEM, V276, P49400, DOI 10.1074/jbc.M106707200; Deleault NR, 2003, NATURE, V425, P717, DOI 10.1038/nature01979; Demuro A, 2005, J BIOL CHEM, V280, P17294, DOI 10.1074/jbc.M500997200; Dobson CM, 1999, TRENDS BIOCHEM SCI, V24, P329, DOI 10.1016/S0968-0004(99)01445-0; Gabus C, 2001, J BIOL CHEM, V276, P19301, DOI 10.1074/jbc.M009754200; Gabus C, 2001, J MOL BIOL, V307, P1011, DOI 10.1006/jmbi.2001.4544; Gotte G, 2003, J BIOL CHEM, V278, P10763, DOI 10.1074/jbc.M213146200; Guijarro JI, 1998, P NATL ACAD SCI USA, V95, P4224, DOI 10.1073/pnas.95.8.4224; Harper JD, 1997, ANNU REV BIOCHEM, V66, P385, DOI 10.1146/annurev.biochem.66.1.385; Hayashi HK, 2005, BIOCHEM BIOPH RES CO, V328, P1024, DOI 10.1016/j.bbrc.2005.01.065; Hsu YT, 1997, J BIOL CHEM, V272, P13829, DOI 10.1074/jbc.272.21.13829; Iconomidou VA, 2000, FEBS LETT, V479, P141, DOI 10.1016/S0014-5793(00)01888-3; Kayed R, 2004, J BIOL CHEM, V279, P46363, DOI 10.1074/jbc.C400260200; Kaylor J, 2005, J MOL BIOL, V353, P357, DOI 10.1016/j.jmb.2005.08.046; Kazlauskaite J, 2003, BIOCHEMISTRY-US, V42, P3295, DOI 10.1021/bi026872q; Kirkitadze MD, 2001, J MOL BIOL, V312, P1103, DOI 10.1006/jmbi.2001.4970; Klein TR, 1998, BIOL CHEM, V379, P655, DOI 10.1515/bchm.1998.379.6.655; Kocisko DA, 1996, BIOCHEMISTRY-US, V35, P13434, DOI 10.1021/bi9610562; Lee AS, 2003, J MOL BIOL, V327, P699, DOI 10.1016/S0022-2836(03)00175-X; Lee S, 2003, NAT STRUCT BIOL, V10, P725, DOI 10.1038/nsb961; Legname G, 2004, SCIENCE, V305, P673, DOI 10.1126/science.1100195; Liu Y, 2002, PROTEIN SCI, V11, P1285, DOI 10.1110/ps.0201402; Liu YS, 2001, NAT STRUCT BIOL, V8, P211, DOI 10.1038/84941; Nishina K, 2004, J BIOL CHEM, V279, P40788, DOI 10.1074/jbc.M406548200; Notari S, 2004, J BIOL CHEM, V279, P16797, DOI 10.1074/jbc.M313220200; Petty SA, 2005, J AM CHEM SOC, V127, P13488, DOI 10.1021/ja054663y; Petty SA, 2005, BIOCHEMISTRY-US, V44, P4720, DOI 10.1021/bi047445a; Prusiner SB, 2001, NEW ENGL J MED, V344, P1516, DOI 10.1056/NEJM200105173442006; Ramirez-Alvarado M, 2000, P NATL ACAD SCI USA, V97, P8979, DOI 10.1073/pnas.150091797; Reches M, 2003, SCIENCE, V300, P625, DOI 10.1126/science.1082387; Saborio GP, 2001, NATURE, V411, P810, DOI 10.1038/35081095; Si K, 2003, CELL, V115, P879, DOI 10.1016/S0092-8674(03)01020-1; Tahiri-Alaoui A, 2004, J BIOL CHEM, V279, P31390, DOI 10.1074/jbc.M401754200; WICKNER RB, 1994, SCIENCE, V264, P566, DOI 10.1126/science.7909170; Wong C, 2001, EMBO J, V20, P377, DOI 10.1093/emboj/20.3.377; Yang SC, 2005, FASEB J, V19, P1778, DOI 10.1096/fj.05-4067hyp; Yutani K, 2000, BIOCHEMISTRY-US, V39, P2769, DOI 10.1021/bi991406v; Zhu M, 2004, J BIOL CHEM, V279, P24452, DOI 10.1074/jbc.M400004200	56	62	64	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 27	2006	281	4					2373	2379		10.1074/jbc.M510840200	http://dx.doi.org/10.1074/jbc.M510840200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	004NV	16314415	hybrid			2022-12-25	WOS:000234760400062
J	Staelens, S; Hadders, MA; Vauterin, S; Platteau, C; De Maeyer, M; Vanhoorelbeke, K; Huizinga, EG; Deckmyn, H				Staelens, S; Hadders, MA; Vauterin, S; Platteau, C; De Maeyer, M; Vanhoorelbeke, K; Huizinga, EG; Deckmyn, H			Paratope determination of the antithrombotic antibody 82D6A3 based on the crystal structure of its complex with the von Willebrand factor A3-domain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEPENDENT PLATELET-ADHESION; VWF MONOCLONAL-ANTIBODY; COLLAGEN-BINDING SITE; GLYCOPROTEIN IIB/IIIA; VONWILLEBRAND-FACTOR; VI COLLAGEN; A3 DOMAIN; I-DOMAIN; EXTRACELLULAR-MATRIX; THROMBUS FORMATION	The antithrombotic monoclonal antibody 82D6A3 is directed against amino acids Arg-963, Pro-981, Asp-1009, Arg-1016, Ser-1020, Met-1022, and His-1023 of the von Willebrand factor A3-domain (Vanhoorelbeke, K., Depraetere, H., Romijn, R. A., Huizinga, E., De Maeyer, M., and Deckmyn, H. (2003) J. Biol. Chem. 278, 37815-37821). By this, it potently inhibits the interaction of von Willebrand factor to collagens, which is a prerequisite for blood platelet adhesion to the injured vessel wall at sites of high shear. To fully understand the mode of action of 82D6A3 at the molecular level, we resolved its crystal structure in complex with the A3-domain and fine mapped its paratope by construction and characterization of 13 mutants. The paratope predominantly consists of two short sequences in the heavy chain CDR1 (Asn-31 and Tyr-32) and CDR3 (Asp-99, Pro-101, Tyr-102 and Tyr-103), forming one patch on the surface of the antibody. Trp-50 of the heavy and His-49 of the light chain, both situated adjacent to the patch, play ancillary roles in antigen binding. The crystal structure furthermore confirms the epitope location, which largely overlaps with the collagen binding site deduced from mutagenesis of the A3-domain ( Romijn, R. A., Westein, E., Bouma, B., Schiphorst, M. E., Sixma, J. J., Lenting, P. J., and Huizinga, E. G. (2003) J. Biol. Chem. 278, 15035-15039). We herewith further consolidate the location of the collagen binding site and reveal that the potent action of the antibody is due to direct competition for the same interaction site. This information allows the design of a paratope-mimicking peptide with antithrombotic properties.	IRC, Lab Thrombosis Res, B-85000 Kortrijk, Belgium; Univ Utrecht, Bijvoet Ctr Biomol Res, Dept Chem, NL-3584 CH Utrecht, Netherlands; Katholieke Univ Leuven, Lab Biomol Modeling, B-3000 Louvain, Belgium	Utrecht University; KU Leuven	Deckmyn, H (corresponding author), IRC, Lab Thrombosis Res, KU Leuven Campus Kortrijk,E Sabbelaan 53, B-85000 Kortrijk, Belgium.	Hans.Deckmyn@kuleuven-kortrijk.be	Deckmyn, Hans/L-9434-2015; Deckmyn, Hans/N-8932-2019	Deckmyn, Hans/0000-0003-3952-5501; Deckmyn, Hans/0000-0003-3952-5501; Vanhoorelbeke, Karen/0000-0003-2288-8277				Alberio L, 1998, BRIT J HAEMATOL, V102, P1212, DOI 10.1046/j.1365-2141.1998.00923.x; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Barnes CS, 2001, SEMIN THROMB HEMOST, V27, P337, DOI 10.1055/s-2001-16887; Bienkowska J, 1997, J BIOL CHEM, V272, P25162, DOI 10.1074/jbc.272.40.25162; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; CALIFF RM, 1994, NEW ENGL J MED, V330, P956, DOI 10.1056/nejm199404073301402; Cauwenberghs N, 2000, ARTERIOSCL THROM VAS, V20, P1347, DOI 10.1161/01.ATV.20.5.1347; Clemetson JM, 1999, J BIOL CHEM, V274, P29019, DOI 10.1074/jbc.274.41.29019; Clemetson KJ, 2001, THROMB HAEMOSTASIS, V86, P189; COLOMBATTI A, 1991, BLOOD, V77, P2305; Cruz CP, 2001, J VASC SURG, V34, P724, DOI 10.1067/mva.2001.116801; DENIS C, 1993, ARTERIOSCLER THROMB, V13, P398, DOI 10.1161/01.ATV.13.3.398; DORING E, 1994, MOL IMMUNOL, V31, P1059, DOI 10.1016/0161-5890(94)90101-5; Eichler J, 2004, PROTEIN PEPTIDE LETT, V11, P281, DOI 10.2174/0929866043406931; Emsley J, 1997, J BIOL CHEM, V272, P28512, DOI 10.1074/jbc.272.45.28512; Fairlie DP, 1998, CURR MED CHEM, V5, P29; Feng JN, 2005, IMMUNOL LETT, V98, P311, DOI 10.1016/j.imlet.2004.12.006; FERNS GAA, 1991, SCIENCE, V253, P1129, DOI 10.1126/science.1653454; Ferns GAA, 2000, INT J EXP PATHOL, V81, P63, DOI 10.1046/j.1365-2613.2000.00143.x; Hoylaerts MF, 1997, BIOCHEM J, V324, P185, DOI 10.1042/bj3240185; Huizinga EG, 1997, STRUCTURE, V5, P1147, DOI 10.1016/S0969-2126(97)00266-9; Kageyama S, 1997, BRIT J PHARMACOL, V122, P165, DOI 10.1038/sj.bjp.0701354; Kageyama S, 2001, THROMB RES, V101, P395, DOI 10.1016/S0049-3848(00)00430-8; Kamata T, 1999, J BIOL CHEM, V274, P32108, DOI 10.1074/jbc.274.45.32108; KAMATA T, 1994, J BIOL CHEM, V269, P26006; Kehrel B, 1998, BLOOD, V91, P491; Lankhof H, 1996, THROMB HAEMOSTASIS, V75, P950; Leslie AGW, 1992, JOINT CCP4 ESF EAMCB, V26; LINDNER V, 1991, P NATL ACAD SCI USA, V88, P3739, DOI 10.1073/pnas.88.9.3739; Mazzucato M, 1999, J BIOL CHEM, V274, P3033, DOI 10.1074/jbc.274.5.3033; Murshudov GN, 1997, ACTA CRYSTALLOGR D, V53, P240, DOI 10.1107/S0907444996012255; Nishida N, 2003, NAT STRUCT BIOL, V10, P53, DOI 10.1038/nsb876; PERKINS SJ, 1994, J MOL BIOL, V238, P104, DOI 10.1006/jmbi.1994.1271; Perrakis A, 1999, NAT STRUCT BIOL, V6, P458, DOI 10.1038/8263; PHILLIPS DR, 1991, CELL, V65, P359, DOI 10.1016/0092-8674(91)90451-4; PHILLIPS DR, 1988, BLOOD, V71, P831; REILLY IAG, 1988, DRUGS, V35, P154, DOI 10.2165/00003495-198835020-00005; Romijn RA, 2003, J BIOL CHEM, V278, P15035, DOI 10.1074/jbc.M208977200; Romijn RAP, 2001, J BIOL CHEM, V276, P9985, DOI 10.1074/jbc.M006548200; ROSS JM, 1995, BLOOD, V85, P1826, DOI 10.1182/blood.V85.7.1826.bloodjournal8571826; Sadler E, 2002, BLOOD, V99, P3491, DOI 10.1182/blood.V99.10.3491a; SANTORO SA, 1986, CELL, V46, P913, DOI 10.1016/0092-8674(86)90073-5; SANTORO SA, 1995, THROMB HAEMOSTASIS, V74, P813; Savage B, 1996, CELL, V84, P289, DOI 10.1016/S0092-8674(00)80983-6; Shattil SJ, 1998, BLOOD, V91, P2645, DOI 10.1182/blood.V91.8.2645.2645_2645_2657; SIXMA JJ, 1991, EUR J BIOCHEM, V196, P369, DOI 10.1111/j.1432-1033.1991.tb15826.x; Sixma JJ, 1997, THROMB HAEMOSTASIS, V78, P434; STAELENS S, 2006, IN PRESS MOL IMMUNOL; Trivedi Shivang M, 2002, J Invasive Cardiol, V14, P423; TSCHOPP TB, 1974, J LAB CLIN MED, V83, P296; vandenElsen JMH, 1997, PROTEINS, V29, P113; Vanhoorelbeke K, 2003, J BIOL CHEM, V278, P37815, DOI 10.1074/jbc.M304289200; Winn MD, 2001, ACTA CRYSTALLOGR D, V57, P122, DOI 10.1107/S0907444900014736; Wu DM, 2002, ARTERIOSCL THROM VAS, V22, P323, DOI 10.1161/hq0202.102321; Wu DM, 2002, BLOOD, V99, P3623, DOI 10.1182/blood.V99.10.3623; Zou JY, 1996, ACTA CRYSTALLOGR D, V52, P833, DOI 10.1107/S0907444995016465	58	24	30	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 27	2006	281	4					2225	2231		10.1074/jbc.M508191200	http://dx.doi.org/10.1074/jbc.M508191200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	004NV	16314412	Green Published, hybrid			2022-12-25	WOS:000234760400046
J	Rubin, J; Murphy, TC; Rahnert, J; Song, H; Nanes, MS; Greenfield, EM; Jo, H; Fan, X				Rubin, J; Murphy, TC; Rahnert, J; Song, H; Nanes, MS; Greenfield, EM; Jo, H; Fan, X			Mechanical inhibition of RANKL expression is regulated by H-Ras-GTPase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STRESS-DEPENDENT ACTIVATION; FOCAL ADHESION KINASE; NITRIC-OXIDE SYNTHASE; KAPPA-B LIGAND; SHEAR-STRESS; OSTEOCLAST DIFFERENTIATION; RECEPTOR ACTIVATOR; CELL-SURFACE; IN-VITRO; K-RAS	Mechanical input is known to regulate bone remodeling, yet the molecular events involved in mechanical signal transduction are poorly understood. We here investigate proximal events leading to the ERK1/2 activation that is required for mechanical repression of RANKL (receptor activator of NF-kappa B ligand) expression, the factor that controls local recruitment of osteoclasts. Using primary murine bone stromal cells we show that dynamic mechanical strain via substrate deformation activates Ras-GTPase, in particular the H-Ras isoform. Pharmacological inhibition of H-Ras function prevents strain activation of H-Ras as well as the downstream mechanical repression of RANKL. Furthermore, small interfering RNA silencing of H-Ras, but not K-Ras, abrogates mechanical strain repression of RANKL. H-Ras-specific inhibition of mechanorepression of RANKL was also demonstrated in a murine pre-osteoblast cell line (CIMC-4). The requirement of cholesterol for H-Ras activation was probed; cholesterol depletion of rafts using methyl-beta-cyclodextrin prevented mechanical H-Ras activation. That the mechanical repression of RANKL requires activation of H-Ras, a specific isoform of Ras-GTP that is known to reside in the lipid raft microdomain, suggests that spatial arrangements are critical for generation of specific downstream events in response to mechanical signals. By partitioning signals this way, cells may be able to generate different downstream responses through seemingly similar signaling cascades.	VAMC, Decatur, GA 30033 USA; Emory Univ, Sch Med, Dept Med, Atlanta, GA 30322 USA; Vet Affairs Med Ctr, Atlanta, GA 30033 USA; Case Western Reserve Univ, Dept Orthopaed, Cleveland, OH 44106 USA; Georgia Inst Technol, Wallace H Coulter Dept Biomed Engn, Atlanta, GA 30322 USA	Emory University; US Department of Veterans Affairs; Veterans Health Administration (VHA); Atlanta VA Health Care System; Case Western Reserve University; University System of Georgia; Georgia Institute of Technology	Rubin, J (corresponding author), VAMC, 151,1670 Clairmont Rd, Decatur, GA 30033 USA.	janet.rubin@emory.edu	Jo, Hanjoong/L-6216-2019	Jo, Hanjoong/0000-0003-1833-372X	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R56AR042360, R01AR052014, R01AR042360] Funding Source: NIH RePORTER; NIAMS NIH HHS [AR 042360, R01 AR042360, R01 AR052014] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Bivona TG, 2003, CURR OPIN CELL BIOL, V15, P136, DOI 10.1016/S0955-0674(03)00016-4; Boutahar N, 2004, J BIOL CHEM, V279, P30588, DOI 10.1074/jbc.M313244200; Brummelkamp TR, 2002, CANCER CELL, V2, P243, DOI 10.1016/S1535-6108(02)00122-8; Carozzi AJ, 2002, J BIOL CHEM, V277, P17944, DOI 10.1074/jbc.M110879200; Couet J, 1997, J BIOL CHEM, V272, P6525, DOI 10.1074/jbc.272.10.6525; Ehrhardt A, 2002, EXP HEMATOL, V30, P1089, DOI 10.1016/S0301-472X(02)00904-9; Fan X, 2004, ENDOCRINOLOGY, V145, P751, DOI 10.1210/en.2003-0726; Fan X, 2003, J BIOL CHEM, V278, P10232, DOI 10.1074/jbc.M209911200; Galbiati F, 1998, EMBO J, V17, P6633, DOI 10.1093/emboj/17.22.6633; Hancock JF, 2003, NAT REV MOL CELL BIO, V4, P373, DOI 10.1038/nrm1105; INOUE D, 2004, J BIOL CHEM, V279, P40805; Jalali S, 1998, ARTERIOSCL THROM VAS, V18, P227, DOI 10.1161/01.ATV.18.2.227; JAMES GL, 1995, METHOD ENZYMOL, V255, P38; JAT PS, 1991, P NATL ACAD SCI USA, V88, P5096, DOI 10.1073/pnas.88.12.5096; Jin ZG, 2005, J BIOL CHEM, V280, P12305, DOI 10.1074/jbc.M500294200; Jo H, 1997, J BIOL CHEM, V272, P1395, DOI 10.1074/jbc.272.2.1395; Jones MK, 1998, J BIOL CHEM, V273, P1782, DOI 10.1074/jbc.273.3.1782; Kranenburg O, 2001, CURR BIOL, V11, P1880, DOI 10.1016/S0960-9822(01)00582-6; LERNER EC, 1995, J BIOL CHEM, V270, P26802, DOI 10.1074/jbc.270.45.26802; Li S, 1997, J BIOL CHEM, V272, P30455, DOI 10.1074/jbc.272.48.30455; Li SW, 1996, J BIOL CHEM, V271, P29182, DOI 10.1074/jbc.271.46.29182; Li YS, 1996, MOL CELL BIOL, V16, P5947; Niv H, 2002, J CELL BIOL, V157, P865, DOI 10.1083/jcb.200202009; Park H, 1998, J BIOL CHEM, V273, P32304, DOI 10.1074/jbc.273.48.32304; Park H, 2000, AM J PHYSIOL-HEART C, V278, pH1285, DOI 10.1152/ajpheart.2000.278.4.H1285; Parton RG, 2001, METHOD ENZYMOL, V333, P172; Prior IA, 2003, J CELL BIOL, V160, P165, DOI 10.1083/jcb.200209091; Prior IA, 2001, NAT CELL BIOL, V3, P368, DOI 10.1038/35070050; Ragab AA, 1998, J BONE MINER RES, V13, P970, DOI 10.1359/jbmr.1998.13.6.970; Ragab AA, 2002, AM J PHYSIOL-CELL PH, V283, pC679, DOI 10.1152/ajpcell.00421.2001; Rizzo V, 1998, J BIOL CHEM, V273, P26323, DOI 10.1074/jbc.273.41.26323; Rosen CJ, 2004, TRENDS ENDOCRIN MET, V15, P229, DOI 10.1016/j.tem.2004.05.005; Roy S, 1999, NAT CELL BIOL, V1, P98, DOI 10.1038/10067; Rubin J, 2002, J BONE MINER RES, V17, P1452, DOI 10.1359/jbmr.2002.17.8.1452; Rubin J, 2000, AM J PHYSIOL-CELL PH, V278, pC1126, DOI 10.1152/ajpcell.2000.278.6.C1126; Rubin J, 1999, J ORTHOPAED RES, V17, P639, DOI 10.1002/jor.1100170504; Rubin J, 2003, J BIOL CHEM, V278, P34018, DOI 10.1074/jbc.M302822200; Rubin J, 1997, J CELL PHYSIOL, V170, P81, DOI 10.1002/(SICI)1097-4652(199701)170:1<81::AID-JCP9>3.0.CO;2-H; Tuschl Thomas, 2002, Mol Interv, V2, P158, DOI 10.1124/mi.2.3.158; Wadhwa S, 2002, J BONE MINER RES, V17, P266, DOI 10.1359/jbmr.2002.17.2.266; Yang CM, 2004, J BIOL CHEM, V279, P22158, DOI 10.1074/jbc.M401343200; Zhuang HM, 1996, BIOCHEM BIOPH RES CO, V229, P449, DOI 10.1006/bbrc.1996.1824	42	22	23	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 20	2006	281	3					1412	1418		10.1074/jbc.M508639200	http://dx.doi.org/10.1074/jbc.M508639200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	002ZS	16306046	hybrid			2022-12-25	WOS:000234652000017
J	Torban, E; Dziarmaga, A; Iglesias, D; Chu, LL; Vassilieva, T; Little, M; Eccles, M; Discenza, M; Pelletier, J; Goodyer, P				Torban, E; Dziarmaga, A; Iglesias, D; Chu, LL; Vassilieva, T; Little, M; Eccles, M; Discenza, M; Pelletier, J; Goodyer, P			PAX2 activates WNT4 expression during mammalian kidney development	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RENAL-COLOBOMA SYNDROME; EPITHELIAL TRANSFORMATION; METANEPHRIC MESENCHYME; APOPTOSIS; GENE; HYPOPLASIA; CELLS; MICE	The transcription factor PAX2 is expressed during normal kidney development and is thought to influence outgrowth and branching of the ureteric bud. Mice with homozygous null Pax2 mutations have developmental defects of the midbrain-hindbrain region, optic nerve, and ear and are anephric. During nephrogenesis, PAX2 is also expressed by mesenchymal cells as they cluster and reorganize to form proximal elements of each nephron, but the function of PAX2 in these cells is unknown. In this study we hypothesized that PAX2 activates expression of WNT4, a secreted glycoprotein known to be critical for successful nephrogenesis. PAX2 protein was identified in distal portions of the "S-shaped" body, and the protein persists in the emerging proximal tubules of murine fetal kidney. PAX2 activated WNT4 promoter activity 5-fold in co-transfection assays with JTC12 cells derived from the proximal tubule. Inspection of the 5'-flanking sequence of the human WNT4 gene identified three novel PAX2 recognition motifs; each exhibited specific PAX2 protein binding in electromobility shift assays. Two motifs were contained within a completely duplicated 0.66-kb cassette. Transfection of JTC12 cells with a PAX2 expression vector was associated with a 7-fold increase in endogenous WNT4 mRNA. In contrast, Wnt4 mRNA was decreased by 60% in mesenchymal cell condensates of fetal kidney from mice with a heterozygous Pax2 mutation. We speculated that a key function of PAX2 is to activate WNT4 gene expression in metanephric mesenchymal cells as they differentiate to form elements of the renal tubules.	McGill Univ, Dept Expt Med & Pediat, Montreal, PQ H3A 2T5, Canada; McGill Univ, Dept Human Genet, Montreal, PQ H3A 2T5, Canada; Univ Queensland, Inst Mol Sci, Brisbane, Qld, Australia; Univ Otago, Dept Pathol, Dev Genet Lab, Dunedin, New Zealand; McGill Univ, Dept Biochem, Montreal, PQ H3G 1Y6, Canada	McGill University; McGill University; University of Queensland; University of Otago; McGill University	Goodyer, P (corresponding author), Montreal Childrens Hosp, Res Inst, 4060 Sainte Catherine St W,Rm 413, Montreal, PQ H3Z 2Z3, Canada.	Paul.Goodyer@muhc.mcgill.ca	Little, Melissa H/A-6170-2010	Little, Melissa H/0000-0003-0380-2263				Bouchard M, 2002, GENE DEV, V16, P2958, DOI 10.1101/gad.240102; Brisken C, 2000, GENE DEV, V14, P650; Brophy PD, 2001, DEVELOPMENT, V128, P4747; Clark P, 2004, J AM SOC NEPHROL, V15, P299, DOI 10.1097/01.ASN.0000111248.23454.19; Cohen ED, 2002, DEV CELL, V2, P437, DOI 10.1016/S1534-5807(02)00142-9; DRESSLER GR, 1990, DEVELOPMENT, V109, P787; Dziarmaga A, 2003, J AM SOC NEPHROL, V14, P2767, DOI 10.1097/01.ASN.0000094082.11026.EE; Guo XZ, 2004, GENE DEV, V18, P2404, DOI 10.1101/gad.1230704; He X, 2004, DEVELOPMENT, V131, P1663, DOI 10.1242/dev.01117; Hou XN, 2004, MOL ENDOCRINOL, V18, P3035, DOI 10.1210/me.2004-0259; Huelsken J, 2001, CURR OPIN GENET DEV, V11, P547, DOI 10.1016/S0959-437X(00)00231-8; Hunter DD, 2004, MOL CELL NEUROSCI, V27, P477, DOI 10.1016/j.mcn.2004.08.003; IGLESIAS DM, 2004, J AM SOC NEPHROL, V15, pA58; Kispert A, 1998, DEVELOPMENT, V125, P4225; Kispert A, 1996, DEVELOPMENT, V122, P3627; Lyons JP, 2004, EXP CELL RES, V298, P369, DOI 10.1016/j.yexcr.2004.04.036; Lyuksyutova AI, 2003, SCIENCE, V302, P1984, DOI 10.1126/science.1089610; Maretto S, 2003, P NATL ACAD SCI USA, V100, P3299, DOI 10.1073/pnas.0434590100; Nusse R, 2005, CELL RES, V15, P28, DOI 10.1038/sj.cr.7290260; Porteous S, 2000, HUM MOL GENET, V9, P1, DOI 10.1093/hmg/9.1.1; Sim EUH, 2002, ONCOGENE, V21, P2948, DOI 10.1038/sj.onc.1205373; STARK K, 1994, NATURE, V372, P679, DOI 10.1038/372679a0; Stayner CK, 1998, J BIOL CHEM, V273, P25472, DOI 10.1074/jbc.273.39.25472; Torban E, 2000, AM J PATHOL, V157, P833, DOI 10.1016/S0002-9440(10)64597-X; Torban E, 1998, BBA-MOL CELL RES, V1401, P53, DOI 10.1016/S0167-4889(97)00119-5; Torres M, 1995, DEVELOPMENT, V121, P4057; Wheat W, 1999, MOL CELL BIOL, V19, P2231	27	53	60	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 5	2006	281	18					12705	12712		10.1074/jbc.M513181200	http://dx.doi.org/10.1074/jbc.M513181200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	037GI	16368682	hybrid			2022-12-25	WOS:000237134700062
J	Chang, CY; Lin, YM; Lee, WP; Hsu, HH; Chen, EIT				Chang, CY; Lin, YM; Lee, WP; Hsu, HH; Chen, EIT			Involvement of Bcl-X-L deamidation in E1A-mediated cisplatin sensitization of ovarian cancer cells	ONCOGENE			English	Article						E1A; Rb; Bcl-X-L; deamidation; apoptosis	RETINOBLASTOMA GENE-PRODUCT; E1A; APOPTOSIS; PROTEIN; INDUCTION; RB; CHEMOSENSITIVITY; ASSOCIATION; SENSITIVITY; SUPPRESSION	The adenovirus E1A protein has been shown to be involved in the potentiation of apoptosis induced by chemotherapeutic agents, yet the molecular events of E1A-mediated apoptosis are not very clear. A recent report has suggested that deamidation of the Bcl-X-L protein inhibits its antiapoptotic ability and leads to apoptosis induced by alkylating agents in Rb-deficient tumor cells. Since Rb is known to interact with E1A, which interrupts Rb's normal function, we examined Bcl-X-L deamidation and cell death induced by cisplatin in E1A transfectants. We found that the E1A transfectants became sensitive to cisplatin-induced apoptosis compared to the parental cells, SKOV3.ip1. Our data show that cisplatin treatment induced the modi. cation of Bcl-X-L in the E1A transfectants in dosage and time-dependent manner. Furthermore, phosphatase treatment had no effect on the level of Bcl-X-L modi. cation, whereas alkaline lysis buffer appeared to induce the same modi. cation of Bcl-X-L. Ectopic expression of the deamidated forms of Bcl-X-L in SKOV3.ip1 cells revealed that the modi. cation to the Bcl-X-L protein molecules was deamidation. Expression of the E1A mutant ( dl1108) which contains deletion at CR2 domain suppressed Bcl-X-L deamidation and apoptosis induced by cisplatin. We also found that expression of the nondeamidated Bcl-X-L protected E1A transfectants from apoptosis. These findings suggest that Bcl-X-L deamidation contributes to E1A-mediated cisplatin sensitization in SKOV3.ip1 cells.	Natl Yang Ming Univ, Inst Biotechnol Med, Taipei 112, Taiwan; Vet Gen Hosp, Div Internal Med, Taipei, Taiwan; Vet Gen Hosp, Ctr Canc, Taipei, Taiwan	National Yang Ming Chiao Tung University	Chen, EIT (corresponding author), Natl Yang Ming Univ, Inst Biotechnol Med, Lee Lun St,Sect 2, Taipei 112, Taiwan.	chenit@ym.edu.tw						ABRAHAM RT, 1995, BIOL CELL, V83, P105, DOI 10.1016/0248-4900(96)81298-6; Agarwal R, 2003, NAT REV CANCER, V3, P502, DOI 10.1038/nrc1123; Amundson SA, 2000, CANCER RES, V60, P6101; Brader KR, 1997, CLIN CANCER RES, V3, P2017; Chattopadhyay D, 2001, J VIROL, V75, P9844, DOI 10.1128/JVI.75.20.9844-9856.2001; Chau BN, 2003, NAT REV CANCER, V3, P130, DOI 10.1038/nrc993; CHELLAPPAN S, 1992, P NATL ACAD SCI USA, V89, P4549, DOI 10.1073/pnas.89.10.4549; CHEN IT, 1995, ONCOGENE, V11, P1931; Deng J, 2002, CANCER RES, V62, P346; Deverman BE, 2002, CELL, V111, P51, DOI 10.1016/S0092-8674(02)00972-8; Deverman BE, 2003, CELL, V115, P503, DOI 10.1016/S0092-8674(03)00892-4; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; Duelli DM, 2000, NAT CELL BIOL, V2, P859, DOI 10.1038/35041112; Frisch SM, 2002, NAT REV MOL CELL BIO, V3, P441, DOI 10.1038/nrm827; Lee WP, 2003, CANCER RES, V63, P6229; Lee WP, 2002, ONCOGENE, V21, P329, DOI 10.1038/sj.onc.1205066; NEVINS JR, 1992, SCIENCE, V258, P424; Poruchynsky MS, 1998, CANCER RES, V58, P3331; Robinson NE, 2002, P NATL ACAD SCI USA, V99, P5283, DOI 10.1073/pnas.082102799; Robinson NE, 2001, P NATL ACAD SCI USA, V98, P12409, DOI 10.1073/pnas.221463198; Samuelson AV, 1997, P NATL ACAD SCI USA, V94, P12094, DOI 10.1073/pnas.94.22.12094; SCHEFFNER M, 1991, P NATL ACAD SCI USA, V88, P5523, DOI 10.1073/pnas.88.13.5523; Shao RP, 1997, J BIOL CHEM, V272, P32739, DOI 10.1074/jbc.272.52.32739; Shisler J, 1996, J VIROL, V70, P68, DOI 10.1128/JVI.70.1.68-77.1996; Strausberg RL, 2002, P NATL ACAD SCI USA, V99, P16899, DOI 10.1073/pnas.242603899; Takehara T, 2003, CANCER RES, V63, P3054; UNEO NT, 1997, ONCOGENE, V10, P1053; UNEO NT, 2000, CLIN CANCER RES, V6, P250; Viniegra JG, 2002, ONCOGENE, V21, P7131, DOI 10.1038/sj.onc.1205934; WANG HGH, 1991, MOL CELL BIOL, V11, P4253, DOI 10.1128/MCB.11.8.4253; White E, 2001, ONCOGENE, V20, P7836, DOI 10.1038/sj.onc.1204861; White E, 1996, GENE DEV, V10, P1, DOI 10.1101/gad.10.1.1; WHYTE P, 1988, NATURE, V334, P124, DOI 10.1038/334124a0; YU DH, 1993, CANCER RES, V53, P891; Zhao R, 2004, CANCER CELL, V5, P37, DOI 10.1016/S1535-6108(03)00333-7	35	11	11	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR	2006	25	18					2656	2665		10.1038/sj.onc.1209294	http://dx.doi.org/10.1038/sj.onc.1209294			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	036TU	16331250				2022-12-25	WOS:000237099400009
J	Fong, SS; Nanchen, A; Palsson, BO; Sauer, U				Fong, SS; Nanchen, A; Palsson, BO; Sauer, U			Latent pathway activation and increased pathway capacity enable Escherichia coli adaptation to loss of key metabolic enzymes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CENTRAL CARBON METABOLISM; PYRIDINE-NUCLEOTIDE TRANSHYDROGENASE; GLOBAL GENE-EXPRESSION; FLUX ANALYSIS; SACCHAROMYCES-CEREVISIAE; ADAPTIVE EVOLUTION; TRANSCRIPTIONAL REGULATION; FUNCTIONAL GENOMICS; ANAEROBIC GROWTH; XYLOSE	The ability of biological systems to adapt to genetic and environmental perturbations is a fundamental but poorly understood process at the molecular level. By quantifying metabolic fluxes and global mRNA abundance, we investigated the genetic and metabolic mechanisms that underlie adaptive evolution of four metabolic gene deletion mutants of Escherichia coli (Delta pgi, Delta ppc, Delta pta, and Delta tpi) in parallel evolution experiments of each mutant. The initial response to the gene deletions was flux rerouting through local bypass reactions or normally latent pathways. The principal effect of evolution was improved capacity of already active pathways, whereas new flux distributions were not observed. Combinatorial changes in capacity and pathway activation, however, led to different intracellular flux states that enabled evolution in three of the four parallel cases tested. The molecular bases of the evolved phenotypes were then elucidated by global mRNA transcript analyses. Activation of latent pathways and flux changes in the tricarboxylic acid cycle were found to correlate well with molecular changes at the transcriptional level. Flux alterations in other central metabolic pathways, in contrast, were apparently not connected to changes in the transcriptional network. These results give new insight into the dynamics of the evolutionary process by demonstrating the flexibility of the metabolic network of E. coli to compensate for genetic perturbations and the utility of combining multiple high throughput data sets to differentiate between causal and noncausal mechanistic changes.	Virginia Commonwealth Univ, Dept Chem & Life Sci Engn, Richmond, VA 23284 USA; ETH, Inst Mol Syst Biol, CH-8093 Zurich, Switzerland; Univ Calif San Diego, Dept Bioengn, La Jolla, CA 92093 USA	Virginia Commonwealth University; Swiss Federal Institutes of Technology Domain; ETH Zurich; University of California System; University of California San Diego	Fong, SS (corresponding author), Virginia Commonwealth Univ, Dept Chem & Life Sci Engn, POB 843028, Richmond, VA 23284 USA.	ssfong@vcu.edu	Sauer, Uwe/Y-3556-2019	Palsson, Bernhard/0000-0003-2357-6785				Adams J, 2004, RES MICROBIOL, V155, P311, DOI 10.1016/j.resmic.2004.01.013; Bailey JE, 1999, NAT BIOTECHNOL, V17, P616, DOI 10.1038/10794; Blank LM, 2005, GENOME BIOL, V6, DOI 10.1186/gb-2005-6-6-r49; Boonstra B, 1999, J BACTERIOL, V181, P1030, DOI 10.1128/JB.181.3.1030-1034.1999; Chang DE, 1999, J BACTERIOL, V181, P6656, DOI 10.1128/JB.181.21.6656-6663.1999; CLARKE DM, 1986, EUR J BIOCHEM, V158, P647, DOI 10.1111/j.1432-1033.1986.tb09802.x; COOPER RA, 1970, FEBS LETT, V11, P273, DOI 10.1016/0014-5793(70)80546-4; Cooper TF, 2003, P NATL ACAD SCI USA, V100, P1072, DOI 10.1073/pnas.0334340100; Cora D, 2004, BMC BIOINFORMATICS, V5, DOI 10.1186/1471-2105-5-57; Daran-Lapujade P, 2004, J BIOL CHEM, V279, P9125, DOI 10.1074/jbc.M309578200; Datsenko KA, 2000, P NATL ACAD SCI USA, V97, P6640, DOI 10.1073/pnas.120163297; Elena SF, 2003, NAT REV GENET, V4, P457, DOI 10.1038/nrg1088; Emmerling M, 2002, J BACTERIOL, V184, P152, DOI 10.1128/JB.184.1.152-164.2002; Ferea TL, 1999, P NATL ACAD SCI USA, V96, P9721, DOI 10.1073/pnas.96.17.9721; Ferguson GP, 1998, ARCH MICROBIOL, V170, P209, DOI 10.1007/s002030050635; Fischer E, 2003, EUR J BIOCHEM, V270, P880, DOI 10.1046/j.1432-1033.2003.03448.x; Fischer E, 2004, ANAL BIOCHEM, V325, P308, DOI 10.1016/j.ab.2003.10.036; Fischer E, 2005, NAT GENET, V37, P636, DOI 10.1038/ng1555; Fong SS, 2004, NAT GENET, V36, P1056, DOI 10.1038/ng1432; Fong SS, 2003, J BACTERIOL, V185, P6400, DOI 10.1128/JB.185.21.6400-6408.2003; Fuhrer T, 2005, J BACTERIOL, V187, P1581, DOI 10.1128/JB.187.5.1581-1590.2005; Gonzalez R, 2002, BIOTECHNOL PROGR, V18, P6, DOI 10.1021/bp010121i; Gunnarsson N, 2004, MOL MICROBIOL, V52, P895, DOI 10.1111/j.1365-2958.2004.04028.x; Hellerstein MK, 2003, ANNU REV NUTR, V23, P379, DOI 10.1146/annurev.nutr.23.011702.073045; HOEK JB, 1988, BIOCHEM J, V254, P1; Honisch C, 2004, GENOME RES, V14, P2495, DOI 10.1101/gr.2977704; HOPPER DJ, 1972, BIOCHEM J, V128, P321, DOI 10.1042/bj1280321; Hua Q, 2003, J BACTERIOL, V185, P7053, DOI 10.1128/JB.185.24.7053-7067.2003; Ibarra RU, 2002, NATURE, V420, P186, DOI 10.1038/nature01149; Irizarry RA, 2003, BIOSTATISTICS, V4, P249, DOI 10.1093/biostatistics/4.2.249; Keseler IM, 2005, NUCLEIC ACIDS RES, V33, pD334, DOI 10.1093/nar/gki108; Kuyper M, 2005, FEMS YEAST RES, V5, P925, DOI 10.1016/j.femsyr.2005.04.004; Mahadevan R, 2003, METAB ENG, V5, P264, DOI 10.1016/j.ymben.2003.09.002; Neidhardt F. C., 1990, PHYSL BACTERIAL CELL, P133; Peng LF, 2004, FEMS MICROBIOL LETT, V235, P17, DOI 10.1016/j.femsle.2004.04.003; Perrenoud A, 2005, J BACTERIOL, V187, P3171, DOI 10.1128/JB.187.9.3171-3179.2005; SAIKUSA T, 1987, AGR BIOL CHEM TOKYO, V51, P1893, DOI 10.1080/00021369.1987.10868320; Sauer U, 1999, J BACTERIOL, V181, P6679, DOI 10.1128/JB.181.21.6679-6688.1999; Sauer U, 2004, CURR OPIN BIOTECH, V15, P58, DOI 10.1016/j.copbio.2003.11.001; Sauer U, 2004, J BIOL CHEM, V279, P6613, DOI 10.1074/jbc.M311657200; Sauer U, 2001, Adv Biochem Eng Biotechnol, V73, P129; Sauer U, 2005, FEMS MICROBIOL REV, V29, P765, DOI 10.1016/j.femsre.2004.11.002; Segre D, 2002, P NATL ACAD SCI USA, V99, P15112, DOI 10.1073/pnas.232349399; Sonderegger M, 2004, APPL ENVIRON MICROB, V70, P2307, DOI 10.1128/AEM.70.4.2307-2317.2004; Sonderegger M, 2003, APPL ENVIRON MICROB, V69, P1990, DOI 10.1128/AEM.69.4.1990-1998.2003; Wolfe AJ, 2003, MOL MICROBIOL, V48, P977, DOI 10.1046/j.1365-2958.2003.03457.x; Zamboni N, 2005, BMC BIOINFORMATICS, V6, DOI 10.1186/1471-2105-6-209; Zelder O, 2000, CURR OPIN MICROBIOL, V3, P248, DOI 10.1016/S1369-5274(00)00084-9	48	137	145	0	27	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 24	2006	281	12					8024	8033		10.1074/jbc.M510016200	http://dx.doi.org/10.1074/jbc.M510016200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	022BZ	16319065	hybrid			2022-12-25	WOS:000236031000039
J	Tahara, H; Shin-ya, K; Seimiya, H; Yamada, H; Tsuruo, T; Ide, T				Tahara, H; Shin-ya, K; Seimiya, H; Yamada, H; Tsuruo, T; Ide, T			G-quadruplex stabilization by telomestatin induces TRF2 protein dissociation from telomeres and anaphase bridge formation accompanied by loss of the 3 ' telomeric overhang in cancer cells	ONCOGENE			English	Article						telomere; telomestatin; G-quadruplex; TRF2; 3 ' telomeric overhang	HYBRIDIZATION PROTECTION ASSAY; G-QUARTET FORMATION; BINDING-PROTEIN; HEPATOCELLULAR CARCINOMAS; HUMAN-CHROMOSOMES; BETA-SUBUNIT; DRUG DESIGN; IN-VITRO; DNA; INHIBITION	Inhibition of telomerase activity by telomerase inhibitors induces a gradual loss of telomeres, and this in turn causes cancer cells to enter to a crisis stage. Here, we report the telomerase inhibitor telomestatin, which is known to stabilize G-quadruplex structures at 30 single-stranded telomeric overhangs ( G-tails), rapidly dissociates TRF2 from telomeres in cancer cells within a week, when given at a concentration that does not cause normal cells to die. The G-tails were dramatically reduced upon short-term treatment with the drug in cancer cell lines, but not in normal. broblasts and epithelial cells. In addition, telomestatin also induced anaphase bridge formation in cancer cell lines. These effects of telomestatin were similar to those of dominant negative TRF2, which also causes a prompt loss of the telomeric G-tails and induces an anaphase bridge. These results indicate that telomestatin exerts its anticancer effect not only through inhibiting telomere elongation, but also by rapidly disrupting the capping function at the very ends of telomeres. Unlike conventional telomerase inhibitors that require long-term treatments, the G-quadruplex stabilizer telomestatin induced prompt cell death, and it was selectively effective in cancer cells. This study also identifies the TRF2 protein as a therapeutic target for treating many types of cancer which have the TRF2 protein at caps of the telomere DNA of each chromosome.	Hiroshima Univ, Sch Biomed Sci, Div Integrated Med Sci, Dept Cellular & Mol Biol, Hiroshima, Japan; Univ Tokyo, Inst Mol & Cellular Biosci, Tokyo, Japan; Japanese Fdn Canc Res, Ctr Canc Chemotherapy, Tokyo 170, Japan	Hiroshima University; University of Tokyo; Japanese Foundation for Cancer Research	Tahara, H (corresponding author), Hiroshima Univ, Sch Biomed Sci, Div Integrated Med Sci, Dept Cellular & Mol Biol, Hiroshima, Japan.	toshi@hiroshima-u.ac.jp; kshinya@jbirc.aist.go.jp		Seimiya, Hiroyuki/0000-0003-3314-9736				Akiyama M, 2003, CANCER RES, V63, P6187; Bodnar AG, 1998, SCIENCE, V279, P349, DOI 10.1126/science.279.5349.349; Broccoli D, 1997, NAT GENET, V17, P231, DOI 10.1038/ng1097-231; Carney SA, 2002, LAB INVEST, V82, P719, DOI 10.1097/01.LAB.0000017499.51216.3E; FANG GW, 1993, BIOCHEMISTRY-US, V32, P11646, DOI 10.1021/bi00094a022; FANG GW, 1993, CELL, V74, P875, DOI 10.1016/0092-8674(93)90467-5; GIRALDO R, 1994, P NATL ACAD SCI USA, V91, P7658, DOI 10.1073/pnas.91.16.7658; Gomez D, 2004, J BIOL CHEM, V279, P41487, DOI 10.1074/jbc.M406123200; Gowan SM, 2002, MOL PHARMACOL, V61, P1154, DOI 10.1124/mol.61.5.1154; Gowan SM, 2001, MOL PHARMACOL, V60, P981, DOI 10.1124/mol.60.5.981; Griffith JD, 1999, CELL, V97, P503, DOI 10.1016/S0092-8674(00)80760-6; Gu J, 2005, CARCINOGENESIS, V26, P1741, DOI 10.1093/carcin/bgi126; Hahn WC, 1999, NAT MED, V5, P1164, DOI 10.1038/13495; Han HY, 2000, TRENDS PHARMACOL SCI, V21, P136, DOI 10.1016/S0165-6147(00)01457-7; Hanaoka S, 2005, PROTEIN SCI, V14, P119, DOI 10.1110/ps.04983705; Hirose M, 1997, J CANCER RES CLIN, V123, P337, DOI 10.1007/BF01438310; Karlseder J, 1999, SCIENCE, V283, P1321, DOI 10.1126/science.283.5406.1321; Kim MY, 2003, CANCER RES, V63, P3247; Kim MY, 2002, J AM CHEM SOC, V124, P2098, DOI 10.1021/ja017308q; Kondo S, 1998, FASEB J, V12, P801, DOI 10.1096/fasebj.12.10.801; Makarov VL, 1997, CELL, V88, P657, DOI 10.1016/S0092-8674(00)81908-X; Mergny JL, 1998, NAT MED, V4, P1366, DOI 10.1038/3949; Nakamura Y, 1999, CLIN CHEM, V45, P1718; Nakanishi K, 2003, CLIN CANCER RES, V9, P1105; Nakayama JI, 1998, NAT GENET, V18, P65, DOI 10.1038/ng0198-65; Nijjar T, 2005, ONCOGENE, V24, P3369, DOI 10.1038/sj.onc.1208482; Parkinson GN, 2002, NATURE, V417, P876, DOI 10.1038/nature755; Riou JF, 2002, P NATL ACAD SCI USA, V99, P2672, DOI 10.1073/pnas.052698099; Rosu F, 2003, CHEM COMMUN, P2702, DOI 10.1039/b309394h; Seimiya H, 2005, CANCER CELL, V7, P25, DOI 10.1016/j.ccr.2004.11.021; Seimiya H, 2004, MOL CELL BIOL, V24, P1944, DOI 10.1128/MCB.24.5.1944-1955.2004; Seimiya H, 2002, MOL CANCER THER, V1, P657; Shay JW, 2005, CANCER CELL, V7, P1, DOI 10.1016/j.ccr.2004.12.012; Shin-ya K, 2001, J AM CHEM SOC, V123, P1262, DOI 10.1021/ja005780q; Smogorzewska A, 2000, MOL CELL BIOL, V20, P1659, DOI 10.1128/MCB.20.5.1659-1668.2000; Stansel RM, 2001, EMBO J, V20, P5532; TAHARA H, 1995, CANCER RES, V55, P2734; Tahara H, 2005, NAT METHODS, V2, P829, DOI 10.1038/NMETH797; Takai H, 2003, CURR BIOL, V13, P1549, DOI 10.1016/S0960-9822(03)00542-6; Tauchi T, 2003, ONCOGENE, V22, P5338, DOI 10.1038/sj.onc.1206833; van Steensel B, 1998, CELL, V92, P401, DOI 10.1016/S0092-8674(00)80932-0; WILLIAMSON JR, 1989, CELL, V59, P871, DOI 10.1016/0092-8674(89)90610-7; Wright WE, 1997, GENE DEV, V11, P2801, DOI 10.1101/gad.11.21.2801; ZAHLER AM, 1991, NATURE, V350, P718, DOI 10.1038/350718a0; Zhang XL, 1999, GENE DEV, V13, P2388, DOI 10.1101/gad.13.18.2388	45	192	202	0	24	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 23	2006	25	13					1955	1966		10.1038/sj.onc.1209217	http://dx.doi.org/10.1038/sj.onc.1209217			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	024VQ	16302000				2022-12-25	WOS:000236224800012
J	Muromoto, R; Nakao, K; Watanabe, T; Sato, N; Sekine, Y; Sugiyama, K; Oritani, K; Shimoda, K; Matsuda, T				Muromoto, R; Nakao, K; Watanabe, T; Sato, N; Sekine, Y; Sugiyama, K; Oritani, K; Shimoda, K; Matsuda, T			Physical and functional interactions between Daxx and STAT3	ONCOGENE			English	Article						IL-6; LIF; STAT3; Daxx; transcriptional regulation	INTERFERON-ALPHA; TRANSCRIPTIONAL ACTIVATION; PML; PROTEIN; EXPRESSION; APOPTOSIS; MELANOMA; GROWTH; CELLS	Signal transducer and activator of transcription 3 (STAT3) play key roles in the intracellular signaling pathways of the interleukin (IL)-6 family of cytokines, which exhibit a diverse set of cellular responses, including cell proliferation and differentiation. Dysregulated IL-6/STAT3 signaling is involved in the pathogenesis of several diseases, for example autoimmune diseases and tumors. Type I interferon (IFN) induces the expression of proapoptotic genes and has been used in the clinical treatment of several tumors. In the present study, we found that type I IFN suppressed IL-6/STAT3-mediated transcription and gene expression. Furthermore, a type I IFN-induced protein, Daxx, also suppressed STAT3-mediated transcriptional activation, while overexpression of Daxx inhibited IL-6/STAT3-mediated gene expression. Importantly, small-interfering RNA-mediated reduction of Daxx expression enhanced IL-6/leukemia inhibitory factor (LIF)-induced STAT3-dependent transcription. Co-immunoprecipitation studies revealed a physical interaction between Daxx and STAT3 in transiently transfected 293T cells. We further found that Daxx and STAT3 were co-localized in the nucleus. These results indicate that Daxx may serve as a transcriptional regulator of type I IFN-mediated suppression of the IL-6/STAT3 signaling pathway.	Hokkaido Univ, Grad Sch Pharmaceut Sci, Dept Immunol, Kita Ku, Sapporo, Hokkaido 0600812, Japan; Nippon Boehringer Ingelheim Co Ltd, Kawanishi Pharma Res Inst, Kawanishi, Hyogo, Japan; Osaka Univ, Grad Sch Med, Dept Hematol & Oncol, Suita, Osaka, Japan; Kyushu Univ, Fac Med, Dept Internal Med 1, Higashi Ku, Fukuoka, Japan	Hokkaido University; Boehringer Ingelheim; Osaka University; Kyushu University	Matsuda, T (corresponding author), Hokkaido Univ, Grad Sch Pharmaceut Sci, Dept Immunol, Kita Ku, Kita 12 Nishi 6, Sapporo, Hokkaido 0600812, Japan.	tmatsuda@pharm.hokudai.ac.jp	Muromoto, Ryuta/E-4203-2012; Sekine, Yuichi/S-8813-2019; Matsuda, Tadashi/A-3835-2012	Muromoto, Ryuta/0000-0002-7474-493X; Sekine, Yuichi/0000-0002-2861-603X; Matsuda, Tadashi/0000-0002-3089-3757				Brender C, 2001, EXP CLIN IMMUNOGENET, V18, P80, DOI 10.1159/000049186; Bromberg J, 2000, BREAST CANCER RES, V2, P86, DOI 10.1186/bcr38; Bromberg JF, 1999, CELL, V98, P295, DOI 10.1016/S0092-8674(00)81959-5; DARNELL JE, 1994, SCIENCE, V264, P1415, DOI 10.1126/science.8197455; Hirano Toshio, 1997, Cytokine and Growth Factor Reviews, V8, P241, DOI 10.1016/S1359-6101(98)80005-1; Hollenbach AD, 1999, EMBO J, V18, P3702, DOI 10.1093/emboj/18.13.3702; Hollenbach AD, 2002, J CELL SCI, V115, P3319; IHLE JN, 1995, NATURE, V377, P591, DOI 10.1038/377591a0; Ishov AM, 1999, J CELL BIOL, V147, P221, DOI 10.1083/jcb.147.2.221; Jelinek DF, 1997, J CLIN INVEST, V99, P447, DOI 10.1172/JCI119179; Kim EJ, 2003, NUCLEIC ACIDS RES, V31, P5356, DOI 10.1093/nar/gkg741; Kirkwood JM, 1999, MOL MED, V5, P11, DOI 10.1007/BF03402135; Levy DE, 2002, J CLIN INVEST, V109, P1143, DOI 10.1172/JCI200215650; Li H, 2000, MOL CELL BIOL, V20, P1784, DOI 10.1128/MCB.20.5.1784-1796.2000; Li RZ, 2000, ONCOGENE, V19, P745, DOI 10.1038/sj.onc.1203385; Li Z, 2004, J INVEST DERMATOL, V123, P737, DOI 10.1111/j.0022-202X.2004.23408.x; Muromoto R, 2004, BIOCHEM BIOPH RES CO, V316, P827, DOI 10.1016/j.bbrc.2004.02.126; Muromoto R, 2004, J IMMUNOL, V172, P2985, DOI 10.4049/jimmunol.172.5.2985; Nakajima K, 1996, EMBO J, V15, P3651, DOI 10.1002/j.1460-2075.1996.tb00734.x; Platanias LC, 2005, NAT REV IMMUNOL, V5, P375, DOI 10.1038/nri1604; Shimoda K, 2002, J IMMUNOL, V169, P4707, DOI 10.4049/jimmunol.169.9.4707; Torii S, 1999, EMBO J, V18, P6037, DOI 10.1093/emboj/18.21.6037; Zhong S, 2000, J EXP MED, V191, P631, DOI 10.1084/jem.191.4.631	23	19	19	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR	2006	25	14					2131	2136		10.1038/sj.onc.1209235	http://dx.doi.org/10.1038/sj.onc.1209235			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	026RL	16331268	Green Submitted			2022-12-25	WOS:000236359700017
J	Vinothkumar, KR; Raunser, S; Jung, H; Kuhlbrandt, W				Vinothkumar, KR; Raunser, S; Jung, H; Kuhlbrandt, W			Oligomeric structure of the carnitine transporter CaiT from Escherichia coli	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BLUE NATIVE ELECTROPHORESIS; PROJECTION STRUCTURE; ELECTRON-MICROSCOPY; CORYNEBACTERIUM-GLUTAMICUM; ERYTHROCYTE-MEMBRANE; QUATERNARY STRUCTURE; ANGSTROM RESOLUTION; PROTEIN; CHANNEL; IMAGES	The carnitine transporter CaiT from Escherichia coli belongs to the betaine, choline, and carnitine transporter family of secondary transporters. It acts as an L-carnitine/gamma-butyrobetaine exchanger and is predicted to span the membrane 12 times. Unlike the other members of this transporter family, it does not require an ion gradient and does not respond to osmotic stress ( Jung, H., Buchholz, M., Clausen, J., Nietschke, M., Revermann, A., Schmid, R., and Jung, K. ( 2002) J. Biol. Chem. 277, 39251-39258). The structure and oligomeric state of the protein was examined in detergent and in lipid bilayers. Blue native gel electrophoresis indicated that CaiT was a trimer in detergent solution. This result was further supported by gel filtration and cross-linking studies. Electron microscopy and single particle analysis of the protein showed a triangular structure of three masses or two parallel elongated densities. Reconstitution of CaiT into lipid bilayers yielded two-dimensional crystals that indicated that CaiT was a trimer in the membrane, similar to its homologue BetP. The implications of the trimeric structure on the function of CaiT are discussed.	Max Planck Inst Biophys, Dept Biol Struct, D-60438 Frankfurt, Germany; Univ Munich, Dept Biol 1, D-80638 Munich, Germany	Max Planck Society; University of Munich	Kuhlbrandt, W (corresponding author), Max Planck Inst Biophys, Dept Biol Struct, Max Von Laue Str 3, D-60438 Frankfurt, Germany.	werner.kuehlbrandt@mpibp-frankfurt.mpg.de	Jung, Heinrich/K-3790-2014; Raunser, Stefan/AHE-1573-2022	Jung, Heinrich/0000-0002-5450-3063; Kuhlbrandt, Werner/0000-0002-2013-4810; Raunser, Stefan/0000-0001-9373-3016				Abramson J, 2003, SCIENCE, V301, P610, DOI 10.1126/science.1088196; AMBUDKAR SV, 1990, J BIOL CHEM, V265, P12287; Bessonneau P, 2002, EMBO J, V21, P995, DOI 10.1093/emboj/21.5.995; CASEY JR, 1991, J BIOL CHEM, V266, P15726; Crowther RA, 1996, J STRUCT BIOL, V116, P9, DOI 10.1006/jsbi.1996.0003; Frank J, 1996, J STRUCT BIOL, V116, P190, DOI 10.1006/jsbi.1996.0030; Gendreau S, 2004, J BIOL CHEM, V279, P39505, DOI 10.1074/jbc.M408038200; HENDERSON R, 1986, ULTRAMICROSCOPY, V19, P147, DOI 10.1016/0304-3991(86)90203-2; Heuberger EHML, 2002, J MOL BIOL, V317, P591, DOI 10.1006/jmbi.2002.5416; Huang YF, 2003, SCIENCE, V301, P616, DOI 10.1126/science.1087619; JUNG H, 1989, BIOCHIM BIOPHYS ACTA, V1003, P270, DOI 10.1016/0005-2760(89)90232-4; Jung H, 2002, J BIOL CHEM, V277, P39251, DOI 10.1074/jbc.M206319200; Kramer R, 2004, BBA-BIOENERGETICS, V1658, P31, DOI 10.1016/j.bbabio.2004.05.006; MARABINI R, 1994, BIOPHYS J, V66, P1804, DOI 10.1016/S0006-3495(94)80974-9; Marabini R, 1996, J STRUCT BIOL, V116, P237, DOI 10.1006/jsbi.1996.0036; Marco S, 1996, ULTRAMICROSCOPY, V66, P5, DOI 10.1016/S0304-3991(96)00083-6; Mindell JA, 2001, NATURE, V409, P219, DOI 10.1038/35051631; Murakami S, 2002, NATURE, V419, P587, DOI 10.1038/nature01050; RADERMACHER M, 1987, J MICROSC-OXFORD, V146, P113, DOI 10.1111/j.1365-2818.1987.tb01333.x; Radermacher M, 2001, J STRUCT BIOL, V135, P26, DOI 10.1006/jsbi.2001.4395; RADERMACHER M, 1997, SCANNING MICROSCOPY, V11, P171; SCHAGGER H, 1991, ANAL BIOCHEM, V199, P223, DOI 10.1016/0003-2697(91)90094-A; Standfuss J, 2004, J BIOL CHEM, V279, P36884, DOI 10.1074/jbc.M402348200; Valiyaveetil FI, 2002, BIOCHEMISTRY-US, V41, P10771, DOI 10.1021/bi026215y; VALPUESTA JM, 1994, J MOL BIOL, V240, P281, DOI 10.1006/jmbi.1994.1445; Veenhoff LM, 2002, TRENDS BIOCHEM SCI, V27, P242, DOI 10.1016/S0968-0004(02)02077-7; Veenhoff LM, 2001, EMBO J, V20, P3056, DOI 10.1093/emboj/20.12.3056; Vinothkumar KR, 2005, EMBO J, V24, P2720, DOI 10.1038/sj.emboj.7600727; WANG DN, 1993, EMBO J, V12, P2233, DOI 10.1002/j.1460-2075.1993.tb05876.x; Williams KA, 1999, EMBO J, V18, P3558, DOI 10.1093/emboj/18.13.3558; Yernool D, 2004, NATURE, V431, P811, DOI 10.1038/nature03018; Ziegler C, 2004, J MOL BIOL, V337, P1137, DOI 10.1016/j.jmb.2004.02.026	32	30	30	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 24	2006	281	8					4795	4801		10.1074/jbc.M508993200	http://dx.doi.org/10.1074/jbc.M508993200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	013RF	16365043	hybrid			2022-12-25	WOS:000235426200030
J	Wu, J; Woodard, RW				Wu, J; Woodard, RW			New insights into the evolutionary links relating to the 3-deoxy-D-arabino-heptulosonate 7-phosphate synthase subfamilies	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							3-DEOXY-D-MANNO-OCTULOSONATE 8-PHOSPHATE SYNTHASE; MONOFUNCTIONAL CHORISMATE MUTASE; SITE-DIRECTED MUTAGENESIS; ESCHERICHIA-COLI; SHIKIMATE METABOLITES; BACILLUS-SUBTILIS; NEISSERIA-GONORRHOEAE; ALLOSTERIC REGULATION; CRYSTAL-STRUCTURE; BIOSYNTHESIS	Bacterial 3-deoxy-d-arabino-heptulosonate 7-phosphate synthases (DAHPSs) have been divided into either of two classes ( Class I/Class II) or subfamilies (AroAI(alpha)/AroAI(alpha)). Our investigation into the biochemical properties of the unique bifunctional DAHPS from Bacillus subtilis provides new insight into the evolutionary link among DAHPS subfamilies. In the present study, the DAHPS( aroA) and chorismate mutase (aroQ) activities of B. subtilis DAHPS are separated by domain truncation. Detailed enzymatic studies with the full-length wild-type protein and the truncated domains led to our hypothesis that the aroQ domain was fused to the N terminus of aroA in B. subtilis during evolution for the purpose of feedback regulation and not for the creation of a bona fide bifunctional enzyme. In addition, examination of aroA and aroQ fusion proteins from Porphyromonas gingivalis, in which the aroQ domain is fused to the C terminus of aroA, further supports the hypothesis. These results, along with sequence structure analysis of the DAHPS families suggest that "feedback regulation" may indeed be the evolutionary link between the two classes/subfamilies. It is likely that DAHPSs evolved from a primitive unregulated member of the AroAI(beta) subfamily. During evolution, some members of the AroAI(beta) subfamily remained unregulated, whereas other members acquired an extra domain for feedback regulation. The AroAI(alpha) subfamilies, however, evolved in a more complex manner to acquire insertions/ extensions in the (beta/alpha)(8) barrel to function as regulatory elements.	Univ Michigan, Coll Pharm, Dept Med Chem, Ann Arbor, MI 48109 USA; Univ Michigan, Dept Chem, Ann Arbor, MI 48109 USA	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan	Woodard, RW (corresponding author), Univ Michigan, Coll Pharm, Dept Med Chem, 428 Church St, Ann Arbor, MI 48109 USA.	rww@umich.edu		Woodard, Ronald/0000-0002-7472-3653	NIGMS NIH HHS [GM 53069] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM053069] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BAASOV T, 1989, J BACTERIOL, V171, P6155, DOI 10.1128/jb.171.11.6155-6160.1989; Birck MR, 2001, J MOL EVOL, V52, P205, DOI 10.1007/s002390010149; DEWICK PM, 1995, NAT PROD REP, V12, P579, DOI 10.1039/np9951200579; GORISCH H, 1971, BIOCHIM BIOPHYS ACTA, V242, P617, DOI 10.1016/0005-2744(71)90154-9; Gosset G, 2001, J BACTERIOL, V183, P4061, DOI 10.1128/JB.183.13.4061-4070.2001; GRAY JV, 1990, BIOCHEMISTRY-US, V29, P376, DOI 10.1021/bi00454a011; Hartmann M, 2003, P NATL ACAD SCI USA, V100, P862, DOI 10.1073/pnas.0337566100; Haslam E., 1993, SHIKIMIC ACID METABO; IP KM, 1979, EUR J BIOCHEM, V98, P431, DOI 10.1111/j.1432-1033.1979.tb13203.x; JENSEN RA, 1966, J BIOL CHEM, V241, P3373; Jensen RA, 2002, J MOL EVOL, V54, P416, DOI 10.1007/s00239-001-0031-z; Knaggs AR, 2003, NAT PROD REP, V20, P119, DOI 10.1039/b100399m; Knaggs AR, 2001, NAT PROD REP, V18, P334, DOI 10.1039/b001717p; RAETZ CRH, 1990, ANNU REV BIOCHEM, V59, P129, DOI 10.1146/annurev.bi.59.070190.001021; Sambrook J., 1989, MOL CLONING LAB MANU, V2; Schofield LR, 2004, PROTEIN EXPRES PURIF, V34, P17, DOI 10.1016/j.pep.2003.11.008; Sheflyan GY, 1999, BIOCHEMISTRY-US, V38, P14320, DOI 10.1021/bi9829884; Shumilin IA, 2004, J MOL BIOL, V341, P455, DOI 10.1016/j.jmb.2004.05.077; Shumilin IA, 1999, STRUCTURE, V7, P865, DOI 10.1016/S0969-2126(99)80109-9; Shumilin IA, 2002, J MOL BIOL, V320, P1147, DOI 10.1016/S0022-2836(02)00545-4; STEPHENS CM, 1991, J BIOL CHEM, V266, P20810; Subramaniam PS, 1998, J BACTERIOL, V180, P119, DOI 10.1128/JB.180.1.119-127.1998; Sundaram AK, 2001, ORG LETT, V3, P21, DOI 10.1021/ol0066126; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; Vrana KE, 1999, NAT STRUCT BIOL, V6, P401, DOI 10.1038/8192; Wagner T, 2000, J MOL BIOL, V301, P389, DOI 10.1006/jmbi.2000.3957; Wu J, 2005, BIOCHEM J, V390, P583, DOI 10.1042/BJ20050294; Wu J, 2003, J BIOL CHEM, V278, P27525, DOI 10.1074/jbc.M304631200; Zhang S, 1996, BIOORGAN MED CHEM, V4, P1015, DOI 10.1016/0968-0896(96)00099-5; Zhang S, 2003, BIOORGAN MED CHEM, V11, P3109, DOI 10.1016/S0968-0896(03)00242-6	30	33	54	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 17	2006	281	7					4042	4048		10.1074/jbc.M512223200	http://dx.doi.org/10.1074/jbc.M512223200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	011NN	16339761	hybrid			2022-12-25	WOS:000235275300033
J	Hanson, SM; Gurevich, VV				Hanson, SM; Gurevich, VV			The differential engagement of arrestin surface charges by the various functional forms of the receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VISUAL ARRESTIN; CRYSTAL-STRUCTURE; BETA-ARRESTIN; PHOSPHORYLATION-RECOGNITION; BINDING; RHODOPSIN; MUTAGENESIS; MECHANISM; SELECTIVITY; TRANSITION	G- protein- coupled receptor signaling is terminated by arrestin proteins that preferentially bind to the activated phosphorylated form of the receptor. Arrestins also bind active unphosphorylated and inactive phosphorylated receptors. Binding to the non- preferred forms of the receptor is important for visual arrestin translocation in rod photoreceptors and the regulation of receptor signaling and trafficking by non- visual arrestins. Given the importance of arrestin interactions with the various functional forms of the receptor, we performed an extensive analysis of the receptor- binding surface of arrestin using site- directed mutagenesis. The data indicated that a large number of surface charges are important for arrestin interaction with all forms of the receptor. Arrestin elements involved in receptor binding are differentially engaged by the various functional forms of the receptor, each requiring a unique subset of arrestin residues in a specific spatial configuration. We identified several additional phosphate- binding elements in the N- domain and demonstrated for the first time that the active receptor preferentially engages the arrestin C- domain. We also found that the interdomain contact surface is important for arrestin interaction with the non- preferred forms of the receptor and that residues in this region play a role in arrestin transition into its high affinity receptor binding state.	Vanderbilt Univ, Dept Pharmacol, Nashville, TN 37232 USA	Vanderbilt University	Gurevich, VV (corresponding author), Vanderbilt Univ, Dept Pharmacol, 2200 Pierce Ave,PRB 418, Nashville, TN 37232 USA.	vsevolod.gurevich@vanderbilt.edu	Gurevich, Vsevolod/A-3236-2008	Gurevich, Vsevolod/0000-0002-3950-5351	NATIONAL EYE INSTITUTE [R01EY011500] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM063097, T32GM007628] Funding Source: NIH RePORTER; NEI NIH HHS [EY11500, R01 EY011500-10, R01 EY011500] Funding Source: Medline; NIGMS NIH HHS [GM07628, GM63097, R01 GM063097] Funding Source: Medline	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Celver J, 2002, J BIOL CHEM, V277, P9043, DOI 10.1074/jbc.M107400200; Dinculescu A, 2002, J BIOL CHEM, V277, P11703, DOI 10.1074/jbc.M111833200; Dinh DT, 2005, MOL PHARMACOL, V67, P375, DOI 10.1124/mol.104.004721; Ferguson SSG, 1996, SCIENCE, V271, P363, DOI 10.1126/science.271.5247.363; GrayKeller MP, 1997, BIOCHEMISTRY-US, V36, P7058, DOI 10.1021/bi963110k; GUREVICH VV, 1992, J BIOL CHEM, V267, P21919; GUREVICH VV, 1993, J BIOL CHEM, V268, P11628; Gurevich VV, 2000, METHOD ENZYMOL, V315, P422; Gurevich VV, 2003, STRUCTURE, V11, P1037, DOI 10.1016/S0969-2126(03)00184-9; Gurevich VV, 2004, TRENDS PHARMACOL SCI, V25, P105, DOI 10.1016/j.tips.2003.12.008; Gurevich VV, 1996, METHOD ENZYMOL, V275, P382; GUREVICH VV, 1995, J BIOL CHEM, V270, P720, DOI 10.1074/jbc.270.2.720; Gurevich VV, 1997, MOL PHARMACOL, V51, P161, DOI 10.1124/mol.51.1.161; Gurevich VV, 1998, J BIOL CHEM, V273, P15501, DOI 10.1074/jbc.273.25.15501; GUREVICH VV, 1995, J BIOL CHEM, V270, P6010, DOI 10.1074/jbc.270.11.6010; GUREVICH VV, 2005, IN PRESS PHARM THER; HAMM HE, 1986, BIOCHEMISTRY-US, V25, P4512, DOI 10.1021/bi00364a010; Han M, 2001, STRUCTURE, V9, P869, DOI 10.1016/S0969-2126(01)00644-X; Hirsch JA, 1999, CELL, V97, P257, DOI 10.1016/S0092-8674(00)80735-7; KIESELBACH T, 1994, EUR J BIOCHEM, V226, P87, DOI 10.1111/j.1432-1033.1994.tb20029.x; Nair KS, 2005, NEURON, V46, P555, DOI 10.1016/j.neuron.2005.03.023; OHGURO H, 1994, PROTEIN SCI, V3, P2428, DOI 10.1002/pro.5560031226; PALCZEWSKI K, 1991, J BIOL CHEM, V266, P18649; Pan L, 2003, J BIOL CHEM, V278, P11623, DOI 10.1074/jbc.M209532200; Perry SJ, 2002, TRENDS CELL BIOL, V12, P130, DOI 10.1016/S0962-8924(01)02239-5; Pulvermuller A, 2000, J BIOL CHEM, V275, P37679, DOI 10.1074/jbc.M006776200; SCHLEICHER A, 1989, BIOCHEMISTRY-US, V28, P1770, DOI 10.1021/bi00430a052; Sutton RB, 2005, J MOL BIOL, V354, P1069, DOI 10.1016/j.jmb.2005.10.023; Vishnivetskiy SA, 2004, J BIOL CHEM, V279, P1262, DOI 10.1074/jbc.M308834200; Vishnivetskiy SA, 2002, J BIOL CHEM, V277, P43961, DOI 10.1074/jbc.M206951200; Vishnivetskiy SA, 2000, J BIOL CHEM, V275, P41049, DOI 10.1074/jbc.M007159200; Vishnivetskiy SK, 1999, J BIOL CHEM, V274, P11451, DOI 10.1074/jbc.274.17.11451	32	73	75	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 10	2006	281	6					3458	3462		10.1074/jbc.M512148200	http://dx.doi.org/10.1074/jbc.M512148200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	009QV	16339758	hybrid, Green Accepted			2022-12-25	WOS:000235128200055
J	Tanaka, T; Masai, H				Tanaka, T; Masai, H			Stabilization of a stalled replication fork by concerted actions of two helicases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; DNA-REPLICATION; PROTEIN PRIA; HOMOLOGOUS RECOMBINATION; HOLLIDAY JUNCTIONS; NASCENT DNA; RECG; PRIMOSOME; BINDING; SEQUENCE	PriA helicase plays crucial roles in restoration of arrested replication forks. It carries a " 3 terminus binding pocket" in its N- terminal DNA binding domain, which is required for high affinity binding of PriA to a fork carrying a 3 - end of a nascent leading strand at the branch. We show that the abrogation of the 3 ' terminus recognition either by a mutation in the 3 ' terminus binding pocket or by the bulky modification of the 3 '- end leads to unwinding of the unreplicated duplex arm on this fork, causing potential fork destabilization. This indicates a critical role of the 3 ' terminus binding pocket of PriA in its " stable" binding at the fork for primosome assembly. In contrast, PriA unwinds the unreplicated duplex region on a fork without a 3 '- end, potentially destabilizing the fork. However, this process is inhibited by RecG helicase, capable of regressing the fork until the 3 '- end of the nascent leading strand reaches the branch. PriA now stably binds to this regressed fork, stabilizing it. Using a model arrest- fork- substrate, we reconstitute the above process in vitro with RecG and PriA proteins. Our results present a novel mechanism by which two helicases function in a highly coordinated manner to generate a structure in which an arrested fork is stabilized for further repair and/ or replication restart.	Tokyo Metropolitan Inst Med Sci, Genome Dynam Project, Tokyo 1138613, Japan	Tokyo Metropolitan Institute of Medical Science	Masai, H (corresponding author), Tokyo Metropolitan Inst Med Sci, Genome Dynam Project, Tokyo 1138613, Japan.	hmasai@rinshoken.or.jp						AlDeib AA, 1996, J BACTERIOL, V178, P6782, DOI 10.1128/jb.178.23.6782-6789.1996; ARAI K, 1981, P NATL ACAD SCI-BIOL, V78, P69, DOI 10.1073/pnas.78.1.69; Bennett RJ, 1999, J MOL BIOL, V289, P235, DOI 10.1006/jmbi.1999.2739; Boddy MN, 2001, CURR BIOL, V11, pR953, DOI 10.1016/S0960-9822(01)00572-3; Brosh RM, 2002, J BIOL CHEM, V277, P23236, DOI 10.1074/jbc.M111446200; CARR AM, 1995, TRENDS CELL BIOL, V5, P32, DOI 10.1016/S0962-8924(00)88934-5; Chen HW, 2004, J BIOL CHEM, V279, P38503, DOI 10.1074/jbc.M404769200; Constantinou A, 2000, EMBO REP, V1, P80, DOI 10.1093/embo-reports/kvd004; Cox MM, 2000, NATURE, V404, P37, DOI 10.1038/35003501; Cox MM, 2001, P NATL ACAD SCI USA, V98, P8173, DOI 10.1073/pnas.131004998; Doe CL, 2002, J BIOL CHEM, V277, P32753, DOI 10.1074/jbc.M202120200; Fukuoh A, 1997, EMBO J, V16, P203, DOI 10.1093/emboj/16.1.203; Gregg AV, 2002, MOL CELL, V9, P241, DOI 10.1016/S1097-2765(02)00455-0; Hishida T, 2004, GENE DEV, V18, P1886, DOI 10.1101/gad.1223804; Jones JM, 2001, J MOL BIOL, V312, P935, DOI 10.1006/jmbi.2001.4930; Jones JM, 1997, EMBO J, V16, P6886, DOI 10.1093/emboj/16.22.6886; Jones JM, 1999, J MOL BIOL, V289, P503, DOI 10.1006/jmbi.1999.2783; Karow JK, 2000, P NATL ACAD SCI USA, V97, P6504, DOI 10.1073/pnas.100448097; Katou Y, 2003, NATURE, V424, P1078, DOI 10.1038/nature01900; Kogoma T, 1997, MICROBIOL MOL BIOL R, V61, P212, DOI 10.1128/.61.2.212-238.1997; KOWALCZYKOWSKI SC, 1994, MICROBIOL REV, V58, P401, DOI 10.1128/MMBR.58.3.401-465.1994; Kuzminov A, 2001, P NATL ACAD SCI USA, V98, P8461, DOI 10.1073/pnas.151260698; LASKEN RS, 1988, J BIOL CHEM, V263, P5512; LEE MS, 1987, P NATL ACAD SCI USA, V84, P8345, DOI 10.1073/pnas.84.23.8345; Liu J, 1999, J BIOL CHEM, V274, P25033, DOI 10.1074/jbc.274.35.25033; Liu JI, 1999, P NATL ACAD SCI USA, V96, P3552, DOI 10.1073/pnas.96.7.3552; LLOYD RG, 1991, J BACTERIOL, V173, P6837, DOI 10.1128/jb.173.21.6837-6843.1991; Lopes M, 2001, NATURE, V412, P557, DOI 10.1038/35087613; Marians KJ, 2000, CURR OPIN GENET DEV, V10, P151, DOI 10.1016/S0959-437X(00)00059-9; Marians KJ, 2000, PROG NUCLEIC ACID RE, V63, P39; MASAI H, 1994, EMBO J, V13, P5338, DOI 10.1002/j.1460-2075.1994.tb06868.x; Masai H, 1999, BIOCHIMIE, V81, P847, DOI 10.1016/S0300-9084(99)00211-4; McGlynn P, 1997, J MOL BIOL, V270, P212, DOI 10.1006/jmbi.1997.1120; McGlynn P, 2000, CELL, V101, P35, DOI 10.1016/S0092-8674(00)80621-2; McGlynn P, 2002, TRENDS GENET, V18, P413, DOI 10.1016/S0168-9525(02)02720-8; McGlynn P, 2001, P NATL ACAD SCI USA, V98, P8227, DOI 10.1073/pnas.111008698; McGlynn P, 2001, P NATL ACAD SCI USA, V98, P8235, DOI 10.1073/pnas.121007798; Michel B, 2004, P NATL ACAD SCI USA, V101, P12783, DOI 10.1073/pnas.0401586101; Michel B, 2001, P NATL ACAD SCI USA, V98, P8181, DOI 10.1073/pnas.111008798; Mizukoshi T, 2003, J BIOL CHEM, V278, P42234, DOI 10.1074/jbc.C300285200; Noguchi E, 2004, MOL CELL BIOL, V24, P8342, DOI 10.1128/MCB.24.19.8342-8355.2004; Noguchi E, 2003, MOL CELL BIOL, V23, P7861, DOI 10.1128/MCB.23.21.7861-7874.2003; Nurse P, 1999, J BIOL CHEM, V274, P25026, DOI 10.1074/jbc.274.35.25026; O'Connell MJ, 2000, TRENDS CELL BIOL, V10, P296, DOI 10.1016/S0962-8924(00)01773-6; OUZOUNIS CA, 1991, NUCLEIC ACIDS RES, V19, P6953, DOI 10.1093/nar/19.24.6953; Sandler SJ, 1996, GENETICS, V143, P5; Sharples GJ, 1999, J BACTERIOL, V181, P5543, DOI 10.1128/JB.181.18.5543-5550.1999; SHLOMAI J, 1980, J BIOL CHEM, V255, P6789; SHLOMAI J, 1980, J BIOL CHEM, V255, P6794; Singleton MR, 2001, CELL, V107, P79, DOI 10.1016/S0092-8674(01)00501-3; Sogo JM, 2002, SCIENCE, V297, P599, DOI 10.1126/science.1074023; Sonoda E, 1998, EMBO J, V17, P598, DOI 10.1093/emboj/17.2.598; Tanaka T, 2002, J BIOL CHEM, V277, P38062, DOI 10.1074/jbc.M204397200; Weinert T, 1998, CURR OPIN GENET DEV, V8, P185, DOI 10.1016/S0959-437X(98)80140-8; ZAVITZ KH, 1992, J BIOL CHEM, V267, P6933	55	42	42	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 10	2006	281	6					3484	3493		10.1074/jbc.M510979200	http://dx.doi.org/10.1074/jbc.M510979200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	009QV	16354656	hybrid			2022-12-25	WOS:000235128200058
J	Tsakadze, NL; Sithu, SD; Sen, U; English, WR; Murphy, G; D'Souza, SE				Tsakadze, NL; Sithu, SD; Sen, U; English, WR; Murphy, G; D'Souza, SE			Tumor necrosis factor-alpha-converting enzyme (TACE/ADAM-17) mediates the ectodomain cleavage of intercellular adhesion molecule-1 (ICAM-1)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMYLOID PRECURSOR PROTEIN; MEMBRANE-PROXIMAL CLEAVAGE; TISSUE INHIBITOR; L-SELECTIN; PROTEOLYTIC RELEASE; SECRETASE CLEAVAGE; CELL-ADHESION; DOMAIN; METALLOPROTEINASE; DISINTEGRIN	Ectodomain shedding has emerged as an important regulatory step in the function of transmembrane proteins. Intercellular adhesion molecule-1 ( ICAM-1), an adhesion receptor that mediates inflammatory and immune responses, undergoes shedding in the presence of inflammatory mediators and phorbol 12-myristate 13-acetate ( PMA). The shedding of ICAM-1 in ICAM-1- transfected 293 cells upon PMA stimulation and in endothelial cells upon tumor necrosis factor-alpha stimulation was blocked by metalloproteinase inhibitors, whereas serine protease inhibitors were ineffective. p-Aminophenylmercuric acetate, a mercuric compound that is known to activate matrix metalloproteinases, up-regulated ICAM-1 shedding. TIMP-3 ( but not TIMP-1 or -2) effectively blocked cleavage. This profile suggests the involvement of the ADAM family of proteases in the cleavage of ICAM-1. The introduction of enzymatically active tumor necrosis factor-alpha-converting enzyme ( TACE) into ICAM-1- expressing cells up-regulated cleavage. Small interfering RNA directed against TACE blocked ICAM-1 cleavage. ICAM-1 transfected into TACE(-/-) fibroblasts did not show increased shedding over constitutive levels in the presence of PMA, whereas cleavage did occur in ICAM-1-transfected TACE(-/-) cells. These results indicate that ICAM-1shedding is mediated by TACE. Blocking the shedding of ICAM-1 altered the cell adhesive function, as ICAM-1- mediated cell adhesion was up-regulated in the presence of TACE small interfering RNA and TIMP-3, but not TIMP-1. However, cleavage was found to occur at multiple sites within the stalk domain of ICAM-1, and numerous point mutations within the region did not affect cleavage, indicating that TACE-mediated cleavage of ICAM-1 may not be sequence-specific.	Univ Louisville, Dept Physiol & Biophys, Hlth Sci Ctr, Louisville, KY 40292 USA; Cambridge Inst Med Res, Dept Oncol, Cambridge CB2 2XY, England; Cambridge Inst Med Res, Addenbrookes Hosp, Cambridge CB2 2XY, England	University of Louisville; University of Cambridge; Cambridge University Hospitals NHS Foundation Trust; Addenbrooke's Hospital; University of Cambridge	D'Souza, SE (corresponding author), Univ Louisville, Dept Physiol & Biophys, Hlth Sci Ctr, A-1115,500 S Preston St, Louisville, KY 40292 USA.	sedsou01@gwise.louisville.edu			NHLBI NIH HHS [HL43721] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R29HL043721, R01HL043721] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Amour A, 1998, FEBS LETT, V435, P39, DOI 10.1016/S0014-5793(98)01031-X; APTE SS, 1995, J BIOL CHEM, V270, P14313, DOI 10.1074/jbc.270.24.14313; Arribas J, 1997, J BIOL CHEM, V272, P17160, DOI 10.1074/jbc.272.27.17160; Arribas J, 2002, CHEM REV, V102, P4627, DOI 10.1021/cr010202t; Arribas J, 1996, J BIOL CHEM, V271, P11376, DOI 10.1074/jbc.271.19.11376; BELDENT V, 1993, J BIOL CHEM, V268, P26428; Black RA, 1997, NATURE, V385, P729, DOI 10.1038/385729a0; Black RA, 2003, BIOCHEM SOC SYMP, V70, P39, DOI 10.1042/bss0700039; Black RA, 1998, CURR OPIN CELL BIOL, V10, P654, DOI 10.1016/S0955-0674(98)80042-2; Bond M, 2000, J BIOL CHEM, V275, P41358, DOI 10.1074/jbc.M007929200; Buxbaum JD, 1998, J BIOL CHEM, V273, P27765, DOI 10.1074/jbc.273.43.27765; CARLOS TM, 1994, BLOOD, V84, P2068; Champagne B, 1998, J IMMUNOL, V161, P6398; CHENG HJ, 1994, MOL BIOL CELL, V5, P943, DOI 10.1091/mbc.5.9.943; Eyries M, 2001, J BIOL CHEM, V276, P5525, DOI 10.1074/jbc.M007706200; Fiore E, 2002, ONCOGENE, V21, P5213, DOI 10.1038/sj.onc.1205684; Gardiner EE, 1997, J BIOL CHEM, V272, P15474, DOI 10.1074/jbc.272.24.15474; Garton KJ, 2003, J BIOL CHEM, V278, P37459, DOI 10.1074/jbc.M305877200; Haro H, 2000, J CLIN INVEST, V105, P143, DOI 10.1172/JCI7091; Hinkle CL, 2004, J BIOL CHEM, V279, P24179, DOI 10.1074/jbc.M312141200; Hooper NM, 1997, BIOCHEM J, V321, P265, DOI 10.1042/bj3210265; Izumi Y, 1998, EMBO J, V17, P7260, DOI 10.1093/emboj/17.24.7260; Jolly-Tornetta C, 2000, BIOCHEMISTRY-US, V39, P15282, DOI 10.1021/bi001723y; KAHN J, 1994, J CELL BIOL, V125, P461, DOI 10.1083/jcb.125.2.461; Labarrere CA, 2000, CIRCULATION, V102, P1549, DOI 10.1161/01.CIR.102.13.1549; Lammich S, 1999, P NATL ACAD SCI USA, V96, P3922, DOI 10.1073/pnas.96.7.3922; Lunn CA, 1997, FEBS LETT, V400, P333, DOI 10.1016/S0014-5793(96)01410-X; Maskos K, 1998, P NATL ACAD SCI USA, V95, P3408, DOI 10.1073/pnas.95.7.3408; Melis M, 2003, AM J RESP CRIT CARE, V167, P1131, DOI 10.1164/rccm.200207-654OC; Merlos-Suarez A, 2001, J BIOL CHEM, V276, P48510, DOI 10.1074/jbc.M103488200; MIGAKI GI, 1995, J EXP MED, V182, P549, DOI 10.1084/jem.182.2.549; Mohan MJ, 2002, BIOCHEMISTRY-US, V41, P9462, DOI 10.1021/bi0260132; MURPHY G, 1995, METHOD ENZYMOL, V248, P496; Nath D, 2000, J CELL SCI, V113, P2319; Nath D, 2001, J CELL SCI, V114, P1213; Okamoto I, 2001, J CELL BIOL, V155, P755, DOI 10.1083/jcb.200108159; Otto VI, 2002, J NEUROCHEM, V80, P824, DOI 10.1046/j.0022-3042.2001.00748.x; Peschon JJ, 1998, SCIENCE, V282, P1281, DOI 10.1126/science.282.5392.1281; Pluskota E, 2000, J BIOL CHEM, V275, P30029, DOI 10.1074/jbc.M000240200; Ridker PM, 1998, LANCET, V351, P88, DOI 10.1016/S0140-6736(97)09032-6; RIECKMANN P, 1995, J NEUROIMMUNOL, V60, P9, DOI 10.1016/0165-5728(95)00047-6; Robledo O, 2003, EUR J IMMUNOL, V33, P1351, DOI 10.1002/eji.200323195; ROTHLEIN R, 1991, J IMMUNOL, V147, P3788; Sadhukhan R, 1999, J BIOL CHEM, V274, P10511, DOI 10.1074/jbc.274.15.10511; SBARBA PD, 2002, BIOL CHEM, V383, P69; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; Schlondorff J, 1999, J CELL SCI, V112, P3603; Sibilia M, 1998, EMBO J, V17, P719, DOI 10.1093/emboj/17.3.719; SPRINGER TA, 1990, NATURE, V346, P425, DOI 10.1038/346425a0; TSAKADZE ML, 2004, AM J PHYSIOL, V287, pC55; vandeStolpe A, 1996, J MOL MED, V74, P13, DOI 10.1007/BF00202069; Werb Z, 1998, SCIENCE, V282, P1279, DOI 10.1126/science.282.5392.1279; WILLENBROCK F, 1993, BIOCHEMISTRY-US, V32, P4330, DOI 10.1021/bi00067a023; Woodman ZL, 2000, BIOCHEM J, V347, P711, DOI 10.1042/0264-6021:3470711; Yeow KM, 2002, MATRIX BIOL, V21, P75, DOI 10.1016/S0945-053X(01)00180-9; Zhao LC, 2001, J BIOL CHEM, V276, P30631, DOI 10.1074/jbc.M103748200; Zheng YF, 2004, J BIOL CHEM, V279, P42898, DOI 10.1074/jbc.M403193200	57	130	134	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 10	2006	281	6					3157	3164		10.1074/jbc.M510797200	http://dx.doi.org/10.1074/jbc.M510797200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	009QV	16332693	hybrid			2022-12-25	WOS:000235128200018
J	Dai, PG; Xiong, WC; Mei, L				Dai, PG; Xiong, WC; Mei, L			Erbin inhibits RAF activation by disrupting the Sur-8-Ras-Raf complex	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MAP KINASE ACTIVATION; BASOLATERAL PDZ PROTEIN; ACETYLCHOLINE-RECEPTOR; EPITHELIAL-CELLS; BINDING DOMAIN; EXPRESSION; LOCALIZATION; NEUREGULINS; SPECIFICITY; INTERACTS	Erbin is amember of the LAP (leucine-rich repeat (LRR) and PDZ domain) family. It inhibits Ras-mediated activation of ERK in response to growth factors. In this study, we investigated the mechanisms by which Erbin regulates the Ras-Raf-MEK pathway. The N-terminal LRR domain was necessary and sufficient to inhibit neuregulin-activated expression of epsilon 416-Luc, a reporter of ERK activation. On the other hand, Erbin had no effect on Ras activation, but it attenuated neuregulin-induced Raf activation, suggesting that Erbin may regulate Raf activation by Ras. Via the LRR domain, Erbin interacts with Sur-8, a scaffold protein necessary for the Ras-Raf complex. Expression of Erbin attenuated the interaction of Sur-8 with active Ras and Raf. Moreover, Erbin-shRNA, which suppressed Erbin expression at mRNA and protein levels, increased the interaction of Sur-8 with Ras and Raf, ERK activation, and neuregulin-induced expression of endogenous acetylcholine receptor epsilon-subunit mRNA. These results demonstrate a regulatory role of Erbin in the Ras-Raf-MEK pathway, suggesting that Erbin may inhibit ERK activation by disrupting the Sur-8-Ras/Raf interaction.	Med Coll Georgia, Inst Mol Med & Genet, Program Dev Neurobiol, Augusta, GA 30912 USA	University System of Georgia; Augusta University	Mei, L (corresponding author), Med Coll Georgia, Inst Mol Med & Genet, Program Dev Neurobiol, CB2803,1120 15th St, Augusta, GA 30912 USA.	lmei@mcg.edu	Mei, Lin/G-8755-2012					Apperson ML, 1996, J NEUROSCI, V16, P6839; Bilder D, 2000, NATURE, V403, P676, DOI 10.1038/35001108; Borg JP, 2000, NAT CELL BIOL, V2, P407, DOI 10.1038/35017038; deRooij J, 1997, ONCOGENE, V14, P623, DOI 10.1038/sj.onc.1201005; Dillin A, 2003, P NATL ACAD SCI USA, V100, P6289, DOI 10.1073/pnas.1232238100; Dillon C, 2002, MOL CELL BIOL, V22, P6553, DOI 10.1128/MCB.22.18.6553-6563.2002; Falls DL, 2003, EXP CELL RES, V284, P14, DOI 10.1016/S0014-4827(02)00102-7; Favre B, 2001, J BIOL CHEM, V276, P32427, DOI 10.1074/jbc.M011005200; Fischbach GD, 1997, ANNU REV NEUROSCI, V20, P429, DOI 10.1146/annurev.neuro.20.1.429; FORSAYETH JR, 1994, BIOTECHNIQUES, V17, P354; HERRMANN C, 1995, J BIOL CHEM, V270, P2901, DOI 10.1074/jbc.270.7.2901; Huang YZ, 2003, J BIOL CHEM, V278, P1108, DOI 10.1074/jbc.M205413200; Huang YZ, 2001, J BIOL CHEM, V276, P19318, DOI 10.1074/jbc.M100494200; Izawa I, 2002, GENES CELLS, V7, P475, DOI 10.1046/j.1365-2443.2002.00533.x; Jaulin-Bastard F, 2002, J BIOL CHEM, V277, P2869, DOI 10.1074/jbc.M109652200; Katz ME, 1997, CURR OPIN GENET DEV, V7, P75, DOI 10.1016/S0959-437X(97)80112-8; Kennedy MB, 1997, TRENDS NEUROSCI, V20, P264, DOI 10.1016/S0166-2236(96)01033-8; Kerkhoff E, 1998, ONCOGENE, V16, P211, DOI 10.1038/sj.onc.1201520; Kirschbaum MH, 2000, J CELL BIOCHEM, P52; KOLCH W, 2003, SCI STKE, pPE37; Laura RP, 2002, J BIOL CHEM, V277, P12906, DOI 10.1074/jbc.M200818200; Legouis R, 2000, NAT CELL BIOL, V2, P415, DOI 10.1038/35017046; Legouis R, 2003, EMBO REP, V4, P1096, DOI 10.1038/sj.embor.7400006; Lemke G, 1996, MOL CELL NEUROSCI, V7, P247, DOI 10.1006/mcne.1996.0019; Li WQ, 2000, GENE DEV, V14, P895; Luo ZJ, 1996, NATURE, V383, P181, DOI 10.1038/383181a0; Navarro C, 2005, ONCOGENE, V24, P4330, DOI 10.1038/sj.onc.1208632; Novina CD, 2004, NATURE, V430, P161, DOI 10.1038/430161a; Ohno H, 2002, ONCOGENE, V21, P7042, DOI 10.1038/sj.onc.1205852; Pawson T, 1997, SCIENCE, V278, P2075, DOI 10.1126/science.278.5346.2075; Rangwala R, 2005, J BIOL CHEM, V280, P11790, DOI 10.1074/jbc.M414154200; Robinson MJ, 1997, CURR OPIN CELL BIOL, V9, P180, DOI 10.1016/S0955-0674(97)80061-0; Saito H, 2001, J BIOL CHEM, V276, P32051, DOI 10.1074/jbc.C100330200; Schaeffer L, 2001, NEURON, V31, P15, DOI 10.1016/S0896-6273(01)00353-1; Scherer LJ, 2003, NAT BIOTECHNOL, V21, P1457, DOI 10.1038/nbt915; Si JT, 1996, J BIOL CHEM, V271, P19752, DOI 10.1074/jbc.271.33.19752; Si JT, 1999, MOL BRAIN RES, V67, P18, DOI 10.1016/S0169-328X(99)00028-5; Tanowitz M, 1999, J NEUROSCI, V19, P9426; Wang ZZ, 1999, J NEUROSCI, V19, P1998; Warner DR, 2003, BIOCHEM BIOPH RES CO, V312, P1185, DOI 10.1016/j.bbrc.2003.11.049	40	77	85	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 13	2006	281	2					927	933		10.1074/jbc.M507360200	http://dx.doi.org/10.1074/jbc.M507360200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	000FV	16301319	hybrid			2022-12-25	WOS:000234447200031
J	Duensing, A; Liu, Y; Tseng, M; Malumbres, M; Barbacid, M; Duensing, S				Duensing, A.; Liu, Y.; Tseng, M.; Malumbres, M.; Barbacid, M.; Duensing, S.			Cyclin-dependent kinase 2 is dispensable for normal centrosome duplication but required for oncogene-induced centrosome overduplication	ONCOGENE			English	Article						centrosome; CDK2; HPV-16 E7; genomic instability	CELL-DIVISION; PRIMARY CILIA; CDK2; IMMORTALIZATION	Cyclin- dependent kinase 2 ( CDK2) has been proposed to function as a master regulator of centrosome duplication. Using mouse embryonic. broblasts ( MEFs) in which Cdk2 has been genetically deleted, we show here that CDK2 is not required for normal centrosome duplication, maturation and bipolar mitotic spindle formation. In contrast, Cdk2 deficiency completely abrogates aberrant centrosome duplication induced by a viral oncogene. Mechanistically, centrosome overduplication in MEFs wild- type for Cdk2 involves the formation of supernumerary immature centrosomes. These results indicate that normal and abnormal centrosome duplication have significantly different requirements for CDK2 activity and point to a role of CDK2 in licensing centrosomes for aberrant duplication. Furthermore, our findings suggest that CDK2 may be a suitable therapeutic target to inhibit centrosome- mediated chromosomal instability in tumor cells.	Univ Pittsburgh, Inst Canc, Mol Virol Program, Hillman Canc Ctr, Pittsburgh, PA 15213 USA; Univ Pittsburgh, Sch Med, Dept Pathol, Pittsburgh, PA 15213 USA; Ctr Nacl Invest Oncol, Mol Oncol Program, Madrid, Spain; Univ Pittsburgh, Sch Med, Dept Mol Genet & Biochem, Pittsburgh, PA 15261 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Duensing, S (corresponding author), Univ Pittsburgh, Inst Canc, Mol Virol Program, Hillman Canc Ctr, Res Pavil Suite 1-8,5117 Ctr Ave, Pittsburgh, PA 15213 USA.	duensing@pitt.edu	Malumbres, Marcos/E-8834-2011; Holt, Janet E/B-2415-2013	Malumbres, Marcos/0000-0002-0829-6315; Duensing, Anette/0000-0002-0168-4067	NCI NIH HHS [R01 CA112598, R01 CA112598-03, CA112598] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA112598] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALBRECHTBUEHLER G, 1980, EXP CELL RES, V126, P427, DOI 10.1016/0014-4827(80)90282-7; Aleem E, 2005, NAT CELL BIOL, V7, P831, DOI 10.1038/ncb1284; Alvarez-Salas LM, 1998, P NATL ACAD SCI USA, V95, P1189, DOI 10.1073/pnas.95.3.1189; Berthet C, 2003, CURR BIOL, V13, P1775, DOI 10.1016/j.cub.2003.09.024; Bornens M, 2002, CURR OPIN CELL BIOL, V14, P25, DOI 10.1016/S0955-0674(01)00290-3; Brinkley BR, 2001, TRENDS CELL BIOL, V11, P18, DOI 10.1016/S0962-8924(00)01872-9; Chen ZH, 2002, DEV CELL, V3, P339, DOI 10.1016/S1534-5807(02)00258-7; Delattre M, 2004, J CELL SCI, V117, P1619, DOI 10.1242/jcs.01128; Doxsey S, 2002, MOL CELL, V10, P439, DOI 10.1016/S1097-2765(02)00654-8; DUENSING A, 2004, P AM ASSOC CANC RES, V45, P2596; Duensing S, 2000, P NATL ACAD SCI USA, V97, P10002, DOI 10.1073/pnas.170093297; Duensing S, 2005, CELL BIOL INT, V29, P352, DOI 10.1016/j.cellbi.2005.03.005; Duensing S, 2004, ONCOGENE, V23, P8206, DOI 10.1038/sj.onc.1208012; Fisk HA, 2001, CELL, V106, P95, DOI 10.1016/S0092-8674(01)00411-1; Guarguaglini G, 2005, MOL BIOL CELL, V16, P1095, DOI 10.1091/mbc.E04-10-0939; Hinchcliffe EH, 2001, GENE DEV, V15, P1167, DOI 10.1101/gad.894001; Hinchcliffe EH, 1999, SCIENCE, V283, P851, DOI 10.1126/science.283.5403.851; Lacey KR, 1999, P NATL ACAD SCI USA, V96, P2817, DOI 10.1073/pnas.96.6.2817; Mason DX, 2004, ONCOGENE, V23, P9238, DOI 10.1038/sj.onc.1208172; Matsumoto Y, 1999, CURR BIOL, V9, P429, DOI 10.1016/S0960-9822(99)80191-2; Matsumoto Y, 2004, SCIENCE, V306, P885, DOI 10.1126/science.1103544; MEIJER L, 1999, PHARM THER, V82; Meraldi P, 1999, NAT CELL BIOL, V1, P88, DOI 10.1038/10054; Munger K, 2002, VIRUS RES, V89, P213, DOI 10.1016/S0168-1702(02)00190-9; Mussman JG, 2000, ONCOGENE, V19, P1635, DOI 10.1038/sj.onc.1203460; Nigg EA, 2002, NAT REV CANCER, V2, P815, DOI 10.1038/nrc924; Okuda M, 2000, CELL, V103, P127, DOI 10.1016/S0092-8674(00)00093-3; Ortega S, 2003, NAT GENET, V35, P25, DOI 10.1038/ng1232; Salisbury JL, 1999, BIOL CELL, V91, P451, DOI 10.1016/S0248-4900(99)80086-0; Tetsu O, 2003, CANCER CELL, V3, P233, DOI 10.1016/S1535-6108(03)00053-9; Wheatley DN, 1996, CELL BIOL INT, V20, P73, DOI 10.1006/cbir.1996.0011; Wong C, 2003, NAT CELL BIOL, V5, P539, DOI 10.1038/ncb993	32	86	88	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY	2006	25	20					2943	2949		10.1038/sj.onc.1209310	http://dx.doi.org/10.1038/sj.onc.1209310			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	041IN	16331279	Green Accepted			2022-12-25	WOS:000237448200013
J	Liu, YJ; Xu, Y; Yu, Q				Liu, YJ; Xu, Y; Yu, Q			Full-length ADAMTS-1 and the ADAMTS-1 fragments display pro- and antimetastatic activity, respectively	ONCOGENE			English	Article						ADAMTS-1; tumor metastasis; invasion; proteolytic cleavage; heparin-binding EGF; amphiregulin	NECROSIS-FACTOR-ALPHA; CD44-MEDIATED TUMOR INVASION; GROWTH-FACTOR RECEPTOR; BREAST-CANCER; CELL-SURFACE; METALLOPROTEINASE-DISINTEGRIN; IN-VIVO; EXTRACELLULAR-MATRIX; CONVERTING-ENZYME; TYPE-1 REPEATS	The exact role of a disintegrin and metalloproteinase with thrombospondin motifs-1 (ADAMTS-1) and the underlying mechanism of its involvement in tumor metastasis have not been established. We have now demonstrated that overexpression of ADAMTS-1 promotes pulmonary metastasis of TA3 mammary carcinoma and Lewis lung carcinoma cells and that a proteinase-dead mutant of ADAMTS-1 (ADAMTS-1E/Q) inhibits their metastasis, indicating that the prometastatic activity of ADAMTS-1 requires its metalloproteinase activity. Overexpression of ADAMTS-1 in these cells promoted tumor angiogenesis and invasion, shedding of the transmembrane precursors of heparin-binding epidermal growth factor (EGF) and amphiregulin (AR), and activation of the EGF receptor and ErbB-2, while overexpression of ADAMTS-1E/Q inhibited these events. Furthermore, we found that ADAMTS-1 undergoes auto-proteolytic cleavage to generate the NH2- and COOH-terminal cleavage fragments containing at least one thrombospondin-type-I-like motif and that overexpression of the NH2- terminal ADAMTS-1 fragment and the COOH-terminal ADAMTS-1 fragment can inhibit pulmonary tumor metastasis. These fragments also inhibited Erk1/2 kinase activation induced by soluble heparin-binding EGF and AR. Taken together, our results suggest that the proteolytic status of ADAMTS-1 determines its effect on tumor metastasis, and that the ADAMTS-1E/Q and the ADAMTS-1 fragments likely inhibit tumor metastasis by negatively regulating the availability and activity of soluble heparin-binding EGF and AR.	Univ Penn, Sch Vet Med, Dept Pathobiol, Philadelphia, PA 19104 USA	University of Pennsylvania	Yu, Q (corresponding author), Univ Penn, Sch Vet Med, Dept Pathobiol, 372E Old Vet,3800 Spruce St, Philadelphia, PA 19104 USA.	qyu@vet.upenn.edu			NCI NIH HHS [R01 CA116510, R01 CA116510-01A1] Funding Source: Medline; NHLBI NIH HHS [R01 HL074117, R01HL074117] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA116510] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL074117] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Adams JC, 2001, ANNU REV CELL DEV BI, V17, P25, DOI 10.1146/annurev.cellbio.17.1.25; Billings SD, 2003, AM J PATHOL, V163, P2451, DOI 10.1016/S0002-9440(10)63600-0; Black RA, 1997, NATURE, V385, P729, DOI 10.1038/385729a0; Blobel CP, 2000, CURR OPIN CELL BIOL, V12, P606, DOI 10.1016/S0955-0674(00)00139-3; Bostwick DG, 2004, PROSTATE, V58, P164, DOI 10.1002/pros.10322; Burgess AW, 2003, MOL CELL, V12, P541, DOI 10.1016/S1097-2765(03)00350-2; Cal S, 2002, GENE, V283, P49, DOI 10.1016/S0378-1119(01)00861-7; Colige A, 2005, J BIOL CHEM, V280, P34397, DOI 10.1074/jbc.M506458200; COOK PW, 1992, CANCER RES, V52, P3224; EBERT M, 1994, CANCER RES, V54, P3959; Flannery CR, 2002, J BIOL CHEM, V277, P42775, DOI 10.1074/jbc.M205309200; Gschwind A, 2003, EMBO J, V22, P2411, DOI 10.1093/emboj/cdg231; HAMID AS, 2000, CANCER RES, V60, P7094; Harris RC, 2003, EXP CELL RES, V284, P2, DOI 10.1016/S0014-4827(02)00105-2; Herren B, 2002, NEWS PHYSIOL SCI, V17, P73, DOI 10.1152/nips.01373.2001; Iruela-Arispe ML, 1999, CIRCULATION, V100, P1423, DOI 10.1161/01.CIR.100.13.1423; Iruela-Arispe ML, 2003, ANN NY ACAD SCI, V995, P183, DOI 10.1111/j.1749-6632.2003.tb03221.x; Iwamoto R, 2003, P NATL ACAD SCI USA, V100, P3221, DOI 10.1073/pnas.0537588100; Jackson LF, 2003, EMBO J, V22, P2704, DOI 10.1093/emboj/cdg264; Kang YB, 2003, CANCER CELL, V3, P537, DOI 10.1016/S1535-6108(03)00132-6; KITADAI Y, 1993, JPN J CANCER RES, V84, P879, DOI 10.1111/j.1349-7006.1993.tb02061.x; Kuno K, 1997, J BIOL CHEM, V272, P556, DOI 10.1074/jbc.272.1.556; Kuno K, 1998, J BIOL CHEM, V273, P13912, DOI 10.1074/jbc.273.22.13912; Kuno K, 1999, J BIOL CHEM, V274, P18821, DOI 10.1074/jbc.274.26.18821; Kuno K, 2004, BIOCHEM BIOPH RES CO, V319, P1327, DOI 10.1016/j.bbrc.2004.05.105; Kuno K, 2000, FEBS LETT, V478, P241, DOI 10.1016/S0014-5793(00)01854-8; Lee DC, 2003, ANN NY ACAD SCI, V995, P22, DOI 10.1111/j.1749-6632.2003.tb03207.x; LEJEUNE S, 1993, CANCER RES, V53, P3597; Luque A, 2003, J BIOL CHEM, V278, P23656, DOI 10.1074/jbc.M212964200; Maeshima Y, 2002, SCIENCE, V295, P140, DOI 10.1126/science.1065298; MASSAGUE J, 1993, ANNU REV BIOCHEM, V62, P515, DOI 10.1146/annurev.bi.62.070193.002503; Masui T, 2001, CLIN CANCER RES, V7, P3437; Merlos-Suarez A, 2001, J BIOL CHEM, V276, P48510, DOI 10.1074/jbc.M103488200; Miao WM, 2001, CANCER RES, V61, P7830; Minn AJ, 2005, J CLIN INVEST, V115, P44, DOI 10.1172/JCI200522320; Miyamoto S, 2004, CANCER RES, V64, P5720, DOI 10.1158/0008-5472.CAN-04-0811; Nokihara H, 2000, CANCER RES, V60, P7002; NORMANNO N, 1995, BREAST CANCER RES TR, V35, P293, DOI 10.1007/BF00665981; O'Reilly MS, 1999, SCIENCE, V285, P1926, DOI 10.1126/science.285.5435.1926; Panico L, 1996, INT J CANCER, V65, P51, DOI 10.1002/(SICI)1097-0215(19960103)65:1<51::AID-IJC9>3.0.CO;2-0; Peschon JJ, 1998, SCIENCE, V282, P1281, DOI 10.1126/science.282.5392.1281; Pfeifer A, 2000, P NATL ACAD SCI USA, V97, P12227, DOI 10.1073/pnas.220399597; Porter S, 2004, CLIN CANCER RES, V10, P2429, DOI 10.1158/1078-0432.CCR-0398-3; Porter S, 2005, BIOCHEM J, V386, P15, DOI 10.1042/BJ20040424; Rodriguez-Manzaneque JC, 2000, J BIOL CHEM, V275, P33471, DOI 10.1074/jbc.M002599200; Russell DL, 2003, J BIOL CHEM, V278, P42330, DOI 10.1074/jbc.M300519200; Sahin U, 2004, J CELL BIOL, V164, P769, DOI 10.1083/jcb.200307137; SALOMON DS, 1995, BREAST CANCER RES TR, V33, P103, DOI 10.1007/BF00682718; Sandy JD, 2001, J BIOL CHEM, V276, P13372, DOI 10.1074/jbc.M009737200; Shindo T, 2000, J CLIN INVEST, V105, P1345, DOI 10.1172/JCI8635; Stern DF, 2000, BREAST CANCER RES, V2, P176, DOI 10.1186/bcr51; Sternlicht MD, 2001, ANNU REV CELL DEV BI, V17, P463, DOI 10.1146/annurev.cellbio.17.1.463; Streit M, 2000, EMBO J, V19, P3272, DOI 10.1093/emboj/19.13.3272; Sunnarborg SW, 2002, J BIOL CHEM, V277, P12838, DOI 10.1074/jbc.M112050200; TOLSMA SS, 1993, J CELL BIOL, V122, P497, DOI 10.1083/jcb.122.2.497; Tucker RP, 2004, INT J BIOCHEM CELL B, V36, P969, DOI 10.1016/j.biocel.2003.12.011; Vazquez F, 1999, J BIOL CHEM, V274, P23349, DOI 10.1074/jbc.274.33.23349; Visscher DW, 1997, BREAST CANCER RES TR, V45, P75, DOI 10.1023/A:1005845512804; Volpert OV, 1998, P NATL ACAD SCI USA, V95, P6343, DOI 10.1073/pnas.95.11.6343; Xu Y, 2004, CANCER RES, V64, P6119, DOI 10.1158/0008-5472.CAN-04-1054; Xu Y, 2004, J BIOL CHEM, V279, P41179, DOI 10.1074/jbc.M400292200; Xu Y, 2003, J BIOL CHEM, V278, P8661, DOI 10.1074/jbc.M208181200; Yamazaki S, 2003, J CELL BIOL, V163, P469, DOI 10.1083/jcb.200307035; Yarden Y, 2001, NAT REV MOL CELL BIO, V2, P127, DOI 10.1038/35052073; Yee KO, 2004, AM J PATHOL, V165, P541, DOI 10.1016/S0002-9440(10)63319-6; Yi M, 2001, P NATL ACAD SCI USA, V98, P620, DOI 10.1073/pnas.98.2.620; Yu Q, 1997, J EXP MED, V186, P1985, DOI 10.1084/jem.186.12.1985; Yu Q, 1999, GENE DEV, V13, P35, DOI 10.1101/gad.13.1.35; Yu Q, 2000, GENE DEV, V14, P163	69	123	131	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR	2006	25	17					2452	2467		10.1038/sj.onc.1209287	http://dx.doi.org/10.1038/sj.onc.1209287			16	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	034RJ	16314835	Green Accepted			2022-12-25	WOS:000236948000004
J	Rego, EM; Ruggero, D; Tribioli, C; Cattoretti, G; Kogan, S; Redner, RL; Pandolfi, PP				Rego, EM; Ruggero, D; Tribioli, C; Cattoretti, G; Kogan, S; Redner, RL; Pandolfi, PP			Leukemia with distinct phenotypes in transgenic mice expressing PML/RAR alpha, PLZF/RAR alpha or NPM/RAR alpha	ONCOGENE			English	Article						acute promyelocytic leukemia; transgenic mouse models; NPM/RAR alpha; PML/RAR alpha; PLZF/RAR alpha	ACUTE PROMYELOCYTIC LEUKEMIA; PML-RAR-ALPHA; ACUTE MYELOGENOUS LEUKEMIA; CYTOPLASMIC NUCLEOPHOSMIN; PROTEINS; GENE; INTERACTS; MODELS; APL	Recurrent chromosomal translocations involving the RAR alpha locus on chromosome 17 are the hallmark of acute promyelocytic leukemia (APL). The RARa gene fuses to variable partners (PML, PLZF, NPM, NuMA and STAT5B: X genes) leading to the expression of APL-specific fusion proteins with identical RARa moieties. To analyse whether the variable X moiety could affect the activity of the fusion protein in vivo, we generated and characterized, on a comparative basis, NPM/RAR alpha transgenic mice ( TM) in which the fusion gene is expressed under the control of a human Cathepsin G ( hCG) minigene. We compared the features of the leukemia observed in these TM with those in hCG-PML/RAR alpha and hCG-PLZF/RAR alpha TM. In all three transgenic models, leukemia developed after a variably long latency, with variable penetrance. However, the three leukemias displayed distinct cytomorphological features. hCG-NPM/RAR alpha leukemic cells resembled monoblasts. This phenotype contrasts with what was observed in the hCG-PML/RAR alpha TM model in which the leukemic phase was characterized by the proliferation of promyelocytic blasts. Similarly, hCG-PLZF/RAR alpha TM displayed a different phenotype where terminally differentiated myeloid cells predominated. Importantly, the NPM/RAR alpha oncoprotein was found to localize in the nucleolus, unlike PML/RAR alpha and PLZF/RAR alpha, thus possibly interfering with the normal function of NPM. Similarly to what was observed in human APL patients, we found that NPM/RAR alpha and PML/RAR alpha, but not PLZF/RAR alpha leukemia, was responsive to all-trans retinoic acid ( ATRA) or As2O3 treatments. Taken together, our results underscore the critical relevance of the X moiety in dictating the biology of the disease and the activity of the APL fusion oncoprotein.	Mem Sloan Kettering Canc Ctr, Canc Biol & Genet Program, Dept Pathol, Mem Sloan Kettering Inst, New York, NY 10021 USA; Univ Sao Paulo, Div Hematol, Dept Internal Med, Med Sch Ribeirao Preto, Sao Paulo, Brazil; Columbia Univ, Dept Pathol, New York, NY USA; Univ Calif San Francisco, Dept Lab Med, San Francisco, CA 94143 USA; Univ Pittsburgh, Med Ctr, Dept Med, Div Hematol Oncol, Pittsburgh, PA USA	Memorial Sloan Kettering Cancer Center; Universidade de Sao Paulo; Columbia University; University of California System; University of California San Francisco; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Pandolfi, PP (corresponding author), Mem Sloan Kettering Canc Ctr, Canc Biol & Genet Program, Dept Pathol, Mem Sloan Kettering Inst, 1275 York Ave,Box 110, New York, NY 10021 USA.	p-pandolfi@ski.mskcc.org	Rego, Eduardo M/A-1058-2012; Cattoretti, Giorgio/H-2340-2011; Rego, Eduardo/AFS-7973-2022; Rego, Eduardo M./Y-5572-2019	Rego, Eduardo M/0000-0003-1567-4086; Rego, Eduardo/0000-0003-1567-4086; Rego, Eduardo M./0000-0003-1567-4086; Cattoretti, Giorgio/0000-0003-3799-3221; TRIBIOLI, CARLA/0000-0003-2544-476X; Kogan, Scott/0000-0002-2395-8479	NATIONAL CANCER INSTITUTE [R01CA074031] Funding Source: NIH RePORTER; NCI NIH HHS [CA-74031] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Alcalay M, 2005, BLOOD, V106, P899, DOI 10.1182/blood-2005-02-0560; BRUNNING RD, 2001, PATHOLOGY GENETICS T, P75; Cheng GX, 1999, P NATL ACAD SCI USA, V96, P6318, DOI 10.1073/pnas.96.11.6318; Degos L, 2003, BRIT J HAEMATOL, V122, P539, DOI 10.1046/j.1365-2141.2003.04460.x; DYCK JA, 1994, CELL, V76, P333, DOI 10.1016/0092-8674(94)90340-9; Falini B, 2005, NEW ENGL J MED, V352, P254, DOI 10.1056/NEJMoa041974; Grisendi S, 2005, NATURE, V437, P147, DOI 10.1038/nature03915; Grisendi S, 2005, NEW ENGL J MED, V352, P291, DOI 10.1056/NEJMe048337; Grisolano JL, 1997, BLOOD, V89, P376, DOI 10.1182/blood.V89.2.376; He LZ, 2000, MOL CELL, V6, P1131, DOI 10.1016/S1097-2765(00)00111-8; He LZ, 1997, P NATL ACAD SCI USA, V94, P5302, DOI 10.1073/pnas.94.10.5302; He LZ, 1998, NAT GENET, V18, P126, DOI 10.1038/ng0298-126; HEUSEL JW, 1993, BLOOD, V81, P1614; Hummel JL, 2002, CELL GROWTH DIFFER, V13, P173; Kurki S, 2004, CANCER CELL, V5, P465, DOI 10.1016/S1535-6108(04)00110-2; Lin HK, 2004, NATURE, V431, P205, DOI 10.1038/nature02783; Okuda M, 2002, ONCOGENE, V21, P6170, DOI 10.1038/sj.onc.1205708; Piazza F, 2001, ONCOGENE, V20, P7216, DOI 10.1038/sj.onc.1204855; Redner RL, 2000, BLOOD, V95, P2683; Rego EM, 2000, P NATL ACAD SCI USA, V97, P10173, DOI 10.1073/pnas.180290497; Rego EM, 2001, SEMIN HEMATOL, V38, P54, DOI 10.1053/shem.2001.20865; Rego EM, 2001, J EXP MED, V193, P521, DOI 10.1084/jem.193.4.521; Ruthardt M, 1998, ONCOGENE, V16, P1945, DOI 10.1038/sj.onc.1201722; Sainty D, 2000, BLOOD, V96, P1287; SIRULNIK A, 2003, BEST PRACT RES CLIN, V17, P71; Zhong S, 2000, NAT CELL BIOL, V2, pE85, DOI 10.1038/35010583	26	51	55	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 23	2006	25	13					1974	1979		10.1038/sj.onc.1209216	http://dx.doi.org/10.1038/sj.onc.1209216			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	024VQ	16331271				2022-12-25	WOS:000236224800014
J	Walker, GE; Antoniono, RJ; Ross, HJ; Paisley, TE; Oh, Y				Walker, GE; Antoniono, RJ; Ross, HJ; Paisley, TE; Oh, Y			Neuroendocrine-like differentiation of non-small cell lung carcinoma cells: regulation by cAMP and the interaction of mac25/IGFBP-rP1 and 25.1	ONCOGENE			English	Article						cAMP; mac25/IGFBP-rP1; 25.1; NE differentiation; NSCLC; lung cancer	PROTEIN-RELATED PROTEIN-1; PROSTATE-CANCER CELLS; EPITHELIAL-CELLS; CHROMOGRANIN-A; GROWTH-FACTORS; STAGE-I; INSULIN; MARKERS; CHEMOTHERAPY; IDENTIFICATION	The need to develop more effective therapies for lung cancer has led to investigations in understanding the molecular mechanisms of the differentiation process, in particular neuroendocrine ( NE) differentiation. Recent studies have demonstrated that NE differentiation in nonsmall cell lung carcinoma (NSCLC) is not uncommon. Those NSCLCs with NE differentiation are considered a form of in transition NE carcinoma and show a more aggressive clinical course compared with NSCLC without NE differentiation. 25.1, a novel protein interacting with mac25/insulin-like growth factor-binding protein-related protein 1 (mac25/IGFBP-rP1), induced NE-like differentiation when collectively overexpressed in M12 prostate cancer cells. We have examined mac25/IGFBP-rP1 and 25.1 as potential molecular regulators in vitro of the NE-differentiation process in lung cancer. In a panel of SCLC and NSCLC cell lines, mac25/IGFBP-rP1 and 25.1 were expressed at higher levels in SCLC. An increase and sustained activation of adenosine 3',5'- cyclic monophosphate ( cAMP) levels induced NE-like differentiation in NSCLC cell lines, and a concomitant increase in the expression of mac25/IGFBP-rP1 and 25.1 was observed during the cAMP-regulated differentiation of NCI-H157 cells, suggesting the involvement of these proteins. Furthermore, the collective overexpression of mac25/IGFBP-rP1 and 25.1 in NSCLC cells induced NE-like differentiation as early as 6 h postinfection. The present data suggest that mac25/IGFBP-rP1 and 25.1 may play a functional role in the NE differentiation of NSCLC cell lines and may provide a novel therapeutic target for treating lung cancers, in particular NSCLC with NE differentiation.	Virginia Commonwealth Univ, Dept Pathol, Richmond, VA 23298 USA; Oregon Hlth Sci Univ, Dept Pediat, Portland, OR 97201 USA; Oregon Hlth Sci Univ, Oregon Canc Ctr, Portland, OR 97201 USA; Earle A Chiles Res Inst, Portland, OR USA; Ist Auxol Italiano Piancavallo, Oggebbio, VA, Italy	Virginia Commonwealth University; Oregon Health & Science University; Oregon Health & Science University; IRCCS Istituto Auxologico Italiano	Oh, Y (corresponding author), Virginia Commonwealth Univ, Dept Pathol, Med Coll Virginia Campus,POB 980622,Sanger Hall, Richmond, VA 23298 USA.	yoh@vcu.edu						Ahmed S, 2003, BIOCHEM BIOPH RES CO, V310, P612, DOI 10.1016/j.bbrc.2003.09.058; AKAOGI K, 1994, BIOCHEM BIOPH RES CO, V198, P1046, DOI 10.1006/bbrc.1994.1149; Akaogi K, 1996, CELL GROWTH DIFFER, V7, P1671; BERENDSEN HH, 1989, J CLIN ONCOL, V7, P1614, DOI 10.1200/JCO.1989.7.11.1614; Burger AM, 1998, ONCOGENE, V16, P2459, DOI 10.1038/sj.onc.1201772; Carnaghi C, 2001, ANN ONCOL, V12, pS119, DOI 10.1093/annonc/12.suppl_2.S119; Cersosimo RJ, 2002, AM J HEALTH-SYST PH, V59, P611, DOI 10.1093/ajhp/59.7.611; Chen TS, 1999, CANCER RES, V59, P213; Cox ME, 2000, J BIOL CHEM, V275, P13812, DOI 10.1074/jbc.275.18.13812; Deeble PD, 2001, MOL CELL BIOL, V21, P8471, DOI 10.1128/MCB.21.24.8471-8482.2001; DIMRI GP, 1995, P NATL ACAD SCI USA, V92, P9363, DOI 10.1073/pnas.92.20.9363; Gajra A, 2002, LUNG CANCER-J IASLC, V36, P159, DOI 10.1016/S0169-5002(01)00463-9; GAZDAR AF, 1988, CANCER RES, V48, P4078; GOSNEY JR, 1995, THORAX, V50, P116, DOI 10.1136/thx.50.2.116; GRAZIANO SL, 1994, CANCER RES, V54, P2908; Graziano SL, 2001, LUNG CANCER, V33, P115, DOI 10.1016/S0169-5002(01)00183-0; Haugk KL, 2000, ENDOCRINOLOGY, V141, P100, DOI 10.1210/en.141.1.100; Heasley LE, 2001, ONCOGENE, V20, P1563, DOI 10.1038/sj.onc.1204183; Hwa V, 1999, ENDOCR REV, V20, P761, DOI 10.1210/er.20.6.761; Iyoda A, 2001, CANCER, V92, P1108, DOI 10.1002/1097-0142(20010901)92:5<1108::AID-CNCR1427>3.0.CO;2-7; Jiang SX, 1999, MODERN PATHOL, V12, P362; Jiang SX, 1996, AM J PATHOL, V148, P837; Jull BA, 2001, J CANCER RES CLIN, V127, P707; LINNOILA RI, 1994, CHEST S6, V106, P367; Lopez-Bermejo A, 2000, ENDOCRINOLOGY, V141, P4072, DOI 10.1210/en.141.11.4072; MURPHY M, 1993, CELL GROWTH DIFFER, V4, P715; Oh YM, 1996, J BIOL CHEM, V271, P30322, DOI 10.1074/jbc.271.48.30322; Pelosi G, 2003, CANCER-AM CANCER SOC, V97, P2487, DOI 10.1002/cncr.11376; Reynolds SD, 2000, AM J PHYSIOL-LUNG C, V278, pL1256, DOI 10.1152/ajplung.2000.278.6.L1256; Schleusener JT, 1996, CANCER-AM CANCER SOC, V77, P1284, DOI 10.1002/(SICI)1097-0142(19960401)77:7<1284::AID-CNCR9>3.0.CO;2-I; SHAW GL, 1993, CANCER RES, V53, P5181; SKOV BG, 1991, ANN ONCOL, V2, P355, DOI 10.1093/oxfordjournals.annonc.a057955; Sprenger CC, 1999, CANCER RES, V59, P2370; SWISSHELM K, 1995, P NATL ACAD SCI USA, V92, P4472, DOI 10.1073/pnas.92.10.4472; Tureckova J, 2001, J BIOL CHEM, V276, P39264, DOI 10.1074/jbc.M104991200; Vossler MR, 1997, CELL, V89, P73, DOI 10.1016/S0092-8674(00)80184-1; Wallace WAH, 2002, EUR J SURG ONCOL, V28, P63, DOI 10.1053/ejso.2001.1170; Wilson EM, 1997, J CLIN ENDOCR METAB, V82, P1301, DOI 10.1210/jc.82.4.1301; Wilson EM, 2001, J CLIN ENDOCR METAB, V86, P4504, DOI 10.1210/jc.86.9.4504; YAMAUCHI T, 1994, BIOCHEM J, V303, P591, DOI 10.1042/bj3030591; Yesner R, 2001, EXP MOL PATHOL, V70, P179, DOI 10.1006/exmp.2001.2373	41	26	32	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 23	2006	25	13					1943	1954		10.1038/sj.onc.1209213	http://dx.doi.org/10.1038/sj.onc.1209213			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	024VQ	16302002				2022-12-25	WOS:000236224800011
J	Hanrott, K; Gudmunsen, L; O'Neill, MJ; Wonnacott, S				Hanrott, K; Gudmunsen, L; O'Neill, MJ; Wonnacott, S			d6-Hydroxydopamine- induced apoptosis is mediated via extracellular auto-oxidation and caspase 3-dependent activation of protein kinase C delta	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CASPASE-3-DEPENDENT PROTEOLYTIC CLEAVAGE; DOPAMINERGIC NEURONAL CELLS; GLAND ACINAR-CELLS; PC12 CELLS; OXIDATIVE STRESS; PKC-DELTA; TYROSINE PHOSPHORYLATION; PARKINSONS-DISEASE; 6-HYDROXYDOPAMINE-INDUCED APOPTOSIS; SUBSTANTIA-NIGRA	6-Hydroxydopamine is a neurotoxin commonly used to lesion dopaminergic pathways and generate experimental models for Parkinson disease, however, the cellular mechanism of 6-hydroxydopamine-induced neurodegeneration is not well defined. In this study we have explored how 6-hydroxydopamine neurotoxicity is initiated. We have also investigated downstream signaling pathways activated in response to 6-hydroxydopamine, using a neuronal-like, catecholaminergic cell line (PC12 cells) as an in vitro model system. We have shown that 6-hydroxydopamine neurotoxicity is initiated via extracellular auto-oxidation and the induction of oxidative stress from the oxidative products generated. Neurotoxicity is completely attenuated by preincubation with catalase, suggesting that hydrogen peroxide, at least in part, evokes neuronal cell death in this model. 6-Hydroxydopamine does not initiate toxicity by dopamine transporter-mediated uptake into PC12 cells, because both GBR-12909 and nisoxetine ( inhibitors of dopamine and noradrenaline transporters, respectively) failed to reduce toxicity. 6-Hydroxydopamine has previously been shown to induce both apoptotic and necrotic cell-death mechanisms. In this study oxidative stress initiated by 6-hydroxydopamine caused mitochondrial dysfunction, activation of caspases 3/7, nuclear fragmentation, and apoptosis. We have shown that, in this model, proteolytic activation of the proapoptotic protein kinase C delta (PKC delta) is a key mediator of 6-hydroxydopamine-induced cell death. 6-Hydroxydopamine induces caspase 3-dependent cleavage of full-length PKC delta( 79 kDa) to yield a catalytic fragment ( 41 kDa). Inhibition of PKC delta ( with rottlerin or via RNA interference-mediated gene suppression) ameliorates the neurotoxicity evoked by 6-hydroxydopamine, implicating this kinase in 6-hydroxydopamine-induced neurotoxicity and Parkinsonian neurodegeneration.	Univ Bath, Dept Biol & Biochem, Bath BA2 7AY, Avon, England; Eli Lilly & Co Ltd, Windlesham GU20 6PH, Surrey, England	University of Bath; Eli Lilly	Wonnacott, S (corresponding author), Univ Bath, Dept Biol & Biochem, 4 South,Claverton Down, Bath BA2 7AY, Avon, England.	S.Wonnacott@bath.ac.uk						Anantharam V, 2002, J NEUROSCI, V22, P1738, DOI 10.1523/JNEUROSCI.22-05-01738.2002; Berretta N, 2005, NEUROTOXICOLOGY, V26, P869, DOI 10.1016/j.neuro.2005.01.014; Bharti A, 1998, MOL CELL BIOL, V18, P6719, DOI 10.1128/MCB.18.11.6719; Blass M, 2002, MOL CELL BIOL, V22, P182, DOI 10.1128/MCB.22.1.182-195.2002; Blum D, 2001, BIOCHEM PHARMACOL, V62, P473, DOI 10.1016/S0006-2952(01)00680-3; Blum D, 2001, PROG NEUROBIOL, V65, P135, DOI 10.1016/S0301-0082(01)00003-X; Blum D, 1997, BRAIN RES, V751, P139, DOI 10.1016/S0006-8993(96)01358-3; Blum D, 2000, NEUROSCI LETT, V283, P193, DOI 10.1016/S0304-3940(00)00948-4; BREESE GR, 1970, J PHARMACOL EXP THER, V174, P413; Brodie C, 2003, APOPTOSIS, V8, P19, DOI 10.1023/A:1021640817208; Chen G, 2004, FASEB J, V18, P1162, DOI 10.1096/fj.04-1551fje; Chen NY, 1999, J BIOL CHEM, V274, P15389, DOI 10.1074/jbc.274.22.15389; Chudapongse N, 2003, J PHARMACOL SCI, V93, P372, DOI 10.1254/jphs.93.372; Clement MW, 2002, J NEUROCHEM, V81, P414, DOI 10.1046/j.1471-4159.2002.00802.x; Cross T, 2000, ONCOGENE, V19, P2331, DOI 10.1038/sj.onc.1203555; Denning MF, 1998, J BIOL CHEM, V273, P29995, DOI 10.1074/jbc.273.45.29995; DeVries TA, 2002, EMBO J, V21, P6050, DOI 10.1093/emboj/cdf606; Ding YM, 2004, J NEUROCHEM, V89, P776, DOI 10.1111/j.1471-4159.2004.02415.x; Dodel RC, 1999, MOL BRAIN RES, V64, P141, DOI 10.1016/S0169-328X(98)00318-0; Elkon H, 2001, CELL MOL NEUROBIOL, V21, P771, DOI 10.1023/A:1015160323009; Eminel S, 2004, J BIOL CHEM, V279, P55385, DOI 10.1074/jbc.M405858200; Emoto Y, 1995, EMBO J, V14, P6148, DOI 10.1002/j.1460-2075.1995.tb00305.x; Fonck C, 2001, BRAIN RES, V905, P199, DOI 10.1016/S0006-8993(01)02551-3; Fukunaga M, 2001, BIOCHEM BIOPH RES CO, V289, P573, DOI 10.1006/bbrc.2001.6025; Ghayur T, 1996, J EXP MED, V184, P2399, DOI 10.1084/jem.184.6.2399; Goldberg M, 1996, BIOCHEM PHARMACOL, V51, P1089, DOI 10.1016/0006-2952(96)00046-9; GSCHWENDT M, 1994, BIOCHEM BIOPH RES CO, V199, P93, DOI 10.1006/bbrc.1994.1199; Han BS, 2003, J NEUROSCI, V23, P5069; Izumi Y, 2005, J NEUROSCI RES, V79, P849, DOI 10.1002/jnr.20382; Jordan J, 2004, J NEUROCHEM, V89, P124, DOI 10.1046/j.1471-4159.2003.02299.x; Kajimoto T, 2004, J BIOL CHEM, V279, P12668, DOI 10.1074/jbc.M312350200; Kanthasamy AG, 2003, ANTIOXID REDOX SIGN, V5, P609, DOI 10.1089/152308603770310275; Kaul S, 2005, J BIOL CHEM, V280, P28721, DOI 10.1074/jbc.M501092200; Kaul S, 2003, EUR J NEUROSCI, V18, P1387, DOI 10.1046/j.1460-9568.2003.02864.x; Kitazawa M, 2004, NEUROTOXICOLOGY, V25, P589, DOI 10.1016/j.neuro.2003.09.014; Kitazawa M, 2003, NEUROSCIENCE, V119, P945, DOI 10.1016/S0306-4522(03)00226-4; Kohda Y, 2005, J PHARMACOL SCI, V98, P49, DOI 10.1254/jphs.FP0040926; Konishi H, 1999, BIOCHEM BIOPH RES CO, V264, P840, DOI 10.1006/bbrc.1999.1579; Latchoumycandane C, 2005, J PHARMACOL EXP THER, V313, P46, DOI 10.1124/jpet.104.078469; LEIBERSPERGER H, 1991, J BIOL CHEM, V266, P14778; Leitges M, 2001, J CLIN INVEST, V108, P1505; Li LW, 1999, MOL CELL BIOL, V19, P8547; Liang QH, 2004, J NEUROSCI RES, V77, P747, DOI 10.1002/jnr.20198; Liao YF, 2005, LIFE SCI, V77, P707, DOI 10.1016/j.lfs.2005.01.010; LJUNGDAHL A, 1971, EXPERIENTIA, V27, P297, DOI 10.1007/BF02138157; Lotharius J, 2002, NAT REV NEUROSCI, V3, P932, DOI 10.1038/nrn983; Lotharius J, 1999, J NEUROSCI, V19, P1284; Majumder PK, 2000, J BIOL CHEM, V275, P21793, DOI 10.1074/jbc.C000048200; Majumder PK, 2001, CELL GROWTH DIFFER, V12, P465; MARTINYBARON G, 1993, J BIOL CHEM, V268, P9194; Matassa AA, 2001, J BIOL CHEM, V276, P29719, DOI 10.1074/jbc.M100273200; Mazzio EA, 2004, BRAIN RES, V1004, P29, DOI 10.1016/j.brainres.2003.12.034; Miguel BG, 2005, BBA-MOL CELL RES, V1743, P215, DOI 10.1016/j.bbamcr.2004.10.011; Mizuno K, 1997, EUR J BIOCHEM, V250, P7, DOI 10.1111/j.1432-1033.1997.00007.x; Munoz AM, 2004, J NEUROSCI RES, V76, P551, DOI 10.1002/jnr.20107; Ochu EE, 1998, J NEUROCHEM, V70, P2637; Ren J, 2002, J BIOL CHEM, V277, P33758, DOI 10.1074/jbc.M110667200; Reyland ME, 1999, J BIOL CHEM, V274, P19115, DOI 10.1074/jbc.274.27.19115; Reyland ME, 2000, CELL DEATH DIFFER, V7, P1200, DOI 10.1038/sj.cdd.4400744; Scheel-Toellner D, 1999, EUR J IMMUNOL, V29, P2603, DOI 10.1002/(SICI)1521-4141(199908)29:08<2603::AID-IMMU2603>3.0.CO;2-L; Seth K, 2002, NEUROSCI LETT, V330, P89, DOI 10.1016/S0304-3940(02)00714-0; Soltoff SP, 2001, J BIOL CHEM, V276, P37986; Soto-Otero R, 2000, J NEUROCHEM, V74, P1605, DOI 10.1046/j.1471-4159.2000.0741605.x; Takai N, 1998, J NEUROSCI RES, V54, P214, DOI 10.1002/(SICI)1097-4547(19981015)54:2<214::AID-JNR9>3.0.CO;2-H; Tapia JA, 2003, J BIOL CHEM, V278, P35220, DOI 10.1074/jbc.M303119200; Tsao CW, 2002, NEUROIMMUNOMODULAT, V10, P328, DOI 10.1159/000071473; WALKINSHAW G, 1994, NEUROSCIENCE, V63, P975, DOI 10.1016/0306-4522(94)90566-5; Woodgate A, 1999, MOL BRAIN RES, V69, P84, DOI 10.1016/S0169-328X(99)00103-5; Yang YJ, 2004, MOL CELL NEUROSCI, V25, P406, DOI 10.1016/j.mcn.2003.11.011; Yuan ZM, 1998, ONCOGENE, V16, P1643, DOI 10.1038/sj.onc.1201698	71	182	202	1	17	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 3	2006	281	9					5373	5382		10.1074/jbc.M511560200	http://dx.doi.org/10.1074/jbc.M511560200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	015RQ	16361258	hybrid			2022-12-25	WOS:000235568900008
J	Grabolle, M; Haumann, M; Muller, C; Liebisch, P; Dau, H				Grabolle, M; Haumann, M; Muller, C; Liebisch, P; Dau, H			Rapid loss of structural motifs in the manganese complex of oxygenic photosynthesis by x-ray irradiation at 10-300 K	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							II MEMBRANE-PARTICLES; PHOTOSYSTEM-II; RADIATION-DAMAGE; ABSORPTION SPECTROSCOPY; CRYSTAL-STRUCTURE; PROTEIN CRYSTALS; EVOLVING COMPLEX; OXIDATION-STATE; CENTERED OXIDATION; GLASS-TRANSITION	Structural changes upon photoreduction caused by x-ray irradiation of the water-oxidizing tetramanganese complex of photosystem II were investigated by x-ray absorption spectroscopy at the manganese K-edge. Photoreduction was directly proportional to the x-ray dose. It was faster in the higher oxidized S-2 state than in S-1; seemingly the oxidizing potential of the metal site governs the rate. X-ray irradiation of the S-1 state at 15 K initially caused single-electron reduction to S-0* accompanied by the conversion of one di-mu-oxo bridge between manganese atoms, previously separated by similar to 2.7 angstrom, to a mono-mu-oxo motif. Thereafter, manganese photoreduction was 100 times slower, and the biphasic increase in its rate between 10 and 300 K with a breakpoint at similar to 200 K suggests that protein dynamics is rate-limiting the radical chemistry. For photoreduction at similar x-ray doses as applied in protein crystallography, halfway to the final Mn-4(II) state the complete loss of inter-manganese distances < 3 angstrom was observed, even at 10 K, because of the destruction of mu-oxo bridges between manganese ions. These results put into question some structural attributions from recent protein crystallography data on photosystem II. It is proposed to employ controlled x-ray photoreduction in metalloprotein research for: (i) population of distinct reduced states, (ii) estimating the redox potential of buried metal centers, and (iii) research on protein dynamics.	Free Univ Berlin, FB Phys, D-14195 Berlin, Germany	Free University of Berlin	Dau, H (corresponding author), Free Univ Berlin, FB Phys, Arnimallee 14, D-14195 Berlin, Germany.	holger.dau@physik.fu-berlin.de	MIchael, Haumann/A-7087-2013	Dau, Holger/0000-0001-6482-7494				ANGELL CA, 1995, P NATL ACAD SCI USA, V92, P6675, DOI 10.1073/pnas.92.15.6675; Baldwin MJ, 1999, INORG CHEM, V38, P4801, DOI 10.1021/ic990346e; Berglund GI, 2002, NATURE, V417, P463, DOI 10.1038/417463a; Biesiadka J, 2004, PHYS CHEM CHEM PHYS, V6, P4733, DOI 10.1039/b406989g; Burmeister WP, 2000, ACTA CRYSTALLOGR D, V56, P328, DOI 10.1107/S0907444999016261; Carugo O, 2005, TRENDS BIOCHEM SCI, V30, P213, DOI 10.1016/j.tibs.2005.02.009; Chamorovsky SK, 2003, EUR BIOPHYS J BIOPHY, V32, P537, DOI 10.1007/s00249-003-0289-8; CHANCE B, 1982, ANAL BIOCHEM, V124, P248, DOI 10.1016/0003-2697(82)90035-5; Cinco RM, 2002, BIOCHEMISTRY-US, V41, P12928, DOI 10.1021/bi026569p; Dau H, 1997, J PHYS IV, V7, P607, DOI 10.1051/jp4/1997112; Dau H, 2005, PHOTOSYNTH RES, V84, P325, DOI 10.1007/s11120-004-7080-2; Dau H, 2003, ANAL BIOANAL CHEM, V376, P562, DOI 10.1007/s00216-003-1982-2; Dau H, 2004, PHYS CHEM CHEM PHYS, V6, P4781, DOI 10.1039/b408146c; Dau H, 2001, BBA-BIOENERGETICS, V1503, P24, DOI 10.1016/S0005-2728(00)00230-9; Dau H, 2005, PHYS SCRIPTA, VT115, P844; DEBUS RJ, 1992, BIOCHIM BIOPHYS ACTA, V1102, P269, DOI 10.1016/0005-2728(92)90133-M; DISMUKES GC, 1981, P NATL ACAD SCI-BIOL, V78, P274, DOI 10.1073/pnas.78.1.274; Dittmer J, 1998, J PHYS CHEM B, V102, P8196, DOI 10.1021/jp981049i; DITTMER J, 1999, THESIS CHRISTIAN ALB; DOSTER W, 1989, NATURE, V337, P754, DOI 10.1038/337754a0; FERRAND M, 1993, P NATL ACAD SCI USA, V90, P9668, DOI 10.1073/pnas.90.20.9668; Ferreira KN, 2004, SCIENCE, V303, P1831, DOI 10.1126/science.1093087; Garman E, 2003, CURR OPIN STRUC BIOL, V13, P545, DOI 10.1016/j.sbi.2003.09.013; GONZALEZ A, 1994, ACTA CRYSTALLOGR D, V50, P874, DOI 10.1107/S0907444994006311; Haumann M, 2005, BIOCHEMISTRY-US, V44, P1894, DOI 10.1021/bi048697e; Haumann M, 2005, J SYNCHROTRON RADIAT, V12, P35, DOI 10.1107/S0909049504027803; Haumann M, 2002, FEBS LETT, V512, P116, DOI 10.1016/S0014-5793(02)02237-8; HAUMANN M, 1996, OXYGENIC PHOTOSYNTHE, P213; Huang P, 2002, J INORG BIOCHEM, V91, P159, DOI 10.1016/S0162-0134(02)00394-X; Hubbell JH, 1999, PHYS MED BIOL, V44, pR1, DOI 10.1088/0031-9155/44/1/001; Iuzzolino L, 1998, BIOCHEMISTRY-US, V37, P17112, DOI 10.1021/bi9817360; JONES GDD, 1987, NATURE, V330, P772, DOI 10.1038/330772a0; Kamiya N, 2003, P NATL ACAD SCI USA, V100, P98, DOI 10.1073/pnas.0135651100; Keppler C, 2000, EUR BIOPHYS J BIOPHY, V29, P146, DOI 10.1007/s002490050260; KOK B, 1970, PHOTOCHEM PHOTOBIOL, V11, P457, DOI 10.1111/j.1751-1097.1970.tb06017.x; Koningsberger DC, 2000, TOP CATAL, V10, P143, DOI 10.1023/A:1019105310221; Kuhn P, 2005, PHOTOSYNTH RES, V84, P317, DOI 10.1007/s11120-004-7079-8; Lee AL, 2001, NATURE, V411, P501, DOI 10.1038/35078119; Li J, 1999, INORG CHEM, V38, P929, DOI 10.1021/ic980731o; MARCUS RA, 1985, BIOCHIM BIOPHYS ACTA, V811, P265, DOI 10.1016/0304-4173(85)90014-X; McEvoy JP, 2004, PHYS CHEM CHEM PHYS, V6, P4754, DOI 10.1039/b407500e; Meinke C, 2000, BIOCHEMISTRY-US, V39, P7033, DOI 10.1021/bi9924258; Messinger J, 2001, J AM CHEM SOC, V123, P7804, DOI 10.1021/ja004307+; NUGENT JHA, 2001, BIOCH BIOPHYS ACTA, V1503; Palenik GJ, 1997, INORG CHEM, V36, P4888, DOI 10.1021/ic9705554; PARAK F, 1982, J MOL BIOL, V161, P177, DOI 10.1016/0022-2836(82)90285-6; Persson P, 2001, PROTEIN SCI, V10, P2480, DOI 10.1110/ps.ps.26201; Pospisil P, 2003, BIOPHYS J, V84, P1370, DOI 10.1016/S0006-3495(03)74952-2; Ravelli RBG, 2000, STRUCTURE, V8, P315, DOI 10.1016/S0969-2126(00)00109-X; REHR JJ, 1991, J AM CHEM SOC, V113, P5135, DOI 10.1021/ja00014a001; Robblee JH, 2002, J AM CHEM SOC, V124, P7459, DOI 10.1021/ja011621a; Robblee JH, 2001, BBA-BIOENERGETICS, V1503, P7, DOI 10.1016/S0005-2728(00)00217-6; SAYGIN O, 1985, PHOTOBIOCH PHOTOBIOP, V10, P71; Schiller H, 2000, J PHOTOCH PHOTOBIO B, V55, P138, DOI 10.1016/S1011-1344(00)00036-1; Schlodder E, 1998, BIOCHEMISTRY-US, V37, P9466, DOI 10.1021/bi973182r; Scott R.A, 2000, PHYS METHODS BIOINOR, P465; Sliz P, 2003, STRUCTURE, V11, P13, DOI 10.1016/S0969-2126(02)00910-3; Sole VA, 1999, J SYNCHROTRON RADIAT, V6, P174, DOI 10.1107/S0909049598017531; Teeter MM, 2001, P NATL ACAD SCI USA, V98, P11242, DOI 10.1073/pnas.201404398; Telser J, 2001, J AM CHEM SOC, V123, P5853, DOI 10.1021/ja010428d; Teng TY, 2000, J SYNCHROTRON RADIAT, V7, P313, DOI 10.1107/S0909049500008694; VASS I, 1991, BIOCHEMISTRY-US, V30, P830, DOI 10.1021/bi00217a037; Weik M, 2003, EUR PHYS J E, V12, P153, DOI 10.1140/epje/i2003-10043-5; Weik M, 2000, P NATL ACAD SCI USA, V97, P623, DOI 10.1073/pnas.97.2.623; Yano J, 2005, P NATL ACAD SCI USA, V102, P12047, DOI 10.1073/pnas.0505207102; Zouni A, 2001, NATURE, V409, P739, DOI 10.1038/35055589	66	165	170	0	23	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 24	2006	281	8					4580	4588		10.1074/jbc.M509724200	http://dx.doi.org/10.1074/jbc.M509724200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	013RF	16352605	hybrid			2022-12-25	WOS:000235426200005
J	Petrushenko, ZM; Lai, CH; Rai, R; Rybenkov, VV				Petrushenko, ZM; Lai, CH; Rai, R; Rybenkov, VV			DNA reshaping by MukB - Right-handed knotting, left-handed supercoiling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; SMC PROTEINS; CHROMOSOME CONDENSATION; STRUCTURAL MAINTENANCE; ELECTRON-MICROSCOPY; MITOTIC CHROMOSOME; COHESIN COMPLEX; TOPOISOMERASE-I; ATP HYDROLYSIS; 13S CONDENSIN	MukB is a bacterial SMC (structural maintenance of chromosome) protein required for faithful chromosome segregation in Escherichia coli. We report here that purified MukB introduces right-handed knots into DNA in the presence of type-2 topoisomerase, indicating that the protein promotes intramolecular DNA condensation. The pattern of generated knots suggests that MukB, similar to eukaryotic condensins, stabilizes large right-handed DNA loops. In contrast to eukaryotic condensins, however, the net supercoiling stabilized by MukB was negative. Furthermore, DNA reshaping by MukB did not require ATP. These data establish that bacterial condensins alter the shape of double-stranded DNA in vitro and lend support to the notions that the right-handed knotting is the most conserved biochemical property of condensins. Finally, we found that MukB can be eluted from a heparin column in two distinct forms, one of which is inert in DNA binding or reshaping. Furthermore, we find that the activity of MukB is reversibly attenuated during chromatographic separation. Thus, MukB has a unique set of topological properties, compared with other SMC proteins, and is likely to exist in two different conformations.	Univ Oklahoma, Dept Chem & Biochem, Norman, OK 73019 USA	University of Oklahoma System; University of Oklahoma - Norman	Rybenkov, VV (corresponding author), Univ Oklahoma, Dept Chem & Biochem, 620 Parrington Oval, Norman, OK 73019 USA.	valya@ou.edu			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM063786] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM63786, R01 GM063786] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Adachi S, 2003, J BACTERIOL, V185, P3690, DOI 10.1128/JB.185.13.3690-3695.2003; Anderson DE, 2002, J CELL BIOL, V156, P419, DOI 10.1083/jcb.200111002; Arumugam P, 2003, CURR BIOL, V13, P1941, DOI 10.1016/j.cub.2003.10.036; Butland G, 2005, NATURE, V433, P531, DOI 10.1038/nature03239; Champoux JJ, 2001, ANNU REV BIOCHEM, V70, P369, DOI 10.1146/annurev.biochem.70.1.369; Cobbe N, 2000, J STRUCT BIOL, V129, P123, DOI 10.1006/jsbi.2000.4255; Corbett KD, 2004, ANNU REV BIOPH BIOM, V33, P95, DOI 10.1146/annurev.biophys.33.110502.140357; COZZARELLI NR, 1990, DNA TOPOLOGY BIOL EF; de Jager M, 2001, MOL CELL, V8, P1129, DOI 10.1016/S1097-2765(01)00381-1; delaRoche MA, 1997, ARCH BIOCHEM BIOPHYS, V344, P159, DOI 10.1006/abbi.1997.0203; DYNAN WS, 1981, J BIOL CHEM, V256, P5860; Gill G, 1997, CHEM RES TOXICOL, V10, P302, DOI 10.1021/tx960170i; Haering CH, 2002, MOL CELL, V9, P773, DOI 10.1016/S1097-2765(02)00515-4; Hagstrom KA, 2002, GENE DEV, V16, P729, DOI 10.1101/gad.968302; Hirano M, 2004, EMBO J, V23, P2664, DOI 10.1038/sj.emboj.7600264; Hirano M, 2002, EMBO J, V21, P5733, DOI 10.1093/emboj/cdf575; Hirano M, 2001, EMBO J, V20, P3238, DOI 10.1093/emboj/20.12.3238; Hirano M, 1998, EMBO J, V17, P7139, DOI 10.1093/emboj/17.23.7139; Hirano T, 1998, CURR OPIN CELL BIOL, V10, P317, DOI 10.1016/S0955-0674(98)80006-9; Holmes VF, 2000, P NATL ACAD SCI USA, V97, P1322, DOI 10.1073/pnas.040576797; Hopfner KP, 2000, CELL, V101, P789, DOI 10.1016/S0092-8674(00)80890-9; Kimura K, 1999, CELL, V98, P239, DOI 10.1016/S0092-8674(00)81018-1; Kimura K, 1997, CELL, V90, P625, DOI 10.1016/S0092-8674(00)80524-3; Kimura K, 2001, J BIOL CHEM, V276, P5417, DOI 10.1074/jbc.C000873200; Lammens A, 2004, CURR BIOL, V14, P1778, DOI 10.1016/j.cub.2004.09.044; Losada A, 2001, CURR BIOL, V11, P268, DOI 10.1016/S0960-9822(01)00066-5; Matoba K, 2005, BIOCHEM BIOPH RES CO, V333, P694, DOI 10.1016/j.bbrc.2005.05.163; Melby TE, 1998, J CELL BIOL, V142, P1595, DOI 10.1083/jcb.142.6.1595; Nasmyth K, 2002, SCIENCE, V297, P559, DOI 10.1126/science.1074757; NIKI H, 1992, EMBO J, V11, P5101, DOI 10.1002/j.1460-2075.1992.tb05617.x; NIKI H, 1991, EMBO J, V10, P183, DOI 10.1002/j.1460-2075.1991.tb07935.x; RYBENKOV VV, 1993, P NATL ACAD SCI USA, V90, P5307, DOI 10.1073/pnas.90.11.5307; Sawitzke JA, 2000, P NATL ACAD SCI USA, V97, P1671, DOI 10.1073/pnas.030528397; Schleiffer A, 2003, MOL CELL, V11, P571, DOI 10.1016/S1097-2765(03)00108-4; Soppa J, 2002, MOL MICROBIOL, V45, P59, DOI 10.1046/j.1365-2958.2002.03012.x; Stray JE, 2005, J BIOL CHEM, V280, P34723, DOI 10.1074/jbc.M506589200; Stray JE, 2003, J BIOL CHEM, V278, P26238, DOI 10.1074/jbc.M302699200; Strunnikov AV, 1999, EUR J BIOCHEM, V263, P6, DOI 10.1046/j.1432-1327.1999.00509.x; Swedlow JR, 2003, MOL CELL, V11, P557, DOI 10.1016/S1097-2765(03)00103-5; Vologodskii A, 1996, BIOPHYS J, V70, P2548, DOI 10.1016/S0006-3495(96)79826-0; WASSERMAN SA, 1991, J BIOL CHEM, V266, P20567; WASSERMAN SA, 1986, SCIENCE, V232, P951, DOI 10.1126/science.3010458; Weitao T, 1999, MOL MICROBIOL, V34, P157, DOI 10.1046/j.1365-2958.1999.01589.x; Weitzer S, 2003, CURR BIOL, V13, P1930, DOI 10.1016/j.cub.2003.10.030; Yamanaka K, 1996, MOL GEN GENET, V250, P241; Yamazoe M, 1999, EMBO J, V18, P5873, DOI 10.1093/emboj/18.21.5873; Zechiedrich EL, 1999, METH MOL B, V94, P99	47	76	76	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 24	2006	281	8					4606	4615		10.1074/jbc.M504754200	http://dx.doi.org/10.1074/jbc.M504754200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	013RF	16368697	Green Accepted, hybrid			2022-12-25	WOS:000235426200008
J	Deb, C; Daniel, J; Sirakova, TD; Abomoelak, B; Dubey, VS; Kolattukudy, PE				Deb, C; Daniel, J; Sirakova, TD; Abomoelak, B; Dubey, VS; Kolattukudy, PE			A novel lipase belonging to the hormone-sensitive lipase family induced under starvation to utilize stored triacylglycerol in Mycobacterium tuberculosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CRYSTAL-STRUCTURE; FATTY-ACIDS; PERSISTENCE; EXPRESSION; ESTERASE; GENE; BIOLOGY	Twenty-four putative lipase/esterase genes of Mycobacterium tuberculosis H37Rv were expressed in Escherichia coli and assayed for long-chain triacylglycerol (TG) hydrolase activity. We show here that the product of Rv3097c (LIPY) hydrolyzed long-chain TG with high specific activity. LIPY was purified after solubilization from inclusion bodies; the enzyme displayed a K-m of 7.57 mM and V-max of 653.3 nmol/mg/min for triolein with optimal activity between pH 8.0 and pH 9.0. LIPY was inhibited by active serine-directed reagents and was inactivated at temperatures above 37 degrees C. Detergents above their critical micellar concentrations and divalent cations inhibited the activity of LIPY. The N-terminal half of LIPY showed sequence homology with the proline glutamic acid-polymorphic GC-rich repetitive sequences protein family of M. tuberculosis. The C-terminal half of LIPY possesses amino acid domains homologous with the hormone-sensitive lipase family and the conserved active-site motif GDSAG. LIPY shows low sequence identity with the annotated lipases of M. tuberculosis and with other bacterial lipases. We demonstrate that hypoxic cultures of M. tuberculosis, which had accumulated TG, hydrolyzed the stored TG when subjected to nutrient starvation. Under such conditions, lipY was induced more than all lipases, suggesting a central role for it in the utilization of stored TG. We also show that in the lipY-deficient mutant, TG utilization was drastically decreased under nutrient-deprived condition. Thus, LIPY may be responsible for the utilization of stored TG during dormancy and reactivation of the pathogen.	Univ Cent Florida, Burnett Coll Biomed Sci, Orlando, FL 32816 USA	State University System of Florida; University of Central Florida	Kolattukudy, PE (corresponding author), Univ Cent Florida, Burnett Coll Biomed Sci, Orlando, FL 32816 USA.	pk@mail.ucf.edu	kolattukudy, pappachan e/A-1350-2012		NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI046582, R01AI035272] Funding Source: NIH RePORTER; NIAID NIH HHS [R01 AI046582, R01 AI035272, AI35272, AI46582] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Arpigny JL, 1999, BIOCHEM J, V343, P177, DOI 10.1042/0264-6021:3430177; Bardarov S, 2002, MICROBIOL-SGM, V148, P3007, DOI 10.1099/00221287-148-10-3007; BELFRAGE P, 1969, J LIPID RES, V10, P341; Bentrup KHZ, 2001, TRENDS MICROBIOL, V9, P597, DOI 10.1016/S0966-842X(01)02238-7; Betts JC, 2002, MOL MICROBIOL, V43, P717, DOI 10.1046/j.1365-2958.2002.02779.x; Brennan MJ, 2002, TRENDS MICROBIOL, V10, P246, DOI 10.1016/S0966-842X(02)02335-1; Canaan S, 2004, EUR J BIOCHEM, V271, P3953, DOI 10.1111/j.1432-1033.2004.04335.x; Cole ST, 1998, NATURE, V393, P537, DOI 10.1038/31159; Danelishvili L, 2004, FEMS MICROBIOL LETT, V239, P41, DOI 10.1016/j.femsle.2004.08.014; Daniel J, 2004, J BACTERIOL, V186, P5017, DOI 10.1128/jb.186.15.5017-5030.2004; Dannenberg Arthur M. Jr., 1994, P459; De Simone G, 2001, J MOL BIOL, V314, P507, DOI 10.1006/jmbi.2001.5152; Derbyshire KM, 2000, MOLECULAR GENETICS OF MYCOBACTERIA, P93; Dye C, 1999, JAMA-J AM MED ASSOC, V282, P677, DOI 10.1001/jama.282.7.677; Fisher MA, 2002, J BACTERIOL, V184, P4025, DOI 10.1128/JB.184.14.4025-4032.2002; Hotelier T, 2004, NUCLEIC ACIDS RES, V32, pD145, DOI 10.1093/nar/gkh141; JACKSON SK, 1989, BRIT J EXP PATHOL, V70, P435; Jaeger KE, 1999, ANNU REV MICROBIOL, V53, P315, DOI 10.1146/annurev.micro.53.1.315; KOLATTUKUDY PE, 1984, LIPASES, P47; MCCUNE RM, 1966, J EXP MED, V123, P445, DOI 10.1084/jem.123.3.445; Munoz-Elias EJ, 2005, NAT MED, V11, P638, DOI 10.1038/nm1252; PAZNOKAS JL, 1977, BIOCHIM BIOPHYS ACTA, V487, P405, DOI 10.1016/0005-2760(77)90212-0; Russell DG, 2003, NAT CELL BIOL, V5, P776, DOI 10.1038/ncb0903-776; SEGAL W, 1956, J BACTERIOL, V72, P132, DOI 10.1128/JB.72.2.132-141.1956; Sirakova TD, 2001, J BIOL CHEM, V276, P16833, DOI 10.1074/jbc.M011468200; Vereecke D, 2002, TRENDS MICROBIOL, V10, P485, DOI 10.1016/S0966-842X(02)02457-5; Voskuil MI, 2004, TUBERCULOSIS, V84, P256, DOI 10.1016/j.tube.2003.12.014; Wayne LG, 2001, ANNU REV MICROBIOL, V55, P139, DOI 10.1146/annurev.micro.55.1.139; Wei YY, 1999, NAT STRUCT BIOL, V6, P340; *WHO, 2005, GLOB ACT CANC NOW, P24; *WHO IUATLD GLOB P, 2004, ANT DRUG RES WORLD 3, P13; Zahrt TC, 2003, MICROBES INFECT, V5, P159, DOI 10.1016/S1286-4579(02)00083-7; Zhang M, 2005, PROTEIN EXPRES PURIF, V42, P59, DOI 10.1016/j.pep.2005.03.022	33	211	223	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 17	2006	281	7					3866	3875		10.1074/jbc.M505556200	http://dx.doi.org/10.1074/jbc.M505556200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	011NN	16354661	Green Accepted, hybrid, Green Published			2022-12-25	WOS:000235275300014
J	Hallows, KR; Fitch, AC; Richardson, CA; Reynolds, PR; Clancy, JP; Dagher, PC; Witters, LA; Kolls, JK; Pilewski, JM				Hallows, KR; Fitch, AC; Richardson, CA; Reynolds, PR; Clancy, JP; Dagher, PC; Witters, LA; Kolls, JK; Pilewski, JM			Up-regulation of AMP-activated kinase by dysfunctional cystic fibrosis transmembrane conductance regulator in cystic fibrosis airway epithelial cells mitigates excessive inflammation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE; C-SRC; 5-AMINOIMIDAZOLE-4-CARBOXAMIDE RIBONUCLEOSIDE; UPSTREAM KINASE; LUNG; EXPRESSION; CFTR; TRANSPORT; GROWTH; BETA	AMP-activatedkinase (AMPK) is a ubiquitous metabolic sensor that inhibits the cystic fibrosis (CF) transmembrane conductance regulator (CFTR). To determine whether CFTR reciprocally regulates AMPK function in airway epithelia and whether such regulation is involved in lung inflammation, AMPK localization, expression, and activity and cellular metabolic profiles were compared as a function of CFTR status in CF and non-CF primary human bronchial epithelial (HBE) cells. As compared with non-CF HBE cells, CF cells had greater and more diffuse AMPK staining and had greater AMPK activity than their morphologically matched non-CF counterparts. The cellular [AMP]/[ATP] ratio was higher in undifferentiated than in differentiated non-CF cells, which correlated with AMPK activity under these conditions. However, this nucleotide ratio did not predict AMPK activity in differentiating CF cells. Inhibiting channel activity in non-CF cells did not affect AMPK activity or metabolic status, but expressing functional CFTR in CF cells reduced AMPK activity without affecting cellular [AMP]/[ATP]. Therefore, lack of functional CFTR expression and not loss of channel activity in CF cells appears to up-regulate AMPK activity in CF HBE cells, presumably through non- metabolic effects on upstream regulatory pathways. Compared with wild-type CFTR-expressing immortalized CF bronchial epithelial (CFBE) cells, Delta F508CFTR-expressing CFBE cells had greater AMPK activity and greater secretion of tumor necrosis factor-alpha and the interleukins IL-6 and IL-8. Further pharmacologic AMPK activation inhibited inflammatory mediator secretion in both wild type- and Delta F508-expressing cells, suggesting that AMPK activation in CF airway cells is an adaptive response that reduces inflammation. We propose that therapies to activate AMPK in the CF airway may be beneficial in reducing excessive airway inflammation, a major cause of CF morbidity.	Univ Pittsburgh, Dept Med, Sch Med, Pittsburgh, PA 15261 USA; Univ Pittsburgh, Dept Pediat, Sch Med, Pittsburgh, PA 15261 USA; Univ Pittsburgh, Ctr Environm & Occupat Hlth, Sch Med, Pittsburgh, PA 15261 USA; Dartmouth Med Sch, Dept Med, Hanover, NH 03755 USA; Dartmouth Med Sch, Dept Biochem, Hanover, NH 03755 USA; Univ Alabama Birmingham, Dept Pediat, Birmingham, AL 35233 USA; Univ Alabama Birmingham, Dept Med, Birmingham, AL 35233 USA; Indiana Univ, Dept Med, Indianapolis, IN 46202 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Dartmouth College; Dartmouth College; University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham; Indiana University System; Indiana University-Purdue University Indianapolis	Hallows, KR (corresponding author), Univ Pittsburgh, Dept Med, Sch Med, S976 Scaife Hall,3550 Terrace St, Pittsburgh, PA 15261 USA.	hallows@pitt.edu	Pilewski, Joseph/AAF-5149-2021; Kolls, Jay/AAH-1829-2019	Kolls, Jay/0000-0001-5151-6304; Hallows, Kenneth/0000-0002-2964-2440	NHLBI NIH HHS [R01-HL067088] Funding Source: Medline; NIDDK NIH HHS [K08-DK059477, R03 DK068390-01, K08 DK059477-05, R01-DK060495, P30-DK072506, K08 DK059477, R03 DK068390-02, K08 DK059477-04, R03 DK068390, R01-DK035712] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL067088] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R03DK068390, P30DK072506, K08DK059477, R01DK035712, R01DK060495] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Altarejos JY, 2005, J BIOL CHEM, V280, P183, DOI 10.1074/jbc.M411810200; AU JLS, 1989, CLIN CHEM, V35, P48; Bebok Z, 2005, J PHYSIOL-LONDON, V569, P601, DOI 10.1113/jphysiol.2005.096669; Becker MN, 2004, AM J RESP CRIT CARE, V169, P645, DOI 10.1164/rccm.200207-765OC; Berger M, 2002, ALLERGY ASTHMA PROC, V23, P19; Boucher RC, 2004, EUR RESPIR J, V23, P146, DOI 10.1183/09031936.03.00057003; Bruscia E, 2002, GENE THER, V9, P683, DOI 10.1038/sj.gt.3301741; Butterworth MB, 2005, J GEN PHYSIOL, V125, P81, DOI 10.1085/jgp.2004.09124; Carattino MD, 2005, J BIOL CHEM, V280, P17608, DOI 10.1074/jbc.M501770200; CARLING D, 1989, EUR J BIOCHEM, V186, P129, DOI 10.1111/j.1432-1033.1989.tb15186.x; Carling D, 2004, TRENDS BIOCHEM SCI, V29, P18, DOI 10.1016/j.tibs.2003.11.005; Chmiel JF, 2003, RESPIR RES, V4, DOI 10.1186/1465-9921-4-8; Chmiel JF, 2002, CLIN REV ALLERG IMMU, V23, P5, DOI 10.1385/CRIAI:23:1:005; CORTON JM, 1995, EUR J BIOCHEM, V229, P558, DOI 10.1111/j.1432-1033.1995.0558k.x; Coyne CB, 2000, AM J RESP CELL MOL, V23, P602, DOI 10.1165/ajrcmb.23.5.4164; CRAWFORD I, 1991, P NATL ACAD SCI USA, V88, P9262, DOI 10.1073/pnas.88.20.9262; Dagenais A, 2004, AM J PHYSIOL-LUNG C, V286, pL301, DOI 10.1152/ajplung.00326.2002; Dagher PC, 2000, AM J PHYSIOL-CELL PH, V279, pC1270, DOI 10.1152/ajpcell.2000.279.4.C1270; Devor DC, 1999, AM J PHYSIOL-CELL PH, V276, pC827, DOI 10.1152/ajpcell.1999.276.4.C827; DUPUIT F, 1995, GENE THER, V2, P156; Freedman SD, 2004, NEW ENGL J MED, V350, P560, DOI 10.1056/NEJMoa021218; Giri S, 2004, J NEUROSCI, V24, P479, DOI 10.1523/JNEUROSCI.4288-03.2004; Gonzalez-Guerrico AM, 2002, J BIOL CHEM, V277, P17239, DOI 10.1074/jbc.M112456200; GRUNE T, 1991, J CHROMATOGR-BIOMED, V563, P53, DOI 10.1016/0378-4347(91)80276-I; Hallows KR, 2003, AM J PHYSIOL-CELL PH, V284, pC1297, DOI 10.1152/ajpcell.00227.2002; Hallows KR, 2005, CURR OPIN NEPHROL HY, V14, P464, DOI 10.1097/01.mnh.0000174145.14798.64; Hallows KR, 2003, J BIOL CHEM, V278, P998, DOI 10.1074/jbc.M210621200; Hallows KR, 2000, J CLIN INVEST, V105, P1711, DOI 10.1172/JCI9622; Hamilton SR, 2001, FEBS LETT, V500, P163, DOI 10.1016/S0014-5793(01)02602-3; Hardie DG, 2004, J CELL SCI, V117, P5479, DOI 10.1242/jcs.01540; Hardie DG, 1998, ANNU REV BIOCHEM, V67, P821, DOI 10.1146/annurev.biochem.67.1.821; Hawley SA, 2005, CELL METAB, V2, P9, DOI 10.1016/j.cmet.2005.05.009; Hawley Simon A, 2003, J Biol, V2, P28, DOI 10.1186/1475-4924-2-28; Huang S, 2003, J BIOL CHEM, V278, P8326, DOI 10.1074/jbc.M208264200; Hurley RL, 2005, J BIOL CHEM, V280, P29060, DOI 10.1074/jbc.M503824200; Kelley TJ, 2001, AM J RESP CELL MOL, V25, P732, DOI 10.1165/ajrcmb.25.6.4574; Kelley TJ, 1998, J CLIN INVEST, V102, P1200, DOI 10.1172/JCI2357; Kemp BE, 2003, BIOCHEM SOC T, V31, P162; Koehler DR, 2004, AM J RESP CELL MOL, V31, P377, DOI 10.1165/rcmb.2004-0124TR; Kreiselmeier NE, 2003, AM J PHYSIOL-LUNG C, V285, pL1286, DOI 10.1152/ajplung.00127.2003; Kube D, 2001, AM J PHYSIOL-LUNG C, V280, pL493, DOI 10.1152/ajplung.2001.280.3.L493; Kunzelmann K, 1999, Rev Physiol Biochem Pharmacol, V137, P1; Lee JY, 2004, AM J RESP CELL MOL, V31, P234, DOI 10.1165/rcmb.2003-0447OC; Lei DC, 1996, GENE THER, V3, P427; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; Ma TH, 2002, J CLIN INVEST, V110, P1651, DOI 10.1172/JCI200216112; Mall M, 2004, NAT MED, V10, P487, DOI 10.1038/nm1028; McAllister F, 2005, J IMMUNOL, V175, P404, DOI 10.4049/jimmunol.175.1.404; Nath N, 2005, J IMMUNOL, V175, P566, DOI 10.4049/jimmunol.175.1.566; Picciano JA, 2003, AM J PHYSIOL-CELL PH, V285, pC1009, DOI 10.1152/ajpcell.00140.2003; Pilewski JM, 1999, PHYSIOL REV, V79, P215; Puchelle Edith, 2002, Paediatr Respir Rev, V3, P115, DOI 10.1016/S1526-0550(02)00005-7; Ribeiro CMP, 2005, J BIOL CHEM, V280, P10202, DOI 10.1074/jbc.M410317200; Ribeiro CMP, 2005, J BIOL CHEM, V280, P17798, DOI 10.1074/jbc.M410618200; Sakamoto K, 2004, AM J PHYSIOL-ENDOC M, V287, pE310, DOI 10.1152/ajpendo.00074.2004; Schwiebert LM, 1999, AM J PHYSIOL-CELL PH, V276, pC700, DOI 10.1152/ajpcell.1999.276.3.C700; Soltys J, 2002, J IMMUNOL, V168, P1903, DOI 10.4049/jimmunol.168.4.1903; Stein SC, 2000, BIOCHEM J, V345, P437, DOI 10.1042/0264-6021:3450437; Venkatakrishnan A, 2000, AM J RESP CELL MOL, V23, P396, DOI 10.1165/ajrcmb.23.3.3949; Weber AJ, 2001, AM J PHYSIOL-LUNG C, V281, pL71, DOI 10.1152/ajplung.2001.281.1.L71; WELSH MJ, 1995, SCI AM, V273, P52, DOI 10.1038/scientificamerican1295-52; Woods A, 2003, CURR BIOL, V13, P2004, DOI 10.1016/j.cub.2003.10.031; Woods A, 2005, CELL METAB, V2, P21, DOI 10.1016/j.cmet.2005.06.005; Woollhead AM, 2005, J PHYSIOL-LONDON, V566, P781, DOI 10.1113/jphysiol.2005.088674; Zou MH, 2004, J BIOL CHEM, V279, P43940, DOI 10.1074/jbc.M404421200; Zou MH, 2003, J BIOL CHEM, V278, P34003, DOI 10.1074/jbc.M300215200	66	58	58	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 17	2006	281	7					4231	4241		10.1074/jbc.M511029200	http://dx.doi.org/10.1074/jbc.M511029200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	011NN	16361706	hybrid			2022-12-25	WOS:000235275300056
J	Milne, JLS; Wu, XW; Borgnia, MJ; Lengyel, JS; Brooks, BR; Shi, D; Perham, RN; Subramaniam, S				Milne, JLS; Wu, XW; Borgnia, MJ; Lengyel, JS; Brooks, BR; Shi, D; Perham, RN; Subramaniam, S			Molecular structure of a 9-MDa icosahedral pyruvate dehydrogenase subcomplex containing the E2 and E3 enzymes using cryoelectron microscopy	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SUBUNIT-BINDING DOMAIN; MULTIENZYME COMPLEX; BACILLUS-STEAROTHERMOPHILUS; ESCHERICHIA-COLI; DIHYDROLIPOAMIDE ACETYLTRANSFERASE; 3-DIMENSIONAL STRUCTURE; COMPONENT ENZYMES; PROTEIN; E1; VISUALIZATION	The pyruvate dehydrogenase multienzyme complexes are among the largest multifunctional catalytic machines in cells, catalyzing the production of acetyl CoA from pyruvate. We have previously reported the molecular architecture of an 11-MDa subcomplex comprising the 60-mer icosahedral dihydrolipoyl acetyltransferase (E2) decorated with 60 copies of the heterotetrameric (alpha(2)beta(2)) 153-kDa pyruvate decarboxylase (E1) from Bacillus stearothermophilus (Milne, J. L. S., Shi, D., Rosenthal, P. B., Sunshine, J. S., Domingo, G. J., Wu, X., Brooks, B. R., Perham, R. N., Henderson, R., and Subramaniam, S. (2002) EMBO J. 21, 5587-5598). An annular gap of similar to 90 angstrom separates the acetyltransferase catalytic domains of the E2 from an outer shell formed of E1 tetramers. Using cryoelectron microscopy, we present here a three-dimensional reconstruction of the E2 core decorated with 60 copies of the homodimeric 100-kDa dihydrolipoyl dehydrogenase (E3). The E2E3 complex has a similar annular gap of similar to 75 angstrom between the inner icosahedral assembly of acetyltransferase domains and the outer shell of E3 homodimers. Automated fitting of the E3 coordinates into the map suggests excellent correspondence between the density of the outer shell map and the positions of the two best fitting orientations of E3. As in the case of E1 in the E1E2 complex, the central 2-fold axis of the E3 homodimer is roughly oriented along the periphery of the shell, making the active sites of the enzyme accessible from the annular gap between the E2 core and the outer shell. The similarities in architecture of the E1E2 and E2E3 complexes indicate fundamental similarities in the mechanism of active site coupling involved in the two key stages requiring motion of the swinging lipoyl domain across the annular gap, namely the synthesis of acetyl CoA and regeneration of the dithiolane ring of the lipoyl domain.	NCI, Cell Biol Lab, NIH, Bethesda, MD 20892 USA; NHLBI, Lab Computat Biol, NIH, Bethesda, MD 20892 USA; Univ Cambridge, Cambridge Ctr Mol Recognit, Dept Biochem, Cambridge CB2 1GA, England	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI); University of Cambridge	Milne, JLS (corresponding author), NCI, Cell Biol Lab, NIH, Bldg 50 Rm 4306,50 S Dr, Bethesda, MD 20892 USA.	jmilne@nih.gov	wang, zm/AAE-1021-2019	wang, zm/0000-0003-2966-7282; Subramaniam, Sriram/0000-0003-4231-4115; Borgnia, Mario/0000-0001-9159-1413	NATIONAL CANCER INSTITUTE [Z01BC010278, ZIABC010278] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [ZIAHL001051, ZIAHL001027, Z01HL001027, Z01HL001051] Funding Source: NIH RePORTER	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AEvarsson A, 1999, NAT STRUCT BIOL, V6, P785; Allen MD, 2005, FEBS J, V272, P259, DOI 10.1111/j.1432-1033.2004.04405.x; Arjunan P, 2002, BIOCHEMISTRY-US, V41, P5213, DOI 10.1021/bi0118557; Borgnia MJ, 2004, J STRUCT BIOL, V147, P136, DOI 10.1016/j.jsb.2004.02.007; BROOKS BR, 1983, J COMPUT CHEM, V4, P187, DOI 10.1002/jcc.540040211; Chauhan HJ, 2000, EUR J BIOCHEM, V267, P7158, DOI 10.1046/j.1432-1327.2000.01820.x; Crowther RA, 1996, J STRUCT BIOL, V116, P9, DOI 10.1006/jsbi.1996.0003; DARDEL F, 1993, J MOL BIOL, V229, P1037, DOI 10.1006/jmbi.1993.1103; Domingo GJ, 1999, EUR J BIOCHEM, V266, P1136, DOI 10.1046/j.1432-1327.1999.00966.x; Frank RAW, 2005, STRUCTURE, V13, P1119, DOI 10.1016/j.str.2005.04.021; Frank RAW, 2004, SCIENCE, V306, P872, DOI 10.1126/science.1101030; Fries M, 2003, EUR J BIOCHEM, V270, P861, DOI 10.1046/j.1432-1033.2003.03444.x; Grigorieff N, 1998, J MOL BIOL, V277, P1033, DOI 10.1006/jmbi.1998.1668; Gu YQ, 2003, P NATL ACAD SCI USA, V100, P7015, DOI 10.1073/pnas.0732060100; Harris M, 2001, ACTA CRYSTALLOGR D, V57, P1201, DOI 10.1107/S0907444901007697; Hiromasa Y, 2004, J BIOL CHEM, V279, P6921, DOI 10.1074/jbc.M308172200; Humphrey W, 1996, J MOL GRAPH MODEL, V14, P33, DOI 10.1016/0263-7855(96)00018-5; Izard T, 1999, P NATL ACAD SCI USA, V96, P1240, DOI 10.1073/pnas.96.4.1240; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Jung HI, 2003, FEBS LETT, V555, P405, DOI 10.1016/S0014-5793(03)01245-6; Jung HI, 2003, EUR J BIOCHEM, V270, P4488, DOI 10.1046/j.1432-1033.2003.03842.x; KALIA YN, 1993, J MOL BIOL, V230, P323, DOI 10.1006/jmbi.1993.1145; Lessard IAD, 1996, BIOCHEMISTRY-US, V35, P16863, DOI 10.1021/bi961683r; Lessard IAD, 1998, EUR J BIOCHEM, V258, P491, DOI 10.1046/j.1432-1327.1998.2580491.x; LESSARD IAD, 1995, BIOCHEM J, V306, P727, DOI 10.1042/bj3060727; Mande SS, 1996, STRUCTURE, V4, P277, DOI 10.1016/S0969-2126(96)00032-9; Milne JLS, 2002, EMBO J, V21, P5587, DOI 10.1093/emboj/cdf574; PATEL MS, 1995, FASEB J, V9, P1164, DOI 10.1096/fasebj.9.12.7672509; Perham RN, 2000, ANNU REV BIOCHEM, V69, P961, DOI 10.1146/annurev.biochem.69.1.961; PERHAM RN, 1991, BIOCHEMISTRY-US, V30, P8501, DOI 10.1021/bi00099a001; Pettersen EF, 2004, J COMPUT CHEM, V25, P1605, DOI 10.1002/jcc.20084; RADFORD SE, 1989, J BIOL CHEM, V264, P767; REED LJ, 1990, J BIOL CHEM, V265, P8971; Rost B, 1996, METHOD ENZYMOL, V266, P525; Smith JM, 1999, J STRUCT BIOL, V125, P223, DOI 10.1006/jsbi.1998.4073; Stoops JK, 1997, J BIOL CHEM, V272, P5757, DOI 10.1074/jbc.272.9.5757; VANHEEL M, 1987, ULTRAMICROSCOPY, V21, P95, DOI 10.1016/0304-3991(87)90010-6; vanHeel M, 1996, J STRUCT BIOL, V116, P17, DOI 10.1006/jsbi.1996.0004; WAGENKNECHT T, 1992, J STRUCT BIOL, V109, P70, DOI 10.1016/1047-8477(92)90069-M; WAGENKNECHT T, 1991, J BIOL CHEM, V266, P24650; WAGENKNECHT T, 1990, J BIOL CHEM, V265, P22402; Wu XW, 2003, J STRUCT BIOL, V141, P63, DOI 10.1016/S1047-8477(02)00570-1; Yeaman SJ, 2000, IMMUNOL REV, V174, P238, DOI 10.1034/j.1600-0528.2002.00021h.x; Zhou ZH, 2001, P NATL ACAD SCI USA, V98, P14802, DOI 10.1073/pnas.011597698	44	51	53	1	22	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 17	2006	281	7					4364	4370		10.1074/jbc.M504363200	http://dx.doi.org/10.1074/jbc.M504363200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	011NN	16308322	Green Accepted, hybrid			2022-12-25	WOS:000235275300072
J	Ryo, A; Togo, T; Nakai, T; Hirai, A; Nishi, M; Yamaguchi, A; Suzuki, K; Hirayasu, Y; Kobayashi, H; Perrem, K; Liou, YC; Aoki, I				Ryo, A; Togo, T; Nakai, T; Hirai, A; Nishi, M; Yamaguchi, A; Suzuki, K; Hirayasu, Y; Kobayashi, H; Perrem, K; Liou, YC; Aoki, I			Prolyl-isomerase Pin1 accumulates in Lewy bodies of Parkinson disease and facilitates formation of alpha-synuclein inclusions	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BODY FORMATION; DROSOPHILA MODEL; SYNPHILIN-1; PHOSPHORYLATION; PROTEIN; UBIQUITINATION; AGGREGATION; DEGRADATION; CANCER; NEURODEGENERATION	Parkinson disease (PD) is a relatively common neurodegenerative disorder that is characterized by the loss of dopaminergic neurons and by the formation of Lewy bodies (LBs), which are cytoplasmic inclusions containing aggregates of alpha-synuclein. Although certain post-translational modifications of alpha-synuclein and its related proteins are implicated in the genesis of LBs, the specific molecular mechanisms that both regulate these processes and initiate subsequent inclusion body formation are not yet well understood. We demonstrate in our current study, however, that the prolyl-isomerase Pin1 localizes to the LBs in PD brain tissue and thereby enhances the formation of alpha-synuclein immunoreactive inclusions. Immunohistochemical analysis of brain tissue from PD patients revealed that Pin1 localizes to 50-60% of the LBs that show an intense halo pattern resembling that of alpha-synuclein. By utilizing a cellular model of alpha-synuclein aggregation, we also demonstrate that, whereas Pin1 overexpression facilitates the formation of alpha-synuclein inclusions, dominant-negative Pin1 expression significantly suppresses this process. Consistent with these observations, Pin1 overexpression enhances the protein half-life and insolubility of alpha-synuclein. Finally, we show that Pin1 binds synphilin-1, an alpha-synuclein partner, via its Ser-211-Pro and Ser-215-Pro motifs, and enhances its interaction with alpha-synuclein, thus likely facilitating the formation of alpha-synuclein inclusions. These results indicate that Pin1-mediated prolyl-isomerization plays a pivotal role in a post-translational modification pathway for alpha-synuclein aggregation and in the resultant Lewy body formations in PD.	Yokohama City Univ, Sch Med, Dept Pathol, Kanazawa Ku, Yokohama, Kanagawa 2360004, Japan; Yokohama City Univ, Sch Med, Dept Psychiat, Kanazawa Ku, Yokohama, Kanagawa 2360004, Japan; Yokohama City Univ, Sch Med, Radioisotope Res Ctr, Kanazawa Ku, Yokohama, Kanagawa 2360004, Japan; Kyushu Univ, Grad Sch Med Sci, Dept Mol Biol, Higashi Ku, Fukuoka 8128582, Japan; Beaumont Hosp, Royal Coll Surg Ireland, Dept Pathol, Mol Oncol Lab, Dublin 9, Ireland; Natl Univ Singapore, Dept Biochem, Singapore 117543, Singapore; Natl Univ Singapore, Dept Biol Sci, Singapore 117543, Singapore	Yokohama City University; Yokohama City University; Yokohama City University; Kyushu University; Royal College of Surgeons - Ireland; National University of Singapore; National University of Singapore	Ryo, A (corresponding author), Yokohama City Univ, Sch Med, Dept Pathol, Kanazawa Ku, 3-9 Fuku Ura, Yokohama, Kanagawa 2360004, Japan.	aryo@yokohama-cu.ac.jp						Alim MA, 2002, J BIOL CHEM, V277, P2112, DOI 10.1074/jbc.M102981200; Auluck PK, 2002, SCIENCE, V295, P865, DOI 10.1126/science.1067389; Baba M, 1998, AM J PATHOL, V152, P879; Chen L, 2005, NAT NEUROSCI, V8, P657, DOI 10.1038/nn1443; Chung KKK, 2001, NAT MED, V7, P1144, DOI 10.1038/nm1001-1144; Cuervo AM, 2004, SCIENCE, V305, P1292, DOI 10.1126/science.1101738; Dunnett SB, 1999, NATURE, V399, pA32, DOI 10.1038/399a032; Engelender S, 1999, NAT GENET, V22, P110, DOI 10.1038/8820; Fujiwara H, 2002, NAT CELL BIOL, V4, P160, DOI 10.1038/ncb748; Geschwind DH, 2003, NEURON, V40, P457, DOI 10.1016/S0896-6273(03)00681-0; Giasson BI, 2003, CELL, V114, P1, DOI 10.1016/S0092-8674(03)00509-9; Goers J, 2003, BIOCHEMISTRY-US, V42, P8465, DOI 10.1021/bi0341152; GOLDMAN JE, 1983, SCIENCE, V221, P1082, DOI 10.1126/science.6308771; Iseki E, 2002, NEUROSCI LETT, V326, P211, DOI 10.1016/S0304-3940(02)00418-4; Ito T, 2003, J BIOL CHEM, V278, P29106, DOI 10.1074/jbc.M302763200; Joseph James D, 2003, Prog Cell Cycle Res, V5, P477; Klucken J, 2004, J BIOL CHEM, V279, P25497, DOI 10.1074/jbc.M400255200; Kruger R, 1998, NAT GENET, V18, P106, DOI 10.1038/ng0298-106; Lee G, 2004, J BIOL CHEM, V279, P6834, DOI 10.1074/jbc.M312760200; Liani E, 2004, P NATL ACAD SCI USA, V101, P5500, DOI 10.1073/pnas.0401081101; Lim KL, 2005, J NEUROSCI, V25, P2002, DOI 10.1523/JNEUROSCI.4474-04.2005; Lindersson E, 2005, J BIOL CHEM, V280, P5703, DOI 10.1074/jbc.M410409200; Liou YC, 2003, NATURE, V424, P556, DOI 10.1038/nature01832; Lotharius J, 2002, NAT REV NEUROSCI, V3, P932, DOI 10.1038/nrn983; Lu KP, 2004, TRENDS BIOCHEM SCI, V29, P200, DOI 10.1016/j.tibs.2004.02.002; Lu PJ, 1999, NATURE, V399, P784; Lundvig D, 2005, MOL BRAIN RES, V134, P3, DOI 10.1016/j.molbrainres.2004.09.001; Messenger MM, 2002, J BIOL CHEM, V277, P23054, DOI 10.1074/jbc.M200111200; Nagano Y, 2003, J BIOL CHEM, V278, P51504, DOI 10.1074/jbc.M306347200; O'Farrell C, 2001, MOL BRAIN RES, V97, P94, DOI 10.1016/S0169-328X(01)00292-3; Okochi M, 2000, J BIOL CHEM, V275, P390, DOI 10.1074/jbc.275.1.390; Polymeropoulos MH, 1997, SCIENCE, V276, P2045, DOI 10.1126/science.276.5321.2045; Recchia A, 2004, FASEB J, V18, P617, DOI 10.1096/fj.03-0338rev; Ryo A, 2003, J CELL SCI, V116, P773, DOI 10.1242/jcs.00276; Ryo A, 2005, CLIN CANCER RES, V11, P7523, DOI 10.1158/1078-0432.CCR-05-0457; Ryo A, 2003, MOL CELL, V12, P1413, DOI 10.1016/S1097-2765(03)00490-8; Ryo A, 2001, NAT CELL BIOL, V3, P793, DOI 10.1038/ncb0901-793; Shin YG, 2005, J BIOL CHEM, V280, P23727, DOI 10.1074/jbc.M503326200; Spillantini MG, 1997, NATURE, V388, P839, DOI 10.1038/42166; Suzuki K, 2003, NEUROREPORT, V14, P551, DOI 10.1097/00001756-200303240-00004; Tanaka M, 2004, J BIOL CHEM, V279, P4625, DOI 10.1074/jbc.M310994200; Zhou XZ, 2000, MOL CELL, V6, P873, DOI 10.1016/S1097-2765(00)00085-X	42	69	70	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 17	2006	281	7					4117	4125		10.1074/jbc.M507026200	http://dx.doi.org/10.1074/jbc.M507026200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	011NN	16365047	hybrid			2022-12-25	WOS:000235275300042
J	Figueiredo, KA; Mui, AL; Nelson, CC; Cox, ME				Figueiredo, KA; Mui, AL; Nelson, CC; Cox, ME			Relaxin stimulates leukocyte adhesion and migration through a relaxin receptor LGR7-dependent mechanism	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NITRIC-OXIDE PATHWAY; ENDOMETRIAL STROMAL CELLS; ENDOTHELIAL GROWTH-FACTOR; HUMAN MONOCYTE CHEMOTAXIS; HUMAN DECIDUAL RELAXIN; BREAST-CANCER CELLS; IN-VITRO; MATRIX METALLOPROTEINASE-1; AUTOCRINE/PARACRINE ROLE; PROSTATE ADENOCARCINOMA	Leukocytes are critical effectors of inflammation and tumor biology. Chemokine-like factors produced by such inflammatory sites are key mediators of tumor growth that activate leukocytic recruitment and tumor infiltration and suppress immune surveillance. Here we report that the endocrine peptide hormone, relaxin, is a regulator of leukocyte biology with properties important in recruitment to sites of inflammation. This study uses the human monocytic cell line THP-1 and normal human peripheral blood mononuclear cells to define a novel role for relaxin in regulation of leukocyte adhesion and migration. Our studies indicate that relaxin promotes adenylate cyclase activation, substrate adhesion, and migratory capacity of mononuclear leukocytes through a relaxin receptor LGR7-dependent mechanism. Relaxin-stimulated cAMP accumulation was observed to occur primarily in non-adherent cells. Relaxin stimulation results in increased substrate adhesion and increased migratory activity of leukocytes. In addition, relaxin-stimulated substrate adhesion resulted in enhanced chemotaxis to monocyte chemoattractant protein-1. These responses in THP-1 and peripheral blood mononuclear cells are relaxin dose-dependent and proportional to cAMP accumulation. We further demonstrate that LGR7 is critical for mediating these biological responses by use of RNA interference lentiviral short hairpin constructs. In summary, we provide evidence that relaxin is a novel leukocyte stimulatory agent with properties affecting adhesion and chemomigration.	Vancouver Gen Hosp, Prostate Ctr, Vancouver, BC V6H 3Z6, Canada; Univ British Columbia, Genet Program, Vancouver, BC V5Z 1M9, Canada; Univ British Columbia, Dept Surg, Vancouver, BC V5Z 1M9, Canada	University of British Columbia; University of British Columbia; University of British Columbia	Cox, ME (corresponding author), Vancouver Gen Hosp, Prostate Ctr, 2660 Oak St, Vancouver, BC V6H 3Z6, Canada.	michael.cox@vch.ca						Anderson DM, 1997, NATURE, V390, P175, DOI 10.1038/36593; ANWER K, 1993, AM J PHYSIOL, V265, P976; AUWERX J, 1991, EXPERIENTIA, V47, P22, DOI 10.1007/BF02041244; Bani D, 1999, ENDOCRINOLOGY, V140, P4434, DOI 10.1210/en.140.10.4434; Bani D, 1998, HYPERTENSION, V31, P1240, DOI 10.1161/01.HYP.31.6.1240; Bani D, 1997, GEN PHARMACOL-VASC S, V28, P13, DOI 10.1016/S0306-3623(96)00171-1; BANI D, 1995, CANCER RES, V55, P5272; BANI D, 1995, LAB INVEST, V73, P709; Bani D, 2002, INT IMMUNOPHARMACOL, V2, P1195, DOI 10.1016/S1567-5769(02)00079-6; BANISACCHI T, 1995, BRIT J PHARMACOL, V116, P1589, DOI 10.1111/j.1476-5381.1995.tb16377.x; Bartsch O, 2001, MOL HUM REPROD, V7, P799, DOI 10.1093/molehr/7.9.799; Bathgate RAD, 2003, TRENDS ENDOCRIN MET, V14, P207, DOI 10.1016/S1043-2760(03)00081-X; Binder C, 2002, MOL HUM REPROD, V8, P789, DOI 10.1093/molehr/8.9.789; Binder C, 2004, BREAST CANCER RES TR, V87, P157, DOI 10.1023/B:BREA.0000041622.30169.16; BOYDEN S, 1962, J EXP MED, V115, P453, DOI 10.1084/jem.115.3.453; Breuil V, 2003, FASEB J, V17, P1751, DOI 10.1096/fj.02-1188fje; Brookes DE, 1998, PROSTATE, V35, P18, DOI 10.1002/(SICI)1097-0045(19980401)35:1<18::AID-PROS3>3.0.CO;2-D; BURNS JC, 1993, P NATL ACAD SCI USA, V90, P8033, DOI 10.1073/pnas.90.17.8033; Carnevale KA, 2003, J BIOL CHEM, V278, P25317, DOI 10.1074/jbc.M304182200; Coussens LM, 2002, NATURE, V420, P860, DOI 10.1038/nature01322; CRONIN MJ, 1987, BIOCHEM BIOPH RES CO, V148, P1246, DOI 10.1016/S0006-291X(87)80266-8; DVORAK HF, 1986, NEW ENGL J MED, V315, P1650; Elbashir SM, 2001, EMBO J, V20, P6877, DOI 10.1093/emboj/20.23.6877; FEI DTW, 1990, BIOCHEM BIOPH RES CO, V170, P214, DOI 10.1016/0006-291X(90)91262-Q; Figueiredo KA, 2005, ANN NY ACAD SCI, V1041, P320, DOI 10.1196/annals.1282.051; GAO JG, 1994, MOL CELL ENDOCRINOL, V104, P39, DOI 10.1016/0303-7207(94)90049-3; Gerszten RE, 1999, NATURE, V398, P718, DOI 10.1038/19546; GUNNERSEN JM, 1995, J MOL ENDOCRINOL, V15, P153, DOI 10.1677/jme.0.0150153; HANSELL DJ, 1991, J CLIN ENDOCR METAB, V72, P899, DOI 10.1210/jcem-72-4-899; Hsu SY, 2002, SCIENCE, V295, P671, DOI 10.1126/science.1065654; Imhof BA, 2004, NAT REV IMMUNOL, V4, P432, DOI 10.1038/nri1375; IVELL R, 1989, MOL CELL ENDOCRINOL, V66, P251, DOI 10.1016/0303-7207(89)90037-3; Ivell R, 2002, TRENDS ENDOCRIN MET, V13, P343, DOI 10.1016/S1043-2760(02)00664-1; Jones LJ, 2001, J IMMUNOL METHODS, V254, P85, DOI 10.1016/S0022-1759(01)00404-5; Kunkel SL, 1999, CONT CANC RES, P3; Kuznetsova L, 1999, REGUL PEPTIDES, V80, P33, DOI 10.1016/S0167-0115(99)00007-5; Lessey BA, 2002, MOL REPROD DEV, V62, P446, DOI 10.1002/mrd.10129; Li J, 2000, P NATL ACAD SCI USA, V97, P1566, DOI 10.1073/pnas.97.4.1566; Luque EH, 1998, BIOL REPROD, V59, P795, DOI 10.1095/biolreprod59.4.795; Masini E, 1997, ENDOCRINOLOGY, V138, P4713, DOI 10.1210/en.138.11.4713; Masini E, 2004, ENDOCRINOLOGY, V145, P1106, DOI 10.1210/en.2003-0833; MASINI E, 1994, J CLIN INVEST, V94, P1974, DOI 10.1172/JCI117549; MATSUSHIMA K, 1989, J EXP MED, V169, P1485, DOI 10.1084/jem.169.4.1485; MAZOUJIAN G, 1990, LANCET, V335, P298, DOI 10.1016/0140-6736(90)90124-N; Mazzucchelli L, 1996, AM J PATHOL, V149, P501; MEERA P, 1995, AM J PHYSIOL-CELL PH, V269, pC312, DOI 10.1152/ajpcell.1995.269.2.C312; Mosheimer BA, 2004, ARTHRITIS RHEUM-US, V50, P2309, DOI 10.1002/art.20352; Naldini L, 1996, P NATL ACAD SCI USA, V93, P11382, DOI 10.1073/pnas.93.21.11382; Nguyen BT, 2003, MOL ENDOCRINOL, V17, P1075, DOI 10.1210/me.2002-0284; Ohleth KM, 1999, STEROIDS, V64, P634, DOI 10.1016/S0039-128X(99)00045-8; OHLETH KM, 1995, BIOL REPROD, V53, P1286, DOI 10.1095/biolreprod53.6.1286; Paddison PJ, 2002, GENE DEV, V16, P948, DOI 10.1101/gad.981002; Palejwala S, 2001, ENDOCRINOLOGY, V142, P3405, DOI 10.1210/en.142.8.3405; Palejwala S, 2002, BIOL REPROD, V66, P1743, DOI 10.1095/biolreprod66.6.1743; Parsell DA, 1996, J BIOL CHEM, V271, P27936, DOI 10.1074/jbc.271.44.27936; Pedraza C, 2000, J IMMUNOL, V165, P5831, DOI 10.4049/jimmunol.165.10.5831; PLUNKETT ER, 1967, BRIT J CANCER, V21, P592, DOI 10.1038/bjc.1967.69; Qin XJ, 1997, BIOL REPROD, V56, P812, DOI 10.1095/biolreprod56.4.812; Qin XJ, 1997, BIOL REPROD, V56, P800, DOI 10.1095/biolreprod56.4.800; ROLLINS BJ, 1991, BLOOD, V78, P1112; Rossi D, 2000, ANNU REV IMMUNOL, V18, P217, DOI 10.1146/annurev.immunol.18.1.217; SACCHI TB, 1994, INT J CANCER, V57, P129, DOI 10.1002/ijc.2910570123; Saji H, 2001, CANCER, V92, P1085, DOI 10.1002/1097-0142(20010901)92:5<1085::AID-CNCR1424>3.0.CO;2-K; Samuel CS, 2003, LAB INVEST, V83, P1055, DOI 10.1097/01.LAB.0000079784.81186.B9; Silvertown JD, 2006, INT J CANCER, V118, P62, DOI 10.1002/ijc.21288; Silvertown JD, 2003, INT J CANCER, V107, P513, DOI 10.1002/ijc.11424; Silvertown JD, 2003, ENDOCRINOLOGY, V144, P3683, DOI 10.1210/en.2003-0248; SOKOL RZ, 1989, J HISTOCHEM CYTOCHEM, V37, P1253, DOI 10.1177/37.8.2666509; SOZZANI S, 1991, J IMMUNOL, V147, P2215; TASHIMA LS, 1994, J MOL ENDOCRINOL, V12, P351, DOI 10.1677/jme.0.0120351; Unemori EN, 2000, WOUND REPAIR REGEN, V8, P361, DOI 10.1111/j.1524-475X.2000.00361.x; UNEMORI EN, 1993, J INVEST DERMATOL, V101, P280, DOI 10.1111/1523-1747.ep12365206; Valkovic T, 1998, PATHOL RES PRACT, V194, P335, DOI 10.1016/S0344-0338(98)80057-5; WINSLOW JW, 1992, ENDOCRINOLOGY, V130, P2660, DOI 10.1210/en.130.5.2660; Wu XY, 2000, MOL THER, V2, P47, DOI 10.1006/mthe.2000.0095; Wyatt TA, 2002, EXP BIOL MED, V227, P1047, DOI 10.1177/153537020222701114; Yen HH, 1997, J LEUKOCYTE BIOL, V61, P529, DOI 10.1002/jlb.61.4.529; Zhang Q, 2002, J CELL BIOCHEM, V85, P536, DOI 10.1002/jcb.10150; ZIGMOND SH, 1973, J EXP MED, V137, P387, DOI 10.1084/jem.137.2.387	79	26	27	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 10	2006	281	6					3030	3039		10.1074/jbc.M506665200	http://dx.doi.org/10.1074/jbc.M506665200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	009QV	16303766	hybrid, Green Published			2022-12-25	WOS:000235128200005
J	Ma, SH; Musa, T; Bag, J				Ma, SH; Musa, T; Bag, J			Reduced stability of mitogen-activated protein kinase kinase-2 mRNA and phosphorylation of poly(A)-binding protein (PABP) in cells overexpressing PABP	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POLY(A) BINDING-PROTEIN; TRANSLATION INITIATION-FACTORS; IDENTIFICATION; EXPRESSION; ELEMENTS; DOMAINS; DEADENYLATION; INHIBITOR; INCREASE; REGION	The poly( A)- binding protein ( PABP) is an important regulator of mRNA translation and stability. The cellular level of PABP is controlled by regulating its mRNA translation by a feedback mechanism. The important aspect of this mechanism is that PABP binds to an adenosine-rich cis-element at the 5'-untranslated region of its own mRNA and inhibits its translation. To assess the importance of controlling the PABP level, we studied the effect of PABP overexpression on the transcription profile using the microarray technique. In PABP-overexpressing cells, 19 mRNAs showed a reduction in cellular levels due to reduced mRNA stability, and one showed an increase due to increased mRNA stability. Among these mRNAs, the MKK-2 mRNA encodes the protein kinase activator of ERK1/2 kinase, which is involved in the phosphorylation of eukaryotic initiation factor ( eIF) 4E. As a result, mRNA translation may be regulated by the cellular level of MKK-2. In this study, we show that the abundance of the MKK-2 polypeptide is reduced in PABP-overexpressing cells. In these cells, the levels of phosphorylated PABP, eIF4E, and ERK2 are also reduced. Treatment of HeLa cells with the MKK-2 inhibitor U0126 reduced PABP phosphorylation, suggesting that the phosphorylation of PABP is mediated by the MKK-2/ ERK signaling pathway. Thus, a novel signaling pathway involving MKK-2 and ERK1/2 may down-regulate the activity of PABP and eIF4E by controlling their phosphorylation and compensates for the effect of excess cellular PABP.	Univ Guelph, Dept Mol & Cellular Biol, Guelph, ON N1G 2W1, Canada	University of Guelph	Bag, J (corresponding author), Univ Guelph, Dept Mol & Cellular Biol, 50 Stone Rd, Guelph, ON N1G 2W1, Canada.	jbag@uoguelph.ca						ADAMOU J, 1992, EUR J BIOCHEM, V209, P803, DOI 10.1111/j.1432-1033.1992.tb17351.x; ALFONINA E, 1998, J BIOL CHEM, V273, P13015; Bag J, 1996, EUR J BIOCHEM, V237, P143, DOI 10.1111/j.1432-1033.1996.0143n.x; Bag J, 2001, J BIOL CHEM, V276, P47352, DOI 10.1074/jbc.M107676200; BERNSTEIN P, 1989, MOL CELL BIOL, V9, P659, DOI 10.1128/MCB.9.2.659; BOTH GW, 1975, P NATL ACAD SCI USA, V72, P1189, DOI 10.1073/pnas.72.3.1189; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BURD CG, 1991, MOL CELL BIOL, V11, P3419, DOI 10.1128/MCB.11.7.3419; CAPONIGRO G, 1995, GENE DEV, V9, P2421, DOI 10.1101/gad.9.19.2421; Chang TC, 2004, GENE DEV, V18, P2010, DOI 10.1101/gad.1219104; Deo RC, 1999, CELL, V98, P835, DOI 10.1016/S0092-8674(00)81517-2; Dever TE, 2002, CELL, V108, P545, DOI 10.1016/S0092-8674(02)00642-6; Favata MF, 1998, J BIOL CHEM, V273, P18623, DOI 10.1074/jbc.273.29.18623; Gallie DR, 1997, J BIOL CHEM, V272, P1046, DOI 10.1074/jbc.272.2.1046; Gebauer F, 2004, NAT REV MOL CELL BIO, V5, P827, DOI 10.1038/nrm1488; Gomez DE, 1997, EUR J CELL BIOL, V74, P111; GRANGE T, 1987, NUCLEIC ACIDS RES, V15, P4771, DOI 10.1093/nar/15.12.4771; Heid CA, 1996, GENOME RES, V6, P986, DOI 10.1101/gr.6.10.986; Hornstein E, 1999, FEBS LETT, V457, P209, DOI 10.1016/S0014-5793(99)01039-X; Hornstein E, 1999, J BIOL CHEM, V274, P1708, DOI 10.1074/jbc.274.3.1708; Imataka H, 1998, EMBO J, V17, P7480, DOI 10.1093/emboj/17.24.7480; Jacobson A., 1996, POLY A METABOLISM TR, P451; Kahvejian A, 2005, GENE DEV, V19, P104, DOI 10.1101/gad.1262905; Khaleghpour K, 2001, MOL CELL BIOL, V21, P5200, DOI 10.1128/MCB.21.15.5200-5213.2001; Kozak M, 2004, GENE, V343, P41, DOI 10.1016/j.gene.2004.08.011; Kozlov G, 2001, P NATL ACAD SCI USA, V98, P4409, DOI 10.1073/pnas.071024998; Kuhn U, 1996, J MOL BIOL, V256, P20, DOI 10.1006/jmbi.1996.0065; Le H, 2000, J BIOL CHEM, V275, P17452, DOI 10.1074/jbc.M001186200; Le H, 1997, J BIOL CHEM, V272, P16247, DOI 10.1074/jbc.272.26.16247; Liu XW, 2003, J BIOL CHEM, V278, P40364, DOI 10.1074/jbc.M302999200; Mangus DA, 2003, GENOME BIOL, V4, DOI 10.1186/gb-2003-4-7-223; Melo EO, 2003, J BIOL CHEM, V278, P46357, DOI 10.1074/jbc.M307624200; Mohr E, 2001, P NATL ACAD SCI USA, V98, P7072, DOI 10.1073/pnas.111146598; NETO OPD, 1995, NUCLEIC ACIDS RES, V23, P2198, DOI 10.1093/nar/23.12.2198; NIETFELD W, 1990, EMBO J, V9, P3699, DOI 10.1002/j.1460-2075.1990.tb07582.x; ORNBJERG WS, 2005, MOL CELL PROTEOMICS, V4, P483; Richter JD, 2005, NATURE, V433, P477, DOI 10.1038/nature03205; Roux PP, 2004, MICROBIOL MOL BIOL R, V68, P320, DOI 10.1128/MMBR.68.2.320-344.2004; Roy G, 2002, MOL CELL BIOL, V22, P3769, DOI 10.1128/MCB.22.11.3769-3782.2002; Scheper GC, 2001, MOL CELL BIOL, V21, P743, DOI 10.1128/MCB.21.3.743-754.2001; Sladic RT, 2004, EUR J BIOCHEM, V271, P450, DOI 10.1046/j.1432-1033.2003.03945.x; Tallada VA, 2002, YEAST, V19, P1139, DOI 10.1002/yea.902; Tarun SZ, 1996, EMBO J, V15, P7168, DOI 10.1002/j.1460-2075.1996.tb01108.x; THOMAS G, 1986, J CELL BIOL, V103, P2137, DOI 10.1083/jcb.103.6.2137; Thomson AM, 1999, BIOTECHNIQUES, V27, P1032, DOI 10.2144/99275rr03; TOWBIN H, 1984, J IMMUNOL METHODS, V72, P313, DOI 10.1016/0022-1759(84)90001-2; VEDA T, 2004, MOL CELL BIOL, V24, P6539; Verlaet M, 2001, BIOCHEM BIOPH RES CO, V283, P12, DOI 10.1006/bbrc.2001.4731; Wang ZR, 2000, MOL CELL BIOL, V20, P6334, DOI 10.1128/MCB.20.17.6334-6341.2000; Winzen R, 2004, MOL CELL BIOL, V24, P4835, DOI 10.1128/MCB.24.11.4835-4847.2004; Wormington M, 1996, EMBO J, V15, P900, DOI 10.1002/j.1460-2075.1996.tb00424.x; Wu J, 1998, J BIOL CHEM, V273, P34535, DOI 10.1074/jbc.273.51.34535; Wyttenbach A, 2002, HUM MOL GENET, V11, P1137, DOI 10.1093/hmg/11.9.1137	53	20	20	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 10	2006	281	6					3145	3156		10.1074/jbc.M508937200	http://dx.doi.org/10.1074/jbc.M508937200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	009QV	16332685	hybrid			2022-12-25	WOS:000235128200017
J	Toth, A; Nickson, P; Qin, LL; Erhardt, P				Toth, A; Nickson, P; Qin, LL; Erhardt, P			Differential regulation of cardiomyocyte survival and hypertrophy by MDM2, an E3 ubiquitin ligase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLYCOGEN-SYNTHASE KINASE-3-BETA; MITOCHONDRIAL DEATH PATHWAY; HYPOXIA-INDUCED APOPTOSIS; SMALL-MOLECULE INHIBITORS; RENIN-ANGIOTENSIN SYSTEM; VENTRICULAR MYOCYTES; P53-MDM2 INTERACTION; ENHANCED EXPRESSION; SIGNALING PATHWAYS; REPERFUSION INJURY	MDM2 is an E3 ubiquitin ligase that regulates the proteasomal degradation and activity of proteins involved in cell growth and apoptosis, including the tumor suppressors p53 and retinoblastoma and the transcription factor E2F1. Although the effect of several MDM2 targets on cardiomyocyte survival and hypertrophy has already been investigated, the role of MDM2 in these processes has not yet been established. We have, therefore, analyzed the effect of overexpression as well as inhibition of MDM2 on cardiac ischemia/reperfusion injury and hypertrophy. Here we show that isolated cardiac myocytes overexpressing MDM2 acquired resistance to hypoxia/reoxygenation-induced cell death. Conversely, inactivation of MDM2 by a peptide inhibitor resulted in elevated p53 levels and promoted hypoxia/reoxygenation-induced apoptosis. Consistent with this, decreased expression of MDM2 in a genetic mouse model was accompanied by reduced functional recovery of the left ventricles determined with the Langendorff ex vivo model of ischemia/reperfusion. In contrast to cell survival, cell hypertrophy induced by the alpha-agonists phenylephrine or endothelin-1 was inhibited by MDM2 overexpression. Collectively, our studies indicate that MDM2 promotes survival and attenuates hypertrophy of cardiac myocytes. This differential regulation of cell growth and cell survival is unique, because most other survival factors are prohypertrophic. MDM2, therefore, might be a potential therapeutic target to down-regulate both cell death and pathologic hypertrophy during remodeling upon cardiac infarction. In addition, our data also suggest that cancer treatments with MDM2 inhibitors to reactivate p53 may have adverse cardiac side effects by promoting cardiomyocyte death.	Boston Biomed Res Inst, Watertown, MA 02472 USA	Boston Biomedical Research Institute	Erhardt, P (corresponding author), Boston Biomed Res Inst, 64 Grove St, Watertown, MA 02472 USA.	Erhardt@bbri.org			NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL068126] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-68126] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Agah R, 1997, J CLIN INVEST, V100, P2722, DOI 10.1172/JCI119817; BARAK Y, 1993, EMBO J, V12, P461, DOI 10.1002/j.1460-2075.1993.tb05678.x; Bialik S, 1997, J CLIN INVEST, V100, P1363, DOI 10.1172/JCI119656; CAHILLYSNYDER L, 1987, SOMAT CELL MOLEC GEN, V13, P235, DOI 10.1007/BF01535205; Chene P, 2003, NAT REV CANCER, V3, P102, DOI 10.1038/nrc991; Condorelli G, 2002, P NATL ACAD SCI USA, V99, P12333, DOI 10.1073/pnas.172376399; Crow MT, 2004, CIRC RES, V95, P957, DOI 10.1161/01.RES.0000148632.35500.d9; Dorn GW, 2005, J CLIN INVEST, V115, P527, DOI 10.1172/JCI200524178; Erhardt P, 1999, MOL CELL BIOL, V19, P5308; Erhardt P, 1997, J BIOL CHEM, V272, P15049, DOI 10.1074/jbc.272.24.15049; FAKHARZADEH SS, 1991, EMBO J, V10, P1565, DOI 10.1002/j.1460-2075.1991.tb07676.x; Feng JH, 2004, J BIOL CHEM, V279, P35510, DOI 10.1074/jbc.M404936200; Force T, 2004, CIRCULATION, V109, P1196, DOI 10.1161/01.CIR.0000118538.21306.A9; Fotouhi N, 2005, CURR TOP MED CHEM, V5, P159, DOI 10.2174/1568026053507705; Fujio Y, 2000, CIRCULATION, V101, P660, DOI 10.1161/01.CIR.101.6.660; Ganguli G, 2003, MOL CANCER RES, V1, P1027; Grazette LP, 2004, J AM COLL CARDIOL, V44, P2231, DOI 10.1016/j.jacc.2004.08.066; Hammond EM, 2005, BIOCHEM BIOPH RES CO, V331, P718, DOI 10.1016/j.bbrc.2005.03.154; Haq S, 2000, J CELL BIOL, V151, P117, DOI 10.1083/jcb.151.1.117; Harris SL, 2005, ONCOGENE, V24, P2899, DOI 10.1038/sj.onc.1208615; Hauck L, 2002, CIRC RES, V91, P782, DOI 10.1161/01.RES.0000041030.98642.41; Haupt Y, 1997, NATURE, V387, P296, DOI 10.1038/387296a0; Iwakuma T, 2003, MOL CANCER RES, V1, P993; JONES SN, 1995, NATURE, V378, P206, DOI 10.1038/378206a0; Kanovsky M, 2001, P NATL ACAD SCI USA, V98, P12438, DOI 10.1073/pnas.211280698; Kirshenbaum LA, 1996, DEV BIOL, V179, P402, DOI 10.1006/dbio.1996.0270; Klein C, 2004, BRIT J CANCER, V91, P1415, DOI 10.1038/sj.bjc.6602164; Kubbutat MHG, 1997, NATURE, V387, P299, DOI 10.1038/387299a0; Kussie PH, 1996, SCIENCE, V274, P948, DOI 10.1126/science.274.5289.948; Leri A, 1999, AM J PATHOL, V154, P567, DOI 10.1016/S0002-9440(10)65302-3; Leri A, 1999, CIRC RES, V84, P752; Liu XW, 2004, AM J PHYSIOL-HEART C, V286, pH933, DOI 10.1152/ajpheart.00759.2003; Long XL, 1998, J CLIN INVEST, V101, P1453, DOI 10.1172/JCI345; Long XL, 1997, J CLIN INVEST, V99, P2635, DOI 10.1172/JCI119452; Loughran O, 2000, MOL CELL BIOL, V20, P2186, DOI 10.1128/MCB.20.6.2186-2197.2000; LUNA RMD, 1995, NATURE, V378, P203; MacLellan WR, 2005, MOL CELL BIOL, V25, P2486, DOI 10.1128/MCB.25.6.2486-2497.2005; Maisse C, 2003, BIOCHEM PHARMACOL, V66, P1555, DOI 10.1016/S0006-2952(03)00511-2; Matsui T, 2001, CIRCULATION, V104, P330; Maulik N, 2000, FEBS LETT, V485, P7, DOI 10.1016/S0014-5793(00)02174-8; Mayo LD, 2001, P NATL ACAD SCI USA, V98, P11598, DOI 10.1073/pnas.181181198; Mendrysa SM, 2003, MOL CELL BIOL, V23, P462, DOI 10.1128/MCB.23.2.462-473.2003; Michael A, 2004, J BIOL CHEM, V279, P21383, DOI 10.1074/jbc.M401413200; Mocanu MM, 2003, FEBS LETT, V555, P302, DOI 10.1016/S0014-5793(03)01260-2; Molkentin JD, 2004, CARDIOVASC RES, V63, P467, DOI 10.1016/j.cardiores.2004.01.021; MOMAND J, 1992, CELL, V69, P1237, DOI 10.1016/0092-8674(92)90644-R; OLINER JD, 1992, NATURE, V358, P80, DOI 10.1038/358080a0; Regula KM, 2001, J MOL CELL CARDIOL, V33, P1435, DOI 10.1006/jmcc.2001.1405; Sanna B, 2005, MOL CELL BIOL, V25, P865, DOI 10.1128/MCB.25.3.865-878.2005; Shiojima I, 2005, J CLIN INVEST, V115, P2108, DOI 10.1172/JCI24682; Shiraishi I, 2004, CIRC RES, V94, P884, DOI 10.1161/01.RES.0000124394.01180.BE; Skurk C, 2005, J BIOL CHEM, V280, P20814, DOI 10.1074/jbc.M500528200; Soonpaa MH, 1996, AM J PHYSIOL-HEART C, V271, pH2183; Steinberg SF, 2005, CIRC RES, V96, P711, DOI 10.1161/01.RES.0000164185.96546.82; Toth A, 2003, FREE RADICAL BIO MED, V35, P1051, DOI 10.1016/S0891-5849(03)00467-2; Wang YB, 1998, J BIOL CHEM, V273, P2161, DOI 10.1074/jbc.273.4.2161; Webster KA, 1999, J CLIN INVEST, V104, P239; Wilkins BJ, 2004, BIOCHEM BIOPH RES CO, V322, P1178, DOI 10.1016/j.bbrc.2004.07.121; Yang YL, 2005, CANCER CELL, V7, P547, DOI 10.1016/j.ccr.2005.04.029; Yue TL, 2000, CIRC RES, V86, P692, DOI 10.1161/01.RES.86.6.692; Zhou BHP, 2001, NAT CELL BIOL, V3, P973, DOI 10.1038/ncb1101-973	61	74	79	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 10	2006	281	6					3679	3689		10.1074/jbc.M509630200	http://dx.doi.org/10.1074/jbc.M509630200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	009QV	16339144	hybrid			2022-12-25	WOS:000235128200080
J	Kern, A; Roempp, B; Prager, K; Walter, J; Behl, C				Kern, A; Roempp, B; Prager, K; Walter, J; Behl, C			Down-regulation of endogenous amyloid precursor protein processing due to cellular aging	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-DIPLOID FIBROBLASTS; AGE-RELATED-CHANGES; BETA-SECRETASE; ALZHEIMERS-DISEASE; LIPID RAFTS; GAMMA-SECRETASE; ALPHA-SECRETASE; TRANSGENIC MICE; IN-VIVO; INTRAMEMBRANE PROTEOLYSIS	Processing of amyloid precursor protein (APP) is a well acknowledged central pathogenic mechanism in Alzheimer disease. However, influences of age-associated cellular alterations on the biochemistry of APP processing have not been studied in molecular detail so far. Here, we report that processing of endogenous APP is down-regulated during the aging of normal human fibroblasts (IMR-90). The generation of intracellular APP cleavage products C99, C83, and AICD gradually declines with increasing life span and is accompanied by a reduced secretion of soluble APP (sAPP) and sAPP alpha. Further, the maturation of APP was reduced in senescent cells, which has been shown to be directly mediated by age-associated increased cellular cholesterol levels. Of the APP processing secretases, protein levels of constituents of the gamma-secretase complex, presenilin-1 (PS1) and nicastrin, were progressively reduced during aging, resulting in a progressive decrease in gamma-secretase enzymatic activity. ADAM10 (a disintegrin and metalloprotease 10) and BACE (beta-site APP-cleaving enzyme) protein levels exhibited no age-associated regulation, but interestingly, BACE enzymatic activity was increased in aged cells. PS1 and BACE are located in detergent-resistant membranes (DRMs), well structured membrane microdomains exhibiting high levels of cholesterol, and caveolin-1. Although total levels of both structural components of DRMs were up-regulated in aged cells, their particular DRM association was decreased. This age-dependent membrane modification was associated with an altered distribution of PS1 and BACE between DRM and non-DRM fractions, very likely affecting their APP processing potential. In conclusion, we have found a significant modulation of endogenous APP processing and maturation in human fibroblasts caused by age-associated alterations in cellular biochemistry.	Johannes Gutenberg Univ Mainz, Sch Med, Inst Physiol Chem & Pathobiochem, D-55099 Mainz, Germany; Univ Bonn, Dept Neurol, D-53121 Bonn, Germany	Johannes Gutenberg University of Mainz; University of Bonn	Behl, C (corresponding author), Johannes Gutenberg Univ Mainz, Sch Med, Inst Physiol Chem & Pathobiochem, D-55099 Mainz, Germany.	cbehl@uni-mainz.de	Walter, Jochen/B-3677-2014; Wang, Caihong/T-5837-2019	Wang, Caihong/0000-0002-6808-3709; Behl, Christian/0000-0001-8453-2378; Walter, Jochen/0000-0002-4678-2912				Abad-Rodriguez J, 2004, J CELL BIOL, V167, P953, DOI 10.1083/jcb.200404149; Anders A, 2001, FASEB J, V15, P1837, DOI 10.1096/fj.01-0007fje; Angeletti B, 2005, J BIOL CHEM, V280, P17930, DOI 10.1074/jbc.M412034200; Atamna H, 2001, FASEB J, V15, P2196, DOI 10.1096/fj.01-0134com; Benjannet S, 2001, J BIOL CHEM, V276, P10879, DOI 10.1074/jbc.M009899200; Bennett BD, 2000, J BIOL CHEM, V275, P37712, DOI 10.1074/jbc.M005339200; Borroni B, 2003, NEUROBIOL AGING, V24, P631, DOI 10.1016/S0197-4580(02)00190-2; Campisi J, 1996, EXP GERONTOL, V31, P7, DOI 10.1016/0531-5565(95)02024-1; Cordy JM, 2003, P NATL ACAD SCI USA, V100, P11735, DOI 10.1073/pnas.1635130100; Cristofalo VJ, 2004, MECH AGEING DEV, V125, P827, DOI 10.1016/j.mad.2004.07.010; Cristofalo VJ, 1999, AGING-CLIN EXP RES, V11, P1; Cristofalo VJ, 1996, EXP GERONTOL, V31, P111, DOI 10.1016/0531-5565(95)02018-7; Dewachter I, 2000, J NEUROSCI, V20, P6452, DOI 10.1523/JNEUROSCI.20-17-06452.2000; Ehehalt R, 2003, J CELL BIOL, V160, P113, DOI 10.1083/jcb.200207113; Francis R, 2002, DEV CELL, V3, P85, DOI 10.1016/S1534-5807(02)00189-2; Fukumoto H, 2004, AM J PATHOL, V164, P719, DOI 10.1016/S0002-9440(10)63159-8; Galbete JL, 2000, BIOCHEM J, V348, P307, DOI 10.1042/0264-6021:3480307; GAMES D, 1995, NATURE, V373, P523, DOI 10.1038/373523a0; Gaudreault SB, 2004, NEUROBIOL AGING, V25, P753, DOI 10.1016/j.neurobiolaging.2003.07.004; GOLDGABER D, 1987, SCIENCE, V235, P877, DOI 10.1126/science.3810169; Haass C, 2004, EMBO J, V23, P483, DOI 10.1038/sj.emboj.7600061; Hardy J, 2002, SCIENCE, V297, P353, DOI 10.1126/science.1072994; HAYFLICK L, 1961, EXP CELL RES, V25, P585, DOI 10.1016/0014-4827(61)90192-6; Herreman A, 2003, J CELL SCI, V116, P1127, DOI 10.1242/jcs.00292; Hsiao K, 1996, SCIENCE, V274, P99, DOI 10.1126/science.274.5284.99; Igbavboa U, 2005, J NEUROL SCI, V229, P225, DOI 10.1016/j.jns.2004.11.037; Kojro E, 2001, P NATL ACAD SCI USA, V98, P5815, DOI 10.1073/pnas.081612998; Lammich S, 1999, P NATL ACAD SCI USA, V96, P3922, DOI 10.1073/pnas.96.7.3922; Lee SF, 2002, J BIOL CHEM, V277, P45013, DOI 10.1074/jbc.M208164200; Lim IK, 2001, ANN NY ACAD SCI, V928, P176; Lucero HA, 2004, ARCH BIOCHEM BIOPHYS, V426, P208, DOI 10.1016/j.abb.2004.03.020; Marlow L, 2003, J MOL NEUROSCI, V20, P233, DOI 10.1385/JMN:20:3:233; Mulas MF, 2005, MECH AGEING DEV, V126, P648, DOI 10.1016/j.mad.2004.11.010; Nakamura M, 2003, EXP CELL RES, V290, P381, DOI 10.1016/S0014-4827(03)00343-4; Naruse S, 1998, NEURON, V21, P1213, DOI 10.1016/S0896-6273(00)80637-6; OLTERSDORF T, 1990, J BIOL CHEM, V265, P4492; PAHLSSON P, 1992, BIOCHEM BIOPH RES CO, V189, P1667, DOI 10.1016/0006-291X(92)90269-Q; Parvathy S, 2004, J NEUROCHEM, V90, P1005, DOI 10.1111/j.1471-4159.2004.02521.x; Riddell DR, 2001, CURR BIOL, V11, P1288, DOI 10.1016/S0960-9822(01)00394-3; Selkoe DJ, 2001, PHYSIOL REV, V81, P741, DOI 10.1152/physrev.2001.81.2.741; Simons K, 2004, ANNU REV BIOPH BIOM, V33, P269, DOI 10.1146/annurev.biophys.32.110601.141803; Simons M, 2001, NEUROLOGY, V57, P1089, DOI 10.1212/WNL.57.6.1089; Steiner H, 2000, NAT REV MOL CELL BIO, V1, P217, DOI 10.1038/35043065; Stuermer CAO, 2005, BIOCHEM SOC SYMP, V72, P109, DOI 10.1042/bss0720109; SturchlerPierrat C, 1997, P NATL ACAD SCI USA, V94, P13287, DOI 10.1073/pnas.94.24.13287; Tamboli IY, 2005, J BIOL CHEM, V280, P28110, DOI 10.1074/jbc.M414525200; Thinakaran G, 1996, NEURON, V17, P181, DOI 10.1016/S0896-6273(00)80291-3; Tomita S, 1998, J BIOL CHEM, V273, P6277, DOI 10.1074/jbc.273.11.6277; Vassar R, 1999, SCIENCE, V286, P735, DOI 10.1126/science.286.5440.735; Verkade P, 1997, HISTOCHEM CELL BIOL, V108, P211, DOI 10.1007/s004180050161; Vetrivel KS, 2004, J BIOL CHEM, V279, P44945, DOI 10.1074/jbc.M407986200; Walter J, 1997, J BIOL CHEM, V272, P1896, DOI 10.1074/jbc.272.3.1896; Wang H, 2004, J BIOL CHEM, V279, P40560, DOI 10.1074/jbc.M404345200; WEIDEMANN A, 1989, CELL, V57, P115, DOI 10.1016/0092-8674(89)90177-3; Wood DR, 2005, J BIOL CHEM, V280, P6663, DOI 10.1074/jbc.M410332200; Yu G, 2000, NATURE, V407, P48, DOI 10.1038/35024009	56	58	58	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 3	2006	281	5					2405	2413		10.1074/jbc.M505625200	http://dx.doi.org/10.1074/jbc.M505625200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	006XT	16303768	hybrid			2022-12-25	WOS:000234931800003
J	Wang, XC; Gu, JG; Ihara, H; Miyoshi, E; Honke, K; Taniguchi, N				Wang, XC; Gu, JG; Ihara, H; Miyoshi, E; Honke, K; Taniguchi, N			Core fucosylation regulates epidermal growth factor receptor-mediated intracellular signaling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TYROSINE KINASE-ACTIVITY; GLIOMA-CELL-LINE; HEPATOCELLULAR-CARCINOMA; MONOCLONAL-ANTIBODY; N-ACETYLGLUCOSAMINE; U373 MG; BINDING; OLIGOSACCHARIDES; GLYCOSYLATION; EXPRESSION	alpha 1,6-Fucosyltransferase (Fut8) catalyzes the transfer of a fucose residue to N-linked oligosaccharides on glycoproteins via an alpha 1,6-linkage to form core fucosylation in mammals. We recently found that disruption of the Fut8 gene induces severe growth retardation and early postnatal death. To investigate the molecular mechanism involved, we have established embryonic fibroblasts of Fut8(+/+) and Fut8(-/-), derived from wild-type and Fut8-null mice, respectively. Interestingly, the epidermal growth factor (EGF)-induced phosphorylation levels of the EGF receptor ( EGFR) were substantially blocked in Fut8(-/-) cells, compared with Fut8(-/-) cells, while there are no significant changes in the total activities of tyrosine phosphatase for phosphorylated EGFR between two cells. The inhibition of EGFR phosphorylation was completely restored by re-introduction of the Fut8 gene to Fut8(-/-) cells. Consistent with this, EGFR-mediated JNK or ERK activation was significantly suppressed in Fut8(-/-) cells. Finally, we found that the core fucosylation of N-glycans is required for the binding of the EGF to its receptor, whereas no effect was observed for the expression levels of EGFR on the cell surface. Collectively, these results strongly suggest that core fucosylation is essential for EGF receptor-mediated biological functions.	Osaka Univ, Dept Biochem, Grad Sch Med, Osaka, Japan; Kochi Univ, Grad Sch Med, Dept Mol Genet, Nanko Ku, Kochi 7838505, Japan	Osaka University; Kochi University	Gu, JG (corresponding author), Osaka Univ, Dept Biochem, Grad Sch Med, Osaka, Japan.	jgu@biochem.med.osaka-u.ac.jp	Taniguchi, Naoyuki/A-7086-2016; Gu, Jianguo/ABC-9257-2020; Taniguchi, Naoyuki/I-4182-2014	Taniguchi, Naoyuki/0000-0001-5889-5968; Ihara, Hideyuki/0000-0003-0490-6355				AKIYAMA SK, 1989, J BIOL CHEM, V264, P18011; BELLOT F, 1990, J CELL BIOL, V110, P491, DOI 10.1083/jcb.110.2.491; CARPENTER G, 1990, J BIOL CHEM, V265, P7709; DEFIZE LHK, 1988, J CELL BIOL, V107, P939, DOI 10.1083/jcb.107.3.939; DEFIZE LHK, 1989, J CELL BIOL, V109, P2495, DOI 10.1083/jcb.109.5.2495; Dennis JW, 1999, BBA-GEN SUBJECTS, V1473, P21, DOI 10.1016/S0304-4165(99)00167-1; DWEK RA, 1995, SCIENCE, V269, P1234, DOI 10.1126/science.7652569; GREGORIOU M, 1984, EMBO J, V3, P929, DOI 10.1002/j.1460-2075.1984.tb01910.x; Gregoriou M, 1993, Methods Mol Biol, V14, P189; Gu JG, 2004, GLYCOBIOLOGY, V14, P177, DOI 10.1093/glycob/cwh016; Hakomori S, 2002, P NATL ACAD SCI USA, V99, P225, DOI 10.1073/pnas.012540899; HAZAN R, 1995, J CELL PHYSIOL, V162, P74, DOI 10.1002/jcp.1041620110; HUTCHINSON WL, 1991, HEPATOLOGY, V13, P683, DOI 10.1002/hep.1840130412; Isaji T, 2004, J BIOL CHEM, V279, P19747, DOI 10.1074/jbc.M311627200; Miyoshi E, 1999, CANCER RES, V59, P2237; NISHIKAWA A, 1992, J BIOL CHEM, V267, P18199; Noda K, 2003, CANCER RES, V63, P6282; Partridge EA, 2004, SCIENCE, V306, P120, DOI 10.1126/science.1102109; Rebbaa A, 1997, J BIOL CHEM, V272, P9275; Rebbaa A, 1996, J NEUROCHEM, V67, P2265; SATO Y, 1993, NEW ENGL J MED, V328, P1802, DOI 10.1056/NEJM199306243282502; Sato Y, 2001, J BIOL CHEM, V276, P11956, DOI 10.1074/jbc.M008551200; SCHACHTER H, 1986, BIOCHEM CELL BIOL, V64, P163, DOI 10.1139/o86-026; SCHLESSINGER J, 1988, TRENDS BIOCHEM SCI, V13, P443, DOI 10.1016/0968-0004(88)90219-8; Shields RL, 2002, J BIOL CHEM, V277, P26733, DOI 10.1074/jbc.M202069200; SHIMIZU H, 1993, J BIOCHEM-TOKYO, V114, P334, DOI 10.1093/oxfordjournals.jbchem.a124177; Shinkawa T, 2003, J BIOL CHEM, V278, P3466, DOI 10.1074/jbc.M210665200; SODERQUIST AM, 1984, J BIOL CHEM, V259, P2586; Stroop CJM, 2000, GLYCOBIOLOGY, V10, P901, DOI 10.1093/glycob/10.9.901; TAKETA K, 1993, CANCER RES, V53, P5419; Tamura M, 1998, SCIENCE, V280, P1614, DOI 10.1126/science.280.5369.1614; Taniguchi N, 1999, BBA-MOL BASIS DIS, V1455, P287, DOI 10.1016/S0925-4439(99)00066-6; Taniguchi N, 2001, PROTEOMICS, V1, P239; ULLRICH A, 1984, NATURE, V309, P418, DOI 10.1038/309418a0; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; Uozumi N, 1996, J BIOCHEM, V120, P385; Wang W, 2001, GLYCOBIOLOGY, V11, P165, DOI 10.1093/glycob/11.2.165; Wang XC, 2005, P NATL ACAD SCI USA, V102, P15791, DOI 10.1073/pnas.0507375102; WYSS DF, 1995, SCIENCE, V269, P1273, DOI 10.1126/science.7544493; ZENG FY, 1995, MOL CELL BIOCHEM, V142, P117, DOI 10.1007/BF00928932; ZHENG MZ, 1994, J BIOL CHEM, V269, P12325	41	242	250	0	18	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 3	2006	281	5					2572	2577		10.1074/jbc.M510893200	http://dx.doi.org/10.1074/jbc.M510893200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	006XT	16316986	hybrid			2022-12-25	WOS:000234931800020
J	Binz, N; Graham, CE; Simpson, K; Lai, YKY; Shen, WY; Lai, CM; Speed, TP; Rakoczy, PE				Binz, Nicolette; Graham, Caroline E.; Simpson, Ken; Lai, Yvonne K. Y.; Shen, Wei-Yong; Lai, Chooi-May; Speed, Terence P.; Rakoczy, P. Elizabeth			Long-term effect of therapeutic laser photocoagulation on gene expression in the eye	FASEB JOURNAL			English	Article									[Binz, Nicolette; Graham, Caroline E.; Lai, Yvonne K. Y.; Shen, Wei-Yong] Lions Eye Inst, Nedlands, WA 6009, Australia; [Binz, Nicolette; Graham, Caroline E.; Lai, Yvonne K. Y.; Shen, Wei-Yong; Lai, Chooi-May; Rakoczy, P. Elizabeth] Univ Western Australia, Ctr Ophthalmol & Visual Sci, Nedlands, WA 6009, Australia; [Simpson, Ken; Speed, Terence P.] Walter & Eliza Hall Inst Med Res, Div Genet & Bioinformat, Melbourne, Vic 3050, Australia	Lions Eye Institute; University of Western Australia; University of Western Australia; Walter & Eliza Hall Institute	Binz, N (corresponding author), Lions Eye Inst, 2 Verdun St, Nedlands, WA 6009, Australia.	binz@cyllene.uwa.edu.au	Speed, Terence P/B-8085-2009	Speed, Terence P/0000-0002-5403-7998; Walker, Caroline/0000-0001-5917-6519					0	22	25	0	2	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	FEB	2006	20	2					383	385		10.1096/fj.05-3890fje	http://dx.doi.org/10.1096/fj.05-3890fje			3	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	V17CJ	16354724				2022-12-25	WOS:000207915000029
J	Malmo, C; Vilasi, S; Iannuzzi, C; Tacchi, S; Cametti, C; Irace, G; Sirangelo, I				Malmo, Clorinda; Vilasi, Silvia; Iannuzzi, Clara; Tacchi, Silvia; Cametti, Cesare; Irace, Gaetano; Sirangelo, Ivana			Tetracycline inhibits W7FW14F apomyoglobin fibril extension and keeps the amyloid protein in a pre-fibrillar, highly cytotoxic state	FASEB JOURNAL			English	Article									[Malmo, Clorinda; Iannuzzi, Clara; Irace, Gaetano; Sirangelo, Ivana] Seconda Univ Napoli, Dipartimento Biochim & Biofis, I-80138 Naples, Italy; [Vilasi, Silvia; Tacchi, Silvia] Univ Perugia, Dipartimento Fis, I-06100 Perugia, Italy; [Cametti, Cesare] Univ Roma La Sapienza, Dipartimento Fis, I-00185 Rome, Italy	Universita della Campania Vanvitelli; University of Perugia; Sapienza University Rome	Sirangelo, I (corresponding author), Seconda Univ Napoli, Dipartimento Biochim & Biofis, Via L De Crecchio 7, I-80138 Naples, Italy.	ivana.sirangelo@unina2.it	Iannuzzi, Clara/H-6764-2012	VILASI, SILVIA/0000-0002-9926-7199; Cametti, Cesare/0000-0003-2077-3660; IANNUZZI, Clara/0000-0003-0092-5997; Sirangelo, Ivana/0000-0002-6408-4990					0	27	28	0	5	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	FEB	2006	20	2					346	347		10.1096/fj.05-4652fje	http://dx.doi.org/10.1096/fj.05-4652fje			2	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	V17CJ	16317065				2022-12-25	WOS:000207915000016
J	Zirah, S; Kozin, SA; Mazur, AK; Blond, A; Cheminant, M; Segalas-Milazzo, I; Debey, P; Rebuffat, S				Zirah, S; Kozin, SA; Mazur, AK; Blond, A; Cheminant, M; Segalas-Milazzo, I; Debey, P; Rebuffat, S			Structural changes of region 1-16 of the Alzheimer disease amyloid beta-peptide upon zinc binding and in vitro aging	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN SECONDARY STRUCTURE; CHEMICAL-SHIFT INDEX; ISOASPARTATE FORMATION; INDUCED AGGREGATION; TITRATION SHIFTS; AMINO-ACIDS; NMR; PLAQUES; MODEL; IDENTIFICATION	Amyloid deposits within the cerebral tissue constitute a characteristic lesion associated with Alzheimer disease. They mainly consist of the amyloid peptide A beta and display an abnormal content in Zn2+ ions, together with many truncated, isomerized, and racemized forms of A beta. The region 1-16 of A beta can be considered the minimal zinc-binding domain and contains two aspartates subject to protein aging. The influence of zinc binding and protein aging related modifications on the conformation of this region of A beta is of importance given the potentiality of this domain to constitute a therapeutic target, especially for immunization approaches. In this study, we determined from NMR data the solution structure of the A beta-(1-16)-Zn2+ complex in aqueous solution at pH 6.5. The residues His(6), His(13), and His(14) and the Glu(11) carboxylate were identified as ligands that tetrahedrally coordinate the Zn(II) cation. In vitro aging experiments on A beta-(1-16) led to the formation of truncated and isomerized species. The major isomer generated, A beta-(1-16)-L-isoAsp(7), displayed a local conformational change in the His(6)-Ser(8) region but kept a zinc binding propensity via a coordination mode involving L-iso-Asp(7). These results are discussed here with regard to A beta fibrillogenesis and the potentiality of the region 1-16 of A beta to be used as a therapeutic target.	Museum Natl Hist Nat, Dept Regulat Dev Divers Mol, Lab Chim Biochim Subst Nat, CNRS,UMR 5154, F-75005 Paris, France; CNRS, UPR 9080, Inst Biol Physicochim, F-75005 Paris, France; Univ Rouen, IFRMP 23, CNRS,IRCOF, UMR 6014,Lab RMN, Mont St Aignan, France; Museum Natl Hist Nat, Lab Regulat Dynam Genomes, Dept Regulat Dev Divers Mol, CNRS,INSERM,UMR 5153,U565, F-75005 Paris, France; RAMS, Inst Biomed Chem, Proteom Dept, Moscow 119121, Russia	Centre National de la Recherche Scientifique (CNRS); Museum National d'Histoire Naturelle (MNHN); Centre National de la Recherche Scientifique (CNRS); CNRS - Institute of Chemistry (INC); UDICE-French Research Universities; Universite Paris Cite; Centre National de la Recherche Scientifique (CNRS); CNRS - Institute of Chemistry (INC); Universite de Rouen Normandie; Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); Museum National d'Histoire Naturelle (MNHN); Russian Academy of Medical Sciences; Institute of Biomedical Chemistry	Rebuffat, S (corresponding author), Museum Natl Hist Nat, Dept Regulat Dev Divers Mol, Lab Chim Biochim Subst Nat, CNRS,UMR 5154, CP 54,57 Rue Cuvier,63 Rue Buffon, F-75005 Paris, France.	rebuffat@mnhn.fr	Rebuffat, Sylvie/AAO-2072-2020; Rebuffat, Sylvie/AAE-4194-2021; Kozin, Sergey A/R-3637-2018; Zirah, Severine/C-9193-2012	Kozin, Sergey A/0000-0002-3018-7932; Zirah, Severine/0000-0001-6082-8414; Mazur, Alexey/0000-0002-9371-0620; Rebuffat, Sylvie/0000-0002-5257-5039				BARROW CJ, 1991, SCIENCE, V253, P179, DOI 10.1126/science.1853202; Bernstein HJ, 2000, TRENDS BIOCHEM SCI, V25, P453, DOI 10.1016/S0968-0004(00)01606-6; BODO B, 1985, J AM CHEM SOC, V107, P6011, DOI 10.1021/ja00307a028; BRAUN W, 1985, J MOL BIOL, V186, P611, DOI 10.1016/0022-2836(85)90134-2; BROOKS BR, 1983, J COMPUT CHEM, V4, P187, DOI 10.1002/jcc.540040211; BUSH AI, 1994, SCIENCE, V265, P1464, DOI 10.1126/science.8073293; Bush AI, 2003, TRENDS NEUROSCI, V26, P207, DOI 10.1016/S0166-2236(03)00067-5; BUSH AI, 1994, J BIOL CHEM, V269, P26618; Chauhan NB, 2005, NEUROSCI LETT, V375, P143, DOI 10.1016/j.neulet.2004.10.090; CHAZIN WJ, 1989, BIOCHEMISTRY-US, V28, P8646, DOI 10.1021/bi00447a055; Choo LP, 1996, BIOPHYS J, V71, P1672, DOI 10.1016/S0006-3495(96)79411-0; Coles M, 1998, BIOCHEMISTRY-US, V37, P11064, DOI 10.1021/bi972979f; CORNELL WD, 1995, J AM CHEM SOC, V117, P5179, DOI 10.1021/ja00124a002; Cuajungco MP, 2005, SUB CELL BIOCHEM, V38, P235; Cuajungco MP, 2003, BRAIN RES REV, V41, P44, DOI 10.1016/S0165-0173(02)00219-9; Curtain CC, 2001, J BIOL CHEM, V276, P20466, DOI 10.1074/jbc.M100175200; Ellis RJ, 2002, NATURE, V416, P483, DOI 10.1038/416483a; Esler WP, 1996, J NEUROCHEM, V66, P723; FABIAN H, 1994, EUR J BIOCHEM, V221, P959, DOI 10.1111/j.1432-1033.1994.tb18811.x; Fonseca MI, 1999, EXP NEUROL, V157, P277, DOI 10.1006/exnr.1999.7058; FORMANKAY JD, 1992, BIOCHEMISTRY-US, V31, P3442, DOI 10.1021/bi00128a019; Frenkel D, 1998, J NEUROIMMUNOL, V88, P85, DOI 10.1016/S0165-5728(98)00098-8; Frenkel D, 2003, VACCINE, V21, P1060, DOI 10.1016/S0264-410X(02)00609-6; GEIGER T, 1987, J BIOL CHEM, V262, P785; Gelinas DS, 2004, P NATL ACAD SCI USA, V101, P14657, DOI 10.1073/pnas.0404866101; Hou LM, 2004, J AM CHEM SOC, V126, P1992, DOI 10.1021/ja036813f; Huang XD, 1997, J BIOL CHEM, V272, P26464, DOI 10.1074/jbc.272.42.26464; Kheterpal I, 2001, BIOCHEMISTRY-US, V40, P11757, DOI 10.1021/bi010805z; Koradi R, 1996, J MOL GRAPHICS, V14, P51, DOI 10.1016/0263-7855(96)00009-4; Kozin SA, 2001, BIOCHEM BIOPH RES CO, V285, P959, DOI 10.1006/bbrc.2001.5284; Kuo YM, 1998, BBA-MOL BASIS DIS, V1406, P291, DOI 10.1016/S0925-4439(98)00014-3; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; LEE JP, 1995, BIOCHEMISTRY-US, V34, P5191, DOI 10.1021/bi00015a033; Liu ST, 1999, BIOCHEMISTRY-US, V38, P9373, DOI 10.1021/bi990205o; Lovell MA, 1998, J NEUROL SCI, V158, P47, DOI 10.1016/S0022-510X(98)00092-6; Malinchik SB, 1998, BIOPHYS J, V74, P537, DOI 10.1016/S0006-3495(98)77812-9; MANTYH PW, 1993, J NEUROCHEM, V61, P1171, DOI 10.1111/j.1471-4159.1993.tb03639.x; Marcinowski KJ, 1998, J AM CHEM SOC, V120, P11082, DOI 10.1021/ja9738687; Matsubara T, 2003, FEBS LETT, V555, P317, DOI 10.1016/S0014-5793(03)01266-3; Mazur AK, 2001, COMPUTATIONAL BIOCHEMISTRY AND BIOPHYSICS, P115; McLaurin J, 2002, NAT MED, V8, P1263, DOI 10.1038/nm790; Mekmouche Y, 2005, CHEMBIOCHEM, V6, P1663, DOI 10.1002/cbic.200500057; Miura T, 2000, BIOCHEMISTRY-US, V39, P7024, DOI 10.1021/bi0002479; NILGES M, 1988, PROTEIN ENG, V2, P27, DOI 10.1093/protein/2.1.27; OHAIR RAJ, 1992, INT J MASS SPECTROM, V117, P23, DOI 10.1016/0168-1176(92)80083-D; Orpiszewski J, 2000, FASEB J, V14, P1255, DOI 10.1096/fasebj.14.9.1255; PARANANDI MV, 1994, J BIOL CHEM, V269, P243; Parbhu A, 2002, PEPTIDES, V23, P1265, DOI 10.1016/S0196-9781(02)00061-X; PARDI A, 1984, J MOL BIOL, V180, P741, DOI 10.1016/0022-2836(84)90035-4; Perez-Canadillas JM, 1998, BIOCHEMISTRY-US, V37, P15865, DOI 10.1021/bi981672t; Petkova AT, 2002, P NATL ACAD SCI USA, V99, P16742, DOI 10.1073/pnas.262663499; ROHER AE, 1993, J BIOL CHEM, V268, P3072; Saido TC, 1996, NEUROSCI LETT, V215, P173, DOI 10.1016/0304-3940(96)12970-0; Serpell LC, 1999, METHOD ENZYMOL, V309, P526; Shao HY, 1999, J MOL BIOL, V285, P755, DOI 10.1006/jmbi.1998.2348; Shimizu T, 2000, ARCH BIOCHEM BIOPHYS, V381, P225, DOI 10.1006/abbi.2000.1955; STEPHENSON RC, 1989, J BIOL CHEM, V264, P6164; STICHT H, 1995, EUR J BIOCHEM, V233, P293, DOI 10.1111/j.1432-1033.1995.293_1.x; Suh SW, 2000, BRAIN RES, V852, P274, DOI 10.1016/S0006-8993(99)02096-X; TALAFOUS J, 1994, BIOCHEMISTRY-US, V33, P7788, DOI 10.1021/bi00191a006; Valko M, 2005, CURR MED CHEM, V12, P1161, DOI 10.2174/0929867053764635; WELLNER D, 1990, P NATL ACAD SCI USA, V87, P1947, DOI 10.1073/pnas.87.5.1947; WISHART DS, 1994, J BIOMOL NMR, V4, P171; WISHART DS, 1992, BIOCHEMISTRY-US, V31, P1647, DOI 10.1021/bi00121a010; Wuthrich K, 1986, NMR PROTEINS NUCL AC; Yang DS, 2000, EUR J BIOCHEM, V267, P6692, DOI 10.1046/j.1432-1327.2000.01767.x; Yoshiike Y, 2001, J BIOL CHEM, V276, P32293, DOI 10.1074/jbc.M010706200; ZAGORSKI MG, 1992, BIOCHEMISTRY-US, V31, P5621, DOI 10.1021/bi00139a028; Zhang S, 2000, J STRUCT BIOL, V130, P130, DOI 10.1006/jsbi.2000.4288; Zirah S, 2004, BIOCHEM BIOPH RES CO, V321, P324, DOI 10.1016/j.bbrc.2004.06.150; Zirah S, 2003, INT J MASS SPECTROM, V228, P999, DOI 10.1016/S1387-3806(03)00221-5	71	242	251	0	39	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 27	2006	281	4					2151	2161		10.1074/jbc.M504454200	http://dx.doi.org/10.1074/jbc.M504454200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	004NV	16301322	Green Published, hybrid			2022-12-25	WOS:000234760400038
J	Cronstein, B				Cronstein, B			Response to RFP: "Rigorous test of intelligent design"	FASEB JOURNAL			English	Editorial Material									NYU, Sch Med, New York, NY 10012 USA	New York University	Cronstein, B (corresponding author), NYU, Sch Med, New York, NY 10012 USA.		Cronstein, Bruce N/D-4678-2011	Cronstein, Bruce N/0000-0002-4295-7383					0	0	0	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	DEC	2005	19	14					1936	1937		10.1096/fj.05-1202ufm	http://dx.doi.org/10.1096/fj.05-1202ufm			2	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	999QR	16319135				2022-12-25	WOS:000234405500002
J	Leon, A; Omri, B; Gely, A; Klein, C; Crisanti, P				Leon, A; Omri, B; Gely, A; Klein, C; Crisanti, P			QN1/KIAA1009: a new essential protein for chromosome segregation and mitotic spindle assembly	ONCOGENE			English	Article						QN1/KIAA1009; ATPase; mitosis; microtubule-associated motor	NERVE GROWTH-FACTOR; PROLIFERATION ARREST; TRANSCRIPTION FACTOR; CELL-PROLIFERATION; CHECKPOINT; MECHANISMS; EXPRESSION; APOPTOSIS; ANAPHASE; BINDING	We previously reported the involvement of QN1 ( quail neuroretina 1) protein in cell cycle control during retinal development. We show here that QN1 is an ATPase conserved through evolution, from fugu to humans. We show that chicken/quail QN1 protein is orthologous to the KIAA1009 protein in humans, the function of which was not known. We demonstrate here for the first time that QN1/KIAA1009 protein is located at the spindle poles of the mitotic apparatus and at centrosomes during mitosis. The siRNA-mediated depletion of KIAA1009 led to abnormal mitosis with chromosome segregation defects and abnormal centrosome separation leading to the death of PC12 and MCF7 cells. Thus, QN1/KIAA1009 is a new microtubule-associated ATPase involved in cell division.	Univ Paris 06, Inst Biomed Cordeliers, INSERM U598, F-75006 Paris, France; Univ Paris 06, Paris, France; Ctr Cordeliers, IFR 58, Ctr Imagerie, Paris, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Sorbonne Universite; Universite Paris Cite; UDICE-French Research Universities; Sorbonne Universite; UDICE-French Research Universities; Sorbonne Universite; Universite Paris Cite	Crisanti, P (corresponding author), Univ Paris 06, Inst Biomed Cordeliers, INSERM U598, 15 Rue Ecole Med, F-75006 Paris, France.	plassiaz@infobiogen.fr		klein, christophe/0000-0001-8015-287X				BIDOU L, 1993, MECH DEVELOP, V43, P159, DOI 10.1016/0925-4773(93)90033-T; Bornens M, 2002, CURR OPIN CELL BIOL, V14, P25, DOI 10.1016/S0955-0674(01)00290-3; Cai ZZ, 1997, J BIOL CHEM, V272, P96; Combet C, 2000, TRENDS BIOCHEM SCI, V25, P147, DOI 10.1016/S0968-0004(99)01540-6; Crisanti P, 2001, ONCOGENE, V20, P5475, DOI 10.1038/sj.onc.1204711; Elbashir SM, 2001, GENE DEV, V15, P188, DOI 10.1101/gad.862301; Gollapudi L, 1997, J NEUROSCI RES, V49, P461, DOI 10.1002/(SICI)1097-4547(19970815)49:4<461::AID-JNR7>3.3.CO;2-6; GREENE LA, 1976, P NATL ACAD SCI USA, V73, P2424, DOI 10.1073/pnas.73.7.2424; Hsu HL, 1996, J CELL SCI, V109, P277; LOMBILLO VA, 1995, NATURE, V373, P161, DOI 10.1038/373161a0; Munnia A, 2001, ONCOGENE, V20, P4853, DOI 10.1038/sj.onc.1204650; Musacchio A, 2002, NAT REV MOL CELL BIO, V3, P731, DOI 10.1038/nrm929; Nagase T, 2000, DNA RES, V7, P65, DOI 10.1093/dnares/7.1.65; Nasmyth K, 2000, SCIENCE, V288, P1379, DOI 10.1126/science.288.5470.1379; Neron B, 2001, MECH DEVELOP, V102, P107, DOI 10.1016/S0925-4773(01)00297-0; Nicklas RB, 1997, SCIENCE, V275, P632, DOI 10.1126/science.275.5300.632; Nugoli M, 2003, BMC CANCER, V3, DOI 10.1186/1471-2407-3-13; Oberdoerster J, 1998, J PHARMACOL EXP THER, V287, P359; RIEDER CL, 1995, J CELL BIOL, V130, P941, DOI 10.1083/jcb.130.4.941; Shah JV, 2000, CELL, V103, P997, DOI 10.1016/S0092-8674(00)00202-6; WALKER JE, 1982, EMBO J, V1, P945, DOI 10.1002/j.1460-2075.1982.tb01276.x; Weaver BAA, 2003, J CELL BIOL, V162, P551, DOI 10.1083/jcb.200303167	22	12	15	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 23	2006	25	13					1887	1895		10.1038/sj.onc.1209215	http://dx.doi.org/10.1038/sj.onc.1209215			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	024VQ	16302001				2022-12-25	WOS:000236224800005
J	He, B; Gampe, RT; Hnat, AT; Faggart, JL; Minges, JT; French, FS; Wilson, EM				He, B; Gampe, RT; Hnat, AT; Faggart, JL; Minges, JT; French, FS; Wilson, EM			Probing the functional link between androgen receptor coactivator and ligand-binding sites in prostate cancer and androgen insensitivity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINO-ACID SUBSTITUTION; GENE-MUTATIONS; STRUCTURAL BASIS; TRANSCRIPTIONAL ACTIVATION; TERMINAL INTERACTION; DOMAIN; SPECIFICITY; INTERDOMAIN; DEPRIVATION; PROTEIN	The androgen receptor (AR) is a ligand-activated transcription factor required for male sex development and virilization and contributes to prostate cancer initiation and progression. High affinity androgen binding triggers conformational changes required for AR transactivation. Here we characterized naturally occurring AR gene mutations in the region of activation function 2 (AF2) that decrease or increase AR transcriptional activity by altering the region bounded by AF2 and the ligand binding pocket without affecting equilibrium androgen binding affinity. In the androgen insensitivity syndrome, germ line AR mutations increase the androgen dissociation rate and reduce AR FXXLF motif binding and the recruitment of steroid receptor coactivator ( SRC)/p160 coactivator LXXLL motifs. In prostate cancer, somatic AR mutations in AF2 or near the bound ligand slow androgen dissociation and increase AR stabilization and coactivator recruitment. Crystal structures of the AR ligand binding domain bound to R1881 and FXXLF or LXXLL motif peptide indicate the mutations are proximal to the AF2 bound peptide, adjacent to the ligand pocket, or in a putative ligand gateway. The results suggest a bidirectional structural relay between bound ligand and coactivator that establishes AR functional potency in vivo.	Univ N Carolina, Lineberger Comprehens Canc Ctr, Dept Pediat Biochem & Biophys, Reprod Biol Lab, Chapel Hill, NC 27599 USA; GlaxoSmithKline, Discovery Res, Res Triangle Pk, NC 27709 USA	University of North Carolina; University of North Carolina Chapel Hill; GlaxoSmithKline	Wilson, EM (corresponding author), Univ N Carolina, Lineberger Comprehens Canc Ctr, Dept Pediat Biochem & Biophys, Reprod Biol Lab, Chapel Hill, NC 27599 USA.	emw@med.unc.edu			FIC NIH HHS [R03TW001234] Funding Source: Medline; NICHD NIH HHS [U54-HD35041, HD16910] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R37HD016910, R01HD016910, U54HD035041] Funding Source: NIH RePORTER; FOGARTY INTERNATIONAL CENTER [R03TW001234] Funding Source: NIH RePORTER	FIC NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); FOGARTY INTERNATIONAL CENTER(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC))		Ahmed SF, 2000, J CLIN ENDOCR METAB, V85, P658, DOI 10.1210/jc.85.2.658; ANDERSON JN, 1975, ENDOCRINOLOGY, V96, P160, DOI 10.1210/endo-96-1-160; Aquilina JW, 1997, JNCI-J NATL CANCER I, V89, P689, DOI 10.1093/jnci/89.10.689; Bai SX, 2005, MOL CELL BIOL, V25, P1238, DOI 10.1128/MCB.25.4.1238-1257.2005; Balk SP, 2002, UROLOGY, V60, P132, DOI 10.1016/S0090-4295(02)01593-5; Bohl CE, 2005, J BIOL CHEM, V280, P37747, DOI 10.1074/jbc.M507464200; Carlsson P, 2005, MOL ENDOCRINOL, V19, P1960, DOI 10.1210/me.2004-0203; Chang CY, 2001, CANCER RES, V61, P8712; CULIG Z, 1993, MOL ENDOCRINOL, V7, P1541, DOI 10.1210/me.7.12.1541; Darimont BD, 1998, GENE DEV, V12, P3343, DOI 10.1101/gad.12.21.3343; DEBELLIS A, 1994, J CLIN ENDOCR METAB, V78, P513, DOI 10.1210/jc.78.3.513; Duff J, 2005, MOL ENDOCRINOL, V19, P2943, DOI 10.1210/me.2005-0231; ELO JP, 1995, J CLIN ENDOCR METAB, V80, P3494, DOI 10.1210/jc.80.12.3494; Essawi M, 1997, DIS MARKERS, V13, P99; Estebanez-Perpina E, 2005, J BIOL CHEM, V280, P8060, DOI 10.1074/jbc.M407046200; Feldman BJ, 2001, NAT REV CANCER, V1, P34, DOI 10.1038/35094009; Feng WJ, 1998, SCIENCE, V280, P1747, DOI 10.1126/science.280.5370.1747; Gee AC, 1999, MOL ENDOCRINOL, V13, P1912, DOI 10.1210/me.13.11.1912; Gelmann EP, 2002, J CLIN ONCOL, V20, P3001, DOI 10.1200/JCO.2002.10.018; Georget V, 1998, J CLIN ENDOCR METAB, V83, P3597, DOI 10.1210/jc.83.10.3597; Glass CK, 2000, GENE DEV, V14, P121; Gottlieb B, 2004, HUM MUTAT, V23, P527, DOI 10.1002/humu.20044; Gregory CW, 2004, J BIOL CHEM, V279, P7119, DOI 10.1074/jbc.M307649200; Gregory CW, 1998, CANCER RES, V58, P5718; Gregory CW, 2001, CANCER RES, V61, P4315; Gruber SB, 2003, PROSTATE, V54, P306, DOI 10.1002/pros.10195; Hara T, 2003, CANCER RES, V63, P149; HARRIS SE, 1991, MOLECULAR AND CELLULAR BIOLOGY OF PROSTATE CANCER, P315; He B, 2002, J BIOL CHEM, V277, P25631, DOI 10.1074/jbc.M202809200; He B, 2002, MOL GENET METAB, V75, P293, DOI 10.1016/S1096-7192(02)00009-4; He B, 2004, J BIOL CHEM, V279, P30643, DOI 10.1074/jbc.M403117200; He B, 2000, J BIOL CHEM, V275, P22986, DOI 10.1074/jbc.M002807200; He B, 2004, MOL CELL, V16, P425, DOI 10.1016/j.molcel.2004.09.036; He B, 2003, MOL CELL BIOL, V23, P2135, DOI 10.1128/MCB.23.6.2135-2150.2003; He B, 1999, J BIOL CHEM, V274, P37219, DOI 10.1074/jbc.274.52.37219; He B, 2001, J BIOL CHEM, V276, P42293, DOI 10.1074/jbc.M107492200; Heinlein CA, 2004, ENDOCR REV, V25, P276, DOI 10.1210/er.2002-0032; HIORT O, 1993, J CLIN ENDOCR METAB, V77, P262, DOI 10.1210/jc.77.1.262; Hiort O, 1998, J PEDIATR-US, V132, P939, DOI 10.1016/S0022-3476(98)70387-7; Holterhus PM, 2000, J CLIN ENDOCR METAB, V85, P3245, DOI 10.1210/jc.85.9.3245; Hur E, 2004, PLOS BIOL, V2, P1303, DOI 10.1371/journal.pbio.0020274; IMPERATO.J, 1974, SCIENCE, V186, P1213, DOI 10.1126/science.186.4170.1213; KEMPPAINEN JA, 1992, J BIOL CHEM, V267, P968; Kemppainen JA, 1999, MOL ENDOCRINOL, V13, P440, DOI 10.1210/me.13.3.440; KOIVISTO P, 1995, AM J PATHOL, V147, P1608; Koivisto P, 1998, AM J PATHOL, V152, P1; Krishnan AV, 2002, ENDOCRINOLOGY, V143, P1889, DOI 10.1210/en.143.5.1889; Langley E, 1998, J BIOL CHEM, V273, P92, DOI 10.1074/jbc.273.1.92; LANGLEY E, 1995, J BIOL CHEM, V270, P29983; Lengauer C, 1998, NATURE, V396, P643, DOI 10.1038/25292; Lonard DM, 2000, MOL CELL, V5, P939, DOI 10.1016/S1097-2765(00)80259-2; MacLean Helen E, 2004, Hum Mutat, V23, P287, DOI 10.1002/humu.9221; Marcelli M, 2000, CANCER RES, V60, P944; Matias PM, 2000, J BIOL CHEM, V275, P26164, DOI 10.1074/jbc.M004571200; Matias PM, 2002, J MED CHEM, V45, P1439, DOI 10.1021/jm011072j; McDonald S, 2000, CANCER RES, V60, P2317; Mohler JL, 2004, CLIN CANCER RES, V10, P440, DOI 10.1158/1078-0432.CCR-1146-03; Mononen N, 2000, CANCER RES, V60, P6479; Moras D, 1998, CURR OPIN CELL BIOL, V10, P384, DOI 10.1016/S0955-0674(98)80015-X; NAKAO R, 1993, J CLIN ENDOCR METAB, V77, P103, DOI 10.1210/jcem.77.1.8325932; Needham M, 2000, J STEROID BIOCHEM, V72, P35, DOI 10.1016/S0960-0760(00)00027-3; NEWMARK JR, 1992, P NATL ACAD SCI USA, V89, P6319, DOI 10.1073/pnas.89.14.6319; PETERZIEL H, 1995, INT J CANCER, V63, P544, DOI 10.1002/ijc.2910630415; PINSKY L, 1992, CLIN INVEST MED, V15, P456; Poujol N, 2002, J CLIN ENDOCR METAB, V87, P5793, DOI 10.1210/jc.2002-020491; Quigley CA, 2004, MECH AGEING DEV, V125, P683, DOI 10.1016/j.mad.2004.08.007; QUIGLEY CA, 1995, ENDOCR REV, V16, P271, DOI 10.1210/er.16.3.271; Sack JS, 2001, P NATL ACAD SCI USA, V98, P4904, DOI 10.1073/pnas.081565498; Shang YF, 2000, CELL, V103, P843, DOI 10.1016/S0092-8674(00)00188-4; Shi XB, 2002, CANCER RES, V62, P1496; SIMENTAL JA, 1991, J BIOL CHEM, V266, P510; Spencer TE, 1997, NATURE, V389, P194, DOI 10.1038/38304; Steketee K, 2002, INT J CANCER, V100, P309, DOI 10.1002/ijc.10495; Tan J, 1997, MOL ENDOCRINOL, V11, P450, DOI 10.1210/me.11.4.450; Taplin ME, 1999, CANCER RES, V59, P2511; TAPLIN ME, 1995, NEW ENGL J MED, V332, P1393, DOI 10.1056/NEJM199505253322101; Taplin ME, 2001, J CLIN ENDOCR METAB, V86, P3467, DOI 10.1210/jc.86.8.3467; Terouanne B, 2003, MOL PHARMACOL, V63, P791, DOI 10.1124/mol.63.4.791; Tilley WD, 1996, CLIN CANCER RES, V2, P277; VANDERKWAST TH, 1991, INT J CANCER, V48, P189, DOI 10.1002/ijc.2910480206; VELDSCHOLTE J, 1990, BIOCHEM BIOPH RES CO, V173, P534, DOI 10.1016/S0006-291X(05)80067-1; Voegel JJ, 1998, EMBO J, V17, P507, DOI 10.1093/emboj/17.2.507; WILSON EM, 1976, J BIOL CHEM, V251, P5620; Zegarra-Moro OL, 2002, CANCER RES, V62, P1008; Zhao XY, 2000, NAT MED, V6, P703, DOI 10.1038/76287; ZHOU ZX, 1995, MOL ENDOCRINOL, V9, P208, DOI 10.1210/me.9.2.208	86	54	58	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 10	2006	281	10					6648	6663		10.1074/jbc.M511738200	http://dx.doi.org/10.1074/jbc.M511738200			16	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	022BX	16365032	Green Published, hybrid			2022-12-25	WOS:000236030800062
J	Lavery, GG; Walker, EA; Draper, N; Jeyasuria, P; Marcos, J; Shackleton, CHL; Parker, KL; White, PC; Stewart, PM				Lavery, GG; Walker, EA; Draper, N; Jeyasuria, P; Marcos, J; Shackleton, CHL; Parker, KL; White, PC; Stewart, PM			Hexose-6-phosphate dehydrogenase knock-out mice lack 11 beta-hydroxysteroid dehydrogenase type 1-mediated glucocorticoid generation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-HYDROXYSTEROID DEHYDROGENASE; HEXOSE 6-PHOSPHATE DEHYDROGENASE; CORTISONE REDUCTASE DEFICIENCY; HEPATIC INSULIN SENSITIVITY; ENDOPLASMIC-RETICULUM; GLUCOSE-DEHYDROGENASE; SELECTIVE-INHIBITION; HYPERGLYCEMIC MICE; LIVER-MICROSOMES; RAT	The local generation of active glucocorticoid by NADPH-dependent, 11 beta-hydroxysteroid dehydrogenase type 1 (11 beta-HSD1) oxoreductase activity, has emerged as an important factor in regulating hepatic glucose output and visceral adiposity. We have proposed that this NADPH is generated within the endoplasmic reticulum by the enzyme hexose-6-phosphate dehydrogenase. To address this hypothesis, we generated mice with a targeted inactivation of the H6PD gene. These mice were unable to convert 11-dehydrocorticosterone (11-DHC) to corticosterone but demonstrated increased corticosterone to 11-DHC conversion consistent with lack of 11 beta-HSD1 oxoreductase and a concomitant increase in dehydrogenase activity. This increased corticosterone clearance in the knock-out mice resulted in a reduction in circulating corticosterone levels. Our studies define the critical requirement of hexose-6-phosphate dehydrogenase for 11 beta-HSD1 oxoreductase activity and add a new dimension to the investigation of 11 beta-HSD1 as a therapeutic target in patients with the metabolic syndrome.	Univ Birmingham, Dept Med, Div Med Sci, Birmingham B15 2TH, W Midlands, England; Univ Texas, SW Med Ctr, Dept Internal Med, Dallas, TX 75390 USA; Univ Texas, SW Med Ctr, Dept Pediat, Dallas, TX 75390 USA; Childrens Hosp, Oakland Res Inst, Oakland, CA 94609 USA	University of Birmingham; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; Children's Hospital Los Angeles; Children's Hospital Oakland Research Institute	Stewart, PM (corresponding author), Univ Birmingham, Dept Med, Div Med Sci, Birmingham B15 2TH, W Midlands, England.	p.m.stewart@bham.ac.uk	Lavery, Gareth/F-9346-2010; Marcos, Josep/F-3545-2015; Jeyasuria, Pancharatnam/B-4710-2008	Marcos, Josep/0000-0002-3624-108X; Jeyasuria, Pancharatnam/0000-0002-1388-906X	MRC [G0100729] Funding Source: UKRI; Medical Research Council [G0100729] Funding Source: Medline	MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))		AGARWAL AK, 1990, MOL ENDOCRINOL, V4, P1827, DOI 10.1210/mend-4-12-1827; Alberts P, 2003, ENDOCRINOLOGY, V144, P4755, DOI 10.1210/en.2003-0344; Alberts P, 2002, DIABETOLOGIA, V45, P1528, DOI 10.1007/s00125-002-0959-6; Atanasov AG, 2004, FEBS LETT, V571, P129, DOI 10.1016/j.febslet.2004.06.065; Banhegyi G, 2004, J BIOL CHEM, V279, P27017, DOI 10.1074/jbc.M404159200; Barf T, 2002, J MED CHEM, V45, P3813, DOI 10.1021/jm025530f; BEUTLER E, 1967, J BIOL CHEM, V242, P5289; Bujalska IJ, 2005, J MOL ENDOCRINOL, V34, P675, DOI 10.1677/jme.1.01718; Clarke JL, 2003, ARCH BIOCHEM BIOPHYS, V415, P229, DOI 10.1016/S0003-9861(03)00229-7; Draper N, 2003, NAT GENET, V34, P434, DOI 10.1038/ng1214; Gerin I, 2002, FEBS LETT, V517, P257, DOI 10.1016/S0014-5793(02)02640-6; Kotelevtsev Y, 1997, P NATL ACAD SCI USA, V94, P14924, DOI 10.1073/pnas.94.26.14924; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MANDULA B, 1970, ARCH BIOCHEM BIOPHYS, V141, P155, DOI 10.1016/0003-9861(70)90118-9; Mason PJ, 1999, BLOOD CELL MOL DIS, V25, P30, DOI 10.1006/bcmd.1999.0224; Masuzaki H, 2003, J CLIN INVEST, V112, P83, DOI 10.1172/JCI17845; Masuzaki H, 2001, SCIENCE, V294, P2166, DOI 10.1126/science.1066285; McCormick KL, 2006, J BIOL CHEM, V281, P341, DOI 10.1074/jbc.M506026200; Morton NM, 2001, J BIOL CHEM, V276, P41293, DOI 10.1074/jbc.M103676200; Odermatt A, 1999, J BIOL CHEM, V274, P28762, DOI 10.1074/jbc.274.40.28762; OZOLS J, 1993, P NATL ACAD SCI USA, V90, P5302, DOI 10.1073/pnas.90.11.5302; Paterson JM, 2004, P NATL ACAD SCI USA, V101, P7088, DOI 10.1073/pnas.0305524101; ROMANELLI A, 1994, BIOCHEM BIOPH RES CO, V200, P1491, DOI 10.1006/bbrc.1994.1619; San Millan JL, 2005, J CLIN ENDOCR METAB, V90, P4157, DOI 10.1210/jc.2004-1523; SHACKLETON CHL, 1993, J STEROID BIOCHEM, V45, P127, DOI 10.1016/0960-0760(93)90132-G; SHACKLETON CHL, 1990, STEROIDS BILE ACID A, P297; TANAHASHI K, 1980, J HISTOCHEM CYTOCHEM, V28, P1175, DOI 10.1177/28.11.7430614; Tomlinson JW, 2004, ENDOCR REV, V25, P831, DOI 10.1210/er.2003-0031; Walker EA, 2001, J BIOL CHEM, V276, P21343, DOI 10.1074/jbc.M011142200; White PC, 2005, J CLIN ENDOCR METAB, V90, P5880, DOI 10.1210/jc.2005-0942; White PC, 1997, ENDOCR REV, V18, P135, DOI 10.1210/er.18.1.135	31	170	173	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 10	2006	281	10					6546	6551		10.1074/jbc.M512635200	http://dx.doi.org/10.1074/jbc.M512635200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	022BX	16356929	hybrid			2022-12-25	WOS:000236030800050
J	Albers, M; Blume, B; Schlueter, T; Wright, MB; Kober, I; Kremoser, C; Deuschle, U; Koegl, M				Albers, M; Blume, B; Schlueter, T; Wright, MB; Kober, I; Kremoser, C; Deuschle, U; Koegl, M			A novel principle for partial agonism of liver X receptor ligands - Competitive recruitment of activators and repressors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CRYSTAL-STRUCTURE; MOLECULAR DETERMINANTS; TISSUE-SPECIFICITY; CHOLESTEROL EFFLUX; LIPID-METABOLISM; GENE-EXPRESSION; BINDING DOMAIN; LXR-ALPHA; COACTIVATOR; IDENTIFICATION	Partial, selective activation of nuclear receptors is a central issue in molecular endocrinology but only partly understood. Using LXRs as an example, we show here that purely agonistic ligands can be clearly and quantitatively differentiated from partial agonists by the cofactor interactions they induce. Although a pure agonist induces a conformation that is incompatible with the binding of repressors, partial agonists such as GW3965 induce a state where the interaction not only with coactivators, but also corepressors is clearly enhanced over the unliganded state. The activities of the natural ligand 22(R)-hydroxycholesterol and of a novel quinazolinone ligand, LN6500 can be further differentiated from GW3965 and T0901317 by their weaker induction of coactivator binding. Using biochemical and cell-based assays, we show that the natural ligand of LXR is a comparably weak partial agonist. As predicted, we find that a change in the coactivator to corepressor ratio in the cell will affect NCoR recruiting compounds more dramatically than NCoR-dissociating compounds. Our data show how competitive binding of coactivators and corepressors can explain the tissue-specific behavior of partial agonists and open up new routes to a rational design of partial agonists for LXRs.	PheneX Pharmaceut AG, D-67056 Ludwigshafen, Germany; F Hoffmann La Roche & Cie AG, Dept Vasc & Metab Dis, CH-4070 Basel, Switzerland	Roche Holding	Koegl, M (corresponding author), RZPD German Resource Ctr Genome Res, Neuenheimer Feld 580, D-69120 Heidelberg, Germany.	koegl@rzpd.de		Wright, matthewwright/0000-0002-0532-3381				Albers M, 2005, MOL CELL PROTEOMICS, V4, P205, DOI 10.1074/mcp.M400169-MCP200; Bramlett KS, 2001, MOL ENDOCRINOL, V15, P909, DOI 10.1210/me.15.6.909; Chang CY, 1999, MOL CELL BIOL, V19, P8226; CHEN JD, 1995, NATURE, V377, P454, DOI 10.1038/377454a0; Chisholm JW, 2003, J LIPID RES, V44, P2039, DOI 10.1194/jlr.M300135-JLR200; Delmas PD, 1997, NEW ENGL J MED, V337, P1641, DOI 10.1056/NEJM199712043372301; Dyer BW, 2000, ANAL BIOCHEM, V282, P158, DOI 10.1006/abio.2000.4605; Farnegardh M, 2003, J BIOL CHEM, V278, P38821, DOI 10.1074/jbc.M304842200; Gronemeyer H, 2004, NAT REV DRUG DISCOV, V3, P950, DOI 10.1038/nrd1551; Hoerer S, 2003, J MOL BIOL, V334, P853, DOI 10.1016/j.jmb.2003.10.033; HORLEIN AJ, 1995, NATURE, V377, P397, DOI 10.1038/377397a0; Hu X, 1999, NATURE, V402, P93, DOI 10.1038/47069; Iannone MA, 2004, MOL ENDOCRINOL, V18, P1064, DOI 10.1210/me.2003-0432; Iannone MA, 2000, CYTOMETRY, V39, P131, DOI 10.1002/(SICI)1097-0320(20000201)39:2<131::AID-CYTO6>3.3.CO;2-L; Joseph SB, 2003, NAT MED, V9, P213, DOI 10.1038/nm820; Joseph SB, 2002, J BIOL CHEM, V277, P11019, DOI 10.1074/jbc.M111041200; Joseph SB, 2003, CURR OPIN PHARMACOL, V3, P192, DOI 10.1016/S1471-4892(03)00009-2; Lala DS, 2004, IDRUGS, V7, P563; LE DB, 1996, EMBO J, V15, P6701; Li AC, 2004, J LIPID RES, V45, P2161, DOI 10.1194/jlr.R400010-JLR200; Lund EG, 2003, ARTERIOSCL THROM VAS, V23, P1169, DOI 10.1161/01.ATV.0000056743.42348.59; McDonnell DP, 2003, ENDOCRINOLOGY, V144, P4237, DOI 10.1210/en.2003-0900; Miao B, 2004, J LIPID RES, V45, P1410, DOI 10.1194/jlr.M300450-JLR200; Paige LA, 1999, P NATL ACAD SCI USA, V96, P3999, DOI 10.1073/pnas.96.7.3999; Perissi V, 1999, GENE DEV, V13, P3198, DOI 10.1101/gad.13.24.3198; Quinet EM, 2004, J LIPID RES, V45, P1929, DOI 10.1194/jlr.M400257-JLR200; Repa JJ, 2000, GENE DEV, V14, P2819, DOI 10.1101/gad.844900; Repa JJ, 2000, SCIENCE, V289, P1524, DOI 10.1126/science.289.5484.1524; Schultz JR, 2000, GENE DEV, V14, P2831, DOI 10.1101/gad.850400; Schulz M, 2002, J BIOL CHEM, V277, P26238, DOI 10.1074/jbc.M203268200; Schwartz K, 2000, BIOCHEM BIOPH RES CO, V274, P794, DOI 10.1006/bbrc.2000.3243; Shang YF, 2002, SCIENCE, V295, P2465, DOI 10.1126/science.1068537; Smith CL, 1997, MOL ENDOCRINOL, V11, P657, DOI 10.1210/me.11.6.657; Smith CL, 2004, ENDOCR REV, V25, P45, DOI 10.1210/er.2003-0023; Sparrow CP, 2002, J BIOL CHEM, V277, P10021, DOI 10.1074/jbc.M108225200; Stanley TB, 2003, BIOCHEMISTRY-US, V42, P9278, DOI 10.1021/bi034472c; Steffensen KR, 2004, DIABETES, V53, pS36, DOI 10.2337/diabetes.53.2007.S36; Svensson S, 2003, EMBO J, V22, P4625, DOI 10.1093/emboj/cdg456; Tangirala RK, 2002, P NATL ACAD SCI USA, V99, P11896, DOI 10.1073/pnas.182199799; Terasaka N, 2003, FEBS LETT, V536, P6, DOI 10.1016/S0014-5793(02)03578-0; Torchia J, 1997, NATURE, V387, P677, DOI 10.1038/42652; Venkateswaran A, 2000, P NATL ACAD SCI USA, V97, P12097, DOI 10.1073/pnas.200367697; Wagner BL, 2003, MOL CELL BIOL, V23, P5780, DOI 10.1128/MCB.23.16.5780-5789.2003; Wang Q, 2004, MOL ENDOCRINOL, V18, P1376, DOI 10.1210/me.2003-0421; Whitney KD, 2001, J BIOL CHEM, V276, P43509, DOI 10.1074/jbc.M106155200; Williams S, 2003, J BIOL CHEM, V278, P27138, DOI 10.1074/jbc.M302260200; Xu HE, 2002, NATURE, V415, P813, DOI 10.1038/415813a; Yoshikawa T, 2001, MOL CELL BIOL, V21, P2991, DOI 10.1128/MCB.21.9.2991-3000.2001; Zechel C, 2002, J RECEPT SIGNAL TR R, V22, P31, DOI 10.1081/RRS-120014587	49	76	81	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 24	2006	281	8					4920	4930		10.1074/jbc.M510101200	http://dx.doi.org/10.1074/jbc.M510101200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	013RF	16354658	hybrid			2022-12-25	WOS:000235426200043
J	Eraly, SA; Vallon, V; Vaughn, DA; Gangoiti, JA; Richter, K; Nagle, M; Monte, JC; Rieg, T; Truong, DM; Long, JM; Barshop, BA; Kaler, G; Nigam, SK				Eraly, SA; Vallon, V; Vaughn, DA; Gangoiti, JA; Richter, K; Nagle, M; Monte, JC; Rieg, T; Truong, DM; Long, JM; Barshop, BA; Kaler, G; Nigam, SK			Decreased renal organic anion secretion and plasma accumulation of endogenous organic anions in OAT1 knock-out mice	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RESISTANCE PROTEIN MRP2; BETA-LACTAM ANTIBIOTICS; MOLECULAR-CLONING; RAT-KIDNEY; TRANSPORTER 1; CATION TRANSPORTERS; PARA-AMINOHIPPURATE; FUNCTIONAL-CHARACTERIZATION; SUBSTRATE-SPECIFICITY; CELLULAR PHYSIOLOGY	The "classical" organic anion secretory pathway of the renal proximal tubule is critical for the renal excretion of the prototypic organic anion, para-aminohippurate, as well as of a large number of commonly prescribed drugs among other significant substrates. Organic anion transporter 1 ( OAT1), originally identified as NKT ( Lopez-Nieto, C. E., You, G., Bush, K. T., Barros, E. J. G., Beier, D. R., and Nigam, S. K. ( 1997) J. Biol. Chem. 272, 6471-6478), has physiological properties consistent with a role in this pathway. However, several other transporters ( e. g. OAT2, OAT3, and MRP1) have also been proposed as important PAH transporters on the basis of in vitro studies; therefore, the relative contribution of OAT1 has remained unclear. We have now generated a colony of OAT1 knockout mice, permitting elucidation of the role of OAT1 in the context of these other potentially functionally redundant transporters. We find that the knock-out mice manifest a profound loss of organic anion transport ( e. g. para-aminohippurate) both ex vivo ( in isolated renal slices) as well as in vivo ( as indicated by loss of renal secretion). In the case of the organic anion, furosemide, loss of renal secretion in the knock-out results in impaired diuretic responsiveness to this drug. These results indicate a critical role for OAT1 in the functioning of the classical pathway. In addition, we have determined the levels of similar to 60 endogenous organic anions in the plasma and urine of wild-type and knock-out mice. This has led to identification of several compounds with significantly higher plasma concentrations and/or lower urinary concentrations in knock-out mice, suggesting the involvement of OAT1 in their renal secretion. We have also demonstrated in xenopus oocytes that some of these compounds interact with OAT1 in vitro. Thus, these latter compounds might represent physiological substrates of OAT1.	Univ Calif San Diego, Dept Med, La Jolla, CA 92093 USA; Univ Calif San Diego, Dept Pharmacol, La Jolla, CA 92093 USA; Univ Calif San Diego, Dept Pediat, La Jolla, CA 92093 USA; Univ Calif San Diego, Dept Cellular & Mol Med, La Jolla, CA 92093 USA; San Diego Vet Affairs Healthcare Syst, Dept Med, La Jolla, CA 92161 USA	University of California System; University of California San Diego; University of California System; University of California San Diego; University of California System; University of California San Diego; University of California System; University of California San Diego	Nigam, SK (corresponding author), Univ Calif San Diego, Dept Med, 9500 Gilman Dr, La Jolla, CA 92093 USA.	snigam@ucsd.edu	Rieg, Timo/W-7478-2019	Rieg, Timo/0000-0001-6082-662X; Vallon, Volker/0000-0002-9211-2063; Truong, David/0000-0002-5121-5111	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD040011] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI057695] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK028602, R01DK056248, K08DK064839] Funding Source: NIH RePORTER; NIAID NIH HHS [AI057695] Funding Source: Medline; NICHD NIH HHS [HD40011] Funding Source: Medline; NIDDK NIH HHS [DK064839, DK28602, DK56248] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Apiwattanakul N, 1999, MOL PHARMACOL, V55, P847; Bahn A, 2004, DRUG METAB DISPOS, V32, P424, DOI 10.1124/dmd.32.4.424; BEERMANN B, 1984, ACTA PHARMACOL TOX, V54, P17; BOUHAMIDI R, 1992, J STEROID BIOCHEM, V42, P345, DOI 10.1016/0960-0760(92)90138-9; BOWMAN HM, 1972, P SOC EXP BIOL MED, V141, P258; Brady KP, 1999, GENOMICS, V56, P254, DOI 10.1006/geno.1998.5722; Buist SCN, 2004, DRUG METAB DISPOS, V32, P620, DOI 10.1124/dmd.32.6.620; Buist SCN, 2003, DRUG METAB DISPOS, V31, P559, DOI 10.1124/dmd.31.5.559; Buist SCN, 2002, J PHARMACOL EXP THER, V301, P145, DOI 10.1124/jpet.301.1.145; BULLETTI C, 1988, AM J OBSTET GYNECOL, V159, P509, DOI 10.1016/S0002-9378(88)80119-4; Burckhardt BC, 2003, REV PHYSIOL BIOCH P, V146, P95, DOI 10.1007/s10254-002-0003-8; Burckhardt G, 2002, CELL BIOCHEM BIOPHYS, V36, P169, DOI 10.1385/CBB:36:2-3:169; Cha SH, 2000, J BIOL CHEM, V275, P4507, DOI 10.1074/jbc.275.6.4507; Cha SH, 2001, MOL PHARMACOL, V59, P1277, DOI 10.1124/mol.59.5.1277; Cihlar T, 2000, ANAL BIOCHEM, V283, P49, DOI 10.1006/abio.2000.4633; Cihlar T, 1999, MOL PHARMACOL, V56, P570, DOI 10.1124/mol.56.3.570; DALTON RN, 1988, KIDNEY INT, V34, P117, DOI 10.1038/ki.1988.153; Dantzler WH, 2003, BBA-BIOMEMBRANES, V1618, P185, DOI 10.1016/j.bbamem.2003.08.015; Dantzler WH, 2002, BBA-BIOMEMBRANES, V1566, P169, DOI 10.1016/S0005-2736(02)00599-0; DONOSO VS, 1986, J LAB CLIN MED, V107, P315; Dresser MJ, 2001, J PHARM SCI, V90, P397, DOI 10.1002/1520-6017(200104)90:4<397::AID-JPS1000>3.3.CO;2-4; Enomoto A, 2002, J PHARMACOL EXP THER, V301, P797, DOI 10.1124/jpet.301.3.797; Enomoto A, 2002, NATURE, V417, P447, DOI 10.1038/nature742; Eraly SA, 2004, MOL PHARMACOL, V65, P479, DOI 10.1124/mol.65.3.479; Eraly SA, 2004, PHYSIOL GENOMICS, V18, P12, DOI 10.1152/physiolgenomics.00014.2004; Eraly SA, 2003, CURR OPIN NEPHROL HY, V12, P551, DOI 10.1097/00041552-200309000-00011; Eraly SA, 2003, BIOCHEM BIOPH RES CO, V300, P333, DOI 10.1016/S0006-291X(02)02853-X; Eraly SA, 2002, BIOCHEM BIOPH RES CO, V297, P1159, DOI 10.1016/S0006-291X(02)02343-4; GOUGOUX A, 1989, AM J PHYSIOL, V257, pF959, DOI 10.1152/ajprenal.1989.257.6.F959; Groves CE, 1998, J PHARMACOL EXP THER, V284, P943; GRUNDEMANN D, 1994, NATURE, V372, P549, DOI 10.1038/372549a0; HOFFMANN G, 1989, CLIN CHEM, V35, P587; Huang DY, 2004, J AM SOC NEPHROL, V15, P885, DOI 10.1097/01.ASN.0000120368.59693.A8; Illum L, 2000, EUR J PHARM SCI, V11, P1, DOI 10.1016/S0928-0987(00)00087-7; Jariyawat S, 1999, J PHARMACOL EXP THER, V290, P672; Kobayashi Y, 2002, MOL PHARMACOL, V62, P7, DOI 10.1124/mol.62.1.7; Kojima R, 2002, J AM SOC NEPHROL, V13, DOI 10.1681/ASN.V134848; Konig J, 1999, BBA-BIOMEMBRANES, V1461, P377, DOI 10.1016/S0005-2736(99)00169-8; Kumps A, 2002, CLIN CHEM, V48, P708; Kusuhara H, 1999, J BIOL CHEM, V274, P13675, DOI 10.1074/jbc.274.19.13675; Kuze K, 1999, J BIOL CHEM, V274, P1519, DOI 10.1074/jbc.274.3.1519; Leier I, 2000, KIDNEY INT, V57, P1636, DOI 10.1046/j.1523-1755.2000.00007.x; Ljubojevic M, 2004, AM J PHYSIOL-RENAL, V287, pF124, DOI 10.1152/ajprenal.00029.2004; Lopez-Nieto C. E., 1996, Journal of the American Society of Nephrology, V7, P1301; LopezNieto CE, 1996, NAT BIOTECHNOL, V14, P857, DOI 10.1038/nbt0796-857; LopezNieto CE, 1997, J BIOL CHEM, V272, P6471, DOI 10.1074/jbc.272.10.6471; Lu R, 1999, AM J PHYSIOL-RENAL, V276, pF295, DOI 10.1152/ajprenal.1999.276.2.F295; MACDOUGALL ML, 1988, J PHYSIOL-LONDON, V397, P459, DOI 10.1113/jphysiol.1988.sp017012; Monte JC, 2004, BIOCHEM BIOPH RES CO, V323, P429, DOI 10.1016/j.bbrc.2004.08.112; Mori K, 1997, FEBS LETT, V417, P371, DOI 10.1016/S0014-5793(97)01325-2; Motohashi H, 2002, J AM SOC NEPHROL, V13, DOI 10.1681/ASN.V134866; Motojima M, 2002, BRIT J PHARMACOL, V135, P555, DOI 10.1038/sj.bjp.0704482; *NIH, 1996, GUID CAR US LAB AN N; Pavlova A, 2000, AM J PHYSIOL-RENAL, V278, pF635, DOI 10.1152/ajprenal.2000.278.4.F635; Pritchard JB, 1996, KIDNEY INT, V49, P1649, DOI 10.1038/ki.1996.240; RICHTERICH R, 1969, CLIN CHEM; Russel FGM, 2002, ANNU REV PHYSIOL, V64, P563, DOI 10.1146/annurev.physiol.64.081501.155913; Schomig E, 1998, FEBS LETT, V425, P79, DOI 10.1016/S0014-5793(98)00203-8; Sekine T, 1998, FEBS LETT, V429, P179, DOI 10.1016/S0014-5793(98)00585-7; Sekine T, 1997, J BIOL CHEM, V272, P18526, DOI 10.1074/jbc.272.30.18526; SIMONSON GD, 1994, J CELL SCI, V107, P1065; SKOV PE, 1977, ACTA MED SCAND, V202, P81; Smeets PHE, 2004, J AM SOC NEPHROL, V15, P2828, DOI 10.1097/01.ASN.0000143473.64430.AC; Sun W, 2001, BIOCHEM BIOPH RES CO, V283, P417, DOI 10.1006/bbrc.2001.4774; Sweet DH, 2005, TOXICOL APPL PHARM, V204, P198, DOI 10.1016/j.taap.2004.10.016; Sweet DH, 2003, AM J PHYSIOL-RENAL, V284, pF763, DOI 10.1152/ajprenal.00405.2002; Sweet DH, 2002, J BIOL CHEM, V277, P26934, DOI 10.1074/jbc.M203803200; Sweet DH, 1997, J BIOL CHEM, V272, P30088, DOI 10.1074/jbc.272.48.30088; Sykes D, 2004, AM J PHYSIOL-RENAL, V286, pF972, DOI 10.1152/ajprenal.00356.2003; Tune BM, 1997, PEDIATR NEPHROL, V11, P768, DOI 10.1007/s004670050386; Uchino H, 2000, BIOCHEM BIOPH RES CO, V270, P254, DOI 10.1006/bbrc.2000.2407; Uwai Y, 2000, J PHARMACOL EXP THER, V295, P261; Vallon V, 1998, J PHARMACOL EXP THER, V286, P1215; Vallon V, 2004, PFLUG ARCH EUR J PHY, V448, P214, DOI 10.1007/s00424-004-1239-8; Van Aubel RAMH, 2000, AM J PHYSIOL-RENAL, V279, pF216, DOI 10.1152/ajprenal.2000.279.2.F216; Van Aubel RAMH, 2000, AM J PHYSIOL-RENAL, V279, pF713, DOI 10.1152/ajprenal.2000.279.4.F713; Vormfelde SV, 2003, PHARMACOGENOMICS, V4, P701, DOI 10.1517/phgs.4.6.701.22817; Wright SH, 2004, PHYSIOL REV, V84, P987, DOI 10.1152/physrev.00040.2003; Youngblood GL, 2004, AM J PHYSIOL-RENAL, V287, pF236, DOI 10.1152/ajprenal.00012.2004	79	171	172	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 24	2006	281	8					5072	5083		10.1074/jbc.M508050200	http://dx.doi.org/10.1074/jbc.M508050200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	013RF	16354673	hybrid			2022-12-25	WOS:000235426200062
J	Mi, KH; Dolan, PJ; Johnson, GVW				Mi, KH; Dolan, PJ; Johnson, GVW			The low density lipoprotein receptor-related protein 6 interacts with glycogen synthase kinase 3 and attenuates activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLYCOGEN-SYNTHASE KINASE-3-BETA; PAIRED HELICAL FILAMENTS; WNT SIGNALING PATHWAY; BETA-CATENIN; ALZHEIMERS-DISEASE; TAU-PROTEIN; CANONICAL PATHWAY; PHOSPHORYLATION; AXIN; KINASE	Glycogen synthase kinase 3 (GSK3) is a widely expressed Ser/Thr protein kinase that phosphorylates numerous substrates. This large number of substrates requires precise and specific regulation of GSK3 activity, which is achieved by a combination of phosphorylation, localization, and interactions with GSK3-binding proteins. Members of the Wnt canonical pathway have been shown to influence GSK3 activity. Through a yeast two-hybrid screen, we identified the Wnt canonical pathway co-receptor protein low density lipoprotein receptor-related protein 6 (LRP6) as a GSK3-binding protein. The interaction between the C terminus of LRP6 and GSK3 was also confirmed by in vitro GST pull-down assays and in situ coimmunoprecipitation assays. In vitro assays using immunoprecipitated proteins demonstrated that the C terminus of LRP6 significantly attenuated the activity of GSK3 beta. In situ, LRP6 significantly decreased GSK3 beta-mediated phosphorylation of tau at both primed and unprimed sites. Finally, it was also demonstrated that GSK3 beta phosphorylates the PPP(S/T) P motifs in the C terminus of LRP6. This is the first identification of a direct interaction between LRP6 and GSK3, which results in an attenuation of GSK3 activity.	Univ Alabama, Dept Psychiat, Birmingham, AL 35294 USA	University of Alabama System; University of Alabama Birmingham	Johnson, GVW (corresponding author), Univ Alabama, Dept Psychiat, 1720 7th Ave S,SC1061, Birmingham, AL 35294 USA.	gvwj@uab.edu	Johnson, Gail V.W./K-4723-2012	Johnson, Gail V.W./0000-0003-3464-0404	NINDS NIH HHS [NS051279] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS051279] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Abraha A, 2000, J CELL SCI, V113, P3737; Amit S, 2002, GENE DEV, V16, P1066, DOI 10.1101/gad.230302; Bafico A, 1998, ONCOGENE, V16, P2819, DOI 10.1038/sj.onc.1201797; Billingsley ML, 1997, BIOCHEM J, V323, P577, DOI 10.1042/bj3230577; Brennan K, 2004, ONCOGENE, V23, P4873, DOI 10.1038/sj.onc.1207642; Caricasole A, 2004, J NEUROSCI, V24, P6021, DOI 10.1523/JNEUROSCI.1381-04.2004; Carmel G, 1996, J BIOL CHEM, V271, P32789, DOI 10.1074/jbc.271.51.32789; Cho JH, 2004, J NEUROCHEM, V88, P349, DOI 10.1046/j.1471-4159.2003.02155.x; Culbert AA, 2001, FEBS LETT, V507, P288, DOI 10.1016/S0014-5793(01)02990-8; Ferkey DM, 2002, J BIOL CHEM, V277, P16147, DOI 10.1074/jbc.M112363200; Gietz RD, 2002, METHOD ENZYMOL, V350, P87; GOEDERT M, 1994, BIOCHEM J, V301, P871, DOI 10.1042/bj3010871; GOEDERT M, 1989, NEURON, V3, P519, DOI 10.1016/0896-6273(89)90210-9; GREENBERG SG, 1990, P NATL ACAD SCI USA, V87, P5827, DOI 10.1073/pnas.87.15.5827; Grimes CA, 2001, PROG NEUROBIOL, V65, P391, DOI 10.1016/S0301-0082(01)00011-9; Hart M, 1999, CURR BIOL, V9, P207, DOI 10.1016/S0960-9822(99)80091-8; Hay E, 2005, J BIOL CHEM, V280, P13616, DOI 10.1074/jbc.M411999200; Hoffmann R, 1997, BIOCHEMISTRY-US, V36, P8114, DOI 10.1021/bi970380+; Holmen SL, 2005, BIOCHEM BIOPH RES CO, V328, P533, DOI 10.1016/j.bbrc.2005.01.009; Huber AH, 1997, CELL, V90, P871, DOI 10.1016/S0092-8674(00)80352-9; Ikeda S, 1998, EMBO J, V17, P1371, DOI 10.1093/emboj/17.5.1371; Johnson G V, 1999, J Alzheimers Dis, V1, P307; Johnson GVW, 1997, J NEUROCHEM, V68, P430; Jope RS, 2004, TRENDS BIOCHEM SCI, V29, P95, DOI 10.1016/j.tibs.2003.12.004; Lau KF, 1999, J PEPT RES, V54, P85, DOI 10.1034/j.1399-3011.1999.00083.x; Li L, 1999, EMBO J, V18, P4233, DOI 10.1093/emboj/18.15.4233; Li YH, 2004, ONCOGENE, V23, P9129, DOI 10.1038/sj.onc.1208123; Liu CM, 2002, CELL, V108, P837, DOI 10.1016/S0092-8674(02)00685-2; Maas T, 2000, J BIOL CHEM, V275, P15733, DOI 10.1074/jbc.M000389200; Mao BY, 2001, NATURE, V411, P321, DOI 10.1038/35077108; Mao JH, 2001, MOL CELL, V7, P801, DOI 10.1016/S1097-2765(01)00224-6; May P, 2002, J BIOL CHEM, V277, P18736, DOI 10.1074/jbc.M201979200; Mi KH, 2005, J CELL BIOCHEM, V95, P328, DOI 10.1002/jcb.20400; Mudher A, 2001, J NEUROSCI, V21, P4987, DOI 10.1523/JNEUROSCI.21-14-04987.2001; OTVOS L, 1994, J NEUROSCI RES, V39, P669, DOI 10.1002/jnr.490390607; Pinson KI, 2000, NATURE, V407, P535, DOI 10.1038/35035124; Seidensticker MJ, 2000, BBA-MOL CELL RES, V1495, P168, DOI 10.1016/S0167-4889(99)00158-5; Semenov MV, 2001, CURR BIOL, V11, P951, DOI 10.1016/S0960-9822(01)00290-1; Stoothof WH, 2002, J NEUROCHEM, V83, P904, DOI 10.1046/j.1471-4159.2002.01197.x; Stoothoff WH, 2005, J BIOL CHEM, V280, P270, DOI 10.1074/jbc.M410061200; Strutt D, 2003, DEVELOPMENT, V130, P4501, DOI 10.1242/dev.00695; Tamai K, 2004, MOL CELL, V13, P149, DOI 10.1016/S1097-2765(03)00484-2; Tamai K, 2000, NATURE, V407, P530, DOI 10.1038/35035117; Thomas GM, 1999, FEBS LETT, V458, P247, DOI 10.1016/S0014-5793(99)01161-8; van Amerongen R, 2005, GENE DEV, V19, P425, DOI 10.1101/gad.326705; Veeman MT, 2003, DEV CELL, V5, P367, DOI 10.1016/S1534-5807(03)00266-1; Watcharasit P, 2002, P NATL ACAD SCI USA, V99, P7951, DOI 10.1073/pnas.122062299; Wehrli M, 2000, NATURE, V407, P527, DOI 10.1038/35035110; WOODGETT JR, 1990, EMBO J, V9, P2431, DOI 10.1002/j.1460-2075.1990.tb07419.x; Zilberberg A, 2004, J BIOL CHEM, V279, P17535, DOI 10.1074/jbc.M311292200; Zorn AM, 2001, CURR BIOL, V11, pR592, DOI 10.1016/S0960-9822(01)00360-8; Zou ZY, 2004, J BIOL CHEM, V279, P34302, DOI 10.1074/jbc.M405608200	52	67	84	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 24	2006	281	8					4787	4794		10.1074/jbc.M508657200	http://dx.doi.org/10.1074/jbc.M508657200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	013RF	16365045	hybrid			2022-12-25	WOS:000235426200029
J	Nacak, TG; Leptien, K; Fellner, D; Augustin, HG; Kroll, J				Nacak, TG; Leptien, K; Fellner, D; Augustin, HG; Kroll, J			The BTB-kelch protein LZTR-1 is a novel Golgi protein that is degraded upon induction of apoptosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CASPASE-MEDIATED CLEAVAGE; CUL3-BASED E3 LIGASE; REPEAT SUPERFAMILY; NRF2; INHIBITION; ADAPTER; ELEMENTS; COMPLEX; BINDING; BRIDGES	Members of the BTB-kelch superfamily play important roles during fundamental cellular processes, such as the regulation of cell morphology, migration, and gene expression. The BTB-kelch protein LZTR-1is deleted in the majority of DiGeorge syndrome patients and is believed to act as a transcriptional regulator. However, functional and expression profiling studies of LZTR-1 have not been performed thus far. Therefore, we examined the subcellular localization and function of LZTR-1 to gain insights into its biological role. Analysis of the primary structure of the protein revealed six N-terminal kelch motifs and two BTB/POZ domains at the C terminus within LZTR-1. Confocal analysis of the subcellular distribution of LZTR-1 using the Golgi markers GM130, Golgin-97, and TGN46 identified a localization of LZTR-1 exclusively on the cytoplasmic surface of the Golgi network that is mediated by its second BTB/POZ domain. In contrast to most other BTB-kelch proteins, LZTR-1 did not co-localize with actin. Treatment with brefeldin A did not lead to redistribution of LZTR-1 to the endoplasmic reticulum but caused its relocalization in dispersed, punctuated structures that were also positive for GM130. These data demonstrate that LZTR-1 is a Golgi matrix-associated protein. Upon induction of apoptosis, LZTR-1 was phosphorylated on tyrosine residues and subsequently degraded; that could be rescued partially by the addition of the caspase inhibitor Z-VAD-fmk and the proteasome inhibitors lactacystin and MG132. Taken together, our experiments identify LZTR-1 as the first BTB-kelch protein that exclusively localizes to the Golgi network, and the binding of LZTR-1 to the Golgi complex is mediated by its second BTB/POZ domain.	Tumor Biol Ctr, Dept Vasc Biol & Angiogenesis Res, D-79106 Freiburg, Germany		Kroll, J (corresponding author), Tumor Biol Ctr, Dept Vasc Biol & Angiogenesis Res, Breisacher Str 117, D-79106 Freiburg, Germany.	kroll@tumorbio.uni-freiburg.de	Augustin, Hellmut/AAA-5246-2020	Augustin, Hellmut/0000-0002-7173-4242				Adams J, 2000, TRENDS CELL BIOL, V10, P17, DOI 10.1016/S0962-8924(99)01673-6; Barr FA, 1999, CURR BIOL, V9, P381, DOI 10.1016/S0960-9822(99)80167-5; Bartke T, 2004, MOL CELL, V14, P801, DOI 10.1016/j.molcel.2004.05.018; Cullen VC, 2004, NEUROREPORT, V15, P873, DOI 10.1097/00001756-200404090-00028; Cullinan SB, 2004, MOL CELL BIOL, V24, P8477, DOI 10.1128/MCB.24.19.8477-8486.2004; Deveraux QL, 1998, EMBO J, V17, P2215, DOI 10.1093/emboj/17.8.2215; Fujimura L, 2004, CARDIOVASC RES, V64, P315, DOI 10.1016/j.cardiores.2004.07.009; Geyer R, 2003, MOL CELL, V12, P783, DOI 10.1016/S1097-2765(03)00341-1; Griffith KJ, 1997, ARTHRITIS RHEUM, V40, P1693, DOI 10.1002/art.1780400920; Hicks SW, 2002, J BIOL CHEM, V277, P35833, DOI 10.1074/jbc.M206280200; Itoh K, 1999, GENE DEV, V13, P76, DOI 10.1101/gad.13.1.76; Keller JN, 2000, J NEUROSCI RES, V61, P436, DOI 10.1002/1097-4547(20000815)61:4<436::AID-JNR10>3.0.CO;2-Z; Kelly KF, 2004, J CELL SCI, V117, P6143, DOI 10.1242/jcs.01541; Kim IF, 1999, GENE, V228, P73, DOI 10.1016/S0378-1119(99)00006-2; Kobayashi A, 2004, MOL CELL BIOL, V24, P7130, DOI 10.1128/MCB.24.16.7130-7139.2004; Kroll J, 2005, MOL CELL BIOL, V25, P8531, DOI 10.1128/MCB.25.19.8531-8540.2005; KURAHASHI H, 1995, HUM MOL GENET, V4, P541, DOI 10.1093/hmg/4.4.541; Lane JD, 2002, J CELL BIOL, V156, P495, DOI 10.1083/jcb.200110007; Lindsay EA, 2001, NAT REV GENET, V2, P858, DOI 10.1038/35098574; Lowe M, 2004, J CELL SCI, V117, P1139, DOI 10.1242/jcs.00950; Maisonpierre PC, 1997, SCIENCE, V277, P55, DOI 10.1126/science.277.5322.55; Mancini M, 2000, J CELL BIOL, V149, P603, DOI 10.1083/jcb.149.3.603; Nakamura N, 1995, J CELL BIOL, V131, P1715, DOI 10.1083/jcb.131.6.1715; Philpott KL, 1996, EUR J NEUROSCI, V8, P1906, DOI 10.1111/j.1460-9568.1996.tb01334.x; Pintard L, 2003, NATURE, V425, P311, DOI 10.1038/nature01959; Prag S, 2003, BMC BIOINFORMATICS, V4, DOI 10.1186/1471-2105-4-42; Prescott AR, 1997, EUR J CELL BIOL, V72, P238; Scambler PJ, 2000, HUM MOL GENET, V9, P2421, DOI 10.1093/hmg/9.16.2421; Sesso A, 1999, TISSUE CELL, V31, P357, DOI 10.1054/tice.1999.0042; Stogios PJ, 2004, TRENDS BIOCHEM SCI, V29, P634, DOI 10.1016/j.tibs.2004.10.003; Wakabayashi N, 2003, NAT GENET, V35, P238, DOI 10.1038/ng1248; XUE FY, 1993, CELL, V72, P681, DOI 10.1016/0092-8674(93)90397-9; Yan W, 2004, P NATL ACAD SCI USA, V101, P7793, DOI 10.1073/pnas.0308025101; Zipper LM, 2002, J BIOL CHEM, V277, P36544, DOI 10.1074/jbc.M206530200	34	41	43	1	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 24	2006	281	8					5065	5071		10.1074/jbc.M509073200	http://dx.doi.org/10.1074/jbc.M509073200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	013RF	16356934	hybrid			2022-12-25	WOS:000235426200061
J	Balatsos, NAA; Nilsson, P; Mazza, C; Cusack, S; Virtanen, A				Balatsos, NAA; Nilsson, P; Mazza, C; Cusack, S; Virtanen, A			Inhibition of mRNA deadenylation by the nuclear cap binding complex (CBC)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EUKARYOTIC TRANSLATION INITIATION; AU-RICH ELEMENTS; POLY(A)-SPECIFIC RIBONUCLEASE; POLY(A)-BINDING PROTEIN; MAMMALIAN-CELLS; POLY(A) BINDING; IN-VITRO; SACCHAROMYCES-CEREVISIAE; CYTOPLASMIC EXTRACTS; YEAST	Poly(A)-specific ribonuclease (PARN) is a cap-interacting and poly(A)-specific 3'-exoribonuclease. Here we have investigated how the cap binding complex ( CBC) affects human PARN activity. We showed that CBC, via its 80-kDa subunit (CBP80), inhibited PARN, suggesting that CBC can regulate mRNA deadenylation. The CBC-mediated inhibition of PARN was cap-independent, and in keeping with this, the CBP80 subunit alone inhibited PARN. Our data suggested a new function for CBC, identified CBC as a potential regulator of PARN, and emphasized the importance of communication between the two extreme ends of the mRNA as a key strategy to regulate mRNA degradation. Based on our data, we have proposed a model for CBC-mediated regulation of PARN, which relies on an interaction between CBP80 and PARN. Association of CBC with PARN might have importance in the regulated recruitment of PARN to the nonsense-mediated decay pathway during the pioneer round of translation.	Uppsala Univ, Dept Cell & Mol Biol, SE-75124 Uppsala, Sweden; European Mol Biol Lab, Grenoble Outstn, F-38042 Grenoble 9, France	Uppsala University; European Molecular Biology Laboratory (EMBL)	Virtanen, A (corresponding author), Uppsala Univ, Dept Cell & Mol Biol, Box 596, SE-75124 Uppsala, Sweden.	anders.virtanen@icm.uu.se		Cusack, Stephen/0000-0002-9324-0796; Balatsos, Nikolaos/0000-0002-1146-1174				ASTRON J, 1999, EMBO J, V10, P3067; Boeck R, 1996, J BIOL CHEM, V271, P432, DOI 10.1074/jbc.271.1.432; Calero G, 2002, NAT STRUCT BIOL, V9, P912, DOI 10.1038/nsb874; CAPONIGRO G, 1995, GENE DEV, V9, P2421, DOI 10.1101/gad.9.19.2421; CHEN CYA, 1995, TRENDS BIOCHEM SCI, V20, P465, DOI 10.1016/S0968-0004(00)89102-1; Chiba Y, 2004, GENE, V328, P95, DOI 10.1016/j.gene.2003.11.028; Coller J, 2004, ANNU REV BIOCHEM, V73, P861, DOI 10.1146/annurev.biochem.73.011303.074032; Coller JM, 1998, GENE DEV, V12, P3226, DOI 10.1101/gad.12.20.3226; Copeland PR, 2001, RNA, V7, P875, DOI 10.1017/S1355838201010020; Daugeron MC, 2001, NUCLEIC ACIDS RES, V29, P2448, DOI 10.1093/nar/29.12.2448; Dehlin E, 2000, EMBO J, V19, P1079, DOI 10.1093/emboj/19.5.1079; Dreyfuss G, 2002, NAT REV MOL CELL BIO, V3, P195, DOI 10.1038/nrm760; Flaherty SM, 1997, P NATL ACAD SCI USA, V94, P11893, DOI 10.1073/pnas.94.22.11893; Fortes P, 2000, MOL CELL, V6, P191, DOI 10.1016/S1097-2765(00)00020-4; Gao M, 2000, MOL CELL, V5, P479, DOI 10.1016/S1097-2765(00)80442-6; Gao M, 2001, EMBO J, V20, P1134, DOI 10.1093/emboj/20.5.1134; Gherzi R, 2004, MOL CELL, V14, P571, DOI 10.1016/j.molcel.2004.05.002; Ishigaki Y, 2001, CELL, V106, P607, DOI 10.1016/S0092-8674(01)00475-5; Izaurralde E, 1995, COLD SPRING HARB SYM, V60, P669, DOI 10.1101/SQB.1995.060.01.072; IZAURRALDE E, 1994, CELL, V78, P657, DOI 10.1016/0092-8674(94)90530-4; JAREBORG N, 1991, J GEN VIROL, V72, P2269, DOI 10.1099/0022-1317-72-9-2269; Khanna R, 2004, EMBO J, V23, P1968, DOI 10.1038/sj.emboj.7600213; Korner CG, 1997, J BIOL CHEM, V272, P10448; Korner CG, 1998, EMBO J, V17, P5427, DOI 10.1093/emboj/17.18.5427; Kuhn U, 2004, BBA-GENE STRUCT EXPR, V1678, P67, DOI 10.1016/j.bbaexp.2004.03.008; Lai WS, 2003, MOL CELL BIOL, V23, P3798, DOI 10.1128/MCB.23.11.3798-3812.2003; Lejeune F, 2004, NAT STRUCT MOL BIOL, V11, P992, DOI 10.1038/nsmb824; Lejeune F, 2003, MOL CELL, V12, P675, DOI 10.1016/S1097-2765(03)00349-6; Maquat LE, 2004, NAT REV MOL CELL BIO, V5, P89, DOI 10.1038/nrm1310; Martinez J, 2001, J BIOL CHEM, V276, P27923, DOI 10.1074/jbc.M102270200; Martinez J, 2000, J BIOL CHEM, V275, P24222, DOI 10.1074/jbc.M001705200; Mazza C, 2002, EMBO J, V21, P5548, DOI 10.1093/emboj/cdf538; Mazza C, 2001, MOL CELL, V8, P383, DOI 10.1016/S1097-2765(01)00299-4; McKendrick L, 2001, MOL CELL BIOL, V21, P3632, DOI 10.1128/MCB.21.11.3632-3641.2001; Meyer S, 2004, CRIT REV BIOCHEM MOL, V39, P197, DOI 10.1080/10409230490513991; Niedzwiecka A, 2002, J MOL BIOL, V319, P615, DOI 10.1016/S0022-2836(02)00328-5; Ohno M, 2000, CELL, V101, P187, DOI 10.1016/S0092-8674(00)80829-6; Parker R, 2004, NAT STRUCT MOL BIOL, V11, P121, DOI 10.1038/nsmb724; Ren YG, 2002, RNA, V8, P1393, DOI 10.1017/S1355838202021015; Sachs AB, 2000, NAT STRUCT BIOL, V7, P356, DOI 10.1038/75120; Seal R, 2005, NUCLEIC ACIDS RES, V33, P376, DOI 10.1093/nar/gki169; Shatkin AJ, 2000, NAT STRUCT BIOL, V7, P838, DOI 10.1038/79583; SHAW G, 1986, CELL, V46, P659, DOI 10.1016/0092-8674(86)90341-7; Tran H, 2004, MOL CELL, V13, P101, DOI 10.1016/S1097-2765(03)00481-7; Tucker M, 2002, EMBO J, V21, P1427, DOI 10.1093/emboj/21.6.1427; Tucker M, 2001, CELL, V104, P377, DOI 10.1016/S0092-8674(01)00225-2; Uchida N, 2004, J BIOL CHEM, V279, P1383, DOI 10.1074/jbc.M309125200; VARNUM SM, 1992, DEV BIOL, V153, P283, DOI 10.1016/0012-1606(92)90113-U; Visa N, 1996, J CELL BIOL, V133, P5, DOI 10.1083/jcb.133.1.5; Viswanathan P, 2003, J BIOL CHEM, V278, P14949, DOI 10.1074/jbc.M211794200; Wilusz CJ, 2001, NAT REV MOL CELL BIO, V2, P237, DOI 10.1038/35067025; Wilusz CJ, 2001, RNA, V7, P1416; Worch R, 2005, RNA, V11, P1355, DOI 10.1261/rna.2850705; Wu MS, 2005, EMBO J, V24, P4082, DOI 10.1038/sj.emboj.7600869	54	51	55	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 17	2006	281	7					4517	4522		10.1074/jbc.M508590200	http://dx.doi.org/10.1074/jbc.M508590200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	011NN	16317009	hybrid			2022-12-25	WOS:000235275300087
J	Eckhardt, ERM; Cai, L; Shetty, S; Zhao, ZZ; Szanto, A; Webb, NR; Van der Westhuyzen, DR				Eckhardt, ERM; Cai, L; Shetty, S; Zhao, ZZ; Szanto, A; Webb, NR; Van der Westhuyzen, DR			High density lipoprotein endocytosis by scavenger receptor SR-BII is clathrin-dependent and requires a carboxyl-terminal dileucine motif	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							B TYPE-I; SELECTIVE LIPID UPTAKE; COATED PIT FORMATION; MEDIATED ENDOCYTOSIS; CHOLESTERYL ESTERS; TRANSPORT; CELLS; METABOLISM; PROTEINS; GLYCOSPHINGOLIPIDS	The high density lipoprotein (HDL) receptor Scavenger Receptor BII (SR-BII) is encoded by an alternatively spliced mRNA from the SR-BI gene and is expressed in various tissues. SR-BII protein differs from SR-BI only in the carboxyl-terminal cytoplasmic tail, which, as we showed previously, must contain a signal that confers predominant intracellular expression and rapid endocytosis of HDL. We haveshown thatSR-BII mediates HDL endocytosis through a clathrin-dependent, caveolae-independent pathway. Two candidate amino acid motifs were identified in the tail that could mediate association with clathrin-containing endocytic vesicles: a putative dileucine motif at position 492-493 and an overlapping tyrosine-based YXXZ motif starting at position 489. Although substitution of tyrosine at position 489 with alanine or histidine did not affect endocytosis, substitution L492A resulted in increased surface binding of HDL and reduced HDL particle endocytosis. Substitution L493A had a less dramatic effect. No other regions in the carboxyl-terminal tail appeared to contain motifs required for HDL endocytosis. Substitutions of leucine at position 492 with the hydrophobic amino acids valine or phenylalanine also reduced HDL endocytosis, stressing the importance of leucine at this position. Introducing the SR-BII YTPLL motif into the carboxyl-terminal cytoplasmic tail of SR-BI converted SR-BI into an endocytic receptor resembling SR-BII. These results demonstrated that SR- BII differs from SR-BI in subcellular localization and trafficking and suggest that the two isoforms differ in the manner in which they target ligands intracellularly.	Univ Kentucky, Grad Ctr Nutr Sci, Lexington, KY 40536 USA; Univ Kentucky, Dept Internal Med, Lexington, KY 40536 USA; Univ Debrecen, Dept Biochem & Mol Biol, Res Ctr Mol Med, Med & Hlth Sci Ctr, H-4012 Debrecen, Hungary	University of Kentucky; University of Kentucky; University of Debrecen	Van der Westhuyzen, DR (corresponding author), Univ Kentucky, Grad Ctr Nutr Sci, Wethington Hlth Sci Bldg,Rm 541,900 S Limestone S, Lexington, KY 40536 USA.	dvwest1@uky.edu	Webb, Nancy/AAL-7030-2021; Szanto, Attila/B-2198-2012; Zhao, Zhenze/AAW-5870-2020; Eckhardt, Erik/G-1567-2010	Eckhardt, Erik/0000-0002-3015-5180				Azhar S, 2002, MOL CELL ENDOCRINOL, V195, P1, DOI 10.1016/S0303-7207(02)00222-8; Azhar S, 1998, J LIPID RES, V39, P1616; BILHEIMER DW, 1972, BIOCHIM BIOPHYS ACTA, V260, P212, DOI 10.1016/0005-2760(72)90034-3; Bonifacino JS, 2003, ANNU REV BIOCHEM, V72, P395, DOI 10.1146/annurev.biochem.72.121801.161800; Bonifacino JS, 1999, J CELL BIOL, V145, P923, DOI 10.1083/jcb.145.5.923; Braun A, 2002, CIRC RES, V90, P270, DOI 10.1161/hh0302.104462; Connelly MA, 2004, CURR OPIN LIPIDOL, V15, P287, DOI 10.1097/00041433-200406000-00008; Duncan KG, 2002, BIOCHEM BIOPH RES CO, V292, P1017, DOI 10.1006/bbrc.2002.6756; Eckhardt ERM, 2004, J BIOL CHEM, V279, P14372, DOI 10.1074/jbc.M313793200; GLASS C, 1983, P NATL ACAD SCI-BIOL, V80, P5435, DOI 10.1073/pnas.80.17.5435; GWYNNE JT, 1989, J BIOL CHEM, V264, P8141; HEUSER JE, 1989, J CELL BIOL, V108, P389, DOI 10.1083/jcb.108.2.389; Krieger M, 1999, ANNU REV BIOCHEM, V68, P523, DOI 10.1146/annurev.biochem.68.1.523; LARKIN JM, 1983, CELL, V33, P273, DOI 10.1016/0092-8674(83)90356-2; Liu B, 2002, J BIOL CHEM, V277, P34125, DOI 10.1074/jbc.M204265200; Maxfield FR, 2002, J CLIN INVEST, V110, P891, DOI 10.1172/JCI200216500; Mayor S, 1998, EMBO J, V17, P4626, DOI 10.1093/emboj/17.16.4626; Mulcahy JV, 2004, BIOCHEM J, V377, P741, DOI 10.1042/bj20030307; Nieland TJF, 2005, BBA-MOL CELL BIOL L, V1734, P44, DOI 10.1016/j.bbalip.2005.02.007; Peng Y, 2004, MOL BIOL CELL, V15, P384, DOI 10.1091/mbc.e03-06-0445; REAVEN E, 1984, J CLIN INVEST, V74, P1384, DOI 10.1172/JCI111549; Rigotti A, 2003, ENDOCR REV, V24, P357, DOI 10.1210/er.2001-0037; Ritsch A, 2004, J LIPID RES, V45, P214, DOI 10.1194/jlr.M300353-JLR200; Rodrigueza WV, 1999, J BIOL CHEM, V274, P20344, DOI 10.1074/jbc.274.29.20344; Rous BA, 2002, MOL BIOL CELL, V13, P1071, DOI 10.1091/mbc.01-08-0409; SCHNITZER JE, 1994, J CELL BIOL, V127, P1217, DOI 10.1083/jcb.127.5.1217; Sharma DK, 2004, MOL BIOL CELL, V15, P3114, DOI 10.1091/mbc.E04-03-0189; Silver DL, 2001, J BIOL CHEM, V276, P25287, DOI 10.1074/jbc.M101726200; Singh RD, 2003, MOL BIOL CELL, V14, P3254, DOI 10.1091/mbc.E02-12-0809; Stangl H, 1999, J BIOL CHEM, V274, P32692, DOI 10.1074/jbc.274.46.32692; STRACHAN AF, 1988, BIOCHEM J, V250, P203, DOI 10.1042/bj2500203; Thilakawardhana S, 2005, NEUROBIOL AGING, V26, P813, DOI 10.1016/j.neurobiolaging.2004.08.004; Trigatti BL, 2003, ARTERIOSCL THROM VAS, V23, P1732, DOI 10.1161/01.ATV.0000091363.28501.84; Webb NR, 1998, J BIOL CHEM, V273, P15241, DOI 10.1074/jbc.273.24.15241; Webb NR, 1997, J LIPID RES, V38, P1490; Wustner D, 2005, J BIOL CHEM, V280, P6766, DOI 10.1074/jbc.M413238200; Wustner D, 2004, J LIPID RES, V45, P427, DOI 10.1194/jlr.M300440-JLR200	37	51	51	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 17	2006	281	7					4348	4353		10.1074/jbc.M513154200	http://dx.doi.org/10.1074/jbc.M513154200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	011NN	16368683	hybrid			2022-12-25	WOS:000235275300070
J	Lee, EB; Leng, LZ; Zhang, B; Kwong, L; Trojanowski, JQ; Abel, T; Lee, VMY				Lee, EB; Leng, LZ; Zhang, B; Kwong, L; Trojanowski, JQ; Abel, T; Lee, VMY			Targeting amyloid-beta peptide (A beta) oligomers by passive immunization with a conformation-selective monoclonal antibody improves learning and memory in A beta precursor protein (APP) transgenic mice	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LONG-TERM POTENTIATION; CENTRAL-NERVOUS-SYSTEM; ALZHEIMERS-DISEASE; MOUSE MODEL; IN-VIVO; BRAIN; IMMUNOTHERAPY; MECHANISMS; DEPOSITION; CLEARANCE	Passive immunization of murine models of Alzheimer disease amyloidosis reduces amyloid-beta peptide (A beta) levels and improves cognitive function. To specifically address the role of A beta oligomers in learning and memory, we generated a novel monoclonal antibody, NAB61, that preferentially recognizes a conformational epitope present in dimeric, small oligomeric, and higher order A beta structures but not full-length amyloid-beta precursor protein or C-terminal amyloid-beta precursor protein fragments. NAB61 also recognized a subset of brain A beta deposits, preferentially mature senile plaques, and amyloid angiopathy. Using NAB61 as immunotherapy, we showed that aged Tg2576 transgenic mice treated with NAB61 displayed significant improvements in spatial learning and memory relative to control mice. These data implicated A beta oligomers as a pathologic substrate for cognitive decline in Alzheimer disease.	Univ Penn, Dept Pathol & Lab Med, Ctr Neurodegenerat Dis Res, Sch Med, Philadelphia, PA 19104 USA; Univ Penn, Sch Med, Inst Aging, Philadelphia, PA 19104 USA; Univ Penn, Sch Med, Dept Biol, Philadelphia, PA 19104 USA	University of Pennsylvania; Pennsylvania Medicine; University of Pennsylvania; University of Pennsylvania	Lee, VMY (corresponding author), Univ Penn, Dept Pathol & Lab Med, Ctr Neurodegenerat Dis Res, Sch Med, 3rd Fl,Maloney Bldg,3600 Spruce St, Philadelphia, PA 19104 USA.	vmylee@mail.med.upenn.edu	Abel, Ted/AAX-2825-2021; Lee, Edward/AAU-8436-2021	Abel, Ted/0000-0003-2423-4592; 	NATIONAL INSTITUTE ON AGING [P01AG011542, P50AG008012, T32AG000255] Funding Source: NIH RePORTER; NIA NIH HHS [AG11542, T32 AG00255, AG008012] Funding Source: Medline	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Backskai BJ, 2001, NAT MED, V7, P369, DOI 10.1038/85525; Bacskai BJ, 2002, J NEUROSCI, V22, P7873; Bard F, 2000, NAT MED, V6, P916, DOI 10.1038/78682; Bard F, 2003, P NATL ACAD SCI USA, V100, P2023, DOI 10.1073/pnas.0436286100; Bitan G, 2001, J BIOL CHEM, V276, P35176, DOI 10.1074/jbc.M102223200; BRAAK H, 1991, ACTA NEUROPATHOL, V82, P239, DOI 10.1007/BF00308809; Bussiere T, 2004, AM J PATHOL, V165, P987, DOI 10.1016/S0002-9440(10)63360-3; Cirrito JR, 2003, J NEUROSCI, V23, P8844; Cleary JP, 2005, NAT NEUROSCI, V8, P79, DOI 10.1038/nn1372; DeMattos RB, 2001, P NATL ACAD SCI USA, V98, P8850, DOI 10.1073/pnas.151261398; Dodart JC, 2002, NAT NEUROSCI, V5, P452, DOI 10.1038/nn842; Gong YS, 2003, P NATL ACAD SCI USA, V100, P10417, DOI 10.1073/pnas.1834302100; Hartley DM, 1999, J NEUROSCI, V19, P8876, DOI 10.1523/JNEUROSCI.19-20-08876.1999; Hartman RE, 2005, J NEUROSCI, V25, P6213, DOI 10.1523/JNEUROSCI.0664-05.2005; Hock C, 2002, NAT MED, V8, P1270, DOI 10.1038/nm783; Hsia AY, 1999, P NATL ACAD SCI USA, V96, P3228, DOI 10.1073/pnas.96.6.3228; Hsiao K, 1996, SCIENCE, V274, P99, DOI 10.1126/science.274.5284.99; Janus C, 2000, NATURE, V408, P979, DOI 10.1038/35050110; Kayed R, 2003, SCIENCE, V300, P486, DOI 10.1126/science.1079469; Klyubin I, 2005, NAT MED, V11, P556, DOI 10.1038/nm1234; Kotilinek LA, 2002, J NEUROSCI, V22, P6331; Lambert MP, 2001, J NEUROCHEM, V79, P595, DOI 10.1046/j.1471-4159.2001.00592.x; Lambert MP, 1998, P NATL ACAD SCI USA, V95, P6448, DOI 10.1073/pnas.95.11.6448; Lee EB, 2005, FEBS LETT, V579, P2564, DOI 10.1016/j.febslet.2005.03.070; Lee EB, 2005, J CELL BIOL, V168, P291, DOI 10.1083/jcb.200407070; Lee EB, 2003, J BIOL CHEM, V278, P4458, DOI 10.1074/jbc.M210105200; Lue LF, 1999, AM J PATHOL, V155, P853, DOI 10.1016/S0002-9440(10)65184-X; McLean CA, 1999, ANN NEUROL, V46, P860, DOI 10.1002/1531-8249(199912)46:6<860::AID-ANA8>3.0.CO;2-M; Moir RD, 2005, J BIOL CHEM, V280, P17458, DOI 10.1074/jbc.M414176200; Morgan D, 2000, NATURE, V408, P982, DOI 10.1038/35050116; Mucke L, 2000, J NEUROSCI, V20, P4050, DOI 10.1523/jneurosci.20-11-04050.2000; Naslund J, 2000, JAMA-J AM MED ASSOC, V283, P1571, DOI 10.1001/jama.283.12.1571; Neely MD, 2002, CHEM RES TOXICOL, V15, P40, DOI 10.1021/tx010115w; Nicoll JAR, 2003, NAT MED, V9, P448, DOI 10.1038/nm840; Norris EH, 2003, J BIOL CHEM, V278, P27230, DOI 10.1074/jbc.M212436200; O'Nuallain B, 2002, P NATL ACAD SCI USA, V99, P1485, DOI 10.1073/pnas.022662599; Orgogozo JM, 2003, NEUROLOGY, V61, P46, DOI 10.1212/01.WNL.0000073623.84147.A8; Schenk D, 1999, NATURE, V400, P173, DOI 10.1038/22124; TROJANOWSKI JQ, 1989, J HISTOCHEM CYTOCHEM, V37, P209, DOI 10.1177/37.2.2492045; Walsh DM, 2002, NATURE, V416, P535, DOI 10.1038/416535a; Westerman MA, 2002, J NEUROSCI, V22, P1858, DOI 10.1523/JNEUROSCI.22-05-01858.2002; Wilcock DM, 2004, J NEUROSCI, V24, P6144, DOI 10.1523/JNEUROSCI.1090-04.2004; Wilcock DM, 2003, J NEUROSCI, V23, P3745, DOI 10.1523/jneurosci.23-09-03745.2003; YANG AJ, 1995, J BIOL CHEM, V270, P14786, DOI 10.1074/jbc.270.24.14786	44	244	283	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 17	2006	281	7					4292	4299		10.1074/jbc.M511018200	http://dx.doi.org/10.1074/jbc.M511018200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	011NN	16361260	hybrid			2022-12-25	WOS:000235275300063
J	Ohyama, Y; Meaney, S; Heverin, M; Ekstrom, L; Brafman, A; Shafir, M; Andersson, U; Olin, M; Eggertsen, G; Diczfalusy, U; Feinstein, E; Bjorkhem, I				Ohyama, Y; Meaney, S; Heverin, M; Ekstrom, L; Brafman, A; Shafir, M; Andersson, U; Olin, M; Eggertsen, G; Diczfalusy, U; Feinstein, E; Bjorkhem, I			Studies on the transcriptional regulation of cholesterol 24-hydroxylase (CYP46A1) - Marked insensitivity toward different regulatory axes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CENTRAL-NERVOUS-SYSTEM; RETINOID-X-RECEPTOR; ALZHEIMERS-DISEASE; BRAIN CHOLESTEROL; APOE PROMOTER; 24S-HYDROXYLASE GENE; STEROL-METABOLISM; APOLIPOPROTEIN-E; FATTY-ACIDS; IN-VIVO	Mammalian CNS contains a disproportionally large and remarkably stable pool of cholesterol. Despite an efficient recycling there is some requirement for elimination of brain cholesterol. Conversion of cholesterol into 24S-hydroxycholesterol by the cholesterol 24-hydroxylase (CYP46A1) is the quantitatively most important mechanism. Based on the protein expression and plasma levels of 24S-hydroxycholesterol, CYP46A1 activity appears to be highly stable in adults. Here we have made a structural and functional characterization of the promoter of the human CYP46A1 gene. No canonical TATA or CAAT boxes were found in the promoter region. Moreover this region had a high GC content, a feature often found in genes considered to have a largely housekeeping function. A broad spectrum of regulatory axes using a variety of promoter constructs did not result in a significant transcriptional regulation. Oxidative stress caused a significant increase in transcriptional activity. The possibility of a substrate-dependent transcriptional regulation was explored in vivo in a sterol-deficient mouse model (Dhcr24 null) in which almost all cholesterol had been replaced with desmosterol, which is not a substrate for CYP46A1. Compared with heterozygous littermates there was no statistically significant difference in the mRNA levels of Cyp46a1. During the first 2 weeks of life in the wild-type mouse, however, a significant increase of Cyp46a1 mRNA levels was found, in parallel with an increase in 24S-hydroxycholesterol level and a reduction of cholesterol synthesis. The failure to demonstrate a significant transcriptional regulation under most conditions is discussed in relation to the turnover of brain and neuronal cholesterol.	Karolinska Univ Hosp, Dept Lab Med, Div Clin Chem, S-14186 Huddinge, Sweden; Karolinska Univ Hosp, Dept Lab Med, Div Clin Pharmacol, S-14186 Huddinge, Sweden; Hiroshima Univ, Grad Sch Sci, Dept Math & Life Sci, Higashihiroshima 7398526, Japan; Quark Biotech, Fremont, CA 94555 USA	Karolinska Institutet; Karolinska University Hospital; Karolinska Institutet; Karolinska University Hospital; Hiroshima University	Bjorkhem, I (corresponding author), Karolinska Univ Hosp, Dept Lab Med, Div Clin Chem, S-14186 Huddinge, Sweden.	ingemar.bjorkhem@karolinska.se	Heverin, Maura B/J-4101-2012; Diczfalusy, Ulf/A-5336-2008; Meaney, Steve/X-9289-2019	Diczfalusy, Ulf/0000-0001-6643-3763; Meaney, Steve/0000-0002-7789-516X; Bjorkhem, Ingemar/0000-0002-0575-9425; Bjorkhem, Ingemar/0000-0001-6087-9190				Ando S, 2003, NEUROCHEM RES, V28, P5, DOI 10.1023/A:1021635826032; Beyer K, 2002, NEUROSCI LETT, V326, P187, DOI 10.1016/S0304-3940(02)00355-5; Bjorkhem I, 2004, ARTERIOSCL THROM VAS, V24, P806, DOI 10.1161/01.ATV.0000120374.59826.1b; Bjorkhem I, 2001, J BIOL CHEM, V276, P37004, DOI 10.1074/jbc.M103828200; Bjorkhem I, 1998, J LIPID RES, V39, P1594; Bjorkhem I, 1997, J BIOL CHEM, V272, P30178, DOI 10.1074/jbc.272.48.30178; Bogdanovica N, 2001, NEUROSCI LETT, V314, P45, DOI 10.1016/S0304-3940(01)02277-7; Borroni B, 2004, NEUROBIOL AGING, V25, P747, DOI 10.1016/j.neurobiolaging.2003.08.004; Bretillon L, 2000, J LIPID RES, V41, P840; Brown J, 2004, J BIOL CHEM, V279, P34674, DOI 10.1074/jbc.M402324200; Chalmers KA, 2004, NEUROREPORT, V15, P95, DOI 10.1097/00001756-200401190-00019; Couronne O, 2003, GENOME RES, V13, P73, DOI 10.1101/gr.762503; de Urquiza AM, 2000, SCIENCE, V290, P2140, DOI 10.1126/science.290.5499.2140; Desai P, 2002, NEUROSCI LETT, V328, P9, DOI 10.1016/S0304-3940(02)00443-3; Dietschy JM, 2001, CURR OPIN LIPIDOL, V12, P105, DOI 10.1097/00041433-200104000-00003; Dietschy JM, 2004, J LIPID RES, V45, P1375, DOI 10.1194/jlr.R400004-JLR200; Fu Q, 1998, J NEUROCHEM, V71, P549; Heverin M, 2004, J LIPID RES, V45, P186, DOI 10.1194/jlr.M300320-JLR200; Ingelsson M, 2004, NEUROSCI LETT, V367, P228, DOI 10.1016/j.neulet.2004.06.011; Johansson A, 2004, HUM GENET, V114, P581, DOI 10.1007/s00439-004-1107-9; Kabbara A, 2004, NEUROSCI LETT, V363, P139, DOI 10.1016/j.neulet.2004.03.066; Kolsch H, 2002, MOL PSYCHIATR, V7, P899, DOI 10.1038/sj.mp.4001109; KOTTI T, 2004, SOC NEUR ANN M SAN D, P1; Lambert JC, 1998, HUM MOL GENET, V7, P533, DOI 10.1093/hmg/7.3.533; Lambert JC, 1998, HUM MOL GENET, V7, P1511, DOI 10.1093/hmg/7.9.1511; Lengqvist J, 2004, MOL CELL PROTEOMICS, V3, P692, DOI 10.1074/mcp.M400003-MCP200; Leoni V, 2004, CLIN CHEM LAB MED, V42, P186, DOI 10.1515/CCLM.2004.034; LIN YY, 1974, BIOCHIM BIOPHYS ACTA, V348, P189; Loots GG, 2004, NUCLEIC ACIDS RES, V32, pW217, DOI 10.1093/nar/gkh383; Lund EG, 1999, P NATL ACAD SCI USA, V96, P7238, DOI 10.1073/pnas.96.13.7238; Lund EG, 2003, J BIOL CHEM, V278, P22980, DOI 10.1074/jbc.M303415200; Lutjohann D, 2001, ACTA PAEDIATR, V90, P652, DOI 10.1080/080352501750258720; Lutjohann D, 1996, P NATL ACAD SCI USA, V93, P9799, DOI 10.1073/pnas.93.18.9799; Mast N, 2003, BIOCHEMISTRY-US, V42, P14284, DOI 10.1021/bi035512f; Meaney S, 2002, J LIPID RES, V43, P2130, DOI 10.1194/jlr.M200293-JLR200; Morris MC, 2003, ARCH NEUROL-CHICAGO, V60, P940, DOI 10.1001/archneur.60.7.940; Papassotiropoulos A, 2003, ARCH NEUROL-CHICAGO, V60, P29, DOI 10.1001/archneur.60.1.29; Pfrieger FW, 2003, BIOESSAYS, V25, P72, DOI 10.1002/bies.10195; PITAS RE, 1987, BIOCHIM BIOPHYS ACTA, V917, P148, DOI 10.1016/0005-2760(87)90295-5; PITAS RE, 1987, J BIOL CHEM, V262, P14352; Quan G, 2003, DEV BRAIN RES, V146, P87, DOI 10.1016/j.devbrainres.2003.09.015; Russell DW, 2003, ANNU REV BIOCHEM, V72, P137, DOI 10.1146/annurev.biochem.72.121801.161712; Ryu H, 2003, J NEUROSCI, V23, P3597; Sambrook J, 2001, MOL CLONING LAB MANU; SMITH LL, 1972, J NEUROCHEM, V19, P899, DOI 10.1111/j.1471-4159.1972.tb01406.x; Sun Y, 2003, J BIOL CHEM, V278, P27688, DOI 10.1074/jbc.M300760200; Thelen KM, 2006, J PHARMACOL EXP THER, V316, P1146, DOI 10.1124/jpet.105.094136; VOLPE JJ, 1977, BIOCHIM BIOPHYS ACTA, V486, P408, DOI 10.1016/0005-2760(77)90090-X; Wang BB, 2004, NEUROSCI LETT, V369, P104, DOI 10.1016/j.neulet.2004.07.020; Wechsler A, 2003, SCIENCE, V302, P2087, DOI 10.1126/science.1090776; Werner T, 1999, MAMM GENOME, V10, P168, DOI 10.1007/s003359900963; Whitney KD, 2002, MOL ENDOCRINOL, V16, P1378, DOI 10.1210/me.16.6.1378; Xie CL, 2003, J LIPID RES, V44, P1780, DOI 10.1194/jlr.M300164-JLR200; Zhang J, 1997, BIOCHEM J, V322, P175, DOI 10.1042/bj3220175	54	110	112	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 17	2006	281	7					3810	3820		10.1074/jbc.M505179200	http://dx.doi.org/10.1074/jbc.M505179200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	011NN	16321981	hybrid			2022-12-25	WOS:000235275300009
J	Toleman, CA; Paterson, AJ; Kudlow, JE				Toleman, CA; Paterson, AJ; Kudlow, JE			The histone acetyltransferase NCOAT contains a zinc finger-like motif involved in substrate recognition	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GCN5-RELATED N-ACETYLTRANSFERASE; GCN5 TRANSCRIPTIONAL COACTIVATOR; CRYSTAL-STRUCTURE; O-GLCNACASE; PHD FINGER; MECHANISM; PROTEIN; DOMAIN; PURIFICATION; SUPERFAMILY	Nuclear cytoplasmic O-GlcNAcase and acetyltransferase (NCOAT) is a bifunctional enzyme with both glycoside hydrolase and alkyltransferase activity. Its O-GlcNAcase active site lies in the N terminus of the enzyme and its histone acetyltransferase (HAT) domain lies in the C terminus. Whereas the HAT domain of the enzyme is catalytically and structurally similar to other acetyltransferases across subfamilies, NCOAT has a motif resembling a zinc finger-like domain unique to the MYST family of HATs. Among the MYST family, this zinc finger, or zinc finger-like domain, is responsible for making contacts with the histone tails within nucleosomes for the HAT to catalyze its respective reaction. Here, we show that NCOAT has the ability to directly associate with both an acetylated and unacetylated histone H4 tail in vitro, and a potential zinc finger-like motif found in NCOAT is implicated in this nucleosomal contact, and is necessary for fully efficient enzymatic activity. Subsequent to the catalysis of acetyltransfer to lysine 8 of histone H4 for the enzyme, however, the substrate is released and NCOAT can no longer bind H4 in our assays. Furthermore, this finger domain by itself is sufficient to bind histone H4.	Univ Alabama, Dept Med, Div Endocrinol Diabet & Metab, Birmingham, AL 35294 USA; Univ Alabama, Dept Cell Biol, Birmingham, AL 35294 USA	University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham	Kudlow, JE (corresponding author), Univ Alabama, Dept Med, Div Endocrinol Diabet & Metab, Birmingham, AL 35294 USA.	kudlow@uab.edu						Akhtar A, 2001, EMBO REP, V2, P113, DOI 10.1093/embo-reports/kve022; Angus-Hill ML, 1999, J MOL BIOL, V294, P1311, DOI 10.1006/jmbi.1999.3338; Bordoli L, 2001, NUCLEIC ACIDS RES, V29, P4462, DOI 10.1093/nar/29.21.4462; DONG DLY, 1994, J BIOL CHEM, V269, P19321; Dutnall RN, 1998, CELL, V94, P427, DOI 10.1016/S0092-8674(00)81584-6; Heckel D, 1998, HUM MOL GENET, V7, P1859, DOI 10.1093/hmg/7.12.1859; Kalkhoven E, 2002, MOL CELL BIOL, V22, P1961, DOI 10.1128/MCB.22.7.1961-1970.2002; Marmorstein R, 2001, J MOL BIOL, V311, P433, DOI 10.1006/jmbi.2001.4859; Pelletier N, 2003, METHODS, V31, P24, DOI 10.1016/S1046-2023(03)00084-7; Poux AN, 2002, P NATL ACAD SCI USA, V99, P14065, DOI 10.1073/pnas.222373899; Ragvin A, 2004, J MOL BIOL, V337, P773, DOI 10.1016/j.jmb.2004.01.051; Schultz J, 1998, P NATL ACAD SCI USA, V95, P5857, DOI 10.1073/pnas.95.11.5857; Schultz J, 2002, FEBS LETT, V529, P179, DOI 10.1016/S0014-5793(02)03322-7; SCHWABE JWR, 1994, NAT STRUCT BIOL, V1, P345, DOI 10.1038/nsb0694-345; Simpson RJY, 2003, J BIOL CHEM, V278, P28011, DOI 10.1074/jbc.M211146200; Takechi S, 1999, BIOCHEM BIOPH RES CO, V266, P405, DOI 10.1006/bbrc.1999.1836; Tanner KG, 2000, BIOCHEMISTRY-US, V39, P11961, DOI 10.1021/bi001272h; Tanner KG, 1999, J BIOL CHEM, V274, P18157, DOI 10.1074/jbc.274.26.18157; Toleman C, 2004, J BIOL CHEM, V279, P53665, DOI 10.1074/jbc.M410406200; Trievel RC, 1999, P NATL ACAD SCI USA, V96, P8931, DOI 10.1073/pnas.96.16.8931; Wolf E, 2002, J MOL BIOL, V317, P215, DOI 10.1006/jmbi.2001.5371; Wolf E, 1998, CELL, V94, P439, DOI 10.1016/S0092-8674(00)81585-8; Yan Y, 2000, MOL CELL, V6, P1195, DOI 10.1016/S1097-2765(00)00116-7; Yang XY, 2002, CELL, V110, P69, DOI 10.1016/S0092-8674(02)00810-3	24	18	19	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 17	2006	281	7					3918	3925		10.1074/JBC.m510485200	http://dx.doi.org/10.1074/JBC.m510485200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	011NN	16356930	hybrid			2022-12-25	WOS:000235275300019
J	Yan, H; Zareen, N; Levinger, L				Yan, H; Zareen, N; Levinger, L			Naturally occurring mutations in human mitochondrial pre-tRNA(Ser(UCN)) can affect the transfer ribonuclease Z cleavage site, processing kinetics, and substrate secondary structure	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSFER-RNA PRECURSORS; POLYADENYLATION FACTOR CPSF-73; CANCER SUSCEPTIBILITY GENE; TRNA(SER(UCN)) GENE; TRNASE-Z; PAIRED SUBSTITUTIONS; THERMOTOGA-MARITIMA; POINT MUTATION; ACCEPTOR STEM; DNA MUTATION	tRNAs are transcribed as precursors with a 5' end leader and a 3' end trailer. The 5' end leader is processed by RNase P, and in most organisms in all three kingdoms, transfer ribonuclease (tRNase) Z can endonucleolytically remove the 3' end trailer. Long ((L)) and short ((S)) forms of the tRNase Z gene are present in the human genome. tRNase Z(L) processes a nuclear-encoded pre-tRNA similar to 1600-fold more efficiently than tRNase Z(S) and is predicted to have a strong mitochondrial transport signal. tRNase Z(L) could, thus, process both nuclear-and mitochondrially encoded pre-tRNAs. More than 150 pathogenesis-associated mutations have been found in the mitochondrial genome, most of them in the 22 mitochondrially encoded tRNAs. All the mutations investigated in human mitochondrial tRNA(Ser(UCN)) affect processing efficiency, and some affect the cleavage site and secondary structure. These changes could affect tRNase Z processing of mutant pre-tRNAs, perhaps contributing to mitochondrial disease.	CUNY, York Coll, Dept Nat Sci Biol, Riyadh 11451, Saudi Arabia		Levinger, L (corresponding author), CUNY, York Coll, Dept Nat Sci Biol, 94-20 Guy R Brewer Blvd, Riyadh 11451, Saudi Arabia.	louie@york.cuny.edu	Yan, Hua/E-5305-2011		NIGMS NIH HHS [S06GM08153] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [S06GM008153] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANDERSON S, 1981, NATURE, V290, P457, DOI 10.1038/290457a0; Baillat D, 2005, CELL, V123, P265, DOI 10.1016/j.cell.2005.08.019; BROWN MD, 1992, AM J HUM GENET, V51, P378; CASTANO JG, 1985, J BIOL CHEM, V260, P9002; CHEN JY, 1988, J BIOL CHEM, V263, P13677; Chen Y, 2005, BMC MOL BIOL, V6, DOI 10.1186/1471-2199-6-12; de la Sierra-Gallay IL, 2005, NATURE, V433, P657, DOI 10.1038/nature03284; Dominski Z, 2005, CELL, V123, P37, DOI 10.1016/j.cell.2005.08.002; Dominski Z, 2005, MOL CELL BIOL, V25, P1489, DOI 10.1128/MCB.25.4.1489-1500.2005; Dubrovsky EB, 2004, NUCLEIC ACIDS RES, V32, P255, DOI 10.1093/nar/gkh182; EHRESMANN C, 1987, NUCLEIC ACIDS RES, V15, P9109, DOI 10.1093/nar/15.22.9109; Fechter P, 1998, FEBS LETT, V436, P99, DOI 10.1016/S0014-5793(98)01096-5; Florentz C, 2001, EMBO REP, V2, P481, DOI 10.1093/embo-reports/kve111; FRENDEWEY D, 1985, J BIOL CHEM, V260, P449; Guan MX, 1998, MOL CELL BIOL, V18, P5868, DOI 10.1128/MCB.18.10.5868; Helm M, 2000, RNA, V6, P1356, DOI 10.1017/S1355838200001047; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; HUTCHIN T, 1993, NUCLEIC ACIDS RES, V21, P4174, DOI 10.1093/nar/21.18.4174; Hutchin TP, 2000, J MED GENET, V37, P692, DOI 10.1136/jmg.37.9.692; Ishii R, 2005, J BIOL CHEM, V280, P14138, DOI 10.1074/jbc.M500355200; Leontis NB, 2002, NUCLEIC ACIDS RES, V30, P3497, DOI 10.1093/nar/gkf481; Levinger L, 1998, J BIOL CHEM, V273, P1015, DOI 10.1074/jbc.273.2.1015; Levinger L, 2004, NUCLEIC ACIDS RES, V32, P5430, DOI 10.1093/nar/gkh884; Levinger L, 2004, J MOL BIOL, V337, P535, DOI 10.1016/j.jmb.2004.02.008; LEVINGER L, 1995, J BIOL CHEM, V270, P18903, DOI 10.1074/jbc.270.32.18903; Levinger L, 2003, NUCLEIC ACIDS RES, V31, P1904, DOI 10.1093/nar/gkg282; Levinger L, 2001, NUCLEIC ACIDS RES, V29, P4334, DOI 10.1093/nar/29.21.4334; Li ZW, 2002, RNA, V8, P97, DOI 10.1017/S1355838202014929; Li ZW, 1996, CELL, V86, P503, DOI 10.1016/S0092-8674(00)80123-3; Marchfelder A, 1996, J BIOL CHEM, V271, P1898, DOI 10.1074/jbc.271.4.1898; MARCHFELDER A, 1990, NUCLEIC ACIDS RES, V18, P1401, DOI 10.1093/nar/18.6.1401; Minagawa A, 2005, CANCER LETT, V222, P211, DOI 10.1016/j.canlet.2004.09.013; Minagawa A, 2004, J BIOL CHEM, V279, P15688, DOI 10.1074/jbc.M313951200; Mohan A, 2000, J MOL BIOL, V303, P605, DOI 10.1006/jmbi.2000.4162; Mohan A, 1999, RNA, V5, P245, DOI 10.1017/S1355838299981256; MONTOYA J, 1981, NATURE, V290, P465, DOI 10.1038/290465a0; Morl M, 2001, EMBO REP, V2, P17, DOI 10.1093/embo-reports/kve006; NAKAMURA M, 1995, BIOCHEM BIOPH RES CO, V214, P86, DOI 10.1006/bbrc.1995.2260; Nashimoto M, 1999, BIOCHEMISTRY-US, V38, P12089, DOI 10.1021/bi9911942; NASHIMOTO M, 1992, NUCLEIC ACIDS RES, V20, P3737, DOI 10.1093/nar/20.14.3737; Nashimoto M, 1997, NUCLEIC ACIDS RES, V25, P1148, DOI 10.1093/nar/25.6.1148; OJALA D, 1981, NATURE, V290, P470, DOI 10.1038/290470a0; Pandya A, 1999, AM J HUM GENET, V65, P1803, DOI 10.1086/302658; Pellegrini O, 2003, EMBO J, V22, P4534, DOI 10.1093/emboj/cdg435; Perez-Iratxeta C, 2005, FEBS LETT, V579, P1795, DOI 10.1016/j.febslet.2005.02.020; Reid FM, 1997, HUM MOL GENET, V6, P443, DOI 10.1093/hmg/6.3.443; REID FM, 1994, HUM MUTAT, V3, P243, DOI 10.1002/humu.1380030311; Ryan K, 2004, RNA, V10, P565, DOI 10.1261/rna.5214404; Schiffer S, 2003, BIOL CHEM, V384, P333, DOI 10.1515/BC.2003.039; Schiffer S, 2002, EMBO J, V21, P2769, DOI 10.1093/emboj/21.11.2769; Sprinzl M, 2005, NUCLEIC ACIDS RES, V33, pD139, DOI 10.1093/nar/gki012; Sue CM, 1999, NEUROLOGY, V52, P1905, DOI 10.1212/WNL.52.9.1905; Takaku H, 2004, NUCLEIC ACIDS RES, V32, P4429, DOI 10.1093/nar/gkh774; Takaku H, 2003, NUCLEIC ACIDS RES, V31, P2272, DOI 10.1093/nar/gkg337; Tavtigian SV, 2001, NAT GENET, V27, P172, DOI 10.1038/84808; THOMANN HU, 1989, J MOL BIOL, V209, P505, DOI 10.1016/0022-2836(89)90590-1; Toompuu M, 2002, J BIOL CHEM, V277, P22240, DOI 10.1074/jbc.M200338200; Vogel A, 2004, BIOCHEMISTRY-US, V43, P10379, DOI 10.1021/bi049703+; Xiao SH, 2002, ANNU REV BIOCHEM, V71, P165, DOI 10.1146/annurev.biochem.71.110601.135352; Yoo CJ, 1997, CELL, V89, P393, DOI 10.1016/S0092-8674(00)80220-2; Zareen N, 2005, J MOL BIOL, V350, P189, DOI 10.1016/j.jmb.2005.04.073	61	44	49	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 17	2006	281	7					3926	3935		10.1074/jbc.M509822200	http://dx.doi.org/10.1074/jbc.M509822200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	011NN	16361254	hybrid			2022-12-25	WOS:000235275300020
J	Yu, Q; Sandmeier, J; Xu, HP; Zou, YF; Bi, X				Yu, Q; Sandmeier, J; Xu, HP; Zou, YF; Bi, X			Mechanism of the long range anti-silencing function of targeted histone acetyltransferases in yeast	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RESOLUTION STRUCTURAL-ANALYSIS; SACCHAROMYCES-CEREVISIAE; HYPERACETYLATED CHROMATIN; EXCLUDES NUCLEOSOMES; GENE-EXPRESSION; HETEROCHROMATIN; ACETYLATION; COMPLEX; TRANSCRIPTION; DNA	Transcriptionally silent chromatin in Saccharomyces cerevisiae is associated with histone hypoacetylation and is formed through the action of the Sir histone deacetylase complex. A histone acetyltransferase (HAT) targeted near silent chromatin can overcome silencing at a distance by increasing histone acetylation in a sizable region. However, how a tethered HAT acetylates distant nucleosomes has not been resolved. We demonstrate here that targeting the histone H3-specific HAT Gcn5p promotes acetylation of not only histone H3 but also histone H4 in a broad region. We also show that long range anti-silencing and histone acetylation by targeted HATs can be blocked by nucleosome-excluding sequences. These results are consistent with the contention that a tethered HAT promotes step-wise propagation of histone acetylation along the chromatin. Because histone hypoacetylation is key to the formation and maintenance of transcriptionally silent chromatin, it is believed that acetylation promoted by a targeted HAT disrupts silent chromatin thereby overcoming silencing. However, we show that the acetylated and transcriptionally active region created by a tethered HAT retains structural hallmarks of Sir-dependent silent chromatin and remains associated with Sir proteins indicating that tethered HATs overcome silencing without completely dismantling silent chromatin.	Univ Rochester, Dept Biol, Rochester, NY 14627 USA	University of Rochester	Bi, X (corresponding author), Univ Rochester, Dept Biol, 601 Elmwood Ave, Rochester, NY 14627 USA.	xinbi@mail.rochester.edu			NIGMS NIH HHS [R01-GM62484] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM062484] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Allard S, 1999, EMBO J, V18, P5108, DOI 10.1093/emboj/18.18.5108; ALLFREY VG, 1964, P NATL ACAD SCI USA, V51, P786, DOI 10.1073/pnas.51.5.786; Bi X, 1999, P NATL ACAD SCI USA, V96, P11934, DOI 10.1073/pnas.96.21.11934; Bi X, 2004, MOL CELL BIOL, V24, P2118, DOI 10.1128/MCB.24.5.2118-2131.2004; BOEKE JD, 1987, METHOD ENZYMOL, V154, P164; Boudreault AA, 2003, GENE DEV, V17, P1415, DOI 10.1101/gad.1056603; Bulger M, 2005, J BIOL CHEM, V280, P21689, DOI 10.1074/jbc.R500004200; Carmen AA, 2002, J BIOL CHEM, V277, P4778, DOI 10.1074/jbc.M110532200; Carrozza MJ, 2003, TRENDS GENET, V19, P321, DOI 10.1016/S0168-9525(03)00115-X; CHEVALLIER MR, 1980, GENE, V11, P11, DOI 10.1016/0378-1119(80)90082-7; Chiu YH, 2003, GENETICS, V165, P115; Deckert J, 2002, MOL CELL BIOL, V22, P6458, DOI 10.1128/MCB.22.18.6458-6470.2002; Dhalluin C, 1999, NATURE, V399, P491, DOI 10.1038/20974; Donze D, 2001, EMBO J, V20, P520, DOI 10.1093/emboj/20.3.520; Fischle W, 2003, NATURE, V425, P475, DOI 10.1038/nature02017; Forsberg EC, 2001, BIOESSAYS, V23, P820, DOI 10.1002/bies.1117; Grant PA, 1997, GENE DEV, V11, P1640, DOI 10.1101/gad.11.13.1640; Grewal SIS, 2003, SCIENCE, V301, P798, DOI 10.1126/science.1086887; Hassan AH, 2002, CELL, V111, P369, DOI 10.1016/S0092-8674(02)01005-X; HECHT A, 1995, CELL, V80, P583, DOI 10.1016/0092-8674(95)90512-X; IYER V, 1995, EMBO J, V14, P2570, DOI 10.1002/j.1460-2075.1995.tb07255.x; Jacobs SA, 2002, SCIENCE, V295, P2080, DOI 10.1126/science.1069473; Jenuwein T, 2001, SCIENCE, V293, P1074, DOI 10.1126/science.1063127; Katan-Khaykovich Y, 2005, EMBO J, V24, P2138, DOI 10.1038/sj.emboj.7600692; Kirkpatrick DT, 1999, MOL CELL BIOL, V19, P7661; Krebs JE, 1999, GENE DEV, V13, P1412, DOI 10.1101/gad.13.11.1412; Kuo MH, 2000, MOL CELL, V6, P1309, DOI 10.1016/S1097-2765(00)00129-5; Kurdistani SK, 2003, NAT REV MOL CELL BIO, V4, P276, DOI 10.1038/nrm1075; Liou GG, 2005, CELL, V121, P515, DOI 10.1016/j.cell.2005.03.035; Luger K, 1997, NATURE, V389, P251, DOI 10.1038/38444; Lusser A, 2003, BIOESSAYS, V25, P1192, DOI 10.1002/bies.10359; Moazed D, 2001, MOL CELL, V8, P489, DOI 10.1016/S1097-2765(01)00340-9; Nielsen PR, 2002, NATURE, V416, P103, DOI 10.1038/nature722; Pirrotta V, 2005, MOL CELL, V18, P395, DOI 10.1016/j.molcel.2005.04.013; Ravindra A, 1999, MOL CELL BIOL, V19, P7944; Reimer SK, 1997, CHROMOSOMA, V106, P136, DOI 10.1007/s004120050233; Richmond TJ, 2003, NATURE, V423, P145, DOI 10.1038/nature01595; Roth SY, 2001, ANNU REV BIOCHEM, V70, P81, DOI 10.1146/annurev.biochem.70.1.81; Rusche LN, 2003, ANNU REV BIOCHEM, V72, P481, DOI 10.1146/annurev.biochem.72.121801.161547; Rusche LN, 2001, GENE DEV, V15, P955; Sekinger EA, 1999, EMBO J, V18, P7041, DOI 10.1093/emboj/18.24.7041; Sendra R, 2000, J BIOL CHEM, V275, P24928, DOI 10.1074/jbc.M003783200; SIMPSON RT, 1979, NUCLEIC ACIDS RES, V6, P1387, DOI 10.1093/nar/6.4.1387; Strahl BD, 2000, NATURE, V403, P41, DOI 10.1038/47412; Sutton A, 2001, MOL CELL BIOL, V21, P3514, DOI 10.1128/MCB.21.10.3514-3522.2001; Wang YH, 1996, P NATL ACAD SCI USA, V93, P8863, DOI 10.1073/pnas.93.17.8863; Weiss K, 1998, MOL CELL BIOL, V18, P5392, DOI 10.1128/MCB.18.9.5392; Workman JL, 1998, ANNU REV BIOCHEM, V67, P545, DOI 10.1146/annurev.biochem.67.1.545; Yang Y, 2003, NOVON, V13, P153, DOI 10.2307/3393581; Zeng L, 2002, FEBS LETT, V513, P124, DOI 10.1016/S0014-5793(01)03309-9	50	10	11	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 17	2006	281	7					3980	3988		10.1074/jbc.M510140200	http://dx.doi.org/10.1074/jbc.M510140200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	011NN	16368686	hybrid			2022-12-25	WOS:000235275300026
J	Zhang, DW; Graf, GA; Gerard, RD; Cohen, JC; Hobbs, HH				Zhang, DW; Graf, GA; Gerard, RD; Cohen, JC; Hobbs, HH			Functional asymmetry of nucleotide-binding domains in ABCG5 and ABCG8	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MULTIDRUG-RESISTANCE PROTEIN-1; BILIARY CHOLESTEROL SECRETION; GLYCOPROTEIN ATPASE ACTIVITY; MYOSIN MOTOR DOMAIN; P-GLYCOPROTEIN; DIETARY-CHOLESTEROL; GLUTAMATE RESIDUES; ESCHERICHIA-COLI; CATALYTIC CYCLE; TRANSPORTER	The ATP-binding cassette half-transporters ABCG5 (G5) and ABCG8 (G8) promote secretion of neutral sterols into bile, a major pathway for elimination of sterols. Mutations in either ABCG5 or ABCG8 cause sitosterolemia, a recessive disorder characterized by impaired biliary and intestinal sterol secretion, sterol accumulation, and premature atherosclerosis. The mechanism by which the G5G8 heterodimer couples ATP hydrolysis to sterol transport is not known. Here we examined the roles of the Walker A, Walker B, and signature motifs in the nucleotide-binding domains (NBD) of G5 and G8 using recombinant adenoviruses to reconstitute biliary sterol transport in G5G8-deficient mice. Mutant forms of each half-transporter were co-expressed with their wild-type partners. Mutations at crucial residues in the Walker A and Walker B domains of G5 prevented biliary sterol secretion, whereas mutations of the corresponding residues in G8 did not. The opposite result was obtained when mutations were introduced into the signature motif; mutations in the signature domain of G8 prevented sterol transport, but substitution of the corresponding residues in G5 did not. Taken together, these findings indicate that the NBDs of G5 and G8 are not functionally equivalent. The integrity of the canonical NBD formed by the Walker A and Walker B motifs of G5 and the signature motif of G8 is essential for G5G8-mediated sterol transport. In contrast, mutations in key residues of the NBD formed by the Walker A and B motifs of G8 and the signature sequence of G5 did not affect sterol secretion.	Univ Texas, SW Med Ctr, Dept Mol Genet, Dallas, TX 75390 USA; Univ Texas, SW Med Ctr, McDermott Ctr Human Growth & Dev, Dallas, TX 75390 USA; Univ Texas, SW Med Ctr, Dept Internal Med, Dallas, TX 75390 USA; Univ Texas, SW Med Ctr, Dept Mol Biol, Dallas, TX 75390 USA; Univ Texas, SW Med Ctr, Howard Hughes Med Inst, Dallas, TX 75390 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; Howard Hughes Medical Institute; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Hobbs, HH (corresponding author), Univ Texas, SW Med Ctr, Dept Mol Genet, 5323 Harry Hines Blvd, Dallas, TX 75390 USA.	helen.hobbs@utsouthwestern.edu	Zhang, Dawei/ABD-8990-2022	Zhang, Dawei/0000-0001-8279-8041; Graf, Gregory/0000-0002-0130-9929	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL072304, P01HL020948] Funding Source: NIH RePORTER; NHLBI NIH HHS [P01HL-20948, R01HL-72304] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BEAUDET L, 1995, J BIOL CHEM, V270, P17159, DOI 10.1074/jbc.270.29.17159; Beaudet L, 1998, BIOCHEMISTRY-US, V37, P9073, DOI 10.1021/bi972656j; Berge KE, 2000, SCIENCE, V290, P1771, DOI 10.1126/science.290.5497.1771; Berger AL, 2005, P NATL ACAD SCI USA, V102, P455, DOI 10.1073/pnas.0408575102; Chang G, 2001, SCIENCE, V293, P1793, DOI 10.1126/science.293.5536.1793; Chen J, 2003, MOL CELL, V12, P651, DOI 10.1016/j.molcel.2003.08.004; Chen M, 2003, J BIOL CHEM, V278, P29686, DOI 10.1074/jbc.M302757200; Chen M, 2004, J BIOL CHEM, V279, P46073, DOI 10.1074/jbc.M404042200; Davidson AL, 2004, ANNU REV BIOCHEM, V73, P241, DOI 10.1146/annurev.biochem.73.011303.073626; FISHER AJ, 1995, BIOCHEMISTRY-US, V34, P8960, DOI 10.1021/bi00028a004; Gao M, 2000, J BIOL CHEM, V275, P13098, DOI 10.1074/jbc.275.17.13098; Graf GA, 2003, J BIOL CHEM, V278, P48275, DOI 10.1074/jbc.M310223200; Graf GA, 2002, J CLIN INVEST, V110, P659, DOI 10.1172/JCI200216000; HIGGINS CF, 1992, ANNU REV CELL BIOL, V8, P67, DOI 10.1146/annurev.cb.08.110192.000435; Hopfner KP, 2000, CELL, V101, P789, DOI 10.1016/S0092-8674(00)80890-9; Hou YX, 2000, J BIOL CHEM, V275, P20280, DOI 10.1074/jbc.M001109200; Hung LW, 1998, NATURE, V396, P703, DOI 10.1038/25393; Jones PM, 1999, FEMS MICROBIOL LETT, V179, P187, DOI 10.1111/j.1574-6968.1999.tb08727.x; Lapinski PE, 2001, J BIOL CHEM, V276, P7526, DOI 10.1074/jbc.M009448200; Lapinski PE, 2003, J BIOL CHEM, V278, P8229, DOI 10.1074/jbc.M208930200; Lee MH, 2001, NAT GENET, V27, P79, DOI 10.1038/83799; Locher KP, 2002, SCIENCE, V296, P1091, DOI 10.1126/science.1071142; Melin P, 2004, BIOCHEM PHARMACOL, V67, P2187, DOI 10.1016/j.bcp.2004.02.022; Nikaido K, 1999, J BIOL CHEM, V274, P26727, DOI 10.1074/jbc.274.38.26727; Payen LF, 2003, J BIOL CHEM, V278, P38537, DOI 10.1074/jbc.M305786200; Repa JJ, 2002, NAT MED, V8, P1243, DOI 10.1038/nm1102-1243; Repa JJ, 2002, J BIOL CHEM, V277, P18793, DOI 10.1074/jbc.M109927200; Reyes CL, 2005, SCIENCE, V308, P1028, DOI 10.1126/science.1107733; Sankaran B, 1997, BIOCHEMISTRY-US, V36, P6847, DOI 10.1021/bi970034s; Sankaran B, 1997, ARCH BIOCHEM BIOPHYS, V341, P160, DOI 10.1006/abbi.1997.9944; Sauna ZE, 2004, J BIOL CHEM, V279, P48855, DOI 10.1074/jbc.M408849200; Sauna ZE, 2002, BIOCHEMISTRY-US, V41, P13989, DOI 10.1021/bi026626e; Senior AE, 1998, ACTA PHYSIOL SCAND, V163, P213; Smith CA, 1996, BIOCHEMISTRY-US, V35, P5404, DOI 10.1021/bi952633+; Smith PC, 2002, MOL CELL, V10, P139, DOI 10.1016/S1097-2765(02)00576-2; Szabo K, 1998, J BIOL CHEM, V273, P10132, DOI 10.1074/jbc.273.17.10132; Szakacs G, 2001, BIOCHEM J, V356, P71, DOI 10.1042/0264-6021:3560071; Tombline G, 2004, J BIOL CHEM, V279, P31212, DOI 10.1074/jbc.M404689200; Tombline G, 2004, J BIOL CHEM, V279, P5363, DOI 10.1074/jbc.M311964200; Tombline G, 2004, J BIOL CHEM, V279, P46518, DOI 10.1074/jbc.M408052200; Urbatsch IL, 1998, BIOCHEMISTRY-US, V37, P4592, DOI 10.1021/bi9728001; Verdon G, 2003, J MOL BIOL, V330, P343, DOI 10.1016/S0022-2836(03)00575-8; Vergani P, 2005, NATURE, V433, P876, DOI 10.1038/nature03313; Yu LQ, 2002, P NATL ACAD SCI USA, V99, P16237, DOI 10.1073/pnas.252582399; Yu LQ, 2002, J CLIN INVEST, V110, P671, DOI [10.1172/JCI200216001, 10.1172/JCI0216001]; Zhang DW, 2003, J BIOL CHEM, V278, P46052, DOI 10.1074/jbc.M308403200; Zhang DW, 2001, J BIOL CHEM, V276, P13231, DOI 10.1074/jbc.M010008200	47	38	42	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 17	2006	281	7					4507	4516		10.1074/jbc.M512277200	http://dx.doi.org/10.1074/jbc.M512277200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	011NN	16352607	hybrid			2022-12-25	WOS:000235275300086
J	Jenkins, HT; Mark, L; Ball, G; Persson, J; Lindahl, G; Uhrin, D; Blom, AM; Barlow, PN				Jenkins, HT; Mark, L; Ball, G; Persson, J; Lindahl, G; Uhrin, D; Blom, AM; Barlow, PN			Human C4b-binding protein, structural basis for interaction with streptococcal M protein, a major bacterial virulence factor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN C4-BINDING PROTEIN; C4B BINDING-PROTEIN; SURFACE-PROTEINS; ALPHA-CHAIN; COMPLEMENT ACTIVATION; SEQUENCE HOMOLOGY; SERUM RESISTANCE; 2 PARTS; RECEPTOR; C3B	Human C4b-binding protein (C4BP) protects host tissue, and those pathogens able to hijack this plasma glycoprotein, from complement-mediated destruction. We now show that the first two complement control protein (CCP) modules of the C4BP alpha-chain, plus the four residues connecting them, are necessary and sufficient for binding a bacterial virulence factor, the Streptococcus pyogenes M4 (Arp4) protein. Structure determination by NMR reveals two tightly coupled CCP modules in an elongated arrangement within this region of C4BP. Chemical shift perturbation studies demonstrate that the N-terminal, hypervariable region of M4 binds to a site including strand 1 of CCP module 2. This interaction is accompanied by an intermodular reorientation within C4BP. We thus provide a detailed picture of an interaction whereby a pathogen evades complement.	Univ Edinburgh, Sch Chem, Edinburgh Biol NMR Unit, Edinburgh EH9 3JJ, Midlothian, Scotland; Lund Univ, Dept Lab Med, Sect Clin Chem, Malmo Univ Hosp, S-20502 Malmo, Sweden; Lund Univ, Dept Lab Med, Div Med Microbiol, SE-22362 Lund, Sweden	University of Edinburgh; Lund University; Skane University Hospital; Lund University	Barlow, PN (corresponding author), Univ Edinburgh, Sch Chem, Edinburgh Biol NMR Unit, Joseph Black Chem Bldg,W Mains Rd, Edinburgh EH9 3JJ, Midlothian, Scotland.	Paul.Barlow@ed.ac.uk	Jenkins, Huw/E-1094-2011; Barlow, Paul N/G-2853-2011; Blom, Anna/AFS-7369-2022; Persson, Jenny J/H-1796-2012; Blom, Anna/B-9607-2009	Jenkins, Huw/0000-0002-3302-6966; Persson, Jenny J/0000-0002-1075-4346; Blom, Anna/0000-0002-1348-1734; Ball, Graeme/0000-0002-6526-2306	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		Accardo P, 1996, J IMMUNOL, V157, P4935; Baker NA, 2001, P NATL ACAD SCI USA, V98, P10037, DOI 10.1073/pnas.181342398; Berggard K, 2001, EUR J IMMUNOL, V31, P2771, DOI 10.1002/1521-4141(200109)31:9<2771::AID-IMMU2771>3.0.CO;2-0; Blom AM, 2000, J IMMUNOL, V164, P5328, DOI 10.4049/jimmunol.164.10.5328; Blom AM, 2003, MOL IMMUNOL, V39, P547, DOI 10.1016/S0161-5890(02)00213-4; Blom AM, 1999, J BIOL CHEM, V274, P19237, DOI 10.1074/jbc.274.27.19237; Blom AM, 2001, J BIOL CHEM, V276, P27136, DOI 10.1074/jbc.M102445200; Brodeur SR, 2003, IMMUNITY, V18, P837, DOI 10.1016/S1074-7613(03)00149-3; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Carlsson F, 2003, J EXP MED, V198, P1057, DOI 10.1084/jem.20030543; Cockburn IA, 2004, P NATL ACAD SCI USA, V101, P272, DOI 10.1073/pnas.0305306101; DAHLBACK B, 1983, P NATL ACAD SCI-BIOL, V80, P3461, DOI 10.1073/pnas.80.11.3461; FISCHETTI VA, 1989, CLIN MICROBIOL REV, V2, P285, DOI 10.1128/CMR.2.3.285-314.1989; Frishman D, 1995, PROTEINS, V23, P566, DOI 10.1002/prot.340230412; FRITHZ E, 1989, MOL MICROBIOL, V3, P1111, DOI 10.1111/j.1365-2958.1989.tb00261.x; FUJITA T, 1979, J EXP MED, V150, P267, DOI 10.1084/jem.150.2.267; FUJITA T, 1978, J EXP MED, V148, P1044, DOI 10.1084/jem.148.4.1044; Fukui A, 2002, J BIOCHEM, V132, P719, DOI 10.1093/oxfordjournals.jbchem.a003279; Ganesh VK, 2004, P NATL ACAD SCI USA, V101, P8924, DOI 10.1073/pnas.0400744101; GIGLI I, 1979, P NATL ACAD SCI USA, V76, P6596, DOI 10.1073/pnas.76.12.6596; Hammel M, 2002, J MOL BIOL, V321, P85, DOI 10.1016/S0022-2836(02)00621-6; Heiring C, 2001, PROTEIN ENG, V14, P183, DOI 10.1093/protein/14.3.183; HILLARP A, 1990, P NATL ACAD SCI USA, V87, P1183, DOI 10.1073/pnas.87.3.1183; Jarva H, 2005, J IMMUNOL, V174, P6299, DOI 10.4049/jimmunol.174.10.6299; Kask L, 2004, J BIOL CHEM, V279, P23869, DOI 10.1074/jbc.C400159200; Kirkitadze MD, 2001, IMMUNOL REV, V180, P146, DOI 10.1034/j.1600-065X.2001.1800113.x; Koradi R, 1996, J MOL GRAPHICS, V14, P29; Krych M, 1998, J BIOL CHEM, V273, P8623, DOI 10.1074/jbc.273.15.8623; KRYCH M, 1994, J BIOL CHEM, V269, P13273; Lancefield RC, 1928, J EXP MED, V47, P91, DOI 10.1084/jem.47.1.91; Meri T, 2004, INFECT IMMUN, V72, P6633, DOI 10.1128/IAI.72.11.6633-6641.2004; Morfeldt E, 2001, J IMMUNOL, V167, P3870, DOI 10.4049/jimmunol.167.7.3870; Navarre WW, 1999, MICROBIOL MOL BIOL R, V63, P174, DOI 10.1128/MMBR.63.1.174-229.1999; Nordstrom T, 2004, J IMMUNOL, V173, P4598, DOI 10.4049/jimmunol.173.7.4598; Prasadarao NV, 2002, J IMMUNOL, V169, P6352, DOI 10.4049/jimmunol.169.11.6352; Ram S, 2001, J EXP MED, V193, P281, DOI 10.1084/jem.193.3.281; SCHARFSTEIN J, 1978, J EXP MED, V148, P207, DOI 10.1084/jem.148.1.207; Schubert M, 2002, J BIOMOL NMR, V24, P149, DOI 10.1023/A:1020997118364; Shindyalov IN, 1998, PROTEIN ENG, V11, P739, DOI 10.1093/protein/11.9.739; Smith BO, 2002, CELL, V108, P769, DOI 10.1016/S0092-8674(02)00672-4; Soares DC, 2005, PROTEIN ENG DES SEL, V18, P379, DOI 10.1093/protein/gzi039; STENBERG L, 1994, J BIOL CHEM, V269, P13458; Stevens DL., 2000, STREPTOCOCCAL INFECT; THERN A, 1995, J IMMUNOL, V154, P375; Trouw LA, 2005, J EXP MED, V201, P1937, DOI 10.1084/jem.20050189; Uhrinova S, 2003, P NATL ACAD SCI USA, V100, P4718, DOI 10.1073/pnas.0730844100; Walport MJ, 2001, NEW ENGL J MED, V344, P1058, DOI 10.1056/NEJM200104053441406; Walport MJ, 2001, NEW ENGL J MED, V344, P1140, DOI 10.1056/NEJM200104123441506; [No title captured]	49	45	48	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 10	2006	281	6					3690	3697		10.1074/jbc.M511563200	http://dx.doi.org/10.1074/jbc.M511563200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	009QV	16330538	hybrid			2022-12-25	WOS:000235128200081
J	Dong, YZ; Tan, JX; Cui, MZ; Zhao, GJ; Mao, GZ; Singh, N; Xu, XM				Dong, Yunzhou; Tan, Jianxin; Cui, Mei-Zhen; Zhao, Guojun; Mao, Guozhang; Singh, Neena; Xu, Xuemin			Calpain inhibitor MDL28170 modulates A beta formation by inhibiting the formation of intermediate A beta(46) and protecting A beta from degradation	FASEB JOURNAL			English	Article									[Dong, Yunzhou; Tan, Jianxin; Cui, Mei-Zhen; Zhao, Guojun; Mao, Guozhang; Xu, Xuemin] Univ Tennessee, Coll Vet Med, Dept Pathobiol, Knoxville, TN 37996 USA; [Singh, Neena] Case Western Reserve Univ, Dept Pathol, Cleveland, OH 44106 USA	University of Tennessee System; University of Tennessee Knoxville; UT Institute of Agriculture; Case Western Reserve University	Xu, XM (corresponding author), Univ Tennessee, Coll Vet Med, Dept Pathobiol, 2407 River Dr, Knoxville, TN 37996 USA.	xmx@utk.edu		Cui, Mei-Zhen/0000-0003-4745-6999	NINDS NIH HHS [NS42314] Funding Source: Medline	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))			0	22	23	0	5	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	FEB	2006	20	2					331	333		10.1096/fj.05-4524fje	http://dx.doi.org/10.1096/fj.05-4524fje			3	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	V17CJ	16354722				2022-12-25	WOS:000207915000011
J	Salameh, A; Frenzel, C; Boldt, A; Rassler, B; Glawe, I; Schulte, J; Muhlberg, K; Zimmer, HG; Pfeiffer, D; Dhein, S				Salameh, A.; Frenzel, C.; Boldt, A.; Rassler, B.; Glawe, I.; Schulte, J.; Muehlberg, K.; Zimmer, H. -G.; Pfeiffer, D.; Dhein, S.			Subchronic alpha- and beta-adrenergic regulation of cardiac gap junction protein expression	FASEB JOURNAL			English	Article									[Salameh, A.; Muehlberg, K.; Pfeiffer, D.] Univ Klin Leipzig, Abt Kardiol, Med Klin 1, Leipzig, Germany; [Boldt, A.; Glawe, I.; Schulte, J.; Dhein, S.] Herzzentrum Univ Leipzig, Klin Herzchirurg, Leipzig, Germany; [Rassler, B.; Zimmer, H. -G.] Univ Leipzig, Carl Ludwig Inst Physiol, Leipzig, Germany	Leipzig University; Leipzig University; Leipzig University	Dhein, S (corresponding author), Heart Ctr Leipzig, Clin Cardiac Surg, Struempellstr 39, D-04289 Leipzig, Germany.	dhes@medizin.uni-leipzig.de	Mühlberg, Katja/GLS-0268-2022						0	56	61	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	FEB	2006	20	2					365	367		10.1096/fj.05-4871fje	http://dx.doi.org/10.1096/fj.05-4871fje			3	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	V17CJ	16352648				2022-12-25	WOS:000207915000023
J	Sumide, T; Nishida, K; Yamato, M; Ide, T; Hayashida, Y; Watanabe, K; Yang, J; Kohno, C; Kikuchi, A; Maeda, N; Watanabe, H; Okano, T; Tano, Y				Sumide, Taizo; Nishida, Kohji; Yamato, Masayuki; Ide, Takeshi; Hayashida, Yasutaka; Watanabe, Katsuhiko; Yang, Joseph; Kohno, Chinatsu; Kikuchi, Akihiko; Maeda, Naoyuki; Watanabe, Hitoshi; Okano, Teruo; Tano, Yasuo			Functional human corneal endothelial cell sheets harvested from temperature-responsive culture surfaces	FASEB JOURNAL			English	Article									[Sumide, Taizo; Nishida, Kohji; Ide, Takeshi; Hayashida, Yasutaka; Watanabe, Katsuhiko; Maeda, Naoyuki; Watanabe, Hitoshi; Okano, Teruo; Tano, Yasuo] Osaka Univ, Dept Ophthalmol, Sch Med, Suita, Osaka 5650871, Japan; [Yamato, Masayuki; Yang, Joseph; Kohno, Chinatsu; Kikuchi, Akihiko] Tokyo Womens Med Univ, Inst Adv Biomed Engn & Sci, Tokyo, Japan	Osaka University; Tokyo Women's Medical University	Nishida, K (corresponding author), Osaka Univ, Dept Ophthalmol, Sch Med, Room E7,2-2 Yamadaoka, Suita, Osaka 5650871, Japan.	knishida@ophthal.med.osaka-u.ac.jp	Okano, Teruo/J-4028-2012	Nishida, Kohji/0000-0001-9069-3610					0	175	190	1	12	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	FEB	2006	20	2					392	394		10.1096/fj.04-3035fje	http://dx.doi.org/10.1096/fj.04-3035fje			3	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	V17CJ	16339916				2022-12-25	WOS:000207915000032
J	Gillingham, AK; Whyte, JRC; Panic, B; Munro, S				Gillingham, AK; Whyte, JRC; Panic, B; Munro, S			Mon2, a relative of large Arf exchange factors, recruits Dop1 to the Golgi apparatus	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADP-RIBOSYLATION FACTORS; BREFELDIN-A; SACCHAROMYCES-CEREVISIAE; DELETION STRAINS; SEC7 DOMAIN; SNARE SNC1P; YEAST; PROTEIN; TRANSPORT; PATHWAY	The protein Mon2 is distantly related to the guanine nucleotide exchange factors ( GEFs) that activate Arf1 on Golgi membranes. However, unlike these "large" Arf GEFs, Mon2 lacks the Sec7 domain that catalyzes nucleotide exchange on Arf1. Here we report that yeast Mon2 shares extensive homology with the noncatalytic parts of both the BIG and Golgi brefeldin A resistance factor subfamilies of ArfGEFs and is located to the trans-Golgi. Moreover, we find that Mon2 forms a complex with Dop1, a large cytoplasmic protein conserved in evolution from humans to protozoa. Deletion of Mon2 results in mislocalization of Dop1 from the Golgi and defects in cycling between endosomes and the Golgi. However, unlike Mon2, Dop1 is essential for yeast viability. A conditional allele of Dop1 shows that loss of Dop1 activity not only affects endosome to Golgi transport but also causes a severe perturbation of the organization of the endoplasmic reticulum. Thus, it appears that Dop1 plays a widespread role in membrane organization, and Mon2 acts as a scaffold to recruit the Golgi-localized pool of Dop1.	MRC, Mol Biol Lab, Cambridge CB2 2QH, England	MRC Laboratory Molecular Biology	Munro, S (corresponding author), MRC, Mol Biol Lab, Hills Rd, Cambridge CB2 2QH, England.	sean@mrc-lmb.cam.ac.uk		Munro, Sean/0000-0001-6160-5773	MRC [MC_U105178783] Funding Source: UKRI; Medical Research Council [MC_U105178783] Funding Source: Medline	MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))		Bensen ES, 2001, MOL BIOL CELL, V12, P13, DOI 10.1091/mbc.12.1.13; Bonangelino CJ, 2002, MOL BIOL CELL, V13, P2486, DOI 10.1091/mbc.02-01-0005; Brachmann CB, 1998, YEAST, V14, P115; CARLSON M, 1982, CELL, V28, P145, DOI 10.1016/0092-8674(82)90384-1; Chantalat S, 2004, J CELL SCI, V117, P711, DOI 10.1242/jcs.00896; Chantalat S, 2003, MOL BIOL CELL, V14, P2357, DOI 10.1091/mbc.E02-10-0693; Cox R, 2004, MOL BIOL CELL, V15, P1487, DOI 10.1091/mbc.E03-06-0443; Efe JA, 2005, J CELL SCI, V118, P4751, DOI 10.1242/jcs.02599; Galan JM, 2001, MOL CELL BIOL, V21, P3105, DOI 10.1128/MCB.21.9.3105-3117.2001; Garcia-Mata R, 2003, EMBO REP, V4, P320, DOI 10.1038/sj.embor.embor762; Guipponi M, 2000, GENOMICS, V68, P30, DOI 10.1006/geno.2000.6250; HEINEMEYER W, 1991, EMBO J, V10, P555, DOI 10.1002/j.1460-2075.1991.tb07982.x; Jackson CL, 2000, TRENDS CELL BIOL, V10, P60, DOI 10.1016/S0962-8924(99)01699-2; Jochum A, 2002, MOL CELL BIOL, V22, P4914, DOI 10.1128/MCB.22.13.4914-4928.2002; KAISER CA, 1990, CELL, V61, P723, DOI 10.1016/0092-8674(90)90483-U; Kawamoto K, 2002, TRAFFIC, V3, P483, DOI 10.1034/j.1600-0854.2002.30705.x; Klarlund JK, 2000, J BIOL CHEM, V275, P32816, DOI 10.1074/jbc.M002435200; Lewis MJ, 2000, MOL BIOL CELL, V11, P23, DOI 10.1091/mbc.11.1.23; Li HW, 2003, P NATL ACAD SCI USA, V100, P1627, DOI 10.1073/pnas.0337678100; Mansour SJ, 1999, P NATL ACAD SCI USA, V96, P7968, DOI 10.1073/pnas.96.14.7968; Mossessova E, 2003, MOL CELL, V12, P1403, DOI 10.1016/S1097-2765(03)00475-1; Mouratou B, 2005, BMC GENOMICS, V6, DOI 10.1186/1471-2164-6-20; Munro S, 2005, BIOCHEM SOC T, V33, P601, DOI 10.1042/BST0330601; Muren E, 2001, YEAST, V18, P163, DOI 10.1002/1097-0061(20010130)18:2<163::AID-YEA659>3.0.CO;2-#; Nie ZZ, 2003, CURR OPIN CELL BIOL, V15, P396, DOI 10.1016/S0955-0674(03)00071-1; Padilla PI, 2003, P NATL ACAD SCI USA, V100, P2322, DOI 10.1073/pnas.2628047100; Panic B, 2003, CURR BIOL, V13, P405, DOI 10.1016/S0960-9822(03)00091-5; Park SK, 2005, MOL BIOL CELL, V16, P3786, DOI 10.1091/mbc.E05-04-0289; Pascon RC, 2000, MOL MICROBIOL, V36, P1250, DOI 10.1046/j.1365-2958.2000.01950.x; Reggiori F, 2000, MOL BIOL CELL, V11, P3737, DOI 10.1091/mbc.11.11.3737; Renault L, 2003, NATURE, V426, P525, DOI 10.1038/nature02197; ROBINSON JS, 1988, MOL CELL BIOL, V8, P4936, DOI 10.1128/MCB.8.11.4936; Setty SRG, 2003, CURR BIOL, V13, P401, DOI 10.1016/S0960-9822(03)00089-7; Shaw JM, 2002, TRENDS CELL BIOL, V12, P178, DOI 10.1016/S0962-8924(01)02246-2; Shevchenko A, 1996, P NATL ACAD SCI USA, V93, P14440, DOI 10.1073/pnas.93.25.14440; Shinotsuka C, 2002, J BIOL CHEM, V277, P9468, DOI 10.1074/jbc.M112427200; SingerKruger B, 1997, EUR J CELL BIOL, V74, P365; Siniossoglou S, 2001, EMBO J, V20, P5991, DOI 10.1093/emboj/20.21.5991; Tong AHY, 2004, SCIENCE, V303, P808, DOI 10.1126/science.1091317; Valdez-Taubas J, 2003, CURR BIOL, V13, P1636, DOI 10.1016/j.cub.2003.09.001; Wach A, 1997, YEAST, V13, P1065, DOI 10.1002/(SICI)1097-0061(19970915)13:11<1065::AID-YEA159>3.3.CO;2-B; Whyte JRC, 2001, DEV CELL, V1, P527, DOI 10.1016/S1534-5807(01)00063-6; Wicky S, 2004, MOL CELL BIOL, V24, P7402, DOI 10.1128/MCB.24.17.7402-7418.2004; Xu KF, 2005, P NATL ACAD SCI USA, V102, P2784, DOI 10.1073/pnas.0409871102; Yamaji R, 2000, P NATL ACAD SCI USA, V97, P2567, DOI 10.1073/pnas.97.6.2567; Zhao XH, 2002, MOL BIOL CELL, V13, P119, DOI 10.1091/mbc.01-08-0420	46	32	36	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 27	2006	281	4					2273	2280		10.1074/jbc.M510176200	http://dx.doi.org/10.1074/jbc.M510176200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	004NV	16301316	hybrid			2022-12-25	WOS:000234760400052
J	Voss, E; Wehkamp, J; Wehkamp, K; Stange, EF; Schroder, JM; Harder, J				Voss, E; Wehkamp, J; Wehkamp, K; Stange, EF; Schroder, JM; Harder, J			NOD2/CARD15 mediates induction of the antimicrobial peptide human beta-defensin-2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; HUMAN BETA-DEFENSINS; ANTIINFLAMMATORY SESQUITERPENE LACTONE; INTESTINAL EPITHELIAL-CELLS; INNATE IMMUNE-RESPONSE; TOLL-LIKE RECEPTORS; HUMAN BETA-DEFENSIN-2; CROHNS-DISEASE; STAPHYLOCOCCUS-AUREUS; HELICOBACTER-PYLORI	Production of inducible antimicrobial peptides offers a first and rapid defense response of epithelial cells against invading microbes. Human beta-defensin-2 (hBD-2) is an antimicrobial peptide induced in various epithelia upon extracellular as well as intracellular bacterial challenge. Nucleotide-binding oligomerization domain protein 2 (NOD2/CARD15) is a cytosolic protein involved in intracellular recognition of microbes by sensing peptidoglycan fragments ( e. g. muramyl dipeptide). We used luciferase as a reporter gene for a 2.3-kb hBD-2 promoter to test the hypothesis that NOD2 mediates the induction of hBD-2. Activation of NOD2 in NOD2-overexpressing human embryonic kidney 293 cells through its ligand muramyl dipeptide ( MDP) induced hBD-2 expression. In contrast, overexpression of NOD2 containing the 3020insC frameshift mutation, the most frequent NOD2 variant associated with Crohn disease, resulted in defective induction of hBD-2 through MDP. Luciferase gene reporter analyses and site-directed mutagenesis experiments demonstrated that functional binding sites for NF-kappa B and AP-1 in the hBD-2 promoter are required for NOD2-mediated induction of hBD-2 through MDP. Moreover, the NF-kappa B inhibitor Helenalin as well as a super-repressor form of the NF-kappa B inhibitor I kappa B strongly inhibited NOD2-mediated hBD-2 promoter activation. Expression of NOD2 was detected in primary keratinocytes, and stimulation of these cells with MDP induced hBD-2 peptide release. In contrast, small interference RNA-mediated downregulation of NOD2 expression in primary keratinocytes resulted in a defective induction of hBD-2 upon MDP treatment. Together, these data suggest that NOD2 serves as an intracellular pattern recognition receptor to enhance host defense by inducing the production of antimicrobial peptides such as hBD-2.	Univ Hosp Schleswig Holstein, Dept Dermatol, D-24105 Kiel, Germany; Univ Calif Davis, Sch Med, Dept Med Microbiol & Immunol, Davis, CA 95616 USA; Robert Bosch Krankenhaus, Dept Internal Med 1, D-70376 Stuttgart, Germany	University of Kiel; Schleswig Holstein University Hospital; University of California System; University of California Davis; Bosch; Robert Bosch Krankenhaus	Harder, J (corresponding author), Univ Hosp Schleswig Holstein, Dept Dermatol, Campus Kiel,Schittenhelmstr 7, D-24105 Kiel, Germany.	jharder@dermatology.uni-kiel.de	Wehkamp, Jan/B-7319-2011; Schroeder, Jens M/B-3994-2009; Harder, Jürgen/B-3162-2010	Wehkamp, Jan/0000-0001-6788-841X; Harder, Jurgen/0000-0002-4075-4603				Boman HG, 2003, J INTERN MED, V254, P197, DOI 10.1046/j.1365-2796.2003.01228.x; Chung WO, 2004, INFECT IMMUN, V72, P352, DOI 10.1128/IAI.72.1.352-358.2004; Dangl JL, 2001, NATURE, V411, P826, DOI 10.1038/35081161; DIAMOND G, 1991, P NATL ACAD SCI USA, V88, P3952, DOI 10.1073/pnas.88.9.3952; Donnarumma G, 2004, EXP DERMATOL, V13, P748, DOI 10.1111/j.0906-6705.2004.00218.x; Fournier B, 2005, CLIN MICROBIOL REV, V18, P521, DOI 10.1128/CMR.18.3.521-540.2005; Ganz T, 1998, CURR OPIN IMMUNOL, V10, P41, DOI 10.1016/S0952-7915(98)80029-0; Girardin SE, 2003, J BIOL CHEM, V278, P8869, DOI 10.1074/jbc.C200651200; Girardin SE, 2003, J BIOL CHEM, V278, P41702, DOI 10.1074/jbc.M307198200; Gutierrez O, 2002, J BIOL CHEM, V277, P41701, DOI 10.1074/jbc.M206473200; Hampe J, 2001, LANCET, V357, P1925, DOI 10.1016/S0140-6736(00)05063-7; Harder J, 2000, AM J RESP CELL MOL, V22, P714, DOI 10.1165/ajrcmb.22.6.4023; Harder J, 2004, J INVEST DERMATOL, V123, P522, DOI 10.1111/j.0022-202X.2004.23234.x; Harder J, 1997, NATURE, V387, P861, DOI 10.1038/43088; Huang GTJ, 2002, HUM GENE THER, V13, P2017, DOI 10.1089/10430340260395875; Hugot JP, 2001, NATURE, V411, P599, DOI 10.1038/35079107; Inohara N, 2003, J BIOL CHEM, V278, P5509, DOI 10.1074/jbc.C200673200; Kao CY, 2004, J IMMUNOL, V173, P3482, DOI 10.4049/jimmunol.173.5.3482; Kobayashi KS, 2005, SCIENCE, V307, P731, DOI 10.1126/science.1104911; Krisanaprakornkit S, 2002, J IMMUNOL, V168, P316, DOI 10.4049/jimmunol.168.1.316; Kulms D, 2000, J BIOL CHEM, V275, P15060, DOI 10.1074/jbc.M910113199; Lala S, 2003, GASTROENTEROLOGY, V125, P47, DOI 10.1016/S0016-5085(03)00661-9; Lehmann J, 2002, BMC INFECT DIS, V2, DOI 10.1186/1471-2334-2-20; Liu LD, 2003, J IMMUNOL, V170, P575, DOI 10.4049/jimmunol.170.1.575; Lyss G, 1998, J BIOL CHEM, V273, P33508, DOI 10.1074/jbc.273.50.33508; Lyss G, 1997, BIOL CHEM, V378, P951, DOI 10.1515/bchm.1997.378.9.951; Mathews M, 1999, INFECT IMMUN, V67, P2740, DOI 10.1128/IAI.67.6.2740-2745.1999; McDermott AM, 2003, INVEST OPHTH VIS SCI, V44, P1859, DOI 10.1167/iovs.02-0787; Menzies BE, 2005, INFECT IMMUN, V73, P5241, DOI 10.1128/IAI.73.8.5241-5244.2005; Niyonsaba F, 2004, IMMUNOLOGY, V111, P273, DOI 10.1111/j.0019-2805.2004.01816.x; Nomura I, 2003, J IMMUNOL, V171, P3262, DOI 10.4049/jimmunol.171.6.3262; O'Neil DA, 2000, INFECT IMMUN, V68, P5412, DOI 10.1128/IAI.68.9.5412-5415.2000; O'Neil DA, 1999, J IMMUNOL, V163, P6718; Ogura Y, 2003, GUT, V52, P1591, DOI 10.1136/gut.52.11.1591; Ogura Y, 2001, NATURE, V411, P603, DOI 10.1038/35079114; Ogura Y, 2001, J BIOL CHEM, V276, P4812, DOI 10.1074/jbc.M008072200; Ogushi K, 2001, J BIOL CHEM, V276, P30521, DOI 10.1074/jbc.M011618200; Ong PY, 2002, NEW ENGL J MED, V347, P1151, DOI 10.1056/NEJMoa021481; Opitz B, 2004, J BIOL CHEM, V279, P36426, DOI 10.1074/jbc.M403861200; Pallen MJ, 2003, CURR OPIN MICROBIOL, V6, P519, DOI 10.1016/j.mib.2003.09.005; Philpott DJ, 2004, MOL IMMUNOL, V41, P1099, DOI 10.1016/j.molimm.2004.06.012; Proud D, 2004, J IMMUNOL, V172, P4637, DOI 10.4049/jimmunol.172.7.4637; Rosenstiel P, 2003, GASTROENTEROLOGY, V124, P1001, DOI 10.1053/gast.2003.50157; Schrager HM, 1996, J CLIN INVEST, V98, P1954, DOI 10.1172/JCI118998; Schroder JM, 1999, INT J BIOCHEM CELL B, V31, P645, DOI 10.1016/S1357-2725(99)00013-8; Schroder JM, 1999, CELL MOL LIFE SCI, V56, P32, DOI 10.1007/s000180050004; Sorensen OE, 2005, J IMMUNOL, V174, P4870, DOI 10.4049/jimmunol.174.8.4870; Tanabe T, 2004, EMBO J, V23, P1587, DOI 10.1038/sj.emboj.7600175; TRAENCKNER EBM, 1995, EMBO J, V14, P2876, DOI 10.1002/j.1460-2075.1995.tb07287.x; Tsutsumi-Ishii Y, 2003, J IMMUNOL, V170, P4226, DOI 10.4049/jimmunol.170.8.4226; Tsutsumi-Ishii Y, 2002, J LEUKOCYTE BIOL, V71, P154; Underhill DM, 2002, CURR OPIN IMMUNOL, V14, P103, DOI 10.1016/S0952-7915(01)00304-1; Viala J, 2004, NAT IMMUNOL, V5, P1166, DOI 10.1038/ni1131; Vora P, 2004, J IMMUNOL, V173, P5398, DOI 10.4049/jimmunol.173.9.5398; Wada A, 1999, BIOCHEM BIOPH RES CO, V263, P770, DOI 10.1006/bbrc.1999.1452; Wehkamp J, 2004, GUT, V53, P1658, DOI 10.1136/gut.2003.032805; Wehkamp J, 2004, INFECT IMMUN, V72, P5750, DOI 10.1128/IAI.72.10.5750-5758.2004; Wehkamp J, 2005, J LEUKOCYTE BIOL, V77, P460, DOI 10.1189/jlb.0904543; Wehkamp J, 2003, INFLAMM BOWEL DIS, V9, P215, DOI 10.1097/00054725-200307000-00001; Wiedow O, 1998, BIOCHEM BIOPH RES CO, V248, P904, DOI 10.1006/bbrc.1998.9069; Wolk K, 2004, IMMUNITY, V21, P241, DOI 10.1016/j.immuni.2004.07.007; Yang D, 1999, SCIENCE, V286, P525, DOI 10.1126/science.286.5439.525; Zasloff M, 2002, NATURE, V415, P389, DOI 10.1038/415389a	63	251	265	0	9	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 27	2006	281	4					2005	2011		10.1074/jbc.M511044200	http://dx.doi.org/10.1074/jbc.M511044200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	004NV	16319062	hybrid			2022-12-25	WOS:000234760400021
J	Hakansson, P; Dahl, L; Chilkova, O; Domkin, V; Thelander, L				Hakansson, P; Dahl, L; Chilkova, O; Domkin, V; Thelander, L			The Schizosaccharomyces pombe replication inhibitor spd1 regulates ribonucleotide reductase activity and dNTPs by binding to the large Cdc22 subunit	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							S-PHASE INHIBITOR; FISSION YEAST; DNA-DAMAGE; RECOMBINANT MOUSE; CELL-CYCLE; CHECKPOINT; LOCALIZATION; PURIFICATION; MUTAGENESIS; PROTEIN	Ribonucleotide reductase (RNR) is an essential enzyme that provides the cell with a balanced supply of deoxyribonucleoside triphosphates for DNA replication and repair. Mutations that affect the regulation of RNR in yeast and mammalian cells can lead to genetic abnormalities and cell death. We have expressed and purified the components of the RNR system in fission yeast, the large subunit Cdc22p, the small subunit Suc22p, and the replication inhibitor Spd1p. It was proposed (Liu, C., Powell, K. A., Mundt, K., Wu, L., Carr, A. M., and Caspari, T. ( 2003) Genes Dev. 17, 1130 1140) that Spd1 is an RNR inhibitor, acting by anchoring the Suc22p inside the nucleus during G(1) phase. Using in vitro assays with highly purified proteins we have demonstrated that Spd1 indeed is a very efficient inhibitor of fission yeast RNR, but acting on Cdc22p. Furthermore, biosensor technique showed that Spd1p binds to the Cdc22p with a K-D of 2.4 mu M, whereas the affinity to Suc22p is negligible. Therefore, Spd1p inhibits fission yeast RNR activity by interacting with the Cdc22p. Similar to the situation in budding yeast, logarithmically growing fission yeast increases the dNTP pools 2-fold after 3 h of incubation in the UV mimetic 4-nitroquinoline-N-oxide. This increase is smaller than the increase observed in budding yeast but of the same order as the dNTP pool increase when synchronous Schizosaccharomyces pombe cdc10 cells are going from G(1) to S-phase.	Umea Univ, Dept Med Biochem & Biophys, SE-90187 Umea, Sweden	Umea University	Hakansson, P (corresponding author), Umea Univ, Dept Med Biochem & Biophys, SE-90187 Umea, Sweden.	pelle.hakanson@medchem.umu.se		Hakansson, Pelle/0000-0003-0421-2433; Shilkova, Olga/0000-0001-8607-4008				Bondar T, 2004, J BIOL CHEM, V279, P9937, DOI 10.1074/jbc.M312570200; Borgne A, 2000, J CELL SCI, V113, P4341; Chabes A, 2003, CELL, V112, P391, DOI 10.1016/S0092-8674(03)00075-8; Chabes A, 2000, P NATL ACAD SCI USA, V97, P2474, DOI 10.1073/pnas.97.6.2474; Chabes A, 1999, J BIOL CHEM, V274, P36679, DOI 10.1074/jbc.274.51.36679; DAVIS R, 1994, J BIOL CHEM, V269, P23171; Domkin V, 2002, J BIOL CHEM, V277, P18574, DOI 10.1074/jbc.M201553200; ENGSTROM Y, 1988, EMBO J, V7, P1615, DOI 10.1002/j.1460-2075.1988.tb02987.x; ENGSTROM Y, 1984, EMBO J, V3, P863, DOI 10.1002/j.1460-2075.1984.tb01897.x; ENGSTROM Y, 1979, BIOCHEMISTRY-US, V18, P2941, DOI 10.1021/bi00581a004; FRIEDBERG EC, 1995, DNA REPAIR MUTAGENES, P42; Hofer A, 1998, J BIOL CHEM, V273, P34098, DOI 10.1074/jbc.273.51.34098; Holmberg C, 2005, GENE DEV, V19, P853, DOI 10.1101/gad.329905; Ingemarson R, 1996, BIOCHEMISTRY-US, V35, P8603, DOI 10.1021/bi960184n; JONSSON U, 1991, BIOTECHNIQUES, V11, P620; Koc A, 2003, J BIOL CHEM, V278, P9345, DOI 10.1074/jbc.M213013200; KUNZ BA, 1991, ANNU REV GENET, V25, P339, DOI 10.1146/annurev.ge.25.120191.002011; Liu C, 2003, GENE DEV, V17, P1130, DOI 10.1101/gad.1090803; LIU C, 2005, IN PRESS EMBO J; MANN GJ, 1991, BIOCHEMISTRY-US, V30, P1939, DOI 10.1021/bi00221a030; Mundt KE, 1999, CURR BIOL, V9, P1427, DOI 10.1016/S0960-9822(00)80091-3; Nielsen O, 2003, CURR BIOL, V13, pR565, DOI 10.1016/S0960-9822(03)00475-5; Nilssen EA, 2003, P NATL ACAD SCI USA, V100, P10758, DOI 10.1073/pnas.1833769100; Rova U, 1999, J BIOL CHEM, V274, P23746, DOI 10.1074/jbc.274.34.23746; ROVA U, 1995, BIOCHEMISTRY-US, V34, P4267, DOI 10.1021/bi00013a016; SARABIA MJF, 1993, MOL GEN GENET, V238, P241, DOI 10.1007/BF00279553; Tanaka H, 2000, NATURE, V404, P42, DOI 10.1038/35003506; Uchiki T, 2004, J BIOL CHEM, V279, P11293, DOI 10.1074/jbc.M309751200; Woollard A, 1996, EMBO J, V15, P4603, DOI 10.1002/j.1460-2075.1996.tb00838.x; Yao RJ, 2003, P NATL ACAD SCI USA, V100, P6628, DOI 10.1073/pnas.1131932100; Zhao XL, 1998, MOL CELL, V2, P329, DOI 10.1016/S1097-2765(00)80277-4; Zhao XL, 2000, MOL CELL BIOL, V20, P9076, DOI 10.1128/MCB.20.23.9076-9083.2000	32	52	54	0	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 20	2006	281	3					1778	1783		10.1074/jbc.M511716200	http://dx.doi.org/10.1074/jbc.M511716200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	002ZS	16317005	hybrid			2022-12-25	WOS:000234652000059
J	Baldwin, RM; Garratt-Lalonde, M; Parolin, DAE; Krzyzanowski, PM; Andrade, MA; Lorimer, IAJ				Baldwin, R. M.; Garratt-Lalonde, M.; Parolin, D. A. E.; Krzyzanowski, P. M.; Andrade, M. A.; Lorimer, I. A. J.			Protection of glioblastoma cells from cisplatin cytotoxicity via protein kinase C iota-mediated attenuation of p38 MAP kinase signaling	ONCOGENE			English	Article						glioblastoma; protein kinase C iota; glia maturation factor beta; p38 MAP kinase; cisplatin	GLIA MATURATION FACTOR; NF-KAPPA-B; GROWTH-FACTOR RECEPTOR; PHOSPHATIDYLINOSITOL 3-KINASE; INDUCED APOPTOSIS; ACTIVATION; ISOFORMS; SURVIVAL; PATHWAY; TARGET	Glioblastoma multiforme is an aggressive form of brain cancer that responds poorly to chemotherapy and is generally incurable. The basis for the poor response of this cancer to chemotherapy is not well understood. The atypical protein kinases C ( PKC iota andPKC zeta) have previously been implicated in leukaemia cell chemoresistance. To assess the role of atypical PKC in glioblastoma cell chemoresistance, RNA interference was used to deplete human glioblastoma cells of PKC iota. Transfection of cells with either of two different RNA duplexes specific for PKC iota causeda partial sensitisation to cell death induced by the chemotherapy agent cisplatin. To screen for possible mechanisms for PKC iota- mediated chemoresistance, microarray analysis of gene expression was performed on RNA from glioblastoma cells that were either untreated or depleted of PKC iota. This identified sets of genes that were regulated either positively or negatively by PKC iota. Within the set of genes that were negatively regulated by PKC iota, the function of the gene coding for GMF beta, an enhancer of p38 mitogen- activated-protein kinase ( MAP kinase) signaling, was investigated further, as the p38 MAP kinase pathway has been previously identified as a key mediator of cisplatin cytotoxicity. The expression of both GMFb mRNA and protein increased upon PKC iota depletion, and this was accompanied by an increase in cisplatin- activated p38 MAP kinase signaling. Transient overexpression of GMFb increased cisplatin-activated p38 MAP kinase signaling and also sensitised cells to cisplatin cytotoxicity. The increase in cisplatin cytotoxicity seen with PKCi depletion was blocked by the p38 MAP kinase inhibitor SKF86002. These data show that PKCi can confer partial resistance to cisplatin in glioblastoma cells by suppressing GMF beta- mediated enhancement of p38 MAP kinase signaling.	Ottawa Hosp Reg Canc Ctr, Ctr Canc Therapeut, Ottawa Hlth Res Inst, Ottawa, ON K1H 8L6, Canada; Univ Ottawa, Dept Biochem Microbiol & Immunol, Ottawa, ON, Canada; Univ Ottawa, Dept Cellular & Mol Med, Ottawa, ON, Canada; Ontario Genom Innovat Ctr, Ottawa, ON, Canada; Univ Ottawa, Dept Med, Ottawa, ON, Canada	University of Ottawa; Ottawa Hospital Research Institute; University of Ottawa; University of Ottawa; University of Ottawa; University of Ottawa	Lorimer, IAJ (corresponding author), Ottawa Hosp Reg Canc Ctr, Ctr Canc Therapeut, Ottawa Hlth Res Inst, 3rd Floor,501 Smyth Rd, Ottawa, ON K1H 8L6, Canada.	ilorimer@ohri.ca		Krzyzanowski, Paul/0000-0001-6430-5995				Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; Benhar M, 2002, EMBO REP, V3, P420, DOI 10.1093/embo-reports/kvf094; Berra E, 1997, MOL CELL BIOL, V17, P4346, DOI 10.1128/MCB.17.8.4346; Brigstock DR, 2003, J ENDOCRINOL, V178, P169, DOI 10.1677/joe.0.1780169; Choi BK, 2004, NEUROTOXICOLOGY, V25, P915, DOI 10.1016/j.neuro.2004.06.002; Diaz-Meco MT, 2001, MOL CELL BIOL, V21, P1218, DOI 10.1128/MCB.21.4.1218-1227.2001; Filomenko R, 2002, CANCER RES, V62, P1815; Garcia-Cao I, 2003, EMBO REP, V4, P307, DOI 10.1038/sj.embor.embor769; Gentleman RC, 2004, GENOME BIOL, V5, DOI 10.1186/gb-2004-5-10-r80; Hanigan MH, 2005, AM J PHYSIOL-RENAL, V288, pF125, DOI 10.1152/ajprenal.00041.2003; Holland EC, 2001, NAT REV GENET, V2, P120, DOI 10.1038/35052535; Inagaki M, 2004, BBA-GEN SUBJECTS, V1670, P208, DOI 10.1016/j.bbagen.2003.12.006; Ishii N, 1999, BRAIN PATHOL, V9, P469, DOI 10.1111/j.1750-3639.1999.tb00536.x; Jin ZJ, 2005, J BIOL CHEM, V280, P16045, DOI 10.1074/jbc.M413488200; Kaimori J, 2003, J BIOL CHEM, V278, P33519, DOI 10.1074/jbc.M301552200; Kanzaki M, 2004, J CELL BIOL, V164, P279, DOI 10.1083/jcb.200306152; LEBAIL O, 1993, EMBO J, V12, P5043, DOI 10.1002/j.1460-2075.1993.tb06197.x; Leitges M, 2001, MOL CELL, V8, P771, DOI 10.1016/S1097-2765(01)00361-6; Lim R, 2004, BRAIN RES, V1024, P225, DOI 10.1016/j.brainres.2004.08.003; Lim R, 1996, J BIOL CHEM, V271, P22953, DOI 10.1074/jbc.271.38.22953; Lorimer IAJ, 2002, CURR CANCER DRUG TAR, V2, P91, DOI 10.2174/1568009023333926; Lorimer IAJ, 2000, J IMMUNOL METHODS, V237, P147, DOI 10.1016/S0022-1759(99)00219-7; Losa JH, 2003, ONCOGENE, V22, P3998, DOI 10.1038/sj.onc.1206608; Lu WG, 2004, CELL, V119, P97, DOI 10.1016/j.cell.2004.09.019; Lu Y, 2001, ONCOGENE, V20, P4777, DOI 10.1038/sj.onc.1204607; MAYO MW, 2000, BIOCHIM BIOPHYS ACTA, V1470, P55; Moscat J, 2000, EMBO REP, V1, P399, DOI 10.1093/embo-reports/kvd098; Moscatello DK, 1998, J BIOL CHEM, V273, P200, DOI 10.1074/jbc.273.1.200; Murray NR, 1997, J BIOL CHEM, V272, P27521, DOI 10.1074/jbc.272.44.27521; Sansal I, 2004, J CLIN ONCOL, V22, P2954, DOI 10.1200/jco.2004.02.141; Semizarov D, 2003, P NATL ACAD SCI USA, V100, P6347, DOI 10.1073/pnas.1131959100; Soloff RS, 2004, J IMMUNOL, V173, P3250, DOI 10.4049/jimmunol.173.5.3250; Stupp R, 2005, NEW ENGL J MED, V352, P987, DOI 10.1056/NEJMoa043330; Tusher VG, 2001, P NATL ACAD SCI USA, V98, P5116, DOI 10.1073/pnas.091062498; Vanhaesebroeck B, 2000, BIOCHEM J, V346, P561, DOI 10.1042/0264-6021:3460561; Zaheer A, 2004, NEUROCHEM RES, V29, P1473, DOI 10.1023/B:NERE.0000029558.82943.00; Zhan Y, 2004, CANCER RES, V64, P8292, DOI 10.1158/0008-5472.CAN-03-3143	37	57	61	1	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY	2006	25	20					2909	2919		10.1038/sj.onc.1209312	http://dx.doi.org/10.1038/sj.onc.1209312			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	041IN	16331246				2022-12-25	WOS:000237448200009
J	Wu, YZ; Manevich, Y; Baldwin, JL; Dodia, C; Yu, K; Feinstein, SI; Fisher, AB				Wu, YZ; Manevich, Y; Baldwin, JL; Dodia, C; Yu, K; Feinstein, SI; Fisher, AB			Interaction of surfactant protein a with peroxiredoxin 6 regulates phospholipase A(2) activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PULMONARY SURFACTANT; RAT LUNG; II CELLS; LAMELLAR BODIES; ALVEOLAR DPPC; KAPPA-B; DIPALMITOYLPHOSPHATIDYLCHOLINE; MEMBRANE; IDENTIFICATION; RECOGNITION	Peroxiredoxin 6 (Prdx6) is a "moonlighting" protein with both GSH peroxidase and phospholipase A(2) (PLA(2)) activities. This protein is responsible for degradation of internalized dipalmitoylphosphatidylcholine, the major phospholipid component of lung surfactant. The PLA(2) activity is inhibited by surfactant protein A (SP-A). We postulate that SP-A regulates the PLA(2) activity of Prdx6 through direct protein-protein interaction. Recombinant human Prdx6 and SP-A isolated from human alveolar proteinosis fluid were studied. Measurement of kinetic constants at pH 4.0 (maximal PLA(2) activity) showed K-m 0.35 mM and V-max 138 nmol/min/mg of protein. SP-A inhibited PLA(2) activity non-competitively with K-i 10 mu g/ml and was Ca2+-independent. Activity at pH 7.4 was similar to 50% less, and inhibition by SP-A was partially dependent on Ca2+. Interaction of SP-A and Prdx6 at pH 7.4 was shown by Prdx6-mediated inhibition of SP-A binding to agarose beads, a pull-down assay using His-tagged Prdx6 and Ni2+-chelating beads, co-immunoprecipitation from lung epithelial cells and from a binary mixture of the two proteins, binding after treatment with a trifunctional cross-linker, and size-exclusion chromatography. Analysis by static light scattering and surface plasmon resonance showed calcium-independent SP-A binding to Prdx6 at pH 4.0 and partial Ca2+ dependence of binding at pH 7.4. These results indicate a direct interaction between SP-A and Prdx6, which provides a mechanism for regulation of the PLA(2) activity of Prdx6 by SP-A.	Univ Penn, Inst Environm Med, Philadelphia, PA 19104 USA	University of Pennsylvania	Fisher, AB (corresponding author), Univ Penn, Inst Environm Med, 1 John Morgan Bldg,3620 Hamilton Walk, Philadelphia, PA 19104 USA.	abf@mail.med.upenn.edu			NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL019737] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL 19737] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Akiba S, 1998, COMP BIOCHEM PHYS B, V120, P393, DOI 10.1016/S0305-0491(98)10046-9; Arbibe L, 1998, J CLIN INVEST, V102, P1152, DOI 10.1172/JCI3236; Bi XH, 2001, BIOCHEMISTRY-US, V40, P13659, DOI 10.1021/bi011188h; Casals C, 2001, PEDIATR PATHOL MOL M, V20, P249, DOI 10.1080/152279501750412216; CHANDER A, 1986, J BIOL CHEM, V261, P6126; CHINOY MR, 1993, AM J PHYSIOL, V264, pL300, DOI 10.1152/ajplung.1993.264.3.L300; FISHER AB, 1994, AM J PHYSIOL, V267, pL335, DOI 10.1152/ajplung.1994.267.3.L335; Fisher AB, 2005, J LIPID RES, V46, P1248, DOI 10.1194/jlr.M400499-JLR200; FISHER AB, 1994, BBA-LIPID LIPID MET, V1211, P256, DOI 10.1016/0005-2760(94)90148-1; Fisher AB, 2001, AM J PHYSIOL-LUNG C, V280, pL748, DOI 10.1152/ajplung.2001.280.4.L748; Fisher AB, 1996, J LIPID RES, V37, P1057; HAAGSMAN HP, 1989, AM J PHYSIOL, V257, pL421, DOI 10.1152/ajplung.1989.257.6.L421; HAAGSMAN HP, 1987, J BIOL CHEM, V262, P13877; HAWGOOD S, 1985, BIOCHEMISTRY-US, V24, P184, DOI 10.1021/bi00322a026; Jain D, 2003, AM J PHYSIOL-LUNG C, V284, pL759, DOI 10.1152/ajplung.00200.2002; KALINA M, 1995, AM J PHYSIOL-LUNG C, V268, pL144, DOI 10.1152/ajplung.1995.268.1.L144; Kim TS, 1998, AM J PHYSIOL-LUNG C, V274, pL750, DOI 10.1152/ajplung.1998.274.5.L750; Kim TS, 1997, J BIOL CHEM, V272, P2542; KUROKI Y, 1991, J BIOL CHEM, V266, P3068; Manevich Y, 2004, P NATL ACAD SCI USA, V101, P3780, DOI 10.1073/pnas.0400181101; Manevich Y, 2002, P NATL ACAD SCI USA, V99, P11599, DOI 10.1073/pnas.182384499; Morrow MR, 2003, BIOPHYS J, V85, P2397, DOI 10.1016/S0006-3495(03)74663-3; Mulugeta S, 2002, J BIOL CHEM, V277, P22147, DOI 10.1074/jbc.M201812200; Piboonpocanun S, 2005, J BIOL CHEM, V280, P9, DOI 10.1074/jbc.M411570200; Rhee SG, 2001, IUBMB LIFE, V52, P35, DOI 10.1080/15216540252774748; RIDER ED, 1991, J BIOL CHEM, V266, P22522; Sato M, 2003, J IMMUNOL, V171, P417, DOI 10.4049/jimmunol.171.1.417; VANGOLDE LMG, 1988, PHYSIOL REV, V68, P374, DOI 10.1152/physrev.1988.68.2.374; WALI A, 1993, AM J PHYSIOL, V264, pL431, DOI 10.1152/ajplung.1993.264.5.L431; Weaver TE, 2002, SEMIN CELL DEV BIOL, V13, P263, DOI 10.1016/S1084952102000551; Weis WI, 1996, ANNU REV BIOCHEM, V65, P441, DOI 10.1146/annurev.bi.65.070196.002301; WRIGHT JR, 1987, J BIOL CHEM, V262, P2888; Wu YZ, 2003, AM J RESP CRIT CARE, V168, P692, DOI 10.1164/rccm.200304-467OC; YOUNG SL, 1991, AM J PHYSIOL, V260, pL161, DOI 10.1152/ajplung.1991.260.2.L161; Zen K, 1998, AM J PHYSIOL-LUNG C, V275, pL172, DOI 10.1152/ajplung.1998.275.1.L172	35	66	70	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 17	2006	281	11					7515	7525		10.1074/jbc.M504525200	http://dx.doi.org/10.1074/jbc.M504525200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	022BY	16330552	hybrid			2022-12-25	WOS:000236030900073
J	Dang, LH; Chen, F; Knock, SA; Huang, EH; Feng, J; Appelman, HD; Dang, DT				Dang, LH; Chen, F; Knock, SA; Huang, EH; Feng, J; Appelman, HD; Dang, DT			CDX2 does not suppress tumorigenicity in the human gastric cancer cell line MKN45	ONCOGENE			English	Article						CDX2; gastric cancer; tumorigenicity; MKN45	HOMEODOMAIN PROTEIN CDX2; HOMEOBOX GENE CDX2; INTESTINAL METAPLASIA; COLON-CANCER; ECTOPIC EXPRESSION; BETA-CATENIN; TRANSCRIPTION FACTORS; ABERRANT EXPRESSION; MESSENGER-RNA; GUT	CDX2 is a Drosophila caudal-related homeobox transcription factor that is expressed specifically in the intestine. In mice, ectopic expression of CDX2 in the gastric mucosa gives rise to intestinal metaplasia and in one model, gastric carcinoma. In humans, increased CDX2 expression is associated with gastric intestinal metaplasia and tubular adenocarcinomas. These patterns of expression have shown that CDX2 is important for the initiation of intestinal metaplasia in the gastric mucosa, but the role of CDX2 in established gastric cancer remains unclear. We sought to determine whether CDX2 contributes to tumorigenic potential in established gastric cancer. The CDX2 gene in MKN45 gastric carcinoma cells was disrupted using targeted homologous recombination. The resulting CDX2(-/-) cells are essentially identical to their parental cells, with the exception of CDX2 ablation. We found no significant differences in the proliferation of CDX2(-/-) cells compared to CDX2(-/-) cells, in vitro or in vivo. Molecular analyses show that loss of CDX2 predominantly altered the expression of genes involved in intestinal glandular differentiation and adhesion. However, there were no microscopic differences in tumor differentiation. We conclude that disruption of CDX2 in MKN45 cells does not significantly affect their tumorigenic potential.	Univ Michigan, Dept Internal Med, Div Hematol Oncol, Ann Arbor, MI 48109 USA; Univ Michigan, Ctr Comprehens Canc, Ann Arbor, MI USA; Univ Michigan, Dept Surg, Div Colorectal Surg, Ann Arbor, MI USA; Johns Hopkins Univ, Div Gastroenterol, Baltimore, MD USA; Univ Michigan, Dept Pathol, Div Anat Pathol, Ann Arbor, MI USA; Univ Michigan, Div Gastroenterol, Dept Internal Med, Ann Arbor, MI USA	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; Johns Hopkins University; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan	Dang, DT (corresponding author), Univ Michigan, Dept Internal Med, Div Hematol Oncol, 1150 W Med Ctr Dr,MSRB 1,Room 6514, Ann Arbor, MI 48109 USA.	dangd@umich.edu		Huang, Emina/0000-0003-2495-4370	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [K08DK059970] Funding Source: NIH RePORTER; NIDDK NIH HHS [K08DK59970] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Almeida R, 2003, J PATHOL, V199, P36, DOI 10.1002/path.1246; Aoki K, 2003, NAT GENET, V35, P323, DOI 10.1038/ng1265; Bai YQ, 2000, MOL CARCINOGEN, V28, P184, DOI 10.1002/1098-2744(200007)28:3<184::AID-MC7>3.0.CO;2-6; Bai YQ, 2003, ONCOGENE, V22, P7942, DOI 10.1038/sj.onc.1206634; Bai YQ, 2002, CANCER LETT, V176, P47, DOI 10.1016/S0304-3835(01)00753-4; Bjerknes M, 1999, GASTROENTEROLOGY, V116, P7, DOI 10.1016/S0016-5085(99)70222-2; BOLLER K, 1988, DIFFERENTIATION, V39, P51, DOI 10.1111/j.1432-0436.1988.tb00080.x; Bonhomme C, 2003, GUT, V52, P1465, DOI 10.1136/gut.52.10.1465; Boudreau F, 2002, J BIOL CHEM, V277, P31909, DOI 10.1074/jbc.M204622200; Brown JP, 1997, SCIENCE, V277, P831, DOI 10.1126/science.277.5327.831; Bunz F, 1999, J CLIN INVEST, V104, P263, DOI 10.1172/JCI6863; Bunz F, 1998, SCIENCE, V282, P1497, DOI 10.1126/science.282.5393.1497; Bunz F, 2002, CURR OPIN ONCOL, V14, P73, DOI 10.1097/00001622-200201000-00013; Chan TA, 1999, NATURE, V401, P616, DOI 10.1038/44188; Chan TA, 2002, P NATL ACAD SCI USA, V99, P8265, DOI 10.1073/pnas.082240999; Chawengsaksophak K, 1997, NATURE, V386, P84, DOI 10.1038/386084a0; CHENG H, 1974, AM J ANAT, V141, P461, DOI 10.1002/aja.1001410403; CORREA P, 1994, CANCER RES, V54, pS1941; CORREA P, 1992, CANCER RES, V52, P6735; Cummins JM, 2004, CANCER RES, V64, P3006, DOI 10.1158/0008-5472.CAN-04-0046; CUMMINS JM, 2004, NATURE, V428, P486, DOI [DOI 10.1038/NATURE02501, 10.1038/nature02501]; Dang DT, 2005, CANCER RES, V65, P9485, DOI 10.1158/0008-5472.CAN-05-1930; Dang DT, 2001, ONCOGENE, V20, P4884, DOI 10.1038/sj.onc.1204645; Dang LH, 2004, CANCER BIOL THER, V3, P326, DOI 10.4161/cbt.3.3.704; DANG LH, 2003, IN PRESS ONCOGENE; DONG Z, 2002, SCI STKE, pPL7; Ebert MPA, 2002, ALIMENT PHARM THER, V16, P1059, DOI 10.1046/j.1365-2036.2002.01288.x; Ebert MPA, 2003, J CLIN ONCOL, V21, P1708, DOI 10.1200/JCO.2003.10.017; Ebert MPA, 2002, CARCINOGENESIS, V23, P87, DOI 10.1093/carcin/23.1.87; Eda A, 2002, J GASTROENTEROL, V37, P94, DOI 10.1007/s005350200002; Fang RX, 2000, GASTROENTEROLOGY, V118, P115, DOI 10.1016/S0016-5085(00)70420-3; FENOGLIOPREISER CM, 2000, PATHOLOGY GENETICS T; Freund JN, 1998, BIOCHEM CELL BIOL, V76, P957, DOI 10.1139/bcb-76-6-957; FRIEDERICH E, 1990, BIOESSAYS, V12, P403, DOI 10.1002/bies.950120902; Gao XP, 1998, MOL CELL BIOL, V18, P2901, DOI 10.1128/MCB.18.5.2901; Grotzinger C, 2001, GUT, V49, P73, DOI 10.1136/gut.49.1.73; Guo RJ, 2004, CANCER BIOL THER, V3, P593, DOI 10.4161/cbt.3.7.913; Guo RJ, 2004, J BIOL CHEM, V279, P36865, DOI 10.1074/jbc.M405213200; Hinoi T, 2003, J BIOL CHEM, V278, P44608, DOI 10.1074/jbc.M307435200; Hinoi T, 2002, GASTROENTEROLOGY, V123, P1565, DOI 10.1053/gast.2002.36598; Ishikawa A, 2004, LAB INVEST, V84, P629, DOI 10.1038/labinvest.3700087; Ji JF, 2002, ONCOGENE, V21, P6549, DOI 10.1038/sj.onc.1205829; Kaimaktchiev V, 2004, MODERN PATHOL, V17, P1392, DOI 10.1038/modpathol.3800205; Katz JP, 2002, DEVELOPMENT, V129, P2619; Keller MS, 2004, AM J PHYSIOL-GASTR L, V287, pG104, DOI 10.1152/ajpgi.00484.2003; Kim JS, 2004, CANCER RES, V64, P1932, DOI 10.1158/0008-5472.CAN-03-3862; Kim JS, 2002, CANCER RES, V62, P2744; Kobayashi M, 1999, P NATL ACAD SCI USA, V96, P4874, DOI 10.1073/pnas.96.9.4874; Kohli M, 2004, NUCLEIC ACIDS RES, V32, DOI 10.1093/nar/gnh009; LAUREN P, 1965, ACTA PATHOL MIC SC, V64, P31, DOI 10.1111/apm.1965.64.1.31; Leung WK, 2002, J PATHOL, V197, P582, DOI 10.1002/path.1147; Mahatan CS, 1999, NUCLEIC ACIDS RES, V27, P4562, DOI 10.1093/nar/27.23.4562; Mallo GV, 1998, J BIOL CHEM, V273, P14030, DOI 10.1074/jbc.273.22.14030; McKenna BJ, 2002, J CLIN GASTROENTEROL, V34, P111, DOI 10.1097/00004836-200202000-00002; Mesquita P, 2003, J BIOL CHEM, V278, P51549, DOI 10.1074/jbc.M309019200; Mizoshita T, 2004, PATHOL INT, V54, P392, DOI 10.1111/j.1440-1827.2004.01647.x; Mizoshita T, 2004, J CANCER RES CLIN, V130, P29, DOI 10.1007/s00432-003-0503-1; Mizoshita T, 2003, J CANCER RES CLIN, V129, P727, DOI 10.1007/s00432-003-0499-6; MOTOYAMA T, 1986, ACTA PATHOL JAPON, V36, P65; Mutoh H, 2004, CANCER RES, V64, P7740, DOI 10.1158/0008-5472.CAN-04-1617; Mutoh H, 2002, BIOCHEM BIOPH RES CO, V294, P470, DOI 10.1016/S0006-291X(02)00480-1; Nakajima T, 2002, DIGEST DIS SCI, V47, P2729, DOI 10.1023/A:1021005221934; Niwa T, 2005, J HISTOCHEM CYTOCHEM, V53, P75, DOI 10.1369/jhc.4A6443.2005; OSBORN M, 1988, VIRCHOWS ARCH A, V413, P303, DOI 10.1007/BF00783022; Peek RM, 2002, NAT REV CANCER, V2, P28, DOI 10.1038/nrc703; Pfaffl MW, 2001, NUCLEIC ACIDS RES, V29, DOI 10.1093/nar/29.9.e45; Pinto D, 1999, J BIOL CHEM, V274, P6476, DOI 10.1074/jbc.274.10.6476; Piso P, 2003, EUR SURG RES, V35, P470, DOI 10.1159/000073385; Rawat VPS, 2004, P NATL ACAD SCI USA, V101, P817, DOI 10.1073/pnas.0305555101; Sakate Y, 2004, J SURG RES, V122, P89, DOI 10.1016/j.jss.2004.06.011; Satoh K, 2002, HELICOBACTER, V7, P192, DOI 10.1046/j.1523-5378.2002.00080.x; SEDIVY JM, 1999, SCIENCE, V283, P9, DOI DOI 10.1126/SCIENCE.283.5398.9A); Seno H, 2002, INT J ONCOL, V21, P769; Shields JM, 1996, J BIOL CHEM, V271, P20009, DOI 10.1074/jbc.271.33.20009; SHIRASAWA S, 1993, SCIENCE, V260, P85, DOI 10.1126/science.8465203; Sikorski R, 1997, SCIENCE, V277, P1848, DOI 10.1126/science.277.5333.1848; Silberg DG, 2002, GASTROENTEROLOGY, V122, P689, DOI 10.1053/gast.2002.31902; Sipponen P, 2000, GASTROENTEROL CLIN N, V29, P579, DOI 10.1016/S0889-8553(05)70131-X; Sonoda H, 2004, J SURG ONCOL, V88, P63, DOI 10.1002/jso.20143; Suh E, 1996, MOL CELL BIOL, V16, P619; SUH E, 1994, MOL CELL BIOL, V14, P7340, DOI 10.1128/MCB.14.11.7340; Taylor JK, 1997, DNA CELL BIOL, V16, P1419, DOI 10.1089/dna.1997.16.1419; Tsukamoto T, 2004, J CANCER RES CLIN, V130, P135, DOI 10.1007/s00432-003-0519-6; Tsukashita S, 2001, INT J CANCER, V94, P166, DOI 10.1002/ijc.1460; Ullman-Cullere MH, 1999, LAB ANIM SCI, V49, P319; Velcich A, 2002, SCIENCE, V295, P1726, DOI 10.1126/science.1069094; WALDMAN T, 1995, CANCER RES, V55, P5187; WALDMAN TA, 2003, METH MOL B, V241, P163; Yamamoto H, 2003, BIOCHEM BIOPH RES CO, V300, P813, DOI 10.1016/S0006-291X(02)02935-2; Yang Q, 2001, SCIENCE, V294, P2155, DOI 10.1126/science.1065718; Yoon HS, 2003, J BIOL CHEM, V278, P2101, DOI 10.1074/jbc.M211027200; Yuasa Y, 2005, CARCINOGENESIS, V26, P193, DOI 10.1093/carcin/bgh304; Yuasa Y, 2003, NAT REV CANCER, V3, P592, DOI 10.1038/nrc1141; Zhang WQ, 2000, J BIOL CHEM, V275, P18391, DOI 10.1074/jbc.C000062200; Zheng Leizhen, 2004, Gastric Cancer, V7, P61	95	11	12	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR	2006	25	14					2048	2059		10.1038/sj.onc.1209243	http://dx.doi.org/10.1038/sj.onc.1209243			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	026RL	16331267				2022-12-25	WOS:000236359700008
J	Ong, CT; Cheng, HT; Chang, LW; Ohtsuka, T; Kageyama, R; Stormo, GD; Kopan, R				Ong, CT; Cheng, HT; Chang, LW; Ohtsuka, T; Kageyama, R; Stormo, GD; Kopan, R			Target selectivity of vertebrate notch proteins - Collaboration between discrete domains and CSL-binding site architecture determines activation probability	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SPLIT COMPLEX GENES; INTRACELLULAR DOMAIN; MAMMALIAN NOTCH; TRANSCRIPTIONAL ACTIVATION; PHYSICAL INTERACTION; SIGNALING PATHWAY; DROSOPHILA NOTCH; ANKYRIN REPEATS; HES PROMOTERS; YIN YANG-1	All four mammalian Notch proteins interact with a single DNA-binding protein (RBP-j kappa), yet they are not equivalent in activating target genes. Parallel assays of three Notch-responsive promoters in several cell lines revealed that relative activation strength is dependent on protein module and promoter context more than the cellular context. Each Notch protein reads binding site orientation and distribution on the promoter differently; Notch1 performs extremely well on paired sites, and Notch3 prefers single sites in conjunction with a proximal zinc finger transcription factor. Although head-head sites can elicit a Notch response on their own, use of CBS (CSL binding site) in tail-tail orientation is context-dependent. Bias for specific DNA elements is achieved by interplay between the N-terminal RAM (RBP-j kappa-associated molecule/ankyrin region), which interprets CBS proximity and orientation, and the C-terminal transactivation domain that interacts specifically with the transcription machinery or nearby factors. To confirm the prediction that modular design underscores the evolution of functional divergence between Notch proteins, we generated a synthetic Notch protein (Notch1 ankyrin with Notch3 transactivation domain) that displayed superior signaling strength on the hes5 promoter. Consistent with the prediction that "preferred" targets (Hes1) should respond faster and at lower Notch concentration than other targets, we showed that Hes5-GFP was extinguished fast and recovered slowly, whereas Hes1-GFP was inhibited late and recovered quickly after a pulse of DAPT in metanephroi cultures.	Washington Univ, Sch Med, Dept Mol Biol & Pharmacol, St Louis, MO 63110 USA; Washington Univ, Sch Med, Dept Med, Div Dermatol, St Louis, MO 63110 USA; Washington Univ, Sch Med, Dept Genet, St Louis, MO 63110 USA; Washington Univ, Sch Med, Dept Biomed Engn, St Louis, MO 63110 USA; Kyoto Univ, Inst Virus Res, Kyoto 6068507, Japan	Washington University (WUSTL); Washington University (WUSTL); Washington University (WUSTL); Washington University (WUSTL); Kyoto University	Kopan, R (corresponding author), Washington Univ, Sch Med, Dept Mol Biol & Pharmacol, St Louis, MO 63110 USA.	kopan@wustl.edu	Kopan, Raphael/AFG-3275-2022; Kopan, Raphael/AAF-1357-2022; Stormo, Gary D/C-5367-2013; CHENG, HUI-TENG/AAD-9899-2020	Stormo, Gary D/0000-0001-6896-1850; CHENG, HUI-TENG/0000-0003-1544-7473; Kopan, Raphael/0000-0002-0350-2730	NICHD NIH HHS [HD44056] Funding Source: Medline; NIGMS NIH HHS [GM55479-09] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD044056] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM055479] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Amsen D, 2004, CELL, V117, P515, DOI 10.1016/S0092-8674(04)00451-9; Apelqvist A, 1999, NATURE, V400, P877, DOI 10.1038/23716; AUSEBEL FM, 2000, CURRENT PROTOCOLS MO, V2; BAILEY AM, 1995, GENE DEV, V9, P2609, DOI 10.1101/gad.9.21.2609; Ball Douglas W, 2003, Cancer Treat Res, V115, P95; Beatus P, 2001, MECH DEVELOP, V104, P3, DOI 10.1016/S0925-4773(01)00373-2; Beatus P, 1999, DEVELOPMENT, V126, P3925; Bigas A, 1998, MOL CELL BIOL, V18, P2324, DOI 10.1128/MCB.18.4.2324; Bray S, 2005, DEV CELL, V8, P279, DOI 10.1016/j.devcel.2004.11.020; Cave JW, 2005, CURR BIOL, V15, P94, DOI 10.1016/j.cub.2004.12.070; Cheng HT, 2003, DEVELOPMENT, V130, P5031, DOI 10.1242/dev.00697; CONLON RA, 1995, DEVELOPMENT, V121, P1533; Domenga V, 2004, GENE DEV, V18, P2730, DOI 10.1101/gad.308904; DOU QP, 1991, P NATL ACAD SCI USA, V88, P1157, DOI 10.1073/pnas.88.4.1157; Duncan AW, 2005, NAT IMMUNOL, V6, P314, DOI 10.1038/ni1164; Fan X, 2004, CANCER RES, V64, P7787, DOI 10.1158/0008-5472.CAN-04-1446; Fryer CJ, 2004, MOL CELL, V16, P509, DOI 10.1016/j.molcel.2004.10.014; Fryer CJ, 2002, GENE DEV, V16, P1397, DOI 10.1101/gad.991602; Furriols M, 2001, CURR BIOL, V11, P60, DOI 10.1016/S0960-9822(00)00044-0; Furriols M, 2000, DEV BIOL, V227, P520, DOI 10.1006/dbio.2000.9923; Gridley T, 2003, HUM MOL GENET, V12, pR9, DOI 10.1093/hmg/ddg052; HSIEH JJD, 1995, SCIENCE, V268, P560, DOI 10.1126/science.7725102; Hsieh JJD, 1997, J VIROL, V71, P1938, DOI 10.1128/JVI.71.3.1938-1945.1997; Itoh F, 2004, EMBO J, V23, P541, DOI 10.1038/sj.emboj.7600065; JARRIAULT S, 1995, NATURE, V377, P355, DOI 10.1038/377355a0; JENNINGS B, 1995, DEVELOPMENT, V121, P3745; Kim J, 1996, NATURE, V382, P133, DOI 10.1038/382133a0; Kovall RA, 2004, EMBO J, V23, P3441, DOI 10.1038/sj.emboj.7600349; Krebs LT, 2003, GENESIS, V37, P139, DOI 10.1002/gene.10241; Krebs LT, 2000, GENE DEV, V14, P1343; Kuroda K, 2003, IMMUNITY, V18, P301, DOI 10.1016/S1074-7613(03)00029-3; Kurooka H, 1998, NUCLEIC ACIDS RES, V26, P5448, DOI 10.1093/nar/26.23.5448; Lahav G, 2004, NAT GENET, V36, P147, DOI 10.1038/ng1293; Le Gall M, 2004, J BIOL CHEM, V279, P29418, DOI 10.1074/jbc.M404589200; LECOURTOIS M, 1995, GENE DEV, V9, P2598, DOI 10.1101/gad.9.21.2598; Li L, 2004, BIOCHEM CELL BIOL, V82, P460, DOI 10.1139/O04-045; Liang YY, 2002, GENE DEV, V16, P1977, DOI 10.1101/gad.996502; Lin SE, 2002, J BIOL CHEM, V277, P50612, DOI 10.1074/jbc.M209529200; Lubman OY, 2005, PROTEIN SCI, V14, P1274, DOI 10.1110/ps.041184105; Lubman OY, 2004, MOL CELL, V13, P619, DOI 10.1016/S1097-2765(04)00120-0; Maekawa Y, 2003, IMMUNITY, V19, P549, DOI 10.1016/S1074-7613(03)00270-X; Maier MM, 2000, BIOCHEM BIOPH RES CO, V275, P652, DOI 10.1006/bbrc.2000.3354; Matys V, 2003, NUCLEIC ACIDS RES, V31, P374, DOI 10.1093/nar/gkg108; McCright B, 2001, DEVELOPMENT, V128, P491; Mizutani T, 2001, P NATL ACAD SCI USA, V98, P9026, DOI 10.1073/pnas.161269998; Mumm JS, 2000, MOL CELL, V5, P197, DOI 10.1016/S1097-2765(00)80416-5; Mumm JS, 2000, DEV BIOL, V228, P151, DOI 10.1006/dbio.2000.9960; Nam Y, 2003, J BIOL CHEM, V278, P21232, DOI 10.1074/jbc.M301567200; Nellesen DT, 1999, DEV BIOL, V213, P33, DOI 10.1006/dbio.1999.9324; Ohtsuka T, 2006, MOL CELL NEUROSCI, V31, P109, DOI 10.1016/j.mcn.2005.09.006; Olave I, 1998, GENE DEV, V12, P1621, DOI 10.1101/gad.12.11.1621; Parr C, 2004, INT J MOL MED, V14, P779; Pece S, 2004, J CELL BIOL, V167, P215, DOI 10.1083/jcb.200406140; Pirot P, 2004, BIOCHEM BIOPH RES CO, V322, P526, DOI 10.1016/j.bbrc.2004.07.157; Radtke F, 2003, NAT REV CANCER, V3, P756, DOI 10.1038/nrc1186; Rangarajan A, 2001, EMBO J, V20, P3427, DOI 10.1093/emboj/20.13.3427; RAO Z, 1995, CELL, V82, P131, DOI 10.1016/0092-8674(95)90059-4; Raya A, 2003, GENE DEV, V17, P1213, DOI 10.1101/gad.1084403; Ronchini C, 2001, MOL CELL BIOL, V21, P5925, DOI 10.1128/MCB.21.17.5925-5934.2001; Sandelin A, 2004, NUCLEIC ACIDS RES, V32, pD91, DOI 10.1093/nar/gkh012; Santiago FS, 2001, J BIOL CHEM, V276, P41143, DOI 10.1074/jbc.M104913200; Saxena MT, 2001, J BIOL CHEM, V276, P40268, DOI 10.1074/jbc.M107234200; SAXENA MT, 2001, THESIS WASHINGTON U; Schroeter EH, 1998, NATURE, V393, P382, DOI 10.1038/30756; Shimizu K, 2002, BIOCHEM BIOPH RES CO, V291, P775, DOI 10.1006/bbrc.2002.6528; Shimizu K, 2000, BIOCHEM BIOPH RES CO, V276, P385, DOI 10.1006/bbrc.2000.3469; SHRIVASTAVA A, 1994, NUCLEIC ACIDS RES, V22, P5151, DOI 10.1093/nar/22.24.5151; Solway J, 1998, AM J RESP CRIT CARE, V158, pS100, DOI 10.1164/ajrccm.158.supplement_2.13tac500; STORMO GD, 1982, NUCLEIC ACIDS RES, V10, P2997, DOI 10.1093/nar/10.9.2997; Strobl LJ, 1997, IMMUNOBIOLOGY, V198, P299, DOI 10.1016/S0171-2985(97)80050-2; Sweeney C, 2004, FASEB J, V18, P1421, DOI 10.1096/fj.04-1700fje; SWIATEK PJ, 1994, GENE DEV, V8, P707, DOI 10.1101/gad.8.6.707; Takizawa T, 2003, NUCLEIC ACIDS RES, V31, P5723, DOI 10.1093/nar/gkg778; Talora C, 2002, GENE DEV, V16, P2252, DOI 10.1101/gad.988902; Tamura K, 1995, CURR BIOL, V5, P1416, DOI 10.1016/S0960-9822(95)00279-X; Tani S, 2001, NUCLEIC ACIDS RES, V29, P1373, DOI 10.1093/nar/29.6.1373; Vardar D, 2003, BIOCHEMISTRY-US, V42, P7061, DOI 10.1021/bi034156y; VASSEUR-COGNET M, 1993, P NATL ACAD SCI USA, V90, P7312, DOI 10.1073/pnas.90.15.7312; Wu L, 2002, MOL CELL BIOL, V22, P7688, DOI 10.1128/MCB.22.21.7688-7700.2002; Yoon K, 2005, NAT NEUROSCI, V8, P709, DOI 10.1038/nn1475; Zavadil J, 2004, EMBO J, V23, P1155, DOI 10.1038/sj.emboj.7600069; Zweifel ME, 2003, PROTEIN SCI, V12, P2622, DOI 10.1110/ps.03279003	82	176	181	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 24	2006	281	8					5106	5119		10.1074/jbc.M506108200	http://dx.doi.org/10.1074/jbc.M506108200			14	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	013RF	16365048	hybrid			2022-12-25	WOS:000235426200065
J	Plummer, LJ; Hildebrandt, ER; Porter, SB; Rogers, VA; McCracken, J; Schmidt, WK				Plummer, LJ; Hildebrandt, ER; Porter, SB; Rogers, VA; McCracken, J; Schmidt, WK			Mutational analysis of the Ras converting enzyme reveals a requirement for glutamate and histidine residues	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ISOPRENYLATED PROTEIN ENDOPROTEASE; A-FACTOR PRECURSOR; SACCHAROMYCES-CEREVISIAE; TOPOLOGY PREDICTION; MEMBRANE-PROTEINS; MATING PHEROMONE; CAAX PROTEASES; YEAST; STE24P; RCE1	The Ras converting enzyme (RCE) promotes a proteolytic activity that is required for the maturation of Ras, the yeast a-factor mating pheromone, and certain other proteins whose precursors bear a C-terminal CAAX tetrapeptide motif. Despite the physiological importance of RCE, the enzymatic mechanism of this protease remains undefined. In this study, we have evaluated the substrate specificity of RCE orthologs from yeast (Rce1p), worm, plant, and human and have determined the importance of conserved residues toward enzymatic activity. Our findings indicate that RCE orthologs have conserved substrate specificity, cleaving CVIA, CTLM, and certain other CAAX motifs, but not the CASQ motif, when these motifs are placed in the context of the yeast a-factor precursor. Our mutational studies of residues conserved between the orthologs indicate that an alanine substitution at His(194) completely inactivates yeast Rce1p enzymatic activity, whereas a substitution at Glu(156) or His(248) results in marginal activity. We have also determined that residues Glu(157), Tyr(160), Phe(190), and Asn(252) impact the substrate selectivity of Rce1p. Computational methods predict that residues influencing Rce1p function are all near or within hydrophobic segments. Combined, our data indicate that yeast Rce1p function requires residues that are invariably conserved among an extended family of prokaryotic and eukaryotic enzymes and that these residues are likely to lie within or immediately adjacent to the transmembrane segments of this membrane-localized enzyme.	Univ Georgia, Dept Biochem & Mol Biol, Athens, GA 30602 USA	University System of Georgia; University of Georgia	Schmidt, WK (corresponding author), Univ Georgia, Dept Biochem & Mol Biol, 120 Green St, Athens, GA 30602 USA.	wschmidt@bmb.uga.edu		McCracken, D. Jay/0000-0001-6305-707X	NIGMS NIH HHS [R01 GM067092-01A2, R01 GM067092] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM067092] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Baum Charles, 2003, Curr Oncol Rep, V5, P99, DOI 10.1007/s11912-003-0096-5; Bergo MO, 2004, J BIOL CHEM, V279, P4729, DOI 10.1074/jbc.M310081200; Bergo MO, 2002, MOL CELL BIOL, V22, P171, DOI 10.1128/MCB.22.1.171-181.2002; Bergo MO, 2002, P NATL ACAD SCI USA, V99, P13049, DOI 10.1073/pnas.192460799; Boyartchuk VL, 1997, SCIENCE, V275, P1796, DOI 10.1126/science.275.5307.1796; Brachmann CB, 1998, YEAST, V14, P115; Bzymek KP, 2004, J BIOL CHEM, V279, P31018, DOI 10.1074/jbc.M404035200; Cadinanos J, 2003, J BIOL CHEM, V278, P42091, DOI 10.1074/jbc.M306700200; Cadinanos J, 2003, BIOCHEM J, V370, P1047, DOI 10.1042/BJ20021514; Chen YL, 1996, BIOCHEMISTRY-US, V35, P3227, DOI 10.1021/bi952529s; CLAROS MG, 1994, COMPUT APPL BIOSCI, V10, P685; Corrigan DP, 2005, BIOCHEM J, V387, P129, DOI 10.1042/BJ20041359; Dolence JM, 2000, BIOCHEMISTRY-US, V39, P4096, DOI 10.1021/bi9923611; ELBLE R, 1992, BIOTECHNIQUES, V13, P18; Freije JMP, 1999, GENOMICS, V58, P270, DOI 10.1006/geno.1999.5834; FujimuraKamada K, 1997, J CELL BIOL, V136, P271, DOI 10.1083/jcb.136.2.271; Fujinaga M, 2004, P NATL ACAD SCI USA, V101, P3364, DOI 10.1073/pnas.0400246101; GIBBS JB, 1991, CELL, V65, P1, DOI 10.1016/0092-8674(91)90352-Y; HOFMANN K, 1993, BIOL CHEM HOPPESEYLE, V374, P166, DOI DOI 10.1515/BCHM3.1993.374.1-6.143; Hollander I, 2000, ANAL BIOCHEM, V286, P129, DOI 10.1006/abio.2000.4795; Kim E, 1999, J BIOL CHEM, V274, P8383, DOI 10.1074/jbc.274.13.8383; Kim H, 2003, J BIOL CHEM, V278, P10208, DOI 10.1074/jbc.M300163200; Krogh A, 2001, J MOL BIOL, V305, P567, DOI 10.1006/jmbi.2000.4315; LEMOUAL H, 1993, FEBS LETT, V324, P196, DOI 10.1016/0014-5793(93)81392-D; MA YT, 1993, BIOCHEMISTRY-US, V32, P2386, DOI 10.1021/bi00060a033; MARCUS S, 1991, MOL CELL BIOL, V11, P3603, DOI 10.1128/MCB.11.7.3603; Maske CP, 2003, J CELL BIOL, V162, P1223, DOI 10.1083/jcb.200303113; MICHAELIS S, 1988, MOL CELL BIOL, V8, P1309, DOI 10.1128/MCB.8.3.1309; Nijbroek GL, 1998, METHOD ENZYMOL, V292, P193; Oldenburg KR, 1997, NUCLEIC ACIDS RES, V25, P451, DOI 10.1093/nar/25.2.451; Otto JC, 1999, J BIOL CHEM, V274, P8379, DOI 10.1074/jbc.274.13.8379; Pei JM, 2001, TRENDS BIOCHEM SCI, V26, P275, DOI 10.1016/S0968-0004(01)01813-8; Pendas AM, 2002, NAT GENET, V31, P94, DOI 10.1038/ng871; POWERS S, 1986, CELL, V47, P413, DOI 10.1016/0092-8674(86)90598-2; Reid TS, 2004, J MOL BIOL, V343, P417, DOI 10.1016/j.jmb.2004.08.056; Rost B, 1996, PROTEIN SCI, V5, P1704, DOI 10.1002/pro.5560050824; Schmidt WK, 1998, P NATL ACAD SCI USA, V95, P11175, DOI 10.1073/pnas.95.19.11175; Schmidt WK, 2000, J BIOL CHEM, V275, P6227, DOI 10.1074/jbc.275.9.6227; SIKORSKI RS, 1989, GENETICS, V122, P19; Tam A, 2001, J BIOL CHEM, V276, P46798, DOI 10.1074/jbc.M106150200; Tam A, 1998, J CELL BIOL, V142, P635, DOI 10.1083/jcb.142.3.635; Trueblood CE, 2000, MOL CELL BIOL, V20, P4381, DOI 10.1128/MCB.20.12.4381-4392.2000; Tusnady GE, 1998, J MOL BIOL, V283, P489, DOI 10.1006/jmbi.1998.2107; Vazeux G, 1996, J BIOL CHEM, V271, P9069, DOI 10.1074/jbc.271.15.9069; VONHEIJNE G, 1992, J MOL BIOL, V225, P487, DOI 10.1016/0022-2836(92)90934-C; Weihofen A, 2003, TRENDS CELL BIOL, V13, P71, DOI 10.1016/S0962-8924(02)00041-7; YOUNG SG, 2001, ENZYMES, P155, DOI DOI 10.1016/01874-6047(0)180020-2; Zhang YM, 2001, MOL BIOL CELL, V12, P1303, DOI 10.1091/mbc.12.5.1303; Zhu Kuichun, 2003, Curr Opin Investig Drugs, V4, P1428	49	38	39	1	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 24	2006	281	8					4596	4605		10.1074/jbc.M506284200	http://dx.doi.org/10.1074/jbc.M506284200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	013RF	16361710	hybrid, Green Accepted			2022-12-25	WOS:000235426200007
J	Smal, C; Vertommen, D; Bertrand, L; Ntamashimikiro, S; Rider, MH; Van Den Neste, E; Bontemps, F				Smal, C; Vertommen, D; Bertrand, L; Ntamashimikiro, S; Rider, MH; Van Den Neste, E; Bontemps, F			Identification of in vivo phosphorylation sites on human deoxycytidine kinase - Role of Ser-74 in the control of enzyme activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHRONIC LYMPHOCYTIC-LEUKEMIA; ACUTE MYELOID-LEUKEMIA; NUCLEOSIDE ANALOGS; PURINE ANALOGS; CELL LEUKEMIA; DNA-SYNTHESIS; ACTIVATION; RESISTANCE; PROTEIN; 2-CHLORO-2'-DEOXYADENOSINE	Deoxycytidine kinase (dCK) catalyzes the rate-limiting step of the deoxyribonucleoside salvage pathway in mammalian cells and plays a key role in the activation of numerous nucleoside analogues used in anti-cancer and antiviral chemotherapy. Although compelling evidence indicated that dCK activity might be regulated by phosphorylation/ dephosphorylation, direct demonstration was lacking. Here we showed that dCK overexpressed in HEK 293T cells was labeled after incubating the cells with [P-32] orthophosphate. Sorbitol, which was reported to decrease dCK activity, also decreased the labeling of dCK. These results indicated that dCK may exist as a phosphoprotein in vivo and that its activity can be correlated with its phosphorylation level. After purification of P-32-labeled dCK, digestion by trypsin, and analysis of the radioactive peptides by tandem mass spectrometry, the following four in vivo phosphorylation sites were identified: Thr-3, Ser-11, Ser-15, and Ser-74, the latter being the major phosphorylation site. Site-directed mutagenesis and use of an anti-phospho-Ser-74 antibody demonstrated that Ser-74 phosphorylation was crucial for dCK activity in HEK 293T cells, whereas phosphorylation of other identified sites did not seem essential. Phosphorylation of Ser-74 was also detected on endogenous dCK in leukemic cells, in which the Ser-74 phosphorylation state was increased by agents that enhanced dCK activity. Our study provided direct evidence that dCK activity can be controlled by phosphorylation in intact cells and highlights the importance of Ser-74 for dCK activity.	Catholic Univ Louvain, ICP 7539, Christian de Duve Inst Cellular Pathol, Physiol Chem Lab, B-1200 Brussels, Belgium; Catholic Univ Louvain, Christian de Duve Inst Cellular Pathol, Hormone & Metab Res Unit, B-1200 Brussels, Belgium; Catholic Univ Louvain, Clin Univ St Luc, Div Cardiol, B-1200 Brussels, Belgium; Catholic Univ Louvain, Clin Univ St Luc, Dept Hematol, B-1200 Brussels, Belgium	Universite Catholique Louvain; Universite Catholique Louvain; Universite Catholique Louvain; Cliniques Universitaires Saint-Luc; Universite Catholique Louvain; Cliniques Universitaires Saint-Luc	Bontemps, F (corresponding author), Catholic Univ Louvain, ICP 7539, Christian de Duve Inst Cellular Pathol, Physiol Chem Lab, 75 Av Hippocrate, B-1200 Brussels, Belgium.	bontemps@bchm.ucl.ac.be		Bertrand, Luc/0000-0003-0655-7099; Vertommen, Didier/0000-0001-7648-8282				ARNER ESJ, 1995, PHARMACOL THERAPEUT, V67, P155, DOI 10.1016/0163-7258(95)00015-9; Arner ESJ, 1996, LEUKEMIA LYMPHOMA, V21, P225, DOI 10.3109/10428199209067604; Blackstock AW, 2001, CLIN CANCER RES, V7, P3263; Blom N, 1999, J MOL BIOL, V294, P1351, DOI 10.1006/jmbi.1999.3310; BOHMAN C, 1988, BIOCHEMISTRY-US, V27, P4258, DOI 10.1021/bi00412a009; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Cardoen S, 2001, CLIN CANCER RES, V7, P3559; CARSON DA, 1980, P NATL ACAD SCI-BIOL, V77, P6865, DOI 10.1073/pnas.77.11.6865; CHOTTINER EG, 1991, P NATL ACAD SCI USA, V88, P1531, DOI 10.1073/pnas.88.4.1531; Csapo Z, 2003, BIOCHEM PHARMACOL, V65, P2031, DOI 10.1016/S0006-2952(03)00182-5; Csapo Z, 2001, BIOCHEM PHARMACOL, V61, P191, DOI 10.1016/S0006-2952(00)00534-7; De Clercq E, 2004, J CLIN VIROL, V30, P115, DOI 10.1016/j.jcv.2004.02.009; Galmarini CM, 2002, LANCET ONCOL, V3, P415, DOI 10.1016/S1470-2045(02)00788-X; Galmarini CM, 2001, LEUKEMIA, V15, P875, DOI 10.1038/sj.leu.2402114; Goodman GR, 2003, CURR OPIN HEMATOL, V10, P258, DOI 10.1097/00062752-200307000-00002; Hatzis P, 1998, J BIOL CHEM, V273, P30239, DOI 10.1074/jbc.273.46.30239; JOHANSSON M, 1995, BIOCHEM PHARMACOL, V50, P163, DOI 10.1016/0006-2952(95)00129-N; KAWASAKI H, 1993, BLOOD, V81, P597; Keszler G, 2004, BIOCHEM PHARMACOL, V67, P947, DOI 10.1016/j.bcp.2003.10.019; Koenig M, 2004, BIOINFORMATICS, V20, P3620, DOI 10.1093/bioinformatics/bth455; Mansson E, 2003, BIOCHEM PHARMACOL, V65, P237, DOI 10.1016/S0006-2952(02)01484-3; MARTENSEN TM, 1984, METHOD ENZYMOL, V107, P3; ORR RM, 1995, CLIN CANCER RES, V1, P391; Pettitt AR, 2003, BRIT J HAEMATOL, V121, P692, DOI 10.1046/j.1365-2141.2003.04336.x; PLUNKETT W, 1997, NUCLEOSIDE ANALOGS C, P1; Robak T, 2005, TRANSFUS APHER SCI, V32, P33, DOI 10.1016/j.transci.2004.10.004; Sabini E, 2003, NAT STRUCT BIOL, V10, P513, DOI 10.1038/nsb942; Sasvari-Szekely M, 1998, BIOCHEM PHARMACOL, V56, P1175, DOI 10.1016/S0006-2952(98)00108-7; Smal C, 2004, BIOCHEM PHARMACOL, V68, P95, DOI 10.1016/j.bcp.2004.02.031; Spasokoukotskaja T, 2000, ADV EXP MED BIOL, V486, P281; Spasokoukotskaja T, 1999, EUR J CANCER, V35, P1862, DOI 10.1016/S0959-8049(99)00223-3; STEGMANN APA, 1995, ANN HEMATOL, V71, P41, DOI 10.1007/s002770050081; Van den Neste E, 2003, BIOCHEM PHARMACOL, V65, P573, DOI 10.1016/S0006-2952(02)01559-9; VERHOEF V, 1981, CANCER RES, V41, P4478; Veuger MJT, 2000, BLOOD, V96, P1517, DOI 10.1182/blood.V96.4.1517.h8001517_1517_1524; WANG LM, 1994, BBA-MOL CELL RES, V1224, P161, DOI 10.1016/0167-4889(94)90186-4; WESSEL D, 1984, ANAL BIOCHEM, V138, P141, DOI 10.1016/0003-2697(84)90782-6; Woods A, 2003, J BIOL CHEM, V278, P28434, DOI 10.1074/jbc.M303946200	38	48	52	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 24	2006	281	8					4887	4893		10.1074/jbc.M512129200	http://dx.doi.org/10.1074/jbc.M512129200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	013RF	16361699	hybrid			2022-12-25	WOS:000235426200039
J	Parnis, A; Rawet, M; Regev, L; Barkan, B; Rotman, M; Gaitner, M; Cassel, D				Parnis, A; Rawet, M; Regev, L; Barkan, B; Rotman, M; Gaitner, M; Cassel, D			Golgi localization determinants in ArfGAP1 and in new tissue-specific ArfGAP1 Isoforms	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GTPASE-ACTIVATING-PROTEIN; ADP-RIBOSYLATION FACTOR; ENDOPLASMIC-RETICULUM; NONCATALYTIC DOMAIN; MEMBRANE CURVATURE; SECRETORY FUNCTION; DEPENDENT BINDING; VESICLE FORMATION; KDEL RECEPTOR; COPI VESICLES	The Arf1-directed GTPase-activating protein ArfGAP1 is a Golgi-localized protein that controls the dynamics of the COPI coat of carriers that mediate transport in the endoplasmic reticulum-Golgi shuttle. Previously the interaction of ArfGAP1 with the Golgi was allocated to a portion of the non-catalytic, carboxyl part of the protein, but the mechanism of this interaction has not been established. In this study we identify a short stretch in the non-catalytic part of ArfGAP1 (residues 204-214) in which several hydrophobic residues contribute to Golgi localization. Even single alanine replacement of two of these residues (Leu-207 and Trp-211) strongly diminished Golgi localization. Mutations in the hydrophobic residues also diminished the in vitro activity of ArfGAP1 on Arf1 bound to Golgi membranes. The stretch containing the hydrophobic residues was recently shown to mediate the binding of ArfGAP1 to loosely packed lipids of highly curved liposomes (Bigay, J., Casella, J. F., Drin, G., Mesmin, B., and Antonny, B. ( 2005) EMBO J. 24, 2244-2253). Whereas short fragments containing the hydrophobic stretch were not Golgi-localized, a proximal 10-residue in-frame insertion that is present in new ArfGAP1 isoforms that we identified in brain and heart tissues could confer Golgi localization on these fragments. This localization was abrogated by alanine replacement of residues Phe-240 or Trp-241 of the insertion sequence but not by their replacement with leucines. Our findings indicate that ArfGAP1 interacts with the Golgi through multiple hydrophobic motifs and that alternative modes of interaction may exist in tissue-specific ArfGAP1 isoforms.	Technion Israel Inst Technol, Dept Biol, IL-32000 Haifa, Israel	Technion Israel Institute of Technology	Cassel, D (corresponding author), Technion Israel Inst Technol, Dept Biol, IL-32000 Haifa, Israel.	danc@tx.technion.ac.il						Antonny B, 1997, J BIOL CHEM, V272, P30848, DOI 10.1074/jbc.272.49.30848; Aoe T, 1999, J BIOL CHEM, V274, P20545, DOI 10.1074/jbc.274.29.20545; Aoe T, 1997, EMBO J, V16, P7305, DOI 10.1093/emboj/16.24.7305; Bankaitis VA, 2002, SCIENCE, V295, P290, DOI 10.1126/science.1068446; BARLOWE C, 1994, CELL, V77, P895, DOI 10.1016/0092-8674(94)90138-4; Bigay J, 2005, EMBO J, V24, P2244, DOI 10.1038/sj.emboj.7600714; Bigay J, 2003, NATURE, V426, P563, DOI 10.1038/nature02108; Bonifacino JS, 2004, CELL, V116, P153, DOI 10.1016/S0092-8674(03)01079-1; CUKIERMAN E, 1995, SCIENCE, V270, P1999, DOI 10.1126/science.270.5244.1999; FRANCO M, 1993, J BIOL CHEM, V268, P24531; Goldberg J, 1999, CELL, V96, P893, DOI 10.1016/S0092-8674(00)80598-X; Hirst J, 2003, MOL BIOL CELL, V14, P625, DOI 10.1091/mbc.E02-09-0552; Holthuis JCM, 2003, DEV CELL, V5, P821, DOI 10.1016/S1534-5807(03)00366-6; Huber I, 1998, J BIOL CHEM, V273, P24786, DOI 10.1074/jbc.273.38.24786; KLAUSNER RD, 1992, J CELL BIOL, V116, P1071, DOI 10.1083/jcb.116.5.1071; Lanoix J, 1999, EMBO J, V18, P4935, DOI 10.1093/emboj/18.18.4935; Lee MCS, 2004, ANNU REV CELL DEV BI, V20, P87, DOI 10.1146/annurev.cellbio.20.010403.105307; Lee SY, 2005, J CELL BIOL, V168, P281, DOI 10.1083/jcb.200404008; Lippincott-Schwartz J, 2003, NATURE, V426, P507, DOI 10.1038/426507a; Litvak V, 2005, NAT CELL BIOL, V7, P225, DOI 10.1038/ncb1221; Liu W, 2005, J CELL BIOL, V168, P1053, DOI 10.1083/jcb.200410142; Liu XQ, 2001, FEBS LETT, V490, P79, DOI 10.1016/S0014-5793(01)02134-2; MAKLER V, 1995, J BIOL CHEM, V270, P5232, DOI 10.1074/jbc.270.10.5232; MALHOTRA V, 1989, CELL, V58, P329, DOI 10.1016/0092-8674(89)90847-7; Matsuoka K, 1998, CELL, V93, P263, DOI 10.1016/S0092-8674(00)81577-9; McMahon HT, 2004, CURR OPIN CELL BIOL, V16, P379, DOI 10.1016/j.ceb.2004.06.009; PAGANO RE, 1988, TRENDS BIOCHEM SCI, V13, P202, DOI 10.1016/0968-0004(88)90082-5; Paris S, 1997, J BIOL CHEM, V272, P22221, DOI 10.1074/jbc.272.35.22221; Poon PP, 1999, EMBO J, V18, P555, DOI 10.1093/emboj/18.3.555; Poon PP, 1996, P NATL ACAD SCI USA, V93, P10074, DOI 10.1073/pnas.93.19.10074; Randazzo PA, 2004, CELL SIGNAL, V16, P401, DOI 10.1016/j.cellsig.2003.09.012; Storrie B, 1998, J CELL BIOL, V143, P1505, DOI 10.1083/jcb.143.6.1505; Szafer E, 2000, J BIOL CHEM, V275, P23615, DOI 10.1074/jbc.M003171200; Szafer E, 2001, J BIOL CHEM, V276, P47834, DOI 10.1074/jbc.M106000200; Watson PJ, 2004, TRAFFIC, V5, P79, DOI 10.1111/j.1600-0854.2004.00158.x; Wong TA, 2005, P NATL ACAD SCI USA, V102, P12777, DOI 10.1073/pnas.0506156102; Yanagisawa LL, 2002, MOL BIOL CELL, V13, P2193, DOI 10.1091/mbc.01-11-0563; Yang JS, 2002, J CELL BIOL, V159, P69, DOI 10.1083/jcb.200206015; YOSHIHISA T, 1993, SCIENCE, V259, P1466, DOI 10.1126/science.8451644; Yu S, 2002, MOL BIOL CELL, V13, P2559, DOI 10.1091/mbc.E02-04-0189; Zhang CG, 2000, GENOMICS, V63, P400, DOI 10.1006/geno.1999.6095; Zhao LY, 1999, J BIOL CHEM, V274, P14198, DOI 10.1074/jbc.274.20.14198	42	18	18	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 17	2006	281	7					3785	3792		10.1074/jbc.M508959200	http://dx.doi.org/10.1074/jbc.M508959200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	011NN	16316994	hybrid			2022-12-25	WOS:000235275300006
J	Rayala, SK; den Hollander, P; Balasenthil, S; Molli, PR; Bean, AJ; Vadlamudi, RK; Wang, RA; Kumar, R				Rayala, SK; den Hollander, P; Balasenthil, S; Molli, PR; Bean, AJ; Vadlamudi, RK; Wang, RA; Kumar, R			Hepatocyte growth factor-regulated tyrosine kinase substrate (HRS) interacts with PELP1 and activates MAPK	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESTROGEN-RECEPTOR; NONGENOMIC ACTIVITY; PROTEIN-KINASE; PHOSPHORYLATION; DOMAIN; MONOUBIQUITINATION; INVOLVEMENT; ENDOCYTOSIS	PELP1 (proline-, glutamic acid-, and leucine- rich protein-1) (also known as the modulator of nongenomic activity of estrogen receptor) plays a role in genomic functions of the estrogen receptor via histone interactions and in nongenomic functions via its influence on the MAPK-Src pathway. However, recent studies have shown that differential compartmentalization of PELP1 could play a crucial role in modulating the status of nongenomic signaling by using molecular mechanisms that remain poorly understood. Hepatocyte growth factor-regulated tyrosine kinase substrate (HRS) is an early endosomal protein that plays a role in regulating the trafficking of growth factor-receptor complexes through early endosomes. By using a yeast two-hybrid screen, we identified HRS as a novel PELP1-binding protein providing evidence of a physiologic interaction between HRS and PELP1. The noted HRS-PELP1 interaction was accompanied by inhibition of the basal coactivator function of PELP1 upon estrogen receptor transactivation. HRS was found to sequester PELP1 in the cytoplasm, leading to the activation of MAPK in a manner that is dependent on the epidermal growth factor receptor but independent of the estrogen receptor, Shc, and Src. In addition, stimulation of MAPK and the subsequent activation of its downstream effector pathway, Elk-1, by HRS or PELP1 were found to depend on the presence of endogenous PELP1 or HRS. Furthermore, HRS was overexpressed and correlated well with the cytoplasmic PELP1, increased MAPK, and EGFR status in breast tumors. These findings highlight a novel role of HRS in up-regulating MAPK, presumably involving interaction with PELP1.	Univ Texas, MD Anderson Canc Ctr, Dept Mol & Cellular Oncol, Houston, TX 77030 USA; Univ Texas, Sch Med, Dept Neurobiol & Anat, Houston, TX 77030 USA; Louisiana State Univ, Hlth Sci Ctr, Stanley S Scott Canc Ctr, Dept Genet, New Orleans, LA 70112 USA	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; Louisiana State University System; Louisiana State University Health Sciences Center New Orleans	Kumar, R (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Mol & Cellular Oncol, 1515 Holcombe Blvd, Houston, TX 77030 USA.	rkumar@mdanderson.org	Messier, Claude/A-2322-2008; Wang, Brian/HGA-9535-2022	Messier, Claude/0000-0002-4791-1763; Wang, Rui-An/0000-0003-2320-1211; Rayala, Suresh/0000-0003-4394-4450	NATIONAL CANCER INSTITUTE [R01CA098823, R01CA090970] Funding Source: NIH RePORTER; NCI NIH HHS [CA90970, CA98823] Funding Source: Medline; NIMH NIH HHS [MH05892] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		Asao H, 1997, J BIOL CHEM, V272, P32785, DOI 10.1074/jbc.272.52.32785; CHEN RH, 1993, P NATL ACAD SCI USA, V90, P10952, DOI 10.1073/pnas.90.23.10952; Chin LS, 2001, J BIOL CHEM, V276, P7069, DOI 10.1074/jbc.M004129200; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; DIKIC I, 1995, J BIOL CHEM, V270, P15125, DOI 10.1074/jbc.270.25.15125; Duan RQ, 2001, J BIOL CHEM, V276, P11590, DOI 10.1074/jbc.M005492200; Gaullier JM, 1998, NATURE, V394, P432, DOI 10.1038/28767; Haglund K, 2003, NAT CELL BIOL, V5, P461, DOI 10.1038/ncb983; Haugh Jason M, 2002, Mol Interv, V2, P292, DOI 10.1124/mi.2.5.292; Ishihara H, 1998, BIOCHEM BIOPH RES CO, V252, P139, DOI 10.1006/bbrc.1998.9621; Jekely G, 2003, EMBO REP, V4, P1163, DOI 10.1038/sj.embor.7400019; KOMADA M, 1995, MOL CELL BIOL, V15, P6213; Komada M, 1999, GENE DEV, V13, P1475, DOI 10.1101/gad.13.11.1475; Komada M, 2001, BIOCHEM BIOPH RES CO, V281, P1065, DOI 10.1006/bbrc.2001.4441; Komada M, 1997, J BIOL CHEM, V272, P20538, DOI 10.1074/jbc.272.33.20538; Kwong J, 2000, J CELL SCI, V113, P2273; Manavathi B, 2005, CANCER RES, V65, P5571, DOI 10.1158/0008-5472.CAN-04-4664; Miura S, 2000, MOL CELL BIOL, V20, P9346, DOI 10.1128/MCB.20.24.9346-9355.2000; Morino C, 2004, EXP CELL RES, V297, P380, DOI 10.1016/j.yexcr.2004.03.038; Nair SS, 2004, CANCER RES, V64, P6416, DOI 10.1158/0008-5472.CAN-04-1786; PELICCI G, 1995, ONCOGENE, V11, P899; Polo S, 2002, NATURE, V416, P451, DOI 10.1038/416451a; Raiborg C, 2001, EMBO J, V20, P5008, DOI 10.1093/emboj/20.17.5008; Sasaki Y, 2001, J BIOL CHEM, V276, P29943, DOI 10.1074/jbc.M104230200; Song RXD, 2002, MOL ENDOCRINOL, V16, P116, DOI 10.1210/me.16.1.116; Urbe S, 2000, MOL CELL BIOL, V20, P7685, DOI 10.1128/MCB.20.20.7685-7692.2000; Vadlamudi RK, 2005, CANCER RES, V65, P7724, DOI 10.1158/0008-5472.CAN-05-0614; Vadlamudi RK, 2005, HUM PATHOL, V36, P670, DOI 10.1016/j.humpath.2005.03.016; Vadlamudi RK, 2004, J CLIN ENDOCR METAB, V89, P6130, DOI 10.1210/jc.2004-0909; Vadlamudi RK, 2001, J BIOL CHEM, V276, P38272; Wang X, 2003, NATURE, V424, P456, DOI 10.1038/nature01818; Wong CW, 2002, P NATL ACAD SCI USA, V99, P14783, DOI 10.1073/pnas.192569699	32	32	36	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 17	2006	281	7					4395	4403		10.1074/jbc.M510368200	http://dx.doi.org/10.1074/jbc.M510368200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	011NN	16352611	hybrid			2022-12-25	WOS:000235275300075
J	Dimova, EY; Kietzmann, T				Dimova, EY; Kietzmann, T			Cell type-dependent regulation of the hypoxia-responsive plasminogen activator inhibitor-1 gene by upstream stimulatory factor-2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INDUCIBLE FACTOR-I; TRANSCRIPTION FACTOR USF; NONCANONICAL E-BOX; HELIX-LOOP-HELIX; RAT HEPATOCYTES; TATA BOX; PROMOTER; EXPRESSION; BINDING; ELEMENT	Transcriptional regulation of the plasminogen activator inhibitor type-1 (PAI-1) gene is an important issue since PAI-1 plays a crucial role in various pathological conditions. The transcription factor USF-2 was shown to be a negative regulator for rat PAI-1 expression, and therefore it was the aim of this study to evaluate the role of USF-2 for human PAI-1 expression. We found in human hepatoma cells (HepG2) that USF-2 induced human PAI-1 expression via two classical E-boxes and the hypoxia-responsive element (HRE) within the promoter. Gel-shift analyses showed that E-box 4 and E-box 5 bound USFs, and although the HRE contributed to the USF-dependent effects, it did not bind them. By contrast, USF-2 inhibited PAI-1 promoter activity in primary rat hepatocytes suggesting that PAI-1 expression depends on either the promoter context or USF activity which might be cell type-specific. Cotransfection of human or rat PAI-1 promoter luciferase constructs with expression vectors for wild-type USF-2 or USF-2 mutants in human HepG2 and rat H4IIE cells as well as in primary rat hepatocytes revealed that the effects of USF on PAI-1 expression depend on the cell type rather than the promoter context and that the USF-specific region domain of USF accounts for the observed cell type-specific effects.	Univ Kaiserslautern, Fac Chem, Dept Biochem, D-67663 Kaiserslautern, Germany	University of Kaiserslautern	Dimova, EY (corresponding author), Univ Kaiserslautern, Fac Chem, Dept Biochem, Erwin Schrodinger Str 54, D-67663 Kaiserslautern, Germany.	edimova@gwdg.de		Dimova, Elitsa/0000-0003-2745-8145; Kietzmann, Thomas/0000-0003-0242-8636				Allen RR, 2005, J CELL PHYSIOL, V203, P156, DOI 10.1002/jcp.20211; BUNGERT J, 1992, J MOL BIOL, V223, P885, DOI 10.1016/0022-2836(92)90250-N; Carter RS, 1997, MOL CELL BIOL, V17, P18, DOI 10.1128/MCB.17.1.18; Chen YH, 2001, J BIOL CHEM, V276, P47658, DOI 10.1074/jbc.M108678200; COGSWELL JP, 1995, MOL CELL BIOL, V15, P2782; COLLEN D, 1991, BLOOD, V78, P3114; Coulson JM, 2003, BIOCHEM J, V369, P549, DOI 10.1042/BJ20021176; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; Dimova EY, 2005, THROMB HAEMOSTASIS, V93, P1176, DOI 10.1160/TH04-11-0761; DU H, 1993, EMBO J, V12, P501, DOI 10.1002/j.1460-2075.1993.tb05682.x; Eisenman RN, 2001, GENE DEV, V15, P2023, DOI 10.1101/gad928101; Fink T, 2002, BLOOD, V99, P2077, DOI 10.1182/blood.V99.6.2077; Goueli BS, 2003, ONCOGENE, V22, P8042, DOI 10.1038/sj.onc.1206847; Harris VK, 2000, J BIOL CHEM, V275, P28539, DOI 10.1074/jbc.M001677200; Henrion AA, 1996, MAMM GENOME, V7, P803, DOI 10.1007/s003359900241; Immenschuh S, 1998, BIOCHEM J, V334, P141, DOI 10.1042/bj3340141; Jiang B, 2003, MOL CELL BIOL, V23, P6117, DOI 10.1128/MCB.23.17.6117-6128.2003; Kietzmann T, 1999, BLOOD, V94, P4177, DOI 10.1182/blood.V94.12.4177.424k14_4177_4185; Kietzmann T, 1997, BIOCHEM J, V321, P17, DOI 10.1042/bj3210017; Kohler HP, 2000, NEW ENGL J MED, V342, P1792, DOI 10.1056/NEJM200006153422406; Koshiji M, 2004, EMBO J, V23, P1949, DOI 10.1038/sj.emboj.7600196; KVIETIKOVA I, 1995, NUCLEIC ACIDS RES, V23, P4542, DOI 10.1093/nar/23.22.4542; LEFRANCOISMARTINEZ AM, 1995, J BIOL CHEM, V270, P2640, DOI 10.1074/jbc.270.6.2640; Levens D, 2002, P NATL ACAD SCI USA, V99, P5757, DOI 10.1073/pnas.102173199; LIJNEN HR, 1988, ENZYME, V40, P90, DOI 10.1159/000469150; LOSKUTOFF DJ, 1989, PROG HEMOST THROMB, V9, P87; Luo X, 1996, MOL CELL BIOL, V16, P1367; Qyang YB, 1999, MOL CELL BIOL, V19, P1508; REISMAN D, 1993, NUCLEIC ACIDS RES, V21, P345, DOI 10.1093/nar/21.2.345; ROY AL, 1991, NATURE, V354, P245, DOI 10.1038/354245a0; Samoylenko A, 2001, BLOOD, V97, P2657, DOI 10.1182/blood.V97.9.2657; SAWADOGO M, 1985, CELL, V43, P165, DOI 10.1016/0092-8674(85)90021-2; Scholtz B, 1996, J BIOL CHEM, V271, P32375, DOI 10.1074/jbc.271.50.32375; SEMENZA GL, 1992, MOL CELL BIOL, V12, P5447, DOI 10.1128/MCB.12.12.5447; Smih F, 2002, DIABETES, V51, P293, DOI 10.2337/diabetes.51.2.293; Takahashi Y, 1997, J BIOL CHEM, V272, P30025, DOI 10.1074/jbc.272.48.30025; Viollet B, 1996, J BIOL CHEM, V271, P1405, DOI 10.1074/jbc.271.3.1405; Virolle T, 2002, NUCLEIC ACIDS RES, V30, P1789, DOI 10.1093/nar/30.8.1789; WANG D, 1995, J BIOL CHEM, V270, P28716, DOI 10.1074/jbc.270.48.28716	39	34	34	1	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 3	2006	281	5					2999	3005		10.1074/jbc.M512078200	http://dx.doi.org/10.1074/jbc.M512078200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	006XT	16330554	hybrid			2022-12-25	WOS:000234931800070
J	Gopalan, SM; Wilczynska, KM; Konik, BS; Bryan, L; Kordula, T				Gopalan, SM; Wilczynska, KM; Konik, BS; Bryan, L; Kordula, T			Astrocyte-specific expression of the alpha(1)-antichymotrypsin and glial fibrillary acidic protein genes requires activator protein-1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTION FACTOR; CHROMATIN-STRUCTURE; ALZHEIMERS-DISEASE; TRANSGENIC MICE; KAPPA-B; INHIBITOR; 14Q32.1; CLUSTER; ALPHA-1-ANTICHYMOTRYPSIN; IDENTIFICATION	An amyloid-associated serine proteinase inhibitor ( serpin), alpha 1-antichymotrypsin (ACT), is encoded by a gene located within the distal serpin subcluster on human chromosome 14q32.1. The expression of these distal serpin genes is determined by tissue-specific chromatin structures that allow their ubiquitous expression in hepatocytes; however, their expression is limited to a single ACT gene in astrocytes. In astrocytes and glioma cells, six specific DNase I-hypersensitive sites (DHSs)were found located exclusively in the 5'- flanking region of the ACT gene. We identified two enhancers that mapped to the two DHSs at -13 kb and -11.5 kb which contain activator protein-1 (AP-1) binding sites, both of which are critical for basal astrocyte-specific expression of ACT reporters. In vivo, these elements are occupied by c-jun homodimers in unstimulated cells and c-jun/c-fos heterodimers in interleukin-1-treated cells. Moreover, functional c-jun is required for the expression of ACT in glioma cells because both transient and stable inducible overexpression of dominant-negative c-jun(TAM67) specifically abrogates basal and reduces cytokine-induced expression of ACT. Expression-associated methylation of lysine 4 of histone H3 was also lost in these cells, but the DHS distribution pattern and global histone acetylation were not changed upstream of the ACT locus. Interestingly, functional AP-1 is also indispensable for the expression of glial fibrillary acidic protein (GFAP), which is an astrocyte-specific marker. We propose that AP-1 is a key transcription factor that, in part, controls astrocyte-specific expression of genes including the ACT and GFAP genes.	Virginia Commonwealth Univ, Dept Biochem, Richmond, VA 23298 USA	Virginia Commonwealth University	Kordula, T (corresponding author), Virginia Commonwealth Univ, Dept Biochem, Med Coll Virginia Campus, Richmond, VA 23298 USA.	tkordula@vcu.edu	Paugh, Barbara/B-3625-2009					ABRAHAM CR, 1988, CELL, V52, P487, DOI 10.1016/0092-8674(88)90462-X; BAEUERLE PA, 1988, SCIENCE, V242, P540, DOI 10.1126/science.3140380; BAUMANN H, 1987, J IMMUNOL, V139, P4122; Baxter EW, 2005, NUCLEIC ACIDS RES, V33, P3313, DOI 10.1093/nar/gki645; BRENNER M, 1994, J NEUROSCI, V14, P1030, DOI 10.1523/JNEUROSCI.14-03-01030.1994; BROWN PH, 1993, ONCOGENE, V8, P877; DAS S, 1995, NEURON, V14, P447, DOI 10.1016/0896-6273(95)90300-3; DELEGEANE AM, 1987, MOL CELL BIOL, V7, P3994, DOI 10.1128/MCB.7.11.3994; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FRIED M, 1981, NUCLEIC ACIDS RES, V9, P6505, DOI 10.1093/nar/9.23.6505; Gopalan S, 2005, J NEUROCHEM, V94, P763, DOI 10.1111/j.1471-4159.2005.03204.x; GORMAN C, 1985, DNA CLONING PRACTICA, V2, P143; Kiss DL, 2005, J NEUROCHEM, V92, P730, DOI 10.1111/j.1471-4159.2004.02900.x; Kordula T, 1998, J BIOL CHEM, V273, P4112, DOI 10.1074/jbc.273.7.4112; Kordula T, 2000, J NEUROSCI, V20, P7510; Krohn K, 1999, J NEUROCHEM, V72, P1353, DOI 10.1046/j.1471-4159.1999.721353.x; Lee JS, 1996, MOL CELL BIOL, V16, P4312; Marsden MD, 2003, MOL CELL BIOL, V23, P3516, DOI 10.1128/MCB.23.10.3516-3526.2003; Namciu SJ, 2004, MAMM GENOME, V15, P162, DOI 10.1007/s00335-003-2311-y; PASTERNACK JM, 1989, AM J PATHOL, V135, P827; Rollini P, 1999, P NATL ACAD SCI USA, V96, P10308, DOI 10.1073/pnas.96.18.10308; Rollini P, 1997, GENOMICS, V46, P409, DOI 10.1006/geno.1997.5077; Sambrook J., 1989, MOL CLONING LAB MANU, V2; SAWADOGO M, 1988, J BIOL CHEM, V263, P11985; Shaulian E, 2002, NAT CELL BIOL, V4, pE131, DOI 10.1038/ncb0502-e131; Vives V, 2003, J COMP NEUROL, V457, P404, DOI 10.1002/cne.10552; WROBLEWSKA Z, 1982, J NEUROL SCI, V54, P189, DOI 10.1016/0022-510X(82)90181-2	27	28	31	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 27	2006	281	4					1956	1963		10.1074/jbc.M510935200	http://dx.doi.org/10.1074/jbc.M510935200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	004NV	16303762	hybrid			2022-12-25	WOS:000234760400014
J	Lin, RT; Yang, L; Nakhaei, P; Sun, Q; Sharif-Askari, E; Julkunen, I; Hiscott, J				Lin, RT; Yang, L; Nakhaei, P; Sun, Q; Sharif-Askari, E; Julkunen, I; Hiscott, J			Negative regulation of the retinoic acid-inducible gene I-induced antiviral state by the ubiquitin-editing protein A20	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; HEPATITIS-C VIRUS; ZINC-FINGER PROTEIN; IRF-3 TRANSCRIPTION FACTOR; TOLL-LIKE RECEPTOR-3; DOUBLE-STRANDED-RNA; RIG-I; SIGNALING PATHWAY; ADAPTER PROTEIN; IKK-EPSILON	Activation of the interferon regulatory factors (IRFs) 3 and 7 transcription factors is essential for the induction of type I interferon (IFN) and development of the innate antiviral response. Retinoic acid-inducible gene I has been shown to contribute to virus-induced IFN production independent of the Toll-like receptor pathways in response to a variety of RNA viruses and double-stranded RNA. In the present study, we demonstrate that the NF-kappa B-inducible, antiapoptotic protein A20 efficiently blocks RIG-I-mediated activation of NF-kappa B-, IRF-3-, and IRF-7-dependent promoters but only weakly interferes with TRIF-TLR-3-mediated IFN activation. Expression of A20 completely blocked CARD domain containing Delta RIG-I-induced IRF-3 Ser-396 phosphorylation, homodimerization, and DNA binding. The level of A20 inhibition was upstream of the TBK1/IKK epsilon kinases that phosphorylate IRF3 and IRF7 and paradoxically, A20 selectively degraded the TRIF protein but not RIG-I. A20 possesses two ubiquitin-editing domains, an N-terminal de-ubiquitination domain and a C-terminal ubiquitin ligase domain consisting of seven zinc finger domains. Deletion of the N-terminal de-ubiquitination domain had no significant effect on the inhibitory effect of A20, whereas deletion or mutation of zinc finger motif 7 ablated the inhibitory function of A20 on IRF- or NF-kappa B-mediated gene expression. Furthermore, cells stably expressing the active form of RIG-I induced an antiviral state that interfered with replication of vesicular stomatitis virus, an effect that was reversed by stable co-expression of A20. These results suggest that the virus-inducible, NF-kappa B-dependent activation of A20 functions as a negative regulator of RIG-I-mediated induction of the antiviral state.	McGill Univ, Lady Davis Inst Med Res, Terry Fox Mol Oncol Grp, Montreal, PQ H3T 1E2, Canada; McGill Univ, Dept Microbiol & Immunol, Montreal, PQ H3T 1E2, Canada; McGill Univ, Dept Med, Montreal, PQ H3T 1E2, Canada; Natl Publ Hlth Inst, FIN-00300 Helsinki, Finland; Univ Helsinki, FIN-00300 Helsinki, Finland	Lady Davis Institute; McGill University; McGill University; McGill University; Finland National Institute for Health & Welfare; University of Helsinki	Lin, RT (corresponding author), McGill Univ, Lady Davis Inst Med Res, Terry Fox Mol Oncol Grp, 3755 Cote Ste Catherine, Montreal, PQ H3T 1E2, Canada.	rongtuan.lin@mcgill.ca	Lin, Rongtuan/A-1442-2008	Lin, Rongtuan/0000-0002-2238-3503				Alexopoulou L, 2001, NATURE, V413, P732, DOI 10.1038/35099560; Au WC, 1998, J BIOL CHEM, V273, P29210, DOI 10.1074/jbc.273.44.29210; Beyaert R, 2000, BIOCHEM PHARMACOL, V60, P1143, DOI 10.1016/S0006-2952(00)00404-4; Bonnard M, 2000, EMBO J, V19, P4976, DOI 10.1093/emboj/19.18.4976; Boone DL, 2004, NAT IMMUNOL, V5, P1052, DOI 10.1038/ni1110; Breiman A, 2005, J VIROL, V79, P3969, DOI 10.1128/JVI.79.7.3969-3978.2005; Diebold SS, 2004, SCIENCE, V303, P1529, DOI 10.1126/science.1093616; Fitzgerald KA, 2003, NAT IMMUNOL, V4, P491, DOI 10.1038/ni921; Fitzgerald KA, 2003, J EXP MED, V198, P1043, DOI 10.1084/jem.20031023; Foy E, 2005, P NATL ACAD SCI USA, V102, P2986, DOI 10.1073/pnas.0408707102; Heil F, 2004, SCIENCE, V303, P1526, DOI 10.1126/science.1093620; Hiscott J, 1999, J INTERF CYTOK RES, V19, P1, DOI 10.1089/107999099314360; Jaattela M, 1996, J IMMUNOL, V156, P1166; Kato H, 2005, IMMUNITY, V23, P19, DOI 10.1016/j.immuni.2005.04.010; Kawai T, 2005, NAT IMMUNOL, V6, P981, DOI 10.1038/ni1243; Klinkenberg M, 2001, FEBS LETT, V498, P93, DOI 10.1016/S0014-5793(01)02504-2; KRIKOS A, 1992, J BIOL CHEM, V267, P17971; Krug A, 2004, IMMUNITY, V21, P107, DOI 10.1016/j.immuni.2004.06.007; Kurt-Jones EA, 2000, NAT IMMUNOL, V1, P398, DOI 10.1038/80833; Lee EG, 2000, SCIENCE, V289, P2350, DOI 10.1126/science.289.5488.2350; Levy DE, 2002, J INTERF CYTOK RES, V22, P87, DOI 10.1089/107999002753452692; Li K, 2005, P NATL ACAD SCI USA, V102, P2992, DOI 10.1073/pnas.0408824102; Lin RT, 2000, J BIOL CHEM, V275, P34320, DOI 10.1074/jbc.M002814200; Lin RT, 1999, MOL CELL BIOL, V19, P959; Lin RT, 1999, MOL CELL BIOL, V19, P2465; Lin RT, 1998, MOL CELL BIOL, V18, P2986, DOI 10.1128/MCB.18.5.2986; Lin RT, 1996, MOL CELL BIOL, V16, P1401; Lund J, 2003, J EXP MED, V198, P513, DOI 10.1084/jem.20030162; Malmgaard L, 2004, J INTERF CYTOK RES, V24, P439, DOI 10.1089/1079990041689665; Mamane Y, 1999, GENE, V237, P1, DOI 10.1016/S0378-1119(99)00262-0; Marie I, 1998, EMBO J, V17, P6660, DOI 10.1093/emboj/17.22.6660; McWhirter SM, 2004, P NATL ACAD SCI USA, V101, P233, DOI 10.1073/pnas.2237236100; Meylan E, 2005, NATURE, V437, P1167, DOI 10.1038/nature04193; Natoli G, 1998, J BIOL CHEM, V273, P31262, DOI 10.1074/jbc.273.47.31262; OPIPARI AW, 1990, J BIOL CHEM, V265, P14705; Oshiumi H, 2003, J BIOL CHEM, V278, P49751, DOI 10.1074/jbc.M305820200; Peters RT, 2000, MOL CELL, V5, P513, DOI 10.1016/S1097-2765(00)80445-1; Pomerantz JL, 1999, EMBO J, V18, P6694, DOI 10.1093/emboj/18.23.6694; Saitoh T, 2005, J IMMUNOL, V174, P1507, DOI 10.4049/jimmunol.174.3.1507; Samuel CE, 2001, CLIN MICROBIOL REV, V14, P778, DOI 10.1128/CMR.14.4.778-809.2001; Sato M, 2000, IMMUNITY, V13, P539, DOI 10.1016/S1074-7613(00)00053-4; Sato M, 1998, FEBS LETT, V425, P112, DOI 10.1016/S0014-5793(98)00210-5; Sato S, 2003, J IMMUNOL, V171, P4304, DOI 10.4049/jimmunol.171.8.4304; Sen GC, 2001, ANNU REV MICROBIOL, V55, P255, DOI 10.1146/annurev.micro.55.1.255; Servant MJ, 2002, BIOCHEM PHARMACOL, V64, P985, DOI 10.1016/S0006-2952(02)01165-6; Servant MJ, 2002, J INTERF CYTOK RES, V22, P49, DOI 10.1089/107999002753452656; Seth RB, 2005, CELL, V122, P669, DOI 10.1016/j.cell.2005.08.012; Sharma S, 2003, SCIENCE, V300, P1148, DOI 10.1126/science.1081315; Storz P, 2005, BIOCHEM J, V387, P47, DOI 10.1042/BJ20041443; Stumper R, 2005, J VIROL, V79, P2689, DOI 10.1128/JVI.79.5.2689-2699.2005; Taniguchi T, 2001, ANNU REV IMMUNOL, V19, P623, DOI 10.1146/annurev.immunol.19.1.623; Tojima Y, 2000, NATURE, V404, P778, DOI 10.1038/35008109; Wang YY, 2004, FEBS LETT, V576, P86, DOI 10.1016/j.febslet.2004.08.071; Wertz IE, 2004, NATURE, V430, P694, DOI 10.1038/nature02794; Xu LG, 2005, MOL CELL, V19, P727, DOI 10.1016/j.molcel.2005.08.014; Yamamoto M, 2003, SCIENCE, V301, P640, DOI 10.1126/science.1087262; Yamamoto M, 2003, NAT IMMUNOL, V4, P1144, DOI 10.1038/ni986; Yoneyama M, 1998, EMBO J, V17, P1087, DOI 10.1093/emboj/17.4.1087; Yoneyama M, 2004, NAT IMMUNOL, V5, P730, DOI 10.1038/ni1087	59	186	198	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 27	2006	281	4					2095	2103		10.1074/jbc.M510326200	http://dx.doi.org/10.1074/jbc.M510326200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	004NV	16306043	hybrid			2022-12-25	WOS:000234760400031
J	Musse, AA; Wang, J; deLeon, GP; Prentice, GA; London, E; Merrill, AR				Musse, AA; Wang, J; deLeon, GP; Prentice, GA; London, E; Merrill, AR			Scanning the membrane-bound conformation of Helix 1 in the colicin E1 channel domain by site-directed fluorescence labeling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FORMING COLICINS; ION-CHANNEL; BIMANE FLUORESCENCE; PROTEIN TOPOLOGY; DIPHTHERIA-TOXIN; LIPID-BILAYERS; PORE FORMATION; CLOSED STATE; PEPTIDE; BINDING	Helix 1 of the membrane-associated closed state of the colicin E1 channel domain was studied by site-directed fluorescence labeling where bimane was covalently attached to a single cysteine residue in each mutant protein. A number of fluorescence properties of the tethered bimane fluorophore were measured in the membrane-bound state of the channel domain, including fluorescence emission maximum, fluorescence quantum yield, fluorescence anisotropy, membrane bilayer penetration depth, surface accessibility, and apparent polarity. The data show that helix 1 is an amphipathic alpha-helix that is situated parallel to the membrane surface. A least squares fit of the various data sets to a harmonic function indicated that the periodicity and angular frequency for helix 1 are typical for an amphipathic alpha-helix (3.7 +/- 0.1 residues per turn and 97 +/- 3.0 degrees, respectively) that is partially bathing into the membrane bilayer. Dual fluorescence quencher analysis also revealed that helix 1 is peripherally membrane- associated, with one face of the helix dipping into the lipid bilayer and the other face projecting toward the solvent. Finally, our data suggest that the helical boundaries of helix 1, at least at the C-terminal region, remain unaffected upon binding to the surface of the membrane in support of a toroidal pore model for this colicin.	Univ Guelph, Dept Cellular & Mol Biol, Guelph, ON N1G 2W1, Canada; SUNY Stony Brook, Dept Biochem & Cell Biol, Stony Brook, NY 11794 USA; SUNY Stony Brook, Dept Chem, Stony Brook, NY 11794 USA	University of Guelph; State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook	Merrill, AR (corresponding author), Univ Guelph, Dept Cellular & Mol Biol, 488 Gordon St,Bldg 140, Guelph, ON N1G 2W1, Canada.	rmerrill@uoguelph.ca	Merrill, Rod/M-8313-2014		NIGMS NIH HHS [GM31986] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM031986] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABRAMS CK, 1991, J GEN PHYSIOL, V98, P77, DOI 10.1085/jgp.98.1.77; BRUNDEN KR, 1984, J BIOL CHEM, V259, P190; Caputo GA, 2003, BIOCHEMISTRY-US, V42, P3265, DOI 10.1021/bi026696l; CORNETTE JL, 1987, J MOL BIOL, V195, P659, DOI 10.1016/0022-2836(87)90189-6; CRAMER WA, 1992, FEMS MICROBIOL IMMUN, V105, P71; CRAMER WA, 1995, ANNU REV BIOPH BIOM, V24, P611, DOI 10.1146/annurev.biophys.24.1.611; CRAMER WA, 1983, BIOCHIM BIOPHYS ACTA, V737, P173, DOI 10.1016/0304-4157(83)90016-3; DANKERT JR, 1982, J BIOL CHEM, V257, P3857; Elkins P, 1997, STRUCTURE, V5, P443, DOI 10.1016/S0969-2126(97)00200-1; FLETCHER AN, 1969, PHOTOCHEM PHOTOBIOL, V9, P439, DOI 10.1111/j.1751-1097.1969.tb07311.x; Fraczkiewicz R, 1998, J COMPUT CHEM, V19, P319, DOI 10.1002/(SICI)1096-987X(199802)19:3<319::AID-JCC6>3.0.CO;2-W; Fridd SL, 2002, BIOCHIMIE, V84, P477, DOI 10.1016/S0300-9084(02)01418-9; Gillor O, 2004, ADV APPL MICROBIOL, V54, P129, DOI 10.1016/S0065-2164(04)54005-4; Hayashibara M, 2005, BIOCHEMISTRY-US, V44, P2183, DOI 10.1021/bi0482093; Heymann JB, 1996, BIOCHEMISTRY-US, V35, P2717, DOI 10.1021/bi951535l; Kim Y, 1998, PROTEIN SCI, V7, P342; KOSOWER EM, 1986, J PHYS CHEM-US, V90, P5552, DOI 10.1021/j100280a014; Lakey JH, 2001, CURR TOP MICROBIOL, V257, P131; Lambotte S, 1998, BIOCHEMISTRY-US, V37, P16, DOI 10.1021/bi9724671; Lindeberg M, 2000, J MOL BIOL, V295, P679, DOI 10.1006/jmbi.1999.3396; Malenbaum SE, 1998, J NAT TOXINS, V7, P269; Mansoor SE, 2002, BIOCHEMISTRY-US, V41, P2475, DOI 10.1021/bi011198i; Mansoor SE, 1999, BIOCHEMISTRY-US, V38, P16383, DOI 10.1021/bi991331v; MERRILL AR, 1990, BIOCHEMISTRY-US, V29, P8529, DOI 10.1021/bi00489a004; Musse AA, 2003, J BIOL CHEM, V278, P24491, DOI 10.1074/jbc.M302371200; PALMER LR, 1994, J BIOL CHEM, V269, P4187; PUGSLEY AP, 1984, MICROBIOL SCI, V1, P203; Riley MA, 2002, ANNU REV MICROBIOL, V56, P117, DOI 10.1146/annurev.micro.56.012302.161024; Salwinski L, 1999, PROTEIN SCI, V8, P562; SATO E, 1988, BIOORG CHEM, V16, P298, DOI 10.1016/0045-2068(88)90017-X; SHIN YK, 1993, SCIENCE, V259, P960, DOI 10.1126/science.8382373; Slatin SL, 2004, J MEMBRANE BIOL, V202, P73, DOI 10.1007/s00232-004-0720-9; Sobko AA, 2004, FEBS LETT, V576, P205, DOI 10.1016/j.febslet.2004.09.016; STRAWBRIDGE KB, 1995, BIOPHYS J, V68, P131, DOI 10.1016/S0006-3495(95)80167-0; Stroud RM, 1998, CURR OPIN STRUC BIOL, V8, P525, DOI 10.1016/S0959-440X(98)80132-2; Taylor R, 1998, J BIOL CHEM, V273, P31113, DOI 10.1074/jbc.273.47.31113; Tory MC, 2002, BBA-BIOMEMBRANES, V1564, P435, DOI 10.1016/S0005-2736(02)00493-5; Tory MC, 1999, J BIOL CHEM, V274, P24539, DOI 10.1074/jbc.274.35.24539; Zakharov SD, 1999, BIOCHEMISTRY-US, V38, P11325, DOI 10.1021/bi9903087; Zakharov SD, 1998, P NATL ACAD SCI USA, V95, P4282, DOI 10.1073/pnas.95.8.4282; Zakharov SD, 2004, BBA-BIOMEMBRANES, V1666, P239, DOI 10.1016/j.bbamem.2004.07.001; ZHANG YL, 1992, PROTEIN SCI, V1, P1666, DOI 10.1002/pro.5560011215; Zhao G, 2005, BIOCHEMISTRY-US, V44, P4488, DOI 10.1021/bi047705o	43	29	31	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 13	2006	281	2					885	895		10.1074/jbc.M511140200	http://dx.doi.org/10.1074/jbc.M511140200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	000FV	16299381	hybrid			2022-12-25	WOS:000234447200027
J	Tanaka, Y; Kanai, F; Tada, M; Asaoka, Y; Guleng, B; Jazag, A; Ohta, M; Ikenoue, T; Tateishi, K; Obi, S; Kawabe, T; Yokosuka, O; Omata, M				Tanaka, Y.; Kanai, F.; Tada, M.; Asaoka, Y.; Guleng, B.; Jazag, A.; Ohta, M.; Ikenoue, T.; Tateishi, K.; Obi, S.; Kawabe, T.; Yokosuka, O.; Omata, M.			Absence of PIK3CA hotspot mutations in hepatocellular carcinoma in Japanese patients	ONCOGENE			English	Article						PIK3CA; mutation; HCC; pseudogene; PI3K	HUMAN CANCER; GENE; OVARIAN; PATHWAY	A recent study revealed that the p110 alpha ( PIK3CA), catalytic subunit of phosphatidylinositol 3- kinase ( PI3K), is somatically mutated in many types of cancer. For example, PIK3CA is mutated in an estimated 35.6% of hepatocellular carcinoma ( HCC) cases. To measure the frequency of PIK3CA hotspot mutations in Japanese HCC patients, exons 9 and 20 of the PIK3CA gene were sequenced in 47 clinical HCC samples. Contrary to expectations, no hotspot mutations were found any of the HCC samples. In addition, we found abnormally migrating waves near the end of exon 9 in the PCR chromatograms from 13 of the 47 samples. PCR amplification and subsequent cloning and sequencing revealed that these chromatograms contained two distinct sequences, the wild- type p110 alpha sequence and a different sequence found on human chromosome 22q11.2, the Cat Eye Syndrome region, which contains a putative pseudogene of PIK3CA. These abnormally migrating waves were also found in noncancerous liver tissue, indicating that this was not a result of HCC- associated mutations. Therefore, it is likely that the percentage of hotspot mutations in the PIK3CA gene of Japanese HCC patients is lower than was previously reported.	Univ Tokyo, Grad Sch Med, Dept Gastroenterol, Bunkyo Ku, Tokyo 1138655, Japan; Chiba Univ, Grad Sch Med, Dept Med & Clin Oncol, Chiba, Japan	University of Tokyo; Chiba University	Kanai, F (corresponding author), Univ Tokyo, Grad Sch Med, Dept Gastroenterol, Bunkyo Ku, 7-3-1 Hongo, Tokyo 1138655, Japan.	kanaif-int@h.u-tokyo.ac.jp	Asaoka, Yoshinari/ABC-5412-2021	Asaoka, Yoshinari/0000-0002-2805-8226; Tanaka, Yasuo/0000-0002-2917-3365				Campbell IG, 2004, CANCER RES, V64, P7678, DOI 10.1158/0008-5472.CAN-04-2933; Cantley LC, 2002, SCIENCE, V296, P1655, DOI 10.1126/science.296.5573.1655; Ikenoue T, 2005, CANCER RES, V65, P4562, DOI 10.1158/0008-5472.CAN-04-4114; Kang SY, 2005, P NATL ACAD SCI USA, V102, P802, DOI 10.1073/pnas.0408864102; Lee JW, 2005, ONCOGENE, V24, P1477, DOI 10.1038/sj.onc.1208304; Levine DA, 2005, CLIN CANCER RES, V11, P2875, DOI 10.1158/1078-0432.CCR-04-2142; Li VSW, 2005, BMC CANCER, V5, DOI 10.1186/1471-2407-5-29; McDermid HE, 2002, AM J HUM GENET, V70, P1077, DOI 10.1086/340363; OR YY, 2005, INT J CANC      0819; Saal LH, 2005, CANCER RES, V65, P2554, DOI 10.1158/0008-5472-CAN-04-3913; Sahin F, 2004, CLIN CANCER RES, V10, P8421, DOI 10.1158/1078-0432.CCR-04-0941; Samuels Y, 2005, CANCER CELL, V7, P561, DOI 10.1016/j.ccr.2005.05.014; Samuels Y, 2004, SCIENCE, V304, P554, DOI 10.1126/science.1096502; Shayesteh L, 1999, NAT GENET, V21, P99, DOI 10.1038/5042; Velho S, 2005, EUR J CANCER, V41, P1649, DOI 10.1016/j.ejca.2005.04.022; Vivanco I, 2002, NAT REV CANCER, V2, P489, DOI 10.1038/nrc839	16	57	61	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY	2006	25	20					2950	2952		10.1038/sj.onc.1209311	http://dx.doi.org/10.1038/sj.onc.1209311			3	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	041IN	16331247				2022-12-25	WOS:000237448200014
J	Nagaraja, GM; Othman, M; Fox, BP; Alsaber, R; Pellegrino, CM; Zeng, Y; Khanna, R; Tamburini, P; Swaroop, A; Kandpal, RP				Nagaraja, GM; Othman, M; Fox, BP; Alsaber, R; Pellegrino, CM; Zeng, Y; Khanna, R; Tamburini, P; Swaroop, A; Kandpal, RP			Gene expression signatures and biomarkers of noninvasive and invasive breast cancer cells: comprehensive profiles by representational difference analysis, microarrays and proteomics	ONCOGENE			English	Article						representational difference analysis; microarrays; proteomics; breast carcinoma; biomarkers; copper homeostasis	CARCINOMA CELLS; LYSYL OXIDASE; PROTEINS; DISEASE; IDENTIFICATION; ADHESION; TUMORS; FAMILY; GROWTH; PROGRESSION	We have characterized comprehensive transcript and proteomic profiles of cell lines corresponding to normal breast (MCF10A), noninvasive breast cancer (MCF7) and invasive breast cancer (MDA-MB-231). The transcript profiles were first analysed by a modified protocol for representational difference analysis (RDA) of cDNAs between MCF7 and MDA-MB-231 cells. The majority of genes identified by RDA showed nearly complete concordance with microarray results, and also led to the identification of some differentially expressed genes such as lysyl oxidase, copper transporter ATP7A, EphB6, RUNX2 and a variant of RUNX2. The altered transcripts identified by microarray analysis were involved in cell-cell or cell-matrix interaction, Rho signaling, calcium homeostasis and copper-binding/sensitive activities. A set of nine genes that included GPCR11, cadherin 11, annexin A1, vimentin, lactate dehydrogenase B (upregulated in MDA-MB-231) and GREB1, S100A8, amyloid beta precursor protein, claudin 3 and cadherin 1 (downregulated in MDA-MB-231) were sufficient to distinguish MDA-MB-231 from MCF7 cells. The downregulation of a set of transcripts for proteins involved in cell-cell interaction indicated these transcripts as potential markers for invasiveness that can be detected by methylation-specific PCR. The proteomic profiles indicated altered abundance of fewer proteins as compared to transcript profiles. Antisense knockdown of selected transcripts led to inhibition of cell proliferation that was accompanied by altered proteomic profiles. The proteomic profiles of antisense transfectants suggest the involvement of peptidylprolyl isomerase, Raf kinase inhibitor and 80 kDa protein kinase C substrate in mediating the inhibition of cell proliferation.	Fordham Univ, Dept Biol Sci, Bronx, NY 10458 USA; Univ Michigan, Dept Ophthalmol & Visual Sci, Ann Arbor, MI 48109 USA; Bayer Corp, West Haven, CT USA	Fordham University; University of Michigan System; University of Michigan; Bayer AG	Kandpal, RP (corresponding author), Fordham Univ, Dept Biol Sci, Larkin Hall,Room 250,441 E Fordham Rd, Bronx, NY 10458 USA.	kandpal@fordham.edu		Swaroop, Anand/0000-0002-1975-1141				Akiri G, 2003, CANCER RES, V63, P1657; Alpan RS, 1996, MOL MED, V2, P469, DOI 10.1007/BF03401906; Arnuthan G, 2002, ONCOGENE, V21, P7839, DOI 10.1038/sj.onc.1205983; Baskaran N, 1996, GENOME RES, V6, P633, DOI 10.1101/gr.6.7.633; Becker M, 2005, MOL CANCER THER, V4, P151; Berger M, 2005, MOL CELL BIOL, V25, P5380, DOI 10.1128/MCB.25.13.5380-5388.2005; BIECHE I, 1995, CLIN CANCER RES, V1, P123; CAMPBELL FC, 1983, BRIT J SURG, V70, P202, DOI 10.1002/bjs.1800700405; CEROSALETTI KM, 1995, GENOMICS, V25, P226, DOI 10.1016/0888-7543(95)80130-E; Costa FF, 2004, ONCOGENE, V23, P1481, DOI 10.1038/sj.onc.1207263; Dan S, 2002, CANCER RES, V62, P1139; Fletcher GC, 2003, BRIT J CANCER, V88, P579, DOI 10.1038/sj.bjc.6600740; Fox BP, 2004, BIOCHEM BIOPH RES CO, V318, P882, DOI 10.1016/j.bbrc.2004.04.102; Hall J, 2005, CANCER LETT, V227, P105, DOI 10.1016/j.canlet.2004.12.001; Jacob ANK, 1997, SOMAT CELL MOLEC GEN, V23, P83, DOI 10.1007/BF02679968; JOHNSON JP, 1991, CANCER METAST REV, V10, P11, DOI 10.1007/BF00046840; Jones CE, 2004, J BIOL CHEM, V279, P32018, DOI 10.1074/jbc.M403467200; Katoh M, 2003, INT J MOL MED, V12, P3; Keller ET, 2004, CANCER LETT, V207, P131, DOI 10.1016/j.canlet.2004.02.006; Khan J, 2001, NAT MED, V7, P673, DOI 10.1038/89044; Kousidou OC, 2004, ANTICANCER RES, V24, P4025; LISITSYN N, 1993, SCIENCE, V259, P946, DOI 10.1126/science.8438152; Luo C, 1996, P NATL ACAD SCI USA, V93, P8907, DOI 10.1073/pnas.93.17.8907; Malliri A, 2003, CURR OPIN CELL BIOL, V15, P583, DOI 10.1016/S0955-0674(03)00098-X; Mantovani F, 2004, CELL CYCLE, V3, P905; Marenholz I, 2004, BIOCHEM BIOPH RES CO, V322, P1111, DOI 10.1016/j.bbrc.2004.07.096; Missiaen L, 2000, CELL CALCIUM, V28, P1, DOI 10.1054/ceca.2000.0131; Moller LB, 2005, HUM MUTAT, V26, P84, DOI 10.1002/humu.20190; Nagaraja GM, 2004, BIOCHEM BIOPH RES CO, V313, P654, DOI 10.1016/j.bbrc.2003.12.001; Pase L, 2004, BIOCHEM J, V378, P1031, DOI 10.1042/BJ20031181; Perou CM, 2000, NATURE, V406, P747, DOI 10.1038/35021093; Pratap J, 2003, CANCER RES, V63, P5357; Reiner A, 2003, BIOINFORMATICS, V19, P368, DOI 10.1093/bioinformatics/btf877; Ridley AJ, 2004, BREAST CANCER RES TR, V84, P13, DOI 10.1023/B:BREA.0000018423.47497.c6; Rosenwald A, 2002, NEW ENGL J MED, V346, P1937, DOI 10.1056/NEJMoa012914; Ross DT, 2000, NAT GENET, V24, P227, DOI 10.1038/73432; Shao Q, 2005, CANCER RES, V65, P2705, DOI 10.1158/0008-5472.CAN-04-2367; SIEGEL RC, 1976, J BIOL CHEM, V251, P5786; Takayama Y, 2003, GENE DEV, V17, P1153, DOI 10.1101/gad.1065903; van't Veer LJ, 2002, NATURE, V415, P530, DOI 10.1038/415530a; Warner SL, 2003, MOL CANCER THER, V2, P589; Westendorf JJ, 2002, MOL CELL BIOL, V22, P7982, DOI 10.1128/MCB.22.22.7982-7992.2002; Wiseman A, 2005, MED HYPOTHESES, V65, P32, DOI 10.1016/j.mehy.2005.01.041; Yoshida S, 2004, HUM MOL GENET, V13, P1487, DOI 10.1093/hmg/ddh160; Yu YX, 2001, INT J ONCOL, V18, P905	45	150	199	1	22	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 13	2006	25	16					2328	2338		10.1038/sj.onc.1209265	http://dx.doi.org/10.1038/sj.onc.1209265			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	032HC	16314837				2022-12-25	WOS:000236764300005
J	Beaujouin, M; Baghdiguian, S; Glondu-Lassis, M; Berchem, G; Liaudet-Coopman, E				Beaujouin, M; Baghdiguian, S; Glondu-Lassis, M; Berchem, G; Liaudet-Coopman, E			Overexpression of both catalytically active and -inactive cathepsin D by cancer cells enhances apoptosis-dependent chemo-sensitivity	ONCOGENE			English	Article						protease; cathepsin D; chemo-cytotoxicity; apoptosis; etoposide; catalytic activity	CYTOCHROME-C RELEASE; BREAST-CANCER; CASPASE ACTIVATION; RAT CARDIOMYOCYTES; TNF-ALPHA; DEATH; INVOLVEMENT; DEFICIENT; GROWTH; FIBROBLASTS	The aspartic protease cathepsin D (cath-D) is a key mediator of induced-apoptosis and its proteolytic activity has been generally involved in this event. During apoptosis, cath-D is translocated to the cytosol. Because cath-D is one of the lysosomal enzymes that requires a more acidic pH to be proteolytically active relative to the cysteine lysosomal enzymes such as cath-B and -L, it is therefore open to question whether cytosolic cath-D might be able to cleave substrate(s) implicated in the apoptotic cascade. Here, we have investigated the role of wild-type cath-D and its proteolytically inactive counterpart overexpressed by 3Y1-Ad12 cancer cells during chemotherapeutic-induced cytotoxicity and apoptosis, as well as the relevance of cath-D catalytic function. We demonstrate that wild-type or mutated catalytically inactive cath-D strongly enhances chemo- sensitivity and apoptotic response to etoposide. Both wild-type and mutated inactive cath-D are translocated to the cytosol, increasing the release of cytochrome c, the activation of caspases-9 and -3 and the induction of a caspase-dependent apoptosis. In addition, pretreatment of cells with the aspartic protease inhibitor, pepstatin A, does not prevent apoptosis. Interestingly therefore, the stimulatory effect of cath- D on cell death is independent of its catalytic activity. Overall, our results imply that cytosolic cath- D stimulates apoptotic pathways by interacting with a member of the apoptotic machinery rather than by cleaving specific substrate( s).	Univ Montpellier I, INSERM U540, F-34090 Montpellier, France; Univ Montpellier 2, CNRS, UMR 5554, Montpellier, France; Ctr Hosp Luxembourg, CRP Sante, Lab Hematocancerol Expt, Luxembourg, France	Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Montpellier; Centre National de la Recherche Scientifique (CNRS); CNRS - Institute of Ecology & Environment (INEE); Institut de Recherche pour le Developpement (IRD); Universite de Montpellier	Liaudet-Coopman, E (corresponding author), Univ Montpellier I, INSERM U540, 60 Rue Navacelles, F-34090 Montpellier, France.	liaudet@montp.inserm.fr	Liaudet-Coopman, Emmanuelle/N-4744-2017; Berchem, Guy/C-9364-2014	Liaudet-Coopman, Emmanuelle/0000-0001-9313-9690; Berchem, Guy/0000-0003-0157-2257; Baghdiguian, Stephen/0000-0002-2992-9708				Berchem G, 2002, ONCOGENE, V21, P5951, DOI 10.1038/sj.onc.1205745; Bidere N, 2003, J BIOL CHEM, V278, P31401, DOI 10.1074/jbc.M301911200; CAPONY F, 1987, J CELL BIOL, V104, P253, DOI 10.1083/jcb.104.2.253; Cirman T, 2004, J BIOL CHEM, V279, P3578, DOI 10.1074/jbc.M308347200; Deiss LP, 1996, EMBO J, V15, P3861, DOI 10.1002/j.1460-2075.1996.tb00760.x; Demoz M, 2002, BIOL CHEM, V383, P1237, DOI 10.1515/BC.2002.137; Emert-Sedlak L, 2005, MOL CANCER THER, V4, P733, DOI 10.1158/1535-7163.MCT-04-0301; Ferrandina G, 1997, BRIT J CANCER, V76, P661, DOI 10.1038/bjc.1997.442; Foekens JA, 1999, BRIT J CANCER, V79, P300, DOI 10.1038/sj.bjc.6990048; GARCIA M, 1990, ONCOGENE, V5, P1809; Glondu M, 2001, ONCOGENE, V20, P6920, DOI 10.1038/sj.onc.1204843; Glondu M, 2002, ONCOGENE, V21, P5127, DOI 10.1038/sj.onc.1205657; Gottlieb RA, 1996, P NATL ACAD SCI USA, V93, P654, DOI 10.1073/pnas.93.2.654; Heinrich M, 2004, CELL DEATH DIFFER, V11, P550, DOI 10.1038/sj.cdd.4401382; Johansson AC, 2003, CELL DEATH DIFFER, V10, P1253, DOI 10.1038/sj.cdd.4401290; Kagedal K, 2001, FASEB J, V15, P1592, DOI 10.1096/fj.00-0708fje; Koike M, 2003, MOL CELL NEUROSCI, V22, P146, DOI 10.1016/S1044-7431(03)00035-6; Koike M, 2000, J NEUROSCI, V20, P6898, DOI 10.1523/JNEUROSCI.20-18-06898.2000; Laurent-Matha V, 2005, J CELL BIOL, V168, P489, DOI 10.1083/jcb.200403078; LIAUDET E, 1994, ONCOGENE, V9, P1145; Matsuyama S, 2000, NAT CELL BIOL, V2, P318, DOI 10.1038/35014006; Nakanishi H, 2001, J NEUROSCI, V21, P7526, DOI 10.1523/JNEUROSCI.21-19-07526.2001; Ollinger K, 2000, ARCH BIOCHEM BIOPHYS, V373, P346, DOI 10.1006/abbi.1999.1567; Reiners JJ, 2002, CELL DEATH DIFFER, V9, P934, DOI 10.1038/sj.cdd.4401048; Roberg K, 1998, AM J PATHOL, V152, P1151; Roberg K, 2002, AM J PATHOL, V161, P89, DOI 10.1016/S0002-9440(10)64160-0; Roberg K, 2001, LAB INVEST, V81, P149, DOI 10.1038/labinvest.3780222; Rochefort H, 1996, EUR J CANCER, V32A, P7, DOI 10.1016/0959-8049(95)00637-0; SAFTIG P, 1995, EMBO J, V14, P3599, DOI 10.1002/j.1460-2075.1995.tb00029.x; Sawada N, 2000, CELL DEATH DIFFER, V7, P761, DOI 10.1038/sj.cdd.4400711; Shibata M, 1998, BIOCHEM BIOPH RES CO, V251, P199, DOI 10.1006/bbrc.1998.9422; Takuma K, 2003, NEUROCHEM INT, V42, P153, DOI 10.1016/S0197-0186(02)00077-3; Tardy C, 2003, CELL DEATH DIFFER, V10, P1090, DOI 10.1038/sj.cdd.4401272; Terman A, 2002, EXP CELL RES, V274, P9, DOI 10.1006/excr.2001.5441; Werneburg NW, 2002, AM J PHYSIOL-GASTR L, V283, pG947, DOI 10.1152/ajpgi.00151.2002; Westley BR, 1996, EUR J CANCER, V32A, P15, DOI 10.1016/0959-8049(95)00530-7; Wu GS, 1998, ONCOGENE, V16, P2177, DOI 10.1038/sj.onc.1201755	37	58	65	1	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 23	2006	25	13					1967	1973		10.1038/sj.onc.1209221	http://dx.doi.org/10.1038/sj.onc.1209221			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	024VQ	16331270	Green Accepted, Green Submitted			2022-12-25	WOS:000236224800013
J	Qasimi, P; Ming-Lum, A; Ghanipour, A; Ong, CJ; Cox, ME; Ihle, J; Cacalano, N; Yoshimura, A; Mui, ALF				Qasimi, P; Ming-Lum, A; Ghanipour, A; Ong, CJ; Cox, ME; Ihle, J; Cacalano, N; Yoshimura, A; Mui, ALF			Divergent mechanisms utilized by SOCS3 to mediate interleukin-10 inhibition of tumor necrosis factor alpha and nitric oxide production by macrophages	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; LIPOPOLYSACCHARIDE-INDUCED ACTIVATION; CYTOKINE SIGNALING-3; TYROSINE PHOSPHORYLATION; CHRONIC ENTEROCOLITIS; INDEPENDENT PATHWAYS; NEGATIVE REGULATION; MOUSE MACROPHAGES; J774 MACROPHAGES; HUMAN MONOCYTES	The cytokine interleukin-10 (IL-10) potently inhibits macrophage function through activation of the transcription factor STAT3. The expression of SOCS3 ( suppressor of cytokine signaling-3) has been shown to be induced by IL-10 in a STAT3-dependent manner. However, the relevance of SOCS3 expression to the anti-inflammatory effect of IL-10 on macrophages has been controversial. Through kinetic analysis of the requirement for SOCS3 in IL-10 inhibition of lipopolysaccharide (LPS)-stimulated tumor necrosis factor-alpha(TNF alpha) transcription and translation, SOCS3 was found to be necessary for TNF alpha expression during the early phase, but not the late phase of IL-10 action. SOCS3 was essential for IL-10 inhibition of LPS-stimulated production of iNOS ( inducible nitric-oxide synthase) protein and nitric oxide ( NO). To determine the domains of SOCS3 protein important in mediating these effects, SOCS3(-/-) macrophages were reconstituted with SOCS3 mutated for the SH2, KIR, SOCS box domains, and tyrosines 204 (Tyr(204)) and 221 (Tyr(221)). The SH2 domain, SOCS box, and both Tyr(204) and Tyr(221) were required for IL-10 inhibition of TNF alpha mRNA and protein expression, but interestingly the KIR domain was necessary only for IL-10 inhibition of TNF alpha protein expression. In contrast, Tyr204 and Tyr221 were the only structural features of SOCS3 that were necessary in mediating IL-10 inhibition of iNOS protein expression and NO production. These data define SOCS3 as an important mediator of IL-10 inhibition of macrophage activation and that SOCS3 interferes with distinct LPS-stimulated signal transduction events through differing mechanisms.	Univ British Columbia, Dept Surg, Jack Bell Res Ctr, Vancouver, BC V6H 3Z6, Canada; Vancouver Coastal Hlth Res Inst, Immun & Infect Res Ctr, Vancouver, BC V6H 3Z6, Canada; Vancouver Coastal Hlth Res Inst, Prostate Canc Res Ctr, Vancouver, BC V6H 3Z6, Canada; St Jude Childrens Hosp, Memphis, TN 38105 USA; Univ Calif Los Angeles, Dept Radiat Oncol, Los Angeles, CA 90095 USA; Kyushu Univ, Div Mol & Cellular Immunol, Fukuoka 8128582, Japan	University of British Columbia; Vancouver Coastal Health Research Institute; Vancouver Coastal Health Research Institute; St Jude Children's Research Hospital; University of California System; University of California Los Angeles; Kyushu University	Mui, ALF (corresponding author), Univ British Columbia, Dept Surg, Jack Bell Res Ctr, 2660 Oak St, Vancouver, BC V6H 3Z6, Canada.	amui@interchange.ubc.ca	Yoshimura, Akihiko/K-5515-2013					Akira S, 2003, BIOCHEM SOC T, V31, P637, DOI 10.1042/BST0310637; Alexander WS, 2004, ANNU REV IMMUNOL, V22, P503, DOI 10.1146/annurev.immunol.22.091003.090312; BACCHETTA R, 1994, J EXP MED, V179, P493, DOI 10.1084/jem.179.2.493; Baetz A, 2004, J BIOL CHEM, V279, P54708, DOI 10.1074/jbc.M410992200; BERG DJ, 1995, J CLIN INVEST, V96, P2339, DOI 10.1172/JCI118290; Berlato C, 2002, J IMMUNOL, V168, P6404, DOI 10.4049/jimmunol.168.12.6404; Bjorbaek C, 2000, J BIOL CHEM, V275, P40649, DOI 10.1074/jbc.M007577200; Black RA, 2002, INT J BIOCHEM CELL B, V34, P1, DOI 10.1016/S1357-2725(01)00097-8; BOGDAN C, 1992, J BIOL CHEM, V267, P23301; BOGDAN C, 1991, J EXP MED, V174, P1549, DOI 10.1084/jem.174.6.1549; BROMBERG JS, 1995, CURR OPIN IMMUNOL, V7, P639, DOI 10.1016/0952-7915(95)80070-0; Cacalano NA, 2001, NAT CELL BIOL, V3, P460, DOI 10.1038/35074525; Campbell J, 2004, J IMMUNOL, V173, P6928, DOI 10.4049/jimmunol.173.11.6928; Crespo A, 2002, EUR J IMMUNOL, V32, P710, DOI 10.1002/1521-4141(200203)32:3<710::AID-IMMU710>3.0.CO;2-T; de Veer MJ, 2003, EUR J IMMUNOL, V33, P2822, DOI 10.1002/eji.200324128; Denys A, 2002, J IMMUNOL, V168, P4837, DOI 10.4049/jimmunol.168.10.4837; DING AH, 1988, J IMMUNOL, V141, P2407; Ding YZ, 2003, J IMMUNOL, V170, P1383, DOI 10.4049/jimmunol.170.3.1383; Donnelly RP, 1999, J INTERF CYTOK RES, V19, P563, DOI 10.1089/107999099313695; Dumitru CD, 2000, CELL, V103, P1071, DOI 10.1016/S0092-8674(00)00210-5; Gadina M, 2000, J BIOL CHEM, V275, P26959; Gao JJ, 1998, J IMMUNOL, V161, P4803; Gingras S, 2004, J BIOL CHEM, V279, P54702, DOI 10.1074/jbc.M411043200; Goldman M, 1996, ANN NY ACAD SCI, V796, P282, DOI 10.1111/j.1749-6632.1996.tb32590.x; Haan S, 2003, J BIOL CHEM, V278, P31972, DOI 10.1074/jbc.M303170200; Hanada T, 2001, J BIOL CHEM, V276, P40746, DOI 10.1074/jbc.M106139200; Hattori Y, 1996, BIOCHEM MOL BIOL INT, V40, P889; Heine Holger, 2005, V86, P99, DOI 10.1159/000086654; Hoebe K, 2003, NAT IMMUNOL, V4, P1223, DOI 10.1038/ni1010; Imai K, 2003, FEMS IMMUNOL MED MIC, V39, P173, DOI 10.1016/S0928-8244(03)00231-1; Ito S, 1999, BLOOD, V93, P1456, DOI 10.1182/blood.V93.5.1456; Jacobs AT, 2001, J BIOL CHEM, V276, P47950, DOI 10.1074/jbc.M106639200; Kamizono S, 2001, J BIOL CHEM, V276, P12530, DOI 10.1074/jbc.M010074200; Kamura T, 1998, GENE DEV, V12, P3872, DOI 10.1101/gad.12.24.3872; Kontoyiannis D, 2001, EMBO J, V20, P3760, DOI 10.1093/emboj/20.14.3760; Krebs DL, 2000, J CELL SCI, V113, P2813; KUHN R, 1993, CELL, V75, P263, DOI 10.1016/0092-8674(93)80068-P; Kuwata H, 2003, BLOOD, V102, P4123, DOI 10.1182/blood-2003-04-1228; Lang R, 2003, NAT IMMUNOL, V4, P546, DOI 10.1038/ni932; Lee TS, 2002, NAT MED, V8, P240, DOI 10.1038/nm0302-240; Mahtani KR, 2001, MOL CELL BIOL, V21, P6461, DOI 10.1128/MCB.21.9.6461-6469.2001; Marine JC, 1999, CELL, V98, P617, DOI 10.1016/S0092-8674(00)80049-5; Moore KW, 2001, ANNU REV IMMUNOL, V19, P683, DOI 10.1146/annurev.immunol.19.1.683; Nakagawa R, 2002, IMMUNITY, V17, P677, DOI 10.1016/S1074-7613(02)00449-1; Narazaki M, 1998, P NATL ACAD SCI USA, V95, P13130, DOI 10.1073/pnas.95.22.13130; Niemand C, 2003, J IMMUNOL, V170, P3263, DOI 10.4049/jimmunol.170.6.3263; O'Farrell AM, 1998, EMBO J, V17, P1006, DOI 10.1093/emboj/17.4.1006; O'Farrell AM, 2000, J IMMUNOL, V164, P4607, DOI 10.4049/jimmunol.164.9.4607; O'Neill LAJ, 2002, CURR TOP MICROBIOL, V270, P47; Oberholzer A, 2001, SHOCK, V16, P83, DOI 10.1097/00024382-200116020-00001; Ohya K, 1997, J BIOL CHEM, V272, P27178, DOI 10.1074/jbc.272.43.27178; Okugawa S, 2003, AM J PHYSIOL-CELL PH, V285, pC399, DOI 10.1152/ajpcell.00026.2003; PENNLINE KJ, 1994, CLIN IMMUNOL IMMUNOP, V71, P169, DOI 10.1006/clin.1994.1068; Peraldi P, 2001, J BIOL CHEM, V276, P24614, DOI 10.1074/jbc.M102209200; RENNICK D, 1995, CLIN IMMUNOL IMMUNOP, V76, pS174, DOI 10.1016/S0090-1229(95)90144-2; Rennick DM, 1997, J LEUKOCYTE BIOL, V61, P389, DOI 10.1002/jlb.61.4.389; Riley JK, 1999, J BIOL CHEM, V274, P16513, DOI 10.1074/jbc.274.23.16513; Riley SG, 2002, AM J KIDNEY DIS, V39, P985, DOI 10.1053/ajkd.2002.32772; Sasaki A, 2000, J BIOL CHEM, V275, P29338, DOI 10.1074/jbc.M003456200; Sasaki A, 1999, GENES CELLS, V4, P339, DOI 10.1046/j.1365-2443.1999.00263.x; Schmitz J, 2000, J BIOL CHEM, V275, P12848, DOI 10.1074/jbc.275.17.12848; Schottelius AJG, 1999, J BIOL CHEM, V274, P31868, DOI 10.1074/jbc.274.45.31868; Shames BD, 1998, SHOCK, V10, P389, DOI 10.1097/00024382-199812000-00002; Sitko JC, 2004, J BIOL CHEM, V279, P37662, DOI 10.1074/jbc.M404007200; Stoiber D, 2001, J IMMUNOL, V166, P466, DOI 10.4049/jimmunol.166.1.466; Suhrbier A, 2003, TRENDS IMMUNOL, V24, P165, DOI 10.1016/S1471-4906(03)00065-6; Takeda K, 1999, IMMUNITY, V10, P39, DOI 10.1016/S1074-7613(00)80005-9; Takeda K, 1997, P NATL ACAD SCI USA, V94, P3801, DOI 10.1073/pnas.94.8.3801; Taylor PR, 2005, ANNU REV IMMUNOL, V23, P901, DOI 10.1146/annurev.immunol.23.021704.115816; Walker J M, 1994, Methods Mol Biol, V32, P5; WANG P, 1995, J BIOL CHEM, V270, P9558, DOI 10.1074/jbc.270.16.9558; Wessells J, 2004, J BIOL CHEM, V279, P49995, DOI 10.1074/jbc.M404246200; Williams L, 2004, J IMMUNOL, V172, P567, DOI 10.4049/jimmunol.172.1.567; Williams LM, 2004, IMMUNOLOGY, V113, P281, DOI 10.1111/j.1365-2567.2004.01988.x; Yasukawa H, 2000, ANNU REV IMMUNOL, V18, P143, DOI 10.1146/annurev.immunol.18.1.143; Yasukawa H, 2003, NAT IMMUNOL, V4, P551, DOI 10.1038/ni938; Zhang JG, 1999, P NATL ACAD SCI USA, V96, P2071, DOI 10.1073/pnas.96.5.2071	77	76	83	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 10	2006	281	10					6316	6324		10.1074/jbc.M508608200	http://dx.doi.org/10.1074/jbc.M508608200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	022BX	16352613	hybrid			2022-12-25	WOS:000236030800025
J	Andersson, FI; Blakytny, R; Kirstein, J; Turgay, K; Bukau, B; Mogk, A; Clarke, AK				Andersson, FI; Blakytny, R; Kirstein, J; Turgay, K; Bukau, B; Mogk, A; Clarke, AK			Cyanobacterial ClpC/HSP100 protein displays intrinsic chaperone activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEAT-SHOCK-PROTEIN; DEPENDENT CLP PROTEASE; ESCHERICHIA-COLI; MOLECULAR CHAPERONE; BACILLUS-SUBTILIS; STRESS TOLERANCE; LISTERIA-MONOCYTOGENES; ACTIVATED ATPASE; ADAPTER PROTEIN; HIGHER-PLANTS	HSP100 proteins are molecular chaperones that belong to the broader family of AAA+ proteins ( ATPases associated with a variety of cellular activities) known to promote protein unfolding, disassembly of protein complexes and translocation of proteins across membranes. The ClpC form of HSP100 is an essential, highly conserved, constitutively expressed protein in cyanobacteria and plant chloroplasts, and yet little is known regarding its specific activity as a molecular chaperone. To address this point, ClpC from the cyanobacterium Synechococcus elongatus (SyClpC) was purified using an Escherichia coli-based overexpression system. Recombinant SyClpC showed basal ATPase activity, similar to that of other types of HSP100 protein in non-photosynthetic organisms but different to ClpC in Bacillus subtilis. SyClpC also displayed distinct intrinsic chaperone activity in vitro, first by preventing aggregation of unfolded polypeptides and second by resolubilizing and refolding aggregated proteins into their native structures. The refolding activity of SyClpC was enhanced 3-fold in the presence of the B. subtilis ClpC adaptor protein MecA. Overall, the distinctive ClpC protein in photosynthetic organisms indeed functions as an independent molecular chaperone, and it is so far unique among HSP100 proteins in having both "holding" and disaggregase chaperone activities without the need of other chaperones or adaptor proteins.	Univ Gothenburg, Inst Bot, S-40530 Gothenburg, Sweden; Fachklin Hornheide, Dept Canc Res, D-48157 Munster, Germany; Free Univ Berlin, Inst Pflanzenphysiol & Mikrobiol, Fachbereich Biol, D-14195 Berlin, Germany; Heidelberg Univ, Zentrum Mol Biol, D-69120 Heidelberg, Germany	University of Gothenburg; Free University of Berlin; Ruprecht Karls University Heidelberg	Clarke, AK (corresponding author), Univ Gothenburg, Inst Bot, Box 461, S-40530 Gothenburg, Sweden.	adrian.clarke@botany.gu.se	Turgay, Kürsad/D-4828-2011; Turgay, Kürşad/Q-5285-2019	Turgay, Kürsad/0000-0002-8959-492X; Turgay, Kürşad/0000-0002-8959-492X; Bukau, Bernd/0000-0003-0521-7199; Kirstein, Janine/0000-0003-4990-2497				Beuron F, 1998, J STRUCT BIOL, V123, P248, DOI 10.1006/jsbi.1998.4039; Bochtler M, 2000, NATURE, V403, P800, DOI 10.1038/35001629; Bukau B, 1998, CELL, V92, P351, DOI 10.1016/S0092-8674(00)80928-9; Clarke AK, 1999, ANN BOT-LONDON, V83, P593, DOI 10.1006/anbo.1999.0878; Clarke AK, 2005, PHYSIOL PLANTARUM, V123, P406, DOI 10.1111/j.1399-3054.2005.00452.x; Clarke AK, 1996, PLANT MOL BIOL, V31, P721, DOI 10.1007/BF00019460; Clarke AK, 1998, PLANT MOL BIOL, V37, P791, DOI 10.1023/A:1006016302074; Dougan DA, 2002, MOL CELL, V9, P673, DOI 10.1016/S1097-2765(02)00485-9; DUBNAU D, 1990, J BACTERIOL, V172, P4048, DOI 10.1128/jb.172.7.4048-4055.1990; Feldman DE, 2000, CURR OPIN STRUC BIOL, V10, P26, DOI 10.1016/S0959-440X(99)00044-5; Glover JR, 1998, CELL, V94, P73, DOI 10.1016/S0092-8674(00)81223-4; Goloubinoff P, 1999, P NATL ACAD SCI USA, V96, P13732, DOI 10.1073/pnas.96.24.13732; Grimaud R, 1998, J BIOL CHEM, V273, P12476, DOI 10.1074/jbc.273.20.12476; Guo FS, 2002, J BIOL CHEM, V277, P46753, DOI 10.1074/jbc.M208104200; Hattendorf DA, 2002, EMBO J, V21, P12, DOI 10.1093/emboj/21.1.12; Hoskins JR, 1998, P NATL ACAD SCI USA, V95, P12135, DOI 10.1073/pnas.95.21.12135; Jarvis P, 2001, BBA-MOL CELL RES, V1541, P64, DOI 10.1016/S0167-4889(01)00147-1; Kaneko T, 1996, DNA Res, V3, P109; Kim KI, 1998, BIOCHEM J, V333, P671, DOI 10.1042/bj3330671; KRUGER E, 1994, J BACTERIOL, V176, P3360; LANZETTA PA, 1979, ANAL BIOCHEM, V100, P95, DOI 10.1016/0003-2697(79)90115-5; Lau GW, 2001, MOL MICROBIOL, V40, P555, DOI 10.1046/j.1365-2958.2001.02335.x; Lee S, 2003, CELL, V115, P229, DOI 10.1016/S0092-8674(03)00807-9; Levchenko I, 2000, SCIENCE, V289, P2354, DOI 10.1126/science.289.5488.2354; Lum R, 2004, J BIOL CHEM, V279, P29139, DOI 10.1074/jbc.M403777200; Lupas AN, 2003, J STRUCT BIOL, V141, P77, DOI 10.1016/S1047-8477(02)00582-8; Mogk A, 1999, EMBO J, V18, P6934, DOI 10.1093/emboj/18.24.6934; MSADEK T, 1994, P NATL ACAD SCI USA, V91, P5788, DOI 10.1073/pnas.91.13.5788; Muffler A, 1996, EMBO J, V15, P1333, DOI 10.1002/j.1460-2075.1996.tb00475.x; Nielsen E, 1997, EMBO J, V16, P935, DOI 10.1093/emboj/16.5.935; Nimura K, 2001, J BACTERIOL, V183, P1320, DOI 10.1128/JB.183.4.1320-1328.2001; PARSELL DA, 1994, NATURE, V372, P475, DOI 10.1038/372475a0; PARSELL DA, 1993, ANNU REV GENET, V27, P437, DOI 10.1146/annurev.ge.27.120193.002253; Persuh M, 1999, MOL MICROBIOL, V33, P886, DOI 10.1046/j.1365-2958.1999.01544.x; Persuh M, 2002, J BACTERIOL, V184, P2310, DOI 10.1128/JB.184.8.2310-2313.2002; RIGGS P, 1990, CURRENT PROTOCOLS MO, P1; Rouquette C, 1996, MOL MICROBIOL, V21, P977, DOI 10.1046/j.1365-2958.1996.641432.x; Rouquette C, 1998, MOL MICROBIOL, V27, P1235, DOI 10.1046/j.1365-2958.1998.00775.x; SANCHEZ Y, 1990, SCIENCE, V248, P1112, DOI 10.1126/science.2188365; Schirmer EC, 1996, TRENDS BIOCHEM SCI, V21, P289, DOI 10.1016/0968-0004(96)10038-4; Schirmer EC, 1998, J BIOL CHEM, V273, P15546, DOI 10.1074/jbc.273.25.15546; Schlothauer T, 2003, P NATL ACAD SCI USA, V100, P2306, DOI 10.1073/pnas.0535717100; SEOL JH, 1994, J BIOL CHEM, V269, P29468; Sjogren LLE, 2004, PLANT PHYSIOL, V136, P4114, DOI 10.1104/pp.104.053835; Sousa MC, 2000, CELL, V103, P633, DOI 10.1016/S0092-8674(00)00166-5; Turgay K, 1997, GENE DEV, V11, P119, DOI 10.1101/gad.11.1.119; Weibezahn J, 2003, J BIOL CHEM, V278, P32608, DOI 10.1074/jbc.M303653200; WICKNER S, 1994, P NATL ACAD SCI USA, V91, P12218, DOI 10.1073/pnas.91.25.12218; WOO KM, 1992, J BIOL CHEM, V267, P20429; Zeth K, 2002, NAT STRUCT BIOL, V9, P906, DOI 10.1038/nsb869; Zheng B, 2002, PHYSIOL PLANTARUM, V114, P92, DOI 10.1034/j.1399-3054.2002.1140113.x; Zolkiewski M, 1999, J BIOL CHEM, V274, P28083, DOI 10.1074/jbc.274.40.28083	52	39	39	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 3	2006	281	9					5468	5475		10.1074/jbc.M509661200	http://dx.doi.org/10.1074/jbc.M509661200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	015RQ	16361263	Green Submitted, hybrid			2022-12-25	WOS:000235568900019
J	Gong, QM; Jones, MA; Zhou, ZF				Gong, QM; Jones, MA; Zhou, ZF			Mechanisms of pharmacological rescue of trafficking-defective hERG mutant channels in human long QT syndrome	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN P-GLYCOPROTEIN; POTASSIUM CHANNEL; INTRACELLULAR-TRANSPORT; QUALITY-CONTROL; CALNEXIN INTERACTION; PROTEIN TRAFFICKING; CARDIAC-ARRHYTHMIA; WILD-TYPE; DOMAIN; MUTATIONS	Long QT syndrome type 2 is caused by mutations in the human ether-a-go-go-related gene (hERG). We previously reported that the N470D mutation is retained in the endoplasmic reticulum ( ER) but can be rescued to the plasma membrane by hERG channel blocker E-4031. The mechanisms of ER retention and how E-4031 rescues the N470D mutant are poorly understood. In this study, we investigated the interaction of hERG channels with the ER chaperone protein calnexin. Using coimmunoprecipitation, we showed that the immature forms of both wild type hERG and N470D associated with calnexin. The association required N-linked glycosylation of hERG channels. Pulse-chase analysis revealed that N470D had a prolonged association with calnexin compared with wild type hERG and E-4031 shortened the time course of calnexin association with N470D. To test whether the prolonged association of N470D with calnexin is due to defective folding of mutant channels, we studied hERG channel folding using the trypsin digestion method. We found that N470D and the immature form of wild type hERG were more sensitive to trypsin digestion than the mature form of wild type hERG. In the presence of E-4031, N470D became more resistant to trypsin even when its ER-to-Golgi transport was blocked by brefeldin A. These results suggest that defective folding of N470D contributes to its prolonged association with calnexin and ER retention and that E-4031 may restore proper folding of the N470D channel leading to its cell surface expression.	Oregon Hlth & Sci Univ, Div Cardiovasc Med, Dept Med, Portland, OR 97239 USA	Oregon Health & Science University	Zhou, ZF (corresponding author), Oregon Hlth & Sci Univ, Div Cardiovasc Med, Dept Med, NRC3,3181 SW Sam Jackson Pk Rd, Portland, OR 97239 USA.	zhouzh@ohsu.edu			NHLBI NIH HHS [R01 HL068854, HL68854] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL068854] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Andersson H, 1996, FEBS LETT, V397, P321, DOI 10.1016/S0014-5793(96)01207-0; Aridor M, 2000, TRAFFIC, V1, P836, DOI 10.1034/j.1600-0854.2000.011104.x; Bellocq C, 2004, MOL PHARMACOL, V66, P1093, DOI 10.1124/mol.104.001065; Bernier V, 2004, TRENDS ENDOCRIN MET, V15, P222, DOI 10.1016/j.tem.2004.05.003; Chugh SS, 2004, J AM COLL CARDIOL, V43, P1625, DOI 10.1016/j.jacc.2003.11.052; CURRAN ME, 1995, CELL, V80, P795, DOI 10.1016/0092-8674(95)90358-5; Delisle BP, 2004, CIRC RES, V94, P1418, DOI 10.1161/01.RES.0000128561.28701.ea; Deprez P, 2005, MOL CELL, V19, P183, DOI 10.1016/j.molcel.2005.05.029; Ellgaard L, 1999, SCIENCE, V286, P1882, DOI 10.1126/science.286.5446.1882; Ellgaard L, 2003, NAT REV MOL CELL BIO, V4, P181, DOI 10.1038/nrm1052; Ficker E, 2003, CIRC RES, V92, pE87, DOI 10.1161/01.RES.0000079028.31393.15; Ficker E, 2002, J BIOL CHEM, V277, P4989, DOI 10.1074/jbc.M107345200; Fodstad H, 2004, ANN MED, V36, P53, DOI 10.1080/17431380410032689; Gong QM, 2005, J BIOL CHEM, V280, P19419, DOI 10.1074/jbc.M502327200; Gong QM, 2004, J MOL CELL CARDIOL, V37, P1225, DOI 10.1016/j.yjmcc.2004.10.002; Gong QM, 2004, AM J PHYSIOL-HEART C, V287, pH652, DOI 10.1152/ajpheart.00052.2004; Gong QM, 2002, AM J PHYSIOL-HEART C, V283, pH77, DOI 10.1152/ajpheart.00008.2002; Higgins MK, 2003, BBA-BIOMEMBRANES, V1610, P124, DOI 10.1016/S0005-2736(02)00715-0; January CT, 2000, J CARDIOVASC ELECTR, V11, P1413, DOI 10.1046/j.1540-8167.2000.01413.x; Keating MT, 1996, SCIENCE, V272, P681, DOI 10.1126/science.272.5262.681; Khanna R, 2004, J CELL SCI, V117, P2897, DOI 10.1242/jcs.01141; Loo TW, 1998, J BIOL CHEM, V273, P14671, DOI 10.1074/jbc.273.24.14671; LOO TW, 1994, J BIOL CHEM, V269, P28683; Manganas LN, 2004, BIOCHEM BIOPH RES CO, V322, P577, DOI 10.1016/j.bbrc.2004.06.182; Manganas LN, 2001, J BIOL CHEM, V276, P49427, DOI 10.1074/jbc.M109325200; Morello JP, 2001, BIOCHEMISTRY-US, V40, P6766, DOI 10.1021/bi002699r; Nagaya N, 1999, RECEPTOR CHANNEL, V6, P229; Paulussen A, 2002, J BIOL CHEM, V277, P48610, DOI 10.1074/jbc.M206569200; PIND S, 1994, J BIOL CHEM, V269, P12784; Popov M, 1999, J BIOL CHEM, V274, P17635, DOI 10.1074/jbc.274.25.17635; Rossenbacker T, 2005, CIRCULATION, V111, P961, DOI 10.1161/01.CIR.0000156327.35255.D8; SANGUINETTI MC, 1995, CELL, V81, P299, DOI 10.1016/0092-8674(95)90340-2; Schulein R, 2004, REV PHYSIOL BIOCH P, V151, P45, DOI 10.1007/s10254-004-0022-8; Splawski I, 2000, CIRCULATION, V102, P1178, DOI 10.1161/01.CIR.102.10.1178; Tamarappoo BK, 1999, J BIOL CHEM, V274, P34825, DOI 10.1074/jbc.274.49.34825; TESTER DJ, 2005, HEART RHYTHM, V2; Thomas D, 2003, CARDIOVASC RES, V60, P235, DOI 10.1016/j.cardiores.2003.08.002; TRUDEAU MC, 1995, SCIENCE, V269, P92, DOI 10.1126/science.7604285; Zhang DC, 2000, BLOOD, V96, P2925; Zhang F, 1998, NAT STRUCT BIOL, V5, P180, DOI 10.1038/nsb0398-180; Zhou ZF, 1998, BIOPHYS J, V74, P230, DOI 10.1016/S0006-3495(98)77782-3; Zhou ZF, 1999, J BIOL CHEM, V274, P31123, DOI 10.1074/jbc.274.44.31123; Zhou ZF, 1998, J BIOL CHEM, V273, P21061, DOI 10.1074/jbc.273.33.21061	43	66	72	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 17	2006	281	7					4069	4074		10.1074/jbc.M511765200	http://dx.doi.org/10.1074/jbc.M511765200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	011NN	16361248	Green Accepted, hybrid			2022-12-25	WOS:000235275300036
J	Gregoire, S; Tremblay, AM; Xiao, L; Yang, Q; Ma, KW; Nie, JY; Mao, ZX; Wu, ZG; Giguere, V; Yang, XJ				Gregoire, S; Tremblay, AM; Xiao, L; Yang, Q; Ma, KW; Nie, JY; Mao, ZX; Wu, ZG; Giguere, V; Yang, XJ			Control of MEF2 transcriptional activity by coordinated phosphorylation and sumoylation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MYOCYTE-ENHANCER FACTOR-2; ACTIVATED PROTEIN-KINASE; DNA-BINDING ACTIVITY; HISTONE DEACETYLASES; SUMO-1 MODIFICATION; MADS-BOX; CALCINEURIN; P300; REPRESSES; APOPTOSIS	A eukaryotic protein is often subject to regulation by multiple modifications like phosphorylation, acetylation, ubiquitination, and sumoylation. How these modifications are coordinated in vivo is an important issue that is poorly understood but is relevant to many biological processes. We recently showed that human MEF2D (myocyte enhancer factor 2D) is sumoylated on Lys-439. Adjacent to the sumoylation motif is Ser-444, which like Lys-439 is highly conserved among MEF2 proteins from diverse species. Here we presented several lines of evidence to demonstrate that Ser-444 of MEF2D is required for sumoylation of Lys-439. Histone deacetylase 4 (HDAC4) stimulated this modification by acting through Ser-444. In addition, phosphorylation of Ser-444 by Cdk5, a cyclin-dependent kinase known to inhibit MEF2 transcriptional activity, stimulated sumoylation. Opposing the actions of HDAC4 and Cdk5, calcineurin (also known as protein phosphatase 2B) dephosphorylated Ser-444 and inhibited sumoylation of Lys-439. This phosphatase, however, exerted minimal effects on the phosphorylation catalyzed by ERK5, an extracellular signal-regulated kinase known to activate MEF2D. These results identified an essential role for Ser-444 in MEF2D sumoylation and revealed a novel mechanism by which calcineurin selectively "edits" phosphorylation at different sites, thereby reiterating that interplay between different modifications represents a general mechanism for coordinated regulation of eukaryotic protein functions in vivo.	MUHC, RVH, Mol Oncol Grp, Dept Med, Montreal, PQ H3A 1A1, Canada; Emory Univ, Sch Med, Dept Pharmacol, Atlanta, GA 30322 USA; Emory Univ, Sch Med, Dept Neurol, Atlanta, GA 30322 USA; Hong Kong Univ Sci & Technol, Dept Biochem, Kowloon, Hong Kong, Peoples R China	McGill University; Royal Victoria Hospital; Emory University; Emory University; Hong Kong University of Science & Technology	Yang, XJ (corresponding author), MUHC, RVH, Mol Oncol Grp, Dept Med, Rm H5-41,687 Pine Ave W, Montreal, PQ H3A 1A1, Canada.	xiang-jiao.yang@mcgill.ca		Giguere, Vincent/0000-0001-9567-3694				Bach S, 2005, J BIOL CHEM, V280, P31208, DOI 10.1074/jbc.M500806200; Bernier-Villamor V, 2002, CELL, V108, P345, DOI 10.1016/S0092-8674(02)00630-X; Bi WZ, 1999, DEV BIOL, V211, P255, DOI 10.1006/dbio.1999.9307; Bossis G, 2005, MOL CELL BIOL, V25, P6964, DOI 10.1128/MCB.25.16.6964-6979.2005; Bouras T, 2005, J BIOL CHEM, V280, P10264, DOI 10.1074/jbc.M408748200; Champagne N, 1999, J BIOL CHEM, V274, P28528, DOI 10.1074/jbc.274.40.28528; Chen SL, 2002, J BIOL CHEM, V277, P4324, DOI 10.1074/jbc.M109835200; Chin ER, 1998, GENE DEV, V12, P2499, DOI 10.1101/gad.12.16.2499; Clarke N, 1998, MOL CELL BIOL, V18, P1065, DOI 10.1128/MCB.18.2.1065; Cox DM, 2003, J BIOL CHEM, V278, P15297, DOI 10.1074/jbc.M211312200; De Angelis L, 1998, P NATL ACAD SCI USA, V95, P12358, DOI 10.1073/pnas.95.21.12358; Dequiedt F, 2003, IMMUNITY, V18, P687, DOI 10.1016/S1074-7613(03)00109-2; Desterro JMP, 1998, MOL CELL, V2, P233, DOI 10.1016/S1097-2765(00)80133-1; Dhavan R, 2001, NAT REV MOL CELL BIO, V2, P749, DOI 10.1038/35096019; Doble BW, 2003, J CELL SCI, V116, P1175, DOI 10.1242/jcs.00384; Fischle W, 2003, NATURE, V425, P475, DOI 10.1038/nature02017; Gill G, 2005, CURR OPIN GENET DEV, V15, P536, DOI 10.1016/j.gde.2005.07.004; Girdwood D, 2003, MOL CELL, V11, P1043, DOI 10.1016/S1097-2765(03)00141-2; Girdwood DWH, 2004, SEMIN CELL DEV BIOL, V15, P201, DOI 10.1016/j.semcdb.2003.12.001; Gong XM, 2003, NEURON, V38, P33, DOI 10.1016/S0896-6273(03)00191-0; Gregoire S, 2005, MOL CELL BIOL, V25, P2273, DOI 10.1128/MCB.25.6.2273-2287.2005; Han J, 1997, NATURE, V386, P296, DOI 10.1038/386296a0; Han JH, 2000, TRENDS CARDIOVAS MED, V10, P19, DOI 10.1016/S1050-1738(00)00039-6; HAN TH, 1995, MOL CELL BIOL, V15, P2907; Hay RT, 2005, MOL CELL, V18, P1, DOI 10.1016/j.molcel.2005.03.012; Heidenreich KA, 2004, MOL NEUROBIOL, V29, P155, DOI 10.1385/MN:29:2:155; Hietakangas V, 2003, MOL CELL BIOL, V23, P2953, DOI 10.1128/MCB.23.8.2953-2968.2003; Ishov AM, 1999, J CELL BIOL, V147, P221, DOI 10.1083/jcb.147.2.221; Johnson ES, 2004, ANNU REV BIOCHEM, V73, P355, DOI 10.1146/annurev.biochem.73.011303.074118; Kasler HG, 2000, MOL CELL BIOL, V20, P8382, DOI 10.1128/MCB.20.22.8382-8389.2000; Kato Y, 2000, J BIOL CHEM, V275, P18534, DOI 10.1074/jbc.M001573200; Kato Y, 1997, EMBO J, V16, P7054, DOI 10.1093/emboj/16.23.7054; Lemercier C, 2000, J BIOL CHEM, V275, P15594, DOI 10.1074/jbc.M908437199; Li MT, 2001, J NEUROSCI, V21, P6544, DOI 10.1523/JNEUROSCI.21-17-06544.2001; Lin Q, 1997, SCIENCE, V276, P1404, DOI 10.1126/science.276.5317.1404; Linseman DA, 2003, J NEUROCHEM, V85, P1488, DOI 10.1046/j.1471-4159.2003.09799.x; Liu SF, 1997, EMBO J, V16, P143, DOI 10.1093/emboj/16.1.143; Long JY, 2005, J BIOL CHEM, V280, P35477, DOI 10.1074/jbc.M504477200; Lu JR, 2000, MOL CELL, V6, P233, DOI 10.1016/S1097-2765(00)00025-3; Lund AH, 2002, NAT GENET, V32, P160, DOI 10.1038/ng956; Lynch J, 2005, J CELL BIOL, V170, P37, DOI 10.1083/jcb.200412156; Ma KW, 2005, MOL CELL BIOL, V25, P3575, DOI 10.1128/MCB.25.9.3575-3582.2005; Mao ZX, 1999, J BIOL CHEM, V274, P31102, DOI 10.1074/jbc.274.43.31102; Mao ZX, 1999, SCIENCE, V286, P785, DOI 10.1126/science.286.5440.785; McKinsey TA, 2002, TRENDS BIOCHEM SCI, V27, P40, DOI 10.1016/S0968-0004(01)02031-X; Miska EA, 1999, EMBO J, V18, P5099, DOI 10.1093/emboj/18.18.5099; Molkentin JD, 1996, J BIOL CHEM, V271, P17199, DOI 10.1074/jbc.271.29.17199; Naya FJ, 2002, NAT MED, V8, P1303, DOI 10.1038/nm789; Okamoto S, 2002, P NATL ACAD SCI USA, V99, P3974, DOI 10.1073/pnas.022036399; Prima V, 2005, LEUKEMIA, V19, P806, DOI 10.1038/sj.leu.2403684; Puri PL, 1997, MOL CELL, V1, P35, DOI 10.1016/S1097-2765(00)80005-2; Ross S, 2002, MOL CELL, V10, P831, DOI 10.1016/S1097-2765(02)00682-2; Sachdev S, 2001, GENE DEV, V15, P3088, DOI 10.1101/gad.944801; Sartorelli V, 1997, MOL CELL BIOL, V17, P1010, DOI 10.1128/MCB.17.2.1010; Sparrow DB, 1999, EMBO J, V18, P5085, DOI 10.1093/emboj/18.18.5085; Suzuki T, 2002, NAT GENET, V32, P166, DOI 10.1038/ng949; Tang XL, 2005, J NEUROSCI, V25, P4823, DOI 10.1523/JNEUROSCI.1331-05.2005; Tatham MH, 2001, J BIOL CHEM, V276, P35368, DOI 10.1074/jbc.M104214200; Verger A, 2003, EMBO REP, V4, P137, DOI 10.1038/sj.embor.embor738; Wang AH, 1999, MOL CELL BIOL, V19, P7816; Wang LJ, 2003, SCIENCE, V302, P1578, DOI 10.1126/science.1088477; Wang XM, 2005, J BIOL CHEM, V280, P16705, DOI 10.1074/jbc.M501819200; Wu H, 2001, EMBO J, V20, P6414, DOI 10.1093/emboj/20.22.6414; Wu XY, 2001, J BIOL CHEM, V276, P24177, DOI 10.1074/jbc.M100412200; Xu Q, 2002, MOL BIOL CELL, V13, P1940, DOI 10.1091/mbc.02-02-0016; Yamashita D, 2004, GENES CELLS, V9, P1017, DOI 10.1111/j.1365-2443.2004.00786.x; Yang CC, 1998, NUCLEIC ACIDS RES, V26, P4771, DOI 10.1093/nar/26.20.4771; Yang SH, 2004, MOL CELL, V13, P611, DOI 10.1016/S1097-2765(04)00060-7; Yang XJ, 2005, MOL CELL BIOL, V25, P2873, DOI 10.1128/MCB.25.8.2873-2884.2005; Yang XJ, 2005, ONCOGENE, V24, P1653, DOI 10.1038/sj.onc.1208173; Youn HD, 2000, EMBO J, V19, P4323, DOI 10.1093/emboj/19.16.4323; Youn HD, 1999, SCIENCE, V286, P790, DOI 10.1126/science.286.5440.790; Youn HD, 2000, IMMUNITY, V13, P85, DOI 10.1016/S1074-7613(00)00010-8; Yuki Y, 2004, CANCER SCI, V95, P503, DOI 10.1111/j.1349-7006.2004.tb03240.x; Zhang Y, 2001, GENE DEV, V15, P2343, DOI 10.1101/gad.927301; Zhao M, 1999, MOL CELL BIOL, V19, P21; Zhao X, 2005, MOL CELL BIOL, V25, P8456, DOI 10.1128/MCB.25.19.8456-8464.2005; Zhou XB, 2000, P NATL ACAD SCI USA, V97, P1056, DOI 10.1073/pnas.97.3.1056; Zhu BM, 2005, J BIOL CHEM, V280, P28749, DOI 10.1074/jbc.M502491200; Zhu BM, 2004, MOL CELL BIOL, V24, P8264, DOI 10.1128/MCB.24.18.8264-8275.2004	80	130	134	0	23	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 17	2006	281	7					4423	4433		10.1074/jbc.M509471200	http://dx.doi.org/10.1074/jbc.M509471200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	011NN	16356933	hybrid			2022-12-25	WOS:000235275300078
J	Eckelman, BP; Salvesen, GS				Eckelman, BP; Salvesen, GS			The human anti-apoptotic proteins cIAP1 and cIAP2 bind but do not inhibit caspases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STRUCTURAL BASIS; BIR DOMAIN; SIGNALING COMPLEX; NMR STRUCTURE; CYTOCHROME-C; CELL-DEATH; XIAP; IAP; SMAC; SURVIVIN	cIAPs (cellular inhibitor of apoptosis proteins) 1 and 2 are able to regulate apoptosis when ectopically expressed in recipient cells and probably also in vivo. Previous work suggested that this is at least partially due to direct caspase inhibition, mediated by two of the three baculovirus IAP repeat (BIR) domains that are contained in these proteins. In support of this we show that the BIR domains 2 and 3 of the two cIAPs are able to bind caspases-7 and -9. However, we demonstrate that neither of these BIR domains is able to inhibit caspases because of critical substitutions in the regions that target caspase inhibition in the X-linked IAP, a tight binding caspase inhibitor. The cIAP BIR domains can be converted to tight binding caspase inhibitors by substituting these critical residues with XIAP residues. Thus, cIAPs maintain protein scaffolds suitable for direct caspase inhibition but have lost or never acquired specific caspase inhibitory interaction sites. Consequently, although the binding function of the cIAP BIRs may be important for their physiologic function, caspase inhibition is not.	Univ Calif San Diego, Program Cell Death & Apoptosis Res, Burnham Inst Med Res, La Jolla, CA 92037 USA; Univ Calif San Diego, Program Cell Death & Apoptosis Res, Grad Program Mol Pathol, La Jolla, CA 92037 USA	Sanford Burnham Prebys Medical Discovery Institute; University of California System; University of California San Diego; University of California System; University of California San Diego	Salvesen, GS (corresponding author), Univ Calif San Diego, Program Cell Death & Apoptosis Res, Burnham Inst Med Res, La Jolla, CA 92037 USA.	gsalvesen@burnham.org			NCI NIH HHS [2T32CA77109] Funding Source: Medline; NIA NIH HHS [AG15402] Funding Source: Medline; NATIONAL CANCER INSTITUTE [T32CA077109] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG015402] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Banks DP, 2000, BLOOD, V96, P4002, DOI 10.1182/blood.V96.12.4002.h8004000c_4002_4003; Bartke T, 2004, MOL CELL, V14, P801, DOI 10.1016/j.molcel.2004.05.018; Chai JJ, 2001, CELL, V104, P769, DOI 10.1016/S0092-8674(02)02034-2; Chu ZL, 1997, P NATL ACAD SCI USA, V94, P10057, DOI 10.1073/pnas.94.19.10057; Clem RJ, 2001, J BIOL CHEM, V276, P7602, DOI 10.1074/jbc.M010259200; Conway EM, 2000, BLOOD, V95, P1435, DOI 10.1182/blood.V95.4.1435.004k01_1435_1442; Davoodi J, 2004, J BIOL CHEM, V279, P40622, DOI 10.1074/jbc.M405963200; Deveraux QL, 1999, GENE DEV, V13, P239, DOI 10.1101/gad.13.3.239; Deveraux QL, 1999, EMBO J, V18, P5242, DOI 10.1093/emboj/18.19.5242; Deveraux QL, 1998, EMBO J, V17, P2215, DOI 10.1093/emboj/17.8.2215; Dohi T, 2004, J BIOL CHEM, V279, P34087, DOI 10.1074/jbc.C400236200; Duckett Colin S, 2005, Biochem J, V385, pe1; Fuentes-Prior P, 2004, BIOCHEM J, V384, P201, DOI 10.1042/BJ20041142; Huang HK, 2000, J BIOL CHEM, V275, P26661; Huang YH, 2003, J BIOL CHEM, V278, P49517, DOI 10.1074/jbc.M310061200; Huang YH, 2001, CELL, V104, P781, DOI 10.1016/S0092-8674(01)00273-2; Li P, 1997, CELL, V91, P479, DOI 10.1016/S0092-8674(00)80434-1; Liston P, 2003, ONCOGENE, V22, P8568, DOI 10.1038/sj.onc.1207101; Maier JKX, 2002, J NEUROSCI, V22, P2035, DOI 10.1523/JNEUROSCI.22-06-02035.2002; Orth R, 1997, J BIOL CHEM, V272, P8841; Renatus M, 2001, P NATL ACAD SCI USA, V98, P14250, DOI 10.1073/pnas.231465798; Riedl SJ, 2001, CELL, V104, P791, DOI 10.1016/S0092-8674(02)02036-6; Rothe M, 1995, CELL, V83, P1243, DOI 10.1016/0092-8674(95)90149-3; Roy N, 1997, EMBO J, V16, P6914, DOI 10.1093/emboj/16.23.6914; Salvesen GS, 2002, NAT REV MOL CELL BIO, V3, P401, DOI 10.1038/nrm830; Samuel T, 2006, J BIOL CHEM, V281, P1080, DOI 10.1074/jbc.M509381200; Scott FL, 2005, EMBO J, V24, P645, DOI 10.1038/sj.emboj.7600544; Shin H, 2005, BIOCHEM J, V385, P1, DOI 10.1042/BJ20041107; Shin S, 2001, BIOCHEMISTRY-US, V40, P1117, DOI 10.1021/bi001603q; Shiozaki EN, 2003, MOL CELL, V11, P519, DOI 10.1016/S1097-2765(03)00054-6; Shu HB, 1996, P NATL ACAD SCI USA, V93, P13973, DOI 10.1073/pnas.93.24.13973; Simons M, 1999, J NEUROCHEM, V72, P292, DOI 10.1046/j.1471-4159.1999.0720292.x; Srinivasula SM, 2001, NATURE, V410, P112, DOI 10.1038/35065125; Stennicke HR, 1999, J BIOL CHEM, V274, P8359, DOI 10.1074/jbc.274.13.8359; Stennicke HR, 1999, METHODS, V17, P313, DOI 10.1006/meth.1999.0745; Sun CH, 2000, J BIOL CHEM, V275, P33777, DOI 10.1074/jbc.M006226200; Sun CH, 1999, NATURE, V401, P818, DOI 10.1038/44617; Tenev T, 2005, NAT CELL BIOL, V7, P70, DOI 10.1038/ncb1204; Uren AG, 1998, TRENDS BIOCHEM SCI, V23, P159, DOI 10.1016/S0968-0004(98)01198-0; Uren AG, 1996, P NATL ACAD SCI USA, V93, P4974, DOI 10.1073/pnas.93.10.4974; Vaux DL, 2005, NAT REV MOL CELL BIO, V6, P287, DOI 10.1038/nrm1621; Verhagen AM, 2001, GENOME BIOL, V2; Vucic D, 2005, BIOCHEM J, V385, P11, DOI 10.1042/BJ20041108; Vucic D, 2002, J BIOL CHEM, V277, P12275, DOI 10.1074/jbc.M112045200; Zou H, 2003, J BIOL CHEM, V278, P8091, DOI 10.1074/jbc.M204783200	45	274	291	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 10	2006	281	6					3254	3260		10.1074/jbc.M510863200	http://dx.doi.org/10.1074/jbc.M510863200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	009QV	16339151	hybrid			2022-12-25	WOS:000235128200030
J	Ferguson, AD; Labunskyy, VM; Fomenko, DE; Arac, D; Chelliah, Y; Amezcua, CA; Rizo, J; Gladyshev, VN; Deisenhofer, J				Ferguson, AD; Labunskyy, VM; Fomenko, DE; Arac, D; Chelliah, Y; Amezcua, CA; Rizo, J; Gladyshev, VN; Deisenhofer, J			NMR structures of the selenoproteins Sep15 and SelM reveal redox activity of a new thioredoxin-like family	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN DISULFIDE-ISOMERASE; ENDOPLASMIC-RETICULUM; GLYCOPROTEIN GLUCOSYLTRANSFERASE; FUNCTIONAL-CHARACTERIZATION; MAMMALIAN SELENOPROTEIN; SPERM MATURATION; UDP-GLUCOSE; SELENIUM; SEQUENCE; DOMAIN	Selenium has significant health benefits, including potent cancer prevention activity and roles in immune function and the male reproductive system. Selenium- containing proteins, which incorporate this essential micronutrient as selenocysteine, are proposed to mediate the positive effects of dietary selenium. Presented here are the solution NMR structures of the selenoprotein SelM and an ortholog of the selenoprotein Sep15. These data reveal that Sep15 and SelM are structural homologs that establish a new thioredoxinlike protein family. The location of the active-site redox motifs within the fold together with the observed localized conformational changes after thiol-disulfide exchange and measured redox potential indicate that they have redox activity. In mammals, Sep15 expression is regulated by dietary selenium, and either decreased or increased expression of this selenoprotein alters redox homeostasis. A physiological role for Sep15 and SelM as thiol- disulfide oxidoreductases and their contribution to the quality control pathways of the endoplasmic reticulum are discussed.	Univ Texas, SW Med Ctr, Dept Biochem, Dallas, TX 75390 USA; Univ Texas, SW Med Ctr, Howard Hughes Med Inst, Dallas, TX 75390 USA; Univ Texas, SW Med Ctr, Dept Pharmacol, Dallas, TX 75390 USA; Univ Nebraska, Dept Biochem, Lincoln, NE 68588 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; Howard Hughes Medical Institute; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Nebraska System; University of Nebraska Lincoln	Deisenhofer, J (corresponding author), Univ Texas, SW Med Ctr, Dept Biochem, Dallas, TX 75390 USA.	Johann.Deisenhofer@utsouthwestern.edu	Labunskyy, Vyacheslav/AAC-8489-2020; Gladyshev, Vadim N/J-6187-2013; Gladyshev, Vadim N/A-9894-2013	Gladyshev, Vadim/0000-0002-0372-7016; Labunskyy, Vyacheslav/0000-0001-9317-1076	NCI NIH HHS [CA080946] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA080946] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Alanen HI, 2003, J BIOL CHEM, V278, P28912, DOI 10.1074/jbc.M304598200; Anelli T, 2002, EMBO J, V21, P835, DOI 10.1093/emboj/21.4.835; Aslund F, 1997, J BIOL CHEM, V272, P30780, DOI 10.1074/jbc.272.49.30780; BEHNE D, 1988, BIOCHIM BIOPHYS ACTA, V966, P12, DOI 10.1016/0304-4165(88)90123-7; Brockmann C, 2004, STRUCTURE, V12, P1645, DOI 10.1016/j.str.2004.06.021; Chou JJ, 2001, J BIOMOL NMR, V21, P377, DOI 10.1023/A:1013336502594; Clark LC, 1996, JAMA-J AM MED ASSOC, V276, P1957, DOI 10.1001/jama.276.24.1957; Cornilescu G, 1999, J BIOMOL NMR, V13, P289, DOI 10.1023/A:1008392405740; DELAGLIO F, 1995, J BIOMOL NMR, V6, P277, DOI 10.1007/BF00197809; Delano W.L, 2002, PYMOL USERS MANUAL; Dyson HJ, 1997, BIOCHEMISTRY-US, V36, P2622, DOI 10.1021/bi961801a; Ellgaard L, 2005, EMBO REP, V6, P28, DOI 10.1038/sj.embor.7400311; Ellgaard L, 2003, NAT REV MOL CELL BIO, V4, P181, DOI 10.1038/nrm1052; Farmer BT, 1996, NAT STRUCT BIOL, V3, P995, DOI 10.1038/nsb1296-995; Fomenko DE, 2003, BIOCHEMISTRY-US, V42, P11214, DOI 10.1021/bi034459s; Frickel EM, 2002, P NATL ACAD SCI USA, V99, P1954, DOI 10.1073/pnas.042699099; Gladyshev VN, 1998, J BIOL CHEM, V273, P8910, DOI 10.1074/jbc.273.15.8910; Gromer S, 2003, P NATL ACAD SCI USA, V100, P12618, DOI 10.1073/pnas.2134510100; Habeck Michael, 2004, Methods Mol Biol, V278, P379; HILL KE, 1992, BIOCHEM BIOPH RES CO, V185, P260, DOI 10.1016/S0006-291X(05)80984-2; Holm L, 1998, NUCLEIC ACIDS RES, V26, P316, DOI 10.1093/nar/26.1.316; Holm L, 2000, BIOINFORMATICS, V16, P566, DOI 10.1093/bioinformatics/16.6.566; HOLMGREN A, 1995, STRUCTURE, V3, P239, DOI 10.1016/S0969-2126(01)00153-8; Huber-Wunderlich M, 1998, FOLD DES, V3, P161, DOI 10.1016/S1359-0278(98)00024-8; Inaba K, 2002, EMBO J, V21, P2646, DOI 10.1093/emboj/21.11.2646; Ip C, 2002, CANCER METAST REV, V21, P281, DOI 10.1023/A:1021263027659; Johnson Bruce A, 2004, Methods Mol Biol, V278, P313; Kemmink J, 1996, BIOCHEMISTRY-US, V35, P7684, DOI 10.1021/bi960335m; Koradi R, 1996, J MOL GRAPHICS, V14, P51, DOI 10.1016/0263-7855(96)00009-4; Korotkov KV, 2002, MOL CELL BIOL, V22, P1402, DOI 10.1128/MCB.22.5.1402-1411.2002; Korotkov KV, 2001, J BIOL CHEM, V276, P15330, DOI 10.1074/jbc.M009861200; Kryukov GV, 2004, EMBO REP, V5, P538, DOI 10.1038/sj.embor.7400126; Kryukov GV, 2003, SCIENCE, V300, P1439, DOI 10.1126/science.1083516; Labunskyy VM, 2005, J BIOL CHEM, V280, P37839, DOI 10.1074/jbc.M508685200; Lappi AK, 2004, J MOL BIOL, V335, P283, DOI 10.1016/j.jmb.2003.10.051; Laskowski RA, 1996, J BIOMOL NMR, V8, P477, DOI 10.1007/BF00228148; LUNDSTROM J, 1993, BIOCHEMISTRY-US, V32, P6649, DOI 10.1021/bi00077a018; MARTIN JL, 1995, STRUCTURE, V3, P245, DOI 10.1016/S0969-2126(01)00154-X; Martin-Romero FJ, 2001, J BIOL CHEM, V276, P29798, DOI 10.1074/jbc.M100422200; Meunier L, 2002, MOL BIOL CELL, V13, P4456, DOI 10.1091/mbc.E02-05-0311; Mossner E, 1998, PROTEIN SCI, V7, P1233; NERI D, 1989, BIOCHEMISTRY-US, V28, P7510, DOI 10.1021/bi00445a003; Poirot O, 2004, NUCLEIC ACIDS RES, V32, pW37, DOI 10.1093/nar/gkh382; Pollock S, 2004, EMBO J, V23, P1020, DOI 10.1038/sj.emboj.7600119; Qi Y, 2005, PROTEINS, V58, P376, DOI 10.1002/prot.20329; SAARINEN M, 1995, STRUCTURE, V3, P1097, DOI 10.1016/S0969-2126(01)00245-3; Sevier CS, 2002, NAT REV MOL CELL BIO, V3, P836, DOI 10.1038/nrm954; Stadtman TC, 1996, ANNU REV BIOCHEM, V65, P83, DOI 10.1146/annurev.bi.65.070196.000503; Su D, 2005, J BIOL CHEM, V280, P26491, DOI 10.1074/jbc.M503638200; Su D, 2004, BIOCHEMISTRY-US, V43, P12177, DOI 10.1021/bi048478t; Ursini F, 1999, SCIENCE, V285, P1393, DOI 10.1126/science.285.5432.1393; Weichsel A, 1996, STRUCTURE, V4, P735, DOI 10.1016/S0969-2126(96)00079-2; Zapun A, 1998, J BIOL CHEM, V273, P6009, DOI 10.1074/jbc.273.11.6009; Zhang ZH, 1997, BIOL TRACE ELEM RES, V57, P147, DOI 10.1007/BF02778198; Zweckstetter M, 2000, J AM CHEM SOC, V122, P3791, DOI 10.1021/ja0000908	55	153	159	2	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 10	2006	281	6					3536	3543		10.1074/jbc.M511386200	http://dx.doi.org/10.1074/jbc.M511386200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	009QV	16319061	hybrid, Green Published			2022-12-25	WOS:000235128200064
J	Lee, CH; Kim, HJ; Lee, JH; Cho, HJ; Kim, J; Chung, KC; Jung, S; Paik, SR				Lee, CH; Kim, HJ; Lee, JH; Cho, HJ; Kim, J; Chung, KC; Jung, S; Paik, SR			Dequalinium-induced protofibril formation of alpha-synuclein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							A-BETA COMPONENT; PROTEIN-KINASE-C; PARKINSONS-DISEASE; ALZHEIMERS-DISEASE; IN-VITRO; INHIBITS FIBRILLATION; SELF-OLIGOMERIZATION; PRECURSOR PROTEIN; AMYLOID FORMATION; LEWY BODIES	alpha- Synuclein is the major constituent of Lewy bodies, a pathological signature of Parkinson disease, found in the degenerating dopaminergic neurons of the substantia nigra pars compacta. Amyloidosis generating the insoluble fibrillar protein deposition has been considered to be responsible for the cell death observed in the neurodegenerative disorder. In order to develop a controlling strategy toward the amyloid formation, 1,1 -( 1,10- decanediyl)- bis-[ 4- amino2- methylquinolinium] ( dequalinium), was selected and examined in terms of its specific molecular interaction with alpha- synuclein. The protein was self- oligomerized by dequalinium, which gave rise to the ladder formation on N-[ 2- hydroxy- 1,1bis( hydroxymethyl) ethyl] glycine/ SDS- PAGE in the presence of a coupling reagent of N-( ethoxycarbonyl)- 2- ethoxy- 1,2- dihydroquinoline. The double- headed structure of dequalinium with the two cationic 4- aminoquinaldinium rings was demonstrated to be critical for the protein self- oligomerization. The dequalinium-binding site was located on the acidic C- terminal region of the protein with an approximate dissociation constant of 5.5 mu M. The protein self- oligomerization induced by the compound has resulted in the protofibril formation of alpha- synuclein before it has developed into amyloids. The protofibrils were demonstrated to affect the membrane intactness of liposomes, and they have also been shown to influence cell viability of human neuroblastoma cells. In addition, dequalinium treatment of the alpha- synuclein- overexpressing cells exerted a significant cell death. Therefore, it is pertinent to consider that dequalinium could be used as amolecular probe to assess toxic mechanisms related to the amyloid formation of alpha- synuclein. Ultimately, the compound could be employed to develop therapeutic and preventive strategies toward alpha- synucleinopathies including Parkinson disease.	Seoul Natl Univ, Sch Chem & Biol Engn, Coll Engn, Seoul 151744, South Korea; Inha Univ, Dept Biochem, Coll Med, Inchon 402751, South Korea; Yonsei Univ, Dept Microbiol, Coll Med, Seoul 120752, South Korea; Yonsei Univ, Dept Biol, Coll Sci, Seoul 120752, South Korea; Konkuk Univ, Dept Microbial Engn, Seoul 143701, South Korea; Konkuk Univ, Biomol Binformat Ctr, Seoul 143701, South Korea	Seoul National University (SNU); Inha University; Yonsei University; Yonsei University Health System; Yonsei University; Konkuk University; Konkuk University	Paik, SR (corresponding author), Seoul Natl Univ, Sch Chem & Biol Engn, Coll Engn, San 56-1, Seoul 151744, South Korea.	srpaik@snu.ac.kr		Kim, Jongsun/0000-0002-3149-669X				Bernstein SL, 2004, J AM SOC MASS SPECTR, V15, P1435, DOI 10.1016/j.jasms.2004.05.003; Betarbet R, 2000, NAT NEUROSCI, V3, P1301, DOI 10.1038/81834; BODDEN WL, 1986, BIOCHEM BIOPH RES CO, V135, P574, DOI 10.1016/0006-291X(86)90032-X; Caughey B, 2003, ANNU REV NEUROSCI, V26, P267, DOI 10.1146/annurev.neuro.26.010302.081142; Chesebro B, 2005, SCIENCE, V308, P1435, DOI 10.1126/science.1110837; Clayton DF, 1999, J NEUROSCI RES, V58, P120, DOI 10.1002/(SICI)1097-4547(19991001)58:1<120::AID-JNR12>3.3.CO;2-5; Clayton DF, 1998, TRENDS NEUROSCI, V21, P249, DOI 10.1016/S0166-2236(97)01213-7; Conway KA, 2000, BIOCHEMISTRY-US, V39, P2552, DOI 10.1021/bi991447r; Conway KA, 1998, NAT MED, V4, P1318, DOI 10.1038/3311; Davidson WS, 1998, J BIOL CHEM, V273, P9443, DOI 10.1074/jbc.273.16.9443; Dickson DW, 2001, CURR OPIN NEUROL, V14, P423, DOI 10.1097/00019052-200108000-00001; Eliezer D, 2001, J MOL BIOL, V307, P1061, DOI 10.1006/jmbi.2001.4538; Feany MB, 2000, NATURE, V404, P394, DOI 10.1038/35006074; Forno LS, 1996, J NEUROPATH EXP NEUR, V55, P259, DOI 10.1097/00005072-199603000-00001; Gai WP, 2000, EXP NEUROL, V166, P324, DOI 10.1006/exnr.2000.7527; Giasson BI, 1999, J BIOL CHEM, V274, P7619, DOI 10.1074/jbc.274.12.7619; Goedert M, 1998, CURR OPIN NEUROBIOL, V8, P619, DOI 10.1016/S0959-4388(98)80090-1; Goldberg MS, 2000, NAT CELL BIOL, V2, pE115, DOI 10.1038/35017124; HAN HY, 1995, CHEM BIOL, V2, P163, DOI 10.1016/1074-5521(95)90071-3; HANSEN MB, 1989, J IMMUNOL METHODS, V119, P203, DOI 10.1016/0022-1759(89)90397-9; Hashimoto M, 1998, BRAIN RES, V799, P301, DOI 10.1016/S0006-8993(98)00514-9; IWAI A, 1995, BIOCHEMISTRY-US, V34, P10139, DOI 10.1021/bi00032a006; JAKES R, 1994, FEBS LETT, V345, P27, DOI 10.1016/0014-5793(94)00395-5; Kim J, 1997, MOL CELLS, V7, P78; Kim YS, 2001, BRAIN RES, V908, P93, DOI 10.1016/S0006-8993(01)02575-6; Kruger R, 1998, NAT GENET, V18, P106, DOI 10.1038/ng0298-106; Lacor PN, 2004, J NEUROSCI, V24, P10191, DOI 10.1523/JNEUROSCI.3432-04.2004; Lashuel HA, 2002, NATURE, V418, P291, DOI 10.1038/418291a; Lee D, 2002, J NEUROCHEM, V82, P1007, DOI 10.1046/j.1471-4159.2002.01024.x; Lee D, 2001, EUR J BIOCHEM, V268, P295, DOI 10.1046/j.1432-1033.2001.01877.x; Lee EN, 2004, BIOCHEMISTRY-US, V43, P3704, DOI 10.1021/bi0356707; Lee JH, 1998, NEUROCHEM RES, V23, P1427, DOI 10.1023/A:1020711025418; Lee M, 2001, J NEUROCHEM, V76, P998, DOI 10.1046/j.1471-4159.2001.00149.x; Lee SS, 2003, NEUROBIOL AGING, V24, P687, DOI 10.1016/S0197-4580(02)00196-3; LeVine H, 1999, METHOD ENZYMOL, V309, P274; Li J, 2004, CHEM BIOL, V11, P1513, DOI 10.1016/j.chembiol.2004.08.025; Manning-Bog AB, 2002, J BIOL CHEM, V277, P1641, DOI 10.1074/jbc.C100560200; Masliah E, 2000, SCIENCE, V287, P1265, DOI 10.1126/science.287.5456.1265; MORRISSEY JH, 1981, ANAL BIOCHEM, V117, P307, DOI 10.1016/0003-2697(81)90783-1; Narhi L, 1999, J BIOL CHEM, V274, P9843, DOI 10.1074/jbc.274.14.9843; Paik SR, 1997, ARCH BIOCHEM BIOPHYS, V344, P325, DOI 10.1006/abbi.1997.0207; Paik SR, 1999, BIOCHEM J, V340, P821, DOI 10.1042/0264-6021:3400821; PAIK SR, 1994, BIOCHEMISTRY-US, V33, P126, DOI 10.1021/bi00167a016; Paik SR, 2003, FEBS LETT, V537, P63, DOI 10.1016/S0014-5793(03)00081-4; Paik SR, 1998, FEBS LETT, V421, P73, DOI 10.1016/S0014-5793(97)01537-8; PENEFSKY HS, 1977, J BIOL CHEM, V252, P2891; Polymeropoulos MH, 1997, SCIENCE, V276, P2045, DOI 10.1126/science.276.5321.2045; Priola SA, 2000, SCIENCE, V287, P1503, DOI 10.1126/science.287.5457.1503; Qin DH, 2000, J MED CHEM, V43, P1413, DOI 10.1021/jm990340z; ROTENBERG SA, 1990, CANCER RES, V50, P677; Serpell LC, 1997, CELL MOL LIFE SCI, V53, P871, DOI 10.1007/s000180050107; Shin HJ, 2000, BBA-PROTEIN STRUCT M, V1481, P139, DOI 10.1016/S0167-4838(00)00106-0; Singleton AB, 2003, SCIENCE, V302, P841, DOI 10.1126/science.1090278; Spillantini MG, 1998, P NATL ACAD SCI USA, V95, P6469, DOI 10.1073/pnas.95.11.6469; Spillantini MG, 1997, NATURE, V388, P839, DOI 10.1038/42166; Spillantini MG, 2000, ANN NY ACAD SCI, V920, P16; Sullivan RM, 2000, MOL PHARMACOL, V58, P729, DOI 10.1124/mol.58.4.729; UEDA K, 1993, P NATL ACAD SCI USA, V90, P11282, DOI 10.1073/pnas.90.23.11282; Uversky VN, 2001, J BIOL CHEM, V276, P10737, DOI 10.1074/jbc.M010907200; Uversky VN, 2002, FEBS LETT, V517, P239, DOI 10.1016/S0014-5793(02)02638-8; Uversky VN, 2001, FEBS LETT, V500, P105, DOI 10.1016/S0014-5793(01)02597-2; Uversky VN, 2001, FEBS LETT, V509, P31, DOI 10.1016/S0014-5793(01)03121-0; Volles MJ, 2003, BIOCHEMISTRY-US, V42, P7871, DOI 10.1021/bi030086j; Volles MJ, 2001, BIOCHEMISTRY-US, V40, P7812, DOI 10.1021/bi0102398; Weinreb PH, 1996, BIOCHEMISTRY-US, V35, P13709, DOI 10.1021/bi961799n; WEISS MJ, 1987, P NATL ACAD SCI USA, V84, P5444, DOI 10.1073/pnas.84.15.5444; Wersinger C, 2003, NEUROSCI LETT, V342, P124, DOI 10.1016/S0304-3940(03)00212-X; Wright PE, 1999, J MOL BIOL, V293, P321, DOI 10.1006/jmbi.1999.3110; Yamin G, 2003, FEBS LETT, V542, P147, DOI 10.1016/S0014-5793(03)00367-3; Zarranz JJ, 2004, ANN NEUROL, V55, P164, DOI 10.1002/ana.10795; Zhu M, 2004, J BIOL CHEM, V279, P26846, DOI 10.1074/jbc.M403129200; ZHUO SQ, 1988, BIOCHEM BIOPH RES CO, V152, P968, DOI 10.1016/S0006-291X(88)80378-4; ZHUO SQ, 1993, BIOCHEMISTRY-US, V32, P2219, DOI 10.1021/bi00060a013; Zourlidou A, 2003, NEUROSCI LETT, V340, P234, DOI 10.1016/S0304-3940(03)00081-8	74	24	26	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 10	2006	281	6					3463	3472		10.1074/jbc.M505307200	http://dx.doi.org/10.1074/jbc.M505307200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	009QV	16330551	hybrid			2022-12-25	WOS:000235128200056
J	Leuranguer, V; Papadopoulos, S; Beam, KG				Leuranguer, V; Papadopoulos, S; Beam, KG			Organization of calcium channel beta(1a) subunits in triad junctions in skeletal muscle	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECEPTOR BETA-1A SUBUNIT; DIHYDROPYRIDINE RECEPTOR; CA2+ CURRENT; ABSENCE; COMPLEX; DOMAIN; INVOLVEMENT; COMPONENTS; TERMINUS	In skeletal muscle, dihydropyridine receptors ( DHPRs) in the plasma membrane interact with the type 1 ryanodine receptor ( RyR1) at junctions with the sarcoplasmic reticulum. This interaction organizes junctional DHPRs into groups of four termed tetrads. In addition to the principle alpha(1S) subunit, the beta(1a) subunit of the DHPR is also important for the interaction with RyR1. To probe this interaction, we measured fluorescence resonance energy transfer ( FRET) of beta(1a) subunits labeled with cyan fluorescent protein ( CFP) and/ or yellow fluorescent protein ( YFP). Expressed in dysgenic (alpha(1S)- null) myotubes, YFP-beta(1a)- CFP and CFP- beta(1a)- YFP were diffusely distributed in the cytoplasm and highly mobile as indicated by fluorescence recovery after photobleaching. Thus, beta(1a) does not appear to bind to other cellular proteins in the absence of alpha(1S). FRET efficiencies for these cytoplasmic beta(1a) subunits were similar to 6 - 7%, consistent with the idea that < 10 nm separates the N and C termini. After coexpression with unlabeled alpha(1S) ( in dysgenic or beta(1)- null myotubes), both constructs produced discrete fluorescent puncta, which correspond to assembled DHPRs in junctions and that did not recover after photobleaching. In beta(1)- null myotubes, FRET efficiencies of doubly labeled beta(1a) in puncta were similar to those of the same constructs diffusely distributed in the cytoplasm and appeared to arise intramolecularly, since no FRET was measured when mixtures of singly labeled beta(1a) ( CFP or YFP at the N or C terminus) were expressed in beta 1- null myotubes. Thus, DHPRs in tetrads may be arranged such that the N and C termini of adjacent beta(1a) subunits are located > 10 nm from one another.	Colorado State Univ, Dept Biomed Sci, Ft Collins, CO 80523 USA; Hannover Med Sch, D-30625 Hannover, Germany	Colorado State University; Hannover Medical School	Beam, KG (corresponding author), Colorado State Univ, Dept Biomed Sci, 1617 Campus Delivery, Ft Collins, CO 80523 USA.	kbeam@lamar.colostate.edu						Arikkath J, 2003, CURR OPIN NEUROBIOL, V13, P298, DOI 10.1016/S0959-4388(03)00066-7; Beam KG, 1997, METHOD CELL BIOL, V52, P283, DOI 10.1016/S0091-679X(08)60384-2; Beurg M, 1999, BIOPHYS J, V76, P1744, DOI 10.1016/S0006-3495(99)77336-4; Beurg M, 1999, BIOPHYS J, V77, P2953, DOI 10.1016/S0006-3495(99)77128-6; BLOCK BA, 1988, J CELL BIOL, V107, P2587, DOI 10.1083/jcb.107.6.2587; Chen YH, 2004, NATURE, V429, P675, DOI 10.1038/nature02641; Gregg RG, 1996, P NATL ACAD SCI USA, V93, P13961, DOI 10.1073/pnas.93.24.13961; Hanlon MR, 1999, FEBS LETT, V445, P366, DOI 10.1016/S0014-5793(99)00156-8; KNUDSON CM, 1989, J BIOL CHEM, V264, P1345; Neuhuber B, 1998, P NATL ACAD SCI USA, V95, P5015, DOI 10.1073/pnas.95.9.5015; Opatowsky Y, 2004, NEURON, V42, P387, DOI 10.1016/S0896-6273(04)00250-8; Paolini C, 2004, J MOL BIOL, V342, P145, DOI 10.1016/j.jmb.2004.07.035; Papadopoulos S, 2004, J BIOL CHEM, V279, P44046, DOI 10.1074/jbc.M405317200; Sheridan DC, 2004, BIOPHYS J, V87, P929, DOI 10.1529/biophysj.104.043810; SIEGEL RM, 2000, SCI STKE, pPL1; Strube C, 1996, BIOPHYS J, V71, P2531, DOI 10.1016/S0006-3495(96)79446-8; Van Petegem F, 2004, NATURE, V429, P671, DOI 10.1038/nature02588; Wolf M, 2003, J MOL BIOL, V332, P171, DOI 10.1016/S0022-2836(03)00899-4	18	18	19	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 10	2006	281	6					3521	3527		10.1074/jbc.M509566200	http://dx.doi.org/10.1074/jbc.M509566200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	009QV	16317008	hybrid			2022-12-25	WOS:000235128200062
J	Peignon, G; Thenet, S; Schreider, C; Fouquet, S; Ribeiro, A; Dussaulx, E; Chambaz, J; Cardot, P; Pincon-Raymond, M; Le Beyec, J				Peignon, G; Thenet, S; Schreider, C; Fouquet, S; Ribeiro, A; Dussaulx, E; Chambaz, J; Cardot, P; Pincon-Raymond, M; Le Beyec, J			E-cadherin-dependent transcriptional control of apolipoprotein A-IV gene expression in intestinal epithelial cells - A role for the hepatic nuclear factor 4	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-KINASE; N-CADHERIN; EXTRACELLULAR-MATRIX; PHOSPHATIDYLINOSITOL 3-KINASE; DIFFERENTIAL EXPRESSION; SUCRASE-ISOMALTASE; DOWN-REGULATION; MESSENGER-RNA; CACO-2 CELLS; FACTOR HNF-4	Cell-matrix and cell-cell adhesion play a central role in the control of cell proliferation, differentiation, and gene expression. Integrins and E- cadherin are the key components involved in these processes in epithelial cells. We recently showed that integrin-dependent adhesion to the extracellular matrix reinforces the formation of E-cadherin-actin complexes inducing the polarization of Caco-2 enterocytes and increases the expression of a marker of enterocyte differentiation, the apolipoprotein A-IV (apoA-IV) gene. By impairing or enhancing E-cadherin-dependent cell adhesion, we demonstrate in the present study its involvement in the transcriptional activation of the apoA-IV gene in Caco- 2 cells. This control requires the regulatory sequence that we have previously identified as necessary and sufficient to drive and restrict apoA-IV gene expression in enterocytes in vivo. Furthermore, using chimeric E-cadherin-Fc homophilic ligand-coated surfaces, we show that a direct activation of E-cadherin triggers the transcriptional activation of the apoA-IV promoter. Finally, E- cadherin- dependent cellcell adhesion controls the nuclear abundance of the transcription factor hepatic nuclear factor 4 alpha, which is involved in the enterocytespecific expression of apoA- IV gene. Altogether, our results suggest that E-cadherin controls enterocyte- specific expression of genes, such as the apoA-IV gene, through the control of hepatic nuclear factor 4 alpha nuclear abundance.	Univ Paris 06, INSERM, UMRS 505, F-75006 Paris, France; Ecole Prat Hautes Etud, Pharmacol Cellulaire & Mol Lab, F-75006 Paris, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Sorbonne Universite; UDICE-French Research Universities; PSL Research University Paris; Ecole Pratique des Hautes Etudes (EPHE)	Le Beyec, J (corresponding author), Univ Paris 06, INSERM, UMRS 505, 15 Rue Ecole Med, F-75006 Paris, France.	jlebihan@bhdc.jussieu.fr	Ribeiro, Agnès/Q-9702-2017; Thenet, Sophie/GQY-5726-2022	Ribeiro, Agnès/0000-0003-2063-6084; Thenet, Sophie/0000-0002-0336-2942; Le Beyec - Le Bihan, johanne/0000-0002-5647-2002				Adams CL, 1998, CURR OPIN CELL BIOL, V10, P572, DOI 10.1016/S0955-0674(98)80031-8; Adams CL, 1998, J CELL BIOL, V142, P1105, DOI 10.1083/jcb.142.4.1105; [Anonymous], 2001, NUCL RECEPTORS GENET; Archer A, 2005, MOL ENDOCRINOL, V19, P2320, DOI 10.1210/me.2004-0462; Beaulieu JF, 1997, PROG HISTOCHEM CYTOC, V31, P1; BEAULIEU JF, 1999, FRONT BIOSCI, V4, P310; Bissell MJ, 1999, CANCER RES, V59, p1757S; Booth C, 2000, J CLIN INVEST, V105, P1493, DOI 10.1172/JCI10229; Boudreau N, 1998, CURR OPIN CELL BIOL, V10, P640, DOI 10.1016/S0955-0674(98)80040-9; Carriere V, 2005, J BIOL CHEM, V280, P5406, DOI 10.1074/jbc.M408002200; CHANTRET I, 1994, J CELL SCI, V107, P213; Charrasse S, 2002, J CELL BIOL, V158, P953, DOI 10.1083/jcb.200202034; CHEN WS, 1994, GENE DEV, V8, P2466, DOI 10.1101/gad.8.20.2466; DARMOUL D, 1992, J BIOL CHEM, V267, P4824; DUNCAN SA, 1994, P NATL ACAD SCI USA, V91, P7598, DOI 10.1073/pnas.91.16.7598; Escaffit F, 2005, EXP CELL RES, V302, P206, DOI 10.1016/j.yexcr.2004.08.033; FEUILLARD J, 1991, CYTOKINE, V3, P257, DOI 10.1016/1043-4666(91)90025-9; Fouquet S, 2004, J BIOL CHEM, V279, P43061, DOI 10.1074/jbc.M405095200; Gavard J, 2004, J BIOL CHEM, V279, P36795, DOI 10.1074/jbc.M401705200; GeorgeWeinstein M, 1997, DEV BIOL, V185, P14, DOI 10.1006/dbio.1997.8542; GORDON JI, 1994, CURR OPIN CELL BIOL, V6, P795, DOI 10.1016/0955-0674(94)90047-7; Gumbiner BM, 2000, J CELL BIOL, V148, P399, DOI 10.1083/jcb.148.3.399; Hayhurst GP, 2001, MOL CELL BIOL, V21, P1393, DOI 10.1128/MCB.21.4.1393-1403.2001; HERMISTON ML, 1995, J CELL BIOL, V129, P489, DOI 10.1083/jcb.129.2.489; Hirokane H, 2004, J BIOL CHEM, V279, P45685, DOI 10.1074/jbc.M404255200; Hirota K, 2003, J BIOL CHEM, V278, P13056, DOI 10.1074/jbc.C200553200; Hodin R A, 1997, J Gastrointest Surg, V1, P433, DOI 10.1016/S1091-255X(97)80130-8; HODIVALA KJ, 1994, J CELL BIOL, V124, P589, DOI 10.1083/jcb.124.4.589; HOLT CE, 1994, P NATL ACAD SCI USA, V91, P10844, DOI 10.1073/pnas.91.23.10844; Hong YH, 2003, J BIOL CHEM, V278, P27495, DOI 10.1074/jbc.M304112200; Houde M, 2001, J BIOL CHEM, V276, P21885, DOI 10.1074/jbc.M100236200; Inoue Y, 2002, J BIOL CHEM, V277, P25257, DOI 10.1074/jbc.M203126200; Jiang GQ, 1997, ARCH BIOCHEM BIOPHYS, V340, P1, DOI 10.1006/abbi.1997.9914; Kandikonda S, 1996, CELL ADHES COMMUN, V4, P13, DOI 10.3109/15419069609010760; Kedinger M, 1998, PHILOS T R SOC B, V353, P847, DOI 10.1098/rstb.1998.0249; Keller MS, 2004, AM J PHYSIOL-GASTR L, V287, pG104, DOI 10.1152/ajpgi.00484.2003; KNUDSEN KA, 1990, EXP CELL RES, V188, P175, DOI 10.1016/0014-4827(90)90157-6; Kovacs EM, 2002, J BIOL CHEM, V277, P6708, DOI 10.1074/jbc.M109640200; KTISTAKI E, 1995, P NATL ACAD SCI USA, V92, P9876, DOI 10.1073/pnas.92.21.9876; Lambert M, 2002, J CELL BIOL, V157, P469, DOI 10.1083/jcb.200107104; Lambert M, 2000, J CELL SCI, V113, P2207; Laprise P, 2002, J BIOL CHEM, V277, P8226, DOI 10.1074/jbc.M110235200; Le Beyec J, 1999, J BIOL CHEM, V274, P4954, DOI 10.1074/jbc.274.8.4954; LeBeyec J, 1997, EXP CELL RES, V236, P311; Leclerc I, 2001, DIABETES, V50, P1515, DOI 10.2337/diabetes.50.7.1515; Lelievre SA, 1998, P NATL ACAD SCI USA, V95, P14711, DOI 10.1073/pnas.95.25.14711; LESUFFLEUR T, 1990, CANCER RES, V50, P6334; Lorentz O, 1997, J CELL BIOL, V139, P1553, DOI 10.1083/jcb.139.6.1553; Lussier C, 2000, MICROSC RES TECHNIQ, V51, P169; Mariadason JM, 2001, CANCER RES, V61, P3465; MEGE RM, 1992, J CELL SCI, V103, P897; Orian-Rousseau V, 1998, J CELL SCI, V111, P1993; Parviz F, 2003, NAT GENET, V34, P292, DOI 10.1038/ng1175; Parviz F, 2002, GENESIS, V32, P130, DOI 10.1002/gene.10058; PINTO M, 1983, BIOL CELL, V47, P323; Plachot C, 2004, EXP CELL RES, V298, P122, DOI 10.1016/j.yexcr.2004.04.024; Potten CS, 1997, INT J EXP PATHOL, V78, P219, DOI 10.1046/j.1365-2613.1997.280362.x; Rodolosse A, 1998, BIOCHEM J, V336, P115, DOI 10.1042/bj3360115; Ruse MD, 2002, MOL CELL BIOL, V22, P1626, DOI 10.1128/MCB.22.6.1626-1638.2002; Sauvaget D, 2002, J BIOL CHEM, V277, P34540, DOI 10.1074/jbc.M206074200; Schreider C, 2002, J CELL SCI, V115, P543; Soutoglou E, 2000, MOL CELL, V5, P745, DOI 10.1016/S1097-2765(00)80253-1; Spath GF, 1997, MOL CELL BIOL, V17, P1913; Spath GF, 1998, J CELL BIOL, V140, P935, DOI 10.1083/jcb.140.4.935; TAKEICHI M, 1995, CURR OPIN CELL BIOL, V7, P619, DOI 10.1016/0955-0674(95)80102-2; TELLER IC, 2001, EXPERT REV MOL MED, P1; Vasioukhin V, 2000, CELL, V100, P209, DOI 10.1016/S0092-8674(00)81559-7; Viollet B, 1997, MOL CELL BIOL, V17, P4208, DOI 10.1128/MCB.17.8.4208; Vleminckx K, 1999, BIOESSAYS, V21, P211, DOI 10.1002/(SICI)1521-1878(199903)21:3<211::AID-BIES5>3.3.CO;2-G; WATABE M, 1994, J CELL BIOL, V127, P247, DOI 10.1083/jcb.127.1.247; Watt FM, 2002, EMBO J, V21, P3919, DOI 10.1093/emboj/cdf399; Weaver VM, 2002, CANCER CELL, V2, P205, DOI 10.1016/S1535-6108(02)00125-3; Wheelock MJ, 2003, ANNU REV CELL DEV BI, V19, P207, DOI 10.1146/annurev.cellbio.19.011102.111135; Yamada A, 2004, GENES CELLS, V9, P843, DOI 10.1111/j.1365-2443.2004.00768.x; Yap AS, 1997, ANNU REV CELL DEV BI, V13, P119, DOI 10.1146/annurev.cellbio.13.1.119; Yap AS, 2003, J CELL BIOL, V160, P11, DOI 10.1083/jcb.200208156; ZANNIS VI, 1985, BIOCHEMISTRY-US, V24, P4450, DOI 10.1021/bi00337a028; Zannis VI, 2001, FRONT BIOSCI-LANDMRK, V6, pD456, DOI 10.2741/Zannis; ZHONG WM, 1993, EMBO J, V12, P537, DOI 10.1002/j.1460-2075.1993.tb05685.x	79	27	29	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 10	2006	281	6					3560	3568		10.1074/jbc.M506360200	http://dx.doi.org/10.1074/jbc.M506360200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	009QV	16338932	hybrid			2022-12-25	WOS:000235128200067
J	Melnikova, VO; Mourad-Zeidan, AA; Lev, DC; Bar-Eli, M				Melnikova, VO; Mourad-Zeidan, AA; Lev, DC; Bar-Eli, M			Platelet-activating factor mediates MMP-2 expression and activation via phosphorylation of cAMP-response element-binding protein and contributes to melanoma metastasis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FACTOR RECEPTOR; IV COLLAGENASE; TUMOR-GROWTH; KAPPA-B; MATRIX METALLOPROTEINASES; REGULATE CREB; PAF RECEPTOR; CANCER CELLS; MAP KINASE; IN-VITRO	Overexpression of cAMP-response element (CRE)-binding protein (CREB) and activating transcription factor (ATF) 1 contributes to melanoma progression and metastasis at least in part by promoting tumor cell survival and stimulating matrix metalloproteinase (MMP) 2 expression. However, little is known about the regulation of CREB and ATF-1 activities and their phosphorylation within the tumor microenvironment. We analyzed the effect of platelet-activating factor (PAF), a potent phospholipid mediator of inflammation, for its ability to activate CREB and ATF-1 in eight cultured human melanoma cell lines, and we found that PAF receptor (PAFR) was expressed in all eight lines. In metastatic melanoma cell lines, PAF induced CREB and ATF-1 phosphorylation via a PAFR-mediated signal transduction mechanism that required pertussis toxin-insensitive G alpha(q) protein and adenylate cyclase activity and was antagonized by a cAMP-dependent protein kinase A and p38 MAPK inhibitors. Addition of PAF to metastatic A375SM cells stimulated CRE-dependent transcription, as observed in a luciferase reporter assay, without increasing the CRE DNA binding capacity of CREB. Furthermore, PAF stimulated the gelatinase activity of MMP-2 by activating transcription and MMP-2 expression. MMP-2 activation correlated with the PAF-induced increase in the expression of an MMP-2 activator, membrane type 1 MMP. PAF-induced expression of pro-MMP-2 was causally related to PAF-induced CREB and ATF-1 phosphorylation; it was prevented by PAFR antagonist and inhibitors of p38 MAPK and protein kinase A and was abrogated upon quenching of CREB and ATF-1 activities by forced overexpression of a dominant-negative form of CREB. PAF-induced MMP-2 activation was also down-regulated by p38 MAPK and protein kinase A inhibitors. Finally, PAFR antagonist PCA4248 inhibited the development of A375SM lung metastasis in nude mice. This result indicated that PAF acts as a promoter of melanoma metastasis in vivo. We proposed that metastatic melanoma cells overexpressing CREB/ATF-1 are better equipped than nonmetastatic cells to respond to PAF within the tumor microenvironment.	Univ Texas, MD Anderson Canc Ctr, Dept Canc Biol, Unit 173, Houston, TX 77030 USA; Univ Texas, Grad Sch Biomed Sci, Program Canc Biol, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center; University of Texas System	Bar-Eli, M (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Canc Biol, Unit 173, 1515 Holcombe Blvd, Houston, TX 77030 USA.	mbareli@mdanderson.org			NCI NIH HHS [CA76098] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA076098] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AMATRUDA TT, 1993, J BIOL CHEM, V268, P10139; Amiri KI, 2005, CANCER METAST REV, V24, P301, DOI 10.1007/s10555-005-1579-7; Axelrad TW, 2004, FASEB J, V18, P568, DOI 10.1096/fj.03-0479fje; Balkwill F, 2001, LANCET, V357, P539, DOI 10.1016/S0140-6736(00)04046-0; Barletta E, 2002, BIOL CHEM, V383, P189, DOI 10.1515/BC.2002.019; BEHRENS TW, 1990, INT J IMMUNOPHARMACO, V12, P175, DOI 10.1016/0192-0561(90)90051-N; BENNETT SAL, 1993, CARCINOGENESIS, V14, P1289, DOI 10.1093/carcin/14.7.1289; Biancone L, 2003, CLIN CANCER RES, V9, P4214; BOHM M, 1995, CELL GROWTH DIFFER, V6, P291; Bussolati B, 2000, AM J PATHOL, V157, P1713, DOI 10.1016/S0002-9440(10)64808-0; BUSSOLINO F, 1995, J CLIN INVEST, V96, P940, DOI 10.1172/JCI118142; CAMUSSI G, 1995, J IMMUNOL, V154, P6492; CHRIVIA JC, 1993, NATURE, V365, P855, DOI 10.1038/365855a0; Coussens LM, 2002, NATURE, V420, P860, DOI 10.1038/nature01322; Deak M, 1998, EMBO J, V17, P4426, DOI 10.1093/emboj/17.15.4426; Deo DD, 2004, J BIOL CHEM, V279, P3497, DOI 10.1074/jbc.M304497200; Du KY, 1998, J BIOL CHEM, V273, P32377, DOI 10.1074/jbc.273.49.32377; Egeblad M, 2002, NAT REV CANCER, V2, P161, DOI 10.1038/nrc745; FERNANDEZGALLARDO S, 1990, J PHARMACOL EXP THER, V255, P34; Fukunaga K, 2001, J BIOL CHEM, V276, P43025, DOI 10.1074/jbc.M108288200; GONZALEZ GA, 1989, CELL, V59, P675, DOI 10.1016/0092-8674(89)90013-5; Goulet AC, 2003, CANCER BIOL THER, V2, P713; HALABAN R, 1987, IN VITRO CELL DEV B, V23, P47; HONDA Z, 1994, J BIOL CHEM, V269, P2307; HONN KV, 1992, CANCER METAST REV, V11, P325, DOI 10.1007/BF01307186; HUHTALA P, 1990, J BIOL CHEM, V265, P11077; Im SY, 1996, CANCER RES, V56, P2662; Ishii S, 2000, PROG LIPID RES, V39, P41, DOI 10.1016/S0163-7827(99)00016-8; Ishii S, 1997, EMBO J, V16, P133, DOI 10.1093/emboj/16.1.133; Jean D, 1998, J BIOL CHEM, V273, P24884, DOI 10.1074/jbc.273.38.24884; Jean D, 2000, ONCOGENE, V19, P2721, DOI 10.1038/sj.onc.1203569; Ko HM, 2005, FEBS LETT, V579, P2369, DOI 10.1016/j.febslet.2005.03.035; KRAVCHENKO VV, 1995, J BIOL CHEM, V270, P14928, DOI 10.1074/jbc.270.25.14928; Kume K, 1997, J BIOL CHEM, V272, P22898, DOI 10.1074/jbc.272.36.22898; KURUVILLA A, 1994, J IMMUNOL, V153, P5433; Leslie MC, 2005, J CELL BIOCHEM, V94, P25, DOI 10.1002/jcb.20296; LI LM, 1989, JNCI-J NATL CANCER I, V81, P1406, DOI 10.1093/jnci/81.18.1406; LUCA M, 1993, MELANOMA RES, V3, P35, DOI 10.1097/00008390-199304000-00006; MAGGI M, 1994, CANCER RES, V54, P4777; Mannori G, 2000, CLIN EXP METASTAS, V18, P89, DOI 10.1023/A:1026548700247; Marrache AM, 2002, J IMMUNOL, V169, P6474, DOI 10.4049/jimmunol.169.11.6474; MATTHEWS RP, 1994, MOL CELL BIOL, V14, P6107, DOI 10.1128/MCB.14.9.6107; Mayr B, 2001, NAT REV MOL CELL BIO, V2, P599, DOI 10.1038/35085068; Mills L, 2002, CANCER RES, V62, P5106; Nakao A, 1997, AM J PHYSIOL-RENAL, V273, pF445, DOI 10.1152/ajprenal.1997.273.3.F445; Nick JA, 1997, J CLIN INVEST, V99, P975, DOI 10.1172/JCI119263; Nishihara H, 2004, J BIOL CHEM, V279, P26176, DOI 10.1074/jbc.M313346200; Ottino P, 2005, INVEST OPHTH VIS SCI, V46, P487, DOI 10.1167/iovs.04-0852; Ottino P, 2001, CURR EYE RES, V23, P77, DOI 10.1076/ceyr.23.2.77.5471; Pei Y, 1998, J IMMUNOL, V161, P1954; Pikarsky E, 2004, NATURE, V431, P461, DOI 10.1038/nature02924; Prescott SM, 2000, ANNU REV BIOCHEM, V69, P419, DOI 10.1146/annurev.biochem.69.1.419; RODRIGUEZ CG, 1995, J BIOL CHEM, V270, P25178, DOI 10.1074/jbc.270.42.25178; Roth M, 1996, J EXP MED, V184, P191, DOI 10.1084/jem.184.1.191; RUTBERG SE, 1994, MOL CARCINOGEN, V10, P82, DOI 10.1002/mc.2940100205; Sato S, 1999, ARCH DERMATOL RES, V291, P614, DOI 10.1007/s004030050463; Shimizu T, 1996, ADV EXP MED BIOL, V416, P79; Stafforini DM, 2003, CRIT REV CL LAB SCI, V40, P643, DOI 10.1080/714037693; STRONGIN AY, 1995, J BIOL CHEM, V270, P5331, DOI 10.1074/jbc.270.10.5331; STRONGIN AY, 1993, J BIOL CHEM, V268, P14033; Tan Y, 1996, EMBO J, V15, P4629, DOI 10.1002/j.1460-2075.1996.tb00840.x; Togo T, 2004, J BIOL CHEM, V279, P44996, DOI 10.1074/jbc.M406327200; vanBiesen T, 1996, J BIOL CHEM, V271, P1266, DOI 10.1074/jbc.271.3.1266; Walterscheid JP, 2002, J EXP MED, V195, P171, DOI 10.1084/jem.20011450; WALTON KM, 1992, MOL ENDOCRINOL, V6, P647, DOI 10.1210/me.6.4.647; Xie SH, 1997, ONCOGENE, V15, P2069, DOI 10.1038/sj.onc.1201358; Yang YM, 1996, ONCOGENE, V12, P2223; Zimmerman GA, 2002, CRIT CARE MED, V30, pS294, DOI 10.1097/00003246-200205001-00020	68	83	89	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 3	2006	281	5					2911	2922		10.1074/jbc.M508683200	http://dx.doi.org/10.1074/jbc.M508683200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	006XT	16306050	hybrid			2022-12-25	WOS:000234931800060
J	Forouhar, F; Hussain, M; Farid, R; Benach, J; Abashidze, M; Edstrom, WC; Vorobiev, SM; Xiao, R; Acton, TB; Fu, ZJ; Kim, JJP; Miziorko, HM; Montelione, GT; Hunt, JF				Forouhar, F; Hussain, M; Farid, R; Benach, J; Abashidze, M; Edstrom, WC; Vorobiev, SM; Xiao, R; Acton, TB; Fu, ZJ; Kim, JJP; Miziorko, HM; Montelione, GT; Hunt, JF			Crystal structures of two bacterial 3-hydroxy-3-methylglutaryl-CoA lyases suggest a common catalytic mechanism among a family of TIM barrel metalloenzymes cleaving carbon-carbon bonds	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACCURATE DOCKING; MOLECULAR-BASIS; PROTEIN; DEFICIENCY; ALIGNMENT; ACIDURIA; PROGRAM; RESIDUE; PREDICTION; INSIGHTS	The enzyme 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) lyase catalyzes the terminal steps in ketone body generation and leucine degradation. Mutations in this enzyme cause a human autosomal recessive disorder called primary metabolic aciduria, which typically kills victims because of an inability to tolerate hypoglycemia. Here we present crystal structures of the HMG-CoA lyases from Bacillus subtilis and Brucella melitensis at 2.7 and 2.3 angstrom resolution, respectively. These enzymes share greater than 45% sequence identity with the human orthologue. Although the enzyme has the anticipated triose-phosphate isomerase (TIM) barrel fold, the catalytic center contains a divalent cation-binding site formed by a cluster of invariant residues that cap the core of the barrel, contrary to the predictions of homology models. Surprisingly, the residues forming this cation-binding site and most of their interaction partners are shared with three other TIM barrel enzymes that catalyze diverse carbon-carbon bond cleavage reactions believed to proceed through enolate intermediates (4-hydroxy-2-ketovalerate aldolase, 2-isopropylmalate synthase, and transcarboxylase 5S). We propose the name "DRE-TIM metallolyases" for this newly identified enzyme family likely to employ a common catalytic reaction mechanism involving an invariant Asp-Arg-Glu (DRE) triplet. The Asp ligates the divalent cation, while the Arg probably stabilizes charge accumulation in the enolate intermediate, and the Glu maintains the precise structural alignment of the Asp and Arg. We propose a detailed model for the catalytic reaction mechanism of HMG-CoA lyase based on the examination of previously reported product complexes of other DRE-TIM metallolyases and induced fit substrate docking studies conducted using the crystal structure of human HMG-CoA lyase (reported in the accompanying paper by Fu, et al. (2006) J. Biol. Chem. 281, 7526-7532). Our model is consistent with extensive mutagenesis results and can guide subsequent studies directed at definitive experimental elucidation of this enzyme's reaction mechanism.	Columbia Univ, Dept Biol Sci, New York, NY 10027 USA; Columbia Univ, NE Struct Genom Consortium, New York, NY 10027 USA; Schrodinger Inc, New York, NY 10036 USA; Rutgers State Univ, Dept Mol Biol & Biochem, Ctr Adv Biotechnol & Med, Piscataway, NJ 08854 USA; Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Dept Biochem, Piscataway, NJ 08854 USA; NE Struct Genom Consortium, Piscataway, NJ 08854 USA; Med Coll Wisconsin, Dept Biochem, Milwaukee, WI 53226 USA; Univ Missouri, Div Mol Biol & Biochem, Kansas City, MO 64110 USA	Columbia University; Columbia University; Rutgers State University New Brunswick; Rutgers State University New Brunswick; Rutgers State University Medical Center; Medical College of Wisconsin; University of Missouri System; University of Missouri Kansas City	Hunt, JF (corresponding author), Columbia Univ, Dept Biol Sci, New York, NY 10027 USA.	jfhunt@biology.columbia.edu		Montelione, Gaetano/0000-0002-9440-3059	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [U54GM074958, P50GM062413] Funding Source: NIH RePORTER; NIGMS NIH HHS [P50 GM 62413, U54 GM 074958] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Cardoso ML, 2004, MOL GENET METAB, V82, P334, DOI 10.1016/j.ymgme.2004.06.003; Casals N, 2003, J BIOL CHEM, V278, P29016, DOI 10.1074/jbc.M304276200; Doublie S, 1996, FEBS LETT, V384, P219, DOI 10.1016/0014-5793(96)00316-X; Ewing TJA, 2001, J COMPUT AID MOL DES, V15, P411, DOI 10.1023/A:1011115820450; Friesner RA, 2004, J MED CHEM, V47, P1739, DOI 10.1021/jm0306430; Fu ZJ, 2006, J BIOL CHEM, V281, P7526, DOI 10.1074/jbc.M506880200; GIBSON KM, 1988, EUR J PEDIATR, V148, P180, DOI 10.1007/BF00441397; Halgren TA, 2004, J MED CHEM, V47, P1750, DOI 10.1021/jm030644s; Hall PR, 2004, EMBO J, V23, P3621, DOI 10.1038/sj.emboj.7600373; Holm L, 1996, NUCLEIC ACIDS RES, V24, P206, DOI 10.1093/nar/24.1.206; HRUZ PW, 1993, BIOCHIM BIOPHYS ACTA, V1162, P149, DOI 10.1016/0167-4838(93)90141-D; HRUZ PW, 1992, PROTEIN SCI, V1, P1144, DOI 10.1002/pro.5560010908; Jacobson MP, 2004, PROTEINS, V55, P351, DOI 10.1002/prot.10613; JANIN J, 1988, J MOL BIOL, V204, P155, DOI 10.1016/0022-2836(88)90606-7; Janin J, 1995, PROTEINS, V23, P580, DOI 10.1002/prot.340230413; Janin J, 1997, NAT STRUCT BIOL, V4, P973, DOI 10.1038/nsb1297-973; Jansson M, 1996, J BIOMOL NMR, V7, P131; Jorgensen WL, 2004, SCIENCE, V303, P1813, DOI 10.1126/science.1096361; Kelley LA, 2000, J MOL BIOL, V299, P499, DOI 10.1006/jmbi.2000.3741; Kontoyianni M, 2004, J MED CHEM, V47, P558, DOI 10.1021/jm0302997; Koon N, 2004, P NATL ACAD SCI USA, V101, P8295, DOI 10.1073/pnas.0400820101; KRAULIS PJ, 1994, J MOL BIOL, V243, P696, DOI 10.1016/0022-2836(94)90042-6; Krovat EM, 2005, CURR COMPUT-AID DRUG, V1, P93, DOI 10.2174/1573409052952314; Lang D, 2000, SCIENCE, V289, P1546, DOI 10.1126/science.289.5484.1546; Manjasetty BA, 2003, P NATL ACAD SCI USA, V100, P6992, DOI 10.1073/pnas.1236794100; McRee DE, 1999, J STRUCT BIOL, V125, P156, DOI 10.1006/jsbi.1999.4094; MERRITT EA, 1994, ACTA CRYSTALLOGR D, V50, P869, DOI 10.1107/S0907444994006396; MITCHELL GA, 1995, PRENATAL DIAG, V15, P725, DOI 10.1002/pd.1970150807; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; Notredame C, 2000, J MOL BIOL, V302, P205, DOI 10.1006/jmbi.2000.4042; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Perola E, 2004, PROTEINS, V56, P235, DOI 10.1002/prot.20088; Pie J, 2003, J PHYSIOL BIOCHEM, V59, P311, DOI 10.1007/BF03179889; Pospisilova E, 2003, J INHERIT METAB DIS, V26, P433, DOI 10.1023/A:1025169210121; Puisac B, 2005, BIOPHYS CHEM, V115, P241, DOI 10.1016/j.bpc.2004.12.031; Rarey M, 1996, J MOL BIOL, V261, P470, DOI 10.1006/jmbi.1996.0477; Roberts JR, 1996, J BIOL CHEM, V271, P24604, DOI 10.1074/jbc.271.40.24604; ROBERTS JR, 1995, J BIOL CHEM, V270, P17311, DOI 10.1074/jbc.270.29.17311; SHERMAN W, 2006, IN PRESS J MED CHEM; Standley DM, 2001, PROTEINS, P133; Terwilliger TC, 1999, ACTA CRYSTALLOGR D, V55, P849, DOI 10.1107/S0907444999000839; Tuinstra RL, 2004, BIOCHEMISTRY-US, V43, P5287, DOI 10.1021/bi0499765; Tuinstra RL, 2003, J BIOL CHEM, V278, P37092, DOI 10.1074/jbc.M304472200; Tuinstra RL, 2002, ARCH BIOCHEM BIOPHYS, V408, P286, DOI 10.1016/S0003-9861(02)00584-2; Weeks CM, 1999, ACTA CRYSTALLOGR D, V55, P492, DOI 10.1107/S0907444998012633; Xu L, 2004, J BIOL CHEM, V279, P50555, DOI 10.1074/jbc.M406801200	47	28	29	1	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 17	2006	281	11					7533	7545		10.1074/jbc.M507996200	http://dx.doi.org/10.1074/jbc.M507996200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	022BY	16330546	hybrid			2022-12-25	WOS:000236030900075
J	Tang, J; Hu, G; Hanai, J; Yadlapalli, G; Lin, YF; Zhang, B; Galloway, J; Bahary, N; Sinha, S; Thisse, B; Thisse, C; Jin, JP; Zon, LI; Sukhatme, VP				Tang, J; Hu, G; Hanai, J; Yadlapalli, G; Lin, YF; Zhang, B; Galloway, J; Bahary, N; Sinha, S; Thisse, B; Thisse, C; Jin, JP; Zon, LI; Sukhatme, VP			A critical role for calponin 2 in vascular development	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-KINASE; SMOOTH-MUSCLE; SIGNAL-TRANSDUCTION; ACTIN CYTOSKELETON; ZEBRAFISH EMBRYOS; EXPRESSION; H2-CALPONIN; BINDING; CLONING; VASCULOGENESIS	Calponin 2 (h2 calponin, CNN2) is an actin-binding protein implicated in cytoskeletal organization. We have found that the expression of calponin 2 is relatively restricted to vasculature from 16 to 30 h post-fertilization during zebrafish ( Danio rerio) development. Forty-eight hours after injecting antisense morpholino oligos against calponin 2 into embryos at the 1 - 4-cell stage, zebrafish demonstrated various cardiovascular defects, including sluggish axial and head circulation, absence of circulation in intersegmental vessels and in the dorsal longitudinal anastomotic vessel, enlarged cerebral ventricles, and pericardial edema, in addition to an excess bending, spiraling tail and twisting of the caudal fin. Knockdown of calponin 2 in the Tg(fli1: EGFP)(y1) zebrafish line ( in which a fli1 promoter drives vascular-specific enhanced green fluorescent protein expression) indicated that diminished calponin 2 expression blocked the proper migration of endothelial cells during formation of intersegmental vessels. In vitro studies showed that basic fibroblast growth factor-induced human umbilical vein endothelial cell migration was down-regulated by knockdown of calponin 2 expression using an antisense adenovirus, and overexpression of calponin 2 enhanced migration and hastened wound healing. These events were correlated with activation of mitogen-activated protein kinase; moreover, inhibition of this pathway blocked the promigratory effect of calponin 2. Collectively, these data suggest that calponin 2 plays an important role in the migration of endothelial cells both in vivo and in vitro and that its expression is critical for proper vascular development.	Beth Israel Deaconess Med Ctr, Div Renal, Boston, MA 02215 USA; Beth Israel Deaconess Med Ctr, Dept Med, Ctr Study Tumor Microenvironm, Boston, MA 02215 USA; Childrens Hosp, Dept Med, Div Hematol Oncol, Boston, MA 02215 USA; Univ Strasbourg 1, INSERM, CNRS, Inst Biol Mol & Cellulaire, F-67404 Illkirch Graffenstaden, CU de Strasbour, France; Northwestern Univ, Feinberg Sch Med, Evanston Northwestern Healthcare, Sect Mol Cardiol, Evanston, IL 60201 USA; Univ Pittsburgh, Sch Med, Pittsburgh, PA 15261 USA	Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Boston Children's Hospital; Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg; NorthShore University Health System; Northwestern University; Feinberg School of Medicine; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Sukhatme, VP (corresponding author), Beth Israel Deaconess Med Ctr, Div Renal, 330 Brookline Ave,RW 563, Boston, MA 02215 USA.	vsukhatm@bidmc.harvard.edu	Sukhatme, Vikas/W-2776-2019	Jin, JP/0000-0001-9932-1063; THISSE, Christine/0000-0002-8684-1681				Abramoff MD, 2004, BIOPHOTONICS INT, V11, P36, DOI DOI 10.1117/1.3589100; APPLEGATE D, 1994, J BIOL CHEM, V269, P10683; Childs S, 2002, DEVELOPMENT, V129, P973; Danninger C, 2000, J CELL SCI, V113, P3725; ElMezgueldi M, 1996, BIOCHEMISTRY-US, V35, P3654, DOI 10.1021/bi952027e; Fujii T, 1997, J BIOCHEM, V122, P344; Fukui Y, 1997, J DERMATOL SCI, V14, P29, DOI 10.1016/S0923-1811(96)00545-2; Galloway JL, 2005, DEV CELL, V8, P109, DOI 10.1016/j.devcel.2004.12.001; GIMONA M, 1996, BIOCH SMOOTH MUSCLE, P91; Graceffa P, 1996, J BIOL CHEM, V271, P30336, DOI 10.1074/jbc.271.48.30336; He TC, 1998, P NATL ACAD SCI USA, V95, P2509, DOI 10.1073/pnas.95.5.2509; Hossain MM, 2005, J BIOL CHEM, V280, P42442, DOI 10.1074/jbc.M509952200; Hossain MM, 2003, AM J PHYSIOL-CELL PH, V284, pC156, DOI 10.1152/ajpcell.00233.2002; Isogai S, 2003, DEVELOPMENT, V130, P5281, DOI 10.1242/dev.00733; Je HD, 2001, J PHYSIOL-LONDON, V537, P567, DOI 10.1111/j.1469-7793.2001.00567.x; Jin JP, 2003, PROTEIN EXPRES PURIF, V31, P231, DOI 10.1016/S1046-5928(03)00185-2; JOWETT T, 1994, TRENDS GENET, V10, P73, DOI 10.1016/0168-9525(94)90220-8; KIMMEL CB, 1995, DEV DYNAM, V203, P253, DOI 10.1002/aja.1002030302; Klemke RL, 1997, J CELL BIOL, V137, P481, DOI 10.1083/jcb.137.2.481; Lai CF, 2001, J BIOL CHEM, V276, P14443, DOI 10.1074/jbc.M010021200; Lawson ND, 2002, DEV BIOL, V248, P307, DOI 10.1006/dbio.2002.0711; Lee P, 2002, P NATL ACAD SCI USA, V99, P10470, DOI 10.1073/pnas.162366299; Leinweber B, 2000, J BIOL CHEM, V275, P40329, DOI 10.1074/jbc.M008257200; Leinweber BD, 1999, BIOCHEM J, V344, P117, DOI 10.1042/0264-6021:3440117; Liang D, 1998, BBA-GENE STRUCT EXPR, V1397, P14, DOI 10.1016/S0167-4781(97)00233-9; Lyons MS, 1998, DEV DYNAM, V212, P133, DOI 10.1002/(SICI)1097-0177(199805)212:1<133::AID-AJA12>3.0.CO;2-8; Mabuchi K, 1997, J BIOL CHEM, V272, P22662, DOI 10.1074/jbc.272.36.22662; Masuda H, 1996, J BIOCHEM-TOKYO, V120, P415; Menice CB, 1997, J BIOL CHEM, V272, P25157, DOI 10.1074/jbc.272.40.25157; Morgan KG, 2001, J APPL PHYSIOL, V91, P953, DOI 10.1152/jappl.2001.91.2.953; Nasevicius A, 2000, NAT GENET, V26, P216, DOI 10.1038/79951; Pintucci G, 2002, FASEB J, V16, P598, DOI 10.1096/fj.01-0815fje; Ransom DG, 1996, DEVELOPMENT, V123, P311; Rikitake Y, 2000, ARTERIOSCL THROM VAS, V20, P1006, DOI 10.1161/01.ATV.20.4.1006; Risau W, 1995, ANNU REV CELL DEV BI, V11, P73, DOI 10.1146/annurev.cb.11.110195.000445; Roman BL, 2000, BIOESSAYS, V22, P882; Sakihara C, 1996, BIOCHEM BIOPH RES CO, V222, P195, DOI 10.1006/bbrc.1996.0721; Samaj J, 2004, J EXP BOT, V55, P189, DOI 10.1093/jxb/erh012; Seth P, 2005, BIOCHEM BIOPH RES CO, V332, P533, DOI 10.1016/j.bbrc.2005.03.250; Szymanski PT, 1997, BIOCHEM J, V321, P519, DOI 10.1042/bj3210519; SZYMANSKI PT, 1993, FEBS LETT, V334, P378; TAKAHASHI K, 1988, J HYPERTENS, V6, pS40, DOI 10.1097/00004872-198812040-00008; Thisse B, 2004, METHOD CELL BIOL, V77, P505; Thompson MA, 1998, DEV BIOL, V197, P248, DOI 10.1006/dbio.1998.8887; Tsakiridis T, 1998, J BIOL CHEM, V273, P28322, DOI 10.1074/jbc.273.43.28322; VANCOMPERNOLLE K, 1990, FEBS LETT, V274, P146, DOI 10.1016/0014-5793(90)81350-W; WEINSTEIN BM, 1995, NAT MED, V1, P1143, DOI 10.1038/nm1195-1143; Westerfield M, 2000, ZEBRAFISH BOOK GUIDE	48	46	52	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 10	2006	281	10					6664	6672		10.1074/jbc.M506991200	http://dx.doi.org/10.1074/jbc.M506991200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	022BX	16317011	hybrid			2022-12-25	WOS:000236030800063
J	DeRossi, C; Bode, L; Eklund, EA; Zhang, FR; Davis, JA; Westphal, V; Wang, L; Borowsky, AD; Freeze, HH				DeRossi, C; Bode, L; Eklund, EA; Zhang, FR; Davis, JA; Westphal, V; Wang, L; Borowsky, AD; Freeze, HH			Ablation of mouse phosphomannose isomerase (Mpi) causes mannose 6-phosphate accumulation, toxicity, and embryonic lethality	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HETEROLOGOUS EXPRESSION; CLONING; GLYCOSYLATION; HYPOGLYCEMIA; GLYCOLYSIS; DEFICIENCY; METABOLISM; INGESTION; THERAPY; IB	MPI encodes phosphomannose isomerase, which interconverts fructose 6-phosphate and mannose 6-phosphate (Man-6-P), used for glycoconjugate biosynthesis. MPI mutations in humans impair protein glycosylation causing congenital disorder of glycosylation Ib (CDG-Ib), but oral mannose supplements normalize glycosylation. To establish a mannose-responsive mouse model for CDG-Ib, we ablated Mpi and provided dams with mannose to rescue the anticipated defective glycosylation. Surprisingly, although glycosylation was normal, Mpi(-/-) embryos died around E11.5. Mannose supplementation even hastened their death, suggesting that mannose was toxic. Mpi(-/-) embryos showed growth retardation and placental hyperplasia. More than 90% of Mpi(-/-) embryos failed to form yolk sac vasculature, and 35% failed chorioallantoic fusion. We generated primary embryonic fibroblasts to investigate the mechanisms leading to embryonic lethality and found that mannose caused a concentration- and time-dependent accumulation of Man-6-P in Mpi(-/-) fibroblasts. In parallel, ATP decreased by more than 70% after 24 h compared with Mpi(+/+) controls. In cell lysates, Man-6- P inhibited hexokinase (70%), phosphoglucose isomerase (65%), and glucose-6-phosphate dehydrogenase (85%), but not phosphofructokinase. Incubating intact Mpi(-/-) fibroblasts with 2-[H-3]deoxyglucose confirmed mannose-dependent hexokinase inhibition. Our results in vitro suggest that mannose toxicity in Mpi(-/-) embryos is caused by Man-6-P accumulation, which inhibits glucose metabolism and depletes intracellular ATP. This was confirmed in E10.5 Mpi(-/-) embryos where Man-6-P increased more than 10 times, and ATP decreased by 50% compared with Mpi(+/+) littermates. Because Mpi ablation is embryonic lethal, a murine CDG-Ib model will require hypomorphic Mpi alleles.	Burnham Inst Med Res, Glycobiol & Carbohydrate Chem Program, La Jolla, CA 92037 USA; Univ Calif Davis, Davis, CA 95616 USA	Sanford Burnham Prebys Medical Discovery Institute; University of California System; University of California Davis	Freeze, HH (corresponding author), Burnham Inst Med Res, Glycobiol & Carbohydrate Chem Program, 10901 N Torrey Pines Rd, La Jolla, CA 92037 USA.	hudson@burnham.org	Borowsky, Alexander D/S-5404-2017	Freeze, Hudson/0000-0001-6316-0501	NIDDK NIH HHS [R01 DK 065091] Funding Source: Medline; NIGMS NIH HHS [R01 GM 55695] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK065091] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM055695] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Adelman DM, 2000, GENE DEV, V14, P3191, DOI 10.1101/gad.853700; Alton G, 1997, BIOCHEM MOL MED, V60, P127, DOI 10.1006/bmme.1997.2574; Alton G, 1998, GLYCOBIOLOGY, V8, P285, DOI 10.1093/glycob/8.3.285; Babovic-Vuksanovic D, 1999, J PEDIATR-US, V135, P775, DOI 10.1016/S0022-3476(99)70103-4; BUCHANAN T, 1985, J CLIN INVEST, V75, P1927, DOI 10.1172/JCI111908; COPP AJ, 1995, TRENDS GENET, V11, P87, DOI 10.1016/S0168-9525(00)89008-3; Davis JA, 2002, GLYCOBIOLOGY, V12, P435, DOI 10.1093/glycob/cwf060; Davis JA, 2001, BBA-GEN SUBJECTS, V1528, P116, DOI 10.1016/S0304-4165(01)00183-0; de Lonlay P, 1999, J PEDIATR-US, V135, P379, DOI 10.1016/S0022-3476(99)70139-3; DELAFUENTE M, 1986, BIOCHEM BIOPH RES CO, V140, P51, DOI 10.1016/0006-291X(86)91056-9; DELAFUENTE M, 1988, BRIT J CANCER, V58, P567, DOI 10.1038/bjc.1988.260; Firulli AB, 1998, NAT GENET, V18, P266, DOI 10.1038/ng0398-266; Freeze HH, 2001, GLYCOBIOLOGY, V11, p129R, DOI 10.1093/glycob/11.12.129R; FREINKEL N, 1984, NEW ENGL J MED, V310, P223, DOI 10.1056/NEJM198401263100404; Harms HK, 2002, ACTA PAEDIATR, V91, P1065, DOI 10.1080/080352502760311566; Joyner AL, 1993, GENE TARGETING PRACT; Kelly A, 1996, DEV DYNAM, V207, P300; Kelly A, 2002, GENESIS, V33, P29, DOI 10.1002/gene.10085; Marquardt T, 2003, EUR J PEDIATR, V162, P359, DOI 10.1007/s00431-002-1136-0; MOORE DCP, 1987, LIFE SCI, V41, P1885, DOI 10.1016/0024-3205(87)90739-9; NICHOLS EA, 1973, BIOCHEM GENET, V8, P47, DOI 10.1007/BF00485556; Niehues R, 1998, J CLIN INVEST, V101, P1414, DOI 10.1172/JCI2350; Oehler R, 1996, ANAL BIOCHEM, V241, P269, DOI 10.1006/abio.1996.0412; Packer NH, 1998, GLYCOCONJUGATE J, V15, P737, DOI 10.1023/A:1006983125913; PAYTON MA, 1991, J BACTERIOL, V173, P2006, DOI 10.1128/jb.173.6.2006-2010.1991; Pitkanen JP, 2004, J BIOL CHEM, V279, P55737, DOI 10.1074/jbc.M410619200; PROUDFOOT AEI, 1994, EUR J BIOCHEM, V219, P415, DOI 10.1111/j.1432-1033.1994.tb19954.x; Sapin V, 2001, TRANSGENIC RES, V10, P377, DOI 10.1023/A:1012085713898; SMITH DJ, 1995, YEAST, V11, P301, DOI 10.1002/yea.320110402; SMITH DJ, 1992, MOL CELL BIOL, V12, P2924, DOI 10.1128/MCB.12.7.2924; Sola-Penna M, 2002, J BIOCHEM BIOPH METH, V50, P129, DOI 10.1016/S0165-022X(01)00180-4; SOLS A, 1960, SCIENCE, V131, P297, DOI 10.1126/science.131.3396.297; Stanford WL, 2001, NAT REV GENET, V2, P756, DOI 10.1038/35093548; STOCCHI V, 1987, ANAL BIOCHEM, V167, P181, DOI 10.1016/0003-2697(87)90150-3; Westphal V, 2001, MOL GENET METAB, V73, P77, DOI 10.1006/mgme.2001.3161; Zambrowicz BP, 1998, NATURE, V392, P608, DOI 10.1038/33423	36	64	69	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 3	2006	281	9					5916	5927		10.1074/jbc.M511982200	http://dx.doi.org/10.1074/jbc.M511982200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	015RQ	16339137	hybrid			2022-12-25	WOS:000235568900072
J	Halenius, A; Momburg, F; Reinhard, H; Bauer, D; Lobigs, M; Hengel, H				Halenius, A; Momburg, F; Reinhard, H; Bauer, D; Lobigs, M; Hengel, H			Physical and functional interactions of the cytomegalovirus US6 glycoprotein with the transporter associated with antigen processing	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MAJOR HISTOCOMPATIBILITY COMPLEX; CLASS-I MOLECULES; INHIBITS PEPTIDE TRANSLOCATION; ENDOPLASMIC-RETICULUM; VACCINIA VIRUS; PROTEIN ICP47; BINDING-SITE; CELL-LINE; TAP; DOMAINS	The endoplasmic reticulum-resident human cytomegalovirus glycoprotein US6 (gpUS6) inhibits peptide translocation by the transporter associated with antigen processing ( TAP) to prevent loading of major histocompatibility complex class I molecules and antigen presentation to CD8+ T cells. TAP is formed by two subunits, TAP1 and TAP2, each containing one multispanning transmembrane domain (TMD) and a cytosolic nucleotide binding domain. Here we reported that the blockade of TAP by gpUS6 is species-restricted, i.e. gpUS6 inhibits human TAP but not rat TAP. Co-expression of human and rat subunits of TAP demonstrates independent binding of gpUS6 to human TAP1 and TAP2, whereas gpUS6 does not bind to rat TAP subunits. gpUS6 associates with preformed TAP1/2 heterodimers but not with unassembled TAP subunits. To locate domains of TAP required for gpUS6 binding and function, we took advantage of reciprocal human/rat intrachain TAP chimeras. Each TAP subunit forms two contact sites within its TMD interacting with gpUS6. The dominant gpUS6-binding site on TAP2 maps to an N-terminal loop, whereas inhibition of peptide transport is mediated by a C-terminal loop of the TMD. For TAP1, two gpUS6 binding domains are formed by loops of the C-terminal TMD. The domain required for TAP inactivation is built by a distal loop of the C-terminal TMD, indicating a topology of TAP1 comprising 10 endoplasmic reticulum transmembrane segments. By forming multimeric complexes, gpUS6 reaches the distant target domains to arrest peptide transport. The data revealed a nonanalogous multipolar bridging of the TAP TMDs by gpUS6.	Robert Koch Inst, Div Viral Infect, D-13353 Berlin, Germany; German Canc Res Ctr, Div Mol Immunol, D-69120 Heidelberg, Germany; Australian Natl Univ, John Curtin Sch Med Res, Div Immunol & Genet, Acton, ACT 0200, Australia; Univ Dusseldorf, Inst Virol, D-40225 Dusseldorf, Germany	Robert Koch Institute; Helmholtz Association; German Cancer Research Center (DKFZ); Australian National University; John Curtin School of Medical Research; Heinrich Heine University Dusseldorf	Hengel, H (corresponding author), Robert Koch Inst, Div Viral Infect, Nordurfer 20, D-13353 Berlin, Germany.	hartmut.hengel@uni-duesseldorf.de	lobigs, mario/ABC-5711-2020					Abele R, 1999, BBA-BIOMEMBRANES, V1461, P405, DOI 10.1016/S0005-2736(99)00171-6; Ahn K, 1997, IMMUNITY, V6, P613, DOI 10.1016/S1074-7613(00)80349-0; Ahn K, 1996, EMBO J, V15, P3247, DOI 10.1002/j.1460-2075.1996.tb00689.x; ANDROLEWICZ MJ, 1994, P NATL ACAD SCI USA, V91, P12716, DOI 10.1073/pnas.91.26.12716; Antoniou AN, 2002, IMMUNOLOGY, V106, P182, DOI 10.1046/j.1365-2567.2002.01415.x; Armandola EA, 1996, EUR J IMMUNOL, V26, P1748, DOI 10.1002/eji.1830260813; ARNOLD B, 1984, CELL, V38, P79, DOI 10.1016/0092-8674(84)90528-2; Arora S, 2001, P NATL ACAD SCI USA, V98, P7241, DOI 10.1073/pnas.131132198; Atalay R, 2002, J VIROL, V76, P8596, DOI 10.1128/JVI.76.17.8596-8608.2002; BANKS TA, 1994, VIROLOGY, V200, P236, DOI 10.1006/viro.1994.1181; Benz C, 2001, J GEN VIROL, V82, P2061, DOI 10.1099/0022-1317-82-9-2061; Bouvier M, 2003, MOL IMMUNOL, V39, P697, DOI 10.1016/S0161-5890(02)00261-4; DEVERSON EV, 1990, NATURE, V348, P738, DOI 10.1038/348738a0; Gaudet R, 2001, EMBO J, V20, P4964, DOI 10.1093/emboj/20.17.4964; Hengel H, 1998, TRENDS MICROBIOL, V6, P190, DOI 10.1016/S0966-842X(98)01255-4; Hengel H, 1996, J GEN VIROL, V77, P2287, DOI 10.1099/0022-1317-77-9-2287; Hengel H, 1997, IMMUNITY, V6, P623, DOI 10.1016/S1074-7613(00)80350-7; Hewitt EW, 2001, EMBO J, V20, P387, DOI 10.1093/emboj/20.3.387; HILL A, 1995, NATURE, V375, P411, DOI 10.1038/375411a0; JOLY E, 1994, IMMUNOGENETICS, V40, P45, DOI 10.1007/BF00163963; KELLY A, 1992, NATURE, V355, P641, DOI 10.1038/355641a0; KLAR D, 1989, EMBO J, V8, P475, DOI 10.1002/j.1460-2075.1989.tb03400.x; Koch J, 2004, J BIOL CHEM, V279, P10142, DOI 10.1074/jbc.M312816200; Koopmann JO, 2000, IMMUNITY, V13, P117, DOI 10.1016/S1074-7613(00)00013-3; Koopmann JO, 1996, EUR J IMMUNOL, V26, P1720, DOI 10.1002/eji.1830260809; Kyritsis C, 2001, J BIOL CHEM, V276, P48031, DOI 10.1074/jbc.M108528200; Lehner PJ, 1997, P NATL ACAD SCI USA, V94, P6904, DOI 10.1073/pnas.94.13.6904; LIVNEH E, 1986, J CELL BIOL, V103, P327, DOI 10.1083/jcb.103.2.327; LOBIGS M, 1995, IMMUNOL CELL BIOL, V73, P181, DOI 10.1038/icb.1995.29; MEYER TH, 1994, FEBS LETT, V351, P443, DOI 10.1016/0014-5793(94)00908-2; Misaghi S, 2004, J VIROL, V78, P413, DOI 10.1128/JVI.78.1.413-423.2004; Momburg F, 2002, CURR TOP MICROBIOL, V269, P57; Momburg F, 2002, MOL IMMUNOL, V39, P217, DOI 10.1016/S0161-5890(02)00103-7; MOMBURG F, 1992, NATURE, V360, P174, DOI 10.1038/360174a0; Momburg F, 1998, ADV IMMUNOL, V68, P191, DOI 10.1016/S0065-2776(08)60560-X; NEEFJES JJ, 1993, SCIENCE, V261, P769, DOI 10.1126/science.8342042; Nijenhuis M, 1996, J IMMUNOL, V157, P5467; Nijenhuis M, 1996, J IMMUNOL, V156, P2186; POWIS SJ, 1991, NATURE, V354, P528, DOI 10.1038/354528a0; Reits EAJ, 2000, NATURE, V404, P774, DOI 10.1038/35008103; RUSS G, 1995, J BIOL CHEM, V270, P21312, DOI 10.1074/jbc.270.36.21312; Tomazin R, 1998, J VIROL, V72, P2560, DOI 10.1128/JVI.72.3.2560-2563.1998; Tomazin R, 1996, EMBO J, V15, P3256, DOI 10.1002/j.1460-2075.1996.tb00690.x; TROWSDALE J, 1990, NATURE, V348, P741, DOI 10.1038/348741a0; van Endert PM, 2002, TRENDS BIOCHEM SCI, V27, P454, DOI 10.1016/S0968-0004(02)02090-X; VANENDERT PM, 1994, IMMUNITY, V1, P491, DOI 10.1016/1074-7613(94)90091-4; VOLKMER H, 1987, J EXP MED, V166, P668, DOI 10.1084/jem.166.3.668; Vos JC, 1999, J IMMUNOL, V163, P6679; Vos JC, 2000, CURR BIOL, V10, P1, DOI 10.1016/S0960-9822(99)00257-2	49	37	39	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 3	2006	281	9					5383	5390		10.1074/jbc.M510223200	http://dx.doi.org/10.1074/jbc.M510223200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	015RQ	16356928	hybrid			2022-12-25	WOS:000235568900009
J	Williams, KJ; Halkes, KM; Kamerling, JP; DeAngelis, PL				Williams, KJ; Halkes, KM; Kamerling, JP; DeAngelis, PL			Critical elements of oligosaccharide acceptor substrates for the Pasteurella multocida hyaluronan synthase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							2 ACTIVE-SITES; MOLECULAR-CLONING; CRYSTAL-STRUCTURE; CHEMOENZYMATIC SYNTHESIS; CHONDROITIN SYNTHASE; HEPAROSAN SYNTHASE; IDENTIFICATION; ENZYME; GLYCOSYLTRANSFERASES; BIOSYNTHESIS	Three-dimensional structures are not available for polysaccharide synthases and only minimal information on the molecular basis for catalysis is known. The Pasteurella multocida hyaluronan synthase (PmHAS) catalyzes the polymerization of the alternating beta 1,3-N-acetylglucosamine-beta 1,4-glucuronic acid sugar chain by the sequential addition of single monosaccharides to the non-reducing terminus. Therefore, PmHAS possesses both GlcNAc-transferase and glucuronic acid (GlcUA)-transferase activities. The recombinant Escherichia coli-derived PmHAS enzyme will elongate exogenously supplied hyaluronan chains in vitro with either a single monosaccharide or a long chain depending on the UDP-sugar availability. Competition studies using pairs of acceptors with distinct termini ( where one oligosaccharide is a substrate that may be elongated, whereas the other cannot) were performed here; the lack of competition suggests that PmHAS contains at least two distinct acceptor sites. We hypothesize that the size of the acceptor binding pockets of the enzyme corresponds to the size of the smallest high efficiency substrates; thus we tested the relative activity of a series of authentic hyaluronan oligosaccharides and related structural analogs. The GlcUA-transferase site readily elongates ( GlcNAc-GlcUA) 2, whereas the GlcNAc-transferase elongates GlcUA-GlcNAc- GlcUA. The minimally sized oligosaccharides, elongated with high efficiency, both contain a trisaccharide with two glucuronic acid residues that enabled the identification of a synthetic, artificial acceptor for the synthase. PmHAS behaves as a fusion of two complete glycosyltransferases, each containing a donor site and an acceptor site, in one polypeptide. Overall, this information advances the knowledge of glycosaminoglycan biosynthesis as well as assists the creation of various therapeutic sugars for medical applications in the future.	Univ Oklahoma, Hlth Sci Ctr, Dept Biochem & Mol Biol, Oklahoma Ctr Med Glycobiol, Oklahoma City, OK 73104 USA; Univ Utrecht, Bijvoet Ctr, Dept Bioorgan Chem, NL-3508 TB Utrecht, Netherlands	University of Oklahoma System; University of Oklahoma Health Sciences Center; Utrecht University	DeAngelis, PL (corresponding author), Univ Oklahoma, Hlth Sci Ctr, Dept Biochem & Mol Biol, Oklahoma Ctr Med Glycobiol, 940 Stanton L Young Blvd, Oklahoma City, OK 73104 USA.	paul-deangelis@ouhsc.edu						DeAngelis PL, 2000, J BIOL CHEM, V275, P24124, DOI 10.1074/jbc.M003385200; DeAngelis PL, 1998, J BIOL CHEM, V273, P8454, DOI 10.1074/jbc.273.14.8454; DeAngelis PL, 2004, J BACTERIOL, V186, P8529, DOI 10.1128/JB.186.24.8529-8532.2004; Deangelis PL, 2003, J BIOL CHEM, V278, P35199, DOI 10.1074/jbc.M306431200; DEANGELIS PL, 1994, BIOCHEMISTRY-US, V33, P9033, DOI 10.1021/bi00197a001; DeAngelis PL, 1999, J BIOL CHEM, V274, P26557, DOI 10.1074/jbc.274.37.26557; DeAngelis PL, 2002, GLYCOBIOLOGY, V12, p9R, DOI 10.1093/glycob/12.1.9R; DeAngelis PL, 2002, J BIOL CHEM, V277, P7209, DOI 10.1074/jbc.M112130200; HADFIELD AT, 1994, J MOL BIOL, V243, P856, DOI 10.1006/jmbi.1994.1688; Halkes KM, 1998, CARBOHYD RES, V309, P161, DOI 10.1016/S0008-6215(98)00116-5; Jing W, 2000, GLYCOBIOLOGY, V10, P883, DOI 10.1093/glycob/10.9.883; Jing W, 2004, J BIOL CHEM, V279, P42345, DOI 10.1074/jbc.M402744200; Jing W, 2003, GLYCOBIOLOGY, V13, P661, DOI 10.1093/glycob/cwg085; LEE HG, 1994, ANAL BIOCHEM, V219, P278, DOI 10.1006/abio.1994.1267; Leemhuis H, 2002, J BIOL CHEM, V277, P1113, DOI 10.1074/jbc.M106667200; Negishi M, 2003, BIOCHEM BIOPH RES CO, V303, P393, DOI 10.1016/S0006-291X(03)00356-5; Ninomiya T, 2002, J BIOL CHEM, V277, P21567, DOI 10.1074/jbc.M201719200; Pedersen LC, 2003, J BIOL CHEM, V278, P14420, DOI 10.1074/jbc.M210532200; Pedersen LC, 2002, J BIOL CHEM, V277, P21869, DOI 10.1074/jbc.M112343200; RUPLEY JA, 1967, P NATL ACAD SCI USA, V57, P496, DOI 10.1073/pnas.57.3.496	20	32	35	0	15	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 3	2006	281	9					5391	5397		10.1074/jbc.M510439200	http://dx.doi.org/10.1074/jbc.M510439200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	015RQ	16361253	hybrid, Green Published			2022-12-25	WOS:000235568900010
J	Appleton, BA; Brooks, J; Loregian, A; Filman, DJ; Coen, DM; Hogle, JM				Appleton, BA; Brooks, J; Loregian, A; Filman, DJ; Coen, DM; Hogle, JM			Crystal structure of the cytomegalovirus DNA polymerase subunit UL44 in complex with the C terminus from the catalytic subunit - Differences in structure and function relative to unliganded UL44	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIMPLEX-VIRUS TYPE-1; ACCESSORY PROTEIN UL44; CLAMP LOADER COMPLEX; CELL NUCLEAR ANTIGEN; PROCESSIVITY FACTOR; BINDING PROTEIN; TRANSIENT COMPLEMENTATION; FLAP ENDONUCLEASE-1; VIRAL REPLICATION; PRIMER-TEMPLATE	The human cytomegalovirus DNA polymerase is composed of a catalytic subunit, UL54, and an accessory protein, UL44, which has a structural fold similar to that of other processivity factors, including herpes simplex virus UL42 and homotrimeric sliding clamps such as proliferating cell nuclear antigen. Several specific residues in the C-terminal region of UL54 and in the "connector loop" of UL44 are required for the association of these proteins. Here, we describe the crystal structure of residues 1-290 of UL44 in complex with a peptide from the extreme C terminus of UL54, which explains this interaction at a molecular level. The UL54 peptide binds to structural elements similar to those used by UL42 and the sliding clamps to associate with their respective binding partners. However, the details of the interaction differ from those of other processivity factor-peptide complexes. Crucial residues include a three-residue hydrophobic "plug" from the UL54 peptide and Ile(135) of UL44, which forms a critical intramolecular hydrophobic anchor for interactions between the connector loop and the peptide. As was the case for the unliganded UL44 structure, the UL44-peptide complex forms a head-to-head dimer that could potentially form a C-shaped clamp on DNA. However, the peptide-bound structure displays subtle differences in the relative orientation of the two subdomains of the protein, resulting in a more open clamp, which we predicted would affect its association with DNA. Indeed, filter binding assays revealed that peptide-bound UL44 binds DNA with higher affinity. Thus, interaction with the catalytic subunit appears to affect both the structure and function of UL44.	Harvard Univ, Sch Med, Dept Biol Chem & Mol Pharmacol, Boston, MA 02115 USA; Harvard Univ, Sch Med, Comm Virol, Boston, MA 02115 USA; Harvard Univ, Sch Med, Summer Honors Undergrad Res Program, Boston, MA 02115 USA	Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School	Hogle, JM (corresponding author), Harvard Univ, Sch Med, Dept Biol Chem & Mol Pharmacol, Bldg C-2,240 Longwood Ave, Boston, MA 02115 USA.	jhogle@hms.harvard.edu	Hogle, James/HIG-9121-2022	Hogle, James/0000-0002-3655-1504; filman, david/0000-0002-8714-1644; LOREGIAN, ARIANNA/0000-0002-8900-861X; Appleton, Brent/0000-0003-1136-5649	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI019838, U01AI032480, R01AI032480] Funding Source: NIH RePORTER; NIAID NIH HHS [AI19838, AI32480, R01 AI019838] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Appleton BA, 2004, MOL CELL, V15, P233, DOI 10.1016/j.molcel.2004.06.018; Bowman GD, 2004, NATURE, V429, P724, DOI 10.1038/nature02585; Bridges KG, 2001, J VIROL, V75, P4990, DOI 10.1128/JVI.75.11.4990-4998.2001; Bridges KG, 2000, J BIOL CHEM, V275, P472, DOI 10.1074/jbc.275.1.472; Bruning JB, 2004, STRUCTURE, V12, P2209, DOI 10.1016/j.str.2004.09.018; Bunting KA, 2003, EMBO J, V22, P5883, DOI 10.1093/emboj/cdg568; Burnouf DY, 2004, J MOL BIOL, V335, P1187, DOI 10.1016/j.jmb.2003.11.049; Chapados BR, 2004, CELL, V116, P39, DOI 10.1016/S0092-8674(03)01036-5; Chen XL, 2004, J BIOL CHEM, V279, P28375, DOI 10.1074/jbc.M400032200; Cihlar T, 1997, PROTEIN EXPRES PURIF, V11, P209, DOI 10.1006/prep.1997.0781; Coen DM, 2003, NAT REV DRUG DISCOV, V2, P278, DOI 10.1038/nrd1065; CRUTE JJ, 1989, J BIOL CHEM, V264, P19266; DIGARD P, 1995, P NATL ACAD SCI USA, V92, P1456, DOI 10.1073/pnas.92.5.1456; DIGARD P, 1993, J VIROL, V67, P398, DOI 10.1128/JVI.67.1.398-406.1993; ERTL PF, 1992, J VIROL, V66, P4126, DOI 10.1128/JVI.66.7.4126-4133.1992; GALLO ML, 1988, J VIROL, V62, P2874, DOI 10.1128/JVI.62.8.2874-2883.1988; GIBSON W, 1981, VIROLOGY, V111, P251, DOI 10.1016/0042-6822(81)90669-3; GOTTLIEB J, 1994, J VIROL, V68, P4937, DOI 10.1128/JVI.68.8.4937-4945.1994; GOTTLIEB J, 1990, J VIROL, V64, P5976, DOI 10.1128/JVI.64.12.5976-5987.1990; Gulbis JM, 1996, CELL, V87, P297, DOI 10.1016/S0092-8674(00)81347-1; Hayward S, 1998, PROTEINS, V30, P144, DOI 10.1002/(SICI)1097-0134(19980201)30:2<144::AID-PROT4>3.0.CO;2-N; HEILBRONN R, 1987, J VIROL, V61, P119, DOI 10.1128/JVI.61.1.119-124.1987; Jeruzalmi D, 2002, CURR OPIN STRUC BIOL, V12, P217, DOI 10.1016/S0959-440X(02)00313-5; Jeruzalmi D, 2001, CELL, V106, P417, DOI 10.1016/S0092-8674(01)00462-7; KONG XP, 1992, CELL, V69, P425, DOI 10.1016/0092-8674(92)90445-I; KOUZARIDES T, 1987, J VIROL, V61, P125, DOI 10.1128/JVI.61.1.125-133.1987; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; KRISHNA TSR, 1994, CELL, V79, P1233, DOI 10.1016/0092-8674(94)90014-0; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; LAWRENCE MC, 1993, J MOL BIOL, V234, P946, DOI 10.1006/jmbi.1993.1648; Loregian A, 2004, J VIROL, V78, P9084, DOI 10.1128/JVI.78.17.9084-9092.2004; Loregian A, 2004, J VIROL, V78, P158, DOI 10.1128/JVI.78.1.158-167.2004; Loregian A, 2003, J VIROL, V77, P8336, DOI 10.1128/JVI.77.15.8336-8344.2003; LOREGIAN A, 2006, IN PRESS CHEM BIOL; Maga G, 2003, J CELL SCI, V116, P3051, DOI 10.1242/jcs.00653; Makhov AM, 2004, J BIOL CHEM, V279, P40358, DOI 10.1074/jbc.M408733200; MAR EC, 1985, J VIROL, V56, P846, DOI 10.1128/JVI.56.3.846-851.1985; Matsumiya S, 2002, GENES CELLS, V7, P911, DOI 10.1046/j.1365-2443.2002.00572.x; McRee DE, 1999, J STRUCT BIOL, V125, P156, DOI 10.1006/jsbi.1999.4094; Merritt EA, 1997, METHOD ENZYMOL, V277, P505, DOI 10.1016/S0076-6879(97)77028-9; Murshudov GN, 1997, ACTA CRYSTALLOGR D, V53, P240, DOI 10.1107/S0907444996012255; NISHIYAMA Y, 1983, VIROLOGY, V124, P221, DOI 10.1016/0042-6822(83)90339-2; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Pages V, 2002, ONCOGENE, V21, P8957, DOI 10.1038/sj.onc.1206006; PARI GS, 1993, J VIROL, V67, P2575, DOI 10.1128/JVI.67.5.2575-2582.1993; PARI GS, 1993, J VIROL, V67, P6979, DOI 10.1128/JVI.67.12.6979-6988.1993; PARRIS DS, 1988, J VIROL, V62, P818, DOI 10.1128/JVI.62.3.818-825.1988; Pilger BD, 2004, CHEM BIOL, V11, P647, DOI 10.1016/j.chembiol.2004.01.018; Randell JCW, 2004, J MOL BIOL, V335, P409, DOI 10.1016/j.jmb.2003.10.064; RIPALTI A, 1995, J VIROL, V69, P2047, DOI 10.1128/JVI.69.4.2047-2057.1995; Sakurai S, 2005, EMBO J, V24, P683, DOI 10.1038/sj.emboj.7600519; Shamoo Y, 1999, CELL, V99, P155, DOI 10.1016/S0092-8674(00)81647-5; Terwilliger TC, 1999, ACTA CRYSTALLOGR D, V55, P849, DOI 10.1107/S0907444999000839; Terwilliger TC, 2000, ACTA CRYSTALLOGR D, V56, P965, DOI 10.1107/S0907444900005072; Thornton KE, 2000, VIROLOGY, V275, P373, DOI 10.1006/viro.2000.0506; Vivona JB, 2003, FEBS LETT, V546, P167, DOI 10.1016/S0014-5793(03)00622-7; WEILAND KL, 1994, VIRUS RES, V34, P191, DOI 10.1016/0168-1702(94)90124-4; Weisshart K, 1999, J VIROL, V73, P55, DOI 10.1128/JVI.73.1.55-66.1999; WU CA, 1988, J VIROL, V62, P435, DOI 10.1128/JVI.62.2.435-443.1988; Zuccola HJ, 2000, MOL CELL, V5, P267, DOI 10.1016/S1097-2765(00)80422-0	60	53	55	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 24	2006	281	8					5224	5232		10.1074/jbc.M506900200	http://dx.doi.org/10.1074/jbc.M506900200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	013RF	16371349	Green Published, hybrid			2022-12-25	WOS:000235426200077
J	Campos, LS; Decker, L; Taylor, V; Skarnes, W				Campos, LS; Decker, L; Taylor, V; Skarnes, W			Notch, epidermal growth factor receptor, and beta 1-integrin pathways are coordinated in neural stem cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RADIAL GLIAL IDENTITY; LIPID RAFTS; SIGNALING PATHWAY; EPITHELIAL-CELLS; PRECURSOR CELLS; EGF-RECEPTOR; INTEGRIN; DIFFERENTIATION; ACTIVATION; PROLIFERATION	Notch1 and beta 1-integrins are cell surface receptors involved in the recognition of the niche that surrounds stem cells through cell-cell and cell-extracellular matrix interactions, respectively. Notch1 is also involved in the control of cell fate choices in the developing central nervous system (Lewis, J. (1998) Semin. Cell Dev. Biol. 9, 583-589). Here we report that Notch and beta 1-integrins are co-expressed and that these proteins cooperate with the epidermal growth factor receptor in neural progenitors. We describe data that suggests that beta 1-integrins may affect Notch signaling through 1) physical interaction (sequestration) of the Notch intracellular domain fragment by the cytoplasmic tail of the beta 1-integrin and 2) affecting trafficking of the Notch intracellular domain via caveolin-mediated mechanisms. Our findings suggest that caveolin 1-containing lipid rafts play a role in the coordination and coupling of beta 1-integrin, Notch1, and tyrosine kinase receptor signaling pathways. We speculate that this will require the presence of the adequate beta 1-activating extracellular matrix or growth factors in restricted regions of the central nervous system and namely in neurogenic niches.	INSERM, Ecole Normale Super, U368, Paris, France; Max Planck Inst Immunobiol, Dept Mol Embryol, D-7800 Freiburg, Germany; Wellcome Trust Sanger Inst, Cambridge CB10 1SA, England	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; PSL Research University Paris; Ecole Normale Superieure (ENS); Max Planck Society; Wellcome Trust Sanger Institute	Campos, LS (corresponding author), INSERM, Ecole Normale Super, U368, Paris, France.	lsc@sanger.ac.uk		Taylor, Verdon/0000-0003-3497-5976	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		Akai J, 2003, CELL, V115, P510, DOI 10.1016/S0092-8674(03)00936-X; Alvarez-Buylla A, 2001, NAT REV NEUROSCI, V2, P287, DOI 10.1038/35067582; ANDERSON RGW, 1993, P NATL ACAD SCI USA, V90, P10909, DOI 10.1073/pnas.90.23.10909; Aszodi A, 2003, GENE DEV, V17, P2465, DOI 10.1101/gad.277003; BAIN G, 1995, DEV BIOL, V168, P342, DOI 10.1006/dbio.1995.1085; Baron W, 2003, CURR BIOL, V13, P151, DOI 10.1016/S0960-9822(02)01437-9; Bibel M, 2004, NAT NEUROSCI, V7, P1003, DOI 10.1038/nn1301; Bill HM, 2004, MOL CELL BIOL, V24, P8586, DOI 10.1128/MCB.24.19.8586-8599.2004; Billon N, 2002, J CELL SCI, V115, P3657, DOI 10.1242/jcs.00049; Blair SS, 2004, CURR BIOL, V14, pR570, DOI 10.1016/j.cub.2004.07.015; Blokzijl A, 2003, J CELL BIOL, V163, P723, DOI 10.1083/jcb.200305112; Brown DA, 2000, J BIOL CHEM, V275, P17221, DOI 10.1074/jbc.R000005200; Brustle O, 1999, SCIENCE, V285, P754, DOI 10.1126/science.285.5428.754; Burrows RC, 1997, NEURON, V19, P251, DOI 10.1016/S0896-6273(00)80937-X; Campos LS, 2004, J NEUROSCI RES, V78, P761, DOI 10.1002/jnr.20333; Campos LS, 2004, DEVELOPMENT, V131, P3433, DOI 10.1242/dev.01199; Campos LS, 2001, J NEUROSCI RES, V64, P590, DOI 10.1002/jnr.1111.abs; Campos LS, 2005, BIOESSAYS, V27, P698, DOI 10.1002/bies.20256; Capela A, 2002, NEURON, V35, P865, DOI 10.1016/S0896-6273(02)00835-8; Chojnacki A, 2003, J NEUROSCI, V23, P1730; Collins AT, 2001, J CELL SCI, V114, P3865; Culi J, 2001, DEVELOPMENT, V128, P299; De Arcangelis A, 2000, TRENDS GENET, V16, P389, DOI 10.1016/S0168-9525(00)02074-6; Decker L, 2004, J NEUROSCI, V24, P3816, DOI 10.1523/JNEUROSCI.5725-03.2004; del Pozo MA, 2005, NAT CELL BIOL, V7, P901, DOI 10.1038/ncb1293; del Pozo MA, 2004, SCIENCE, V303, P839, DOI 10.1126/science.1092571; Doetsch F, 2003, NAT NEUROSCI, V6, P1127, DOI 10.1038/nn1144; DRAGO J, 1991, EXP CELL RES, V196, P246, DOI 10.1016/0014-4827(91)90258-V; Faux CH, 2001, J NEUROSCI, V21, P5587, DOI 10.1523/JNEUROSCI.21-15-05587.2001; Flores GV, 2000, CELL, V103, P75, DOI 10.1016/S0092-8674(00)00106-9; Forster E, 2002, P NATL ACAD SCI USA, V99, P13178, DOI 10.1073/pnas.202035899; Franklin JL, 1999, CURR BIOL, V9, P1448, DOI 10.1016/S0960-9822(00)80114-1; Gaiano N, 2002, ANNU REV NEUROSCI, V25, P471, DOI 10.1146/annurev.neuro.25.030702.130823; Gaiano N, 2000, NEURON, V26, P395, DOI 10.1016/S0896-6273(00)81172-1; Georges-Labouesse E, 1998, CURR BIOL, V8, P983, DOI 10.1016/S0960-9822(98)70402-6; Giniger E, 1998, NEURON, V20, P667, DOI 10.1016/S0896-6273(00)81007-7; Golub T, 2004, CURR OPIN NEUROBIOL, V14, P542, DOI 10.1016/j.conb.2004.08.003; Gotz M, 2005, NEURON, V46, P369, DOI 10.1016/j.neuron.2005.04.012; Grandbarbe L, 2003, DEVELOPMENT, V130, P1391, DOI 10.1242/dev.00374; Hart A, 2003, DEV DYNAM, V228, P185, DOI 10.1002/dvdy.10368; Hitoshi S, 2002, GENE DEV, V16, P846, DOI 10.1101/gad.975202; Jacques TS, 1998, DEVELOPMENT, V125, P3167; Kuwada SK, 2000, MOL BIOL CELL, V11, P2485, DOI 10.1091/mbc.11.7.2485; Lai EC, 2003, J CELL BIOL, V162, P365, DOI 10.1083/jcb.200307087; Leitinger B, 2002, J CELL SCI, V115, P963; Leone DP, 2005, J CELL SCI, V118, P2589, DOI 10.1242/jcs.02396; Leong KG, 2002, MOL CELL BIOL, V22, P2830, DOI 10.1128/MCB.22.8.2830-2841.2002; Lewis J, 1998, SEMIN CELL DEV BIOL, V9, P583, DOI 10.1006/scdb.1998.0266; Lillien L, 2000, DEVELOPMENT, V127, P4993; Liour SS, 2003, GLIA, V42, P109, DOI 10.1002/glia.10202; Lundell MJ, 2003, DEVELOPMENT, V130, P4109, DOI 10.1242/dev.00593; Maillard I, 2003, IMMUNITY, V19, P781, DOI 10.1016/S1074-7613(03)00325-X; Martens DJ, 2000, J NEUROSCI, V20, P1085, DOI 10.1523/JNEUROSCI.20-03-01085.2000; Miyamoto Y, 2003, CANCER CELL, V3, P565, DOI 10.1016/S1535-6108(03)00140-5; Morimura T, 2000, J BIOL CHEM, V275, P36523, DOI 10.1074/jbc.M006415200; Moro L, 1998, EMBO J, V17, P6622, DOI 10.1093/emboj/17.22.6622; Munro S, 2003, CELL, V115, P377, DOI 10.1016/S0092-8674(03)00882-1; Nelson WJ, 2004, SCIENCE, V303, P1483, DOI 10.1126/science.1094291; Prince JM, 2002, DEV DYNAM, V223, P497, DOI 10.1002/dvdy.10070; Ramalho-Santos M, 2002, SCIENCE, V298, P597, DOI 10.1126/science.1072530; REYNOLDS BA, 1992, J NEUROSCI, V12, P4565, DOI 10.1523/jneurosci.12-11-04565.1992; REYNOLDS BA, 1992, SCIENCE, V255, P1707, DOI 10.1126/science.1553558; Sade H, 2004, J BIOL CHEM, V279, P2937, DOI 10.1074/jbc.M309924200; Schweisguth F, 2004, CURR BIOL, V14, pR129, DOI 10.1016/j.cub.2004.01.023; Sestan N, 1999, SCIENCE, V286, P741, DOI 10.1126/science.286.5440.741; Seugnet L, 1997, DEV BIOL, V192, P585, DOI 10.1006/dbio.1997.8723; Simons K, 2000, NAT REV MOL CELL BIO, V1, P31, DOI 10.1038/35036052; SVENDSEN CN, 1995, EXP BRAIN RES, V102, P407; Takagi J, 2002, CELL, V110, P599, DOI 10.1016/S0092-8674(02)00935-2; Tropepe V, 2001, NEURON, V30, P65, DOI 10.1016/S0896-6273(01)00263-X; Wang F, 1998, P NATL ACAD SCI USA, V95, P14821, DOI 10.1073/pnas.95.25.14821; Wang WD, 2004, DEVELOPMENT, V131, P5367, DOI 10.1242/dev.01413; Watanabe N, 2003, J BONE MINER METAB, V21, P344, DOI 10.1007/s00774-003-0428-4; Watt FM, 2002, J DERMATOL SCI, V28, P173, DOI 10.1016/S0923-1811(02)00003-8; Yanagisawa M, 2004, GENES CELLS, V9, P801, DOI 10.1111/j.1365-2443.2004.00764.x; Ying QL, 2003, NAT BIOTECHNOL, V21, P183, DOI 10.1038/nbt780; Yoon KJ, 2004, J NEUROSCI, V24, P9497, DOI 10.1523/JNEUROSCI.0993-04.2004; Zhong WM, 1997, DEVELOPMENT, V124, P1887; Zine A, 2001, J NEUROSCI, V21, P4712, DOI 10.1523/JNEUROSCI.21-13-04712.2001	79	120	128	0	17	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 24	2006	281	8					5300	5309		10.1074/jbc.M511886200	http://dx.doi.org/10.1074/jbc.M511886200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	013RF	16332675	hybrid			2022-12-25	WOS:000235426200084
J	Sher, RB; Aoyama, C; Huebsch, KA; Ji, SN; Kerner, J; Yang, Y; Frankel, WN; Hoppel, CL; Wood, PA; Vance, DE; Cox, GA				Sher, RB; Aoyama, C; Huebsch, KA; Ji, SN; Kerner, J; Yang, Y; Frankel, WN; Hoppel, CL; Wood, PA; Vance, DE; Cox, GA			A rostrocaudal muscular dystrophy caused by a defect in choline kinase beta, the first enzyme in phosphatidylcholine biosynthesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CARNITINE PALMITOYLTRANSFERASE-I; CHOLINE/ETHANOLAMINE KINASE; MEMBRANE-REPAIR; NERVOUS-SYSTEM; MOUSE MODELS; RAT-LIVER; SKELETAL; GENE; DISRUPTION; DYSFERLIN	Muscular dystrophies include a diverse group of genetically heterogeneous disorders that together affect 1 in 2000 births worldwide. The diseases are characterized by progressive muscle weakness and wasting that lead to severe disability and often premature death. Rostrocaudal muscular dystrophy (rmd) is a new recessive mouse mutation that causes a rapidly progressive muscular dystrophy and a neonatal forelimb bone deformity. The rmd mutation is a 1.6-kb intragenic deletion within the choline kinase beta (Chkb) gene, resulting in a complete loss of CHKB protein and enzymatic activity. CHKB is one of two mammalian choline kinase (CHK) enzymes (alpha and beta) that catalyze the phosphorylation of choline to phosphocholine in the biosynthesis of the major membrane phospholipid phosphatidylcholine. While mutant rmd mice show a dramatic decrease of CHK activity in all tissues, the dystrophy is only evident in skeletal muscle tissues in an unusual rostral-to-caudal gradient. Minor membrane disruption similar to dysferlinopathies suggest that membrane fusion defects may underlie this dystrophy, because severe membrane disruptions are not evident as determined by creatine kinase levels, Evans Blue infiltration, and unaltered levels of proteins in the dystrophin-glycoprotein complex. The rmd mutant mouse offers the first demonstration of a defect in a phospholipid biosynthetic enzyme causing muscular dystrophy, representing a unique model for understanding mechanisms of muscle degeneration.	Jackson Lab, Bar Harbor, ME 04609 USA; Univ Alberta, Dept Biochem, Edmonton, AB T6G 252, Canada; Univ Alabama Birmingham, Dept Genet, Birmingham, AL 35294 USA; Case Western Reserve Univ, Dept Nutr, Cleveland, OH 44106 USA; Case Western Reserve Univ, Dept Pharmacol, Cleveland, OH 44106 USA; Case Western Reserve Univ, Dept Med, Cleveland, OH 44106 USA; Louis Stokes Vet Affairs Med Ctr, Cleveland, OH 44106 USA	Jackson Laboratory; University of Alberta; University of Alabama System; University of Alabama Birmingham; Case Western Reserve University; Case Western Reserve University; Case Western Reserve University; US Department of Veterans Affairs; Veterans Health Administration (VHA); Case Western Reserve University; Louis Stokes Cleveland Veterans Affairs Medical Center	Cox, GA (corresponding author), Jackson Lab, 600 Main St, Bar Harbor, ME 04609 USA.	gac@jax.org			NATIONAL CANCER INSTITUTE [P30CA034196] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [R01RR002599] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR049043] Funding Source: NIH RePORTER; NCI NIH HHS [CA34196] Funding Source: Medline; NCRR NIH HHS [R01-RR-02599] Funding Source: Medline; NIAMS NIH HHS [AR-49043] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		ADACHI K, 1994, EXP MOL PATHOL, V61, P134, DOI 10.1006/exmp.1994.1032; ANDERSON JE, 1991, BIOCHEM CELL BIOL, V69, P835, DOI 10.1139/o91-124; Aoyama C, 2004, PROG LIPID RES, V43, P266, DOI 10.1016/j.plipres.2003.12.001; Aoyama C, 2000, J LIPID RES, V41, P452; Aoyama C, 2002, BIOCHEM J, V363, P777, DOI 10.1042/0264-6021:3630777; Ausubel F. M., 1999, SHORT PROTOCOLS MOL; BAKKER E, 1998, NEUROMUSCULAR DISORD, P59; Balci B, 2005, NEUROMUSCULAR DISORD, V15, P271, DOI 10.1016/j.nmd.2005.01.013; Bansal D, 2004, TRENDS CELL BIOL, V14, P206, DOI 10.1016/j.tcb.2004.03.001; Bansal D, 2003, NATURE, V423, P168, DOI 10.1038/nature01573; Bergo MO, 2002, J BIOL CHEM, V277, P47701, DOI 10.1074/jbc.M207734200; Boas FE, 1998, P NATL ACAD SCI USA, V95, P3077, DOI 10.1073/pnas.95.6.3077; Boon JM, 2002, MED RES REV, V22, P251, DOI 10.1002/med.10009; Cohn RD, 2000, MUSCLE NERVE, V23, P1456, DOI 10.1002/1097-4598(200010)23:10<1456::AID-MUS2>3.0.CO;2-T; Connor WE, 1997, J LIPID RES, V38, P2516; Cui Z, 2002, BBA-MOL CELL BIOL L, V1585, P87, DOI 10.1016/S1388-1981(02)00328-1; Daleke DL, 2003, J LIPID RES, V44, P233, DOI 10.1194/jlr.R200019-JLR200; Devaux PF, 2004, TRAFFIC, V5, P241, DOI 10.1111/j.1600-0854.2004.0170.x; Emery AEH, 2002, NEUROMUSCULAR DISORD, V12, P343, DOI 10.1016/S0960-8966(01)00303-0; ERVASTI JM, 1990, NATURE, V345, P315, DOI 10.1038/345315a0; EUSEBI F, 1986, BIOCHIM BIOPHYS ACTA, V855, P197, DOI 10.1016/0005-2736(86)90206-3; FOLCH J, 1957, J BIOL CHEM, V226, P497; Grewal PK, 2003, HUM MOL GENET, V12, pR259, DOI 10.1093/hmg/ddg272; Hanshaw RG, 2005, BIOORGAN MED CHEM, V13, P5035, DOI 10.1016/j.bmc.2005.04.071; Hayashi YK, 2003, LANCET, V362, P843, DOI 10.1016/S0140-6736(03)14346-2; Ho M, 2004, HUM MOL GENET, V13, P1999, DOI 10.1093/hmg/ddh212; Hoppel CL, 1998, J BIOL CHEM, V273, P23495, DOI 10.1074/jbc.273.36.23495; Ilkovski B, 2001, AM J HUM GENET, V68, P1333, DOI 10.1086/320605; Infante JP, 1999, MOL CELL BIOCHEM, V195, P155, DOI 10.1023/A:1006972315739; Ishidate K, 1997, BBA-LIPID LIPID MET, V1348, P70, DOI 10.1016/S0005-2760(97)00118-5; ISHIDATE K, 1992, METHOD ENZYMOL, V209, P121; Kiss Z, 1999, CELL SIGNAL, V11, P149, DOI 10.1016/S0898-6568(98)00057-6; Le Rumeur E, 2003, J BIOL CHEM, V278, P5993, DOI 10.1074/jbc.M207321200; Liu J, 1998, NAT GENET, V20, P31, DOI 10.1038/1682; Lykidis A, 2001, PROG NUCLEIC ACID RE, V65, P361; MACBRINN MC, 1968, J LIPID RES, V9, P552; Manno S, 2002, P NATL ACAD SCI USA, V99, P1943, DOI 10.1073/pnas.042688399; McNeil PL, 2003, ANNU REV CELL DEV BI, V19, P697, DOI 10.1146/annurev.cellbio.19.111301.140101; McNeil PL, 2003, P NATL ACAD SCI USA, V100, P4592, DOI 10.1073/pnas.0736739100; Meeusen SL, 2005, CURR OPIN CELL BIOL, V17, P389, DOI 10.1016/j.ceb.2005.06.014; Michele DE, 2003, J BIOL CHEM, V278, P15457, DOI 10.1074/jbc.R200031200; Michele DE, 2002, NATURE, V418, P417, DOI 10.1038/nature00837; MOGGIO M, 1994, MUSCLE NERVE, V17, P485, DOI 10.1002/mus.880170503; MYHER JJ, 1989, LIPIDS, V24, P408, DOI 10.1007/BF02535148; NISHIJIMA M, 1984, J BIOL CHEM, V259, P7101; O'Brien KF, 2001, MOL GENET METAB, V74, P75, DOI 10.1006/mgme.2001.3220; OBrien TP, 1996, GENETICS, V143, P447; Pan HJ, 2005, DIABETES, V54, P1854, DOI 10.2337/diabetes.54.6.1854; Pereira J, 1999, THROMB HAEMOSTASIS, V82, P1318; RAND RP, 1989, BIOCHIM BIOPHYS ACTA, V988, P351, DOI 10.1016/0304-4157(89)90010-5; Rodriguez-Gonzalez A, 2005, INT J ONCOL, V26, P999; *SAS I, 2004, JMP STAT GRAPH GUID; Sasarman F, 2002, HUM MOL GENET, V11, P1669, DOI 10.1093/hmg/11.14.1669; Sharma U, 2003, NMR BIOMED, V16, P213, DOI 10.1002/nbm.832; Sharma U, 2003, MAGN RESON IMAGING, V21, P145, DOI 10.1016/S0730-725X(02)00646-X; Straub V, 1997, J CELL BIOL, V139, P375, DOI 10.1083/jcb.139.2.375; TANDLER B, 1986, ANN NY ACAD SCI, V488, P65; Tandler B, 2002, ULTRASTRUCT PATHOL, V26, P177, DOI 10.1080/01913120290076847; van der Leij FR, 2002, J BIOL CHEM, V277, P26994, DOI 10.1074/jbc.M203189200; VANCE DE, 1990, BIOCHEM CELL BIOL, V68, P1151, DOI 10.1139/o90-172; Walkey CJ, 1998, J BIOL CHEM, V273, P27043, DOI 10.1074/jbc.273.42.27043; Walkey CJ, 1997, P NATL ACAD SCI USA, V94, P12880, DOI 10.1073/pnas.94.24.12880; Wu H, 1996, BIOCHEMISTRY-US, V35, P12602, DOI 10.1021/bi960168q; Yamazaki N, 2000, J BIOL CHEM, V275, P31739, DOI 10.1074/jbc.M006322200; Yamazaki N, 2003, J BIOCHEM, V133, P523, DOI 10.1093/jb/mvg069; Yang Y, 2003, HUM MOL GENET, V12, P975, DOI 10.1093/hmg/ddg118	66	88	96	1	4	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 24	2006	281	8					4938	4948		10.1074/jbc.M512578200	http://dx.doi.org/10.1074/jbc.M512578200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	013RF	16371353	hybrid			2022-12-25	WOS:000235426200045
J	Angelo, PF; Lima, AR; Alves, FM; Blaber, SI; Scarisbrick, IA; Blaber, M; Juliano, L; Juliano, MA				Angelo, PF; Lima, AR; Alves, FM; Blaber, SI; Scarisbrick, IA; Blaber, M; Juliano, L; Juliano, MA			Substrate specificity of human kallikrein 6 - Salt and glycosaminoglycan activation effects	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN TISSUE KALLIKREIN; MOUSE SUBMANDIBULAR-GLAND; PROSTATE-SPECIFIC ANTIGEN; SERINE-PROTEASE; ZYME/PROTEASE M/NEUROSIN; CHONDROITIN SULFATE; MOLECULAR-CLONING; GENE FAMILY; IDENTIFICATION; TRYPSIN	Human kallikrein 6 ( hK6) is abundantly expressed in the central nervous system and is implicated in demyelinating disease. This study provided biochemical data about the substrate specificity and activation of hK6 by glycosaminoglycans and by kosmotropic salts, which followed the Hofmeister series. The screening of fluorescence resonance energy transfer ( FRET) peptide families derived from Abz-KLRSSKQ-EDDnp resulted in the finding that Abz-AFRFSQ- EDDnp ( where Abz is ortho-aminobenzoic acid and EDDnp is N-[2,4-dinitrophenyl]ethylenediamine)) is the best synthetic substrate described so far for hK6 ( k(cat)/K-m = 38,667 s(-1)mM(-1)). It is noteworthy that the AFRFS sequence was found as a motif in the amino-terminal domain of seven human ionotropic glutamate receptor subunits. We also examined the hK6 hydrolytic activity on FRET peptides derived from human myelin basic protein, precursor of the A beta amyloid peptide, reactive center loop of alpha(1)-antichymotrypsin, plasminogen, and maturation and inactivation cleavage sites of hK6, which were described earlier as natural substrates for hK6. The best substrates were derived from myelin basic protein. The hK6 maturation cleavage site was poorly hydrolyzed, and no evidence was found to support a two-step self-activation process reported previously. Finally, we assayed FRET peptides derived from sequences that span the cleavage sites for activation of protease-activated receptors ( PAR) 1 - 4, and only the substrate with the PAR 2 sequence was hydrolyzed. These results further supported the hypothesis that hK6 expressed in the central nervous system is involved in normal myelin turnover/demyelination processes, but it is unlikely to self-activate. This report also suggested the possible modulation of ionotropic glutamate receptors and activation of PAR 2 by hK6.	Univ Fed Sao Paulo, Dept Biofis Escola Paulista Med, BR-04044020 Sao Paulo, Brazil; Florida State Univ, Coll Med, Dept Biomed Sci, Tallahassee, FL 32306 USA; Mayo Med Rochester, Dept Neurol, Mayo Clin & Grad Sch, Rochester, MN 55905 USA; Mayo Med Rochester, Dept Phys Med, Mayo Clin & Grad Sch, Rochester, MN 55905 USA; Mayo Med Rochester, Dept Rehabil, Mayo Clin & Grad Sch, Rochester, MN 55905 USA	Universidade Federal de Sao Paulo (UNIFESP); State University System of Florida; Florida State University; Mayo Clinic; Mayo Clinic; Mayo Clinic	Juliano, MA (corresponding author), Univ Fed Sao Paulo, Dept Biofis Escola Paulista Med, Rua Tres Maio 100, BR-04044020 Sao Paulo, Brazil.	juliano.biof@epm.br	Juliano, Luiz/D-7204-2012; Blaber, Michael/N-1083-2019; Blaber, Michael/E-7478-2011; Messier, Claude/A-2322-2008; Blaber, Michael/ABA-5031-2021	Juliano, Luiz/0000-0002-5589-2822; Blaber, Michael/0000-0002-6856-1643; Messier, Claude/0000-0002-4791-1763; 				Anisowicz A, 1996, MOL MED, V2, P624, DOI 10.1007/BF03401646; Axen R., 1966, BIOCHEM BIOPH RES CO, V5, P353; Back SA, 2005, NAT MED, V11, P966, DOI 10.1038/nm1279; Bandtlow CE, 2000, PHYSIOL REV, V80, P1267, DOI 10.1152/physrev.2000.80.4.1267; Bayes A, 2004, BIOL CHEM, V385, P517, DOI 10.1515/BC.2004.061; Bernett MJ, 2002, J BIOL CHEM, V277, P24562, DOI 10.1074/jbc.M202392200; BLABER M, 1989, BIOCHEMISTRY-US, V28, P7813, DOI 10.1021/bi00445a043; Blaber SI, 2004, FASEB J, V18, P920, DOI 10.1096/fj.03-1212fje; Blaber SI, 2002, BIOCHEMISTRY-US, V41, P1165, DOI 10.1021/bi015781a; Borgono CA, 2004, NAT REV CANCER, V4, P876, DOI 10.1038/nrc1474; BOTHWELL MA, 1979, J BIOL CHEM, V254, P7287; Bourgeois L, 1997, J BIOL CHEM, V272, P29590, DOI 10.1074/jbc.272.47.29590; Bovolenta P, 2000, PROG NEUROBIOL, V61, P113, DOI 10.1016/S0301-0082(99)00044-1; Cacace MG, 1997, Q REV BIOPHYS, V30, P241, DOI 10.1017/S0033583597003363; CHAGAS JR, 1992, BIOCHEMISTRY-US, V31, P4969, DOI 10.1021/bi00136a008; CHAGAS JR, 1995, BIOCHEM J, V306, P63, DOI 10.1042/bj3060063; CHOI DW, 1992, J NEUROBIOL, V23, P1261, DOI 10.1002/neu.480230915; DELNERY E, 1995, BIOCHEM J, V312, P233, DOI 10.1042/bj3120233; Deperthes D, 1996, J ANDROL, V17, P659; Diamandis EP, 2000, CLIN BIOCHEM, V33, P579, DOI 10.1016/S0009-9120(00)00182-X; Dietrich CP, 1998, CELL MOL BIOL, V44, P417; ElMoujahed A, 1997, EUR J BIOCHEM, V247, P652; EVANS B, 1983, J BIOL CHEM, V258, P227; Felber LM, 2005, BIOL CHEM, V386, P291, DOI 10.1515/BC.2005.035; Fiedler F, 1979, Adv Exp Med Biol, V120A, P261; Fogaca SE, 2004, BIOCHEM J, V380, P775, DOI 10.1042/BJ20031047; GERALD WL, 1986, BIOCHIM BIOPHYS ACTA, V866, P1, DOI 10.1016/0167-4781(86)90093-X; Ghosh MC, 2004, TUMOR BIOL, V25, P193, DOI 10.1159/000081102; Gomis-Ruth FX, 2002, J BIOL CHEM, V277, P27273, DOI 10.1074/jbc.M201534200; Harvey TJ, 2000, J BIOL CHEM, V275, P37397, DOI 10.1074/jbc.M004525200; Hirata IY, 1995, LETT PEPT SCI, V1, P299, DOI DOI 10.1007/BF00119771; HOSOI K, 1994, J BIOCHEM-TOKYO, V115, P137, DOI 10.1093/oxfordjournals.jbchem.a124288; Huang XY, 2001, BIOCHEMISTRY-US, V40, P11734, DOI 10.1021/bi010364j; Hutchinson S, 2003, CLIN CHEM, V49, P746, DOI 10.1373/49.5.746; JAMESON GW, 1973, BIOCHEM J, V131, P107, DOI 10.1042/bj1310107; Jelesarov I, 1998, BIOCHEMISTRY-US, V37, P7539, DOI 10.1021/bi972977v; KIM WS, 1991, J BIOL CHEM, V266, P19283; Laxmikanthan G, 2005, PROTEINS, V58, P802, DOI 10.1002/prot.20368; Leatherbarrow R. J., 1992, GRAFIT VERSION 3 0; Lerma J, 2003, NAT REV NEUROSCI, V4, P481, DOI 10.1038/nrn1118; Little SP, 1997, J BIOL CHEM, V272, P25135, DOI 10.1074/jbc.272.40.25135; Madden DR, 2002, NAT REV NEUROSCI, V3, P91, DOI 10.1038/nrn725; Magklara A, 2003, BIOCHEM BIOPH RES CO, V307, P948, DOI 10.1016/S0006-291X(03)01271-3; MASON AJ, 1983, NATURE, V303, P300, DOI 10.1038/303300a0; McDonald JW, 1998, NAT MED, V4, P291, DOI 10.1038/nm0398-291; Melo RL, 2001, BIOCHEMISTRY-US, V40, P5226, DOI 10.1021/bi002003u; Mitsui S, 2002, ANN NY ACAD SCI, V977, P216, DOI 10.1111/j.1749-6632.2002.tb04818.x; Ni X, 2004, BRIT J CANCER, V91, P725, DOI 10.1038/sj.bjc.6602041; Ossovskaya VS, 2004, PHYSIOL REV, V84, P579, DOI 10.1152/physrev.00028.2003; Oswald RE, 2004, ADV PROTEIN CHEM, V68, P313; Pimenta DC, 1999, BIOCHEM J, V339, P473, DOI 10.1042/0264-6021:3390473; Rauch U, 2004, CELL MOL LIFE SCI, V61, P2031, DOI 10.1007/s00018-004-4043-x; Rehault S, 2002, BBA-PROTEIN STRUCT M, V1596, P55, DOI 10.1016/S0167-4838(02)00204-2; Rehault S, 2001, EUR J BIOCHEM, V268, P2960, DOI 10.1046/j.1432-1327.2001.02185.x; Rhodes KE, 2004, J ANAT, V204, P33, DOI 10.1111/j.1469-7580.2004.00261.x; Scarisbrick IA, 2000, GLIA, V30, P219, DOI 10.1002/(SICI)1098-1136(200005)30:3<219::AID-GLIA2>3.0.CO;2-2; Scarisbrick IA, 2002, BRAIN, V125, P1283, DOI 10.1093/brain/awf142; Scarisbrick IA, 2001, J COMP NEUROL, V431, P347; Scarisbrick IA, 1997, J NEUROSCI, V17, P8156; SmithSwintosky VL, 1997, J NEUROCHEM, V69, P1890; Steinhoff M, 2000, NAT MED, V6, P151, DOI 10.1038/72247; Striggow F, 2001, EUR J NEUROSCI, V14, P595, DOI 10.1046/j.0953-816x.2001.01676.x; Sugahara K, 2003, CURR OPIN STRUC BIOL, V13, P612, DOI 10.1016/j.sbi.2003.09.011; TIMASHEFF SN, 1993, ANNU REV BIOPH BIOM, V22, P67, DOI 10.1146/annurev.bb.22.060193.000435; Vergnolle N, 2001, NAT MED, V7, P821, DOI 10.1038/89945; VU TKH, 1991, CELL, V64, P1057, DOI 10.1016/0092-8674(91)90261-V; WINES DR, 1989, J BIOL CHEM, V264, P7653; WINES DR, 1991, J MOL EVOL, V32, P476, DOI 10.1007/BF02102650; Wollmuth LP, 2004, TRENDS NEUROSCI, V27, P321, DOI 10.1016/j.tins.2004.04.005; Yamanaka H, 1999, MOL BRAIN RES, V71, P217, DOI 10.1016/S0169-328X(99)00187-4; Yamashiro K, 1997, BBA-GENE STRUCT EXPR, V1350, P11, DOI 10.1016/S0167-4781(96)00187-X; Yousef GM, 1999, GENOMICS, V62, P251, DOI 10.1006/geno.1999.6012; Yousef GM, 2001, ENDOCR REV, V22, P184, DOI 10.1210/er.22.2.184; Zani ML, 2001, BBA-PROTEIN STRUCT M, V1547, P387, DOI 10.1016/S0167-4838(01)00208-4; Zarghooni M, 2002, CLIN BIOCHEM, V35, P225, DOI 10.1016/S0009-9120(02)00292-8	75	89	91	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 10	2006	281	6					3116	3126		10.1074/jbc.M510096200	http://dx.doi.org/10.1074/jbc.M510096200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	009QV	16321973	hybrid			2022-12-25	WOS:000235128200014
J	Khan, MT; Wagner, L; Yule, DI; Bhanumathy, C; Joseph, SK				Khan, MT; Wagner, L; Yule, DI; Bhanumathy, C; Joseph, SK			Akt kinase phosphorylation of inositol 1,4,5-trisphosphate receptors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEPENDENT PROTEIN-KINASE; TRISPHOSPHATE RECEPTOR; CALCIUM-RELEASE; IP3 RECEPTOR; INTRACELLULAR CALCIUM; ENDOPLASMIC-RETICULUM; RAT HEPATOCYTES; APOPTOSIS; TYPE-1; CELLS	A consensus RXRXX(S/T) substrate motif for Akt kinase is conserved in the C-terminal tail of all three inositol 1,4,5-trisphosphate (IP3) receptor (IP3R) isoforms. We have shown that IP3R can be phosphorylated by Akt kinase in vitro and in vivo. Endogenous IP(3)Rs in Chinese hamster ovary T-cells were phosphorylated in response to Akt activation by insulin. LnCAP cells, a prostate cancer cell line with constitutively active Akt kinase, also showed a constitutive phosphorylation of endogenous type I IP(3)Rs. In all cases, the IP3R phosphorylation was diminished by the addition of LY294002, an inhibitor of phosphatidylinositol 3-kinase. Mutation of IP3R serine 2681 in the Akt substrate motif to alanine (S2681A) or glutamate (S2681E) prevented IP3R phosphorylation in COS cells transfected with constitutively active Akt kinase. Analysis of the Ca2+ flux properties of these IP3R mutants expressed in COS cell microsomes or in DT40 triple knock-out (TKO) cells did not reveal any modification of channel function. However, staurosporine-induced caspase-3 activation in DT40 TKO cells stably expressing the S2681A mutant was markedly enhanced when compared with wild-type or S2681E IP(3)Rs. We conclude that IP3 receptors are in vivo substrates for Akt kinase and that phosphorylation of the IP3R may provide one mechanism to restrain the apoptotic effects of calcium.	Thomas Jefferson Univ, Dept Pathol & Cell Biol, Sch Med, Philadelphia, PA 19107 USA; Univ Rochester, Dept Pharmacol & Physiol, Rochester, NY 14642 USA	Jefferson University; University of Rochester	Joseph, SK (corresponding author), Thomas Jefferson Univ, Dept Pathol & Cell Biol, Sch Med, Rm 230A JAH,1020 Locust St, Philadelphia, PA 19107 USA.	suresh.joseph@mail.tju.edu			NIDCR NIH HHS [DE14756] Funding Source: Medline; NIDDK NIH HHS [DK34804, DK54568] Funding Source: Medline; NINDS NIH HHS [R21-NS051822] Funding Source: Medline; NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH [R01DE014756] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [R56DE014756] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK034804, R56DK054568, R01DK054568] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R21NS051822] Funding Source: NIH RePORTER	NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Ahmed NN, 1997, P NATL ACAD SCI USA, V94, P3627, DOI 10.1073/pnas.94.8.3627; Assefa Z, 2004, J BIOL CHEM, V279, P43227, DOI 10.1074/jbc.M403872200; BERRIDGE MJ, 1993, NATURE, V361, P315, DOI 10.1038/361315a0; Boehning D, 2000, J BIOL CHEM, V275, P21492, DOI 10.1074/jbc.M001724200; Boehning D, 2000, EMBO J, V19, P5450, DOI 10.1093/emboj/19.20.5450; Boehning D, 2003, NAT CELL BIOL, V5, P1051, DOI 10.1038/ncb1063; Brazil DP, 2004, TRENDS BIOCHEM SCI, V29, P233, DOI 10.1016/j.tibs.2004.03.006; Breckenridge DG, 2003, ONCOGENE, V22, P8608, DOI 10.1038/sj.onc.1207108; Calera MR, 1998, J BIOL CHEM, V273, P7201, DOI 10.1074/jbc.273.13.7201; Cantley LC, 1999, P NATL ACAD SCI USA, V96, P4240, DOI 10.1073/pnas.96.8.4240; Carson JP, 1999, CANCER RES, V59, P1449; Chen R, 2004, J CELL BIOL, V166, P193, DOI 10.1083/jcb.200309146; Cui J, 2004, J BIOL CHEM, V279, P16311, DOI 10.1074/jbc.M400206200; Dufner A, 1999, MOL CELL BIOL, V19, P4525; ENDEMANN G, 1990, J BIOL CHEM, V265, P396; FERRIS CD, 1991, BIOCHEM BIOPH RES CO, V175, P192, DOI 10.1016/S0006-291X(05)81219-7; FERRIS CD, 1991, P NATL ACAD SCI USA, V88, P2232, DOI 10.1073/pnas.88.6.2232; Franke TF, 2003, ONCOGENE, V22, P8983, DOI 10.1038/sj.onc.1207115; Hajnoczky G, 2003, BIOCHEM BIOPH RES CO, V304, P445, DOI 10.1016/S0006-291X(03)00616-8; Hang LS, 2000, J NEUROCHEM, V75, P1852; Hirota J, 1999, J BIOL CHEM, V274, P34433, DOI 10.1074/jbc.274.48.34433; Jayaraman T, 1997, MOL CELL BIOL, V17, P3005, DOI 10.1128/MCB.17.6.3005; JOSEPH SK, 1993, J BIOL CHEM, V268, P6477; JOSEPH SK, 1993, J BIOL CHEM, V268, P23059; KOMALAVILAS P, 1994, J BIOL CHEM, V269, P8701; Lawlor MA, 2001, J CELL SCI, V114, P2903; Malathi K, 2003, J CELL BIOCHEM, V90, P1186, DOI 10.1002/jcb.10720; Miyakawa T, 1999, EMBO J, V18, P1303, DOI 10.1093/emboj/18.5.1303; Nakayama T, 2004, BIOCHEM J, V377, P299, DOI 10.1042/BJ20030599; Oakes SA, 2005, P NATL ACAD SCI USA, V102, P105, DOI 10.1073/pnas.0408352102; Ozeki M, 2004, MOL CELL BIOCHEM, V259, P169, DOI 10.1023/B:MCBI.0000021369.17958.f4; Patel S, 1999, CELL CALCIUM, V25, P247, DOI 10.1054/ceca.1999.0021; Patterson RL, 2004, ANNU REV BIOCHEM, V73, P437, DOI 10.1146/annurev.biochem.73.071403.161303; Ravichandran LV, 2001, MOL ENDOCRINOL, V15, P1768, DOI 10.1210/me.15.10.1768; Rizzuto Rosario, 2004, Sci STKE, V2004, pre1, DOI 10.1126/stke.2152004re1; Rooney TA, 1996, J BIOL CHEM, V271, P19817, DOI 10.1074/jbc.271.33.19817; Sato M, 2003, NAT CELL BIOL, V5, P1016, DOI 10.1038/ncb1054; Schlossmann J, 2000, NATURE, V404, P197, DOI 10.1038/35004606; Soulsby MD, 2004, FEBS LETT, V557, P181, DOI 10.1016/S0014-5793(03)01487-X; Sugawara H, 1997, EMBO J, V16, P3078, DOI 10.1093/emboj/16.11.3078; SUPATTAPONE S, 1988, P NATL ACAD SCI USA, V85, P8747, DOI 10.1073/pnas.85.22.8747; Tang D, 2001, J BIOL CHEM, V276, P30461, DOI 10.1074/jbc.M102045200; Tantral L, 2004, CELL BIOCHEM FUNCT, V22, P35, DOI 10.1002/cbf.1050; Tsunoda T, 2005, ONCOGENE, V24, P1396, DOI 10.1038/sj.onc.1208313; Vermassen E, 2004, BIOL CELL, V96, P3, DOI 10.1016/j.biolcel.2003.11.004; Wagner LE, 2004, J BIOL CHEM, V279, P46242, DOI 10.1074/jbc.M405849200; Wagner LE, 2003, J BIOL CHEM, V278, P45811, DOI 10.1074/jbc.M306270200; Whiteman EL, 2002, TRENDS ENDOCRIN MET, V13, P444, DOI 10.1016/S1043-2760(02)00662-8; WOJCIKIEWICZ RJH, 1995, J BIOL CHEM, V270, P11678, DOI 10.1074/jbc.270.19.11678	49	112	114	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 10	2006	281	6					3731	3737		10.1074/jbc.M509262200	http://dx.doi.org/10.1074/jbc.M509262200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	009QV	16332683	hybrid			2022-12-25	WOS:000235128200085
J	Kulikowicz, T; Shapiro, TA				Kulikowicz, T; Shapiro, TA			Distinct genes encode type II topoisomerases for the nucleus and mitochondrion in the protozoan parasite Trypanosoma brucei	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEMOFLAGELLATE LEISHMANIA-DONOVANI; HUMAN AFRICAN TRYPANOSOMIASIS; KINETOPLAST DNA MINICIRCLES; CRITHIDIA-FASCICULATA; CELL-CYCLE; RNA INTERFERENCE; EXPRESSION; CLONING; GENOME; TARGET	Topoisomerases are essential for orderly nucleic acid metabolism and cell survival and are proven targets for clinically useful antimicrobial and anticancer drugs. Interest in the topologically intricate mitochondrial DNA ( kinetoplast or kDNA) of Trypanosoma brucei brucei and related kinetoplastid protozoan parasites has led to many reports of type II topoisomerases that participate in kDNA metabolism ( we term the T. brucei brucei gene TbTOP2mt). We have now identified and characterized two new genes for type II topoisomerases in T. brucei brucei, termed TbTOP2 alpha and TbTOP2 beta. Phylogenetically, they share a common node with other nuclear topoisomerases, clearly distinct from a clade that includes the previously reported kinetoplastid genes, all of which are homologs of TbTOP2mt. Southern blot analysis reveals the new genes are single copy and positioned similar to 1.7 kb apart. Cognate mRNAs are expressed in African trypanosomes, but only a single message is detected in Leishmania or Crithidia. TbTOP2 alpha encodes an ATP-dependent topoisomerase that appears as a single similar to 170kDa band on immunoblots and localizes to the nucleus; RNA interference leads to pleomorphic nuclear ( but not kDNA) abnormalities and early growth arrest. The role of TbTOP2 beta is unclear. Although transcribed in trypanosomes, TbTOP2 beta is not detected by beta-specific antiserum, and RNAi silencing results in no obvious phenotype. These studies indicate that African trypanosomes and related kinetoplastid human pathogens are unusual in having independent topoisomerase II genes to service their nuclear and mitochondrial genomes, and they highlight TbTOP2 alpha as a promising target for the development of much-needed new therapies.	Johns Hopkins Univ, Sch Med, Div Pharmacol, Dept Med, Baltimore, MD 21205 USA; Johns Hopkins Univ, Sch Med, Div Pharmacol, Dept Pharmacol & Mol Sci, Baltimore, MD 21205 USA	Johns Hopkins University; Johns Hopkins University	Shapiro, TA (corresponding author), Johns Hopkins Univ, Sch Med, Div Pharmacol, Dept Med, 303 Hunterian Bldg,725 N Wolfe St, Baltimore, MD 21205 USA.	tshapiro@jhmi.edu			NIAID NIH HHS [AI28855] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI028855, R56AI028855] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Aravind L, 1998, NUCLEIC ACIDS RES, V26, P4205, DOI 10.1093/nar/26.18.4205; Bakshi RP, 2004, MOL BIOCHEM PARASIT, V136, P249, DOI 10.1016/j.molbiopara.2004.04.006; Berriman M, 2005, SCIENCE, V309, P416, DOI 10.1126/science.1112642; Bingle LEH, 2001, MICROBIOL-SGM, V147, P3231, DOI 10.1099/00221287-147-12-3231; BODLEY AL, 1995, J INFECT DIS, V172, P1157, DOI 10.1093/infdis/172.4.1157; BORST P, 1982, MOL BIOCHEM PARASIT, V6, P13, DOI 10.1016/0166-6851(82)90049-4; BRUN R, 1979, ACTA TROP, V36, P289; CARRUTHERS VB, 1992, P NATL ACAD SCI USA, V89, P8818, DOI 10.1073/pnas.89.18.8818; CHAKRABORTY AK, 1987, MOL BIOCHEM PARASIT, V26, P215, DOI 10.1016/0166-6851(87)90074-0; CHAKRABORTY AK, 1991, BIOCHEM BIOPH RES CO, V180, P279, DOI 10.1016/S0006-291X(05)81289-6; Champoux JJ, 2001, ANNU REV BIOCHEM, V70, P369, DOI 10.1146/annurev.biochem.70.1.369; CHRISTIANSON TW, 1992, GENE, V110, P119, DOI 10.1016/0378-1119(92)90454-W; CHURCH GM, 1984, P NATL ACAD SCI-BIOL, V81, P1991, DOI 10.1073/pnas.81.7.1991; Das A, 2001, NUCLEIC ACIDS RES, V29, P1844, DOI 10.1093/nar/29.9.1844; De Sousa JMA, 2003, SCAND J INFECT DIS, V35, P826, DOI 10.1080/00365540310017023; Djikeng A, 1998, GENE, V221, P93, DOI 10.1016/S0378-1119(98)00427-2; DOUCRASY S, 1988, BIOL CELL, V64, P145, DOI 10.1016/0248-4900(88)90074-3; Ersfeld K, 1999, PARASITOL TODAY, V15, P58, DOI 10.1016/S0169-4758(98)01378-7; Field MC, 2004, MICROSC MICROANAL, V10, P621, DOI 10.1017/S1431927604040942; FRAGOSO SP, 1992, MOL BIOCHEM PARASIT, V55, P127, DOI 10.1016/0166-6851(92)90133-5; Fragoso SP, 1998, MOL BIOCHEM PARASIT, V94, P197, DOI 10.1016/S0166-6851(98)00066-8; Furuya T, 2002, P NATL ACAD SCI USA, V99, P14177, DOI 10.1073/pnas.222454899; GIAEVER GN, 1988, CELL, V55, P849, DOI 10.1016/0092-8674(88)90140-7; Gibson W, 1999, ADV PARASIT, V43, P1, DOI 10.1016/S0065-308X(08)60240-7; Grab DJ, 2004, J PARASITOL, V90, P970, DOI 10.1645/GE-287R; Hanke T, 2003, NUCLEIC ACIDS RES, V31, P4917, DOI 10.1093/nar/gkg671; Hsiung Y, 1996, CANCER RES, V56, P91; Huang W M, 1994, Adv Pharmacol, V29A, P201; Li ZY, 2003, J BIOL CHEM, V278, P20652, DOI 10.1074/jbc.M301635200; Low RL, 2003, EUR J BIOCHEM, V270, P4173, DOI 10.1046/j.1432-1033.2003.03814.x; MELENDY T, 1988, CELL, V55, P1083, DOI 10.1016/0092-8674(88)90252-8; MELENDY T, 1989, J BIOL CHEM, V264, P1870; Mirabella A, 1997, EMBO J, V16, P523, DOI 10.1093/emboj/16.3.523; Moore AC, 2002, NEW ENGL J MED, V346, P2069, DOI 10.1056/NEJMcpc010056; NIGRO JM, 1992, MOL CELL BIOL, V12, P1357, DOI 10.1128/MCB.12.3.1357; PARSONS M, 1984, CELL, V38, P309, DOI 10.1016/0092-8674(84)90552-X; PASION SG, 1992, MOL BIOCHEM PARASIT, V50, P57, DOI 10.1016/0166-6851(92)90244-E; Ploubidou A, 1999, J CELL SCI, V112, P4641; ROBINSON DR, 1995, J CELL BIOL, V128, P1163, DOI 10.1083/jcb.128.6.1163; SHAPIRO TA, 1995, ANNU REV MICROBIOL, V49, P117, DOI 10.1146/annurev.mi.49.100195.001001; SHAPIRO TA, 1990, P NATL ACAD SCI USA, V87, P950, DOI 10.1073/pnas.87.3.950; SHAPIRO TA, 1989, J BIOL CHEM, V264, P4173; Shlomai J, 2004, CURR MOL MED, V4, P623, DOI 10.2174/1566524043360096; SHLOMAI J, 1984, ADV EXP MED BIOL, V179, P409; Simpson L, 2003, RNA, V9, P265, DOI 10.1261/rna.2178403; Smith DH, 1998, BRIT MED BULL, V54, P341, DOI 10.1093/oxfordjournals.bmb.a011692; Stich A, 2002, BRIT MED J, V325, P203, DOI 10.1136/bmj.325.7357.203; STRAUSS PR, 1990, MOL BIOCHEM PARASIT, V38, P141, DOI 10.1016/0166-6851(90)90214-7; STUART KD, 1971, J CELL BIOL, V49, P189, DOI 10.1083/jcb.49.1.189; Swofford DL, 2002, PHYLOGENETIC ANAL US; Thompson JD, 1997, NUCLEIC ACIDS RES, V25, P4876, DOI 10.1093/nar/25.24.4876; Tu XM, 2005, EUKARYOT CELL, V4, P755, DOI 10.1128/EC.4.4.755-764.2005; Wang JC, 2002, NAT REV MOL CELL BIO, V3, P430, DOI 10.1038/nrm831; Wang JC, 1996, ANNU REV BIOCHEM, V65, P635, DOI 10.1146/annurev.bi.65.070196.003223; Wang ZF, 2002, EMBO J, V21, P4998, DOI 10.1093/emboj/cdf482; Wang ZF, 2001, EMBO J, V20, P4674, DOI 10.1093/emboj/20.17.4674; Wirtz E, 1999, MOL BIOCHEM PARASIT, V99, P89, DOI 10.1016/S0166-6851(99)00002-X	57	32	32	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 10	2006	281	6					3048	3056		10.1074/jbc.M505977200	http://dx.doi.org/10.1074/jbc.M505977200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	009QV	16316982	hybrid			2022-12-25	WOS:000235128200007
J	Rendic, D; Linder, A; Paschinger, K; Borth, N; Wilson, IBH; Fabini, GV				Rendic, D; Linder, A; Paschinger, K; Borth, N; Wilson, IBH; Fabini, GV			Modulation of neural carbohydrate epitope expression in Drosophila melanogaster cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CORE ALPHA-1,3-LINKED FUCOSE; N-GLYCAN ANALYSIS; HORSERADISH-PEROXIDASE; LINKED CARBOHYDRATE; GENE-EXPRESSION; ANTIBODIES; CLONING; OLIGOSACCHARIDES; IDENTIFICATION; GLYCOPROTEINS	Neural pathways in invertebrates are often tracked using anti-horseradish peroxidase, a cross-reaction due to the presence of core alpha 1,3-fucosylated N-glycans. In order to investigate the molecular basis of this epitope in a cellular context, we compared two Drosophila melanogaster cell lines: the S2 and the neuronal-like BG2-c6 cell lines. As shown by mass spectrometric and chromatographic analyses, only the BG2-c6 cell line expresses alpha 1,3/alpha 1,6-difucosylated N-glycans, a result that correlates with anti-horseradish peroxidase binding. Of all four alpha 1,3-fucosyltransferase homologues previously identified, the core alpha 1,3-fucosyltransferase (FucTA; EC 2.4.1.214) is expressed in the neuronal cell line as well as throughout fly development and in heads and bodies of flies of both sexes. This pattern is distinctive in comparison with the expression of the other three alpha 1,3-fucosyltransferase homologues (FucTB, FucTC, and FucTD). Furthermore, only transfection of FucTA cDNA into S2 cells resulted in expression of the anti-horseradish peroxidase epitope, a result compatible with its substrate specificity in vitro. Finally, silencing of FucTA by RNAi in the neuronal cell line led to a significant reduction of anti-horseradish peroxidase binding. The present study, in conjunction with our previous in vitro data, thereby shows that FucTA is indispensable for expression of the neural carbohydrate epitope in Drosophila cells.	Univ Bodenkultur Wien, Dept Chem, A-1190 Vienna, Austria; Univ Bodenkultur Wien, Dept Biotechnol, A-1190 Vienna, Austria	University of Natural Resources & Life Sciences, Vienna; University of Natural Resources & Life Sciences, Vienna	Rendic, D (corresponding author), Univ Bodenkultur Wien, Dept Chem, Muthgasse 18, A-1190 Vienna, Austria.	dubravko.rendic@boku.ac.at	Rendic, Dubravko/A-9368-2010; Wilson, Iain/B-3326-2009	Wilson, Iain/0000-0001-8996-1518; Paschinger, Katharina/0000-0002-3594-7136; Borth, Nicole/0000-0001-6324-9338				Adams MD, 2000, SCIENCE, V287, P2185, DOI 10.1126/science.287.5461.2185; ALTMANN F, 1995, J BIOL CHEM, V270, P17344, DOI 10.1074/jbc.270.29.17344; Bencurova M, 2004, GLYCOBIOLOGY, V14, P457, DOI 10.1093/glycob/cwh058; Bouyain S, 2002, J BIOL CHEM, V277, P22566, DOI 10.1074/jbc.M202825200; Breton C, 1998, GLYCOBIOLOGY, V8, P87, DOI 10.1093/glycob/8.1.87; Fabini G, 2001, J BIOL CHEM, V276, P28058, DOI 10.1074/jbc.M100573200; Haase A, 2001, DEV GENES EVOL, V211, P428, DOI 10.1007/s004270100173; HASE S, 1984, J BIOCHEM-TOKYO, V95, P197, DOI 10.1093/oxfordjournals.jbchem.a134585; Haslam SM, 2000, GLYCOBIOLOGY, V10, P223, DOI 10.1093/glycob/10.2.223; Ivey-Hoyle M, 1991, Curr Opin Biotechnol, V2, P704, DOI 10.1016/0958-1669(91)90038-7; JAN LY, 1982, P NATL ACAD SCI-BIOL, V79, P2700, DOI 10.1073/pnas.79.8.2700; KATZ F, 1988, EMBO J, V7, P3471, DOI 10.1002/j.1460-2075.1988.tb03222.x; Kim YK, 2005, BIOTECHNOL BIOENG, V92, P452, DOI 10.1002/bit.20605; Kolarich D, 2000, ANAL BIOCHEM, V285, P64, DOI 10.1006/abio.2000.4737; KUBELKA V, 1995, GLYCOCONJUGATE J, V12, P77, DOI 10.1007/BF00731872; KUBELKA V, 1994, ARCH BIOCHEM BIOPHYS, V308, P148, DOI 10.1006/abbi.1994.1021; KUBELKA V, 1993, EUR J BIOCHEM, V213, P1193, DOI 10.1111/j.1432-1033.1993.tb17870.x; KUROSAKA A, 1991, J BIOL CHEM, V266, P4168; Lai EC, 2003, GENOME BIOL, V4, DOI 10.1186/gb-2003-4-7-r42; Leiter H, 1999, J BIOL CHEM, V274, P21830, DOI 10.1074/jbc.274.31.21830; Oriol R, 1999, GLYCOBIOLOGY, V9, P323, DOI 10.1093/glycob/9.4.323; Parisi M, 2004, GENOME BIOL, V5, DOI 10.1186/gb-2004-5-6-r40; Paschinger K, 2004, J BIOL CHEM, V279, P49588, DOI 10.1074/jbc.M408978200; Paschinger K, 2005, GLYCOBIOLOGY, V15, P463, DOI 10.1093/glycob/cwi028; Sarkar M, 2001, BIOL CHEM, V382, P209, DOI 10.1515/BC.2001.028; Seppo A, 2003, DEVELOPMENT, V130, P1439, DOI 10.1242/dev.00347; SIDDIQUI SS, 1991, J NEUROGENET, V7, P193, DOI 10.3109/01677069109167433; SNOW PM, 1987, J NEUROSCI, V7, P4137; Tsitilou SG, 2003, BIOCHEM BIOPH RES CO, V312, P1372, DOI 10.1016/j.bbrc.2003.11.059; UI K, 1994, IN VITRO CELL DEV-AN, V30A, P209; WANG X, 1994, INSECT BIOCHEM MOLEC, V24, P233, DOI 10.1016/0965-1748(94)90002-7; Wilson IBH, 2001, GLYCOBIOLOGY, V11, P261, DOI 10.1093/glycob/11.4.261; Wilson IBH, 1998, GLYCOCONJUGATE J, V15, P1055, DOI 10.1023/A:1006960401562; Worby C A, 2001, Sci STKE, V2001, ppl1, DOI 10.1126/stke.2001.95.pl1	34	40	40	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 10	2006	281	6					3343	3353		10.1074/jbc.M508334200	http://dx.doi.org/10.1074/jbc.M508334200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	009QV	16314421	hybrid			2022-12-25	WOS:000235128200042
J	Ischebeck, T; Zbierzak, AM; Kanwischer, M; Dormann, P				Ischebeck, T; Zbierzak, AM; Kanwischer, M; Dormann, P			A salvage pathway for phytol metabolism in Arabidopsis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ISOPRENOID BIOSYNTHESIS; SPINACH-CHLOROPLASTS; VITAMIN-E; HOMOGENTISATE PHYTYLTRANSFERASE; DIACYLGLYCEROL ACYLTRANSFERASE; CHLOROPHYLL DEGRADATION; PRECURSOR PROTEINS; PHOSPHATE KINASE; TISSUE CULTURES; HIGHER-PLANTS	Chlorophyll is the most abundant photosynthetic pigment in higher plants. During senescence, chlorophyll is hydrolyzed, resulting in the release of free phytol and chlorophyllide. Although the degradation of chlorophyllide has been studied in depth, the metabolic fate of phytol in plants is less clear. Here, we provide evidence that phytol can be incorporated into chlorophyll, tocopherol, and lipid esters by Arabidopsis seedlings. Phytol is phosphorylated to phytyl-phosphate and phytyl-diphosphate by two successive kinase activities associated with chloroplast envelope membranes of Arabidopsis. Although phytol kinase is CTP-dependent, the second kinase reaction, phytyl-phosphate kinase, shows broader specificity for CTP, GTP, UTP, and ATP. Therefore, in addition to de novo synthesis from geranylgeranyl-diphosphate, phosphorylation of free phytol represents an alternative route for phytyl-diphosphate production as the precursor for chloroplast prenyl lipid synthesis. Lipid esters are produced after feeding phytol to Arabidopsis seedlings, and they also accumulate in large amounts in leaves during senescence. The predominant phytyl ester that accumulates during senescence is hexadecatrienoic acid phytyl ester. Fatty acid phytyl ester synthesis by protein extracts of Arabidopsis is stimulated in the presence of phytol- and acyl-CoA esters. Thus, Arabidopsis contains a distinct enzymatic machinery for redirecting free phytol released from chlorophyll degradation into chloroplast lipid metabolism.	Max Planck Inst Mol Plant Physiol, Dept Mol Physiol, D-14476 Golm, Germany	Max Planck Society	Dormann, P (corresponding author), Max Planck Inst Mol Plant Physiol, Dept Mol Physiol, Muhlenberg 1, D-14476 Golm, Germany.	doermann@mpimp-golm.mpg.de	Ischebeck, Till/AAM-4327-2020	Ischebeck, Till/0000-0003-0737-3822; Kanwischer, Marion/0000-0002-2317-0112				ANDERSON WH, 1984, PHYTOCHEMISTRY, V23, P2594; Arigoni D, 1997, P NATL ACAD SCI USA, V94, P10600, DOI 10.1073/pnas.94.20.10600; Bentinger M, 1998, ARCH BIOCHEM BIOPHYS, V353, P191, DOI 10.1006/abbi.1998.0611; Bergmuller E, 2003, PLANT MOL BIOL, V52, P1181, DOI 10.1023/B:PLAN.0000004307.62398.91; Collakova E, 2003, PLANT PHYSIOL, V133, P930, DOI 10.1104/pp.103.026138; Collakova E, 2001, PLANT PHYSIOL, V127, P1113, DOI 10.1104/pp.010421; CRANWELL PA, 1985, LIPIDS, V20, P645, DOI 10.1007/BF02534382; CRANWELL PA, 1990, PHYTOCHEMISTRY, V29, P145; CRICK DC, 1994, J BIOL CHEM, V269, P10559; CSUPOR L, 1971, PLANTA MED, V19, P37; Fitzpatrick LM, 2001, PLANT J, V27, P59, DOI 10.1046/j.0960-7412.2001.01061.x; FURUYA T, 1987, PHYTOCHEMISTRY, V26, P2741, DOI 10.1016/S0031-9422(00)83582-7; Gaude N, 2004, J BIOL CHEM, V279, P34624, DOI 10.1074/jbc.M404098200; GELLERMAN JL, 1975, LIPIDS, V10, P656, DOI 10.1007/BF02532757; Havaux M, 2005, PLANT CELL, V17, P3451, DOI 10.1105/tpc.105.037036; HELLER L, 1992, P NATL ACAD SCI USA, V89, P7013, DOI 10.1073/pnas.89.15.7013; Hortensteiner S, 1999, CELL MOL LIFE SCI, V56, P330, DOI 10.1007/s000180050434; INOUE H, 1994, BIOCHEM BIOPH RES CO, V200, P1036, DOI 10.1006/bbrc.1994.1554; Kalscheuer R, 2003, J BIOL CHEM, V278, P8075, DOI 10.1074/jbc.M210533200; Kaup MT, 2002, PLANT PHYSIOL, V129, P1616, DOI 10.1104/pp.003087; Keller Y, 1998, EUR J BIOCHEM, V251, P413, DOI 10.1046/j.1432-1327.1998.2510413.x; Lange BM, 2003, PLANT MOL BIOL, V51, P925, DOI 10.1023/A:1023005504702; Lardizabal KD, 2000, PLANT PHYSIOL, V122, P645, DOI 10.1104/pp.122.3.645; Laule O, 2003, P NATL ACAD SCI USA, V100, P6866, DOI 10.1073/pnas.1031755100; Lichtenthaler HK, 1999, ANNU REV PLANT PHYS, V50, P47, DOI 10.1146/annurev.arplant.50.1.47; MURASHIGE T, 1962, PHYSIOL PLANTARUM, V15, P473, DOI 10.1111/j.1399-3054.1962.tb08052.x; Ohnuma S, 1996, J BIOCHEM-TOKYO, V119, P541; PATTERSON GW, 1993, PHYTOCHEMISTRY, V33, P1381, DOI 10.1016/0031-9422(93)85095-9; PEISKER C, 1989, J PLANT PHYSIOL, V135, P428, DOI 10.1016/S0176-1617(89)80099-9; Pereira AS, 2002, PHYTOCHEMISTRY, V61, P711, DOI 10.1016/S0031-9422(02)00348-5; PERRY SE, 1994, PLANT CELL, V6, P93, DOI 10.1105/tpc.6.1.93; Porfirova S, 2002, P NATL ACAD SCI USA, V99, P12495, DOI 10.1073/pnas.182330899; RISE M, 1989, PLANT PHYSIOL, V89, P1028, DOI 10.1104/pp.89.4.1028; Rontani JF, 1999, APPL ENVIRON MICROB, V65, P221; SCHULTZ G, 1981, EUR J BIOCHEM, V117, P329, DOI 10.1111/j.1432-1033.1981.tb06341.x; Shimada H, 2005, PLANT J, V41, P627, DOI 10.1111/j.1365-313X.2004.02326.x; SOLL J, 1980, ARCH BIOCHEM BIOPHYS, V204, P544, DOI 10.1016/0003-9861(80)90066-1; SOLL J, 1983, PLANT PHYSIOL, V71, P849, DOI 10.1104/pp.71.4.849; Takamiya K, 2000, TRENDS PLANT SCI, V5, P426, DOI 10.1016/S1360-1385(00)01735-0; Thai L, 1999, P NATL ACAD SCI USA, V96, P13080, DOI 10.1073/pnas.96.23.13080; Tsuchiya T, 1999, P NATL ACAD SCI USA, V96, P15362, DOI 10.1073/pnas.96.26.15362; Valentin HE, 2005, APPL MICROBIOL BIOT, V68, P436, DOI 10.1007/s00253-005-0017-7; van den Brink DM, 2004, MOL GENET METAB, V82, P33, DOI 10.1016/j.ymgme.2004.01.019; Westfall D, 1997, BIOCHEM BIOPH RES CO, V230, P562, DOI 10.1006/bbrc.1996.6014	44	140	144	4	28	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 3	2006	281	5					2470	2477		10.1074/jbc.M509222200	http://dx.doi.org/10.1074/jbc.M509222200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	006XT	16306049	hybrid			2022-12-25	WOS:000234931800009
J	Mayeenuddin, LH; Garrison, JC				Mayeenuddin, LH; Garrison, JC			Phosphorylation of P-Rex1 by the cyclic AMP-dependent protein kinase inhibits the phosphatidylinositiol (3,4,5)-trisphosphate and G beta gamma-mediated regulation of its activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEOTIDE EXCHANGE FACTOR; COUPLED RECEPTORS; DIFFERENTIAL SENSITIVITY; LYSOPHOSPHATIDIC ACID; RHO-GTPASES; ACTIVATION; RAC; EXPRESSION; PURIFICATION; CHEMOKINES	Rac activation is a key step in chemotaxis of hematopoietic cells, which is both positively and negatively regulated by receptors coupled to heterotrimeric G proteins. P-Rex1, a Rac-specific guanine nucleotide exchange factor, is dually activated by phosphatidylinositol (3,4,5)-trisphosphate (PIP3) and the G beta gamma subunits of heterotrimeric G proteins. This study explored the regulation of P-Rex1 by phosphorylation with the cAMP-dependent protein kinase ( protein kinase A) in vitro and by G(i)- and G(s)-coupled receptors in HEK293T cells. P-Rex1 isolated from Sf9 and HEK293T cells migrates as two distinct bands that are partially phosphorylated. Phosphorylation of P-Rex1 with protein kinase A (PKA) inhibits the PIP3- and G beta gamma-stimulated P-Rex1 guanine nucleotide exchange activity on Rac. The guanine nucleotide exchange factor activity of three different forms of P-Rex1 ( native Sf9, de-phosphorylated, and phosphorylated) was examined in the presence of PIP3 and varying concentrations of G beta(1)gamma(2). G beta(1)gamma(2) was 47-fold less potent in activating the phosphorylated form of P-Rex1 compared with the de-phosphorylated form. HEK293T cells expressing P-Rex1 were labeled with P-32 and stimulated with lysophosphatidic acid (LPA) to release G beta gamma or isoproterenol to activate PKA. Treatment with isoproterenol or S-p-cAMPS, a potent activator of PKA, increased the incorporation of P-32 into P-Rex1. LPA increased the amount of GTP-bound Rac in the cells and isoproterenol reduced basal levels of GTP-bound Rac and blunted the effect of LPA. Treatment of the cells with Sp-cAMPS also reduced the levels of GTP-bound Rac. These results outline a novel mechanism for G(s)-linked receptors to regulate the function of P-Rex1 and inhibit its function in cells.	Univ Virginia, Hlth Syst, Dept Pharmacol, Charlottesville, VA 22908 USA	University of Virginia	Mayeenuddin, LH (corresponding author), POB 800735, Charlottesville, VA 22908 USA.	lhm4n@virginia.edu			NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK019952] Funding Source: NIH RePORTER; NCI NIH HHS [CA 40042] Funding Source: Medline; NIDDK NIH HHS [DK 19952] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Alderton F, 2001, BRIT J PHARMACOL, V134, P6, DOI 10.1038/sj.bjp.0704278; Baggiolini M, 1997, ANNU REV IMMUNOL, V15, P675, DOI 10.1146/annurev.immunol.15.1.675; Benard V, 2002, METHOD ENZYMOL, V345, P349; Blom N, 1999, J MOL BIOL, V294, P1351, DOI 10.1006/jmbi.1999.3310; Brass LF, 1999, J CLIN INVEST, V104, P1663, DOI 10.1172/JCI8944; BURKEY TH, 1993, BIOCHIM BIOPHYS ACTA, V1175, P312, DOI 10.1016/0167-4889(93)90223-C; Bustelo XR, 2000, MOL CELL BIOL, V20, P1461, DOI 10.1128/MCB.20.5.1461-1477.2000; Cherfils J, 1999, TRENDS BIOCHEM SCI, V24, P306, DOI 10.1016/S0968-0004(99)01429-2; CRONSTEIN BN, 1992, BLOOD, V80, P1052; DellaRocca GJ, 1997, J BIOL CHEM, V272, P19125, DOI 10.1074/jbc.272.31.19125; Donald S, 2004, FEBS LETT, V572, P172, DOI 10.1016/j.febslet.2004.06.096; Fleming IN, 1997, J BIOL CHEM, V272, P33105, DOI 10.1074/jbc.272.52.33105; Fleming IN, 1998, FEBS LETT, V429, P229, DOI 10.1016/S0014-5793(98)00566-3; Fleming IN, 1999, J BIOL CHEM, V274, P12753, DOI 10.1074/jbc.274.18.12753; Friedman J, 2002, MOL PHARMACOL, V62, P1094, DOI 10.1124/mol.62.5.1094; Giembycz MA, 2000, PULM PHARMACOL THER, V13, P195, DOI 10.1006/pupt.2000.0250; GRABER SG, 1994, METHOD ENZYMOL, V237, P212; GRABER SG, 1992, J BIOL CHEM, V267, P13123; GRABER SG, 1996, METH NEUROSCI, V29, P207; Gregg D, 2003, AM J PHYSIOL-CELL PH, V285, pC723, DOI 10.1152/ajpcell.00230.2003; Hill K, 2005, J BIOL CHEM, V280, P4166, DOI 10.1074/jbc.M411262200; Kerchner KR, 2004, J BIOL CHEM, V279, P44554, DOI 10.1074/jbc.M406071200; Linden J, 2001, ANNU REV PHARMACOL, V41, P775, DOI 10.1146/annurev.pharmtox.41.1.775; Locati M, 1999, ANNU REV MED, V50, P425, DOI 10.1146/annurev.med.50.1.425; Lopez-Lago M, 2000, MOL CELL BIOL, V20, P1678, DOI 10.1128/MCB.20.5.1678-1691.2000; Luster AD, 1998, NEW ENGL J MED, V338, P436, DOI 10.1056/NEJM199802123380706; Mantovani A, 1999, IMMUNOL TODAY, V20, P254, DOI 10.1016/S0167-5699(99)01469-3; Mayeenuddin LH, 2006, J BIOL CHEM, V281, P1913, DOI 10.1074/jbc.M506034200; McIntire WE, 2001, J BIOL CHEM, V276, P15801, DOI 10.1074/jbc.M011233200; MICHIELS F, 1995, NATURE, V375, P338, DOI 10.1038/375338a0; Michiels F, 1997, J CELL BIOL, V137, P387, DOI 10.1083/jcb.137.2.387; MOTULSKY HJ, 1987, FASEB J, V1, P365, DOI 10.1096/fasebj.1.5.3315805; Rosenfeldt H, 2004, FEBS LETT, V572, P167, DOI 10.1016/j.febslet.2004.06.097; ROTHERMEL JD, 1988, BIOCHEM J, V251, P757, DOI 10.1042/bj2510757; Satinover DL, 2004, P NATL ACAD SCI USA, V101, P8625, DOI 10.1073/pnas.0402966101; Schmidt A, 2002, GENE DEV, V16, P1587, DOI 10.1101/gad.1003302; Schuebel KE, 1998, EMBO J, V17, P6608, DOI 10.1093/emboj/17.22.6608; Sullivan GW, 2001, BRIT J PHARMACOL, V132, P1017, DOI 10.1038/sj.bjp.0703893; Sullivan GW, 1999, J INFECT DIS, V180, P1550, DOI 10.1086/315084; Tatsumoto T, 1999, J CELL BIOL, V147, P921, DOI 10.1083/jcb.147.5.921; Welch HCE, 2002, CELL, V108, P809, DOI 10.1016/S0092-8674(02)00663-3; Zheng Y, 2001, TRENDS BIOCHEM SCI, V26, P724, DOI 10.1016/S0968-0004(01)01973-9; ZHUO S, 1993, J BIOL CHEM, V268, P17754	43	38	38	0	1	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 27	2006	281	4					1921	1928		10.1074/jbc.M506035200	http://dx.doi.org/10.1074/jbc.M506035200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	004NV	16301320	hybrid			2022-12-25	WOS:000234760400010
